STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 137365

TO: James Schultz **Location: REM/2D18/2C18** **Art Unit: 1635** **Monday, November 08, 2004** **Case Serial Number: 10/023782**	**From: David Schreiber** **Location: Biotech-Chem Library** **Remsen E01A61** **Phone: 272-2526** **david.schreiber@uspto.gov**

Search Notes

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner #: _____ Date: _____
Art Unit: _____ Phone Number 30_____ Serial Number: _____
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: R. Schnizbein	NA Sequence (#) 11	STN
Searcher Phone #: 272-2521	AA Sequence (#)	Dialog
Searcher Location: Remsen EIC/1641	Structure (#)	Questel/Orbit
Date Searcher Picked Up	Bibliographic	Dr.Link
Date Completed: 11/8	Litigation	Lexis/Nexis
Searcher Prep & Review Time: 15	Fulltext	Sequence Systems: Geneseq
Clerical Prep Time	Patent Family	WWW/Internet
Online Time: 66	Other	Other (specify)

137365

Schr iber, David

From: Schultz, James
Sent: Friday, October 22, 2004 5:21 PM
To: Schreiber, David
Subject: score over length search request, 10/023,782

Hello
I need a score over length nucleotide sequence search on nucleobases 1529 through 2087 or SEQ ID NO:3 in the above entitled case. I need the lower and upper limits to be 8 and 50, respectively, I need any hits that are above 65% complementarity, and please transfer as many hits into the excel program as possible. Please do not search the interference databases at this time.

Thanks,
Doug Schultz

James Douglas Schultz, PhD
AU 1635 (Biotechnology)
Patent Examiner
United States Patent and Trademark Office
(Office) REM 2D18
(Mail) REM 2C18
(571) 272-0763

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 65%.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 08:37:42 ; Search time 0.001 Seconds
(without alignments)
493.038 Million cell updates/sec

Title: US-10-023-782A-3
Perfect score: 559
Sequence: 1 gaagaaaggttaggagagta.....agtggtatctgacacactct 559

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 24 seqs, 441 residues

Total number of hits satisfying chosen parameters: 48

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 26 summaries

Database : rst3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.		Score	% Query Match	Length	DB	ID	Description
1		17	3.0	25	1	AZ658622	ACCESSION:AZ658622
2	c	16.8	3.0	25	1	AZ404619	ACCESSION:AZ404619
3		16.6	3.0	25	1	BH856226	ACCESSION:BH856226
4	c	15	2.7	23	1	AZ810709	ACCESSION:AZ810709
5	c	14.6	2.6	22	1	BQ595200	ACCESSION:BQ595200
6	c	13.8	2.5	21	1	AZ386904	ACCESSION:AZ386904
7	c	13.8	2.5	21	1	AZ788269	ACCESSION:AZ788269
8		13.2	2.4	19	1	AZ648404	ACCESSION:AZ648404
9	c	13.2	2.4	19	1	AZ841555	ACCESSION:AZ841555
10		13.2	2.4	20	1	AJ590206	ACCESSION:AJ590206
11	c	13	2.3	20	1	AZ834769	ACCESSION:AZ834769
12		12.8	2.3	16	1	BQ591425	ACCESSION:BQ591425
13	c	12.6	2.3	19	1	AZ595570	ACCESSION:AZ595570
14	c	11.4	2.0	15	1	AJ666289	ACCESSION:AJ666289
15		11.2	2.0	17	1	AJ684952	ACCESSION:AJ684952
16		11.2	2.0	17	1	CL436465	ACCESSION:CL436465
17		11	2.0	16	1	AJ592205	ACCESSION:AJ592205
18		10.8	1.9	14	1	AJ588201	ACCESSION:AJ588201
19		10.8	1.9	16	1	AI424037	ACCESSION:AI424037
20	c	10.8	1.9	16	1	BG926060	ACCESSION:BG926060
21		10.8	1.9	19	1	AZ595570	ACCESSION:AZ595570
22	c	10.6	1.9	25	1	BH856226	ACCESSION:BH856226
23	c	10.4	1.9	12	1	AJ666282	ACCESSION:AJ666282
24		10.4	1.9	13	1	BQ586028	ACCESSION:BQ586028
25	c	10.4	1.9	15	1	BM658732	ACCESSION:BM658732
26		10.4	1.9	15	1	CF291030	ACCESSION:CF291030

ALIGNMENTS

RESULT 1
AZ658622

```
LOCUS       AZ658622                 25 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0535F04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0535F04 R, genomic survey sequence.
ACCESSION   AZ658622
VERSION     AZ658622.1  GI:11795768
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0535  row: F  column: 04
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0535F04"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match              3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 1.7;
  Matches   20;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1781 TGAACCCCATTCTTTCCTTCTCTGA 1805
                |||  |||||||||| || | ||||
Db          1 TGACTCCCATTCTTTGCTGCACTGA 25
```

RESULT 2
AZ404619/c

```
LOCUS       AZ404619                 25 bp    DNA     linear   GSS 03-OCT-2000
```

```
DEFINITION  1M0173L20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0173L20 F, genomic survey sequence.
ACCESSION   AZ404619
VERSION     AZ404619.1  GI:10528632
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0173  row: L  column: 20
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0173L20"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             3.0%;  Score 16.8;  DB 1;  Length 25;
  Best Local Similarity   90.0%;  Pred. No. 1.9;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1869 TAGCCATTGAAATGTCAAAT 1888
              |||||||| |||| ||||||
Db         22 TAGCCATTCAAATATCAAAT 3


RESULT 3
BH856226
LOCUS       BH856226                 25 bp    DNA     linear   GSS 08-JUL-2002
DEFINITION  SALK_083159.52.35.x Arabidopsis thaliana TDNA insertion lines
            Arabidopsis thaliana genomic clone SALK_083159.52.35.x, genomic
            survey sequence.
ACCESSION   BH856226
VERSION     BH856226.1  GI:21705816
KEYWORDS    GSS.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,
            Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
            Shinn,P., Zimmerman,J. and Ecker,J.R.
  TITLE     A Sequence-Indexed Library of Insertion Mutations in the
            Arabidopsis Genome
  JOURNAL   Unpublished (2001)
COMMENT     Contact: Joseph R. Ecker
            Salk Institute Genomic Analysis Laboratory (SIGnAL)
            The Salk Institute for Biological Studies
            10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
            Tel: 858 453 4100 x1752
            Fax: 858 558 6379
            Email: ecker@salk.edu
            This is single pass sequence recovered from the left border of
            TDNA.
            Class: TDNA tagged.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /ecotype="Col-0"
                     /db_xref="taxon:3702"
                     /clone="SALK_083159.52.35.x"
                     /clone_lib="Arabidopsis thaliana TDNA insertion lines"
                     /note="PCR was performed on Arabidopsis thaliana lines
                     each of which contains  one or more TDNA insertion
                     elements. The resultant fragment for each  line was
                     directly sequenced to determine the genomic sequence at
                     the  site of insertion. Details of the protocols used can
                     be found at  http://signal.salk.edu/tdna_protocols.html"

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 2.1;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAGTGTGTAT 1998
              || ||| |||||||||| ||| ||
Db          2 TTAAAAGAAAGAAAAGAGTGAAT 24


RESULT 4
AZ810709/c
LOCUS       AZ810709                 23 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0076M20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0076M20 F, genomic survey sequence.
ACCESSION   AZ810709
VERSION     AZ810709.1  GI:12978228
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
```

```
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0076  row: M  column: 20
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 23.
FEATURES              Location/Qualifiers
     source           1. .23
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC2M0076M20"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             2.7%;  Score 15;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 3.8;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1817 TAAGTTTTAGAATCTTTTAAATA 1839
                ||||||||| ||| |||   |||
Db         23 TAAGTTTTAAAATTTTTATTATA 1


RESULT 5
BQ595200/c
LOCUS       BQ595200                 22 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012709-024-023-E04-SP6 MPIZ-ADIS-024-developing root Beta vulgaris
            cDNA clone 024-023-E04 5-PRIME, mRNA sequence.
ACCESSION   BQ595200
VERSION     BQ595200.1  GI:26124783
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 22)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 22   Std Error: 0.00
            Plate: 23  row: E  column: 04
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES              Location/Qualifiers
     source           1. .22
                      /organism="Beta vulgaris"
                      /mol_type="mRNA"
                      /cultivar="KWS2320 (double haploid, monogerm breeding
                      line)"
                      /db_xref="GABI:191654"
                      /db_xref="taxon:161934"
                      /clone="024-023-E04"
                      /tissue_type="developing root"
                      /lab_host="EMDH10B"
                      /clone_lib="MPIZ-ADIS-024-developing root"
                      /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                      cDNA library from sugar beet, library provided by KWS
                      Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                      b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                      orientation:
                      SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                      Sequencing granted in the context of the GABI-Beet
                      project, local PI: Dr. Katharina Schneider, coordinator:
                      Prof. Christian Jung;  Sequence submission managed by
                      RZPD/GABI-Primary database: http://gabi.rzpd.de"

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 4.2;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1775 TTTTTTTGAACCCCATTCTTT 1795
                ||||||  |||||| || |||
Db         22 TTTTTTGAAACCCCCTTTTTT 2


RESULT 6
AZ386904/c
LOCUS       AZ386904                 21 bp    DNA     linear   GSS 02-OCT-2000
DEFINITION  1M0146C12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0146C12 F, genomic survey sequence.
ACCESSION   AZ386904
VERSION     AZ386904.1  GI:10500604
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0146  row: C  column: 12
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
```

```
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC1M0146C12"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 5.6;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1941 TAATGGTTGGTTTTTGT 1957
                | |||||||||||  |||
Db         17 TCATGGTTGGTTTGTGT 1


RESULT 7
AZ788269/c
LOCUS       AZ788269                 21 bp    DNA     linear   GSS 16-FEB-2001
DEFINITION  2M0035D18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0035D18 F, genomic survey sequence.
ACCESSION   AZ788269
VERSION     AZ788269.1  GI:12927898
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0035  row: D  column: 18
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 21.
FEATURES             Location/Qualifiers
```

```
     source          1. .21
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0035D18"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 5.6;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACAC 1867
                || ||| ||||||||||
Db         19 CCTACACACCCACACAC 3


RESULT 8
AZ648404
LOCUS       AZ648404                 19 bp    DNA     linear   GSS 14-DEC-2000
DEFINITION  1M0517I23F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0517I23 F, genomic survey sequence.
ACCESSION   AZ648404
VERSION     AZ648404.1  GI:11780837
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0517  row: I  column: 23
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES             Location/Qualifiers
     source          1. .19
```

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0517I23"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 6;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1900 AGATCAACAGATCAACAA 1917
              | | ||||||| ||||||
Db          2 ACAACAACAGAACAACAA 19
```

RESULT 9
AZ841555/c
LOCUS AZ841555 19 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0139P06R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0139P06 R, genomic survey sequence.
ACCESSION AZ841555
VERSION AZ841555.1 GI:13011463
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 19)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0139 row: P column: 06
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
FEATURES Location/Qualifiers
source 1. .19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0139P06"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 6;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1861 CACACACTTAGCCATTGA 1878
              |||||| ||||| ||| |
Db         19 CACACATTTAGCGATTCA 2
```

RESULT 10
AJ590206
LOCUS AJ590206 20 bp DNA linear GSS 15-JAN-2004
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 565B12, genomic survey sequence.
ACCESSION AJ590206
VERSION AJ590206.1 GI:37939830
KEYWORDS GSS; left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1
AUTHORS Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F., Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G., Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2 (bases 1 to 20)
AUTHORS Balzergue,S.
TITLE Direct Submission
JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at http://dbsgap.versailles.inra.fr/publiclines/. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (http://www.genoplante.com and

```
          http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="565B12"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .20
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 6.7;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCTTTT 1774
              |||||| || | ||||||
Db          3 TTTATTTATGAGGCTTTT 20


RESULT 11
AZ834769/c
LOCUS       AZ834769                 20 bp    DNA     linear   GSS 20-FEB-2001
DEFINITION  2M0117F08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0117F08 R, genomic survey sequence.
ACCESSION   AZ834769
VERSION     AZ834769.1  GI:13004677
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0117  row: F  column: 08
            Seq primer: CACACAGGAAACAGCTATGACC
            Class: plasmid ends
            High quality sequence stop: 20.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="C57BL/6J"
                     /db_xref="taxon:10090"
                     /clone="UUGC2M0117F08"
                     /sex="Male"
                     /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                     /clone_lib="Mouse 10kb plasmid UUGC1M library"
                     /note="Vector: PWD42nv; Purified genomic DNA from M.
                     musculus C57BL/6J (male) was obtained  from the Jackson
                     Laboratory Mouse DNA Resource
                     (http://www.jax.org/resources/documents/dnares/). The DNA
                     was hydrodynamically sheared by repeated passage through a
                     0.005 inch orifice at constant velocity. The sheared DNA
                     was blunt end-repaired with T4 DNA polymerase and T4
                     polynucleotide kinase. Adaptor oligonucleotides were
                     ligated to the blunt ends in high  molar excess. The
                     adaptored DNA was purified and size-selected for a 9.5 to
                     10.5 kb range using preparative agarose gel
                     electrophoresis. Vector DNA was prepared from a derivative
                     of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                     inducible derivative of plasmid R1. The vector was ligated
                     with adaptors complementary to the insert adaptors and
                     purified. The sheared, adaptored mouse DNA was annealed to
                     adaptored vector DNA, and transformed into
                     chemically-competent E. coli XL10-Gold (Stratagene) cells
                     and selected for ampicillin resistance."

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 7.4;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1947 TTGGTTTTGTGT 1959
              ||||||||||||
Db         18 TTGGTTTTGTGT 6


RESULT 12
BQ591425
LOCUS       BQ591425                 16 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012712-024-017-C11-T7 MPIZ-ADIS-024-storage root Beta vulgaris
            cDNA clone 024-017-C11 3-PRIME, mRNA sequence.
ACCESSION   BQ591425
VERSION     BQ591425.1  GI:26121008
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 16   Std Error: 0.00
            Plate: 17  row: C  column: 11
            Seq primer: T7; GTAATACGACTCACTATAGGGC.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:188698"
                     /db_xref="taxon:161934"
                     /clone="024-017-C11"
                     /tissue_type="storage root"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-storage root"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
```

RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 2.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 4.9;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1632 CCTTACTATTTAAAGA 1647
              |||||||||| ||| |
Db          1 CCTTACTATTAAAAAA 16
```

RESULT 13
AZ595570/c
LOCUS AZ595570 19 bp DNA linear GSS 13-DEC-2000
DEFINITION 1M0408I15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0408I15 F, genomic survey sequence.
ACCESSION AZ595570
VERSION AZ595570.1 GI:11717760
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 19)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0408 row: I column: 15
Seq primer: CGTTGTAAAACGACGGCCAGT
Class: plasmid ends
High quality sequence stop: 19.
FEATURES Location/Qualifiers
source 1. .19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0408I15"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 8;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       2032 AGGCAAAGGTTCTATCTGC 2050
              |||||||| ||  | ||||
Db         19 AGGCAAAGTTTGGAGCTGC 1
```

RESULT 14
AJ666289/c
LOCUS AJ666289 15 bp mRNA linear EST 28-JUN-2004
DEFINITION AJ666289 CSEQRAN09 Sus scrofa cDNA clone C0000033_L14, mRNA sequence.
ACCESSION AJ666289
VERSION AJ666289.1 GI:49350740
KEYWORDS EST.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 15)
AUTHORS Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
TITLE Development of cDNA and EST resources for studying reproduction and embryo development in pigs and cattle
JOURNAL Unpublished (2004)
COMMENT Contact: Anderson SI
Genomics and Bioinformatics
Roslin Institute
Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
Single pass sequencing. Bases called and trimmed with phred v0.020425.c. Vector identified by cross_match with the -minscore 20 and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1: EcoRI R. Site 2: NotI Description: Normalised library constructed from pooled tissue from day 30 placentas. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institite, Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.
FEATURES Location/Qualifiers
source 1. .15
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="C0000033_L14"
/tissue_type="placenta"
/clone_lib="CSEQRAN09"
/note="Vector: pBlueScriptII(KS+); Site_1: EcoRI; Site_2: NotI; Single pass sequencing. Normalised library constructed from pooled tissue from day 30 placentas."

Query Match 2.0%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 8.5;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1583 CGCACAGACTGGG 1595
              ||| |||||||||
Db         13 CGCCCAGACTGGG 1
```

RESULT 15
AJ684952
LOCUS AJ684952 17 bp mRNA linear EST 29-JUN-2004
DEFINITION AJ684952 CSEQRAN04 Sus scrofa cDNA clone C0001807_H20, mRNA sequence.
ACCESSION AJ684952
VERSION AJ684952.1 GI:49417542
KEYWORDS EST.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 17)
AUTHORS Anderson,S.I., Finlayson,H.A. and Archibald,A.L.

```
  TITLE     Development of cDNA and EST resources for studying reproduction and
            embryo development in pigs and cattle
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Anderson SI
            Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
            Single pass sequencing. Bases called and trimmed with phred
            v0.020425.c. Vector identified by cross_match with the -minscore 20
            and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site1: EcoRI
            R. Site2: NotI 5' Seq Primer M13F Normalised library constructed
            from pig uterus. Clones available from UK Centre for Functional
            Genomics in Farm Animals, Roslin Institite, Roslin, Midlothian, UK,
            EH25 9PS, www.arkgenomics.org.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
                     /clone="C0001807_H20"
                     /tissue_type="uterus"
                     /clone_lib="CSEQRAN04"
                     /note="Vector: pBlueScriptII(KS+); Site_1: EcoRI; Site_2:
                     NotI; Single pass sequencing. Normalised library
                     constructed from pig uterus."

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 12;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
              || || || |||||||
Db          2 CCTCACTCCTTCCTTC 17


RESULT 16
CL436465
LOCUS       CL436465                 17 bp    DNA     linear   GSS 18-MAR-2004
DEFINITION  PST3066-NR.Seq MICB1 Mus musculus genomic clone PST3066-NR.Seq
            similar to 3110002K08Rik, genomic survey sequence.
ACCESSION   CL436465
VERSION     CL436465.1  GI:45571286
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Hicks,G.G.
  TITLE     www.EScells.ca
  JOURNAL   Unpublished (2002)
COMMENT     Contact: Hicks GG
            Mammalian Functional Genomics Centre
            Manitoba Institute of Cell Biology, Universitry of Manitoba
            ON5029, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada
            Tel: 204 787 2133
            Fax: 204 787 2190
            Email: hicksgg@cc.umanitoba.ca
            U3NeoSV1 gene trap. Tag generated by plasmid rescue. Additional
            sequence information and target gene cloning can be generated. ES
            cell line harboring insertion mutation of target gene is available.
            Sequence analysis available from
            http://140.193.242.7/esdb/public_search_frame.php?PST=PST3066-NR.Se
            q
            Class: Gene Trap.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /strain="129 sv"
                     /db_xref="taxon:10090"
                     /clone="PST3066-NR.Seq"
                     /sex="Male"
                     /cell_type="Embryonic stem cell"
                     /cell_line="D3H (J1 subclone)"
                     /clone_lib="MICB1"
                     /note="Vector: U3NeoSV1"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 12;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1849 GGCCAACAGACCCACA 1864
              | |||||||||| || |
Db          2 GACCAACAGACACATA 17


RESULT 17
AJ592205
LOCUS       AJ592205                 16 bp    DNA     linear   GSS 15-JAN-2004
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            368G08, genomic survey sequence.
ACCESSION   AJ592205
VERSION     AJ592205.1  GI:37941829
KEYWORDS    GSS; left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 16)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="368G08"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .16
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             2.0%;  Score 11;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 12;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTT 1955
              |||||||||||
Db          6 GGTTGGTTTTT 16
```

```
RESULT 18
AJ588201
LOCUS       AJ588201                 14 bp    DNA     linear   GSS 15-JAN-2004
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            352C02, genomic survey sequence.
ACCESSION   AJ588201
VERSION     AJ588201.1  GI:37937825
KEYWORDS    GSS; left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 14)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="Arabidopsis thaliana"
                     /mol_type="genomic DNA"
                     /cultivar="Wassillewskija"
                     /db_xref="taxon:3702"
                     /clone="352C02"
                     /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature    1. .14
                     /note="T-DNA flanking sequence
                     left border"

  Query Match             1.9%;  Score 10.8;  DB 1;  Length 14;
  Best Local Similarity   85.7%;  Pred. No. 9.8;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1820 GTTTTAGAATCTTT 1833
              ||||||| | ||||
Db          1 GTTTTAGGAACTTT 14


RESULT 19
AI424037
LOCUS       AI424037                 16 bp    mRNA    linear   EST 09-MAR-1999
DEFINITION  tf51h06.x1 NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE:2102843 3'
            similar to TR:Q69566 Q69566 ;, mRNA sequence.
ACCESSION   AI424037
VERSION     AI424037.1  GI:4269968
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   NCI/NINDS-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute / National Institute of Neurological
            Disorders and Stroke, Brain Tumor Genome Anatomy Project
            (CGAP/BTGAP), Tumor Gene Index
  JOURNAL   Unpublished (1998)
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: David N. Louis, M.D., Myrna R. Rosenfeld M.D.,
            Ph.D.
             cDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima
            Bonaldo, Ph.D.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html

            Trace considered overall poor quality
            Seq primer: -40UP from Gibco
            High quality sequence stop: 1.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:2102843"
                     /tissue_type="glioblastoma (pooled)"
                     /lab_host="DH10B"
                     /clone_lib="NCI_CGAP_Brn23"
                     /note="Organ: brain; Vector: pT7T3D-Pac (Pharmacia) with a
                     modified polylinker; Site_1: Not I; Site_2: Eco RI; 1st
                     strand cDNA was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCATATCTTTTTTTTTTTTTTTTTTTTTTT
                     T 3']; double-stranded cDNA was ligated to Eco RI
                     adaptors (Pharmacia), digested with Not I and cloned into
                     the Not I and Eco RI sites of the modified pT7T3 vector.
                     Library is normalized, and was constructed by Bento
                     Soares and M.Fatima Bonaldo."

  Query Match             1.9%;  Score 10.8;  DB 1;  Length 16;
  Best Local Similarity   85.7%;  Pred. No. 13;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              ||| || |||||||
Db          1 ACATACACACACAC 14


RESULT 20
BG926060/c
LOCUS       BG926060                 16 bp    mRNA    linear   EST 06-NOV-2001
DEFINITION  HNC23-1-E1.R HNC (Human Normal Cartilage) Homo sapiens cDNA, mRNA
            sequence.
ACCESSION   BG926060
VERSION     BG926060.1  GI:14320583
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Kumar,S., Connor,J.R., Dodds,R.A., Halsey,W., Van Horn,M., Mao,J.,
            Sathe,G., Mui,P., Agarwal,P., Badger,A.M., Lee,J.C., Gowen,M. and
            Lark,M.W.
  TITLE     Identification and initial characterization of 5000 expressed
            sequenced tags (ESTs) each from adult human normal and
            osteoarthritic cartilage cDNA libraries
  JOURNAL   Osteoarthr. Cartil. 9 (7), 641-653 (2001)
  MEDLINE   21482651
   PUBMED   11597177
COMMENT     Contact: Sanjay Kumar
            UW2109
            GlaxoSmithKline
            709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406, USA
```

```
            Tel: 610-270-7245
            Fax: 610-270-5598
            Email: sanjay_kumar-1@gsk.com
            Seq primer: T7.
FEATURES              Location/Qualifiers
     source           1. .16
                      /organism="Homo sapiens"
                      /mol_type="mRNA"
                      /db_xref="taxon:9606"
                      /tissue_type="cartilage"
                      /lab_host="E.coli DH10 B"
                      /clone_lib="HNC (Human Normal Cartilage)"
                      /note="Vector: pSPORT I; Site_1: SalI; Site_2: NotI;
                      Directional"

  Query Match             1.9%;  Score 10.8;  DB 1;  Length 16;
  Best Local Similarity   85.7%;  Pred. No. 13;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1549 GGGAAGGAACAGGA 1562
              ||||||||| || |
Db         16 GGGAAGGAAGAGAA 3


RESULT 21
AZ595570
LOCUS       AZ595570                 19 bp    DNA     linear   GSS 13-DEC-2000
DEFINITION  1M0408I15F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC1M0408I15 F, genomic survey sequence.
ACCESSION   AZ595570
VERSION     AZ595570.1  GI:11717760
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
            Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D.,Weiss,R.
  TITLE     Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
  JOURNAL   Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000   Std Error: 0.00
            Plate: 0408  row: I  column: 15
            Seq primer: CGTTGTAAAACGACGGCCAGT
            Class: plasmid ends
            High quality sequence stop: 19.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Mus musculus"
                      /mol_type="genomic DNA"
                      /strain="C57BL/6J"
                      /db_xref="taxon:10090"
                      /clone="UUGC1M0408I15"
                      /sex="Male"
                      /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
                      /clone_lib="Mouse 10kb plasmid UUGC1M library"
                      /note="Vector: PWD42nv; Purified genomic DNA from M.
                      musculus C57BL/6J (male) was obtained  from the Jackson
                      Laboratory Mouse DNA Resource
                      (http://www.jax.org/resources/documents/dnares/). The DNA
                      was hydrodynamically sheared by repeated passage through a
                      0.005 inch orifice at constant velocity. The sheared DNA
                      was blunt end-repaired with T4 DNA polymerase and T4
                      polynucleotide kinase. Adaptor oligonucleotides were
                      ligated to the blunt ends in high  molar excess. The
                      adaptored DNA was purified and size-selected for a 9.5 to
                      10.5 kb range using preparative agarose gel
                      electrophoresis. Vector DNA was prepared from a derivative
                      of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
                      inducible derivative of plasmid R1. The vector was ligated
                      with adaptors complementary to the insert adaptors and
                      purified. The sheared, adaptored mouse DNA was annealed to
                      adaptored vector DNA, and transformed into
                      chemically-competent E. coli XL10-Gold (Stratagene) cells
                      and selected for ampicillin resistance."

  Query Match             1.9%;  Score 10.8;  DB 1;  Length 19;
  Best Local Similarity   85.7%;  Pred. No. 18;
  Matches   12;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1710 ATCTCCTAACTTTG 1723
              | |||| |||||||
Db          3 AGCTCCAAACTTTG 16


RESULT 22
BH856226/c
LOCUS       BH856226                 25 bp    DNA     linear   GSS 08-JUL-2002
DEFINITION  SALK_083159.52.35.x Arabidopsis thaliana TDNA insertion lines
            Arabidopsis thaliana genomic clone SALK_083159.52.35.x, genomic
            survey sequence.
ACCESSION   BH856226
VERSION     BH856226.1  GI:21705816
KEYWORDS    GSS.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,
            Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
            Shinn,P., Zimmerman,J. and Ecker,J.R.
  TITLE     A Sequence-Indexed Library of Insertion Mutations in the
            Arabidopsis Genome
  JOURNAL   Unpublished (2001)
COMMENT     Contact: Joseph R. Ecker
            Salk Institute Genomic Analysis Laboratory (SIGnAL)
            The Salk Institute for Biological Studies
            10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
            Tel: 858 453 4100 x1752
            Fax: 858 558 6379
            Email: ecker@salk.edu
            This is single pass sequence recovered from the left border of
            TDNA.
            Class: TDNA tagged.
FEATURES              Location/Qualifiers
     source           1. .25
                      /organism="Arabidopsis thaliana"
                      /mol_type="genomic DNA"
                      /ecotype="Col-0"
                      /db_xref="taxon:3702"
                      /clone="SALK_083159.52.35.x"
                      /clone_lib="Arabidopsis thaliana TDNA insertion lines"
                      /note="PCR was performed on Arabidopsis thaliana lines
                      each of which contains  one or more TDNA insertion
                      elements. The resultant fragment for each  line was
                      directly sequenced to determine the genomic sequence at
                      the  site of insertion. Details of the protocols used can
                      be found at  http://signal.salk.edu/tdna_protocols.html"

  Query Match             1.9%;  Score 10.6;  DB 1;  Length 25;
  Best Local Similarity   64.0%;  Pred. No. 26;
  Matches   16;  Conservative    0;  Mismatches    9;  Indels    0;  Gaps    0;
```

```
Qy       1783 AACCCCATTCTTTCCTTCTCTGAAA 1807
              ||  |  |  |||| |||| | |||
Db         25 AATTCACTCTTTTCTTTCTTTTAAA 1
```

```
RESULT 23
AJ666282/c
LOCUS       AJ666282                 12 bp    mRNA    linear   EST 28-JUN-2004
DEFINITION  AJ666282 CSEQRAN09 Sus scrofa cDNA clone C0000033_B14, mRNA
            sequence.
ACCESSION   AJ666282
VERSION     AJ666282.1  GI:49350733
KEYWORDS    EST.
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE   1  (bases 1 to 12)
  AUTHORS   Anderson,S.I., Finlayson,H.A. and Archibald,A.L.
  TITLE     Development of cDNA and EST resources for studying reproduction and
            embryo development in pigs and cattle
  JOURNAL   Unpublished (2004)
COMMENT     Contact: Anderson SI
            Genomics and Bioinformatics
            Roslin Institute
            Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
            Single pass sequencing. Bases called and trimmed with phred
            v0.020425.c. Vector identified by cross_match with the -minscore 20
            and -minmatch 12 options. Vector:pBlueScriptII(KS+) R. Site 1:
            EcoRI R. Site 2: NotI Description: Normalised library constructed
            from pooled tissue from day 30 placentas. Clones available from UK
            Centre for Functional Genomics in Farm Animals, Roslin Institite,
            Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.
FEATURES             Location/Qualifiers
     source          1. .12
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
                     /clone="C0000033_B14"
                     /tissue_type="placenta"
                     /clone_lib="CSEQRAN09"
                     /note="Vector: pBlueScriptII(KS+); Site_1: EcoRI; Site_2:
                     NotI; Single pass sequencing. Normalised library
                     constructed from pooled tissue from day 30 placentas."

  Query Match             1.9%;  Score 10.4;  DB 1;  Length 12;
  Best Local Similarity   91.7%;  Pred. No. 8.5;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1809 TGGTGCTATAAG 1820
              ||||| ||||||
Db         12 TGGTGGTATAAG 1

RESULT 24
BQ586028
LOCUS       BQ586028                 13 bp    mRNA    linear   EST 06-DEC-2002
DEFINITION  E012394-024-013-F21-SP6 MPIZ-ADIS-024-leaf Beta vulgaris cDNA clone
            024-013-F21 5-PRIME, mRNA sequence.
ACCESSION   BQ586028
VERSION     BQ586028.1  GI:26115610
KEYWORDS    EST.
SOURCE      Beta vulgaris
  ORGANISM  Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
            Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
            and Radelof,U.
  TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
            fingerprinting allows access to 25 000 potential sugar beet genes
  JOURNAL   Plant J. 32 (5), 845-857 (2002)
  MEDLINE   22362189
   PUBMED   12472698
COMMENT     Contact: Weisshaar B
            ADIS DNA core facility at MPIZ
            Max-Planck-Institute for Plant Breeding Research
            Carl-von-Linne Weg 10, 50829 Koeln, Germany
            Fax: 00492215062851
            Email: weisshaa@mpiz-koeln.mpg.de
            Insert Length: 13   Std Error: 0.00
            Plate: 13  row: F  column: 21
            Seq primer: SP6; CATACGATTTAGGTGACACTATAG.
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Beta vulgaris"
                     /mol_type="mRNA"
                     /cultivar="KWS2320 (double haploid, monogerm breeding
                     line)"
                     /db_xref="GABI:186838"
                     /db_xref="taxon:161934"
                     /clone="024-013-F21"
                     /tissue_type="leaf"
                     /lab_host="EMDH10B"
                     /clone_lib="MPIZ-ADIS-024-leaf"
                     /note="Vector: pCMVSPORT6; Site_1: SalI; Site_2: NotI;
                     cDNA library from sugar beet, library provided by KWS
                     Kleinwanzlebener Saatzucht AG Einbeck, Germany, contact:
                     b.schulz@kws.de; cloning sites SalI-NotI, primer sites and
                     orientation:
                     SP6-SalI-CCACGCGTCCG-5prime-cDNA-polyA-CC-NotI-T7;  Note:
                     Sequencing granted in the context of the GABI-Beet
                     project, local PI: Dr. Katharina Schneider, coordinator:
                     Prof. Christian Jung;  Sequence submission managed by
                     RZPD/GABI-Primary database:http://gabi.rzpd.de"

  Query Match             1.9%;  Score 10.4;  DB 1;  Length 13;
  Best Local Similarity   91.7%;  Pred. No. 10;
  Matches   11;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2046 TCTGCTTAGCAA 2057
              |||||||| |||
Db          2 TCTGCTTAACAA 13

RESULT 25
BM658732/c
LOCUS       BM658732                 15 bp    mRNA    linear   EST 27-FEB-2002
DEFINITION  LZV602768445.R1 CSEQFXL37 pig adrenal Sus scrofa cDNA, mRNA
            sequence.
ACCESSION   BM658732
VERSION     BM658732.1  GI:18959003
KEYWORDS    EST.
SOURCE      Sus scrofa (pig)
  ORGANISM  Sus scrofa
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Adelson,D.L. and Gill,C.A.
  TITLE     Porcine ESTs
  JOURNAL   Unpublished (2002)
COMMENT     Contact: David L. Adelson
            Animal Breeding and Genetics
            Texas A&M University
            Animal Science Dept., TAMU-2471, College Station, TX 77843-2471,
            USA
            Tel: 9798452616
            Fax: 9798456970
            Email: david.adelson@tamu.edu.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="Sus scrofa"
                     /mol_type="mRNA"
                     /db_xref="taxon:9823"
```

/clone_lib="CSEQFXL37 pig adrenal"
/note="Organ: adrenal gland; Vector: pBluescript SK+;
Site_1: NotI; Site_2: EcoRI; sequence 5' of the insert
(5'-NNN. . .NNNinsert)
GCGAATTGGAGCTCCACCGCGGTGGCGGCCGCGGCTCGAG. Sequence 3' of
the inserts (AAGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAG.
non-normalized library, sequenced 3' with M13R primer."

Query Match 1.9%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 14;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1979 AAAAAAAGAAAA 1990
              |||||| |||||
Db         14 AAAAAACGAAAA 3
```

RESULT 26
CF291030
LOCUS CF291030 15 bp mRNA linear EST 14-AUG-2003
DEFINITION 14ROOT--01-E19.g1 Rice root plasmid cDNA library (14ROOT) Oryza sativa (japonica cultivar-group) cDNA clone 14ROOT--01-E19, mRNA sequence.
ACCESSION CF291030
VERSION CF291030.1 GI:33660063
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.
REFERENCE 1 (bases 1 to 15)
AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, MyongJi University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES Location/Qualifiers
source 1. .15
/organism="Oryza sativa (japonica cultivàr-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="14ROOT--01-E19"
/tissue_type="root"
/dev_stage="14 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice root plasmid cDNA library (14ROOT)"
/note="Vector: pCR4-TOPO; Site_1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 1.9%; Score 10.4; DB 1; Length 15;
Best Local Similarity 91.7%; Pred. No. 14;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1979 AAAAAAAGAAAA 1990
              ||||||| ||||
Db          1 AAAAAAATAAAA 12
```

Search completed: November 8, 2004, 08:37:43
Job time : 1 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 08:36:03 ; Search time 6 Seconds
(without alignments)
3.326 Million cell updates/sec

Title: US-10-023-782A-3
Perfect score: 559
Sequence: 1 gaagaaaggttaggagagta.....agtggtatctgacacactct 559

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 981 seqs, 17848 residues

Total number of hits satisfying chosen parameters: 1962

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 995 summaries

Database : rnpb3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20	3.6	20	1	US-10-023-782A-55	Sequence 55, Appl
c	2	20	3.6	20	1	US-10-023-782A-56	Sequence 56, Appl
c	3	20	3.6	20	1	US-10-023-782A-57	Sequence 57, Appl
c	4	20	3.6	20	1	US-10-023-782A-58	Sequence 58, Appl
c	5	20	3.6	20	1	US-10-023-782A-59	Sequence 59, Appl
c	6	20	3.6	20	1	US-10-023-782A-60	Sequence 60, Appl
c	7	20	3.6	20	1	US-10-023-782A-61	Sequence 61, Appl
c	8	20	3.6	20	1	US-10-023-782A-62	Sequence 62, Appl
c	9	20	3.6	20	1	US-10-023-782A-63	Sequence 63, Appl
c	10	20	3.6	20	1	US-10-023-782A-64	Sequence 64, Appl
c	11	20	3.6	20	1	US-10-023-782A-65	Sequence 65, Appl
c	12	20	3.6	20	1	US-10-023-782A-66	Sequence 66, Appl
	13	18.2	3.3	23	1	US-10-158-735-22	Sequence 22, Appl
c	14	17.2	3.1	25	1	US-10-206-561-3	Sequence 3, Appli
c	15	17	3.0	25	1	US-10-098-263B-2693	Sequence 2693, Ap
c	16	17	3.0	25	1	US-10-098-263B-3329	Sequence 3329, Ap
	17	17	3.0	25	1	US-10-098-263B-61992	Sequence 61992, A
c	18	17	3.0	25	1	US-10-339-674-1277	Sequence 1277, Ap
c	19	16.6	3.0	25	1	US-10-098-263B-99036	Sequence 99036, A
	20	16.4	2.9	20	1	US-10-277-216-162	Sequence 162, App
	21	16.4	2.9	20	1	US-10-126-022-162	Sequence 162, App
c	22	16.4	2.9	21	1	US-10-786-720-11753	Sequence 11753, A
	23	16.2	2.9	21	1	US-10-349-143-8160	Sequence 8160, Ap
	24	16.2	2.9	21	1	US-10-786-720-191	Sequence 191, App
c	25	16	2.9	19	1	US-10-357-567-71	Sequence 71, Appl
	26	16	2.9	21	1	US-10-786-720-12408	Sequence 12408, A
c	27	15.8	2.8	20	1	US-10-148-188-15	Sequence 15, Appl
c	28	15.8	2.8	22	1	US-10-449-741B-30	Sequence 30, Appl
	29	15.4	2.8	19	1	US-10-265-689-23	Sequence 23, Appl
c	30	15.4	2.8	20	1	US-09-935-464-8	Sequence 8, Appli
c	31	15.4	2.8	20	1	US-10-125-835-8	Sequence 8, Appli
	32	15.4	2.8	20	1	US-10-265-689-21	Sequence 21, Appl
c	33	15.4	2.8	21	1	US-10-786-720-11752	Sequence 11752, A
	34	15.4	2.8	21	1	US-10-786-720-11754	Sequence 11754, A
	35	15.4	2.8	23	1	US-10-363-514-5	Sequence 5, Appli
	36	15.2	2.7	20	1	US-10-007-814-29	Sequence 29, Appl
	37	15.2	2.7	20	1	US-10-002-491-85	Sequence 85, Appl
	38	15.2	2.7	20	1	US-10-084-555-53	Sequence 53, Appl
	39	15.2	2.7	20	1	US-10-671-395-1626	Sequence 1626, Ap
	40	15.2	2.7	21	1	US-10-786-720-6806	Sequence 6806, Ap
	41	15.2	2.7	21	1	US-10-786-720-9074	Sequence 9074, Ap
c	42	15.2	2.7	23	1	US-10-466-836-21	Sequence 21, Appl
c	43	15	2.7	20	1	US-10-186-157-76	Sequence 76, Appl
c	44	15	2.7	21	1	US-10-786-720-11755	Sequence 11755, A
	45	15	2.7	21	1	US-10-786-720-11757	Sequence 11757, A
c	46	15	2.7	21	1	US-10-786-720-12406	Sequence 12406, A
	47	15	2.7	23	1	US-10-204-254A-101	Sequence 101, App
	48	15	2.7	23	1	US-10-635-145-7	Sequence 7, Appli
	49	14.8	2.6	19	1	US-10-275-071-6	Sequence 6, Appli
c	50	14.8	2.6	20	1	US-09-767-421-69	Sequence 69, Appl
c	51	14.8	2.6	20	1	US-10-300-820-49	Sequence 49, Appl
	52	14.8	2.6	20	1	US-10-300-820-124	Sequence 124, App
c	53	14.8	2.6	20	1	US-10-316-389-85	Sequence 85, Appl
c	54	14.8	2.6	21	1	US-10-136-860-17	Sequence 17, Appl
c	55	14.8	2.6	21	1	US-10-786-720-12071	Sequence 12071, A
	56	14.6	2.6	21	1	US-10-786-720-190	Sequence 190, App
c	57	14.6	2.6	21	1	US-10-786-720-12407	Sequence 12407, A
c	58	14.6	2.6	21	1	US-10-786-720-12564	Sequence 12564, A
	59	14.6	2.6	22	1	US-09-881-572A-22	Sequence 22, Appl
	60	14.6	2.6	22	1	US-10-005-469-7	Sequence 7, Appli
	61	14.6	2.6	22	1	US-10-434-842-7	Sequence 7, Appli
c	62	14.6	2.6	22	1	US-10-236-392-269	Sequence 269, App
	63	14.4	2.6	19	1	US-09-985-335-8	Sequence 8, Appli
	64	14.4	2.6	19	1	US-09-771-933-177	Sequence 177, App
	65	14.4	2.6	19	1	US-10-265-689-15	Sequence 15, Appl
	66	14.4	2.6	20	1	US-09-848-585-35	Sequence 35, Appl
c	67	14.4	2.6	20	1	US-10-289-762-4828	Sequence 4828, Ap
	68	14.4	2.6	20	1	US-10-289-762-6111	Sequence 6111, Ap
	69	14.4	2.6	20	1	US-10-642-149-35	Sequence 35, Appl
c	70	14.4	2.6	20	1	US-10-293-863-24	Sequence 24, Appl
	71	14.4	2.6	20	1	US-10-293-863-59	Sequence 59, Appl
	72	14.4	2.6	21	1	US-09-294-764-1	Sequence 1, Appli
	73	14.4	2.6	21	1	US-10-786-720-91	Sequence 91, Appl
	74	14.4	2.6	21	1	US-10-786-720-92	Sequence 92, Appl
c	75	14.4	2.6	21	1	US-10-786-720-93	Sequence 93, Appl
	76	14.4	2.6	21	1	US-10-786-720-274	Sequence 274, App
	77	14.4	2.6	21	1	US-10-786-720-275	Sequence 275, App
c	78	14.4	2.6	21	1	US-10-786-720-276	Sequence 276, App
c	79	14.4	2.6	21	1	US-10-786-720-12070	Sequence 12070, A
	80	14.4	2.6	21	1	US-10-786-720-12072	Sequence 12072, A
	81	14.4	2.6	22	1	US-09-771-933-204	Sequence 204, App
	82	14.4	2.6	22	1	US-10-132-080-5	Sequence 5, Appli
	83	14.4	2.6	22	1	US-10-125-690-3	Sequence 3, Appli
	84	14.4	2.6	22	1	US-10-100-556-5	Sequence 5, Appli
	85	14.4	2.6	22	1	US-10-100-218-5	Sequence 5, Appli
	86	14.4	2.6	22	1	US-10-134-296-5	Sequence 5, Appli
	87	14.4	2.6	22	1	US-10-141-533-5	Sequence 5, Appli
	88	14.4	2.6	22	1	US-10-072-611-3	Sequence 3, Appli
	89	14.4	2.6	22	1	US-10-135-185-5	Sequence 5, Appli
	90	14.4	2.6	22	1	US-10-125-693-3	Sequence 3, Appli
	91	14.4	2.6	22	1	US-10-164-854-5	Sequence 5, Appli
	92	14.4	2.6	22	1	US-10-087-996-5	Sequence 5, Appli
	93	14.4	2.6	22	1	US-10-100-230-5	Sequence 5, Appli
	94	14.4	2.6	22	1	US-10-100-272-5	Sequence 5, Appli
	95	14.4	2.6	22	1	US-10-325-466-5	Sequence 5, Appli
	96	14.4	2.6	22	1	US-10-151-467A-5	Sequence 5, Appli
	97	14.4	2.6	22	1	US-10-124-747-5	Sequence 5, Appli
	98	14.4	2.6	22	1	US-10-307-204-5	Sequence 5, Appli
	99	14.4	2.6	22	1	US-10-607-848-5	Sequence 5, Appli
	100	14.4	2.6	22	1	US-10-307-210-5	Sequence 5, Appli
c	101	14.2	2.5	19	1	US-10-665-951-199	Sequence 199, App
	102	14.2	2.5	19	1	US-10-665-951-311	Sequence 311, App
	103	14.2	2.5	19	1	US-10-665-951-626	Sequence 626, App
c	104	14.2	2.5	19	1	US-10-665-951-738	Sequence 738, App
	105	14.2	2.5	19	1	US-10-665-951-882	Sequence 882, App
c	106	14.2	2.5	19	1	US-10-665-951-1206	Sequence 1206, Ap

107	14.2	2.5	20	1	US-09-920-394-25	Sequence 25, Appl
c 108	14.2	2.5	20	1	US-10-057-550-121	Sequence 121, App
c 109	14.2	2.5	20	1	US-10-173-225B-99	Sequence 99, Appl
110	14.2	2.5	20	1	US-10-094-749-3339	Sequence 3339, Ap
111	14.2	2.5	20	1	US-10-159-266-72	Sequence 72, Appl
c 112	14.2	2.5	20	1	US-10-159-266-145	Sequence 145, App
113	14.2	2.5	20	1	US-10-177-554-75	Sequence 75, Appl
c 114	14.2	2.5	20	1	US-10-289-762-5020	Sequence 5020, Ap
115	14.2	2.5	20	1	US-10-210-833-45	Sequence 45, Appl
c 116	14.2	2.5	20	1	US-10-210-833-145	Sequence 145, App
117	14.2	2.5	20	1	US-10-671-395-1678	Sequence 1678, Ap
118	14.2	2.5	20	1	US-10-671-395-1694	Sequence 1694, Ap
c 119	14.2	2.5	21	1	US-09-918-779-50	Sequence 50, Appl
c 120	14.2	2.5	21	1	US-10-345-092-50	Sequence 50, Appl
121	14.2	2.5	21	1	US-10-032-585-4086	Sequence 4086, Ap
122	14.2	2.5	21	1	US-10-084-555-55	Sequence 55, Appl
123	14.2	2.5	21	1	US-10-388-263-911	Sequence 911, App
c 124	14.2	2.5	21	1	US-10-388-263-947	Sequence 947, App
c 125	14.2	2.5	21	1	US-10-336-552-3	Sequence 3, Appli
126	14.2	2.5	21	1	US-10-336-213B-88	Sequence 88, Appl
c 127	14.2	2.5	21	1	US-10-624-932-50	Sequence 50, Appl
c 128	14.2	2.5	21	1	US-10-786-720-192	Sequence 192, App
129	14.2	2.5	21	1	US-10-786-720-358	Sequence 358, App
130	14.2	2.5	21	1	US-10-786-720-8090	Sequence 8090, Ap
131	14.2	2.5	21	1	US-10-786-720-10322	Sequence 10322, A
c 132	14.2	2.5	21	1	US-10-786-720-15052	Sequence 15052, A
c 133	14.2	2.5	21	1	US-10-786-720-15053	Sequence 15053, A
134	14.2	2.5	21	1	US-10-786-720-15054	Sequence 15054, A
135	14	2.5	20	1	US-09-854-883-32	Sequence 32, Appl
c 136	14	2.5	20	1	US-10-181-107-130	Sequence 130, App
137	14	2.5	20	1	US-10-360-510-32	Sequence 32, Appl
c 138	14	2.5	20	1	US-10-173-817-30	Sequence 30, Appl
c 139	14	2.5	20	1	US-10-643-432-30	Sequence 30, Appl
140	14	2.5	21	1	US-10-786-720-19526	Sequence 19526, A
c 141	13.8	2.5	17	1	US-09-866-108-1346	Sequence 1346, Ap
c 142	13.8	2.5	17	1	US-09-866-108-7642	Sequence 7642, Ap
c 143	13.8	2.5	17	1	US-09-866-108-7643	Sequence 7643, Ap
144	13.8	2.5	17	1	US-09-730-289B-867	Sequence 867, App
c 145	13.8	2.5	17	1	US-10-723-361-1346	Sequence 1346, Ap
c 146	13.8	2.5	17	1	US-10-723-361-7642	Sequence 7642, Ap
c 147	13.8	2.5	17	1	US-10-723-361-7643	Sequence 7643, Ap
148	13.8	2.5	18	1	US-09-969-373-2654	Sequence 2654, Ap
149	13.8	2.5	19	1	US-09-901-484A-46	Sequence 46, Appl
150	13.8	2.5	19	1	US-09-901-484A-380	Sequence 380, App
151	13.8	2.5	19	1	US-09-853-526-46	Sequence 46, Appl
152	13.8	2.5	19	1	US-09-853-526-380	Sequence 380, App
153	13.8	2.5	19	1	US-10-225-023-79	Sequence 79, Appl
154	13.8	2.5	19	1	US-10-225-023-120	Sequence 120, App
155	13.8	2.5	19	1	US-10-225-023-164	Sequence 164, App
c 156	13.8	2.5	19	1	US-10-225-023-817	Sequence 817, App
c 157	13.8	2.5	19	1	US-10-225-023-858	Sequence 858, App
c 158	13.8	2.5	19	1	US-10-225-023-902	Sequence 902, App
c 159	13.8	2.5	19	1	US-10-346-514-2	Sequence 2, Appli
160	13.8	2.5	19	1	US-10-282-174-182	Sequence 182, App
161	13.8	2.5	19	1	US-10-349-143-7856	Sequence 7856, Ap
162	13.8	2.5	19	1	US-10-333-429-549	Sequence 549, App
c 163	13.8	2.5	20	1	US-09-280-030-46	Sequence 46, Appl
c 164	13.8	2.5	20	1	US-09-944-036-47	Sequence 47, Appl
165	13.8	2.5	20	1	US-09-946-406-15	Sequence 15, Appl
166	13.8	2.5	20	1	US-09-784-674-556	Sequence 556, App
167	13.8	2.5	20	1	US-09-784-674-557	Sequence 557, App
168	13.8	2.5	20	1	US-09-784-674-558	Sequence 558, App
169	13.8	2.5	20	1	US-09-784-674-559	Sequence 559, App
170	13.8	2.5	20	1	US-10-181-846-166	Sequence 166, App
171	13.8	2.5	20	1	US-10-003-919-25	Sequence 25, Appl
c 172	13.8	2.5	20	1	US-10-425-975-47	Sequence 47, Appl
c 173	13.8	2.5	20	1	US-10-289-762-2718	Sequence 2718, Ap
c 174	13.8	2.5	20	1	US-10-304-116-91	Sequence 91, Appl
175	13.8	2.5	20	1	US-10-688-706-1604	Sequence 1604, Ap
176	13.8	2.5	20	1	US-10-688-706-2325	Sequence 2325, Ap
177	13.8	2.5	20	1	US-10-688-706-2367	Sequence 2367, Ap
178	13.8	2.5	20	1	US-10-688-706-2504	Sequence 2504, Ap
c 179	13.8	2.5	20	1	US-10-317-280-33	Sequence 33, Appl
180	13.8	2.5	20	1	US-10-317-280-109	Sequence 109, App
c 181	13.8	2.5	20	1	US-10-317-649-47	Sequence 47, Appl
c 182	13.8	2.5	20	1	US-10-766-185-53	Sequence 53, Appl
183	13.8	2.5	20	1	US-10-684-978-15	Sequence 15, Appl
c 184	13.8	2.5	21	1	US-09-944-036-11	Sequence 11, Appl
c 185	13.8	2.5	21	1	US-09-944-036-46	Sequence 46, Appl
186	13.8	2.5	21	1	US-09-820-339A-28	Sequence 28, Appl
187	13.8	2.5	21	1	US-09-726-774-40	Sequence 40, Appl
c 188	13.8	2.5	21	1	US-10-425-975-11	Sequence 11, Appl
c 189	13.8	2.5	21	1	US-10-425-975-46	Sequence 46, Appl
c 190	13.8	2.5	21	1	US-10-349-143-8235	Sequence 8235, Ap
191	13.8	2.5	21	1	US-10-349-143-10171	Sequence 10171, A
192	13.8	2.5	21	1	US-10-719-633-40	Sequence 40, Appl
193	13.8	2.5	21	1	US-10-786-720-19529	Sequence 19529, A
194	13.6	2.4	20	1	US-09-758-881-43	Sequence 43, Appl
c 195	13.6	2.4	20	1	US-09-854-883-183	Sequence 183, App
c 196	13.6	2.4	20	1	US-09-888-326-4	Sequence 4, Appli
c 197	13.6	2.4	20	1	US-09-888-326-5	Sequence 5, Appli
198	13.6	2.4	20	1	US-09-888-326-9	Sequence 9, Appli
c 199	13.6	2.4	20	1	US-09-888-326-542	Sequence 542, App
c 200	13.6	2.4	20	1	US-09-784-674-354	Sequence 354, App
c 201	13.6	2.4	20	1	US-09-776-479-353	Sequence 353, App
c 202	13.6	2.4	20	1	US-09-776-479-353	Sequence 353, App
c 203	13.6	2.4	20	1	US-09-776-479-525	Sequence 525, App
c 204	13.6	2.4	20	1	US-09-776-479-525	Sequence 525, App
205	13.6	2.4	20	1	US-09-776-479-776	Sequence 776, App
206	13.6	2.4	20	1	US-09-776-479-776	Sequence 776, App
c 207	13.6	2.4	20	1	US-09-776-479-855	Sequence 855, App
c 208	13.6	2.4	20	1	US-09-776-479-855	Sequence 855, App
c 209	13.6	2.4	20	1	US-10-112-653-342	Sequence 342, App
c 210	13.6	2.4	20	1	US-10-112-653-502	Sequence 502, App
211	13.6	2.4	20	1	US-10-112-653-749	Sequence 749, App
c 212	13.6	2.4	20	1	US-10-112-653-826	Sequence 826, App
c 213	13.6	2.4	20	1	US-10-017-995-353	Sequence 353, App
c 214	13.6	2.4	20	1	US-10-017-995-525	Sequence 525, App
215	13.6	2.4	20	1	US-10-017-995-776	Sequence 776, App
c 216	13.6	2.4	20	1	US-10-017-995-855	Sequence 855, App
217	13.6	2.4	20	1	US-10-181-107-164	Sequence 164, App
c 218	13.6	2.4	20	1	US-10-181-846-109	Sequence 109, App
219	13.6	2.4	20	1	US-10-161-229-99	Sequence 99, Appl
c 220	13.6	2.4	20	1	US-10-356-625-116	Sequence 116, App
c 221	13.6	2.4	20	1	US-10-314-578-353	Sequence 353, App
c 222	13.6	2.4	20	1	US-10-314-578-525	Sequence 525, App
223	13.6	2.4	20	1	US-10-314-578-776	Sequence 776, App
c 224	13.6	2.4	20	1	US-10-314-578-855	Sequence 855, App
c 225	13.6	2.4	20	1	US-10-360-510-183	Sequence 183, App
c 226	13.6	2.4	20	1	US-10-188-779A-64	Sequence 64, Appl
227	13.6	2.4	20	1	US-10-349-143-5752	Sequence 5752, Ap
228	13.6	2.4	20	1	US-10-309-290-169	Sequence 169, App
229	13.6	2.4	20	1	US-10-280-183A-421	Sequence 421, App
c 230	13.6	2.4	20	1	US-10-298-404-21	Sequence 21, Appl
231	13.6	2.4	20	1	US-10-298-404-56	Sequence 56, Appl
232	13.6	2.4	20	1	US-10-302-027-17	Sequence 17, Appl
233	13.6	2.4	20	1	US-10-376-770-208	Sequence 208, App
c 234	13.6	2.4	20	1	US-10-467-008-84	Sequence 84, Appl
235	13.6	2.4	20	1	US-10-671-395-53	Sequence 53, Appl
236	13.6	2.4	20	1	US-10-671-395-1105	Sequence 1105, Ap
237	13.6	2.4	20	1	US-10-671-395-1754	Sequence 1754, Ap
238	13.6	2.4	20	1	US-10-728-399-588	Sequence 588, App
239	13.6	2.4	20	1	US-10-661-165-208	Sequence 208, App
c 240	13.6	2.4	20	1	US-10-619-739-578	Sequence 578, App
c 241	13.4	2.4	16	1	US-10-138-674-5864	Sequence 5864, Ap
c 242	13.4	2.4	16	1	US-10-287-949A-5864	Sequence 5864, Ap
243	13.4	2.4	17	1	US-09-780-533A-398	Sequence 398, App
244	13.4	2.4	17	1	US-09-780-533A-2234	Sequence 2234, Ap
c 245	13.4	2.4	17	1	US-09-776-474-445	Sequence 445, App
c 246	13.4	2.4	17	1	US-09-776-474-1098	Sequence 1098, Ap
c 247	13.4	2.4	17	1	US-10-163-552-852	Sequence 852, App
c 248	13.4	2.4	17	1	US-10-230-006-787	Sequence 787, App
c 249	13.4	2.4	17	1	US-10-230-006-2220	Sequence 2220, Ap
c 250	13.4	2.4	17	1	US-10-138-674-577	Sequence 577, App
c 251	13.4	2.4	17	1	US-10-138-674-578	Sequence 578, App
c 252	13.4	2.4	17	1	US-10-138-674-579	Sequence 579, App

c 253	13.4	2.4	17	1	US-10-287-949A-577	Sequence 577, App	
c 254	13.4	2.4	17	1	US-10-287-949A-578	Sequence 578, App	
c 255	13.4	2.4	17	1	US-10-287-949A-579	Sequence 579, App	
c 256	13.4	2.4	18	1	US-09-839-583-5	Sequence 5, Appli	
c 257	13.4	2.4	18	1	US-09-804-014A-59	Sequence 59, Appl	
258	13.4	2.4	18	1	US-10-108-260A-4912	Sequence 4912, Ap	
259	13.4	2.4	18	1	US-10-349-143-7270	Sequence 7270, Ap	
c 260	13.4	2.4	18	1	US-10-680-341-14	Sequence 14, Appl	
c 261	13.4	2.4	18	1	US-10-680-341-16	Sequence 16, Appl	
c 262	13.4	2.4	19	1	US-10-665-951-100	Sequence 100, App	
263	13.4	2.4	19	1	US-10-665-951-527	Sequence 527, App	
c 264	13.4	2.4	19	1	US-10-683-990-66	Sequence 66, Appl	
265	13.4	2.4	19	1	US-10-683-990-163	Sequence 163, App	
266	13.4	2.4	20	1	US-09-854-883-130	Sequence 130, App	
c 267	13.4	2.4	20	1	US-09-899-422-42	Sequence 42, Appl	
c 268	13.4	2.4	20	1	US-09-898-234-42	Sequence 42, Appl	
c 269	13.4	2.4	20	1	US-09-899-429A-52	Sequence 52, Appl	
c 270	13.4	2.4	20	1	US-09-792-356-42	Sequence 42, Appl	
c 271	13.4	2.4	20	1	US-09-816-460C-20	Sequence 20, Appl	
272	13.4	2.4	20	1	US-10-002-491-84	Sequence 84, Appl	
273	13.4	2.4	20	1	US-10-360-510-130	Sequence 130, App	
274	13.4	2.4	20	1	US-10-289-762-3480	Sequence 3480, Ap	
c 275	13.4	2.4	20	1	US-10-289-762-4153	Sequence 4153, Ap	
276	13.4	2.4	20	1	US-10-298-994-50	Sequence 50, Appl	
277	13.4	2.4	20	1	US-10-298-994-91	Sequence 91, Appl	
c 278	13.4	2.4	20	1	US-10-298-994-165	Sequence 165, App	
c 279	13.4	2.4	20	1	US-10-298-994-198	Sequence 198, App	
280	13.4	2.4	20	1	US-10-688-706-2305	Sequence 2305, Ap	
281	13.4	2.4	20	1	US-10-688-706-2602	Sequence 2602, Ap	
282	13.2	2.4	18	1	US-09-878-582-47	Sequence 47, Appl	
c 283	13.2	2.4	18	1	US-09-950-935-9	Sequence 9, Appli	
284	13.2	2.4	18	1	US-10-067-125-180	Sequence 180, App	
285	13.2	2.4	18	1	US-10-388-263-867	Sequence 867, App	
286	13.2	2.4	18	1	US-10-336-213B-47	Sequence 47, Appl	
287	13.2	2.4	18	1	US-10-416-041-19	Sequence 19, Appl	
288	13.2	2.4	18	1	US-10-664-639A-76	Sequence 76, Appl	
289	13.2	2.4	19	1	US-10-391-413-19	Sequence 19, Appl	
290	13.2	2.4	19	1	US-10-251-117-844	Sequence 844, App	
c 291	13.2	2.4	19	1	US-10-251-117-1151	Sequence 1151, Ap	
292	13.2	2.4	19	1	US-10-349-143-4542	Sequence 4542, Ap	
293	13.2	2.4	19	1	US-10-206-705-78	Sequence 78, Appl	
c 294	13.2	2.4	19	1	US-10-206-705-263	Sequence 263, App	
295	13.2	2.4	20	1	US-09-736-271-9	Sequence 9, Appli	
296	13.2	2.4	20	1	US-09-790-264-26	Sequence 26, Appl	
297	13.2	2.4	20	1	US-09-834-291-14	Sequence 14, Appl	
c 298	13.2	2.4	20	1	US-09-972-473-30	Sequence 30, Appl	
299	13.2	2.4	20	1	US-09-972-469-49	Sequence 49, Appl	
c 300	13.2	2.4	20	1	US-09-972-469-186	Sequence 186, App	
c 301	13.2	2.4	20	1	US-09-816-460C-44	Sequence 44, Appl	
302	13.2	2.4	20	1	US-09-998-027-145	Sequence 145, App	
c 303	13.2	2.4	20	1	US-10-271-887-146	Sequence 146, App	
c 304	13.2	2.4	20	1	US-10-238-011-35	Sequence 35, Appl	
305	13.2	2.4	20	1	US-10-269-353-26	Sequence 26, Appl	
306	13.2	2.4	20	1	US-10-003-354-81	Sequence 81, Appl	
307	13.2	2.4	20	1	US-10-003-919-33	Sequence 33, Appl	
c 308	13.2	2.4	20	1	US-10-003-919-54	Sequence 54, Appl	
309	13.2	2.4	20	1	US-10-348-485-65	Sequence 65, Appl	
310	13.2	2.4	20	1	US-10-319-221-6	Sequence 6, Appli	
311	13.2	2.4	20	1	US-10-165-099-145	Sequence 145, App	
c 312	13.2	2.4	20	1	US-10-161-983-29	Sequence 29, Appl	
313	13.2	2.4	20	1	US-10-161-983-61	Sequence 61, Appl	
c 314	13.2	2.4	20	1	US-10-173-208-25	Sequence 25, Appl	
315	13.2	2.4	20	1	US-10-173-208-61	Sequence 61, Appl	
c 316	13.2	2.4	20	1	US-10-189-268-47	Sequence 47, Appl	
c 317	13.2	2.4	20	1	US-10-349-143-4087	Sequence 4087, Ap	
c 318	13.2	2.4	20	1	US-10-189-267-101	Sequence 101, App	
319	13.2	2.4	20	1	US-10-289-762-2313	Sequence 2313, Ap	
320	13.2	2.4	20	1	US-10-210-723-47	Sequence 47, Appl	
c 321	13.2	2.4	20	1	US-10-210-723-116	Sequence 116, App	
322	13.2	2.4	20	1	US-10-210-838-60	Sequence 60, Appl	
c 323	13.2	2.4	20	1	US-10-280-183A-393	Sequence 393, App	
c 324	13.2	2.4	20	1	US-10-304-125-59	Sequence 59, Appl	
325	13.2	2.4	20	1	US-10-304-125-126	Sequence 126, App	
326	13.2	2.4	20	1	US-10-688-706-1855	Sequence 1855, Ap	
327	13.2	2.4	20	1	US-10-688-706-2139	Sequence 2139, Ap	
328	13.2	2.4	20	1	US-10-688-706-2365	Sequence 2365, Ap	
c 329	13.2	2.4	20	1	US-10-319-893-88	Sequence 88, Appl	
330	13.2	2.4	20	1	US-10-319-893-157	Sequence 157, App	
331	13.2	2.4	20	1	US-10-671-395-120	Sequence 120, App	
332	13.2	2.4	20	1	US-10-671-395-163	Sequence 163, App	
333	13.2	2.4	20	1	US-10-671-395-227	Sequence 227, App	
334	13.2	2.4	20	1	US-10-671-395-1122	Sequence 1122, Ap	
335	13.2	2.4	20	1	US-10-671-395-1294	Sequence 1294, Ap	
336	13.2	2.4	20	1	US-10-671-395-1343	Sequence 1343, Ap	
337	13.2	2.4	20	1	US-10-671-395-1366	Sequence 1366, Ap	
338	13.2	2.4	20	1	US-10-671-395-1367	Sequence 1367, Ap	
c 339	13.2	2.4	20	1	US-10-473-368-8	Sequence 8, Appli	
340	13.2	2.4	20	1	US-10-731-739-618	Sequence 618, App	
341	13.2	2.4	20	1	US-10-741-789A-89	Sequence 89, Appl	
342	13	2.3	15	1	US-10-197-019-48	Sequence 48, Appl	
343	13	2.3	17	1	US-09-818-875-2314	Sequence 2314, Ap	
c 344	13	2.3	17	1	US-09-818-875-2315	Sequence 2315, Ap	
345	13	2.3	17	1	US-09-818-875-2318	Sequence 2318, Ap	
c 346	13	2.3	17	1	US-09-818-875-2319	Sequence 2319, Ap	
347	13	2.3	17	1	US-09-818-875-2322	Sequence 2322, Ap	
c 348	13	2.3	17	1	US-09-818-875-2323	Sequence 2323, Ap	
349	13	2.3	17	1	US-09-818-875-2326	Sequence 2326, Ap	
c 350	13	2.3	17	1	US-09-818-875-2327	Sequence 2327, Ap	
c 351	13	2.3	17	1	US-09-776-474-933	Sequence 933, App	
c 352	13	2.3	17	1	US-10-061-201-955	Sequence 955, App	
c 353	13	2.3	17	1	US-10-061-201-956	Sequence 956, App	
c 354	13	2.3	17	1	US-10-061-201-957	Sequence 957, App	
c 355	13	2.3	17	1	US-10-061-201-958	Sequence 958, App	
c 356	13	2.3	17	1	US-10-061-201-959	Sequence 959, App	
357	13	2.3	17	1	US-10-187-253A-60	Sequence 60, Appl	
358	13	2.3	17	1	US-10-209-787-2314	Sequence 2314, Ap	
c 359	13	2.3	17	1	US-10-209-787-2315	Sequence 2315, Ap	
360	13	2.3	17	1	US-10-209-787-2318	Sequence 2318, Ap	
c 361	13	2.3	17	1	US-10-209-787-2319	Sequence 2319, Ap	
362	13	2.3	17	1	US-10-209-787-2322	Sequence 2322, Ap	
c 363	13	2.3	17	1	US-10-209-787-2323	Sequence 2323, Ap	
364	13	2.3	17	1	US-10-209-787-2326	Sequence 2326, Ap	
c 365	13	2.3	17	1	US-10-209-787-2327	Sequence 2327, Ap	
366	13	2.3	17	1	US-10-261-185-2314	Sequence 2314, Ap	
c 367	13	2.3	17	1	US-10-261-185-2315	Sequence 2315, Ap	
368	13	2.3	17	1	US-10-261-185-2318	Sequence 2318, Ap	
c 369	13	2.3	17	1	US-10-261-185-2319	Sequence 2319, Ap	
370	13	2.3	17	1	US-10-261-185-2322	Sequence 2322, Ap	
c 371	13	2.3	17	1	US-10-261-185-2323	Sequence 2323, Ap	
372	13	2.3	17	1	US-10-261-185-2326	Sequence 2326, Ap	
c 373	13	2.3	17	1	US-10-261-185-2327	Sequence 2327, Ap	
374	13	2.3	17	1	US-10-681-074-2314	Sequence 2314, Ap	
c 375	13	2.3	17	1	US-10-681-074-2315	Sequence 2315, Ap	
376	13	2.3	17	1	US-10-681-074-2318	Sequence 2318, Ap	
c 377	13	2.3	17	1	US-10-681-074-2319	Sequence 2319, Ap	
378	13	2.3	17	1	US-10-681-074-2322	Sequence 2322, Ap	
c 379	13	2.3	17	1	US-10-681-074-2323	Sequence 2323, Ap	
380	13	2.3	17	1	US-10-681-074-2326	Sequence 2326, Ap	
c 381	13	2.3	17	1	US-10-681-074-2327	Sequence 2327, Ap	
c 382	13	2.3	18	1	US-10-076-597-23	Sequence 23, Appl	
c 383	13	2.3	19	1	US-10-444-925-276	Sequence 276, App	
c 384	13	2.3	20	1	US-09-883-825-1	Sequence 1, Appli	
c 385	13	2.3	20	1	US-10-445-097-29	Sequence 29, Appl	
c 386	13	2.3	20	1	US-10-697-894-1	Sequence 1, Appli	
387	13	2.3	21	1	US-10-786-720-12564	Sequence 12564, A	
388	12.8	2.3	16	1	US-09-955-410-30	Sequence 30, Appl	
389	12.8	2.3	16	1	US-09-983-210-30	Sequence 30, Appl	
390	12.8	2.3	16	1	US-10-154-890-30	Sequence 30, Appl	
c 391	12.8	2.3	17	1	US-09-866-108-1345	Sequence 1345, Ap	
c 392	12.8	2.3	17	1	US-09-866-108-1347	Sequence 1347, Ap	
c 393	12.8	2.3	17	1	US-09-866-108-1580	Sequence 1580, Ap	
c 394	12.8	2.3	17	1	US-09-866-108-1581	Sequence 1581, Ap	
c 395	12.8	2.3	17	1	US-09-866-108-7641	Sequence 7641, Ap	
c 396	12.8	2.3	17	1	US-09-866-108-7644	Sequence 7644, Ap	
397	12.8	2.3	17	1	US-09-866-108-7957	Sequence 7957, Ap	
398	12.8	2.3	17	1	US-09-866-108-7958	Sequence 7958, Ap	

	399	12.8	2.3	17	1	US-09-827-998-311	Sequence 311, App
	400	12.8	2.3	17	1	US-09-827-998-312	Sequence 312, App
	401	12.8	2.3	17	1	US-09-730-289B-316	Sequence 316, App
	402	12.8	2.3	17	1	US-09-730-289B-905	Sequence 905, App
c	403	12.8	2.3	17	1	US-09-780-533A-2445	Sequence 2445, Ap
	404	12.8	2.3	17	1	US-09-848-754A-545	Sequence 545, App
	405	12.8	2.3	17	1	US-09-848-754A-546	Sequence 546, App
c	406	12.8	2.3	17	1	US-09-780-164-137	Sequence 137, App
c	407	12.8	2.3	17	1	US-09-780-164-503	Sequence 503, App
	408	12.8	2.3	17	1	US-10-060-830-247	Sequence 247, App
	409	12.8	2.3	17	1	US-10-060-830-248	Sequence 248, App
	410	12.8	2.3	17	1	US-10-060-756A-1168	Sequence 1168, Ap
	411	12.8	2.3	17	1	US-10-060-756A-1169	Sequence 1169, Ap
	412	12.8	2.3	17	1	US-10-211-059-117	Sequence 117, App
	413	12.8	2.3	17	1	US-10-211-059-118	Sequence 118, App
	414	12.8	2.3	17	1	US-10-163-552-969	Sequence 969, App
	415	12.8	2.3	17	1	US-10-156-306-47	Sequence 47, Appl
	416	12.8	2.3	17	1	US-10-156-306-1313	Sequence 1313, Ap
	417	12.8	2.3	17	1	US-10-156-306-3609	Sequence 3609, Ap
c	418	12.8	2.3	17	1	US-10-156-306-7108	Sequence 7108, Ap
	419	12.8	2.3	17	1	US-10-238-700-458	Sequence 458, App
	420	12.8	2.3	17	1	US-10-238-700-669	Sequence 669, App
	421	12.8	2.3	17	1	US-10-238-700-904	Sequence 904, App
c	422	12.8	2.3	17	1	US-10-238-700-3477	Sequence 3477, Ap
	423	12.8	2.3	17	1	US-10-339-782-260	Sequence 260, App
c	424	12.8	2.3	17	1	US-10-331-329-32	Sequence 32, Appl
	425	12.8	2.3	17	1	US-10-297-068-1103	Sequence 1103, Ap
	426	12.8	2.3	17	1	US-10-307-005-1527	Sequence 1527, Ap
c	427	12.8	2.3	17	1	US-10-307-005-1528	Sequence 1528, Ap
	428	12.8	2.3	17	1	US-10-675-685-311	Sequence 311, App
	429	12.8	2.3	17	1	US-10-675-685-312	Sequence 312, App
c	430	12.8	2.3	17	1	US-10-138-674-749	Sequence 749, App
c	431	12.8	2.3	17	1	US-10-138-674-778	Sequence 778, App
c	432	12.8	2.3	17	1	US-10-138-674-779	Sequence 779, App
	433	12.8	2.3	17	1	US-10-138-674-1042	Sequence 1042, Ap
c	434	12.8	2.3	17	1	US-10-138-674-2869	Sequence 2869, Ap
	435	12.8	2.3	17	1	US-10-138-674-8039	Sequence 8039, Ap
	436	12.8	2.3	17	1	US-10-138-674-8128	Sequence 8128, Ap
c	437	12.8	2.3	17	1	US-10-287-949A-749	Sequence 749, App
c	438	12.8	2.3	17	1	US-10-287-949A-778	Sequence 778, App
c	439	12.8	2.3	17	1	US-10-287-949A-779	Sequence 779, App
	440	12.8	2.3	17	1	US-10-287-949A-1042	Sequence 1042, Ap
c	441	12.8	2.3	17	1	US-10-287-949A-2869	Sequence 2869, Ap
	442	12.8	2.3	17	1	US-10-287-949A-8039	Sequence 8039, Ap
	443	12.8	2.3	17	1	US-10-287-949A-8128	Sequence 8128, Ap
c	444	12.8	2.3	17	1	US-10-712-672-960	Sequence 960, App
c	445	12.8	2.3	17	1	US-10-712-672-961	Sequence 961, App
c	446	12.8	2.3	17	1	US-10-723-361-1345	Sequence 1345, Ap
c	447	12.8	2.3	17	1	US-10-723-361-1347	Sequence 1347, Ap
c	448	12.8	2.3	17	1	US-10-723-361-1580	Sequence 1580, Ap
c	449	12.8	2.3	17	1	US-10-723-361-1581	Sequence 1581, Ap
c	450	12.8	2.3	17	1	US-10-723-361-7641	Sequence 7641, Ap
c	451	12.8	2.3	17	1	US-10-723-361-7644	Sequence 7644, Ap
	452	12.8	2.3	17	1	US-10-723-361-7957	Sequence 7957, Ap
	453	12.8	2.3	17	1	US-10-723-361-7958	Sequence 7958, Ap
	454	12.8	2.3	18	1	US-10-151-484-142	Sequence 142, App
c	455	12.8	2.3	18	1	US-10-349-143-7869	Sequence 7869, Ap
	456	12.8	2.3	18	1	US-10-349-143-11530	Sequence 11530, A
	457	12.8	2.3	18	1	US-10-731-739-450	Sequence 450, App
c	458	12.8	2.3	19	1	US-09-216-393-337	Sequence 337, App
c	459	12.8	2.3	19	1	US-09-539-382-28	Sequence 28, Appl
c	460	12.8	2.3	19	1	US-10-067-790-28	Sequence 28, Appl
c	461	12.8	2.3	19	1	US-10-067-892-28	Sequence 28, Appl
c	462	12.8	2.3	19	1	US-10-067-893-28	Sequence 28, Appl
c	463	12.8	2.3	19	1	US-10-390-303-17	Sequence 17, Appl
	464	12.8	2.3	19	1	US-10-225-023-143	Sequence 143, App
	465	12.8	2.3	19	1	US-10-225-023-156	Sequence 156, App
	466	12.8	2.3	19	1	US-10-225-023-503	Sequence 503, App
c	467	12.8	2.3	19	1	US-10-225-023-881	Sequence 881, App
c	468	12.8	2.3	19	1	US-10-225-023-894	Sequence 894, App
c	469	12.8	2.3	19	1	US-10-225-023-1241	Sequence 1241, Ap
c	470	12.8	2.3	19	1	US-10-321-856-337	Sequence 337, App
	471	12.8	2.3	19	1	US-10-401-343-26	Sequence 26, Appl
	472	12.8	2.3	19	1	US-10-349-143-4047	Sequence 4047, Ap
c	473	12.8	2.3	19	1	US-10-349-143-11179	Sequence 11179, A
c	474	12.8	2.3	19	1	US-10-648-512-70	Sequence 70, Appl
	475	12.8	2.3	19	1	US-10-606-133-191	Sequence 191, App
c	476	12.8	2.3	19	1	US-10-665-951-270	Sequence 270, App
	477	12.8	2.3	19	1	US-10-665-951-697	Sequence 697, App
c	478	12.8	2.3	19	1	US-10-741-601-26328	Sequence 26328, A
	479	12.6	2.3	19	1	US-09-791-932-142	Sequence 142, App
	480	12.6	2.3	19	1	US-10-229-370-6	Sequence 6, Appli
	481	12.6	2.3	19	1	US-10-224-005-73	Sequence 73, Appl
c	482	12.6	2.3	19	1	US-10-224-005-234	Sequence 234, App
	483	12.6	2.3	19	1	US-10-345-092-33	Sequence 33, Appl
c	484	12.6	2.3	19	1	US-10-349-143-8902	Sequence 8902, Ap
c	485	12.6	2.3	19	1	US-10-349-143-9136	Sequence 9136, Ap
	486	12.6	2.3	19	1	US-10-444-925-478	Sequence 478, App
	487	12.6	2.3	19	1	US-10-114-270-414	Sequence 414, App
c	488	12.6	2.3	19	1	US-10-444-795B-220	Sequence 220, App
c	489	12.6	2.3	19	1	US-10-255-120-451	Sequence 451, App
c	490	12.6	2.3	19	1	US-10-665-951-1101	Sequence 1101, Ap
	491	12.6	2.3	19	1	US-10-665-951-1425	Sequence 1425, Ap
c	492	12.4	2.2	15	1	US-09-510-378-111	Sequence 111, App
c	493	12.4	2.2	16	1	US-10-387-384-26	Sequence 26, Appl
c	494	12.4	2.2	16	1	US-10-387-384-28	Sequence 28, Appl
c	495	12.4	2.2	16	1	US-10-387-384-30	Sequence 30, Appl
c	496	12.4	2.2	16	1	US-10-387-384-32	Sequence 32, Appl
c	497	12.4	2.2	16	1	US-10-387-384-34	Sequence 34, Appl
c	498	12.4	2.2	17	1	US-09-866-108-7187	Sequence 7187, Ap
c	499	12.4	2.2	17	1	US-09-866-108-7188	Sequence 7188, Ap
c	500	12.4	2.2	17	1	US-09-866-108-7189	Sequence 7189, Ap
c	501	12.4	2.2	17	1	US-09-866-108-7190	Sequence 7190, Ap
c	502	12.4	2.2	17	1	US-09-866-108-7639	Sequence 7639, Ap
c	503	12.4	2.2	17	1	US-09-866-108-7640	Sequence 7640, Ap
	504	12.4	2.2	17	1	US-09-780-533A-595	Sequence 595, App
	505	12.4	2.2	17	1	US-09-780-533A-1278	Sequence 1278, Ap
	506	12.4	2.2	17	1	US-09-780-533A-1749	Sequence 1749, Ap
	507	12.4	2.2	17	1	US-09-780-533A-2294	Sequence 2294, Ap
c	508	12.4	2.2	17	1	US-09-877-478-253	Sequence 253, App
	509	12.4	2.2	17	1	US-09-877-478-442	Sequence 442, App
	510	12.4	2.2	17	1	US-09-877-478-443	Sequence 443, App
c	511	12.4	2.2	17	1	US-09-877-478-938	Sequence 938, App
	512	12.4	2.2	17	1	US-09-877-478-1166	Sequence 1166, Ap
	513	12.4	2.2	17	1	US-09-877-478-1167	Sequence 1167, Ap
c	514	12.4	2.2	17	1	US-09-877-478-1704	Sequence 1704, Ap
c	515	12.4	2.2	17	1	US-09-740-332-229	Sequence 229, App
c	516	12.4	2.2	17	1	US-09-740-332-230	Sequence 230, App
	517	12.4	2.2	17	1	US-09-740-332-4326	Sequence 4326, Ap
c	518	12.4	2.2	17	1	US-09-817-879-229	Sequence 229, App
c	519	12.4	2.2	17	1	US-09-817-879-230	Sequence 230, App
	520	12.4	2.2	17	1	US-09-817-879-4326	Sequence 4326, Ap
	521	12.4	2.2	17	1	US-10-060-830-245	Sequence 245, App
	522	12.4	2.2	17	1	US-10-060-830-246	Sequence 246, App
c	523	12.4	2.2	17	1	US-10-287-919-2130	Sequence 2130, Ap
c	524	12.4	2.2	17	1	US-10-287-919-2391	Sequence 2391, Ap
	525	12.4	2.2	17	1	US-10-156-306-449	Sequence 449, App
	526	12.4	2.2	17	1	US-10-156-306-450	Sequence 450, App
	527	12.4	2.2	17	1	US-10-156-306-451	Sequence 451, App
	528	12.4	2.2	17	1	US-10-238-700-905	Sequence 905, App
	529	12.4	2.2	17	1	US-10-238-700-3171	Sequence 3171, Ap
c	530	12.4	2.2	17	1	US-10-230-006-163	Sequence 163, App
c	531	12.4	2.2	17	1	US-10-342-902-253	Sequence 253, App
	532	12.4	2.2	17	1	US-10-342-902-442	Sequence 442, App
	533	12.4	2.2	17	1	US-10-342-902-443	Sequence 443, App
c	534	12.4	2.2	17	1	US-10-342-902-938	Sequence 938, App
	535	12.4	2.2	17	1	US-10-342-902-1166	Sequence 1166, Ap
	536	12.4	2.2	17	1	US-10-342-902-1167	Sequence 1167, Ap
c	537	12.4	2.2	17	1	US-10-342-902-1704	Sequence 1704, Ap
	538	12.4	2.2	17	1	US-10-138-674-3230	Sequence 3230, Ap
c	539	12.4	2.2	17	1	US-10-138-674-4869	Sequence 4869, Ap
c	540	12.4	2.2	17	1	US-10-138-674-6658	Sequence 6658, Ap
c	541	12.4	2.2	17	1	US-10-138-674-6659	Sequence 6659, Ap
c	542	12.4	2.2	17	1	US-10-138-674-7730	Sequence 7730, Ap
c	543	12.4	2.2	17	1	US-10-676-154-564	Sequence 564, App
c	544	12.4	2.2	17	1	US-10-676-154-565	Sequence 565, App

545	12.4	2.2	17	1	US-10-287-949A-3230	Sequence 3230, Ap
c 546	12.4	2.2	17	1	US-10-287-949A-4869	Sequence 4869, Ap
c 547	12.4	2.2	17	1	US-10-287-949A-6658	Sequence 6658, Ap
c 548	12.4	2.2	17	1	US-10-287-949A-6659	Sequence 6659, Ap
c 549	12.4	2.2	17	1	US-10-287-949A-7730	Sequence 7730, Ap
c 550	12.4	2.2	17	1	US-10-669-841-253	Sequence 253, App
551	12.4	2.2	17	1	US-10-669-841-442	Sequence 442, App
552	12.4	2.2	17	1	US-10-669-841-443	Sequence 443, App
c 553	12.4	2.2	17	1	US-10-669-841-938	Sequence 938, App
554	12.4	2.2	17	1	US-10-669-841-1166	Sequence 1166, Ap
555	12.4	2.2	17	1	US-10-669-841-1167	Sequence 1167, Ap
c 556	12.4	2.2	17	1	US-10-669-841-1704	Sequence 1704, Ap
c 557	12.4	2.2	17	1	US-10-669-841-2822	Sequence 2822, Ap
c 558	12.4	2.2	17	1	US-10-669-841-2823	Sequence 2823, Ap
559	12.4	2.2	17	1	US-10-669-841-6919	Sequence 6919, Ap
c 560	12.4	2.2	17	1	US-10-723-361-7187	Sequence 7187, Ap
c 561	12.4	2.2	17	1	US-10-723-361-7188	Sequence 7188, Ap
c 562	12.4	2.2	17	1	US-10-723-361-7189	Sequence 7189, Ap
c 563	12.4	2.2	17	1	US-10-723-361-7190	Sequence 7190, Ap
c 564	12.4	2.2	17	1	US-10-723-361-7639	Sequence 7639, Ap
c 565	12.4	2.2	17	1	US-10-723-361-7640	Sequence 7640, Ap
c 566	12.4	2.2	18	1	US-09-805-630-2	Sequence 2, Appli
567	12.4	2.2	18	1	US-09-907-190-27	Sequence 27, Appl
c 568	12.4	2.2	18	1	US-09-839-583-1	Sequence 1, Appli
569	12.4	2.2	18	1	US-09-839-583-2	Sequence 2, Appli
570	12.4	2.2	18	1	US-09-839-583-6	Sequence 6, Appli
c 571	12.4	2.2	18	1	US-09-970-971A-23	Sequence 23, Appl
572	12.4	2.2	18	1	US-10-335-059-5	Sequence 5, Appli
c 573	12.4	2.2	18	1	US-10-271-602B-59	Sequence 59, Appl
c 574	12.4	2.2	18	1	US-10-108-260A-5317	Sequence 5317, Ap
c 575	12.4	2.2	18	1	US-10-108-260A-5454	Sequence 5454, Ap
576	12.4	2.2	18	1	US-10-349-143-4678	Sequence 4678, Ap
577	12.4	2.2	18	1	US-10-349-143-4857	Sequence 4857, Ap
c 578	12.4	2.2	18	1	US-10-731-739-138	Sequence 138, App
c 579	12.4	2.2	18	1	US-10-731-739-522	Sequence 522, App
580	12.4	2.2	19	1	US-09-901-484A-407	Sequence 407, App
581	12.4	2.2	19	1	US-09-853-526-407	Sequence 407, App
c 582	12.4	2.2	19	1	US-09-935-464-76	Sequence 76, Appl
c 583	12.4	2.2	19	1	US-09-823-031-4	Sequence 4, Appli
c 584	12.4	2.2	19	1	US-09-823-031-5	Sequence 5, Appli
c 585	12.4	2.2	19	1	US-09-823-031-6	Sequence 6, Appli
c 586	12.4	2.2	19	1	US-09-823-031-7	Sequence 7, Appli
c 587	12.4	2.2	19	1	US-09-823-031-9	Sequence 9, Appli
c 588	12.4	2.2	19	1	US-10-071-179-115	Sequence 115, App
c 589	12.4	2.2	19	1	US-10-126-704-115	Sequence 115, App
590	12.4	2.2	19	1	US-10-225-023-108	Sequence 108, App
591	12.4	2.2	19	1	US-10-225-023-210	Sequence 210, App
c 592	12.4	2.2	19	1	US-10-225-023-846	Sequence 846, App
c 593	12.4	2.2	19	1	US-10-225-023-948	Sequence 948, App
c 594	12.4	2.2	19	1	US-10-080-979-71	Sequence 71, Appl
595	12.4	2.2	19	1	US-10-349-143-5778	Sequence 5778, Ap
596	12.4	2.2	19	1	US-10-349-143-8050	Sequence 8050, Ap
597	12.4	2.2	19	1	US-10-349-143-9088	Sequence 9088, Ap
c 598	12.4	2.2	19	1	US-10-349-143-9761	Sequence 9761, Ap
c 599	12.4	2.2	19	1	US-10-665-951-1165	Sequence 1165, Ap
600	12.4	2.2	19	1	US-10-665-951-1489	Sequence 1489, Ap
c 601	12.2	2.2	17	1	US-09-866-108-2108	Sequence 2108, Ap
c 602	12.2	2.2	17	1	US-09-866-108-2784	Sequence 2784, Ap
603	12.2	2.2	17	1	US-09-866-108-7956	Sequence 7956, Ap
604	12.2	2.2	17	1	US-09-866-108-7960	Sequence 7960, Ap
c 605	12.2	2.2	17	1	US-09-866-108-10544	Sequence 10544, A
c 606	12.2	2.2	17	1	US-09-864-785-1544	Sequence 1544, Ap
607	12.2	2.2	17	1	US-09-730-289B-49	Sequence 49, Appl
c 608	12.2	2.2	17	1	US-09-730-289B-366	Sequence 366, App
609	12.2	2.2	17	1	US-09-780-533A-845	Sequence 845, App
c 610	12.2	2.2	17	1	US-09-780-533A-1982	Sequence 1982, Ap
c 611	12.2	2.2	17	1	US-09-780-533A-2206	Sequence 2206, Ap
c 612	12.2	2.2	17	1	US-09-780-533A-2209	Sequence 2209, Ap
613	12.2	2.2	17	1	US-09-927-046-367	Sequence 367, App
c 614	12.2	2.2	17	1	US-09-927-046-437	Sequence 437, App
615	12.2	2.2	17	1	US-09-927-046-532	Sequence 532, App
c 616	12.2	2.2	17	1	US-09-927-046-542	Sequence 542, App
617	12.2	2.2	17	1	US-09-927-046-851	Sequence 851, App
c 618	12.2	2.2	17	1	US-09-927-046-946	Sequence 946, App
619	12.2	2.2	17	1	US-09-927-046-1195	Sequence 1195, Ap
620	12.2	2.2	17	1	US-09-927-046-1761	Sequence 1761, Ap
621	12.2	2.2	17	1	US-09-877-478-605	Sequence 605, App
622	12.2	2.2	17	1	US-09-877-478-930	Sequence 930, App
c 623	12.2	2.2	17	1	US-09-877-478-1073	Sequence 1073, Ap
624	12.2	2.2	17	1	US-09-848-754A-750	Sequence 750, App
625	12.2	2.2	17	1	US-09-848-754A-751	Sequence 751, App
626	12.2	2.2	17	1	US-09-848-754A-752	Sequence 752, App
627	12.2	2.2	17	1	US-09-848-754A-2478	Sequence 2478, Ap
c 628	12.2	2.2	17	1	US-09-776-474-446	Sequence 446, App
629	12.2	2.2	17	1	US-09-930-423-1236	Sequence 1236, Ap
630	12.2	2.2	17	1	US-09-930-423-1601	Sequence 1601, Ap
c 631	12.2	2.2	17	1	US-09-780-164-502	Sequence 502, App
c 632	12.2	2.2	17	1	US-09-740-332-1959	Sequence 1959, Ap
c 633	12.2	2.2	17	1	US-09-740-332-2221	Sequence 2221, Ap
634	12.2	2.2	17	1	US-09-745-237A-1236	Sequence 1236, Ap
635	12.2	2.2	17	1	US-09-745-237A-1601	Sequence 1601, Ap
c 636	12.2	2.2	17	1	US-09-817-879-1959	Sequence 1959, Ap
c 637	12.2	2.2	17	1	US-09-817-879-2221	Sequence 2221, Ap
c 638	12.2	2.2	17	1	US-10-041-856-21	Sequence 21, Appl
639	12.2	2.2	17	1	US-10-060-830-282	Sequence 282, App
c 640	12.2	2.2	17	1	US-10-060-830-816	Sequence 816, App
c 641	12.2	2.2	17	1	US-10-060-830-817	Sequence 817, App
642	12.2	2.2	17	1	US-10-060-756A-1166	Sequence 1166, Ap
643	12.2	2.2	17	1	US-10-060-756A-1167	Sequence 1167, Ap
644	12.2	2.2	17	1	US-10-190-438-4	Sequence 4, Appli
645	12.2	2.2	17	1	US-10-211-059-119	Sequence 119, App
646	12.2	2.2	17	1	US-10-060-998-561	Sequence 561, App
c 647	12.2	2.2	17	1	US-10-060-998-725	Sequence 725, App
648	12.2	2.2	17	1	US-10-156-306-343	Sequence 343, App
649	12.2	2.2	17	1	US-10-156-306-456	Sequence 456, App
650	12.2	2.2	17	1	US-10-156-306-457	Sequence 457, App
c 651	12.2	2.2	17	1	US-10-156-306-5185	Sequence 5185, Ap
c 652	12.2	2.2	17	1	US-10-238-700-349	Sequence 349, App
c 653	12.2	2.2	17	1	US-10-238-700-608	Sequence 608, App
654	12.2	2.2	17	1	US-10-238-700-670	Sequence 670, App
655	12.2	2.2	17	1	US-10-238-700-671	Sequence 671, App
656	12.2	2.2	17	1	US-10-238-700-938	Sequence 938, App
c 657	12.2	2.2	17	1	US-10-238-700-3058	Sequence 3058, Ap
c 658	12.2	2.2	17	1	US-10-238-700-3359	Sequence 3359, Ap
659	12.2	2.2	17	1	US-10-238-700-3455	Sequence 3455, Ap
660	12.2	2.2	17	1	US-10-061-201-953	Sequence 953, App
661	12.2	2.2	17	1	US-10-061-201-1931	Sequence 1931, Ap
c 662	12.2	2.2	17	1	US-10-230-006-786	Sequence 786, App
663	12.2	2.2	17	1	US-10-342-902-605	Sequence 605, App
664	12.2	2.2	17	1	US-10-342-902-930	Sequence 930, App
c 665	12.2	2.2	17	1	US-10-342-902-1073	Sequence 1073, Ap
666	12.2	2.2	17	1	US-10-138-674-2521	Sequence 2521, Ap
c 667	12.2	2.2	17	1	US-10-138-674-3205	Sequence 3205, Ap
668	12.2	2.2	17	1	US-10-138-674-3527	Sequence 3527, Ap
669	12.2	2.2	17	1	US-10-138-674-3794	Sequence 3794, Ap
670	12.2	2.2	17	1	US-10-138-674-3940	Sequence 3940, Ap
671	12.2	2.2	17	1	US-10-138-674-4919	Sequence 4919, Ap
672	12.2	2.2	17	1	US-10-138-674-5300	Sequence 5300, Ap
673	12.2	2.2	17	1	US-10-138-674-6155	Sequence 6155, Ap
674	12.2	2.2	17	1	US-10-138-674-6156	Sequence 6156, Ap
675	12.2	2.2	17	1	US-10-138-674-6199	Sequence 6199, Ap
676	12.2	2.2	17	1	US-10-138-674-7325	Sequence 7325, Ap
c 677	12.2	2.2	17	1	US-10-138-674-7729	Sequence 7729, Ap
678	12.2	2.2	17	1	US-10-138-674-7953	Sequence 7953, Ap
679	12.2	2.2	17	1	US-10-138-674-8238	Sequence 8238, Ap
c 680	12.2	2.2	17	1	US-10-138-674-8259	Sequence 8259, Ap
681	12.2	2.2	17	1	US-10-138-674-8468	Sequence 8468, Ap
682	12.2	2.2	17	1	US-10-287-949A-2521	Sequence 2521, Ap
c 683	12.2	2.2	17	1	US-10-287-949A-3205	Sequence 3205, Ap
684	12.2	2.2	17	1	US-10-287-949A-3527	Sequence 3527, Ap
685	12.2	2.2	17	1	US-10-287-949A-3794	Sequence 3794, Ap
686	12.2	2.2	17	1	US-10-287-949A-3940	Sequence 3940, Ap
687	12.2	2.2	17	1	US-10-287-949A-4919	Sequence 4919, Ap
688	12.2	2.2	17	1	US-10-287-949A-5300	Sequence 5300, Ap
689	12.2	2.2	17	1	US-10-287-949A-6155	Sequence 6155, Ap
690	12.2	2.2	17	1	US-10-287-949A-6156	Sequence 6156, Ap

691	12.2	2.2	17	1	US-10-287-949A-6199	Sequence 6199, Ap
692	12.2	2.2	17	1	US-10-287-949A-7325	Sequence 7325, Ap
c 693	12.2	2.2	17	1	US-10-287-949A-7729	Sequence 7729, Ap
694	12.2	2.2	17	1	US-10-287-949A-7953	Sequence 7953, Ap
695	12.2	2.2	17	1	US-10-287-949A-8238	Sequence 8238, Ap
c 696	12.2	2.2	17	1	US-10-287-949A-8259	Sequence 8259, Ap
697	12.2	2.2	17	1	US-10-287-949A-8468	Sequence 8468, Ap
c 698	12.2	2.2	17	1	US-10-712-672-755	Sequence 755, App
c 699	12.2	2.2	17	1	US-10-712-672-756	Sequence 756, App
700	12.2	2.2	17	1	US-10-712-672-862	Sequence 862, App
701	12.2	2.2	17	1	US-10-669-841-605	Sequence 605, App
702	12.2	2.2	17	1	US-10-669-841-930	Sequence 930, App
c 703	12.2	2.2	17	1	US-10-669-841-1073	Sequence 1073, Ap
c 704	12.2	2.2	17	1	US-10-669-841-4552	Sequence 4552, Ap
c 705	12.2	2.2	17	1	US-10-669-841-4814	Sequence 4814, Ap
c 706	12.2	2.2	17	1	US-10-723-361-2108	Sequence 2108, Ap
c 707	12.2	2.2	17	1	US-10-723-361-2784	Sequence 2784, Ap
708	12.2	2.2	17	1	US-10-723-361-7956	Sequence 7956, Ap
709	12.2	2.2	17	1	US-10-723-361-7960	Sequence 7960, Ap
c 710	12.2	2.2	17	1	US-10-723-361-10544	Sequence 10544, A
711	12.2	2.2	18	1	US-09-875-338-75	Sequence 75, Appl
712	12.2	2.2	18	1	US-09-756-095-10	Sequence 10, Appl
713	12.2	2.2	18	1	US-09-969-373-1657	Sequence 1657, Ap
c 714	12.2	2.2	18	1	US-09-969-373-2266	Sequence 2266, Ap
715	12.2	2.2	18	1	US-09-969-373-3927	Sequence 3927, Ap
716	12.2	2.2	18	1	US-09-941-492-10	Sequence 10, Appl
717	12.2	2.2	18	1	US-09-791-489-32	Sequence 32, Appl
718	12.2	2.2	18	1	US-09-756-096A-10	Sequence 10, Appl
719	12.2	2.2	18	1	US-09-838-858-10	Sequence 10, Appl
c 720	12.2	2.2	18	1	US-09-823-031-17	Sequence 17, Appl
c 721	12.2	2.2	18	1	US-09-823-031-21	Sequence 21, Appl
722	12.2	2.2	18	1	US-10-077-023-75	Sequence 75, Appl
c 723	12.2	2.2	18	1	US-10-029-598-22	Sequence 22, Appl
c 724	12.2	2.2	18	1	US-10-085-774-22	Sequence 22, Appl
725	12.2	2.2	18	1	US-10-302-554-43	Sequence 43, Appl
726	12.2	2.2	18	1	US-10-349-143-5792	Sequence 5792, Ap
c 727	12.2	2.2	18	1	US-10-349-143-7594	Sequence 7594, Ap
728	12.2	2.2	18	1	US-10-349-143-9126	Sequence 9126, Ap
c 729	12.2	2.2	18	1	US-10-261-382-1	Sequence 1, Appli
c 730	12.2	2.2	18	1	US-10-261-382-2	Sequence 2, Appli
c 731	12.2	2.2	18	1	US-10-261-382-3	Sequence 3, Appli
c 732	12.2	2.2	18	1	US-10-261-382-4	Sequence 4, Appli
c 733	12.2	2.2	18	1	US-10-261-382-5	Sequence 5, Appli
734	12.2	2.2	18	1	US-10-138-674-1461	Sequence 1461, Ap
735	12.2	2.2	18	1	US-10-287-949A-1461	Sequence 1461, Ap
c 736	12.2	2.2	18	1	US-10-376-770-99	Sequence 99, Appl
737	12.2	2.2	18	1	US-10-630-660-5	Sequence 5, Appli
c 738	12.2	2.2	18	1	US-10-661-165-99	Sequence 99, Appl
c 739	12.2	2.2	18	1	US-10-777-838-22	Sequence 22, Appl
740	12.2	2.2	18	1	US-10-735-308-31	Sequence 31, Appl
c 741	12.2	2.2	19	1	US-10-265-689-15	Sequence 15, Appl
742	12	2.1	15	1	US-08-892-503-1	Sequence 1, Appli
c 743	12	2.1	15	1	US-08-892-503-2	Sequence 2, Appli
c 744	12	2.1	15	1	US-09-805-296D-12	Sequence 12, Appl
745	12	2.1	15	1	US-09-918-995-38044	Sequence 38044, A
c 746	12	2.1	15	1	US-09-918-995-38045	Sequence 38045, A
c 747	12	2.1	15	1	US-10-072-975-12	Sequence 12, Appl
748	12	2.1	15	1	US-10-187-251A-1	Sequence 1, Appli
c 749	12	2.1	15	1	US-10-051-436-12	Sequence 12, Appl
c 750	12	2.1	15	1	US-10-440-850-112	Sequence 112, App
c 751	12	2.1	15	1	US-10-440-850-113	Sequence 113, App
c 752	12	2.1	15	1	US-10-360-275-12	Sequence 12, Appl
c 753	12	2.1	16	1	US-09-955-410-29	Sequence 29, Appl
c 754	12	2.1	16	1	US-09-983-210-29	Sequence 29, Appl
c 755	12	2.1	16	1	US-10-154-890-29	Sequence 29, Appl
756	12	2.1	17	1	US-09-877-478-441	Sequence 441, App
757	12	2.1	17	1	US-09-877-478-1165	Sequence 1165, Ap
758	12	2.1	17	1	US-10-060-756A-1170	Sequence 1170, Ap
759	12	2.1	17	1	US-10-060-756A-1171	Sequence 1171, Ap
760	12	2.1	17	1	US-10-060-756A-1172	Sequence 1172, Ap
761	12	2.1	17	1	US-10-060-756A-1173	Sequence 1173, Ap
762	12	2.1	17	1	US-10-156-306-204	Sequence 204, App
763	12	2.1	17	1	US-10-156-306-205	Sequence 205, App
764	12	2.1	17	1	US-10-156-306-206	Sequence 206, App
765	12	2.1	17	1	US-10-156-306-1429	Sequence 1429, Ap
766	12	2.1	17	1	US-10-156-306-3601	Sequence 3601, Ap
c 767	12	2.1	17	1	US-10-061-201-954	Sequence 954, App
c 768	12	2.1	17	1	US-10-061-201-960	Sequence 960, App
c 769	12	2.1	17	1	US-10-230-006-2221	Sequence 2221, Ap
770	12	2.1	17	1	US-10-342-902-441	Sequence 441, App
771	12	2.1	17	1	US-10-342-902-1165	Sequence 1165, Ap
772	12	2.1	17	1	US-10-676-154-510	Sequence 510, App
773	12	2.1	17	1	US-10-669-841-441	Sequence 441, App
774	12	2.1	17	1	US-10-669-841-1165	Sequence 1165, Ap
c 775	12	2.1	18	1	US-10-468-199-64	Sequence 64, Appl
c 776	12	2.1	21	1	US-10-786-720-358	Sequence 358, App
c 777	11.8	2.1	15	1	US-09-263-959-69	Sequence 69, Appl
778	11.8	2.1	15	1	US-09-971-843-28	Sequence 28, Appl
c 779	11.8	2.1	15	1	US-09-848-754A-9106	Sequence 9106, Ap
c 780	11.8	2.1	15	1	US-09-927-811A-4	Sequence 4, Appli
c 781	11.8	2.1	15	1	US-10-287-919-1164	Sequence 1164, Ap
782	11.8	2.1	15	1	US-10-287-919-1165	Sequence 1165, Ap
783	11.8	2.1	15	1	US-10-287-919-2029	Sequence 2029, Ap
c 784	11.8	2.1	15	1	US-10-287-919-2625	Sequence 2625, Ap
785	11.8	2.1	15	1	US-10-287-919-2699	Sequence 2699, Ap
c 786	11.8	2.1	15	1	US-10-091-281-97	Sequence 97, Appl
787	11.8	2.1	15	1	US-10-440-850-307	Sequence 307, App
c 788	11.8	2.1	15	1	US-10-719-995-16	Sequence 16, Appl
789	11.8	2.1	16	1	US-09-791-190A-9	Sequence 9, Appli
790	11.8	2.1	16	1	US-09-828-455-37	Sequence 37, Appl
c 791	11.8	2.1	16	1	US-10-287-919-600	Sequence 600, App
c 792	11.8	2.1	16	1	US-10-287-919-777	Sequence 777, App
c 793	11.8	2.1	16	1	US-10-287-919-796	Sequence 796, App
c 794	11.8	2.1	16	1	US-10-287-919-2205	Sequence 2205, Ap
c 795	11.8	2.1	16	1	US-10-108-164-68	Sequence 68, Appl
796	11.8	2.1	16	1	US-10-255-120-462	Sequence 462, App
c 797	11.8	2.1	17	1	US-09-866-108-1344	Sequence 1344, Ap
c 798	11.8	2.1	17	1	US-09-866-108-1348	Sequence 1348, Ap
c 799	11.8	2.1	17	1	US-09-866-108-1579	Sequence 1579, Ap
c 800	11.8	2.1	17	1	US-09-866-108-1582	Sequence 1582, Ap
801	11.8	2.1	17	1	US-09-866-108-1700	Sequence 1700, Ap
802	11.8	2.1	17	1	US-09-866-108-1701	Sequence 1701, Ap
803	11.8	2.1	17	1	US-09-866-108-1702	Sequence 1702, Ap
c 804	11.8	2.1	17	1	US-09-866-108-7645	Sequence 7645, Ap
805	11.8	2.1	17	1	US-09-866-108-7959	Sequence 7959, Ap
c 806	11.8	2.1	17	1	US-09-866-108-8582	Sequence 8582, Ap
c 807	11.8	2.1	17	1	US-09-866-108-8583	Sequence 8583, Ap
c 808	11.8	2.1	17	1	US-09-866-108-8584	Sequence 8584, Ap
c 809	11.8	2.1	17	1	US-09-866-108-10542	Sequence 10542, A
c 810	11.8	2.1	17	1	US-09-866-108-10543	Sequence 10543, A
811	11.8	2.1	17	1	US-09-827-998-310	Sequence 310, App
812	11.8	2.1	17	1	US-09-827-998-313	Sequence 313, App
c 813	11.8	2.1	17	1	US-09-864-785-7	Sequence 7, Appli
c 814	11.8	2.1	17	1	US-09-864-785-1429	Sequence 1429, Ap
c 815	11.8	2.1	17	1	US-09-864-785-2972	Sequence 2972, Ap
c 816	11.8	2.1	17	1	US-09-864-785-2973	Sequence 2973, Ap
817	11.8	2.1	17	1	US-09-730-289B-246	Sequence 246, App
818	11.8	2.1	17	1	US-09-730-289B-613	Sequence 613, App
c 819	11.8	2.1	17	1	US-09-730-289B-646	Sequence 646, App
820	11.8	2.1	17	1	US-09-730-289B-721	Sequence 721, App
821	11.8	2.1	17	1	US-09-730-289B-741	Sequence 741, App
c 822	11.8	2.1	17	1	US-09-780-533A-1225	Sequence 1225, Ap
c 823	11.8	2.1	17	1	US-09-780-533A-1250	Sequence 1250, Ap
824	11.8	2.1	17	1	US-09-780-533A-1416	Sequence 1416, Ap
c 825	11.8	2.1	17	1	US-09-780-533A-1680	Sequence 1680, Ap
826	11.8	2.1	17	1	US-09-780-533A-1734	Sequence 1734, Ap
c 827	11.8	2.1	17	1	US-09-780-533A-1761	Sequence 1761, Ap
c 828	11.8	2.1	17	1	US-09-780-533A-1865	Sequence 1865, Ap
c 829	11.8	2.1	17	1	US-09-780-533A-2309	Sequence 2309, Ap
c 830	11.8	2.1	17	1	US-09-780-533A-2444	Sequence 2444, Ap
c 831	11.8	2.1	17	1	US-09-780-533A-2486	Sequence 2486, Ap
c 832	11.8	2.1	17	1	US-09-780-533A-2487	Sequence 2487, Ap
833	11.8	2.1	17	1	US-09-927-046-351	Sequence 351, App
c 834	11.8	2.1	17	1	US-09-927-046-438	Sequence 438, App
c 835	11.8	2.1	17	1	US-09-927-046-543	Sequence 543, App
c 836	11.8	2.1	17	1	US-09-927-046-544	Sequence 544, App

837	11.8	2.1	17	1	US-09-927-046-1003	Sequence 1003, Ap
838	11.8	2.1	17	1	US-09-927-046-1004	Sequence 1004, Ap
c 839	11.8	2.1	17	1	US-09-927-046-1118	Sequence 1118, Ap
840	11.8	2.1	17	1	US-09-927-046-1296	Sequence 1296, Ap
841	11.8	2.1	17	1	US-09-927-046-1521	Sequence 1521, Ap
c 842	11.8	2.1	17	1	US-09-927-046-1765	Sequence 1765, Ap
843	11.8	2.1	17	1	US-09-877-478-604	Sequence 604, App
844	11.8	2.1	17	1	US-09-877-478-2130	Sequence 2130, Ap
c 845	11.8	2.1	17	1	US-09-848-754A-129	Sequence 129, App
846	11.8	2.1	17	1	US-09-848-754A-747	Sequence 747, App
847	11.8	2.1	17	1	US-09-848-754A-748	Sequence 748, App
848	11.8	2.1	17	1	US-09-848-754A-1852	Sequence 1852, Ap
c 849	11.8	2.1	17	1	US-09-930-423-249	Sequence 249, App
c 850	11.8	2.1	17	1	US-09-930-423-250	Sequence 250, App
c 851	11.8	2.1	17	1	US-09-930-423-919	Sequence 919, App
c 852	11.8	2.1	17	1	US-09-780-164-138	Sequence 138, App
c 853	11.8	2.1	17	1	US-09-827-395A-451	Sequence 451, App
854	11.8	2.1	17	1	US-09-740-332-1403	Sequence 1403, Ap
855	11.8	2.1	17	1	US-09-740-332-1415	Sequence 1415, Ap
c 856	11.8	2.1	17	1	US-09-740-332-3140	Sequence 3140, Ap
c 857	11.8	2.1	17	1	US-09-745-237A-249	Sequence 249, App
c 858	11.8	2.1	17	1	US-09-745-237A-250	Sequence 250, App
c 859	11.8	2.1	17	1	US-09-745-237A-919	Sequence 919, App
860	11.8	2.1	17	1	US-09-817-879-1403	Sequence 1403, Ap
861	11.8	2.1	17	1	US-09-817-879-1415	Sequence 1415, Ap
c 862	11.8	2.1	17	1	US-09-817-879-3140	Sequence 3140, Ap
863	11.8	2.1	17	1	US-10-060-830-249	Sequence 249, App
c 864	11.8	2.1	17	1	US-10-287-919-2382	Sequence 2382, Ap
865	11.8	2.1	17	1	US-10-211-059-116	Sequence 116, App
866	11.8	2.1	17	1	US-10-060-998-559	Sequence 559, App
867	11.8	2.1	17	1	US-10-060-998-560	Sequence 560, App
c 868	11.8	2.1	17	1	US-10-060-998-784	Sequence 784, App
c 869	11.8	2.1	17	1	US-10-060-998-785	Sequence 785, App
c 870	11.8	2.1	17	1	US-10-060-998-786	Sequence 786, App
c 871	11.8	2.1	17	1	US-10-060-998-901	Sequence 901, App
c 872	11.8	2.1	17	1	US-10-060-998-902	Sequence 902, App
c 873	11.8	2.1	17	1	US-10-060-998-903	Sequence 903, App
874	11.8	2.1	17	1	US-10-156-306-48	Sequence 48, Appl
875	11.8	2.1	17	1	US-10-156-306-1312	Sequence 1312, Ap
876	11.8	2.1	17	1	US-10-156-306-1382	Sequence 1382, Ap
877	11.8	2.1	17	1	US-10-156-306-1458	Sequence 1458, Ap
c 878	11.8	2.1	17	1	US-10-156-306-2869	Sequence 2869, Ap
879	11.8	2.1	17	1	US-10-156-306-3552	Sequence 3552, Ap
c 880	11.8	2.1	17	1	US-10-156-306-5815	Sequence 5815, Ap
881	11.8	2.1	17	1	US-10-156-306-6825	Sequence 6825, Ap
c 882	11.8	2.1	17	1	US-10-156-306-6859	Sequence 6859, Ap
c 883	11.8	2.1	17	1	US-10-238-700-3360	Sequence 3360, Ap
884	11.8	2.1	17	1	US-10-339-782-155	Sequence 155, App
c 885	11.8	2.1	17	1	US-10-339-782-373	Sequence 373, App
c 886	11.8	2.1	17	1	US-10-430-882-451	Sequence 451, App
887	11.8	2.1	17	1	US-10-307-005-2507	Sequence 2507, Ap
c 888	11.8	2.1	17	1	US-10-307-005-2508	Sequence 2508, Ap
889	11.8	2.1	17	1	US-10-307-005-2511	Sequence 2511, Ap
c 890	11.8	2.1	17	1	US-10-307-005-2512	Sequence 2512, Ap
891	11.8	2.1	17	1	US-10-342-902-604	Sequence 604, App
892	11.8	2.1	17	1	US-10-342-902-2130	Sequence 2130, Ap
893	11.8	2.1	17	1	US-10-675-685-310	Sequence 310, App
894	11.8	2.1	17	1	US-10-675-685-313	Sequence 313, App
895	11.8	2.1	17	1	US-10-138-674-315	Sequence 315, App
896	11.8	2.1	17	1	US-10-138-674-611	Sequence 611, App
c 897	11.8	2.1	17	1	US-10-138-674-750	Sequence 750, App
c 898	11.8	2.1	17	1	US-10-138-674-777	Sequence 777, App
c 899	11.8	2.1	17	1	US-10-138-674-1141	Sequence 1141, Ap
c 900	11.8	2.1	17	1	US-10-138-674-2276	Sequence 2276, Ap
c 901	11.8	2.1	17	1	US-10-138-674-2868	Sequence 2868, Ap
c 902	11.8	2.1	17	1	US-10-138-674-3206	Sequence 3206, Ap
903	11.8	2.1	17	1	US-10-138-674-3528	Sequence 3528, Ap
904	11.8	2.1	17	1	US-10-138-674-4920	Sequence 4920, Ap
c 905	11.8	2.1	17	1	US-10-138-674-5162	Sequence 5162, Ap
906	11.8	2.1	17	1	US-10-138-674-6409	Sequence 6409, Ap
c 907	11.8	2.1	17	1	US-10-138-674-7210	Sequence 7210, Ap
c 908	11.8	2.1	17	1	US-10-138-674-7211	Sequence 7211, Ap
c 909	11.8	2.1	17	1	US-10-138-674-7880	Sequence 7880, Ap
910	11.8	2.1	17	1	US-10-138-674-7954	Sequence 7954, Ap
c 911	11.8	2.1	17	1	US-10-138-674-8181	Sequence 8181, Ap
912	11.8	2.1	17	1	US-10-287-949A-315	Sequence 315, App
913	11.8	2.1	17	1	US-10-287-949A-611	Sequence 611, App
c 914	11.8	2.1	17	1	US-10-287-949A-750	Sequence 750, App
c 915	11.8	2.1	17	1	US-10-287-949A-777	Sequence 777, App
c 916	11.8	2.1	17	1	US-10-287-949A-1141	Sequence 1141, Ap
c 917	11.8	2.1	17	1	US-10-287-949A-2276	Sequence 2276, Ap
c 918	11.8	2.1	17	1	US-10-287-949A-2868	Sequence 2868, Ap
c 919	11.8	2.1	17	1	US-10-287-949A-3206	Sequence 3206, Ap
920	11.8	2.1	17	1	US-10-287-949A-3528	Sequence 3528, Ap
921	11.8	2.1	17	1	US-10-287-949A-4920	Sequence 4920, Ap
c 922	11.8	2.1	17	1	US-10-287-949A-5162	Sequence 5162, Ap
923	11.8	2.1	17	1	US-10-287-949A-6409	Sequence 6409, Ap
c 924	11.8	2.1	17	1	US-10-287-949A-7210	Sequence 7210, Ap
c 925	11.8	2.1	17	1	US-10-287-949A-7211	Sequence 7211, Ap
c 926	11.8	2.1	17	1	US-10-287-949A-7880	Sequence 7880, Ap
927	11.8	2.1	17	1	US-10-287-949A-7954	Sequence 7954, Ap
c 928	11.8	2.1	17	1	US-10-287-949A-8181	Sequence 8181, Ap
c 929	11.8	2.1	17	1	US-10-712-672-959	Sequence 959, App
c 930	11.8	2.1	17	1	US-10-712-672-1413	Sequence 1413, Ap
c 931	11.8	2.1	17	1	US-10-712-672-1414	Sequence 1414, Ap
c 932	11.8	2.1	17	1	US-10-712-672-2206	Sequence 2206, Ap
933	11.8	2.1	17	1	US-10-712-672-2689	Sequence 2689, Ap
934	11.8	2.1	17	1	US-10-669-841-604	Sequence 604, App
935	11.8	2.1	17	1	US-10-669-841-3996	Sequence 3996, Ap
936	11.8	2.1	17	1	US-10-669-841-4008	Sequence 4008, Ap
c 937	11.8	2.1	17	1	US-10-669-841-5733	Sequence 5733, Ap
c 938	11.8	2.1	17	1	US-10-723-361-1344	Sequence 1344, Ap
c 939	11.8	2.1	17	1	US-10-723-361-1348	Sequence 1348, Ap
c 940	11.8	2.1	17	1	US-10-723-361-1579	Sequence 1579, Ap
c 941	11.8	2.1	17	1	US-10-723-361-1582	Sequence 1582, Ap
942	11.8	2.1	17	1	US-10-723-361-1700	Sequence 1700, Ap
943	11.8	2.1	17	1	US-10-723-361-1701	Sequence 1701, Ap
944	11.8	2.1	17	1	US-10-723-361-1702	Sequence 1702, Ap
c 945	11.8	2.1	17	1	US-10-723-361-7645	Sequence 7645, Ap
946	11.8	2.1	17	1	US-10-723-361-7959	Sequence 7959, Ap
c 947	11.8	2.1	17	1	US-10-723-361-8582	Sequence 8582, Ap
c 948	11.8	2.1	17	1	US-10-723-361-8583	Sequence 8583, Ap
c 949	11.8	2.1	17	1	US-10-723-361-8584	Sequence 8584, Ap
c 950	11.8	2.1	17	1	US-10-723-361-10542	Sequence 10542, A
c 951	11.8	2.1	17	1	US-10-723-361-10543	Sequence 10543, A
c 952	11.8	2.1	18	1	US-09-823-699-18	Sequence 18, Appl
953	11.8	2.1	18	1	US-09-969-373-4180	Sequence 4180, Ap
954	11.8	2.1	18	1	US-09-918-186A-117	Sequence 117, App
955	11.8	2.1	18	1	US-09-771-933-176	Sequence 176, App
c 956	11.8	2.1	18	1	US-10-177-063-7	Sequence 7, Appli
957	11.8	2.1	18	1	US-10-025-524-20	Sequence 20, Appl
958	11.8	2.1	18	1	US-10-206-839-43	Sequence 43, Appl
c 959	11.8	2.1	18	1	US-10-223-646-6	Sequence 6, Appli
c 960	11.8	2.1	18	1	US-10-160-764-15	Sequence 15, Appl
961	11.8	2.1	18	1	US-10-367-438-162	Sequence 162, App
c 962	11.8	2.1	18	1	US-10-339-674-715	Sequence 715, App
963	11.8	2.1	18	1	US-10-181-316-117	Sequence 117, App
964	11.8	2.1	18	1	US-10-282-174-42	Sequence 42, Appl
965	11.8	2.1	18	1	US-10-388-263-223	Sequence 223, App
c 966	11.8	2.1	18	1	US-10-349-143-4956	Sequence 4956, Ap
967	11.8	2.1	18	1	US-10-349-143-4997	Sequence 4997, Ap
968	11.8	2.1	18	1	US-10-349-143-5155	Sequence 5155, Ap
c 969	11.8	2.1	18	1	US-10-349-143-5351	Sequence 5351, Ap
970	11.8	2.1	18	1	US-10-349-143-5769	Sequence 5769, Ap
c 971	11.8	2.1	18	1	US-10-349-143-5871	Sequence 5871, Ap
c 972	11.8	2.1	18	1	US-10-349-143-6093	Sequence 6093, Ap
c 973	11.8	2.1	18	1	US-10-349-143-7562	Sequence 7562, Ap
c 974	11.8	2.1	18	1	US-10-349-143-7804	Sequence 7804, Ap
c 975	11.8	2.1	18	1	US-10-349-143-8887	Sequence 8887, Ap
976	11.8	2.1	18	1	US-10-349-143-9171	Sequence 9171, Ap
c 977	11.8	2.1	18	1	US-10-349-143-9321	Sequence 9321, Ap
978	11.8	2.1	18	1	US-10-349-143-9456	Sequence 9456, Ap
c 979	11.8	2.1	18	1	US-10-229-541A-21	Sequence 21, Appl
c 980	11.8	2.1	18	1	US-10-453-792-264	Sequence 264, App
981	11.8	2.1	18	1	US-10-432-531-22	Sequence 22, Appl
c 982	11.8	2.1	18	1	US-10-765-500-58	Sequence 58, Appl

983	11.8	2.1	18	1	US-10-731-739-449	Sequence 449, App
984	11.8	2.1	19	1	US-10-665-951-1165	Sequence 1165, Ap
c 985	11.8	2.1	19	1	US-10-665-951-1489	Sequence 1489, Ap
c 986	11.6	2.1	16	1	US-10-681-074-2303	Sequence 2303, Ap
987	11.6	2.1	20	1	US-10-023-782A-60	Sequence 60, Appl
c 988	11.4	2.0	21	1	US-10-786-720-191	Sequence 191, App
989	11.4	2.0	21	1	US-10-786-720-192	Sequence 192, App
990	11.4	2.0	25	1	US-10-339-674-1277	Sequence 1277, Ap
991	11.2	2.0	17	1	US-10-138-674-749	Sequence 749, App
992	11.2	2.0	17	1	US-10-287-949A-749	Sequence 749, App
993	11.2	2.0	17	1	US-10-061-201-954	Sequence 954, App
994	11.2	2.0	17	1	US-10-138-674-750	Sequence 750, App
995	11.2	2.0	17	1	US-10-287-949A-750	Sequence 750, App

ALIGNMENTS

```
RESULT 1
US-10-023-782A-55/c
; Sequence 55, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 55
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-55

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGAGAGTA 1548
              ||||||||||||||||||||
Db         20 GAAGAAAGGTTAGGAGAGTA 1


RESULT 2
US-10-023-782A-56/c
; Sequence 56, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 56
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-56

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1564 TGCAAAAATCCTTCTCCACC 1583
              ||||||||||||||||||||
Db         20 TGCAAAAATCCTTCTCCACC 1


RESULT 3
US-10-023-782A-57/c
; Sequence 57, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 57
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-57

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1645 AGAGCCTTCACTGGTTCTGC 1664
              ||||||||||||||||||||
Db         20 AGAGCCTTCACTGGTTCTGC 1


RESULT 4
US-10-023-782A-58/c
; Sequence 58, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 58
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-58

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1712 CTCCTAACTTTGGACCTATT 1731
              ||||||||||||||||||||
Db         20 CTCCTAACTTTGGACCTATT 1


RESULT 5
US-10-023-782A-59/c
; Sequence 59, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
```

```
; SEQ ID NO 59
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-59

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1733 TCAGAAGGTGACAAGTACTG 1752
             ||||||||||||||||||||
Db         20 TCAGAAGGTGACAAGTACTG 1


RESULT 6
US-10-023-782A-60/c
; Sequence 60, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 60
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-60

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1751 TGGCTCTTTATTCATTAAGC 1770
             ||||||||||||||||||||
Db         20 TGGCTCTTTATTCATTAAGC 1


RESULT 7
US-10-023-782A-61/c
; Sequence 61, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 61
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-61

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTCCC 1846
             ||||||||||||||||||||
Db         20 AATCTTTTAAATACATTCCC 1


RESULT 8
US-10-023-782A-62/c
; Sequence 62, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 62
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-62

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1864 ACACTTAGCCATTGAAATGT 1883
             ||||||||||||||||||||
Db         20 ACACTTAGCCATTGAAATGT 1


RESULT 9
US-10-023-782A-63/c
; Sequence 63, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 63
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-63

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1877 GAAATGTCAAATTGATGTGC 1896
             ||||||||||||||||||||
Db         20 GAAATGTCAAATTGATGTGC 1


RESULT 10
US-10-023-782A-64/c
; Sequence 64, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 64
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-64

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGGCAAAGG 2040
              ||||||||||||||||||||
Db         20 CCTCTGGTAGGAGGCAAAGG 1


RESULT 11
US-10-023-782A-65/c
; Sequence 65, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 65
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-65

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2029 AGGAGGCAAAGGTTCTATCT 2048
              ||||||||||||||||||||
Db         20 AGGAGGCAAAGGTTCTATCT 1


RESULT 12
US-10-023-782A-66/c
; Sequence 66, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 66
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-66

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 AGTGGTATCTGACACACTCT 2087
              ||||||||||||||||||||
Db         20 AGTGGTATCTGACACACTCT 1


RESULT 13
US-10-158-735-22
; Sequence 22, Application US/10158735
; Publication No. US20020182724A1
; GENERAL INFORMATION:
;  APPLICANT: Zambrowicz, Brian
;  APPLICANT:  Friedrich, Glenn A.
;  APPLICANT:  Lilleberg, Stan
;  APPLICANT:  Sands, Arthur T.
;  TITLE OF INVENTION: VECTORS FOR GENE MUTAGENESIS AND GENE
;  TITLE OF INVENTION:  DISCOVERY
;  FILE REFERENCE: 7705-0006-01
;  CURRENT APPLICATION NUMBER: US/10/158,735
;  CURRENT FILING DATE:  2002-05-29
;  PRIOR APPLICATION NUMBER: US 09/276,533
;  PRIOR FILING DATE: 1999-03-25
;  PRIOR APPLICATION NUMBER: US 60/079,729
;  PRIOR FILING DATE: 1998-03-27
;  PRIOR APPLICATION NUMBER: US 60/081,727
;  PRIOR FILING DATE: 1998-04-14
;  PRIOR APPLICATION NUMBER: US 60/109,302
;  PRIOR FILING DATE: 1998-11-20
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-158-735-22

  Query Match             3.3%;  Score 18.2;  DB 1;  Length 23;
  Best Local Similarity   87.0%;  Pred. No. 34;
  Matches   20;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1999 CTAGCTTCTTCAGAGATCAAGTC 2021
              | ||  ||||||||||||||||||
Db          1 CCAGAGTCTTCAGAGATCAAGTC 23


RESULT 14
US-10-206-561-3/c
; Sequence 3, Application US/10206561
; Publication No. US20030157507A1
; GENERAL INFORMATION:
;  APPLICANT: Lipsky, Robert  H.
;  APPLICANT:  Mazzanti, Chiara
;  APPLICANT:  Goldman, David
;  TITLE OF INVENTION: METHOD FOR DETECTING NUCLEIC ACID SEQUENCE VARIATION
;  FILE REFERENCE: 4239-62563
;  CURRENT APPLICATION NUMBER: US/10/206,561
;  CURRENT FILING DATE:  2002-07-25
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Fragments of the human HTR2A sequence
US-10-206-561-3

  Query Match             3.1%;  Score 17.2;  DB 1;  Length 25;
  Best Local Similarity   86.4%;  Pred. No. 65;
  Matches   19;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATCAAGTC 2021
              |||||||| ||||| | |||||
Db         23 TAGCTTCTCCAGAGTTAAAGTC 2
```

```
RESULT 15
US-10-098-263B-2693/c
; Sequence 2693, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
;  APPLICANT: Mittman, Michael
;  TITLE OF INVENTION: Human Microarray
;  FILE REFERENCE: 3118.1
;  CURRENT APPLICATION NUMBER: US/10/098,263B
;  CURRENT FILING DATE:  2003-01-08
;  PRIOR APPLICATION NUMBER: 60/276,759
;  PRIOR FILING DATE: 2001-03-16
;  NUMBER OF SEQ ID NOS: 131066
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 2693
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-10-098-263B-2693

  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 71;
  Matches   20;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGGGAAGGAACA 1559
             |||||| || | |||||| ||| ||
Db         25 AGGTTACGACAATAGGGACGGACCA 1


RESULT 16
US-10-098-263B-3329/c
; Sequence 3329, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
;  APPLICANT: Mittman, Michael
;  TITLE OF INVENTION: Human Microarray
;  FILE REFERENCE: 3118.1
;  CURRENT APPLICATION NUMBER: US/10/098,263B
;  CURRENT FILING DATE:  2003-01-08
;  PRIOR APPLICATION NUMBER: 60/276,759
;  PRIOR FILING DATE: 2001-03-16
;  NUMBER OF SEQ ID NOS: 131066
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 3329
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-10-098-263B-3329

  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 71;
  Matches   20;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGGAAGGAACAG 1560
             ||||| || | |||||| ||| |||
Db         25 GGTTACGACAATAGGGACGGACCAG 1


RESULT 17
US-10-098-263B-61992
; Sequence 61992, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
;  APPLICANT: Mittman, Michael
;  TITLE OF INVENTION: Human Microarray
;  FILE REFERENCE: 3118.1
;  CURRENT APPLICATION NUMBER: US/10/098,263B
;  CURRENT FILING DATE:  2003-01-08
;  PRIOR APPLICATION NUMBER: 60/276,759
;  PRIOR FILING DATE: 2001-03-16
;  NUMBER OF SEQ ID NOS: 131066
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 61992
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-10-098-263B-61992

  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 71;
  Matches   20;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTGTTAAGGT 1941
              | || | | |||||||||||| ||||
Db          1 AGACTTGTCTTTTCAGTGTTCAGGT 25


RESULT 18
US-10-339-674-1277/c
; Sequence 1277, Application US/10339674
; Publication No. US20030204318A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/339,674
;  CURRENT FILING DATE:  2003-06-06
;  NUMBER OF SEQ ID NOS: 3537
;  SOFTWARE: Proprietary
; SEQ ID NO 1277
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Escherichia coli K-12 MG1655 complete genome.
;   FEATURE:
;   LOCATION: (1530784)...(1530809)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =  1678
US-10-339-674-1277

  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 71;
  Matches   20;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1546 GTAGGGAAGGAACAGGACTGCAAAA 1570
              |||  ||| ||| | ||||||||||
Db         25 GTAATGAATGAAGACGACTGCAAAA 1


RESULT 19
US-10-098-263B-99036/c
; Sequence 99036, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
;  APPLICANT: Mittman, Michael
;  TITLE OF INVENTION: Human Microarray
;  FILE REFERENCE: 3118.1
;  CURRENT APPLICATION NUMBER: US/10/098,263B
;  CURRENT FILING DATE:  2003-01-08
;  PRIOR APPLICATION NUMBER: 60/276,759
;  PRIOR FILING DATE: 2001-03-16
;  NUMBER OF SEQ ID NOS: 131066
;  SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 99036
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-10-098-263B-99036

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 87;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCTTTC 1796
              || |||||| || | ||||||||
Db         24 TTCTTTTTGTACACGATTCTTTC 2
```

```
RESULT 20
US-10-277-216-162
; Sequence 162, Application US/10277216
; Publication No. US20040002470A1
; GENERAL INFORMATION:
;  APPLICANT: KEITH, TIM
;  TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
;  TITLE OF INVENTION:  OBESITY, AND INFLAMMATORY BOWEL DISEASE
;  FILE REFERENCE: 2976-4051
;  CURRENT APPLICATION NUMBER: US/10/277,216
;  CURRENT FILING DATE:  2002-10-17
;  PRIOR APPLICATION NUMBER: 10/126,022
;  PRIOR FILING DATE: 2002-04-19
;  PRIOR APPLICATION NUMBER: 09/834,597
;  PRIOR FILING DATE: 2001-04-13
;  PRIOR APPLICATION NUMBER: 09/548,797
;  PRIOR FILING DATE: 2000-04-13
;  NUMBER OF SEQ ID NOS: 420
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 162
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-277-216-162

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 65;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1558 CAGGACTGCAAAAATCCT 1575
              ||||||||||||| |||||
Db          1 CAGGACTGCAAACATCCT 18


RESULT 21
US-10-126-022-162
; Sequence 162, Application US/10126022
; Publication No. US20040023215A1
; GENERAL INFORMATION:
;  APPLICANT: KEITH, TIM
;  TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
;  TITLE OF INVENTION:  OBESITY, AND INFLAMMATORY BOWEL DISEASE
;  FILE REFERENCE: 2976-4039US2
;  CURRENT APPLICATION NUMBER: US/10/126,022
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: 09/834,597
;  PRIOR FILING DATE: 2001-04-13
;  PRIOR APPLICATION NUMBER: 09/548,797
;  PRIOR FILING DATE: 2000-04-13
;  NUMBER OF SEQ ID NOS: 420
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 162
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-162

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 65;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1558 CAGGACTGCAAAAATCCT 1575
              ||||||||||||| |||||
Db          1 CAGGACTGCAAACATCCT 18


RESULT 22
US-10-786-720-11753/c
; Sequence 11753, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11753
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-11753

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 21;
  Best Local Similarity   94.4%;  Pred. No. 71;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1743 ACAAGTACTGGCTCTTTA 1760
              |||||||||||||||| |
Db         20 ACAAGTACTGGCTCTTCA 3


RESULT 23
US-10-349-143-8160
; Sequence 8160, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8160
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..21
;   OTHER INFORMATION: downstream amplification primer 99-14072 for SEQ 295, in compleme
US-10-349-143-8160

  Query Match             2.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 78;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACCGCAC 1587
              || |||| |||||||| ||||
Db          1 AATAATCTTTCTCCACTGCAC 21


RESULT 24
US-10-786-720-191
; Sequence 191, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
```

```
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 191
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-191

  Query Match             2.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   57.1%;  Pred. No. 78;
  Matches   12;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1869 TAGCCATTGAAATGTCAAATT 1889
              :|||||::||||:|   ||::
Db          1 UAGCCAUUGAAAUGGAUAAUU 21


RESULT 25
US-10-357-567-71/c
; Sequence 71, Application US/10357567
; Publication No. US20040038382A1
; GENERAL INFORMATION:
;  APPLICANT: Coschigano, Peter
;  TITLE OF INVENTION: Compositions and Methods for Bioremdiation
;  FILE REFERENCE: OHU-07748
;  CURRENT APPLICATION NUMBER: US/10/357,567
;  CURRENT FILING DATE:  2003-02-04
;  PRIOR APPLICATION NUMBER: 09/072,433
;  PRIOR FILING DATE: 1998-05-04
;  PRIOR APPLICATION NUMBER: 60/046,845
;  PRIOR FILING DATE: 1997-05-05
;  NUMBER OF SEQ ID NOS: 71
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 71
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-357-567-71

  Query Match             2.9%;  Score 16;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 72;
  Matches   16;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAGAG 1620
              ||||||||||||||||
Db         16 TGGCCTGGGGGAAGAG 1


RESULT 26
US-10-786-720-12408
; Sequence 12408, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12408
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-12408

  Query Match             2.9%;  Score 16;  DB 1;  Length 21;
  Best Local Similarity   62.5%;  Pred. No. 86;
  Matches   10;  Conservative    6;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1744 CAAGTACTGGCTCTTT 1759
              ||||:||:|||:|:::
Db          6 CAAGUACUGGCUCUUU 21


RESULT 27
US-10-148-188-15/c
; Sequence 15, Application US/10148188
; Publication No. US20030148489A1
; GENERAL INFORMATION:
;  APPLICANT: OKADA, YUKIO
;  APPLICANT:  ITO, KAZUTOSHI
;  TITLE OF INVENTION: Farnesyl pyrophosphate synthase protein, nucleic acid encoding th
;  TITLE OF INVENTION:  and promoter region thereof
;  FILE REFERENCE: 223968US0PCT
;  CURRENT APPLICATION NUMBER: US/10/148,188
;  CURRENT FILING DATE:  2002-06-06
;  PRIOR APPLICATION NUMBER: JP 2000-308054
;  PRIOR FILING DATE: 2000-10-06
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: ARTIFICIAL SEQUENCE
;   FEATURE:
;   OTHER INFORMATION: SYNTHETIC DNA
US-10-148-188-15

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 87;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCTTCTC 1579
              | |||| ||||||||||||
Db         20 GGCTGCCAAAATCCTTCTC 2


RESULT 28
US-10-449-741B-30/c
; Sequence 30, Application US/10449741B
; Publication No. US20040142387A1
; GENERAL INFORMATION:
;  APPLICANT: LERNMARK, Ake
;  APPLICANT:  LUO, Dong
;  APPLICANT:  MACMURRAY, Armand
;  APPLICANT:  ETTINGER, Ruth
;  APPLICANT:  MORALEJO, Daniel
;  APPLICANT:  RUTLEDGE, Elizabeth A.
;  TITLE OF INVENTION: MUTANTS OF GAD65 AND IAN5 RELATING TO DIABETES
;  FILE REFERENCE: 16336-19
;  CURRENT APPLICATION NUMBER: US/10/449,741B
;  CURRENT FILING DATE:  2003-05-29
;  PRIOR APPLICATION NUMBER: US 60/383,913
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 30
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: PCR Primer
US-10-449-741B-30
```

```
  Query Match             2.8%;  Score 15.8;  DB 1;  Length 22;
  Best Local Similarity   89.5%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTTACCTAC 1632
              ||||||||||||| ||| ||
Db         21 GGAAGAGTTTGTGACCCAC 3


RESULT 29
US-10-265-689-23
; Sequence 23, Application US/10265689
; Publication No. US20030119775A1
; GENERAL INFORMATION:
;  APPLICANT: SURWIT, RICHARD S.
;  APPLICANT:  COLLINS, SHEILA A.
;  APPLICANT:  WARDEN, CRAIG H.
;  APPLICANT:  SELDIN, MICHAEL F.
;  APPLICANT:  RICQUIER, DANIEL
;  APPLICANT:  BOUILLAUD, FREDERIC
;  TITLE OF INVENTION: RESPIRATION UNCOUPLING PROTEIN
;  FILE REFERENCE: 1579-376
;  CURRENT APPLICATION NUMBER: US/10/265,689
;  CURRENT FILING DATE:  2002-10-08
;  PRIOR APPLICATION NUMBER: US/09/353,645
;  PRIOR FILING DATE: 1999-07-15
;  PRIOR APPLICATION NUMBER: PCT/US97/06864
;  PRIOR FILING DATE: 1997-04-22
;  PRIOR APPLICATION NUMBER: 60/034,960
;  PRIOR FILING DATE: 1997-01-15
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide
US-10-265-689-23

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 97;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGA 1556
              ||||||| |||||||||
Db          1 AGGAGAGAAGGGAAGGA 17


RESULT 30
US-09-935-464-8/c
; Sequence 8, Application US/09935464
; Publication No. US20030027153A1
; GENERAL INFORMATION:
;  APPLICANT: Meyer, Joanne
;  APPLICANT:  Barrington-Martin, Rory
;  APPLICANT:  Parker, Alexander
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING NEUROPSYCHIA
;  TITLE OF INVENTION:  DISORDERS SUCH AS SCHIZOPHRENIA
;  FILE REFERENCE: 3322/1H702 US1
;  CURRENT APPLICATION NUMBER: US/09/935,464
;  CURRENT FILING DATE:  2001-08-23
;  PRIOR APPLICATION NUMBER: US 09/757,300
;  PRIOR FILING DATE: 2001-01-09
;  NUMBER OF SEQ ID NOS: 90
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: DNA primer
US-09-935-464-8

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              |||||||||| ||||||
Db         17 CCCCATTCTTCCCTTCT 1


RESULT 31
US-10-125-835-8/c
; Sequence 8, Application US/10125835
; Publication No. US20030092019A1
; GENERAL INFORMATION:
;  APPLICANT: Meyer, Joanne
;  APPLICANT:  Barrington-Martin, Rory
;  APPLICANT:  Parker, Alexander
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING
;  TITLE OF INVENTION:  NEUROPSYCHIATRIC
;  TITLE OF INVENTION:  DISORDERS SUCH AS SCHIZOPHRENIA
;  FILE REFERENCE: 3322/0H702 US0
;  CURRENT APPLICATION NUMBER: US/10/125,835
;  CURRENT FILING DATE:  2002-04-19
;  PRIOR APPLICATION NUMBER: US/09/757,300
;  PRIOR FILING DATE: 2001-01-09
;  NUMBER OF SEQ ID NOS: 50
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Forward PCR primer
US-10-125-835-8

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              |||||||||| ||||||
Db         17 CCCCATTCTTCCCTTCT 1


RESULT 32
US-10-265-689-21
; Sequence 21, Application US/10265689
; Publication No. US20030119775A1
; GENERAL INFORMATION:
;  APPLICANT: SURWIT, RICHARD S.
;  APPLICANT:  COLLINS, SHEILA A.
;  APPLICANT:  WARDEN, CRAIG H.
;  APPLICANT:  SELDIN, MICHAEL F.
;  APPLICANT:  RICQUIER, DANIEL
;  APPLICANT:  BOUILLAUD, FREDERIC
;  TITLE OF INVENTION: RESPIRATION UNCOUPLING PROTEIN
;  FILE REFERENCE: 1579-376
;  CURRENT APPLICATION NUMBER: US/10/265,689
;  CURRENT FILING DATE:  2002-10-08
;  PRIOR APPLICATION NUMBER: US/09/353,645
;  PRIOR FILING DATE: 1999-07-15
;  PRIOR APPLICATION NUMBER: PCT/US97/06864
;  PRIOR FILING DATE: 1997-04-22
;  PRIOR APPLICATION NUMBER: 60/034,960
;  PRIOR FILING DATE: 1997-01-15
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 20
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide
US-10-265-689-21

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGA 1556
              ||||||| |||||||||
Db          2 AGGAGAGAAGGGAAGGA 18


RESULT 33
US-10-786-720-11752/c
; Sequence 11752, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11752
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-11752

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 21;
  Best Local Similarity   94.1%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 CAAGTACTGGCTCTTTA 1760
              ||||||||||||||| |
Db         21 CAAGTACTGGCTCTTCA 5


RESULT 34
US-10-786-720-11754
; Sequence 11754, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11754
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-11754

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 21;
  Best Local Similarity   64.7%;  Pred. No. 1.2e+02;
  Matches   11;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1744 CAAGTACTGGCTCTTTA 1760
              ||||:||:|||:|:: |
Db          1 CAAGUACUGGCUCUUCA 17


RESULT 35
US-10-363-514-5
; Sequence 5, Application US/10363514
; Publication No. US20040029770A1
; GENERAL INFORMATION:
;  APPLICANT: Eling, Thomas E
;  APPLICANT:  Baek, Seung Joon
;  TITLE OF INVENTION: A NON-STEROIDAL ANTI-INFLAMMATORY DRUG ACTIVATED GENE WITH ANTI-
;  TITLE OF INVENTION:  TUMORIGENIC PROPERTIES
;  FILE REFERENCE: 221473
;  CURRENT APPLICATION NUMBER: US/10/363,514
;  CURRENT FILING DATE:  2003-09-28
;  PRIOR APPLICATION NUMBER: PCT/US01/27544
;  PRIOR FILING DATE: 2001-09-06
;  PRIOR APPLICATION NUMBER: 60/231,246
;  PRIOR FILING DATE: 2000-09-08
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-363-514-5

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 23;
  Best Local Similarity   94.1%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTGC 1566
              ||||||| |||||||||
Db          5 GGAAGGACCAGGACTGC 21


RESULT 36
US-10-007-814-29
; Sequence 29, Application US/10007814
; Publication No. US20020160479A1
; GENERAL INFORMATION:
;  APPLICANT: Wojnowski, Leszek
;  APPLICANT:  Gellner, Klaus
;  APPLICANT:  Eiselt, Regina
;  TITLE OF INVENTION: IDENTIFICATION OF A NEW MEMBER OF THE CYTOCHROME P450 3A
;  TITLE OF INVENTION:  (CYP3A) GENE FAMILY: CYP3AX
;  FILE REFERENCE: 310115.401D1
;  CURRENT APPLICATION NUMBER: US/10/007,814
;  CURRENT FILING DATE:  2001-11-09
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-007-814-29

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1863 CACACTTAGCCATTGAAATG 1882
              || |||| ||||| ||||||
Db          1 CAAACTTTGCCATGGAAATG 20


RESULT 37
US-10-002-491-85
; Sequence 85, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
```

```
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 85
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-85

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1892 TGTGCCCTAGATCAACAGAT 1911
              | | |||||| |||||||||
Db          1 TTTTCCCTAGTTCAACAGAT 20


RESULT 38
US-10-084-555-53
; Sequence 53, Application US/10084555
; Publication No. US20030190616A1
; GENERAL INFORMATION:
;  APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
;  APPLICANT:  GOGGINS, Michael G.
;  APPLICANT:  UEKI, Takashi
;  TITLE OF INVENTION: DIFFERENTIALLY METHYLATED SEQUENCES IN PANCREATIC CANCER
;  FILE REFERENCE: JHU1700-1
;  CURRENT APPLICATION NUMBER: US/10/084,555
;  CURRENT FILING DATE:  2002-02-25
;  PRIOR APPLICATION NUMBER: US 60/271,268
;  PRIOR FILING DATE: 2001-02-23
;  NUMBER OF SEQ ID NOS: 114
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer
US-10-084-555-53

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1530 AAGAAAGGTTAGGAGAGTAG 1549
              |||| ||| | |||||||||
Db          1 AAGAGAGGGTTGGAGAGTAG 20


RESULT 39
US-10-671-395-1626
; Sequence 1626, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1626
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1626

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGACCCACAC 1865
              ||| ||| | ||||||||||
Db          1 CTGTGCCCAGAGACCCACAC 20


RESULT 40
US-10-786-720-6806
; Sequence 6806, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6806
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-6806

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 21;
  Best Local Similarity   40.0%;  Pred. No. 1.3e+02;
  Matches    8;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGTTGGTTTT 1954
              ::|||| | : |::||:::: 
Db          2 UUAAGGCAUUUGUUGGUUUU 21


RESULT 41
US-10-786-720-9074
; Sequence 9074, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9074
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-9074

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 21;
  Best Local Similarity   40.0%;  Pred. No. 1.3e+02;
  Matches    8;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGTTGGTTTT 1954
              ::|||| | : |::||:::: 
Db          2 UUAAGGCAUUUGUUGGUUUU 21
```

```
RESULT 42
US-10-466-836-21/c
; Sequence 21, Application US/10466836
; Publication No. US20040110922A1
; GENERAL INFORMATION:
;  APPLICANT: GAVISH-GALILEE BIO-APPLICATIONS LTD.
;  TITLE OF INVENTION: CHIMERIC PROTEINS FOR PREVENTION AND TREATMENT OF HIV   INFECTION
;  FILE REFERENCE: GAVISH-003 PCT
;  CURRENT APPLICATION NUMBER: US/10/466,836
;  CURRENT FILING DATE:  2003-11-14
;  PRIOR APPLICATION NUMBER: IL 141023
;  PRIOR FILING DATE: 2001-03-22
;  NUMBER OF SEQ ID NOS: 26
;  SOFTWARE: PatentIn Version 3.1
; SEQ ID NO 21
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: HUMAN
US-10-466-836-21

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 23;
  Best Local Similarity   85.0%;  Pred. No. 1.5e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1566 CAAAAATCCTTCTCCACCGC 1585
              ||||| ||| |||||| |||
Db         20 CAAAACTCCATCTCCAGCGC 1


RESULT 43
US-10-186-157-76/c
; Sequence 76, Application US/10186157
; Publication No. US20040002151A1
; GENERAL INFORMATION:
;  APPLICANT: Andrew T. Watt
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SELENOPHOSPHATE SYNTHETASE 2 EXPRESSION
;  FILE REFERENCE: RTS-0193
;  CURRENT APPLICATION NUMBER: US/10/186,157
;  CURRENT FILING DATE:  2002-06-28
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-186-157-76

  Query Match             2.7%;  Score 15;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 AAGTACTGGCTCTTT 1759
              |||||||||||||||
Db         18 AAGTACTGGCTCTTT 4


RESULT 44
US-10-786-720-11755/c
; Sequence 11755, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11755
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-11755

  Query Match             2.7%;  Score 15;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1744 CAAGTACTGGCTCTT 1758
              |||||||||||||||
Db         15 CAAGTACTGGCTCTT 1


RESULT 45
US-10-786-720-11757
; Sequence 11757, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11757
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-11757

  Query Match             2.7%;  Score 15;  DB 1;  Length 21;
  Best Local Similarity   66.7%;  Pred. No. 1.4e+02;
  Matches   10;  Conservative    5;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1744 CAAGTACTGGCTCTT 1758
              ||||:||:|||:|::
Db          7 CAAGUACUGGCUCUU 21


RESULT 46
US-10-786-720-12406/c
; Sequence 12406, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12406
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-12406

  Query Match             2.7%;  Score 15;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1744 CAAGTACTGGCTCTT 1758
              |||||||||||||||
```

```
Db         16 CAAGTACTGGCTCTT 2


RESULT 47
US-10-204-254A-101
; Sequence 101, Application US/10204254A
; Publication No. US20030176649A1
; GENERAL INFORMATION:
;  APPLICANT: VIKKULA, Miikka
;  TITLE OF INVENTION: VMGLOM gene and its mutations causing disorders with a vascular c
;  FILE REFERENCE: DELCE59.001APC
;  CURRENT APPLICATION NUMBER: US/10/204,254A
;  CURRENT FILING DATE:  2002-08-16
;  PRIOR APPLICATION NUMBER: PCT/EP01/01760
;  PRIOR FILING DATE: 2001-02-16
;  PRIOR APPLICATION NUMBER: 00870022.1
;  PRIOR FILING DATE: 2000-02-16
;  PRIOR APPLICATION NUMBER: 60/195,777
;  PRIOR FILING DATE: 2000-04-10
;  PRIOR APPLICATION NUMBER: 00870320.9
;  PRIOR FILING DATE: 2000-12-22
;  NUMBER OF SEQ ID NOS: 153
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 101
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-204-254A-101

  Query Match             2.7%;  Score 15;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1924 TTTTTTCAGTGTTAAGGTAATGG 1946
                ||||| ||||| |||||| | |
Db          1 TTTTTGTAGTGTCAAGGTATTAG 23


RESULT 48
US-10-635-145-7
; Sequence 7, Application US/10635145
; Publication No. US20040142440A1
; GENERAL INFORMATION:
;  APPLICANT: Hopkins, Nancy H.
;  APPLICANT:  Amsterdam, Adam H.
;  TITLE OF INVENTION: SERYL TRANSFER RNA SYNTHETASE
;  TITLE OF INVENTION:  POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE THEREOF
;  FILE REFERENCE: 0050.2049-001
;  CURRENT APPLICATION NUMBER: US/10/635,145
;  CURRENT FILING DATE:  2003-08-06
;  PRIOR APPLICATION NUMBER: US 60/401,556
;  PRIOR FILING DATE: 2002-08-06
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 7
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer sequence
US-10-635-145-7

  Query Match             2.7%;  Score 15;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTAGCGCTGA 1706
                ||||||||  || ||  ||  | |||
Db          1 CTTAGTTGCTTGTCCAGGGTTGA 23


RESULT 49
US-10-275-071-6
; Sequence 6, Application US/10275071
; Publication No. US20030186268A1
; GENERAL INFORMATION:
;  APPLICANT: Crouzet, Joel
;  APPLICANT:  Scherman, Daniel
;  APPLICANT:  Wils, Pierre
;  APPLICANT:  Cameron, Beatrice
;  APPLICANT:  Blanche, Francis
;  TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
;  TITLE OF INVENTION:  IMMOBILIZED OLIGONUCLEOTIDE
;  FILE REFERENCE: 08888.0138-02
;  CURRENT APPLICATION NUMBER: US/10/275,071
;  CURRENT FILING DATE:  2003-04-07
;  PRIOR APPLICATION NUMBER: 09/580,923
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: 08/860,038
;  PRIOR FILING DATE: 1997-06-09
;  PRIOR APPLICATION NUMBER: PCT/FR95/01468
;  PRIOR FILING DATE: 1995-11-08
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-10-275-071-6

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.3e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
                ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 50
US-09-767-421-69/c
; Sequence 69, Application US/09767421
; Publication No. US20030175954A1
; GENERAL INFORMATION:
;  APPLICANT:  Shamblott, Michael
;  APPLICANT:  Gearhart, John
;  TITLE OF INVENTION:  Human Embryoid Body-Derived Cells
;  FILE REFERENCE:  Unassigned
;  CURRENT APPLICATION NUMBER: US/09/767,421
;  CURRENT FILING DATE:  2001-01-22
;  NUMBER OF SEQ ID NOS:  74
;  SOFTWARE:  PatentIn version 3.0
; SEQ ID NO 69
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-767-421-69

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAGGTT 2042
                ||||||  ||||||||||
Db         19 TGGTAGAGGGCAAAGGTT 2


RESULT 51
US-10-300-820-49/c
; Sequence 49, Application US/10300820
; Publication No. US20040097452A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF KALLIKREIN 6 EXPRESSION
;  FILE REFERENCE: RTS-0444
;  CURRENT APPLICATION NUMBER: US/10/300,820
;  CURRENT FILING DATE:  2002-11-19
;  NUMBER OF SEQ ID NOS: 162
; SEQ ID NO 49
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-820-49

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGA 1619
              |||||| |||||| ||||
Db         19 TCCTGGGCTGGGGCAAGA 2


RESULT 52
US-10-300-820-124
; Sequence 124, Application US/10300820
; Publication No. US20040097452A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF KALLIKREIN 6 EXPRESSION
;  FILE REFERENCE: RTS-0444
;  CURRENT APPLICATION NUMBER: US/10/300,820
;  CURRENT FILING DATE:  2002-11-19
;  NUMBER OF SEQ ID NOS: 162
; SEQ ID NO 124
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-300-820-124

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGA 1619
              |||||| |||||| ||||
Db          2 TCCTGGGCTGGGGCAAGA 19


RESULT 53
US-10-316-389-85/c
; Sequence 85, Application US/10316389
; Publication No. US20040110699A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF ABCC2 EXPRESSION
;  FILE REFERENCE: RTS-0382
;  CURRENT APPLICATION NUMBER: US/10/316,389
;  CURRENT FILING DATE:  2002-12-10
;  NUMBER OF SEQ ID NOS: 143
; SEQ ID NO 85
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-389-85

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGGT 1947
              |||||  ||||||||||
Db         18 CAGTGACAAGGTAATGGT 1


RESULT 54
US-10-136-860-17/c
; Sequence 17, Application US/10136860
; Publication No. US20030203472A1
; GENERAL INFORMATION:
;  APPLICANT: Portnoy, Daniel A.
;  APPLICANT:  Calendar, Richard
;  APPLICANT:  Lauer, Peter M.
;  TITLE OF INVENTION: SITE SPECIFIC LISTERIA INTEGRATION
;  TITLE OF INVENTION:  VECTORS AND METHODS FOR USING THE SAME
;  FILE REFERENCE: BERK-017
;  CURRENT APPLICATION NUMBER: US/10/136,860
;  CURRENT FILING DATE:  2002-04-30
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 17
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
US-10-136-860-17

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 21;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1960 CCGCTAAATATTTACCTT 1977
              ||||| ||||||||| ||
Db         21 CCGCTCAATATTTACATT 4


RESULT 55
US-10-786-720-12071/c
; Sequence 12071, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12071
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-12071

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 21;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1743 ACAAGTACTGGCTCTTTA 1760
              | ||||||||||||||| |
Db         21 AAAAGTACTGGCTCTTCA 4


RESULT 56
US-10-786-720-190
; Sequence 190, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 190
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-190

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 1.7e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATGTCAAA 1887
              | ||||||||||||||   ||
Db          1 CATAGCCATTGAAATGGATAA 21


RESULT 57
US-10-786-720-12407/c
; Sequence 12407, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12407
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-12407

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 1.7e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGGCTCT 1757
              |||    ||||||||||||||
Db         21 AAGTCAGCAAGTACTGGCTCT 1


RESULT 58
US-10-786-720-12564/c
; Sequence 12564, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12564
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-12564

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 1.7e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2017 AAGTCCTCTGGTAGGAGGCAA 2037
              || | ||| ||||||| ||||
Db         21 AAATTCTCAGGTAGGAAGCAA 1


RESULT 59
US-09-881-572A-22
; Sequence 22, Application US/09881572A
; Patent No. US20020164583A1
; GENERAL INFORMATION:
;  APPLICANT: Roth, Monica;
;  APPLICANT:  Bupp, Keith;
;  APPLICANT:  University of Medicine and Dentistry of New Jersey
;  TITLE OF INVENTION: Targeting Viral Vectors to Specific Cells
;  FILE REFERENCE: 601-1-095
;  CURRENT APPLICATION NUMBER: US/09/881,572A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 60/212,239
;  PRIOR FILING DATE: 2000-06-16
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Feline Leukemia Virus
US-09-881-572A-22

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTTACCTACCT 1634
              ||| ||||||  ||||||| |
Db          2 GGAGGAGTTTTATACCTACAT 22


RESULT 60
US-10-005-469-7
; Sequence 7, Application US/10005469
; Publication No. US20020155133A1
; GENERAL INFORMATION:
;  APPLICANT: ANADYS Pharmaceuticals, Inc.
;  APPLICANT:  Bichko, Vadim
;  TITLE OF INVENTION: HEPATITIS C VIRUS CONSTRUCTS CHARACTERIZED BY HIGH EFFICIENCY REPI
;  FILE REFERENCE: 0342/1H395US1
;  CURRENT APPLICATION NUMBER: US/10/005,469
;  CURRENT FILING DATE:  2002-04-18
;  PRIOR APPLICATION NUMBER: US 60/245,866
;  PRIOR FILING DATE: 2000-11-07
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: primer for NS5B region between nt 7435 and 7750
US-10-005-469-7

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGATCAAC 1915
              |||||||||   |||||| ||
Db          1 GCCCTAGATTGTCAGATCTAC 21
```

```
RESULT 61
US-10-434-842-7
; Sequence 7, Application US/10434842
; Publication No. US20040005549A1
; GENERAL INFORMATION:
;  APPLICANT: Bichko, Vadim
;  TITLE OF INVENTION: HEPATITIS C VIRUS CONSTRUCTS CHARACTERIZED BY HIGH EFFICIENCY REP
;  FILE REFERENCE: 0342/1H395US3
;  CURRENT APPLICATION NUMBER: US/10/434,842
;  CURRENT FILING DATE: 2003-05-09
;  PRIOR APPLICATION NUMBER: US 10/233,307
;  PRIOR FILING DATE: 2002-08-28
;  PRIOR APPLICATION NUMBER: US 10/005,469
;  PRIOR FILING DATE: 2001-11-07
;  PRIOR APPLICATION NUMBER: US 60/245,866
;  PRIOR FILING DATE: 2000-11-07
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: RT-PCR primer for NS5B region between nt 7435 and 7750
US-10-434-842-7

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGATCAAC 1915
             |||||||||   |||||| ||
Db          1 GCCCTAGATTGTCAGATCTAC 21


RESULT 62
US-10-236-392-269/c
; Sequence 269, Application US/10236392
; Publication No. US20040067490A1
; GENERAL INFORMATION:
;  APPLICANT: Anderson, David W
;  APPLICANT:  Boldog, Ferenc L
;  APPLICANT:  Burgess, Catherine, E
;  APPLICANT:  Casman, Stacie J
;  APPLICANT:  Catterton, Elina
;  APPLICANT:  Chapoval, Andrei
;  APPLICANT:  Crabtree, Julie
;  APPLICANT:  Edinger, Shlomit, R
;  APPLICANT:  Ellerman, Karen
;  APPLICANT:  Gerlach, Valerie
;  APPLICANT:  Gorman, Linda
;  APPLICANT:  Grosse, William M
;  APPLICANT:  Gusev, Vladamir
;  APPLICANT:  Kekuda, Ramesh
;  APPLICANT:  LaRochelle, William J
;  APPLICANT:  Li, Li
;  APPLICANT:  MacDougall, John R
;  APPLICANT:  Malyankar, Uriel M
;  APPLICANT:  Miller, Charles E
;  APPLICANT:  Millet, Isabelle
;  APPLICANT:  Padigaru, Muralidhara
;  APPLICANT:  Patturajan, Meera
;  APPLICANT:  Pena, Carol A
;  APPLICANT:  Peyman, John A
;  APPLICANT:  Rastelli, Luca
;  APPLICANT:  Reiger, Daniel K
;  APPLICANT:  Rothenberg, Mark E
;  APPLICANT:  Shenoy, Suresh
;  APPLICANT:  Shimkets, Richard A
;  APPLICANT:  Smithson, Glennda
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME
;  FILE REFERENCE: 21402-442A
;  CURRENT APPLICATION NUMBER: US/10/236,392
;  CURRENT FILING DATE:  2002-09-06
;  PRIOR APPLICATION NUMBER: US09/540,763
;  PRIOR FILING DATE: 2000-03-30
;  PRIOR APPLICATION NUMBER: US60/390,155
;  PRIOR FILING DATE: 2002-06-19
;  PRIOR APPLICATION NUMBER: US09/635,949
;  PRIOR FILING DATE: 2000-08-10
;  PRIOR APPLICATION NUMBER: US60/318,765
;  PRIOR FILING DATE: 2001-09-12
;  PRIOR APPLICATION NUMBER: US60/357,303
;  PRIOR FILING DATE: 2002-02-15
;  PRIOR APPLICATION NUMBER: US60/367,753
;  PRIOR FILING DATE: 2002-03-25
;  PRIOR APPLICATION NUMBER: US60/369,479
;  PRIOR FILING DATE: 2002-04-02
;  PRIOR APPLICATION NUMBER: US09/659,634
;  PRIOR FILING DATE: 2000-09-12
;  PRIOR APPLICATION NUMBER: US60/318,120
;  PRIOR FILING DATE: 2001-09-07
;  PRIOR APPLICATION NUMBER: US60/318,130
;  PRIOR FILING DATE: 2001-09-07
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 794
;  SOFTWARE: Custom
; SEQ ID NO 269
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Reverse Primer
US-10-236-392-269

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1829 TCTTTTAAATACATTCCCTGG 1849
             |||||| |  ||||||| |||
Db         21 TCTTTTGATGACATTCCATGG 1


RESULT 63
US-09-985-335-8
; Sequence 8, Application US/09985335
; Publication No. US20020164794A1
; GENERAL INFORMATION:
;  APPLICANT: Wernet, Peter
;  TITLE OF INVENTION: HUMAN CORD BLOOD DERIVED UNRESTRICTED SOMATIC STEM CELLS (USSC)
;  FILE REFERENCE: P66065US1
;  CURRENT APPLICATION NUMBER: US/09/985,335
;  CURRENT FILING DATE:  2001-11-02
;  PRIOR APPLICATION NUMBER: U.S. 60/245,168
;  PRIOR FILING DATE: 2000-11-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: primer sequence
US-09-985-335-8

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 19;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2024 CTGGTAGGAGGCAAAG 2039
             ||||||||||||||| |
Db          2 CTGGTAGGAGGCAATG 17
```

```
RESULT 64
US-09-771-933-177
; Sequence 177, Application US/09771933
; Publication No. US20030023387A1
; GENERAL INFORMATION:
;  APPLICANT: Gill-Garrison, Rosalynn D
;  APPLICANT:  Martin, Christopher J
;  APPLICANT:  Sanchez-Felix, Manuel V
;  TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk
;  TITLE OF INVENTION:  Factors
;  FILE REFERENCE: 620-130
;  CURRENT APPLICATION NUMBER: US/09/771,933
;  CURRENT FILING DATE:  2001-01-30
;  NUMBER OF SEQ ID NOS: 205
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 177
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-771-933-177

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 19;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          4 ATCTTTAAAATACATT 19


RESULT 65
US-10-265-689-15
; Sequence 15, Application US/10265689
; Publication No. US20030119775A1
; GENERAL INFORMATION:
;  APPLICANT: SURWIT, RICHARD S.
;  APPLICANT:  COLLINS, SHEILA A.
;  APPLICANT:  WARDEN, CRAIG H.
;  APPLICANT:  SELDIN, MICHAEL F.
;  APPLICANT:  RICQUIER, DANIEL
;  APPLICANT:  BOUILLAUD, FREDERIC
;  TITLE OF INVENTION: RESPIRATION UNCOUPLING PROTEIN
;  FILE REFERENCE: 1579-376
;  CURRENT APPLICATION NUMBER: US/10/265,689
;  CURRENT FILING DATE:  2002-10-08
;  PRIOR APPLICATION NUMBER: US/09/353,645
;  PRIOR FILING DATE: 1999-07-15
;  PRIOR APPLICATION NUMBER: PCT/US97/06864
;  PRIOR FILING DATE: 1997-04-22
;  PRIOR APPLICATION NUMBER: 60/034,960
;  PRIOR FILING DATE: 1997-01-15
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide
US-10-265-689-15

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 19;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1541 GGAGAGTAGGGAAGGA 1556
              |||||| |||||||||
Db          1 GGAGAGAAGGGAAGGA 16


RESULT 66
US-09-848-585-35
; Sequence 35, Application US/09848585
; Patent No. US20020146391A1
; GENERAL INFORMATION:
;  APPLICANT: LEVITT, Roy Clifford
;  APPLICANT:  MALOY, W. Lee
;  APPLICANT:  KARI, U. Prasad
;  APPLICANT:  NICOLAIDES, Nicholas C.
;  TITLE OF INVENTION: Asthma Associated Factors As Targets For Treating Atopic Allergie
;  TITLE OF INVENTION:  Including Asthma And Related Disorders
;  FILE REFERENCE: 36870-5056-12-US
;  CURRENT APPLICATION NUMBER: US/09/848,585
;  CURRENT FILING DATE:  2001-05-04
;  PRIOR APPLICATION NUMBER: US 60/002,765
;  PRIOR FILING DATE: 1995-08-24
;  PRIOR APPLICATION NUMBER: US 08/697,419
;  PRIOR FILING DATE: 1996-08-23
;  PRIOR APPLICATION NUMBER: US 08/874,503
;  PRIOR FILING DATE: 1997-06-13
;  PRIOR APPLICATION NUMBER: US 09/325,571
;  PRIOR FILING DATE: 1999-06-04
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: PCR oligonucleotide primer
US-09-848-585-35

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
              |||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20


RESULT 67
US-10-289-762-4828/c
; Sequence 4828, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, prever
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4828
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-4828

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCAC 1582
              |||||||| ||||||
Db         20 AAAAATCCTCCTCCAC 5


RESULT 68
US-10-289-762-6111
; Sequence 6111, Application US/10289762
```

; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, preve
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6111

Query Match 2.6%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1556 AACAGGACTGCAAAAA 1571
|| ||||||||||||||
Db 4 AAGAGGACTGCAAAAA 19

RESULT 69
US-10-642-149-35
; Sequence 35, Application US/10642149
; Publication No. US20040076607A1
; GENERAL INFORMATION:
; APPLICANT: LEVITT, Roy Clifford
; APPLICANT: MALOY, W. Lee
; APPLICANT: KARI, U. Prasad
; APPLICANT: NICOLAIDES, Nicholas C.
; TITLE OF INVENTION: Asthma Associated Factors As Targets For Treating Atopic Allergie
; TITLE OF INVENTION: Including Asthma And Related Disorders
; FILE REFERENCE: 36870-5056-12-US
; CURRENT APPLICATION NUMBER: US/10/642,149
; CURRENT FILING DATE: 2003-08-18
; PRIOR APPLICATION NUMBER: US/09/848,585
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/002,765
; PRIOR FILING DATE: 1995-08-24
; PRIOR APPLICATION NUMBER: US 08/697,419
; PRIOR FILING DATE: 1996-08-23
; PRIOR APPLICATION NUMBER: US 08/874,503
; PRIOR FILING DATE: 1997-06-13
; PRIOR APPLICATION NUMBER: US 09/325,571
; PRIOR FILING DATE: 1999-06-04
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR oligonucleotide primer
US-10-642-149-35

Query Match 2.6%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1641 TTAAAGAGCCTTCACT 1656
|||||||| ||||||
Db 5 TTAAAGAGCATTCACT 20

RESULT 70
US-10-293-863-24/c
; Sequence 24, Application US/10293863
; Publication No. US20040092464A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 11 E
; FILE REFERENCE: HTS-0090
; CURRENT APPLICATION NUMBER: US/10/293,863
; CURRENT FILING DATE: 2002-11-11
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-293-863-24

Query Match 2.6%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1600 CCTCCTGGCCTGGGGG 1615
||||||| ||||||||
Db 18 CCTCCTGCCCTGGGGG 3

RESULT 71
US-10-293-863-59
; Sequence 59, Application US/10293863
; Publication No. US20040092464A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 11 F
; FILE REFERENCE: HTS-0090
; CURRENT APPLICATION NUMBER: US/10/293,863
; CURRENT FILING DATE: 2002-11-11
; NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-293-863-59

Query Match 2.6%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1600 CCTCCTGGCCTGGGGG 1615
||||||| ||||||||
Db 3 CCTCCTGCCCTGGGGG 18

RESULT 72
US-09-294-764-1
; Sequence 1, Application US/09294764
; Publication No. US20020146395A1
; GENERAL INFORMATION:
; APPLICANT: Weinstein, David E.
; TITLE OF INVENTION: METHODS OF INDUCING NERVOUS TISSUE REGENERATION
; FILE REFERENCE: 96700/496
; CURRENT APPLICATION NUMBER: US/09/294,764
; CURRENT FILING DATE: 1999-04-19
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-294-764-1

```
  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   93.8%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              |||||||| |||||||
Db          6 TCTCCACCCCACAGAC 21


RESULT 73
US-10-786-720-91
; Sequence 91, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 91
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-91

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   93.8%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              | ||||||||||||||
Db          4 CATAGCCATTGAAATG 19


RESULT 74
US-10-786-720-92
; Sequence 92, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 92
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-92

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   68.8%;  Pred. No. 1.9e+02;
  Matches   11;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              | :|||||::||||:|
Db          2 CAUAGCCAUUGAAAUG 17


RESULT 75
US-10-786-720-93/c
; Sequence 93, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 93
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-93

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   93.8%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              | ||||||||||||||
Db         18 CATAGCCATTGAAATG 3


RESULT 76
US-10-786-720-274
; Sequence 274, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-274

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   93.8%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              | ||||||||||||||
Db          5 CATAGCCATTGAAATG 20


RESULT 77
US-10-786-720-275
; Sequence 275, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 275
```

```
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-275

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   68.8%;  Pred. No. 1.9e+02;
  Matches   11;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              | :|||||::||||:|
Db          3 CAUAGCCAUUGAAAUG 18


RESULT 78
US-10-786-720-276/c
; Sequence 276, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 276
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-276

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   93.8%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              | ||||||||||||||
Db         17 CATAGCCATTGAAATG 2


RESULT 79
US-10-786-720-12070/c
; Sequence 12070, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12070
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-12070

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   93.8%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1745 AAGTACTGGCTCTTTA 1760
              |||||||||||||| |
Db         21 AAGTACTGGCTCTTCA 6


RESULT 80
US-10-786-720-12072
; Sequence 12072, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12072
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-12072

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   62.5%;  Pred. No. 1.9e+02;
  Matches   10;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1745 AAGTACTGGCTCTTTA 1760
              |||:||:|||:|:: |
Db          1 AAGUACUGGCUCUUCA 16


RESULT 81
US-09-771-933-204
; Sequence 204, Application US/09771933
; Publication No. US20030023387A1
; GENERAL INFORMATION:
;  APPLICANT: Gill-Garrison, Rosalynn D
;  APPLICANT:  Martin, Christopher J
;  APPLICANT:  Sanchez-Felix, Manuel V
;  TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk
;  TITLE OF INVENTION:  Factors
;  FILE REFERENCE: 620-130
;  CURRENT APPLICATION NUMBER: US/09/771,933
;  CURRENT FILING DATE:  2001-01-30
;  NUMBER OF SEQ ID NOS: 205
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 204
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-771-933-204

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          2 ATCTTTAAAATACATT 17


RESULT 82
US-10-132-080-5
; Sequence 5, Application US/10132080
; Publication No. US20030049204A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: INDIVIDUALIZATION OF THERAPY WITH
;  TITLE OF INVENTION:  GASTROESOPHAGEAL REFLUX DISEASE AGENTS
;  FILE REFERENCE: 3298.1011-000
;  CURRENT APPLICATION NUMBER: US/10/132,080
```

```
;  CURRENT FILING DATE:  2002-08-16
;  PRIOR APPLICATION NUMBER: 60/285,687
;  PRIOR FILING DATE: 2001-04-24
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;    LENGTH: 22
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Primer
US-10-132-080-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 83
US-10-125-690-3
; Sequence 3, Application US/10125690
; Publication No. US20030053950A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: INDIVIDUALIZATION OF THERAPY WITH
;  TITLE OF INVENTION:  HYPERLIPIDEMIA AGENTS
;  FILE REFERENCE: 3298.1009-000
;  CURRENT APPLICATION NUMBER: US/10/125,690
;  CURRENT FILING DATE:  2002-08-06
;  PRIOR APPLICATION NUMBER: 60/284,210
;  PRIOR FILING DATE: 2001-04-18
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;    LENGTH: 22
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Primer
US-10-125-690-3

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 84
US-10-100-556-5
; Sequence 5, Application US/10100556
; Publication No. US20030068273A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Immunosuppressants
;  FILE REFERENCE: 3298.1004-000
;  CURRENT APPLICATION NUMBER: US/10/100,556
;  CURRENT FILING DATE:  2002-03-14
;  PRIOR APPLICATION NUMBER: US 60/275,489
;  PRIOR FILING DATE: 2001-03-14
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;    LENGTH: 22
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Sequence to be used as a Primer
US-10-100-556-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 85
US-10-100-218-5
; Sequence 5, Application US/10100218
; Publication No. US20030072710A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Antidepressants
;  FILE REFERENCE: 3298.1005-000
;  CURRENT APPLICATION NUMBER: US/10/100,218
;  CURRENT FILING DATE:  2002-03-14
;  PRIOR APPLICATION NUMBER: US 60/275,490
;  PRIOR FILING DATE: 2001-03-14
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;    LENGTH: 22
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Sequence to be used as a Primer
US-10-100-218-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 86
US-10-134-296-5
; Sequence 5, Application US/10134296
; Publication No. US20030073133A1
; GENERAL INFORMATION:
;  APPLICANT: Brian Leyland-Jones
;  TITLE OF INVENTION: INDIVIDUALIZATION OF THERAPY WITH
;  TITLE OF INVENTION:  ERECTILE DYSFUNCTION AGENTS
;  FILE REFERENCE: 3298.1012-000
;  CURRENT APPLICATION NUMBER: US/10/134,296
;  CURRENT FILING DATE:  2002-04-26
;  PRIOR APPLICATION NUMBER: 60/286,336
;  PRIOR FILING DATE: 2001-04-26
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;    LENGTH: 22
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Sequence to be used as a Primer
US-10-134-296-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
```

```
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 87
US-10-141-533-5
; Sequence 5, Application US/10141533
; Publication No. US20030077222A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: INDIVIDUALIZATION OF THERAPY WITH
;  TITLE OF INVENTION:  ANALGESICS
;  FILE REFERENCE: 3298.1014-000
;  CURRENT APPLICATION NUMBER: US/10/141,533
;  CURRENT FILING DATE:  2002-05-07
;  PRIOR APPLICATION NUMBER: 60/288,786
;  PRIOR FILING DATE: 2001-05-07
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-141-533-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 88
US-10-072-611-3
; Sequence 3, Application US/10072611
; Publication No. US20030091975A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones,  Brian
;  TITLE OF INVENTION: MULTIPLE DETERMINANTS FOR METABOLIC
;  TITLE OF INVENTION:  PHENOTYPES
;  FILE REFERENCE: 3298.1001-000
;  CURRENT APPLICATION NUMBER: US/10/072,611
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: 60/267,472
;  PRIOR FILING DATE: 2001-02-09
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-072-611-3

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 89
US-10-135-185-5
; Sequence 5, Application US/10135185
; Publication No. US20030108484A1
; GENERAL INFORMATION:
;  APPLICANT: Brian Leyland-Jones
;  TITLE OF INVENTION: INDIVIDUALIZATION OF THERAPY WITH
;  TITLE OF INVENTION:  ANTINEOPLASTIC AGENTS
;  FILE REFERENCE: 3298.1013-000
;  CURRENT APPLICATION NUMBER: US/10/135,185
;  CURRENT FILING DATE:  2002-04-29
;  PRIOR APPLICATION NUMBER: 60/287,014
;  PRIOR FILING DATE: 2001-04-30
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Sequence to be used as a Primer
US-10-135-185-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 90
US-10-125-693-3
; Sequence 3, Application US/10125693
; Publication No. US20030124636A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: INDIVIDUALIZATION OF THERAPY WITH
;  TITLE OF INVENTION:  ANTIARRHYTHMICS
;  FILE REFERENCE: 3298.1008-000
;  CURRENT APPLICATION NUMBER: US/10/125,693
;  CURRENT FILING DATE:  2002-04-17
;  PRIOR APPLICATION NUMBER: 60/284,191
;  PRIOR FILING DATE: 2001-04-18
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-125-693-3

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 91
US-10-164-854-5
; Sequence 5, Application US/10164854
; Publication No. US20030138375A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: INDIVIDUALIZATION OF THERAPY WITH
;  TITLE OF INVENTION:  ALZHEIMER'S DISEASE AGENTS
;  FILE REFERENCE: 3298.1016-000
;  CURRENT APPLICATION NUMBER: US/10/164,854
;  CURRENT FILING DATE:  2002-06-06
;  PRIOR APPLICATION NUMBER: 60/295,860
;  PRIOR FILING DATE: 2001-06-06
;  NUMBER OF SEQ ID NOS: 25
```

```
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-164-854-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 92
US-10-087-996-5
; Sequence 5, Application US/10087996
; Publication No. US20030138377A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: USE OF METABOLIC PHENOTYPING IN
;  TITLE OF INVENTION:  INDIVIDUALIZED TREATMENT WITH AMONAFIDE
;  FILE REFERENCE: 3298.1003-000
;  CURRENT APPLICATION NUMBER: US/10/087,996
;  CURRENT FILING DATE:  2002-02-28
;  PRIOR APPLICATION NUMBER: 60/271,714
;  PRIOR FILING DATE: 2001-02-28
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-087-996-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 93
US-10-100-230-5
; Sequence 5, Application US/10100230
; Publication No. US20030170176A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Antipsychotics
;  FILE REFERENCE: 3298.1006-000
;  CURRENT APPLICATION NUMBER: US/10/100,230
;  CURRENT FILING DATE:  2002-03-14
;  PRIOR APPLICATION NUMBER: US 60/275,462
;  PRIOR FILING DATE: 2001-03-14
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Sequence to be used as a primer
US-10-100-230-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 94
US-10-100-272-5
; Sequence 5, Application US/10100272
; Publication No. US20030175210A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Anxiolitics
;  FILE REFERENCE: 3298.1007-000
;  CURRENT APPLICATION NUMBER: US/10/100,272
;  CURRENT FILING DATE:  2002-03-14
;  PRIOR APPLICATION NUMBER: US 60/275,493
;  PRIOR FILING DATE: 2001-03-14
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Sequence to be used as a Primer
US-10-100-272-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 95
US-10-325-466-5
; Sequence 5, Application US/10325466
; Publication No. US20030180823A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Antihistamines
;  FILE REFERENCE: 3298.1020-000
;  CURRENT APPLICATION NUMBER: US/10/325,466
;  CURRENT FILING DATE:  2002-12-19
;  PRIOR APPLICATION NUMBER: 60/340,827
;  PRIOR FILING DATE: 2001-12-19
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-325-466-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20
```

```
RESULT 96
US-10-151-467A-5
; Sequence 5, Application US/10151467A
; Publication No. US20030186339A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Antibiotic Agents
;  FILE REFERENCE: 3298.1015-000
;  CURRENT APPLICATION NUMBER: US/10/151,467A
;  CURRENT FILING DATE:  2002-05-17
;  PRIOR APPLICATION NUMBER: 60/291,336
;  PRIOR FILING DATE: 2001-05-17
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-151-467A-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 97
US-10-124-747-5
; Sequence 5, Application US/10124747
; Publication No. US20030190671A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: USE OF METABOLIC PHENOTYPING IN
;  TITLE OF INVENTION:  INDIVIDUALIZED TREATMENT WITH AMONAFIDE
;  FILE REFERENCE: 3298.1003-001
;  CURRENT APPLICATION NUMBER: US/10/124,747
;  CURRENT FILING DATE:  2002-08-30
;  PRIOR APPLICATION NUMBER: 10/087,996
;  PRIOR FILING DATE: 2002-02-28
;  PRIOR APPLICATION NUMBER: 60/271,714
;  PRIOR FILING DATE: 2001-02-28
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-124-747-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 98
US-10-307-204-5
; Sequence 5, Application US/10307204
; Publication No. US20030195350A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Antiviral Agents
;  FILE REFERENCE: 3287.1004-000
;  CURRENT APPLICATION NUMBER: US/10/307,204
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: 60/333,500
;  PRIOR FILING DATE: 2001-11-28
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Sequence to be used as a Primer
US-10-307-204-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 99
US-10-607-848-5
; Sequence 5, Application US/10607848
; Publication No. US20040084867A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Anticoagulants
;  FILE REFERENCE: 3287.1005-000
;  CURRENT APPLICATION NUMBER: US/10/607,848
;  CURRENT FILING DATE:  2003-06-27
;  PRIOR APPLICATION NUMBER: 60/391,976
;  PRIOR FILING DATE: 2002-06-28
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Sequence to be used as a Primer
US-10-607-848-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 100
US-10-307-210-5
; Sequence 5, Application US/10307210
; Publication No. US20040101477A1
; GENERAL INFORMATION:
;  APPLICANT: Leyland-Jones, Brian
;  TITLE OF INVENTION: Individualization of Therapy with
;  TITLE OF INVENTION:  Anesthetics
;  FILE REFERENCE: 3287.1003-000
;  CURRENT APPLICATION NUMBER: US/10/307,210
;  CURRENT FILING DATE:  2003-03-18
;  PRIOR APPLICATION NUMBER: 60/333,486
;  PRIOR FILING DATE: 2001-11-28
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
```

```
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Sequence to be used as a Primer
US-10-307-210-5

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
                ||||||  |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 101
US-10-665-951-199/c
; Sequence 199, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 199
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-199

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCTTCTC 1579
                ||||||||||  ||||  ||
Db         19 GACTGCAAAAGTCCTCATC 1


RESULT 102
US-10-665-951-311
; Sequence 311, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 311
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-311

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 1.7e+02;
  Matches   11;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCACT 1656
                :| ::|| ||||| :|||:
Db          1 UAGUUAAUGAGCCAUCACU 19


RESULT 103
US-10-665-951-626
; Sequence 626, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
```

```
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 626
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-626

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 1.7e+02;
  Matches   12;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCTTCTC 1579
              |||:|||||| :||:  :|
Db          1 GACUGCAAAAGUCCUCAUC 19


RESULT 104
US-10-665-951-738/c
; Sequence 738, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 738
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-738

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCACT 1656
              || |||| ||||| |||||
Db         19 TAGTTAATGAGCCATCACT 1


RESULT 105
US-10-665-951-882
; Sequence 882, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 882
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-882

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 1.7e+02;
  Matches   11;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATTATCAGA 1737
              |:::|| || |: |:||||
Db          1 CUUUGGCCCAAUAAUCAGA 19


RESULT 106
```

```
US-10-665-951-1206/c
; Sequence 1206, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1206
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-1206

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 1.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATTATCAGA 1737
                ||||||  ||  ||  ||||||
Db         19 CTTTGGCCCAATAATCAGA 1

RESULT 107
US-09-920-394-25
; Sequence 25, Application US/09920394
; Publication No. US20030096773A1
; GENERAL INFORMATION:
;  APPLICANT: Rosanne M. Crooke
;  APPLICANT:  Mark J. Graham
;  APPLICANT:  Kristina M. Lemonidis
;  TITLE OF INVENTION: ANTISENSE MODULATION OF ACYL COENZYME A CHOLESTEROL ACYLTRANSFERA
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: ISPH-0589
;  CURRENT APPLICATION NUMBER: US/09/920,394
;  CURRENT FILING DATE:  2001-08-01
;  NUMBER OF SEQ ID NOS: 62
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-920-394-25

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAGAGTTT 1623
                |||||  ||  |||||||  ||
Db          1 TGGCCCGGTGGAAGAGGTT 19

RESULT 108
US-10-057-550-121/c
; Sequence 121, Application US/10057550
; Publication No. US20030032607A1
; GENERAL INFORMATION:
;  APPLICANT: Monia, Brett P.
;  TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
;  FILE REFERENCE:
;  CURRENT APPLICATION NUMBER: US/10/057,550
;  CURRENT FILING DATE:  2002-01-25
;  PRIOR APPLICATION NUMBER: 09/506,073
;  PRIOR FILING DATE: 2000-02-18
;  PRIOR APPLICATION NUMBER: US 09/143,214
;  PRIOR FILING DATE: 1998-08-28
;  PRIOR APPLICATION NUMBER: PCT/US98/13961
;  PRIOR FILING DATE: 1998-07-06
;  PRIOR APPLICATION NUMBER: US 08/888,982
;  PRIOR FILING DATE: 1997-07-07
;  PRIOR APPLICATION NUMBER: US 08/756,806
;  PRIOR FILING DATE: 1996-11-26
;  PRIOR APPLICATION NUMBER: PCT/US95/07111
;  PRIOR FILING DATE: 1995-05-31
;  PRIOR APPLICATION NUMBER: US 08/250,856
;  PRIOR FILING DATE: 1994-05-31
;  NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 121
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-10-057-550-121

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
                |||  ||  |  ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2

RESULT 109
US-10-173-225B-99/c
; Sequence 99, Application US/10173225B
; Publication No. US20030119769A1
; GENERAL INFORMATION:
;  APPLICANT: Monia, Brett P.
;  TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
;  FILE REFERENCE: ISPH-0665
;  CURRENT APPLICATION NUMBER: US/10/173,225B
;  CURRENT FILING DATE:  2002-12-06
;  PRIOR APPLICATION NUMBER: US 10/057,550
;  PRIOR FILING DATE: 2002-01-25
;  PRIOR APPLICATION NUMBER: US 09/143,214
;  PRIOR FILING DATE: 1998-08-28
;  PRIOR APPLICATION NUMBER: PCT/US98/13961
;  PRIOR FILING DATE: 1998-07-06
;  PRIOR APPLICATION NUMBER: US 08/888,982
;  PRIOR FILING DATE: 1997-07-07
;  PRIOR APPLICATION NUMBER: US 08/756,806
```

```
;  PRIOR FILING DATE: 1996-11-26
;  PRIOR APPLICATION NUMBER: PCT/US95/07111
;  PRIOR FILING DATE: 1995-05-31
;  PRIOR APPLICATION NUMBER: US 08/250,856
;  PRIOR FILING DATE: 1994-05-31
;  NUMBER OF SEQ ID NOS: 109
; SEQ ID NO 99
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-10-173-225B-99

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 110
US-10-094-749-3339
; Sequence 3339, Application US/10094749
; Publication No. US20030219741A1
; GENERAL INFORMATION:
;  APPLICANT: ISOGAI, TAKAO
;  APPLICANT:  SUGIYAMA, TOMOYASU
;  APPLICANT:  OTSUKI, TETSUJI
;  APPLICANT:  WAKAMATSU, AI
;  APPLICANT:  SATO, HIROYUKI
;  APPLICANT:  ISHII, SHIZUKO
;  APPLICANT:  YAMAMOTO, JUN-ICHI
;  APPLICANT:  ISONO, YUUKO
;  APPLICANT:  HIO, YURI
;  APPLICANT:  OTSUKA, KAORU
;  APPLICANT:  NAGAI, KEIICHI
;  APPLICANT:  IRIE, RYOTARO
;  APPLICANT:  TAMECHIKA, ICHIRO
;  APPLICANT:  SEKI, NAOHIKO
;  APPLICANT:  YOSHIKAWA, TSUTOMU
;  APPLICANT:  OTSUKA, MOTOYUKI
;  APPLICANT:  NAGAHARI, KENJI
;  APPLICANT:  MASUHO, YASUHIKO
;  TITLE OF INVENTION: NOVEL FULL-LENGTH cDNA
;  FILE REFERENCE: 084335/0160
;  CURRENT APPLICATION NUMBER: US/10/094,749
;  CURRENT FILING DATE:  2002-03-12
;  PRIOR APPLICATION NUMBER: 60/350,435
;  PRIOR FILING DATE: 2002-01-24
;  PRIOR APPLICATION NUMBER: JP 2001-328381
;  PRIOR FILING DATE: 2001-09-14
;  NUMBER OF SEQ ID NOS: 3381
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3339
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: an artificially
;   OTHER INFORMATION: synthesized primer sequence
US-10-094-749-3339

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTGT 1935
              ||| || || |||||||||
Db          1 ATAGCTCTTGTTTCAGTGT 19


RESULT 111
US-10-159-266-72
; Sequence 72, Application US/10159266
; Publication No. US20030224511A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CATHEPSIN Z EXPRESSION
;  FILE REFERENCE: RTS-0398
;  CURRENT APPLICATION NUMBER: US/10/159,266
;  CURRENT FILING DATE:  2002-05-31
;  NUMBER OF SEQ ID NOS: 158
; SEQ ID NO 72
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-159-266-72

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2010 AGAGATCAAGTCCTCTGGT 2028
              | | |||||||||||||| |
Db          2 AAATATCAAGTCCTCTGCT 20


RESULT 112
US-10-159-266-145/c
; Sequence 145, Application US/10159266
; Publication No. US20030224511A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CATHEPSIN Z EXPRESSION
;  FILE REFERENCE: RTS-0398
;  CURRENT APPLICATION NUMBER: US/10/159,266
;  CURRENT FILING DATE:  2002-05-31
;  NUMBER OF SEQ ID NOS: 158
; SEQ ID NO 145
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-159-266-145

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2010 AGAGATCAAGTCCTCTGGT 2028
              | | |||||||||||||| |
Db         19 AAATATCAAGTCCTCTGCT 1


RESULT 113
US-10-177-554-75
; Sequence 75, Application US/10177554
; Publication No. US20030235911A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  APPLICANT:  Hong Zhang
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PRL-3 EXPRESSION
;  FILE REFERENCE: RTS-0370
;  CURRENT APPLICATION NUMBER: US/10/177,554
;  CURRENT FILING DATE:  2002-06-20
;  NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 75
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-177-554-75

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGCCTGG 1612
              ||| ||||| |||| ||||
Db          2 GGAGCCCCTGCTGGGCTGG 20


RESULT 114
US-10-289-762-5020/c
; Sequence 5020, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5020
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-5020

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1585 CACAGACTGGGAACCCCTC 1603
              |||||| |||||| ||| |
Db         19 CACAGATTGGGAAGCCCCC 1


RESULT 115
US-10-210-833-45
; Sequence 45, Application US/10210833
; Publication No. US20040023383A1
; GENERAL INFORMATION:
;  APPLICANT: Sanjay Bhanot
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RESISTIN EXPRESSION
;  FILE REFERENCE: RTS-0396
;  CURRENT APPLICATION NUMBER: US/10/210,833
;  CURRENT FILING DATE:  2002-07-31
;  NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 45
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-833-45

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGGG 1614
              ||||||||| | ||||| |
Db          1 AACCCCTCCGGACCTGGAG 19


RESULT 116
US-10-210-833-145/c
; Sequence 145, Application US/10210833
; Publication No. US20040023383A1
; GENERAL INFORMATION:
;  APPLICANT: Sanjay Bhanot
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RESISTIN EXPRESSION
;  FILE REFERENCE: RTS-0396
;  CURRENT APPLICATION NUMBER: US/10/210,833
;  CURRENT FILING DATE:  2002-07-31
;  NUMBER OF SEQ ID NOS: 165
; SEQ ID NO 145
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-210-833-145

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGGG 1614
              ||||||||| | ||||| |
Db         20 AACCCCTCCGGACCTGGAG 2


RESULT 117
US-10-671-395-1678
; Sequence 1678, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1678
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1678

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGACCCACA 1864
              ||| ||| | |||||||||
Db          2 CTGTGCCCAGAGACCCACA 20


RESULT 118
US-10-671-395-1694
; Sequence 1694, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 1694
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1694

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCACAC 1865
              || ||| | ||||||||||
Db          1 TGTGCCCAGAGACCCACAC 19


RESULT 119
US-09-918-779-50/c
; Sequence 50, Application US/09918779
; Publication No. US20030064369A1
; GENERAL INFORMATION:
;  APPLICANT: Taupier, Raymond
;  APPLICANT:  Padigaru, Muralidhara
;  APPLICANT:  Rastelli, Luca
;  APPLICANT:  Spaderna, Steven
;  APPLICANT:  Shimkets, Richard
;  APPLICANT:  Zerhusen, Bryan
;  APPLICANT:  Spytek, Kimberly
;  APPLICANT:  Shenoy, Suresh
;  APPLICANT:  Li, Li
;  APPLICANT:  Gusev, Vladimir
;  APPLICANT:  Grosse, William
;  APPLICANT:  Alsobrook, John
;  APPLICANT:  Lepley, Denise
;  APPLICANT:  Burgess, Catherine
;  APPLICANT:  Gerlach, Valerie
;  APPLICANT:  Ellerman, Karen
;  APPLICANT:  MacDougall, John
;  APPLICANT:  Stone, David
;  APPLICANT:  Smithson, Glennda
;  TITLE OF INVENTION: Novel Proteins and Nucleic Acids Encoding Same
;  FILE REFERENCE: 21402-074 US
;  CURRENT APPLICATION NUMBER: US/09/918,779
;  CURRENT FILING DATE:  2001-07-30
;  PRIOR APPLICATION NUMBER: 60/221,409
;  PRIOR FILING DATE: 2000-07-28
;  PRIOR APPLICATION NUMBER: 60/222,840
;  PRIOR FILING DATE: 2000-08-04
;  PRIOR APPLICATION NUMBER: 60/223,752
;  PRIOR FILING DATE: 2000-08-08
;  PRIOR APPLICATION NUMBER: 60/223,762
;  PRIOR FILING DATE: 2000-08-08
;  PRIOR APPLICATION NUMBER: 60/223,770
;  PRIOR FILING DATE: 2000-08-08
;  PRIOR APPLICATION NUMBER: 60/223,769
;  PRIOR FILING DATE: 2000-08-08
;  PRIOR APPLICATION NUMBER: 60/225,146
;  PRIOR FILING DATE: 2000-08-14
;  PRIOR APPLICATION NUMBER: 60/225,392
;  PRIOR FILING DATE: 2000-08-15
;  PRIOR APPLICATION NUMBER: 60/225,470
;  PRIOR FILING DATE: 2000-08-15
;  PRIOR APPLICATION NUMBER: 60/225,697
;  PRIOR FILING DATE: 2000-08-16
;  PRIOR APPLICATION NUMBER: 60/263,662
;  PRIOR FILING DATE: 2001-02-01
;  PRIOR APPLICATION NUMBER: 60/281,645
;  PRIOR FILING DATE: 2001-04-05
;  NUMBER OF SEQ ID NOS: 61
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 50
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Oligonucleotide
;   OTHER INFORMATION: primers
US-09-918-779-50

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1992 TGTGTATCTAGCTTCTTCA 2010
              ||||| |||  ||||||||
Db         20 TGTGTTTCTGCCTTCTTCA 2


RESULT 120
US-10-345-092-50/c
; Sequence 50, Application US/10345092
; Publication No. US20030165506A1
; GENERAL INFORMATION:
;  APPLICANT: Vlaams Interuniversitair Instituut voor Biotechnol
;  TITLE OF INVENTION: No. US20030165506A1el alpha-catenin expressed in heart and testis
;  FILE REFERENCE: FVR/aTc/V067
;  CURRENT APPLICATION NUMBER: US/10/345,092
;  CURRENT FILING DATE:  2003-01-13
;  PRIOR APPLICATION NUMBER: 00202472.7
;  PRIOR FILING DATE: 2000-07-12
;  PRIOR APPLICATION NUMBER: US 60/218,309
;  PRIOR FILING DATE: 2000-07-14
;  NUMBER OF SEQ ID NOS: 134
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 50
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: lower primer
;   OTHER INFORMATION: FVR2520
US-10-345-092-50

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAAGTGG 1811
              |||| |||||||||  |||
Db         20 TTTCATTCTCTGAACCTGG 2


RESULT 121
US-10-032-585-4086
; Sequence 4086, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
;  APPLICANT: Terry, Roemer D.
;  APPLICANT:  Bo, Jiang
;  APPLICANT:  Charles, Boone
;  APPLICANT:  Howard, Bussey
;  TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
;  FILE REFERENCE: 10182-005-999
;  CURRENT APPLICATION NUMBER: US/10/032,585
;  CURRENT FILING DATE:  2001-12-20
;  NUMBER OF SEQ ID NOS: 8000
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4086
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Candida albicans
US-10-032-585-4086

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
```

```
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATCAA 1906
              |||||| | || |||||||
Db          1 TTGATGGGTCCGAGATCAA 19


RESULT 122
US-10-084-555-55
; Sequence 55, Application US/10084555
; Publication No. US20030190616A1
; GENERAL INFORMATION:
;  APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
;  APPLICANT:  GOGGINS, Michael G.
;  APPLICANT:  UEKI, Takashi
;  TITLE OF INVENTION: DIFFERENTIALLY METHYLATED SEQUENCES IN PANCREATIC CANCER
;  FILE REFERENCE: JHU1700-1
;  CURRENT APPLICATION NUMBER: US/10/084,555
;  CURRENT FILING DATE:  2002-02-25
;  PRIOR APPLICATION NUMBER: US 60/271,268
;  PRIOR FILING DATE: 2001-02-23
;  NUMBER OF SEQ ID NOS: 114
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 55
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer
US-10-084-555-55

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGGAAG 1554
              || | ||||||||||| ||
Db          1 GGGTTGGAGAGTAGGGGAG 19


RESULT 123
US-10-388-263-911
; Sequence 911, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
;  APPLICANT: Cowsert, Lex M.
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  McNeil, John
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Sasmor, Henri M.
;  APPLICANT:  Brooks, Douglas G.
;  APPLICANT:  Ohashi, Cara
;  APPLICANT:  Wyatt, Jacqueline R.
;  APPLICANT:  Borchers, Alexander
;  APPLICANT:  Vickers, Timothy A.
;  TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
;  TITLE OF INVENTION:  MODULATION BY OLIGONUCLEOTIDES AND
;  TITLE OF INVENTION:  GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
;  FILE REFERENCE: ISIS-4503
;  CURRENT APPLICATION NUMBER: US/10/388,263
;  CURRENT FILING DATE:  2003-03-12
;  NUMBER OF SEQ ID NOS: 947
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 911
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligomeric Compound
US-10-388-263-911

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTTT 1795
              | ||| || ||||||||||
Db          1 TGTTTCAAGCCCATTCTTT 19


RESULT 124
US-10-388-263-947/c
; Sequence 947, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
;  APPLICANT: Cowsert, Lex M.
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  McNeil, John
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Sasmor, Henri M.
;  APPLICANT:  Brooks, Douglas G.
;  APPLICANT:  Ohashi, Cara
;  APPLICANT:  Wyatt, Jacqueline R.
;  APPLICANT:  Borchers, Alexander
;  APPLICANT:  Vickers, Timothy A.
;  TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
;  TITLE OF INVENTION:  MODULATION BY OLIGONUCLEOTIDES AND
;  TITLE OF INVENTION:  GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
;  FILE REFERENCE: ISIS-4503
;  CURRENT APPLICATION NUMBER: US/10/388,263
;  CURRENT FILING DATE:  2003-03-12
;  NUMBER OF SEQ ID NOS: 947
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 947
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligomeric Compound
US-10-388-263-947

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTTT 1795
              | ||| || ||||||||||
Db         19 TGTTTCAAGCCCATTCTTT 1


RESULT 125
US-10-336-552-3/c
; Sequence 3, Application US/10336552
; Publication No. US20040002082A1
; GENERAL INFORMATION:
;  APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
;  APPLICANT:  FEINBERG, Andrew P.
;  TITLE OF INVENTION: METHODS FOR IDENTIFYING CANCER RISK
;  FILE REFERENCE: JHU1830-1
;  CURRENT APPLICATION NUMBER: US/10/336,552
;  CURRENT FILING DATE:  2003-01-03
;  PRIOR APPLICATION NUMBER: US 60/391,810
;  PRIOR FILING DATE: 2002-06-27
;  NUMBER OF SEQ ID NOS: 5
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: PCR primer
US-10-336-552-3

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||  ||||| |||||||||
Db         19 AGGGAGGTTGGGAGAGTAG 1
```

RESULT 126
US-10-336-213B-88
; Sequence 88, Application US/10336213B
; Publication No. US20040002153A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsert
; APPLICANT: Robert McKay
; APPLICANT: Tim Vickers
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
; FILE REFERENCE: ISIS0004-100
; CURRENT APPLICATION NUMBER: US/10/336,213B
; CURRENT FILING DATE: 2003-01-03
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: US 09/878,582
; PRIOR FILING DATE: 2001-06-11
; PRIOR APPLICATION NUMBER: US 09/577,902
; PRIOR FILING DATE: 2000-05-24
; PRIOR APPLICATION NUMBER: PCT/US99/29594
; PRIOR FILING DATE: 1999-12-14
; PRIOR APPLICATION NUMBER: US 09/358,381
; PRIOR FILING DATE: 1999-07-21
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 88
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-336-213B-88

Query Match 2.5%; Score 14.2; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1777 TTTTTGAACCCCATTCTTT 1795
              | ||| || ||||||||||
Db          1 TGTTTCAAGCCCATTCTTT 19
```

RESULT 127
US-10-624-932-50/c
; Sequence 50, Application US/10624932
; Publication No. US20040096877A1
; GENERAL INFORMATION:
; APPLICANT: Taupier, Raymond
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Rastelli, Luca
; APPLICANT: Spaderna, Steven
; APPLICANT: Shimkets, Richard
; APPLICANT: Zerhusen, Bryan
; APPLICANT: Spytek, Kimberly
; APPLICANT: Shenoy, Suresh
; APPLICANT: Li, Li
; APPLICANT: Gusev, Vladimir
; APPLICANT: Grosse, William
; APPLICANT: Alsobrook, John
; APPLICANT: Lepley, Denise
; APPLICANT: Burgess, Catherine
; APPLICANT: Gerlach, Valerie
; APPLICANT: Ellerman, Karen
; APPLICANT: MacDougall, John
; APPLICANT: Stone, David
; APPLICANT: Smithson, Glennda
; TITLE OF INVENTION: Novel Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-074 US
; CURRENT APPLICATION NUMBER: US/10/624,932
; CURRENT FILING DATE: 2003-07-21
; PRIOR APPLICATION NUMBER: 09/918,779
; PRIOR FILING DATE: 2001-07-03
; PRIOR APPLICATION NUMBER: 60/221,409
; PRIOR FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: 60/222,840
; PRIOR FILING DATE: 2000-08-04
; PRIOR APPLICATION NUMBER: 60/223,752
; PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: 60/223,762
; PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: 60/223,770
; PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: 60/223,769
; PRIOR FILING DATE: 2000-08-08
; PRIOR APPLICATION NUMBER: 60/225,146
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/225,392
; PRIOR FILING DATE: 2000-08-15
; PRIOR APPLICATION NUMBER: 60/225,470
; PRIOR FILING DATE: 2000-08-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 61
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Oligonucleotide
; OTHER INFORMATION: primers
US-10-624-932-50

Query Match 2.5%; Score 14.2; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1992 TGTGTATCTAGCTTCTTCA 2010
              ||||| |||  ||||||||
Db         20 TGTGTTTCTGCCTTCTTCA 2
```

RESULT 128
US-10-786-720-192/c
; Sequence 192, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 192
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-192

Query Match 2.5%; Score 14.2; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1869 TAGCCATTGAAATGTCAAA 1887
              ||||||||||||||   ||
Db         19 TAGCCATTGAAATGGATAA 1
```

```
RESULT 129
US-10-786-720-358
; Sequence 358, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 358
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-358

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1869 TAGCCATTGAAATGTCAAA 1887
              ||||||||||||||   ||
Db          1 TAGCCATTGAAATGGATAA 19


RESULT 130
US-10-786-720-8090
; Sequence 8090, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8090
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-8090

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   42.1%;  Pred. No. 2.1e+02;
  Matches    8;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGTTGGTTT 1953
              ::|||| | : |::||:::
Db          3 UUAAGGCAUUUGUUGGUUU 21


RESULT 131
US-10-786-720-10322
; Sequence 10322, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10322
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-10322

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   42.1%;  Pred. No. 2.1e+02;
  Matches    8;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGTTGGTTT 1953
              ::|||| | : |::||:::
Db          3 UUAAGGCAUUUGUUGGUUU 21


RESULT 132
US-10-786-720-15052/c
; Sequence 15052, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15052
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-15052

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1994 TGTATCTAGCTTCTTCAGA 2012
              || |||| |||||||||| |
Db         21 TGGATCTGGCTTCTTCAAA 3


RESULT 133
US-10-786-720-15053/c
; Sequence 15053, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15053
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-15053

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1994 TGTATCTAGCTTCTTCAGA 2012
```

```
              || |||| ||||||||| |
Db         19 TGGATCTGGCTTCTTCAAA 1


RESULT 134
US-10-786-720-15054
; Sequence 15054, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15054
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-15054

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   47.4%;  Pred. No. 2.1e+02;
  Matches    9;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1994 TGTATCTAGCTTCTTCAGA 2012
              :| |:|: ||::|::|| |
Db          1 UGGAUCUGGCUUCUUCAAA 19


RESULT 135
US-09-854-883-32
; Sequence 32, Application US/09854883
; Patent No. US20020055479A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0576
;  CURRENT APPLICATION NUMBER: US/09/854,883
;  CURRENT FILING DATE:  2001-05-14
;  PRIOR APPLICATION NUMBER: US 09/629,644
;  PRIOR FILING DATE: 2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 32
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-854-883-32

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
              ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 136
US-10-181-107-130/c
; Sequence 130, Application US/10181107
; Publication No. US20030083295A1
; GENERAL INFORMATION:
;  APPLICANT: Hong Zhang
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 3 EXPRESSION
;  FILE REFERENCE: RTSP-0325
;  CURRENT APPLICATION NUMBER: US/10/181,107
;  CURRENT FILING DATE:  2002-07-11
;  PRIOR APPLICATION NUMBER: PCT/US01/00888
;  PRIOR FILING DATE: 2001-01-11
;  PRIOR APPLICATION NUMBER: 09/484,617
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-107-130

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAG 2013
              ||||||||||||||
Db          20 TAGCTTCTTCAGAG 7


RESULT 137
US-10-360-510-32
; Sequence 32, Application US/10360510
; Publication No. US20030220282A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0576
;  CURRENT APPLICATION NUMBER: US/10/360,510
;  CURRENT FILING DATE:  2003-02-07
;  PRIOR APPLICATION NUMBER: US/09/854,883
;  PRIOR FILING DATE: 2001-05-14
;  PRIOR APPLICATION NUMBER: US 09/629,644
;  PRIOR FILING DATE: 2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 32
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-360-510-32

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
              ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 138
US-10-173-817-30/c
; Sequence 30, Application US/10173817
```

; Publication No. US20030232438A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF KOX 1 EXPRESSION
; FILE REFERENCE: RTS-0359
; CURRENT APPLICATION NUMBER: US/10/173,817
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 131
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-173-817-30

Query Match 2.5%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1799 TCTCTGAAAGTGGT 1812
||||||||||||||
Db 20 TCTCTGAAAGTGGT 7

RESULT 139
US-10-643-432-30/c
; Sequence 30, Application US/10643432
; Publication No. US20040087536A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF KOX 1 EXPRESSION
; FILE REFERENCE: RTS-0359
; CURRENT APPLICATION NUMBER: US/10/643,432
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US/10/173,817
; PRIOR FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 131
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-432-30

Query Match 2.5%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1799 TCTCTGAAAGTGGT 1812
||||||||||||||
Db 20 TCTCTGAAAGTGGT 7

RESULT 140
US-10-786-720-19526
; Sequence 19526, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19526
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-19526

Query Match 2.5%; Score 14; DB 1; Length 21;
Best Local Similarity 42.9%; Pred. No. 2.3e+02;
Matches 6; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 1761 TTCATTAAGCTTTT 1774
::||::||||::::
Db 8 UUCAUUAAGCUUUU 21

RESULT 141
US-09-866-108-1346/c
; Sequence 1346, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1346
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1346

Query Match 2.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1785 CCCCATTCTTTCCTTCT 1801

```
                    |||||| |||||||||
Db         17 CCCCATCTTTTCCTTCT 1


RESULT 142
US-09-866-108-7642/c
; Sequence 7642, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7642
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7642

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCTAGC 1701
                || |||| |||||||||
Db         17 TTTGTTGGTTCTCTAGC 1


RESULT 143
US-09-866-108-7643/c
; Sequence 7643, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7643
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7643

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTAG 1700
                ||| |||| |||||||||
Db         17 CTTTGTTGGTTCTCTAG 1


RESULT 144
US-09-730-289B-867
; Sequence 867, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 867
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-867

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 1.8e+02;
  Matches    9;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTAT 1640
              |::||||:| |::|| |:
Db          1 GUUACCUAGCUUACCAU 17


RESULT 145
US-10-723-361-1346/c
; Sequence 1346, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1346
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1346

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              ||||||  |||||||||
Db         17 CCCCATCTTTTCCTTCT 1


RESULT 146
US-10-723-361-7642/c
; Sequence 7642, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7642
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7642

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCTAGC 1701
              || |||| |||||||||
Db         17 TTTGTTGGTTCTCTAGC 1


RESULT 147
US-10-723-361-7643/c
; Sequence 7643, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
```

```
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7643
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-7643

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTAG 1700
              ||| |||| ||||||||
Db         17 CTTTGTTGGTTCTCTAG 1


RESULT 148
US-09-969-373-2654
; Sequence 2654, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2654
;    LENGTH: 18
;    TYPE: DNA
;    ORGANISM: Glycine max
US-09-969-373-2654

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACACA 1866
              ||||||| || ||||||
Db          2 GCCAACACACACACACA 18


RESULT 149
US-09-901-484A-46
; Sequence 46, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  APPLICANT:  Bougueleret, Lydie
;  TITLE OF INVENTION: Prostate Cancer Gene
;  FILE REFERENCE: GEN-T111XC3D2
;  CURRENT APPLICATION NUMBER: US/09/901,484A
;  CURRENT FILING DATE:  2001-07-09
;  PRIOR APPLICATION NUMBER: US 08/996,306
;  PRIOR FILING DATE: 1997-12-22
;  PRIOR APPLICATION NUMBER: US 60/099,658
;  PRIOR FILING DATE: 1998-09-09
;  PRIOR APPLICATION NUMBER: US 09/218,207
;  PRIOR FILING DATE: 1998-12-22
;  PRIOR APPLICATION NUMBER: US 09/338,907
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: US 09/853,526
;  PRIOR FILING DATE: 2001-05-11
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 46
;    LENGTH: 19
;    TYPE: DNA
;    ORGANISM: Homo sapiens
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(19)
;    OTHER INFORMATION: upstream amplification primer 99-221-PU
US-09-901-484A-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 150
US-09-901-484A-380
; Sequence 380, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  APPLICANT:  Bougueleret, Lydie
;  TITLE OF INVENTION: Prostate Cancer Gene
;  FILE REFERENCE: GEN-T111XC3D2
;  CURRENT APPLICATION NUMBER: US/09/901,484A
;  CURRENT FILING DATE:  2001-07-09
;  PRIOR APPLICATION NUMBER: US 08/996,306
;  PRIOR FILING DATE: 1997-12-22
;  PRIOR APPLICATION NUMBER: US 60/099,658
;  PRIOR FILING DATE: 1998-09-09
;  PRIOR APPLICATION NUMBER: US 09/218,207
;  PRIOR FILING DATE: 1998-12-22
;  PRIOR APPLICATION NUMBER: US 09/338,907
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: US 09/853,526
;  PRIOR FILING DATE: 2001-05-11
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 380
;    LENGTH: 19
;    TYPE: DNA
;    ORGANISM: Homo sapiens
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION: (1)..(19)
;    OTHER INFORMATION: upstream amplification primer for SEQ 260, SEQ 337
US-09-901-484A-380

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 151
US-09-853-526-46
; Sequence 46, Application US/09853526
; Patent No. US20020165345A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Ilya, Chumakov
;  APPLICANT:  Bougueleret, Lydie
;  TITLE OF INVENTION: PROSTATE CANCER GENE
;  FILE REFERENCE: GENSET.18CP1CP
;  CURRENT APPLICATION NUMBER: US/09/853,526
;  CURRENT FILING DATE:  2001-05-11
;  PRIOR APPLICATION NUMBER: 09/338,907
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: 08/996,306
;  PRIOR FILING DATE: 1997-12-22
;  PRIOR APPLICATION NUMBER: 60/099,658
;  PRIOR FILING DATE: 1998-09-09
;  PRIOR APPLICATION NUMBER: 09/218,207
;  PRIOR FILING DATE: 1998-12-22
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 46
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-221-PU
US-09-853-526-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 152
US-09-853-526-380
; Sequence 380, Application US/09853526
; Patent No. US20020165345A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Ilya, Chumakov
;  APPLICANT:  Bougueleret, Lydie
;  TITLE OF INVENTION: PROSTATE CANCER GENE
;  FILE REFERENCE: GENSET.18CP1CP
;  CURRENT APPLICATION NUMBER: US/09/853,526
;  CURRENT FILING DATE:  2001-05-11
;  PRIOR APPLICATION NUMBER: 09/338,907
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: 08/996,306
;  PRIOR FILING DATE: 1997-12-22
;  PRIOR APPLICATION NUMBER: 60/099,658
;  PRIOR FILING DATE: 1998-09-09
;  PRIOR APPLICATION NUMBER: 09/218,207
;  PRIOR FILING DATE: 1998-12-22
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 380
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer for SEQ 260, SEQ 337
US-09-853-526-380

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 153
US-10-225-023-79
; Sequence 79, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 79
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-225-023-79

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 2.1e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |::|:||||||| | ||
Db          3 AUUAUCAGAAGGAGCCA 19


RESULT 154
US-10-225-023-120
; Sequence 120, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 120
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-225-023-120

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 2.1e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |::|:|||||||  | ||
Db          2 AUUAUCAGAAGGAGCCA 18


RESULT 155
US-10-225-023-164
; Sequence 164, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 164
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-225-023-164

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 2.1e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |::|:|||||||  | ||
Db          1 AUUAUCAGAAGGAGCCA 17


RESULT 156
US-10-225-023-817/c
; Sequence 817, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 817
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-225-023-817

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||  | ||
Db         17 ATTATCAGAAGGAGCCA 1


RESULT 157
US-10-225-023-858/c
; Sequence 858, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 858
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-225-023-858

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||  | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 158
US-10-225-023-902/c
; Sequence 902, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
```

```
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 902
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-225-023-902

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1729 ATTATCAGAAGGTGACA 1745
             ||||||||||||| | ||
Db        19 ATTATCAGAAGGAGCCA 3


RESULT 159
US-10-346-514-2/c
; Sequence 2, Application US/10346514
; Publication No. US20030211522A1
; GENERAL INFORMATION:
;  APPLICANT: Landes, Gregory M.
;  APPLICANT:  Michalowsky, Lesley
;  APPLICANT:  Miller, Glenn
;  APPLICANT:  Weber, William
;  TITLE OF INVENTION: METHODS FOR FETAL DNA DETECTION AND
;  TITLE OF INVENTION:  ALLELE QUANTITATION
;  FILE REFERENCE: GZ 2086.00
;  CURRENT APPLICATION NUMBER: US/10/346,514
;  CURRENT FILING DATE:  2003-01-17
;  PRIOR APPLICATION NUMBER: 60/349,877
;  PRIOR FILING DATE: 2002-01-18
;  NUMBER OF SEQ ID NOS: 13
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-346-514-2

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1535 AGGTTAGGAGAGTAGGG 1551
             ||||||||||||| | ||
Db        17 AGGTTAGGAGAGGAAGG 1


RESULT 160
US-10-282-174-182
; Sequence 182, Application US/10282174
; Publication No. US20030224380A1
; GENERAL INFORMATION:
;  APPLICANT: Becker, Kenneth David
;  APPLICANT:  Velicelebi, Gonul
;  APPLICANT:  Elliot, Kathryn J.
;  APPLICANT:  Wang, Xin
;  APPLICANT:  Tanzi, Rudolph E.
;  APPLICANT:  Bertram, Lars
;  APPLICANT:  Saunders, Aleister J.
;  APPLICANT:  Mullin, Kristina M.
;  APPLICANT:  Sampson, Andrew Johnson
;  APPLICANT:  Blacker, Deborah Lynne
;  TITLE OF INVENTION: GENES AND POLYMORPHISMS ON CHROMOSOME 10
;  TITLE OF INVENTION:  ASSOCIATED WITH ALZHEIMER'S DISEASE AND OTHER
;  TITLE OF INVENTION:  NEURODEGENERATIVE DISEASES
;  FILE REFERENCE: 37481-3308
;  CURRENT APPLICATION NUMBER: US/10/282,174
;  CURRENT FILING DATE:  2002-10-25
;  PRIOR APPLICATION NUMBER: US 60/339,525
;  PRIOR FILING DATE: 2001-10-25
;  PRIOR APPLICATION NUMBER: US 60/338,010
;  PRIOR FILING DATE: 2001-11-08
;  PRIOR APPLICATION NUMBER: US 60/336,929
;  PRIOR FILING DATE: 2001-11-08
;  PRIOR APPLICATION NUMBER: US 60/338,363
;  PRIOR FILING DATE: 2001-11-09
;  PRIOR APPLICATION NUMBER: US 60/337,052
;  PRIOR FILING DATE: 2001-12-04
;  PRIOR APPLICATION NUMBER: US 60/368,919
;  PRIOR FILING DATE: 2002-03-28
;  NUMBER OF SEQ ID NOS: 564
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 182
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-282-174-182

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1529 GAAGAAAGGTTAGGAGA 1545
             |||||||||| || |||
Db         3 GAAGAAAGGTCAGCAGA 19


RESULT 161
US-10-349-143-7856
; Sequence 7856, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7856
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-221 for SEQ 3922,
US-10-349-143-7856

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy      1920 CCTTTTTTTTCAGTGTT 1936
             ||||||| |||| ||||
Db         2 CCTTTTTCTTCACTGTT 18


RESULT 162
```

```
US-10-333-429-549
; Sequence 549, Application US/10333429
; Publication No. US20040048265A1
; GENERAL INFORMATION:
;  APPLICANT: GENSET
;  TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps
;  FILE REFERENCE: G-083US02PCT
;  CURRENT APPLICATION NUMBER: US/10/333,429
;  CURRENT FILING DATE:  2003-01-17
;  PRIOR APPLICATION NUMBER: PCT/IB01/01477
;  PRIOR FILING DATE: 2001-06-28
;  PRIOR APPLICATION NUMBER: US 60/219,704
;  PRIOR FILING DATE: 2000-07-18
;  NUMBER OF SEQ ID NOS: 579
;  SOFTWARE: Patent.pm
; SEQ ID NO 549
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-221 for SEQ 527,
US-10-333-429-549

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 163
US-09-280-030-46/c
; Sequence 46, Application US/09280030A
; Patent No. US20010021515A1
; GENERAL INFORMATION:
;  APPLICANT: Sato, Seiji
;  APPLICANT: Higashikuni, Naohiko
;  APPLICANT: Kudo, Toshiyuki
;  APPLICANT: Kondo, Masaaki
;  TITLE OF INVENTION: DNAS ENCODING NEW FUSION PROTEINS AND PROCESSES FOR
;  TITLE OF INVENTION: PREPARING USEFUL POLYPEPTIDES THROUGH EXPRESSION OF THE
;  TITLE OF INVENTION: DNAS
;  FILE REFERENCE: 382.1026
;  CURRENT APPLICATION NUMBER: US/09/280,030A
;  CURRENT FILING DATE: 1999-03-26
;  EARLIER APPLICATION NUMBER: JP10-87339/1998
;  EARLIER FILING DATE: 1998-03-31
;  NUMBER OF SEQ ID NOS: 66
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 46
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Designated is
;   OTHER INFORMATION: a forward primer for PCR amplification of human
;   OTHER INFORMATION: growth hormone DNA
US-09-280-030-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1934 GTTAAGGTAATGGTTGG 1950
              | ||||| |||||||||
Db         20 GATAAGGGAATGGTTGG 4


RESULT 164
US-09-944-036-47/c
; Sequence 47, Application US/09944036
; Patent No. US20020055095A1
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/09/944,036
;  CURRENT FILING DATE:  2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 47
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
US-09-944-036-47

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         20 ATTATCAGAAGGAGCCA 4


RESULT 165
US-09-946-406-15
; Sequence 15, Application US/09946406
; Patent No. US20020172956A1
; GENERAL INFORMATION:
;  APPLICANT: Herman, Gail E.
;  APPLICANT:  Kelley, Richard I.
;  APPLICANT:  Grange, Dorothy K.
;  TITLE OF INVENTION: MATERIALS AND METHODS RELATING TO CHOLESTEROL
;  TITLE OF INVENTION:  BIOSYNTHESIS ENZYMES
;  FILE REFERENCE: 28335/36435
;  CURRENT APPLICATION NUMBER: US/09/946,406
;  CURRENT FILING DATE:  2001-09-05
;  PRIOR APPLICATION NUMBER: 09/588,976
;  PRIOR FILING DATE: 2000-06-01
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: hH105-4F
;   OTHER INFORMATION: primer
US-09-946-406-15

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCAAA 1887
              ||||||||  |||||||
Db          2 GCCATTGACCTGTCAAA 18


RESULT 166
US-09-784-674-556
```

```
; Sequence 556, Application US/09784674
; Publication No. US20030054346A1
;   GENERAL INFORMATION:
;        APPLICANT: Shannon, Karen W.
;                   Wolber, Paul K.
;                   Delenstarr, Glenda C.
;                   Webb, Peter G.
;                   Kincaid, Robert H.
;        TITLE OF INVENTION: Methods for evaluating oligonucleotide
;                            probe sequences
;        NUMBER OF SEQUENCES: 1165
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
;                        Company M/S 20BO
;             STREET: 3000 Hanover Street
;             CITY: Palo Alto
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 94304
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/784,674
;             FILING DATE: 15-Feb-2001
;             CLASSIFICATION: No. US20030054346A1 available
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/021,701
;             FILING DATE: 10-FEB-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Choi, Wendy A.
;             REGISTRATION NUMBER: 36,697
;             REFERENCE/DOCKET NUMBER: 10971464-1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 650-236-2386
;             TELEFAX: 650-852-8063
;   INFORMATION FOR SEQ ID NO: 556:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 556:
US-09-784-674-556

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          4 TTTTTCTTTTTTAACCC 20


RESULT 167
US-09-784-674-557
; Sequence 557, Application US/09784674
; Publication No. US20030054346A1
;   GENERAL INFORMATION:
;        APPLICANT: Shannon, Karen W.
;                   Wolber, Paul K.
;                   Delenstarr, Glenda C.
;                   Webb, Peter G.
;                   Kincaid, Robert H.
;        TITLE OF INVENTION: Methods for evaluating oligonucleotide
;                            probe sequences
;        NUMBER OF SEQUENCES: 1165
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
;                        Company M/S 20BO
;             STREET: 3000 Hanover Street
;             CITY: Palo Alto
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 94304
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/784,674
;             FILING DATE: 15-Feb-2001
;             CLASSIFICATION: No. US20030054346A1 available
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/021,701
;             FILING DATE: 10-FEB-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Choi, Wendy A.
;             REGISTRATION NUMBER: 36,697
;             REFERENCE/DOCKET NUMBER: 10971464-1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 650-236-2386
;             TELEFAX: 650-852-8063
;   INFORMATION FOR SEQ ID NO: 557:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 557:
US-09-784-674-557

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          3 TTTTTCTTTTTTAACCC 19


RESULT 168
US-09-784-674-558
; Sequence 558, Application US/09784674
; Publication No. US20030054346A1
;   GENERAL INFORMATION:
;        APPLICANT: Shannon, Karen W.
;                   Wolber, Paul K.
;                   Delenstarr, Glenda C.
;                   Webb, Peter G.
;                   Kincaid, Robert H.
;        TITLE OF INVENTION: Methods for evaluating oligonucleotide
;                            probe sequences
;        NUMBER OF SEQUENCES: 1165
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
;                        Company M/S 20BO
;             STREET: 3000 Hanover Street
;             CITY: Palo Alto
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 94304
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
```

```
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/784,674
;            FILING DATE: 15-Feb-2001
;            CLASSIFICATION: No. US20030054346A1 available
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/021,701
;            FILING DATE: 10-FEB-1998
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Choi, Wendy A.
;            REGISTRATION NUMBER: 36,697
;            REFERENCE/DOCKET NUMBER: 10971464-1
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 650-236-2386
;            TELEFAX: 650-852-8063
;   INFORMATION FOR SEQ ID NO: 558:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: cDNA
;       HYPOTHETICAL: NO
;       ANTI-SENSE: NO
;       SEQUENCE DESCRIPTION: SEQ ID NO: 558:
US-09-784-674-558

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          2 TTTTTCTTTTTTAACCC 18


RESULT 169
US-09-784-674-559
; Sequence 559, Application US/09784674
; Publication No. US20030054346A1
;   GENERAL INFORMATION:
;       APPLICANT: Shannon, Karen W.
;                  Wolber, Paul K.
;                  Delenstarr, Glenda C.
;                  Webb, Peter G.
;                  Kincaid, Robert H.
;       TITLE OF INVENTION: Methods for evaluating oligonucleotide
;                           probe sequences.
;       NUMBER OF SEQUENCES: 1165
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
;                       Company M/S 20BO
;            STREET: 3000 Hanover Street
;            CITY: Palo Alto
;            STATE: CA
;            COUNTRY: USA
;            ZIP: 94304
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/784,674
;            FILING DATE: 15-Feb-2001
;            CLASSIFICATION: No. US20030054346A1 available
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/021,701
;            FILING DATE: 10-FEB-1998
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Choi, Wendy A.
;            REGISTRATION NUMBER: 36,697
;            REFERENCE/DOCKET NUMBER: 10971464-1
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 650-236-2386
;            TELEFAX: 650-852-8063
;   INFORMATION FOR SEQ ID NO: 559:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: cDNA
;       HYPOTHETICAL: NO
;       ANTI-SENSE: NO
;       SEQUENCE DESCRIPTION: SEQ ID NO: 559:
US-09-784-674-559

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          1 TTTTTCTTTTTTAACCC 17


RESULT 170
US-10-181-846-166
; Sequence 166, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
;  FILE REFERENCE: RTSP-0363
;  CURRENT APPLICATION NUMBER: US/10/181,846
;  CURRENT FILING DATE:  2002-07-17
;  PRIOR APPLICATION NUMBER: PCT/US01/01416
;  PRIOR FILING DATE: 2001-01-16
;  PRIOR APPLICATION NUMBER: 09/490,692
;  PRIOR FILING DATE: 2000-01-24
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 166
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-166

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2032 AGGCAAAGGTTCTATCT 2048
              |||||||| ||| ||||
Db          1 AGGCAAAGCTTCCATCT 17


RESULT 171
US-10-003-919-25
; Sequence 25, Application US/10003919
; Publication No. US20030114401A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SHIP-1 EXPRESSION
;  FILE REFERENCE: RTS-0256
;  CURRENT APPLICATION NUMBER: US/10/003,919
;  CURRENT FILING DATE:  2001-12-06
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-919-25

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              ||||||  |||||||||
Db          2 CCCCATGTTTTCCTTCT 18


RESULT 172
US-10-425-975-47/c
; Sequence 47, Application US/10425975
; Publication No. US20030228574A1
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/10/425,975
;  CURRENT FILING DATE:  2003-04-28
;  PRIOR APPLICATION NUMBER: US/09/944,036
;  PRIOR FILING DATE: 2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 47
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
US-10-425-975-47

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         20 ATTATCAGAAGGAGCCA 4


RESULT 173
US-10-289-762-2718/c
; Sequence 2718, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2718
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-2718

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTG 1606
              |||| |||||||||  ||
Db         17 ACTGCGAACCCCTCTTG 1


RESULT 174
US-10-304-116-91/c
; Sequence 91, Application US/10304116
; Publication No. US20040101857A1
; GENERAL INFORMATION:
;  APPLICANT: Donna T. Ward
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF CYTOKINE-INDUCIBLE KINASE EXPRESSION
;  FILE REFERENCE: RTS-0397
;  CURRENT APPLICATION NUMBER: US/10/304,116
;  CURRENT FILING DATE:  2002-11-23
;  NUMBER OF SEQ ID NOS: 138
; SEQ ID NO 91
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-304-116-91

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGG 1612
              ||||| |||||||| ||
Db         17 AACCCATCCTGGCCGGG 1


RESULT 175
US-10-688-706-1604
; Sequence 1604, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Broschat, Kay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
;  FILE REFERENCE: 01393/1
;  CURRENT APPLICATION NUMBER: US/10/688,706
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,268
;  PRIOR FILING DATE: 2002-10-17
;  NUMBER OF SEQ ID NOS: 3071
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1604
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: human GFAT antisense
US-10-688-706-1604

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||||||| ||||| |
Db          1 TTTTTCAGTTTTAAGTT 17


RESULT 176
US-10-688-706-2325
; Sequence 2325, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
```

; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2325
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-2325

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1925 TTTTTCAGTGTTAAGGT 1941
||||||||| ||||| |
Db 2 TTTTTCAGTTTTAAGTT 18

RESULT 177
US-10-688-706-2367
; Sequence 2367, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2367
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-2367

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1925 TTTTTCAGTGTTAAGGT 1941
||||||||| ||||| |
Db 3 TTTTTCAGTTTTAAGTT 19

RESULT 178
US-10-688-706-2504
; Sequence 2504, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2504
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-2504

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1925 TTTTTCAGTGTTAAGGT 1941
||||||||| ||||| |
Db 4 TTTTTCAGTTTTAAGTT 20

RESULT 179
US-10-317-280-33/c
; Sequence 33, Application US/10317280
; Publication No. US20040110160A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Tamara Balac Sipes
; TITLE OF INVENTION: MODULATION OF SEDL EXPRESSION
; FILE REFERENCE: RTS-0459
; CURRENT APPLICATION NUMBER: US/10/317,280
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 157
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-280-33

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1777 TTTTTGAACCCCATTCT 1793
||| ||||||| |||||
Db 20 TTTATGAACCCAATTCT 4

RESULT 180
US-10-317-280-109
; Sequence 109, Application US/10317280
; Publication No. US20040110160A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Tamara Balac Sipes
; TITLE OF INVENTION: MODULATION OF SEDL EXPRESSION
; FILE REFERENCE: RTS-0459
; CURRENT APPLICATION NUMBER: US/10/317,280
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 157
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-317-280-109

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1777 TTTTTGAACCCCATTCT 1793
||| ||||||| |||||
Db 1 TTTATGAACCCAATTCT 17

```
RESULT 181
US-10-317-649-47/c
; Sequence 47, Application US/10317649
; Publication No. US20040115638A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF TUMOR SUSCEPTIBILITY GENE 101 EXPRESSION
;  FILE REFERENCE: HTS-0048
;  CURRENT APPLICATION NUMBER: US/10/317,649
;  CURRENT FILING DATE:  2002-12-11
;  NUMBER OF SEQ ID NOS: 68
; SEQ ID NO 47
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-649-47

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1726 CCTATTATCAGAAGGTG 1742
              ||| ||||||| |||||
Db         17 CCTTTTATCAGTAGGTG 1

RESULT 182
US-10-766-185-53/c
; Sequence 53, Application US/10766185
; Publication No. US20040152655A1
; GENERAL INFORMATION:
;  APPLICANT: Yoon, Heejeong
;  APPLICANT:  Ahn, Chang Ho
;  APPLICANT:  Lee, Young  Bok
;  APPLICANT:  Mao, Lingjun
;  APPLICANT:  Jiang, Xiaoming
;  TITLE OF INVENTION: Antisense Oligonucleotides that inhibit expression of HIF-1
;  FILE REFERENCE: REX 7034
;  CURRENT APPLICATION NUMBER: US/10/766,185
;  CURRENT FILING DATE:  2004-01-28
;  NUMBER OF SEQ ID NOS: 130
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 53
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligonucleotide
US-10-766-185-53

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCT 1793
              ||||||| |||| ||||
Db         20 TTTTTGATCCCCTTTCT 4

RESULT 183
US-10-684-978-15
; Sequence 15, Application US/10684978
; Publication No. US20040166485A1
; GENERAL INFORMATION:
;  APPLICANT: Herman, Gail E.
;  APPLICANT:  Kelley, Richard I.
;  APPLICANT:  Grange, Dorothy K.
;  TITLE OF INVENTION: MATERIALS AND METHODS RELATING TO CHOLESTEROL
;  TITLE OF INVENTION:  BIOSYNTHESIS ENZYMES
;  FILE REFERENCE: 28335/36435
;  CURRENT APPLICATION NUMBER: US/10/684,978
;  CURRENT FILING DATE:  2003-10-14
;  PRIOR APPLICATION NUMBER: US/09/588,976
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: 60/137,020
;  PRIOR FILING DATE: 1999-06-01
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: hH105-4F
;   OTHER INFORMATION: primer
US-10-684-978-15

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCAAA 1887
              |||||||| |||||||
Db          2 GCCATTGACCTGTCAAA 18

RESULT 184
US-09-944-036-11/c
; Sequence 11, Application US/09944036
; Patent No. US20020055095A1
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/09/944,036
;  CURRENT FILING DATE:  2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
US-09-944-036-11

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         18 ATTATCAGAAGGAGCCA 2

RESULT 185
US-09-944-036-46/c
; Sequence 46, Application US/09944036
; Patent No. US20020055095A1
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
```

```
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/09/944,036
;  CURRENT FILING DATE:  2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
US-09-944-036-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 186
US-09-820-339A-28
; Sequence 28, Application US/09820339A
; Patent No. US20020081652A1
; GENERAL INFORMATION:
;  APPLICANT: FUCHS, Sara
;  APPLICANT:  BARCHAN, Dora
;  APPLICANT:  SOUROUJON, Miriam
;  TITLE OF INVENTION: RECOMBINANT FRAGMENTS OF THE HUMAN ACETYLCHOLINE RECEPTOR AND THE
;  TITLE OF INVENTION:  FOR TREATMENT OF MYASTHENIA GRAVIS
;  FILE REFERENCE: FUCHS=2A
;  CURRENT APPLICATION NUMBER: US/09/820,339A
;  CURRENT FILING DATE:  1999-11-08
;  PRIOR APPLICATION NUMBER: 09/423,398
;  PRIOR FILING DATE: 1999-11-08
;  PRIOR APPLICATION NUMBER: PCT/IL98/00211
;  PRIOR FILING DATE: 1998-05-06
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 28
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic
US-09-820-339A-28

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1682 TTCTTAGTTGTTTCTCT 1698
              |||||  ||||||||||
Db          3 TTCTTGTTTGTTTCTCT 19


RESULT 187
US-09-726-774-40
; Sequence 40, Application US/09726774
; Patent No. US20020082226A1
; GENERAL INFORMATION:
;  APPLICANT: Iversen, Patrick L.
;  TITLE OF INVENTION: Antisense Antibacterial Method and
;  TITLE OF INVENTION:  Composition
;  FILE REFERENCE: 0450-0032.30
;  CURRENT APPLICATION NUMBER: US/09/726,774
;  CURRENT FILING DATE:  2000-11-29
;  PRIOR APPLICATION NUMBER: US 60/168,150
;  PRIOR FILING DATE: 1999-11-29
;  NUMBER OF SEQ ID NOS: 139
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 40
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligomer
US-09-726-774-40

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTCCTCT 2025
              ||||||  ||||  |||||
Db          1 CAGAGAGCAAGCCCTCT 17


RESULT 188
US-10-425-975-11/c
; Sequence 11, Application US/10425975
; Publication No. US20030228574A1
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/10/425,975
;  CURRENT FILING DATE:  2003-04-28
;  PRIOR APPLICATION NUMBER: US/09/944,036
;  PRIOR FILING DATE: 2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
US-10-425-975-11

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 189
US-10-425-975-46/c
; Sequence 46, Application US/10425975
; Publication No. US20030228574A1
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
```

```
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/10/425,975
;  CURRENT FILING DATE:  2003-04-28
;  PRIOR APPLICATION NUMBER: US/09/944,036
;  PRIOR FILING DATE: 2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
US-10-425-975-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 190
US-10-349-143-8235/c
; Sequence 8235, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8235
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..21
;   OTHER INFORMATION: downstream amplification primer 99-14601 for SEQ 370, in compleme
US-10-349-143-8235

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2062 TTAATAAGTGGTATCTG 2078
              || ||||||| |||||||
Db         19 TTCATAAGTAGTATCTG 3


RESULT 191
US-10-349-143-10171
; Sequence 10171, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10171
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..21
;   OTHER INFORMATION: downstream amplification primer 99-10304 for SEQ 2306, in compleme
US-10-349-143-10171

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACC 1583
              ||||| ||| |||||||
Db          1 AAAAAACCTGCTCCACC 17


RESULT 192
US-10-719-633-40
; Sequence 40, Application US/10719633
; Publication No. US20040137485A1
; GENERAL INFORMATION:
;  APPLICANT: Iversen, Patrick L.
;  TITLE OF INVENTION: Antisense Antibacterial Method and
;  TITLE OF INVENTION:  Composition
;  FILE REFERENCE: 0450-0032.30
;  CURRENT APPLICATION NUMBER: US/10/719,633
;  CURRENT FILING DATE:  2003-11-21
;  PRIOR APPLICATION NUMBER: US/09/726,774
;  PRIOR FILING DATE: 2000-11-29
;  PRIOR APPLICATION NUMBER: US 60/168,150
;  PRIOR FILING DATE: 1999-11-29
;  NUMBER OF SEQ ID NOS: 139
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 40
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligomer
US-10-719-633-40

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTCCTCT 2025
              |||||| |||| |||||
Db          1 CAGAGAGCAAGCCCTCT 17


RESULT 193
US-10-786-720-19529
; Sequence 19529, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19529
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-19529

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   35.3%;  Pred. No. 2.5e+02;
  Matches    6;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1761 TTCATTAAGCTTTTTTT 1777
              ::||::||||::  :::
Db          5 UUCAUUAAGCUUGAUUU 21


RESULT 194
US-09-758-881-43
; Sequence 43, Application US/09758881
; Patent No. US20010029250A1
; GENERAL INFORMATION:
;  APPLICANT:  Karras, James G
;  TITLE OF INVENTION:  Antisense Oligonucleotide Modulation of STAT3
;  TITLE OF INVENTION:  Expression
;  FILE REFERENCE:  ISPH-0532
;  CURRENT APPLICATION NUMBER: US/09/758,881
;  CURRENT FILING DATE:  2001-01-11
;  PRIOR APPLICATION NUMBER:  PCT/US00/09054
;  PRIOR FILING DATE:  2000-04-06
;  PRIOR APPLICATION NUMBER:  09/288,461
;  PRIOR FILING DATE:  1999-04-08
;  NUMBER OF SEQ ID NOS:  152
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 43
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-758-881-43

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGGCTCTTTA 1760
              ||||||| | ||| ||| ||
Db          1 TGACAAGGAGTGGGTCTCTA 20


RESULT 195
US-09-854-883-183/c
; Sequence 183, Application US/09854883
; Patent No. US20020055479A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0576
;  CURRENT APPLICATION NUMBER: US/09/854,883
;  CURRENT FILING DATE:  2001-05-14
;  PRIOR APPLICATION NUMBER: US 09/629,644
;  PRIOR FILING DATE: 2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 183
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-854-883-183

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
              ||||| | ||| ||||||  |
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 196
US-09-888-326-4/c
; Sequence 4, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 4
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: Chimeric phosphorothioate/phosphodiester backbone
;   OTHER INFORMATION: with phosphorothioate at 5' and 3' ends
US-09-888-326-4

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 197
US-09-888-326-5/c
; Sequence 5, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
```

```
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 5
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: phosphorodithioate backbone
US-09-888-326-5

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 198
US-09-888-326-9
; Sequence 9, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 9
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: chimeric phosphorothioate/phosphodiester backbone
;   OTHER INFORMATION: with phosphorothioate at 5' and 3' ends
US-09-888-326-9

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 199
US-09-888-326-542/c
; Sequence 542, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
;  APPLICANT: Weiner, George
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
;  TITLE OF INVENTION:  Cell Lysis and Treating Cancer
;  FILE REFERENCE: C1039/7052 (AWS)
;  CURRENT APPLICATION NUMBER: US/09/888,326
;  CURRENT FILING DATE:  2001-06-22
;  PRIOR APPLICATION NUMBER: US 60/213,346
;  PRIOR FILING DATE: 2000-06-22
;  NUMBER OF SEQ ID NOS: 848
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 542
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (0)...(0)
;   OTHER INFORMATION: phosphodiester backbone
US-09-888-326-542

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  |||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 200
US-09-784-674-354/c
; Sequence 354, Application US/09784674
; Publication No. US20030054346A1
;   GENERAL INFORMATION:
;        APPLICANT: Shannon, Karen W.
;                   Wolber, Paul K.
;                   Delenstarr, Glenda C.
;                   Webb, Peter G.
;                   Kincaid, Robert H.
;        TITLE OF INVENTION: Methods for evaluating oligonucleotide
;                            probe sequences
;        NUMBER OF SEQUENCES: 1165
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
;                        Company M/S 20BO
;             STREET: 3000 Hanover Street
;             CITY: Palo Alto
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 94304
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/784,674
;             FILING DATE: 15-Feb-2001
;             CLASSIFICATION: No. US20030054346A1 available
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 09/021,701
;             FILING DATE: 10-FEB-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Choi, Wendy A.
;             REGISTRATION NUMBER: 36,697
;             REFERENCE/DOCKET NUMBER: 10971464-1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 650-236-2386
;             TELEFAX: 650-852-8063
;   INFORMATION FOR SEQ ID NO: 354:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 354:
```

US-09-784-674-354

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1818 AAGTTTTAGAATCTTTTAAA 1837
              || | |||||  ||||||||
Db         20 AAATCTTAGAGCCTTTTAAA 1
```

RESULT 201
US-09-776-479-353/c
; Sequence 353, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 353
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-353

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  |||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1
```

RESULT 202
US-09-776-479-353/c
; Sequence 353, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 353
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-353

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  |||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1
```

RESULT 203
US-09-776-479-525/c
; Sequence 525, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 525
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-525

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1
```

RESULT 204
US-09-776-479-525/c
; Sequence 525, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 525
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-525

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1
```

```
RESULT 205
US-09-776-479-776
; Sequence 776, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 776
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-776

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 206
US-09-776-479-776
; Sequence 776, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 776
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-776

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 207
US-09-776-479-855/c
; Sequence 855, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 855
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-855

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 208
US-09-776-479-855/c
; Sequence 855, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  APPLICANT:  Petersen, Deanna M.
;  APPLICANT:  Fouron, Yves
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
;  TITLE OF INVENTION:  Treatment of Asthma and Allergy
;  FILE REFERENCE: C1037/7013 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/776,479
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,991
;  PRIOR FILING DATE: 2000-02-03
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 855
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-776-479-855

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 209
US-10-112-653-342/c
; Sequence 342, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
```

```
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 342
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-342

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
             ||| |  |||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 210
US-10-112-653-502/c
; Sequence 502, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 502
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-502

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
             ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 211
US-10-112-653-749
; Sequence 749, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 749
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-749

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
             || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 212
US-10-112-653-826/c
; Sequence 826, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Berg, Daniel J.
;  TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
;  TITLE OF INVENTION:  TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
;  FILE REFERENCE: C01039/70060(AWS)
;  CURRENT APPLICATION NUMBER: US/10/112,653
;  CURRENT FILING DATE:  2002-03-29
;  PRIOR APPLICATION NUMBER: US 60/279,642
;  PRIOR FILING DATE: 2001-03-29
;  NUMBER OF SEQ ID NOS: 1040
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 826
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-826

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
             ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 213
US-10-017-995-353/c
; Sequence 353, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 353
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-353

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
```

```
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  |||||||||  |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 214
US-10-017-995-525/c
; Sequence 525, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 525
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-525

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 215
US-10-017-995-776
; Sequence 776, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 776
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-776

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 216
US-10-017-995-855/c
; Sequence 855, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
;  APPLICANT: Bratzler, Robert L.
;  TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
;  FILE REFERENCE: C1037/7025 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/017,995
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 60/255,534
;  PRIOR FILING DATE: 2000-12-14
;  NUMBER OF SEQ ID NOS: 1093
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 855
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-017-995-855

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 217
US-10-181-107-164
; Sequence 164, Application US/10181107
; Publication No. US20030083295A1
; GENERAL INFORMATION:
;  APPLICANT: Hong Zhang
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 3 EXPRESSION
;  FILE REFERENCE: RTSP-0325
;  CURRENT APPLICATION NUMBER: US/10/181,107
;  CURRENT FILING DATE:  2002-07-11
;  PRIOR APPLICATION NUMBER: PCT/US01/00888
;  PRIOR FILING DATE: 2001-01-11
;  PRIOR APPLICATION NUMBER: 09/484,617
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 164
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-107-164

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1742 GACAAGTACTGGCTCTTTAT 1761
              ||||  |||| |||| ||||
Db          1 GACAGTTACTTGCTCCTTAT 20


RESULT 218
US-10-181-846-109/c
; Sequence 109, Application US/10181846
; Publication No. US20030083297A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
;  FILE REFERENCE: RTSP-0363
;  CURRENT APPLICATION NUMBER: US/10/181,846
;  CURRENT FILING DATE:  2002-07-17
;  PRIOR APPLICATION NUMBER: PCT/US01/01416
```

```
;  PRIOR FILING DATE: 2001-01-16
;  PRIOR APPLICATION NUMBER: 09/490,692
;  PRIOR FILING DATE: 2000-01-24
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 109
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-846-109

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1992 TGTGTATCTAGCTTCTTCAG 2011
              ||||| ||| || ||| |||
Db         20 TGTGTTTCTGGCCTCTGCAG 1


RESULT 219
US-10-161-229-99
; Sequence 99, Application US/10161229
; Publication No. US20030100527A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Hartmann, Gunther
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acid Molecules for
;  TITLE OF INVENTION:  Activating Dendritic Cells
;  FILE REFERENCE: C01039/70061
;  CURRENT APPLICATION NUMBER: US/10/161,229
;  CURRENT FILING DATE:  2002-06-03
;  PRIOR APPLICATION NUMBER: US 09/191,170
;  PRIOR FILING DATE: 1998-11-13
;  PRIOR APPLICATION NUMBER: US 08/960,774
;  PRIOR FILING DATE: 1997-10-30
;  PRIOR APPLICATION NUMBER: US 08/738,652
;  PRIOR FILING DATE: 1996-10-30
;  PRIOR APPLICATION NUMBER: US 08/386,063
;  PRIOR FILING DATE: 1995-02-07
;  PRIOR APPLICATION NUMBER: US 08/276,358
;  PRIOR FILING DATE: 1994-07-15
;  NUMBER OF SEQ ID NOS: 99
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 99
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-161-229-99

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 220
US-10-356-625-116/c
; Sequence 116, Application US/10356625
; Publication No. US20030186290A1
; GENERAL INFORMATION:
;  APPLICANT: Tournier-Lasserve, Elisabeth
;  APPLICANT:  Joutel, Anne
;  APPLICANT:  Bousser, Marie-Germaine
;  APPLICANT:  Bach, Jean-Francois
;  TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
;  TITLE OF INVENTION:  THERAPEUTIC APPLICATION
;  FILE REFERENCE: 03715.0048-00000
;  CURRENT APPLICATION NUMBER: US/10/356,625
;  CURRENT FILING DATE:  2003-02-03
;  PRIOR APPLICATION NUMBER: US/09/230,652
;  PRIOR FILING DATE: 1999-05-17
;  PRIOR APPLICATION NUMBER: FR 96 09733
;  PRIOR FILING DATE: 1996-08-01
;  PRIOR APPLICATION NUMBER: FR 97 04680
;  PRIOR FILING DATE: 1997-04-16
;  PRIOR APPLICATION NUMBER: PCT/FR97/01433
;  PRIOR FILING DATE: 1997-07-31
;  NUMBER OF SEQ ID NOS: 163
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 116
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-356-625-116

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAACA 1559
              |||||||| |   |||||||
Db         20 AGGAGAGTGGCACAGGAACA 1


RESULT 221
US-10-314-578-353/c
; Sequence 353, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 353
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-353

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  ||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 222
US-10-314-578-525/c
; Sequence 525, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
```

```
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 525
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-525

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 223
US-10-314-578-776
; Sequence 776, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 776
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-776

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 224
US-10-314-578-855/c
; Sequence 855, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT:  Schetter, Christian
;  APPLICANT:  Vollmer, Jorg
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acids
;  FILE REFERENCE: C1039/7035 (HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/314,578
;  CURRENT FILING DATE:  2002-12-09
;  PRIOR APPLICATION NUMBER: US 60/156,113
;  PRIOR FILING DATE: 1999-09-25
;  PRIOR APPLICATION NUMBER: US 60/156,135
;  PRIOR FILING DATE: 1999-09-27
;  PRIOR APPLICATION NUMBER: US 60/227,436
;  PRIOR FILING DATE: 2000-08-23
;  NUMBER OF SEQ ID NOS: 1145
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 855
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-10-314-578-855

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 225
US-10-360-510-183/c
; Sequence 183, Application US/10360510
; Publication No. US20030220282A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0576
;  CURRENT APPLICATION NUMBER: US/10/360,510
;  CURRENT FILING DATE:  2003-02-07
;  PRIOR APPLICATION NUMBER: US/09/854,883
;  PRIOR FILING DATE: 2001-05-14
;  PRIOR APPLICATION NUMBER: US 09/629,644
;  PRIOR FILING DATE: 2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 183
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-360-510-183

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
              ||||| | ||| ||||||  |
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 226
US-10-188-779A-64/c
```

; Sequence 64, Application US/10188779A
; Publication No. US20040005567A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CYCLIN-DEPENDENT KINASE 4 EXPRESSION
; FILE REFERENCE: PTS-0042
; CURRENT APPLICATION NUMBER: US/10/188,779A
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 282
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-188-779A-64

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1593 GGGAACCCCTCCTGGCCTGG 1612
| |||||| ||||||| ||
Db 20 GAGAACCCATCCTGGCTGGG 1

RESULT 227
US-10-349-143-5752
; Sequence 5752, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5752
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-6613 for SEQ 1818,
US-10-349-143-5752

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1535 AGGTTAGGAGAGTAGGGAAG 1554
|| | ||||| | |||||||
Db 1 AGATGAGGAGTGGAGGGAAG 20

RESULT 228
US-10-309-290-169
; Sequence 169, Application US/10309290
; Publication No. US20040023241A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook II, John P.
; APPLICANT: Anderson, David W.
; APPLICANT: Boldog, Ferenc L.
; APPLICANT: Burgess, Catherine E.
; APPLICANT: Chillakuru, Rajeev A.
; APPLICANT: Edinger, Shlomit R.
; APPLICANT: Gerlach, Valerie L.
; APPLICANT: Gorman, Linda
; APPLICANT: Gould-Rothberg, Bonnie E.
; APPLICANT: Guo, Xiaojia
; APPLICANT: Jeffers, Michael E.
; APPLICANT: Ji, Weizhen
; APPLICANT: Li, Li
; APPLICANT: Malyankar, Uriel M.
; APPLICANT: Miller, Charles E.
; APPLICANT: Murphey, Ryan
; APPLICANT: Patturajan, Meera
; APPLICANT: Peyman, John A.
; APPLICANT: Rastelli, Luca
; APPLICANT: Rieger, Daniel K.
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Smithson, Glennda
; APPLICANT: Starling, Gary
; APPLICANT: Taupier, Raymond J.
; APPLICANT: Voss, Edward Z.
; APPLICANT: Zhong, Haihong
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-502A
; CURRENT APPLICATION NUMBER: US/10/309,290
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/336,600
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: 60/338,285
; PRIOR FILING DATE: 2001-12-07
; PRIOR APPLICATION NUMBER: 60/341,346
; PRIOR FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/341,477
; PRIOR FILING DATE: 2001-12-17
; PRIOR APPLICATION NUMBER: 60/341,540
; PRIOR FILING DATE: 2001-12-17
; PRIOR APPLICATION NUMBER: 60/342,592
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: 60/344,297
; PRIOR FILING DATE: 2001-12-27
; PRIOR APPLICATION NUMBER: 60/344,903
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: 60/373,288
; PRIOR FILING DATE: 2002-04-17
; PRIOR APPLICATION NUMBER: 60/380,981
; PRIOR FILING DATE: 2002-05-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 274
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artifical Sequence: Primer/Probe
US-10-309-290-169

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1650 CTTCACTGGTTCTGCATCAC 1669
|||| |||||| ||| |||
Db 1 CTTCCCTGGTTGAGCACCAC 20

RESULT 229
US-10-280-183A-421

```
; Sequence 421, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
;  APPLICANT: Pfizer Inc.
;  APPLICANT:  Bachmanov, Alexander A
;  APPLICANT:  Beauchamp, Gary K.
;  APPLICANT:  Chatterjee, Aurobindo
;  APPLICANT:  De  Jong, Pieter J.
;  APPLICANT:  Li, Shanru
;  APPLICANT:  Li, Xia
;  APPLICANT:  Ohmen, Jeffrey D
;  APPLICANT:  Reed, Danielle R.
;  APPLICANT:  Ross, David
;  APPLICANT:  Tordoff, Michael G.
;  TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
;  TITLE OF INVENTION:  CARBOHYDRATE COMPOUNDS AND OTHER SWEETNERS
;  FILE REFERENCE: PC18306A
;  CURRENT APPLICATION NUMBER: US/10/280,183A
;  CURRENT FILING DATE:  2002-10-25
;  PRIOR APPLICATION NUMBER: 60/200,794
;  PRIOR FILING DATE: 2000-04-28
;  NUMBER OF SEQ ID NOS: 652
;  SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 421
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Mouse
US-10-280-183A-421

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCTTCTCCA 1581
              ||||||||  |||  |||||
Db          1 ACTGCAAATGTCCAACTCCA 20


RESULT 230
US-10-298-404-21/c
; Sequence 21, Application US/10298404
; Publication No. US20040097443A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF JERKY-LIKE 1 EXPRESSION
;  FILE REFERENCE: HTS-0011
;  CURRENT APPLICATION NUMBER: US/10/298,404
;  CURRENT FILING DATE:  2002-11-16
;  NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 21
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-298-404-21

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1720 TTTGGACCTATTATCAGAAG 1739
              ||||  ||  ||  ||||||||
Db         20 TTTGTACAGATAATCAGAAG 1


RESULT 231
US-10-298-404-56
; Sequence 56, Application US/10298404
; Publication No. US20040097443A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF JERKY-LIKE 1 EXPRESSION
;  FILE REFERENCE: HTS-0011
;  CURRENT APPLICATION NUMBER: US/10/298,404
;  CURRENT FILING DATE:  2002-11-16
;  NUMBER OF SEQ ID NOS: 79
; SEQ ID NO 56
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-298-404-56

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1720 TTTGGACCTATTATCAGAAG 1739
              ||||  ||  ||  ||||||||
Db          1 TTTGTACAGATAATCAGAAG 20


RESULT 232
US-10-302-027-17
; Sequence 17, Application US/10302027
; Publication No. US20040102391A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: MODULATION OF GANKYRIN EXPRESSION
;  FILE REFERENCE: PTS-0068
;  CURRENT APPLICATION NUMBER: US/10/302,027
;  CURRENT FILING DATE:  2002-11-21
;  NUMBER OF SEQ ID NOS: 135
; SEQ ID NO 17
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-302-027-17

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1919 ACCTTTTTTTTCAGTGTTAA 1938
              ||  ||||  ||||||  ||  ||
Db          1 ACATTTTATTTCAGAGTAAA 20


RESULT 233
US-10-376-770-208
; Sequence 208, Application US/10376770
; Publication No. US20040106102A1
; GENERAL INFORMATION:
;  APPLICANT: Dhallan, Ravinder S.
;  TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME
;  FILE REFERENCE: 543312000320
;  CURRENT APPLICATION NUMBER: US/10/376,770
;  CURRENT FILING DATE:  2003-02-28
;  PRIOR APPLICATION NUMBER: US 10/093,618
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/360,232
;  PRIOR FILING DATE: 2002-03-01
;  PRIOR APPLICATION NUMBER: US 60/378,354
;  PRIOR FILING DATE: 2002-05-08
;  NUMBER OF SEQ ID NOS: 262
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 208
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
```

```
;   LOCATION: (6)...(10)
;   OTHER INFORMATION: These nucleotides may be absent
US-10-376-770-208

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATCTAG 2002
              |||||||||  || | ||||
Db          1 AAAGAAAAGATTGGAACTAG 20


RESULT 234
US-10-467-008-84/c
; Sequence 84, Application US/10467008
; Publication No. US20040116366A1
; GENERAL INFORMATION:
;  APPLICANT: Isis Pharmaceuticals, Inc.
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PROTEIN PHOSPHATASE 2 CATALYTIC SUBUNIT E
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: ISPH-0746
;  CURRENT APPLICATION NUMBER: US/10/467,008
;  CURRENT FILING DATE:  2003-08-01
;  PRIOR APPLICATION NUMBER: PCT/US02/02805
;  PRIOR FILING DATE: 2002-01-31
;  PRIOR APPLICATION NUMBER: US 09/780,045
;  PRIOR FILING DATE: 2001-02-09
;  NUMBER OF SEQ ID NOS: 135
; SEQ ID NO 84
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-467-008-84

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTTTGAA 1784
              |||  |||| |||| |||||
Db         20 TTATCCTTTATTTTATTGAA 1


RESULT 235
US-10-671-395-53
; Sequence 53, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 53
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-53

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1921 CTTTTTTTTCAGTGTTAAGG 1940
              || | |||||| ||||| ||
Db          1 CTCTCTTTTCACTGTTAGGG 20


RESULT 236
US-10-671-395-1105
; Sequence 1105, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1105
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1105

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1848 GGGCCAACAGACCCACACAC 1867
              | ||| | |||||||||| |
Db          1 GTGCCCAGAGACCCACACGC 20


RESULT 237
US-10-671-395-1754
; Sequence 1754, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1754
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1754

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1844 CCCTGGGCCAACAGACCCAC 1863
              | ||| ||| | ||||||||
Db          1 CACTGTGCCCAGAGACCCAC 20
```

```
RESULT 238
US-10-728-399-588
; Sequence 588, Application US/10728399
; Publication No. US20040132078A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Colca, Jerry
;  TITLE OF INVENTION: ANTISENSE MODULATION OF mitoNEET EXPRESSION
;  FILE REFERENCE: 01455_1
;  CURRENT APPLICATION NUMBER: US/10/728,399
;  CURRENT FILING DATE:  2003-12-05
;  NUMBER OF SEQ ID NOS: 627
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 588
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: human mitoNEET antisense
US-10-728-399-588

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1579 CCACCGCACAGACTGGGAAC 1598
              || |  |||||| |||||||
Db          1 CCCCATCACAGAATGGGAAC 20


RESULT 239
US-10-661-165-208
; Sequence 208, Application US/10661165
; Publication No. US20040137470A1
; GENERAL INFORMATION:
;  APPLICANT: Dhallan, Ravinder S.
;  TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC
;  TITLE OF INVENTION:  DISORDERS
;  FILE REFERENCE: 543312000420
;  CURRENT APPLICATION NUMBER: US/10/661,165
;  CURRENT FILING DATE:  2003-09-11
;  PRIOR APPLICATION NUMBER: PCT/US03/06198
;  PRIOR FILING DATE: 2003-02-28
;  PRIOR APPLICATION NUMBER: US 60/378,354
;  PRIOR FILING DATE: 2002-05-08
;  PRIOR APPLICATION NUMBER: US 10/093,618
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/360,232
;  PRIOR FILING DATE: 2002-03-01
;  PRIOR APPLICATION NUMBER: PCT/US03/27308
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/376,770
;  PRIOR FILING DATE: 2003-02-28
;  NUMBER OF SEQ ID NOS: 628
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 208
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (6)...(10)
;   OTHER INFORMATION: These nucleotides may be present
US-10-661-165-208

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATCTAG 2002
              |||||||||  || | ||||
Db          1 AAAGAAAAGATTGGAACTAG 20


RESULT 240
US-10-619-739-578/c
; Sequence 578, Application US/10619739
; Publication No. US20040175719A1
; GENERAL INFORMATION:
;  APPLICANT: Christians, Frederick C.
;  TITLE OF INVENTION: Synthetic Tag Genes
;  FILE REFERENCE: 3502.1
;  CURRENT APPLICATION NUMBER: US/10/619,739
;  CURRENT FILING DATE:  2003-07-14
;  PRIOR APPLICATION NUMBER: 60/395,530
;  PRIOR FILING DATE: 2002-07-12
;  NUMBER OF SEQ ID NOS: 2068
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 578
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
US-10-619-739-578

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.5e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2043 CTATCTGCTTAGCAACTAGT 2062
              ||||| |||||||  ||| |
Db         20 CTATCAGCTTAGCGCCTATT 1


RESULT 241
US-10-138-674-5864/c
; Sequence 5864, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5864
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5864

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              |||||||||| ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 242
US-10-287-949A-5864/c
; Sequence 5864, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
```

```
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5864
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5864

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||| ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 243
US-09-780-533A-398
; Sequence 398, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 398
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-398

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   40.0%;  Pred. No. 2.1e+02;
  Matches    6;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAA 1836
              ::: |||:|::::|| 
Db          1 UUUGGAAUCUUUUAA 15


RESULT 244
US-09-780-533A-2234
; Sequence 2234, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2234
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2234

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   40.0%;  Pred. No. 2.1e+02;
  Matches    6;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAA 1836
              ::: |||:|::::|| 
Db          3 UUUGGAAUCUUUUAA 17


RESULT 245
US-09-776-474-445/c
; Sequence 445, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Booher, Robert
;  APPLICANT:  Holman, Patricia
;  APPLICANT:  Fattaey, Ali
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK
;  TITLE OF INVENTION:  Enzyme
;  FILE REFERENCE: MBHB00-955-A (400/008)
;  CURRENT APPLICATION NUMBER: US/09/776,474
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,983
;  PRIOR FILING DATE: 2000-03-02
;  NUMBER OF SEQ ID NOS: 2992
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 445
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-776-474-445

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         17 ACTGGTTCTGCATGA 3


RESULT 246
US-09-776-474-1098/c
; Sequence 1098, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Booher, Robert
;  APPLICANT:  Holman, Patricia
;  APPLICANT:  Fattaey, Ali
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK
;  TITLE OF INVENTION:  Enzyme
;  FILE REFERENCE: MBHB00-955-A (400/008)
;  CURRENT APPLICATION NUMBER: US/09/776,474
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,983
;  PRIOR FILING DATE: 2000-03-02
;  NUMBER OF SEQ ID NOS: 2992
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1098
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-776-474-1098

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         16 ACTGGTTCTGCATGA 2


RESULT 247
US-10-163-552-852/c
; Sequence 852, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
;  TITLE OF INVENTION:  HER2
;  FILE REFERENCE: MBHB01-1653-A (400/014)
;  CURRENT APPLICATION NUMBER: US/10/163,552
;  CURRENT FILING DATE:  2002-06-06
;  NUMBER OF SEQ ID NOS: 1997
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 852
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-163-552-852

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              |||||||||||| |||
Db         15 ACCCCATTCTTCCCT 1


RESULT 248
US-10-230-006-787/c
; Sequence 787, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 787
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-230-006-787

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAGATC 2016
              ||||||||||||| ||
Db         17 GCTTCTTCAGAGGTC 3


RESULT 249
US-10-230-006-2220/c
; Sequence 2220, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2220
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-230-006-2220

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAGATC 2016
              ||||||||||||| ||
Db         16 GCTTCTTCAGAGGTC 2


RESULT 250
US-10-138-674-577/c
; Sequence 577, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 577
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-577

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              |||||||||| ||||
Db         17 GACTGCAAAAGTCCT 3


RESULT 251
US-10-138-674-578/c
; Sequence 578, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 578
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-578

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
                ||||||||||| ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 252
US-10-138-674-579/c
; Sequence 579, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 579
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-579

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
                ||||||||||| ||||
Db         15 GACTGCAAAAGTCCT 1


RESULT 253
US-10-287-949A-577/c
; Sequence 577, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 577
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-577

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
                ||||||||||| ||||
Db         17 GACTGCAAAAGTCCT 3


RESULT 254
US-10-287-949A-578/c
; Sequence 578, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 578
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-578

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
                ||||||||||| ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 255
US-10-287-949A-579/c
; Sequence 579, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 579
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-579
```

```
  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||  ||||
Db         15 GACTGCAAAAGTCCT 1


RESULT 256
US-09-839-583-5/c
; Sequence 5, Application US/09839583
; Publication No. US20020052485A1
; GENERAL INFORMATION:
;  APPLICANT: COLOSI, Peter
;  TITLE OF INVENTION: POLYNUCLEOTIDES FOR USE IN RECOMBINANT ADENO-ASSOCIATED VIRUS
;  TITLE OF INVENTION:  VIRION PRODUCTION
;  FILE REFERENCE: 0800-0023
;  CURRENT APPLICATION NUMBER: US/09/839,583
;  CURRENT FILING DATE:  2001-04-20
;  PRIOR APPLICATION NUMBER: 60/200,453
;  PRIOR FILING DATE: 2000-04-28
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: oligo
US-09-839-583-5

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2057 ACTAGTTAATAAGTG 2071
              ||||||||||  ||||
Db         18 ACTAGTTAATTAGTG 4


RESULT 257
US-09-804-014A-59/c
; Sequence 59, Application US/09804014A
; Publication No. US20030064489A1
; GENERAL INFORMATION:
;  APPLICANT: Li, Li
;  APPLICANT:  Padigaru, Muralidhara
;  APPLICANT:  Vernet, Corine
;  APPLICANT:  Fernandes, Elma
;  APPLICANT:  Shimkets, Richard
;  APPLICANT:  Spaderna, Steven
;  APPLICANT:  Majumder, Kumud
;  TITLE OF INVENTION: Novel Polypeptides and Nucleic Acids Encoding Same
;  FILE REFERENCE: 15966-721 US
;  CURRENT APPLICATION NUMBER: US/09/804,014A
;  CURRENT FILING DATE:  2002-04-24
;  PRIOR APPLICATION NUMBER: 60/188,316
;  PRIOR FILING DATE: 2000-03-10
;  PRIOR APPLICATION NUMBER: 60/188,277
;  PRIOR FILING DATE: 2000-03-10
;  PRIOR APPLICATION NUMBER: 60/189,139
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: 60/189,140
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: 60/190,401
;  PRIOR FILING DATE: 2000-03-17
;  PRIOR APPLICATION NUMBER: 60/190,231
;  PRIOR FILING DATE: 2000-03-17
;  NUMBER OF SEQ ID NOS: 75
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 59
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer
US-09-804-014A-59

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGA 1616
              ||||||||||  ||||
Db         17 TCCTGGCCTGTGGGA 3


RESULT 258
US-10-108-260A-4912
; Sequence 4912, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
;  APPLICANT: HELIX RESEARCH INSTITUTE
;  TITLE OF INVENTION: No. US20040005560A1el full length cDNA
;  FILE REFERENCE: H1-A0106
;  CURRENT APPLICATION NUMBER: US/10/108,260A
;  CURRENT FILING DATE:  2002-03-27
;  NUMBER OF SEQ ID NOS: 5458
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4912
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized p
US-10-108-260A-4912

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1944 TGGTTGGTTTTTGTG 1958
              |||||||  |||||||
Db          3 TGGTTGGATTTTGTG 17


RESULT 259
US-10-349-143-7270
; Sequence 7270, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7270
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
```

```
;   OTHER INFORMATION: upstream amplification primer 99-3373 for SEQ 3336,
US-10-349-143-7270

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1907 CAGATCAACAATACC 1921
                ||| ||||||||||
Db          3 CAGCTCAACAATACC 17


RESULT 260
US-10-680-341-14/c
; Sequence 14, Application US/10680341
; Publication No. US20040091923A1
; GENERAL INFORMATION:
;  APPLICANT: Reyes, Antonio A.
;  APPLICANT:  Wallace, Robert B.
;  APPLICANT:  Ugozzoli, Luis A
;  TITLE OF INVENTION: Linked Linear Amplification of Nucleic Acids
;  FILE REFERENCE: 3239-0105P
;  CURRENT APPLICATION NUMBER: US/10/680,341
;  CURRENT FILING DATE:  2003-10-06
;  NUMBER OF SEQ ID NOS: 83
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA Molecule: URACIL
;   OTHER INFORMATION: NUCLEOSIDE IS A RIBONUCLEOSIDE
US-10-680-341-14

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
                ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 261
US-10-680-341-16/c
; Sequence 16, Application US/10680341
; Publication No. US20040091923A1
; GENERAL INFORMATION:
;  APPLICANT: Reyes, Antonio A.
;  APPLICANT:  Wallace, Robert B.
;  APPLICANT:  Ugozzoli, Luis A
;  TITLE OF INVENTION: Linked Linear Amplification of Nucleic Acids
;  FILE REFERENCE: 3239-0105P
;  CURRENT APPLICATION NUMBER: US/10/680,341
;  CURRENT FILING DATE:  2003-10-06
;  NUMBER OF SEQ ID NOS: 83
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-680-341-16

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
                ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 262
US-10-665-951-100/c
; Sequence 100, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 100
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-100

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   93.3%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCT 1803
                ||||||||||||| |
Db         15 ATTCTTTCCTTCTAT 1


RESULT 263
US-10-665-951-527
; Sequence 527, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
```

```
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 527
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-527

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   33.3%;  Pred. No. 2.6e+02;
  Matches    5;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCT 1803
              |::|:::||::|: :
Db          5 AUUCUUUCCUUCUAU 19


RESULT 264
US-10-683-990-66/c
; Sequence 66, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using SHort Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/134 (02-742-H)
;  CURRENT APPLICATION NUMBER: US/10/683,990
;  CURRENT FILING DATE:  2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 256
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-683-990-66

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   93.3%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTT 1799
              |||| ||||||||||
Db         15 CCCCCTTCTTTCCTT 1


RESULT 265
US-10-683-990-163
; Sequence 163, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Usman, Nassim
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
;  TITLE OF INVENTION:  Gene Expression Using SHort Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/134 (02-742-H)
;  CURRENT APPLICATION NUMBER: US/10/683,990
;  CURRENT FILING DATE:  2003-10-10
;  PRIOR APPLICATION NUMBER: PCT/US03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/406,784
;  PRIOR FILING DATE: 2002-08-29
;  PRIOR APPLICATION NUMBER: US 60/408,378
;  PRIOR FILING DATE: 2002-09-05
;  PRIOR APPLICATION NUMBER: US 60/409,293
;  PRIOR FILING DATE: 2002-09-09
;  PRIOR APPLICATION NUMBER: US 60/440,129
;  PRIOR FILING DATE: 2003-01-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 256
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 163
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-683-990-163

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   46.7%;  Pred. No. 2.6e+02;
  Matches    7;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTT 1799
              |||| ::|:::||::
Db          5 CCCCCUUCUUUCCUU 19


RESULT 266
```

```
US-09-854-883-130
; Sequence 130, Application US/09854883
; Patent No. US20020055479A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0576
;  CURRENT APPLICATION NUMBER: US/09/854,883
;  CURRENT FILING DATE:  2001-05-14
;  PRIOR APPLICATION NUMBER: US 09/629,644
;  PRIOR FILING DATE: 2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-854-883-130

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
                | ||||||||||||
Db             6 CATCTTCAGAGATCA 20


RESULT 267
US-09-899-422-42/c
; Sequence 42, Application US/09899422
; Patent No. US20020090676A1
; GENERAL INFORMATION:
;  APPLICANT: Hauptmann, Rudolph
;  APPLICANT:  Himmler, Adolph
;  APPLICANT:  Maurer-Fogy, Ingrid
;  APPLICANT:  Stratowa, Christian
;  TITLE OF INVENTION: TNF Receptors, TNF Binding Proteins and DNAs Coding for
;  TITLE OF INVENTION:  Them
;  FILE REFERENCE: 98,385-H
;  CURRENT APPLICATION NUMBER: US/09/899,422
;  CURRENT FILING DATE:  2001-08-21
;  PRIOR APPLICATION NUMBER: 09/525,998
;  PRIOR FILING DATE: 2000-03-15
;  PRIOR APPLICATION NUMBER: 08/383,676
;  PRIOR FILING DATE: 1995-02-01
;  PRIOR APPLICATION NUMBER: 08/153,287
;  PRIOR FILING DATE: 1993-11-17
;  PRIOR APPLICATION NUMBER: 07/821,750
;  PRIOR FILING DATE: 1992-01-02
;  PRIOR APPLICATION NUMBER: 07/511,430
;  PRIOR FILING DATE: 1990-04-20
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 42
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Hybridization
;   OTHER INFORMATION: probe
US-09-899-422-42

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTG 1978
                || ||||||||||||
Db         15 TATATATTTACCTTG 1


RESULT 268
US-09-898-234-42/c
; Sequence 42, Application US/09898234
; Patent No. US20020155112A1
; GENERAL INFORMATION:
;  APPLICANT: Hauptmann, Rudolph
;  APPLICANT:  Himmler, Adolph
;  APPLICANT:  Maurer-Fogy, Ingrid
;  APPLICANT:  Stratowa, Christian
;  TITLE OF INVENTION: TNF Receptors, TNF Binding Proteins and DNAs Coding for
;  TITLE OF INVENTION:  Them
;  FILE REFERENCE: 98,385-I
;  CURRENT APPLICATION NUMBER: US/09/898,234
;  CURRENT FILING DATE:  2001-07-03
;  PRIOR APPLICATION NUMBER: 09/525,998
;  PRIOR FILING DATE: 2000-03-15
;  PRIOR APPLICATION NUMBER: 08/383,676
;  PRIOR FILING DATE: 1995-02-01
;  PRIOR APPLICATION NUMBER: 08/153,287
;  PRIOR FILING DATE: 1993-11-17
;  PRIOR APPLICATION NUMBER: 07/821,750
;  PRIOR FILING DATE: 1992-01-02
;  PRIOR APPLICATION NUMBER: 07/511,430
;  PRIOR FILING DATE: 1990-04-20
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 42
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Hybridization
;   OTHER INFORMATION: probe
US-09-898-234-42

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTG 1978
                || ||||||||||||
Db         15 TATATATTTACCTTG 1


RESULT 269
US-09-899-429A-52/c
; Sequence 52, Application US/09899429A
; Patent No. US20020169118A1
; GENERAL INFORMATION:
;  APPLICANT: Hauptmann, Rudolph
;  APPLICANT:  Himmler, Adolph
;  APPLICANT:  Maurer-Fogy, Ingrid
;  APPLICANT:  Stratowa, Christian
;  TITLE OF INVENTION: TNF Receptors, TNF Binding Proteins and DNAs Coding for
;  TITLE OF INVENTION:  Them
;  FILE REFERENCE: 98-385-J
;  CURRENT APPLICATION NUMBER: US/09/899,429A
;  CURRENT FILING DATE:  2001-07-03
;  PRIOR APPLICATION NUMBER: 09/792,356
;  PRIOR FILING DATE: 2000-02-23
;  PRIOR APPLICATION NUMBER: 08/477,639
;  PRIOR FILING DATE: 1955-06-07
;  PRIOR APPLICATION NUMBER: 08/383,676
;  PRIOR FILING DATE: 1995-02-01
;  PRIOR APPLICATION NUMBER: 08/153,287
;  PRIOR FILING DATE: 1993-11-17
```

```
;  PRIOR APPLICATION NUMBER: 07/821,750
;  PRIOR FILING DATE: 1992-01-02
;  PRIOR APPLICATION NUMBER: 07/511,430
;  PRIOR FILING DATE: 1990-04-20
;  NUMBER OF SEQ ID NOS: 97
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 52
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: hybridization
;   OTHER INFORMATION: probe
US-09-899-429A-52

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTG 1978
                || ||||||||||||
Db         15 TATATATTTACCTTG 1


RESULT 270
US-09-792-356-42/c
; Sequence 42, Application US/09792356
; Publication No. US20020183485A1
; GENERAL INFORMATION:
;  APPLICANT: Hauptmann, Rudolph
;  APPLICANT:  Himmler, Adolph
;  APPLICANT:  Maurer-Fogy, Ingrid
;  APPLICANT:  Stratowa, Christian
;  TITLE OF INVENTION: TNF Receptors, TNF Binding Proteins and DNAs Coding for
;  TITLE OF INVENTION:  Them
;  FILE REFERENCE: 98,385-G
;  CURRENT APPLICATION NUMBER: US/09/792,356
;  CURRENT FILING DATE:  2001-08-17
;  PRIOR APPLICATION NUMBER: 08/477,639
;  PRIOR FILING DATE: 1995-06-07
;  PRIOR APPLICATION NUMBER: 08/383,676
;  PRIOR FILING DATE: 1995-02-01
;  PRIOR APPLICATION NUMBER: 08/153,287
;  PRIOR FILING DATE: 1993-11-17
;  PRIOR APPLICATION NUMBER: 07/821,750
;  PRIOR FILING DATE: 1992-01-02
;  PRIOR APPLICATION NUMBER: 07/511,430
;  PRIOR FILING DATE: 1990-04-20
;  NUMBER OF SEQ ID NOS: 87
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 42
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Hybridization
;   OTHER INFORMATION: probe
US-09-792-356-42

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTG 1978
                || ||||||||||||
Db         15 TATATATTTACCTTG 1


RESULT 271
US-09-816-460C-20/c
; Sequence 20, Application US/09816460C
; Publication No. US20030087235A1
; GENERAL INFORMATION:
;  APPLICANT: Dairkee, Shanaz H.
;  APPLICANT:  Li, Zheng
;  TITLE OF INVENTION: PROGNOSTIC METHODS FOR BREAST CANCER
;  FILE REFERENCE: CPMC-010/00US
;  CURRENT APPLICATION NUMBER: US/09/816,460C
;  CURRENT FILING DATE:  2001-03-23
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic primer
US-09-816-460C-20

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAA 1557
                ||||| |||||||||
Db         19 AGAGTGGGGAAGGAA 5


RESULT 272
US-10-002-491-84
; Sequence 84, Application US/10002491
; Publication No. US20030109467A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF FXR EXPRESSION
;  FILE REFERENCE: RTS-0239
;  CURRENT APPLICATION NUMBER: US/10/002,491
;  CURRENT FILING DATE:  2001-11-15
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 84
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-002-491-84

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 CCTAGATCAACAGAT 1911
                ||||| |||||||||
Db          1 CCTAGTTCAACAGAT 15


RESULT 273
US-10-360-510-130
; Sequence 130, Application US/10360510
; Publication No. US20030220282A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0576
;  CURRENT APPLICATION NUMBER: US/10/360,510
;  CURRENT FILING DATE:  2003-02-07
;  PRIOR APPLICATION NUMBER: US/09/854,883
;  PRIOR FILING DATE: 2001-05-14
;  PRIOR APPLICATION NUMBER: US 09/629,644
;  PRIOR FILING DATE: 2000-07-31
```

```
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 389
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-360-510-130

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | ||||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 274
US-10-289-762-3480
; Sequence 3480, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3480
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-3480

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              ||||||||||||| |
Db          6 AGGGAAGGAACAGAA 20


RESULT 275
US-10-289-762-4153/c
; Sequence 4153, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4153
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-4153

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 AGCTATCTCCTAACT 1720
              |||||||||||  |||
Db         18 AGCTATCTCCTTACT 4


RESULT 276
US-10-298-994-50
; Sequence 50, Application US/10298994
; Publication No. US20040097446A1
; GENERAL INFORMATION:
;  APPLICANT: William Gaarde
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: MODULATION OF CHECKPOINT KINASE 1 EXPRESSION
;  FILE REFERENCE: HTS-0006
;  CURRENT APPLICATION NUMBER: US/10/298,994
;  CURRENT FILING DATE:  2002-11-16
;  NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 50
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-298-994-50

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db          4 ACTGGTTCTGCATGA 18


RESULT 277
US-10-298-994-91
; Sequence 91, Application US/10298994
; Publication No. US20040097446A1
; GENERAL INFORMATION:
;  APPLICANT: William Gaarde
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: MODULATION OF CHECKPOINT KINASE 1 EXPRESSION
;  FILE REFERENCE: HTS-0006
;  CURRENT APPLICATION NUMBER: US/10/298,994
;  CURRENT FILING DATE:  2002-11-16
;  NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 91
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-298-994-91

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db          2 ACTGGTTCTGCATGA 16


RESULT 278
US-10-298-994-165/c
; Sequence 165, Application US/10298994
; Publication No. US20040097446A1
; GENERAL INFORMATION:
;  APPLICANT: William Gaarde
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
```

```
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: MODULATION OF CHECKPOINT KINASE 1 EXPRESSION
;  FILE REFERENCE: HTS-0006
;  CURRENT APPLICATION NUMBER: US/10/298,994
;  CURRENT FILING DATE:  2002-11-16
;  NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 165
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-298-994-165

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         17 ACTGGTTCTGCATGA 3


RESULT 279
US-10-298-994-198/c
; Sequence 198, Application US/10298994
; Publication No. US20040097446A1
; GENERAL INFORMATION:
;  APPLICANT: William Gaarde
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: MODULATION OF CHECKPOINT KINASE 1 EXPRESSION
;  FILE REFERENCE: HTS-0006
;  CURRENT APPLICATION NUMBER: US/10/298,994
;  CURRENT FILING DATE:  2002-11-16
;  NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 198
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: M. musculus
;   FEATURE:
US-10-298-994-198

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         19 ACTGGTTCTGCATGA 5


RESULT 280
US-10-688-706-2305
; Sequence 2305, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Broschat, Kay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
;  FILE REFERENCE: 01393/1
;  CURRENT APPLICATION NUMBER: US/10/688,706
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,268
;  PRIOR FILING DATE: 2002-10-17
;  NUMBER OF SEQ ID NOS: 3071
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2305
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: human GFAT antisense
US-10-688-706-2305

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAG 1939
              ||||||||| |||||
Db          6 TTTTTCAGTTTTAAG 20


RESULT 281
US-10-688-706-2602
; Sequence 2602, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Broschat, Kay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
;  FILE REFERENCE: 01393/1
;  CURRENT APPLICATION NUMBER: US/10/688,706
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,268
;  PRIOR FILING DATE: 2002-10-17
;  NUMBER OF SEQ ID NOS: 3071
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2602
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: human GFAT antisense
US-10-688-706-2602

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAG 1939
              ||||||||| |||||
Db          5 TTTTTCAGTTTTAAG 19


RESULT 282
US-09-878-582-47
; Sequence 47, Application US/09878582
; Patent No. US20020058638A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: ISPH-0463
;  CURRENT APPLICATION NUMBER: US/09/878,582
;  CURRENT FILING DATE:  2001-06-11
;  PRIOR APPLICATION NUMBER: 09/577,902
;  PRIOR FILING DATE: 2000-05-24
;  PRIOR APPLICATION NUMBER: US 09/358,381
;  PRIOR FILING DATE: 1999-07-21
;  PRIOR APPLICATION NUMBER: PCT/US99/29594,
;  PRIOR FILING DATE: 1999-12-14
;  NUMBER OF SEQ ID NOS: 51
; SEQ ID NO 47
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-878-582-47

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1777 TTTTTGAACCCCATTCTT 1794
                | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 283
US-09-950-935-9/c
; Sequence 9, Application US/09950935
; Publication No. US20030032022A1
; GENERAL INFORMATION:
;  APPLICANT: Hill, Joseph A.
;  APPLICANT:  Wang, Zhigang C.
;  TITLE OF INVENTION: Variants of IL-1 Beta Gene CD46 Gene for Diagnosing Unexplained R
;  TITLE OF INVENTION:  Pregnancy Loss
;  FILE REFERENCE: B0801/7227 (ERP)
;  CURRENT APPLICATION NUMBER: US/09/950,935
;  CURRENT FILING DATE:  2001-09-12
;  PRIOR APPLICATION NUMBER: US60/231,785
;  PRIOR FILING DATE: 2000-09-12
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: homo sapiens
US-09-950-935-9

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1751 TGGCTCTTTATTCATTAA 1768
                |||| || | ||||||||
Db         18 TGGCCCTGTCTTCATTAA 1


RESULT 284
US-10-067-125-180
; Sequence 180, Application US/10067125
; Publication No. US20030055015A1
; GENERAL INFORMATION:
;  APPLICANT: Baker, Brenda F.
;  APPLICANT:  Cowsert, Lex M.
;  APPLICANT:  Monia, Brett P.
;  APPLICANT:  Xu, Xiaoxing S.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRAF EXPRESSION
;  FILE REFERENCE: ISPH-0321
;  CURRENT APPLICATION NUMBER: US/10/067,125
;  CURRENT FILING DATE:  2002-02-04
;  PRIOR APPLICATION NUMBER: 09/167,109
;  PRIOR FILING DATE: 1998-10-06
;  NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 180
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-10-067-125-180

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1565 GCAAAAATCCTTCTCCAC 1582
                |||||| ||| |||| ||
Db          1 GCAAAACTCCGTCTCTAC 18


RESULT 285
US-10-388-263-867
; Sequence 867, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
;  APPLICANT: Cowsert, Lex M.
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  McNeil, John
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Sasmor, Henri M.
;  APPLICANT:  Brooks, Douglas G.
;  APPLICANT:  Ohashi, Cara
;  APPLICANT:  Wyatt, Jacqueline R.
;  APPLICANT:  Borchers, Alexander
;  APPLICANT:  Vickers, Timothy A.
;  TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
;  TITLE OF INVENTION:  MODULATION BY OLIGONUCLEOTIDES AND
;  TITLE OF INVENTION:  GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
;  FILE REFERENCE: ISIS-4503
;  CURRENT APPLICATION NUMBER: US/10/388,263
;  CURRENT FILING DATE:  2003-03-12
;  NUMBER OF SEQ ID NOS: 947
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 867
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-867

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTT 1794
                | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 286
US-10-336-213B-47
; Sequence 47, Application US/10336213B
; Publication No. US20040002153A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  APPLICANT:  Tim Vickers
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: ISIS0004-100
;  CURRENT APPLICATION NUMBER: US/10/336,213B
;  CURRENT FILING DATE:  2003-01-03
;  PRIOR APPLICATION NUMBER: US 60/411,780
;  PRIOR FILING DATE: 2002-09-18
;  PRIOR APPLICATION NUMBER: US 09/878,582
;  PRIOR FILING DATE: 2001-06-11
;  PRIOR APPLICATION NUMBER: US 09/577,902
;  PRIOR FILING DATE: 2000-05-24
;  PRIOR APPLICATION NUMBER: PCT/US99/29594
;  PRIOR FILING DATE: 1999-12-14
;  PRIOR APPLICATION NUMBER: US 09/358,381
;  PRIOR FILING DATE: 1999-07-21
;  NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 47
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-336-213B-47

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1777 TTTTTGAACCCCATTCTT 1794
              | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 287
US-10-416-041-19
; Sequence 19, Application US/10416041
; Publication No. US20040093635A1
; GENERAL INFORMATION:
;  APPLICANT: Van Enckevort, Lenora Johanna Gertruda
;  APPLICANT:  Jacobsen, Evert
;  APPLICANT:  Stiekema, Willem Johannes
;  APPLICANT:  Pereira, Andy
;  TITLE OF INVENTION: DNA SEQUENCES ENCODING PROTEINS CONFERRING PHYTOPHTHORA
;  TITLE OF INVENTION:  INFESTANS RESISTANCE ON PLANTS
;  FILE REFERENCE: U 014591-5
;  CURRENT APPLICATION NUMBER: US/10/416,041
;  CURRENT FILING DATE:  2003-10-24
;  PRIOR APPLICATION NUMBER: EP 00203911.3
;  PRIOR FILING DATE: 2000-11-09
;  NUMBER OF SEQ ID NOS: 23
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-416-041-19

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTTC 1930
              |||||| ||||| || ||
Db          1 AACAATGCCTTTCTTCTC 18


RESULT 288
US-10-664-639A-76
; Sequence 76, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
;  APPLICANT: Vickers, Timothy
;  APPLICANT:  Koo, Seongjoon
;  APPLICANT:  Bennett, C. Frank
;  APPLICANT:  Crooke, Stanley T.
;  APPLICANT:  Dean, Nicholas, M.
;  APPLICANT:  Baker, Brenda F.
;  TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
;  TITLE OF INVENTION:  Double-Stranded Oligomeric Compounds
;  FILE REFERENCE: ISIS0001-100 (CORE00027US)
;  CURRENT APPLICATION NUMBER: US/10/664,639A
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 60/411,780
;  PRIOR FILING DATE: 2002-09-18
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 76
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(4)
;   OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (15)..(18)
;   OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-76

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTT 1794
              | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 289
US-10-391-413-19
; Sequence 19, Application US/10391413
; Publication No. US20030167482A1
; GENERAL INFORMATION:
;  APPLICANT: KIMURA, Toru et al.
;  TITLE OF INVENTION: NOVEL SEMAPHORIN Z AND GENE ENCODING THE SAME
;  FILE REFERENCE: 0020-5120P
;  CURRENT APPLICATION NUMBER: US/10/391,413
;  CURRENT FILING DATE:  2003-03-19
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Adapter DNA used to ligate the various parts of the rSZexII
;   OTHER INFORMATION: plasmid
US-10-391-413-19

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.8e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1724 GACCTATTATCAGAAGGT 1741
              || |||||||||| | ||
Db          2 GAACTATTATCAGGACGT 19


RESULT 290
US-10-251-117-844
; Sequence 844, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor Re
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering RNA
;  FILE REFERENCE: 900/042 (MBHB02-468-A)
;  CURRENT APPLICATION NUMBER: US/10/251,117
;  CURRENT FILING DATE:  2003-02-24
;  PRIOR APPLICATION NUMBER: US 60/393,924
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 09/916,466
;  PRIOR FILING DATE: 2001-07-25
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  NUMBER OF SEQ ID NOS: 1213
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 844
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense re
US-10-251-117-844
```

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   38.9%;  Pred. No. 2.8e+02;
  Matches    7;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTCT 1803
              ||||:: :::||:  :|:
Db          2 CCCAUUUUUUCCUAAUCU 19


RESULT 291
US-10-251-117-1151/c
; Sequence 1151, Application US/10251117
; Publication No. US20030170891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Epidermal Growth Factor R
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering RNA
;  FILE REFERENCE: 900/042 (MBHB02-468-A)
;  CURRENT APPLICATION NUMBER: US/10/251,117
;  CURRENT FILING DATE:  2003-02-24
;  PRIOR APPLICATION NUMBER: US 60/393,924
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/163,552
;  PRIOR FILING DATE: 2002-06-06
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 09/916,466
;  PRIOR FILING DATE: 2001-07-25
;  PRIOR APPLICATION NUMBER: US 60/296,249
;  PRIOR FILING DATE: 2001-06-06
;  NUMBER OF SEQ ID NOS: 1213
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1151
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-251-117-1151

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.8e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTCT 1803
              ||||||  ||||||  |||
Db         18 CCCATTTTTTCCTAATCT 1


RESULT 292
US-10-349-143-4542
; Sequence 4542, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4542
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-15728 for SEQ 608,
US-10-349-143-4542

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.8e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAAAAAA 1984
              ||||||||||  || | ||
Db          1 ATATTTACCTGGAGAGAA 18


RESULT 293
US-10-206-705-78
; Sequence 78, Application US/10206705
; Publication No. US20040019001A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceutical, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Protein Tyrosine Phosphat
;  TITLE OF INVENTION:  (PTP-1B) Gene Expression using Short Interfering RNA
;  FILE REFERENCE: 900/035 (MBHB02-738)
;  CURRENT APPLICATION NUMBER: US/10/206,705
;  CURRENT FILING DATE:  2002-07-26
;  NUMBER OF SEQ ID NOS: 388
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 78
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-206-705-78

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   66.7%;  Pred. No. 2.8e+02;
  Matches   12;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGG 1607
              ||:|| | ||| :||:||
Db          2 ACUGGAAGCCCUUCCUGG 19


RESULT 294
US-10-206-705-263/c
; Sequence 263, Application US/10206705
; Publication No. US20040019001A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceutical, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Protein Tyrosine Phosphat
;  TITLE OF INVENTION:  (PTP-1B) Gene Expression using Short Interfering RNA
;  FILE REFERENCE: 900/035 (MBHB02-738)
;  CURRENT APPLICATION NUMBER: US/10/206,705
;  CURRENT FILING DATE:  2002-07-26
;  NUMBER OF SEQ ID NOS: 388
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 263
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-206-705-263

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.8e+02;
```

```
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGG 1607
              ||||| | ||| ||||||
Db         18 ACTGGAAGCCCTTCCTGG 1


RESULT 295
US-09-736-271-9
; Sequence 9, Application US/09736271
; Publication No. US20010044937A1
; GENERAL INFORMATION:
;  APPLICANT: OREGON HEALTH SCIENCES UNIVERSITY
;  APPLICANT:  Schatten, Gerald
;  APPLICANT:  Chan, Anthony W.S.
;  TITLE OF INVENTION: METHODS FOR PRODUCING TRANSGENIC ANIMALS
;  FILE REFERENCE: 899-58374
;  CURRENT APPLICATION NUMBER: US/09/736,271
;  CURRENT FILING DATE:  2000-12-15
;  NUMBER OF SEQ ID NOS: 9
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer
US-09-736-271-9

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1932 GTGTTAAGGTAATGGTTG 1949
              ||| | ||||| ||||||
Db          3 GTGCTCAGGTAGTGGTTG 20


RESULT 296
US-09-790-264-26
; Sequence 26, Application US/09790264
; Patent No. US20020028508A1
; GENERAL INFORMATION:
;  APPLICANT: Holtzman, Douglas A.
;  APPLICANT:  Goodearl, Andrew D.J.
;  APPLICANT:  McCarthy, Sean A.
;  TITLE OF INVENTION: NOVEL GENES ENCODING PROTEINS HAVING
;  TITLE OF INVENTION:  PROGNASTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER
;  TITLE OF INVENTION:  USES
;  FILE REFERENCE: 07334-322001
;  CURRENT APPLICATION NUMBER: US/09/790,264
;  CURRENT FILING DATE:  2001-02-21
;  PRIOR APPLICATION NUMBER: US 09/065,661
;  PRIOR FILING DATE: 1998-04-23
;  PRIOR APPLICATION NUMBER: US 09/298,531
;  PRIOR FILING DATE: 1999-04-23
;  PRIOR APPLICATION NUMBER: US 09/065,363
;  PRIOR FILING DATE: 1998-04-23
;  PRIOR APPLICATION NUMBER: US 09/337,930
;  PRIOR FILING DATE: 1999-06-22
;  PRIOR APPLICATION NUMBER: US 09/102,705
;  PRIOR FILING DATE: 1998-06-22
;  PRIOR APPLICATION NUMBER: US 09/363,630
;  PRIOR FILING DATE: 1999-07-29
;  PRIOR APPLICATION NUMBER: US 09/124,538
;  PRIOR FILING DATE: 1998-07-29
;  NUMBER OF SEQ ID NOS: 68
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 26
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide for PCR
US-09-790-264-26

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGG 1613
              | |||||| ||||||| |
Db          1 AGCCCCTCATGGCCTGTG 18


RESULT 297
US-09-834-291-14
; Sequence 14, Application US/09834291
; Patent No. US20020042064A1
; GENERAL INFORMATION:
;  APPLICANT: Krammer, Peter
;  APPLICANT:  Muller-Schilling, Martina
;  APPLICANT:  Oren, Moshe
;  TITLE OF INVENTION: p53 Binding Areas
;  FILE REFERENCE: 4121-122
;  CURRENT APPLICATION NUMBER: US/09/834,291
;  CURRENT FILING DATE:  2001-08-21
;  PRIOR APPLICATION NUMBER: PCT/DE99/03343
;  PRIOR FILING DATE: 1999-10-18
;  PRIOR APPLICATION NUMBER: DE 198 47 779.1
;  PRIOR FILING DATE: 1998-10-16
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-834-291-14

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTTT 1776
              | ||  ||||||||||||
Db          3 TGTTGCTTAAGCTTTTTT 20


RESULT 298
US-09-972-473-30/c
; Sequence 30, Application US/09972473
; Publication No. US20030068312A1
; GENERAL INFORMATION:
;  APPLICANT: McCarthy, Sean A.
;  TITLE OF INVENTION: NOVEL HUMAN DICKKOPF-RELATED PROTEIN AND NUCLEIC ACID
;  TITLE OF INVENTION:  MOLECULES AND USES THEREFOR
;  FILE REFERENCE: MNI-108CP2
;  CURRENT APPLICATION NUMBER: US/09/972,473
;  CURRENT FILING DATE:  2001-10-04
;  PRIOR APPLICATION NUMBER: 09/263,022
;  PRIOR FILING DATE: 1999-03-05
;  PRIOR APPLICATION NUMBER: 08/843,704
;  PRIOR FILING DATE: 1997-04-16
;  PRIOR APPLICATION NUMBER: 08/842,898
;  PRIOR FILING DATE: 1997-04-17
;  PRIOR APPLICATION NUMBER: 60/071,589
;  PRIOR FILING DATE: 1998-01-15
;  PRIOR APPLICATION NUMBER: 09/009,802
;  PRIOR FILING DATE: 1998-01-20
;  NUMBER OF SEQ ID NOS: 38
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 30
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-972-473-30

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGACTG 1593
              ||||||| ||||  ||||
Db         18 TCTCCACAGCACTCACTG 1


RESULT 299
US-09-972-469-49
; Sequence 49, Application US/09972469
; Publication No. US20030073085A1
; GENERAL INFORMATION:
;  APPLICANT: Lai, Fang
;  APPLICANT:  Zhou, Daixing
;  TITLE OF INVENTION: AMPLIFYING EXPRESSED SEQUENCES FROM GENOMIC DNA OF HIGHER-ORDER
;  TITLE OF INVENTION:  EUKARYOTIC ORGANISMS FOR DNA ARRAYS
;  FILE REFERENCE: SP01-290
;  CURRENT APPLICATION NUMBER: US/09/972,469
;  CURRENT FILING DATE:  2001-10-05
;  NUMBER OF SEQ ID NOS: 196
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 49
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-972-469-49

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCACA 1588
              ||||||||||||  | |
Db          3 ATCCTTCTCCACCAAAGA 20


RESULT 300
US-09-972-469-186/c
; Sequence 186, Application US/09972469
; Publication No. US20030073085A1
; GENERAL INFORMATION:
;  APPLICANT: Lai, Fang
;  APPLICANT:  Zhou, Daixing
;  TITLE OF INVENTION: AMPLIFYING EXPRESSED SEQUENCES FROM GENOMIC DNA OF HIGHER-ORDER
;  TITLE OF INVENTION:  EUKARYOTIC ORGANISMS FOR DNA ARRAYS
;  FILE REFERENCE: SP01-290
;  CURRENT APPLICATION NUMBER: US/09/972,469
;  CURRENT FILING DATE:  2001-10-05
;  NUMBER OF SEQ ID NOS: 196
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 186
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-972-469-186

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAAGTG 1810
              | ||||||||||| || ||
Db         20 TGTCCTTCTCTGGAAATG 3


RESULT 301
US-09-816-460C-44/c
; Sequence 44, Application US/09816460C
; Publication No. US20030087235A1
; GENERAL INFORMATION:
;  APPLICANT: Dairkee, Shanaz H.
;  APPLICANT:  Li, Zheng
;  TITLE OF INVENTION: PROGNOSTIC METHODS FOR BREAST CANCER
;  FILE REFERENCE: CPMC-010/00US
;  CURRENT APPLICATION NUMBER: US/09/816,460C
;  CURRENT FILING DATE:  2001-03-23
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic primer
US-09-816-460C-44

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTCT 2044
              | ||||||| |||| ||||
Db         20 GCAGGAGGGAAAGTTTCT 3


RESULT 302
US-09-998-027-145
; Sequence 145, Application US/09998027
; Publication No. US20030093819A1
; GENERAL INFORMATION:
;  APPLICANT: D'Andrea et al.
;  TITLE OF INVENTION: Methods and Compositions for the
;  TITLE OF INVENTION:  Diagnosis and Treatment of Cancers Associated with Defective
;  TITLE OF INVENTION:  DNA Repair Mechanisms
;  FILE REFERENCE: 2486/101
;  CURRENT APPLICATION NUMBER: US/09/998,027
;  CURRENT FILING DATE:  2001-11-02
;  NUMBER OF SEQ ID NOS: 191
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 145
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: MG779
US-09-998-027-145

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTG 1934
              ||||||| |||| | |||
Db          2 ATACCTTCTTTTGCTGTG 19


RESULT 303
US-10-271-887-146/c
; Sequence 146, Application US/10271887
; Publication No. US20030087871A1
; GENERAL INFORMATION:
;  APPLICANT: Hong Zhang
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 9 EXPRESSION
;  FILE REFERENCE: RTS-0183
;  CURRENT APPLICATION NUMBER: US/10/271,887
;  CURRENT FILING DATE:  2002-10-15
;  PRIOR APPLICATION NUMBER: US/09/659,845A
;  PRIOR FILING DATE: 2001-07-23
;  NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 146
;   LENGTH: 20
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-271-887-146

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1674 CCCTGGACTTCTTAGTTG 1691
              ||||||||| ||| || |
Db         18 CCCTGGACTGCTTTGTGG 1


RESULT 304
US-10-238-011-35/c
; Sequence 35, Application US/10238011
; Publication No. US20030091568A1
; GENERAL INFORMATION:
;  APPLICANT: Frey Jurgen
;  APPLICANT:  Frey, Jurgen
;  TITLE OF INVENTION: Inhibitors for the Formation of Soluble Human CD23
;  FILE REFERENCE: 516326-2002
;  CURRENT APPLICATION NUMBER: US/10/238,011
;  CURRENT FILING DATE:  2002-09-09
;  PRIOR APPLICATION NUMBER: EP 00 107 515.9
;  PRIOR FILING DATE: 2000-04-07
;  PRIOR APPLICATION NUMBER: 09/827,406
;  PRIOR FILING DATE: 2000-04-05
;  NUMBER OF SEQ ID NOS: 39
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-238-011-35

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1743 ACAAGTACTGGCTCTTTA 1760
              ||| |||||||| ||| |
Db         20 ACAGGTACTGGCGCTTCA 3


RESULT 305
US-10-269-353-26
; Sequence 26, Application US/10269353
; Publication No. US20030104447A1
; GENERAL INFORMATION:
;  APPLICANT: Holtzman, Douglas A.
;  APPLICANT:  Goodearl, Andrew D.J.
;  APPLICANT:  McCarthy, Sean A.
;  TITLE OF INVENTION: NOVEL GENES ENCODING PROTEINS HAVING
;  TITLE OF INVENTION:  PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER
;  TITLE OF INVENTION:  USES
;  FILE REFERENCE: MPI2000-538OMNICN1M
;  CURRENT APPLICATION NUMBER: US/10/269,353
;  CURRENT FILING DATE:  2002-10-11
;  PRIOR APPLICATION NUMBER: US 09/790,264
;  PRIOR FILING DATE: 2001-02-21
;  PRIOR APPLICATION NUMBER: US 09/065,661
;  PRIOR FILING DATE: 1998-04-23
;  PRIOR APPLICATION NUMBER: US 09/298,531
;  PRIOR FILING DATE: 1999-04-23
;  PRIOR APPLICATION NUMBER: US 09/065,363
;  PRIOR FILING DATE: 1998-04-23
;  PRIOR APPLICATION NUMBER: US 09/337,930
;  PRIOR FILING DATE: 1999-06-22
;  PRIOR APPLICATION NUMBER: US 09/102,705
;  PRIOR FILING DATE: 1998-06-22
;  PRIOR APPLICATION NUMBER: US 09/363,630
;  PRIOR FILING DATE: 1999-07-29
;  PRIOR APPLICATION NUMBER: US 09/124,538
;  PRIOR FILING DATE: 1998-07-29
;  NUMBER OF SEQ ID NOS: 68
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 26
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide for PCR
US-10-269-353-26

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGG 1613
              | ||||||| ||||||| |
Db          1 AGCCCCTCATGGCCTGTG 18


RESULT 306
US-10-003-354-81
; Sequence 81, Application US/10003354
; Publication No. US20030114400A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: RTS-0348
;  CURRENT APPLICATION NUMBER: US/10/003,354
;  CURRENT FILING DATE:  2001-12-06
;  NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 81
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-354-81

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1556 AACAGGACTGCAAAAATC 1573
              ||||||| | ||| ||||
Db          1 AACAGGAATTCAACAATC 18


RESULT 307
US-10-003-919-33
; Sequence 33, Application US/10003919
; Publication No. US20030114401A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SHIP-1 EXPRESSION
;  FILE REFERENCE: RTS-0256
;  CURRENT APPLICATION NUMBER: US/10/003,919
;  CURRENT FILING DATE:  2001-12-06
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 33
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-919-33

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
```

Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1670 CCGCCCCTGGACTTCTTA 1687
              ||  || ||||||||||
Db          2 CCATCCTTGGACTTCTTA 19
```

RESULT 308
US-10-003-919-54/c
; Sequence 54, Application US/10003919
; Publication No. US20030114401A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF SHIP-1 EXPRESSION
; FILE REFERENCE: RTS-0256
; CURRENT APPLICATION NUMBER: US/10/003,919
; CURRENT FILING DATE: 2001-12-06
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-003-919-54

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       2013 GATCAAGTCCTCTGGTAG 2030
              || | |||||||||| ||
Db         20 GACCGAGTCCTCTGGAAG 3
```

RESULT 309
US-10-348-485-65
; Sequence 65, Application US/10348485
; Publication No. US20030148989A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Holmlund, Jon T.
; APPLICANT: Dorr, F. Andrew
; TITLE OF INVENTION: Oligonucleotide Modulation Of Protein Kinase C
; FILE REFERENCE: ISIS4954
; CURRENT APPLICATION NUMBER: US/10/348,485
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/10/025,139
; PRIOR FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 08/829,637
; PRIOR FILING DATE: 1997-03-31
; PRIOR APPLICATION NUMBER: US 08/478,178
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: US 08/089,996
; PRIOR FILING DATE: 1993-07-09
; PRIOR APPLICATION NUMBER: US 07/852,852
; PRIOR FILING DATE: 1992-03-16
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-348-485-65

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19
```

RESULT 310
US-10-319-221-6
; Sequence 6, Application US/10319221
; Publication No. US20030159169A1
; GENERAL INFORMATION:
; APPLICANT: Collodi, Paul
; APPLICANT: Fan, Lianchun
; APPLICANT: Ma, Chunguang
; TITLE OF INVENTION: CELL CULTURE SYSTEM AND METHODS OF USE
; FILE REFERENCE: 290.00300101
; CURRENT APPLICATION NUMBER: US/10/319,221
; CURRENT FILING DATE: 2002-12-13
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: primer
US-10-319-221-6

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1932 GTGTTAAGGTAATGGTTG 1949
              ||| | ||||| ||||||
Db          1 GTGCTCAGGTAGTGGTTG 18
```

RESULT 311
US-10-165-099-145
; Sequence 145, Application US/10165099
; Publication No. US20030188326A1
; GENERAL INFORMATION:
; APPLICANT: D'Andrea, Alan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CANCER SUSCEPTIBILI
; TITLE OF INVENTION: DEFECTIVE DNA REPAIR MECHANISMS AND TREATMENT THEREOF
; FILE REFERENCE: 7032/2055
; CURRENT APPLICATION NUMBER: US/10/165,099
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 09/998,027
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: US 60/245,756
; PRIOR FILING DATE: 2000-11-03
; NUMBER OF SEQ ID NOS: 352
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-165-099-145

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1917 ATACCTTTTTTTTCAGTG 1934
              ||||||| |||| | |||
Db          2 ATACCTTCTTTTGCTGTG 19
```

RESULT 312
US-10-161-983-29/c

```
; Sequence 29, Application US/10161983
; Publication No. US20030225015A1
; GENERAL INFORMATION:
;  APPLICANT: Donna T. Ward
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RB2/P130 EXPRESSION
;  FILE REFERENCE: HTS-0020
;  CURRENT APPLICATION NUMBER: US/10/161,983
;  CURRENT FILING DATE:  2002-05-31
;  NUMBER OF SEQ ID NOS: 74
; SEQ ID NO 29
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-161-983-29

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTC 1844
              ||| ||| ||||| ||||
Db         18 AATGTTTGAAATATATTC 1


RESULT 313
US-10-161-983-61
; Sequence 61, Application US/10161983
; Publication No. US20030225015A1
; GENERAL INFORMATION:
;  APPLICANT: Donna T. Ward
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF RB2/P130 EXPRESSION
;  FILE REFERENCE: HTS-0020
;  CURRENT APPLICATION NUMBER: US/10/161,983
;  CURRENT FILING DATE:  2002-05-31
;  NUMBER OF SEQ ID NOS: 74
; SEQ ID NO 61
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-161-983-61

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTC 1844
              ||| ||| ||||| ||||
Db          3 AATGTTTGAAATATATTC 20


RESULT 314
US-10-173-208-25/c
; Sequence 25, Application US/10173208
; Publication No. US20030232435A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF AMYLOID BETA PROTEIN PRECURSOR EXPRESSION
;  FILE REFERENCE: HTS-0023
;  CURRENT APPLICATION NUMBER: US/10/173,208
;  CURRENT FILING DATE:  2002-06-14
;  NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-173-208-25

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTTTGT 1625
              ||  |||| |||||||||
Db         20 CCGAGGGGTAGAGTTTGT 3


RESULT 315
US-10-173-208-61
; Sequence 61, Application US/10173208
; Publication No. US20030232435A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF AMYLOID BETA PROTEIN PRECURSOR EXPRESSION
;  FILE REFERENCE: HTS-0023
;  CURRENT APPLICATION NUMBER: US/10/173,208
;  CURRENT FILING DATE:  2002-06-14
;  NUMBER OF SEQ ID NOS: 78
; SEQ ID NO 61
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
US-10-173-208-61

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTTTGT 1625
              ||  |||| |||||||||
Db          1 CCGAGGGGTAGAGTTTGT 18


RESULT 316
US-10-189-268-47/c
; Sequence 47, Application US/10189268
; Publication No. US20040005570A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF GERANYLGERANYL DIPHOSPHATE SYNTHASE 1 EXPI
;  FILE REFERENCE: PTS-0021
;  CURRENT APPLICATION NUMBER: US/10/189,268
;  CURRENT FILING DATE:  2002-07-02
;  NUMBER OF SEQ ID NOS: 131
; SEQ ID NO 47
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-189-268-47

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              |||  |||||| ||||||
Db         19 TAGGTTCTTTTGAATACA 2


RESULT 317
US-10-349-143-4087/c
; Sequence 4087, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
```

```
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4087
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..20
;   OTHER INFORMATION: upstream amplification primer 99-13229 for SEQ 153,
US-10-349-143-4087

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1681 CTTCTTAGTTGTTTCTCT 1698
              ||||  |||||||| |||
Db         20 CTTCCAAGTTGTTTTTCT 3


RESULT 318
US-10-189-267-101/c
; Sequence 101, Application US/10189267
; Publication No. US20040006030A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TGF-BETA 2 EXPRESSION
;  FILE REFERENCE: PTS-0038
;  CURRENT APPLICATION NUMBER: US/10/189,267
;  CURRENT FILING DATE:  2002-07-02
;  NUMBER OF SEQ ID NOS: 284
; SEQ ID NO 101
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-189-267-101

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1830 CTTTTAAATACATTCCCT 1847
              |||||||| |||| | ||
Db         18 CTTTTAAAAACATGCACT 1


RESULT 319
US-10-289-762-2313
; Sequence 2313, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/10/289,762
;  CURRENT FILING DATE:  2003-03-27
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2313
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-10-289-762-2313

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2046 TCTGCTTAGCAACTAGTT 2063
              ||||||||| |||| | |
Db          3 TCTGCTTAGGAACTTGCT 20


RESULT 320
US-10-210-723-47
; Sequence 47, Application US/10210723
; Publication No. US20040023382A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PPP3CB EXPRESSION
;  FILE REFERENCE: PTS-0028
;  CURRENT APPLICATION NUMBER: US/10/210,723
;  CURRENT FILING DATE:  2002-07-31
;  NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 47
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-723-47

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTTGT 1692
              ||||||  ||| ||||||
Db          2 CCTGGAGCTCTGAGTTGT 19


RESULT 321
US-10-210-723-116/c
; Sequence 116, Application US/10210723
; Publication No. US20040023382A1
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT:  C. Frank Bennett
;  APPLICANT:  Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PPP3CB EXPRESSION
;  FILE REFERENCE: PTS-0028
;  CURRENT APPLICATION NUMBER: US/10/210,723
;  CURRENT FILING DATE:  2002-07-31
;  NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 116
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-723-116

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1675 CCTGGACTTCTTAGTTGT 1692
              ||||||  ||| ||||||
Db         19 CCTGGAGCTCTGAGTTGT 2
```

RESULT 322
US-10-210-838-60
; Sequence 60, Application US/10210838
; Publication No. US20040023905A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF LAR EXPRESSION
; FILE REFERENCE: PTS-0013
; CURRENT APPLICATION NUMBER: US/10/210,838
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 198
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-838-60

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1640 TTTAAAGAGCCTTCACTG 1657
              ||  |||||| |||||||
Db          2 TTGGAAGAGCTTTCACTG 19
```

RESULT 323
US-10-280-183A-393/c
; Sequence 393, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Chatterjee, Aurobindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shanru
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G.
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; TITLE OF INVENTION: CARBOHYDRATE COMPOUNDS AND OTHER SWEETNERS
; FILE REFERENCE: PC18306A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 393
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mouse
US-10-280-183A-393

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1571 ATCCTTCTCCACCGCACA 1588
              |||||| |||||| || |
Db         20 ATCCTTTTCCACCCCAAA 3
```

RESULT 324
US-10-304-125-59/c
; Sequence 59, Application US/10304125
; Publication No. US20040102405A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SQUALENE SYNTHASE EXPRESSION
; FILE REFERENCE: PTS-0056
; CURRENT APPLICATION NUMBER: US/10/304,125
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 145
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-304-125-59

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1740 GTGACAAGTACTGGCTCT 1757
              | ||||||||||| | ||
Db         18 GGGACAAGTACTGCCACT 1
```

RESULT 325
US-10-304-125-126
; Sequence 126, Application US/10304125
; Publication No. US20040102405A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SQUALENE SYNTHASE EXPRESSION
; FILE REFERENCE: PTS-0056
; CURRENT APPLICATION NUMBER: US/10/304,125
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 145
; SEQ ID NO 126
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-304-125-126

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1740 GTGACAAGTACTGGCTCT 1757
              | ||||||||||| | ||
Db          3 GGGACAAGTACTGCCACT 20
```

RESULT 326
US-10-688-706-1855
; Sequence 1855, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broschat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION

```
;  FILE REFERENCE: 01393/1
;  CURRENT APPLICATION NUMBER: US/10/688,706
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,268
;  PRIOR FILING DATE: 2002-10-17
;  NUMBER OF SEQ ID NOS: 3071
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1855
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: human GFAT antisense
US-10-688-706-1855

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              ||||||||||   |||||
Db          3 TAGAATCTTTCTGATACA 20


RESULT 327
US-10-688-706-2139
; Sequence 2139, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Broschat, Kay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
;  FILE REFERENCE: 01393/1
;  CURRENT APPLICATION NUMBER: US/10/688,706
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,268
;  PRIOR FILING DATE: 2002-10-17
;  NUMBER OF SEQ ID NOS: 3071
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2139
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: human GFAT antisense
US-10-688-706-2139

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              ||||||||||   |||||
Db          2 TAGAATCTTTCTGATACA 19


RESULT 328
US-10-688-706-2365
; Sequence 2365, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Broschat, Kay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
;  FILE REFERENCE: 01393/1
;  CURRENT APPLICATION NUMBER: US/10/688,706
;  CURRENT FILING DATE:  2003-10-17
;  PRIOR APPLICATION NUMBER: 60/419,268
;  PRIOR FILING DATE: 2002-10-17
;  NUMBER OF SEQ ID NOS: 3071
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2365
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: human GFAT antisense
US-10-688-706-2365

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              ||||||||||   |||||
Db          1 TAGAATCTTTCTGATACA 18


RESULT 329
US-10-319-893-88/c
; Sequence 88, Application US/10319893
; Publication No. US20040115649A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF ABCC5 EXPRESSION
;  FILE REFERENCE: RTS-0419
;  CURRENT APPLICATION NUMBER: US/10/319,893
;  CURRENT FILING DATE:  2002-12-12
;  NUMBER OF SEQ ID NOS: 157
; SEQ ID NO 88
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-319-893-88

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAGATCAAG 2019
              ||| || ||||||  ||||
Db         19 GCTGCTGCAGAGAACAAG 2


RESULT 330
US-10-319-893-157
; Sequence 157, Application US/10319893
; Publication No. US20040115649A1
; GENERAL INFORMATION:
;  APPLICANT: Kenneth W. Dobie
;  TITLE OF INVENTION: ANTISENSE MODULATION OF ABCC5 EXPRESSION
;  FILE REFERENCE: RTS-0419
;  CURRENT APPLICATION NUMBER: US/10/319,893
;  CURRENT FILING DATE:  2002-12-12
;  NUMBER OF SEQ ID NOS: 157
; SEQ ID NO 157
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: H. sapiens
;   FEATURE:
US-10-319-893-157

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAGATCAAG 2019
              ||| || ||||||  ||||
Db          2 GCTGCTGCAGAGAACAAG 19


RESULT 331
US-10-671-395-120
; Sequence 120, Application US/10671395
```

```
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 120
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-120

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2012 AGATCAAGTCCTCTGGTA 2029
              | ||||||||| | ||||
Db          3 ACATCAAGTCCCCAGGTA 20


RESULT 332
US-10-671-395-163
; Sequence 163, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 163
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-163

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2012 AGATCAAGTCCTCTGGTA 2029
              | ||||||||| | ||||
Db          2 ACATCAAGTCCCCAGGTA 19


RESULT 333
US-10-671-395-227
; Sequence 227, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 227
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-227

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2012 AGATCAAGTCCTCTGGTA 2029
              | ||||||||| | ||||
Db          1 ACATCAAGTCCCCAGGTA 18


RESULT 334
US-10-671-395-1122
; Sequence 1122, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1122
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1122

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACACAC 1867
              ||| | |||||||||| |
Db          2 GCCCAGAGACCCACACGC 19


RESULT 335
US-10-671-395-1294
; Sequence 1294, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1294
```

```
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1294

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACACAC 1867
              ||| | ||||||||||  |
Db          1 GCCCAGAGACCCACACGC 18


RESULT 336
US-10-671-395-1343
; Sequence 1343, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1343
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1343

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1853 AACAGACCCACACACTTA 1870
              |||| || ||||||| ||
Db          1 AACATACACACACACATA 18


RESULT 337
US-10-671-395-1366
; Sequence 1366, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1366
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1366

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1853 AACAGACCCACACACTTA 1870
              |||| || ||||||| ||
Db          2 AACATACACACACACATA 19


RESULT 338
US-10-671-395-1367
; Sequence 1367, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
;  APPLICANT: Pharmacia Corp.
;  APPLICANT:  Gierse, James K
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: 1179/1/US
;  CURRENT APPLICATION NUMBER: US/10/671,395
;  CURRENT FILING DATE:  2003-09-25
;  PRIOR APPLICATION NUMBER: 60/413,549
;  PRIOR FILING DATE: 2002-09-25
;  NUMBER OF SEQ ID NOS: 1809
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1367
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial
;   FEATURE:
;   OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1367

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1853 AACAGACCCACACACTTA 1870
              |||| || ||||||| ||
Db          3 AACATACACACACACATA 20


RESULT 339
US-10-473-368-8/c
; Sequence 8, Application US/10473368
; Publication No. US20040175706A1
; GENERAL INFORMATION:
;  APPLICANT: SHIOZAWA, Shunichi
;  APPLICANT:  KOMAI, Koichiro
;  APPLICANT:  YAGI, Hirofumi
;  APPLICANT:  MATSUURA, Nao
;  TITLE OF INVENTION: Genomic DNAss involved in participating in rheumatoid arthritis,
;  TITLE OF INVENTION:  a method of diagnosing or judging onset risk of the same,
;  TITLE OF INVENTION:  method of judging onset risk thereof and diagnostic kit for dete
;  FILE REFERENCE: 2003-1388A/WMC/00653
;  CURRENT APPLICATION NUMBER: US/10/473,368
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: JP2001-102006
;  PRIOR FILING DATE: 2001-03-30
;  NUMBER OF SEQ ID NOS: 13
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthesized oligonucleotide
US-10-473-368-8

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1730 TTATCAGAAGGTGACAAG 1747
              ||| || ||||||| |||
Db         18 TTACCACAAGGTGAGAAG 1
```

RESULT 340
US-10-731-739-618
; Sequence 618, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/10/731,739
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US/09/544,398B
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: PastSEQ for Windows Version 4.0
; SEQ ID NO 618
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-731-739-618

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTATC 2047
              ||||||| | ||||| ||
Db          2 GGAGGCACAAGTTCTTTC 19
```

RESULT 341
US-10-741-789A-89
; Sequence 89, Application US/10741789A
; Publication No. US20040205839A1
; GENERAL INFORMATION:
; APPLICANT: Doutriaux, Marie-Pascale
; APPLICANT: Betzner, Andreas
; APPLICANT: Freyssinet, Georges
; APPLICANT: Perez, Pascal
; TITLE OF INVENTION: METHOD FOR OBTAINING PLANT VARIETIES
; FILE REFERENCE: A33153-PCT-USA 075118.0115
; CURRENT APPLICATION NUMBER: US/10/741,789A
; CURRENT FILING DATE: 2003-12-19
; PRIOR APPLICATION NUMBER: PCT/EP98/06977
; PRIOR FILING DATE: 1998-10-09
; NUMBER OF SEQ ID NOS: 103
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Reverse primer for PCR amplification of NGA106 SSLP marker in
; OTHER INFORMATION: Arabidopsis thaliana subspecies
US-10-741-789A-89

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCTC 1802
              ||||||| | | ||||||
Db          3 CCCCATTTTGTTCTTCTC 20
```

RESULT 342
US-10-197-019-48
; Sequence 48, Application US/10197019
; Publication No. US20030207284A1
; GENERAL INFORMATION:
; APPLICANT: Chew, Anne
; APPLICANT: Denton, R. Rex
; APPLICANT: Gilson, Christopher Raleigh
; APPLICANT: Nandabalan, Krishnan
; APPLICANT: Parks, Katie E.
; TITLE OF INVENTION: HAPLOTYPES OF THE UCP2 GENE
; FILE REFERENCE: MWH-0042US
; CURRENT APPLICATION NUMBER: US/10/197,019
; CURRENT FILING DATE: 2002-07-16
; PRIOR APPLICATION NUMBER: PCT/US01/02485
; PRIOR FILING DATE: 2001-01-25
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 48
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-197-019-48

```
  Query Match             2.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 2.1e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTG 1934
              |||||||| ||||:|
Db          1 CCTTTTTTCTCAGKG 15
```

RESULT 343
US-09-818-875-2314
; Sequence 2314, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2314
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-2314

```
  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          4 GGAAGAGTTTGTT 16
```

```
RESULT 344
US-09-818-875-2315/c
; Sequence 2315, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2315
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-2315

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
             |||||||||||||
Db         14 GGAAGAGTTTGTT 2


RESULT 345
US-09-818-875-2318
; Sequence 2318, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2318
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-2318

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
             |||||||||||||
Db          4 GGAAGAGTTTGTT 16


RESULT 346
US-09-818-875-2319/c
; Sequence 2319, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2319
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-2319

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
             |||||||||||||
Db         14 GGAAGAGTTTGTT 2


RESULT 347
US-09-818-875-2322
; Sequence 2322, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2322
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-2322

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          1 GGAAGAGTTTGTT 13


RESULT 348
US-09-818-875-2323/c
; Sequence 2323, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2323
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-2323

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         17 GGAAGAGTTTGTT 5


RESULT 349
US-09-818-875-2326
; Sequence 2326, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2326
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-2326

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          2 GGAAGAGTTTGTT 14


RESULT 350
US-09-818-875-2327/c
; Sequence 2327, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/09/818,875
;  CURRENT FILING DATE:  2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2327
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-818-875-2327

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         16 GGAAGAGTTTGTT 4


RESULT 351
US-09-776-474-933/c
; Sequence 933, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Booher, Robert
;  APPLICANT:  Holman, Patricia
;  APPLICANT:  Pattaey, Ali
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK
;  TITLE OF INVENTION:  Enzyme
;  FILE REFERENCE: MBHB00-955-A (400/008)
;  CURRENT APPLICATION NUMBER: US/09/776,474
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,983
;  PRIOR FILING DATE: 2000-03-02
;  NUMBER OF SEQ ID NOS: 2992
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 933
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-776-474-933

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCAT 1666
              |||||||||||||
Db         14 ACTGGTTCTGCAT 2


RESULT 352
US-10-061-201-955/c
; Sequence 955, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 955
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-955

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         17 TATCTCCTAACTT 5


RESULT 353
US-10-061-201-956/c
; Sequence 956, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 956
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-956

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         16 TATCTCCTAACTT 4


RESULT 354
US-10-061-201-957/c
; Sequence 957, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 957
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-957

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
```

```
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         15 TATCTCCTAACTT 3


RESULT 355
US-10-061-201-958/c
; Sequence 958, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 958
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-958

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         14 TATCTCCTAACTT 2


RESULT 356
US-10-061-201-959/c
; Sequence 959, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 959
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-959

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         13 TATCTCCTAACTT 1


RESULT 357
US-10-187-253A-60
; Sequence 60, Application US/10187253A
; Publication No. US20030170612A1
; GENERAL INFORMATION:
;  APPLICANT: Pichuantes, Sergio
;  APPLICANT:  Shyamala, Venkatakrishna
;  TITLE OF INVENTION: DIAGNOSTIC ASSAYS FOR PARVOVIRUS B19
;  FILE REFERENCE: CHIR-17194/03US / PP17194.004
;  CURRENT APPLICATION NUMBER: US/10/187,253A
;  CURRENT FILING DATE:  2003-03-10
;  NUMBER OF SEQ ID NOS: 92
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  primer VSP1
US-10-187-253A-60

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTT 2042
              |||||||||||||
Db          1 GGAGGCAAAGGTT 13


RESULT 358
US-10-209-787-2314
; Sequence 2314, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
```

; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2314
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-2314

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||
Db 4 GGAAGAGTTTGTT 16

RESULT 359
US-10-209-787-2315/c
; Sequence 2315, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2315
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-2315

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||
Db 14 GGAAGAGTTTGTT 2

RESULT 360
US-10-209-787-2318
; Sequence 2318, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2318
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-2318

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||
Db 4 GGAAGAGTTTGTT 16

RESULT 361
US-10-209-787-2319/c
; Sequence 2319, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2319
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-2319

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||
Db 14 GGAAGAGTTTGTT 2

```
RESULT 362
US-10-209-787-2322
; Sequence 2322, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2322
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-2322

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          1 GGAAGAGTTTGTT 13


RESULT 363
US-10-209-787-2323/c
; Sequence 2323, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2323
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-2323

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          5 GGAAGAGTTTGTT 17


RESULT 364
US-10-209-787-2326
; Sequence 2326, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2326
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-2326

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          2 GGAAGAGTTTGTT 14


RESULT 365
US-10-209-787-2327/c
; Sequence 2327, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: Napro-4
;  CURRENT APPLICATION NUMBER: US/10/209,787
;  CURRENT FILING DATE:  2002-07-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2327
```

```
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-209-787-2327

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         16 GGAAGAGTTTGTT 4


RESULT 366
US-10-261-185-2314
; Sequence 2314, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2314
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-2314

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          4 GGAAGAGTTTGTT 16


RESULT 367
US-10-261-185-2315/c
; Sequence 2315, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2315
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-2315

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         14 GGAAGAGTTTGTT 2


RESULT 368
US-10-261-185-2318
; Sequence 2318, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2318
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-2318

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          4 GGAAGAGTTTGTT 16


RESULT 369
US-10-261-185-2319/c
; Sequence 2319, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
```

```
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2319
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-2319

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         14 GGAAGAGTTTGTT 2


RESULT 370
US-10-261-185-2322
; Sequence 2322, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2322
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-2322

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          1 GGAAGAGTTTGTT 13


RESULT 371
US-10-261-185-2323/c
; Sequence 2323, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2323
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-2323

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         17 GGAAGAGTTTGTT 5


RESULT 372
US-10-261-185-2326
; Sequence 2326, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2326
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-2326

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          2 GGAAGAGTTTGTT 14
```

```
RESULT 373
US-10-261-185-2327/c
; Sequence 2327, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
;  APPLICANT: Kmiec, Eric B.
;  APPLICANT:  Gamper, Howard B.
;  APPLICANT:  Rice, Michael C.
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
;  TITLE OF INVENTION:  Stranded Oligonucleotides
;  FILE REFERENCE: NaPro-4CON
;  CURRENT APPLICATION NUMBER: US/10/261,185
;  CURRENT FILING DATE:  2002-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/09761
;  PRIOR FILING DATE: 2001-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,176
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/192,179
;  PRIOR FILING DATE: 2000-03-27
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  NUMBER OF SEQ ID NOS: 4385
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2327
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-261-185-2327

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
             |||||||||||||
Db         16 GGAAGAGTTTGTT 4


RESULT 374
US-10-681-074-2314
; Sequence 2314, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2314
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-2314

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
             |||||||||||||
Db          4 GGAAGAGTTTGTT 16


RESULT 375
US-10-681-074-2315/c
; Sequence 2315, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2315
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-2315

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
             |||||||||||||
Db         14 GGAAGAGTTTGTT 2


RESULT 376
US-10-681-074-2318
; Sequence 2318, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2318
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-2318

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
             |||||||||||||
Db          4 GGAAGAGTTTGTT 16


RESULT 377
US-10-681-074-2319/c
; Sequence 2319, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2319
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-2319

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         14 GGAAGAGTTTGTT 2


RESULT 378
US-10-681-074-2322
; Sequence 2322, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2322
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-2322

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          1 GGAAGAGTTTGTT 13


RESULT 379
US-10-681-074-2323/c
; Sequence 2323, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2323
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-2323

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         17 GGAAGAGTTTGTT 5


RESULT 380
US-10-681-074-2326
; Sequence 2326, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2326
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-2326

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          2 GGAAGAGTTTGTT 14


RESULT 381
US-10-681-074-2327/c
; Sequence 2327, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2327
```

```
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-681-074-2327

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         16 GGAAGAGTTTGTT 4


RESULT 382
US-10-076-597-23/c
; Sequence 23, Application US/10076597
; Publication No. US20030045490A1
; GENERAL INFORMATION:
;  APPLICANT: Dale, Roderic M. K.
;  APPLICANT:  Arrow, Amy
;  APPLICANT:  Thompson, Terry
;  TITLE OF INVENTION: Antisense Phosphodiesterase Inhibitors
;  FILE REFERENCE: OLIG-003CIP
;  CURRENT APPLICATION NUMBER: US/10/076,597
;  CURRENT FILING DATE:  2002-02-19
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/364,626
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-07-29
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/223,586
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-12-30
;  NUMBER OF SEQ ID NOS: 51
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 23
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthesized Oligonucleotide
US-10-076-597-23

  Query Match             2.3%;  Score 13;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1735 AGAAGGTGACAAG 1747
              |||||||||||||
Db         18 AGAAGGTGACAAG 6


RESULT 383
US-10-444-925-276/c
; Sequence 276, Application US/10444925
; Publication No. US20040009946A1
; GENERAL INFORMATION:
;  APPLICANT: Lewis, Stephen Patrick
;  APPLICANT:  Klinghoffer, Richard
;  APPLICANT:  Wilson, Linda K.
;  TITLE OF INVENTION: MODULATION OF PTP1B SIGNAL TRANSDUCTION
;  TITLE OF INVENTION:  BY RNA INTERFERENCE
;  FILE REFERENCE: 200125.441
;  CURRENT APPLICATION NUMBER: US/10/444,925
;  CURRENT FILING DATE:  2003-05-23
;  NUMBER OF SEQ ID NOS: 599
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 276
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Small interfering RNA
US-10-444-925-276

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2006 CTTCAGAGATCAA 2018
              |||||||||||||
Db         19 CTTCAGAGATCAA 7


RESULT 384
US-09-883-825-1/c
; Sequence 1, Application US/09883825
; Patent No. US20020151024A1
;  GENERAL INFORMATION:
;       APPLICANT: Beavo, Joseph A.
;                  Bentley, Kelley
;                  Charbonneau, Harry
;                  Sonnenburg, William K.
;       TITLE OF INVENTION: DNA Encoding Mammalian
;                           Phosphodiesterases
;       NUMBER OF SEQUENCES: 58
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
;                       Bicknell
;            STREET: Two First National Plaza, 20 South Clark
;                    Street
;            CITY: Chicago
;            STATE: Illinois
;            COUNTRY: USA
;            ZIP: 60603
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/883,825
;            FILING DATE: 18-Jun-2001
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/123,783
;            FILING DATE: <Unknown>
;            APPLICATION NUMBER: 08/297,494
;            FILING DATE: <Unknown>
;            APPLICATION NUMBER: US 07/688,356
;            FILING DATE: 04-APR-1991
;       ATTORNEY/AGENT INFORMATION:
;            NAME: No. US20020151024A1and, Greta E.
;            REGISTRATION NUMBER: 35,302
;            REFERENCE/DOCKET NUMBER: 27866/30822
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (312) 346-5750
;            TELEFAX: (312) 984-9740
;            TELEX: 25-3856
;   INFORMATION FOR SEQ ID NO: 1:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-883-825-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 385
```

```
US-10-445-097-29/c
; Sequence 29, Application US/10445097
; Publication No. US20030228620A1
; GENERAL INFORMATION:
;  APPLICANT: Lastrucci, Rusla M. Du Breuil
;  TITLE OF INVENTION: Nested PCR Employing Degradable Primers
;  FILE REFERENCE: 0942.5380001
;  CURRENT APPLICATION NUMBER: US/10/445,097
;  CURRENT FILING DATE:  2003-05-27
;  PRIOR APPLICATION NUMBER: US 60/382,578
;  PRIOR FILING DATE: 2002-05-24
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 29
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (7)..(7)
;   OTHER INFORMATION: deoxyuridine
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (19)..(19)
;   OTHER INFORMATION: deoxyuridine
US-10-445-097-29

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCAC 1669
              ||||||||| ||||
Db         16 TGGTTCTGCNTCAC 3


RESULT 386
US-10-697-894-1/c
; Sequence 1, Application US/10697894
; Publication No. US20040126866A1
;   GENERAL INFORMATION:
;        APPLICANT: Beavo, Joseph A.
;                   Bentley, Kelley
;                   Charbonneau, Harry
;                   Sonnenburg, William K.
;        TITLE OF INVENTION: DNA Encoding Mammalian
;                            Phosphodiesterases
;        NUMBER OF SEQUENCES: 58
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
;                        Bicknell
;             STREET: Two First National Plaza, 20 South Clark
;                     Street
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: USA
;             ZIP: 60603
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/697,894
;             FILING DATE: 30-Oct-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/123,783
;             FILING DATE: 28-July-1998
;             APPLICATION NUMBER: 08/297,494
;             FILING DATE: <Unknown>
;             APPLICATION NUMBER: US 07/688,356
;             FILING DATE: 04-APR-1991
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Noland, Greta E.
;             REGISTRATION NUMBER: 35,302
;             REFERENCE/DOCKET NUMBER: 27866/30822
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (312) 346-5750
;             TELEFAX: (312) 984-9740
;             TELEX: 25-3856
;   INFORMATION FOR SEQ ID NO: 1:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-697-894-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  ||||| |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 387
US-10-786-720-12564
; Sequence 12564, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12564
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-12564

  Query Match             2.3%;  Score 13;  DB 1;  Length 21;
  Best Local Similarity   38.1%;  Pred. No. 3.6e+02;
  Matches    8;  Conservative    8;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1622 TTGTTACCTACCTTACTATTT 1642
              ::| : ||:|||: |  |:::
Db          1 UUGCUUCCUACCUGAGAAUUU 21


RESULT 388
US-09-955-410-30
; Sequence 30, Application US/09955410
; Patent No. US20020146718A1
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids Having 2,6-Diaminopurine Nucleobases
;  FILE REFERENCE: ISIS4800
;  CURRENT APPLICATION NUMBER: US/09/955,410
;  CURRENT FILING DATE:  2001-09-18
;  PRIOR APPLICATION NUMBER: 08/108,591
```

```
;  PRIOR FILING DATE: 1993-11-22
;  PRIOR APPLICATION NUMBER: 09/686,114
;  PRIOR FILING DATE: 1996-07-24
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 30
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20020146718A1el Sequence
US-09-955-410-30

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 389
US-09-983-210-30
; Sequence 30, Application US/09983210
; Patent No. US20020160383A1
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  THE USE OF NUCLEIC ACID ANALOGUES IN
;    TITLE OF INVENTION:  DIAGNOSTICS AND ANALYTICAL PROCEDURES
;    NUMBER OF SEQUENCES:  40
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Wordperfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/983,210
;      FILING DATE:  2001-OCT-23
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/150156
;      FILING DATE:  1994-APR-05
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0986/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0987/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0510/92
;      FILING DATE:  15-APR-1992
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    PUBLICATION INFORMATION:
;      DOCUMENT NUMBER:  WO PCT/EP92/01220
;      FILING DATE:  22-MAY-1992
US-09-983-210-30

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 390
US-10-154-890-30
; Sequence 30, Application US/10154890
; Publication No. US20030180734A1
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/10/154,890
;  CURRENT FILING DATE:  2002-05-23
;  PRIOR APPLICATION NUMBER: US/08/108,591
;  PRIOR FILING DATE: 2001-08-13
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 30
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030180734A1el Sequence
US-10-154-890-30

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 391
US-09-866-108-1345/c
; Sequence 1345, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1345
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1345

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCT 1801
                ||||| |||||||||
Db         17 CCCATCTTTTCCTTCT 2


RESULT 392
US-09-866-108-1347/c
; Sequence 1347, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1347
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1347

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
                ||||||  ||||||||
Db         16 CCCCATCTTTTCCTTC 1


RESULT 393
US-09-866-108-1580/c
; Sequence 1580, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1580
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1580

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1571 ATCCTTCTCCACCGCA 1586
              ||||||||||  |||
Db         17 ATCCTTCTCCAGAGCA 2


RESULT 394
US-09-866-108-1581/c
; Sequence 1581, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1581
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1581

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
              ||||||||||  |||
Db         16 ATCCTTCTCCAGAGCA 1


RESULT 395
US-09-866-108-7641/c
; Sequence 7641, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7641
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7641

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1686 TAGTTGTTTCTCTAGC 1701
              | ||||  |||||||||
Db         17 TTGTTGGTTCTCTAGC 2


RESULT 396
US-09-866-108-7644/c
; Sequence 7644, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
```

```
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7644
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7644

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTA 1699
              ||| |||| |||||||
Db         16 CTTTGTTGGTTCTCTA 1

RESULT 397
US-09-866-108-7957
; Sequence 7957, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7957
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7957

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          2 GCCCTTGAGCAACAGA 17

RESULT 398
US-09-866-108-7958
; Sequence 7958, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7958
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7958

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          1 GCCCTTGAGCAACAGA 16


RESULT 399
US-09-827-998-311
; Sequence 311, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 311
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-311

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGGA 1562
              |||||||||||| | ||
Db          2 TAGGGAAGGAAGAAGA 17


RESULT 400
US-09-827-998-312
; Sequence 312, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 312
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-312

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGGA 1562
              |||||||||||| | ||
Db          1 TAGGGAAGGAAGAAGA 16


RESULT 401
US-09-730-289B-316
; Sequence 316, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 316
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-316

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 2.8e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTA 1639
              |::|||:| |::|| |
Db          2 GUUACCUAGCUUACCA 17


RESULT 402
US-09-730-289B-905
; Sequence 905, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 905
;  LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-905

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
```

```
  Best Local Similarity   62.5%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              |: | |||::||||:|
Db          2 CUCAACCAUUGAAAUG 17


RESULT 403
US-09-780-533A-2445/c
; Sequence 2445, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2445
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2445

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTGA 1805
              || || ||||||||||
Db         16 TTTTTGCCTTCTCTGA 1


RESULT 404
US-09-848-754A-545
; Sequence 545, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 545
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-545

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 2.8e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || :||::|:|| :||
Db          2 CAGUGGUUCUGCUUCA 17


RESULT 405
US-09-848-754A-546
; Sequence 546, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 546
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-546

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 2.8e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || :||::|:|| :||
Db          1 CAGUGGUUCUGCUUCA 16


RESULT 406
US-09-780-164-137/c
; Sequence 137, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
;  FILE REFERENCE: 400/010
;  CURRENT APPLICATION NUMBER: US/09/780,164
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: 60/185,516
;  PRIOR FILING DATE: 2000-02-28
;  NUMBER OF SEQ ID NOS: 2603
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 137
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-164-137

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2024 CTGGTAGGAGGCAAAG 2039
              |||| || ||||||||
Db         16 CTGGAAGAAGGCAAAG 1


RESULT 407
US-09-780-164-503/c
; Sequence 503, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
;  FILE REFERENCE: 400/010
;  CURRENT APPLICATION NUMBER: US/09/780,164
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: 60/185,516
;  PRIOR FILING DATE: 2000-02-28
;  NUMBER OF SEQ ID NOS: 2603
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 503
;   LENGTH: 17
```

```
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-164-503

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2024 CTGGTAGGAGGCAAAG 2039
              |||| || ||||||||
Db         17 CTGGAAGAAGGCAAAG 2


RESULT 408
US-10-060-830-247
; Sequence 247, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 247
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-247

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGGCA 2036
              || |||||||||||  |
Db          2 CCACTGGTAGGAGGAA 17


RESULT 409
US-10-060-830-248
; Sequence 248, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 248
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-248

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGGCA 2036
              || |||||||||||  |
Db          1 CCACTGGTAGGAGGAA 16


RESULT 410
US-10-060-756A-1168
; Sequence 1168, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1168
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1168

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
              ||  ||||||||||||
Db          2 TTGGCCTTGAAAAAAA 17


RESULT 411
US-10-060-756A-1169
```

; Sequence 1169, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1169
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1169

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1970 TTTACCTTGAAAAAAA 1985
|| |||||||||||
Db 1 TTGGCCTTGAAAAAAA 16

RESULT 412
US-10-211-059-117
; Sequence 117, Application US/10211059
; Publication No. US20030100495A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN NAC-1 PROTEIN
; FILE REFERENCE: PB0149
; CURRENT APPLICATION NUMBER: US/10/211,059
; CURRENT FILING DATE: 2002-08-02
; PRIOR APPLICATION NUMBER: US 60/311,034
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 322
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 117
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-211-059-117

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1587 CAGACTGGGAACCCCT 1602
|||| |||||||| ||
Db 2 CAGATTGGGAACCGCT 17

RESULT 413
US-10-211-059-118
; Sequence 118, Application US/10211059
; Publication No. US20030100495A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN NAC-1 PROTEIN
; FILE REFERENCE: PB0149
; CURRENT APPLICATION NUMBER: US/10/211,059
; CURRENT FILING DATE: 2002-08-02
; PRIOR APPLICATION NUMBER: US 60/311,034
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 322
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 118
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-211-059-118

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1587 CAGACTGGGAACCCCT 1602
|||| |||||||| ||
Db 1 CAGATTGGGAACCGCT 16

RESULT 414
US-10-163-552-969
; Sequence 969, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBHB01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 969
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-969

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.8e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1550 GGAAGGAACAGGACTG 1565
||||||||||| :|
Db 2 GGAAGGAACAGCAAUG 17

RESULT 415
US-10-156-306-47
; Sequence 47, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 47
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens

```
US-10-156-306-47

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 2.8e+02;
  Matches    4;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTT 1780
              ::|||| :: ::::::
Db          1 UUAAGCCUUCUUUUUU 16


RESULT 416
US-10-156-306-1313
; Sequence 1313, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1313
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-1313

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 2.8e+02;
  Matches    4;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTT 1780
              ::|||| :: ::::::
Db          2 UUAAGCCUUCUUUUUU 17


RESULT 417
US-10-156-306-3609
; Sequence 3609, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3609
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-3609

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 2.8e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGAC 1744
              |: |:| |||||:|||
Db          2 AUCAUCUGAAGGUGAC 17


RESULT 418
US-10-156-306-7108/c
; Sequence 7108, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7108
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-7108

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
              ||||||||||  ||||
Db         16 CCCCATTCTTGACTTC 1


RESULT 419
US-10-238-700-458
; Sequence 458, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 458
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-458

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 2.8e+02;
  Matches    7;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
              |||::::| ||:|: :
Db          2 AAGUUUUACAAUCUCU 17


RESULT 420
US-10-238-700-669
; Sequence 669, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 669
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-669

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 2.8e+02;
  Matches    7;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCTT 1772
              :: |::||: ||||::
Db          2 UUAAUUCAUGAAGCUU 17


RESULT 421
US-10-238-700-904
; Sequence 904, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 904
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-904

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 2.8e+02;
  Matches    7;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1933 TGTTAAGGTAATGGTT 1948
              : ::||||:| :||::
Db          2 UUUUAAGGUAGUGGUU 17


RESULT 422
US-10-238-700-3477/c
; Sequence 3477, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3477
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-3477

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGGGA 1616
              |||||||||| ||| |
Db         16 CTCCTGGCCTCGGGAA 1


RESULT 423
US-10-339-782-260
; Sequence 260, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
;  APPLICANT: Lynx Therapeutics, Inc.
;  APPLICANT:  Goodman, Laurie J
;  APPLICANT:  Bowen, Benjamin A
;  TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
;  FILE REFERENCE: 37-000110US
;  CURRENT APPLICATION NUMBER: US/10/339,782
;  CURRENT FILING DATE:  2003-01-08
;  NUMBER OF SEQ ID NOS: 495
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 260
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-339-782-260

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1595 GAACCCCTCCTGGCCT 1610
              || |||||||| |||
Db          1 GATCCCCTCCTGCCCT 16


RESULT 424
US-10-331-329-32/c
; Sequence 32, Application US/10331329
; Publication No. US20030180267A1
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: 0221-0003CON
;  CURRENT APPLICATION NUMBER: US/10/331,329
;  CURRENT FILING DATE:  2002-12-30
;  PRIOR APPLICATION NUMBER: 09/276,820
;  PRIOR FILING DATE: 1999-03-26
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-10-331-329-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 425
US-10-297-068-1103
; Sequence 1103, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
;  APPLICANT: INOKO, Hidetoshi
;  APPLICANT:  KAGIYA, Taeko
;  APPLICANT:  ICHIHARA, Tatsuo
;  APPLICANT:  Matsumura, Yoshiyuki
;  APPLICANT:  MORIYA, Shogo
;  APPLICANT:  NISHIDA, Michio
;  TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
;  FILE REFERENCE: 1314OP1174
;  CURRENT APPLICATION NUMBER: US/10/297,068
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: JP 2000-164798
;  PRIOR FILING DATE: 2000-06-01
;  NUMBER OF SEQ ID NOS: 1298
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1103
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:capture
US-10-297-068-1103

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1906 ACAGATCAACAATACC 1921
              ||||||| |||| |||
Db          1 ACAGATCTACAAGACC 16


RESULT 426
US-10-307-005-1527
; Sequence 1527, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
;  APPLICANT: University of Delaware
;  APPLICANT:  Eric B. Kmiec
;  APPLICANT:  Howard B. Gamper
;  APPLICANT:  Michael C. Rice
;  APPLICANT:  Jungsup Kim
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
;  TITLE OF INVENTION:  Using Modified Single Stranded Oligonucleotides
;  FILE REFERENCE: Napro/009 PCT
;  CURRENT APPLICATION NUMBER: US/10/307,005
;  CURRENT FILING DATE:  2002-11-26
;  PRIOR APPLICATION NUMBER: PCT/US01/17672
;  PRIOR FILING DATE: 2001-06-01
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  NUMBER OF SEQ ID NOS: 2717
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1527
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Arabidopsis thaliana
US-10-307-005-1527

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTA 2045
              |||||||||||  |||
Db          1 GGAGGCAAAGGAGCTA 16


RESULT 427
US-10-307-005-1528/c
; Sequence 1528, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
;  APPLICANT: University of Delaware
;  APPLICANT:  Eric B. Kmiec
;  APPLICANT:  Howard B. Gamper
;  APPLICANT:  Michael C. Rice
;  APPLICANT:  Jungsup Kim
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
;  TITLE OF INVENTION:  Using Modified Single Stranded Oligonucleotides
;  FILE REFERENCE: Napro/009 PCT
;  CURRENT APPLICATION NUMBER: US/10/307,005
;  CURRENT FILING DATE:  2002-11-26
;  PRIOR APPLICATION NUMBER: PCT/US01/17672
;  PRIOR FILING DATE: 2001-06-01
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  NUMBER OF SEQ ID NOS: 2717
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1528
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Arabidopsis thaliana
US-10-307-005-1528

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTA 2045
              |||||||||||  |||
Db         17 GGAGGCAAAGGAGCTA 2


RESULT 428
US-10-675-685-311
; Sequence 311, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: PB0114
;  CURRENT APPLICATION NUMBER: US/10/675,685
;  CURRENT FILING DATE:  2003-09-30
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 311
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-675-685-311

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
```

Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1547 TAGGGAAGGAACAGGA 1562
              |||||||||| | ||
Db          2 TAGGGAAGGAAGAAGA 17
```

RESULT 429
US-10-675-685-312
; Sequence 312, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 312
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-312

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1547 TAGGGAAGGAACAGGA 1562
              |||||||||| | ||
Db          1 TAGGGAAGGAAGAAGA 16
```

RESULT 430
US-10-138-674-749/c
; Sequence 749, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 749
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-749

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1692 TTTCTCTAGCGCTGAG 1707
              |||||||| | |||||
Db         16 TTTCTCTAACACTGAG 1
```

RESULT 431
US-10-138-674-778/c
; Sequence 778, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 778
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-778

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         17 AGCCACTGAAATGGCA 2
```

RESULT 432
US-10-138-674-779/c
; Sequence 779, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 779
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-779

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         16 AGCCACTGAAATGGCA 1
```

RESULT 433
US-10-138-674-1042
; Sequence 1042, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

```
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1042
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-1042

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   31.2%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCT 1698
              :|:: |::|:: |:|:
Db          2 UCUUUGUUGUUCCUCU 17


RESULT 434
US-10-138-674-2869/c
; Sequence 2869, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2869
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-2869

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAAC 1558
              |||||  ||||||||||
Db         17 AGAGTCCGGAAGGAAC 2


RESULT 435
US-10-138-674-8039
; Sequence 8039, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8039
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-8039

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
              ::|| ||||| :|||:
Db          2 UUAAUGAGCCAUCACU 17


RESULT 436
US-10-138-674-8128
; Sequence 8128, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8128
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-8128

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   31.2%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCT 1698
              :|:: |::|:: |:|:
Db          1 UCUUUGUUGUUCCUCU 16


RESULT 437
US-10-287-949A-749/c
; Sequence 749, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 749
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-749

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGAG 1707
```

```
              |||||||| | |||||
Db         16 TTTCTCTAACACTGAG 1


RESULT 438
US-10-287-949A-778/c
; Sequence 778, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 778
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-778

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         17 AGCCACTGAAATGGCA 2


RESULT 439
US-10-287-949A-779/c
; Sequence 779, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 779
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-779

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         16 AGCCACTGAAATGGCA 1


RESULT 440
US-10-287-949A-1042
; Sequence 1042, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1042
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-1042

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   31.2%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCT 1698
              :|:: |::|:: |:|:
Db          2 UCUUUGUUGUUCCUCU 17


RESULT 441
US-10-287-949A-2869/c
; Sequence 2869, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2869
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-2869

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAAC 1558
              |||||  |||||||||
Db         17 AGAGTCCGGAAGGAAC 2


RESULT 442
US-10-287-949A-8039
; Sequence 8039, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
```

```
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8039
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-287-949A-8039

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 2.8e+02;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
              ::|| ||||| :|||:
Db          2 UUAAUGAGCCAUCACU 17


RESULT 443
US-10-287-949A-8128
; Sequence 8128, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8128
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-287-949A-8128

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   31.2%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCT 1698
              :|:: |::|:: |:|:
Db          1 UCUUUGUUGUUCCUCU 16


RESULT 444
US-10-712-672-960/c
; Sequence 960, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 960
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-712-672-960

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGAAG 1618
              |||| |||||||||  |
Db         17 CCTGTCCTGGGGGATG 2


RESULT 445
US-10-712-672-961/c
; Sequence 961, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 961
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: Homo sapiens
US-10-712-672-961

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGAAG 1618
              |||| |||||||||  |
Db         16 CCTGTCCTGGGGGATG 1


RESULT 446
US-10-723-361-1345/c
; Sequence 1345, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1345
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1345

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCT 1801
              |||||  |||||||||
Db         17 CCCATCTTTTCCTTCT 2


RESULT 447
US-10-723-361-1347/c
; Sequence 1347, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1347
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1347

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
              ||||||  ||||||||
Db         16 CCCCATCTTTTCCTTC 1


RESULT 448
US-10-723-361-1580/c
; Sequence 1580, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1580
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1580

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
              ||||||||||  |||
Db         17 ATCCTTCTCCAGAGCA 2


RESULT 449
US-10-723-361-1581/c
; Sequence 1581, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
```

```
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1581
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1581

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
              ||||||||||| |||
Db         16 ATCCTTCTCCAGAGCA 1


RESULT 450
US-10-723-361-7641/c
; Sequence 7641, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7641
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7641

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1686 TAGTTGTTTCTCTAGC 1701
              | |||| |||||||||
Db         17 TTGTTGGTTCTCTAGC 2


RESULT 451
US-10-723-361-7644/c
; Sequence 7644, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7644
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7644

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
```

```
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTA 1699
              ||| |||| |||||||
Db         16 CTTTGTTGGTTCTCTA 1


RESULT 452
US-10-723-361-7957
; Sequence 7957, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7957
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7957

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          2 GCCCTTGAGCAACAGA 17


RESULT 453
US-10-723-361-7958
; Sequence 7958, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7958
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7958

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          1 GCCCTTGAGCAACAGA 16


RESULT 454
US-10-151-484-142
; Sequence 142, Application US/10151484
; Publication No. US20030134293A1
; GENERAL INFORMATION:
;  APPLICANT: Liu, Zhiping
;  TITLE OF INVENTION: METHOD FOR RAPID AND ACCURATE
;  TITLE OF INVENTION:  IDENTIFICATION OF MICROORGANISMS
;  FILE REFERENCE: 501332000120
;  CURRENT APPLICATION NUMBER: US/10/151,484
;  CURRENT FILING DATE:  2002-05-16
;  PRIOR APPLICATION NUMBER: PCT/US00/31579
;  PRIOR FILING DATE: 2000-11-16
;  PRIOR APPLICATION NUMBER: US 60/165,881
;  PRIOR FILING DATE: 1999-11-16
;  NUMBER OF SEQ ID NOS: 165
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 142
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Parainfluenza virus type 3 (PIV-3)
US-10-151-484-142

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1568 AAAATCCTTCTCCACC 1583
```

```
                    ||||||||||| |||
Db          3 AAAATCCTTCTATACC 18


RESULT 455
US-10-349-143-7869/c
; Sequence 7869, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7869
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-1151 for SEQ 4, in complement
US-10-349-143-7869

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1939 GGTAATGGTTGGTTTT 1954
                ||||| ||||||| ||
Db         18 GGTAAGGGTTGGTGTT 3


RESULT 456
US-10-349-143-11530
; Sequence 11530, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11530
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-9362 for SEQ 3665, in compleme
US-10-349-143-11530

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTTGTGTC 1960
                ||||||||||| ||
Db          3 GGTTGGTTTTTGCCTC 18


RESULT 457
US-10-731-739-450
; Sequence 450, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/10/731,739
;  CURRENT FILING DATE:  2003-12-10
;  PRIOR APPLICATION NUMBER: US/09/544,398B
;  PRIOR FILING DATE: 2002-06-10
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 450
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-731-739-450

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1782 GAACCCCATTCTTTCC 1797
                ||| ||| ||||||||
Db          2 GAATCCCTTTCTTTCC 17


RESULT 458
US-09-216-393-337/c
; Sequence 337, Application US/09216393
; Patent No. US20010014447A1
; GENERAL INFORMATION:
;  APPLICANT: Milhausen, Michael James
;  TITLE OF INVENTION: TOXOPLASMA GONDII PROTEINS, NUCLEIC ACID MOLECULES, AND
;  TITLE OF INVENTION: USES THEREOF
;  FILE REFERENCE: TX-1-C2
;  CURRENT APPLICATION NUMBER: US/09/216,393
;  CURRENT FILING DATE: 1998-12-18
;  EARLIER APPLICATION NUMBER: 08/994,825
;  EARLIER FILING DATE: 1997-12-19
;  NUMBER OF SEQ ID NOS: 364
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 337
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
;   OTHER INFORMATION: Primer
US-09-216-393-337
```

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1648 GCCTTCACTGGTTCTG 1663
              ||||| |||| |||||
Db         19 GCCTTGACTGCTTCTG 4


RESULT 459
US-09-539-382-28/c
; Sequence 28, Application US/09539382
; Publication No. US20030044417A1
; GENERAL INFORMATION:
;  APPLICANT: McCORMICK, Alison
;  APPLICANT:  TUSE, Daniel
;  APPLICANT:  REINL, Stephen
;  APPLICANT:  LINDBO, John
;  APPLICANT:  TURPEN, Thomas
;  TITLE OF INVENTION: SELF ANTIGEN VACCINES FOR TREATING B CELL LYMPHOMAS AND OTHER CAN
;  FILE REFERENCE: 18696-169195
;  CURRENT APPLICATION NUMBER: US/09/539,382
;  CURRENT FILING DATE:  2000-03-10
;  PRIOR APPLICATION NUMBER: US 60/155,579
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 62
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 28
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: primer
US-09-539-382-28

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              |||| |||||| ||||
Db         18 CTGGGTCTGCAACACC 3


RESULT 460
US-10-067-790-28/c
; Sequence 28, Application US/10067790
; Publication No. US20030035807A1
; GENERAL INFORMATION:
;  APPLICANT: McCORMICK, Alison
;  APPLICANT:  TUSE, Daniel
;  APPLICANT:  REINL, Stephen
;  APPLICANT:  LINDBO, John
;  APPLICANT:  TURPEN, Thomas
;  TITLE OF INVENTION: SELF ANTIGEN VACCINES FOR TREATING B CELL LYMPHOMAS AND OTHER CAN
;  FILE REFERENCE: 18696-169194
;  CURRENT APPLICATION NUMBER: US/10/067,790
;  CURRENT FILING DATE:  2002-02-08
;  PRIOR APPLICATION NUMBER: US/09/522,900
;  PRIOR FILING DATE: 2000-03-10
;  PRIOR APPLICATION NUMBER: US 60/155,579
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 62
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 28
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: primer
US-10-067-790-28

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              |||| |||||| ||||
Db         18 CTGGGTCTGCAACACC 3


RESULT 461
US-10-067-892-28/c
; Sequence 28, Application US/10067892
; Publication No. US20030039659A1
; GENERAL INFORMATION:
;  APPLICANT: McCORMICK, Alison
;  APPLICANT:  TUSE, Daniel
;  APPLICANT:  REINL, Stephen
;  APPLICANT:  LINDBO, John
;  APPLICANT:  TURPEN, Thomas
;  TITLE OF INVENTION: SELF ANTIGEN VACCINES FOR TREATING B CELL LYMPHOMAS
;  TITLE OF INVENTION:  AND OTHER CANCERS
;  FILE REFERENCE: 18696-169194
;  CURRENT APPLICATION NUMBER: US/10/067,892
;  CURRENT FILING DATE:  2002-02-08
;  PRIOR APPLICATION NUMBER: US/09/522,900
;  PRIOR FILING DATE: 2000-03-10
;  NUMBER OF SEQ ID NOS: 62
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 28
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: primer
US-10-067-892-28

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              |||| |||||| ||||
Db         18 CTGGGTCTGCAACACC 3


RESULT 462
US-10-067-893-28/c
; Sequence 28, Application US/10067893
; Publication No. US20030044420A1
; GENERAL INFORMATION:
;  APPLICANT: McCORMICK, Alison
;  APPLICANT:  TUSE, Daniel
;  APPLICANT:  REINL, Stephen
;  APPLICANT:  LINDBO, John
;  APPLICANT:  TURPEN, Thomas
;  TITLE OF INVENTION: SELF ANTIGEN VACCINES FOR TREATING B CELL LYMPHOMAS AND OTHER CANC
;  FILE REFERENCE: 18696-169194
;  CURRENT APPLICATION NUMBER: US/10/067,893
;  CURRENT FILING DATE:  2002-02-08
;  PRIOR APPLICATION NUMBER: 09/522,900
;  PRIOR FILING DATE: 2000-03-10
;  PRIOR APPLICATION NUMBER: US 60/155,579
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 62
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 28
;   LENGTH: 19
;   TYPE: DNA
```

```
;   ORGANISM: Unknown
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: primer
US-10-067-893-28

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
                ||||  ||||||  ||||
Db         18 CTGGGTCTGCAACACC 3


RESULT 463
US-10-390-303-17/c
; Sequence 17, Application US/10390303
; Publication No. US20030171569A1
; GENERAL INFORMATION:
;  APPLICANT: JCR Pharmaceuticals Co., Ltd.
;  TITLE OF INVENTION: Human Tumor Suppressing Gene
;  FILE REFERENCE:
;  CURRENT APPLICATION NUMBER: US/10/390,303
;  CURRENT FILING DATE:  2003-03-18
;  NUMBER OF SEQ ID NOS: 22
; SEQ ID NO 17
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-390-303-17

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAGG 2040
                ||||||||  |||||  |
Db         18 TGGTAGGACGCAAACG 3


RESULT 464
US-10-225-023-143
; Sequence 143, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 143
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-225-023-143

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   68.8%;  Pred. No. 3.4e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGAC 1744
                |::|:|||||||  | |
Db          4 AUUAUCAGAAGGAGCC 19


RESULT 465
US-10-225-023-156
; Sequence 156, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 156
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-225-023-156

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   68.8%;  Pred. No. 3.4e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1730 TTATCAGAAGGTGACA 1745
                ::|:|||||||  | ||
Db          1 UUAUCAGAAGGAGCCA 16


RESULT 466
US-10-225-023-503
; Sequence 503, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 503
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-225-023-503

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1848 GGGCCAACAGACCCAC 1863
              | |||||||| |||||
Db          1 GAGCCAACAGCCCCAC 16
```

RESULT 467
US-10-225-023-881/c
; Sequence 881, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
; TITLE OF INVENTION: Interfering RNA
; FILE REFERENCE: 400/054 (MBHB01-665-B)
; CURRENT APPLICATION NUMBER: US/10/225,023
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US 60/398,036
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 1494
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 881
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-225-023-881

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1729 ATTATCAGAAGGTGAC 1744
              |||||||||||| | |
Db         16 ATTATCAGAAGGAGCC 1
```

RESULT 468
US-10-225-023-894/c
; Sequence 894, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
; TITLE OF INVENTION: Interfering RNA
; FILE REFERENCE: 400/054 (MBHB01-665-B)
; CURRENT APPLICATION NUMBER: US/10/225,023
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US 60/398,036
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 1494
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 894
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-225-023-894

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1730 TTATCAGAAGGTGACA 1745
              |||||||||||| | ||
Db         19 TTATCAGAAGGAGCCA 4
```

RESULT 469
US-10-225-023-1241/c
; Sequence 1241, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
; TITLE OF INVENTION: Interfering RNA
; FILE REFERENCE: 400/054 (MBHB01-665-B)
; CURRENT APPLICATION NUMBER: US/10/225,023
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US 60/398,036
; PRIOR FILING DATE: 2002-07-23
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; NUMBER OF SEQ ID NOS: 1494
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1241
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-225-023-1241

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1848 GGGCCAACAGACCCAC 1863
              | |||||||| |||||
Db         19 GAGCCAACAGCCCCAC 4
```

RESULT 470
US-10-321-856-337/c
; Sequence 337, Application US/10321856
; Publication No. US20030194393A1
; GENERAL INFORMATION:
; APPLICANT: Milhausen, Michael James
; TITLE OF INVENTION: TOXOPLASMA GONDII PROTEINS, NUCLEIC ACID MOLECULES, AND USES THERI
; FILE REFERENCE: TX-1-C2-1
; CURRENT APPLICATION NUMBER: US/10/321,856
; CURRENT FILING DATE: 2002-12-17
; PRIOR APPLICATION NUMBER: 09/216,393
; PRIOR FILING DATE: 1998-12-18
; PRIOR APPLICATION NUMBER: 08/994,825
; PRIOR FILING DATE: 1997-12-19
; NUMBER OF SEQ ID NOS: 366
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 337
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Primer
US-10-321-856-337

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1648 GCCTTCACTGGTTCTG 1663
              ||||| |||| |||||
Db         19 GCCTTGACTGCTTCTG 4


RESULT 471
US-10-401-343-26
; Sequence 26, Application US/10401343
; Publication No. US20030194735A1
; GENERAL INFORMATION:
;  APPLICANT: Barnett, Charles J
;  APPLICANT:  Beck, James J
;  TITLE OF INVENTION: Detection of Wheat and Barley Fungal Pathogens which are
;  TITLE OF INVENTION:  Resistant To Certain Fungicides Using The Polymerase Chain
;  TITLE OF INVENTION:  Reaction
;  FILE REFERENCE: 70008USNP
;  CURRENT APPLICATION NUMBER: US/10/401,343
;  CURRENT FILING DATE:  2003-03-27
;  PRIOR APPLICATION NUMBER: 60/369,796
;  PRIOR FILING DATE: 2002-04-03
;  NUMBER OF SEQ ID NOS: 77
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
US-10-401-343-26

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1671 CGCCCCTGGACTTCTT 1686
              ||||| ||||| ||||
Db          3 CGCCCTTGGACCTCTT 18


RESULT 472
US-10-349-143-4047
; Sequence 4047, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4047
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-12914 for SEQ 113,
US-10-349-143-4047

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1532 GAAAGGTTAGGAGAGT 1547
              |||||  |||||||||
Db          3 GAAAGAATAGGAGAGT 18


RESULT 473
US-10-349-143-11179/c
; Sequence 11179, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11179
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-3167 for SEQ 3314, in compleme
US-10-349-143-11179

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGG 1555
              ||||||| || |||||
Db         18 AGGAGAGAAGAGAAGG 3


RESULT 474
US-10-648-512-70/c
; Sequence 70, Application US/10648512
; Publication No. US20040096922A1
; GENERAL INFORMATION:
;  APPLICANT: Hildebrandt, Friedhelm
;  APPLICANT:  Otto, Edgar
;  APPLICANT:  Hoefele, Julia
;  APPLICANT:  Ruf, Rainer
;  APPLICANT:  Mueller, Adelheid M.
;  APPLICANT:  Hiller, Karl S.
;  APPLICANT:  Wolf, Matthias T.F.
;  APPLICANT:  Schuermann, Maria J.
;  APPLICANT:  Becker, Achim
;  TITLE OF INVENTION: NPHP Nucleic Acids and Proteins
;  FILE REFERENCE: UM-08333
;  CURRENT APPLICATION NUMBER: US/10/648,512
;  CURRENT FILING DATE:  2003-08-26
;  NUMBER OF SEQ ID NOS: 102
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 70
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-648-512-70

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1937 AAGGTAATGGTTGGTT 1952
              ||||| |||| |||||
Db         18 AAGGTCATGGGTGGTT 3


RESULT 475
US-10-606-133-191
; Sequence 191, Application US/10606133
; Publication No. US20040132047A1
; GENERAL INFORMATION:
;  APPLICANT: Fortina, Paolo
;  APPLICANT:  Maris, John M.
;  APPLICANT:  Gelfand, Craig A.
;  TITLE OF INVENTION: Methods for Detection of Genetic
;  TITLE OF INVENTION:  Alterations Associated with Cancer
;  FILE REFERENCE: CHOP.0182US
;  CURRENT APPLICATION NUMBER: US/10/606,133
;  CURRENT FILING DATE:  2003-06-25
;  PRIOR APPLICATION NUMBER: 60/391,515
;  PRIOR FILING DATE: 2002-06-25
;  NUMBER OF SEQ ID NOS: 282
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 191
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-606-133-191

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1553 AGGAACAGGACTGCAA 1568
              ||||||||||  ||||
Db          2 AGGAACAGGAACGCAA 17


RESULT 476
US-10-665-951-270/c
; Sequence 270, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 270
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-665-951-270

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| |||||||  ||
Db         19 AGCCACTGAAATGGCA 4


RESULT 477
US-10-665-951-697
; Sequence 697, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 697
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
```

US-10-665-951-697

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 75.0%; Pred. No. 3.4e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| :||||:| ||
Db             1 AGCCACUGAAAUGGCA 16
```

RESULT 478
US-10-741-601-26328/c
; Sequence 26328, Application US/10741601
; Publication No. US20040166519A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: STENOSIS, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001500
; CURRENT APPLICATION NUMBER: US/10/741,601
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 26415
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 26328
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-601-26328

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1838 TACATTCCCTGGGCCA 1853
              ||||||| | ||||||
Db            18 TACATTCTCAGGGCCA 3
```

RESULT 479
US-09-791-932-142
; Sequence 142, Application US/09791932
; Publication No. US20030003451A1
; GENERAL INFORMATION:
; APPLICANT: Vogeli, Gabriel
; APPLICANT: Parodi, Luis A.
; APPLICANT: Hiebsch, Ronald R.
; APPLICANT: Lind, Peter
; APPLICANT: Kaytes, Paul S.
; APPLICANT: Ruff, Valerie
; APPLICANT: Huff, Rita M.
; APPLICANT: Wood, Linda S.
; TITLE OF INVENTION: No. US20030003451A1el G Protein-Coupled Receptors Cross-Referen
; FILE REFERENCE: 00325.US1
; CURRENT APPLICATION NUMBER: US/09/791,932
; CURRENT FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: 60/184,305
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/184,304
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/184,303
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/184,397
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/184,247
; PRIOR FILING DATE: 2000-02-23
; PRIOR APPLICATION NUMBER: 60/188,880
; PRIOR FILING DATE: 2000-03-13
; PRIOR APPLICATION NUMBER: 60/217,369
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/217,370
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/218,492
; PRIOR FILING DATE: 2000-07-20
; PRIOR APPLICATION NUMBER: 60/186,810
; PRIOR FILING DATE: 2000-03-03
; PRIOR APPLICATION NUMBER: 60/188,064
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: 60/186,457
; PRIOR FILING DATE: 2000-03-02
; PRIOR APPLICATION NUMBER: 60/213,861
; PRIOR FILING DATE: 2000-06-23
; PRIOR APPLICATION NUMBER: 60/194,344
; PRIOR FILING DATE: 2000-04-03
; PRIOR APPLICATION NUMBER: 60/218,337
; PRIOR FILING DATE: 2000-07-14
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 142
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer
US-09-791-932-142

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1649 CCTTCACTGGTTCTGCATC 1667
              ||| |||| || || ||||
Db             1 CCTCCACTTGTGCTTCATC 19
```

RESULT 480
US-10-229-370-6
; Sequence 6, Application US/10229370
; Publication No. US20030082600A1
; GENERAL INFORMATION:
; APPLICANT: Olek, Alexander
; APPLICANT: Berlin, Kurt
; TITLE OF INVENTION: Highly sensitive method for the detection of cytosine methylation
; TITLE OF INVENTION: patterns
; FILE REFERENCE: 81859
; CURRENT APPLICATION NUMBER: US/10/229,370
; CURRENT FILING DATE: 2002-08-27
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-229-370-6

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 3.7e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       2026 GGTAGGAGGCAAAGGTTCT 2044
              || | |||| ||||||| |
Db             1 GGAAAGAGGGAAAGGTTTT 19
```

RESULT 481
US-10-224-005-73
; Sequence 73, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Fosnaugh, Kathy
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADO
; TITLE OF INVENTION: Gene Expression Using Short Interfering RNA

```
;  FILE REFERENCE: 900/041 (MBHB01-1110-A)
;  CURRENT APPLICATION NUMBER: US/10/224,005
;  CURRENT FILING DATE:  2002-08-20
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 347
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 73
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-224-005-73

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   42.1%;  Pred. No. 3.7e+02;
  Matches    8;  Conservative    7;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTATTT 1642
              |: |||: ||::|  |:::
Db          1 GUCACCUUCCUUAAGAUUU 19


RESULT 482
US-10-224-005-234/c
; Sequence 234, Application US/10224005
; Publication No. US20030143732A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Fosnaugh, Kathy
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Adenosine A1 Receptor (AD
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering RNA
;  FILE REFERENCE: 900/041 (MBHB01-1110-A)
;  CURRENT APPLICATION NUMBER: US/10/224,005
;  CURRENT FILING DATE:  2002-08-20
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 347
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 234
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-224-005-234

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTATTT 1642
              || |||| |||||  ||||
Db         19 GTCACCTTCCTTAAGATTT 1


RESULT 483
US-10-345-092-33
; Sequence 33, Application US/10345092
; Publication No. US20030165506A1
; GENERAL INFORMATION:
;  APPLICANT: Vlaams Interuniversitair Instituut voor Biotechnol
;  TITLE OF INVENTION: No. US20030165506A1el alpha-catenin expressed in heart and testis
;  FILE REFERENCE: FVR/aTc/V067
;  CURRENT APPLICATION NUMBER: US/10/345,092
;  CURRENT FILING DATE:  2003-01-13
;  PRIOR APPLICATION NUMBER: 00202472.7
;  PRIOR FILING DATE: 2000-07-12
;  PRIOR APPLICATION NUMBER: US 60/218,309
;  PRIOR FILING DATE: 2000-07-14
;  NUMBER OF SEQ ID NOS: 134
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: splice acceptor 13
US-10-345-092-33

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCCCA 1789
              || ||||| | | ||||||
Db          1 TTCTTTTTATAGGACCCCA 19


RESULT 484
US-10-349-143-8902/c
; Sequence 8902, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8902
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-1948 for SEQ 1037, in complemer
US-10-349-143-8902

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTTGTT 1693
              ||| ||||| |  ||||||
Db         19 CCTTGACTTATGTGTTGTT 1


RESULT 485
US-10-349-143-9136/c
; Sequence 9136, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
```

```
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9136
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-22506 for SEQ 1271, in complem
US-10-349-143-9136

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1859 CCCACACACTTAGCCATTG 1877
              || || ||||| ||| |||
Db         19 CCTACTCACTTTGCCCTTG 1


RESULT 486
US-10-444-925-478
; Sequence 478, Application US/10444925
; Publication No. US20040009946A1
; GENERAL INFORMATION:
;  APPLICANT: Lewis, Stephen Patrick
;  APPLICANT:  Klinghoffer, Richard
;  APPLICANT:  Wilson, Linda K.
;  TITLE OF INVENTION: MODULATION OF PTP1B SIGNAL TRANSDUCTION
;  TITLE OF INVENTION:  BY RNA INTERFERENCE
;  FILE REFERENCE: 200125.441
;  CURRENT APPLICATION NUMBER: US/10/444,925
;  CURRENT FILING DATE:  2003-05-23
;  NUMBER OF SEQ ID NOS: 599
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 478
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Small interfering RNA
US-10-444-925-478

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1591 CTGGGAACCCCTCCTGGCC 1609
              |:|| | ||| :||:|| |
Db          1 CUGGAAGCCCUUCCUGGUC 19


RESULT 487
US-10-114-270-414
; Sequence 414, Application US/10114270
; Publication No. US20040030110A1
; GENERAL INFORMATION:
;  APPLICANT: Guo, Xiaojia
;  APPLICANT:  Kekuda, Ramesh
;  APPLICANT:  Miller, Charles E.
;  APPLICANT:  Malyankar, Uriel M.
;  APPLICANT:  Spytek, Kimberly A.
;  APPLICANT:  Patturajan, Meera
;  APPLICANT:  Liu, Ziaohong
;  APPLICANT:  Gusev, Vladimir Y.
;  APPLICANT:  Li, Li
;  APPLICANT:  Vernet, Corine
;  APPLICANT:  Zerhusen, Bryan D.
;  APPLICANT:  Gorman, Linda
;  APPLICANT:  Shenoy, Suresh G.
;  APPLICANT:  Pena, Carol E.A.
;  APPLICANT:  Smithson, Glennda
;  APPLICANT:  Burgess, Catherine E.
;  APPLICANT:  Gerlach, Valerie
;  APPLICANT:  Padigaru, Muralidhara
;  APPLICANT:  Shimkets, Richard A.
;  APPLICANT:  Gangolli, Esha A.
;  APPLICANT:  Taupier Jr., Raymond J.
;  APPLICANT:  Casman, Stacie J.
;  APPLICANT:  Ji, Weizhen
;  APPLICANT:  Anderson, David W.
;  APPLICANT:  Liete, Mario W.
;  APPLICANT:  Rastelli, Luca
;  APPLICANT:  Edinger, Shlomit R.
;  APPLICANT:  Stone, David J.
;  APPLICANT:  MacDougall, John R.
;  APPLICANT:  Rothenberg, Mark E.
;  TITLE OF INVENTION: No. US20040030110A1el Proteins and Nucleic Acids Encoding Same
;  FILE REFERENCE: 21402-322C
;  CURRENT APPLICATION NUMBER: US/10/114,270
;  CURRENT FILING DATE:  2002-11-27
;  PRIOR APPLICATION NUMBER: 60/281,086
;  PRIOR FILING DATE: 2001-04-03
;  PRIOR APPLICATION NUMBER: 60/281,136
;  PRIOR FILING DATE: 2001-04-03
;  PRIOR APPLICATION NUMBER: 60/281,863
;  PRIOR FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 60/281,906
;  PRIOR FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 60/282,020
;  PRIOR FILING DATE: 2001-04-06
;  PRIOR APPLICATION NUMBER: 60/282,930
;  PRIOR FILING DATE: 2001-04-10
;  PRIOR APPLICATION NUMBER: 60/282,934
;  PRIOR FILING DATE: 2001-04-10
;  PRIOR APPLICATION NUMBER: 60/283,512
;  PRIOR FILING DATE: 2001-04-12
;  PRIOR APPLICATION NUMBER: 60/283,710
;  PRIOR FILING DATE: 2001-04-13
;  PRIOR APPLICATION NUMBER: 60/284,234
;  PRIOR FILING DATE: 2001-04-17
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 470
; SEQ ID NO 414
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Forward Primer
US-10-114-270-414

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGACCCACA 1864
              |||| || ||| || ||||
Db          1 CTGGACCCACACACTCACA 19


RESULT 488
US-10-444-795B-220/c
; Sequence 220, Application US/10444795B
; Publication No. US20040077574A1
; GENERAL INFORMATION:
;  APPLICANT: Klinghoffer, Richard
;  APPLICANT:  Lewis, Stephen Patrick
;  TITLE OF INVENTION: MODULATION OF BIOLOGICAL SIGNAL
;  TITLE OF INVENTION:  TRANSDUCTION BY RNA INTERFERENCE
;  FILE REFERENCE: 200125.449
;  CURRENT APPLICATION NUMBER: US/10/444,795B
```

```
;  CURRENT FILING DATE:  2003-05-23
;  NUMBER OF SEQ ID NOS: 842
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 220
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Small interfering RNA
US-10-444-795B-220

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2010 AGAGATCAAGTCCTCTGGT 2028
              |||||| || ||||  |||
Db         19 AGAGATTAATTCCTTGGGT 1


RESULT 489
US-10-255-120-451/c
; Sequence 451, Application US/10255120
; Publication No. US20040091865A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Helicobacter pylori, strain J99 complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/255,120
;  CURRENT FILING DATE:  2002-11-19
;  NUMBER OF SEQ ID NOS: 903
;  SOFTWARE: Proprietary
; SEQ ID NO 451
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Helicobacter pylori, strain J99 complete genome.
;   FEATURE:
;   LOCATION: (777547)...(777565)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =   672
US-10-255-120-451

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1761 TTCATTAAGCTTTTTTTTT 1779
              ||  | ||||| |||||||
Db         19 TTTTTCAAGCTCTTTTTTT 1


RESULT 490
US-10-665-951-1101/c
; Sequence 1101, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1101
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense re
US-10-665-951-1101

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3.7e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1551 GAAGGAACAGGACTGCAAA 1569
              ||| |||||  ||| ||||
Db         19 GAAAGAACAACACTTCAAA 1


RESULT 491
US-10-665-951-1425
; Sequence 1425, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1425
;   LENGTH: 19
;   TYPE: RNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-1425

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1551 GAAGGAACAGGACTGCAAA 1569
             ||| |||||  ||: ||||
Db          1 GAAAGAACAACACUUCAAA 19


RESULT 492
US-09-510-378-111/c
; Sequence 111, Application US/09510378
; Publication No. US20030165823A1
;   GENERAL INFORMATION:
;        APPLICANT: Cronin, Maureen T.
;                   Miyada, Charles Garrett
;                   Hubbell, Earl A.
;                   Chee, Mark
;                   Fodor, Stephen P.A.
;                   Huang, Xiaohua C.
;                   Lipshutz, Robert J.
;                   Lobban, Peter E.
;                   Morris, Macdonald S.
;                   Sheldon, Edward L.
;        TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
;                            Detecting Cystic Fibrosis
;        NUMBER OF SEQUENCES: 250
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, 8th Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/510,378
;             FILING DATE: 22-Feb-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/544,381
;             FILING DATE: <Unknown>
;             APPLICATION NUMBER: US 08/510,521
;             FILING DATE: 02-AUG-1995
;             APPLICATION NUMBER: PCT/US94/12305
;             FILING DATE: 26-OCT-1994
;             APPLICATION NUMBER: US 08/284,064
;             FILING DATE: 02-AUG-1994
;             APPLICATION NUMBER: US 08/143,312
;             FILING DATE: 26-OCT-1993
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Liebeschuetz, Joe
;             REGISTRATION NUMBER: 37,505
;             REFERENCE/DOCKET NUMBER: 018547-004130US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 415-576-0200
;             TELEFAX: 415-576-0300
;   INFORMATION FOR SEQ ID NO: 111:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (oligonucleotide)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 111:
US-09-510-378-111

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1682 TTCTTAGTTGTTTCT 1696
              ||||| || ||||||
Db         15 TTCTTTGTNGTTTCT 1


RESULT 493
US-10-387-384-26/c
; Sequence 26, Application US/10387384
; Publication No. US20030233671A1
; GENERAL INFORMATION:
;  APPLICANT: SELVARAJ, GOPALAN
;  APPLICANT:  HUANG, JUN
;  APPLICANT:  DATLA, RAJU
;  TITLE OF INVENTION: PROMOTERS FOR MOLECULAR FARMING AND/OR EARLY DETECTION
;  TITLE OF INVENTION:  OF TRANSGENIC PLANTS
;  FILE REFERENCE: 11372-1
;  CURRENT APPLICATION NUMBER: US/10/387,384
;  CURRENT FILING DATE:  2003-03-14
;  PRIOR APPLICATION NUMBER: 60/364,115
;  PRIOR FILING DATE: 2002-03-15
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-387-384-26

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAAGAAA 1989
              ||||| ||||||||
Db         14 TTGAAGAAAAAGAAA 1


RESULT 494
US-10-387-384-28/c
; Sequence 28, Application US/10387384
; Publication No. US20030233671A1
; GENERAL INFORMATION:
;  APPLICANT: SELVARAJ, GOPALAN
;  APPLICANT:  HUANG, JUN
;  APPLICANT:  DATLA, RAJU
;  TITLE OF INVENTION: PROMOTERS FOR MOLECULAR FARMING AND/OR EARLY DETECTION
;  TITLE OF INVENTION:  OF TRANSGENIC PLANTS
;  FILE REFERENCE: 11372-1
;  CURRENT APPLICATION NUMBER: US/10/387,384
;  CURRENT FILING DATE:  2003-03-14
;  PRIOR APPLICATION NUMBER: 60/364,115
;  PRIOR FILING DATE: 2002-03-15
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-387-384-28

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
```

```
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAA 1989
              ||||| ||||||||
Db         14 TTGAAGAAAAGAAA 1


RESULT 495
US-10-387-384-30/c
; Sequence 30, Application US/10387384
; Publication No. US20030233671A1
; GENERAL INFORMATION:
;  APPLICANT: SELVARAJ, GOPALAN
;  APPLICANT:  HUANG, JUN
;  APPLICANT:  DATLA, RAJU
;  TITLE OF INVENTION: PROMOTERS FOR MOLECULAR FARMING AND/OR EARLY DETECTION
;  TITLE OF INVENTION:  OF TRANSGENIC PLANTS
;  FILE REFERENCE: 11372-1
;  CURRENT APPLICATION NUMBER: US/10/387,384
;  CURRENT FILING DATE:  2003-03-14
;  PRIOR APPLICATION NUMBER: 60/364,115
;  PRIOR FILING DATE: 2002-03-15
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-387-384-30

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAA 1989
              ||||| ||||||||
Db         14 TTGAAGAAAAGAAA 1


RESULT 496
US-10-387-384-32/c
; Sequence 32, Application US/10387384
; Publication No. US20030233671A1
; GENERAL INFORMATION:
;  APPLICANT: SELVARAJ, GOPALAN
;  APPLICANT:  HUANG, JUN
;  APPLICANT:  DATLA, RAJU
;  TITLE OF INVENTION: PROMOTERS FOR MOLECULAR FARMING AND/OR EARLY DETECTION
;  TITLE OF INVENTION:  OF TRANSGENIC PLANTS
;  FILE REFERENCE: 11372-1
;  CURRENT APPLICATION NUMBER: US/10/387,384
;  CURRENT FILING DATE:  2003-03-14
;  PRIOR APPLICATION NUMBER: 60/364,115
;  PRIOR FILING DATE: 2002-03-15
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-387-384-32

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAA 1989
              ||||| ||||||||
Db         14 TTGAAGAAAAGAAA 1


RESULT 497
US-10-387-384-34/c
; Sequence 34, Application US/10387384
; Publication No. US20030233671A1
; GENERAL INFORMATION:
;  APPLICANT: SELVARAJ, GOPALAN
;  APPLICANT:  HUANG, JUN
;  APPLICANT:  DATLA, RAJU
;  TITLE OF INVENTION: PROMOTERS FOR MOLECULAR FARMING AND/OR EARLY DETECTION
;  TITLE OF INVENTION:  OF TRANSGENIC PLANTS
;  FILE REFERENCE: 11372-1
;  CURRENT APPLICATION NUMBER: US/10/387,384
;  CURRENT FILING DATE:  2003-03-14
;  PRIOR APPLICATION NUMBER: 60/364,115
;  PRIOR FILING DATE: 2002-03-15
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 34
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-387-384-34

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAA 1989
              ||||| ||||||||
Db         14 TTGAAGAAAAGAAA 1


RESULT 498
US-09-866-108-7187/c
; Sequence 7187, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7187
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7187

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         17 TCAGAGGTCAAGTC 4


RESULT 499
US-09-866-108-7188/c
; Sequence 7188, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7188
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7188

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         16 TCAGAGGTCAAGTC 3


RESULT 500
US-09-866-108-7189/c
; Sequence 7189, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7189
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7189

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2008 TCAGAGATCAAGTC 2021
             |||||| |||||||
Db         15 TCAGAGGTCAAGTC 2


RESULT 501
US-09-866-108-7190/c
; Sequence 7190, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7190
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7190

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
             |||||| |||||||
Db         14 TCAGAGGTCAAGTC 1


RESULT 502
US-09-866-108-7639/c
; Sequence 7639, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7639
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7639

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         17 GTTGGTTCTCTAGC 4


RESULT 503
US-09-866-108-7640/c
; Sequence 7640, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
```

```
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7640
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7640

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         16 GTTGGTTCTCTAGC 3


RESULT 504
US-09-780-533A-595
; Sequence 595, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 595
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-595

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   35.7%;  Pred. No. 3.4e+02;
  Matches    5;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
              ::||::| ::|:|:
Db          4 UUAGUUGAUUCUCU 17


RESULT 505
US-09-780-533A-1278
; Sequence 1278, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1278
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1278

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 3.4e+02;
  Matches    6;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAA 1836
              :: |||:|::::||
Db          1 UUGGAAUCUUUUAA 14


RESULT 506
US-09-780-533A-1749
; Sequence 1749, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1749
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1749

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   35.7%;  Pred. No. 3.4e+02;
  Matches    5;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
              ::||::| ::|:|:
Db          3 UUAGUUGAUUCUCU 16
```

```
RESULT 507
US-09-780-533A-2294
; Sequence 2294, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2294
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2294

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   35.7%;  Pred. No. 3.4e+02;
  Matches    5;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
              ::||::| ::|:|:
Db          2 UUAGUUGAUUCUCU 15


RESULT 508
US-09-877-478-253/c
; Sequence 253, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 253
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-253

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         15 CCAAAAGACCCACA 2


RESULT 509
US-09-877-478-442
; Sequence 442, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 442
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-442

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          4 UUCUUUCCUUCUAU 17


RESULT 510
US-09-877-478-443
; Sequence 443, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
```

```
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 443
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-443

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          3 UUCUUUCCUUCUAU 16


RESULT 511
US-09-877-478-938/c
; Sequence 938, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 938
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-938

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
                ||||.|||||||||
Db         14 CCAAAAGACCCACA 1


RESULT 512
US-09-877-478-1166
; Sequence 1166, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1166
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1166

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          2 UUCUUUCCUUCUAU 15


RESULT 513
US-09-877-478-1167
; Sequence 1167, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
```

```
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1167
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1167

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          1 UUCUUUCCUUCUAU 14


RESULT 514
US-09-877-478-1704/c
; Sequence 1704, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1704
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1704

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         17 CCAAAAGACCCACA 4


RESULT 515
US-09-740-332-229/c
; Sequence 229, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 229
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-229

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||| ||||||||
Db         16 GATCATGTCCTCTG 3


RESULT 516
US-09-740-332-230/c
; Sequence 230, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 230
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-230

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||| ||||||||
Db         14 GATCATGTCCTCTG 1


RESULT 517
US-09-740-332-4326
; Sequence 4326, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
```

```
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4326
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: artificial sequence
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION:
;    OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4326

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   64.3%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||:|| |:||:|:|
Db          3 GAUCAUGUCCUCUG 16


RESULT 518
US-09-817-879-229/c
; Sequence 229, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 229
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: artificial sequence
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION:
;    OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-229

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||| ||||||||
Db         16 GATCATGTCCTCTG 3


RESULT 519
US-09-817-879-230/c
; Sequence 230, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 230
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: artificial sequence
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION:
;    OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-230

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||| ||||||||
Db         14 GATCATGTCCTCTG 1


RESULT 520
US-09-817-879-4326
; Sequence 4326, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4326
;    LENGTH: 17
;    TYPE: RNA
;    ORGANISM: artificial sequence
;    FEATURE:
;    NAME/KEY: misc_feature
;    LOCATION:
;    OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4326

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   64.3%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||:|| |:||:|:|
Db          3 GAUCAUGUCCUCUG 16


RESULT 521
US-10-060-830-245
; Sequence 245, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
```

; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 245
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-245

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2021 CCTCTGGTAGGAGG 2034
|| ||||||||||||
Db 4 CCACTGGTAGGAGG 17

RESULT 522
US-10-060-830-246
; Sequence 246, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 246
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-246

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2021 CCTCTGGTAGGAGG 2034
|| ||||||||||||
Db 3 CCACTGGTAGGAGG 16

RESULT 523
US-10-287-919-2130/c
; Sequence 2130, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Methanococcus jannaschii complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,919
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2706
; SOFTWARE: Proprietary
; SEQ ID NO 2130
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Methanococcus jannaschii complete genome.
; FEATURE:
; LOCATION: (1267747)...(1267763)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 2710
US-10-287-919-2130

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1766 TAAGCTTTTTTTT 1779
|||||||||||| ||
Db 14 TAAGCTTTTTTATT 1

RESULT 524
US-10-287-919-2391/c
; Sequence 2391, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Methanococcus jannaschii complete genome.
; FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/287,919
; CURRENT FILING DATE: 2002-11-05
; NUMBER OF SEQ ID NOS: 2706
; SOFTWARE: Proprietary
; SEQ ID NO 2391
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Methanococcus jannaschii complete genome.
; FEATURE:
; LOCATION: (1467127)...(1467144)
; OTHER INFORMATION: Chromosome = 1 Strand = positive ConnectronObjectNumber = 3058
US-10-287-919-2391

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1766 TAAGCTTTTTTTT 1779
|||||||||||| ||
Db 14 TAAGCTTTTTTATT 1

RESULT 525
US-10-156-306-449
; Sequence 449, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 449
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-449

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 42.9%; Pred. No. 3.4e+02;
Matches 6; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 1964 TAAATATTTACCTT 1977
:| |:|:::|||::

```
Db          4 UAGAUAUUUACCUU 17


RESULT 526
US-10-156-306-450
; Sequence 450, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 450
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-450

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 3.4e+02;
  Matches    6;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTT 1977
              :| |:|:::|||::
Db          2 UAGAUAUUUACCUU 15


RESULT 527
US-10-156-306-451
; Sequence 451, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 451
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-451

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 3.4e+02;
  Matches    6;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTT 1977
              :| |:|:::|||::
Db          1 UAGAUAUUUACCUU 14


RESULT 528
US-10-238-700-905
; Sequence 905, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 905
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-905

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 3.4e+02;
  Matches    7;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGTT 1948
              ::||||:| :||::
Db          1 UUAAGGUAGUGGUU 14


RESULT 529
US-10-238-700-3171
; Sequence 3171, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3171
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-3171

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   71.4%;  Pred. No. 3.4e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGG 1614
              |:||:||||:| ||
Db          3 CUCCUGGCCUGCGG 16


RESULT 530
US-10-230-006-163/c
; Sequence 163, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 163
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-230-006-163
```

```
  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATC 2016
              ||||||||||| ||
Db         17 CTTCTTCAGAGGTC 4


RESULT 531
US-10-342-902-253/c
; Sequence 253, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 253
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-253

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         15 CCAAAAGACCCACA 2


RESULT 532
US-10-342-902-442
; Sequence 442, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 442
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-442

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          4 UUCUUUCCUUCUAU 17


RESULT 533
US-10-342-902-443
; Sequence 443, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 443
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-443

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          3 UUCUUUCCUUCUAU 16


RESULT 534
```

```
US-10-342-902-938/c
; Sequence 938, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 938
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-938

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
                ||||  |||||||||
Db         14 CCAAAAGACCCACA 1

RESULT 535
US-10-342-902-1166
; Sequence 1166, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1166
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-1166

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
                ::|:::||::|: :
Db          2 UUCUUUCCUUCUAU 15

RESULT 536
US-10-342-902-1167
; Sequence 1167, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1167
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-1167

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
                ::|:::||::|: :
Db          1 UUCUUUCCUUCUAU 14

RESULT 537
US-10-342-902-1704/c
; Sequence 1704, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
```

```
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1704
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-1704

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         17 CCAAAAGACCCACA 4


RESULT 538
US-10-138-674-3230
; Sequence 3230, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3230
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3230

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   78.6%;  Pred. No. 3.4e+02;
  Matches   11;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAACA 1856
              :|||: ||||||||
Db          4 UCCCUCGGCCAACA 17


RESULT 539
US-10-138-674-4869/c
; Sequence 4869, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4869
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-4869

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCT 1575
              ||||||||| ||||
Db         17 ACTGCAAAAGTCCT 4


RESULT 540
US-10-138-674-6658/c
; Sequence 6658, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6658
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-6658

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGG 1612
              |||||||||| |||
Db         16 CCCTCCTGGCTTGG 3


RESULT 541
US-10-138-674-6659/c
; Sequence 6659, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 6659
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-6659

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGG 1612
              ||||||||||| |||
Db         15 CCCTCCTGGCTTGG 2


RESULT 542
US-10-138-674-7730/c
; Sequence 7730, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7730
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7730

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCC 1574
              ||||||||||| |||
Db         14 GACTGCAAAAGTCC 1


RESULT 543
US-10-676-154-564/c
; Sequence 564, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/676,154
;  CURRENT FILING DATE:  2003-09-29
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 564
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-10-676-154-564

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACACACACAC 2


RESULT 544
US-10-676-154-565/c
; Sequence 565, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/676,154
;  CURRENT FILING DATE:  2003-09-29
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 565
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-10-676-154-565

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACGCACACAC 2


RESULT 545
US-10-287-949A-3230
; Sequence 3230, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3230
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3230

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   78.6%;  Pred. No. 3.4e+02;
  Matches   11;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAACA 1856
              :|||: ||||||||
```

```
Db          4 UCCCUCGGCCAACA 17


RESULT 546
US-10-287-949A-4869/c
; Sequence 4869, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4869
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-4869

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCT 1575
              ||||||||| ||||
Db         17 ACTGCAAAAGTCCT 4


RESULT 547
US-10-287-949A-6658/c
; Sequence 6658, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6658
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6658

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGG 1612
              |||||||||| |||
Db         16 CCCTCCTGGCTTGG 3


RESULT 548
US-10-287-949A-6659/c
; Sequence 6659, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6659
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6659

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGG 1612
              |||||||||| |||
Db         15 CCCTCCTGGCTTGG 2


RESULT 549
US-10-287-949A-7730/c
; Sequence 7730, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7730
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7730

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCC 1574
              |||||||||| |||
Db         14 GACTGCAAAAGTCC 1


RESULT 550
US-10-669-841-253/c
; Sequence 253, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
```

```
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 253
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-253

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
                ||||  |||||||||
Db         15 CCAAAAGACCCACA 2


RESULT 551
US-10-669-841-442
; Sequence 442, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 442
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-442

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
                ::|:::||::|: :
Db          4 UUCUUUCCUUCUAU 17


RESULT 552
US-10-669-841-443
; Sequence 443, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 443
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-443
```

```
  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          3 UUCUUUCCUUCUAU 16


RESULT 553
US-10-669-841-938/c
; Sequence 938, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 938
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-938

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         14 CCAAAAGACCCACA 1


RESULT 554
US-10-669-841-1166
; Sequence 1166, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1166
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-1166

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 3.4e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          2 UUCUUUCCUUCUAU 15


RESULT 555
US-10-669-841-1167
; Sequence 1167, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
```

; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1167
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1167

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 28.6%; Pred. No. 3.4e+02;
Matches 4; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          1 UUCUUUCCUUCUAU 14
```

RESULT 556
US-10-669-841-1704/c
; Sequence 1704, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1704
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1704

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         17 CCAAAAGACCCACA 4
```

RESULT 557
US-10-669-841-2822/c
; Sequence 2822, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-2822

```
  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||| ||||||||
Db         16 GATCATGTCCTCTG 3


RESULT 558
US-10-669-841-2823/c
; Sequence 2823, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2823
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-2823

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||| ||||||||
Db         14 GATCATGTCCTCTG 1


RESULT 559
US-10-669-841-6919
; Sequence 6919, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6919
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6919

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   64.3%;  Pred. No. 3.4e+02;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||:|| |:||:|:|
Db          3 GAUCAUGUCCUCUG 16


RESULT 560
US-10-723-361-7187/c
; Sequence 7187, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
```

```
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7187
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7187

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         17 TCAGAGGTCAAGTC 4


RESULT 561
US-10-723-361-7188/c
; Sequence 7188, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7188
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7188

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         16 TCAGAGGTCAAGTC 3


RESULT 562
US-10-723-361-7189/c
; Sequence 7189, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7189
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7189

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         15 TCAGAGGTCAAGTC 2


RESULT 563
US-10-723-361-7190/c
; Sequence 7190, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7190
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7190

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         14 TCAGAGGTCAAGTC 1


RESULT 564
US-10-723-361-7639/c
; Sequence 7639, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7639
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7639

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         17 GTTGGTTCTCTAGC 4


RESULT 565
US-10-723-361-7640/c
; Sequence 7640, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7640
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7640

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         16 GTTGGTTCTCTAGC 3


RESULT 566
US-09-805-630-2/c
; Sequence 2, Application US/09805630
; Publication No. US20010027251A1
; GENERAL INFORMATION:
;  APPLICANT: Cook, Phillip Dan
;  APPLICANT:  Manoharan, Muthiah
;  TITLE OF INVENTION: Phosphorothioate Oligonucleotides Having Modified Internucleoside
;  TITLE OF INVENTION:  Linkages
;  FILE REFERENCE: ISIS-4718
;  CURRENT APPLICATION NUMBER: US/09/805,630
;  CURRENT FILING DATE:  2001-03-14
;  PRIOR APPLICATION NUMBER: 09/115,027
;  PRIOR FILING DATE: 1998-07-14
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide primer
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(2)
;   OTHER INFORMATION: MMI linkage
US-09-805-630-2

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
              |||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 567
US-09-907-190-27
; Sequence 27, Application US/09907190
; Publication No. US20020025528A1
;   GENERAL INFORMATION:
;        APPLICANT: BLUMENFELD, ANAT; GUSELLA, JAMES F;
;                   BREAKEFIELD, XANDRA, O;
;                   SLAUGENHAUPT, SUSAN
;        TITLE OF INVENTION: USE OF GENETIC MARKERS TO
;                            DIAGNOSE FAMILIAL DYSAUTONOMIA
;        NUMBER OF SEQUENCES: 34
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
;             STREET: 345 PARK AVENUE
;             CITY: NEW YORK
;             STATE: NEW YORK
;             COUNTRY: USA
;             ZIP: 10154
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: FLOPPY DISK
;             COMPUTER: IBM PC COMPATIBLE
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: ASCII
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/907,190
;             FILING DATE: 17-Jul-2001
;             CLASSIFICATION: 435
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/08/480,655
;             FILING DATE: 07-JUNE-1995
;             APPLICATION NUMBER: 08/049,678
;             FILING DATE: 16-APRIL-1993
;             APPLICATION NUMBER: US/07/890,719
;             FILING DATE: 29-MAY-1992
;        ATTORNEY/AGENT INFORMATION:
;             NAME: KENNETH H. SONNENFELD
;             REGISTRATION NUMBER: 33,285
;             REFERENCE/DOCKET NUMBER: 1829-4001US1
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 212-451-8513
;             TELEFAX: 212-751-6849
;   INFORMATION FOR SEQ ID NO: 27:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18
;             TYPE: NUCLEIC ACID
;             STRANDEDNESS: SINGLE
;             TOPOLOGY: UNKNOWN
;        MOLECULE TYPE: OLIGONUCLEOTIDE
;        HYPOTHETICAL: No
;        FEATURE:
;             NAME/KEY:  PRIMER SEQUENCE OF D9S310 LOCUS
;             LOCATION:  CHROMOSOME 9
;             IDENTIFICATION METHOD:
;             OTHER INFORMATION:
;        SEQUENCE DESCRIPTION: SEQ ID NO: 27:
US-09-907-190-27

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 CCTGGGCCAACAGA 1858
              ||||||| ||||||
Db          2 CCTGGGCAAACAGA 15


RESULT 568
US-09-839-583-1/c
; Sequence 1, Application US/09839583
; Publication No. US20020052485A1
; GENERAL INFORMATION:
;  APPLICANT: COLOSI, Peter
;  TITLE OF INVENTION: POLYNUCLEOTIDES FOR USE IN RECOMBINANT ADENO-ASSOCIATED VIRUS
;  TITLE OF INVENTION:  VIRION PRODUCTION
;  FILE REFERENCE: 0800-0023
;  CURRENT APPLICATION NUMBER: US/09/839,583
;  CURRENT FILING DATE:  2001-04-20
;  PRIOR APPLICATION NUMBER: 60/200,453
;  PRIOR FILING DATE: 2000-04-28
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: oligos 1
US-09-839-583-1
```

```
  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2057 ACTAGTTAATAAGT 2070
              |||||||||| |||
Db         18 ACTAGTTAATTAGT 5


RESULT 569
US-09-839-583-2
; Sequence 2, Application US/09839583
; Publication No. US20020052485A1
; GENERAL INFORMATION:
;  APPLICANT: COLOSI, Peter
;  TITLE OF INVENTION: POLYNUCLEOTIDES FOR USE IN RECOMBINANT ADENO-ASSOCIATED VIRUS
;  TITLE OF INVENTION:  VIRION PRODUCTION
;  FILE REFERENCE: 0800-0023
;  CURRENT APPLICATION NUMBER: US/09/839,583
;  CURRENT FILING DATE:  2001-04-20
;  PRIOR APPLICATION NUMBER: 60/200,453
;  PRIOR FILING DATE: 2000-04-28
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: oligo 2
US-09-839-583-2

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2057 ACTAGTTAATAAGT 2070
              |||||||||| |||
Db          5 ACTAGTTAATTAGT 18


RESULT 570
US-09-839-583-6
; Sequence 6, Application US/09839583
; Publication No. US20020052485A1
; GENERAL INFORMATION:
;  APPLICANT: COLOSI, Peter
;  TITLE OF INVENTION: POLYNUCLEOTIDES FOR USE IN RECOMBINANT ADENO-ASSOCIATED VIRUS
;  TITLE OF INVENTION:  VIRION PRODUCTION
;  FILE REFERENCE: 0800-0023
;  CURRENT APPLICATION NUMBER: US/09/839,583
;  CURRENT FILING DATE:  2001-04-20
;  PRIOR APPLICATION NUMBER: 60/200,453
;  PRIOR FILING DATE: 2000-04-28
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: oglio
US-09-839-583-6

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2057 ACTAGTTAATAAGT 2070
              |||||||||| |||
Db          5 ACTAGTTAATTAGT 18


RESULT 571
US-09-970-971A-23/c
; Sequence 23, Application US/09970971A
; Publication No. US20030096979A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Mohan, Venkatraman
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Kawasaki, Andrew M.
;  TITLE OF INVENTION: Oligonucleotides Having  DNA Form and B-DNA Form Conformational Ge
;  FILE REFERENCE: ISIS4789
;  CURRENT APPLICATION NUMBER: US/09/970,971A
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 34
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030096979A1el Sequence
US-09-970-971A-23

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
              |||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 572
US-10-335-059-5
; Sequence 5, Application US/10335059
; Publication No. US20030219725A1
; GENERAL INFORMATION:
;  APPLICANT: Johnston-Dow, Leslie
;  APPLICANT:  Demeter Lisa
;  APPLICANT:  White Camille B.
;  APPLICANT:  Song Keming
;  APPLICANT:  Kohlenberger Robert
;  APPLICANT:  Conrad Morgan
;  APPLICANT:  Myers Angela
;  TITLE OF INVENTION: No. US20030219725A1el Methods for HIV Sequencing and Genotyping
;  FILE REFERENCE: 07414.0005-02000
;  CURRENT APPLICATION NUMBER: US/10/335,059
;  CURRENT FILING DATE:  2002-12-21
;  PRIOR APPLICATION NUMBER: 10/092,022
;  PRIOR FILING DATE: 2002-03-05
;  PRIOR APPLICATION NUMBER: 09/158,695
;  PRIOR FILING DATE: 1998-09-21
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: HIV
US-10-335-059-5

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCAC 1863
              |||||||| |||||
Db          2 GCCAACAGCCCCAC 15


RESULT 573
US-10-271-602B-59/c
; Sequence 59, Application US/10271602B
```

```
; Publication No. US20040002073A1
; GENERAL INFORMATION:
;  APPLICANT: Alice Xiang Li
;  APPLICANT:  Ghazala Hashmi
;  APPLICANT:  Michael Seul
;  TITLE OF INVENTION: MULTIPLEXED ANALYSIS OF POLYMORPHIC LOCI
;  TITLE OF INVENTION:  BY CONCURRENT INTERROGATION AND ENZYME-MEDIATED DETECTION
;  FILE REFERENCE: eMAP-US
;  CURRENT APPLICATION NUMBER: US/10/271,602B
;  CURRENT FILING DATE:  2002-10-15
;  PRIOR APPLICATION NUMBER: 60/329,427
;  PRIOR FILING DATE: 2001-10-14
;  PRIOR APPLICATION NUMBER: 60/329,620
;  PRIOR FILING DATE: 2001-10-15
;  PRIOR APPLICATION NUMBER: 60/329,428
;  PRIOR FILING DATE: 2001-10-14
;  PRIOR APPLICATION NUMBER: 60/329,619
;  PRIOR FILING DATE: 2001-10-15
;  PRIOR APPLICATION NUMBER: 60/364,416
;  PRIOR FILING DATE: 2002-03-14
;  NUMBER OF SEQ ID NOS: 212
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 59
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Probe sequence derived from human genomic sequence
US-10-271-602B-59

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGG 1607
              ||||| ||||||||
Db         18 GGAACTCCTCCTGG 5


RESULT 574
US-10-108-260A-5317/c
; Sequence 5317, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
;  APPLICANT: HELIX RESEARCH INSTITUTE
;  TITLE OF INVENTION: No. US20040005560A1el full length cDNA
;  FILE REFERENCE: H1-A0106
;  CURRENT APPLICATION NUMBER: US/10/108,260A
;  CURRENT FILING DATE:  2002-03-27
;  NUMBER OF SEQ ID NOS: 5458
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5317
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized p
US-10-108-260A-5317

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAG 1688
              || ||||||||||||
Db         14 CCAGGACTTCTTAG 1


RESULT 575
US-10-108-260A-5454/c
; Sequence 5454, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
;  APPLICANT: HELIX RESEARCH INSTITUTE
;  TITLE OF INVENTION: No. US20040005560A1el full length cDNA
;  FILE REFERENCE: H1-A0106
;  CURRENT APPLICATION NUMBER: US/10/108,260A
;  CURRENT FILING DATE:  2002-03-27
;  NUMBER OF SEQ ID NOS: 5458
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5454
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized p
US-10-108-260A-5454

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1798 TTCTCTGAAAGTGG 1811
              |||||| |||||||
Db         14 TTCTCTCAAAGTGG 1


RESULT 576
US-10-349-143-4678
; Sequence 4678, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4678
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-16990 for SEQ 744,
US-10-349-143-4678

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              ||||||| ||||||
Db          5 AAAGGTTTGGAGAG 18


RESULT 577
US-10-349-143-4857
; Sequence 4857, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
```

```
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4857
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-18253 for SEQ 923,
US-10-349-143-4857

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCT 1798
                | ||||||||||||
Db          2 CTCCATTCTTTCCT 15


RESULT 578
US-10-731-739-138/c
; Sequence 138, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/10/731,739
;  CURRENT FILING DATE:  2003-12-10
;  PRIOR APPLICATION NUMBER: US/09/544,398B
;  PRIOR FILING DATE: 2002-06-10
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 138
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-731-739-138

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGA 1616
                ||||||||||| ||
Db         15 CCTGGCCTGGGTGA 2


RESULT 579
US-10-731-739-522/c
; Sequence 522, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/10/731,739
;  CURRENT FILING DATE:  2003-12-10
;  PRIOR APPLICATION NUMBER: US/09/544,398B
;  PRIOR FILING DATE: 2002-06-10
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 522
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-731-739-522

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAA 2038
                ||||||||| |||||
Db         15 TGGTAGGAAGCAAA 2


RESULT 580
US-09-901-484A-407
; Sequence 407, Application US/09901484A
; Patent No. US20020119460A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  APPLICANT:  Bougueleret, Lydie
;  TITLE OF INVENTION: Prostate Cancer Gene
;  FILE REFERENCE: GEN-T111XC3D2
;  CURRENT APPLICATION NUMBER: US/09/901,484A
;  CURRENT FILING DATE:  2001-07-09
;  PRIOR APPLICATION NUMBER: US 08/996,306
;  PRIOR FILING DATE: 1997-12-22
;  PRIOR APPLICATION NUMBER: US 60/099,658
;  PRIOR FILING DATE: 1998-09-09
;  PRIOR APPLICATION NUMBER: US 09/218,207
;  PRIOR FILING DATE: 1998-12-22
;  PRIOR APPLICATION NUMBER: US 09/338,907
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: US 09/853,526
;  PRIOR FILING DATE: 2001-05-11
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 407
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(19)
;   OTHER INFORMATION: downstream amplification primer for SEQ 235, SEQ 312
US-09-901-484A-407

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       2034 GCAAAGGTTCTATC 2047
             ||||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 581
US-09-853-526-407
; Sequence 407, Application US/09853526
; Patent No. US20020165345A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Ilya, Chumakov
;  APPLICANT:  Bougueleret, Lydie
;  TITLE OF INVENTION: PROSTATE CANCER GENE
;  FILE REFERENCE: GENSET.18CP1CP
;  CURRENT APPLICATION NUMBER: US/09/853,526
;  CURRENT FILING DATE:  2001-05-11
;  PRIOR APPLICATION NUMBER: 09/338,907
;  PRIOR FILING DATE: 1999-06-23
;  PRIOR APPLICATION NUMBER: 08/996,306
;  PRIOR FILING DATE: 1997-12-22
;  PRIOR APPLICATION NUMBER: 60/099,658
;  PRIOR FILING DATE: 1998-09-09
;  PRIOR APPLICATION NUMBER: 09/218,207
;  PRIOR FILING DATE: 1998-12-22
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 407
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer for SEQ 235, SEQ 312
US-09-853-526-407

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2034 GCAAAGGTTCTATC 2047
             ||||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 582
US-09-935-464-76/c
; Sequence 76, Application US/09935464
; Publication No. US20030027153A1
; GENERAL INFORMATION:
;  APPLICANT: Meyer, Joanne
;  APPLICANT:  Barrington-Martin, Rory
;  APPLICANT:  Parker, Alexander
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING NEUROPSYCHIA
;  TITLE OF INVENTION:  DISORDERS SUCH AS SCHIZOPHRENIA
;  FILE REFERENCE: 3322/1H702 US1
;  CURRENT APPLICATION NUMBER: US/09/935,464
;  CURRENT FILING DATE:  2001-08-23
;  PRIOR APPLICATION NUMBER: US 09/757,300
;  PRIOR FILING DATE: 2001-01-09
;  NUMBER OF SEQ ID NOS: 90
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 76
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: DNA primer
US-09-935-464-76

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAA 1557
             |||| |||||||||
Db         16 GAGTGGGGAAGGAA 3


RESULT 583
US-09-823-031-4/c
; Sequence 4, Application US/09823031
; Publication No. US20030208061A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Guzaev, Andrei P.
;  TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same And Compounds U
;  TITLE OF INVENTION:  Therefor
;  FILE REFERENCE: ISIS4723
;  CURRENT APPLICATION NUMBER: US/09/823,031
;  CURRENT FILING DATE:  2001-03-30
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
US-09-823-031-4

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
             ||||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 584
US-09-823-031-5/c
; Sequence 5, Application US/09823031
; Publication No. US20030208061A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Guzaev, Andrei P.
;  TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same And Compounds U
;  TITLE OF INVENTION:  Therefor
;  FILE REFERENCE: ISIS4723
;  CURRENT APPLICATION NUMBER: US/09/823,031
;  CURRENT FILING DATE:  2001-03-30
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
US-09-823-031-5

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
             ||||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 585
```

```
US-09-823-031-6/c
; Sequence 6, Application US/09823031
; Publication No. US20030208061A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Guzaev, Andrei P.
;  TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same And Compounds U
;  TITLE OF INVENTION:  Therefor
;  FILE REFERENCE: ISIS4723
;  CURRENT APPLICATION NUMBER: US/09/823,031
;  CURRENT FILING DATE:  2001-03-30
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
US-09-823-031-6

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
             ||||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 586
US-09-823-031-7/c
; Sequence 7, Application US/09823031
; Publication No. US20030208061A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Guzaev, Andrei P.
;  TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same And Compounds U
;  TITLE OF INVENTION:  Therefor
;  FILE REFERENCE: ISIS4723
;  CURRENT APPLICATION NUMBER: US/09/823,031
;  CURRENT FILING DATE:  2001-03-30
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
US-09-823-031-7

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
             ||||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 587
US-09-823-031-9/c
; Sequence 9, Application US/09823031
; Publication No. US20030208061A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Guzaev, Andrei P.
;  TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same And Compounds U
;  TITLE OF INVENTION:  Therefor
;  FILE REFERENCE: ISIS4723
;  CURRENT APPLICATION NUMBER: US/09/823,031
;  CURRENT FILING DATE:  2001-03-30
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
US-09-823-031-9

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
             ||||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 588
US-10-071-179-115/c
; Sequence 115, Application US/10071179
; Publication No. US20030108882A1
; GENERAL INFORMATION:
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: A NUCLEIC ACID ENCODING A RETINOBLASTOMA BINDING PROTEIN (RBP-7)
;  TITLE OF INVENTION:  AND POLYMORPHIC MARKERS ASSOCIATED WITH SAID NUCLEIC ACID.
;  FILE REFERENCE: GENSET.031A
;  CURRENT APPLICATION NUMBER: US/10/071,179
;  CURRENT FILING DATE:  2002-02-07
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/345,882
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-06-30
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/091,315
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-06-30
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/111,909
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-12-10
;  NUMBER OF SEQ ID NOS: 140
;  SOFTWARE: Patent.pm
; SEQ ID NO 115
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: microsequencing oligo for 5-140-348.mis1
US-10-071-179-115

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAA 1980
             || ||||||||||||
Db         15 ATGTTTACCTTGAA 2


RESULT 589
US-10-126-704-115/c
; Sequence 115, Application US/10126704
; Publication No. US20030170647A1
; GENERAL INFORMATION:
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: A NUCLEIC ACID ENCODING A RETINOBLASTOMA BINDING PROTEIN (RBP-7)
;  TITLE OF INVENTION:  AND POLYMORPHIC MARKERS ASSOCIATED WITH SAID NUCLEIC ACID.
;  FILE REFERENCE: 44.US5.DIV
;  CURRENT APPLICATION NUMBER: US/10/126,704
;  CURRENT FILING DATE:  2002-04-20
;  PRIOR APPLICATION NUMBER: US 60/091,315
;  PRIOR FILING DATE: 1998-06-30
```

```
;  PRIOR APPLICATION NUMBER: US 60/111,909
;  PRIOR FILING DATE: 1998-12-10
;  NUMBER OF SEQ ID NOS: 140
;  SOFTWARE: Patent.pm
; SEQ ID NO 115
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: microsequencing oligo for 5-140-348.mis1
US-10-126-704-115

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAA 1980
              || ||||||||||
Db         15 ATGTTTACCTTGAA 2


RESULT 590
US-10-225-023-108
; Sequence 108, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 108
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-225-023-108

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   71.4%;  Pred. No. 4e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTG 1742
              |::|:|||||| |
Db          5 AUUAUCAGAAGGAG 18


RESULT 591
US-10-225-023-210
; Sequence 210, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 210
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target sequence/siNA sense r
US-10-225-023-210

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   71.4%;  Pred. No. 4e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTG 1742
              |::|:|||||| |
Db          6 AUUAUCAGAAGGAG 19


RESULT 592
US-10-225-023-846/c
; Sequence 846, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 846
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-225-023-846

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTG 1742
              ||||||||||||| |
Db         15 ATTATCAGAAGGAG 2


RESULT 593
US-10-225-023-948/c
; Sequence 948, Application US/10225023
; Publication No. US20030175950A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of HIV Gene Expression Using
;  TITLE OF INVENTION:  Interfering RNA
;  FILE REFERENCE: 400/054 (MBHB01-665-B)
;  CURRENT APPLICATION NUMBER: US/10/225,023
;  CURRENT FILING DATE:  2003-01-06
```

```
;  PRIOR APPLICATION NUMBER: US 60/398,036
;  PRIOR FILING DATE: 2002-07-23
;  PRIOR APPLICATION NUMBER: US 60/294,140
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 10/157,580
;  PRIOR FILING DATE: 2002-05-29
;  NUMBER OF SEQ ID NOS: 1494
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 948
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-225-023-948

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTG 1742
              ||||||||||||| |
Db         14 ATTATCAGAAGGAG 1


RESULT 594
US-10-080-979-71/c
; Sequence 71, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:
;  APPLICANT: Cook,  Philip Dan
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Bennett, Frank C.
;  TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
;  FILE REFERENCE: Isis-5028
;  CURRENT APPLICATION NUMBER: US/10/080,979
;  CURRENT FILING DATE:  2002-02-22
;  NUMBER OF SEQ ID NOS: 78
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 71
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(1)
;   OTHER INFORMATION: 2'-O-modified phosphoramidite
US-10-080-979-71

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
              ||||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 595
US-10-349-143-5778
; Sequence 5778, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5778
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-6820 for SEQ 1844,
US-10-349-143-5778

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1948 TGGTTTTTGTGTCC 1961
              |||||||| |||||
Db          2 TGGTTTTTCTGTCC 15


RESULT 596
US-10-349-143-8050
; Sequence 8050, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8050
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-134 for SEQ 185, in complement
US-10-349-143-8050

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2034 GCAAAGGTTCTATC 2047
              |||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 597
US-10-349-143-9088
; Sequence 9088, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
```

```
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9088
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-22096 for SEQ 1223, in complem
US-10-349-143-9088

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTT 1781
              |||||||||| |||
Db          3 AGCTTTTTTTCTTT 16


RESULT 598
US-10-349-143-9761/c
; Sequence 9761, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9761
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-7172 for SEQ 1896, in compleme
US-10-349-143-9761

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGA 1556
              | ||||||||||||
Db         16 AAAGTAGGGAAGGA 3


RESULT 599
US-10-665-951-1165/c
; Sequence 1165, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1165
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-1165

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAA 1784
              |||| |||||||||
Db         17 TTTTCTTTTTTGAA 4


RESULT 600
US-10-665-951-1489
; Sequence 1489, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
```

```
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1489
;   LENGTH: 19
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-1489

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   21.4%;  Pred. No. 4e+02;
  Matches    3;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAA 1784
                  :::: :::::::|||
Db          3 UUUUCUUUUUUGAA 16


RESULT 601
US-09-866-108-2108/c
; Sequence 2108, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2108
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-2108

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACCC 1671
                  ||||||| ||| | |||
Db         17 CTGGTTCAGCAGCGCCC 1


RESULT 602
US-09-866-108-2784/c
; Sequence 2784, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
```

```
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2784
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108-2784

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1804 GAAAGTGGTGCTATAAG 1820
              ||| ||||||||  |||
Db         17 GAAGGTGGTGCTTGAAG 1


RESULT 603
US-09-866-108-7956
; Sequence 7956, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7956
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108-7956

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1893 GTGCCCTAGATCAACAG 1909
              | ||||| || ||||||
Db          1 GCGCCCTTGAGCAACAG 17


RESULT 604
US-09-866-108-7960
; Sequence 7960, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7960
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-09-866-108-7960

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAA 1990
              ||||||  || ||||||
Db          1 CCTTGAGCAACAGAAAA 17


RESULT 605
US-09-866-108-10544/c
; Sequence 10544, Application US/09866108
```

```
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10544
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10544

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCT 1771
              | ||| ||||||| |||
Db         17 TATTTCTTCATTATGCT 1


RESULT 606
US-09-864-785-1544/c
; Sequence 1544, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1544
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-1544

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTGC 1566
              |||||| |||| | |||
Db         17 GGAAGGCACAGCAATGC 1


RESULT 607
US-09-730-289B-49
; Sequence 49, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 49
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-49

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 3.7e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1868 TTAGCCATTGAAATGTC 1884
              : | |||::||||:| |
Db          1 UCAACCAUUGAAAUGCC 17


RESULT 608
US-09-730-289B-366/c
; Sequence 366, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 366
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-366
```

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       2056 AACTAGTTAATAAGTGG 2072
              || |||||||||  |||
Db         17 AATTAGTTAATATTTGG 1
```

RESULT 609
US-09-780-533A-845
; Sequence 845, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-845

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 3.7e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1593 GGGAACCCCTCCTGGCC 1609
              ||| |||||: | ||||
Db          1 GGGGACCCCUGCCGGCC 17
```

RESULT 610
US-09-780-533A-1982/c
; Sequence 1982, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1982
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1982

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1920 CCTTTTTTTTCAGTGTT 1936
              |||||||  |||  ||||
Db         17 CCTTTTTGCTCAATGTT 1
```

RESULT 611
US-09-780-533A-2206/c
; Sequence 2206, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2206
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2206

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1768 AGCTTTTTTTTTTGAA 1784
              ||||| | ||| |||||
Db         17 AGCTTCTGTTTCTTGAA 1
```

RESULT 612
US-09-780-533A-2209/c
; Sequence 2209, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2209
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2209

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1767 AAGCTTTTTTTTTTGA 1783
              ||||||| ||| ||| |
Db         17 AAGCTTTGTTTCTTTAA 1
```

RESULT 613
US-09-927-046-367
; Sequence 367, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:

```
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 367
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-367

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 3.7e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAA 1981
              ||| | ::|||::| ||
Db          1 AAACAGUUACCUUGGAA 17


RESULT 614
US-09-927-046-437/c
; Sequence 437, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 437
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-437

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1908 AGATCAACAATACCTTT 1924
              ||||||| ||||| | |
Db         17 AGATCAAGAATACTTGT 1


RESULT 615
US-09-927-046-532
; Sequence 532, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 532
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-532

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   23.5%;  Pred. No. 3.7e+02;
  Matches    4;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1762 TCATTAAGCTTTTTTTT 1778
              :||:: | | :::::::
Db          1 UCAUUCAUCCUUUUUUU 17


RESULT 616
US-09-927-046-542/c
; Sequence 542, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 542
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-542

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAA 1837
              |||||||| ||||| |
Db         17 TTTTAGAAAATTTTATA 1


RESULT 617
US-09-927-046-851
; Sequence 851, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
```

```
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 851
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-851

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 3.7e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1877 GAAATGTCAAATTGATG 1893
              ||||: :| || :||:|
Db          1 GAAAUAUCCAACUGAUG 17


RESULT 618
US-09-927-046-946/c
; Sequence 946, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 946
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-946

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1949 GGTTTTTGTGTCCGCTA 1965
              ||| ||| ||||| |||
Db         17 GGTGTTTTTGTCCACTA 1


RESULT 619
US-09-927-046-1195
; Sequence 1195, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1195
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1195

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 3.7e+02;
  Matches    7;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1953 TTTGTGTCCGCTAAATA 1969
              ::: :|:| | :|||:|
Db          1 UUUUUGUCAGAUAAAUA 17


RESULT 620
US-09-927-046-1761
; Sequence 1761, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1761
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1761

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTTCTC 1579
              |: |  |||:||::|:|
Db          1 CUCCCCAAAUCCUUCUC 17


RESULT 621
US-09-877-478-605
; Sequence 605, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
```

```
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 605
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-605

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.7e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTGA 1979
              |:|||:|::: || : |
Db          1 CUAAAUAUUUGCCCUUA 17


RESULT 622
US-09-877-478-930
; Sequence 930, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 930
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-930

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGTGT 1996
              ||||||  ||| :|:|:
Db          1 AAAAAAUCAAAAUGUGU 17


RESULT 623
US-09-877-478-1073/c
; Sequence 1073, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1073
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1073

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCC 1600
              ||||||||  ||||  ||
Db         17 GCACAGACGGGGAGTCC 1


RESULT 624
US-09-848-754A-750
; Sequence 750, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 750
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-750

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 3.7e+02;
  Matches    7;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              ||||:: :::||:  :|
Db          1 CCCAUUUUUUCCUAAUC 17


RESULT 625
US-09-848-754A-751
```

```
; Sequence 751, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 751
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-751

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.7e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              |||:: :::||:  :|:
Db          1 CCAUUUUUUCCUAAUCU 17


RESULT 626
US-09-848-754A-752
; Sequence 752, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 752
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-752

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.7e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1788 CATTCTTTCCTTCTCTG 1804
              ||:: :::||:  :|:|
Db          1 CAUUUUUUCCUAAUCUG 17


RESULT 627
US-09-848-754A-2478
; Sequence 2478, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2478
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-2478

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2031 GAGGCAAAGGTTCTATC 2047
              |||||||||   |:|:|
Db          1 GAGGCAAAGUGCCUAUC 17


RESULT 628
US-09-776-474-446/c
; Sequence 446, Application US/09776474
; Publication No. US20030087847A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  Booher, Robert
;  APPLICANT:  Holman, Patricia
;  APPLICANT:  Fattaey, Ali
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK
;  TITLE OF INVENTION:  Enzyme
;  FILE REFERENCE: MBHB00-955-A (400/008)
;  CURRENT APPLICATION NUMBER: US/09/776,474
;  CURRENT FILING DATE:  2001-02-02
;  PRIOR APPLICATION NUMBER: US 60/179,983
;  PRIOR FILING DATE: 2000-03-02
;  NUMBER OF SEQ ID NOS: 2992
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 446
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-776-474-446

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1649 CCTTCACTGGTTCTGCA 1665
              | |  ||||||||||||
Db         17 CATCAACTGGTTCTGCA 1


RESULT 629
US-09-930-423-1236
; Sequence 1236, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1236
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-1236

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1591 CTGGGAACCCCTCCTGG 1607
              |:|||||  | :||:||
Db          1 CUGGGAAGGCAUCCUGG 17
```

```
RESULT 630
US-09-930-423-1601
; Sequence 1601, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1601
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-1601

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTG 1606
              ||:|||||  | :||:|
Db          1 ACUGGGAAGGCAUCCUG 17


RESULT 631
US-09-780-164-502/c
; Sequence 502, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
;  FILE REFERENCE: 400/010
;  CURRENT APPLICATION NUMBER: US/09/780,164
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: 60/185,516
;  PRIOR FILING DATE: 2000-02-28
;  NUMBER OF SEQ ID NOS: 2603
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 502
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-164-502

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAGGT 2041
              ||| || |||||||| |
Db         17 TGGAAGAAGGCAAAGAT 1


RESULT 632
US-09-740-332-1959/c
; Sequence 1959, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1959
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1959

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGGCA 2036
              | |||||| ||| |||
Db         17 TTCTCTGGTTGGACGCA 1


RESULT 633
US-09-740-332-2221/c
; Sequence 2221, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2221
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2221

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2067 AAGTGGTATCTGACACA 2083
              ||| |||| ||| ||||
Db         17 AAGAGGTACCTGCCACA 1


RESULT 634
US-09-745-237A-1236
; Sequence 1236, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1236
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-745-237A-1236
```

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1591 CTGGGAACCCCTCCTGG 1607
              |:|||||  | :||:||
Db          1 CUGGGAAGGCAUCCUGG 17
```

RESULT 635
US-09-745-237A-1601
; Sequence 1601, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1601
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1601

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1590 ACTGGGAACCCCTCCTG 1606
              ||:|||||  | :||:|
Db          1 ACUGGGAAGGCAUCCUG 17
```

RESULT 636
US-09-817-879-1959/c
; Sequence 1959, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1959
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1959

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       2020 TCCTCTGGTAGGAGGCA 2036
              | ||||||| ||| |||
Db         17 TTCTCTGGTTGGACGCA 1
```

RESULT 637
US-09-817-879-2221/c
; Sequence 2221, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2221
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2221

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       2067 AAGTGGTATCTGACACA 2083
              ||| |||| ||| ||||
Db         17 AAGAGGTACCTGCCACA 1
```

RESULT 638
US-10-041-856-21/c
; Sequence 21, Application US/10041856
; Publication No. US20020169299A1
; GENERAL INFORMATION:
; APPLICANT: SLAUGENHAUPT, SUSAN
; APPLICANT: GUSELLA, JAMES F.
; TITLE OF INVENTION: GENE FOR IDENTIFYING INDIVIDUALS WITH FAMILIAL
; TITLE OF INVENTION: DYSAUTONOMIA
; FILE REFERENCE: 1829-4004US1
; CURRENT APPLICATION NUMBER: US/10/041,856
; CURRENT FILING DATE: 2002-07-08
; PRIOR APPLICATION NUMBER: 60/260,080
; PRIOR FILING DATE: 2001-01-06
; NUMBER OF SEQ ID NOS: 88
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Mus sp.
US-10-041-856-21

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.7e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1973 ACCTTGAAAAAAAGAAA 1989
              |||| ||||| || |||
Db         17 ACCTAGAAAACAAAAAA 1
```

RESULT 639
US-10-060-830-282
; Sequence 282, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 282
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-282

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAA 1981
              ||| || |||||| |||
Db          1 AAAGATCTACCTTTAAA 17


RESULT 640
US-10-060-830-816/c
; Sequence 816, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 816
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-816

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              ||||| | ||||| |||
Db         17 CCCATCCCTTCCTGCTC 1


RESULT 641
US-10-060-830-817/c
; Sequence 817, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 817
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-817

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              |||||| | ||||| ||
Db         17 CCCCATCCCTTCCTGCT 1


RESULT 642
US-10-060-756A-1166
; Sequence 1166, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
```

```
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1166
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1166

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAAAAA 1983
              || ||  ||||||||||
Db          1 ATCTTGGCCTTGAAAAA 17


RESULT 643
US-10-060-756A-1167
; Sequence 1167, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1167
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1167

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1968 TATTTACCTTGAAAAAA 1984
              | ||  ||||||||||
Db          1 TCTTGGCCTTGAAAAAA 17


RESULT 644
US-10-190-438-4
; Sequence 4, Application US/10190438
; Publication No. US20030051272A1
; GENERAL INFORMATION:
;  APPLICANT: Regents of the University of California
;  APPLICANT:  Schmidt, Robert J.
;  APPLICANT:  Moose, Stephen P.
;  APPLICANT:  Vicente-Carbajosa, Jesus
;  TITLE OF INVENTION: Transgenic Maize Comprising Recombinant PBF Genes
;  FILE REFERENCE: 1133.015US1
;  CURRENT APPLICATION NUMBER: US/10/190,438
;  CURRENT FILING DATE:  2002-07-03
;  PRIOR APPLICATION NUMBER: PCT/US00/35185
;  PRIOR FILING DATE: 2000-12-22
;  PRIOR APPLICATION NUMBER: US 60/174,403
;  PRIOR FILING DATE: 2000-01-05
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Zea mays
US-10-190-438-4

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1876 TGAAATGTCAAATTGAT 1892
              ||| |||| || |||||
Db          1 TGACATGTAAAGTTGAT 17


RESULT 645
US-10-211-059-119
; Sequence 119, Application US/10211059
; Publication No. US20030100495A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN NAC-1 PROTEIN
;  FILE REFERENCE: PB0149
;  CURRENT APPLICATION NUMBER: US/10/211,059
;  CURRENT FILING DATE:  2002-08-02
;  PRIOR APPLICATION NUMBER: US 60/311,034
;  PRIOR FILING DATE: 2001-08-08
;  NUMBER OF SEQ ID NOS: 322
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 119
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-211-059-119

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCTCC 1604
              ||| |||||||| || |
Db          1 AGATTGGGAACCGCTGC 17


RESULT 646
US-10-060-998-561
; Sequence 561, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 561
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-561
```

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1717 AACTTTGGACCTATTAT 1733
              ||||| ||| ||||| |
Db          1 AACTTAGGATCTATTTT 17


RESULT 647
US-10-060-998-725/c
; Sequence 725, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 725
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-725

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              ||||||| |||| | ||
Db         17 TCACTGGATCTGTAGCA 1


RESULT 648
US-10-156-306-343
; Sequence 343, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 343
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-343

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 3.7e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAA 1985
              |: :|| :: |||||||
Db          1 AUAUACAUUCAAAAAAA 17


RESULT 649
US-10-156-306-456
; Sequence 456, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 456
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-456

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   29.4%;  Pred. No. 3.7e+02;
  Matches    5;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGTG 1934
              :|||:::: ::: | :|
Db          1 UACCUUUUAUUUUAAUG 17


RESULT 650
US-10-156-306-457
; Sequence 457, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 457
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-457

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   23.5%;  Pred. No. 3.7e+02;
  Matches    4;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||:::: ::: | :|::
Db          1 CCUUUUAUUUUAAUGUU 17


RESULT 651
US-10-156-306-5185/c
; Sequence 5185, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5185
;   LENGTH: 17
;   TYPE: RNA
```

```
;   ORGANISM: Homo sapiens
US-10-156-306-5185

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              |||||||||  |||| |
Db         17 CCCATTCTTGACTTCCC 1


RESULT 652
US-10-238-700-349/c
; Sequence 349, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 349
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-349

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAA 1837
              | |||  |||||||| ||
Db         17 TGTTAAAATCTTTTCAA 1


RESULT 653
US-10-238-700-608/c
; Sequence 608, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 608
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-608

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACACTCT 2087
              ||||||||  || | |||
Db         17 GGTATCTGTCAGATTCT 1


RESULT 654
US-10-238-700-670
; Sequence 670, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 670
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-670

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.7e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1761 TTCATTAAGCTTTTTTT 1777
              ::||: ||||::  :::
Db          1 UUCAUGAAGCUUACUUU 17


RESULT 655
US-10-238-700-671
; Sequence 671, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 671
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-671

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   23.5%;  Pred. No. 3.7e+02;
  Matches    4;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTT 1781
              : ||||::  :::::::
Db          1 UGAAGCUUACUUUUUU 17


RESULT 656
US-10-238-700-938
; Sequence 938, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 938
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-938

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1866 ACTTAGCCATTGAAATG 1882
              ||::|| ||:: | |:|
Db          1 ACUUAGGCAUUAACAUG 17


RESULT 657
US-10-238-700-3058/c
; Sequence 3058, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3058
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-3058

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGGGGGA 1616
              |||||||||| | || |
Db         17 CCTCCTGGCCGGCGGTA 1


RESULT 658
US-10-238-700-3359/c
; Sequence 3359, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3359
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-3359

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAACAG 1560
              |||| ||| |||| |||
Db         17 GAGTGGGGCAGGAGCAG 1


RESULT 659
US-10-238-700-3455
; Sequence 3455, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3455
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-3455

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGG 1614
              ||||: |:| || ||||
Db          1 CCCCUUCUGUCCAGGGG 17


RESULT 660
US-10-061-201-953
; Sequence 953, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 953
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-953

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGAGA 1545
              ||||  | |||||||||
Db          1 GAAGGCAAGTTAGGAGA 17


RESULT 661
US-10-061-201-1931
; Sequence 1931, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1931
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-1931

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1593 GGGAACCCCTCCTGGCC 1609
              |||| ||||||||  ||
Db          1 GGGATCCCCTCCTCCCC 17


RESULT 662
US-10-230-006-786/c
; Sequence 786, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Fosnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 786
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-230-006-786

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCAAGT 2020
              |||||||||| ||  ||
Db         17 TTCTTCAGAGGTCCTGT 1


RESULT 663
US-10-342-902-605
; Sequence 605, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 605
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-605

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.7e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTGA 1979
              |:|||:|::: || : |
Db          1 CUAAAUAUUUGCCCUUA 17
```

```
RESULT 664
US-10-342-902-930
; Sequence 930, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 930
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-930

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGTGT 1996
              ||||||  ||| :|:|:
Db          1 AAAAAAUCAAAAUGUGU 17


RESULT 665
US-10-342-902-1073/c
; Sequence 1073, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1073
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-1073

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCC 1600
              ||||||| ||||  ||
Db         17 GCACAGACGGGGAGTCC 1


RESULT 666
US-10-138-674-2521
; Sequence 2521, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2521
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-2521

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGGC 1851
              ||| |||:: ||:|| |
Db          1 AAAGACAUUGCCUGGUC 17


RESULT 667
US-10-138-674-3205/c
; Sequence 3205, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3205
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3205

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
```

```
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCA 1654
              | |||||| |||||| |
Db         17 TTTTTAAATAGCCTTGA 1


RESULT 668
US-10-138-674-3527
; Sequence 3527, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3527
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3527

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTGCC 1897
              : :||||:: |:| |||
Db          1 UUUCAAAUUCAUGAGCC 17


RESULT 669
US-10-138-674-3794
; Sequence 3794, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3794
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3794

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.7e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTT 1775
              :|:: |::|||| :::
Db          1 UAUUUAUUAAGCACUUU 17


RESULT 670
US-10-138-674-3940
; Sequence 3940, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3940
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3940

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.7e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              :| |:||::|:|| : |
Db          1 UCUCUGGUUCUGCUUAA 17


RESULT 671
US-10-138-674-4919
; Sequence 4919, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4919
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-4919

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.7e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | :| : ||::|:|:||
Db          1 ACUCCUGCCUUCUCUGA 17


RESULT 672
US-10-138-674-5300
; Sequence 5300, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
```

```
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5300
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5300

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1642 TAAAGAGCCTTCACTGG 1658
              :|| ||||| :|||: |
Db          1 UAAUGAGCCAUCACUAG 17


RESULT 673
US-10-138-674-6155
; Sequence 6155, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6155
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-6155

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATTATCA 1735
              |:::|| || |: |:||
Db          1 CUUUGGCCCAAUAAUCA 17


RESULT 674
US-10-138-674-6156
; Sequence 6156, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6156
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-6156

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1720 TTTGGACCTATTATCAG 1736
              :::|| || |: |:|||
Db          1 UUUGGCCCAAUAAUCAG 17


RESULT 675
US-10-138-674-6199
; Sequence 6199, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6199
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-6199

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              | ||||| |||| :|:|
Db          1 ACAAAAACAAAACUGUG 17


RESULT 676
US-10-138-674-7325
; Sequence 7325, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7325
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7325

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGTG 1993
```

```
              :|||||||| || || |
Db          1 UGAAAAAAAUAAGAGAG 17


RESULT 677
US-10-138-674-7729/c
; Sequence 7729, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7729
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7729

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1564 TGCAAAAATCCTTCTCC 1580
              ||||||| ||||  |||
Db         17 TGCAAAAGTCCTCATCC 1


RESULT 678
US-10-138-674-7953
; Sequence 7953, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7953
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7953

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTA 1816
              |: :| |||:||: |:|
Db          1 CUAUGGAAGUGGUUCUA 17


RESULT 679
US-10-138-674-8238
; Sequence 8238, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8238
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-8238

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1557 ACAGGACTGCAAAAATC 1573
              ||| || :||||| |:|
Db          1 ACAAGAAUGCAAACAUC 17


RESULT 680
US-10-138-674-8259/c
; Sequence 8259, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8259
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-8259

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACAC 1867
              || ||| || |||||||
Db         17 CCCACACACACACACAC 1


RESULT 681
US-10-138-674-8468
; Sequence 8468, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
```

```
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8468
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-8468

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 3.7e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1721 TTGGACCTATTATCAGA 1737
              ::|| || |: |:|||
Db          1 UUGGCCCAAUAAUCAGA 17


RESULT 682
US-10-287-949A-2521
; Sequence 2521, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2521
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-2521

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGGC 1851
              ||| |||:: ||:|| |
Db          1 AAAGACAUUGCCUGGUC 17


RESULT 683
US-10-287-949A-3205/c
; Sequence 3205, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3205
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3205

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCA 1654
              | |||||| |||||| |
Db         17 TTTTTAAATAGCCTTGA 1


RESULT 684
US-10-287-949A-3527
; Sequence 3527, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3527
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3527

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTGCC 1897
              : :|||:: |:| |||
Db          1 UUUCAAAUUCAUGAGCC 17


RESULT 685
US-10-287-949A-3794
; Sequence 3794, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3794
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3794

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.7e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTT 1775
              :|:: |::|||| :::
Db          1 UAUUUAUUAAGCACUUU 17
```

```
RESULT 686
US-10-287-949A-3940
; Sequence 3940, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3940
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3940

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.7e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              :| |:||::|:|| : |
Db          1 UCUCUGGUUCUGCUUAA 17


RESULT 687
US-10-287-949A-4919
; Sequence 4919, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4919
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-4919

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.7e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | :| : ||::|:|:||
Db          1 ACUCCUGCCUUCUCUGA 17


RESULT 688
US-10-287-949A-5300
; Sequence 5300, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5300
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5300

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1642 TAAAGAGCCTTCACTGG 1658
              :|| ||||| :|||: |
Db          1 UAAUGAGCCAUCACUAG 17


RESULT 689
US-10-287-949A-6155
; Sequence 6155, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6155
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6155

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATTATCA 1735
              |:::|| || |: |:||
Db          1 CUUUGGCCCAAUAAUCA 17


RESULT 690
US-10-287-949A-6156
; Sequence 6156, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6156
```

```
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6156

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1720 TTTGGACCTATTATCAG 1736
              :::|| || |: |:|||
Db          1 UUUGGCCCAAUAAUCAG 17


RESULT 691
US-10-287-949A-6199
; Sequence 6199, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6199
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6199

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              | ||||| |||| :|:|
Db          1 ACAAAAACAAAACUGUG 17


RESULT 692
US-10-287-949A-7325
; Sequence 7325, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7325
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7325

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGTG 1993
              :|||||||| || || |
Db          1 UGAAAAAAAUAAGAGAG 17


RESULT 693
US-10-287-949A-7729/c
; Sequence 7729, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7729
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7729

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1564 TGCAAAAATCCTTCTCC 1580
              ||||||| ||||  |||
Db         17 TGCAAAAGTCCTCATCC 1


RESULT 694
US-10-287-949A-7953
; Sequence 7953, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7953
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7953

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.7e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTA 1816
              |: :| |||:||: |:|
Db          1 CUAUGGAAGUGGUUCUA 17


RESULT 695
US-10-287-949A-8238
; Sequence 8238, Application US/10287949A
; Publication No. US20040102389A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8238
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-8238

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1557 ACAGGACTGCAAAAATC 1573
              ||| || :||||| |:|
Db          1 ACAAGAAUGCAAACAUC 17


RESULT 696
US-10-287-949A-8259/c
; Sequence 8259, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8259
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-8259

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACAC 1867
              || ||| || |||||||
Db         17 CCCACACACACACACAC 1


RESULT 697
US-10-287-949A-8468
; Sequence 8468, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8468
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-8468

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 3.7e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1721 TTGGACCTATTATCAGA 1737
              ::|| || |: |:||||
Db          1 UUGGCCCAAUAAUCAGA 17


RESULT 698
US-10-712-672-755/c
; Sequence 755, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 755
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-755

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1575 TTCTCCACCGCACAGAC 1591
              ||||||   ||||||||
Db         17 TTCTCCCGGGCACAGAC 1


RESULT 699
US-10-712-672-756/c
; Sequence 756, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
```

```
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 756
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-756

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1574 CTTCTCCACCGCACAGA 1590
              |||||||   |||||||
Db         17 CTTCTCCCGGGCACAGA 1

RESULT 700
US-10-712-672-862
; Sequence 862, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 862
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-862

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 3.7e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1743 ACAAGTACTGGCTCTTT 1759
              | ||| || |||:|:::
Db          1 AAAAGAACAGGCUCUUU 17

RESULT 701
US-10-669-841-605
; Sequence 605, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 605
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-605

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.7e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTGA 1979
              |:|||:|::: || : |
Db          1 CUAAAUAUUUGCCCUUA 17

RESULT 702
US-10-669-841-930
; Sequence 930, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
```

```
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 930
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-930

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.7e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGTGT 1996
              ||||||  ||| :|:|:
Db          1 AAAAAAUCAAAAUGUGU 17


RESULT 703
US-10-669-841-1073/c
; Sequence 1073, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1073
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-1073

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCC 1600
              |||||||| ||||  ||
Db         17 GCACAGACGGGGAGTCC 1


RESULT 704
US-10-669-841-4552/c
; Sequence 4552, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4552
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4552

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGGCA 2036
              | |||||||  ||| |||
Db         17 TTCTCTGGTTGGACGCA 1


RESULT 705
US-10-669-841-4814/c
; Sequence 4814, Application US/10669841
; Publication No. US20040127446A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4814
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4814

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2067 AAGTGGTATCTGACACA 2083
              ||| |||| ||| ||||
Db         17 AAGAGGTACCTGCCACA 1


RESULT 706
US-10-723-361-2108/c
; Sequence 2108, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2108
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-2108

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACCC 1671
              ||||||| ||| | |||
Db         17 CTGGTTCAGCAGCGCCC 1


RESULT 707
US-10-723-361-2784/c
; Sequence 2784, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2784
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-2784

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1804 GAAAGTGGTGCTATAAG 1820
                ||| ||||||||  |||
Db         17 GAAGGTGGTGCTTGAAG 1


RESULT 708
US-10-723-361-7956
; Sequence 7956, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7956
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7956

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1893 GTGCCCTAGATCAACAG 1909
                | ||||| || ||||||
Db          1 GCGCCCTTGAGCAACAG 17


RESULT 709
US-10-723-361-7960
; Sequence 7960, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7960
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7960

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAA 1990
                ||||||  || ||||||
Db          1 CCTTGAGCAACAGAAAA 17


RESULT 710
US-10-723-361-10544/c
; Sequence 10544, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
```

```
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10544
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-10544

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCT 1771
              | ||| ||||||| |||
Db         17 TATTTCTTCATTATGCT 1

RESULT 711
US-09-875-338-75
; Sequence 75, Application US/09875338
; Patent No. US20020095024A1
; GENERAL INFORMATION:
;  APPLICANT: MIKESELL, GLEN E.
;  APPLICANT:  CHANG, HAN
;  APPLICANT:  FINGER, JOSHUA N.
;  APPLICANT:  YANG, GUCHEN
;  APPLICANT:  LU, PIN
;  APPLICANT:  ZHOU, XIA-DI
;  APPLICANT:  PEACH, ROBERT
;  TITLE OF INVENTION: B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR
;  TITLE OF INVENTION:  IMMUNOMODULATION
;  FILE REFERENCE: 3053-4071US2
;  CURRENT APPLICATION NUMBER: US/09/875,338
;  CURRENT FILING DATE:  2001-06-06
;  PRIOR APPLICATION NUMBER: 60/272,107
;  PRIOR FILING DATE: 2001-02-28
;  PRIOR APPLICATION NUMBER: 60/209,811
;  PRIOR FILING DATE: 2000-06-06
;  NUMBER OF SEQ ID NOS: 94
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-875-338-75

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1797 CTTCTCTGAAAGTGGTG 1813
              ||| ||||||| || ||
Db          2 CTTATCTGAAATTGCTG 18

RESULT 712
US-09-756-095-10
; Sequence 10, Application US/09756095
; Patent No. US20020115207A1
; GENERAL INFORMATION:
;  APPLICANT: Mitchell, Lloyd G.
;  APPLICANT:  Garcia-Blanco, Mariano A.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
;  TITLE OF INVENTION:  SPLICEOSOME MEDIATED RNA TRANS-SPLICING
;  FILE REFERENCE: A31304-B-A 072874.0134
;  CURRENT APPLICATION NUMBER: US/09/756,095
;  CURRENT FILING DATE:  2001-01-08
;  PRIOR APPLICATION NUMBER: 09/158,863
;  PRIOR FILING DATE: 1998-09-23
;  PRIOR APPLICATION NUMBER: 09/133,717
;  PRIOR FILING DATE: 1998-08-13
;  PRIOR APPLICATION NUMBER: 09/087,233
;  PRIOR FILING DATE: 1998-05-28
;  PRIOR APPLICATION NUMBER: 08/766,354
;  PRIOR FILING DATE: 1996-12-13
;  PRIOR APPLICATION NUMBER: 60/008,317
;  PRIOR FILING DATE: 1995-12-07
;  NUMBER OF SEQ ID NOS: 105
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-09-756-095-10

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| ||||||| ||||
Db          1 TGCTTCACCCGGGCCTG 17

RESULT 713
US-09-969-373-1657
; Sequence 1657, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1657
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-1657

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1937 AAGGTAATGGTTGGTTT 1953
              |||| |||||| | |||
```

```
Db          2 AAGGAAATGGTGGCTTT 18


RESULT 714
US-09-969-373-2266/c
; Sequence 2266, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2266
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-2266

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1612 GGGGAAGAGTTTGTTAC 1628
              || |||||| ||||| |
Db         18 GGTGAAGAGGTTGTTCC 2


RESULT 715
US-09-969-373-3927
; Sequence 3927, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
;  APPLICANT: Effertz, Roger J.
;  APPLICANT:  Hauge, Brian M.
;  TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
;  FILE REFERENCE: 38-10(52679)A
;  CURRENT APPLICATION NUMBER: US/09/969,373
;  CURRENT FILING DATE:  2001-10-02
;  PRIOR APPLICATION NUMBER: US 09/754,853
;  PRIOR FILING DATE: 2001-01-05
;  PRIOR APPLICATION NUMBER: US 09/760,427
;  PRIOR FILING DATE: 2001-01-13
;  PRIOR APPLICATION NUMBER: US 09/855,768
;  PRIOR FILING DATE: 2001-05-15
;  NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3927
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Glycine max
US-09-969-373-3927

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2026 GGTAGGAGGCAAAGGTT 2042
              || ||||| || |||||
Db          1 GGGAGGAGCCATAGGTT 17


RESULT 716
US-09-941-492-10
; Sequence 10, Application US/09941492
; Publication No. US20030027250A1
; GENERAL INFORMATION:
;  APPLICANT: Mitchell, Lloyd
;  APPLICANT:  Garcia-Blanco, Mariano M.
;  APPLICANT:  Puttaraju, Madaiah
;  APPLICANT:  Mansfield, Gary S.
;  TITLE OF INVENTION: METHODS OF COMPOSITIONS FOR USE IN
;  TITLE OF INVENTION:  SPLICEOSOME MEDIATED RNA TRANS-SPLICING
;  FILE REFERENCE: A31304-BAE (072874.0156)
;  CURRENT APPLICATION NUMBER: US/09/941,492
;  CURRENT FILING DATE:  2002-04-01
;  PRIOR APPLICATION NUMBER: 09/838,858
;  PRIOR FILING DATE: 2001-04-20
;  PRIOR APPLICATION NUMBER: 09/756,096
;  PRIOR FILING DATE: 2001-01-08
;  PRIOR APPLICATION NUMBER: 09/158,863
;  PRIOR FILING DATE: 1998-09-23
;  PRIOR APPLICATION NUMBER: 09/133,717
;  PRIOR FILING DATE: 1998-08-13
;  PRIOR APPLICATION NUMBER: 09/087,233
;  PRIOR FILING DATE: 1998-05-28
;  PRIOR APPLICATION NUMBER: 08/766,354
;  PRIOR FILING DATE: 1996-12-13
;  NUMBER OF SEQ ID NOS: 125
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-09-941-492-10

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| |||||||  ||||
Db          1 TGCTTCACCCGGGCCTG 17


RESULT 717
US-09-791-489-32
; Sequence 32, Application US/09791489
; Publication No. US20030041357A1
;   GENERAL INFORMATION:
;        APPLICANT: Jepson, Ian
;                   Thomas, Paul Graham
;                   Thompson, Paul Anthony
;                   Hawkes, Timothy Robert
;                   Knight, Mary Elizabeth
;        TITLE OF INVENTION: Herbicide Resistant Plants
;        NUMBER OF SEQUENCES: 32
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Hale and Dorr LLP
;             STREET: 60 State Street
;             CITY: Boston
;             STATE: Massachusetts
;             COUNTRY: United States
;             ZIP: 02109
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/791,489
;             FILING DATE: 23-Feb-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 09/297,706
;             FILING DATE: 05-MAY-1999
;             APPLICATION NUMBER: WO PCT/GB97/02996
;             FILING DATE: 31-OCT-1997
;             APPLICATION NUMBER: GB 9623248.3
```

```
;             FILING DATE: 07-NOV-1996
;             APPLICATION NUMBER: GB 9625957.7
;             FILING DATE: 13-DEC-1996
;             APPLICATION NUMBER: GB 9703855.8
;             FILING DATE: 25-FEB-1997
;       ATTORNEY/AGENT INFORMATION:
;             NAME: Superko, Colleen
;             REGISTRATION NUMBER: 39,850
;             REFERENCE/DOCKET NUMBER: 109846.255(SYN042CN)
;       TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (617) 526-6000
;             TELEFAX: (617) 526-5000
;   INFORMATION FOR SEQ ID NO: 32:
;       SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: unknown
;       MOLECULE TYPE: other nucleic acid
;             DESCRIPTION: /desc = "primer"
;       HYPOTHETICAL: NO
;       ANTI-SENSE: NO
;       ORIGINAL SOURCE:
;             ORGANISM: primer
;       SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-09-791-489-32

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1932 GTGTTAAGGTAATGGTT 1948
              || | || |||||||||
Db          1 GTCTCAATGTAATGGTT 17


RESULT 718
US-09-756-096A-10
; Sequence 10, Application US/09756096A
; Publication No. US20030077754A1
; GENERAL INFORMATION:
;  APPLICANT: Mitchell, Lloyd G.
;  APPLICANT:  Garcia-Blanco, Mariano A.
;  APPLICANT:  Puttaraju, Madaiah
;  APPLICANT:  Mansfield, Gary S.
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
;  TITLE OF INVENTION:  SPLICEOSOME MEDIATED RNA TRANS-SPLICING
;  FILE REFERENCE: A31304-B-A-B 072874.0135
;  CURRENT APPLICATION NUMBER: US/09/756,096A
;  CURRENT FILING DATE:  2001-01-08
;  PRIOR APPLICATION NUMBER: 09/158,863
;  PRIOR FILING DATE: 1998-09-23
;  PRIOR APPLICATION NUMBER: 09/133,717
;  PRIOR FILING DATE: 1998-08-13
;  PRIOR APPLICATION NUMBER: 09/087,233
;  PRIOR FILING DATE: 1998-05-28
;  PRIOR APPLICATION NUMBER: 08/766,354
;  PRIOR FILING DATE: 1996-12-13
;  PRIOR APPLICATION NUMBER: 60/008,317
;  PRIOR FILING DATE: 1995-12-15
;  NUMBER OF SEQ ID NOS: 105
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-09-756-096A-10

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| |||||||  ||||
Db          1 TGCTTCACCCGGGCCTG 17


RESULT 719
US-09-838-858-10
; Sequence 10, Application US/09838858
; Publication No. US20030148937A1
; GENERAL INFORMATION:
;  APPLICANT: Mansfield, Gary S.
;  APPLICANT:  Mitchell, Lloyd G.
;  APPLICANT:  Garcia-Blanco, Mariano A.
;  APPLICANT:  Walsh, Christopher E.
;  APPLICANT:  Chao, Hengjun
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
;  TITLE OF INVENTION:  SPLICEOSOME MEDIATED RNA TRANS-SPLICING
;  FILE REFERENCE: A31304-BAD 072874.01
;  CURRENT APPLICATION NUMBER: US/09/838,858
;  CURRENT FILING DATE:  2001-04-20
;  PRIOR APPLICATION NUMBER: 09/756,096
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: 09/158,863
;  PRIOR FILING DATE: 1998-09-23
;  PRIOR APPLICATION NUMBER: 09/133,717
;  PRIOR FILING DATE: 1998-08-13
;  PRIOR APPLICATION NUMBER: 09/087,233
;  PRIOR FILING DATE: 1998-05-28
;  PRIOR APPLICATION NUMBER: 08/766,354
;  PRIOR FILING DATE: 1996-12-13
;  PRIOR APPLICATION NUMBER: 60/008,317
;  PRIOR FILING DATE: 1995-12-15
;  NUMBER OF SEQ ID NOS: 113
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapien
US-09-838-858-10

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| |||||||  ||||
Db          1 TGCTTCACCCGGGCCTG 17


RESULT 720
US-09-823-031-17/c
; Sequence 17, Application US/09823031
; Publication No. US20030208061A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  APPLICANT:  Guzaev, Andrei P.
;  TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same And Compounds Us
;  TITLE OF INVENTION:  Therefor
;  FILE REFERENCE: ISIS4723
;  CURRENT APPLICATION NUMBER: US/09/823,031
;  CURRENT FILING DATE:  2001-03-30
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Oligonucleotide
US-09-823-031-17

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2
```

RESULT 721
US-09-823-031-21/c
; Sequence 21, Application US/09823031
; Publication No. US20030208061A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Guzaev, Andrei P.
; TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same And Compounds U
; TITLE OF INVENTION: Therefor
; FILE REFERENCE: ISIS4723
; CURRENT APPLICATION NUMBER: US/09/823,031
; CURRENT FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 21
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Oligonucleotide
US-09-823-031-21

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2
```

RESULT 722
US-10-077-023-75
; Sequence 75, Application US/10077023
; Publication No. US20030031675A1
; GENERAL INFORMATION:
; APPLICANT: MIKESELL, GLEN E.
; APPLICANT: CHANG, HAN
; APPLICANT: FINGER, JOSHUA N.
; APPLICANT: YANG, GUCHEN
; APPLICANT: LU, PIN
; APPLICANT: ZHOU, XIA-DI
; APPLICANT: PEACH, ROBERT
; TITLE OF INVENTION: B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR
; TITLE OF INVENTION: IMMUNOMODULATION
; FILE REFERENCE: 3053-4071US3
; CURRENT APPLICATION NUMBER: US/10/077,023
; CURRENT FILING DATE: 2002-02-15
; PRIOR APPLICATION NUMBER: 60/272,107
; PRIOR FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/209,811
; PRIOR FILING DATE: 2000-06-06
; NUMBER OF SEQ ID NOS: 138
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-077-023-75

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1797 CTTCTCTGAAAGTGGTG 1813
              ||| ||||||| || ||
Db          2 CTTATCTGAAATTGCTG 18
```

RESULT 723
US-10-029-598-22/c
; Sequence 22, Application US/10029598
; Publication No. US20030040497A1
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E.
; APPLICANT: Ecker, David J.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions And Methods For No. US20030040497A1-Parental Deliver
; FILE REFERENCE: ISIS4945
; CURRENT APPLICATION NUMBER: US/10/029,598
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 08/082,624
; PRIOR FILING DATE: 1998-05-21
; PRIOR APPLICATION NUMBER: 09/315,298
; PRIOR FILING DATE: 1999-05-20
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 22
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Sequence
US-10-029-598-22

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2
```

RESULT 724
US-10-085-774-22/c
; Sequence 22, Application US/10085774
; Publication No. US20030082566A1
; GENERAL INFORMATION:
; APPLICANT: Pyrosequencing AB
; TITLE OF INVENTION: Method of determining allele frequencies
; FILE REFERENCE: 14255.01-461290-11
; CURRENT APPLICATION NUMBER: US/10/085,774
; CURRENT FILING DATE: 2002-02-27
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22
; LENGTH: 18
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: ()..()
; OTHER INFORMATION: Primer - PSO 155
US-10-085-774-22

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1602 TCCTGGCCTGGGGGAAG 1618
              | |||||||| ||| ||
Db         18 TTCTGGCCTGTGGGTAG 2
```

```
RESULT 725
US-10-302-554-43
; Sequence 43, Application US/10302554
; Publication No. US20030148467A1
; GENERAL INFORMATION:
;  APPLICANT: West, Robert R.
;  APPLICANT:  Sheppard, Paul O.
;  APPLICANT:  Gao, Zeren
;  TITLE OF INVENTION: INTERLEUKIN-1 HOMOLOG ZIL1A4
;  FILE REFERENCE: 98-59
;  CURRENT APPLICATION NUMBER: US/10/302,554
;  CURRENT FILING DATE:  2002-11-22
;  PRIOR APPLICATION NUMBER: US/09/428,118
;  PRIOR FILING DATE: 1999-10-27
;  PRIOR APPLICATION NUMBER: US 60/105,824
;  PRIOR FILING DATE: 1998-10-27
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 43
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: oligonucleotide primer ZC20,360
US-10-302-554-43

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
                ||  ||||||||||  ||
Db          2 CCCCTCTTTCCTTCACT 18


RESULT 726
US-10-349-143-5792
; Sequence 5792, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5792
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-6951 for SEQ 1858,
US-10-349-143-5792

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACC 1583
                ||| ||| ||| |||||
Db          2 AAACATCATTCACCACC 18


RESULT 727
US-10-349-143-7594/c
; Sequence 7594, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7594
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-9145 for SEQ 3660,
US-10-349-143-7594

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAGG 1555
                ||  ||||||||||  ||
Db         17 TATTAGAGTAGGGATGG 1


RESULT 728
US-10-349-143-9126
; Sequence 9126, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9126
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-22442 for SEQ 1261, in compleme
```

US-10-349-143-9126

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1538 TTAGGAGAGTAGGGAAG 1554
|| |||||| || ||||
Db 2 TTGGGAGAGAAGAGAAG 18

RESULT 729
US-10-261-382-1/c
; Sequence 1, Application US/10261382
; Publication No. US20040063618A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Peptide Nucleic Acids Having Improved Uptake And Tissue
; TITLE OF INVENTION: Distribution
; FILE REFERENCE: ISIS-5078
; CURRENT APPLICATION NUMBER: US/10/261,382
; CURRENT FILING DATE: 2002-12-20
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: 2'-O-Me, P=S backbone
US-10-261-382-1

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1930 CAGTGTTAAGGTAATGG 1946
| | |||||||||||| |
Db 18 CTGGGTTAAGGTAATAG 2

RESULT 730
US-10-261-382-2/c
; Sequence 2, Application US/10261382
; Publication No. US20040063618A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Peptide Nucleic Acids Having Improved Uptake And Tissue
; TITLE OF INVENTION: Distribution
; FILE REFERENCE: ISIS-5078
; CURRENT APPLICATION NUMBER: US/10/261,382
; CURRENT FILING DATE: 2002-12-20
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: 2'-O-MOE, P=S backbone
US-10-261-382-2

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1930 CAGTGTTAAGGTAATGG 1946
| | |||||||||||| |
Db 18 CTGGGTTAAGGTAATAG 2

RESULT 731
US-10-261-382-3/c
; Sequence 3, Application US/10261382
; Publication No. US20040063618A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Peptide Nucleic Acids Having Improved Uptake And Tissue
; TITLE OF INVENTION: Distribution
; FILE REFERENCE: ISIS-5078
; CURRENT APPLICATION NUMBER: US/10/261,382
; CURRENT FILING DATE: 2002-12-20
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: Morpholino backbone
US-10-261-382-3

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1930 CAGTGTTAAGGTAATGG 1946
| | |||||||||||| |
Db 18 CTGGGTTAAGGTAATAG 2

RESULT 732
US-10-261-382-4/c
; Sequence 4, Application US/10261382
; Publication No. US20040063618A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Peptide Nucleic Acids Having Improved Uptake And Tissue
; TITLE OF INVENTION: Distribution
; FILE REFERENCE: ISIS-5078
; CURRENT APPLICATION NUMBER: US/10/261,382
; CURRENT FILING DATE: 2002-12-20
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: PNA backbone
US-10-261-382-4

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 4.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1930 CAGTGTTAAGGTAATGG 1946
| | |||||||||||| |
Db 18 CTGGGTTAAGGTAATAG 2

```
RESULT 733
US-10-261-382-5/c
; Sequence 5, Application US/10261382
; Publication No. US20040063618A1
; GENERAL INFORMATION:
;  APPLICANT: Manoharan, Muthiah
;  TITLE OF INVENTION: Peptide Nucleic Acids Having Improved Uptake And Tissue
;  TITLE OF INVENTION:  Distribution
;  FILE REFERENCE: ISIS-5078
;  CURRENT APPLICATION NUMBER: US/10/261,382
;  CURRENT FILING DATE:  2002-12-20
;  NUMBER OF SEQ ID NOS: 25
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Oligonucleotide
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: PNA backbone
US-10-261-382-5

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 734
US-10-138-674-1461
; Sequence 1461, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1461
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-1461

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   47.1%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | :| : ||::|:|:||
Db          2 ACUCCUGCCUUCUCUGA 18


RESULT 735
US-10-287-949A-1461
; Sequence 1461, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1461
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-1461

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   47.1%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | :| : ||::|:|:||
Db          2 ACUCCUGCCUUCUCUGA 18


RESULT 736
US-10-376-770-99/c
; Sequence 99, Application US/10376770
; Publication No. US20040106102A1
; GENERAL INFORMATION:
;  APPLICANT: Dhallan, Ravinder S.
;  TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME
;  FILE REFERENCE: 543312000320
;  CURRENT APPLICATION NUMBER: US/10/376,770
;  CURRENT FILING DATE:  2003-02-28
;  PRIOR APPLICATION NUMBER: US 10/093,618
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/360,232
;  PRIOR FILING DATE: 2002-03-01
;  PRIOR APPLICATION NUMBER: US 60/378,354
;  PRIOR FILING DATE: 2002-05-08
;  NUMBER OF SEQ ID NOS: 262
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 99
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 5, 6, 7, 8
;   OTHER INFORMATION: These nucleotides may be
;   OTHER INFORMATION: absent
US-10-376-770-99

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1988 AAAGTGTGTATCTAGCT 2004
              ||||||| | ||| |||
Db         17 AAAGTGTTTGTCTGGCT 1


RESULT 737
US-10-630-660-5
; Sequence 5, Application US/10630660
; Publication No. US20040127444A1
; GENERAL INFORMATION:
;  APPLICANT: Spradling, Allan C.
;  APPLICANT:  Stewart, Dianne R.
;  APPLICANT:  Tulin, Alexei V.
;  TITLE OF INVENTION: Poly-(ADP) ribose polymerase enzyme and uses thereof
```

```
;  FILE REFERENCE: 56100-5031-US
;  CURRENT APPLICATION NUMBER: US/10/630,660
;  CURRENT FILING DATE:  2003-07-31
;  PRIOR APPLICATION NUMBER: US 60/399,460
;  PRIOR FILING DATE: 2002-07-31
;  NUMBER OF SEQ ID NOS: 10
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: primer R4 for amplifying PARP-I or PARP-e
US-10-630-660-5

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTC 1792
              |||| |||| || ||||
Db          1 TTTTATGAAACCAATTC 17


RESULT 738
US-10-661-165-99/c
; Sequence 99, Application US/10661165
; Publication No. US20040137470A1
; GENERAL INFORMATION:
;  APPLICANT: Dhallan, Ravinder S.
;  TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC
;  TITLE OF INVENTION:  DISORDERS
;  FILE REFERENCE: 543312000420
;  CURRENT APPLICATION NUMBER: US/10/661,165
;  CURRENT FILING DATE:  2003-09-11
;  PRIOR APPLICATION NUMBER: PCT/US03/06198
;  PRIOR FILING DATE: 2003-02-28
;  PRIOR APPLICATION NUMBER: US 60/378,354
;  PRIOR FILING DATE: 2002-05-08
;  PRIOR APPLICATION NUMBER: US 10/093,618
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/360,232
;  PRIOR FILING DATE: 2002-03-01
;  PRIOR APPLICATION NUMBER: PCT/US03/27308
;  PRIOR FILING DATE: 2003-08-29
;  PRIOR APPLICATION NUMBER: US 10/376,770
;  PRIOR FILING DATE: 2003-02-28
;  NUMBER OF SEQ ID NOS: 628
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 99
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (5)...(8)
;   OTHER INFORMATION: These nucleotides may be absent
US-10-661-165-99

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1988 AAAGTGTGTATCTAGCT 2004
              ||||||| | ||| |||
Db         17 AAAGTGTTTGTCTGGCT 1


RESULT 739
US-10-777-838-22/c
; Sequence 22, Application US/10777838
; Publication No. US20040162259A1
; GENERAL INFORMATION:
;  APPLICANT: Wedel, Mark K.
;  APPLICANT:  Miner, Philip B.
;  TITLE OF INVENTION: Compositions and Methods for Treatment of Pouchitis
;  FILE REFERENCE: ISIC0008-100
;  CURRENT APPLICATION NUMBER: US/10/777,838
;  CURRENT FILING DATE:  2004-02-12
;  PRIOR APPLICATION NUMBER: 60/518,053
;  PRIOR FILING DATE: 2003-11-07
;  PRIOR APPLICATION NUMBER: 60/477,215
;  PRIOR FILING DATE: 2003-02-13
;  NUMBER OF SEQ ID NOS: 53
; SEQ ID NO 22
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-10-777-838-22

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | |||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 740
US-10-735-308-31
; Sequence 31, Application US/10735308
; Publication No. US20040203029A1
; GENERAL INFORMATION:
;  APPLICANT: Snaidr, Jiri
;  APPLICANT:  Beimfohr, Claudia
;  TITLE OF INVENTION: METHOD FOR SPECIFIC FAST DETECTION OF
;  TITLE OF INVENTION:  THREADLIKE BACTERIA
;  FILE REFERENCE: MAIWAM4.004C1
;  CURRENT APPLICATION NUMBER: US/10/735,308
;  CURRENT FILING DATE:  2003-12-11
;  PRIOR APPLICATION NUMBER: PCT/EP02/06467
;  PRIOR FILING DATE: 2002-06-12
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide
US-10-735-308-31

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCCCT 1677
              ||||| ||||  |||||
Db          2 CTGCACCACCGACCCCT 18


RESULT 741
US-10-265-689-15/c
; Sequence 15, Application US/10265689
; Publication No. US20030119775A1
; GENERAL INFORMATION:
;  APPLICANT: SURWIT, RICHARD S.
;  APPLICANT:  COLLINS, SHEILA A.
;  APPLICANT:  WARDEN, CRAIG H.
;  APPLICANT:  SELDIN, MICHAEL F.
;  APPLICANT:  RICQUIER, DANIEL
;  APPLICANT:  BOUILLAUD, FREDERIC
```

```
;  TITLE OF INVENTION: RESPIRATION UNCOUPLING PROTEIN
;  FILE REFERENCE: 1579-376
;  CURRENT APPLICATION NUMBER: US/10/265,689
;  CURRENT FILING DATE:  2002-10-08
;  PRIOR APPLICATION NUMBER: US/09/353,645
;  PRIOR FILING DATE: 1999-07-15
;  PRIOR APPLICATION NUMBER: PCT/US97/06864
;  PRIOR FILING DATE: 1997-04-22
;  PRIOR APPLICATION NUMBER: 60/034,960
;  PRIOR FILING DATE: 1997-01-15
;  NUMBER OF SEQ ID NOS: 47
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide
US-10-265-689-15

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 4.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              || | ||| ||||||||
Db         19 CCCTCCTTCCCTTCTCT 3


RESULT 742
US-08-892-503-1
; Sequence 1, Application US/08892503
; Publication No. US20020042048A1
; GENERAL INFORMATION:
;  APPLICANT:  Drmanac, Radoje
;  TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR DETECTION
;  TITLE OF INVENTION:  OR QUANTIFICATION OF NUCLEIC ACID SPECIES
;  FILE REFERENCE:  9598-0013-999
;  CURRENT APPLICATION NUMBER: US/08/892,503
;  CURRENT FILING DATE:  1997-07-14
;  NUMBER OF SEQ ID NOS:  13
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 1
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Artificially synthesized oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(15)
;   OTHER INFORMATION: n = A,T,C or G
US-08-892-503-1

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db          2 CTTTTTNTTTTTG 14


RESULT 743
US-08-892-503-2/c
; Sequence 2, Application US/08892503
; Publication No. US20020042048A1
; GENERAL INFORMATION:
;  APPLICANT:  Drmanac, Radoje
;  TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR DETECTION
;  TITLE OF INVENTION:  OR QUANTIFICATION OF NUCLEIC ACID SPECIES
;  FILE REFERENCE:  9598-0013-999
;  CURRENT APPLICATION NUMBER: US/08/892,503
;  CURRENT FILING DATE:  1997-07-14
;  NUMBER OF SEQ ID NOS:  13
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 2
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Artificially synthesized oligonucleotide
;   NAME/KEY: misc_feature
;   LOCATION: (1)...(15)
;   OTHER INFORMATION: n = A,T,C or G
US-08-892-503-2

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db         14 CTTTTTNTTTTTG 2


RESULT 744
US-09-805-296D-12/c
; Sequence 12, Application US/09805296D
; Patent No. US20020155989A1
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Pernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Chakhmakhcheau, Oksana
;  APPLICANT:  Buryakova, Alla
;  APPLICANT:  Choob, Mikhail
;  APPLICANT:  Hondorp, Kyle
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USI
;  FILE REFERENCE: AM102.P.1US
;  CURRENT APPLICATION NUMBER: US/09/805,296D
;  CURRENT FILING DATE:  2001-03-13
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: US 60/250,334
;  PRIOR FILING DATE: 2000-11-30
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Synthetic Sequence
US-09-805-296D-12

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAA 1990
              ||||||||||||
Db         15 AAAAAAAGAAAA 4


RESULT 745
US-09-918-995-38044
; Sequence 38044, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc.
;  TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
```

```
;  TITLE OF INVENTION:  FROM VARIOUS cDNA LIBRARIES
;  FILE REFERENCE: 20411-756
;  CURRENT APPLICATION NUMBER: US/09/918,995
;  CURRENT FILING DATE:  2001-07-30
;  PRIOR APPLICATION NUMBER: US/09/235,076
;  PRIOR FILING DATE: 1999-01-20
;  NUMBER OF SEQ ID NOS: 38054
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 38044
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary oligonucleotide primer used in sequence
;   OTHER INFORMATION: assembly process
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (8)...(8)
;   OTHER INFORMATION: n=a, t, c, g or
;   OTHER INFORMATION: 1-(2-deoxy-D-ribfuranosyl)-3-nitropyrrole
US-09-918-995-38044

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db          2 CTTTTTNTTTTTG 14


RESULT 746
US-09-918-995-38045/c
; Sequence 38045, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
;  APPLICANT: Hyseq, Inc.
;  TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
;  TITLE OF INVENTION:  FROM VARIOUS cDNA LIBRARIES
;  FILE REFERENCE: 20411-756
;  CURRENT APPLICATION NUMBER: US/09/918,995
;  CURRENT FILING DATE:  2001-07-30
;  PRIOR APPLICATION NUMBER: US/09/235,076
;  PRIOR FILING DATE: 1999-01-20
;  NUMBER OF SEQ ID NOS: 38054
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 38045
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary oligonucleotide primer used in sequence
;   OTHER INFORMATION: assembly process
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (8)...(8)
;   OTHER INFORMATION: n=a, t, c, g or
;   OTHER INFORMATION: 1-(2-deoxy-D-ribfuranosyl)-3-nitropyrrole
US-09-918-995-38045

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db         14 CTTTTTNTTTTTG 2


RESULT 747
US-10-072-975-12/c
; Sequence 12, Application US/10072975
; Publication No. US20030059789A1
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Fernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Chakhmakhcheau, Oksana
;  APPLICANT:  Buryakova, Alla
;  APPLICANT:  Choob, Mikhail
;  APPLICANT:  Hondorp, Kyle
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF US
;  FILE REFERENCE: AM102.P.1.1US
;  CURRENT APPLICATION NUMBER: US/10/072,975
;  CURRENT FILING DATE:  2002-02-09
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: US 60/250,334
;  PRIOR FILING DATE: 2000-11-30
;  PRIOR APPLICATION NUMBER: 09/805,296
;  PRIOR FILING DATE: 2001-03-13
;  PRIOR APPLICATION NUMBER: PCT/US01/0811
;  PRIOR FILING DATE: 2001-03-13
;  NUMBER OF SEQ ID NOS: 36
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Synthetic Sequence
US-10-072-975-12

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAA 1990
              ||||||||||||
Db         15 AAAAAAAGAAAA 4


RESULT 748
US-10-187-251A-1
; Sequence 1, Application US/10187251A
; Publication No. US20030108897A1
; GENERAL INFORMATION:
;  APPLICANT: Drmanac, Radoje
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DETECTION OR QUANTIFICATION OF NUCLE
;  TITLE OF INVENTION:  ACID SPECIES
;  FILE REFERENCE: 30311/0015A
;  CURRENT APPLICATION NUMBER: US/10/187,251A
;  CURRENT FILING DATE:  2003-02-14
;  PRIOR APPLICATION NUMBER: US 08/947,779
;  PRIOR FILING DATE: 1997-10-09
;  PRIOR APPLICATION NUMBER: US 08/912,885
;  PRIOR FILING DATE: 1997-08-15
;  PRIOR APPLICATION NUMBER: US 08/892,503
;  PRIOR FILING DATE: 1997-07-14
;  PRIOR APPLICATION NUMBER: US 08/812,951
;  PRIOR FILING DATE: 1997-03-04
;  PRIOR APPLICATION NUMBER: US 08/784,787
;  PRIOR FILING DATE: 1997-01-16
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic primer
;   FEATURE:
```

```
;   NAME/KEY: misc_feature
;   LOCATION: (8)
;   OTHER INFORMATION: n = A or T or G or C or M
US-10-187-251A-1

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db          2 CTTTTTNTTTTTG 14


RESULT 749
US-10-051-436-12/c
; Sequence 12, Application US/10051436
; Publication No. US20030138045A1
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Fernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Chakhmakhcheau, Oksana
;  APPLICANT:  Buryakova, Alla
;  APPLICANT:  Choob, Mikhail
;  APPLICANT:  Hondorp, Kyle
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF US
;  FILE REFERENCE: AM102.P.1US
;  CURRENT APPLICATION NUMBER: US/10/051,436
;  CURRENT FILING DATE:  2002-01-18
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  PRIOR APPLICATION NUMBER: US 60/250,334
;  PRIOR FILING DATE: 2000-11-30
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Synthetic Sequence
US-10-051-436-12

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAA 1990
              ||||||||||||
Db         15 AAAAAAAGAAAA 4


RESULT 750
US-10-440-850-112/c
; Sequence 112, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Rever
;  TITLE OF INVENTION:  Immune Responses
;  FILE REFERENCE: 250/130 (MBHB00-900-A)
;  CURRENT APPLICATION NUMBER: US/10/440,850
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: US/09/650,012
;  PRIOR FILING DATE: 2000-08-28
;  PRIOR APPLICATION NUMBER: US 08/585,684
;  PRIOR FILING DATE: 1996-01-12
;  PRIOR APPLICATION NUMBER: US 60/000,951
;  PRIOR FILING DATE: 1995-07-07
;  PRIOR APPLICATION NUMBER: US 09/038,073
;  PRIOR FILING DATE: 1998-03-11
;  NUMBER OF SEQ ID NOS: 2285
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 112
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-440-850-112

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGG 1946
              ||||||||||||
Db         15 TTAAGGTAATGG 4


RESULT 751
US-10-440-850-113/c
; Sequence 113, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Rever
;  TITLE OF INVENTION:  Immune Responses
;  FILE REFERENCE: 250/130 (MBHB00-900-A)
;  CURRENT APPLICATION NUMBER: US/10/440,850
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: US/09/650,012
;  PRIOR FILING DATE: 2000-08-28
;  PRIOR APPLICATION NUMBER: US 08/585,684
;  PRIOR FILING DATE: 1996-01-12
;  PRIOR APPLICATION NUMBER: US 60/000,951
;  PRIOR FILING DATE: 1995-07-07
;  PRIOR APPLICATION NUMBER: US 09/038,073
;  PRIOR FILING DATE: 1998-03-11
;  NUMBER OF SEQ ID NOS: 2285
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 113
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-440-850-113

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGG 1946
              ||||||||||||
Db         14 TTAAGGTAATGG 3


RESULT 752
US-10-360-275-12/c
; Sequence 12, Application US/10360275
; Publication No. US20040014644A1
; GENERAL INFORMATION:
;  APPLICANT: Active Motif
;  APPLICANT:  Efimov, Vladimir
;  APPLICANT:  Fernandez, Joseph
;  APPLICANT:  Archdeacon, Dorothy
;  APPLICANT:  Archdeacon, John
;  APPLICANT:  Choob, Mikhail
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES AND METHODS OF USE FOR MODULATING GENE
```

```
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: AM102.P.1.1.1US
;  CURRENT APPLICATION NUMBER: US/10/360,275
;  CURRENT FILING DATE:  2003-02-07
;  PRIOR APPLICATION NUMBER: US 10/072,975
;  PRIOR FILING DATE: 2002-02-09
;  PRIOR APPLICATION NUMBER: US 09/805,296
;  PRIOR FILING DATE: 2001-03-13
;  PRIOR APPLICATION NUMBER: US 60/189,190
;  PRIOR FILING DATE: 2000-03-14
;  NUMBER OF SEQ ID NOS: 37
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Construct
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Synthetic Sequence
US-10-360-275-12

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAA 1990
              ||||||||||||
Db         15 AAAAAAAGAAAA 4


RESULT 753
US-09-955-410-29/c
; Sequence 29, Application US/09955410
; Patent No. US20020146718A1
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids Having 2,6-Diaminopurine Nucleobases
;  FILE REFERENCE: ISIS4800
;  CURRENT APPLICATION NUMBER: US/09/955,410
;  CURRENT FILING DATE:  2001-09-18
;  PRIOR APPLICATION NUMBER: 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  PRIOR APPLICATION NUMBER: 09/686,114
;  PRIOR FILING DATE: 1996-07-24
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20020146718A1el Sequence
US-09-955-410-29

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 754
US-09-983-210-29/c
; Sequence 29, Application US/09983210
; Patent No. US20020160383A1
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  THE USE OF NUCLEIC ACID ANALOGUES IN
;    TITLE OF INVENTION:  DIAGNOSTICS AND ANALYTICAL PROCEDURES
;    NUMBER OF SEQUENCES:  40
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Wordperfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/983,210
;      FILING DATE:  2001-OCT-23
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/150156
;      FILING DATE:  1994-APR-05
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0986/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0987/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0510/92
;      FILING DATE:  15-APR-1992
;  INFORMATION FOR SEQ ID NO:  29:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    PUBLICATION INFORMATION:
;      DOCUMENT NUMBER:  WO PCT/EP92/01220
;      FILING DATE:  22-MAY-1992
US-09-983-210-29

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 755
US-10-154-890-29/c
; Sequence 29, Application US/10154890
; Publication No. US20030180734A1
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/10/154,890
;  CURRENT FILING DATE:  2002-05-23
;  PRIOR APPLICATION NUMBER: US/08/108,591
;  PRIOR FILING DATE: 2001-08-13
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. US20030180734A1el Sequence
US-10-154-890-29

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
```

```
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 756
US-09-877-478-441
; Sequence 441, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 441
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-441

  Query Match              2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   33.3%;  Pred. No. 4.1e+02;
  Matches    4;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCT 1801
              ::|:::||::|:
Db          5 UUCUUUCCUUCU 16


RESULT 757
US-09-877-478-1165
; Sequence 1165, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1165
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-1165

  Query Match              2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   33.3%;  Pred. No. 4.1e+02;
  Matches    4;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCT 1801
              ::|:::||::|:
Db          6 UUCUUUCCUUCU 17


RESULT 758
US-10-060-756A-1170
; Sequence 1170, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1170
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1170

  Query Match              2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAA 1985
              ||||||||||||
Db          4 CCTTGAAAAAAA 15


RESULT 759
```

```
US-10-060-756A-1171
; Sequence 1171, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1171
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1171

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAA 1985
                ||||||||||||
Db          3 CCTTGAAAAAAA 14


RESULT 760
US-10-060-756A-1172
; Sequence 1172, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1172
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1172

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAA 1985
                ||||||||||||
Db          2 CCTTGAAAAAAA 13


RESULT 761
US-10-060-756A-1173
; Sequence 1173, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
;  FILE REFERENCE: PB0177
;  CURRENT APPLICATION NUMBER: US/10/060,756A
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/327,898
;  PRIOR FILING DATE: 2001-10-09
;  NUMBER OF SEQ ID NOS: 4804
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1173
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-756A-1173

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAA 1985
                ||||||||||||
Db          1 CCTTGAAAAAAA 12


RESULT 762
US-10-156-306-204
; Sequence 204, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 204
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

```
US-10-156-306-204

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAG 1739
              :|::|:||||||
Db          6 UAUUAUCAGAAG 17


RESULT 763
US-10-156-306-205
; Sequence 205, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 205
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-205

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAG 1739
              :|::|:||||||
Db          5 UAUUAUCAGAAG 16


RESULT 764
US-10-156-306-206
; Sequence 206, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 206
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-206

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAG 1739
              :|::|:||||||
Db          3 UAUUAUCAGAAG 14


RESULT 765
US-10-156-306-1429
; Sequence 1429, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1429
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-1429

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAG 1739
              :|::|:||||||
Db          2 UAUUAUCAGAAG 13


RESULT 766
US-10-156-306-3601
; Sequence 3601, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3601
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-3601

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.1e+02;
  Matches    8;  Conservative    4;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAG 1739
              :|::|:||||||
Db          1 UAUUAUCAGAAG 12


RESULT 767
US-10-061-201-954/c
; Sequence 954, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 954
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-954

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1710 ATCTCCTAACTT 1721
             ||||||||||||
Db         17 ATCTCCTAACTT 6


RESULT 768
US-10-061-201-960/c
; Sequence 960, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 960
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-960

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACT 1720
             ||||||||||||
Db         12 TATCTCCTAACT 1


RESULT 769
US-10-230-006-2221/c
; Sequence 2221, Application US/10230006
; Publication No. US20030191077A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Posnaugh, Kathy
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF ASTHMA AND ALLERGIC CONDI
;  FILE REFERENCE: 400/056 (MBHB01-1110)
;  CURRENT APPLICATION NUMBER: US/10/230,006
;  CURRENT FILING DATE:  2002-11-18
;  PRIOR APPLICATION NUMBER: US 60/315,315
;  PRIOR FILING DATE: 2001-08-28
;  NUMBER OF SEQ ID NOS: 2678
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2221
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-230-006-2221

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAG 2013
             ||||||||||||
Db         13 GCTTCTTCAGAG 2


RESULT 770
US-10-342-902-441
; Sequence 441, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 441
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-441

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   33.3%;  Pred. No. 4.1e+02;
  Matches    4;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1790 TTCTTTCCTTCT 1801
              ::|:::||::|:
Db          5 UUCUUUCCUUCU 16


RESULT 771
US-10-342-902-1165
; Sequence 1165, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1165
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-1165

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   33.3%;  Pred. No. 4.1e+02;
  Matches    4;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCT 1801
              ::|:::||::|:
Db          6 UUCUUUCCUUCU 17


RESULT 772
US-10-676-154-510
; Sequence 510, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/10/676,154
;  CURRENT FILING DATE:  2003-09-29
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 510
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-10-676-154-510

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAA 1854
              ||||||||||||
Db          1 TCCCTGGGCCAA 12


RESULT 773
US-10-669-841-441
; Sequence 441, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 441
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-441

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   33.3%;  Pred. No. 4.1e+02;
  Matches    4;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCT 1801
              ::|:::||::|:
Db          5 UUCUUUCCUUCU 16


RESULT 774
US-10-669-841-1165
; Sequence 1165, Application US/10669841
; Publication No. US20040127446A1
```

```
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1165
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-1165

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   33.3%;  Pred. No. 4.1e+02;
  Matches    4;  Conservative    8;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCT 1801
              ::|:::||::|:
Db          6 UUCUUUCCUUCU 17


RESULT 775
US-10-468-199-64/c
; Sequence 64, Application US/10468199
; Publication No. US20040096942A1
; GENERAL INFORMATION:
;  APPLICANT: Palli, Subba R.
;  APPLICANT:  Kapitskaya, Marianna Z.
;  TITLE OF INVENTION: Chimeric retinoid X receptors and their use in a novel ecdysone
;  TITLE OF INVENTION:  receptor-based inducible gene expression system
;  FILE REFERENCE: A01238-US
;  CURRENT APPLICATION NUMBER: US/10/468,199
;  CURRENT FILING DATE:  2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/294,819
;  PRIOR FILING DATE: 2001-05-31
;  PRIOR APPLICATION NUMBER: PCT/US02/05706
;  PRIOR FILING DATE: 2002-02-20
;  NUMBER OF SEQ ID NOS: 75
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 64
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Locusta migratoria
US-10-468-199-64

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1732 ATCAGAAGGTGA 1743
              ||||||||||||
Db         12 ATCAGAAGGTGA 1


RESULT 776
US-10-786-720-358/c
; Sequence 358, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 358
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-786-720-358

  Query Match             2.1%;  Score 12;  DB 1;  Length 21;
  Best Local Similarity   75.0%;  Pred. No. 5.5e+02;
  Matches   15;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATGTCAA 1886
              |||| |||||  |||| | |
Db         20 CTTATCCATTTCAATGGCTA 1


RESULT 777
US-09-263-959-69/c
; Sequence 69, Application US/09263959
; Patent No. US20020150891A1
;  GENERAL INFORMATION:
;    APPLICANT:  Hood, Leroy E.
;    APPLICANT:  Rowen, Lee
;    APPLICANT:  Koop, Ben F.
;    TITLE OF INVENTION:  DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
;    NUMBER OF SEQUENCES:  1279
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Seed and Berry LLP
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  US
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/263,959
;      FILING DATE:  05-MAR-1999
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  920010.426C2
```

```
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  69:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-263-959-69

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1651 TTCACTGGTTCTGCA 1665
              ||||||||  |||||
Db         15 TTCACTGGACCTGCA 1

RESULT 778
US-09-971-843-28
; Sequence 28, Application US/09971843
; Publication No. US20030013162A1
; GENERAL INFORMATION:
;  APPLICANT: Conklin, Darrell C.
;  APPLICANT:  Grant, Francis J.
;  APPLICANT:  Rixon, Mark W.
;  APPLICANT:  Kindsvogel, Wayne
;  TITLE OF INVENTION: Interferon-epsilon
;  FILE REFERENCE: 98-46D1
;  CURRENT APPLICATION NUMBER: US/09/971,843
;  CURRENT FILING DATE:  2001-10-04
;  PRIOR APPLICATION NUMBER: 60/101,012
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/118,578
;  PRIOR FILING DATE: 1999-02-05
;  PRIOR APPLICATION NUMBER: 60/142,766
;  PRIOR FILING DATE: 1999-07-08
;  PRIOR APPLICATION NUMBER: 09/397,992
;  PRIOR FILING DATE: 1999-09-16
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 28
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Mutated coding sequence.
US-09-971-843-28

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1857 GACCCACACACTTAG 1871
              ||||||  || |||||
Db          1 GACCCAGACCCTTAG 15

RESULT 779
US-09-848-754A-9106/c
; Sequence 9106, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9106
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Enzymatic Nucleic acid
US-09-848-754A-9106

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| |||||||| ||
Db         15 TCACCAATACCTATT 1

RESULT 780
US-09-927-811A-4/c
; Sequence 4, Application US/09927811A
; Publication No. US20040086998A1
; GENERAL INFORMATION:
;  APPLICANT: RheinBiotech Gesellschaft fur neue biotechnologische Prozesse und
;  APPLICANT:  Produkte mbH
;  APPLICANT:  Romano, Ivano
;  APPLICANT:  Gellissen, Gerd
;  APPLICANT:  DeVergilio, Claudio
;  TITLE OF INVENTION: Heat-Inducible Promoter
;  FILE REFERENCE: PCT1106-01966
;  CURRENT APPLICATION NUMBER: US/09/927,811A
;  CURRENT FILING DATE:  2002-02-22
;  PRIOR APPLICATION NUMBER: PCT/EP00/01144
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Nucleic acid sequence of a heat shock element
US-09-927-811A-4

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1640 TTTAAAGAGCCTTCA 1654
              ||| ||||| |||||
Db         15 TTTCAAGAGGCTTCA 1

RESULT 781
US-10-287-919-1164/c
; Sequence 1164, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 1164
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (513204)...(513219)
;   OTHER INFORMATION: Chromosome = 1  Strand = positive  ConnectronObjectNumber =  1419
US-10-287-919-1164
```

```
  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1996 TATCTAGCTTCTTCA 2010
              | | ||||||||||||
Db         15 TTTTTAGCTTCTTCA 1


RESULT 782
US-10-287-919-1165
; Sequence 1165, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 1165
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (513204)...(513219)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =  1418
US-10-287-919-1165

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1996 TATCTAGCTTCTTCA 2010
              | | ||||||||||||
Db          1 TTTTTAGCTTCTTCA 15


RESULT 783
US-10-287-919-2029
; Sequence 2029, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 2029
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (1232468)...(1232481)
;   OTHER INFORMATION: Chromosome = 1  Strand = positive  ConnectronObjectNumber =  2594
US-10-287-919-2029

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1996 TATCTAGCTTCTTCA 2010
              | | ||||||||||||
Db          1 TTTTTAGCTTCTTCA 15


RESULT 784
US-10-287-919-2625/c
; Sequence 2625, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 2625
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (1597536)...(1597550)
;   OTHER INFORMATION: Chromosome = 1  Strand = positive  ConnectronObjectNumber =  3348
US-10-287-919-2625

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1996 TATCTAGCTTCTTCA 2010
              | | ||||||||||||
Db         15 TTTTTAGCTTCTTCA 1


RESULT 785
US-10-287-919-2699
; Sequence 2699, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 2699
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (1653351)...(1653365)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =  3450
US-10-287-919-2699

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTG 1993
              |||||| ||||| ||
Db          1 AAAAAATGAAAACTG 15


RESULT 786
US-10-091-281-97/c
; Sequence 97, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
;  APPLICANT: RAYMOND, VINCENT
;  APPLICANT:  SI, ERWIN
;  APPLICANT:  MORISETTE, JEAN
;  TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
;  FILE REFERENCE: 13587.338
;  CURRENT APPLICATION NUMBER: US/10/091,281
;  CURRENT FILING DATE:  2002-03-06
;  NUMBER OF SEQ ID NOS: 463
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 97
;   LENGTH: 15
;   TYPE: DNA
```

```
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Putative 1RFF/ISRE.01 motif
US-10-091-281-97

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              | ||||||||| ||||
Db         15 TACTTTCCTTTTCTG 1


RESULT 787
US-10-440-850-307
; Sequence 307, Application US/10440850
; Publication No. US20030207837A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Jarvis, Thale
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Induction of Graft Tolerance and Rever
;  TITLE OF INVENTION:  Immune Responses
;  FILE REFERENCE: 250/130 (MBHB00-900-A)
;  CURRENT APPLICATION NUMBER: US/10/440,850
;  CURRENT FILING DATE:  2003-05-19
;  PRIOR APPLICATION NUMBER: US/09/650,012
;  PRIOR FILING DATE: 2000-08-28
;  PRIOR APPLICATION NUMBER: US 08/585,684
;  PRIOR FILING DATE: 1996-01-12
;  PRIOR APPLICATION NUMBER: US 60/000,951
;  PRIOR FILING DATE: 1995-07-07
;  PRIOR APPLICATION NUMBER: US 09/038,073
;  PRIOR FILING DATE: 1998-03-11
;  NUMBER OF SEQ ID NOS: 2285
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 307
;   LENGTH: 15
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-440-850-307

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.7e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 788
US-10-719-995-16/c
; Sequence 16, Application US/10719995
; Publication No. US20040161782A1
; GENERAL INFORMATION:
;  APPLICANT: Plasterk, Ronald
;  APPLICANT:  Tijsterman, Marcel
;  TITLE OF INVENTION: MEANS AND METHODS FOR IDENTIFYING GENES AND PROTEINS INVOLVED IN
;  TITLE OF INVENTION:  THE PREVENTION AND/OR REPAIR OF A REPLICATION ERROR
;  FILE REFERENCE: 2183-6201US
;  CURRENT APPLICATION NUMBER: US/10/719,995
;  CURRENT FILING DATE:  2003-11-21
;  PRIOR APPLICATION NUMBER: EP 01201936.0
;  PRIOR FILING DATE: 2001-05-22
;  PRIOR APPLICATION NUMBER: PCT/NL02/00322
;  PRIOR FILING DATE: 2002-05-22
;  NUMBER OF SEQ ID NOS: 30
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Caenorhabditis elegans
US-10-719-995-16

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTGAA 1784
              ||| ||||||| |||
Db         15 CTTCTTTTTTGGAA 1


RESULT 789
US-09-791-190A-9
; Sequence 9, Application US/09791190A
; Publication No. US20030104372A1
; GENERAL INFORMATION:
;  APPLICANT: Pyrosequencing AB
;  APPLICANT:  Ahmadian, Afshin
;  APPLICANT:  Lundeberg, Joakim
;  APPLICANT:  Nyren, Pal
;  TITLE OF INVENTION: Allele Specific Primer Extension Assay
;  FILE REFERENCE: Docket 14259
;  CURRENT APPLICATION NUMBER: US/09/791,190A
;  CURRENT FILING DATE:  2002-09-25
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: Primer
US-09-791-190A-9

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1760 ATTCATTAAGCTTTT 1774
              |||  ||||||||||
Db          2 ATTTGTTAAGCTTTT 16


RESULT 790
US-09-828-455-37
; Sequence 37, Application US/09828455
; Publication No. US20030104621A1
;   GENERAL INFORMATION:
;        APPLICANT: TAMAOKI, TAIKI
;                   NAKABAYASHI, HIDEKAZU
;        TITLE OF INVENTION: IMPROVED METHOD OF EXPRESSING GENES IN
;                            MAMMALIAN CELLS
;        NUMBER OF SEQUENCES: 46
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
;             STREET: 699 PRINCE STREET
;             CITY: ALEXANDRIA
;             STATE: VA
;             COUNTRY: USA
;             ZIP: 22313-1404
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/828,455
;             FILING DATE: 09-Apr-2001
;             CLASSIFICATION: 435
```

```
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/08/645,215
;            FILING DATE: 13-MAY-1996
;            APPLICATION NUMBER: US 08/148,058
;            FILING DATE: 04-NOV-1993
;       ATTORNEY/AGENT INFORMATION:
;            NAME: MOOI, LESLIE A.
;            REGISTRATION NUMBER: 37,047
;            REFERENCE/DOCKET NUMBER: 028722-135
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 415-854-7400
;            TELEFAX: 415-854-8275
;   INFORMATION FOR SEQ ID NO: 37:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 37:
US-09-828-455-37

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
                || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 791
US-10-287-919-600/c
; Sequence 600, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 600
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (179913)...(179928)
;   OTHER INFORMATION: Chromosome = 1  Strand = positive  ConnectronObjectNumber =   715
US-10-287-919-600

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTG 1782
                | ||||| |||||||
Db         15 ATCTTTTGTTTTTTG 1


RESULT 792
US-10-287-919-777/c
; Sequence 777, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 777
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (279397)...(279412)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =   950
US-10-287-919-777

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1764 ATTAAGCTTTTTTTT 1778
                ||| ||||||| |||
Db         15 ATTTAGCTTTTATTT 1


RESULT 793
US-10-287-919-796/c
; Sequence 796, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 796
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (315314)...(315328)
;   OTHER INFORMATION: Chromosome = 1  Strand = positive  ConnectronObjectNumber =   981
US-10-287-919-796

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTG 1782
                | ||||| |||||||
Db         15 ATCTTTTGTTTTTTG 1


RESULT 794
US-10-287-919-2205/c
; Sequence 2205, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 2205
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (1362748)...(1362763)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =  2819
US-10-287-919-2205

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1764 ATTAAGCTTTTTTTT 1778
```

```
              ||| ||||||| |||
Db         15 ATTTAGCTTTTATTT 1


RESULT 795
US-10-108-164-68/c
; Sequence 68, Application US/10108164
; Publication No. US20030104356A1
; GENERAL INFORMATION:
;  APPLICANT: Berger, Shelley L.
;  APPLICANT:  Fraser, Nigel W.
;  APPLICANT:  Tal-Singer, Ruth
;  APPLICANT:  Leary, Jeffrey J.
;  TITLE OF INVENTION: Compounds And Methods For Treating And
;  TITLE OF INVENTION:  Screening Viral Reactivation
;  FILE REFERENCE: P50682C1
;  CURRENT APPLICATION NUMBER: US/10/108,164
;  CURRENT FILING DATE:  2002-03-26
;  PRIOR APPLICATION NUMBER: 09/424,348
;  PRIOR FILING DATE: 1999-07-01
;  PRIOR APPLICATION NUMBER: PCT/US98/13733
;  PRIOR FILING DATE: 1998-07-01
;  PRIOR APPLICATION NUMBER: 60/051,633
;  PRIOR FILING DATE: 1997-07-03
;  PRIOR APPLICATION NUMBER: 60/054,515
;  PRIOR FILING DATE: 1997-08-01
;  PRIOR APPLICATION NUMBER: 60/080,352
;  PRIOR FILING DATE: 1998-04-01
;  NUMBER OF SEQ ID NOS: 145
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 68
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Herpes simplex virus
US-10-108-164-68

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1984 AAGAAAAGTGTGTAT 1998
              ||||||||||  |||
Db         16 AAGAAAAGTGATTAT 2


RESULT 796
US-10-255-120-462
; Sequence 462, Application US/10255120
; Publication No. US20040091865A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Helicobacter pylori, strain J99 complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/255,120
;  CURRENT FILING DATE:  2002-11-19
;  NUMBER OF SEQ ID NOS: 903
;  SOFTWARE: Proprietary
; SEQ ID NO 462
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Helicobacter pylori, strain J99 complete genome.
;   FEATURE:
;   LOCATION: (801758)...(801773)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =   693
US-10-255-120-462

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1973 ACCTTGAAAAAAAGA 1987
              ||| | |||||||||
Db          2 ACCCTTAAAAAAAGA 16


RESULT 797
US-09-866-108-1344/c
; Sequence 1344, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1344
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1344

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCT 1801
              ||||  |||||||||
Db         17 CCATCTTTTCCTTCT 3


RESULT 798
US-09-866-108-1348/c
; Sequence 1348, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
```

```
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1348
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1348

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTT 1799
              ||||||  |||||||
Db         15 CCCCATCTTTTCCTT 1


RESULT 799
US-09-866-108-1579/c
; Sequence 1579, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1579
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1579

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1572 TCCTTCTCCACCGCA 1586
              ||||||||||  |||
Db         17 TCCTTCTCCAGAGCA 3


RESULT 800
US-09-866-108-1582/c
; Sequence 1582, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1582
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1582

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGC 1585
              ||||||||||  ||
Db         15 ATCCTTCTCCAGAGC 1


RESULT 801
US-09-866-108-1700
; Sequence 1700, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1700
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-1700

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
              ||||| |||||| ||
Db          3 TGGTATGAGGCAGAG 17


RESULT 802
US-09-866-108-1701
; Sequence 1701, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
```

; SEQ ID NO 1701
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1701

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2025 TGGTAGGAGGCAAAG 2039
||||| |||||| ||
Db 2 TGGTATGAGGCAGAG 16

RESULT 803
US-09-866-108-1702
; Sequence 1702, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1702
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1702

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2025 TGGTAGGAGGCAAAG 2039
||||| |||||| ||
Db 1 TGGTATGAGGCAGAG 15

RESULT 804
US-09-866-108-7645/c
; Sequence 7645, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7645
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-7645

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1684 CTTAGTTGTTTCTCT 1698
||| |||| ||||||
Db 15 CTTTGTTGGTTCTCT 1

RESULT 805
US-09-866-108-7959
; Sequence 7959, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:

```
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7959
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-7959

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
                ||||  ||  |||||||
Db          1 CCCTTGAGCAACAGA 15


RESULT 806
US-09-866-108-8582/c
; Sequence 8582, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8582
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8582

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
                || ||||||||||  |
Db         17 TGCTTCTGCATCAGC 3


RESULT 807
US-09-866-108-8583/c
; Sequence 8583, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8583
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8583

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         16 TGCTTCTGCATCAGC 2


RESULT 808
US-09-866-108-8584/c
; Sequence 8584, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8584
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-8584

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         15 TGCTTCTGCATCAGC 1


RESULT 809
US-09-866-108-10542/c
; Sequence 10542, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
```

```
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10542
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10542

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
              ||| ||||||| |||
Db         17 TTTCTTCATTATGCT 3


RESULT 810
US-09-866-108-10543/c
; Sequence 10543, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 60/266,860
;  PRIOR FILING DATE: 2001-02-05
;  NUMBER OF SEQ ID NOS: 15752
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10543
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108-10543

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
              ||| ||||||| |||
Db         16 TTTCTTCATTATGCT 2


RESULT 811
US-09-827-998-310
; Sequence 310, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 310
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-310

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGG 1561
              ||||||||||| | |
Db          3 TAGGGAAGGAAGAAG 17


RESULT 812
US-09-827-998-313
; Sequence 313, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 313
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-313

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              |||||||||| | ||
Db          1 AGGGAAGGAAGAAGA 15


RESULT 813
```

```
US-09-864-785-7/c
; Sequence 7, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-7

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1611 GGGGGAAGAGTTTGT 1625
             ||||||| |||| ||
Db         17 GGGGGAACAGTTCGT 3


RESULT 814
US-09-864-785-1429/c
; Sequence 1429, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1429
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-1429

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1611 GGGGGAAGAGTTTGT 1625
             ||||||| |||| ||
Db         16 GGGGGAACAGTTCGT 2


RESULT 815
US-09-864-785-2972/c
; Sequence 2972, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2972
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-2972

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1627 ACCTACCTTACTATT 1641
             || |||| |||||||
Db         16 ACTTACCCTACTATT 2


RESULT 816
US-09-864-785-2973/c
; Sequence 2973, Application US/09864785
; Patent No. US20020177568A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Draper, Ken
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of NF-Kappa B
;  FILE REFERENCE: 400/022 (MBHB00-812-D)
;  CURRENT APPLICATION NUMBER: US/09/864,785
;  CURRENT FILING DATE:  2001-05-23
;  NUMBER OF SEQ ID NOS: 3929
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2973
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
US-09-864-785-2973

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1627 ACCTACCTTACTATT 1641
             || |||| |||||||
Db         15 ACTTACCCTACTATT 1


RESULT 817
US-09-730-289B-246
; Sequence 246, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 246
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-246

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   40.0%;  Pred. No. 4.5e+02;
  Matches    6;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAAA 1837
              ::|  |:|::::|||
Db          2 UUAACAUCUUUUAAA 16


RESULT 818
US-09-730-289B-613
; Sequence 613, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 613
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-613

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   53.3%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAAA 1837
              : ||||:|:: :|||
Db          1 UCAGAAUCUUCUAAA 15


RESULT 819
US-09-730-289B-646/c
; Sequence 646, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 646
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-646

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2061 GTTAATAAGTGGTAT 2075
              |||| |||||| |||
Db         16 GTTAGTAAGTGATAT 2


RESULT 820
US-09-730-289B-721
; Sequence 721, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 721
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-721

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1631 ACCTTACTATTTAAA 1645
              |||::||:|  :|||
Db          2 ACCUUACUACAUAAA 16


RESULT 821
US-09-730-289B-741
; Sequence 741, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
;  FILE REFERENCE: MBHB00-864-A (400/006)
;  CURRENT APPLICATION NUMBER: US/09/730,289B
;  CURRENT FILING DATE:  2000-12-05
;  PRIOR APPLICATION NUMBER: US 60/169,100
;  PRIOR FILING DATE: 1999-12-06
;  NUMBER OF SEQ ID NOS: 3897
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 741
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-730-289B-741

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.5e+02;
  Matches   10;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTC 1884
              | |||::||||:| |
Db          2 AACCAUUGAAAUGCC 16


RESULT 822
US-09-780-533A-1225/c
; Sequence 1225, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1225
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1225

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              ||||||| ||| |||
Db         15 AAGCTTTGTTTCTTT 1


RESULT 823
US-09-780-533A-1250/c
; Sequence 1250, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1250
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1250

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              |||||||| | ||||
Db         17 ACTGGTTCAGAATCA 3


RESULT 824
US-09-780-533A-1416
; Sequence 1416, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1416
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1416

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1838 TACATTCCCTGGGCC 1852
              :|||:: ||: ||||  .
Db          1 UACAUUGCCUUGGCC 15


RESULT 825
US-09-780-533A-1680/c
; Sequence 1680, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1680
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1680

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              |||||||| | ||||
Db         16 ACTGGTTCAGAATCA 2


RESULT 826
US-09-780-533A-1734
; Sequence 1734, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1734
;   LENGTH: 17
```

```
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1734

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1838 TACATTCCCTGGGCC 1852
              :|||:: ||: ||||
Db          3 UACAUUGCCUUGGCC 17


RESULT 827
US-09-780-533A-1761/c
; Sequence 1761, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1761
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1761

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTT 1773
              | |||||| ||||||
Db         17 TTTTCATTCAGCTTT 3


RESULT 828
US-09-780-533A-1865/c
; Sequence 1865, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1865
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-1865

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              || || |||||||||
Db         15 TTTTTGCCTTCTCTG 1


RESULT 829
US-09-780-533A-2309/c
; Sequence 2309, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2309
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2309

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTT 1773
              | |||||| ||||||
Db         15 TTTTCATTCAGCTTT 1


RESULT 830
US-09-780-533A-2444/c
; Sequence 2444, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2444
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2444

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAA 1807
              || |||||||||| |
Db         16 TTGCCTTCTCTGAGA 2


RESULT 831
```

```
US-09-780-533A-2486/c
; Sequence 2486, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2486
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2486

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1626 TACCTACCTTACTAT 1640
              || || |||||||||
Db         16 TATCTTCCTTACTAT 2


RESULT 832
US-09-780-533A-2487/c
; Sequence 2487, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  Haeberli, Pete
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
;  FILE REFERENCE: MBHB00,878-A (400/011)
;  CURRENT APPLICATION NUMBER: US/09/780,533A
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: US 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 6679
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2487
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-533A-2487

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1626 TACCTACCTTACTAT 1640
              || || |||||||||
Db         15 TATCTTCCTTACTAT 1


RESULT 833
US-09-927-046-351
; Sequence 351, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 351
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-351

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.5e+02;
  Matches   10;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2016 CAAGTCCTCTGGTAG 2030
              | || ||:|:||:||
Db          1 CCAGCCCUCUGGUAG 15


RESULT 834
US-09-927-046-438/c
; Sequence 438, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 438
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-438

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1908 AGATCAACAATACCT 1922
              ||||||| ||||| |
Db         16 AGATCAAGAATACTT 2


RESULT 835
US-09-927-046-543/c
; Sequence 543, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
```

```
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 543
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-543

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTA 1835
              ||||||||  |||||
Db         16 TTTTAGAAAATTTTA 2


RESULT 836
US-09-927-046-544/c
; Sequence 544, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 544
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-544

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTA 1835
              ||||||||  |||||
Db         15 TTTTAGAAAATTTTA 1


RESULT 837
US-09-927-046-1003
; Sequence 1003, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1003
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1003

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.5e+02;
  Matches   10;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2016 CAAGTCCTCTGGTAG 2030
              | || ||:|:||:||
Db          3 CCAGCCCUCUGGUAG 17


RESULT 838
US-09-927-046-1004
; Sequence 1004, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1004
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-927-046-1004

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.5e+02;
  Matches   10;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2016 CAAGTCCTCTGGTAG 2030
              | || ||:|:||:||
Db          2 CCAGCCCUCUGGUAG 16


RESULT 839
US-09-927-046-1118/c
; Sequence 1118, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Thompson, Jim
;  APPLICANT:  McKenzie, Tim
;  APPLICANT:  Ayers, Dave
;  APPLICANT:  Grupe, Andrew
;  APPLICANT:  Szymkowski, Edmund
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
;  TITLE OF INVENTION:  Channel-1
;  FILE REFERENCE: 249/021
;  CURRENT APPLICATION NUMBER: US/09/927,046
;  CURRENT FILING DATE:  2001-08-09
;  NUMBER OF SEQ ID NOS: 5450
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1118
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

US-09-927-046-1118

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1908 AGATCAACAATACCT 1922
              ||||||| ||||| |
Db         15 AGATCAAGAATACTT 1
```

RESULT 840
US-09-927-046-1296
; Sequence 1296, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1296
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1296

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1805 AAAGTGGTGCTATAA 1819
              ||||:||:|| |: |
Db          1 AAAGUGGUGCCAUCA 15
```

RESULT 841
US-09-927-046-1521
; Sequence 1521, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1521
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1521

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1805 AAAGTGGTGCTATAA 1819
              ||||:||:|| |: |
Db          3 AAAGUGGUGCCAUCA 17
```

RESULT 842
US-09-927-046-1765/c
; Sequence 1765, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1765
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1765

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1947 TTGGTTTTTGTGTCC 1961
              ||||| ||| |||||
Db         15 TTGGTGTTTTTGTCC 1
```

RESULT 843
US-09-877-478-604
; Sequence 604, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 604

```
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-604

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTT 1977
              |:|||:|::: || :
Db          3 CUAAAUAUUUGCCCU 17


RESULT 844
US-09-877-478-2130
; Sequence 2130, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: MBHB00-845-H (400/029)
;  CURRENT APPLICATION NUMBER: US/09/877,478
;  CURRENT FILING DATE:  2001-12-31
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 08/433,993
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 08/434,504
;  PRIOR FILING DATE: 1995-05-04
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2130
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-09-877-478-2130

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTT 1977
              |:|||:|::: || :
Db          3 CUAAAUAUUUGCCCU 17


RESULT 845
US-09-848-754A-129/c
; Sequence 129, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 129
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-129

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| |||||||| ||
Db         16 TCACCAATACCTATT 2


RESULT 846
US-09-848-754A-747
; Sequence 747, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 747
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-747

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | ||||:: :::||:
Db          2 AGCCCAUUUUUUCCU 16


RESULT 847
US-09-848-754A-748
; Sequence 748, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 748
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-748

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | ||||:: :::||:
Db          1 AGCCCAUUUUUUCCU 15


RESULT 848
```

```
US-09-848-754A-1852
; Sequence 1852, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of Epidermal Growth Factor Receptors
;  FILE REFERENCE: MBHB00-958-I (400/018)
;  CURRENT APPLICATION NUMBER: US/09/848,754A
;  CURRENT FILING DATE:  2001-05-03
;  NUMBER OF SEQ ID NOS: 9645
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1852
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-848-754A-1852

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   53.3%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              | :||::|:|| :||
Db          1 AGUGGUUCUGCUUCA 15


RESULT 849
US-09-930-423-249/c
; Sequence 249, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 249
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-249

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAG 1991
              ||||| ||||||||
Db         16 TGAAACTAAGAAAAG 2


RESULT 850
US-09-930-423-250/c
; Sequence 250, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 250
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-250

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAG 1991
              ||||| ||||||||
Db         15 TGAAACTAAGAAAAG 1


RESULT 851
US-09-930-423-919/c
; Sequence 919, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: MBHB00,918-A 400/027
;  CURRENT APPLICATION NUMBER: US/09/930,423
;  CURRENT FILING DATE:  2001-08-15
;  NUMBER OF SEQ ID NOS: 4553
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 919
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo Sapiens
US-09-930-423-919

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAG 1991
              ||||| ||||||||
Db         17 TGAAACTAAGAAAAG 3


RESULT 852
US-09-780-164-138/c
; Sequence 138, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
;  FILE REFERENCE: 400/010
;  CURRENT APPLICATION NUMBER: US/09/780,164
;  CURRENT FILING DATE:  2001-02-09
;  PRIOR APPLICATION NUMBER: 60/185,516
;  PRIOR FILING DATE: 2000-02-28
;  NUMBER OF SEQ ID NOS: 2603
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 138
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-780-164-138

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2024 CTGGTAGGAGGCAAA 2038
              |||| || |||||||
Db         15 CTGGAAGAAGGCAAA 1


RESULT 853
```

```
US-09-827-395A-451/c
; Sequence 451, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;  FILE REFERENCE: MBHB00-878-C (400/017)
;  CURRENT APPLICATION NUMBER: US/09/827,395A
;  CURRENT FILING DATE:  2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 451
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-827-395A-451

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1887 ATTGATGTGCCCTAG 1901
              ||||||||||| | |
Db         16 ATTGATGTGCCGTGG 2


RESULT 854
US-09-740-332-1403
; Sequence 1403, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1403
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1403

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   80.0%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1589 GACTGGGAACCCCTC 1603
              | |:||||||||| |
Db          1 GCCUGGGAACCCCGC 15


RESULT 855
US-09-740-332-1415
; Sequence 1415, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1415
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1415

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCC 1675
              |: ||:|||| ||||
Db          2 CUCCAUCACCAGCCC 16


RESULT 856
US-09-740-332-3140/c
; Sequence 3140, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relatec
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: RPI 400/003
;  CURRENT APPLICATION NUMBER: US/09/740,332
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9704
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3140
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3140

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCC 1675
              || ||||||| ||||
Db         17 CTCCATCACCAGCCC 3


RESULT 857
US-09-745-237A-249/c
; Sequence 249, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 249
;   LENGTH: 17
;   TYPE: RNA
```

```
;   ORGANISM: Homo sapiens
US-09-745-237A-249

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAG 1991
              ||||| ||||||||
Db         16 TGAAACTAAGAAAAG 2


RESULT 858
US-09-745-237A-250/c
; Sequence 250, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 250
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-745-237A-250

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAG 1991
              ||||| ||||||||
Db         15 TGAAACTAAGAAAAG 1


RESULT 859
US-09-745-237A-919/c
; Sequence 919, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
;  FILE REFERENCE: 400/007 (MBHB00-918-A)
;  CURRENT APPLICATION NUMBER: US/09/745,237A
;  CURRENT FILING DATE:  2002-04-15
;  NUMBER OF SEQ ID NOS: 4550
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 919
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-745-237A-919

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAG 1991
              ||||| ||||||||
Db         17 TGAAACTAAGAAAAG 3


RESULT 860
US-09-817-879-1403
; Sequence 1403, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1403
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1403

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   80.0%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1589 GACTGGGAACCCCTC 1603
              | |:|||||||| |
Db          1 GCCUGGGAACCCCGC 15


RESULT 861
US-09-817-879-1415
; Sequence 1415, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1415
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1415

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCC 1675
              |: ||:|||| ||||
Db          2 CUCCAUCACCAGCCC 16


RESULT 862
US-09-817-879-3140/c
; Sequence 3140, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals Inc.
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Hepatitis C Virus Infection
;  FILE REFERENCE: MBHB00-801-F
;  CURRENT APPLICATION NUMBER: US/09/817,879
;  CURRENT FILING DATE:  2001-03-26
;  NUMBER OF SEQ ID NOS: 9703
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3140
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3140

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCC 1675
              || ||||||| ||||
Db         17 CTCCATCACCAGCCC 3


RESULT 863
US-10-060-830-249
; Sequence 249, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Nguyen, Cung-Tuong
;  TITLE OF INVENTION: HUMAN LCCL DOMAN CONTAINING PROTEIN
;  FILE REFERENCE: PB0169
;  CURRENT APPLICATION NUMBER: US/10/060,830
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/325,062
;  PRIOR FILING DATE: 2001-09-25
;  NUMBER OF SEQ ID NOS: 1123
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 249
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-830-249

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCA 2036
              | ||||||||||| |
Db          1 CACTGGTAGGAGGAA 15


RESULT 864
US-10-287-919-2382/c
; Sequence 2382, Application US/10287919
; Publication No. US20030085830A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Methanococcus jannaschii complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/287,919
;  CURRENT FILING DATE:  2002-11-05
;  NUMBER OF SEQ ID NOS: 2706
;  SOFTWARE: Proprietary
; SEQ ID NO 2382
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Methanococcus jannaschii complete genome.
;   FEATURE:
;   LOCATION: (1462414)...(1462429)
;   OTHER INFORMATION: Chromosome = 1  Strand = positive  ConnectronObjectNumber =  3045
US-10-287-919-2382

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTT 1779
              || |||| |||||||
Db         16 TTTAGCTATTTTTTT 2


RESULT 865
US-10-211-059-116
; Sequence 116, Application US/10211059
; Publication No. US20030100495A1
; GENERAL INFORMATION:
;  APPLICANT: Zhang, Jian
;  TITLE OF INVENTION: HUMAN NAC-1 PROTEIN
;  FILE REFERENCE: PB0149
;  CURRENT APPLICATION NUMBER: US/10/211,059
;  CURRENT FILING DATE:  2002-08-02
;  PRIOR APPLICATION NUMBER: US 60/311,034
;  PRIOR FILING DATE: 2001-08-08
;  NUMBER OF SEQ ID NOS: 322
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 116
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-211-059-116

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1587 CAGACTGGGAACCCC 1601
              |||| |||||||| |
Db          3 CAGATTGGGAACCGC 17


RESULT 866
US-10-060-998-559
; Sequence 559, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 559
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-559
```

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1717 AACTTTGGACCTATT 1731
||||| ||| |||||
Db 3 AACTTAGGATCTATT 17

RESULT 867
US-10-060-998-560
; Sequence 560, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 560
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-560

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1717 AACTTTGGACCTATT 1731
||||| ||| |||||
Db 2 AACTTAGGATCTATT 16

RESULT 868
US-10-060-998-784/c
; Sequence 784, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 784
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-784

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1983 AAAGAAAAGTGTGTA 1997
||| || ||||||||
Db 17 AAACAAGAGTGTGTA 3

RESULT 869
US-10-060-998-785/c
; Sequence 785, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 785
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-785

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1983 AAAGAAAAGTGTGTA 1997
||| || ||||||||
Db 16 AAACAAGAGTGTGTA 2

RESULT 870
US-10-060-998-786/c
; Sequence 786, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 786
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-786

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1983 AAAGAAAAGTGTGTA 1997
||| || ||||||||
Db 15 AAACAAGAGTGTGTA 1

RESULT 871
US-10-060-998-901/c
; Sequence 901, Application US/10060998
; Publication No. US20030104530A1

```
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 901
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-901

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGA 1596
              || |||||||||| |
Db         17 CCCCACAGACTGGAA 3


RESULT 872
US-10-060-998-902/c
; Sequence 902, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 902
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-902

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGA 1596
              || |||||||||| |
Db         16 CCCCACAGACTGGAA 2


RESULT 873
US-10-060-998-903/c
; Sequence 903, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
;  FILE REFERENCE: PB01108
;  CURRENT APPLICATION NUMBER: US/10/060,998
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/343,331
;  PRIOR FILING DATE: 2001-12-21
;  NUMBER OF SEQ ID NOS: 3056
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 903
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-060-998-903

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGA 1596
              || |||||||||| |
Db         15 CCCCACAGACTGGAA 1


RESULT 874
US-10-156-306-48
; Sequence 48, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 48
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-48

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   26.7%;  Pred. No. 4.5e+02;
  Matches    4;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1766 TAAGCTTTTTTTTT 1780
              :|||| :: ::::::
Db          1 UAAGCCUUCUUUUUU 15


RESULT 875
US-10-156-306-1312
; Sequence 1312, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1312
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-1312

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   26.7%;  Pred. No. 4.5e+02;
```

Matches 4; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1765 TTAAGCTTTTTTTTT 1779
              ::|||| :: :::::
Db          3 UUAAGCCUUCUUUUU 17
```

RESULT 876
US-10-156-306-1382
; Sequence 1382, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1382
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1382

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1729 ATTATCAGAAGGTGA 1743
              |:: |||||||:||
Db          3 AUUUCCAGAAGGUGA 17
```

RESULT 877
US-10-156-306-1458
; Sequence 1458, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1458
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1458

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1729 ATTATCAGAAGGTGA 1743
              |: |:| |||||:||
Db          3 AUCAUCUGAAGGUGA 17
```

RESULT 878
US-10-156-306-2869/c
; Sequence 2869, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2869
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2869

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1887 ATTGATGTGCCCTAG 1901
              ||||||.|.||||||
Db         16 ATTGATATTCCCTAG 2
```

RESULT 879
US-10-156-306-3552
; Sequence 3552, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3552
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3552

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1729 ATTATCAGAAGGTGA 1743
              |:: |||||||:||
Db          2 AUUUCCAGAAGGUGA 16
```

RESULT 880
US-10-156-306-5815/c
; Sequence 5815, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5815

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1997 ATCTAGCTTCTTCAG 2011
              ||| ||||||| |||
Db         15 ATCGAGCTTCTCCAG 1


RESULT 881
US-10-156-306-6825
; Sequence 6825, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6825
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-6825

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   66.7%;  Pred. No. 4.5e+02;
  Matches   10;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              |:||| ||||||: :
Db          3 CUGGGCGAAGAGUCU 17


RESULT 882
US-10-156-306-6859/c
; Sequence 6859, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
;  TITLE OF INVENTION:  Levels of IKK-Gamma and PKR
;  FILE REFERENCE: MBHB01-664-A (400/050)
;  CURRENT APPLICATION NUMBER: US/10/156,306
;  CURRENT FILING DATE:  2002-05-28
;  NUMBER OF SEQ ID NOS: 8013
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6859
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-156-306-6859

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1569 AAATCCTTCTCCACC 1583
              || |||||||||| ||
Db         17 AACTCCTTCTCCTCC 3


RESULT 883
US-10-238-700-3360/c
; Sequence 3360, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  McSwiggen, James
;  TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
;  FILE REFERENCE: 400/057  (MBHB01-1158-A)
;  CURRENT APPLICATION NUMBER: US/10/238,700
;  CURRENT FILING DATE:  2002-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 02/16840
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/318,471
;  PRIOR FILING DATE: 2001-09-10
;  NUMBER OF SEQ ID NOS: 4666
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3360
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-238-700-3360

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1541 GGAGAGTAGGGAAGG 1555
              ||||||| ||| |||
Db         15 GGAGAGTGGGGCAGG 1


RESULT 884
US-10-339-782-155
; Sequence 155, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
;  APPLICANT: Lynx Therapeutics, Inc.
;  APPLICANT:  Goodman, Laurie J
;  APPLICANT:  Bowen, Benjamin A
;  TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
;  FILE REFERENCE: 37-000110US
;  CURRENT APPLICATION NUMBER: US/10/339,782
;  CURRENT FILING DATE:  2003-01-08
;  NUMBER OF SEQ ID NOS: 495
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 155
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-339-782-155

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGC 1585
              |||| ||||||| ||
Db          2 ATCCATCTCCACAGC 16


RESULT 885
US-10-339-782-373/c
; Sequence 373, Application US/10339782
; Publication No. US20030166026A1
; GENERAL INFORMATION:
;  APPLICANT: Lynx Therapeutics, Inc.
;  APPLICANT:  Goodman, Laurie J
;  APPLICANT:  Bowen, Benjamin A
;  TITLE OF INVENTION: Identification of Specific Biomarkers for Breast Cancer Cells
;  FILE REFERENCE: 37-000110US
;  CURRENT APPLICATION NUMBER: US/10/339,782
;  CURRENT FILING DATE:  2003-01-08
;  NUMBER OF SEQ ID NOS: 495
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 373
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-339-782-373

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
```

```
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAAC 1598
              ||| ||||||||| |
Db         15 GCAGAGACTGGGATC 1


RESULT 886
US-10-430-882-451/c
; Sequence 451, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Lawrence Blatt
;  APPLICANT:  James McSwiggen
;  APPLICANT:  Bharat Chowrira
;  APPLICANT:  Peter Haeberli
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;  FILE REFERENCE: MBHB00-878-H (400/112)
;  CURRENT APPLICATION NUMBER: US/10/430,882
;  CURRENT FILING DATE:  2003-05-06
;  PRIOR APPLICATION NUMBER: 09/827,395
;  PRIOR FILING DATE: 2001-04-05
;  PRIOR APPLICATION NUMBER: 09/780,533
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: PCT/US01/04273
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/181,797
;  PRIOR FILING DATE: 2000-02-11
;  PRIOR APPLICATION NUMBER: PCT/US02/10512
;  PRIOR FILING DATE: 2002-04-03
;  NUMBER OF SEQ ID NOS: 2617
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 451
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-430-882-451

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1887 ATTGATGTGCCCTAG 1901
              ||||||||||| | |
Db         16 ATTGATGTGCCGTGG 2


RESULT 887
US-10-307-005-2507
; Sequence 2507, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
;  APPLICANT: University of Delaware
;  APPLICANT:  Eric B. Kmiec
;  APPLICANT:  Howard B. Gamper
;  APPLICANT:  Michael C. Rice
;  APPLICANT:  Jungsup Kim
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
;  TITLE OF INVENTION:  Using Modified Single Stranded Oligonucleotides
;  FILE REFERENCE: Napro/009 PCT
;  CURRENT APPLICATION NUMBER: US/10/307,005
;  CURRENT FILING DATE:  2002-11-26
;  PRIOR APPLICATION NUMBER: PCT/US01/17672
;  PRIOR FILING DATE: 2001-06-01
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  NUMBER OF SEQ ID NOS: 2717
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2507
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Ricinus communis
US-10-307-005-2507

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTG 1742
              |||||| |||| |||
Db          3 TATTATGAGAATGTG 17


RESULT 888
US-10-307-005-2508/c
; Sequence 2508, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
;  APPLICANT: University of Delaware
;  APPLICANT:  Eric B. Kmiec
;  APPLICANT:  Howard B. Gamper
;  APPLICANT:  Michael C. Rice
;  APPLICANT:  Jungsup Kim
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
;  TITLE OF INVENTION:  Using Modified Single Stranded Oligonucleotides
;  FILE REFERENCE: Napro/009 PCT
;  CURRENT APPLICATION NUMBER: US/10/307,005
;  CURRENT FILING DATE:  2002-11-26
;  PRIOR APPLICATION NUMBER: PCT/US01/17672
;  PRIOR FILING DATE: 2001-06-01
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  NUMBER OF SEQ ID NOS: 2717
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2508
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Ricinus communis
US-10-307-005-2508

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTG 1742
              |||||| |||| |||
Db         15 TATTATGAGAATGTG 1


RESULT 889
US-10-307-005-2511
; Sequence 2511, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
;  APPLICANT: University of Delaware
;  APPLICANT:  Eric B. Kmiec
;  APPLICANT:  Howard B. Gamper
;  APPLICANT:  Michael C. Rice
;  APPLICANT:  Jungsup Kim
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
;  TITLE OF INVENTION:  Using Modified Single Stranded Oligonucleotides
;  FILE REFERENCE: Napro/009 PCT
;  CURRENT APPLICATION NUMBER: US/10/307,005
;  CURRENT FILING DATE:  2002-11-26
;  PRIOR APPLICATION NUMBER: PCT/US01/17672
;  PRIOR FILING DATE: 2001-06-01
```

```
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  NUMBER OF SEQ ID NOS: 2717
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2511
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Ricinus communis
US-10-307-005-2511

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTG 1742
                ||||||||  || |||
Db          1 TATTATCATAATGTG 15


RESULT 890
US-10-307-005-2512/c
; Sequence 2512, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
;  APPLICANT: University of Delaware
;  APPLICANT:  Eric B. Kmiec
;  APPLICANT:  Howard B. Gamper
;  APPLICANT:  Michael C. Rice
;  APPLICANT:  Jungsup Kim
;  TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
;  TITLE OF INVENTION:  Using Modified Single Stranded Oligonucleotides
;  FILE REFERENCE: Napro/009 PCT
;  CURRENT APPLICATION NUMBER: US/10/307,005
;  CURRENT FILING DATE:  2002-11-26
;  PRIOR APPLICATION NUMBER: PCT/US01/17672
;  PRIOR FILING DATE: 2001-06-01
;  PRIOR APPLICATION NUMBER: US 60/208,538
;  PRIOR FILING DATE: 2000-06-01
;  PRIOR APPLICATION NUMBER: US 60/244,989
;  PRIOR FILING DATE: 2000-10-30
;  PRIOR APPLICATION NUMBER: US 09/818,875
;  PRIOR FILING DATE: 2001-03-27
;  NUMBER OF SEQ ID NOS: 2717
;  SOFTWARE: Friedman macro Napro4
; SEQ ID NO 2512
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Ricinus communis
US-10-307-005-2512

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTG 1742
                ||||||||  || |||
Db         17 TATTATCATAATGTG 3


RESULT 891
US-10-342-902-604
; Sequence 604, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 604
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-604

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTT 1977
                |:|||:|::: || :
Db          3 CUAAAUAUUUGCCCU 17


RESULT 892
US-10-342-902-2130
; Sequence 2130, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Draper, Kenneth
;  APPLICANT:  Blatt, Larry
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Morrissey, Dave
;  TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
;  FILE REFERENCE: 400/075 (MBHB00-845-I)
;  CURRENT APPLICATION NUMBER: US/10/342,902
;  CURRENT FILING DATE:  2003-01-15
;  PRIOR APPLICATION NUMBER: US 09/877,478
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 09/531,025
;  PRIOR FILING DATE: 2000-03-20
;  PRIOR APPLICATION NUMBER: US 09/636,385
;  PRIOR FILING DATE: 2000-08-09
;  PRIOR APPLICATION NUMBER: US 09/696,347
;  PRIOR FILING DATE: 2000-10-24
;  PRIOR APPLICATION NUMBER: US 08/193,627
;  PRIOR FILING DATE: 1994-02-07
;  PRIOR APPLICATION NUMBER: US 07/882,712
;  PRIOR FILING DATE: 1992-05-14
;  PRIOR APPLICATION NUMBER: US 09/436,430
;  PRIOR FILING DATE: 1999-11-08
;  NUMBER OF SEQ ID NOS: 6592
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2130
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B virus
US-10-342-902-2130

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
```

Matches 7; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1963 CTAAATATTTACCTT 1977
              |:|||:|::: || :
Db          3 CUAAAUAUUUGCCCU 17
```

RESULT 893
US-10-675-685-310
; Sequence 310, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 310
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-310

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1547 TAGGGAAGGAACAGG 1561
              ||||||||||| | |
Db          3 TAGGGAAGGAAGAAG 17
```

RESULT 894
US-10-675-685-313
; Sequence 313, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 313
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-313

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1548 AGGGAAGGAACAGGA 1562
              |||||||||| | ||
Db          1 AGGGAAGGAAGAAGA 15
```

RESULT 895
US-10-138-674-315
; Sequence 315, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 315
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-315

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 4.5e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1971 TTACCTTGAAAAAAA 1985
              ::| |::| ||||||
Db          3 UUAACUUGGAAAAAA 17
```

RESULT 896
US-10-138-674-611
; Sequence 611, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 611
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-611

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 46.7%; Pred. No. 4.5e+02;
Matches 7; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1791 TCTTTCCTTCTCTGA 1805
              :| : ||::|:|:||
Db          1 UCCUGCCUUCUCUGA 15
```

RESULT 897
US-10-138-674-750/c
; Sequence 750, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

```
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 750
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-750

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGA 1706
              ||||||||  | ||||
Db         15 TTTCTCTAACACTGA 1


RESULT 898
US-10-138-674-777/c
; Sequence 777, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 777
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-777

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCA 1885
              ||||  |||||||  ||
Db         17 GCCACTGAAATGGCA 3


RESULT 899
US-10-138-674-1141/c
; Sequence 1141, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1141
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-1141

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAG 1769
              |||||  | |||||||
Db         15 TCTTTCTACATTAAG 1


RESULT 900
US-10-138-674-2276/c
; Sequence 2276, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2276
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-2276

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| |||||||  |||
Db         16 TCACCAATACCCTTT 2


RESULT 901
US-10-138-674-2868/c
; Sequence 2868, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2868
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-2868

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAAC 1558
              ||||  |||||||||
```

```
Db         17 GAGTCCGGAAGGAAC 3


RESULT 902
US-10-138-674-3206/c
; Sequence 3206, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3206
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3206

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTT 1652
                | |||||| ||||||
Db         15 TTTTTAAATAGCCTT 1


RESULT 903
US-10-138-674-3528
; Sequence 3528, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3528
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-138-674-3528

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCC 1897
              :||||:: |:| |||
Db          2 UCAAAUUCAUGAGCC 16


RESULT 904
US-10-138-674-4920
; Sequence 4920, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4920
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-4920

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              :| : ||::|:|:||
Db          2 UCCUGCCUUCUCUGA 16


RESULT 905
US-10-138-674-5162/c
; Sequence 5162, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5162
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-5162

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTC 1884
              ||||| ||||||| |
Db         15 AGCCACTGAAATGGC 1


RESULT 906
US-10-138-674-6409
; Sequence 6409, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
```

```
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6409
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-6409

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGT 1994
              |||||| |||| :|:
Db          2 AAAAAACAAAACUGU 16


RESULT 907
US-10-138-674-7210/c
; Sequence 7210, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7210
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7210

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1772 TTTTTTTTTTGAACC 1786
              ||||  |||||||||
Db         15 TTTTAATTTTGAACC 1


RESULT 908
US-10-138-674-7211/c
; Sequence 7211, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7211
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7211

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAA 1836
              || || |||||||||
Db         16 TTCAGGATCTTTTAA 2


RESULT 909
US-10-138-674-7880/c
; Sequence 7880, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7880
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7880

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1693 TTCTCTAGCGCTGAG 1707
              ||||||| | |||||
Db         17 TTCTCTAACACTGAG 3


RESULT 910
US-10-138-674-7954
; Sequence 7954, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7954
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-7954

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   53.3%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1803 TGAAAGTGGTGCTAT 1817
              :| |||:||: |:|:
Db          1 UGGAAGUGGUUCUAU 15


RESULT 911
```

```
US-10-138-674-8181/c
; Sequence 8181, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8181
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-8181

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAG 1769
                ||||| | |||||||
Db         17 TCTTTCTACATTAAG 3


RESULT 912
US-10-287-949A-315
; Sequence 315, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 315
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-315

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAA 1985
                ::| |::| ||||||
Db          3 UUAACUUGGAAAAAA 17


RESULT 913
US-10-287-949A-611
; Sequence 611, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 611
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-611

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
                :| : ||::|:|:||
Db          1 UCCUGCCUUCUCUGA 15


RESULT 914
US-10-287-949A-750/c
; Sequence 750, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 750
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-750

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGA 1706
                ||||||| | ||||
Db         15 TTTCTCTAACACTGA 1


RESULT 915
US-10-287-949A-777/c
; Sequence 777, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 777
;   LENGTH: 17
```

```
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-777

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCA 1885
              |||| ||||||| ||
Db         17 GCCACTGAAATGGCA 3


RESULT 916
US-10-287-949A-1141/c
; Sequence 1141, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1141
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-1141

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAG 1769
              ||||| | |||||||
Db         15 TCTTTCTACATTAAG 1


RESULT 917
US-10-287-949A-2276/c
; Sequence 2276, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2276
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-2276

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| ||||||| |||
Db         16 TCACCAATACCCTTT 2


RESULT 918
US-10-287-949A-2868/c
; Sequence 2868, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2868
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-2868

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAAC 1558
              ||||  |||||||||
Db         17 GAGTCCGGAAGGAAC 3


RESULT 919
US-10-287-949A-3206/c
; Sequence 3206, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3206
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3206

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTT 1652
              | |||||| ||||||
Db         15 TTTTTAAATAGCCTT 1


RESULT 920
US-10-287-949A-3528
; Sequence 3528, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3528
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus musculus
US-10-287-949A-3528

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 4.5e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCC 1897
             :||||:: |:| |||
Db          2 UCAAAUUCAUGAGCC 16


RESULT 921
US-10-287-949A-4920
; Sequence 4920, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4920
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-4920

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
             :| : ||::|:|:||
Db          2 UCCUGCCUUCUCUGA 16


RESULT 922
US-10-287-949A-5162/c
; Sequence 5162, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5162
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-5162

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTC 1884
             ||||| ||||||| |
Db         15 AGCCACTGAAATGGC 1


RESULT 923
US-10-287-949A-6409
; Sequence 6409, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6409
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-6409

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGT 1994
             |||||| |||| :|:
Db          2 AAAAAACAAAACUGU 16


RESULT 924
US-10-287-949A-7210/c
; Sequence 7210, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7210
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7210
```

```
  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1772 TTTTTTTTTTGAACC 1786
              ||||  |||||||||
Db         15 TTTTAATTTTGAACC 1


RESULT 925
US-10-287-949A-7211/c
; Sequence 7211, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7211
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7211

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAA 1836
              || || |||||||||
Db         16 TTCAGGATCTTTTAA 2


RESULT 926
US-10-287-949A-7880/c
; Sequence 7880, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7880
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7880

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1693 TTCTCTAGCGCTGAG 1707
              ||||||| | |||||
Db         17 TTCTCTAACACTGAG 3


RESULT 927
US-10-287-949A-7954
; Sequence 7954, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7954
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-7954

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   53.3%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1803 TGAAAGTGGTGCTAT 1817
              :| |||:||: |:|:
Db          1 UGGAAGUGGUUCUAU 15


RESULT 928
US-10-287-949A-8181/c
; Sequence 8181, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8181
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-8181

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAG 1769
              ||||| | |||||||
Db         17 TCTTTCTACATTAAG 3


RESULT 929
US-10-712-672-959/c
; Sequence 959, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
```

```
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 959
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-959

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1604 CTGGCCTGGGGGAAG 1618
              ||| |||||||||  |
Db         17 CTGTCCTGGGGGATG 3


RESULT 930
US-10-712-672-1413/c
; Sequence 1413, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1413
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-1413

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2026 GGTAGGAGGCAAAGG 2040
              ||| | |||||||||
Db         16 GGTGGAAGGCAAAGG 2


RESULT 931
US-10-712-672-1414/c
; Sequence 1414, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1414
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-1414

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2026 GGTAGGAGGCAAAGG 2040
              ||| | |||||||||
Db         15 GGTGGAAGGCAAAGG 1


RESULT 932
US-10-712-672-2206/c
; Sequence 2206, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2206
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-2206

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1682 TTCTTAGTTGTTTCT 1696
              ||||| ||||||  ||
Db         17 TTCTTGGTTGTTCCT 3


RESULT 933
US-10-712-672-2689
; Sequence 2689, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Chowrira, Bharat
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
;  FILE REFERENCE: MBHB00-882-C (400/019)
```

```
;  CURRENT APPLICATION NUMBER: US/10/712,672
;  CURRENT FILING DATE:  2003-11-13
;  PRIOR APPLICATION NUMBER: US/09/653,225
;  PRIOR FILING DATE: 2000-08-31
;  PRIOR APPLICATION NUMBER: 60/197,769
;  PRIOR FILING DATE: 2000-04-14
;  PRIOR APPLICATION NUMBER: 60/150,713
;  PRIOR FILING DATE: 1999-08-31
;  NUMBER OF SEQ ID NOS: 5586
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2689
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-712-672-2689

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   80.0%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGA 1596
                ||||||  | |:||||
Db          2 CCGCACCGGCUGGGA 16


RESULT 934
US-10-669-841-604
; Sequence 604, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 604
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Hepatitis B Virus
US-10-669-841-604

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 4.5e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTT 1977
                |:|||:|::: || :
Db          3 CUAAAUAUUUGCCCU 17


RESULT 935
US-10-669-841-3996
; Sequence 3996, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3996
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3996

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   80.0%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1589 GACTGGGAACCCCTC 1603
                | |:||||||||| |
Db          1 GCCUGGGAACCCCGC 15


RESULT 936
```

```
US-10-669-841-4008
; Sequence 4008, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4008
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4008

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCC 1675
              |: ||:|||| ||||
Db          2 CUCCAUCACCAGCCC 16


RESULT 937
US-10-669-841-5733/c
; Sequence 5733, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  Lawrence, Blatt
;  APPLICANT:  Dennis, Macejak
;  APPLICANT:  James, McSwiggen
;  APPLICANT:  David, Morrissey
;  APPLICANT:  Pamela, Pavco
;  APPLICANT:  Patrice, Lee
;  APPLICANT:  Kenneth, Draper
;  APPLICANT:  Elisabeth, Roberts
;  TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
;  TITLE OF INVENTION:  VIRUS REPLICATION
;  FILE REFERENCE: 400/042US  (MBHB02-249-E)
;  CURRENT APPLICATION NUMBER: US/10/669,841
;  CURRENT FILING DATE:  2003-09-23
;  PRIOR APPLICATION NUMBER: PCT/US02/09187
;  PRIOR FILING DATE: 2002-03-26
;  PRIOR APPLICATION NUMBER: US 60/296,876
;  PRIOR FILING DATE: 2001-06-08
;  PRIOR APPLICATION NUMBER: US 60/335,059
;  PRIOR FILING DATE: 2001-10-24
;  PRIOR APPLICATION NUMBER: US 60/337,055
;  PRIOR FILING DATE: 2001-12-05
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 09/817,879
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: US 09/740,332
;  PRIOR FILING DATE: 2000-12-18
;  PRIOR APPLICATION NUMBER: US 09/611,931
;  PRIOR FILING DATE: 2000-07-07
;  PRIOR APPLICATION NUMBER: US 09/504,321
;  PRIOR FILING DATE: 2000-02-15
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 16207
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5733
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Nucleic Acid
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION:
;   OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5733

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCC 1675
              || ||||||| ||||
Db         17 CTCCATCACCAGCCC 3


RESULT 938
US-10-723-361-1344/c
; Sequence 1344, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
```

```
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1344
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-1344

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCT 1801
                ||||  |||||||||
Db         17 CCATCTTTTCCTTCT 3


RESULT 939
US-10-723-361-1348/c
; Sequence 1348, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1348
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-1348

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTT 1799
                ||||||  |||||||
Db         15 CCCCATCTTTTCCTT 1


RESULT 940
US-10-723-361-1579/c
; Sequence 1579, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1579
;    LENGTH: 17
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-723-361-1579

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1572 TCCTTCTCCACCGCA 1586
                ||||||||||  |||
Db         17 TCCTTCTCCAGAGCA 3


RESULT 941
US-10-723-361-1582/c
; Sequence 1582, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
```

```
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1582
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1582

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGC 1585
              ||||||||||  ||
Db         15 ATCCTTCTCCAGAGC 1


RESULT 942
US-10-723-361-1700
; Sequence 1700, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1700
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-1700

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
              ||||| ||||||  ||
Db          3 TGGTATGAGGCAGAG 17


RESULT 943
US-10-723-361-1701
; Sequence 1701, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1701
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
```

US-10-723-361-1701

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2025 TGGTAGGAGGCAAAG 2039
||||| |||||| ||
Db 2 TGGTATGAGGCAGAG 16

RESULT 944
US-10-723-361-1702
; Sequence 1702, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1702
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1702

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2025 TGGTAGGAGGCAAAG 2039
||||| |||||| ||
Db 1 TGGTATGAGGCAGAG 15

RESULT 945
US-10-723-361-7645/c
; Sequence 7645, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7645
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7645

Query Match 2.1%; Score 11.8; DB 1; Length 17;
Best Local Similarity 86.7%; Pred. No. 4.5e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1684 CTTAGTTGTTTCTCT 1698
||| |||| ||||||
Db 15 CTTTGTTGGTTCTCT 1

RESULT 946
US-10-723-361-7959
; Sequence 7959, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7959
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-7959

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
                ||||  ||  |||||||
Db          1 CCCTTGAGCAACAGA 15


RESULT 947
US-10-723-361-8582/c
; Sequence 8582, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8582
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-8582

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
                ||  ||||||||||  |
Db         17 TGCTTCTGCATCAGC 3


RESULT 948
US-10-723-361-8583/c
; Sequence 8583, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8583
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-8583

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
                ||  ||||||||||  |
Db         16 TGCTTCTGCATCAGC 2


RESULT 949
US-10-723-361-8584/c
; Sequence 8584, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
```

```
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8584
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-8584

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
                || |||||||||| |
Db         15 TGCTTCTGCATCAGC 1


RESULT 950
US-10-723-361-10542/c
; Sequence 10542, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10542
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-10542

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
                ||| ||||||| |||                                .
Db         17 TTTCTTCATTATGCT 3


RESULT 951
US-10-723-361-10543/c
; Sequence 10543, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
;  FILE REFERENCE: PB0105
;  CURRENT APPLICATION NUMBER: US/10/723,361
;  CURRENT FILING DATE:  2003-11-26
;  PRIOR APPLICATION NUMBER: US 09/866,108
;  PRIOR FILING DATE: 2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10543
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-723-361-10543

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1757 TTTATTCATTAAGCT 1771
              ||| ||||||| |||
Db         16 TTTCTTCATTATGCT 2
```

RESULT 952
US-09-823-699-18/c
; Sequence 18, Application US/09823699
; Patent No. US20020002143A1
; GENERAL INFORMATION:
; APPLICANT: Kano, Munehide
; APPLICANT: Matano, Tetsuro
; APPLICANT: Kato, Atsushi
; APPLICANT: Nagai, Yoshiyuki
; APPLICANT: Hasegawa, Mamoru
; TITLE OF INVENTION: AIDS Virus Vaccines Using Sendai Virus
; TITLE OF INVENTION: Vector
; FILE REFERENCE: 50026/022002
; CURRENT APPLICATION NUMBER: US/09/823,699
; CURRENT FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: US 60/193,127
; PRIOR FILING DATE: 2000-03-30
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: artificially synthesized sequence
US-09-823-699-18

Query Match 2.1%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 4.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1584 GCACAGACTGGGAAC 1598
              |||||| || |||||
Db         18 GCACAGGCTTGGAAC 4
```

RESULT 953
US-09-969-373-4180
; Sequence 4180, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 4180
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-4180

Query Match 2.1%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 4.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1654 ACTGGTTCTGCATCA 1668
              | | ||||||||||||
Db         3 AGTTGTTCTGCATCA 17
```

RESULT 954
US-09-918-186A-117
; Sequence 117, Application US/09918186A
; Patent No. US20020137708A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Elizabeth J. Ackermann
; APPLICANT: Eric E. Swayze
; APPLICANT: Lex M. Cowsert
; TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
; FILE REFERENCE: ISPH-0585
; CURRENT APPLICATION NUMBER: US/09/918,186A
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 09/496,694
; PRIOR FILING DATE: 2000-02-02
; PRIOR APPLICATION NUMBER: 09/286,407
; PRIOR FILING DATE: 1999-04-05
; PRIOR APPLICATION NUMBER: 09/163,162
; PRIOR FILING DATE: 1998-09-29
; NUMBER OF SEQ ID NOS: 250
; SEQ ID NO 117
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-918-186A-117

Query Match 2.1%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 4.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1800 CTCTGAAAGTGGTGC 1814
              | ||| |||||||||
Db         3 CCCTGGAAGTGGTGC 17
```

RESULT 955
US-09-771-933-176
; Sequence 176, Application US/09771933
; Publication No. US20030023387A1
; GENERAL INFORMATION:
; APPLICANT: Gill-Garrison, Rosalynn D
; APPLICANT: Martin, Christopher J
; APPLICANT: Sanchez-Felix, Manuel V
; TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk
; TITLE OF INVENTION: Factors
; FILE REFERENCE: 620-130
; CURRENT APPLICATION NUMBER: US/09/771,933
; CURRENT FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 205
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 176
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-771-933-176

Query Match 2.1%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 4.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1828 ATCTTTTAAATACAT 1842
              |||||| ||| ||||
Db         4 ATCTTTAAAAGACAT 18
```

RESULT 956
US-10-177-063-7/c
; Sequence 7, Application US/10177063

```
; Publication No. US20030054386A1
; GENERAL INFORMATION:
;  APPLICANT: University of Geneva
;  TITLE OF INVENTION: Method for Detecting Disease Caused by Chromosomal Imbalances
;  FILE REFERENCE: 27067/2002
;  CURRENT APPLICATION NUMBER: US/10/177,063
;  CURRENT FILING DATE:  2002-06-21
;  PRIOR APPLICATION NUMBER: US 60/300266
;  PRIOR FILING DATE: 2001-06-22
;  NUMBER OF SEQ ID NOS: 28
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic oligonucleotide sequencing primer SIMAS
US-10-177-063-7

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1849 GGCCAACAGACCCAC 1863
              ||||| ||| |||||
Db         15 GGCCACCAGCCCCAC 1


RESULT 957
US-10-025-524-20
; Sequence 20, Application US/10025524
; Publication No. US20030068659A1
;   GENERAL INFORMATION:
;        APPLICANT: Gallatin, W. Michael
;                   Kilgannon, Patrick D.
;        TITLE OF INVENTION: ICAM-4 Materials and Methods
;        NUMBER OF SEQUENCES: 42
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;             STREET: 233 South Wacker Drive, 6300 Sears Tower
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: United States of America
;             ZIP: 60606-6402
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/025,524
;             FILING DATE: 18-Dec-2001
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 07/827,689
;             FILING DATE: 27-JAN-1992
;             APPLICATION NUMBER: US 07/889,724
;             FILING DATE: 26-MAY-1992
;             APPLICATION NUMBER: US 07/894,061
;             FILING DATE: 05-JUN-1992
;             APPLICATION NUMBER: US 08/009,266
;             FILING DATE: 22-JAN-1993
;             APPLICATION NUMBER: US 08/102,852
;             FILING DATE: 05-AUG-1993
;             APPLICATION NUMBER: US 08/245,295
;             FILING DATE: 18-MAY-1994
;             APPLICATION NUMBER: US 08/485,604
;             FILING DATE: 07-JUN-1995
;        ATTORNEY/AGENT INFORMATION:
;             NAME: WILLIAMS, JR. JOSEPH A.
;             REGISTRATION NUMBER: 38,659
;             REFERENCE/DOCKET NUMBER: 27866/33321
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 312-474-6300
;             TELEFAX: 312-474-0448
;             TELEX: 25-3856
;   INFORMATION FOR SEQ ID NO: 20:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: cDNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-10-025-524-20

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 958
US-10-206-839-43
; Sequence 43, Application US/10206839
; Publication No. US20030099977A1
; GENERAL INFORMATION:
;  APPLICANT: Guida, Marco
;  APPLICANT:  Kurth, Janice
;  TITLE OF INVENTION: Genotyping Human Phenol Sulfotransferase
;  TITLE OF INVENTION:  (STP2)
;  FILE REFERENCE: 4389-6 (formerly SEQ-16P)
;  CURRENT APPLICATION NUMBER: US/10/206,839
;  CURRENT FILING DATE:  2002-07-26
;  PRIOR APPLICATION NUMBER: 09/328,174
;  PRIOR FILING DATE: 1999-06-08
;  NUMBER OF SEQ ID NOS: 110
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 43
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: H. sapiens
US-10-206-839-43

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1677 TGGACTTCTTAGTTG 1691
              ||||| |||| ||||
Db          4 TGGACCTCTTGGTTG 18


RESULT 959
US-10-223-646-6/c
; Sequence 6, Application US/10223646
; Publication No. US20030140372A1
; GENERAL INFORMATION:
;  APPLICANT: Shen, Jennie B.
;  APPLICANT:  E. I. du Pont de Nemours and Company
;  TITLE OF INVENTION: GENES FOR DESATURASES TO ALTER LIPID PROFILES IN CORN
;  FILE REFERENCE: BB-1137
;  CURRENT APPLICATION NUMBER: US/10/223,646
;  CURRENT FILING DATE:  2002-08-19
;  PRIOR APPLICATION NUMBER: US/09/326,285
;  PRIOR FILING DATE: 1999-06-07
;  PRIOR APPLICATION NUMBER: 60/088,987
;  PRIOR FILING DATE: JUNE 11, 1998
;  NUMBER OF SEQ ID NOS: 59
;  SOFTWARE: Microsoft Office 97
; SEQ ID NO 6
;   LENGTH: 18
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  SYNTHETIC
;   OTHER INFORMATION: OLIGONUCLEOTIDE
US-10-223-646-6

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   61.1%;  Pred. No. 4.9e+02;
  Matches   11;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCAAGTC 2021
              :||:|| | :|||| :||
Db         18 YTCYTCNGTDATCATRTC 1


RESULT 960
US-10-160-764-15/c
; Sequence 15, Application US/10160764
; Publication No. US20030167535A1
; GENERAL INFORMATION:
;  APPLICANT: Huang, Yafan
;  APPLICANT:  Chalifoux, Maryse
;  APPLICANT:  Wang, Yang
;  APPLICANT:  Kuzma, Monika Maria
;  APPLICANT:  Gilley, Angela Patricia
;  TITLE OF INVENTION: Compositions and Methods of Increasing Stress Tolerance
;  TITLE OF INVENTION:  in Plants
;  FILE REFERENCE: 22542-008
;  CURRENT APPLICATION NUMBER: US/10/160,764
;  CURRENT FILING DATE:  2002-05-31
;  PRIOR APPLICATION NUMBER: 60/294,766
;  PRIOR FILING DATE: 2001-05-31
;  PRIOR APPLICATION NUMBER: 60/348,909
;  PRIOR FILING DATE: 2001-10-22
;  NUMBER OF SEQ ID NOS: 90
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-10-160-764-15

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAG 1620
              ||| ||| |||||||
Db         16 GGCATGGAGGAAGAG 2


RESULT 961
US-10-367-438-162
; Sequence 162, Application US/10367438
; Publication No. US20030180773A1
;   GENERAL INFORMATION:
;        APPLICANT: COHEN, Daniel
;                   BLUMENFELD, Marta
;                   TCHOUMAKOV, Ilia
;        TITLE OF INVENTION: Biallelic markers for use in
;                            constructing a high density disequilibrium map of
;                            the human genome.
;        NUMBER OF SEQUENCES: 336
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Knobbe, Martens, Olson & Bear
;             STREET: 550 West C Street
;             CITY: San Diego
;             STATE: California
;             COUNTRY: USA
;             ZIP: 92101
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy Disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: Win95
;             SOFTWARE: Word
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/367,438
;             FILING DATE: 14-Feb-2003
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/463,075A
;             FILING DATE: 14-Jan-2000
;   INFORMATION FOR SEQ ID NO: 162:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: NUCLEIC ACID
;             STRANDEDNESS: SINGLE
;             TOPOLOGY: LINEAR
;        MOLECULE TYPE: DNA
;        ORIGINAL SOURCE:
;             ORGANISM: Homo sapiens
;        FEATURE:
;             NAME/KEY:  downstream amplification primer for SEQ ID12, SEQ ID62
;             LOCATION:  1..18
;        SEQUENCE DESCRIPTION: SEQ ID NO: 162:
US-10-367-438-162

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2045 ATCTGCTTAGCAACT 2059
              | ||||| |||||||
Db          1 AACTGCTCAGCAACT 15


RESULT 962
US-10-339-674-715/c
; Sequence 715, Application US/10339674
; Publication No. US20030204318A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/339,674
;  CURRENT FILING DATE:  2003-06-06
;  NUMBER OF SEQ ID NOS: 3537
;  SOFTWARE: Proprietary
; SEQ ID NO 715
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Escherichia coli K-12 MG1655 complete genome.
;   FEATURE:
;   LOCATION: (737579)...(737597)
;   OTHER INFORMATION: Chromosome = 1  Strand = positive  ConnectronObjectNumber =  937
US-10-339-674-715

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2054 GCAACTAGTTAATAA 2068
              ||| | |||||||||
Db         18 GCATCCAGTTAATAA 4


RESULT 963
US-10-181-316-117
; Sequence 117, Application US/10181316
; Publication No. US20030211607A1
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Elizabeth J. Ackermann
;  APPLICANT:  Eric E. Swayze
;  APPLICANT:  Lex M. Cowsert
```

```
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: ISPH-0650
;  CURRENT APPLICATION NUMBER: US/10/181,316
;  CURRENT FILING DATE:  2002-07-16
;  PRIOR APPLICATION NUMBER: PCT/US01/02939
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: 09/496,694
;  PRIOR FILING DATE: 2000-02-02
;  PRIOR APPLICATION NUMBER: 09/286,407
;  PRIOR FILING DATE: 1999-04-05
;  PRIOR APPLICATION NUMBER: 09/163,162
;  PRIOR FILING DATE: 1998-09-29
;  NUMBER OF SEQ ID NOS: 249
; SEQ ID NO 117
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-316-117

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGC 1814
              | ||| |||||||||
Db          3 CCCTGGAAGTGGTGC 17


RESULT 964
US-10-282-174-42
; Sequence 42, Application US/10282174
; Publication No. US20030224380A1
; GENERAL INFORMATION:
;  APPLICANT: Becker, Kenneth David
;  APPLICANT:  Velicelebi, Gonul
;  APPLICANT:  Elliot, Kathryn J.
;  APPLICANT:  Wang, Xin
;  APPLICANT:  Tanzi, Rudolph E.
;  APPLICANT:  Bertram, Lars
;  APPLICANT:  Saunders, Aleister J.
;  APPLICANT:  Mullin, Kristina M.
;  APPLICANT:  Sampson, Andrew Johnson
;  APPLICANT:  Blacker, Deborah Lynne
;  TITLE OF INVENTION: GENES AND POLYMORPHISMS ON CHROMOSOME 10
;  TITLE OF INVENTION:  ASSOCIATED WITH ALZHEIMER'S DISEASE AND OTHER
;  TITLE OF INVENTION:  NEURODEGENERATIVE DISEASES
;  FILE REFERENCE: 37481-3308
;  CURRENT APPLICATION NUMBER: US/10/282,174
;  CURRENT FILING DATE:  2002-10-25
;  PRIOR APPLICATION NUMBER: US 60/339,525
;  PRIOR FILING DATE: 2001-10-25
;  PRIOR APPLICATION NUMBER: US 60/338,010
;  PRIOR FILING DATE: 2001-11-08
;  PRIOR APPLICATION NUMBER: US 60/336,929
;  PRIOR FILING DATE: 2001-11-08
;  PRIOR APPLICATION NUMBER: US 60/338,363
;  PRIOR FILING DATE: 2001-11-09
;  PRIOR APPLICATION NUMBER: US 60/337,052
;  PRIOR FILING DATE: 2001-12-04
;  PRIOR APPLICATION NUMBER: US 60/368,919
;  PRIOR FILING DATE: 2002-03-28
;  NUMBER OF SEQ ID NOS: 564
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 42
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-282-174-42

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAGA 1619
              ||||||||| ||||
Db          3 TGGCCTGGGCTAAGA 17


RESULT 965
US-10-388-263-223
; Sequence 223, Application US/10388263
; Publication No. US20030228597A1
; GENERAL INFORMATION:
;  APPLICANT: Cowsert, Lex M.
;  APPLICANT:  Baker, Brenda F.
;  APPLICANT:  McNeil, John
;  APPLICANT:  Freier, Susan M.
;  APPLICANT:  Sasmor, Henri M.
;  APPLICANT:  Brooks, Douglas G.
;  APPLICANT:  Ohashi, Cara
;  APPLICANT:  Wyatt, Jacqueline R.
;  APPLICANT:  Borchers, Alexander
;  APPLICANT:  Vickers, Timothy A.
;  TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
;  TITLE OF INVENTION:  MODULATION BY OLIGONUCLEOTIDES AND
;  TITLE OF INVENTION:  GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
;  FILE REFERENCE: ISIS-4503
;  CURRENT APPLICATION NUMBER: US/10/388,263
;  CURRENT FILING DATE:  2003-03-12
;  NUMBER OF SEQ ID NOS: 947
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 223
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-223

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2069 GTGGTATCTGACACA 2083
              ||||| |||| ||||
Db          4 GTGGTTTCTGGCACA 18


RESULT 966
US-10-349-143-4956/c
; Sequence 4956, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4956
;   LENGTH: 18
;   TYPE: DNA
```

```
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-18995 for SEQ 1022,
US-10-349-143-4956

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1864 ACACTTAGCCATTGA 1878
              ||||||||||  || |
Db         17 ACACTTAGCCTTTCA 3


RESULT 967
US-10-349-143-4997
; Sequence 4997, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4997
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-2010 for SEQ 1063,
US-10-349-143-4997

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 TTTTTTTGAACCCCA 1789
              ||||||||  |||||
Db          2 TTTTTTTGTCCCCCA 16


RESULT 968
US-10-349-143-5155
; Sequence 5155, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5155
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-2209 for SEQ 1221,
US-10-349-143-5155

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAG 1554
              | ||||||||| |||
Db          4 ATGAGAGTAGGAAAG 18


RESULT 969
US-10-349-143-5351/c
; Sequence 5351, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5351
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-24270 for SEQ 1417,
US-10-349-143-5351

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTT 1954
              | ||||| ||||||
Db         16 GAAATGGTGGGTTTT 2


RESULT 970
US-10-349-143-5769
; Sequence 5769, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
```

```
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5769
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-6730 for SEQ 1835,
US-10-349-143-5769

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTG 1624
              |||| |||||| |||
Db          4 TGGGAGAAGAGATTG 18


RESULT 971
US-10-349-143-5871/c
; Sequence 5871, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5871
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-7453 for SEQ 1937,
US-10-349-143-5871

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAA 1807
              || || |||||||||
Db         16 TTGCCCTCTCTGAAA 2


RESULT 972
US-10-349-143-6093/c
; Sequence 6093, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6093
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-8885 for SEQ 2159,
US-10-349-143-6093

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACA 1864
              |||||||||| |||
Db         16 GCCAACAGACAAACA 2


RESULT 973
US-10-349-143-7562/c
; Sequence 7562, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7562
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-8006 for SEQ 3628,
US-10-349-143-7562

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1658 GTTCTGCATCACCCG 1672
```

```
                ||||||||||  ||
Db         18 GTTCTGCATCAATCG 4


RESULT 974
US-10-349-143-7804/c
; Sequence 7804, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7804
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-4110 for SEQ 3870,
US-10-349-143-7804

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1650 CTTCACTGGTTCTGC 1664
                ||||  |||  ||||||
Db         18 CTTCCCTGATTCTGC 4


RESULT 975
US-10-349-143-8887/c
; Sequence 8887, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8887
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-18995 for SEQ 1022, in complem
US-10-349-143-8887

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2035 CAAAGGTTCTATCTG 2049
                ||||||||| || ||
Db         18 CAAAGGTTCCATGTG 4


RESULT 976
US-10-349-143-9171
; Sequence 9171, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9171
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-2271 for SEQ 1306, in compleme
US-10-349-143-9171

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2045 ATCTGCTTAGCAACT 2059
                | |||||  |||||||
Db          1 AACTGCTCAGCAACT 15


RESULT 977
US-10-349-143-9321/c
; Sequence 9321, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9321
```

```
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-24778 for SEQ 1456, in complem
US-10-349-143-9321

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCT 1602
                ||||||||||| | |
Db         15 AGACTGGGAACTCAT 1


RESULT 978
US-10-349-143-9456
; Sequence 9456, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT:  Blumenfeld, Marta
;  APPLICANT:  Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/10/349,143
;  CURRENT FILING DATE:  2003-01-21
;  PRIOR APPLICATION NUMBER: US/09/422,978
;  PRIOR FILING DATE: 1999-10-20
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
;  PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
;  PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
;  PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9456
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-490 for SEQ 1591, in complemen
US-10-349-143-9456

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1836 AATACATTCCCTGGG 1850
                || |||||| |||||
Db          3 AAAACATTCTCTGGG 17


RESULT 979
US-10-229-541A-21/c
; Sequence 21, Application US/10229541A
; Publication No. US20040010821A1
; GENERAL INFORMATION:
;  APPLICANT: McCourt, Peter
;  APPLICANT:  Ghassemian, Majid
;  APPLICANT:  Cutler, Sean
;  APPLICANT:  Bonetta, Dario
;  TITLE OF INVENTION: Stress Tolerance and Delayed Senescence in Plants
;  FILE REFERENCE: 22542-007CIP2
;  CURRENT APPLICATION NUMBER: US/10/229,541A
;  CURRENT FILING DATE:  2002-08-27
;  PRIOR APPLICATION NUMBER: 10/160,764
;  PRIOR FILING DATE: 2002-05-31
;  PRIOR APPLICATION NUMBER: 60/294,766
;  PRIOR FILING DATE: 2001-05-31
;  PRIOR APPLICATION NUMBER: 60/348,909
;  PRIOR FILING DATE: 2001-10-22
;  PRIOR APPLICATION NUMBER: 10/210,760
;  PRIOR FILING DATE: 2002-08-01
;  PRIOR APPLICATION NUMBER: 60/309,396
;  PRIOR FILING DATE: 2001-08-01
;  PRIOR APPLICATION NUMBER: 60/337,084
;  PRIOR FILING DATE: 2001-12-04
;  PRIOR APPLICATION NUMBER: 09/191,687
;  PRIOR FILING DATE: 1998-11-13
;  NUMBER OF SEQ ID NOS: 176
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: PCR primer
US-10-229-541A-21

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAG 1620
                ||| ||| |||||||
Db         16 GGCATGGAGGAAGAG 2


RESULT 980
US-10-453-792-264/c
; Sequence 264, Application US/10453792
; Publication No. US20040029110A1
;   GENERAL INFORMATION:
;        APPLICANT: STUYVER, LIEVEN
;                   ROSSAU, RUDI
;                   MAERTENS, GEERT
;        TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
;        NUMBER OF SEQUENCES: 313
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: NIXON & VANDERHYE P.C.
;             STREET: 1100 NORTH GLEBE ROAD
;             CITY: ARLINGTON
;             STATE: VIRGINIA
;             COUNTRY: U.S.A.
;             ZIP: 22201-4714
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/10/453,792
;             FILING DATE: 04-Jun-2003
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US/09/155,885A
;             FILING DATE: 08-Oct-1998
;             APPLICATION NUMBER: PCT/EP97/02002
;             FILING DATE: 21-APR-1997
;             APPLICATION NUMBER: EP 96870053.4
;             FILING DATE: 19-APR-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: SADOFF, B.J.
;             REGISTRATION NUMBER: 36,663
;             REFERENCE/DOCKET NUMBER: 2551-5
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (703) 816-4000
;             TELEFAX: (703) 816-4100
;   INFORMATION FOR SEQ ID NO: 264:
;        SEQUENCE CHARACTERISTICS:
```

```
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 264:
US-10-453-792-264

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1905 AACAGATCAACAATA 1919
                | ||||||| |||||
Db         17 ACCAGATCATCAATA 3


RESULT 981
US-10-432-531-22
; Sequence 22, Application US/10432531
; Publication No. US20040088763A1
; GENERAL INFORMATION:
;  APPLICANT: Yano, Masahiro
;  APPLICANT:  Kojima, Shoko
;  TITLE OF INVENTION: HD3A GENE INDUCING FLOWERING OF PLANT AND UTILIZATION THEREOF
;  FILE REFERENCE: 2144.0070000
;  CURRENT APPLICATION NUMBER: US/10/432,531
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: PCT/JP01/10237
;  PRIOR FILING DATE: 2001-11-22
;  PRIOR APPLICATION NUMBER: JP 2000-356839
;  PRIOR FILING DATE: 2000-11-24
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:an artificially
;   OTHER INFORMATION: synthesized primer sequence
US-10-432-531-22

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2049 GCTTAGCAACTAGTT 2063
                ||| |||||| ||||
Db          2 GCTCAGCAACGAGTT 16


RESULT 982
US-10-765-500-58/c
; Sequence 58, Application US/10765500
; Publication No. US20040137501A1
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia and Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
;  FILE REFERENCE: RTSP-0100
;  CURRENT APPLICATION NUMBER: US/10/765,500
;  CURRENT FILING DATE:  2004-01-26
;  PRIOR APPLICATION NUMBER: US/09/763,748
;  PRIOR FILING DATE: 2001-02-27
;  PRIOR APPLICATION NUMBER: 09/143,212
;  PRIOR FILING DATE: 1998-08-28
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 58
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic
US-10-765-500-58

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 ACCCGCCCCTGGACT 1682
                ||||| | |||||||
Db         16 ACCCGGCGCTGGACT 2


RESULT 983
US-10-731-739-449
; Sequence 449, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/10/731,739
;  CURRENT FILING DATE:  2003-12-10
;  PRIOR APPLICATION NUMBER: US/09/544,398B
;  PRIOR FILING DATE: 2002-06-10
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 449
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-731-739-449

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1808 GTGGTGCTATAAGTT 1822
                |||||||| |||||
Db          1 GTGGTGCTGCAAGTT 15


RESULT 984
US-10-665-951-1165
; Sequence 1165, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
```

```
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1165
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/siNA sense r
US-10-665-951-1165

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 19;
  Best Local Similarity   73.3%;  Pred. No. 5.2e+02;
  Matches   11;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAA 1990
              ::  ||||||||||
Db          3 UUUCAAAAAAGAAAA 17


RESULT 985
US-10-665-951-1489/c
; Sequence 1489, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
;  APPLICANT: Sirna Therapeutics, Inc.
;  APPLICANT:  McSwiggen, James
;  APPLICANT:  Beigelman, Leonid
;  APPLICANT:  Pavco, Pamela
;  TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;  TITLE OF INVENTION:  Growth Factor and Vascular Endothelial Growth Factor Receptor
;  TITLE OF INVENTION:  Gene Expression Using Short Interfering Nucleic Acid (siNA)
;  FILE REFERENCE: 400/131 (MBHB02-742-F)
;  CURRENT APPLICATION NUMBER: US/10/665,951
;  CURRENT FILING DATE:  2003-09-18
;  PRIOR APPLICATION NUMBER: US 10/664,668
;  PRIOR FILING DATE: 2003-09-18
;  PRIOR APPLICATION NUMBER: PCT/US 03/05022
;  PRIOR FILING DATE: 2003-02-20
;  PRIOR APPLICATION NUMBER: US 60/399,348
;  PRIOR FILING DATE: 2002-07-29
;  PRIOR APPLICATION NUMBER: US 60/393,796
;  PRIOR FILING DATE: 2002-07-03
;  PRIOR APPLICATION NUMBER: US 10/287,949
;  PRIOR FILING DATE: 2002-11-04
;  PRIOR APPLICATION NUMBER: US 10/306,747
;  PRIOR FILING DATE: 2002-11-27
;  PRIOR APPLICATION NUMBER: PCT/US 02/17674
;  PRIOR FILING DATE: 2002-05-29
;  PRIOR APPLICATION NUMBER: US 60/358,580
;  PRIOR FILING DATE: 2002-02-20
;  PRIOR APPLICATION NUMBER: US 60/363,124
;  PRIOR FILING DATE: 2002-03-11
;  PRIOR APPLICATION NUMBER: US 60/386,782
;  PRIOR FILING DATE: 2002-06-06
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 2455
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1489
;    LENGTH: 19
;    TYPE: RNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-665-951-1489

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 19;
  Best Local Similarity   86.7%;  Pred. No. 5.2e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAA 1990
              ||  ||||||||||
Db         17 TTTCAAAAAAGAAAA 3


RESULT 986
US-10-681-074-2303/c
; Sequence 2303, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
;  APPLICANT: KMIEC, ERIC B.
;  APPLICANT:  VAN BRABANT, ANJA
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
;  TITLE OF INVENTION:  OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
;  FILE REFERENCE: NaPro-18 US
;  CURRENT APPLICATION NUMBER: US/10/681,074
;  CURRENT FILING DATE:  2003-10-07
;  PRIOR APPLICATION NUMBER: US 60/453,360
;  PRIOR FILING DATE: 2003-03-07
;  PRIOR APPLICATION NUMBER: US 60/416,983
;  PRIOR FILING DATE: 2002-10-07
;  NUMBER OF SEQ ID NOS: 4375
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2303
;    LENGTH: 16
;    TYPE: DNA
;    ORGANISM: Homo sapiens
US-10-681-074-2303

  Query Match             2.1%;  Score 11.6;  DB 1;  Length 16;
  Best Local Similarity   91.7%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1613 GGGAAGAGTTTG 1624
              :|||||||||||
Db         12 KGGAAGAGTTTG 1


RESULT 987
US-10-023-782A-60
; Sequence 60, Application US/10023782A
; Publication No. US20030147863A1
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TFAP2C EXPRESSION
;  FILE REFERENCE: RTS-0343
;  CURRENT APPLICATION NUMBER: US/10/023,782A
;  CURRENT FILING DATE:  2001-12-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 60
;    LENGTH: 20
;    TYPE: DNA
;    ORGANISM: Artificial Sequence
;    FEATURE:
;    OTHER INFORMATION: Antisense Oligonucleotide
US-10-023-782A-60

  Query Match             2.1%;  Score 11.6;  DB 1;  Length 20;
  Best Local Similarity   77.8%;  Pred. No. 6.1e+02;
  Matches   14;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1633 CTTACTATTTAAAGAGCC 1650
```

```
              |||| |   |||||||||
Db          2 CTTAATGAATAAAGAGCC 19


RESULT 988
US-10-786-720-191/c
; Sequence 191, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 191
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-sense strand
US-10-786-720-191

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 21;
  Best Local Similarity   71.4%;  Pred. No. 7e+02;
  Matches   15;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1866 ACTTAGCCATTGAAATGTCAA 1886
              | ||| |||||  |||| | |
Db         21 AATTATCCATTTCAATGGCTA 1


RESULT 989
US-10-786-720-192
; Sequence 192, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
;  APPLICANT: Wyeth
;  APPLICANT:  O'Toole, Margot
;  APPLICANT:  Liu, Wei
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
;  TITLE OF INVENTION:  DISEASES
;  FILE REFERENCE: 031896-023000 (AM101331L)
;  CURRENT APPLICATION NUMBER: US/10/786,720
;  CURRENT FILING DATE:  2004-02-26
;  NUMBER OF SEQ ID NOS: 21135
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 192
;   LENGTH: 21
;   TYPE: RNA
;   ORGANISM: RNAi-antisense strand
US-10-786-720-192

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 21;
  Best Local Similarity   42.9%;  Pred. No. 7e+02;
  Matches    9;  Conservative    6;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1868 TTAGCCATTGAAATGTCAAAT 1888
              ::| |||::  ||:| | | :
Db          1 UUAUCCAUUUCAAUGGCUAUU 21


RESULT 990
US-10-339-674-1277
; Sequence 1277, Application US/10339674
; Publication No. US20030204318A1
; GENERAL INFORMATION:
;  APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
;  TITLE OF INVENTION: Escherichia coli K-12 MG1655 complete genome.
;  FILE REFERENCE: Jim Zegeer Law Offices - 703-684-8333
;  CURRENT APPLICATION NUMBER: US/10/339,674
;  CURRENT FILING DATE:  2003-06-06
;  NUMBER OF SEQ ID NOS: 3537
;  SOFTWARE: Proprietary
; SEQ ID NO 1277
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Escherichia coli K-12 MG1655 complete genome.
;   FEATURE:
;   LOCATION: (1530784)...(1530809)
;   OTHER INFORMATION: Chromosome = 1  Strand = negative  ConnectronObjectNumber =  1678
US-10-339-674-1277

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 25;
  Best Local Similarity   92.3%;  Pred. No. 8.3e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTA 1767
              |||| ||||||||
Db         12 TCTTCATTCATTA 24


RESULT 991
US-10-138-674-749
; Sequence 749, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 749
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-749

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.8e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              :|||:|::|  | ||:
Db          2 UCAGUGUUAGAGAAAU 17


RESULT 992
US-10-287-949A-749
; Sequence 749, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 749
;   LENGTH: 17
;   TYPE: RNA
```

```
;   ORGANISM: Homo sapiens
US-10-287-949A-749

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.8e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              :|||:|::|  | ||:
Db          2 UCAGUGUUAGAGAAAU 17


RESULT 993
US-10-061-201-954
; Sequence 954, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
;  APPLICANT: Shannon, Mark
;  TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
;  FILE REFERENCE: PB0178
;  CURRENT APPLICATION NUMBER: US/10/061,201
;  CURRENT FILING DATE:  2002-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 09/864,761
;  PRIOR FILING DATE: 2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/328,205
;  PRIOR FILING DATE: 2001-10-10
;  NUMBER OF SEQ ID NOS: 4162
;  SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 954
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-061-201-954

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1530 AAGAAAGGTTAGGAGA 1545
              |||  | |||||||||
Db          1 AAGGCAAGTTAGGAGA 16


RESULT 994
US-10-138-674-750
; Sequence 750, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/138,674
;  CURRENT FILING DATE:  2002-05-03
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 750
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-138-674-750

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.8e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              :|||:|::|  | ||:
Db          1 UCAGUGUUAGAGAAAU 16


RESULT 995
US-10-287-949A-750
; Sequence 750, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00-876-N (400/049)
;  CURRENT APPLICATION NUMBER: US/10/287,949A
;  CURRENT FILING DATE:  2003-04-11
;  NUMBER OF SEQ ID NOS: 20822
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 750
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-10-287-949A-750

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.8e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              :|||:|::|  | ||:
Db          1 UCAGUGUUAGAGAAAU 16


Search completed: November  8, 2004, 08:36:13
Job time : 10 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 08:33:54 ; Search time 5 Seconds
(without alignments)
3.646 Million cell updates/sec

Title: US-10-023-782A-3
Perfect score: 559
Sequence: 1 gaagaaaggttaggagagta.....agtggtatctgacacactct 559

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 945 seqs, 16305 residues

Total number of hits satisfying chosen parameters: 1890

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 960 summaries

Database : rni3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	18.2	3.3	23	1	US-09-057-328-6	Sequence 6, Appli
	2	18.2	3.3	23	1	US-09-276-533A-22	Sequence 22, Appl
	3	18.2	3.3	23	1	US-10-158-735-22	Sequence 22, Appl
	4	16.6	3.0	25	1	US-09-352-608-9	Sequence 9, Appli
	5	16.4	2.9	24	1	US-08-671-548C-66	Sequence 66, Appl
c	6	16.2	2.9	21	1	US-09-475-947A-64	Sequence 64, Appl
	7	16.2	2.9	21	1	US-09-422-978-8160	Sequence 8160, Ap
	8	15.8	2.8	23	1	US-08-660-402-3	Sequence 3, Appli
c	9	15.8	2.8	23	1	US-08-660-402-7	Sequence 7, Appli
	10	15.8	2.8	23	1	PCT-US96-10035-3	Sequence 3, Appli
c	11	15.8	2.8	23	1	PCT-US96-10035-7	Sequence 7, Appli
	12	15.4	2.8	21	1	US-09-657-472-1091	Sequence 1091, Ap
	13	15.2	2.7	20	1	US-09-583-447A-29	Sequence 29, Appl
c	14	15	2.7	21	1	US-09-696-791-4440	Sequence 4440, Ap
	15	14.8	2.6	19	1	US-08-860-038-6	Sequence 6, Appli
	16	14.8	2.6	19	1	US-09-580-923-6	Sequence 6, Appli
	17	14.8	2.6	19	1	US-09-153-838-10	Sequence 10, Appl
	18	14.8	2.6	20	1	US-08-817-384A-2	Sequence 2, Appli
c	19	14.8	2.6	20	1	US-09-495-714C-15	Sequence 15, Appl
	20	14.6	2.6	22	1	US-09-881-572A-22	Sequence 22, Appl
	21	14.4	2.6	16	1	US-08-753-147-140	Sequence 140, App
	22	14.4	2.6	20	1	US-08-702-105A-35	Sequence 35, Appl
	23	14.4	2.6	20	1	US-08-702-110A-35	Sequence 35, Appl
	24	14.4	2.6	20	1	US-09-325-571-35	Sequence 35, Appl
c	25	14.4	2.6	20	1	US-09-198-452A-4828	Sequence 4828, Ap
	26	14.4	2.6	20	1	US-09-198-452A-6111	Sequence 6111, Ap
	27	14.4	2.6	20	1	US-09-848-585-35	Sequence 35, Appl
	28	14.4	2.6	21	1	US-09-294-764-1	Sequence 1, Appli
c	29	14.2	2.5	19	1	US-08-222-177A-193	Sequence 193, App
c	30	14.2	2.5	20	1	US-08-888-982A-32	Sequence 32, Appl
	31	14.2	2.5	20	1	US-09-517-584A-54	Sequence 54, Appl
c	32	14.2	2.5	20	1	US-09-462-261-32	Sequence 32, Appl
c	33	14.2	2.5	20	1	US-09-506-073-121	Sequence 121, App
c	34	14.2	2.5	20	1	US-09-198-452A-5020	Sequence 5020, Ap
c	35	14.2	2.5	21	1	US-08-053-867A-18	Sequence 18, Appl
	36	14.2	2.5	21	1	US-09-792-024-402	Sequence 402, App
	37	14	2.5	20	1	US-09-487-368A-32	Sequence 32, Appl
c	38	14	2.5	20	1	US-09-484-617-130	Sequence 130, App
	39	14	2.5	20	1	US-09-629-644A-32	Sequence 32, Appl
c	40	13.8	2.5	17	1	US-09-866-108A-1346	Sequence 1346, Ap
c	41	13.8	2.5	17	1	US-09-866-108A-7642	Sequence 7642, Ap
c	42	13.8	2.5	17	1	US-09-866-108A-7643	Sequence 7643, Ap
	43	13.8	2.5	19	1	US-08-996-306-46	Sequence 46, Appl
	44	13.8	2.5	19	1	US-09-338-907-46	Sequence 46, Appl
	45	13.8	2.5	19	1	US-09-338-907-380	Sequence 380, App
	46	13.8	2.5	19	1	US-09-218-207-46	Sequence 46, Appl
	47	13.8	2.5	19	1	US-09-218-207-380	Sequence 380, App
	48	13.8	2.5	19	1	US-09-422-978-7856	Sequence 7856, Ap
c	49	13.8	2.5	19	1	US-09-696-791-1991	Sequence 1991, Ap
c	50	13.8	2.5	20	1	US-08-531-747-5	Sequence 5, Appli
c	51	13.8	2.5	20	1	US-08-531-749-5	Sequence 5, Appli
c	52	13.8	2.5	20	1	US-08-781-432-5	Sequence 5, Appli
c	53	13.8	2.5	20	1	US-08-854-041-5	Sequence 5, Appli
	54	13.8	2.5	20	1	US-09-490-692-166	Sequence 166, App
c	55	13.8	2.5	20	1	US-08-930-285-23	Sequence 23, Appl
	56	13.8	2.5	20	1	US-09-021-701-556	Sequence 556, App
	57	13.8	2.5	20	1	US-09-021-701-557	Sequence 557, App
	58	13.8	2.5	20	1	US-09-021-701-558	Sequence 558, App
	59	13.8	2.5	20	1	US-09-021-701-559	Sequence 559, App
c	60	13.8	2.5	20	1	US-09-280-030-46	Sequence 46, Appl
c	61	13.8	2.5	20	1	US-09-198-452A-2718	Sequence 2718, Ap
c	62	13.8	2.5	20	1	US-09-944-036-47	Sequence 47, Appl
	63	13.8	2.5	20	1	US-09-522-775A-5	Sequence 5, Appli
	64	13.8	2.5	21	1	US-09-052-333A-62	Sequence 62, Appl
c	65	13.8	2.5	21	1	US-09-422-978-8235	Sequence 8235, Ap
	66	13.8	2.5	21	1	US-09-422-978-10171	Sequence 10171, A
c	67	13.8	2.5	21	1	US-09-944-036-11	Sequence 11, Appl
c	68	13.8	2.5	21	1	US-09-944-036-46	Sequence 46, Appl
	69	13.8	2.5	21	1	US-09-726-774-40	Sequence 40, Appl
c	70	13.6	2.4	20	1	US-09-009-913-327	Sequence 327, App
c	71	13.6	2.4	20	1	US-09-157-177-29	Sequence 29, Appl
	72	13.6	2.4	20	1	US-09-288-461-43	Sequence 43, Appl
c	73	13.6	2.4	20	1	US-09-490-692-109	Sequence 109, App
c	74	13.6	2.4	20	1	US-09-021-701-354	Sequence 354, App
c	75	13.6	2.4	20	1	US-09-487-368A-183	Sequence 183, App
	76	13.6	2.4	20	1	US-09-484-617-164	Sequence 164, App
	77	13.6	2.4	20	1	US-09-629-645A-37	Sequence 37, Appl
	78	13.6	2.4	20	1	US-09-742-703-49	Sequence 49, Appl
	79	13.6	2.4	20	1	US-09-191-170-99	Sequence 99, Appl
c	80	13.6	2.4	20	1	US-09-629-644A-183	Sequence 183, App
	81	13.6	2.4	20	1	US-09-422-978-5752	Sequence 5752, Ap
c	82	13.6	2.4	20	1	US-09-230-652-116	Sequence 116, App
c	83	13.6	2.4	20	1	US-09-780-045-84	Sequence 84, Appl
	84	13.6	2.4	20	1	US-09-758-881-43	Sequence 43, Appl
c	85	13.6	2.4	20	1	US-09-541-210-29	Sequence 29, Appl
c	86	13.4	2.4	16	1	US-09-371-772B-5864	Sequence 5864, Ap
c	87	13.4	2.4	17	1	US-08-747-121-5	Sequence 5, Appli
c	88	13.4	2.4	17	1	US-08-744-905A-5	Sequence 5, Appli
c	89	13.4	2.4	17	1	US-08-584-040-2032	Sequence 2032, Ap
c	90	13.4	2.4	17	1	US-08-584-040-2033	Sequence 2033, Ap
c	91	13.4	2.4	17	1	US-08-584-040-2034	Sequence 2034, Ap
c	92	13.4	2.4	17	1	US-09-371-772B-577	Sequence 577, App
c	93	13.4	2.4	17	1	US-09-371-772B-578	Sequence 578, App
c	94	13.4	2.4	17	1	US-09-371-772B-579	Sequence 579, App
c	95	13.4	2.4	18	1	US-09-213-768-36	Sequence 36, Appl
c	96	13.4	2.4	18	1	US-08-826-532-16	Sequence 16, Appl
c	97	13.4	2.4	18	1	US-08-826-532-18	Sequence 18, Appl
c	98	13.4	2.4	18	1	US-09-228-324A-16	Sequence 16, Appl
c	99	13.4	2.4	18	1	US-09-228-324A-18	Sequence 18, Appl
	100	13.4	2.4	18	1	US-09-422-978-7270	Sequence 7270, Ap
c	101	13.4	2.4	20	1	US-08-529-878B-25	Sequence 25, Appl
	102	13.4	2.4	20	1	US-09-467-082-25	Sequence 25, Appl
	103	13.4	2.4	20	1	US-09-487-368A-130	Sequence 130, App
	104	13.4	2.4	20	1	US-09-629-644A-130	Sequence 130, App
	105	13.4	2.4	20	1	US-09-198-452A-3480	Sequence 3480, Ap
c	106	13.4	2.4	20	1	US-09-198-452A-4153	Sequence 4153, Ap

	107	13.2	2.4	18	1	US-08-564-002-28	Sequence 28, Appl
	108	13.2	2.4	18	1	US-09-358-381-47	Sequence 47, Appl
	109	13.2	2.4	18	1	US-08-577-081A-65	Sequence 65, Appl
c	110	13.2	2.4	18	1	US-09-448-176-4	Sequence 4, Appli
c	111	13.2	2.4	18	1	US-09-632-580A-90	Sequence 90, Appl
	112	13.2	2.4	18	1	US-09-577-902-47	Sequence 47, Appl
	113	13.2	2.4	18	1	US-09-167-109-180	Sequence 180, App
c	114	13.2	2.4	19	1	US-08-699-628-10	Sequence 10, Appl
	115	13.2	2.4	19	1	US-09-422-978-4542	Sequence 4542, Ap
	116	13.2	2.4	19	1	US-09-077-940A-19	Sequence 19, Appl
c	117	13.2	2.4	19	1	US-09-696-791-1908	Sequence 1908, Ap
	118	13.2	2.4	19	1	US-09-696-791-2251	Sequence 2251, Ap
c	119	13.2	2.4	20	1	US-08-222-177A-344	Sequence 344, App
c	120	13.2	2.4	20	1	US-08-167-113-13	Sequence 13, Appl
	121	13.2	2.4	20	1	US-08-478-178A-65	Sequence 65, Appl
	122	13.2	2.4	20	1	US-08-488-177-65	Sequence 65, Appl
	123	13.2	2.4	20	1	US-08-481-072A-65	Sequence 65, Appl
	124	13.2	2.4	20	1	US-08-664-336-65	Sequence 65, Appl
	125	13.2	2.4	20	1	US-08-481-066A-65	Sequence 65, Appl
c	126	13.2	2.4	20	1	US-08-886-161-13	Sequence 13, Appl
	127	13.2	2.4	20	1	US-09-120-853-16	Sequence 16, Appl
c	128	13.2	2.4	20	1	US-09-358-384-44	Sequence 44, Appl
	129	13.2	2.4	20	1	US-09-103-875-128	Sequence 128, App
	130	13.2	2.4	20	1	US-09-313-930-5	Sequence 5, Appli
	131	13.2	2.4	20	1	US-09-377-309-75	Sequence 75, Appl
	132	13.2	2.4	20	1	US-08-829-637A-65	Sequence 65, Appl
c	133	13.2	2.4	20	1	US-09-907-843-31	Sequence 31, Appl
c	134	13.2	2.4	20	1	US-09-659-845A-146	Sequence 146, App
c	135	13.2	2.4	20	1	US-09-422-978-4087	Sequence 4087, Ap
	136	13.2	2.4	20	1	US-10-025-139-65	Sequence 65, Appl
	137	13.2	2.4	20	1	US-09-198-452A-2313	Sequence 2313, Ap
c	138	13.2	2.4	20	1	US-09-657-013-9	Sequence 9, Appli
	139	13.2	2.4	20	1	US-09-529-239D-89	Sequence 89, Appl
c	140	13.2	2.4	20	1	US-09-935-038A-10	Sequence 10, Appl
	141	13.2	2.4	20	1	US-09-544-398B-618	Sequence 618, App
	142	13.2	2.4	20	1	US-09-834-291-14	Sequence 14, Appl
c	143	13	2.3	19	1	US-08-948-113D-2	Sequence 2, Appli
	144	13	2.3	19	1	US-09-696-791-2249	Sequence 2249, Ap
	145	13	2.3	19	1	US-09-696-791-2250	Sequence 2250, Ap
c	146	13	2.3	20	1	US-07-872-644-1	Sequence 1, Appli
	147	13	2.3	20	1	US-08-474-542A-112	Sequence 112, App
c	148	13	2.3	20	1	US-08-474-542A-118	Sequence 118, App
c	149	13	2.3	20	1	US-08-297-494-1	Sequence 1, Appli
c	150	13	2.3	20	1	US-08-297-510-1	Sequence 1, Appli
	151	13	2.3	20	1	US-08-457-648-112	Sequence 112, App
c	152	13	2.3	20	1	US-08-457-648-118	Sequence 118, App
c	153	13	2.3	20	1	US-08-479-532-1	Sequence 1, Appli
c	154	13	2.3	20	1	US-08-455-526-1	Sequence 1, Appli
c	155	13	2.3	20	1	US-08-455-525-1	Sequence 1, Appli
c	156	13	2.3	20	1	US-09-139-491-1	Sequence 1, Appli
c	157	13	2.3	20	1	US-09-488-074-5	Sequence 5, Appli
c	158	13	2.3	20	1	US-09-883-825-1	Sequence 1, Appli
c	159	13	2.3	20	1	PCT-US92-03222-1	Sequence 1, Appli
	160	12.8	2.3	16	1	US-08-283-591-19	Sequence 19, Appl
	161	12.8	2.3	16	1	US-08-088-658-37	Sequence 37, Appl
	162	12.8	2.3	16	1	US-08-431-080-3	Sequence 3, Appli
	163	12.8	2.3	16	1	US-08-938-534-3	Sequence 3, Appli
	164	12.8	2.3	16	1	US-08-471-907A-37	Sequence 37, Appl
	165	12.8	2.3	16	1	US-08-088-661F-32	Sequence 32, Appl
	166	12.8	2.3	16	1	US-08-150-156A-30	Sequence 30, Appl
	167	12.8	2.3	16	1	US-09-345-294-3	Sequence 3, Appli
	168	12.8	2.3	16	1	US-08-108-591B-30	Sequence 30, Appl
	169	12.8	2.3	16	1	US-08-468-719A-30	Sequence 30, Appl
	170	12.8	2.3	16	1	US-08-462-977B-30	Sequence 30, Appl
	171	12.8	2.3	16	1	US-09-442-054A-37	Sequence 37, Appl
c	172	12.8	2.3	17	1	US-08-390-850-602	Sequence 602, App
	173	12.8	2.3	17	1	US-08-390-850-679	Sequence 679, App
	174	12.8	2.3	17	1	US-08-373-124A-518	Sequence 518, App
c	175	12.8	2.3	17	1	US-08-373-124A-2177	Sequence 2177, Ap
c	176	12.8	2.3	17	1	US-08-435-634-602	Sequence 602, App
	177	12.8	2.3	17	1	US-08-435-634-679	Sequence 679, App
	178	12.8	2.3	17	1	US-08-435-628-518	Sequence 518, App
c	179	12.8	2.3	17	1	US-08-435-628-2177	Sequence 2177, Ap
	180	12.8	2.3	17	1	US-08-985-162-545	Sequence 545, App
	181	12.8	2.3	17	1	US-08-985-162-546	Sequence 546, App
c	182	12.8	2.3	17	1	US-08-584-040-2204	Sequence 2204, Ap
c	183	12.8	2.3	17	1	US-08-584-040-2233	Sequence 2233, Ap
c	184	12.8	2.3	17	1	US-08-584-040-2234	Sequence 2234, Ap
	185	12.8	2.3	17	1	US-08-584-040-2518	Sequence 2518, Ap
c	186	12.8	2.3	17	1	US-08-584-040-6032	Sequence 6032, Ap
c	187	12.8	2.3	17	1	US-09-479-122-32	Sequence 32, Appl
c	188	12.8	2.3	17	1	US-09-484-997-32	Sequence 32, Appl
c	189	12.8	2.3	17	1	US-09-481-355-32	Sequence 32, Appl
c	190	12.8	2.3	17	1	US-09-481-282-32	Sequence 32, Appl
c	191	12.8	2.3	17	1	US-09-371-772B-749	Sequence 749, App
c	192	12.8	2.3	17	1	US-09-371-772B-778	Sequence 778, App
c	193	12.8	2.3	17	1	US-09-371-772B-779	Sequence 779, App
	194	12.8	2.3	17	1	US-09-371-772B-1042	Sequence 1042, Ap
c	195	12.8	2.3	17	1	US-09-371-772B-2869	Sequence 2869, Ap
c	196	12.8	2.3	17	1	US-09-455-659A-32	Sequence 32, Appl
c	197	12.8	2.3	17	1	US-09-484-996-32	Sequence 32, Appl
	198	12.8	2.3	17	1	US-09-401-063-545	Sequence 545, App
	199	12.8	2.3	17	1	US-09-401-063-546	Sequence 546, App
	200	12.8	2.3	17	1	US-09-827-998-311	Sequence 311, App
	201	12.8	2.3	17	1	US-09-827-998-312	Sequence 312, App
c	202	12.8	2.3	17	1	US-09-479-123-32	Sequence 32, Appl
c	203	12.8	2.3	17	1	US-09-866-108A-1345	Sequence 1345, Ap
c	204	12.8	2.3	17	1	US-09-866-108A-1347	Sequence 1347, Ap
c	205	12.8	2.3	17	1	US-09-866-108A-1580	Sequence 1580, Ap
c	206	12.8	2.3	17	1	US-09-866-108A-1581	Sequence 1581, Ap
c	207	12.8	2.3	17	1	US-09-866-108A-7641	Sequence 7641, Ap
c	208	12.8	2.3	17	1	US-09-866-108A-7644	Sequence 7644, Ap
	209	12.8	2.3	17	1	US-09-866-108A-7957	Sequence 7957, Ap
	210	12.8	2.3	17	1	US-09-866-108A-7958	Sequence 7958, Ap
c	211	12.8	2.3	17	1	US-09-484-317A-32	Sequence 32, Appl
	212	12.8	2.3	18	1	US-08-459-568-15	Sequence 15, Appl
	213	12.8	2.3	18	1	US-08-399-411-15	Sequence 15, Appl
c	214	12.8	2.3	18	1	US-08-634-350-21	Sequence 21, Appl
	215	12.8	2.3	18	1	US-08-775-009-22	Sequence 22, Appl
	216	12.8	2.3	18	1	US-08-516-859A-15	Sequence 15, Appl
	217	12.8	2.3	18	1	US-09-035-220-13	Sequence 13, Appl
	218	12.8	2.3	18	1	US-09-586-472-15	Sequence 15, Appl
	219	12.8	2.3	18	1	US-09-430-114-2	Sequence 2, Appli
	220	12.8	2.3	18	1	US-09-528-706-15	Sequence 15, Appl
c	221	12.8	2.3	18	1	US-09-422-978-7869	Sequence 7869, Ap
	222	12.8	2.3	18	1	US-09-422-978-11530	Sequence 11530, A
	223	12.8	2.3	18	1	US-09-544-398B-450	Sequence 450, App
	224	12.8	2.3	18	1	US-09-856-662-112	Sequence 112, App
	225	12.8	2.3	19	1	US-09-061-764A-3	Sequence 3, Appli
c	226	12.8	2.3	19	1	US-09-216-393B-337	Sequence 337, App
	227	12.8	2.3	19	1	US-09-422-978-4047	Sequence 4047, Ap
c	228	12.8	2.3	19	1	US-09-422-978-11179	Sequence 11179, A
	229	12.8	2.3	19	1	US-09-831-642-52	Sequence 52, Appl
	230	12.8	2.3	19	1	US-09-696-791-1556	Sequence 1556, Ap
c	231	12.8	2.3	19	1	US-09-696-791-1990	Sequence 1990, Ap
c	232	12.6	2.3	19	1	US-08-607-384A-40	Sequence 40, Appl
c	233	12.6	2.3	19	1	US-08-801-898A-8	Sequence 8, Appli
c	234	12.6	2.3	19	1	US-09-422-978-8902	Sequence 8902, Ap
c	235	12.6	2.3	19	1	US-09-422-978-9136	Sequence 9136, Ap
	236	12.6	2.3	19	1	US-09-696-791-1391	Sequence 1391, Ap
	237	12.6	2.3	19	1	US-09-696-791-1392	Sequence 1392, Ap
	238	12.6	2.3	19	1	US-09-696-791-3422	Sequence 3422, Ap
c	239	12.4	2.2	15	1	US-08-334-847-582	Sequence 582, App
c	240	12.4	2.2	15	1	US-08-334-847-583	Sequence 583, App
	241	12.4	2.2	15	1	US-08-930-371-9	Sequence 9, Appli
	242	12.4	2.2	15	1	US-08-930-371-21	Sequence 21, Appl
c	243	12.4	2.2	15	1	US-08-544-381B-111	Sequence 111, App
	244	12.4	2.2	16	1	US-08-320-559-6	Sequence 6, Appli
	245	12.4	2.2	16	1	US-08-327-392-6	Sequence 6, Appli
	246	12.4	2.2	16	1	US-08-545-860D-6	Sequence 6, Appli
	247	12.4	2.2	16	1	US-08-929-140-5	Sequence 5, Appli
	248	12.4	2.2	16	1	US-08-929-140-7	Sequence 7, Appli
	249	12.4	2.2	16	1	US-09-560-579A-5	Sequence 5, Appli
	250	12.4	2.2	16	1	US-09-560-579A-7	Sequence 7, Appli
	251	12.4	2.2	16	1	PCT-US94-04496-6	Sequence 6, Appli
	252	12.4	2.2	17	1	US-08-584-040-7423	Sequence 7423, Ap

253	12.4	2.2	17	1	US-09-371-772B-3230	Sequence 3230, Ap
c 254	12.4	2.2	17	1	US-09-371-772B-4869	Sequence 4869, Ap
c 255	12.4	2.2	17	1	US-09-371-772B-6658	Sequence 6658, Ap
c 256	12.4	2.2	17	1	US-09-371-772B-6659	Sequence 6659, Ap
c 257	12.4	2.2	17	1	US-09-866-108A-7187	Sequence 7187, Ap
c 258	12.4	2.2	17	1	US-09-866-108A-7188	Sequence 7188, Ap
c 259	12.4	2.2	17	1	US-09-866-108A-7189	Sequence 7189, Ap
c 260	12.4	2.2	17	1	US-09-866-108A-7190	Sequence 7190, Ap
c 261	12.4	2.2	17	1	US-09-866-108A-7639	Sequence 7639, Ap
c 262	12.4	2.2	17	1	US-09-866-108A-7640	Sequence 7640, Ap
c 263	12.4	2.2	17	1	US-09-404-912-564	Sequence 564, App
c 264	12.4	2.2	17	1	US-09-404-912-565	Sequence 565, App
265	12.4	2.2	18	1	US-08-480-655-27	Sequence 27, Appl
266	12.4	2.2	18	1	US-09-255-912-26	Sequence 26, Appl
c 267	12.4	2.2	18	1	US-09-115-027-2	Sequence 2, Appli
268	12.4	2.2	18	1	US-09-455-683-27	Sequence 27, Appl
269	12.4	2.2	18	1	US-09-158-695-5	Sequence 5, Appli
270	12.4	2.2	18	1	US-10-092-022-5	Sequence 5, Appli
271	12.4	2.2	18	1	US-09-422-978-4678	Sequence 4678, Ap
272	12.4	2.2	18	1	US-09-422-978-4857	Sequence 4857, Ap
c 273	12.4	2.2	18	1	US-09-544-398B-138	Sequence 138, App
c 274	12.4	2.2	18	1	US-09-544-398B-522	Sequence 522, App
275	12.4	2.2	19	1	US-08-364-076-2	Sequence 2, Appli
276	12.4	2.2	19	1	US-08-132-168A-11	Sequence 11, Appl
c 277	12.4	2.2	19	1	US-08-836-261A-40	Sequence 40, Appl
278	12.4	2.2	19	1	US-09-338-907-407	Sequence 407, App
c 279	12.4	2.2	19	1	US-09-275-505-1	Sequence 1, Appli
280	12.4	2.2	19	1	US-09-218-207-407	Sequence 407, App
c 281	12.4	2.2	19	1	US-09-345-882-115	Sequence 115, App
282	12.4	2.2	19	1	US-09-422-978-5778	Sequence 5778, Ap
283	12.4	2.2	19	1	US-09-422-978-8050	Sequence 8050, Ap
284	12.4	2.2	19	1	US-09-422-978-9088	Sequence 9088, Ap
c 285	12.4	2.2	19	1	US-09-422-978-9761	Sequence 9761, Ap
286	12.4	2.2	19	1	US-09-696-791-7	Sequence 7, Appli
287	12.4	2.2	19	1	US-09-696-791-2364	Sequence 2364, Ap
c 288	12.2	2.2	17	1	US-08-373-124A-2141	Sequence 2141, Ap
289	12.2	2.2	17	1	US-08-758-306-1159	Sequence 1159, Ap
c 290	12.2	2.2	17	1	US-08-435-628-2141	Sequence 2141, Ap
291	12.2	2.2	17	1	US-08-985-162-750	Sequence 750, App
292	12.2	2.2	17	1	US-08-985-162-751	Sequence 751, App
293	12.2	2.2	17	1	US-08-985-162-752	Sequence 752, App
294	12.2	2.2	17	1	US-08-584-040-5631	Sequence 5631, Ap
c 295	12.2	2.2	17	1	US-08-584-040-7397	Sequence 7397, Ap
296	12.2	2.2	17	1	US-08-584-040-7742	Sequence 7742, Ap
297	12.2	2.2	17	1	US-08-584-040-8011	Sequence 8011, Ap
298	12.2	2.2	17	1	US-08-584-040-8157	Sequence 8157, Ap
299	12.2	2.2	17	1	US-09-371-772B-2521	Sequence 2521, Ap
c 300	12.2	2.2	17	1	US-09-371-772B-3205	Sequence 3205, Ap
301	12.2	2.2	17	1	US-09-371-772B-3527	Sequence 3527, Ap
302	12.2	2.2	17	1	US-09-371-772B-3794	Sequence 3794, Ap
303	12.2	2.2	17	1	US-09-371-772B-3940	Sequence 3940, Ap
304	12.2	2.2	17	1	US-09-371-772B-4919	Sequence 4919, Ap
305	12.2	2.2	17	1	US-09-371-772B-5300	Sequence 5300, Ap
306	12.2	2.2	17	1	US-09-371-772B-6155	Sequence 6155, Ap
307	12.2	2.2	17	1	US-09-371-772B-6156	Sequence 6156, Ap
308	12.2	2.2	17	1	US-09-371-772B-6199	Sequence 6199, Ap
309	12.2	2.2	17	1	US-09-401-063-750	Sequence 750, App
310	12.2	2.2	17	1	US-09-401-063-751	Sequence 751, App
311	12.2	2.2	17	1	US-09-401-063-752	Sequence 752, App
c 312	12.2	2.2	17	1	US-09-866-108A-2108	Sequence 2108, Ap
c 313	12.2	2.2	17	1	US-09-866-108A-2784	Sequence 2784, Ap
314	12.2	2.2	17	1	US-09-866-108A-7956	Sequence 7956, Ap
315	12.2	2.2	17	1	US-09-866-108A-7960	Sequence 7960, Ap
c 316	12.2	2.2	17	1	US-09-866-108A-10544	Sequence 10544, A
c 317	12.2	2.2	18	1	US-08-218-303-17	Sequence 17, Appl
c 318	12.2	2.2	18	1	US-08-453-224-5	Sequence 5, Appli
319	12.2	2.2	18	1	US-08-233-009-35	Sequence 35, Appl
c 320	12.2	2.2	18	1	US-08-379-079-5	Sequence 5, Appli
321	12.2	2.2	18	1	US-08-363-240A-1102	Sequence 1102, Ap
322	12.2	2.2	18	1	US-08-758-306-533	Sequence 533, App
323	12.2	2.2	18	1	US-08-173-489C-21	Sequence 21, Appl
c 324	12.2	2.2	18	1	US-08-802-384-5	Sequence 5, Appli
c 325	12.2	2.2	18	1	US-09-197-378-9	Sequence 9, Appli
c 326	12.2	2.2	18	1	US-09-302-390-5	Sequence 5, Appli
327	12.2	2.2	18	1	US-09-339-964-9	Sequence 9, Appli
c 328	12.2	2.2	18	1	US-08-867-381A-19	Sequence 19, Appl
329	12.2	2.2	18	1	US-09-133-717-10	Sequence 10, Appl
c 330	12.2	2.2	18	1	US-08-559-397A-24	Sequence 24, Appl
331	12.2	2.2	18	1	US-09-158-863C-10	Sequence 10, Appl
c 332	12.2	2.2	18	1	US-09-521-144-19	Sequence 19, Appl
333	12.2	2.2	18	1	US-08-584-040-3033	Sequence 3033, Ap
c 334	12.2	2.2	18	1	US-09-270-140A-10	Sequence 10, Appl
c 335	12.2	2.2	18	1	US-09-270-140A-13	Sequence 13, Appl
c 336	12.2	2.2	18	1	US-09-270-140A-16	Sequence 16, Appl
337	12.2	2.2	18	1	US-09-422-978-5792	Sequence 5792, Ap
c 338	12.2	2.2	18	1	US-09-422-978-7594	Sequence 7594, Ap
339	12.2	2.2	18	1	US-09-422-978-9126	Sequence 9126, Ap
340	12.2	2.2	18	1	US-09-371-772B-1461	Sequence 1461, Ap
c 341	12.2	2.2	18	1	US-10-029-598-22	Sequence 22, Appl
c 342	12.2	2.2	18	1	US-09-696-791-4169	Sequence 4169, Ap
c 343	12.2	2.2	18	1	PCT-US94-05181-5	Sequence 5, Appli
344	12	2.1	13	1	US-08-173-489C-139	Sequence 139, App
c 345	12	2.1	14	1	US-09-531-000-65	Sequence 65, Appl
c 346	12	2.1	15	1	US-08-334-847-584	Sequence 584, App
c 347	12	2.1	15	1	US-08-334-847-585	Sequence 585, App
c 348	12	2.1	15	1	US-08-585-684B-203	Sequence 203, App
c 349	12	2.1	15	1	US-08-585-684B-204	Sequence 204, App
c 350	12	2.1	15	1	US-09-038-073-203	Sequence 203, App
c 351	12	2.1	15	1	US-09-038-073-204	Sequence 204, App
352	12	2.1	15	1	US-08-812-951B-1	Sequence 1, Appli
c 353	12	2.1	15	1	US-08-812-951B-2	Sequence 2, Appli
354	12	2.1	15	1	US-08-784-747-2	Sequence 2, Appli
c 355	12	2.1	15	1	US-08-784-747-3	Sequence 3, Appli
356	12	2.1	15	1	US-09-409-778-9	Sequence 9, Appli
c 357	12	2.1	15	1	US-09-409-778-10	Sequence 10, Appl
c 358	12	2.1	16	1	US-08-283-591-18	Sequence 18, Appl
c 359	12	2.1	16	1	US-08-088-658-36	Sequence 36, Appl
c 360	12	2.1	16	1	US-08-471-907A-36	Sequence 36, Appl
c 361	12	2.1	16	1	US-08-088-661F-31	Sequence 31, Appl
c 362	12	2.1	16	1	US-08-150-156A-29	Sequence 29, Appl
c 363	12	2.1	16	1	US-08-108-591B-29	Sequence 29, Appl
c 364	12	2.1	16	1	US-08-468-719A-29	Sequence 29, Appl
c 365	12	2.1	16	1	US-08-462-977B-29	Sequence 29, Appl
c 366	12	2.1	16	1	US-09-442-054A-36	Sequence 36, Appl
c 367	12	2.1	17	1	US-08-292-620A-1679	Sequence 1679, Ap
c 368	12	2.1	17	1	US-08-292-620A-1756	Sequence 1756, Ap
c 369	12	2.1	17	1	US-08-292-620A-1764	Sequence 1764, Ap
c 370	12	2.1	17	1	US-08-292-620A-1864	Sequence 1864, Ap
c 371	12	2.1	17	1	US-08-292-620A-1885	Sequence 1885, Ap
c 372	12	2.1	17	1	US-08-292-620A-1999	Sequence 1999, Ap
c 373	12	2.1	17	1	US-09-071-845-1679	Sequence 1679, Ap
c 374	12	2.1	17	1	US-09-071-845-1756	Sequence 1756, Ap
c 375	12	2.1	17	1	US-09-071-845-1764	Sequence 1764, Ap
c 376	12	2.1	17	1	US-09-071-845-1864	Sequence 1864, Ap
c 377	12	2.1	17	1	US-09-071-845-1885	Sequence 1885, Ap
c 378	12	2.1	17	1	US-09-071-845-1999	Sequence 1999, Ap
379	12	2.1	17	1	US-09-404-912-510	Sequence 510, App
c 380	12	2.1	18	1	US-08-455-627-17	Sequence 17, Appl
c 381	12	2.1	18	1	US-08-689-856-17	Sequence 17, Appl
c 382	12	2.1	18	1	US-08-787-321-17	Sequence 17, Appl
c 383	11.8	2.1	15	1	US-08-311-486C-142	Sequence 142, App
384	11.8	2.1	15	1	US-08-311-486C-569	Sequence 569, App
385	11.8	2.1	15	1	US-08-292-620A-124	Sequence 124, App
386	11.8	2.1	15	1	US-08-585-684B-609	Sequence 609, App
387	11.8	2.1	15	1	US-08-585-684B-610	Sequence 610, App
388	11.8	2.1	15	1	US-08-585-684B-611	Sequence 611, App
389	11.8	2.1	15	1	US-08-585-684B-612	Sequence 612, App
c 390	11.8	2.1	15	1	US-08-641-291A-57	Sequence 57, Appl
391	11.8	2.1	15	1	US-09-071-845-124	Sequence 124, App
c 392	11.8	2.1	15	1	US-09-121-286-18	Sequence 18, Appl
393	11.8	2.1	15	1	US-09-038-073-609	Sequence 609, App
394	11.8	2.1	15	1	US-09-038-073-610	Sequence 610, App
395	11.8	2.1	15	1	US-09-038-073-611	Sequence 611, App
396	11.8	2.1	15	1	US-09-038-073-612	Sequence 612, App
c 397	11.8	2.1	15	1	US-09-180-437-143	Sequence 143, App
398	11.8	2.1	15	1	US-09-397-992A-28	Sequence 28, Appl

399	11.8	2.1	15	1	US-09-971-843-28	Sequence 28, Appl
c 400	11.8	2.1	16	1	US-08-061-697-23	Sequence 23, Appl
c 401	11.8	2.1	16	1	US-08-131-365B-23	Sequence 23, Appl
402	11.8	2.1	16	1	US-08-486-721A-21	Sequence 21, Appl
c 403	11.8	2.1	16	1	US-08-486-721A-21	Sequence 21, Appl
c 404	11.8	2.1	16	1	US-08-753-147-151	Sequence 151, App
c 405	11.8	2.1	16	1	US-08-294-424-1	Sequence 1, Appli
406	11.8	2.1	16	1	US-08-294-424-2	Sequence 2, Appli
407	11.8	2.1	16	1	US-08-148-058A-37	Sequence 37, Appl
408	11.8	2.1	16	1	US-08-478-042-37	Sequence 37, Appl
409	11.8	2.1	16	1	US-08-645-215-37	Sequence 37, Appl
410	11.8	2.1	16	1	US-08-466-604-37	Sequence 37, Appl
c 411	11.8	2.1	16	1	US-08-668-123-23	Sequence 23, Appl
412	11.8	2.1	16	1	US-09-509-565-35	Sequence 35, Appl
413	11.8	2.1	16	1	US-09-043-816E-34	Sequence 34, Appl
414	11.8	2.1	16	1	US-08-483-941-6	Sequence 6, Appli
c 415	11.8	2.1	16	1	US-08-483-941-6	Sequence 6, Appli
416	11.8	2.1	16	1	US-08-845-381E-13	Sequence 13, Appl
417	11.8	2.1	16	1	US-08-845-381E-70	Sequence 70, Appl
418	11.8	2.1	16	1	US-09-479-005A-256	Sequence 256, App
419	11.8	2.1	16	1	PCT-US91-08442-3	Sequence 3, Appli
c 420	11.8	2.1	16	1	PCT-US91-08442-3	Sequence 3, Appli
c 421	11.8	2.1	16	1	5256545-4	Patent No. 5256545
422	11.8	2.1	16	1	5256545-33	Patent No. 5256545
423	11.8	2.1	16	1	5312912-9	Patent No. 5312912
424	11.8	2.1	17	1	US-08-272-372-3	Sequence 3, Appli
c 425	11.8	2.1	17	1	US-08-390-850-709	Sequence 709, App
426	11.8	2.1	17	1	US-08-373-124A-516	Sequence 516, App
c 427	11.8	2.1	17	1	US-08-373-124A-2179	Sequence 2179, Ap
c 428	11.8	2.1	17	1	US-08-435-634-709	Sequence 709, App
c 429	11.8	2.1	17	1	US-08-758-306-1001	Sequence 1001, Ap
430	11.8	2.1	17	1	US-08-435-628-516	Sequence 516, App
c 431	11.8	2.1	17	1	US-08-435-628-2179	Sequence 2179, Ap
c 432	11.8	2.1	17	1	US-08-292-620A-1931	Sequence 1931, Ap
c 433	11.8	2.1	17	1	US-08-985-162-129	Sequence 129, App
434	11.8	2.1	17	1	US-08-985-162-747	Sequence 747, App
435	11.8	2.1	17	1	US-08-985-162-748	Sequence 748, App
c 436	11.8	2.1	17	1	US-09-071-845-1931	Sequence 1931, Ap
437	11.8	2.1	17	1	US-08-584-040-1770	Sequence 1770, Ap
438	11.8	2.1	17	1	US-08-584-040-2066	Sequence 2066, Ap
c 439	11.8	2.1	17	1	US-08-584-040-2205	Sequence 2205, Ap
c 440	11.8	2.1	17	1	US-08-584-040-2232	Sequence 2232, Ap
c 441	11.8	2.1	17	1	US-08-584-040-2617	Sequence 2617, Ap
c 442	11.8	2.1	17	1	US-08-584-040-5376	Sequence 5376, Ap
c 443	11.8	2.1	17	1	US-08-584-040-6031	Sequence 6031, Ap
c 444	11.8	2.1	17	1	US-08-584-040-7398	Sequence 7398, Ap
445	11.8	2.1	17	1	US-08-584-040-7743	Sequence 7743, Ap
c 446	11.8	2.1	17	1	US-09-573-377-4	Sequence 4, Appli
c 447	11.8	2.1	17	1	US-09-573-377-14	Sequence 14, Appl
448	11.8	2.1	17	1	US-09-371-772B-315	Sequence 315, App
449	11.8	2.1	17	1	US-09-371-772B-611	Sequence 611, App
c 450	11.8	2.1	17	1	US-09-371-772B-750	Sequence 750, App
c 451	11.8	2.1	17	1	US-09-371-772B-777	Sequence 777, App
c 452	11.8	2.1	17	1	US-09-371-772B-1141	Sequence 1141, Ap
c 453	11.8	2.1	17	1	US-09-371-772B-2276	Sequence 2276, Ap
c 454	11.8	2.1	17	1	US-09-371-772B-2868	Sequence 2868, Ap
c 455	11.8	2.1	17	1	US-09-371-772B-3206	Sequence 3206, Ap
456	11.8	2.1	17	1	US-09-371-772B-3528	Sequence 3528, Ap
457	11.8	2.1	17	1	US-09-371-772B-4920	Sequence 4920, Ap
c 458	11.8	2.1	17	1	US-09-371-772B-5162	Sequence 5162, Ap
459	11.8	2.1	17	1	US-09-371-772B-6409	Sequence 6409, Ap
c 460	11.8	2.1	17	1	US-09-401-063-129	Sequence 129, App
461	11.8	2.1	17	1	US-09-401-063-747	Sequence 747, App
462	11.8	2.1	17	1	US-09-401-063-748	Sequence 748, App
463	11.8	2.1	17	1	US-09-827-998-310	Sequence 310, App
464	11.8	2.1	17	1	US-09-827-998-313	Sequence 313, App
c 465	11.8	2.1	17	1	US-09-866-108A-1344	Sequence 1344, Ap
c 466	11.8	2.1	17	1	US-09-866-108A-1348	Sequence 1348, Ap
c 467	11.8	2.1	17	1	US-09-866-108A-1579	Sequence 1579, Ap
c 468	11.8	2.1	17	1	US-09-866-108A-1582	Sequence 1582, Ap
469	11.8	2.1	17	1	US-09-866-108A-1700	Sequence 1700, Ap
470	11.8	2.1	17	1	US-09-866-108A-1701	Sequence 1701, Ap
471	11.8	2.1	17	1	US-09-866-108A-1702	Sequence 1702, Ap
c 472	11.8	2.1	17	1	US-09-866-108A-7645	Sequence 7645, Ap
473	11.8	2.1	17	1	US-09-866-108A-7959	Sequence 7959, Ap
c 474	11.8	2.1	17	1	US-09-866-108A-8582	Sequence 8582, Ap
c 475	11.8	2.1	17	1	US-09-866-108A-8583	Sequence 8583, Ap
c 476	11.8	2.1	17	1	US-09-866-108A-8584	Sequence 8584, Ap
c 477	11.8	2.1	17	1	US-09-866-108A-10542	Sequence 10542, A
c 478	11.8	2.1	17	1	US-09-866-108A-10543	Sequence 10543, A
c 479	11.8	2.1	18	1	US-08-393-219-21	Sequence 21, Appl
480	11.8	2.1	18	1	US-08-245-295-20	Sequence 20, Appl
481	11.8	2.1	18	1	US-08-481-130-20	Sequence 20, Appl
482	11.8	2.1	18	1	US-08-656-984A-20	Sequence 20, Appl
483	11.8	2.1	18	1	US-08-485-604-20	Sequence 20, Appl
484	11.8	2.1	18	1	US-08-758-306-531	Sequence 531, App
485	11.8	2.1	18	1	US-08-526-583-22	Sequence 22, Appl
486	11.8	2.1	18	1	US-08-487-595-20	Sequence 20, Appl
487	11.8	2.1	18	1	US-08-734-973-31	Sequence 31, Appl
488	11.8	2.1	18	1	US-08-734-973-32	Sequence 32, Appl
489	11.8	2.1	18	1	US-09-213-767-26	Sequence 26, Appl
490	11.8	2.1	18	1	US-09-166-203-23	Sequence 23, Appl
c 491	11.8	2.1	18	1	US-09-205-860-81	Sequence 81, Appl
492	11.8	2.1	18	1	US-09-256-496-58	Sequence 58, Appl
c 493	11.8	2.1	18	1	US-09-143-212-58	Sequence 58, Appl
494	11.8	2.1	18	1	US-08-834-224-6	Sequence 6, Appli
c 495	11.8	2.1	18	1	US-09-213-719-48	Sequence 48, Appl
c 496	11.8	2.1	18	1	US-09-066-046-43	Sequence 43, Appl
497	11.8	2.1	18	1	US-09-377-309-23	Sequence 23, Appl
498	11.8	2.1	18	1	US-09-496-694B-117	Sequence 117, App
499	11.8	2.1	18	1	US-09-328-174A-43	Sequence 43, Appl
c 500	11.8	2.1	18	1	US-09-422-978-4956	Sequence 4956, Ap
501	11.8	2.1	18	1	US-09-422-978-4997	Sequence 4997, Ap
502	11.8	2.1	18	1	US-09-422-978-5155	Sequence 5155, Ap
c 503	11.8	2.1	18	1	US-09-422-978-5351	Sequence 5351, Ap
504	11.8	2.1	18	1	US-09-422-978-5769	Sequence 5769, Ap
c 505	11.8	2.1	18	1	US-09-422-978-5871	Sequence 5871, Ap
c 506	11.8	2.1	18	1	US-09-422-978-6093	Sequence 6093, Ap
c 507	11.8	2.1	18	1	US-09-422-978-7562	Sequence 7562, Ap
c 508	11.8	2.1	18	1	US-09-422-978-7804	Sequence 7804, Ap
c 509	11.8	2.1	18	1	US-09-422-978-8887	Sequence 8887, Ap
510	11.8	2.1	18	1	US-09-422-978-9171	Sequence 9171, Ap
c 511	11.8	2.1	18	1	US-09-422-978-9321	Sequence 9321, Ap
512	11.8	2.1	18	1	US-09-422-978-9456	Sequence 9456, Ap
c 513	11.8	2.1	18	1	US-08-993-765-2	Sequence 2, Appli
c 514	11.8	2.1	18	1	US-08-993-765-3	Sequence 3, Appli
c 515	11.8	2.1	18	1	US-09-155-885A-264	Sequence 264, App
516	11.8	2.1	18	1	US-09-544-398B-449	Sequence 449, App
c 517	11.8	2.1	18	1	US-09-696-791-4188	Sequence 4188, Ap
c 518	11.4	2.0	13	1	US-08-431-080-2	Sequence 2, Appli
519	11.4	2.0	13	1	US-08-781-550-22	Sequence 22, Appl
520	11.4	2.0	13	1	US-08-781-550-26	Sequence 26, Appl
c 521	11.4	2.0	13	1	US-08-938-534-2	Sequence 2, Appli
522	11.4	2.0	13	1	US-08-544-381B-201	Sequence 201, App
523	11.4	2.0	13	1	US-08-778-794A-10	Sequence 10, Appl
c 524	11.4	2.0	13	1	US-09-345-294-2	Sequence 2, Appli
525	11.4	2.0	13	1	US-09-341-399-10	Sequence 10, Appl
526	11.4	2.0	14	1	US-08-242-664-15	Sequence 15, Appl
527	11.4	2.0	14	1	US-08-484-138-15	Sequence 15, Appl
c 528	11.4	2.0	14	1	US-09-874-601-115	Sequence 115, App
529	11.4	2.0	14	1	PCT-US95-06379-15	Sequence 15, Appl
530	11.4	2.0	15	1	US-07-703-778D-11	Sequence 11, Appl
c 531	11.4	2.0	15	1	US-07-991-855-5	Sequence 5, Appli
532	11.4	2.0	15	1	US-07-991-855-45	Sequence 45, Appl
533	11.4	2.0	15	1	US-08-063-167A-34	Sequence 34, Appl
534	11.4	2.0	15	1	US-08-007-997A-34	Sequence 34, Appl
c 535	11.4	2.0	15	1	US-08-319-492B-102	Sequence 102, App
c 536	11.4	2.0	15	1	US-08-291-932A-63	Sequence 63, Appl
c 537	11.4	2.0	15	1	US-08-334-847-579	Sequence 579, App
c 538	11.4	2.0	15	1	US-08-311-486C-83	Sequence 83, Appl
539	11.4	2.0	15	1	US-08-440-740A-34	Sequence 34, Appl
540	11.4	2.0	15	1	US-08-585-684B-1199	Sequence 1199, Ap
541	11.4	2.0	15	1	US-08-344-155C-34	Sequence 34, Appl
542	11.4	2.0	15	1	US-08-982-845B-34	Sequence 34, Appl
543	11.4	2.0	15	1	US-08-991-525B-34	Sequence 34, Appl
544	11.4	2.0	15	1	US-09-085-759-34	Sequence 34, Appl

545	11.4	2.0	15	1	US-09-128-496-34	Sequence 34, Appl
546	11.4	2.0	15	1	US-09-038-073-1199	Sequence 1199, Ap
547	11.4	2.0	15	1	US-09-009-490A-34	Sequence 34, Appl
548	11.4	2.0	15	1	US-09-311-079-3	Sequence 3, Appli
c 549	11.4	2.0	15	1	US-09-081-646-94	Sequence 94, Appl
c 550	11.4	2.0	15	1	US-09-081-646-768	Sequence 768, App
551	11.4	2.0	15	1	PCT-US93-08101-34	Sequence 34, Appl
552	11.4	2.0	16	1	US-08-320-559-8	Sequence 8, Appli
553	11.4	2.0	16	1	US-08-327-392-8	Sequence 8, Appli
c 554	11.4	2.0	16	1	US-08-753-147-183	Sequence 183, App
555	11.4	2.0	16	1	US-08-527-060-17	Sequence 17, Appl
556	11.4	2.0	16	1	US-08-545-860D-8	Sequence 8, Appli
557	11.4	2.0	16	1	US-08-088-661F-36	Sequence 36, Appl
558	11.4	2.0	16	1	US-08-108-591B-33	Sequence 33, Appl
c 559	11.4	2.0	16	1	US-09-371-772B-6072	Sequence 6072, Ap
560	11.4	2.0	16	1	US-09-479-005A-396	Sequence 396, App
561	11.4	2.0	16	1	US-08-468-719A-33	Sequence 33, Appl
562	11.4	2.0	16	1	US-08-462-977B-33	Sequence 33, Appl
563	11.4	2.0	16	1	US-09-696-791-4155	Sequence 4155, Ap
564	11.4	2.0	16	1	US-09-696-791-4373	Sequence 4373, Ap
565	11.4	2.0	16	1	US-10-071-411A-12	Sequence 12, Appl
566	11.4	2.0	16	1	PCT-US94-04496-8	Sequence 8, Appli
c 567	11.4	2.0	17	1	US-07-991-855-15	Sequence 15, Appl
c 568	11.4	2.0	17	1	US-07-991-855-16	Sequence 16, Appl
569	11.4	2.0	17	1	US-07-991-855-56	Sequence 56, Appl
c 570	11.4	2.0	17	1	US-08-119-773-20	Sequence 20, Appl
571	11.4	2.0	17	1	US-08-242-664-33	Sequence 33, Appl
572	11.4	2.0	17	1	US-08-281-940-5	Sequence 5, Appli
573	11.4	2.0	17	1	US-08-390-850-418	Sequence 418, App
574	11.4	2.0	17	1	US-08-390-850-657	Sequence 657, App
575	11.4	2.0	17	1	US-08-390-850-658	Sequence 658, App
576	11.4	2.0	17	1	US-08-390-850-659	Sequence 659, App
577	11.4	2.0	17	1	US-08-390-850-680	Sequence 680, App
578	11.4	2.0	17	1	US-08-484-138-33	Sequence 33, Appl
579	11.4	2.0	17	1	US-08-435-634-418	Sequence 418, App
580	11.4	2.0	17	1	US-08-435-634-657	Sequence 657, App
581	11.4	2.0	17	1	US-08-435-634-658	Sequence 658, App
582	11.4	2.0	17	1	US-08-435-634-659	Sequence 659, App
583	11.4	2.0	17	1	US-08-435-634-680	Sequence 680, App
c 584	11.4	2.0	17	1	US-08-758-306-149	Sequence 149, App
585	11.4	2.0	17	1	US-08-710-134-5	Sequence 5, Appli
586	11.4	2.0	17	1	US-08-229-528-8	Sequence 8, Appli
587	11.4	2.0	17	1	US-08-485-885-5	Sequence 5, Appli
588	11.4	2.0	17	1	US-08-174-672D-2	Sequence 2, Appli
589	11.4	2.0	17	1	US-08-985-162-632	Sequence 632, App
590	11.4	2.0	17	1	US-08-985-162-633	Sequence 633, App
591	11.4	2.0	17	1	US-08-985-162-749	Sequence 749, App
592	11.4	2.0	17	1	US-08-463-903-89	Sequence 89, Appl
593	11.4	2.0	17	1	US-08-945-654-4	Sequence 4, Appli
594	11.4	2.0	17	1	US-07-935-695-89	Sequence 89, Appl
c 595	11.4	2.0	17	1	US-08-584-040-1689	Sequence 1689, Ap
c 596	11.4	2.0	17	1	US-08-584-040-1690	Sequence 1690, Ap
597	11.4	2.0	17	1	US-08-584-040-2802	Sequence 2802, Ap
598	11.4	2.0	17	1	US-08-584-040-4250	Sequence 4250, Ap
599	11.4	2.0	17	1	US-08-584-040-4251	Sequence 4251, Ap
600	11.4	2.0	17	1	US-08-584-040-4252	Sequence 4252, Ap
601	11.4	2.0	17	1	US-08-584-040-4253	Sequence 4253, Ap
602	11.4	2.0	17	1	US-08-584-040-5820	Sequence 5820, Ap
603	11.4	2.0	17	1	US-08-584-040-5821	Sequence 5821, Ap
604	11.4	2.0	17	1	US-08-584-040-5822	Sequence 5822, Ap
605	11.4	2.0	17	1	US-08-584-040-5823	Sequence 5823, Ap
c 606	11.4	2.0	17	1	US-08-584-040-7531	Sequence 7531, Ap
607	11.4	2.0	17	1	US-08-584-040-7814	Sequence 7814, Ap
608	11.4	2.0	17	1	US-08-584-040-7815	Sequence 7815, Ap
609	11.4	2.0	17	1	US-08-584-040-7816	Sequence 7816, Ap
610	11.4	2.0	17	1	US-08-584-040-7817	Sequence 7817, Ap
611	11.4	2.0	17	1	US-08-584-040-8156	Sequence 8156, Ap
c 612	11.4	2.0	17	1	US-09-474-432B-847	Sequence 847, App
613	11.4	2.0	17	1	US-09-474-432B-874	Sequence 874, App
c 614	11.4	2.0	17	1	US-09-371-772B-234	Sequence 234, App
c 615	11.4	2.0	17	1	US-09-371-772B-235	Sequence 235, App
616	11.4	2.0	17	1	US-09-371-772B-1326	Sequence 1326, Ap
617	11.4	2.0	17	1	US-09-371-772B-2017	Sequence 2017, Ap
618	11.4	2.0	17	1	US-09-371-772B-2018	Sequence 2018, Ap
619	11.4	2.0	17	1	US-09-371-772B-2019	Sequence 2019, Ap
620	11.4	2.0	17	1	US-09-371-772B-2020	Sequence 2020, Ap
c 621	11.4	2.0	17	1	US-09-371-772B-3336	Sequence 3336, Ap
622	11.4	2.0	17	1	US-09-371-772B-3598	Sequence 3598, Ap
623	11.4	2.0	17	1	US-09-371-772B-3599	Sequence 3599, Ap
624	11.4	2.0	17	1	US-09-371-772B-3600	Sequence 3600, Ap
625	11.4	2.0	17	1	US-09-371-772B-3601	Sequence 3601, Ap
626	11.4	2.0	17	1	US-09-371-772B-3939	Sequence 3939, Ap
627	11.4	2.0	17	1	US-09-371-772B-5580	Sequence 5580, Ap
c 628	11.4	2.0	17	1	US-09-476-387-846	Sequence 846, App
629	11.4	2.0	17	1	US-09-476-387-873	Sequence 873, App
630	11.4	2.0	17	1	US-09-401-063-632	Sequence 632, App
631	11.4	2.0	17	1	US-09-401-063-633	Sequence 633, App
632	11.4	2.0	17	1	US-09-401-063-749	Sequence 749, App
633	11.4	2.0	17	1	US-09-827-998-308	Sequence 308, App
634	11.4	2.0	17	1	US-09-827-998-309	Sequence 309, App
c 635	11.4	2.0	17	1	US-09-866-108A-6296	Sequence 6296, Ap
c 636	11.4	2.0	17	1	US-09-866-108A-6297	Sequence 6297, Ap
c 637	11.4	2.0	17	1	US-09-866-108A-6298	Sequence 6298, Ap
c 638	11.4	2.0	17	1	US-09-866-108A-6299	Sequence 6299, Ap
c 639	11.4	2.0	17	1	US-09-866-108A-6300	Sequence 6300, Ap
c 640	11.4	2.0	17	1	US-09-866-108A-7186	Sequence 7186, Ap
c 641	11.4	2.0	17	1	US-09-866-108A-7191	Sequence 7191, Ap
c 642	11.4	2.0	17	1	US-09-866-108A-7638	Sequence 7638, Ap
c 643	11.4	2.0	17	1	US-09-866-108A-8585	Sequence 8585, Ap
c 644	11.4	2.0	17	1	US-09-866-108A-8586	Sequence 8586, Ap
645	11.4	2.0	17	1	US-09-649-371-2	Sequence 2, Appli
646	11.4	2.0	17	1	PCT-US95-06379-33	Sequence 33, Appl
c 647	11.2	2.0	16	1	US-08-753-147-140	Sequence 140, App
648	11.2	2.0	16	1	US-08-087-387-1	Sequence 1, Appli
649	11.2	2.0	16	1	US-08-455-627-1	Sequence 1, Appli
650	11.2	2.0	16	1	US-08-242-664-21	Sequence 21, Appl
651	11.2	2.0	16	1	US-08-242-664-22	Sequence 22, Appl
652	11.2	2.0	16	1	US-08-234-613-20	Sequence 20, Appl
c 653	11.2	2.0	16	1	US-08-122-792-9	Sequence 9, Appli
654	11.2	2.0	16	1	US-08-427-863-3	Sequence 3, Appli
c 655	11.2	2.0	16	1	US-08-427-863-3	Sequence 3, Appli
656	11.2	2.0	16	1	US-08-192-941-2	Sequence 2, Appli
657	11.2	2.0	16	1	US-08-484-138-21	Sequence 21, Appl
658	11.2	2.0	16	1	US-08-484-138-22	Sequence 22, Appl
659	11.2	2.0	16	1	US-08-461-271-1	Sequence 1, Appli
660	11.2	2.0	16	1	US-08-484-192-92	Sequence 92, Appl
661	11.2	2.0	16	1	US-08-713-685A-1	Sequence 1, Appli
662	11.2	2.0	16	1	US-08-689-856-1	Sequence 1, Appli
c 663	11.2	2.0	16	1	US-08-292-620A-1549	Sequence 1549, Ap
664	11.2	2.0	16	1	US-08-237-973-33	Sequence 33, Appl
665	11.2	2.0	16	1	US-08-412-376-1	Sequence 1, Appli
c 666	11.2	2.0	16	1	US-08-173-489C-126	Sequence 126, App
667	11.2	2.0	16	1	US-08-763-417-2	Sequence 2, Appli
c 668	11.2	2.0	16	1	US-08-763-417-2	Sequence 2, Appli
669	11.2	2.0	16	1	US-09-070-477-1	Sequence 1, Appli
670	11.2	2.0	16	1	US-07-808-452-17	Sequence 17, Appl
c 671	11.2	2.0	16	1	US-08-464-582-17	Sequence 17, Appl
c 672	11.2	2.0	16	1	US-09-071-845-1549	Sequence 1549, Ap
c 673	11.2	2.0	16	1	US-08-462-513-17	Sequence 17, Appl
674	11.2	2.0	16	1	US-08-787-321-1	Sequence 1, Appli
c 675	11.2	2.0	16	1	US-08-787-321-16	Sequence 16, Appl
c 676	11.2	2.0	16	1	US-09-479-524-6	Sequence 6, Appli
c 677	11.2	2.0	16	1	US-09-060-299-430	Sequence 430, App
c 678	11.2	2.0	16	1	US-09-402-923A-430	Sequence 430, App
679	11.2	2.0	16	1	US-09-371-772B-5933	Sequence 5933, Ap
c 680	11.2	2.0	16	1	US-09-371-772B-6067	Sequence 6067, Ap
c 681	11.2	2.0	16	1	US-09-371-772B-6070	Sequence 6070, Ap
682	11.2	2.0	16	1	US-09-371-772B-6967	Sequence 6967, Ap
c 683	11.2	2.0	16	1	US-09-371-772B-7107	Sequence 7107, Ap
c 684	11.2	2.0	16	1	US-09-328-925-53	Sequence 53, Appl
685	11.2	2.0	16	1	US-09-479-005A-112	Sequence 112, App
c 686	11.2	2.0	16	1	US-09-479-005A-468	Sequence 468, App
c 687	11.2	2.0	16	1	US-09-479-005A-501	Sequence 501, App
c 688	11.2	2.0	16	1	US-08-031-801-18	Sequence 18, Appl
c 689	11.2	2.0	16	1	US-08-031-801-30	Sequence 30, Appl
690	11.2	2.0	16	1	US-09-155-885A-19	Sequence 19, Appl

	691	11.2	2.0	16	1	PCT-US92-10770-17	Sequence 17, Appl
	692	11.2	2.0	16	1	PCT-US92-10792-15	Sequence 15, Appl
	693	11.2	2.0	16	1	PCT-US94-06799-2	Sequence 2, Appli
c	694	11.2	2.0	16	1	PCT-US94-06799-2	Sequence 2, Appli
	695	11.2	2.0	16	1	PCT-US95-06379-21	Sequence 21, Appl
	696	11.2	2.0	16	1	PCT-US95-06379-22	Sequence 22, Appl
	697	11.2	2.0	17	1	US-08-584-040-2204	Sequence 2204, Ap
	698	11.2	2.0	17	1	US-09-371-772B-749	Sequence 749, App
	699	11.2	2.0	17	1	US-08-584-040-2205	Sequence 2205, Ap
	700	11.2	2.0	17	1	US-09-371-772B-750	Sequence 750, App
	701	11.2	2.0	17	1	US-08-206-384-2	Sequence 2, Appli
c	702	11.2	2.0	17	1	US-08-234-613-25	Sequence 25, Appl
	703	11.2	2.0	17	1	US-08-281-940-24	Sequence 24, Appl
	704	11.2	2.0	17	1	US-08-281-940-41	Sequence 41, Appl
	705	11.2	2.0	17	1	US-08-243-391-3	Sequence 3, Appli
	706	11.2	2.0	17	1	US-08-373-124A-454	Sequence 454, App
c	707	11.2	2.0	17	1	US-08-373-124A-806	Sequence 806, App
c	708	11.2	2.0	17	1	US-08-373-124A-808	Sequence 808, App
	709	11.2	2.0	17	1	US-08-373-124A-980	Sequence 980, App
	710	11.2	2.0	17	1	US-08-373-124A-982	Sequence 982, App
c	711	11.2	2.0	17	1	US-08-373-124A-1643	Sequence 1643, Ap
	712	11.2	2.0	17	1	US-08-373-124A-2061	Sequence 2061, Ap
	713	11.2	2.0	17	1	US-08-373-124A-2063	Sequence 2063, Ap
c	714	11.2	2.0	17	1	US-08-373-124A-2139	Sequence 2139, Ap
c	715	11.2	2.0	17	1	US-08-373-124A-2143	Sequence 2143, Ap
c	716	11.2	2.0	17	1	US-08-373-124A-2145	Sequence 2145, Ap
c	717	11.2	2.0	17	1	US-08-373-124A-2147	Sequence 2147, Ap
	718	11.2	2.0	17	1	US-08-373-124A-2363	Sequence 2363, Ap
c	719	11.2	2.0	17	1	US-08-485-602-25	Sequence 25, Appl
c	720	11.2	2.0	17	1	US-08-757-180-24	Sequence 24, Appl
	721	11.2	2.0	17	1	US-08-451-893-3	Sequence 3, Appli
c	722	11.2	2.0	17	1	US-08-484-192-97	Sequence 97, Appl
c	723	11.2	2.0	17	1	US-08-745-638-25	Sequence 25, Appl
	724	11.2	2.0	17	1	US-08-758-306-1157	Sequence 1157, Ap
	725	11.2	2.0	17	1	US-08-435-628-454	Sequence 454, App
c	726	11.2	2.0	17	1	US-08-435-628-806	Sequence 806, App
c	727	11.2	2.0	17	1	US-08-435-628-808	Sequence 808, App
	728	11.2	2.0	17	1	US-08-435-628-980	Sequence 980, App
	729	11.2	2.0	17	1	US-08-435-628-982	Sequence 982, App
c	730	11.2	2.0	17	1	US-08-435-628-1643	Sequence 1643, Ap
	731	11.2	2.0	17	1	US-08-435-628-2061	Sequence 2061, Ap
	732	11.2	2.0	17	1	US-08-435-628-2063	Sequence 2063, Ap
c	733	11.2	2.0	17	1	US-08-435-628-2139	Sequence 2139, Ap
c	734	11.2	2.0	17	1	US-08-435-628-2143	Sequence 2143, Ap
c	735	11.2	2.0	17	1	US-08-435-628-2145	Sequence 2145, Ap
c	736	11.2	2.0	17	1	US-08-435-628-2147	Sequence 2147, Ap
	737	11.2	2.0	17	1	US-08-435-628-2363	Sequence 2363, Ap
	738	11.2	2.0	17	1	US-08-710-134-24	Sequence 24, Appl
	739	11.2	2.0	17	1	US-08-710-134-41	Sequence 41, Appl
c	740	11.2	2.0	17	1	US-08-292-620A-1659	Sequence 1659, Ap
c	741	11.2	2.0	17	1	US-08-292-620A-1722	Sequence 1722, Ap
c	742	11.2	2.0	17	1	US-08-237-973-38	Sequence 38, Appl
	743	11.2	2.0	17	1	US-08-485-885-24	Sequence 24, Appl
	744	11.2	2.0	17	1	US-08-485-885-41	Sequence 41, Appl
c	745	11.2	2.0	17	1	US-08-894-772-9	Sequence 9, Appli
	746	11.2	2.0	17	1	US-08-451-894-3	Sequence 3, Appli
c	747	11.2	2.0	17	1	US-09-207-844-9	Sequence 9, Appli
c	748	11.2	2.0	17	1	US-08-776-900C-13	Sequence 13, Appl
	749	11.2	2.0	17	1	US-08-752-722-2	Sequence 2, Appli
	750	11.2	2.0	17	1	US-08-181-664-64	Sequence 64, Appl
	751	11.2	2.0	17	1	US-08-985-162-381	Sequence 381, App
c	752	11.2	2.0	17	1	US-08-985-162-498	Sequence 498, App
	753	11.2	2.0	17	1	US-08-985-162-643	Sequence 643, App
	754	11.2	2.0	17	1	US-08-231-439A-3	Sequence 3, Appli
	755	11.2	2.0	17	1	US-08-998-099-30	Sequence 30, Appl
c	756	11.2	2.0	17	1	US-09-071-845-1659	Sequence 1659, Ap
c	757	11.2	2.0	17	1	US-09-071-845-1722	Sequence 1722, Ap
c	758	11.2	2.0	17	1	US-09-009-521A-5	Sequence 5, Appli
c	759	11.2	2.0	17	1	US-09-268-195C-13	Sequence 13, Appl
	760	11.2	2.0	17	1	US-08-446-921-3	Sequence 3, Appli
	761	11.2	2.0	17	1	US-08-446-928-3	Sequence 3, Appli
c	762	11.2	2.0	17	1	US-09-441-346A-6	Sequence 6, Appli
c	763	11.2	2.0	17	1	US-08-192-946-11	Sequence 11, Appl
c	764	11.2	2.0	17	1	US-08-980-832-60	Sequence 60, Appl
c	765	11.2	2.0	17	1	US-08-584-040-1902	Sequence 1902, Ap
	766	11.2	2.0	17	1	US-08-584-040-1939	Sequence 1939, Ap
	767	11.2	2.0	17	1	US-08-584-040-1940	Sequence 1940, Ap
c	768	11.2	2.0	17	1	US-08-584-040-2016	Sequence 2016, Ap
	769	11.2	2.0	17	1	US-08-584-040-2059	Sequence 2059, Ap
c	770	11.2	2.0	17	1	US-08-584-040-2059	Sequence 2059, Ap
c	771	11.2	2.0	17	1	US-08-584-040-2092	Sequence 2092, Ap
	772	11.2	2.0	17	1	US-08-584-040-2197	Sequence 2197, Ap
	773	11.2	2.0	17	1	US-08-584-040-2289	Sequence 2289, Ap
	774	11.2	2.0	17	1	US-08-584-040-2394	Sequence 2394, Ap
	775	11.2	2.0	17	1	US-08-584-040-2395	Sequence 2395, Ap
	776	11.2	2.0	17	1	US-08-584-040-2466	Sequence 2466, Ap
c	777	11.2	2.0	17	1	US-08-584-040-2565	Sequence 2565, Ap
	778	11.2	2.0	17	1	US-08-584-040-2622	Sequence 2622, Ap
	779	11.2	2.0	17	1	US-08-584-040-2623	Sequence 2623, Ap
	780	11.2	2.0	17	1	US-08-584-040-2692	Sequence 2692, Ap
	781	11.2	2.0	17	1	US-08-584-040-2695	Sequence 2695, Ap
	782	11.2	2.0	17	1	US-08-584-040-2803	Sequence 2803, Ap
	783	11.2	2.0	17	1	US-08-584-040-3748	Sequence 3748, Ap
c	784	11.2	2.0	17	1	US-08-584-040-3917	Sequence 3917, Ap
	785	11.2	2.0	17	1	US-08-584-040-3970	Sequence 3970, Ap
c	786	11.2	2.0	17	1	US-08-584-040-4073	Sequence 4073, Ap
	787	11.2	2.0	17	1	US-08-584-040-5392	Sequence 5392, Ap
	788	11.2	2.0	17	1	US-08-584-040-5565	Sequence 5565, Ap
	789	11.2	2.0	17	1	US-08-584-040-5597	Sequence 5597, Ap
	790	11.2	2.0	17	1	US-08-584-040-5743	Sequence 5743, Ap
c	791	11.2	2.0	17	1	US-08-584-040-5903	Sequence 5903, Ap
c	792	11.2	2.0	17	1	US-08-584-040-7276	Sequence 7276, Ap
c	793	11.2	2.0	17	1	US-08-584-040-7396	Sequence 7396, Ap
c	794	11.2	2.0	17	1	US-08-584-040-7445	Sequence 7445, Ap
c	795	11.2	2.0	17	1	US-08-584-040-7719	Sequence 7719, Ap
c	796	11.2	2.0	17	1	US-08-584-040-7744	Sequence 7744, Ap
	797	11.2	2.0	17	1	US-08-584-040-7749	Sequence 7749, Ap
	798	11.2	2.0	17	1	US-08-584-040-8010	Sequence 8010, Ap
c	799	11.2	2.0	17	1	US-08-584-040-8033	Sequence 8033, Ap
	800	11.2	2.0	17	1	US-08-584-040-8158	Sequence 8158, Ap
c	801	11.2	2.0	17	1	US-08-679-645-153	Sequence 153, App
	802	11.2	2.0	17	1	US-08-679-645-756	Sequence 756, App
c	803	11.2	2.0	17	1	US-09-480-017-9	Sequence 9, Appli
	804	11.2	2.0	17	1	US-09-305-856B-35	Sequence 35, Appl
	805	11.2	2.0	17	1	US-09-305-856B-51	Sequence 51, Appl
c	806	11.2	2.0	17	1	US-09-789-453A-6	Sequence 6, Appli
	807	11.2	2.0	17	1	US-09-673-809-80	Sequence 80, Appl
	808	11.2	2.0	17	1	US-09-474-432B-721	Sequence 721, App
c	809	11.2	2.0	17	1	US-09-474-432B-795	Sequence 795, App
	810	11.2	2.0	17	1	US-09-549-697-3	Sequence 3, Appli
	811	11.2	2.0	17	1	US-09-312-245-3	Sequence 3, Appli
c	812	11.2	2.0	17	1	US-09-371-772B-447	Sequence 447, App
	813	11.2	2.0	17	1	US-09-371-772B-484	Sequence 484, App
	814	11.2	2.0	17	1	US-09-371-772B-485	Sequence 485, App
c	815	11.2	2.0	17	1	US-09-371-772B-561	Sequence 561, App
	816	11.2	2.0	17	1	US-09-371-772B-604	Sequence 604, App
c	817	11.2	2.0	17	1	US-09-371-772B-604	Sequence 604, App
c	818	11.2	2.0	17	1	US-09-371-772B-637	Sequence 637, App
	819	11.2	2.0	17	1	US-09-371-772B-742	Sequence 742, App
	820	11.2	2.0	17	1	US-09-371-772B-834	Sequence 834, App
	821	11.2	2.0	17	1	US-09-371-772B-939	Sequence 939, App
	822	11.2	2.0	17	1	US-09-371-772B-940	Sequence 940, App
	823	11.2	2.0	17	1	US-09-371-772B-990	Sequence 990, App
c	824	11.2	2.0	17	1	US-09-371-772B-1089	Sequence 1089, Ap
	825	11.2	2.0	17	1	US-09-371-772B-1146	Sequence 1146, Ap
	826	11.2	2.0	17	1	US-09-371-772B-1147	Sequence 1147, Ap
	827	11.2	2.0	17	1	US-09-371-772B-1216	Sequence 1216, Ap
	828	11.2	2.0	17	1	US-09-371-772B-1219	Sequence 1219, Ap
	829	11.2	2.0	17	1	US-09-371-772B-1327	Sequence 1327, Ap
	830	11.2	2.0	17	1	US-09-371-772B-1515	Sequence 1515, Ap
c	831	11.2	2.0	17	1	US-09-371-772B-1684	Sequence 1684, Ap
	832	11.2	2.0	17	1	US-09-371-772B-1737	Sequence 1737, Ap
c	833	11.2	2.0	17	1	US-09-371-772B-1840	Sequence 1840, Ap
	834	11.2	2.0	17	1	US-09-371-772B-2291	Sequence 2291, Ap
	835	11.2	2.0	17	1	US-09-371-772B-2455	Sequence 2455, Ap
	836	11.2	2.0	17	1	US-09-371-772B-2487	Sequence 2487, Ap

837	11.2	2.0	17	1	US-09-371-772B-2622	Sequence 2622, Ap
c 838	11.2	2.0	17	1	US-09-371-772B-2742	Sequence 2742, Ap
c 839	11.2	2.0	17	1	US-09-371-772B-3085	Sequence 3085, Ap
c 840	11.2	2.0	17	1	US-09-371-772B-3204	Sequence 3204, Ap
c 841	11.2	2.0	17	1	US-09-371-772B-3251	Sequence 3251, Ap
c 842	11.2	2.0	17	1	US-09-371-772B-3504	Sequence 3504, Ap
843	11.2	2.0	17	1	US-09-371-772B-3533	Sequence 3533, Ap
844	11.2	2.0	17	1	US-09-371-772B-3793	Sequence 3793, Ap
c 845	11.2	2.0	17	1	US-09-371-772B-3816	Sequence 3816, Ap
846	11.2	2.0	17	1	US-09-371-772B-3941	Sequence 3941, Ap
847	11.2	2.0	17	1	US-09-371-772B-4693	Sequence 4693, Ap
c 848	11.2	2.0	17	1	US-09-371-772B-4759	Sequence 4759, Ap
c 849	11.2	2.0	17	1	US-09-371-772B-4938	Sequence 4938, Ap
850	11.2	2.0	17	1	US-09-371-772B-5012	Sequence 5012, Ap
851	11.2	2.0	17	1	US-09-371-772B-5013	Sequence 5013, Ap
c 852	11.2	2.0	17	1	US-09-371-772B-5222	Sequence 5222, Ap
853	11.2	2.0	17	1	US-09-371-772B-5241	Sequence 5241, Ap
854	11.2	2.0	17	1	US-09-371-772B-5301	Sequence 5301, Ap
855	11.2	2.0	17	1	US-09-371-772B-5483	Sequence 5483, Ap
856	11.2	2.0	17	1	US-09-371-772B-6131	Sequence 6131, Ap
857	11.2	2.0	17	1	US-09-371-772B-6154	Sequence 6154, Ap
858	11.2	2.0	17	1	US-09-371-772B-6382	Sequence 6382, Ap
859	11.2	2.0	17	1	US-09-371-772B-6398	Sequence 6398, Ap
860	11.2	2.0	17	1	US-09-371-772B-6399	Sequence 6399, Ap
861	11.2	2.0	17	1	US-09-371-772B-6518	Sequence 6518, Ap
c 862	11.2	2.0	17	1	US-09-371-772B-6675	Sequence 6675, Ap
c 863	11.2	2.0	17	1	US-09-371-772B-6676	Sequence 6676, Ap
c 864	11.2	2.0	17	1	US-09-335-231-8	Sequence 8, Appli
865	11.2	2.0	17	1	US-09-476-387-720	Sequence 720, App
c 866	11.2	2.0	17	1	US-09-476-387-794	Sequence 794, App
867	11.2	2.0	17	1	US-09-401-063-381	Sequence 381, App
c 868	11.2	2.0	17	1	US-09-401-063-498	Sequence 498, App
869	11.2	2.0	17	1	US-09-401-063-643	Sequence 643, App
c 870	11.2	2.0	17	1	US-09-827-998-237	Sequence 237, App
c 871	11.2	2.0	17	1	US-09-827-998-238	Sequence 238, App
c 872	11.2	2.0	17	1	US-09-827-998-254	Sequence 254, App
c 873	11.2	2.0	17	1	US-09-827-998-255	Sequence 255, App
874	11.2	2.0	17	1	US-09-827-998-606	Sequence 606, App
875	11.2	2.0	17	1	US-09-827-998-607	Sequence 607, App
c 876	11.2	2.0	17	1	US-09-920-923B-60	Sequence 60, Appl
c 877	11.2	2.0	17	1	US-09-958-221A-17	Sequence 17, Appl
878	11.2	2.0	17	1	US-09-958-221A-19	Sequence 19, Appl
879	11.2	2.0	17	1	US-09-866-108A-146	Sequence 146, App
880	11.2	2.0	17	1	US-09-866-108A-147	Sequence 147, App
881	11.2	2.0	17	1	US-09-866-108A-866	Sequence 866, App
882	11.2	2.0	17	1	US-09-866-108A-867	Sequence 867, App
883	11.2	2.0	17	1	US-09-866-108A-888	Sequence 888, App
884	11.2	2.0	17	1	US-09-866-108A-889	Sequence 889, App
885	11.2	2.0	17	1	US-09-866-108A-1012	Sequence 1012, Ap
886	11.2	2.0	17	1	US-09-866-108A-1013	Sequence 1013, Ap
887	11.2	2.0	17	1	US-09-866-108A-1081	Sequence 1081, Ap
888	11.2	2.0	17	1	US-09-866-108A-1082	Sequence 1082, Ap
889	11.2	2.0	17	1	US-09-866-108A-1869	Sequence 1869, Ap
890	11.2	2.0	17	1	US-09-866-108A-1870	Sequence 1870, Ap
891	11.2	2.0	17	1	US-09-866-108A-2003	Sequence 2003, Ap
892	11.2	2.0	17	1	US-09-866-108A-2004	Sequence 2004, Ap
c 893	11.2	2.0	17	1	US-09-866-108A-2107	Sequence 2107, Ap
c 894	11.2	2.0	17	1	US-09-866-108A-2109	Sequence 2109, Ap
c 895	11.2	2.0	17	1	US-09-866-108A-2113	Sequence 2113, Ap
c 896	11.2	2.0	17	1	US-09-866-108A-2114	Sequence 2114, Ap
897	11.2	2.0	17	1	US-09-866-108A-2164	Sequence 2164, Ap
898	11.2	2.0	17	1	US-09-866-108A-2165	Sequence 2165, Ap
c 899	11.2	2.0	17	1	US-09-866-108A-2373	Sequence 2373, Ap
c 900	11.2	2.0	17	1	US-09-866-108A-2374	Sequence 2374, Ap
c 901	11.2	2.0	17	1	US-09-866-108A-2783	Sequence 2783, Ap
c 902	11.2	2.0	17	1	US-09-866-108A-2785	Sequence 2785, Ap
c 903	11.2	2.0	17	1	US-09-866-108A-2862	Sequence 2862, Ap
c 904	11.2	2.0	17	1	US-09-866-108A-2863	Sequence 2863, Ap
905	11.2	2.0	17	1	US-09-866-108A-7955	Sequence 7955, Ap
906	11.2	2.0	17	1	US-09-866-108A-7961	Sequence 7961, Ap
c 907	11.2	2.0	17	1	US-09-866-108A-8044	Sequence 8044, Ap
c 908	11.2	2.0	17	1	US-09-866-108A-8045	Sequence 8045, Ap
909	11.2	2.0	17	1	US-09-866-108A-8149	Sequence 8149, Ap
910	11.2	2.0	17	1	US-09-866-108A-8150	Sequence 8150, Ap
c 911	11.2	2.0	17	1	US-09-866-108A-8247	Sequence 8247, Ap
c 912	11.2	2.0	17	1	US-09-866-108A-8248	Sequence 8248, Ap
c 913	11.2	2.0	17	1	US-09-866-108A-8267	Sequence 8267, Ap
c 914	11.2	2.0	17	1	US-09-866-108A-8268	Sequence 8268, Ap
c 915	11.2	2.0	17	1	US-09-866-108A-10545	Sequence 10545, A
c 916	11.2	2.0	17	1	US-09-866-108A-10573	Sequence 10573, A
c 917	11.2	2.0	17	1	US-09-866-108A-10574	Sequence 10574, A
c 918	11.2	2.0	17	1	US-09-866-108A-10609	Sequence 10609, A
c 919	11.2	2.0	17	1	US-09-866-108A-10610	Sequence 10610, A
920	11.2	2.0	17	1	US-09-404-912-81	Sequence 81, Appl
921	11.2	2.0	17	1	US-09-404-912-176	Sequence 176, App
922	11.2	2.0	17	1	US-09-404-912-330	Sequence 330, App
923	11.2	2.0	17	1	US-09-404-912-394	Sequence 394, App
c 924	11.2	2.0	17	1	US-09-404-912-494	Sequence 494, App
c 925	11.2	2.0	17	1	US-09-404-912-523	Sequence 523, App
c 926	11.2	2.0	17	1	US-09-404-912-531	Sequence 531, App
c 927	11.2	2.0	17	1	US-09-856-662-34	Sequence 34, Appl
c 928	11.2	2.0	20	1	US-09-191-170-99	Sequence 99, Appl
c 929	11.2	2.0	25	1	US-09-352-608-9	Sequence 9, Appli
c 930	11	2.0	12	1	US-08-173-489C-155	Sequence 155, App
931	11	2.0	13	1	US-08-242-664-14	Sequence 14, Appl
932	11	2.0	13	1	US-08-484-138-14	Sequence 14, Appl
933	11	2.0	13	1	US-08-173-489C-171	Sequence 171, App
934	11	2.0	13	1	PCT-US95-06379-14	Sequence 14, Appl
c 935	11	2.0	14	1	US-08-442-513A-9	Sequence 9, Appli
c 936	11	2.0	14	1	US-08-442-513A-14	Sequence 14, Appl
937	11	2.0	14	1	US-09-152-059-116	Sequence 116, App
938	11	2.0	15	1	US-08-311-760A-31	Sequence 31, Appl
939	11	2.0	15	1	US-08-311-486C-64	Sequence 64, Appl
c 940	11	2.0	15	1	US-08-311-486C-208	Sequence 208, App
941	11	2.0	15	1	US-08-311-486C-581	Sequence 581, App
c 942	11	2.0	15	1	US-08-311-486C-729	Sequence 729, App
c 943	11	2.0	15	1	US-08-292-620A-80	Sequence 80, Appl
944	11	2.0	15	1	US-08-774-310-31	Sequence 31, Appl
c 945	11	2.0	15	1	US-09-071-845-80	Sequence 80, Appl
c 946	11	2.0	15	1	US-09-115-446-3	Sequence 3, Appli
c 947	11	2.0	15	1	US-09-081-646-154	Sequence 154, App
948	11	2.0	15	1	US-09-081-646-266	Sequence 266, App
949	11	2.0	15	1	US-09-081-646-745	Sequence 745, App
c 950	11	2.0	15	1	US-09-081-646-798	Sequence 798, App
c 951	11	2.0	15	1	US-09-275-505-3	Sequence 3, Appli
c 952	11	2.0	15	1	US-09-565-590-3	Sequence 3, Appli
c 953	11	2.0	16	1	US-07-988-194A-14	Sequence 14, Appl
c 954	11	2.0	16	1	US-08-880-557-3	Sequence 3, Appli
c 955	11	2.0	16	1	US-09-189-583-3	Sequence 3, Appli
c 956	11	2.0	16	1	US-08-479-737-14	Sequence 14, Appl
c 957	11	2.0	16	1	US-08-475-442A-14	Sequence 14, Appl
c 958	11	2.0	16	1	US-09-043-816E-27	Sequence 27, Appl
c 959	11	2.0	16	1	US-09-531-000-9	Sequence 9, Appli
960	11	2.0	16	1	US-09-931-381A-4	Sequence 4, Appli

ALIGNMENTS

```
RESULT 1
US-09-057-328-6
; Sequence 6, Application US/09057328
; Patent No. 6080576
;  GENERAL INFORMATION:
;    APPLICANT:  Zambrowicz, Brian
;    APPLICANT:  Friedrich, Glenn
;    APPLICANT:  Sands, Arthur T.
;    TITLE OF INVENTION:  VECTORS FOR GENE TRAPPING
;    TITLE OF INVENTION:  AND GENE ACTIVATION
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds, LLP
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  NY
;      COUNTRY:  USA
```

```
;       ZIP:  10036-2811
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  Windows
;       SOFTWARE:  FastSEQ for Windows Version 2.0b
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/057,328
;       FILING DATE:  08-APR-1998
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Coruzzi, Laura A
;       REGISTRATION NUMBER:  30,742
;       REFERENCE/DOCKET NUMBER:  8535-0020-999
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  650-493-4935
;       TELEFAX:  650-493-5556
;       TELEX:  66141 PENNIE
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  23 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-057-328-6

  Query Match             3.3%;  Score 18.2;  DB 1;  Length 23;
  Best Local Similarity   87.0%;  Pred. No. 21;
  Matches   20;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1999 CTAGCTTCTTCAGAGATCAAGTC 2021
             | ||  ||||||||||||||||||
Db          1 CCAGAGTCTTCAGAGATCAAGTC 23


RESULT 2
US-09-276-533A-22
; Sequence 22, Application US/09276533A
; Patent No. 6436707
; GENERAL INFORMATION:
;  APPLICANT: Zambrowicz, Brian
;  APPLICANT:  Friedrich, Glenn A.
;  APPLICANT:  Lilleberg, Stan
;  APPLICANT:  Sands, Arthur T.
;  TITLE OF INVENTION: VECTORS FOR GENE MUTAGENESIS AND GENE
;  TITLE OF INVENTION:  DISCOVERY
;  FILE REFERENCE: 07705-0006-00000
;  CURRENT APPLICATION NUMBER: US/09/276,533A
;  CURRENT FILING DATE:  2001-01-31
;  PRIOR APPLICATION NUMBER: US 60/079,729
;  PRIOR FILING DATE: 1998-03-27
;  PRIOR APPLICATION NUMBER: US 60/081,727
;  PRIOR FILING DATE: 1998-04-14
;  PRIOR APPLICATION NUMBER: US 60/109,302
;  PRIOR FILING DATE: 1998-11-20
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-276-533A-22

  Query Match             3.3%;  Score 18.2;  DB 1;  Length 23;
  Best Local Similarity   87.0%;  Pred. No. 21;
  Matches   20;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1999 CTAGCTTCTTCAGAGATCAAGTC 2021
             | ||  ||||||||||||||||||
Db          1 CCAGAGTCTTCAGAGATCAAGTC 23


RESULT 3
US-10-158-735-22
; Sequence 22, Application US/10158735
; Patent No. 6776988
; GENERAL INFORMATION:
;  APPLICANT: Zambrowicz, Brian
;  APPLICANT:  Friedrich, Glenn A.
;  APPLICANT:  Lilleberg, Stan
;  APPLICANT:  Sands, Arthur T.
;  TITLE OF INVENTION: VECTORS FOR GENE MUTAGENESIS AND GENE
;  TITLE OF INVENTION:  DISCOVERY
;  FILE REFERENCE: 7705-0006-01
;  CURRENT APPLICATION NUMBER: US/10/158,735
;  CURRENT FILING DATE:  2002-05-29
;  PRIOR APPLICATION NUMBER: US 09/276,533
;  PRIOR FILING DATE: 1999-03-25
;  PRIOR APPLICATION NUMBER: US 60/079,729
;  PRIOR FILING DATE: 1998-03-27
;  PRIOR APPLICATION NUMBER: US 60/081,727
;  PRIOR FILING DATE: 1998-04-14
;  PRIOR APPLICATION NUMBER: US 60/109,302
;  PRIOR FILING DATE: 1998-11-20
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
;   LENGTH: 23
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-10-158-735-22

  Query Match             3.3%;  Score 18.2;  DB 1;  Length 23;
  Best Local Similarity   87.0%;  Pred. No. 21;
  Matches   20;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1999 CTAGCTTCTTCAGAGATCAAGTC 2021
             | ||  ||||||||||||||||||
Db          1 CCAGAGTCTTCAGAGATCAAGTC 23


RESULT 4
US-09-352-608-9
; Sequence 9, Application US/09352608
; Patent No. 6218598
; GENERAL INFORMATION:
;  APPLICANT: ISHIGE, Fumiharu
;  APPLICANT: NISHIKAWA, Satomi
;  APPLICANT: OEDA, Kenji
;  TITLE OF INVENTION: Plant Promoter
;  FILE REFERENCE: 2185-0353P
;  CURRENT APPLICATION NUMBER: US/09/352,608
;  CURRENT FILING DATE: 1999-07-13
;  EARLIER APPLICATION NUMBER: 10-200372 JAPAN
;  EARLIER FILING DATE: 1998-07-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:primer
US-09-352-608-9

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 53;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;
```

```
Qy       1896 CCCTAGATCAACAGATCAACAAT 1918
             | |||||||||||  |||||| |
Db          2 CTCTAGATCAACACCTCAACATT 24
```

RESULT 5
US-08-671-548C-66
; Sequence 66, Application US/08671548C
; Patent No. 6486130
; GENERAL INFORMATION:
; APPLICANT: LIVEY, Ian
; APPLICANT: CROWE, Brian
; APPLICANT: DORNER, Friedrich
; TITLE OF INVENTION: IMMUNOGENIC FORMULATION OF OSPC ANTIGEN VACCINE FOR THE PREVENTIC
; TITLE OF INVENTION: TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPAR
; TITLE OF INVENTION: ANTIGENS
; FILE REFERENCE: 37974-0023
; CURRENT APPLICATION NUMBER: US/08/671,548C
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: US 08/284,667
; PRIOR FILING DATE: 1994-08-19
; PRIOR APPLICATION NUMBER: 08/053,863
; PRIOR FILING DATE: 1993-04-29
; PRIOR APPLICATION NUMBER: PCT/EP94/01365
; PRIOR FILING DATE: 1994-04-29
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 66
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: ()..()
; OTHER INFORMATION: primer
US-08-671-548C-66

Query Match 2.9%; Score 16.4; DB 1; Length 24;
Best Local Similarity 94.4%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1760 ATTCATTAAGCTTTTTTT 1777
             |||||||||| |||||||
Db          4 ATTCATTAAGGTTTTTTT 21
```

RESULT 6
US-09-475-947A-64/c
; Sequence 64, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 64
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-64

Query Match 2.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 54;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1938 AGGTAATGGTTGGTTTTTGTG 1958
             ||| |||||| ||||||| ||
Db         21 AGGGAATGGTGGGTTTTTCTG 1
```

RESULT 7
US-09-422-978-8160
; Sequence 8160, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8160
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..21
; OTHER INFORMATION: downstream amplification primer 99-14072 for SEQ 295, in complemer
US-09-422-978-8160

Query Match 2.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 54;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1567 AAAAATCCTTCTCCACCGCAC 1587
             || |||| |||||||| ||||
Db          1 AATAATCTTTCTCCACTGCAC 21
```

RESULT 8
US-08-660-402-3
; Sequence 3, Application US/08660402
; Patent No. 5834193
; GENERAL INFORMATION:
; APPLICANT: Michael R. Kozlowski
; APPLICANT: Karen R. Prowse
; APPLICANT: Sharon Wong
; APPLICANT: Sy-Shi Wang
; APPLICANT: Nam Woo Kim
; APPLICANT: Richard Allsopp
; TITLE OF INVENTION: METHODS FOR MEASURING TELOMERE
; TITLE OF INVENTION: LENGTH
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Geron Corporation
; STREET: 200 Constitution Drive
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 2.0 Mb
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh System 7.5.2
; SOFTWARE: MicrosoftWord (Version 6.0.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/660,402
; FILING DATE: herewith
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/479,916
; FILING DATE: June 7, 1995

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kaster, Kevin
;      REGISTRATION NUMBER:  32,704
;      REFERENCE/DOCKET NUMBER:  041/036P
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 473-7779
;      TELEFAX:  (415) 473-7750
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-660-402-3

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 73;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db          3 CTCTGAAAGTGGACCWATCAG 23


RESULT 9
US-08-660-402-7/c
; Sequence 7, Application US/08660402
; Patent No. 5834193
;  GENERAL INFORMATION:
;    APPLICANT:  Michael R. Kozlowski
;    APPLICANT:  Karen R. Prowse
;    APPLICANT:  Sharon Wong
;    APPLICANT:  Sy-Shi Wang
;    APPLICANT:  Nam Woo Kim
;    APPLICANT:  Richard Allsopp
;    TITLE OF INVENTION:  METHODS FOR MEASURING TELOMERE
;    TITLE OF INVENTION:  LENGTH
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Geron Corporation
;      STREET:  200 Constitution Drive
;      CITY:  Menlo Park
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 2.0 Mb
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh System 7.5.2
;      SOFTWARE:  MicrosoftWord (Version 6.0.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/660,402
;      FILING DATE:  herewith
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/479,916
;      FILING DATE:  June 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kaster, Kevin
;      REGISTRATION NUMBER:  32,704
;      REFERENCE/DOCKET NUMBER:  041/036P
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 473-7779
;      TELEFAX:  (415) 473-7750
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-660-402-7

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 73;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db         21 CTCTGAAAGTGGACCWATCAG 1


RESULT 10
PCT-US96-10035-3
; Sequence 3, Application PC/TUS9610035
;  GENERAL INFORMATION:
;    APPLICANT:  Michael R. Kozlowski
;    APPLICANT:  Karen R. Prowse
;    APPLICANT:  Sharon Wong
;    APPLICANT:  Sy-Shi Wang
;    APPLICANT:  Nam Woo Kim
;    APPLICANT:  Richard Allsopp
;    TITLE OF INVENTION:  METHODS FOR MEASURING TELOMERE
;    TITLE OF INVENTION:  LENGTH
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Geron Corporation
;      STREET:  200 Constitution Drive
;      CITY:  Menlo Park
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 2.0 Mb
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh System 7.5.2
;      SOFTWARE:  MicrosoftWord (Version 6.0.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/10035
;      FILING DATE:  herewith
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/479,916
;      FILING DATE:  June 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kaster, Kevin
;      REGISTRATION NUMBER:  32,704
;      REFERENCE/DOCKET NUMBER:  041/036P
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 473-7779
;      TELEFAX:  (415) 473-7750
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
PCT-US96-10035-3

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 73;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db          3 CTCTGAAAGTGGACCWATCAG 23


RESULT 11
PCT-US96-10035-7/c
; Sequence 7, Application PC/TUS9610035
;  GENERAL INFORMATION:
;    APPLICANT:  Michael R. Kozlowski
;    APPLICANT:  Karen R. Prowse
;    APPLICANT:  Sharon Wong
;    APPLICANT:  Sy-Shi Wang
;    APPLICANT:  Nam Woo Kim
```

```
;    APPLICANT:  Richard Allsopp
;    TITLE OF INVENTION:  METHODS FOR MEASURING TELOMERE
;    TITLE OF INVENTION:  LENGTH
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Geron Corporation
;      STREET:  200 Constitution Drive
;      CITY:  Menlo Park
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 2.0 Mb
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh System 7.5.2
;      SOFTWARE:  MicrosoftWord (Version 6.0.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/10035
;      FILING DATE:  herewith
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/479,916
;      FILING DATE:  June 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kaster, Kevin
;      REGISTRATION NUMBER:  32,704
;      REFERENCE/DOCKET NUMBER:  041/036P
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 473-7779
;      TELEFAX:  (415) 473-7750
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
PCT-US96-10035-7

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 73;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
             ||||||||||||  |:|| ||
Db         21 CTCTGAAAGTGGACCWATCAG 1


RESULT 12
US-09-657-472-1091
; Sequence 1091, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
;  APPLICANT: Lander, Eric S.
;  APPLICANT:  Cargill, Michele
;  APPLICANT:  Ireland, James S.
;  APPLICANT:  Bolk, Stacey
;  APPLICANT:  Daley, George Q.
;  APPLICANT:  McCarthy, Jeanette J.
;  TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
;  FILE REFERENCE: 2825.1027-001
;  CURRENT APPLICATION NUMBER: US/09/657,472
;  CURRENT FILING DATE:  2000-09-07
;  PRIOR APPLICATION NUMBER: US 60/153,357
;  PRIOR FILING DATE: 1999-09-10
;  PRIOR APPLICATION NUMBER: US 60/220,947
;  PRIOR FILING DATE: 2000-07-26
;  PRIOR APPLICATION NUMBER: US 60/225,724
;  PRIOR FILING DATE: 2000-08-16
;  NUMBER OF SEQ ID NOS: 2551
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1091
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-657-472-1091

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 82;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCAAGTCC 2022
              | || |||||:||||||||
Db          1 TACTCCAGAGRTCAAGTCC 19


RESULT 13
US-09-583-447A-29
; Sequence 29, Application US/09583447A
; Patent No. 6645745
; GENERAL INFORMATION:
;  APPLICANT: WOJNOWSKI, Leszek
;  APPLICANT:  GELLNER, Klaus
;  APPLICANT:  EISELT, Regina
;  TITLE OF INVENTION: IDENTIFICATION OF A NEW MEMBER OF THE CYTOCHROME P450 3A
;  TITLE OF INVENTION:  (CYP3A) GENE FAMILY: CYP3AX
;  FILE REFERENCE: 310115.401
;  CURRENT APPLICATION NUMBER: US/09/583,447A
;  CURRENT FILING DATE:  2000-05-30
;  NUMBER OF SEQ ID NOS: 45
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-583-447A-29

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 86;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1863 CACACTTAGCCATTGAAATG 1882
              || |||| ||||| ||||||
Db          1 CAAACTTTGCCATGGAAATG 20


RESULT 14
US-09-696-791-4440/c
; Sequence 4440, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4440
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo sapien
;   FEATURE:
;   OTHER INFORMATION: IL8 ribozyme recognition site
US-09-696-791-4440

  Query Match             2.7%;  Score 15;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACA 1866
              |||||||||||||||
Db         16 CAACAGACCCACACA 2
```

```
RESULT 15
US-08-860-038-6
; Sequence 6, Application US/08860038
; Patent No. 6287762
;  GENERAL INFORMATION:
;    APPLICANT:  CROUZET, Joel
;    APPLICANT:  SCHERMAN, Daniel
;    APPLICANT:  WILS, Pierre
;    TITLE OF INVENTION:  PURIFICATION OF A TRIPLE HELIX FORMATION
;    TITLE OF INVENTION:  WITH AN IMMOBILIZED OLIGONUCLEOTIDE
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rhone-Poulenc Rorer Inc.
;      STREET:  500 Arcola Road, Mailstop 3C43
;      CITY:  Collegeville
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19426
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/860,038
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 94/15162
;      FILING DATE:  16-DEC-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  WO FR95/01468
;      FILING DATE:  08-NOV-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Savitzky Esq., Martin F.
;      REGISTRATION NUMBER:  29,699
;      REFERENCE/DOCKET NUMBER:  ST94090-US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (610) 454-3816
;      TELEFAX:  (610) 454-3808
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotide"
US-08-860-038-6

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 16
US-09-580-923-6
; Sequence 6, Application US/09580923
; Patent No. 6319672
; GENERAL INFORMATION:
;  APPLICANT:  Crouzet, Joel
;  APPLICANT:  Scherman, Daniel
;  APPLICANT:  Wils, Pierre
;  APPLICANT:  Cameron, Beatrice
;  APPLICANT:  Blanche, Francis
;  TITLE OF INVENTION:  PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
;  TITLE OF INVENTION:  IMMOBILIZED OLIGONUCLEOTIDE
;  FILE REFERENCE:  03804.0138-01
;  CURRENT APPLICATION NUMBER: US/09/580,923
;  CURRENT FILING DATE:  2000-05-26
;  PRIOR APPLICATION NUMBER:  08/860,038
;  PRIOR FILING DATE:  1997-06-09
;  PRIOR APPLICATION NUMBER:  PCT/FR95/01468
;  PRIOR FILING DATE:  1995-11-08
;  NUMBER OF SEQ ID NOS:  36
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 6
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-09-580-923-6

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 17
US-09-153-838-10
; Sequence 10, Application US/09153838A
; Patent No. 6730781
; GENERAL INFORMATION:
;  APPLICANT: Wils, Pierre
;  APPLICANT: Ollivier, Monique
;  TITLE OF INVENTION: PURIFICATION OF PHARMACEUTICAL-GRADE PLASMID DNA
;  FILE REFERENCE: ST96016-US
;  CURRENT APPLICATION NUMBER: US/09/153,838A
;  CURRENT FILING DATE: 1998-09-15
;  EARLIER APPLICATION NUMBER: PCT/FR97/00472
;  EARLIER FILING DATE: 1997-03-17
;  EARLIER APPLICATION NUMBER: FR96/03519
;  EARLIER FILING DATE: 1996-03-21
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: triple helix
;   OTHER INFORMATION: forming oligonucleotide
US-09-153-838-10

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 18
US-08-817-384A-2
; Sequence 2, Application US/08817384A
; Patent No. 6235468
;  GENERAL INFORMATION:
;    APPLICANT:  Duncan Martin BAIRD
;    APPLICANT:  Alec John JEFFREYS
;    APPLICANT:  Nicola Jane ROYLE
;    TITLE OF INVENTION:  Method For Characterising Variability in
;    TITLE OF INVENTION:  Telomere DNA by PCR
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PILLSBURY MADISON & SUTRO, L.L.P.
```

```
;       STREET:  1100 New York Avenue, N.W.
;       CITY:  WASHINGTON
;       STATE:  D.C.
;       COUNTRY:  U.S.A.
;       ZIP:  20005-3918
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  Microsoft Word
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/817,384A
;       FILING DATE:  16-APR-1997
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  WO PCT/GB95/02467
;       FILING DATE:  19-OCT-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  GB 9510639.9
;       FILING DATE:  25-MAY-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  GB 9421234.7
;       FILING DATE:  21-OCT-1994
;   INFORMATION FOR SEQ ID NO:  2:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-817-384A-2

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTAT 1817
              ||||||||||| ||||
Db          3 CTCTGAAAGTGGACCTAT 20


RESULT 19
US-09-495-714C-15/c
; Sequence 15, Application US/09495714C
; Patent No. 6670465
; GENERAL INFORMATION:
;  APPLICANT: University Technologies International Inc.
;  TITLE OF INVENTION: RETINAL CALCIUM CHANNEL (ALPHA) 1F-SUBUNIT GENE
;  FILE REFERENCE: 45499.4 (formerly 45074.6)
;  CURRENT APPLICATION NUMBER: US/09/495,714C
;  CURRENT FILING DATE:  2000-02-01
;  NUMBER OF SEQ ID NOS: 138
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Mus musculus
US-09-495-714C-15

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.1e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTGAAA 1807
              |||||||||||| | ||
Db         18 TTCTTTCCTTCTCCGGAA 1


RESULT 20
US-09-881-572A-22
; Sequence 22, Application US/09881572A
; Patent No. 6762031
; GENERAL INFORMATION:
;  APPLICANT: Roth, Monica;
;  APPLICANT:  Bupp, Keith;
;  APPLICANT:  University of Medicine and Dentistry of New Jersey
;  TITLE OF INVENTION: Targeting Viral Vectors to Specific Cells
;  FILE REFERENCE: 601-1-095
;  CURRENT APPLICATION NUMBER: US/09/881,572A
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 60/212,239
;  PRIOR FILING DATE: 2000-06-16
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22
;   LENGTH: 22
;   TYPE: DNA
;   ORGANISM: Feline Leukemia Virus
US-09-881-572A-22

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTTACCTACCT 1634
              ||| ||||||  ||||||| |
Db          2 GGAGGAGTTTTATACCTACAT 22


RESULT 21
US-08-753-147-140
; Sequence 140, Application US/08753147
; Patent No. 5770372
;  GENERAL INFORMATION:
;    APPLICANT:  Concannon, Patrick
;    TITLE OF INVENTION:  Detection of Mutations in the Human ATM Gene
;    NUMBER OF SEQUENCES:  196
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson and Kindness
;      STREET:  1420 5th Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/753,147
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  VMRC-1-9714
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 743-4387
;      TELEFAX:  (206) 224 0779
;  INFORMATION FOR SEQ ID NO:  140:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapiens
US-08-753-147-140

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 16;
  Best Local Similarity   93.8%;  Pred. No. 1e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1923 TTTTTTTCAGTGTTAA 1938
              ||||||||||||| ||
Db          1 TTTTTTTCAGTGTCAA 16


RESULT 22
US-08-702-105A-35
; Sequence 35, Application US/08702105A
; Patent No. 5908839
;  GENERAL INFORMATION:
;    APPLICANT:  Levitt, Roy C.
;    APPLICANT:  Maloy, W. Lee
;    APPLICANT:  Kari, U. Prasad
;    APPLICANT:  Nicolaides, Nicholas C.
;    TITLE OF INVENTION:  Asthma Associated Factors As Targets For
;    TITLE OF INVENTION:  Treating Atopic Allergies Including Asthma And Related
;    TITLE OF INVENTION:  Disorders
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;      ADDRESSEE:  Dunner L.L.P.
;      STREET:  1300 I Street N.W., Suite 700
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20005-3315
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/702,105A
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/874,503
;      FILING DATE:  13-JUN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fordis, Jean B.
;      REGISTRATION NUMBER:  32984
;      REFERENCE/DOCKET NUMBER:  05387.0056-01000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 408-4000
;      TELEFAX:  (202) 408-4400
;  INFORMATION FOR SEQ ID NO:  35:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-702-105A-35

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
              ||||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20


RESULT 23
US-08-702-110A-35
; Sequence 35, Application US/08702110A
; Patent No. 6037149
;  GENERAL INFORMATION:
;    APPLICANT:  Levitt, Roy C.
;    APPLICANT:  Maloy, W. Lee
;    APPLICANT:  Kari, U. Prasad
;    APPLICANT:  Nicolaides, Nicholas C.
;    TITLE OF INVENTION:  Asthma Associated Factors As Targets For
;    TITLE OF INVENTION:  Treating Atopic Allergies Including Asthma And Related
;    TITLE OF INVENTION:  Disorders
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;      ADDRESSEE:  Dunner L.L.P.
;      STREET:  1300 I Street N.W., Suite 700
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20005-3315
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/702,110A
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/874,503
;      FILING DATE:  13-JUN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fordis, Jean B.
;      REGISTRATION NUMBER:  32984
;      REFERENCE/DOCKET NUMBER:  05387.0056-01000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 408-4000
;      TELEFAX:  (202) 408-4400
;  INFORMATION FOR SEQ ID NO:  35:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-702-110A-35

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
              ||||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20


RESULT 24
US-09-325-571-35
; Sequence 35, Application US/09325571
; Patent No. 6261559
;  GENERAL INFORMATION:
;    APPLICANT:  Levitt, Roy C.
;    APPLICANT:  Maloy, W. Lee
;    APPLICANT:  Kari, U. Prasad
;    APPLICANT:  Nicolaides, Nicholas C.
;    TITLE OF INVENTION:  Asthma Associated Factors As Targets For
;    TITLE OF INVENTION:  Treating Atopic Allergies Including Asthma And Related
;    TITLE OF INVENTION:  Disorders
;    NUMBER OF SEQUENCES:  41
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Finnegan, Henderson, Farabow, Garrett &
;      ADDRESSEE:  Dunner L.L.P.
;      STREET:  1300 I Street N.W., Suite 700
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  USA
;      ZIP:  20005-3315
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
```

```
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/325,571
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/874,503
;      FILING DATE:  13-JUN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fordis, Jean B.
;      REGISTRATION NUMBER:  32984
;      REFERENCE/DOCKET NUMBER:  05387.0056-01000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 408-4000
;      TELEFAX:  (202) 408-4400
;  INFORMATION FOR SEQ ID NO:  35:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-09-325-571-35

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
             ||||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20


RESULT 25
US-09-198-452A-4828/c
; Sequence 4828, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4828
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4828

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCAC 1582
             ||||||||| ||||||
Db         20 AAAAATCCTCCTCCAC 5


RESULT 26
US-09-198-452A-6111
; Sequence 6111, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6111
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6111

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1556 AACAGGACTGCAAAAA 1571
              || |||||||||||||
Db          4 AAGAGGACTGCAAAAA 19


RESULT 27
US-09-848-585-35
; Sequence 35, Application US/09848585
; Patent No. 6645492
; GENERAL INFORMATION:
;  APPLICANT: LEVITT, Roy Clifford
;  APPLICANT:  MALOY, W. Lee
;  APPLICANT:  KARI, U. Prasad
;  APPLICANT:  NICOLAIDES, Nicholas C.
;  TITLE OF INVENTION: Asthma Associated Factors As Targets For Treating Atopic Allergies
;  TITLE OF INVENTION:  Including Asthma And Related Disorders
;  FILE REFERENCE: 36870-5056-12-US
;  CURRENT APPLICATION NUMBER: US/09/848,585
;  CURRENT FILING DATE:  2001-05-04
;  PRIOR APPLICATION NUMBER: US 60/002,765
;  PRIOR FILING DATE: 1995-08-24
;  PRIOR APPLICATION NUMBER: US 08/697,419
;  PRIOR FILING DATE: 1996-08-23
;  PRIOR APPLICATION NUMBER: US 08/874,503
;  PRIOR FILING DATE: 1997-06-13
;  PRIOR APPLICATION NUMBER: US 09/325,571
;  PRIOR FILING DATE: 1999-06-04
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: PCR oligonucleotide primer
US-09-848-585-35

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 1.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
             ||||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20


RESULT 28
US-09-294-764-1
; Sequence 1, Application US/09294764
; Patent No. 6569423
; GENERAL INFORMATION:
;  APPLICANT: Weinstein, David E.
;  TITLE OF INVENTION: METHODS OF INDUCING NERVOUS TISSUE REGENERATION
;  FILE REFERENCE: 96700/496
;  CURRENT APPLICATION NUMBER: US/09/294,764
;  CURRENT FILING DATE:  1999-04-19
;  NUMBER OF SEQ ID NOS: 2
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-294-764-1

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   93.8%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              |||||||| |||||||
Db          6 TCTCCACCCCACAGAC 21


RESULT 29
US-08-222-177A-193/c
; Sequence 193, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  193:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd48p1
US-08-222-177A-193

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1727 CTATTATCAGAAGGTGACA 1745
              ||||| |||| ||| ||||
Db         19 CTATTCTCAGCAGGAGACA 1


RESULT 30
US-08-888-982A-32/c
; Sequence 32, Application US/08888982A
; Patent No. 5981731
;  GENERAL INFORMATION:
;    APPLICANT:  Brett P. Monia
;    TITLE OF INVENTION:  Antisense Oligonucleotide Modulation
;    TITLE OF INVENTION:  of raf Gene Expression
;    NUMBER OF SEQUENCES:  42
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Jane Massey Licata, Esq.
;      STREET:  66 East Main Street
;      CITY:  Marlton
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08053
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM 486
;      OPERATING SYSTEM:  WINDOWS FOR WORKGROUPS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/888,982A
;      FILING DATE:  Herewith
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/756,806
;      FILING DATE:  No. 5981731ember 26, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/07111
;      FILING DATE:  May 31, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/250,856
;      FILING DATE:  May 31, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0212
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (609) 779-2400
;      TELEFAX:  (609) 779-8488
;  INFORMATION FOR SEQ ID NO:  32:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
US-08-888-982A-32

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 31
US-09-517-584A-54
; Sequence 54, Application US/09517584A
; Patent No. 6187587
; GENERAL INFORMATION:
;  APPLICANT:      Ian Popoff
;  APPLICANT:  Vickie L. Brown-Driver
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION:      ANTISENSE MODULATION OF E2F TRANSCRIPTION FACTOR 1 EXPRESSION
;  FILE REFERENCE:      RTS-0121
;  CURRENT APPLICATION NUMBER: US/09/517,584A
;  CURRENT FILING DATE:  2000-03-22
;  NUMBER OF SEQ ID NOS:      89
; SEQ ID NO 54
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-584A-54

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2017 AAGTCCTCTGGTAGGAGGC 2035
              || ||||| || ||||||||
Db          2 AACTCCTCAGGGAGGAGGC 20


RESULT 32
US-09-462-261-32/c
; Sequence 32, Application US/09462261
; Patent No. 6391636
;   GENERAL INFORMATION:
;        APPLICANT: Brett P. Monia
;        TITLE OF INVENTION: Antisense Oligonucleotide
;                            Modulation of raf Gene Expression
;        NUMBER OF SEQUENCES: 42
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Jane Massey Licata, Esq.
;             STREET: 66 East Main Street
;             CITY: Marlton
;             STATE: NJ
;             COUNTRY: USA
;             ZIP: 08053
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;             COMPUTER: Pentium
;             OPERATING SYSTEM: Windows 95
;             SOFTWARE: WORDPERFECT 6.1
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/462,261
;             FILING DATE: 01-Mar-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/756,806
;             FILING DATE: No. 6391636ember 26, 1996
;             APPLICATION NUMBER: PCT/US95/07111
;             FILING DATE: May 31, 1995
;             APPLICATION NUMBER: 08/250,856
;             FILING DATE: May 31, 1994
;             APPLICATION NUMBER: 08/888,982
;             FILING DATE: July 7, 1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Jane Massey Licata
;             REGISTRATION NUMBER: 32,257
;             REFERENCE/DOCKET NUMBER: ISPH-0312
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (609) 779-2400
;             TELEFAX: (609) 810-1454
;   INFORMATION FOR SEQ ID NO: 32:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 20
;             TYPE: Nucleic Acid
;             STRANDEDNESS: Single
;             TOPOLOGY: Linear
;        ANTI-SENSE: Yes
;        SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-09-462-261-32

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 33
US-09-506-073-121/c
; Sequence 121, Application US/09506073
; Patent No. 6410518
; GENERAL INFORMATION:
;  APPLICANT: Monia, Brett P.
;  TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
;  FILE REFERENCE:
;  CURRENT APPLICATION NUMBER: US/09/506,073
;  CURRENT FILING DATE: 2000-02-18
;  EARLIER APPLICATION NUMBER: US 09/143,214
;  EARLIER FILING DATE: 1998-08-28
;  EARLIER APPLICATION NUMBER: PCT/US98/13961
;  EARLIER FILING DATE: 1998-07-06
;  EARLIER APPLICATION NUMBER: US 08/888,982
;  EARLIER FILING DATE: 1997-07-07
;  EARLIER APPLICATION NUMBER: US 08/756,806
;  EARLIER FILING DATE: 1996-11-26
;  EARLIER APPLICATION NUMBER: PCT/US95/07111
;  EARLIER FILING DATE: 1995-05-31
;  EARLIER APPLICATION NUMBER: US 08/250,856
;  EARLIER FILING DATE: 1994-05-31
;  NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 121
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: artificial sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-09-506-073-121

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 34
US-09-198-452A-5020/c
; Sequence 5020, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, prever
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 5020
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-5020

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1585 CACAGACTGGGAACCCCTC 1603
              |||||| |||||| ||| |
Db         19 CACAGATTGGGAAGCCCCC 1


RESULT 35
US-08-053-867A-18/c
; Sequence 18, Application US/08053867A
; Patent No. 5545545
;  GENERAL INFORMATION:
;    APPLICANT:  Gengenbach, Burle G.
```

```
;    APPLICANT:  Somers, David A.
;    APPLICANT:  Bittel, Douglas C.
;    APPLICANT:  Shaver, Jonathan M.
;    TITLE OF INVENTION:  Lysine-Insensitive Maize
;    TITLE OF INVENTION:  Dihydrodipicolinic Acid Synthase
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merchant & Gould
;      STREET:  3100 No. 5545545west Center
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55403
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/053,867A
;      FILING DATE:  27-APR-1993
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Woessner, Warren D.
;      REGISTRATION NUMBER:  30,440
;      REFERENCE/DOCKET NUMBER:  600.263-US-01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612/332-5300
;      TELEFAX:  612/332-3081
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-053-867A-18

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTCTA 2045
                | |||||||  ||||||||
Db         19 GAAGGAGGCCCAGGTTCTA 1


RESULT 36
US-09-792-024-402
; Sequence 402, Application US/09792024
; Patent No. 6783985
; GENERAL INFORMATION:
;  APPLICANT: Roemer, Terry
;  APPLICANT:  Jiang, Bo
;  APPLICANT:  Boone, Charles
;  APPLICANT:  Bussey, Howard
;  TITLE OF INVENTION: Gene Disruption Methodologies for Drug
;  TITLE OF INVENTION:  Targets Discovery
;  FILE REFERENCE: 10182-004-999
;  CURRENT APPLICATION NUMBER: US/09/792,024
;  CURRENT FILING DATE:  2001-02-20
;  NUMBER OF SEQ ID NOS: 490
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 402
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: DNA primer
US-09-792-024-402

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATCAA 1906
                ||||||  | ||  |||||||
Db          1 TTGATGGGTCCGAGATCAA 19


RESULT 37
US-09-487-368A-32
; Sequence 32, Application US/09487368A
; Patent No. 6261840
; GENERAL INFORMATION:
;  APPLICANT:      Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION:      ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE:      RTS-0093
;  CURRENT APPLICATION NUMBER: US/09/487,368A
;  CURRENT FILING DATE:  2000-01-18
;  NUMBER OF SEQ ID NOS:      240
; SEQ ID NO 32
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-368A-32

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
              ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 38
US-09-484-617-130/c
; Sequence 130, Application US/09484617
; Patent No. 6303374
; GENERAL INFORMATION:
;  APPLICANT: Hong Zhang
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 3 EXPRESSION
;  FILE REFERENCE: RTS-0103
;  CURRENT APPLICATION NUMBER: US/09/484,617
;  CURRENT FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-484-617-130

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAG 2013
              ||||||||||||||
Db         20 TAGCTTCTTCAGAG 7


RESULT 39
US-09-629-644A-32
; Sequence 32, Application US/09629644A
; Patent No. 6492345
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
```

```
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0478
;  CURRENT APPLICATION NUMBER: US/09/629,644A
;  CURRENT FILING DATE:  2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 242
; SEQ ID NO 32
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-644A-32

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
              ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 40
US-09-866-108A-1346/c
; Sequence 1346, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1346
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1346

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              ||||||  |||||||||
Db         17 CCCCATCTTTTCCTTCT 1


RESULT 41
US-09-866-108A-7642/c
; Sequence 7642, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7642
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7642

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCTAGC 1701
              || |||| |||||||||
Db         17 TTTGTTGGTTCTCTAGC 1


RESULT 42
US-09-866-108A-7643/c
; Sequence 7643, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
```

```
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7643
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7643

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTAG 1700
              ||| |||| ||||||||
Db         17 CTTTGTTGGTTCTCTAG 1


RESULT 43
US-08-996-306-46
; Sequence 46, Application US/08996306
; Patent No. 5945522
;  GENERAL INFORMATION:
;    APPLICANT:  Cohen, Daniel
;    APPLICANT:  Chumakov, Ilya
;    APPLICANT:  Blumenfeld, Marta
;    APPLICANT:  Bougueleret, Lydie
;    TITLE OF INVENTION:  Prostate cancer gene
;    NUMBER OF SEQUENCES:  68
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson & Bear
;      STREET:  501 West Broadway
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92101-3505
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy Disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  Win95
;      SOFTWARE:  Word
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/996,306
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Israelsen, Ned A.
;      REGISTRATION NUMBER:  29,655
;      REFERENCE/DOCKET NUMBER:  GENSET.018A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 235-8550
;      TELEFAX:  (619) 235-0176
;  INFORMATION FOR SEQ ID NO:  46:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  SINGLE
;      TOPOLOGY:  LINEAR
;    MOLECULE TYPE:  DNA
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapiens
;    FEATURE:
;      NAME/KEY:  99-221-PU upstream primer
;      LOCATION:  1..19
US-08-996-306-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 44
US-09-338-907-46
; Sequence 46, Application US/09338907
; Patent No. 6265546
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Ilya, Chumakov
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: PROSTATE CANCER GENE
;  FILE REFERENCE: GENSET.18CP1CP
;  CURRENT APPLICATION NUMBER: US/09/338,907
;  CURRENT FILING DATE: 1999-06-23
;  EARLIER APPLICATION NUMBER: 08/996,306
;  EARLIER FILING DATE: 1997-12-22
;  EARLIER APPLICATION NUMBER: 60/099,658
;  EARLIER FILING DATE: 1998-09-09
;  EARLIER APPLICATION NUMBER: 09/218,207
;  EARLIER FILING DATE: 1998-12-22
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 46
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-221-PU
US-09-338-907-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 45
US-09-338-907-380
; Sequence 380, Application US/09338907
```

```
; Patent No. 6265546
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Ilya, Chumakov
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: PROSTATE CANCER GENE
;  FILE REFERENCE: GENSET.18CP1CP
;  CURRENT APPLICATION NUMBER: US/09/338,907
;  CURRENT FILING DATE: 1999-06-23
;  EARLIER APPLICATION NUMBER: 08/996,306
;  EARLIER FILING DATE: 1997-12-22
;  EARLIER APPLICATION NUMBER: 60/099,658
;  EARLIER FILING DATE: 1998-09-09
;  EARLIER APPLICATION NUMBER: 09/218,207
;  EARLIER FILING DATE: 1998-12-22
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 380
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer for SEQ 260, SEQ 337
US-09-338-907-380

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 46
US-09-218-207-46
; Sequence 46, Application US/09218207
; Patent No. 6346381
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Ilya, Chumakov
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: Prostate cancer gene
;  FILE REFERENCE: GENSET.018CP1
;  CURRENT APPLICATION NUMBER: US/09/218,207
;  CURRENT FILING DATE: 1998-12-22
;  EARLIER APPLICATION NUMBER: 08/996,306
;  EARLIER FILING DATE: 1997-12-22
;  EARLIER APPLICATION NUMBER: 60/099,658
;  EARLIER FILING DATE: 1998-09-09
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 46
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-221-PU
US-09-218-207-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 47
US-09-218-207-380
; Sequence 380, Application US/09218207
; Patent No. 6346381
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Ilya, Chumakov
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: Prostate cancer gene
;  FILE REFERENCE: GENSET.018CP1
;  CURRENT APPLICATION NUMBER: US/09/218,207
;  CURRENT FILING DATE: 1998-12-22
;  EARLIER APPLICATION NUMBER: 08/996,306
;  EARLIER FILING DATE: 1997-12-22
;  EARLIER APPLICATION NUMBER: 60/099,658
;  EARLIER FILING DATE: 1998-09-09
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 380
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer for SEQ 260, SEQ 337
US-09-218-207-380

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 48
US-09-422-978-7856
; Sequence 7856, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7856
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-221 for SEQ 3922,
US-09-422-978-7856

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 49
US-09-696-791-1991/c
; Sequence 1991, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1991
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin D3 ribozyme binding site
US-09-696-791-1991

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGTT 1622
              |||| ||||||||| ||
Db         19 GGCCAGGGGGAAGACTT 3


RESULT 50
US-08-531-747-5/c
; Sequence 5, Application US/08531747
; Patent No. 5631147
;  GENERAL INFORMATION:
;    APPLICANT:  Lohman, Kenton L.
;    APPLICANT:  Ostrerova, Natalie V.
;    APPLICANT:  Van Cleve, Mark
;    APPLICANT:  Reid, Robert A.
;    TITLE OF INVENTION:  DETECTION OF NUCLEIC ACIDS IN CELLS BY
;    TITLE OF INVENTION:  THERMOPHILIC STRAND DISPLACEMENT AMPLIFICATION
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick, Becton Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  US
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/531,747
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fugit, Donna R.
;      REGISTRATION NUMBER:  32,135
;      REFERENCE/DOCKET NUMBER:  P-3462
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-531-747-5

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 51
US-08-531-749-5/c
; Sequence 5, Application US/08531749
; Patent No. 5733752
;  GENERAL INFORMATION:
;    APPLICANT:  Lohman, Kenton L.
;    APPLICANT:  Ostrerova, Natalie V.
;    APPLICANT:  Van Cleve, Mark
;    APPLICANT:  Reid, Robert A.
;    TITLE OF INVENTION:  DETECTION OF NUCLEIC ACIDS IN CELLS BY
;    TITLE OF INVENTION:  THERMOPHILIC STRAND DISPLACEMENT AMPLIFICATION
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick, Becton Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  US
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/531,749
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fugit, Donna R.
;      REGISTRATION NUMBER:  32,135
;      REFERENCE/DOCKET NUMBER:  P-3462
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-531-749-5

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 52
US-08-781-432-5/c
; Sequence 5, Application US/08781432
; Patent No. 5756702
;  GENERAL INFORMATION:
;    APPLICANT:  Lohman, Kenton L.
;    APPLICANT:  Ostrerova, Natalie V.
;    APPLICANT:  Van Cleve, Mark
```

```
;    APPLICANT:  Reid, Robert A.
;    TITLE OF INVENTION:  DETECTION OF NUCLEIC ACIDS IN CELLS BY
;    TITLE OF INVENTION:  THERMOPHILIC STRAND DISPLACEMENT AMPLIFICATION
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Richard J. Rodrick, Becton Dickinson and
;      ADDRESSEE:  Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  US
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/781,432
;      FILING DATE:
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/531,747
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fugit, Donna R.
;      REGISTRATION NUMBER:  32,135
;      REFERENCE/DOCKET NUMBER:  P-3462
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-781-432-5

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 53
US-08-854-041-5/c
; Sequence 5, Application US/08854041
; Patent No. 5916779
;  GENERAL INFORMATION:
;    APPLICANT:  Pearson, Robert E.
;    APPLICANT:  Dickson, Julie A.
;    APPLICANT:  Mehrpouyan, Majid
;    TITLE OF INVENTION:  STRAND DISPLACEMENT AMPLIFICATION OF RNA
;    TITLE OF INVENTION:  TARGETS
;    NUMBER OF SEQUENCES:  5
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  R. J. Rodrick, Becton Dickinson and Company
;      STREET:  1 Becton Drive
;      CITY:  Franklin Lakes
;      STATE:  NJ
;      COUNTRY:  US
;      ZIP:  07417
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/854,041
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fugit, Donna R.
;      REGISTRATION NUMBER:  32,135
;      REFERENCE/DOCKET NUMBER:  P-3853
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-854-041-5

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 54
US-09-490-692-166
; Sequence 166, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
;  FILE REFERENCE: RTS-0120
;  CURRENT APPLICATION NUMBER: US/09/490,692
;  CURRENT FILING DATE: 2000-01-24
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 166
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-166

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2032 AGGCAAAGGTTCTATCT 2048
              ||||||||  |||  ||||
Db          1 AGGCAAAGCTTCCATCT 17


RESULT 55
US-08-930-285-23/c
; Sequence 23, Application US/08930285
; Patent No. 6222099
;  GENERAL INFORMATION:
;    APPLICANT:  Regents of the University of Minnesota, et al.
;    TITLE OF INVENTION:  TRANSGENIC PLANTS EXPRESSING ACETYL COA CARBOXYLASE GE
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Schwegman, Lundberg, Woessner & Kluth, P. A.
;      STREET:  P. O. Box 2938
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/930,285
;      FILING DATE:  13-APR-1998
```

```
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US96/04625
;      FILING DATE:  04-APR-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Embretson, Janet E.
;      REGISTRATION NUMBER:  39,665
;      REFERENCE/DOCKET NUMBER:  600.318US4
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-339-0331
;      TELEFAX:  612-339-3061
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:
;    ORIGINAL SOURCE:
US-08-930-285-23

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACAG 1589
              ||||||| | |||||||
Db         18 CCTTCTCAAACGCACAG 2


RESULT 56
US-09-021-701-556
; Sequence 556, Application US/09021701
; Patent No. 6251588
;  GENERAL INFORMATION:
;    APPLICANT:  Shannon, Karen W.
;    APPLICANT:  Wolber, Paul K.
;    APPLICANT:  Delenstarr, Glenda C.
;    APPLICANT:  Webb, Peter G.
;    APPLICANT:  Kincaid, Robert H.
;    TITLE OF INVENTION:  Methods for evaluating oligonucleotide
;    TITLE OF INVENTION:  probe sequences
;    NUMBER OF SEQUENCES:  1165
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Records Manager, Legal Department, Hewlett-Packard Company M/S 20
;      STREET:  3000 Hanover Street
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/021,701
;      FILING DATE:  10-FEB-1998
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Choi, Wendy A.
;      REGISTRATION NUMBER:  36,697
;      REFERENCE/DOCKET NUMBER:  10971464-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-236-2386
;      TELEFAX:  650-852-8063
;  INFORMATION FOR SEQ ID NO:  556:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-09-021-701-556

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          4 TTTTTCTTTTTTAACCC 20


RESULT 57
US-09-021-701-557
; Sequence 557, Application US/09021701
; Patent No. 6251588
;  GENERAL INFORMATION:
;    APPLICANT:  Shannon, Karen W.
;    APPLICANT:  Wolber, Paul K.
;    APPLICANT:  Delenstarr, Glenda C.
;    APPLICANT:  Webb, Peter G.
;    APPLICANT:  Kincaid, Robert H.
;    TITLE OF INVENTION:  Methods for evaluating oligonucleotide
;    TITLE OF INVENTION:  probe sequences
;    NUMBER OF SEQUENCES:  1165
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Records Manager, Legal Department, Hewlett-Packard Company M/S 20
;      STREET:  3000 Hanover Street
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/021,701
;      FILING DATE:  10-FEB-1998
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Choi, Wendy A.
;      REGISTRATION NUMBER:  36,697
;      REFERENCE/DOCKET NUMBER:  10971464-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-236-2386
;      TELEFAX:  650-852-8063
;  INFORMATION FOR SEQ ID NO:  557:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-09-021-701-557

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          3 TTTTTCTTTTTTAACCC 19
```

```
RESULT 58
US-09-021-701-558
; Sequence 558, Application US/09021701
; Patent No. 6251588
;  GENERAL INFORMATION:
;    APPLICANT:  Shannon, Karen W.
;    APPLICANT:  Wolber, Paul K.
;    APPLICANT:  Delenstarr, Glenda C.
;    APPLICANT:  Webb, Peter G.
;    APPLICANT:  Kincaid, Robert H.
;    TITLE OF INVENTION:  Methods for evaluating oligonucleotide
;    TITLE OF INVENTION:  probe sequences
;    NUMBER OF SEQUENCES:  1165
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Records Manager, Legal Department, Hewlett-Packard Company M/S 20
;      STREET:  3000 Hanover Street
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/021,701
;      FILING DATE:  10-FEB-1998
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Choi, Wendy A.
;      REGISTRATION NUMBER:  36,697
;      REFERENCE/DOCKET NUMBER:  10971464-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-236-2386
;      TELEFAX:  650-852-8063
;  INFORMATION FOR SEQ ID NO:  558:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-09-021-701-558

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          2 TTTTTCTTTTTTAACCC 18


RESULT 59
US-09-021-701-559
; Sequence 559, Application US/09021701
; Patent No. 6251588
;  GENERAL INFORMATION:
;    APPLICANT:  Shannon, Karen W.
;    APPLICANT:  Wolber, Paul K.
;    APPLICANT:  Delenstarr, Glenda C.
;    APPLICANT:  Webb, Peter G.
;    APPLICANT:  Kincaid, Robert H.
;    TITLE OF INVENTION:  Methods for evaluating oligonucleotide
;    TITLE OF INVENTION:  probe sequences
;    NUMBER OF SEQUENCES:  1165
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Records Manager, Legal Department, Hewlett-Packard Company M/S 20
;      STREET:  3000 Hanover Street
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/021,701
;      FILING DATE:  10-FEB-1998
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Choi, Wendy A.
;      REGISTRATION NUMBER:  36,697
;      REFERENCE/DOCKET NUMBER:  10971464-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-236-2386
;      TELEFAX:  650-852-8063
;  INFORMATION FOR SEQ ID NO:  559:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-09-021-701-559

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          1 TTTTTCTTTTTTAACCC 17


RESULT 60
US-09-280-030-46/c
; Sequence 46, Application US/09280030A
; Patent No. 6506595
; GENERAL INFORMATION:
;  APPLICANT: Sato, Seiji
;  APPLICANT: Higashikuni, Naohiko
;  APPLICANT: Kudo, Toshiyuki
;  APPLICANT: Kondo, Masaaki
;  TITLE OF INVENTION: DNAS ENCODING NEW FUSION PROTEINS AND PROCESSES FOR
;  TITLE OF INVENTION: PREPARING USEFUL POLYPEPTIDES THROUGH EXPRESSION OF THE
;  TITLE OF INVENTION: DNAS
;  FILE REFERENCE: 382.1026
;  CURRENT APPLICATION NUMBER: US/09/280,030A
;  CURRENT FILING DATE: 1999-03-26
;  EARLIER APPLICATION NUMBER: JP10-87339/1998
;  EARLIER FILING DATE: 1998-03-31
;  NUMBER OF SEQ ID NOS: 66
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 46
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Designated is
;   OTHER INFORMATION: a forward primer for PCR amplification of human
;   OTHER INFORMATION: growth hormone DNA
US-09-280-030-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1934 GTTAAGGTAATGGTTGG 1950
```

```
              | ||||| |||||||||
Db         20 GATAAGGGAATGGTTGG 4


RESULT 61
US-09-198-452A-2718/c
; Sequence 2718, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2718
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-2718

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTG 1606
              |||| ||||||||| ||
Db         17 ACTGCGAACCCCTCTTG 1


RESULT 62
US-09-944-036-47/c
; Sequence 47, Application US/09944036
; Patent No. 6582920
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/09/944,036
;  CURRENT FILING DATE:  2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 47
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
US-09-944-036-47

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||| | ||
Db         20 ATTATCAGAAGGAGCCA 4


RESULT 63
US-09-522-775A-5
; Sequence 5, Application US/09522775A
; Patent No. 6660906
; GENERAL INFORMATION:
;  APPLICANT: Tsichlis, Philip N.
;  TITLE OF INVENTION: Inhibition of Tpl2 To Treat inflammatory Diseases
;  FILE REFERENCE: OTT-3202
;  CURRENT APPLICATION NUMBER: US/09/522,775A
;  CURRENT FILING DATE:  2000-03-08
;  NUMBER OF SEQ ID NOS: 13
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-522-775A-5

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 1.7e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACACTTAG 1871
              ||||||| |||||| ||
Db          4 CAGACCCTCACACTCAG 20


RESULT 64
US-09-052-333A-62
; Sequence 62, Application US/09052333A
; Patent No. 6261769
;  GENERAL INFORMATION:
;    APPLICANT:  Everett, Karin D.E.
;    APPLICANT:  Andersen, Arthur A.
;    TITLE OF INVENTION:  Intergenic Spacer Target Sequence for
; Patent No. 6261769
;    TITLE OF INVENTION:  Detecting and Distinguishing Chlamydial Strains
;    NUMBER OF SEQUENCES:  73
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Curtis P. Ribando
;      STREET:  1815 N. University Street
;      CITY:  Peoria
;      STATE:  IL
;      COUNTRY:  US
;      ZIP:  61604
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/052,333A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Ribando, Curtis P.
;      REGISTRATION NUMBER:  27,976
;      REFERENCE/DOCKET NUMBER:  0211.97
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  309/681-6513
;      TELEFAX:  309/681-6688
;  INFORMATION FOR SEQ ID NO:  62:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  21 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA to rRNA
;    ANTI-SENSE:  NO
;    ORIGINAL SOURCE:
;      ORGANISM:  Chlamydiaceae
US-09-052-333A-62

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
```

```
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1926 TTTTCAGTGTTAAGGTA 1942
              ||| || ||||||||||
Db          3 TTTGCATTGTTAAGGTA 19


RESULT 65
US-09-422-978-8235/c
; Sequence 8235, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8235
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..21
;   OTHER INFORMATION: downstream amplification primer 99-14601 for SEQ 370, in compleme
US-09-422-978-8235

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2062 TTAATAAGTGGTATCTG 2078
              || |||||| |||||||
Db         19 TTCATAAGTAGTATCTG 3


RESULT 66
US-09-422-978-10171
; Sequence 10171, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 10171
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..21
;   OTHER INFORMATION: downstream amplification primer 99-10304 for SEQ 2306, in complem
US-09-422-978-10171

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACC 1583
              ||||| ||| |||||||
Db          1 AAAAAACCTGCTCCACC 17


RESULT 67
US-09-944-036-11/c
; Sequence 11, Application US/09944036
; Patent No. 6582920
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/09/944,036
;  CURRENT FILING DATE:  2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
US-09-944-036-11

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 68
US-09-944-036-46/c
; Sequence 46, Application US/09944036
; Patent No. 6582920
; GENERAL INFORMATION:
;  APPLICANT: YANG, Yeasing Y.
;  APPLICANT:  BRENTANO, Steven T.
;  APPLICANT:  BABOLA, Odile
;  APPLICANT:  TRAN, Nathalie
;  APPLICANT:  VERNET, Guy
;  TITLE OF INVENTION: AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF
;  TITLE OF INVENTION:  SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS
;  FILE REFERENCE: GP114-02.UT
;  CURRENT APPLICATION NUMBER: US/09/944,036
;  CURRENT FILING DATE:  2001-08-31
;  PRIOR APPLICATION NUMBER: US 60/229,790
;  PRIOR FILING DATE: 2000-09-01
;  NUMBER OF SEQ ID NOS: 70
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: Oligonucleotide primer for Gag target sequence
```

```
US-09-944-036-46

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 69
US-09-726-774-40
; Sequence 40, Application US/09726774
; Patent No. 6677153
; GENERAL INFORMATION:
;  APPLICANT: Iversen, Patrick L.
;  TITLE OF INVENTION: Antisense Antibacterial Method and
;  TITLE OF INVENTION:  Composition
;  FILE REFERENCE: 0450-0032.30
;  CURRENT APPLICATION NUMBER: US/09/726,774
;  CURRENT FILING DATE:  2000-11-29
;  PRIOR APPLICATION NUMBER: US 60/168,150
;  PRIOR FILING DATE: 1999-11-29
;  NUMBER OF SEQ ID NOS: 139
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 40
;   LENGTH: 21
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense oligomer
US-09-726-774-40

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTCCTCT 2025
              |||||| |||| |||||
Db          1 CAGAGAGCAAGCCCTCT 17


RESULT 70
US-09-009-913-327/c
; Sequence 327, Application US/09009913
; Patent No. 6087485
;  GENERAL INFORMATION:
;    APPLICANT:  AxyS Pharmaceuticals, Inc.
;    TITLE OF INVENTION:  Asthma Related Genes
;    NUMBER OF SEQUENCES:  339
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Bozicevic & Reed, LLP
;      STREET:  285 Hamilton Ave, Suite 200
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94301
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/009,913
;      FILING DATE:  21-JAN-1998
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sherwood, Pamela J
;      REGISTRATION NUMBER:  36,677
;      REFERENCE/DOCKET NUMBER:  SEQ-4P
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-327-3231
;      TELEFAX:  650-327-3231
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  327:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-009-913-327

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1619 AGTTTGTTACCTACCTTACT 1638
              |||| |||||||||  | ||
Db         20 AGTTAGTTACCTACTGTGCT 1


RESULT 71
US-09-157-177-29/c
; Sequence 29, Application US/09157177
; Patent No. 6090558
; GENERAL INFORMATION:
;  APPLICANT: Butler, John M.
;  APPLICANT: Li, Jia
;  APPLICANT: Monforte, Joseph A.
;  APPLICANT: Becker, Christopher H.
;  TITLE OF INVENTION: DNA TYPING BY MASS SPECTROMETRY WITH  POLYMORPHIC DNA
;  TITLE OF INVENTION: REPEAT MARKERS
;  FILE REFERENCE: GETR:017/GETR017P
;  CURRENT APPLICATION NUMBER: US/09/157,177
;  CURRENT FILING DATE: 1998-09-18
;  EARLIER APPLICATION NUMBER: 60/059,415
;  EARLIER FILING DATE: 1997-09-19
;  NUMBER OF SEQ ID NOS: 135
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 29
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-157-177-29

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAACAGG 1561
              | || || || |||||||||
Db         20 GGGAATAAGGGAGGAACAGG 1


RESULT 72
US-09-288-461-43
; Sequence 43, Application US/09288461
; Patent No. 6159694
; GENERAL INFORMATION:
;  APPLICANT: Karras, James G.
;  TITLE OF INVENTION: Antisense Oligonucleotide Modulation of STAT3
;  TITLE OF INVENTION: Expression
;  FILE REFERENCE: ISPH-0338
;  CURRENT APPLICATION NUMBER: US/09/288,461
;  CURRENT FILING DATE: 1999-04-08
;  NUMBER OF SEQ ID NOS: 107
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Synthetic Sequence
US-09-288-461-43

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGGCTCTTTA 1760
              ||||||| | ||| ||| ||
Db          1 TGACAAGGAGTGGGTCTCTA 20


RESULT 73
US-09-490-692-109/c
; Sequence 109, Application US/09490692
; Patent No. 6180353
; GENERAL INFORMATION:
;  APPLICANT: Nicholas M. Dean
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF DAXX EXPRESSION
;  FILE REFERENCE: RTS-0120
;  CURRENT APPLICATION NUMBER: US/09/490,692
;  CURRENT FILING DATE: 2000-01-24
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 109
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-490-692-109

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1992 TGTGTATCTAGCTTCTTCAG 2011
              ||||| ||| || ||| |||
Db         20 TGTGTTTCTGGCCTCTGCAG 1


RESULT 74
US-09-021-701-354/c
; Sequence 354, Application US/09021701
; Patent No. 6251588
;  GENERAL INFORMATION:
;    APPLICANT:  Shannon, Karen W.
;    APPLICANT:  Wolber, Paul K.
;    APPLICANT:  Delenstarr, Glenda C.
;    APPLICANT:  Webb, Peter G.
;    APPLICANT:  Kincaid, Robert H.
;    TITLE OF INVENTION:  Methods for evaluating oligonucleotide
;    TITLE OF INVENTION:  probe sequences
;    NUMBER OF SEQUENCES:  1165
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Records Manager, Legal Department, Hewlett-Packard Company M/S 20
;      STREET:  3000 Hanover Street
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/021,701
;      FILING DATE:  10-FEB-1998
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Choi, Wendy A.
;      REGISTRATION NUMBER:  36,697
;      REFERENCE/DOCKET NUMBER:  10971464-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  650-236-2386
;      TELEFAX:  650-852-8063
;  INFORMATION FOR SEQ ID NO:  354:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
US-09-021-701-354

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTTTAAA 1837
              || | |||||  ||||||||
Db         20 AAATCTTAGAGCCTTTTAAA 1


RESULT 75
US-09-487-368A-183/c
; Sequence 183, Application US/09487368A
; Patent No. 6261840
; GENERAL INFORMATION:
;  APPLICANT:      Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION:      ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE:      RTS-0093
;  CURRENT APPLICATION NUMBER: US/09/487,368A
;  CURRENT FILING DATE:  2000-01-18
;  NUMBER OF SEQ ID NOS:      240
; SEQ ID NO 183
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-368A-183

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
              ||||| | ||| ||||||  |
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 76
US-09-484-617-164
; Sequence 164, Application US/09484617
; Patent No. 6303374
; GENERAL INFORMATION:
;  APPLICANT: Hong Zhang
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 3 EXPRESSION
;  FILE REFERENCE: RTS-0103
;  CURRENT APPLICATION NUMBER: US/09/484,617
;  CURRENT FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 164
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-484-617-164
```

```
  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1742 GACAAGTACTGGCTCTTTAT 1761
              ||||  |||| |||| ||||
Db          1 GACAGTTACTTGCTCCTTAT 20


RESULT 77
US-09-629-645A-37
; Sequence 37, Application US/09629645A
; Patent No. 6365354
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF LYSOPHOSPHOLIPASE I EXPRESSION
;  FILE REFERENCE: RTS-0137
;  CURRENT APPLICATION NUMBER: US/09/629,645A
;  CURRENT FILING DATE:  2000-07-31
;  NUMBER OF SEQ ID NOS: 164
; SEQ ID NO 37
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-645A-37

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1782 GAACCCCATTCTTTCCTTCT 1801
              |||  ||||||||  |||||
Db          1 GAATGCCATTCTTCACTTCT 20


RESULT 78
US-09-742-703-49
; Sequence 49, Application US/09742703
; Patent No. 6423543
; GENERAL INFORMATION:
;  APPLICANT:  Patrick Allen Marcotte
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION:  ANTISENSE MODULATION OF HEPSIN EXPRESSION
;  FILE REFERENCE:  RTS-0090
;  CURRENT APPLICATION NUMBER: US/09/742,703
;  CURRENT FILING DATE:  2000-12-20
;  NUMBER OF SEQ ID NOS:  49
; SEQ ID NO 49
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-742-703-49

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1627 ACCTACCTTACTATTTAAAG 1646
              |||  | ||| |||||||||
Db          1 ACCATCTTTATTATTTAAAG 20


RESULT 79
US-09-191-170-99
; Sequence 99, Application US/09191170
; Patent No. 6429199
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT: Hartmann, Gunther
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acid Molecules
;  TITLE OF INVENTION: for Activating Dendritic Cells
;  FILE REFERENCE: C1039/7017
;  CURRENT APPLICATION NUMBER: US/09/191,170
;  CURRENT FILING DATE: 1998-11-13
;  EARLIER APPLICATION NUMBER: US 08/960,774
;  EARLIER FILING DATE: 1997-10-30
;  EARLIER APPLICATION NUMBER: US 08/738,652
;  EARLIER FILING DATE: 1996-10-30
;  EARLIER APPLICATION NUMBER: US 08/386,063
;  EARLIER FILING DATE: 1995-02-07
;  EARLIER APPLICATION NUMBER: US 08/276,358
;  EARLIER FILING DATE: 1994-07-15
;  NUMBER OF SEQ ID NOS: 99
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 99
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic oligonucleotide
US-09-191-170-99

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 80
US-09-629-644A-183/c
; Sequence 183, Application US/09629644A
; Patent No. 6602857
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0478
;  CURRENT APPLICATION NUMBER: US/09/629,644A
;  CURRENT FILING DATE:  2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 242
; SEQ ID NO 183
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-644A-183

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
              ||||| | ||| |||||| |
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 81
US-09-422-978-5752
; Sequence 5752, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
```

```
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5752
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..20
;   OTHER INFORMATION: upstream amplification primer 99-6613 for SEQ 1818,
US-09-422-978-5752

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGGGAAG 1554
              || | ||||| | |||||||
Db          1 AGATGAGGAGTGGAGGGAAG 20


RESULT 82
US-09-230-652-116/c
; Sequence 116, Application US/09230652A
; Patent No. 6537775
; GENERAL INFORMATION:
;  APPLICANT: Tournier-Lasserve, Elisabeth
;  APPLICANT: Joutel, Anne
;  APPLICANT: Bousser, Marie-Germaine
;  APPLICANT: Bach, Jean-Francois
;  TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
;  TITLE OF INVENTION: THERAPEUTIC APPLICATION
;  FILE REFERENCE: 03715.0048-00000
;  CURRENT APPLICATION NUMBER: US/09/230,652A
;  CURRENT FILING DATE: 1999-05-17
;  EARLIER APPLICATION NUMBER: FR 96 09733
;  EARLIER FILING DATE: 1996-08-01
;  EARLIER APPLICATION NUMBER: FR 97 04680
;  EARLIER FILING DATE: 1997-04-16
;  EARLIER APPLICATION NUMBER: PCT/FR97/01433
;  EARLIER FILING DATE: 1997-07-31
;  NUMBER OF SEQ ID NOS: 163
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 116
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-230-652-116

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAACA 1559
              |||||||| |   |||||||
Db         20 AGGAGAGTGGCACAGGAACA 1


RESULT 83
US-09-780-045-84/c
; Sequence 84, Application US/09780045
; Patent No. 6602713
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PROTEIN PHOSPHATASE 2 CATALYTIC SUBUNIT BI
;  TITLE OF INVENTION:  EXPRESSION
;  FILE REFERENCE: RTS-0130
;  CURRENT APPLICATION NUMBER: US/09/780,045
;  CURRENT FILING DATE:  2001-02-09
;  NUMBER OF SEQ ID NOS: 135
; SEQ ID NO 84
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-780-045-84

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTTTGAA 1784
              |||  |||| |||| |||||
Db         20 TTATCCTTTATTTTATTGAA 1


RESULT 84
US-09-758-881-43
; Sequence 43, Application US/09758881
; Patent No. 6727064
; GENERAL INFORMATION:
;  APPLICANT:  Karras, James G
;  TITLE OF INVENTION:  Antisense Oligonucleotide Modulation of STAT3
;  TITLE OF INVENTION:  Expression
;  FILE REFERENCE:  ISPH-0532
;  CURRENT APPLICATION NUMBER: US/09/758,881
;  CURRENT FILING DATE:  2001-01-11
;  PRIOR APPLICATION NUMBER:  PCT/US00/09054
;  PRIOR FILING DATE:  2000-04-06
;  PRIOR APPLICATION NUMBER:  09/288,461
;  PRIOR FILING DATE:  1999-04-08
;  NUMBER OF SEQ ID NOS:  152
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 43
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-758-881-43

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGGCTCTTTA 1760
              ||||||| | ||| ||| ||
Db          1 TGACAAGGAGTGGGTCTCTA 20


RESULT 85
US-09-541-210-29/c
; Sequence 29, Application US/09541210
; Patent No. 6764822
; GENERAL INFORMATION:
;  APPLICANT: Butler, John M.
;  APPLICANT: Li, Jia
;  APPLICANT: Monforte, Joseph A.
;  APPLICANT: Becker, Christopher H.
;  TITLE OF INVENTION: DNA TYPING BY MASS SPECTROMETRY WITH  POLYMORPHIC DNA
```

```
;  TITLE OF INVENTION: REPEAT MARKERS
;  FILE REFERENCE: GETR:017/GETR017P
;  CURRENT APPLICATION NUMBER: US/09/541,210
;  CURRENT FILING DATE: 2000-04-03
;  EARLIER APPLICATION NUMBER: 60/059,415
;  EARLIER FILING DATE: 1997-09-19
;  NUMBER OF SEQ ID NOS: 135
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 29
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-541-210-29

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAACAGG 1561
              | || || || |||||||||
Db         20 GGGAATAAGGGAGGAACAGG 1


RESULT 86
US-09-371-772B-5864/c
; Sequence 5864, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5864
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5864

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 1.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              |||||||||| ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 87
US-08-747-121-5/c
; Sequence 5, Application US/08747121
; Patent No. 5874290
;  GENERAL INFORMATION:
;    APPLICANT:  Murphy, Gerald
;    APPLICANT:  Boynton, Alton
;    APPLICANT:  Sehgal, Anil
;    TITLE OF INVENTION:  NUCLEOTIDE AND AMINO ACID
;    TITLE OF INVENTION:  SEQUENCES OF A D2-2 GENE ASSOCIATED WITH
;    TITLE OF INVENTION:  BRAIN TUMORS AND METHODS BASED THEREON
;    NUMBER OF SEQUENCES:  20
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/747,121
;      FILING DATE:  08-NOV-1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Baldwin, Geraldine F
;      REGISTRATION NUMBER:  31,232
;      REFERENCE/DOCKET NUMBER:  8511-008
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212)7909090
;      TELEFAX:  (212)8698864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    FEATURE:
;      NAME/KEY:  Modified Base
;      LOCATION:  1
;      OTHER INFORMATION:  Where N is any nucleotide
US-08-747-121-5

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1891 ATGTGCCCTAGATCA 1905
              ||||||| |||||||
Db         16 ATGTGCCTTAGATCA 2


RESULT 88
US-08-744-905A-5/c
; Sequence 5, Application US/08744905A
; Patent No. 5990294
;  GENERAL INFORMATION:
;    APPLICANT:  Murphy, Gerald
;    APPLICANT:  Boynton, Alton
;    APPLICANT:  Sehgal, Anil
;    TITLE OF INVENTION:  NUCLEOTIDE AND AMINO ACID
;    TITLE OF INVENTION:  SEQUENCES OF C4-2, A TUMOR SUPPRESSOR GENE,
;    TITLE OF INVENTION:  AND METHODS OF USE THEREOF
;    NUMBER OF SEQUENCES:  14
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  NY
;      COUNTRY:  USA
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/744,905A
;      FILING DATE:  08-NOV-1996
```

```
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Baldwin, Geraldine F
;      REGISTRATION NUMBER:  31,232
;      REFERENCE/DOCKET NUMBER:  8511-009
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212)7909090
;      TELEFAX:  (212)8698864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    FEATURE:
;      NAME/KEY:  Modified Base
;      LOCATION:  1
;      OTHER INFORMATION:  Where N is any nucleotide
US-08-744-905A-5

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1891 ATGTGCCCTAGATCA 1905
                ||||||| |||||||
Db         16 ATGTGCCTTAGATCA 2


RESULT 89
US-08-584-040-2032/c
; Sequence 2032, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2032:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2032

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
                ||||||||||  ||||
Db         17 GACTGCAAAAGTCCT 3


RESULT 90
US-08-584-040-2033/c
; Sequence 2033, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2033:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2033
```

```
  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||  ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 91
US-08-584-040-2034/c
; Sequence 2034, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2034:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2034

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||  ||||
Db         15 GACTGCAAAAGTCCT 1


RESULT 92
US-09-371-772B-577/c
; Sequence 577, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 577
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-577

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||  ||||
Db         17 GACTGCAAAAGTCCT 3


RESULT 93
US-09-371-772B-578/c
; Sequence 578, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 578
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-578

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||  ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 94
US-09-371-772B-579/c
; Sequence 579, Application US/09371772B
; Patent No. 6566127
```

```
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 579
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-579

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||  ||||
Db         15 GACTGCAAAAGTCCT 1


RESULT 95
US-09-213-768-36/c
; Sequence 36, Application US/09213768
; Patent No. 5985664
; GENERAL INFORMATION:
;  APPLICANT: Brenda F. Baker
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SENTRIN EXPRESSION
;  FILE REFERENCE: RTS-0026
;  CURRENT APPLICATION NUMBER: US/09/213,768
;  CURRENT FILING DATE: 1998-12-17
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 36
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-213-768-36

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1753 GCTCTTTATTCATTA 1767
              ||||  ||||||||||
Db         16 GCTCATTATTCATTA 2


RESULT 96
US-08-826-532-16/c
; Sequence 16, Application US/08826532B
; Patent No. 6027923
; GENERAL INFORMATION:
;  APPLICANT: Wallace, Robert B.
;  TITLE OF INVENTION: Linked Linear Amplification of Nucleic Acids
;  FILE REFERENCE: 3239-102P
;  CURRENT APPLICATION NUMBER: US/08/826,532B
;  CURRENT FILING DATE: 1997-04-02
;  EARLIER APPLICATION NUMBER: US 08/475,605
;  EARLIER FILING DATE: 1995-06-07
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 16
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA
;   OTHER INFORMATION: Molecule:synthesized primer
US-08-826-532-16

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              |||||  |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 97
US-08-826-532-18/c
; Sequence 18, Application US/08826532B
; Patent No. 6027923
; GENERAL INFORMATION:
;  APPLICANT: Wallace, Robert B.
;  TITLE OF INVENTION: Linked Linear Amplification of Nucleic Acids
;  FILE REFERENCE: 3239-102P
;  CURRENT APPLICATION NUMBER: US/08/826,532B
;  CURRENT FILING DATE: 1997-04-02
;  EARLIER APPLICATION NUMBER: US 08/475,605
;  EARLIER FILING DATE: 1995-06-07
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-08-826-532-18

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              |||||  |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 98
US-09-228-324A-16/c
; Sequence 16, Application US/09228324A
; Patent No. 6335184
; GENERAL INFORMATION:
;  APPLICANT: Reyes, Antonio A
;  APPLICANT:  Wallace, Robert B.
;  APPLICANT:  Ugozzoli, Luis A.
;  TITLE OF INVENTION: Linked Linear Amplification of Nucleic Acids
;  FILE REFERENCE: 3239-103P
;  CURRENT APPLICATION NUMBER: US/09/228,324A
;  CURRENT FILING DATE:  1999-01-11
;  PRIOR APPLICATION NUMBER: US 08/826,532
;  PRIOR FILING DATE: 1997-04-02
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 16
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Description of Combined DNA/RNA
;   OTHER INFORMATION: Molecule:synthesized primer
US-09-228-324A-16
```

```
  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 99
US-09-228-324A-18/c
; Sequence 18, Application US/09228324A
; Patent No. 6335184
; GENERAL INFORMATION:
;  APPLICANT: Reyes, Antonio A
;  APPLICANT:  Wallace, Robert B.
;  APPLICANT:  Ugozzoli, Luis A.
;  TITLE OF INVENTION: Linked Linear Amplification of Nucleic Acids
;  FILE REFERENCE: 3239-103P
;  CURRENT APPLICATION NUMBER: US/09/228,324A
;  CURRENT FILING DATE:  1999-01-11
;  PRIOR APPLICATION NUMBER: US 08/826,532
;  PRIOR FILING DATE: 1997-04-02
;  NUMBER OF SEQ ID NOS: 64
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-228-324A-18

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 100
US-09-422-978-7270
; Sequence 7270, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7270
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-3373 for SEQ 3336,
US-09-422-978-7270

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 1.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1907 CAGATCAACAATACC 1921
              ||| ||||||||||||
Db          3 CAGCTCAACAATACC 17


RESULT 101
US-08-529-878B-25/c
; Sequence 25, Application US/08529878B
; Patent No. 5932556
;  GENERAL INFORMATION:
;    APPLICANT:  Tam, Robert C.
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  REGULATION OF CD28 EXPRESSION
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Crockett & Fish
;      STREET:  3000 S. Augusta Court
;      CITY:  La Habra
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  90631
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPerfect 6.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/529,878B
;      FILING DATE:  13-SEP-1995
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fish, Robert D.
;      REGISTRATION NUMBER:  33,880
;      REFERENCE/DOCKET NUMBER:  213/003
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714-525-3433
;      TELEFAX:  714-525-3303
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  DNA (genomic)
US-08-529-878B-25

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGA 1543
              ||||||||| |||||
Db         15 GAAGAAAGGCTAGGA 1


RESULT 102
US-09-467-082-25
; Sequence 25, Application US/09467082
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PKA CATALYTIC SUBUNIT C-ALPHA EXPRESSION
;  FILE REFERENCE: RTS-0088
;  CURRENT APPLICATION NUMBER: US/09/467,082
;  CURRENT FILING DATE:  1999-12-17
;  NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 25
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
```

```
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-467-082-25

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCC 1675
              | ||||||||||||||
Db          2 CAGCATCACCCGCCC 16


RESULT 103
US-09-487-368A-130
; Sequence 130, Application US/09487368A
; Patent No. 6261840
; GENERAL INFORMATION:
;  APPLICANT:      Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  TITLE OF INVENTION:      ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE:      RTS-0093
;  CURRENT APPLICATION NUMBER: US/09/487,368A
;  CURRENT FILING DATE:  2000-01-18
;  NUMBER OF SEQ ID NOS:      240
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-368A-130

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | ||||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 104
US-09-629-644A-130
; Sequence 130, Application US/09629644A
; Patent No. 6602857
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  APPLICANT:  Jacqueline Wyatt
;  APPLICANT:  Susan M. Freier
;  APPLICANT:  Brett P. Monia
;  APPLICANT:  Madeline M. Butler
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTP1B EXPRESSION
;  FILE REFERENCE: ISPH-0478
;  CURRENT APPLICATION NUMBER: US/09/629,644A
;  CURRENT FILING DATE:  2000-07-31
;  PRIOR APPLICATION NUMBER: US 09/487,368
;  PRIOR FILING DATE: 2000-01-18
;  NUMBER OF SEQ ID NOS: 242
; SEQ ID NO 130
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-644A-130

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | ||||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 105
US-09-198-452A-3480
; Sequence 3480, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, prever
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3480
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-3480

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              ||||||||||||| |
Db          6 AGGGAAGGAACAGAA 20


RESULT 106
US-09-198-452A-4153/c
; Sequence 4153, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, prever
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4153
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4153

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.1e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 AGCTATCTCCTAACT 1720
              |||||||||||  |||
Db         18 AGCTATCTCCTTACT 4


RESULT 107
US-08-564-002-28
; Sequence 28, Application US/08564002
; Patent No. 5714329
;  GENERAL INFORMATION:
;    APPLICANT:  Dracopoli, Nicolas
;    APPLICANT:  Tucker, Margaret
;    APPLICANT:  Goldstein, Alissa
;    TITLE OF INVENTION:  Methods for the Diagnosis of a Genetic
;    TITLE OF INVENTION:  Predisposition to Cancer Associated with Variant CDK4
;    TITLE OF INVENTION:  Allele
;    NUMBER OF SEQUENCES:  30
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
```

```
;      STREET:  4 Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/564,002
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sherwood, Pamela J.
;      REGISTRATION NUMBER:  36,677
;      REFERENCE/DOCKET NUMBER:  A-62562
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 781-1989
;      TELEFAX:  (415) 398-3249
;  INFORMATION FOR SEQ ID NO:  28:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Primer"
US-08-564-002-28

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1840 CATTCCCTGGGCCAACAG 1857
                 | ||||||| ||| ||||
Db          1 CTTTCCCTGTGCCCACAG 18


RESULT 108
US-09-358-381-47
; Sequence 47, Application US/09358381
; Patent No. 6020199
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE: RTS-0079
;  CURRENT APPLICATION NUMBER: US/09/358,381
;  CURRENT FILING DATE: 1999-07-21
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 47
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-358-381-47

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTT 1794
                 | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 109
US-08-577-081A-65
; Sequence 65, Application US/08577081A
; Patent No. 6030775
;  GENERAL INFORMATION:
;    APPLICANT:  Yang, Soo Young
;    APPLICANT:  Cereb, Nezih
;    TITLE OF INVENTION:  Methods and Reagents for Typing HLA
;    TITLE OF INVENTION:  Class I Genes
;    NUMBER OF SEQUENCES:  84
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Oppedahl & Larson
;      STREET:  1992 Commerce Street Suite 309
;      CITY:  Yorktown
;      STATE:  NY
;      COUNTRY:  US
;      ZIP:  10598
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette - 3.5 inch, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  MS DOS
;      SOFTWARE:  Word Perfect
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/577,081A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Larson, Marina T.
;      REGISTRATION NUMBER:  32,038
;      REFERENCE/DOCKET NUMBER:  MSK.P-001-US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (914) 245-3252
;      TELEFAX:  (914) 962-4330
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  65:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  yes
;    FRAGMENT TYPE:  internal
;    ORIGINAL SOURCE:
;      ORGANISM:  human
;    FEATURE:
;      OTHER INFORMATION:  hybridization probe EE2-210 for typing of
;      OTHER INFORMATION:  HLA Class I genes
US-08-577-081A-65

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCCC 1601
                 ||||||||  ||||| ||
Db          1 GCACAGACACGGAACACC 18


RESULT 110
US-09-448-176-4/c
; Sequence 4, Application US/09448176
; Patent No. 6248533
;  GENERAL INFORMATION:
;       APPLICANT: KAMIZONO, Shintaro
;                  YAMADA, Akira
;                  HIGUCHI, Takafumi
;                  KATO, Hirohisa
;                  ITOH, Kyogo
;                  SEKI, Naoko
;       TITLE OF INVENTION: GENE DIAGNOSIS OF DISEASES WHEREIN
;                           TNF-ALPHA PROMOTERS PARTICIPATE
;       NUMBER OF SEQUENCES: 11
```

```
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: FOLEY & LARDNER
;            STREET: 3000 K Street, N.W.
;            CITY: Washington
;            STATE: D.C.
;            COUNTRY: U.S.A.
;            ZIP: 20007-5109
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/448,176
;            FILING DATE: 24-No. 6248533-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: WO PCT/JP98/02270
;            FILING DATE: 25-MAY-1998
;            APPLICATION NUMBER: WO PCT/JP97/04304
;            FILING DATE: 26-NOV-1997
;            APPLICATION NUMBER: JP 9-173900
;            FILING DATE: 30-JUN-1997
;            APPLICATION NUMBER: JP 9-134973
;            FILING DATE: 26-MAY-1997
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Wegner, Harold C.
;            REGISTRATION NUMBER: 25,258
;            REFERENCE/DOCKET NUMBER: 74129/472
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (202) 672-5300
;            TELEFAX: (202) 672-5399
;   INFORMATION FOR SEQ ID NO: 4:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 18 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: other nucleic acid
;            DESCRIPTION: /desc = "Allele specific
;       SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-448-176-4

  Query Match              2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1752 GGCTCTTTATTCATTAAG 1769
              ||| || | |||||||||
Db         18 GGCCCTGTCTTCATTAAG 1


RESULT 111
US-09-632-580A-90/c
; Sequence 90, Application US/09632580A
; Patent No. 6255111
; GENERAL INFORMATION:
;  APPLICANT:      C. Frank Bennett
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION:      ANTISENSE MODULATION OF HER-4 EXPRESSION
;  FILE REFERENCE:      RTS-0054
;  CURRENT APPLICATION NUMBER: US/09/632,580A
;  CURRENT FILING DATE:  2000-07-31
;  NUMBER OF SEQ ID NOS:      93
; SEQ ID NO 90
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-632-580A-90

  Query Match              2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCT 1793
              |||| ||||| ||||| |
Db         18 TTTTCTGAACTCCATTTT 1


RESULT 112
US-09-577-902-47
; Sequence 47, Application US/09577902
; Patent No. 6284538
; GENERAL INFORMATION:
;  APPLICANT:     Brett P. Monia
;  APPLICANT:  Lex M. Cowsert
;  APPLICANT:  Robert McKay
;  TITLE OF INVENTION:     ANTISENSE MODULATION OF PTEN EXPRESSION
;  FILE REFERENCE:     ISPH-0463
;  CURRENT APPLICATION NUMBER: US/09/577,902
;  CURRENT FILING DATE:  2000-05-24
;  PRIOR APPLICATION NUMBER:  US 09/358,381
;  PRIOR FILING DATE:  1999-07-21
;  PRIOR APPLICATION NUMBER:  PCT/US99/29594,
;  PRIOR FILING DATE:  1999-12-14
;  NUMBER OF SEQ ID NOS:     51
; SEQ ID NO 47
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-577-902-47

  Query Match              2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTT 1794
              | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 113
US-09-167-109-180
; Sequence 180, Application US/09167109
; Patent No. 6399297
; GENERAL INFORMATION:
;  APPLICANT: Baker, Brenda F.
;  APPLICANT: Cowsert, Lex M.
;  APPLICANT: Monia, Brett P.
;  APPLICANT: Xu, Xiaoxing S.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRAF EXPRESSION
;  FILE REFERENCE: ISPH-0321
;  CURRENT APPLICATION NUMBER: US/09/167,109
;  CURRENT FILING DATE: 1998-10-06
;  NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 180
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-09-167-109-180

  Query Match              2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1565 GCAAAAATCCTTCTCCAC 1582
              |||||| ||| |||| ||
Db          1 GCAAAACTCCGTCTCTAC 18
```

```
RESULT 114
US-08-699-628-10/c
; Sequence 10, Application US/08699628
; Patent No. 6013436
; GENERAL INFORMATION:
;   APPLICANT:  Hui, May
;   APPLICANT:  Dunn, James M.
;   APPLICANT:  Stevens, John, K.
;   APPLICANT:  Capatos, Denis
;   APPLICANT:  Matthews, David E
;   TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR DIAGNOSIS OF
;   TITLE OF INVENTION:  MUTATION IN THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR GENE
;   NUMBER OF SEQUENCES:  24
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Oppedahl & Larson
;     STREET:  1992 Commerce Street Suite 309
;     CITY:  Yorktown
;     STATE:  NY
;     COUNTRY:  US
;     ZIP:  10598
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Diskette - 3.5 inch, 1.44 Mb storage
;     COMPUTER:  IBM compatible
;     OPERATING SYSTEM:  MS DOS
;     SOFTWARE:  Word Perfect
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/699,628
;     FILING DATE:  19-Aug-96
;     CLASSIFICATION:  435
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  08/583,289
;     FILING DATE:  05-Jan-96
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Larson, Marina T.
;     REGISTRATION NUMBER:  32,038
;     REFERENCE/DOCKET NUMBER:  VGEN.P-032-US
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  (914) 245-3252
;     TELEFAX:  (914) 962-4330
;     TELEX:
;  INFORMATION FOR SEQ ID NO:  10:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  19
;     TYPE:  nucleic acid
;     STRANDEDNESS:  double
;     TOPOLOGY:  linear
;   MOLECULE TYPE:  other nucleic acid
;   HYPOTHETICAL:  no
;   ANTI-SENSE:  yes
;   FRAGMENT TYPE:  internal
;   ORIGINAL SOURCE:
;     ORGANISM:  human
;   FEATURE:
;     OTHER INFORMATION:  amplification primer for VHL
US-08-699-628-10

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1642 TAAAGAGCCTTCACTGGT 1659
              |||||||||  ||| |||
Db         19 TAAAGAGCCCACACCGGT 2


RESULT 115
US-09-422-978-4542
; Sequence 4542, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4542
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-15728 for SEQ 608,
US-09-422-978-4542

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAAAAAA 1984
              |||||||||| || | ||
Db          1 ATATTTACCTGGAGAGAA 18


RESULT 116
US-09-077-940A-19
; Sequence 19, Application US/09077940A
; Patent No. 6576441
; GENERAL INFORMATION:
;  APPLICANT: KIMURA, Toru et al.
;  TITLE OF INVENTION: NOVEL SEMAPHORIN Z AND GENE ENCODING THE SAME
;  FILE REFERENCE: 0020-4426P
;  CURRENT APPLICATION NUMBER: US/09/077,940A
;  CURRENT FILING DATE:  1998-06-05
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Adapter DNA used to ligate the various parts of the rSZexII
;   OTHER INFORMATION: plasmid
US-09-077-940A-19

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1724 GACCTATTATCAGAAGGT 1741
              || |||||||||| | ||
Db          2 GAACTATTATCAGGACGT 19


RESULT 117
US-09-696-791-1908/c
; Sequence 1908, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
```

```
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1908
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin D2 ribozyme binding site
US-09-696-791-1908

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGA 1619
              || ||||| | |||||||
Db         19 TCATGGCCAGAGGGAAGA 2


RESULT 118
US-09-696-791-2251
; Sequence 2251, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 2251
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin E ribozyme binding site
US-09-696-791-2251

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCACA 1588
              ||||||||||||  | |
Db          2 ATCCTTCTCCACCAAAGA 19


RESULT 119
US-08-222-177A-344/c
; Sequence 344, Application US/08222177A
; Patent No. 5582979
;  GENERAL INFORMATION:
;    APPLICANT:  Weber, James L.
;    TITLE OF INVENTION:  LENGTH POLYMORPHISMS IN
;    TITLE OF INVENTION:  (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
;    NUMBER OF SEQUENCES:  460
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DeWitt Ross & Stevens, S.C.
;      STREET:  8000 Excelsior Drive, Suite 401
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53717-1914
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/222,177A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/341,562
;      FILING DATE:  21-APR-1989
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sara, Charles S.
;      REGISTRATION NUMBER:  30,492
;      REFERENCE/DOCKET NUMBER:  09865.601
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 831-2100
;      TELEFAX:  (608) 831-2106
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  344:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  mfd108p1
US-08-222-177A-344

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1996 TATCTAGCTTCTTCAGAG 2013
              ||| ||||  ||||||||
Db         20 TATTTAGCCACTTCAGAG 3


RESULT 120
US-08-167-113-13/c
; Sequence 13, Application US/08167113
; Patent No. 5776672
;  GENERAL INFORMATION:
;    APPLICANT:  HASHIMOTO, Koji
;    APPLICANT:  ITO, Keiko
;    APPLICANT:  ISHIMORI, Yoshio
;    APPLICANT:  GOTOH, Masanori
;    TITLE OF INVENTION:  GENE DETECTION METHOD
;    NUMBER OF SEQUENCES:  21
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT
;      STREET:  1755 S. JEFFERSON DAVIS HWY, SUITE 400
;      CITY:  ARLINGTON
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/167,113
;      FILING DATE:  16-DEC-1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/766,064
;      FILING DATE:  27-SEP-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 2-259011
;      FILING DATE:  28-SEP-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 3-90879
;      FILING DATE:  22-APR-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 3-191868
;      FILING DATE:  31-JUL-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  OBLON, NORMAN F
```

```
;      REGISTRATION NUMBER:  24,618
;      REFERENCE/DOCKET NUMBER:  39-3751-0 FWC CIP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-413-3000
;      TELEFAX:  703-413-2220
;      TELEX:  248855 OPAT UR
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
US-08-167-113-13

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1597 ACCCCTCCTGGCCTGGGG 1614
              || |||||||||| | ||
Db         19 ACTCCTCCTGGCCGGCGG 2


RESULT 121
US-08-478-178A-65
; Sequence 65, Application US/08478178A
; Patent No. 5882927
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas Dean, C. Frank Bennett
;    TITLE OF INVENTION:  Oligonucleotide Modulation of
;    TITLE OF INVENTION:  Protein                                Kinase C
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & No. 5882927ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/478,178A
;      FILING DATE:  herewith
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  852,852
;      FILING DATE:  March 16, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Rebecca Ralph Gaumond
;      REGISTRATION NUMBER:  35,152
;      REFERENCE/DOCKET NUMBER:  ISIS-1154
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  65:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  yes
US-08-478-178A-65

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 122
US-08-488-177-65
; Sequence 65, Application US/08488177
; Patent No. 5885970
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas Dean, C. Frank Bennett
;    TITLE OF INVENTION:  Oligonucleotide Modulation of
;    TITLE OF INVENTION:  Protein Kinase C
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & No. 5885970ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/488,177
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  852,852
;      FILING DATE:  March 16, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul K. Legaard
;      REGISTRATION NUMBER:  38,534
;      REFERENCE/DOCKET NUMBER:  ISIS-1995
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  65:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  yes
US-08-488-177-65

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 123
US-08-481-072A-65
; Sequence 65, Application US/08481072A
; Patent No. 5916807
;  GENERAL INFORMATION:
;    APPLICANT:  Nicholas Dean, C. Frank Bennett
;    TITLE OF INVENTION:  Oligonucleotide Modulation of
;    TITLE OF INVENTION:  Protein                                Kinase C
;    NUMBER OF SEQUENCES:  121
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & No. 5916807ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
```

```
;       STATE:  PA
;       COUNTRY:  USA
;       ZIP:  19103
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;       COMPUTER:  IBM PS/2
;       OPERATING SYSTEM:  PC-DOS
;       SOFTWARE:  WORDPERFECT 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/481,072A
;       FILING DATE:  herewith
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  852,852
;       FILING DATE:  March 16, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Rebecca Ralph Gaumond
;       REGISTRATION NUMBER:  35,152
;       REFERENCE/DOCKET NUMBER:  ISIS-1154
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (215) 568-3100
;       TELEFAX:  (215) 568-3439
;   INFORMATION FOR SEQ ID NO:  65:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     ANTI-SENSE:  yes
US-08-481-072A-65

  Query Match           2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 124
US-08-664-336-65
; Sequence 65, Application US/08664336
; Patent No. 5922686
;  GENERAL INFORMATION:
;     APPLICANT:  Nicholas Dean, C. Frank Bennett
;     TITLE OF INVENTION:  Oligonucleotide Modulation of Protein
;     NUMBER OF SEQUENCES:  121
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Woodcock Washburn Kurtz
;       ADDRESSEE:  Mackiewicz & No. 5922686ris
;       STREET:  One Liberty Place - 46th Floor
;       CITY:  Philadelphia
;       STATE:  PA
;       COUNTRY:  USA
;       ZIP:  19103
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  DISKETTE, 3.5 INCH, 720 kb STORAGE
;       COMPUTER:  IBM PS/2
;       OPERATING SYSTEM:  PC-DOS
;       SOFTWARE:  WORDPERFECT 6.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/664,336
;       FILING DATE:  herewith
;       CLASSIFICATION:  536
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  852,852
;       FILING DATE:  March 16, 1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  089,996
;       FILING DATE:  July 9, 1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Paul K. Legaard
;       REGISTRATION NUMBER:  38,534
;       REFERENCE/DOCKET NUMBER:  ISIS-2345
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (215) 568-3100
;       TELEFAX:  (215) 568-3439
;   INFORMATION FOR SEQ ID NO:  65:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     ANTI-SENSE:  yes
US-08-664-336-65

  Query Match           2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 125
US-08-481-066A-65
; Sequence 65, Application US/08481066A
; Patent No. 5959096
;  GENERAL INFORMATION:
;     APPLICANT:  Nicholas Dean, C. Frank Bennett
;     TITLE OF INVENTION:  Oligonucleotide Modulation of
;     TITLE OF INVENTION:  Protein Kinase C
;     NUMBER OF SEQUENCES:  121
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Woodcock Washburn Kurtz
;       ADDRESSEE:  Mackiewicz & No. 5959096ris
;       STREET:  One Liberty Place - 46th Floor
;       CITY:  Philadelphia
;       STATE:  PA
;       COUNTRY:  USA
;       ZIP:  19103
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;       COMPUTER:  IBM PS/2
;       OPERATING SYSTEM:  PC-DOS
;       SOFTWARE:  WORDPERFECT 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/481,066A
;       FILING DATE:  herewith
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  852,852
;       FILING DATE:  March 16, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Rebecca Ralph Gaumond
;       REGISTRATION NUMBER:  35,152
;       REFERENCE/DOCKET NUMBER:  ISIS-1154
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (215) 568-3100
;       TELEFAX:  (215) 568-3439
;   INFORMATION FOR SEQ ID NO:  65:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     ANTI-SENSE:  yes
US-08-481-066A-65

  Query Match           2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
```

```
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 126
US-08-886-161-13/c
; Sequence 13, Application US/08886161
; Patent No. 5972692
;  GENERAL INFORMATION:
;    APPLICANT:  HASHIMOTO, Koji
;    APPLICANT:  ITO, Keiko
;    APPLICANT:  ISHIMORI, Yoshio
;    APPLICANT:  GOTOH, Masanori
;    TITLE OF INVENTION:  GENE DETECTION METHOD
;    NUMBER OF SEQUENCES:  21
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT
;      STREET:  1755 S. JEFFERSON DAVIS HWY, SUITE 400
;      CITY:  ARLINGTON
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/886,161
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/167,113
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 2-259011
;      FILING DATE:  28-SEP-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 3-90879
;      FILING DATE:  22-APR-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 3-191868
;      FILING DATE:  31-JUL-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  OBLON, NORMAN F
;      REGISTRATION NUMBER:  24,618
;      REFERENCE/DOCKET NUMBER:  39-3751-0 FWC CIP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-413-3000
;      TELEFAX:  703-413-2220
;      TELEX:  248855 OPAT UR
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
US-08-886-161-13

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1597 ACCCCTCCTGGCCTGGGG 1614
              || |||||||||| | ||
Db         19 ACTCCTCCTGGCCGGCGG 2


RESULT 127
US-09-120-853-16
; Sequence 16, Application US/09120853
; Patent No. 6057437
; GENERAL INFORMATION:
;  APPLICANT: Kamiya, Kinya
;  APPLICANT: Matsuda, Yoko
;  APPLICANT: Uchida, Kiyoshi
;  TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID COMPOUND
;  FILE REFERENCE: 07898/030001
;  CURRENT APPLICATION NUMBER: US/09/120,853
;  CURRENT FILING DATE: 1998-07-21
;  EARLIER APPLICATION NUMBER: JP 213838/1997
;  EARLIER FILING DATE: 1997-07-25
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 16
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Artificial
;   OTHER INFORMATION: nucleic acid sequence
US-09-120-853-16

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAACAGGA 1562
              || || ||||||| ||||
Db          2 AGAAGAGAAGGAAGAGGA 19


RESULT 128
US-09-358-384-44/c
; Sequence 44, Application US/09358384
; Patent No. 6130088
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 1 EXPRESSI
;  FILE REFERENCE: RTS-0083
;  CURRENT APPLICATION NUMBER: US/09/358,384
;  CURRENT FILING DATE: 1999-07-21
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 44
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-358-384-44

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1921 CTTTTTTTTCAGTGTTAA 1938
              ||||| || ||||||| |
Db         19 CTTTTGTTCCAGTGTTTA 2


RESULT 129
US-09-103-875-128
; Sequence 128, Application US/09103875A
; Patent No. 6221849
; GENERAL INFORMATION:
;  APPLICANT: Szyf, Moshe
;  APPLICANT: Bigey, Pascal
;  APPLICANT: Ramchandani, Shyam
;  TITLE OF INVENTION: DNA METHYLTRANSFERASE GENOMIC SEQUENCES AND ANTISENSE
;  TITLE OF INVENTION: OLIGONUCLEOTIDES
;  FILE REFERENCE: 106101.194
;  CURRENT APPLICATION NUMBER: US/09/103,875A
;  CURRENT FILING DATE: 1998-06-24
;  EARLIER APPLICATION NUMBER: 60/069,865
```

; EARLIER FILING DATE: 1997-12-17
; EARLIER APPLICATION NUMBER: 08/866,340
; EARLIER FILING DATE: 1997-05-30
; NUMBER OF SEQ ID NOS: 138
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 128
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide
US-09-103-875-128

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1741 TGACAAGTACTGGCTCTT 1758
||||| ||| |||||||
Db 2 TGACACCTACCGGCTCTT 19

RESULT 130
US-09-313-930-5
; Sequence 5, Application US/09313930
; Patent No. 6235723
; GENERAL INFORMATION:
; APPLICANT: Dean, Nicholas M.
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of Human Protein
; TITLE OF INVENTION: Kinase C-delta Expression
; FILE REFERENCE: ISPH-0357
; CURRENT APPLICATION NUMBER: US/09/313,930
; CURRENT FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-313-930-5

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1660 TCTGCATCACCCGCCCCT 1677
|||| || || |||||||
Db 2 TCTGGATGACGCGCCCCT 19

RESULT 131
US-09-377-309-75
; Sequence 75, Application US/09377309B
; Patent No. 6258790
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Condon, Tom P.
; APPLICANT: Cowsert, Lex M.
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN 4 EXPRESSION
; FILE REFERENCE: ISPH-0390
; CURRENT APPLICATION NUMBER: US/09/377,309B
; CURRENT FILING DATE: 1999-08-19
; EARLIER APPLICATION NUMBER: 09/166,203
; EARLIER FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 99
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-09-377-309-75

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1900 AGATCAACAGATCAACAA 1917
|||||||||| ||||
Db 3 AGATCAACAGAAGTACAA 20

RESULT 132
US-08-829-637A-65
; Sequence 65, Application US/08829637A
; Patent No. 6339066
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Phillip Dan Cook
; APPLICANT: Nicholas Dean
; APPLICANT: Glenn Hoke
; TITLE OF INVENTION: OLIGONUCLEOTIDES WHICH HAVE
; TITLE OF INVENTION: PHOSPHOROTHIOATE LINKAGES OF HIGH CHIRAL PURITY AND
; TITLE OF INVENTION: WHICH MODULATE aI, aII, , k, n, AND ISOFORMS OF
; TITLE OF INVENTION: PROTEIN KINASE C
; NUMBER OF SEQUENCES: 136
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: John W. Caldwell (28,937) Woodcock
; ADDRESSEE: Washburn Kurtz Mackiewicz & No. 6339066ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/829,637A
; FILING DATE: herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/481,066
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/470,129
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/469,851
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/468,569
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/089,996
; FILING DATE: 09-JUL-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/058,023
; FILING DATE: 05-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/777,007
; FILING DATE: 16-OCT-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/777,760
; FILING DATE: 15-OCT-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/852,852
; FILING DATE: 16-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/00243
; FILING DATE: 11-JAN-1991

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/566,977
;      FILING DATE:  13-AUG-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/436,358
;      FILING DATE:  11-JAN-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  _____
;      REGISTRATION NUMBER:  _____
;      REFERENCE/DOCKET NUMBER:  ISIS-____
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  65:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  yes
US-08-829-637A-65

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
                ||||  ||  ||  |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 133
US-09-907-843-31/c
; Sequence 31, Application US/09907843
; Patent No. 6440739
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Susan M. Freier
;  TITLE OF INVENTION: ANTISENSE MODULATION OF GLIOMA-ASSOCIATED ONCOGENE-2 EXPRESSION
;  FILE REFERENCE: RTS-0279
;  CURRENT APPLICATION NUMBER: US/09/907,843
;  CURRENT FILING DATE:  2001-07-17
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 31
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-907-843-31

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACCG 1584
                | |||  |||||||||  ||
Db         18 ACAAAGCCTTCTCCAACG 1


RESULT 134
US-09-659-845A-146/c
; Sequence 146, Application US/09659845A
; Patent No. 6492170
; GENERAL INFORMATION:
;  APPLICANT: Hong Zhang
;  APPLICANT:  Andrew T. Watt
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 9 EXPRESSION
;  FILE REFERENCE: RTS-0183
;  CURRENT APPLICATION NUMBER: US/09/659,845A
;  CURRENT FILING DATE:  2001-07-23
;  NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 146
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-845A-146

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1674 CCCTGGACTTCTTAGTTG 1691
                ||||||||| ||| || |
Db         18 CCCTGGACTGCTTTGTGG 1


RESULT 135
US-09-422-978-4087/c
; Sequence 4087, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4087
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..20
;   OTHER INFORMATION: upstream amplification primer 99-13229 for SEQ 153,
US-09-422-978-4087

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1681 CTTCTTAGTTGTTTCTCT 1698
                ||||  |||||||| |||
Db         20 CTTCCAAGTTGTTTTTCT 3


RESULT 136
US-10-025-139-65
; Sequence 65, Application US/10025139
; Patent No. 6537973
; GENERAL INFORMATION:
;  APPLICANT: Bennett, C. Frank
;  APPLICANT:  Dean, Nicholas M.
;  APPLICANT:  Holmlund, Jon T.
;  APPLICANT:  Dorr, F. Andrew
;  TITLE OF INVENTION: Oligonucleotide Modulation Of Protein Kinase C
;  FILE REFERENCE: ISIS4954
;  CURRENT APPLICATION NUMBER: US/10/025,139
;  CURRENT FILING DATE:  2001-12-18
;  PRIOR APPLICATION NUMBER: US 08/829,637
;  PRIOR FILING DATE: 1997-03-31
;  PRIOR APPLICATION NUMBER: US 08/478,178
;  PRIOR FILING DATE: 1995-06-07
;  PRIOR APPLICATION NUMBER: US 08/089,996
;  PRIOR FILING DATE: 1993-07-09
```

```
;  PRIOR APPLICATION NUMBER: US 07/852,852
;  PRIOR FILING DATE: 1992-03-16
;  NUMBER OF SEQ ID NOS: 121
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 65
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-10-025-139-65

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 137
US-09-198-452A-2313
; Sequence 2313, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, preve
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2313
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-2313

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2046 TCTGCTTAGCAACTAGTT 2063
              ||||||||| |||| | |
Db          3 TCTGCTTAGGAACTTGCT 20


RESULT 138
US-09-657-013-9/c
; Sequence 9, Application US/09657013
; Patent No. 6709817
; GENERAL INFORMATION:
;  APPLICANT: Zoghbi, Huda Y.
;  APPLICANT:  Van den Veyver, Ignatia B
;  APPLICANT:  Amir, Ruthie
;  APPLICANT:  Francke, Uta
;  TITLE OF INVENTION: Methods of Identifying Mutations in a Methyl-CPG-Binding Domain
;  TITLE OF INVENTION:  Containing Gene or Protein in Neurodevelopmental Disease and Tre
;  FILE REFERENCE: HO-P01893US1/09905371
;  CURRENT APPLICATION NUMBER: US/09/657,013
;  CURRENT FILING DATE:  2000-09-07
;  PRIOR APPLICATION NUMBER: US 60/152,778
;  PRIOR FILING DATE: 1999-09-07
;  NUMBER OF SEQ ID NOS: 114
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-657-013-9

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1677 TGGACTTCTTAGTTGTTT 1694
              ||| |||||||| || ||
Db         18 TGGGCTTCTTAGGTGGTT 1


RESULT 139
US-09-529-239D-89
; Sequence 89, Application US/09529239D
; Patent No. 6734019
; GENERAL INFORMATION:
;  APPLICANT: Doutriaux, Marie-Pascale
;  APPLICANT:  Betzner, Andreas
;  APPLICANT:  Freyssinet, Georges
;  APPLICANT:  Perez, Pascal
;  TITLE OF INVENTION: METHOD FOR OBTAINING PLANT VARIETIES
;  FILE REFERENCE: A33153-PCT-USA  072667.0128
;  CURRENT APPLICATION NUMBER: US/09/529,239D
;  CURRENT FILING DATE:  2000-10-27
;  PRIOR APPLICATION NUMBER: PCT/EP98/06977
;  PRIOR FILING DATE: 1998-10-09
;  NUMBER OF SEQ ID NOS: 100
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 89
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Reverse primer for PCR amplification of NGA106
;   OTHER INFORMATION: SSLP marker in Arabidopsis thaliana subspecies.
US-09-529-239D-89

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCTC 1802
              ||||||| | | ||||||
Db          3 CCCCATTTTGTTCTTCTC 20


RESULT 140
US-09-935-038A-10/c
; Sequence 10, Application US/09935038A
; Patent No. 6743603
; GENERAL INFORMATION:
;  APPLICANT: Kwok, Simon
;  APPLICANT:  Daskal, Ierachimiel
;  APPLICANT:  Albert Einstein Healthcare Network
;  TITLE OF INVENTION: No. 6743603el Tumor Suppressor Encoding Nucleic
;  TITLE OF INVENTION:  Acid, PTX1, And Methods Of Use Thereof
;  FILE REFERENCE: AEHN.012
;  CURRENT APPLICATION NUMBER: US/09/935,038A
;  CURRENT FILING DATE:  2001-08-22
;  PRIOR APPLICATION NUMBER: 60/226,993
;  PRIOR FILING DATE: 2000-08-22
;  NUMBER OF SEQ ID NOS: 31
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Sequence
US-09-935-038A-10

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
```

```
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAAA 1982
              ||||  ||||||  |||||
Db         18 AAATGATTACCTAGAAAA 1


RESULT 141
US-09-544-398B-618
; Sequence 618, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/09/544,398B
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 618
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-544-398B-618

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTATC 2047
              ||||||| | ||||| ||
Db          2 GGAGGCACAAGTTCTTTC 19


RESULT 142
US-09-834-291-14
; Sequence 14, Application US/09834291
; Patent No. 6770474
; GENERAL INFORMATION:
;  APPLICANT: Krammer, Peter
;  APPLICANT:  Muller-Schilling, Martina
;  APPLICANT:  Oren, Moshe
;  TITLE OF INVENTION: p53 Binding Areas
;  FILE REFERENCE: 4121-122
;  CURRENT APPLICATION NUMBER: US/09/834,291
;  CURRENT FILING DATE:  2001-08-21
;  PRIOR APPLICATION NUMBER: PCT/DE99/03343
;  PRIOR FILING DATE: 1999-10-18
;  PRIOR APPLICATION NUMBER: DE 198 47 779.1
;  PRIOR FILING DATE: 1998-10-16
;  NUMBER OF SEQ ID NOS: 32
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-834-291-14

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTTT 1776
              | ||  ||||||||||||
Db          3 TGTTGCTTAAGCTTTTTT 20


RESULT 143
US-08-948-113D-2/c
; Sequence 2, Application US/08948113D
; Patent No. 6482937
; GENERAL INFORMATION:
;  APPLICANT: Baetscher, Manfred W.
;  APPLICANT:  Akiyoshi, Donna E.
;  APPLICANT:  Kaplan, Ruth A.
;  TITLE OF INVENTION: Pluripotent Porcine Cells, Genetically Modified Porcine
;  TITLE OF INVENTION:  Cells and Pigs for Use in Said Method, Transgenic Pigs
;  FILE REFERENCE: 61750-309
;  CURRENT APPLICATION NUMBER: US/08/948,113D
;  CURRENT FILING DATE:  1997-10-09
;  NUMBER OF SEQ ID NOS: 39
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Degenerate
;   OTHER INFORMATION: antisense primer for PCR amplification of
;   OTHER INFORMATION: Oct-family member gene
US-08-948-113D-2

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 2.4e+02;
  Matches   13;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACCCGCC 1674
              ||||||||:| |  :||:|
Db         19 TGGTTCTGYAACCGSCGSC 1


RESULT 144
US-09-696-791-2249
; Sequence 2249, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 2249
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin E ribozyme binding site
US-09-696-791-2249

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db          5 ATCCTTCTCCACC 17


RESULT 145
US-09-696-791-2250
; Sequence 2250, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
```

```
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 2250
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin E ribozyme binding site
US-09-696-791-2250

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db             4 ATCCTTCTCCACC 16


RESULT 146
US-07-872-644-1/c
; Sequence 1, Application US/07872644
; Patent No. 5389527
;  GENERAL INFORMATION:
;    APPLICANT:  Beavo, Joseph A.
;    APPLICANT:  Bentley, Kelley
;    APPLICANT:  Charbonneau, Harry
;    APPLICANT:  Sonnenburg, William K.
;    TITLE OF INVENTION:  DNA Encoding Mammalian
;    TITLE OF INVENTION:  Phosphodiesterases
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray &
;      ADDRESSEE:  Bicknell
;      STREET:  Two First National Plaza, 20 South Clark
;      STREET:  Street
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/872,644
;      FILING DATE:  19920420
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/688,356
;      FILING DATE:  04-APR-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  No. 5389527and, Greta E.
;      REGISTRATION NUMBER:  35,302
;      REFERENCE/DOCKET NUMBER:  27866/30822
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (312) 346-5750
;      TELEFAX:  (312) 984-9740
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-07-872-644-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 147
US-08-474-542A-112
; Sequence 112, Application US/08474542A
; Patent No. 5527898
;  GENERAL INFORMATION:
;    APPLICANT:  Bauer, Heidi M.
;    APPLICANT:  Gravitt, Patti E.
;    APPLICANT:  Greer, Catherine E.
;    APPLICANT:  Impraim, Chaka C.
;    APPLICANT:  Manos, M. Michele
;    APPLICANT:  Resnick, Robert M.
;    TITLE OF INVENTION:  Detection of Human Papillomavirus by the
;    TITLE OF INVENTION:  Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  298
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/474,542A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  9234
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  112:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-474-542A-112

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db          2 GTAMWGGMTGGTTTATG 18


RESULT 148
US-08-474-542A-118/c
; Sequence 118, Application US/08474542A
; Patent No. 5527898
;  GENERAL INFORMATION:
;    APPLICANT:  Bauer, Heidi M.
```

```
;    APPLICANT:  Gravitt, Patti E.
;    APPLICANT:  Greer, Catherine E.
;    APPLICANT:  Impraim, Chaka C.
;    APPLICANT:  Manos, M. Michele
;    APPLICANT:  Resnick, Robert M.
;    TITLE OF INVENTION:  Detection of Human Papillomavirus by the
;    TITLE OF INVENTION:  Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  298
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/474,542A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  9234
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  118:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-474-542A-118

  Query Match              2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| ||||||  ||
Db         19 GTAMWGGMTGGTTTATG 3


RESULT 149
US-08-297-494-1/c
; Sequence 1, Application US/08297494
; Patent No. 5580771
;  GENERAL INFORMATION:
;    APPLICANT:  Beavo, Joseph A.
;    APPLICANT:  Bentley, Kelley
;    APPLICANT:  Charbonneau, Harry
;    APPLICANT:  Sonnenburg, William K.
;    TITLE OF INVENTION:  DNA Encoding Mammalian
;    TITLE OF INVENTION:  Phosphodiesterases
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray &
;      ADDRESSEE:  Bicknell
;      STREET:  Two First National Plaza, 20 South Clark
;      STREET:  Street
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/297,494
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/688,356
;      FILING DATE:  04-APR-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  No. 5580771and, Greta E.
;      REGISTRATION NUMBER:  35,302
;      REFERENCE/DOCKET NUMBER:  27866/30822
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (312) 346-5750
;      TELEFAX:  (312) 984-9740
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-297-494-1

  Query Match              2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 150
US-08-297-510-1/c
; Sequence 1, Application US/08297510
; Patent No. 5602019
;  GENERAL INFORMATION:
;    APPLICANT:  Beavo, Joseph A.
;    APPLICANT:  Bentley, Kelley
;    APPLICANT:  Charbonneau, Harry
;    APPLICANT:  Sonnenburg, William K.
;    TITLE OF INVENTION:  DNA Encoding Mammalian
;    TITLE OF INVENTION:  Phosphodiesterases
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray &
;      ADDRESSEE:  Bicknell
;      STREET:  Two First National Plaza, 20 South Clark
;      STREET:  Street
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/297,510
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/688,356
;      FILING DATE:  04-APR-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  No. 5602019and, Greta E.
;      REGISTRATION NUMBER:  35,302
;      REFERENCE/DOCKET NUMBER:  27866/30822
;    TELECOMMUNICATION INFORMATION:
```

```
;      TELEPHONE:  (312) 346-5750
;      TELEFAX:  (312) 984-9740
;      TELEX:  25-3856
;   INFORMATION FOR SEQ ID NO:  1:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  20 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-08-297-510-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 151
US-08-457-648-112
; Sequence 112, Application US/08457648
; Patent No. 5639871
;  GENERAL INFORMATION:
;    APPLICANT:  Bauer, Heidi M.
;    APPLICANT:  Gravitt, Patti E.
;    APPLICANT:  Greer, Catherine E.
;    APPLICANT:  Impraim, Chaka C.
;    APPLICANT:  Manos, M. Michele
;    APPLICANT:  Resnick, Robert M.
;    TITLE OF INVENTION:  Detection of Human Papillomavirus by the
;    TITLE OF INVENTION:  Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  298
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/457,648
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  9205
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  112:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-457-648-112

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| ||||||  ||
Db          2 GTAMWGGMTGGTTTATG 18


RESULT 152
US-08-457-648-118/c
; Sequence 118, Application US/08457648
; Patent No. 5639871
;  GENERAL INFORMATION:
;    APPLICANT:  Bauer, Heidi M.
;    APPLICANT:  Gravitt, Patti E.
;    APPLICANT:  Greer, Catherine E.
;    APPLICANT:  Impraim, Chaka C.
;    APPLICANT:  Manos, M. Michele
;    APPLICANT:  Resnick, Robert M.
;    TITLE OF INVENTION:  Detection of Human Papillomavirus by the
;    TITLE OF INVENTION:  Polymerase Chain Reaction
;    NUMBER OF SEQUENCES:  298
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hoffmann-La Roche Inc.
;      STREET:  340 Kingsland Street
;      CITY:  Nutley
;      STATE:  New Jersey
;      COUNTRY:  U.S.A.
;      ZIP:  07110
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/457,648
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Petry, Douglas A.
;      REGISTRATION NUMBER:  35,321
;      REFERENCE/DOCKET NUMBER:  9205
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (510) 814-2974
;      TELEFAX:  (510) 814-2977
;  INFORMATION FOR SEQ ID NO:  118:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-457-648-118

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| ||||||  ||
Db         19 GTAMWGGMTGGTTTATG 3


RESULT 153
US-08-479-532-1/c
; Sequence 1, Application US/08479532
; Patent No. 5776752
;  GENERAL INFORMATION:
;    APPLICANT:  Beavo, Joseph A.
;    APPLICANT:  Bentley, Kelley
;    APPLICANT:  Charbonneau, Harry
;    APPLICANT:  Sonnenburg, William K.
;    TITLE OF INVENTION:  DNA Encoding Mammalian
;    TITLE OF INVENTION:  Phosphodiesterases
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray &
;      ADDRESSEE:  Bicknell
```

```
;      STREET:  Two First National Plaza, 20 South Clark
;      STREET:  Street
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/479,532
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/297,494
;      FILING DATE:
;      APPLICATION NUMBER:  US 07/688,356
;      FILING DATE:  04-APR-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  No. 5776752and, Greta E.
;      REGISTRATION NUMBER:  35,302
;      REFERENCE/DOCKET NUMBER:  27866/30822
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (312) 346-5750
;      TELEFAX:  (312) 984-9740
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-479-532-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
                ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 154
US-08-455-526-1/c
; Sequence 1, Application US/08455526
; Patent No. 5789553
;  GENERAL INFORMATION:
;    APPLICANT:  Beavo, Joseph A.
;    APPLICANT:  Bentley, Kelley
;    APPLICANT:  Charbonneau, Harry
;    APPLICANT:  Sonnenburg, William K.
;    TITLE OF INVENTION:  DNA Encoding Mammalian
;    TITLE OF INVENTION:  Phosphodiesterases
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray &
;      ADDRESSEE:  Bicknell
;      STREET:  Two First National Plaza, 20 South Clark
;      STREET:  Street
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,526
;      FILING DATE:  31-MAY-1995
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/297,494
;      FILING DATE:  29-AUG-1994
;      APPLICATION NUMBER:  US 07/688,356
;      FILING DATE:  04-APR-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  No. 5789553and, Greta E.
;      REGISTRATION NUMBER:  35,302
;      REFERENCE/DOCKET NUMBER:  27866/30822
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (312) 346-5750
;      TELEFAX:  (312) 984-9740
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-455-526-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
                ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 155
US-08-455-525-1/c
; Sequence 1, Application US/08455525
; Patent No. 5800987
;  GENERAL INFORMATION:
;    APPLICANT:  Beavo, Joseph A.
;    APPLICANT:  Bentley, Kelley
;    APPLICANT:  Charbonneau, Harry
;    APPLICANT:  Sonnenburg, William K.
;    TITLE OF INVENTION:  DNA Encoding Mammalian
;    TITLE OF INVENTION:  Phosphodiesterases
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray &
;      ADDRESSEE:  Bicknell
;      STREET:  Two First National Plaza, 20 South Clark
;      STREET:  Street
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,525
;      FILING DATE:  31-MAY-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/297,494
;      FILING DATE:
;      APPLICATION NUMBER:  US 07/688,356
;      FILING DATE:  04-APR-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  No. 5800987and, Greta E.
;      REGISTRATION NUMBER:  35,302
;      REFERENCE/DOCKET NUMBER:  27866/30822
```

```
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (312) 346-5750
;      TELEFAX:  (312) 984-9740
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-455-525-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 156
US-09-139-491-1/c
; Sequence 1, Application US/09139491
; Patent No. 6015677
;  GENERAL INFORMATION:
;    APPLICANT:  Beavo, Joseph A.
;    APPLICANT:  Bentley, Kelley
;    APPLICANT:  Charbonneau, Harry
;    APPLICANT:  Sonnenburg, William K.
;    TITLE OF INVENTION:  DNA Encoding Mammalian
;    TITLE OF INVENTION:  Phosphodiesterases
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray &
;      ADDRESSEE:  Bicknell
;      STREET:  Two First National Plaza, 20 South Clark
;      STREET:  Street
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/139,491
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,525
;      FILING DATE:  31-MAY-1995
;      APPLICATION NUMBER:  08/297,494
;      FILING DATE:
;      APPLICATION NUMBER:  US 07/688,356
;      FILING DATE:  04-APR-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  No. 6015677and, Greta E.
;      REGISTRATION NUMBER:  35,302
;      REFERENCE/DOCKET NUMBER:  27866/30822
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (312) 346-5750
;      TELEFAX:  (312) 984-9740
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-09-139-491-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 157
US-09-488-074-5/c
; Sequence 5, Application US/09488074
; Patent No. 6339071
; GENERAL INFORMATION:
;  APPLICANT: LEVESQUE, Luc
;  TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATING
;  TITLE OF INVENTION: CYCLIN E GENE EXPRESSION AND THERAPEUTIC USES THEREOF
;  FILE REFERENCE: 12168-3US
;  CURRENT APPLICATION NUMBER: US/09/488,074
;  CURRENT FILING DATE: 2000-01-20
;  EARLIER APPLICATION NUMBER: US 60/140,446
;  EARLIER FILING DATE: 1999-06-23
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 5
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense oligonucleotide
US-09-488-074-5

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db         13 ATCCTTCTCCACC 1


RESULT 158
US-09-883-825-1/c
; Sequence 1, Application US/09883825
; Patent No. 6642040
;   GENERAL INFORMATION:
;        APPLICANT: Beavo, Joseph A.
;                   Bentley, Kelley
;                   Charbonneau, Harry
;                   Sonnenburg, William K.
;        TITLE OF INVENTION: DNA Encoding Mammalian
;                            Phosphodiesterases
;        NUMBER OF SEQUENCES: 58
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
;                        Bicknell
;             STREET: Two First National Plaza, 20 South Clark
;                     Street
;             CITY: Chicago
;             STATE: Illinois
;             COUNTRY: USA
;             ZIP: 60603
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/883,825
;             FILING DATE: 18-Jun-2001
```

```
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 09/123,783
;            FILING DATE: <Unknown>
;            APPLICATION NUMBER: 08/297,494
;            FILING DATE: <Unknown>
;            APPLICATION NUMBER: US 07/688,356
;            FILING DATE: 04-APR-1991
;       ATTORNEY/AGENT INFORMATION:
;            NAME: No. 6642040and, Greta E.
;            REGISTRATION NUMBER: 35,302
;            REFERENCE/DOCKET NUMBER: 27866/30822
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (312) 346-5750
;            TELEFAX: (312) 984-9740
;            TELEX: 25-3856
;   INFORMATION FOR SEQ ID NO: 1:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 20 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-883-825-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 159
PCT-US92-03222-1/c
; Sequence 1, Application PC/TUS9203222
;  GENERAL INFORMATION:
;    APPLICANT:  Beavo, Joseph A.
;    APPLICANT:  Bentley, Kelley
;    APPLICANT:  Charbonneau, Harry
;    APPLICANT:  Sonnenburg, William K.
;    TITLE OF INVENTION:  DNA Encoding Mammalian
;    TITLE OF INVENTION:  Phosphodiesterases
;    NUMBER OF SEQUENCES:  58
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray &
;      ADDRESSEE:  Bicknell
;      STREET:  Two First National Plaza, 20 South Clark
;      STREET:  Street
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  USA
;      ZIP:  60603
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/03222
;      FILING DATE:  19920420
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/688,356
;      FILING DATE:  04-APR-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Noland, Greta E.
;      REGISTRATION NUMBER:  35,302
;      REFERENCE/DOCKET NUMBER:  27866/30822
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (312) 346-5750
;      TELEFAX:  (312) 984-9740
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  20 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
PCT-US92-03222-1

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 160
US-08-283-591-19
; Sequence 19, Application US/08283591
; Patent No. 5629152
;  GENERAL INFORMATION:
;    APPLICANT:  Ravikumar, Vasulinga
;    TITLE OF INVENTION:  NOVEL TRISUBSTITUTED  -LACTAMS AND
;    TITLE OF INVENTION:  OLIGO  -LACTAMAMIDES
;    NUMBER OF SEQUENCES:  28
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5629152ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/283,591
;      FILING DATE:  N/A
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:
;      REGISTRATION NUMBER:
;      REFERENCE/DOCKET NUMBER:
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-283-591-19

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16
```

```
RESULT 161
US-08-088-658-37
; Sequence 37, Application US/08088658
; Patent No. 5641625
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker, David J.
;    APPLICANT:  Buchardt, Ole
;    APPLICANT:  Egholm, Michael
;    APPLICANT:  Nielsen, Peter E.
;    APPLICANT:  Berg, Rolf H.
;    APPLICANT:  M llegaard, Niels E.
;    TITLE OF INVENTION:  HIGH ORDER STRUCTURE AND BINDING OF PEPTIDE
;    TITLE OF INVENTION:  NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  56
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 5641625ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/088,658
;      FILING DATE:  19930702
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/054,363
;      FILING DATE:  26-APRIL-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lucci, Joseph
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-1052
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-088-658-37

  Query Match           2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 162
US-08-431-080-3
; Sequence 3, Application US/08431080
; Patent No. 5698686
;  GENERAL INFORMATION:
;    APPLICANT:  Gottschling, Daniel E.
;    APPLICANT:  Singer, Miriam S.
;    TITLE OF INVENTION:  Telomerase Compositions and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  TEXAS
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/431,080
;      FILING DATE:  Concurrently Herewith
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  SN 08/326,781
;      FILING DATE:  October 20, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  ARCD:155/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (713) 789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-431-080-3

  Query Match           2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
              || || ||||||||||
Db          1 CACCACACCCACACAC 16


RESULT 163
US-08-938-534-3
; Sequence 3, Application US/08938534
; Patent No. 5916752
;  GENERAL INFORMATION:
;    APPLICANT:  Gottschling, Daniel E.
;    APPLICANT:  Singer, Miriam S.
;    TITLE OF INVENTION:  Telomerase Compositions and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  TEXAS
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/938,534
;      FILING DATE:  26-SEP-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/431,080
;      FILING DATE:
;      APPLICATION NUMBER:  SN 08/326,781
;      FILING DATE:  October 20, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  ARCD:155/PAR
;    TELECOMMUNICATION INFORMATION:
```

```
;       TELEPHONE:  (512) 418-3000
;       TELEFAX:  (713) 789-2679
;       TELEX:  79-0924
;   INFORMATION FOR SEQ ID NO:  3:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-938-534-3

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
                || ||  ||||||||||
Db          1 CACCACACCCACACAC 16


RESULT 164
US-08-471-907A-37
; Sequence 37, Application US/08471907A
; Patent No. 5986053
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker, David J.
;    APPLICANT:  Buchardt, Ole
;    APPLICANT:  Egholm, Michael
;    APPLICANT:  Nielsen, Peter E.
;    APPLICANT:  Berg, Rolf H.
;    APPLICANT:  M llegaard, Niels E.
;    TITLE OF INVENTION:  HIGH ORDER STRUCTURE AND BINDING OF PEPTIDE
;    TITLE OF INVENTION:  NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  56
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 5986053ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/471,907A
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/088,658
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lucci, Joseph
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-1052
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-471-907A-37

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
                | ||  ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 165
US-08-088-661F-32
; Sequence 32, Application US/08088661F
; Patent No. 6228982
; GENERAL INFORMATION:
;  APPLICANT:  No. 6228982den, Benget
;  APPLICANT:  Wittung, Pernilla
;  APPLICANT:  Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter E.
;  APPLICANT:  Berg, Rolf
;  TITLE OF INVENTION:  Double-Stranded Peptide Nucleic Acids
;  FILE REFERENCE:  ISIS1108
;  CURRENT APPLICATION NUMBER: US/08/088,661F
;  CURRENT FILING DATE:  1993-07-02
;  PRIOR APPLICATION NUMBER:  08/054,363
;  PRIOR FILING DATE:  1993-04-26
;  PRIOR APPLICATION NUMBER:  PCT/EP92/01219
;  PRIOR FILING DATE:  1992-05-19
;  NUMBER OF SEQ ID NOS:  42
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6228982el Sequence
US-08-088-661F-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
                | ||  ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 166
US-08-150-156A-30
; Sequence 30, Application US/08150156A
; Patent No. 6357163
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  THE USE OF NUCLEIC ACID ANALOGUES IN
;    TITLE OF INVENTION:  DIAGNOSTICS AND ANALYTICAL PROCEDURES
;    NUMBER OF SEQUENCES:  40
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Wordperfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/150,156A
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0986/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0987/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0510/92
;      FILING DATE:  15-APR-1992
;  INFORMATION FOR SEQ ID NO:  30:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    PUBLICATION INFORMATION:
;      DOCUMENT NUMBER:  WO PCT/EP92/01220
;      FILING DATE:  22-MAY-1992
US-08-150-156A-30

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 167
US-09-345-294-3
; Sequence 3, Application US/09345294
; Patent No. 6387619
;  GENERAL INFORMATION:
;       APPLICANT: Gottschling, Daniel E.
;                  Singer, Miriam S.
;       TITLE OF INVENTION: Telomerase Compositions and Methods
;       NUMBER OF SEQUENCES: 32
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Arnold, White & Durkee
;            STREET: P.O. Box 4433
;            CITY: Houston
;            STATE: TEXAS
;            COUNTRY: UNITED STATES OF AMERICA
;            ZIP: 77210
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/345,294
;            FILING DATE: 30-Jun-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/431,080
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Parker, David L.
;            REGISTRATION NUMBER: 32,165
;            REFERENCE/DOCKET NUMBER: ARCD:155/PAR
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (512) 418-3000
;            TELEFAX: (713) 789-2679
;            TELEX: 79-0924
;  INFORMATION FOR SEQ ID NO: 3:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-345-294-3

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
              || || ||||||||||
Db          1 CACCACACCCACACAC 16


RESULT 168
US-08-108-591B-30
; Sequence 30, Application US/08108591B
; Patent No. 6395474
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/08/108,591B
;  CURRENT FILING DATE:  2001-08-13
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 30
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. 6395474el Sequence
US-08-108-591B-30

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 169
US-08-468-719A-30
; Sequence 30, Application US/08468719A
; Patent No. 6710163
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter E.
;  APPLICANT:  Berg, Rolf H.
;  TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS SYNTHONS
;  FILE REFERENCE: ISPS-1999
;  CURRENT APPLICATION NUMBER: US/08/468,719A
;  CURRENT FILING DATE:  1995-06-06
;  PRIOR APPLICATION NUMBER: US 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 30
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide Primer
US-08-468-719A-30

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 170
US-08-462-977B-30
; Sequence 30, Application US/08462977B
; Patent No. 6713602
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
```

```
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS-1993
;  CURRENT APPLICATION NUMBER: US/08/462,977B
;  CURRENT FILING DATE:  1995-06-05
;  PRIOR APPLICATION NUMBER: 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 30
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6713602el Sequence
US-08-462-977B-30

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 171
US-09-442-054A-37
; Sequence 37, Application US/09442054A
; Patent No. 6770738
; GENERAL INFORMATION:
;  APPLICANT: Ecker, David J.
;  APPLICANT:  Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Berg, Rolf H.
;  APPLICANT:  Mollegaard, Neils E.
;  TITLE OF INVENTION: Higher Order Structure And Binding Of Peptide Nucleic Acids
;  FILE REFERENCE: ISIS4290
;  CURRENT APPLICATION NUMBER: US/09/442,054A
;  CURRENT FILING DATE:  2002-05-07
;  PRIOR APPLICATION NUMBER: 08/471,907
;  PRIOR FILING DATE: 1995-06-07
;  PRIOR APPLICATION NUMBER: 08/054,363
;  PRIOR FILING DATE: 1993-04-26
;  PRIOR APPLICATION NUMBER: PCT/ EP92/01219
;  PRIOR FILING DATE: 1992-05-19
;  NUMBER OF SEQ ID NOS: 89
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 37
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. 6770738el Sequence
US-09-442-054A-37

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 172
US-08-390-850-602/c
; Sequence 602, Application US/08390850
; Patent No. 5612215
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/390,850
;      FILING DATE:  February 17, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5612215ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  602:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-390-850-602

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTGAAA 1807
              |||||||| || ||||
Db         16 CTTTCCTTATCAGAAA 1


RESULT 173
US-08-390-850-679
; Sequence 679, Application US/08390850
; Patent No. 5612215
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
```

```
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/390,850
;       FILING DATE:  February 17, 1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/354,920
;       FILING DATE:  December 13, 1994
;       APPLICATION NUMBER:  08/152,487
;       FILING DATE:  No. 5612215ember 12, 1993
;       APPLICATION NUMBER:  07/989,848
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  211/084
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  679:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-390-850-679

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 2.4e+02;
  Matches    8;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1989 AAGTGTGTATCTAGCT 2004
              || :|:|:|:|:| |:
Db          1 AACUGUGUAUCUAACU 16


RESULT 174
US-08-373-124A-518
; Sequence 518, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  518:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-518

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 2.4e+02;
  Matches    8;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCA 1789
              : ::::: ||||||||
Db          2 UGUUUUUAGAACCCCA 17


RESULT 175
US-08-373-124A-2177/c
; Sequence 2177, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
```

```
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2177:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-373-124A-2177

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              |||| |||| ||||||
Db         16 TTGACAAAAGGAAAAG 1


RESULT 176
US-08-435-634-602/c
; Sequence 602, Application US/08435634
; Patent No. 5731295
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,634
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/390,850
;      FILING DATE:  February 17, 1995
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5731295ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  602:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-634-602

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTGAAA 1807
              |||||||| || ||||
Db         16 CTTTCCTTATCAGAAA 1


RESULT 177
US-08-435-634-679
; Sequence 679, Application US/08435634
; Patent No. 5731295
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,634
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/390,850
;      FILING DATE:  February 17, 1995
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5731295ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  679:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-634-679
```

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 2.4e+02;
  Matches    8;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1989 AAGTGTGTATCTAGCT 2004
              || :|:|:|:|:| |:
Db          1 AACUGUGUAUCUAACU 16


RESULT 178
US-08-435-628-518
; Sequence 518, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  518:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-518

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 2.4e+02;
  Matches    8;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCA 1789
                : ::::: ||||||||
Db          2 UGUUUUUAGAACCCCA 17


RESULT 179
US-08-435-628-2177/c
; Sequence 2177, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2177:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2177

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              |||| |||| ||||||
Db         16 TTGACAAAAGGAAAAG 1


RESULT 180
US-08-985-162-545
```

```
; Sequence 545, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  545:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-545

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 2.4e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || :||::|:|| :||
Db          2 CAGUGGUUCUGCUUCA 17


RESULT 181
US-08-985-162-546
; Sequence 546, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  546:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-546

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 2.4e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || :||::|:|| :||
Db          1 CAGUGGUUCUGCUUCA 16


RESULT 182
US-08-584-040-2204/c
; Sequence 2204, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2204:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2204

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGAG 1707
              ||||||||  | |||||
Db         16 TTTCTCTAACACTGAG 1


RESULT 183
US-08-584-040-2233/c
; Sequence 2233, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2233:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2233

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              |||||  |||||||  ||
Db         17 AGCCACTGAAATGGCA 2


RESULT 184
US-08-584-040-2234/c
; Sequence 2234, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2234:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2234

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
```

```
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         16 AGCCACTGAAATGGCA 1


RESULT 185
US-08-584-040-2518
; Sequence 2518, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2518:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2518

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   31.2%;  Pred. No. 2.4e+02;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCT 1698
              :|:: |::|:: |:|:
Db          2 UCUUUGUUGUUCCUCU 17


RESULT 186
US-08-584-040-6032/c
; Sequence 6032, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  6032:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-6032

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAAC 1558
              |||||  |||||||||
Db         17 AGAGTCCGGAAGGAAC 2


RESULT 187
US-09-479-122-32/c
; Sequence 32, Application US/09479122
; Patent No. 6410266
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: 0221-0003C
;  CURRENT APPLICATION NUMBER: US/09/479,122
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: 09/276,820
;  PRIOR FILING DATE: 1999-03-26
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
```

```
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-09-479-122-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 188
US-09-484-997-32/c
; Sequence 32, Application US/09484997
; Patent No. 6524818
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: 0221-0003J
;  CURRENT APPLICATION NUMBER: US/09/484,997
;  CURRENT FILING DATE:  2000-01-18
;  PRIOR APPLICATION NUMBER: 09/276,820
;  PRIOR FILING DATE: 1999-03-26
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-09-484-997-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 189
US-09-481-355-32/c
; Sequence 32, Application US/09481355
; Patent No. 6524824
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: 0221-0003F
;  CURRENT APPLICATION NUMBER: US/09/481,355
;  CURRENT FILING DATE:  2000-01-12
;  PRIOR APPLICATION NUMBER: 09/276,820
;  PRIOR FILING DATE: 1999-03-26
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-09-481-355-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 190
US-09-481-282-32/c
; Sequence 32, Application US/09481282
; Patent No. 6541221
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: 0221-0003US
;  CURRENT APPLICATION NUMBER: US/09/481,282
;  CURRENT FILING DATE:  2000-01-11
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-09-481-282-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
```

```
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 191
US-09-371-772B-749/c
; Sequence 749, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 749
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-749

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGAG 1707
              |||||||| | |||||
Db         16 TTTCTCTAACACTGAG 1


RESULT 192
US-09-371-772B-778/c
; Sequence 778, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 778
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-778

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         17 AGCCACTGAAATGGCA 2


RESULT 193
US-09-371-772B-779/c
; Sequence 779, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 779
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-779

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         16 AGCCACTGAAATGGCA 1


RESULT 194
US-09-371-772B-1042
; Sequence 1042, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1042
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1042

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   31.2%;  Pred. No. 2.4e+02;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1683 TCTTAGTTGTTTCTCT 1698
              :|:: |::|:: |:|:
Db          2 UCUUUGUUGUUCCUCU 17


RESULT 195
US-09-371-772B-2869/c
; Sequence 2869, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2869
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2869

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAAC 1558
              |||||  |||||||||
Db         17 AGAGTCCGGAAGGAAC 2


RESULT 196
US-09-455-659A-32/c
; Sequence 32, Application US/09455659A
; Patent No. 6602686
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: 0221-0003A
;  CURRENT APPLICATION NUMBER: US/09/455,659A
;  CURRENT FILING DATE:  1999-12-07
;  PRIOR APPLICATION NUMBER: 09/276,820
;  PRIOR FILING DATE: 1999-03-26
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-09-455-659A-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 197
US-09-484-996-32/c
; Sequence 32, Application US/09484996
; Patent No. 6623958
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: 0221-0003H
;  CURRENT APPLICATION NUMBER: US/09/484,996
;  CURRENT FILING DATE:  2000-01-18
;  PRIOR APPLICATION NUMBER: 09/276,820
;  PRIOR FILING DATE: 1999-03-26
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1998-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-09-484-996-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 198
US-09-401-063-545
; Sequence 545, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
```

```
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ for Windows 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/401,063
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/985,162
;       FILING DATE:  04 December 1997
;       APPLICATION NUMBER:  60/036,476
;       FILING DATE:  31 January 1997
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  230/107
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213)  955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  545:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-401-063-545

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 2.4e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || :||::|:|| :||
Db          2 CAGUGGUUCUGCUUCA 17


RESULT 199
US-09-401-063-546
; Sequence 546, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  546:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-546

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 2.4e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || :||::|:|| :||
Db          1 CAGUGGUUCUGCUUCA 16


RESULT 200
US-09-827-998-311
; Sequence 311, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 311
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-311

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGGA 1562
              |||||||||| | ||
Db          2 TAGGGAAGGAAGAAGA 17


RESULT 201
US-09-827-998-312
; Sequence 312, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
```

```
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 312
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-312

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGGA 1562
              |||||||||| | ||
Db             1 TAGGGAAGGAAGAAGA 16


RESULT 202
US-09-479-123-32/c
; Sequence 32, Application US/09479123
; Patent No. 6670185
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: 0221-0003B
;  CURRENT APPLICATION NUMBER: US/09/479,123
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-09-479-123-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db            17 CATCACCTGCCCATGG 2


RESULT 203
US-09-866-108A-1345/c
; Sequence 1345, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1345
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1345

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCT 1801
              |||||  |||||||||
Db            17 CCCATCTTTTCCTTCT 2


RESULT 204
US-09-866-108A-1347/c
; Sequence 1347, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1347
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1347

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
                ||||||  ||||||||
Db         16 CCCCATCTTTTCCTTC 1


RESULT 205
US-09-866-108A-1580/c
; Sequence 1580, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1580
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1580

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
                ||||||||||  |||
Db         17 ATCCTTCTCCAGAGCA 2


RESULT 206
US-09-866-108A-1581/c
; Sequence 1581, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1581
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1581

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
                ||||||||||  |||
Db         16 ATCCTTCTCCAGAGCA 1


RESULT 207
US-09-866-108A-7641/c
; Sequence 7641, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
```

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7641
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7641

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1686 TAGTTGTTTCTCTAGC 1701
              | |||| |||||||||
Db         17 TTGTTGGTTCTCTAGC 2
```

RESULT 208
US-09-866-108A-7644/c
; Sequence 7644, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7644
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7644

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1684 CTTAGTTGTTTCTCTA 1699
              ||| |||| |||||||
Db         16 CTTTGTTGGTTCTCTA 1
```

RESULT 209
US-09-866-108A-7957
; Sequence 7957, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7957
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

```
US-09-866-108A-7957

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          2 GCCCTTGAGCAACAGA 17


RESULT 210
US-09-866-108A-7958
; Sequence 7958, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7958
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7958

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          1 GCCCTTGAGCAACAGA 16


RESULT 211
US-09-484-317A-32/c
; Sequence 32, Application US/09484317A
; Patent No. 6740503
; GENERAL INFORMATION:
;  APPLICANT: HARRINGTON, JOHN J.
;  APPLICANT:  SHERF, BRUCE
;  APPLICANT:  RUNDLETT, STEPHEN
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR NON-TARGETED ACTIVATION OF
;  TITLE OF INVENTION:  ENDOGENOUS GENES
;  FILE REFERENCE: ATX-007CP4DV11
;  CURRENT APPLICATION NUMBER: US/09/484,317A
;  CURRENT FILING DATE:  2000-01-18
;  PRIOR APPLICATION NUMBER: 09/276,820
;  PRIOR FILING DATE: 1999-03-26
;  PRIOR APPLICATION NUMBER: 09/263,814
;  PRIOR FILING DATE: 1999-03-08
;  PRIOR APPLICATION NUMBER: 09/253,022
;  PRIOR FILING DATE: 1999-02-19
;  PRIOR APPLICATION NUMBER: 09/159,643
;  PRIOR FILING DATE: 1998-09-24
;  PRIOR APPLICATION NUMBER: 08/941,223
;  PRIOR FILING DATE: 1997-09-26
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Vector
;   OTHER INFORMATION: Promoter
US-09-484-317A-32

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 2.4e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 212
US-08-459-568-15
; Sequence 15, Application US/08459568
; Patent No. 5811304
;  GENERAL INFORMATION:
;    APPLICANT:  Huang, Shi
;    TITLE OF INVENTION:  Retinoblastoma Protein - Interacting
;    TITLE OF INVENTION:  Zinc Finger Proteins
;    NUMBER OF SEQUENCES:  93
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell and Flores
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/459,568
;      FILING DATE:  02-JUN-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/399,411
;      FILING DATE:  06-MAR-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-LJ 1264
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-459-568-15

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 213
US-08-399-411-15
; Sequence 15, Application US/08399411
; Patent No. 5831008
;  GENERAL INFORMATION:
;    APPLICANT:  Huang, Shi
;    TITLE OF INVENTION:  Retinoblastoma Protein - Interacting
;    TITLE OF INVENTION:  Zinc Finger Proteins
;    NUMBER OF SEQUENCES:  93
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell and Flores
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/399,411
;      FILING DATE:  06-MAR-1995
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-LJ 1264
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-399-411-15

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 214
US-08-634-350-21/c
; Sequence 21, Application US/08634350
; Patent No. 5911982
;  GENERAL INFORMATION:
;    APPLICANT:  Chao, Yu-Chan
;    TITLE OF INVENTION:  Hz-1 VIRUS PERSISTENCE-ASSOCIATED
;    TITLE OF INVENTION:  GENE 1(pag1) PROMOTER, USES
;    TITLE OF INVENTION:  THEREFOR, AND COMPOSITIONS
;    TITLE OF INVENTION:  CONTAINING SAME OR PRODUCTS
;    TITLE OF INVENTION:  THEREFROM
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Curtis, Morris & Safford, P.C.
;      STREET:  530 Fifth Avenue
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  United States of America
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/634,350
;      FILING DATE:  18-APR-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lawrence, William F.
;      REGISTRATION NUMBER:  28,029
;      REFERENCE/DOCKET NUMBER:  516450-2008
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 840-3333
;      TELEFAX:  (212) 840-0712
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-634-350-21

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              | ||||||||||| |||
Db         16 ACCAATACCTTTGTTT 1


RESULT 215
US-08-775-009-22
; Sequence 22, Application US/08775009
; Patent No. 5935783
;  GENERAL INFORMATION:
;    APPLICANT:  Gong, Weilong
;    APPLICANT:  Emanuel, Beverly S.
;    APPLICANT:  Budarf, Marcia L.
;    APPLICANT:  Roe, Bruce
;    TITLE OF INVENTION:  No. 5935783el Genes Mapping in the Digeorge and
;    TITLE OF INVENTION:  Veliocardiofacial Syndrome Minimal Critical Region
;    NUMBER OF SEQUENCES:  45
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz &
;      ADDRESSEE:  No. 5935783ris, LLP
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/775,009
;      FILING DATE:  27-DEC-1996
;      CLASSIFICATION:  435
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Trujillo, Doreen Yatko
;      REGISTRATION NUMBER:  35,719
;      REFERENCE/DOCKET NUMBER:  CH-0681
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-775-009-22

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCCC 1676
              ||||||||||  ||||
Db          1 CTGCATCACCTTCCCC 16


RESULT 216
US-08-516-859A-15
; Sequence 15, Application US/08516859A
; Patent No. 6069231
;  GENERAL INFORMATION:
;    APPLICANT:  Huang, Shi
;    TITLE OF INVENTION:  Retinoblastoma Protein - Interacting
;    TITLE OF INVENTION:  Zinc Finger Proteins
;    NUMBER OF SEQUENCES:  106
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell & Flores LLP
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/516,859A
;      FILING DATE:  18-AUG-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/399,411
;      FILING DATE:  06-MAR-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/292,683
;      FILING DATE:  18-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-LJ 1776
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-516-859A-15

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 217
US-09-035-220-13
; Sequence 13, Application US/09035220
; Patent No. 6130042
;  GENERAL INFORMATION:
;    APPLICANT:  Diehl, Scott R.
;    APPLICANT:  Schenkein, Harvey A.
;    APPLICANT:  Wang, Yue-Fen
;    TITLE OF INVENTION:  Compositions and Methods for Diagnosing
;    TITLE OF INVENTION:  Periodontal Disease
;    NUMBER OF SEQUENCES:  47
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Medlen & Carroll, LLP
;      STREET:  220 Montgomery Street, Suite 2200
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94104
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/035,220
;      FILING DATE:  05-MAR-1998
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Carroll, Peter G.
;      REGISTRATION NUMBER:  32,837
;      REFERENCE/DOCKET NUMBER:  NIH-05027
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 705-8410
;      TELEFAX:  (415) 397-8338
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-09-035-220-13

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1644 AAGAGCCTTCACTGGT 1659
              | |||||||||  ||||
Db          3 ATGAGCCTTCAATGGT 18


RESULT 218
US-09-586-472-15
; Sequence 15, Application US/09586472
; Patent No. 6323335
;   GENERAL INFORMATION:
;        APPLICANT: Huang, Shi
;        TITLE OF INVENTION: Retinoblastoma Protein - Interacting
;                            Zinc Finger Proteins
;        NUMBER OF SEQUENCES: 106
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Campbell & Flores LLP
;             STREET: 4370 La Jolla Village Drive, Suite 700
;             CITY: San Diego
```

```
;            STATE: California
;            COUNTRY: USA
;            ZIP: 92122
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/586,472
;            FILING DATE: 01-Jun-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US 09/528,706
;            FILING DATE: 17-MAR-2000
;            APPLICATION NUMBER: US 08/516,859
;            FILING DATE: 18-AUG-1995
;            APPLICATION NUMBER: US 08/399,411
;            FILING DATE: 06-MAR-1995
;            APPLICATION NUMBER: US 08/292,683
;            FILING DATE: 18-AUG-1994
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Campbell, Cathryn A.
;            REGISTRATION NUMBER: 31,815
;            REFERENCE/DOCKET NUMBER: P-LJ 4130
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (619) 535-9001
;            TELEFAX: (619) 535-8949
;   INFORMATION FOR SEQ ID NO: 15:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 18 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-586-472-15

  Query Match           2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
             ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 219
US-09-430-114-2
; Sequence 2, Application US/09430114
; Patent No. 6333313
; GENERAL INFORMATION:
;  APPLICANT: COPLAND III, JOHN A.
;  APPLICANT: IVES, KIRK LORNE
;  APPLICANT: SIMMONS, DAVID
;  APPLICANT: SOLOFF, MELVYN
;  TITLE OF INVENTION: CLINICAL USE OF OXYTOCIN ALONE OR IN COMBINATION TO
;  TITLE OF INVENTION: TREAT BONE DISORDERS
;  FILE REFERENCE: UTSG:226
;  CURRENT APPLICATION NUMBER: US/09/430,114
;  CURRENT FILING DATE: 1999-10-29
;  EARLIER APPLICATION NUMBER: 60/106,134
;  EARLIER FILING DATE: 1998-10-28
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
;   OTHER INFORMATION: Primer
US-09-430-114-2

  Query Match           2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1939 GGTAATGGTTGGTTTT 1954
             ||| ||||| ||||||
Db          1 GGTGATGGTGGGTTTT 16


RESULT 220
US-09-528-706-15
; Sequence 15, Application US/09528706
; Patent No. 6468985
;  GENERAL INFORMATION:
;    APPLICANT:  Huang, Shi
;    TITLE OF INVENTION:  Retinoblastoma Protein - Interacting
;    TITLE OF INVENTION:  Zinc Finger Proteins
;    NUMBER OF SEQUENCES:  106
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Campbell & Flores LLP
;      STREET:  4370 La Jolla Village Drive, Suite 700
;      CITY:  San Diego
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  92122
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/528,706
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/516,859
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/292,683
;      FILING DATE:  18-AUG-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Campbell, Cathryn A.
;      REGISTRATION NUMBER:  31,815
;      REFERENCE/DOCKET NUMBER:  P-LJ 1776
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 535-9001
;      TELEFAX:  (619) 535-8949
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-528-706-15

  Query Match           2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
             ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 221
US-09-422-978-7869/c
; Sequence 7869, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
```

```
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7869
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-1151 for SEQ 4, in complement
US-09-422-978-7869

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1939 GGTAATGGTTGGTTTT 1954
              ||||| ||||||| ||
Db         18 GGTAAGGGTTGGTGTT 3


RESULT 222
US-09-422-978-11530
; Sequence 11530, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya .
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11530
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-9362 for SEQ 3665, in compleme
US-09-422-978-11530

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTTGTGTC 1960
              |||||||||||||  ||
Db          3 GGTTGGTTTTTGCCTC 18


RESULT 223
US-09-544-398B-450
; Sequence 450, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/09/544,398B
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 450
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-544-398B-450

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1782 GAACCCCATTCTTTCC 1797
              ||| ||| ||||||||
Db          2 GAATCCCTTTCTTTCC 17


RESULT 224
US-09-856-662-112
; Sequence 112, Application US/09856662
; Patent No. 6790616
; GENERAL INFORMATION:
;  APPLICANT: MORIBE, Toyoki et al.
;  TITLE OF INVENTION: Method for typing HLA class 1 genes
;  FILE REFERENCE: 0032-0261P
;  CURRENT APPLICATION NUMBER: US/09/856,662
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: JP P1998-335151
;  PRIOR FILING DATE: 1998-11-26
;  NUMBER OF SEQ ID NOS: 130
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 112
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:DNA probe
;   OTHER INFORMATION: BL272A
US-09-856-662-112

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1906 ACAGATCAACAATACC 1921
              ||||||| |||| |||
Db          1 ACAGATCTACAAGACC 16


RESULT 225
US-09-061-764A-3
; Sequence 3, Application US/09061764A
; Patent No. 6284879
;  GENERAL INFORMATION:
;    APPLICANT:  Faustman, Denise L
;    TITLE OF INVENTION:  TRANSPORT ASSOCIATED PROTEIN SPLICE VARIANTS
;    TITLE OF INVENTION:  AND MODEL FOR IMMUNE DIVERSITY
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Yankwich & Associates
```

```
;       STREET:  130 Bishop Allen Drive
;       CITY:  Cambridge
;       STATE:  Massachusetts
;       COUNTRY:  United States of America
;       ZIP:  02139
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette, 3.50 inch, 1.44Mb storage
;       COMPUTER:  IBM PC Compatible
;       OPERATING SYSTEM:  Windows 95
;       SOFTWARE:  Microsoft Word 97 SR-1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/061,764A
;       FILING DATE:  April 16, 1998
;       CLASSIFICATION:  424
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Yankwich, Leon R
;       REGISTRATION NUMBER:  30,237
;       REFERENCE/DOCKET NUMBER:  MGH-002.0 US/MHG-1247.0
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  617-491-4343
;       TELEFAX:  617-491-8801
;   INFORMATION FOR SEQ ID NO:  3:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  19 bases
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  synthetic DNA fragment
US-09-061-764A-3

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAG 1554
              |||| ||| |||||||
Db          4 TAGGGGAGAAGGGAAG 19


RESULT 226
US-09-216-393B-337/c
; Sequence 337, Application US/09216393B
; Patent No. 6514694
; GENERAL INFORMATION:
;  APPLICANT: Milhausen, Michael James
;  TITLE OF INVENTION: TOXOPLASMA GONDII PROTEINS, NUCLEIC ACID MOLECULES, AND USES THER
;  FILE REFERENCE: TX-1-C2
;  CURRENT APPLICATION NUMBER: US/09/216,393B
;  CURRENT FILING DATE:  1998-12-18
;  PRIOR APPLICATION NUMBER: 08/994,825
;  PRIOR FILING DATE: 1997-12-19
;  NUMBER OF SEQ ID NOS: 366
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 337
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial sequence
;   FEATURE:
;   OTHER INFORMATION: Synthetic Primer
US-09-216-393B-337

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1648 GCCTTCACTGGTTCTG 1663
              ||||| |||| |||||
Db         19 GCCTTGACTGCTTCTG 4


RESULT 227
US-09-422-978-4047
; Sequence 4047, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4047
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-12914 for SEQ 113,
US-09-422-978-4047

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1532 GAAAGGTTAGGAGAGT 1547
              |||||  |||||||||
Db          3 GAAAGAATAGGAGAGT 18


RESULT 228
US-09-422-978-11179/c
; Sequence 11179, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11179
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-3167 for SEQ 3314, in complemer
US-09-422-978-11179

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGG 1555
```

```
              ||||||| || |||||
Db          18 AGGAGAGAAGAGAAGG 3


RESULT 229
US-09-831-642-52
; Sequence 52, Application US/09831642
; Patent No. 6635751
; GENERAL INFORMATION:
;  APPLICANT: HAZE, Kyosuke et al.
;  TITLE OF INVENTION: ENDOPLASMIC RETICULUM STRESS TRANSCRIPTION FACTORS ATF6 AND CREB-
;  FILE REFERENCE: 1422-0474P
;  CURRENT APPLICATION NUMBER: US/09/831,642
;  CURRENT FILING DATE:  2001-05-11
;  NUMBER OF SEQ ID NOS: 83
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 52
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Ricinus communis
US-09-831-642-52

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTC 1802
              |||||||||  || |||
Db          1 CCATTCTTTGCTGCTC 16


RESULT 230
US-09-696-791-1556
; Sequence 1556, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1556
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin A2 ribozyme binding site
US-09-696-791-1556

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1659 TTCTGCATCACCCGCC 1674
              ||||||||||  | |||
Db          2 TTCTGCATCAGCAGCC 17


RESULT 231
US-09-696-791-1990/c
; Sequence 1990, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1990
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin D3 ribozyme binding site
US-09-696-791-1990

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTT 1622
              ||| |||||||||  ||
Db         19 GCCAGGGGGAAGACTT 4


RESULT 232
US-08-607-384A-40/c
; Sequence 40, Application US/08607384A
; Patent No. 5849488
;  GENERAL INFORMATION:
;    APPLICANT:  ALATOSSAVA, JOUKO TAPANI
;    APPLICANT:  FORSMAN, P IVI TUULIKKI
;    APPLICANT:  TILSALA-TIMISJ RVI, ANU KYLLIKKI
;    TITLE OF INVENTION:  DNA SEQUENCE-BASED DIAGNOSIS OF MASTITIS
;    TITLE OF INVENTION:  FROM A MILK SAMPLE
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NIXON & VANDERHYE P.C.
;      STREET:  1100 NORTH GLEBE ROAD
;      CITY:  ARLINGTON
;      STATE:  VIRGINIA
;      COUNTRY:  U.S.A.
;      ZIP:  22201-4714
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/607,384A
;      FILING DATE:  27-FEB-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  BYRNE, THOMAS E.
;      REGISTRATION NUMBER:  32,205
;      REFERENCE/DOCKET NUMBER:  227-75
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 816-4000
;      TELEFAX:  (703) 816-4100
;  INFORMATION FOR SEQ ID NO:  40:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-607-384A-40

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCCCT 1602
              ||||  ||||||||  |||
Db         19 GCACTTACTGGGAATTCCT 1


RESULT 233
```

```
US-08-801-898A-8/c
; Sequence 8, Application US/08801898A
; Patent No. 5998602
;  GENERAL INFORMATION:
;    APPLICANT:  Torrence, Paul F.
;    APPLICANT:  Silverman, Robert H.
;    APPLICANT:  Cirino, Nick M.
;    APPLICANT:  Li, Guiying
;    APPLICANT:  Xiao, Wei
;    TITLE OF INVENTION:  RNASE L ACTIVATORS AND ANTISENSE
;    TITLE OF INVENTION:  OLIGONUCLEOTIDES EFFECTIVE TO TREAT RSV INFECTIONS
;    NUMBER OF SEQUENCES:  29
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds LLP
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  NY
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/801,898A
;      FILING DATE:  18-FEB-1997
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Poissant, Brian M.
;      REGISTRATION NUMBER:  28,462
;      REFERENCE/DOCKET NUMBER:  8656-009
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-790-9090
;      TELEFAX:  212-869-9741
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    FEATURE:
;      NAME/KEY:  Activator-antisense complex
;      LOCATION:  1...19
;      OTHER INFORMATION:  spA4-antiRSV3'-3'T/(51-69)
US-08-801-898A-8

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1732 ATCAGAAGGTGACAAGTAC 1750
              || |||| ||| ||||||
Db         19 ATAAGAATTTGATAAGTAC 1


RESULT 234
US-09-422-978-8902/c
; Sequence 8902, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8902
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-1948 for SEQ 1037, in complemer
US-09-422-978-8902

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTTGTT 1693
              ||| ||||| |  ||||||
Db         19 CCTTGACTTATGTGTTGTT 1


RESULT 235
US-09-422-978-9136/c
; Sequence 9136, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9136
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-22506 for SEQ 1271, in compleme
US-09-422-978-9136

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1859 CCCACACACTTAGCCATTG 1877
              || || ||||| ||| |||
Db         19 CCTACTCACTTTGCCCTTG 1


RESULT 236
US-09-696-791-1391
; Sequence 1391, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
```

```
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1391
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cdk-we-hu ribozyme binding site
US-09-696-791-1391

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAAGA 1987
              ||| || || | |||||||
Db          1 ATTCACTTTTACAAAAAGA 19


RESULT 237
US-09-696-791-1392
; Sequence 1392, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 1392
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cdk-we-hu ribozyme binding site
US-09-696-791-1392

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAAGAA 1988
              || || || | ||||||||
Db          1 TTCACTTTTACAAAAAGAA 19


RESULT 238
US-09-696-791-3422
; Sequence 3422, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 3422
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin B1 ribozyme binding site
US-09-696-791-3422

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2038 AGGTTCTATCTGCTTAGCA 2056
              |||  || | |||||||||
Db          1 AGGAGCTTTTTGCTTAGCA 19


RESULT 239
US-08-334-847-582/c
; Sequence 582, Application US/08334847
; Patent No. 5693532
;  GENERAL INFORMATION:
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  Pavco, Pam
;    APPLICANT:  Woolf, Tod
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING RESPIRATORY
;    TITLE OF INVENTION:  SYNCYTIAL VIRUS
;    NUMBER OF SEQUENCES:  909
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/334,847
;      FILING DATE:  No. 5693532ember 4, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/032
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  582:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-334-847-582

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTT 1576
              |||||||||||| |
Db         15 CTGCAAAAATCCCT 2


RESULT 240
US-08-334-847-583/c
; Sequence 583, Application US/08334847
; Patent No. 5693532
;  GENERAL INFORMATION:
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Draper, Kenneth
```

```
;    APPLICANT:  Pavco, Pam
;    APPLICANT:  Woolf, Tod
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING RESPIRATORY
;    TITLE OF INVENTION:  SYNCYTIAL VIRUS
;    NUMBER OF SEQUENCES:  909
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/334,847
;      FILING DATE:  No. 5693532ember 4, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/032
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  583:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-334-847-583

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTT 1576
                ||||||||||| |
Db         14 CTGCAAAAATCCCT 1


RESULT 241
US-08-930-371-9
; Sequence 9, Application US/08930371
; Patent No. 5977340
;  GENERAL INFORMATION:
;    APPLICANT:  PIROTZKY, EDUARDO; COLOTE, SOUDHIR
;    TITLE OF INVENTION:  ANTISENSE OLIGONUCLEOTIDES
;    TITLE OF INVENTION:  FOR INHIBITING HELICOBACTER PYLORI ACTIVITY
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BIERMAN, MUSERLIAN AND
;      ADDRESSEE:  LUCAS LLP
;      STREET:  600 THIRD AVENUE
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10016
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MSDOS
;      SOFTWARE:  MICROSOFT WORD 97
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/930,371
;      FILING DATE:  01-OCT-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/FR96/00407
;      APPLICATION NUMBER:  18-MAR-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  GB 9505438.3
;      FILING DATE:  17-MAR-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CHARLES A. MUSERLIAN
;      REGISTRATION NUMBER:  19,683
;      REFERENCE/DOCKET NUMBER:  427.006
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 661-8000
;      TELEFAX:  (212) 661-8002
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  YES
US-08-930-371-9

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 TTGGACCTATTATC 1734
                ||||| ||||||||
Db          1 TTGGAACTATTATC 14


RESULT 242
US-08-930-371-21
; Sequence 21, Application US/08930371
; Patent No. 5977340
;  GENERAL INFORMATION:
;    APPLICANT:  PIROTZKY, EDUARDO; COLOTE, SOUDHIR
;    TITLE OF INVENTION:  ANTISENSE OLIGONUCLEOTIDES
;    TITLE OF INVENTION:  FOR INHIBITING HELICOBACTER PYLORI ACTIVITY
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BIERMAN, MUSERLIAN AND
;      ADDRESSEE:  LUCAS LLP
;      STREET:  600 THIRD AVENUE
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10016
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MSDOS
;      SOFTWARE:  MICROSOFT WORD 97
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/930,371
;      FILING DATE:  01-OCT-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/FR96/00407
;      APPLICATION NUMBER:  18-MAR-1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  GB 9505438.3
;      FILING DATE:  17-MAR-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  CHARLES A. MUSERLIAN
;      REGISTRATION NUMBER:  19,683
;      REFERENCE/DOCKET NUMBER:  427.006
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 661-8000
;      TELEFAX:  (212) 661-8002
```

```
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  YES
;    FEATURE:
;      NAME/KEY:  modified-bond
;      LOCATION:  1-15
;      OTHER INFORMATION:  /note ="Phosphorothioate
;      OTHER INFORMATION:  bond"
US-08-930-371-21

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 TTGGACCTATTATC 1734
              ||||| ||||||||
Db          1 TTGGAACTATTATC 14


RESULT 243
US-08-544-381B-111/c
; Sequence 111, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/544,381B
;      FILING DATE:  10-OCT-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/510,521
;      FILING DATE:  02-AUG-1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/12305
;      FILING DATE:  26-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Liebeschuetz, Joe
;      REGISTRATION NUMBER:  37,505
;      REFERENCE/DOCKET NUMBER:  018547-004130US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-576-0200
;      TELEFAX:  415-576-0300
;  INFORMATION FOR SEQ ID NO:  111:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-544-381B-111

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 2.6e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1682 TTCTTAGTTGTTTCT 1696
              ||||| || ||||||
Db         15 TTCTTTGTNGTTTCT 1


RESULT 244
US-08-320-559-6
; Sequence 6, Application US/08320559
; Patent No. 5633135
;  GENERAL INFORMATION:
;    APPLICANT:  Croce, Carlo
;    APPLICANT:  Canaani, Eli
;    TITLE OF INVENTION:  Diagnostics, Therapeutics and Methods for
;    TITLE OF INVENTION:  Detection and Treatment of Acute Leukemias
;    TITLE OF INVENTION:  Resulting from Chromosome Abnormalities in the
;    TITLE OF INVENTION:  All-1 Region
;    NUMBER OF SEQUENCES:  44
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5633135ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/320,559
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/062,443
;      FILING DATE:  14 MAY 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,094
;      FILING DATE:  30-OCT-92
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/888,830
;      FILING DATE:  27-MAY-92
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/805,093
;      FILING DATE:  11-DEC-91
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca, Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-0855
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  No
US-08-320-559-6

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              |||||| |||||||
Db          3 AAAGGTGAGGAGAG 16


RESULT 245
US-08-327-392-6
; Sequence 6, Application US/08327392
; Patent No. 5633136
;  GENERAL INFORMATION:
;    APPLICANT:  Croce, Carlo
;    APPLICANT:  Canaani, Eli
;    TITLE OF INVENTION:  ALL-1 Polynucleotides and Monoclonal
;    TITLE OF INVENTION:  Antibodies for Leukemia Detection and
;    TITLE OF INVENTION:  Treatment
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5633136ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/327,392
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/971,094
;      FILING DATE:  30-OCT-92
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/888,830
;      FILING DATE:  27-MAY-92
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/805,093
;      FILING DATE:  11-DEC-91
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca, Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-1331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  No
US-08-327-392-6

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              |||||| |||||||
Db          3 AAAGGTGAGGAGAG 16


RESULT 246
US-08-545-860D-6
; Sequence 6, Application US/08545860D
; Patent No. 6040140
;  GENERAL INFORMATION:
;    APPLICANT:  Croce, Carlo
;    APPLICANT:  Canaani, Eli
;    TITLE OF INVENTION:  Diagnostics, Therapeutics and Methods
;    TITLE OF INVENTION:  for Detection and Treatment of Acute Leukemias
;    TITLE OF INVENTION:  Resulting from Chromosome Abnormalities in the All-1 Region
;    NUMBER OF SEQUENCES:  94
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewitz &
;      ADDRESSEE:  No. 6040140ris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/545,860D
;      FILING DATE:  07-MAR-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/04496
;      FILING DATE:  22-APR-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/10930
;      FILING DATE:  09-DEC-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/327,392
;      FILING DATE:  19-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/320,559
;      FILING DATE:  11-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/062,443
;      FILING DATE:  14-MAY-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/971,094
;      FILING DATE:  30-OCT-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/888,839
;      FILING DATE:  27-MAY-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/805,093
;      FILING DATE:  11-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca Esq., Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-1262
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  No
US-08-545-860D-6

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1533 AAAGGTTAGGAGAG 1546
              |||||| |||||||
Db          3 AAAGGTGAGGAGAG 16


RESULT 247
US-08-929-140-5
; Sequence 5, Application US/08929140
; Patent No. 6084090
;  GENERAL INFORMATION:
;    APPLICANT:  DiPaolo, Joseph
;    APPLICANT:  Alvarez-Salas, Luis
;    TITLE OF INVENTION:  HUMAN PAPILLOMA VIRUS INHIBITION
;    TITLE OF INVENTION:  BY ANTISENSE OLIGONUCLEOTIDES
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson & Bear
;      STREET:  620 Newport Center Drive   Sixteenth Flo
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/929,140
;      FILING DATE:
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  NIH138.001A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714/760-0404
;      TELEFAX:  714/760-9503
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-929-140-5

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   64.3%;  Pred. No. 2.8e+02;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCA 2017
              ::|::|||||| ||
Db          1 UUCUUCAGAGAACA 14


RESULT 248
US-08-929-140-7
; Sequence 7, Application US/08929140
; Patent No. 6084090
;  GENERAL INFORMATION:
;    APPLICANT:  DiPaolo, Joseph
;    APPLICANT:  Alvarez-Salas, Luis
;    TITLE OF INVENTION:  HUMAN PAPILLOMA VIRUS INHIBITION
;    TITLE OF INVENTION:  BY ANTISENSE OLIGONUCLEOTIDES
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Knobbe, Martens, Olson & Bear
;      STREET:  620 Newport Center Drive   Sixteenth Flo
;      CITY:  Newport Beach
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  92660
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/929,140
;      FILING DATE:
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Altman, Daniel E
;      REGISTRATION NUMBER:  34,115
;      REFERENCE/DOCKET NUMBER:  NIH138.001A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  714/760-0404
;      TELEFAX:  714/760-9503
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  7:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-929-140-7

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCA 2017
              |||||||||||| ||
Db          1 TTCTTCAGAGAACA 14


RESULT 249
US-09-560-579A-5
; Sequence 5, Application US/09560579A
; Patent No. 6277980
;   GENERAL INFORMATION:
;        APPLICANT: DiPaolo, Joseph
;                   Alvarez-Salas, Luis
;        TITLE OF INVENTION: HUMAN PAPILLOMA VIRUS INHIBITION
;                            BY ANTISENSE OLIGONUCLEOTIDES
;        NUMBER OF SEQUENCES: 17
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Knobbe, Martens, Olson & Bear
;             STREET: 620 Newport Center Drive   Sixteenth Flo
;             CITY: Newport Beach
;             STATE: CA
;             COUNTRY: USA
;             ZIP: 92660
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Diskette
;             COMPUTER: IBM Compatible
;             OPERATING SYSTEM: DOS
;             SOFTWARE: FastSEQ for Windows Version 2.0
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/560,579A
;             FILING DATE: 28-Apr-2000
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/929,140
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
```

```
;            NAME: Altman, Daniel E
;            REGISTRATION NUMBER: 34,115
;            REFERENCE/DOCKET NUMBER: NIH138.001A
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 714/760-0404
;            TELEFAX: 714/760-9503
;            TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 5:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: cDNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-560-579A-5

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   64.3%;  Pred. No. 2.8e+02;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCA 2017
              ::|::|||||| ||
Db          1 UUCUUCAGAGAACA 14


RESULT 250
US-09-560-579A-7
; Sequence 7, Application US/09560579A
; Patent No. 6277980
;   GENERAL INFORMATION:
;       APPLICANT: DiPaolo, Joseph
;                  Alvarez-Salas, Luis
;       TITLE OF INVENTION: HUMAN PAPILLOMA VIRUS INHIBITION
;                           BY ANTISENSE OLIGONUCLEOTIDES
;       NUMBER OF SEQUENCES: 17
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Knobbe, Martens, Olson & Bear
;            STREET: 620 Newport Center Drive   Sixteenth Flo
;            CITY: Newport Beach
;            STATE: CA
;            COUNTRY: USA
;            ZIP: 92660
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Diskette
;            COMPUTER: IBM Compatible
;            OPERATING SYSTEM: DOS
;            SOFTWARE: FastSEQ for Windows Version 2.0
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/560,579A
;            FILING DATE: 28-Apr-2000
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/929,140
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Altman, Daniel E
;            REGISTRATION NUMBER: 34,115
;            REFERENCE/DOCKET NUMBER: NIH138.001A
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 714/760-0404
;            TELEFAX: 714/760-9503
;            TELEX: <Unknown>
;   INFORMATION FOR SEQ ID NO: 7:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: cDNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-560-579A-7

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCA 2017
              |||||||||||| ||
Db          1 TTCTTCAGAGAACA 14


RESULT 251
PCT-US94-04496-6
; Sequence 6, Application PC/TUS9404496
;  GENERAL INFORMATION:
;    APPLICANT:  Croce, Carlo
;    APPLICANT:  Canaani, Eli
;    TITLE OF INVENTION:  Diagnostics, Therapeutics and Methods
;    TITLE OF INVENTION:  for Detection and Treatment of Acute Leukemias
;    TITLE OF INVENTION:  Resulting from Chromosome Abnormalities in the All-1
;    NUMBER OF SEQUENCES:  86
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewitz &
;      ADDRESSEE:  Norris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/04496
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca Esq., Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-1242
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  No
PCT-US94-04496-6

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 2.8e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              |||||| |||||||
Db          3 AAAGGTGAGGAGAG 16


RESULT 252
US-08-584-040-7423
; Sequence 7423, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
```

```
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7423:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7423

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   78.6%;  Pred. No. 2.9e+02;
  Matches   11;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAACA 1856
              :|||: ||||||||
Db          4 UCCCUCGGCCAACA 17


RESULT 253
US-09-371-772B-3230
; Sequence 3230, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3230
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3230

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   78.6%;  Pred. No. 2.9e+02;
  Matches   11;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAACA 1856
              :|||: ||||||||
Db          4 UCCCUCGGCCAACA 17


RESULT 254
US-09-371-772B-4869/c
; Sequence 4869, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4869
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4869

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCT 1575
              ||||||||| ||||
Db         17 ACTGCAAAAGTCCT 4


RESULT 255
US-09-371-772B-6658/c
; Sequence 6658, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6658
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
```

US-09-371-772B-6658

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1599 CCCTCCTGGCCTGG 1612
              |||||||||| |||
Db         16 CCCTCCTGGCTTGG 3
```

RESULT 256
US-09-371-772B-6659/c
; Sequence 6659, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6659
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6659

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1599 CCCTCCTGGCCTGG 1612
              |||||||||| |||
Db         15 CCCTCCTGGCTTGG 2
```

RESULT 257
US-09-866-108A-7187/c
; Sequence 7187, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7187
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7187

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         17 TCAGAGGTCAAGTC 4
```

RESULT 258
US-09-866-108A-7188/c
; Sequence 7188, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7188
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

```
US-09-866-108A-7188

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         16 TCAGAGGTCAAGTC 3


RESULT 259
US-09-866-108A-7189/c
; Sequence 7189, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7189
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7189

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         15 TCAGAGGTCAAGTC 2


RESULT 260
US-09-866-108A-7190/c
; Sequence 7190, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7190
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7190

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         14 TCAGAGGTCAAGTC 1


RESULT 261
US-09-866-108A-7639/c
; Sequence 7639, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7639
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7639

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         17 GTTGGTTCTCTAGC 4


RESULT 262
US-09-866-108A-7640/c
; Sequence 7640, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7640
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7640

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         16 GTTGGTTCTCTAGC 3


RESULT 263
US-09-404-912-564/c
; Sequence 564, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 564
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-564

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACACACACAC 2


RESULT 264
US-09-404-912-565/c
; Sequence 565, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 565
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-565
```

```
  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 2.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACGCACACAC 2


RESULT 265
US-08-480-655-27
; Sequence 27, Application US/08480655
; Patent No. 5998133
;  GENERAL INFORMATION:
;    APPLICANT:  BLUMENFELD, ANAT; GUSELLA, JAMES F;
;    APPLICANT:  BREAKEFIELD, XANDRA, O;
;    APPLICANT:  SLAUGENHAUPT, SUSAN
;    TITLE OF INVENTION:  USE OF GENETIC MARKERS TO
;    TITLE OF INVENTION:  DIAGNOSE FAMILIAL DYSAUTONOMIA
;    NUMBER OF SEQUENCES:  34
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORGAN & FINNEGAN, L.L.P.
;      STREET:  345 PARK AVENUE
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10154
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  FLOPPY DISK
;      COMPUTER:  IBM PC COMPATIBLE
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/480,655
;      FILING DATE:  07-JUNE-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/049,678
;      FILING DATE:  16-APRIL-1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/890,719
;      FILING DATE:  29-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KENNETH H. SONNENFELD
;      REGISTRATION NUMBER:  33,285
;      REFERENCE/DOCKET NUMBER:  1829-4001US1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-451-8513
;      TELEFAX:  212-751-6849
;  INFORMATION FOR SEQ ID NO:  27:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  SINGLE
;      TOPOLOGY:  UNKNOWN
;    MOLECULE TYPE:  OLIGONUCLEOTIDE
;    HYPOTHETICAL:  No
;    FEATURE:
;      NAME/KEY:  PRIMER SEQUENCE OF D9S310 LOCUS
;      LOCATION:  CHROMOSOME 9
;      IDENTIFICATION METHOD:
;      OTHER INFORMATION:
US-08-480-655-27

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 CCTGGGCCAACAGA 1858
              ||||||| ||||||
Db          2 CCTGGGCAAACAGA 15


RESULT 266
US-09-255-912-26
; Sequence 26, Application US/09255912
; Patent No. 6037142
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD2 EXPRESSION
;  FILE REFERENCE: RTS-0044
;  CURRENT APPLICATION NUMBER: US/09/255,912
;  CURRENT FILING DATE: 1999-02-23
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 26
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-255-912-26

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1799 TCTCTGAAAGTGGT 1812
              ||||||| ||||||
Db          1 TCTCTGATAGTGGT 14


RESULT 267
US-09-115-027-2/c
; Sequence 2, Application US/09115027
; Patent No. 6242589
; GENERAL INFORMATION:
;  APPLICANT:  Cook, Phillip D
;  APPLICANT:  Manoharan, Muthiah
;  TITLE OF INVENTION:  Phosphorothioate Oligonucleotides Having Modified
;  TITLE OF INVENTION:  Internucleoside Linkages
;  FILE REFERENCE:  ISIS2953
;  CURRENT APPLICATION NUMBER: US/09/115,027
;  CURRENT FILING DATE:  1998-07-14
;  NUMBER OF SEQ ID NOS:  6
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  No. 6242589el
;   OTHER INFORMATION: Sequence
US-09-115-027-2

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
              ||||||||||||  |
Db         16 TGGCCTGGGGGATG 3


RESULT 268
US-09-455-683-27
; Sequence 27, Application US/09455683
; Patent No. 6262250
;   GENERAL INFORMATION:
;        APPLICANT: BLUMENFELD, ANAT; GUSELLA, JAMES F;
;                   BREAKEFIELD, XANDRA, O;
;                   SLAUGENHAUPT, SUSAN
;        TITLE OF INVENTION: USE OF GENETIC MARKERS TO
;                            DIAGNOSE FAMILIAL DYSAUTONOMIA
;        NUMBER OF SEQUENCES: 34
```

```
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
;            STREET: 345 PARK AVENUE
;            CITY: NEW YORK
;            STATE: NEW YORK
;            COUNTRY: USA
;            ZIP: 10154
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: FLOPPY DISK
;            COMPUTER: IBM PC COMPATIBLE
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: ASCII
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/455,683
;            FILING DATE: 07-Dec-1999
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/480,655
;            FILING DATE: 07-JUNE-1995
;            APPLICATION NUMBER: 08/049,678
;            FILING DATE: 16-APRIL-1993
;            APPLICATION NUMBER: US/07/890,719
;            FILING DATE: 29-MAY-1992
;       ATTORNEY/AGENT INFORMATION:
;            NAME: KENNETH H. SONNENFELD
;            REGISTRATION NUMBER: 33,285
;            REFERENCE/DOCKET NUMBER: 1829-4001US2
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 212-451-8513
;            TELEFAX: 212-751-6849
;   INFORMATION FOR SEQ ID NO: 27:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 18 BASE PAIRS
;            TYPE: NUCLEIC ACID
;            STRANDEDNESS: SINGLE
;            TOPOLOGY: UNKNOWN
;       MOLECULE TYPE: OLIGONUCLEOTIDE
;       HYPOTHETICAL: No
;       FEATURE:
;            NAME/KEY:  PRIMER SEQUENCE OF D9S310 LOCUS
;            LOCATION:  CHROMOSOME 9
;       SEQUENCE DESCRIPTION: SEQ ID NO: 27:
US-09-455-683-27

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 CCTGGGCCAACAGA 1858
             ||||||| ||||||
Db          2 CCTGGGCAAACAGA 15


RESULT 269
US-09-158-695-5
; Sequence 5, Application US/09158695
; Patent No. 6379957
; GENERAL INFORMATION:
;  APPLICANT:  Johnston-Dow, Leslie
;  APPLICANT:  Demeter, Lisa
;  APPLICANT:  White, Camille B.
;  APPLICANT:  Song, Keming
;  APPLICANT:  Kohlenberger, Robert
;  APPLICANT:  Conrad, Morgan
;  APPLICANT:  Myers, Angela
;  TITLE OF INVENTION:  No. 6379957el Methods for HIV Sequencing and Genotyping
;  FILE REFERENCE:  07414.0005
;  CURRENT APPLICATION NUMBER: US/09/158,695
;  CURRENT FILING DATE:  1998-09-21
;  NUMBER OF SEQ ID NOS:  18
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: HIV
US-09-158-695-5

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCAC 1863
             ||||||| |||||
Db          2 GCCAACAGCCCCAC 15


RESULT 270
US-10-092-022-5
; Sequence 5, Application US/10092022
; Patent No. 6531588
; GENERAL INFORMATION:
;  APPLICANT: Johnston-Dow, Leslie
;  APPLICANT:  Demeter, Lisa
;  APPLICANT:  White, Camille B.
;  APPLICANT:  Song, Keming
;  APPLICANT:  Kohlenberger, Robert
;  APPLICANT:  Conrad, Morgan
;  APPLICANT:  Myers, Angela
;  TITLE OF INVENTION: No. 6531588el Methods for HIV Sequencing and Genotyping
;  FILE REFERENCE: 07414.0005-01000
;  CURRENT APPLICATION NUMBER: US/10/092,022
;  CURRENT FILING DATE:  2002-03-05
;  PRIOR APPLICATION NUMBER: 09/158,695
;  PRIOR FILING DATE: 1998-09-21
;  NUMBER OF SEQ ID NOS: 18
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: HIV
US-10-092-022-5

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 3.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCAC 1863
             ||||||| |||||
Db          2 GCCAACAGCCCCAC 15


RESULT 271
US-09-422-978-4678
; Sequence 4678, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4678
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
```

; OTHER INFORMATION: upstream amplification primer 99-16990 for SEQ 744,
US-09-422-978-4678

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1533 AAAGGTTAGGAGAG 1546
              ||||||| ||||||
Db          5 AAAGGTTTGGAGAG 18
```

RESULT 272
US-09-422-978-4857
; Sequence 4857, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4857
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-18253 for SEQ 923,
US-09-422-978-4857

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1785 CCCCATTCTTTCCT 1798
              | ||||||||||||
Db          2 CTCCATTCTTTCCT 15
```

RESULT 273
US-09-544-398B-138/c
; Sequence 138, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 138
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-138

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1603 CCTGGCCTGGGGGA 1616
              |||||||||||  ||
Db         15 CCTGGCCTGGGTGA 2
```

RESULT 274
US-09-544-398B-522/c
; Sequence 522, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 522
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-522

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 3.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2025 TGGTAGGAGGCAAA 2038
              |||||||| |||||
Db         15 TGGTAGGAAGCAAA 2
```

RESULT 275
US-08-364-076-2
; Sequence 2, Application US/08364076
; Patent No. 5595899
; GENERAL INFORMATION:
; APPLICANT: Sato, Masahiro
; APPLICANT: Tada, No. 5595899uhiro
; TITLE OF INVENTION: Methods of Introducing Foreign DNA into
; TITLE OF INVENTION: Cells
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

```
;      APPLICATION NUMBER:  US/08/364,076
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/030,085
;      FILING DATE:  23-MAR-1993
;      APPLICATION NUMBER:  WO PCT/JP91/01269
;      FILING DATE:  24-SEP-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP HEI-2-251843
;      FILING DATE:  25-SEP-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Einaudi, Carol P.
;      REGISTRATION NUMBER:  32,220
;      REFERENCE/DOCKET NUMBER:  02481.1291-00000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-408-4000
;      TELEFAX:  202-408-4400
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-364-076-2

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAA 1988
              ||||| ||||||||
Db          1 CTTGACAAAAAGAA 14


RESULT 276
US-08-132-168A-11
; Sequence 11, Application US/08132168A
; Patent No. 5783680
;  GENERAL INFORMATION:
;    APPLICANT:  Brunner, H. G.
;    APPLICANT:  Breakefield, X.
;    TITLE OF INVENTION:  Genetic Diagnosis and Treatment for
;    TITLE OF INVENTION:  Impulsive Aggression
;    NUMBER OF SEQUENCES:  33
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Sterne, Kessler, Goldstein & Fox P.L.L.C.
;      STREET:  1100 New York Avenue, N.W. Suite 600
;      CITY:  Washington
;      STATE:  DC
;      ZIP:  20005
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/132,168A
;      FILING DATE:  06-OCT-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Goldstein, Jorge A.
;      REGISTRATION NUMBER:  29,021
;      REFERENCE/DOCKET NUMBER:  0609.4000000
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 371-2600
;      TELEFAX:  (202) 371-2540
;      TELEX:  248636 SSK
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-132-168A-11

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1621 TTTGTTACCTACCT 1634
              ||| ||||||||||
Db          2 TTTCTTACCTACCT 15


RESULT 277
US-08-836-261A-40/c
; Sequence 40, Application US/08836261A
; Patent No. 6221582
;  GENERAL INFORMATION:
;    APPLICANT:  GIESENDORF, BELINDA
;    APPLICANT:  QUINT, WILHELMUS
;    APPLICANT:  VAN DOORN, LEENDERT-JAN
;    TITLE OF INVENTION:  NEW POLYNUCLEIC ACID SEQUENCES FOR USE IN THE
;    TITLE OF INVENTION:  DETECTION AND DIFFERENTIATION OF PROKARYOTIC ORGANISMS
;    NUMBER OF SEQUENCES:  96
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ARNOLD, WHITE & DURKEE
;      STREET:  P.O. BOX 4433
;      CITY:  HOUSTON
;      STATE:  TEXAS
;      COUNTRY:  USA
;      ZIP:  77210-4433
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Microsoft Word 6.0 / ASCII text output
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/836,261A
;      FILING DATE:  25 Apr 1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/EP95/04264
;      FILING DATE:  30 Oct 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  EP 94870171.9
;      FILING DATE:  28 Oct 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KAMMERER, PATRICIA A.
;      REGISTRATION NUMBER:  29,775
;      REFERENCE/DOCKET NUMBER:  INNS:005
;  INFORMATION FOR SEQ ID NO:  40:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  19 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-836-261A-40

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCTAG 1700
              | ||| |:|| |||||:|
Db         19 TTTTATTKGTATCTCTWG 2


RESULT 278
US-09-338-907-407
; Sequence 407, Application US/09338907
; Patent No. 6265546
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
```

```
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Ilya, Chumakov
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: PROSTATE CANCER GENE
;  FILE REFERENCE: GENSET.18CP1CP
;  CURRENT APPLICATION NUMBER: US/09/338,907
;  CURRENT FILING DATE: 1999-06-23
;  EARLIER APPLICATION NUMBER: 08/996,306
;  EARLIER FILING DATE: 1997-12-22
;  EARLIER APPLICATION NUMBER: 60/099,658
;  EARLIER FILING DATE: 1998-09-09
;  EARLIER APPLICATION NUMBER: 09/218,207
;  EARLIER FILING DATE: 1998-12-22
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 407
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer for SEQ 235, SEQ 312
US-09-338-907-407

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2034 GCAAAGGTTCTATC 2047
              ||||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 279
US-09-275-505-1/c
; Sequence 1, Application US/09275505
; Patent No. 6335434
; GENERAL INFORMATION:
;  APPLICANT:  Manoharan, Muthiah
;  APPLICANT:  Guzaev, Andrei P.
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Bhat, Balkrishen
;  TITLE OF INVENTION:  Nucleosidic And No. 6335434-Nucleosidic Folate Conjugates
;  FILE REFERENCE:  ISIS-3453
;  CURRENT APPLICATION NUMBER: US/09/275,505
;  CURRENT FILING DATE:  1999-03-24
;  PRIOR APPLICATION NUMBER:  09/098,166
;  PRIOR FILING DATE:  1998-06-16
;  NUMBER OF SEQ ID NOS:  3
;  SOFTWARE:  PatentIn version 3.0
; SEQ ID NO 1
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: No. 6335434el Sequence
US-09-275-505-1

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
              ||||||||||||| |
Db         15 TGGCCTGGGGGATG 2


RESULT 280
US-09-218-207-407
; Sequence 407, Application US/09218207
; Patent No. 6346381
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Ilya, Chumakov
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: Prostate cancer gene
;  FILE REFERENCE: GENSET.018CP1
;  CURRENT APPLICATION NUMBER: US/09/218,207
;  CURRENT FILING DATE: 1998-12-22
;  EARLIER APPLICATION NUMBER: 08/996,306
;  EARLIER FILING DATE: 1997-12-22
;  EARLIER APPLICATION NUMBER: 60/099,658
;  EARLIER FILING DATE: 1998-09-09
;  NUMBER OF SEQ ID NOS: 578
;  SOFTWARE: Patent.pm
; SEQ ID NO 407
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer for SEQ 235, SEQ 312
US-09-218-207-407

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2034 GCAAAGGTTCTATC 2047
              ||||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 281
US-09-345-882-115/c
; Sequence 115, Application US/09345882
; Patent No. 6399373
; GENERAL INFORMATION:
;  APPLICANT: Bougueleret, Lydie
;  TITLE OF INVENTION: A NUCLEIC ACID ENCODING A RETINOBLASTOMA BINDING PROTEIN (RBP-7)
;  TITLE OF INVENTION:  AND POLYMORPHIC MARKERS ASSOCIATED WITH SAID NUCLEIC ACID.
;  FILE REFERENCE: GENSET.031A
;  CURRENT APPLICATION NUMBER: US/09/345,882
;  CURRENT FILING DATE:  1999-06-30
;  PRIOR APPLICATION NUMBER: US 60/091,315
;  PRIOR FILING DATE: 1998-06-30
;  PRIOR APPLICATION NUMBER: US 60/111,909
;  PRIOR FILING DATE: 1998-12-10
;  NUMBER OF SEQ ID NOS: 140
;  SOFTWARE: Patent.pm
; SEQ ID NO 115
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: microsequencing oligo for 5-140-348.mis1
US-09-345-882-115

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAA 1980
              || ||||||||||
Db         15 ATGTTTACCTTGAA 2


RESULT 282
US-09-422-978-5778
; Sequence 5778, Application US/09422978
; Patent No. 6537751
```

```
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5778
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: upstream amplification primer 99-6820 for SEQ 1844,
US-09-422-978-5778

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1948 TGGTTTTTGTGTCC 1961
              ||||||||| |||||
Db          2 TGGTTTTTCTGTCC 15


RESULT 283
US-09-422-978-8050
; Sequence 8050, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8050
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-134 for SEQ 185, in complement
US-09-422-978-8050

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2034 GCAAAGGTTCTATC 2047
              ||||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 284
US-09-422-978-9088
; Sequence 9088, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9088
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-22096 for SEQ 1223, in complem
US-09-422-978-9088

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTT 1781
              |||||||||| |||
Db          3 AGCTTTTTTTCTTT 16


RESULT 285
US-09-422-978-9761/c
; Sequence 9761, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9761
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..19
;   OTHER INFORMATION: downstream amplification primer 99-7172 for SEQ 1896, in compleme
US-09-422-978-9761

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGA 1556
              | ||||||||||||
Db         16 AAAGTAGGGAAGGA 3
```

```
RESULT 286
US-09-696-791-7
; Sequence 7, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 7
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cdk1 ribozyme binding site
US-09-696-791-7

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGG 1607
              ||||||||||||  |
Db          1 GGAACCCCTCCTTG 14


RESULT 287
US-09-696-791-2364
; Sequence 2364, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 2364
;   LENGTH: 19
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Cyclin F ribozyme binding site
US-09-696-791-2364

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1998 TCTAGCTTCTTCAG 2011
              ||| ||||||||||
Db          3 TCTCGCTTCTTCAG 16


RESULT 288
US-08-373-124A-2141/c
; Sequence 2141, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2141:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-2141

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.2e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              ||||| | |||||| ||
Db         17 AAAAATAAAAAAGTCTG 1


RESULT 289
US-08-758-306-1159
; Sequence 1159, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
```

```
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSeq Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/758,306
;       FILING DATE:  December 3, 1996
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  212/132
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1159:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-758-306-1159

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.2e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2039 GGTTCTATCTGCTTAGC 2055
              | ::|: :|:|| :|||
Db          1 GCUUCUCUCUGCCUAGC 17


RESULT 290
US-08-435-628-2141/c
; Sequence 2141, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2141:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2141

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.2e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              ||||| | |||||| ||
Db         17 AAAAATAAAAAAGTCTG 1


RESULT 291
US-08-985-162-750
; Sequence 750, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
```

```
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  750:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-750

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 3.2e+02;
  Matches    7;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              ||||:: :::||:  :|
Db          1 CCCAUUUUUUCCUAAUC 17


RESULT 292
US-08-985-162-751
; Sequence 751, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  751:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-751

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.2e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              |||:: :::||:  :|:
Db          1 CCAUUUUUUCCUAAUCU 17


RESULT 293
US-08-985-162-752
; Sequence 752, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  752:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-752

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.2e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1788 CATTCTTTCCTTCTCTG 1804
              ||:: :::||:  :|:|
Db          1 CAUUUUUUCCUAAUCUG 17


RESULT 294
US-08-584-040-5631
; Sequence 5631, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
```

```
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5631:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5631

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGGC 1851
              ||| |||:: ||:|| |
Db          1 AAAGACAUUGCCUGGUC 17


RESULT 295
US-08-584-040-7397/c
; Sequence 7397, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7397:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7397

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.2e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCA 1654
              | |||||| |||||| |
Db         17 TTTTTAAATAGCCTTGA 1


RESULT 296
US-08-584-040-7742
; Sequence 7742, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
```

```
;       FILING DATE:  January 11, 1996
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/005,974
;       FILING DATE:  October 26, 1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/064
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  7742:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-7742

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.2e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTGCC 1897
              : :||||:: |:| |||
Db          1 UUUCAAAUUCAUGAGCC 17


RESULT 297
US-08-584-040-8011
; Sequence 8011, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  8011:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-8011

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.2e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTT 1775
              :|:: |::|||| :::
Db          1 UAUUUAUUAAGCACUUU 17


RESULT 298
US-08-584-040-8157
; Sequence 8157, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  8157:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-8157

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.2e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1652 TCACTGGTTCTGCATCA 1668
              :| |:||::|:|| : |
Db          1 UCUCUGGUUCUGCUUAA 17
```

RESULT 299
US-09-371-772B-2521
; Sequence 2521, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2521
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2521

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.2e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1835 AAATACATTCCCTGGGC 1851
              ||| |||:: ||:|| |
Db          1 AAAGACAUUGCCUGGUC 17
```

RESULT 300
US-09-371-772B-3205/c
; Sequence 3205, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3205
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3205

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1638 TATTTAAAGAGCCTTCA 1654
              | |||||| |||||| |
Db         17 TTTTTAAATAGCCTTGA 1
```

RESULT 301
US-09-371-772B-3527
; Sequence 3527, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3527
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3527

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.2e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1881 TGTCAAATTGATGTGCC 1897
              : :||||:: |:| |||
Db          1 UUUCAAAUUCAUGAGCC 17
```

RESULT 302
US-09-371-772B-3794
; Sequence 3794, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3794
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3794

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 35.3%; Pred. No. 3.2e+02;
Matches 6; Conservative 8; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1759 TATTCATTAAGCTTTTT 1775
```

```
              :|:: |::|||| :::
Db          1 UAUUUAUUAAGCACUUU 17


RESULT 303
US-09-371-772B-3940
; Sequence 3940, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3940
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3940

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.2e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              :| |:||::|:|| : |
Db          1 UCUCUGGUUCUGCUUAA 17


RESULT 304
US-09-371-772B-4919
; Sequence 4919, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4919
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4919

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 3.2e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | :| : ||::|:|:||
Db          1 ACUCCUGCCUUCUCUGA 17


RESULT 305
US-09-371-772B-5300
; Sequence 5300, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5300
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5300

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 3.2e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1642 TAAAGAGCCTTCACTGG 1658
              :|| ||||| :|||: |
Db          1 UAAUGAGCCAUCACUAG 17


RESULT 306
US-09-371-772B-6155
; Sequence 6155, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6155
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6155

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.2e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATTATCA 1735
              |:::|| || |: |:||
Db          1 CUUUGGCCCAAUAAUCA 17
```

```
RESULT 307
US-09-371-772B-6156
; Sequence 6156, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6156
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6156

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 3.2e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1720 TTTGGACCTATTATCAG 1736
              :::|| || |: |:|||
Db          1 UUUGGCCCAAUAAUCAG 17


RESULT 308
US-09-371-772B-6199
; Sequence 6199, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6199
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6199

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              | ||||| |||| :|:|
Db          1 ACAAAAACAAAACUGUG 17


RESULT 309
US-09-401-063-750
; Sequence 750, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  750:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-750

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 3.2e+02;
  Matches    7;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              ||||:: :::||:  :|
Db          1 CCCAUUUUUUCCUAAUC 17


RESULT 310
US-09-401-063-751
; Sequence 751, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
```

```
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  751:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-751

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.2e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              |||:: :::||:  :|:
Db          1 CCAUUUUUUCCUAAUCU 17


RESULT 311
US-09-401-063-752
; Sequence 752, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  752:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-752

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 3.2e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1788 CATTCTTTCCTTCTCTG 1804
              ||:: :::||:  :|:|
Db          1 CAUUUUUUCCUAAUCUG 17


RESULT 312
US-09-866-108A-2108/c
; Sequence 2108, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2108
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2108

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.2e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACCC 1671
              ||||||| ||| | |||
Db         17 CTGGTTCAGCAGCGCCC 1


RESULT 313
US-09-866-108A-2784/c
; Sequence 2784, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2784
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2784

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.2e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1804 GAAAGTGGTGCTATAAG 1820
              ||| ||||||||  |||
Db         17 GAAGGTGGTGCTTGAAG 1


RESULT 314
US-09-866-108A-7956
; Sequence 7956, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7956
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7956

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.2e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1893 GTGCCCTAGATCAACAG 1909
              | ||||| || ||||||
Db          1 GCGCCCTTGAGCAACAG 17


RESULT 315
US-09-866-108A-7960
; Sequence 7960, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
```

```
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7960
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7960

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.2e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAA 1990
                ||||||  || ||||||
Db          1 CCTTGAGCAACAGAAAA 17


RESULT 316
US-09-866-108A-10544/c
; Sequence 10544, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10544
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10544

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 3.2e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCT 1771
                | ||| ||||||| |||
Db         17 TATTTCTTCATTATGCT 1


RESULT 317
US-08-218-303-17/c
; Sequence 17, Application US/08218303
; Patent No. 5547867
;  GENERAL INFORMATION:
;    APPLICANT:  Kara, Bhuphendra V.
;    APPLICANT:  Hockney, Robert C.
;    APPLICANT:  Fitton, John E.
;    TITLE OF INVENTION:  FERMENTATION PROCESS
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cushman, Darby & Cushman
;      STREET:  1615 L Street, N.W.
;      CITY:  Washington
;      STATE:  D.C.
;      COUNTRY:  U.S.A.
;      ZIP:  20036-5601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/218,303
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/841,533
;      FILING DATE:  26-FEB-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kokulis, Paul N.
;      REGISTRATION NUMBER:  16,773
;      REFERENCE/DOCKET NUMBER:  PNK/3893/94908/MJW
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-861-3000
;      TELEFAX:  202-822-0944
;      TELEX:  6714627 CUSH
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..18
US-08-218-303-17

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1979 AAAAAAAGAAAAGTGTG 1995
              ||  |||||||| ||||
Db         18 AAGCAAAGAAAACTGTG 2


RESULT 318
US-08-453-224-5/c
; Sequence 5, Application US/08453224
; Patent No. 5627274
;  GENERAL INFORMATION:
;    APPLICANT:  Kole, Ryszard
;    APPLICANT:  Dominski, Zbigniew T.
;    TITLE OF INVENTION:  Antisense Oligonucleotides Which Combat
;    TITLE OF INVENTION:  Aberrant Splicing and Methods of Using the Same
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kenneth D. Sibley; Bell, Seltzer, Park and
;      ADDRESSEE:  Gibson
;      STREET:  Post Office Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 5627274th Carolina
;      COUNTRY:  U.S.A.
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/453,224
;      FILING DATE:  30-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/379,079
;      FILING DATE:  26-JAN-1995
;      APPLICATION NUMBER:  US/08/062,471
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5470-63
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA (genomic)
;    ANTI-SENSE:  YES
US-08-453-224-5

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 319
US-08-233-009-35
; Sequence 35, Application US/08233009
; Patent No. 5646156
;  GENERAL INFORMATION:
;    APPLICANT:  Jacobson, Marlene A
;    APPLICANT:  Johnson, Robert G
;    APPLICANT:  Salvatore, Christopher A
;    TITLE OF INVENTION:  INHIBITION OF EOSINOPHIL
;    TITLE OF INVENTION:  ACTIVATION THROUGH A3 ADENOSINE RECEPTOR ANTAGONISM
;    NUMBER OF SEQUENCES:  56
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merck & Co., Inc.
;      STREET:  P.O.Box 2000
;      CITY:  Rahway
;      STATE:  New Jersey
;      COUNTRY:  United States
;      ZIP:  07065
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/233,009
;      FILING DATE:  25-APR-1994
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bencen, Gerard H
;      REGISTRATION NUMBER:  35,746
;      REFERENCE/DOCKET NUMBER:  19219
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (908) 594-3901
;      TELEFAX:  (908)594-4720
;  INFORMATION FOR SEQ ID NO:  35:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  both
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  YES
US-08-233-009-35

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTAT 1640
              ||||||||| | || ||
Db          1 GTTACCTACATCACCAT 17


RESULT 320
US-08-379-079-5/c
; Sequence 5, Application US/08379079
; Patent No. 5665593
;  GENERAL INFORMATION:
;    APPLICANT:  Kole, Ryszard
;    APPLICANT:  Dominski, Zbigniew T.
;    TITLE OF INVENTION:  Antisense Oligonucleotides Which Combat
;    TITLE OF INVENTION:  Aberrant Splicing and Methods of Using the Same
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kenneth D. Sibley; Bell, Seltzer, Park and
;      ADDRESSEE:  Gibson
;      STREET:  Post Office Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 5665593th Carolina
;      COUNTRY:  U.S.A.
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/379,079
;      FILING DATE:
;      CLASSIFICATION:  514
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/062,471
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5470-63
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA (genomic)
;    ANTI-SENSE:  YES
US-08-379-079-5

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
                | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 321
US-08-363-240A-1102
; Sequence 1102, Application US/08363240A
; Patent No. 5705388
;  GENERAL INFORMATION:
;    APPLICANT:  Couture, Larry
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Bisgaier, Charles
;    APPLICANT:  Pape, Michael
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  PREVENTION, INHIBITION OF
;    TITLE OF INVENTION:  PROGRESSION AND REGRESSION
;    TITLE OF INVENTION:  OF VASCULAR DISEASES
;    NUMBER OF SEQUENCES:  1243
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/363,240A
;      FILING DATE:  December 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  210/096
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1102:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-363-240A-1102

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1553 AGGAACAGGACTGCAAA 1569
                ||| ||||  |:|||||
Db          1 AGGGACAGAUCUGCAAA 17


RESULT 322
US-08-758-306-533
; Sequence 533, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  533:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-533

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGAAC 1598
                ||| || |||:|||| |
Db          1 CCGGACUGACUGGGACC 17
```

```
RESULT 323
US-08-173-489C-21
; Sequence 21, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Genomic DNA
;      DESCRIPTION:  n-myc gene (Accession # Y00664)
;      DESCRIPTION:  nucleotides 5619 to 5636
;    HYPOTHETICAL:  No
;    ANTI-SENSE:  No
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapiens
;    PUBLICATION INFORMATION:
;      AUTHORS:  Ibson, J M,  Rabbitts, P H.
;      TITLE:  Sequence of a germ-line N-myc
; Patent No. 5861244
;      TITLE:  gene and amplification as a mechanism of
;      TITLE:  activation
;      JOURNAL:  Oncogene
;      VOLUME:  2
;      PAGES:  399-402
;      DATE:  1988
;      RELEVANT RESIDUES IN SEQ ID NO:  21 :FROM 1 TO 18
US-08-173-489C-21

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGA 1556
              ||||||| |||||| |
Db          2 AGGAGAGAGGGGAAGAA 18
```

```
RESULT 324
US-08-802-384-5/c
; Sequence 5, Application US/08802384
; Patent No. 5916808
;  GENERAL INFORMATION:
;    APPLICANT:  Kole, Ryszard
;    APPLICANT:  Dominski, Zbigniew T.
;    TITLE OF INVENTION:  Antisense Oligonucleotides Which Combat
;    TITLE OF INVENTION:  Aberrant Splicing and Methods of Using the Same
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kenneth D. Sibley; Bell, Seltzer, Park and
;      ADDRESSEE:  Gibson
;      STREET:  Post Office Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 5916808th Carolina
;      COUNTRY:  U.S.A.
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/802,384
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/379,079
;      FILING DATE:
;      APPLICATION NUMBER:  US/08/062,471
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5470-63
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA (genomic)
;    ANTI-SENSE:  YES
US-08-802-384-5

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | |||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2
```

```
RESULT 325
US-09-197-378-9/c
; Sequence 9, Application US/09197378
; Patent No. 5959097
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF MEK2 EXPRESSION
;  FILE REFERENCE: RTS-0017
;  CURRENT APPLICATION NUMBER: US/09/197,378
;  CURRENT FILING DATE: 1998-11-20
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 9
;   LENGTH: 18
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-197-378-9

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAG 1618
              | |||||| || |||||
Db         17 TGCTGGCCCGGAGGAAG 1


RESULT 326
US-09-302-390-5/c
; Sequence 5, Application US/09302390
; Patent No. 5976879
;  GENERAL INFORMATION:
;    APPLICANT:  Kole, Ryszard
;    APPLICANT:  Dominski, Zbigniew T.
;    TITLE OF INVENTION:  Antisense Oligonucleotides Which Combat
;    TITLE OF INVENTION:  Aberrant Splicing and Methods of Using the Same
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kenneth D. Sibley; Bell, Seltzer, Park and
;      ADDRESSEE:  Gibson
;      STREET:  Post Office Drawer 34009
;      CITY:  Charlotte
;      STATE:  No. 5976879th Carolina
;      COUNTRY:  U.S.A.
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/302,390
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/379,079
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D.
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5470-63
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA (genomic)
;    ANTI-SENSE:  YES
US-09-302-390-5

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | |||||||||||  |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 327
US-09-339-964-9
; Sequence 9, Application US/09339964
; Patent No. 6025198
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SHIP-2 EXPRESSION
;  FILE REFERENCE: RTS-0065
;  CURRENT APPLICATION NUMBER: US/09/339,964
;  CURRENT FILING DATE: 1999-06-25
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 9
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-339-964-9

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACAG 1589
              |||| |||||| ||| |
Db          1 CCTTGTCCACCTCACTG 17


RESULT 328
US-08-867-381A-19/c
; Sequence 19, Application US/08867381A
; Patent No. 6075123
;  GENERAL INFORMATION:
;    APPLICANT:  Lahti, Jill M.
;    APPLICANT:  Kidd, Vincent J.
;    TITLE OF INVENTION:  CYCLIN-C VARIANT, AND DIAGNOSTIC AND
;    TITLE OF INVENTION:  THERAPEUTIC USES THEREOF
;    NUMBER OF SEQUENCES:  53
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  David A. Jackson, Esq.
;      STREET:  411 Hackensack Ave, Continental Plaza, 4th
;      STREET:  Floor
;      CITY:  Hackensack
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/867,381A
;      FILING DATE:
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jackson Esq., David A.
;      REGISTRATION NUMBER:  26,742
;      REFERENCE/DOCKET NUMBER:  1340-1-001 N
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-487-5800
;      TELEFAX:  201-343-1684
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotides C-13"
;    HYPOTHETICAL:  NO
US-08-867-381A-19
```

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1702 GCTGAGCTATCTCCTAA 1718
              ||||||||||||  | |
Db         18 GCTGAGCTATCTGTTGA 2
```

RESULT 329
US-09-133-717-10
; Sequence 10, Application US/09133717
; Patent No. 6083702
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; TITLE OF INVENTION: METHODS AND COMPOSITION FOR USE IN SPLICEOSOME MEDIATED
; TITLE OF INVENTION: RNA TRANS-SPLICING
; FILE REFERENCE: A31304-B
; CURRENT APPLICATION NUMBER: US/09/133,717
; CURRENT FILING DATE: 1998-08-13
; EARLIER APPLICATION NUMBER: 09/087,233
; EARLIER FILING DATE: 1998-05-28
; EARLIER APPLICATION NUMBER: 08/766,354
; EARLIER FILING DATE: 1996-12-13
; EARLIER APPLICATION NUMBER: 60/008,317
; EARLIER FILING DATE: 1995-12-07
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Human
US-09-133-717-10

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| ||||||| ||||
Db          1 TGCTTCACCCGGGCCTG 17
```

RESULT 330
US-08-559-397A-24/c
; Sequence 24, Application US/08559397A
; Patent No. 6083713
; GENERAL INFORMATION:
; APPLICANT: Manly, Susan P.
; APPLICANT: Kozlowski, Michael R.
; APPLICANT: Neve, Rachael L.
; TITLE OF INVENTION: CLONING AND EXPRESSION OF
; TITLE OF INVENTION: BETA APP-C100 RECEPTOR (C100-R)
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036/2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/559,397A
; FILING DATE: 15-NOV-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 6013-135
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-790-9090
; TELEFAX: 212-869=8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-559-397A-24

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1765 TTAAGCTTTTTTTTTTT 1781
              ||  |||||| ||||||
Db         18 TTTTGCTTTTGTTTTTT 2
```

RESULT 331
US-09-158-863C-10
; Sequence 10, Application US/09158863C
; Patent No. 6280978
; GENERAL INFORMATION:
; APPLICANT: Mitchell, Lloyd G.
; APPLICANT: Garcia-Blanco, Mariano A.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR USE IN
; TITLE OF INVENTION: SPLICEOSOME MEDIATED RNA TRANS-SPLICING
; FILE REFERENCE: 31304-B-A
; CURRENT APPLICATION NUMBER: US/09/158,863C
; CURRENT FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 09/133,717
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 09/087,233
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 08/766,354
; PRIOR FILING DATE: 1996-12-13
; PRIOR APPLICATION NUMBER: 60/008,317
; PRIOR FILING DATE: 1995-12-07
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-158-863C-10

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| ||||||| ||||
Db          1 TGCTTCACCCGGGCCTG 17
```

RESULT 332
US-09-521-144-19/c
; Sequence 19, Application US/09521144
; Patent No. 6306648
; GENERAL INFORMATION:
; APPLICANT: Lahti, Jill M.
; APPLICANT: Kidd, Vincent J.
; TITLE OF INVENTION: CYCLIN-C VARIANT, AND DIAGNOSTIC AND
; TITLE OF INVENTION: THERAPEUTIC USES THEREOF
; NUMBER OF SEQUENCES: 53
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David A. Jackson, Esq.
; STREET: 411 Hackensack Ave, Continental Plaza, 4th

```
;      STREET:  Floor
;      CITY:  Hackensack
;      STATE:  New Jersey
;      COUNTRY:  USA
;      ZIP:  07601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/521,144
;      FILING DATE:  08-MAR-2000
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/867,381
;      FILING DATE:  02-JUN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jackson Esq., David A.
;      REGISTRATION NUMBER:  26,742
;      REFERENCE/DOCKET NUMBER:  1340-1-001 N
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  201-487-5800
;      TELEFAX:  201-343-1684
;  INFORMATION FOR SEQ ID NO:  19:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotides C-13"
;    HYPOTHETICAL:  NO
US-09-521-144-19

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1702 GCTGAGCTATCTCCTAA 1718
              ||||||||||||  | |
Db         18 GCTGAGCTATCTGTTGA 2


RESULT 333
US-08-584-040-3033
; Sequence 3033, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  3033:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-3033

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   47.1%;  Pred. No. 3.4e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | :| : ||::|:|:||
Db          2 ACUCCUGCCUUCUCUGA 18


RESULT 334
US-09-270-140A-10/c
; Sequence 10, Application US/09270140A
; Patent No. 6361941
; GENERAL INFORMATION:
;  APPLICANT: Todd, Alison
;  APPLICANT:  Fuery, Caroline
;  APPLICANT:  Cairns, Murray
;  TITLE OF INVENTION: Catalytic Nucleic Acid base Diagnostic Methods
;  FILE REFERENCE: J&J1799
;  CURRENT APPLICATION NUMBER: US/09/270,140A
;  CURRENT FILING DATE:  1999-03-16
;  PRIOR APPLICATION NUMBER: 60/079,651
;  PRIOR FILING DATE: 1998-03-27
;  NUMBER OF SEQ ID NOS: 96
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:wildtype RNA
;   OTHER INFORMATION: for H-ras codon 61
US-09-270-140A-10

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGG 1614
              | |||||||||| | ||
Db         18 CTCCTCCTGGCCGGCGG 2


RESULT 335
US-09-270-140A-13/c
; Sequence 13, Application US/09270140A
; Patent No. 6361941
; GENERAL INFORMATION:
;  APPLICANT: Todd, Alison
;  APPLICANT:  Fuery, Caroline
```

```
;  APPLICANT:  Cairns, Murray
;  TITLE OF INVENTION: Catalytic Nucleic Acid base Diagnostic Methods
;  FILE REFERENCE: J&J1799
;  CURRENT APPLICATION NUMBER: US/09/270,140A
;  CURRENT FILING DATE:  1999-03-16
;  PRIOR APPLICATION NUMBER: 60/079,651
;  PRIOR FILING DATE: 1998-03-27
;  NUMBER OF SEQ ID NOS: 96
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:wildtype RNA
;   OTHER INFORMATION: for H-ras codon  61
US-09-270-140A-13

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGG 1614
              | |||||||||| | ||
Db         18 CTCCTCCTGGCCGGCGG 2


RESULT 336
US-09-270-140A-16/c
; Sequence 16, Application US/09270140A
; Patent No. 6361941
; GENERAL INFORMATION:
;  APPLICANT: Todd, Alison
;  APPLICANT:  Fuery, Caroline
;  APPLICANT:  Cairns, Murray
;  TITLE OF INVENTION: Catalytic Nucleic Acid base Diagnostic Methods
;  FILE REFERENCE: J&J1799
;  CURRENT APPLICATION NUMBER: US/09/270,140A
;  CURRENT FILING DATE:  1999-03-16
;  PRIOR APPLICATION NUMBER: 60/079,651
;  PRIOR FILING DATE: 1998-03-27
;  NUMBER OF SEQ ID NOS: 96
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:wildtype RNA
;   OTHER INFORMATION: for H-ras codon 61, position 3
US-09-270-140A-16

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGG 1614
              | |||||||||| | ||
Db         18 CTCCTCCTGGCCGGCGG 2


RESULT 337
US-09-422-978-5792
; Sequence 5792, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5792
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-6951 for SEQ 1858,
US-09-422-978-5792

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACC 1583
              ||| ||| ||| |||||
Db          2 AAACATCATTCACCACC 18


RESULT 338
US-09-422-978-7594/c
; Sequence 7594, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7594
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-9145 for SEQ 3660,
US-09-422-978-7594

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAGG 1555
              ||  |||||||||| ||
Db         17 TATTAGAGTAGGGATGG 1


RESULT 339
US-09-422-978-9126
; Sequence 9126, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
```

```
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9126
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-22442 for SEQ 1261, in complem
US-09-422-978-9126

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1538 TTAGGAGAGTAGGGAAG 1554
              || |||||| || ||||
Db          2 TTGGGAGAGAAGAGAAG 18


RESULT 340
US-09-371-772B-1461
; Sequence 1461, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1461
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1461

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   47.1%;  Pred. No. 3.4e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | :| : ||::|:|:||
Db          2 ACUCCUGCCUUCUCUGA 18


RESULT 341
US-10-029-598-22/c
; Sequence 22, Application US/10029598
; Patent No. 6747014
; GENERAL INFORMATION:
;  APPLICANT: Teng, Ching-Leou
;  APPLICANT:  Cook, Phillip Dan
;  APPLICANT:  Tillman, Lloyd
;  APPLICANT:  Hardee, Gregory E.
;  APPLICANT:  Ecker, David J.
;  APPLICANT:  Manoharan, Muthiah
;  TITLE OF INVENTION: Compositions And Methods For No. 6747014-Parental Delivery Of Olig
;  FILE REFERENCE: ISIS4945
;  CURRENT APPLICATION NUMBER: US/10/029,598
;  CURRENT FILING DATE:  2001-12-21
;  PRIOR APPLICATION NUMBER: 08/082,624
;  PRIOR FILING DATE: 1998-05-21
;  PRIOR APPLICATION NUMBER: 09/315,298
;  PRIOR FILING DATE: 1999-05-20
;  NUMBER OF SEQ ID NOS: 58
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 22
;   LENGTH: 18
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Sequence
US-10-029-598-22

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 342
US-09-696-791-4169/c
; Sequence 4169, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4169
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase
US-09-696-791-4169

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2059 TAGTTAATAAGTGGTAT 2075
              |||||| | | ||||||
Db         18 TAGTTAGTCAATGGTAT 2


RESULT 343
PCT-US94-05181-5/c
; Sequence 5, Application PC/TUS9405181
;  GENERAL INFORMATION:
;    APPLICANT:  Kole, Ryszard
;    APPLICANT:  Dominski, Zbigniew T
;    TITLE OF INVENTION:  Antisense Oligonucleotides which
;    TITLE OF INVENTION:  Combat Aberrant Splicing and Methods of Using the Same
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kenneth D. Sibley; Bell, Seltzer, Park
;      ADDRESSEE:  and Gibson
```

```
;      STREET:  Post Office Drawer 34009
;      CITY:  Charlotte
;      STATE:  North Carolina
;      COUNTRY:  U.S.A.
;      ZIP:  28234
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/05181
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sibley, Kenneth D
;      REGISTRATION NUMBER:  31,665
;      REFERENCE/DOCKET NUMBER:  5470-63
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  919-881-3140
;      TELEFAX:  919-881-3175
;      TELEX:  575102
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  RNA (genomic)
;    ANTI-SENSE:  YES
PCT-US94-05181-5

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | |||||||||||  |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 344
US-08-173-489C-139
; Sequence 139, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021,
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  139:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;      DESCRIPTION:  hepatitis B virus adr isolate,
;      DESCRIPTION:  nucleotides 1838 to 1850
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:
;      ORGANISM:  Hepatitis B virus
;      INDIVIDUAL ISOLATE:  adr
;    PUBLICATION INFORMATION:
;      AUTHORS:  Fujiyama, A,  Miyanchara, A,  No. 5861244aki, C,
;      AUTHORS:  Yoneyama, T, Ohromo, N,  Matsubara, K.
;      TITLE:  Cloning and structural
;      TITLE:  analysis of Hepatitis B virus DNAs subtype adr
;      JOURNAL:  Nucleic Acids Research
;      VOLUME:  11
;      PAGES:  4601-4610
;      DATE:  1983
;      RELEVANT RESIDUES IN SEQ ID NO:  139 :FROM 1 TO 13
US-08-173-489C-139

  Query Match             2.1%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCT 1801
              ||||||||||||
Db          2 TTCTTTCCTTCT 13


RESULT 345
US-09-531-000-65/c
; Sequence 65, Application US/09531000
; Patent No. 6461810
; GENERAL INFORMATION:
;  APPLICANT:  JOHNSON, Marion D.
;  APPLICANT:  FRESCO, Jacques R.
;  TITLE OF INVENTION:  TRIPLEX IN-SITU HYBRIDIZATION
;  FILE REFERENCE:  2448-103
;  CURRENT APPLICATION NUMBER: US/09/531,000
;  CURRENT FILING DATE:  2000-09-08
;  PRIOR APPLICATION NUMBER:  PCT/US98/23765
;  PRIOR FILING DATE:  1998-11-10
;  PRIOR APPLICATION NUMBER:  60/064,997
;  PRIOR FILING DATE:  1997-11-10
;  NUMBER OF SEQ ID NOS:  77
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 65
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target
;   OTHER INFORMATION: sequences
US-09-531-000-65

  Query Match             2.1%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1572 TCCTTCTCCACC 1583
              ||||||||||||
Db          12 TCCTTCTCCACC 1
```

```
RESULT 346
US-08-334-847-584/c
; Sequence 584, Application US/08334847
; Patent No. 5693532
;  GENERAL INFORMATION:
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  Pavco, Pam
;    APPLICANT:  Woolf, Tod
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING RESPIRATORY
;    TITLE OF INVENTION:  SYNCYTIAL VIRUS
;    NUMBER OF SEQUENCES:  909
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/334,847
;      FILING DATE:  No. 5693532ember 4, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/032
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  584:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-334-847-584

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCC 1574
              ||||||||||||
Db         13 CTGCAAAAATCC 2


RESULT 347
US-08-334-847-585/c
; Sequence 585, Application US/08334847
; Patent No. 5693532
;  GENERAL INFORMATION:
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  Pavco, Pam
;    APPLICANT:  Woolf, Tod
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING RESPIRATORY
;    TITLE OF INVENTION:  SYNCYTIAL VIRUS
;    NUMBER OF SEQUENCES:  909
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/334,847
;      FILING DATE:  No. 5693532ember 4, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/032
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  585:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-334-847-585

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCC 1574
              ||||||||||||
Db         12 CTGCAAAAATCC 1


RESULT 348
US-08-585-684B-203/c
; Sequence 203, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  203:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-203

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGG 1946
              ||||||||||||
Db         15 TTAAGGTAATGG 4


RESULT 349
US-08-585-684B-204/c
; Sequence 204, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  204:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-204

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGG 1946
              ||||||||||||
Db         14 TTAAGGTAATGG 3


RESULT 350
US-09-038-073-203/c
; Sequence 203, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  203:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-203

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGG 1946
              ||||||||||||
Db         15 TTAAGGTAATGG 4


RESULT 351
US-09-038-073-204/c
; Sequence 204, Application US/09038073
; Patent No. 6194150
```

```
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  204:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-204

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGG 1946
              ||||||||||||
Db         14 TTAAGGTAATGG 3


RESULT 352
US-08-812-951B-1
; Sequence 1, Application US/08812951B
; Patent No. 6297006
;  GENERAL INFORMATION:
;    APPLICANT:  Drmanac, Radoje T.
;    APPLICANT:  Drmanac, Snezana
;    APPLICANT:  Hou, Aaron
;    APPLICANT:  Houser, Brian
;    TITLE OF INVENTION:  Methods and Compositions for
;    TITLE OF INVENTION:  Detection or Quantification of Nucleic Acid Species
;    NUMBER OF SEQUENCES:  15
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  McCutchen, Doyle, Brown & Enersen LLP
;      STREET:  Three Embarcadero Center
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/812,951B
;      FILING DATE:  04-MAR-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US08/784747
;      FILING DATE:  16-JAN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kumamoto, Andrew A
;      REGISTRATION NUMBER:  40,690
;      REFERENCE/DOCKET NUMBER:  20411-701
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-393-2000
;      TELEFAX:  415-393-2286
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-812-951B-1

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db          2 CTTTTTNTTTTTG 14


RESULT 353
US-08-812-951B-2/c
; Sequence 2, Application US/08812951B
; Patent No. 6297006
;  GENERAL INFORMATION:
;    APPLICANT:  Drmanac, Radoje T.
;    APPLICANT:  Drmanac, Snezana
;    APPLICANT:  Hou, Aaron
;    APPLICANT:  Houser, Brian
;    TITLE OF INVENTION:  Methods and Compositions for
;    TITLE OF INVENTION:  Detection or Quantification of Nucleic Acid Species
;    NUMBER OF SEQUENCES:  15
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  McCutchen, Doyle, Brown & Enersen LLP
;      STREET:  Three Embarcadero Center
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/812,951B
;      FILING DATE:  04-MAR-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US08/784747
;      FILING DATE:  16-JAN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kumamoto, Andrew A
;      REGISTRATION NUMBER:  40,690
;      REFERENCE/DOCKET NUMBER:  20411-701
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-393-2000
```

```
;      TELEFAX:  415-393-2286
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-812-951B-2

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db         14 CTTTTTNTTTTTG 2


RESULT 354
US-08-784-747-2
; Sequence 2, Application US/08784747
; Patent No. 6309824
;  GENERAL INFORMATION:
;    APPLICANT:  Drmanac, Radoje T.
;    TITLE OF INVENTION:  Methods and Compositions for
;    TITLE OF INVENTION:  Detection or Quantification of Nucleic Acid Species
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  McCutchen, Doyle, Brown & Enersen LLP
;      STREET:  Three Embarcadero Center
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/784,747
;      FILING DATE:  16-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kumamoto, Andrew A
;      REGISTRATION NUMBER:  40,690
;      REFERENCE/DOCKET NUMBER:  20411-708
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-393-2000
;      TELEFAX:  415-393-2286
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-784-747-2

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db          2 CTTTTTNTTTTTG 14


RESULT 355
US-08-784-747-3/c
; Sequence 3, Application US/08784747
; Patent No. 6309824
;  GENERAL INFORMATION:
;    APPLICANT:  Drmanac, Radoje T.
;    TITLE OF INVENTION:  Methods and Compositions for
;    TITLE OF INVENTION:  Detection or Quantification of Nucleic Acid Species
;    NUMBER OF SEQUENCES:  13
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  McCutchen, Doyle, Brown & Enersen LLP
;      STREET:  Three Embarcadero Center
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ for Windows Version 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/784,747
;      FILING DATE:  16-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kumamoto, Andrew A
;      REGISTRATION NUMBER:  40,690
;      REFERENCE/DOCKET NUMBER:  20411-708
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-393-2000
;      TELEFAX:  415-393-2286
;      TELEX:
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-784-747-3

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db         14 CTTTTTNTTTTTG 2


RESULT 356
US-09-409-778-9
; Sequence 9, Application US/09409778
; Patent No. 6472173
; GENERAL INFORMATION:
;  APPLICANT:      Ford, John
;  APPLICANT:  Yeung, George
;  TITLE OF INVENTION:  A NOVEL CHEMOKINE RECEPTOR OBTAINED FROM
;  TITLE OF INVENTION:  A cDNA LIBRARY OF FETAL LIVER-SPLEEN
;  FILE REFERENCE:  20411-742CON2 (now 28110/36057B)
;  CURRENT APPLICATION NUMBER: US/09/409,778
;  CURRENT FILING DATE:  1999-09-22
;  PRIOR APPLICATION NUMBER:  PCT/US99/12829
;  PRIOR FILING DATE:  1999-06-29
;  PRIOR APPLICATION NUMBER:  US 09/236,166
;  PRIOR FILING DATE:  1999-01-22
;  PRIOR APPLICATION NUMBER:  US 09/106,800
;  PRIOR FILING DATE:  1998-06-26
;  NUMBER OF SEQ ID NOS:  25
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 9
```

```
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary oligonucleotide primer used in sequence assembly proces
;   NAME/KEY: misc_feature
;   LOCATION: (8)...(8)
;   OTHER INFORMATION: n = A, T, C, G or 1-(2-deoxy-D-ribfuranosyl)-3-nitropyrrole
US-09-409-778-9

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db          2 CTTTTTNTTTTTG 14


RESULT 357
US-09-409-778-10/c
; Sequence 10, Application US/09409778
; Patent No. 6472173
; GENERAL INFORMATION:
;  APPLICANT:      Ford, John
;  APPLICANT:  Yeung, George
;  TITLE OF INVENTION:  A NOVEL CHEMOKINE RECEPTOR OBTAINED FROM
;  TITLE OF INVENTION:  A cDNA LIBRARY OF FETAL LIVER-SPLEEN
;  FILE REFERENCE:  20411-742CON2 (now 28110/36057B)
;  CURRENT APPLICATION NUMBER: US/09/409,778
;  CURRENT FILING DATE:  1999-09-22
;  PRIOR APPLICATION NUMBER:  PCT/US99/12829
;  PRIOR FILING DATE:  1999-06-29
;  PRIOR APPLICATION NUMBER:  US 09/236,166
;  PRIOR FILING DATE:  1999-01-22
;  PRIOR APPLICATION NUMBER:  US 09/106,800
;  PRIOR FILING DATE:  1998-06-26
;  NUMBER OF SEQ ID NOS:  25
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 10
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Exemplary oligonucleotide primer used in sequence assembly proces
;   NAME/KEY: misc_feature
;   LOCATION: (8)...(8)
;   OTHER INFORMATION: n = A, T, C, G or 1-(2-deoxy-D-ribfuranosyl)-3-nitropyrrole
US-09-409-778-10

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db         14 CTTTTTNTTTTTG 2


RESULT 358
US-08-283-591-18/c
; Sequence 18, Application US/08283591
; Patent No. 5629152
;  GENERAL INFORMATION:
;    APPLICANT:  Ravikumar, Vasulinga
;    TITLE OF INVENTION:  NOVEL TRISUBSTITUTED  -LACTAMS AND
;    TITLE OF INVENTION:  OLIGO  -LACTAMAMIDES
;    NUMBER OF SEQUENCES:  28
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and
;      ADDRESSEE:  No. 5629152ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/283,591
;      FILING DATE:  N/A
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:
;      REGISTRATION NUMBER:
;      REFERENCE/DOCKET NUMBER:
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-283-591-18

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 359
US-08-088-658-36/c
; Sequence 36, Application US/08088658
; Patent No. 5641625
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker, David J.
;    APPLICANT:  Buchardt, Ole
;    APPLICANT:  Egholm, Michael
;    APPLICANT:  Nielsen, Peter E.
;    APPLICANT:  Berg, Rolf H.
;    APPLICANT:  M llegaard, Niels E.
;    TITLE OF INVENTION:  HIGH ORDER STRUCTURE AND BINDING OF PEPTIDE
;    TITLE OF INVENTION:  NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  56
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 5641625ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/088,658
;      FILING DATE:  19930702
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/054,363
;      FILING DATE:  26-APRIL-1993
;    ATTORNEY/AGENT INFORMATION:
```

```
;      NAME:  Lucci, Joseph
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-1052
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  36:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-088-658-36

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 360
US-08-471-907A-36/c
; Sequence 36, Application US/08471907A
; Patent No. 5986053
;  GENERAL INFORMATION:
;    APPLICANT:  Ecker, David J.
;    APPLICANT:  Buchardt, Ole
;    APPLICANT:  Egholm, Michael
;    APPLICANT:  Nielsen, Peter E.
;    APPLICANT:  Berg, Rolf H.
;    APPLICANT:  M llegaard, Niels E.
;    TITLE OF INVENTION:  HIGH ORDER STRUCTURE AND BINDING OF PEPTIDE
;    TITLE OF INVENTION:  NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  56
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz and No. 5986053ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  U.S.A.
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/471,907A
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/088,658
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Lucci, Joseph
;      REGISTRATION NUMBER:  33,307
;      REFERENCE/DOCKET NUMBER:  ISIS-1052
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-568-3100
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  36:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-471-907A-36

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 361
US-08-088-661F-31/c
; Sequence 31, Application US/08088661F
; Patent No. 6228982
; GENERAL INFORMATION:
;  APPLICANT:  No. 6228982den, Benget
;  APPLICANT:  Wittung, Pernilla
;  APPLICANT:  Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter E.
;  APPLICANT:  Berg, Rolf
;  TITLE OF INVENTION:  Double-Stranded Peptide Nucleic Acids
;  FILE REFERENCE:  ISIS1108
;  CURRENT APPLICATION NUMBER: US/08/088,661F
;  CURRENT FILING DATE:  1993-07-02
;  PRIOR APPLICATION NUMBER:  08/054,363
;  PRIOR FILING DATE:  1993-04-26
;  PRIOR APPLICATION NUMBER:  PCT/EP92/01219
;  PRIOR FILING DATE:  1992-05-19
;  NUMBER OF SEQ ID NOS:  42
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 31
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6228982el Sequence
US-08-088-661F-31

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 362
US-08-150-156A-29/c
; Sequence 29, Application US/08150156A
; Patent No. 6357163
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  THE USE OF NUCLEIC ACID ANALOGUES IN
;    TITLE OF INVENTION:  DIAGNOSTICS AND ANALYTICAL PROCEDURES
;    NUMBER OF SEQUENCES:  40
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  Wordperfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/150,156A
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0986/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0987/91
;      FILING DATE:  24-MAY-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  DK 0510/92
;      FILING DATE:  15-APR-1992
;  INFORMATION FOR SEQ ID NO:  29:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    PUBLICATION INFORMATION:
;      DOCUMENT NUMBER:  WO PCT/EP92/01220
;      FILING DATE:  22-MAY-1992
US-08-150-156A-29

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 363
US-08-108-591B-29/c
; Sequence 29, Application US/08108591B
; Patent No. 6395474
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/08/108,591B
;  CURRENT FILING DATE:  2001-08-13
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. 6395474el Sequence
US-08-108-591B-29

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 364
US-08-468-719A-29/c
; Sequence 29, Application US/08468719A
; Patent No. 6710163
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter E.
;  APPLICANT:  Berg, Rolf H.
;  TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS SYNTHONS
;  FILE REFERENCE: ISPS-1999
;  CURRENT APPLICATION NUMBER: US/08/468,719A
;  CURRENT FILING DATE:  1995-06-06
;  PRIOR APPLICATION NUMBER: US 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide Primer
US-08-468-719A-29

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 365
US-08-462-977B-29/c
; Sequence 29, Application US/08462977B
; Patent No. 6713602
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS-1993
;  CURRENT APPLICATION NUMBER: US/08/462,977B
;  CURRENT FILING DATE:  1995-06-05
;  PRIOR APPLICATION NUMBER: 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 29
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6713602el Sequence
US-08-462-977B-29

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 366
US-09-442-054A-36/c
; Sequence 36, Application US/09442054A
; Patent No. 6770738
; GENERAL INFORMATION:
;  APPLICANT: Ecker, David J.
;  APPLICANT:  Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Berg, Rolf H.
;  APPLICANT:  Mollegaard, Neils E.
;  TITLE OF INVENTION: Higher Order Structure And Binding Of Peptide Nucleic Acids
;  FILE REFERENCE: ISIS4290
;  CURRENT APPLICATION NUMBER: US/09/442,054A
;  CURRENT FILING DATE:  2002-05-07
;  PRIOR APPLICATION NUMBER: 08/471,907
;  PRIOR FILING DATE: 1995-06-07
;  PRIOR APPLICATION NUMBER: 08/054,363
;  PRIOR FILING DATE: 1993-04-26
;  PRIOR APPLICATION NUMBER: PCT/ EP92/01219
;  PRIOR FILING DATE: 1992-05-19
;  NUMBER OF SEQ ID NOS: 89
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 36
;   LENGTH: 16
```

```
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. 6770738el Sequence
US-09-442-054A-36

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 367
US-08-292-620A-1679/c
; Sequence 1679, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1679:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1679

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 368
US-08-292-620A-1756/c
; Sequence 1756, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1756:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1756

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6
```

```
RESULT 369
US-08-292-620A-1764/c
; Sequence 1764, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1764:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1764

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 370
US-08-292-620A-1864/c
; Sequence 1864, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1864:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1864

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 371
US-08-292-620A-1885/c
; Sequence 1885, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
```

```
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1885:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1885

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 372
US-08-292-620A-1999/c
; Sequence 1999, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1999:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1999

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 373
US-09-071-845-1679/c
; Sequence 1679, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
```

```
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/071,845
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/292,620
;       FILING DATE:  August 17, 1994
;       APPLICATION NUMBER:  08/008,895
;       FILING DATE:  January 19, 1993
;       APPLICATION NUMBER:  07/989,849
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  208/149
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  1679:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-09-071-845-1679

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 374
US-09-071-845-1756/c
; Sequence 1756, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1756:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1756

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 375
US-09-071-845-1764/c
; Sequence 1764, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1764:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1764

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 376
US-09-071-845-1864/c
; Sequence 1864, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1864:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1864

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 377
US-09-071-845-1885/c
; Sequence 1885, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1885:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
```

```
US-09-071-845-1885

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 378
US-09-071-845-1999/c
; Sequence 1999, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1999:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1999

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 379
US-09-404-912-510
; Sequence 510, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 510
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-510

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAA 1854
              ||||||||||||
Db          1 TCCCTGGGCCAA 12


RESULT 380
US-08-455-627-17/c
; Sequence 17, Application US/08455627
; Patent No. 5571677
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-843-5000
;      TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
```

```
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-455-627-17

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTG 1993
              ||||||||||||
Db         12 AAAAGAAAAGTG 1


RESULT 381
US-08-689-856-17/c
; Sequence 17, Application US/08689856
; Patent No. 5830658
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/689,856
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-843-5000
;      TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-689-856-17

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTG 1993
              ||||||||||||
Db         12 AAAAGAAAAGTG 1


RESULT 382
US-08-787-321-17/c
; Sequence 17, Application US/08787321A
; Patent No. 6180777
; GENERAL INFORMATION:
;  APPLICANT: Horn, Thomas
;  TITLE OF INVENTION: SYNTHESIS OF BRANCHED NUCLEIC ACIDS
;  FILE REFERENCE: (1300)-1199.002
;  CURRENT APPLICATION NUMBER: US/08/787,321A
;  CURRENT FILING DATE: 1997-01-03
;  EARLIER APPLICATION NUMBER: US PROV 60/009,918
;  EARLIER FILING DATE: 1996-01-12
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-08-787-321-17

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTG 1993
              ||||||||||||
Db         12 AAAAGAAAAGTG 1


RESULT 383
US-08-311-486C-142/c
; Sequence 142, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-`
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
```

```
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  142:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-142

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1679 GACTTCTTAGTTGTT 1693
                || |||||||| |||
Db         15 GAATTCTTAGTGGTT 1


RESULT 384
US-08-311-486C-569
; Sequence 569, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  569:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-569

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 3.5e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1856 AGACCCACACACTTA 1870
                ||||||  |||||: |
Db          1 AGACCCUCACACUCA 15


RESULT 385
US-08-292-620A-124
; Sequence 124, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  124:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-124

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 3.5e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1603 CCTGGCCTGGGGGAA 1617
              || ||| :|||||||
Db          1 CCAGGCUUGGGGGAA 15


RESULT 386
US-08-585-684B-609
; Sequence 609, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  609:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-609

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 387
US-08-585-684B-610
; Sequence 610, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  610:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-610

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 388
US-08-585-684B-611
; Sequence 611, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  611:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-611

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 389
US-08-585-684B-612
; Sequence 612, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  612:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-612

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 390
US-08-641-291A-57/c
; Sequence 57, Application US/08641291A
; Patent No. 6037122
;  GENERAL INFORMATION:
;    APPLICANT:  MABILAT Claude
;    APPLICANT:  RUIMY Raymond
;    TITLE OF INVENTION:  NUCLEOTIDE FRAGMENT OF THE 16S RIBOSOMAL RNA OF CORYNEBACTERI
;    NUMBER OF SEQUENCES:  92
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Oliff & Berridge
;      STREET:  700 South Washington Street, Suite 300
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  U.S.A.
;      ZIP:  22314
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IMB PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release  # 1.0, version  # 1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/641,291A
;      FILING DATE:  30-APR-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Berridge, William P.
;      REGISTRATION NUMBER:  30,024
;      REFERENCE/DOCKET NUMBER:  WPB 38273
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-836-6400
;      TELEFAX:  703-836-2787
;  INFORMATION FOR SEQ ID NO:  57:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleotide
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  rRNA
US-08-641-291A-57

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1856 AGACCCACACACTTA 1870
              ||||||  ||||| ||
Db         15 AGACCCTCACACCTA 1


RESULT 391
US-09-071-845-124
; Sequence 124, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
```

```
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  124:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-124

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   80.0%;  Pred. No. 3.5e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGAA 1617
              || ||| :|||||||
Db          1 CCAGGCUUGGGGGAA 15


RESULT 392
US-09-121-286-18/c
; Sequence 18, Application US/09121286
; Patent No. 6146848
; GENERAL INFORMATION:
;  APPLICANT: WONG, Wan K
;  APPLICANT: LAM, Kat H
;  TITLE OF INVENTION: Bacterial Expression System
;  FILE REFERENCE: M98/0273/US
;  CURRENT APPLICATION NUMBER: US/09/121,286
;  CURRENT FILING DATE: 1998-07-23
;  NUMBER OF SEQ ID NOS: 21
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:stop codon
US-09-121-286-18

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db         15 CTTAATTAATTAAGC 1


RESULT 393
US-09-038-073-609
; Sequence 609, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  609:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-609

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 394
US-09-038-073-610
```

```
; Sequence 610, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  610:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-610

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 395
US-09-038-073-611
; Sequence 611, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  611:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-611

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 396
US-09-038-073-612
; Sequence 612, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
```

```
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  612:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-612

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   33.3%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    8;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              :|::| : |:::|:|
Db          1 UCUUACUAGUUUCUC 15


RESULT 397
US-09-180-437-143/c
; Sequence 143, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
;  APPLICANT: FUKUSAKO, Shioji
;  APPLICANT: MORISAWA, Yoshifumi
;  APPLICANT: KUSUYAMA, Takeshi
;  TITLE OF INVENTION: Antisense Compounds to CD14
;  FILE REFERENCE: 1110-209P
;  CURRENT APPLICATION NUMBER: US/09/180,437
;  CURRENT FILING DATE: 1998-11-06
;  EARLIER APPLICATION NUMBER: PCT/JP98/00953
;  EARLIER FILING DATE: 1998-03-09
;  EARLIER APPLICATION NUMBER: 09-053518 JAPAN
;  EARLIER FILING DATE: 1997-03-07
;  NUMBER OF SEQ ID NOS: 289
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 143
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:other nucleic
;   OTHER INFORMATION: acid
US-09-180-437-143

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACT 1564
              |||||  ||||||||
Db         15 GGAAGCCACAGGACT 1


RESULT 398
US-09-397-992A-28
; Sequence 28, Application US/09397992A
; Patent No. 6329175
; GENERAL INFORMATION:
;  APPLICANT: Conklin, Darrell
;  APPLICANT:  Grant, Francis J.
;  APPLICANT:  Rixon, Mark W.
;  APPLICANT:  Kindsvogel, Wayne
;  TITLE OF INVENTION: Interferon-epsilon
;  FILE REFERENCE: 98-46
;  CURRENT APPLICATION NUMBER: US/09/397,992A
;  CURRENT FILING DATE:  1999-09-16
;  PRIOR APPLICATION NUMBER: 60/101,012
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/118,578
;  PRIOR FILING DATE: 1999-02-05
;  PRIOR APPLICATION NUMBER: 60/142,766
;  PRIOR FILING DATE: 1999-07-08
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 28
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Mutated coding sequence.
US-09-397-992A-28

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1857 GACCCACACACTTAG 1871
              |||||| || |||||
Db          1 GACCCAGACCCTTAG 15


RESULT 399
US-09-971-843-28
; Sequence 28, Application US/09971843
; Patent No. 6544505
; GENERAL INFORMATION:
;  APPLICANT: Conklin, Darrell C.
;  APPLICANT:  Grant, Francis J.
;  APPLICANT:  Rixon, Mark W.
;  APPLICANT:  Kindsvogel, Wayne
;  TITLE OF INVENTION: Interferon-epsilon
;  FILE REFERENCE: 98-46D1
;  CURRENT APPLICATION NUMBER: US/09/971,843
;  CURRENT FILING DATE:  2001-10-04
;  PRIOR APPLICATION NUMBER: 60/101,012
;  PRIOR FILING DATE: 1998-09-18
;  PRIOR APPLICATION NUMBER: 60/118,578
;  PRIOR FILING DATE: 1999-02-05
;  PRIOR APPLICATION NUMBER: 60/142,766
;  PRIOR FILING DATE: 1999-07-08
;  PRIOR APPLICATION NUMBER: 09/397,992
;  PRIOR FILING DATE: 1999-09-16
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 28
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Mutated coding sequence.
US-09-971-843-28

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1857 GACCCACACACTTAG 1871
              |||||| || |||||
Db          1 GACCCAGACCCTTAG 15


RESULT 400
US-08-061-697-23/c
; Sequence 23, Application US/08061697
; Patent No. 5498696
;  GENERAL INFORMATION:
;    APPLICANT:  Brown, Michael S.; Briggs, Michael R.; Wang,
;    APPLICANT:  Xiaodong; Goldstein, Joseph L.
;    TITLE OF INVENTION:  Sterol Regulatory Element Binding Proteins
;    TITLE OF INVENTION:  and Their Use in Screening Assays
```

```
;    NUMBER OF SEQUENCES:  36
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P. O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  USA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/061,697
;      FILING DATE:  Concurrently Herewith
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTSD:347/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 320-7200
;      TELEFAX:  (512) 474-7577
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-061-697-23

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db         15 CAGGGGGAGGAGTTT 1


RESULT 401
US-08-131-365B-23/c
; Sequence 23, Application US/08131365B
; Patent No. 5527690
;  GENERAL INFORMATION:
;    APPLICANT:  Brown, Michael S.
;    APPLICANT:  Briggs, Michael R.
;    APPLICANT:  Wang, Xiaodong
;    APPLICANT:  Goldstein, Joseph L.
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS RELATING
;    TITLE OF INVENTION:  TO STEROL REGULATORY ELEMENT BINDING
;    TITLE OF INVENTION:  PROTEINS
;    NUMBER OF SEQUENCES:  64
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  U.S.A.
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/131,365B
;      FILING DATE:  01-OCT-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTSD:372/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (512) 474-7577
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-131-365B-23

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db         15 CAGGGGGAGGAGTTT 1


RESULT 402
US-08-486-721A-21
; Sequence 21, Application US/08486721A
; Patent No. 5739025
;  GENERAL INFORMATION:
;    APPLICANT:  Fukazawa, Chikafusa
;    TITLE OF INVENTION:  Method of Producing
;    TITLE OF INVENTION:  Asparaginyl Endoprotease
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Frishauf, Holtz, Goodman, Langer & Chick
;      STREET:  767 Third Avenue
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10017-2023
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3+ inch, 1.4 mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  MS DOS
;      SOFTWARE:  ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,721A
;      FILING DATE:  7-JUNE-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/091,991
;      FILING DATE:  12-JULY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Barth, Richard S.
;      REGISTRATION NUMBER:  28,180
;      REFERENCE/DOCKET NUMBER:  930587/HG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 319-4900
;      TELEFAX:  (212) 319-5101
;      TELEX:  236268
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-486-721A-21

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
```

```
                  ||| ||| |||||||
Db          2 CTTAATTAATTAAGC 16


RESULT 403
US-08-486-721A-21/c
; Sequence 21, Application US/08486721A
; Patent No. 5739025
;  GENERAL INFORMATION:
;    APPLICANT:  Fukazawa, Chikafusa
;    TITLE OF INVENTION:  Method of Producing
;    TITLE OF INVENTION:  Asparaginyl Endoprotease
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Frishauf, Holtz, Goodman, Langer & Chick
;      STREET:  767 Third Avenue
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10017-2023
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3+ inch, 1.4 mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  MS DOS
;      SOFTWARE:  ASCII
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/486,721A
;      FILING DATE:  7-JUNE-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/091,991
;      FILING DATE:  12-JULY-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Barth, Richard S.
;      REGISTRATION NUMBER:  28,180
;      REFERENCE/DOCKET NUMBER:  930587/HG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 319-4900
;      TELEFAX:  (212) 319-5101
;      TELEX:  236268
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-486-721A-21

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
                  ||| ||| |||||||
Db         15 CTTAATTAATTAAGC 1


RESULT 404
US-08-753-147-151/c
; Sequence 151, Application US/08753147
; Patent No. 5770372
;  GENERAL INFORMATION:
;    APPLICANT:  Concannon, Patrick
;    TITLE OF INVENTION:  Detection of Mutations in the Human ATM Gene
;    NUMBER OF SEQUENCES:  196
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson and Kindness
;      STREET:  1420 5th Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/753,147
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  VMRC-1-9714
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 743-4387
;      TELEFAX:  (206) 224 0779
;  INFORMATION FOR SEQ ID NO:  151:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapiens
US-08-753-147-151

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAA 1980
                  ||||||||||  ||
Db         15 AATATTTACCTGTAA 1


RESULT 405
US-08-294-424-1/c
; Sequence 1, Application US/08294424
; Patent No. 5800984
;  GENERAL INFORMATION:
;    APPLICANT:  Vary, Calvin
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCE DETECTION BY
;    TITLE OF INVENTION:  TRIPLE HELIX FORMATION
;    NUMBER OF SEQUENCES:  49
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM PS/2 Model 50Z or 55SX
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 3.30)
;      SOFTWARE:  WordPerfect (Version 5.0)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/294,424
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/000,922
;      FILING DATE:  16 JAN 1993
;      APPLICATION NUMBER:  US/07/629,601B
;      FILING DATE:  17-DEC-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Freeman, John W.
;      REGISTRATION NUMBER:  29,066
;      REFERENCE/DOCKET NUMBER:  00088-037001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
```

```
;      TELEFAX:  (617) 542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  1 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-294-424-1

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTC 1800
                | | ||||||||||||
Db         16 CTCCTTCTTTCCTTC 2


RESULT 406
US-08-294-424-2
; Sequence 2, Application US/08294424
; Patent No. 5800984
;  GENERAL INFORMATION:
;    APPLICANT:  Vary, Calvin
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCE DETECTION BY
;    TITLE OF INVENTION:  TRIPLE HELIX FORMATION
;    NUMBER OF SEQUENCES:  49
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM PS/2 Model 50Z or 55SX
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 3.30)
;      SOFTWARE:  WordPerfect (Version 5.0)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/294,424
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/000,922
;      FILING DATE:  16 JAN 1993
;      APPLICATION NUMBER:  US/07/629,601B
;      FILING DATE:  17-DEC-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Freeman, John W.
;      REGISTRATION NUMBER:  29,066
;      REFERENCE/DOCKET NUMBER:  00088-037001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
;      TELEFAX:  (617) 542-8906
;      TELEX:  200154
;  INFORMATION FOR SEQ ID NO:  2 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-294-424-2

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTC 1800
                | | ||||||||||||
Db          1 CTCCTTCTTTCCTTC 15


RESULT 407
US-08-148-058A-37
; Sequence 37, Application US/08148058A
; Patent No. 5804407
;  GENERAL INFORMATION:
;    APPLICANT:  TAMAOKI, TAIKI
;    APPLICANT:  NAKABAYASHI, HIDEKAZU
;    TITLE OF INVENTION:  IMPROVED METHOD OF EXPRESSING GENES IN
;    TITLE OF INVENTION:  MAMMALIAN CELLS
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BURNS, DOANE, SWECKER & MATHIS
;      STREET:  699 PRINCE STREET
;      CITY:  ALEXANDRIA
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22313-1404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/148,058A
;      FILING DATE:  04-NOV-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MOOI, LESLIE A.
;      REGISTRATION NUMBER:  37,047
;      REFERENCE/DOCKET NUMBER:  028722-074
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-854-7400
;      TELEFAX:  415-854-8275
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-148-058A-37

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
                || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 408
US-08-478-042-37
; Sequence 37, Application US/08478042
; Patent No. 5807738
;  GENERAL INFORMATION:
;    APPLICANT:  TAMAOKI, TAIKI
;    APPLICANT:  NAKABAYASHI, HIDEKAZU
;    TITLE OF INVENTION:  IMPROVED METHOD OF EXPRESSING GENES IN
;    TITLE OF INVENTION:  MAMMALIAN CELLS
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BURNS, DOANE, SWECKER & MATHIS
;      STREET:  699 PRINCE STREET
;      CITY:  ALEXANDRIA
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22313-1404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/478,042
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/148,058
;      FILING DATE:  04-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MOOI, LESLIE A.
;      REGISTRATION NUMBER:  37,047
;      REFERENCE/DOCKET NUMBER:  028722-126
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-854-7400
;      TELEFAX:  415-854-8275
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-478-042-37

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
              || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 409
US-08-645-215-37
; Sequence 37, Application US/08645215
; Patent No. 5827686
;  GENERAL INFORMATION:
;    APPLICANT:  TAMAOKI, TAIKI
;    APPLICANT:  NAKABAYASHI, HIDEKAZU
;    TITLE OF INVENTION:  IMPROVED METHOD OF EXPRESSING GENES IN
;    TITLE OF INVENTION:  MAMMALIAN CELLS
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BURNS, DOANE, SWECKER & MATHIS, L.L.P.
;      STREET:  699 PRINCE STREET
;      CITY:  ALEXANDRIA
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22313-1404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/645,215
;      FILING DATE:  13-MAY-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/148,058
;      FILING DATE:  04-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MOOI, LESLIE A.
;      REGISTRATION NUMBER:  37,047
;      REFERENCE/DOCKET NUMBER:  028722-135
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-854-7400
;      TELEFAX:  415-854-8275
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-645-215-37

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
              || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 410
US-08-466-604-37
; Sequence 37, Application US/08466604
; Patent No. 5843776
;  GENERAL INFORMATION:
;    APPLICANT:  TAMAOKI, TAIKI
;    APPLICANT:  NAKABAYASHI, HIDEKAZU
;    TITLE OF INVENTION:  IMPROVED METHOD OF EXPRESSING GENES IN
;    TITLE OF INVENTION:  MAMMALIAN CELLS
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BURNS, DOANE, SWECKER & MATHIS
;      STREET:  699 PRINCE STREET
;      CITY:  ALEXANDRIA
;      STATE:  VA
;      COUNTRY:  USA
;      ZIP:  22313-1404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/466,604
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/148,058
;      FILING DATE:  04-NOV-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MOOI, LESLIE A.
;      REGISTRATION NUMBER:  37,047
;      REFERENCE/DOCKET NUMBER:  028722-125
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-854-7400
;      TELEFAX:  415-854-8275
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-466-604-37

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
              || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 411
US-08-668-123-23/c
; Sequence 23, Application US/08668123
; Patent No. 5891631
;  GENERAL INFORMATION:
;    APPLICANT:  Brown, Michael S.
;    APPLICANT:  Briggs, Michael R.
;    APPLICANT:  Wang, Xiaodong
;    APPLICANT:  Goldstein, Joseph L.
```

```
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS RELATING
;    TITLE OF INVENTION:  TO STEROL REGULATORY ELEMENT BINDING
;    TITLE OF INVENTION:  PROTEINS
;    NUMBER OF SEQUENCES:  64
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  Texas
;      COUNTRY:  U.S.A.
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/668,123
;      FILING DATE:  14-JUN-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/131,365
;      FILING DATE:  01-OCT-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  UTSD:372/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (512) 474-7577
;  INFORMATION FOR SEQ ID NO:  23:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "DNA"
US-08-668-123-23

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
             | |||||| ||||||
Db         15 CAGGGGGAGGAGTTT 1


RESULT 412
US-09-509-565-35
; Sequence 35, Application US/09509565
; Patent No. 6399340
; GENERAL INFORMATION:
;  APPLICANT: SAITO, YOSHIMASA
;  APPLICANT:  NOGUCHI, YUJI
;  APPLICANT:  YOSHIKAWA, KOJI
;  APPLICANT:  SOEDA, SHINSUKE
;  TITLE OF INVENTION: PLASMID VECTORS
;  FILE REFERENCE: 0018-1105-0PCT
;  CURRENT APPLICATION NUMBER: US/09/509,565
;  CURRENT FILING DATE:  2000-06-23
;  PRIOR APPLICATION NUMBER: PCT/JP9804611
;  PRIOR FILING DATE: 1998-10-13
;  PRIOR APPLICATION NUMBER: JP9/303395
;  PRIOR FILING DATE: 1997-10-16
;  NUMBER OF SEQ ID NOS: 42
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 35
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: Description of Artificial Sequence: synthetic DNA
US-09-509-565-35

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1532 GAAAGGTTAGGAGAG 1546
             ||| |||| ||||||
Db          1 GAACGGTTCGGAGAG 15


RESULT 413
US-09-043-816E-34
; Sequence 34, Application US/09043816E
; Patent No. 6414128
; GENERAL INFORMATION:
;  APPLICANT: Hilton, Douglas J.
;  APPLICANT:  Willson, Tracy
;  APPLICANT:  Nicola, Nicos A.
;  APPLICANT:  Gainsford, Timothy
;  APPLICANT:  Alexander, Warren S.
;  APPLICANT:  Metcalf, Donald
;  APPLICANT:  Ng, Ashley
;  TITLE OF INVENTION: A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES
;  TITLE OF INVENTION:  ENCODING SAME
;  FILE REFERENCE: 11268
;  CURRENT APPLICATION NUMBER: US/09/043,816E
;  CURRENT FILING DATE:  1998-09-17
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 34
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic
US-09-043-816E-34

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTG 1895
             | |||||| ||||||
Db          1 TTTCAAATAGATGTG 15


RESULT 414
US-08-483-941-6
; Sequence 6, Application US/08483941
; Patent No. 6555370
;  GENERAL INFORMATION:
;    APPLICANT:  LUPTON, STEPHEN D.
;    TITLE OF INVENTION:  BIFUNCTIONAL SELECTABLE FUSION GENES
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 Page Mill Road
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94304-1018
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/483,941
;      FILING DATE:
;      CLASSIFICATION:  435
```

```
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/066,388
;       FILING DATE:
;       APPLICATION NUMBER:  US 07/791,932
;       FILING DATE:  12-NOV-1991
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  LUTHER, BARBARA J.
;       REGISTRATION NUMBER:  33,954
;       REFERENCE/DOCKET NUMBER:  22627-20003.21
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 813-5600
;       TELEFAX:  (415) 494-0792
;       TELEX:  706141
;   INFORMATION FOR SEQ ID NO:  6:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-483-941-6

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
                ||| ||| |||||||
Db          2 CTTAATTAATTAAGC 16


RESULT 415
US-08-483-941-6/c
; Sequence 6, Application US/08483941
; Patent No. 6555370
;  GENERAL INFORMATION:
;    APPLICANT:  LUPTON, STEPHEN D.
;    TITLE OF INVENTION:  BIFUNCTIONAL SELECTABLE FUSION GENES
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 Page Mill Road
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94304-1018
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/483,941
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/066,388
;      FILING DATE:
;      APPLICATION NUMBER:  US 07/791,932
;      FILING DATE:  12-NOV-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LUTHER, BARBARA J.
;      REGISTRATION NUMBER:  33,954
;      REFERENCE/DOCKET NUMBER:  22627-20003.21
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 813-5600
;      TELEFAX:  (415) 494-0792
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-483-941-6

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
                ||| ||| |||||||
Db          15 CTTAATTAATTAAGC 1


RESULT 416
US-08-845-381E-13
; Sequence 13, Application US/08845381E
; Patent No. 6602681
;  GENERAL INFORMATION:
;    APPLICANT:  OHSUYE, Kazuhiro
;    APPLICANT:  KITANO, Katsuhiko
;    APPLICANT:  TANAKA, Shoji
;    APPLICANT:  MATSUO, Hisayuki
;    APPLICANT:  MIZUNO, Kensaku
;    TITLE OF INVENTION:  RECOMBINANT C-TERMINAL ALPHA-AMIDATING
;    TITLE OF INVENTION:  ENZYME
;    NUMBER OF SEQUENCES:  77
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BURNS, DOANE, SWECKER & MATHIS, L.L.P.
;      STREET:  1737 King Street, Suite 500
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  United States
;      ZIP:  22314-2756
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/845,381E
;      FILING DATE:  25-APR-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 62177184
;      FILING DATE:  17-JUL-1987
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 62306867
;      FILING DATE:  05-DEC-1987
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/219,375
;      FILING DATE:  15-JUL-1988
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/509,583
;      FILING DATE:  16-APR-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dadio, Susan M.
;      REGISTRATION NUMBER:  40,373
;      REFERENCE/DOCKET NUMBER:  001560-296
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 836-6620
;      TELEFAX:  (703) 836-2021
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-845-381E-13

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
```

```
              ||| ||| |||||||
Db          1 CTTAATTAATTAAGC 15


RESULT 417
US-08-845-381E-70
; Sequence 70, Application US/08845381E
; Patent No. 6602681
;  GENERAL INFORMATION:
;    APPLICANT:  OHSUYE, Kazuhiro
;    APPLICANT:  KITANO, Katsuhiko
;    APPLICANT:  TANAKA, Shoji
;    APPLICANT:  MATSUO, Hisayuki
;    APPLICANT:  MIZUNO, Kensaku
;    TITLE OF INVENTION:  RECOMBINANT C-TERMINAL ALPHA-AMIDATING
;    TITLE OF INVENTION:  ENZYME
;    NUMBER OF SEQUENCES:  77
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  BURNS, DOANE, SWECKER & MATHIS, L.L.P.
;      STREET:  1737 King Street, Suite 500
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  United States
;      ZIP:  22314-2756
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/845,381E
;      FILING DATE:  25-APR-1997
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 62177184
;      FILING DATE:  17-JUL-1987
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  JP 62306867
;      FILING DATE:  05-DEC-1987
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/219,375
;      FILING DATE:  15-JUL-1988
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/509,583
;      FILING DATE:  16-APR-1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dadio, Susan M.
;      REGISTRATION NUMBER:  40,373
;      REFERENCE/DOCKET NUMBER:  001560-296
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 836-6620
;      TELEFAX:  (703) 836-2021
;  INFORMATION FOR SEQ ID NO:  70:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-845-381E-70

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db          1 CTTAATTAATTAAGC 15


RESULT 418
US-09-479-005A-256
; Sequence 256, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 256
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-256

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   46.7%;  Pred. No. 3.7e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
              :: |::||: ||||:
Db          2 UUAAUUCAUGAAGCU 16


RESULT 419
PCT-US91-08442-3
; Sequence 3, Application PC/TUS9108442
;  GENERAL INFORMATION:
;    APPLICANT:  Lupton, Stephen D.
;    TITLE OF INVENTION:  Bifunctional Selectable Fusion Genes
;    NUMBER OF SEQUENCES:  3
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Immunex Corporation
;      STREET:  51 University Street
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/08442
;      FILING DATE:  19911112
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wight, Christopher L.
;      REGISTRATION NUMBER:  31,680
;      REFERENCE/DOCKET NUMBER:  2702-WO
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206)587-0430
;      TELEFAX:  (206)587-0606
;      TELEX:  756822
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
;    IMMEDIATE SOURCE:
;      CLONE:  oligonucleotide
```

```
PCT-US91-08442-3

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db          2 CTTAATTAATTAAGC 16


RESULT 420
PCT-US91-08442-3/c
; Sequence 3, Application PC/TUS9108442
;  GENERAL INFORMATION:
;    APPLICANT:  Lupton, Stephen D.
;    TITLE OF INVENTION:  Bifunctional Selectable Fusion Genes
;    NUMBER OF SEQUENCES:  3
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Immunex Corporation
;      STREET:  51 University Street
;      CITY:  Seattle
;      STATE:  WA
;      COUNTRY:  USA
;      ZIP:  98101
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/08442
;      FILING DATE:  19911112
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wight, Christopher L.
;      REGISTRATION NUMBER:  31,680
;      REFERENCE/DOCKET NUMBER:  2702-WO
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206)587-0430
;      TELEFAX:  (206)587-0606
;      TELEX:  756822
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FRAGMENT TYPE:  internal
;    IMMEDIATE SOURCE:
;      CLONE:  oligonucleotide
PCT-US91-08442-3

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db         15 CTTAATTAATTAAGC 1


RESULT 421
5256545-4/c
;Patent No. 5256545
;    APPLICANT: BROWN, MICHAEL S.;GOLDSTEIN, JOSEPH L.;RUSSELL,
;DAVID W.;SUDHOF, THOMAS C.
;    TITLE OF INVENTION: STEROL REGULATORY ELEMENTS
;    NUMBER OF SEQUENCES: 42
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/425,852
;      FILING DATE: 20-OCT-1989
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER: 33,330
;      FILING DATE: 30-MAR-1987
;      APPLICATION NUMBER: 33,081
;      FILING DATE: 30-MAR-1987
;SEQ ID NO:4:
;      LENGTH: 16
5256545-4

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db         15 CAGGGGGAGGAGTTT 1


RESULT 422
5256545-33
;Patent No. 5256545
;    APPLICANT: BROWN, MICHAEL S.;GOLDSTEIN, JOSEPH L.;RUSSELL,
;DAVID W.;SUDHOF, THOMAS C.
;    TITLE OF INVENTION: STEROL REGULATORY ELEMENTS
;    NUMBER OF SEQUENCES: 42
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/425,852
;      FILING DATE: 20-OCT-1989
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER: 33,330
;      FILING DATE: 30-MAR-1987
;      APPLICATION NUMBER: 33,081
;      FILING DATE: 30-MAR-1987
;SEQ ID NO:33:
;      LENGTH: 16
5256545-33

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db          2 CAGGGGGAGGAGTTT 16


RESULT 423
5312912-9
;Patent No. 5312912
;    APPLICANT: HADWIGER, LEE A.;CHIANG, CHIN C.;HOROVITZ,
;DANIEL A.
;    TITLE OF INVENTION: PROCEDURES AND REGULATORY DNA SEQUENCES
;FOR GENETICALLY ENGINEERING DISEASE RESISTANCE AND OTHER
;INDUCIBLE TRAITS IN PLANTS
;    NUMBER OF SEQUENCES: 9
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/393,301
;      FILING DATE: 13-JUN-1989
;SEQ ID NO:9:
;      LENGTH: 16
5312912-9

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1868 TTAGCCATTGAAATG 1882
              | | ||||||||||||
Db          2 TAAACCATTGAAATG 16
```

```
RESULT 424
US-08-272-372-3
; Sequence 3, Application US/08272372
; Patent No. 5512439
;  GENERAL INFORMATION:
;    APPLICANT:  HORNES, Erik
;    APPLICANT:  KORSNES, Lars
;    TITLE OF INVENTION:  NUCLEIC ACID PROBES
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  1800 Diagonal Road, Suite 500
;      CITY:  Alexandria
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22313-0299
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/272,372
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/688,484
;      FILING DATE:  14-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  BENT, Stephen A.
;      REGISTRATION NUMBER:  29,768
;      REFERENCE/DOCKET NUMBER:  16787/148 DFBC
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703)836-9300
;      TELEFAX:  (703)683-4109
;      TELEX:  899149
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Synthetic DNA oligonucleotide
US-08-272-372-3

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1555 GAACAGGACTGCAAA 1569
              |||  ||||||||||
Db          2 GAATTGGACTGCAAA 16


RESULT 425
US-08-390-850-709/c
; Sequence 709, Application US/08390850
; Patent No. 5612215
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/390,850
;      FILING DATE:  February 17, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5612215ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  709:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-390-850-709

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1754 CTCTTTATTCATTAA 1768
              ||||||||| | |||
Db         17 CTCTTTATTAAATAA 3


RESULT 426
US-08-373-124A-516
; Sequence 516, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
```

```
;       FILING DATE:  January 13, 1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  516:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-373-124A-516

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCC 1788
              : ::::: |||||||
Db          3 UGUUUUUAGAACCCC 17


RESULT 427
US-08-373-124A-2179/c
; Sequence 2179, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2179:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-2179

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAA 1990
              |||| |||| |||||
Db         15 TTGACAAAAGGAAAA 1


RESULT 428
US-08-435-634-709/c
; Sequence 709, Application US/08435634
; Patent No. 5731295
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,634
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/390,850
;      FILING DATE:  February 17, 1995
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5731295ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
```

```
;       TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  709:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-435-634-709

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1754 CTCTTTATTCATTAA 1768
              ||||||||| | |||
Db         17 CTCTTTATTAAATAA 3


RESULT 429
US-08-758-306-1001/c
; Sequence 1001, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1001:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-1001

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2065 ATAAGTGGTATCTGA 2079
              ||||| || ||||||
Db         17 ATAAGAGGGATCTGA 3


RESULT 430
US-08-435-628-516
; Sequence 516, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  516:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-516

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCC 1788
              : ::::: |||||||
Db          3 UGUUUUUAGAACCCC 17


RESULT 431
US-08-435-628-2179/c
```

```
; Sequence 2179, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2179:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2179

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAA 1990
                |||| |||| |||||
Db         15 TTGACAAAAGGAAAA 1

RESULT 432
US-08-292-620A-1931/c
; Sequence 1931, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1931:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1931

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCA 2036
                || ||| ||||||||
Db         15 CTGTGGGAGGAGGCA 1

RESULT 433
US-08-985-162-129/c
; Sequence 129, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
```

```
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSEQ for Windows 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/985,162
;       FILING DATE:  04 December 1997
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/036,476
;       FILING DATE:  31 January 1997
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  230/107
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213)  955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  129:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-985-162-129

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
                ||| |||||||| ||
Db         16 TCACCAATACCTATT 2


RESULT 434
US-08-985-162-747
; Sequence 747, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  747:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-747

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
                | ||||:: :::||:
Db          2 AGCCCAUUUUUUCCU 16


RESULT 435
US-08-985-162-748
; Sequence 748, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  748:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-748

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | ||||:: :::||:
Db          1 AGCCCAUUUUUUCCU 15


RESULT 436
US-09-071-845-1931/c
; Sequence 1931, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1931:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1931

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCA 2036
              || ||| ||||||||
Db         15 CTGTGGGAGGAGGCA 1


RESULT 437
US-08-584-040-1770
; Sequence 1770, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1770:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-1770

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 3.9e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAA 1985
              ::| |::| ||||||
Db          3 UUAACUUGGAAAAAA 17


RESULT 438
US-08-584-040-2066
; Sequence 2066, Application US/08584040
```

```
; Patent No. 6346398
; GENERAL INFORMATION:
;   APPLICANT: Pavco, Pamela
;   APPLICANT: McSwiggen, James
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Escobedo, Jaime
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: TREATMENT OF DISEASES OR
;   TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;   TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;   TITLE OF INVENTION: GROWTH FACTOR
;   NUMBER OF SEQUENCES: 8502
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: Word Perfect 5.1
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/584,040
;     FILING DATE: January 11, 1996
;     CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 60/005,974
;     FILING DATE: October 26, 1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard J.
;     REGISTRATION NUMBER: 32,327
;     REFERENCE/DOCKET NUMBER: 218/064
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (213) 489-1600
;     TELEFAX: (213) 955-0440
;     TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2066:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 17 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
US-08-584-040-2066

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              :| : ||::|:|:||
Db          1 UCCUGCCUUCUCUGA 15


RESULT 439
US-08-584-040-2205/c
; Sequence 2205, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
;   APPLICANT: Pavco, Pamela
;   APPLICANT: McSwiggen, James
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Escobedo, Jaime
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: TREATMENT OF DISEASES OR
;   TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;   TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;   TITLE OF INVENTION: GROWTH FACTOR
;   NUMBER OF SEQUENCES: 8502
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: Word Perfect 5.1
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/584,040
;     FILING DATE: January 11, 1996
;     CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 60/005,974
;     FILING DATE: October 26, 1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard J.
;     REGISTRATION NUMBER: 32,327
;     REFERENCE/DOCKET NUMBER: 218/064
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (213) 489-1600
;     TELEFAX: (213) 955-0440
;     TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2205:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 17 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
US-08-584-040-2205

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGA 1706
              |||||||| | ||||
Db         15 TTTCTCTAACACTGA 1


RESULT 440
US-08-584-040-2232/c
; Sequence 2232, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
;   APPLICANT: Pavco, Pamela
;   APPLICANT: McSwiggen, James
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Escobedo, Jaime
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: TREATMENT OF DISEASES OR
;   TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;   TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;   TITLE OF INVENTION: GROWTH FACTOR
;   NUMBER OF SEQUENCES: 8502
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
```

```
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2232:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2232

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCA 1885
              |||| ||||||| ||
Db         17 GCCACTGAAATGGCA 3


RESULT 441
US-08-584-040-2617/c
; Sequence 2617, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2617:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2617

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAG 1769
              ||||| | |||||||
Db         15 TCTTTCTACATTAAG 1


RESULT 442
US-08-584-040-5376/c
; Sequence 5376, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5376:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5376
```

```
  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| ||||||| |||
Db         16 TCACCAATACCCTTT 2


RESULT 443
US-08-584-040-6031/c
; Sequence 6031, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  6031:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-6031

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAAC 1558
              |||| |||||||||
Db         17 GAGTCCGGAAGGAAC 3


RESULT 444
US-08-584-040-7398/c
; Sequence 7398, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7398:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7398

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTT 1652
              | |||||| ||||||
Db         15 TTTTTAAATAGCCTT 1


RESULT 445
US-08-584-040-7743
; Sequence 7743, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
```

```
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7743:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7743

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 3.9e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCC 1897
              :||||:: |:| |||
Db          2 UCAAAUUCAUGAGCC 16


RESULT 446
US-09-573-377-4/c
; Sequence 4, Application US/09573377
; Patent No. 6379892
; GENERAL INFORMATION:
;  APPLICANT:  Kacena, Katherine
;  TITLE OF INVENTION:  METHODS, KITS AND COMPOSITIONS OF MATTER USEFUL FOR
;  TITLE OF INVENTION:  DETERMINING CHLAMYDIA PNEUMONIAE
;  FILE REFERENCE:  2283-115B
;  CURRENT APPLICATION NUMBER: US/09/573,377
;  CURRENT FILING DATE:  2000-05-18
;  NUMBER OF SEQ ID NOS:  16
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-573-377-4

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGA 1545
              |||||| | ||||||
Db         15 AGAAAGTTAAGGAGA 1


RESULT 447
US-09-573-377-14/c
; Sequence 14, Application US/09573377
; Patent No. 6379892
; GENERAL INFORMATION:
;  APPLICANT:  Kacena, Katherine
;  TITLE OF INVENTION:  METHODS, KITS AND COMPOSITIONS OF MATTER USEFUL FOR
;  TITLE OF INVENTION:  DETERMINING CHLAMYDIA PNEUMONIAE
;  FILE REFERENCE:  2283-115B
;  CURRENT APPLICATION NUMBER: US/09/573,377
;  CURRENT FILING DATE:  2000-05-18
;  NUMBER OF SEQ ID NOS:  16
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 14
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Chlamydia pneumoniae
US-09-573-377-14

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGA 1545
              |||||| | ||||||
Db         15 AGAAAGTTAAGGAGA 1


RESULT 448
US-09-371-772B-315
; Sequence 315, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 315
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-315

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 3.9e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAA 1985
              ::| |::| ||||||
Db          3 UUAACUUGGAAAAAA 17


RESULT 449
US-09-371-772B-611
; Sequence 611, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
```

```
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 611
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-611

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              :| : ||::|:|:||
Db          1 UCCUGCCUUCUCUGA 15


RESULT 450
US-09-371-772B-750/c
; Sequence 750, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 750
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-750

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGA 1706
              ||||||||  | ||||
Db         15 TTTCTCTAACACTGA 1


RESULT 451
US-09-371-772B-777/c
; Sequence 777, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 777
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-777

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCA 1885
              ||||  ||||||| ||
Db         17 GCCACTGAAATGGCA 3


RESULT 452
US-09-371-772B-1141/c
; Sequence 1141, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1141
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1141

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAG 1769
              |||||  | |||||||
Db         15 TCTTTCTACATTAAG 1


RESULT 453
US-09-371-772B-2276/c
; Sequence 2276, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
```

```
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2276
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2276

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| ||||||| |||
Db         16 TCACCAATACCCTTT 2


RESULT 454
US-09-371-772B-2868/c
; Sequence 2868, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2868
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2868

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAAC 1558
              ||||  |||||||||
Db         17 GAGTCCGGAAGGAAC 3


RESULT 455
US-09-371-772B-3206/c
; Sequence 3206, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3206
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3206

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTT 1652
              | ||||||  ||||||
Db         15 TTTTTAAATAGCCTT 1


RESULT 456
US-09-371-772B-3528
; Sequence 3528, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3528
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3528

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   60.0%;  Pred. No. 3.9e+02;
  Matches    9;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCC 1897
              :|||:: |:| |||
Db          2 UCAAAUUCAUGAGCC 16


RESULT 457
US-09-371-772B-4920
; Sequence 4920, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
```

```
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4920
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4920

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              :| : ||::|:|:||
Db          2 UCCUGCCUUCUCUGA 16


RESULT 458
US-09-371-772B-5162/c
; Sequence 5162, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5162
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5162

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTC 1884
              ||||| ||||||| |
Db         15 AGCCACTGAAATGGC 1


RESULT 459
US-09-371-772B-6409
; Sequence 6409, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6409
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6409

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 3.9e+02;
  Matches   11;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGT 1994
              |||||| |||| :|:
Db          2 AAAAAACAAAACUGU 16


RESULT 460
US-09-401-063-129/c
; Sequence 129, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  129:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
```

```
;      TOPOLOGY:  linear
US-09-401-063-129

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| |||||||| || .
Db         16 TCACCAATACCTATT 2


RESULT 461
US-09-401-063-747
; Sequence 747, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  747:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-747

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | ||||:: :::||:
Db          2 AGCCCAUUUUUUCCU 16


RESULT 462
US-09-401-063-748
; Sequence 748, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  748:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-748

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   46.7%;  Pred. No. 3.9e+02;
  Matches    7;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | ||||:: :::||:
Db          1 AGCCCAUUUUUUCCU 15


RESULT 463
US-09-827-998-310
; Sequence 310, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
```

```
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 310
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-310

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGG 1561
              ||||||||||| | |
Db          3 TAGGGAAGGAAGAAG 17


RESULT 464
US-09-827-998-313
; Sequence 313, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 313
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-313

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              |||||||||| | ||
Db          1 AGGGAAGGAAGAAGA 15


RESULT 465
US-09-866-108A-1344/c
; Sequence 1344, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1344
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1344

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCT 1801
              ||||  |||||||||
Db         17 CCATCTTTTCCTTCT 3


RESULT 466
US-09-866-108A-1348/c
; Sequence 1348, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1348
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1348

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTT 1799
              ||||||  |||||||
Db         15 CCCCATCTTTTCCTT 1


RESULT 467
US-09-866-108A-1579/c
; Sequence 1579, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1579
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1579

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1572 TCCTTCTCCACCGCA 1586
              ||||||||||  |||
Db         17 TCCTTCTCCAGAGCA 3


RESULT 468
US-09-866-108A-1582/c
; Sequence 1582, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1582
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1582

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGC 1585
              ||||||||||  ||
Db         15 ATCCTTCTCCAGAGC 1


RESULT 469
US-09-866-108A-1700
; Sequence 1700, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
```

```
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1700
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1700

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
              ||||| |||||| ||
Db          3 TGGTATGAGGCAGAG 17


RESULT 470
US-09-866-108A-1701
; Sequence 1701, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1701
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1701

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
              ||||| |||||| ||
Db          2 TGGTATGAGGCAGAG 16


RESULT 471
US-09-866-108A-1702
; Sequence 1702, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1702
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1702

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
              ||||| |||||| ||
Db          1 TGGTATGAGGCAGAG 15
```

```
RESULT 472
US-09-866-108A-7645/c
; Sequence 7645, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7645
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7645

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCT 1698
                ||| |||| ||||||
Db         15 CTTTGTTGGTTCTCT 1


RESULT 473
US-09-866-108A-7959
; Sequence 7959, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7959
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7959

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
                ||||  || |||||||
Db          1 CCCTTGAGCAACAGA 15


RESULT 474
US-09-866-108A-8582/c
; Sequence 8582, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
```

```
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8582
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8582

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         17 TGCTTCTGCATCAGC 3


RESULT 475
US-09-866-108A-8583/c
; Sequence 8583, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8583
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8583

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         16 TGCTTCTGCATCAGC 2


RESULT 476
US-09-866-108A-8584/c
; Sequence 8584, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8584
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8584

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         15 TGCTTCTGCATCAGC 1


RESULT 477
US-09-866-108A-10542/c
; Sequence 10542, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
```

```
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10542
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10542

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
                 ||| ||||||| |||
Db         17 TTTCTTCATTATGCT 3


RESULT 478
US-09-866-108A-10543/c
; Sequence 10543, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10543
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10543

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
                 ||| ||||||| |||
Db         16 TTTCTTCATTATGCT 2


RESULT 479
US-08-393-219-21/c
; Sequence 21, Application US/08393219
; Patent No. 5689040
;  GENERAL INFORMATION:
;    APPLICANT:  HARADA, John J.
;    TITLE OF INVENTION:  PLANT PROMOTER SEQUENCES USEFUL FOR GENE
;    TITLE OF INVENTION:  EXPRESSION IN SEEDS AND SEEDLINGS
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend Khourie and Crew
;      STREET:  One Market Plaza, Steuart Street Tower, 20th
;      STREET:  Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  US
;      ZIP:  94105
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/393,219
;      FILING DATE:  23-FEB-1995
;      CLASSIFICATION:  800
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Bastian, Kevin L.
;      REGISTRATION NUMBER:  34,774
;      REFERENCE/DOCKET NUMBER:  2307E-581
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 543-9600
;      TELEFAX:  (415) 543-5043
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-393-219-21

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1820 GTTTTAGAATCTTTT 1834
                 ||| || ||||||||
Db         18 GTTATATAATCTTTT 4


RESULT 480
```

```
US-08-245-295-20
; Sequence 20, Application US/08245295
; Patent No. 5700658
;  GENERAL INFORMATION:
;    APPLICANT:  Gallatin, W. Michael
;    APPLICANT:  Kilgannon, Patrick D.
;    TITLE OF INVENTION:  ICAM-4 Materials and Methods
;    NUMBER OF SEQUENCES:  23
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  233 South Wacker Drive, Suite 6300
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/245,295
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/827,689
;      FILING DATE:  27-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/889,724
;      FILING DATE:  26-MAY-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/894,061
;      FILING DATE:  05-JUN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/009,266
;      FILING DATE:  22-JAN-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/102,852
;      FILING DATE:  05-AUG-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Borun, Michael F.
;      REGISTRATION NUMBER:  25,447
;      REFERENCE/DOCKET NUMBER:  27866/32055
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312-474-6300
;      TELEFAX:  312-474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-245-295-20

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 481
US-08-481-130-20
; Sequence 20, Application US/08481130
; Patent No. 5702917
;  GENERAL INFORMATION:
;    APPLICANT:  Gallatin, W. Michael
;    APPLICANT:  Kilgannon, Patrick D.
;    TITLE OF INVENTION:  ICAM-4 Materials and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  233 South Wacker Drive, 6300 Sears Tower
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/481,130
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/827,689
;      FILING DATE:  27-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/889,724
;      FILING DATE:  26-MAY-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/894,061
;      FILING DATE:  05-JUN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/009,266
;      FILING DATE:  22-JAN-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/102,852
;      FILING DATE:  05-AUG-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/245,295
;      FILING DATE:  18-MAY-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WILLIAMS, JR. JOSEPH A.
;      REGISTRATION NUMBER:  38,659
;      REFERENCE/DOCKET NUMBER:  27866/32713
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312-474-6300
;      TELEFAX:  312-474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-481-130-20

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 482
US-08-656-984A-20
; Sequence 20, Application US/08656984A
; Patent No. 5753502
;  GENERAL INFORMATION:
;    APPLICANT:  Gallatin, W. Michael
;    APPLICANT:  Kilgannon, Patrick D.
;    TITLE OF INVENTION:  ICAM-4 Materials and Methods
;    NUMBER OF SEQUENCES:  42
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  233 South Wacker Drive, 6300 Sears Tower
```

```
;       CITY:  Chicago
;       STATE:  Illinois
;       COUNTRY:  United States of America
;       ZIP:  60606-6402
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/656,984A
;       FILING DATE:
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/827,689
;       FILING DATE:  27-JAN-1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/889,724
;       FILING DATE:  26-MAY-1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/894,061
;       FILING DATE:  05-JUN-1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/009,266
;       FILING DATE:  22-JAN-1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/102,852
;       FILING DATE:  05-AUG-1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/245,295
;       FILING DATE:  18-MAY-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/485,604
;       FILING DATE:  07-JUN-1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  WILLIAMS, JR. JOSEPH A.
;       REGISTRATION NUMBER:  38,659
;       REFERENCE/DOCKET NUMBER:  27866/33321
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  312-474-6300
;       TELEFAX:  312-474-0448
;       TELEX:  25-3856
;   INFORMATION FOR SEQ ID NO:  20:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
US-08-656-984A-20

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 483
US-08-485-604-20
; Sequence 20, Application US/08485604
; Patent No. 5773293
;  GENERAL INFORMATION:
;    APPLICANT:  WP, W. Michael
;    APPLICANT:  Kilgannon, Patrick D.
;    TITLE OF INVENTION:  ICAM-4 Materials and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  233 South Wacker Drive, 6300 Sears Tower
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/485,604
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/827,689
;      FILING DATE:  27-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/889,724
;      FILING DATE:  26-MAY-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/894,061
;      FILING DATE:  05-JUN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/009,266
;      FILING DATE:  22-JAN-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/102,852
;      FILING DATE:  05-AUG-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/245,295
;      FILING DATE:  18-MAY-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WILLIAMS, JR. JOSEPH A.
;      REGISTRATION NUMBER:  38,659
;      REFERENCE/DOCKET NUMBER:  27866/32715
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312-474-6300
;      TELEFAX:  312-474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-485-604-20

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 484
US-08-758-306-531
; Sequence 531, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
```

```
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  FastSeq Version 1.5
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/758,306
;       FILING DATE:  December 3, 1996
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:
;       FILING DATE:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  212/132
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  531:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  18 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-758-306-531

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   80.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1581 ACCGCACAGACTGGG 1595
                ||||  ||  |||:|||
Db          4 ACCGGACUGACUGGG 18


RESULT 485
US-08-526-583-22
; Sequence 22, Application US/08526583
; Patent No. 5840300
;  GENERAL INFORMATION:
;    APPLICANT:  Williams, William V
;    APPLICANT:  Weiner, David B
;    TITLE OF INVENTION:  CLONING AND BIOLOGICAL CHARACTERIZATION
;    TITLE OF INVENTION:  OF HUMAN SINGLE CHAIN FV FRAGMENTS THAT MEDIATE
;    TITLE OF INVENTION:  NEUTRALIZATION OF HIV-1
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  WOODCOCK WASHBURN et al.
;      STREET:  One Liberty Place  46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/526,583
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Leary, Kathryn
;      REGISTRATION NUMBER:  36,317
;      REFERENCE/DOCKET NUMBER:  UPN-2134
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  215-564-8335
;      TELEFAX:  215-568-3439
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-526-583-22

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1816 ATAAGTTTTAGAATC 1830
                |||||  ||||||  ||
Db          4 ATAAGATTTAGATTC 18


RESULT 486
US-08-487-595-20
; Sequence 20, Application US/08487595
; Patent No. 5852170
;  GENERAL INFORMATION:
;    APPLICANT:  Gallatin, W. Michael
;    APPLICANT:  Kilgannon, Patrick D.
;    TITLE OF INVENTION:  ICAM-4 Materials and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Marshall, O'Toole, Gerstein, Murray & Borun
;      STREET:  233 South Wacker Drive, 6300 Sears Tower
;      CITY:  Chicago
;      STATE:  Illinois
;      COUNTRY:  United States of America
;      ZIP:  60606-6402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/487,595
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/827,689
;      FILING DATE:  27-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/889,724
;      FILING DATE:  26-MAY-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/894,061
;      FILING DATE:  05-JUN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/009,266
;      FILING DATE:  22-JAN-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/102,852
;      FILING DATE:  05-AUG-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/245,295
;      FILING DATE:  18-MAY-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WILLIAMS, JR. JOSEPH A.
;      REGISTRATION NUMBER:  38,659
;      REFERENCE/DOCKET NUMBER:  27866/32714
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312-474-6300
;      TELEFAX:  312-474-0448
;      TELEX:  25-3856
;  INFORMATION FOR SEQ ID NO:  20:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-487-595-20

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 487
US-08-734-973-31
; Sequence 31, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  31 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-31

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACT 1868
              ||| || ||||||||
Db          4 ACACACACACACACT 18


RESULT 488
US-08-734-973-32
; Sequence 32, Application US/08734973
; Patent No. 5912147
;  GENERAL INFORMATION:
;    APPLICANT:  Stoler, Daniel L.
;    APPLICANT:  Basik, Mark
;    APPLICANT:  Anderson, Garth R.
;    TITLE OF INVENTION:  A Rapid Means For Quantitating
;    TITLE OF INVENTION:  Genomic Instability
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hodgson, Russ, Andrews, Woods & Goodyear
;      STREET:  1800 One M&T Plaza
;      CITY:  Buffalo
;      STATE:  New York
;      COUNTRY:  United States
;      ZIP:  14203-2391
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 inch
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  MS-DOS/ Microsoft Windows
;      SOFTWARE:  Wordperfect for Windows
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/734,973
;      FILING DATE:  October 1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nelson, M. Bud
;      REGISTRATION NUMBER:  35,300
;      REFERENCE/DOCKET NUMBER:  03551.0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (716) 856-4000
;      TELEFAX:  (716) 849-0349
;  INFORMATION FOR SEQ ID NO:  32 :
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single-stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  No
US-08-734-973-32

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   80.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACT 1868
              ||| || |||||||:
Db          4 ACACACACACACACU 18


RESULT 489
US-09-213-767-26
; Sequence 26, Application US/09213767
; Patent No. 5948680
; GENERAL INFORMATION:
;  APPLICANT: Brenda F. Baker
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF ELK-1 EXPRESSION
;  FILE REFERENCE: RTS-0024
;  CURRENT APPLICATION NUMBER: US/09/213,767
;  CURRENT FILING DATE: 1998-12-17
;  NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 26
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-213-767-26

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2069 GTGGTATCTGACACA 2083
```

```
                 ||||| |||| ||||
Db          4 GTGGTTTCTGGCACA 18


RESULT 490
US-09-166-203-23
; Sequence 23, Application US/09166203A
; Patent No. 5968826
; GENERAL INFORMATION:
;  APPLICANT: Bennett, C. Frank
;  APPLICANT: Condon, Tom P.
;  APPLICANT: Cowsert, Lex M.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN 4 EXPRESSION
;  FILE REFERENCE: ISPH-0323
;  CURRENT APPLICATION NUMBER: US/09/166,203A
;  CURRENT FILING DATE: 1998-10-05
;  NUMBER OF SEQ ID NOS: 60
; SEQ ID NO 23
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-09-166-203-23

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1579 CCACCGCACAGACTG 1593
                 |||| |||||||| |
Db          1 CCACAGCACAGACAG 15


RESULT 491
US-09-205-860-81/c
; Sequence 81, Application US/09205860
; Patent No. 5981732
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION
;  FILE REFERENCE: RTS-0031
;  CURRENT APPLICATION NUMBER: US/09/205,860
;  CURRENT FILING DATE: 1998-12-04
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 81
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-860-81

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1820 GTTTTAGAATCTTTT 1834
                 ||||||  |||||||
Db         15 GTTTTAATATCTTTT 1


RESULT 492
US-09-256-496-58
; Sequence 58, Application US/09256496
; Patent No. 5998206
; GENERAL INFORMATION:
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF G-APLHA-12 EXPRESSION
;  FILE REFERENCE: RTS-0056
;  CURRENT APPLICATION NUMBER: US/09/256,496
;  CURRENT FILING DATE: 1999-02-23
;  NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 58
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-256-496-58

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGC 1608
                 |||||| || |||||
Db          3 GGAACCACTTCTGGC 17


RESULT 493
US-09-143-212-58/c
; Sequence 58, Application US/09143212B
; Patent No. 6077672
; GENERAL INFORMATION:
;  APPLICANT: Brett P. Monia and Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF TRADD EXPRESSION
;  FILE REFERENCE: RTS-0005
;  CURRENT APPLICATION NUMBER: US/09/143,212B
;  CURRENT FILING DATE: 1998-08-28
;  NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 58
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-143-212-58

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 ACCCGCCCCTGGACT 1682
                 ||||| | |||||||
Db         16 ACCCGGCGCTGGACT 2


RESULT 494
US-08-834-224-6
; Sequence 6, Application US/08834224
; Patent No. 6114306
;  GENERAL INFORMATION:
;    APPLICANT:  DE MEDICIS, Eveline
;    APPLICANT:  LAROCHELLE, Andre
;    TITLE OF INVENTION:  A CYTOKINE RELATED TO HEMOLYTIC ANEMIA
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  NIXON & VANDERHYE P.C.
;      STREET:  8th Floor, 1100 No. 6114306th Glebe Road
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  United States
;      ZIP:  22201-4714
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/834,224
;      FILING DATE:  15-APR-1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/546,872
;      FILING DATE:  23-OCT-1995
```

```
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WILSON, Mary J.
;      REGISTRATION NUMBER:  32,955
;      REFERENCE/DOCKET NUMBER:  163-26
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 816-4011
;      TELEFAX:  (703) 816-4100
;  INFORMATION FOR SEQ ID NO:  6:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  18 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-834-224-6

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGGG 1615
              ||||||| ||||| |
Db          3 CTCCTGGGCTGGGCG 17


RESULT 495
US-09-213-719-48/c
; Sequence 48, Application US/09213719B
; Patent No. 6150162
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT: Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF CD44 EXPRESSION
;  FILE REFERENCE: RTS-0006
;  CURRENT APPLICATION NUMBER: US/09/213,719B
;  CURRENT FILING DATE: 1998-12-17
;  NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 48
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-213-719-48

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGGG 1613
              ||||| |||||| ||
Db         18 CCCTCTTGGCCTTGG 4


RESULT 496
US-09-066-046-43/c
; Sequence 43, Application US/09066046A
; Patent No. 6204252
;   GENERAL INFORMATION:
;        APPLICANT: MURPHY, Cheryl
;                   STOREY, James
;                   BELTZ, Gerald A.
;                   COUGHLIN, Richard T.
;        TITLE OF INVENTION: CHARACTERIZATION OF GRANULOCYTIC
;                            EHRLICHIA AND METHODS OF USE
;        NUMBER OF SEQUENCES: 65
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: HALE AND DORR LLP
;             STREET: 60 State Street
;             CITY: Boston
;             STATE: MA
;             COUNTRY: United States
;             ZIP: 02109
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/066,046A
;             FILING DATE: 24-Apr-1998
;             CLASSIFICATION: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Superko, Colleen
;             REGISTRATION NUMBER: 39,850
;             REFERENCE/DOCKET NUMBER: 106.941.155
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (617) 526-6000
;             TELEFAX: (617) 526-5000
;   INFORMATION FOR SEQ ID NO: 43:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-09-066-046-43

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
              ||||| | |||||||
Db         16 CCCTATAGCAACAGA 2


RESULT 497
US-09-377-309-23
; Sequence 23, Application US/09377309B
; Patent No. 6258790
; GENERAL INFORMATION:
;  APPLICANT: Bennett, C. Frank
;  APPLICANT: Condon, Tom P.
;  APPLICANT: Cowsert, Lex M.
;  TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN 4 EXPRESSION
;  FILE REFERENCE: ISPH-0390
;  CURRENT APPLICATION NUMBER: US/09/377,309B
;  CURRENT FILING DATE: 1999-08-19
;  EARLIER APPLICATION NUMBER: 09/166,203
;  EARLIER FILING DATE: 1998-10-05
;  NUMBER OF SEQ ID NOS: 99
; SEQ ID NO 23
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: antisense sequence
US-09-377-309-23

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1579 CCACCGCACAGACTG 1593
              |||| |||||||| |
Db          1 CCACAGCACAGACAG 15


RESULT 498
US-09-496-694B-117
; Sequence 117, Application US/09496694B
; Patent No. 6335194
; GENERAL INFORMATION:
;  APPLICANT: C. Frank Bennett
;  APPLICANT:  Elizabeth J. Ackermann
```

```
;  APPLICANT:  Eric E. Swayze
;  APPLICANT:  Lex M. Cowsert
;  TITLE OF INVENTION: ANTISENSE MODULATION OF SURVIVIN EXPRESSION
;  FILE REFERENCE: ISPH-0439
;  CURRENT APPLICATION NUMBER: US/09/496,694B
;  CURRENT FILING DATE:  2000-02-02
;  PRIOR APPLICATION NUMBER: 09/286,407
;  PRIOR FILING DATE: 1999-04-05
;  PRIOR APPLICATION NUMBER: 09/163,162
;  PRIOR FILING DATE: 1998-09-29
;  NUMBER OF SEQ ID NOS: 249
; SEQ ID NO 117
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Antisense Oligonucleotide
US-09-496-694B-117

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGC 1814
              | ||| |||||||||
Db          3 CCCTGGAAGTGGTGC 17


RESULT 499
US-09-328-174A-43
; Sequence 43, Application US/09328174A
; Patent No. 6448003
; GENERAL INFORMATION:
;  APPLICANT:  Guida, Marco
;  APPLICANT:  Kurth, Janice
;  TITLE OF INVENTION:  Genotyping Human Phenol Sulfotransferase
;  TITLE OF INVENTION:  (STP2)
;  FILE REFERENCE:  4389-6 (formerly SEQ-16P)
;  CURRENT APPLICATION NUMBER: US/09/328,174A
;  CURRENT FILING DATE:  1999-06-08
;  PRIOR APPLICATION NUMBER:  09/328,174
;  PRIOR FILING DATE:  1999-06-08
;  NUMBER OF SEQ ID NOS:  110
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 43
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: H. sapiens
US-09-328-174A-43

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1677 TGGACTTCTTAGTTG 1691
              ||||| |||| ||||
Db          4 TGGACCTCTTGGTTG 18


RESULT 500
US-09-422-978-4956/c
; Sequence 4956, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4956
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-18995 for SEQ 1022,
US-09-422-978-4956

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1864 ACACTTAGCCATTGA 1878
              |||||||||| || |
Db         17 ACACTTAGCCTTTCA 3


RESULT 501
US-09-422-978-4997
; Sequence 4997, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4997
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-2010 for SEQ 1063,
US-09-422-978-4997

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 TTTTTTTGAACCCCA 1789
              ||||||||  |||||
Db          2 TTTTTTTGTCCCCCA 16


RESULT 502
US-09-422-978-5155
; Sequence 5155, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
```

```
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5155
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-2209 for SEQ 1221,
US-09-422-978-5155

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAG 1554
              | ||||||||| |||
Db          4 ATGAGAGTAGGAAAG 18


RESULT 503
US-09-422-978-5351/c
; Sequence 5351, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5351
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-24270 for SEQ 1417,
US-09-422-978-5351

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTT 1954
              | |||||| ||||||
Db         16 GAAATGGTGGGTTTT 2


RESULT 504
US-09-422-978-5769
; Sequence 5769, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5769
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-6730 for SEQ 1835,
US-09-422-978-5769

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTG 1624
              |||| |||||| |||
Db          4 TGGGAGAAGAGATTG 18


RESULT 505
US-09-422-978-5871/c
; Sequence 5871, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5871
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-7453 for SEQ 1937,
US-09-422-978-5871

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAA 1807
              || || |||||||||
Db         16 TTGCCCTCTCTGAAA 2


RESULT 506
US-09-422-978-6093/c
; Sequence 6093, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
```

```
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6093
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-8885 for SEQ 2159,
US-09-422-978-6093

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACA 1864
              ||||||||||  |||
Db         16 GCCAACAGACAAACA 2


RESULT 507
US-09-422-978-7562/c
; Sequence 7562, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7562
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-8006 for SEQ 3628,
US-09-422-978-7562

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1658 GTTCTGCATCACCCG 1672
              ||||||||||  ||
Db         18 GTTCTGCATCAATCG 4


RESULT 508
US-09-422-978-7804/c
; Sequence 7804, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7804
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: upstream amplification primer 99-4110 for SEQ 3870,
US-09-422-978-7804

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1650 CTTCACTGGTTCTGC 1664
              |||| ||| ||||||
Db         18 CTTCCCTGATTCTGC 4


RESULT 509
US-09-422-978-8887/c
; Sequence 8887, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8887
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-18995 for SEQ 1022, in compleme
US-09-422-978-8887

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2035 CAAAGGTTCTATCTG 2049
              ||||||||| || ||
Db         18 CAAAGGTTCCATGTG 4
```

```
RESULT 510
US-09-422-978-9171
; Sequence 9171, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9171
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-2271 for SEQ 1306, in compleme
US-09-422-978-9171

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2045 ATCTGCTTAGCAACT 2059
              | ||||| |||||||
Db          1 AACTGCTCAGCAACT 15


RESULT 511
US-09-422-978-9321/c
; Sequence 9321, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9321
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-24778 for SEQ 1456, in complem
US-09-422-978-9321

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCT 1602
                ||||||||||| | |
Db         15 AGACTGGGAACTCAT 1


RESULT 512
US-09-422-978-9456
; Sequence 9456, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
;  APPLICANT: Cohen, Daniel
;  APPLICANT: Blumenfeld, Marta
;  APPLICANT: Chumakov, Ilya
;  TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
;  FILE REFERENCE: GENSET.020CP1
;  CURRENT APPLICATION NUMBER: US/09/422,978
;  CURRENT FILING DATE: 1999-10-20
;  EARLIER APPLICATION NUMBER: US 09/298,850
;  EARLIER FILING DATE: 1999-04-21
;  EARLIER APPLICATION NUMBER: US 60/109,732
;  EARLIER FILING DATE: 1998-11-23
;  EARLIER APPLICATION NUMBER: US 60/082,614
;  EARLIER FILING DATE: 1998-04-21
;  NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 9456
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
;   FEATURE:
;   NAME/KEY: primer_bind
;   LOCATION: 1..18
;   OTHER INFORMATION: downstream amplification primer 99-490 for SEQ 1591, in complemen
US-09-422-978-9456

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1836 AATACATTCCCTGGG 1850
              || |||||| |||||
Db          3 AAAACATTCTCTGGG 17


RESULT 513
US-08-993-765-2/c
; Sequence 2, Application US/08993765
; Patent No. 6610841
; GENERAL INFORMATION:
;  APPLICANT:  Warren, Stephen
;  TITLE OF INVENTION:  Nucleotide-Based Prodrugs
;  FILE REFERENCE:  NEX65/CPA
;  CURRENT APPLICATION NUMBER: US/08/993,765
;  CURRENT FILING DATE:  1997-12-18
;  NUMBER OF SEQ ID NOS:  3
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 2
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
;   OTHER INFORMATION: Sequence
;   NAME/KEY: modified_base
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: U's at positions 2,4, 6, 8, 10, 12, 14 and 16 are
;   OTHER INFORMATION: 5-bromo-deoxyuridine; A's at positions 1, 9, and
;   OTHER INFORMATION: 17 are deoxyadenosine; C's at positions 3 and 11
;   OTHER INFORMATION: are deoxycytosine;
;   NAME/KEY: modified_base
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: G's at positions 5 and 13 are deoxyguanosine; T's
;   OTHER INFORMATION: at positions 7 and 15 are deoxythymidine; T at
;   OTHER INFORMATION: position 18 is a 3'-3' dT cap.
US-08-993-765-2
```

```
  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1902 ATCAACAGATCAACA 1916
                || ||||||| ||||
Db         18 ATAAACAGATAAACA 4


RESULT 514
US-08-993-765-3/c
; Sequence 3, Application US/08993765
; Patent No. 6610841
; GENERAL INFORMATION:
;  APPLICANT:  Warren, Stephen
;  TITLE OF INVENTION:  Nucleotide-Based Prodrugs
;  FILE REFERENCE:  NEX65/CPA
;  CURRENT APPLICATION NUMBER: US/08/993,765
;  CURRENT FILING DATE:  1997-12-18
;  NUMBER OF SEQ ID NOS:  3
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 3
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
;   OTHER INFORMATION: Sequence
;   NAME/KEY: modified_base
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: A's at positions 1, 9 and 17 are 2'-OMe adenosine;
;   OTHER INFORMATION: C's at positons 3 and 11 are 2'OMe cytosine; G's
;   OTHER INFORMATION: at positions 5 and 13 are 2' OMe guanosine;
;   NAME/KEY: modified_base
;   LOCATION: (1)..(18)
;   OTHER INFORMATION: U's at positions 2, 4, 6, 8, 10, 12 14 and 16 are
;   OTHER INFORMATION: 5-bromodeoxyuridine; T's at positions 7 and 15 are
;   OTHER INFORMATION: 2'- OMe thymidine; T at position 18 is a 3' - 3'
;   OTHER INFORMATION: dT cap.
US-08-993-765-3

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1902 ATCAACAGATCAACA 1916
                || ||||||| ||||
Db         18 ATAAACAGATAAACA 4


RESULT 515
US-09-155-885A-264/c
; Sequence 264, Application US/09155885A
; Patent No. 6709812
;   GENERAL INFORMATION:
;        APPLICANT: STUYVER, LIEVEN
;                   ROSSAU, RUDI
;                   MAERTENS, GEERT
;        TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
;        NUMBER OF SEQUENCES: 313
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: NIXON & VANDERHYE P.C.
;             STREET: 1100 NORTH GLEBE ROAD
;             CITY: ARLINGTON
;             STATE: VIRGINIA
;             COUNTRY: U.S.A.
;             ZIP: 22201-4714
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/155,885A
;             FILING DATE: 08-Oct-1998
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: PCT/EP97/02002
;             FILING DATE: 21-APR-1997
;             APPLICATION NUMBER: EP 96870053.4
;             FILING DATE: 19-APR-1996
;        ATTORNEY/AGENT INFORMATION:
;             NAME: SADOFF, B.J.
;             REGISTRATION NUMBER: 36,663
;             REFERENCE/DOCKET NUMBER: 2551-5
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (703) 816-4000
;             TELEFAX: (703) 816-4100
;   INFORMATION FOR SEQ ID NO: 264:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 18 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA (genomic)
;        HYPOTHETICAL: NO
;        ANTI-SENSE: NO
;        SEQUENCE DESCRIPTION: SEQ ID NO: 264:
US-09-155-885A-264

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1905 AACAGATCAACAATA 1919
                | ||||||| |||||
Db         17 ACCAGATCATCAATA 3


RESULT 516
US-09-544-398B-449
; Sequence 449, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
;  APPLICANT: Carulli, John P.
;  APPLICANT:  Little, Randall D.
;  APPLICANT:  Recker, Robert R.
;  APPLICANT:  Johnson, Mark L.
;  TITLE OF INVENTION: High bone mass gene of 11q13.3
;  FILE REFERENCE: 032796-013
;  CURRENT APPLICATION NUMBER: US/09/544,398B
;  CURRENT FILING DATE:  2002-06-10
;  PRIOR APPLICATION NUMBER: US 09/229,319
;  PRIOR FILING DATE: 1999-01-13
;  PRIOR APPLICATION NUMBER: US 60/071,449
;  PRIOR FILING DATE: 1998-01-13
;  PRIOR APPLICATION NUMBER: US 60/105,511
;  PRIOR FILING DATE: 1998-10-23
;  NUMBER OF SEQ ID NOS: 641
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 449
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-544-398B-449

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1808 GTGGTGCTATAAGTT 1822
                |||||||  |||||
Db          1 GTGGTGCTGCAAGTT 15
```

```
RESULT 517
US-09-696-791-4188/c
; Sequence 4188, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4188
;   LENGTH: 18
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase
US-09-696-791-4188

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCC 1604
              ||| |||||||||  |
Db         15 ACTAGGAACCCCTTC 1


RESULT 518
US-08-431-080-2/c
; Sequence 2, Application US/08431080
; Patent No. 5698686
;  GENERAL INFORMATION:
;    APPLICANT:  Gottschling, Daniel E.
;    APPLICANT:  Singer, Miriam S.
;    TITLE OF INVENTION:  Telomerase Compositions and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  TEXAS
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/431,080
;      FILING DATE:  Concurrently Herewith
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  SN 08/326,781
;      FILING DATE:  October 20, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  ARCD:155/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (713) 789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-431-080-2

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACAC 1867
              || ||||||||||
Db         13 CACACCCACACAC 1


RESULT 519
US-08-781-550-22
; Sequence 22, Application US/08781550
; Patent No. 5861242
;  GENERAL INFORMATION:
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Gingeras, Thomas R.
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Morris, Macdonald S.
;    TITLE OF INVENTION:  HIV Diagnosis by Arrays of Nucleic Acid
;    TITLE OF INVENTION:  Probes on Biological Chips
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend Khourie and Crew
;      STREET:  One Market Plaza, Steuart Tower, Suite 2000
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94105
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/781,550
;      FILING DATE:  09-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/082,937
;      FILING DATE:  25-JUN-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stevens, Lauren L.
;      REGISTRATION NUMBER:  36,691
;      REFERENCE/DOCKET NUMBER:  1046.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-326-2400
;      TELEFAX:  415-326-2422
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-781-550-22

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 GTACTGGCTCTTT 1759
              ||||||||| |||
Db          1 GTACTGGCTTTTT 13
```

```
RESULT 520
US-08-781-550-26
; Sequence 26, Application US/08781550
; Patent No. 5861242
;  GENERAL INFORMATION:
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Gingeras, Thomas R.
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Morris, Macdonald S.
;    TITLE OF INVENTION:  HIV Diagnosis by Arrays of Nucleic Acid
;    TITLE OF INVENTION:  Probes on Biological Chips
;    NUMBER OF SEQUENCES:  48
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend Khourie and Crew
;      STREET:  One Market Plaza, Steuart Tower, Suite 2000
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94105
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/781,550
;      FILING DATE:  09-JAN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/284,064
;      FILING DATE:  02-AUG-1994
;      APPLICATION NUMBER:  US 08/143,312
;      FILING DATE:  26-OCT-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/082,937
;      FILING DATE:  25-JUN-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stevens, Lauren L.
;      REGISTRATION NUMBER:  36,691
;      REFERENCE/DOCKET NUMBER:  1046.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-326-2400
;      TELEFAX:  415-326-2422
;  INFORMATION FOR SEQ ID NO:  26:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (oligonucleotide)
US-08-781-550-26

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1746 AGTACTGGCTCTT 1758
              ||||||||||  ||
Db          1 AGTACTGGCTTTT 13


RESULT 521
US-08-938-534-2/c
; Sequence 2, Application US/08938534
; Patent No. 5916752
;  GENERAL INFORMATION:
;    APPLICANT:  Gottschling, Daniel E.
;    APPLICANT:  Singer, Miriam S.
;    TITLE OF INVENTION:  Telomerase Compositions and Methods
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  TEXAS
;      COUNTRY:  UNITED STATES OF AMERICA
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS/ASCII
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/938,534
;      FILING DATE:  26-SEP-1997
;      CLASSIFICATION:  536
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/431,080
;      FILING DATE:
;      APPLICATION NUMBER:  SN 08/326,781
;      FILING DATE:  October 20, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Parker, David L.
;      REGISTRATION NUMBER:  32,165
;      REFERENCE/DOCKET NUMBER:  ARCD:155/PAR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (512) 418-3000
;      TELEFAX:  (713) 789-2679
;      TELEX:  79-0924
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-938-534-2

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACAC 1867
              || ||||||||||
Db         13 CACACCCACACAC 1


RESULT 522
US-08-544-381B-201
; Sequence 201, Application US/08544381B
; Patent No. 6027880
;  GENERAL INFORMATION:
;    APPLICANT:  Cronin, Maureen T.
;    APPLICANT:  Miyada, Charles Garrett
;    APPLICANT:  Hubbell, Earl A.
;    APPLICANT:  Chee, Mark
;    APPLICANT:  Fodor, Stephen P.A.
;    APPLICANT:  Huang, Xiaohua C.
;    APPLICANT:  Lipshutz, Robert J.
;    APPLICANT:  Lobban, Peter E.
;    APPLICANT:  Morris, Macdonald S.
;    APPLICANT:  Sheldon, Edward L.
;    TITLE OF INVENTION:  Arrays of Nucleic Acid Probes for
;    TITLE OF INVENTION:  Detecting Cystic Fibrosis
;    NUMBER OF SEQUENCES:  250
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew LLP
;      STREET:  Two Embarcadero Center, 8th Floor
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
```

```
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/544,381B
;       FILING DATE:  10-OCT-1995
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/510,521
;       FILING DATE:  02-AUG-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US94/12305
;       FILING DATE:  26-OCT-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/284,064
;       FILING DATE:  02-AUG-1994
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/143,312
;       FILING DATE:  26-OCT-1993
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Liebeschuetz, Joe
;       REGISTRATION NUMBER:  37,505
;       REFERENCE/DOCKET NUMBER:  018547-004130US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  415-576-0200
;       TELEFAX:  415-576-0300
;   INFORMATION FOR SEQ ID NO:  201:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (probe)
US-08-544-381B-201

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 GTACTGGCTCTTT 1759
              ||||||||| |||
Db          1 GTACTGGCTTTTT 13


RESULT 523
US-08-778-794A-10
; Sequence 10, Application US/08778794A
; Patent No. 6309823
;  GENERAL INFORMATION:
;     APPLICANT:  Cronin, Maureen T.
;     APPLICANT:  Miyada, Charles Garrett
;     APPLICANT:  Hubbell, Earl A.
;     APPLICANT:  Chee, Mark
;     APPLICANT:  Fodor, Stephen P.A.
;     APPLICANT:  Huang, Xiaohua C.
;     APPLICANT:  Lipshutz, Robert J.
;     APPLICANT:  Lobban, Peter E.
;     APPLICANT:  Morris, MacDonald S.
;     APPLICANT:  Sheldon, Edward L.
;     TITLE OF INVENTION:  Arrays of Nucleic Acid Probes
;     TITLE OF INVENTION:  for Analyzing Biotransformation Genes
;     NUMBER OF SEQUENCES:  156
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Townsend and Townsend and Crew LLP
;       STREET:  Two Embarcadero Center, Eighth Floor
;       CITY:  San Francisco
;       STATE:  CA
;       COUNTRY:  USA
;       ZIP:  94111-3834
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Diskette
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  DOS
;       SOFTWARE:  FastSEQ for Windows Version 2.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/778,794A
;       FILING DATE:  03-JAN-1997
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/143,312
;       FILING DATE:  26-OCT-1993
;       APPLICATION NUMBER:  US 08/284,064
;       FILING DATE:  02-AUG-1994
;       APPLICATION NUMBER:  WO PCT/US94/12305
;       FILING DATE:  26-OCT-1994
;       APPLICATION NUMBER:  US 08/510,521
;       FILING DATE:  02-AUG-1995
;       APPLICATION NUMBER:  US 08/544,381
;       FILING DATE:  10-OCT-1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Liebeschuetz, Joe
;       REGISTRATION NUMBER:  37,505
;       REFERENCE/DOCKET NUMBER:  018547-015700US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (415) 576-0200
;       TELEFAX:  (415) 576-0200
;       TELEX:
;   INFORMATION FOR SEQ ID NO:  10:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  13 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
US-08-778-794A-10

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 GTACTGGCTCTTT 1759
              ||||||||| |||
Db          1 GTACTGGCTTTTT 13


RESULT 524
US-09-345-294-2/c
; Sequence 2, Application US/09345294
; Patent No. 6387619
;  GENERAL INFORMATION:
;       APPLICANT: Gottschling, Daniel E.
;                  Singer, Miriam S.
;       TITLE OF INVENTION: Telomerase Compositions and Methods
;       NUMBER OF SEQUENCES: 32
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Arnold, White & Durkee
;            STREET: P.O. Box 4433
;            CITY: Houston
;            STATE: TEXAS
;            COUNTRY: UNITED STATES OF AMERICA
;            ZIP: 77210
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/345,294
;            FILING DATE: 30-Jun-1999
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/431,080
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Parker, David L.
;            REGISTRATION NUMBER: 32,165
;            REFERENCE/DOCKET NUMBER: ARCD:155/PAR
```

```
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (512) 418-3000
;             TELEFAX: (713) 789-2679
;             TELEX: 79-0924
;   INFORMATION FOR SEQ ID NO: 2:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 13 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-345-294-2

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACAC 1867
              || ||||||||||
Db         13 CACACCCACACAC 1


RESULT 525
US-09-341-399-10
; Sequence 10, Application US/09341399
; Patent No. 6468744
;   GENERAL INFORMATION:
;        APPLICANT: Cronin, Maureen T.
;                   Sheldon, Edward L.
;                   Miyada, Charles G.
;                   Hubbell, Earl A.
;                   Chee, Mark
;                   Fodor, Stephen P.A.
;                   Huang, Xiaohua C.
;                   Lipshutz, Robert J.
;                   Lobban, Peter E.
;                   Morris, MacDonald S.
;        TITLE OF INVENTION: Analysis of Genetic Polymorphisms and
;                            Gene Copy Number
;        NUMBER OF SEQUENCES: 51
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Townsend and Townsend and Crew LLP
;             STREET: Two Embarcadero Center, Eighth Floor
;             CITY: San Francisco
;             STATE: California
;             COUNTRY: USA
;             ZIP: 94111-3834
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/341,399
;             FILING DATE: 17-No. 6468744-1999
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: US 08/143,312
;             FILING DATE: 26-OCT-1993
;             APPLICATION NUMBER: US 08/284,064
;             FILING DATE: 02-AUG-1994
;             APPLICATION NUMBER: WO PCT/US94/12305
;             FILING DATE: 26-OCT-1994
;             APPLICATION NUMBER: US 08/510,521
;             FILING DATE: 02-AUG-1995
;             APPLICATION NUMBER: US 08/544,381
;             FILING DATE: 10-OCT-1995
;             APPLICATION NUMBER: US 08/778,794
;             FILING DATE: 03-JAN-1997
;             APPLICATION NUMBER: WO PCT/US98/06414
;             FILING DATE: 02-JAN-1998
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Liebeschuetz, Joe
;             REGISTRATION NUMBER: 37,505
;             REFERENCE/DOCKET NUMBER: 018547-015710US
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (415) 576-0200
;             TELEFAX: (415) 576-0300
;   INFORMATION FOR SEQ ID NO: 10:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 13 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: DNA
;        SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-341-399-10

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 3.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1747 GTACTGGCTCTTT 1759
              ||||||||| |||
Db          1 GTACTGGCTTTTT 13


RESULT 526
US-08-242-664-15
; Sequence 15, Application US/08242664
; Patent No. 5571937
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/242,664
;      FILING DATE:  May 12, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-242-664-15

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
              |||||| ||||||
Db          1 AAAAAAGGAAAAG 13
```

```
RESULT 527
US-08-484-138-15
; Sequence 15, Application US/08484138
; Patent No. 5652350
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,138
;      FILING DATE:  June 7, 1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-Z/JPW/MJG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-484-138-15

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
             |||||| ||||||
Db          1 AAAAAAGGAAAAG 13


RESULT 528
US-09-874-601-115/c
; Sequence 115, Application US/09874601
; Patent No. 6632057
; GENERAL INFORMATION:
;  APPLICANT: LEWIN, ALFRED S.
;  APPLICANT:  SHAW, LYNN C.
;  APPLICANT:  GRANT, MARIA B.
;  TITLE OF INVENTION: ADENO-ASSOCIATED VIRUS-DELIVERED RIBOZYME COMPOSITIONS AND METHOD
;  TITLE OF INVENTION:  THE TREATMENT OF RETINAL DISEASES
;  FILE REFERENCE: 4300.014100
;  CURRENT APPLICATION NUMBER: US/09/874,601
;  CURRENT FILING DATE:  2001-05-01
;  PRIOR APPLICATION NUMBER: 09/063,667
;  PRIOR FILING DATE: 1998-04-21
;  PRIOR APPLICATION NUMBER: 60/046,147
;  PRIOR FILING DATE: 1997-05-09
;  PRIOR APPLICATION NUMBER: 60/044,492
;  PRIOR FILING DATE: 1997-04-21
;  NUMBER OF SEQ ID NOS: 182
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 115
;   LENGTH: 14
;   TYPE: RNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: ()..()
;   OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-874-601-115

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1572 TCCTTCTCCACCG 1584
              |||||||||| |
Db         13 TCCTTCTCCACAG 1


RESULT 529
PCT-US95-06379-15
; Sequence 15, Application PC/TUS9506379
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/06379
;      FILING DATE:  May 13, 1994
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-278-0400
;      TELEFAX:  212-391-0526
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US95-06379-15

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 14;
  Best Local Similarity   92.3%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
             |||||| ||||||
Db          1 AAAAAAGGAAAAG 13


RESULT 530
US-07-703-778D-11
; Sequence 11, Application US/07703778D
```

```
; Patent No. 5296366
; GENERAL INFORMATION:
;   APPLICANT:  Garcia,M.P.E. et al
;   TITLE OF INVENTION:  METHOD FOR THE ISOLATION AND EXPRESSION
;   TITLE OF INVENTION:  OF A GENE WHICH CODES FOR STREPTOKINASE, NUCLEOTIDE SEQUENCE
;   TITLE OF INVENTION:  OBTAINED, RECOMBINANT DNA AND TRANSFORMED MICROORGANISMS
;   NUMBER OF SEQUENCES:  14
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Stanger, Michaelson, Spivak and Wallace, Esq.
;     STREET:  Parkway 109 Office Center, 328 Newman Springs Road,
;     STREET:  P. O. Box 8489
;     CITY:  Red Bank
;     STATE:  New Jersey
;     COUNTRY:  USA
;     ZIP:  07701
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  3 1/2" 1.44Mb IBM compatible diskette
;     COMPUTER:  IBM PS/2 Model 80
;     OPERATING SYSTEM:  MS-DOS 5.0
;     SOFTWARE:  Microsoft Word for Windows 2.0
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/07/703,778D
;     FILING DATE:  19910522
;     CLASSIFICATION:  435
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Michaelson, Peter L.
;     REGISTRATION NUMBER:  30090
;     REFERENCE/DOCKET NUMBER:  Centro-1
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  (908)530-6671
;     TELEFAX:  (908)530-6584
; INFORMATION FOR SEQ ID NO:  11:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  15 bases
;     TYPE:  NUCLEOTIDE
;     STRANDEDNESS:  single
;     TOPOLOGY:  linear
US-07-703-778D-11

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTC 2021
              ||||||||| |||
Db          1 CAGAGATCAGGTC 13


RESULT 531
US-07-991-855-5/c
; Sequence 5, Application 07/991855
; Patent No. 5420032
; GENERAL INFORMATION:
;   APPLICANT:  Marshall, Philip
;   APPLICANT:  Lemieux, Claude
;   TITLE OF INVENTION:  Homing Endonuclease Which Originates
;   TITLE OF INVENTION:  From Chlamydomonas Eugametos and Recognizes and Cleaves a
;   TITLE OF INVENTION:  15, 17 or 19 Degenerate Doublee Stranded Nucleotide
;   TITLE OF INVENTION:  Sequence
;   NUMBER OF SEQUENCES:  74
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Merchant & Gould
;     STREET:  3100 No. 5420032west Center
;     CITY:  Minneapolis
;     STATE:  MN
;     COUNTRY:  USA
;     ZIP:  55402
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:  IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:  PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  07/991,855
;     FILING DATE:  16-DEC-1992
;     CLASSIFICATION:  435
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 07/813,129
;     FILING DATE:  23-DEC-1991
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Woessner, Warren D.
;     REGISTRATION NUMBER:  30,440
;     REFERENCE/DOCKET NUMBER:  9555.18-US-01
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  612-332-5300
;     TELEFAX:  612-332-9081
; INFORMATION FOR SEQ ID NO:  5:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  15 base pairs
;     TYPE:  nucleic acid
;     STRANDEDNESS:  single
;     TOPOLOGY:  linear
;   MOLECULE TYPE:  DNA (genomic)
US-07-991-855-5

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTAACTTTGGACC 1727
              ||| |||||||||
Db         15 CTACCTTTGGACC 3


RESULT 532
US-07-991-855-45
; Sequence 45, Application 07/991855
; Patent No. 5420032
; GENERAL INFORMATION:
;   APPLICANT:  Marshall, Philip
;   APPLICANT:  Lemieux, Claude
;   TITLE OF INVENTION:  Homing Endonuclease Which Originates
;   TITLE OF INVENTION:  From Chlamydomonas Eugametos and Recognizes and Cleaves a
;   TITLE OF INVENTION:  15, 17 or 19 Degenerate Doublee Stranded Nucleotide
;   TITLE OF INVENTION:  Sequence
;   NUMBER OF SEQUENCES:  74
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Merchant & Gould
;     STREET:  3100 No. 5420032west Center
;     CITY:  Minneapolis
;     STATE:  MN
;     COUNTRY:  USA
;     ZIP:  55402
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:  IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:  PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  07/991,855
;     FILING DATE:  16-DEC-1992
;     CLASSIFICATION:  435
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 07/813,129
;     FILING DATE:  23-DEC-1991
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Woessner, Warren D.
;     REGISTRATION NUMBER:  30,440
;     REFERENCE/DOCKET NUMBER:  9555.18-US-01
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  612-332-5300
;     TELEFAX:  612-332-9081
; INFORMATION FOR SEQ ID NO:  45:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  15 base pairs
;     TYPE:  nucleic acid
```

```
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-991-855-45

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTAACTTTGGACC 1727
              ||| ||||||||
Db          1 CTACCTTTGGACC 13


RESULT 533
US-08-063-167A-34
; Sequence 34, Application US/08063167A
; Patent No. 5514788
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Mirabelli
;    TITLE OF INVENTION:  Oligonucleotide Modulation
;    TITLE OF INVENTION:  of Cell Adhesion
;    NUMBER OF SEQUENCES:  85
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodland Falls Corporate Park
;      STREET:  210 Lake Drive East, Suie 201
;      CITY:  Cherry Hill
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08002
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/063,167A
;      FILING DATE:  19930517
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/05209
;      FILING DATE:  July 23, 1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0002
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
US-08-063-167A-34

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 534
US-08-007-997A-34
; Sequence 34, Application US/08007997A
; Patent No. 5591623
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Mirabelli
;    TITLE OF INVENTION:  Oligonucleotide Modulation
;    TITLE OF INVENTION:  of Cell Adhesion
;    NUMBER OF SEQUENCES:  82
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & No. 5591623ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/007,997A
;      FILING DATE:  19930121
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/05209
;      FILING DATE:  July 23, 1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISIS-0709
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
US-08-007-997A-34

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 535
US-08-319-492B-102/c
; Sequence 102, Application US/08319492B
; Patent No. 5616488
;  GENERAL INFORMATION:
;    APPLICANT:  Sullivan, Sean M.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
```

```
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF IL-5
;    NUMBER OF SEQUENCES:  751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/319,492B
;      FILING DATE:  October 7, 1994
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                Two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/276
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  102:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-319-492B-102

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||||||||| ||
Db         15 AAATATTTACTTT 3


RESULT 536
US-08-291-932A-63/c
; Sequence 63, Application US/08291932A
; Patent No. 5658780
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  NF-KB
;    NUMBER OF SEQUENCES:  830
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/291,932A
;      FILING DATE:  August 15, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                Two
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/157
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  63:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-291-932A-63

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGG 1753
              || ||||||||||
Db         15 TGGCAAGTACTGG 3


RESULT 537
US-08-334-847-579/c
; Sequence 579, Application US/08334847
; Patent No. 5693532
;  GENERAL INFORMATION:
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  Pavco, Pam
;    APPLICANT:  Woolf, Tod
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING RESPIRATORY
;    TITLE OF INVENTION:  SYNCYTIAL VIRUS
;    NUMBER OF SEQUENCES:  909
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/334,847
;      FILING DATE:  No. 5693532ember 4, 1994
;    PRIOR APPLICATION DATA:
```

```
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/032
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  579:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-334-847-579

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAG 2033
              ||||||||||  ||
Db         15 CCTCTGGTAGAAG 3


RESULT 538
US-08-311-486C-83/c
; Sequence 83, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  83:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-83

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2023 TCTGGTAGGAGGC 2035
              ||||||||||| |
Db         13 TCTGGTAGGAGAC 1


RESULT 539
US-08-440-740A-34
; Sequence 34, Application US/08440740A
; Patent No. 5843738
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Mirabelli
;    TITLE OF INVENTION:  Oligonucleotide Modulation
;    TITLE OF INVENTION:  of Cell Adhesion
;    NUMBER OF SEQUENCES:  85
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Jane Massey Licata
;      STREET:  66 East Main Street
;      CITY:  Marlton
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08053
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/440,740A
;      FILING DATE:  May 12, 1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  063,167
;      FILING DATE:  May 17, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  969,151
;      FILING DATE:  February 10, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  007,997
;      FILING DATE:  January 20, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0133
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (609) 779-2400
;      TELEFAX:  (609) 779-8488
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
```

```
US-08-440-740A-34

  Query Match           2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 540
US-08-585-684B-1199
; Sequence 1199, Application US/08585684B
; Patent No. 5877021
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/585,684B
;      FILING DATE:  January 16, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/000,951
;      FILING DATE:  July 7, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1199:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-585-684B-1199

  Query Match           2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   38.5%;  Pred. No. 4.2e+02;
  Matches    5;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTG 1804
              |::: |::|:|:|
Db          1 CUUUGCUUCUCUG 13


RESULT 541
US-08-344-155C-34
; Sequence 34, Application US/08344155C
; Patent No. 5883082
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Stepkowski
;    TITLE OF INVENTION:  Compositions and Methods for Preventing
;    TITLE OF INVENTION:  and Treating Allograft Rejection
;    NUMBER OF SEQUENCES:  99
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodland Falls Corporate Park
;      STREET:  210 Lake Drive East, Suite 201
;      CITY:  Cherry Hill
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08002
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/344,155C
;      FILING DATE:  No. 5883082ember 23, 1994
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/05209
;      FILING DATE:  July 23, 1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/063,167
;      FILING DATE:  5/17/93
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/007,997
;      FILING DATE:  1/21/93
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/939,855
;      FILING DATE:  9/2/92
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/567,286
;      FILING DATE:  8/14/90
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0098
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (609) 779-2400
;      TELEFAX:  (609) 779-8488
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
US-08-344-155C-34

  Query Match           2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 542
US-08-982-845B-34
; Sequence 34, Application US/08982845B
; Patent No. 6015894
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Mirabelli
;    TITLE OF INVENTION:  Oligonucleotide Modulation
;    TITLE OF INVENTION:  of Cell Adhesion
;    NUMBER OF SEQUENCES:  87
;    CORRESPONDENCE ADDRESS:
```

```
;      ADDRESSEE:  Law Offices of Jane Massey Licata
;      STREET:  66 East Main Street
;      CITY:  Marlton
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08053
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  WORDPERFECT 6.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/982,845B
;      FILING DATE:  December 2, 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/440,740
;      FILING DATE:  May 12, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  063,167
;      FILING DATE:  May 17, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  969,151
;      FILING DATE:  February 10, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  007,997
;      FILING DATE:  January 21, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0243
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (609) 779-2400
;      TELEFAX:  (609) 779-8488
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
US-08-982-845B-34

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 543
US-08-991-525B-34
; Sequence 34, Application US/08991525B
; Patent No. 6093811
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Mirabelli
;    TITLE OF INVENTION:  Oligonucleotide Modulation
;    TITLE OF INVENTION:  of Cell Adhesion
;    NUMBER OF SEQUENCES:  87
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Jane Massey Licata
;      STREET:  66 East Main Street
;      CITY:  Marlton
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08053
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  WORDPERFECT 6.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/991,525B
;      FILING DATE:  December 16, 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  440,740
;      FILING DATE:  May 12, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  063,167
;      FILING DATE:  May 17, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  969,151
;      FILING DATE:  February 10, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  007,997
;      FILING DATE:  January 21, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (856) 810-1515
;      TELEFAX:  (856) 810-1454
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
US-08-991-525B-34

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 544
US-09-085-759-34
; Sequence 34, Application US/09085759
; Patent No. 6096722
;  GENERAL INFORMATION:
;    APPLICANT:  C. Frank Bennett, Christopher Mirabelli,
;    APPLICANT:  Brenda Baker
;    TITLE OF INVENTION:  Antisense Modulation of Cell Adhesion
;    TITLE OF INVENTION:  Molecule Expression and Treatment of Cell Adhesion
;    TITLE OF INVENTION:  Molecule-Associated Diseases
;    NUMBER OF SEQUENCES:  109
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Jane Massey Licata
;      STREET:  66 East Main Street
;      CITY:  Marlton
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08053
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
```

```
;       COMPUTER:  IBM PS/2
;       OPERATING SYSTEM:  PC-DOS
;       SOFTWARE:  WORDPERFECT 5.0
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/085,759
;       FILING DATE:  herewith
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/440,740
;       FILING DATE:  May 12, 1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  063,167
;       FILING DATE:  May 17, 1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  969,151
;       FILING DATE:  February 10, 1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  007,997
;       FILING DATE:  January 20, 1993
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  939,855
;       FILING DATE:  September 2, 1992
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  567,286
;       FILING DATE:  August 14, 1990
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Jane Massey Licata
;       REGISTRATION NUMBER:  32,257
;       REFERENCE/DOCKET NUMBER:  ISPH-0311
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (609) 779-2400
;       TELEFAX:  (609) 779-8488
;   INFORMATION FOR SEQ ID NO:  34:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15
;       TYPE:  Nucleic Acid
;       STRANDEDNESS:  Single
;       TOPOLOGY:  Linear
;     ANTI-SENSE:  Yes
US-09-085-759-34

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 545
US-09-128-496-34
; Sequence 34, Application US/09128496
; Patent No. 6169079
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Mirabelli
;    TITLE OF INVENTION:  Oligonucleotide Modulation
;    TITLE OF INVENTION:  of Cell Adhesion
;    NUMBER OF SEQUENCES:  85
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Jane Massey Licata
;      STREET:  66 East Main Street
;      CITY:  Marlton
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08053
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/128,496
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/440,740
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  969,151
;      FILING DATE:  February 10, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  007,997
;      FILING DATE:  January 20, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0133
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (609) 779-2400
;      TELEFAX:  (609) 779-8488
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
US-09-128-496-34

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 546
US-09-038-073-1199
; Sequence 1199, Application US/09038073
; Patent No. 6194150
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  Jarvis, Thale
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  INDUCTION OF GRAFT TOLERANCE
;    TITLE OF INVENTION:  AND REVERSAL OF IMMUNE RESPONSES
;    NUMBER OF SEQUENCES:  2751
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/038,073
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/585,684
```

```
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/078
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1199:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-038-073-1199

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   38.5%;  Pred. No. 4.2e+02;
  Matches    5;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTG 1804
              |::: |::|:|:|
Db          1 CUUUGCUUCUCUG 13


RESULT 547
US-09-009-490A-34
; Sequence 34, Application US/09009490A
; Patent No. 6300491
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Mirabelli
;    TITLE OF INVENTION:  Oligonucleotide Modulation
;    TITLE OF INVENTION:  of Cell Adhesion
;    NUMBER OF SEQUENCES:  95
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Office of Jane Massey Licata
;      STREET:  66 East Main Street
;      CITY:  Marlton
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08053
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  Windows 95
;      SOFTWARE:  WORDPERFECT 6.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/009,490A
;      FILING DATE:  January 20, 1998
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  440,740
;      FILING DATE:  May 12, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  063,167
;      FILING DATE:  May 17, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  969,151
;      FILING DATE:  February 10, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  007,997
;      FILING DATE:  January 20, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0268
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (609) 810-1515
;      TELEFAX:  (609) 810-1454
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
US-09-009-490A-34

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 548
US-09-311-079-3
; Sequence 3, Application US/09311079
; Patent No. 6331618
; GENERAL INFORMATION:
;  APPLICANT: Bloch, William
;  APPLICANT: Werner, William E.
;  APPLICANT: Egholm, Michael
;  APPLICANT: Myers, Rene L.
;  TITLE OF INVENTION: Compositions of Solvents and High
;  TITLE OF INVENTION: Concentrations of Nucleic Acid Analogs
;  FILE REFERENCE: 4444
;  CURRENT APPLICATION NUMBER: US/09/311,079
;  CURRENT FILING DATE: 1999-05-13
;  NUMBER OF SEQ ID NOS: 6
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 3
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Unknown
;   FEATURE:
;   OTHER INFORMATION: Test Sequence
US-09-311-079-3

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTG 1804
              ||||||||| |||
Db          1 CTTTCCTTCACTG 13


RESULT 549
US-09-081-646-94/c
; Sequence 94, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 94
```

```
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-94

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1998 TCTAGCTTCTTCA 2010
              |||| ||||||||
Db         15 TCTATCTTCTTCA 3


RESULT 550
US-09-081-646-768/c
; Sequence 768, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 768
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-768

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1998 TCTAGCTTCTTCA 2010
              |||| ||||||||
Db         15 TCTATCTTCTTCA 3


RESULT 551
PCT-US93-08101-34
; Sequence 34, Application PC/TUS9308101
;  GENERAL INFORMATION:
;    APPLICANT:  Bennett and Mirabelli
;    TITLE OF INVENTION:  Oligonucleotide Modulation
;    TITLE OF INVENTION:  of Cell Adhesion
;    NUMBER OF SEQUENCES:  85
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodland Falls Corporate Park
;      STREET:  210 Lake Drive East, Suie 201
;      CITY:  Cherry Hill
;      STATE:  NJ
;      COUNTRY:  USA
;      ZIP:  08002
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/08101
;      FILING DATE:  Herewith
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  939,855
;      FILING DATE:  September 2, 1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/05209
;      FILING DATE:  July 23, 1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  567,286
;      FILING DATE:  August 14, 1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jane Massey Licata
;      REGISTRATION NUMBER:  32,257
;      REFERENCE/DOCKET NUMBER:  ISPH-0002
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  34:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  Yes
PCT-US93-08101-34

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACA 2083
              ||||| |||||||
Db          1 GGTATTTGACACA 13


RESULT 552
US-08-320-559-8
; Sequence 8, Application US/08320559
; Patent No. 5633135
;  GENERAL INFORMATION:
;    APPLICANT:  Croce, Carlo
;    APPLICANT:  Canaani, Eli
;    TITLE OF INVENTION:  Diagnostics, Therapeutics and Methods for
;    TITLE OF INVENTION:  Detection and Treatment of Acute Leukemias
;    TITLE OF INVENTION:  Resulting from Chromosome Abnormalities in the
;    TITLE OF INVENTION:  All-1 Region
;    NUMBER OF SEQUENCES:  44
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5633135ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/320,559
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/062,443
;      FILING DATE:  14 MAY 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/971,094
;      FILING DATE:  30-OCT-92
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/888,830
;      FILING DATE:  27-MAY-92
;    PRIOR APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  US/07/805,093
;      FILING DATE:  11-DEC-91
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca, Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-0855
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  No
US-08-320-559-8

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGT 1947
              ||||||||| |||
Db          2 TTAAGGTAAAGGT 14


RESULT 553
US-08-327-392-8
; Sequence 8, Application US/08327392
; Patent No. 5633136
;  GENERAL INFORMATION:
;    APPLICANT:  Croce, Carlo
;    APPLICANT:  Canaani, Eli
;    TITLE OF INVENTION:  ALL-1 Polynucleotides and Monoclonal
;    TITLE OF INVENTION:  Antibodies for Leukemia Detection and
;    TITLE OF INVENTION:  Treatment
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz Mackiewicz & No. 5633136ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/327,392
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/971,094
;      FILING DATE:  30-OCT-92
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/888,830
;      FILING DATE:  27-MAY-92
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/805,093
;      FILING DATE:  11-DEC-91
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca, Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-1331
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  No
US-08-327-392-8

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGT 1947
              ||||||||| |||
Db          2 TTAAGGTAAAGGT 14


RESULT 554
US-08-753-147-183/c
; Sequence 183, Application US/08753147
; Patent No. 5770372
;  GENERAL INFORMATION:
;    APPLICANT:  Concannon, Patrick
;    TITLE OF INVENTION:  Detection of Mutations in the Human ATM Gene
;    NUMBER OF SEQUENCES:  196
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson and Kindness
;      STREET:  1420 5th Avenue
;      CITY:  Seattle
;      STATE:  Washingtion
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/753,147
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  VMRC-1-9714
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 743-4387
;      TELEFAX:  (206) 224 0779
;  INFORMATION FOR SEQ ID NO:  183:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapiens
US-08-753-147-183

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              ||||| |||||||
Db         16 AAATAGTTACCTT 4


RESULT 555
US-08-527-060-17
; Sequence 17, Application US/08527060
; Patent No. 5834440
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Goldenberg, Tsvi
;    APPLICANT:  Tritz, Richard
;    TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT
;    TITLE OF INVENTION:  AND/OR PREVENTION OF RESTENOSIS
;    NUMBER OF SEQUENCES:  35
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SEED and BERRY
;      STREET:  6300 Columbia Center, 701 Fifth Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  USA
;      ZIP:  98104-7092
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/527,060
;      FILING DATE:  12-SEP-1995
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  McMasters, David D.
;      REGISTRATION NUMBER:  33,963
;      REFERENCE/DOCKET NUMBER:  480124.402C1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 622-4900
;      TELEFAX:  (206) 682-6031
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-527-060-17

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1649 CCTTCACTGGTTC 1661
              || ||||||||||
Db          4 CCGTCACTGGTTC 16


RESULT 556
US-08-545-860D-8
; Sequence 8, Application US/08545860D
; Patent No. 6040140
;  GENERAL INFORMATION:
;    APPLICANT:  Croce, Carlo
;    APPLICANT:  Canaani, Eli
;    TITLE OF INVENTION:  Diagnostics, Therapeutics and Methods
;    TITLE OF INVENTION:  for Detection and Treatment of Acute Leukemias
;    TITLE OF INVENTION:  Resulting from Chromosome Abnormalities in the All-1 Region
;    NUMBER OF SEQUENCES:  94
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewitz &
;      ADDRESSEE:  No. 6040140ris
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/545,860D
;      FILING DATE:  07-MAR-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/04496
;      FILING DATE:  22-APR-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/10930
;      FILING DATE:  09-DEC-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/327,392
;      FILING DATE:  19-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/320,559
;      FILING DATE:  11-OCT-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/062,443
;      FILING DATE:  14-MAY-1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/971,094
;      FILING DATE:  30-OCT-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/888,839
;      FILING DATE:  27-MAY-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/805,093
;      FILING DATE:  11-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca Esq., Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-1262
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  No
US-08-545-860D-8

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGT 1947
              ||||||||| |||
Db          2 TTAAGGTAAAGGT 14


RESULT 557
US-08-088-661F-36
; Sequence 36, Application US/08088661F
; Patent No. 6228982
; GENERAL INFORMATION:
;  APPLICANT:  No. 6228982den, Benget
;  APPLICANT:  Wittung, Pernilla
;  APPLICANT:  Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter E.
;  APPLICANT:  Berg, Rolf
;  TITLE OF INVENTION:  Double-Stranded Peptide Nucleic Acids
;  FILE REFERENCE:  ISIS1108
;  CURRENT APPLICATION NUMBER: US/08/088,661F
;  CURRENT FILING DATE:  1993-07-02
;  PRIOR APPLICATION NUMBER:  08/054,363
;  PRIOR FILING DATE:  1993-04-26
;  PRIOR APPLICATION NUMBER:  PCT/EP92/01219
;  PRIOR FILING DATE:  1992-05-19
;  NUMBER OF SEQ ID NOS:  42
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 36
;   LENGTH: 16
;   TYPE: DNA
```

```
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: No. 6228982el Sequence
US-08-088-661F-36

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGTG 1993
              || ||||||||||
Db          2 AAGAAGAAAAGTG 14


RESULT 558
US-08-108-591B-33
; Sequence 33, Application US/08108591B
; Patent No. 6395474
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS0540
;  CURRENT APPLICATION NUMBER: US/08/108,591B
;  CURRENT FILING DATE:  2001-08-13
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 33
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: No. 6395474el Sequence
US-08-108-591B-33

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGTG 1993
              || ||||||||||
Db          2 AAGAAGAAAAGTG 14


RESULT 559
US-09-371-772B-6072/c
; Sequence 6072, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6072
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6072

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACAC 1867
              || ||||||||||
Db         13 CACACCCACACAC 1


RESULT 560
US-09-479-005A-396
; Sequence 396, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 396
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-396

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   61.5%;  Pred. No. 4.5e+02;
  Matches    8;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAA 1981
              | ::|||::||||
Db          2 AGUUACCUUGAAA 14


RESULT 561
US-08-468-719A-33
; Sequence 33, Application US/08468719A
; Patent No. 6710163
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter E.
;  APPLICANT:  Berg, Rolf H.
;  TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS SYNTHONS
;  FILE REFERENCE: ISPS-1999
;  CURRENT APPLICATION NUMBER: US/08/468,719A
;  CURRENT FILING DATE:  1995-06-06
;  PRIOR APPLICATION NUMBER: US 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 48
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Oligonucleotide Primer
US-08-468-719A-33

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGTG 1993
              || ||||||||||
```

```
Db          2 AAGAAGAAAAGTG 14


RESULT 562
US-08-462-977B-33
; Sequence 33, Application US/08462977B
; Patent No. 6713602
; GENERAL INFORMATION:
;  APPLICANT: Buchardt, Ole
;  APPLICANT:  Egholm, Michael
;  APPLICANT:  Nielsen, Peter Eigil
;  APPLICANT:  Berg, Rolf Henrik
;  TITLE OF INVENTION: Peptide Nucleic Acids
;  FILE REFERENCE: ISIS-1993
;  CURRENT APPLICATION NUMBER: US/08/462,977B
;  CURRENT FILING DATE:  1995-06-05
;  PRIOR APPLICATION NUMBER: 08/108,591
;  PRIOR FILING DATE: 1993-11-22
;  NUMBER OF SEQ ID NOS: 43
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 33
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: misc_feature
;   OTHER INFORMATION: No. 6713602el Sequence
US-08-462-977B-33

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGTG 1993
              || ||||||||||
Db          2 AAGAAGAAAAGTG 14


RESULT 563
US-09-696-791-4155
; Sequence 4155, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4155
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hairpin ribozyme recognition site for lysyl oxidase
US-09-696-791-4155

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1649 CCTTCACTGGTTC 1661
              || ||||||||||
Db          4 CCGTCACTGGTTC 16


RESULT 564
US-09-696-791-4373
; Sequence 4373, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
;  APPLICANT:  Robbins, Joan M.
;  APPLICANT:  Tritz, Richard
;  TITLE OF INVENTION:  RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
;  TITLE OF INVENTION:  SKIN AND EYE DISEASES
;  FILE REFERENCE:  480124.407
;  CURRENT APPLICATION NUMBER: US/09/696,791
;  CURRENT FILING DATE:  2000-10-25
;  NUMBER OF SEQ ID NOS:  4523
;  SOFTWARE:  PatentIn Ver. 2.0
; SEQ ID NO 4373
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Hammerhead ribozyme recognition site for lysyl oxidase
US-09-696-791-4373

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1649 CCTTCACTGGTTC 1661
              || ||||||||||
Db          4 CCGTCACTGGTTC 16


RESULT 565
US-10-071-411A-12
; Sequence 12, Application US/10071411A
; Patent No. 6797475
; GENERAL INFORMATION:
;  APPLICANT: Glenn Barnes
;  APPLICANT:  Joanne Meyer
;  TITLE OF INVENTION: Detection of Polymorphisms in the Human
;  TITLE OF INVENTION:  5-Lipoxygenase Gene
;  FILE REFERENCE: MRI-021
;  CURRENT APPLICATION NUMBER: US/10/071,411A
;  CURRENT FILING DATE:  2002-02-07
;  PRIOR APPLICATION NUMBER: 60/267,515
;  PRIOR FILING DATE: 2001-02-08
;  PRIOR APPLICATION NUMBER: 60/314,248
;  PRIOR FILING DATE: 2001-08-21
;  NUMBER OF SEQ ID NOS: 66
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 12
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-10-071-411A-12

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1669 CCCGCCCCTGGAC 1681
              |||||||||| ||
Db          2 CCCGCCCCTGCAC 14


RESULT 566
PCT-US94-04496-8
; Sequence 8, Application PC/TUS9404496
;  GENERAL INFORMATION:
;    APPLICANT:  Croce, Carlo
;    APPLICANT:  Canaani, Eli
;    TITLE OF INVENTION:  Diagnostics, Therapeutics and Methods
;    TITLE OF INVENTION:  for Detection and Treatment of Acute Leukemias
;    TITLE OF INVENTION:  Resulting from Chromosome Abnormalities in the All-1
;    NUMBER OF SEQUENCES:  86
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock, Washburn, Kurtz, Mackiewitz &
;      ADDRESSEE:  Norris
```

```
;      STREET:  One Liberty Place, 46th floor
;      CITY:  Philadelphia
;      STATE:  Pennsylvania
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US94/04496
;      FILING DATE:
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  DeLuca Esq., Mark
;      REGISTRATION NUMBER:  33,229
;      REFERENCE/DOCKET NUMBER:  TJU-1242
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    ANTI-SENSE:  No
PCT-US94-04496-8

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 16;
  Best Local Similarity   92.3%;  Pred. No. 4.5e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGT 1947
                ||||||||| |||
Db          2 TTAAGGTAAAGGT 14


RESULT 567
US-07-991-855-15/c
; Sequence 15, Application 07/991855
; Patent No. 5420032
;  GENERAL INFORMATION:
;    APPLICANT:  Marshall, Philip
;    APPLICANT:  Lemieux, Claude
;    TITLE OF INVENTION:  Homing Endonuclease Which Originates
;    TITLE OF INVENTION:  From Chlamydomonas Eugametos and Recognizes and Cleaves a
;    TITLE OF INVENTION:  15, 17 or 19 Degenerate Doublee Stranded Nucleotide
;    TITLE OF INVENTION:  Sequence
;    NUMBER OF SEQUENCES:  74
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merchant & Gould
;      STREET:  3100 No. 5420032west Center
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  07/991,855
;      FILING DATE:  16-DEC-1992
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/813,129
;      FILING DATE:  23-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Woessner, Warren D.
;      REGISTRATION NUMBER:  30,440
;      REFERENCE/DOCKET NUMBER:  9555.18-US-01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-332-5300
;      TELEFAX:  612-332-9081
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-991-855-15

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTAACTTTGGACC 1727
                ||| |||||||||
Db         17 CTACCTTTGGACC 5


RESULT 568
US-07-991-855-16/c
; Sequence 16, Application 07/991855
; Patent No. 5420032
;  GENERAL INFORMATION:
;    APPLICANT:  Marshall, Philip
;    APPLICANT:  Lemieux, Claude
;    TITLE OF INVENTION:  Homing Endonuclease Which Originates
;    TITLE OF INVENTION:  From Chlamydomonas Eugametos and Recognizes and Cleaves a
;    TITLE OF INVENTION:  15, 17 or 19 Degenerate Doublee Stranded Nucleotide
;    TITLE OF INVENTION:  Sequence
;    NUMBER OF SEQUENCES:  74
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merchant & Gould
;      STREET:  3100 No. 5420032west Center
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  07/991,855
;      FILING DATE:  16-DEC-1992
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/813,129
;      FILING DATE:  23-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Woessner, Warren D.
;      REGISTRATION NUMBER:  30,440
;      REFERENCE/DOCKET NUMBER:  9555.18-US-01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-332-5300
;      TELEFAX:  612-332-9081
;  INFORMATION FOR SEQ ID NO:  16:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-991-855-16

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1715 CTAACTTTGGACC 1727
              ||| |||||||||
Db         17 CTACCTTTGGACC 5


RESULT 569
US-07-991-855-56
; Sequence 56, Application 07/991855
; Patent No. 5420032
;  GENERAL INFORMATION:
;    APPLICANT:  Marshall, Philip
;    APPLICANT:  Lemieux, Claude
;    TITLE OF INVENTION:  Homing Endonuclease Which Originates
;    TITLE OF INVENTION:  From Chlamydomonas Eugametos and Recognizes and Cleaves a
;    TITLE OF INVENTION:  15, 17 or 19 Degenerate Doublee Stranded Nucleotide
;    TITLE OF INVENTION:  Sequence
;    NUMBER OF SEQUENCES:  74
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Merchant & Gould
;      STREET:  3100 No. 5420032west Center
;      CITY:  Minneapolis
;      STATE:  MN
;      COUNTRY:  USA
;      ZIP:  55402
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  07/991,855
;      FILING DATE:  16-DEC-1992
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/813,129
;      FILING DATE:  23-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Woessner, Warren D.
;      REGISTRATION NUMBER:  30,440
;      REFERENCE/DOCKET NUMBER:  9555.18-US-01
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  612-332-5300
;      TELEFAX:  612-332-9081
;  INFORMATION FOR SEQ ID NO:  56:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-07-991-855-56

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1715 CTAACTTTGGACC 1727
              ||| |||||||||
Db          1 CTACCTTTGGACC 13


RESULT 570
US-08-119-773-20/c
; Sequence 20, Application US/08119773
; Patent No. 5460942
;  GENERAL INFORMATION:
;    APPLICANT:  Chou, Janice Y.
;    APPLICANT:  Lei, Ke-Jian
;    APPLICANT:  Shelly, Leslie L.
;    TITLE OF INVENTION:  GLUCOSE-6-PHOSPHATASE: THE GENE AND
;    TITLE OF INVENTION:  PROTEIN AND RELATED MUTATIONS
;    NUMBER OF SEQUENCES:  36
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend Khourie and Crew
;      STREET:  Steuart Street Tower, One Market Plaza
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  US
;      ZIP:  94105-1493
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/119,773
;      FILING DATE:  10-SEP-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Weber, Kenneth A.
;      REGISTRATION NUMBER:  31,677
;      REFERENCE/DOCKET NUMBER:  15280-175
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 543-9600
;      TELEFAX:  (415) 543-5043
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-119-773-20

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2072 GTATCTGACACAC 2084
              ||| |||||||||
Db         16 GTAGCTGACACAC 4


RESULT 571
US-08-242-664-33
; Sequence 33, Application US/08242664
; Patent No. 5571937
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/242,664
;      FILING DATE:  May 12, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  33:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-242-664-33

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
              |||||| ||||||
Db          4 AAAAAAGGAAAAG 16


RESULT 572
US-08-281-940-5
; Sequence 5, Application US/08281940
; Patent No. 5589330
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  METHOD FOR MULTIPLE ALLELE-SPECIFIC
;    TITLE OF INVENTION:  DISEASE ANALYSIS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DARBY & DARBY P.C.
;      STREET:  805 THIRD AVENUE
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10022
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/281,940
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LUDWIG, S. PETER
;      REGISTRATION NUMBER:  25351
;      REFERENCE/DOCKET NUMBER:  0372/09696
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212/527-7700
;      TELEFAX:  212/753-6237
;      TELEX:  236687
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapien
;    IMMEDIATE SOURCE:
;      CLONE:  W1282XM
US-08-281-940-5

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTG 1804
              ||||||||| |||
Db          1 CTTTCCTTCACTG 13


RESULT 573
US-08-390-850-418
; Sequence 418, Application US/08390850
; Patent No. 5612215
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/390,850
;      FILING DATE:  February 17, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5612215ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  418:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-390-850-418

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   76.9%;  Pred. No. 4.7e+02;
  Matches   10;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1973 ACCTTGAAAAAAA 1985
              |||::|||||| |
Db          5 ACCUUGAAAAAGA 17


RESULT 574
US-08-390-850-657
; Sequence 657, Application US/08390850
; Patent No. 5612215
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
```

```
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/390,850
;      FILING DATE:  February 17, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5612215ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  657:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-390-850-657

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTAAAT 1838
                ||| : ::::|||:
Db          3 GAAUGUUUUAAAU 15


RESULT 575
US-08-390-850-658
; Sequence 658, Application US/08390850
; Patent No. 5612215
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/390,850
;      FILING DATE:  February 17, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5612215ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  658:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-390-850-658

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTAAAT 1838
                ||| : ::::|||:
Db          2 GAAUGUUUUAAAU 14


RESULT 576
US-08-390-850-659
; Sequence 659, Application US/08390850
; Patent No. 5612215
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/390,850
;      FILING DATE:  February 17, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
```

```
;       FILING DATE:  No. 5612215ember 12, 1993
;       APPLICATION NUMBER:  07/989,848
;       FILING DATE:  December 7, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  211/084
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  659:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-390-850-659

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAAT 1838
                ||||: :::::|||:
Db          1 GAAUGUUUUAAAU 13


RESULT 577
US-08-390-850-680
; Sequence 680, Application US/08390850
; Patent No. 5612215
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/390,850
;      FILING DATE:  February 17, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5612215ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  680:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-390-850-680

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1992 TGTGTATCTAGCT 2004
                :|:|:|:|:| |:
Db          2 UGUGUAUCUAACU 14


RESULT 578
US-08-484-138-33
; Sequence 33, Application US/08484138
; Patent No. 5652350
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,138
;      FILING DATE:  June 7, 1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-Z/JPW/MJG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-484-138-33

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
                |||||| ||||||
Db          4 AAAAAAGGAAAAG 16


RESULT 579
US-08-435-634-418
; Sequence 418, Application US/08435634
; Patent No. 5731295
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,634
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/390,850
;      FILING DATE:  February 17, 1995
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5731295ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  418:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-634-418

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   76.9%;  Pred. No. 4.7e+02;
  Matches   10;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1973 ACCTTGAAAAAAA 1985
              |||::|||||| |
Db             5 ACCUUGAAAAAGA 17


RESULT 580
US-08-435-634-657
; Sequence 657, Application US/08435634
; Patent No. 5731295
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,634
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/390,850
;      FILING DATE:  February 17, 1995
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5731295ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  657:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-634-657

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAAT 1838
              |||: ::::|||:
Db          3 GAAUGUUUUAAAU 15


RESULT 581
US-08-435-634-658
; Sequence 658, Application US/08435634
; Patent No. 5731295
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
```

```
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,634
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/390,850
;      FILING DATE:  February 17, 1995
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5731295ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  658:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-634-658

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAAT 1838
              |||: ::::|||:
Db          2 GAAUGUUUUAAAU 14


RESULT 582
US-08-435-634-659
; Sequence 659, Application US/08435634
; Patent No. 5731295
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,634
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/390,850
;      FILING DATE:  February 17, 1995
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
;      FILING DATE:  No. 5731295ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  659:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-634-659

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAAT 1838
              |||: ::::|||:
Db          1 GAAUGUUUUAAAU 13


RESULT 583
US-08-435-634-680
; Sequence 680, Application US/08435634
; Patent No. 5731295
;  GENERAL INFORMATION:
;    APPLICANT:  Draper, Kenneth G.
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Gustofson, John
;    APPLICANT:  Stinchcomb, Dan T.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR TREATMENT
;    TITLE OF INVENTION:  OF ARTHRITIC CONDITIONS
;    NUMBER OF SEQUENCES:  1151
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,634
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/390,850
;      FILING DATE:  February 17, 1995
;      APPLICATION NUMBER:  08/354,920
;      FILING DATE:  December 13, 1994
;      APPLICATION NUMBER:  08/152,487
```

```
;      FILING DATE:  No. 5731295ember 12, 1993
;      APPLICATION NUMBER:  07/989,848
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  211/084
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  680:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-634-680

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1992 TGTGTATCTAGCT 2004
              :|:|:|:|:| |:
Db          2 UGUGUAUCUAACU 14


RESULT 584
US-08-758-306-149/c
; Sequence 149, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  149:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-149

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1819 AGTTTTAGAATCT 1831
              |||||||| ||||
Db         14 AGTTTTAGCATCT 2


RESULT 585
US-08-710-134-5
; Sequence 5, Application US/08710134
; Patent No. 5834181
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  HIGH THROUGHPUT SCREENING METHOD FOR
;    TITLE OF INVENTION:  SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genzyme Corporation
;      STREET:  One Mountain Road
;      CITY:  Framingham
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  01701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/710,134
;      FILING DATE:  13-SEP-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dugan, Deborah A.
;      REGISTRATION NUMBER:  37,315
;      REFERENCE/DOCKET NUMBER:  IG5-8.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  508-872-8400
;      TELEFAX:  508-872-5415
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotides"
US-08-710-134-5

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTG 1804
              ||||||||| |||
Db          1 CTTTCCTTCACTG 13


RESULT 586
US-08-229-528-8
; Sequence 8, Application US/08229528
; Patent No. 5837447
;  GENERAL INFORMATION:
;    APPLICANT:  GORSKI, Jack
;    TITLE OF INVENTION:  MONITORING AN IMMUNE RESPONSE BY ANALYSIS OF AMPLIFIED IMMUNO
;    NUMBER OF SEQUENCES:  51
```

```
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Foley & Lardner
;      STREET:  P. O. Box 1497
;      CITY:  Madison
;      STATE:  Wisconsin
;      COUNTRY:  USA
;      ZIP:  53701-1497
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette,3.50 inch, 1.44 Mb storage
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  MS-DOS 3.3
;      SOFTWARE:  WordPerfect, Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/229,528
;      FILING DATE:  18-APR-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/868,569
;      FILING DATE:  15-APR-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Scanlon, William J.
;      REGISTRATION NUMBER:  30,136
;      REFERENCE/DOCKET NUMBER:  30383/133
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (608) 258-4284
;      TELEFAX:  (608) 258-4258
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid;
;      DESCRIPTION:  Synthetic DNA oligonucleotide
US-08-229-528-8

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1578 TCCACCGCACAGA 1590
              |||| ||||||||
Db          3 TCCAGCGCACAGA 15


RESULT 587
US-08-485-885-5
; Sequence 5, Application US/08485885
; Patent No. 5849483
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  HIGH THROUGHPUT SCREENING METHOD FOR
;    TITLE OF INVENTION:  SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genzyme Corporation
;      STREET:  One Mountain Road
;      CITY:  Framingham
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  01701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/485,885
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dugan, Deborah A.
;      REGISTRATION NUMBER:  37,315
;      REFERENCE/DOCKET NUMBER:  GEN4-12.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  508-872-8400
;      TELEFAX:  508-872-5415
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotides"
US-08-485-885-5

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTG 1804
              ||||||||| |||
Db          1 CTTTCCTTCACTG 13


RESULT 588
US-08-174-672D-2
; Sequence 2, Application US/08174672D
; Patent No. 5877009
;  GENERAL INFORMATION:
;    APPLICANT:  Zannis Ph.D., Vassilis I.
;    APPLICANT:  Cladaras Ph.D., Christos
;    TITLE OF INVENTION:  APOLIPOPROTEIN GENE REGULATION
;    NUMBER OF SEQUENCES:  113
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Choate, Hall & Stewart
;      STREET:  53 State Street
;      CITY:  Boston
;      STATE:  MA
;      COUNTRY:  USA
;      ZIP:  02109-2891
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/174,672D
;      FILING DATE:  28-DEC-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Jarrell Ph.D., Brenda H.
;      REGISTRATION NUMBER:  39,223
;      REFERENCE/DOCKET NUMBER:  0079571-0005
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 248-5000
;      TELEFAX:  (617) 248 4000
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  both
;      TOPOLOGY:  not relevant
;    MOLECULE TYPE:  DNA (genomic)
;    IMMEDIATE SOURCE:
;      CLONE:  apoB promoter region -79 to -63
US-08-174-672D-2

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATT 1731
              |||||||||| ||
Db          5 CTTTGGACCTTTT 17
```

```
RESULT 589
US-08-985-162-632
; Sequence 632, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  632:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-632

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              :|:|:||:|| ::
Db          4 UAUCUCCUAAUUU 16


RESULT 590
US-08-985-162-633
; Sequence 633, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  633:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-633

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              :|:|:||:|| ::
Db          1 UAUCUCCUAAUUU 13


RESULT 591
US-08-985-162-749
; Sequence 749, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  749:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-749

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCT 1798
              |||||:: :::||:
Db          2 CCCAUUUUUUCCU 14


RESULT 592
US-08-463-903-89
; Sequence 89, Application US/08463903
; Patent No. 6071515
; GENERAL INFORMATION:
;  APPLICANT: Mezes, Peter S.
;  APPLICANT: Richard, Ruth A.
;  APPLICANT: Affholter, Joseph A.
;  APPLICANT: Kotite, Nicolas J.
;  TITLE OF INVENTION: Dimer and Multimer Forms of Single Chain Polypeptides
;  FILE REFERENCE: 40224A US
;  CURRENT APPLICATION NUMBER: US/08/463,903
;  CURRENT FILING DATE: 1995-06-05
;  EARLIER APPLICATION NUMBER: US 07/935,695
;  EARLIER FILING DATE: 1992-08-21
;  NUMBER OF SEQ ID NOS: 102
;  SOFTWARE: MS-Word for Windows, Ver. 7.0
; SEQ ID NO 89
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: Aint2 primer
;   LOCATION: 1..17
US-08-463-903-89

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACA 1864
              || ||||||||||
Db          1 CACCAGACCCACA 13


RESULT 593
US-08-945-654-4
; Sequence 4, Application US/08945654
; Patent No. 6071747
;  GENERAL INFORMATION:
;    APPLICANT:
;    TITLE OF INVENTION:  IMMORTALIZED CELL LINES FROM HUMAN
;    TITLE OF INVENTION:  ADIPOSE TISSUE, PROCESS FOR PREPARING SAME AND APPLICATIONS
;    TITLE OF INVENTION:  THEREOF.
;    NUMBER OF SEQUENCES:  22
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/945,654
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 9504922
;      FILING DATE:  25-APR-1995
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "PRIMER"
US-08-945-654-4

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              ||||| |||||||
Db          4 ATCCTGCTCCACC 16


RESULT 594
US-07-935-695-89
; Sequence 89, Application US/07935695
; Patent No. 6329507
; GENERAL INFORMATION:
;  APPLICANT:  Mezes, Peter S.
;  APPLICANT:  Richard, Ruth A.
;  APPLICANT:  Affholter, Joseph A.
;  APPLICANT:  Kotite, Nicolas J.
;  TITLE OF INVENTION:  Dimer and Multimer Forms of Single Chain Polypeptides
;  FILE REFERENCE:  40224A US
;  CURRENT APPLICATION NUMBER: US/07/935,695
;  CURRENT FILING DATE:  1992-08-21
;  PRIOR APPLICATION NUMBER:  US 08/463,903
;  PRIOR FILING DATE:  1995-06-05
;  NUMBER OF SEQ ID NOS:  102
;  SOFTWARE:  MS-Word for Windows, Ver. 7.0
; SEQ ID NO 89
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   NAME/KEY: Aint2 primer
;   LOCATION: 1..17
;   OTHER INFORMATION: :
US-07-935-695-89

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACA 1864
              || ||||||||||
Db          1 CACCAGACCCACA 13


RESULT 595
US-08-584-040-1689/c
```

```
; Sequence 1689, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
;   APPLICANT: Pavco, Pamela
;   APPLICANT: McSwiggen, James
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Escobedo, Jaime
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: TREATMENT OF DISEASES OR
;   TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;   TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;   TITLE OF INVENTION: GROWTH FACTOR
;   NUMBER OF SEQUENCES: 8502
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: Word Perfect 5.1
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/584,040
;     FILING DATE: January 11, 1996
;     CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 60/005,974
;     FILING DATE: October 26, 1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard J.
;     REGISTRATION NUMBER: 32,327
;     REFERENCE/DOCKET NUMBER: 218/064
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (213) 489-1600
;     TELEFAX: (213) 955-0440
;     TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1689:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 17 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
US-08-584-040-1689

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1831 TTTTAAATACATT 1843
              ||||||| |||||
Db         14 TTTTAAACACATT 2


RESULT 596
US-08-584-040-1690/c
; Sequence 1690, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
;   APPLICANT: Pavco, Pamela
;   APPLICANT: McSwiggen, James
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Escobedo, Jaime
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: TREATMENT OF DISEASES OR
;   TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;   TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;   TITLE OF INVENTION: GROWTH FACTOR
;   NUMBER OF SEQUENCES: 8502
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: Word Perfect 5.1
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/584,040
;     FILING DATE: January 11, 1996
;     CLASSIFICATION: 514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 60/005,974
;     FILING DATE: October 26, 1995
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard J.
;     REGISTRATION NUMBER: 32,327
;     REFERENCE/DOCKET NUMBER: 218/064
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (213) 489-1600
;     TELEFAX: (213) 955-0440
;     TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1690:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 17 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
US-08-584-040-1690

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1831 TTTTAAATACATT 1843
              ||||||| |||||
Db         13 TTTTAAACACATT 1


RESULT 597
US-08-584-040-2802
; Sequence 2802, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
;   APPLICANT: Pavco, Pamela
;   APPLICANT: McSwiggen, James
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Escobedo, Jaime
;   TITLE OF INVENTION: METHOD AND REAGENT FOR THE
;   TITLE OF INVENTION: TREATMENT OF DISEASES OR
;   TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;   TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;   TITLE OF INVENTION: GROWTH FACTOR
;   NUMBER OF SEQUENCES: 8502
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
```

```
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/584,040
;       FILING DATE:  January 11, 1996
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/005,974
;       FILING DATE:  October 26, 1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/064
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2802:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-2802

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   53.8%;  Pred. No. 4.7e+02;
  Matches    7;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1962 GCTAAATATTTAC 1974
              ||:|||:|::: |
Db          2 GCUAAAUAUUUUC 14


RESULT 598
US-08-584-040-4250
; Sequence 4250, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4250:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-4250

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          5 AAAUAUUUUCCUU 17


RESULT 599
US-08-584-040-4251
; Sequence 4251, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4251:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
```

```
US-08-584-040-4251

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          3 AAAUAUUUUCCUU 15


RESULT 600
US-08-584-040-4252
; Sequence 4252, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4252:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-4252

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          2 AAAUAUUUUCCUU 14


RESULT 601
```

```
US-08-584-040-4253
; Sequence 4253, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4253:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-4253

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          1 AAAUAUUUUCCUU 13


RESULT 602
US-08-584-040-5820
; Sequence 5820, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
```

```
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5820:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5820

  Query Match              2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          5 AAAUAUUUUCCUU 17


RESULT 603
US-08-584-040-5821
; Sequence 5821, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5821:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5821

  Query Match              2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          3 AAAUAUUUUCCUU 15


RESULT 604
US-08-584-040-5822
; Sequence 5822, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
```

```
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/064
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  5822:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-5822

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          2 AAAUAUUUUCCUU 14


RESULT 605
US-08-584-040-5823
; Sequence 5823, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5823:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5823

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          1 AAAUAUUUUCCUU 13


RESULT 606
US-08-584-040-7531/c
; Sequence 7531, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7531:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7531

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACC 1786
              || ||||||||||
Db         17 TTGTTTTTGAACC 5
```

```
RESULT 607
US-08-584-040-7814
; Sequence 7814, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7814:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7814

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   15.4%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTT 1781
              ||:::::: ::::
Db          5 GCUUUUUUGUUUU 17


RESULT 608
US-08-584-040-7815
; Sequence 7815, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7815:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7815

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   15.4%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTT 1781
              ||:::::: ::::
Db          4 GCUUUUUUGUUUU 16


RESULT 609
US-08-584-040-7816
; Sequence 7816, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
```

```
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/584,040
;       FILING DATE:  January 11, 1996
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/005,974
;       FILING DATE:  October 26, 1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/064
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  7816:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-7816

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   15.4%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTT 1781
              ||:::::: ::::
Db          3 GCUUUUUUGUUUU 15


RESULT 610
US-08-584-040-7817
; Sequence 7817, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7817:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7817

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   15.4%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTT 1781
              ||:::::: ::::
Db          2 GCUUUUUUGUUUU 14


RESULT 611
US-08-584-040-8156
; Sequence 8156, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  8156:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
```

```
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-8156

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1651 TTCACTGGTTCTG 1663
              ::| |:||::|:|
Db          5 UUCUCUGGUUCUG 17


RESULT 612
US-09-474-432B-847/c
; Sequence 847, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 847
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-847

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1575 TTCTCCACCGCAC 1587
              |||||||| ||||
Db         16 TTCTCCACGGCAC 4


RESULT 613
US-09-474-432B-874
; Sequence 874, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 874
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-874

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   84.6%;  Pred. No. 4.7e+02;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1553 AGGAACAGGACTG 1565
              |||||||| ||:|
Db          2 AGGAACAGCACUG 14


RESULT 614
US-09-371-772B-234/c
; Sequence 234, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 234
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-234

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1831 TTTTAAATACATT 1843
              ||||||| |||||
Db         14 TTTTAAACACATT 2


RESULT 615
US-09-371-772B-235/c
; Sequence 235, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
```

```
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 235
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-235

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1831 TTTTAAATACATT 1843
              ||||||| |||||
Db         13 TTTTAAACACATT 1


RESULT 616
US-09-371-772B-1326
; Sequence 1326, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1326
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1326

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   53.8%;  Pred. No. 4.7e+02;
  Matches    7;  Conservative    5;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1962 GCTAAATATTTAC 1974
              ||:|||:|::: |
Db          2 GCUAAAUAUUUUC 14


RESULT 617
US-09-371-772B-2017
; Sequence 2017, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2017
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-2017

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          5 AAAUAUUUUCCUU 17


RESULT 618
US-09-371-772B-2018
; Sequence 2018, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2018
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-2018

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          3 AAAUAUUUUCCUU 15


RESULT 619
US-09-371-772B-2019
; Sequence 2019, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
```

```
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2019
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-2019

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          2 AAAUAUUUUCCUU 14


RESULT 620
US-09-371-772B-2020
; Sequence 2020, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2020
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-2020

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTT 1977
              |||:|::: ||::
Db          1 AAAUAUUUUCCUU 13


RESULT 621
US-09-371-772B-3336/c
; Sequence 3336, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3336
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3336

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACC 1786
              || ||||||||||
Db         17 TTGTTTTTGAACC 5


RESULT 622
US-09-371-772B-3598
; Sequence 3598, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3598
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3598

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   15.4%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTT 1781
              ||:::::: ::::
Db          5 GCUUUUUUGUUUU 17


RESULT 623
US-09-371-772B-3599
; Sequence 3599, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
```

```
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3599
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3599

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   15.4%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTT 1781
              ||:::::: ::::
Db          4 GCUUUUUUGUUUU 16


RESULT 624
US-09-371-772B-3600
; Sequence 3600, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3600
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3600

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   15.4%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTT 1781
              ||:::::: ::::
Db          3 GCUUUUUUGUUUU 15


RESULT 625
US-09-371-772B-3601
; Sequence 3601, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3601
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3601

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   15.4%;  Pred. No. 4.7e+02;
  Matches    2;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTT 1781
              ||:::::: ::::
Db          2 GCUUUUUUGUUUU 14


RESULT 626
US-09-371-772B-3939
; Sequence 3939, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3939
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3939

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1651 TTCACTGGTTCTG 1663
              ::| |:||::|:|
Db          5 UUCUCUGGUUCUG 17


RESULT 627
US-09-371-772B-5580
; Sequence 5580, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
```

```
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5580
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5580

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   30.8%;  Pred. No. 4.7e+02;
  Matches    4;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTT 1779
              |||| ::::::: 
Db          5 AAGCUCUUUUUU 17


RESULT 628
US-09-476-387-846/c
; Sequence 846, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 846
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-846

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1575 TTCTCCACCGCAC 1587
              |||||||| |||| 
Db         16 TTCTCCACGGCAC 4


RESULT 629
US-09-476-387-873
; Sequence 873, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 873
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-873

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   84.6%;  Pred. No. 4.7e+02;
  Matches   11;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1553 AGGAACAGGACTG 1565
              |||||||| ||:| 
Db          2 AGGAACAGCACUG 14


RESULT 630
US-09-401-063-632
; Sequence 632, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
```

```
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  632:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-632

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              :|:|:||:|| ::
Db          4 UAUCUCCUAAUUU 16


RESULT 631
US-09-401-063-633
; Sequence 633, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  633:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-633

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              :|:|:||:|| ::
Db          1 UAUCUCCUAAUUU 13


RESULT 632
US-09-401-063-749
; Sequence 749, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  749:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-749

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   46.2%;  Pred. No. 4.7e+02;
  Matches    6;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCT 1798
              ||||:: :::||:
Db          2 CCCAUUUUUUCCU 14


RESULT 633
US-09-827-998-308
; Sequence 308, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
```

```
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 308
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-308

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACA 1559
              ||||||||||| |
Db          5 TAGGGAAGGAAGA 17


RESULT 634
US-09-827-998-309
; Sequence 309, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 309
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-309

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACA 1559
              ||||||||||| |
Db          4 TAGGGAAGGAAGA 16


RESULT 635
US-09-866-108A-6296/c
; Sequence 6296, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6296
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6296

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTG 1611
              |||||| ||||||
Db         17 CCCTCCAGGCCTG 5


RESULT 636
US-09-866-108A-6297/c
; Sequence 6297, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6297
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6297

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTG 1611
              |||||| ||||||
Db         16 CCCTCCAGGCCTG 4


RESULT 637
US-09-866-108A-6298/c
; Sequence 6298, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6298
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6298

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTG 1611
              |||||| ||||||
Db         15 CCCTCCAGGCCTG 3


RESULT 638
US-09-866-108A-6299/c
; Sequence 6299, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6299
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6299

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTG 1611
              |||||| ||||||
Db         14 CCCTCCAGGCCTG 2


RESULT 639
US-09-866-108A-6300/c
; Sequence 6300, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
```

```
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6300
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-6300

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTG 1611
              |||||| ||||||
Db         13 CCCTCCAGGCCTG 1


RESULT 640
US-09-866-108A-7186/c
; Sequence 7186, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7186
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7186

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTC 2021
              ||||| |||||||
Db         17 CAGAGGTCAAGTC 5


RESULT 641
US-09-866-108A-7191/c
; Sequence 7191, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7191
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7191

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
```

```
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGT 2020
              |||||| ||||||
Db         13 TCAGAGGTCAAGT 1


RESULT 642
US-09-866-108A-7638/c
; Sequence 7638, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7638
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7638

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1689 TTGTTTCTCTAGC 1701
              ||| |||||||||
Db         17 TTGGTTCTCTAGC 5


RESULT 643
US-09-866-108A-8585/c
; Sequence 8585, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8585
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8585

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCA 1668
              || ||||||||||
Db         14 TGCTTCTGCATCA 2


RESULT 644
US-09-866-108A-8586/c
; Sequence 8586, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
```

```
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8586
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8586

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCA 1668
              || ||||||||||
Db         13 TGCTTCTGCATCA 1


RESULT 645
US-09-649-371-2
; Sequence 2, Application US/09649371
; Patent No. 6794135
; GENERAL INFORMATION:
;  APPLICANT: Kopreski, Michael S.
;  APPLICANT: Gocke, Christopher D.
;  TITLE OF INVENTION: Method for Detection of 5T4 RNA in Plasma or Serum
;  FILE REFERENCE: 09/649,371
;  CURRENT APPLICATION NUMBER: US/09/649,371
;  CURRENT FILING DATE:  2000-08-28
;  PRIOR APPLICATION NUMBER: 09/155,152
;  PRIOR FILING DATE: 1996-03-26
;  NUMBER OF SEQ ID NOS: 3
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-649-371-2

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGA 1562
              ||||||||| |||
Db          5 GGAAGGAACGGGA 17


RESULT 646
PCT-US95-06379-33
; Sequence 33, Application PC/TUS9506379
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/06379
;      FILING DATE:  May 13, 1994
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-278-0400
;      TELEFAX:  212-391-0526
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US95-06379-33

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
              |||||| ||||||
Db          4 AAAAAAGGAAAAG 16


RESULT 647
US-08-753-147-140/c
; Sequence 140, Application US/08753147
; Patent No. 5770372
;  GENERAL INFORMATION:
;    APPLICANT:  Concannon, Patrick
;    TITLE OF INVENTION:  Detection of Mutations in the Human ATM Gene
;    NUMBER OF SEQUENCES:  196
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Christensen O'Connor Johnson and Kindness
;      STREET:  1420 5th Avenue
;      CITY:  Seattle
;      STATE:  Washington
;      COUNTRY:  USA
;      ZIP:  98101-2347
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/753,147
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sheiness, Diana K.
;      REGISTRATION NUMBER:  35,356
;      REFERENCE/DOCKET NUMBER:  VMRC-1-9714
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (206) 743-4387
;      TELEFAX:  (206) 224 0779
;  INFORMATION FOR SEQ ID NO:  140:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
```

```
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapiens
US-08-753-147-140

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
              || ||  |||||||||
Db         16 TTGACACTGAAAAAAA 1


RESULT 648
US-08-087-387-1
; Sequence 1, Application US/08087387
; Patent No. 5473060
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Oligonucleotide clamps having diagnostic andtherapeutic applic
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics
;      STREET:  465 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5.25 inch diskette
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 3.1/DOS 5.0
;      SOFTWARE:  Microsoft Word for Windows, vers. 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/087,387
;      FILING DATE:  19930702
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 358-7855
;      TELEFAX:  (415) 358-7794
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-087-387-1

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              ||||||||||  | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 649
US-08-455-627-1
; Sequence 1, Application US/08455627
; Patent No. 5571677
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-843-5000
;      TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-455-627-1

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              ||||||||||  | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 650
US-08-242-664-21
; Sequence 21, Application US/08242664
; Patent No. 5571937
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/242,664
;      FILING DATE:  May 12, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
```

```
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-242-664-21

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              ||||||||||  | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 651
US-08-242-664-22
; Sequence 22, Application US/08242664
; Patent No. 5571937
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/242,664
;      FILING DATE:  May 12, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-242-664-22

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              ||||||||||  | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 652
US-08-234-613-20
; Sequence 20, Application US/08234613
; Patent No. 5582981
;  GENERAL INFORMATION:
;    APPLICANT:  TOOLE, JOHN J.
;    APPLICANT:  LATHAM, JOHN
;    APPLICANT:  BOCK, LOUIS C.
;    APPLICANT:  GRIFFIN, LINDA C.
;    TITLE OF INVENTION:  APTAMER TARGET ELUTION METHOD
;    NUMBER OF SEQUENCES:  49
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 PAGE MILL ROAD
;      CITY:  PALO ALTO
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304-1018
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/234,613
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/744,870
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GRACEY, NANCEY J.
;      REGISTRATION NUMBER:  28,216
;      REFERENCE/DOCKET NUMBER:  24610-20030.00
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 813-5600
;      TELEFAX:  (415) 494-0792
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-234-613-20

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGG 1550
              |||||  ||||  ||  ||
Db          1 AGGTTGGGAGGGTGGG 16


RESULT 653
US-08-122-792-9/c
; Sequence 9, Application US/08122792
; Patent No. 5583000
;  GENERAL INFORMATION:
;    APPLICANT:  Ortiz de Montellano, Paul R.
;    APPLICANT:  Kuntz, Irwin D.
;    APPLICANT:  Craik, Charles S.
;    APPLICANT:  Furth, Paul S.
;    APPLICANT:  Alvarez, Juan C.
;    APPLICANT:  Caldera, Patricia S.
;    APPLICANT:  DeCamp, Dianne L.
;    APPLICANT:  Babe, Lilia M.
;    APPLICANT:  De Voss, James
;    APPLICANT:  Salto, Rafael
;    APPLICANT:  Sui, Zhihua
;    TITLE OF INVENTION:  PROTEASE-BINDING COMPOUNDS AND METHODS
;    TITLE OF INVENTION:  OF USE
;    NUMBER OF SEQUENCES:  11
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew
```

```
;      STREET:  One Market Plaza, Steuart Street Tower
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94105-1492
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/122,792
;      FILING DATE:  16-SEP-1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/753,878
;      FILING DATE:  03-SEP-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Heines, M. Henry
;      REGISTRATION NUMBER:  28,219
;      REFERENCE/DOCKET NUMBER:  2307Z-501
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-543-9600
;      TELEFAX:  415-543-5043
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
;    HYPOTHETICAL:  NO
US-08-122-792-9

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1798 TTCTCTGAAAGTGGTG 1813
              ||||||||||   ||
Db         16 TTCTCTGAAAGCCATG 1


RESULT 654
US-08-427-863-3
; Sequence 3, Application US/08427863
; Patent No. 5593834
;  GENERAL INFORMATION:
;    APPLICANT:  LANE, Michael J., BENIGHT, Albert S., and
;    APPLICANT:  FALDASZ, Brian D.
;    TITLE OF INVENTION:  METHOD OF PREPARING DNA SEQUENCES WITH KNOWN
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  60 State Street, suite 510
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/427,863
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17 JUNE 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TNI-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-427-863-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              || || | ||||||||
Db          1 AAAAAAAGCTTTTTTT 16


RESULT 655
US-08-427-863-3/c
; Sequence 3, Application US/08427863
; Patent No. 5593834
;  GENERAL INFORMATION:
;    APPLICANT:  LANE, Michael J., BENIGHT, Albert S., and
;    APPLICANT:  FALDASZ, Brian D.
;    TITLE OF INVENTION:  METHOD OF PREPARING DNA SEQUENCES WITH KNOWN
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  60 State Street, suite 510
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/427,863
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17 JUNE 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TNI-001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-427-863-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              || || | ||||||||
```

```
Db         16 AAAAAAAGCTTTTTTT 1


RESULT 656
US-08-192-941-2
; Sequence 2, Application US/08192941
; Patent No. 5622854
;  GENERAL INFORMATION:
;    APPLICANT:  DRAPER
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING T-CELL LEUKEMIA
;    TITLE OF INVENTION:  VIRUS REPLICATION
;    NUMBER OF SEQUENCES:  25
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/192,941
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/882,714
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/281
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-192-941-2

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   75.0%;  Pred. No. 4.9e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCAAC 1915
              ||| || ||||:|| |
Db          1 AGAGCAUCAGAUCACC 16


RESULT 657
US-08-484-138-21
; Sequence 21, Application US/08484138
; Patent No. 5652350
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,138
;      FILING DATE:  June 7, 1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-Z/JPW/MJG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-484-138-21

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 658
US-08-484-138-22
; Sequence 22, Application US/08484138
; Patent No. 5652350
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,138
;      FILING DATE:  June 7, 1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-Z/JPW/MJG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
```

```
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-484-138-22

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              ||||||||||  | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 659
US-08-461-271-1
; Sequence 1, Application US/08461271
; Patent No. 5741643
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Oligonucleotide clamps having diagnostic
;    TITLE OF INVENTION:  and therapeutic applications
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics
;      STREET:  465 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5.25 inch diskette
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 3.1/DOS 5.0
;      SOFTWARE:  Microsoft Word for Windows, vers. 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/461,271
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/087,387
;      FILING DATE:  2-Jul-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 358-7855
;      TELEFAX:  (415) 358-7794
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-461-271-1

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              ||||||||||  | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 660
US-08-484-192-92
; Sequence 92, Application US/08484192
; Patent No. 5756291
;  GENERAL INFORMATION:
;    APPLICANT:  GRIFFIN, LINDA C.
;    APPLICANT:  ALBRECHT, GLENN
;    APPLICANT:  LATHAM, JOHN
;    APPLICANT:  LEUNG, LAWRENCE
;    APPLICANT:  VERMAAS, ERIC
;    APPLICANT:  TOOLE, JOHN J.
;    TITLE OF INVENTION:  APTAMERS SPECIFIC FOR BIOMOLECULES AND
;    TITLE OF INVENTION:  METHODS OF MAKING
;    NUMBER OF SEQUENCES:  181
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 PAGE MILL ROAD
;      CITY:  PALO ALTO
;      STATE:  CALIFORNIA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,192
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/934,387
;      FILING DATE:  21-AUG-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GRACEY, NANCY J.
;      REGISTRATION NUMBER:  28,216
;      REFERENCE/DOCKET NUMBER:  246102002221
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-813-5600
;      TELEFAX:  415-494-0792
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  92:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-484-192-92

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGG 1550
              |||||  ||||  ||  ||
Db          1 AGGTTGGGAGGGTGGG 16


RESULT 661
US-08-713-685A-1
; Sequence 1, Application US/08713685A
; Patent No. 5817795
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Oligonucleotide clamps having diagnostic
;    TITLE OF INVENTION:  and therapeutic applications
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics
;      STREET:  465 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5.25 inch diskette
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 3.1/DOS 5.0
;      SOFTWARE:  Microsoft Word for Windows, vers. 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/713,685A
```

```
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/461,271
;      FILING DATE:
;      APPLICATION NUMBER:  08/087,387
;      FILING DATE:  2-Jul-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 358-7855
;      TELEFAX:  (415) 358-7794
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-713-685A-1

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 662
US-08-689-856-1
; Sequence 1, Application US/08689856
; Patent No. 5830658
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Convergent Synthesis of Branched and Multiply
;    TITLE OF INVENTION:  Connected Macromolecular Structures
;    NUMBER OF SEQUENCES:  26
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooley Godward LLP
;      STREET:  Five Palo Alto Square, 3000 El Camino Real
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94306-2155
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/689,856
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/455,627
;      FILING DATE:  31-MAY-1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Nakamura, Jackie N.
;      REGISTRATION NUMBER:  35,966
;      REFERENCE/DOCKET NUMBER:  LYNX-003/01 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-843-5000
;      TELEFAX:  415-857-0663
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA
US-08-689-856-1

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 663
US-08-292-620A-1549/c
; Sequence 1549, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1549:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1549

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCTC 1603
```

```
              ||||||||||| | |
Db         16 AGACTGGGAACAGCCC 1


RESULT 664
US-08-237-973-33
; Sequence 33, Application US/08237973
; Patent No. 5840867
;  GENERAL INFORMATION:
;    APPLICANT:  TOOLE, JOHN J.
;    APPLICANT:  LATHAM, JOHN
;    APPLICANT:  BOCK, LOUIS C.
;    APPLICANT:  GRIFFIN, LINDA C.
;    TITLE OF INVENTION:  APTAMER ANALOGS SPECIFIC FOR
;    TITLE OF INVENTION:  BIOMOLECULES
;    NUMBER OF SEQUENCES:  62
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 Page Mill Road
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304-1018
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/237,973
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/787,921
;      FILING DATE:  06-NOV-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GRACEY, NANCY J.
;      REGISTRATION NUMBER:  28,216
;      REFERENCE/DOCKET NUMBER:  24610-20032.21
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 813-5600
;      TELEFAX:  (415) 494-0792
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  33:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-237-973-33

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGG 1550
              ||||| |||| || ||
Db          1 AGGTTGGGAGGGTGGG 16


RESULT 665
US-08-412-376-1
; Sequence 1, Application US/08412376
; Patent No. 5849900
;  GENERAL INFORMATION:
;    APPLICANT:  Moelling, Karin
;    TITLE OF INVENTION:  Inhibition Of Viruses By Antisense
;    TITLE OF INVENTION:  Oligomers Capable Of Binding To Polypurine-Rich Tract Of Singl
;    TITLE OF INVENTION:  Stranded RNA Or RNA-DNA Hybrids
;    NUMBER OF SEQUENCES:  42
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Woodcock Washburn Kurtz
;      ADDRESSEE:  Mackiewicz & No. 5849900ris
;      STREET:  One Liberty Place - 46th Floor
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;      COMPUTER:  IBM PS/2
;      OPERATING SYSTEM:  PC-DOS
;      SOFTWARE:  WORDPERFECT 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/412,376
;      FILING DATE:  Herewith
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/954,184
;      FILING DATE:  29-SEP-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Doreen Yatko Trujillo
;      REGISTRATION NUMBER:  35,719
;      REFERENCE/DOCKET NUMBER:  APOL-0021
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215) 568-3100
;      TELEFAX:  (215) 568-3439
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16
;      TYPE:  Nucleic Acid
;      STRANDEDNESS:  Single
;      TOPOLOGY:  Linear
;    ANTI-SENSE:  No
US-08-412-376-1

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 666
US-08-173-489C-126/c
; Sequence 126, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
```

```
;       REGISTRATION NUMBER:  26,179
;       REFERENCE/DOCKET NUMBER:  U9518-6
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (attorney) (212) 708-1880
;       TELEFAX:  (attorney) (212) 246-8959
;   INFORMATION FOR SEQ ID NO:  126:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 bases
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single stranded
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  third strand derived from alpha-2-
;       DESCRIPTION:  globin sequence region in Seq ID No. 5861244125
;     HYPOTHETICAL:  yes
;     ANTI-SENSE:  no
;     PUBLICATION INFORMATION:
;       RELEVANT RESIDUES IN SEQ ID NO:  126 :FROM 1 TO 16
US-08-173-489C-126

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAA 1557
              | ||| |||| |||||
Db         16 GGGAGGAGGGGAGGAA 1


RESULT 667
US-08-763-417-2
; Sequence 2, Application US/08763417
; Patent No. 6027884
;  GENERAL INFORMATION:
;    APPLICANT:  LANE, Michael J., BENIGHT, Albert S., and
;    APPLICANT:  FALDASZ, Brian D.
;    TITLE OF INVENTION:  THERMODYNAMICS, DESIGN, AND USE OF
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  60 State Street, suite 510
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/763,417
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/260,200
;      FILING DATE:  17-JUN-1994
;      APPLICATION NUMBER:  US 08/224,840
;      FILING DATE:  8-APR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17-JUN-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TMI-010
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-763-417-2

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              || || | ||||||||
Db          1 AAAAAAAGCTTTTTTT 16


RESULT 668
US-08-763-417-2/c
; Sequence 2, Application US/08763417
; Patent No. 6027884
;  GENERAL INFORMATION:
;    APPLICANT:  LANE, Michael J., BENIGHT, Albert S., and
;    APPLICANT:  FALDASZ, Brian D.
;    TITLE OF INVENTION:  THERMODYNAMICS, DESIGN, AND USE OF
;    TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES
;    NUMBER OF SEQUENCES:  8
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  LAHIVE & COCKFIELD
;      STREET:  60 State Street, suite 510
;      CITY:  Boston
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  02109
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  ASCII text
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/763,417
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/260,200
;      FILING DATE:  17-JUN-1994
;      APPLICATION NUMBER:  US 08/224,840
;      FILING DATE:  8-APR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/078,759
;      FILING DATE:  17-JUN-1993
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Paul Louis Myers
;      REGISTRATION NUMBER:  35,965
;      REFERENCE/DOCKET NUMBER:  TMI-010
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 227-7400
;      TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-763-417-2

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1913 AACAATACCTTTTTTT 1928
              || || | ||||||||
Db         16 AAAAAAAGCTTTTTTT 1


RESULT 669
US-09-070-477-1
; Sequence 1, Application US/09070477
; Patent No. 6048974
;  GENERAL INFORMATION:
;    APPLICANT:  Sergei M. Gryaznov
;    TITLE OF INVENTION:  Oligonucleotide clamps having diagnostic
;    TITLE OF INVENTION:  and therapeutic applications
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Stephen C. Macevicz, Lynx Therapeutics
;      STREET:  465 Lincoln Centre Drive
;      CITY:  Foster City
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  5.25 inch diskette
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  Windows 3.1/DOS 5.0
;      SOFTWARE:  Microsoft Word for Windows, vers. 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/070,477
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/713,685
;      FILING DATE:
;      APPLICATION NUMBER:  08/461,271
;      FILING DATE:
;      APPLICATION NUMBER:  08/087,387
;      FILING DATE:  2-Jul-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Stephen C. Macevicz
;      REGISTRATION NUMBER:  30,285
;      REFERENCE/DOCKET NUMBER:  104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 358-7855
;      TELEFAX:  (415) 358-7794
;  INFORMATION FOR SEQ ID NO:  1:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 nucleotides
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-070-477-1

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 670
US-07-808-452-17
; Sequence 17, Application US/07808452
; Patent No. 6063612
;  GENERAL INFORMATION:
;    APPLICANT:  Jayasena, Sumedha D.
;    APPLICANT:  Johnston, Brian H.
;    TITLE OF INVENTION:  Antiviral Reagents Based on
;    TITLE OF INVENTION:  RNA-Binding Proteins
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Law Offices of Peter Dehlinger
;      STREET:  350 Cambridge Avenue, Suite 300
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94306
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/808,452
;      FILING DATE:  19911213
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fabian, Gary R.
;      REGISTRATION NUMBER:  33,875
;      REFERENCE/DOCKET NUMBER:  8255-008
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 324-0880
;      TELEFAX:  (415) 324-0960
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ORIGINAL SOURCE:
;      INDIVIDUAL ISOLATE:  SINGLE STRAND OLIGONUCLEOTIDE, 12/K
US-07-808-452-17

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 671
US-08-464-582-17/c
; Sequence 17, Application US/08464582
; Patent No. 6114598
; GENERAL INFORMATION:
;  APPLICANT: Kucherlapati, Raju
;  APPLICANT: Jakobovits, Aya
;  APPLICANT: Klapholz, Sue
;  APPLICANT: Brenner, Daniel G.
;  APPLICANT: Capon, Daniel J.
;  TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
;  FILE REFERENCE: CELL 4.10
;  CURRENT APPLICATION NUMBER: US/08/464,582
;  CURRENT FILING DATE: 1995-06-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-464-582-17

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGCC 1609
              |||||||||   ||||
Db         16 GGAACCCCTTGCGGCC 1
```

```
RESULT 672
US-09-071-845-1549/c
; Sequence 1549, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1549:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1549

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCTC 1603
                ||||||||||| | |
Db         16 AGACTGGGAACAGCCC 1


RESULT 673
US-08-462-513-17/c
; Sequence 17, Application US/08462513
; Patent No. 6162963
; GENERAL INFORMATION:
;  APPLICANT: Kucherlapati, Raju
;  APPLICANT: Jakobovits, Aya
;  APPLICANT: Klapholz, Sue
;  APPLICANT: Brenner, Daniel G.
;  APPLICANT: Capon, Daniel J.
;  TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
;  FILE REFERENCE: CELL 4.16
;  CURRENT APPLICATION NUMBER: US/08/462,513
;  CURRENT FILING DATE: 1995-06-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-462-513-17

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGCC 1609
                ||||||||| ||||
Db         16 GGAACCCCTTGCGGCC 1


RESULT 674
US-08-787-321-1
; Sequence 1, Application US/08787321A
; Patent No. 6180777
; GENERAL INFORMATION:
;  APPLICANT: Horn, Thomas
;  TITLE OF INVENTION: SYNTHESIS OF BRANCHED NUCLEIC ACIDS
;  FILE REFERENCE: (1300)-1199.002
;  CURRENT APPLICATION NUMBER: US/08/787,321A
;  CURRENT FILING DATE: 1997-01-03
;  EARLIER APPLICATION NUMBER: US PROV 60/009,918
;  EARLIER FILING DATE: 1996-01-12
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-08-787-321-1

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
                |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 675
US-08-787-321-16/c
; Sequence 16, Application US/08787321A
; Patent No. 6180777
; GENERAL INFORMATION:
;  APPLICANT: Horn, Thomas
;  TITLE OF INVENTION: SYNTHESIS OF BRANCHED NUCLEIC ACIDS
;  FILE REFERENCE: (1300)-1199.002
;  CURRENT APPLICATION NUMBER: US/08/787,321A
;  CURRENT FILING DATE: 1997-01-03
;  EARLIER APPLICATION NUMBER: US PROV 60/009,918
;  EARLIER FILING DATE: 1996-01-12
;  NUMBER OF SEQ ID NOS: 27
```

```
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:
;   OTHER INFORMATION: oligonucleotide
US-08-787-321-16

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db         16 AAAAGAAAAGGGGGGA 1


RESULT 676
US-09-479-524-6/c
; Sequence 6, Application US/09479524
; Patent No. 6268350
; GENERAL INFORMATION:
;  APPLICANT: Barbera-Guillem, Emilio
;  TITLE OF INVENTION: Polynucleotides For Inhibiting Metastasis And Tumor Cell Growth
;  FILE REFERENCE: B-37
;  CURRENT APPLICATION NUMBER: US/09/479,524
;  CURRENT FILING DATE: 2000-01-07
;  EARLIER APPLICATION NUMBER: US 09/170,948
;  EARLIER FILING DATE: 1998-10-13
;  EARLIER APPLICATION NUMBER: US 60/062,733
;  EARLIER FILING DATE: 1997-10-23
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: WordPerfect
; SEQ ID NO 6
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   NAME/KEY:
;   LOCATION:
;   OTHER INFORMATION: synthesized
US-09-479-524-6

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACTT 1869
              | | |||||| |||||
Db         16 AAACACCCACTCACTT 1


RESULT 677
US-09-060-299-430/c
; Sequence 430, Application US/09060299
; Patent No. 6545137
;  GENERAL INFORMATION:
;    APPLICANT:  Todd, John A
;    APPLICANT:  Hess, John W
;    APPLICANT:  Caskey, Charles T
;    APPLICANT:  Cox, Roger D
;    APPLICANT:  Gerhold, David
;    APPLICANT:  Hammond, Holly
;    APPLICANT:  Hey, Patricia
;    APPLICANT:  Kawaguchi, Yoshihiko
;    APPLICANT:  Merriman, Tony R
;    APPLICANT:  Metzker, Michael L
;    TITLE OF INVENTION:  No. 6545137el Receptor
;    NUMBER OF SEQUENCES:  455
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Nixon and Vanderhye
;      STREET:  1100 No. 6545137th Glebe Road, Eighth Floor
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  US
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/060,299
;      FILING DATE:  15-APR-1998
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/043,553
;      FILING DATE:  15-APR-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 60/048,740
;      FILING DATE:  05-JUN-1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  B.J.Sadoff
;      REGISTRATION NUMBER:  36,663
;      REFERENCE/DOCKET NUMBER:  620-35
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703)816-4091
;      TELEFAX:  (703)816-4100
;  INFORMATION FOR SEQ ID NO:  430:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-09-060-299-430

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1862 ACACACTTAGCCATTG 1877
              | ||||||| || |||
Db         16 AAACACTTACCCCTTG 1


RESULT 678
US-09-402-923A-430/c
; Sequence 430, Application US/09402923A
; Patent No. 6555654
;  GENERAL INFORMATION:
;       APPLICANT: Todd, John A
;                  Hess, John W
;                  Caskey, Charles T
;                  Cox, Roger D
;                  Gerhold, David
;                  Hammond, Holly
;                  Hey, Patricia
;                  Kawaguchi, Yoshihiko
;                  Merriman, Tony R
;                  Metzker, Michael L
;       TITLE OF INVENTION: No. 6555654el LDL-Receptor
;       NUMBER OF SEQUENCES: 455
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Nixon and Vanderhye
;            STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
;            CITY: Arlington
;            STATE: Virginia
;            COUNTRY: US
;            ZIP: VA 22201-4714
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
;       CURRENT APPLICATION DATA:
```

```
;             APPLICATION NUMBER: US/09/402,923A
;             FILING DATE: 14-Feb-2001
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: PCT/GB98/01102
;             FILING DATE: 15-APR-1998
;             APPLICATION NUMBER: US 60/043,553
;             FILING DATE: 15-APR-1997
;             APPLICATION NUMBER: US 60/048,740
;             FILING DATE: 05-JUN-1997
;        ATTORNEY/AGENT INFORMATION:
;             NAME: B.J.Sadoff
;             REGISTRATION NUMBER: 36,663
;             REFERENCE/DOCKET NUMBER: 620-81
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: (703)816-4091
;             TELEFAX: (703)816-4100
;   INFORMATION FOR SEQ ID NO: 430:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 16 base pairs
;             TYPE: nucleic acid
;             STRANDEDNESS: double
;             TOPOLOGY: linear
;        SEQUENCE DESCRIPTION: SEQ ID NO: 430:
US-09-402-923A-430

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1862 ACACACTTAGCCATTG 1877
              | ||||||| || |||
Db         16 AAACACTTACCCCTTG 1

RESULT 679
US-09-371-772B-5933
; Sequence 5933, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5933
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5933

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   75.0%;  Pred. No. 4.9e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1555 GAACAGGACTGCAAAA 1570
              |||||  ||:|| |||
Db          1 GAACACUACUGCUAAA 16

RESULT 680
US-09-371-772B-6067/c
; Sequence 6067, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6067
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6067

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACTT 1869
              ||| || |||||| ||
Db         16 ACACACACACACAGTT 1

RESULT 681
US-09-371-772B-6070/c
; Sequence 6070, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6070
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6070

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
              | ||| || |||||||
Db         16 CCACACACACACACAC 1

RESULT 682
US-09-371-772B-6967
; Sequence 6967, Application US/09371772B
; Patent No. 6566127
```

```
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6967
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6967

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   37.5%;  Pred. No. 4.9e+02;
  Matches    6;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1690 TGTTTCTCTAGCGCTG 1705
              :|:::|:|: |  |:|
Db          1 UGUUUCUCUUGAUCUG 16


RESULT 683
US-09-371-772B-7107/c
; Sequence 7107, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7107
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-7107

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1758 TTATTCATTAAGCTTT 1773
              || ||||| || ||||
Db         16 TTCTTCATCAATCTTT 1


RESULT 684
US-09-328-925-53/c
; Sequence 53, Application US/09328925
; Patent No. 6610906
; GENERAL INFORMATION:
;  APPLICANT: Kurachi, Kotoku
;  APPLICANT: Kurachi, Sumiko
;  TITLE OF INVENTION: Nucleotide Sequences for Gene Regulation and Methods of
;  TITLE OF INVENTION: Use Thereof
;  FILE REFERENCE: UM-03603
;  CURRENT APPLICATION NUMBER: US/09/328,925
;  CURRENT FILING DATE: 1999-06-09
;  NUMBER OF SEQ ID NOS: 84
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 53
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Synthetic
US-09-328-925-53

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTG 1978
              ||| |||||||  |||
Db         16 CTATATATTTATATTG 1


RESULT 685
US-09-479-005A-112
; Sequence 112, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 112
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-112

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   50.0%;  Pred. No. 4.9e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2035 CAAAGGTTCTATCTGC 2050
              ||||||:: : :|: |
Db          1 CAAAGGUUUUGUCUCC 16


RESULT 686
US-09-479-005A-468/c
; Sequence 468, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
```

```
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 468
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-468

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1577 CTCCACCGCACAGACT 1592
              || ||| ||||| |||
Db         16 CTTCACAGCACATACT 1


RESULT 687
US-09-479-005A-501/c
; Sequence 501, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
;  FILE REFERENCE: MBHB00-884-C
;  CURRENT APPLICATION NUMBER: US/09/479,005A
;  CURRENT FILING DATE:  2000-01-07
;  PRIOR APPLICATION NUMBER: US 09/444,209
;  PRIOR FILING DATE: 1999-11-19
;  PRIOR APPLICATION NUMBER: US 09/159,274
;  PRIOR FILING DATE: 1998-09-22
;  PRIOR APPLICATION NUMBER: US 60/059,473
;  PRIOR FILING DATE: 1997-09-22
;  NUMBER OF SEQ ID NOS: 1208
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 501
;   LENGTH: 16
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-479-005A-501

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1910 ATCAACAATACCTTTT 1925
              ||| |||  |||||||
Db         16 ATCCACAGCACCTTTT 1


RESULT 688
US-08-031-801-18/c
; Sequence 18, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.4 CPA RCE
;  CURRENT APPLICATION NUMBER: US/08/031,801
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: PCT/US91/00245
;  PRIOR FILING DATE: 1991-01-11
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: oligonucleotide
US-08-031-801-18

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGCC 1609
              |||||||||   ||||
Db         16 GGAACCCCTTGCGGCC 1


RESULT 689
US-08-031-801-30/c
; Sequence 30, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
;  APPLICANT: KUCHERLAPATI, RAJU
;  APPLICANT:  JAKOBOVITS, AYA
;  APPLICANT:  KLAPHOLZ, SUE
;  APPLICANT:  BRENNER, DANIEL G.
;  APPLICANT:  CAPON, DANIEL J.
;  TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
;  FILE REFERENCE: CELL 4.4 CPA RCE
;  CURRENT APPLICATION NUMBER: US/08/031,801
;  CURRENT FILING DATE:  2003-01-10
;  PRIOR APPLICATION NUMBER: 07/919,297
;  PRIOR FILING DATE: 1992-07-24
;  PRIOR APPLICATION NUMBER: PCT/US91/00245
;  PRIOR FILING DATE: 1991-01-11
;  PRIOR APPLICATION NUMBER: 07/610,515
;  PRIOR FILING DATE: 1990-11-08
;  PRIOR APPLICATION NUMBER: 07/466,008
;  PRIOR FILING DATE: 1990-01-12
;  NUMBER OF SEQ ID NOS: 33
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;   OTHER INFORMATION: polylinker
US-08-031-801-30

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGCC 1609
              |||||||||   ||||
Db         16 GGAACCCCTTGCGGCC 1


RESULT 690
US-09-155-885A-19
; Sequence 19, Application US/09155885A
; Patent No. 6709812
;   GENERAL INFORMATION:
;        APPLICANT: STUYVER, LIEVEN
;                   ROSSAU, RUDI
;                   MAERTENS, GEERT
;        TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
;        NUMBER OF SEQUENCES: 313
```

```
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: NIXON & VANDERHYE P.C.
;            STREET: 1100 NORTH GLEBE ROAD
;            CITY: ARLINGTON
;            STATE: VIRGINIA
;            COUNTRY: U.S.A.
;            ZIP: 22201-4714
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/09/155,885A
;            FILING DATE: 08-Oct-1998
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: PCT/EP97/02002
;            FILING DATE: 21-APR-1997
;            APPLICATION NUMBER: EP 96870053.4
;            FILING DATE: 19-APR-1996
;       ATTORNEY/AGENT INFORMATION:
;            NAME: SADOFF, B.J.
;            REGISTRATION NUMBER: 36,663
;            REFERENCE/DOCKET NUMBER: 2551-5
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (703) 816-4000
;            TELEFAX: (703) 816-4100
;   INFORMATION FOR SEQ ID NO: 19:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA (genomic)
;       HYPOTHETICAL: NO
;       ANTI-SENSE: NO
;       SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-155-885A-19

  Query Match              2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGT 1625
              |||||||||| | | |
Db          1 TGGGGGAAGAATATTT 16


RESULT 691
PCT-US92-10770-17
; Sequence 17, Application PC/TUS9210770
;  GENERAL INFORMATION:
;    APPLICANT:  Jayasena, Sumedha D.
;    APPLICANT:  Johnston, Brian H.
;    TITLE OF INVENTION:  Antiviral Reagents Based on
;    TITLE OF INVENTION:  RNA-Binding Proteins
;    NUMBER OF SEQUENCES:  24
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SRI International
;      STREET:  333 Ravenswood Avenue
;      CITY:  Menlo Park
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/10770
;      FILING DATE:  19921211
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/808,452
;      FILING DATE:  13-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fabian, Gary R.
;      REGISTRATION NUMBER:  33,875
;      REFERENCE/DOCKET NUMBER:  P-2962
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 859-4550
;      TELEFAX:  (415) 859-3880
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  NUCLEIC ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ORIGINAL SOURCE:
;      INDIVIDUAL ISOLATE:  SINGLE STRAND OLIGONUCLEOTIDE, 12/K
PCT-US92-10770-17

  Query Match              2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 692
PCT-US92-10792-15
; Sequence 15, Application PC/TUS9210792
;  GENERAL INFORMATION:
;    APPLICANT:  Jayasena, Sumedha D.
;    APPLICANT:  Johnston, Brian H.
;    TITLE OF INVENTION:  Triple Helix Formation at
;    TITLE OF INVENTION:  (PuNPyN)-(PuNPyN) Tracts
;    NUMBER OF SEQUENCES:  53
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  SRI International
;      STREET:  333 Ravenswood Avenue
;      CITY:  Menlo Park
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94025
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US92/10792
;      FILING DATE:  19921211
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/826,934
;      FILING DATE:  21-JAN-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/808,452
;      FILING DATE:  13-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fabian, Gary R.
;      REGISTRATION NUMBER:  33,875
;      REFERENCE/DOCKET NUMBER:  P-3141
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 859-4550
;      TELEFAX:  (415) 859-3880
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
```

```
;       TYPE:  NUCLEIC ACID
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
;     HYPOTHETICAL:  NO
;     ORIGINAL SOURCE:
;       INDIVIDUAL ISOLATE:  FIGURE 10, K
PCT-US92-10792-15

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              |||||||||| | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 693
PCT-US94-06799-2
; Sequence 2, Application PC/TUS9406799
;  GENERAL INFORMATION:
;     APPLICANT:
;     TITLE OF INVENTION:  THERMODYNAMICS, DESIGN, AND USE OF
;     TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES
;     NUMBER OF SEQUENCES:  8
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  ASCII text
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US94/06799
;       FILING DATE:  17-JUN-1994
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/224,840
;       FILING DATE:  8-APR-1994
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/078,759
;       FILING DATE:  17-JUN-1993
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Paul Louis Myers
;       REGISTRATION NUMBER:  35,965
;       REFERENCE/DOCKET NUMBER:  TMI-010PC
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (617) 227-7400
;       TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  2:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
PCT-US94-06799-2

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              || || | ||||||||
Db          1 AAAAAAAGCTTTTTTT 16


RESULT 694
PCT-US94-06799-2/c
; Sequence 2, Application PC/TUS9406799
;  GENERAL INFORMATION:
;     APPLICANT:
;     TITLE OF INVENTION:  THERMODYNAMICS, DESIGN, AND USE OF
;     TITLE OF INVENTION:  NUCLEIC ACID SEQUENCES
;     NUMBER OF SEQUENCES:  8
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  ASCII text
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US94/06799
;       FILING DATE:  17-JUN-1994
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/224,840
;       FILING DATE:  8-APR-1994
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/078,759
;       FILING DATE:  17-JUN-1993
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Paul Louis Myers
;       REGISTRATION NUMBER:  35,965
;       REFERENCE/DOCKET NUMBER:  TMI-010PC
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (617) 227-7400
;       TELEFAX:  (617) 227-4951
;  INFORMATION FOR SEQ ID NO:  2:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  16 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  double
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
PCT-US94-06799-2

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              || || | ||||||||
Db         16 AAAAAAAGCTTTTTTT 1


RESULT 695
PCT-US95-06379-21
; Sequence 21, Application PC/TUS9506379
;  GENERAL INFORMATION:
;     APPLICANT:  Watanabe, Kyoichi A.
;     APPLICANT:  Ren, Wu-Yun
;     APPLICANT:  Weil, Roger
;     TITLE OF INVENTION:  Complementary DNA and Toxins
;     NUMBER OF SEQUENCES:  43
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Cooper & Dunham LLP
;       STREET:  1185 Avenue of the Americas
;       CITY:  New York
;       STATE:  New York
;       COUNTRY:  U.S.A.
;       ZIP:  10036
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5 inch 1.44Mb
;       COMPUTER:  IBM PC
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.24
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/US95/06379
;       FILING DATE:  May 13, 1994
;       CLASSIFICATION:
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  White, John P.
;       REGISTRATION NUMBER:  28,678
```

```
;      REFERENCE/DOCKET NUMBER:  44683-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-278-0400
;      TELEFAX:  212-391-0526
;  INFORMATION FOR SEQ ID NO:  21:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US95-06379-21

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              ||||||||||  | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 696
PCT-US95-06379-22
; Sequence 22, Application PC/TUS9506379
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/06379
;      FILING DATE:  May 13, 1994
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-278-0400
;      TELEFAX:  212-391-0526
;  INFORMATION FOR SEQ ID NO:  22:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US95-06379-22

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 16;
  Best Local Similarity   81.2%;  Pred. No. 4.9e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTGTGTA 1997
              ||||||||||  | | |
Db          1 AAAAGAAAAGGGGGGA 16


RESULT 697
US-08-584-040-2204
; Sequence 2204, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2204:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2204

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              :|||:|::|  | ||:
Db          2 UCAGUGUUAGAGAAAU 17


RESULT 698
US-09-371-772B-749
; Sequence 749, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
```

```
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 749
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-749

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              :|||:|::|  | ||:
Db          2 UCAGUGUUAGAGAAAU 17


RESULT 699
US-08-584-040-2205
; Sequence 2205, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2205:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2205

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              :|||:|::|  | ||:
Db          1 UCAGUGUUAGAGAAAU 16


RESULT 700
US-09-371-772B-750
; Sequence 750, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 750
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-750

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              :|||:|::|  | ||:
Db          1 UCAGUGUUAGAGAAAU 16


RESULT 701
US-08-206-384-2
; Sequence 2, Application US/08206384
; Patent No. 5576176
;  GENERAL INFORMATION:
;    APPLICANT:  MELANIE ADAMS
;    APPLICANT:  JOSEPH ROMEO
;    APPLICANT:  BORIS MATIJA PETERLIN
;    APPLICANT:  MICHAEL PAUL BUSCH
;    TITLE OF INVENTION:  A MARKER AND AN ASSAY FOR
;    TITLE OF INVENTION:  DETECTION AND MONITORING OF
;    TITLE OF INVENTION:  HUMAN IMMUNODEFICIENCY VIRUS
;    TITLE OF INVENTION:  ACTIVATION
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PHILLIPS, MOORE, LEMPIO & FINLEY
;      STREET:  385 Sherman Avenue, Suite 6
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94306-1840
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette - 3.5 inch, 1.44 Kb storage
;      COMPUTER:  PC
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  Wordperfect 5.1
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/206,384
;      FILING DATE:  March 3, 1994
;      CLASSIFICATION:  436
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  N/A
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Hana Dolezalova
;      REGISTRATION NUMBER:  30,518
;      REFERENCE/DOCKET NUMBER:  480.12 (HHD)
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 324-1677
;      TELEFAX:  (415) 324-1678
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  synthetic oligonucleotide
US-08-206-384-2

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2039 GGTTCTATCTGCTTAG 2054
              || ||| |||| ||||
Db          1 GGGTCTCTCTGGTTAG 16


RESULT 702
US-08-234-613-25/c
; Sequence 25, Application US/08234613
; Patent No. 5582981
;  GENERAL INFORMATION:
;    APPLICANT:  TOOLE, JOHN J.
;    APPLICANT:  LATHAM, JOHN
;    APPLICANT:  BOCK, LOUIS C.
;    APPLICANT:  GRIFFIN, LINDA C.
;    TITLE OF INVENTION:  APTAMER TARGET ELUTION METHOD
;    NUMBER OF SEQUENCES:  49
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 PAGE MILL ROAD
;      CITY:  PALO ALTO
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304-1018
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/234,613
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/744,870
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GRACEY, NANCEY J.
;      REGISTRATION NUMBER:  28,216
;      REFERENCE/DOCKET NUMBER:  24610-20030.00
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 813-5600
;      TELEFAX:  (415) 494-0792
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-234-613-25

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACA 1866
              ||||| ||||||  ||
Db         16 CCAACCGACCCAACCA 1

RESULT 703
US-08-281-940-24
; Sequence 24, Application US/08281940
; Patent No. 5589330
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  METHOD FOR MULTIPLE ALLELE-SPECIFIC
;    TITLE OF INVENTION:  DISEASE ANALYSIS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DARBY & DARBY P.C.
;      STREET:  805 THIRD AVENUE
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10022
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/281,940
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LUDWIG, S. PETER
;      REGISTRATION NUMBER:  25351
;      REFERENCE/DOCKET NUMBER:  0372/09696
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212/527-7700
;      TELEFAX:  212/753-6237
;      TELEX:  236687
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapien
;    IMMEDIATE SOURCE:
;      CLONE:  2184dAM
US-08-281-940-24

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTTGTGTC 1960
              | ||| ||||||| ||
Db          1 GATTGCTTTTTGTTTC 16


RESULT 704
US-08-281-940-41
; Sequence 41, Application US/08281940
; Patent No. 5589330
```

```
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  METHOD FOR MULTIPLE ALLELE-SPECIFIC
;    TITLE OF INVENTION:  DISEASE ANALYSIS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  DARBY & DARBY P.C.
;      STREET:  805 THIRD AVENUE
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10022
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/281,940
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LUDWIG, S. PETER
;      REGISTRATION NUMBER:  25351
;      REFERENCE/DOCKET NUMBER:  0372/09696
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212/527-7700
;      TELEFAX:  212/753-6237
;      TELEX:  236687
;  INFORMATION FOR SEQ ID NO:  41:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
;    ORIGINAL SOURCE:
;      ORGANISM:  Homo sapien
;    IMMEDIATE SOURCE:
;      CLONE:  R560TN
US-08-281-940-41

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1968 TATTTACCTTGAAAAA 1983
                |||| ||||||  |||
Db          1 TATTCACCTTGCTAAA 16


RESULT 705
US-08-243-391-3
; Sequence 3, Application US/08243391
; Patent No. 5641670
;  GENERAL INFORMATION:
;    APPLICANT:  Treco, Douglas A.
;    APPLICANT:  Heartlein, Michael W.
;    APPLICANT:  Selden, Richard F
;    TITLE OF INVENTION:  Protein Production and Protein Delivery
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/243,391
;      FILING DATE:  13-MAY-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/985,586
;      FILING DATE:  03-DEC-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/789,188
;      FILING DATE:  05-NOV-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/911,533
;      FILING DATE:  10-JUL-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/787,840
;      FILING DATE:  05-NOV-1991
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/11704
;      FILING DATE:  02-DEC-1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Granahan, Patricia
;      REGISTRATION NUMBER:  32,227
;      REFERENCE/DOCKET NUMBER:  TKT92-03MA2
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 861-6240
;      TELEFAX:  (617) 861-9540
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-243-391-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCA 1862
                |||||   ||||||||
Db          1 TGGGCTTCCAGACCCA 16


RESULT 706
US-08-373-124A-454
; Sequence 454, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  454:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-454

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 5.1e+02;
  Matches    6;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
              || :: :||| :|:::
Db          2 AAUUUAUAGAUUCUUU 17


RESULT 707
US-08-373-124A-806/c
; Sequence 806, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  806:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-806

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAATACA 1841
              ||  |||| |||||||
Db         17 GATCCTTTAAAATACA 2


RESULT 708
US-08-373-124A-808/c
; Sequence 808, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  808:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-808

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTAAATACA 1841
              ||  |||| |||||||
Db         16 GATCCTTTAAAATACA 1


RESULT 709
US-08-373-124A-980
; Sequence 980, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  980:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-980

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
              :|  ::::: ::|||:
Db          2 UAUAUUUUUAUUCAGU 17


RESULT 710
US-08-373-124A-982
; Sequence 982, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  982:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-982

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
              :|  ::::: ::|||:
Db          1 UAUAUUUUUAUUCAGU 16


RESULT 711
US-08-373-124A-1643/c
```

```
; Sequence 1643, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Draper, Kenneth
;   APPLICANT: McSwiggen, James
;   APPLICANT: Jarvis, Thale
;   TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;   TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
;   TITLE OF INVENTION: CANCER USING RIBOZYMES
;   NUMBER OF SEQUENCES: 2627
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: Word Perfect 5.1
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/373,124A
;     FILING DATE: January 13, 1995
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/245,466
;     FILING DATE: May 18, 1994
;     APPLICATION NUMBER: 08/192,943
;     FILING DATE: February 7, 1994
;     APPLICATION NUMBER: 07/987,132
;     FILING DATE: December 7, 1992
;     APPLICATION NUMBER: 07/936,422
;     FILING DATE: August 26, 1992
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard
;     REGISTRATION NUMBER: 32,327
;     REFERENCE/DOCKET NUMBER: 209/035
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (213) 489-1600
;     TELEFAX: (213) 955-0440
;     TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1643:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 17 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
US-08-373-124A-1643

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTT 1622
              ||||| | ||| ||||
Db         17 GCCTGCGAGAACAGTT 2


RESULT 712
US-08-373-124A-2061
; Sequence 2061, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Draper, Kenneth
;   APPLICANT: McSwiggen, James
;   APPLICANT: Jarvis, Thale
;   TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;   TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
;   TITLE OF INVENTION: CANCER USING RIBOZYMES
;   NUMBER OF SEQUENCES: 2627
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     MEDIUM TYPE: storage
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: Word Perfect 5.1
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/08/373,124A
;     FILING DATE: January 13, 1995
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER: 08/245,466
;     FILING DATE: May 18, 1994
;     APPLICATION NUMBER: 08/192,943
;     FILING DATE: February 7, 1994
;     APPLICATION NUMBER: 07/987,132
;     FILING DATE: December 7, 1992
;     APPLICATION NUMBER: 07/936,422
;     FILING DATE: August 26, 1992
;   ATTORNEY/AGENT INFORMATION:
;     NAME: Warburg, Richard
;     REGISTRATION NUMBER: 32,327
;     REFERENCE/DOCKET NUMBER: 209/035
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE: (213) 489-1600
;     TELEFAX: (213) 955-0440
;     TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2061:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 17 base pairs
;     TYPE: nucleic acid
;     STRANDEDNESS: single
;     TOPOLOGY: linear
US-08-373-124A-2061

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
              :|  ::::: ::|||:
Db          2 UAUAUUUUUAUUCAGU 17


RESULT 713
US-08-373-124A-2063
; Sequence 2063, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
;   APPLICANT: Stinchcomb, Dan T.
;   APPLICANT: Draper, Kenneth
;   APPLICANT: McSwiggen, James
;   APPLICANT: Jarvis, Thale
;   TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;   TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
;   TITLE OF INVENTION: CANCER USING RIBOZYMES
;   NUMBER OF SEQUENCES: 2627
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     STREET: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
```

```
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/373,124A
;       FILING DATE:  January 13, 1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2063:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-373-124A-2063

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
              :|  ::::: ::|||:
Db          1 UAUAUUUUUAUUCAGU 16


RESULT 714
US-08-373-124A-2139/c
; Sequence 2139, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2139:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-2139

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGTG 1995
              |||| | |||||| ||
Db         17 AAAATAAAAAAGTCTG 2


RESULT 715
US-08-373-124A-2143/c
; Sequence 2143, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
```

```
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2143:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-373-124A-2143

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGT 1994
              ||||| | |||||| |
Db         16 AAAAATAAAAAAGTCT 1


RESULT 716
US-08-373-124A-2145/c
; Sequence 2145, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;     APPLICANT:  Stinchcomb, Dan T.
;     APPLICANT:  Draper, Kenneth
;     APPLICANT:  McSwiggen, James
;     APPLICANT:  Jarvis, Thale
;     TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;     TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;     TITLE OF INVENTION:  CANCER USING RIBOZYMES
;     NUMBER OF SEQUENCES:  2627
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/373,124A
;       FILING DATE:  January 13, 1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2145:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-373-124A-2145

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGT 1992
              | ||||| | ||||||
Db         17 TAAAAAATAAAAAAGT 2


RESULT 717
US-08-373-124A-2147/c
; Sequence 2147, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;     APPLICANT:  Stinchcomb, Dan T.
;     APPLICANT:  Draper, Kenneth
;     APPLICANT:  McSwiggen, James
;     APPLICANT:  Jarvis, Thale
;     TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;     TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;     TITLE OF INVENTION:  CANCER USING RIBOZYMES
;     NUMBER OF SEQUENCES:  2627
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  Lyon & Lyon
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/373,124A
;       FILING DATE:  January 13, 1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  2147:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-373-124A-2147

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
```

```
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGT 1992
              | ||||| | ||||||
Db         16 TAAAAAATAAAAAAGT 1


RESULT 718
US-08-373-124A-2363
; Sequence 2363, Application US/08373124A
; Patent No. 5646042
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/373,124A
;      FILING DATE:  January 13, 1995
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2363:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-373-124A-2363

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              |::|| | : ||||:|
Db          1 CUUAGACUUGGAAAUG 16


RESULT 719
US-08-485-602-25/c
; Sequence 25, Application US/08485602
; Patent No. 5712095
;  GENERAL INFORMATION:
;    APPLICANT:  Britschgi, Theresa B.
;    APPLICANT:  Cangelosi, Gerard A.
;    TITLE OF INVENTION:  Rapid and Sensitive Detection of
;    TITLE OF INVENTION:  Antibiotic-Resistant Mycobacteria Using Oligonucleotide
;    TITLE OF INVENTION:  Probes Specific for Ribosomal RNA Precursors
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew
;      STREET:  One Market Plaza, Steuart Street Tower
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94105-1492
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/485,602
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/261,068
;      FILING DATE:  16-JUN-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Weber, Kenneth A.
;      REGISTRATION NUMBER:  31,677
;      REFERENCE/DOCKET NUMBER:  11652-79-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 543-9600
;      TELEFAX:  (415) 543-5043
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  rRNA
;    ORIGINAL SOURCE:
;      ORGANISM:  Mycobacterium lufu
;    FEATURE:
;      NAME/KEY:  precursor_RNA
;      LOCATION:  1..17
;      OTHER INFORMATION:  /note= "pre-rRNA open region"
US-08-485-602-25

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACA 1866
              | | || ||||||||||
Db         16 CAACCATACCCACACA 1


RESULT 720
US-08-757-180-24/c
; Sequence 24, Application US/08757180
; Patent No. 5726021
;  GENERAL INFORMATION:
;    APPLICANT:  Britschgi, Theresa B
;    APPLICANT:  Cangelosi, Gerard A
;    TITLE OF INVENTION:  RAPID LYSIS METHODS FOR RELEASING INTACT
;    TITLE OF INVENTION:  RIBOSOMAL RNA PRECURSORS FROM MYCOBACTERIUM
;    NUMBER OF SEQUENCES:  98
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Neave
;      STREET:  1251 Avenue of the Americas
```

```
;       CITY:  New York
;       STATE:  New York
;       COUNTRY:  United States of America
;       ZIP:  10020
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/757,180
;       FILING DATE:  27-NOV-1996
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 08/261,068
;       FILING DATE:  16-JUN-1994
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Hsi, Petrina S
;       REGISTRATION NUMBER:  38,496
;       REFERENCE/DOCKET NUMBER:  BD3
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  212-596-9000
;       TELEFAX:  212-596-9090
;   INFORMATION FOR SEQ ID NO:  24:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  rRNA
;     ORIGINAL SOURCE:
;       ORGANISM:  Mycobacterium lufu
US-08-757-180-24

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACA 1866
                | | ||  |||||||||
Db         16 CAACCATACCCACACA 1


RESULT 721
US-08-451-893-3
; Sequence 3, Application US/08451893
; Patent No. 5733761
;  GENERAL INFORMATION:
;    APPLICANT:  Treco, Douglas
;    APPLICANT:  Heartlein, Michael W.
;    APPLICANT:  Selden, Richard F
;    TITLE OF INVENTION:  Protein Production and Protein Delivery
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/451,893
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/985,586
;      FILING DATE:  03-DEC-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Granahan, Patricia
;      REGISTRATION NUMBER:  32,227
;      REFERENCE/DOCKET NUMBER:  TKT92-03MA4
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 861-6240
;      TELEFAX:  (617) 861-9540
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-451-893-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCA 1862
                |||||   ||||||||
Db          1 TGGGCTTCCAGACCCA 16


RESULT 722
US-08-484-192-97/c
; Sequence 97, Application US/08484192
; Patent No. 5756291
;  GENERAL INFORMATION:
;    APPLICANT:  GRIFFIN, LINDA C.
;    APPLICANT:  ALBRECHT, GLENN
;    APPLICANT:  LATHAM, JOHN
;    APPLICANT:  LEUNG, LAWRENCE
;    APPLICANT:  VERMAAS, ERIC
;    APPLICANT:  TOOLE, JOHN J.
;    TITLE OF INVENTION:  APTAMERS SPECIFIC FOR BIOMOLECULES AND
;    TITLE OF INVENTION:  METHODS OF MAKING
;    NUMBER OF SEQUENCES:  181
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 PAGE MILL ROAD
;      CITY:  PALO ALTO
;      STATE:  CALIFORNIA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,192
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/934,387
;      FILING DATE:  21-AUG-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GRACEY, NANCY J.
;      REGISTRATION NUMBER:  28,216
;      REFERENCE/DOCKET NUMBER:  246102002221
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-813-5600
;      TELEFAX:  415-494-0792
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  97:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-484-192-97
```

```
  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACA 1866
                ||||| ||||||  ||
Db         16 CCAACCGACCCAACCA 1


RESULT 723
US-08-745-638-25/c
; Sequence 25, Application US/08745638
; Patent No. 5770373
;  GENERAL INFORMATION:
;    APPLICANT:  Britschgi, Theresa B.
;    APPLICANT:  Cangelosi, Gerard A.
;    TITLE OF INVENTION:  Rapid and Sensitive Detection of
;    TITLE OF INVENTION:  Antibiotic-Resistant Mycobacteria Using Oligonucleotide
;    TITLE OF INVENTION:  Probes Specific for Ribosomal RNA Precursors
;    NUMBER OF SEQUENCES:  89
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Townsend and Townsend and Crew
;      STREET:  One Market Plaza, Steuart Street Tower
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94105-1492
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/745,638
;      FILING DATE:  08-NOV-1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/485,602
;      FILING DATE:  07-JUN-1995
;      APPLICATION NUMBER:  US 08/261,068
;      FILING DATE:  16-JUN-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Weber, Kenneth A.
;      REGISTRATION NUMBER:  31,677
;      REFERENCE/DOCKET NUMBER:  11652-79-1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 543-9600
;      TELEFAX:  (415) 543-5043
;  INFORMATION FOR SEQ ID NO:  25:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  rRNA
;    ORIGINAL SOURCE:
;      ORGANISM:  Mycobacterium lufu
;    FEATURE:
;      NAME/KEY:  precursor_RNA
;      LOCATION:  1..17
;      OTHER INFORMATION:  /note= "pre-rRNA open region"
US-08-745-638-25

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACA 1866
                | | || |||||||||
Db         16 CAACCATACCCACACA 1


RESULT 724
US-08-758-306-1157
; Sequence 1157, Application US/08758306
; Patent No. 5807743
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James A.
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES
;    TITLE OF INVENTION:  ASSOCIATED WITH
;    TITLE OF INVENTION:  INTERLEUKIN-2 RECEPTOR
;    TITLE OF INVENTION:  GAMMA-CHAIN EXPRESSION
;    NUMBER OF SEQUENCES:  1379
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSeq Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/758,306
;      FILING DATE:  December 3, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  212/132
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1157:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-758-306-1157

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 5.1e+02;
  Matches    7;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2038 AGGTTCTATCTGCTTA 2053
                || ::|: :|:|| :|
Db          2 AGCUUCUCUCUGCCUA 17


RESULT 725
US-08-435-628-454
; Sequence 454, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
```

```
;       STREET:  633 West Fifth Street
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/435,628
;       FILING DATE:  05-MAY-1995
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/373,124
;       FILING DATE:  January 13, 1995
;       APPLICATION NUMBER:  08/245,466
;       FILING DATE:  May 18, 1994
;       APPLICATION NUMBER:  08/192,943
;       FILING DATE:  February 7, 1994
;       APPLICATION NUMBER:  07/987,132
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  454:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-435-628-454

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 5.1e+02;
  Matches    6;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
                || :: :||| :|:::
Db          2 AAUUUAUAGAUUCUUU 17


RESULT 726
US-08-435-628-806/c
; Sequence 806, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  806:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-806

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAATACA 1841
                ||  |||| |||||||
Db         17 GATCCTTTAAAATACA 2


RESULT 727
US-08-435-628-808/c
; Sequence 808, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  808:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-808

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTAAATACA 1841
                ||  |||| |||||||
Db         16 GATCCTTTAAAATACA 1


RESULT 728
US-08-435-628-980
; Sequence 980, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  980:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-980

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
                :|  ::::: ::|||:
Db          2 UAUAUUUUUAUUCAGU 17


RESULT 729
US-08-435-628-982
; Sequence 982, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
```

```
;       FILING DATE:  December 7, 1992
;       APPLICATION NUMBER:  07/936,422
;       FILING DATE:  August 26, 1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  209/035
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  982:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-435-628-982

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
              :|  ::::: ::|||:
Db          1 UAUAUUUUUAUUCAGU 16


RESULT 730
US-08-435-628-1643/c
; Sequence 1643, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1643:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-1643

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTT 1622
              ||||| | ||| ||||
Db         17 GCCTGCGAGAACAGTT 2


RESULT 731
US-08-435-628-2061
; Sequence 2061, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2061:
```

```
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2061

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
              :|  ::::: ::|||:
Db          2 UAUAUUUUUAUUCAGU 17


RESULT 732
US-08-435-628-2063
; Sequence 2063, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2063:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2063

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
              :|  ::::: ::|||:
Db          1 UAUAUUUUUAUUCAGU 16


RESULT 733
US-08-435-628-2139/c
; Sequence 2139, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2139:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2139

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGTG 1995
```

```
              |||| | |||||| ||
Db          17 AAAATAAAAAAGTCTG 2


RESULT 734
US-08-435-628-2143/c
; Sequence 2143, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2143:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2143

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGT 1994
              ||||| | |||||| |
Db         16 AAAAATAAAAAAGTCT 1


RESULT 735
US-08-435-628-2145/c
; Sequence 2145, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2145:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2145

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGT 1992
              | ||||| | ||||||
Db         17 TAAAAAATAAAAAAGT 2


RESULT 736
US-08-435-628-2147/c
; Sequence 2147, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
```

```
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2147:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2147

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGT 1992
                | ||||| | ||||||
Db         16 TAAAAAATAAAAAAGT 1


RESULT 737
US-08-435-628-2363
; Sequence 2363, Application US/08435628
; Patent No. 5817796
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Draper, Kenneth
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Jarvis, Thale
;    TITLE OF INVENTION:  METHODS AND COMPOSITIONS FOR
;    TITLE OF INVENTION:  TREATMENT OF RESTENOSIS AND
;    TITLE OF INVENTION:  CANCER USING RIBOZYMES
;    NUMBER OF SEQUENCES:  2627
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/435,628
;      FILING DATE:  05-MAY-1995
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/373,124
;      FILING DATE:  January 13, 1995
;      APPLICATION NUMBER:  08/245,466
;      FILING DATE:  May 18, 1994
;      APPLICATION NUMBER:  08/192,943
;      FILING DATE:  February 7, 1994
;      APPLICATION NUMBER:  07/987,132
;      FILING DATE:  December 7, 1992
;      APPLICATION NUMBER:  07/936,422
;      FILING DATE:  August 26, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/035
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2363:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-435-628-2363

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1867 CTTAGCCATTGAAATG 1882
              |::|| | : ||||:|
Db          1 CUUAGACUUGGAAAUG 16


RESULT 738
US-08-710-134-24
; Sequence 24, Application US/08710134
; Patent No. 5834181
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  HIGH THROUGHPUT SCREENING METHOD FOR
;    TITLE OF INVENTION:  SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genzyme Corporation
;      STREET:  One Mountain Road
;      CITY:  Framingham
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  01701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
```

```
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/710,134
;       FILING DATE:  13-SEP-1996
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Dugan, Deborah A.
;       REGISTRATION NUMBER:  37,315
;       REFERENCE/DOCKET NUMBER:  IG5-8.1
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  508-872-8400
;       TELEFAX:  508-872-5415
;   INFORMATION FOR SEQ ID NO:  24:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  other nucleic acid
;       DESCRIPTION:  /desc = "Oligonucleotides"
US-08-710-134-24

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTTGTGTC 1960
              | ||| ||||||| ||
Db          1 GATTGCTTTTTGTTTC 16


RESULT 739
US-08-710-134-41
; Sequence 41, Application US/08710134
; Patent No. 5834181
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  HIGH THROUGHPUT SCREENING METHOD FOR
;    TITLE OF INVENTION:  SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genzyme Corporation
;      STREET:  One Mountain Road
;      CITY:  Framingham
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  01701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/710,134
;      FILING DATE:  13-SEP-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dugan, Deborah A.
;      REGISTRATION NUMBER:  37,315
;      REFERENCE/DOCKET NUMBER:  IG5-8.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  508-872-8400
;      TELEFAX:  508-872-5415
;  INFORMATION FOR SEQ ID NO:  41:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotides"
US-08-710-134-41

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1968 TATTTACCTTGAAAAA 1983
              |||| ||||||  |||
Db          1 TATTCACCTTGCTAAA 16


RESULT 740
US-08-292-620A-1659/c
; Sequence 1659, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                      two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1659:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1659

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGGC 2035
              ||||  |||||| |||
Db         17 TCCTAAGGTAGGGGGC 2
```

```
RESULT 741
US-08-292-620A-1722/c
; Sequence 1722, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1722:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-1722

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1816 ATAAGTTTTAGAATCT 1831
                | ||||| |||| |||
Db         17 AAAAGTTGTAGATTCT 2


RESULT 742
US-08-237-973-38/c
; Sequence 38, Application US/08237973
; Patent No. 5840867
;  GENERAL INFORMATION:
;    APPLICANT:  TOOLE, JOHN J.
;    APPLICANT:  LATHAM, JOHN
;    APPLICANT:  BOCK, LOUIS C.
;    APPLICANT:  GRIFFIN, LINDA C.
;    TITLE OF INVENTION:  APTAMER ANALOGS SPECIFIC FOR
;    TITLE OF INVENTION:  BIOMOLECULES
;    NUMBER OF SEQUENCES:  62
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  755 Page Mill Road
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304-1018
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/237,973
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/787,921
;      FILING DATE:  06-NOV-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  GRACEY, NANCY J.
;      REGISTRATION NUMBER:  28,216
;      REFERENCE/DOCKET NUMBER:  24610-20032.21
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 813-5600
;      TELEFAX:  (415) 494-0792
;      TELEX:  706141
;  INFORMATION FOR SEQ ID NO:  38:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-237-973-38

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACA 1866
                ||||| ||||||  ||
Db         16 CCAACCGACCCAACCA 1


RESULT 743
US-08-485-885-24
; Sequence 24, Application US/08485885
; Patent No. 5849483
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  HIGH THROUGHPUT SCREENING METHOD FOR
;    TITLE OF INVENTION:  SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genzyme Corporation
;      STREET:  One Mountain Road
;      CITY:  Framingham
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  01701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
```

```
;      APPLICATION NUMBER:  US/08/485,885
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dugan, Deborah A.
;      REGISTRATION NUMBER:  37,315
;      REFERENCE/DOCKET NUMBER:  GEN4-12.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  508-872-8400
;      TELEFAX:  508-872-5415
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotides"
US-08-485-885-24

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTTGTGTC 1960
              | ||| ||||||| ||
Db          1 GATTGCTTTTTGTTTC 16


RESULT 744
US-08-485-885-41
; Sequence 41, Application US/08485885
; Patent No. 5849483
;  GENERAL INFORMATION:
;    APPLICANT:  SHUBER, ANTHONY P.
;    TITLE OF INVENTION:  HIGH THROUGHPUT SCREENING METHOD FOR
;    TITLE OF INVENTION:  SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
;    NUMBER OF SEQUENCES:  65
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Genzyme Corporation
;      STREET:  One Mountain Road
;      CITY:  Framingham
;      STATE:  Massachusetts
;      COUNTRY:  USA
;      ZIP:  01701
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/485,885
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Dugan, Deborah A.
;      REGISTRATION NUMBER:  37,315
;      REFERENCE/DOCKET NUMBER:  GEN4-12.1
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  508-872-8400
;      TELEFAX:  508-872-5415
;  INFORMATION FOR SEQ ID NO:  41:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Oligonucleotides"
US-08-485-885-41

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1968 TATTTACCTTGAAAAA 1983
              |||| ||||||  |||
Db          1 TATTCACCTTGCTAAA 16


RESULT 745
US-08-894-772-9/c
; Sequence 9, Application US/08894772
; Patent No. 5861280
;  GENERAL INFORMATION:
;    APPLICANT:  Lehmbeck, Jan
;    TITLE OF INVENTION:  Host Cell Expressing Reduced Levels
;    TITLE OF INVENTION:  Of A Metalloprotease And Methods Using The Host Cell In Protei
;    TITLE OF INVENTION:  Production
;    NUMBER OF SEQUENCES:  10
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  No. 5861280o No. 5861280disk of No. 5861280th America, Inc.
;      STREET:  405 Lexington Avenue, Suite 6400
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10174-6401
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/894,772
;      FILING DATE:  27-AUG-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Gregg, Valeta A.
;      REGISTRATION NUMBER:  35,127
;      REFERENCE/DOCKET NUMBER:  4300.204-US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-867-0123
;      TELEFAX:  212-867-0298
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-894-772-9

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGG 1551
              |||| ||| || ||||
Db         16 GGTTTGGAAAGAAGGG 1


RESULT 746
US-08-451-894-3
; Sequence 3, Application US/08451894
; Patent No. 5968502
;  GENERAL INFORMATION:
;    APPLICANT:  Treco, Douglas
;    APPLICANT:  Heartlein, Michael W.
;    APPLICANT:  Selden, Richard F
;    TITLE OF INVENTION:  Protein Production and Protein Delivery
;    NUMBER OF SEQUENCES:  17
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
```

```
;       STREET:  Two Militia Drive
;       CITY:  Lexington
;       STATE:  Massachusetts
;       COUNTRY:  U.S.A.
;       ZIP:  02173
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/451,894
;       FILING DATE:
;       CLASSIFICATION:  435
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/985,586
;       FILING DATE:  03-DEC-1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Granahan, Patricia
;       REGISTRATION NUMBER:  32,227
;       REFERENCE/DOCKET NUMBER:  TKT92-03MZ
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (617) 861-6240
;       TELEFAX:  (617) 861-9540
;   INFORMATION FOR SEQ ID NO:  3:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA (genomic)
US-08-451-894-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCA 1862
                ||||| |||||||| 
Db          1 TGGGCTTCCAGACCCA 16


RESULT 747
US-09-207-844-9/c
; Sequence 9, Application US/09207844
; Patent No. 5968774
;  GENERAL INFORMATION:
;     APPLICANT:  Lehmbeck, Jan
;     TITLE OF INVENTION:  Host Cell Expressing Reduced Levels
;     TITLE OF INVENTION:  Of A Metalloprotease And Methods Using The Host Cell In Protei
;     TITLE OF INVENTION:  Production
;     NUMBER OF SEQUENCES:  10
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  No. 5968774o No. 5968774disk of No. 5968774th America, Inc.
;       STREET:  405 Lexington Avenue, Suite 6400
;       CITY:  New York
;       STATE:  New York
;       COUNTRY:  U.S.A.
;       ZIP:  10174-6401
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/09/207,844
;       FILING DATE:
;       CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  08/894,772
;       FILING DATE:  27-AUG-1997
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Gregg, Valeta A.
;       REGISTRATION NUMBER:  35,127
;       REFERENCE/DOCKET NUMBER:  4300.204-US
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  212-867-0123
;       TELEFAX:  212-867-0298
;   INFORMATION FOR SEQ ID NO:  9:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  cDNA
US-09-207-844-9

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGG 1551
                |||| ||| || ||||
Db         16 GGTTTGGAAAGAAGGG 1


RESULT 748
US-08-776-900C-13/c
; Sequence 13, Application US/08776900C
; Patent No. 6020477
;  GENERAL INFORMATION:
;     APPLICANT:  DIU, Anita; FAUCHEU, Chi; Hercend, Thierry;
;     APPLICANT:  LALANNE, Jean-Louis, LIVINGSTON, David and
;     APPLICANT:  SU, Michael
;     TITLE OF INVENTION:  DNA SEQUENCES CODING FOR THE HUMAN
;     TITLE OF INVENTION:  PROTEINS TX AND TY RELATED TO THE
;     TITLE OF INVENTION:  INTERLEUKIN-1BETA CONVERTING ENZYME
;     NUMBER OF SEQUENCES:  42
;     CORRESPONDENCE ADDRESS:
;       ADDRESSEE:  BIERMAN & MUSERLIAN
;       STREET:  600 THIRD AVENUE
;       CITY:  NEW YORK
;       STATE:  NEW YORK
;       COUNTRY:  USA
;       ZIP:  10016
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  FLOPPY DISK
;       COMPUTER:  IBM PC COMPATIBLE
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  WORDPERFECT 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/776,900C
;       FILING DATE:  30-APR-1997
;       CLASSIFICATION:  536
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/FR95/01035
;       FILING DATE:  01-AUG-1995
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  FR/94/09567
;       FILING DATE:  02-AUG-1994
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  CHARLES A. MUSERLIAN
;       REGISTRATION NUMBER:  19,683
;       REFERENCE/DOCKET NUMBER:  146.1265
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (212) 661-8000
;       TELEFAX:  (212) 661-8002
;   INFORMATION FOR SEQ ID NO:  13:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  DNA
;     FEATURE:
;       OTHER INFORMATION:  SEQ ID NO: 1 complementary
```

```
;      OTHER INFORMATION:  from 995 to 1011
US-08-776-900C-13

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1752 GGCTCTTTATTCATTA 1767
              |||||| | ||||| |
Db         16 GGCTCTATCTTCATCA 1


RESULT 749
US-08-752-722-2
; Sequence 2, Application US/08752722
; Patent No. 6025124
;  GENERAL INFORMATION:
;    APPLICANT:  MELANIE ADAMS
;    APPLICANT:  JOSEPH ROMEO
;    APPLICANT:  BORIS MATIJA PETERLIN
;    APPLICANT:  MICHAEL PAUL BUSCH
;    TITLE OF INVENTION:  A MARKER AND AN ASSAY FOR DETECTION AND MONITORING OF LATENCY
;    TITLE OF INVENTION:  OF HUMAN IMMUNODEFICIENCY
;    TITLE OF INVENTION:  VIRUS
;    NUMBER OF SEQUENCES:  7
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PETERS, VERNY, JONES & BIK A, L.L.P.
;      STREET:  385 Sherman Avenue, Suite 6
;      CITY:  Palo Alto
;      STATE:  California
;      COUNTRY:  United States of America
;      ZIP:  94306-1840
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette - 3.5 inch, 1.44 Kb storage
;      COMPUTER:  PC
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  Wordperfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/752,722
;      FILING DATE:  No. 6025124ember 19, 1996
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/206,384
;      FILING DATE:  March 3, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Hana Verny
;      REGISTRATION NUMBER:  30,518
;      REFERENCE/DOCKET NUMBER:  480.12-1 (HV)
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 324-1677
;      TELEFAX:  (415) 324-1678
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  synthetic oligonucleotide
US-08-752-722-2

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2039 GGTTCTATCTGCTTAG 2054
              || ||| |||| ||||
Db          1 GGGTCTCTCTGGTTAG 16


RESULT 750
US-08-181-664-64
; Sequence 64, Application US/08181664
; Patent No. 6025127
;  GENERAL INFORMATION:
;    APPLICANT:  Sidransky, David
;    TITLE OF INVENTION:  NUCLEIC ACID MUTATION DETECTION IN
;    TITLE OF INVENTION:  HISTOLOGIC TISSUE
;    NUMBER OF SEQUENCES:  82
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Spensley Horn Jubas & Lubitz
;      STREET:  1880 Century Park East, Suite 500
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90067
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/181,664
;      FILING DATE:  JANUARY 14, 1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Wetherell, Jr., Ph.D., John R.
;      REGISTRATION NUMBER:  31,678
;      REFERENCE/DOCKET NUMBER:  PD-3055
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (619) 455-5100
;      TELEFAX:  (619) 455-5110
;  INFORMATION FOR SEQ ID NO:  64:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    FEATURE:
;      NAME/KEY:  CDS
;      LOCATION:  1..17
US-08-181-664-64

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1604 CTGGCCTGGGGGAAGA 1619
              ||| |||||||  |||
Db          1 CTGTCCTGGGGAGAGA 16


RESULT 751
US-08-985-162-381
; Sequence 381, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
```

```
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  381:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-381

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1577 CTCCACCGCACAGACT 1592
                |:||||  ||| |||:
Db          1 CUCCACGUCACGGACU 16


RESULT 752
US-08-985-162-498/c
; Sequence 498, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  498:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-498

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTTT 1926
                ||||  |||||| |||
Db         16 TCAAATATACCTCTTT 1


RESULT 753
US-08-985-162-643
; Sequence 643, Application US/08985162
; Patent No. 6057156
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/985,162
;      FILING DATE:  04 December 1997
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  643:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-985-162-643

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
```

```
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1557 ACAGGACTGCAAAAAT 1572
              | | |||: ||||||:
Db          1 AGAAGACUACAAAAAU 16


RESULT 754
US-08-231-439A-3
; Sequence 3, Application US/08231439A
; Patent No. 6063630
;  GENERAL INFORMATION:
;    APPLICANT:  Treco, Douglas
;    APPLICANT:  Heartlein, Michael W.
;    APPLICANT:  Selden, Richard F
;    TITLE OF INVENTION:  Targeted Introduction of DNA Into
;    TITLE OF INVENTION:  Primary or Secondary Cells and Their Use for Gene Therapy
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/231,439A
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/231,439
;      FILING DATE:  20-APR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/789,188
;      FILING DATE:  05-NOV-1991
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Granahan, Patricia
;      REGISTRATION NUMBER:  32,227
;      REFERENCE/DOCKET NUMBER:  TKT91-02
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-861-6240
;      TELEFAX:  617-861-9540
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-08-231-439A-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCA 1862
              |||||   ||||||||
Db          1 TGGGCTTCCAGACCCA 16


RESULT 755
US-08-998-099-30
; Sequence 30, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
;  APPLICANT: JARVIS, THALE
;  APPLICANT: MCSWIGGEN, JAMES A.
;  APPLICANT: STINCHCOMB, DAN T.
;  TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
;  TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF C-FOS
;  FILE REFERENCE: 231/175
;  CURRENT APPLICATION NUMBER: US/08/998,099A
;  CURRENT FILING DATE: 1997-12-24
;  EARLIER APPLICATION NUMBER: 60/037,658
;  EARLIER FILING DATE: 1997-01-23
;  EARLIER APPLICATION NUMBER: 08/373,124
;  EARLIER FILING DATE: 1995-01-13
;  EARLIER APPLICATION NUMBER: 08/245,466
;  EARLIER FILING DATE: 1994-05-18
;  NUMBER OF SEQ ID NOS: 375
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 30
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-08-998-099-30

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1568 AAAATCCTTCTCCACC 1583
              | | :||::|:||| |
Db          1 AGACUCCUUCUCCAGC 16


RESULT 756
US-09-071-845-1659/c
; Sequence 1659, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
```

```
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1659:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1659

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGGC 2035
              ||||  |||||| |||
Db         17 TCCTAAGGTAGGGGGC 2


RESULT 757
US-09-071-845-1722/c
; Sequence 1722, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1722:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-1722

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1816 ATAAGTTTTAGAATCT 1831
              | ||||| |||| |||
Db         17 AAAAGTTGTAGATTCT 2


RESULT 758
US-09-009-521A-5/c
; Sequence 5, Application US/09009521A
; Patent No. 6136582
;  GENERAL INFORMATION:
;    APPLICANT:  Gao, Guangxia
;    APPLICANT:  Goff, Stephen P.
;    TITLE OF INVENTION:  REVERSE TRANSCRIPTASE OF MOLONEY MURINE
;    TITLE OF INVENTION:  LEUKEMIA VIRUS WITH RNA POLYMERASE ACTIVITY
;    NUMBER OF SEQUENCES:  6
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/009,521A
;      FILING DATE:  January 20, 1998
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  0575/53970
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 278-0400
;      TELEFAX:  (212) 391-0525
;  INFORMATION FOR SEQ ID NO:  5:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-09-009-521A-5

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCT 1815
              ||||| | |||| |||
Db         17 CTCTGTATGTGGGGCT 2


RESULT 759
US-09-268-195C-13/c
; Sequence 13, Application US/09268195C
; Patent No. 6180386
;  GENERAL INFORMATION:
;    APPLICANT:  ROUSSEL UCLAF
;    TITLE OF INVENTION:  DNA SEQUENCES CODING FOR THE HUMAN
```

```
;    NUMBER OF SEQUENCES:  42
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  ROUSSEL UCLAF
;      STREET:  102, Route de No. 6180386sy
;      CITY:  ROMAINVILLE
;      COUNTRY:  FRANCE
;      ZIP:  93230
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30 (OEB)
;      SOFTWARE:  + Corrections under WORDPERFECT 5.1 for SEQ ID NO 22
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/268,195C
;      FILING DATE:  15-MAR-1999
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 9409567
;      FILING DATE:  AUG-02-1994
;      APPLICATION NUMBER:  776,900
;      FILING DATE:  JANUARY 31, 1998
;  INFORMATION FOR SEQ ID NO:  13:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17
;      TYPE:  nucleotide
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  Other nucleic acid
;      DESCRIPTION:  /desc = "OLIGONUCLEOTIDE"
;    FEATURE:
;      NAME/KEY:  misc_feature
;      LOCATION:  complement (1..17)
;      OTHER INFORMATION:  /note= "SEQ ID NO 1 COMPLEMENTARY
;      OTHER INFORMATION:  FROM 995 TO 1011"
US-09-268-195C-13

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1752 GGCTCTTTATTCATTA 1767
              |||||| | ||||| |
Db         16 GGCTCTATCTTCATCA 1


RESULT 760
US-08-446-921-3
; Sequence 3, Application US/08446921
; Patent No. 6187305
;  GENERAL INFORMATION:
;    APPLICANT:  Treco, Douglas
;    APPLICANT:  Heartlein, Michael W.
;    APPLICANT:  Selden, Richard F
;    TITLE OF INVENTION:  Targeted Introduction of DNA Into
;    TITLE OF INVENTION:  Primary or Secondary Cells and Their Use for Gene Therapy
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/446,921
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/231,439
;      FILING DATE:  20-APR-1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/789,188
;      FILING DATE:  05-NOV-1991
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Granahan, Patricia
;      REGISTRATION NUMBER:  32,227
;      REFERENCE/DOCKET NUMBER:  TKT91-02
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-861-6240
;      TELEFAX:  617-861-9540
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-08-446-921-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCA 1862
              |||||   ||||||||
Db          1 TGGGCTTCCAGACCCA 16


RESULT 761
US-08-446-928-3
; Sequence 3, Application US/08446928
; Patent No. 6214622
;  GENERAL INFORMATION:
;    APPLICANT:  Treco, Douglas
;    APPLICANT:  Heartlein, Michael W.
;    APPLICANT:  Selden, Richard F
;    TITLE OF INVENTION:  Targeted Introduction of DNA Into
;    TITLE OF INVENTION:  Primary or Secondary Cells and Their Use for Gene Therapy
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Hamilton, Brook, Smith & Reynolds, P.C.
;      STREET:  Two Militia Drive
;      CITY:  Lexington
;      STATE:  Massachusetts
;      COUNTRY:  U.S.A.
;      ZIP:  02173
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/446,928
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/231,439
;      FILING DATE:  20-APR-1994
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  07/789,188
;      FILING DATE:  05-NOV-1991
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Granahan, Patricia
;      REGISTRATION NUMBER:  32,227
;      REFERENCE/DOCKET NUMBER:  TKT91-02
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  617-861-6240
;      TELEFAX:  617-861-9540
```

```
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
US-08-446-928-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCA 1862
              |||||   ||||||||
Db             1 TGGGCTTCCAGACCCA 16


RESULT 762
US-09-441-346A-6/c
; Sequence 6, Application US/09441346A
; Patent No. 6242588
; GENERAL INFORMATION:
;  APPLICANT:  Sheppard, Paul O.
;  APPLICANT:  Piddington, Christopher S.
;  APPLICANT:  Ellsworth, Jeff L.
;  TITLE OF INVENTION:  TESTIS-SPECIFIC GLYCOPROTEIN ZPEP10
;  FILE REFERENCE:  98-34
;  CURRENT APPLICATION NUMBER: US/09/441,346A
;  CURRENT FILING DATE:  1999-11-16
;  PRIOR APPLICATION NUMBER:  60/109,216
;  PRIOR FILING DATE:  1998-11-20
;  NUMBER OF SEQ ID NOS:  14
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 6
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Degenerate oligonucleotide probe
;   NAME/KEY: variation
;   LOCATION: (1)...(17)
;   OTHER INFORMATION: Each N is independently any nucleotide.
US-09-441-346A-6

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1750 CTGGCTCTTTATTCAT 1765
              | |  :|:||:|||||
Db            16 CNGTNYCYTTRTTCAT 1


RESULT 763
US-08-192-946-11/c
; Sequence 11, Application US/08192946
; Patent No. 6258585
;  GENERAL INFORMATION:
;    APPLICANT:  KENNETH G. DRAPER
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR
;    TITLE OF INVENTION:  INHIBITING INFLUENZA VIRUS
;    TITLE OF INVENTION:  REPLICATION
;    NUMBER OF SEQUENCES:  32
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  611 West Sixth Street
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  90017
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb storage
;      COMPUTER:  IBM compatible
;      OPERATING SYSTEM:  IBM P.C. DOS (Version 5.0)
;      SOFTWARE:  WordPerfect (Version 5.1)
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/192,946
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/882,713
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  197/294
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-192-946-11

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1918 TACCTTTTTTTTCAGT 1933
              || || | ||||||||
Db            16 TATCTCTCTTTTCAGT 1


RESULT 764
US-08-980-832-60/c
; Sequence 60, Application US/08980832B
; Patent No. 6291204
; GENERAL INFORMATION:
;  APPLICANT: Pasamontes, Luis
;  APPLICANT: Tsygankov, Yuri
;  TITLE OF INVENTION: Improved Fermentative Carotenoid Production
;  FILE REFERENCE: Improved Fermentive Carotenoid
;  CURRENT APPLICATION NUMBER: US/08/980,832B
;  CURRENT FILING DATE: 1997-12-01
;  NUMBER OF SEQ ID NOS: 66
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 60
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Primer crtW106
US-08-980-832-60

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCT 1605
              |:|||||:| :| :||
Db            16 AYTGGGARCAYCAYCT 1


RESULT 765
US-08-584-040-1902/c
; Sequence 1902, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
```

```
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1902:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-1902

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCCC 1898
              || || |||| |||||
Db         16 TCCAAGTGATTTGCCC 1


RESULT 766
US-08-584-040-1939
; Sequence 1939, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1939:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-1939

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAAC 1785
              |:: :::::: : |||
Db          2 CUUAUUUUUUCUCAAC 17


RESULT 767
US-08-584-040-1940
; Sequence 1940, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
```

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  1940:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-1940

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAAC 1785
              |:: :::::: : |||
Db          1 CUUAUUUUUUCUCAAC 16


RESULT 768
US-08-584-040-2016/c
; Sequence 2016, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2016:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2016

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1809 TGGTGCTATAAGTTTT 1824
              ||||||| ||  ||||
Db         17 TGGTGCTGTAGATTTT 2


RESULT 769
US-08-584-040-2059
; Sequence 2059, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2059:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2059

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1938 AGGTAATGGTTGGTTT 1953
```

```
              ||| ||: |: ||:::
Db          2 AGGAAAUAGUGGGUUU 17


RESULT 770
US-08-584-040-2059/c
; Sequence 2059, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2059:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2059

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1783 AACCCCATTCTTTCCT 1798
              || |||| | ||||||
Db         17 AAACCCACTATTTCCT 2


RESULT 771
US-08-584-040-2092/c
; Sequence 2092, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2092:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2092

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
              ||| ||| || |||||
Db         17 AAGGTTTTGATTCTTT 2


RESULT 772
US-08-584-040-2197
; Sequence 2197, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
```

```
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2197:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2197

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1555 GAACAGGACTGCAAAA 1570
              |||||  ||:|| |||
Db          2 GAACACUACUGCUAAA 17


RESULT 773
US-08-584-040-2289
; Sequence 2289, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2289:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2289

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGGCA 2036
              ||:|: |:| || |||
Db          1 CCUCUAGUAAGAUGCA 16


RESULT 774
US-08-584-040-2394
; Sequence 2394, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
```

```
;  INFORMATION FOR SEQ ID NO:  2394:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2394

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1635 TACTATTTAAAGAGCC 1650
              :| :| ::|| |||||
Db          2 UAUUAGUUAAUGAGCC 17


RESULT 775
US-08-584-040-2395
; Sequence 2395, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2395:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2395

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1635 TACTATTTAAAGAGCC 1650
              :| :| ::|| |||||
Db          1 UAUUAGUUAAUGAGCC 16


RESULT 776
US-08-584-040-2466
; Sequence 2466, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2466:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2466

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1615 GAAGAGTTTGTTACCT 1630
              ||||||: :| : ||:
Db          2 GAAGAGUAUGCUUCCU 17


RESULT 777
US-08-584-040-2565/c
; Sequence 2565, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
```

```
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2565:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2565

  Query Match              2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1766 TAAGCTTTTTTTTTT 1781
              |||| |||| ||| ||
Db         17 TAAGGTTTTATTTGTT 2


RESULT 778
US-08-584-040-2622
; Sequence 2622, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2622:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2622

  Query Match              2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2056 AACTAGTTAATAAGTG 2071
              | |:||::|  |||:|
Db          2 AGCUAGUUACAAAGUG 17


RESULT 779
US-08-584-040-2623
; Sequence 2623, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
```

```
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2623:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2623

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2056 AACTAGTTAATAAGTG 2071
                | |:||::|  |||:|
Db          1 AGCUAGUUACAAAGUG 16


RESULT 780
US-08-584-040-2692
; Sequence 2692, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2692:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2692

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1632 CCTTACTATTTAAAGA 1647
                | : ||:|:::|| ||
Db          2 CAUAACUAUUUAAGGA 17


RESULT 781
US-08-584-040-2695
; Sequence 2695, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2695:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2695

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1636 ACTATTTAAAGAGCCT 1651
              ||:|:::|| ||  |:
Db          2 ACUAUUUAAGGAAACU 17


RESULT 782
US-08-584-040-2803
; Sequence 2803, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  2803:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-2803

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 5.1e+02;
  Matches    7;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTG 1978
              |:|||:|::: |  :|
Db          1 CUAAAUAUUUUCAAUG 16


RESULT 783
US-08-584-040-3748
; Sequence 3748, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  3748:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-3748

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 5.1e+02;
  Matches    6;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1690 TGTTTCTCTAGCGCTG 1705
              :|:::|:|: |  |:|
Db          2 UGUUUCUCUUGAUCUG 17


RESULT 784
US-08-584-040-3917/c
; Sequence 3917, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
```

```
;       STREET:  Suite 4700
;       CITY:  Los Angeles
;       STATE:  California
;       COUNTRY:  U.S.A.
;       ZIP:  90071-2066
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;       MEDIUM TYPE:  storage
;       COMPUTER:  IBM Compatible
;       OPERATING SYSTEM:  IBM P.C. DOS 5.0
;       SOFTWARE:  Word Perfect 5.1
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/584,040
;       FILING DATE:  January 11, 1996
;       CLASSIFICATION:  514
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  60/005,974
;       FILING DATE:  October 26, 1995
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Warburg, Richard J.
;       REGISTRATION NUMBER:  32,327
;       REFERENCE/DOCKET NUMBER:  218/064
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (213) 489-1600
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;   INFORMATION FOR SEQ ID NO:  3917:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-3917

  Query Match              2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACACTC 2086
                ||  |||||||| |||
Db         16 GGATTCTGACACGCTC 1


RESULT 785
US-08-584-040-3970
; Sequence 3970, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  3970:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-3970

  Query Match              2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2014 ATCAAGTCCTCTGGTA 2029
                |:||  :|| |:||:|
Db          2 AUCACAUCCACUGGUA 17


RESULT 786
US-08-584-040-4073/c
; Sequence 4073, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
```

```
;       TELEFAX:  (213) 955-0440
;       TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  4073:
;    SEQUENCE CHARACTERISTICS:
;       LENGTH:  17 base pairs
;       TYPE:  nucleic acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
US-08-584-040-4073

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCTG 1848
              || |||||| | ||||
Db         17 TTCAATACAATGCCTG 2


RESULT 787
US-08-584-040-5392
; Sequence 5392, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5392:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5392

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1645 AGAGCCTTCACTGGTT 1660
              | ||||: |||:| ::
Db          2 AUAGCCUCCACUGUUU 17


RESULT 788
US-08-584-040-5565
; Sequence 5565, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5565:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5565

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGACCC 1861
              |:|  || ||||||||
Db          1 CUGCUCCUACAGACCC 16


RESULT 789
US-08-584-040-5597
; Sequence 5597, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
```

```
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5597:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5597

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1816 ATAAGTTTTAGAATCT 1831
              |:| |::: |||| |:
Db          2 AUACGUUUGAGAACCU 17


RESULT 790
US-08-584-040-5743
; Sequence 5743, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5743:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5743

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 5.1e+02;
  Matches    7;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1616 AAGAGTTTGTTACCTA 1631
              | || :::|:: ||:|
Db          2 AUGAAUUUGUUCCCUA 17


RESULT 791
US-08-584-040-5903/c
; Sequence 5903, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  5903:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-5903

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1587 CAGACTGGGAACCCCT 1602
                ||||||| | || ||
Db         17 CAGACTGGTAGCCACT 2


RESULT 792
US-08-584-040-7276/c
; Sequence 7276, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7276:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7276

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAA 1980
                ||||||  ||  |||||
Db         16 AAATATGTAGATTGAA 1


RESULT 793
US-08-584-040-7396/c
; Sequence 7396, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7396:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7396

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
```

```
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1645 AGAGCCTTCACTGGTT 1660
              | |||||| |||| ||
Db         17 ATAGCCTTGACTGCTT 2


RESULT 794
US-08-584-040-7445/c
; Sequence 7445, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7445:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7445

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1794 TTCCTTCTCTGAAAGT 1809
              ||||||| |||  ||
Db         16 TTCCTTCTATGACCGT 1


RESULT 795
US-08-584-040-7719/c
; Sequence 7719, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7719:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7719

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGT 1625
              |||||| |||| |||
Db         17 TGGGGGTCGAGTATGT 2


RESULT 796
US-08-584-040-7744/c
; Sequence 7744, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
```

```
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7744:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7744

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
              ||| ||| || |||||
Db         17 AAGGTTTTGATTCTTT 2


RESULT 797
US-08-584-040-7749
; Sequence 7749, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  7749:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-7749

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1705 GAGCTATCTCCTAACT 1720
              |||| : :| || |||:
Db          2 GAGCUUUCACCGAACU 17


RESULT 798
US-08-584-040-8010
; Sequence 8010, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL .
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
```

```
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  8010:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-8010

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 5.1e+02;
  Matches    6;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTT 1774
              :|:: |::|||| ::
Db          2 UAUUUAUUAAGCACUU 17


RESULT 799
US-08-584-040-8033/c
; Sequence 8033, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  8033:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-8033

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGT 1992
              |||||| |||| | ||
Db         16 TGAAAATAAGATAGGT 1


RESULT 800
US-08-584-040-8158
; Sequence 8158, Application US/08584040
; Patent No. 6346398
;  GENERAL INFORMATION:
;    APPLICANT:  Pavco, Pamela
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  Escobedo, Jaime
;    TITLE OF INVENTION:  METHOD AND REAGENT FOR THE
;    TITLE OF INVENTION:  TREATMENT OF DISEASES OR
;    TITLE OF INVENTION:  CONDITIONS RELATED TO LEVELS
;    TITLE OF INVENTION:  OF VASCULAR ENDOTHELIAL
;    TITLE OF INVENTION:  GROWTH FACTOR
;    NUMBER OF SEQUENCES:  8502
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/584,040
;      FILING DATE:  January 11, 1996
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/005,974
;      FILING DATE:  October 26, 1995
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  218/064
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  8158:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-584-040-8158

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              | |:||::|:|| : |
Db          1 CUCUGGUUCUGCUUAA 16


RESULT 801
US-08-679-645-153/c
; Sequence 153, Application US/08679645
```

```
; Patent No. 6350934
;  GENERAL INFORMATION:
;    APPLICANT:  Zwick, Michael G.
;    APPLICANT:  Edington, Brent E.
;    APPLICANT:  McSwiggen, James A.
;    APPLICANT:  Merlo, Patricia Ann Owens
;    APPLICANT:  Guo, Lining
;    APPLICANT:  Skokut, Thomas A.
;    APPLICANT:  Young, Scott A.
;    APPLICANT:  Folkerts, Otto
;    APPLICANT:  Merlo, Donald J.
;    TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
;    TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;    TITLE OF INVENTION:  IN PLANTS
;    NUMBER OF SEQUENCES:  1263
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/679,645
;      FILING DATE:  July 12, 1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/001,135
;      FILING DATE:  July 13, 1995
;      APPLICATION NUMBER:  08/300,726
;      FILING DATE:  September 2, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  219/247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  153:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-679-645-153

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1589 GACTGGGAACCCCTCC 1604
              | ||||||||  ||||
Db         16 GCCTGGGAACTTCTCC 1


RESULT 802
US-08-679-645-756
; Sequence 756, Application US/08679645
; Patent No. 6350934
;  GENERAL INFORMATION:
;    APPLICANT:  Zwick, Michael G.
;    APPLICANT:  Edington, Brent E.
;    APPLICANT:  McSwiggen, James A.
;    APPLICANT:  Merlo, Patricia Ann Owens
;    APPLICANT:  Guo, Lining
;    APPLICANT:  Skokut, Thomas A.
;    APPLICANT:  Young, Scott A.
;    APPLICANT:  Folkerts, Otto
;    APPLICANT:  Merlo, Donald J.
;    TITLE OF INVENTION:  COMPOSITION AND METHODS FOR
;    TITLE OF INVENTION:  MODULATION OF GENE EXPRESSION
;    TITLE OF INVENTION:  IN PLANTS
;    NUMBER OF SEQUENCES:  1263
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/679,645
;      FILING DATE:  July 12, 1996
;      CLASSIFICATION:  800
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  60/001,135
;      FILING DATE:  July 13, 1995
;      APPLICATION NUMBER:  08/300,726
;      FILING DATE:  September 2, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  219/247
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  756:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-679-645-756

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2045 ATCTGCTTAGCAACTA 2060
              |:|:||: | ||| :|
Db          2 AUCUGCUCAACAAGUA 17


RESULT 803
US-09-480-017-9/c
; Sequence 9, Application US/09480017
; Patent No. 6388067
; GENERAL INFORMATION:
;  APPLICANT: Yu, Su-May
;  APPLICANT:  Tong, Wu-Fu
;  TITLE OF INVENTION: RICE CYSTEINE PROTEINASE GENE PROMOTER
;  FILE REFERENCE: 08919-038001
;  CURRENT APPLICATION NUMBER: US/09/480,017
;  CURRENT FILING DATE:  2000-01-10
;  NUMBER OF SEQ ID NOS: 11
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
```

```
;   FEATURE:
;   OTHER INFORMATION: synthesized primer
US-09-480-017-9

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACA 1588
              || ||||| ||| |||
Db         16 CCATCTCCGCCGTACA 1


RESULT 804
US-09-305-856B-35
; Sequence 35, Application US/09305856B
; Patent No. 6479236
; GENERAL INFORMATION:
;  APPLICANT:  Penny, Laura
;  APPLICANT:  Galvin, Margaret
;  TITLE OF INVENTION:  Genotyping the Human
;  TITLE OF INVENTION:  UDP-Glucuronosyltransferase 1 (UGT1) Gene
;  FILE REFERENCE:  4389-7 (formerly SEQ-17CIP)
;  CURRENT APPLICATION NUMBER: US/09/305,856B
;  CURRENT FILING DATE:  1999-05-05
;  PRIOR APPLICATION NUMBER:  60/084,807
;  PRIOR FILING DATE:  1998-05-07
;  NUMBER OF SEQ ID NOS:  124
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 35
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-305-856B-35

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCAA 2037
              |||||| |||||  ||
Db          1 CTCTGGCAGGAGCAAA 16


RESULT 805
US-09-305-856B-51
; Sequence 51, Application US/09305856B
; Patent No. 6479236
; GENERAL INFORMATION:
;  APPLICANT:  Penny, Laura
;  APPLICANT:  Galvin, Margaret
;  TITLE OF INVENTION:  Genotyping the Human
;  TITLE OF INVENTION:  UDP-Glucuronosyltransferase 1 (UGT1) Gene
;  FILE REFERENCE:  4389-7 (formerly SEQ-17CIP)
;  CURRENT APPLICATION NUMBER: US/09/305,856B
;  CURRENT FILING DATE:  1999-05-05
;  PRIOR APPLICATION NUMBER:  60/084,807
;  PRIOR FILING DATE:  1998-05-07
;  NUMBER OF SEQ ID NOS:  124
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 51
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Primer
US-09-305-856B-51

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCAA 2037
              |||||| |||||  ||
Db          1 CTCTGGCAGGAGCAAA 16


RESULT 806
US-09-789-453A-6/c
; Sequence 6, Application US/09789453A
; Patent No. 6498235
; GENERAL INFORMATION:
;  APPLICANT: Sheppard, Paul O.
;  APPLICANT:  Piddington, Christopher S.
;  APPLICANT:  Ellsworth, Jeff L.
;  TITLE OF INVENTION: TESTIS-SPECIFIC GLYCOPROTEIN ZPEP10
;  FILE REFERENCE: 98-34D1
;  CURRENT APPLICATION NUMBER: US/09/789,453A
;  CURRENT FILING DATE:  2001-08-20
;  PRIOR APPLICATION NUMBER: 09/441,346
;  PRIOR FILING DATE: 1999-11-16
;  PRIOR APPLICATION NUMBER: 60/109,216
;  PRIOR FILING DATE: 1998-11-20
;  NUMBER OF SEQ ID NOS: 14
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Degenerate oligonucleotide probe
;   NAME/KEY: variation
;   LOCATION: (1)...(17)
;   OTHER INFORMATION: Each N is independently any nucleotide.
US-09-789-453A-6

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1750 CTGGCTCTTTATTCAT 1765
              | |  :|:||:|||||
Db         16 CNGTNYCYTTRTTCAT 1


RESULT 807
US-09-673-809-80
; Sequence 80, Application US/09673809
; Patent No. 6528261
; GENERAL INFORMATION:
;  APPLICANT:  INNOGENETICS N.V.
;  TITLE OF INVENTION:  Method for typing of HLA alleles.
;  FILE REFERENCE:  PCT99.86.HLA
;  CURRENT APPLICATION NUMBER: US/09/673,809
;  CURRENT FILING DATE:  2000-10-20
;  PRIOR APPLICATION NUMBER:  98870088.6
;  PRIOR FILING DATE:  1998-04-20
;  NUMBER OF SEQ ID NOS:  107
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 80
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-673-809-80

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1906 ACAGATCAACAATACC 1921
              |||||||  ||| |||
Db          1 ACAGATCTGCAAGACC 16
```

```
RESULT 808
US-09-474-432B-721
; Sequence 721, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 721
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-721

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2011 GAGATCAAGTCCTCTG 2026
              |||| | || ||:|:|
Db          1 GAGAGCCAGCCCUCUG 16


RESULT 809
US-09-474-432B-795/c
; Sequence 795, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Burgin, Alex
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka
;  APPLICANT:  Sweedler, David
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
;  FILE REFERENCE: MBHB00-831-B (247/276)
;  CURRENT APPLICATION NUMBER: US/09/474,432B
;  CURRENT FILING DATE:  1999-12-19
;  PRIOR APPLICATION NUMBER: US 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  PRIOR APPLICATION NUMBER: US 60/084,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: US 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: US 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  NUMBER OF SEQ ID NOS: 1526
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 795
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-474-432B-795

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2007 TTCAGAGATCAAGTCC 2022
              |||||| | ||| |||
Db         17 TTCAGACACCAACTCC 2


RESULT 810
US-09-549-697-3
; Sequence 3, Application US/09549697
; Patent No. 6537542
; GENERAL INFORMATION:
;  APPLICANT: Treco, Douglas A.
;  APPLICANT:  Heartlein, Michael W.
;  APPLICANT:  Selden, Richard F
;  TITLE OF INVENTION: Targeted Introduction of DNA into
;  TITLE OF INVENTION:  Primary or Secondary Cells and Their Use for Gene Therapy
;  TITLE OF INVENTION:  and Protein Production
;  FILE REFERENCE: 50010/006005
;  CURRENT APPLICATION NUMBER: US/09/549,697
;  CURRENT FILING DATE:  2000-04-14
;  PRIOR APPLICATION NUMBER: US 08/446,921
;  PRIOR FILING DATE: 1995-05-18
;  PRIOR APPLICATION NUMBER: US 08/231,439
;  PRIOR FILING DATE: 1994-04-20
;  PRIOR APPLICATION NUMBER: US 07/789,188
;  PRIOR FILING DATE: 1991-11-05
;  NUMBER OF SEQ ID NOS: 4
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-549-697-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCA 1862
              |||||   ||||||||
Db          1 TGGGCTTCCAGACCCA 16


RESULT 811
US-09-312-245-3
; Sequence 3, Application US/09312245
; Patent No. 6565844
;   GENERAL INFORMATION:
;        APPLICANT: Treco, Douglas
;                   Heartlein, Michael W.
;                   Selden, Richard F
;        TITLE OF INVENTION: Protein Production and Protein Delivery
;        NUMBER OF SEQUENCES: 17
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
;             STREET: Two Militia Drive
;             CITY: Lexington
;             STATE: Massachusetts
;             COUNTRY: U.S.A.
;             ZIP: 02173
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.25
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/312,245
;             FILING DATE: 14-May-1999
```

```
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 07/985,586
;            FILING DATE: <Unknown>
;            APPLICATION NUMBER: US 07/911,533
;            FILING DATE: 10-JUL-1992
;            APPLICATION NUMBER: US 07/787,840
;            FILING DATE: 05-NOV-1991
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Granahan, Patricia
;            REGISTRATION NUMBER: 32,227
;            REFERENCE/DOCKET NUMBER: TKT92-03M
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (617) 861-6240
;            TELEFAX: (617) 861-9540
;   INFORMATION FOR SEQ ID NO: 3:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 17 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: DNA (genomic)
;       SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-312-245-3

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCA 1862
              |||||   ||||||||
Db          1 TGGGCTTCCAGACCCA 16


RESULT 812
US-09-371-772B-447/c
; Sequence 447, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 447
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-447

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCCC 1898
              || || |||| |||||
Db         16 TCCAAGTGATTTGCCC 1


RESULT 813
US-09-371-772B-484
; Sequence 484, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 484
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-484

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAAC 1785
              |:: :::::: : |||
Db          2 CUUAUUUUUUCUCAAC 17


RESULT 814
US-09-371-772B-485
; Sequence 485, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 485
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-485

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAAC 1785
              |:: :::::: : |||
Db          1 CUUAUUUUUUCUCAAC 16


RESULT 815
US-09-371-772B-561/c
; Sequence 561, Application US/09371772B
; Patent No. 6566127
```

```
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 561
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-561

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1809 TGGTGCTATAAGTTTT 1824
              ||||||| ||  ||||
Db         17 TGGTGCTGTAGATTTT 2


RESULT 816
US-09-371-772B-604
; Sequence 604, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 604
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-604

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1938 AGGTAATGGTTGGTTT 1953
              ||| ||: |: ||:::
Db          2 AGGAAAUAGUGGGUUU 17


RESULT 817
US-09-371-772B-604/c
; Sequence 604, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 604
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-604

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1783 AACCCCATTCTTTCCT 1798
              || |||| | ||||||
Db         17 AAACCCACTATTTCCT 2


RESULT 818
US-09-371-772B-637/c
; Sequence 637, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 637
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-637

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
              ||| ||| || |||||
Db         17 AAGGTTTTGATTCTTT 2


RESULT 819
US-09-371-772B-742
; Sequence 742, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 742
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-742

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1555 GAACAGGACTGCAAAA 1570
              ||||| ||:|| |||
Db          2 GAACACUACUGCUAAA 17


RESULT 820
US-09-371-772B-834
; Sequence 834, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 834
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-834

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGGCA 2036
              ||:|: |:| || |||
Db          1 CCUCUAGUAAGAUGCA 16


RESULT 821
US-09-371-772B-939
; Sequence 939, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 939
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-939

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1635 TACTATTTAAAGAGCC 1650
              :| :| ::|| |||||
Db          2 UAUUAGUUAAUGAGCC 17


RESULT 822
US-09-371-772B-940
; Sequence 940, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 940
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-940

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1635 TACTATTTAAAGAGCC 1650
              :| :| ::|| |||||
Db          1 UAUUAGUUAAUGAGCC 16


RESULT 823
US-09-371-772B-990
; Sequence 990, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
```

; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 990
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-990

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 5.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1615 GAAGAGTTTGTTACCT 1630
||||||: :| : ||:
Db 2 GAAGAGUAUGCUUCCU 17

RESULT 824
US-09-371-772B-1089/c
; Sequence 1089, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1089
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1089

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1766 TAAGCTTTTTTTTTTT 1781
|||| |||| ||| ||
Db 17 TAAGGTTTTATTTGTT 2

RESULT 825
US-09-371-772B-1146
; Sequence 1146, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1146
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1146

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 5.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 2056 AACTAGTTAATAAGTG 2071
| |:||::| |||:|
Db 2 AGCUAGUUACAAAGUG 17

RESULT 826
US-09-371-772B-1147
; Sequence 1147, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1147
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1147

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 5.1e+02;
Matches 9; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 2056 AACTAGTTAATAAGTG 2071
| |:||::| |||:|
Db 1 AGCUAGUUACAAAGUG 16

RESULT 827
US-09-371-772B-1216
; Sequence 1216, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

```
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1216
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1216

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1632 CCTTACTATTTAAAGA 1647
              | : ||:|:::|| ||
Db          2 CAUAACUAUUUAAGGA 17


RESULT 828
US-09-371-772B-1219
; Sequence 1219, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1219
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1219

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1636 ACTATTTAAAGAGCCT 1651
              ||:|:::|| ||  |:
Db          2 ACUAUUUAAGGAAACU 17


RESULT 829
US-09-371-772B-1327
; Sequence 1327, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1327
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1327

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 5.1e+02;
  Matches    7;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTG 1978
              |:|||:|::: |  :|
Db          1 CUAAAUAUUUUCAAUG 16


RESULT 830
US-09-371-772B-1515
; Sequence 1515, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1515
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1515

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 5.1e+02;
  Matches    6;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1690 TGTTTCTCTAGCGCTG 1705
              :|:::|:|: |  |:|
Db          2 UGUUUCUCUUGAUCUG 17


RESULT 831
US-09-371-772B-1684/c
; Sequence 1684, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
```

```
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1684
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1684

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2071 GGTATCTGACACACTC 2086
              ||  |||||||| |||
Db         16 GGATTCTGACACGCTC 1


RESULT 832
US-09-371-772B-1737
; Sequence 1737, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1737
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1737

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2014 ATCAAGTCCTCTGGTA 2029
              |:||  :|| |:||:|
Db          2 AUCACAUCCACUGGUA 17


RESULT 833
US-09-371-772B-1840/c
; Sequence 1840, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1840
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-1840

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCTG 1848
              || |||||| | ||||
Db         17 TTCAATACAATGCCTG 2


RESULT 834
US-09-371-772B-2291
; Sequence 2291, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2291
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2291

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1645 AGAGCCTTCACTGGTT 1660
              | ||||: |||:| ::
Db          2 AUAGCCUCCACUGUUU 17


RESULT 835
US-09-371-772B-2455
; Sequence 2455, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
```

```
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2455
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2455

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGACCC 1861
              |:|  || ||||||||
Db          1 CUGCUCCUACAGACCC 16


RESULT 836
US-09-371-772B-2487
; Sequence 2487, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2487
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2487

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1816 ATAAGTTTTAGAATCT 1831
              |:| |::: |||| |:
Db          2 AUACGUUUGAGAACCU 17


RESULT 837
US-09-371-772B-2622
; Sequence 2622, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2622
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2622

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 5.1e+02;
  Matches    7;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1616 AAGAGTTTGTTACCTA 1631
              | || :::|:: ||:|
Db          2 AUGAAUUUGUUCCCUA 17


RESULT 838
US-09-371-772B-2742/c
; Sequence 2742, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2742
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-2742

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1587 CAGACTGGGAACCCCT 1602
              |||||||| | || ||
Db         17 CAGACTGGTAGCCACT 2


RESULT 839
US-09-371-772B-3085/c
; Sequence 3085, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
```

```
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3085
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3085

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAA 1980
              |||||| ||  |||||
Db         16 AAATATGTAGATTGAA 1


RESULT 840
US-09-371-772B-3204/c
; Sequence 3204, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3204
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3204

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1645 AGAGCCTTCACTGGTT 1660
              | ||||||  |||| ||
Db         17 ATAGCCTTGACTGCTT 2


RESULT 841
US-09-371-772B-3251/c
; Sequence 3251, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3251
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3251

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1794 TTCCTTCTCTGAAAGT 1809
              |||||||| |||  ||
Db         16 TTCCTTCTATGACCGT 1


RESULT 842
US-09-371-772B-3504/c
; Sequence 3504, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3504
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3504

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGT 1625
              ||||||  |||| |||
Db         17 TGGGGGTCGAGTATGT 2


RESULT 843
US-09-371-772B-3533
; Sequence 3533, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
```

```
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3533
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3533

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1705 GAGCTATCTCCTAACT 1720
              ||||: :| || |||:
Db          2 GAGCUUUCACCGAACU 17


RESULT 844
US-09-371-772B-3793
; Sequence 3793, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3793
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3793

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 5.1e+02;
  Matches    6;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTT 1774
              :|:: |::|||  ::
Db          2 UAUUUAUUAAGCACUU 17


RESULT 845
US-09-371-772B-3816/c
; Sequence 3816, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3816
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3816

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGT 1992
              |||||| |||| | ||
Db         16 TGAAAATAAGATAGGT 1


RESULT 846
US-09-371-772B-3941
; Sequence 3941, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3941
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Mus sp.
US-09-371-772B-3941

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              | |:||::|:|| : |
Db          1 CUCUGGUUCUGCUUAA 16


RESULT 847
US-09-371-772B-4693
; Sequence 4693, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
```

```
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4693
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4693

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCAA 2018
              |::|::| || |: ||
Db          2 CUUCUUCUGAAAUAAA 17


RESULT 848
US-09-371-772B-4759/c
; Sequence 4759, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4759
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4759

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGGGG 1614
              ||||||| || ||| |
Db         16 CCCTCCTTGCTTGGTG 1


RESULT 849
US-09-371-772B-4938/c
; Sequence 4938, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4938
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-4938

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
              ||| ||| || |||||
Db         16 AAGGTTTTGATTCTTT 1


RESULT 850
US-09-371-772B-5012
; Sequence 5012, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5012
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5012

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1669 CCCGCCCCTGGACTTC 1684
              |||||||  |||: |
Db          2 CCCGCCCCCAGACUAC 17


RESULT 851
US-09-371-772B-5013
; Sequence 5013, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rr
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5013
```

```
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5013

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1669 CCCGCCCCTGGACTTC 1684
              |||||||  |||: |
Db          1 CCCGCCCCCAGACUAC 16


RESULT 852
US-09-371-772B-5222/c
; Sequence 5222, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5222
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5222

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGGGG 1614
              || || |||||||| |
Db         16 CCATCATGGCCTGGAG 1


RESULT 853
US-09-371-772B-5241
; Sequence 5241, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5241
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5241

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1530 AAGAAAGGTTAGGAGA 1545
              ||||||| : || |||
Db          1 AAGAAAGCUGAGAAGA 16


RESULT 854
US-09-371-772B-5301
; Sequence 5301, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5301
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-5301

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1643 AAAGAGCCTTCACTGG 1658
              || ||||| :|||: |
Db          1 AAUGAGCCAUCACUAG 16


RESULT 855
US-09-371-772B-5483
; Sequence 5483, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5483
;   LENGTH: 17
;   TYPE: RNA
```

```
;   ORGANISM: Homo sapiens
US-09-371-772B-5483

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2058 CTAGTTAATAAGTGGT 2073
              |:||::|  |||:| :
Db          1 CUAGUUACAAAGUGCU 16


RESULT 856
US-09-371-772B-6131
; Sequence 6131, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6131
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6131

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   37.5%;  Pred. No. 5.1e+02;
  Matches    6;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1690 TGTTTCTCTAGCGCTG 1705
              :|:::|:|: |  |:|
Db          1 UGUUUCUCUUGAUCUG 16


RESULT 857
US-09-371-772B-6154
; Sequence 6154, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6154
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6154

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.1e+02;
  Matches    8;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATTATC 1734
              |:::|| || |: |:|
Db          2 CUUUGGCCCAAUAAUC 17


RESULT 858
US-09-371-772B-6382
; Sequence 6382, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6382
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6382

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2014 ATCAAGTCCTCTGGTA 2029
              |:||  :|| |:||:|
Db          1 AUCACAUCCACUGGUA 16


RESULT 859
US-09-371-772B-6398
; Sequence 6398, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6398
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6398
```

```
  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACTT 1869
              ||| ||||| || |::
Db          2 ACAAACCCAUACCCUU 17


RESULT 860
US-09-371-772B-6399
; Sequence 6399, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6399
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6399

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACTT 1869
              ||| ||||| || |::
Db          1 ACAAACCCAUACCCUU 16


RESULT 861
US-09-371-772B-6518
; Sequence 6518, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6518
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6518

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1738 AGGTGACAAGTACTGG 1753
              ||  ||||||:| :||
Db          2 AGACGACAAGUAUUGG 17


RESULT 862
US-09-371-772B-6675/c
; Sequence 6675, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6675
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6675

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2023 TCTGGTAGGAGGCAAA 2038
              ||| ||||| | ||||
Db         17 TCTTGTAGGGGACAAA 2


RESULT 863
US-09-371-772B-6676/c
; Sequence 6676, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Pavco, Pam
;  APPLICANT:  McSwiggen, Jim
;  APPLICANT:  Stinchcomb, Dan
;  APPLICANT:  Escobedo, Jaime
;  TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
;  TITLE OF INVENTION:  Levels of Vascular Endothelial Growth Factor Receptor
;  FILE REFERENCE: MBHB00,876-J (237/198)
;  CURRENT APPLICATION NUMBER: US/09/371,772B
;  CURRENT FILING DATE:  1999-08-10
;  PRIOR APPLICATION NUMBER: US 60/005,974
;  PRIOR FILING DATE: 1995-10-26
;  PRIOR APPLICATION NUMBER: US 08/584,040
;  PRIOR FILING DATE: 1996-01-08
;  NUMBER OF SEQ ID NOS: 14225
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6676
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-371-772B-6676

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
```

```
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2023 TCTGGTAGGAGGCAAA 2038
              ||| ||||| | ||||
Db         16 TCTTGTAGGGGACAAA 1


RESULT 864
US-09-335-231-8/c
; Sequence 8, Application US/09335231
; Patent No. 6576420
; GENERAL INFORMATION:
;  APPLICANT:  Carson, Dennis A.
;  APPLICANT:  Schmid, Mathias
;  APPLICANT:  Carrera, Carlos J.
;  APPLICANT:  The Regents of the University of California
;  TITLE OF INVENTION:  Method for Early Diagnosis of, and Determination of
;  TITLE OF INVENTION:  Prognosis in, Cancer
;  FILE REFERENCE:  023070-108010US
;  CURRENT APPLICATION NUMBER: US/09/335,231
;  CURRENT FILING DATE:  1999-06-17
;  PRIOR APPLICATION NUMBER:  US 60/090,411
;  PRIOR FILING DATE:  1998-06-23
;  NUMBER OF SEQ ID NOS:  25
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 8
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:anti-sense
;   OTHER INFORMATION: primer
US-09-335-231-8

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1637 CTATTTAAAGAGCCTT 1652
              |||| |||| | ||||
Db         17 CTATGTAAATATCCTT 2


RESULT 865
US-09-476-387-720
; Sequence 720, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 720
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-720

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2011 GAGATCAAGTCCTCTG 2026
              |||| | || ||:|:|
Db          1 GAGAGCCAGCCCUCUG 16


RESULT 866
US-09-476-387-794/c
; Sequence 794, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
;  APPLICANT: Ribozyme Pharmaceuticals, Inc.
;  APPLICANT:  Beigelman, Leo
;  APPLICANT:  Beaudry, Amber
;  APPLICANT:  Karpeisky, Alex
;  APPLICANT:  Adamic, Jasenka Matulic
;  APPLICANT:  Sweedler, Dave
;  APPLICANT:  Zinnen, Shawn
;  TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
;  FILE REFERENCE: MBHB00-831-C (249/073)
;  CURRENT APPLICATION NUMBER: US/09/476,387
;  CURRENT FILING DATE:  2001-04-04
;  PRIOR APPLICATION NUMBER: 09/474,432
;  PRIOR FILING DATE: 1999-12-29
;  PRIOR APPLICATION NUMBER: 09/301,511
;  PRIOR FILING DATE: 1999-04-28
;  PRIOR APPLICATION NUMBER: 09/186,675
;  PRIOR FILING DATE: 1998-11-04
;  PRIOR APPLICATION NUMBER: 60/083,727
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/064,866
;  PRIOR FILING DATE: 1997-11-05
;  NUMBER OF SEQ ID NOS: 1524
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 794
;   LENGTH: 17
;   TYPE: RNA
;   ORGANISM: Homo sapiens
US-09-476-387-794

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2007 TTCAGAGATCAAGTCC 2022
              |||||| | ||| |||
Db         17 TTCAGACACCAACTCC 2


RESULT 867
US-09-401-063-381
; Sequence 381, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
```

```
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  381:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-381

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1577 CTCCACCGCACAGACT 1592
              |:||||  ||| |||:
Db          1 CUCCACGUCACGGACU 16


RESULT 868
US-09-401-063-498/c
; Sequence 498, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  498:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-498

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTTT 1926
              ||||  |||||| |||
Db         16 TCAAATATACCTCTTT 1


RESULT 869
US-09-401-063-643
; Sequence 643, Application US/09401063
; Patent No. 6623962
;  GENERAL INFORMATION:
;    APPLICANT:  Akhtar, Saghir
;    APPLICANT:  Fell, Patricia
;    APPLICANT:  McSwiggen, James
;    TITLE OF INVENTION:  ENZYMATIC NUCLEIC ACID TREATMENT
;    TITLE OF INVENTION:  OF DISEASES OR CONDITIONS RELATED
;    TITLE OF INVENTION:  TO LEVELS OF EPIDERMAL GROWTH
;    TITLE OF INVENTION:  FACTOR RECEPTORS
;    NUMBER OF SEQUENCES:  1877
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ for Windows 2.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/401,063
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/985,162
;      FILING DATE:  04 December 1997
;      APPLICATION NUMBER:  60/036,476
;      FILING DATE:  31 January 1997
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  230/107
```

```
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213)  955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  643:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-401-063-643

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1557 ACAGGACTGCAAAAAT 1572
                | | |||: ||||||:
Db          1 AGAAGACUACAAAAAU 16


RESULT 870
US-09-827-998-237/c
; Sequence 237, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 237
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-237

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1812 TGCTATAAGTTTTAGA 1827
                |||||  ||  |||||  |
Db         17 TGCTAGAACTTTTACA 2


RESULT 871
US-09-827-998-238/c
; Sequence 238, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 238
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-238

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1812 TGCTATAAGTTTTAGA 1827
                |||||  ||  |||||  |
Db         16 TGCTAGAACTTTTACA 1


RESULT 872
US-09-827-998-254/c
; Sequence 254, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 254
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-254

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
                || |||||  |||  |||
Db         17 TTCACCTTAAAACAAA 2


RESULT 873
US-09-827-998-255/c
; Sequence 255, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 255
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-255

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
```

```
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
              || ||||| ||| |||
Db         16 TTCACCTTAAAACAAA 1

RESULT 874
US-09-827-998-606
; Sequence 606, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 606
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-606

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGG 1850
              ||  |||| |||||||
Db          2 AAGCACATGCCCTGGG 17

RESULT 875
US-09-827-998-607
; Sequence 607, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
;  APPLICANT: Gu, Yizhong
;  APPLICANT:  Shannon, Mark
;  TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
;  FILE REFERENCE: MDhMORF-8
;  CURRENT APPLICATION NUMBER: US/09/827,998
;  CURRENT FILING DATE:  2001-04-06
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  NUMBER OF SEQ ID NOS: 1881
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 607
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-827-998-607

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGG 1850
              ||  |||| |||||||
Db          1 AAGCACATGCCCTGGG 16

RESULT 876
US-09-920-923B-60/c
; Sequence 60, Application US/09920923B
; Patent No. 6677134
; GENERAL INFORMATION:
;  APPLICANT: Pasamontes, Luis
;  APPLICANT:  Tsygankov, Yuri
;  TITLE OF INVENTION: Fermentative Carotenoid Production
;  FILE REFERENCE: 15464 US (C38435/125944)
;  CURRENT APPLICATION NUMBER: US/09/920,923B
;  CURRENT FILING DATE:  2001-08-02
;  PRIOR APPLICATION NUMBER: 08/980,832
;  PRIOR FILING DATE: 1997-12-01
;  NUMBER OF SEQ ID NOS: 66
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 60
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial
;   FEATURE:
;   OTHER INFORMATION: Primer crtW106
US-09-920-923B-60

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCT 1605
              |:|||||:| :| :||
Db         16 AYTGGGARCAYCAYCT 1

RESULT 877
US-09-958-221A-17/c
; Sequence 17, Application US/09958221A
; Patent No. 6686160
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
;  TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
;  FILE REFERENCE: 92750/64
;  CURRENT APPLICATION NUMBER: US/09/958,221A
;  CURRENT FILING DATE:  2001-10-03
;  PRIOR APPLICATION NUMBER: EP 00200757.3
;  PRIOR FILING DATE: 2000-03-03
;  PRIOR APPLICATION NUMBER: PCT/NL01/00177
;  PRIOR FILING DATE: 2001-03-05
;  NUMBER OF SEQ ID NOS: 27
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-17

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACTT 1869
              ||| || ||||||| |
Db         16 ACACACACACACACAT 1

RESULT 878
US-09-958-221A-19
; Sequence 19, Application US/09958221A
; Patent No. 6686160
; GENERAL INFORMATION:
;  APPLICANT: Haeringen van, Willem A.
;  APPLICANT:  Haeringen van, Hendrik
```

; TITLE OF INVENTION: UNIVERSAL VARIABLE FRAGMENTS
; FILE REFERENCE: 92750/64
; CURRENT APPLICATION NUMBER: US/09/958,221A
; CURRENT FILING DATE: 2001-10-03
; PRIOR APPLICATION NUMBER: EP 00200757.3
; PRIOR FILING DATE: 2000-03-03
; PRIOR APPLICATION NUMBER: PCT/NL01/00177
; PRIOR FILING DATE: 2001-03-05
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 19
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-958-221A-19

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1852 CAACAGACCCACACAC 1867
| ||| || |||||||
Db 1 CCACACACACACACAC 16

RESULT 879
US-09-866-108A-146
; Sequence 146, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 146
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-146

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1664 CATCACCCGCCCCTGG 1679
|||| | || ||||||
Db 2 CATCTCACGGCCCTGG 17

RESULT 880
US-09-866-108A-147
; Sequence 147, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 147
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-147

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1664 CATCACCCGCCCCTGG 1679
|||| | || ||||||
Db 1 CATCTCACGGCCCTGG 16

RESULT 881
US-09-866-108A-866
; Sequence 866, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.

```
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 866
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-866

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGAG 1544
              ||| |||||  |||||
Db          2 GAAAAAAGGCGAGGAG 17


RESULT 882
US-09-866-108A-867
; Sequence 867, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 867
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-867

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGAG 1544
              ||| |||||  |||||
Db          1 GAAAAAAGGCGAGGAG 16


RESULT 883
US-09-866-108A-888
; Sequence 888, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 888
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-888
```

```
  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGG 1555
              || | ||| |||||||
Db          2 AGCATAGTGGGGAAGG 17


RESULT 884
US-09-866-108A-889
; Sequence 889, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 889
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-889

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGG 1555
              || | ||| |||||||
Db          1 AGCATAGTGGGGAAGG 16


RESULT 885
US-09-866-108A-1012
; Sequence 1012, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1012
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1012

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1541 GGAGAGTAGGGAAGGA 1556
              ||| || || ||||||
Db          2 GGAAAGCAGAGAAGGA 17


RESULT 886
US-09-866-108A-1013
; Sequence 1013, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1013
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1013

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1541 GGAGAGTAGGGAAGGA 1556
              ||| || || ||||||
Db          1 GGAAAGCAGAGAAGGA 16


RESULT 887
US-09-866-108A-1081
; Sequence 1081, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1081
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1081

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1541 GGAGAGTAGGGAAGGA 1556
              |||| | ||||||| |
Db          2 GGAGTGAAGGGAAGCA 17


RESULT 888
US-09-866-108A-1082
; Sequence 1082, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1082
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1082

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1541 GGAGAGTAGGGAAGGA 1556
              |||| | ||||||| |
Db          1 GGAGTGAAGGGAAGCA 16


RESULT 889
US-09-866-108A-1869
; Sequence 1869, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
```

```
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1869
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1869

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1597 ACCCCTCCTGGCCTGG 1612
              | ||||||||  ||||
Db          2 AACCCTCCTGAGCTGG 17


RESULT 890
US-09-866-108A-1870
; Sequence 1870, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1870
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-1870

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1597 ACCCCTCCTGGCCTGG 1612
              | ||||||||  ||||
Db          1 AACCCTCCTGAGCTGG 16


RESULT 891
US-09-866-108A-2003
; Sequence 2003, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2003
;   LENGTH: 17
;   TYPE: DNA
```

```
;   ORGANISM: Homo sapiens
US-09-866-108A-2003

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGGGGG 1615
              ||||| | || |||||
Db          2 CCTCCAGCCCCGGGGG 17


RESULT 892
US-09-866-108A-2004
; Sequence 2004, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2004
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2004

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGGGGG 1615
              ||||| | || |||||
Db          1 CCTCCAGCCCCGGGGG 16


RESULT 893
US-09-866-108A-2107/c
; Sequence 2107, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2107
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2107

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACCC 1671
              |||||| ||| | |||
Db         17 TGGTTCAGCAGCGCCC 2


RESULT 894
US-09-866-108A-2109/c
; Sequence 2109, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2109
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2109

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              ||||||| ||| | ||
Db         16 CTGGTTCAGCAGCGCC 1


RESULT 895
US-09-866-108A-2113/c
; Sequence 2113, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2113
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2113

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1650 CTTCACTGGTTCTGCA 1665
              || | ||||||| |||
Db         17 CTCCGCTGGTTCAGCA 2


RESULT 896
US-09-866-108A-2114/c
; Sequence 2114, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2114
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2114

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1650 CTTCACTGGTTCTGCA 1665
              || | ||||||| |||
Db         16 CTCCGCTGGTTCAGCA 1


RESULT 897
US-09-866-108A-2164
; Sequence 2164, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2164
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2164

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1591 CTGGGAACCCCTCCTG 1606
              ||||||| || ||||
Db          2 CTGGGAAGACCACCTG 17
```

RESULT 898
US-09-866-108A-2165
; Sequence 2165, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2165
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2165

Query Match 2.0%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 5.1e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1591 CTGGGAACCCCTCCTG 1606
              ||||||| || ||||
Db          1 CTGGGAAGACCACCTG 16
```

RESULT 899
US-09-866-108A-2373/c
; Sequence 2373, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2373

```
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2373

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1693 TTCTCTAGCGCTGAGC 1708
              || ||| | |||||||
Db         17 TTGTCTGGAGCTGAGC 2


RESULT 900
US-09-866-108A-2374/c
; Sequence 2374, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2374
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2374

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1693 TTCTCTAGCGCTGAGC 1708
              || ||| | |||||||
Db         16 TTGTCTGGAGCTGAGC 1


RESULT 901
US-09-866-108A-2783/c
; Sequence 2783, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2783
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2783

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1805 AAAGTGGTGCTATAAG 1820
              || |||||||  |||
Db         17 AAGGTGGTGCTTGAAG 2


RESULT 902
US-09-866-108A-2785/c
; Sequence 2785, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2785
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2785

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1804 GAAAGTGGTGCTATAA 1819
                ||| ||||||||  ||
Db         16 GAAGGTGGTGCTTGAA 1


RESULT 903
US-09-866-108A-2862/c
; Sequence 2862, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2862
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2862

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1694 TCTCTAGCGCTGAGCT 1709
                ||| ||| |||||||
Db         17 TCTTGAGCCCTGAGCT 2


RESULT 904
US-09-866-108A-2863/c
; Sequence 2863, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2863
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-2863

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1694 TCTCTAGCGCTGAGCT 1709
                ||| ||| |||||||
Db         16 TCTTGAGCCCTGAGCT 1


RESULT 905
US-09-866-108A-7955
; Sequence 7955, Application US/09866108A
```

```
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7955
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7955

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1893 GTGCCCTAGATCAACA 1908
                | ||||| || |||||
Db          2 GCGCCCTTGAGCAACA 17


RESULT 906
US-09-866-108A-7961
; Sequence 7961, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7961
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-7961

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAAA 1990
                ||||| || ||||||
Db          1 CTTGAGCAACAGAAAA 16


RESULT 907
US-09-866-108A-8044/c
; Sequence 8044, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
```

```
; Patent No. 6686188
; SEQ ID NO 8044
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8044

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCC 1675
              ||||| ||| |||| |
Db         17 TCTGCTTCATCCGCTC 2


RESULT 908
US-09-866-108A-8045/c
; Sequence 8045, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8045
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8045

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCC 1675
              ||||| ||| |||| |
Db         16 TCTGCTTCATCCGCTC 1


RESULT 909
US-09-866-108A-8149
; Sequence 8149, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8149
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8149

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTTG 1624
              |||| | |||||| ||
Db          2 CTGGAGCAAGAGTATG 17


RESULT 910
US-09-866-108A-8150
; Sequence 8150, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
```

```
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8150
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8150

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTTG 1624
              |||| | |||||| ||
Db          1 CTGGAGCAAGAGTATG 16


RESULT 911
US-09-866-108A-8247/c
; Sequence 8247, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8247
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8247

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1574 CTTCTCCACCGCACAG 1589
              |||||||||  || ||
Db         17 CTTCTCCACATCAAAG 2


RESULT 912
US-09-866-108A-8248/c
; Sequence 8248, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8248
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8248

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1574 CTTCTCCACCGCACAG 1589
              |||||||||  || ||
Db         16 CTTCTCCACATCAAAG 1


RESULT 913
```

```
US-09-866-108A-8267/c
; Sequence 8267, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8267
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8267

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1703 CTGAGCTATCTCCTAA 1718
                ||||| | ||||| ||
Db         17 CTGAGGTCTCTCCGAA 2


RESULT 914
US-09-866-108A-8268/c
; Sequence 8268, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8268
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-8268

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1703 CTGAGCTATCTCCTAA 1718
                ||||| | ||||| ||
Db         16 CTGAGGTCTCTCCGAA 1


RESULT 915
US-09-866-108A-10545/c
; Sequence 10545, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10545
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10545

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGC 1770
              | ||| ||||||| ||
Db         16 TATTTCTTCATTATGC 1


RESULT 916
US-09-866-108A-10573/c
; Sequence 10573, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10573
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10573

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1646 GAGCCTTCACTGGTTC 1661
              ||| ||  ||||||||
Db         17 GAGGCTGAACTGGTTC 2


RESULT 917
US-09-866-108A-10574/c
; Sequence 10574, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10574
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10574

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1646 GAGCCTTCACTGGTTC 1661
              ||| ||  ||||||||
Db         16 GAGGCTGAACTGGTTC 1


RESULT 918
US-09-866-108A-10609/c
; Sequence 10609, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
```

```
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10609
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10609

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAG 1554
                | | ||||| ||||||
Db         17 TTGTAGAGTCGGGAAG 2


RESULT 919
US-09-866-108A-10610/c
; Sequence 10610, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
;  APPLICANT: GU, Yizhong
;  APPLICANT:  JI, Yonggang
;  APPLICANT:  PENN, Sharron G.
;  APPLICANT:  HANZEL, David K.
;  APPLICANT:  RANK, David R.
;  APPLICANT:  CHEN, Wensheng
;  APPLICANT:  SHANNON, Mark
;  TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;  FILE REFERENCE: AEOMICA-7
;  CURRENT APPLICATION NUMBER: US/09/866,108A
;  CURRENT FILING DATE:  2001-05-25
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 15755
;  SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10610
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-866-108A-10610

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAG 1554
                | | ||||| ||||||
Db         16 TTGTAGAGTCGGGAAG 1


RESULT 920
US-09-404-912-81
; Sequence 81, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 81
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-81

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACA 1866
                ||||| || || ||||
Db          1 CCAACTGAACCGCACA 16


RESULT 921
US-09-404-912-176
; Sequence 176, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
```

```
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 176
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-176

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1681 CTTCTTAGTTGTTTCT 1696
              ||||| |||| | |||
Db          1 CTTCTAAGTTTTGTCT 16


RESULT 922
US-09-404-912-330
; Sequence 330, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 330
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-330

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
              ||||||||| ||  ||
Db          2 AAGTTTTAGGATTCTT 17


RESULT 923
US-09-404-912-394
; Sequence 394, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 394
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-394

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1914 ACAATACCTTTTTTTT 1929
              | |||||  |||||||
Db          2 AGAATACAGTTTTTTT 17


RESULT 924
US-09-404-912-494/c
; Sequence 494, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 494
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-494

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1587 CAGACTGGGAACCCCT 1602
              || | |||| ||||||
Db         17 CAAATTGGGGACCCCT 2


RESULT 925
US-09-404-912-523/c
; Sequence 523, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 523
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-523
```

```
  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACTT 1869
              ||| || ||||||| |
Db         17 ACACACGCACACACCT 2


RESULT 926
US-09-404-912-531/c
; Sequence 531, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
;  APPLICANT: John Landers
;  APPLICANT:  David Houseman
;  APPLICANT:  Barbara Jordan
;  APPLICANT:  Alain Charest
;  TITLE OF INVENTION: Methods and Products Related to
;  TITLE OF INVENTION:  Genotyping and DNA Analysis
;  FILE REFERENCE: M0656/7045(HCL/MAT)
;  CURRENT APPLICATION NUMBER: US/09/404,912
;  CURRENT FILING DATE:  1999-09-24
;  PRIOR APPLICATION NUMBER: US 60/101,757
;  PRIOR FILING DATE: 1998-09-25
;  PRIOR APPLICATION NUMBER: PCT/US99/22283
;  PRIOR FILING DATE: 1999-09-24
;  NUMBER OF SEQ ID NOS: 691
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 531
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Homo Sapiens
US-09-404-912-531

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1587 CAGACTGGGAACCCCT 1602
              || | |||| ||||||
Db         17 CAAATTGGGGACCCCT 2


RESULT 927
US-09-856-662-34/c
; Sequence 34, Application US/09856662
; Patent No. 6790616
; GENERAL INFORMATION:
;  APPLICANT: MORIBE, Toyoki et al.
;  TITLE OF INVENTION: Method for typing HLA class 1 genes
;  FILE REFERENCE: 0032-0261P
;  CURRENT APPLICATION NUMBER: US/09/856,662
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: JP P1998-335151
;  PRIOR FILING DATE: 1998-11-26
;  NUMBER OF SEQ ID NOS: 130
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 34
;   LENGTH: 17
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:DNA probe A779A
US-09-856-662-34

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTG 1611
              | |||||  | ||||||
Db         16 ATCCCCTTCAGGCCTG 1


RESULT 928
US-09-191-170-99/c
; Sequence 99, Application US/09191170
; Patent No. 6429199
; GENERAL INFORMATION:
;  APPLICANT: Krieg, Arthur M.
;  APPLICANT: Hartmann, Gunther
;  TITLE OF INVENTION: Immunostimulatory Nucleic Acid Molecules
;  TITLE OF INVENTION: for Activating Dendritic Cells
;  FILE REFERENCE: C1039/7017
;  CURRENT APPLICATION NUMBER: US/09/191,170
;  CURRENT FILING DATE: 1998-11-13
;  EARLIER APPLICATION NUMBER: US 08/960,774
;  EARLIER FILING DATE: 1997-10-30
;  EARLIER APPLICATION NUMBER: US 08/738,652
;  EARLIER FILING DATE: 1996-10-30
;  EARLIER APPLICATION NUMBER: US 08/386,063
;  EARLIER FILING DATE: 1995-02-07
;  EARLIER APPLICATION NUMBER: US 08/276,358
;  EARLIER FILING DATE: 1994-07-15
;  NUMBER OF SEQ ID NOS: 99
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 99
;   LENGTH: 20
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: synthetic oligonucleotide
US-09-191-170-99

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 20;
  Best Local Similarity   81.2%;  Pred. No. 5.8e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1923 TTTTTTTCAGTGTTAA 1938
              |||||||||  ||| |
Db         20 TTTTTTTCAACGTTGA 5


RESULT 929
US-09-352-608-9/c
; Sequence 9, Application US/09352608
; Patent No. 6218598
; GENERAL INFORMATION:
;  APPLICANT: ISHIGE, Fumiharu
;  APPLICANT: NISHIKAWA, Satomi
;  APPLICANT: OEDA, Kenji
;  TITLE OF INVENTION: Plant Promoter
;  FILE REFERENCE: 2185-0353P
;  CURRENT APPLICATION NUMBER: US/09/352,608
;  CURRENT FILING DATE: 1999-07-13
;  EARLIER APPLICATION NUMBER: 10-200372 JAPAN
;  EARLIER FILING DATE: 1998-07-15
;  NUMBER OF SEQ ID NOS: 20
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:primer
US-09-352-608-9

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 25;
  Best Local Similarity   66.7%;  Pred. No. 6.6e+02;
  Matches   16;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy       1679 GACTTCTTAGTTGTTTCTCTAGCG 1702
              || |  | || ||||  ||||| |
Db         25 GAATGTTGAGGTGTTGATCTAGAG 2
```

```
RESULT 930
US-08-173-489C-155/c
; Sequence 155, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  155:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  12 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;      DESCRIPTION:  hepatitis B virus ayw isolate,
;      DESCRIPTION:  nucleotides 1208 to 1219
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:
;      ORGANISM:  Hepatitis B virus
;      INDIVIDUAL ISOLATE:  ayw
;    PUBLICATION INFORMATION:
;      AUTHORS:  Galibert, F,  Mandart, E,  Fitoussi, F,
;      AUTHORS:  Tiollais, P,  Charnay, P.
;      TITLE:  Nucleotide sequence of the
;      TITLE:  Hepatitis B virus genome (subtype ayw) cloned
;      TITLE:  in E coli
;      JOURNAL:  Nature
;      VOLUME:  281
;      PAGES:  646-650
;      DATE:  1979
;      RELEVANT RESIDUES IN SEQ ID NO:  155 :FROM 1 TO 12
US-08-173-489C-155

  Query Match             2.0%;  Score 11;  DB 1;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTC 1800
                ||||||||||
Db         11 TTCTTTCCTTC 1
```

```
RESULT 931
US-08-242-664-14
; Sequence 14, Application US/08242664
; Patent No. 5571937
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/242,664
;      FILING DATE:  May 12, 1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-242-664-14

  Query Match             2.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAA 1990
                ||||||||||
Db          1 AAAAAAGAAAA 11
```

```
RESULT 932
US-08-484-138-14
; Sequence 14, Application US/08484138
; Patent No. 5652350
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
```

```
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/484,138
;      FILING DATE:  June 7, 1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-Z/JPW/MJG
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
US-08-484-138-14

  Query Match             2.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAA 1990
              ||||||||||| 
Db          1 AAAAAAGAAAA 11


RESULT 933
US-08-173-489C-171
; Sequence 171, Application US/08173489C
; Patent No. 5861244
;  GENERAL INFORMATION:
;    APPLICANT:  WANG, C. -G.
;    APPLICANT:  HEPBURN, A. G.
;    TITLE OF INVENTION:  GENETIC SEQUENCE ASSAY USING DNA
;    TITLE OF INVENTION:  TRIPLE-STRAND FORMATION.
;    NUMBER OF SEQUENCES:  365
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  PROFILE DIAGNOSTIC SCIENCES, INC.,
;      STREET:  510 EAST 73RD STREET,
;      CITY:  NEW YORK
;      STATE:  NEW YORK
;      COUNTRY:  USA
;      ZIP:  10021.
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch, 1.44Mb storage
;      COMPUTER:  IBM PC/XT/AT
;      OPERATING SYSTEM:  MS-DOS version 6.2
;      SOFTWARE:  Wordperfect Version 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/173,489C
;      FILING DATE:  22 DEC 1993
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/968,436
;      FILING DATE:  29 OCT 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Handelman, Joseph H.
;      REGISTRATION NUMBER:  26,179
;      REFERENCE/DOCKET NUMBER:  U9518-6
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (attorney) (212) 708-1880
;      TELEFAX:  (attorney) (212) 246-8959
;  INFORMATION FOR SEQ ID NO:  171:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double stranded
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  genomic DNA
;      DESCRIPTION:  hepatitis B virus adw2 isolate,
;      DESCRIPTION:  nucleotides 154 to 166
;    HYPOTHETICAL:  no
;    ANTI-SENSE:  no
;    ORIGINAL SOURCE:
;      ORGANISM:  Hepatitis B virus
;    . INDIVIDUAL ISOLATE:  adw2
;    PUBLICATION INFORMATION:
;      AUTHORS:  Valenzuela, P,  Quiroga, M,  Zaldivar, J,
;      AUTHORS:  Gray, P,  Ruter, W J.
;      TITLE:  The nucleotide sequence of
;      TITLE:  the Hepatitis B viral genome and the
;      JOURNAL:  In "Animal Virus Genetics", Fields, B N,
;      JOURNAL:  Jaenisch, R,  Fox C F eds
;      VOLUME:
;      PAGES:  57-70
;      DATE:  1980
;      RELEVANT RESIDUES IN SEQ ID NO:  171 :FROM 1 TO 13
US-08-173-489C-171

  Query Match             2.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTC 1800
              ||||||||||| 
Db          2 TTCTTTCCTTC 12


RESULT 934
PCT-US95-06379-14
; Sequence 14, Application PC/TUS9506379
;  GENERAL INFORMATION:
;    APPLICANT:  Watanabe, Kyoichi A.
;    APPLICANT:  Ren, Wu-Yun
;    APPLICANT:  Weil, Roger
;    TITLE OF INVENTION:  Complementary DNA and Toxins
;    NUMBER OF SEQUENCES:  43
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham LLP
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5 inch 1.44Mb
;      COMPUTER:  IBM PC
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/06379
;      FILING DATE:  May 13, 1994
;      CLASSIFICATION:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  44683-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-278-0400
;      TELEFAX:  212-391-0526
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  double
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
PCT-US95-06379-14

  Query Match             2.0%;  Score 11;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1980 AAAAAAGAAAA 1990
                ||||||||||
Db          1 AAAAAAGAAAA 11


RESULT 935
US-08-442-513A-9/c
; Sequence 9, Application US/08442513A
; Patent No. 5646031
;  GENERAL INFORMATION:
;    APPLICANT:  DeYoung, Mary Beth
;    APPLICANT:  Siwkowski, Andrew M.
;    APPLICANT:  Hampel, Arnold E.
;    TITLE OF INVENTION:  METHOD FOR DERIVING RIBOZYMES FROM
;    TITLE OF INVENTION:  NUCLEOTIDE SEQUENCES AND RIBOZYMES DERIVED THEREOF
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kohn & Associates
;      STREET:  30500 No. 5646031thwestern Hwy., Suite 410
;      CITY:  Farmington Hills
;      STATE:  Michigan
;      COUNTRY:  US
;      ZIP:  48334
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/442,513A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kohn, Kenneth I.
;      REGISTRATION NUMBER:  30,995
;      REFERENCE/DOCKET NUMBER:  2384.00014
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (810) 539-5050
;      TELEFAX:  (810) 539-5055
;  INFORMATION FOR SEQ ID NO:  9:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Ribozyme substrate
;      DESCRIPTION:  sequence"
US-08-442-513A-9

  Query Match             2.0%;  Score 11;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1556 AACAGGACTGC 1566
                ||||||||||
Db         13 AACAGGACTGC 3


RESULT 936
US-08-442-513A-14/c
; Sequence 14, Application US/08442513A
; Patent No. 5646031
;  GENERAL INFORMATION:
;    APPLICANT:  DeYoung, Mary Beth
;    APPLICANT:  Siwkowski, Andrew M.
;    APPLICANT:  Hampel, Arnold E.
;    TITLE OF INVENTION:  METHOD FOR DERIVING RIBOZYMES FROM
;    TITLE OF INVENTION:  NUCLEOTIDE SEQUENCES AND RIBOZYMES DERIVED THEREOF
;    NUMBER OF SEQUENCES:  19
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Kohn & Associates
;      STREET:  30500 No. 5646031thwestern Hwy., Suite 410
;      CITY:  Farmington Hills
;      STATE:  Michigan
;      COUNTRY:  US
;      ZIP:  48334
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/442,513A
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Kohn, Kenneth I.
;      REGISTRATION NUMBER:  30,995
;      REFERENCE/DOCKET NUMBER:  2384.00014
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (810) 539-5050
;      TELEFAX:  (810) 539-5055
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  14 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  other nucleic acid
;      DESCRIPTION:  /desc = "Ribozyme substrate"
US-08-442-513A-14

  Query Match             2.0%;  Score 11;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1556 AACAGGACTGC 1566
                ||||||||||
Db         13 AACAGGACTGC 3


RESULT 937
US-09-152-059-116
; Sequence 116, Application US/09152059
; Patent No. 6794499
; GENERAL INFORMATION:
;  APPLICANT: WENGEL, JESPER
;  APPLICANT:  NIELSEN, POUL
;  TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;  FILE REFERENCE: 49165 (71994)
;  CURRENT APPLICATION NUMBER: US/09/152,059
;  CURRENT FILING DATE:  1998-09-11
;  PRIOR APPLICATION NUMBER: 60/058,541
;  PRIOR FILING DATE: 1997-09-12
;  PRIOR APPLICATION NUMBER: 60/068,293
;  PRIOR FILING DATE: 1997-12-19
;  PRIOR APPLICATION NUMBER: 60/071,682
;  PRIOR FILING DATE: 1998-01-16
;  PRIOR APPLICATION NUMBER: 60/076,591
;  PRIOR FILING DATE: 1998-03-03
;  PRIOR APPLICATION NUMBER: 60/083,507
;  PRIOR FILING DATE: 1998-04-29
;  PRIOR APPLICATION NUMBER: 60/088,309
;  PRIOR FILING DATE: 1998-06-05
;  PRIOR APPLICATION NUMBER: 60/094,355
;  PRIOR FILING DATE: 1998-07-28
;  NUMBER OF SEQ ID NOS: 146
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 116
;   LENGTH: 14
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence: Synthetic
```

```
;   OTHER INFORMATION: oligonucleotide
US-09-152-059-116

  Query Match             2.0%;  Score 11;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAA 1990
              ||||||||||
Db          1 AAAAAAGAAAA 11


RESULT 938
US-08-311-760A-31
; Sequence 31, Application US/08311760A
; Patent No. 5599706
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Dan T.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Newton, Roger S.
;    APPLICANT:  Ramharack, Randy
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
;    TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
;    TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  392
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,760A
;      FILING DATE:  September 23, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:
;      FILING DATE:
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/155
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  31:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-760A-31

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   36.4%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1775 TTTTTTTGAAC 1785
              :::::::||||
Db          4 UUUUUUUGAAC 14


RESULT 939
US-08-311-486C-64
; Sequence 64, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  64:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-64

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   81.8%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCC 1609
              |||:||:||||
Db          4 CCCUCCUGGCC 14


RESULT 940
US-08-311-486C-208/c
; Sequence 208, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
```

```
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  208:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-208

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1834 TAAATACATTC 1844
             ||||||||||| 
Db         12 TAAATACATTC 2


RESULT 941
US-08-311-486C-581
; Sequence 581, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  581:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-581

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   81.8%;  Pred. No. 5.1e+02;
  Matches    9;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCC 1609
              |||:||:|||| 
Db          4 CCCUCCUGGCC 14


RESULT 942
US-08-311-486C-729/c
; Sequence 729, Application US/08311486C
; Patent No. 5811300
;  GENERAL INFORMATION:
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth Draper
;    APPLICANT:  Kevin Kisich
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  TNF-'
;    NUMBER OF SEQUENCES:  1157
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
```

```
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,486C
;      FILING DATE:  September 23, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  209/166
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  729:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-311-486C-729

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1834 TAAATACATTC 1844
             ||||||||||| 
Db         12 TAAATACATTC 2


RESULT 943
US-08-292-620A-80/c
; Sequence 80, Application US/08292620A
; Patent No. 5837542
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620A
;      FILING DATE:  August 17, 1994
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;    PRIOR APPLICATION DATA:  including application
;    PRIOR APPLICATION DATA:  described below:                    two
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  80:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-292-620A-80

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAAC 1598
             ||||||||||| 
Db         15 AGACTGGGAAC 5


RESULT 944
US-08-774-310-31
; Sequence 31, Application US/08774310
; Patent No. 5877022
;  GENERAL INFORMATION:
;    APPLICANT:  Stinchcomb, Daniel T.
;    APPLICANT:  McSwiggen, James
;    APPLICANT:  Newton, Roger S.
;    APPLICANT:  Ramharack, Randy
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF DISEASES
;    TITLE OF INVENTION:  OR CONDITIONS RELATED TO LEVELS OF
;    TITLE OF INVENTION:  PLASMA LIPOPROTEIN (a) [LP(a)] BY
;    TITLE OF INVENTION:  INHIBITING APOLIPOPROTEIN
;    TITLE OF INVENTION:
;    NUMBER OF SEQUENCES:  392
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/774,310
;      FILING DATE:  December 23, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/311,760
;      FILING DATE:  September 23, 1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  223/229
;    TELECOMMUNICATION INFORMATION:
```

```
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  31:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-08-774-310-31

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   36.4%;  Pred. No. 5.1e+02;
  Matches    4;  Conservative    7;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1775 TTTTTTTGAAC 1785
              :::::::||||
Db          4 UUUUUUUGAAC 14


RESULT 945
US-09-071-845-80/c
; Sequence 80, Application US/09071845
; Patent No. 6132967
;  GENERAL INFORMATION:
;    APPLICANT:  Susan Grimm
;    APPLICANT:  Dan T. Stinchcomb
;    APPLICANT:  James McSwiggen
;    APPLICANT:  Sean Sullivan
;    APPLICANT:  Kenneth G. Draper
;    TITLE OF INVENTION:  RIBOZYME TREATMENT OF
;    TITLE OF INVENTION:  DISEASES OR CONDITIONS
;    TITLE OF INVENTION:  RELATED TO LEVELS OF
;    TITLE OF INVENTION:  INTRACELLULAR ADHESION
;    TITLE OF INVENTION:  MOLECULE-1 (I-CAM-1)
;    NUMBER OF SEQUENCES:  2390
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Lyon & Lyon
;      STREET:  633 West Fifth Street
;      STREET:  Suite 4700
;      CITY:  Los Angeles
;      STATE:  California
;      COUNTRY:  U.S.A.
;      ZIP:  90071-2066
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  3.5" Diskette, 1.44 Mb
;      MEDIUM TYPE:  storage
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  IBM P.C. DOS 5.0
;      SOFTWARE:  Word Perfect 5.1
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/071,845
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/292,620
;      FILING DATE:  August 17, 1994
;      APPLICATION NUMBER:  08/008,895
;      FILING DATE:  January 19, 1993
;      APPLICATION NUMBER:  07/989,849
;      FILING DATE:  December 7, 1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Warburg, Richard J.
;      REGISTRATION NUMBER:  32,327
;      REFERENCE/DOCKET NUMBER:  208/149
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (213) 489-1600
;      TELEFAX:  (213) 955-0440
;      TELEX:  67-3510
;  INFORMATION FOR SEQ ID NO:  80:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
US-09-071-845-80

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAAC 1598
              ||||||||||||
Db         15 AGACTGGGAAC 5


RESULT 946
US-09-115-446-3/c
; Sequence 3, Application US/09115446
; Patent No. 6165719
; GENERAL INFORMATION:
;  APPLICANT: Chandy, George K.
;  APPLICANT: Gargus, Jay J.
;  APPLICANT: Gutman, George
;  APPLICANT: Fantino, Emmanuelle
;  APPLICANT: Kalman, Katarin
;  TITLE OF INVENTION: hKCA3/KCNN3 SMALL CONDUCTANCE CALCIUM
;  TITLE OF INVENTION: ACTIVATED POTASSIUM CHANNEL: A DIAGNOSTIC
;  TITLE OF INVENTION: MARKER AND THERAPEUTIC TARGET
;  FILE REFERENCE: 07306/014001
;  CURRENT APPLICATION NUMBER: US/09/115,446
;  CURRENT FILING DATE: 1998-07-14
;  EARLIER APPLICATION NUMBER: 60/052,556
;  EARLIER FILING DATE: 1997-07-15
;  EARLIER APPLICATION NUMBER: 60/070,741
;  EARLIER FILING DATE: 1998-01-08
;  NUMBER OF SEQ ID NOS: 15
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-115-446-3

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAA 1990
              ||||||||||||
Db         13 AAAAAAGAAAA 3


RESULT 947
US-09-081-646-154/c
; Sequence 154, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
;  APPLICANT: Kinzler, Kenneth
;  APPLICANT: Vogelstein, Bert
;  APPLICANT: Zhang, Lin
;  APPLICANT: Zhou, Wei
;  TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
;  TITLE OF INVENTION: Cancer Cells
;  FILE REFERENCE: 01107.74664
;  CURRENT APPLICATION NUMBER: US/09/081,646
;  CURRENT FILING DATE: 1998-05-20
;  EARLIER APPLICATION NUMBER: 60/047,352
;  EARLIER FILING DATE: 1997-05-21
;  NUMBER OF SEQ ID NOS: 871
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 154
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-081-646-154
```

Query Match 2.0%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1721 TTGGACCTATT 1731
             ||||||||||| 
Db         15 TTGGACCTATT 5
```

RESULT 948
US-09-081-646-266
; Sequence 266, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 266
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-266

Query Match 2.0%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1572 TCCTTCTCCAC 1582
             ||||||||||| 
Db          5 TCCTTCTCCAC 15
```

RESULT 949
US-09-081-646-745
; Sequence 745, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 745
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-745

Query Match 2.0%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1572 TCCTTCTCCAC 1582
             ||||||||||| 
Db          5 TCCTTCTCCAC 15
```

RESULT 950
US-09-081-646-798/c
; Sequence 798, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 798
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-798

Query Match 2.0%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1721 TTGGACCTATT 1731
             ||||||||||| 
Db         15 TTGGACCTATT 5
```

RESULT 951
US-09-275-505-3/c
; Sequence 3, Application US/09275505
; Patent No. 6335434
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Guzaev, Andrei P.
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bhat, Balkrishen
; TITLE OF INVENTION: Nucleosidic And No. 6335434-Nucleosidic Folate Conjugates
; FILE REFERENCE: ISIS-3453
; CURRENT APPLICATION NUMBER: US/09/275,505
; CURRENT FILING DATE: 1999-03-24
; PRIOR APPLICATION NUMBER: 09/098,166
; PRIOR FILING DATE: 1998-06-16
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 6335434el Sequence
US-09-275-505-3

Query Match 2.0%; Score 11; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1605 TGGCCTGGGGG 1615
             ||||||||||| 
Db         11 TGGCCTGGGGG 1
```

RESULT 952
US-09-565-590-3/c
; Sequence 3, Application US/09565590

```
; Patent No. 6653100
; GENERAL INFORMATION:
;  APPLICANT:  Chandy, George K.
;  APPLICANT:  Gargus, Jay J.
;  APPLICANT:  Gutman, George
;  APPLICANT:  Fantino, Emmanuelle
;  APPLICANT:  Kalman, Katarin
;  TITLE OF INVENTION:  hKCA3/KCNN3 SMALL CONDUCTANCE CALCIUM
;  TITLE OF INVENTION:  ACTIVATED POTASSIUM CHANNEL: A DIAGNOSTIC
;  TITLE OF INVENTION:  MARKER AND THERAPEUTIC TARGET
;  FILE REFERENCE:  07306/014001
;  CURRENT APPLICATION NUMBER: US/09/565,590
;  CURRENT FILING DATE:  2000-05-04
;  PRIOR APPLICATION NUMBER:  09/115,446
;  PRIOR FILING DATE:  1998-07-14
;  PRIOR APPLICATION NUMBER:  60/070,741
;  PRIOR FILING DATE:  1998-01-08
;  NUMBER OF SEQ ID NOS:  15
;  SOFTWARE:  FastSEQ for Windows Version 4.0
; SEQ ID NO 3
;   LENGTH: 15
;   TYPE: DNA
;   ORGANISM: Homo sapiens
US-09-565-590-3

  Query Match             2.0%;  Score 11;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAA 1990
              ||||||||||| |
Db         13 AAAAAAGAAAA 3


RESULT 953
US-07-988-194A-14/c
; Sequence 14, Application US/07988194A
; Patent No. 5359046
;  GENERAL INFORMATION:
;    APPLICANT:  Capon, Daniel J.
;    APPLICANT:  Weiss, Arthur
;    APPLICANT:  Irving, Brian A.
;    APPLICANT:  Roberts, Margo R.
;    APPLICANT:  Zsebo, Krisztina
;    TITLE OF INVENTION:  Chimeric Chains for Receptor
;    TITLE OF INVENTION:  Associated Signal Transduction Pathways
;    NUMBER OF SEQUENCES:  49
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Flehr, Hohbach, Test, Albritton &
;      ADDRESSEE:  Herbert
;      STREET:  4 Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy Disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/988,194A
;      FILING DATE:  December 9, 1992
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Rowland, Bertram I.
;      REGISTRATION NUMBER:  20015
;      REFERENCE/DOCKET NUMBER:  A-55107-1  CELL-0051
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-781-1989
;      TELEFAX:  415-398-3249
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-07-988-194A-14

  Query Match             2.0%;  Score 11;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAG 2013
              ||||||||||| |
Db         15 CTTCTTCAGAG 5


RESULT 954
US-08-880-557-3/c
; Sequence 3, Application US/08880557
; Patent No. 5876988
;  GENERAL INFORMATION:
;    APPLICANT:  SELTEN, GERARDUS CORNELIUS MAIA
;    APPLICANT:  SWINKELS, BART WILLEM
;    APPLICANT:  VAN GORCOM, ROBERTUS
;    APPLICANT:  FRANCISCUS MARIA
;    TITLE OF INVENTION:  SELECTION MARKER GENE FREE RECOMBINANT
;    TITLE OF INVENTION:  STRAINS:  A METHOD FOR OBTAINING THEM AND THE USE OF THESE
;    TITLE OF INVENTION:  STRAINS
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  2000 Pennsylvania Ave. N.W., Suite 5500
;      CITY:  Washington, D.C.
;      COUNTRY:  USA
;      ZIP:  20006-1888
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/880,557
;      FILING DATE:  23-JUN-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/279,980
;      FILING DATE:  22-JUL-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MURASHIGE, KATE H.
;      REGISTRATION NUMBER:  29,959
;      REFERENCE/DOCKET NUMBER:  4615-0042.00
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 887-1500
;      TELEFAX:  (202) 887-0763
;      TELEX:  90-4030
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    IMMEDIATE SOURCE:
;      CLONE:  TN0001
US-08-880-557-3

  Query Match             2.0%;  Score 11;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2056 AACTAGTTAAT 2066
```

```
                ||||||||||
Db         14 AACTAGTTAAT 4


RESULT 955
US-09-189-583-3/c
; Sequence 3, Application US/09189583
; Patent No. 6063614
;  GENERAL INFORMATION:
;    APPLICANT:  SELTEN, GERARDUS CORNELIUS MAIA
;    APPLICANT:  SWINKELS, BART WILLEM
;    APPLICANT:  VAN GORCOM, ROBERTUS
;    APPLICANT:  FRANCISCUS MARIA
;    TITLE OF INVENTION:  SELECTION MARKER GENE FREE RECOMBINANT
;    TITLE OF INVENTION:  STRAINS:  A METHOD FOR OBTAINING THEM AND THE USE OF THESE
;    TITLE OF INVENTION:  STRAINS
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  MORRISON & FOERSTER
;      STREET:  2000 Pennsylvania Ave. N.W., Suite 5500
;      CITY:  Washington, D.C.
;      COUNTRY:  USA
;      ZIP:  20006-1888
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/189,583
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/880,557
;      FILING DATE:  23-JUN-1997
;      APPLICATION NUMBER:  US 08/279,980
;      FILING DATE:  22-JUL-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  MURASHIGE, KATE H.
;      REGISTRATION NUMBER:  29,959
;      REFERENCE/DOCKET NUMBER:  4615-0042.00
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 887-1500
;      TELEFAX:  (202) 887-0763
;      TELEX:  90-4030
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  DNA (genomic)
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    IMMEDIATE SOURCE:
;      CLONE:  TN0001
US-09-189-583-3

  Query Match             2.0%;  Score 11;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2056 AACTAGTTAAT 2066
                ||||||||||
Db         14 AACTAGTTAAT 4


RESULT 956
US-08-479-737-14/c
; Sequence 14, Application US/08479737
; Patent No. 6319494
;  GENERAL INFORMATION:
;       APPLICANT: Capon, Daniel J
;                  Weiss, Arthur
;                  Irving, Brian A
;                  Roberts, Margo R
;                  Zsebo, Krisztina
;       TITLE OF INVENTION: CHIMERIC CHAINS FOR RECEPTOR ASSOCIATED
;                           SIGNAL TRANSDUCTION PATHWAYS
;       NUMBER OF SEQUENCES: 51
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: CELL GENESYS, INC.
;            STREET: 322 Lakeside Drive
;            CITY: Foster City
;            STATE: California
;            COUNTRY: USA
;            ZIP: 94404
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.25
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/08/479,737
;            FILING DATE: 07-Jun-1995
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: 08/238,405
;            FILING DATE: 05-MAY-1994
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Mandel, SaraLynn
;            REGISTRATION NUMBER: 31,853
;            REFERENCE/DOCKET NUMBER: Cell 5.3
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: (415) 358-9600
;            TELEFAX: (415) 358-0803
;  INFORMATION FOR SEQ ID NO: 14:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 16 base pairs
;            TYPE: nucleic acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: cDNA
;       SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-08-479-737-14

  Query Match             2.0%;  Score 11;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAG 2013
                ||||||||||
Db         15 CTTCTTCAGAG 5


RESULT 957
US-08-475-442A-14/c
; Sequence 14, Application US/08475442A
; Patent No. 6407221
;  GENERAL INFORMATION:
;    APPLICANT:  CAPON, DANIEL J
;    APPLICANT:  WEISS, ARTHUR
;    APPLICANT:  IRVING, BRIAN A
;    APPLICANT:  ROBERTS, MARGO R
;    APPLICANT:  ZSEBO, KRISZTINA
;    TITLE OF INVENTION:  CHIMERIC CHAINS FOR
;    TITLE OF INVENTION:  RECEPTOR-ASSOCIATED SIGNAL TRANSDUCTION PATHWAYS
;    NUMBER OF SEQUENCES:  51
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  CELL GENESYS, INC.
;      STREET:  322 LAKESIDE DRIVE
;      CITY:  FOSTER CITY
;      STATE:  CALIFORNIA
;      COUNTRY:  USA
;      ZIP:  94404
;    COMPUTER READABLE FORM:
```

```
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/475,442A
;      FILING DATE:  06-JUN-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/238,405
;      FILING DATE:  05-MAY-1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/988,194
;      FILING DATE:  09-DEC-1992
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/627,643
;      FILING DATE:  14-DEC-1990
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US91/09431
;      FILING DATE:  12-DEC-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  KRUPEN, KAREN I
;      REGISTRATION NUMBER:  34,647
;      REFERENCE/DOCKET NUMBER:  CELL5.5
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415)358-9600x131
;      TELEFAX:  (415)349-7392
;  INFORMATION FOR SEQ ID NO:  14:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 base pairs
;      TYPE:  nucleic acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  cDNA
US-08-475-442A-14

  Query Match             2.0%;  Score 11;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAG 2013
             ||||||||||||
Db         15 CTTCTTCAGAG 5


RESULT 958
US-09-043-816E-27/c
; Sequence 27, Application US/09043816E
; Patent No. 6414128
; GENERAL INFORMATION:
;  APPLICANT: Hilton, Douglas J.
;  APPLICANT:  Willson, Tracy
;  APPLICANT:  Nicola, Nicos A.
;  APPLICANT:  Gainsford, Timothy
;  APPLICANT:  Alexander, Warren S.
;  APPLICANT:  Metcalf, Donald
;  APPLICANT:  Ng, Ashley
;  TITLE OF INVENTION: A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES
;  TITLE OF INVENTION:  ENCODING SAME
;  FILE REFERENCE: 11268
;  CURRENT APPLICATION NUMBER: US/09/043,816E
;  CURRENT FILING DATE:  1998-09-17
;  NUMBER OF SEQ ID NOS: 44
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 27
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:Synthetic
US-09-043-816E-27

  Query Match             2.0%;  Score 11;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1914 ACAATACCTTT 1924
             ||||||||||||
Db         13 ACAATACCTTT 3


RESULT 959
US-09-531-000-9/c
; Sequence 9, Application US/09531000
; Patent No. 6461810
; GENERAL INFORMATION:
;  APPLICANT:  JOHNSON, Marion D.
;  APPLICANT:  FRESCO, Jacques R.
;  TITLE OF INVENTION:  TRIPLEX IN-SITU HYBRIDIZATION
;  FILE REFERENCE:  2448-103
;  CURRENT APPLICATION NUMBER: US/09/531,000
;  CURRENT FILING DATE:  2000-09-08
;  PRIOR APPLICATION NUMBER:  PCT/US98/23765
;  PRIOR FILING DATE:  1998-11-10
;  PRIOR APPLICATION NUMBER:  60/064,997
;  PRIOR FILING DATE:  1997-11-10
;  NUMBER OF SEQ ID NOS:  77
;  SOFTWARE:  PatentIn Ver. 2.1
; SEQ ID NO 9
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Description of Artificial Sequence:  Target
;   OTHER INFORMATION: sequences
US-09-531-000-9

  Query Match             2.0%;  Score 11;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 5.3e+02;
  Matches   11;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAG 1991
             ||||||||||||
Db         11 AAAAAGAAAAG 1


RESULT 960
US-09-931-381A-4
; Sequence 4, Application US/09931381A
; Patent No. 6692922
; GENERAL INFORMATION:
;  APPLICANT: Butcher, Eugene C.
;  APPLICANT:  Kunkel, Eric J.
;  APPLICANT:  Pan, Junliang
;  APPLICANT:  Soler-Ferran, Dulce
;  TITLE OF INVENTION: Method for Identifying Agents Which
;  TITLE OF INVENTION:  Modulate Chemokine "MEC"-Induced Functions of CCR3 and/or
;  TITLE OF INVENTION:  CCR10
;  FILE REFERENCE: 1855.2010-003
;  CURRENT APPLICATION NUMBER: US/09/931,381A
;  CURRENT FILING DATE:  2001-08-15
;  PRIOR APPLICATION NUMBER: U.S. 09/638,914
;  PRIOR FILING DATE: 2000-08-15
;  NUMBER OF SEQ ID NOS: 24
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 4
;   LENGTH: 16
;   TYPE: DNA
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: exon
;   LOCATION: (1)...(8)
;   NAME/KEY: intron
;   LOCATION: (9)...(16)
US-09-931-381A-4
```

Query Match 2.0%; Score 11; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 5.3e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1733 TCAGAAGGTGA 1743
              ||||||||||| 
Db          2 TCAGAAGGTGA 12
```

Search completed: November 8, 2004, 08:34:04
Job time : 10 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 08:30:52 ; Search time 8 Seconds
(without alignments)
3.809 Million cell updates/sec

Title: US-10-023-782A-3
Perfect score: 559
Sequence: 1 gaagaaaggttaggagagta.....agtggtatctgacacactct 559

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1454 seqs, 27253 residues

Total number of hits satisfying chosen parameters: 2908

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1454 summaries

Database : rng3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
c	1	20	3.6	20	1	AAL62320	Human transcriptio
c	2	20	3.6	20	1	AAL62325	Human transcriptio
c	3	20	3.6	20	1	AAL62327	Human transcriptio
c	4	20	3.6	20	1	AAL62316	Human transcriptio
c	5	20	3.6	20	1	AAL62319	Human transcriptio
c	6	20	3.6	20	1	AAL62323	Human transcriptio
c	7	20	3.6	20	1	AAL62317	Human transcriptio
c	8	20	3.6	20	1	AAL62321	Human transcriptio
c	9	20	3.6	20	1	AAL62324	Human transcriptio
c	10	20	3.6	20	1	AAL62326	Human transcriptio
c	11	20	3.6	20	1	AAL62318	Human transcriptio
c	12	20	3.6	20	1	AAL62322	Human transcriptio
	13	18.2	3.3	23	1	AAZ28229	Second round PCR p
	14	18.2	3.3	23	1	AAA29299	Second round prime
c	15	17.2	3.1	25	1	ADF65678	Human HTR2A polymo
c	16	17	3.0	25	1	AAS06803	Protein kinase cDN
c	17	17	3.0	25	1	ACI03338	Human microarray D
	18	17	3.0	25	1	ACI62001	Human microarray D
c	19	17	3.0	25	1	ACI02702	Human microarray D
c	20	16.8	3.0	21	1	AAT76021	DEN-2 cloning/sequ
	21	16.6	3.0	23	1	ADN12041	Primer of the inve
	22	16.6	3.0	23	1	ADO57397	Kidney developmenp
	23	16.6	3.0	24	1	AAF84874	Sequence of the ac
	24	16.6	3.0	25	1	AAX07505	Synthetic IDDMK1.2
	25	16.6	3.0	25	1	AAX07482	Synthetic IDDMK1.2
	26	16.6	3.0	25	1	AAX07199	IDDM-associated re
	27	16.6	3.0	25	1	AAX07220	Retroviral R-poly(
	28	16.6	3.0	25	1	AAZ49618	PCR primer-2 for s
c	29	16.6	3.0	25	1	ACI99045	Human microarray D
	30	16.4	2.9	20	1	ABZ72190	Gene 216 SSCP sequ
	31	16.4	2.9	20	1	ABX75043	Human gene 216 pol
	32	16.4	2.9	20	1	ADJ36771	Human gene 216 SNP
	33	16.4	2.9	20	1	ADL81350	Gene 216 polymorph
	34	16.4	2.9	24	1	ABX92831	Borrelia burgdofer
	35	16.2	2.9	21	1	AAZ73804	Human biallelic ma
c	36	16.2	2.9	21	1	ABX79739	EST polymorphic DN
c	37	16	2.9	24	1	AAX26962	PCR primer used to
c	38	16	2.9	24	1	AAC70288	Single nucleotide
	39	16	2.9	24	1	ABL56688	PCR primer #2 for
c	40	15.8	2.8	20	1	AAX27854	PCR primer for mut
c	41	15.8	2.8	20	1	AAL42562	Humulus lupulus fa
c	42	15.8	2.8	22	1	ADF66211	Ian5 gene related
	43	15.8	2.8	23	1	AAT60786	Subtelomeric prime
c	44	15.8	2.8	23	1	AAT60790	Subtelomeric prime
c	45	15.8	2.8	23	1	AAV62118	Telomere length an
	46	15.8	2.8	23	1	AAV62114	Telomere length an
	47	15.6	2.8	24	1	AAC91993	T-box binding site
	48	15.6	2.8	24	1	ABL40063	DNA-cysteine methy
	49	15.6	2.8	24	1	ABV74368	Ubiquitin specific
	50	15.4	2.8	17	1	ABT34888	Tumour suppression
	51	15.4	2.8	19	1	AAV44628	Human uncoupling p
	52	15.4	2.8	20	1	AAV44626	Human uncoupling p
c	53	15.4	2.8	20	1	ABK99977	Human CADPKL DNA P
c	54	15.4	2.8	21	1	AAQ71626	Primer to amplify
	55	15.4	2.8	21	1	AAC59861	Oligonucleotide pr
	56	15.4	2.8	23	1	ABL51554	Human NSAID regula
	57	15.2	2.7	20	1	AAQ95389	Primer A (Group 2,
	58	15.2	2.7	20	1	AAZ06095	PCR primer used to
	59	15.2	2.7	20	1	ADJ78671	Pancreatic cancer-
	60	15.2	2.7	20	1	ABX12581	Human cytochrome P
	61	15.2	2.7	20	1	AAL61401	Human FXR antisens
c	62	15.2	2.7	20	1	ABZ85316	Human oligonucleot
c	63	15.2	2.7	20	1	ABD21546	S100 calcium bindi
	64	15.2	2.7	20	1	ADG20539	Human cytochrome P
	65	15.2	2.7	20	1	ADH63711	Human glucocortico
	66	15.2	2.7	20	1	ADH63688	Human glucocortico
	67	15.2	2.7	20	1	ADJ17527	Antisense DNA olig
	68	15.2	2.7	20	1	ADL59408	Human ESM-1 antise
	69	15.2	2.7	20	1	ADM15439	Human mPGES-1 chim
	70	15.2	2.7	20	1	ADO53251	Farnesoid X recept
	71	15.2	2.7	20	1	ADO53592	Farnesoid X recept
	72	15.2	2.7	20	1	ADO53744	Farnesoid X recept
c	73	15.2	2.7	21	1	AAF81140	Primer used for se
	74	15.2	2.7	21	1	ABL44934	Human chromosome 1
	75	15.2	2.7	22	1	ABT33591	NOV reverse PCR pr
c	76	15.2	2.7	23	1	ABK90968	PCR primer, 22164,
c	77	15.2	2.7	23	1	ADO12655	Single multiplex P
c	78	15	2.7	17	1	ABQ64253	Human KTOM1a porti
c	79	15	2.7	17	1	ABQ64255	Human KTOM1a porti
c	80	15	2.7	17	1	ABQ64254	Human KTOM1a porti
c	81	15	2.7	20	1	ADN06232	Human SPS2 specifi
c	82	15	2.7	21	1	AAH62016	IL8 hairpin/hammer
	83	15	2.7	23	1	AAS13613	Forward PCR primer
	84	14.8	2.6	19	1	AAT32774	Triple helix-formi
	85	14.8	2.6	19	1	AAV05816	Oligonucleotide #4
	86	14.8	2.6	19	1	AAZ59024	Oligonucleotide GA
	87	14.8	2.6	19	1	AAZ59016	Triple helix formi
	88	14.8	2.6	19	1	AAS19331	Triple helix formi
	89	14.8	2.6	19	1	ADP75317	Human endophilin 2
	90	14.8	2.6	20	1	AAT13503	PCR primer (TSK8B)
c	91	14.8	2.6	20	1	AAZ46525	Mouse CACNA1F exon
c	92	14.8	2.6	20	1	AAH42680	Primer and probe f
	93	14.8	2.6	20	1	ABZ68360	Primer XpYpB2 used
c	94	14.8	2.6	20	1	ABZ93604	Human oligonucleot
c	95	14.8	2.6	20	1	ABZ90035	Human oligonucleot
	96	14.8	2.6	20	1	ABZ86258	Human oligonucleot
c	97	14.8	2.6	20	1	ABD29834	AA069372-derived o
	98	14.8	2.6	20	1	ABD22488	Human cathepsin C-
c	99	14.8	2.6	20	1	ABD26265	AA398883-derived o
	100	14.8	2.6	20	1	ADJ17462	Antisense DNA olig
	101	14.8	2.6	20	1	ADJ17701	Antisense DNA olig
	102	14.8	2.6	20	1	ADL59566	Human ESM-1 antise
	103	14.8	2.6	20	1	ADL59369	Human ESM-1 antise
	104	14.8	2.6	20	1	ADO53993	Farnesoid X recept
	105	14.8	2.6	20	1	ADO54709	Farnesoid X recept
	106	14.8	2.6	20	1	ADN29250	Human kallikrein 6

c 107	14.8	2.6	20	1	ADN29175	Human kallikrein 6
c 108	14.8	2.6	20	1	ADP19958	Human ABCC2 DNA an
c 109	14.8	2.6	21	1	ADG38979	tRNAArg/PSA attach
110	14.6	2.6	21	1	AAZ26114	Human polymorphic
c 111	14.6	2.6	21	1	AAZ58833	Human beta2-microg
c 112	14.6	2.6	21	1	ABQ83354	Beta-2-microglobul
c 113	14.6	2.6	21	1	ABQ83360	Beta-2-microglobul
c 114	14.6	2.6	21	1	ADF18209	Human beta2-microg
115	14.6	2.6	22	1	AAV74151	Human thyroid gene
116	14.6	2.6	22	1	AAL47282	Hepatitis C virus
117	14.6	2.6	22	1	ACC90648	Human CYP1A2 PCR p
c 118	14.6	2.6	22	1	ACD06310	Reverse RT-PCR pri
c 119	14.6	2.6	22	1	ADO10732	Single multiplex P
c 120	14.4	2.6	17	1	AAF06327	Hammerhead ribozym
c 121	14.4	2.6	17	1	ACN11557	WNV minus strand I
122	14.4	2.6	17	1	ACN05924	WNV Amberzyme subs
123	14.4	2.6	17	1	ACN05925	WNV Amberzyme subs
c 124	14.4	2.6	17	1	ACN08989	WNV minus strand H
125	14.4	2.6	17	1	ADB44223	Tumour suppression
c 126	14.4	2.6	18	1	AAD40585	HIV-1 LTR lucifera
127	14.4	2.6	18	1	ACF62964	Human p16 PCR prim
c 128	14.4	2.6	18	1	ACF62962	Human p16 PCR prim
c 129	14.4	2.6	18	1	ABZ10570	Haematopoietic cel
c 130	14.4	2.6	18	1	ADB54572	Hybridisation olig
c 131	14.4	2.6	18	1	ADC70087	Primer oligo used
132	14.4	2.6	19	1	AAV44620	Human uncoupling p
133	14.4	2.6	20	1	AAT87898	Lower primer for e
134	14.4	2.6	20	1	AAV41334	Interleukin-9 (IL-
c 135	14.4	2.6	20	1	AAX95502	PCR primer used to
136	14.4	2.6	20	1	AAX96785	PCR primer used to
c 137	14.4	2.6	20	1	ABQ65350	Human gene methyla
c 138	14.4	2.6	20	1	ABK34138	Human MHC PCR prim
c 139	14.4	2.6	20	1	ABK28076	Human MHC methylat
c 140	14.4	2.6	20	1	ADA20513	Prostate tumour re
c 141	14.4	2.6	20	1	ADA84316	Human G6E PCR prim
142	14.4	2.6	20	1	ADL59070	Human ESM-1 antise
143	14.4	2.6	20	1	ADL59174	Human ESM-1 antise
144	14.4	2.6	20	1	ADO54121	Farnesoid X recept
145	14.4	2.6	20	1	ADO54074	Farnesoid X recept
146	14.4	2.6	20	1	ADO40175	Human MAP3K11 DNA
c 147	14.4	2.6	20	1	ADO40140	Human MAP3K11 anti
148	14.4	2.6	21	1	ABX11284	Mouse P0 gene 5' U
149	14.4	2.6	21	1	ADP05604	Novel microbe dete
c 150	14.4	2.6	22	1	AAV51724	Zea mays genome re
151	14.4	2.6	22	1	ABV73127	N-acetyltransferas
152	14.4	2.6	22	1	ABV74921	NAT1*14 allele spe
153	14.4	2.6	22	1	ABA00253	NAT1 A560G mutatio
154	14.4	2.6	22	1	ADG34628	Human NAT1*14 PCR
155	14.4	2.6	22	1	AAD50983	NAT1 allele specif
156	14.4	2.6	22	1	ABZ20529	Human NAT1 genotyp
157	14.4	2.6	22	1	ABZ23147	PCR primer used to
158	14.4	2.6	22	1	ABV72580	Primer used to det
159	14.4	2.6	22	1	AAL53876	Gastroesophageal r
160	14.4	2.6	22	1	AAD51919	N-acetyl transfera
161	14.4	2.6	22	1	ABZ23435	Primer used to amp
162	14.4	2.6	22	1	AAD47697	N-acetyltransferss
163	14.4	2.6	22	1	ABV76236	N-acetyltransferas
164	14.4	2.6	22	1	ACF05573	N-acetyltransferas
165	14.4	2.6	22	1	ACC79724	N-acetyltransferas
166	14.4	2.6	22	1	ACC83560	N-acetyltransferas
167	14.4	2.6	22	1	ACF04612	Human NAT1 NAT1*14
168	14.4	2.6	22	1	AAD54260	NAT1 mutant allele
169	14.4	2.6	22	1	ABZ75815	NAT1 allele NAT1*1
170	14.4	2.6	22	1	ADJ71307	Human metabolic en
171	14.4	2.6	22	1	ADO71016	Human N-acetyltran
c 172	14.2	2.5	19	1	AAT65892	Primer #1 to ampli
c 173	14.2	2.5	19	1	ADF36917	Human VEGFR2 short
c 174	14.2	2.5	19	1	ADF36449	Human VEGFR1 short
175	14.2	2.5	19	1	ADF36022	Human VEGFR1 short
c 176	14.2	2.5	19	1	ADF35910	Human VEGFR1 short
177	14.2	2.5	19	1	ADF36337	Human VEGFR1 short
178	14.2	2.5	19	1	ADF36593	Human VEGFR2 short
179	14.2	2.5	19	1	ADF48099	Human Myc siNA low
c 180	14.2	2.5	19	1	ADF47981	Human Myc transcri
181	14.2	2.5	19	1	ADO18477	Analytical probe c
182	14.2	2.5	19	1	ADO18527	Analytical probe c
c 183	14.2	2.5	20	1	AAT41311	Human gene signatu
c 184	14.2	2.5	20	1	AAX21925	Human B-raf kinase
c 185	14.2	2.5	20	1	AAX95694	PCR primer used to
186	14.2	2.5	20	1	AAC60958	Interleukin 2 shor
187	14.2	2.5	20	1	AAF91339	Human E2F transcri
c 188	14.2	2.5	20	1	AAS08770	Human PD-ABC form
c 189	14.2	2.5	20	1	AAS08861	Human PD-ABC form
190	14.2	2.5	20	1	ABL96288	Primer #1 related
c 191	14.2	2.5	20	1	ABA03194	Human KRGF1 PCR pr
c 192	14.2	2.5	20	1	AAD44809	Human B-raf kinase
193	14.2	2.5	20	1	ABZ74905	Human acyl coenzym
c 194	14.2	2.5	20	1	ADF09803	Human b-raf kinase
195	14.2	2.5	20	1	ABZ98046	Human MCP4 oligonu
c 196	14.2	2.5	20	1	ABZ90034	Human oligonucleot
197	14.2	2.5	20	1	ABZ98097	Human MCP4 oligonu
c 198	14.2	2.5	20	1	ABZ86102	Human oligonucleot
199	14.2	2.5	20	1	ABZ87395	Human oligonucleot
200	14.2	2.5	20	1	ADA55771	Human protein-rela
c 201	14.2	2.5	20	1	ABQ84614	DPP10 related PSQ
c 202	14.2	2.5	20	1	ACD42192	Antisense oligonuc
c 203	14.2	2.5	20	1	ABD22332	Human cathepsin C-
204	14.2	2.5	20	1	ABD31077	Human MCP4-derived
205	14.2	2.5	20	1	ABD31128	Human MCP4-derived
206	14.2	2.5	20	1	ABD23625	Human myosin X-der
c 207	14.2	2.5	20	1	ABD26264	AA398883-derived o
c 208	14.2	2.5	20	1	ADH10874	Human cathepsin Z
209	14.2	2.5	20	1	ADH10801	Human cathepsin Z
210	14.2	2.5	20	1	ADH64238	Human glucocortico
211	14.2	2.5	20	1	ADH66032	Human glucocortico
212	14.2	2.5	20	1	ADH63625	Human glucocortico
213	14.2	2.5	20	1	ADH65755	Human glucocortico
214	14.2	2.5	20	1	ADI28168	Antisense oligonuc
215	14.2	2.5	20	1	ADJ59913	Oligonucleotide as
216	14.2	2.5	20	1	ADJ59964	Oligonucleotide as
217	14.2	2.5	20	1	ADJ38656	Human resistin ant
c 218	14.2	2.5	20	1	ADJ38756	Human resistin ant
219	14.2	2.5	20	1	ADJ17488	Antisense DNA olig
220	14.2	2.5	20	1	ADJ23454	Human endothelial
221	14.2	2.5	20	1	ADJ23409	Human endothelial
c 222	14.2	2.5	20	1	ADL58638	Human ESM-1 antise
223	14.2	2.5	20	1	ADL59344	Human ESM-1 antise
c 224	14.2	2.5	20	1	ADL58637	Human ESM-1 antise
225	14.2	2.5	20	1	ADL58426	Human ESM-1 antise
226	14.2	2.5	20	1	ADL58120	Human ESM-1 antise
227	14.2	2.5	20	1	ADM15491	Human mPGES-1 chim
228	14.2	2.5	20	1	ADM15507	Human mPGES-1 chim
229	14.2	2.5	20	1	ADO45454	Human oligonucleot
230	14.2	2.5	20	1	ADO45403	Human oligonucleot
231	14.2	2.5	20	1	ADO53030	Farnesoid X recept
c 232	14.2	2.5	21	1	AAT42561	3' primer #1087-11
c 233	14.2	2.5	21	1	AAV60859	Primer #2 for the
234	14.2	2.5	21	1	AAV51661	Zea mays genome fo
235	14.2	2.5	21	1	AAD00468	Human MINT1 clone
236	14.2	2.5	21	1	AAF96326	Human gene single
237	14.2	2.5	21	1	AAH20432	PCR primer used in
238	14.2	2.5	21	1	AAS23721	Primer A #35 used
c 239	14.2	2.5	21	1	ABK41517	Human CTNNA3 exon-
240	14.2	2.5	21	1	ABZ29935	Candida albicans G
c 241	14.2	2.5	21	1	ABK37957	Forward RT-PCR pri
242	14.2	2.5	21	1	ADJ78673	Pancreatic cancer-
243	14.2	2.5	21	1	ADI30262	Human PTEN specifi
c 244	14.2	2.5	21	1	ADH74629	PCR primer #2 for
c 245	14.2	2.5	21	1	ADJ47508	Human IGF2 gene DM
c 246	14.2	2.5	21	1	ADJ97663	Human Flt-1 DNA se
c 247	14	2.5	17	1	ABQ64252	Human KTOM1a porti
c 248	14	2.5	17	1	ABQ64256	Human KTOM1a porti
249	14	2.5	17	1	ACC64866	Murine oligonucleo
250	14	2.5	17	1	ACC63818	Murine oligonucleo
251	14	2.5	17	1	ADB40646	Tumour suppression
252	14	2.5	18	1	ABX95294	Human ABCA7 associ

c 253	14	2.5	19	1	ADE27175	Stearoyl-CoA desat
254	14	2.5	19	1	ADE27465	Stearoyl-CoA desat
c 255	14	2.5	20	1	AAS10630	Human caspase 3 an
256	14	2.5	20	1	AAD11975	Human PTP1B antise
257	14	2.5	20	1	ABK85050	Human PTP1B antise
258	14	2.5	20	1	ABK37219	Human PTP1B mRNA 1
c 259	14	2.5	20	1	ADC51216	PCR primer #1 for
c 260	14	2.5	20	1	ADF82970	Glucose-6-phosphat
c 261	14	2.5	20	1	ADI36748	Human KOX 1 DNA, a
262	14	2.5	20	1	ADI13780	Antisense DNA olig
263	14	2.5	20	1	ADL59480	Human ESM-1 antise
264	14	2.5	20	1	ADL59090	Human ESM-1 antise
c 265	14	2.5	20	1	ADM93188	Human KOX-1 antise
c 266	13.8	2.5	17	1	AAV96447	Potato citrate syn
c 267	13.8	2.5	17	1	AAF06326	Hammerhead ribozym
c 268	13.8	2.5	17	1	ABN07651	Human GDMLP-1 17-m
c 269	13.8	2.5	17	1	ABN01354	Human GDMLP-1 17-m
c 270	13.8	2.5	17	1	ABN07650	Human GDMLP-1 17-m
c 271	13.8	2.5	17	1	ACN08988	WNV minus strand H
272	13.8	2.5	17	1	ACC68550	Murine oligonucleo
273	13.8	2.5	17	1	ACC65305	Murine oligonucleo
c 274	13.8	2.5	17	1	ACC52259	Human tumour suppr
275	13.8	2.5	18	1	ADG76790	Human olfactory re
276	13.8	2.5	19	1	AAZ00903	Primer for PG1 bia
277	13.8	2.5	19	1	AAZ01223	PCR primer for PG1
c 278	13.8	2.5	19	1	AAA84405	Cyclin D3 ribozyme
279	13.8	2.5	19	1	AAZ73500	Human biallelic ma
c 280	13.8	2.5	19	1	AAH59567	Cyclin D3 ribozyme
281	13.8	2.5	19	1	ABK41301	Human prostate can
c 282	13.8	2.5	19	1	ADE36637	Human ERG gene PCR
283	13.8	2.5	19	1	ADE43577	Human IDE sequenci
c 284	13.8	2.5	19	1	ADG36015	HIV siNA oligonucl
285	13.8	2.5	19	1	ADG35236	HIV siNA oligonucl
286	13.8	2.5	19	1	ADG35277	HIV siNA oligonucl
c 287	13.8	2.5	19	1	ADG35974	HIV siNA oligonucl
c 288	13.8	2.5	19	1	ADG36059	HIV siNA oligonucl
289	13.8	2.5	19	1	ADG35321	HIV siNA oligonucl
290	13.8	2.5	19	1	ADJ94201	Human MYOC gene mu
291	13.8	2.5	19	1	ADH54055	Human neurodegener
292	13.8	2.5	19	1	ADH75215	IFN-associated gen
293	13.8	2.5	19	1	ADQ61592	Anti-RAD1 siRNA re
c 294	13.8	2.5	20	1	AAQ41528	Antisense oligomer
c 295	13.8	2.5	20	1	AAQ45269	Primer to amplify
c 296	13.8	2.5	20	1	AAT39924	Maize acetyl CoA c
c 297	13.8	2.5	20	1	AAT88934	Detector probe 1 f
298	13.8	2.5	20	1	AAV19518	Retroviral DNA bas
c 299	13.8	2.5	20	1	AAV68581	Nucleotide sequenc
c 300	13.8	2.5	20	1	AAX93392	PCR primer used to
c 301	13.8	2.5	20	1	AAZ49841	PCR primer 28sst-1
c 302	13.8	2.5	20	1	AAZ59205	Forward PCR primer
c 303	13.8	2.5	20	1	AAZ59204	Second strand cDNA
c 304	13.8	2.5	20	1	AAK95000	Human cDNA clone-s
305	13.8	2.5	20	1	AAF73065	Human daxx inhibit
306	13.8	2.5	20	1	AAD17451	Human TNF-alpha cD
307	13.8	2.5	20	1	AAH80592	Oligonucleotide hy
308	13.8	2.5	20	1	AAH80595	Oligonucleotide hy
309	13.8	2.5	20	1	AAH80593	Oligonucleotide hy
310	13.8	2.5	20	1	AAH80594	Oligonucleotide hy
c 311	13.8	2.5	20	1	ABK53147	HIV-1 Gag gene spe
312	13.8	2.5	20	1	ABK13157	En8183 EN transpos
c 313	13.8	2.5	20	1	AAD39347	Human Von Willebra
c 314	13.8	2.5	20	1	AAL45509	HIV-1 gag amplific
315	13.8	2.5	20	1	AAD61201	Human Ship-1 antis
316	13.8	2.5	20	1	ADD81486	HIV PRT antisense
317	13.8	2.5	20	1	ADD81484	HIV PRT antisense
318	13.8	2.5	20	1	ADD81485	HIV PRT antisense
319	13.8	2.5	20	1	ADD81483	HIV PRT antisense
c 320	13.8	2.5	20	1	ADG17897	Primer of the inve
321	13.8	2.5	20	1	ABZ90674	Human oligonucleot
c 322	13.8	2.5	20	1	ABZ93123	Human oligonucleot
323	13.8	2.5	20	1	ABZ90507	Human oligonucleot
324	13.8	2.5	20	1	ABZ89893	Human oligonucleot
325	13.8	2.5	20	1	ABZ88668	Human oligonucleot
326	13.8	2.5	20	1	ABX13312	Human NSDHL gene,
327	13.8	2.5	20	1	ADK81935	Human PP10484 PCR
328	13.8	2.5	20	1	ABD26904	AA678160-derived o
329	13.8	2.5	20	1	ABD24898	AI095492-derived o
c 330	13.8	2.5	20	1	ABD29353	AA001432-derived o
331	13.8	2.5	20	1	ABD26123	AA463249-derived o
332	13.8	2.5	20	1	ABD26737	N35316-derived oli
c 333	13.8	2.5	20	1	ADP75399	Human NRG2 gene ex
c 334	13.8	2.5	20	1	ADI18956	HIV-I gag1 gene am
c 335	13.8	2.5	20	1	ADJ18839	Antisense DNA olig
336	13.8	2.5	20	1	ADJ18174	Antisense DNA olig
c 337	13.8	2.5	20	1	ADJ18857	Antisense DNA olig
c 338	13.8	2.5	20	1	ADJ18351	Antisense DNA olig
c 339	13.8	2.5	20	1	ADJ18220	Antisense DNA olig
c 340	13.8	2.5	20	1	ADL32212	Clone specific PCR
c 341	13.8	2.5	20	1	ADN36336	Human ZNF365 gene
342	13.8	2.5	20	1	ADP77805	Chimeric phosphoro
343	13.8	2.5	20	1	ADP78705	Chimeric phosphoro
344	13.8	2.5	20	1	ADP78526	Chimeric phosphoro
345	13.8	2.5	20	1	ADP78568	Chimeric phosphoro
c 346	13.8	2.5	20	1	ADN30105	Human cytokine-ind
c 347	13.8	2.5	20	1	ADP27401	Human SEDL antisen
348	13.8	2.5	20	1	ADP27477	Human SEDL antisen
c 349	13.8	2.5	20	1	ADP82592	Human TSG101 antis
c 350	13.8	2.5	21	1	AAV40572	Human TSC gene exo
c 351	13.8	2.5	21	1	AAZ73879	Human biallelic ma
352	13.8	2.5	21	1	AAZ75815	Human biallelic ma
353	13.8	2.5	21	1	AAF96440	Human gene single
354	13.8	2.5	21	1	AAH28431	PCR primer for int
355	13.8	2.5	21	1	AAS11058	Bacterial 16s RNA
c 356	13.8	2.5	21	1	ABK53146	HIV-1 Gag gene spe
c 357	13.8	2.5	21	1	ABK53111	HIV-1 Gag gene spe
c 358	13.8	2.5	21	1	AAL45508	HIV-1 gag amplific
c 359	13.8	2.5	21	1	AAL45473	HIV-1 gag amplific
c 360	13.8	2.5	21	1	ADE53231	FEN-1 related DNA
361	13.8	2.5	21	1	ADP89599	Human EGF motif co
c 362	13.8	2.5	21	1	ADI18920	HIV-I gag1 gene am
c 363	13.8	2.5	21	1	ADI18955	HIV-I gag1 gene am
c 364	13.8	2.5	21	1	ADJ97479	Human Flt-1 DNA se
c 365	13.6	2.4	20	1	AAQ34754	Blocker oligonucle
c 366	13.6	2.4	20	1	AAV57186	Human Notch-3 muta
c 367	13.6	2.4	20	1	AAV57115	Human Notch3 mutan
368	13.6	2.4	20	1	AAZ31349	CXCR4 gene inhibit
c 369	13.6	2.4	20	1	AAX33699	DNA tandem nucleot
370	13.6	2.4	20	1	AAZ04150	PCR primer used to
371	13.6	2.4	20	1	AAZ06015	PCR primer used to
c 372	13.6	2.4	20	1	AAZ18677	ASTH1 gene intron/
373	13.6	2.4	20	1	AAZ71396	Human biallelic ma
c 374	13.6	2.4	20	1	AAA80059	Hepatitis B virus
375	13.6	2.4	20	1	AAC93192	Human STAT3 phosph
c 376	13.6	2.4	20	1	AAA80584	Human ASTH1J gene
c 377	13.6	2.4	20	1	AAF73008	Human daxx inhibit
378	13.6	2.4	20	1	AAH56570	S. pneumoniae groE
379	13.6	2.4	20	1	AAS10664	Human caspase 3 an
380	13.6	2.4	20	1	AAF29930	Human estrogen rec
c 381	13.6	2.4	20	1	AAF99650	Immunostimulatory
c 382	13.6	2.4	20	1	AAF99396	Immunostimulatory
383	13.6	2.4	20	1	AAF99576	Immunostimulatory
c 384	13.6	2.4	20	1	AAF99225	Immunostimulatory
c 385	13.6	2.4	20	1	AAD12126	Rat PTP1B antisens
c 386	13.6	2.4	20	1	AAH80390	Oligonucleotide hy
387	13.6	2.4	20	1	AAD40874	Human hepsin antis
388	13.6	2.4	20	1	AAS96809	Human STAT3 antise
389	13.6	2.4	20	1	AAS97811	Murine SAC1 gene-s
390	13.6	2.4	20	1	ABK37064	Human lysophosphol
c 391	13.6	2.4	20	1	ABS77869	Angiogenesis inhib
c 392	13.6	2.4	20	1	ABS78371	Angiogenesis inhib
393	13.6	2.4	20	1	ABS78292	Angiogenesis inhib
c 394	13.6	2.4	20	1	ABS78041	Angiogenesis inhib
c 395	13.6	2.4	20	1	ABT07470	Human protein phos
c 396	13.6	2.4	20	1	ABL38651	Immunostimulatory
c 397	13.6	2.4	20	1	ABL39120	Immunostimulatory
398	13.6	2.4	20	1	ABL38654	Immunostimulatory

c 399	13.6	2.4	20	1	ABL38650	Immunostimulatory
c 400	13.6	2.4	20	1	ABK85201	Rat PTPB1 antisens
401	13.6	2.4	20	1	AAD40692	Human hepsin antis
c 402	13.6	2.4	20	1	ABK37370	Rat PTP1B mRNA lev
403	13.6	2.4	20	1	ABS70610	Dendritic cell sti
c 404	13.6	2.4	20	1	ABI94166	Capture oligonucle
405	13.6	2.4	20	1	ABT43367	Neuroblastoma-rela
406	13.6	2.4	20	1	ABT32534	Neuroblastoma-rela
c 407	13.6	2.4	20	1	ACD99656	Immunostimulatory
408	13.6	2.4	20	1	ACH03114	Immunostimulatory
c 409	13.6	2.4	20	1	ACD99816	Immunostimulatory
c 410	13.6	2.4	20	1	ACH03191	Immunostimulatory
c 411	13.6	2.4	20	1	ADB37152	Immunostimulatory
c 412	13.6	2.4	20	1	ADB36727	Immunostimulatory
c 413	13.6	2.4	20	1	ADB36898	Immunostimulatory
414	13.6	2.4	20	1	ADB37078	Immunostimulatory
c 415	13.6	2.4	20	1	ADC53902	Pediococcus detect
416	13.6	2.4	20	1	AAD60260	Oligonucleotide 16
c 417	13.6	2.4	20	1	ADD81281	HIV PRT antisense
418	13.6	2.4	20	1	ADE95637	Human NOVX protein
419	13.6	2.4	20	1	ADF78411	Chromosomal abnorm
420	13.6	2.4	20	1	ADH53216	Human APC (adenoma
c 421	13.6	2.4	20	1	ADH93357	Human gene PCR pri
c 422	13.6	2.4	20	1	ABZ91627	Human oligonucleot
423	13.6	2.4	20	1	ABZ90987	Human oligonucleot
c 424	13.6	2.4	20	1	ABZ90974	Human oligonucleot
425	13.6	2.4	20	1	ABQ84589	DPP10 related PSQ
426	13.6	2.4	20	1	ACC68889	Human TGR23 phosph
427	13.6	2.4	20	1	ADM57498	M. tuberculosis PC
c 428	13.6	2.4	20	1	ABD27857	AA258396-derived o
429	13.6	2.4	20	1	ABD27217	AA180912-derived o
c 430	13.6	2.4	20	1	ABD27204	AA180912-derived o
431	13.6	2.4	20	1	ADP75384	Human ADAM19 gene
432	13.6	2.4	20	1	ADH65754	Human glucocortico
c 433	13.6	2.4	20	1	ADH64065	Human glucocortico
434	13.6	2.4	20	1	ADH66141	Human glucocortico
c 435	13.6	2.4	20	1	ADH63542	Human glucocortico
436	13.6	2.4	20	1	ADH65954	Human glucocortico
c 437	13.6	2.4	20	1	ADI13931	Antisense DNA olig
c 438	13.6	2.4	20	1	ADI26879	Cyclin dependent k
c 439	13.6	2.4	20	1	ADJ85510	Nucleic acid analy
c 440	13.6	2.4	20	1	ADJ23949	Human endothelial
c 441	13.6	2.4	20	1	ADK81359	Chimeric phosphoro
442	13.6	2.4	20	1	ADK80553	Chimeric phosphoro
c 443	13.6	2.4	20	1	ADK77601	Chimeric phosphoro
444	13.6	2.4	20	1	ADK78472	Chimeric phosphoro
c 445	13.6	2.4	20	1	ADK78038	Chimeric phosphoro
c 446	13.6	2.4	20	1	ADK81049	Chimeric phosphoro
c 447	13.6	2.4	20	1	ADK81645	Chimeric phosphoro
448	13.6	2.4	20	1	ADL58723	Human ESM-1 antise
c 449	13.6	2.4	20	1	ADL59044	Human ESM-1 antise
c 450	13.6	2.4	20	1	ADL59127	Human ESM-1 antise
451	13.6	2.4	20	1	ADL59120	Human ESM-1 antise
452	13.6	2.4	20	1	ADL59321	Human ESM-1 antise
453	13.6	2.4	20	1	ADL58019	Human ESM-1 antise
454	13.6	2.4	20	1	ADM13866	Human mPGES-1 chim
455	13.6	2.4	20	1	ADM15567	Human mPGES-1 chim
456	13.6	2.4	20	1	ADM14918	Human mPGES-1 chim
457	13.6	2.4	20	1	ADM16151	Murine SAC1 DNA PC
458	13.6	2.4	20	1	ADO53353	Farnesoid X recept
459	13.6	2.4	20	1	ADN37137	Human Gankyrin DNA
c 460	13.6	2.4	20	1	ADP10780	Set 1 left PCR pri
c 461	13.6	2.4	20	1	ADO48959	Human jerky-like 1
462	13.6	2.4	20	1	ADO48994	Human jerky-like 1
463	13.6	2.4	20	1	ADP69694	Human mitoNEET-spe
464	13.4	2.4	15	1	AAF46541	IGFBP2 oligonucleo
465	13.4	2.4	15	1	AAF46543	IGFBP2 oligonucleo
466	13.4	2.4	15	1	AAF46540	IGFBP2 oligonucleo
467	13.4	2.4	15	1	AAF46542	IGFBP2 oligonucleo
c 468	13.4	2.4	16	1	AAQ30227	Oligomer HIV103 fo
c 469	13.4	2.4	16	1	AAZ97698	HIV-1 protease gen
c 470	13.4	2.4	17	1	AAX69282	Human flt1 VEGF re
c 471	13.4	2.4	17	1	AAX69283	Human flt1 VEGF re
c 472	13.4	2.4	17	1	AAX69284	Human flt1 VEGF re
c 473	13.4	2.4	17	1	AAV38823	Homo sapiens C4-2
c 474	13.4	2.4	17	1	AAV36506	Differential displ
475	13.4	2.4	17	1	AAA20972	Integrin alpha 6 s
476	13.4	2.4	17	1	AAF06309	Hammerhead ribozym
477	13.4	2.4	17	1	AAF06310	Hammerhead ribozym
478	13.4	2.4	17	1	AAF06311	Hammerhead ribozym
c 479	13.4	2.4	17	1	AAH95020	Human Chk1 ribozym
c 480	13.4	2.4	17	1	AAH95850	Human Chk1 ribozym
481	13.4	2.4	17	1	ABK00398	Human NOGO Hammerh
482	13.4	2.4	17	1	ABK02234	Human NOGO DNAzyme
c 483	13.4	2.4	17	1	AAI71147	Human cell growth
484	13.4	2.4	17	1	AAF57379	Murine Cdc25A exon
485	13.4	2.4	17	1	ACN05923	WNV Amberzyme subs
486	13.4	2.4	17	1	ACN03707	WNV Zinzyme substr
487	13.4	2.4	17	1	ACN01809	WNV Inozyme substr
c 488	13.4	2.4	17	1	ACN11558	WNV minus strand I
c 489	13.4	2.4	17	1	ACN13346	WNV minus strand Z
490	13.4	2.4	17	1	ACN04860	WNV DNAzyme substr
c 491	13.4	2.4	17	1	ACN14060	WNV minus strand D
c 492	13.4	2.4	17	1	ACN11739	WNV minus strand I
493	13.4	2.4	17	1	ACN00282	WNV Hammerhead Rib
c 494	13.4	2.4	17	1	ABT38096	Tumour suppression
c 495	13.4	2.4	17	1	ABZ65395	Human HER2 DNAzyme
c 496	13.4	2.4	17	1	ADB42007	Tumour suppression
c 497	13.4	2.4	17	1	ADI51049	Human tumour suppr
c 498	13.4	2.4	17	1	ADL51924	Human PTGDR substr
c 499	13.4	2.4	17	1	ADL51441	Human PTGDR substr
500	13.4	2.4	17	1	ADK13320	Human glioma endot
c 501	13.4	2.4	18	1	AAT50832	Human growth hormo
c 502	13.4	2.4	18	1	AAT50830	Ribonucleoside con
c 503	13.4	2.4	18	1	AAZ35894	Human sentrin phos
504	13.4	2.4	18	1	AAZ72914	Human biallelic ma
c 505	13.4	2.4	18	1	AAS13346	Human NOV3 protein
c 506	13.4	2.4	18	1	AAI67726	Adenovirus-2 E1B55
c 507	13.4	2.4	18	1	ABK14274	GH-3 human growth
c 508	13.4	2.4	18	1	ABK14272	GH-1 human growth
509	13.4	2.4	18	1	ADM06227	Human PCR primer S
c 510	13.4	2.4	18	1	ADO48369	cDNA amplification
c 511	13.4	2.4	18	1	ADO48367	cDNA amplification
c 512	13.4	2.4	19	1	AAK99165	Human related 19-m
513	13.4	2.4	19	1	AAH23630	PCR primer p51/378
c 514	13.4	2.4	19	1	AAH23642	PCR primer #3. Un
515	13.4	2.4	19	1	ABS97868	Human UDP-glucuron
c 516	13.4	2.4	19	1	ADF35811	Human VEGFR1 short
517	13.4	2.4	19	1	ADF36238	Human VEGFR1 short
c 518	13.4	2.4	20	1	AAT36218	Antisense oligo ta
c 519	13.4	2.4	20	1	AAX90312	Oligonucleotide RT
520	13.4	2.4	20	1	AAT17552	11 kDa fibrin-bind
521	13.4	2.4	20	1	AAZ06110	PCR primer used to
522	13.4	2.4	20	1	AAX94154	PCR primer used to
c 523	13.4	2.4	20	1	AAX94827	PCR primer used to
c 524	13.4	2.4	20	1	AAD04838	Mouse leptin recep
525	13.4	2.4	20	1	AAH56745	S. aureus groE ope
526	13.4	2.4	20	1	AAH56571	S. pneumoniae groE
527	13.4	2.4	20	1	AAD12073	Rat PTP1B antisens
528	13.4	2.4	20	1	AAD09652	Human PKA C-alpha
529	13.4	2.4	20	1	ABK85148	Rat PTPB1 antisens
530	13.4	2.4	20	1	ABK37317	Rat PTP1B mRNA lev
c 531	13.4	2.4	20	1	AAD48392	Forward PCR primer
532	13.4	2.4	20	1	ABT43119	Neuroblastoma-rela
533	13.4	2.4	20	1	ABT32294	Neuroblastoma-rela
534	13.4	2.4	20	1	AAL61400	Human FXR antisens
c 535	13.4	2.4	20	1	ABZ91737	Human oligonucleot
c 536	13.4	2.4	20	1	ABZ85670	Human oligonucleot
c 537	13.4	2.4	20	1	ABZ89097	Human oligonucleot
c 538	13.4	2.4	20	1	ABZ91736	Human oligonucleot
c 539	13.4	2.4	20	1	ABD21900	Human stanniocalci
c 540	13.4	2.4	20	1	ABD27966	AA497002-derived o
c 541	13.4	2.4	20	1	ABD25327	AI096522-derived o
c 542	13.4	2.4	20	1	ABD27967	AA497002-derived o
543	13.4	2.4	20	1	ADI13878	Antisense DNA olig
c 544	13.4	2.4	20	1	ADJ33955	Human polo-like ki

545	13.4	2.4	20	1	ADK96927	Primer of the inve
c 546	13.4	2.4	20	1	ADJ18865	Antisense DNA olig
c 547	13.4	2.4	20	1	ADJ18849	Antisense DNA olig
548	13.4	2.4	20	1	ADK74412	Chimeric phosphoro
549	13.4	2.4	20	1	ADK73800	Chimeric phosphoro
550	13.4	2.4	20	1	ADK73945	Chimeric phosphoro
551	13.4	2.4	20	1	ADK73908	Chimeric phosphoro
552	13.4	2.4	20	1	ADK73661	Chimeric phosphoro
553	13.4	2.4	20	1	ADK73660	Chimeric phosphoro
554	13.4	2.4	20	1	ADO54049	Farnesoid X recept
c 555	13.4	2.4	20	1	ADO54540	Farnesoid X recept
c 556	13.4	2.4	20	1	ADO53904	Farnesoid X recept
c 557	13.4	2.4	20	1	ADO54304	Farnesoid X recept
c 558	13.4	2.4	20	1	ADO54044	Farnesoid X recept
c 559	13.4	2.4	20	1	ADO54619	Farnesoid X recept
c 560	13.4	2.4	20	1	ADO53903	Farnesoid X recept
561	13.4	2.4	20	1	ADP78803	Chimeric phosphoro
562	13.4	2.4	20	1	ADP78506	Chimeric phosphoro
c 563	13.4	2.4	20	1	ADO25116	Mouse checkpoint k
564	13.4	2.4	20	1	ADO25009	Mouse checkpoint k
c 565	13.4	2.4	20	1	ADO25083	Human checkpoint k
566	13.4	2.4	20	1	ADO24968	Human checkpoint k
567	13.4	2.4	20	1	ADP64804	Human Na+-coupled
568	13.2	2.4	18	1	AAV02719	Human Class I HLA
569	13.2	2.4	18	1	AAV12843	Reverse primer for
c 570	13.2	2.4	18	1	AAX18577	Human tumour necro
c 571	13.2	2.4	18	1	AAX18586	Human tumour necro
572	13.2	2.4	18	1	AAA55669	TRAF5 antisense ol
573	13.2	2.4	18	1	AAZ91407	Human PTEN phospho
574	13.2	2.4	18	1	AAA11103	Hybridisation prob
c 575	13.2	2.4	18	1	AAH75295	Human inducible NO
576	13.2	2.4	18	1	AAS14033	Human PTEN antisen
c 577	13.2	2.4	18	1	AAH25395	Antisense oligonuc
c 578	13.2	2.4	18	1	AAD35200	Human TNFA promote
579	13.2	2.4	18	1	AAD40068	Human PTEN antisen
580	13.2	2.4	18	1	ABN83367	Solanum tuberosum
581	13.2	2.4	18	1	ADF43171	Human phosphatase
582	13.2	2.4	18	1	ADI30222	Human PTEN specifi
c 583	13.2	2.4	18	1	ADI20852	Hybridisation dete
c 584	13.2	2.4	19	1	AAT75111	PCR primer 1 for t
c 585	13.2	2.4	19	1	AAA84322	Cyclin D2 ribozyme
586	13.2	2.4	19	1	AAA84665	Cyclin E ribozyme
587	13.2	2.4	19	1	AAZ70186	Human biallelic ma
c 588	13.2	2.4	19	1	AAH59484	Cyclin D2 ribozyme
589	13.2	2.4	19	1	AAH59827	Cyclin E ribozyme
590	13.2	2.4	19	1	ABL88856	HIV-1 related bind
591	13.2	2.4	19	1	ABS98086	Human multidrug re
c 592	13.2	2.4	19	1	ACA98663	Human CYP2C8 SNP d
593	13.2	2.4	19	1	ACA98666	Human CYP2C8 SNP d
c 594	13.2	2.4	19	1	ABZ68441	Reverse PCR primer
595	13.2	2.4	19	1	ADE27245	Stearoyl-CoA desat
c 596	13.2	2.4	19	1	ADE27535	Stearoyl-CoA desat
c 597	13.2	2.4	19	1	ADF71268	Protein tyrosine p
598	13.2	2.4	19	1	ADF71342	Protein tyrosine p
599	13.2	2.4	19	1	ADF75537	Sense siNA that do
c 600	13.2	2.4	19	1	ADF75722	Antisense siNA tha
601	13.2	2.4	19	1	ADF84550	Human ABL1-targete
c 602	13.2	2.4	19	1	ADF84869	Human ABL1-targete
c 603	13.2	2.4	19	1	ADL79932	Human HER1 (EGFR)
604	13.2	2.4	19	1	ADL79625	Human HER1 (EGFR)
605	13.2	2.4	19	1	ADN34562	siNA upper strand
c 606	13.2	2.4	19	1	ADN34570	siNA upper strand
607	13.2	2.4	19	1	ADN34828	siNA lower strand
c 608	13.2	2.4	19	1	ADN34820	siNA lower strand
c 609	13.2	2.4	19	1	AAL52548	Human RSK interfer
610	13.2	2.4	19	1	ADO18614	Analytical probe c
611	13.2	2.4	19	1	ADO18429	Analytical probe c
c 612	13.2	2.4	20	1	AAQ53097	Gene detection seq
c 613	13.2	2.4	20	1	AAT66012	Primer #1 to ampli
c 614	13.2	2.4	20	1	AAV03708	Primer SHR-2 for H
c 615	13.2	2.4	20	1	AAV15107	Human VEGF antisen
616	13.2	2.4	20	1	AAZ18220	Tyrosine phosphata
617	13.2	2.4	20	1	AAV99217	Sense primer for i
618	13.2	2.4	20	1	AAX22626	Human protein kina
619	13.2	2.4	20	1	AAX15611	Fragment of upstre
c 620	13.2	2.4	20	1	AAX15778	Antisense oligonuc
621	13.2	2.4	20	1	AAZ31341	CXCR4 gene inhibit
622	13.2	2.4	20	1	AAV73096	Human ras oncogene
623	13.2	2.4	20	1	AAX78588	Human PKC-delta ol
c 624	13.2	2.4	20	1	AAZ05834	PCR primer used to
625	13.2	2.4	20	1	AAZ04608	PCR primer used to
c 626	13.2	2.4	20	1	AAZ04719	PCR primer used to
627	13.2	2.4	20	1	AAX83696	Human protein kina
628	13.2	2.4	20	1	AAX93012	PCR primer used to
629	13.2	2.4	20	1	AAX79152	Primer NGA106-R fo
630	13.2	2.4	20	1	AAX19191	Human PKC-delta an
631	13.2	2.4	20	1	AAZ27330	Human protein kina
632	13.2	2.4	20	1	AAZ89062	Human nibrin PCR p
633	13.2	2.4	20	1	AAZ37137	Primer used for am
634	13.2	2.4	20	1	AAZ54547	Neisseria chromoso
635	13.2	2.4	20	1	AAZ54539	Neisseria chromoso
c 636	13.2	2.4	20	1	AAA54278	Antisense oligonuc
637	13.2	2.4	20	1	AAZ88724	Human CD95 recepto
c 638	13.2	2.4	20	1	AAZ69731	Human biallelic ma
c 639	13.2	2.4	20	1	AAA78230	Anti-human Fas ant
c 640	13.2	2.4	20	1	AAA75141	PCR primer for cDN
641	13.2	2.4	20	1	AAH56624	Streptococcus pyog
642	13.2	2.4	20	1	AAF87049	PCR primer for Nkx
643	13.2	2.4	20	1	AAC84225	Human PKC-delta mR
644	13.2	2.4	20	1	AAS10290	Antisense oligonuc
645	13.2	2.4	20	1	ABA82593	Zmax1 gene region
646	13.2	2.4	20	1	ABT13242	Fanconi anaemia FA
c 647	13.2	2.4	20	1	AAS97783	Murine SAC1 gene-s
648	13.2	2.4	20	1	ABL90918	Human protein kina
c 649	13.2	2.4	20	1	ABS97478	Human epoxide hydr
650	13.2	2.4	20	1	ABK23390	Human Zmax1 cDNA r
c 651	13.2	2.4	20	1	ABK12363	Human tumour suppr
652	13.2	2.4	20	1	AAD33542	PCR primer #4 used
c 653	13.2	2.4	20	1	ABS73441	Chimeric phosphoro
c 654	13.2	2.4	20	1	ABX34041	Human cancer suppr
c 655	13.2	2.4	20	1	ABK69368	Chimeric phosphoro
c 656	13.2	2.4	20	1	AAD48416	Forward PCR primer
657	13.2	2.4	20	1	ABZ77182	Geranylgeranyl dip
c 658	13.2	2.4	20	1	ABV76820	PCR primer used to
659	13.2	2.4	20	1	ACC45973	Human HBM STS mark
660	13.2	2.4	20	1	ACF06330	Zebrafish EGFP PCR
661	13.2	2.4	20	1	ACH11197	Human protein kina
662	13.2	2.4	20	1	ABT43829	Human PIP5KIa anti
663	13.2	2.4	20	1	ACH66461	Sense PCR primer u
c 664	13.2	2.4	20	1	ACH66616	Antisense PCR prim
665	13.2	2.4	20	1	ADB98671	Sequence tagged si
c 666	13.2	2.4	20	1	ADB32050	Human FCTR5 cDNA r
667	13.2	2.4	20	1	ADC42479	FANCD2 PCR primer
668	13.2	2.4	20	1	ADD20028	Oreochromis niloti
669	13.2	2.4	20	1	AAD61440	Human TANGO cDNA r
670	13.2	2.4	20	1	AAD61209	Human Ship-1 antis
c 671	13.2	2.4	20	1	AAD61230	Human Ship-1 antis
c 672	13.2	2.4	20	1	ABZ86926	Human oligonucleot
673	13.2	2.4	20	1	ABZ99348	Human PDE4C oligon
674	13.2	2.4	20	1	ABZ93531	Human oligonucleot
675	13.2	2.4	20	1	ABZ86346	Human oligonucleot
676	13.2	2.4	20	1	ABZ87246	Human oligonucleot
677	13.2	2.4	20	1	ABZ86049	Human oligonucleot
c 678	13.2	2.4	20	1	ABZ99307	Human PDE4C oligon
c 679	13.2	2.4	20	1	ABZ90050	Human oligonucleot
c 680	13.2	2.4	20	1	ABZ93124	Human oligonucleot
681	13.2	2.4	20	1	ABZ85806	Human oligonucleot
c 682	13.2	2.4	20	1	ABZ92234	Human oligonucleot
c 683	13.2	2.4	20	1	ABZ92608	Human oligonucleot
c 684	13.2	2.4	20	1	ABZ76978	Bovine DGAT PCR pr
685	13.2	2.4	20	1	ABD22576	Human cathepsin C-
c 686	13.2	2.4	20	1	ABD32338	Human PDE4C-derive
687	13.2	2.4	20	1	ABD22036	Human stanniocalci
c 688	13.2	2.4	20	1	ABD23156	Human myosin X-der
689	13.2	2.4	20	1	ABD23476	Human myosin X-der
c 690	13.2	2.4	20	1	ABD28838	W81570-derived oli

c 691	13.2	2.4	20	1	ABD29354	AA001432-derived o
c 692	13.2	2.4	20	1	ABD28464	R33851-derived oli
c 693	13.2	2.4	20	1	ABD26280	AA425700-derived o
694	13.2	2.4	20	1	ABD22279	Human stanniocalci
695	13.2	2.4	20	1	ABD29761	R37953-derived oli
696	13.2	2.4	20	1	ABD32379	Human PDE4C-derive
697	13.2	2.4	20	1	ADO84933	Human BRCA 1 and B
698	13.2	2.4	20	1	ADH47972	Protein kinase C d
699	13.2	2.4	20	1	ADH44450	Human Rb2/p130 DNA
c 700	13.2	2.4	20	1	ADH44418	Human Rb2/p130 DNA
701	13.2	2.4	20	1	ADH63855	Human glucocortico
702	13.2	2.4	20	1	ADH64498	Human glucocortico
703	13.2	2.4	20	1	ADH66033	Human glucocortico
c 704	13.2	2.4	20	1	ADH63700	Human glucocortico
c 705	13.2	2.4	20	1	ADI80100	Mouse transforming
c 706	13.2	2.4	20	1	ADJ31752	Human amyloid beta
707	13.2	2.4	20	1	ADJ31788	Human amyloid beta
c 708	13.2	2.4	20	1	ADI25098	Human ARHGEF10 exo
c 709	13.2	2.4	20	1	ADJ53580	Human PPP3CB DNA a
710	13.2	2.4	20	1	ADJ53511	Human PPP3CB DNA a
711	13.2	2.4	20	1	ADJ47533	Human IGF2 gene DM
c 712	13.2	2.4	20	1	ADJ61192	Oligonucleotide as
713	13.2	2.4	20	1	ADJ61233	Oligonucleotide as
c 714	13.2	2.4	20	1	ADJ16956	Antisense DNA olig
c 715	13.2	2.4	20	1	ADJ17890	Antisense DNA olig
c 716	13.2	2.4	20	1	ADJ16415	Antisense DNA olig
717	13.2	2.4	20	1	ADJ16904	Antisense DNA olig
718	13.2	2.4	20	1	ADJ23122	Human endothelial
719	13.2	2.4	20	1	ADJ23492	Human endothelial
c 720	13.2	2.4	20	1	ADK81738	Chimeric phosphoro
721	13.2	2.4	20	1	ADK78354	Chimeric phosphoro
c 722	13.2	2.4	20	1	ADK75591	Chimeric phosphoro
c 723	13.2	2.4	20	1	ADK81648	Chimeric phosphoro
c 724	13.2	2.4	20	1	ADK75747	Chimeric phosphoro
725	13.2	2.4	20	1	ADK79271	Chimeric phosphoro
726	13.2	2.4	20	1	ADK79667	Chimeric phosphoro
c 727	13.2	2.4	20	1	ADK76252	Chimeric phosphoro
728	13.2	2.4	20	1	ADL01102	Human VEGF co-regu
729	13.2	2.4	20	1	ADL01119	Human VEGF co-regu
730	13.2	2.4	20	1	ADL01083	Human VEGF co-regu
c 731	13.2	2.4	20	1	ADK13907	Human methyl-CpG-b
c 732	13.2	2.4	20	1	ADL58499	Human ESM-1 antise
733	13.2	2.4	20	1	ADL58076	Human ESM-1 antise
c 734	13.2	2.4	20	1	ADL59085	Human ESM-1 antise
c 735	13.2	2.4	20	1	ADL58560	Human ESM-1 antise
c 736	13.2	2.4	20	1	ADL58842	Human ESM-1 antise
737	13.2	2.4	20	1	ADL58546	Human ESM-1 antise
c 738	13.2	2.4	20	1	ADJ10298	Phosphorothioate a
739	13.2	2.4	20	1	ADM15107	Human mPGES-1 chim
740	13.2	2.4	20	1	ADM15156	Human mPGES-1 chim
741	13.2	2.4	20	1	ADM14040	Human mPGES-1 chim
742	13.2	2.4	20	1	ADM13933	Human mPGES-1 chim
743	13.2	2.4	20	1	ADM15179	Human mPGES-1 chim
744	13.2	2.4	20	1	ADM13976	Human mPGES-1 chim
745	13.2	2.4	20	1	ADM15180	Human mPGES-1 chim
746	13.2	2.4	20	1	ADM14935	Human mPGES-1 chim
747	13.2	2.4	20	1	ADO46623	Human oligonucleot
c 748	13.2	2.4	20	1	ADO46582	Human oligonucleot
c 749	13.2	2.4	20	1	ADM16123	Murine SAC1 DNA PC
750	13.2	2.4	20	1	ADN06668	Human FLAP related
751	13.2	2.4	20	1	ADO53936	Farnesoid X recept
752	13.2	2.4	20	1	ADO52938	Farnesoid X recept
753	13.2	2.4	20	1	ADO53992	Farnesoid X recept
754	13.2	2.4	20	1	ADO54060	Farnesoid X recept
755	13.2	2.4	20	1	ADO16356	4 synthesis-period
756	13.2	2.4	20	1	ADP78340	Chimeric phosphoro
757	13.2	2.4	20	1	ADP78566	Chimeric phosphoro
758	13.2	2.4	20	1	ADP78056	Chimeric phosphoro
c 759	13.2	2.4	20	1	ADP10954	Set 1 left PCR pri
760	13.2	2.4	20	1	ADP11852	Set 2 left PCR pri
761	13.2	2.4	20	1	ADP44531	Human ABCC5 DNA an
c 762	13.2	2.4	20	1	ADP44462	Human ABCC5 DNA an
c 763	13.2	2.4	20	1	ADQ91497	PCR primer G1 used
764	13.2	2.4	20	1	ADQ25821	Chimaeric zebrafis
c 765	13	2.3	13	1	ABF14533	Oligonucleotide SE
c 766	13	2.3	13	1	ABF01171	Oligonucleotide SE
767	13	2.3	13	1	ABH16496	Oligonucleotide SE
c 768	13	2.3	13	1	ABF39622	Oligonucleotide SE
769	13	2.3	13	1	ABC68356	Oligonucleotide SE
770	13	2.3	13	1	ABF39623	Oligonucleotide SE
c 771	13	2.3	13	1	ABC68357	Oligonucleotide SE
772	13	2.3	13	1	ABF01170	Oligonucleotide SE
c 773	13	2.3	13	1	ABH59369	Oligonucleotide SE
774	13	2.3	13	1	ABH65388	Oligonucleotide SE
c 775	13	2.3	13	1	ABC03683	Oligonucleotide SE
776	13	2.3	13	1	ABH59368	Oligonucleotide SE
777	13	2.3	13	1	ABC48299	Oligonucleotide SE
c 778	13	2.3	13	1	ABH65389	Oligonucleotide SE
779	13	2.3	13	1	ABF14532	Oligonucleotide SE
c 780	13	2.3	13	1	ABH16497	Oligonucleotide SE
c 781	13	2.3	13	1	ABC48298	Oligonucleotide SE
782	13	2.3	13	1	ABC03682	Oligonucleotide SE
783	13	2.3	15	1	AAD26689	Human GPR31 gene p
784	13	2.3	15	1	ABQ72847	Human GRM8 allele-
785	13	2.3	15	1	ADG65452	UCP2 allele specif
c 786	13	2.3	17	1	AAH95600	Human Chk1 ribozym
c 787	13	2.3	17	1	ABA79481	Factor IX mutation
788	13	2.3	17	1	ABA79480	Factor IX mutation
789	13	2.3	17	1	ABA79476	Factor IX mutation
c 790	13	2.3	17	1	ABA79477	Factor IX mutation
791	13	2.3	17	1	ABA79468	Factor IX mutation
c 792	13	2.3	17	1	ABA79469	Factor IX mutation
793	13	2.3	17	1	ABA79472	Factor IX mutation
c 794	13	2.3	17	1	ABA79473	Factor IX mutation
c 795	13	2.3	17	1	ABQ64257	Human KTOM1a porti
c 796	13	2.3	17	1	ABQ64251	Human KTOM1a porti
c 797	13	2.3	17	1	ABV90244	Human POSHL1 scann
c 798	13	2.3	17	1	ABV90245	Human POSHL1 scann
c 799	13	2.3	17	1	ABV90243	Human POSHL1 scann
c 800	13	2.3	17	1	ABV90242	Human POSHL1 scann
c 801	13	2.3	17	1	ABV90246	Human POSHL1 scann
c 802	13	2.3	17	1	ACC65383	Murine oligonucleo
803	13	2.3	17	1	ACC65669	Murine oligonucleo
804	13	2.3	17	1	ABZ59602	Human parvovirus B
c 805	13	2.3	17	1	ADB44145	Tumour suppression
c 806	13	2.3	18	1	AAA57790	Antisense oligonuc
c 807	13	2.3	19	1	AAX57180	Porcine Oct-4 exon
808	13	2.3	19	1	AAA84663	Cyclin E ribozyme
809	13	2.3	19	1	AAA84664	Cyclin E ribozyme
810	13	2.3	19	1	AAH59825	Cyclin E ribozyme
811	13	2.3	19	1	AAH59826	Cyclin E ribozyme
812	13	2.3	19	1	ADF49462	Human BCL2 siNA lo
c 813	13	2.3	19	1	ADF49876	Human BCL2 siNA lo
814	13	2.3	19	1	ADM80438	Human HERV-H PCR p
815	13	2.3	19	1	ADM80423	Human HERV-H PCR p
c 816	13	2.3	19	1	ADH01664	Protein tyrosine p
c 817	13	2.3	19	1	ADK72436	Cycloclasticus gyr
c 818	13	2.3	19	1	ADQ27935	RNA interference t
819	13	2.3	20	1	AAQ56478	E1 positive strand
c 820	13	2.3	20	1	AAQ56484	E1 negative strand
c 821	13	2.3	20	1	AAQ83955	Cyclic-GMP stimula
c 822	13	2.3	20	1	AAT44867	HPV E1 consensus n
823	13	2.3	20	1	AAT44861	HPV E1 consensus p
c 824	13	2.3	20	1	AAT51092	Primer #1 for calc
825	13	2.3	20	1	AAT77976	Human papillomavir
c 826	13	2.3	20	1	AAT77982	Human papillomavir
c 827	13	2.3	20	1	AAT67204	Bovine brain 61 kD
c 828	13	2.3	20	1	AAV54738	PCR primer CaM PCR
c 829	13	2.3	20	1	AAV17463	Primer TYN06 for h
830	13	2.3	20	1	AAV17471	Primer TYP06 for h
c 831	13	2.3	20	1	AAV48182	Ca2+/calmodulin st
c 832	13	2.3	20	1	AAV36135	Primer CaM PCR-2S
c 833	13	2.3	20	1	AAZ90358	Bovine 61 kD CaM-P
c 834	13	2.3	20	1	AAF27130	Human cyclin E ant
835	13	2.3	20	1	ABQ93273	T. tauschii/wheat
c 836	13	2.3	20	1	ABX78835	Bovine 61kDa CaM-P

c 837	13	2.3	20	1	ABZ88892	Human oligonucleot
838	13	2.3	20	1	ABZ89699	Human oligonucleot
839	13	2.3	20	1	ABD25929	AA505075-derived o
c 840	13	2.3	20	1	ABD25122	AI041482-derived o
841	13	2.3	20	1	ADL59472	Human ESM-1 antise
c 842	13	2.3	20	1	ADQ94921	Bovine 61 kDa CaM-
843	12.8	2.3	16	1	AAT27053	Telomerase templat
c 844	12.8	2.3	16	1	AAT91229	Hairpin ribozyme r
c 845	12.8	2.3	16	1	AAV18124	Human HNG gene exo
846	12.8	2.3	16	1	AAV28957	in vitro mutagenes
847	12.8	2.3	17	1	AAQ94630	Brush-1 gene prime
848	12.8	2.3	17	1	AAT81245	Human c-myb hammer
c 849	12.8	2.3	17	1	AAX63970	Rabbit stromelysin
850	12.8	2.3	17	1	AAX64047	Rabbit stromelysin
851	12.8	2.3	17	1	AAX69768	Human flt1 VEGF re
c 852	12.8	2.3	17	1	AAX73282	Mouse flk-1 VEGF r
c 853	12.8	2.3	17	1	AAX69483	Human flt1 VEGF re
c 854	12.8	2.3	17	1	AAX69454	Human flt1 VEGF re
c 855	12.8	2.3	17	1	AAX69484	Human flt1 VEGF re
856	12.8	2.3	17	1	AAV97765	Human EGF-R target
857	12.8	2.3	17	1	AAV97766	Human EGF-R target
c 858	12.8	2.3	17	1	AAV95640	Solanidine glucosy
859	12.8	2.3	17	1	AAV95949	Solanidine glucosy
c 860	12.8	2.3	17	1	AAV95638	Solanidine glucosy
c 861	12.8	2.3	17	1	AAV95639	Solanidine glucosy
862	12.8	2.3	17	1	AAV48869	ErbB-2 gene antise
c 863	12.8	2.3	17	1	AAA18484	Human TIE-2 substr
864	12.8	2.3	17	1	AAA25113	Oestrogen receptor
865	12.8	2.3	17	1	AAF03259	Hammerhead ribozym
866	12.8	2.3	17	1	AAF06265	Hammerhead ribozym
c 867	12.8	2.3	17	1	AAF02870	Hammerhead ribozym
868	12.8	2.3	17	1	AAF02937	Hammerhead ribozym
c 869	12.8	2.3	17	1	ABK03204	Human CD20 Inozyme
c 870	12.8	2.3	17	1	ABK02445	Human NOGO Amberzy
c 871	12.8	2.3	17	1	ABK02838	Human CD20 Hammerh
872	12.8	2.3	17	1	AAH91870	Human inflammatory
c 873	12.8	2.3	17	1	ABN01355	Human GDMLP-1 17-m
c 874	12.8	2.3	17	1	ABN01588	Human GDMLP-1 17-m
875	12.8	2.3	17	1	ABN07965	Human GDMLP-1 17-m
c 876	12.8	2.3	17	1	ABN07649	Human GDMLP-1 17-m
877	12.8	2.3	17	1	ABN07966	Human GDMLP-1 17-m
c 878	12.8	2.3	17	1	ABN01589	Human GDMLP-1 17-m
c 879	12.8	2.3	17	1	ABN01353	Human GDMLP-1 17-m
c 880	12.8	2.3	17	1	ABN07652	Human GDMLP-1 17-m
881	12.8	2.3	17	1	ABK26167	Increased starch p
c 882	12.8	2.3	17	1	ABK26168	Increased starch p
883	12.8	2.3	17	1	ABV79923	Human HTPL scannin
884	12.8	2.3	17	1	ABV79922	Human HTPL scannin
885	12.8	2.3	17	1	ABS74786	Human PAPP-Ea asso
886	12.8	2.3	17	1	ABS74785	Human PAPP-Ea asso
887	12.8	2.3	17	1	ABL31614	Human HLA genotypi
c 888	12.8	2.3	17	1	ACN08987	WNV minus strand H
889	12.8	2.3	17	1	ACD00706	G-protein coupled
890	12.8	2.3	17	1	ACD00705	G-protein coupled
891	12.8	2.3	17	1	ABT36453	Tumour suppression
892	12.8	2.3	17	1	ABT38296	Tumour suppression
893	12.8	2.3	17	1	ABT35540	Tumour suppression
894	12.8	2.3	17	1	ABT40056	Tumour suppression
895	12.8	2.3	17	1	ABZ60557	Human K-Ras DNAzym
896	12.8	2.3	17	1	ABZ60346	Human K-Ras DNAzym
897	12.8	2.3	17	1	ABZ60792	Human K-Ras DNAzym
c 898	12.8	2.3	17	1	ABZ62044	Human H-Ras DNAzym
899	12.8	2.3	17	1	ABZ65512	Human HER2 DNAzyme
900	12.8	2.3	17	1	ACC67200	Murine oligonucleo
c 901	12.8	2.3	17	1	ACC64381	Murine oligonucleo
c 902	12.8	2.3	17	1	ACC65861	Murine oligonucleo
903	12.8	2.3	17	1	ACC66597	Murine oligonucleo
c 904	12.8	2.3	17	1	ADB40425	Tumour suppression
905	12.8	2.3	17	1	ADB41070	Tumour suppression
906	12.8	2.3	17	1	ADB42768	Tumour suppression
c 907	12.8	2.3	17	1	ADC37718	Human AMLP1a scann
c 908	12.8	2.3	17	1	ADC37719	Human AMLP1a scann
909	12.8	2.3	17	1	ADB45705	Tumour suppression
c 910	12.8	2.3	17	1	ADB44190	Tumour suppression
911	12.8	2.3	17	1	ADB45019	Tumour suppression
912	12.8	2.3	17	1	ADF64454	Human PCCP1 DNA fr
913	12.8	2.3	17	1	ADF64455	Human PCCP1 DNA fr
914	12.8	2.3	17	1	ADI49767	Human tumour suppr
915	12.8	2.3	17	1	ADI47542	Human tumour suppr
916	12.8	2.3	17	1	ADI49784	Human tumour suppr
917	12.8	2.3	17	1	ADI51285	Human tumour suppr
c 918	12.8	2.3	17	1	ABZ76061	Antigene inhibitin
919	12.8	2.3	17	1	ACC51590	Human tumour suppr
920	12.8	2.3	17	1	ADK12618	Human NAC-1 gene-s
921	12.8	2.3	17	1	ADK12617	Human NAC-1 gene-s
c 922	12.8	2.3	17	1	ADL48853	Human IKK-gamma su
923	12.8	2.3	17	1	ADL49568	Human PKR substrat
924	12.8	2.3	17	1	ADL50564	Human PKR substrat
925	12.8	2.3	17	1	ADL48933	Human PKR substrat
926	12.8	2.3	17	1	ADL82289	Human ER+ breast c
c 927	12.8	2.3	17	1	ADN44859	Mutant cell identi
928	12.8	2.3	17	1	ADN44858	Mutant cell identi
929	12.8	2.3	18	1	AAT73318	Primer 22-cSTS10 f
c 930	12.8	2.3	18	1	AAX76900	Hz-1 Pag1 gene dir
931	12.8	2.3	18	1	AAA60110	Oligonucleotide #
932	12.8	2.3	18	1	AAZ77174	Human biallelic ma
c 933	12.8	2.3	18	1	AAZ73513	Human biallelic ma
934	12.8	2.3	18	1	AAA67054	Human leukocyte an
935	12.8	2.3	18	1	AAC63013	Human IL-1 alpha g
936	12.8	2.3	18	1	ABA82425	Zmax1 gene region
c 937	12.8	2.3	18	1	ABK28903	HPV blocker probe
938	12.8	2.3	18	1	ABV73436	Human V1a vasopres
939	12.8	2.3	18	1	ABK23222	Human Zmax1 cDNA r
c 940	12.8	2.3	18	1	ABL40874	Nucleotide sequenc
941	12.8	2.3	18	1	ABK17341	Rat Rb-interacting
c 942	12.8	2.3	18	1	ACF62961	Human p16 PCR prim
943	12.8	2.3	18	1	ACF62963	Human p16 PCR prim
944	12.8	2.3	18	1	ABZ10476	Haematopoietic cel
c 945	12.8	2.3	18	1	ABZ10569	Haematopoietic cel
c 946	12.8	2.3	18	1	ABZ11028	Haematopoietic cel
947	12.8	2.3	18	1	ABZ11030	Haematopoietic cel
948	12.8	2.3	18	1	ACC45805	Human HBM STS mark
949	12.8	2.3	18	1	ADB98503	Sequence tagged si
c 950	12.8	2.3	18	1	ADB54056	Oligonucleotide 48
c 951	12.8	2.3	18	1	ADB54571	Hybridisation olig
c 952	12.8	2.3	18	1	ADC70086	Primer oligo used
953	12.8	2.3	18	1	ADE84624	Mammalian RIZ prot
954	12.8	2.3	18	1	ADE84360	Human lymphoid cel
c 955	12.8	2.3	18	1	ABZ77008	Bovine DGAT PCR pr
c 956	12.8	2.3	18	1	ABZ76952	Bovine DGAT BAC-DN
c 957	12.8	2.3	18	1	ADN35838	Human NSCLC gene a
c 958	12.8	2.3	19	1	AAT76153	Human vascular cel
c 959	12.8	2.3	19	1	AAX09851	Human biallelic po
c 960	12.8	2.3	19	1	AAX91457	T. gondii OC-2 gen
c 961	12.8	2.3	19	1	AAX53950	Vascular cell adhe
962	12.8	2.3	19	1	AAZ34529	Transporter protei
c 963	12.8	2.3	19	1	AAA33393	Low adenosine anti
964	12.8	2.3	19	1	AAA83970	Cyclin A2 ribozyme
c 965	12.8	2.3	19	1	AAA84404	Cyclin D3 ribozyme
c 966	12.8	2.3	19	1	AAZ76823	Human biallelic ma
967	12.8	2.3	19	1	AAZ69691	Human biallelic ma
c 968	12.8	2.3	19	1	AAF19515	Human VCAM-1 polyn
969	12.8	2.3	19	1	AAA28678	Calreticulin promo
c 970	12.8	2.3	19	1	AAC72827	Single nucleotide
c 971	12.8	2.3	19	1	AAC72812	Single nucleotide
c 972	12.8	2.3	19	1	AAA59141	PCR primer used to
c 973	12.8	2.3	19	1	AAS42780	T. gondii immunoge
c 974	12.8	2.3	19	1	AAS45556	Tumour-specific Ig
975	12.8	2.3	19	1	AAS05706	Polypyrimidine reg
976	12.8	2.3	19	1	AAS95216	Otoferlin exon PCR
977	12.8	2.3	19	1	AAH59132	Cyclin A2 ribozyme
c 978	12.8	2.3	19	1	AAH59566	Cyclin D3 ribozyme
c 979	12.8	2.3	19	1	ABL43091	Human chromosome 1
c 980	12.8	2.3	19	1	ABL58835	Staphylococcus PCR
c 981	12.8	2.3	19	1	ACD40350	Tumour IgV PCR 5'
982	12.8	2.3	19	1	ACA98667	Human CYP2C8 SNP d

c 983	12.8	2.3	19	1	ACA98664	Human CYP2C8 SNP d
c 984	12.8	2.3	19	1	ACD06865	Tumour immunoglobu
c 985	12.8	2.3	19	1	ACD06123	Tumour immunoglobu
c 986	12.8	2.3	19	1	ACD45075	B-cell lymphona va
987	12.8	2.3	19	1	ADD20080	Oreochromis niloti
988	12.8	2.3	19	1	ADF36408	Human VEGFR1 short
c 989	12.8	2.3	19	1	ADF35981	Human VEGFR1 short
990	12.8	2.3	19	1	ADF69468	Tapesia yallundae
991	12.8	2.3	19	1	ADG35660	HIV siNA oligonucl
992	12.8	2.3	19	1	ADG35300	HIV siNA oligonucl
c 993	12.8	2.3	19	1	ADG36398	HIV siNA oligonucl
c 994	12.8	2.3	19	1	ADG36038	HIV siNA oligonucl
c 995	12.8	2.3	19	1	ADG36051	HIV siNA oligonucl
996	12.8	2.3	19	1	ADG35313	HIV siNA oligonucl
997	12.8	2.3	19	1	ADF84778	Human ABL1-targete
c 998	12.8	2.3	19	1	ADF84459	Human ABL1-targete
c 999	12.8	2.3	19	1	ADG17387	T. gondii PCR prim
c1000	12.8	2.3	19	1	ABZ95209	Human VCAM-1 oligo
1001	12.8	2.3	19	1	ADN34190	Upper strand of cy
c1002	12.8	2.3	19	1	ADN34429	Lower strand of cy
c1003	12.8	2.3	19	1	ABD19154	Human VCAM-1 DNA f
1004	12.8	2.3	19	1	ADH28072	Human chromosome 1
c1005	12.8	2.3	19	1	ADL15516	PCR primer 26 used
1006	12.8	2.3	19	1	ADO18674	Analytical probe c
1007	12.8	2.3	19	1	ADO18433	Analytical probe c
1008	12.8	2.3	19	1	ADO18410	Analytical probe c
1009	12.8	2.3	19	1	ADO18584	Analytical probe c
1010	12.6	2.3	13	1	ABC37874	Oligonucleotide SE
c1011	12.6	2.3	13	1	ABC14546	Oligonucleotide SE
1012	12.6	2.3	13	1	ABC36865	Oligonucleotide SE
1013	12.6	2.3	13	1	ABC14547	Oligonucleotide SE
1014	12.6	2.3	13	1	ABF78869	Oligonucleotide SE
c1015	12.6	2.3	13	1	ABC36864	Oligonucleotide SE
c1016	12.6	2.3	13	1	ABF78868	Oligonucleotide SE
c1017	12.6	2.3	13	1	ABC37875	Oligonucleotide SE
1018	12.6	2.3	15	1	AAD47752	Human GNB3 gene po
1019	12.6	2.3	15	1	AAD47739	Human GNB3 gene po
1020	12.6	2.3	17	1	AAT16992	E-Dex integrin inh
c1021	12.6	2.3	19	1	AAV02659	Eukaryotic 18S rRN
c1022	12.6	2.3	19	1	AAT78425	Antisense oligonuc
1023	12.6	2.3	19	1	AAV54628	LU105 EST-specific
c1024	12.6	2.3	19	1	AAX09160	Human biallelic po
c1025	12.6	2.3	19	1	AAX59691	Activator-antisens
1026	12.6	2.3	19	1	AAX34643	cDNA clone BED1 cl
1027	12.6	2.3	19	1	AAA85836	Cyclin B1 ribozyme
1028	12.6	2.3	19	1	AAA83806	cdk-we-hu ribozyme
1029	12.6	2.3	19	1	AAA83805	cdk-we-hu ribozyme
c1030	12.6	2.3	19	1	AAZ74780	Human biallelic ma
c1031	12.6	2.3	19	1	AAZ74546	Human biallelic ma
1032	12.6	2.3	19	1	AAA95932	Human NES1 gene PC
c1033	12.6	2.3	19	1	AAH27389	PCR primer #58. H
1034	12.6	2.3	19	1	AAS42887	Human G Protein-Co
1035	12.6	2.3	19	1	AAH58968	Cdk-we-hu ribozyme
1036	12.6	2.3	19	1	AAH60998	Cyclin B1 ribozyme
1037	12.6	2.3	19	1	AAH58967	Cdk-we-hu ribozyme
1038	12.6	2.3	19	1	ABK41500	Human CTNNA3 gene
1039	12.6	2.3	19	1	AAF88975	Human GSTPi Peptid
1040	12.6	2.3	19	1	ABL45146	Human chromosome 1
1041	12.6	2.3	19	1	ABX72477	Human NOVX DNA PCR
c1042	12.6	2.3	19	1	ADE65586	Human c-fos transc
1043	12.6	2.3	19	1	ADE65702	Human c-fos siNA l
c1044	12.6	2.3	19	1	ADE06873	Cancer-related all
c1045	12.6	2.3	19	1	ADE29480	Mitogen activated
1046	12.6	2.3	19	1	ADE29643	Mitogen activated
1047	12.6	2.3	19	1	ADF37136	Human VEGFR2 short
c1048	12.6	2.3	19	1	ADF36812	Human VEGFR2 short
1049	12.6	2.3	19	1	ADF71282	Protein tyrosine p
c1050	12.6	2.3	19	1	ADF71356	Protein tyrosine p
c1051	12.6	2.3	19	1	ADF92637	Human CHK-1 transc
1052	12.6	2.3	19	1	ADF92749	Human CHK-1 siNA l
c1053	12.6	2.3	19	1	ADG34976	Human TNF receptor
1054	12.6	2.3	19	1	ADG34853	Human TNF receptor
1055	12.6	2.3	19	1	ADG35062	Human TNF receptor
c1056	12.6	2.3	19	1	ADG34939	Human TNF receptor
1057	12.6	2.3	19	1	ADH79299	Horse probe SEQ ID
c1058	12.6	2.3	19	1	ADJ66393	Human TGFb-R siNA
1059	12.6	2.3	19	1	ADJ66265	Human TGFb-R trans
c1060	12.6	2.3	19	1	ADM92878	SNP-containing car
1061	12.6	2.3	19	1	ADM77344	Human fibrocystin
1062	12.6	2.3	19	1	ADH01866	Protein tyrosine p
1063	12.6	2.3	19	1	ADL18581	Human cytochrome P
c1064	12.6	2.3	19	1	ADM32949	PCR primer To32-30
c1065	12.6	2.3	19	1	ADN75395	Human CD45 CR regi
c1066	12.6	2.3	19	1	ADO49828	H. pylori strain J
c1067	12.6	2.3	19	1	ADQ27450	RNA interference t
1068	12.6	2.3	19	1	ADQ62357	Anti-CASP10 siRNA
1069	12.6	2.3	19	1	ADQ62566	Anti-TAP1 siRNA SE
1070	12.6	2.3	19	1	ADQ60763	Anti-AKT1 siRNA re
c1071	12.4	2.2	14	1	AAV11925	Hepatocyte growth
1072	12.4	2.2	14	1	AAV11924	Hepatocyte growth
c1073	12.4	2.2	15	1	AAT57313	RSV N hammerhead r
c1074	12.4	2.2	15	1	AAT57311	RSV N hammerhead r
c1075	12.4	2.2	15	1	AAA06101	CFTR gene analysis
1076	12.4	2.2	15	1	AAF46544	IGFBP2 oligonucleo
1077	12.4	2.2	15	1	AAF46539	IGFBP2 oligonucleo
1078	12.4	2.2	15	1	ADF32124	Probe #48 used to
c1079	12.4	2.2	15	1	ADF48919	DNA array associat
1080	12.4	2.2	16	1	AAQ43528	ALL-1 gene exon 6/
1081	12.4	2.2	16	1	AAQ75196	ALL-1 breakpoint c
1082	12.4	2.2	16	1	AAX33869	HPV-16 inhibitor.
1083	12.4	2.2	16	1	AAX33872	HPV-16 inhibitor.
c1084	12.4	2.2	16	1	AAX54337	Inducible nitric o
c1085	12.4	2.2	16	1	AAA33781	Low adenosine anti
c1086	12.4	2.2	16	1	AAZ97699	HIV-1 protease gen
c1087	12.4	2.2	16	1	AAF19903	Human inducible ni
c1088	12.4	2.2	16	1	AAF24327	Human NFAR-1/NFAR-
1089	12.4	2.2	16	1	ADF13651	Chromosome 21 segm
1090	12.4	2.2	16	1	ADI20606	Putative eRNA sequ
c1091	12.4	2.2	16	1	ABZ95597	Human inducible ni
c1092	12.4	2.2	16	1	ABD19756	Human inducible ni
c1093	12.4	2.2	17	1	AAQ98017	PNA oligomer targe
1094	12.4	2.2	17	1	AAX74673	Mouse flt-1 VEGF r
c1095	12.4	2.2	17	1	AAA36506	Human genomic SNP
c1096	12.4	2.2	17	1	AAA36505	Human genomic SNP
1097	12.4	2.2	17	1	AAF06308	Hammerhead ribozym
1098	12.4	2.2	17	1	AAF02093	Hammerhead ribozym
1099	12.4	2.2	17	1	AAF06312	Hammerhead ribozym
1100	12.4	2.2	17	1	AAF02092	Hammerhead ribozym
c1101	12.4	2.2	17	1	AAF03240	Hammerhead ribozym
1102	12.4	2.2	17	1	ABK01749	Human NOGO Zinzyme
1103	12.4	2.2	17	1	ABK02294	Human NOGO DNAzyme
1104	12.4	2.2	17	1	ABK00595	Human NOGO Hammerh
1105	12.4	2.2	17	1	ABK01278	Human NOGO Inozyme
c1106	12.4	2.2	17	1	ABN07647	Human GDMLP-1 17-m
c1107	12.4	2.2	17	1	ABN07648	Human GDMLP-1 17-m
c1108	12.4	2.2	17	1	ABN07198	Human GDMLP-1 17-m
c1109	12.4	2.2	17	1	ABN07195	Human GDMLP-1 17-m
c1110	12.4	2.2	17	1	ABN07197	Human GDMLP-1 17-m
c1111	12.4	2.2	17	1	ABN07196	Human GDMLP-1 17-m
c1112	12.4	2.2	17	1	ACN11763	WNV minus strand I
1113	12.4	2.2	17	1	ACN05922	WNV Amberzyme subs
1114	12.4	2.2	17	1	ACN00281	WNV Hammerhead Rib
c1115	12.4	2.2	17	1	ACN09109	WNV minus strand H
1116	12.4	2.2	17	1	ACN00283	WNV Hammerhead Rib
c1117	12.4	2.2	17	1	ACN11559	WNV minus strand I
1118	12.4	2.2	17	1	ACN05805	WNV Amberzyme subs
1119	12.4	2.2	17	1	ACN01808	WNV Inozyme substr
c1120	12.4	2.2	17	1	ACN09108	WNV minus strand H
1121	12.4	2.2	17	1	ABT35130	Tumour suppression
c1122	12.4	2.2	17	1	ABT39205	Tumour suppression
c1123	12.4	2.2	17	1	ABT35289	Tumour suppression
1124	12.4	2.2	17	1	ABT38105	Tumour suppression
1125	12.4	2.2	17	1	ABT35588	Tumour suppression
1126	12.4	2.2	17	1	ABT38195	Tumour suppression
c1127	12.4	2.2	17	1	ABT38459	Tumour suppression
1128	12.4	2.2	17	1	ABZ60793	Human K-Ras DNAzym

1129	12.4	2.2	17	1	ABZ61738	Human H-Ras DNAzym
c1130	12.4	2.2	17	1	ACD52107	HBV inozyme substr
c1131	12.4	2.2	17	1	ACD53828	HBV zinzyme substr
c1132	12.4	2.2	17	1	ACD57252	HCV DNAzyme substr
1133	12.4	2.2	17	1	ACD52591	HBV inozyme substr
1134	12.4	2.2	17	1	ACD52590	HBV inozyme substr
c1135	12.4	2.2	17	1	ACD50754	HBV hammerhead rib
c1136	12.4	2.2	17	1	ACD57251	HCV DNAzyme substr
1137	12.4	2.2	17	1	ACD51148	HBV hammerhead rib
1138	12.4	2.2	17	1	ACD65418	HCV minus strand D
1139	12.4	2.2	17	1	ACD51147	HBV hammerhead rib
1140	12.4	2.2	17	1	ACC65425	Murine oligonucleo
1141	12.4	2.2	17	1	ACC68551	Murine oligonucleo
1142	12.4	2.2	17	1	ACC68538	Murine oligonucleo
1143	12.4	2.2	17	1	ACC65316	Murine oligonucleo
c1144	12.4	2.2	17	1	ACC66327	Murine oligonucleo
c1145	12.4	2.2	17	1	ACC67926	Murine oligonucleo
1146	12.4	2.2	17	1	ADB44162	Tumour suppression
1147	12.4	2.2	17	1	ADB41409	Tumour suppression
c1148	12.4	2.2	17	1	ADB41530	Tumour suppression
1149	12.4	2.2	17	1	ADB43929	Tumour suppression
c1150	12.4	2.2	17	1	ADF62559	Human PCCP1 DNA fr
c1151	12.4	2.2	17	1	ADF62560	Human PCCP1 DNA fr
c1152	12.4	2.2	17	1	ADF62561	Human PCCP1 DNA fr
c1153	12.4	2.2	17	1	ADF62562	Human PCCP1 DNA fr
1154	12.4	2.2	17	1	ADI50278	Human tumour suppr
c1155	12.4	2.2	17	1	ADI52771	Human tumour suppr
1156	12.4	2.2	17	1	ADI52732	Human tumour suppr
1157	12.4	2.2	17	1	ADI52639	Human tumour suppr
1158	12.4	2.2	17	1	ACC54457	Human tumour suppr
c1159	12.4	2.2	17	1	ACC51609	Human tumour suppr
1160	12.4	2.2	17	1	ADL49336	Human PKR substrat
1161	12.4	2.2	17	1	ADL49335	Human PKR substrat
1162	12.4	2.2	17	1	ADL49337	Human PKR substrat
c1163	12.4	2.2	17	1	ADL51044	Human PTGDR substr
c1164	12.4	2.2	17	1	ADM59570	Hepatitis B virus
1165	12.4	2.2	17	1	ADM58308	Hepatitis B virus
1166	12.4	2.2	17	1	ADM59033	Hepatitis B virus
c1167	12.4	2.2	17	1	ADM58119	Hepatitis B virus
1168	12.4	2.2	17	1	ADM58309	Hepatitis B virus
1169	12.4	2.2	17	1	ADM59032	Hepatitis B virus
c1170	12.4	2.2	17	1	ADM58804	Hepatitis B virus
c1171	12.4	2.2	17	1	ADI82983	HCV DNAzyme substr
1172	12.4	2.2	17	1	ADI87080	HCV DNAzyme substr
c1173	12.4	2.2	17	1	ADI82984	HCV DNAzyme substr
1174	12.4	2.2	18	1	AAZ43635	Human familial dys
1175	12.4	2.2	18	1	AAA10565	Smad2 antisense ol
1176	12.4	2.2	18	1	AAZ70501	Human biallelic ma
1177	12.4	2.2	18	1	AAZ70322	Human biallelic ma
1178	12.4	2.2	18	1	AAZ98488	H. discus derived
1179	12.4	2.2	18	1	AAA95181	Reverse primer use
1180	12.4	2.2	18	1	AAH56595	S. pneumoniae groE
1181	12.4	2.2	18	1	AAH56823	S. aureus groE ope
1182	12.4	2.2	18	1	AAS09265	PCR primer #1 for
c1183	12.4	2.2	18	1	ABA82497	Zmax1 gene region
c1184	12.4	2.2	18	1	ABA82113	Zmax1 gene region
1185	12.4	2.2	18	1	AAI67723	Adenovirus-2 E1 al
c1186	12.4	2.2	18	1	AAI67722	Adenovirus-2 E1 al
1187	12.4	2.2	18	1	AAI67727	Adenovirus-2 E1B55
c1188	12.4	2.2	18	1	ABL88822	HIV-1 related bind
1189	12.4	2.2	18	1	ABL61267	HIV Pol sequencing
c1190	12.4	2.2	18	1	ABK22910	Human Zmax1 cDNA r
c1191	12.4	2.2	18	1	ABK23294	Human Zmax1 cDNA r
1192	12.4	2.2	18	1	ABK11999	Human D9S310 genet
c1193	12.4	2.2	18	1	ACF63006	Human progesterone
1194	12.4	2.2	18	1	ACF63008	Human progesterone
c1195	12.4	2.2	18	1	ACC45877	Human HBM STS mark
c1196	12.4	2.2	18	1	ACC45493	Human HBM STS mark
c1197	12.4	2.2	18	1	ADB98191	Sequence tagged si
c1198	12.4	2.2	18	1	ADB98575	Sequence tagged si
c1199	12.4	2.2	18	1	ADE14972	Beer spoilage-asso
c1200	12.4	2.2	18	1	ADE77591	Human probe SSP16
1201	12.4	2.2	18	1	ADI34074	HIV pol region DNA
1202	12.4	2.2	18	1	ABZ97363	Human IL4-R oligon
1203	12.4	2.2	18	1	ABZ97260	Human nucleic acid
c1204	12.4	2.2	18	1	ADM06769	Human PCR primer S
c1205	12.4	2.2	18	1	ADM06632	Human PCR primer S
1206	12.4	2.2	18	1	ABD30394	Human IL4-R derive
1207	12.4	2.2	18	1	ADH02714	Sequencing primer
1208	12.4	2.2	18	1	ADJ59182	Oligonucleotide as
1209	12.4	2.2	18	1	ADJ61652	IL-4Ra receptor #9
1210	12.4	2.2	18	1	ADO44672	Human oligonucleot
1211	12.4	2.2	18	1	ADO47043	Human oligonucleot
c1212	12.4	2.2	19	1	AAQ85824	Anti-mseICAM 2'-O-
c1213	12.4	2.2	19	1	AAT36525	Thermophilic Campy
1214	12.4	2.2	19	1	AAT79957	Immunoglobulin hea
1215	12.4	2.2	19	1	AAV27778	Monamine oxidase A
c1216	12.4	2.2	19	1	AAV49018	rb gene antisense
1217	12.4	2.2	19	1	AAZ01250	PCR primer for PG1
c1218	12.4	2.2	19	1	AAZ87048	RBP-7 microsequenc
1219	12.4	2.2	19	1	AAA82421	cdk1 ribozyme bind
1220	12.4	2.2	19	1	AAA84778	Cyclin F ribozyme
1221	12.4	2.2	19	1	AAZ71422	Human biallelic ma
1222	12.4	2.2	19	1	AAZ74732	Human biallelic ma
c1223	12.4	2.2	19	1	AAZ75405	Human biallelic ma
1224	12.4	2.2	19	1	AAZ73694	Human biallelic ma
1225	12.4	2.2	19	1	AAZ44184	Human neuropsin DN
1226	12.4	2.2	19	1	AAH59940	Cyclin F ribozyme
1227	12.4	2.2	19	1	AAH57583	Cell-cycle depende
1228	12.4	2.2	19	1	AAD38665	Human CDKN1A promo
c1229	12.4	2.2	19	1	ABS51273	Human CADPKL DNA P
c1230	12.4	2.2	19	1	ADF36876	Human VEGFR2 short
1231	12.4	2.2	19	1	ADF37200	Human VEGFR2 short
c1232	12.4	2.2	19	1	ADF71335	Protein tyrosine p
1233	12.4	2.2	19	1	ADF71261	Protein tyrosine p
c1234	12.4	2.2	19	1	ADF70357	ICAM antisense oli
c1235	12.4	2.2	19	1	ADG36105	HIV siNA oligonucl
1236	12.4	2.2	19	1	ADG35367	HIV siNA oligonucl
c1237	12.4	2.2	19	1	ADG36003	HIV siNA oligonucl
1238	12.4	2.2	19	1	ADG35265	HIV siNA oligonucl
1239	12.4	2.2	19	1	ADF84558	Human ABL1-targete
c1240	12.4	2.2	19	1	ADF84239	Human ABL1-targete
c1241	12.4	2.2	19	1	ADF84506	Human ABL1-targete
1242	12.4	2.2	19	1	ADF84825	Human ABL1-targete
1243	12.4	2.2	19	1	ABX77193	Mouse alpha-1-acid
c1244	12.2	2.2	17	1	AAQ36432	GRP-R primer (EXT
c1245	12.2	2.2	17	1	AAX74647	Mouse flt-1 VEGF r
1246	12.2	2.2	17	1	AAX74992	Mouse flt-1 VEGF r
1247	12.2	2.2	17	1	AAX75261	Mouse flt-1 VEGF r
1248	12.2	2.2	17	1	AAX75407	Mouse flt-1 VEGF r
1249	12.2	2.2	17	1	AAX72881	Mouse flk-1 VEGF r
1250	12.2	2.2	17	1	AAV97970	Human EGF-R target
1251	12.2	2.2	17	1	AAV97972	Human EGF-R target
1252	12.2	2.2	17	1	AAV97971	Human EGF-R target
1253	12.2	2.2	17	1	AAV95150	Canine IL-2 recept
c1254	12.2	2.2	17	1	AAA22484	Integrin subunit b
c1255	12.2	2.2	17	1	AAA22485	Integrin subunit b
1256	12.2	2.2	17	1	AAA23040	Integrin subunit b
1257	12.2	2.2	17	1	AAA20575	Integrin alpha 6 s
1258	12.2	2.2	17	1	AAA23041	Integrin subunit b
c1259	12.2	2.2	17	1	AAV91293	Human C-raf target
1260	12.2	2.2	17	1	AAV93691	Human B-raf substr
1261	12.2	2.2	17	1	AAA25379	Oestrogen receptor
1262	12.2	2.2	17	1	AAA25550	Oestrogen receptor
c1263	12.2	2.2	17	1	AAC70187	Single nucleotide
c1264	12.2	2.2	17	1	AAC70178	Single nucleotide
c1265	12.2	2.2	17	1	AAC70184	Single nucleotide
1266	12.2	2.2	17	1	AAF04549	Hammerhead ribozym
c1267	12.2	2.2	17	1	AAF07408	Hammerhead ribozym
c1268	12.2	2.2	17	1	AAF02869	Hammerhead ribozym
c1269	12.2	2.2	17	1	AAF06965	Hammerhead ribozym
1270	12.2	2.2	17	1	AAF02473	Hammerhead ribozym
c1271	12.2	2.2	17	1	AAF02650	Hammerhead ribozym
c1272	12.2	2.2	17	1	AAF04597	Hammerhead ribozym
c1273	12.2	2.2	17	1	AAF06328	Hammerhead ribozym
c1274	12.2	2.2	17	1	AAF02363	Hammerhead ribozym

1275	12.2	2.2	17	1	AAA97982	B. brevis NRPS gen
c1276	12.2	2.2	17	1	AAH95021	Human Chk1 ribozym
c1277	12.2	2.2	17	1	ABK03203	Human CD20 Inozyme
c1278	12.2	2.2	17	1	ABK02209	Human NOGO DNAzyme
c1279	12.2	2.2	17	1	ABK02206	Human NOGO DNAzyme
c1280	12.2	2.2	17	1	ABK01982	Human NOGO Zinzyme
1281	12.2	2.2	17	1	ABK00845	Human NOGO Inozyme
c1282	12.2	2.2	17	1	ABN02792	Human GDMLP-1 17-m
c1283	12.2	2.2	17	1	ABN10552	Human GDMLP-1 17-m
1284	12.2	2.2	17	1	ABN07964	Human GDMLP-1 17-m
c1285	12.2	2.2	17	1	ABN02116	Human GDMLP-1 17-m
1286	12.2	2.2	17	1	ABN07968	Human GDMLP-1 17-m
1287	12.2	2.2	17	1	ABV79921	Human HTPL scannin
1288	12.2	2.2	17	1	ABV79920	Human HTPL scannin
c1289	12.2	2.2	17	1	ABQ99673	Murine Ikbkap exon
c1290	12.2	2.2	17	1	ABK17691	Human ERG hammerhe
1291	12.2	2.2	17	1	ABV91218	Human POSHL1 scann
1292	12.2	2.2	17	1	ABV90240	Human POSHL1 scann
1293	12.2	2.2	17	1	ABK57390	Human CLCA1 gene e
1294	12.2	2.2	17	1	ABK56824	Human CLCA1 gene e
c1295	12.2	2.2	17	1	ABK56171	Human CLCA1 gene e
1296	12.2	2.2	17	1	ABK56480	Human CLCA1 gene e
1297	12.2	2.2	17	1	ABK56161	Human CLCA1 gene e
c1298	12.2	2.2	17	1	ABK56575	Human CLCA1 gene e
c1299	12.2	2.2	17	1	ABK56066	Human CLCA1 gene e
1300	12.2	2.2	17	1	ABK55996	Human CLCA1 gene e
1301	12.2	2.2	17	1	ACN07093	WNV Amberzyme subs
1302	12.2	2.2	17	1	ACN08703	WNV minus strand H
c1303	12.2	2.2	17	1	ACN11244	WNV minus strand I
1304	12.2	2.2	17	1	ACN09402	WNV minus strand H
1305	12.2	2.2	17	1	ACN09416	WNV minus strand H
c1306	12.2	2.2	17	1	ACN08986	WNV minus strand H
c1307	12.2	2.2	17	1	ACN14358	WNV minus strand A
c1308	12.2	2.2	17	1	ACN07705	WNV minus strand H
c1309	12.2	2.2	17	1	ACN11556	WNV minus strand I
1310	12.2	2.2	17	1	ACN03124	WNV Inozyme substr
1311	12.2	2.2	17	1	ACN04456	WNV Zinzyme substr
c1312	12.2	2.2	17	1	ACN06186	WNV Amberzyme subs
c1313	12.2	2.2	17	1	ACN09914	WNV minus strand I
c1314	12.2	2.2	17	1	ACN11555	WNV minus strand I
1315	12.2	2.2	17	1	ACN05926	WNV Amberzyme subs
c1316	12.2	2.2	17	1	ACD00530	G-protein coupled
c1317	12.2	2.2	17	1	ACD00895	G-protein coupled
c1318	12.2	2.2	17	1	ABT38163	Tumour suppression
c1319	12.2	2.2	17	1	ABT35153	Tumour suppression
c1320	12.2	2.2	17	1	ABT35973	Tumour suppression
c1321	12.2	2.2	17	1	ABT34449	Tumour suppression
c1322	12.2	2.2	17	1	ABT38381	Tumour suppression
1323	12.2	2.2	17	1	ABT39157	Tumour suppression
c1324	12.2	2.2	17	1	ABT35103	Tumour suppression
1325	12.2	2.2	17	1	ABT36551	Tumour suppression
c1326	12.2	2.2	17	1	ABT34619	Tumour suppression
1327	12.2	2.2	17	1	ABT34881	Tumour suppression
c1328	12.2	2.2	17	1	ABT40205	Tumour suppression
c1329	12.2	2.2	17	1	ACA07725	NFKB sub-unit modu
c1330	12.2	2.2	17	1	ADB00317	Human MDZ3 scannin
c1331	12.2	2.2	17	1	ADB00318	Human MDZ3 scannin
1332	12.2	2.2	17	1	ADB03129	Human MDZ4 scannin
1333	12.2	2.2	17	1	ABQ81025	Plasmid pXL3676-re
c1334	12.2	2.2	17	1	ABZ60237	Human K-Ras DNAzym
c1335	12.2	2.2	17	1	ABZ60496	Human K-Ras DNAzym
c1336	12.2	2.2	17	1	ABZ61926	Human H-Ras DNAzym
1337	12.2	2.2	17	1	ABZ60826	Human K-Ras DNAzym
c1338	12.2	2.2	17	1	ABZ61625	Human H-Ras DNAzym
1339	12.2	2.2	17	1	ABZ62022	Human H-Ras DNAzym
1340	12.2	2.2	17	1	ABZ60558	Human K-Ras DNAzym
1341	12.2	2.2	17	1	ABZ60559	Human K-Ras DNAzym
c1342	12.2	2.2	17	1	ACD61203	HCV DNAzyme substr
1343	12.2	2.2	17	1	ACD51463	HBV hammerhead rib
c1344	12.2	2.2	17	1	ACD60717	HCV DNAzyme substr
1345	12.2	2.2	17	1	ACD52099	HBV inozyme substr
c1346	12.2	2.2	17	1	ACD52395	HBV inozyme substr
c1347	12.2	2.2	17	1	ACC66076	Murine oligonucleo
c1348	12.2	2.2	17	1	ACC65570	Murine oligonucleo
1349	12.2	2.2	17	1	ACC65424	Murine oligonucleo
c1350	12.2	2.2	17	1	ACC66052	Murine oligonucleo
1351	12.2	2.2	17	1	ACC66777	Murine oligonucleo
1352	12.2	2.2	17	1	ACC68751	Murine oligonucleo
c1353	12.2	2.2	17	1	ADB41339	Tumour suppression
c1354	12.2	2.2	17	1	ADB42009	Tumour suppression
c1355	12.2	2.2	17	1	ADB43952	Tumour suppression
c1356	12.2	2.2	17	1	ADB41045	Tumour suppression
1357	12.2	2.2	17	1	ADB43429	Tumour suppression
1358	12.2	2.2	17	1	ADC04074	Human Na/H exchang
c1359	12.2	2.2	17	1	ADC04238	Human Na/H exchang
c1360	12.2	2.2	17	1	ADB45521	Tumour suppression
c1361	12.2	2.2	17	1	ADI47782	Human tumour suppr
1362	12.2	2.2	17	1	ADI52201	Human tumour suppr
1363	12.2	2.2	17	1	ADI49823	Human tumour suppr
c1364	12.2	2.2	17	1	ADI51713	Human tumour suppr
c1365	12.2	2.2	17	1	ADI47836	Human tumour suppr
c1366	12.2	2.2	17	1	ADI48705	Human tumour suppr
1367	12.2	2.2	17	1	ADI52158	Human tumour suppr
c1368	12.2	2.2	17	1	ACC53104	Human tumour suppr
1369	12.2	2.2	17	1	ACC52152	Human tumour suppr
c1370	12.2	2.2	17	1	ACC52822	Human tumour suppr
1371	12.2	2.2	17	1	ACC51346	Human tumour suppr
1372	12.2	2.2	17	1	ADK12619	Human NAC-1 gene-s
c1373	12.2	2.2	17	1	ADL48121	Human IKK-gamma su
1374	12.2	2.2	17	1	ADL49342	Human PKR substrat
1375	12.2	2.2	17	1	ADL49229	Human PKR substrat
1376	12.2	2.2	17	1	ADL49343	Human PKR substrat
c1377	12.2	2.2	17	1	ADL51440	Human PTGDR substr
1378	12.2	2.2	17	1	ADK13078	Human glioma endot
c1379	12.2	2.2	17	1	ADM58939	Hepatitis B virus
1380	12.2	2.2	17	1	ADM58471	Hepatitis B virus
1381	12.2	2.2	17	1	ADM58796	Hepatitis B virus
c1382	12.2	2.2	17	1	ADI84975	HCV DNAzyme substr
c1383	12.2	2.2	17	1	ADI84713	HCV DNAzyme substr
c1384	12.2	2.2	18	1	AAQ50936	T-cell antigen rec
1385	12.2	2.2	18	1	AAT07600	RT-PCR primer/prob
c1386	12.2	2.2	18	1	AAT04089	Trypsin inhibitory
c1387	12.2	2.2	18	1	AAQ79507	Beta-globulin intr
1388	12.2	2.2	18	1	AAT00672	Primer 230 for hum
1389	12.2	2.2	18	1	AAT50619	Human CETP hairpin
1390	12.2	2.2	18	1	AAX70283	Human flt1 VEGF re
1391	12.2	2.2	18	1	AAV40683	Primer BARJAP2R fo
c1392	12.2	2.2	18	1	AAV28198	Antisense oligonuc
c1393	12.2	2.2	18	1	AAV49126	rb gene antisense
1394	12.2	2.2	18	1	AAV94837	Human IL-2 recepto
c1395	12.2	2.2	18	1	AAZ21406	Human MEK2 antisen
c1396	12.2	2.2	18	1	AAZ24027	Human GDNF PCR pri
c1397	12.2	2.2	18	1	AAZ24033	Human GDNF PCR pri
1398	12.2	2.2	18	1	AAX14634	Triple helix formi
c1399	12.2	2.2	18	1	AAX18731	Target beta-thalas
c1400	12.2	2.2	18	1	AAZ34348	Nucleic acid-based
c1401	12.2	2.2	18	1	AAZ34354	Nucleic acid-based
c1402	12.2	2.2	18	1	AAZ34351	Nucleic acid-based
c1403	12.2	2.2	18	1	AAX23610	Deletion sequence
1404	12.2	2.2	18	1	AAZ37256	PCR primer for AV3
1405	12.2	2.2	18	1	AAD00239	Sense primer for m
c1406	12.2	2.2	18	1	AAA86579	Cdc 2 kinase hamme
1407	12.2	2.2	18	1	AAZ91416	Human Ship-2 phosp
1408	12.2	2.2	18	1	AAZ71436	Human biallelic ma
1409	12.2	2.2	18	1	AAZ74770	Human biallelic ma
c1410	12.2	2.2	18	1	AAZ73238	Human biallelic ma
c1411	12.2	2.2	18	1	AAZ49357	Beta-thalassaemia
1412	12.2	2.2	18	1	AAZ99357	Binding/non-bindin
1413	12.2	2.2	18	1	AAZ99359	Binding/non-bindin
1414	12.2	2.2	18	1	AAZ99360	Binding/non-bindin
1415	12.2	2.2	18	1	AAC73474	Reverse primer #10
c1416	12.2	2.2	18	1	AAC73430	Reverse primer #90
c1417	12.2	2.2	18	1	AAH61745	Cdc 2 kinase hamme
1418	12.2	2.2	18	1	ABK24076	B7-related protein
c1419	12.2	2.2	18	1	ABL43686	Human chromosome 1
c1420	12.2	2.2	18	1	ABL44451	Human chromosome 1

c1421	12.2	2.2	18	1	AAL46988	Sponge okadaic aci
1422	12.2	2.2	18	1	ABQ73424	Pre-trans-splicing
1423	12.2	2.2	18	1	ABQ73425	Pre-trans-splicing
1424	12.2	2.2	18	1	ABQ73422	Pre-trans-splicing
c1425	12.2	2.2	18	1	ABK98126	Triple helix formi
1426	12.2	2.2	18	1	ABZ10618	Haematopoietic cel
1427	12.2	2.2	18	1	ABZ10514	Haematopoietic cel
1428	12.2	2.2	18	1	ABZ10868	Haematopoietic cel
1429	12.2	2.2	18	1	ADA83712	Filament forming b
c1430	12.2	2.2	18	1	ABZ81503	PCR primer, SEQ ID
c1431	12.2	2.2	18	1	ADB54685	Hybridisation olig
1432	12.2	2.2	18	1	ADB54966	Hybridisation olig
1433	12.2	2.2	18	1	ADC15721	E. intestinalis sp
1434	12.2	2.2	18	1	ADC70155	Primer oligo used
1435	12.2	2.2	18	1	ADC70024	Primer oligo used
c1436	12.2	2.2	18	1	AAD59000	5' antisense RNA u
c1437	12.2	2.2	18	1	ADC45678	PCR primer, PSO 15
1438	12.2	2.2	18	1	ADE84386	Human lymphoid cel
1439	12.2	2.2	18	1	ADE84452	Human lymphoid cel
c1440	12.2	2.2	18	1	ADF13019	Human PCM1 exon 26
c1441	12.2	2.2	18	1	ADF78302	Chromosomal abnorm
c1442	12.2	2.2	18	1	ADH53107	Human APC (adenoma
1443	12.2	2.2	18	1	ADH89104	PCR primer #1for h
c1444	12.2	2.2	18	1	AAD50290	Cholesterol-conjug
c1445	12.2	2.2	18	1	AAD50294	Kole654, oligonucl
c1446	12.2	2.2	18	1	ADK96425	Primer of the inve
c1447	12.2	2.2	18	1	ADO47678	Antisense oligonuc
c1448	12.2	2.2	18	1	ADO47677	Antisense oligonuc
c1449	12.2	2.2	18	1	ADO47680	Antisense oligonuc
c1450	12.2	2.2	18	1	ADO47679	Antisense oligonuc
c1451	12.2	2.2	18	1	ADO47676	Antisense oligonuc
c1452	12.2	2.2	18	1	ADO47675	Antisense oligonuc
c1453	12.2	2.2	18	1	ADO16641	4 synthesis-period
1454	12.2	2.2	18	1	ADQ17040	Drosophila melanog

ALIGNMENTS

```
RESULT 1
AAL62320/c
ID   AAL62320 standard; DNA; 20 BP.
XX
AC   AAL62320;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128174.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1733 TCAGAAGGTGACAAGTACTG 1752
              ||||||||||||||||||||
Db         20 TCAGAAGGTGACAAGTACTG 1

RESULT 2
AAL62325/c
ID   AAL62325 standard; DNA; 20 BP.
XX
AC   AAL62325;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128179.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
```

```
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM, Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Example 15; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGGCAAAGG 2040
              ||||||||||||||||||||
Db         20 CCTCTGGTAGGAGGCAAAGG 1


RESULT 3
AAL62327/c
ID   AAL62327 standard; DNA; 20 BP.
XX
AC   AAL62327;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128181.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM, Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2068 AGTGGTATCTGACACACTCT 2087
              ||||||||||||||||||||
Db         20 AGTGGTATCTGACACACTCT 1


RESULT 4
AAL62316/c
ID   AAL62316 standard; DNA; 20 BP.
XX
AC   AAL62316;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128170.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
```

```
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Example 15; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 3 A; 8 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGAGAGTA 1548
              ||||||||||||||||||||
Db         20 GAAGAAAGGTTAGGAGAGTA 1


RESULT 5
AAL62319/c
ID   AAL62319 standard; DNA; 20 BP.
XX
AC   AAL62319;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128173.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 8 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1712 CTCCTAACTTTGGACCTATT 1731
              ||||||||||||||||||||
Db         20 CTCCTAACTTTGGACCTATT 1


RESULT 6
AAL62323/c
ID   AAL62323 standard; DNA; 20 BP.
XX
```

```
AC   AAL62323;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128177.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 6 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1864 ACACTTAGCCATTGAAATGT 1883
              ||||||||||||||||||||
Db         20 ACACTTAGCCATTGAAATGT 1

RESULT 7
AAL62317/c
ID   AAL62317 standard; DNA; 20 BP.
XX
AC   AAL62317;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128171.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 5 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
```

```
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1564 TGCAAAAATCCTTCTCCACC 1583
              ||||||||||||||||||||
Db         20 TGCAAAAATCCTTCTCCACC 1


RESULT 8
AAL62321/c
ID   AAL62321 standard; DNA; 20 BP.
XX
AC   AAL62321;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128175.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 9 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1751 TGGCTCTTTATTCATTAAGC 1770
              ||||||||||||||||||||
Db         20 TGGCTCTTTATTCATTAAGC 1


RESULT 9
AAL62324/c
ID   AAL62324 standard; DNA; 20 BP.
XX
AC   AAL62324;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128178.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
```

```
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 6 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1877 GAAATGTCAAATTGATGTGC 1896
              ||||||||||||||||||||
Db         20 GAAATGTCAAATTGATGTGC 1


RESULT 10
AAL62326/c
ID   AAL62326 standard; DNA; 20 BP.
XX
AC   AAL62326;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128180.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2029 AGGAGGCAAAGGTTCTATCT 2048
              ||||||||||||||||||||
Db         20 AGGAGGCAAAGGTTCTATCT 1


RESULT 11
AAL62318/c
ID   AAL62318 standard; DNA; 20 BP.
XX
AC   AAL62318;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128172.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
```

```
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Claim 3; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1645 AGAGCCTTCACTGGTTCTGC 1664
             ||||||||||||||||||||
Db         20 AGAGCCTTCACTGGTTCTGC 1


RESULT 12
AAL62322/c
ID   AAL62322 standard; DNA; 20 BP.
XX
AC   AAL62322;
XX
DT   06-OCT-2003  (first entry)
XX
DE   Human transcription factor-2 gamma antisense oligo, ISIS 128176.
XX
KW   Transcription factor-2 gamma; TFAP2C; AP-2 gamma; AP2-gamma; AP-2.2;
KW   Stra2; activating enhancer-binding protein 2 gamma; antisense therapy;
KW   oestrogen receptor factor-1; ERF-1; hyperproliferative disorder; cancer;
KW   breast; colon; developmental disorder; human; phosphorothioate backbone;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003051308-A2.
XX
PD   26-JUN-2003.
XX
PF   12-DEC-2002; 2002WO-US040100.
XX
PR   17-DEC-2001; 2001US-00023782.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Freier SM;
XX
DR   WPI; 2003-569107/53.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   transcription factor-2 gamma, useful for inhibiting expression of the
PT   nucleic acid, and for treating cancer e.g. breast cancer or colon cancer.
XX
PS   Example 15; Page 80; 107pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of transcription factor-2 gamma (TFAP2C).
CC   TFAP2C is also known as AP-2 gamma, AP2-gamma, AP-2.2, Stra2, activating
CC   enhancer-binding protein 2 gamma, oestrogen receptor factor-1 and ERF-1.
CC   The invention is useful for inhibiting the expression of TFAP2C in cells
CC   or tissues. It is useful for treating an animal having a disease or
CC   condition associated with TFAP2C, e.g., a hyperproliferative disorder
CC   such as cancer e.g. breast cancer or colon cancer and a developmental
CC   disorder. The invention is also useful for diagnostics, therapeutics,
CC   prophylaxis and as research reagents and kits. It is also used in
CC   antisense therapy. The present sequence is an antisense oligonucleotide
CC   targetted to human TFAP2C DNA. This sequence is used to illustrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 8 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             3.6%;  Score 20;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 15;
  Matches   20;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTCCC 1846
             ||||||||||||||||||||
Db         20 AATCTTTTAAATACATTCCC 1


RESULT 13
AAZ28229
ID   AAZ28229 standard; DNA; 23 BP.
XX
AC   AAZ28229;
XX
DT   20-DEC-1999  (first entry)
XX
DE   Second round PCR primer #5 for amplifying gene trapped cDNA.
XX
KW   Gene trapping; splicing; integration; mutation; genome; intron; exon;
KW   splice acceptor; identification; reverse transcription; ss.
XX
OS   Synthetic.
XX
PN   WO9950426-A1.
XX
PD   07-OCT-1999.
XX
PF   26-MAR-1999;   99WO-US006474.
XX
PR   27-MAR-1998;   98US-0079729P.
PR   08-APR-1998;   98US-00057328.
PR   14-APR-1998;   98US-0081727P.
XX
PA   (LEXI-) LEXICON GENETICS INC.
XX
PI   Zambrowicz B,  Friedrich GA,  Sands AT;
XX
DR   WPI; 1999-591324/50.
XX
PT   New gene trapping vectors, useful for identifying, activating or mutating
PT   genes in eukaryotic cells.
XX
PS   Example 2; Page 53; 74pp; English.
```

XX
CC This sequence represents a PCR primer, #5, used in a second round of PCR
CC amplification of a cDNA. The cDNA had previously been amplified by a
CC first round of PCR from cDNA produced by reverse transcription of RNA
CC which had been generated after 3' gene trapping. The amplified cDNA was
CC then sequenced to obtain the gene trapped sequence. Such gene trapping
CC can be used to acquire novel sequence information from the trapped exons,
CC useful to identify new genes and in screening e.g., to identify the
CC genetic basis of diseases (such as cancer) or phenotypes, especially in
CC the analysis of single nucleotide polymorphisms. The vector can also be
CC introduced into a cell to activate expression of a naturally occurring
CC cellular gene, useful to study gene function. They can be used to produce
CC mutated cells or animals, and are useful in screening, for example, to
CC identify mutations associated with tumorigenic phenotypes. They can also
CC be used to create cDNA libraries of cells, useful for large scale genetic
CC analysis of the genome and to identify novel and mutated genes. The
CC vectors are more efficient (e.g., their use identified 13-fold more
CC genes) than conventional 3' gene trap vectors that rely on gene trapping
CC as detected by antibiotic selection. Use of vectors incorporating 5' gene
CC trap cassettes increase the probability of identifying the 5' ends of
CC gene open reading frames, important because these are difficult to obtain
CC by conventional methods, and often code for the signal sequence in
CC secreted and transmembrane proteins, an important group for potential
CC drug targets
XX
SQ Sequence 23 BP; 7 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 3.3%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 40;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1999 CTAGCTTCTTCAGAGATCAAGTC 2021
| || ||||||||||||||||||
Db 1 CCAGAGTCTTCAGAGATCAAGTC 23

RESULT 14
AAA29299
ID AAA29299 standard; DNA; 23 BP.
XX
AC AAA29299;
XX
DT 12-SEP-2000 (first entry)
XX
DE Second round primer Btk-i for 3' gene trapped cDNA from ES cells.
XX
KW Splice acceptor; vector; gene trap; gene discovery; cloning; analysis;
KW shuttling; gene activation; over-expression; primer; 3' gene trap;
KW embryonic stem cell; ES; ss.
XX
OS Synthetic.
XX
PN WO200031236-A2.
XX
PD 02-JUN-2000.
XX
PF 19-NOV-1999; 99WO-US027366.
XX
PR 20-NOV-1998; 98US-0109302P.
PR 25-MAR-1999; 99US-00276533.
XX
PA (LEXI-) LEXICON GENETICS INC.
XX
PI Zambrowicz B, Friedrich GA, Lilleberg S, Sands AT;
XX
DR WPI; 2000-400053/34.
XX
PT Recombinant vectors for use in, for example, gene discovery, gene cloning
PT and gene mutation.
XX
PS Example 2; Page 62; 78pp; English.
XX
CC A 3' gene trapping vector was constructed containing the murine
CC phosphoglycerate kinase (PGK) gene promoter, the first exon of the murine
CC btk gene (nucleotides 40043-40250) and a splice donor (SD) sequence. The
CC PGKbtkSD vector lacks a 3' polyadenylation signal. Any transcript
CC produced by the cassette cannot be properly processed, and therefore
CC identified by 3' RACE, unless it is spliced to a 3' exon that can be
CC polyadenylated. The btk vector was introduced into embryonic stem cells
CC and G418 resistant cells were subsequently isolated and subjected to RNA
CC isolation, reverse transcription, PCR and sequencing to obtain the gene
CC trapped sequences. The claimed genetically engineered vectors comprise 5'
CC and 3' gene trap cassettes. The vectors incorporate structural elements
CC which, after integration into the host cell genome, enhance the number of
CC cellular genes that can be identified and mutated. A 5' gene trap
CC cassette comprises a splice acceptor (SA), an exon sequence (Ex1) located
CC 3' to the SA, which encodes a marker enabling the identification of a
CC cell expressing the exon and a polyadenylation sequence defining the 3'
CC end of Ex1. The vectors may be used for gene discovery, gene cloning,
CC gene mutation, gene regulation, shuttling nucleic acid sequences
CC throughout the genome and gene activation and over expression. The
CC vectors can be used to trap genes with a high level of efficiency
CC regardless of whether the genes are normally expressed in the cell type
CC into which the vector is incorporated. Cells harboring the vectors can be
CC screened using automated gene identification assays such as 3' RACE.
CC Using these vectors, it is possible to produce large numbers of mutations
CC and rapidly identify the mutated or trapped genes
XX
SQ Sequence 23 BP; 7 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 3.3%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 40;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1999 CTAGCTTCTTCAGAGATCAAGTC 2021
| || ||||||||||||||||||
Db 1 CCAGAGTCTTCAGAGATCAAGTC 23

RESULT 15
ADF65678/c
ID ADF65678 standard; DNA; 25 BP.
XX
AC ADF65678;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human HTR2A polymorphism containing DNA fragment #3.
XX
KW ds; nucleic acid sequence variation; single-nucleotide polymorphism;
KW human; genetic disease; sickle cell anaemia; diabetes;
KW Alzheimer's disease; Huntington's disease; breast cancer; retinoblastoma;
KW cystic fibrosis; Factor VIII haemophilia;
KW Duchenne/Becker muscular dystrophy; Type 1 von Willebrand disease;
KW familial Alzheimer's disease; familial hypercholesterolaemia;
KW low-density lipoprotein receptor related disease.
XX
OS Homo sapiens.
XX
PN US2003157507-A1.
XX
PD 21-AUG-2003.
XX
PF 25-JUL-2002; 2002US-00206561.
XX
PR 31-JAN-2002; 2002US-0353941P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Lipsky RH, Mazzanti CM, Goldman D;
XX
DR WPI; 2003-777988/73.
XX
PT Detecting a nucleic acid sequence variation comprises detecting a
PT difference between the melting profiles of two double-stranded nucleic
PT acids or amplicons.

```
XX
PS   Example 1; SEQ ID NO 3; 35pp; English.
XX
CC   The invention relates to a method of detecting a nucleic acid sequence
CC   variation. The method is useful for detecting single-nucleotide
CC   polymorphisms or insertions or deletions of less than 10 bases in
CC   mammalian DNA (especially human), where the insertion or deletion is less
CC   than 5 % of the total sequence of the nucleic acid, in order to diagnose
CC   genetic diseases, especially sickle cell anaemia, diabetes, Alzheimer's
CC   disease, Huntington's disease, breast cancer, retinoblastoma, cystic
CC   fibrosis, Factor VIII haemophilia, Duchenne/Becker muscular dystrophy,
CC   Type 1 von Willebrand disease, familial Alzheimer's disease, familial
CC   hypercholesterolaemia, or a disease resulting from a mutation in nucleic
CC   acid encoding the low-density lipoprotein receptor. The present sequence
CC   represents a polymorphism containing DNA fragment of human HTR2A.
XX
SQ   Sequence 25 BP; 8 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             3.1%;  Score 17.2;  DB 1;  Length 25;
  Best Local Similarity   86.4%;  Pred. No. 71;
  Matches   19;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATCAAGTC 2021
              |||||||| ||||| | |||||
Db         23 TAGCTTCTCCAGAGTTAAAGTC 2

RESULT 16
AAS06803/c
ID   AAS06803 standard; DNA; 25 BP.
XX
AC   AAS06803;
XX
DT   12-SEP-2001  (first entry)
XX
DE   Protein kinase cDNA PCR primer #26.
XX
KW   Human; protein kinase; PTK; STK; cancer; cardiovascular disease;
KW   metabolic disorder; immune related disease; neurological disorder;
KW   neurodegenerative disorder; inflammatory disorder; infectious disease;
KW   reproductive disorder; gene therapy; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200138503-A2.
XX
PD   31-MAY-2001.
XX
PF   22-NOV-2000; 2000WO-US032085.
XX
PR   24-NOV-1999;   99US-0167482P.
XX
PA   (SUGE-) SUGEN INC.
XX
PI   Plowman GD,  Whyte D,  Manning G,  Sudarsanam S,  Martinez R;
PI   Flanagan P,  Clary D;
XX
DR   WPI; 2001-343950/36.
XX
PT   Nucleic acids encoding human kinase polypeptides, useful for preventing
PT   diagnosing and/or treating e.g. cancer, immune, cardiovascular and
PT   neuronal-associated diseases, and microbial infections.
XX
PS   Example 2C; Page 298; 433pp; English.
XX
CC   AAS06778-AAS06827 represent PCR primers used to amplify human cDNA
CC   sequences encoding for novel protein kinases (AAU03501-AAU03557). The
CC   novel protein kinases have been identified as members of the tyrosine or
CC   serine/threonine kinase (PTK and STK) families. The polynucleotides
CC   encoding protein kinases and the polypeptides may be used in the
CC   prevention, diagnosis and treatment of diseases associated with
CC   inappropriate kinase expression. For example, they may be used to treat
CC   cancers (especially cancers of haematopoietic origin), cardiovascular
CC   disease (e.g. atherosclerosis), metabolic disorders (e.g. diabetes),
CC   immune related diseases (e.g. rheumatoid arthritis), neurological
CC   disorders (e.g. schizophrenia), neurodegenerative disorders (e.g.
CC   Parkinson's disease), inflammatory disorders (e.g. asthma), infectious
CC   disease (e.g. HIV) and reproductive disorders (e.g. infertility).
CC   Additionally, polynucleotides encoding protein kinases may be used for
CC   gene therapy and as DNA probes in diagnostic assays. The protein kinase
CC   polypeptides may be used as antigens in the production of antibodies
CC   against the protein kinases and in assays to identify modulators of
CC   protein kinase expression and activity
XX
SQ   Sequence 25 BP; 12 A; 1 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 78;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              |||||||||||||||||
Db         19 CCCATTCTTTCCTTCTC 3

RESULT 17
ACI03338/c
ID   ACI03338 standard; DNA; 25 BP.
XX
AC   ACI03338;
XX
DT   13-OCT-2003  (first entry)
XX
DE   Human microarray DNA oligonucleotide SEQ ID NO 3329.
XX
KW   EST; ss; probe; expressed sequence tag; microarray; gene expression;
KW   genetic variation; biallelic marker; polymorphism; human;
KW   cross-species comparison.
XX
OS   Homo sapiens.
XX
PN   US2003104410-A1.
XX
PD   05-JUN-2003.
XX
PF   15-MAR-2002; 2002US-00098263.
XX
PR   16-MAR-2001; 2001US-0276759P.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Mittmann MP;
XX
DR   WPI; 2003-567953/53.
XX
PT   New array of nucleic acid probes, useful for in situ hybridization, in
PT   Southern, Northern or dot-blot hybridization to identify or detect the
PT   sequence or specific mutations of any gene.
XX
PS   Claim 1; SEQ ID NO 3329; 9pp; English.
XX
CC   The invention discloses a microarray comprising a plurality of nucleic
CC   acid probes including one of 2,018,500 fully defined sequences, or its
CC   perfect match, perfect mismatch, antisense match or antisense mismatch.
CC   Also disclosed is a method of gene expression analysis. The array is used
CC   in monitoring gene expression levels by hybridisation to a DNA library,
CC   in analysis of genetic variation or in hybridisation of tag-labelled
CC   compounds. The nucleic acid probes are specifically designed for analysis
CC   of at least one target sequence. The method of analysis comprises
CC   hybridising at least one or more nucleic acids to at least two or more
CC   nucleic acid probes and detecting the hybridisation. The nucleic acid
CC   probes are attached to a solid support. The analysis comprises monitoring
CC   gene expression levels, identifying biallelic markers or polymorphisms,
CC   or family members of a gene and a cross-species comparison. Each of the
CC   nucleic acids further comprises a tag sequence. The array of nucleic acid
CC   probes is useful in in situ hybridisation, in Southern, Northern or dot-
```

```
CC   blot hybridisation to identify or detect the sequence or specific
CC   mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC   primer extensions or in screening cDNA or genomic libraries or subclones
CC   for additional subclones containing segments of DNA that have been
CC   isolated and previously sequenced. The sequence presented is one of the
CC   nucleic acid probes incorporated in the microarray. Note: The sequence
CC   data for this patent can also be obtained in electronic format directly
CC   from USPTO at seqdata.uspto.goc/sequence.html
XX
SQ   Sequence 25 BP; 3 A; 9 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 78;
  Matches   20;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGGAAGGAACAG 1560
              ||||| || | |||||| ||| |||
Db         25 GGTTACGACAATAGGGACGGACCAG 1


RESULT 18
ACI62001
ID   ACI62001 standard; DNA; 25 BP.
XX
AC   ACI62001;
XX
DT   13-OCT-2003  (first entry)
XX
DE   Human microarray DNA oligonucleotide SEQ ID NO 61992.
XX
KW   EST; ss; probe; expressed sequence tag; microarray; gene expression;
KW   genetic variation; biallelic marker; polymorphism; human;
KW   cross-species comparison.
XX
OS   Homo sapiens.
XX
PN   US2003104410-A1.
XX
PD   05-JUN-2003.
XX
PF   15-MAR-2002; 2002US-00098263.
XX
PR   16-MAR-2001; 2001US-0276759P.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Mittmann MP;
XX
DR   WPI; 2003-567953/53.
XX
PT   New array of nucleic acid probes, useful for in situ hybridization, in
PT   Southern, Northern or dot-blot hybridization to identify or detect the
PT   sequence or specific mutations of any gene.
XX
PS   Claim 1; SEQ ID NO 61992; 9pp; English.
XX
CC   The invention discloses a microarray comprising a plurality of nucleic
CC   acid probes including one of 2,018,500 fully defined sequences, or its
CC   perfect match, perfect mismatch, antisense match or antisense mismatch.
CC   Also disclosed is a method of gene expression analysis. The array is used
CC   in monitoring gene expression levels by hybridisation to a DNA library,
CC   in analysis of genetic variation or in hybridisation of tag-labelled
CC   compounds. The nucleic acid probes are specifically designed for analysis
CC   of at least one target sequence. The method of analysis comprises
CC   hybridising at least one or more nucleic acids to at least two or more
CC   nucleic acid probes and detecting the hybridisation. The nucleic acid
CC   probes are attached to a solid support. The analysis comprises monitoring
CC   gene expression levels, identifying biallelic markers or polymorphisms,
CC   or family members of a gene and a cross-species comparison. Each of the
CC   nucleic acids further comprises a tag sequence. The array of nucleic acid
CC   probes is useful in in situ hybridisation, in Southern, Northern or dot-
CC   blot hybridisation to identify or detect the sequence or specific
CC   mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC   primer extensions or in screening cDNA or genomic libraries or subclones
CC   for additional subclones containing segments of DNA that have been
CC   isolated and previously sequenced. The sequence presented is one of the
CC   nucleic acid probes incorporated in the microarray. Note: The sequence
CC   data for this patent can also be obtained in electronic format directly
CC   from USPTO at seqdata.uspto.goc/sequence.html
XX
SQ   Sequence 25 BP; 4 A; 4 C; 6 G; 11 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 78;
  Matches   20;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTGTTAAGGT 1941
              | || | | |||||||||||| ||||
Db          1 AGACTTGTCTTTTCAGTGTTCAGGT 25


RESULT 19
ACI02702/c
ID   ACI02702 standard; DNA; 25 BP.
XX
AC   ACI02702;
XX
DT   13-OCT-2003  (first entry)
XX
DE   Human microarray DNA oligonucleotide SEQ ID NO 2693.
XX
KW   EST; ss; probe; expressed sequence tag; microarray; gene expression;
KW   genetic variation; biallelic marker; polymorphism; human;
KW   cross-species comparison.
XX
OS   Homo sapiens.
XX
PN   US2003104410-A1.
XX
PD   05-JUN-2003.
XX
PF   15-MAR-2002; 2002US-00098263.
XX
PR   16-MAR-2001; 2001US-0276759P.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Mittmann MP;
XX
DR   WPI; 2003-567953/53.
XX
PT   New array of nucleic acid probes, useful for in situ hybridization, in
PT   Southern, Northern or dot-blot hybridization to identify or detect the
PT   sequence or specific mutations of any gene.
XX
PS   Claim 1; SEQ ID NO 2693; 9pp; English.
XX
CC   The invention discloses a microarray comprising a plurality of nucleic
CC   acid probes including one of 2,018,500 fully defined sequences, or its
CC   perfect match, perfect mismatch, antisense match or antisense mismatch.
CC   Also disclosed is a method of gene expression analysis. The array is used
CC   in monitoring gene expression levels by hybridisation to a DNA library,
CC   in analysis of genetic variation or in hybridisation of tag-labelled
CC   compounds. The nucleic acid probes are specifically designed for analysis
CC   of at least one target sequence. The method of analysis comprises
CC   hybridising at least one or more nucleic acids to at least two or more
CC   nucleic acid probes and detecting the hybridisation. The nucleic acid
CC   probes are attached to a solid support. The analysis comprises monitoring
CC   gene expression levels, identifying biallelic markers or polymorphisms,
CC   or family members of a gene and a cross-species comparison. Each of the
CC   nucleic acids further comprises a tag sequence. The array of nucleic acid
CC   probes is useful in in situ hybridisation, in Southern, Northern or dot-
CC   blot hybridisation to identify or detect the sequence or specific
CC   mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC   primer extensions or in screening cDNA or genomic libraries or subclones
CC   for additional subclones containing segments of DNA that have been
```

```
CC   isolated and previously sequenced. The sequence presented is one of the
CC   nucleic acid probes incorporated in the microarray. Note: The sequence
CC   data for this patent can also be obtained in electronic format directly
CC   from USPTO at seqdata.uspto.goc/sequence.html
XX
SQ   Sequence 25 BP; 3 A; 8 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   80.0%;  Pred. No. 78;
  Matches   20;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGGGAAGGAACA 1559
              |||||| || | |||||| ||| ||
Db         25 AGGTTACGACAATAGGGACGGACCA 1


RESULT 20
AAT76021/c
ID   AAT76021 standard; DNA; 21 BP.
XX
AC   AAT76021;
XX
DT   16-SEP-1997  (first entry)
XX
DE   DEN-2 cloning/sequencing antisense primer, cD2-10261.
XX
KW   Dengue 2 virus; polyprotein; capsid; prM; M; E; NS1; NS2A; NS2B; NS3;
KW   NS4A; NS4B; NS5; PDK-53; quadravalent vaccine; immunity; serotype;
KW   chimeric DEN-2/1 virus; chimeric DEN-2/3 virus; chimeric DEN-2/4 virus;
KW   dengue fever; fatal dengue haemorrhagic fever; dengue shock syndrome;
KW   DHF; DSS; PCR; amplify; polymerase chain reaction; primer; ss.
XX
OS   Synthetic.
XX
PN   WO9640933-A1.
XX
PD   19-DEC-1996.
XX
PF   06-JUN-1996;   96WO-US009209.
XX
PR   07-JUN-1995;   95US-00483292.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
PA   (UYMA-) UNIV MAHIDOL AT SALAYA.
XX
PI   Bhamarapravati N,  Butrapet S,  Chang J,  Gubler DJ,  Halstead SB;
PI   Kinney R,  Trent DW;
XX
DR   WPI; 1997-052330/05.
XX
PT   PDK-53, a clone of infectious attenuated Dengue 2 virus strain 16681 -
PT   also chimeric DEN-2/1, DEN-2/3 and DEN-1/4 viruses, used as a
PT   quadravalent vaccine for protecting against Dengue virus infection.
XX
PS   Example; Page 104; 261pp; English.
XX
CC   The sequences given in AAT75909-T76029 are primers which were used in the
CC   amplification, cloning and sequencing of the Dengue-2 viral cDNA's of the
CC   invention. The Dengue 2 viral DNA encodes a polyprotein which comprises
CC   the capsid, prM, M, E, NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 proteins.
CC   The quadravalent vaccine of the invention comprises an attenuated Dengue
CC   virus clone, PDK-53, and a chimeric DEN-2/1 virus, a chimeric DEN-2/3
CC   virus, and/or a chimeric DEN-2/4 virus. The new quadravalent vaccines are
CC   used to protect against infection by all four serotypes of dengue virus,
CC   DEN-1, DEN-2, DEN-3 and DEN-4, which can lead to dengue fever or fatal
CC   dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Host cells are
CC   used to produce the recombinant protein products of the DNA constructs
CC   which are used in the vaccines
XX
SQ   Sequence 21 BP; 4 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.8;  DB 1;  Length 21;
  Best Local Similarity   90.0%;  Pred. No. 76;
  Matches   18;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2019 GTCCTCTGGTAGGAGGCAAA 2038
              ||||| |||||| |||||||
Db         21 GTCCTGTGGTAGAAGGCAAA 2


RESULT 21
ADN12041
ID   ADN12041 standard; DNA; 23 BP.
XX
AC   ADN12041;
XX
DT   17-JUN-2004  (first entry)
XX
DE   Primer of the invention #8.
XX
KW   tumor; Cytostatic; metastatic; cancer; lymph node metastasis;
KW   intestinal-type gastric cancer; ss; primer.
XX
OS   Synthetic.
XX
PN   WO2004007770-A2.
XX
PD   22-JAN-2004.
XX
PF   08-JUL-2003; 2003WO-JP008651.
XX
PR   10-JUL-2002; 2002US-0394941P.
XX
PA   (ONCO-) ONCOTHERAPY SCI INC.
PA   (UYTY ) UNIV TOKYO.
XX
PI   Nakamura Y,  Furukawa Y;
XX
DR   WPI; 2004-156536/15.
XX
PT   Determining whether a tumor is metastatic, useful for distinguishing
PT   malignant from non-malignant tissue or early stage cancers from
PT   metastatic cancers comprises comparing level of expression of a gene in
PT   the tumor to a control value.
XX
PS   Example; SEQ ID NO 11; 63pp; English.
XX
CC   The present invention relates to determining whether a tumor is
CC   metastatic comprises comparing the level of expression of a gene in the
CC   tumor compared to a control value, where an increase or decrease in the
CC   level of expression in the tumor compared to the control value indicates
CC   that the tumor is metastatic. The method is useful for determining
CC   whether a tumor is metastatic. The method is useful for distinguishing
CC   malignant from non-malignant tissue as well as early stage cancers from
CC   metastatic cancers, particularly those that have undergone lymph node
CC   metastasis. The method is useful for diagnosing intestinal-type gastric
CC   cancer in a subject, for predicting lymph node-negative cancers and lymph
CC   node-positive cancers, useful in screening for a therapeutic agent useful
CC   in treating or preventing intestinal-type gastric cancer, useful for
CC   treating or preventing intestinal-type gastric cancer in a subject. The
CC   method is a sensitive, reliable and powerful tool that facilitates
CC   sensitive, specific and precise diagnosis of intestinal-type gastric
CC   tumors. The present sequence represents a primer of the invention.
XX
SQ   Sequence 23 BP; 7 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 90;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTGCAAAAAT 1572
              ||||||| |||||||||   | ||
Db          1 GGAAGGACCAGGACTGCTCATAT 23


RESULT 22
```

```
ADO57397
ID   ADO57397 standard; DNA; 23 BP.
XX
AC   ADO57397;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Kidney developmenprotein expression associated primer #4.
XX
KW   nephrotropic; cardiant; antiinfertility; cerebroprotective;
KW   neuroprotective; muscular; cytostatic; osteopathic; gene therapy;
KW   kidney development; kidney disorder; developmental disorder;
KW   circulatory disorder; hearing disorder; heart defect; infertility;
KW   stroke; mental retardation; muscle defect; proliferative disorder;
KW   bone defect; bone disorder; PCR; primer; ss; packaging cell line; RAGI.
XX
OS   Unidentified.
XX
PN   US2004068763-A1.
XX
PD   08-APR-2004.
XX
PF   28-MAR-2003; 2003US-00403571.
XX
PR   29-MAR-2002; 2002US-0368760P.
XX
PA   (HOPK/) HOPKINS N.
PA   (GOLL/) GOLLING G.
PA   (AMST/) AMSTERDAM A.
PA   (SUNZ/) SUN Z.
XX
PI   Hopkins N,  Golling G,  Amsterdam A,  Sun Z;
XX
DR   WPI; 2004-304692/28.
XX
PT   New 459 nucleic acids and encoded polypeptides, useful for diagnosing,
PT   treating or preventing a kidney disorder in an organism, or in screening
PT   for compounds that modulate the development of an organism.
XX
PS   Disclosure; Page 82; 347pp; English.
XX
CC   The invention describes an isolated nucleic acid molecule (I) comprising
CC   a sequence having at least 75% sequence identity to the 459 nucleic acid
CC   sequence of 2808 base pairs (SEQ ID NO: 59) given in the specification,
CC   over at least 600 contiguous base pairs, where the nucleic acid functions
CC   in kidney development. (I) is useful for treating or preventing a kidney
CC   disorder in an organism, where the nucleic acid elicits an alteration in
CC   expression of a 459 nucleic acid sequence in the organism and
CC   subsequently treats or prevents a kidney disorder. The nucleic acid may
CC   also be used in diagnosing, preventing and treating a variety of
CC   mammalian diseases and developmental disorders (e.g. circulatory
CC   disorders, hearing disorders, heart defect, infertility, stroke, mental
CC   retardation, muscle defects, proliferative disorders, or bone defects or
CC   disorders) as well as in screening for compounds that modulate the
CC   development of an organism as a whole or of specific tissues or organs
CC   within that organism. This sequence represents a primer used to identify
CC   zebrafish embryos comprising altered kidney development proteins by
CC   detection of RAGI sequences.
XX
SQ   Sequence 23 BP; 3 A; 5 C; 6 G; 9 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 90;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTAGCGCTGA 1706
              ||||||| ||||| || | |||
Db          1 CTTAGTTGCTTCTCCAGGGTTGA 23


RESULT 23
AAF84874
ID   AAF84874 standard; cDNA; 24 BP.
XX
AC   AAF84874;
XX
DT   09-JUL-2001  (first entry)
XX
DE   Sequence of the acceptor site of intron/exon border of exon 5.
XX
KW   Human; SPG4 gene; spastin; PSF-AD; gene therapy; probe;
KW   autosomal dominant familial spastic paraplegia; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   FR2798138-A1.
XX
PD   09-MAR-2001.
XX
PF   03-SEP-1999;   99FR-00011097.
XX
PR   03-SEP-1999;   99FR-00011097.
XX
PA   (CNRS ) CNRS CENT NAT RECH SCI.
XX
PI   Weissenbach J,  Hazan J;
XX
DR   WPI; 2001-283966/30.
XX
PT   New human nucleic acid from the SPG4 gene, useful e.g. for diagnosis of
PT   autosomal dominant familial spastic paraplegia and in drug screening.
XX
PS   Claim 6; Page 30; 145pp; French.
XX
CC   AAF84871-AAF84902 represent the acceptor and donor sites of the
CC   intron/exon and exon/intron borders of the human SPG4 gene. The SPG4 gene
CC   encodes a spastin polypeptide. The sequences may be used as PCR primers
CC   and probes. Mutations in the SPG4 gene are responsible for autosomal
CC   dominant familial spastic paraplegia. SPG4 polynucleotides, and their
CC   fragments, are used to screen DNA banks for sequences that encode spastin
CC   (particularly sequences in other mammals, specifically mice); to identify
CC   SPG4 mutations, or other genetic anomalies, particularly for diagnosis of
CC   autosomal dominant familial spastic paraplegia (PSF-AD); to identify
CC   promoters and other regulatory elements of the SPG4 gene; for detection
CC   and amplification; for recombinant production of spastin; and for
CC   diagnostic genotyping of PSF-AD
XX
SQ   Sequence 24 BP; 6 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 24;
  Best Local Similarity   82.6%;  Pred. No. 93;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGAAAGTGG 1811
              | | ||||||| || ||||||||
Db          1 ACTTTTTCCTTGTCAGAAAGTGG 23


RESULT 24
AAX07505
ID   AAX07505 standard; DNA; 25 BP.
XX
AC   AAX07505;
XX
DT   08-JUN-1999  (first entry)
XX
DE   Synthetic IDDMK1.2-22 PCR primer.
XX
KW   IDDM; insulin-dependent diabetes mellitus; endogenous retrovirus; SAg;
KW   superantigen; provirus; autoimmune disease; type 1 diabetes; diagnosis;
KW   PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP893691-A1.
```

```
XX
PD   27-JAN-1999.
XX
PF   23-JUL-1997;   97EP-00401773.
XX
PR   23-JUL-1997;   97EP-00401773.
XX
PA   (MACH/) MACH B F.
XX
PI   Conrad B,  Mach B;
XX
DR   WPI; 1999-097928/09.
XX
PT   Diagnosing human autoimmune disease by detecting retrovirus with
PT   superantigen activity - new retrovirus associated with type 1 diabetes,
PT   its proviral DNA, and related vectors, transformed cells, proteins,
PT   antibodies and specific binding agents, used for treating or preventing
PT   autoimmune disease.
XX
PS   Example; Page 34; 92pp; English.
XX
CC   The sequence is that of an insulin-dependent diabetes mellitus associated
CC   human endogenous retrovirus (IDDMK1.2-22) PCR primer. The retrovirus has
CC   Superantigen (SAg) activity. It can be used as part of a method is
CC   specifically used to diagnose type 1 diabetes mellitus. Modified proteins
CC   expressed by the retroviral sequence (without SAg activity but still able
CC   to induce an immune response) are useful in vaccines to treat or prevent
CC   SAg-related autoimmune disease; nucleic acid sequences encoding
CC   (modified) SAg can be used similarly to treat such diseases. Retroviral-
CC   encoded SAg are important in pathogenesis of autoimmune disease, probably
CC   by activating autoreactive T cells. The method is very specific (it can
CC   differentiate between expressed and non-expressed viral nucleic acids)
CC   and can be used even where the pathogen is an ubiquitous endogenous
CC   retrovirus. Blood or plasma samples can be tested without extensive
CC   preparation and diagnosis can be made before clinical signs are apparent,
CC   allowing early intervention before severe tissue damage has occurred
XX
SQ   Sequence 25 BP; 4 A; 4 C; 3 G; 14 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 96;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1951 TTTTTGTGTCCGCTAAATATTTA 1973
              |||||| |||| || | ||||||
Db          1 TTTTTGAGTCCCCTTAGTATTTA 23


RESULT 25
AAX07482
ID   AAX07482 standard; DNA; 25 BP.
XX
AC   AAX07482;
XX
DT   08-JUN-1999  (first entry)
XX
DE   Synthetic IDDMK1.2-22 poly(A) specific primer.
XX
KW   IDDM; insulin-dependent diabetes mellitus; endogenous retrovirus; SAg;
KW   superantigen; provirus; autoimmune disease; type 1 diabetes; diagnosis;
KW   primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP893691-A1.
XX
PD   27-JAN-1999.
XX
PF   23-JUL-1997;   97EP-00401773.
XX
PR   23-JUL-1997;   97EP-00401773.
XX
PA   (MACH/) MACH B F.
XX
PI   Conrad B,  Mach B;
XX
DR   WPI; 1999-097928/09.
XX
PT   Diagnosing human autoimmune disease by detecting retrovirus with
PT   superantigen activity - new retrovirus associated with type 1 diabetes,
PT   its proviral DNA, and related vectors, transformed cells, proteins,
PT   antibodies and specific binding agents, used for treating or preventing
PT   autoimmune disease.
XX
PS   Claim 9; Page 52; 92pp; English.
XX
CC   The sequence is that of an insulin-dependent diabetes mellitus associated
CC   human endogenous retrovirus (IDDMK1.2-22) poly(A) specific primer. The
CC   retrovirus has Superantigen (SAg) activity. It can be used as part of a
CC   method is specifically used to diagnose type 1 diabetes mellitus.
CC   Modified proteins expressed by the retroviral sequence (without SAg
CC   activity but still able to induce an immune response) are useful in
CC   vaccines to treat or prevent SAg-related autoimmune disease; nucleic acid
CC   sequences encoding (modified) SAg can be used similarly to treat such
CC   diseases. Retroviral-encoded SAg are important in pathogenesis of
CC   autoimmune disease, probably by activating autoreactive T cells. The
CC   method is very specific (it can differentiate between expressed and non-
CC   expressed viral nucleic acids) and can be used even where the pathogen is
CC   an ubiquitous endogenous retrovirus. Blood or plasma samples can be
CC   tested without extensive preparation and diagnosis can be made before
CC   clinical signs are apparent, allowing early intervention before severe
CC   tissue damage has occurred
XX
SQ   Sequence 25 BP; 4 A; 4 C; 3 G; 14 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 96;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1951 TTTTTGTGTCCGCTAAATATTTA 1973
              |||||| |||| || | ||||||
Db          1 TTTTTGAGTCCCCTTAGTATTTA 23


RESULT 26
AAX07199
ID   AAX07199 standard; DNA; 25 BP.
XX
AC   AAX07199;
XX
DT   21-MAY-1999  (first entry)
XX
DE   IDDM-associated retrovirus polyA specific probe.
XX
KW   HERV; IDDKK1.2-22; superantigen; SAg; antigen; IDDM;
KW   insulin-dependent diabetes mellitus; autoimmune disease; diagnosis;
KW   therapy; vaccine; probe; PCR; primer; ss.
XX
OS   Synthetic.
OS   Human endogenous retrovirus.
XX
PN   WO9905527-A2.
XX
PD   04-FEB-1999.
XX
PF   22-JUL-1998;   98WO-EP004926.
XX
PR   22-JUL-1997;   97EP-00112482.
PR   23-JUL-1997;   97EP-00401773.
XX
PA   (MEDI-) MEDIGEN SA.
XX
PI   Conrad B,  Mach B;
XX
DR   WPI; 1999-143118/12.
```

```
XX
PT   New isolated human endogenous retrovirus - used to develop products for
PT   the diagnosis, prevention and treatment of autoimmune disease,
PT   particularly insulin dependent diabetes mellitus.
XX
PS   Claim 8; Page 90; 165pp; English.
XX
CC   This oligonucleotide is specific to the polyA signal present in the 3' R-
CC   poly(A) sequences at the 3' extremity of IDDMK1.2-22, a newly identified
CC   human endogenous retrovirus (HERV) that is the source of superantigen
CC   (SAg) activity in insulin-dependent diabetes mellitus (IDDM) patients. It
CC   can be used as a probe or primer (claimed) in a method for the diagnosis
CC   of a human autoimmune disease. IDDMK1.2-22 is ubiquitous in the human
CC   genome but is only expressed in diabetic individuals. The invention
CC   provides IDDMK1.2-22 nucleic acids (see AAX07186-91) and encoded
CC   polypeptides (see AAW97745-48). These can be used in methods for the
CC   diagnosis, treatment and prevention of IDDM
XX
SQ   Sequence 25 BP; 4 A; 4 C; 3 G; 14 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 96;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1951 TTTTTGTGTCCGCTAAATATTTA 1973
                 |||||| |||| || | ||||||
Db          1 TTTTTGAGTCCCCTTAGTATTTA 23


RESULT 27
AAX07220
ID   AAX07220 standard; DNA; 25 BP.
XX
AC   AAX07220;
XX
DT   27-AUG-2003  (revised)
DT   21-MAY-1999  (first entry)
XX
DE   Retroviral R-poly(A) primer.
XX
KW   Human endogenous retrovirus; HERV; IDDKK1.2-22; superantigen; SAg;
KW   antigen; IDDM; insulin-dependent diabetes mellitus; autoimmune disease;
KW   diagnosis; therapy; vaccine; PCR; primer; ss.
XX
OS   Synthetic.
OS   Retroviridae.
XX
PN   WO9905527-A2.
XX
PD   04-FEB-1999.
XX
PF   22-JUL-1998;   98WO-EP004926.
XX
PR   22-JUL-1997;   97EP-00112482.
PR   23-JUL-1997;   97EP-00401773.
XX
PA   (MEDI-) MEDIGEN SA.
XX
PI   Conrad B,  Mach B;
XX
DR   WPI; 1999-143118/12.
XX
PT   New isolated human endogenous retrovirus - used to develop products for
PT   the diagnosis, prevention and treatment of autoimmune disease,
PT   particularly insulin dependent diabetes mellitus.
XX
PS   Disclosure; Page 75; 165pp; English.
XX
CC   This is the nucleotide sequence of primer R-poly(A), which was used with
CC   a U3 primer (see AAX07221) in epidemiological studies of IDDMK1.2-22, a
CC   newly identified human endogenous retrovirus that is the source of
CC   superantigen activity in insulin-dependent diabetes mellitus (IDDM)
CC   patients. IDDMK1.2-22 is found in the plasma of IDDM patients at disease
CC   onset but not in the plasma of healthy controls. The invention provides
CC   nucleic acids (see AAX07186-91) and encoded polypeptides (see AAW97745-
CC   48) of IDDMK1.2-22. These can be used in methods for the diagnosis,
CC   treatment and prevention of IDDM. (Updated on 27-AUG-2003 to correct OS
CC   field.)
XX
SQ   Sequence 25 BP; 4 A; 4 C; 3 G; 14 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 96;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1951 TTTTTGTGTCCGCTAAATATTTA 1973
                 |||||| |||| || | ||||||
Db          1 TTTTTGAGTCCCCTTAGTATTTA 23


RESULT 28
AAZ49618
ID   AAZ49618 standard; DNA; 25 BP.
XX
AC   AAZ49618;
XX
DT   07-APR-2000  (first entry)
XX
DE   PCR primer-2 for synthesis of carrot CR16.1 fragment for plant promoter.
XX
KW   PCR primer; synthetic DNA; plant promoter; CR16 fragment; carrot;
KW   transgenic plant; soybean glycinin; stearoyl-ACP-desaturase gene;
KW   male sterility-related gene; ss.
XX
OS   Daucus carota.
XX
PN   EP976832-A2.
XX
PD   02-FEB-2000.
XX
PF   13-JUL-1999;   99EP-00113732.
XX
PR   15-JUL-1998;   98JP-00200372.
XX
PA   (SUMO ) SUMITOMO CHEM CO LTD.
XX
PI   Ishige F,  Nishikawa S,  Oeda K;
XX
DR   WPI; 2000-128374/12.
XX
PT   Novel promoter used to produce transgenic plants with higher expression
PT   of a desired gene.
XX
PS   Example 1; Page 14; 24pp; English.
XX
CC   The present sequence is a PCR primer used to synthesise carrot CR16.1
CC   fragment. This fragment along with a 10 bp synthetic DNA is used in the
CC   construction of a plant promoter. The promoter is used for controlling
CC   the expression of a desired gene e.g. soybean glycinin, stearoyl-ACP-
CC   desaturase and S-locus type specific RNase gene (male sterility-related
CC   gene) in a host cell especially a microorganism or a plant cell. The
CC   transformed plant cells can be used to produce transgenic plants. The
CC   promoter is compact and therefore suitable for higher expression of a
CC   desired gene in a particular tissue compared to other host tissues
XX
SQ   Sequence 25 BP; 8 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 96;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATCAACAAT 1918
                 | ||||||||||| |||||| |
Db          2 CTCTAGATCAACACCTCAACATT 24
```

```
RESULT 29
ACI99045/c
ID   ACI99045 standard; DNA; 25 BP.
XX
AC   ACI99045;
XX
DT   14-OCT-2003  (first entry)
XX
DE   Human microarray DNA oligonucleotide SEQ ID NO 99036.
XX
KW   EST; ss; probe; expressed sequence tag; microarray; gene expression;
KW   genetic variation; biallelic marker; polymorphism; human;
KW   cross-species comparison.
XX
OS   Homo sapiens.
XX
PN   US2003104410-A1.
XX
PD   05-JUN-2003.
XX
PF   15-MAR-2002; 2002US-00098263.
XX
PR   16-MAR-2001; 2001US-0276759P.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Mittmann MP;
XX
DR   WPI; 2003-567953/53.
XX
PT   New array of nucleic acid probes, useful for in situ hybridization, in
PT   Southern, Northern or dot-blot hybridization to identify or detect the
PT   sequence or specific mutations of any gene.
XX
PS   Claim 1; SEQ ID NO 99036; 9pp; English.
XX
CC   The invention discloses a microarray comprising a plurality of nucleic
CC   acid probes including one of 2,018,500 fully defined sequences, or its
CC   perfect match, perfect mismatch, antisense match or antisense mismatch.
CC   Also disclosed is a method of gene expression analysis. The array is used
CC   in monitoring gene expression levels by hybridisation to a DNA library,
CC   in analysis of genetic variation or in hybridisation of tag-labelled
CC   compounds. The nucleic acid probes are specifically designed for analysis
CC   of at least one target sequence. The method of analysis comprises
CC   hybridising at least one or more nucleic acids to at least two or more
CC   nucleic acid probes and detecting the hybridisation. The nucleic acid
CC   probes are attached to a solid support. The analysis comprises monitoring
CC   gene expression levels, identifying biallelic markers or polymorphisms,
CC   or family members of a gene and a cross-species comparison. Each of the
CC   nucleic acids further comprises a tag sequence. The array of nucleic acid
CC   probes is useful in in situ hybridisation, in Southern, Northern or dot-
CC   blot hybridisation to identify or detect the sequence or specific
CC   mutations of any gene, in mapping the 5' termini of mRNA molecules by
CC   primer extensions or in screening cDNA or genomic libraries or subclones
CC   for additional subclones containing segments of DNA that have been
CC   isolated and previously sequenced. The sequence presented is one of the
CC   nucleic acid probes incorporated in the microarray. Note: The sequence
CC   data for this patent can also be obtained in electronic format directly
CC   from USPTO at seqdata.uspto.goc/sequence.html
XX
SQ   Sequence 25 BP; 14 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 96;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCTTTC 1796
                 || |||||| || | ||||||||
Db         24 TTCTTTTTGTACACGATTCTTTC 2


RESULT 30
ABZ72190
ID   ABZ72190 standard; DNA; 20 BP.
XX
AC   ABZ72190;
XX
DT   03-APR-2003  (first entry)
XX
DE   Gene 216 SSCP sequencing primer SEQ ID NO 162.
XX
KW   Human; Gene 216; chromosome 20p13-p12; antiasthmatic; anorectic;
KW   antiinflammatory; gastrointestinal; gene therapy; vaccine; asthma;
KW   obesity; inflammatory bowel disease; primer; ss.
XX
OS   Synthetic.
XX
PN   WO200178894-A2.
XX
PD   25-OCT-2001.
XX
PF   13-APR-2001; 2001WO-US012245.
XX
PR   13-APR-2000; 2000US-00548797.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Keith T;
XX
DR   WPI; 2001-639428/73.
XX
PT   Isolated genes (Gene 216) from human chromosome 20p13-p12 and the
PT   proteins they encode, useful for the prevention, diagnosis and treatment
PT   of asthma, obesity and inflammatory bowel disease.
XX
PS   Example 10; Page 150; 520pp; English.
XX
CC   The invention relates to isolated genes (Gene 216) from human chromosome
CC   20p13-p12 and the proteins they encode. The nucleic acids and proteins
CC   may be used in the prevention, diagnosis and treatment of diseases
CC   associated with inappropriate Gene 216 expression. For example, the
CC   nucleic acids (or vectors) and proteins may be used to treat disorders
CC   associated with decreased expression by rectifying mutations or deletions
CC   in a patient's genome that affect the activity of gene 216 by expressing
CC   inactive proteins or to supplement the patients own production of Gene
CC   216 proteins. Additionally, the nucleic acids may be used to produce the
CC   secreted Gene 216 protein, by inserting the nucleic acids into a host
CC   cell and culturing the cell to express the protein. The nucleic acids and
CC   complementary sequences may also be used as DNA probes in diagnostic
CC   assays to detect and quantitate the presence of similar nucleic acid
CC   sequences in samples and therefore which patients may be in need of
CC   restorative therapy. The Gene 216 protein may also be used as antigens in
CC   the production of antibodies against Gene 216 and in assays to identify
CC   modulators of Gene 216 expression and activity. The anti-Gene 216
CC   antibodies and antagonists may also be used to down regulate expression
CC   and activity. The anti-Gene 216 antibodies may also be used as diagnostic
CC   agents for detecting the presence of Gene 216 proteins in samples (e.g.
CC   by enzyme linked immunosorbant assay or ELISA). Disorders that may be
CC   prevented, diagnosed and/or treated by the above methods include, for
CC   example asthma, obesity and inflammatory bowel disease. The present
CC   sequence is that of a Gene 216 related primer used in examples of the
CC   invention. The primers are used in the physical mapping of the gene
CC   (ABZ72067-ABZ72088), polymorphism identifiction using single strand
CC   conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184),
CC   sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362)
XX
SQ   Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 90;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1558 CAGGACTGCAAAAATCCT 1575
                ||||||||||||| |||||
Db          1 CAGGACTGCAAACATCCT 18
```

```
RESULT 31
ABX75043
ID   ABX75043 standard; DNA; 20 BP.
XX
AC   ABX75043;
XX
DT   25-MAR-2003  (first entry)
XX
DE   Human gene 216 polymorphism detection PCR primer #100.
XX
KW   Human; mouse; ss; primer; gene 216; antiasthmatic; antiinflammatory;
KW   anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
KW   gene therapy; respiratory disease; asthma; obesity; PCR;
KW   bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
KW   adult respiratory distress syndrome; inflammatory bowel syndrome.
XX
OS   Homo sapiens.
XX
PN   WO200283077-A2.
XX
PD   24-OCT-2002.
XX
PF   15-APR-2002; 2002WO-US012063.
XX
PR   13-APR-2001; 2001US-00834597.
PR   13-APR-2001; 2001WO-US012245.
XX
PA   (SCHE ) SCHERING CORP.
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Keith T,  Little RD,  Van Eerdewegh P,  Dupuis J,  Del Mastro RG;
PI   Simon J,  Allen K,  Pandit S;
XX
DR   WPI; 2003-092960/08.
XX
PT   New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
PT   treating a disorder, such as asthma, bronchial hyper-responsiveness,
PT   chronic obstructive pulmonary disease, obesity or inflammatory bowel
PT   syndrome.
XX
PS   Example 10; Page 156; 650pp; English.
XX
CC   This invention relates to a novel isolated nucleic acid, gene 216,
CC   identified from human chromosome 20p13-p12. The invention also discloses
CC   regions of the 216 gene that contain single nucleotide polymorphisms
CC   (SNP's) which may be used as markers for disease susceptibility or
CC   severity. The nucleotides of the invention may have antiasthmatic,
CC   antiinflammatory or anorectic activities and may be used in gene therapy.
CC   The nucleic acids, antibodies or its fragments are useful for diagnosing,
CC   preventing or treating a disorder, such as respiratory diseases (e.g.
CC   asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
CC   disease or adult respiratory distress syndrome), obesity, or inflammatory
CC   bowel syndrome. The nucleic acids are also useful for identifying
CC   increased susceptibility of a subject to the disorders mentioned. The
CC   nucleic acids can also be used as primers and templates for the
CC   recombinant production of disorder-associated peptides or polypeptides,
CC   for chromosome and gene mapping, or for tissue distribution studies. The
CC   present sequence represents a gene 216 specific PCR primer used in the
CC   scope of the invention
XX
SQ   Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 90;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1558 CAGGACTGCAAAAATCCT 1575
              ||||||||||||| |||||
Db          1 CAGGACTGCAAACATCCT 18

RESULT 32
ADJ36771
ID   ADJ36771 standard; DNA; 20 BP.
XX
AC   ADJ36771;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human gene 216 SNP detection primer seq id 162.
XX
KW   antiasthmatic; respiratory; gene therapy; asthma;
KW   bronchial hyperresponsiveness; atopy; chronic obstructive lung disease;
KW   adult respiratory distress syndrome; obesity; inflammatory bowel disease;
KW   human; gene 216; single nucleotide polymorphism; SNP; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   US2004002470-A1.
XX
PD   01-JAN-2004.
XX
PF   17-OCT-2002; 2002US-00277216.
XX
PR   13-APR-2000; 2000US-00548797.
PR   13-APR-2001; 2001US-00834597.
PR   19-APR-2002; 2002US-00126022.
XX
PA   (KEIT/) KEITH T.
PA   (LITT/) LITTLE R D.
PA   (VEER/) VAN EERDEWEGH P.
PA   (DUPU/) DUPUIS J.
PA   (DMAS/) DEL MASTRO R G.
PA   (SIMO/) SIMON J.
PA   (ALLE/) ALLEN K.
PA   (PAND/) PANDIT S.
XX
PI   Keith T,  Little RD,  Eerdewegh PV,  Dupuis J,  Del Mastro RG;
PI   Simon J,  Allen K,  Pandit S;
XX
DR   WPI; 2004-061675/06.
XX
PT   Gene 216 nucleic acid, useful for preparing a composition for treating
PT   disorders e.g., asthma, bronchial hyperresponsiveness, atopy, chronic
PT   obstructive lung disease and adult respiratory distress syndrome.
XX
PS   Example 10; SEQ ID NO 162; 441pp; English.
XX
CC   The invention describes a new isolated nucleic acid comprising a fully
CC   defined sequence having 23574 bp or at least its 50 or 15 contiguous
CC   nucleotides and includes: allele G of single nucleotide polymorphism
CC   (SNP) AB+2; allele G of SNP BC+1; and allele C of SNP BC+2. The invention
CC   describes identifying increased susceptibility to a disorder comprising
CC   asthma, bronchial hyperresponsiveness, atopy, chronic obstructive lung
CC   disease and adult respiratory distress syndrome in a subject comprising
CC   testing a biological sample obtained from a subject for the presence of
CC   at least one allele or haplotype given in the specification, where the
CC   presence identifies an increased susceptibility to the disorder. The
CC   nucleic acid is useful for preparing a composition for treating disorders
CC   comprising asthma, bronchial hyperresponsiveness, atopy, chronic
CC   obstructive lung disease and adult respiratory distress syndrome. This
CC   sequence represents a primer used to detect single nucleotide
CC   polymorphisms in the human gene 216.
XX
SQ   Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 90;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1558 CAGGACTGCAAAAATCCT 1575
              ||||||||||||| |||||
Db          1 CAGGACTGCAAACATCCT 18
```

```
RESULT 33
ADL81350
ID   ADL81350 standard; DNA; 20 BP.
XX
AC   ADL81350;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Gene 216 polymorphism sequencing primer #6.
XX
KW   asthma; bronchial hyperresponsiveness; obesity;
KW   inflammatory bowel disease; human; gene 216; ss; primer.
XX
OS   Homo sapiens.
XX
PN   US2004023215-A1.
XX
PD   05-FEB-2004.
XX
PF   19-APR-2002; 2002US-00126022.
XX
PR   13-APR-1999;   99US-0129391P.
PR   13-APR-2000; 2000US-00548797.
PR   13-APR-2001; 2001US-00834597.
XX
PA   (KEIT/) KEITH T.
PA   (LITT/) LITTLE R D.
PA   (EERD/) EERDEWEGH P V.
PA   (DUPU/) DUPUIS J.
PA   (DMAS/) DEL MASTRO R G.
PA   (SIMO/) SIMON J.
PA   (ALLE/) ALLEN K.
PA   (PAND/) PANDIT S.
XX
PI   Keith T,  Little RD,  Eerdewegh PV,  Dupuis J,  Del Mastro RG;
PI   Simon J,  Allen K,  Pandit S;
XX
DR   WPI; 2004-142647/14.
XX
PT   New isolated nucleic acid molecules useful for diagnosing or treating
PT   asthma or bronchial hyperresponsiveness, or other diseases such as
PT   obesity or inflammatory bowel disease.
XX
PS   Example 10; SEQ ID NO 162; 485pp; English.
XX
CC   The invention relates to an isolated nucleic acid molecule, or a set of
CC   nucleic acid molecules each given in the specification. The composition
CC   and methods are useful in diagnosing or treating asthma or bronchial
CC   hyperresponsiveness, and other diseases such as obesity or inflammatory
CC   bowel disease. The present sequence is used in the exemplification of the
CC   present invention.
XX
SQ   Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 90;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1558 CAGGACTGCAAAAATCCT 1575
              ||||||||||| |||||
Db          1 CAGGACTGCAAACATCCT 18


RESULT 34
ABX92831
ID   ABX92831 standard; DNA; 24 BP.
XX
AC   ABX92831;
XX
DT   16-MAY-2003  (first entry)
XX
DE   Borrelia burgdoferi KlL10 ZS7 B31 E61 and PKO primer.
XX
KW   ss; primer; ospC; vaccine; antibacterial; Lyme disease; erythema migrans;
KW   acrodermatitis chronica atrophicans; neuro-borreliosis; arthritis; PCR.
XX
OS   Borrelia burgdoferi.
XX
PN   US6486130-B1.
XX
PD   26-NOV-2002.
XX
PF   27-JUN-1996;   96US-00671548.
XX
PR   11-JUL-1991;   91US-00727245.
PR   22-JAN-1992;   92US-00824161.
PR   25-JUN-1992;   92US-00903580.
PR   29-APR-1993;   93US-00053863.
PR   19-AUG-1994;   94US-00284667.
XX
PA   (BAXT ) BAXTER VACCINE AG.
XX
PI   Livey I,  Crowe B,  Dorner F;
XX
DR   WPI; 2003-287432/28.
XX
PT   Recombinant Borrelia burgdorferi DNA sequence, OspC DNA sequence, useful
PT   for the production of OspC antigen which is useful as a vaccine for
PT   treating Lyme diseases.
XX
PS   Example 8; Col 29-30; 112pp; English.
XX
CC   The invention relates to a recombinant Borrelia burgdorferi DNA sequence,
CC   named ospC that encodes an OspC antigen containing amino acid sequence.
CC   The nucleic acid and an expression vector containing it are useful for
CC   the recombinant production of OspC antigen which is useful as a vaccine
CC   for treating Lyme disease and its related disorders e.g. erythema
CC   migrans, acrodermatitis chronica atrophicans, neuro-borreliosis and
CC   arthritis. The present sequence represents a PCR primer used to amplify
CC   Borrelia ospC genes
XX
SQ   Sequence 24 BP; 6 A; 1 C; 6 G; 11 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 24;
  Best Local Similarity   94.4%;  Pred. No. 1e+02;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1760 ATTCATTAAGCTTTTTTT 1777
              |||||||||| |||||||
Db          4 ATTCATTAAGGTTTTTTT 21


RESULT 35
AAZ73804
ID   AAZ73804 standard; DNA; 21 BP.
XX
AC   AAZ73804;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:8160.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
```

```
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1970; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 21 BP; 6 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 1e+02;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACCGCAC 1587
              || |||| |||||||| ||||
Db          1 AATAATCTTTCTCCACTGCAC 21


RESULT 36
ABX79739/c
ID   ABX79739 standard; cDNA; 21 BP.
XX
AC   ABX79739;
XX
DT   17-APR-2003  (first entry)
XX
DE   EST polymorphic DNA repeat polynucleotide #64.
XX
KW   EST; expressed sequence tag; ss; polymorphic repeat; tandem repeat;
KW   polymorphic marker prediction of ubiquitous simple sequences; POMPOUS;
KW   Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
KW   Haw River syndrome; Huntington's disease; fragile-X syndrome;
KW   Fredreich's ataxis; myotonic dystrophy; hyperandrogenaemia;
KW   spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
XX
OS   Homo sapiens.
XX
PN   US6472154-B1.
XX
PD   29-OCT-2002.
XX
PF   31-DEC-1999;   99US-00475947.
XX
PR   31-DEC-1999;   99US-00475947.
XX
PA   (TEXA ) UNIV TEXAS SYSTEM.
XX
PI   Garner HR,  Wren JD,  Minna JD,  Fondon JW;
XX
DR   WPI; 2003-208818/20.
XX
PT   Identifying a candidate polymorphic repeat within a coding sequence, for
PT   understanding or treating genetic disease, comprises detecting tandem
PT   repeats in a target coding sequence and scoring the repeats for
PT   polymorphic probability.
XX
PS   Example; Col 273; 588pp; English.
XX
CC   The invention discloses a method for identifying a candidate polymorphic
CC   repeat within a coding sequence (expressed sequence tag, EST), which
CC   comprises detecting tandem repeats in a target coding sequence, scoring
CC   the repeats for polymorphic probability and generating a dataset
CC   correlating the repeats with polymorphic probability to identify a
CC   candidate polymorphic repeat. The computational methods (polymorphic
CC   marker prediction of ubiquitous simple sequences, POMPOUS, and Rep-X) are
CC   useful for identifying and detecting candidate polymorphic repeats in
CC   human genes, which can be used to understand, treat or eliminate genetic
CC   diseases, predispositions or adverse drug-treatment reactions. Examples
CC   of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
CC   syndrome, Huntington's disease, fragile-X syndrome, Fredreich's ataxis,
CC   myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and
CC   spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
CC   the polymorphic repeats identified for a search of human ESTs
XX
SQ   Sequence 21 BP; 8 A; 9 C; 1 G; 3 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 1e+02;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1938 AGGTAATGGTTGGTTTTTGTG 1958
              ||| |||||| ||||||| ||
Db         21 AGGGAATGGTGGGTTTTTCTG 1
```

```
RESULT 37
AAX26962/c
ID   AAX26962 standard; DNA; 24 BP.
XX
AC   AAX26962;
XX
DT   24-JUN-1999  (first entry)
XX
DE   PCR primer used to amplify autoimmune regulator-1 (AIR-1) cDNA.
XX
KW   Autoimmune regulator-1; AIR-1; immune maturation; immune response;
KW   disease; autoimmune polyendocrinopathy candidiasis ectodermal dystrophy;
KW   APECED; autoimmune polyglandular syndrome type I; APS I; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9915559-A1.
XX
PD   01-APR-1999.
XX
PF   23-SEP-1998;   98WO-FI000749.
XX
PR   23-SEP-1997;   97FI-00003762.
XX
PA   (FIIM-) FINNISH IMMUNOTECHNOLOGY LTD.
XX
PI   Krohn K,  Heino M,  Peterson P,  Scott H,  Antonarakis S,  Lalioti M;
PI   Shimizu N,  Kudoh J;
XX
DR   WPI; 1999-244390/20.
XX
PT   Autoimmune regulator 1 (AIR1) DNA sequence.
XX
PS   Example 5; Page 16; 59pp; English.
XX
CC   PCR primers AAX26957-62 were used to amplify human autoimmune regulator-1
CC   (AIR-1) cDNA fragments. The amplified products were used as probes. The
```

```
CC   peptide was used to raise antibodies against AIR-1. The AIR polypeptides
CC   and polynucleotides can be used in methods for the diagnosis and
CC   treatment of diseases related to immune maturation and regulation of
CC   immune response towards self and nonself. They can be used particularly
CC   in the diagnosis and treatment of autoimmune polyendocrinopathy
CC   candidiasis ectodermal dystrophy (APECED) (also known as autoimmune
CC   polyglandular syndrome type I (APS I))
XX
SQ   Sequence 24 BP; 6 A; 8 C; 9 G; 1 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1.3e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1591 CTGGGAACCCCTCCTGGCCTGGGG 1614
             | |||| || ||||| |||||| |
Db         24 CCGGGAGCCTCTCCTTGCCTGGTG 1


RESULT 38
AAC70288/c
ID   AAC70288 standard; DNA; 24 BP.
XX
AC   AAC70288;
XX
DT   09-FEB-2001  (first entry)
XX
DE   Single nucleotide polymorphism PCR primer #79.
XX
KW   Single nucleotide polymorphism; SNP; human; genetic disease;
KW   disease susceptibility; cardiovascular system; endocrine system;
KW   neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200058519-A2.
XX
PD   05-OCT-2000.
XX
PF   30-MAR-2000; 2000WO-US008440.
XX
PR   31-MAR-1999;   99US-0127248P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Altshuler D,  Cargill M,  Daley GQ,  Ireland JS,  Lander ES;
PI   Lipshutz RJ,  Patil N,  Sklar P;
XX
DR   WPI; 2000-611722/58.
XX
PT   Nucleic acid selected from one of 106 genes comprising single nucleotide
PT   polymorphisms, allele-specific oligonucleotides to the genes are useful
PT   for phenotypic correlations, forensics, paternity testing, medicine and
PT   genetic analysis.
XX
PS   Claim 8; Fig 5; 214pp; English.
XX
CC   The present invention is concerned with a number of human single
CC   nucleotide polymorphisms (SNPs) which the inventors identified in human
CC   genes. These SNPs can be used in disease diagnosis and prediction of an
CC   individual's susceptibility to disease, in forensic and paternity testing
CC   and in genetic mapping. In particular, the SNPs of the invention can be
CC   used to diagnose susceptibility to diseases of the cardiovascular,
CC   endocrine and neurological systems, such as coronary artery disease,
CC   schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC   diseases
XX
SQ   Sequence 24 BP; 7 A; 3 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1.3e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTGAAAAAAAG 1986
              || || ||||  |||||| ||||||
Db         24 CTCAACATTTGTCTTGAACAAAAG 1


RESULT 39
ABL56688
ID   ABL56688 standard; DNA; 24 BP.
XX
AC   ABL56688;
XX
DT   30-JUL-2002  (first entry)
XX
DE   PCR primer #2 for human class III MHC 61 cDNA.
XX
KW   Human; class III MHC 61; immunological disease; inflammation;
KW   organ transplantation; gene therapy; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200226828-A1.
XX
PD   04-APR-2002.
XX
PF   02-JUL-2001; 2001WO-CN001116.
XX
PR   07-JUL-2000; 2000CN-00117015.
XX
PA   (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2002-281324/32.
XX
PT   Human class III MHC 61 and encoding polynucleotide, used in diagnosis and
PT   treatment of immunological diseases and inflammation and in organ
PT   transplantation.
XX
PS   Example 3; Page 13; 40pp; Chinese.
XX
CC   PCR primers ABL56687-88 were used to amplify cDNA encoding human class
CC   III MHC 61. The polypeptide and polynucleotide are used in diagnosis and
CC   treatment of immunological diseases and inflammation and in organ
CC   transplantation. The polynucleotide may also be used for gene therapy
XX
SQ   Sequence 24 BP; 10 A; 2 C; 0 G; 12 T; 0 U; 0 Other;

  Query Match             2.9%;  Score 16;  DB 1;  Length 24;
  Best Local Similarity   79.2%;  Pred. No. 1.3e+02;
  Matches   19;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTTTCAGTGTT 1936
              || |||||||||| || | | ||
Db          1 AAAAATACCTTTTTATTAATTATT 24


RESULT 40
AAX27854/c
ID   AAX27854 standard; DNA; 20 BP.
XX
AC   AAX27854;
XX
DT   02-JUN-1999  (first entry)
XX
DE   PCR primer for mutant lipase coding sequence.
XX
KW   Lipase; mutant; methyl (2R,3S)-3-(4-methoxyphenyl)glycidate;
KW   (-)-MPGM production; PCR primer; ss.
XX
OS   Synthetic.
OS   Pseudomonas sp.
XX
```

PN JP10304875-A.
XX
PD 17-NOV-1998.
XX
PF 08-MAY-1997; 97JP-00117353.
XX
PR 08-MAY-1997; 97JP-00117353.
XX
PA (SHIO) SHIONOGI & CO LTD.
XX
DR WPI; 1999-232450/20.
XX
PT New lipase protein - useful for production of methyl (2R,3S)-3-(4-
PT methoxyphenyl)glycidate ((-)-MPGM).
XX
PS Example 1; Page 6; 15pp; Japanese.
XX
CC This sequence is a PCR primer for DNA encoding the mutant lipase protein
CC of the invention. The lipase can be used for the production of methyl
CC (2R,3S)-3-(4-methoxyphenyl)glycidate ((-)-MPGM). Microbes transformed
CC with the DNA sequence can produce (-)-MPGM of high optical purity
XX
SQ Sequence 20 BP; 7 A; 2 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1914 ACAATACCTTTTTTTTCAG 1932
|||| |||||||| |||||
Db 20 ACAACACCTTTTTGTTCAG 2

RESULT 41
AAL42562/c
ID AAL42562 standard; DNA; 20 BP.
XX
AC AAL42562;
XX
DT 08-JUL-2002 (first entry)
XX
DE Humulus lupulus farnesyl pyrophosphate synthase PCR primer 12.
XX
KW Farnesyl pyrophosphate synthase protein; hop secondary metabolites;
KW hop based genetic engineering; drug application; ss; PCR; primer.
XX
OS Humulus lupulus.
XX
PN WO200231164-A1.
XX
PD 18-APR-2002.
XX
PF 05-OCT-2001; 2001WO-JP008816.
XX
PR 06-OCT-2000; 2000JP-00308054.
XX
PA (SAPB) SAPPORO BREWERIES LTD.
XX
PI Okada Y, Ito K;
XX
DR WPI; 2002-362680/39.
XX
PT Farnesyl pyrophosphate synthase protein and encoded nucleic acid with
PT promoter region specifically expressed in hop lupulin glandular hair,
PT useful in producing pharmacologically-active hop secondary metabolites.
XX
PS Example 2; Page 17; 49pp; Japanese.
XX
CC The invention comprises the amino acid and coding sequence of the Humulus
CC lupulus farnesyl pyrophosphate synthase protein. The DNA and amino acid
CC sequences of the invention are useful in producing pharmacologically-
CC active hop secondary metabolites in vitro by transformant hop based
CC genetic engineering (e.g. for application in drugs). The present DNA
CC sequence represents a PCR primer specific for the gene sequence of the
CC Humulus lupulus farnesyl pyrophosphate synthase protein
XX
SQ Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 2.8%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1561 GACTGCAAAAATCCTTCTC 1579
| |||| ||||||||||||
Db 20 GGCTGCCAAAATCCTTCTC 2

RESULT 42
ADF66211/c
ID ADF66211 standard; DNA; 22 BP.
XX
AC ADF66211;
XX
DT 26-FEB-2004 (first entry)
XX
DE Ian5 gene related PCR primer SEQ ID NO:30.
XX
KW GAD65; type 1 diabetes; rat; Ian5(+); Ian5(lyp); Ian5; antidiabetic;
KW gene therapy; diabetes; PCR primer; ss.
XX
OS Synthetic.
OS Rattus sp.
XX
PN WO2003102147-A2.
XX
PD 11-DEC-2003.
XX
PF 29-MAY-2003; 2003WO-US017206.
XX
PR 29-MAY-2002; 2002US-0383913P.
XX
PA (UNIW) UNIV WASHINGTON.
XX
PI Lernmark A, Luo D, Macmurray A, Ettinger RA, Moralejo D;
PI Rutledge EA;
XX
DR WPI; 2004-053464/05.
XX
PT New GAD65 polypeptide comprising an E517P mutation, useful for detecting
PT the presence of or risk of developing type 1 diabetes or a related
PT disorder in human subjects.
XX
PS Example 2; SEQ ID NO 30; 87pp; English.
XX
CC The present invention describes a GAD65 polypeptide comprising an E517P
CC mutation. The polypeptide is characterised by decreased specific binding
CC to an antibody selected from GAD6, MICA-1, MICA-3, MICA-4 and MICA-6,
CC where the decreased binding is relative to a corresponding GAD65
CC polypeptide not having the E517P mutation. Also described: (1) methods
CC for detecting the presence of or risk of type 1 diabetes in a subject;
CC (2) an isolated nucleic acid selected from: (a) nucleic acids which
CC encode the rat Ian5(+) polypeptide; (b) nucleic acids which encode the
CC rat Ian5(lyp) polypeptide; or (c) full length complements of the nucleic
CC acids of (a) or (b); (3) an antibody that: (a) specifically binds to rat
CC Ian5(+) polypeptide, where the antibody is not immunologically cross-
CC reactive with human Ian5 or mouse Ian5 polypeptide; or (b) specifically
CC binds to rat Ian5(lyp) polypeptide, where the antibody is not
CC immunologically cross-reactive with rat Ian5(+), human Ian5 or mouse Ian5
CC polypeptide; (4) an expression construct comprising the following
CC elements linked in operable combination: a transcriptional promoter, a
CC nucleic acid described above, and a transcriptional terminator; (5) a
CC prokaryotic or eukaryotic cell transformed or transfected with the
CC expression construct described above; (6) a vector comprising the
CC expression construct described above; (7) an isolated host cell
CC comprising the vector; (8) a method for producing an Ian5 polypeptide;
CC (9) an in vitro method of identifying agonists or antagonists of an Ian5

```
CC   pathway to identify candidates for type 1 diabetes drug development; (10)
CC   methods for developing gene therapy for type 1 diabetes; and (11) a
CC   method for identifying a genetic mutation that correlates with type 1
CC   diabetes. GAD65 has antidiabetic activity, and can be used in gene
CC   therapy. The composition and methods of the present invention are useful
CC   in diagnosing, preventing or treating diabetes. The methods may also be
CC   used in screening for agonists or antagonists of Ian5 pathways to
CC   identify candidate agents for diabetes drug development, or in developing
CC   gene therapy for type 1 diabetes or a related disorder. The present
CC   sequence is used in the exemplification of the present invention.
XX
SQ   Sequence 22 BP; 5 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 22;
  Best Local Similarity   89.5%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTTACCTAC 1632
              ||||||||||||  ||| ||
Db         21 GGAAGAGTTTGTGACCCAC 3


RESULT 43
AAT60786
ID   AAT60786 standard; DNA; 23 BP.
XX
AC   AAT60786;
XX
DT   28-OCT-1997  (first entry)
XX
DE   Subtelomeric primer XpJCTN for measuring telomere length.
XX
KW   Telomere; hybridisation; cell turnover; tumour; osteoarthritis;
KW   alpha-thalassaemia; liver cirrhosis; muscular dystrophy; atherosclerosis;
KW   Hutchison-Gifford progeria; Down's syndrome; cardiovascular disease;
KW   HIV infection; fertility; PCR; polymerase chain reaction; ss.
XX
OS   Synthetic.
XX
PN   WO9641016-A1.
XX
PD   19-DEC-1996.
XX
PF   06-JUN-1996;   96WO-US010035.
XX
PR   07-JUN-1995;   95US-00479916.
XX
PA   (GERO-) GERON CORP.
XX
PI   Kozlowski MR,  Prowse KR,  Wang S,  Wong S,  Kim NW;
XX
DR   WPI; 1997-108648/10.
XX
PT   Measuring telomere length - by forming primer extension prods.
PT   complementary to telomere, or by hybridisation with complementary
PT   labelled probe.
XX
PS   Disclosure; Page 19; 64pp; English.
XX
CC   A method for measuring telomere length has been produced which involves:
CC   (a) covalently attaching an oligonucleotide linker to a telomere; (b)
CC   contacting a primer comprising a sequence sufficiently complementary to
CC   the linker to hybridise specifically under conditions so that the primer
CC   extends to form a primer extension product complementary to the telomere;
CC   and (c) correlating telomere length with primer extension product size,
CC   to provide a measure of telomere length. The present sequence represents
CC   a subtelomeric primer XpJCTN used in this invention. As telomere length
CC   serves as a biomarker for cell turnover, determination of telomere length
CC   can be used to diagnose and stage diseases and conditions such as
CC   tumours, alpha-thalassaemia, liver cirrhosis, muscular dystrophy,
CC   osteoarthritis, Hutchison-Gifford progeria, Down's syndrome,
CC   atherosclerosis, cardiovascular disease, HIV infection and fertility
CC   problems. The methods can also be used to monitor the effectiveness of
CC   various therapeutics in expanding, and/or reducing the proliferative
CC   lifespan of cells. The methods are conducive to high throughput or
CC   automated processes, provide for intracellular and intracellular telomere
CC   length determination and comparison and for the separation of cells or
CC   chromosomes based on telomere length
XX
SQ   Sequence 23 BP; 6 A; 7 C; 5 G; 4 T; 0 U; 1 Other;

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db          3 CTCTGAAAGTGGACCWATCAG 23


RESULT 44
AAT60790/c
ID   AAT60790 standard; DNA; 23 BP.
XX
AC   AAT60790;
XX
DT   28-OCT-1997  (first entry)
XX
DE   Subtelomeric primer revXpJCTN for measuring telomere length.
XX
KW   Telomere; hybridisation; cell turnover; tumour; osteoarthritis;
KW   alpha-thalassaemia; liver cirrhosis; muscular dystrophy; atherosclerosis;
KW   Hutchison-Gifford progeria; Down's syndrome; cardiovascular disease;
KW   HIV infection; fertility; PCR; polymerase chain reaction; ss.
XX
OS   Synthetic.
XX
PN   WO9641016-A1.
XX
PD   19-DEC-1996.
XX
PF   06-JUN-1996;   96WO-US010035.
XX
PR   07-JUN-1995;   95US-00479916.
XX
PA   (GERO-) GERON CORP.
XX
PI   Kozlowski MR,  Prowse KR,  Wang S,  Wong S,  Kim NW;
XX
DR   WPI; 1997-108648/10.
XX
PT   Measuring telomere length - by forming primer extension prods.
PT   complementary to telomere, or by hybridisation with complementary
PT   labelled probe.
XX
PS   Disclosure; Page 19; 64pp; English.
XX
CC   A method for measuring telomere length has been produced which involves:
CC   (a) covalently attaching an oligonucleotide linker to a telomere; (b)
CC   contacting a primer comprising a sequence sufficiently complementary to
CC   the linker to hybridise specifically under conditions so that the primer
CC   extends to form a primer extension product complementary to the telomere;
CC   and (c) correlating telomere length with primer extension product size,
CC   to provide a measure of telomere length. The present sequence represents
CC   a subtelomeric primer revXpJCTN used in this invention. As telomere
CC   length serves as a biomarker for cell turnover, determination of telomere
CC   length can be used to diagnose and stage diseases and conditions such as
CC   tumours, alpha-thalassaemia, liver cirrhosis, muscular dystrophy,
CC   osteoarthritis, Hutchison-Gifford progeria, Down's syndrome,
CC   atherosclerosis, cardiovascular disease, HIV infection and fertility
CC   problems. The methods can also be used to monitor the effectiveness of
CC   various therapeutics in expanding, and/or reducing the proliferative
CC   lifespan of cells. The methods are conducive to high throughput or
CC   automated processes, provide for intracellular and intracellular telomere
CC   length determination and comparison and for the separation of cells or
CC   chromosomes based on telomere length
```

```
XX
SQ   Sequence 23 BP; 4 A; 5 C; 7 G; 6 T; 0 U; 1 Other;

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db         21 CTCTGAAAGTGGACCWATCAG 1


RESULT 45
AAV62118/c
ID   AAV62118 standard; DNA; 23 BP.
XX
AC   AAV62118;
XX
DT   15-JAN-1999  (first entry)
XX
DE   Telomere length analysis primer #7.
XX
KW   Telomere; primer; cell turnover; proliferative capacity; diagnosis;
KW   prognosis; cancer, cell senescence; disease; liver cirrhosis; modulator;
KW   muscular dystrophy: osteoporosis; wound healing; fertility; treatment;
KW   chemotherapy; ss.
XX
OS   Synthetic.
XX
PN   US5834193-A.
XX
PD   10-NOV-1998.
XX
PF   07-JUN-1996;   96US-00660402.
XX
PR   07-JUN-1995;   95US-00479916.
XX
PA   (GERO-) GERON CORP.
XX
PI   Kozlowski MR,  Kim NW,  Wang S,  Allsopp R,  Prowse KR,  Wong S;
XX
DR   WPI; 1999-008698/01.
XX
PT   Determining telomere length by hybridisation of chromosomal DNA with
PT   labelled probe - useful for assessing age and proliferative status of
PT   cells, e.g. for diagnosis and prognosis of cancer and in cell senescence.
XX
PS   Disclosure; Col 11; 23pp; English.
XX
CC   AAV62112-V62122 are primers used in a novel method to determine telomere
CC   length. The method involves treating denatured chromosomal DNA, that has
CC   not been fractionated by gel electrophoresis, with a labelled probe
CC   complementary to a telomere repeat sequence. The amount of bound probe
CC   can be correlated with the telomere length, by comparison with results
CC   for a control of known length. Telomere length is a marker of cell
CC   turnover, e.g. the relative age or proliferative capacity, and its
CC   measurement is used in diagnosis, staging and prognosis of cancer, cell
CC   senescence or other diseases (e.g. liver cirrhosis, muscular dystrophy,
CC   osteoporosis, wound healing and fertility problems). Telomere length can
CC   also be used to monitor treatment with compounds that modulate telomere
CC   length, e.g. in cancer chemotherapy. The method can also be used to
CC   identify modulators of telomere length, telomerase activity or the rate
CC   of telomere loss, and to detect telomerase activity. The method is quick,
CC   with better sensitivity, efficiency, reliability and accuracy than known
CC   methods and does not require gels. The method is suitable for automation
CC   and can be applied to single chromosomes (for comparing interchromosome
CC   variations). The method allows separation of cells and/or chromosomes
CC   according to telomere length
XX
SQ   Sequence 23 BP; 4 A; 5 C; 7 G; 6 T; 0 U; 1 Other;

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db         21 CTCTGAAAGTGGACCWATCAG 1


RESULT 46
AAV62114
ID   AAV62114 standard; DNA; 23 BP.
XX
AC   AAV62114;
XX
DT   15-JAN-1999  (first entry)
XX
DE   Telomere length analysis primer #3.
XX
KW   Telomere; primer; cell turnover; proliferative capacity; diagnosis;
KW   prognosis; cancer, cell senescence; disease; liver cirrhosis; modulator;
KW   muscular dystrophy: osteoporosis; wound healing; fertility; treatment;
KW   chemotherapy; ss.
XX
OS   Synthetic.
XX
PN   US5834193-A.
XX
PD   10-NOV-1998.
XX
PF   07-JUN-1996;   96US-00660402.
XX
PR   07-JUN-1995;   95US-00479916.
XX
PA   (GERO-) GERON CORP.
XX
PI   Kozlowski MR,  Kim NW,  Wang S,  Allsopp R,  Prowse KR,  Wong S;
XX
DR   WPI; 1999-008698/01.
XX
PT   Determining telomere length by hybridisation of chromosomal DNA with
PT   labelled probe - useful for assessing age and proliferative status of
PT   cells, e.g. for diagnosis and prognosis of cancer and in cell senescence.
XX
PS   Disclosure; Col 11; 23pp; English.
XX
CC   AAV62112-V62122 are primers used in a novel method to determine telomere
CC   length. The method involves treating denatured chromosomal DNA, that has
CC   not been fractionated by gel electrophoresis, with a labelled probe
CC   complementary to a telomere repeat sequence. The amount of bound probe
CC   can be correlated with the telomere length, by comparison with results
CC   for a control of known length. Telomere length is a marker of cell
CC   turnover, e.g. the relative age or proliferative capacity, and its
CC   measurement is used in diagnosis, staging and prognosis of cancer, cell
CC   senescence or other diseases (e.g. liver cirrhosis, muscular dystrophy,
CC   osteoporosis, wound healing and fertility problems). Telomere length can
CC   also be used to monitor treatment with compounds that modulate telomere
CC   length, e.g. in cancer chemotherapy. The method can also be used to
CC   identify modulators of telomere length, telomerase activity or the rate
CC   of telomere loss, and to detect telomerase activity. The method is quick,
CC   with better sensitivity, efficiency, reliability and accuracy than known
CC   methods and does not require gels. The method is suitable for automation
CC   and can be applied to single chromosomes (for comparing interchromosome
CC   variations). The method allows separation of cells and/or chromosomes
CC   according to telomere length
XX
SQ   Sequence 23 BP; 6 A; 7 C; 5 G; 4 T; 0 U; 1 Other;

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db          3 CTCTGAAAGTGGACCWATCAG 23
```

```
RESULT 47
AAC91993
ID   AAC91993 standard; DNA; 24 BP.
XX
AC   AAC91993;
XX
DT   20-MAR-2001  (first entry)
XX
DE   T-box binding site in human IL-2 promoter.
XX
KW   T-bet; T box expressed in T cells protein; autoimmune disease; human;
KW   Th2-type dysfunction; T-box binding site; IL-2 promoter; ss.
XX
OS   Homo sapiens.
XX
PN   WO200073453-A1.
XX
PD   07-DEC-2000.
XX
PF   01-JUN-2000; 2000WO-US015345.
XX
PR   02-JUN-1999;   99US-0137085P.
XX
PA   (HARD ) HARVARD COLLEGE.
XX
PI   Glimcher LH,  Szabo SJ;
XX
DR   WPI; 2001-061537/07.
XX
PT   Novel protein, T-bet, a new member of T-box family of transcription
PT   factors is useful for identifying modulators of T-bet activity which
PT   treat allergies, cancers, autoimmune and infectious diseases.
XX
PS   Example 13; Page 82; 126pp; English.
XX
CC   The present invention relates to human anmd murine T box expressed in T
CC   cells (T-bet) protein and coding sequences (see AAC91988-C91989 and
CC   AAB51013-B51014). T-bet can be used in the treatment of autoimmune
CC   diseases associated with a Th2-type dysfunction e.g. diabetes mellitus,
CC   arthritis, multiple sclerosis, autoimmune thyroiditis, psoriasis,
CC   keratoconjunctivitis, alopecia areata, allergic responses due to
CC   arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis,
CC   conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma,
CC   allergic asthma, cutaneous lupus, erythematosus, scleroderma, vaginitis,
CC   proctitis, and drug eruptions. The present sequence is a T-box binding
CC   site from human IL-2 promoter
XX
SQ   Sequence 24 BP; 6 A; 5 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.6;  DB 1;  Length 24;
  Best Local Similarity   81.8%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1705 GAGCTATCTCCTAACTTTGGAC 1726
              |||||||| ||||| | ||| |
Db          1 GAGCTATCACCTAAGTGTGGGC 22


RESULT 48
ABL40063
ID   ABL40063 standard; DNA; 24 BP.
XX
AC   ABL40063;
XX
DT   15-MAY-2002  (first entry)
XX
DE   DNA-cysteine methyltransferase methylation protein 10 PCR primer #2.
XX
KW   Human; DNA-cysteine methyltransferase methylation protein 10; enzyme;
KW   cytostatic; antihormone; gene therapy; malignant tumour;
KW   embryonic development disorder; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200200827-A2.
XX
PD   03-JAN-2002.
XX
PF   11-JUN-2001; 2001WO-CN000943.
XX
PR   12-JUN-2000; 2000CN-00116428.
XX
PA   (BIOW-) BIOWINDOW GENE DEV INC.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2002-075671/10.
XX
PT   DNA-cysteine methytransferase methylation protein 10 and encoding
PT   polynucleotide, used in diagnosis and treatment of malignant tumors, and
PT   embryonic development disorders.
XX
PS   Disclosure; Page 29; 31pp; Chinese.
XX
CC   The present invention describes human DNA-cysteine methyltransferase
CC   methylation protein 10 (I). (I) has cytostatic and antihormone
CC   activities. The polynucleotide (II) encoding (I) can be used in gene
CC   therapy. (I) and (II) can be used in the diagnosis and treatment of
CC   malignant tumour, and embryonic development disorders. The present
CC   sequence represents a PCR primer which is given in the present invention.
CC   N.B. The present sequence is designated as SEQ ID NO:4 in the Sequence
CC   Listing, but does not correspond with the SEQ ID NO:4 sequence given in
CC   Example 3
XX
SQ   Sequence 24 BP; 6 A; 1 C; 5 G; 12 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.6;  DB 1;  Length 24;
  Best Local Similarity   81.8%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1762 TCATTAAGCTTTTTTTTTTGA 1783
              | || |||||||||| ||| |||
Db          2 TTATGAAGCTTTTTATTTGTGA 23


RESULT 49
ABV74368
ID   ABV74368 standard; DNA; 24 BP.
XX
AC   ABV74368;
XX
DT   31-JAN-2003  (first entry)
XX
DE   Ubiquitin specific proteinase 23.10 PCR primer SEQ ID NO 4.
XX
KW   Ubiquitin specific proteinase 23.10; enzyme; tumour; diabetes;
KW   menstrual disorder; peptic ulcer; arrhythmia; anaemia; epilepsy;
KW   cytostatic; PCR; primer; ss.
XX
OS   Unidentified.
XX
PN   CN1345976-A.
XX
PD   24-APR-2002.
XX
PF   29-SEP-2000; 2000CN-00125542.
XX
PR   29-SEP-2000; 2000CN-00125542.
XX
PA   (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
XX
PI   Mao Y,  Xie Y;
XX
DR   WPI; 2002-575979/62.
```

```
XX
PT   Novel ubiquitin specific proteinase 23.10 polypeptide and polynucleotide
PT   for encoding the polypeptide, useful for curing several diseases, such as
PT   tumor, diabetes, menstrual disorder, peptic ulcer, arrhythmic, anemia and
PT   epilepsy.
XX
PS   Example 3; Page 17 (Disclosure); 31pp; Chinese.
XX
CC   The invention relates to ubiquitin specific proteinase 23.10 and the
CC   polynucleotide encoding it. The polypeptide is useful for curing several
CC   diseases, such as tumour, diabetes, menstrual disorder, peptic ulcer,
CC   arrhythmia, anaemia and epilepsy. The present sequence is that of a
CC   ubiquitin specific proteinase 23.10 PCR primer, useful in examples of the
CC   invention
XX
SQ   Sequence 24 BP; 4 A; 1 C; 1 G; 18 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.6;  DB 1;  Length 24;
  Best Local Similarity   81.8%;  Pred. No. 1.5e+02;
  Matches   18;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCTTTTTTTT 1778
              |||||||||| |   | ||||||
Db          2 TTTATTCATTTATTTATTTTTT 23


RESULT 50
ABT34888
ID   ABT34888 standard; DNA; 17 BP.
XX
AC   ABT34888;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 525.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 95; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 1.3e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTGGTA 2029
              ||||||||| |||||||
Db          1 GATCAAGTCTTCTGGTA 17


RESULT 51
AAV44628
ID   AAV44628 standard; DNA; 19 BP.
XX
AC   AAV44628;
XX
DT   24-NOV-1998  (first entry)
XX
DE   Human uncoupling protein-2 UCP2 gene primer hUCP2.CDSR5.
XX
KW   Uncoupling protein-2; UCP2 gene; human; respiration; thermogenesis;
KW   obesity; hyperinsulinaemia; glucose intolerance; diabetes; syndrome X;
KW   hypothermia; wasting; cachexia; anorexia; inflammation; fever;
KW   hyperthermia; gene therapy; diagnosis; PCR; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9831396-A1.
XX
PD   23-JUL-1998.
XX
PF   22-APR-1997;   97WO-US006864.
XX
PR   15-JAN-1997;   97US-0034960P.
XX
PA   (UYDU-) UNIV DUKE.
PA   (REGC ) UNIV CALIFORNIA.
PA   (CNRS ) CENT NAT RECH SCI.
XX
PI   Surwit RS,  Collins SA,  Warden CH,  Seldin MF,  Ricquier D;
PI   Bouillaud F;
XX
DR   WPI; 1998-413823/35.
XX
PT   Method for treating disease associated with altered UCP-2 expression - by
PT   administering agent which enhances or inhibits UCP-2 activity,
PT   effectively to treat obesity, diabetes, fever, hyperthermia, cachexia
PT   etc.
XX
PS   Disclosure; Fig 1F; 98pp; English.
XX
CC   Primer hUCP2.CDSR5 is used with forward primer hUCP2.CDSF5 (see AAV44627)
CC   in the PCR amplification of a 1125 bp region of the human uncoupling
CC   protein-2 (UCP2) gene coding sequence (see also AAV44595). The invention
CC   relates to a method for treating diseases associated with altered UCP2
CC   expression, such as obesity, diabetes, syndrome X, hypothermia,
CC   hyperinsulinaemia, glucose intolerance, wasting, anorexia, inflammation,
CC   cachexia, fever or hyperthermia
```

```
XX
SQ   Sequence 19 BP; 8 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 19;
  Best Local Similarity   94.1%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGA 1556
              ||||||| |||||||||
Db          1 AGGAGAGAAGGGAAGGA 17


RESULT 52
AAV44626
ID   AAV44626 standard; DNA; 20 BP.
XX
AC   AAV44626;
XX
DT   24-NOV-1998  (first entry)
XX
DE   Human uncoupling protein-2 UCP2 gene primer hUCP2.CDSR4.
XX
KW   Uncoupling protein-2; UCP2 gene; human; respiration; thermogenesis;
KW   obesity; hyperinsulinaemia; glucose intolerance; diabetes; syndrome X;
KW   hypothermia; wasting; cachexia; anorexia; inflammation; fever;
KW   hyperthermia; gene therapy; diagnosis; PCR; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9831396-A1.
XX
PD   23-JUL-1998.
XX
PF   22-APR-1997;   97WO-US006864.
XX
PR   15-JAN-1997;   97US-0034960P.
XX
PA   (UYDU-) UNIV DUKE.
PA   (REGC ) UNIV CALIFORNIA.
PA   (CNRS ) CENT NAT RECH SCI.
XX
PI   Surwit RS,  Collins SA,  Warden CH,  Seldin MF,  Ricquier D;
PI   Bouillaud F;
XX
DR   WPI; 1998-413823/35.
XX
PT   Method for treating disease associated with altered UCP-2 expression - by
PT   administering agent which enhances or inhibits UCP-2 activity,
PT   effectively to treat obesity, diabetes, fever, hyperthermia, cachexia
PT   etc.
XX
PS   Disclosure; Fig 1F; 98pp; English.
XX
CC   Primer hUCP2.CDSR4 is used with forward primer hUCP2.CDSF4 (see AAV44625)
CC   in the PCR amplification of a 1100 bp region of the human uncoupling
CC   protein-2 (UCP2) gene coding sequence (see also AAV44595). The invention
CC   relates to a method for treating diseases associated with altered UCP2
CC   expression, such as obesity, diabetes, syndrome X, hypothermia,
CC   hyperinsulinaemia, glucose intolerance, wasting, anorexia, inflammation,
CC   cachexia, fever or hyperthermia
XX
SQ   Sequence 20 BP; 9 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGA 1556
              ||||||| |||||||||
Db          2 AGGAGAGAAGGGAAGGA 18


RESULT 53
ABK99977/c
ID   ABK99977 standard; DNA; 20 BP.
XX
AC   ABK99977;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human CADPKL DNA PCR primer #1.
XX
KW   Human; calcium/calmodulin-dependent protein kinase-like gene; CADPKL; ss;
KW   PCR; neuropsychiatric disorder; attention deficit disorder; ADD; primer;
KW   schizoaffective disorder; bipolar disorder; unipolar affective disorder;
KW   schizophrenia; adolescent conduct disorder; pharmacogenomics;
KW   fingerprinting; paternity testing; antidepressant; neuroleptic.
XX
OS   Homo sapiens.
XX
PN   WO200254939-A2.
XX
PD   18-JUL-2002.
XX
PF   07-JAN-2002; 2002WO-US000367.
XX
PR   09-JAN-2001; 2001US-00757300.
PR   23-AUG-2001; 2001US-00935464.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Meyer JM,  Barrington-Martin R,  Parker A;
XX
DR   WPI; 2002-590643/63.
XX
PT   New variants of calcium/calmodulin-dependent protein kinase-like nucleic
PT   acids and polypeptides, useful for diagnosing and treating
PT   neuropsychiatric disorders, e.g. schizophrenia, schizoaffective disorder,
PT   and bipolar disorder.
XX
PS   Claim 17; Page 98; 223pp; English.
XX
CC   The invention relates to a nucleic acid comprising a polymorphic region
CC   of a Calcium/Calmodulin-dependent protein kinase-like gene (CADPKL)
CC   allelic variant, and the polypeptide it encodes. CADPKL allelic variants
CC   are useful in determining whether a subject has or is at risk of
CC   developing a neuropsychiatric disorder, such as schizophrenia, attention
CC   deficit disorder (ADD), schizoaffective disorder, bipolar disorder,
CC   unipolar affective disorder and adolescent conduct disorder. The
CC   polypeptides, polynucleotides, antibodies and modulators of the CADPKL
CC   allelic variants are useful for diagnosing or treating these
CC   neuropsychiatric disorders. The polypeptides may be used to raise
CC   antibodies to a CADPKL polypeptide. The nucleic acids may be used as
CC   probes or primers, in pharmacogenomics for designing therapies for the
CC   disorders, and in fingerprinting for detection of different individuals
CC   with the same species (e.g. paternity testing). This sequence represents
CC   a PCR primer used to amplify human CADPKL DNA of the invention
XX
SQ   Sequence 20 BP; 8 A; 0 C; 11 G; 1 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 20;
  Best Local Similarity   94.1%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              |||||||||| ||||||
Db         17 CCCCATTCTTCCCTTCT 1


RESULT 54
AAQ71626/c
ID   AAQ71626 standard; DNA; 21 BP.
XX
AC   AAQ71626;
XX
```

DT 25-MAR-2003 (revised)
DT 29-MAR-1995 (first entry)
XX
DE Primer to amplify streptococcal pyrogenic exotoxin C (speC).
XX
KW mitogenic factor; microdetection; group A streptococci; spe;
KW erythrogenic toxin; streptococcal pyrogenic exotoxin; blastogens;
KW scarlet fever toxin; erythematous skin reaction; infectious disease;
KW delayed hypersensitivity; primer; PCR; polymerase chain reaction;
KW streptolysin O; slo; speA; speB; speC; ss.
XX
OS Synthetic.
XX
PN EP613947-A2.
XX
PD 07-SEP-1994.
XX
PF 31-JAN-1994; 94EP-00101386.
XX
PR 01-FEB-1993; 93JP-00037383.
XX
PA (SHIO) SHIONOGI & CO LTD.
XX
PI Yutsudo T, Okumura K, Iwasaki M, Hara A, Kishishita M, Takeda Y;
PI Igarashi H, Hinuma Y;
XX
DR WPI; 1994-272994/34.
XX
PT New mitogenic factor gene from Streptococcus pyogenes - used to develop
PT prods. for the early diagnosis of infectious disease caused by gp A
PT streptococci.
XX
PS Example 3; Page 10; 20pp; English.
XX
CC The primers AAQ71619-26 were used to compare the methods of
CC microdetection of group A streptococci, the distribution of the genes
CC encoding other erythrogenic toxins produced by S. pyrogenes was studied.
CC Unlike the streptolysin O (slo) and streptococcal pyrogenic exotoxin
CC (spe) genes, the distribution of the mitogenic factor is limited to group
CC A Streptococci. (See also AAQ71613-18). (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
SQ Sequence 21 BP; 9 A; 2 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.8%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1967 ATATTTACCTTGAAAAA 1983
||||||| |||||||||
Db 17 ATATTTATCTTGAAAAA 1

RESULT 55
AAC59861
ID AAC59861 standard; DNA; 21 BP.
XX
AC AAC59861;
XX
DT 26-JAN-2001 (first entry)
XX
DE Oligonucleotide probe for human DNA clone vb27 1.
XX
KW Secreted protein; human; autoimmune disorder; multiple sclerosis; ulcer;
KW systemic lupus erythematosus; rheumatoid arthritis; anaemia; stroke;
KW haematopoiesis regulation; tissue regrowth; wound healing; haemophilia;
KW Alzheimer's disease; Parkinson's disease; Shy-drager syndrome; cancer;
KW contraceptive; infection; growth inhibition; hyperproliferative disorder;
KW psoriasis; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200055375-A1.
XX
PD 21-SEP-2000.
XX
PF 17-MAR-2000; 2000WO-US007285.
XX
PR 17-MAR-1999; 99US-0124808P.
PR 17-MAR-1999; 99US-0124916P.
PR 17-AUG-1999; 99US-0149639P.
PR 01-OCT-1999; 99US-0157247P.
PR 29-NOV-1999; 99US-0167824P.
PR 15-FEB-2000; 2000US-0182711P.
XX
PA (ALPH-) ALPHAGENE INC.
XX
PI Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
XX
DR WPI; 2000-638211/61.
XX
PT Novel proteins and polypeptides useful for the treatment of e.g multiple
PT sclerosis, systemic lupus erythmatosus, rheumatoid arthritis, cancer,
PT Alzheimer's disease, Parkinson's disease, stroke, anemia and ulcers.
XX
PS Disclosure; Page 467; 493pp; English.
XX
CC This invention relates to 59 human secreted proteins and the nucleotide
CC sequences encoding them. Sequences AAC59788-C59846 and AAB34687-B34745
CC represent the proteins and their encoding nucleotide sequences, and
CC sequences AAB34746-B34771 represent fragments of the proteins. Probes for
CC the DNA sequences are represented by sequences AAC59847-C59596. The
CC proteins exhibit neuroprotective, dermatological, immunosuppressive,
CC antiinflammatory, antianaemic, nootropic, antiparkinsonian,
CC cerebroprotective, haemostatic, vulnerary, cytostatic, antipsoriatic,
CC antibacterial, virucide, and fungicide activity. The proteins and
CC nucleotide sequences are useful as nutritional sources or supplements and
CC in research. The proteins are useful for treating immune deficiency and
CC disorders, which may be genetic or resulting from infections, autoimmune
CC disorders such as multiple sclerosis, systemic lupus erythmatosus,
CC rheumatoid arthritis, and for treating myeloid or lymphoid cell
CC deficiencies such as anaemias by regulating haematopoiesis. The proteins
CC are also useful in compositions for bone, cartilage, tendon, ligament
CC and/or nerve tissue growth or regeneration, for wound healing, tissue
CC repair and replacement and in the treatment of wounds, incisions and
CC ulcers. Other uses include in the treatment of central and peripheral
CC nervous system and neuropathies such as Alzheimer's and Parkinson's
CC diseases and Shy-Drager syndrome, and mechanical and traumatic disorders,
CC such as spinal cord disorders, head trauma and stroke. The proteins may
CC also be used as a contraceptive, and for treating coagulation disorders
CC such as haemophilias. The protein and nucleotide sequences with cadherin
CC activity are useful for treating cancer. Other uses for the protein
CC include for inhibiting the growth, infection or function of, or killing,
CC infectious agents such as bacteria, virus, fungi and other parasites, for
CC effecting bodily characteristics such as height, weight, hair colour,
CC effecting biorhythms or cardiac cycles or rhythms, effecting metabolism,
CC catabolism, anabolism, processing, utilization, storage or elimination of
CC dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors,
CC effecting behavioural characteristics, providing analgesic effects and
CC for treating hyperproliferative disorders such as psoriasis
XX
SQ Sequence 21 BP; 6 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 2.8%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1832 TTTAAATACATTCCCTG 1848
|||||| ||||||||||
Db 1 TTTAAACACATTCCCTG 17

RESULT 56
ABL51554
ID ABL51554 standard; DNA; 23 BP.
XX

```
AC   ABL51554;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human NSAID regulated gene INDO29 antisense PCR primer SEQ ID NO:5.
XX
KW   Human; NAG-1; NSAID associated gene; nonsteroidal anti-inflammatory drug;
KW   promoter; MIC-1; macrophage inhibitory cytokine-1; cytostatic; cancer;
KW   anticancer; NSAID regulated gene; INDO29; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200220759-A2.
XX
PD   14-MAR-2002.
XX
PF   06-SEP-2001; 2001WO-US027544.
XX
PR   08-SEP-2000; 2000US-0231246P.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Eling TE,  Baek SJ;
XX
DR   WPI; 2002-362249/39.
XX
PT   New non-steroidal anti-inflammatory drug activated gene with anti-
PT   tumorigenic properties, useful in drug screening, particularly for
PT   identifying and characterizing agents or compounds having anti-cancer
PT   properties.
XX
PS   Example 1; Page 34; 67pp; English.
XX
CC   The present invention describes an isolated and purified non-steroidal
CC   anti-inflammatory drug activated gene (NSAID associated gene, also
CC   designated NAG-1), which comprises a 8902 base pair sequence (I). (I) has
CC   cytostatic activity. (I) is useful in drug screening, particularly for
CC   identifying and characterising agents that are agonistic or antagonistic
CC   to the activation of the promoter region of the NAG-1 gene, the
CC   activation of which is correlated with the apoptotic elimination of
CC   certain cancers. In particular, the DNA is useful for identifying
CC   compounds having anti-cancer properties. NAG-1 peptides encoded by (I)
CC   are useful for treating cancer. The NAG-1 gene given in the present
CC   invention, having Genbank accession number AF019770, is designated as
CC   human macrophage inhibitory cytokine-1 (MIC-1). The present sequence
CC   represents a PCR primer for a human NSAID regulated gene designated
CC   INDO29, which is used in an example from the present invention
XX
SQ   Sequence 23 BP; 6 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 23;
  Best Local Similarity   94.1%;  Pred. No. 1.6e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTGC 1566
              ||||||| |||||||||
Db          5 GGAAGGACCAGGACTGC 21


RESULT 57
AAQ95389
ID   AAQ95389 standard; DNA; 20 BP.
XX
AC   AAQ95389;
XX
DT   08-FEB-1996  (first entry)
XX
DE   Primer A (Group 2, Set B) for marker IL-9, chromosome 5.
XX
KW   primer; polymerase chain reaction; PCR; linkage study; locus;
KW   microsatellite marker sequence; automated genotyping; allele;
KW   polymorphism; detection; Homo sapiens; ss.
XX
OS   Synthetic.
XX
PN   WO9515400-A1.
XX
PD   08-JUN-1995.
XX
PF   05-DEC-1994;   94WO-US013945.
XX
PR   03-DEC-1993;   93US-00160837.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Levitt RC;
XX
DR   WPI; 1995-215278/28.
XX
PT   Kit for automated genotyping contg. pairs of PCR primers - designed to
PT   amplify polymorphic nucleotide repeat sequences, arranged in sets each
PT   with a characteristic fluorescence label, useful e.g. in detection of
PT   disease related genetic rearrangement.
XX
PS   Claim 4; Fig 7B-2; 104pp; English.
XX
CC   The method aims to provide a collection of highly reproducible
CC   microsatellite marker sequences (MMS) at approx. 10-50 cM intervals
CC   throughout the human genome which can be detectably labelled. The MSS are
CC   polymorphic, simple sequence repeats and can be used in automated
CC   genotyping, esp. fluorescence-based. The primers correspond to the unique
CC   DNA sequence surrounding each marker, and PCR is used to detect each
CC   polymorphism. When the MSS show considerable polypmorphism (ie. a
CC   difference in the number of repeats) between individuals, the markers can
CC   be particularly informative. The MSS can be ideal for linkage studies.
CC   Kits comprise at least 4 groups, of at least 3 sets, each comprising
CC   labelled primers for PCR amplification of the DNA. Group 2 primer pairs
CC   are shown in AAQ95369-416. The published size range of the IL-9 allele is
CC   271-283 bp, and the degree of heterozygosity in the population is about
CC   63%
XX
SQ   Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1860 CCACACACTTAGCCATTGAA 1879
              || ||| |||||||||||  |
Db          1 CCCCACTCTTAGCCATTGTA 20


RESULT 58
AAZ06095
ID   AAZ06095 standard; DNA; 20 BP.
XX
AC   AAZ06095;
XX
DT   07-OCT-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW   Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW   paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW   nongonococcal uretritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW   bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS   Synthetic.
OS   Chlamydia trachomatis.
XX
PN   WO9928475-A2.
XX
PD   10-JUN-1999.
XX
PF   27-NOV-1998;   98WO-IB001939.
XX
```

```
PR   28-NOV-1997;   97FR-00015041.
PR   17-DEC-1997;   97FR-00016034.
PR   04-NOV-1998;   98US-0107077P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-371125/31.
XX
PT   Genome sequence of Chlamydia trachomatis.
XX
PS   Disclosure; Page 1824; 1755pp; English.
XX
CC   PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC   (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC   encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC   against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC   be used to control growth of the microorganism. Chlamydia trachomatis is
CC   responsible for a large number of diseases, e.g. eye diseases such as
CC   conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC   conjunctivitis; genital diseases such as nongonococcal uretritis,
CC   epidymitis, cervicitis, salpingitis, perihepatitis, bartholinitis;
CC   pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC   The polypeptides of the invention may be of use in treating these
CC   diseases
XX
SQ   Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1697 CTAGCGCTGAGCTATCTCCT 1716
              || ||| ||| |||||||||
Db          1 CTCGCGATGACCTATCTCCT 20


RESULT 59
ADJ78671
ID   ADJ78671 standard; DNA; 20 BP.
XX
AC   ADJ78671;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Pancreatic cancer-related gene methylation-specific PCR primer #11.
XX
KW   differential methylation; pancreatic cancer;
KW   cellular proliferative disorder; cancer screening; risk-assessment;
KW   prognosis; minimal-residual disease identification;
KW   therapeutic target identification; ss; methylation-specific PCR; MSP;
KW   primer.
XX
OS   Unidentified.
XX
PN   WO200268694-A1.
XX
PD   06-SEP-2002.
XX
PF   25-FEB-2002; 2002WO-US005681.
XX
PR   23-FEB-2001; 2001US-0271268P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI   Goggins MG,  Ueki T;
XX
DR   WPI; 2002-707019/76.
XX
PT   New isolated nucleic acid molecules comprising differentially methylated
PT   sequences, and associated regulatory sequences, useful for cancer
PT   screening, risk-assessment, prognosis, or minimal-residual disease
PT   identification.
XX
PS   Claim 21; SEQ ID NO 53; 73pp; English.
XX
CC   The invention comprises 42 gene sequences which were found to be
CC   differentially methylated in pancreatic cancer. The DNA sequences of the
CC   invention are useful in detecting cellular proliferative disorders in a
CC   patient. The DNA sequences of the invention are useful for cancer
CC   screening, risk-assessment, prognosis, minimal-residual disease
CC   identification, staging and identification of therapeutic targets. The
CC   present DNA sequence represents a methylation-specific PCR (MSP) primer
CC   of the invention.
XX
SQ   Sequence 20 BP; 7 A; 0 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1530 AAGAAAGGTTAGGAGAGTAG 1549
              |||| ||| | |||||||||
Db          1 AAGAGAGGGTTGGAGAGTAG 20


RESULT 60
ABX12581
ID   ABX12581 standard; DNA; 20 BP.
XX
AC   ABX12581;
XX
DT   10-MAY-2003  (first entry)
XX
DE   Human cytochrome P450, CYP3AX, PCR primer #7.
XX
KW   Human; cytochrome P450; CYP3AX; cancer; primer; ss.
XX
OS   Homo sapiens.
XX
PN   US2002160479-A1.
XX
PD   31-OCT-2002.
XX
PF   09-NOV-2001; 2001US-00007814.
XX
PR   30-MAY-2000; 2000US-00583447.
XX
PA   (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI   Wojnowski L,  Gellner K,  Eiselt R;
XX
DR   WPI; 2003-288110/28.
XX
PT   New polynucleotide encoding a cytochrome P450 (CYP) 3AX polypeptide,
PT   useful for diagnosing or treating disorders related to the expression of
PT   a molecular variant CYP3AX gene, e.g. cancer.
XX
PS   Example 3; Page 18; 52pp; English.
XX
CC   The invention relates to a polynucleotide which encodes a cytochrome P450
CC   (CYP) 3AX polypeptide. The polynucleotide is useful in diagnosing or
CC   treating a disorder related to the expression of a molecular variant
CC   CYP3AX gene in a subject, such as cancer. It may also be used for
CC   identifying and obtaining drug candidates and inhibitors for therapy of
CC   disorders related to the malfunction of CYP3AX encoding genes. The
CC   present sequence represents a CYP3AX PCR primer of the invention
XX
SQ   Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1863 CACACTTAGCCATTGAAATG 1882
```

```
                 || |||| ||||| ||||||
Db          1 CAAACTTTGCCATGGAAATG 20


RESULT 61
AAL61401
ID   AAL61401 standard; DNA; 20 BP.
XX
AC   AAL61401;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145348.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 75; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 5 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1892 TGTGCCCTAGATCAACAGAT 1911
                | | |||||| |||||||||
Db          1 TTTTCCCTAGTTCAACAGAT 20


RESULT 62
ABZ85316/c
ID   ABZ85316 standard; DNA; 20 BP.
XX
AC   ABZ85316;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Claim 15; SEQ ID NO 558; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 11 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
```

```
  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1760 ATTCATTAAGCTTTTTTTTT 1779
              ||||| ||| |||||||| |
Db         20 ATTCAATAAACTTTTTTTGT 1


RESULT 63
ABD21546/c
ID   ABD21546 standard; DNA; 20 BP.
XX
AC   ABD21546;
XX
DT   29-JUL-2004  (first entry)
XX
DE   S100 calcium binding protein A2-derived oligo SEQ ID 558.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 558; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 11 A; 1 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1760 ATTCATTAAGCTTTTTTTTT 1779
              ||||| ||| |||||||| |
Db         20 ATTCAATAAACTTTTTTTGT 1


RESULT 64
ADG20539
ID   ADG20539 standard; DNA; 20 BP.
XX
AC   ADG20539;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human cytochrome P450 CYP3AX PCR primer #7.
XX
KW   cytochrome P450; CYP3AX; gene therapy; cancer; lung cancer;
KW   breast cancer; kidney cancer; human; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   US6645745-B1.
XX
PD   11-NOV-2003.
XX
PF   30-MAY-2000; 2000US-00583447.
XX
PR   30-MAY-2000; 2000US-00583447.
XX
PA   (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI   Wojnowski L,  Gellner K,  Eiselt R;
XX
DR   WPI; 2004-008602/01.
XX
PT   New cytochrome P450 (CYP) 3AX polypeptides and polynucleotides, useful in
PT   gene therapy, and for diagnosing and treating cancer, particularly lung,
PT   breast and kidney cancer, and other diseases.
XX
PS   Example 3; SEQ ID NO 29; 49pp; English.
XX
CC   The invention relates to an isolated polynucleotide encoding a cytochrome
CC   P450 (CYP) 3AX that retains biological activity. The CYP3AX
CC   polynucleotides, polypeptides are useful in gene therapy, and for
CC   diagnosing and treating cancer, particularly lung, breast and kidney
CC   cancer, and other diseases. The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1863 CACACTTAGCCATTGAAATG 1882
              || |||| ||||| ||||||
Db          1 CAAACTTTGCCATGGAAATG 20
```

```
RESULT 65
ADH63711
ID   ADH63711 standard; DNA; 20 BP.
XX
AC   ADH63711;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #545.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 545; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1948 TGGTTTTTGTGTCCGCTAAA 1967
              ||| ||| ||||||| ||||
Db          1 TGGGTTTAGTGTCCGGTAAA 20


RESULT 66
ADH63688
ID   ADH63688 standard; DNA; 20 BP.
XX
AC   ADH63688;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #522.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 522; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 3 A; 2 C; 7 G; 8 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1947 TTGGTTTTGTGTCCGCTAA 1966
              |||| ||| ||||||| |||
Db          1 TTGGGTTTAGTGTCCGGTAA 20


RESULT 67
ADJ17527
ID   ADJ17527 standard; DNA; 20 BP.
XX
AC   ADJ17527;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 2077.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
```

```
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 2077; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 10 A; 2 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAAGTG 1993
              | ||||  ||||||||||||
Db          1 CATTGAGCAAAAGAAAAGTG 20


RESULT 68
ADL59408
ID   ADL59408 standard; DNA; 20 BP.
XX
AC   ADL59408;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1657.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1657; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 4 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTGAAAAA 1983
              |||||||||||||| | | |
Db          1 TAAATATTTACCTTCATACA 20


RESULT 69
ADM15439
ID   ADM15439 standard; DNA; 20 BP.
XX
AC   ADM15439;
XX
DT   01-JUL-2004  (first entry)
XX
```

```
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1626.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1626; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGACCCACAC 1865
              ||| ||| | ||||||||||
Db          1 CTGTGCCCAGAGACCCACAC 20


RESULT 70
ADO53251
ID   ADO53251 standard; DNA; 20 BP.
XX
AC   ADO53251;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #624.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 624; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1890 GATGTGCCCTAGATCAACAG 1909
              ||| | |||||| |||||||
```

```
Db          1 GATTTTCCCTAGTTCAACAG 20


RESULT 71
ADO53592
ID   ADO53592 standard; DNA; 20 BP.
XX
AC   ADO53592;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #965.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 965; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 6 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1891 ATGTGCCCTAGATCAACAGA 1910
              || | |||||| ||||||||
Db          1 ATTTTCCCTAGTTCAACAGA 20


RESULT 72
ADO53744
ID   ADO53744 standard; DNA; 20 BP.
XX
AC   ADO53744;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1117.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1117; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.6e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1892 TGTGCCCTAGATCAACAGAT 1911
              | | |||||| |||||||||
Db          1 TTTTCCCTAGTTCAACAGAT 20


RESULT 73
AAF81140/c
ID   AAF81140 standard; DNA; 21 BP.
XX
AC   AAF81140;
XX
DT   02-MAY-2001  (first entry)
```

XX
DE Primer used for sequencing PTGS2 exon 1 SEQ ID 246.
XX
KW Human; prostaglandin-endoperoxide synthase 2; PTGS2; cyclooxygenase 2;
KW single nucleotide polymorphism; SNP; immune-related disorder; arthritis;
KW inflammation; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200107662-A1.
XX
PD 01-FEB-2001.
XX
PF 24-JUL-2000; 2000WO-US020114.
XX
PR 22-JUL-1999; 99US-0145170P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Denton RR, Nandabalan K, Sanchis A, Stephens JC, Tanguay DA;
XX
DR WPI; 2001-182805/18.
XX
PT New nucleic acid containing polymorphisms in the cyclooxygenase-2 gene,
PT for gene therapy of inflammation and for establishing a genotype or
PT haplotype.
XX
PS Example 1b; Page 40; 118pp; English.
XX
CC This invention relates to a polynucleotide sequence that is a polymorphic
CC variant of the human prostaglandin-endoperoxide synthase 2 (PTGS2) gene
CC also referred to as cyclooxygenase 2. The human PTGS2 gene sequence
CC AAF80896 contains 27 single nucleotide polymorphisms (SNPs). AAF80896 and
CC AAF80897 represent human PTGS2 gene and coding sequence, and the PTGS2
CC protein is represented by AAB72199. The invention includes PCR and
CC sequencing primers, and probes represented in AAF80898 - AAF81151 which
CC are used to isolated and characterise the PTGS2 gene sequence, and to
CC locate the positions of the SNPs. PTGS2 proteins and polynucleotide
CC sequences are used to express variant PTGS2 proteins, for structural
CC analysis or drug-binding studies and also in gene therapy (either
CC expressing PTGS2 or inhibitory RNA). Antibodies raised against PTGS2 are
CC useful for diagnosis, prognosis and therapy and analysis of the new, and
CC known, polymorphisms and used to determine PTGS2 haplotype and genotype,
CC especially for determining association between a particular trait, e.g. a
CC clinical response to drugs that target PTGS2 but also disease
CC susceptibility, severity or stage. Anti-PTGS2 antibodies are particularly
CC used for developing diagnostic tests and treatments for immune-related
CC disorders such as arthritis and inflammation. The polymorphisms may also
CC be used to study expression and biological function of PTGS2. Transgenic
CC animals that express PTGS2 are used to study expression of PTGS2
CC isogenes, for in vivo drug screening and testing, and for assessing
CC effects of therapeutic agents
XX
SQ Sequence 21 BP; 7 A; 9 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 2.7%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1610 TGGGGGAAGAGTTTGTTACC 1629
||||||| || |||| |||||
Db 20 TGGGGGCAGGGTTTTTTACC 1

RESULT 74
ABL44934
ID ABL44934 standard; DNA; 21 BP.
XX
AC ABL44934;
XX
DT 11-APR-2002 (first entry)
XX
DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1978.
XX
KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.
XX
OS Homo sapiens.
XX
PN JP2001321190-A.
XX
PD 20-NOV-2001.
XX
PF 12-MAR-2001; 2001JP-00068285.
XX
PR 10-MAR-2000; 2000JP-00066716.
XX
PA (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
XX
DR WPI; 2002-144136/19.
XX
PT Arraying genome clones.
XX
PS Claim 4; Page 43; 528pp; Japanese.
XX
CC The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
SQ Sequence 21 BP; 3 A; 0 C; 10 G; 8 T; 0 U; 0 Other;

Query Match 2.7%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1939 GGTAATGGTTGGTTTTTGTG 1958
||||||| | |||| |||||
Db 2 GGTAATGATGGGTTGTTGTG 21

RESULT 75
ABT33591
ID ABT33591 standard; DNA; 22 BP.
XX
AC ABT33591;
XX
DT 22-MAY-2003 (first entry)
XX
DE NOV reverse PCR primer SEQ ID No 507.
XX
KW Hepatotropic; immunosuppressive; cardiant; hypertensive; tranquilizer;
KW vulnerary; virucide; antibacterial; protozoacide; fungicide; nootropic;
KW antiparasitic; neuroprotective; cerebroprotective; antiparkinsonian;
KW anticonvulsant; antiaddictive; analgesic; dermatological; keratolytic;
KW antiseborrheic; antirheumatic; antiarthritic; antiinflammatory; anti-HIV;
KW cytostatic; antiasthmatic; antipsoriatic; hypotensive; osteopathic;
KW antiulcer; anorectic; antidiabetic; antiallergic; haemostatic;

KW neuroleptic; antidepressant; antiinfertility; NOVX; human disease;
KW NOVX-associated disorder; trauma; viral; bacterial; fungal; protozoal;
KW parasitic infection; Alzheimer's disease; stroke; forensic biology;
KW immunogen; non-human transgenic animal; gene therapy; PCR; primer; ss.
XX
OS Unidentified.
XX
PN WO200281517-A2.
XX
PD 17-OCT-2002.
XX
PF 22-JAN-2002; 2002WO-US002064.
XX
PR 19-JAN-2001; 2001US-0262892P.
PR 23-JAN-2001; 2001US-0263598P.
PR 24-JAN-2001; 2001US-0263799P.
PR 25-JAN-2001; 2001US-0264117P.
PR 25-JAN-2001; 2001US-0264139P.
PR 26-JAN-2001; 2001US-0264478P.
PR 30-JAN-2001; 2001US-0263351P.
PR 02-MAR-2001; 2001US-0272870P.
PR 14-MAR-2001; 2001US-0275927P.
PR 14-MAR-2001; 2001US-0275990P.
PR 15-MAR-2001; 2001US-0276449P.
PR 20-MAR-2001; 2001US-0277358P.
PR 23-MAR-2001; 2001US-0278151P.
PR 29-MAR-2001; 2001US-0279857P.
PR 20-APR-2001; 2001US-0285140P.
PR 20-APR-2001; 2001US-0285141P.
PR 30-APR-2001; 2001US-0287484P.
PR 17-MAY-2001; 2001US-0291701P.
PR 08-JUN-2001; 2001US-0296960P.
PR 10-JUL-2001; 2001US-0304353P.
PR 10-JUL-2001; 2001US-0304355P.
PR 12-JUL-2001; 2001US-0304886P.
PR 09-AUG-2001; 2001US-0311289P.
PR 13-AUG-2001; 2001US-0311975P.
PR 16-AUG-2001; 2001US-0312937P.
PR 18-OCT-2001; 2001US-0330227P.
PR 29-NOV-2001; 2001US-0334198P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Decristofaro MF, Padigaru M, Miller C, Tchernev V, Zhong H;
PI Zhong M, Anderson D, Ballinger R, Gerlach V, Spytek KA, Rastelli L;
PI Kekuda R, Guo X, Zerhusen B, Andrew D, Mezes P, Patturajan M;
PI Burgess CE, Eisen A, Wolenc A, Baumgartner J, Shimkets RA, Gusev V;
PI Vernet CAM, Taupier RJ, Pena C, Shenoy S, Li L, Casman S, Boldog F;
PI Fernandes E, Smithson G, Malyankar U, Taillon B, Liu X;
XX
DR WPI; 2003-058504/05.
XX
PT New polypeptides, designated as NOVX, useful for diagnosing and treating
PT infections, neurological diseases, cancer, allergy, and bone,
PT immunological, skin, renal, brain, muscle and autoimmune disorders.
XX
PS Example 3; Page 659; 672pp; English.
XX
CC The invention relates to a novel isolated polypeptide, designated NOVX
CC (NOV1 - 33), consisting of a mature form of one of 61 sequences, given in
CC the specification, or its variant, where amino acid residue(s) in the
CC variant differ from the mature form, provided that the variant differs in
CC not more than 15 % of the amino acids from the sequence of the mature
CC form. The NOVX polypeptides, nucleic acids encoding the polypeptides, and
CC an antibody to the polypeptides, are useful for treating or preventing a
CC NOVX-associated disorder in humans and for treating a syndrome associated
CC with a human disease (NOVX-associated disorder). NOVX polypeptides and
CC the encoding nucleic acids, are useful for determining the presence of or
CC predisposition to a disease associated with altered levels of NOVX
CC polypeptide and polynucleotide, by measuring the level of polypeptide
CC expression or the amount of nucleic acid from a mammal and comparing it
CC with another mammal not having or not predisposed to the disease. NOVX
CC polypeptide is also useful for identifying an agent that binds to NOVX
CC and a cell expressing NOVX is useful for identifying an agent that
CC modulates the expression or activity of NOVX. The antibodies and a
CC polypeptide having 95 % sequence identity to NOVX polypeptide are useful
CC for treating a pathological state in a mammal. The antibodies are also
CC useful for determining the presence or amount of NOVX in a sample. NOVX
CC polypeptides, polynucleotides and antibodies specific for the
CC polypeptides are useful for treating or preventing disorders or syndromes
CC including trauma, viral, bacterial, fungal, protozoal, and parasitic
CC infections. They can also treat disorders such as e.g., Alzheimer's
CC disease or a stroke. The NOVX encoding nucleic acids are useful for
CC expressing the NOVX proteins, to detect NOVX mRNA, or a genetic lesion in
CC a NOVX gene and to modulate NOVX activity. NOVX sequences are also useful
CC for identifying a cell or tissue type in a biological sample, to amplify
CC DNA sequences from very small biological samples such as tissues e.g.
CC hair or skin or body fluids in forensic biology and as primers and probes
CC for use in identifying and/or cloning NOVX homologues in other cell
CC types. The NOVX proteins are useful as an immunogen to generate
CC antibodies which are useful for diagnostically monitoring protein levels
CC and modulating NOVX activity. Cells comprising NOVX nucleic acids are
CC useful for producing non-human transgenic animals which are useful for
CC studying the function and/or activity of NOVX protein and for identifying
CC and/or evaluating modulators of NOVX protein activity. The NOVX nucleic
CC acids can be used in gene therapy. This polynucleotide sequence
CC represents a NOVX PCR primer of the invention
XX
SQ Sequence 22 BP; 3 A; 2 C; 11 G; 6 T; 0 U; 0 Other;

```
  Query Match             2.7%;  Score 15.2;  DB 1;  Length 22;
  Best Local Similarity   85.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGTTTGT 1625
              ||||||  ||| ||||||||
Db          2 GGCCTGATGGAGGAGTTTGT 21
```

RESULT 76
ABK90968/c
ID ABK90968 standard; DNA; 23 BP.
XX
AC ABK90968;
XX
DT 05-NOV-2002 (first entry)
XX
DE PCR primer, 22164, used to amplify human VH3 gene.
XX
KW Human; PCR; primer; ss; antiHIV; chimeric protein; HIV-1;
KW human immunodeficiency virus-1; envelope glycoprotein; env; gp120; CD4;
KW cellular receptor; immunoglobulin; Ig; V1; V2; variable region;
KW variable region-like membrane distal domain; antibody; heavy chain; VH;
KW VH3; gene therapy; HIV infection; virus replication.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200259258-A2.
XX
PD 01-AUG-2002.
XX
PF 22-JAN-2002; 2002WO-IL000060.
XX
PR 22-JAN-2001; 2001IL-00141023.
XX
PA (GAVI-) GAVISH-GALILEE BIO APPL LTD.
XX
PI Gross G, Meyuhas R;
XX
DR WPI; 2002-608450/65.
XX
PT New nucleic acid molecule encoding chimeric proteins with binding
PT specificity for a site on HIV envelope glycoprotein gp120 and a site on
PT gp120 protein or on the extracellular portion of human CD4, for
PT preventing or treating HIV infection.

```
XX
PS   Example 4; Page 29; 48pp; English.
XX
CC   The invention discloses a nucleic acid molecule encoding a functional
CC   chimeric protein with binding specificity for at least two different
CC   sites. At least one site is on the human immunodeficiency virus-1 (HIV-1)
CC   envelope glycoprotein (env), gp120, and the other site is either on the
CC   gp120 protein or on the extracellular portion of human CD4, the major
CC   cellular receptor for HIV. The chimeric protein essentially comprises a
CC   first binding region of a soluble extracellular portion of human CD4,
CC   consisting of the immunoglobulin (Ig) variable region-like membrane
CC   distal domains (V1 and V2) and a second binding region of a variable
CC   region of an antibody heavy chain (VH), encoded by the VH3 gene, which is
CC   capable of being attached to an adjacent and non-overlapping site on the
CC   gp120 protein, or to a site on the extracellular portion of human CD4,
CC   and is capable of increasing the capacity of the extracellular portion of
CC   human CD4 to interact with gp120 and to block the interaction of HIV with
CC   membranal CD4. These two binding regions are physically connected by a
CC   linker region. The chimeric protein of the invention is useful for gene
CC   therapy and for preventing and treating an HIV infection and for
CC   neutralising and inhibiting virus replication and infectivity in a
CC   subject, preferably a mammal. The sequence presented is the PCR primer,
CC   22164, which was used to amplify the human VH3 gene, used in the
CC   construction of the VH3-CD4 (V1 and V2) chimeric protein
XX
SQ   Sequence 23 BP; 3 A; 3 C; 11 G; 6 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 23;
  Best Local Similarity   85.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1566 CAAAAATCCTTCTCCACCGC 1585
              ||||| ||| |||||| |||
Db         20 CAAAACTCCATCTCCAGCGC 1


RESULT 77
ADO12655/c
ID   ADO12655 standard; DNA; 23 BP.
XX
AC   ADO12655;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Single multiplex PCR primer #2027.
XX
KW   ss; primer; simultaneous amplification;
KW   single multiplex polymerase chain reaction; multifactorial disease;
KW   genetic alteration; pharmacogenetic reaction; genotyping; polymorphism;
KW   gene expression profiling.
XX
OS   Synthetic.
XX
PN   WO2004033649-A2.
XX
PD   22-APR-2004.
XX
PF   07-OCT-2003; 2003WO-US031874.
XX
PR   07-OCT-2002; 2002US-0417009P.
XX
PA   (UYNE-) UNIV NEW JERSEY MEDICINE & DENTISTRY.
XX
PI   Li H,  Li J;
XX
DR   WPI; 2004-340914/31.
XX
PT   Designing primers for simultaneous amplification of target DNA fragments
PT   in a single multiplex polymerase chain reaction, for high throughput
PT   multiplex DNA sequence amplification, comprises aligning two primers.
XX
PS   Disclosure; Page 42; 120pp; English.
XX
CC   The invention relates to a method of designing primers for simultaneous
CC   amplification of target DNA fragments in a single multiplex polymerase
CC   chain reaction by aligning a first primer and a second primer. The method
CC   comprises: (a) aligning a first primer and a second primer; and (b)
CC   selecting the first primer where the first primer at its 3' end does not
CC   contain four or more bases that are perfectly matching to the 3' end
CC   sequence of the first primer or a second primer, the first primer at its
CC   3' end does not contain seven or more bases that are perfectly matching
CC   except one mismatch to the 3' end sequence of the first primer or the
CC   second primer, the first primer at its 3' end does not contain six or
CC   more bases that are perfectly matching to a sequence anywhere of the
CC   first primer or the second primer, and the first primer at its 3' end
CC   does not contain eleven or more bases that are perfectly matching except
CC   one mismatch to a sequence anywhere of the first primer or the second
CC   primer. The method is useful for designing primers for simultaneous
CC   amplification of target DNA fragments in a single multiplex polymerase
CC   chain reaction. It is also useful in the identification of multiple genes
CC   related to multifactorial diseases, the genome-scale detection of genetic
CC   alterations, the studies in pharmacogenetic reactions, the genotyping
CC   genetic polymorphisms in a large population, the gene expression
CC   profiling in various samples and high throughput genotyping technologies.
CC   This sequence corresponds to an example of a primer of the invention.
XX
SQ   Sequence 23 BP; 5 A; 3 C; 13 G; 2 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 23;
  Best Local Similarity   85.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1658 GTTCTGCATCACCCGCCCCT 1677
              ||||||| || || ||||||
Db         20 GTTCTGCCTCCCCAGCCCCT 1


RESULT 78
ABQ64253/c
ID   ABQ64253 standard; DNA; 17 BP.
XX
AC   ABQ64253;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 966.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
```

```
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 284; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACTGG 1753
              |||||||||||||||
Db         17 GGTGACAAGTACTGG 3


RESULT 79
ABQ64255/c
ID   ABQ64255 standard; DNA; 17 BP.
XX
AC   ABQ64255;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 968.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 284; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACTGG 1753
              |||||||||||||||
Db         15 GGTGACAAGTACTGG 1


RESULT 80
ABQ64254/c
ID   ABQ64254 standard; DNA; 17 BP.
XX
AC   ABQ64254;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 967.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
```

```
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 284; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match          2.7%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACTGG 1753
              |||||||||||||||
Db         16 GGTGACAAGTACTGG 2


RESULT 81
ADN06232/c
ID   ADN06232 standard; DNA; 20 BP.
XX
AC   ADN06232;
XX
DT   17-JUN-2004  (first entry)
XX
DE   Human SPS2 specific antisense oligonucleotide, ISIS 138303.
XX
KW   Selenophosphate synthetase 2; SPS2; rheumatoid arthritis; infection;
KW   inflammation; tumour; antisense therapy; human; antisense;
KW   phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone in which all cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl nucleotides"
XX
PN   US2004002151-A1.
XX
PD   01-JAN-2004.
XX
PF   28-JUN-2002; 2002US-00186157.
XX
PR   28-JUN-2002; 2002US-00186157.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Watt AT,  Freier SM;
XX
DR   WPI; 2004-070740/07.
XX
PT   New antisense oligonucleotides for modulating selenophosphate synthetase
PT   2 (SPS2) expression, useful for diagnosing, preventing or treating
PT   conditions associated with SPS2, e.g. rheumatoid arthritis, inflammation
PT   or tumors.
XX
PS   Claim 1; SEQ ID NO 76; 47pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of selenophosphate synthetase 2 (SPS2). The
CC   composition comprises antisense oligonucleotides targeted to SPS2 gene.
CC   The antisense oligonucleotide is useful for modulating the expression of
CC   SPS2 in cells or tissues to treat diseases associated with their
CC   expression, e.g. rheumatoid arthritis, infections, inflammation or
CC   tumours. It is also used for diagnostics, prophylaxis, or as research
CC   reagents or kits. The antisense oligonucleotide is useful in antisense
CC   therapy. The present sequence is an antisense oligonucleotide targeted to
CC   human SPS2 DNA. This sequence is used in the exemplification of the
CC   invention.
XX
SQ   Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match          2.7%;  Score 15;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1745 AAGTACTGGCTCTTT 1759
              |||||||||||||||
Db         18 AAGTACTGGCTCTTT 4


RESULT 82
AAH62016/c
ID   AAH62016 standard; DNA; 21 BP.
XX
AC   AAH62016;
XX
DT   10-SEP-2001  (first entry)
XX
DE   IL8 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4440.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
```

```
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 22; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 21 BP; 1 A; 1 C; 10 G; 9 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACA 1866
              |||||||||||||||
Db         16 CAACAGACCCACACA 2


RESULT 83
AAS13613
ID   AAS13613 standard; DNA; 23 BP.
XX
AC   AAS13613;
XX
DT   17-DEC-2001  (first entry)
XX
DE   Forward PCR primer used to amplify exon 14 of the human VMGLOM gene.
XX
KW   Human; VMGLOM; glomulin; venous malformation glomangioma; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200160856-A2.
XX
PD   23-AUG-2001.
XX
PF   16-FEB-2001; 2001WO-EP001760.
XX
PR   16-FEB-2000; 2000EP-00870022.
PR   10-APR-2000; 2000US-0195777P.
PR   22-DEC-2000; 2000EP-00870320.
XX
PA   (UYLO-) UNIV CATHOLIQUE LOUVAIN.
XX
PI   Vikkula M;
XX
DR   WPI; 2001-557643/62.
XX
PT   New VMGLOM genes and polypeptides, useful in gene therapy or for
PT   preventing, treating or alleviating disorders with vascular component,
PT   e.g. varicosities, cardiopathies, cerebral disorders or cancer.
XX
PS   Disclosure; Page 72; 157pp; English.
XX
CC   The present invention relates to the isolation of novel human and mouse
CC   VMGLOM polypeptides (long form and short form), and the nucleic acid
CC   molecules encoding them. VMGLOMs (also referred to as glomulins) are a
CC   subtype of venous malformations (VMs) called glomangiomas. In humans,
CC   VMGLOM has been mapped to chromosome 1p21-22. VMGLOMs and the nucleic
CC   acids encoding for them are useful as a medicament or for incorporation
CC   into a diagnostic kit. Such medicaments are useful for preventing,
CC   treating or alleviating disorders with a vascular component, particularly
CC   where alteration of vascular smooth muscle cell phenotype is needed, e.g.
CC   varicosities, cardiopathies or cardiomyopathies, cerebral disorders and
CC   cancer. The nucleic acids are also useful in gene therapy. The present
CC   sequence for forward PCR primer is used to amplify exon 14 of the human
CC   VMGLOM gene in the methods of the present invention
XX
SQ   Sequence 23 BP; 5 A; 1 C; 6 G; 11 T; 0 U; 0 Other;

  Query Match             2.7%;  Score 15;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 2e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1924 TTTTTTCAGTGTTAAGGTAATGG 1946
              |||||  ||||| |||||| | |
Db          1 TTTTTGTAGTGTCAAGGTATTAG 23


RESULT 84
AAT32774
ID   AAT32774 standard; DNA; 19 BP.
XX
AC   AAT32774;
XX
DT   18-FEB-1997  (first entry)
XX
DE   Triple helix-forming oligonucleotide.
XX
KW   Triple helix; triplex formation; Hoogsteen base pairing; plasmid;
KW   purification; double-stranded DNA; homopyrimidine; polypurine; ss.
XX
OS   Synthetic.
XX
PN   WO9618744-A2.
XX
PD   20-JUN-1996.
XX
PF   08-NOV-1995;   95WO-FR001468.
XX
PR   16-DEC-1994;   94FR-00015162.
XX
PA   (RHON ) RHONE POULENC RORER SA.
XX
PI   Crouzet J,  Scherman D,  Wils P;
XX
DR   WPI; 1996-300660/30.
XX
PT   Purificn. of double stranded DNA by triple helix formation - comprises
PT   hybridising immobilised oligo-nucleotide to specific sequence in target
PT   DNA.
XX
PS   Claim 11; Page 22; 34pp; French.
XX
CC   Double-stranded (ds) DNA can be purified from complex mixtures of nucleic
CC   acids, proteins, endotoxins, nucleases, etc. by passing the mixture over
CC   a support to which an oligonucleotide is covalently attached; the
CC   oligonucleotide is able to form a triple helix by hybridisation with a
CC   specific sequence present in the dsDNA. The present sequence is a
CC   preferred oligonucleotide which can form a triple-helix with the
CC   homopurine target sequence in AAT32773. The target sequence may be
CC   present naturally, e.g. in a plasmid origin of replication, or can be
```

```
CC   introduced artificially. The method is particularly suited to
CC   purification of plasmid DNA
XX
SQ   Sequence 19 BP; 8 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 85
AAV05816
ID   AAV05816 standard; cDNA; 19 BP.
XX
AC   AAV05816;
XX
DT   20-MAY-1998  (first entry)
XX
DE   Oligonucleotide #4 for purification of plasmid DNA.
XX
KW   Purification; double-stranded DNA; pharmaceutical purity; gene therapy;
KW   cellular therapy; affinity chromatography; ceramic hydroxyapatite;
KW   immobilised oligonucleotide; triple-helix; marker gene;
KW   origin of replication; ss.
XX
OS   Synthetic.
XX
PN   WO9735002-A1.
XX
PD   25-SEP-1997.
XX
PF   17-MAR-1997;   97WO-FR000472.
XX
PR   21-MAR-1996;   96FR-00003519.
XX
PA   (RHON ) RHONE-POULENC RORER SA.
XX
PI   Wils P,  Ollivier M;
XX
DR   WPI; 1997-480209/44.
XX
PT   Purification of double-stranded DNA to pharmaceutical purity - using
PT   ceramic hydroxy:apatite and affinity or ion-exchange chromatography,
PT   particularly for plasmids intended for gene therapy.
XX
PS   Disclosure; Page 6; 51pp; French.
XX
CC   This sequence represents an oligonucleotide used in a method of purifying
CC   double-stranded DNA to pharmaceutical purity, especially for use in gene
CC   or cellular therapy. The method comprises at least one stage of
CC   chromatography on a column of ceramic hydroxyapatite (HA), and another
CC   stage comprising an affinity chromatography purification, preferably with
CC   an immobilised oligonucleotide able to form a triple-helix structure.
CC   This sequence is an example of such a triple-helix forming oligomer. The
CC   oligonucleotide preferably binds to a sequence present in the plasmid to
CC   be purified, especially in a marker gene or the origin of replication
XX
SQ   Sequence 19 BP; 8 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 86
AAZ59024
ID   AAZ59024 standard; DNA; 19 BP.
XX
AC   AAZ59024;
XX
DT   11-APR-2000  (first entry)
XX
DE   Oligonucleotide GA19 for linking to maleimide peptide.
XX
KW   Antitumour; antiviral; antimicrobial; transfer vector; targeting system;
KW   triplex; triple helix; antisense; ribozyme; gene therapy; blood factor;
KW   hormone; tumour suppressor; antigenic peptide; vaccine; immunotherapy;
KW   cancer; protooncogene; ss.
XX
OS   Synthetic.
XX
PN   WO9949067-A1.
XX
PD   30-SEP-1999.
XX
PF   19-MAR-1999;   99WO-FR000643.
XX
PR   24-MAR-1998;   98FR-00003573.
PR   18-MAY-1998;   98US-0085848P.
XX
PA   (RHON ) RHONE-POULENC RORER SA.
XX
PI   Ciolina C,  Scherman D,  Wils P;
XX
DR   WPI; 1999-572204/48.
XX
PT   New nucleic acid transfer vector comprising double-stranded DNA linked to
PT   oligonucleotide, used for gene therapy.
XX
PS   Example 1; Page 30; 72pp; French.
XX
CC   The invention relates to a method of delivering a therapeutic double
CC   stranded DNA to a target cell or tissue by administering the DNA in a
CC   transfer vector. The vector comprises the double-stranded DNA molecule
CC   and at least one oligonucleotide that is linked to a targeting system and
CC   can form a triplex with a specific sequence within target cell or tissue.
CC   This sequence represents an example of an oligonucleotide able to form a
CC   linkage with a trgeting system ewhere the targeting system is a maleimide
CC   peptide-nuclear localisation signal. The vector is used to deliver
CC   therapeutic DNA (including antisense sequences or ribozymes) for gene
CC   therapy, e.g. sequences that encode enzymes, blood factors, hormones,
CC   tumour suppressors, also antigenic peptides for use as vaccines or
CC   immunotherapeutic agents for control of microbial or viral infections, or
CC   cancer
XX
SQ   Sequence 19 BP; 8 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 87
AAZ59016
ID   AAZ59016 standard; DNA; 19 BP.
XX
AC   AAZ59016;
XX
DT   11-APR-2000  (first entry)
XX
DE   Triple helix forming oligonucleotide target sequence #1.
XX
KW   Antitumour; antiviral; antimicrobial; transfer vector; targeting system;
KW   triplex; triple helix; antisense; ribozyme; gene therapy; blood factor;
```

KW hormone; tumour suppressor; antigenic peptide; vaccine; immunotherapy;
KW cancer; ss.
XX
OS Synthetic.
XX
PN WO9949067-A1.
XX
PD 30-SEP-1999.
XX
PF 19-MAR-1999; 99WO-FR000643.
XX
PR 24-MAR-1998; 98FR-00003573.
PR 18-MAY-1998; 98US-0085848P.
XX
PA (RHON) RHONE-POULENC RORER SA.
XX
PI Ciolina C, Scherman D, Wils P;
XX
DR WPI; 1999-572204/48.
XX
PT New nucleic acid transfer vector comprising double-stranded DNA linked to
PT oligonucleotide, used for gene therapy.
XX
PS Claim 10; Page 40; 72pp; French.
XX
CC The invention relates to a method of delivering a therapeutic double
CC stranded DNA to a target cell or tissue by administering the DNA in a
CC transfer vector. The vector comprises the double-stranded DNA molecule
CC and at least one oligonucleotide that is linked to a targeting system and
CC can form a triplex with a specific sequence within target cell or tissue.
CC This sequence represents an example of a target sequence able to form a
CC triple helix with the oligonucleotides. The vector is used to deliver
CC therapeutic DNA (including antisense sequences or ribozymes) for gene
CC therapy, e.g. sequences that encode enzymes, blood factors, hormones,
CC tumour suppressors, also antigenic peptides for use as vaccines or
CC immunotherapeutic agents for control of microbial or viral infections, or
CC cancer
XX
SQ Sequence 19 BP; 8 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1540 AGGAGAGTAGGGAAGGAA 1557
||||||| ||||| ||||
Db 2 AGGAGAGGAGGGAGGGAA 19

RESULT 88
AAS19331
ID AAS19331 standard; DNA; 19 BP.
XX
AC AAS19331;
XX
DT 20-MAR-2002 (first entry)
XX
DE Triple helix forming oligonucleotide used in plasmid purification #2.
XX
KW ss; DNA purification; triple helix; plasmid purification.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_binding 1. .19
FT /*tag= a
FT /bound_moiety= "Binds nucleotides 1-19 of the sequences
FT represented in AAS19330 and AAS19332 to form a triple
FT helix"
XX
PN WO200192511-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US017122.
XX
PR 26-MAY-2000; 2000US-00580923.
XX
PA (AVET) AVENTIS PHARMA SA.
XX
PI Crouzet J, Scherman D, Wils P, Blanche F, Cameron B;
XX
DR WPI; 2002-097772/13.
XX
PT Purifying double-stranded (ds) DNA from a solution containing dsDNA and
PT other components, comprises passing the solution through a support
PT comprising a covalently coupled oligonucleotide able to form a triple
PT helix with the dsDNA.
XX
PS Disclosure; Page 5; 40pp; English.
XX
CC This invention comprises a method of purifying double-stranded DNA from a
CC solution containing the double-stranded DNA mixed with other components,
CC comprising passing the solution through a support comprising a covalently
CC coupled oligonucleotide capable of forming a triple helix with the double
CC -stranded DNA by hybridisation with a specific sequence present in the
CC double-stranded DNA. The method is useful for purifying double-stranded
CC DNA contained in a solution and mixed with other components. The new
CC method is a simple, rapid and effective method for DNA purification, and
CC makes it possible to obtain especially high purities with high yields.
CC The method enables DNA to be purified from complex mixtures comprising
CC other nucleic acids, proteins, endotoxins, nucleases and the like. The
CC supports may be readily recycled, and the DNAs obtained display improved
CC properties to pharmaceutical safety. Further, the method entails only one
CC step contrary to prior art. The present sequence represents an
CC oligonucleotide sequence used to create a triple helix in the DNA
CC purification method of the invention
XX
SQ Sequence 19 BP; 8 A; 0 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1540 AGGAGAGTAGGGAAGGAA 1557
||||||| ||||| ||||
Db 2 AGGAGAGGAGGGAGGGAA 19

RESULT 89
ADP75317
ID ADP75317 standard; DNA; 19 BP.
XX
AC ADP75317;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human endophilin 2 gene exon F SSCP forward primer.
XX
KW Human; SSCP; ss; primer; ADAM19; Endophilin 1; Endophilin 2; NRG2;
KW ADAMTS2; a disintegrin and metalloprotease; neuroregulin 2; SNP;
KW single nucleotide polymorphism;
KW a disintegrin and metalloprotease with thrombospondin type1 motif 2;
KW asthma; atopy; obesity; inflammatory bowel disease; respiratory disorder;
KW single-strand conformation polymorphism.
XX
OS Homo sapiens.
XX
PN WO2003031594-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032700.
XX
PR 11-OCT-2001; 2001US-0328424P.
XX

```
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Keith T,  Little RD,  Van Eerdewegh P,  Dupuis J,  Del Mastro RG;
PI   Allen K;
XX
DR   WPI; 2003-381712/36.
XX
PT   New isolated nucleic acid or alternate splice variant, useful for
PT   diagnosing and treating a disintegrin and metalloprotease (ADAM) or
PT   interactor gene-associated disorder, e.g. asthma, atopy, obesity or
PT   inflammatory bowel disease.
XX
PS   Claim 2; Page 125; 338pp; English.
XX
CC   The invention relates to an isolated nucleic acid or alternate splice
CC   variant comprising a nucleotide sequence containing at least one of the
CC   single nucleotide polymorphisms given in the specification, a nucleotide
CC   sequence having at least 15 contiguous nucleotides of them, or
CC   complements of them. The genes are ADAM19 (a disintegrin and
CC   metalloprotease 19, also known as gene 845), NRG2 (neuroregulin 2, also
CC   known as gene 847), endophilin 1 (also known as gene 874), endophilin 2
CC   (also known as gene 803) and ADAMTS2 (a disintegrin and metalloprotease
CC   with thrombospondin type1 motif 2, also known as gene 962). Also included
CC   are a vector comprising the isolated nucleic acid (or alternate splice
CC   variant), a host cell containing the vector, an isolated polypeptide
CC   encoded by the novel nucleic acid (or alternate splice variant), an
CC   antibody or antibody fragment that binds to the polypeptide,
CC   pharmaceutical compositions (comprising the nucleic acid or alternate
CC   splice variant, vector, polypeptide or antibody , and a carrier,
CC   excipient or diluent), a kit for detecting a disintegrin and
CC   metalloprotease (ADAM) gene nucleotide sequence (comprising the isolated
CC   nucleic acid or alternate splice variant, antibody or antibody fragment,
CC   and at least one component to detect the hybridisation of the variant or
CC   the binding of the antibody to an ADAM gene amino acid sequence), a kit
CC   for detecting an interactor gene amino acid sequence (comprising the
CC   antibody or antibody fragment, and at least one component to detect the
CC   binding of the antibody to the interactor gene amino acid sequence),
CC   diagnosing an ADAM or interactor gene-associated disorder or a
CC   respiratory disorder in a human subject, determining an ADAM or
CC   interactor gene pharmacogenetic profile in a human subject, identifying
CC   an orthologue of a human ADAM or interactor gene, treating an ADAM or
CC   interactor gene-associated disorder (or a respiratory disorder) by
CC   administering the pharmaceutical composition, a transgenic mouse (whose
CC   genome comprises an introduced null mutation in an endogenous gene that
CC   is orthologous to a human ADAM gene), making a homozygous transgenic
CC   knockout mouse, forming a crystal of the isolated polypeptide, a cell
CC   line comprising the isolated nucleic acid or alternate splice variant, a
CC   biochip comprising the isolated nucleic acid or alternate splice variant,
CC   an isolated nucleic acid probe or primer comprising at least 8 contiguous
CC   nucleotides of the nucleic acid, an isolated antisense nucleic acid,
CC   identifying an ADAM or interactor gene ligand and an isolated nucleic
CC   acid variant of Gene 803, 845, 847, 874 or 962. The nucleic acid or
CC   alternate splice variants, methods, kits and antibody/antibody fragment
CC   are useful for diagnosing and treating an ADAM or interactor gene-
CC   associated disorder, e.g. asthma, atopy, obesity or inflammatory bowel
CC   disease. The present sequence is an SSCP (single-strand conformation
CC   polymorphism) primer used to analyse the above genes for the presence of
CC   polymorphisms.
XX
SQ   Sequence 19 BP; 7 A; 3 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGACTG 1565
              |||||||| ||||||| |
Db          1 AGGGAAGGCACAGGACAG 18


RESULT 90
AAT13503
ID   AAT13503 standard; DNA; 20 BP.
XX
AC   AAT13503;
XX
DT   20-NOV-1996  (first entry)
XX
DE   PCR primer (TSK8B) for Xp/Yp PAR1 proximal target sequence.
XX
KW   Human; Xp/Yp; pseudoautosomal region; PAR1; telomere repeat array;
KW   primer; genomic DNA; characterisation; amplification; PCR;
KW   internal repeat unit; detection; disease predisposition; abnormal;
KW   cell growth; cell division; diagnosis; family relationship;
KW   telomere mapping; human chromosome; flanking sequence;
KW   cancer identification; polymerase chain reaction; ss.
XX
OS   Homo sapiens.
XX
PN   GB2294322-A.
XX
PD   24-APR-1996.
XX
PF   19-OCT-1995;   95GB-00021447.
XX
PR   21-OCT-1994;   94GB-00021234.
PR   21-MAY-1995;   95GB-00010639.
XX
PA   (ZENE ) ZENECA LTD.
XX
PI   Baird DM,  Royle NJ,  Jeffreys AJ;
XX
DR   WPI; 1996-190531/20.
XX
PT   Characterising genomic DNA by amplifying selected internal repeat units -
PT   in telomere repeat array used for, e.g. disease diagnosis, determn. of
PT   family relationships, telomere mapping, etc.
XX
PS   Claim 18; Page 52; 68pp; English.
XX
CC   The present sequence is a PCR primer for a sequence proximal to the human
CC   Xp/Yp pseudoautosomal region (PAR1) telomere repeat array, produced using
CC   sequence information obtd. from 32 Caucasian and 21 African DNAs. The
CC   sequence was found to contain 20 substitution polymorphisms, and a 10 bp
CC   deletion/insertion polymorphism found only in African DNAs. Claimed type
CC   specific primers, which hybridise to loci contained in the sequence, can
CC   be used for the characterisation of a genomic DNA test sample by
CC   amplifying selected internal repeat units in a telomere repeat array.
CC   This characterisation is useful in the detection of inherited or acquired
CC   disease predisposition, abnormal cell division or growth diagnosis (e.g.
CC   cancer), individual and family relationship identification and telomere
CC   mapping of human chromosomes from DNA flanking sequences
XX
SQ   Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTAT 1817
              |||||||||||  ||||
Db          3 CTCTGAAAGTGGACCTAT 20


RESULT 91
AAZ46525/c
ID   AAZ46525 standard; DNA; 20 BP.
XX
AC   AAZ46525;
XX
DT   13-MAR-2000  (first entry)
XX
DE   Mouse CACNA1F exon 40N-48N amplifying forward primer.
XX
KW   Retinal calcium channel; RCC gene; alpha1F-subunit; retinal disorder;
KW   myopia; nystagmus; strabismus; calcium-regulated development pathway;
```

KW eye disorder; mouse; CACNA1F; CSNB; PCR primer; ss.
XX
OS Synthetic.
OS Mus sp.
XX
PN WO9963078-A2.
XX
PD 09-DEC-1999.
XX
PF 02-JUN-1999; 99WO-CA000514.
XX
PR 02-JUN-1998; 98US-0087635P.
XX
PA (UYTE-) UNIV TECHNOLOGIES INT INC.
XX
PI Bech-Hansen T, Naylor MJ;
XX
DR WPI; 2000-097327/08.
XX
PT New isolated mammalian retinal calcium channel gene, used to develop
PT products for the diagnosis and treatment of incomplete congenital
PT stationary night blindness and related disorders.
XX
PS Example 4; Page 27; 55pp; English.
XX
CC The invention provides a DNA molecule comprising a sequence of
CC nucleotides encoding an alpha1F-subunit of a mammalian retinal calcium
CC channel (RCC), including a human alpha1F-subunit, a murine alpha1F-
CC subunit and orthologs of the human and murine alpha1F-subunits. The RCC
CC gene may be used to develop products for diagnostic tests, for incomplete
CC CSMB and risk assessment in affected families. The RCC gene can provide
CC information as to the basic defect in this retinal conditions, which
CC could lead to effective methods for treatment or cure of the disorder. As
CC the associated features of myopia, nystagmus and strabismus frequently
CC observed in patients with incomplete CSNB may be caused by calcium-
CC regulated development pathways, identification of the RCC gene may help
CC to elucidate the molecular details of eye development and which may lead
CC to treatment for related eye disorders or diseases. Sequences AAZ46522-
CC 540 represent PCR primers used for the isolation of murine CACNA1F
CC (alpha1F- subunit of RCC gene) ortholog
XX
SQ Sequence 20 BP; 10 A; 2 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1790 TTCTTTCCTTCTCTGAAA 1807
||||||||||||| | ||
Db 18 TTCTTTCCTTCTCCGGAA 1

RESULT 92
AAH42680/c
ID AAH42680 standard; DNA; 20 BP.
XX
AC AAH42680;
XX
DT 01-OCT-2001 (first entry)
XX
DE Primer and probe for the human endoderm cell marker aldolase B.
XX
KW Human; embryo-derived cell; EBD cell; ectodermal cell; mesodermal cell;
KW endodermal cell; nestin; vimentin; myf6; flk1; alpha-1 fetoprotein;
KW myosin light-chain 2 ventricular isoform; GATA-4; cell culture;
KW tissue transplantation; tissue engineering; drug discovery; gene therapy;
KW transplantation therapy; Parkinson's disease; spinal cord injury;
KW amyotrophic lateral sclerosis; stroke; motor neuron injury; diabetes;
KW brain injury; ischemia; cardiac disease; skeletal disease; eye disease;
KW smooth muscles disease; liver disease; pancreas disease; cell marker;
KW vascular disease; artificial chromosome; probe; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200153465-A1.
XX
PD 26-JUL-2001.
XX
PF 22-JAN-2001; 2001WO-US002230.
XX
PR 21-JAN-2000; 2000US-0177287P.
XX
PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI Shamblott MJ, Gearhart JD;
XX
DR WPI; 2001-476113/51.
XX
PT Human embryo-derived cell culture comprising cells that simultaneously
PT express polypeptide or mRNA markers that are characteristic of at least 2
PT cell types, useful in tissue transplantation, drug discovery, gene
PT therapy.
XX
PS Example 7; Page 75; 107pp; English.
XX
CC The specification describes a human embryo-derived (EBD) cell culture
CC that comprises cells which simultaneously express polypeptide or mRNA
CC markers that are characteristic of at least 2 different cell types. The
CC cell types are ectodermal, mesodermal, and/or endodermal cells. The
CC markers include nestin, vimentin, myf6, myosin light-chain 2 ventricular
CC isoform, flk1, alpha-1 fetoprotein and GATA-4. The EBD cells are useful
CC in cell culture, tissue transplantation, tissue engineering, drug
CC discovery and gene therapy. They are especially useful in transplantation
CC therapies for the treatment of Parkinson's disease, amyotrophic lateral
CC sclerosis, stroke, injury to motor neurons, including spinal cord injury,
CC and diabetes. Human EBD cells can be implanted into the central nervous
CC system for the treatment of disease or physical brain injury, such as
CC ischemia or chemical injury, as well as to treat diseases of cardiac,
CC skeletal or smooth muscles, liver, pancreas, eyes, vascular diseases, to
CC repopulate bone marrow, in organotypic co-culture, in the biosynthetic
CC production of macromolecules, and in the construction and testing of
CC human artificial chromosomes. AAH42612-85 represent PCR primers and
CC probes for markers of human cells. They were used to examine the mRNA
CC expression profiles of human cells
XX
SQ Sequence 20 BP; 5 A; 9 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2025 TGGTAGGAGGCAAAGGTT 2042
|||||| ||||||||||
Db 19 TGGTAGAGGGCAAAGGTT 2

RESULT 93
ABZ68360
ID ABZ68360 standard; DNA; 20 BP.
XX
AC ABZ68360;
XX
DT 22-APR-2003 (first entry)
XX
DE Primer XpYpB2 used for determining telomere length.
XX
KW Telomere; cancer; age; telomerase; male infertility; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003000927-A2.
XX
PD 03-JAN-2003.
XX
PF 21-JUN-2002; 2002WO-GB002855.
XX

PR 23-JUN-2001; 2001GB-00015451.
PR 21-SEP-2001; 2001GB-00022755.
XX
PA (UYWA-) UNIV WALES COLLEGE OF MEDICINE.
XX
PI Baird DM;
XX
DR WPI; 2003-175294/17.
XX
PT Determining telomere length of mammalian chromosomal DNA by annealing and
PT covalently binding telorettes, useful in assessing a potential anti-
PT cancer treatment and/or assessing, treating or diagnosing male
PT infertility.
XX
PS Claim 23; Page 36; 50pp; English.
XX
CC The present sequence represents a primer, which is used in the method of
CC the invention for determining telomere length. The method comprises
CC annealing the 3' end of a single-stranded oligonucleotide to a single-
CC stranded overhang comprising TTAGGG repeat sequences, and covalently
CC binding the oligonucleotide to the 5' end of the C-rich telomeric strand
CC forming a ligation product. This ligation product is amplified to form a
CC primer extension product, whose length is then detected. The method is
CC useful in assessing potential anti-cancer treatments and cancer-related
CC procedures. It can also be used in assessing telomere dynamics with age,
CC effect of modulating telomerase activity, and in assessing, treating or
CC diagnosing male infertility
XX
SQ Sequence 20 BP; 6 A; 4 C; 5 G; 4 T; 0 U; 1 Other;

Query Match 2.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 2e+02;
Matches 16; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1801 TCTGAAAGTGGTGCTATAAG 1820
||||||||||| |:|| ||
Db 1 TCTGAAAGTGGACCWATCAG 20

RESULT 94
ABZ93604/c
ID ABZ93604 standard; DNA; 20 BP.
XX
AC ABZ93604;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 8846; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 12 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1544 GAGTAGGGAAGGAACAGG 1561
| |||||||||||| |||
Db 20 GGGTAGGGAAGGAAGAGG 3

RESULT 95
ABZ90035/c
ID ABZ90035 standard; DNA; 20 BP.
XX
AC ABZ90035;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX

```
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 5277; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 8 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATCT 2000
              ||||||| |||||| |||
Db         18 AAAGAAATGTGTGTTTCT 1


RESULT 96
ABZ86258
ID   ABZ86258 standard; DNA; 20 BP.
XX
AC   ABZ86258;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
```

```
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Claim 15; SEQ ID NO 1500; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 9 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1555 GAACAGGACTGCAAAAAT 1572
              |||||||||||  |||||
Db          2 GAACAGGACTGACAAAAT 19


RESULT 97
ABD29834/c
ID   ABD29834 standard; DNA; 20 BP.
XX
AC   ABD29834;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA069372-derived oligonucleotide SEQ ID 8846.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
```

```
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 8846; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 2 A; 12 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAACAGG 1561
              | ||||||||||||| |||
Db         20 GGGTAGGGAAGGAAGAGG 3


RESULT 98
ABD22488
ID   ABD22488 standard; DNA; 20 BP.
XX
AC   ABD22488;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human cathepsin C-derived oligo SEQ ID 1500.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 1500; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 9 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1555 GAACAGGACTGCAAAAAT 1572
              |||||||||||  |||||
Db          2 GAACAGGACTGACAAAAT 19


RESULT 99
ABD26265/c
ID   ABD26265 standard; DNA; 20 BP.
XX
AC   ABD26265;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA398883-derived oligonucleotide SEQ ID 5277.
XX
```

```
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 5277; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 8 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATCT 2000
              ||||||| |||||| |||
Db         18 AAAGAAATGTGTGTTTCT 1
```

```
RESULT 100
ADJ17462
ID   ADJ17462 standard; DNA; 20 BP.
XX
AC   ADJ17462;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 2012.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 2012; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
```

```
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 10 A; 2 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAGTG 1993
              ||||  ||||||||||||
Db          2 TTGAGCAAAAGAAAAGTG 19


RESULT 101
ADJ17701
ID   ADJ17701 standard; DNA; 20 BP.
XX
AC   ADJ17701;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 2251.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 2251; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 10 A; 2 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAGTG 1993
              ||||  ||||||||||||
Db          1 TTGAGCAAAAGAAAAGTG 18


RESULT 102
ADL59566
ID   ADL59566 standard; DNA; 20 BP.
XX
AC   ADL59566;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1815.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
```

```
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1815; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 4 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTGAAA 1981
                ||||||||||||| | |
Db          2 TAAATATTTACCTTCATA 19


RESULT 103
ADL59369
ID   ADL59369 standard; DNA; 20 BP.
XX
AC   ADL59369;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1618.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1618; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 3 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTGAAA 1981
                ||||||||||||| | |
Db          3 TAAATATTTACCTTCATA 20


RESULT 104
ADO53993
ID   ADO53993 standard; DNA; 20 BP.
XX
AC   ADO53993;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1366.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
```

```
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1366; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 6 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1894 TGCCCTAGATCAACAGAT 1911
              | |||||| |||||||||
Db          2 TTCCCTAGTTCAACAGAT 19


RESULT 105
ADO54709
ID   ADO54709 standard; DNA; 20 BP.
XX
AC   ADO54709;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #2082.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 2082; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1894 TGCCCTAGATCAACAGAT 1911
              | |||||| |||||||||
Db          1 TTCCCTAGTTCAACAGAT 18


RESULT 106
ADN29250
ID   ADN29250 standard; DNA; 20 BP.
XX
AC   ADN29250;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human kallikrein 6 antisense oligonucleotide seqid 124.
XX
KW   cytostatic; kallikrein 6 modulator; antisense therapy; gene therapy;
KW   kallikrein 6; hyperproliferative disorder; kallikrein 6 expression;
KW   antisense technology; human; antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004097452-A1.
XX
PD   20-MAY-2004.
XX
PF   19-NOV-2002; 2002US-00300820.
XX
PR   19-NOV-2002; 2002US-00300820.
XX
```

```
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-389193/36.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding kallikrein 6, useful for treating diseases associated with
PT   kallikrein 6, e.g. hyperproliferative disorders.
XX
PS   Example 15; SEQ ID NO 124; 56pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted
CC   to, and which specifically hybridises with, a nucleic acid molecule
CC   encoding kallikrein 6, and inhibits the expression of kallikrein 6. Also
CC   described are: a method for inhibiting the expression of kallikrein 6 in
CC   cells or tissues by contacting the cells or tissues with the compound so
CC   that expression of kallikrein 6 is inhibited; a method for screening a
CC   modulator of kallikrein 6 by contacting a preferred segment of a nucleic
CC   acid molecule encoding kallikrein 6 with one or more candidate modulators
CC   of kallikrein 6, and identifying one or more modulators of kallikrein 6
CC   expression which modulate the expression of kallikrein 6; a diagnostic
CC   method for identifying a disease state by identifying the presence of
CC   kallikrein 6 in a sample using any of the primers or probes given in the
CC   specification; a kit or assay device comprising the compound; and a
CC   method of treating an animal having a disease or condition associated
CC   with by kallikrein 6 administering to the animal a therapeutic or
CC   prophylactic amount of the compound so that expression of kallikrein 6 is
CC   inhibited. The compound, composition and methods are useful for treating
CC   a disease or condition associated with kallikrein 6, such as a
CC   hyperproliferative disorder. They are also useful in research and
CC   diagnostics for modulating the expression of kallikrein 6. This sequence
CC   represents a human kallikrein 6 antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGA 1619
              |||||| |||||| ||||
Db          2 TCCTGGGCTGGGGCAAGA 19


RESULT 107
ADN29175/c
ID   ADN29175 standard; DNA; 20 BP.
XX
AC   ADN29175;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human kallikrein 6 antisense oligonucleotide seqid 49.
XX
KW   cytostatic; kallikrein 6 modulator; antisense therapy; gene therapy;
KW   kallikrein 6; hyperproliferative disorder; kallikrein 6 expression;
KW   antisense technology; human; antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004097452-A1.
XX
PD   20-MAY-2004.
XX
PF   19-NOV-2002; 2002US-00300820.
XX
PR   19-NOV-2002; 2002US-00300820.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-389193/36.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding kallikrein 6, useful for treating diseases associated with
PT   kallikrein 6, e.g. hyperproliferative disorders.
XX
PS   Example 15; SEQ ID NO 49; 56pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted
CC   to, and which specifically hybridises with, a nucleic acid molecule
CC   encoding kallikrein 6, and inhibits the expression of kallikrein 6. Also
CC   described are: a method for inhibiting the expression of kallikrein 6 in
CC   cells or tissues by contacting the cells or tissues with the compound so
CC   that expression of kallikrein 6 is inhibited; a method for screening a
CC   modulator of kallikrein 6 by contacting a preferred segment of a nucleic
CC   acid molecule encoding kallikrein 6 with one or more candidate modulators
CC   of kallikrein 6, and identifying one or more modulators of kallikrein 6
CC   expression which modulate the expression of kallikrein 6; a diagnostic
CC   method for identifying a disease state by identifying the presence of
CC   kallikrein 6 in a sample using any of the primers or probes given in the
CC   specification; a kit or assay device comprising the compound; and a
CC   method of treating an animal having a disease or condition associated
CC   with by kallikrein 6 administering to the animal a therapeutic or
CC   prophylactic amount of the compound so that expression of kallikrein 6 is
CC   inhibited. The compound, composition and methods are useful for treating
CC   a disease or condition associated with kallikrein 6, such as a
CC   hyperproliferative disorder. They are also useful in research and
CC   diagnostics for modulating the expression of kallikrein 6. This sequence
CC   represents a human kallikrein 6 antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGA 1619
              |||||| |||||| ||||
Db         19 TCCTGGGCTGGGGCAAGA 2


RESULT 108
ADP19958/c
ID   ADP19958 standard; DNA; 20 BP.
XX
AC   ADP19958;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Human ABCC2 DNA antisense oligonucleotide #74.
XX
KW   Human; ABCC2; ss; antisense oligonucleotide; phosphorothioate linkage;
KW   2'-O-methoxyethyl sugar moiety; 5-methylcytosine; drug clearance;
KW   ATP-binding cassette subfamily C.
XX
OS   Homo sapiens.
XX
PN   US2004110699-A1.
```

```
XX
PD   10-JUN-2004.
XX
PF   10-DEC-2002; 2002US-00316389.
XX
PR   10-DEC-2002; 2002US-00316389.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-440379/41.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding ATP-binding cassette C2 (ABCC2), useful for treating disease or
PT   condition that affects drug clearance.
XX
PS   Example 15; SEQ ID NO 85; 54pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid molecule
CC   encoding the human ATP-binding cassette subfamily C (ABCC2) polypeptide.
CC   The compound is an antisense oligonucleotide that specifically hybridises
CC   with the nucleic acid and inhibits expression of the polypeptide. The
CC   antisense oligonucleotide comprises at least one modified internucleoside
CC   linkage i.e. a phosphorothioate linkage, at least one modified sugar
CC   moiety, preferably a 2'-O-methoxyethyl sugar moiety, or at least one
CC   modified nucleobase comprising a 5-methylcytosine. The antisense
CC   compounds are useful for modulating the expression of the human ABCC2
CC   polypeptide and in preparation of a composition for treating disorders
CC   associated with ABCC2, such as diseases or conditions that affect drug
CC   clearance. This sequence represents DNA encoding the human ABCC2
CC   polypeptide of the invention. This sequence represents an antisense
CC   oligonucleotide targeted to human ABCC2 DNA of the invention.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGGT 1947
              ||||| ||||||||||
Db         18 CAGTGACAAGGTAATGGT 1


RESULT 109
ADG38979/c
ID   ADG38979 standard; DNA; 21 BP.
XX
AC   ADG38979;
XX
DT   26-FEB-2004  (first entry)
XX
DE   tRNAArg/PSA attachment site (attBB') inverse PCR primer #2.
XX
KW   PCR; ss; primer; pPL1; integration vector; listeria; immunostimulant;
KW   vaccine; cellular immune response; bacteriophage attachment site;
KW   tRNAArg; PSA; attBB'; attachment site; inverse PCR.
XX
OS   Listeria monocytogenes.
XX
PN   US2003203472-A1.
XX
PD   30-OCT-2003.
XX
PF   30-APR-2002; 2002US-00136860.
XX
PR   30-APR-2002; 2002US-00136860.
XX
PA   (PORT/) PORTNOY D A.
PA   (CALE/) CALENDAR R.
PA   (LAUE/) LAUER P M.
XX
PI   Portnoy DA, Calendar R, Lauer PM;
XX
DR   WPI; 2003-875648/81.
XX
PT   New site-specific Listeria species integration vector, useful in
PT   eliciting or boosting a cellular immune response, in preparing vaccine or
PT   in research or in Listerial delivery preparation applications.
XX
PS   Example; SEQ ID NO 17; 17pp; English.
XX
CC   The invention relates to an integration vector capable of site-specific
CC   Listeria genome integration. Also included are transforming a Listeria
CC   (comprising contacting the Listeria with an integration vector under
CC   conditions sufficient for the integration vector to integrate into the
CC   genome of Listeria), a Listeria transformed with a vector, eliciting or
CC   boosting a cellular immune response to an antigen in a subject comprises
CC   administering to the subject an amount of vector transformed Listeria
CC   cells, a vaccine comprising a strain of Listeria cells of (2), which
CC   express a heterologous antigen; a recombinant culture of vector
CC   transformed Listeria cells, a kit, for preparing a vector or a cell
CC   (comprising a vector, at least one nuclease that cuts the vector at the
CC   multiple cloning site and a Listeria cell, a system for preparing the
CC   vaccine comprising a vector, at least one nuclease that cuts the vector
CC   at the multiple cloning site, a coding sequence for the heterologous
CC   antigen and Listeria cells). The integration vector comprises a
CC   bacteriophage (listeriophage) integrase gene and a bacteriophage
CC   attachment site. The attachment site provides for integration at an
CC   integration site, the comK or the tRNAArg integration site. The
CC   integration vector further includes a multiple cloning site and a coding
CC   sequence encoding a polypeptide, specifically an antigen. The integration
CC   vector and methods are useful in eliciting or boosting a cellular immune
CC   response, in preparing vaccine or in research or in Listerial delivery
CC   preparation applications. The present sequence is an inverse PCR primer
CC   (for tRNAArg/PSA attachment site (attBB')) used in the construction of
CC   the integrating vector pPL2.
XX
SQ   Sequence 21 BP; 8 A; 2 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 21;
  Best Local Similarity   88.9%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1960 CCGCTAAATATTTACCTT 1977
              ||||| ||||||||| ||
Db         21 CCGCTCAATATTTACATT 4


RESULT 110
AAZ26114
ID   AAZ26114 standard; DNA; 21 BP.
XX
AC   AAZ26114;
XX
DT   30-NOV-1999  (first entry)
XX
DE   Human polymorphic region 303.
XX
KW   Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;
KW   cell viability; loss of heterozygosity; precancerous condition; ASI;
KW   allele specific inhibitor; somatic cell; diagnosis; prevention;
KW   atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;
KW   dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
KW   graft versus host disease; malignant cell removal; bone marrow; ss.
XX
OS   Homo sapiens.
XX
PN   WO9841648-A2.
XX
PD   24-SEP-1998.
XX
PF   19-MAR-1998;   98WO-US005419.
XX
PR   20-MAR-1997;   97US-0041057P.
```

XX
PA (VARI-) VARIAGENICS INC.
XX
PI Housman D, Ledley FD, Stanton VP;
XX
DR WPI; 1998-521232/44.
XX
PT Identifying target genes for allele-specific drugs - used for diagnosis,
PT prevention and treatment of, e.g. cancers, atherosclerotic plaque,
PT dysplastic lesions, endometriosis or graft versus host disease.
XX
PS Disclosure; Fig 7; 605pp; English.
XX
CC This invention describes a novel method for identifying an inhibitor
CC potentially useful for treatment of cancer, where the inhibitor is active
CC on a gene vital for cell growth or viability, and where the gene is
CC subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is
CC used for preventing the development of cancer in a patient having a
CC precancerous condition, by administering to the patient a first allele
CC specific inhibitor (ASI) targeted to an allele of a first essential gene
CC present in cells of the precancerous condition, where the normal somatic
CC cells of the patient are heterozygous for the first gene, the inhibitor
CC is active on at least one but less than all allelic forms of the gene
CC present in a population and targets only one allelic form present in the
CC normal somatic cells, and the first gene. The products and methods can be
CC used in the diagnosis, prevention and treatment of LOH disorders, e.g.
CC cancers, atherosclerotic plaques, premalignant metaplastic or dysplastic
CC lesions, benign tumours, endometriosis, polycystic kidney disease, and
CC graft versus host disease. The method can also be used to remove
CC malignant cells from bone marrow transplants. AAZ25812-Z26825 represent
CC human polymorphic sites described in the method of the invention
XX
SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1639 ATTTAAAGAGCCTTCACTGGT 1659
| | || |||||| |||||||
Db 1 ACTGAATGAGCCTCCACTGGT 21

RESULT 111
AAZ58833/c
ID AAZ58833 standard; DNA; 21 BP.
XX
AC AAZ58833;
XX
DT 25-APR-2000 (first entry)
XX
DE Human beta2-microglobulin gene specific primer beta-21F.
XX
KW Mucin; MUC11; MUC12; human; chromosome 7q22; epithelial inflammation;
KW Crohn's disease; ulcerative colitis; asthma; chronic bronchitis;
KW colorectal cancer; cystic fibrosis; inflammatory bowel disease;
KW breast cancer; beta2-microglobulin; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200004142-A1.
XX
PD 27-JAN-2000.
XX
PF 16-JUL-1999; 99WO-AU000579.
XX
PR 16-JUL-1998; 98AU-00004708.
XX
PA (COUN-) COUNCIL QUEENSLAND INST MEDICAL RES.
PA (ORDE-) ORDER OF SISTERS OF MERCY IN QUEENSLAND.
XX
PI Williams SJ, Antalis TM, Mcguckin MA, Gotley DC;
XX
DR WPI; 2000-182416/16.
XX
PT Novel MUC nucleic acid corresponding to mucin gene, useful for treating
PT associated disease conditions e.g. colorectal, breast cancer, cystic
PT fibrosis and inflammatory bowel disease.
XX
PS Example 7; Page 40; 103pp; English.
XX
CC The invention provides mucin genes (MUC11 and MUC12) located on human
CC chromosome 7q22. The mucin genes or its portion is used in detecting
CC polymorphism, mutation, deletion, truncation and expansion in the gene or
CC its gene transcript. Pharmaceutical compositions and gene therapy
CC constructs comprising the mucin genes are used for treating disease
CC conditions associated with aberrant Mucin expression, altered properties
CC of mucus or epithelial inflammatory processes involving Mucins like
CC Crohn's disease, ulcerative colitis, asthma, chronic bronchitis and
CC colorectal cancer, cystic fibrosis, inflammatory bowel disease and breast
CC cancer. The mucin genes and the polypeptides are used for determining
CC these diseases or their predisposition. The MUC11 and MUC12 polypeptides
CC are used for preparing antagonist and antibodies. Sequences AAZ58833-34
CC represent beta2-microglobulin gene specific primers
XX
SQ Sequence 21 BP; 3 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.6; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1858 ACCCACACACTTAGCCATTGA 1878
||||| |||| |||| ||| |
Db 21 ACCCAGACACATAGCAATTCA 1

RESULT 112
ABQ83354/c
ID ABQ83354 standard; DNA; 21 BP.
XX
AC ABQ83354;
XX
DT 20-JAN-2003 (first entry)
XX
DE Beta-2-microglobulin PCR primer #1.
XX
KW Human; KLK4; cancer; benign tumour; cytostatic; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200277243-A1.
XX
PD 03-OCT-2002.
XX
PF 27-MAR-2002; 2002WO-AU000378.
XX
PR 27-MAR-2001; 2001AU-00004022.
XX
PA (UYQU-) UNIV QUEENSLAND TECHNOLOGY.
XX
PI Dong Y, Clements JA;
XX
DR WPI; 2003-029939/02.
XX
PT Detecting the presence or diagnosing the risk of cancer or benign tumor,
PT e.g. an ovarian, endometrial or prostate cancer, by determining the
PT presence of or detecting aberrant expression of KLK4 in a biological
PT sample from the patient.
XX
PS Example 2; Page 67; 126pp; English.
XX
CC The present invention describes a method (M1) for detecting the presence
CC or diagnosing the risk of cancer or benign tumour in a patient. M1
CC comprises determining the presence of or detecting aberrant expression of
CC KLK4 in a biological sample obtained from the patient. KLK4 has

```
CC   cytostatic activity. The method is useful for detecting the presence or
CC   diagnosing the risk of a cancer or a benign tumour in a patient,
CC   particularly an ovarian, endometrial or prostate cancer, or a cancer or
CC   benign tumour associated with an organ or tissue from the ovaries,
CC   endometrium or prostate. An agent which can be used for restoring or
CC   modulating KLK4 expression can be used for treating or preventing cancer
CC   or benign tumour. KLK4 polynucleotides, polypeptides or antigen-binding
CC   molecules from the present invention can be used for detecting aberrant
CC   KLK4 polynucleotides or aberrant K4 polypeptides that correlate with a
CC   cancer or a benign tumour. The present sequence represents a PCR primer
CC   for beta-2-microglobulin, which is used in an example from the present
CC   invention
XX
SQ   Sequence 21 BP; 3 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1858 ACCCACACACTTAGCCATTGA 1878
              ||||| |||| |||| ||| |
Db         21 ACCCAGACACATAGCAATTCA 1


RESULT 113
ABQ83360/c
ID   ABQ83360 standard; DNA; 21 BP.
XX
AC   ABQ83360;
XX
DT   20-JAN-2003  (first entry)
XX
DE   Beta-2-microglobulin PCR primer #3.
XX
KW   Human; KLK4; cancer; benign tumour; cytostatic; PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200277243-A1.
XX
PD   03-OCT-2002.
XX
PF   27-MAR-2002; 2002WO-AU000378.
XX
PR   27-MAR-2001; 2001AU-00004022.
XX
PA   (UYQU-) UNIV QUEENSLAND TECHNOLOGY.
XX
PI   Dong Y,  Clements JA;
XX
DR   WPI; 2003-029939/02.
XX
PT   Detecting the presence or diagnosing the risk of cancer or benign tumor,
PT   e.g. an ovarian, endometrial or prostate cancer, by determining the
PT   presence of or detecting aberrant expression of KLK4 in a biological
PT   sample from the patient.
XX
PS   Example 4; Page 68; 126pp; English.
XX
CC   The present invention describes a method (M1) for detecting the presence
CC   or diagnosing the risk of cancer or benign tumour in a patient. M1
CC   comprises determining the presence of or detecting aberrant expression of
CC   KLK4 in a biological sample obtained from the patient. KLK4 has
CC   cytostatic activity. The method is useful for detecting the presence or
CC   diagnosing the risk of a cancer or a benign tumour in a patient,
CC   particularly an ovarian, endometrial or prostate cancer, or a cancer or
CC   benign tumour associated with an organ or tissue from the ovaries,
CC   endometrium or prostate. An agent which can be used for restoring or
CC   modulating KLK4 expression can be used for treating or preventing cancer
CC   or benign tumour. KLK4 polynucleotides, polypeptides or antigen-binding
CC   molecules from the present invention can be used for detecting aberrant
CC   KLK4 polynucleotides or aberrant K4 polypeptides that correlate with a
CC   cancer or a benign tumour. The present sequence represents a PCR primer
CC   for beta-2-microglobulin, which is used in an example from the present
CC   invention
XX
SQ   Sequence 21 BP; 3 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1858 ACCCACACACTTAGCCATTGA 1878
              ||||| |||| |||| ||| |
Db         21 ACCCAGACACATAGCAATTCA 1


RESULT 114
ADF18209/c
ID   ADF18209 standard; DNA; 21 BP.
XX
AC   ADF18209;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human beta2-microglobulin forward PCR primer.
XX
KW   Prostate specific antigen; kallikrein 2; beta2-microglobulin;
KW   prostate cancer; cytostatic; gene therapy; vaccine; PCR; primer; human;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2003089932-A1.
XX
PD   30-OCT-2003.
XX
PF   16-APR-2003; 2003WO-AU000454.
XX
PR   22-APR-2002; 2002AU-00001870.
XX
PA   (UYQU-) UNIV QUEENSLAND TECHNOLOGY.
XX
PI   Clements JA;
XX
DR   WPI; 2003-854153/79.
XX
PT   Detecting the presence or diagnosing the risk of prostate cancer in a
PT   patient by detecting a level or functional activity of an aberrant
PT   prostate specific antigen or kallikrein 2 expression product in a
PT   biological sample.
XX
PS   Example 2; SEQ ID NO 28; 84pp; English.
XX
CC   The present sequence is that of a forward primer for human beta2-
CC   microglobulin. Use with a reverse primer ADF18210 generates a 238 bp
CC   product. RT-PCR was used to examine kallikrein 2 (KLK2) and prostate
CC   specific antigen (PSA) mRNA species in prostate cancer and benign
CC   prostate hyperplasia (BPH) tissues. The primer pair was also used in a
CC   real-time PCR analysis. The invention is based on the discovery that
CC   patients with prostate cancer produce different levels of aberrant
CC   transcripts, and presumably of aberrant polypeptides, corresponding to
CC   the PSA and KLK2 genes compared to patients with BPH. The invention
CC   provides a method for detecting the presence or diagnosing the risk of
CC   prostate cancer in a patient, based on detecting a level or functional
CC   activity of an aberrant expression product of a PSA or KLK2 gene which
CC   correlates with the presence of risk of prostate cancer. Claimed methods
CC   for the treatment and/or prophylaxis of prostate cancer involve
CC   administering an antisense oligonucleotide, a ribozyme or an RNAi-
CC   mediated molecule that binds to, or specifically interacts with, an
CC   aberrant transcript of a PSA or KLK2 gene, or administering an antigen-
CC   binding molecule that is immuno-reactive with an aberrant PSA or KLK2
CC   polypeptide, or administering an antigen-presenting cell expressing a
CC   processed form of the aberrant polypeptide for presentation to, and
CC   modulation of, T-cells.
```

```
XX
SQ   Sequence 21 BP; 3 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 21;
  Best Local Similarity   81.0%;  Pred. No. 2.3e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1858 ACCCACACACTTAGCCATTGA 1878
              ||||| |||| |||| ||| |
Db         21 ACCCAGACACATAGCAATTCA 1

RESULT 115
AAV74151
ID   AAV74151 standard; DNA; 22 BP.
XX
AC   AAV74151;
XX
DT   15-MAR-1999  (first entry)
XX
DE   Human thyroid gene NIS PCR primer DNA #1.
XX
KW   Thyroid; NIS gene; detection; epithelial cell; thyroid-specific gene;
KW   blood cell; cancer; recurrence; cell sorting; thyroidectomy; diagnosis;
KW   hormone replacement therapy; thyroglobulin; immunoassay; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9856953-A1.
XX
PD   17-DEC-1998.
XX
PF   09-JUN-1998;   98WO-US011934.
XX
PR   10-JUN-1997;   97US-0049144P.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI   Levine MA,  Ringel MD;
XX
DR   WPI; 1999-070335/06.
XX
PT   Detecting thyroid epithelial cells in blood - by detecting cDNA from
PT   thyroid-specific RNA, particularly for monitoring treatment and recovery
PT   from thyroid cancer following thyroidectomy.
XX
PS   Claim 29; Page 63; 80pp; English.
XX
CC   AAV74143-V74155 are PCR primers and probes used to detect thyroid
CC   epithelial cells (TEC) in a patient. The detection method comprises
CC   detecting a transcript of a thyroid-specific gene in a sample of reverse-
CC   transcribed total RNA of blood cells. The specification also describes a
CC   method for detecting TEC by polymerase chain reaction (PCR) of reverse-
CC   transcribed RNA (not necessarily total RNA) from blood cells, using
CC   primers that produce an amplicon that spans at least one intron, then
CC   detecting the PCR product and also a method for monitoring recurrence of
CC   thyroid cancer in a recovering patient by detecting, in a sample of
CC   reverse-transcribed total RNA of blood cells, a transcript of a thyroid-
CC   specific gene as an indicator of recurrence. The specification also
CC   describes a method for detecting TEC by cell-sorting to isolate a TEC-
CC   containing fraction from blood, then detecting TEC in this fraction. The
CC   methods are used to monitor treatment of, and recovery from, thyroid
CC   cancer, in patients who have had a total thyroidectomy. The method does
CC   not require the patient to stop thyroid hormone replacement therapy and
CC   is not subject to interference from antibodies against thyroglobulin
CC   which may falsify the conventional immunoassay. Peripheral blood is an
CC   easily obtained source of sample and the process is more sensitive than
CC   immunoassay. By amplifying fragments from several thyroid specific genes,
CC   even rare forms of thyroid cancer may be diagnosed
XX
SQ   Sequence 22 BP; 4 A; 10 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 2.4e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1585 CACAGACTGGGAACCCCTCCT 1605
              ||| ||||| || || |||||
Db          2 CACTGACTGCGACCCTCTCCT 22

RESULT 116
AAL47282
ID   AAL47282 standard; DNA; 22 BP.
XX
AC   AAL47282;
XX
DT   30-AUG-2002  (first entry)
XX
DE   Hepatitis C virus NS5B region PCR primer #1.
XX
KW   Hepatitis; HCV; core-neo; NS3 proteinase/helicase; vaccine; diagnosis;
KW   virucide; hepatotropic; gene therapy; anti-viral; PCR; primer; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200238793-A2.
XX
PD   16-MAY-2002.
XX
PF   02-NOV-2001; 2001WO-US046350.
XX
PR   07-NOV-2000; 2000US-0245866P.
XX
PA   (ANAD-) ANADYS PHARM INC.
XX
PI   Bichko V;
XX
DR   WPI; 2002-490082/52.
XX
PT   Novel nucleic acid encoding replication competent recombinant hepatitis C
PT   virus genome useful for screening anti-hepatitis C virus therapeutics and
PT   for vaccine development.
XX
PS   Example 1; Page 75; 85pp; English.
XX
CC   The present invention provides protein and coding sequences from
CC   Hepatitis C virus (HCV), comprising all or part of the HCV genome and
CC   able to replicate efficiently when transfected into a susceptible cell
CC   line without reducing the growth rate of the cell line by more than 10
CC   fold. The sequences are useful for screening for anti-HCV therapeutics,
CC   for detecting antibodies to HCV in a biological sample such as blood,
CC   serum, plasma, blood cells, lymphocytes, or liver cells from a subject,
CC   for deriving authentic HCV components such as replication-complement non-
CC   infectious, replication-defective infection-component, and replication-
CC   defective non-infectious HCV, in gene therapy or gene vaccination
CC   targeted to hepatic tissue for treating an animal infected or susceptible
CC   to HCV infection and for studying HCV infection and propagation. The
CC   present sequence is a PCR primer used to amplify the HCV NS5B region in
CC   the exemplification of the invention
XX
SQ   Sequence 22 BP; 5 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 2.4e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGATCAAC 1915
              |||||||||   |||||| ||
Db          1 GCCCTAGATTGTCAGATCTAC 21

RESULT 117
ACC90648
ID   ACC90648 standard; DNA; 22 BP.
```

XX
AC ACC90648;
XX
DT 13-AUG-2003 (first entry)
XX
DE Human CYP1A2 PCR primer SEQ ID NO:14.
XX
KW CYP1A2; cytochrome P450; cytostatic; hepatotropic; dermatological;
KW cerebroprotective; gene therapy; cancer; congenital jaundice;
KW porphyria cutanea tarda; tardive dyskinesia; schizophrenia; human; PCR;
KW primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003014387-A2.
XX
PD 20-FEB-2003.
XX
PF 08-AUG-2002; 2002WO-EP008893.
XX
PR 08-AUG-2001; 2001EP-00118770.
XX
PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI Wojnowski L, Presecan-Siedel E;
XX
DR WPI; 2003-256599/25.
XX
PT New CYP1A2 polynucleotide and polypeptide, useful for the preparation of
PT a diagnostic or therapeutic composition for cancer, congenital jaundice,
PT porphyria cutanea tarda or tardive dyskinesia in schizophrenia.
XX
PS Example 1; Page 38; 117pp; English.
XX
CC The invention relates to a novel polynucleotide comprising any of 37 11-
CC 761 base pair sequences, given in the specification, encoding a
CC polypeptide with any of 4 28-31 residue amino acid sequences, in the
CC specification, hybridising to a CYP1A2 gene, or encoding a CYP1A2
CC polypeptide or fragment comprising an amino acid substitution at position
CC 61, 298, 401 or 438. A polypeptide of the invention has cytostatic,
CC hepatotropic, dermatological, and cerebroprotective activity. A
CC polynucleotide of the invention may act as a CYP1A2-antagonist or CPY1A2-
CC agonist, and may have a use in gene therapy. The methods and compositions
CC of the present invention are useful for the preparation of a diagnostic
CC or therapeutic composition for a disease, in particular cancer,
CC congenital jaundice, porphyria cutanea tarda or tardive dyskinesia in
CC schizophrenia. The sequences shown in ACC90635-ACC90686 represent PCR
CC primer used in the invention to screen for polymorphisms within CYP1A2
XX
SQ Sequence 22 BP; 3 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.6; DB 1; Length 22;
Best Local Similarity 81.0%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1675 CCTGGACTTCTTAGTTGTTTC 1695
||||| | || |||||| |||
Db 2 CCTGGCCATCCTAGTTGATTC 22

RESULT 118
ACD06310/c
ID ACD06310 standard; DNA; 22 BP.
XX
AC ACD06310;
XX
DT 06-AUG-2003 (first entry)
XX
DE Reverse RT-PCR primer for human NOV7a.
XX
KW Human; ss; PCR; NOVX; cardiomyopathy; atherosclerosis; hypertension;
KW congenital heart defect; prostate cancer; diabetes; metabolic disorder;
KW neoplasm; graft versus host disease; AIDS; bronchial asthma; primer;
KW Crohn's disease; multiple sclerosis; infectious disease; anorexia;
KW cancer-associated cachexia; neurodegenerative disorder; RT-PCR;
KW Alzheimer's disease; Parkinson's disease; immune disorder;
KW haematopoietic disorder; dyslipidaemia; wasting disorder; gene therapy;
KW reverse transcriptase PCR.
XX
OS Homo sapiens.
XX
PN WO2003023008-A2.
XX
PD 20-MAR-2003.
XX
PF 09-SEP-2002; 2002WO-US028596.
XX
PR 07-SEP-2001; 2001US-0318120P.
PR 07-SEP-2001; 2001US-0318130P.
PR 10-SEP-2001; 2001US-0318430P.
PR 12-SEP-2001; 2001US-0318765P.
PR 17-SEP-2001; 2001US-0322781P.
PR 17-SEP-2001; 2001US-0322816P.
PR 19-SEP-2001; 2001US-0323519P.
PR 20-SEP-2001; 2001US-0323631P.
PR 20-SEP-2001; 2001US-0323636P.
PR 25-SEP-2001; 2001US-0324969P.
PR 25-SEP-2001; 2001US-0325091P.
PR 26-SEP-2001; 2001US-0324990P.
PR 15-FEB-2002; 2002US-0357303P.
PR 28-FEB-2002; 2002US-0360973P.
PR 20-MAR-2002; 2002US-0366131P.
PR 25-MAR-2002; 2002US-0367753P.
PR 02-APR-2002; 2002US-0369479P.
PR 10-MAY-2002; 2002US-0379532P.
PR 17-MAY-2002; 2002US-0381664P.
PR 17-MAY-2002; 2002US-0381672P.
PR 28-MAY-2002; 2002US-0383651P.
PR 29-MAY-2002; 2002US-0384012P.
PR 19-JUN-2002; 2002US-0390155P.
PR 06-SEP-2002; 2002US-00390155.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Zhong M, Li L, Gorman L, Spytek KA, Kekuda R, Taupier RJ;
PI Anderson DW, Vernet CAM, Catterton E, Miller CE, Shenoy SG;
PI Patturajan M, Pena CEA, Tchernev VT, Padigaru M, Gusev VY;
PI Malyankar UM, Burgess CE, Gerlach VL, Casman SJ, Rieger DK;
PI Grosse WM, Smithson G, Peyman JA, Starling G, Rothenberg ME;
PI Larochelle WJ, Shimkets RA, Crabtree J, Rastelli L, Voss EZ;
PI Boldog FL, Edinger SR, Millet I, Macdougall JR, Ellerman K;
PI Chapoval A;
XX
DR WPI; 2003-313246/30.
XX
PT New polypeptides and polynucleotides having properties related to
PT stimulation of biochemical or physiological responses in a cell or
PT tissue, useful for diagnosing or preventing e.g. atherosclerosis,
PT hypertension, prostate cancer.
XX
PS Example C; Page 332; 849pp; English.
XX
CC The invention relates to an isolated polypeptide comprising one of 127
CC sequences (appearing as ABO1288-ABO1414) designated as NOVX, a mature
CC form of NOVX, an amino acid sequence which is at least 95% identical to
CC NOVX or an amino acid sequence comprising one or more conservative
CC substitutions in NOVX. Also included are nucleic acids encoding NOVX
CC proteins, determining the presence or amount of NOVX or NOVX DNA in a
CC sample (by introducing the sample to an antibody that binds
CC immunospecifically to the polypeptide, and determining the presence or
CC amount of antibody bound to the polypeptide), determining the presence of
CC or predisposition to a disease associated with altered levels of
CC expression of NOVX or NOVX DNA in a first mammalian subject, identifying
CC an agent that binds to NOVX, identifying a potential therapeutic agent
CC for treatment of a pathology related to aberrant expression or aberrant
CC physiological interactions of NOVX, screening for a modulator of activity

```
CC   of or of latency or predisposition to a pathology associated with NOVX, a
CC   vector comprising NOVX DNA, a cell comprising the vector (used to produce
CC   NOVX) and an anti-NOVX antibody. The NOVX nucleic acids and polypeptides
CC   are useful as a marker for cell or tissue type, and in diagnosing and
CC   treating pathologies, diseases, conditions or disorders associated with
CC   NOVX sequences, including cardiomyopathy, atherosclerosis, hypertension,
CC   congenital heart defects, prostate cancer, diabetes, metabolic disorders,
CC   neoplasm, graft versus host disease, AIDS, bronchial asthma, Crohn's
CC   disease, multiple sclerosis, infectious diseases, anorexia, cancer-
CC   associated cachexia, neurodegenerative disorders (e.g. Alzheimer's
CC   disease or Parkinson's disease), immune disorders, haematopoietic
CC   disorders, dyslipidaemias, and wasting disorders associated with chronic
CC   diseases. These may also be used to screen for molecules which inhibit or
CC   enhance NOVX activity or function, and for detecting specific cell types.
CC   These may also be used in chromosome mapping, gene therapy, tissue
CC   typing, and in forensic biology. The present sequence is a reverse
CC   transcriptase (RT)-PCR primer used to assess the tissue specific
CC   expression of mRNA encoding a NOVX protein
XX
SQ   Sequence 22 BP; 9 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 2.4e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1829 TCTTTTAAATACATTCCCTGG 1849
              |||||| |  ||||||| |||
Db         21 TCTTTTGATGACATTCCATGG 1

RESULT 119
ADO10732/c
ID   ADO10732 standard; DNA; 22 BP.
XX
AC   ADO10732;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Single multiplex PCR primer #104.
XX
KW   ss; primer; simultaneous amplification;
KW   single multiplex polymerase chain reaction; multifactorial disease;
KW   genetic alteration; pharmacogenetic reaction; genotyping; polymorphism;
KW   gene expression profiling.
XX
OS   Synthetic.
XX
PN   WO2004033649-A2.
XX
PD   22-APR-2004.
XX
PF   07-OCT-2003; 2003WO-US031874.
XX
PR   07-OCT-2002; 2002US-0417009P.
XX
PA   (UYNE-) UNIV NEW JERSEY MEDICINE & DENTISTRY.
XX
PI   Li H,  Li J;
XX
DR   WPI; 2004-340914/31.
XX
PT   Designing primers for simultaneous amplification of target DNA fragments
PT   in a single multiplex polymerase chain reaction, for high throughput
PT   multiplex DNA sequence amplification, comprises aligning two primers.
XX
PS   Disclosure; Page 33; 120pp; English.
XX
CC   The invention relates to a method of designing primers for simultaneous
CC   amplification of target DNA fragments in a single multiplex polymerase
CC   chain reaction by aligning a first primer and a second primer. The method
CC   comprises: (a) aligning a first primer and a second primer; and (b)
CC   selecting the first primer where the first primer at its 3' end does not
CC   contain four or more bases that are perfectly matching to the 3' end
CC   sequence of the first primer or a second primer, the first primer at its
CC   3' end does not contain seven or more bases that are perfectly matching
CC   except one mismatch to the 3' end sequence of the first primer or the
CC   second primer, the first primer at its 3' end does not contain six or
CC   more bases that are perfectly matching to a sequence anywhere of the
CC   first primer or the second primer, and the first primer at its 3' end
CC   does not contain eleven or more bases that are perfectly matching except
CC   one mismatch to a sequence anywhere of the first primer or the second
CC   primer. The method is useful for designing primers for simultaneous
CC   amplification of target DNA fragments in a single multiplex polymerase
CC   chain reaction. It is also useful in the identification of multiple genes
CC   related to multifactorial diseases, the genome-scale detection of genetic
CC   alterations, the studies in pharmacogenetic reactions, the genotyping
CC   genetic polymorphisms in a large population, the gene expression
CC   profiling in various samples and high throughput genotyping technologies.
CC   This sequence corresponds to an example of a primer of the invention.
XX
SQ   Sequence 22 BP; 2 A; 10 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 2.4e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1549 GGGAAGGAACAGGACTGCAAA 1569
              | |  |||||||||||| |||
Db         22 GTGGGGGAACAGGACTGGAAA 2

RESULT 120
AAF06327/c
ID   AAF06327 standard; DNA; 17 BP.
XX
AC   AAF06327;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3124.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 127; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 7 A; 1 C; 2 G; 0 T; 7 U; 0 Other;
```

```
  Query Match             2.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
              ||||||||||| ||||
Db         17 TTTACCTTGAATAAAA 2


RESULT 121
ACN11557/c
ID   ACN11557 standard; RNA; 17 BP.
XX
AC   ACN11557;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11560.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11560; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 8 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGT 1621
              ||||||||| ||||||
Db         16 GGCCTGGGGAAAGAGT 1


RESULT 122
ACN05924
ID   ACN05924 standard; RNA; 17 BP.
XX
AC   ACN05924;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 5927.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 5927; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 8 G; 0 T; 2 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 2.2e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGT 1621
              ||||:|||| |||||:
Db          2 GGCCUGGGGAAAGAGU 17


RESULT 123
ACN05925
ID   ACN05925 standard; RNA; 17 BP.
XX
```

```
AC   ACN05925;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 5928.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 5928; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 8 G; 0 T; 2 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 2.2e+02;
  Matches   13;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGT 1621
              ||||:|||| |||||:
Db          1 GGCCUGGGGAAAGAGU 16


RESULT 124
ACN08989/c
ID   ACN08989 standard; RNA; 17 BP.
XX
AC   ACN08989;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8992.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 8992; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 8 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGT 1621
              ||||||||| ||||||
Db         17 GGCCTGGGGAAAGAGT 2


RESULT 125
ADB44223
ID   ADB44223 standard; DNA; 17 BP.
XX
AC   ADB44223;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #4546.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
```

XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 563; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 7 A; 2 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1828 ATCTTTTAAATACATT 1843
|||| ||||||||||
Db 2 ATCTATTAAATACATT 17

RESULT 126
AAD40585/c
ID AAD40585 standard; DNA; 18 BP.
XX
AC AAD40585;
XX
DT 30-OCT-2002 (first entry)
XX
DE HIV-1 LTR luciferase reporter gene mutant fragment, A3.
XX
KW Human immunodeficiency virus; HIV; infection; transcriptional repressor;
KW OTK18; brain; polymorphonuclear blood mononucleocyte; neuronal injury;
KW CD4+ T cell; antiretroviral; mononuclear phagocyte; MP; macrophage;
KW gene therapy; anti-HIV; mutant; ds.
XX
OS Human immunodeficiency virus 1.
OS Synthetic.
XX
PN WO200235981-A2.
XX
PD 10-MAY-2002.
XX
PF 06-NOV-2001; 2001WO-US044336.
XX
PR 06-NOV-2000; 2000US-0246331P.
PR 06-APR-2001; 2001US-00828648.
XX
PA (UYNE-) UNIV NEBRASKA.
XX
PI Ikezu T, Leisman G, Carlson KA, Gendelman HE;
XX
DR WPI; 2002-519218/55.
XX
PT New truncated OTK18 transcriptional repressor protein, useful for
PT treating human immunodeficiency virus infection and for identifying OTK18
PT expression in a biological sample.
XX
PS Example 2; Fig 11A; 96pp; English.
XX
CC The invention relates to methods and compositions for the treatment of
CC human immunodeficiency virus (HIV) infection. The invention also relates
CC to OTK18 transcriptional repressor protein and its corresponding nucleic
CC acid. An antibody to OTK18 is useful for identifying OTK18 expression in
CC a biological sample (e.g. polymorphonuclear blood mononucleocytes, brain
CC tissue, macrophages and CD4+ T cells). OTK18 is used for treating HIV
CC infection. It is useful for screening molecules that modulate or affect
CC its activity. Its antibody is useful for identifying multinuclear giant
CC cells in HIV encephalitic brains or immune activated mononuclear
CC phagocytes (MP) in the brains, for fluorescent activated cell sorting
CC (FACS) analysis of peripheral blood cells to evaluate the antiretroviral
CC reaction of MP and for immunoprecipitating proteins from a sample
CC containing a mixture of proteins and other biological molecules. OTK18
CC molecules are useful in the treatment and diagnosis of HIV infection, as
CC research tools to identify the control of gene expression in response to
CC HIV infection and subsequent neuronal injury. OTK18 DNA is useful in gene
CC therapy. The present sequence is HIV-1 LTR luciferase reporter gene
CC derived mutant DNA fragment used to illustrate the method of the
CC invention
XX
SQ Sequence 18 BP; 3 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1899 TAGATCAACAGATCAA 1914
|||||| |||||||||
Db 18 TAGATCCACAGATCAA 3

RESULT 127
ACF62964
ID ACF62964 standard; DNA; 18 BP.
XX
AC ACF62964;
XX
DT 09-OCT-2003 (first entry)
XX
DE Human p16 PCR primer SEQ ID NO:213.
XX
KW Human; colon cancer; oestrogen receptor; myoglobin; p21; p27; p16; p53;
KW progesterone receptor; pcna; CEA; cdc2; c-erbB2; methylation; CpG;
KW characterisation; classification; diagnosis; differentiation;
KW colon cell proliferative disorder; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003014388-A2.
XX
PD 20-FEB-2003.
XX
PF 09-AUG-2002; 2002WO-EP008939.
XX
PR 09-AUG-2001; 2001DE-01039283.

```
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Distler J,  Model F,  Taubert H;
XX
DR   WPI; 2003-256600/25.
XX
PT   Determining methylation status of CpG dinucleotides using modified
PT   genomic sequences, oligonucleotides and/or PNA-oligomers, useful in the
PT   characterization, grading, staging and/or diagnosis of colon cancer.
XX
PS   Claim 26; Page 159; 219pp; English.
XX
CC   The present invention describes a method for determining the methylation
CC   status of CpG dinucleotides within the genes for oestrogen receptor, p21,
CC   p27, p16, progesterone receptor, myoglobin, pcna, cdc2, c-erB2, p53
CC   and/or CEA, which comprises contacting the target nucleic acid with a
CC   reagent that distinguishes between methylated and non-methylated CpG
CC   dinucleotides, and determining from the methylation status of the CpG
CC   positions the presence of a colon cancer. A set of oligomers or peptide
CC   nucleic acid (PNA)-oligomers can be used as probes for determining the
CC   cytosine methylation state and/or single nucleotide polymorphisms (SNP)
CC   of a corresponding genomic DNA by analysis of a chemically pretreated
CC   genomic DNA. The pretreated genomic DNA is useful for the determination
CC   of the methylation status of a corresponding genomic DNA and/or detection
CC   of SNPs. The methods and pretreated genomic DNA are also useful for the
CC   characterisation, classification, diagnosis and differentiation of colon
CC   cell proliferative disorders. ACF62752 to ACF63278 represent sequences
CC   used in the exemplification of the present invention
XX
SQ   Sequence 18 BP; 6 A; 4 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
                ||||||||||||| ||
Db          1 TTTAAATACATTCACT 16


RESULT 128
ACF62962/c
ID   ACF62962 standard; DNA; 18 BP.
XX
AC   ACF62962;
XX
DT   09-OCT-2003  (first entry)
XX
DE   Human p16 PCR primer SEQ ID NO:211.
XX
KW   Human; colon cancer; oestrogen receptor; myoglobin; p21; p27; p16; p53;
KW   progesterone receptor; pcna; CEA; cdc2; c-erbB2; methylation; CpG;
KW   characterisation; classification; diagnosis; differentiation;
KW   colon cell proliferative disorder; PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003014388-A2.
XX
PD   20-FEB-2003.
XX
PF   09-AUG-2002; 2002WO-EP008939.
XX
PR   09-AUG-2001; 2001DE-01039283.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Distler J,  Model F,  Taubert H;
XX
DR   WPI; 2003-256600/25.
XX
PT   Determining methylation status of CpG dinucleotides using modified
PT   genomic sequences, oligonucleotides and/or PNA-oligomers, useful in the
PT   characterization, grading, staging and/or diagnosis of colon cancer.
XX
PS   Claim 26; Page 158; 219pp; English.
XX
CC   The present invention describes a method for determining the methylation
CC   status of CpG dinucleotides within the genes for oestrogen receptor, p21,
CC   p27, p16, progesterone receptor, myoglobin, pcna, cdc2, c-erB2, p53
CC   and/or CEA, which comprises contacting the target nucleic acid with a
CC   reagent that distinguishes between methylated and non-methylated CpG
CC   dinucleotides, and determining from the methylation status of the CpG
CC   positions the presence of a colon cancer. A set of oligomers or peptide
CC   nucleic acid (PNA)-oligomers can be used as probes for determining the
CC   cytosine methylation state and/or single nucleotide polymorphisms (SNP)
CC   of a corresponding genomic DNA by analysis of a chemically pretreated
CC   genomic DNA. The pretreated genomic DNA is useful for the determination
CC   of the methylation status of a corresponding genomic DNA and/or detection
CC   of SNPs. The methods and pretreated genomic DNA are also useful for the
CC   characterisation, classification, diagnosis and differentiation of colon
CC   cell proliferative disorders. ACF62752 to ACF63278 represent sequences
CC   used in the exemplification of the present invention
XX
SQ   Sequence 18 BP; 8 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
                ||||||||||||| ||
Db         18 TTTAAATACATTCACT 3


RESULT 129
ABZ10570/c
ID   ABZ10570 standard; DNA; 18 BP.
XX
AC   ABZ10570;
XX
DT   16-JAN-2003  (first entry)
XX
DE   Haematopoietic cell proliferation disorder related oligonucleotide #710.
XX
KW   Human; haematopoietic cell proliferation disorder; cytostatic;
KW   gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW   cytosine methylation state; probe; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200277272-A2.
XX
PD   03-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-EP003401.
XX
PR   26-MAR-2001; 2001US-0278333P.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Berlin K,  Braun A,  Distler J,  Guetig D,  Howe A,  Mueller J;
PI   Olek A,  Piepenbrock C,  Adorjan P,  Grabs G,  Lesche R,  Leu E;
PI   Lewin A,  Lipscher E,  Maier S,  Model F,  Mueller V,  Otto T,  Pelet C;
PI   Schwope I,  Ziebarth H;
XX
DR   WPI; 2003-018942/01.
XX
PT   Detecting and differentiating between hematopoietic cell proliferative
PT   disorders, comprises contacting a target nucleic acid with a reagent that
PT   distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS   Claim 15; Page 50; 117pp; English.
```

```
XX
CC   The present invention describes a method for detecting and
CC   differentiating between haematopoietic cell proliferative disorders
CC   associated with at least 1 gene and/or their regulatory regions in a
CC   subject. The method comprises contacting a target nucleic acid in a
CC   biological sample obtained from the subject with at least 1 reagent,
CC   which distinguishes between methylated and non-methylated CpG
CC   dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC   represent specifically claimed nucleotide sequences from the present
CC   invention. Oligonucleotides from the present invention can be used: for
CC   differentiating between healthy haematopoietic cells and proliferative
CC   disorder haematopoietic cells; for differentiating between acute
CC   lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC   determining the cytosine methylation state and/or single nucleotide
CC   polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC   related sequences and their complements; and as primers for the
CC   amplification of haematopoietic cell proliferation disorder related DNA
CC   sequences. The nucleotide sequences from the present invention can also
CC   be used for detecting a predisposition to, differentiation between
CC   subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC   haematopoietic cell proliferative disorders. The present method enables a
CC   highly specific classification of haematopoietic cell proliferative
CC   disorders allowing for improved and informed treatment of patients
XX
SQ   Sequence 18 BP; 8 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
                ||||||||||||| ||
Db         18 TTTAAATACATTCACT 3


RESULT 130
ADB54572/c
ID   ADB54572 standard; DNA; 18 BP.
XX
AC   ADB54572;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Hybridisation oligonucleotide 110 used to analyse genomic DNA region.
XX
KW   colon cell proliferative disorder; non methylated CpG dinucleotide;
KW   cytostatic; cancer; adenoma; carcinoma; cytosine methylation state; ss;
KW   probe.
XX
OS   Unidentified.
XX
PN   WO2003072821-A2.
XX
PD   04-SEP-2003.
XX
PF   27-FEB-2003; 2003WO-EP002035.
XX
PR   27-FEB-2002; 2002EP-00004551.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Adorjan P,  Burger M,  Maier S,  Nimmrich I,  Becker E,  Lesche R;
PI   Rujan T,  Schmitt A;
XX
DR   WPI; 2003-731620/69.
XX
PT   Detecting and differentiating between colon cell proliferative disorders
PT   associated with a gene or its regulatory regions comprises contacting a
PT   target nucleic acid in a biological sample obtained from the subject with
PT   a reagent.
XX
PS   Claim 36; Page 32; 74pp; English.
XX
CC   The invention relates to a novel method for detecting and differentiating
CC   between colon cell proliferative disorders associated with at least one
CC   gene or its regulatory regions. The method comprises contacting a target
CC   nucleic acid in a biological sample obtained from the subject with at
CC   least one reagent or a series of reagents, where the reagent or series of
CC   reagents, distinguishes between methylated and non methylated CpG
CC   dinucleotides within the target nucleic acid. The molecules of the
CC   invention demonstrate cytostatic activity whilst the method may useful
CC   for detecting and differentiating between colon cell proliferative
CC   disorders, including cancers such as colon adenoma and colon carcinoma.
CC   The PNA (peptide nucleic acid)-oligomers are useful as probes for
CC   determining cytosine methylation state or single nucleotide
CC   polymorphisms. The current sequence is that of the hybridisation
CC   oligonucleotide of the invention which was used to analyse the genomic
CC   DNA region.
XX
SQ   Sequence 18 BP; 8 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
                ||||||||||||| ||
Db         18 TTTAAATACATTCACT 3


RESULT 131
ADC70087/c
ID   ADC70087 standard; DNA; 18 BP.
XX
AC   ADC70087;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Primer oligo used for analysing CpG islands in genomic DNA (SeqID 577).
XX
KW   PCR; primer; ss; lung cell proliferative disorder; CpG dinucleotide;
KW   adenocarcinoma; squamous cell carcinoma; cytostatic; probe; PNA-oligomer;
KW   cytosine methylation state.
XX
OS   Unidentified.
XX
PN   WO2003052135-A2.
XX
PD   26-JUN-2003.
XX
PF   10-DEC-2002; 2002WO-EP014026.
XX
PR   14-DEC-2001; 2001DE-01061625.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Burger M,  Field JK,  Genc B,  Liloglou T,  Lipscher E,  Maier S;
PI   Nimmrich I;
XX
DR   WPI; 2003-533029/50.
XX
PT   Detecting and differentiating cytosine methylation state of genomic DNA,
PT   useful for diagnosing, treating prognosticating and/or monitoring lung
PT   cell proliferative disorders e.g. adenocarcinoma and squamous cell
PT   carcinoma.
XX
PS   Claim 15; SEQ ID NO 577; 58pp; English.
XX
CC   This invention relates to a novel method for detecting and
CC   differentiating between lung cell proliferative disorders associated with
CC   at least one gene and/or their regulatory regions. Specifically, it
CC   refers to a method comprising contacting a target nucleic acid in a
CC   biological sample with at least one reagent, wherein the reagent is able
CC   to distinguish between methylated and non-methylated CpG dinucleotides
CC   present in the target DNA. As such, it is possible to further
CC   differentiate and diagnose medical conditions including adenocarcinoma
```

```
CC   and squamous cell carcinoma, and their respective adjacent lung tissue.
CC   The present invention describes cytostatic oligomers and PNA-oligomers
CC   that are useful as probes for determining the cytosine methylation state
CC   or single nucleotide polymorphisms (SNPs) of the target sequence. This
CC   oligonucleotide sequence is a primer oligomer used for the analysis of
CC   CpG positions within genomic DNA, used in an exemplification of the
CC   invention.
XX
SQ   Sequence 18 BP; 8 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||||||| ||
Db         18 TTTAAATACATTCACT 3


RESULT 132
AAV44620
ID   AAV44620 standard; DNA; 19 BP.
XX
AC   AAV44620;
XX
DT   24-NOV-1998  (first entry)
XX
DE   Human uncoupling protein-2 UCP2 gene primer hUCP2.CDSR1.
XX
KW   Uncoupling protein-2; UCP2 gene; human; respiration; thermogenesis;
KW   obesity; hyperinsulinaemia; glucose intolerance; diabetes; syndrome X;
KW   hypothermia; wasting; cachexia; anorexia; inflammation; fever;
KW   hyperthermia; gene therapy; diagnosis; PCR; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9831396-A1.
XX
PD   23-JUL-1998.
XX
PF   22-APR-1997;   97WO-US006864.
XX
PR   15-JAN-1997;   97US-0034960P.
XX
PA   (UYDU-) UNIV DUKE.
PA   (REGC ) UNIV CALIFORNIA.
PA   (CNRS ) CENT NAT RECH SCI.
XX
PI   Surwit RS,  Collins SA,  Warden CH,  Seldin MF,  Ricquier D;
PI   Bouillaud F;
XX
DR   WPI; 1998-413823/35.
XX
PT   Method for treating disease associated with altered UCP-2 expression - by
PT   administering agent which enhances or inhibits UCP-2 activity,
PT   effectively to treat obesity, diabetes, fever, hyperthermia, cachexia
PT   etc.
XX
PS   Disclosure; Fig 1F; 98pp; English.
XX
CC   Primer hUCP2.CDSR1 is used with forward primer hUCP2.CDSF1 (see AAV44619)
CC   in the PCR amplification of a 1098 bp region of the human uncoupling
CC   protein-2 (UCP2) gene coding sequence (see also AAV44595). The invention
CC   relates to a method for treating diseases associated with altered UCP2
CC   expression, such as obesity, diabetes, syndrome X, hypothermia,
CC   hyperinsulinaemia, glucose intolerance, wasting, anorexia, inflammation,
CC   cachexia, fever or hyperthermia
XX
SQ   Sequence 19 BP; 7 A; 0 C; 12 G; 0 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 19;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1541 GGAGAGTAGGGAAGGA 1556
              |||||| |||||||||
Db          1 GGAGAGAAGGGAAGGA 16


RESULT 133
AAT87898
ID   AAT87898 standard; DNA; 20 BP.
XX
AC   AAT87898;
XX
DT   12-JAN-1998  (first entry)
XX
DE   Lower primer for exon 2 of human interleukin 9 gene.
XX
KW   Human; interleukin 9; asthma associated factor 1; IL-9; primer;
KW   atopic allergy; asthma; bronchial hyperesponsiveness; BHR; eczema;
KW   rhinitis; urticaria; allergic inflammation; bowel; amplification;
KW   polymorphism; polymerase chain reaction; PCR; exon 2; ss.
XX
OS   Synthetic.
XX
PN   WO9708321-A1.
XX
PD   06-MAR-1997.
XX
PF   23-AUG-1996;   96WO-US012757.
XX
PR   24-AUG-1995;   95US-0002765P.
PR   06-AUG-1996;   96US-0023800P.
XX
PA   (MAGA-) MAGAININ PHARM INC.
XX
PI   Levitt RC,  Lee MW,  Prasad KU,  Nicholas N;
XX
DR   WPI; 1997-179278/16.
XX
PT   Human interleukin-9 variant with Met at position 117 - useful for
PT   treating atopic allergy, esp. asthma.
XX
PS   Disclosure; Page 42; 142pp; English.
XX
CC   The present sequence is a primer for the PCR amplification of exon 2 from
CC   the human interleukin 9 (hIL-9), also known as asthma associated factor
CC   1, gene. hIL-9 plays a role in atopic allergy, asthma and related
CC   disorders, e.g. bronchial hyperesponsiveness (BHR), rhinitis, urticaria,
CC   allergic inflammatory disorders of the bowel and various forms of eczema.
CC   A naturally occurring polymorphism has been identified at position 117 of
CC   hIL-9, individuals homozygous for Met at position 117 demonstrate, e.g. a
CC   lack of asthma and low serum immunoglobulin E (IgE) levels, while Thr/Thr
CC   homozygotes and Thr/Met heterozygotes are susceptible to asthma
XX
SQ   Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
              ||||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20


RESULT 134
AAV41334
ID   AAV41334 standard; DNA; 20 BP.
XX
AC   AAV41334;
XX
DT   06-OCT-1998  (first entry)
XX
```

```
DE   Interleukin-9 (IL-9) gene exon 2 specific lower primer.
XX
KW   Interleukin; IL-9; AAF1; asthma associated factor; human; IBD;
KW   inflammatory bowel disease; Th2 mediated immune response; lupus;
KW   Crohn's disease; chronic non-specific ulcerative colitis; diabetes;
KW   multiple sclerosis; arthritis; autoimmune disease; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9827997-A1.
XX
PD   02-JUL-1998.
XX
PF   22-DEC-1997;   97WO-US023527.
XX
PR   20-DEC-1996;   96US-0034331P.
PR   19-DEC-1997;   97US-00994986.
XX
PA   (MAGA-) MAGAININ PHARM INC.
XX
PI   Levitt RC,  Nicolaides NC;
XX
DR   WPI; 1998-377404/32.
XX
PT   Treating inflammatory bowel diseases, e.g. Crohn's disease - and chronic
PT   non-specific ulcerative colitis by administering compounds up-regulating
PT   function of interleukin-9 or its receptor.
XX
PS   Disclosure; Page 23; 61pp; English.
XX
CC   Sequences shown in AAV41331 to AAV41340 represent exon specific primers
CC   of human interleukin (IL-9) gene. The invention provides a method for the
CC   treatment of inflammatory bowel disease (IBD) or related disorders that
CC   comprises administering a compound that up-regulates the function of IL-9
CC   or the IL-9 receptor. A method for monitoring humans undergoing IBD
CC   treatment with polypeptides with human IL-9 sequence (or fragments), by
CC   evaluating IL-9 levels in samples taken at different times, and a method
CC   for screening for cells expressing the IL-9 receptor by detecting binding
CC   of a specific ligand are also provided. Compounds up-regulating the
CC   function of IL-9 or the IL-9 receptor can be used therapeutically (in
CC   pharmaceutical compositions, optionally with acceptable carriers) to
CC   treat IBD and other related inflammatory disorders. IBDs (which include
CC   Crohn's diseases and chronic non-specific ulcerative colitis) are
CC   diseases characterised by an inappropriate inflammatory response to
CC   environmental stimuli. Immune responses to antigens are classified as Th1
CC   or Th2 responses, and evidence suggests that IBDs are dominated by a Th1
CC   mediated, antigen induced, inflammatory response. Other related Th1
CC   mediated diseases include multiple sclerosis, diabetes, arthritis, lupus
CC   and autoimmune diseases. The method is based on the observation that the
CC   Th2 response is up-regulated by IL-9
XX
SQ   Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1641 TTAAAGAGCCTTCACT 1656
              ||||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20


RESULT 135
AAX95502/c
ID   AAX95502 standard; DNA; 20 BP.
XX
AC   AAX95502;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
XX
PR   21-NOV-1997;   97FR-00014673.
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1753; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 4 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCAC 1582
              ||||||||| ||||||
Db         20 AAAAATCCTCCTCCAC 5


RESULT 136
AAX96785
ID   AAX96785 standard; DNA; 20 BP.
XX
AC   AAX96785;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
XX
PR   21-NOV-1997;   97FR-00014673.
```

```
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1853; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 10 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1556 AACAGGACTGCAAAAA 1571
              || ||||||||||||
Db          4 AAGAGGACTGCAAAAA 19


RESULT 137
ABQ65350/c
ID   ABQ65350 standard; DNA; 20 BP.
XX
AC   ABQ65350;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human gene methylation status determination method PCR primer #90.
XX
KW   Toxicological diagnosis; DNA methylation; methylation status;
KW   toxic response; human; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200240710-A2.
XX
PD   23-MAY-2002.
XX
PF   08-NOV-2001; 2001WO-EP012951.
XX
PR   14-NOV-2000; 2000DE-01056802.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2002-463571/49.
XX
PT   Toxicological diagnosis, useful for diagnosis and prognosis of adverse
PT   reactions, based on effect of test compounds on methylation status of
PT   selected genes, involves determining changes in DNA methylation status.
XX
PS   Example 2; Page 104; 113pp; German.
XX
CC   The present invention relates to a method of toxicological diagnosis,
CC   involving taking a DNA-containing sample from an organism or cell culture
CC   that has been treated with a test compound and determining any changes in
CC   the DNA methylation status or pattern caused by said test compound. The
CC   method is used for diagnosis and prognosis of adverse toxic responses in
CC   individuals. The present sequence is a PCR primer used to demonstrate the
CC   method of the invention
XX
SQ   Sequence 20 BP; 3 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGG 1550
              || |||||||||||||
Db         19 AGATTAGGAGAGTAGG 4


RESULT 138
ABK34138/c
ID   ABK34138 standard; DNA; 20 BP.
XX
AC   ABK34138;
XX
DT   18-JUN-2002  (first entry)
XX
DE   Human MHC PCR primer #14.
XX
KW   Human; ss; astrocytoma; cytostatic; staging; cysteine methylation; CpG;
KW   bisulphite; brain tissue; MALDI; ESI; electron spray mass spectrometry;
KW   matrix assisted laser desorption/ionization mass spectrometry; primer.
XX
OS   Homo sapiens.
XX
PN   WO200202808-A2.
XX
PD   10-JAN-2002.
XX
PF   02-JUL-2001; 2001WO-EP007538.
XX
PR   30-JUN-2000; 2000DE-01032529.
PR   01-SEP-2000; 2000DE-01043826.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2002-171649/22.
XX
PT   Novel chemically modified genomic DNA sequences, useful in the
PT   characterization, classification, differentiation, grading, staging,
PT   treatment and/or diagnosis of astrocytomas or predisposition to
PT   astrocytomas.
XX
PS   Example; Page 25; 37pp; English.
XX
CC   The invention relates to a nucleic acid comprising a sequence (I) of at
CC   least 18 bases in length of a segment of chemically pre-treated genomic
CC   DNA which has any one of the sequences of (ABK33919-ABK34032) or its
CC   complement. Also included are an oligonucleotide or peptide nucleic acid
CC   (or set thereof) of at least 9 nucleotides which hybridises to (I),
CC   primers for (I), probes for detecting cytosine methylation or single-
CC   nucleotide polymorphisms (SNP) in (I), an array of oligomers or peptide
CC   nucleic acids for analysing diseases associated with the methylation
CC   states of the CpG dinucleotides of (I). The array is useful for
CC   determining genetic and/or epigenetic parameters, classification,
CC   differentiation, grading, staging, treatment and/or diagnosis of
CC   astrocytomas, or the predisposition to astrocytomas by analysing cytosine
CC   methylations, involves obtaining a biological sample containing genomic
CC   DNA, extracting the genomic DNA, converting cytosine bases which are
CC   unmethylated at the 5-position, in the genomic DNA sample, to uracil or
CC   another base which is dissimilar to cytosine in terms of hybridisation
CC   behaviour, by chemical treatment and amplifying chemically pre-treated
CC   genomic DNA fragments using the array and a polymerase, where the
CC   amplificates carry a detectable label. The method further involves
```

```
CC   identifying methylation status of one or more cytosine positions, and
CC   analysing methylation status of the cytosine positions by reference to
CC   one or more data sets. The genomic DNA is chemically treated by using a
CC   bisulphite, hydrogen sulphite or disulphite. The amplification step
CC   amplifies DNA which is of particular interest in astrocytoma or brain
CC   tissue, based on the specific genomic methylation status of brain
CC   tissues, as opposed to background DNA. The amplificates carry a
CC   fluorescent label or radionuclide. Optionally, the labels of the
CC   amplificates are detachable molecule fragments having a typical mass
CC   which are detected in a mass spectrometer. The fragments of chemically
CC   pre-treated genomic DNA to be amplified, have a single positive or
CC   negative charge for a better detectability in the mass spectrometer.
CC   Preferably, the amplificates or fragments of the amplificates are
CC   detected by matrix assisted laser desorption/ionization mass spectrometry
CC   (MALDI) or using electron spray mass spectrometry (ESI). The present
CC   sequence is a PCR primer used to amplify a region containing a methylated
CC   cytosine from one of the chemically pre-treated reference DNA samples of
CC   the invention. Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 3 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGG 1550
              || |||||||||||||
Db         19 AGATTAGGAGAGTAGG 4


RESULT 139
ABK28076/c
ID   ABK28076 standard; DNA; 20 BP.
XX
AC   ABK28076;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human MHC methylation state PCR primer #14.
XX
KW   Human; ss; astrocytoma; oligoastrocytoma; oligodendroglioma; antitumour;
KW   cytostatic; cytosine methylation state; single nucleotide polymorphism;
KW   SNP; CpG; brain tumour; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   WO200200705-A2.
XX
PD   03-JAN-2002.
XX
PF   02-JUL-2001; 2001WO-EP007539.
XX
PR   30-JUN-2000; 2000DE-01032529.
PR   01-SEP-2000; 2000DE-01043826.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2002-139900/18.
XX
PT   Oligonucleotide for diagnosing and treating tumors and cancer especially
PT   gliomas, astrocytomas and oligodendromas, comprises chemically modified
PT   genomic sequences of genes associated with tumors and cancers.
XX
PS   Example 4; Page 22; 31pp; English.
XX
CC   The invention relates to a nucleic acid (I) comprising a sequence of at
CC   least 18 bases of a segment of chemically pretreated genomic DNA (II)
CC   according to one of the sequences (S1) selected from 120 sequences, and
CC   its complementary sequences. Also included are an oligomer (III),
CC   especially an oligonucleotide or peptide nucleic acid (PNA)-oligomer,
CC   comprising a sequence of at least 9 nucleotides which hybridises to or is
CC   identical to (II), and complementary sequences, a set of oligomers (IV)
CC   comprising at least two (III) and their use for detecting the cytosine
CC   methylation state and/or single nucleotide polymorphisms (SNPs) in (II),
CC   and manufacturing (M1) an arrangement of different oligomers (array)
CC   fixed to a carrier material for analysing diseases associated with the
CC   methylation state of the CpG dinucleotide of (S1), where at least one
CC   oligomer is coupled to solid phase. The set of oligomers (IV) are useful
CC   as primer oligonucleotides for the amplification of (II) especially for
CC   characterising classifying and differentiating oligodendroglioma,
CC   astrocytoma and oligoastrocytoma tumours (by ascertaining genetic and/or
CC   epigenetic parameters of genomic DNA by analysing cytosine methylation
CC   and single nucleotide polymorphisms). The present sequence is a PCR
CC   primer used to amplify the modified genomic sequence from a gene
CC   associated with brain tumours
XX
SQ   Sequence 20 BP; 3 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGG 1550
              || |||||||||||||
Db         19 AGATTAGGAGAGTAGG 4


RESULT 140
ADA20513/c
ID   ADA20513 standard; DNA; 20 BP.
XX
AC   ADA20513;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Prostate tumour related gene MLH1 PCR primer #2.
XX
KW   cytostatic; gene therapy; genetic marker; epigenetic parameter;
KW   classification; differentiation; diagnosis; prostate tumour;
KW   prostate cancer; cytosine methylation; uracil;
KW   single nucleotide polymorphism; SNP; prostate carcinoma; ss; primer; PCR.
XX
OS   Homo sapiens.
XX
PN   WO2002103042-A2.
XX
PD   27-DEC-2002.
XX
PF   14-JUN-2002; 2002WO-EP006605.
XX
PR   14-JUN-2001; 2001DE-01028508.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Distler J,  Model F,  Adorjan P;
XX
DR   WPI; 2003-167536/16.
XX
PT   Determining genetic and/or epigenetic parameters, useful for the
PT   classification, differentiation and/or diagnosis of prostate tumors or a
PT   predisposition to prostate cancer, comprises analyzing cytosine
PT   methylation.
XX
PS   Example 2; Page 17; 376pp; English.
XX
CC   The invention relates to a method of determining genetic and/or
CC   epigenetic parameters for the classification, differentiation and/or
CC   diagnosis of prostate tumours or the predisposition to prostate cancer,
CC   by analysing cytosine methylation in a sample of genomic DNA. The method
CC   comprises chemically treating unmethylated cytosine bases at the 5-
CC   position to uracil or another base, which is dissimilar to cytosine in
CC   terms of hybridization behaviour; followed by amplifying at least one
```

```
CC   fragment of the chemically pre-treated genomic DNA using sets of primer
CC   oligonucleotides and a polymerase. The oligomers or probes derived from
CC   them are useful for detecting the methylation state of all CpG
CC   dinucleotides and/or single nucleotide polymorphisms (SNPs) in a
CC   chemically pre-treated genomic DNA. They are all useful for treating
CC   prostate carcinoma. This sequence represents an oligonucleotide used to
CC   amplify a gene possibly involved in predisposition to prostate cancer
CC   which may contain methylated or unmethylated CpG dinucleotides.
XX
SQ   Sequence 20 BP; 3 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGG 1550
              || |||||||||||||
Db         19 AGATTAGGAGAGTAGG 4


RESULT 141
ADA84316/c
ID   ADA84316 standard; DNA; 20 BP.
XX
AC   ADA84316;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human G6E PCR primer 2.
XX
KW   renal cancer; prostate cancer; cytosine methylation;
KW   single nucleotide polymorphism; histological; cytological; ss; primer;
KW   PCR.
XX
OS   Homo sapiens.
XX
PN   WO2002103041-A2.
XX
PD   27-DEC-2002.
XX
PF   14-JUN-2002; 2002WO-EP006603.
XX
PR   14-JUN-2001; 2001DE-01028509.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Distler J,  Model F,  Adorjan P;
XX
DR   WPI; 2003-183991/18.
XX
PT   Method for characterizing, classifying and/or differentiating renal and
PT   prostate cancers, by analyzing the genetic and/or epigenetic parameters
PT   of genomic DNA, particularly by determining its cytosine methylation
PT   status.
XX
PS   Example 2; Page 17; 211pp; English.
XX
CC   The invention relates to a novel method for characterising, classifying
CC   and/or differentiating renal and prostate cancer. The method comprises
CC   extracting genomic DNA from a biological sample, converting cytosine
CC   bases (by chemical treatment) that are unmethylated at the 5-position to
CC   uracil or another base, and amplifying at least one fragment of the
CC   chemically pretreated genomic DNA using sets of primer oligonucleotides
CC   and a polymerase. The method is useful for detecting the cytosine
CC   methylation state and/or single nucleotide polymorphisms in genomic DNA,
CC   particularly for characterising, classifying and/or differentiating renal
CC   and prostate cancers. The oligomers are useful as primer oligonucleotides
CC   for the amplification of any of the 112 DNA sequences of the invention.
CC   The set of oligomer probes is useful for detecting the cytosine
CC   methylation state and/or single nucleotide polymorphisms in any of the
CC   112 chemically pretreated genomic DNA sequences. The method is also
CC   useful for identifying the tissue of origin of cancer cells. The method
CC   allows the classification, differentiation and/or diagnosis of cancer
CC   tissues using minute samples which would be inadequate for histological
CC   or cytological analysis. The present sequence is used in the
CC   exemplification of the invention.
XX
SQ   Sequence 20 BP; 3 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGG 1550
              || |||||||||||||
Db         19 AGATTAGGAGAGTAGG 4


RESULT 142
ADL59070
ID   ADL59070 standard; DNA; 20 BP.
XX
AC   ADL59070;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1319.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1319; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
```

```
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 3 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTGA 1979
              ||||||||||||||| |
Db          5 TAAATATTTACCTTCA 20


RESULT 143
ADL59174
ID   ADL59174 standard; DNA; 20 BP.
XX
AC   ADL59174;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1423.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1423; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 3 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTGA 1979
              ||||||||||||||| |
Db          4 TAAATATTTACCTTCA 19


RESULT 144
ADO54121
ID   ADO54121 standard; DNA; 20 BP.
XX
AC   ADO54121;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1494.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1494; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
```

```
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGAT 1911
              |||||| |||||||||
Db          2 CCCTAGTTCAACAGAT 17


RESULT 145
ADO54074
ID   ADO54074 standard; DNA; 20 BP.
XX
AC   ADO54074;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1447.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1447; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGAT 1911
              |||||| |||||||||
Db          1 CCCTAGTTCAACAGAT 16


RESULT 146
ADO40175
ID   ADO40175 standard; DNA; 20 BP.
XX
AC   ADO40175;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human MAP3K11 DNA target site #12.
XX
KW   Mitogen-activated protein kinase kinase kinase 11; MAP3K11;
KW   mixed-lineage protein kinase 3; MLK-3;
KW   SH3-containing proline-rich protein kinase; SPRK; cellular apoptosis;
KW   gene therapy; human; ds.
XX
OS   Homo sapiens.
XX
PN   US2004092464-A1.
XX
PD   13-MAY-2004.
XX
PF   11-NOV-2002; 2002US-00293863.
XX
PR   11-NOV-2002; 2002US-00293863.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Dean NM,  Dobie KW;
XX
DR   WPI; 2004-374982/35.
XX
PT   New compound that modulates mitogen-activated protein kinase kinase
PT   kinase 11 expression, useful in treating an animal having a disease or
PT   condition involving dysregulation of cellular apoptosis.
XX
PS   Example 15; SEQ ID NO 59; 39pp; English.
XX
CC   The invention relates to compounds, compositions and methods for
CC   modulating the expression of mitogen-activated protein kinase kinase
CC   kinase 11 (also called MAP3K11, mixed-lineage protein kinase 3, MLK-3,
CC   SH3-containing proline-rich protein kinase, SPRK). The composition
CC   comprise antisense oligonucleotides targeted to MAP3K11. The compound and
CC   the methods are useful in treating an animal having a disease or
CC   condition involving dysregulation of cellular apoptosis. The invention is
CC   also useful in gene therapy. The present sequence is human MAP3K11 DNA
CC   target site. This sequence is used to illustrate the method of the
CC   invention.
XX
SQ   Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGGGGG 1615
              ||||||| ||||||||
Db          3 CCTCCTGCCCTGGGGG 18


RESULT 147
```

```
ADO40140/c
ID   ADO40140 standard; DNA; 20 BP.
XX
AC   ADO40140;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human MAP3K11 antisense oligonucleotide, ISIS 176625.
XX
KW   Mitogen-activated protein kinase kinase kinase 11; MAP3K11;
KW   mixed-lineage protein kinase 3; MLK-3;
KW   SH3-containing proline-rich protein kinase; SPRK; cellular apoptosis;
KW   gene therapy; human; antisense; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone in which all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) bases"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) bases"
XX
PN   US2004092464-A1.
XX
PD   13-MAY-2004.
XX
PF   11-NOV-2002; 2002US-00293863.
XX
PR   11-NOV-2002; 2002US-00293863.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Dean NM,  Dobie KW;
XX
DR   WPI; 2004-374982/35.
XX
PT   New compound that modulates mitogen-activated protein kinase kinase
PT   kinase 11 expression, useful in treating an animal having a disease or
PT   condition involving dysregulation of cellular apoptosis.
XX
PS   Example 15; SEQ ID NO 24; 39pp; English.
XX
CC   The invention relates to compounds, compositions and methods for
CC   modulating the expression of mitogen-activated protein kinase kinase
CC   kinase 11 (also called MAP3K11, mixed-lineage protein kinase 3, MLK-3,
CC   SH3-containing proline-rich protein kinase, SPRK). The composition
CC   comprise antisense oligonucleotides targeted to MAP3K11. The compound and
CC   the methods are useful in treating an animal having a disease or
CC   condition involving dysregulation of cellular apoptosis. The invention is
CC   also useful in gene therapy. The present sequence is an antisense
CC   oligonucleotide targeted to human MAP3K11 DNA. This sequence is used to
CC   illustrate the method of the invention.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 20;
  Best Local Similarity   93.8%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGGGGG 1615
              ||||||| ||||||||
Db         18 CCTCCTGCCCTGGGGG 3
```

```
RESULT 148
ABX11284
ID   ABX11284 standard; DNA; 21 BP.
XX
AC   ABX11284;
XX
DT   29-APR-2003  (first entry)
XX
DE   Mouse P0 gene 5' UTR PCR primer.
XX
KW   Mouse; ss; PCR; primer; P0; myelin structural protein; SCIP; Oct-6;
KW   Tst-1; transcription factor; peripheral nervous system; PNS;
KW   Schwann cell; nerve regeneration; transgenic; Alzheimer's disease;
KW   Pick's disease; Huntington's disease; Parkinson's disease;
KW   cerebral palsy; amyotrophic lateral sclerosis; ALS; muscular dystrophy;
KW   multiple sclerosis; myasthenia gravis; Binswanger's disease;
KW   vascular lesion; brain trauma; spinal chord trauma; cerebral haemorrhage;
KW   intracranial aneurysm; hypertensive encephalopathy; spina bifida;
KW   subarachanoid haemorrhage; developmental disorder;
KW   congenital hydrocephalus; neurodegenerative disorder.
XX
OS   Mus sp.
XX
PN   US2002146395-A1.
XX
PD   10-OCT-2002.
XX
PF   19-APR-1999;   99US-00294764.
XX
PR   19-APR-1999;   99US-00294764.
XX
PA   (WEIN/) WEINSTEIN D E.
XX
PI   Weinstein DE;
XX
DR   WPI; 2003-237963/23.
XX
PT   Regenerating nervous tissue, involves contacting the tissue with Schwann
PT   cells expressing DeltaSCIP to regenerate the nervous tissue.
XX
PS   Disclosure; Page 5; 21pp; English.
XX
CC   The invention relates to regenerating nervous tissue, involves contacting
CC   the tissue with Schwann cells expressing DeltaSCIP (a mutant form of the
CC   SCIP (not defined) gene under control of the P0 promoter (a myelin
CC   structural protein). SCIP is a transcription factor also known as Oct-6
CC   and Tst-1) to regenerate the nervous tissue. Also included are treating a
CC   subject in need of nervous tissue regeneration, by introducing Schwann
CC   cells expressing DeltaSCIP and inducing nervous tissue regeneration in a
CC   subject in need of such treatment, by administering to the subject,
CC   DeltaSCIP to induce nervous tissue regeneration in the subject. The
CC   methods are useful for useful for regenerating nervous tissue and for
CC   treating a subject in need of nervous tissue regeneration, where the
CC   subject in need of nervous tissue regeneration has a neurodegenerative
CC   disease. The neurodegenerative disease is Alzheimer's disease, Pick's
CC   disease, Huntington's disease, Parkinson's disease, cerebral palsy,
CC   amyotrophic lateral sclerosis (ALS), muscular dystrophy, multiple
CC   sclerosis, myasthenia gravis, or Binswanger's disease. The subject in
CC   need of nervous tissue regeneration has one or more damaged neurons. The
CC   damage to the neurons are caused by vascular lesions of the brain and
CC   spinal chord, trauma to the brain and spinal chord, cerebral haemorrhage,
CC   intracranial aneurysms, hypertensive encephalopathy, subarachanoid
CC   haemorrhage or developmental disorders. The developmental disorder is a
CC   disorder of the brain or spinal cord e.g. congenital hydrocephalus or
CC   spina bifida. The present sequence is a PCR primer used to genotype mice
CC   which are transgenic for the P0/deltaSCIP construct
XX
SQ   Sequence 21 BP; 4 A; 12 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 21;
  Best Local Similarity   93.8%;  Pred. No. 2.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||||  |||||||
Db          6 TCTCCACCCCACAGAC 21
```

RESULT 149
ADP05604
ID ADP05604 standard; DNA; 21 BP.
XX
AC ADP05604;
XX
DT 26-AUG-2004 (first entry)
XX
DE Novel microbe detection apparatus-related PCR primer SeqID109.
XX
KW microbe detection; microbe identification; virus; viral particle;
KW pathogenic bacterium; cellular microbe; acellular microbe;
KW clinical diagnosis; research; epidemiological surveillance;
KW bioterrorism countermeasure; environmental pathogen survey;
KW food contaminant; radioimmunoassay; ELISA; PCR; primer; ss.
XX
OS Viruses.
XX
PN WO2004045365-A2.
XX
PD 03-JUN-2004.
XX
PF 23-MAY-2003; 2003WO-US016461.
XX
PR 15-NOV-2002; 2002US-00295787.
XX
PA (REGC) UNIV CALIFORNIA.
XX
PI Jia XY, Berger MA, Tilles JG;
XX
DR WPI; 2004-449626/42.
XX
PT New (microarray) apparatus comprising a substrate with attached nucleic
PT acid probes, useful for detecting one or more microbes in a sample.
XX
PS Claim 29; SEQ ID NO 109; 89pp; English.
XX
CC This invention relates to a novel apparatus for detecting a microbe in a
CC sample which comprises a substrate having multiple microbe identification
CC sites, each having a unique address indicative of the position of that
CC microbe identification site on the substrate and groups of nucleic acid
CC probes disposed at the microbe identification sites, each group being
CC complementary to a target nucleic acid to provide a detectable signal at
CC one or more microbe identification sites. The apparatus is useful for
CC detecting the presence of one or more microbes in a sample, such as virus
CC or viral particle, (non-)pathogenic bacteria, or cellular or acellular
CC microbe. The apparatus is particularly useful for clinical diagnosis,
CC research, epidemiological surveillance, bioterrorism countermeasures,
CC environmental pathogen surveys, and monitoring food contaminants. Current
CC testing procedures or devices, such as radioimmunoassays and ELISA, are
CC difficult to implement, time consuming, expensive, outdated, and
CC typically rely on the use of agents that recognise and bind to membrane
CC bound proteins or carbohydrates of the pathogen. These further cannot
CC assay multiple pathogens. The new apparatus or device for detecting
CC microbes overcomes these disadvantages. The apparatus is compact,
CC sensitive, and quick to detect the presence of any of a number of
CC pathogens present in a sample. The present sequence is that of a PCR
CC primer which is related to the micorbe detection apparatus of the
CC invention.
XX
SQ Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 21;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1843 TCCCTGGGCCAACAGA 1858
                ||||||| ||||||||
Db          1 TCCCTGGTCCAACAGA 16
```

RESULT 150
AAV51724/c
ID AAV51724 standard; DNA; 22 BP.
XX
AC AAV51724;
XX
DT 02-FEB-1999 (first entry)
XX
DE Zea mays genome reverse PCR primer #20.
XX
KW Polymorphic marker; allele-specific; probe; amplification; PCR primer;
KW hybridisation; plant; hybrid certification; genetic contribution;
KW progeny; back-cross; hybrid; ancestry; corn; ss.
XX
OS Synthetic.
OS Zea mays.
XX
PN WO9824796-A1.
XX
PD 11-JUN-1998.
XX
PF 01-DEC-1997; 97WO-US021782.
XX
PR 02-DEC-1996; 96US-0032069P.
PR 07-MAR-1997; 97US-00813507.
XX
PA (AFFY-) AFFYMETRIX INC.
XX
PI Lemieux B, Landry BS, Sapolsky RJ, Murigneux A;
XX
DR WPI; 1998-333252/29.
XX
PT Brassica species allele-specific oligonucleotide probes and primers -
PT useful for plant breeding.
XX
PS Example 1; Page 50; 65pp; English.
XX
CC AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
CC Zea mays genome in order to detect polymorphic markers. Such markers can
CC be used in the construction of allele-specific primers and probes for
CC amplification or hybridisation, e.g. to determine common or disparate
CC ancestry between 2 or more plants, to monitor the genetic contribution of
CC an ancestral plant, to trace the progeny of proprietary plants, in
CC certification of a hybrid plant or to identify the progeny of a back-
CC crossed plant with an ancestral plant
XX
SQ Sequence 22 BP; 10 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 22;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1916 AATACCTTTTTTTTCA 1931
              ||||||||||||| |||
Db         19 AATACCTTTTTTGTCA 4
```

RESULT 151
ABV73127
ID ABV73127 standard; DNA; 22 BP.
XX
AC ABV73127;
XX
DT 08-JAN-2003 (first entry)
XX
DE N-acetyltransferase NAT1*14 allele specific primer.
XX
KW Immunosuppressive; genotyping; N-acetyltransferase; NAT1; allele; PCR;
KW primer; ss.

XX
OS Homo sapiens.
XX
PN WO200273205-A2.
XX
PD 19-SEP-2002.
XX
PF 14-MAR-2002; 2002WO-CA000360.
XX
PR 14-MAR-2001; 2001US-0275489P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2002-740823/80.
XX
PT Characterizing a metabolic phenotype for an immunosuppressant agent,
PT comprises administering a probe substrate specific to a metabolic pathway
PT of the determinant and detecting metabolites of the pathway.
XX
PS Disclosure; Page 79; 225pp; English.
XX
CC The invention relates to characterising a multi-determinant metabolic
CC phenotype (P) for an immunosuppressant agent. The method involves: (a)
CC administering to an individual a probe substrate specific to a metabolic
CC pathway for an immunosuppressant agent; (b) detecting metabolites of MPs
CC in a biological sample from the individual; and (c) characterizing
CC respective phenotypic determinants of (P). The method is useful for
CC characterizing a multi-determinant metabolic phenotype for an
CC immunosuppressant agent such as cyclosporine, Tacrolimus (RTM),
CC Sirolimus, Prednisone, Cellcept (RTM) and OKT3. (P) can be used to
CC individualize a treatment regimen for an immunosuppressant agent for an
CC individual, by determining (P) of the individual using the method, and
CC determining/selecting a safe and therapeutically effective dose of the
CC immunosuppressant agent for treatment based on (P) of the individual. A
CC new method of genotyping individuals to identify those lacking an allelic
CC variation known to prompt toxicity of the immunosuppressant agent, and
CC characterizing (P) of the identified individual to determine each
CC individual's ability to metabolize the immunosuppressant agent is also
CC provided. This is useful for identifying those individuals at high risk
CC for serious adverse events. The present sequence represents an allele-
CC specific primer used for genotyping the N-acetyltransferase (NAT1) gene,
CC by amplifying NAT1*14 allele
XX
SQ Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

```
  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20
```

RESULT 152
ABV74921
ID ABV74921 standard; DNA; 22 BP.
XX
AC ABV74921;
XX
DT 22-JAN-2003 (first entry)
XX
DE NAT1*14 allele specific primer.
XX
KW Naphthalidimide; anticancer; amonafide; phenotype; drug development;
KW N-acetyltransferase; NAT1; allele; genotyping; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200271060-A2.
XX
PD 12-SEP-2002.
XX
PF 28-FEB-2002; 2002WO-CA000256.
XX
PR 28-FEB-2001; 2001US-0271714P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2002-740767/80.
XX
PT Characterizing multi-determinant metabolic phenotypes of N-(aryl
PT substituted)-naphthalidimide compounds, useful for individualizing
PT therapy with amonafide, comprises determining metabolic phenotype from
PT detected metabolites.
XX
PS Disclosure; Page 89; 351pp; English.
XX
CC The invention relates to characterizing a multi-determinant metabolic
CC phenotype for a class of N-(aryl substituted)-naphthalidimide compounds
CC (I) (the phenotypic determinants correspond to respective metabolic
CC characteristics). The method involves (a) administering to an individual
CC a probe substrate specific to metabolic pathway(s) of (I); (b) detecting
CC metabolites of the pathway in a biological sample in response to the
CC probe substrate; and (c) characterizing the determinants of the metabolic
CC phenotype based on detected metabolites. The method is useful for the
CC individualization of treatment with the anticancer drug, amonafide, on
CC the basis of a phenotypic profile of an individual. It may also be used
CC in research and in the development of new drugs. The present sequence
CC represents an allele specific PCR primer for amplifying the NAT1*14
CC allele, used in NAT1 genotyping
XX
SQ Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

```
  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20
```

RESULT 153
ABA00253
ID ABA00253 standard; DNA; 22 BP.
XX
AC ABA00253;
XX
DT 29-NOV-2002 (first entry)
XX
DE NAT1 A560G mutation detection primer #4.
XX
KW Primer; PCR; amplify; multi-determinant; metabolic phenotype;
KW phenotypic determinant; probe substrate; metabolic pathway; drug therapy;
KW fast metabolism; inhibitor; ss.
XX
OS Homo sapiens.
XX
PN WO200264816-A2.
XX
PD 22-AUG-2002.
XX
PF 08-FEB-2002; 2002WO-CA000161.
XX
PR 09-FEB-2001; 2001US-0267472P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2002-667012/71.

```
XX
PT   Characterizing metabolic phenotype based on phenotypic determinants, by
PT   administering a probe substrate specific to a metabolic pathway of the
PT   determinant and detecting metabolites of pathway in response to
PT   substrate.
XX
PS   Disclosure; Page 78; 268pp; English.
XX
CC   The sequences given in ABA00250-87 are primers which were used in the
CC   method of the invention for characterizing multi-determinant metabolic
CC   phenotype based on a number of phenotypic determinants (PDs). The method
CC   comprises administering to an individual a probe substrate (PS) specific
CC   to a metabolic pathway (MP) of each of the PDs, detecting metabolites of
CC   MPs in a biological sample from the individual in response to PS, and
CC   characterizing respective PDs of metabolic phenotypes based on detected
CC   metabolites. This primer is used in the determination of the N-acetyl
CC   transferase (NAT1) alleles NAT1*4 (wt) and the mutant NAT1*14 (A560G).
CC   The first PCR reaction produces a 175 bp fragment which when incubated
CC   with BsaI is cleaved in the presence of NAT1*4, but NAT1*14 is uncleaved.
CC   The NAT1*14 allele is confirmed using the second PCR reaction. Knowledge
CC   of the metabolic phenotype is useful for determining a combination drug
CC   therapy where an individual's phenotype is indicative of a fast
CC   metabolizer, and a corresponding inhibitor is selected for combined
CC   treatment with a drug to improve the therapeutic effect in the
CC   individual. The method of the invention is useful for diagnosing a
CC   disease or condition associated with altered function in a drug
CC   metabolizing enzyme. It is also useful for selecting a treatment for an
CC   individual corresponding to the individual's metabolic phenotype and for
CC   screening a number of individuals for participation in a drug treatment
CC   trial assessing the therapeutic effect of a candidate drug treatment
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 154
ADG34628
ID   ADG34628 standard; DNA; 22 BP.
XX
AC   ADG34628;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human NAT1*14 PCR primer SEQ ID NO:5.
XX
KW   ss; primer; PCR; human; antipsychotic; nootropic; neuroprotective.
XX
OS   Homo sapiens.
XX
PN   WO200273196-A2.
XX
PD   19-SEP-2002.
XX
PF   14-MAR-2002; 2002WO-CA000343.
XX
PR   14-MAR-2001; 2001US-0275462P.
XX
PA   (UYMC-) UNIV MCGILL.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2002-759850/82.
XX
PT   Characterization of a multi-determinant metabolic phenotype for an
PT   antipsychotic agent for treating an individual, comprises detecting
PT   metabolites of metabolic pathway(s) in response to the probe substrate.
XX
PS   Disclosure; SEQ ID NO 5; 226pp; English.
XX
CC   The invention relates to a novel method for characterising a multi-
CC   determinant metabolic phenotype for an antipsychotic agent. The method of
CC   the invention has nootropic, and neuroprotective activity. The method is
CC   used for characterisation a multi-determinant metabolic phenotype for an
CC   antipsychotic agent, useful for treating an individual having a condition
CC   treatable with an antipsychotic agent with individualisation of the
CC   treatment. The present sequence is used in the exemplification of the
CC   invention.
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 155
AAD50983
ID   AAD50983 standard; DNA; 22 BP.
XX
AC   AAD50983;
XX
DT   02-APR-2003  (first entry)
XX
DE   NAT1 allele specific PCR primer #3.
XX
KW   Antibiotic agent; therapy; research development; drug development; PCR;
KW   primer; ss.
XX
OS   Unidentified.
XX
PN   WO200293162-A2.
XX
PD   21-NOV-2002.
XX
PF   17-MAY-2002; 2002WO-CA000725.
XX
PR   17-MAY-2001; 2001US-0291336P.
XX
PA   (UYMC-) UNIV MCGILL.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2003-112080/10.
XX
PT   Characterization of a multi-determinant metabolic phenotype for at least
PT   one antibiotic agent for treating an individual having a condition
PT   treatable with at least one antibiotic agent.
XX
PS   Disclosure; Col 266; 270pp; English.
XX
CC   The invention relates to a method of characterisation of a multi-
CC   determinant metabolic phenotype for at least one antibiotic agent. The
CC   method involves administering a probe substrate specific to metabolic
CC   pathways for antibiotic agents; detecting metabolites of the metabolic
CC   pathways in response to the probe substrate and characterising respective
CC   phenotypic determinants of the metabolic phenotype based on detected
CC   metabolites. The method is used for characterisation of multi-determinant
CC   metabolic phenotype for at least one antibiotic agent, useful for
CC   treating an individual having a condition treatable with at least one
CC   antibiotic agent with individualisation of the treatment and for
CC   selecting an individual treatment regime. The invention is useful in
CC   research and drug development. The present sequence is NAT1 (N-
CC   acetyltransferase) 1 allele specific PCR primer, used to illustrate the
CC   method of the invention
XX
```

```
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 156
ABZ20529
ID   ABZ20529 standard; DNA; 22 BP.
XX
AC   ABZ20529;
XX
DT   03-MAR-2003  (first entry)
XX
DE   Human NAT1 genotyping PCR primer #1.
XX
KW   Antiarrhythmic; individualisation of therapy; phenotype; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200284288-A2.
XX
PD   24-OCT-2002.
XX
PF   17-APR-2002; 2002WO-CA000525.
XX
PR   18-APR-2001; 2001US-0284191P.
XX
PA   (UYMC-) UNIV MCGILL.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2003-093044/08.
XX
PT   Characterization of a multi-determinant metabolic phenotype for at least
PT   one antiarrhythmic agent for treating an individual having a condition
PT   treatable with at least one antiarrhythmic agent.
XX
PS   Disclosure; Page 226; 231pp; English.
XX
CC   The present invention relates to the characterisation of a multi-
CC   determinant metabolic phenotype. This comprises: (a) administering to an
CC   individual a probe substrate specific to metabolic pathway(s) for
CC   antiarrhythmic agent(s); (b) detecting metabolites of the metabolic
CC   pathway(s) in response to the probe substrate; and (c) characterising
CC   respective phenotypic determinants of the multi-determinant metabolic
CC   phenotype based on detected metabolites. This useful for treating an
CC   individual having a condition treatable with at least one antiarrhythmic
CC   agent with individualisation of the treatment and for selecting an
CC   individual treatment regime. The present sequence is a PCR primer used to
CC   identify an individual's metabolic phenotype
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 157
ABZ23147
ID   ABZ23147 standard; DNA; 22 BP.
XX
AC   ABZ23147;
XX
DT   24-MAR-2003  (first entry)
XX
DE   PCR primer used to amplify a 175 bp fragment of the human NAT1 gene.
XX
KW   N-acetyltransferase-1; NAT2; metabolic phenotype; Alzheimer's disease;
KW   acetylcholinesterase inhibitor; nicotinic compound;
KW   gamma secretase inhibitor; M2 antagonist; donezepil; CYP2C9; CYP2C19;
KW   drug metabolizing enzyme; NAT1; CYP1A2; CYP2D6; CYP2A6; CYP2E1; CYP3A4;
KW   PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200299422-A2.
XX
PD   12-DEC-2002.
XX
PF   06-JUN-2002; 2002WO-CA000838.
XX
PR   06-JUN-2001; 2001US-0295860P.
XX
PA   (UYMC-) UNIV MCGILL.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2003-148687/14.
XX
PT   Characterizing multi-determinant metabolic phenotype for Alzheimer's
PT   disease agent, involves administering probe substrate specific to
PT   metabolic pathway of agent and detecting metabolites in response to
PT   substrate.
XX
PS   Disclosure; Page 91; 251pp; English.
XX
CC   PCR primers ABZ23145-47 were used to amplify a 175 bp fragment of the
CC   human N-acetyltransferase-1 (NAT1) gene. Restriction analysis of the
CC   amplified fragment allowed the identification of the mutant and wild type
CC   alleles. Drugs which are affected by the NAT1 pathway are used to treat
CC   Alzheimer's disease. The specification describes a method for
CC   characterizing the multi-determinant metabolic phenotype for at least one
CC   Alzheimer's disease agent. The method comprises administering a probe
CC   substrate specific to metabolic pathway(s) for the Alzheimer's disease
CC   agent, detecting metabolites of the pathway(s) in a sample in response to
CC   the substrate and characterizing phenotypic determinants of the metabolic
CC   phenotype based on detected metabolites. The method is useful for
CC   characterizing a multi-determinant metabolic phenotype for at least one
CC   Alzheimer's disease agent such as acetylcholinesterase inhibitor,
CC   nicotinic compound, gamma secretase inhibitor and M2 antagonist,
CC   especially donezepil. The multi-determinant metabolic phenotype is
CC   comprised of at least one determinant indicative of an individual's
CC   metabolic capacity for at least one drug metabolizing enzyme, such as N-
CC   acetyltransferase-1 (NAT1), NAT2, CYP1A2, CYP2D6, CYP2A6, CYP2E1, CYP2C9,
CC   CYP2C19, UGTs, GSTs, and STs, preferably CYP3A4. The method is useful to
CC   individualize a treatment regimen for at least one Alzheimer's disease
CC   agent
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 158
ABV72580
ID   ABV72580 standard; DNA; 22 BP.
XX
AC   ABV72580;
XX
```

DT 12-FEB-2003 (first entry)
XX
DE Primer used to determine N-acetyltransferase 1 A560G mutation.
XX
KW Metabolic phenotype; antidepressant; metabolic pathway;
KW tricyclic antidepressant; serotonin reuptake inhibitor;
KW monoamine oxidase inhibitor; psychostimulant; N-acetyltransferase 1;
KW NAT1; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200273197-A2.
XX
PD 19-SEP-2002.
XX
PF 14-MAR-2002; 2002WO-CA000361.
XX
PR 14-MAR-2001; 2001US-0275490P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2003-058322/05.
XX
PT Characterizing a metabolic phenotype for an antidepressant agent,
PT comprises administering a probe substrate specific to a metabolic pathway
PT of a determinant and detecting metabolites of the pathway.
XX
PS Disclosure; Page 82; 225pp; English.
XX
CC The specification describes a method for characterizing a multi-
CC determinant metabolic phenotype for an antidepressant agent. The method
CC comprises administering to an individual a probe substrate specific to a
CC metabolic pathway for an antidepressant agent; detecting metabolites of
CC the metabolic pathway in a sample from the individual in response to the
CC probe substrate; and characterizing respective phenotypic determinants of
CC the phenotype based on detected metabolites. The method is useful for
CC characterizing a multi-determinant metabolic phenotype for an
CC antidepressant agent such as tricyclic antidepressants, selective
CC serotonin reuptake inhibitors, monoamine oxidase inhibitors,
CC psychostimulants and atypical (or nontricyclic) antidepressants. The
CC present PCR primer (ABV72578) was used to determine the presence of the N
CC -acetyltransferase 1 (NAT1) allele NAT1*14, comprising the A560G
CC mutation. The primers were used in the method of the invention for
CC indirect phenotyping (genotyping) of NAT1
XX
SQ Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 22;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20
```

RESULT 159
AAL53876
ID AAL53876 standard; DNA; 22 BP.
XX
AC AAL53876;
XX
DT 18-FEB-2003 (first entry)
XX
DE Gastroesophageal reflux disease agent therapy related PCR primer #5.
XX
KW H2-receptor antagonist; proton pump inhibitor; N-acetyltransferase-1;
KW gastroesophageal reflux disease; multi-determinant metabolic phenotype;
KW GERD agent; metabolic pathway; NAT-1; drug metabolising enzyme; PCR;
KW primer; ss.
XX
OS Unidentified.
XX
PN WO200286504-A2.
XX
PD 31-OCT-2002.
XX
PF 24-APR-2002; 2002WO-CA000607.
XX
PR 24-APR-2001; 2001US-0285687P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2003-075640/07.
XX
PT Characterizing multi-determinant metabolic phenotype for gastroesophageal
PT reflux disease agent, by administering probe substrate specific to
PT metabolic pathway of agent and detecting metabolites in response to
PT substrate.
XX
PS Disclosure; Page 89; 241pp; English.
XX
CC The invention relates to characterising method for a multi-determinant
CC metabolic phenotype for a gastroesophageal reflux disease (GERD) agent.
CC The method involves administering to a subject a probe substrate specific
CC to metabolic pathway(s) for a GERD agent and detecting metabolites of the
CC pathway(s) in a sample from the subject in response to the substrate. The
CC method is useful for characterising a multi-determinant metabolic
CC phenotype for at least one GERD agent such as H_2-receptor antagonists,
CC promotility agents and proton pump inhibitors. The multi-determinant
CC metabolic phenotype is comprised of at least one determinant indicative
CC of an individual's metabolic capacity for at least one drug metabolising
CC enzyme, such as N-acetyltransferase-1 (NAT-1), NAT-2, CYP1A2, CYP2D6,
CC CYP2A6, CYP2E1, CYP2C9, CYP2C19, UGTs, GSTs, and STs, preferably CYP3A4.
CC The characterising method is useful to individualise a treatment regimen
CC for at least one GERD agent for an individual. This polynucleotide
CC sequence represents a PCR primer used in the characterising method of the
CC invention
XX
SQ Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 22;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20
```

RESULT 160
AAD51919
ID AAD51919 standard; DNA; 22 BP.
XX
AC AAD51919;
XX
DT 02-MAY-2003 (first entry)
XX
DE N-acetyl transferase (NAT)1 allele specific PCR primer #3.
XX
KW Antineoplastic agent; PCR; primer; N-acetyl transferase; NAT; ss.
XX
OS Unidentified.
XX
PN WO200288714-A2.
XX
PD 07-NOV-2002.
XX
PF 29-APR-2002; 2002WO-CA000642.
XX
PR 30-APR-2001; 2001US-0287014P.
XX

PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2003-140176/13.
XX
PT Characterizing metabolic phenotype for antineoplastic agent, based on
PT phenotypic determinants, by administering probe substrate specific to
PT metabolic pathway of determinant and detecting metabolites of pathway.
XX
PS Disclosure; Page 247; 251pp; English.
XX
CC The invention relates to a method of characterizing a multi-determinant
CC metabolic phenotype for an antineoplastic agent. The method involves
CC administering to an individual a probe substrate specific to a metabolic
CC pathway for an antineoplastic agent, detecting metabolites of metabolic
CC pathway in a biological sample from the individual in response to probe
CC substrate, and characterising respective phenotypic determinants of
CC metabolic phenotype based on detected metabolites. The method is useful
CC for characterising a multi-determinant metabolic phenotype for an
CC antineoplastic agent such as taxanes, estrogen antagonists, camptothecin
CC derivatives, anthracyclines, alkylating agents, podophyllotoxins, vinca
CC alkaloids, receptor tyrosine kinase inhibitors, nitrosureas, platinum
CC analogues and antimetabolites. The present sequence is N-acetyl
CC transferase (NAT)1 allele specific PCR primer used to illustrate the
CC method of the invention
XX
SQ Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 22;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1828 ATCTTTTAAATACATT 1843
||||||| ||||||||
Db 5 ATCTTTAAAATACATT 20

RESULT 161
ABZ23435
ID ABZ23435 standard; DNA; 22 BP.
XX
AC ABZ23435;
XX
DT 07-APR-2003 (first entry)
XX
DE Primer used to amplify a fragment of N-acetyltransferase-1 DNA.
XX
KW Metabolic phenotype; erectile dysfunction; phosphodiesterase 5 inhibitor;
KW sildenafil Viagra; drug metabolizing enzyme; N-acetyltransferase-1;
KW NAT-1; NAT-2; cytochrome P450; CYP1A2; CYP2D6; CYP2A6; CYP2E1; CYP2C9;
KW CYP2C19; UDP-glucuronosyltransferase; glutathione-S-transferase;
KW stromelysin; CYP3A4; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200288753-A1.
XX
PD 07-NOV-2002.
XX
PF 25-APR-2002; 2002WO-CA000586.
XX
PR 26-APR-2001; 2001US-0286336P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2003-175049/17.
XX
PT Characterizing a multi-determinant metabolic phenotype for an erectile
PT dysfunction agent, comprises administering a probe substrate to the
PT metabolic pathway of the agent and detecting metabolites in response to
PT the substrate.
XX
PS Disclosure; Page 89; 247pp; English.
XX
CC The specification describes a method for characterizing a multi-
CC determinant metabolic phenotype for a erectile dysfunction (ED) agent.
CC The method comprises administering to a subject a probe substrate
CC specific to the metabolic pathway(s) for an ED agent; detecting
CC metabolites of the pathway(s) in a sample from the subject in response to
CC the substrate; and characterizing respective phenotypic determinants of
CC the multi-determinant metabolic phenotype. The method is useful for
CC characterizing a multi-determinant metabolic phenotype for an ED agent
CC such as a phosphodiesterase 5 (PDE5) inhibitor, in particular sildenafil
CC Viagra (RTM). The multi-determinant metabolic phenotype is comprised of a
CC determinant indicative of an individual's metabolic capacity for a drug
CC metabolizing enzyme, such as N-acetyltransferase-1 (NAT-1), NAT-2,
CC cytochrome P450 (CYP)1A2, CYP2D6, CYP2A6, CYP2E1, CYP2C9, CYP2C19, UDP-
CC glucuronosyltransferase (UGT)s, glutathione-S-transferase (GST)s, and
CC stromelysin (ST)s, preferably CYP3A4. PCR primers ABZ23433-35 were used
CC to amplify fragments of the NAT-1 gene. The amplified fragment was
CC analysed by restriction analysis to identify the wild type and mutant
CC alleles. The primers were used for indirect phenotyping (genotyping) of
CC NAT-1, in the course of the invention
XX
SQ Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 22;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1828 ATCTTTTAAATACATT 1843
||||||| ||||||||
Db 5 ATCTTTAAAATACATT 20

RESULT 162
AAD47697
ID AAD47697 standard; DNA; 22 BP.
XX
AC AAD47697;
XX
DT 24-FEB-2003 (first entry)
XX
DE N-acetyltransfersse gene (NAT) 1 allele specific PCR primer #3.
XX
KW Therapy; antipsychotic; phenothiazine; dibenzodiazepine; dihydroindole;
KW piperazine; thioxanthene; benzisoxazole; phenylindole; butyrophenone;
KW N-acetyltransfersse; NAT; PCR; primer; ss.
XX
OS Unidentified.
XX
PN WO200273206-A2.
XX
PD 19-SEP-2002.
XX
PF 14-MAR-2002; 2002WO-CA000362.
XX
PR 14-MAR-2001; 2001US-0275493P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2003-018748/01.
XX
PT Characterizing a metabolic phenotype for an antipsychotic agent,
PT comprises administering a probe substrate specific to a metabolic pathway
PT of a determinant and detecting metabolites of the pathway.
XX
PS Disclosure; Page 87; 233pp; English.
XX
CC The invention relates to the individualisation of therapy on the basis of
CC a phenotypic profile of an individual. The method is useful for

```
CC   characterising a multi-determinant metabolic phenotype for an
CC   antipsychotic agent such as phenothiazines/piperazines, thioxanthene,
CC   dibenzodiazepines, dibenzoxazepines, dihydroindoles, benzisoxazoles,
CC   phenylindoles or butyrophenones. It is useful to individualise a
CC   treatment regimen for an antipsychotic agent for an individual. It is
CC   useful for identifying those individuals at high risk for serious adverse
CC   events. The present sequence is a PCR primer specific for N-
CC   acetyltransfersse gene (NAT) 1 allele. This sequence is used to
CC   illustrate the method of the invention
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 163
ABV76236
ID   ABV76236 standard; DNA; 22 BP.
XX
AC   ABV76236;
XX
DT   28-MAR-2003  (first entry)
XX
DE   N-acetyltransferase NAT1 PCR primer used for genotyping.
XX
KW   N-acetyltransferase; enzyme; NAT1; human; genotyping; phenotyping;
KW   analgesic; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200290994-A2.
XX
PD   14-NOV-2002.
XX
PF   07-MAY-2002; 2002WO-CA000687.
XX
PR   07-MAY-2001; 2001US-0288786P.
XX
PA   (UYMC-) UNIV MCGILL.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2003-129192/12.
XX
PT   Characterizing metabolic phenotype for analgesic, based on phenotypic
PT   determinants, by administering probe substrate specific to metabolic
PT   pathway of determinant and detecting metabolites of pathway.
XX
PS   Disclosure; Page 96; 246pp; English.
XX
CC   The present sequence is a primer used with the primer given in ABV76234
CC   in an allele-specific PCR to confirm the NAT1*14 allele of an N-
CC   acetyltransferase (NAT1) gene. Studies have demonstrated the presence of
CC   one wild-type allele and 6 mutant alleles of NAT1. NAT1 metabolizes
CC   several drugs (including the antimalarial dapsone) and dietary
CC   constituents, and activates some environmental procarcinogens. It has 2
CC   phenotypes: slow and rapid acetylators. The present invention relates to
CC   the individualization of therapy, especially of treatment with
CC   analgesics, on the basis of a phenotyping profile of an individual. In
CC   the case of NAT1, an example of indirect phenotyping (genotyping)
CC   involves the PCR amplification of a 175 bp fragment which includes an
CC   A560G mutation, using the present primer and the primer given in
CC   ABV76235. The 175 bp fragment is incubated with BsaI. The wild-type
CC   allele produces fragments of 155 and 20 bp, whereas mutant allele NAT1*14
CC   is uncleaved
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 164
ACF05573
ID   ACF05573 standard; DNA; 22 BP.
XX
AC   ACF05573;
XX
DT   06-NOV-2003  (first entry)
XX
DE   N-acetyltransferase-1 PCR primer.
XX
KW   N-acetyltransferase-1; NAT1; drug metabolism; metabolic phenotype; human;
KW   enzyme; genotyping; antihistamine; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003052123-A1.
XX
PD   26-JUN-2003.
XX
PF   18-DEC-2002; 2002WO-CA001962.
XX
PR   19-DEC-2001; 2001US-0340827P.
XX
PA   (XANT-) XANTHUS LIFE SCI INC.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2003-618024/58.
XX
PT   Characterizing multi-determinant metabolic phenotype for an
PT   antihistamine, by administering a probe substrate specific to metabolic
PT   pathway of the antihistamine and detecting metabolites in response to
PT   substrate.
XX
PS   Disclosure; Page 84; 237pp; English.
XX
CC   The present sequence is a primer for the PCR amplification of the N-
CC   acetyltransferase (NAT1) gene. NAT1 activity varies broadly in a given
CC   population. The NAT1*4 genotype is associated with slow drug metabolizers
CC   and is found at a frequency of 50%, 30% and 35% in Indian, Malaysian and
CC   Chinese populations, respectively. The NAT1*4 (wild-type) and the mutant
CC   NAT1*14 alleles can be determined by PCR-RFLP of a fragment of the gene
CC   containing an A560G mutation. PCR is performed with the primers fiven in
CC   ACF05571 and ACF05572. The 175 bp product is incubated with BsaI. The
CC   Nat1*1 allele produces 155 and 20 bp fragments, while the mutant NAT1*14
CC   is uncleaved. The NAT1*14 allele is confirmed using the present primer
CC   with the primer given in ACF05571. The present invention provides a
CC   method for using multi-determinant phenotyping for the individualization
CC   of treatment with an antihistamine, especially where the multi-
CC   determinant phenotype is comprised of a determinant indicative of an
CC   individual's metabolic capacity for a drug metabolizing enzyme such as
CC   NAT1. The method involves administering a probe substrate specific to the
CC   metabolic pathway of the antihistamine and detecting metabolites in
CC   response to the substrate
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
```

```
Db          5 ATCTTTAAAATACATT 20


RESULT 165
ACC79724
ID   ACC79724 standard; DNA; 22 BP.
XX
AC   ACC79724;
XX
DT   28-AUG-2003  (first entry)
XX
DE   N-acetyltransferase 1 mutation related PCR primer SEQ ID NO:5.
XX
KW   Characterisation; multi-determinant metabolic phenotype; antiviral;
KW   metabolic pathway; metabolite; detection; virucide; NAT1;
KW   N-acetyltransferase 1; PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003046559-A2.
XX
PD   05-JUN-2003.
XX
PF   27-NOV-2002; 2002WO-CA001824.
XX
PR   28-NOV-2001; 2001US-0333500P.
XX
PA   (XANT-) XANTHUS LIFE SCI INC.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2003-493450/46.
XX
PT   Characterizing multi-determinant metabolic phenotype for an antiviral
PT   agent, by administering a probe substrate specific to metabolic pathway
PT   of the antiviral agent and detecting metabolites in response to
PT   substrate.
XX
PS   Disclosure; Page 88; 256pp; English.
XX
CC   The present invention describes a method (M1) for characterising the
CC   multi-determinant metabolic phenotype (MP) for at least one antiviral
CC   agent (I), which involves administering to a subject, a probe substrate
CC   specific to metabolic pathway(s) for (I), detecting metabolites of the
CC   pathway(s) in a sample from the subject in response to the substrate, and
CC   characterising respective phenotypic determinants of MP based on detected
CC   metabolites. (I) has virucide activity. (M1) is useful for characterising
CC   a multi-determinant metabolic phenotype for at least one antiviral agent
CC   such as nucleoside analogue reverse transcriptase inhibitor (NRT1), non-
CC   nucleoside reverse transcriptase inhibitor (NNRT1), a protease inhibitor
CC   (PI), an immune response modifier, preferably ritonavir. The multi-
CC   determinant metabolic phenotype is comprised of at least one determinant
CC   indicative of an individual's metabolic capacity for at least one drug
CC   metabolising enzyme, such as CYP3A4, or chosen from N-acetyltransferase-1
CC   (NAT-1), NAT-2, CYP1A2, CYP2D6, CYP2A6, CYP3A4, CYP2C9, CYP2C19, UGTs,
CC   GSTs and STs. (M1) is useful to individualise a treatment regimen for at
CC   least one antiviral agent compound for an individual. The method quickly
CC   and accurately determines phenotypic determinants for the metabolic
CC   pathways of drug metabolising enzymes, and avoids the severe side effects
CC   and frustration that accompany trial and error treatment. The present
CC   sequence represents a PCR primer for amplifying a NAT-1 mutant, which is
CC   used in the exemplification of the present invention
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 166
ACC83560
ID   ACC83560 standard; DNA; 22 BP.
XX
AC   ACC83560;
XX
DT   08-SEP-2003  (first entry)
XX
DE   N-acetyltransferase-1 PCR primer.
XX
KW   N-acetyltransferase; NAT1; drug metabolism; metabolic phenotype; human;
KW   anaesthetic; genotyping; enzyme; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003046583-A2.
XX
PD   05-JUN-2003.
XX
PF   27-NOV-2002; 2002WO-CA001823.
XX
PR   28-NOV-2001; 2001US-0333486P.
XX
PA   (XANT-) XANTHUS LIFE SCI INC.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2003-482556/45.
XX
PT   Characterizing multi-determinant metabolic phenotype for an anesthetic,
PT   by administering a probe substrate specific to metabolic pathway of the
PT   anesthetic and detecting metabolites in response to substrate.
XX
PS   Disclosure; Page 90; 239pp; English.
XX
CC   The present sequence is a primer for the PCR amplification of the N-
CC   acetyltransferase (NAT1) gene. NAT1 activity varies broadly in a given
CC   population. The NAT1*4 genotype is associated with slow drug metabolizers
CC   and is found at a frequency of 50%, 30% and 35% in Indian, Malaysian and
CC   Chinese populations, respectively. The NAT1*4 (wild-type) and the mutant
CC   NAT1*14 alleles can be determined by PCR-RFLP of a fragment of the gene
CC   containing an A560G mutation. PCR is performed with the primers given in
CC   ACC83558 and ACC83559. The 175 bp product is incubated with BsaI. The
CC   Nat1*1 allele produces 155 and 20 bp fragments, while the mutant NAT1*14
CC   is uncleaved. The NAT1*14 allele is confirmed using the present primer
CC   with the primer given in ACC83558. The present invention provides a
CC   method for using multi-determinant phenotyping for the individualization
CC   of treatment with an anaesthetic, especially where the multi-determinant
CC   phenotype is comprised of a determinant indicative of an individual's
CC   metabolic capacity for a drug metabolizing enzyme such as NAT1. The
CC   method involves administering a probe substrate specific to the metabolic
CC   pathway of the anaesthetic and detecting metabolites in response to the
CC   substrate
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 167
ACF04612
ID   ACF04612 standard; DNA; 22 BP.
XX
AC   ACF04612;
XX
```

DT 18-DEC-2003 (first entry)
XX
DE Human NAT1 NAT1*14 allele coding sequence PCR primer #1.
XX
KW Individualisation of therapy; phenotype; metabolic phenotyping;
KW anxiolytic agent; metabolism; therapy; PCR; primer; anxiolytic; ss.
XX
OS Homo sapiens.
XX
PN WO2003067257-A1.
XX
PD 14-AUG-2003.
XX
PF 08-OCT-2002; 2002WO-CA001512.
XX
PR 08-FEB-2002; 2002US-00072611.
PR 14-MAR-2002; 2002US-00100272.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2003-767277/72.
XX
PT Characterization of a multi-determinant metabolic phenotype for at least
PT one anxiolytic compound for treating an individual having a condition
PT treatable with at least one anxiolytic compound.
XX
PS Disclosure; Page 225; 117pp; English.
XX
CC The present invention relates to a method of characterising a multi-
CC determinant metabolic phenotype for at least one anxiolytic compound,
CC which involves administering to an individual a probe substrate specific
CC to metabolic pathway(s) for anxiolytic compound(s), detecting metabolites
CC of the metabolic pathway(s) in response to the probe substrate and
CC characterising respective phenotypic determinants of multi-determinant
CC metabolic phenotype based on the detected metabolites. The method can be
CC used for the characterization of a multi-determinant metabolic phenotype
CC for at least one anxiolytic compound, useful for treating an individual
CC having a condition treatable with at least one anxiolytic compound with
CC individualisation of the treatment and for selecting an individual
CC treatment regime. The present sequence is a PCR primer used in the
CC exemplification of the invention
XX
SQ Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 22;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1828 ATCTTTTAAATACATT 1843
                ||||||  |||||||||
Db          5 ATCTTTAAAATACATT 20
```

RESULT 168
AAD54260
ID AAD54260 standard; DNA; 22 BP.
XX
AC AAD54260;
XX
DT 17-JUN-2003 (first entry)
XX
DE NAT1 mutant allele (NAT1*14) amplifying primer.
XX
KW Hyperlipidaemia agent; therapy; N-acetyltransferase; NAT; PCR; primer;
KW ss.
XX
OS Unidentified.
XX
PN WO200295402-A2.
XX
PD 28-NOV-2002.
XX
PF 17-APR-2002; 2002WO-CA000526.
XX
PR 18-APR-2001; 2001US-0284210P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2003-120822/11.
XX
PT Characterizing a multi-determinant metabolic phenotype for a
PT hyperlipidemia agent, comprises administering a probe substrate specific
PT to a metabolic pathway for an agent and detecting metabolites of the
PT pathway.
XX
PS Disclosure; Page 94; 245pp; English.
XX
CC The invention relates to a method for characterising a multi-determinant
CC metabolic phenotype for an hyperlipidaemia agent. The method involves
CC administering a probe substrate specific to a metabolic pathway for an
CC agent and detecting metabolites of the pathway. The method is useful for
CC screening a number of individuals for participation in a drug treatment
CC trial assessing the therapeutic effect of the hyperlipidaemia agent. The
CC invention is also useful for treating an individual having a condition
CC treatable with hyperlipidemia agent. The present sequence is a primer
CC used to amplify N-acetyltransferase (NAT) mutant allele. This primer is
CC used to illustrate the method of the invention
XX
SQ Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.6%; Score 14.4; DB 1; Length 22;
Best Local Similarity 93.8%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1828 ATCTTTTAAATACATT 1843
                ||||||  |||||||||
Db          5 ATCTTTAAAATACATT 20
```

RESULT 169
ABZ75815
ID ABZ75815 standard; DNA; 22 BP.
XX
AC ABZ75815;
XX
DT 15-MAY-2003 (first entry)
XX
DE NAT1 allele NAT1*14 genotyping primer.
XX
KW Genotyping; therapy; drug dosing; CYP3A4; CYP2D6; NAT1; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003008637-A2.
XX
PD 30-JAN-2003.
XX
PF 17-JUL-2002; 2002WO-CA001103.
XX
PR 17-JUL-2001; 2001US-0305630P.
XX
PA (UYMC-) UNIV MCGILL.
XX
PI Leyland-Jones B;
XX
DR WPI; 2003-239358/23.
XX
PT Use of genotyping for the individualization of therapy and/or treatment,
PT and the individual is genotype for a specific metabolic factor and a
PT corresponding genotypic determinant is characterized.
XX
PS Disclosure; Page 35; 147pp; English.

```
XX
CC   The invention relates to the use of genotyping for the individualization
CC   of therapy and/or treatment, where an individual is genotype for a
CC   specific metabolic factor and a corresponding genotypic determinant is
CC   characterized. The method is useful for the individualization of therapy
CC   and/or treatment, for quantifying an individualized dosage regime of a
CC   drug, and to identify an individual having a metabolic incompatibility
CC   with a selected therapy and/or treatment. The method is useful for the
CC   individualization of drug dosing, to identify individuals having a
CC   particular allelic variation known to influence the ability to
CC   effectively metabolize a given drug or class of drugs, to characterize a
CC   metabolic determinant and identify an individualized dosage for a given
CC   drug treatment regime, and for identifying those individuals who is at
CC   risk for a particular drug treatment regime. The method quickly and
CC   accurately determines phenotypic determinants for the CYP3A4 or CYP2D6
CC   metabolic pathway. Sequences ABZ75813-815 represent PCR primers for
CC   genotyping the NAT1 determinants
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 170
ADJ71307
ID   ADJ71307 standard; DNA; 22 BP.
XX
AC   ADJ71307;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human metabolic enzyme NAT1 genotyping PCR primer #3.
XX
KW   ss; primer; PCR; human; NAT1; N-acetyltransferase; genotype; metabolism;
KW   individualisation of therapy.
XX
OS   Homo sapiens.
XX
PN   WO2004003550-A2.
XX
PD   08-JAN-2004.
XX
PF   27-JUN-2003; 2003WO-CA000978.
XX
PR   28-JUN-2002; 2002US-0391976P.
XX
PA   (XANT-) XANTHUS LIFE SCI INC.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2004-203387/19.
XX
PT   Characterizing multi-determinant metabolic phenotype for anticoagulant
PT   agent by administering probe substrate specific to metabolic pathway for
PT   anticoagulant agent, detecting metabolites of pathway.
XX
PS   Disclosure; Page 160; 353pp; English.
XX
CC   The present invention relates to a method of characterising a multi-
CC   determinant metabolic phenotype for an anticoagulant agent, comprising
CC   administering to an individual a probe substrate specific to the
CC   metabolic pathway for the anticoagulant agent, detecting metabolites of
CC   the metabolic pathway in a biological sample from the individual in
CC   response to probe the substrate, and characterising the respective
CC   phenotypic determinants of the multi-determinant metabolic phenotype
CC   based on the detected metabolites. The method is useful for
CC   characterising a multi-determinant metabolic phenotype for one or more
CC   anticoagulant agents, where several phenotypic determinants are
CC   identified as corresponding to respective metabolic characteristics. The
CC   present sequence is a PCR primer used to genotype the human NAT1 gene in
CC   the exemplification of the invention.
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 171
ADO71016
ID   ADO71016 standard; DNA; 22 BP.
XX
AC   ADO71016;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human N-acetyltransferase NAT1 PCR primer #3.
XX
KW   anaesthetic;
KW   anaesthetic multi-determinant metabolic phenotype for anaesthetic;
KW   treatment regimen; drug treatment trial; human; N-acetyltransferase;
KW   NAT1; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   US2004101477-A1.
XX
PD   27-MAY-2004.
XX
PF   27-NOV-2002; 2002US-00307210.
XX
PR   27-NOV-2002; 2002US-00307210.
XX
PA   (XANT-) XANTHUS LIFE SCI INC.
XX
PI   Leyland-Jones B;
XX
DR   WPI; 2004-459877/43.
XX
PT   Characterizing multi-determinant metabolic phenotype for anesthetic by
PT   administering to individual substrate specific to metabolic pathways for
PT   anesthetic and determining phenotypic determinants based on metabolites
PT   of metabolic pathway.
XX
PS   Disclosure; SEQ ID NO 5; 74pp; English.
XX
CC   The invention relates to a method of characterising multi-determinant
CC   metabolic phenotype for anaesthetic. The method is useful for
CC   characterising multi-determinant metabolic phenotype for at least one
CC   anaesthetic. The method is useful for individualising a treatment regimen
CC   for at least one anaesthetic compound for an individual. The method is
CC   useful for administering to an individual at least one anaesthetic
CC   compound. The method is also useful for screening several individuals for
CC   participation in a drug treatment trial assessing the therapeutic effect
CC   of at least one anaesthetic compound. An assay system is useful in an
CC   enzyme-specific assay for the individualisation of administration of at
CC   least one anaesthetic compound. The present sequence represents a human N
CC   -acetyltransferase NAT1 PCR primer.
XX
SQ   Sequence 22 BP; 7 A; 4 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 172
AAT65892/c
ID   AAT65892 standard; DNA; 19 BP.
XX
AC   AAT65892;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   Primer #1 to amplify repeat sequence marker Mfd48.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Synthetic.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Disclosure; Col 11-12; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The primers AAT65798-T66047 were used to PCR
CC   amplify the inserts from the isolated clones containing the repeat
CC   sequences. The primers AAT65892-3 were used to amplify the repeat
CC   sequence marker clone Mfd48 (AAT65748). (Updated on 25-MAR-2003 to
CC   correct PF field.)
XX
SQ   Sequence 19 BP; 4 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.6e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1727 CTATTATCAGAAGGTGACA 1745
              ||||| |||| ||| ||||
Db         19 CTATTCTCAGCAGGAGACA 1


RESULT 173
ADF36917/c
ID   ADF36917 standard; RNA; 19 BP.
XX
AC   ADF36917;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1206.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1206; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 5 A; 3 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.6e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1719 CTTTGGACCTATTATCAGA 1737
              |||||| || || ||||||
Db         19 CTTTGGCCCAATAATCAGA 1

RESULT 174
ADF36449/c
ID   ADF36449 standard; RNA; 19 BP.
XX
AC   ADF36449;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:738.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 738; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 6 A; 3 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.6e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCACT 1656
              || |||| ||||| |||||
Db         19 TAGTTAATGAGCCATCACT 1

RESULT 175
ADF36022
ID   ADF36022 standard; RNA; 19 BP.
XX
AC   ADF36022;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:311.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 311; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
```

CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 19 BP; 6 A; 4 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 2.6e+02;
Matches 11; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1638 TATTTAAAGAGCCTTCACT 1656
              :| ::|| ||||| :|||:
Db          1 UAGUUAAUGAGCCAUCACU 19
```

RESULT 176
ADF35910/c
ID ADF35910 standard; RNA; 19 BP.
XX
AC ADF35910;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:199.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 199; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 19 BP; 4 A; 3 C; 6 G; 0 T; 6 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.6e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1561 GACTGCAAAAATCCTTCTC 1579
              |||||||||| ||||  ||
Db         19 GACTGCAAAAGTCCTCATC 1
```

RESULT 177
ADF36337
ID ADF36337 standard; RNA; 19 BP.
XX
AC ADF36337;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:626.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.

```
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 626; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 6 A; 6 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 2.6e+02;
  Matches   12;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCTTCTC 1579
              |||:|||||| :||:  :|
Db          1 GACUGCAAAAGUCCUCAUC 19


RESULT 178
ADF36593
ID   ADF36593 standard; RNA; 19 BP.
XX
AC   ADF36593;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:882.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 882; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 6 A; 5 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   57.9%;  Pred. No. 2.6e+02;
  Matches   11;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATTATCAGA 1737
              |:::|| || |: |:||||
Db          1 CUUUGGCCCAAUAAUCAGA 19


RESULT 179
ADF48099
ID   ADF48099 standard; RNA; 19 BP.
XX
AC   ADF48099;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human Myc siNA lower strand, SEQ ID 236.
XX
KW   Human; Myc; Myb; cancer; proliferative disease; restenosis;
KW   polycystic kidney disease; RNA interference;
KW   short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW   double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW   expression modulation; gene therapy; drug screening; diagnosis;
KW   therapeutic target identification; pharmacogenomics;
KW   gene function analysis; gene mapping; cytostatic; vasotropic;
KW   nephrotropic; ss.
```

```
XX
OS   Homo sapiens.
XX
PN   WO2003070917-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005326.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-OCT-2002; 2002US-0418655P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-689784/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of Myc or Myb genes.
XX
PS   Example 7; Page 129; 161pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human Myc or Myb genes by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The 'invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of the Myc or Myb genes in cells, tissue
CC   explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
CC   transplants for the treatment of a variety of conditions. They may be
CC   used for treating cancers and other proliferative diseases, such as
CC   restenosis and polycystic kidney disease. The siNAs are also useful for
CC   drug screening, diagnosis, therapeutic target identification and
CC   validation, genetic engineering, pharmacogenomics, studying gene
CC   function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC   The present sequence represents the lower strand of a human Myc-targeted
CC   double-stranded siNA.
XX
SQ   Sequence 19 BP; 10 A; 1 C; 0 G; 0 T; 8 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 2.6e+02;
  Matches    9;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAAATACA 1841
              ::| ||: ::::||| |||
Db          1 UUAAAAUUUUUUAAAAACA 19


RESULT 180
ADF47981/c
ID   ADF47981 standard; RNA; 19 BP.
XX
AC   ADF47981;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human Myc transcript target sequence/siNA upper strand, SEQ ID 118.
XX
KW   Human; Myc; Myb; cancer; proliferative disease; restenosis;
KW   polycystic kidney disease; RNA interference;
KW   short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW   double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW   expression modulation; gene therapy; drug screening; diagnosis;
KW   therapeutic target identification; pharmacogenomics;
KW   gene function analysis; gene mapping; cytostatic; vasotropic;
KW   nephrotropic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070917-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005326.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-OCT-2002; 2002US-0418655P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-689784/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of Myc or Myb genes.
XX
PS   Example 7; Page 129; 161pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human Myc or Myb genes by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of the Myc or Myb genes in cells, tissue
CC   explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
CC   transplants for the treatment of a variety of conditions. They may be
CC   used for treating cancers and other proliferative diseases, such as
CC   restenosis and polycystic kidney disease. The siNAs are also useful for
CC   drug screening, diagnosis, therapeutic target identification and
CC   validation, genetic engineering, pharmacogenomics, studying gene
CC   function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC   The present sequence represents the upper strand of a human Myc-targeted
CC   double-stranded siNA, which is identical to the Myc transcript target
CC   sequence.
XX
SQ   Sequence 19 BP; 8 A; 0 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.6e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAAATACA 1841
              ||| ||| ||||||| |||
Db         19 TTAAAATTTTTTAAAAACA 1


RESULT 181
```

```
ADO18477
ID   ADO18477 standard; DNA; 19 BP.
XX
AC   ADO18477;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Analytical probe chip of the invention #236.
XX
KW   analytical chip; bacterial 16S-rRNA; genotypic characterization; probe;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO2004033720-A2.
XX
PD   22-APR-2004.
XX
PF   24-SEP-2003; 2003WO-EP010626.
XX
PR   09-OCT-2002; 2002EP-00022631.
XX
PA   (UYGE-) UNIV GENEVE HOPITAUX.
XX
PI   Schrenzel J,  Francois P,  Charbonnier Y,  Jacquet JG,  Utinger D;
PI   Kresbach GM,  Abel A,  Ehrat M;
XX
DR   WPI; 2004-375537/35.
XX
PT   Analytical chip useful for simultaneous determination of one or more
PT   different bacterial 16S-rRNA in liquid sample, comprising evanescent
PT   field measurement platform as solid carrier and several specific
PT   recognition elements.
XX
PS   Claim 1; SEQ ID NO 236; 82pp; English.
XX
CC   The present invention relates to an analytical chip for simultaneous
CC   determination of one or more different bacterial 16S-rRNA in liquid
CC   sample. The chip is useful for detecting one or more bacterial 16S-rRNA,
CC   derived from bacteria such as Achromobacter xylosoxidans , Acinetobacter
CC   baumannii , Actinomyces israelii , Aerococcus viridans , Aeromonas
CC   hydrophilia , Agrobacterium radiobacter , Bacillus sp. , Bacteroides
CC   ovatus , Campylobacter fetus , Citrobacter freundii , Enterococcus avium
CC   , Eubacterium lentum , Escherichia coli , Flavobacterium breve ,
CC   Fusobacterium nucleatum , Gemella morbillorum , Gardnerella vaginalis ,
CC   Haemophilus influenzae , Hafnia alvei , Kingella sp. , Klebsiella oxytoca
CC   , Lactobacillus acidophilus , Legionella pneumophila , Moraxella
CC   catarrhalis , Mycobacterium avium , Neisseria cinerea , Nocardia sp. ,
CC   Ochrobactrum anthropi , Pasteurella multocida , Peptostreptococcus magnus
CC   , Salmonella typhi , Shigella sonnei , Veillonella parvula , Veillonella
CC   sp. or Yersinia enterocolitica . The chip is useful for detecting
CC   clinically relevant bacteria. The chip enables determination of one or
CC   more different bacterial 16S-rRNA in a liquid sample, simultaneously and
CC   enables rapid, accurate, easy and reliable identification of bacteria by
CC   genotypic characterization in a provided sample and also enables
CC   identification of a bacterium even in a complex biological sample. The
CC   chip which is produced at reduced cost, enables determination of 16S-rRNA
CC   in a sample with reduced experimental error and variation. The present
CC   sequence represents a probe of the invention used as an analytical chip.
XX
SQ   Sequence 19 BP; 7 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.6e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2051 TTAGCAACTAGTTAATAAG 2069
                 ||| ||||||| ||||| |
Db          1 TTACCAACTAGCTAATACG 19


RESULT 182
ADO18527
ID   ADO18527 standard; DNA; 19 BP.
XX
AC   ADO18527;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Analytical probe chip of the invention #286.
XX
KW   analytical chip; bacterial 16S-rRNA; genotypic characterization; probe;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO2004033720-A2.
XX
PD   22-APR-2004.
XX
PF   24-SEP-2003; 2003WO-EP010626.
XX
PR   09-OCT-2002; 2002EP-00022631.
XX
PA   (UYGE-) UNIV GENEVE HOPITAUX.
XX
PI   Schrenzel J,  Francois P,  Charbonnier Y,  Jacquet JG,  Utinger D;
PI   Kresbach GM,  Abel A,  Ehrat M;
XX
DR   WPI; 2004-375537/35.
XX
PT   Analytical chip useful for simultaneous determination of one or more
PT   different bacterial 16S-rRNA in liquid sample, comprising evanescent
PT   field measurement platform as solid carrier and several specific
PT   recognition elements.
XX
PS   Claim 1; SEQ ID NO 286; 82pp; English.
XX
CC   The present invention relates to an analytical chip for simultaneous
CC   determination of one or more different bacterial 16S-rRNA in liquid
CC   sample. The chip is useful for detecting one or more bacterial 16S-rRNA,
CC   derived from bacteria such as Achromobacter xylosoxidans , Acinetobacter
CC   baumannii , Actinomyces israelii , Aerococcus viridans , Aeromonas
CC   hydrophilia , Agrobacterium radiobacter , Bacillus sp. , Bacteroides
CC   ovatus , Campylobacter fetus , Citrobacter freundii , Enterococcus avium
CC   , Eubacterium lentum , Escherichia coli , Flavobacterium breve ,
CC   Fusobacterium nucleatum , Gemella morbillorum , Gardnerella vaginalis ,
CC   Haemophilus influenzae , Hafnia alvei , Kingella sp. , Klebsiella oxytoca
CC   , Lactobacillus acidophilus , Legionella pneumophila , Moraxella
CC   catarrhalis , Mycobacterium avium , Neisseria cinerea , Nocardia sp. ,
CC   Ochrobactrum anthropi , Pasteurella multocida , Peptostreptococcus magnus
CC   , Salmonella typhi , Shigella sonnei , Veillonella parvula , Veillonella
CC   sp. or Yersinia enterocolitica . The chip is useful for detecting
CC   clinically relevant bacteria. The chip enables determination of one or
CC   more different bacterial 16S-rRNA in a liquid sample, simultaneously and
CC   enables rapid, accurate, easy and reliable identification of bacteria by
CC   genotypic characterization in a provided sample and also enables
CC   identification of a bacterium even in a complex biological sample. The
CC   chip which is produced at reduced cost, enables determination of 16S-rRNA
CC   in a sample with reduced experimental error and variation. The present
CC   sequence represents a probe of the invention used as an analytical chip.
XX
SQ   Sequence 19 BP; 7 A; 5 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 2.6e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2051 TTAGCAACTAGTTAATAAG 2069
                 ||| ||||||| ||||| |
Db          1 TTACCAACTAGCTAATACG 19


RESULT 183
AAT41311/c
ID   AAT41311 standard; DNA; 20 BP.
```

```
XX
AC   AAT41311;
XX
DT   04-DEC-1996  (first entry)
XX
DE   Human gene signature HUMGS01057-derived sense primer.
XX
KW   Gene signature; messenger RNA; mRNA; relative abundance; frequency;
KW   human; cloning; mapping; non-biased library; diagnosis; detection;
KW   cell typing; abnormal cell function; primer; PCR; amplification;
KW   polymerase chain reaction; ss.
XX
OS   Synthetic.
XX
PN   WO9514772-A1.
XX
PD   01-JUN-1995.
XX
PF   11-NOV-1994;   94WO-JP001916.
XX
PR   12-NOV-1993;   93JP-00355504.
XX
PA   (MATS/) MATSUBARA K.
PA   (OKUB/) OKUBO K.
XX
PI   Matsubara K,  Okubo K;
XX
DR   WPI; 1995-206931/27.
XX
PT   Single-stranded DNA for identifying gene signatures - isolated from 3'-
PT   directed human cDNA library that reflects relative abundance of corresp.
PT   mRNA in specific human tissues.
XX
PS   Example 7; Fig 10; 2245pp; Japanese.
XX
CC   Primers T41001-T41382 are derived from novel human gene signature (GS)
CC   sequences which did not match with sequences deposited in Genbank release
CC   76. The GS sequences (T19001-T26837) were obtained from 3'-directed cDNA
CC   libraries prepared from various human tissues; synthesis of cDNA was
CC   initiated from the 3'-end of mRNA by using poly(T) as the sole primer.
CC   Each library is constructed so as to reflect accurately the relative
CC   abundance of different mRNAs in the particular tissue from which it was
CC   derived. The appearance frequency of a given GS in a cDNA library can be
CC   determined (esp. using primers and probes derived from the GS sequences)
CC   as a means of diagnosing abnormal cell function or for recognising
CC   different cell types. The primers T41311-2 amplify clone pm2049 which
CC   comprises the GS HUMGS001057 (T20057). This amplification reaction gave a
CC   prod. indistinguisable from the same PCR using Chinese hamster ovary DNA
CC   as a template
XX
SQ   Sequence 20 BP; 9 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1943 ATGGTTGGTTTTTGTGTCC 1961
              || | |||| |||||||||
Db         20 ATAGCTGGTGTTTGTGTCC 2


RESULT 184
AAX21925/c
ID   AAX21925 standard; DNA; 20 BP.
XX
AC   AAX21925;
XX
DT   18-MAY-1999  (first entry)
XX
DE   Human B-raf kinase antisense oligonucleotide Isis#13742.
XX
KW   Antisense oligonucleotide; B-raf; human; inhibitor; T-cell activation;
KW   hyperproliferative disorder; cancer; restenosis; psoriasis;
KW   atherosclerosis; raf-associated tumour; diagnosis; therapy; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /note= "phosphorothioate bases"
XX
PN   WO9902167-A1.
XX
PD   21-JAN-1999.
XX
PF   06-JUL-1998;   98WO-US013961.
XX
PR   07-JUL-1997;   97US-00888982.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP;
XX
DR   WPI; 1999-120502/10.
XX
PT   New antisense oligonucleotides - for modulation of human B-raf gene
PT   expression.
XX
PS   Claim 7; Page 22; 72pp; English.
XX
CC   This sequence represents an example of an antisense oligonucleotide of
CC   the invention. The oligonucleotides are 8-50 nucleotides in length, and
CC   are targeted to a nucleic acid encoding human B-raf and which is capable
CC   of inhibiting human B-raf expression. The oligonucleotides is used to
CC   inhibit the (abnormal) expression of human B-raf, to inhibit
CC   hyperproliferation of cells, to treat or prevent an abnormal
CC   proliferative condition, e.g. hyperproliferative disorders such as cancer
CC   (e.g. of the brain or nervous system), restenosis, psoriasis or a
CC   disorder characterised by T-cell activation and growth. They may also be
CC   used to diagnose these diseases, as well as atherosclerosis. The
CC   oligonucleotides of the invention may be used to distinguish raf-
CC   associated tumours from tumours having other etiologies. The antisense
CC   oligonucleotides can also be used to quantify raf expression in assays
XX
SQ   Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 185
AAX95694/c
ID   AAX95694 standard; DNA; 20 BP.
XX
AC   AAX95694;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
```

PD 03-JUN-1999.
XX
PF 20-NOV-1998; 98WO-IB001890.
XX
PR 21-NOV-1997; 97FR-00014673.
PR 04-NOV-1998; 98US-0107078P.
XX
PA (GEST) GENSET.
XX
PI Griffais R;
XX
DR WPI; 1999-357842/30.
XX
PT Genome sequence of Chlamydia pneumoniae.
XX
PS Page 1768; Disclosure; 1912pp; English.
XX
CC AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC (see AAX91990). C. pneumoniae causes respiratory disease such as
CC pneumonia and bronchitis and is thought to be a contributing factor in
CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae
XX
SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1585 CACAGACTGGGAACCCCTC 1603
|||||| |||||| ||| |
Db 19 CACAGATTGGGAAGCCCCC 1

RESULT 186
AAC60958
ID AAC60958 standard; DNA; 20 BP.
XX
AC AAC60958;
XX
DT 13-FEB-2001 (first entry)
XX
DE Interleukin 2 short tandem repeat primer SEQ ID NO:18.
XX
KW Short tandem repeat; primer; STR; susceptibility; HIV; infection; AIDS;
KW detection; polymorphism; interleukin 10 promoter; IL-10;
KW chromosome position 4q26-q27; interleukin 2; ss.
XX
OS Homo sapiens.
XX
PN WO200061811-A2.
XX
PD 19-OCT-2000.
XX
PF 06-APR-2000; 2000WO-US009355.
XX
PR 09-APR-1999; 99US-0128521P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Smith MW, Shin HD, O'brien SJ;
XX
DR WPI; 2000-687051/67.
XX
PT Predicting susceptibility to HIV infection or progression useful for
PT selection of therapeutic treatment for persons infected with HIV virus,
PT comprises detecting polymorphism in human interleukin-10 promoter.
XX
PS Example 1; Page 11; 40pp; English.
XX
CC The present invention describes a method for predicting susceptibility to
CC HIV infection or HIV progression in a subject. The method involves
CC detecting a polymorphism in a human interleukin-10 (IL-10) promoter,
CC where the presence of the polymorphism indicates susceptibility to HIV
CC infection or HIV progression. The method provides prognostic information
CC to persons infected with HIV virus and is useful to help select
CC treatments (such as administration of IL-10 or gene therapy with IL-10).
CC The presence of polymorphism is useful as predictor that very aggressive
CC treatment could substantially eradicate the virus from the infected
CC person. The method is useful for the generation of normograms or other
CC predictive algorithms that can be used, in association with allele
CC status, to prognose probable survival or years to development of AIDS
CC following HIV seroconversion. It indicates that increased expression of
CC the IL-10 gene helps to reduce HIV-1 infection and pathogenic progression
CC and enables a variety of new therapeutic interventions in the treatment
CC of HIV disease. The present sequence represents a short tandem repeat
CC (STR) primer which is used in an example from the present invention
XX
SQ Sequence 20 BP; 4 A; 3 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1767 AAGCTTTTTTTTTTGAAC 1785
| ||||| |||| ||||||
Db 2 ATGCTTTATTTTCTTGAAC 20

RESULT 187
AAF91339
ID AAF91339 standard; DNA; 20 BP.
XX
AC AAF91339;
XX
DT 04-MAY-2001 (first entry)
XX
DE Human E2F transcription factor 1 antisense oligonucleotide #45.
XX
KW Antisense; E2F transcription factor 1; human; infection; inflammation;
KW tumour; ss.
XX
OS Homo sapiens.
XX
PN US6187587-B1.
XX
PD 13-FEB-2001.
XX
PF 02-MAR-2000; 2000US-00517584.
XX
PR 02-MAR-2000; 2000US-00517584.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Popoff I, Brown-Driver VL, Cowsert LM;
XX
DR WPI; 2001-190981/19.
XX
PT Antisense compound capable of inhibiting the expression of E2F
PT transcription factor 1, useful for preventing or delaying infection,
PT inflammation or tumor formation.
XX
PS Claim 1; Col 42; 40pp; English.
XX
CC The present invention relates to antisense compounds up to 30 nucleobases
CC in length targeted to a E2F transcription factor 1 The invention is
CC useful for inhibiting the expression of E2F transcription factor 1 in
CC cells or tissues. The antisense oligonucleotides may also be used as a
CC research agent and to prevent infection, inflammation or tumours
XX

```
SQ   Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2017 AAGTCCTCTGGTAGGAGGC 2035
              || ||||| || |||||||
Db          2 AACTCCTCAGGGAGGAGGC 20


RESULT 188
AAS08770/c
ID   AAS08770 standard; DNA; 20 BP.
XX
AC   AAS08770;
XX
DT   26-SEP-2001  (first entry)
XX
DE   Human PD-ABC form 1 DNA exon 26 3' splice site.
XX
KW   PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
KW   peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
KW   cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
KW   epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
KW   familial high-density lipoprotein deficiency; fatty liver disease;
KW   atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
KW   alcoholism; retinal degeneration; hypertension; vascular disease.
XX
OS   Homo sapiens.
XX
PN   WO200153490-A1.
XX
PD   26-JUL-2001.
XX
PF   23-JAN-2001; 2001WO-US002191.
XX
PR   24-JAN-2000; 2000US-0177889P.
PR   30-JUN-2000; 2000US-0215405P.
XX
PA   (WARN ) WARNER LAMBERT CO.
XX
PI   Johns MA,  Tafuri SR,  Wang M;
XX
DR   WPI; 2001-442259/47.
XX
PT   New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
PT   of dyslipidemia, epilepsy and diseases related to abnormal calcium flux.
XX
PS   Disclosure; Page 38; 77pp; English.
XX
CC   The sequence represents a splice site within a DNA molecule encoding
CC   human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
CC   19p13.3 and is expressed in various tissues including spleen, thymus,
CC   peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
CC   molecules and proteins are used to diagnose and treat cardiovascular
CC   disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
CC   related to abnormal calcium flux, coronary artery disease, Tangier's
CC   disease, familial high-density lipoprotein deficiency, atherosclerosis,
CC   diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
CC   retinal degeneration, hypertension and vascular disease. The sequences
CC   are also used in drug screening assays
XX
SQ   Sequence 20 BP; 3 A; 4 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGGGGGAA 1617
              |||||||  |||||| |||
Db         20 CCCTCCTCACCTGGGCGAA 2


RESULT 189
AAS08861/c
ID   AAS08861 standard; DNA; 20 BP.
XX
AC   AAS08861;
XX
DT   26-SEP-2001  (first entry)
XX
DE   Human PD-ABC form 2 DNA exon 26 3' splice site.
XX
KW   PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
KW   peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
KW   cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
KW   epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
KW   familial high-density lipoprotein deficiency; fatty liver disease;
KW   atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
KW   alcoholism; retinal degeneration; hypertension; vascular disease.
XX
OS   Homo sapiens.
XX
PN   WO200153490-A1.
XX
PD   26-JUL-2001.
XX
PF   23-JAN-2001; 2001WO-US002191.
XX
PR   24-JAN-2000; 2000US-0177889P.
PR   30-JUN-2000; 2000US-0215405P.
XX
PA   (WARN ) WARNER LAMBERT CO.
XX
PI   Johns MA,  Tafuri SR,  Wang M;
XX
DR   WPI; 2001-442259/47.
XX
PT   New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
PT   of dyslipidemia, epilepsy and diseases related to abnormal calcium flux.
XX
PS   Disclosure; Page 40; 77pp; English.
XX
CC   The sequence represents a splice site within a DNA molecule encoding
CC   human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
CC   19p13.3 and is expressed in various tissues including spleen, thymus,
CC   peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
CC   molecules and proteins are used to diagnose and treat cardiovascular
CC   disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
CC   related to abnormal calcium flux, coronary artery disease, Tangier's
CC   disease, familial high-density lipoprotein deficiency, atherosclerosis,
CC   diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
CC   retinal degeneration, hypertension and vascular disease. The sequences
CC   are also used in drug screening assays
XX
SQ   Sequence 20 BP; 3 A; 4 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGGGGGAA 1617
              |||||||  |||||| |||
Db         20 CCCTCCTCACCTGGGCGAA 2


RESULT 190
ABL96288
ID   ABL96288 standard; DNA; 20 BP.
XX
AC   ABL96288;
XX
DT   21-AUG-2002  (first entry)
XX
DE   Primer #1 related to human NHAD3.
```

XX
KW Human; alcohol dehydrogenase type III; NHAD3; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN CN1292419-A.
XX
PD 25-APR-2001.
XX
PF 10-OCT-1999; 99CN-00116953.
XX
PR 10-OCT-1999; 99CN-00116953.
XX
PA (SHAN-) SHANGHAI SHENGYUAN GENE DEV CO LTD.
XX
PI Mao Y, Xie Y;
XX
DR WPI; 2001-409819/44.
XX
PT Human III type ethanol dehydrogenase and its coding sequence.
XX
PS Example 3; Page 12 (Disclosure); 21pp; Chinese.
XX
CC The present invention discloses a new polypeptide-novel human alcohol
CC dehydrogenase type III, called NHAD3. The invention also discloses the
CC method for curing several diseases by using novel human alcohol
CC dehydrogenase type III. The present sequence represents a primer related
CC to novel human alcohol dehydrogenase type III, NHAD3
XX
SQ Sequence 20 BP; 7 A; 3 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1550 GGAAGGAACAGGACTGCAA 1568
||| |||| |||||| |||
Db 1 GGAGGGAAGAGGACTCCAA 19

RESULT 191
ABA03194/c
ID ABA03194 standard; DNA; 20 BP.
XX
AC ABA03194;
XX
DT 08-FEB-2002 (first entry)
XX
DE Human KRGF1 PCR primer #1.
XX
KW Kidney repair factor; KRGF1; antiinflammatory; nephrotropic; PCR primer;
KW gene therapy; vaccine; kidney damage; kidney failure; inflammation;
KW human; ss.
XX
OS Homo sapiens.
XX
PN WO200168817-A1.
XX
PD 20-SEP-2001.
XX
PF 16-MAR-2001; 2001WO-JP002087.
XX
PR 16-MAR-2000; 2000JP-00073632.
XX
PA (KYOW) KYOWA HAKKO KOGYO KK.
XX
PI Takeuchi K, Kato Y, Sekine S, Kikuchi Y, Sakurada K;
XX
DR WPI; 2002-055101/07.
XX
PT Kidney repair factor KRGF1 for the treatment and diagnosis of damage to
PT kidney tissue comprises monitoring the increased expression in damaged
PT kidney tissue of KRGF1 and antibodies recognizing it.
XX
PS Example 6; Page 114; 121pp; Japanese.
XX
CC The present invention relates to human kidney repair factor, KRGF1 (see
CC AAM47451). KRGF1 was found to have increased expression in damaged kidney
CC tissue. KRGF1 can be used for the diagnosis of kidney tissue damage and
CC kidney failure; and for the treatment of damaged/inflamed kidney tissues.
CC The present sequence is a PCR primer, which was used in an example from
CC the present invention
XX
SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1576 TCTCCACCGCACAGACTGG 1594
|||| ||| ||||| ||||
Db 19 TCTCAACCTCACAGCCTGG 1

RESULT 192
AAD44809/c
ID AAD44809 standard; DNA; 20 BP.
XX
AC AAD44809;
XX
DT 13-DEC-2002 (first entry)
XX
DE Human B-raf kinase antisense oligonucleotide ISIS #13742.
XX
KW Human; raf; hyperproliferation; neovascularisation; ocular angiogenesis;
KW therapy; cancer; cytostatic; anti-angiogenic; vascular; ophthalmological;
KW antisense; phosphorothioate backbone; B-raf kinase; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
PN US6410518-B1.
XX
PD 25-JUN-2002.
XX
PF 18-FEB-2000; 2000US-00506073.
XX
PR 31-MAY-1994; 94US-00250856.
PR 31-MAY-1995; 95WO-US007111.
PR 26-NOV-1996; 96US-00756806.
PR 07-JUL-1997; 97US-00888982.
PR 06-JUL-1998; 98WO-US013961.
PR 28-AUG-1998; 98US-00143214.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP;
XX
DR WPI; 2002-597918/64.
XX
PT Treating cancer, angiogenesis or neovascularization by administering
PT antisense oligonucleotides targeted to human raf sequences.
XX
PS Example 18; Col 26; 41pp; English.
XX
CC The present invention relates to novel antisense oligonucleotides which
CC are targetted to nucleic acids encoding human raf proteins and capable of
CC inhibiting raf expression. The invention also relates to methods of
CC inhibiting hyperproliferation of cells which involves contacting the
CC hyperproliferating cells with a therapeutically effective amount of an

```
CC   oligonucleotide of the invention. The method is useful for treating
CC   cancer, angiogenesis or neovascularisation, especially ocular
CC   angiogenesis or neovascularisation. The present DNA sequence is an
CC   antisense oligonucleotide targetted to human B-raf kinase
XX
SQ   Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 193
ABZ74905
ID   ABZ74905 standard; DNA; 20 BP.
XX
AC   ABZ74905;
XX
DT   10-MAY-2003  (first entry)
XX
DE   Human acyl coenzyme A cholesterol acyltransferase-1 antisense oligo #25.
XX
KW   Human; acyl coenzyme A cholesterol acyltransferase-1; ACAT; liver;
KW   chromosome 1q25; chromosome 1; chromosome 7; cholesterol metabolism;
KW   free sterol regulation; cholesterol metabolism disorder;
KW   lipid metabolism disorder; atherosclerosis; cardiovascular disease;
KW   cardiant; expression inhibition; phosphorothioate;
KW   antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT                   cytosines are 5-methylcytosine"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT                   cytosines are 5-methylcytosine"
XX
PN   WO2003012144-A1.
XX
PD   13-FEB-2003.
XX
PF   17-JUL-2002; 2002WO-US022696.
XX
PR   01-AUG-2001; 2001US-00920394.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Crooke RM,  Graham MJ,  Lemonidis KM;
XX
DR   WPI; 2003-239532/23.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding acyl
PT   coenzyme A cholesterol acyltransferase-1, useful for treating a
PT   disease/condition involving abnormal lipid or cholesterol metabolism,
PT   e.g. atherosclerosis.
XX
PS   Claim 3; Page 91; 117pp; English.
XX
CC   Sequences ABZ74897-ABZ74942 represent antisense oligonucleotides targeted
CC   to the human or murine acyl coenzyme A cholesterol acyltransferase-1
CC   gene, which inhibit its expression. The antisense oligonucleotides were
CC   designed to target different regions of the human or murine acyl coenzyme
CC   A cholesterol acyltransferase-1 RNA, and were analysed for their effect
CC   on acyl coenzyme A cholesterol acyltransferase-1 mRNA levels by
CC   quantitative real-time PCR. Acyl coenzyme A cholesterol acyltransferase
CC   (ACAT) enzymes catalyse the synthesis of cholesterol esters from free
CC   cholesterol and fatty acyl-CoA, and are also involved in regulating the
CC   concentration of cellular free sterols. The human acyl coenzyme A
CC   cholesterol acyltransferase-1 is the predominant ACAT isoform in the
CC   liver, and the gene encoding it is located on chromosome 1q25, although a
CC   subsequent study has indicated that one acyl coenzyme A cholesterol
CC   acyltransferase-1 mRNA is produced from genes on two different
CC   chromosomes (chromosomes 1 and 7) by a novel RNA recombination mechanism
CC   involving trans-splicing of the two discontinuous precursor mRNAs. The
CC   oligonucleotides of the invention are useful for the prevention and
CC   treatment of conditions associated with acyl coenzyme A cholesterol
CC   acyltransferase-1, such as disorders involving abnormal lipid or
CC   cholesterol metabolism, e.g., atherosclerosis or cardiovascular disease.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of acyl coenzyme A cholesterol acyltransferase-1
XX
SQ   Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAGAGTTT 1623
              ||||| || ||||||| ||
Db          1 TGGCCCGGTGGAAGAGGTT 19


RESULT 194
ADF09803/c
ID   ADF09803 standard; DNA; 20 BP.
XX
AC   ADF09803;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human b-raf kinase antisense oligonucleotide seq id 72.
XX
KW   tumour metastasis; human; raf; raf expression inhibitor; cytostatic;
KW   antiarteriosclerotic; antisense-therapy; hyperproliferative disorder;
KW   atherosclerosis; tumour; b-raf kinase; antisense oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   US2003119769-A1.
XX
PD   26-JUN-2003.
XX
PF   14-JUN-2002; 2002US-00173225.
XX
PR   31-MAY-1994;   94US-00250856.
PR   31-MAY-1995;   95WO-US007111.
PR   26-NOV-1996;   96US-00756806.
PR   07-JUL-1997;   97US-00888982.
PR   06-JUL-1998;   98WO-US013961.
PR   28-AUG-1998;   98US-00143214.
PR   18-FEB-2000; 2000US-00506073.
PR   25-JAN-2002; 2002US-00057550.
XX
PA   (MONI/) MONIA B P.
XX
PI   Monia BP;
XX
DR   WPI; 2003-863446/80.
XX
PT   Preventing and/or treating conditions associated with raf expression,
PT   such as hyperproliferative disorders, atherosclerosis and tumors, using
PT   antisense oligonucleotide modulation of human raf gene expression.
```

XX
PS Example 18; SEQ ID NO 99; 41pp; English.
XX
CC The invention describes a method of preventing or treating tumour
CC metastasis in an animal comprising administering to the animal an
CC oligonucleotide 8-50 nucleotides in length, which is targeted to mRNA
CC encoding human raf and capable of inhibiting raf expression. Also
CC disclosed are raf oligonucleotides, nucleic acids, proteins and
CC compositions used in the methods of the invention. The oligonucleotides
CC have cytostatic and antiarteriosclerotic properties, are useful as Raf-
CC inhibitors and in antisense-therapy. The methods and compositions of the
CC present invention are useful for preventing and/or treating conditions
CC associated with raf expression, such as hyperproliferative disorders,
CC atherosclerosis and tumours. This sequence represents a human b-raf
CC kinase antisense oligonucleotide.
XX
SQ Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1531 AGAAAGGTTAGGAGAGTAG 1549
||| || | ||||||||||
Db 20 AGAGAGTTCAGGAGAGTAG 2

RESULT 195
ABZ98046
ID ABZ98046 standard; DNA; 20 BP.
XX
AC ABZ98046;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human MCP4 oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13288; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2009 CAGAGATCAAGTCCTCTGG 2027
||||| ||||||| || ||
Db 1 CAGAGTTCAAGTCTTCAGG 19

RESULT 196
ABZ90034/c
ID ABZ90034 standard; DNA; 20 BP.
XX
AC ABZ90034;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 5276; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 9 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1987 AAAAGTGTGTATCTAGCTT 2005
||| |||||| ||||| ||
Db 20 AAATGTGTGTTTCTAGGTT 2

RESULT 197
ABZ98097
ID ABZ98097 standard; DNA; 20 BP.
XX
AC ABZ98097;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human MCP4 oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13339; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2009 CAGAGATCAAGTCCTCTGG 2027
||||| ||||||| || ||
Db 1 CAGAGTTCAAGTCTTCAGG 19

RESULT 198
ABZ86102/c
ID ABZ86102 standard; DNA; 20 BP.
XX
AC ABZ86102;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 1344; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 10 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy . 1812 TGCTATAAGTTTTAGAATC 1830
||||||| ||||| ||||
Db 19 TGCTATATTTTTTAAAATC 1

RESULT 199
ABZ87395
ID ABZ87395 standard; DNA; 20 BP.
XX
AC ABZ87395;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 2637; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2026 GGTAGGAGGCAAAGGTTCT 2044
| |||||||| ||| ||||
Db 1 GCTAGGAGGCCAAGTTTCT 19

RESULT 200
ADA55771
ID ADA55771 standard; DNA; 20 BP.
XX
AC ADA55771;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human protein-related PCR primer, SEQ ID 3339.
XX
KW Cytostatic; Anti-inflammatory; Osteopathic; Neuroprotective; Nootropic;
KW Gene Therapy; human; secretory protein; membrane proteins; cancer;
KW inflammatory disease; osteoporosis; neurological disease; PCR; primer;
KW ss.
XX
OS Homo sapiens.
XX
PN EP1293569-A2.
XX
PD 19-MAR-2003.
XX
PF 21-MAR-2002; 2002EP-00006586.
XX
PR 14-SEP-2001; 2001JP-00328381.
PR 24-JAN-2002; 2002US-0350435P.
XX
PA (HELI-) HELIX RES INST.
PA (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;
XX
DR WPI; 2003-395539/38.
XX
PT New polynucleotides encoding full-length polypeptides, e.g. secretory
PT and/or membrane proteins, useful for developing medicines for diseases in
PT which the gene is involved, or as target molecules for gene therapy.
XX
PS Example 8; Page 112; 205pp; English.
XX
CC The present invention relates to novel human secretory or membrane
CC proteins (ADA54072-ADA55710) and their coding sequences (ADA52433-
CC ADA54071). The coding sequences are useful in the gene therapy of
CC diseases caused by abnormalities of the proteins, e.g. cancer,
CC inflammatory diseases, osteoporosis or neurological disease. The present

```
CC   sequence was used in an example from the invention.
XX
SQ   Sequence 20 BP; 3 A; 3 C; 5 G; 9 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTGT 1935
              ||| || || |||||||||
Db          1 ATAGCTCTTGTTTCAGTGT 19


RESULT 201
ABQ84614/c
ID   ABQ84614 standard; DNA; 20 BP.
XX
AC   ABQ84614;
XX
DT   20-FEB-2003  (first entry)
XX
DE   DPP10 related PSQ assay oligonucleotide #99.
XX
KW   DPP10; dipeptidyl peptidase; prolyloligopeptidase; enzyme; asthma;
KW   antiinflammatory; antiasthmatic; antipsoriatic; antiarthritic;
KW   antirheumatic; vaccine; gene therapy; inflammatory disease;
KW   inflammatory bowel disease; atopy; rheumatoid arthritis; psoriasis;
KW   chromosome 2q14; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO200286113-A2.
XX
PD   31-OCT-2002.
XX
PF   24-APR-2002; 2002WO-GB001887.
XX
PR   24-APR-2001; 2001GB-00010044.
PR   24-APR-2001; 2001GB-00010046.
PR   12-OCT-2001; 2001GB-00024575.
PR   12-OCT-2001; 2001GB-00024594.
XX
PA   (ISIS-) ISIS INNOVATIONS LTD.
XX
PI   Cookson WOCM,  Moffat MF,  Allen M,  Lench N;
XX
DR   WPI; 2003-093132/08.
XX
PT   New nucleic acid sequence comprising DPP10 mRNA, useful for the
PT   manufacture of a medicament for regulating DPP10 protein expression or
PT   for preventing or treating inflammatory disease e.g., inflammatory bowel
PT   disease.
XX
PS   Disclosure; Page 321; 321pp; English.
XX
CC   The present invention describes a new isolated nucleic acid sequence (I)
CC   comprising a DPP10 mRNA sequence. DPP10 is a dipeptidyl peptidase (also
CC   known as prolyloligopeptidase). (I) has antiinflammatory, antiasthmatic,
CC   antipsoriatic, antiarthritic and antirheumatic activities, and can be
CC   used in vaccines and gene therapy. A composition comprising (I) can be
CC   used for the manufacture of a medicament for regulating DPP10 expression
CC   or for preventing or treating inflammatory disease e.g., inflammatory
CC   bowel disease, asthma, atopy, rheumatoid arthritis or psoriasis. (I) can
CC   also be used in an assay for detecting or measuring DPP10 in a sample. A
CC   host cell comprising (I) can be used for producing recombinant DPP10 gene
CC   products, or in drug screening systems to identify agents for diagnosis
CC   or treatment of individuals having or susceptible to inflammatory
CC   disease. Human DPP10 is located on chromosome 2, more specifically
CC   chromosome 2q14. ABQ84254 to ABQ84612 and ABP55569 to ABP55629 represent
CC   sequences used in the exemplification of the present invention
XX
SQ   Sequence 20 BP; 11 A; 1 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTATTT 1642
              || |||||| || ||||||
Db         20 GTCACCTACTTTTCTATTT 2


RESULT 202
ACD42192/c
ID   ACD42192 standard; DNA; 20 BP.
XX
AC   ACD42192;
XX
DT   05-SEP-2003  (first entry)
XX
DE   Antisense oligonucleotide targeting human b-raf, ISIS13742.
XX
KW   Human; ss; antisense; c-raf; a-raf; b-raf; protein kinase; cancer;
KW   signal transduction; cell proliferation; lung carcinoma; cytostatic;
KW   antisense gene therapy; chemotherapeutic agent; angiogenesis;
KW   hyperproliferative condition; neovascularisation; ocular angiogenesis.
XX
OS   Homo sapiens.
XX
PN   US2003032607-A1.
XX
PD   13-FEB-2003.
XX
PF   25-JAN-2002; 2002US-00057550.
XX
PR   31-MAY-1994;   94US-00250856.
PR   31-MAY-1995;   95WO-US007111.
PR   26-NOV-1996;   96US-00756806.
PR   07-JUL-1997;   97US-00888982.
PR   06-JUL-1998;   98WO-US013961.
PR   28-AUG-1998;   98US-00143214.
PR   18-FEB-2000; 2000US-00506073.
XX
PA   (MONI/) MONIA B P.
XX
PI   Monia BP;
XX
DR   WPI; 2003-503332/47.
XX
PT   Novel antisense oligonucleotide which is targeted to mRNA encoding human
PT   raf and which is capable of inhibiting raf expression, useful for
PT   treating or preventing hyperproliferative conditions such as cancer.
XX
PS   Example 18; Page 14; 42pp; English.
XX
CC   The invention relates to an oligonucleotide 8-50 nucleotides in length
CC   which is targeted to mRNA encoding human c-raf, a-raf or b-raf (raf is a
CC   protein kinase playing a regulatory role in signal transduction,
CC   regulating cell proliferation and has been implicated in lung carcinoma),
CC   and which is capable of inhibiting raf expression. Also included is a
CC   composition comprising the oligonucleotide and a pharmaceutically
CC   acceptable carrier. The antisense oligonucleotide is useful for
CC   inhibiting the expression of human raf in human cells or tissues, by
CC   contacting the human cells or tissues with the oligo. The oligo. is also
CC   is useful for treating or preventing a disease or condition associated
CC   with the expression of raf by administering it in combination with a
CC   chemotherapeutic agent to a human or cells of the human, where the
CC   expression of raf is abnormal expression, and the condition is a
CC   hyperproliferative condition such as cancer, angiogenesis or
CC   neovascularisation (preferably ocular angiogenesis or
CC   neovascularisation). The oligo. is also useful for inhibiting
CC   hyperproliferation of cells. The oligos. are also useful as tools, for
CC   example for detecting and determining the role of raf expression in
CC   various cell functions and physiological processes and conditions and for
CC   diagnosing conditions associated with raf expression and for research
CC   purposes. The present sequence is an antisense oligonucleotide targeting
```

```
CC   a human raf mRNA
XX
SQ   Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 203
ABD22332/c
ID   ABD22332 standard; DNA; 20 BP.
XX
AC   ABD22332;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human cathepsin C-derived oligo SEQ ID 1344.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 1344; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 10 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1812 TGCTATAAGTTTTAGAATC 1830
              ||||||| ||||| ||||
Db         19 TGCTATATTTTTTAAAATC 1


RESULT 204
ABD31077
ID   ABD31077 standard; DNA; 20 BP.
XX
AC   ABD31077;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human MCP4-derived oligonucleotide SEQ ID 13288.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 13288; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
```

CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2009 CAGAGATCAAGTCCTCTGG 2027
||||| ||||||| || ||
Db 1 CAGAGTTCAAGTCTTCAGG 19

RESULT 205
ABD31128
ID ABD31128 standard; DNA; 20 BP.
XX
AC ABD31128;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human MCP4-derived oligonucleotide SEQ ID 13339.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 13339; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2009 CAGAGATCAAGTCCTCTGG 2027
||||| ||||||| || ||
Db 1 CAGAGTTCAAGTCTTCAGG 19

RESULT 206
ABD23625
ID ABD23625 standard; DNA; 20 BP.
XX
AC ABD23625;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human myosin X-derived oligonucleotide SEQ ID 2637.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 2637; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2026 GGTAGGAGGCAAAGGTTCT 2044
| ||||||||| ||| ||||
Db 1 GCTAGGAGGCCAAGTTTCT 19

RESULT 207
ABD26264/c
ID ABD26264 standard; DNA; 20 BP.
XX
AC ABD26264;
XX
DT 29-JUL-2004 (first entry)
XX
DE AA398883-derived oligonucleotide SEQ ID 5276.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 5276; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 9 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1987 AAAAGTGTGTATCTAGCTT 2005
||| |||||| ||||| ||
Db 20 AAATGTGTGTTTCTAGGTT 2

```
RESULT 208
ADH10874/c
ID   ADH10874 standard; DNA; 20 BP.
XX
AC   ADH10874;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human cathepsin Z target region ISIS #124573.
XX
KW   human; ss; cathepsin Z; antisense; encephalitis; viral infection;
KW   hyperproliferative disorder; cancer; infection; inflammation; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003224511-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00159266.
XX
PR   31-MAY-2002; 2002US-00159266.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-060543/06.
XX
PT   New antisense compound targeted to nucleic acid molecules encoding
PT   cathepsin Z, useful for treating diseases associated with expression of
PT   cathepsin Z, e.g. encephalitis, viral infection, or hyperproliferative
PT   disorder.
XX
PS   Example 15; SEQ ID NO 145; 67pp; English.
XX
CC   The invention relates to a compound 8-80 nucleobases in length targeted
CC   to a nucleic acid molecule encoding cathepsin Z. The antisense
CC   oligonucleotides and compounds are useful for inhibiting the expression
CC   of cathepsin Z, and for treating diseases or conditions associated with
CC   expression of cathepsin Z, e.g. encephalitis, viral infection, or
CC   hyperproliferative disorder, such as cancer. The antisense compounds are
CC   also useful as research reagents and kits, or in diagnostic, therapeutic
CC   and prophylaxis applications, e.g. to prevent or delay infection,
CC   inflammation or tumour formation. The present sequence represents a human
CC   cathepsin Z target region.
XX
SQ   Sequence 20 BP; 6 A; 2 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2010 AGAGATCAAGTCCTCTGGT 2028
              | | ||||||||||||| |
Db         19 AAATATCAAGTCCTCTGCT 1


RESULT 209
ADH10801
ID   ADH10801 standard; DNA; 20 BP.
XX
AC   ADH10801;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human cathepsin Z antisense oligonucleotide ISIS #206937.
XX
KW   human; ss; cathepsin Z; antisense; encephalitis; viral infection;
KW   hyperproliferative disorder; cancer; infection; inflammation; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003224511-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00159266.
XX
PR   31-MAY-2002; 2002US-00159266.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-060543/06.
XX
PT   New antisense compound targeted to nucleic acid molecules encoding
PT   cathepsin Z, useful for treating diseases associated with expression of
PT   cathepsin Z, e.g. encephalitis, viral infection, or hyperproliferative
PT   disorder.
XX
PS   Example 15; SEQ ID NO 72; 67pp; English.
XX
CC   The invention relates to a compound 8-80 nucleobases in length targeted
CC   to a nucleic acid molecule encoding cathepsin Z. The antisense
CC   oligonucleotides and compounds are useful for inhibiting the expression
CC   of cathepsin Z, and for treating diseases or conditions associated with
CC   expression of cathepsin Z, e.g. encephalitis, viral infection, or
CC   hyperproliferative disorder, such as cancer. The antisense compounds are
CC   also useful as research reagents and kits, or in diagnostic, therapeutic
CC   and prophylaxis applications, e.g. to prevent or delay infection,
CC   inflammation or tumour formation. The present sequence represents a human
CC   cathepsin Z antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 7 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2010 AGAGATCAAGTCCTCTGGT 2028
              | | ||||||||||||| |
Db          2 AAATATCAAGTCCTCTGCT 20


RESULT 210
ADH64238
ID   ADH64238 standard; DNA; 20 BP.
XX
AC   ADH64238;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #1072.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
```

```
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 1072; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 5 A; 2 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1949 GGTTTTTGTGTCCGCTAAA 1967
              || ||| ||||||| ||||
Db          1 GGGTTTAGTGTCCGGTAAA 19


RESULT 211
ADH66032
ID   ADH66032 standard; DNA; 20 BP.
XX
AC   ADH66032;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #2866.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 2866; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 8 A; 2 C; 0 G; 10 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAATA 1839
              ||||| |||| ||| ||||
Db          2 TTTTACAATCATTTTAATA 20


RESULT 212
ADH63625
ID   ADH63625 standard; DNA; 20 BP.
XX
AC   ADH63625;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #459.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 459; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 2 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1947 TTGGTTTTTGTGTCCGCTA 1965
              |||| ||| ||||||| ||
Db          2 TTGGGTTTAGTGTCCGGTA 20


RESULT 213
ADH65755
```

```
ID   ADH65755 standard; DNA; 20 BP.
XX
AC   ADH65755;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #2589.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 2589; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 8 A; 2 C; 0 G; 10 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAATA 1839
              ||||| |||| ||| ||||
Db          1 TTTTACAATCATTTTAATA 19


RESULT 214
ADI28168
ID   ADI28168 standard; DNA; 20 BP.
XX
AC   ADI28168;
XX
DT   22-APR-2004  (first entry)
XX
DE   Antisense oligonucleotide targeting human PRL3 ISIS 217495.
XX
KW   Human; antisense gene therapy; ss; PRL3;
KW   protein tyrosine phosphatase type IVA member  3; colorectal cancer;
KW   diabetes; glucose tolerance; insulin resistance; obesity;
KW   hyperproliferative disorder; cytostatic.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone and all cytidines are 5
FT                   -methyl cytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residues"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residues"
XX
PN   US2003235911-A1.
XX
PD   25-DEC-2003.
XX
PF   20-JUN-2002; 2002US-00177554.
XX
PR   20-JUN-2002; 2002US-00177554.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW,  Zhang H;
XX
DR   WPI; 2004-070585/07.
XX
PT   New antisense oligonucleotide, comprising a sequence targeted to a
PT   nucleic acid encoding protein tyrosine phosphatase type IVA member 3 (PRL
PT   -3), useful for preparing a composition for treating hyperproliferative
PT   disorders, e.g., cancer.
XX
PS   Example 15; SEQ ID NO 75; 77pp; English.
XX
CC   The invention relates to a compound comprising a sequence comprising 8-80
CC   base pairs (bp) targeted to a nucleic acid encoding protein tyrosine
CC   phosphatase type IVA member 3 (PRL-3), that specifically hybridises with
CC   the nucleic acid encoding PRL-3 and inhibits expression of PRL-3, i.e. is
CC   an antisense oligonucleotide (AO). Also included are a composition
CC   comprising the compound and a carrier or diluent, inhibiting the
CC   expression of PRL-3 in cells or tissues, treating an animal having or
CC   suspected of having a disease or condition associated with PRL-3 and
CC   screening for an antisense compound. The antisense oligonucleotide is
CC   useful for preparing a composition for treating hyperproliferative
CC   disorder, particularly cancer ((e.g. colorectal cancer), diabetes,
CC   reduced glucose tolerance, insulin resistance and obesity. The present
CC   sequence is an antisense oligonucleotide targeting human PRL3.
XX
SQ   Sequence 20 BP; 1 A; 6 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGCCTGG 1612
              ||| ||||| |||| ||||
Db          2 GGAGCCCCTGCTGGGCTGG 20


RESULT 215
ADJ59913
ID   ADJ59913 standard; DNA; 20 BP.
XX
AC   ADJ59913;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Oligonucleotide associated to MCP4 #31.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
```

```
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 769; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTCCTCTGG 2027
              ||||| ||||||| || ||
Db          1 CAGAGTTCAAGTCTTCAGG 19


RESULT 216
ADJ59964
ID   ADJ59964 standard; DNA; 20 BP.
XX
AC   ADJ59964;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Oligonucleotide associated to MCP4 #82.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 820; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTCCTCTGG 2027
              ||||| ||||||| || ||
Db          1 CAGAGTTCAAGTCTTCAGG 19


RESULT 217
ADJ38656
ID   ADJ38656 standard; DNA; 20 BP.
XX
AC   ADJ38656;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human resistin antisense oligonucleotide seq id 45.
XX
KW   antidiabetic; anorectic; cardiant; antiarteriosclerotic;
KW   resistin inhibitor; resistin; metabolic disease; diabetes; obesity;
KW   atherosclerosis; antisense technology; human; antisense oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
```

```
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004023383-A1.
XX
PD   05-FEB-2004.
XX
PF   31-JUL-2002; 2002US-00210833.
XX
PR   31-JUL-2002; 2002US-00210833.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bhanot S, Freier SM;
XX
DR   WPI; 2004-142664/14.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding resistin, useful for treating a metabolic disorder,
PT   e.g. diabetes or obesity, or atherosclerosis.
XX
PS   Example 15; SEQ ID NO 45; 75pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted
CC   to, and which specifically hybridises with a nucleic acid molecule
CC   encoding resistin, and inhibits the expression of resistin. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with resistin, such as a metabolic disease, e.g. diabetes or
CC   obesity, or atherosclerosis. They are also useful in research and
CC   diagnostics for modulating the expression of resistin. This sequence
CC   represents a human resistin antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 4 A; 9 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGGG 1614
              ||||||||| | ||||| |
Db          1 AACCCCTCCGGACCTGGAG 19


RESULT 218
ADJ38756/c
ID   ADJ38756 standard; DNA; 20 BP.
XX
AC   ADJ38756;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human resistin antisense oligonucleotide seq id 145.
XX
KW   antidiabetic; anorectic; cardiant; antiarteriosclerotic;
KW   resistin inhibitor; resistin; metabolic disease; diabetes; obesity;
KW   atherosclerosis; antisense technology; human; antisense oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004023383-A1.
XX
PD   05-FEB-2004.
XX
PF   31-JUL-2002; 2002US-00210833.
XX
PR   31-JUL-2002; 2002US-00210833.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bhanot S, Freier SM;
XX
DR   WPI; 2004-142664/14.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding resistin, useful for treating a metabolic disorder,
PT   e.g. diabetes or obesity, or atherosclerosis.
XX
PS   Example 15; SEQ ID NO 145; 75pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted
CC   to, and which specifically hybridises with a nucleic acid molecule
CC   encoding resistin, and inhibits the expression of resistin. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with resistin, such as a metabolic disease, e.g. diabetes or
CC   obesity, or atherosclerosis. They are also useful in research and
CC   diagnostics for modulating the expression of resistin. This sequence
CC   represents a human resistin antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 2 A; 5 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGGG 1614
              ||||||||| | ||||| |
Db         20 AACCCCTCCGGACCTGGAG 2


RESULT 219
ADJ17488
ID   ADJ17488 standard; DNA; 20 BP.
XX
AC   ADJ17488;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 2038.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
```

```
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 2038; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 10 A; 2 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAAGT 1992
              | ||||  ||||||||||
Db          2 CATTGAGCAAAAGAAAAGT 20


RESULT 220
ADJ23454
ID   ADJ23454 standard; DNA; 20 BP.
XX
AC   ADJ23454;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human endothelial lipase antisense oligonucleotide, SEQ ID 1852.
XX
KW   Antilipaemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW   Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW   cardiovascular disorder; metabolic syndrome X; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 4 nucleotides in length. Also all
FT                   cytidine residues are 5-methylcytidines"
XX
PN   WO2004009541-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022410.
XX
PR   19-JUL-2002; 2002US-0397106P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Bhat BG;
XX
DR   WPI; 2004-132912/13.
XX
PT   New antisense oligonucleotide for modulating endothelial lipase
PT   expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT   high density lipoprotein or cardiovascular disorders.
XX
PS   Claim 3; SEQ ID NO 1852; 1007pp; English.
XX
CC   The present invention relates to antisense oligonucleotides (ADJ21603-
CC   ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC   (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC   with and inhibits the expression of EL. The antisense oligonucleotides
CC   are useful for modulating the expression of endothelial lipase in cells
CC   or tissues to treat diseases associated with EL expression, such as
CC   dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC   disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC   used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ   Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2065 ATAAGTGGTATCTGACACA 2083
              |||||  ||| ||||||||
Db          2 ATAAGGTGTAACTGACACA 20


RESULT 221
ADJ23409
ID   ADJ23409 standard; DNA; 20 BP.
XX
AC   ADJ23409;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human endothelial lipase antisense oligonucleotide, SEQ ID 1807.
XX
KW   Antilipaemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW   Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW   cardiovascular disorder; metabolic syndrome X; ss.
```

```
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 4 nucleotides in length. Also all
FT                   cytidine residues are 5-methylcytidines"
XX
PN   WO2004009541-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022410.
XX
PR   19-JUL-2002; 2002US-0397106P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Bhat BG;
XX
DR   WPI; 2004-132912/13.
XX
PT   New antisense oligonucleotide for modulating endothelial lipase
PT   expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT   high density lipoprotein or cardiovascular disorders.
XX
PS   Claim 3; SEQ ID NO 1807; 1007pp; English.
XX
CC   The present invention relates to antisense oligonucleotides (ADJ21603-
CC   ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC   (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC   with and inhibits the expression of EL. The antisense oligonucleotides
CC   are useful for modulating the expression of endothelial lipase in cells
CC   or tissues to treat diseases associated with EL expression, such as
CC   dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC   disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC   used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ   Sequence 20 BP; 8 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2065 ATAAGTGGTATCTGACACA 2083
                ||||| ||| ||||||||
Db          1 ATAAGGTGTAACTGACACA 19


RESULT 222
ADL58638/c
ID   ADL58638 standard; DNA; 20 BP.
XX
AC   ADL58638;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 887.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 887; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 7 A; 8 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1612 GGGGAAGAGTTTGTTACCT 1630
                || |||||||||| || ||
Db         20 GGTGAAGAGTTTGGTATCT 2


RESULT 223
ADL59344
ID   ADL59344 standard; DNA; 20 BP.
XX
AC   ADL59344;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1593.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
```

```
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1593; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 5 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAAAA 1983
              ||||||||||||| | | |
Db          1 AAATATTTACCTTCATACA 19


RESULT 224
ADL58637/c
ID   ADL58637 standard; DNA; 20 BP.
XX
AC   ADL58637;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 886.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 886; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1612 GGGGAAGAGTTTGTTACCT 1630
              || |||||||||| || ||
Db         19 GGTGAAGAGTTTGGTATCT 1


RESULT 225
ADL58426
ID   ADL58426 standard; DNA; 20 BP.
XX
AC   ADL58426;
XX
DT   03-JUN-2004  (first entry)
```

```
XX
DE   Human ESM-1 antisense oligonucleotide seqid 675.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 675; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 4 A; 4 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1680 ACTTCTTAGTTGTTTCTCT 1698
              ||||||||| | | |||||
Db          1 ACTTCTTAGATTTATCTCT 19


RESULT 226
ADL58120
ID   ADL58120 standard; DNA; 20 BP.
XX
AC   ADL58120;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 369.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 369; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 4 A; 4 C; 1 G; 11 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1680 ACTTCTTAGTTGTTTCTCT 1698
              ||||||||| | | |||||
Db          2 ACTTCTTAGATTTATCTCT 20
```

```
RESULT 227
ADM15491
ID   ADM15491 standard; DNA; 20 BP.
XX
AC   ADM15491;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1678.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1678; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 6 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGACCCACA 1864
                ||| ||| | |||||||||
Db          2 CTGTGCCCAGAGACCCACA 20


RESULT 228
ADM15507
ID   ADM15507 standard; DNA; 20 BP.
XX
AC   ADM15507;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1694.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
```

```
XX
PS   Claim 4; SEQ ID NO 1694; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1847 TGGGCCAACAGACCCACAC 1865
                || ||| | ||||||||||
Db          1 TGTGCCCAGAGACCCACAC 19


RESULT 229
ADO45454
ID   ADO45454 standard; DNA; 20 BP.
XX
AC   ADO45454;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #820.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
XX
PF   25-JUL-2003; 2003US-00627930.
XX
PR   23-APR-2002; 2002WO-US013135.
PR   23-APR-2002; 2002WO-US013143.
XX
PA   (NYCE/) NYCE J W.
PA   (SAND/) SANDRASAGRA A.
PA   (TANG/) TANG L.
PA   (AGUI/) AGUILAR D.
PA   (MILL/) MILLER S.
PA   (SHAH/) SHAHABUDDIN S.
PA   (LUHH/) LU H.
PA   (CONG/) CONG H.
XX
PI   Nyce JW,  Sandrasagra A,  Tang L,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-293804/27.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT   RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT   asthma.
XX
PS   Claim 2; SEQ ID NO 820; 174pp; English.
XX
CC   The invention relates to oligonucleotides anti-sense to an initiation
CC   codon, coding region, 5' or 3' intron-exon junction, intron or region
CC   with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC   chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC   -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC   tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC   also relates to a method of screening a candidate compound that binds to
CC   one or more nucleic acid target(s) or expressed product(s), for the
CC   prevention and/or treatment of a respiratory or lung disease. The
CC   oligonucleotides are useful for reducing or inhibiting expression of a
CC   gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC   CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC   tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC   useful for preventing or treating a respiratory or lung disease. The
CC   respiratory or lung disease is associated with hyper-responsiveness to
CC   and/or increased levels of, adenosine and/or levels of adenosine A
CC   receptor(s), and/or asthma and/or lung allergies associated with
CC   inflammation or an inflammatory disease. The respiratory or lung disease
CC   is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC   cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC   allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC   hypertension, lung inflammation, bronchitis, airway obstruction or
CC   bronchoconstriction. This sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTCCTCTGG 2027
                 ||||| ||||||| || ||
Db          1 CAGAGTTCAAGTCTTCAGG 19


RESULT 230
ADO45403
ID   ADO45403 standard; DNA; 20 BP.
XX
AC   ADO45403;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #769.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
```

XX
PF 25-JUL-2003; 2003US-00627930.
XX
PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 769; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2009 CAGAGATCAAGTCCTCTGG 2027
||||| ||||||| || ||
Db 1 CAGAGTTCAAGTCTTCAGG 19

RESULT 231
ADO53030
ID ADO53030 standard; DNA; 20 BP.
XX
AC ADO53030;
XX
DT 15-JUL-2004 (first entry)
XX
DE Farnesoid X receptor gene expression antisense inhibitory oligo #403.
XX
KW ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS Homo sapiens.
XX
PN WO2004030750-A1.
XX
PD 15-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030353.
XX
PR 25-SEP-2002; 2002US-0413588P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Kane CD;
XX
DR WPI; 2004-347928/32.
XX
PT New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.
XX
PS Claim 4; SEQ ID NO 403; 150pp; English.
XX
CC The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 2.7e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1890 GATGTGCCCTAGATCAACA 1908
||| | |||||| ||||||
Db 2 GATTTTCCCTAGTTCAACA 20

RESULT 232
AAT42561/c
ID AAT42561 standard; cDNA; 21 BP.
XX
AC AAT42561;
XX
DT 14-JAN-1997 (first entry)
XX
DE 3' primer #1087-1107 for DHPS:chloroplast transit peptide fusion protein.
XX
KW Dihydrodipicolinic acid synthase; DHPS; chloroplast transit peptide; PCR;
KW chloroplast; maize; L-Lysine; recombinant plant; nutrition; grain crop;
KW forage plant; clover; fescue; alfalfa; processed plant; tomatoe; lupin;
KW soyabean; feed; food; food additive; polymerase chain reaction; primer;
KW amplify; ss.

```
XX
OS   Synthetic.
XX
PN   US5545545-A.
XX
PD   13-AUG-1996.
XX
PF   27-APR-1993;   93US-00053867.
XX
PR   27-APR-1993;   93US-00053867.
XX
PA   (MINU ) UNIV MINNESOTA.
XX
PI   Sellner JM,  Somers DA,  Bittel DC,  Gengenbach BG,  Shaver JM;
XX
DR   WPI; 1996-383670/38.
XX
PT   DNA encoding maize di:hydro:di:picolinic acid synthase mutant - resistant
PT   to feedback inhibition by lysine.
XX
PS   Example 7; Col 20; 35pp; English.
XX
CC   AAT42552-T42561 represent amplification primers for the recombinant DNA
CC   sequence used in the method of the invention. The method of the invention
CC   is for increasing the level of L-Lysine in a plant. In the method, a
CC   recombinant DNA sequence is introduced into the cells of a plant tissue
CC   source. The recombinant sequence comprises an altered mature Zea mays
CC   dihydrodipicolinic acid (DHPS) sequence (see AAT42547) which is
CC   substantially resistant to feedback inhibition by endogenously produced
CC   free L-Lysine, and a second sequence which encodes a chloroplast transit
CC   sequence (see AAT42549). The DHPS used has at least one amino acid
CC   alteration contained within residues 100-125, and is more than 400 times
CC   less sensitive to lysine than wild-type DHPS. The chloroplast transit
CC   sequence localises the altered mature DHPS in the chloroplasts of the
CC   plant cells. The transfected plant cells are then used to generate plants
CC   expressing the recombinant DNA in their cells. The plants regenerated
CC   from the transformed cells have increased levels of free L-Lysine, which
CC   improves their nutritional value. The plants which can be improved by
CC   this transformation include maize and other grain crops, forage plants
CC   (such as clover, fescue, and alfalfa), and processed plants (such as
CC   tomatoes, soyabeans and lupins). The plants can be used directly as feed
CC   or food, or the L-Lysine can be extracted for use as a feed or food
CC   additive
XX
SQ   Sequence 21 BP; 3 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTCTA 2045
              | |||||||  ||||||||
Db         19 GAAGGAGGCCCAGGTTCTA 1


RESULT 233
AAV60859/c
ID   AAV60859 standard; DNA; 21 BP.
XX
AC   AAV60859;
XX
DT   25-JAN-1999  (first entry)
XX
DE   Primer #2 for the B. flavum fumarase gene.
XX
KW   Fumarase; recombinant vector; inactivation; homologous recombination;
KW   amino acid; aspartic acid; alanine; primer; PCR; amplification; ss.
XX
OS   Synthetic.
OS   Brevibacterium flavum.
XX
PN   JP10262684-A.
XX
PD   06-OCT-1998.
XX
PF   19-AUG-1997;   97JP-00237758.
XX
PR   23-JAN-1997;   97JP-00024407.
XX
PA   (MITU ) MITSUBISHI CHEM CORP.
XX
DR   WPI; 1998-587296/50.
XX
PT   Nucleic acids and vectors encoding fumarase gene - used for producing
PT   fumarase gene-destroying bacterial strain, for production of aspartic
PT   acid and alanine.
XX
PS   Example 4; Page 9; 14pp; Japanese.
XX
CC   Primers AAV60858-V60859 are used to PCR amplify the fumarase gene from
CC   the microorganism Brevibacterium flavum (AAV60855). The product is then
CC   cloned into the E. coli vector JM109. The DNA, and recombinant vectors
CC   containing it, can be used for the preparation of a microbial strain in
CC   which the fumarase gene is inactivated by homologous recombination with
CC   the DNA. The fumarase-negative strain can be used for the preparation of
CC   the amino acids aspartic acid or alanine
XX
SQ   Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGGGA 1616
              | |||||| ||| ||||||
Db         19 CGCCTCCTAGCCCGGGGGA 1


RESULT 234
AAV51661
ID   AAV51661 standard; DNA; 21 BP.
XX
AC   AAV51661;
XX
DT   02-FEB-1999  (first entry)
XX
DE   Zea mays genome forward PCR primer #261.
XX
KW   Polymorphic marker; allele-specific; probe; amplification; PCR primer;
KW   hybridisation; plant; hybrid certification; genetic contribution;
KW   progeny; back-cross; hybrid; ancestry; corn; ss.
XX
OS   Synthetic.
OS   Zea mays.
XX
PN   WO9824796-A1.
XX
PD   11-JUN-1998.
XX
PF   01-DEC-1997;   97WO-US021782.
XX
PR   02-DEC-1996;   96US-0032069P.
PR   07-MAR-1997;   97US-00813507.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Lemieux B,  Landry BS,  Sapolsky RJ,  Murigneux A;
XX
DR   WPI; 1998-333252/29.
XX
PT   Brassica species allele-specific oligonucleotide probes and primers -
PT   useful for plant breeding.
XX
PS   Example 1; Page 54; 65pp; English.
XX
CC   AAV51401-V51704 are forward PCR primers used to amplify fragments of the
```

```
CC   Zea mays genome in order to detect polymorphic markers. Such markers can
CC   be used in the construction of allele-specific primers and probes for
CC   amplification or hybridisation, e.g. to determine common or disparate
CC   ancestry between 2 or more plants, to monitor the genetic contribution of
CC   an ancestral plant, to trace the progeny of proprietary plants, in
CC   certification of a hybrid plant or to identify the progeny of a back-
CC   crossed plant with an ancestral plant
XX
SQ   Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTGACAA 1746
                  ||||| | | |||||||||
Db          2 TATTACCCGTAGGTGACAA 20


RESULT 235
AAD00468
ID   AAD00468 standard; DNA; 21 BP.
XX
AC   AAD00468;
XX
DT   29-AUG-2000  (first entry)
XX
DE   Human MINT1 clone specific PCR primer-1.
XX
KW   Methylated CpG island Amplification; MCA; CGI; CpG site; DNA methylation;
KW   restriction endonuclease; SmaI; isoschizomer; XmaI; neoplastic cell;
KW   diagnosis; age-related disorder; dementia; artherosclerosis; astrocytoma;
KW   diabetes mellitus; cell proliferative disorder; cancer; kidney; colon;
KW   breast; uterus; prostate; lung; leukaemia; glioblastoma; neuroblastoma;
KW   modulating agent; screen; hypermethylation; human; Methylated IN Tumour;
KW   MINT; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200026401-A1.
XX
PD   11-MAY-2000.
XX
PF   02-NOV-1999;   99WO-US025251.
XX
PR   03-NOV-1998;   98US-0106925P.
PR   10-MAY-1999;   99US-00309175.
XX
PA   (UYJO ) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI   Issa J,  Baylin S,  Toyota M;
XX
DR   WPI; 2000-365641/31.
XX
PT   Methylated CpG island amplification (MCA) used to determine DNA
PT   methylation status of CpG sites in a given locus, useful for diagnosis of
PT   age-related disorders e.g. colon cancer and dementia.
XX
PS   Example 8; Page 69; 100pp; English.
XX
CC   The patent discloses a method known as Methylated CpG island (CGI)
CC   Amplification (MCA) to identify methylated CpG sites (cytosine residues
CC   5' of neighbouring guanine). The method uses a methylation-sensitive
CC   restriction endonuclease SmaI, that cleaves unmethylated CpG sites and
CC   its isoschizomer XmaI, that cleaves both methylated and unmethylated
CC   CGIs. It involves amplification of closely spaced methylated SmaI sites.
CC   This method is used to determine the DNA methylation status of CpG sites
CC   in a given locus, in normal and neoplastic cells. It can be used for
CC   diagnosis of age-related disorders, associated with methylation of CGIs,
CC   e.g. dementia, artherosclerosis and diabetes mellitus, cell proliferative
CC   disorders, e.g. cancer of the kidney, colon, breast, uterus, prostate and
CC   lung, leukaemia, glioblastoma, astrocytoma and neuroblastoma. It is also
CC   used to evaluate the cell response to a methylation modulating agent. It
CC   can also be used to screen samples for the presence of hypermethylation
CC   of specific genes. The present DNA sequence is the human MINT1 clone
CC   (Methylated IN Tumour) specific PCR primer-1, used for amplification and
CC   bisulphite-restriction methylation analysis
XX
SQ   Sequence 21 BP; 4 A; 0 C; 12 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGGAAG 1554
                  || | |||||||||||  ||
Db          1 GGGTTGGAGAGTAGGGGAG 19


RESULT 236
AAF96326
ID   AAF96326 standard; DNA; 21 BP.
XX
AC   AAF96326;
XX
DT   06-JUN-2001  (first entry)
XX
DE   Human gene single nucleotide polymorphism #1087.
XX
KW   Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW   polymorphism; vascular disease; coronary artery disease; forensics;
KW   myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW   pulmonary embolism; paternity test; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Variation       replace(11,A)
FT                   /*tag=  a
FT                   /standard_name= "single nucleotide polymorphism"
XX
PN   WO200118250-A2.
XX
PD   15-MAR-2001.
XX
PF   07-SEP-2000; 2000WO-US024503.
XX
PR   10-SEP-1999;   99US-0153357P.
PR   26-JUL-2000; 2000US-0220947P.
PR   16-AUG-2000; 2000US-0225724P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Lander ES,  Gargill M,  Ireland JS,  Bolk S,  Daley GQ,  Mccarthy JJ;
XX
DR   WPI; 2001-226749/23.
XX
PT   Nucleic acids comprising single nucleotide polymorphisms, useful in
PT   applications such as forensics, paternity testing, medicine, genetic
PT   analysis and phenotype correlations to diseases such as diabetes and
PT   atherosclerosis.
XX
PS   Example; Page 126; 242pp; English.
XX
CC   The present invention provides a method of diagnosing a vascular disease
CC   in an individual, involving determining the sequence at various
CC   polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC   genes. The sequences at a number of polymorphic sites are also provided
CC   in the specification. In particular, the method can be used in the
CC   diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC   disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC   pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC   useful in forensics, paternity testing, genetic analysis and phenotype
CC   correlations to diseases. The present sequence is an example of one of
CC   the human gene SNPS shown in the specification
```

```
XX
SQ   Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCAAGTCC 2022
              | || ||||| ||||||||
Db          1 TACTCCAGAGGTCAAGTCC 19


RESULT 237
AAH20432
ID   AAH20432 standard; DNA; 21 BP.
XX
AC   AAH20432;
XX
DT   06-AUG-2001  (first entry)
XX
DE   PCR primer used in pTalpha assay for immature T cell detection.
XX
KW   T cell production; haematopoietic T cell progenitor; immunodeficiency;
KW   immunoproliferative disorder; immune disorder; AIDS; DiGeorge's syndrome;
KW   lymphoma; pTalpha; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200132841-A2.
XX
PD   10-MAY-2001.
XX
PF   27-OCT-2000; 2000WO-US029655.
XX
PR   29-OCT-1999;   99US-0162574P.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Ruiz M,  Kinter A,  Dybul M,  Catanzaro A,  Fauci AS;
XX
DR   WPI; 2001-335829/35.
XX
PT   In vitro production of T cells, useful for treating immune disorders e.g.
PT   AIDS, lymphoma and DiGeorge's Syndrome, involves culturing a lymph node
PT   cell in vitro with a primate hematopoietic T cell progenitor cell.
XX
PS   Example 6; Page 22; 41pp; English.
XX
CC   This invention relates to a method for the in vitro production of T
CC   cells. The T cells are generated from a population of haematopoietic T
CC   cell progenitor cells. One example comprises culturing a lymph node cell
CC   in vitro with a primate haematopoietic T-cell progenitor cell. The method
CC   is useful for modifying a haematopoietic stem cell to produce a
CC   descendent cell containing a nucleotide sequence of interest. This
CC   comprises contacting the primate hematopoietic T cell progenitor cell and
CC   the lymph node cells with an expression vector such as a viral vector,
CC   comprising a nucleotide sequence of interest, so as to allow the virus to
CC   enter the haematopoietic T cell progenitor cell. The method is also
CC   useful for treating a subject having an immune disorder such as an
CC   immunodeficiency or immunoproliferative disorder, further comprising
CC   administering the progenitor cell or its descendent to the subject.
CC   Factors such as cytokines are also administered to the lymph node in the
CC   subject. The method is useful for treating immune disorders such as AIDS,
CC   DiGeorge's Syndrome (Complete Athymia), and immunoproliferative disorders
CC   such as lymphoma. Haematopoietic T cells produced by the method and their
CC   progeny are used as carriers for the production of a wide variety of
CC   products where the host cell is genetically deficient or as a result of
CC   subsequent diseases as become genetically deficient. The present sequence
CC   represents a PCR primer used to amplify cDNA in a pTalpha assay. The
CC   assay is used to determine the presence or absence of immature T cells,
CC   in an example illustrating the method of the invention
XX
SQ   Sequence 21 BP; 2 A; 9 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTCTG 1804
              | ||  |||||||||||||
Db          3 CACACCCTTTCCTTCTCTG 21


RESULT 238
AAS23721
ID   AAS23721 standard; DNA; 21 BP.
XX
AC   AAS23721;
XX
DT   04-DEC-2001  (first entry)
XX
DE   Primer A #35 used as probe for identifying C. albicans GRACE strain.
XX
KW   Gene identification; essential gene; GRACE; pathogenic fungus;
KW   gene replacement and conditional expression; fungal infection; probe; ss.
XX
OS   Candida albicans.
OS   Synthetic.
XX
PN   WO200160975-A2.
XX
PD   23-AUG-2001.
XX
PF   20-FEB-2001; 2001WO-US005551.
XX
PR   18-FEB-2000; 2000US-0183534P.
XX
PA   (ELIT-) ELITRA PHARM INC.
XX
PI   Roemer T,  Jiang B,  Boone C,  Bussey H;
XX
DR   WPI; 2001-489080/53.
XX
PT   Identifying genes essential to fungal metabolisms and identifying
PT   potential therapeutic agents that target these genes.
XX
PS   Disclosure; Page 307; 324pp; English.
XX
CC   The present invention relates to novel methods for constructing fungal
CC   strains useful for identification and validation of gene products as
CC   targets for therapeutic agents, for creating a collection of identified
CC   essential genes, and screening assays for the discovery of new drugs. The
CC   invention provides the GRACE (gene replacement and conditional
CC   expression) method for the construction of mutant organisms referred to
CC   as GRACE strains of the organism. The invention can be applied to any
CC   organism, particularly a pathogenic fungus e.g. Candida albicans,
CC   Aspergillus fumigatus and Cryptococcus neoformans. The methods are useful
CC   to identify agents that may be used in the treatment of fungal
CC   infections. AAS23687-AAS23747 represent primers A #1-61 used as probes
CC   for identifying C. albicans GRACE strains
XX
SQ   Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATCAA 1906
              |||||| | || |||||||
Db          1 TTGATGGGTCCGAGATCAA 19


RESULT 239
ABK41517/c
ID   ABK41517 standard; DNA; 21 BP.
XX
```

```
AC   ABK41517;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Human CTNNA3 exon-specific lower PCR primer #4.
XX
KW   Human; mouse; alpha-catenin; primer; ss; cytostatic; antiinfertility;
KW   cadherin-catenin related pathway; heart testis; cancer; gene therapy;
KW   cadherin-catenin related disease; specifically dilated cardiomyopathy;
KW   cardiomyopathy; male infertility; CTNNA3; PCR; alpha T-catenin.
XX
OS   Homo sapiens.
XX
PN   WO200204636-A1.
XX
PD   17-JAN-2002.
XX
PF   28-JUN-2001; 2001WO-EP007392.
XX
PR   12-JUL-2000; 2000EP-00202472.
PR   14-JUL-2000; 2000US-0218309P.
XX
PA   (VLAA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI   Van Roy F,  Goossens S,  Janssens B,  Vanpoucke G;
XX
DR   WPI; 2002-171717/22.
XX
PT   New alpha catenin polypeptides and polynucleotides encoding them, useful
PT   for predicting, diagnosing or treating cadherin-catenin related diseases,
PT   particularly cardiomyopathies, cancer and male infertility.
XX
PS   Example; Page 35; 132pp; English.
XX
CC   The invention relates to human and mouse alpha-catenin polypeptides and
CC   their associated polynucleotides. The polypeptides and related antibodies
CC   are useful for modulating the cadherin-catenin related pathway in
CC   selected organs, such as the heart and testis. The nucleic acids and the
CC   antibodies are useful in the diagnosis and/or prediction of the
CC   likelihood of developing cadherin-catenin related diseases. The nucleic
CC   acids may also be used to predict the likelihood of developing cancer or
CC   in diagnosing cancer, and in gene therapy. The polypeptide, the nucleic
CC   acid or the antibody is useful in manufacturing a medicament for treating
CC   cadherin-catenin related diseases, such as cancer, cardiomyopathy,
CC   specifically dilated cardiomyopathy, and male infertility. Sequences
CC   ABK41510-ABK41599 represent PCR primers used to amplify DNA encoding
CC   human and mouse alpha-catenin polypeptides, including the CTNNA3 gene
CC   which encodes human alpha T-catenin
XX
SQ   Sequence 21 BP; 8 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAAGTGG 1811
              |||| |||||||||  |||
Db         20 TTTCATTCTCTGAACCTGG 2


RESULT 240
ABZ29935
ID   ABZ29935 standard; DNA; 21 BP.
XX
AC   ABZ29935;
XX
DT   30-JAN-2003  (first entry)
XX
DE   Candida albicans GRACE strain PCR primer SEQ ID NO 4086.
XX
KW   Fungus; yeast; tetracyclin; promoter; GRACE strain; biosynthesis;
KW   signal transduction; DNA replication; cell division; growth;
KW   proliferation; Candida albicans; fungicide; antifungal; PCR; primer; ss.
XX
OS   Candida albicans.
XX
PN   WO200253728-A2.
XX
PD   11-JUL-2002.
XX
PF   26-DEC-2001; 2001WO-US049486.
XX
PR   29-DEC-2000; 2000US-0259128P.
PR   20-FEB-2001; 2001US-00792024.
PR   22-AUG-2001; 2001US-0314050P.
XX
PA   (ELIT-) ELITRA PHARM INC.
XX
PI   Roemer T,  Jiang B,  Boone C,  Bussey H,  Ohlsen KL;
XX
DR   WPI; 2002-566694/60.
XX
PT   Constructing strains for identifying gene products as effective targets
PT   for therapeutic intervention, by inactivating in the strain one allele of
PT   a gene and placing other allele of the gene under conditional expression.
XX
PS   Claim 36; SEQ ID NO 4086; 167pp + Sequence Listing; English.
XX
CC   The invention relates to constructing (M1) a strain of diploid fungal
CC   cells in which both alleles of a gene are modified, comprising modifying
CC   one allele by insertion or replacement by a cassette having an
CC   expressible selectable marker and modifying other allele by
CC   recombination, of a promoter replacement fragment with a heterologous
CC   promoter, so that expression of the second allele is regulated by the
CC   promoter. (M1) is useful for constructing a strain of diploid fungal
CC   cells in which both alleles of a gene are modified. The diploid fungal
CC   cells having both alleles modified are useful for identifying a gene that
CC   is essential to the survival or growth of a fungus, a gene that
CC   contributes to the virulence and/or pathogenicity of a fungus, a gene
CC   that contributes to the resistance of a diploid fungus to an antifungal
CC   agent, an antifungal agent that inhibits the growth of a diploid fungus
CC   and for identifying a therapeutic agent for treatment of a mammalian
CC   disease. (M1) is useful for identifying a compound which modulates the
CC   activity of a gene product, preferably enzymatic activity, carbon
CC   compound catabolism, biosynthetic, transporter, transcriptional,
CC   translational, signal transduction, DNA replication and cell division
CC   activity. The method is useful for identifying a compound having the
CC   ability to inhibit growth or proliferation of C. albicans cells and for
CC   treating infection by C. albicans. The present sequence is that of a PCR
CC   primer used in the method of the invention. Note: The sequence data for
CC   this patent is not represented in the printed specification but is based
CC   on sequence information supplied to Derwent by the European Patent Office
XX
SQ   Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATCAA 1906
              |||||| | || |||||||
Db          1 TTGATGGGTCCGAGATCAA 19


RESULT 241
ABK37957/c
ID   ABK37957 standard; DNA; 21 BP.
XX
AC   ABK37957;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Forward RT-PCR primer for NOV7.
XX
KW   Human; NOVX; ss; cardiomyopathy; atherosclerosis; diabetes; PCR; primer;
KW   cell signal processing disorder; metabolic disorder; obesity; infection;
```

KW anorexia; cancer-associated cachexia; cancer; neurodegenerative disorder;
KW Alzheimer's disease; Parkinson's disease; immune disorder;
KW haematopoietic disorders; dyslipidaemia; pain; asthma; hypertension;
KW osteoporosis; Crohn's disease; multiple sclerosis; angina pectoris;
KW myocardial infarction; ulcer; allergy; benign prostatic hypertrophy;
KW psychosis; neurological disorder; anxiety; schizophrenia;
KW manic depression; dementia; dyskinesia; Huntington's disease;
KW Gilles de la Tourette's syndrome; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200210216-A2.
XX
PD 07-FEB-2002.
XX
PF 30-JUL-2001; 2001WO-US024225.
XX
PR 28-JUL-2000; 2000US-0221409P.
PR 04-AUG-2000; 2000US-0222840P.
PR 04-AUG-2000; 2000US-0223752P.
PR 04-AUG-2000; 2000US-0223762P.
PR 04-AUG-2000; 2000US-0223769P.
PR 04-AUG-2000; 2000US-0223770P.
PR 14-AUG-2000; 2000US-0225146P.
PR 15-AUG-2000; 2000US-0225392P.
PR 15-AUG-2000; 2000US-0225470P.
PR 16-AUG-2000; 2000US-0225697P.
PR 01-FEB-2001; 2001US-0263662P.
PR 05-APR-2001; 2001US-0281645P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Padigaru M, Mezes P, Mishra V, Burgess C, Casman S, Grosse WM;
PI Alsobrook JP, Lepley DM, Gerlach VL, Macdougall JR, Smithson G;
XX
DR WPI; 2002-180074/23.
XX
PT New isolated cytoplasmic, nuclear, membrane bound, or secreted
PT polypeptide, useful for treating cardiomyopathy, atherosclerosis,
PT infections, cancer, neurodegenerative, metabolic, hematopoietic and
PT immune disorders.
XX
PS Example 7; Page 173; 213pp; English.
XX
CC The invention relates to an isolated cytoplasmic, nuclear, membrane
CC bound, or secreted polypeptide (NOVX, x= 1-14) their variants or mature
CC form. Also included are the nucleic acids encoding the NOVX proteins, a
CC vector comprising the nucleic acid, a cell comprising the vector, an anti
CC -NOVX antibody and modulators of NOVX. NOVX, the nucleic acid and the
CC antibody are useful for treating or preventing a NOVX-associated
CC disorder, where the disorder is selected from cardiomyopathy,
CC atherosclerosis, diabetes, a disorder related to cell signal processing
CC and metabolic pathway modulation, metabolic disorders, obesity,
CC infectious disease, anorexia, cancer-associated cachexia, cancer,
CC neurodegenerative disorders, Alzheimer's disease, Parkinson's disease,
CC immune disorders, haematopoietic disorders, and the various
CC dyslipidaemias, metabolic disturbances associated with obesity, the
CC metabolic syndrome X and wasting disorders associated with chronic
CC diseases, bacterial, fungal, protozoal and viral infections, pain,
CC bulimia, asthma, hypertension, urinary retention, osteoporosis, Crohn's
CC disease, multiple sclerosis, Albright Hereditary Osteodystrophy, angina
CC pectoris, myocardial infarction, ulcer, allergy, benign prostatic
CC hypertrophy, and psychotic and neurological disorders, including anxiety,
CC schizophrenia, manic depression, delirium, dementia, and dyskinesias,
CC such as Huntington's disease and Gilles de la Tourette's syndrome. The
CC nucleic acid is useful in gene therapy. The present sequence is an RT-PCR
CC (reverse transcriptase PCR) primer used to quantitate tissue specific
CC expression of a NOVX transcript
XX
SQ Sequence 21 BP; 11 A; 3 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1992 TGTGTATCTAGCTTCTTCA 2010
||||| ||| ||||||||
Db 20 TGTGTTTCTGCCTTCTTCA 2

RESULT 242
ADJ78673
ID ADJ78673 standard; DNA; 21 BP.
XX
AC ADJ78673;
XX
DT 06-MAY-2004 (first entry)
XX
DE Pancreatic cancer-related gene methylation-specific PCR primer #13.
XX
KW differential methylation; pancreatic cancer;
KW cellular proliferative disorder; cancer screening; risk-assessment;
KW prognosis; minimal-residual disease identification;
KW therapeutic target identification; ss; methylation-specific PCR; MSP;
KW primer.
XX
OS Unidentified.
XX
PN WO200268694-A1.
XX
PD 06-SEP-2002.
XX
PF 25-FEB-2002; 2002WO-US005681.
XX
PR 23-FEB-2001; 2001US-0271268P.
XX
PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
XX
PI Goggins MG, Ueki T;
XX
DR WPI; 2002-707019/76.
XX
PT New isolated nucleic acid molecules comprising differentially methylated
PT sequences, and associated regulatory sequences, useful for cancer
PT screening, risk-assessment, prognosis, or minimal-residual disease
PT identification.
XX
PS Claim 21; SEQ ID NO 55; 73pp; English.
XX
CC The invention comprises 42 gene sequences which were found to be
CC differentially methylated in pancreatic cancer. The DNA sequences of the
CC invention are useful in detecting cellular proliferative disorders in a
CC patient. The DNA sequences of the invention are useful for cancer
CC screening, risk-assessment, prognosis, minimal-residual disease
CC identification, staging and identification of therapeutic targets. The
CC present DNA sequence represents a methylation-specific PCR (MSP) primer
CC of the invention.
XX
SQ Sequence 21 BP; 4 A; 0 C; 12 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1536 GGTTAGGAGAGTAGGGAAG 1554
|| | |||||||||||| ||
Db 1 GGGTTGGAGAGTAGGGGAG 19

RESULT 243
ADI30262
ID ADI30262 standard; DNA; 21 BP.
XX
AC ADI30262;
XX
DT 22-APR-2004 (first entry)

```
XX
DE   Human PTEN specific antisense oligonucleotide, ISIS 29613.
XX
KW   PTEN; metabolic disease; type 2 diabetes; hyperproliferative condition;
KW   prophylaxis; gene therapy; human; MMAC1; phosphorothioate backbone; TEP1;
KW   antisense; ds.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   20. .21
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
XX
PN   US2004002153-A1.
XX
PD   01-JAN-2004.
XX
PF   03-JAN-2003; 2003US-00336213.
XX
PR   21-JUL-1999;   99US-00358381.
PR   14-DEC-1999;   99WO-US029594.
PR   24-MAY-2000; 2000US-00577902.
PR   11-JUN-2001; 2001US-00878582.
PR   18-SEP-2002; 2002US-0411780P.
XX
PA   (MONI/) MONIA B P.
PA   (BENN/) BENNETT C F.
PA   (BAKE/) BAKER B F.
PA   (VICK/) VICKERS T.
XX
PI   Monia BP,  Bennett CF,  Baker BF,  Vickers T;
XX
DR   WPI; 2004-061664/06.
XX
PT   New double-stranded oligomeric compounds that modulate PTEN expression,
PT   useful for diagnosing, preventing or treating conditions associated with
PT   PTEN, e.g. metabolic diseases, type 2 diabetes or hyperproliferative
PT   diseases.
XX
PS   Claim 14; SEQ ID NO 88; 54pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of PTEN (also known as MMAC1 and TEP1). The
CC   compound is useful for inhibiting the expression of PTEN in cells or
CC   tissues to treat diseases associated with their expression, e.g.
CC   metabolic diseases or conditions, type 2 diabetes or hyperproliferative
CC   conditions. In addition, the compound is used for diagnostics,
CC   prophylaxis, or as research reagents or kits. The invention is useful in
CC   gene therapy. The present sequence is human PTEN DNA specific double
CC   stranded antisense oligonucleotide.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 2 G; 11 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTTT 1795
                | ||| || ||||||||||
Db          1 TGTTTCAAGCCCATTCTTT 19


RESULT 244
ADH74629/c
ID   ADH74629 standard; DNA; 21 BP.
XX
AC   ADH74629;
XX
DT   22-APR-2004  (first entry)
XX
DE   PCR primer #2 for differentially methylated region of human IGF2 gene.
XX
KW   Cancer risk; imprinting; insulin-like growth factor 2; IGF2;
KW   hypomethylation; differentially methylated region; DMR;
KW   hyperproliferative disorder; colorectal cancer; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   US2004002082-A1.
XX
PD   01-JAN-2004.
XX
PF   03-JAN-2003; 2003US-00336552.
XX
PR   27-JUN-2002; 2002US-0391810P.
XX
PA   (FEIN/) FEINBERG A P.
XX
PI   Feinberg AP;
XX
DR   WPI; 2004-061657/06.
XX
PT   Identifying increased risk of developing cancer in subject, involves
PT   analyzing first biological sample from subject for loss of imprinting of
PT   IGF2 gene, indicative of increased risk of developing cancer in subject.
XX
PS   Claim 9; SEQ ID NO 3; 19pp; English.
XX
CC   The present invention relates to a method for identifying an increased
CC   risk of developing cancer in a subject. The method involves analysing a
CC   first biological sample from the subject for loss of imprinting of the
CC   insulin-like growth factor 2 (IGF2) gene, where a loss of imprinting is
CC   indicative of an increased risk of developing cancer. The method includes
CC   analysing genomic DNA for altered methylation of the IGF2 gene. The
CC   altered methylation includes hypomethylation of a differentially
CC   methylated region (DMR) of IGF2. The method is useful for managing the
CC   health of a subject having a hyperproliferative disorder such as cancer,
CC   particularly colorectal cancer. The present sequence represents a PCR
CC   primer for amplifying the DMR of the human IGF2 gene.
XX
SQ   Sequence 21 BP; 5 A; 11 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.8e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
                ||  ||||| |||||||||
Db         19 AGGGAGGTTGGGAGAGTAG 1


RESULT 245
ADJ47508/c
ID   ADJ47508 standard; DNA; 21 BP.
XX
AC   ADJ47508;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human IGF2 gene DMR PCR primer SEQ ID NO:3.
XX
KW   loss of imprinting; IGF2; hypomethylation;
KW   differentially methylated region; DMR; cancer; human; PCR; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004010850-A2.
XX
PD   05-FEB-2004.
XX
PF   28-JUL-2003; 2003WO-US023725.
XX
```

PR 26-JUL-2002; 2002US-0398660P.
PR 03-JAN-2003; 2003US-00336552.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Feinberg AP;
XX
DR WPI; 2004-143710/14.
XX
PT Identifying loss of imprinting of the IGF2 gene to determine increased
PT risk of developing cancer comprises analyzing biological sample from the
PT subject for hypomethylation of a differentially methylated region (DMR)
PT of the H19 or IGF2 gene.
XX
PS Claim 9; SEQ ID NO 3; 122pp; English.
XX
CC The present invention describes a method for identifying loss of
CC imprinting of the IGF2 gene in a subject. The method comprises analysing
CC a biological sample from the subject for hypomethylation of a
CC differentially methylated region (DMR) of at least one of the H19 gene
CC and the IGF2 gene. Also described: (1) identifying an increased risk of
CC developing cancer in a human subject; and (2) a kit for determining a
CC methylation status of a differentially methylated region (DMR) of IGF2 or
CC H19 comprising the primer pair. The method is useful for identifying loss
CC of imprinting of the IGF2 gene to determine an increased risk of
CC developing cancer in a subject. The present sequence represents a PCR
CC primer for the DMR of the human IGF2 gene, which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 5 A; 11 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1531 AGAAAGGTTAGGAGAGTAG 1549
|| ||||| |||||||||
Db 19 AGGGAGGTTGGGAGAGTAG 1

RESULT 246
ADJ97663/c
ID ADJ97663 standard; DNA; 21 BP.
XX
AC ADJ97663;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 436.
XX
KW human; ss; short interfering RNA; siRNA; angiogenesis;
KW vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW age-related macular degeneration; inflammatory disease; psoriasis;
KW rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW antipsoriatic; antirheumatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN WO2004009769-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022444.
XX
PR 24-JUL-2002; 2002US-0398417P.
PR 14-NOV-2002; 2002US-00294228.
XX
PA (UYPE-) UNIV PENNSYLVANIA.
XX
PI Tolentino MJ, Reich SJ;
XX
DR WPI; 2004-203472/19.
XX
PT Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT strands, useful for inhibiting expression of human vascular endothelial
PT growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT retinopathy and cancer.
XX
PS Disclosure; SEQ ID NO 436; 218pp; English.
XX
CC This invention relates to novel compositions that comprise short
CC interfering RNA (siRNA) molecules, which can be used to inhibit
CC angiogenesis. Specifically, it refers to siRNAs that target and cause
CC RNAi-induced degradation of mRNA from human vascular endothelial growth
CC factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC region) genes, as well as mutants derived thereof. The present invention
CC describes sense and antisense RNA strands that form an RNA duplex and
CC bind to the target mRNA, such that expression is inhibited and the target
CC degraded. As such, siRNA administered in combination with a therapeutic
CC agent is useful for treating diseases associated with angiogenesis and
CC the overexpression of VEGF, which include diabetic retinopathy, age-
CC related macular degeneration, inflammatory disease, psoriasis and
CC rheumatoid arthritis. Furthermore, it can be used to treat various
CC cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC oligo, a target for siRNA inhibition of the invention.
XX
SQ Sequence 21 BP; 6 A; 2 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 2.5%; Score 14.2; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1563 CTGCAAAAATCCTTCTCCA 1581
|||||||| |||| ||||
Db 21 CTGCAAAAGTCCTCATCCA 3

RESULT 247
ABQ64252/c
ID ABQ64252 standard; DNA; 17 BP.
XX
AC ABQ64252;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 965.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 284; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1740 GTGACAAGTACTGG 1753
||||||||||||||
Db 17 GTGACAAGTACTGG 4

RESULT 248
ABQ64256/c
ID ABQ64256 standard; DNA; 17 BP.
XX
AC ABQ64256;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 969.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
PS Example 2; Page 284; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1739 GGTGACAAGTACTG 1752
||||||||||||||
Db 14 GGTGACAAGTACTG 1

RESULT 249
ACC64866
ID ACC64866 standard; DNA; 17 BP.
XX
AC ACC64866;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour supression, SEQ ID 2113.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 278; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 6 A; 5 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2074 ATCTGACACACTCT 2087
||||||||||||||
Db 2 ATCTGACACACTCT 15

RESULT 250
ACC63818
ID ACC63818 standard; DNA; 17 BP.
XX
AC ACC63818;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour supression, SEQ ID 1065.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 155; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2074 ATCTGACACACTCT 2087
||||||||||||||
Db 2 ATCTGACACACTCT 15

RESULT 251
ADB40646
ID ADB40646 standard; DNA; 17 BP.
XX
AC ADB40646;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #969.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 145; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

```
  Query Match             2.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1865 CACTTAGCCATTGA 1878
              ||||||||||||||
Db          4 CACTTAGCCATTGA 17


RESULT 252
ABX95294
ID   ABX95294 standard; DNA; 18 BP.
XX
AC   ABX95294;
XX
DT   18-JUN-2003  (first entry)
XX
DE   Human ABCA7 associated RT-PCR primer #1.
XX
KW   Human; ATP-binding cassette transporter protein A7; ABC transporter;
KW   ABCA7; autoimmune disease; Sjogren's syndrome; inflammation;
KW   abnormal lipid metabolism; arteriosclerosis; ABCA-SSN inhibitor;
KW   immunomodulator; immunosuppressive; antiinflammatory;
KW   antiarteriosclerotic; reverse transcriptase-PCR; RT-PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003010315-A1.
XX
PD   06-FEB-2003.
XX
PF   24-JUL-2002; 2002WO-JP007487.
XX
PR   25-JUL-2001; 2001JP-00224176.
PR   06-DEC-2001; 2001JP-00372530.
XX
PA   (KYOW ) KYOWA HAKKO KOGYO KK.
PA   (KAZU-) KAZUSA DNA RES INST FOUND.
XX
PI   Ueda K,  Nakagawa S,  Nagase T;
XX
DR   WPI; 2003-239444/23.
XX
PT   Novel ABC transporter protein, ABCA7 splicing variant, participating in
PT   the immune system, applicable in diagnosis of and screening drugs for
PT   e.g. autoimmune diseases, Sjoegren's syndrome and inflammations.
XX
PS   Example 2; Page 162; 183pp; Japanese.
XX
CC   The present invention relates to the isolation of human ATP-binding
CC   cassette (ABC) transporter protein A7 (ABCA7) splice variants, and the
CC   polynucleotide sequences encoding them. The protein is applicable in the
CC   diagnosis and screening of drugs for autoimmune diseases, Sjogren's
CC   syndrome, inflammations, abnormal lipid metabolism and arteriosclerosis.
CC   It may also be used in a method for screening ABCA-SSN inhibitors. The
CC   present sequence represents a reverse transcriptase (RT)-PCR primer used
CC   in the examples of the present invention
XX
SQ   Sequence 18 BP; 2 A; 10 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1667 CACCCGCCCCTGGA 1680
              ||||||||||||||
Db          4 CACCCGCCCCTGGA 17


RESULT 253
ADE27175/c
ID   ADE27175 standard; RNA; 19 BP.
XX
AC   ADE27175;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Stearoyl-CoA desaturase siNA oligonucleotide SEQ ID NO:119.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KW   stearoyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KW   antiarteriosclerotic; cytostatic; virucide; obesity; diabetes;
KW   atherosclerosis; cancer; viral infection; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS   Synthetic.
XX
PN   WO2003070885-A2.
XX
PD   28-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-US004317.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   20-SEP-2002; 2002US-0412304P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Thompson J;
XX
DR   WPI; 2003-721687/68.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of obesity or diabetes, downregulates expression of the
PT   stearoyl-CoA desaturase gene.
XX
PS   Example 3; SEQ ID NO 119; 139pp; English.
XX
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of the SCD (stearoyl-CoA desaturase) gene
CC   by RNA interference. Also described: (1) modulating expression of SCD
CC   genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC   kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC   complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC   siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC   virucide activities. The siNAs can be used to modulate expression of SCD
CC   genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC   diabetes (types I and II); atherosclerosis; cancer and viral infections.
CC   They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents an SCD siNA, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 1 A; 3 C; 0 G; 0 T; 15 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAAG 1991
              ||||||||||||||
Db         15 GAAAAAAAGAAAAG 2


RESULT 254
ADE27465
ID   ADE27465 standard; RNA; 19 BP.
XX
```

```
AC   ADE27465;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Stearoyl-CoA desaturase siNA oligonucleotide SEQ ID NO:409.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KW   stearoyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KW   antiarteriosclerotic; cytostatic; virucide; obesity; diabetes;
KW   atherosclerosis; cancer; viral infection; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS   Synthetic.
XX
PN   WO2003070885-A2.
XX
PD   28-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-US004317.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   20-SEP-2002; 2002US-0412304P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Thompson J;
XX
DR   WPI; 2003-721687/68.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of obesity or diabetes, downregulates expression of the
PT   stearoyl-CoA desaturase gene.
XX
PS   Example 3; SEQ ID NO 409; 139pp; English.
XX
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of the SCD (stearoyl-CoA desaturase) gene
CC   by RNA interference. Also described: (1) modulating expression of SCD
CC   genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC   kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC   complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC   siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC   virucide activities. The siNAs can be used to modulate expression of SCD
CC   genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC   diabetes (types I and II); atherosclerosis; cancer and viral infections.
CC   They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents an SCD siNA, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 15 A; 0 C; 3 G; 0 T; 1 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAAG 1991
              ||||||||||||||
Db          5 GAAAAAAAGAAAAG 18


RESULT 255
AAS10630/c
ID   AAS10630 standard; DNA; 20 BP.
XX
AC   AAS10630;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human caspase 3 antisense oligonucleotide 108954.
XX
KW   Human; caspase 3; apoptosis; hyperproliferative disorder; hepatitis;
KW   viral infection; haematopoietic disorder; autoimmune disorder;
KW   atherosclerosis; neurological disorder; antisense; phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate internucleotide linkages.
FT                   Some bases especially bases 1-5 and bases 16-20 are 2'-
FT                   methoxyethyl (2'-MOE) bases, bases 6-15 are 2'-
FT                   deoxynucleotides and all cytidine bases are 5'-
FT                   methylcytidines"
XX
PN   WO200153310-A1.
XX
PD   26-JUL-2001.
XX
PF   11-JAN-2001; 2001WO-US000888.
XX
PR   18-JAN-2000; 2000US-00484617.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Zhang H,  Cowsert LM;
XX
DR   WPI; 2001-442252/47.
XX
PT   New antisense compound to inhibit caspase 3 is useful for treating
PT   hepatitis and atherosclerosis.
XX
PS   Example 17; Page 87; 127pp; English.
XX
CC   The present sequence for human caspase 3 antisense oligonucleotide 108954
CC   is 1 of various novel antisense oligonucleotides (AAS10517-AAS10676)
CC   described in the present invention. Also described are methods of using
CC   these compounds for the modulation of caspase 3 expression. The caspase 3
CC   antisense oligonucleotides specifically hybridise with and inhibit the
CC   expression of caspase 3. Antisense compounds targeted to caspase 3 are
CC   useful to inhibit caspase 3 expression in cells or tissues and to
CC   modulate apoptosis. The caspase 3 antisense oligonucleotides are useful
CC   for treating disorders associated with expression of caspase 3. Such
CC   disorders include hyperproliferative disorders (e.g. cancer), viral
CC   infections (e.g. hepatitis), haematopoietic disorders, autoimmune
CC   disorders, atherosclerosis and neurological disorders (e.g. Alzheimer's
CC   disease)
XX
SQ   Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAG 2013
              ||||||||||||||
Db         20 TAGCTTCTTCAGAG 7


RESULT 256
AAD11975
ID   AAD11975 standard; DNA; 20 BP.
XX
AC   AAD11975;
XX
DT   25-SEP-2001  (first entry)
XX
```

```
DE   Human PTP1B antisense oligonucleotide (ISIS# 107784).
XX
KW   Human; PTP1B; protein phosphatase 1B inhibitor; antisense; gene therapy;
KW   infection; inflammation; tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Methoxyethyl residues"
FT   modified_base   7
FT                   /*tag=  d
FT                   /mod_base= m5c
FT   modified_base   10
FT                   /*tag=  e
FT                   /mod_base= m5c
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "Methoxyethyl residues"
FT   modified_base   17
FT                   /*tag=  f
FT                   /mod_base= m5c
XX
PN   US6261840-B1.
XX
PD   17-JUL-2001.
XX
PF   18-JAN-2000; 2000US-00487368.
XX
PR   18-JAN-2000; 2000US-00487368.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Wyatt J;
XX
DR   WPI; 2001-432181/46.
XX
PT   New antisense compounds capable of modulating expression of human protein
PT   phosphatase 1B, useful for diagnosis, prophylaxis and treatment of
PT   diseases associated with expression of protein phosphatase.
XX
PS   Claim 1; Col 42; 71pp; English.
XX
CC   The invention is directed to antisense compounds, particularly
CC   oligonucleotides which are targetted to a DNA encoding protein
CC   phosphatase 1B (PTP1B) to modulate its expression. The antisense
CC   compounds are useful for diagnosis, prophylaxis and treatment of diseases
CC   associated with the expression of PTP1B, to prevent or delay infection,
CC   inflammation and tumour formation and as a research reagent. The PTP1B
CC   DNA is useful in gene therapy. The present sequence is an antisense
CC   oligonucleotide with a phosphorothioate backbone. This oligo is targetted
CC   to human PTP1B to inhibit its expression
XX
SQ   Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
              ||||||||||||||
Db          6 TCTTCAGAGATCAA 19
```

RESULT 257

```
ABK85050
ID   ABK85050 standard; DNA; 20 BP.
XX
AC   ABK85050;
XX
DT   13-AUG-2002  (first entry)
XX
DE   Human PTP1B antisense oligonucleotide ISIS 107784.
XX
KW   Antisense; protein phosphatase 1B; PTP1B; ss; probe; human;
KW   type 2 diabetes; obesity; ovarian cancer; chronic myeloid leukaemia;
KW   hyperproliferative disease; antidiabetic; anorectic; cytostatic;
KW   blood glucose; gene therapy.
XX
OS   Homo sapiens.
XX
PN   US2002055479-A1.
XX
PD   09-MAY-2002.
XX
PF   14-MAY-2001; 2001US-00854883.
XX
PR   18-JAN-2000; 2000US-00487368.
PR   31-JUL-2000; 2000US-00629644.
XX
PA   (COWS/) COWSERT L M.
PA   (WYAT/) WYATT J.
PA   (FREI/) FREIER S M.
PA   (MONI/) MONIA B P.
PA   (BUTL/) BUTLER M M.
PA   (MCKA/) MCKAY R.
XX
PI   Cowsert LM,  Wyatt J,  Freier SM,  Monia BP,  Butler MM,  Mckay R;
XX
DR   WPI; 2002-462914/49.
XX
PT   Compound for inhibiting the expression of protein phosphatase 1B (PTP1B)
PT   and for treating diabetes, cancer, or obesity, comprises an antisense
PT   oligonucleotide targeted to nucleic acid encoding PTP1B.
XX
PS   Claim 3; Page 23; 133pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases in length
CC   targeted to a nucleic acid encoding protein phosphatase 1B (PTP1B), where
CC   the compound specifically hybridises with and inhibits the expression of
CC   PTP1B (e.g. an antisense oligonucleotide). Also included are (1) a
CC   compound of 8-50 nucleobases in length which specifically hybridises with
CC   an 8 nucleobase portion of an active site on a nucleic acid encoding
CC   PTP1B; (2) inhibiting the expression of PTP1B in cells or tissues
CC   comprising contacting the cells or tissues with the compound; treating an
CC   animal having or suspected of having a disease or condition associated
CC   with PTP1B comprising administering the compound; (4) decreasing blood
CC   sugar levels in an animal comprising administering the compound; (5)
CC   preventing or delaying the onset of a disease or condition associated
CC   with PTP1B in an animal comprising administering the compound; and (6)
CC   preventing or delaying the onset of an increase in blood glucose levels
CC   in an animal comprising administering the compound. The compound is used
CC   to inhibit the expression of PTP1B in cells or tissues, to treat or
CC   prevent or delay the onset of a disease or condition associated with
CC   PTP1B, such as type 2 diabetes, obesity, cancer (especially ovarian
CC   cancer, chronic myeloid leukaemia and hyperproliferative diseases in an
CC   animal having or suspected of having the disease or condition, and for
CC   decreasing blood sugar levels or preventing or delaying the onset of an
CC   increase in blood glucose levels in an animal. The compound is also used
CC   in diagnostics, therapeutics, prophylaxis, and in research reagents and
CC   kits. The present sequence is an antisense compound of the invention
CC   targetting human PTP1B
XX
SQ   Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       2005 TCTTCAGAGATCAA 2018
             ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 258
ABK37219
ID   ABK37219 standard; DNA; 20 BP.
XX
AC   ABK37219;
XX
DT   08-MAY-2002  (first entry)
XX
DE   Human PTP1B mRNA level inhibition antisense DNA #16.
XX
KW   Human; mouse; rat; protein tyrosine phosphatase 1B; PTP1B; ss; adipose;
KW   liver; kidney; metabolic disease; type 2 diabetes; obesity; cancer;
KW   hyperproliferative condition; blood serum; blood plasma; antidiabetic;
KW   blood glucose level; cytostatic; anorectic; antisense gene therapy;
KW   PTP1B mRNA level inhibition.
XX
OS   Homo sapiens.
XX
PN   WO200210378-A2.
XX
PD   07-FEB-2002.
XX
PF   30-JUL-2001; 2001WO-US023874.
XX
PR   31-JUL-2000; 2000US-00629644.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Wyatt J,  Freier SM,  Monia BP,  Butler MM,  Mckay R;
XX
DR   WPI; 2002-180079/23.
XX
PT   Novel antisense compound useful for treating type 2 diabetes, cancer and
PT   obesity, is targeted to nucleic acid encoding human protein phosphatase
PT   1B, and hybridizes and inhibits PTP1B expression.
XX
PS   Claim 3; Page 67; 142pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid molecule
CC   encoding protein phosphatase 1B (PTP1B), which specifically hybridises
CC   with and inhibits the expression of PTP1B. The compounds of the invention
CC   are useful for inhibiting the expression of PTP1B in liver, kidney or
CC   adipose cells or tissues and for treating an animal, preferably human,
CC   having a disease or condition associated with PTP1B, including metabolic
CC   diseases or conditions, e.g. type 2 diabetes and obesity, or
CC   hyperproliferative conditions such as cancer. The sequences are also
CC   useful for decreasing blood (serum or plasma) glucose levels in an animal
CC   e.g. a diabetic human or rodent, for preventing or delaying the onset of
CC   a disease or condition associated with PTP1B , and for preventing or
CC   delaying the onset of an increase in blood glucose levels. This sequence
CC   represents a PTP1B mRNA level inhibition antisense oligonucleotide of the
CC   invention
XX
SQ   Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
             ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 259
ADC51216/c
ID   ADC51216 standard; DNA; 20 BP.
XX
AC   ADC51216;
XX
DT   18-DEC-2003  (first entry)
XX
DE   PCR primer #1 for DNA encoding Spirotrichonympha leidyi cellulase.
XX
KW   Protozoa; cellulase; industrial enzyme agent; detergent; fodder additive;
KW   textile processing industry; PCR; primer; ss.
XX
OS   Spirotrichonympha leidyi.
XX
PN   JP2003070475-A.
XX
PD   11-MAR-2003.
XX
PF   03-SEP-2001; 2001JP-00266454.
XX
PR   03-SEP-2001; 2001JP-00266454.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
PA   (RIKA ) RIKAGAKU KENKYUSHO.
XX
DR   WPI; 2003-782806/74.
XX
PT   Novel protein having cellulase activity obtained from termite symbiosis
PT   protozoa, useful in textile processing, as fodder additive and detergent.
XX
PS   Example; SEQ ID NO 3; 10pp; Japanese.
XX
CC   The present invention relates to the isolation of a protozoa
CC   (Spirotrichonympha leidyi) cellulase, and the polynucleotide sequence
CC   encoding it. The protein is useful as an industrial enzyme agent, e.g.
CC   detergents, fodder additive, and in textile processing industries. The
CC   polynucleotide sequence encoding the cellulase is useful for producing
CC   the protein by recombinant techniques. The present sequence represents a
CC   PCR primer used in the examples of the present invention.
XX
SQ   Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1910 ATCAACAATACCTT 1923
             ||||||||||||||
Db         18 ATCAACAATACCTT 5


RESULT 260
ADF82970/c
ID   ADF82970 standard; DNA; 20 BP.
XX
AC   ADF82970;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Glucose-6-phosphate dehydrogenase outer PCR primer G6PDFU.
XX
KW   Human; glucose-6-phosphate dehydrogenase; PCR; primer; DNA-RNA hybrid;
KW   enzyme; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003100019-A2.
XX
PD   04-DEC-2003.
XX
PF   27-MAY-2003; 2003WO-US016634.
XX
PR   24-MAY-2002; 2002US-0382578P.
XX
PA   (INVI-) INVITROGEN CORP.
```

```
XX
PI   Lastrucci RMD;
XX
DR   WPI; 2004-035126/03.
XX
PT   A composition for amplifying and/or detecting nucleic acids comprises a
PT   template nucleic acid molecule comprising a target nucleic acid sequence,
PT   a primer, a nucleotide polymerase enzyme and an agent capable of
PT   degrading a nucleotide.
XX
PS   Disclosure; SEQ ID NO 29; 95pp; English.
XX
CC   The invention is directed to one-tube nested PCR methods which use one or
CC   more outer primers containing at least one exo-sample nucleotide and
CC   inner primers. An exo-sample nucleotide is a nucleotide, e.g.
CC   deoxyuridine, that is not generally found in substantial amounts (more
CC   than 3%) in the sample or nucleic acid molecule to be amplified. Nested
CC   amplification methods are performed in the presence of an agent, e.g.
CC   uracil DNA glycosylase, that degrades the exo-sample nucleotide-
CC   containing primers in time-course fashion during the PCR cycles. The
CC   method alleviates the major contamination issue associated with classical
CC   nested PCR, and is also more convenient and economical. The present
CC   sequence is that of glucose-6-phosphate dehydrogenase (G6PD) specific
CC   outer primer G6PDFU. This is one of a set of primers for G6PD ADF82970-
CC   ADF82973 used to illustrate the one tube nested PCR method of the
CC   invention.
XX
SQ   Sequence 20 BP; 7 A; 6 C; 4 G; 1 T; 2 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCAC 1669
              ||||||||||||||
Db         16 TGGTTCTGCATCAC 3


RESULT 261
ADI36748/c
ID   ADI36748 standard; DNA; 20 BP.
XX
AC   ADI36748;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human KOX 1 DNA, antisense oligonucleotide #18.
XX
KW   Human; KOX 1; zinc finger protein 10; antisense therapy;
KW   hyperproliferative disorder; cancer; viral infection;
KW   bacterial infection; hyperactivation; immune response; cytostatic;
KW   virucide; antibacterial; immunosuppressive; phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2'-methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 5 nucleotides in length at each
FT                   end. All cytidine residues are 5-methylcytidines"
XX
PN   US2003232438-A1.
XX
PD   18-DEC-2003.
XX
PF   17-JUN-2002; 2002US-00173817.
XX
PR   17-JUN-2002; 2002US-00173817.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW,  Freier SM;
XX
DR   WPI; 2004-052172/05.
XX
PT   New antisense oligonucleotide targeted to a nucleic acid encoding KOX 1,
PT   useful for treating cancer, viral or bacterial infections or a disease
PT   involving hyperactivation of an immune response.
XX
PS   Example 15; SEQ ID NO 30; 80pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding human KOX 1 (zinc finger protein 10). The antisense
CC   compound comprises an antisense oligonucleotide that specifically
CC   hybridises with the nucleic acid and inhibits the expression of KOX 1.
CC   The antisense oligonucleotide is a chimeric oligonucleotide. The
CC   antisense oligonucleotide comprises at least one modified internucleoside
CC   linkage, preferably a phosphorothioate linkage. It also comprises at
CC   least one modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE)
CC   sugar moiety. The antisense oligonucleotide further comprises at least
CC   one modified nucleobase, preferably a 5-methylcytosine. The antisense
CC   oligonucleotides are useful for the treatment of diseases such as
CC   hyperproliferative disorders, e.g. cancer, viral or bacterial infections,
CC   and diseases involving hyperactivation of an immune response. The present
CC   sequence represents an antisense oligonucleotide used in the examples of
CC   the present invention.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1799 TCTCTGAAAGTGGT 1812
              ||||||||||||||
Db         20 TCTCTGAAAGTGGT 7


RESULT 262
ADI13780
ID   ADI13780 standard; DNA; 20 BP.
XX
AC   ADI13780;
XX
DT   22-APR-2004  (first entry)
XX
DE   Antisense DNA oligo to target human PTP1B DNA SeqID 32.
XX
KW   human; ss; antisense; PTP1B; protein phosphatase 1B; PTPN1;
KW   phosphorothioate backbone; hyperproliferative condition; cancer;
KW   cytostatic; antidiabetic; anorectic; type 2 diabetes; obesity.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
FT                   nucleobases are 5' methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
FT                   nucleobases are 5' methylcytidine."
XX
PN   US2003220282-A1.
XX
```

```
PD   27-NOV-2003.
XX
PF   07-FEB-2003; 2003US-00360510.
XX
PR   18-JAN-2000; 2000US-00487368.
PR   31-JUL-2000; 2000US-00629644.
PR   14-MAY-2001; 2001US-00854883.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bhanot S,  Cowsert LM,  Wyatt JR,  Monia BP,  Butler MM,  Mckay R;
PI   Freier SM;
XX
DR   WPI; 2004-051719/05.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding PTP1B, useful for treating a disease/condition
PT   associated with PTP1B, such as cancer, diabetes or obesity.
XX
PS   Claim 3; SEQ ID NO 32; 143pp; English.
XX
CC   This invention relates to novel compositions and methods for modulating
CC   the expression of PTP1B (also known as protein phosphatase 1B and PTPN1).
CC   Specifically, it refers to antisense compounds that can target and
CC   hybridise with a nucleic acid molecule encoding PTP1B, as well as splice
CC   variants thereof and inhibit expression accordingly. PTP1B is a tyrosine
CC   phosphatase that plays an essential regulatory role in signalling
CC   mediated by the insulin receptor and as such is useful for treating
CC   diseases such as type 2 diabetes and obesity. Furthermore, PTP1B can
CC   suppress transformation of oncogenic genes, such that compositions of
CC   this invention can also be used to treat hyperproliferative conditions
CC   including cancer. Accordingly, these compounds can be described as having
CC   cytostatic, antidiabetic and anorectic activities. This oligonucleotide
CC   sequence is an antisense DNA oligo that targets human PTP1B DNA, and
CC   which has a phosphorothioate backbone and 2'-O-methoxyethyl wings, used
CC   in an exemplification of the invention.
XX
SQ   Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
              ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 263
ADL59480
ID   ADL59480 standard; DNA; 20 BP.
XX
AC   ADL59480;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1729.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "OTHER= phosphorothioate backbone. All cytidine
FT                    residues are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1729; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 9 A; 2 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTT 1977
              ||||||||||||||
Db          7 TAAATATTTACCTT 20


RESULT 264
ADL59090
ID   ADL59090 standard; DNA; 20 BP.
XX
AC   ADL59090;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1339.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
```

```
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1339; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 3 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTT 1977
              ||||||||||||||
Db          6 TAAATATTTACCTT 19


RESULT 265
ADM93188/c
ID   ADM93188 standard; DNA; 20 BP.
XX
AC   ADM93188;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human KOX-1 antisense oligonucleotide ISIS206084.
XX
KW   Human; ss; antisense; KOX-1; zinc finger protein 10;
KW   chromosome 12q13-qter; hyperproliferative disorder; cancer;
KW   bacterial infection; viral infection; immune response.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate linkages and all cytidines are 5
FT                   -methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residues"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl residues"
XX
PN   US2004087536-A1.
XX
PD   06-MAY-2004.
XX
PF   19-AUG-2003; 2003US-00643432.
XX
PR   17-JUN-2002; 2002US-00173817.
XX
PA   (DOBI/) DOBIE K W.
PA   (FREI/) FREIER S M.
XX
PI   Dobie KW,  Freier SM;
XX
DR   WPI; 2004-364533/34.
XX
PT   New antisense oligonucleotides that inhibit the expression of the zinc
PT   finger transcriptional repressor KOX 1, useful for treating conditions
PT   such as cancer, and hyperactivation of an immune response.
XX
PS   Example 15; SEQ ID NO 30; 80pp; English.
XX
CC   The invention relates to a compound 8-80 nucleobases in length targeted
CC   to, and which specifically hybridises with a nucleic acid molecule
CC   encoding KOX 1 (also known as zinc finger protein 10, whose gene is
CC   located on chromosome 12q13-qter), and inhibits the expression of KOX 1,
CC   i.e. an antisense oligonucleotide. Also included are inhibiting the
CC   expression of KOX 1 in cells or tissues by contacting the cells or
CC   tissues with the compound, treating an animal having a disease or
CC   condition associated with by KOX 1 administering to the animal a
CC   therapeutic or prophylactic amount of the compound and screening an
CC   antisense compound by contacting a preferred target region of a nucleic
CC   acid molecule encoding KOX 1 with one or more candidate antisense
CC   compounds and selecting for one or more candidate antisense compounds
CC   that inhibit the expression of a nucleic acid encoding KOX 1. The
CC   compound, composition and methods are useful for treating diseases or
CC   conditions associated with KOX 1, such as hyperproliferative disorders
CC   (e.g. cancer), conditions arising from bacterial or viral infection, or
CC   conditions involving hyperactivation of an immune response. They are also
CC   useful in research and diagnostics. The present sequence is an antisense
CC   oligonucleotide targeting human KOX-1.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1799 TCTCTGAAAGTGGT 1812
              ||||||||||||||
Db         20 TCTCTGAAAGTGGT 7


RESULT 266
AAV96447/c
ID   AAV96447 standard; RNA; 17 BP.
XX
AC   AAV96447;
XX
DT   01-MAR-1999  (first entry)
```

```
XX
DE   Potato citrate synthase target sequence position 348.
XX
KW   Solanidine; glucosyltransferase; potato; citrate synthase; target;
KW   hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW   flower formation; cleavage; solanaceous plant; ss.
XX
OS   Solanum tuberosum.
XX
PN   WO9832843-A2.
XX
PD   30-JUL-1998.
XX
PF   14-JAN-1998;   98WO-US000738.
XX
PR   28-JAN-1997;   97US-0036545P.
PR   28-JAN-1997;   97US-0036599P.
PR   24-NOV-1997;   97US-00979416.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Zwick MG,  Mcswiggen JA;
XX
DR   WPI; 1998-427939/36.
XX
PT   New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT   biosynthesis or regulating flowering.
XX
PS   Claim 53; Page 53; 79pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   -cleaving activity (e.g. ribozymes) which are capable of modulating the
CC   expression of plant genes: (i) involved in biosynthesis of alkaloids; or
CC   (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
CC   AAV96354 represent potato solanidine glucosyltransferase hammerhead and
CC   hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
CC   AAV96734 represent potato solanidine glucosyltransferase target
CC   sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
CC   potato citrate synthase hammerhead and hairpin ribozymes, respectively.
CC   AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
CC   synthase target sequences. Ribozymes of the present invention can be used
CC   to inhibit the synthesis of toxic alkaloids in solanaceous plants,
CC   particularly potato but also tomato, pepper, aubergine and ditura or to
CC   inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
CC   arugula, kale, collards, chard, beet, turnip, sweet potato and turf
CC   grass. Also the ribozymes can be used for RNA manipulation in the same
CC   way that restriction endonucleases are for DNA, as well as to examine
CC   genetic drift and mutations in plants and to detect specific RNA. The
CC   ribozymes can be targeted to specific genes or to consensus sequences
CC   within a family of related genes, and being catalytic need to be present
CC   at only very low concentrations
XX
SQ   Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAATG 1945
              |||| || |||||||||
Db         17 TCAGGGTCAAGGTAATG 1


RESULT 267
AAF06326/c
ID   AAF06326 standard; DNA; 17 BP.
XX
AC   AAF06326;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3123.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 127; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 6 A; 1 C; 2 G; 0 T; 8 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAAGA 1987
              |||||||||| |||| |
Db         17 TTACCTTGAATAAAATA 1


RESULT 268
ABN07651/c
ID   ABN07651 standard; DNA; 17 BP.
XX
AC   ABN07651;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7643.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
```

```
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7643; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 9 A; 4 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTAG 1700
              ||| |||| ||||||||
Db         17 CTTTGTTGGTTCTCTAG 1


RESULT 269
ABN01354/c
ID   ABN01354 standard; DNA; 17 BP.
XX
AC   ABN01354;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1346.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1346; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 8 A; 0 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              ||||||  |||||||||
Db         17 CCCCATCTTTTCCTTCT 1


RESULT 270
ABN07650/c
ID   ABN07650 standard; DNA; 17 BP.
XX
AC   ABN07650;
XX
```

```
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7642.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7642; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 9 A; 4 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCTAGC 1701
              || |||| |||||||||
Db         17 TTTGTTGGTTCTCTAGC 1

RESULT 271
ACN08988/c
ID   ACN08988 standard; RNA; 17 BP.
XX
AC   ACN08988;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8991.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 8991; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 7 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTTT 1623
              |||||||| |||||| |
Db         17 GCCTGGGGAAAGAGTAT 1

RESULT 272
ACC68550
```

```
ID   ACC68550 standard; DNA; 17 BP.
XX
AC   ACC68550;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 5797.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 708; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTGGTA 2029
              ||||||||||| || ||
Db          1 GATCAAGTCCTTTGTTA 17


RESULT 273
ACC65305
ID   ACC65305 standard; DNA; 17 BP.
XX
AC   ACC65305;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 2552.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 329; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTGGTA 2029
              ||||||||||| ||| |
Db          1 GATCAAGTCCTTTGGGA 17


RESULT 274
ACC52259/c
ID   ACC52259 standard; DNA; 17 BP.
XX
AC   ACC52259;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #1026.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
```

```
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 277; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 4 A; 5 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATC 1999
              ||||||| ||||| |||
Db         17 AAAGAAATGTGTGGATC 1


RESULT 275
ADG76790
ID   ADG76790 standard; DNA; 18 BP.
XX
AC   ADG76790;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human olfactory receptor gene identification oligonucleotide SEQ ID:67.
XX
KW   identification; olfactory receptor gene; allelic variant; chromosome 17;
KW   17p13.3; male infertility; reduced sperm motility; human; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003091388-A2.
XX
PD   06-NOV-2003.
XX
PF   24-APR-2003; 2003WO-IL000336.
XX
PR   23-APR-2002; 2002US-0374508P.
XX
PA   (YEDA ) YEDA RES & DEV CO LTD.
XX
PI   Lancet D,  Menashe I,  Man O,  Gilad Y;
XX
DR   WPI; 2004-108244/11.
XX
PT   New oligonucleotides for identifying olfactory receptor genes, useful in
PT   designing pleasing scents and flavors, and in diagnosing male
PT   infertility.
XX
PS   Claim 4; SEQ ID NO 67; 97pp; English.
XX
CC   The present invention describes an oligonucleotide (I) comprising a
CC   nucleic acid sequence suitable for identifying an olfactory receptor gene
CC   selected from a group comprising SEQ ID Nos. 79-104, or an allelic
CC   variant. Also described: (1) a kit for identifying an olfactory receptor
CC   gene comprising at least one oligonucleotide (I); (2) an array suitable
CC   for detecting the presence of at least one allelic variant of an
CC   olfactory receptor gene, comprising at least one oligonucleotide (I)
CC   contained in or attached to a support; (3) typing (M1) a subject
CC   according to presence or absence of allelic variants of olfactory
CC   receptor genes comprising detecting the presence or absence of at least
CC   one olfactory receptor gene in a biological sample; (4) a nucleic acid
CC   construct comprising a polynucleotide encoding an olfactory receptor
CC   gene, or an allelic variant, selected from SEQ ID Nos. 79-104, and a
CC   promoter for directing transcription; and (5) a cell comprising the
CC   nucleic acid construct. The oligonucleotide (I) can be useful in
CC   detecting olfactory receptor genes, and in typing a subject according to
CC   the presence or absence of olfactory receptor genes. The olfactory
CC   receptor gene cluster is located on human chromosome 17p13.3. The
CC   oligonucleotides (I) may also be used to detect/diagnose male
CC   infertility, specifically that associated with reduced sperm motility or
CC   to detect specific odorants that may enhance or suppress sperm motility.
CC   The present sequence represents a specifically claimed oligonucleotide
CC   used in the identification of an olfactory receptor gene, which is used
CC   in the exemplification of the present invention.
XX
SQ   Sequence 18 BP; 3 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGGCA 2036
              ||||||||| ||||||
Db          2 TCCTCTGGTTTGAGGCA 18


RESULT 276
AAZ00903
ID   AAZ00903 standard; DNA; 19 BP.
XX
AC   AAZ00903;
XX
DT   27-SEP-1999  (first entry)
XX
DE   Primer for PG1 biallelic marker 99-221.
XX
KW   PG1 gene; biallelic marker; PCR primer; PG1-related biallelic marker;
KW   cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
KW   PSA; human; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9932644-A2.
XX
PD   01-JUL-1999.
XX
PF   22-DEC-1998;   98WO-IB002133.
XX
PR   22-DEC-1997;   97US-00996306.
PR   09-SEP-1998;   98US-0099658P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I,  Bougueleret L;
XX
DR   WPI; 1999-405178/34.
XX
PT   Use of a prostate cancer associated gene and biallelic markers derived
PT   from it.
XX
PS   Example 6; Fig 6A; 385pp; English.
XX
CC   The invention relates to a mammalian PG1 gene and protein, and a set of
CC   PG1 biallelic markers. The PG1 polynucleotide and biallelic markers are
CC   used in a hybridisation assay, a sequencing assay, or in an allele-
CC   specific amplification assay for determining the identity of a nucleotide
CC   at a PG1-related biallelic marker. The methods can be used to detect and
CC   to assess the risk of developing cancer or prostate cancer. Early-stage
CC   diagnosis of prostate cancer relies on prostate specific antigen (PSA)
CC   dosage. However, the effectiveness of this is limited due to its
CC   inability to discriminate between malignant and non-malignant affections
CC   of the organ. A need exists for both a reliable diagnostic procedure
CC   which would enable early-stage diagnosis, and for preventative and
CC   curative treatments of the disease. The PG1 gene can be used for
```

```
CC   detection of prostate cancer, and the risk of developing it in the
CC   future, and can also be used to determine therapies for the disease
XX
SQ   Sequence 19 BP; 1 A; 7 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 277
AAZ01223
ID   AAZ01223 standard; DNA; 19 BP.
XX
AC   AAZ01223;
XX
DT   27-SEP-1999  (first entry)
XX
DE   PCR primer for PG1 biallelic marker 99-221-442.
XX
KW   PG1 gene; biallelic marker; PCR primer; PG1-related biallelic marker;
KW   cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
KW   PSA; human; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9932644-A2.
XX
PD   01-JUL-1999.
XX
PF   22-DEC-1998;   98WO-IB002133.
XX
PR   22-DEC-1997;   97US-00996306.
PR   09-SEP-1998;   98US-0099658P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I,  Bougueleret L;
XX
DR   WPI; 1999-405178/34.
XX
PT   Use of a prostate cancer associated gene and biallelic markers derived
PT   from it.
XX
PS   Claim 4; Page 352; 385pp; English.
XX
CC   The invention relates to a mammalian PG1 gene and protein, and a set of
CC   PG1 biallelic markers. The PG1 polynucleotide and biallelic markers are
CC   used in a hybridisation assay, a sequencing assay, or in an allele-
CC   specific amplification assay for determining the identity of a nucleotide
CC   at a PG1-related biallelic marker. The methods can be used to detect and
CC   to assess the risk of developing cancer or prostate cancer. Early-stage
CC   diagnosis of prostate cancer relies on prostate specific antigen (PSA)
CC   dosage. However, the effectiveness of this is limited due to its
CC   inability to discriminate between malignant and non-malignant affections
CC   of the organ. A need exists for both a reliable diagnostic procedure
CC   which would enable early-stage diagnosis, and for preventative and
CC   curative treatments of the disease. The PG1 gene can be used for
CC   detection of prostate cancer, and the risk of developing it in the
CC   future, and can also be used to determine therapies for the disease
XX
SQ   Sequence 19 BP; 1 A; 7 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 278
AAA84405/c
ID   AAA84405 standard; DNA; 19 BP.
XX
AC   AAA84405;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin D3 ribozyme binding site #17.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 76; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 2 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGTT 1622
              |||| |||||||||| ||
Db         19 GGCCAGGGGGAAGACTT 3


RESULT 279
AAZ73500
ID   AAZ73500 standard; DNA; 19 BP.
XX
AC   AAZ73500;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:7856.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
```

XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Example 13; Page 1905; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 1 A; 7 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1920 CCTTTTTTTTCAGTGTT 1936
||||||| |||| ||||
Db 2 CCTTTTTCTTCACTGTT 18

RESULT 280
AAH59567/c
ID AAH59567 standard; DNA; 19 BP.
XX
AC AAH59567;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin D3 ribozyme binding site SEQ ID NO:1991.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 216; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 2 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1606 GGCCTGGGGGAAGAGTT 1622
|||| ||||||||| ||
Db 19 GGCCAGGGGGAAGACTT 3

RESULT 281
ABK41301
ID ABK41301 standard; DNA; 19 BP.
XX
AC ABK41301;
XX
DT 21-MAY-2002 (first entry)
XX
DE Human prostate cancer-associated marker upstream PCR primer #8.
XX
KW Human; obesity associated-biallelic marker; ss; prostate cancer; primer;
KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
KW insulin disorder; atheromatous disease; cardiac insufficiency; obesity.
XX
OS Homo sapiens.
XX
PN WO200206525-A2.
XX
PD 24-JAN-2002.
XX

PF 28-JUN-2001; 2001WO-IB001477.
XX
PR 18-JUL-2000; 2000US-0219704P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;
XX
DR WPI; 2002-155043/20.
XX
PT Set of novel map-related biallelic markers, preferably located on obesity
PT disorder-associated chromosomal regions on chromosomes 3, 10 and 19,
PT useful, for e.g. detecting statistical correlations between marker allele
PT and a phenotype.
XX
PS Example 20; Page 305; 311pp; English.
XX
CC The invention relates to a set of novel map-related biallelic markers,
CC preferably located on obesity disorder-associated chromosomal regions on
CC chromosomes 3, 10 and 19. The markers are useful for genotyping or
CC estimating the frequency of an allele in a population, for detecting an
CC association between a genotype or haplotype and a phenotype, e.g. a
CC disease involving drug responses, obesity or disorders related to
CC obesity, such as hyperuricaemia, digestive pathology, hepatic function
CC disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,
CC insulin disorders, atheromatous disease and cardiac insufficiency. The
CC markers are useful for detecting a statistical correlation between a
CC biallelic marker allele and a phenotype and/or between a biallelic marker
CC haplotype and a phenotype. This sequence represents a PCR primer used to
CC amplify a human prostate cancer-associated biallelic marker
XX
SQ Sequence 19 BP; 1 A; 7 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1920 CCTTTTTTTTCAGTGTT 1936
||||||| |||| ||||
Db 2 CCTTTTTCTTCACTGTT 18

RESULT 282
ADE36637/c
ID ADE36637 standard; DNA; 19 BP.
XX
AC ADE36637;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human ERG gene PCR primer.
XX
KW foetal aneuploidy; foetal allele; detection; foetal DNA; prenatal;
KW chromosome aberration; chromosome mutation; PCR primer; human; ERG gene;
KW chromosome 21; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003062441-A1.
XX
PD 31-JUL-2003.
XX
PF 17-JAN-2003; 2003WO-US001551.
XX
PR 18-JAN-2002; 2002US-0349877P.
XX
PA (GENZ) GENZYME CORP.
XX
PI Landes GM, Michalowsky L, Miller G, Weber W;
XX
DR WPI; 2003-902657/82.
XX
PT Detecting fetal aneuploidies or alleles of a gene of interest in fetal
PT DNA by determining the ratio of methylated and unmethylated DNA in
PT maternal serum is useful for prenatal detection of chromosome aberrations
PT and mutations.
XX
PS Example 4; Page 17; 31pp; English.
XX
CC The present invention describes methods for detecting foetal
CC aneuploidies, alleles of a gene of interest in foetal DNA and imprinted
CC genes in a subject. Also described: (1) detecting foetal aneuploidies
CC comprising treating DNA from maternal serum with a reagent that
CC differentially modifies methylated and non-methylated DNA and performing
CC quantitative PCR using one primer pair on a potentially aneuploid
CC chromosome and a on a non-aneuploid chromosome with an different primer
CC pair and comparing the ratio of the quantity of the two PCR products; (2)
CC detecting alleles of a gene of interest in foetal DNA, comprising
CC treating DNA isolated from maternal serum with bisulfite, performing PCR
CC with a primer pair that amplifies the gene of interest and analysing the
CC PCR product to identify the allele of the gene of interest; (3) detecting
CC imprinted genes in a subject comprises treating DNA isolated from the
CC subject with bisulfite, performing PCR with a primer pair for a
CC polymorphic region that only amplifies bisulfite-treated unmethylated DNA
CC and analysing the PCR product to identify the polymorphism thereby
CC detecting imprinted genes. The invention is used for prenatal detection
CC of chromosome aberrations and mutations. The present sequence represents
CC a PCR primer for the human ERG gene, which is used in an example from the
CC present invention. The human ERG gene is located on chromosome 21 within
CC the Down's critical region.
XX
SQ Sequence 19 BP; 3 A; 10 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1535 AGGTTAGGAGAGTAGGG 1551
||||||||||| | ||
Db 17 AGGTTAGGAGAGGAAGG 1

RESULT 283
ADE43577
ID ADE43577 standard; DNA; 19 BP.
XX
AC ADE43577;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human IDE sequencing primer, SEQ ID 182.
XX
KW Neurodegenerative disease; uPA; SNCG; IDE; KNSL1; LIPA; TNFRSF6;
KW Alzheimer's disease; neuroprotective; nootropic; gene therapy;
KW Chromosome 10; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003054143-A2.
XX
PD 03-JUL-2003.
XX
PF 25-OCT-2002; 2002WO-US034679.
XX
PR 25-OCT-2001; 2001US-0339525P.
PR 08-NOV-2001; 2001US-0336929P.
PR 08-NOV-2001; 2001US-0338010P.
PR 09-NOV-2001; 2001US-0338363P.
PR 04-DEC-2001; 2001US-0337052P.
PR 28-MAR-2002; 2002US-0368919P.
XX
PA (NEUR-) NEUROGENETICS INC.
PA (GEHO) GEN HOSPITAL CORP.
XX
PI Becker KD, Velicelebi G, Elliott KJ, Wang X, Tanzi RE, Bertram L;

PI Saunders AJ, Mullin KM, Sampson AJ, Blacker DL;
XX
DR WPI; 2003-559131/52.
XX
PT Determining a predisposition for or the occurrence of neurodegenerative
PT disease, e.g. Alzheimer's disease by detecting in a target nucleic acid
PT the presence or absence of an allelic variant of one or more polymorphic
PT regions.
XX
PS Example 3; Page 277; 848pp; English.
XX
CC The present invention relates to a method (M1) for determining a
CC predisposition for or the occurrence of neurodegenerative disease in a
CC subject. The method comprises detecting in a target nucleic acid obtained
CC from the subject the presence or absence of an allelic variant of one or
CC more polymorphic regions of one or more genes selected from uPA
CC (Urokinase plasminogen activator), SNCG (gamma-synuclein), IDE (insulin-
CC degrading enzyme), KNSL1 (Kinesin-like protein 1), LIPA (lysosomal acid
CC lypase), and TNFRSF6 (Tumour Necrosis Factor Receptor-SF6), where the
CC presence of at least one of the allelic variant of one or more
CC polymorphic regions is indicative of a predisposition for or the
CC occurrence of neurodegenerative disease. The genes are all located on
CC chromosome 10. M1 is useful for determining a predisposition for or the
CC occurrence of, and for treating neurodegenerative disease, particularly
CC Alzheimer's disease. The present sequence is a PCR primer, which was used
CC in the method of the invention.
XX
SQ Sequence 19 BP; 9 A; 3 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1529 GAAGAAAGGTTAGGAGA 1545
|||||||||| || |||
Db 3 GAAGAAAGGTCAGCAGA 19

RESULT 284
ADG36015/c
ID ADG36015 standard; RNA; 19 BP.
XX
AC ADG36015;
XX
DT 26-FEB-2004 (first entry)
XX
DE HIV siNA oligonucleotide SEQ ID NO:858.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW HIV replication inhibition; HIV infection; ss.
XX
OS Synthetic.
OS Human immunodeficiency virus 1.
XX
PN WO2003070193-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005190.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 22-APR-2002; 2002US-0374722P.
PR 29-MAY-2002; 2002US-00157580.
PR 06-JUN-2002; 2002US-0386782P.
PR 23-JUL-2002; 2002US-0398036P.
PR 21-AUG-2002; 2002US-00225023.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
PA (MCSW/) MCSWIGGEN J.
XX
PI Mcswiggen J, Beigelman L, Macejak D;
XX
DR WPI; 2003-679850/64.
XX
PT New double-stranded short interfering nucleic acid, useful for treating
PT infection with human immune deficiency virus, comprises sugar-modified
PT pyrimidine bases.
XX
PS Example 3; SEQ ID NO 858; 170pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of HIV gene by RNA interference. The siNAs may or
CC may not comprise ribonucleotides and may be double or single stranded.
CC They further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA), double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNAs are used to modulate
CC expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC by ex vivo gene therapy), or in grafts and transplants for the treatment
CC of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC used for inhibiting replication of HIV and may be used to treat HIV
CC infection. The siNAs are also useful for drug screening, diagnosis,
CC therapeutic target identification and validation, genetic engineering,
CC pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC single nucleotide polymorphisms). The present sequence represents the
CC lower strand of an HIV-targeted double-stranded siNA.
XX
SQ Sequence 19 BP; 3 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1729 ATTATCAGAAGGTGACA 1745
|||||||||||| | ||
Db 18 ATTATCAGAAGGAGCCA 2

RESULT 285
ADG35236
ID ADG35236 standard; RNA; 19 BP.
XX
AC ADG35236;
XX
DT 26-FEB-2004 (first entry)
XX
DE HIV siNA oligonucleotide SEQ ID NO:79.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW HIV replication inhibition; HIV infection; ss; target sequence.
XX
OS Synthetic.
OS Human immunodeficiency virus 1.
XX
PN WO2003070193-A2.
XX
PD 28-AUG-2003.
XX

```
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J, Beigelman L, Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 79; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   upper strand of HIV-targeted double-stranded siNA, which is identical to
CC   the HIV transcript target sequence.
XX
SQ   Sequence 19 BP; 7 A; 4 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |::|:|||||||  | ||
Db          3 AUUAUCAGAAGGAGCCA 19


RESULT 286
ADG35277
ID   ADG35277 standard; RNA; 19 BP.
XX
AC   ADG35277;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:120.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss; target sequence.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J, Beigelman L, Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 120; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   upper strand of HIV-targeted double-stranded siNA, which is identical to
CC   the HIV transcript target sequence.
XX
SQ   Sequence 19 BP; 7 A; 5 C; 4 G; 0 T; 3 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |::|:|||||||  | ||
Db          2 AUUAUCAGAAGGAGCCA 18
```

```
RESULT 287
ADG35974/c
ID   ADG35974 standard; RNA; 19 BP.
XX
AC   ADG35974;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:817.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 817; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   lower strand of an HIV-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 3 A; 5 C; 4 G; 0 T; 7 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         17 ATTATCAGAAGGAGCCA 1


RESULT 288
ADG36059/c
ID   ADG36059 standard; RNA; 19 BP.
XX
AC   ADG36059;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:902.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 902; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
```

```
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   lower strand of an HIV-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 3 A; 4 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
                ||||||||||||  | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 289
ADG35321
ID   ADG35321 standard; RNA; 19 BP.
XX
AC   ADG35321;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:164.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss; target sequence.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 164; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   upper strand of HIV-targeted double-stranded siNA, which is identical to
CC   the HIV transcript target sequence.
XX
SQ   Sequence 19 BP; 7 A; 5 C; 4 G; 0 T; 3 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   70.6%;  Pred. No. 3.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
                |::|:|||||||  | ||
Db          1 AUUAUCAGAAGGAGCCA 17


RESULT 290
ADJ94201
ID   ADJ94201 standard; DNA; 19 BP.
XX
AC   ADJ94201;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human MYOC gene mutation detection primer M-SR4.
XX
KW   glaucoma; detection; mutation; MYOC; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003083108-A1.
XX
PD   09-OCT-2003.
XX
PF   19-MAR-2003; 2003WO-JP003307.
XX
PR   29-MAR-2002; 2002JP-00093443.
XX
PA   (SYSM-) SYSMEX CORP.
XX
PI   Asano K,  Takahata T,  Numada S,  Masago A,  Kouchi Y;
XX
DR   WPI; 2003-804059/75.
XX
PT   Examining genes to assess the risk of the onset of glaucoma by detecting
PT   mutations in the MYOC gene or the region upstream from it.
XX
PS   Example 1; SEQ ID NO 15; 42pp; Japanese.
XX
CC   The invention relates to a method of examining genes to assess the risk
CC   of the onset of glaucoma comprising detection of at least two mutations
CC   in the glaucoma related gene encoding region and/or a region upstream
CC   from it. The glaucoma related gene is preferably the MYOC gene. The
CC   method is useful for the prevention or early detection of glaucoma. This
CC   sequence corresponds to a PCR primer used to detect mutations in the
```

```
CC   human MYOC gene (ADJ94187).
XX
SQ   Sequence 19 BP; 2 A; 6 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTGAA 1806
              ||||| |||||||||| |
Db          1 TTCTTACCTTCTCTGGA 17


RESULT 291
ADH54055
ID   ADH54055 standard; DNA; 19 BP.
XX
AC   ADH54055;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human neurodegenerative disease-related sequencing primer SeqID182.
XX
KW   human; neurodegenerative disease; urokinase plasminogen activator; uPA;
KW   gamma-synuclein; SNCG; insulin degrading enzyme; IDE;
KW   kinesin-like protein 1; KNSL1; lysosomal acid lipase; LIPA;
KW   tumour necrosis factor receptor SF6; TNFRSF6; Alzheimer's disease; PCR;
KW   primer; ss; sequencing.
XX
OS   Homo sapiens.
XX
PN   US2003224380-A1.
XX
PD   04-DEC-2003.
XX
PF   25-OCT-2002; 2002US-00282174.
XX
PR   25-OCT-2001; 2001US-0339525P.
PR   25-OCT-2001; 2001US-0348065P.
PR   02-NOV-2001; 2001US-0336983P.
PR   08-NOV-2001; 2001US-0336929P.
PR   08-NOV-2001; 2001US-0338010P.
PR   09-NOV-2001; 2001US-0338363P.
PR   04-DEC-2001; 2001US-0337052P.
PR   28-MAR-2002; 2002US-0368919P.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Becker KD,  Velicelebi G,  Ellliott KJ,  Wang X,  Tanzi RE;
PI   Bertram L,  Saunders AJ,  Mullin KM,  Sampson AJ;
XX
DR   WPI; 2004-060538/06.
XX
PT   Determining a predisposition for or the occurrence of neurodegenerative
PT   disease, particularly Alzheimer's disease, comprises determining the
PT   presence of a polymorphism in the uPA, SNCG, IDE, KNSL1, LIPA or TNFRSF6
PT   gene.
XX
PS   Example 3; SEQ ID NO 182; 205pp; English.
XX
CC   This invention relates to a novel method of determining a predisposition
CC   for or the occurrence of neurodegenerative disease comprising detecting
CC   in a target nucleic acid obtained from the subject the presence of an
CC   allelic variant of polymorphic regions of human genes selected from
CC   urokinase plasminogen activator (uPA), gamma-synuclein (SNCG), insulin
CC   degrading enzyme (IDE), kinesin-like protein 1 (KNSL1), lysosomal acid
CC   lipase (LIPA) and tumour necrosis factor receptor SF6 (TNFRSF6). The
CC   method is useful in determining the presence or predisposition to a
CC   neurodegenerative disease, particularly Alzheimer's disease. The present
CC   sequence is that of a sequencing primer which was used for sequencing of
CC   a region of the human IDE gene in the exemplification of the invention.
XX
SQ   Sequence 19 BP; 9 A; 3 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGAGA 1545
              |||||||||| || |||
Db          3 GAAGAAAGGTCAGCAGA 19


RESULT 292
ADH75215
ID   ADH75215 standard; DNA; 19 BP.
XX
AC   ADH75215;
XX
DT   22-APR-2004  (first entry)
XX
DE   IFN-associated gene IFNAR2 PCR primer, SEQ ID NO:4.
XX
KW   Interferon therapy; cancer; viral disease; viral infection;
KW   interferon-alpha; IFN-alpha; cyclooxygenase-2 inhibitor; Cox-2 inhibitor;
KW   apoptosis induction; colon cancer; lung cancer; pancreas cancer;
KW   breast cancer; stomach cancer; liver cancer; kidney cancer;
KW   nerve cell cancer; skin cancer; muscle cancer; uterus cancer;
KW   throat cancer; hepatitis B; hepatitis C; cytostatic; virucide;
KW   cancer cell; interferon-associated gene; IFNAR2; real-time PCR; primer;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004005549-A1.
XX
PD   15-JAN-2004.
XX
PF   30-JUN-2003; 2003WO-JP008296.
XX
PR   03-JUL-2002; 2002JP-00195147.
XX
PA   (HAYB ) HAYASHIBARA SEIBUTSU KAGAKU.
XX
PI   Yanai Y,  Yamamoto S,  Yamamoto K,  Yamauchi H;
XX
DR   WPI; 2004-108824/11.
XX
PT   Measurement of Cox-2 gene expression in cancer or virus-infected cells
PT   for estimating the therapeutic effect of an interferon in cancer and
PT   viral disease.
XX
PS   Disclosure; SEQ ID NO 4; 90pp; Japanese.
XX
CC   The invention relates to a method for estimating the therapeutic effect
CC   of interferon in the treatment of cancer or viral disease. The method
CC   involves determining the amount of expression of an interferon-associated
CC   gene in cancer cells or virus-infected cells. The invention also relates
CC   to drug compositions for the treatment of cancer and viral diseases
CC   containing interferon-alpha together with a cyclooxygenase-2 (Cox-2)
CC   inhibitor such as indomethacin which potentiates the apoptosis induction
CC   effect of the interferon. The method and compositions of the invention
CC   are useful in the treatment and prevention of cancers (e.g., cancer of
CC   the colon, lung, pancreas, breast, stomach, liver, kidney, nerve cell,
CC   skin, muscle, uterus and throat) and viral infections (e.g., hepatitis B
CC   and C). The present sequence represents a PCR primer used in real-time
CC   PCR to determine the amount of expression of an interferon-associated
CC   gene in cancer cells cultured in the presence of interferon-alpha.
XX
SQ   Sequence 19 BP; 4 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAG 1618
```

```
              |||||||| || |||||
Db          3 TCCTGGCCAGGTGGAAG 19


RESULT 293
ADQ61592
ID   ADQ61592 standard; RNA; 19 BP.
XX
AC   ADQ61592;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Anti-RAD1 siRNA related DNA sequence SEQ ID NO:1294.
XX
KW   ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW   RNA interference.
XX
OS   Synthetic.
XX
PN   WO2004045543-A2.
XX
PD   03-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-US036787.
XX
PR   14-NOV-2002; 2002US-0426137P.
PR   10-SEP-2003; 2003US-0502050P.
XX
PA   (DHAR-) DHARMACON INC.
XX
PI   Anastasia K,  Angela R,  Devin L,  William M,  Stephen S;
XX
DR   WPI; 2004-420527/39.
XX
PT   Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT   by selecting a target gene and measuring the functionality of the
PT   nucleotide sequences that are complementary to a stretch of nucleotides
PT   of the target sequence.
XX
PS   Example 12; SEQ ID NO 1294; 199pp; English.
XX
CC   The invention relates to a novel method for selecting siRNA (short
CC   interfering RNA) comprising selecting an siRNA molecule of 19-25
CC   nucleoside bases by selecting a target gene and measuring the
CC   functionality of sequences of 19-25 nucleotides in length that are
CC   substantially complementary to a stretch of nucleotides of the target
CC   sequence, where the functionality is dependent upon non-target specific
CC   criteria. Also claimed are methods for gene-silencing, developing an
CC   siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC   functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC   effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC   siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC   sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC   GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC   CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC   GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC   comprises a sense strand and an anti-sense strand. The siRNA molecule
CC   comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC   pairs. The kit comprises at least two siRNA, comprising a first optimised
CC   siRNA and a second optimised siRNA. The method is useful in selecting
CC   siRNA for generating a gene silencing reagent. The present sequence is
CC   used in the exemplification of the invention. The sequence is shown in
CC   the specification as DNA, but described as siRNA.
XX
SQ   Sequence 19 BP; 4 A; 2 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTTACCT 1630
              |||||||| |||||| |
Db          1 GGAAGAGTCTGTTACTT 17


RESULT 294
AAQ41528/c
ID   AAQ41528 standard; DNA; 20 BP.
XX
AC   AAQ41528;
XX
DT   25-MAR-2003  (revised)
DT   10-AUG-1993  (first entry)
XX
DE   Antisense oligomer targetting EBER-2 internal sequence.
XX
KW   Epstein Barr virus; EBV; hybridisation; antisense modulator; replication;
KW   nasopharyngeal carcinoma; Burkitt lymphoma; Sjogren's; syndrome;
KW   infectious mononucleosis; latent; active; infection; ss.
XX
OS   Synthetic.
XX
PN   WO9307882-A1.
XX
PD   29-APR-1993.
XX
PF   23-OCT-1992;   92WO-US008989.
XX
PR   25-OCT-1991;   91US-00783605.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Anderson KP,  Ecker DJ;
XX
DR   WPI; 1993-152174/18.
XX
PT   Oligo:nucleotide(s) hybridising with RNA of Epstein Barr virus - for
PT   treating active, latent and chronic EBV infections and associated
PT   diseases e.g. nasopharyngeal carcinoma, Burkitt's lymphoma.
XX
PS   Claim 1; Page 20; 45pp; English.
XX
CC   The synthetic peptide is an antisense modulator of Epstein Barr virus and
CC   pref. contains at least one phosphorothioate linking gp. and
CC   modifications in the 2' position. These modifications improve penetration
CC   into regions of the cell that contain nucleic acid and also resistance to
CC   degradation by nucleases. The oligonucleotide targets an EBER-2 internal
CC   sequence and hybridises, thus inhibiting replication of EBV. The oligomer
CC   may be used for treating or preventing EBV-associated diseases, e.g.
CC   nasopharyngeal carcinoma, Burkitt's lymphoma, Sjogren's syndrome,
CC   infectious mononucleosis etc. The oligomer is effective against both
CC   latent and active EBV infection. See also AAQ40575-9 and AAQ41517-44.
CC   (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2068 AGTGGTATCTGACACAC 2084
              |||||| || |||||||
Db         18 AGTGGTTTCGGACACAC 2


RESULT 295
AAQ45269/c
ID   AAQ45269 standard; DNA; 20 BP.
XX
AC   AAQ45269;
XX
DT   25-MAR-2003  (revised)
DT   28-OCT-1994  (first entry)
XX
DE   Primer to amplify sequence tagged site for human chromosome 15.
XX
```

```
KW   Yeast Artificial Chromosome; YAC; polymerase chain reaction; PCR;
KW   sequence tagged site; genetic disorder; diagnosis; abnormality;
KW   Prader-Willi; Angelman; Beckwith-Wiedermann; syndrome; ss.
XX
OS   Synthetic.
XX
PN   WO9406936-A1.
XX
PD   31-MAR-1994.
XX
PF   10-SEP-1993;   93WO-US008501.
XX
PR   11-SEP-1992;   92US-00943639.
XX
PA   (BAYU ) BAYLOR COLLEGE MEDICINE.
XX
PI   Airhart SD,  Mutirangura A,  Ledbetter DH;
XX
DR   WPI; 1994-118484/14.
XX
PT   Diagnosis of genetic disorders associated with chromosomal abnormalities
PT   and uniparental disomy, e.g. Prader-Willi:Angelman syndrome - using in
PT   situ hybridisation using probes spanning the IR4-3R or GABRB3 regions.
XX
PS   Example 5; Page 34; 91pp; English.
XX
CC   Primers AAQ45269 and AAQ45270 amplify a 100bp sequence tagged site (STS)
CC   from a yeast artificial chromosome, useful as a probe to diagnose Prader-
CC   Willi/Angelman Syndrome. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 20 BP; 9 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCAAGT 2020
              ||||||||||| | ||||
Db         20 TTCTTCAGAGTTAAAGT 4


RESULT 296
AAT39924/c
ID   AAT39924 standard; cDNA; 20 BP.
XX
AC   AAT39924;
XX
DT   23-JAN-1997  (first entry)
XX
DE   Maize acetyl CoA carboxylase 3' PCR primer 28sst-110F.
XX
KW   Acetyl CoA carboxylase; ACCase; herbicide tolerance; cyclohexanedione;
KW   aryloxyphenoxypropionic acid; vegetable oil; oilseed; maize; corn;
KW   polymerase chain reaction; PCR; primer; Zea mays; ss.
XX
OS   Synthetic.
XX
PN   WO9631609-A2.
XX
PD   10-OCT-1996.
XX
PF   04-APR-1996;   96WO-US004625.
XX
PR   05-APR-1995;   95US-00417089.
XX
PA   (MINU ) UNIV MINNESOTA.
XX
PI   Gengenbach BG,  Somers DA,  Wyse DL,  Gronwald JW,  Egli MA,  Lutz SM;
XX
DR   WPI; 1996-465030/46.
XX
PT   DNA encoding maize acetyl coenzyme A carboxylase gene - used for prodn.
PT   of plants with herbicide tolerance or altered oil content.
XX
PS   Example 7; Page 60; 131pp; English.
XX
CC   PCR primers 28sst-110F (AAT39924) and 28sst-2T3+ (AAT39925) cover a
CC   sequence coding for a conserved amino acid sequence found in all acetyl
CC   CoA carboxylases (ACCase). They are used as 3' primers with PCR primers
CC   specific for the 5' untranslated region of ACCase Type A1 genomic clones
CC   (see also AAT39906-07). ACCase Type A2 genomic clones (see also AAT39908-
CC   13) are weakly amplified by these primer combinations, and A2 amplified
CC   products differ in sequence from A1 amplified products. Sequence
CC   differences in the 5' region should provide a means of distinguishing
CC   between expression of A1 and A2 ACCase genes
XX
SQ   Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACAG 1589
              ||||||| | |||||||
Db         18 CCTTCTCAAACGCACAG 2


RESULT 297
AAT88934/c
ID   AAT88934 standard; DNA; 20 BP.
XX
AC   AAT88934;
XX
DT   22-JAN-1998  (first entry)
XX
DE   Detector probe 1 for the gag gene of HIV.
XX
KW   HIV; gag; HLA-DQ-alpha; human acute myelogenous leukaemia; AML; PCR;
KW   primer; thermophilic strand displacement amplification; tSDA;
KW   in situ amplification; probe; screening; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus.
XX
PN   WO9711196-A2.
XX
PD   27-MAR-1997.
XX
PF   12-SEP-1996;   96WO-US014648.
XX
PR   21-SEP-1995;   95US-00531747.
PR   21-SEP-1995;   95US-00531749.
XX
PA   (BECT ) BECTON DICKINSON CO.
XX
PI   Lohman KL,  Ostrerova NV,  Van Cleve M,  Reid RA;
XX
DR   WPI; 1997-202902/18.
XX
PT   Detection of nucleic acids in cells - by in situ amplification of target
PT   sequences by thermophilic strand displacement amplification.
XX
PS   Claim 14; Page 16; 37pp; English.
XX
CC   This 32P labelled primer is an example of a detector probe for the
CC   amplified products of the gag gene of HIV. It is used in a modified
CC   version of thermophilic strand displacement amplification (tSDA) to
CC   amplify double stranded DNA in situ. Amplification primers (see AAT88932-
CC   3) are hybridised to both strands of the gene, and are extended. Both
CC   primers have a restriction endonuclease (RE) recognition site, and the
CC   products will also contain these sites. The products are displaced from
CC   the target sequence, by extension of the bumper primers (see AAT88941-
CC   42), which anneal upstream of the amplification primers, and made double
CC   stranded by synthesising complementary strands. Making the products
CC   double stranded causes "nicks" to be created (via the RE recognition
CC   sites). Further extension occurs from the nicks, thereby displacing a
```

```
CC   copy of the target sequence from the double stranded amplification primer
CC   extension products. The nicking, extending and displacing steps are
CC   repeated, and the target sequence amplified in situ. The method can be
CC   used for the amplification of DNA in situ in cells in suspension, on
CC   slides or in tissues, with speed, sensitivity and specificity. In situ
CC   tSDA also remains compatible with immunochemical techniques in spite of
CC   the increased reaction temparature so both amplification of DNA and
CC   immunological staining can be performed on the same specimen
XX
SQ   Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||| | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 298
AAV19518
ID   AAV19518 standard; DNA; 20 BP.
XX
AC   AAV19518;
XX
DT   16-JUL-1998  (first entry)
XX
DE   Retroviral DNA base sequences amplifying primer MZ8.
XX
KW   Retrovirus; AIDS; serum; HIV; human immunodeficiency virus;
KW   antigen measurement; diagnosis; nested PCR primer; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 2.
XX
PN   JP10094394-A.
XX
PD   14-APR-1998.
XX
PF   20-SEP-1996;   96JP-00271467.
XX
PR   20-SEP-1996;   96JP-00271467.
XX
PA   (EIKE ) EIKEN KAGAKU KK.
XX
DR   WPI; 1998-279230/25.
XX
PT   Retrovirus reacting with AIDS patient serum - useful for the exact
PT   diagnosis of an unknown AIDS causing virus.
XX
PS   Example; Page 7; 16pp; Japanese.
XX
CC   This primer is used in the nested PCR amplification of the DNA base
CC   sequences isolated from a retrovirus particle collected from the blood of
CC   an AIDS patient. The specification provides DNA base sequences encoding a
CC   retroviral protein which reacts with serum of AIDS patients. It provides
CC   an antigen for the detection of an antibody against retrovirus which
CC   consists of a peptide derived from these base sequences. The invention
CC   provides a method for antigen measurement in which the above antigen is
CC   contacted with a sample blood to determine immunoglobulin reacting with
CC   the antigen and a method for screening the infection of retrovirus other
CC   than HIV-1, HIV-2 subtype A which can be collected from an AIDS patient
CC   blood by the above antibody measurement. The method can diagnose exactly
CC   an unknown AIDS-causing virus
XX
SQ   Sequence 20 BP; 7 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||| | ||
Db          3 ATTATCAGAAGGAGCCA 19


RESULT 299
AAV68581/c
ID   AAV68581 standard; DNA; 20 BP.
XX
AC   AAV68581;
XX
DT   16-FEB-1999  (first entry)
XX
DE   Nucleotide sequence of a detection primer.
XX
KW   Detection primer; hybridisation; Strand Displacement Amplification; SDA;
KW   RNA target; RNA-related disease; viraemas; upregulation; cancer; ss.
XX
OS   Synthetic.
XX
PN   EP878553-A2.
XX
PD   18-NOV-1998.
XX
PF   05-MAY-1998;   98EP-00108154.
XX
PR   08-MAY-1997;   97US-00854041.
XX
PA   (BECT ) BECTON DICKINSON & CO.
XX
PI   Pearson RE,  Dickson JA,  Mehrpouyan M;
XX
DR   WPI; 1998-585754/50.
XX
PT   Amplification of RNA targets - using reverse transcription Strand
PT   Displacement Amplification.
XX
PS   Example 1; Page 8; 14pp; English.
XX
CC   This is a detection primer (probe) used in the method of the invention to
CC   amplify a target sequence involving Strand Displacement Amplification
CC   (SDA). Amplification of RNA targets by SDA is useful in diagnostics, and
CC   is especially useful for monitoring RNA-related diseases including
CC   viraemas and upregulation of cancer genes
XX
SQ   Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||| | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 300
AAX93392/c
ID   AAX93392 standard; DNA; 20 BP.
XX
AC   AAX93392;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
```

```
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
XX
PR   21-NOV-1997;   97FR-00014673.
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1588; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 7 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTG 1606
              |||| ||||||||| ||
Db         17 ACTGCGAACCCCTCTTG 1


RESULT 301
AAZ49841/c
ID   AAZ49841 standard; cDNA; 20 BP.
XX
AC   AAZ49841;
XX
DT   18-APR-2000  (first entry)
XX
DE   PCR primer 28sst-110F for oat ACCase cDNA amplification.
XX
KW   PCR primer; herbicide resistance; gene modification; herbicide;
KW   oat ACCase; maize acetyl CoA carboxylase; ACCase; plant oil content;
KW   marker-assisted plant selection; groat oil trait;
KW   restriction fragment length polymorphism mapping;
KW   high-energy animal feed; low-fat human food; ss.
XX
OS   Zea mays.
XX
PN   WO9967367-A1.
XX
PD   29-DEC-1999.
XX
PF   22-JUN-1999;   99WO-US014022.
XX
PR   22-JUN-1998;   98US-0090240P.
PR   02-JUL-1998;   98US-0091640P.
XX
PA   (MINU ) UNIV MINNESOTA.
PA   (USDA ) US DEPT OF AGRICULTURE.
PA   (EGLI/) EGLI M A.
PA   (GROH/) GROH S.
PA   (KIAN/) KIANIAN S F.
PA   (PHIL/) PHILLIPS R L.
PA   (RINE/) RINES H W.
PA   (SOME/) SOMERS D A.
XX
PI   Egli MA,  Groh S,  Kianian SF,  Phillips RL,  Rines HW,  Somers DA;
XX
DR   WPI; 2000-147205/13.
XX
PT   New DNA encoding acetyl-CoA carboxylase from oats, used to produce
PT   transformed plants with herbicide resistance and altered oil content.
XX
PS   Example 7; Page 58; 197pp; English.
XX
CC   The present sequence is a maize PCR primer 28sst-110F for amplification
CC   of oat ACCase (acetyl CoA carboxylase) cDNA. The primer is located within
CC   the transcarboxylase domain, surrounding the acetyl CoA binding site of
CC   ACCase. Transformation of plants with ACCase imparts resistance to
CC   cyclohexanedione and aryloxyphenoxypropanoic acid herbicides and alter
CC   the oil content. The ACCase DNA is also used as source of probes and
CC   primers for the identification of transgenic plants; in marker -assisted
CC   plant selection and for restriction fragment length polymorphism mapping,
CC   used for high-energy animal feed and high-fiber, low-fat human food and
CC   in genetic dissection of the groat oil trait
XX
SQ   Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACAG 1589
              ||||||| | |||||||
Db         18 CCTTCTCAAACGCACAG 2


RESULT 302
AAZ59205/c
ID   AAZ59205 standard; DNA; 20 BP.
XX
AC   AAZ59205;
XX
DT   20-APR-2000  (first entry)
XX
DE   Forward PCR primer for human growth hormone gene.
XX
KW   Fusion protein; Bacillus; cell wall protein; promoter; cleavage site;
KW   TEV protease; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP11341991-A.
XX
PD   14-DEC-1999.
XX
PF   30-MAR-1999;   99JP-00089488.
XX
PR   31-MAR-1998;   98JP-00087339.
XX
PA   (ITOH-) ITOHAM FOODS INC.
PA   (UDAK/) UDAKA S.
XX
PI   Sato S,  Higashikuni N,  Kudo T,  Kondo M;
XX
DR   WPI; 2000-101697/09.
XX
PT   A DNA coding a new fused protein and preparation of a useful peptide
PT   through its expression.
XX
PS   Example 9; Page 16; 43pp; Japanese.
XX
CC   The invention relates to a DNA construct encoding a fusion protein
CC   comprising a Bacillus species cell wall protein fused to a cleavage
CC   peptide and a heterologous protein. The fusion construct is placed
```

```
CC   downstream of a Bacillus species promoter sequence. An example of the
CC   construct is construct MWPsp-MWPmp20-TEV-GH, which comprises the Bacillus
CC   brevis middle wall protein mp20 linked to the human growth hormone
CC   protein via a TEV protease cleavable linker sequence. This sequence
CC   represents the forward PCR primer for the human growth hormone (GH) gene
XX
SQ   Sequence 20 BP; 4 A; 9 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1934 GTTAAGGTAATGGTTGG 1950
              | ||||| |||||||||
Db         20 GATAAGGGAATGGTTGG 4


RESULT 303
AAZ59204/c
ID   AAZ59204 standard; DNA; 20 BP.
XX
AC   AAZ59204;
XX
DT   20-APR-2000  (first entry)
XX
DE   Second strand cDNA synthesis primer for human growth hormone gene.
XX
KW   Fusion protein; Bacillus; cell wall protein; promoter; cleavage site;
KW   TEV protease; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP11341991-A.
XX
PD   14-DEC-1999.
XX
PF   30-MAR-1999;   99JP-00089488.
XX
PR   31-MAR-1998;   98JP-00087339.
XX
PA   (ITOH-) ITOHAM FOODS INC.
PA   (UDAK/) UDAKA S.
XX
PI   Sato S,  Higashikuni N,  Kudo T,  Kondo M;
XX
DR   WPI; 2000-101697/09.
XX
PT   A DNA coding a new fused protein and preparation of a useful peptide
PT   through its expression.
XX
PS   Example 8; Page 16; 43pp; Japanese.
XX
CC   The invention relates to a DNA construct encoding a fusion protein
CC   comprising a Bacillus species cell wall protein fused to a cleavage
CC   peptide and a heterologous protein. The fusion construct is placed
CC   downstream of a Bacillus species promoter sequence. An example of the
CC   construct is construct MWPsp-MWPmp20-TEV-GH, which comprises the Bacillus
CC   brevis middle wall protein mp20 linked to the human growth hormone
CC   protein via a cleavable linker sequence. This sequence represents a
CC   primer for the synthesis of the second cDNA strand of the human growth
CC   hormone (GH) gene from purified mRNA
XX
SQ   Sequence 20 BP; 4 A; 9 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1934 GTTAAGGTAATGGTTGG 1950
              | ||||| |||||||||
Db         20 GATAAGGGAATGGTTGG 4


RESULT 304
AAK95000/c
ID   AAK95000 standard; DNA; 20 BP.
XX
AC   AAK95000;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human cDNA clone-specific primer, SEQ ID NO: 4245.
XX
KW   Human; full length cDNA; cDNA synthesis; oligo-capping; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1130094-A2.
XX
PD   05-SEP-2001.
XX
PF   07-JUL-2000; 2000EP-00114089.
XX
PR   08-JUL-1999;   99JP-00194486.
PR   11-JAN-2000; 2000JP-00118774.
PR   02-MAY-2000; 2000JP-00183765.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Nishikawa T,  Isogai T,  Hayashi K,  Ishii S,  Kawai Y;
PI   Wakamatsu A,  Sugiyama T,  Nagai K,  Kojima S,  Otsuki T,  Koga H;
XX
DR   WPI; 2001-524255/58.
XX
PT   830 Primers useful for synthesizing full length cDNA clones and their use
PT   in genetic manipulation.
XX
PS   Example 18; Page 128; 1380pp + Sequence Listing; English.
XX
CC   The invention relates to primers for synthesising full length cDNA
CC   clones. 830 cDNA molecules encoding a human protein have been isolated
CC   and nucleotide sequences of 5'- and 3'-ends of the cDNA molecules have
CC   been determined. Primers for synthesising the full length cDNA are useful
CC   for clarifying the function of the protein encoded by the cDNA. The full
CC   length clones were obtained by construction of full length enriched cDNA
CC   libraries that were synthesised by the oligo-capping method. The primers
CC   enable the production of the full length cDNA easily without any special
CC   methods. The present sequence is a primer used to amplify a human cDNA
CC   clone provided in the invention
XX
SQ   Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1647 AGCCTTCACTGGTTCTG 1663
              ||||||| ||| |||||
Db         20 AGCCTTCTCTGTTTCTG 4


RESULT 305
AAF73065
ID   AAF73065 standard; DNA; 20 BP.
XX
AC   AAF73065;
XX
DT   24-APR-2001  (first entry)
XX
DE   Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ:166.
XX
KW   Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
KW   Fas binding protein; CENP-C binding protein; dap6; EAP; cytostatic;
KW   antiinflammatory; death associated protein 6; Ets-1 associated protein;
KW   infection; inflammation; tumour formation; ss.
XX
```

```
OS   Homo sapiens.
XX
PN   US6180353-B1.
XX
PD   30-JAN-2001.
XX
PF   24-JAN-2000; 2000US-00490692.
XX
PR   24-JAN-2000; 2000US-00490692.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Cowsert LM;
XX
DR   WPI; 2001-217744/22.
XX
PT   Novel antisense compounds capable of modulating expression of daxx useful
PT   for diagnosis, prophylaxis and treatment of diseases associated with
PT   expression of daxx.
XX
PS   Claim 1; Col 49; 59pp; English.
XX
CC   The present invention describes an antisense compound (I) up to 30
CC   nucleobases in length, where (I) inhibits expression of daxx (also known
CC   as Fas binding protein, CENP-C binding protein, dap6 for death associated
CC   protein 6 and EAP for Ets-1 associated protein). (I) has cytostatic and
CC   antiinflammatory activity, and can be used in antisense therapy and as a
CC   modulator of daxx. (I) is useful for inhibiting the expression of daxx in
CC   cells or tissues in vitro. (I) can be utilised for diagnostics,
CC   therapeutics for the treatment of diseases associated with the expression
CC   of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
CC   tumour formation and as research reagent. The present sequence represents
CC   an inhibitory human daxx antisense phosphorothioate oligonucleotide which
CC   is used in the exemplification of the present invention
XX
SQ   Sequence 20 BP; 6 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2032 AGGCAAAGGTTCTATCT 2048
              ||||||| ||| ||||
Db          1 AGGCAAAGCTTCCATCT 17


RESULT 306
AAD17451
ID   AAD17451 standard; DNA; 20 BP.
XX
AC   AAD17451;
XX
DT   10-DEC-2001  (first entry)
XX
DE   Human TNF-alpha cDNA amplifying gene specific RT-PCR primer #1.
XX
KW   Human; Tp12; serine threonine kinase; tumour necrosis factor; TNFalpha;
KW   inflammatory disease; therapy; rheumatoid arthritis; endotoxin shock;
KW   research tool; LPS; lipopolysaccharide; RT-PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200166559-A1.
XX
PD   13-SEP-2001.
XX
PF   08-MAR-2001; 2001WO-US007588.
XX
PR   08-MAR-2000; 2000US-00522775.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Tsichlis PN;
XX
DR   WPI; 2001-582266/65.
XX
PT   Knock-out animal resistant to lipopolysaccharide-induced endotoxin shock
PT   and tumor necrosis factor alpha-mediated inflammatory disease, comprises
PT   a functionally disrupted endogenous Tp12 gene.
XX
PS   Example 7; Page 48; 98pp; English.
XX
CC   The invention relates to an animal with a structurally intact Tp12 gene
CC   but functionally disrupted endogenous Tp12 (a protooncogene which encodes
CC   a cytoplasmic serine threonine protein kinase). The animal has increased
CC   resistance to lipopolysaccharide-induced endotoxin shock or tumour
CC   necrosis factor (TNF) alpha-mediated inflammatory diseases. Tp12 protein
CC   and DNA are useful for identifying compounds that agonise or inhibit the
CC   function of Tp12 protein. Tp12 is useful for treating rheumatoid
CC   arthritis. TNFalpha-mediated inflammatory diseases or LPS induced
CC   endotoxin shock, may be treated by transfecting bone marrow derived cells
CC   invitro with a DNA construct which encodes sequences that interferes with
CC   the expression of function of the endogenous Tp12 in the cells and
CC   administering the cells to an animal. The knock out animals and the
CC   constructs used to generate the animals are useful in the development of
CC   compositions and methods of treating inflammation. Tp12 agonist and
CC   antagonist are useful as targets for the development of novel therapeutic
CC   agents which eliminate the functional role of Tp12 and as research tools
CC   to facilitate the elucidation of the mechanistic action of the novel
CC   genetic and protein interactions involved in inflammatory disorders. Tp12
CC   polynucleotide sequences facilitate the discovery and development of anti
CC   endotoxin shock and/or antiinflammatory compounds. The present sequence
CC   is a reverse transcription (RT) PCR used for amplifying human TNFalpha
CC   cDNA
XX
SQ   Sequence 20 BP; 5 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACACTTAG 1871
              ||||||| |||||| ||
Db          4 CAGACCCTCACACTCAG 20


RESULT 307
AAH80592
ID   AAH80592 standard; cDNA; 20 BP.
XX
AC   AAH80592;
XX
DT   11-SEP-2003  (revised)
DT   19-SEP-2001  (first entry)
XX
DE   Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 556.
XX
KW   Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KW   disease diagnosis; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US6251588-B1.
XX
PD   26-JUN-2001.
XX
PF   10-FEB-1998;   98US-00021701.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2001-424456/45.
XX
```

```
PT   Predicting the potential of an oligonucleotide to hybridize to a target
PT   nucleotide sequence, useful for evaluating oligonucleotide probe
PT   sequences, by identifying a oligonucleotides based on the evaluation of
PT   parameters.
XX
PS   Example 2; Col 65; 342pp; English.
XX
CC   The present invention describes a method for predicting the potential of
CC   an oligonucleotide to hybridise to a (complementary) target nucleotide
CC   sequence, involving identifying a subset of oligonucleotides within the
CC   predetermined number of unique oligonucleotides based on the evaluation
CC   of the parameter. Oligonucleotides in the subset are identified that are
CC   clustered along a region of the nucleotide sequence that is hybridisable
CC   to the target nucleotide sequence. This is useful for evaluating
CC   oligonucleotide probe sequences. The present sequence is an
CC   oligonucleotide described in the exemplification of the invention.
CC   (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ   Sequence 20 BP; 3 A; 4 C; 1 G; 12 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          4 TTTTTCTTTTTTAACCC 20


RESULT 308
AAH80595
ID   AAH80595 standard; cDNA; 20 BP.
XX
AC   AAH80595;
XX
DT   11-SEP-2003  (revised)
DT   19-SEP-2001  (first entry)
XX
DE   Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 559.
XX
KW   Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KW   disease diagnosis; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US6251588-B1.
XX
PD   26-JUN-2001.
XX
PF   10-FEB-1998;   98US-00021701.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2001-424456/45.
XX
PT   Predicting the potential of an oligonucleotide to hybridize to a target
PT   nucleotide sequence, useful for evaluating oligonucleotide probe
PT   sequences, by identifying a oligonucleotides based on the evaluation of
PT   parameters.
XX
PS   Example 2; Col 65; 342pp; English.
XX
CC   The present invention describes a method for predicting the potential of
CC   an oligonucleotide to hybridise to a (complementary) target nucleotide
CC   sequence, involving identifying a subset of oligonucleotides within the
CC   predetermined number of unique oligonucleotides based on the evaluation
CC   of the parameter. Oligonucleotides in the subset are identified that are
CC   clustered along a region of the nucleotide sequence that is hybridisable
CC   to the target nucleotide sequence. This is useful for evaluating
CC   oligonucleotide probe sequences. The present sequence is an
CC   oligonucleotide described in the exemplification of the invention.
CC   (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ   Sequence 20 BP; 2 A; 5 C; 1 G; 12 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          1 TTTTTCTTTTTTAACCC 17


RESULT 309
AAH80593
ID   AAH80593 standard; cDNA; 20 BP.
XX
AC   AAH80593;
XX
DT   11-SEP-2003  (revised)
DT   19-SEP-2001  (first entry)
XX
DE   Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 557.
XX
KW   Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KW   disease diagnosis; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US6251588-B1.
XX
PD   26-JUN-2001.
XX
PF   10-FEB-1998;   98US-00021701.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2001-424456/45.
XX
PT   Predicting the potential of an oligonucleotide to hybridize to a target
PT   nucleotide sequence, useful for evaluating oligonucleotide probe
PT   sequences, by identifying a oligonucleotides based on the evaluation of
PT   parameters.
XX
PS   Example 2; Col 65; 342pp; English.
XX
CC   The present invention describes a method for predicting the potential of
CC   an oligonucleotide to hybridise to a (complementary) target nucleotide
CC   sequence, involving identifying a subset of oligonucleotides within the
CC   predetermined number of unique oligonucleotides based on the evaluation
CC   of the parameter. Oligonucleotides in the subset are identified that are
CC   clustered along a region of the nucleotide sequence that is hybridisable
CC   to the target nucleotide sequence. This is useful for evaluating
CC   oligonucleotide probe sequences. The present sequence is an
CC   oligonucleotide described in the exemplification of the invention.
CC   (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ   Sequence 20 BP; 3 A; 4 C; 0 G; 13 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          3 TTTTTCTTTTTTAACCC 19
```

```
RESULT 310
AAH80594
ID   AAH80594 standard; cDNA; 20 BP.
XX
AC   AAH80594;
XX
DT   11-SEP-2003  (revised)
DT   19-SEP-2001  (first entry)
XX
DE   Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 558.
XX
KW   Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KW   disease diagnosis; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US6251588-B1.
XX
PD   26-JUN-2001.
XX
PF   10-FEB-1998;   98US-00021701.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2001-424456/45.
XX
PT   Predicting the potential of an oligonucleotide to hybridize to a target
PT   nucleotide sequence, useful for evaluating oligonucleotide probe
PT   sequences, by identifying a oligonucleotides based on the evaluation of
PT   parameters.
XX
PS   Example 2; Col 65; 342pp; English.
XX
CC   The present invention describes a method for predicting the potential of
CC   an oligonucleotide to hybridise to a (complementary) target nucleotide
CC   sequence, involving identifying a subset of oligonucleotides within the
CC   predetermined number of unique oligonucleotides based on the evaluation
CC   of the parameter. Oligonucleotides in the subset are identified that are
CC   clustered along a region of the nucleotide sequence that is hybridisable
CC   to the target nucleotide sequence. This is useful for evaluating
CC   oligonucleotide probe sequences. The present sequence is an
CC   oligonucleotide described in the exemplification of the invention.
CC   (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ   Sequence 20 BP; 2 A; 4 C; 1 G; 13 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          2 TTTTTCTTTTTAACCC 18


RESULT 311
ABK53147/c
ID   ABK53147 standard; DNA; 20 BP.
XX
AC   ABK53147;
XX
DT   29-AUG-2003  (revised)
DT   12-AUG-2002  (first entry)
XX
DE   HIV-1 Gag gene specific oligonucleotide primer #11.
XX
KW   HIV; human immunodeficiency virus; ss; primer; gag; pol; protease;
KW   reverse transcriptase; infection; PCR.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US2002055095-A1.
XX
PD   09-MAY-2002.
XX
PF   31-AUG-2001; 2001US-00944036.
XX
PR   01-SEP-2000; 2000US-0229790P.
XX
PA   (YANG/) YANG Y Y.
PA   (BREN/) BRENTANO S T.
PA   (BABO/) BABOLA O.
PA   (TRAN/) TRAN N.
PA   (VERN/) VERNET G.
XX
PI   Yang YY,  Brentano ST,  Babola O,  Tran N,  Vernet G;
XX
DR   WPI; 2002-462902/49.
XX
PT   New nucleic acid oligomers for amplifying a nucleotide sequence from HIV-
PT   1 and probes for detecting the amplified product are specific for gag and
PT   pol regions and are useful to detect different subtypes of HIV-1.
XX
PS   Claim 1; Page 27; 37pp; English.
XX
CC   This invention relates to a series of nucleic acid oligomers for
CC   amplifying and detecting a nucleotide sequence of human immunodeficiency
CC   virus type 1 (HIV-1). The invention also comprises a labeled
CC   oligonucleotide that specifically hybridises to an HIV-1 sequence derived
CC   from gag or pol sequences, having one of the sequences fully defined in
CC   the specification, and a method for detecting HIV-1 in a biological
CC   sample, comprising mixing the sample with two or more of the
CC   amplification oligomers that specifically amplify at least one HIV-1
CC   target sequence within gag and a pol sequence which is a protease or
CC   reverse transcriptase sequence, amplifying the target, and detecting the
CC   amplified product. The oligonucleotides of the invention may be used to
CC   diagnose HIV-1 infection. The presents sequence represents a PCR primer
CC   used to amplify the HIV-1 Gag gene in the HIV detection method of the
CC   invention. (Updated on 29-AUG-2003 to standardise OS field)
XX
SQ   Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         20 ATTATCAGAAGGAGCCA 4


RESULT 312
ABK13157
ID   ABK13157 standard; DNA; 20 BP.
XX
AC   ABK13157;
XX
DT   07-AUG-2003  (revised)
DT   23-APR-2002  (first entry)
XX
DE   En8183 EN transposon specific PCR primer.
XX
KW   Short-root; SHR; cell cell division regulator; gravitropism;
KW   root organisation; antibody; immunogen; transgenic plant; En8183;
KW   lodging; PCR; primer; transposon; Maize; ss.
XX
OS   Zea mays.
XX
PN   WO200190314-A1.
XX
PD   29-NOV-2001.
```

XX
PF 24-MAY-2001; 2001WO-US017273.
XX
PR 24-MAY-2000; 2000US-00578827.
XX
PA (UYNY) UNIV NEW YORK STATE.
XX
PI Benfey PN, Helariutta Y, Fukaki H, Nakajima K;
XX
DR WPI; 2002-147582/19.
XX
PT New SHORT-ROOT genes, useful for improving agronomically valuable plants,
PT particularly for altering or regulating the root and/or stem structure of
PT transgenic plants to produce plants that are less susceptible to lodging.
XX
PS Example 6.14; Page 68; 142pp; English.
XX
CC This invention relates to the nucleic acid and protein sequence of a
CC novel gene Short-root (SHR). SHR is expressed mainly in roots and
CC controls cell cell division of certain types of roots affecting
CC gravitropism and the organisation of root and stem. The invention also
CC comprises an antibody that immunospecifically binds the SHR protein and
CC plants genetically-engineered to overexpress or underexpress a SHR
CC protein or polypeptide, so that cell division is modified, and root
CC and/or stem development is altered. The SHR genes are useful for
CC improving agronomically valuable plants. The SHR genes are particularly
CC useful for altering or regulating the root and/or stem structure, and the
CC gravitropism of aerial structures of transgenic plants. The genes are
CC also useful for developing straighter transgenic plants that are less
CC susceptible to lodging. The present sequence represents the En8183 maize
CC transposon En-specific PCR primer, this primer was used in conjunction
CC with the primer En7631 (ABK14156) to generate an En-specific probe to
CC allow genotyping of progeny from an Shr3 heterozygote. Shr-3 and Shr-4
CC alleles were identified in lines containing the autonomously replicating
CC maize transposon En. (Updated on 07-AUG-2003 to correct OS field.)
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1857 GACCCACACACTTAGCC 1873
|||| |||| |||||||
Db 4 GACCGACACTCTTAGCC 20

RESULT 313
AAD39347/c
ID AAD39347 standard; DNA; 20 BP.
XX
AC AAD39347;
XX
DT 04-OCT-2002 (first entry)
XX
DE Human Von Willebrand factor-cleaving protease cloning PCR primer, 6395.
XX
KW Human; Von Willebrand factor-cleaving protease; vWF-cp; therapy; enzyme;
KW transgenic animal; immunisation; thromboembolic disease; preeclampsia;
KW thrombotic thrombocytic purpura; TTP; Henoch-Schonlein purpura;
KW thrombosis; neonatal thrombocytopaenia; haemolytic-uraemic syndrome;
KW transgenic; anticoagulant; RT-PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200242441-A2.
XX
PD 30-MAY-2002.
XX
PF 20-NOV-2001; 2001WO-EP013391.
XX
PR 22-NOV-2000; 2000US-00721254.
PR 12-APR-2001; 2001US-00833328.
XX
PA (BAXT) BAXTER AG.
XX
PI Laemmle B, Gerritsen HE, Furlan M, Turecek P, Schwarz H;
PI Scheiflinger F, Antoine G, Kerschbaumer R, Tagliavacca L;
PI Zimmermann K, Voelkel D;
XX
DR WPI; 2002-479950/51.
XX
PT Novel isolated or substantially purified Von Willebrand factor-cleaving
PT protease, useful for producing preparation for therapy of thrombosis and
PT thromboembolic disease such as thrombotic thrombocytic purpura.
XX
PS Example 3; Page 34; 93pp; English.
XX
CC The invention relates to an isolated or substantially pure Von Willebrand
CC factor-cleaving protease (vWF-cp) polypeptide. vWF-cp is useful for
CC purifying vWF which involves providing vWF-cp as a ligand, contacting a
CC solution comprising vWF with the polypeptide ligand under conditions
CC where vWF is bound to the ligand and recovering from the ligand purified
CC vWF. vWF-cp is useful for producing anti-vWF cp polypeptide antibodies
CC which involves immunising an animal with vWF-cp and isolating the anti-
CC vWF cp polypeptide antibodies from the animal. vWF-cp is useful for
CC producing a preparation of prophylaxis and therapy of thrombosis and
CC thromboembolic disease such as thrombotic thrombocytic purpura (TTP),
CC Henoch-Schonlein purpura, preeclampsia, neonatal thrombocytopaenia or
CC haemolytic-uraemic syndrome. vWF-cp can also be used for processing
CC plasmatic or recombinantly produced vWF. The invention is useful for
CC construction expression systems and generating transgenic animals which
CC express the polypeptide in vivo. The present sequence is human vWF-cp
CC gene cloning RT-PCR primer
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1591 CTGGGAACCCCTCCTGG 1607
||||| |||||||| ||
Db 17 CTGGGGACCCCTCCAGG 1

RESULT 314
AAL45509/c
ID AAL45509 standard; DNA; 20 BP.
XX
AC AAL45509;
XX
DT 29-AUG-2003 (revised)
DT 06-JUN-2002 (first entry)
XX
DE HIV-1 gag amplification oligomer SEQ ID NO: 47.
XX
KW HIV-1; gag gene; pol gene; PCR; primer; drug resistance; genetic subtype;
KW probe; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN WO200220852-A1.
XX
PD 14-MAR-2002.
XX
PF 01-SEP-2000; 2000WO-US024117.
XX
PR 01-SEP-2000; 2000WO-US024117.
XX
PA (GENP-) GEN-PROBE INC.
PA (INMR) BIOMERIEUX SA.
XX
PI Yang YY, Brentano ST, Babola O, Tran N, Vernet G;
XX
DR WPI; 2002-292273/33.

```
XX
PT   New nucleic acid oligomer, useful for detecting selected regions of gag
PT   and pol genes of human immune deficiency virus, particularly for
PT   assessing drug resistance.
XX
PS   Claim 1; Page 62; 82pp; English.
XX
CC   The present invention provides a number of nucleic acid oligomers which
CC   can be used to amplify the gag and pol genes of human immunodeficiency
CC   virus type I (HIV-1). These are used to detect regions of the gag and pol
CC   genes, especially regions associated with drug resistance, and also for
CC   identifying genetic subtypes of the virus. The present sequence is an
CC   oligomer of the invention. (Updated on 29-AUG-2003 to standardise OS
CC   field)
XX
SQ   Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||| | ||
Db         20 ATTATCAGAAGGAGCCA 4


RESULT 315
AAD61201
ID   AAD61201 standard; DNA; 20 BP.
XX
AC   AAD61201;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Human Ship-1 antisense oligonucleotide ISIS #168282.
XX
KW   Human; Ship-1; SH2-containing phosphatidylinositol phosphatase-1; INPP5D;
KW   insensitivity to apoptotic signal; developmental disorder; inflammation;
KW   immunosuppressive; autoimmune disorder; antisense therapy; antisense;
KW   phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methyl cytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2003114401-A1.
XX
PD   19-JUN-2003.
XX
PF   06-DEC-2001; 2001US-00003919.
XX
PR   06-DEC-2001; 2001US-00003919.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Freier SM;
XX
DR   WPI; 2003-801302/75.
XX
PT   Antisense compounds targeted to nucleic acid molecule encoding Ship-1,
PT   useful for treating diseases associated with expression of Ship-1, such
PT   as autoimmune and developmental disorders.
XX
PS   Claim 3; Page 25; 0pp; English.
XX
CC   The present invention provides antisense compounds targetted to nucleic
CC   acid molecule encoding Ship-1 (also known as SH2-containing
CC   phosphatidylinositol phosphatase-1 and INPP5D) to modulate/inhibit the
CC   expression of Ship-1. The invention is useful in treatment of diseases
CC   such as insensitivity to apoptotic signals, autoimmune disorders,
CC   developmental disorders and inflammatory disorders. The present sequence
CC   is human Ship-1 antisense oligonucleotide
XX
SQ   Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              ||||||  |||||||||
Db          2 CCCCATGTTTTCCTTCT 18


RESULT 316
ADD81486
ID   ADD81486 standard; DNA; 20 BP.
XX
AC   ADD81486;
XX
DT   29-JAN-2004  (first entry)
XX
DE   HIV PRT antisense derived probe #415.
XX
KW   ss; oligonucleotide hybridisation potential; efficient hybridisation;
KW   large array; minimum oligonucleotide synthesis; probe.
XX
OS   Human immunodeficiency virus.
XX
PN   US2003054346-A1.
XX
PD   20-MAR-2003.
XX
PF   15-FEB-2001; 2001US-00784674.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (SHAN/) SHANNON K W.
PA   (WOLB/) WOLBER P K.
PA   (DELE/) DELENSTARR G C.
PA   (WEBB/) WEBB P G.
PA   (KINC/) KINCAID R H.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2003-743746/70.
XX
PT   Predicting potential of oligonucleotides to hybridize to target
PT   nucleotide sequence comprises determining and evaluating for each
PT   oligonucleotide a parameter predictive of the oligonucleotides ability to
PT   hybridize with target.
XX
PS   Example 2; SEQ ID NO 559; 423pp; English.
XX
CC   The invention relates to a method of predicting the potential of
CC   oligonucleotides to hybridise to target nucleotide sequences. The method
CC   is useful for predicting the potential of an oligonucleotide to hybridise
CC   to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
CC   contains chemically modified nucleotides. The method is also useful for
CC   predicting the potential of the oligonucleotides to hybridise to a
CC   complementary target nucleotide sequence. The method is useful to predict
CC   efficient hybridisation oligonucleotides for each of multiple target
```

```
CC   sequences therefore very large arrays may be constructed and tested with
CC   minimum synthesis of oligonucleotides. The present sequence represents a
CC   HIV PRT antisense derived probe.
XX
SQ   Sequence 20 BP; 2 A; 5 C; 1 G; 12 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          1 TTTTTCTTTTTTAACCC 17


RESULT 317
ADD81484
ID   ADD81484 standard; DNA; 20 BP.
XX
AC   ADD81484;
XX
DT   29-JAN-2004  (first entry)
XX
DE   HIV PRT antisense derived probe #413.
XX
KW   ss; oligonucleotide hybridisation potential; efficient hybridisation;
KW   large array; minimum oligonucleotide synthesis; probe.
XX
OS   Human immunodeficiency virus.
XX
PN   US2003054346-A1.
XX
PD   20-MAR-2003.
XX
PF   15-FEB-2001; 2001US-00784674.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (SHAN/) SHANNON K W.
PA   (WOLB/) WOLBER P K.
PA   (DELE/) DELENSTARR G C.
PA   (WEBB/) WEBB P G.
PA   (KINC/) KINCAID R H.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2003-743746/70.
XX
PT   Predicting potential of oligonucleotides to hybridize to target
PT   nucleotide sequence comprises determining and evaluating for each
PT   oligonucleotide a parameter predictive of the oligonucleotides ability to
PT   hybridize with target.
XX
PS   Example 2; SEQ ID NO 557; 423pp; English.
XX
CC   The invention relates to a method of predicting the potential of
CC   oligonucleotides to hybridise to target nucleotide sequences. The method
CC   is useful for predicting the potential of an oligonucleotide to hybridise
CC   to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
CC   contains chemically modified nucleotides. The method is also useful for
CC   predicting the potential of the oligonucleotides to hybridise to a
CC   complementary target nucleotide sequence. The method is useful to predict
CC   efficient hybridisation oligonucleotides for each of multiple target
CC   sequences therefore very large arrays may be constructed and tested with
CC   minimum synthesis of oligonucleotides. The present sequence represents a
CC   HIV PRT antisense derived probe.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 0 G; 13 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          3 TTTTTCTTTTTTAACCC 19


RESULT 318
ADD81485
ID   ADD81485 standard; DNA; 20 BP.
XX
AC   ADD81485;
XX
DT   29-JAN-2004  (first entry)
XX
DE   HIV PRT antisense derived probe #414.
XX
KW   ss; oligonucleotide hybridisation potential; efficient hybridisation;
KW   large array; minimum oligonucleotide synthesis; probe.
XX
OS   Human immunodeficiency virus.
XX
PN   US2003054346-A1.
XX
PD   20-MAR-2003.
XX
PF   15-FEB-2001; 2001US-00784674.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (SHAN/) SHANNON K W.
PA   (WOLB/) WOLBER P K.
PA   (DELE/) DELENSTARR G C.
PA   (WEBB/) WEBB P G.
PA   (KINC/) KINCAID R H.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2003-743746/70.
XX
PT   Predicting potential of oligonucleotides to hybridize to target
PT   nucleotide sequence comprises determining and evaluating for each
PT   oligonucleotide a parameter predictive of the oligonucleotides ability to
PT   hybridize with target.
XX
PS   Example 2; SEQ ID NO 558; 423pp; English.
XX
CC   The invention relates to a method of predicting the potential of
CC   oligonucleotides to hybridise to target nucleotide sequences. The method
CC   is useful for predicting the potential of an oligonucleotide to hybridise
CC   to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
CC   contains chemically modified nucleotides. The method is also useful for
CC   predicting the potential of the oligonucleotides to hybridise to a
CC   complementary target nucleotide sequence. The method is useful to predict
CC   efficient hybridisation oligonucleotides for each of multiple target
CC   sequences therefore very large arrays may be constructed and tested with
CC   minimum synthesis of oligonucleotides. The present sequence represents a
CC   HIV PRT antisense derived probe.
XX
SQ   Sequence 20 BP; 2 A; 4 C; 1 G; 13 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          2 TTTTTCTTTTTTAACCC 18


RESULT 319
ADD81483
ID   ADD81483 standard; DNA; 20 BP.
XX
AC   ADD81483;
```

```
XX
DT   29-JAN-2004  (first entry)
XX
DE   HIV PRT antisense derived probe #412.
XX
KW   ss; oligonucleotide hybridisation potential; efficient hybridisation;
KW   large array; minimum oligonucleotide synthesis; probe.
XX
OS   Human immunodeficiency virus.
XX
PN   US2003054346-A1.
XX
PD   20-MAR-2003.
XX
PF   15-FEB-2001; 2001US-00784674.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (SHAN/) SHANNON K W.
PA   (WOLB/) WOLBER P K.
PA   (DELE/) DELENSTARR G C.
PA   (WEBB/) WEBB P G.
PA   (KINC/) KINCAID R H.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2003-743746/70.
XX
PT   Predicting potential of oligonucleotides to hybridize to target
PT   nucleotide sequence comprises determining and evaluating for each
PT   oligonucleotide a parameter predictive of the oligonucleotides ability to
PT   hybridize with target.
XX
PS   Example 2; SEQ ID NO 556; 423pp; English.
XX
CC   The invention relates to a method of predicting the potential of
CC   oligonucleotides to hybridise to target nucleotide sequences. The method
CC   is useful for predicting the potential of an oligonucleotide to hybridise
CC   to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
CC   contains chemically modified nucleotides. The method is also useful for
CC   predicting the potential of the oligonucleotides to hybridise to a
CC   complementary target nucleotide sequence. The method is useful to predict
CC   efficient hybridisation oligonucleotides for each of multiple target
CC   sequences therefore very large arrays may be constructed and tested with
CC   minimum synthesis of oligonucleotides. The present sequence represents a
CC   HIV PRT antisense derived probe.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 1 G; 12 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTGAACCC 1787
                ||||| ||||| |||||
Db          4 TTTTTCTTTTTTAACCC 20


RESULT 320
ADG17897/c
ID   ADG17897 standard; DNA; 20 BP.
XX
AC   ADG17897;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Primer of the invention #6.
XX
KW   cell-wall protein; CWP; enzymatic cleavage; primer; ss.
XX
OS   Synthetic.
XX
PN   JP2003079379-A.
XX
PD   18-MAR-2003.
XX
PF   13-SEP-2001; 2001JP-00278534.
XX
PR   13-SEP-2001; 2001JP-00278534.
XX
PA   (ITOH-) ITO HAM KK.
PA   (UTAK/) UTAKA S.
XX
DR   WPI; 2003-816982/77.
XX
PT   New DNA for producing phytamin, encodes a fusion protein comprising a
PT   leader peptide having amino acids from a Bacillus cell-wall protein, a
PT   growth hormone sequence for enzymatic cleavage, and the phytamin amino
PT   acid sequence.
XX
PS   Example 1; SEQ ID NO 12; 38pp; Japanese.
XX
CC   The present invention relates to DNA encoding a fusion protein comprising
CC   a leader peptide having a sequence comprising one or more amino acid
CC   residues from N-terminus of the cell-wall protein (CWP) of Bacillus , an
CC   amino acid sequence of growth hormone for enzymatic cleavage, and a
CC   phytamin amino acid sequence or its fragment, variant or analog,
CC   connected in order. The DNA is useful in the production of phytamin or
CC   its functional fragment, variant or analog. The present sequence a primer
CC   of the invention.
XX
SQ   Sequence 20 BP; 4 A; 9 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1934 GTTAAGGTAATGGTTGG 1950
                | ||||| |||||||||
Db         20 GATAAGGGAATGGTTGG 4


RESULT 321
ABZ90674
ID   ABZ90674 standard; DNA; 20 BP.
XX
AC   ABZ90674;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
```

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 5916; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 13 A; 2 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1973 ACCTTGAAAAAAAGAAA 1989
|| ||| ||||||||||||
Db 4 ATCTTTAAAAAAAGAAA 20

RESULT 322
ABZ93123/c
ID ABZ93123 standard; DNA; 20 BP.
XX
AC ABZ93123;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 8365; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1672 GCCCCTGGACTTCTTAG 1688
|||||||||||||| ||
Db 18 GCCCCTGGACTTCCAAG 2

RESULT 323
ABZ90507
ID ABZ90507 standard; DNA; 20 BP.
XX
AC ABZ90507;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 5749; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 8 A; 1 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1823 TTAGAATCTTTTAAATA 1839
||||||| ||||||| |
Db 1 TTAGAATTTTTTAAAGA 17

RESULT 324
ABZ89893
ID ABZ89893 standard; DNA; 20 BP.
XX
AC ABZ89893;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 5135; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 2 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1764 ATTAAGCTTTTTTTTTT 1780
||||| |||||||| ||
Db 1 ATTAAACTTTTTTTCTT 17

RESULT 325
ABZ88668
ID ABZ88668 standard; DNA; 20 BP.
XX
AC ABZ88668;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX

```
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 3910; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 6 A; 3 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1758 TTATTCATTAAGCTTTT 1774
              ||||||||  ||  |||||
Db          1 TTATTCATGAAACTTTT 17


RESULT 326
ABX13312
ID   ABX13312 standard; DNA; 20 BP.
XX
AC   ABX13312;
XX
DT   14-MAY-2003  (first entry)
XX
DE   Human NSDHL gene, exon 4 PCR primer #1.
XX
KW   Human; ss; PCR; 3beta-hydroxysteroid dehydrogenase; 3beta-HSD; NSDHL;
KW   cholesterol biosynthesis; mevalonic aciduria; desmosterolosis;
KW   Smith-Lemli-Opitz syndrome; SLOS; Conradi-Hunermann-Happle syndrome;
KW   chondroplasia punctata; X-linked disease; chromosome Xq28; psoriasis;
KW   CHILD syndrome; bone disorder; osteoporosis; osteosclerosis;
KW   congenital hemidysplasia; ichthyosiform erythroderma and limb defect;
KW   ichthyosis; eye disorder; cataract; microopthalmia; arthritis;
KW   cholest-8(9)-en-3beta-ol; skin disorder; primer.
XX
OS   Homo sapiens.
XX
PN   US2002172956-A1.
XX
PD   21-NOV-2002.
XX
PF   05-SEP-2001; 2001US-00946406.
XX
PR   01-JUN-1999;   99US-0137020P.
PR   01-JUN-2000; 2000US-00588976.
XX
PA   (CHIL-) CHILDRENS HOSPITAL INC.
XX
PI   Herman GE,  Kelley RI,  Grange DK;
XX
DR   WPI; 2003-310984/30.
XX
PT   Diagnosing CHILD syndrome or psoriasis, by detecting differences between
PT   patient and wild type genes encoding 3 beta-hydroxysteroid dehydrogenase
PT   or accumulation of sterol intermediates in body fluids of the patient.
XX
PS   Disclosure; Page 2; 23pp; English.
XX
CC   The invention relates to diagnosing congenital hemidysplasia,
CC   ichthyosiform erythroderma and limb defects (CHILD) syndrome or psoriasis
CC   in a patient, involves detecting nucleotide difference between patient
CC   NSDHL oligonucleotide (gene encoding 3beta-hydroxysteroid dehydrogenase
CC   (3beta-HSD)) and wild type NSDHL gene, or detecting accumulation of
CC   sterol intermediates before the generation of cholest-8(9)-en-3beta-ol in
CC   the cholesterol biosynthetic pathway, in the body fluids or cells of the
CC   patient. The method is useful for diagnosing CHILD syndrome and psoriasis
CC   in a patient. Other diseases implicated in defects of the cholesterol
CC   biosynthetic pathway include mevalonic aciduria, desmosterolosis, Smith-
CC   Lemli-Opitz syndrome (SLOS), Conradi-Hunermann- Happle syndrome;
CC   chondroplasia punctata (X-linked disease), bone disorders, osteoporosis,
CC   osteosclerosis, skin disorders, ichthyosis, eye disorders, (e.g. cataract
CC   and microopthalmia) and arthritis. The human NSDHL gene is located on
CC   chromosome X128. The present sequence is a primer for routine sequencing
CC   of and mutation detection in the human NSDHL gene (one of 8 exons or the
CC   non-coding region)
XX
SQ   Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCAAA 1887
              |||||||| |||||||
Db          2 GCCATTGACCTGTCAAA 18


RESULT 327
ADK81935
ID   ADK81935 standard; DNA; 20 BP.
XX
AC   ADK81935;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human PP10484 PCR primer #2.
XX
KW   human; 3T3 cell conversion promoting function;
KW   3T3 cell conversion promoting; PCR; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   CN1403476-A.
XX
PD   19-MAR-2003.
XX
PF   12-SEP-2001; 2001CN-00126724.
XX
PR   12-SEP-2001; 2001CN-00126724.
XX
PA   (SHAN-) SHANGHAI XINSHIJIE GENE TECHN DEV CO LTD.
XX
PI   Gu J,  Yang S;
XX
DR   WPI; 2003-494225/47.
XX
PT   Human protein with function of promoting 3T3 cell conversion and its
PT   coding sequence.
XX
PS   Example 2; SEQ ID NO 51; 41pp; Chinese.
XX
CC   The present invention describes human proteins (I) with 3T3 cell
```

```
CC   conversion promoting function. Also described are polynucleotides
CC   encoding (I) and the recombinant process of producing (I). The present
CC   invention also discloses the agonist resisting (I) and its treatment
CC   effect. The present sequence represents a PCR primer for a human 3T3 cell
CC   conversion promoting protein, which is used in an example from the
CC   present invention.
XX
SQ   Sequence 20 BP; 2 A; 7 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1674 CCCTGGACTTCTTAGTT 1690
                ||||  ||||||| ||||
Db          2 CCCTTGACTTCTGAGTT 18


RESULT 328
ABD26904
ID   ABD26904 standard; DNA; 20 BP.
XX
AC   ABD26904;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA678160-derived oligonucleotide SEQ ID 5916.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 5916; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 13 A; 2 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1973 ACCTTGAAAAAAAGAAA 1989
                | |||  ||||||||||
Db          4 ATCTTTAAAAAAAGAAA 20


RESULT 329
ABD24898
ID   ABD24898 standard; DNA; 20 BP.
XX
AC   ABD24898;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AI095492-derived oligonucleotide SEQ ID 3910.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 3910; 763pp; English.
XX
```

CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 6 A; 3 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1758 TTATTCATTAAGCTTTT 1774
||||||| || |||||
Db 1 TTATTCATGAAACTTTT 17

RESULT 330
ABD29353/c
ID ABD29353 standard; DNA; 20 BP.
XX
AC ABD29353;
XX
DT 29-JUL-2004 (first entry)
XX
DE AA001432-derived oligonucleotide SEQ ID 8365.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 8365; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1672 GCCCCTGGACTTCTTAG 1688
||||||||||||| ||
Db 18 GCCCCTGGACTTCCAAG 2

RESULT 331
ABD26123
ID ABD26123 standard; DNA; 20 BP.
XX
AC ABD26123;
XX
DT 29-JUL-2004 (first entry)
XX
DE AA463249-derived oligonucleotide SEQ ID 5135.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX

OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 5135; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 5 A; 2 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1764 ATTAAGCTTTTTTTTTT 1780
|||||| |||||||| ||
Db 1 ATTAAACTTTTTTTCTT 17

RESULT 332
ABD26737
ID ABD26737 standard; DNA; 20 BP.
XX
AC ABD26737;
XX
DT 29-JUL-2004 (first entry)
XX
DE N35316-derived oligonucleotide SEQ ID 5749.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 5749; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 8 A; 1 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 20;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1823 TTAGAATCTTTTAAATA 1839
              ||||||| ||||||| |
Db          1 TTAGAATTTTTTAAAGA 17
```

RESULT 333
ADP75399/c
ID ADP75399 standard; DNA; 20 BP.
XX
AC ADP75399;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human NRG2 gene exon F forward sequencing primer.
XX
KW Human; ss; primer; ADAM19; Endophilin 1; Endophilin 2; NRG2; ADAMTS2;
KW a disintegrin and metalloprotease; neuroregulin 2; SNP;
KW single nucleotide polymorphism;
KW a disintegrin and metalloprotease with thrombospondin type1 motif 2;
KW asthma; atopy; obesity; inflammatory bowel disease; respiratory disorder.
XX
OS Homo sapiens.
XX
PN WO2003031594-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032700.
XX
PR 11-OCT-2001; 2001US-0328424P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Keith T, Little RD, Van Eerdewegh P, Dupuis J, Del Mastro RG;
PI Allen K;
XX
DR WPI; 2003-381712/36.
XX
PT New isolated nucleic acid or alternate splice variant, useful for
PT diagnosing and treating a disintegrin and metalloprotease (ADAM) or
PT interactor gene-associated disorder, e.g. asthma, atopy, obesity or
PT inflammatory bowel disease.
XX
PS Claim 2; Page 128; 338pp; English.
XX
CC The invention relates to an isolated nucleic acid or alternate splice
CC variant comprising a nucleotide sequence containing at least one of the
CC single nucleotide polymorphisms given in the specification, a nucleotide
CC sequence having at least 15 contiguous nucleotides of them, or
CC complements of them. The genes are ADAM19 (a disintegrin and
CC metalloprotease 19, also known as gene 845), NRG2 (neuroregulin 2, also
CC known as gene 847), endophilin 1 (also known as gene 874), endophilin 2
CC (also known as gene 803) and ADAMTS2 (a disintegrin and metalloprotease
CC with thrombospondin type1 motif 2, also known as gene 962). Also included
CC are a vector comprising the isolated nucleic acid (or alternate splice
CC variant), a host cell containing the vector, an isolated polypeptide
CC encoded by the novel nucleic acid (or alternate splice variant), an
CC antibody or antibody fragment that binds to the polypeptide,
CC pharmaceutical compositions (comprising the nucleic acid or alternate
CC splice variant, vector, polypeptide or antibody , and a carrier,
CC excipient or diluent), a kit for detecting a disintegrin and
CC metalloprotease (ADAM) gene nucleotide sequence (comprising the isolated
CC nucleic acid or alternate splice variant, antibody or antibody fragment,
CC and at least one component to detect the hybridisation of the variant or
CC the binding of the antibody to an ADAM gene amino acid sequence), a kit
CC for detecting an interactor gene amino acid sequence (comprising the
CC antibody or antibody fragment, and at least one component to detect the
CC binding of the antibody to the interactor gene amino acid sequence),
CC diagnosing an ADAM or interactor gene-associated disorder or a
CC respiratory disorder in a human subject, determining an ADAM or
CC interactor gene pharmacogenetic profile in a human subject, identifying
CC an orthologue of a human ADAM or interactor gene, treating an ADAM or
CC interactor gene-associated disorder (or a respiratory disorder) by
CC administering the pharmaceutical composition, a transgenic mouse (whose
CC genome comprises an introduced null mutation in an endogenous gene that
CC is orthologous to a human ADAM gene), making a homozygous transgenic
CC knockout mouse, forming a crystal of the isolated polypeptide, a cell
CC line comprising the isolated nucleic acid or alternate splice variant, a
CC biochip comprising the isolated nucleic acid or alternate splice variant,
CC an isolated nucleic acid probe or primer comprising at least 8 contiguous
CC nucleotides of the nucleic acid, an isolated antisense nucleic acid,
CC identifying an ADAM or interactor gene ligand and an isolated nucleic
CC acid variant of Gene 803, 845, 847, 874 or 962. The nucleic acid or
CC alternate splice variants, methods, kits and antibody/antibody fragment
CC are useful for diagnosing and treating an ADAM or interactor gene-
CC associated disorder, e.g. asthma, atopy, obesity or inflammatory bowel
CC disease. The present sequence is a primer used to sequence the regions
CC surrounding polymorphisms in the above genes.
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

```
  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGTAC 1750
              |||||||||| ||| |
Db         18 CAGAAGGTGACTAGTTC 2
```

RESULT 334
ADI18956/c
ID ADI18956 standard; DNA; 20 BP.
XX
AC ADI18956;
XX
DT 22-APR-2004 (first entry)
XX
DE HIV-I gag1 gene amplifying primer #7.
XX
KW Human immune deficiency virus; HIV-1; drug-resistance; primer; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN US2003228574-A1.
XX
PD 11-DEC-2003.
XX
PF 28-APR-2003; 2003US-00425975.
XX
PR 01-SEP-2000; 2000US-0229790P.
PR 31-AUG-2001; 2001US-00944036.
XX
PA (YANG/) YANG Y Y.
PA (BREN/) BRENTANO S T.
PA (BABO/) BABOLA O.
PA (TRAN/) TRAN N.
PA (VERN/) VERNET G.
XX
PI Yang YY, Brentano ST, Babola O, Tran N, Vernet G;
XX
DR WPI; 2004-060998/06.
XX
PT New nucleic acid oligomer for amplifying and detecting HIV-1 nucleotide
PT sequences and in providing information about the infective agent, e.g.
PT genetic subgroup or drug-resistance phenotype based on detectable
PT sequence information.
XX
PS Claim 1; SEQ ID NO 47; 39pp; English.
XX
CC The present invention relates to a nucleic acid oligomer for amplifying a
CC nucleotide sequence of human immune deficiency virus (HIV)-1. The
CC invention is useful in amplifying and detecting HIV-1 nucleic acid
CC sequences and in providing additional information about the infective
CC agent, such as its genetic subgroup or drug-resistance phenotype based on
CC detectable sequence information. The present sequence is HIV-I gag1 gene

```
CC   amplifying primer.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         20 ATTATCAGAAGGAGCCA 4


RESULT 335
ADJ18839/c
ID   ADJ18839 standard; DNA; 20 BP.
XX
AC   ADJ18839;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 3389.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 3389; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || ||||||||||||  |
Db         18 TATCTTCTTCAGAGAAC 2


RESULT 336
ADJ18174
ID   ADJ18174 standard; DNA; 20 BP.
XX
AC   ADJ18174;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 2724.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
```

```
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 2724; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 10 A; 2 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGTG 1993
              |||  ||||||||||||
Db          1 TGAGCAAAAGAAAAGTG 17


RESULT 337
ADJ18857/c
ID   ADJ18857 standard; DNA; 20 BP.
XX
AC   ADJ18857;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 3407.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 3407; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 7 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || |||||||||||| |
Db         17 TATCTTCTTCAGAGAAC 1


RESULT 338
ADJ18351/c
ID   ADJ18351 standard; DNA; 20 BP.
XX
AC   ADJ18351;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 2901.
```

```
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 2901; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 8 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || |||||||||||  |
Db         19 TATCTTCTTCAGAGAAC 3


RESULT 339
ADJ18220/c
ID   ADJ18220 standard; DNA; 20 BP.
XX
AC   ADJ18220;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 2770.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 2770; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
```

```
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 8 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
                || ||||||||||||  |
Db         20 TATCTTCTTCAGAGAAC 4


RESULT 340
ADL32212/c
ID   ADL32212 standard; DNA; 20 BP.
XX
AC   ADL32212;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Clone specific PCR primer to amplify human full length cDNA SeqID 4245.
XX
KW   human; medicine; signal transduction; glycoprotein; transcription;
KW   oligo-capping method; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   EP1396543-A2.
XX
PD   10-MAR-2004.
XX
PF   07-JUL-2000; 2003EP-00025638.
XX
PR   08-JUL-1999;   99JP-00194486.
PR   11-JAN-2000; 2000JP-00118774.
PR   02-MAY-2000; 2000JP-00183865.
PR   07-JUL-2000; 2000EP-00114089.
XX
PA   (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI   Ota T,  Nishikawa T,  Isogai T,  Hayashi K,  Ishii S,  Kawai Y;
PI   Wakamatsu A,  Sugiyama T,  Nagai K,  Kojima S,  Otsuki T,  Koga H;
XX
DR   WPI; 2004-204755/20.
XX
PT   New oligonucleotide primers (830 cDNAs) useful for synthesizing full
PT   length human cDNAs.
XX
PS   Example 18; SEQ ID NO 4245; 1340pp; English.
XX
CC   This invention relates to a novel primers useful for synthesising full
CC   length cDNA molecules that encode human proteins. Specifically, it refers
CC   to secretory or membrane proteins that are potential therapeutic agents/
CC   target molecules in the field of medicine, and in particular genes
CC   encoding proteins that are associated with signal transduction,
CC   glycoproteins and transcription. The present invention describes a method
CC   for efficiently cloning a full length human cDNA from both the 5' and 3'
CC   ends using the oligo-capping method. This oligonucleotide sequence is a
CC   human clone specific PCR primer used in an exemplification of the
CC   invention.
XX
SQ   Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1647 AGCCTTCACTGGTTCTG 1663
                |||||||  |||  |||||
Db         20 AGCCTTCTCTGTTTCTG 4


RESULT 341
ADN36336/c
ID   ADN36336 standard; DNA; 20 BP.
XX
AC   ADN36336;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human ZNF365 gene exon 6-intron 6 boundary sequence.
XX
KW   ss; litholytic; nephrotropic; ZNF365; diagnosis; kidney stone; mutation;
KW   chromosome 10.
XX
OS   Homo sapiens.
XX
PN   WO2004035828-A2.
XX
PD   29-APR-2004.
XX
PF   14-OCT-2003; 2003WO-IT000627.
XX
PR   15-OCT-2002; 2002IT-RM000525.
XX
PA   (SHAR-) SHARDNA SPA.
XX
PI   Pirastu M,  Gianfrancesco F,  Esposito T,  Ombra MN;
XX
DR   WPI; 2004-348477/32.
XX
PT   New nucleic acids comprising at least one fragment of the human gene
PT   ZNF365 which encodes for a functional portion of ZNF365 proteins, useful
PT   for diagnosing or treating pathologies associated with kidney stones.
XX
PS   Disclosure; SEQ ID NO 13; 37pp; English.
XX
CC   The invention relates to a nucleic acid (I) comprising at least one
CC   fragment of the human gene ZNF365 which encodes for a functional portion
CC   of at least one of the proteins of the ZNF365 group, for use in the
CC   diagnosis or treatment of pathologies associated with kidney stones. The
CC   method further comprises detection of mutations in the ZNF365 genes which
CC   are associated with kidney stone pathologies. This sequence corresponds
CC   to an exon/intron boundary sequence from the ZNF365 gene.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTGAAAG 1808
                ||||||  |||||||||
Db         20 CTTTCCAGCTCTGAAAG 4


RESULT 342
ADP77805
ID   ADP77805 standard; DNA; 20 BP.
XX
AC   ADP77805;
XX
DT   12-AUG-2004  (first entry)
```

```
XX
DE   Chimeric phosphorothioate oligonucleotide #1604.
XX
KW   GFAT; Antidiabetic; Cardiant;
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag=  b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO,  Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 1604; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 4 A; 1 C; 2 G; 13 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||||||| ||||| |
Db          1 TTTTTCAGTTTTAAGTT 17


RESULT 343
ADP78705
ID   ADP78705 standard; DNA; 20 BP.
XX
AC   ADP78705;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #2504.
XX
KW   GFAT; Antidiabetic; Cardiant;
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag=  b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO,  Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 2504; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 6 A; 1 C; 2 G; 11 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||||||| ||||| |
Db          4 TTTTTCAGTTTTAAGTT 20


RESULT 344
ADP78526
ID   ADP78526 standard; DNA; 20 BP.
XX
AC   ADP78526;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #2325.
XX
KW   GFAT; Antidiabetic; Cardiant;
```

```
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag=  b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO,  Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 2325; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 4 A; 1 C; 2 G; 13 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||||||| ||||| |
Db          2 TTTTTCAGTTTTAAGTT 18


RESULT 345
ADP78568
ID   ADP78568 standard; DNA; 20 BP.
XX
AC   ADP78568;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #2367.
XX
KW   GFAT; Antidiabetic; Cardiant;
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag=  b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO,  Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 2367; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 5 A; 1 C; 2 G; 12 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||||||| ||||| |
Db          3 TTTTTCAGTTTTAAGTT 19


RESULT 346
ADN30105/c
ID   ADN30105 standard; DNA; 20 BP.
XX
AC   ADN30105;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human cytokine-inducible kinase antisense oligonucleotide #76.
XX
KW   cytostatic; antisense therapy; cytokine-inducible kinase;
KW   cytokine-inducible kinase inhibitor; antisense technology;
KW   cytokine-inducible kinase expression; hyperproliferative disorder; human;
KW   antisense oligonucleotide; ss.
XX
```

```
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004101857-A1.
XX
PD   27-MAY-2004.
XX
PF   23-NOV-2002; 2002US-00304116.
XX
PR   23-NOV-2002; 2002US-00304116.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Ward DT,  Dobie KW;
XX
DR   WPI; 2004-399685/37.
XX
PT   New antisense oligonucleotides useful for modulating Cytokine-inducible
PT   kinase expression, useful for diagnosing, preventing or treating
PT   conditions associated with aberrant kinase expression e.g.
PT   hyperproliferative disorders.
XX
PS   Example 15; SEQ ID NO 91; 56pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted to
CC   a nucleic acid molecule encoding Cytokine-inducible kinase. The compound
CC   specifically hybridises with the nucleic acid molecule encoding Cytokine-
CC   inducible kinase (which comprises a sequence of 2169 bp fully defined in
CC   the specification) and inhibits the expression of Cytokine-inducible
CC   kinase. Also described are: a method of inhibiting the expression of
CC   Cytokine-inducible kinase in cells or tissues, comprising contacting the
CC   cells or tissues with the new compound so that the expression of Cytokine
CC   -inducible kinase is inhibited; a method of screening for a modulator of
CC   Cytokine-inducible kinase, comprising contacting a preferred target
CC   segment of the nucleic acid encoding Cytokine-inducible kinase with one
CC   or more candidate modulators of Cytokine-inducible kinase, and
CC   identifying one or more modulators that modulate the expression of
CC   Cytokine-inducible kinase; a diagnostic method for identifying a disease
CC   state, comprising identifying the presence of Cytokine-inducible kinase
CC   in a sample using at least one of the primers or probe comprising the
CC   nucleotide sequences as mentioned in the specification; a kit or assay
CC   device comprising the above compound; and a method of treating an animal
CC   having a disease or condition associated with Cytokine-inducible kinase,
CC   comprising administering to the animal a therapeutic or prophylactic
CC   amount of the compound so that expression of Cytokine-inducible kinase is
CC   inhibited. The antisense oligonucleotide is useful for inhibiting the
CC   expression of Cytokine-inducible kinase in cells or tissues to prevent or
CC   treat diseases associated with the kinase expression, such as
CC   hyperproliferative disorders. In addition, the compound is used for
CC   diagnostics, prophylaxis, or as research reagents or kits. This sequence
CC   represents a human cytokine-inducible kinase antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGG 1612
                 ||||| |||||||| ||
Db         17 AACCCATCCTGGCCGGG 1

RESULT 347
ADP27401/c
ID   ADP27401 standard; DNA; 20 BP.
XX
AC   ADP27401;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Human SEDL antisense oligonucleotide seqid 33.
XX
KW   osteopathic; antisense therapy; spondyloepiphyseal dysplasia late; SEDL;
KW   SEDL associated disorder; bone growth disorder; human;
KW   antisense oligonucleotide; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004110160-A1.
XX
PD   10-JUN-2004.
XX
PF   10-DEC-2002; 2002US-00317280.
XX
PR   10-DEC-2002; 2002US-00317280.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW,  Sipes TB;
XX
DR   WPI; 2004-440348/41.
XX
PT   New antisense oligonucleotides for modulating spondyloepiphyseal
PT   dysplasia late (SEDL) expression, useful for diagnosing, preventing or
PT   treating diseases or conditions involving inappropriate bone growth.
XX
PS   Example 15; SEQ ID NO 33; 62pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted to
CC   a nucleic acid molecule encoding spondyloepiphyseal dysplasia late
CC   (SEDL). The compound specifically hybridises with the nucleic acid
CC   molecule encoding SEDL (which comprises a sequence of 2816 bp fully
CC   defined in the specification) and inhibits the expression of SEDL. Also
CC   described are: a method of inhibiting the expression of SEDL in cells or
CC   tissues; a method of screening for a modulator of SEDL; a diagnostic
CC   method for identifying a disease state; a kit or assay device comprising
CC   the above compound; and a method of treating an animal having a disease
CC   or condition associated with SEDL, comprising administering to the animal
CC   a therapeutic or prophylactic amount of the compound so that expression
CC   of SEDL is inhibited. The antisense oligonucleotide is useful for
CC   inhibiting the expression of SEDL in cells or tissues to prevent or treat
CC   diseases associated with aberrant SEDL expression, such as diseases or
CC   conditions involving inappropriate bone growth. In addition, the compound
CC   is used for diagnostics, prophylaxis, or as research reagents or kits.
CC   This sequence represents a human spondyloepiphyseal dysplasia late (SEDL)
CC   antisense oligonucleotide.
```

```
XX
SQ   Sequence 20 BP; 8 A; 1 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCT 1793
              ||| ||||||| |||||
Db         20 TTTATGAACCCAATTCT 4


RESULT 348
ADP27477
ID   ADP27477 standard; DNA; 20 BP.
XX
AC   ADP27477;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Human SEDL antisense oligonucleotide seqid 109.
XX
KW   osteopathic; antisense therapy; spondyloepiphyseal dysplasia late; SEDL;
KW   SEDL associated disorder; bone growth disorder; human;
KW   antisense oligonucleotide; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004110160-A1.
XX
PD   10-JUN-2004.
XX
PF   10-DEC-2002; 2002US-00317280.
XX
PR   10-DEC-2002; 2002US-00317280.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW,  Sipes TB;
XX
DR   WPI; 2004-440348/41.
XX
PT   New antisense oligonucleotides for modulating spondyloepiphyseal
PT   dysplasia late (SEDL) expression, useful for diagnosing, preventing or
PT   treating diseases or conditions involving inappropriate bone growth.
XX
PS   Example 15; SEQ ID NO 109; 62pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted to
CC   a nucleic acid molecule encoding spondyloepiphyseal dysplasia late
CC   (SEDL). The compound specifically hybridises with the nucleic acid
CC   molecule encoding SEDL (which comprises a sequence of 2816 bp fully
CC   defined in the specification) and inhibits the expression of SEDL. Also
CC   described are: a method of inhibiting the expression of SEDL in cells or
CC   tissues; a method of screening for a modulator of SEDL; a diagnostic
CC   method for identifying a disease state; a kit or assay device comprising
CC   the above compound; and a method of treating an animal having a disease
CC   or condition associated with SEDL, comprising administering to the animal
CC   a therapeutic or prophylactic amount of the compound so that expression
CC   of SEDL is inhibited. The antisense oligonucleotide is useful for
CC   inhibiting the expression of SEDL in cells or tissues to prevent or treat
CC   diseases associated with aberrant SEDL expression, such as diseases or
CC   conditions involving inappropriate bone growth. In addition, the compound
CC   is used for diagnostics, prophylaxis, or as research reagents or kits.
CC   This sequence represents a human spondyloepiphyseal dysplasia late (SEDL)
CC   antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 5 A; 6 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCT 1793
              ||| ||||||| |||||
Db          1 TTTATGAACCCAATTCT 17


RESULT 349
ADP82592/c
ID   ADP82592 standard; DNA; 20 BP.
XX
AC   ADP82592;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Human TSG101 antisense oligonucleotide, ISIS 180884.
XX
KW   Tumour susceptibility gene 101; TSG101; hyperproliferative disorder;
KW   cancer; gene therapy; human; antisense; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone in which all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) bases"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl (2'-MOE) bases"
XX
PN   US2004115638-A1.
XX
PD   17-JUN-2004.
XX
PF   11-DEC-2002; 2002US-00317649.
XX
PR   11-DEC-2002; 2002US-00317649.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-449379/42.
XX
PT   New oligonucleotide compound that inhibits expression of tumor
PT   susceptibility gene 101, useful for preparing a composition for treating
PT   hyperproliferative disorder, e.g., cancer.
XX
PS   Example 15; SEQ ID NO 47; 35pp; English.
XX
CC   The invention relates to compounds, compositions and methods for
CC   modulating the expression of tumour susceptibility gene 101 (TSG101). The
```

```
CC   composition comprise antisense oligonucleotides targeted to TSG101. The
CC   oligonucleotide compound is useful for preparing a composition for
CC   treating hyperproliferative disorder, e.g. cancer. It is also useful in
CC   gene therapy. The present sequence is an antisense oligonucleotide
CC   targeted to human TSG101 gene. This sequence is used to illustrate the
CC   method of the invention.
XX
SQ   Sequence 20 BP; 9 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 3.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1726 CCTATTATCAGAAGGTG 1742
                ||| ||||||| |||||
Db         17 CCTTTTATCAGTAGGTG 1


RESULT 350
AAV40572/c
ID   AAV40572 standard; DNA; 21 BP.
XX
AC   AAV40572;
XX
DT   21-DEC-1998  (first entry)
XX
DE   Human TSC gene exon 3 reverse primer hTSCex3.
XX
KW   Thiazide-sensitive Na-Cl cotransporter; TSC; hTSC gene; human;
KW   ion transport; Gitelman's syndrome; Bartter's syndrome;
KW   hypokalaemic alkalosis; hypocalciuria; hypomagnesemia; diagnosis;
KW   therapy; SSCP; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9829431-A1.
XX
PD   09-JUL-1998.
XX
PF   19-DEC-1997;   97WO-US023553.
XX
PR   31-DEC-1996;   96US-00778052.
XX
PA   (UYYA ) UNIV YALE.
XX
PI   Lifton RP,  Simon DB;
XX
DR   WPI; 1998-388029/33.
XX
PT   Thiazide sensitive cotransporter and ATP sensitive potassium channel
PT   genes - useful for developing products for the diagnosis and treatment of
PT   ion transport disorders, e.g. Gitelman's Syndrome or Bartter's Syndrome.
XX
PS   Example 1; Page 51; 105pp; English.
XX
CC   Primers hTSCex3 forward and reverse (see AAV40571 and AAV40572,
CC   respectively) are designed to amplify exon 3 of the human hTSC gene (see
CC   AAV40561) that codes for thiazide-sensitive Na-Cl cotransporter TSC (see
CC   AAW29682). Both primers are located within introns of hTSC. 27 Sets of
CC   specific primers (see AAV40565-V40618) were used for SSCP analysis of
CC   hTSC. Amplified products were analysed for molecular variants by
CC   electrophoresis, and identified variants were sequenced. Complete linkage
CC   of Gitelman's syndrome with TSC was demonstrated. Identification of the
CC   molecular basis of Gitelman's syndrome allows for the genetic diagnosis
CC   of this disorder. The invention provides products and methods useful for
CC   diagnosis and treatment of Gitelman's syndrome and other ion transport
CC   disorders
XX
SQ   Sequence 21 BP; 6 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1781 TGAACCCCATTCTTTCC 1797
                ||||  |||||||||  ||
Db         20 TGAATCCCATTCTTCCC 4


RESULT 351
AAZ73879/c
ID   AAZ73879 standard; DNA; 21 BP.
XX
AC   AAZ73879;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:8235.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1986; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 21 BP; 9 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2062 TTAATAAGTGGTATCTG 2078
                ||  ||||||  |||||||
Db         19 TTCATAAGTAGTATCTG 3


RESULT 352
```

```
AAZ75815
ID   AAZ75815 standard; DNA; 21 BP.
XX
AC   AAZ75815;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:10171.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 9; Page 2399; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 21 BP; 8 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACC 1583
              ||||| ||| |||||||
Db          1 AAAAAACCTGCTCCACC 17


RESULT 353
AAF96440
ID   AAF96440 standard; DNA; 21 BP.
XX
AC   AAF96440;
XX
DT   06-JUN-2001  (first entry)
XX
DE   Human gene single nucleotide polymorphism #1201.
XX
KW   Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW   polymorphism; vascular disease; coronary artery disease; forensics;
KW   myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW   pulmonary embolism; paternity test; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Variation       replace(11,A)
FT                   /*tag=  a
FT                   /standard_name= "single nucleotide polymorphism"
XX
PN   WO200118250-A2.
XX
PD   15-MAR-2001.
XX
PF   07-SEP-2000; 2000WO-US024503.
XX
PR   10-SEP-1999;   99US-0153357P.
PR   26-JUL-2000; 2000US-0220947P.
PR   16-AUG-2000; 2000US-0225724P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Lander ES,  Gargill M,  Ireland JS,  Bolk S,  Daley GQ,  Mccarthy JJ;
XX
DR   WPI; 2001-226749/23.
XX
PT   Nucleic acids comprising single nucleotide polymorphisms, useful in
PT   applications such as forensics, paternity testing, medicine, genetic
PT   analysis and phenotype correlations to diseases such as diabetes and
PT   atherosclerosis.
XX
PS   Example; Page 133; 242pp; English.
XX
CC   The present invention provides a method of diagnosing a vascular disease
CC   in an individual, involving determining the sequence at various
CC   polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC   genes. The sequences at a number of polymorphic sites are also provided
CC   in the specification. In particular, the method can be used in the
CC   diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC   disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC   pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC   useful in forensics, paternity testing, genetic analysis and phenotype
CC   correlations to diseases. The present sequence is an example of one of
CC   the human gene SNPS shown in the specification
XX
SQ   Sequence 21 BP; 6 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCC 1600
              || ||||| |||||||||
Db          1 GCTCAGACAGGGAACCC 17


RESULT 354
AAH28431
ID   AAH28431 standard; DNA; 21 BP.
XX
AC   AAH28431;
XX
DT   17-SEP-2001  (first entry)
XX
DE   PCR primer for intergenic spacer between 16S and 23S rRNA genes.
XX
KW   Intergenic spacer; Chlamydiaceae; 16S rRNA; 23S rRNA; Region A; Region B;
KW   chlamydial infection; PCR primer; ss.
XX
```

OS Chlamydia suis.
XX
PN US6261769-B1.
XX
PD 17-JUL-2001.
XX
PF 31-MAR-1998; 98US-00052333.
XX
PR 31-MAR-1998; 98US-00052333.
XX
PA (USDA) US SEC OF AGRIC.
XX
PI Everett KDE, Andersen AA;
XX
DR WPI; 2001-440857/47.
XX
PT New primers and probes derived from sequences of intergenic spacer
PT between 16S and 23S genes and region of Domain I in 23S region of
PT Chlamydiaceae, useful for assaying and identifying all strains of
PT Chlamydiaceae.
XX
PS Claim 2; Col 11; 89pp; English.
XX
CC The present PCR primer was used to amplify intergenic spacer target
CC sequences derived from Chlamydiaceae. The sequences comprise the
CC intergenic spacer between the 16S and the 23S rRNA genes, including the
CC far downstream end of the 16S and the far upstream end of the 23S domain
CC I flanking intergenic spacer (referred to as Region A), and secondarily,
CC a 131 bp region in the 3' end of Domain I (referred to as Region B). The
CC sequences provide suitable target sequences for developing probes and
CC primers which are useful for identifying and detecting Chlamydiaceae. The
CC primers and probes can be used to identify the presence of Chlamydiaceae
CC in a test sample, or to distinguish one strain from another, and for
CC diagnosing chlamydial infections in humans and animals
XX
SQ Sequence 21 BP; 5 A; 3 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 21;
Best Local Similarity 88.2%; Pred. No. 3.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1926 TTTTCAGTGTTAAGGTA 1942
              ||| || ||||||||||
Db          3 TTTGCATTGTTAAGGTA 19
```

RESULT 355
AASI1058
ID AAS11058 standard; DNA; 21 BP.
XX
AC AAS11058;
XX
DT 24-OCT-2001 (first entry)
XX
DE Bacterial 16s RNA antisense oligomer #24.
XX
KW Antisense; bacterial 16s ribosomal RNA; rRNA; bacterial infection; human;
KW food grain supplement; livestock; poultry; therapeutic; ss.
XX
OS Pseudomonas aeruginosa.
XX
PN WO200142457-A2.
XX
PD 14-JUN-2001.
XX
PF 29-NOV-2000; 2000WO-US042391.
XX
PR 29-NOV-1999; 99US-0168150P.
XX
PA (AVIB-) AVI BIOPHARMA INC.
XX
PI Iversen PL;
XX
DR WPI; 2001-457295/49.
XX
PT Antibacterial compound, useful for treating bacterial infections and as
PT livestock and poultry food supplement, comprises antisense
PT oligonucleotides complementary to bacterial 16S and 23S rRNA.
XX
PS Disclosure; Page 26; 62pp; English.
XX
CC AAS11035-AAS11157 represent the coding sequences of bacterial 16S
CC ribosomal RNA (rRNA) antisense oligomers. These sequences are
CC antibacterial compounds comprising substantially uncharged antisense
CC oligomers containing 8-40 nucleotide subunits, including a targeting
CC nucleic acid sequence at least 10 nucleotides in length which is
CC complementary to a bacterial 16S or 23S rRNA nucleic acid sequence. The
CC antisense oligomers are used for treating a bacterial infection in a
CC human or a mammalian animal produced by Escherichia coli, Salmonella
CC typhimurium, Pseudomonas aeruginosa, Vibrio cholera, Neisseria
CC gonorrhoea, Helicobacter pylori, Bartonella henselae, Haemophilus
CC influenza, Shigella dysenterae, Staphylococcus aureus, Mycobacterium
CC tuberculosis, Streptococcus pneumoniae, Treponema palladium and Chlamydia
CC trachomatis. The antibacterial compound may be used as a food grain
CC supplement in livestock and poultry food composition
XX
SQ Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.5%; Score 13.8; DB 1; Length 21;
Best Local Similarity 88.2%; Pred. No. 3.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       2009 CAGAGATCAAGTCCTCT 2025
              |||||| |||| |||||
Db          1 CAGAGAGCAAGCCCTCT 17
```

RESULT 356
ABK53146/c
ID ABK53146 standard; DNA; 21 BP.
XX
AC ABK53146;
XX
DT 29-AUG-2003 (revised)
DT 12-AUG-2002 (first entry)
XX
DE HIV-1 Gag gene specific oligonucleotide primer #10.
XX
KW HIV; human immunodeficiency virus; ss; primer; gag; pol; protease;
KW reverse transcriptase; infection; PCR.
XX
OS Human immunodeficiency virus 1.
XX
PN US2002055095-A1.
XX
PD 09-MAY-2002.
XX
PF 31-AUG-2001; 2001US-00944036.
XX
PR 01-SEP-2000; 2000US-0229790P.
XX
PA (YANG/) YANG Y Y.
PA (BREN/) BRENTANO S T.
PA (BABO/) BABOLA O.
PA (TRAN/) TRAN N.
PA (VERN/) VERNET G.
XX
PI Yang YY, Brentano ST, Babola O, Tran N, Vernet G;
XX
DR WPI; 2002-462902/49.
XX
PT New nucleic acid oligomers for amplifying a nucleotide sequence from HIV-
PT 1 and probes for detecting the amplified product are specific for gag and
PT pol regions and are useful to detect different subtypes of HIV-1.
XX
PS Claim 1; Page 27; 37pp; English.

```
XX
CC   This invention relates to a series of nucleic acid oligomers for
CC   amplifying and detecting a nucleotide sequence of human immunodeficiency
CC   virus type 1 (HIV-1). The invention also comprises a labeled
CC   oligonucleotide that specifically hybridises to an HIV-1 sequence derived
CC   from gag or pol sequences, having one of the sequences fully defined in
CC   the specification, and a method for detecting HIV-1 in a biological
CC   sample, comprising mixing the sample with two or more of the
CC   amplification oligomers that specifically amplify at least one HIV-1
CC   target sequence within gag and a pol sequence which is a protease or
CC   reverse transcriptase sequence, amplifying the target, and detecting the
CC   amplified product. The oligonucleotides of the invention may be used to
CC   diagnose HIV-1 infection. The presents sequence represents a PCR primer
CC   used to amplify the HIV-1 Gag gene in the HIV detection method of the
CC   invention. (Updated on 29-AUG-2003 to standardise OS field)
XX
SQ   Sequence 21 BP; 3 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 357
ABK53111/c
ID   ABK53111 standard; DNA; 21 BP.
XX
AC   ABK53111;
XX
DT   29-AUG-2003  (revised)
DT   12-AUG-2002  (first entry)
XX
DE   HIV-1 Gag gene specific oligonucleotide primer #3.
XX
KW   HIV; human immunodeficiency virus; ss; primer; gag; pol; protease;
KW   reverse transcriptase; infection; PCR.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US2002055095-A1.
XX
PD   09-MAY-2002.
XX
PF   31-AUG-2001; 2001US-00944036.
XX
PR   01-SEP-2000; 2000US-0229790P.
XX
PA   (YANG/) YANG Y Y.
PA   (BREN/) BRENTANO S T.
PA   (BABO/) BABOLA O.
PA   (TRAN/) TRAN N.
PA   (VERN/) VERNET G.
XX
PI   Yang YY,  Brentano ST,  Babola O,  Tran N,  Vernet G;
XX
DR   WPI; 2002-462902/49.
XX
PT   New nucleic acid oligomers for amplifying a nucleotide sequence from HIV-
PT   1 and probes for detecting the amplified product are specific for gag and
PT   pol regions and are useful to detect different subtypes of HIV-1.
XX
PS   Claim 1; Page 15; 37pp; English.
XX
CC   This invention relates to a series of nucleic acid oligomers for
CC   amplifying and detecting a nucleotide sequence of human immunodeficiency
CC   virus type 1 (HIV-1). The invention also comprises a labeled
CC   oligonucleotide that specifically hybridises to an HIV-1 sequence derived
CC   from gag or pol sequences, having one of the sequences fully defined in
CC   the specification, and a method for detecting HIV-1 in a biological
CC   sample, comprising mixing the sample with two or more of the
CC   amplification oligomers that specifically amplify at least one HIV-1
CC   target sequence within gag and a pol sequence which is a protease or
CC   reverse transcriptase sequence, amplifying the target, and detecting the
CC   amplified product. The oligonucleotides of the invention may be used to
CC   diagnose HIV-1 infection. The presents sequence represents a PCR primer
CC   used to amplify the HIV-1 Gag gene in the HIV detection method of the
CC   invention. (Updated on 29-AUG-2003 to standardise OS field)
XX
SQ   Sequence 21 BP; 3 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 358
AAL45508/c
ID   AAL45508 standard; DNA; 21 BP.
XX
AC   AAL45508;
XX
DT   29-AUG-2003  (revised)
DT   06-JUN-2002  (first entry)
XX
DE   HIV-1 gag amplification oligomer SEQ ID NO: 46.
XX
KW   HIV-1; gag gene; pol gene; PCR; primer; drug resistance; genetic subtype;
KW   probe; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO200220852-A1.
XX
PD   14-MAR-2002.
XX
PF   01-SEP-2000; 2000WO-US024117.
XX
PR   01-SEP-2000; 2000WO-US024117.
XX
PA   (GENP-) GEN-PROBE INC.
PA   (INMR ) BIOMERIEUX SA.
XX
PI   Yang YY,  Brentano ST,  Babola O,  Tran N,  Vernet G;
XX
DR   WPI; 2002-292273/33.
XX
PT   New nucleic acid oligomer, useful for detecting selected regions of gag
PT   and pol genes of human immune deficiency virus, particularly for
PT   assessing drug resistance.
XX
PS   Claim 1; Page 62; 82pp; English.
XX
CC   The present invention provides a number of nucleic acid oligomers which
CC   can be used to amplify the gag and pol genes of human immunodeficiency
CC   virus type I (HIV-1). These are used to detect regions of the gag and pol
CC   genes, especially regions associated with drug resistance, and also for
CC   identifying genetic subtypes of the virus. The present sequence is an
CC   oligomer of the invention. (Updated on 29-AUG-2003 to standardise OS
CC   field)
XX
SQ   Sequence 21 BP; 3 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
```

```
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 359
AAL45473/c
ID   AAL45473 standard; DNA; 21 BP.
XX
AC   AAL45473;
XX
DT   29-AUG-2003  (revised)
DT   06-JUN-2002  (first entry)
XX
DE   HIV-1 gag amplification oligomer SEQ ID NO: 11.
XX
KW   HIV-1; gag gene; pol gene; PCR; primer; drug resistance; genetic subtype;
KW   probe; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO200220852-A1.
XX
PD   14-MAR-2002.
XX
PF   01-SEP-2000; 2000WO-US024117.
XX
PR   01-SEP-2000; 2000WO-US024117.
XX
PA   (GENP-) GEN-PROBE INC.
PA   (INMR ) BIOMERIEUX SA.
XX
PI   Yang YY,  Brentano ST,  Babola O,  Tran N,  Vernet G;
XX
DR   WPI; 2002-292273/33.
XX
PT   New nucleic acid oligomer, useful for detecting selected regions of gag
PT   and pol genes of human immune deficiency virus, particularly for
PT   assessing drug resistance.
XX
PS   Claim 1; Page 40; 82pp; English.
XX
CC   The present invention provides a number of nucleic acid oligomers which
CC   can be used to amplify the gag and pol genes of human immunodeficiency
CC   virus type I (HIV-1). These are used to detect regions of the gag and pol
CC   genes, especially regions associated with drug resistance, and also for
CC   identifying genetic subtypes of the virus. The present sequence is an
CC   oligomer of the invention. (Updated on 29-AUG-2003 to standardise OS
CC   field)
XX
SQ   Sequence 21 BP; 3 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 360
ADE53231/c
ID   ADE53231 standard; DNA; 21 BP.
XX
AC   ADE53231;
XX
DT   29-JAN-2004  (first entry)
XX
DE   FEN-1 related DNA used within the scope of the invention, #367.
XX
KW   Flap endonuclease-1; FEN-1; endonuclease; structure-specific nuclease;
KW   invasive cleavage structure; thermostable; DNA polymerase; 5' nuclease;
KW   viral infection; bacterial infection; cancer; forensic analysis;
KW   paternity determination; ds.
XX
OS   Methanocaldococcus jannaschii.
XX
PN   WO200270755-A2.
XX
PD   12-SEP-2002.
XX
PF   15-NOV-2001; 2001WO-US044953.
XX
PR   15-NOV-2000; 2000US-00713601.
PR   17-NOV-2000; 2000US-00714935.
XX
PA   (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
PI   Lyamichev VI,  Kaiser MW,  Lyamicheva N;
XX
DR   WPI; 2002-750464/81.
XX
PT   New composition useful for detecting and characterizing nucleic acid
PT   sequences and sequence variants for detecting the presence of viral or
PT   bacterial infections or cancer, comprises purified or chimerical FEN-1
PT   endonuclease.
XX
PS   Example 65; SEQ ID NO 413; 871pp; English.
XX
CC   The invention discloses a new composition (I) which comprises a purified
CC   flap endonuclease-1 (FEN-1) from e.g. Sulfolobus solfataricus,
CC   Pyrobaculom aerophilum or a chimerical FEN-1 endonuclease having a
CC   portion of the above endonuclease in addition to that of Pyrococcus
CC   horikoshii and Aeropyrum pernix. Also claimed is a composition comprising
CC   an isolated nucleic acid sequence encoding the endonuclease mentioned
CC   above, a composition comprising a vector having the nucleic acid sequence
CC   cited above, a composition comprising a host cell and vector cited above,
CC   a mixture comprising a first structure-specific nuclease selected from
CC   the species mentioned in composition (I), and a purified second structure
CC   -specific nuclease and detecting a target sequence, comprising: (a)
CC   providing a sample suspected of containing the target sequence,
CC   oligonucleotides capable of forming an invasive cleavage structure in the
CC   presence of the target sequence, and a FEN-1 endonuclease selected from
CC   the species cited above and (b) exposing the sample to the
CC   oligonucleotides and FEN-1 endonuclease. The second structure-specific
CC   nuclease also comprises a thermostable DNA polymerase. It has a 5'
CC   nuclease derived from a DNA polymerase altered in amino acid sequence
CC   such that it exhibits reduced DNA synthetic activity from that of the
CC   wild-type DNA polymerase but retains substantially the same 5' nuclease
CC   activity of the wild-type DNA polymerase. The second structure is
CC   selected from CLEAVASE BN enzyme, CLEAVASE DA enzyme, CLEAVASE DN enzyme,
CC   CLEAVASE DV enzyme, CLEAVASE BN/thrombin enzyme, CLEAVASE TThDN enzyme,
CC   T. aquaticus DNA polymerase, T. thermophilus DNA polymerase, E. coli Exo
CC   III and S. cerevisiae Rad1/Rad10 complex. The nucleic acid treatment kit
CC   comprises (I) and oligonucleotides capable of forming an invasive
CC   cleavage structure in the presence of a target nucleic acid. The
CC   oligonucleotides comprise: (a) a first oligonucleotide having a 5'
CC   portion complementary to a first portion of a target nucleic acid and (b)
CC   a second oligonucleotide comprising a 5' portion complementary to a
CC   second portion of the target nucleic acid downstream of and contiguous to
CC   the first portion and a 3' portion. The 3' portion of the second
CC   oligonucleotide comprises a single 3' terminal nucleotide not
CC   complementary to the target nucleic acid. Additionally, the kit has a
CC   third oligonucleotide complementary to a third portion of the target
CC   nucleic acid upstream of the first portion of the first target nucleic
CC   acid. In detecting a target sequence, the oligonucleotides and
CC   endonuclease are mixed under conditions where an invasive cleavage
CC   structure is formed between the target sequence and the oligonucleotides
CC   if the target sequence is present in the sample, where the invasive
CC   cleavage structure is cleaved by the endonuclease to form a cleavage
CC   product. The composition is useful in detecting and characterising
CC   specific nucleic acid sequences and sequence variants which can be used
CC   in detecting the presence of viral or bacterial infections, and other
CC   diseases such as cancer. The composition may also be used in forensic
CC   analysis or for paternity determinations. The sequence presented is a FEN
CC   -1 related DNA used within the scope of the invention.
XX
```

```
SQ   Sequence 21 BP; 11 A; 3 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTGAA 1784
              |||| ||| ||||||||
Db         20 AGCTCTTTCTTTTTGAA 4


RESULT 361
ADF89599
ID   ADF89599 standard; DNA; 21 BP.
XX
AC   ADF89599;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human EGF motif containing polypeptide PCR primer #9.
XX
KW   cancer; lung cancer; brain cancer; prostate cancer; breast cancer;
KW   skin cancer; colon cancer; pancreatic cancer; ovarian cancer; lymphoma;
KW   leukaemia; sarcoma; human; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   US2003165886-A1.
XX
PD   04-SEP-2003.
XX
PF   01-MAY-2002; 2002US-00136227.
XX
PR   22-NOV-1997;   97US-00968800.
PR   12-FEB-1999;   99US-00249697.
PR   28-JUL-1999;   99US-00363316.
PR   13-OCT-2000; 2000US-00687860.
PR   15-OCT-2001; 2001US-00981649.
XX
PA   (FORD/) FORD J E.
PA   (YEUN/) YEUNG G.
PA   (ZHOU/) ZHOU H.
XX
PI   Ford JE,  Yeung G,  Zhou H;
XX
DR   WPI; 2003-898050/82.
XX
PT   Detecting a cancerous cell expressing the polynucleotide by detecting the
PT   complex, where the complex indicates the expression of polynucleotide in
PT   the cancerous cell and comparing the expression to a standard indicative
PT   of cancer.
XX
PS   Example 5; SEQ ID NO 25; 77pp; English.
XX
CC   The invention relates to a method of detecting a cancerous cell
CC   expressing the polynucleotide. The method is useful for detecting a
CC   cancerous cell and for preparing a composition for treating cancer e.g.
CC   lung, brain, prostate, breast, skin, colon, pancreatic or ovarian cancer,
CC   lymphoma, leukaemia or sarcoma. The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 21 BP; 6 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGAAGA 1619
              |||||| |||| |||||
Db          1 CCTGGCATGGGAGAAGA 17


RESULT 362
ADI18920/c
ID   ADI18920 standard; DNA; 21 BP.
XX
AC   ADI18920;
XX
DT   22-APR-2004  (first entry)
XX
DE   HIV-I gag1 gene amplifying primer #2.
XX
KW   Human immune deficiency virus; HIV-1; drug-resistance; primer; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US2003228574-A1.
XX
PD   11-DEC-2003.
XX
PF   28-APR-2003; 2003US-00425975.
XX
PR   01-SEP-2000; 2000US-0229790P.
PR   31-AUG-2001; 2001US-00944036.
XX
PA   (YANG/) YANG Y Y.
PA   (BREN/) BRENTANO S T.
PA   (BABO/) BABOLA O.
PA   (TRAN/) TRAN N.
PA   (VERN/) VERNET G.
XX
PI   Yang YY,  Brentano ST,  Babola O,  Tran N,  Vernet G;
XX
DR   WPI; 2004-060998/06.
XX
PT   New nucleic acid oligomer for amplifying and detecting HIV-1 nucleotide
PT   sequences and in providing information about the infective agent, e.g.
PT   genetic subgroup or drug-resistance phenotype based on detectable
PT   sequence information.
XX
PS   Claim 1; SEQ ID NO 11; 39pp; English.
XX
CC   The present invention relates to a nucleic acid oligomer for amplifying a
CC   nucleotide sequence of human immune deficiency virus (HIV)-1. The
CC   invention is useful in amplifying and detecting HIV-1 nucleic acid
CC   sequences and in providing additional information about the infective
CC   agent, such as its genetic subgroup or drug-resistance phenotype based on
CC   detectable sequence information. The present sequence is HIV-I gag1 gene
CC   amplifying primer.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 363
ADI18955/c
ID   ADI18955 standard; DNA; 21 BP.
XX
AC   ADI18955;
XX
DT   22-APR-2004  (first entry)
XX
DE   HIV-I gag1 gene amplifying primer #6.
XX
KW   Human immune deficiency virus; HIV-1; drug-resistance; primer; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US2003228574-A1.
```

```
XX
PD   11-DEC-2003.
XX
PF   28-APR-2003; 2003US-00425975.
XX
PR   01-SEP-2000; 2000US-0229790P.
PR   31-AUG-2001; 2001US-00944036.
XX
PA   (YANG/) YANG Y Y.
PA   (BREN/) BRENTANO S T.
PA   (BABO/) BABOLA O.
PA   (TRAN/) TRAN N.
PA   (VERN/) VERNET G.
XX
PI   Yang YY,  Brentano ST,  Babola O,  Tran N,  Vernet G;
XX
DR   WPI; 2004-060998/06.
XX
PT   New nucleic acid oligomer for amplifying and detecting HIV-1 nucleotide
PT   sequences and in providing information about the infective agent, e.g.
PT   genetic subgroup or drug-resistance phenotype based on detectable
PT   sequence information.
XX
PS   Claim 1; SEQ ID NO 46; 39pp; English.
XX
CC   The present invention relates to a nucleic acid oligomer for amplifying a
CC   nucleotide sequence of human immune deficiency virus (HIV)-1. The
CC   invention is useful in amplifying and detecting HIV-1 nucleic acid
CC   sequences and in providing additional information about the infective
CC   agent, such as its genetic subgroup or drug-resistance phenotype based on
CC   detectable sequence information. The present sequence is HIV-I gag1 gene
CC   amplifying primer.
XX
SQ   Sequence 21 BP; 3 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||  | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 364
ADJ97479/c
ID   ADJ97479 standard; DNA; 21 BP.
XX
AC   ADJ97479;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human Flt-1 DNA sequence, a target for siRNA inhibition SeqID 252.
XX
KW   human; ss; short interfering RNA; siRNA; angiogenesis;
KW   vascular endothelial growth factor; VEGF; VEGF receptor; Flt-1;
KW   Flk-1/KDR; kinase domain region; diabetic retinopathy;
KW   age-related macular degeneration; inflammatory disease; psoriasis;
KW   rheumatoid arthritis; cancer; breast; retinoblastoma; Wilm's tumour;
KW   lymphoma; cytostatic; antidiabetic; ophthalmological; antiinflammatory;
KW   antipsoriatic; antirheumatic; antiarthritic.
XX
OS   Homo sapiens.
XX
PN   WO2004009769-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022444.
XX
PR   24-JUL-2002; 2002US-0398417P.
PR   14-NOV-2002; 2002US-00294228.
XX
PA   (UYPE-) UNIV PENNSYLVANIA.
XX
PI   Tolentino MJ,  Reich SJ;
XX
DR   WPI; 2004-203472/19.
XX
PT   Novel short interfering RNA (siRNA) comprises sense and antisense RNA
PT   strands, useful for inhibiting expression of human vascular endothelial
PT   growth factor mRNA, for treating angiogenic disease, e.g. diabetic
PT   retinopathy and cancer.
XX
PS   Disclosure; SEQ ID NO 252; 218pp; English.
XX
CC   This invention relates to novel compositions that comprise short
CC   interfering RNA (siRNA) molecules, which can be used to inhibit
CC   angiogenesis. Specifically, it refers to siRNAs that target and cause
CC   RNAi-induced degradation of mRNA from human vascular endothelial growth
CC   factor (VEGF), the VEGF receptor (Flt-1) and the Flk-1/KDR (kinase domain
CC   region) genes, as well as mutants derived thereof. The present invention
CC   describes sense and antisense RNA strands that form an RNA duplex and
CC   bind to the target mRNA, such that expression is inhibited and the target
CC   degraded. As such, siRNA administered in combination with a therapeutic
CC   agent is useful for treating diseases associated with angiogenesis and
CC   the overexpression of VEGF, which include diabetic retinopathy, age-
CC   related macular degeneration, inflammatory disease, psoriasis and
CC   rheumatoid arthritis. Furthermore, it can be used to treat various
CC   cancers including breast, retinoblastoma, Wilm's tumour and lymphoma.
CC   Accordingly, these compositions exhibit cytostatic, antidiabetic,
CC   ophthalmological, antiinflammatory, antipsoriatic, antirheumatic and
CC   antiarthritic activities. This oligonucleotide is a human Flt-1 DNA
CC   oligo, a target for siRNA inhibition of the invention.
XX
SQ   Sequence 21 BP; 14 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 3.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              ||||||||||||  | |
Db         19 ATTCTTTCCTTCTATTA 3


RESULT 365
AAQ34754/c
ID   AAQ34754 standard; DNA; 20 BP.
XX
AC   AAQ34754;
XX
DT   25-MAR-2003  (revised)
DT   03-JUN-1993  (first entry)
XX
DE   Blocker oligonucleotide CFTR(C).
XX
KW   Cystic Fibrosis transregulator; assay; ss.
XX
OS   Synthetic.
XX
PN   WO9301313-A1.
XX
PD   21-JAN-1993.
XX
PF   06-JUL-1992;   92WO-GB001229.
XX
PR   05-JUL-1991;   91GB-00014525.
XX
PA   (CYTO-) CYTOCELL LTD.
XX
PI   Cardy DLN,  Delnatte SYJ;
XX
DR   WPI; 1993-045514/05.
XX
PT   Homogeneous assay for nucleic acid sequences - obtd. by modulating enzyme
```

```
PT   activity, by hybridisation of derived nucleic acid probes.
XX
PS   Example 1; Page 22; 51pp; English.
XX
CC   The blocker oligonucleotide CFTR(C) comprises a sequence complementary to
CC   a site on the CFTR gene adjacent to that of the activator oligonucleotide
CC   probes CFRT(A) and CFA508(A). The nucleotide was synthesised with a 5'
CC   bromodeoxyuridine nucleoside and may be used in an assay for the
CC   detection of Cystic Fibrosis transregulator (CFTR) related genes in human
CC   DNA. See also AAQ34750-62. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 20 BP; 9 A; 2 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1994 TGTATCTAGCTTCTTCAGAG 2013
                ||||||||  ||| ||| ||
Db         20 TGTATCTATATTCATCATAG 1


RESULT 366
AAV57186/c
ID   AAV57186 standard; DNA; 20 BP.
XX
AC   AAV57186;
XX
DT   25-MAR-2003  (revised)
DT   06-JAN-1999  (first entry)
XX
DE   Human Notch-3 mutant gene primer #23.
XX
KW   Human; Notch3; transmembrane receptor; lateral inhibition; regulation;
KW   developmental cascade; neurogenic gene; mutant; neurological disorder;
KW   cerebral autosomal dominant arteriopathy; subcortical infarct; CADASIL;
KW   leukoencephalopathy; therapy; PCR; primer; amplification; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   FR2751985-A1.
XX
PD   06-FEB-1998.
XX
PF   01-AUG-1996;   96FR-00009733.
XX
PR   01-AUG-1996;   96FR-00009733.
XX
PA   (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX
PI   Tournier LE,  Joutel A,  Bousser MG,  Bach JF;
XX
DR   WPI; 1998-133137/13.
XX
PT   Human Notch3 nucleic acids - and methods for identifying pre-disposition
PT   to cerebral autosomal dominant arteriopathy with sub-cortical infarcts
PT   and leukoencephalopathy.
XX
PS   Example 3; Page 21; 42pp; French.
XX
CC   Primers AAV57164-V57197 are used to detect mutations in a partial human
CC   Notch-3 gene (AAV57163). Primers AAV57186-V57187 amplify a fragment from
CC   exon N17. Notch3 is a transmembrane receptor protein involved in lateral
CC   inhibition and regulating developmental cascades of neurogenic genes.
CC   Mutated Notch3 proteins are thought to be involved in neurological
CC   disorders, especially of the cerebral autosomal dominant arteriopathy
CC   with subcortical infarcts and leukoencephalopathy (CADASIL) type.
CC   Blocking expression of a mutated Notch3 gene or by substitution therapy
CC   with non-mutated Notch3 gene or protein can be used to treat CADASIL or
CC   related disorders. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ   Sequence 20 BP; 1 A; 8 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAACA 1559
                ||||||||  |   |||||||
Db         20 AGGAGAGTGGCACAGGAACA 1


RESULT 367
AAV57115/c
ID   AAV57115 standard; DNA; 20 BP.
XX
AC   AAV57115;
XX
DT   25-MAR-2003  (revised)
DT   21-DEC-1998  (first entry)
XX
DE   Human Notch3 mutant gene primer N7F.
XX
KW   Human; Notch3; transmembrane receptor; lateral inhibition; regulation;
KW   developmental cascade; neurogenic gene; mutant; neurological disorder;
KW   cerebral autosomal dominant arteriopathy; subcortical infarct; CADASIL;
KW   leukoencephalopathy; therapy; PCR; primer; amplification; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   FR2751986-A1.
XX
PD   06-FEB-1998.
XX
PF   16-APR-1997;   97FR-00004680.
XX
PR   01-AUG-1996;   96FR-00009733.
XX
PA   (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX
PI   Tournier LE,  Joutel A,  Bousser MG,  Bach JF;
XX
DR   WPI; 1998-133138/13.
XX
PT   Human Notch3 nucleic acids - and methods for identifying pre-disposition
PT   to cerebral autosomal dominant arteriopathy with sub-cortical infarcts
PT   and leukoencephalopathy.
XX
PS   Example 3; Page 24; 45pp; French.
XX
CC   Primers AAV57066-V57162 are used to detect mutations in the human Notch3
CC   gene (AAV57001). Primers AAV57115-V57116 amplify a 249 bp fragment from
CC   the EGF27-28 domain sequences found in exon 20. Notch3 is a transmembrane
CC   receptor protein involved in lateral inhibition and regulating
CC   developmental cascades of neurogenic genes. Mutated Notch3 proteins are
CC   thought to be involved in neurological disorders, especially of the
CC   cerebral autosomal dominant arteriopathy with subcortical infarcts and
CC   leukoencephalopathy (CADASIL) type. Blocking expression of a mutated
CC   Notch3 gene or by substitution therapy with non-mutated Notch3 gene or
CC   protein can be used to treat CADASIL or related disorders. (Updated on 25
CC   -MAR-2003 to correct PI field.)
XX
SQ   Sequence 20 BP; 1 A; 8 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAACA 1559
                ||||||||  |   |||||||
Db         20 AGGAGAGTGGCACAGGAACA 1


RESULT 368
```

```
AAZ31349
ID   AAZ31349 standard; DNA; 20 BP.
XX
AC   AAZ31349;
XX
DT   24-JAN-2000  (first entry)
XX
DE   CXCR4 gene inhibiting antisense oligo AS(s)-106.
XX
KW   HIV cofactor inhibitor; HIV infection; CXCR4 gene; CCR5 gene;
KW   drug composition; antisense; ss.
XX
OS   Synthetic.
XX
PN   WO9951751-A1.
XX
PD   14-OCT-1999.
XX
PF   01-APR-1999;   99WO-JP001722.
XX
PR   02-APR-1998;   98JP-00125452.
XX
PA   (MARI-) MARINE BIO CO LTD.
XX
PI   Takaku H,  Yamamoto N,  Kimura T,  Takai K,  Wada A;
XX
DR   WPI; 1999-620207/53.
XX
PT   Antisense oligonucleotide-based HIV cofactor inhibitors, as drug
PT   compositions for treatment of HIV infection.
XX
PS   Claim 6; Page 18; 59pp; Japanese.
XX
CC   The invention provides HIV cofactor inhibitors that contain
CC   oligonucleotides with a base sequence complementary to the CXCR4 or CCR5
CC   genes. Such inhibitors can be formulated into drug compositions for
CC   prevention or treatment of HIV infection, with inhibition of expression
CC   of CXCR4 or/and CCR5 gene. Sequences AAZ31307-362 represent antisense
CC   oligonucleotides to the CXCR4 gene
XX
SQ   Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
                || | |||||||||| || |
Db          1 TTGTCTGAACCCCATCCTCT 20


RESULT 369
AAX33699/c
ID   AAX33699 standard; DNA; 20 BP.
XX
AC   AAX33699;
XX
DT   25-JUN-1999  (first entry)
XX
DE   DNA tandem nucleotide repeat locus PCR primer SEQ ID NO 29.
XX
KW   DNA tandem nucleotide repeat locus; human; DTNR allele; genetic mapping;
KW   genetic identity detection; forensic identification; paternity testing;
KW   PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9914375-A2.
XX
PD   25-MAR-1999.
XX
PF   18-SEP-1998;   98WO-US019578.
XX
PR   19-SEP-1997;   97US-0059415P.
XX
PA   (GENE-) GENETRACE SYSTEMS INC.
XX
PI   Butler JM,  Li J,  Monforte J,  Becker CA;
XX
DR   WPI; 1999-229554/19.
XX
PT   Analysis of DNA tandem nucleotide repeat alleles by extending a target
PT   nucleic acid using primers and analysis by mass spectrometry.
XX
PS   Claim 99; Page 25; 136pp; English.
XX
CC   This sequence represents a PCR primer for a DNA tandem nucleotide repeat
CC   (DTNR) locus that can be used in the method of the invention. The method
CC   is for analysing DTNR alleles in a target nucleic acid, and comprises
CC   extending the target nucleic acid using primers complementary to
CC   sequences flanking the repeat and analysis by mass spectrometry. The
CC   products and methods can be used for genetic identity detection including
CC   forensic identification and paternity testing as well as genetic mapping.
CC   The use of mass spectrometry for characterising DTNRs provides for high
CC   speed of analysis (a few seconds per sample) and accurate direct mass
CC   measurements
XX
SQ   Sequence 20 BP; 1 A; 10 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAACAGG 1561
                | || || || |||||||||
Db         20 GGGAATAAGGGAGGAACAGG 1


RESULT 370
AAZ04150
ID   AAZ04150 standard; DNA; 20 BP.
XX
AC   AAZ04150;
XX
DT   07-OCT-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW   Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW   paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW   nongonococcal uretritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW   bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS   Synthetic.
OS   Chlamydia trachomatis.
XX
PN   WO9928475-A2.
XX
PD   10-JUN-1999.
XX
PF   27-NOV-1998;   98WO-IB001939.
XX
PR   28-NOV-1997;   97FR-00015041.
PR   17-DEC-1997;   97FR-00016034.
PR   04-NOV-1998;   98US-0107077P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-371125/31.
XX
PT   Genome sequence of Chlamydia trachomatis.
XX
PS   Disclosure; Page 1665; 1755pp; English.
```

```
XX
CC   PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC   (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC   encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC   against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC   be used to control growth of the microorganism. Chlamydia trachomatis is
CC   responsible for a large number of diseases, e.g. eye diseases such as
CC   conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC   conjunctivitis; genital diseases such as nongonococcal uretritis,
CC   epidymitis, cervicitis, salpingitis, perihepatitis, bartholinitis;
CC   pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC   The polypeptides of the invention may be of use in treating these
CC   diseases
XX
SQ   Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1560 GGACTGCAAAAATCCTTCTC 1579
              || || |||||| | |||||
Db          1 GGGCTTCAAAAAGCGTTCTC 20


RESULT 371
AAZ06015
ID   AAZ06015 standard; DNA; 20 BP.
XX
AC   AAZ06015;
XX
DT   07-OCT-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW   Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW   paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW   nongonococcal uretritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW   bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS   Synthetic.
OS   Chlamydia trachomatis.
XX
PN   WO9928475-A2.
XX
PD   10-JUN-1999.
XX
PF   27-NOV-1998;   98WO-IB001939.
XX
PR   28-NOV-1997;   97FR-00015041.
PR   17-DEC-1997;   97FR-00016034.
PR   04-NOV-1998;   98US-0107077P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-371125/31.
XX
PT   Genome sequence of Chlamydia trachomatis.
XX
PS   Disclosure; Page 1818; 1755pp; English.
XX
CC   PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC   (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC   encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC   against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC   be used to control growth of the microorganism. Chlamydia trachomatis is
CC   responsible for a large number of diseases, e.g. eye diseases such as
CC   conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC   conjunctivitis; genital diseases such as nongonococcal uretritis,
CC   epidymitis, cervicitis, salpingitis, perihepatitis, bartholinitis;
CC   pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC   The polypeptides of the invention may be of use in treating these
CC   diseases
XX
SQ   Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1560 GGACTGCAAAAATCCTTCTC 1579
              || || |||||| | |||||
Db          1 GGGCTTCAAAAAGCGTTCTC 20


RESULT 372
AAZ18677/c
ID   AAZ18677 standard; DNA; 20 BP.
XX
AC   AAZ18677;
XX
DT   19-OCT-1999  (first entry)
XX
DE   ASTH1 gene intron/exon junction sequence.
XX
KW   ASTH1; asthma; human; chromosome 11p; ASTH1I; ASTHIJ; genetic locus;
KW   therapeutic; immunogen; polymorphism; junction; ss.
XX
OS   Homo sapiens.
XX
PN   WO9937809-A1.
XX
PD   29-JUL-1999.
XX
PF   21-JAN-1998;   98WO-US001260.
XX
PR   21-JAN-1998;   98WO-US001260.
XX
PA   (AXYS-) AXYS PHARM INC.
XX
PI   Brooks-Wilson AR,  Buckler A,  Cardon L,  Carey AH,  Galvin M;
PI   Miller A,  North M;
XX
DR   WPI; 1999-479058/40.
XX
PT   Mammalian asthma related genes, useful for diagnosis of a predisposition
PT   to development of asthma.
XX
PS   Disclosure; Page 58; 195pp; English.
XX
CC   The invention identifies a genetic locus ASTH1, associated with asthma,
CC   mapped to human chromosome 11p. ASTH1I and ASTHIJ are genes present
CC   within the locus, located close to each other on human chromosome 11p,
CC   and have similar patterns of expression, and common sequence motifs. The
CC   ASTH1 genes and fragments, encoded protein, genomic regulatory regions
CC   and anti-ASTH1 antibodies are useful in the identification of individuals
CC   predisposed to development of asthma, and for the modulation of gene
CC   activity in vivo for prophylactic and therapeutic purposes. The ASTH1
CC   protein is useful as an immunogen to raise specific antibodies, in drug
CC   screening for compositions that mimic or modulate ASTH1 activity or
CC   expression, including altered forms of ASTH1 protein, and as a
CC   therapeutic. Sequences AAZ18643-Z18685 intron/exon junction sequences of
CC   ASTH1I and ASTH1J genes
XX
SQ   Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1619 AGTTTGTTACCTACCTTACT 1638
              |||| |||||||||  | ||
Db         20 AGTTAGTTACCTACTGTGCT 1
```

```
RESULT 373
AAZ71396
ID   AAZ71396 standard; DNA; 20 BP.
XX
AC   AAZ71396;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:5752.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1457; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 20 BP; 7 A; 0 C; 11 G; 2 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGGGAAG 1554
              || | ||||| | |||||||
Db          1 AGATGAGGAGTGGAGGGAAG 20


RESULT 374
AAA80059/c
ID   AAA80059 standard; DNA; 20 BP.
XX
AC   AAA80059;
XX
DT   20-NOV-2000  (first entry)
XX
DE   Hepatitis B virus related oligonucleotide probe #322.
XX
KW   Hepatitis B virus; HBV; Hepatitis A virus; HAV; probe; detection;
KW   mutation; high-density gene chip; ss.
XX
OS   Hepatitis B virus.
XX
PN   CN1252452-A.
XX
PD   10-MAY-2000.
XX
PF   24-SEP-1999;   99CN-00114460.
XX
PR   24-SEP-1999;   99CN-00114460.
XX
PA   (UYDO-) UNIV DONGNAN.
XX
PI   Sun X,  Lu Z,  Wang Y;
XX
DR   WPI; 2000-443233/39.
XX
PT   High-density gene chip making process.
XX
PS   Example 1; Fig 15; 19pp; Chinese.
XX
CC   The present invention describes a method which comprises making a high-
CC   density gene chip, specifically for making high-density micro-array of
CC   oligonucleotide probes. An oligonucleotide probe selecting process to
CC   seek preferentially length variable and coverage variable probes is
CC   provided to ensure identical cross melting temperature of probes to the
CC   maximum limit, and this can make the cross control of gene chip
CC   relatively simple and raise the reliability of the gene chip detecting
CC   results. The process proposes a specific probe selection method for
CC   detecting target sequence directly, detecting mutation in both specific
CC   and non-specific sites and a probe overall arrangement scheme. AAA79738
CC   to AAA80201 represent oligonucleotide probe sequences which are used in
CC   examples from the present invention
XX
SQ   Sequence 20 BP; 11 A; 5 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1678 GGACTTCTTAGTTGTTTCTC 1697
              || |||||| ||||||  ||
Db         20 GGTCTTCTTGGTTGTTCTTC 1


RESULT 375
AAC93192
ID   AAC93192 standard; DNA; 20 BP.
XX
AC   AAC93192;
XX
DT   15-FEB-2001  (first entry)
XX
DE   Human STAT3 phosphorothioate antisense oligonucleotide SEQ ID NO:43.
XX
KW   Human; mouse; STAT3; phosphorothioate; antisense oligonucleotide;
KW   modulation; signal transducer and activator of transcription;
KW   DNA-binding protein; signal transduction; inhibition; apoptosis;
KW   inflammatory disease; cancer; antiinflammatory; antirheumatic;
KW   cytostatic; immunostimulatory; rheumatoid arthritis; leukaemia; myeloma;
KW   melanoma; lymphoma; diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061602-A1.
XX
PD   19-OCT-2000.
XX
```

```
PF   06-APR-2000; 2000WO-US009054.
XX
PR   08-APR-1999;   99US-00288461.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Karras JG;
XX
DR   WPI; 2000-619223/59.
XX
PT   New antisense compound for inhibiting the expression of signal transducer
PT   and activator of transcription 3 (STAT3) in cells or tissues and treating
PT   diseases or condition associated with STAT3, such as rheumatoid arthritis
PT   and cancer.
XX
PS   Example 2; Page 47; 104pp; English.
XX
CC   The present invention describes an antisense compound (I), 8 to 30
CC   nucleobases in length, that is targeted to a nucleic acid molecule
CC   encoding STAT3 (Signal Transducer and Activator of Transcription) and
CC   which inhibits the expression of it. (I) has antiinflammatory,
CC   antirheumatic, cytostatic and immunostimulatory activities. (I) is used
CC   for inhibiting the expression of STAT3 in cells or tissues, treating an
CC   animal having a disease or condition associated with STAT3 or a human
CC   having a disease or condition characterised by a reduction in apoptosis,
CC   and inducing apoptosis in a cell. Diseases or conditions that are treated
CC   are rheumatoid arthritis, cancer of the breast, prostate, brain, head
CC   and/or neck, leukaemia, myeloma, melanoma or lymphoma. (I) can also be
CC   used for diagnostic methods in detecting and determining the role of
CC   STAT3 in various cell functions, physiological processes and conditions
CC   and for diagnosing the conditions associated with expression of STAT3.
CC   (I) can be used alone or with other drugs as an immunostimulator. (I) is
CC   used in sandwich and colourimetric assays, involving enzyme conjugation
CC   and radiolabeling and is used in diagnostic kits. AAC93150 encodes human
CC   STAT3 and AAC93231 encodes mouse STAT3 as given in the exemplification of
CC   the present invention. AAC93151 to AAC93230 and AAC93232 to AAC93299
CC   represent STAT3 phosphorothioate antisense oligonucleotides, and AAC93300
CC   represents a mismatch control oligonucleotide which are used in example
CC   from the present invention
XX
SQ   Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGGCTCTTTA 1760
              ||||||| | ||| ||| ||
Db          1 TGACAAGGAGTGGGTCTCTA 20


RESULT 376
AAA80584/c
ID   AAA80584 standard; DNA; 20 BP.
XX
AC   AAA80584;
XX
DT   22-NOV-2000  (first entry)
XX
DE   Human ASTH1J gene exon e 3' boundary region.
XX
KW   ASTH1 locus; ASTH1J; human; chromosome 11p; asthma;
KW   bronchial hyperreactivity; ets family; transcription factor;
KW   splice variant; genetic predisposition; polymorphism; antibody;
KW   drug screening; prophylaxis; therapy; diagnosis; exon boundary; ss.
XX
OS   Homo sapiens.
XX
PN   US6087485-A.
XX
PD   11-JUL-2000.
XX
PF   21-JAN-1998;   98US-00009913.
XX
PR   21-JAN-1997;   97US-0035663P.
PR   01-JUL-1997;   97US-0051432P.
XX
PA   (AXYS-) AXYS PHARM INC.
XX
PI   Galvin M, Miller A, North M, Cardon L, Buckler A;
PI   Brooks-Wilson AR, Carey AH;
XX
DR   WPI; 2000-505109/45.
XX
PT   New nucleic acids other than naturally occurring chromosomes encoding
PT   ASTH1 protein, for e.g. screening compositions that modulate expression
PT   or function of ASTH1 proteins or as diagnostics for genetic
PT   predisposition to asthma.
XX
PS   Example; Col 38; 131pp; English.
XX
CC   The invention relates to the ASTH1 locus on the short arm of human
CC   chromosome (11p). This locus comprises the ASTH1I and ASTH1J genes, which
CC   are associated with a genetic predisposition to asthma and bronchial
CC   hyperreactivity. The ASTH1I and ASTH1J genes are oriented in opposite
CC   directions with the ASTH1 locus, and have similar patterns of expression
CC   and common sequence motifs. They are both expressed in trachea, lung and
CC   several other tissues. ASTH1I and ASTH1J are novel members of the ets
CC   family of transcription factors, which have been implicated in the
CC   activation of a variety of genes including the TCRa gene and cytokine
CC   genes known to be important in the aetiology of asthma. Both ASTH1I and
CC   ASTH1J mRNAs are alternatively spliced. Alternative splicing of
CC   transcripts has no effect on the open reading frame of ASTH1J, as the
CC   exons involved are all 5' to the start codon in exon b. In contrast,
CC   alternative splicing of ASTH1I transcripts results in 3 different ASTH1I
CC   isoforms. The invention also encompasses mouse asth1j protein. The ASTH1
CC   nucleic acids are useful as diagnostics to identify a hereditary
CC   predisposition to asthma, as probes for identifying ASTH1 related genes,
CC   for identifying expression of the gene in a biological specimen, and for
CC   generating genetically modified non-human animals or site specific gene
CC   modifications in cell lines. The encoded ASTH1 proteins are useful as
CC   immunogens to raise specific antibodies; in drug screening for
CC   compositions that mimic or modulate activity or expression of ASTH1I
CC   and/or ASTH1J (including altered forms of these proteins); and as a
CC   therapeutic. The ASTH1 genes or fragments thereof, encoded proteins,
CC   ASTH1 genomic regulatory regions, and anti-ASTH1I and anti-ASTH1J
CC   antibodies are useful in the identification of individuals predisposed to
CC   development of asthma, and for modulation of gene activity in vivo for
CC   prophylactic and therapeutic purposes. The intact ASTH1I or ASTH1J
CC   proteins or active fragments thereof may be used to modulate or reduce
CC   bronchial hyperreactivity. Sequences AAA80571-A80594 represent the exon
CC   boundary regions of the human ASTH1J gene
XX
SQ   Sequence 20 BP; 8 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1619 AGTTTGTTACCTACCTTACT 1638
              |||| |||||||||  | ||
Db         20 AGTTAGTTACCTACTGTGCT 1


RESULT 377
AAF73008/c
ID   AAF73008 standard; DNA; 20 BP.
XX
AC   AAF73008;
XX
DT   24-APR-2001  (first entry)
XX
DE   Human daxx inhibitory antisense phosphorothioate oligonucleotide SEQ:109.
XX
KW   Antisense oligonucleotide; daxx; inhibition; phosphorothioate;
KW   Fas binding protein; CENP-C binding protein; dap6; EAP; cytostatic;
```

```
KW   antiinflammatory; death associated protein 6; Ets-1 associated protein;
KW   infection; inflammation; tumour formation; ss.
XX
OS   Homo sapiens.
XX
PN   US6180353-B1.
XX
PD   30-JAN-2001.
XX
PF   24-JAN-2000; 2000US-00490692.
XX
PR   24-JAN-2000; 2000US-00490692.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Cowsert LM;
XX
DR   WPI; 2001-217744/22.
XX
PT   Novel antisense compounds capable of modulating expression of daxx useful
PT   for diagnosis, prophylaxis and treatment of diseases associated with
PT   expression of daxx.
XX
PS   Claim 1; Col 47; 59pp; English.
XX
CC   The present invention describes an antisense compound (I) up to 30
CC   nucleobases in length, where (I) inhibits expression of daxx (also known
CC   as Fas binding protein, CENP-C binding protein, dap6 for death associated
CC   protein 6 and EAP for Ets-1 associated protein). (I) has cytostatic and
CC   antiinflammatory activity, and can be used in antisense therapy and as a
CC   modulator of daxx. (I) is useful for inhibiting the expression of daxx in
CC   cells or tissues in vitro. (I) can be utilised for diagnostics,
CC   therapeutics for the treatment of diseases associated with the expression
CC   of daxx, prophylaxis e.g. to prevent or delay infection, inflammation or
CC   tumour formation and as research reagent. The present sequence represents
CC   an inhibitory human daxx antisense phosphorothioate oligonucleotide which
CC   is used in the exemplification of the present invention
XX
SQ   Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1992 TGTGTATCTAGCTTCTTCAG 2011
              ||||| ||| || ||| |||
Db         20 TGTGTTTCTGGCCTCTGCAG 1


RESULT 378
AAH56570
ID   AAH56570 standard; DNA; 20 BP.
XX
AC   AAH56570;
XX
DT   06-SEP-2001  (first entry)
XX
DE   S. pneumoniae groE operon antisense oligonucleotide SEQ ID NO:218.
XX
KW   Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
KW   microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
KW   Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
KW   antibacterial; antiviral; antiproliferative; antisense therapy;
KW   microbial infection; ss.
XX
OS   Streptococcus pneumoniae.
XX
PN   WO200136625-A2.
XX
PD   25-MAY-2001.
XX
PF   20-NOV-2000; 2000WO-CA001347.
XX
PR   18-NOV-1999;  99US-0166249P.
XX
PA   (GENE-) GENESENSE TECHNOLOGIES INC.
XX
PI   Wright JA,  Young AH,  Dugourd D;
XX
DR   WPI; 2001-355633/37.
XX
PT   Novel antisense compounds targeting nucleic acid encoding groEL or groES
PT   gene of microorganism, which hybridize with and inhibit expression of the
PT   genes, useful to inhibit growth of microorganism having the genes.
XX
PS   Claim 3; Page 46; 110pp; English.
XX
CC   The present invention specifically claims AAH56368 to AAH56832 which are
CC   antisense oligonucleotides to nucleotide sequences encoding groE. More
CC   generally, antisense compounds (I) comprising antisense oligonucleotides
CC   of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC   shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
CC   microorganism, where the antisense compound is complementary to GL or GS
CC   of a microorganism and specifically hybridises with and inhibits the
CC   expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
CC   antiproliferative activities, and can be used in antisense therapy and
CC   for inhibition of expression of groES or groEL. (I) are useful for
CC   inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
CC   also useful for inhibiting the growth of a microorganism, or inhibiting
CC   the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC   virus) having a GL or GS gene which involves administering to the
CC   microorganism or to a cell infected with the microorganism, (I). (I) are
CC   also useful for treating a mammalian pathological condition mediated by
CC   the microorganisms which involves identifying a eukaryotic organism
CC   having a pathological condition mediated by microorganisms having a GL or
CC   GS gene and administering (I) such that the growth of microorganism is
CC   inhibited. The antisense compounds are utilised for diagnostics,
CC   therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC   prevent or delay microbial infections in humans. They are also useful as
CC   molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC   represent PCR primers for groE sequences which are used in the
CC   exemplification of the present invention. AAH56855 to AAH56870 represent
CC   groE nucleotide sequence given in the present invention
XX
SQ   Sequence 20 BP; 8 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTTTCAG 1932
              |||||||||| ||   |||
Db          1 AACAATACCTTCTTCAACAG 20


RESULT 379
AAS10664
ID   AAS10664 standard; DNA; 20 BP.
XX
AC   AAS10664;
XX
DT   24-OCT-2001  (first entry)
XX
DE   Human caspase 3 antisense oligonucleotide 108988.
XX
KW   Human; caspase 3; apoptosis; hyperproliferative disorder; hepatitis;
KW   viral infection; haematopoietic disorder; autoimmune disorder;
KW   atherosclerosis; neurological disorder; antisense; phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate internucleotide linkages.
```

```
FT                   Some bases especially bases 1-5 and bases 16-20 are 2'-
FT                   methoxyethyl (2'-MOE) bases, bases 6-15 are 2'-
FT                   deoxynucleotides and all cytidine bases are 5'-
FT                   methylcytidines"
XX
PN   WO200153310-A1.
XX
PD   26-JUL-2001.
XX
PF   11-JAN-2001; 2001WO-US000888.
XX
PR   18-JAN-2000; 2000US-00484617.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Zhang H,  Cowsert LM;
XX
DR   WPI; 2001-442252/47.
XX
PT   New antisense compound to inhibit caspase 3 is useful for treating
PT   hepatitis and atherosclerosis.
XX
PS   Claim 3; Page 87; 127pp; English.
XX
CC   The present sequence for human caspase 3 antisense oligonucleotide 108988
CC   is 1 of various novel antisense oligonucleotides (AAS10517-AAS10676)
CC   described in the present invention. Also described are methods of using
CC   these compounds for the modulation of caspase 3 expression. The caspase 3
CC   antisense oligonucleotides specifically hybridise with and inhibit the
CC   expression of caspase 3. Antisense compounds targeted to caspase 3 are
CC   useful to inhibit caspase 3 expression in cells or tissues and to
CC   modulate apoptosis. The caspase 3 antisense oligonucleotides are useful
CC   for treating disorders associated with expression of caspase 3. Such
CC   disorders include hyperproliferative disorders (e.g. cancer), viral
CC   infections (e.g. hepatitis), haematopoietic disorders, autoimmune
CC   disorders, atherosclerosis and neurological disorders (e.g. Alzheimer's
CC   disease)
XX
SQ   Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1742 GACAAGTACTGGCTCTTTAT 1761
              ||||  |||| |||| ||||
Db          1 GACAGTTACTTGCTCCTTAT 20


RESULT 380
AAF29930
ID   AAF29930 standard; DNA; 20 BP.
XX
AC   AAF29930;
XX
DT   04-APR-2001  (first entry)
XX
DE   Human estrogen receptor alpha isoform primer #5.
XX
KW   Human; estrogen receptor alpha; cancer; osteoporosis; bone; Alzheimer's;
KW   cardiovascular; ss.
XX
OS   Homo sapiens.
XX
PN   WO200100823-A1.
XX
PD   04-JAN-2001.
XX
PF   27-JUN-2000; 2000WO-EP005981.
XX
PR   29-JUN-1999;   99IT-MI001433.
XX
PA   (EUMO-) EURO MOLECULAR BIOLOGY LAB.
XX
PI   Gannon F,  Denger S,  Flouriot G;
XX
DR   WPI; 2001-137955/14.
XX
PT   Novel isoforms of human estrogen receptor alpha useful for preparing
PT   therapeutic agents for treating cancer, osteoporosis, Alzheimer's disease
PT   and cardiovascular diseases.
XX
PS   Disclosure; Page 15; 53pp; English.
XX
CC   The present invention relates to a human estrogen receptor (hER)-alpha
CC   isoform. Molecules which modulate the activity of the estrogen receptor
CC   are useful for the preparation of therapeutic agents for treating cancer,
CC   osteoporosis and other bone disorders, Alzheimer's disease and
CC   cardiovascular diseases
XX
SQ   Sequence 20 BP; 1 A; 8 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1666 TCACCCGCCCCTGGACTTCT 1685
              || | || |||| |||||||
Db          1 TCTCTCGGCCCTTGACTTCT 20


RESULT 381
AAF99650/c
ID   AAF99650 standard; DNA; 20 BP.
XX
AC   AAF99650;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #766.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
XX
PR   25-SEP-1999;   99US-0156113P.
PR   27-SEP-1999;   99US-0156135P.
PR   23-AUG-2000; 2000US-0227436P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Schetter C,  Vollmer J;
XX
DR   WPI; 2001-273485/28.
XX
PT   Vaccinating against tumors, infectious diseases, allergies and asthma
PT   using immunostimulatory Py-rich and TG nucleic acids.
XX
PS   Claim 101; Page 55; 338pp; English.
XX
CC   The present invention relates to a method for stimulating an immune
CC   response. The method comprises administering an immunostimulatory nucleic
CC   acid to a non-rodent subject in sufficient quantity to stimulate an
CC   immune response. The present sequence is one such immunostimulatory
CC   nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC   (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
```

```
CC   against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC   and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC   haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC   staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC   also useful for preventing cancer, asthma, infectious disease, allergy or
CC   immune deficiency. The present sequence can also be used to redirect a
CC   Th2 to a Th1 immune response and to activate immune cells. Note: the
CC   present sequence may have a phosphorothioate backbone
XX
SQ   Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 382
AAF99396/c
ID   AAF99396 standard; DNA; 20 BP.
XX
AC   AAF99396;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #512.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
XX
PR   25-SEP-1999;   99US-0156113P.
PR   27-SEP-1999;   99US-0156135P.
PR   23-AUG-2000; 2000US-0227436P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Schetter C,  Vollmer J;
XX
DR   WPI; 2001-273485/28.
XX
PT   Vaccinating against tumors, infectious diseases, allergies and asthma
PT   using immunostimulatory Py-rich and TG nucleic acids.
XX
PS   Claim 101; Page 48; 338pp; English.
XX
CC   The present invention relates to a method for stimulating an immune
CC   response. The method comprises administering an immunostimulatory nucleic
CC   acid to a non-rodent subject in sufficient quantity to stimulate an
CC   immune response. The present sequence is one such immunostimulatory
CC   nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC   (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC   against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC   and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC   haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC   staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC   also useful for preventing cancer, asthma, infectious disease, allergy or
CC   immune deficiency. The present sequence can also be used to redirect a
CC   Th2 to a Th1 immune response and to activate immune cells. Note: the
CC   present sequence may have a phosphorothioate backbone
XX
SQ   Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 383
AAF99576
ID   AAF99576 standard; DNA; 20 BP.
XX
AC   AAF99576;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #692.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
XX
PR   25-SEP-1999;   99US-0156113P.
PR   27-SEP-1999;   99US-0156135P.
PR   23-AUG-2000; 2000US-0227436P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Schetter C,  Vollmer J;
XX
DR   WPI; 2001-273485/28.
XX
PT   Vaccinating against tumors, infectious diseases, allergies and asthma
PT   using immunostimulatory Py-rich and TG nucleic acids.
XX
PS   Claim 101; Page 53; 338pp; English.
XX
CC   The present invention relates to a method for stimulating an immune
CC   response. The method comprises administering an immunostimulatory nucleic
CC   acid to a non-rodent subject in sufficient quantity to stimulate an
CC   immune response. The present sequence is one such immunostimulatory
CC   nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC   (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC   against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC   and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC   haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC   staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC   also useful for preventing cancer, asthma, infectious disease, allergy or
CC   immune deficiency. The present sequence can also be used to redirect a
CC   Th2 to a Th1 immune response and to activate immune cells. Note: the
CC   present sequence may have a phosphorothioate backbone
XX
SQ   Sequence 20 BP; 13 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
```

```
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 384
AAF99225/c
ID   AAF99225 standard; DNA; 20 BP.
XX
AC   AAF99225;
XX
DT   12-JUN-2001  (first entry)
XX
DE   Immunostimulatory nucleic acid #341.
XX
KW   Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW   immunostimulatory; tumour; viral infection; bacterial infection;
KW   fungal infection; parasitic infection; cancer; asthma;
KW   infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
OS   Synthetic.
XX
PN   WO200122972-A2.
XX
PD   05-APR-2001.
XX
PF   25-SEP-2000; 2000WO-US026383.
XX
PR   25-SEP-1999;   99US-0156113P.
PR   27-SEP-1999;   99US-0156135P.
PR   23-AUG-2000; 2000US-0227436P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
PA   (COLE-) COLEY PHARM GMBH.
XX
PI   Krieg AM,  Schetter C,  Vollmer J;
XX
DR   WPI; 2001-273485/28.
XX
PT   Vaccinating against tumors, infectious diseases, allergies and asthma
PT   using immunostimulatory Py-rich and TG nucleic acids.
XX
PS   Claim 101; Page 45; 338pp; English.
XX
CC   The present invention relates to a method for stimulating an immune
CC   response. The method comprises administering an immunostimulatory nucleic
CC   acid to a non-rodent subject in sufficient quantity to stimulate an
CC   immune response. The present sequence is one such immunostimulatory
CC   nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC   (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC   against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
CC   and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC   haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC   staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC   also useful for preventing cancer, asthma, infectious disease, allergy or
CC   immune deficiency. The present sequence can also be used to redirect a
CC   Th2 to a Th1 immune response and to activate immune cells. Note: the
CC   present sequence may have a phosphorothioate backbone
XX
SQ   Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  ||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 385
AAD12126/c
ID   AAD12126 standard; DNA; 20 BP.
XX
AC   AAD12126;
XX
DT   25-SEP-2001  (first entry)
XX
DE   Rat PTP1B antisense oligonucleotide (ISIS# 106409).
XX
KW   Rat; PTP1B; protein phosphatase 1B inhibitor; antisense; gene therapy;
KW   infection; inflammation; tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Rattus norvegicus.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "Methoxyethyl residues"
FT   modified_base    3. .4
FT                    /*tag=  d
FT                    /mod_base= m5c
FT   modified_base    13
FT                    /*tag=  e
FT                    /mod_base= m5c
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "Methoxyethyl residues"
FT   modified_base    16. .17
FT                    /*tag=  f
FT                    /mod_base= m5c
XX
PN   US6261840-B1.
XX
PD   17-JUL-2001.
XX
PF   18-JAN-2000; 2000US-00487368.
XX
PR   18-JAN-2000; 2000US-00487368.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Wyatt J;
XX
DR   WPI; 2001-432181/46.
XX
PT   New antisense compounds capable of modulating expression of human protein
PT   phosphatase 1B, useful for diagnosis, prophylaxis and treatment of
PT   diseases associated with expression of protein phosphatase.
XX
PS   Claim 1; Col 51-52; 71pp; English.
XX
CC   The invention is directed to antisense compounds, particularly
CC   oligonucleotides which are targetted to a DNA encoding protein
CC   phosphatase 1B (PTP1B) to modulate its expression. The antisense
CC   compounds are useful for diagnosis, prophylaxis and treatment of diseases
CC   associated with the expression of PTP1B, to prevent or delay infection,
CC   inflammation and tumour formation and as a research reagent. The PTP1B
CC   DNA is useful in gene therapy. The present sequence is an antisense
CC   oligonucleotide with a phosphorothioate backbone. This oligo is targetted
CC   to rat PTP1B to inhibit its expression
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
              ||||| | ||| |||||| |
```

```
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 386
AAH80390/c
ID   AAH80390 standard; cDNA; 20 BP.
XX
AC   AAH80390;
XX
DT   11-SEP-2003  (revised)
DT   19-SEP-2001  (first entry)
XX
DE   Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 354.
XX
KW   Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KW   disease diagnosis; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   US6251588-B1.
XX
PD   26-JUN-2001.
XX
PF   10-FEB-1998;   98US-00021701.
XX
PR   10-FEB-1998;   98US-00021701.
XX
PA   (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI   Shannon KW,  Wolber PK,  Delenstarr GC,  Webb PG,  Kincaid RH;
XX
DR   WPI; 2001-424456/45.
XX
PT   Predicting the potential of an oligonucleotide to hybridize to a target
PT   nucleotide sequence, useful for evaluating oligonucleotide probe
PT   sequences, by identifying a oligonucleotides based on the evaluation of
PT   parameters.
XX
PS   Example 2; Col 59; 342pp; English.
XX
CC   The present invention describes a method for predicting the potential of
CC   an oligonucleotide to hybridise to a (complementary) target nucleotide
CC   sequence, involving identifying a subset of oligonucleotides within the
CC   predetermined number of unique oligonucleotides based on the evaluation
CC   of the parameter. Oligonucleotides in the subset are identified that are
CC   clustered along a region of the nucleotide sequence that is hybridisable
CC   to the target nucleotide sequence. This is useful for evaluating
CC   oligonucleotide probe sequences. The present sequence is an
CC   oligonucleotide described in the exemplification of the invention.
CC   (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ   Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTTTAAA 1837
              || | |||||  ||||||||
Db         20 AAATCTTAGAGCCTTTTAAA 1


RESULT 387
AAD40874
ID   AAD40874 standard; DNA; 20 BP.
XX
AC   AAD40874;
XX
DT   30-OCT-2002  (first entry)
XX
DE   Human hepsin antisense oligonucleotide, ISIS 107148.
XX
KW   Human; hepsin; antisense compound; antisense therapy; antisense;
KW   phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   2
FT                   /*tag=  d
FT                   /mod_base= m5c
FT   modified_base   3
FT                   /*tag=  e
FT                   /mod_base= m5c
FT   modified_base   6
FT                   /*tag=  f
FT                   /mod_base= m5c
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO200250247-A2.
XX
PD   27-JUN-2002.
XX
PF   14-DEC-2001; 2001WO-US048341.
XX
PR   20-DEC-2000; 2000US-00742482.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM;
XX
DR   WPI; 2002-519882/55.
XX
PT   Novel antisense compound targeted to nucleic acids encoding human hepsin,
PT   useful for inhibiting the expression of hepsin in human cells or tissues,
PT   and for treating humans having a disease associated with human hepsin.
XX
PS   Example 15; Page 100; 100pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of hepsin. The compositions comprise
CC   antisense compounds, particularly antisense oligonucleotides, targetted
CC   to nucleic acids encoding hepsin. The antisense compound is useful for
CC   inhibiting the expression of hepsin in human cells or tissues. It is also
CC   useful for treating an animal having a disease or condition associated
CC   with hepsin, by inhibiting expression of hepsin. It is useful for
CC   diagnostics, therapeutics, prophylaxis and as research reagents and kits.
CC   It is also used in antisense therapy. The present sequence is an
CC   antisense oligonucleotide targetted to human hepsin DNA. This sequence is
CC   used in the exemplification of the invention
XX
SQ   Sequence 20 BP; 7 A; 3 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1627 ACCTACCTTACTATTTAAAG 1646
              |||  | ||| |||||||||
Db          1 ACCATCTTTATTATTTAAAG 20


RESULT 388
AAS96809
```

```
ID   AAS96809 standard; DNA; 20 BP.
XX
AC   AAS96809;
XX
DT   26-FEB-2002  (first entry)
XX
DE   Human STAT3 antisense phosphorothioate oligodeoxynucleotide #42.
XX
KW   STAT3; human; signal transducer and activator of transcription; ss; STAT;
KW   antisense gene therapy; Fas-mediated apoptosis; inflammatory disease;
KW   autoimmune disease; rheumatoid arthritis; cancer; breast; prostate; head;
KW   neck; brain; leukaemia; myeloma; melanoma; lymphoma; apoptosis;
KW   antiinflammatory; immunosuppressive; antirheumatic; antiarthritic;
KW   cytostatic.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US2001029250-A1.
XX
PD   11-OCT-2001.
XX
PF   11-JAN-2001; 2001US-00758881.
XX
PR   08-APR-1999;   99US-00288461.
PR   06-APR-2000; 2000WO-US009054.
XX
PA   (KARR/) KARRAS J G.
XX
PI   Karras JG;
XX
DR   WPI; 2002-009991/01.
XX
PT   Novel antisense compound useful for treating and diagnosing inflammatory
PT   diseases and cancers, is targeted to a nucleic acid molecule encoding
PT   signal transducer and activator of transcription proteins.
XX
PS   Example 2; Page 13; 21pp; English.
XX
CC   The invention relates to antisense compounds targeted to a nucleic acid
CC   molecule encoding a signal transducer and activator of transcription
CC   (STAT) protein, specifically STAT3, where the antisense compounds inhibit
CC   the expression of STAT3. The antisense sequences are useful for
CC   inhibiting the expression of STAT3 in cells or tissues, inducing Fas-
CC   mediated apoptosis in cells, and sensitising cells to apoptosis. They are
CC   also useful for treating an animal having a disease or condition
CC   associated with STAT3. These disorders include inflammatory or autoimmune
CC   disease, particularly rheumatoid arthritis, cancers, such as those of the
CC   breast, prostate, brain and head and neck and leukaemias, myelomas,
CC   melanomas and lymphomas. Also treatable are human diseases or conditions
CC   characterised by a reduction in apoptosis or an insensitivity to
CC   apoptotic signals. The sequences of the invention can be used in clinical
CC   research, for detecting and determining the role of STAT3 in various cell
CC   functions and physiological processes and for diagnosing conditions
CC   associated with the expression of STAT3. The sequences represent cDNA
CC   encoding human STAT3 and human STAT3 oligonucleotides
XX
SQ   Sequence 20 BP; 5 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGGCTCTTTA 1760
              ||||||| | ||| ||| ||
Db          1 TGACAAGGAGTGGGTCTCTA 20


RESULT 389
AAS97811
ID   AAS97811 standard; DNA; 20 BP.
XX
AC   AAS97811;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Murine SAC1 gene-specific oligonucleotide PCR primer #378.
XX
KW   Human; mouse; SAC1; carbohydrate; sweetener; ethanol; alcoholism; ss;
KW   obesity; diabetes; transgenic embryo; body tissue; body fluid; pancreas;
KW   blood; tongue; PCR primer; anorectic; antidiabetic; gene therapy;
KW   protein replacement therapy.
XX
OS   Mus sp.
XX
PN   WO200183749-A2.
XX
PD   08-NOV-2001.
XX
PF   25-APR-2001; 2001WO-US013387.
XX
PR   28-APR-2000; 2000US-0200794P.
PR   28-JUL-2000; 2000US-0221419P.
PR   10-NOV-2000; 2000US-0247443P.
XX
PA   (WARN ) WARNER LAMBERT CO.
PA   (MONE-) MONELL CHEM SENSES CENT.
XX
PI   Bachmanov AA,  Beauchamp GK,  Chatterjee A,  De Jong PJ,  Li S,  Li X;
PI   Ohmen JD,  Reed DR,  Ross D,  Tordoff MG;
XX
DR   WPI; 2002-075162/10.
XX
PT   Novel isolated polypeptide comprising variant form of mouse or human SAC1
PT   polypeptide, and is associated with altered preference for carbohydrates
PT   or other sweeteners, useful for preventing obesity, diabetes, alcoholism.
XX
PS   Claim 14; Page 88; 239pp; English.
XX
CC   The invention relates to an isolated polypeptide, comprising a variant
CC   form of mouse or human SAC1 polypeptide. The variant form is associated
CC   with altered preference for carbohydrates, other sweeteners or ethanol.
CC   The polypeptide and its associated DNA sequence can be produced by
CC   recombinant techniques and is useful for preventing obesity, diabetes or
CC   alcoholism associated with SAC1 expression. The sequences are useful in
CC   screening for drugs and sweeteners. Recombinant cell lines and transgenic
CC   embryos may be used in screening for and identifying agents that induce
CC   or repress function of SAC1. Predisposition to diabetes, obesity or
CC   alcoholism can be ascertained by testing any fluid or tissue of a human
CC   (such as blood, pancreas or tongue) for sequence variations of the SAC1
CC   gene. A sequence variation of the SAC1 locus may indicate a
CC   predisposition to diabetes, obesity and/or alcoholism and may provide a
CC   diagnostic mark. The polynucleotide can be detected in a biological
CC   sample by contacting the DNA with a probe to form a hybridisation complex
CC   which is then detected. The sequences represent cDNA encoding human and
CC   mouse SAC1 polypeptides and PCR primers specific for the SCA1 genes
XX
SQ   Sequence 20 BP; 7 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCTTCTCCA 1581
              ||||||||  |||  |||||
Db          1 ACTGCAAATGTCCAACTCCA 20


RESULT 390
ABK37064
ID   ABK37064 standard; DNA; 20 BP.
XX
AC   ABK37064;
XX
DT   08-MAY-2002  (first entry)
XX
```

DE Human lysophospholipase I gene, antisense oligonucleotide #16.
XX
KW Human; mouse; antiinflammatory; antiarteriosclerotic; vasotropic;
KW antilipaemic; cardiant; lysophospholipase I; inflammation; ischaemia;
KW hyperlipidaemia; cardiovascular disorder; atherosclerosis;
KW antisense gene therapy; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200210185-A1.
XX
PD 07-FEB-2002.
XX
PF 20-JUL-2001; 2001WO-US022975.
XX
PR 31-JUL-2000; 2000US-00629645.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Wyatt JR;
XX
DR WPI; 2002-188720/24.
XX
PT Novel antisense compound useful for treating inflammation,
PT hyperlipidemia, and cardiovascular disorders such as atherosclerosis and
PT myocardial ischemia, inhibits Lysophospholipase I.
XX
PS Claim 3; Page 79; 131pp; English.
XX
CC The invention relates to an antisense compound (I) 8-30 nucleobases in
CC length targeted to a nucleic acid molecule encoding lysophospholipase I
CC (II), where (I) specifically hybridises with and inhibits the expression
CC of (II). (I) is useful for inhibiting the expression of (II) in cells or
CC tissues, and for treating a human having a disease or condition
CC associated with Lysophospholipase I e.g. inflammation, hyperlipidaemia,
CC and cardiovascular disorders such as atherosclerosis and myocardial
CC ischaemia. (I) is useful as research reagent and diagnostics. (I) is also
CC useful for distinguishing functions of various members of a biological
CC pathway. (I) is useful in antisense gene therapy. ABK37028-ABK37191
CC represent lysophospholipase I coding sequences, antisense
CC oligonucleotides and related PCR primers of the invention. Note:
CC Antisense oligonucleotides are modified such that bases 1-5 and 16-20 are
CC 2'-methoxyethyl (2'-MOE) nucleotides, all bases have phosphorothioate
CC linkages, and all cytidines are 5-methyl cytidines
XX
SQ Sequence 20 BP; 4 A; 6 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1782 GAACCCCATTCTTTCCTTCT 1801
                ||| |||||||| |||||
Db          1 GAATGCCATTCTTCACTTCT 20
```

RESULT 391
ABS77869/c
ID ABS77869 standard; DNA; 20 BP.
XX
AC ABS77869;
XX
DT 13-DEC-2002 (first entry)
XX
DE Angiogenesis inhibitory oligonucleotide #353.
XX
KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW plaque neovascularisation; telangiectasia; haemophiliac joint;
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW scleroderma; hypertrophic scar.
XX
OS Synthetic.
XX
PN WO200253141-A2.
XX
PD 11-JUL-2002.
XX
PF 14-DEC-2001; 2001WO-US048458.
XX
PR 14-DEC-2000; 2000US-0255534P.
XX
PA (COLE-) COLEY PHARM GROUP INC.
XX
PI Bratzler RL;
XX
DR WPI; 2002-566690/60.
XX
PT Inhibiting angiogenesis in a subject, involves administering at least one
PT antiangiogenic nucleic acid molecule to the subject.
XX
PS Claim 2; Page 25; 276pp; English.
XX
CC The invention relates to inhibiting angiogenesis in a subject, comprising
CC administering at least one antiangiogenic nucleic acid molecule. Also
CC included is a kit comprising a first container housing the antiangiogenic
CC nucleic acids, and instructions for administering them to a subject
CC having a condition characterised by unwanted angiogenesis. The method is
CC useful for inhibiting angiogenesis associated with solid tumour growth,
CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC acid of the invention
XX
SQ Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
                ||| |  ||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1
```

RESULT 392
ABS78371/c
ID ABS78371 standard; DNA; 20 BP.
XX
AC ABS78371;
XX
DT 13-DEC-2002 (first entry)
XX
DE Angiogenesis inhibitory oligonucleotide #855.
XX
KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW plaque neovascularisation; telangiectasia; haemophiliac joint;
KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW scleroderma; hypertrophic scar.
XX
OS Synthetic.
XX
PN WO200253141-A2.
XX

```
PD   11-JUL-2002.
XX
PF   14-DEC-2001; 2001WO-US048458.
XX
PR   14-DEC-2000; 2000US-0255534P.
XX
PA   (COLE-) COLEY PHARM GROUP INC.
XX
PI   Bratzler RL;
XX
DR   WPI; 2002-566690/60.
XX
PT   Inhibiting angiogenesis in a subject, involves administering at least one
PT   antiangiogenic nucleic acid molecule to the subject.
XX
PS   Claim 2; Page 34; 276pp; English.
XX
CC   The invention relates to inhibiting angiogenesis in a subject, comprising
CC   administering at least one antiangiogenic nucleic acid molecule. Also
CC   included is a kit comprising a first container housing the antiangiogenic
CC   nucleic acids, and instructions for administering them to a subject
CC   having a condition characterised by unwanted angiogenesis. The method is
CC   useful for inhibiting angiogenesis associated with solid tumour growth,
CC   tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC   diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC   corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC   rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC   neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC   wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC   hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC   acid of the invention
XX
SQ   Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
                ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1

RESULT 393
ABS78292
ID   ABS78292 standard; DNA; 20 BP.
XX
AC   ABS78292;
XX
DT   13-DEC-2002  (first entry)
XX
DE   Angiogenesis inhibitory oligonucleotide #776.
XX
KW   Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW   tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW   diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW   corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW   rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW   plaque neovascularisation; telangiectasia; haemophiliac joint;
KW   angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW   scleroderma; hypertrophic scar.
XX
OS   Synthetic.
XX
PN   WO200253141-A2.
XX
PD   11-JUL-2002.
XX
PF   14-DEC-2001; 2001WO-US048458.
XX
PR   14-DEC-2000; 2000US-0255534P.
XX
PA   (COLE-) COLEY PHARM GROUP INC.
XX
PI   Bratzler RL;
XX
DR   WPI; 2002-566690/60.
XX
PT   Inhibiting angiogenesis in a subject, involves administering at least one
PT   antiangiogenic nucleic acid molecule to the subject.
XX
PS   Claim 2; Page 33; 276pp; English.
XX
CC   The invention relates to inhibiting angiogenesis in a subject, comprising
CC   administering at least one antiangiogenic nucleic acid molecule. Also
CC   included is a kit comprising a first container housing the antiangiogenic
CC   nucleic acids, and instructions for administering them to a subject
CC   having a condition characterised by unwanted angiogenesis. The method is
CC   useful for inhibiting angiogenesis associated with solid tumour growth,
CC   tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC   diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC   corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC   rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC   neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC   wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC   hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC   acid of the invention
XX
SQ   Sequence 20 BP; 13 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
                || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20

RESULT 394
ABS78041/c
ID   ABS78041 standard; DNA; 20 BP.
XX
AC   ABS78041;
XX
DT   13-DEC-2002  (first entry)
XX
DE   Angiogenesis inhibitory oligonucleotide #525.
XX
KW   Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KW   tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KW   diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KW   corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KW   rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
KW   plaque neovascularisation; telangiectasia; haemophiliac joint;
KW   angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KW   scleroderma; hypertrophic scar.
XX
OS   Synthetic.
XX
PN   WO200253141-A2.
XX
PD   11-JUL-2002.
XX
PF   14-DEC-2001; 2001WO-US048458.
XX
PR   14-DEC-2000; 2000US-0255534P.
XX
PA   (COLE-) COLEY PHARM GROUP INC.
XX
PI   Bratzler RL;
XX
DR   WPI; 2002-566690/60.
XX
PT   Inhibiting angiogenesis in a subject, involves administering at least one
PT   antiangiogenic nucleic acid molecule to the subject.
```

```
XX
PS   Claim 2; Page 28; 276pp; English.
XX
CC   The invention relates to inhibiting angiogenesis in a subject, comprising
CC   administering at least one antiangiogenic nucleic acid molecule. Also
CC   included is a kit comprising a first container housing the antiangiogenic
CC   nucleic acids, and instructions for administering them to a subject
CC   having a condition characterised by unwanted angiogenesis. The method is
CC   useful for inhibiting angiogenesis associated with solid tumour growth,
CC   tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC   diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC   corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC   rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
CC   neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC   wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC   hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC   acid of the invention
XX
SQ   Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 395
ABT07470/c
ID   ABT07470 standard; DNA; 20 BP.
XX
AC   ABT07470;
XX
DT   14-NOV-2002  (first entry)
XX
DE   Human protein phosphatase 2 oligo inhibitor SEQ ID No 84.
XX
KW   Cytostatic; antidiabetic; antisense therapy; aberrant insulin regulation;
KW   protein phosphatase 2 catalytic beta subunit; antisense compound; cancer;
KW   hyperproliferative disorder; diabetes; inflammation; tumour; human; ds.
XX
OS   Homo sapiens.
XX
PN   WO200264737-A2.
XX
PD   22-AUG-2002.
XX
PF   31-JAN-2002; 2002WO-US002805.
XX
PR   09-FEB-2001; 2001US-00780045.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Wyatt JR;
XX
DR   WPI; 2002-657588/70.
XX
PT   New antisense oligonucleotides targeted to nucleic acid encoding Protein
PT   Phosphatase 2 catalytic subunit beta, useful for treating diseases
PT   related to Protein Phosphatase 2 catalytic subunit beta expression, such
PT   as cancer.
XX
PS   Example 15; Page 95; 137pp; English.
XX
CC   The invention relates to a novel compound 8-50 nucleotides in length
CC   targeted to a nucleic acid molecule encoding a protein phosphatase 2
CC   catalytic beta subunit, where the compound specifically hybridises with
CC   and inhibits the expression of protein phosphatase 2 catalytic beta
CC   subunits, or specifically hybridises with at least an 8-nucleotide
CC   portion of an active site on a nucleic acid molecule encoding a protein
CC   phosphatase 2 catalytic beta subunit. The antisense compounds are useful
CC   for modulating the expression of protein phosphatase 2 catalytic beta
CC   subunits and for treating diseases or conditions associated with
CC   expression of protein phosphatase 2 catalytic beta subunits, e.g.
CC   aberrant insulin regulation or diabetes or a hyperproliferative disorder,
CC   particularly cancer. The antisense compounds are also useful for
CC   diagnostics, therapeutics, prophylaxis, e.g. to prevent or delay
CC   infection, inflammation or tumour formation, as research reagents and
CC   kits, and in distinguishing between functions of various members of a
CC   biological pathway. This polynucleotide sequence represents an
CC   oligonucleotide inhibitor of human protein phosphatase 2 catalytic beta
CC   subunit mRNA levels of the invention. NOTE: This oligonucleotide contains
CC   phosphorothioate residues and has 2'- MOE wings with a deoxy gap
XX
SQ   Sequence 20 BP; 12 A; 1 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTTGAA 1784
              |||  |||| |||| |||||
Db         20 TTATCCTTTATTTTATTGAA 1


RESULT 396
ABL38651/c
ID   ABL38651 standard; DNA; 20 BP.
XX
AC   ABL38651;
XX
DT   16-APR-2002  (first entry)
XX
DE   Immunostimulatory nucleic acid SEQ ID NO: 5.
XX
KW   Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
KW   angiogenesis; metastasis; cytostatic; phosphorodithioate backbone; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "phosphorodithioate backbone"
XX
PN   WO200197843-A2.
XX
PD   27-DEC-2001.
XX
PF   22-JUN-2001; 2001WO-US020154.
XX
PR   22-JUN-2000; 2000US-0213346P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
XX
PI   Weiner G,  Hartmann G;
XX
DR   WPI; 2002-154611/20.
XX
PT   Treating or preventing cancer, such as basal cell carcinoma, comprises
PT   administering immunostimulatory nucleic acids that induce expression of
PT   cell surface antigens and antibodies to a subject having or at risk of
PT   developing cancer.
XX
PS   Disclosure; Page 96; 312pp; English.
XX
CC   The present invention relates to methods for treating or preventing
CC   cancer, involving administering to a subject having or at risk of
CC   developing cancer immunostimulatory nucleic acids that induce expression
CC   of cell surface antigens and antibodies. The methods are useful for
CC   treating or preventing cancer such as basal cell carcinoma, bladder
CC   cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC   breast cancer, cervical cancer, colon and rectum cancer, connective
```

```
CC   tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx
CC   cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC   Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC   cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC   cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC   present sequence is an immunostimulatory oligonucleotide described in the
CC   exemplification of the invention
XX
SQ   Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 397
ABL39120/c
ID   ABL39120 standard; DNA; 20 BP.
XX
AC   ABL39120;
XX
DT   16-APR-2002  (first entry)
XX
DE   Immunostimulatory nucleic acid SEQ ID NO: 542.
XX
KW   Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
KW   angiogenesis; metastasis; cytostatic; ss.
XX
OS   Synthetic.
XX
PN   WO200197843-A2.
XX
PD   27-DEC-2001.
XX
PF   22-JUN-2001; 2001WO-US020154.
XX
PR   22-JUN-2000; 2000US-0213346P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
XX
PI   Weiner G,  Hartmann G;
XX
DR   WPI; 2002-154611/20.
XX
PT   Treating or preventing cancer, such as basal cell carcinoma, comprises
PT   administering immunostimulatory nucleic acids that induce expression of
PT   cell surface antigens and antibodies to a subject having or at risk of
PT   developing cancer.
XX
PS   Disclosure; Page 233; 312pp; English.
XX
CC   The present invention relates to methods for treating or preventing
CC   cancer, involving administering to a subject having or at risk of
CC   developing cancer immunostimulatory nucleic acids that induce expression
CC   of cell surface antigens and antibodies. The methods are useful for
CC   treating or preventing cancer such as basal cell carcinoma, bladder
CC   cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC   breast cancer, cervical cancer, colon and rectum cancer, connective
CC   tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx
CC   cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC   Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC   cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC   cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC   present sequence is an immunostimulatory oligonucleotide described in the
CC   exemplification of the invention
XX
SQ   Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  |||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 398
ABL38654
ID   ABL38654 standard; DNA; 20 BP.
XX
AC   ABL38654;
XX
DT   16-APR-2002  (first entry)
XX
DE   Immunostimulatory nucleic acid SEQ ID NO: 9.
XX
KW   Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
KW   angiogenesis; metastasis; cytostatic; ss.
XX
OS   Synthetic.
XX
PN   WO200197843-A2.
XX
PD   27-DEC-2001.
XX
PF   22-JUN-2001; 2001WO-US020154.
XX
PR   22-JUN-2000; 2000US-0213346P.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
XX
PI   Weiner G,  Hartmann G;
XX
DR   WPI; 2002-154611/20.
XX
PT   Treating or preventing cancer, such as basal cell carcinoma, comprises
PT   administering immunostimulatory nucleic acids that induce expression of
PT   cell surface antigens and antibodies to a subject having or at risk of
PT   developing cancer.
XX
PS   Disclosure; Page 97; 312pp; English.
XX
CC   The present invention relates to methods for treating or preventing
CC   cancer, involving administering to a subject having or at risk of
CC   developing cancer immunostimulatory nucleic acids that induce expression
CC   of cell surface antigens and antibodies. The methods are useful for
CC   treating or preventing cancer such as basal cell carcinoma, bladder
CC   cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC   breast cancer, cervical cancer, colon and rectum cancer, connective
CC   tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx
CC   cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC   Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC   cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC   cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC   present sequence is an immunostimulatory oligonucleotide described in the
CC   exemplification of the invention
XX
SQ   Sequence 20 BP; 13 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 399
ABL38650/c
ID   ABL38650 standard; DNA; 20 BP.
```

XX
AC ABL38650;
XX
DT 16-APR-2002 (first entry)
XX
DE Immunostimulatory nucleic acid SEQ ID NO: 4.
XX
KW Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
KW angiogenesis; metastasis; cytostatic; ss.
XX
OS Synthetic.
XX
PN WO200197843-A2.
XX
PD 27-DEC-2001.
XX
PF 22-JUN-2001; 2001WO-US020154.
XX
PR 22-JUN-2000; 2000US-0213346P.
XX
PA (IOWA) UNIV IOWA RES FOUND.
XX
PI Weiner G, Hartmann G;
XX
DR WPI; 2002-154611/20.
XX
PT Treating or preventing cancer, such as basal cell carcinoma, comprises
PT administering immunostimulatory nucleic acids that induce expression of
PT cell surface antigens and antibodies to a subject having or at risk of
PT developing cancer.
XX
PS Disclosure; Page 96; 312pp; English.
XX
CC The present invention relates to methods for treating or preventing
CC cancer, involving administering to a subject having or at risk of
CC developing cancer immunostimulatory nucleic acids that induce expression
CC of cell surface antigens and antibodies. The methods are useful for
CC treating or preventing cancer such as basal cell carcinoma, bladder
CC cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC breast cancer, cervical cancer, colon and rectum cancer, connective
CC tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx
CC cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC present sequence is an immunostimulatory oligonucleotide described in the
CC exemplification of the invention
XX
SQ Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1776 TTTTTTGAACCCCATTCTTT 1795
|||||||||| ||| |||
Db 20 TTTTTTGAACGTCATGTTTT 1

RESULT 400
ABK85201/c
ID ABK85201 standard; DNA; 20 BP.
XX
AC ABK85201;
XX
DT 13-AUG-2002 (first entry)
XX
DE Rat PTPB1 antisense oligonucleotide ISIS 106409.
XX
KW Antisense; protein phosphatase 1B; PTP1B; ss; probe; rat;
KW type 2 diabetes; obesity; ovarian cancer; chronic myeloid leukaemia;
KW hyperproliferative disease; antidiabetic; anorectic; cytostatic;
KW blood glucose; gene therapy.
XX
OS Rattus norvegicus.
XX
PN US2002055479-A1.
XX
PD 09-MAY-2002.
XX
PF 14-MAY-2001; 2001US-00854883.
XX
PR 18-JAN-2000; 2000US-00487368.
PR 31-JUL-2000; 2000US-00629644.
XX
PA (COWS/) COWSERT L M.
PA (WYAT/) WYATT J.
PA (FREI/) FREIER S M.
PA (MONI/) MONIA B P.
PA (BUTL/) BUTLER M M.
PA (MCKA/) MCKAY R.
XX
PI Cowsert LM, Wyatt J, Freier SM, Monia BP, Butler MM, Mckay R;
XX
DR WPI; 2002-462914/49.
XX
PT Compound for inhibiting the expression of protein phosphatase 1B (PTP1B)
PT and for treating diabetes, cancer, or obesity, comprises an antisense
PT oligonucleotide targeted to nucleic acid encoding PTP1B.
XX
PS Claim 3; Page 24; 133pp; English.
XX
CC The invention relates to a compound of 8-50 nucleobases in length
CC targeted to a nucleic acid encoding protein phosphatase 1B (PTP1B), where
CC the compound specifically hybridises with and inhibits the expression of
CC PTP1B (e.g. an antisense oligonucleotide). Also included are (1) a
CC compound of 8-50 nucleobases in length which specifically hybridises with
CC an 8 nucleobase portion of an active site on a nucleic acid encoding
CC PTP1B; (2) inhibiting the expression of PTP1B in cells or tissues
CC comprising contacting the cells or tissues with the compound; treating an
CC animal having or suspected of having a disease or condition associated
CC with PTP1B comprising administering the compound; (4) decreasing blood
CC sugar levels in an animal comprising administering the compound; (5)
CC preventing or delaying the onset of a disease or condition associated
CC with PTP1B in an animal comprising administering the compound; and (6)
CC preventing or delaying the onset of an increase in blood glucose levels
CC in an animal comprising administering the compound. The compound is used
CC to inhibit the expression of PTP1B in cells or tissues, to treat or
CC prevent or delay the onset of a disease or condition associated with
CC PTP1B, such as type 2 diabetes, obesity, cancer (especially ovarian
CC cancer, chronic myeloid leukaemia and hyperproliferative diseases in an
CC animal having or suspected of having the disease or condition, and for
CC decreasing blood sugar levels or preventing or delaying the onset of an
CC increase in blood glucose levels in an animal. The compound is also used
CC in diagnostics, therapeutics, prophylaxis, and in research reagents and
CC kits. The present sequence is an antisense compound of the invention
CC targetting rat PTP1B
XX
SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1590 ACTGGGAACCCCTCCTGGCC 1609
||||| | ||| |||||| |
Db 20 ACTGGAAGCCCTTCCTGGTC 1

RESULT 401
AAD40692
ID AAD40692 standard; DNA; 20 BP.
XX
AC AAD40692;
XX
DT 30-OCT-2002 (first entry)

```
XX
DE   Human hepsin antisense oligonucleotide, ISIS 107148.
XX
KW   Human; antisense; hepsin; inflammation; tumour; gene therapy; cytostatic;
KW   phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   2
FT                   /*tag= d
FT                   /mod_base= m5c
FT   modified_base   3
FT                   /*tag= e
FT                   /mod_base= m5c
FT   modified_base   6
FT                   /*tag= f
FT                   /mod_base= m5c
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO200250248-A2.
XX
PD   27-JUN-2002.
XX
PF   14-DEC-2001; 2001WO-US048431.
XX
PR   20-DEC-2000; 2000US-00742703.
XX
PA   (ISIS-) ISIS PHARM INC.
PA   (ABBO ) ABBOTT LAB.
XX
PI   Marcotte PA,  Cowsert LM;
XX
DR   WPI; 2002-519883/55.
XX
PT   New antisense oligonucleotides that modulate (particularly inhibit) human
PT   hepsin, useful for treating a disease or condition associated with the
PT   expression of hepsin, e.g. inflammation or tumor growth.
XX
PS   Example 15; Page 83; 101pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targetted to a nucleic acid molecule encoding human hepsin. The antisense
CC   compound specifically hybridises with and inhibits the expression of
CC   human hepsin. The antisense compound or the pharmaceutical composition is
CC   useful for treating animals and humans having a disease or condition
CC   associated with the expression of hepsin, e.g. inflammation or tumour
CC   growth. The antisense compounds are useful also for diagnostics,
CC   prophylaxis (e.g. to prevent or delay infection, inflammation or tumour
CC   formation) or as research reagents and kits. The method is useful for
CC   modulating, specifically inhibiting the expression of hepsin which may be
CC   used in research, e.g to distinguish between functions of various members
CC   of a biological pathway. The invention is used in gene therapy. The
CC   present sequence is human hepsin antisense oligonucleotide
XX
SQ   Sequence 20 BP; 7 A; 3 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1627 ACCTACCTTACTATTTAAAG 1646
              |||  | |||  |||||||||
Db          1 ACCATCTTTATTATTTAAAG 20


RESULT 402
ABK37370/c
ID   ABK37370 standard; DNA; 20 BP.
XX
AC   ABK37370;
XX
DT   08-MAY-2002  (first entry)
XX
DE   Rat PTP1B mRNA level inhibition antisense DNA #87.
XX
KW   Human; mouse; rat; protein tyrosine phosphatase 1B; PTP1B; ss; adipose;
KW   liver; kidney; metabolic disease; type 2 diabetes; obesity; cancer;
KW   hyperproliferative condition; blood serum; blood plasma; antidiabetic;
KW   blood glucose level; cytostatic; anorectic; antisense gene therapy;
KW   PTP1B mRNA level inhibition.
XX
OS   Rattus norvegicus.
XX
PN   WO200210378-A2.
XX
PD   07-FEB-2002.
XX
PF   30-JUL-2001; 2001WO-US023874.
XX
PR   31-JUL-2000; 2000US-00629644.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Wyatt J,  Freier SM,  Monia BP,  Butler MM,  Mckay R;
XX
DR   WPI; 2002-180079/23.
XX
PT   Novel antisense compound useful for treating type 2 diabetes, cancer and
PT   obesity, is targeted to nucleic acid encoding human protein phosphatase
PT   1B, and hybridizes and inhibits PTP1B expression.
XX
PS   Claim 3; Page 72; 142pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid molecule
CC   encoding protein phosphatase 1B (PTP1B), which specifically hybridises
CC   with and inhibits the expression of PTP1B. The compounds of the invention
CC   are useful for inhibiting the expression of PTP1B in liver, kidney or
CC   adipose cells or tissues and for treating an animal, preferably human,
CC   having a disease or condition associated with PTP1B, including metabolic
CC   diseases or conditions, e.g. type 2 diabetes and obesity, or
CC   hyperproliferative conditions such as cancer. The sequences are also
CC   useful for decreasing blood (serum or plasma) glucose levels in an animal
CC   e.g. a diabetic human or rodent, for preventing or delaying the onset of
CC   a disease or condition associated with PTP1B , and for preventing or
CC   delaying the onset of an increase in blood glucose levels. This sequence
CC   represents a PTP1B mRNA level inhibition antisense oligonucleotide of the
CC   invention
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
              ||||| | ||| |||||| |
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 403
ABS70610
ID   ABS70610 standard; DNA; 20 BP.
XX
```

```
AC   ABS70610;
XX
DT   25-NOV-2002  (first entry)
XX
DE   Dendritic cell stimulating CpG oligodeoxynucleotide #99.
XX
KW   CpG; ss; dendritic cell; dendritic cell activation; cytostatic;
KW   antiallergic; cancer; immunotherapy; infectious disease; allergy.
XX
OS   Synthetic.
XX
PN   US6429199-B1.
XX
PD   06-AUG-2002.
XX
PF   13-NOV-1998;   98US-00191170.
XX
PR   15-JUL-1994;   94US-00276358.
PR   07-FEB-1995;   95US-00386063.
PR   30-OCT-1996;   96US-00738652.
PR   30-OCT-1997;   97US-00960774.
XX
PA   (IOWA ) UNIV IOWA RES FOUND.
XX
PI   Krieg AM,  Hartmann G;
XX
DR   WPI; 2002-689667/74.
XX
PT   Activating a dendritic cell for cancer immunotherapy or for treating
PT   infectious or allergy disease, by contacting a dendritic cell with an
PT   isolated nucleic acid containing at least one unmethylated CpG
PT   dinucleotide.
XX
PS   Example 6; Col 34; 52pp; English.
XX
CC   This invention relates to a novel method for activating or causing
CC   maturation of a dendritic cell. The method comprises contacting a
CC   dendritic cell with an isolated nucleic acid containing at least one
CC   unmethylated CpG dinucleotide in an amount effective to activate or cause
CC   maturation of the dendritic cell, where the activation is performed ex
CC   vivo. The method of the invention may have cytostatic or antiallergic
CC   activities. The method of the invention is useful for cancer
CC   immunotherapy or for treating an infectious disease or allergy, by
CC   administering an activated dendritic cell that express a specific cancer,
CC   microbial or allergy causing antigen, to a subject having a cancer
CC   including the cancer antigen, to a subject having an infection with a
CC   microorganism including the microbial antigen or to a subject having an
CC   allergic reaction to the allergy causing antigen, where the activated
CC   dendritic cell is prepared using the method of the invention. The method
CC   is useful for generating a high yield of dendritic cells by administering
CC   an isolated nucleic acid containing at least one unmethylated CpG
CC   dinucleotide, where the nucleic acid is 8-80 bases in length in an amount
CC   effective to activate the dendritic cells to a subject, and isolating
CC   dendritic cells from the subject. The use of CpG allows the generation of
CC   mature dendritic cells from peripheral blood within two days in a well
CC   defined system. The application of CpG for this purpose is superior to
CC   granulocyte macrophage-colony stimulating factor (GM-CSF), which is
CC   currently used for this purpose. CpG oligonucleotides have a longer half
CC   life, are less expensive, and show a greater magnitude of immune effects.
CC   The present sequence represents a CpG oligonucleotide used in the method
CC   of the invention
XX
SQ   Sequence 20 BP; 13 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20
```

```
RESULT 404
ABI94166/c
ID   ABI94166 standard; DNA; 20 BP.
XX
AC   ABI94166;
XX
DT   16-FEB-2002  (first entry)
XX
DE   Capture oligonucleptide Zip ID#1253 oligo #9.
XX
KW   Human; K-ras; PCR primer; probe; capture probe; mutation detection;
KW   ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
KW   infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
KW   oncogene; tumour suppressor; human papillomavirus; forensic;
KW   environmental monitoring; food industry; feed industry; ss.
XX
OS   Synthetic.
XX
PN   WO200179548-A2.
XX
PD   25-OCT-2001.
XX
PF   04-APR-2001; 2001WO-US010958.
XX
PR   14-APR-2000; 2000US-0197271P.
XX
PA   (CORR ) CORNELL RES FOUND INC.
XX
PI   Barany F,  Zirvi M,  Gerry NP,  Favis R,  Kliman R;
XX
DR   WPI; 2002-034366/04.
XX
PT   Designing capture oligonucleotide probes for use on a support to which
PT   complementary oligonucleotides hybridize with little mismatch.
XX
PS   Example 5; Fig 29; 300pp; English.
XX
CC   The present invention describes a method (M1) for designing capture
CC   oligonucleotide probes (I) for use on a support to which complementary
CC   oligonucleotide probes (II) will hybridise with little mismatch, where
CC   (I) have melting temperatures within a narrow range. The method is useful
CC   for detecting infectious diseases caused by bacterial infectious agents
CC   e.g. Salmonella, Listeria monocytogenes and Haemophilus influenza, fungal
CC   infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC   Aspergillus fumigautus, viruses e.g. T-cell lymphocytotrophis cirus,
CC   Epstein-Barr virus and polio virus, and parasitic infectious agents
CC   selected from Onchoverva volvulus, Entamoeba histolytica and Dracunculus
CC   medinesis. The method is also useful for detecting genetic diseases such
CC   as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC   Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC   involved in DNA amplification, replication, recombination or repair, the
CC   cancer is specifically associated with a gene selected from BRCA1 gene,
CC   p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC   method is also used for environmental monitoring, forensics and the food
CC   and feed industry, detecting comprises scanning (using e.g. a scanning
CC   electron microscope and infrared microscope) the support at the
CC   particular sites and identifying if ligation of the oligonucleotide probe
CC   sets occurred and correlating (using a computer) identified ligation to a
CC   presence or absence of the target nucleotide sequences. ABI82074 to
CC   ABI97546 represent oligonucleotide sequences used in the exemplification
CC   of the present invention
XX
SQ   Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1593 GGGAACCCCTCCTGGCCTGG 1612
              |||||| | |||| || |||
Db         20 GGGAACTCGTCCTTGCATGG 1
```

```
RESULT 405
ABT43367
ID   ABT43367 standard; DNA; 20 BP.
XX
AC   ABT43367;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Neuroblastoma-related DNA sequence #282.
XX
KW   Neuroblastoma; prognosis; ds; oligonucleotide.
XX
OS   Unidentified.
XX
PN   WO2002103017-A1.
XX
PD   27-DEC-2002.
XX
PF   30-MAY-2002; 2002WO-JP005295.
XX
PR   31-MAY-2001; 2001JP-00163666.
PR   24-AUG-2001; 2001JP-00255260.
XX
PA   (CHIB-) CHIBA PREFECTURE.
PA   (HISM ) HISAMITSU PHARM CO LTD.
XX
PI   Nakagawara A;
XX
DR   WPI; 2003-167523/16.
XX
PT   Nucleic acids isolated from neuroblastoma showing enhanced expression in
PT   human neuroblastoma with good prognosis, useful in clarifying good/poor
PT   prognosis of neuroblastoma and providing genetic data.
XX
PS   Example 5; Page 25; 444pp; Japanese.
XX
CC   The invention comprises DNA sequences that show enhanced expression in
CC   human neuroblastoma with good prognosis. The DNA sequences of the
CC   invention are useful in clarifying good/poor prognosis of neuroblastoma.
CC   The present DNA sequence was used in the exemplification of the invention
XX
SQ   Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCTTCTCT 1803
              |||||| |||||   |||||
Db          1 ACCCCACTCTTTGGGTCTCT 20


RESULT 406
ABT32534
ID   ABT32534 standard; DNA; 20 BP.
XX
AC   ABT32534;
XX
DT   08-MAY-2003  (first entry)
XX
DE   Neuroblastoma-related oligonucleotide #311.
XX
KW   Neuroblastoma; prognosis; spontaneous regression; primer; probe; ds;
KW   high malignancy.
XX
OS   Unidentified.
XX
PN   WO200297093-A1.
XX
PD   05-DEC-2002.
XX
PF   30-MAY-2002; 2002WO-JP005294.
XX
PR   30-MAY-2001; 2001JP-00162775.
PR   24-AUG-2001; 2001JP-00255226.
XX
PA   (CHIB-) CHIBA PREFECTURE.
PA   (HISM ) HISAMITSU PHARM CO LTD.
XX
PI   Nakagawara A;
XX
DR   WPI; 2003-140476/13.
XX
PT   Nucleic acids having higher expression in human neuroblastoma with poor
PT   prognosis for diagnostic prediction of neuroblastoma prognosis.
XX
PS   Example 5; Page 28; 111pp; Japanese.
XX
CC   The invention comprises nucleic acids that show increased expression in
CC   human neuroblastomas with poor prognosis over those with a good
CC   prognosis. The nucleic acids of the invention are useful as a tool for
CC   distinguishing neuroblastomas with a favourable prognosis (spontaneous
CC   regression) from neuroblastomas with a poor prognosis (high malignancy).
CC   The DNA sequences ABT32224 - ABT32571 represent oligonucleotides used in
CC   an example of the invention
XX
SQ   Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCTTCTCT 1803
              |||||| |||||   |||||
Db          1 ACCCCACTCTTTGGGTCTCT 20


RESULT 407
ACD99656/c
ID   ACD99656 standard; DNA; 20 BP.
XX
AC   ACD99656;
XX
DT   25-SEP-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #342.
XX
KW   Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW   antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW   psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW   inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS   Synthetic.
XX
PN   US2003050268-A1.
XX
PD   13-MAR-2003.
XX
PF   29-MAR-2002; 2002US-00112653.
XX
PR   29-MAR-2001; 2001US-0279642P.
XX
PA   (KRIE/) KRIEG A M.
PA   (BERG/) BERG D J.
XX
PI   Krieg AM,  Berg DJ;
XX
DR   WPI; 2003-521815/49.
XX
PT   Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT   allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT   disease by administering an immunostimulatory nucleic acid.
XX
PS   Disclosure; Page 18; 229pp; English.
XX
CC   The invention describes a method of treating non-allergic inflammatory
```

```
CC   disease comprising administering to a subject having or at risk of
CC   developing a non-allergic inflammatory disease an immunostimulatory
CC   nucleic acid for prevention or treatment of the disease. The method is
CC   useful for treating non-allergic inflammatory diseases, such as
CC   psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC   inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC   This sequence represents an immunostimulatory nucleic acid
XX
SQ   Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  |||||||||  |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 408
ACH03114
ID   ACH03114 standard; DNA; 20 BP.
XX
AC   ACH03114;
XX
DT   25-SEP-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #749.
XX
KW   Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW   antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW   psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW   inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS   Synthetic.
XX
PN   US2003050268-A1.
XX
PD   13-MAR-2003.
XX
PF   29-MAR-2002; 2002US-00112653.
XX
PR   29-MAR-2001; 2001US-0279642P.
XX
PA   (KRIE/) KRIEG A M.
PA   (BERG/) BERG D J.
XX
PI   Krieg AM,  Berg DJ;
XX
DR   WPI; 2003-521815/49.
XX
PT   Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT   allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT   disease by administering an immunostimulatory nucleic acid.
XX
PS   Disclosure; Page 29; 229pp; English.
XX
CC   The invention describes a method of treating non-allergic inflammatory
CC   disease comprising administering to a subject having or at risk of
CC   developing a non-allergic inflammatory disease an immunostimulatory
CC   nucleic acid for prevention or treatment of the disease. The method is
CC   useful for treating non-allergic inflammatory diseases, such as
CC   psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC   inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC   This sequence represents an immunostimulatory nucleic acid
XX
SQ   Sequence 20 BP; 13 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
                || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 409
ACD99816/c
ID   ACD99816 standard; DNA; 20 BP.
XX
AC   ACD99816;
XX
DT   25-SEP-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #502.
XX
KW   Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW   antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW   psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW   inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS   Synthetic.
XX
PN   US2003050268-A1.
XX
PD   13-MAR-2003.
XX
PF   29-MAR-2002; 2002US-00112653.
XX
PR   29-MAR-2001; 2001US-0279642P.
XX
PA   (KRIE/) KRIEG A M.
PA   (BERG/) BERG D J.
XX
PI   Krieg AM,  Berg DJ;
XX
DR   WPI; 2003-521815/49.
XX
PT   Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT   allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT   disease by administering an immunostimulatory nucleic acid.
XX
PS   Disclosure; Page 22; 229pp; English.
XX
CC   The invention describes a method of treating non-allergic inflammatory
CC   disease comprising administering to a subject having or at risk of
CC   developing a non-allergic inflammatory disease an immunostimulatory
CC   nucleic acid for prevention or treatment of the disease. The method is
CC   useful for treating non-allergic inflammatory diseases, such as
CC   psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC   inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC   This sequence represents an immunostimulatory nucleic acid
XX
SQ   Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 410
ACH03191/c
ID   ACH03191 standard; DNA; 20 BP.
XX
AC   ACH03191;
XX
DT   25-SEP-2003  (first entry)
XX
DE   Immunostimulatory nucleic acid #826.
XX
KW   Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
```

KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
OS Synthetic.
XX
PN US2003050268-A1.
XX
PD 13-MAR-2003.
XX
PF 29-MAR-2002; 2002US-00112653.
XX
PR 29-MAR-2001; 2001US-0279642P.
XX
PA (KRIE/) KRIEG A M.
PA (BERG/) BERG D J.
XX
PI Krieg AM, Berg DJ;
XX
DR WPI; 2003-521815/49.
XX
PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT disease by administering an immunostimulatory nucleic acid.
XX
PS Disclosure; Page 31; 229pp; English.
XX
CC The invention describes a method of treating non-allergic inflammatory
CC disease comprising administering to a subject having or at risk of
CC developing a non-allergic inflammatory disease an immunostimulatory
CC nucleic acid for prevention or treatment of the disease. The method is
CC useful for treating non-allergic inflammatory diseases, such as
CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC This sequence represents an immunostimulatory nucleic acid
XX
SQ Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1776 TTTTTTGAACCCCATTCTTT 1795
|||||||||| ||| |||
Db 20 TTTTTTGAACGTCATGTTTT 1

RESULT 411
ADB37152/c
ID ADB37152 standard; DNA; 20 BP.
XX
AC ADB37152;
XX
DT 04-DEC-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #766.
XX
KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW hypo-responsive subject; immunostimulatory.
XX
OS Synthetic.
XX
PN US2003087848-A1.
XX
PD 08-MAY-2003.
XX
PF 02-FEB-2001; 2001US-00776479.
XX
PR 03-FEB-2000; 2000US-0179991P.
XX
PA (BRAT/) BRATZLER R L.
PA (PETE/) PETERSEN D M.
PA (FOUR/) FOURON Y.
XX
PI Bratzler RL, Petersen DM, Fouron Y;
XX
DR WPI; 2003-657977/62.
XX
PT Treating and/or preventing allergy or asthma using an immunostimulatory
PT nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS Disclosure; Page 17; 221pp; English.
XX
CC The invention relates to a method of treating or preventing allergy or
CC asthma which comprises administering to a subject a poly-G nucleic acid
CC in an aerosol formulation. The methods and compositions of the present
CC invention are useful for diagnosing and/or treating asthma and allergy
CC especially in a hypo-responsive subject. The present sequence represents
CC an immunostimulatory nucleic acid of the invention.
XX
SQ Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1776 TTTTTTGAACCCCATTCTTT 1795
|||||||||| ||| |||
Db 20 TTTTTTGAACGTCATGTTTT 1

RESULT 412
ADB36727/c
ID ADB36727 standard; DNA; 20 BP.
XX
AC ADB36727;
XX
DT 04-DEC-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #341.
XX
KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW hypo-responsive subject; immunostimulatory.
XX
OS Synthetic.
XX
PN US2003087848-A1.
XX
PD 08-MAY-2003.
XX
PF 02-FEB-2001; 2001US-00776479.
XX
PR 03-FEB-2000; 2000US-0179991P.
XX
PA (BRAT/) BRATZLER R L.
PA (PETE/) PETERSEN D M.
PA (FOUR/) FOURON Y.
XX
PI Bratzler RL, Petersen DM, Fouron Y;
XX
DR WPI; 2003-657977/62.
XX
PT Treating and/or preventing allergy or asthma using an immunostimulatory
PT nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS Disclosure; Page 10; 221pp; English.
XX
CC The invention relates to a method of treating or preventing allergy or
CC asthma which comprises administering to a subject a poly-G nucleic acid
CC in an aerosol formulation. The methods and compositions of the present
CC invention are useful for diagnosing and/or treating asthma and allergy
CC especially in a hypo-responsive subject. The present sequence represents
CC an immunostimulatory nucleic acid of the invention.
XX
SQ Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  ||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1
```

RESULT 413
ADB36898/c
ID ADB36898 standard; DNA; 20 BP.
XX
AC ADB36898;
XX
DT 04-DEC-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #512.
XX
KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW hypo-responsive subject; immunostimulatory.
XX
OS Synthetic.
XX
PN US2003087848-A1.
XX
PD 08-MAY-2003.
XX
PF 02-FEB-2001; 2001US-00776479.
XX
PR 03-FEB-2000; 2000US-0179991P.
XX
PA (BRAT/) BRATZLER R L.
PA (PETE/) PETERSEN D M.
PA (FOUR/) FOURON Y.
XX
PI Bratzler RL, Petersen DM, Fouron Y;
XX
DR WPI; 2003-657977/62.
XX
PT Treating and/or preventing allergy or asthma using an immunostimulatory
PT nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS Disclosure; Page 12; 221pp; English.
XX
CC The invention relates to a method of treating or preventing allergy or
CC asthma which comprises administering to a subject a poly-G nucleic acid
CC in an aerosol formulation. The methods and compositions of the present
CC invention are useful for diagnosing and/or treating asthma and allergy
CC especially in a hypo-responsive subject. The present sequence represents
CC an immunostimulatory nucleic acid of the invention.
XX
SQ Sequence 20 BP; 12 A; 3 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1
```

RESULT 414
ADB37078
ID ADB37078 standard; DNA; 20 BP.
XX
AC ADB37078;
XX
DT 04-DEC-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #692.
XX
KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW hypo-responsive subject; immunostimulatory.
XX
OS Synthetic.
XX
PN US2003087848-A1.
XX
PD 08-MAY-2003.
XX
PF 02-FEB-2001; 2001US-00776479.
XX
PR 03-FEB-2000; 2000US-0179991P.
XX
PA (BRAT/) BRATZLER R L.
PA (PETE/) PETERSEN D M.
PA (FOUR/) FOURON Y.
XX
PI Bratzler RL, Petersen DM, Fouron Y;
XX
DR WPI; 2003-657977/62.
XX
PT Treating and/or preventing allergy or asthma using an immunostimulatory
PT nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS Disclosure; Page 16; 221pp; English.
XX
CC The invention relates to a method of treating or preventing allergy or
CC asthma which comprises administering to a subject a poly-G nucleic acid
CC in an aerosol formulation. The methods and compositions of the present
CC invention are useful for diagnosing and/or treating asthma and allergy
CC especially in a hypo-responsive subject. The present sequence represents
CC an immunostimulatory nucleic acid of the invention.
XX
SQ Sequence 20 BP; 13 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20
```

RESULT 415
ADC53902/c
ID ADC53902 standard; DNA; 20 BP.
XX
AC ADC53902;
XX
DT 18-DEC-2003 (first entry)
XX
DE Pediococcus detection PCR primer #2.
XX
KW Pediococcus bacteria detection; spacer region; 16S rRNA; 23S rRNA;
KW beer brewery; fermented-food; ss; PCR; primer.
XX
OS Pediococcus acidilactici.
OS Pediococcus pentosaceus.
XX
PN JP2003038181-A.
XX
PD 12-FEB-2003.
XX
PF 01-JUN-2001; 2001JP-00165989.
XX
PR 01-JUN-2001; 2001JP-00165989.
XX
PA (ASAK) ASAHI BREWERIES LTD.
XX
DR WPI; 2003-590691/56.
XX
PT Oligonucleotide for detecting bacteria, comprises sequence of spacer

PT region between genes encoding 16S rRNA and 23S rRNA of Pediococcus
PT dextrinicus, Pediococcus parvulus, Pediococcus acidilactici, Pediococcus
PT pentosaceus.
XX
PS Claim 21; SEQ ID NO 18; 18pp; Japanese.
XX
CC The invention comprises oligonucleotides for detecting bacteria, the
CC oligonucleotides contain a gene sequence of a spacer region between genes
CC encoding 16S rRNA and 23S rRNA of Pediococcus dextrinicus, P. parvulus,
CC P. acidilactici or P. pentosaceus. The oligonucleotides of the invention
CC are useful as primers for detecting P. dextrinicus, P. parvulus, P.
CC acidilactici and P. pentosaceus, in beer brewery and in fermented-food
CC preparation process. The present DNA sequence represents a detection PCR
CC primer of the invention.
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1734 CAGAAGGTGACAAGTACTGG 1753
|||||| || |||| ||||
Db 20 CAGAAGATGTCAAGACCTGG 1

RESULT 416
AAD60260
ID AAD60260 standard; DNA; 20 BP.
XX
AC AAD60260;
XX
DT 18-DEC-2003 (first entry)
XX
DE Oligonucleotide 1638 used for activating dendritic cells.
XX
KW Dendritic cell activation; cancer immunotherapy; infectious disease;
KW allergy; cell therapy; ss.
XX
OS Unidentified.
XX
PN US2003100527-A1.
XX
PD 29-MAY-2003.
XX
PF 03-JUN-2002; 2002US-00161229.
XX
PR 15-JUL-1994; 94US-00276358.
PR 07-FEB-1995; 95US-00386063.
PR 30-OCT-1996; 96US-00738652.
PR 30-OCT-1997; 97US-00960774.
PR 13-NOV-1998; 98US-00191170.
XX
PA (IOWA) UNIV IOWA RES FOUND.
XX
PI Krieg AM, Hartmann G;
XX
DR WPI; 2003-708674/67.
XX
PT Activating a dendritic cell useful for treating cancer, infectious
PT diseases or allergies, comprises contacting the dendritic cell with an
PT amount of an isolated nucleic acid that contains at least one
PT unmethylated CpG dinucleotide.
XX
PS Disclosure; Page 11; 51pp; English.
XX
CC The invention relates to a method of activating a dendritic cell. The
CC method involves contacting the dendritic cell with an isolated nucleic
CC acid containing at least one unmethylated CpG dinucleotide, where the
CC nucleic acid is about 8-80 bases in length, in an amount that activates
CC the dendritic cell. The compositions and methods of the invention are
CC useful for cancer immunotherapy, or for treating an infectious disease
CC (e.g. viral, bacterial or fungal infections) or allergy. The invention is
CC useful in cell therapy. The present sequence is an oligonucleotide used
CC for activating dendritic cells
XX
SQ Sequence 20 BP; 13 A; 2 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1966 AATATTTACCTTGAAAAAAA 1985
|| || || ||||||||||
Db 1 AAAATCAACGTTGAAAAAAA 20

RESULT 417
ADD81281/c
ID ADD81281 standard; DNA; 20 BP.
XX
AC ADD81281;
XX
DT 29-JAN-2004 (first entry)
XX
DE HIV PRT antisense derived probe #210.
XX
KW ss; oligonucleotide hybridisation potential; efficient hybridisation;
KW large array; minimum oligonucleotide synthesis; probe.
XX
OS Human immunodeficiency virus.
XX
PN US2003054346-A1.
XX
PD 20-MAR-2003.
XX
PF 15-FEB-2001; 2001US-00784674.
XX
PR 10-FEB-1998; 98US-00021701.
XX
PA (SHAN/) SHANNON K W.
PA (WOLB/) WOLBER P K.
PA (DELE/) DELENSTARR G C.
PA (WEBB/) WEBB P G.
PA (KINC/) KINCAID R H.
XX
PI Shannon KW, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
XX
DR WPI; 2003-743746/70.
XX
PT Predicting potential of oligonucleotides to hybridize to target
PT nucleotide sequence comprises determining and evaluating for each
PT oligonucleotide a parameter predictive of the oligonucleotides ability to
PT hybridize with target.
XX
PS Example 2; SEQ ID NO 354; 423pp; English.
XX
CC The invention relates to a method of predicting the potential of
CC oligonucleotides to hybridise to target nucleotide sequences. The method
CC is useful for predicting the potential of an oligonucleotide to hybridise
CC to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
CC contains chemically modified nucleotides. The method is also useful for
CC predicting the potential of the oligonucleotides to hybridise to a
CC complementary target nucleotide sequence. The method is useful to predict
CC efficient hybridisation oligonucleotides for each of multiple target
CC sequences therefore very large arrays may be constructed and tested with
CC minimum synthesis of oligonucleotides. The present sequence represents a
CC HIV PRT antisense derived probe.
XX
SQ Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1818 AAGTTTTAGAATCTTTTAAA 1837

```
                || | |||||  ||||||||
Db         20 AAATCTTAGAGCCTTTTAAA 1


RESULT 418
ADE95637
ID   ADE95637 standard; DNA; 20 BP.
XX
AC   ADE95637;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human NOVX protein-related PCR primer Ag5928 reverse.
XX
KW   NOVX protein; biochemical stimulation; physiological stimulation;
KW   cardiant; antiarteriosclerotic; hypotensive; cytostatic; anorectic;
KW   antirheumatic; antiarthritic; antidiabetic; nephrotropic; dermatological;
KW   immunosuppressive; anti-HIV; antiinflammatory; neuroprotective;
KW   nootropic; antipsoriatic; antiparkinsonian; antiasthmatic; neuroleptic;
KW   antidepressant; antiallergic; gynaecological; gene therapy; vaccine;
KW   NOVX-associated disorder; cardiomyopathy; atherosclerosis; hypertension;
KW   cancer; obesity; rheumatoid arthritis; diabetes; glomerulonephritis;
KW   psoriasis; skin disorder; AIDS; inflammation; multiple sclerosis;
KW   Alzheimer's disease; Parkinson's disease; asthma; schizophrenia;
KW   depression; allergy; fertility disorder; PCR; primer; ss; Ag5928 reverse.
XX
OS   Homo sapiens.
XX
PN   WO2003050245-A2.
XX
PD   19-JUN-2003.
XX
PF   03-DEC-2002; 2002WO-US038594.
XX
PR   05-DEC-2001; 2001US-0336600P.
PR   07-DEC-2001; 2001US-0338285P.
PR   12-DEC-2001; 2001US-0341346P.
PR   17-DEC-2001; 2001US-0341477P.
PR   17-DEC-2001; 2001US-0341540P.
PR   20-DEC-2001; 2001US-0342592P.
PR   27-DEC-2001; 2001US-0344297P.
PR   31-DEC-2001; 2001US-0344903P.
PR   17-APR-2002; 2002US-0373288P.
PR   15-MAY-2002; 2002US-0380981P.
PR   17-MAY-2002; 2002US-0381495P.
PR   28-MAY-2002; 2002US-0383534P.
PR   28-MAY-2002; 2002US-0383744P.
PR   29-MAY-2002; 2002US-0383829P.
PR   29-MAY-2002; 2002US-0384024P.
PR   07-AUG-2002; 2002US-0401788P.
PR   26-AUG-2002; 2002US-0406353P.
PR   31-OCT-2002; 2002US-00401788.
PR   02-DEC-2002; 2002US-00406353.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Anderson DW,  Boldog FL,  Burgess CE,  Chillakuru RA;
PI   Edinger SR,  Gerlach VL,  Gorman L,  Gould-Rothberg BE,  Guo X;
PI   Jeffers ME,  Ji W,  Li L,  Malyankar UM,  Miller CE,  Murphey R;
PI   Patturajan M,  Peyman JA,  Rastelli L,  Rieger DK,  Shenoy SG;
PI   Smithson G,  Starling G,  Taupier RJ,  Voss EZ,  Zhong H,  Zhong M;
XX
DR   WPI; 2003-513974/48.
XX
PT   New NOVX polypeptides and nucleic acids, useful for preventing or
PT   treating NOVX-associated disorders, e.g. cancer, cardiomyopathy,
PT   atherosclerosis or diabetes, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Example B; SEQ ID NO 169; 211pp; English.
XX
CC   This invention relates to novel NOVX proteins, and the DNA sequence which
CC   encode them, having properties related to stimulation of biochemical or
CC   physiological responses in a cell, a tissue, an organ or an organism.
CC   Compounds which modulate the proteins of the invention may have cardiant,
CC   antiarteriosclerotic, hypotensive, cytostatic, anorectic, antirheumatic,
CC   antiarthritic, antidiabetic, nephrotropic, dermatological,
CC   immunosuppressive, anti-HIV, antiinflammatory, neuroprotective,
CC   nootropic, antipsoriatic, antiparkinsonian, antiasthmatic, neuroleptic,
CC   antidepressant, antiallergic or gynaecological activities. The DNA
CC   sequences of the invention may be useful for gene therapy whilst the
CC   protein sequences may allow the development of a vaccine. The protein is
CC   useful in the manufacture of a medicament for treating a syndrome
CC   associated with a human disease. The invention may be useful in
CC   diagnosing, treating or preventing NOVX-associated disorders, for example
CC   cardiomyopathy, atherosclerosis, hypertension, cancer, obesity,
CC   rheumatoid arthritis, diabetes, glomerulonephritis, psoriasis, skin
CC   disorders, AIDS, inflammation, multiple sclerosis, Alzheimer's disease,
CC   Parkinson's disease, asthma, schizophrenia, depression, allergies or
CC   fertility disorders. The nucleic acids may further be used as
CC   hybridisation probes, in chromosome mapping, tissue typing, preventive
CC   medicine, and pharmacogenomics. The present sequence is that of PCR
CC   primer Ag5928 reverse which was used for the amplification of a human
CC   gene sequence during the analysis of gene expression in the
CC   exemplification of the invention.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1650 CTTCACTGGTTCTGCATCAC 1669
                |||| ||||||  ||| |||
Db          1 CTTCCCTGGTTGAGCACCAC 20


RESULT 419
ADF78411
ID   ADF78411 standard; DNA; 20 BP.
XX
AC   ADF78411;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Chromosomal abnormality detection-related APC small deletion DNA 157.
XX
KW   chromosomal abnormality; maternal locus; genetic disorder; foetus;
KW   mutation; translocation; transversion; monosomy; trisomy; trisomy 21;
KW   chromosome 21; Down's Syndrome; anueoplodies; chromosome deletion;
KW   chromosome addition; chromosome amplification; chromosome translocation;
KW   chromosome rearrangement; single nucleotide polymorphism detection;
KW   SNP detection; pregnant female; APC; adenomatous polyposis coli; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003074723-A2.
XX
PD   12-SEP-2003.
XX
PF   28-FEB-2003; 2003WO-US006198.
XX
PR   01-MAR-2002; 2002US-0360232P.
PR   11-MAR-2002; 2002US-00093618.
PR   08-MAY-2002; 2002US-0378354P.
XX
PA   (DHAL/) DHALLAN R.
XX
PI   Dhallan R;
XX
DR   WPI; 2003-845073/78.
XX
PT   Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
PT   invasively in a fetus, comprises forming a ratio of amounts of alleles at
PT   a locus of interest and a different heterozygous locus.
XX
```

```
PS   Example 7; Page 164; 164pp; English.
XX
CC   This invention relates to a novel method of detecting chromosomal
CC   abnormalities by determining the sequence of alleles of a locus of
CC   interest from template DNA, determining which alleles are present and
CC   comparing to amounts of alleles at a different, selected heterozygous
CC   locus (for example on another chromosome or a maternal locus); relative
CC   amounts are expressed as a ratio indicating presence or absence of the
CC   abnormality. The method is useful for the detection of genetic disorders,
CC   especially in a foetus, including chromosomal abnormalities and
CC   mutations, for example translocations, transversions, monosomies,
CC   trisomies (for example trisomy 21 in which an additional copy of
CC   chromosome 21 results in Down's Syndrome) and other anueoplodies,
CC   deletions, additions, amplifications, translocations and rearrangements.
CC   It can be used to detect any alterations in a gene sequence, especially
CC   single nucleotide polymorphisms (SNPs), and may be used to detect
CC   numerous abnormalities simultaneously, for example if several SNPs are
CC   associated with a particular disease. The method provides a rapid, non-
CC   invasive method for determining the sequence of DNA from a foetus using a
CC   sample from a pregnant female, for example to detect genetic disorders as
CC   above or to determine if a foetus is a carrier of a disease or
CC   predisposed to a disease.
XX
SQ   Sequence 20 BP; 11 A; 1 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATCTAG 2002
              |||||||||  || | ||||
Db          1 AAAGAAAAGATTGGAACTAG 20


RESULT 420
ADH53216
ID   ADH53216 standard; DNA; 20 BP.
XX
AC   ADH53216;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human APC (adenomatous polyposis coli) DNA fragment 153.
XX
KW   sequence determination; recognition site; restriction endonuclease;
KW   human; APC; adenomatous polyposis coli; chromosome 5q21-22;
KW   colorectal cancer; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003074740-A1.
XX
PD   12-SEP-2003.
XX
PF   28-FEB-2003; 2003WO-US006376.
XX
PR   01-MAR-2002; 2002US-0360232P.
PR   11-MAR-2002; 2002US-00093618.
PR   08-MAY-2002; 2002US-0378354P.
XX
PA   (DHAL/) DHALLAN R.
XX
PI   Dhallan R;
XX
DR   WPI; 2003-756772/71.
XX
PT   Determining a sequence of a locus of interest comprises replicating a
PT   region of DNA comprising a locus of interest from a template
PT   polynucleotide by using a first and a second primer.
XX
PS   Example 5; Page 141; 190pp; English.
XX
CC   The invention relates to a novel method for determining the sequence of a
CC   locus of interest which comprises replicating a region of DNA comprising
CC   a locus of interest from a template polynucleotide by using a first and a
CC   second primer where the second primer contains a sequence that generates
CC   a recognition site for a restriction enzyme such that digestion with the
CC   restriction enzyme generates a 5' overhang containing the locus of
CC   interest. The method may be useful for determining the sequences of
CC   multiple loci of interest concurrently and for determining the sequence
CC   of a mutant allele in the presence of a normal allele. The current
CC   sequence is that of the human APC (adenomatous polyposis coli) DNA
CC   fragment of the invention which is located on chromosome 5q21-22 and in
CC   which mutations are associated with colorectal cancer.
XX
SQ   Sequence 20 BP; 11 A; 1 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATCTAG 2002
              |||||||||  || | ||||
Db          1 AAAGAAAAGATTGGAACTAG 20


RESULT 421
ADH93357/c
ID   ADH93357 standard; DNA; 20 BP.
XX
AC   ADH93357;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human gene PCR primer #202.
XX
KW   human; gene sequence; single nucleotide polymorphism; SNP;
KW   disease diagnosis; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   JP2003174883-A.
XX
PD   24-JUN-2003.
XX
PF   11-DEC-2001; 2001JP-00377637.
XX
PR   11-DEC-2001; 2001JP-00377637.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2003-819215/77.
XX
PT   Polynucleotide for detecting single nucleotide polymorphisms existing in
PT   human gene, contains isolated human gene having specified sequence.
XX
PS   Claim 2; SEQ ID NO 1194; 529pp; Japanese.
XX
CC   The invention comprises isolated human gene sequences and PCR primer
CC   sequences which can be used to detect single nucleotide polymorphisms
CC   (SNPs). The DNA sequences of the invention are useful for detecting SNPs
CC   existing in human genes and for the diagnosis of human disease. The
CC   present DNA sequence represents a human gene PCR primer of the invention.
XX
SQ   Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1840 CATTCCCTGGGCCAACAGAC 1859
              |||||||| || || ||| |
Db         20 CATTCCCTAGGTCAGCAGCC 1


RESULT 422
```

ABZ91627/c
ID ABZ91627 standard; DNA; 20 BP.
XX
AC ABZ91627;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 6869; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 10 A; 4 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1793 TTTCCTTCTCTGAAAGTGGT 1812
              ||||||| |  |||| ||||
Db         20 TTTCCTTTTTGGAAAATGGT 1
```

RESULT 423

ABZ90987
ID ABZ90987 standard; DNA; 20 BP.
XX
AC ABZ90987;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 6229; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 2 C; 11 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1605 TGGCCTGGGGGAAGAGTTTG 1624
              ||||| |||||||| |  ||
Db          1 TGGCCAGGGGGAAGTGGATG 20
```

RESULT 424

```
ABZ90974/c
ID   ABZ90974 standard; DNA; 20 BP.
XX
AC   ABZ90974;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 6216; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTTTTTTT 1928
             ||||| |||| |||  ||||
Db         20 GATCACCAATGCCTGCTTTT 1

RESULT 425
```

```
ABQ84589
ID   ABQ84589 standard; DNA; 20 BP.
XX
AC   ABQ84589;
XX
DT   20-FEB-2003  (first entry)
XX
DE   DPP10 related PSQ assay oligonucleotide #74.
XX
KW   DPP10; dipeptidyl peptidase; prolyloligopeptidase; enzyme; asthma;
KW   antiinflammatory; antiasthmatic; antipsoriatic; antiarthritic;
KW   antirheumatic; vaccine; gene therapy; inflammatory disease;
KW   inflammatory bowel disease; atopy; rheumatoid arthritis; psoriasis;
KW   chromosome 2q14; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO200286113-A2.
XX
PD   31-OCT-2002.
XX
PF   24-APR-2002; 2002WO-GB001887.
XX
PR   24-APR-2001; 2001GB-00010044.
PR   24-APR-2001; 2001GB-00010046.
PR   12-OCT-2001; 2001GB-00024575.
PR   12-OCT-2001; 2001GB-00024594.
XX
PA   (ISIS-) ISIS INNOVATIONS LTD.
XX
PI   Cookson WOCM,  Moffat MF,  Allen M,  Lench N;
XX
DR   WPI; 2003-093132/08.
XX
PT   New nucleic acid sequence comprising DPP10 mRNA, useful for the
PT   manufacture of a medicament for regulating DPP10 protein expression or
PT   for preventing or treating inflammatory disease e.g., inflammatory bowel
PT   disease.
XX
PS   Disclosure; Page 321; 321pp; English.
XX
CC   The present invention describes a new isolated nucleic acid sequence (I)
CC   comprising a DPP10 mRNA sequence. DPP10 is a dipeptidyl peptidase (also
CC   known as prolyloligopeptidase). (I) has antiinflammatory, antiasthmatic,
CC   antipsoriatic, antiarthritic and antirheumatic activities, and can be
CC   used in vaccines and gene therapy. A composition comprising (I) can be
CC   used for the manufacture of a medicament for regulating DPP10 expression
CC   or for preventing or treating inflammatory disease e.g., inflammatory
CC   bowel disease, asthma, atopy, rheumatoid arthritis or psoriasis. (I) can
CC   also be used in an assay for detecting or measuring DPP10 in a sample. A
CC   host cell comprising (I) can be used for producing recombinant DPP10 gene
CC   products, or in drug screening systems to identify agents for diagnosis
CC   or treatment of individuals having or susceptible to inflammatory
CC   disease. Human DPP10 is located on chromosome 2, more specifically
CC   chromosome 2q14. ABQ84254 to ABQ84612 and ABP55569 to ABP55629 represent
CC   sequences used in the exemplification of the present invention
XX
SQ   Sequence 20 BP; 9 A; 2 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1630 TACCTTACTATTTAAAGAGC 1649
              ||  ||| ||||||||||  |
Db          1 TAAATTAGTATTTAAAGACC 20

RESULT 426
ACC68889
ID   ACC68889 standard; DNA; 20 BP.
XX
AC   ACC68889;
```

```
XX
DT   02-JUL-2003  (first entry)
XX
DE   Human TGR23 phosphorothioate oligonucleotide SEQ ID NO:123.
XX
KW   G protein-coupled receptor; GPCR; TGR23-2; TGR23-1; TGR23; anorectic;
KW   cytostatic; obesity disorder; cancer; appetite stimulation;
KW   phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003025179-A1.
XX
PD   27-MAR-2003.
XX
PF   13-SEP-2002; 2002WO-JP009446.
XX
PR   14-SEP-2001; 2001JP-00279232.
PR   12-OCT-2001; 2001JP-00315148.
PR   10-APR-2002; 2002JP-00108621.
PR   10-JUN-2002; 2002JP-00169232.
XX
PA   (TAKE ) TAKEDA CHEM IND LTD.
XX
PI   Mori M,  Hayashi K,  Miya H,  Sato S,  Kitada C,  Matsumoto H;
PI   Nagi T,  Shimomura Y;
XX
DR   WPI; 2003-313356/30.
XX
PT   Polypeptides binding to G-protein coupled receptors TGR23-1 and TGR23-2
PT   for prevention and treatment of obesity, cancer and appetite disorders.
XX
PS   Example 46; Page 330; 338pp; Japanese.
XX
CC   The present invention describes polypeptides (I) and their amides, esters
CC   and salts which bind to the human G protein-coupled receptor (GPCR)
CC   proteins TGR23-1 and TGR23-2. TGR23 proteins have anorectic and
CC   cytostatic activities. (I) can be used in the treatment, prevention and
CC   diagnosis of obesity disorders and cancer (including cancer of the
CC   intestines, colon, breast, lung (including non-small cell lung cancer),
CC   prostate, oesophagus, stomach, liver, pancreas, kidney, womb, ovary,
CC   testis, bladder and brain, and blood cancers). (I) can also be used in
CC   appetite stimulation. ACC68807 to ACC68890 and ABP97241 to ABP97280
CC   represent sequences used in the exemplification of the present invention
XX
SQ   Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1857 GACCCACACACTTAGCCATT 1876
              |||||||| | ||| | |||
Db          1 GACCCACAGAGTTATCAATT 20


RESULT 427
ADM57498
ID   ADM57498 standard; DNA; 20 BP.
XX
AC   ADM57498;
XX
DT   03-JUN-2004  (first entry)
XX
DE   M. tuberculosis PCR primer RD11-Rv2646R.
XX
KW   antibacterial; vaccine; mmpL6; Mycobacterium; BCG; TbD1; ss; PCR; primer.
XX
OS   Mycobacterium tuberculosis.
XX
PN   EP1338657-A1.
XX
PD   27-AUG-2003.
XX
PF   25-FEB-2002; 2002EP-00290458.
XX
PR   25-FEB-2002; 2002EP-00290458.
XX
PA   (INSP ) INST PASTEUR.
XX
PI   Cole S,  Brosch R,  Gordon S,  Eiglmeier K,  Garnier T;
XX
DR   WPI; 2003-699254/67.
XX
PT   New TbD1 nucleic acids having the mutation CTG to CGG at codon 463 of
PT   gene katG, useful for distinguishing Mycobacterium tuberculosis infection
PT   from M. africanum, M. canetti, M. microti, M. bovis, or M. bovis BCG
PT   infection.
XX
PS   Disclosure; Page 20; 73pp; English.
XX
CC   The invention relates to a novel isolated or purified nucleic acid. A
CC   polypeptide encoded by a nucleic acid of the invention has antibacterial
CC   activity, and may have a use in a vaccine. The nucleic acid is a TbD1
CC   nucleic acid having a fully defined sequence of 3953 bp given in the
CC   specification. The TbD1 deletion or mmpL6 551 polymorphism is useful as a
CC   genetic marker for the differentiation of Mycobacterium strain of M.
CC   tuberculosis complex. The genetic marker in association with at least one
CC   genetic markers selected from RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8,
CC   RD9, RD10, Rd11, RD13, RD14, RvD1, RvD2, RvD3, RvD4, RvD5, katG463 ,
CC   gyrA95 , oxyR'285 , and pncA57, may be used for the differentiation of
CC   Mycobacterium strain of M. tuberculosis complex. The nucleic acids may
CC   also be used to distinguish an infection resulting from M. tuberculosis
CC   from an infection resulting from M. africanum, M. canetti, M. microti, M.
CC   bovis, M. bovis BCG. The present sequence is used in the exemplification
CC   of the invention.
XX
SQ   Sequence 20 BP; 4 A; 3 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1805 AAAGTGGTGCTATAAGTTTT 1824
              || ||| ||| ||| |||||
Db          1 AACGTGCTGCGATAGGTTTT 20


RESULT 428
ABD27857/c
ID   ABD27857 standard; DNA; 20 BP.
XX
AC   ABD27857;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA258396-derived oligonucleotide SEQ ID 6869.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
```

PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 6869; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 10 A; 4 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1793 TTTCCTTCTCTGAAAGTGGT 1812
||||||| | |||| ||||
Db 20 TTTCCTTTTTGGAAAATGGT 1

RESULT 429
ABD27217
ID ABD27217 standard; DNA; 20 BP.
XX
AC ABD27217;
XX
DT 29-JUL-2004 (first entry)
XX
DE AA180912-derived oligonucleotide SEQ ID 6229.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 6229; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 2 C; 11 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1605 TGGCCTGGGGGAAGAGTTTG 1624
||||| |||||||| | ||
Db 1 TGGCCAGGGGGAAGTGGATG 20

RESULT 430
ABD27204/c
ID ABD27204 standard; DNA; 20 BP.

```
XX
AC   ABD27204;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA180912-derived oligonucleotide SEQ ID 6216.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 6216; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTTTTTTT 1928
              ||||| |||| |||  ||||
Db         20 GATCACCAATGCCTGCTTTT 1


RESULT 431
ADP75384
ID   ADP75384 standard; DNA; 20 BP.
XX
AC   ADP75384;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human ADAM19 gene exon X reverse sequencing primer.
XX
KW   Human; ss; primer; ADAM19; Endophilin 1; Endophilin 2; NRG2; ADAMTS2;
KW   a disintegrin and metalloprotease; neuroregulin 2; SNP;
KW   single nucleotide polymorphism;
KW   a disintegrin and metalloprotease with thrombospondin type1 motif 2;
KW   asthma; atopy; obesity; inflammatory bowel disease; respiratory disorder.
XX
OS   Homo sapiens.
XX
PN   WO2003031594-A2.
XX
PD   17-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032700.
XX
PR   11-OCT-2001; 2001US-0328424P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Keith T,  Little RD,  Van Eerdewegh P,  Dupuis J,  Del Mastro RG;
PI   Allen K;
XX
DR   WPI; 2003-381712/36.
XX
PT   New isolated nucleic acid or alternate splice variant, useful for
PT   diagnosing and treating a disintegrin and metalloprotease (ADAM) or
PT   interactor gene-associated disorder, e.g. asthma, atopy, obesity or
PT   inflammatory bowel disease.
XX
PS   Claim 2; Page 128; 338pp; English.
XX
CC   The invention relates to an isolated nucleic acid or alternate splice
CC   variant comprising a nucleotide sequence containing at least one of the
CC   single nucleotide polymorphisms given in the specification, a nucleotide
CC   sequence having at least 15 contiguous nucleotides of them, or
CC   complements of them. The genes are ADAM19 (a disintegrin and
CC   metalloprotease 19, also known as gene 845), NRG2 (neuroregulin 2, also
CC   known as gene 847), endophilin 1 (also known as gene 874), endophilin 2
CC   (also known as gene 803) and ADAMTS2 (a disintegrin and metalloprotease
CC   with thrombospondin type1 motif 2, also known as gene 962). Also included
CC   are a vector comprising the isolated nucleic acid (or alternate splice
CC   variant), a host cell containing the vector, an isolated polypeptide
CC   encoded by the novel nucleic acid (or alternate splice variant), an
CC   antibody or antibody fragment that binds to the polypeptide,
CC   pharmaceutical compositions (comprising the nucleic acid or alternate
CC   splice variant, vector, polypeptide or antibody , and a carrier,
CC   excipient or diluent), a kit for detecting a disintegrin and
CC   metalloprotease (ADAM) gene nucleotide sequence (comprising the isolated
CC   nucleic acid or alternate splice variant, antibody or antibody fragment,
CC   and at least one component to detect the hybridisation of the variant or
CC   the binding of the antibody to an ADAM gene amino acid sequence), a kit
CC   for detecting an interactor gene amino acid sequence (comprising the
CC   antibody or antibody fragment, and at least one component to detect the
CC   binding of the antibody to the interactor gene amino acid sequence),
CC   diagnosing an ADAM or interactor gene-associated disorder or a
```

CC respiratory disorder in a human subject, determining an ADAM or
CC interactor gene pharmacogenetic profile in a human subject, identifying
CC an orthologue of a human ADAM or interactor gene, treating an ADAM or
CC interactor gene-associated disorder (or a respiratory disorder) by
CC administering the pharmaceutical composition, a transgenic mouse (whose
CC genome comprises an introduced null mutation in an endogenous gene that
CC is orthologous to a human ADAM gene), making a homozygous transgenic
CC knockout mouse, forming a crystal of the isolated polypeptide, a cell
CC line comprising the isolated nucleic acid or alternate splice variant, a
CC biochip comprising the isolated nucleic acid or alternate splice variant,
CC an isolated nucleic acid probe or primer comprising at least 8 contiguous
CC nucleotides of the nucleic acid, an isolated antisense nucleic acid,
CC identifying an ADAM or interactor gene ligand and an isolated nucleic
CC acid variant of Gene 803, 845, 847, 874 or 962. The nucleic acid or
CC alternate splice variants, methods, kits and antibody/antibody fragment
CC are useful for diagnosing and treating an ADAM or interactor gene-
CC associated disorder, e.g. asthma, atopy, obesity or inflammatory bowel
CC disease. The present sequence is a primer used to sequence the regions
CC surrounding polymorphisms in the above genes.
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1638 TATTTAAAGAGCCTTCACTG 1657
|| | |||||||||| | |||
Db 1 TCTCTAAAGAGCCTGCCCTG 20

RESULT 432
ADH65754
ID ADH65754 standard; DNA; 20 BP.
XX
AC ADH65754;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human glucocorticoid receptor-specific antisense oligonucleotide #2588.
XX
KW antisense oligonucleotide; glucocorticoid receptor; infection;
KW inflammation; tumour formation; diabetes; obesity;
KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS Homo sapiens.
XX
PN WO2003099215-A2.
XX
PD 04-DEC-2003.
XX
PF 20-MAY-2003; 2003WO-US016084.
XX
PR 20-MAY-2002; 2002US-0381857P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Crosby SD, Nalseth AE;
XX
DR WPI; 2004-035034/03.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS Claim 4; SEQ ID NO 2588; 985pp; English.
XX
CC The invention comprises an antisense oligonucleotides that are targeted
CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC antisense oligonucleotides of the invention are useful for preventing or
CC delaying infection, inflammation or tumour formation. The antisense
CC oligonucleotides are also useful for treating diabetes, obesity,
CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC present DNA sequence represents an antisense oligonucleotide that targets
CC the human glucocorticoid receptor gene. NOTE: The present sequence
CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ Sequence 20 BP; 9 A; 2 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1822 TTTAGAATCTTTTAAATACA 1841
|||| |||| ||| |||| |
Db 1 TTTACAATCATTTTAATAAA 20

RESULT 433
ADH64065/c
ID ADH64065 standard; DNA; 20 BP.
XX
AC ADH64065;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human glucocorticoid receptor-specific antisense oligonucleotide #899.
XX
KW antisense oligonucleotide; glucocorticoid receptor; infection;
KW inflammation; tumour formation; diabetes; obesity;
KW cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS Homo sapiens.
XX
PN WO2003099215-A2.
XX
PD 04-DEC-2003.
XX
PF 20-MAY-2003; 2003WO-US016084.
XX
PR 20-MAY-2002; 2002US-0381857P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Crosby SD, Nalseth AE;
XX
DR WPI; 2004-035034/03.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS Claim 4; SEQ ID NO 899; 985pp; English.
XX
CC The invention comprises an antisense oligonucleotides that are targeted
CC to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC antisense oligonucleotides of the invention are useful for preventing or
CC delaying infection, inflammation or tumour formation. The antisense
CC oligonucleotides are also useful for treating diabetes, obesity,
CC cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC present DNA sequence represents an antisense oligonucleotide that targets
CC the human glucocorticoid receptor gene. NOTE: The present sequence
CC contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ Sequence 20 BP; 10 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1992 TGTGTATCTAGCTTCTTCAG 2011
| ||||| || || ||||||
Db 20 TTTGTATATATCTGCTTCAG 1

```
RESULT 434
ADH66141
ID   ADH66141 standard; DNA; 20 BP.
XX
AC   ADH66141;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #2975.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 2975; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 9 A; 2 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACATT 1843
              || |||| ||| |||| |||
Db          1 TACAATCATTTTAATAAATT 20


RESULT 435
ADH63542/c
ID   ADH63542 standard; DNA; 20 BP.
XX
AC   ADH63542;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #376.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 376; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 9 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1994 TGTATCTAGCTTCTTCAGAG 2013
              ||||| || || |||||| |
Db         20 TGTATATATCTGCTTCAGTG 1


RESULT 436
ADH65954
ID   ADH65954 standard; DNA; 20 BP.
XX
AC   ADH65954;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #2788.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
```

```
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 2788; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 9 A; 2 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAAATACAT 1842
                ||| |||| ||| |||| ||
Db          1 TTACAATCATTTTAATAAAT 20


RESULT 437
ADI13931/c
ID   ADI13931 standard; DNA; 20 BP.
XX
AC   ADI13931;
XX
DT   22-APR-2004  (first entry)
XX
DE   Antisense DNA oligo to target rat PTP1B DNA SeqID 183.
XX
KW   rat; ss; antisense; PTP1B; protein phosphatase 1B; PTPN1;
KW   phosphorothioate backbone; hyperproliferative condition; cancer;
KW   cytostatic; antidiabetic; anorectic; type 2 diabetes; obesity.
XX
OS   Rattus norvegicus.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
FT                   nucleobases are 5' methylcytidine."
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
FT                   nucleobases are 5' methylcytidine."
XX
PN   US2003220282-A1.
XX
PD   27-NOV-2003.
XX
PF   07-FEB-2003; 2003US-00360510.
XX
PR   18-JAN-2000; 2000US-00487368.
PR   31-JUL-2000; 2000US-00629644.
PR   14-MAY-2001; 2001US-00854883.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bhanot S, Cowsert LM, Wyatt JR, Monia BP, Butler MM, Mckay R;
PI   Freier SM;
XX
DR   WPI; 2004-051719/05.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding PTP1B, useful for treating a disease/condition
PT   associated with PTP1B, such as cancer, diabetes or obesity.
XX
PS   Claim 3; SEQ ID NO 183; 143pp; English.
XX
CC   This invention relates to novel compositions and methods for modulating
CC   the expression of PTP1B (also known as protein phosphatase 1B and PTPN1).
CC   Specifically, it refers to antisense compounds that can target and
CC   hybridise with a nucleic acid molecule encoding PTP1B, as well as splice
CC   variants thereof and inhibit expression accordingly. PTP1B is a tyrosine
CC   phosphatase that plays an essential regulatory role in signalling
CC   mediated by the insulin receptor and as such is useful for treating
CC   diseases such as type 2 diabetes and obesity. Furthermore, PTP1B can
CC   suppress transformation of oncogenic genes, such that compositions of
CC   this invention can also be used to treat hyperproliferative conditions
CC   including cancer. Accordingly, these compounds can be described as having
CC   cytostatic, antidiabetic and anorectic activities. This oligonucleotide
CC   sequence is an antisense DNA oligo that targets rat PTP1B DNA, and which
CC   has a phosphorothioate backbone and 2'-O-methoxyethyl wings, used in an
CC   exemplification of the invention.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
                ||||| | ||| ||||||  |
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 438
ADI26879/c
ID   ADI26879 standard; DNA; 20 BP.
XX
AC   ADI26879;
XX
DT   22-APR-2004  (first entry)
XX
DE   Cyclin dependent kinase 4 antisense oligonucleotide #45.
XX
KW   cytostatic; antidiabetic; antiinfertility; gene therapy;
KW   cyclin-dependent kinase 4; diabetes; infertility;
KW   hyperproliferative disorder; cancer; antisense technology; human; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004005567-A1.
XX
PD   08-JAN-2004.
```

```
XX
PF   02-JUL-2002; 2002US-00188779.
XX
PR   02-JUL-2002; 2002US-00188779.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Freier SM,  Dobie KW;
XX
DR   WPI; 2004-081710/08.
XX
PT   New antisense oligonucleotide, having a sequence targeted to a nucleic
PT   acid encoding cyclin-dependent kinase 4, useful for preparing a
PT   composition for treating diabetes, infertility or hyperproliferative
PT   disorder, e.g., cancer.
XX
PS   Example 15; SEQ ID NO 64; 90pp; English.
XX
CC   The invention describes a new antisense oligonucleotide, having a
CC   sequence comprising 8-80 bp targeted to a nucleic acid encoding cyclin-
CC   dependent kinase 4, specifically hybridises with the nucleic acid
CC   encoding cyclin-dependent kinase 4 and inhibits expression of cyclin-
CC   dependent kinase 4. The antisense oligonucleotide is useful for preparing
CC   a composition for treating diabetes, infertility or hyperproliferative
CC   disorder, e.g., cancer. This sequence represents a human cyclin dependent
CC   kinase 4 antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1593 GGGAACCCCTCCTGGCCTGG 1612
              | |||||| |||||||  ||
Db         20 GAGAACCCATCCTGGCTGGG 1


RESULT 439
ADJ85510/c
ID   ADJ85510 standard; DNA; 20 BP.
XX
AC   ADJ85510;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Nucleic acid analysis-related Tag probe SeqID578.
XX
KW   restriction endonuclease site; T3 promoter site; Tag gene; Poly A site;
KW   T7 Promoter; nucleic acid analysis; synthetic Tag gene; assay control;
KW   assay development; product development; product validation;
KW   quality control; probe; ss.
XX
OS   Synthetic.
OS   Unidentified.
XX
PN   WO2004007684-A2.
XX
PD   22-JAN-2004.
XX
PF   14-JUL-2003; 2003WO-US021990.
XX
PR   12-JUL-2002; 2002US-0395530P.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Christians FC;
XX
DR   WPI; 2004-122923/12.
XX
PT   New DNA molecules made by annealing and extending overlapping 60mer
PT   oligonucleotides, useful in producing synthetic Tag genes useful as assay
PT   controls, in assay development, product development and for quality
PT   control.
XX
PS   Disclosure; SEQ ID NO 578; 91pp; English.
XX
CC   This invention relates to a novel DNA molecule which comprises a DNA
CC   molecule made up of the following elements in a 5' to 3' direction: a
CC   first restriction endonuclease site; a T3 promoter site; at least one Tag
CC   gene comprising at least 5 20mer Tag sequences; a Poly A site having at
CC   least 21 consecutive A residues; a second restriction endonuclease site
CC   which may be the same or different than the first restriction
CC   endonuclease site; or a T7 Promoter on the opposite strand as the T3
CC   promoter. The invention may be useful in nucleic acid analysis, in
CC   particular to synthetic Tag genes useful as assay controls, in assay
CC   development, product development and validation and for quality control.
CC   The present sequence is that of a Tag oligonucleotide probe which may be
CC   used during the creation of the novel DNA molecule of the invention.
XX
SQ   Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2043 CTATCTGCTTAGCAACTAGT 2062
              ||||| |||||||  ||| |
Db         20 CTATCAGCTTAGCGCCTATT 1


RESULT 440
ADJ23949/c
ID   ADJ23949 standard; DNA; 20 BP.
XX
AC   ADJ23949;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human endothelial lipase antisense oligonucleotide, SEQ ID 2347.
XX
KW   Antilipaemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW   Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW   cardiovascular disorder; metabolic syndrome X; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "This oligonucleotide has a phosphorothioate
FT                    backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT                    and 3' ends, which are 4 nucleotides in length. Also all
FT                    cytidine residues are 5-methylcytidines"
XX
PN   WO2004009541-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022410.
XX
PR   19-JUL-2002; 2002US-0397106P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Bhat BG;
XX
DR   WPI; 2004-132912/13.
XX
PT   New antisense oligonucleotide for modulating endothelial lipase
PT   expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT   high density lipoprotein or cardiovascular disorders.
XX
PS   Claim 3; SEQ ID NO 2347; 1007pp; English.
```

```
XX
CC   The present invention relates to antisense oligonucleotides (ADJ21603-
CC   ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC   (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC   with and inhibits the expression of EL. The antisense oligonucleotides
CC   are useful for modulating the expression of endothelial lipase in cells
CC   or tissues to treat diseases associated with EL expression, such as
CC   dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC   disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC   used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ   Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTATCTG 2049
              ||||||||||  | | ||||
Db         20 GGAGGCAAAGTCTATCTCTG 1


RESULT 441
ADK81359/c
ID   ADK81359 standard; DNA; 20 BP.
XX
AC   ADK81359;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8693.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 8693; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 9 A; 6 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1927 TTTCAGTGTTAAGGTAATGG 1946
              |||||||||  |  || ||||
Db         20 TTTCAGTGTCATTGTGATGG 1


RESULT 442
ADK80553
ID   ADK80553 standard; DNA; 20 BP.
XX
AC   ADK80553;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #7887.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 7887; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 4 A; 2 C; 4 G; 10 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1763 CATTAAGCTTTTTTTTTTG 1782
              ||||||  |||||  ||| ||
Db          1 CATTAAACTTTTGGTTTGTG 20
```

```
RESULT 443
ADK77601/c
ID   ADK77601 standard; DNA; 20 BP.
XX
AC   ADK77601;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4935.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 4935; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 13 A; 2 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCTTTTTT 1776
              |||||||||  |  ||||||
Db         20 TTTATTCATAGATGTTTTTT 1


RESULT 444
ADK78472
ID   ADK78472 standard; DNA; 20 BP.
XX
AC   ADK78472;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5806.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 5806; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 13 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGTGTATC 1999
              ||||||  ||||  |  |  ||||
Db          1 AAAAAACAAAAATTTATATC 20


RESULT 445
ADK78038/c
ID   ADK78038 standard; DNA; 20 BP.
XX
AC   ADK78038;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5372.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
```

PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 5372; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 13 A; 2 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1758 TTATTCATTAAGCTTTTTTT 1777
|||||||| | |||||||
Db 20 TTATTCATAGATGTTTTTTT 1

RESULT 446
ADK81049/c
ID ADK81049 standard; DNA; 20 BP.
XX
AC ADK81049;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8383.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 8383; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 12 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1766 TAAGCTTTTTTTTTTGAAC 1785
||| |||| ||||||| ||
Db 20 TAAATTTTGTTTTTTGCAC 1

RESULT 447
ADK81645/c
ID ADK81645 standard; DNA; 20 BP.
XX
AC ADK81645;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8979.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 8979; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a

```
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 10 A; 2 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCTTTT 1774
              ||||||||||  | |||| |
Db         20 TCTTTATTCAGCATGCTTAT 1


RESULT 448
ADL58723
ID   ADL58723 standard; DNA; 20 BP.
XX
AC   ADL58723;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 972.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 972; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 6 A; 5 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAATACATTCC 1845
              || ||||| ||||| | |||
Db          1 GATTCTTTCAAATATACTCC 20


RESULT 449
ADL59044/c
ID   ADL59044 standard; DNA; 20 BP.
XX
AC   ADL59044;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1293.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
```

```
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1293; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGTTACC 1629
              | || |||||||||| || |
Db         20 TTGGTGAAGAGTTTGGTATC 1


RESULT 450
ADL59127/c
ID   ADL59127 standard; DNA; 20 BP.
XX
AC   ADL59127;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1376.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1376; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 7 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1613 GGGAAGAGTTTGTTACCTAC 1632
              | |||||||||| || || |
Db         20 GTGAAGAGTTTGGTATCTGC 1


RESULT 451
ADL59120
ID   ADL59120 standard; DNA; 20 BP.
XX
AC   ADL59120;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1369.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
```

```
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1369; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 7 A; 4 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1825 AGAATCTTTTAAATACATTC 1844
              ||| ||||| ||||| | ||
Db          1 AGATTCTTTCAAATATACTC 20


RESULT 452
ADL59321
ID   ADL59321 standard; DNA; 20 BP.
XX
AC   ADL59321;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1570.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1570; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 8 A; 5 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              |||||||||||| | | | |
Db          1 AATATTTACCTTCATACACA 20


RESULT 453
ADL58019
ID   ADL58019 standard; DNA; 20 BP.
XX
AC   ADL58019;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 268.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
```

```
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 268; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 4 A; 3 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTTGTTAC 1628
              |||  |||||| || |||||
Db          1 CTGTTGGAAGACTTGGTTAC 20


RESULT 454
ADM13866
ID   ADM13866 standard; DNA; 20 BP.
XX
AC   ADM13866;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:53.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers

FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "phosphorothioate linkages and all cytidine
FT                    residues are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "2'-O-methocyethyls"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 53; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 2 A; 5 C; 4 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1921 CTTTTTTTTCAGTGTTAAGG 1940
              || | |||||| ||||| ||
Db          1 CTCTCTTTTCACTGTTAGGG 20


RESULT 455
ADM15567
ID   ADM15567 standard; DNA; 20 BP.
XX
AC   ADM15567;
XX
DT   01-JUL-2004  (first entry)
XX
```

```
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1754.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1754; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1844 CCCTGGGCCAACAGACCCAC 1863
              |||| ||| | ||||||||
Db          1 CACTGTGCCCAGAGACCCAC 20


RESULT 456
ADM14918
ID   ADM14918 standard; DNA; 20 BP.
XX
AC   ADM14918;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1105.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1105; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
```

CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 5 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1848 GGGCCAACAGACCCACACAC 1867
| ||| | |||||||||| |
Db 1 GTGCCCAGAGACCCACACGC 20

RESULT 457
ADM16151
ID ADM16151 standard; DNA; 20 BP.
XX
AC ADM16151;
XX
DT 15-JUL-2004 (first entry)
XX
DE Murine SAC1 DNA PCR primer #378.
XX
KW Mouse; SAC1; PCR; ss; carbohydrate; sweetener; ethanol; obesity;
KW diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;
KW primer.
XX
OS Mus musculus.
XX
PN US2004081964-A1.
XX
PD 29-APR-2004.
XX
PF 25-OCT-2002; 2002US-00280183.
XX
PR 25-OCT-2002; 2002US-00280183.
XX
PA (BACH/) BACHMANOV A A.
PA (BEAU/) BEAUCHAMP G K.
PA (LISS/) LI S.
PA (LIXX/) LI X.
PA (REED/) REED D R.
PA (TORD/) TORDOFF M G.
PA (ROSS/) ROSS D A.
PA (OHMA/) OHMAN J D.
PA (CHAT/) CHATTERJEE A.
PA (DJON/) DE JONG P J.
XX
PI Bachmanov AA, Beauchamp GK, Li S, Li X, Reed DR, Tordoff MG;
PI Ross DA, Ohman JD, Chatterjee A, De Jong PJ;
XX
DR WPI; 2004-340133/31.
XX
PT New isolated polynucleotides for sensing carbohydrates, other sweeteners,
PT or ethanol, useful for screening drugs for inhibition or restoration of
PT gene function as antidiabetic, antiobesity or antialcohol consumption
PT therapies.
XX
PS Example 12; SEQ ID NO 421; 148pp; English.
XX
CC The invention relates to SAC1 polypeptides and the polynucleotides
CC encoding them. The polynucleotides contain a variation associated with
CC sensing carbohydrates, other sweeteners or ethanol. The invention also
CC relates to a method for analysing a biomolecule in a biological sample,
CC comprising altering SAC1 activity in the sample and measuring the
CC activity, a method for analysing a polynucleotide in a biological sample,
CC comprising contacting a polynucleotide in a biological sample with a
CC probe where the probe hybridises to a SAC1 polynucleotide to form a
CC hybridisation complex and detecting the hybridisation complex, a method
CC of identifying susceptibility to obesity or diabetes comprising comparing
CC the nucleotide sequence of the suspected SAC1 allele with a wild type
CC nucleotide sequence, where the difference between the suspected allele
CC and the wild-type sequence identifies a sequence variation of the SAC1
CC nucleotide sequence, and a method of treating or preventing obesity,
CC diabetes or alcoholism associated with expression of SAC1, comprising
CC administering to a subject a pharmaceutical composition and a transgenic
CC animal that carries an altered SAC1 allele. The methods and compositions
CC of the invention are useful for screening drugs for inhibition or
CC restoration of gene function as antidiabetic, antiobesity or antialcohol
CC consumption therapies and for identifying sweeteners and alcohols. This
CC sequence represents a PCR primer used to amplify murine SAC1 DNA of the
CC invention.
XX
SQ Sequence 20 BP; 7 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1562 ACTGCAAAAATCCTTCTCCA 1581
|||||||| ||| |||||
Db 1 ACTGCAAATGTCCAACTCCA 20

RESULT 458
ADO53353
ID ADO53353 standard; DNA; 20 BP.
XX
AC ADO53353;
XX
DT 15-JUL-2004 (first entry)
XX
DE Farnesoid X receptor gene expression antisense inhibitory oligo #726.
XX
KW ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS Homo sapiens.
XX
PN WO2004030750-A1.
XX
PD 15-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030353.
XX
PR 25-SEP-2002; 2002US-0413588P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Kane CD;
XX
DR WPI; 2004-347928/32.
XX
PT New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.
XX
PS Claim 4; SEQ ID NO 726; 150pp; English.

```
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1748 TACTGGCTCTTTATTCATTA 1767
              ||||| |||| ||| | |||
Db          1 TACTGCCTCTCTATCCTTTA 20


RESULT 459
ADN37137
ID   ADN37137 standard; DNA; 20 BP.
XX
AC   ADN37137;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human Gankyrin DNA, antisense oligonucleotide #4.
XX
KW   Antisense therapy; human; Gankyrin; hyperproliferative disorder; cancer;
KW   cytostatic; phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "This oligonucleotide has a phosphorothioate
FT                    backbone and 2'-methyoxyethyl (2'-MOE) wings at the 5'
FT                    and 3' ends, which are 5 nucleotides in length at each
FT                    end. All cytidine residues are 5-methylcytidines"
XX
PN   US2004102391-A1.
XX
PD   27-MAY-2004.
XX
PF   21-NOV-2002; 2002US-00302027.
XX
PR   21-NOV-2002; 2002US-00302027.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Dobie KW;
XX
DR   WPI; 2004-399721/37.
XX
PT   New compound targeted to a nucleic acid molecule encoding Gankyrin and
PT   inhibits the expression of Gankyrin, useful for modulating the expression
PT   of Gankyrin or for diagnosing or treating, e.g. hyperproliferative
PT   disorder.
XX
PS   Example 15; SEQ ID NO 17; 52pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding human Gankyrin. The antisense compound comprises an
CC   antisense oligonucleotide that specifically hybridises with the nucleic
CC   acid and inhibits the expression of Gankyrin. The antisense
CC   oligonucleotide is a chimeric oligonucleotide. The antisense
CC   oligonucleotide comprises at least one modified internucleoside linkage,
CC   preferably a phosphorothioate linkage. It also comprises at least one
CC   modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar
CC   moiety. The antisense oligonucleotide further comprises at least one
CC   modified nucleobase, preferably a 5-methylcytosine. The antisense
CC   oligonucleotides are useful for the treatment of diseases such as
CC   hyperproliferative disorders, e.g. cancer. The present sequence
CC   represents an antisense oligonucleotide used in the examples of the
CC   present invention.
XX
SQ   Sequence 20 BP; 8 A; 2 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1919 ACCTTTTTTTTCAGTGTTAA 1938
              || |||| |||||| || ||
Db          1 ACATTTTATTTCAGAGTAAA 20


RESULT 460
ADP10780/c
ID   ADP10780 standard; DNA; 20 BP.
XX
AC   ADP10780;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Set 1 left PCR primer for marker probe #125.
XX
KW   transplant rejection; immune system; rheumatoid arthritis; lupus;
KW   inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO2004042346-A2.
XX
PD   21-MAY-2004.
XX
PF   24-APR-2003; 2003WO-US012946.
XX
PR   24-APR-2002; 2002US-00131831.
PR   20-DEC-2002; 2002US-00325899.
XX
PA   (EXPR-) EXPRESSION DIAGNOSTICS INC.
XX
PI   Wohlgemuth J,  Fry K,  Woodward R,  Ly N,  Prentice J,  Morris M;
PI   Rosenberg S;
XX
DR   WPI; 2004-400724/37.
XX
PT   Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,
PT   pancreas, pancreatic islet, lung, bone marrow or stem cell transplant
PT   rejection, in an individual, comprises detecting the expression level of
PT   the genes.
XX
PS   Claim 58; SEQ ID NO 789; 1762pp; English.
XX
CC   The present invention relates to diagnosing or monitoring transplant
CC   rejection, e.g. cardiac or kidney transplant rejection, in an individual
CC   comprises detecting the expression level of one or more genes. The
CC   methods, system and kits are useful in diagnosing or monitoring
CC   transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic
CC   islet, lung, bone marrow or stem cell transplant rejection,
CC   xenotransplant rejection or mechanical organ replacement rejection, in an
CC   individual. The method is also useful in assessing the immune status of
CC   an individual. The methods are also useful in diagnosing and monitoring
CC   diseases that involve the immune system, e.g. rheumatoid arthritis,
```

```
CC   lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or
CC   viral, bacterial or fungal infection. The present sequence represents a
CC   primer for a 50 mer oligonucleotide marker for diagnosis and monitoring
CC   of allograft rejection and other disorders.
XX
SQ   Sequence 20 BP; 3 A; 2 C; 8 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1837 ATACATTCCCTGGGCCAACA 1856
              | || |||||||| ||||
Db         20 AAACCTTCCCTGGCACAACA 1

RESULT 461
ADO48959/c
ID   ADO48959 standard; DNA; 20 BP.
XX
AC   ADO48959;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human jerky-like 1 antisense oligonculeotide seqid 21.
XX
KW   antiepileptic; jerky-like 1 modulator; jerky-like 1;
KW   gene expression inhibition; jerky-like 1 modulator; epilepsy; human;
KW   antisense oligonucleotide; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004097443-A1.
XX
PD   20-MAY-2004.
XX
PF   16-NOV-2002; 2002US-00298404.
XX
PR   16-NOV-2002; 2002US-00298404.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-447697/42.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding jerky-like 1, useful for treating diseases associated with jerky
PT   -like 1, e.g. epilepsy.
XX
PS   Example 15; SEQ ID NO 21; 38pp; English.
XX
CC   The invention describes a compound 8-80 nucleobases in length targeted
CC   to, and which specifically hybridises with, a nucleic acid molecule
CC   encoding jerky-like 1, and inhibits the expression of jerky-like 1. Also
CC   described are: inhibiting the expression of jerky-like 1 in cells or
CC   tissues by contacting the cells or tissues with the compound so that
CC   expression of jerky-like 1 is inhibited; screening a modulator of jerky-
CC   like 1; a diagnostic method for identifying a disease state by
CC   identifying the presence of jerky-like 1 in a sample using any of the
CC   primers or probes given in the specification; a kit or assay device
CC   comprising the compound; and treating an animal having a disease or
CC   condition associated with by jerky-like 1 administering to the animal a
CC   therapeutic or prophylactic amount of the compound so that expression of
CC   jerky-like 1 is inhibited. The compound, composition and methods are
CC   useful for treating a disease or condition associated with jerky-like 1,
CC   such as epilepsy. They are also useful in research and diagnostics for
CC   modulating the expression of jerky-like 1. This sequence represents an
CC   antisense oligonucleotide used to control the expression of human jerky-
CC   like 1.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 3.6e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1720 TTTGGACCTATTATCAGAAG 1739
              |||| ||  || ||||||||
Db         20 TTTGTACAGATAATCAGAAG 1

RESULT 462
ADO48994
ID   ADO48994 standard; DNA; 20 BP.
XX
AC   ADO48994;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human jerky-like 1 antisense oligonculeotide seqid 56.
XX
KW   antiepileptic; jerky-like 1 modulator; jerky-like 1;
KW   gene expression inhibition; jerky-like 1 modulator; epilepsy; human;
KW   antisense oligonucleotide; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= Phosphorothioate backbone. All cytidines
FT                   are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   15. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2004097443-A1.
XX
PD   20-MAY-2004.
XX
PF   16-NOV-2002; 2002US-00298404.
XX
PR   16-NOV-2002; 2002US-00298404.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-447697/42.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding jerky-like 1, useful for treating diseases associated with jerky
PT   -like 1, e.g. epilepsy.
XX
```

PS Example 15; SEQ ID NO 56; 38pp; English.
XX
CC The invention describes a compound 8-80 nucleobases in length targeted
CC to, and which specifically hybridises with, a nucleic acid molecule
CC encoding jerky-like 1, and inhibits the expression of jerky-like 1. Also
CC described are: inhibiting the expression of jerky-like 1 in cells or
CC tissues by contacting the cells or tissues with the compound so that
CC expression of jerky-like 1 is inhibited; screening a modulator of jerky-
CC like 1; a diagnostic method for identifying a disease state by
CC identifying the presence of jerky-like 1 in a sample using any of the
CC primers or probes given in the specification; a kit or assay device
CC comprising the compound; and treating an animal having a disease or
CC condition associated with by jerky-like 1 administering to the animal a
CC therapeutic or prophylactic amount of the compound so that expression of
CC jerky-like 1 is inhibited. The compound, composition and methods are
CC useful for treating a disease or condition associated with jerky-like 1,
CC such as epilepsy. They are also useful in research and diagnostics for
CC modulating the expression of jerky-like 1. This sequence represents an
CC antisense oligonucleotide used to control the expression of human jerky-
CC like 1.
XX
SQ Sequence 20 BP; 8 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1720 TTTGGACCTATTATCAGAAG 1739
|||| || || ||||||||
Db 1 TTTGTACAGATAATCAGAAG 20

RESULT 463
ADP69694
ID ADP69694 standard; DNA; 20 BP.
XX
AC ADP69694;
XX
DT 09-SEP-2004 (first entry)
XX
DE Human mitoNEET-specific antisense oligonucleotide #588.
XX
KW human; antisense oligonucleotide; mitochondrial membrane;
KW insulin sensitising antidiabetic thiazolodinediones; mitoNEET; diabetes;
KW immunological disorder; cardiovascular disorder; including hypertension;
KW neurological disorders; ischaemia; reperfusion; ss;
KW 2'-methoxyethyl gapmer; 2'-MOE gapmer; phosphorothioate backbone.
XX
OS Homo sapiens.
XX
PN WO2004053060-A2.
XX
PD 24-JUN-2004.
XX
PF 25-NOV-2003; 2003WO-US037621.
XX
PR 06-DEC-2002; 2002US-0431529P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Colca JR;
XX
DR WPI; 2004-468836/44.
XX
PT New antisense oligonucleotides encoding mitoNEET, useful for modulating
PT mitoNEET expression or for treating diseases associated with mitoNEET,
PT e.g. diabetes, immunological disorders or cardiovascular disorders.
XX
PS Claim 4; SEQ ID NO 588; 226pp; English.
XX
CC The invention comprises antisense oligonucleotides that are targeted to
CC the nucleic acids encoding a family of human proteins from mitochondrial
CC membranes, which bind insulin sensitising, antidiabetic
CC thiazolodinediones (referred to as: mitoNEET). The antisense
CC oligonucleotides of the invention are useful for modulating mitoNEET
CC expression and for treating diseases or conditions associated with
CC mitoNEET, such as: diabetes, immunological disorders, cardiovascular
CC disorders including hypertension, neurological disorders, and
CC ischaemia/reperfusion injuries. The present DNA sequence represents a
CC mitoNEET-specific antisense oligonucleotide of the invention. NOTE: The
CC present sequence is a 2'-methoxyethyl (2'-MOE) gapmer with a
CC phosphorothioate backbone.
XX
SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.6; DB 1; Length 20;
Best Local Similarity 80.0%; Pred. No. 3.6e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1579 CCACCGCACAGACTGGGAAC 1598
|| | |||||| |||||||
Db 1 CCCCATCACAGAATGGGAAC 20

RESULT 464
AAF46541
ID AAF46541 standard; DNA; 15 BP.
XX
AC AAF46541;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #1380.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 43; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,

CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 2 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1772 TTTTTTTTTTGAACC 1786
|||| ||||||||||
Db 1 TTTTATTTTTGAACC 15

RESULT 465
AAF46543
ID AAF46543 standard; DNA; 15 BP.
XX
AC AAF46543;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #1382.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 43; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1774 TTTTTTTTGAACCCC 1788
|| ||||||||||||
Db 1 TTATTTTTGAACCCC 15

RESULT 466
AAF46540
ID AAF46540 standard; DNA; 15 BP.
XX
AC AAF46540;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #1379.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 43; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 3 A; 1 C; 1 G; 10 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAAC 1785
              ||||| |||||||||
Db          1 TTTTTATTTTTGAAC 15


RESULT 467
AAF46542
ID   AAF46542 standard; DNA; 15 BP.
XX
AC   AAF46542;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1381.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 43; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 3 A; 3 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 15;
  Best Local Similarity   93.3%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1773 TTTTTTTTTGAACCC 1787
              ||| ||||||||||
Db          1 TTTATTTTTGAACCC 15


RESULT 468
AAQ30227/c
ID   AAQ30227 standard; DNA; 16 BP.
XX
AC   AAQ30227;
XX
DT   25-MAR-2003  (revised)
DT   07-DEC-1992  (first entry)
XX
DE   Oligomer HIV103 for forming triplex with HIV target duplex.
XX
KW   Human immunodeficiency virus; AIDS; modified; HIV; hepatitis; herpes;
KW   hepatitis; malignancy; inflammation; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   2
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT   modified_base   3
FT                   /*tag=  b
FT                   /mod_base= m5c
FT   modified_base   4
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT   modified_base   5
FT                   /*tag=  d
FT                   /mod_base= m5c
FT   modified_base   6
FT                   /*tag=  e
FT                   /mod_base= OTHER
FT                   /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT   modified_base   10
FT                   /*tag=  f
FT                   /mod_base= m5c
XX
PN   WO9209705-A1.
XX
PD   11-JUN-1992.
XX
PF   25-NOV-1991;   91WO-US008811.
XX
PR   23-NOV-1990;   90US-00617907.
PR   18-JAN-1991;   91US-00643382.
PR   08-APR-1991;   91US-00683420.
PR   17-APR-1991;   91US-00686544.
PR   17-APR-1991;   91US-00686546.
PR   17-APR-1991;   91US-00686547.
PR   27-SEP-1991;   91US-00766733.
XX
PA   (GILE-) GILEAD SCI INC.
XX
PI   Froehler B,  Krawczyk S,  Matteucci MD,  Milligan J;
XX
DR   WPI; 1992-217083/26.
XX
PT   New oligomers contg. modified bases - which form a triplex with G-C
PT   doublet in a DNA duplex, for treating and diagnosing HIV, hepatitis,
PT   herpes malignancy and inflammation.
XX
PS   Claim 12; Page 65; 77pp; English.
XX
CC   The synthetic oligomer is capable of forming a triplex at physiological
CC   pH with a purine rich target sequence by coupling into the major groove
CC   of the duplex. The specific target sequence of this oligomer is an HIV
```

```
CC   target duplex contg. a purine-rich region concentrated on one chain of
CC   the duplex. The oligomer, and others like it are useful in diagnosis and
CC   therapy of diseases characterised by specific DNA duplex targets, e.g.
CC   HIV, hepatitis, herpes, malignant tumours and inflammation. The triple
CC   helices form under mild conditions thus assays may be carried out without
CC   subjecting the test specimen to harsh conditions. Additional
CC   modifications, such as altered inter- nucleotide linkages may also be
CC   incorporated, rendering the oligomer e.g. stable to nuclease activity.
CC   The oligomer is able to inhibit gene expression, as verified by in vitro
CC   systems. See also AAQ25452-25501 and AAQ30226-448. (Updated on 25-MAR-
CC   2003 to correct PN field.)
XX
SQ   Sequence 16 BP; 3 A; 3 C; 0 G; 10 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGT 1994
                ||||||||||  ||||
Db         16 AAAAAAGAAATGTGT 2


RESULT 469
AAZ97698/c
ID   AAZ97698 standard; DNA; 16 BP.
XX
AC   AAZ97698;
XX
DT   15-SEP-2003  (revised)
DT   26-APR-2000  (first entry)
XX
DE   HIV-1 protease gene probe SEQ ID NO:188.
XX
KW   Human immunodeficiency virus; HIV; protease; probe; detection;
KW   drug selected mutation; hybridisation; genotyping; infection;
KW   drug resistance; ss.
XX
OS   Human immunodeficiency virus 1.
XX
PN   WO9967428-A2.
XX
PD   29-DEC-1999.
XX
PF   22-JUN-1999;   99WO-EP004317.
XX
PR   24-JUN-1998;   98EP-00870143.
XX
PA   (INNO-) INNOGENETICS NV.
XX
PI   Stuyver L;
XX
DR   WPI; 2000-147219/13.
XX
PT   Detection of drug-selected mutations in the HIV protease gene used to
PT   treat HIV infections.
XX
PS   Claim 3; Page 37; 76pp; English.
XX
CC   The present invention describes the detection of drug-selected mutations
CC   in the HIV protease gene. The method of detection allows the simultaneous
CC   characterisation of a range of codons involved in drug resistance using
CC   sets of probes optimised to function together in a reverse-hybridisation
CC   assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC   in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC   protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC   AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC   and AAZ97516 represents an HIV protease probe used in an example from the
CC   present invention. The method, probes and primers can be used for the
CC   detection of drug-selected mutations in the HIV protease gene. The method
CC   allows the simultaneous characterisation of a range of codons involved in
CC   drug resistance. The method may also be used for HIV protease genotyping
CC   assays. The probes are able to discriminate between wild type and mutated
CC   protease sequences. The method allows rapid and reliable detection of
CC   drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC   field).
XX
SQ   Sequence 16 BP; 6 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 3.4e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAA 1984
                ||||||||||  ||||
Db         16 TTTACCTTGATAAAA 2


RESULT 470
AAX69282/c
ID   AAX69282 standard; RNA; 17 BP.
XX
AC   AAX69282;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human flt1 VEGF receptor hammerhead ribozyme substrate #577.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 64; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 3 A; 3 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
```

```
                    |||||||||| ||||
Db          17 GACTGCAAAAGTCCT 3


RESULT 471
AAX69283/c
ID   AAX69283 standard; RNA; 17 BP.
XX
AC   AAX69283;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human flt1 VEGF receptor hammerhead ribozyme substrate #578.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 64; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
                ||||||||||  ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 472
AAX69284/c
ID   AAX69284 standard; RNA; 17 BP.
XX
AC   AAX69284;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human flt1 VEGF receptor hammerhead ribozyme substrate #579.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 64; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 3 A; 4 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
                ||||||||||  ||||
Db         15 GACTGCAAAAGTCCT 1


RESULT 473
AAV38823/c
ID   AAV38823 standard; DNA; 17 BP.
XX
AC   AAV38823;
XX
DT   27-OCT-1998  (first entry)
XX
DE   Homo sapiens C4-2 PCR primer.
XX
KW   C4-2; tumour suppressor gene; cancer; treatment; glioblastoma;
KW   cell proliferative disorders; brain tumour; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9820021-A1.
XX
```

PD 14-MAY-1998.
XX
PF 07-NOV-1997; 97WO-US020408.
XX
PR 08-NOV-1996; 96US-00744905.
XX
PA (NWBI-) NORTHWEST BIOTHERAPEUTICS LLC.
XX
PI Murphy GP, Boynton AL, Sehgal A;
XX
DR WPI; 1998-286852/25.
XX
PT Tumour suppressor, C4-2 - useful for treatment of proliferative diseases
PT e.g. cancer.
XX
PS Example; Page 73; 112pp; English.
XX
CC The sequence is that of a PCR primer which was used in the isolation and
CC amplification of the C4-2 tumour suppressor gene
XX
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 4 T; 0 U; 1 Other;

Query Match 2.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1891 ATGTGCCCTAGATCA 1905
||||||| |||||||
Db 16 ATGTGCCTTAGATCA 2

RESULT 474
AAV36506/c
ID AAV36506 standard; DNA; 17 BP.
XX
AC AAV36506;
XX
DT 28-SEP-1998 (first entry)
XX
DE Differential display PCR 5' primer BT-12.
XX
KW D2-2 gene; brain tumour; glioblastoma; glioma; meningioma; astocytoma;
KW medulloblastoma; neuroectodermal cancer; neuroblastoma; brain cancer;
KW breast cancer; colon cancer; prostate cancer; B cell lymphoma;
KW cell proliferation; hyperproliferative disorder;
KW benign dysproliferative disorder; wound healing; trauma;
KW hypoprolifrative disease; therapy; diagnosis; animal model; human; PCR;
KW primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9819692-A1.
XX
PD 14-MAY-1998.
XX
PF 07-NOV-1997; 97WO-US020410.
XX
PR 08-NOV-1996; 96US-00747121.
XX
PA (NWBI-) NORTHWEST BIOTHERAPEUTICS LLC.
XX
PI Murphy GP, Boynton AL, Sehgal A;
XX
DR WPI; 1998-286589/25.
XX
PT D2-2 protein associated with cell proliferation - used for developing
PT products for treating e.g. tumours, hyperproliferation and degenerative
PT disorders, growth deficiencies, lesions and wounds.
XX
PS Example 6.1.2; Page 89; 118pp; English.
XX
CC Differential display PCR was performed on cDNA from glioblastoma
CC multiforme tumour tissue and normal brain tissue using an oligo-T 3'
CC primer and three 5' primers, BT-8 (see AAV36504), BT-10 (see AAV36505)
CC and BT-12. A partial clone, D2-2, was obtained that is overexpressed in
CC glioblastoma tumour tissue. This was used to screen a human foetal brain
CC library to isolate a 2002 bp D2-2 clone (see AAW36503) that codes for D2-
CC 2 protein (see AAW49763). D2-2 expression is associated with cell
CC proliferation, especially with brain tumours. The invention provides
CC compositions and methods for the treatment and diagnosis of e.g. tumours,
CC hyper- and hypoproliferation disorders, growth deficiencies, lesions and
CC wounds
XX
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 4 T; 0 U; 1 Other;

Query Match 2.4%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.6e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1891 ATGTGCCCTAGATCA 1905
||||||| |||||||
Db 16 ATGTGCCTTAGATCA 2

RESULT 475
AAA20972
ID AAA20972 standard; RNA; 17 BP.
XX
AC AAA20972;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4198.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
PS Claim 55; Page 179; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme

```
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 10 A; 2 C; 2 G; 0 T; 3 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   73.3%;  Pred. No. 3.6e+02;
  Matches   11;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAA 1985
              : |||::||||||||
Db          3 UAACCUUGAAAAAAA 17


RESULT 476
AAF06309
ID   AAF06309 standard; DNA; 17 BP.
XX
AC   AAF06309;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3106.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 127; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 2 C; 2 G; 0 T; 10 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   26.7%;  Pred. No. 3.6e+02;
  Matches    4;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              |||:::::: ::::
Db          3 AAGCUUUUUUAUUUU 17


RESULT 477
AAF06310
ID   AAF06310 standard; DNA; 17 BP.
XX
AC   AAF06310;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3107.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 127; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 2 C; 1 G; 0 T; 11 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   26.7%;  Pred. No. 3.6e+02;
  Matches    4;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              |||:::::: ::::
Db          2 AAGCUUUUUUAUUUU 16


RESULT 478
AAF06311
ID   AAF06311 standard; DNA; 17 BP.
XX
AC   AAF06311;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3108.
```

```
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 127; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 1 C; 1 G; 0 T; 12 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   26.7%;  Pred. No. 3.6e+02;
  Matches    4;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              ||||:::::: ::::
Db          1 AAGCUUUUUUAUUUU 15


RESULT 479
AAH95020/c
ID   AAH95020 standard; RNA; 17 BP.
XX
AC   AAH95020;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Human Chk1 ribozyme substrate SEQ ID NO: 445.
XX
KW   Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW   RNA cleavage; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157206-A2.
XX
PD   09-AUG-2001.
XX
PF   02-FEB-2001; 2001WO-US003504.
XX
PR   03-FEB-2000; 2000US-0179983P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (FATT/) FATTAEY A R.
XX
PI   Fattaey AR,  Jarvis T,  Mcswiggen J,  Booher RN,  Holman PS;
XX
DR   WPI; 2001-496922/54.
XX
PT   Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT   molecules, which downregulates expression of a checkpoint kinase-1 gene,
PT   useful for treating colorectal, lung, breast or prostate cancers.
XX
PS   Claim 4; Page 61; 115pp; English.
XX
CC   The present invention provides nucleic acid molecules capable of
CC   downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC   gene. These may be antisense or ribozyme sequences, and are useful in the
CC   treatment of diseases associated with conditions affected by Chk1 levels,
CC   including cancer. The present sequence is an oligonucleotide described in
CC   the exemplification of the invention
XX
SQ   Sequence 17 BP; 5 A; 4 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         17 ACTGGTTCTGCATGA 3


RESULT 480
AAH95850/c
ID   AAH95850 standard; RNA; 17 BP.
XX
AC   AAH95850;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Human Chk1 ribozyme substrate SEQ ID NO: 1275.
XX
KW   Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW   RNA cleavage; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157206-A2.
XX
PD   09-AUG-2001.
XX
PF   02-FEB-2001; 2001WO-US003504.
XX
PR   03-FEB-2000; 2000US-0179983P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (FATT/) FATTAEY A R.
XX
PI   Fattaey AR,  Jarvis T,  Mcswiggen J,  Booher RN,  Holman PS;
XX
DR   WPI; 2001-496922/54.
XX
PT   Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT   molecules, which downregulates expression of a checkpoint kinase-1 gene,
PT   useful for treating colorectal, lung, breast or prostate cancers.
XX
PS   Claim 4; Page 91; 115pp; English.
XX
CC   The present invention provides nucleic acid molecules capable of
CC   downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC   gene. These may be antisense or ribozyme sequences, and are useful in the
CC   treatment of diseases associated with conditions affected by Chk1 levels,
CC   including cancer. The present sequence is an oligonucleotide described in
CC   the exemplification of the invention
XX
SQ   Sequence 17 BP; 5 A; 4 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
```

```
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
                ||||||||||||| |
Db         16 ACTGGTTCTGCATGA 2


RESULT 481
ABK00398
ID   ABK00398 standard; RNA; 17 BP.
XX
AC   ABK00398;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Hammerhead Ribozyme #398.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 72; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a hammerhead ribozyme of the invention
XX
SQ   Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   40.0%;  Pred. No. 3.6e+02;
  Matches    6;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAA 1836
                ::: |||:|::::||
Db          1 UUUGGAAUCUUUUAA 15


RESULT 482
ABK02234
ID   ABK02234 standard; RNA; 17 BP.
XX
AC   ABK02234;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO DNAzyme #146.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
```

```
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 115; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a DNAzyme molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   40.0%;  Pred. No. 3.6e+02;
  Matches    6;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAA 1836
              ::: |||:|::::||
Db          3 UUUGGAAUCUUUUAA 17


RESULT 483
AAI71147/c
ID   AAI71147 standard; DNA; 17 BP.
XX
AC   AAI71147;
XX
DT   19-DEC-2001  (first entry)
XX
DE   Human cell growth promotion related protein related PCR primer SEQ:4.
XX
KW   Human; cell growth; cell growth promotion; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP2001204471-A.
XX
PD   31-JUL-2001.
XX
PF   20-JAN-2000; 2000JP-00011458.
XX
PR   20-JAN-2000; 2000JP-00011458.
XX
PA   (SUMO ) SUMITOMO CHEM CO LTD.
XX
DR   WPI; 2001-609512/70.
XX
PT   Promotion of cell growth.
XX
PS   Example; Page 8; 9pp; Japanese.
XX
CC   The present invention describes a method for promoting cell growth using
CC   the human protein given in AAG68094 having a 219 amino acid sequence, or
CC   a such a protein with at least one mutation. The method is used for
CC   promoting cell growth. The present sequence represents a PCR primer which
CC   is used in the exemplification of the present invention
XX
SQ   Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGGG 1615
              ||||||| ||||||
Db         16 CTCCTGGCTTGGGGG 2


RESULT 484
AAF57379
ID   AAF57379 standard; DNA; 17 BP.
XX
AC   AAF57379;
XX
DT   11-JUN-2001  (first entry)
XX
DE   Murine Cdc25A exon 3/intron 3 splice junction sequence.
XX
KW   Cdc25; Cdc25 phosphatase; transcription; modulator; murine; CDc25A; exon;
KW   intron; ds.
XX
OS   Mus sp.
XX
PN   WO200120034-A2.
XX
PD   22-MAR-2001.
XX
PF   11-SEP-2000; 2000WO-US024838.
XX
PR   13-SEP-1999;   99US-0153639P.
XX
PA   (BADI ) BASF AG.
XX
PI   Voss J,  Timm J;
XX
DR   WPI; 2001-244825/25.
XX
PT   Assay for screening modulators of Cdc25 activity by using a cell having a
PT   recombinant Cdc25 phosphatase gene whose expression alters the
PT   transcription of a selected gene in the presence of a modulator.
XX
PS   Example 1; Page 15; 55pp; English.
XX
CC   The invention relates to a method of identifying a modulator of Cdc25
CC   activity that comprises contacting a test cell having a recombinant Cdc25
CC   phosphatase gene whose expression alters transcription of a selected
CC   gene, with a compound under conditions where recombinant Cdc25
CC   phosphatase gene is expressed and alters the transcription of a selected
CC   gene as an indication of the compound being a modulator of Cdc25-mediated
CC   transcription. The method is useful for identifying modulators of Cdc25
CC   activity. Sequences AAF57377-390 represent exon/intron splice junction
CC   sequences of the murine Cdc25A gene
XX
SQ   Sequence 17 BP; 8 A; 1 C; 3 G; 5 T; 0 U; 0 Other;
```

```
  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1984 AAGAAAAGTGTGTAT 1998
              ||||||||| |||||
Db          1 AAGAAAAGTATGTAT 15


RESULT 485
ACN05923
ID   ACN05923 standard; RNA; 17 BP.
XX
AC   ACN05923;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 5926.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 5926; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 6 A; 2 C; 8 G; 0 T; 1 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAG 1620
              ||||:|||| |||||
Db          3 GGCCUGGGGAAAGAG 17


RESULT 486
ACN03707
ID   ACN03707 standard; RNA; 17 BP.
XX
AC   ACN03707;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Zinzyme substrate SEQ ID NO 3710.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 3710; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 4 C; 3 G; 0 T; 8 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   40.0%;  Pred. No. 3.6e+02;
  Matches    6;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTG 1934
              ||:::: :::|||:|
Db          3 CCUUUUGUUUCAGUG 17


RESULT 487
ACN01809
ID   ACN01809 standard; RNA; 17 BP.
XX
AC   ACN01809;
```

```
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Inozyme substrate SEQ ID NO 1799.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 1799; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 9 A; 4 C; 2 G; 0 T; 2 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCAA 1914
              ||| |||||||:|||
Db          1 AGAACAACAGAUCAA 15


RESULT 488
ACN11558/c
ID   ACN11558 standard; RNA; 17 BP.
XX
AC   ACN11558;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11561.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11561; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 8 C; 2 G; 0 T; 6 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAG 1620
              ||||||||| |||||
Db         15 GGCCTGGGGAAAGAG 1


RESULT 489
ACN13346/c
ID   ACN13346 standard; RNA; 17 BP.
XX
AC   ACN13346;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Zinzyme substrate SEQ ID NO 13349.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
```

```
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 13349; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 3 C; 3 G; 0 T; 9 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCAA 1914
             ||| ||||||||||
Db         16 AGAACAACAGATCAA 2


RESULT 490
ACN04860
ID   ACN04860 standard; RNA; 17 BP.
XX
AC   ACN04860;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV DNAzyme substrate SEQ ID NO 4863.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 4863; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 9 A; 3 C; 4 G; 0 T; 1 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCAA 1914
             ||| ||||||:|||
Db          3 AGAACAACAGAUCAA 17


RESULT 491
ACN14060/c
ID   ACN14060 standard; RNA; 17 BP.
XX
AC   ACN14060;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand DNAzyme substrate SEQ ID NO 14063.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
```

```
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 14063; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 8 A; 4 C; 4 G; 0 T; 1 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTG 1934
                ||||||  ||||||||
Db         16 CCTTTTGTTTCAGTG 2


RESULT 492
ACN11739/c
ID   ACN11739 standard; RNA; 17 BP.
XX
AC   ACN11739;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11742.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11742; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 2 C; 4 G; 0 T; 9 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCAA 1914
                ||| ||||||||||
Db         17 AGAACAACAGATCAA 3


RESULT 493
ACN00282
ID   ACN00282 standard; RNA; 17 BP.
XX
AC   ACN00282;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Hammerhead Ribozyme substrate SEQ ID NO 272.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 272; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
```

```
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   40.0%;  Pred. No. 3.6e+02;
  Matches    6;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTG 1934
              ||:::: :::|||:|
Db          1 CCUUUUGUUUCAGUG 15


RESULT 494
ABT38096/c
ID   ABT38096 standard; DNA; 17 BP.
XX
AC   ABT38096;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 3733.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 470; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 10 A; 1 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              ||||||||||| |||
Db         17 TCTTTCCTTCTTTGA 3


RESULT 495
ABZ65395/c
ID   ABZ65395 standard; RNA; 17 BP.
XX
AC   ABZ65395;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 DNAzyme substrate #852.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 149; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 5 A; 1 C; 9 G; 0 T; 2 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1784 ACCCCATTCTTTCCT 1798
                ||||||||||| |||
Db         15 ACCCCATTCTTCCCT 1

RESULT 496
ADB42007/c
ID   ADB42007 standard; DNA; 17 BP.
XX
AC   ADB42007;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #2330.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 304; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 10 A; 1 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
                ||||||||||| |||
Db         17 TCTTTCCTTCTTTGA 3

RESULT 497
ADI51049/c
ID   ADI51049 standard; DNA; 17 BP.
XX
AC   ADI51049;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID3552.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 3552; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 10 A; 1 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
                ||||||||||| |||
Db         17 TCTTTCCTTCTTTGA 3

RESULT 498
ADL51924/c
ID   ADL51924 standard; RNA; 17 BP.
XX
AC   ADL51924;
```

```
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PTGDR substrate sequence #1043.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 161; SEQ ID NO 5457; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAGATC 2016
              ||||||||||||  ||
Db         16 GCTTCTTCAGAGGTC 2


RESULT 499
ADL51441/c
ID   ADL51441 standard; RNA; 17 BP.
XX
AC   ADL51441;
```

```
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PTGDR substrate sequence #560.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 161; SEQ ID NO 4974; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAGATC 2016
              ||||||||||||  ||
Db         17 GCTTCTTCAGAGGTC 3


RESULT 500
ADK13320
ID   ADK13320 standard; DNA; 17 BP.
XX
AC   ADK13320;
```

```
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human glioma endothelial marker (GEM) long tag SEQ ID NO:498.
XX
KW   glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;
KW   anticancer; antiglioma; immune response; cytostatic;
KW   multi-drug sensitive glioma; human; long tag; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004016758-A2.
XX
PD   26-FEB-2004.
XX
PF   15-AUG-2003; 2003WO-US025614.
XX
PR   15-AUG-2002; 2002US-0403390P.
PR   01-APR-2003; 2003US-0458978P.
XX
PA   (GENZ ) GENZYME CORP.
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Madden SI,  Wang CJ,  Cook BP,  Lattera J,  Walter K;
XX
DR   WPI; 2004-247973/23.
XX
PT   Diagnosing glioma by detecting expression product of any one of 255
PT   genes, glioma endothelial markers, in brain tissue sample suspected of
PT   being neoplastic, and comparing the expression with expression in normal
PT   brain tissue sample.
XX
PS   Example 2; SEQ ID NO 498; 114pp; English.
XX
CC   The present invention describes a method (M1) for aiding in the diagnosis
CC   of glioma. (M1) involves detecting an expression product of at least one
CC   gene (I) in a first brain tissue sample (T) suspected of being
CC   neoplastic, where (I) is chosen from any one of 255 genes (glioma
CC   endothelial markers (GEMs)) as given in specification, and comparing the
CC   expression of (I) in (T) with expression of (I) in a second normal brain
CC   tissue sample (R), where increased expression of (I) in (T) relative to
CC   (R), identifies (T) as likely to be neoplastic. Also described: (1)
CC   treating (M2) glioma involves contacting cells of the glioma with an
CC   antibody that specifically binds to a extracellular epitope; (2)
CC   identifying (M3) a test compound as potential anticancer or antiglioma
CC   drug involves contacting a test compound with the cell which expresses
CC   (I), monitoring an expression product of the at least one gene and
CC   identifying test compound as a potential anticancer drug if it decreases
CC   the expression of at least one gene; (3) identifying (M4) a test compound
CC   as potential anticancer or antiglioma drug involves contacting a test
CC   compound with the cell which expresses mRNA of at least one gene
CC   identified by a tag as described above, monitoring mRNA of the gene, and
CC   identifying the test compound as a potential anticancer drug if it
CC   decreases the expression of at least one gene; and (4) inducing (M5) an
CC   immune response to glioma involves administering to a mammal, a protein
CC   or (I). (I) have cytostatic activities, and can be used to trigger immune
CC   destruction of glioma cells, and as immune response inducers. (M1) is
CC   useful for aiding in diagnosing glioma. (M2) is useful for treating multi
CC   -drug sensitive glioma in a human. (M5) is useful for inducing an immune
CC   response to a glioma in a mammal having glioma or in a mammal who has had
CC   a glioma surgically removed. The present sequence represents a human GEM
CC   long tag oligonucleotide, which is used in the exemplification of the
CC   present invention.
XX
SQ   Sequence 17 BP; 1 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 3.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGGGG 1614
              ||||||| |||||||
Db          3 CCTCCTGCCCTGGGG 17


RESULT 501
AAT50832/c
ID   AAT50832 standard; DNA; 18 BP.
XX
AC   AAT50832;
XX
DT   02-OCT-1997  (first entry)
XX
DE   Human growth hormone primer GH3.
XX
KW   Amplification; polymerase chain reaction; PCR; primer;
KW   linked linear amplification; human; growth hormone; ss.
XX
OS   Synthetic.
XX
PN   WO9640972-A1.
XX
PD   19-DEC-1996.
XX
PF   06-JUN-1996;   96WO-US010059.
XX
PR   07-JUN-1995;   95US-00475605.
XX
PA   (BIRA ) BIO-RAD LAB INC.
XX
PI   Wallace RB;
XX
DR   WPI; 1997-087064/08.
XX
PT   Linked linear amplification of target nucleic acid using primer with non-
PT   replicable element - provides system relatively insensitive to
PT   contamination, partic. for detecting allele(s) characteristic of disease,
PT   esp. sickle cell anaemia.
XX
PS   Example 7; Page 38; 64pp; English.
XX
CC   The present sequence is a primer for the production of specific human
CC   growth hormone DNA fragments by linked linear amplification
XX
SQ   Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 502
AAT50830/c
ID   AAT50830 standard; DNA; 18 BP.
XX
AC   AAT50830;
XX
DT   02-OCT-1997  (first entry)
XX
DE   Ribonucleoside containing human growth hormone primer GH1.
XX
KW   Amplification; polymerase chain reaction; PCR; primer;
KW   linked linear amplification; human; growth hormone; ss.
XX
OS   Synthetic.
XX
PN   WO9640972-A1.
XX
PD   19-DEC-1996.
XX
PF   06-JUN-1996;   96WO-US010059.
```

```
XX
PR   07-JUN-1995;   95US-00475605.
XX
PA   (BIRA ) BIO-RAD LAB INC.
XX
PI   Wallace RB;
XX
DR   WPI; 1997-087064/08.
XX
PT   Linked linear amplification of target nucleic acid using primer with non-
PT   replicable element - provides system relatively insensitive to
PT   contamination, partic. for detecting allele(s) characteristic of disease,
PT   esp. sickle cell anaemia.
XX
PS   Example 7; Page 38; 64pp; English.
XX
CC   The present sequence is a ribonucleoside containing primer for the
CC   production of specific human growth hormone DNA fragments by linked
CC   linear amplification
XX
SQ   Sequence 18 BP; 4 A; 8 C; 0 G; 5 T; 1 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 503
AAZ35894/c
ID   AAZ35894 standard; DNA; 18 BP.
XX
AC   AAZ35894;
XX
DT   03-FEB-2000  (first entry)
XX
DE   Human sentrin phosphorothioate antisense oligonucleotide SEQ ID NO:36.
XX
KW   Human; sentrin; antisense oligonucleotide; phosphorothioate; inhibition;
KW   modulation; expression; diagnosis; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /note= "phosphorothioate linkages"
XX
PN   US5985664-A.
XX
PD   16-NOV-1999.
XX
PF   17-DEC-1998;   98US-00213768.
XX
PR   17-DEC-1998;   98US-00213768.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Cowsert LM;
XX
DR   WPI; 2000-022284/02.
XX
PT   Antisense compound which modulates human sentrin expression, useful for
PT   treating diseases associated with sentrin expression.
XX
PS   Example 15; Col 38; 29pp; English.
XX
CC   The present invention describes an antisense compound (I) 8-30
CC   nucleotides long targeted to a nucleic acid molecule encoding human
CC   sentrin. The antisense compound comprises a phosphorothioate antisense
CC   oligonucleotide which inhibits expression of human sentrin. (I) is useful
CC   for inhibiting expression of sentrin in human cells or tissues in vitro,
CC   for treating humans or other animals suspected of having or being prone
CC   to a disease associated with sentrin expression. (I) can also be used for
CC   research or diagnostic purposes. The present sequence represents a human
CC   sentrin phosphorothioate antisense oligonucleotide from the present
CC   invention
XX
SQ   Sequence 18 BP; 9 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1753 GCTCTTTATTCATTA 1767
              |||| ||||||||||
Db         16 GCTCATTATTCATTA 2


RESULT 504
AAZ72914
ID   AAZ72914 standard; DNA; 18 BP.
XX
AC   AAZ72914;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:7270.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 9; Page 1781; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
```

```
XX
SQ   Sequence 18 BP; 6 A; 7 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1907 CAGATCAACAATACC 1921
                ||| ||||||||||
Db          3 CAGCTCAACAATACC 17


RESULT 505
AAS13346/c
ID   AAS13346 standard; DNA; 18 BP.
XX
AC   AAS13346;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human NOV3 protein PCR primer #1.
XX
KW   Human; NOV3; ss; cytostatic; nootropic; neuroprotective; vulnerary;
KW   cerebroprotective; antiparkinsonian; hypotensive; antiasthmatic;
KW   antidiabetic; antipsoriatic; antiinflammatory; immunosuppressive;
KW   antiatherosclerotic; dermatological; cancer; neurological disorder;
KW   Parkinson's disease; diabetes mellitus; asthma; enamel defect;
KW   immune disorder; autoimmune disease; respiratory disorder; bone disorder;
KW   musculoskeletal disorders; leukaemia; lymphoma;
KW   cell growth regulation disorder; lesional psoriatic skin;
KW   atherosclerosis; abdominal aortic aneurysm; PCR primer.
XX
OS   Homo sapiens.
XX
PN   WO200168851-A2.
XX
PD   20-SEP-2001.
XX
PF   12-MAR-2001; 2001WO-US007735.
XX
PR   10-MAR-2000; 2000US-0188277P.
PR   10-MAR-2000; 2000US-0188316P.
PR   14-MAR-2000; 2000US-0189139P.
PR   14-MAR-2000; 2000US-0189140P.
PR   17-MAR-2000; 2000US-0190231P.
PR   17-MAR-2000; 2000US-0190401P.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Padigaru M,  Vernet CAM,  Fernandes E,  Shimkets RA,  Spaderna SK;
PI   Majumder K,  Li L;
XX
DR   WPI; 2001-570869/64.
XX
PT   Novel polypeptides and nucleic acids homologous to members of collagen,
PT   potassium channel, tuftelin family of proteins for diagnosing, treating
PT   cancer, atherosclerosis, neurological, skin and enamel defect disorders.
XX
PS   Example 1; Page 116; 128pp; English.
XX
CC   The invention relates to isolated NOVX (NOVX1-11) polypeptides and the
CC   polynucleotides that encode them. NOVX polypeptides, polynucleotides and
CC   anti-NOVX antibodies are useful for treating or preventing a pathology
CC   associated with NOVX polypeptide in humans and for treating a syndrome
CC   associated with human disease e.g. disorders characterised by altered
CC   cell motility, proliferation and migration e.g. cancer, angiogenesis and
CC   wound healing (NOV1-3), neurological disorders, e.g. episodic ataxia,
CC   autosomal dominant myokymia, stroke, Parkinson's disease, Alzheimer's
CC   disease, non-insulin dependent diabetes mellitus, asthma, hypertension
CC   and seizure (NOV4), enamel defects, such as amelogenesis imperfecta and
CC   disorders involving enamel defects, including hypoplasia and
CC   hypomineralisation (NOV5-7), paraneoplastic neurological disorders, e.g.
CC   paraneoplastic limbic of brain-stem encephalitis occurring during
CC   testicular cancer, diabetes, reproductive health, metabolic and endocrine
CC   disorders, gastrointestinal disorders, immune disorders and autoimmune
CC   diseases, respiratory disorders, bone disorders, musculoskeletal
CC   disorders, leukaemia/lymphoma and tissue/cell growth regulation disorders
CC   (NOV8), lesional psoriatic skin (NOV9-10) and atherosclerosis, abdominal
CC   aortic aneurysm and neurological disorders (NOV11). NOVX polypeptide is
CC   also useful for identifying an agent that binds to it and a cell
CC   expressing NOVX polypeptide is useful for identifying a therapeutic agent
CC   for use in treatment of a NOVX related pathology. The antibodies and a
CC   polypeptide having 95% sequence identity to NOVX polypeptide are useful
CC   for treating a pathological state in a mammal. The present sequence is a
CC   PCR primer used to isolate the cDNA encoding NOV3, a new collagen family
CC   member
XX
SQ   Sequence 18 BP; 4 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGA 1616
                ||||||||||| ||||
Db         17 TCCTGGCCTGTGGGA 3


RESULT 506
AAI67726/c
ID   AAI67726 standard; DNA; 18 BP.
XX
AC   AAI67726;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Adenovirus-2 E1B55K alterations generating oligonucleotide.
XX
KW   Adenoassociated virus; rAAV; virion; E4; E2A; E1A; E1B; adenovirus; ss.
XX
OS   Synthetic.
XX
PN   WO200183797-A2.
XX
PD   08-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US040561.
XX
PR   28-APR-2000; 2000US-0200453P.
XX
PA   (AVIG-) AVIGEN INC.
XX
PI   Colosi P;
XX
DR   WPI; 2002-049353/06.
XX
PT   New nucleic acids, useful in recombinant adeno-associated virus virion
PT   production, comprises adenoviral coding region of VA RNA, E4 ORF6, E2A
PT   72kD and E1A, and E1B region lacking intact E1B55K coding region.
XX
PS   Example 1; Page 32; 61pp; English.
XX
CC   The invention relates to a nucleic acid molecule which provides one or
CC   more accessory functions for supporting recombinant adenoassociated virus
CC   (rAAV) virion production in a suitable host cell. The molecule comprises
CC   a VA RNA coding region, E4 open reading frame (ORF) 6 coding region, E2A
CC   72kD coding region, E1A coding region and E1B region lacking an intact
CC   E1B55K coding region of an adenovirus (AV). An accessory function vector
CC   comprising the molecule is useful for producing rAAV. The method
CC   comprises introducing AAV vector into a suitable host cell, introducing
CC   an AAV helper construct into the cell, where the helper construct
CC   comprises AAV coding regions that are expressed in the host cell to
CC   complement AAV helper functions missing from AAV vector, introducing the
CC   accessory function vector into the cell; and culturing the cell to
CC   produce rAAV virions. The method can alternately be performed by two
CC   other methods. The molecule yields significant levels of rAAV particles
```

```
CC   without also generating significant levels of infectious helper virus or
CC   contaminating by-products. Sequences AAI67726-27 represent oligos used
CC   for causing E1B55K alterations
XX
SQ   Sequence 18 BP; 7 A; 4 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2057 ACTAGTTAATAAGTG 2071
              ||||||||||  ||||
Db         18 ACTAGTTAATTAGTG 4


RESULT 507
ABK14274/c
ID   ABK14274 standard; DNA; 18 BP.
XX
AC   ABK14274;
XX
DT   08-MAY-2002  (first entry)
XX
DE   GH-3 human growth hormone linked linear amplification primer.
XX
KW   Nucleic acid amplification; linked linear amplification; LLA;
KW   human growth hormone; GH-3; primer; ss.
XX
OS   Homo sapiens.
XX
PN   US6335184-B1.
XX
PD   01-JAN-2002.
XX
PF   11-JAN-1999;   99US-00228324.
XX
PR   23-JUL-1993;   93US-00095442.
PR   02-APR-1997;   97US-00826532.
XX
PA   (BIRA ) BIO-RAD LAB INC.
XX
PI   Reyes AA,  Wallace RB,  Ugozzoli LA;
XX
DR   WPI; 2002-163204/21.
XX
PT   Linked linear amplification of nucleic acid sequence of interest
PT   contained within complementary nucleic acids by using series of nested
PT   primers each of which contains a non-replicable element and/or cleavable
PT   element.
XX
PS   Example 7; Col 20; 42pp; English.
XX
CC   This invention relates to a novel method of nucleic acid amplification
CC   called linked linear amplification (LLA). The method involves
CC   simultaneously combining a series of nested primers by combining nucleic
CC   acid template with nested primer each containing non-replicable element
CC   and/or cleavable element. The series of nested primers comprise primers
CC   complementary to different portions of the template and are 5' to one
CC   another with respect to the template and do not overlap with one another
CC   at the position of the non-replicable and cleavable elements. The method
CC   of the invention may be used for amplifying nucleic acid sequences of
CC   interest contained in the complementary first and second nucleic acid
CC   strands which are prepared from RNA by reverse transcription. This method
CC   is capable of producing large quantities of a specific nucleic acid
CC   sequence of interest. The products are single stranded and do not have to
CC   be denatured prior to detection. As the products accumulate linearly,
CC   they can be accurately identified. The occurrence of false positives will
CC   be reduced in comparison with exponential processes that use newly
CC   synthesised DNA as template in subsequent rounds using the same primer.
CC   The present sequence represents the GH-3 human growth hormone linked
CC   linear amplification primer used to amplify human growth hormone gene
CC   using the method of the invention
XX
SQ   Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              |||||  |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 508
ABK14272/c
ID   ABK14272 standard; DNA; 18 BP.
XX
AC   ABK14272;
XX
DT   08-MAY-2002  (first entry)
XX
DE   GH-1 human growth hormone linked linear amplification primer.
XX
KW   Nucleic acid amplification; linked linear amplification; LLA;
KW   human growth hormone; GH-1; primer; DNA-RNA hybrid; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_RNA        11
FT                   /*tag=  a
FT                   /label= RNA
XX
PN   US6335184-B1.
XX
PD   01-JAN-2002.
XX
PF   11-JAN-1999;   99US-00228324.
XX
PR   23-JUL-1993;   93US-00095442.
PR   02-APR-1997;   97US-00826532.
XX
PA   (BIRA ) BIO-RAD LAB INC.
XX
PI   Reyes AA,  Wallace RB,  Ugozzoli LA;
XX
DR   WPI; 2002-163204/21.
XX
PT   Linked linear amplification of nucleic acid sequence of interest
PT   contained within complementary nucleic acids by using series of nested
PT   primers each of which contains a non-replicable element and/or cleavable
PT   element.
XX
PS   Example 7; Col 20; 42pp; English.
XX
CC   This invention relates to a novel method of nucleic acid amplification
CC   called linked linear amplification (LLA). The method involves
CC   simultaneously combining a series of nested primers by combining nucleic
CC   acid template with nested primer each containing non-replicable element
CC   and/or cleavable element. The series of nested primers comprise primers
CC   complementary to different portions of the template and are 5' to one
CC   another with respect to the template and do not overlap with one another
CC   at the position of the non-replicable and cleavable elements. The method
CC   of the invention may be used for amplifying nucleic acid sequences of
CC   interest contained in the complementary first and second nucleic acid
CC   strands which are prepared from RNA by reverse transcription. This method
CC   is capable of producing large quantities of a specific nucleic acid
CC   sequence of interest. The products are single stranded and do not have to
CC   be denatured prior to detection. As the products accumulate linearly,
CC   they can be accurately identified. The occurrence of false positives will
CC   be reduced in comparison with exponential processes that use newly
CC   synthesised DNA as template in subsequent rounds using the same primer.
CC   The present sequence represents the GH-1 human growth hormone linked
CC   linear amplification primer used to amplify human growth hormone gene
```

```
CC   using the method of the invention
XX
SQ   Sequence 18 BP; 4 A; 8 C; 0 G; 5 T; 1 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 509
ADM06227
ID   ADM06227 standard; DNA; 18 BP.
XX
AC   ADM06227;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PCR primer SEQ ID NO:4912.
XX
KW   human; gene therapy; diagnostic marker; pharmaceutical; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   EP1347046-A1.
XX
PD   24-SEP-2003.
XX
PF   12-APR-2002; 2002EP-00008400.
XX
PR   22-MAR-2002; 2002JP-00137785.
XX
PA   (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI   Isogai T,  Sugiyama T,  Otsuki T,  Wakamatsu A,  Sato H,  Ishii S;
PI   Yamamoto J,  Isono Y,  Hio Y,  Otsuka K,  Nagai K,  Irie R,  Tamechika I;
PI   Seki N,  Yoshikawa T,  Otsuka M,  Nagahari K,  Masuho Y;
XX
DR   WPI; 2003-723558/69.
XX
PT   New polynucleotides and polypeptides are useful in gene therapy, for
PT   developing a diagnostic marker or medicines for regulating their
PT   expression and activity, or as a target of gene therapy.
XX
PS   Example 8; SEQ ID NO 4912; 305pp; English.
XX
CC   The invention relates to a novel human polynucleotide and the encoded
CC   polypeptide. A polynucleotide of the invention may have a use in gene
CC   therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful
CC   as a primer for synthesizing the polynucleotide or as a probe for
CC   detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are
CC   useful in gene therapy, for developing a diagnostic marker or medicines
CC   for regulating their expression and activity, or as a target of gene
CC   therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
CC   are useful as pharmaceutical agents. The present sequence represents an
CC   oligonucleotide used in the invention.
XX
SQ   Sequence 18 BP; 1 A; 2 C; 6 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1944 TGGTTGGTTTTTGTG 1958
              ||||||| |||||||
Db          3 TGGTTGGATTTTGTG 17


RESULT 510
ADO48369/c
ID   ADO48369 standard; DNA; 18 BP.
XX
AC   ADO48369;
XX
DT   29-JUL-2004  (first entry)
XX
DE   cDNA amplification method associated oligo #12.
XX
KW   cDNA generation; non-replicable element; in vitro replication;
KW   1,3 propane diol moiety; ss.
XX
OS   Synthetic.
XX
PN   US2004091923-A1.
XX
PD   13-MAY-2004.
XX
PF   06-OCT-2003; 2003US-00680341.
XX
PR   23-JUL-1993;   93US-00095442.
PR   02-APR-1997;   97US-00826532.
PR   11-JAN-1999;   99US-00228324.
PR   07-APR-2000; 2000US-00544773.
XX
PA   (BIRA ) BIO-RAD LAB INC.
XX
PI   Reyes AA,  Wallace RB,  Ugozzoli LA;
XX
DR   WPI; 2004-374946/35.
XX
PT   Generating cDNA molecules using a linked series of multi-cycle primer
PT   extension reactions, useful for the in vitro replication of nucleic
PT   acids, in particular for replicating a nucleic acid sequence of interest
PT   in large quantities.
XX
PS   Example 7; SEQ ID NO 16; 54pp; English.
XX
CC   The invention describes a process for generating a cDNA molecule from an
CC   RNA molecule. The method comprises annealing a first primer containing a
CC   non-replicable element, to an RNA molecule, generating a first strand
CC   product, separating the first cDNA from its template to produce single
CC   stranded molecules, annealing a second primer containing a non-replicable
CC   element, to the first cDNA product, and generating a second cDNA product
CC   that is a complement of the first cDNA. The first and second primers in
CC   the process cited above is with or without a cleavable element. The
CC   methods and compositions are useful for the in vitro replication of
CC   nucleic acids, in particular for replicating a nucleic acid sequence of
CC   interest, with large quantities of the desired sequence ultimately
CC   resulting from the linkage of extension reactions where the sequence of
CC   interest accumulates in a mathematically linear fashion. This sequence
CC   represents a polynucleotide template DNA used to demonstrate the ability
CC   of the 1,3 propane diol moiety to serve as a non-replicable element.
XX
SQ   Sequence 18 BP; 4 A; 8 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 511
ADO48367/c
ID   ADO48367 standard; DNA; 18 BP.
XX
AC   ADO48367;
XX
DT   29-JUL-2004  (first entry)
XX
DE   cDNA amplification method associated oligo #10.
```

```
XX
KW   cDNA generation; non-replicable element; in vitro replication;
KW   1,3 propane diol moiety; ss.
XX
OS   Synthetic.
XX
PN   US2004091923-A1.
XX
PD   13-MAY-2004.
XX
PF   06-OCT-2003; 2003US-00680341.
XX
PR   23-JUL-1993;   93US-00095442.
PR   02-APR-1997;   97US-00826532.
PR   11-JAN-1999;   99US-00228324.
PR   07-APR-2000; 2000US-00544773.
XX
PA   (BIRA ) BIO-RAD LAB INC.
XX
PI   Reyes AA,  Wallace RB,  Ugozzoli LA;
XX
DR   WPI; 2004-374946/35.
XX
PT   Generating cDNA molecules using a linked series of multi-cycle primer
PT   extension reactions, useful for the in vitro replication of nucleic
PT   acids, in particular for replicating a nucleic acid sequence of interest
PT   in large quantities.
XX
PS   Example 7; SEQ ID NO 14; 54pp; English.
XX
CC   The invention describes a process for generating a cDNA molecule from an
CC   RNA molecule. The method comprises annealing a first primer containing a
CC   non-replicable element, to an RNA molecule, generating a first strand
CC   product, separating the first cDNA from its template to produce single
CC   stranded molecules, annealing a second primer containing a non-replicable
CC   element, to the first cDNA product, and generating a second cDNA product
CC   that is a complement of the first cDNA. The first and second primers in
CC   the process cited above is with or without a cleavable element. The
CC   methods and compositions are useful for the in vitro replication of
CC   nucleic acids, in particular for replicating a nucleic acid sequence of
CC   interest, with large quantities of the desired sequence ultimately
CC   resulting from the linkage of extension reactions where the sequence of
CC   interest accumulates in a mathematically linear fashion. This sequence
CC   represents a polynucleotide template DNA used to demonstrate the ability
CC   of the 1,3 propane diol moiety to serve as a non-replicable element.
XX
SQ   Sequence 18 BP; 4 A; 8 C; 0 G; 5 T; 1 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 512
AAK99165/c
ID   AAK99165 standard; DNA; 19 BP.
XX
AC   AAK99165;
XX
DT   12-JUN-2002  (first entry)
XX
DE   Human related 19-mer oligonucleotide #1 of the invention.
XX
KW   PCR; primer; human growth hormone expression vector; ss.
XX
OS   Homo sapiens.
XX
PN   KR99017407-A.
XX
PD   15-MAR-1999.
XX
PF   22-AUG-1997;   97KR-00040321.
XX
PR   22-AUG-1997;   97KR-00040321.
XX
PA   (MOKA-) MOK AM LIFE ENG RES INST.
XX
PI   Lee EG,  Park DH,  Chung SI;
XX
DR   WPI; 2000-235150/20.
XX
PT   Human growth hormone expression vector and process for preparing human
PT   growth hormone using the same.
XX
PS   Disclosure; Page 4; 12pp; Korean.
XX
CC   The invention relates to a human growth hormone expression vector. The
CC   invention also relates to a process for preparing human growth hormone.
CC   This polynucleotide sequence represents a human related 19-mer
CC   oligonucleotide of the invention
XX
SQ   Sequence 19 BP; 4 A; 8 C; 0 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   93.3%;  Pred. No. 3.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
              ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 513
AAH23630
ID   AAH23630 standard; DNA; 19 BP.
XX
AC   AAH23630;
XX
DT   03-AUG-2001  (first entry)
XX
DE   PCR primer p51/378.
XX
KW   Cytostatic; gene therapy; p53; tumour; p73; PCR primer; ss.
XX
OS   Unidentified.
XX
PN   JP2000354488-A.
XX
PD   26-DEC-2000.
XX
PF   09-APR-1999;   99JP-00139034.
XX
PR   09-APR-1999;   99JP-00139034.
XX
PA   (IKAW/) IKAWA H.
PA   (SAKA ) OTSUKA PHARM CO LTD.
XX
DR   WPI; 2001-268293/28.
XX
PT   Chimera gene of the p53 family, useful for gene therapy, and treatment of
PT   cancer, comprises a transcription activating region and a DNA binding
PT   region.
XX
PS   Example 1; Page 23; 57pp; Japanese.
XX
CC   The present invention relates to a chimera gene of p53 family encoding a
CC   transcription activating region, a DNA binding region, and an oligomer
CC   formation region of different p53 family proteins. The chimeric gene can
CC   be used for gene therapy of p53 variant human tumours, and analysis of
CC   the function of the p53 family gene. The present sequence was used in the
CC   present invention
XX
```

```
SQ   Sequence 19 BP; 3 A; 11 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   93.3%;  Pred. No. 3.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCC 1674
              ||| ||||||||||||
Db          2 TCTCCATCACCCGCC 16


RESULT 514
AAH23642/c
ID   AAH23642 standard; DNA; 19 BP.
XX
AC   AAH23642;
XX
DT   03-AUG-2001  (first entry)
XX
DE   PCR primer #3.
XX
KW   Cytostatic; gene therapy; p53; tumour; p73; PCR primer; ss.
XX
OS   Unidentified.
XX
PN   JP2000354488-A.
XX
PD   26-DEC-2000.
XX
PF   09-APR-1999;   99JP-00139034.
XX
PR   09-APR-1999;   99JP-00139034.
XX
PA   (IKAW/) IKAWA H.
PA   (SAKA ) OTSUKA PHARM CO LTD.
XX
DR   WPI; 2001-268293/28.
XX
PT   Chimera gene of the p53 family, useful for gene therapy, and treatment of
PT   cancer, comprises a transcription activating region and a DNA binding
PT   region.
XX
PS   Example 1; Page 23; 57pp; Japanese.
XX
CC   The present invention relates to a chimera gene of p53 family encoding a
CC   transcription activating region, a DNA binding region, and an oligomer
CC   formation region of different p53 family proteins. The chimeric gene can
CC   be used for gene therapy of p53 variant human tumours, and analysis of
CC   the function of the p53 family gene. The present sequence was used in the
CC   present invention
XX
SQ   Sequence 19 BP; 4 A; 1 C; 11 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   93.3%;  Pred. No. 3.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCC 1674
              ||| ||||||||||||
Db         18 TCTCCATCACCCGCC 4


RESULT 515
ABS97868
ID   ABS97868 standard; DNA; 19 BP.
XX
AC   ABS97868;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human UDP-glucuronosyl transferase 24B gene PCR primer #5.
XX
KW   Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
KW   cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW   adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW   aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW   cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW   epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW   glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW   HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW   NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
KW   UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW   UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW   multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW   multidrug resistance associated protein 3; cancer; prostate;
KW   acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW   altered drug metabolism; cardiovascular function; colorectal tumour;
KW   central nervous system; pulmonary; immunological.
XX
OS   Homo sapiens.
XX
PN   WO200257410-A2.
XX
PD   25-JUL-2002.
XX
PF   28-NOV-2001; 2001WO-US044838.
XX
PR   28-NOV-2000; 2000US-00724389.
XX
PA   (DNAS-) DNA SCI LAB INC.
XX
PI   Guida M,  Hall J;
XX
DR   WPI; 2002-698522/75.
XX
PT   Isolated nucleic acid molecules having polymorphisms in known human genes
PT   e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
PT   for locating, identifying and characterizing the genes responsible for
PT   disorder-related traits.
XX
PS   Example 18; Page 133; 714pp; English.
XX
CC   This invention relates to the sequence of an isolated nucleic acid
CC   molecule comprising at least one base variation from that of a known
CC   human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC   cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
CC   aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC   (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
CC   inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
CC   protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
CC   transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl
CC   transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC   sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC   (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC   transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
CC   (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC   (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
CC   receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC   The polymorphisms in the human genes cited in the invention are useful as
CC   genetic linkage markers for locating and characterising the genes that
CC   are responsible for specific traits within the genome and eventually
CC   identifying the genes responsible for a variety of disorder-related
CC   traits as a result of their e.g., overexpression, constitutive
CC   expression, mutation or underexpression, which may be used in diagnosing
CC   and/or treating the disorders. The nucleic acid molecules comprising the
CC   polymorphic sequences contained in CYP4501A1, CYPP4501A2, CYP4502E1,
CC   ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
CC   MDR1 and/or MDR3 are useful for screening individuals for altered drug
CC   metabolism. The polymorphic sequences contained in CYP4501A1, CYPP4501A2,
CC   AHR, MDR1 and/or MDR3 may also be used to screen individuals for
CC   susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
CC   used to screen for altered cardiovascular function, in COX2 for altered
CC   susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
CC   nervous system function, in FLAP and HNMT for altered pulmonary,
CC   immunological or haematological function, in KLK2 for altered serine
CC   protease activity in the prostate, in LTF for altered immunological or
```

```
CC   haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC   peripheral nervous system function. The present sequence represents a PCR
CC   primer used to amplify the sequences of the invention
XX
SQ   Sequence 19 BP; 5 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   93.3%;  Pred. No. 3.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATT 1791
              ||||||||||  ||||
Db          1 TTTTTGAACCACATT 15


RESULT 516
ADF35811/c
ID   ADF35811 standard; RNA; 19 BP.
XX
AC   ADF35811;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:100.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 100; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 12 A; 0 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   93.3%;  Pred. No. 3.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCT 1803
              ||||||||||||| |
Db         15 ATTCTTTCCTTCTAT 1


RESULT 517
ADF36238
ID   ADF36238 standard; RNA; 19 BP.
XX
AC   ADF36238;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:527.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
```

```
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 527; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 2 A; 5 C; 0 G; 0 T; 12 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   33.3%;  Pred. No. 3.8e+02;
  Matches    5;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCT 1803
              |::|:::||::|: :
Db          5 AUUCUUUCCUUCUAU 19


RESULT 518
AAT36218/c
ID   AAT36218 standard; DNA; 20 BP.
XX
AC   AAT36218;
XX
DT   25-MAR-2003  (revised)
DT   16-APR-1997  (first entry)
XX
DE   Antisense oligo targetting CD28 3'-UTR (nt 1136-1155).
XX
KW   Reduction; T cell; CD28; gene expression; treatment; immune system;
KW   disorder; graft versus host disease; septic shock; viral disease;
KW   psoriasis; type I diabetes mellitus; thyroiditis; sarcoides;
KW   multiple sclerosis; uveitis; rheumatoid arthritis; 3'-UTR;
KW   systemic lupus erythematosus; inflammatory bowel disease; antisense;
KW   oligonucleotide; 3'-untranslated region; ss.
XX
OS   Synthetic.
XX
PN   WO9624380-A1.
XX
PD   15-AUG-1996.
XX
PF   05-FEB-1996;   96WO-US001507.
XX
PR   09-FEB-1995;   95US-00387041.
PR   18-SEP-1995;   95US-00529878.
XX
PA   (ICNC ) ICN PHARM INC.
XX
PI   Tam RC;
XX
DR   WPI; 1996-384228/38.
XX
PT   Oligo:nucleotide which reduces CD28 gene expression in T cells - for
PT   treating immune system diseases, e.g. graft vs. host disease, septic
PT   shock, psoriasis, etc.
XX
PS   Example 1; Page 27; 77pp; English.
XX
CC   The present oligonucleotide reduces T cell CD28 gene expression, useful
CC   in the treatment of CD28 mediated diseases, particularly immune system
CC   disorders, e.g. graft versus host disease, septic shock, viral disease,
CC   psoriasis, type I diabetes mellitus, thyroiditis, sarcoides, multiple
CC   sclerosis, uveitis, rheumatoid arthritis, systemic lupus erythematosus,
CC   inflammatory bowel disease, etc. . Reducing CD28 expression may reduce the
CC   effects of antigenic stimulation of CD28 positive T cells, with a
CC   consequent reduction in cytokine release. (Updated on 25-MAR-2003 to
CC   correct PR field.)
XX
SQ   Sequence 20 BP; 3 A; 7 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGA 1543
              ||||||||| |||||
Db         15 GAAGAAAGGCTAGGA 1


RESULT 519
AAX90312/c
ID   AAX90312 standard; DNA; 20 BP.
XX
AC   AAX90312;
XX
DT   24-SEP-1999  (first entry)
XX
DE   Oligonucleotide RT18 used in an Example from US5932556.
XX
KW   CD28; inhibition; antisense oligonucleotide; interleukin 2; IL-2;
KW   immune system mediated disease; gamma-interferon; IL-8; ss.
XX
OS   Synthetic.
XX
PN   US5932556-A.
XX
PD   03-AUG-1999.
XX
PF   18-SEP-1995;   95US-00529878.
XX
PR   09-FEB-1995;   95US-00387041.
PR   18-SEP-1995;   95US-00529878.
XX
PA   (TAMR/) TAM R C.
XX
PI   Tam RC;
XX
DR   WPI; 1996-384228/38.
XX
PT   Oligo:nucleotide which reduces CD28 gene expression in T cells - for
PT   treating immune system diseases, e.g. graft vs. host disease, septic
PT   shock, psoriasis, etc.
XX
PS   Example; Col 15; 45pp; English.
XX
CC   The present invention describes a method for inhibiting the expression of
CC   CD28, IL-2, gamma-interferon or IL-8 in a mammal. The method comprises
CC   subcutaneous administration of an oligonucleotide (OGN). AAX90288 to
CC   AAX90291 represent specifically claimed OGNs for use in the method. The
CC   OGNs are used for the treatment of immune system-mediated diseases.
CC   AAX90292 to AAX90323 represent oligonucleotides used in the
CC   exemplification of the present invention
XX
SQ   Sequence 20 BP; 3 A; 7 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1529 GAAGAAAGGTTAGGA 1543
              ||||||||| |||||
Db         15 GAAGAAAGGCTAGGA 1

RESULT 520
AAT17552
ID   AAT17552 standard; DNA; 20 BP.
XX
AC   AAT17552;
XX
DT   21-JUN-1996  (first entry)
XX
DE   11 kDa fibrin-binding peptide PCR primer 11K A.
XX
KW   Fribrin-binding peptide; fibronectin; fibrinolysis; fibrinogenesis;
KW   thrombus; pulmonary embolus; atherosclerosis; tumour; diagnosis; therapy;
KW   polymerase chain reaction; PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   WO9604304-A1.
XX
PD   15-FEB-1996.
XX
PF   01-AUG-1995;   95WO-US009819.
XX
PR   01-AUG-1994;   94US-00283857.
XX
PA   (UYNY ) UNIV NEW YORK STATE.
XX
PI   Gold LI,  Rostagno AA;
XX
DR   WPI; 1996-129333/13.
XX
PT   New fibrin-binding peptide molecules - used for the diagnosis and
PT   treatment of conditions associated with fibrin deposition, e.g. thrombi.
XX
PS   Example 4; Page 61; 146pp; English.
XX
CC   PCR primers (AAT17552-69) were used to amplify DNA encoding C-terminal
CC   fragments of human fibronectin (Fn). This C-terminal region includes an
CC   11 kDa fibrin-binding peptide (amino acids 2123-2230) that covers the
CC   type I modules 10F1.11F1 of Fn (see also AAR92778). It is useful for the
CC   diagnosis and treatment of conditions associated with fibrin deposition.
CC   Peptides were expressed from a system based on the yeast alpha-factor
CC   secretion pathway and were obtd. in yields of 10-100 mg/ml. Use of
CC   primers 11K A (AAT17552) and 11K B (AAT17553) amplified DNA coding for
CC   the 11 kDa fibrin-binding peptide
XX
SQ   Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1615 GAAGAGTTTGTTACC 1629
              |||||| ||||||||
Db          1 GAAGAGGTTGTTACC 15


RESULT 521
AAZ06110
ID   AAZ06110 standard; DNA; 20 BP.
XX
AC   AAZ06110;
XX
DT   07-OCT-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW   Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW   paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW   nongonococcal uretritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW   bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS   Synthetic.
OS   Chlamydia trachomatis.
XX
PN   WO9928475-A2.
XX
PD   10-JUN-1999.
XX
PF   27-NOV-1998;   98WO-IB001939.
XX
PR   28-NOV-1997;   97FR-00015041.
PR   17-DEC-1997;   97FR-00016034.
PR   04-NOV-1998;   98US-0107077P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-371125/31.
XX
PT   Genome sequence of Chlamydia trachomatis.
XX
PS   Disclosure; Page 1825; 1755pp; English.
XX
CC   PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC   (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC   encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC   against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC   be used to control growth of the microorganism. Chlamydia trachomatis is
CC   responsible for a large number of diseases, e.g. eye diseases such as
CC   conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC   conjunctivitis; genital diseases such as nongonococcal uretritis,
CC   epidymitis, cervicitis, salpingitis, perihepatitis, bartholinitis;
CC   pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC   The polypeptides of the invention may be of use in treating these
CC   diseases
XX
SQ   Sequence 20 BP; 7 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1554 GGAACAGGACTGCAA 1568
              ||||||||||| ||||
Db          1 GGAACAGGACAGCAA 15


RESULT 522
AAX94154
ID   AAX94154 standard; DNA; 20 BP.
XX
AC   AAX94154;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
```

```
XX
PR   21-NOV-1997;   97FR-00014673.
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1647; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 9 A; 3 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              ||||||||||||| |
Db          6 AGGGAAGGAACAGAA 20


RESULT 523
AAX94827/c
ID   AAX94827 standard; DNA; 20 BP.
XX
AC   AAX94827;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
XX
PR   21-NOV-1997;   97FR-00014673.
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1700; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 7 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 AGCTATCTCCTAACT 1720
              ||||||||||| |||
Db         18 AGCTATCTCCTTACT 4


RESULT 524
AAD04838/c
ID   AAD04838 standard; DNA; 20 BP.
XX
AC   AAD04838;
XX
DT   17-JUL-2001  (first entry)
XX
DE   Mouse leptin receptor gene exon 20 forward RT-PCR primer.
XX
KW   Mouse; leptin receptor; anorectic; anabolic; fertility; energy balance;
KW   thermoregulation; puberty; immunomodulatory; appetite; angiogenesis;
KW   immunity; RT-PCR primer; ss.
XX
OS   Mus sp.
XX
PN   WO200130963-A2.
XX
PD   03-MAY-2001.
XX
PF   23-OCT-2000; 2000WO-IL000674.
XX
PR   29-OCT-1999;   99US-0162220P.
XX
PA   (AGRI-) AGRIC RES ORG VOLCANI CENT.
XX
PI   Einat-Friedman M,  Horev G,  Eshdat Y;
XX
DR   WPI; 2001-308624/32.
XX
PT   New polynucleotide encoding avian lectin receptor, for e.g. identifying
PT   modulators for controlling appetite and energy balance in poultry.
XX
PS   Example; Page 28; 67pp; English.
XX
CC   The present DNA sequence is mouse specific leptin receptor forward RT
CC   (Reverse Transcriptase)-PCR primer which is used for amplifying the cDNAs
CC   corresponding to exon 20 of mouse leptin receptor gene. The invention
CC   relates to chicken leptin receptor and its corresponding DNA molecule.
CC   Leptin receptor is used for regulating appetite and other aspects of
CC   energy balance in poultry such as food consumption, fat deposition,
CC   puberty, thermoregulation, immunity, angiogenesis and energy expenditure.
CC   Leptin receptor is specifically used for attenuating leptin activity in
CC   vivo (particularly using a soluble form of the receptor, optionally
CC   expressed from a transgene). Leptin receptor provides a replacement for
CC   the forced molting procedure to improve performance and profitablity of
CC   old laying hens. The invention provides an assay for screening leptin
CC   agonists and antagonists. The invention is also used to isolate leptin
CC   gene and to establish a bioassay for leptin activity, e.g. to screen for
CC   birds with high or low leptin levels in the blood (e.g. for breeding
```

```
CC   purposes) and/or for isolation of mutated genes
XX
SQ   Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCAT 1666
              ||||||  ||||||||
Db         20 TCACTGATTCTGCAT 6


RESULT 525
AAH56745
ID   AAH56745 standard; DNA; 20 BP.
XX
AC   AAH56745;
XX
DT   06-SEP-2001  (first entry)
XX
DE   S. aureus groE operon antisense oligonucleotide SEQ ID NO:393.
XX
KW   Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
KW   microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
KW   Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
KW   antibacterial; antiviral; antiproliferative; antisense therapy;
KW   microbial infection; ss.
XX
OS   Staphylococcus aureus.
XX
PN   WO200136625-A2.
XX
PD   25-MAY-2001.
XX
PF   20-NOV-2000; 2000WO-CA001347.
XX
PR   18-NOV-1999;   99US-0166249P.
XX
PA   (GENE-) GENESENSE TECHNOLOGIES INC.
XX
PI   Wright JA,  Young AH,  Dugourd D;
XX
DR   WPI; 2001-355633/37.
XX
PT   Novel antisense compounds targeting nucleic acid encoding groEL or groES
PT   gene of microorganism, which hybridize with and inhibit expression of the
PT   genes, useful to inhibit growth of microorganism having the genes.
XX
PS   Claim 3; Page 52; 110pp; English.
XX
CC   The present invention specifically claims AAH56368 to AAH56832 which are
CC   antisense oligonucleotides to nucleotide sequences encoding groE. More
CC   generally, antisense compounds (I) comprising antisense oligonucleotides
CC   of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC   shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
CC   microorganism, where the antisense compound is complementary to GL or GS
CC   of a microorganism and specifically hybridises with and inhibits the
CC   expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
CC   antiproliferative activities, and can be used in antisense therapy and
CC   for inhibition of expression of groES or groEL. (I) are useful for
CC   inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
CC   also useful for inhibiting the growth of a microorganism, or inhibiting
CC   the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC   virus) having a GL or GS gene which involves administering to the
CC   microorganism or to a cell infected with the microorganism, (I). (I) are
CC   also useful for treating a mammalian pathological condition mediated by
CC   the microorganisms which involves identifying a eukaryotic organism
CC   having a pathological condition mediated by microorganisms having a GL or
CC   GS gene and administering (I) such that the growth of microorganism is
CC   inhibited. The antisense compounds are utilised for diagnostics,
CC   therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC   prevent or delay microbial infections in humans. They are also useful as
CC   molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC   represent PCR primers for groE sequences which are used in the
CC   exemplification of the present invention. AAH56855 to AAH56870 represent
CC   groE nucleotide sequence given in the present invention
XX
SQ   Sequence 20 BP; 7 A; 7 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1912 CAACAATACCTTTTT 1926
              ||||||||||| ||
Db          2 CAACAATACCTTCTT 16


RESULT 526
AAH56571
ID   AAH56571 standard; DNA; 20 BP.
XX
AC   AAH56571;
XX
DT   06-SEP-2001  (first entry)
XX
DE   S. pneumoniae groE operon antisense oligonucleotide SEQ ID NO:219.
XX
KW   Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
KW   microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
KW   Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
KW   antibacterial; antiviral; antiproliferative; antisense therapy;
KW   microbial infection; ss.
XX
OS   Streptococcus pneumoniae.
XX
PN   WO200136625-A2.
XX
PD   25-MAY-2001.
XX
PF   20-NOV-2000; 2000WO-CA001347.
XX
PR   18-NOV-1999;   99US-0166249P.
XX
PA   (GENE-) GENESENSE TECHNOLOGIES INC.
XX
PI   Wright JA,  Young AH,  Dugourd D;
XX
DR   WPI; 2001-355633/37.
XX
PT   Novel antisense compounds targeting nucleic acid encoding groEL or groES
PT   gene of microorganism, which hybridize with and inhibit expression of the
PT   genes, useful to inhibit growth of microorganism having the genes.
XX
PS   Claim 3; Page 46; 110pp; English.
XX
CC   The present invention specifically claims AAH56368 to AAH56832 which are
CC   antisense oligonucleotides to nucleotide sequences encoding groE. More
CC   generally, antisense compounds (I) comprising antisense oligonucleotides
CC   of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC   shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
CC   microorganism, where the antisense compound is complementary to GL or GS
CC   of a microorganism and specifically hybridises with and inhibits the
CC   expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
CC   antiproliferative activities, and can be used in antisense therapy and
CC   for inhibition of expression of groES or groEL. (I) are useful for
CC   inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
CC   also useful for inhibiting the growth of a microorganism, or inhibiting
CC   the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC   virus) having a GL or GS gene which involves administering to the
CC   microorganism or to a cell infected with the microorganism, (I). (I) are
CC   also useful for treating a mammalian pathological condition mediated by
CC   the microorganisms which involves identifying a eukaryotic organism
CC   having a pathological condition mediated by microorganisms having a GL or
CC   GS gene and administering (I) such that the growth of microorganism is
```

```
CC   inhibited. The antisense compounds are utilised for diagnostics,
CC   therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC   prevent or delay microbial infections in humans. They are also useful as
CC   molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC   represent PCR primers for groE sequences which are used in the
CC   exemplification of the present invention. AAH56855 to AAH56870 represent
CC   groE nucleotide sequence given in the present invention
XX
SQ   Sequence 20 BP; 7 A; 7 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1912 CAACAATACCTTTTT 1926
              ||||||||||| ||
Db          2 CAACAATACCTTCTT 16


RESULT 527
AAD12073
ID   AAD12073 standard; DNA; 20 BP.
XX
AC   AAD12073;
XX
DT   25-SEP-2001  (first entry)
XX
DE   Rat PTP1B antisense oligonucleotide (ISIS# 113690).
XX
KW   Rat; PTP1B; protein phosphatase 1B inhibitor; antisense; gene therapy;
KW   infection; inflammation; tumour; prophylaxis; phosphorothioate; ss.
XX
OS   Rattus norvegicus.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "Methoxyethyl residues"
FT   modified_base    1
FT                    /*tag=  d
FT                    /mod_base= m5c
FT   modified_base    6
FT                    /*tag=  e
FT                    /mod_base= m5c
FT   modified_base    9
FT                    /*tag=  f
FT                    /mod_base= m5c
FT   modified_base    12
FT                    /*tag=  g
FT                    /mod_base= m5c
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "Methoxyethyl residues"
FT   modified_base    19
FT                    /*tag=  h
FT                    /mod_base= m5c
XX
PN   US6261840-B1.
XX
PD   17-JUL-2001.
XX
PF   18-JAN-2000; 2000US-00487368.
XX
PR   18-JAN-2000; 2000US-00487368.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Wyatt J;
XX
DR   WPI; 2001-432181/46.
XX
PT   New antisense compounds capable of modulating expression of human protein
PT   phosphatase 1B, useful for diagnosis, prophylaxis and treatment of
PT   diseases associated with expression of protein phosphatase.
XX
PS   Claim 1; Col 47-48; 71pp; English.
XX
CC   The invention is directed to antisense compounds, particularly
CC   oligonucleotides which are targetted to a DNA encoding protein
CC   phosphatase 1B (PTP1B) to modulate its expression. The antisense
CC   compounds are useful for diagnosis, prophylaxis and treatment of diseases
CC   associated with the expression of PTP1B, to prevent or delay infection,
CC   inflammation and tumour formation and as a research reagent. The PTP1B
CC   DNA is useful in gene therapy. The present sequence is an antisense
CC   oligonucleotide with a phosphorothioate backbone. This oligo is targetted
CC   to rat PTP1B to inhibit its expression
XX
SQ   Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | ||||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 528
AAD09652
ID   AAD09652 standard; DNA; 20 BP.
XX
AC   AAD09652;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human PKA C-alpha chimeric antisense oligonucleotide (ISIS# 102660).
XX
KW   Human; protein kinase A; PKA catalytic subunit C-alpha inhibitor;
KW   therapy; infection; inflammation; tumour; prophylaxis; antisense;
KW   phosphorothioate backbone; chimeric; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
OS   Chimeric.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "Methoxyethyl residues"
FT   modified_base    1. .2
FT                    /*tag=  c
FT                    /mod_base= m5c
FT   modified_base    5
FT                    /*tag=  d
FT                    /mod_base= m5c
FT   misc_feature     6. .15
FT                    /*tag=  e
FT                    /note= "Central gap region"
FT   modified_base    16. .20
FT                    /*tag=  f
FT                    /mod_base= OTHER
FT                    /note= "Methoxyethyl residues"
FT   modified_base    16
```

```
FT                   /*tag=  g
FT                   /mod_base= m5c
XX
PN   US6248586-B1.
XX
PD   19-JUN-2001.
XX
PF   17-DEC-1999;   99US-00467082.
XX
PR   17-DEC-1999;   99US-00467082.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2001-407321/43.
XX
PT   Antisense oligonucleotides for inhibiting the expression of the human
PT   protein kinase A catalytic subunit C-alpha, particularly useful for
PT   preventing, delaying or treating infection, inflammation or tumor
PT   formation.
XX
PS   Claim 1; Col 45; 35pp; English.
XX
CC   The invention is directed to antisense compounds, particularly
CC   oligonucleotides which are targetted to a DNA encoding human protein
CC   kinase A (PKA) catalytic subunit C-alpha to modulate (inhibit) its
CC   expression. The antisense compounds are useful for diagnostics,
CC   therapeutics, prophylaxis and as research reagents or kits. The antisense
CC   oligonucleotides are useful for treating human, suspected of having or
CC   being prone to a disease or condition associated with the expression of
CC   PKA catalytic subunit C-alpha. In particular, the antisense
CC   oligonucleotides are useful for preventing, delaying or treating
CC   infection, inflammation and tumour formation. They are also useful in
CC   antisense therapy. The present sequence is a chimeric antisense
CC   oligonucleotide with a phosphorothioate backbone. This oligo is targetted
CC   to the coding region of human PKA catalytic subunit C-alpha to inhibit
CC   its expression
XX
SQ   Sequence 20 BP; 5 A; 10 C; 4 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCC 1675
              | ||||||||||||||
Db          2 CAGCATCACCCGCCC 16


RESULT 529
ABK85148
ID   ABK85148 standard; DNA; 20 BP.
XX
AC   ABK85148;
XX
DT   13-AUG-2002  (first entry)
XX
DE   Rat PTPB1 antisense oligonucleotide ISIS 113690.
XX
KW   Antisense; protein phosphatase 1B; PTP1B; ss; probe; rat;
KW   type 2 diabetes; obesity; ovarian cancer; chronic myeloid leukaemia;
KW   hyperproliferative disease; antidiabetic; anorectic; cytostatic;
KW   blood glucose; gene therapy.
XX
OS   Rattus norvegicus.
XX
PN   US2002055479-A1.
XX
PD   09-MAY-2002.
XX
PF   14-MAY-2001; 2001US-00854883.
XX
PR   18-JAN-2000; 2000US-00487368.
PR   31-JUL-2000; 2000US-00629644.
XX
PA   (COWS/) COWSERT L M.
PA   (WYAT/) WYATT J.
PA   (FREI/) FREIER S M.
PA   (MONI/) MONIA B P.
PA   (BUTL/) BUTLER M M.
PA   (MCKA/) MCKAY R.
XX
PI   Cowsert LM,  Wyatt J,  Freier SM,  Monia BP,  Butler MM,  Mckay R;
XX
DR   WPI; 2002-462914/49.
XX
PT   Compound for inhibiting the expression of protein phosphatase 1B (PTP1B)
PT   and for treating diabetes, cancer, or obesity, comprises an antisense
PT   oligonucleotide targeted to nucleic acid encoding PTP1B.
XX
PS   Claim 3; Page 24; 133pp; English.
XX
CC   The invention relates to a compound of 8-50 nucleobases in length
CC   targeted to a nucleic acid encoding protein phosphatase 1B (PTP1B), where
CC   the compound specifically hybridises with and inhibits the expression of
CC   PTP1B (e.g. an antisense oligonucleotide). Also included are (1) a
CC   compound of 8-50 nucleobases in length which specifically hybridises with
CC   an 8 nucleobase portion of an active site on a nucleic acid encoding
CC   PTP1B; (2) inhibiting the expression of PTP1B in cells or tissues
CC   comprising contacting the cells or tissues with the compound; treating an
CC   animal having or suspected of having a disease or condition associated
CC   with PTP1B comprising administering the compound; (4) decreasing blood
CC   sugar levels in an animal comprising administering the compound; (5)
CC   preventing or delaying the onset of a disease or condition associated
CC   with PTP1B in an animal comprising administering the compound; and (6)
CC   preventing or delaying the onset of an increase in blood glucose levels
CC   in an animal comprising administering the compound. The compound is used
CC   to inhibit the expression of PTP1B in cells or tissues, to treat or
CC   prevent or delay the onset of a disease or condition associated with
CC   PTP1B, such as type 2 diabetes, obesity, cancer (especially ovarian
CC   cancer, chronic myeloid leukaemia and hyperproliferative diseases in an
CC   animal having or suspected of having the disease or condition, and for
CC   decreasing blood sugar levels or preventing or delaying the onset of an
CC   increase in blood glucose levels in an animal. The compound is also used
CC   in diagnostics, therapeutics, prophylaxis, and in research reagents and
CC   kits. The present sequence is an antisense compound of the invention
CC   targetting rat PTP1B
XX
SQ   Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | ||||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 530
ABK37317
ID   ABK37317 standard; DNA; 20 BP.
XX
AC   ABK37317;
XX
DT   08-MAY-2002  (first entry)
XX
DE   Rat PTP1B mRNA level inhibition antisense DNA #34.
XX
KW   Human; mouse; rat; protein tyrosine phosphatase 1B; PTP1B; ss; adipose;
KW   liver; kidney; metabolic disease; type 2 diabetes; obesity; cancer;
KW   hyperproliferative condition; blood serum; blood plasma; antidiabetic;
KW   blood glucose level; cytostatic; anorectic; antisense gene therapy;
KW   PTP1B mRNA level inhibition.
XX
```

```
OS   Rattus norvegicus.
XX
PN   WO200210378-A2.
XX
PD   07-FEB-2002.
XX
PF   30-JUL-2001; 2001WO-US023874.
XX
PR   31-JUL-2000; 2000US-00629644.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cowsert LM,  Wyatt J,  Freier SM,  Monia BP,  Butler MM,  Mckay R;
XX
DR   WPI; 2002-180079/23.
XX
PT   Novel antisense compound useful for treating type 2 diabetes, cancer and
PT   obesity, is targeted to nucleic acid encoding human protein phosphatase
PT   1B, and hybridizes and inhibits PTP1B expression.
XX
PS   Claim 3; Page 71; 142pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid molecule
CC   encoding protein phosphatase 1B (PTP1B), which specifically hybridises
CC   with and inhibits the expression of PTP1B. The compounds of the invention
CC   are useful for inhibiting the expression of PTP1B in liver, kidney or
CC   adipose cells or tissues and for treating an animal, preferably human,
CC   having a disease or condition associated with PTP1B, including metabolic
CC   diseases or conditions, e.g. type 2 diabetes and obesity, or
CC   hyperproliferative conditions such as cancer. The sequences are also
CC   useful for decreasing blood (serum or plasma) glucose levels in an animal
CC   e.g. a diabetic human or rodent, for preventing or delaying the onset of
CC   a disease or condition associated with PTP1B , and for preventing or
CC   delaying the onset of an increase in blood glucose levels. This sequence
CC   represents a PTP1B mRNA level inhibition antisense oligonucleotide of the
CC   invention
XX
SQ   Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | ||||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 531
AAD48392/c
ID   AAD48392 standard; DNA; 20 BP.
XX
AC   AAD48392;
XX
DT   24-FEB-2003  (first entry)
XX
DE   Forward PCR primer #3 used for LOH analysis.
XX
KW   Breast tumour; loss of heterozygosity; LOH; tumour; neoplastic disease;
KW   PCR; primer; ss.
XX
OS   Unidentified.
XX
PN   WO200276286-A2.
XX
PD   03-OCT-2002.
XX
PF   20-MAR-2002; 2002WO-US009068.
XX
PR   23-MAR-2001; 2001US-00816460.
XX
PA   (CALP-) CALIFORNIA PACIFIC MEDICAL CENT RES INST.
XX
PI   Dairkee SH,  Li Z;
XX
DR   WPI; 2003-046744/04.
XX
PT   Determining the likelihood of tumor re-occurrence in a patient previously
PT   diagnosed with a breast tumor to determine treatment modalities,
PT   comprises analyzing the cell sample for loss of heterozygosity to
PT   chromosomal locus 3p24.3.
XX
PS   Example 1; Page 37; 42pp; English.
XX
CC   The invention relates to a method of determining the likelihood of tumour
CC   re-occurrence in a patient previously diagnosed with a breast tumour. The
CC   method involves analysing the target cell sample for loss of
CC   heterozygosity (LOH) to chromosomal locus 3p24.3. The method is useful
CC   for determining the likelihood of tumour re-occurrence in a patient
CC   previously diagnosed with a breast tumour and subsequently useful in
CC   determining the degree of aggressive treatment indicated. The prognostic
CC   method is especially useful in making decisions concerning treatment
CC   modalities, including therapeutic intervention, diagnostic criteria such
CC   as disease staging and disease monitoring and surveillance for metastasis
CC   or recurrence of neoplastic disease. The present sequence is a PCR primer
CC   used for LOH analysis. This primer is used to illustrate the method of
CC   the invention
XX
SQ   Sequence 20 BP; 2 A; 10 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAA 1557
              ||||| |||||||||
Db         19 AGAGTGGGGAAGGAA 5


RESULT 532
ABT43119
ID   ABT43119 standard; DNA; 20 BP.
XX
AC   ABT43119;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Neuroblastoma-related DNA sequence #34.
XX
KW   Neuroblastoma; prognosis; ds; oligonucleotide.
XX
OS   Unidentified.
XX
PN   WO2002103017-A1.
XX
PD   27-DEC-2002.
XX
PF   30-MAY-2002; 2002WO-JP005295.
XX
PR   31-MAY-2001; 2001JP-00163666.
PR   24-AUG-2001; 2001JP-00255260.
XX
PA   (CHIB-) CHIBA PREFECTURE.
PA   (HISM ) HISAMITSU PHARM CO LTD.
XX
PI   Nakagawara A;
XX
DR   WPI; 2003-167523/16.
XX
PT   Nucleic acids isolated from neuroblastoma showing enhanced expression in
PT   human neuroblastoma with good prognosis, useful in clarifying good/poor
PT   prognosis of neuroblastoma and providing genetic data.
XX
PS   Example 5; Page 23; 444pp; Japanese.
XX
CC   The invention comprises DNA sequences that show enhanced expression in
```

```
CC   human neuroblastoma with good prognosis. The DNA sequences of the
CC   invention are useful in clarifying good/poor prognosis of neuroblastoma.
CC   The present DNA sequence was used in the exemplification of the invention
XX
SQ   Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1733 TCAGAAGGTGACAAG 1747
              ||||||||||||| |
Db          2 TCAGAAGGTGACACG 16


RESULT 533
ABT32294
ID   ABT32294 standard; DNA; 20 BP.
XX
AC   ABT32294;
XX
DT   08-MAY-2003  (first entry)
XX
DE   Neuroblastoma-related oligonucleotide #71.
XX
KW   Neuroblastoma; prognosis; spontaneous regression; primer; probe; ds;
KW   high malignancy.
XX
OS   Unidentified.
XX
PN   WO200297093-A1.
XX
PD   05-DEC-2002.
XX
PF   30-MAY-2002; 2002WO-JP005294.
XX
PR   30-MAY-2001; 2001JP-00162775.
PR   24-AUG-2001; 2001JP-00255226.
XX
PA   (CHIB-) CHIBA PREFECTURE.
PA   (HISM ) HISAMITSU PHARM CO LTD.
XX
PI   Nakagawara A;
XX
DR   WPI; 2003-140476/13.
XX
PT   Nucleic acids having higher expression in human neuroblastoma with poor
PT   prognosis for diagnostic prediction of neuroblastoma prognosis.
XX
PS   Example 5; Page 26; 111pp; Japanese.
XX
CC   The invention comprises nucleic acids that show increased expression in
CC   human neuroblastomas with poor prognosis over those with a good
CC   prognosis. The nucleic acids of the invention are useful as a tool for
CC   distinguishing neuroblastomas with a favourable prognosis (spontaneous
CC   regression) from neuroblastomas with a poor prognosis (high malignancy).
CC   The DNA sequences ABT32224 - ABT32571 represent oligonucleotides used in
CC   an example of the invention
XX
SQ   Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1733 TCAGAAGGTGACAAG 1747
              ||||||||||||| |
Db          2 TCAGAAGGTGACACG 16


RESULT 534
AAL61400
ID   AAL61400 standard; DNA; 20 BP.
XX
AC   AAL61400;
XX
DT   22-SEP-2003  (first entry)
XX
DE   Human FXR antisense oligonucleotide, ISIS 145347.
XX
KW   Human; farnesoid X receptor; FXR; cardiovascular disease; gene therapy;
KW   atherosclerosis; hypercholesterolaemia; NR1H4; bile acid receptor; BAR;
KW   retinoid X receptor-interacting protein 14; phosphorothioate backbone;
KW   RIP14; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'methoxyethyl nucleotides"
XX
PN   WO2003044167-A2.
XX
PD   30-MAY-2003.
XX
PF   13-NOV-2002; 2002WO-US036691.
XX
PR   15-NOV-2001; 2001US-00002491.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Watt AT;
XX
DR   WPI; 2003-468767/44.
XX
PT   New antisense oligonucleotides for modulating human farnesoid X receptor
PT   (FXR) expression, useful for treating conditions associated with FXR in
PT   humans, e.g. cardiovascular disease, atherosclerosis or
PT   hypercholesterolemia.
XX
PS   Claim 3; Page 75; 127pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of human farnesoid X receptor (FXR). FXR is
CC   also known as NR1H4, retinoid X receptor-interacting protein 14 (RIP14)
CC   and bile acid receptor (BAR). The antisense oligonucleotide is useful for
CC   inhibiting the expression of human FXR in cells or tissues. It is
CC   particularly useful for treating or preventing a disease or condition
CC   associated with FXR in a human, e.g. cardiovascular disease,
CC   atherosclerosis or hypercholesterolaemia. The antisense compound is
CC   useful for diagnostics, therapeutics, prophylaxis, or as research
CC   reagents or kits. It is also used in gene therapy. The present sequence
CC   is an antisense oligonucleotide targetted to human FXR DNA. This sequence
CC   is used to illustrate the method of the invention
XX
SQ   Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 CCTAGATCAACAGAT 1911
              ||||| |||||||||
Db          1 CCTAGTTCAACAGAT 15
```

```
RESULT 535
ABZ91737/c
ID   ABZ91737 standard; DNA; 20 BP.
XX
AC   ABZ91737;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 6979; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 9 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1764 ATTAAGCTTTTTTTT 1778
              ||||||||||  ||||
Db         15 ATTAAGCTTTATTTT 1
```

```
RESULT 536
ABZ85670/c
ID   ABZ85670 standard; DNA; 20 BP.
XX
AC   ABZ85670;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Claim 15; SEQ ID NO 912; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 1 A; 2 C; 0 G; 17 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAA 1990
              | ||||||||||||||
Db         15 TAGAAAAAAAGAAAA 1
```

RESULT 537
ABZ89097/c
ID ABZ89097 standard; DNA; 20 BP.
XX
AC ABZ89097;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 4339; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1756 CTTTATTCATTAAGC 1770
|| ||||||||||||
Db 19 CTGTATTCATTAAGC 5

RESULT 538
ABZ91736/c
ID ABZ91736 standard; DNA; 20 BP.
XX
AC ABZ91736;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 6978; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 12 A; 1 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1765 TTAAGCTTTTTTTTT 1779
||||||||| |||||
Db 20 TTAAGCTTTATTTTT 6

```
RESULT 539
ABD21900/c
ID   ABD21900 standard; DNA; 20 BP.
XX
AC   ABD21900;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human stanniocalcin-derived oligo SEQ ID 912.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 912; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 1 A; 2 C; 0 G; 17 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAA 1990
              | ||||||||||||||
Db         15 TAGAAAAAAAGAAAA 1


RESULT 540
ABD27966/c
ID   ABD27966 standard; DNA; 20 BP.
XX
AC   ABD27966;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA497002-derived oligonucleotide SEQ ID 6978.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 6978; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
```

```
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 12 A; 1 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTT 1779
              ||||||||| |||||
Db         20 TTAAGCTTTATTTTT 6


RESULT 541
ABD25327/c
ID   ABD25327 standard; DNA; 20 BP.
XX
AC   ABD25327;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AI096522-derived oligonucleotide SEQ ID 4339.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 4339; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              || ||||||||||||
Db         19 CTGTATTCATTAAGC 5


RESULT 542
ABD27967/c
ID   ABD27967 standard; DNA; 20 BP.
XX
AC   ABD27967;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AA497002-derived oligonucleotide SEQ ID 6979.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
```

```
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 6979; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 9 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1764 ATTAAGCTTTTTTTT 1778
              ||||||||||  ||||
Db         15 ATTAAGCTTTATTTT 1


RESULT 543
ADI13878
ID   ADI13878 standard; DNA; 20 BP.
XX
AC   ADI13878;
XX
DT   22-APR-2004  (first entry)
XX
DE   Antisense DNA oligo to target rat PTP1B DNA SeqID 130.
XX
KW   rat; ss; antisense; PTP1B; protein phosphatase 1B; PTPN1;
KW   phosphorothioate backbone; hyperproliferative condition; cancer;
KW   cytostatic; antidiabetic; anorectic; type 2 diabetes; obesity.
XX
OS   Rattus norvegicus.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
FT                   nucleobases are 5' methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl nucleotides. All cytidine
FT                   nucleobases are 5' methylcytidine."
XX
PN   US2003220282-A1.
XX
PD   27-NOV-2003.
XX
PF   07-FEB-2003; 2003US-00360510.
XX
PR   18-JAN-2000; 2000US-00487368.
PR   31-JUL-2000; 2000US-00629644.
PR   14-MAY-2001; 2001US-00854883.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bhanot S,  Cowsert LM,  Wyatt JR,  Monia BP,  Butler MM,  Mckay R;
PI   Freier SM;
XX
DR   WPI; 2004-051719/05.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding PTP1B, useful for treating a disease/condition
PT   associated with PTP1B, such as cancer, diabetes or obesity.
XX
PS   Claim 3; SEQ ID NO 130; 143pp; English.
XX
CC   This invention relates to novel compositions and methods for modulating
CC   the expression of PTP1B (also known as protein phosphatase 1B and PTPN1).
CC   Specifically, it refers to antisense compounds that can target and
CC   hybridise with a nucleic acid molecule encoding PTP1B, as well as splice
CC   variants thereof and inhibit expression accordingly. PTP1B is a tyrosine
CC   phosphatase that plays an essential regulatory role in signalling
CC   mediated by the insulin receptor and as such is useful for treating
CC   diseases such as type 2 diabetes and obesity. Furthermore, PTP1B can
CC   suppress transformation of oncogenic genes, such that compositions of
CC   this invention can also be used to treat hyperproliferative conditions
CC   including cancer. Accordingly, these compounds can be described as having
CC   cytostatic, antidiabetic and anorectic activities. This oligonucleotide
CC   sequence is an antisense DNA oligo that targets rat PTP1B DNA, and which
CC   has a phosphorothioate backbone and 2'-O-methoxyethyl wings, used in an
CC   exemplification of the invention.
XX
SQ   Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | ||||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 544
ADJ33955/c
ID   ADJ33955 standard; DNA; 20 BP.
XX
AC   ADJ33955;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human polo-like kinase antisense oligonucleotide SEQ ID NO:15.
XX
KW   polo-like kinase; polo-like kinase inhibitor; antisense oligonucleotide;
KW   cytostatic; antiinflammatory; antimicrobial; antisense gene therapy;
KW   kinase inhibitor; hyperproliferative disorder; cancer;
```

```
KW   non-small cell lung cancer; oesophageal cancer; infection; inflammation;
KW   tumour; human; phosphorothioate; 2'-O-methoxyethyl; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004011610-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023413.
XX
PR   30-JUL-2002; 2002US-00209405.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Wyatt JR,  Freier SM;
XX
DR   WPI; 2004-143840/14.
XX
PT   New antisense compounds targeted to nucleic acid molecules encoding polo-
PT   like kinase, useful for treating diseases associated with aberrant
PT   expression of polo-like kinase, e.g. non-small cell lung cancer or
PT   esophageal cancer.
XX
PS   Example 15; SEQ ID NO 15; 138pp; English.
XX
CC   The present invention describes a compound (I) of 8-80 nucleobases in
CC   length targeted to a nucleic acid molecule encoding polo-like kinase,
CC   where (I) specifically hybridises with nucleic acid molecule encoding
CC   polo-like kinase and inhibits the expression of polo-like kinase, or
CC   specifically hybridises with at least an 8-nucleobase portion of a
CC   preferred target region on a nucleic acid molecule encoding polo-like
CC   kinase. Also described: (1) a composition comprising (I) and a
CC   pharmaceutical carrier or diluent; (2) inhibiting the expression of polo-
CC   like kinase in cells or tissues comprising contacting the cells or
CC   tissues with (I); (3) treating an animal having a disease or condition
CC   associated with polo-like kinase comprising administering to the animal a
CC   therapeutic or prophylactic amount of (I) so that expression of polo-like
CC   kinase is inhibited; and (4) screening for an antisense compound
CC   comprising contacting a preferred target region of a nucleic acid
CC   molecule encoding polo-like kinase with one or more candidate antisense
CC   compounds comprising at least an 8-nucleobase portion which is
CC   complementary to the preferred target region, and selecting for one or
CC   more candidate antisense compounds which inhibits the expression of a
CC   nucleic acid molecule encoding polo-like kinase. (I) has cytostatic,
CC   antiinflammatory and antimicrobial activities, and can be used in
CC   antisense gene therapy, and as a kinase inhibitor. The antisense
CC   oligonucleotides or compounds (I) can be used for inhibiting the
CC   expression of polo-like kinase, and for treating diseases or conditions
CC   associated with aberrant expression of polo-like kinase, e.g.
CC   hyperproliferative disorder such as cancer, including non-small cell lung
CC   cancer or oesophageal cancer. The antisense compounds are also useful as
CC   research reagents and kits, or in diagnostic, therapeutic and
CC   prophylactic applications, e.g. to prevent or delay infection,
CC   inflammation or tumour formation. The present sequence represents a human
CC   polo-like kinase chimeric phosphorothioate antisense oligonucleotide,
CC   which is used in an example from the present invention.
XX
SQ   Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1553 AGGAACAGGACTGCA 1567
              ||||||| |||||||
Db         17 AGGAACATGACTGCA 3


RESULT 545
ADK96927
ID   ADK96927 standard; DNA; 20 BP.
XX
AC   ADK96927;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Primer of the invention #2647.
XX
KW   human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS   Synthetic.
XX
PN   JP2003259875-A.
XX
PD   16-SEP-2003.
XX
PF   08-MAR-2002; 2002JP-00064373.
XX
PR   08-MAR-2002; 2002JP-00064373.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2004-093977/10.
XX
PT   Novel polynucleotide useful for PCR amplification along with two DNA
PT   fragment from another set of sequences, or for detecting single
PT   nucleotide polymorphism in human gene.
XX
PS   Claim 2; SEQ ID NO 5956; 2627pp; Japanese.
XX
CC   The present invention relates to a polynucleotide isolated from a human
CC   gene and is useful for detecting a single nucleotide polymorphism in a
CC   human gene or for diagnosing of disease. The invention enables the
CC   detection of a single nucleotide polymorphism in a human gene. The
CC   present sequence represents a primer of the invention.
XX
SQ   Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1892 TGTGCCCTAGATCAA 1906
              ||||||| |||||||
Db          1 TGTGCCCAAGATCAA 15


RESULT 546
ADJ18865/c
ID   ADJ18865 standard; DNA; 20 BP.
XX
AC   ADJ18865;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 3415.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
```

```
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 3415; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match              2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGA 2014
                || |||||||||||||
Db         16 TATCTTCTTCAGAGA 2


RESULT 547
ADJ18849/c
ID   ADJ18849 standard; DNA; 20 BP.
XX
AC   ADJ18849;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 3399.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 3399; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
```

```
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGA 2014
              || ||||||||||||
Db         15 TATCTTCTTCAGAGA 1


RESULT 548
ADK74412
ID   ADK74412 standard; DNA; 20 BP.
XX
AC   ADK74412;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #1746.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 1746; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 0 A; 4 C; 3 G; 13 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              ||||||| |||||||
Db          3 TTCTTTCTTTCTCTG 17


RESULT 549
ADK73800
ID   ADK73800 standard; DNA; 20 BP.
XX
AC   ADK73800;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #1134.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 1134; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 0 A; 4 C; 1 G; 15 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              ||||||| |||||||
Db          5 TTCTTTCTTTCTCTG 19
```

```
RESULT 550
ADK73945
ID   ADK73945 standard; DNA; 20 BP.
XX
AC   ADK73945;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #1279.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 1279; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 1 A; 4 C; 3 G; 12 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              ||||||| |||||||
Db          1 TTCTTTCTTTCTCTG 15


RESULT 551
ADK73908
ID   ADK73908 standard; DNA; 20 BP.
XX
AC   ADK73908;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #1242.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 1242; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 1 A; 4 C; 3 G; 12 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              ||||||| |||||||
Db          2 TTCTTTCTTTCTCTG 16


RESULT 552
ADK73661
ID   ADK73661 standard; DNA; 20 BP.
XX
AC   ADK73661;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #995.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
```

```
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 995; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 0 A; 4 C; 1 G; 15 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              ||||||| |||||||
Db          6 TTCTTTCTTTCTCTG 20


RESULT 553
ADK73660
ID   ADK73660 standard; DNA; 20 BP.
XX
AC   ADK73660;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #994.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 994; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 0 A; 4 C; 2 G; 14 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              ||||||| |||||||
Db          4 TTCTTTCTTTCTCTG 18


RESULT 554
ADO54049
ID   ADO54049 standard; DNA; 20 BP.
XX
AC   ADO54049;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1422.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
```

```
XX
PS   Claim 4; SEQ ID NO 1422; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1897 CCTAGATCAACAGAT 1911
             ||||| |||||||||
Db          1 CCTAGTTCAACAGAT 15


RESULT 555
ADO54540/c
ID   ADO54540 standard; DNA; 20 BP.
XX
AC   ADO54540;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1913.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1913; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 3 A; 2 C; 8 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
              ||| ||||||||||||
Db         19 CCCCAGATCAACAGA 5


RESULT 556
ADO53904/c
ID   ADO53904 standard; DNA; 20 BP.
XX
AC   ADO53904;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1277.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1277; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
```

CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 2 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1896 CCCTAGATCAACAGA 1910
||| ||||||||||
Db 16 CCCCAGATCAACAGA 2

RESULT 557
ADO54304/c
ID ADO54304 standard; DNA; 20 BP.
XX
AC ADO54304;
XX
DT 15-JUL-2004 (first entry)
XX
DE Farnesoid X receptor gene expression antisense inhibitory oligo #1677.
XX
KW ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS Homo sapiens.
XX
PN WO2004030750-A1.
XX
PD 15-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030353.
XX
PR 25-SEP-2002; 2002US-0413588P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Kane CD;
XX
DR WPI; 2004-347928/32.
XX
PT New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.
XX
PS Claim 4; SEQ ID NO 1677; 150pp; English.
XX
CC The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 2 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.4; DB 1; Length 20;
Best Local Similarity 93.3%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1896 CCCTAGATCAACAGA 1910
||| ||||||||||
Db 18 CCCCAGATCAACAGA 4

RESULT 558
ADO54044/c
ID ADO54044 standard; DNA; 20 BP.
XX
AC ADO54044;
XX
DT 15-JUL-2004 (first entry)
XX
DE Farnesoid X receptor gene expression antisense inhibitory oligo #1417.
XX
KW ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW neuroprotective; vasotropic; antisense; gene therapy;
KW Farnesoid X receptor; diabetes; immunological disorder;
KW cardiovascular disorder; dyslipidemia; atherosclerosis;
KW high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS Homo sapiens.
XX
PN WO2004030750-A1.
XX
PD 15-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030353.
XX
PR 25-SEP-2002; 2002US-0413588P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Kane CD;
XX
DR WPI; 2004-347928/32.
XX
PT New antisense oligonucleotides useful for modulating expression of
PT Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT e.g. diabetes, immunological disorders, cardiovascular disorders,
PT gallstones or obesity.
XX
PS Claim 4; SEQ ID NO 1417; 150pp; English.
XX
CC The invention relates to an antisense compound 8-30 nucleobases in length
CC targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC where the antisense compound specifically hybridizes with and inhibits
CC the expression of FXR. The composition and methods are useful for
CC inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC tissues, or for treating diseases or conditions associated with FXR, such
CC as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC lipoprotein), elevated LDL (low density lipoprotein) or
CC hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC neurological disorders, or ischemia/reperfusion injury. In addition, the
CC composition is used for diagnostics, prophylaxis, or as research reagents
CC or kits. This sequence corresponds to an antisense oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 2 C; 8 G; 7 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
              ||| ||||||||||||
Db         17 CCCCAGATCAACAGA 3


RESULT 559
ADO54619/c
ID   ADO54619 standard; DNA; 20 BP.
XX
AC   ADO54619;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1992.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1992; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
              ||| ||||||||||||
Db         20 CCCCAGATCAACAGA 6


RESULT 560
ADO53903/c
ID   ADO53903 standard; DNA; 20 BP.
XX
AC   ADO53903;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1276.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1276; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 2 A; 2 C; 8 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
              ||| ||||||||||||
Db         15 CCCCAGATCAACAGA 1


RESULT 561
```

```
ADP78803
ID   ADP78803 standard; DNA; 20 BP.
XX
AC   ADP78803;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #2602.
XX
KW   GFAT; Antidiabetic; Cardiant;
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag=  b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO,  Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 2602; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 7 A; 1 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAG 1939
              |||||||||  |||||
Db          5 TTTTTCAGTTTTAAG 19


RESULT 562
ADP78506
ID   ADP78506 standard; DNA; 20 BP.
XX
AC   ADP78506;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #2305.
XX
KW   GFAT; Antidiabetic; Cardiant;
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag=  b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO,  Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 2305; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 7 A; 1 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAG 1939
              |||||||||  |||||
Db          6 TTTTTCAGTTTTAAG 20


RESULT 563
ADO25116/c
ID   ADO25116 standard; DNA; 20 BP.
XX
AC   ADO25116;
```

```
XX
DT   12-AUG-2004  (first entry)
XX
DE   Mouse checkpoint kinase 1 DNA target sequence #29.
XX
KW   Antisense therapy; mouse; checkpoint kinase 1; Chk1;
KW   hyperproliferative disorder; cancer; cytostatic; ds.
XX
OS   Mus musculus.
XX
PN   US2004097446-A1.
XX
PD   20-MAY-2004.
XX
PF   16-NOV-2002; 2002US-00298994.
XX
PR   16-NOV-2002; 2002US-00298994.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Dobie KW,  Watt AT;
XX
DR   WPI; 2004-430923/40.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding checkpoint kinase 1, useful for treating diseases associated
PT   with checkpoint kinase 1, e.g. hyperproliferative disorders.
XX
PS   Example 16; SEQ ID NO 198; 66pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding human/mouse checkpoint kinase 1 (Chk1). The
CC   antisense compound comprises an antisense oligonucleotide that
CC   specifically hybridises with the nucleic acid and inhibits the expression
CC   of Chk1. The antisense oligonucleotide is a chimeric oligonucleotide. The
CC   antisense oligonucleotide comprises at least one modified internucleoside
CC   linkage, preferably a phosphorothioate linkage. It also comprises at
CC   least one modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE)
CC   sugar moiety. The antisense oligonucleotide further comprises at least
CC   one modified nucleobase, preferably a 5-methylcytosine. The antisense
CC   oligonucleotides are useful for the treatment of diseases such as
CC   hyperproliferative disorders, e.g. cancer. The present sequence
CC   represents mouse Chk1 DNA target sequence for an antisense
CC   oligonucleotide.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         19 ACTGGTTCTGCATGA 5


RESULT 564
ADO25009
ID   ADO25009 standard; DNA; 20 BP.
XX
AC   ADO25009;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Mouse checkpoint kinase 1 DNA, antisense oligonucleotide #36.
XX
KW   Antisense therapy; mouse; checkpoint kinase 1; Chk1;
KW   hyperproliferative disorder; cancer; cytostatic; phosphorothioate; ss.
XX
OS   Mus musculus.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "This oligonucleotide has a phosphorothioate
FT                    backbone and 2'-methyoxyethyl (2'-MOE) wings at the 5'
FT                    and 3' ends, which are 5 nucleotides in length at each
FT                    end. All cytidine residues are 5-methylcytidines"
XX
PN   US2004097446-A1.
XX
PD   20-MAY-2004.
XX
PF   16-NOV-2002; 2002US-00298994.
XX
PR   16-NOV-2002; 2002US-00298994.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Dobie KW,  Watt AT;
XX
DR   WPI; 2004-430923/40.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding checkpoint kinase 1, useful for treating diseases associated
PT   with checkpoint kinase 1, e.g. hyperproliferative disorders.
XX
PS   Example 16; SEQ ID NO 91; 66pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding human/mouse checkpoint kinase 1 (Chk1). The
CC   antisense compound comprises an antisense oligonucleotide that
CC   specifically hybridises with the nucleic acid and inhibits the expression
CC   of Chk1. The antisense oligonucleotide is a chimeric oligonucleotide. The
CC   antisense oligonucleotide comprises at least one modified internucleoside
CC   linkage, preferably a phosphorothioate linkage. It also comprises at
CC   least one modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE)
CC   sugar moiety. The antisense oligonucleotide further comprises at least
CC   one modified nucleobase, preferably a 5-methylcytosine. The antisense
CC   oligonucleotides are useful for the treatment of diseases such as
CC   hyperproliferative disorders, e.g. cancer. The present sequence
CC   represents an antisense oligonucleotide used in the examples of the
CC   present invention.
XX
SQ   Sequence 20 BP; 6 A; 3 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db          2 ACTGGTTCTGCATGA 16


RESULT 565
ADO25083/c
ID   ADO25083 standard; DNA; 20 BP.
XX
AC   ADO25083;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human checkpoint kinase 1 DNA target sequence #32.
XX
KW   Antisense therapy; human; checkpoint kinase 1; Chk1;
KW   hyperproliferative disorder; cancer; cytostatic; ds.
XX
OS   Homo sapiens.
XX
PN   US2004097446-A1.
XX
PD   20-MAY-2004.
XX
PF   16-NOV-2002; 2002US-00298994.
```

```
XX
PR   16-NOV-2002; 2002US-00298994.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Dobie KW,  Watt AT;
XX
DR   WPI; 2004-430923/40.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding checkpoint kinase 1, useful for treating diseases associated
PT   with checkpoint kinase 1, e.g. hyperproliferative disorders.
XX
PS   Example 16; SEQ ID NO 165; 66pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding human/mouse checkpoint kinase 1 (Chk1). The
CC   antisense compound comprises an antisense oligonucleotide that
CC   specifically hybridises with the nucleic acid and inhibits the expression
CC   of Chk1. The antisense oligonucleotide is a chimeric oligonucleotide. The
CC   antisense oligonucleotide comprises at least one modified internucleoside
CC   linkage, preferably a phosphorothioate linkage. It also comprises at
CC   least one modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE)
CC   sugar moiety. The antisense oligonucleotide further comprises at least
CC   one modified nucleobase, preferably a 5-methylcytosine. The antisense
CC   oligonucleotides are useful for the treatment of diseases such as
CC   hyperproliferative disorders, e.g. cancer. The present sequence
CC   represents human Chk1 DNA target sequence for an antisense
CC   oligonucleotide.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         17 ACTGGTTCTGCATGA 3


RESULT 566
ADO24968
ID   ADO24968 standard; DNA; 20 BP.
XX
AC   ADO24968;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Human checkpoint kinase 1 DNA, antisense oligonucleotide #33.
XX
KW   Antisense therapy; human; checkpoint kinase 1; Chk1;
KW   hyperproliferative disorder; cancer; cytostatic; phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "This oligonucleotide has a phosphorothioate
FT                    backbone and 2'-methyoxyethyl (2'-MOE) wings at the 5'
FT                    and 3' ends, which are 5 nucleotides in length at each
FT                    end. All cytidine residues are 5-methylcytidines"
XX
PN   US2004097446-A1.
XX
PD   20-MAY-2004.
XX
PF   16-NOV-2002; 2002US-00298994.
XX
PR   16-NOV-2002; 2002US-00298994.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Gaarde W,  Freier SM,  Dobie KW,  Watt AT;
XX
DR   WPI; 2004-430923/40.
XX
PT   New compounds, particularly oligonucleotides targeted to a nucleic acid
PT   encoding checkpoint kinase 1, useful for treating diseases associated
PT   with checkpoint kinase 1, e.g. hyperproliferative disorders.
XX
PS   Example 15; SEQ ID NO 50; 66pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding human/mouse checkpoint kinase 1 (Chk1). The
CC   antisense compound comprises an antisense oligonucleotide that
CC   specifically hybridises with the nucleic acid and inhibits the expression
CC   of Chk1. The antisense oligonucleotide is a chimeric oligonucleotide. The
CC   antisense oligonucleotide comprises at least one modified internucleoside
CC   linkage, preferably a phosphorothioate linkage. It also comprises at
CC   least one modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE)
CC   sugar moiety. The antisense oligonucleotide further comprises at least
CC   one modified nucleobase, preferably a 5-methylcytosine. The antisense
CC   oligonucleotides are useful for the treatment of diseases such as
CC   hyperproliferative disorders, e.g. cancer. The present sequence
CC   represents an antisense oligonucleotide used in the examples of the
CC   present invention.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db          4 ACTGGTTCTGCATGA 18


RESULT 567
ADP64804
ID   ADP64804 standard; DNA; 20 BP.
XX
AC   ADP64804;
XX
DT   26-AUG-2004  (first entry)
XX
DE   Human Na+-coupled citrate transporter protein gene primer #1.
XX
KW   ss; primer; sodium-coupled citrate transporter;
KW   transmembrane citrate transporter; lifespan; weight reduction;
KW   weight gain prevention; blood cholesterol; triglyceride;
KW   low density lipopolysaccharide; glucose; obesity; hyperlipidemia;
KW   hypercholesterolemia; INDY protein.
XX
OS   Homo sapiens.
XX
PN   WO2004048925-A2.
XX
PD   10-JUN-2004.
XX
PF   20-NOV-2003; 2003WO-US037054.
XX
PR   22-NOV-2002; 2002US-0428469P.
PR   01-APR-2003; 2003US-0459441P.
XX
PA   (MEDI-) MEDICAL COLLEGE GEORGIA RES INST.
PA   (GANA/) GANAPATHY V.
PA   (INOU/) INOUE K.
PA   (FEIY/) FEI Y.
XX
PI   Ganapathy V,  Inoue K,  Fei Y;
XX
DR   WPI; 2004-460797/43.
```

```
XX
PT   New isolated polynucleotide encoding a Na+-coupled citrate transporter
PT   (NaCT) polypeptide, useful as a drug target for the treatment of obesity,
PT   hyperlipidemia, and hypercholesterolemia.
XX
PS   Example 3; SEQ ID NO 19; 186pp; English.
XX
CC   The invention relates to novel Na+-coupled citrate transporter proteins
CC   and their encoding genes. Inhibitors of transmembrane citrate
CC   transporters are useful for extending the lifespan, reducing weight,
CC   preventing weight gain or lowering blood cholesterol, triglyceride, LDL
CC   or glucose levels in a subject. The NaCT polypeptide is useful as a drug
CC   target for the treatment of obesity, hyperlipidemia, and
CC   hypercholesterolemia. This sequence corresponds to a PCR primer to
CC   amplify the human gene encoding an Na+-coupled citrate transporter
CC   protein.
XX
SQ   Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 3.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1700 GCGCTGAGCTATCTC 1714
              ||||||||||| ||
Db          5 GCGCTGAGCTATGTC 19


RESULT 568
AAV02719
ID   AAV02719 standard; DNA; 18 BP.
XX
AC   AAV02719;
XX
DT   19-MAY-1998  (first entry)
XX
DE   Human Class I HLA gene probe EE2-210.
XX
KW   Human leukocyte antigen class I gene; allele testing; probe; donor;
KW   tissue matching; recipient; graft rejection; class typing; ds.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9723645-A1.
XX
PD   03-JUL-1997.
XX
PF   04-JAN-1996;   96WO-US000362.
XX
PR   04-JAN-1996;   96WO-US000362.
XX
PA   (SLOK ) SLOAN KETTERING INST CANCER RES.
XX
PI   Yang SY,  Cereb N;
XX
DR   WPI; 1997-351080/32.
XX
PT   DNA-based human leukocyte antigen class I gene typing method - useful for
PT   tissue matching and prevention of graft versus host disease.
XX
PS   Disclosure; Page 10; 89pp; English.
XX
CC   AAV02716-V02738 are hybridisation probes used in a novel method for
CC   testing tissue samples to determine the allelic type of a human leukocyte
CC   antigen (HLA) class I gene in the sample. The HLA Class I gene is
CC   selected from among HLA-A, -B and -C genes. The method comprises of
CC   treating the tissue sample to obtain nucleic acid polymers suitable for
CC   amplification then combining these polymers with a first primer which
CC   hybridises with a portion of intron 1 or intron 3 of the HLA Class I gene
CC   and a second primer which hybridises with a different portion of the HLA
CC   Class I gene under conditions suitable for amplification to obtain an
CC   amplified product. The product is then evaluated to determine the allelic
CC   type of the HLA-Class I gene. The method is useful for tissue matching
CC   HLA class I antigens between donors and recipients and hence for
CC   preventing graft versus host disease
XX
SQ   Sequence 18 BP; 7 A; 7 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCCC 1601
              |||||||  ||||| ||
Db          1 GCACAGACACGGAACACC 18


RESULT 569
AAV12843
ID   AAV12843 standard; DNA; 18 BP.
XX
AC   AAV12843;
XX
DT   13-MAY-1998  (first entry)
XX
DE   Reverse primer for exon 7 of CDK4.
XX
KW   PCR primer; amplify; CDK4; cyclin-dependant kinase 4; human;
KW   cancer predisposition; inherited cancer; familial melanoma detection; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5714329-A.
XX
PD   03-FEB-1998.
XX
PF   29-NOV-1995;   95US-00564002.
XX
PR   29-NOV-1995;   95US-00564002.
XX
PA   (SEQU-) SEQUANA THERAPEUTICS INC.
PA   (USGO ) US GOVERNMENT.
XX
PI   Tucker M,  Dracopoli N,  Goldstein A;
XX
DR   WPI; 1998-129856/12.
XX
PT   Detecting inherited pre-disposition to cancer, specifically melanoma -
PT   from presence of mutation in gene for cyclin-dependent kinase 4,
PT   particularly one preventing binding of natural inhibitor p16.
XX
PS   Example; Col 7; 14pp; English.
XX
CC   This sequence represents a primer for an exon of the human cyclin-
CC   dependant kinase 4 (CDK4) gene. This sequence can be used in the method
CC   of the invention for detecting inherited predisposition to cancer by
CC   analysing the germ line genomic DNA for presence of a CDK4 allele that
CC   includes a predisposing mutation. The method is specifically used to
CC   determine predisposition to familial melanoma, indicated by replacement
CC   of R by C at amino acid 24 of CDK4. Many other tumours may also involve
CC   alterations in the control of CDK4, e.g. lymphomas, leukaemias, Ewing's
CC   sarcoma, Wilms tumour and non-small cell lung cancer
XX
SQ   Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1840 CATTCCCTGGGCCAACAG 1857
              | ||||||| ||| ||||
Db          1 CTTTCCCTGTGCCCACAG 18
```

```
RESULT 570
AAX18577/c
ID   AAX18577 standard; DNA; 18 BP.
XX
AC   AAX18577;
XX
DT   06-MAY-1999  (first entry)
XX
DE   Human tumour necrosis factor alpha 5'-flanking region probe #2.
XX
KW   Human; tumour necrosis factor alpha; TNF-alpha; promoter; diagnosis;
KW   juvenile rheumatoid arthritis; chronic rheumatoid arthritis;
KW   insulin-dependent diabetes; insulin-independent diabetes; probe; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9854309-A1.
XX
PD   03-DEC-1998.
XX
PF   26-NOV-1997;   97WO-JP004304.
XX
PR   26-MAY-1997;   97JP-00134973.
PR   30-JUN-1997;   97JP-00173900.
XX
PA   (SHIO ) SHIONOGI & CO LTD.
XX
PI   Kamizono S,  Yamada A,  Higuchi T,  Kato H,  Itoh K;
XX
DR   WPI; 1999-059829/05.
XX
PT   Diagnosis of genetic variation associated with diseases involving TNF
PT   alpha - such as rheumatoid arthritis or diabetes, by detecting mutation
PT   at positions 857, 863 or 1031 of the TNF alpha gene.
XX
PS   Example 4; Page 10; 34pp; Japanese.
XX
CC   The present sequence represents a probe for the human tumour necrosis
CC   factor alpha (TNF-alpha) 5'-flanking region. The present invention
CC   describes genetic variations involved in diseases associated with TNF-
CC   alpha which are screened for by detecting the presence or absence of one
CC   or more of the following mutations in the 5'-flanking region of the human
CC   TNF-alpha gene: (1) T in place of C at position -857; (2) A instead of C
CC   at -863; and (3) C instead of T at -1031 (positions 373, 367 and 199
CC   respectively of the sequence given in AAX18575). The mutations increase
CC   TNF-alpha production in the cells involved. A suitable method for
CC   detection of these mutations is allele-specific oligonucleotide
CC   hybridisation (ASOH). TNF-alpha genetic variations associated with TNF
CC   alpha-implicated diseases such as juvenile rheumatoid arthritis, chronic
CC   rheumatoid arthritis, insulin-dependent diabetes or insulin-independent
CC   diabetes
XX
SQ   Sequence 18 BP; 6 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1752 GGCTCTTTATTCATTAAG 1769
                ||| || | |||||||||
Db         18 GGCCCTGTCTTCATTAAG 1


RESULT 571
AAX18586/c
ID   AAX18586 standard; DNA; 18 BP.
XX
AC   AAX18586;
XX
DT   06-MAY-1999  (first entry)
XX
DE   Human tumour necrosis factor alpha 5'-flanking region probe #2.
XX
KW   Human; tumour necrosis factor alpha; TNF-alpha; promoter; diagnosis;
KW   juvenile rheumatoid arthritis; chronic rheumatoid arthritis;
KW   insulin-dependent diabetes; insulin-independent diabetes; probe; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9854361-A1.
XX
PD   03-DEC-1998.
XX
PF   25-MAY-1998;   98WO-JP002270.
XX
PR   26-MAY-1997;   97JP-00134973.
PR   30-JUN-1997;   97JP-00173900.
PR   26-NOV-1997;   97WO-JP004304.
XX
PA   (SHIO ) SHIONOGI & CO LTD.
XX
PI   Kamizono S,  Yamada A,  Higuchi T,  Kato H,  Itoh K,  Seki N;
XX
DR   WPI; 1999-059851/05.
XX
PT   Diagnosis of genetic variation associated with diseases involving TNF
PT   alpha - such as juvenile rheumatoid arthritis, by detecting mutation at
PT   positions 857, 863 or 1031 of the TNF alpha gene.
XX
PS   Example 4; Page 10; 46pp; Japanese.
XX
CC   The present sequence represents a probe for the human tumour necrosis
CC   factor alpha (TNF-alpha) 5'-flanking region. The present invention
CC   describes genetic variations involved in diseases associated with TNF-
CC   alpha which are screened for by detecting the presence or absence of one
CC   or more of the following mutations in the 5'-flanking region of the human
CC   TNF-alpha gene: (1) T in place of C at position -857; (2) A instead of C
CC   at -863; and (3) C instead of T at -1031 (positions 373, 367 and 199
CC   respectively of the sequence given in AAX18584). The mutations increase
CC   TNF-alpha production in the cells involved. A suitable method for
CC   detection of these mutations is allele-specific oligonucleotide
CC   hybridisation (ASOH). TNF-alpha genetic variations associated with TNF
CC   alpha-implicated diseases such as juvenile rheumatoid arthritis, chronic
CC   rheumatoid arthritis, insulin-dependent diabetes or insulin-independent
CC   diabetes
XX
SQ   Sequence 18 BP; 6 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1752 GGCTCTTTATTCATTAAG 1769
                ||| || | |||||||||
Db         18 GGCCCTGTCTTCATTAAG 1


RESULT 572
AAA55669
ID   AAA55669 standard; DNA; 18 BP.
XX
AC   AAA55669;
XX
DT   30-AUG-2000  (first entry)
XX
DE   TRAF5 antisense oligonucleotide ISIS# 26969.
XX
KW   Tumour necrosis factor receptor-associated factor; TRAF; human;
KW   antisense oligonucleotide; phosphorothioate; antiproliferative;
KW   anti-inflammatory; E-selectin; jun kinase; ss.
XX
OS   Synthetic.
XX
PN   WO200020435-A1.
```

```
XX
PD   13-APR-2000.
XX
PF   05-OCT-1999;   99WO-US023171.
XX
PR   06-OCT-1998;   98US-00167109.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Baker BF,  Cowsert LM,  Monia BP,  Xu XS;
XX
DR   WPI; 2000-303732/26.
XX
PT   Antisense oligonucleotides targeted to nucleic acids encoding human tumor
PT   necrosis factor receptor-associated factor (TRAF), useful for treating
PT   diseases associated with TRAF expression such as inflammatory diseases.
XX
PS   Example 21; Page 66; 170pp; English.
XX
CC   The present invention relates to antisense oligonucleotides (see AAA55496
CC   -A55757) which are targeted to nucleic acids encoding a human tumour
CC   necrosis factor receptor-associated factor (TRAF). The antisense
CC   sequences comprise at least one modified internucleotide linkage, which
CC   is a phosphorothioate linkage. The oligonucleotides also include at least
CC   one modified sugar moiety such as a 2'-O-methoxyethyl sugar moiety.
CC   Sequences AAA55490-A55495 represent nucleotide sequences encoding human
CC   TRAF1-6. Included in the invention is a method for treating a human
CC   having a disease associated with the expression of TRAF comprising
CC   administering an antisense oligonucleotide. The reduction of jun kinase
CC   activation in cells comprises contacting the cells with an antisense
CC   oligonucleotide targeted to TRAF-6. A method for the reduction of E-
CC   selectin expression in cells or tissues comprises contacting the cells or
CC   tissues with an antisense oligonucleotide targeted to TRAF-2 or TRAF-6.
CC   The antisense oligonucleotides have antiproliferative and anti-
CC   inflammatory activity and are useful for treating disorders associated
CC   with cell proliferation and inflammation. The antisense oligonucleotides
CC   may also be used as a diagnostic probe for studying gene function
XX
SQ   Sequence 18 BP; 5 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1565 GCAAAAATCCTTCTCCAC 1582
              |||||| ||| |||| ||
Db          1 GCAAAACTCCGTCTCTAC 18


RESULT 573
AAZ91407
ID   AAZ91407 standard; DNA; 18 BP.
XX
AC   AAZ91407;
XX
DT   22-MAY-2000  (first entry)
XX
DE   Human PTEN phosphorothioate antisense oligonucleotide #29573.
XX
KW   Human; PTEN; MMAC1; TEP1; phosphorothioate; antisense oligonucleotide;
KW   inhibition; protein phosphatase; tumour; diagnosis; inflammation;
KW   anticancer; anti-inflammatory; anti-infective; infection; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .18
FT                    /*tag=  a
FT                    /note= "phosphorothioate linkages"
XX
PN   US6020199-A.
XX
PD   01-FEB-2000.
XX
PF   21-JUL-1999;   99US-00358381.
XX
PR   21-JUL-1999;   99US-00358381.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2000-181363/16.
XX
PT   New antisense compounds useful for treating, preventing or diagnosing
PT   e.g. tumors or inflammation, are targeted to the human dual specificity
PT   protein phosphatase (PTEN) sequence.
XX
PS   Claim 3; Col 41; 32pp; English.
XX
CC   The present invention describes phosphorothioate antisense
CC   oligonucleotides that are targeted to the 3'-untranslated region (UTR) of
CC   the sequence encoding a human dual specificity protein phosphatase
CC   designated PTEN (also known as MMAC1 and TEP1), and hybridise
CC   specifically to the human PTEN nucleotide sequence given in AAZ91361. The
CC   antisense oligonucleotides have anticancer, anti-inflammatory and anti-
CC   infective activities. The phosphorothioate antisense oligonucleotides can
CC   be used for diagnosis, treatment and prevention of PTEN-related diseases,
CC   e.g. infections, inflammation and tumours. The present sequence
CC   represents a phosphorothioate antisense oligonucleotide for human PTEN,
CC   from the present invention
XX
SQ   Sequence 18 BP; 3 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTT 1794
              | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 574
AAA11103
ID   AAA11103 standard; DNA; 18 BP.
XX
AC   AAA11103;
XX
DT   28-JUL-2000  (first entry)
XX
DE   Hybridisation probe EE2-210 for typing HLA Class I genes.
XX
KW   Tissue sample testing; allelic typing; human leukocyte antigen;
KW   PCR primer; probe; hybridisation; intron; amplification; ss;
KW   allelic variation; non-classical HLA class I gene; exon.
XX
OS   Homo sapiens.
XX
PN   US6030775-A.
XX
PD   29-FEB-2000.
XX
PF   22-DEC-1995;   95US-00577081.
XX
PR   22-DEC-1995;   95US-00577081.
XX
PA   (CERE/) CEREB N.
PA   (YANG/) YANG S Y.
XX
PI   Cereb N,  Yang SY;
XX
DR   WPI; 2000-223159/19.
XX
PT   Testing a tissue sample to determine the allelic type of a human
PT   leukocyte antigen class I gene comprises amplification of nucleic acid
```

```
PT   polymers with primers which flank a region including an allelic variation
PT   of the HLA class I gene.
XX
PS   Disclosure; Col 8; 90pp; English.
XX
CC   The invention relates to a method (I) for testing a tissue sample to
CC   determine the allelic type of a human leukocyte antigen (HLA) class I
CC   gene in the sample, where the HLA class I gene is selected from HLA-A,
CC   HLA-B or HLA-C, by: (a) treating the tissue sample to obtain nucleic acid
CC   polymers suitable for amplification; (b) combining the nucleic acid
CC   polymers with a primer which hybridizes with a portion of intron 1 or
CC   intron 3 of the HLA class I gene, and a second primer which hybridizes
CC   with a different portion of the HLA class I gene and performing
CC   amplification, where the primers flank a region including at least one
CC   site of allelic variation in at least one of exons 2 or 3 of the HLA
CC   class I gene and where the first primer is a locus specific primer which
CC   hybridizes with intron 1 or 3 of only one of the HLA class I genes; and
CC   (c) evaluating the amplified product to determine the allelic type of the
CC   HLA class I gene. The method is useful for testing a tissue sample to
CC   determine the allelic type of a classical or non-classical HLA class I
CC   gene in the sample. The sequences AAA11039-A11122 represent consensus
CC   sequences of introns and exons of the HLA genes and primers and probes
CC   used to isolate and analyse the HLA genes
XX
SQ   Sequence 18 BP; 7 A; 7 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match              2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCCC 1601
              ||||||||  ||||| ||
Db          1 GCACAGACACGGAACACC 18


RESULT 575
AAH75295/c
ID   AAH75295 standard; DNA; 18 BP.
XX
AC   AAH75295;
XX
DT   02-OCT-2001  (first entry)
XX
DE   Human inducible NOS antisense oligonucleotide SEQ ID NO 139.
XX
KW   Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
KW   modulate expression; immunomodulator; antidiabetic; cardiovascular;
KW   cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
KW   2'-O-methoxyethyl; phosphorothioate; human; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate backbone, 5' and 3' four
FT                   nucleotide 2'-MOE (2'-O-methoxyethyl) wings, all cytidine
FT                   residues are 5-methylcytidines and a deoxy gap"
XX
PN   WO200152902-A1.
XX
PD   26-JUL-2001.
XX
PF   15-JAN-2001; 2001WO-US001381.
XX
PR   24-JAN-2000; 2000US-00490208.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Dean NM,  Cowsert LM;
XX
DR   WPI; 2001-465340/50.
XX
PT   New antisense oligonucleotides for modulating the expression of inducible
PT   nitric oxide synthase in cells or tissues, particularly useful for
PT   treating e.g. immunological, cardiovascular or neurological disorders, or
PT   ischemia.
XX
PS   Example 15; Page 85; 144pp; English.
XX
CC   The invention relates to antisense compounds, especially
CC   oligonucleotides, which are targeted to a nucleic acid encoding inducible
CC   nitric oxide synthase and which specifically hybridise to and modulate
CC   expression of inducible nitric oxide synthase. The antisense compounds
CC   have immunomodulator, antidiabetic, cardiovascular, cardiant,
CC   neuroprotective, disorder and vasotropic activity. The antisense
CC   oligonucleotides are useful for inhibiting the expression of inducible
CC   nitric oxide synthase in cells or tissues. In particular, the antisense
CC   oligonucleotides are useful for treating diseases or disorders associated
CC   with inducible nitric oxide synthase, e.g. diabetes, immunological
CC   disorder, cardiovascular disorder, neurological disorder or
CC   ischaemia/reperfusion injury. The antisense oligonucleotides are also
CC   useful for research and diagnostics. The present sequence is that of an
CC   antisense 2'-O-methoxyethyl gapmer oligonucleotide with a
CC   phosphorothioate backbone, a central "gap" region of ten nucleotides
CC   flanked by four nucleotide 2'-MOE (2'-methoxyethyl) wings and 5-
CC   methylcytidine residues throughout the oligonucleotide. The antisense
CC   olignucleotide is targeted to human inducible nitric oxide synthase (NOS)
CC   mRNA (AAH47973)
XX
SQ   Sequence 18 BP; 10 A; 1 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match              2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCT 1793
              |||| ||||| ||||| |
Db         18 TTTTCTGAACTCCATTTT 1


RESULT 576
AAS14033
ID   AAS14033 standard; DNA; 18 BP.
XX
AC   AAS14033;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human PTEN antisense oligonucleotide ISIS 29573.
XX
KW   Human; PTEN; MMAC1; TEP1; protein phosphatase; antisense; ss;
KW   antiinflammatory; cytostatic; antidiabetic; antilipaemic; infection;
KW   inflammation; tumour; diabetes; insulin resistance; insulin sensitivity;
KW   triglyceride control; cholesterol control; ISIS 29573.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  b
FT                   /note= "Optionally 2'-methoxyethyl residue (2'-MOE). When
FT                   1-4 are 2'-MOE all cytosines in this region are 5-
FT                   methylcytosines"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /note= "Optionally 2'-methoxyethyl residue (2'-MOE). When
FT                   15-18 are 2'-MOE all cytosines in this region are 5-
FT                   methylcytosines"
XX
PN   US6284538-B1.
```

```
XX
PD   04-SEP-2001.
XX
PF   24-MAY-2000; 2000US-00577902.
XX
PR   21-JUL-1999;   99US-00358381.
PR   14-DEC-1999;   99WO-US029594.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM,  Mckay R;
XX
DR   WPI; 2001-588976/66.
XX
PT   New antisense oligonucleotides targeting nucleic acids encoding PTEN,
PT   useful for treating diabetes, increasing insulin sensitivity, or
PT   decreasing insulin resistance, blood triglyceride or cholesterol levels
PT   in a diabetic animal.
XX
PS   Example 15; Col 43; 38pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid encoding
CC   PTEN (a dual specificity protein phosphatase), where the compound is an
CC   antisense oligonucleotide. The antisense oligonucleotides are useful in
CC   modulating the function of nucleic acids encoding PTEN, ultimately
CC   modulating the amount of PTEN produced. The antisense compounds can used
CC   as diagnostics, therapeutics, prophylactics (e.g. to prevent or delay
CC   infection, inflammation or tumour formation), and as research agents and
CC   kits. The antisense compounds are also useful in treating diabetes,
CC   decreasing insulin resistance, increasing insulin sensitivity and
CC   decreasing blood triglyceride or cholesterol levels in a diabetic animal.
CC   The present sequence is an antisense oligonucleotide targetting the DNA
CC   encoding PTEN (also known as MMAC1/TEP1)
XX
SQ   Sequence 18 BP; 3 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTT 1794
              | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 577
AAH25395/c
ID   AAH25395 standard; DNA; 18 BP.
XX
AC   AAH25395;
XX
DT   22-AUG-2001  (first entry)
XX
DE   Antisense oligonucleotide targeted to human Her-4 3' UTR.
XX
KW   Antisense oligonucleotide; Her-4; receptor kinase; tyrosine kinase;
KW   infection; inflammation; tumour; phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  b
FT                   /note= "all cytidine residues are 5-methylcytidines"
FT   modified_base   1. .18
FT                   /*tag=  c
FT                   /note= "all internucleoside linkages are phosphorothioate
FT                   linkages"
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   5. .14
FT                   /*tag=  d
FT                   /note= "2'-deoxynucleotides"
FT   modified_base   15. .18
FT                   /*tag=  e
FT                   /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   US6255111-B1.
XX
PD   03-JUL-2001.
XX
PF   31-JUL-2000; 2000US-00632580.
XX
PR   31-JUL-2000; 2000US-00632580.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM;
XX
DR   WPI; 2001-388929/41.
XX
PT   Compound for inhibiting the expression of Her-4 (a receptor/tyrosine
PT   kinase) e.g. in preventing tumor formation, comprises an antisense
PT   oligonucleotide that hybridizes to a nucleic acid encoding Her-4.
XX
PS   Example 15; Col 45-46; 44pp; English.
XX
CC   The specification describes antisense oligonucleotides which are targeted
CC   to a nucleic acid encoding Her-4 (a receptor/tyrosine kinase). The
CC   antisense oligonucleotides are used to inhibit the expression of Her-4 in
CC   cells or tissues in vitro. They can be used in diagnostics, therapeutics,
CC   prophylaxis and as a probe in research reagents. The antisense
CC   oligonucleotides can be used to prevent or delay infection, inflammation
CC   or tumour formation. AAH25315-AAH25398 represent antisense
CC   oligonucleotides which are targeted to different regions of the human Her
CC   -4 gene
XX
SQ   Sequence 18 BP; 10 A; 1 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCT 1793
              |||| ||||| ||||| |
Db         18 TTTTCTGAACTCCATTTT 1


RESULT 578
AAD35200/c
ID   AAD35200 standard; DNA; 18 BP.
XX
AC   AAD35200;
XX
DT   25-JUL-2002  (first entry)
XX
DE   Human TNFA promoter polymorphism (-856T) analysing probe.
XX
KW   Unexplained recurrent pregnancy loss; immunologic reproductive failure;
KW   URPL; interleukin-1beta; IL-1beta; human; tumour necrosis factor a;
KW   probe; promoter; polymorphism; sequence specific oligonucleotide probe;
KW   TNFA; SSOP; ss.
XX
OS   Homo sapiens.
XX
PN   WO200222877-A2.
XX
PD   21-MAR-2002.
XX
PF   12-SEP-2001; 2001WO-US028465.
XX
PR   12-SEP-2000; 2000US-0231785P.
XX
PA   (BGHM ) BRIGHAM & WOMENS HOSPITAL INC.
PA   (DAND ) DANA FARBER CANCER INST INC.
```

```
XX
PI   Hill JA,  Wang ZC,  Anderson DJ,  Yunis EJ;
XX
DR   WPI; 2002-362362/39.
XX
PT   Evaluating risk of unexplained recurrent pregnancy loss in a subject, by
PT   testing presence of a variant in interleukin-1 beta promoter region
PT   and/or in CD46 gene intron 1 region in a sample obtained from the
PT   subject.
XX
PS   Example 1; Page 21; 57pp; English.
XX
CC   The invention relates to a method for evaluating and treating risk of
CC   unexplained recurrent pregnancy loss (URPL) in a subject suspected of
CC   having immunologic reproductive failure. The method involves testing a
CC   sample obtained from the subject for the presence of a variant in the
CC   human interleukin-1beta (IL-1beta) promoter region, and/or a variant in
CC   the CD46 gene intron 1 region, where the presence of the variant,
CC   indicates an elevated risk of developing recurrent pregnancy loss. The
CC   present sequence is human tumour necrosis factor a (TNFA) promoter
CC   polymorphism analysing sequence specific oligonucleotide probe (SSOP)
CC   used in the exemplification of the invention
XX
SQ   Sequence 18 BP; 7 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1751 TGGCTCTTTATTCATTAA 1768
              |||| || | ||||||||
Db         18 TGGCCCTGTCTTCATTAA 1


RESULT 579
AAD40068
ID   AAD40068 standard; DNA; 18 BP.
XX
AC   AAD40068;
XX
DT   22-OCT-2002  (first entry)
XX
DE   Human PTEN antisense oligonucleotide, ISIS 29613.
XX
KW   Human; phosphoinositide phosphatase; PTEN; liver; kidney; cholesterol;
KW   metabolic disease; diabetes; hyperproliferative; glucose; insulin; PEPCK;
KW   triglyceride; antisense gene therapy; cytostatic; adipose cell;
KW   antiproliferative; antisense; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .18
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone"
FT   modified_base    1. .4
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
FT   modified_base    13
FT                    /*tag=  d
FT                    /mod_base= m5c
FT   modified_base    15. .18
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'methoxyethyl nucleotides"
XX
PN   US2002058638-A1.
XX
PD   16-MAY-2002.
XX
PF   11-JUN-2001; 2001US-00878582.
XX
PR   21-JUL-1999;   99US-00358381.
PR   14-DEC-1999;   99WO-US029594.
PR   24-MAY-2000; 2000US-00577902.
XX
PA   (MONI/) MONIA B P.
PA   (COWS/) COWSERT L M.
PA   (MCKA/) MCKAY R.
XX
PI   Monia BP,  Cowsert LM,  Mckay R;
XX
DR   WPI; 2002-479187/51.
XX
PT   New compound, preferably an antisense oligonucleotide, that hybridizes
PT   and inhibits the expression of phosphoinositide phosphatase (PTEN), for
PT   treating diseases such as diabetes, or a hyperproliferative condition.
XX
PS   Claim 7; Page 36; 39pp; English.
XX
CC   The invention relates to antisense compounds, compositions and methods
CC   for modulating the expression of phosphoinositide phosphatase (PTEN). The
CC   antisense compound is used to inhibit the expression of PTEN in cells or
CC   tissues, preferably human, or rodent, such as mouse or rat, liver, kidney
CC   or adipose cells or tissues. It is used to treat a disease or condition
CC   associated with PTEN, such as a metabolic disease or condition,
CC   preferably diabetes, especially Type 2 diabetes, or a hyperproliferative
CC   condition. It is also used to decrease blood glucose or insulin levels in
CC   an animal, preferably a diabetic human or rodent. It is also used to
CC   inhibit expression of PEPCK in cells or tissues. It is also used to
CC   decrease insulin resistance, or increase insulin sensitivity, in an
CC   animal, preferably a diabetic human or rodent. It is used to decrease
CC   blood triglyceride or cholesterol levels in an animal, preferably a
CC   diabetic human or rodent. It is also used in antisense gene therapy. The
CC   present sequence is an antisense oligonucleotide targetted to human PTEN
CC   DNA
XX
SQ   Sequence 18 BP; 3 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTT 1794
              | |||  || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 580
ABN83367
ID   ABN83367 standard; DNA; 18 BP.
XX
AC   ABN83367;
XX
DT   15-AUG-2002  (first entry)
XX
DE   Solanum tuberosum protein kinase-related PCR primer #6.
XX
KW   Protein kinase; StPK-B; transposon tagging; Phytophthora infestans;
KW   potato; transgenic plant; PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   EP1205543-A1.
XX
PD   15-MAY-2002.
XX
PF   09-NOV-2000; 2000EP-00203911.
XX
PR   09-NOV-2000; 2000EP-00203911.
XX
PA   (PLAN-) PLANT RES INT BV.
XX
```

```
PI   Van Enckevort LJG,  Jacobsen E,  Stiekema WJ,  Pereira A;
XX
DR   WPI; 2002-437394/47.
XX
PT   New DNA sequence isolated from potato encodes a protein which confers
PT   Phytophthora infestans resistance on plants and is useful to generate
PT   transgenic plants particularly potatoes and tomatoes with Phytophthora
PT   resistance.
XX
PS   Disclosure; Page 4; 41pp; English.
XX
CC   The present invention relates to a DNA sequence encoding a fragment of
CC   the Solanum tuberosum protein kinase (StPK-B, ABN83351). ABN83351 is part
CC   of the StPK-B gene, and encodes the protein kinase domain, but lacks the
CC   N-terminal portion of the gene including the translation start.
CC   Transposon tagging using the Ds transposon was used to isolate ABN83351.
CC   StPK-B confers Phytophthora infestans resistance on plants, specifically
CC   potatoes, and can be used for generating transgenic plants, particularly
CC   Solenaceae, which are resistant to Phytophthora species. The present
CC   sequence is a PCR primer, used to illustrate the invention
XX
SQ   Sequence 18 BP; 4 A; 6 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTTTC 1930
              |||||| ||||| || ||
Db          1 AACAATGCCTTTCTTCTC 18


RESULT 581
ADF43171
ID   ADF43171 standard; DNA; 18 BP.
XX
AC   ADF43171;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human phosphatase and tensin (PTEN) antisense oligonucleotide SeqID43.
XX
KW   Alzheimer's disease marker; phosphatase and tensin homologue;
KW   chromosome 10; PTEN; p70 S6 kinase gene; Alzheimer's disease; diagnosis;
KW   human; antisense therapy; ss.
XX
OS   Homo sapiens.
XX
PN   JP2003339378-A.
XX
PD   02-DEC-2003.
XX
PF   24-MAY-2002; 2002JP-00150115.
XX
PR   24-MAY-2002; 2002JP-00150115.
XX
PA   (SUMU ) SUMITOMO SEIYAKU KK.
XX
DR   WPI; 2004-039518/04.
XX
PT   Alzheimer's disease marker present in base sequence of phosphatase and
PT   tensin homolog deleted on chromosome ten gene or p70 S6 kinase gene
PT   useful as probe or primer for diagnosis of Alzheimer's disease.
XX
PS   Disclosure; SEQ ID NO 43; 38pp; Japanese.
XX
CC   This invention relates to a novel human Alzheimer's disease marker which
CC   consists of at least 15 contiguous bases of phosphatase and tensin (PTEN)
CC   gene homologue deleted on chromosome 10 or a p70 S6 kinase gene. The
CC   invention is useful for diagnosis of Alzheimer's disease. By making the
CC   marker into a parameter, therapeutic agents for Alzheimer's disease can
CC   be screened. The invention provides a precise diagnosis of Alzheimer's
CC   disease and thus more suitable treatment can be provided to the patient.
XX
SQ   Sequence 18 BP; 3 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 4.1e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1777 TTTTTGAACCCCATTCTT 1794
              | ||| || |||||||||
Db          1 TGTTTCAAGCCCATTCTT 18


RESULT 582
ADI30222
ID   ADI30222 standard; DNA; 18 BP.
XX
AC   ADI30222;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human PTEN specific antisense oligonucleotide, ISIS 29573.
XX
KW   PTEN; metabolic disease; type 2 diabetes; hyperproliferative condition;
KW   prophylaxis; gene therapy; human; MMAC1; phosphorothioate backbone; TEP1;
KW   antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl bases, where all cytidines are 5-
FT                   methylcytidines"
FT   modified_base   15. .18
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-methoxyethyl bases, where all cytidines are 5-
FT                   methylcytidines"
XX
PN   US2004002153-A1.
XX
PD   01-JAN-2004.
XX
PF   03-JAN-2003; 2003US-00336213.
XX
PR   21-JUL-1999;   99US-00358381.
PR   14-DEC-1999;   99WO-US029594.
PR   24-MAY-2000; 2000US-00577902.
PR   11-JUN-2001; 2001US-00878582.
PR   18-SEP-2002; 2002US-0411780P.
XX
PA   (MONI/) MONIA B P.
PA   (BENN/) BENNETT C F.
PA   (BAKE/) BAKER B F.
PA   (VICK/) VICKERS T.
XX
PI   Monia BP,  Bennett CF,  Baker BF,  Vickers T;
XX
DR   WPI; 2004-061664/06.
XX
PT   New double-stranded oligomeric compounds that modulate PTEN expression,
PT   useful for diagnosing, preventing or treating conditions associated with
PT   PTEN, e.g. metabolic diseases, type 2 diabetes or hyperproliferative
PT   diseases.
XX
PS   Claim 14; SEQ ID NO 47; 54pp; English.
XX
```

CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of PTEN (also known as MMAC1 and TEP1). The
CC compound is useful for inhibiting the expression of PTEN in cells or
CC tissues to treat diseases associated with their expression, e.g.
CC metabolic diseases or conditions, type 2 diabetes or hyperproliferative
CC conditions. In addition, the compound is used for diagnostics,
CC prophylaxis, or as research reagents or kits. The invention is useful in
CC gene therapy. The present sequence is human PTEN DNA specific antisense
CC oligonucleotide.
XX
SQ Sequence 18 BP; 3 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1777 TTTTTGAACCCCATTCTT 1794
| ||| || |||||||||
Db 1 TGTTTCAAGCCCATTCTT 18

RESULT 583
ADI20852/c
ID ADI20852 standard; DNA; 18 BP.
XX
AC ADI20852;
XX
DT 06-MAY-2004 (first entry)
XX
DE Hybridisation detection oligonucleotide #50.
XX
KW DD3; CpG dinucleotide; cell proliferative disorder; ss.
XX
OS Synthetic.
XX
PN WO2004005543-A1.
XX
PD 15-JAN-2004.
XX
PF 25-JUN-2003; 2003WO-EP006690.
XX
PR 08-JUL-2002; 2002DE-01030692.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Horns T;
XX
DR WPI; 2004-091385/09.
XX
PT Detecting methylation of 5' and promoter region of DD3 gene for
PT diagnosing proliferative disorders comprising contacting target nucleic
PT acid with a reagent that distinguishes between methylated and non-
PT methylated CpG dinucleotide.
XX
PS Claim 6; SEQ ID NO 55; 56pp; English.
XX
CC The present invention relates to detecting the methylation state of the
CC 5' and promoter region of the gene DD3 within a subject comprising
CC contacting a target nucleic acid having one or more sequences selected
CC from 5 3581 base pair sequences in a biological sample with at least one
CC reagent or a series of reagents. The method is useful for detecting the
CC methylation state of the 5' and promoter region of the gene DD3 within a
CC subject. The set of oligonucleotides comprising at least three of the
CC oligomers is useful for detecting the cytosine methylation state and/or
CC single nucleotide polymorphisms (SNPs) within SEQ. ID NO. 1-5 and its
CC complementary sequences. The set of oligomers is also useful for
CC detecting the methylation state of all CpG dinucleotides within SEQ ID
CC NO. 1 and its complementary sequences. The set of at least two
CC oligonucleotides can be used as primer oligonucleotides for the
CC amplification of DNA sequences selected from SEQ ID NO. 1-5 and its
CC complementary sequences. The DNA- and/or PNA-array is useful for
CC analyzing diseases associated with the methylation state of the gene DD3
CC comprising at least one nucleic acid. The methods, nucleic acids,
CC oligonucleotide or PNA-oligomer, kit, array or the set of
CC oligonucleotides is useful for the characterization, classification,
CC differentiation, grading, staging, and/or diagnosis of cell proliferative
CC disorders, or the predisposition to cell proliferative disorders. It can
CC also be used for the therapy of cell proliferative disorders. The present
CC sequence represents a detection oligonucleotide of the invention.
XX
SQ Sequence 18 BP; 4 A; 0 C; 3 G; 11 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 4.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1899 TAGATCAACAGATCAACA 1916
|| ||||||| ||||| |
Db 18 TAAATCAACAAATCAATA 1

RESULT 584
AAT75111/c
ID AAT75111 standard; DNA; 19 BP.
XX
AC AAT75111;
XX
DT 11-MAR-1998 (first entry)
XX
DE PCR primer 1 for the von Hippel-Lindau tumour suppressor gene exon 2.
XX
KW von Hippel-Lindau tumour suppressor gene; VHL tumour suppressor gene;
KW insertion mutation; deletion mutation; copy number mutation; exon 2;
KW hierarchical assay system; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9724974-A2.
XX
PD 17-JUL-1997.
XX
PF 06-JAN-1997; 97WO-CA000006.
XX
PR 05-JAN-1996; 96US-00583289.
PR 19-AUG-1996; 96US-00699628.
XX
PA (VISI-) VISIBLE GENETICS INC.
XX
PI Hui M, Dunn JM, Stevens JK, Capatos D, Matthews DE;
XX
DR WPI; 1997-372541/34.
XX
PT Poly:nucleotide(s) for identification of mutation(s) in Von Hippel-Lindau
PT tumour suppressor gene - and hierarchical test system utilising them,
PT useful for detecting tumours.
XX
PS Claim 1; Page 27; 51pp; English.
XX
CC PCR primers AAT75107-14 and AAT75124-26 are novel oligonucleotides that
CC are used for the identification of mutations in the von Hippel-Lindau
CC (VHL) tumour suppressor gene. The oligonucleotides can be used for the
CC identification and diagnosis of insertion/deletion mutations and for copy
CC number mutations. The primers are designed to hybridise to genomic DNA,
CC particularly in the flanking intron regions adjacent to the exons of the
CC VHL tumour suppressor gene. The present 5' primer hybridises to the
CC intron sequence 5' of exon 2. The oligonucleotides are used in a
CC hierarchical system of assays, which comprise a first assay providing a
CC highly specific test for the disease associated mutation, and a final
CC assay providing a highly sensitive and highly specific test for the
CC disease associated mutation. In the first assay exons of VHL tumour
CC suppressor gene are amplified using the above primers. If no mutations
CC are detected i.e. the result is negative, the sample is examined for
CC point mutations in the DNA sequence by sequencing (AAT75115-22, T751127-
CC 29). The major advantage of the hierarchical system used in this test is
CC the ability to dramatically reduce the per sample cost of targeted

```
CC   genetic screening and diagnosis for VHL tumour suppressor gene mutations
XX
SQ   Sequence 19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1642 TAAAGAGCCTTCACTGGT 1659
              ||||||||| ||| |||
Db         19 TAAAGAGCCCACACCGGT 2


RESULT 585
AAA84322/c
ID   AAA84322 standard; DNA; 19 BP.
XX
AC   AAA84322;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin D2 ribozyme binding site #19.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 75; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 2 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGA 1619
              || ||||| | |||||||
Db         19 TCATGGCCAGAGGGAAGA 2


RESULT 586
AAA84665
ID   AAA84665 standard; DNA; 19 BP.
XX
AC   AAA84665;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin E ribozyme binding site #198.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 80; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 6 A; 8 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCACA 1588
              |||||||||||||  | |
Db          2 ATCCTTCTCCACCAAAGA 19


RESULT 587
AAZ70186
ID   AAZ70186 standard; DNA; 19 BP.
XX
AC   AAZ70186;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:4542.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
```

PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 1199; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1967 ATATTTACCTTGAAAAAA 1984
||||||||||| || | ||
Db 1 ATATTTACCTGGAGAGAA 18

RESULT 588
AAH59484/c
ID AAH59484 standard; DNA; 19 BP.
XX
AC AAH59484;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin D2 ribozyme binding site SEQ ID NO:1908.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 210; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 2 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1602 TCCTGGCCTGGGGGAAGA 1619
|| ||||| | |||||||
Db 19 TCATGGCCAGAGGGAAGA 2

RESULT 589
AAH59827
ID AAH59827 standard; DNA; 19 BP.
XX
AC AAH59827;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin E ribozyme binding site SEQ ID NO:2251.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.

```
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 235; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 6 A; 8 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCACA 1588
              ||||||||||||  | |
Db          2 ATCCTTCTCCACCAAAGA 19


RESULT 590
ABL88856
ID   ABL88856 standard; DNA; 19 BP.
XX
AC   ABL88856;
XX
DT   22-MAY-2002  (first entry)
XX
DE   HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:78.
XX
KW   Binding molecule; HIV-1; human immunodeficiency virus type 1;
KW   reverse transcriptase; binding group; ss.
XX
OS   Human immunodeficiency virus 1.
OS   Synthetic.
XX
PN   EP1174518-A1.
XX
PD   23-JAN-2002.
XX
PF   20-JUL-2000; 2000EP-00202611.
XX
PR   20-JUL-2000; 2000EP-00202611.
XX
PA   (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
PI   Loukachov VV,  Van Gemen B,  Goudsmit J;
XX
DR   WPI; 2002-156696/21.
XX
PT   Collection of binding groups for determining or typing samples,
PT   especially clinical samples, has groups capable to identify essentially
PT   all members of the family of nucleic acids of relatively high
PT   significance.
XX
PS   Disclosure; Page 26; 166pp; English.
XX
CC   The present invention describes a collection of binding groups for a
CC   family of nucleic acids comprising members of relative high and relative
CC   low significance, where the binding groups are selected to be capable to
CC   identify, alone or in combination, essentially all members of the family
CC   of nucleic acids of relatively high significance. The collection of
CC   binding groups is useful for typing of nucleic acid in a clinical sample,
CC   by contacting the nucleic acid with the collection and determining
CC   whether one or more binding groups bound to the nucleic acid of the
CC   sample. This method is useful for determining whether the sample
CC   comprises at least a part of a member of relatively high significance of
CC   a family of nucleic acids. The collection of binding groups is useful for
CC   diagnosing the severity of a disease caused by a pathogen containing a
CC   member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC   oligonucleotide sequences used in the exemplification of the present
CC   invention
XX
SQ   Sequence 19 BP; 10 A; 3 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAA 1983
              |||||||  || | |||||
Db          2 AATATTTGCCATAAAAAA 19


RESULT 591
ABS98086
ID   ABS98086 standard; DNA; 19 BP.
XX
AC   ABS98086;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human multidrug resistance gene sequencing primer #10.
XX
KW   Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
KW   cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW   adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW   aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW   cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW   epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW   glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW   HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW   NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
KW   UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW   UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW   multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW   multidrug resistance associated protein 3; cancer; prostate;
KW   acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW   altered drug metabolism; cardiovascular function; colorectal tumour;
KW   central nervous system; pulmonary; immunological; sequencing.
XX
OS   Homo sapiens.
XX
PN   WO200257410-A2.
XX
PD   25-JUL-2002.
XX
PF   28-NOV-2001; 2001WO-US044838.
XX
PR   28-NOV-2000; 2000US-00724389.
XX
PA   (DNAS-) DNA SCI LAB INC.
```

```
XX
PI   Guida M,  Hall J;
XX
DR   WPI; 2002-698522/75.
XX
PT   Isolated nucleic acid molecules having polymorphisms in known human genes
PT   e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
PT   for locating, identifying and characterizing the genes responsible for
PT   disorder-related traits.
XX
PS   Example 22; Page 142; 714pp; English.
XX
CC   This invention relates to the sequence of an isolated nucleic acid
CC   molecule comprising at least one base variation from that of a known
CC   human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC   cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
CC   aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC   (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
CC   inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
CC   protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
CC   transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl
CC   transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC   sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC   (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC   transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
CC   (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC   (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
CC   receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC   The polymorphisms in the human genes cited in the invention are useful as
CC   genetic linkage markers for locating and characterising the genes that
CC   are responsible for specific traits within the genome and eventually
CC   identifying the genes responsible for a variety of disorder-related
CC   traits as a result of their e.g., overexpression, constitutive
CC   expression, mutation or underexpression, which may be used in diagnosing
CC   and/or treating the disorders. The nucleic acid molecules comprising the
CC   polymorphic sequences contained in CYP4501A1, CYPP4501A2, CYP4502E1,
CC   ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
CC   MDR1 and/or MDR3 are useful for screening individuals for altered drug
CC   metabolism. The polymorphic sequences contained in CYP4501A1, CYPP4501A2,
CC   AHR, MDR1 and/or MDR3 may also be used to screen individuals for
CC   susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
CC   used to screen for altered cardiovascular function, in COX2 for altered
CC   susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
CC   nervous system function, in FLAP and HNMT for altered pulmonary,
CC   immunological or haematological function, in KLK2 for altered serine
CC   protease activity in the prostate, in LTF for altered immunological or
CC   haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC   peripheral nervous system function. The present sequence represents a
CC   sequencing primer used to sequence the polymorphic genes of the invention
XX
SQ   Sequence 19 BP; 7 A; 7 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1557 ACAGGACTGCAAAAATCC 1574
              ||||||||| | | ||||
Db          2 ACAGGACTGAACACATCC 19


RESULT 592
ACA98663/c
ID   ACA98663 standard; DNA; 19 BP.
XX
AC   ACA98663;
XX
DT   28-JUL-2003  (first entry)
XX
DE   Human CYP2C8 SNP detection PCR primer #103.
XX
KW   Cytochrome P450 polypeptide 2C8; CYP2C8; arachidonic acid metabolism;
KW   cancer; cardiovascular disease; cytostatic; cardiovascular; gene therapy;
KW   single nucleotide polymorphism detection; SNP detection; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200299099-A2.
XX
PD   12-DEC-2002.
XX
PF   31-MAY-2002; 2002WO-EP006000.
XX
PR   01-JUN-2001; 2001EP-00112899.
XX
PA   (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI   Penger A,  Sprenger R,  Brinkmann U;
XX
DR   WPI; 2003-167344/16.
XX
PT   New polymorphic variants of the gene encoding Cytochrome P450 polypeptide
PT   2C8 (CYP2C8), useful for diagnosing or treating a disease, e.g.
PT   arachidonic acid metabolism, cancer or cardiovascular diseases.
XX
PS   Example 2; Page 50; 178pp; English.
XX
CC   The invention describes a new polynucleotide comprises a polynucleotide:
CC   (a) having any of 101 nucleic acid sequences with 18-19 bp fully defined
CC   in the specification; (b) encoding any of seven polypeptides having 7
CC   amino acids, or a polypeptide with 3 amino acids; (c) capable of
CC   hybridising to a Cytochrome P450 polypeptide 2C8 (CYP2C8) gene; (d)
CC   encoding a molecular CYP2C8 variant polypeptide or its fragment. The
CC   polynucleotide, gene, vector, polypeptide or antibody is useful for
CC   diagnosing or treating a disease, for preparing a diagnostic composition
CC   for diagnosing a disease, or for preparing a pharmaceutical composition
CC   for treating a disease. This disease includes arachidonic acid
CC   metabolism, cancer or cardiovascular diseases. This sequence represents a
CC   primer used to isolate regions of the human cytochrome P450 polypetide
CC   2C8 gene (CYP2C8) in order to identify the single nucleotide polymorphism
CC   (SNP) in that region of different individuals useful in disease diagnosis
XX
SQ   Sequence 19 BP; 10 A; 4 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTG 1934
              |||| |||||| | ||||
Db         19 ATACTTTTTTTCTGAGTG 2


RESULT 593
ACA98666
ID   ACA98666 standard; DNA; 19 BP.
XX
AC   ACA98666;
XX
DT   28-JUL-2003  (first entry)
XX
DE   Human CYP2C8 SNP detection PCR primer #106.
XX
KW   Cytochrome P450 polypeptide 2C8; CYP2C8; arachidonic acid metabolism;
KW   cancer; cardiovascular disease; cytostatic; cardiovascular; gene therapy;
KW   single nucleotide polymorphism detection; SNP detection; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200299099-A2.
XX
PD   12-DEC-2002.
XX
PF   31-MAY-2002; 2002WO-EP006000.
XX
PR   01-JUN-2001; 2001EP-00112899.
```

```
XX
PA   (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI   Penger A,  Sprenger R,  Brinkmann U;
XX
DR   WPI; 2003-167344/16.
XX
PT   New polymorphic variants of the gene encoding Cytochrome P450 polypeptide
PT   2C8 (CYP2C8), useful for diagnosing or treating a disease, e.g.
PT   arachidonic acid metabolism, cancer or cardiovascular diseases.
XX
PS   Example 2; Page 51; 178pp; English.
XX
CC   The invention describes a new polynucleotide comprises a polynucleotide:
CC   (a) having any of 101 nucleic acid sequences with 18-19 bp fully defined
CC   in the specification; (b) encoding any of seven polypeptides having 7
CC   amino acids, or a polypeptide with 3 amino acids; (c) capable of
CC   hybridising to a Cytochrome P450 polypeptide 2C8 (CYP2C8) gene; (d)
CC   encoding a molecular CYP2C8 variant polypeptide or its fragment. The
CC   polynucleotide, gene, vector, polypeptide or antibody is useful for
CC   diagnosing or treating a disease, for preparing a diagnostic composition
CC   for diagnosing a disease, or for preparing a pharmaceutical composition
CC   for treating a disease. This disease includes arachidonic acid
CC   metabolism, cancer or cardiovascular diseases. This sequence represents a
CC   primer used to isolate regions of the human cytochrome P450 polypetide
CC   2C8 gene (CYP2C8) in order to identify the single nucleotide polymorphism
CC   (SNP) in that region of different individuals useful in disease diagnosis
XX
SQ   Sequence 19 BP; 3 A; 2 C; 4 G; 10 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTCAGTG 1934
              |||| |||||| | ||||
Db          1 ATACTTTTTTTCTGAGTG 18


RESULT 594
ABZ68441/c
ID   ABZ68441 standard; DNA; 19 BP.
XX
AC   ABZ68441;
XX
DT   22-APR-2003  (first entry)
XX
DE   Reverse PCR primer used to amplify marker 14-5 in Barley genome.
XX
KW   Nucleic acid analysis; HAPPY mapping; linkage phase; allele;
KW   polymorphic DNA loci; haplotyping; gene mapping; barley; marker 14-5;
KW   PCR; primer; ss.
XX
OS   Hordeum vulgare.
XX
PN   WO2002103046-A2.
XX
PD   27-DEC-2002.
XX
PF   18-JUN-2002; 2002WO-GB002763.
XX
PR   18-JUN-2001; 2001GB-00014853.
XX
PA   (MEDI-) MEDICAL RES COUNCIL.
XX
PI   Dear PH,  Thangavelu M,  Bankier A;
XX
DR   WPI; 2003-167539/16.
XX
PT   Analyzing a nucleic acid by cleaving the nucleic acid into multiple
PT   fragments at a defined sequence and selectively amplifying the fragments
PT   to produce a map by a modified HAPPY mapping technique.
XX
PS   Example; Page 23; 29pp; English.
XX
CC   The specification describes a method for nucleic acid analysis. The
CC   method comprises providing a HAPPY mapping panel comprising many nucleic
CC   acid samples, cleaving the nucleic acids in the samples to completion at
CC   a defined sequence to produce nucleic acid fragments, ligating a linker
CC   to the fragments, amplifying the nucleic acid using linker-specific
CC   primers and hybridizing specific probes to the sample. The method is
CC   useful for nucleic acid analysis and for determining the linkage phase
CC   between the alleles of two or more polymorphic DNA loci. The HAPPY
CC   mapping techniques may be applied to any mapping project, especially
CC   haplotyping and main applications of HAPPY mapping include genome and
CC   gene mapping, detection of strain diversity, population analysis,
CC   epidemiology, gene expression and the demonstration of phylogenetic and
CC   taxonomic relationships. PCR primers ABZ68440-41 were used to amplify a
CC   marker in the barley genome, in the course of the invention
XX
SQ   Sequence 19 BP; 1 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1579 CCACCGCACAGACTGGGA 1596
              ||| || |||||||| ||
Db         19 CCAACGAACAGACTGCGA 2


RESULT 595
ADE27245
ID   ADE27245 standard; RNA; 19 BP.
XX
AC   ADE27245;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Stearoyl-CoA desaturase siNA oligonucleotide SEQ ID NO:189.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KW   stearoyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KW   antiarteriosclerotic; cytostatic; virucide; obesity; diabetes;
KW   atherosclerosis; cancer; viral infection; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS   Synthetic.
XX
PN   WO2003070885-A2.
XX
PD   28-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-US004317.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   20-SEP-2002; 2002US-0412304P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Thompson J;
XX
DR   WPI; 2003-721687/68.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of obesity or diabetes, downregulates expression of the
PT   stearoyl-CoA desaturase gene.
XX
PS   Example 3; SEQ ID NO 189; 139pp; English.
XX
```

```
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of the SCD (stearoyl-CoA desaturase) gene
CC   by RNA interference. Also described: (1) modulating expression of SCD
CC   genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC   kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC   complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC   siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC   virucide activities. The siNAs can be used to modulate expression of SCD
CC   genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC   diabetes (types I and II); atherosclerosis; cancer and viral infections.
CC   They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents an SCD siNA, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 7 A; 2 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   61.1%;  Pred. No. 4.2e+02;
  Matches   11;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTCT 2044
              |:|||||| ||  |::|:
Db          2 GUAGGAGGAAACAGUUCU 19


RESULT 596
ADE27535/c
ID   ADE27535 standard; RNA; 19 BP.
XX
AC   ADE27535;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Stearoyl-CoA desaturase siNA oligonucleotide SEQ ID NO:479.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition; SCD;
KW   stearoyl-CoA desaturase; RNA interference; anorectic; antidiabetic;
KW   antiarteriosclerotic; cytostatic; virucide; obesity; diabetes;
KW   atherosclerosis; cancer; viral infection; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS   Synthetic.
XX
PN   WO2003070885-A2.
XX
PD   28-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-US004317.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   20-SEP-2002; 2002US-0412304P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Thompson J;
XX
DR   WPI; 2003-721687/68.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of obesity or diabetes, downregulates expression of the
PT   stearoyl-CoA desaturase gene.
XX
PS   Example 3; SEQ ID NO 479; 139pp; English.
XX
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of the SCD (stearoyl-CoA desaturase) gene
CC   by RNA interference. Also described: (1) modulating expression of SCD
CC   genes in cells, tissue explants or organisms by introduction of siNA; (2)
CC   kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or
CC   complexes of siNA; and (4) vectors that express siNA. SCD inhibiting
CC   siNAs have anorectic, antidiabetic, antiarteriosclerotic, cytostatic and
CC   virucide activities. The siNAs can be used to modulate expression of SCD
CC   genes, in cells, tissue explants or organisms, e.g. for treating obesity;
CC   diabetes (types I and II); atherosclerosis; cancer and viral infections.
CC   They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents an SCD siNA, which is
CC   used in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 4 A; 6 C; 2 G; 0 T; 7 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTCT 2044
              ||||||| ||  |||||
Db         18 GTAGGAGGAAACAGTTCT 1


RESULT 597
ADF71268/c
ID   ADF71268 standard; RNA; 19 BP.
XX
AC   ADF71268;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID No 53.
XX
KW   short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070886-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004347.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697606/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer , downregulates expression of a protein tyrosine
PT   phosphatase type IVa gene.
XX
PS   Example 3; SEQ ID NO 53; 131pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of a protein tyrosine phosphatase type IV
CC   (PRL3) gene by RNA interference. The invention further relates to
CC   modulating the expression of PRL3 genes in cells, tissue explants or
CC   organisms by the introduction of an siNA; kits for in vitro or in vivo
```

CC delivery of an siNA; conjugates and/or complexes of siNA; and vectors
CC that express siNA. The novel siNA's of the invention have cytostatic
CC activity. siNA's are used to modulate expression of PRL3 genes, in cells,
CC tissue explants or organisms, e.g. for treating cancer but also for drug
CC screening; diagnosis; target identification and validation; genetic
CC engineering; pharmacogenomics; studying gene function and gene mapping
CC (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC represents a short interfering nucleic acid for downregulating the
CC expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC invention.
XX
SQ Sequence 19 BP; 4 A; 8 C; 6 G; 0 T; 1 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1594 GGAACCCCTCCTGGCCTG 1611
||| ||||| |||| |||
Db 18 GGAGCCCCTGCTGGGCTG 1

RESULT 598
ADF71342
ID ADF71342 standard; RNA; 19 BP.
XX
AC ADF71342;
XX
DT 12-FEB-2004 (first entry)
XX
DE Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID No 127.
XX
KW short interfering nucleic acid; siNA;
KW protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO2003070886-A2.
XX
PD 28-AUG-2003.
XX
PF 11-FEB-2003; 2003WO-US004347.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Usman N;
XX
DR WPI; 2003-697606/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer , downregulates expression of a protein tyrosine
PT phosphatase type IVa gene.
XX
PS Example 3; SEQ ID NO 127; 131pp; English.
XX
CC The invention relates to a novel short interfering nucleic acid (siNA)
CC that downregulates expression of a protein tyrosine phosphatase type IV
CC (PRL3) gene by RNA interference. The invention further relates to
CC modulating the expression of PRL3 genes in cells, tissue explants or
CC organisms by the introduction of an siNA; kits for in vitro or in vivo
CC delivery of an siNA; conjugates and/or complexes of siNA; and vectors
CC that express siNA. The novel siNA's of the invention have cytostatic
CC activity. siNA's are used to modulate expression of PRL3 genes, in cells,
CC tissue explants or organisms, e.g. for treating cancer but also for drug
CC screening; diagnosis; target identification and validation; genetic
CC engineering; pharmacogenomics; studying gene function and gene mapping
CC (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC represents a short interfering nucleic acid for downregulating the
CC expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC invention.
XX
SQ Sequence 19 BP; 1 A; 6 C; 8 G; 0 T; 4 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 4.2e+02;
Matches 12; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1594 GGAACCCCTCCTGGCCTG 1611
||| |||| |:|| |:|
Db 2 GGAGCCCCUGCUGGGCUG 19

RESULT 599
ADF75537
ID ADF75537 standard; RNA; 19 BP.
XX
AC ADF75537;
XX
DT 26-FEB-2004 (first entry)
XX
DE Sense siNA that down regulates human PTP-1B expression (SeqID 78).
XX
KW human; ss; siRNA; short interfering nucleic acid; siNA;
KW protein tyrosine phosphatase-1B; PTP-1B; RNA interference; RNAi;
KW micro-RNA; miRNA; short hairpin RNA; shRNA; gene silencing; antisense;
KW obesity; insulin resistance; diabetes; anorectic; antidiabetic.
XX
OS Homo sapiens.
XX
PN WO2003070881-A2.
XX
PD 28-AUG-2003.
XX
PF 11-FEB-2003; 2003WO-US004123.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 26-JUL-2002; 2002US-00206705.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Usman N;
XX
DR WPI; 2003-697604/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of obesity, downregulates expression of a protein tyrosine
PT phosphatase-1B gene.
XX
PS Example 3; SEQ ID NO 78; 140pp; English.
XX
CC This invention relates to novel short interfering nucleic acid (siNA)
CC molecules that downregulate expression of a protein tyrosine phosphatase-
CC 1B (PTP-1B) gene by RNA interference (RNAi). Specifically, the siNAs can
CC be short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA
CC (miRNA) or short hairpin RNA (shRNA), all of which can mediate inhibition
CC of PTP-1B. The present invention describes sequence-specific post-
CC trancriptional gene silencing in animals using siNA molecules and
CC antisense oligonucleotides to modulate PTP-1B gene expression or
CC activity. Furthermore, these siNA molecules provide useful reagents for a
CC variety of therapeutic and diagnostic purposes, and as such can be used
CC for treating obesity, insulin resistance or diabetes (types I and II), as

```
CC   well as for drug screening, target identification and validation, genetic
CC   engineering, pharmacogenomics and for studying gene function and gene
CC   mapping (for example of single-nucleotide polymorphisms). Accordingly,
CC   these molecules exhibit anorectic and antidiabetic activities. This
CC   oligonucleotide sequence is a sense siNA molecule that targets human PTP-
CC   1B RNA of the invention.
XX
SQ   Sequence 19 BP; 3 A; 6 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   66.7%;  Pred. No. 4.2e+02;
  Matches   12;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGG 1607
              ||:|| | ||| :||:||
Db          2 ACUGGAAGCCCUUCCUGG 19


RESULT 600
ADF75722/c
ID   ADF75722 standard; RNA; 19 BP.
XX
AC   ADF75722;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Antisense siNA that down regulates human PTP-1B expression (SeqID 263).
XX
KW   human; ss; siRNA; short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase-1B; PTP-1B; RNA interference; RNAi;
KW   micro-RNA; miRNA; short hairpin RNA; shRNA; gene silencing; antisense;
KW   obesity; insulin resistance; diabetes; anorectic; antidiabetic;
KW   antisense.
XX
OS   Homo sapiens.
XX
PN   WO2003070881-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004123.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   26-JUL-2002; 2002US-00206705.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697604/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of obesity, downregulates expression of a protein tyrosine
PT   phosphatase-1B gene.
XX
PS   Example 3; SEQ ID NO 263; 140pp; English.
XX
CC   This invention relates to novel short interfering nucleic acid (siNA)
CC   molecules that downregulate expression of a protein tyrosine phosphatase-
CC   1B (PTP-1B) gene by RNA interference (RNAi). Specifically, the siNAs can
CC   be short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA
CC   (miRNA) or short hairpin RNA (shRNA), all of which can mediate inhibition
CC   of PTP-1B. The present invention describes sequence-specific post-
CC   trancriptional gene silencing in animals using siNA molecules and
CC   antisense oligonucleotides to modulate PTP-1B gene expression or
CC   activity. Furthermore, these siNA molecules provide useful reagents for a
CC   variety of therapeutic and diagnostic purposes, and as such can be used
CC   for treating obesity, insulin resistance or diabetes (types I and II), as
CC   well as for drug screening, target identification and validation, genetic
CC   engineering, pharmacogenomics and for studying gene function and gene
CC   mapping (for example of single-nucleotide polymorphisms). Accordingly,
CC   these molecules exhibit anorectic and antidiabetic activities. This
CC   oligonucleotide sequence is an antisense siNA molecule that targets human
CC   PTP-1B RNA of the invention.
XX
SQ   Sequence 19 BP; 5 A; 5 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGG 1607
              ||||| | ||| ||||||
Db         18 ACTGGAAGCCCTTCCTGG 1


RESULT 601
ADF84550
ID   ADF84550 standard; RNA; 19 BP.
XX
AC   ADF84550;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 844.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 844; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human ABL1-targeted siRNA of the invention.
XX
```

```
SQ   Sequence 19 BP; 7 A; 0 C; 2 G; 0 T; 10 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   38.9%;  Pred. No. 4.2e+02;
  Matches    7;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAAATA 1839
              : :|| |: ::::|||:|
Db          1 UGUAGUAUUUUUUAAAUA 18


RESULT 602
ADF84869/c
ID   ADF84869 standard; RNA; 19 BP.
XX
AC   ADF84869;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 1163.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 1163; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human ABL1-targeted siRNA of the invention.
XX
SQ   Sequence 19 BP; 10 A; 2 C; 0 G; 0 T; 7 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAAATA 1839
              | ||| || |||||||||
Db         19 TGTAGTATTTTTTAAATA 2


RESULT 603
ADL79932/c
ID   ADL79932 standard; RNA; 19 BP.
XX
AC   ADL79932;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human HER1 (EGFR) siNA lower strand, SEQ ID NO:1097.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; cancer;
KW   cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW   HER1; c-erb-B-1; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070912-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005045.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US016840.
PR   06-JUN-2002; 2002US-00163552.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393924P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   19-SEP-2002; 2002US-00251117.
PR   21-OCT-2002; 2002US-00277494.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Pavco P,  Beigelman L,  Fosnaugh K,  Jamison S;
XX
DR   WPI; 2003-697612/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of the epidermal growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1097; 171pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of one or more human epidermal growth factor
CC   receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of EGFR genes in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating a wide range of cancers such as breast and ovarian cancer. The
CC   siNAs are also useful for drug screening, diagnosis, therapeutic target
CC   identification and validation, genetic engineering, pharmacogenomics,
```

```
CC   studying gene function, and gene mapping (e.g., of single nucleotide
CC   polymorphisms). The present sequence represents the lower strand of a
CC   human HER1 (EGFR)-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 9 A; 1 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTCT 1803
              |||||| ||||||  |||
Db         18 CCCATTTTTTCCTAATCT 1

RESULT 604
ADL79625
ID   ADL79625 standard; RNA; 19 BP.
XX
AC   ADL79625;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human HER1 (EGFR) transcript target sequence/siNA upper strand, SEQ:790.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; cancer;
KW   cytostatic; human; oncogene; epidermal growth factor receptor; EGFR;
KW   HER1; c-erb-B-1; target sequence; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070912-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005045.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US016840.
PR   06-JUN-2002; 2002US-00163552.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393924P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   19-SEP-2002; 2002US-00251117.
PR   21-OCT-2002; 2002US-00277494.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Pavco P,  Beigelman L,  Fosnaugh K,  Jamison S;
XX
DR   WPI; 2003-697612/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of the epidermal growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 790; 171pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of one or more human epidermal growth factor
CC   receptor (EGFR) genes (including HER1, HER2 HER3 and HER4) by RNA
CC   interference. The siNAs may or may not comprise ribonucleotides and may
CC   be double or single stranded. They further comprise sense and antisense
CC   regions, or alternatively are assembled from a sense oligonucleotide and
CC   an antisense oligonucleotide. Specifically, the siNAs include short
CC   interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC   hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC   can contain deoxyribonucleotides, and can be chemically synthesised,
CC   expressed from a vector or enzymatically synthesised. The invention also
CC   relates to kits for the in vitro or in vivo delivery of siNA; conjugates
CC   and/or complexes of siNA; and vectors that express siNA. The siNAs are
CC   used to modulate expression of EGFR genes in cells, tissue explants or
CC   organisms (e.g., by ex vivo gene therapy), or in grafts and transplants
CC   for the treatment of a variety of conditions. They may be used for
CC   treating a wide range of cancers such as breast and ovarian cancer. The
CC   siNAs are also useful for drug screening, diagnosis, therapeutic target
CC   identification and validation, genetic engineering, pharmacogenomics,
CC   studying gene function, and gene mapping (e.g., of single nucleotide
CC   polymorphisms). The present sequence represents the upper strand of a
CC   human HER1 (EGFR)-targeted double-stranded siNA, which is identical to
CC   the HER1 transcript target sequence.
XX
SQ   Sequence 19 BP; 3 A; 6 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   38.9%;  Pred. No. 4.2e+02;
  Matches    7;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTCT 1803
              ||||:: :::||:  :|:
Db          2 CCCAUUUUUUCCUAAUCU 19

RESULT 605
ADN34562
ID   ADN34562 standard; RNA; 19 BP.
XX
AC   ADN34562;
XX
DT   01-JUL-2004  (first entry)
XX
DE   siNA upper strand target sequence #63.
XX
KW   short interfering nucleic acid; siNA; multidrug resistance; MDR;
KW   P-glycoprotein; Cytostatic; cancer; drug screening; genetic engineering;
KW   pharmacogenomics; gene mapping; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070884-A2.
XX
PD   28-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-US004250.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   26-SEP-2002; 2002US-0413714P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Thompson J;
XX
DR   WPI; 2003-697605/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancers, downregulates expression of the multidrug
PT   resistance gene.
XX
PS   Example 3; SEQ ID NO 63; 143pp; English.
XX
CC   The present invention relates to short interfering nucleic acid (siNA)
CC   that downregulates expression of a multidrug resistance (MDR; P-
```

CC glycoprotein) gene by RNA interference, modulating expression of MDR
CC genes in cells, tissue explants or organisms by introduction of siNA;
CC kits for in vitro or in vivo delivery of siNA; conjugates and/or
CC complexes of siNA; and vectors that express siNA. The method relates to
CC the modulation (inhibition) of expression or activity of MDR by RNA
CC interference, siNA target mRNA, RNA splice variants, post-
CC transcriptionally modified RNA, pre-RNA and/or RNA templates. siNA are
CC used to modulate expression of MDR genes, in cells, tissue explants or
CC organisms, e.g. for treating multidrug-resistant cancers but also for
CC drug screening; diagnosis; target identification and validation; genetic
CC engineering; pharmacogenomics; studying gene function and gene mapping
CC (e.g. of single-nucleotide polymorphisms).The present sequence represents
CC the upper strand of human MDR targeted double stranded siNA which is
CC identical to the MDR transcript target sequence.
XX
SQ Sequence 19 BP; 6 A; 4 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 4.2e+02;
Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 2033 GGCAAAGGTTCTATCTGC 2050
|||||| : |:|:|: |
Db 2 GGCAAAGAUACUAUCUUC 19

RESULT 606
ADN34570/c
ID ADN34570 standard; RNA; 19 BP.
XX
AC ADN34570;
XX
DT 01-JUL-2004 (first entry)
XX
DE siNA upper strand target sequence #71.
XX
KW short interfering nucleic acid; siNA; multidrug resistance; MDR;
KW P-glycoprotein; Cytostatic; cancer; drug screening; genetic engineering;
KW pharmacogenomics; gene mapping; ss.
XX
OS Homo sapiens.
XX
PN WO2003070884-A2.
XX
PD 28-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004250.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 26-SEP-2002; 2002US-0413714P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Thompson J;
XX
DR WPI; 2003-697605/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancers, downregulates expression of the multidrug
PT resistance gene.
XX
PS Example 3; SEQ ID NO 71; 143pp; English.
XX
CC The present invention relates to short interfering nucleic acid (siNA)
CC that downregulates expression of a multidrug resistance (MDR; P-
CC glycoprotein) gene by RNA interference, modulating expression of MDR
CC genes in cells, tissue explants or organisms by introduction of siNA;
CC kits for in vitro or in vivo delivery of siNA; conjugates and/or
CC complexes of siNA; and vectors that express siNA. The method relates to
CC the modulation (inhibition) of expression or activity of MDR by RNA
CC interference, siNA target mRNA, RNA splice variants, post-
CC transcriptionally modified RNA, pre-RNA and/or RNA templates. siNA are
CC used to modulate expression of MDR genes, in cells, tissue explants or
CC organisms, e.g. for treating multidrug-resistant cancers but also for
CC drug screening; diagnosis; target identification and validation; genetic
CC engineering; pharmacogenomics; studying gene function and gene mapping
CC (e.g. of single-nucleotide polymorphisms).The present sequence represents
CC the upper strand of human MDR targeted double stranded siNA which is
CC identical to the MDR transcript target sequence.
XX
SQ Sequence 19 BP; 10 A; 1 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1821 TTTTAGAATCTTTTAAAT 1838
|||||| |||| |||||
Db 18 TTTTAGCTTCTTCTAAAT 1

RESULT 607
ADN34828
ID ADN34828 standard; RNA; 19 BP.
XX
AC ADN34828;
XX
DT 01-JUL-2004 (first entry)
XX
DE siNA lower strand target sequence #71.
XX
KW short interfering nucleic acid; siNA; multidrug resistance; MDR;
KW P-glycoprotein; Cytostatic; cancer; drug screening; genetic engineering;
KW pharmacogenomics; gene mapping; ss.
XX
OS Homo sapiens.
XX
PN WO2003070884-A2.
XX
PD 28-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004250.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 26-SEP-2002; 2002US-0413714P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Thompson J;
XX
DR WPI; 2003-697605/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancers, downregulates expression of the multidrug
PT resistance gene.
XX
PS Example 3; SEQ ID NO 329; 143pp; English.
XX
CC The present invention relates to short interfering nucleic acid (siNA)
CC that downregulates expression of a multidrug resistance (MDR; P-
CC glycoprotein) gene by RNA interference, modulating expression of MDR
CC genes in cells, tissue explants or organisms by introduction of siNA;
CC kits for in vitro or in vivo delivery of siNA; conjugates and/or
CC complexes of siNA; and vectors that express siNA. The method relates to

```
CC   the modulation (inhibition) of expression or activity of MDR by RNA
CC   interference, siNA target mRNA, RNA splice variants, post-
CC   transcriptionally modified RNA, pre-RNA and/or RNA templates. siNA are
CC   used to modulate expression of MDR genes, in cells, tissue explants or
CC   organisms, e.g. for treating multidrug-resistant cancers but also for
CC   drug screening; diagnosis; target identification and validation; genetic
CC   engineering; pharmacogenomics; studying gene function and gene mapping
CC   (e.g. of single-nucleotide polymorphisms).The present sequence represents
CC   the lower strand of human MDR targeted double stranded siNA.
XX
SQ   Sequence 19 BP; 4 A; 4 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   33.3%;  Pred. No. 4.2e+02;
  Matches    6;  Conservative    9;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAAT 1838
              ::::||  :|:: :|||:
Db          2 UUUUAGCUUCUUCUAAAU 19


RESULT 608
ADN34820/c
ID   ADN34820 standard; RNA; 19 BP.
XX
AC   ADN34820;
XX
DT   01-JUL-2004  (first entry)
XX
DE   siNA lower strand target sequence #63.
XX
KW   short interfering nucleic acid; siNA; multidrug resistance; MDR;
KW   P-glycoprotein; Cytostatic; cancer; drug screening; genetic engineering;
KW   pharmacogenomics; gene mapping; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070884-A2.
XX
PD   28-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-US004250.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   26-SEP-2002; 2002US-0413714P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Thompson J;
XX
DR   WPI; 2003-697605/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancers, downregulates expression of the multidrug
PT   resistance gene.
XX
PS   Example 3; SEQ ID NO 321; 143pp; English.
XX
CC   The present invention relates to short interfering nucleic acid (siNA)
CC   that downregulates expression of a multidrug resistance (MDR; P-
CC   glycoprotein) gene by RNA interference, modulating expression of MDR
CC   genes in cells, tissue explants or organisms by introduction of siNA;
CC   kits for in vitro or in vivo delivery of siNA; conjugates and/or
CC   complexes of siNA; and vectors that express siNA. The method relates to
CC   the modulation (inhibition) of expression or activity of MDR by RNA
CC   interference, siNA target mRNA, RNA splice variants, post-
CC   transcriptionally modified RNA, pre-RNA and/or RNA templates. siNA are
CC   used to modulate expression of MDR genes, in cells, tissue explants or
CC   organisms, e.g. for treating multidrug-resistant cancers but also for
CC   drug screening; diagnosis; target identification and validation; genetic
CC   engineering; pharmacogenomics; studying gene function and gene mapping
CC   (e.g. of single-nucleotide polymorphisms).The present sequence represents
CC   the lower strand of human MDR targeted double stranded siNA.
XX
SQ   Sequence 19 BP; 5 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2033 GGCAAAGGTTCTATCTGC 2050
              ||||||| | ||||||  |
Db         18 GGCAAAGATACTATCTTC 1


RESULT 609
AAL52548/c
ID   AAL52548 standard; RNA; 19 BP.
XX
AC   AAL52548;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human RSK interfering RNA (RNAi) SEQ ID NO: 16.
XX
KW   RSK; inhibitor; p90 ribosomal S6 kinase; enzyme; cytostatic; RNAi;
KW   neuroprotective; anticonvulsant; cancer; neurological disease;
KW   interfering RNA; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003105766-A2.
XX
PD   24-DEC-2003.
XX
PF   12-JUN-2003; 2003WO-US018734.
XX
PR   12-JUN-2002; 2002US-0388006P.
PR   24-FEB-2003; 2003US-0449553P.
XX
PA   (UYVI-) UNIV VIRGINIA PATENT FOUND.
XX
PI   Smith JA,  Lannigan-Macara DA,  Poteet-Smith CE,  Hecht SM,  Xu Y;
PI   Brautigan DL;
XX
DR   WPI; 2004-090735/09.
XX
PT   Composition useful to treat neoplastic and neurological diseases
PT   comprises ribosomal S6 kinase (Rsk) specific inhibitor.
XX
PS   Disclosure; Page 76; 0pp; English.
XX
CC   The present invention relates to a composition comprising a flavanoid
CC   ribosomal S6 kinase (Rsk) specific inhibitor. The composition is used to
CC   treat a disease or condition caused by inappropriate Rsk activity.
CC   Inhibitors are used as anti-cancer therapeutics, inhibit proliferation of
CC   a transformed cell without substantially altering the proliferation rate
CC   of non-transformed cell growth and are used to treat neoplastic disease
CC   and neurological disease (e.g. epilepsy). The present sequence is an
CC   interfering RNA (RNSi) used in the exemplification of the invention
XX
SQ   Sequence 19 BP; 7 A; 4 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 4.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTGCCC 1898
              ||| || |||||||| ||
Db         18 TGTTAACTTGATGTGACC 1
```

RESULT 610
ADO18614
ID ADO18614 standard; DNA; 19 BP.
XX
AC ADO18614;
XX
DT 15-JUL-2004 (first entry)
XX
DE Analytical probe chip of the invention #373.
XX
KW analytical chip; bacterial 16S-rRNA; genotypic characterization; probe;
KW ss.
XX
OS Synthetic.
XX
PN WO2004033720-A2.
XX
PD 22-APR-2004.
XX
PF 24-SEP-2003; 2003WO-EP010626.
XX
PR 09-OCT-2002; 2002EP-00022631.
XX
PA (UYGE-) UNIV GENEVE HOPITAUX.
XX
PI Schrenzel J, Francois P, Charbonnier Y, Jacquet JG, Utinger D;
PI Kresbach GM, Abel A, Ehrat M;
XX
DR WPI; 2004-375537/35.
XX
PT Analytical chip useful for simultaneous determination of one or more
PT different bacterial 16S-rRNA in liquid sample, comprising evanescent
PT field measurement platform as solid carrier and several specific
PT recognition elements.
XX
PS Claim 86; SEQ ID NO 373; 82pp; English.
XX
CC The present invention relates to an analytical chip for simultaneous
CC determination of one or more different bacterial 16S-rRNA in liquid
CC sample. The chip is useful for detecting one or more bacterial 16S-rRNA,
CC derived from bacteria such as Achromobacter xylosoxidans , Acinetobacter
CC baumannii , Actinomyces israelii , Aerococcus viridans , Aeromonas
CC hydrophilia , Agrobacterium radiobacter , Bacillus sp. , Bacteroides
CC ovatus , Campylobacter fetus , Citrobacter freundii , Enterococcus avium
CC , Eubacterium lentum , Escherichia coli , Flavobacterium breve ,
CC Fusobacterium nucleatum , Gemella morbillorum , Gardnerella vaginalis ,
CC Haemophilus influenzae , Hafnia alvei , Kingella sp. , Klebsiella oxytoca
CC , Lactobacillus acidophilus , Legionella pneumophila , Moraxella
CC catarrhalis , Mycobacterium avium , Neisseria cinerea , Nocardia sp. ,
CC Ochrobactrum anthropi , Pasteurella multocida , Peptostreptococcus magnus
CC , Salmonella typhi , Shigella sonnei , Veillonella parvula , Veillonella
CC sp. or Yersinia enterocolitica . The chip is useful for detecting
CC clinically relevant bacteria. The chip enables determination of one or
CC more different bacterial 16S-rRNA in a liquid sample, simultaneously and
CC enables rapid, accurate, easy and reliable identification of bacteria by
CC genotypic characterization in a provided sample and also enables
CC identification of a bacterium even in a complex biological sample. The
CC chip which is produced at reduced cost, enables determination of 16S-rRNA
CC in a sample with reduced experimental error and variation. The present
CC sequence represents a probe of the invention used as an analytical chip.
XX
SQ Sequence 19 BP; 6 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1879 AATGTCAAATTGATGTGC 1896
              || ||||| ||||||| |
Db          2 AACGTCAATTTGATGTAC 19
```

RESULT 611
ADO18429
ID ADO18429 standard; DNA; 19 BP.
XX
AC ADO18429;
XX
DT 15-JUL-2004 (first entry)
XX
DE Analytical probe chip of the invention #188.
XX
KW analytical chip; bacterial 16S-rRNA; genotypic characterization; probe;
KW ss.
XX
OS Synthetic.
XX
PN WO2004033720-A2.
XX
PD 22-APR-2004.
XX
PF 24-SEP-2003; 2003WO-EP010626.
XX
PR 09-OCT-2002; 2002EP-00022631.
XX
PA (UYGE-) UNIV GENEVE HOPITAUX.
XX
PI Schrenzel J, Francois P, Charbonnier Y, Jacquet JG, Utinger D;
PI Kresbach GM, Abel A, Ehrat M;
XX
DR WPI; 2004-375537/35.
XX
PT Analytical chip useful for simultaneous determination of one or more
PT different bacterial 16S-rRNA in liquid sample, comprising evanescent
PT field measurement platform as solid carrier and several specific
PT recognition elements.
XX
PS Claim 1; SEQ ID NO 188; 82pp; English.
XX
CC The present invention relates to an analytical chip for simultaneous
CC determination of one or more different bacterial 16S-rRNA in liquid
CC sample. The chip is useful for detecting one or more bacterial 16S-rRNA,
CC derived from bacteria such as Achromobacter xylosoxidans , Acinetobacter
CC baumannii , Actinomyces israelii , Aerococcus viridans , Aeromonas
CC hydrophilia , Agrobacterium radiobacter , Bacillus sp. , Bacteroides
CC ovatus , Campylobacter fetus , Citrobacter freundii , Enterococcus avium
CC , Eubacterium lentum , Escherichia coli , Flavobacterium breve ,
CC Fusobacterium nucleatum , Gemella morbillorum , Gardnerella vaginalis ,
CC Haemophilus influenzae , Hafnia alvei , Kingella sp. , Klebsiella oxytoca
CC , Lactobacillus acidophilus , Legionella pneumophila , Moraxella
CC catarrhalis , Mycobacterium avium , Neisseria cinerea , Nocardia sp. ,
CC Ochrobactrum anthropi , Pasteurella multocida , Peptostreptococcus magnus
CC , Salmonella typhi , Shigella sonnei , Veillonella parvula , Veillonella
CC sp. or Yersinia enterocolitica . The chip is useful for detecting
CC clinically relevant bacteria. The chip enables determination of one or
CC more different bacterial 16S-rRNA in a liquid sample, simultaneously and
CC enables rapid, accurate, easy and reliable identification of bacteria by
CC genotypic characterization in a provided sample and also enables
CC identification of a bacterium even in a complex biological sample. The
CC chip which is produced at reduced cost, enables determination of 16S-rRNA
CC in a sample with reduced experimental error and variation. The present
CC sequence represents a probe of the invention used as an analytical chip.
XX
SQ Sequence 19 BP; 6 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 4.2e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1879 AATGTCAAATTGATGTGC 1896
              || ||||| ||||||| |
Db          2 AACGTCAATTTGATGTAC 19
```

```
RESULT 612
AAQ53097/c
ID   AAQ53097 standard; DNA; 20 BP.
XX
AC   AAQ53097;
XX
DT   03-JUN-1994  (first entry)
XX
DE   Gene detection sequence 21.
XX
KW   Gene detection; radio-isotopes; target gene; electrode; detection;
KW   optical fibre; hybridise; hybridisation; electrochemical; photochemical;
KW   electrolysis; probe; ss.
XX
OS   Synthetic.
XX
PN   JP05285000-A.
XX
PD   02-NOV-1993.
XX
PF   10-SEP-1992;   92JP-00242397.
XX
PR   13-FEB-1992;   92JP-00025621.
XX
PA   (TOKE ) TOSHIBA KK.
XX
DR   WPI; 1993-382240/48.
XX
PT   Detection method of gene without using radio-isotope - by hybridisation
PT   of nucleic acid probe which is single strand having complementary
PT   sequence of gene and single strand denatured sample DNA.
XX
PS   Disclosure; Page 21; 26pp; Japanese.
XX
CC   The sequences (AAQ53077-Q53136) are used in the invention to detect
CC   specific genes without the use of radio-isotopes. Detection is carried
CC   out by hybridisation of denatured (ss) sample DNA with a (ss) nucleic
CC   acid probe, complementary to the target sequence. Hybridisation occurs on
CC   the surface of an electrode or optical fibre and detection is visualised
CC   by the addition of an entity that recognises (ds) hybridised DNA and is
CC   electrochemically / photochemically active
XX
SQ   Sequence 20 BP; 5 A; 6 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1597 ACCCCTCCTGGCCTGGGG 1614
              || |||||||||| | ||
Db         19 ACTCCTCCTGGCCGGCGG 2


RESULT 613
AAT66012/c
ID   AAT66012 standard; DNA; 20 BP.
XX
AC   AAT66012;
XX
DT   25-MAR-2003  (revised)
DT   18-JUN-1997  (first entry)
XX
DE   Primer #1 to amplify repeat sequence marker Mfd108.
XX
KW   Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW   PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW   linkage analysis; genetic disease; animal; plant; breeding; locus;
KW   hybridisation; chromosome; ds.
XX
OS   Synthetic.
XX
PN   US5582979-A.
XX
PD   10-DEC-1996.
XX
PF   04-APR-1994;   94US-00222177.
XX
PR   21-APR-1989;   89US-00341562.
PR   05-SEP-1991;   91US-00754351.
XX
PA   (MARS-) MARSHFIELD CLINIC.
XX
PI   Weber JL;
XX
DR   WPI; 1997-042299/04.
XX
PT   Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT   using novel nucleic acid mols. as primers.
XX
PS   Claim 7; Col 13-14; 186pp; English.
XX
CC   The invention relates to the isolation of polymorphic repeat sequences
CC   having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC   markers. Primers based on these sequences can be used to detect these
CC   repeats, especially for use in e.g paternity or maternity testing, human
CC   genetic analysis such as linkage analysis of genetic disease, commercial
CC   animal or plant breeding or pedigree analysis. Clones containing the
CC   repeat sequences were isolated by hybridisation of chromosome-specific
CC   phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
CC   repeat blocks were isolated. The primers AAT65798-T66047 were used to PCR
CC   amplify the inserts from the isolated clones containing the repeat
CC   sequences. The primers AAT66012-3 were used to amplify the repeat
CC   sequence marker clone Mfd108 (AAT65779). (Updated on 25-MAR-2003 to
CC   correct PF field.)
XX
SQ   Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1996 TATCTAGCTTCTTCAGAG 2013
              ||| ||||  ||||||||
Db         20 TATTTAGCCACTTCAGAG 3


RESULT 614
AAV03708/c
ID   AAV03708 standard; DNA; 20 BP.
XX
AC   AAV03708;
XX
DT   15-APR-1998  (first entry)
XX
DE   Primer SHR-2 for H chain of Fas specific antibody coding sequence.
XX
KW   Fas; antibody; human; immunoglobulin; variable region; rheumatism;
KW   autoimmune disease; rheumatoid arthritis; therapy; CDR; heavy chain;
KW   complementarity determining region; PCR primer; amplify; ss.
XX
OS   Synthetic.
OS   Mus sp.
XX
PN   EP799891-A1.
XX
PD   08-OCT-1997.
XX
PF   27-MAR-1997;   97EP-00302415.
XX
PR   01-APR-1996;   96JP-00078570.
XX
PA   (SANY ) SANKYO CO LTD.
XX
PI   Serizawa N,  Ichikawa K,  Nakahara K,  Yonehara S;
XX
DR   WPI; 1997-482673/45.
```

```
XX
PT   Anti-Fas recombinant antibodies - useful for treating auto-immune
PT   diseases, especially rheumatoid arthritis.
XX
PS   Example 4; Page 16; 72pp; English.
XX
CC   This sequence represents a primer for the coding sequence for the protein
CC   of the invention. The protein of the invention is a recombinant protein
CC   (A), that comprises at least one region corresponding to an
CC   immunoglobulin (Ig) variable region which enables the protein to
CC   recognise and specifically bind to an antigen, preferably human Fas, and
CC   has substantially no more immunogenicity in a human patient than a human
CC   antibody. The proteins are useful for treating autoimmune diseases,
CC   especially rheumatism (rheumatoid arthritis). (A) is based on a murine
CC   monoclonal antibody. As the protein lacks the constant region, it has
CC   substantially no more immunogenicity in the human patient than a human
CC   antibody
XX
SQ   Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1643 AAAGAGCCTTCACTGGTT 1660
              |||||||||| | ||| |
Db         18 AAAGAGCCTTGAGTGGAT 1


RESULT 615
AAV15107/c
ID   AAV15107 standard; DNA; 20 BP.
XX
AC   AAV15107;
XX
DT   20-MAY-1998  (first entry)
XX
DE   Human VEGF antisense oligonucleotide U0853T-S.
XX
KW   Human; vascular endothelial cell growth factor; VEGF; diagnosis;
KW   antisense oligonucleotide; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   JP10052285-A.
XX
PD   24-FEB-1998.
XX
PF   20-MAY-1997;   97JP-00129767.
XX
PR   23-MAY-1996;   96JP-00128192.
XX
PA   (TOAG ) TOA GOSEI CHEM IND LTD.
XX
DR   WPI; 1998-200633/18.
XX
PT   Preparation of anti-sense nucleic acid - by assigning numerical value to
PT   target mRNA region and preparing new molecule with nucleic acid
PT   complementary to sequence with low value.
XX
PS   Example 3; Page 9; 19pp; Japanese.
XX
CC   The present sequence represents an antisense oligonucleotide for human
CC   derived vascular endothelial cell growth factor (VEGF), used in an
CC   example of the present invention. The present invention describes the
CC   preparation of an antisense nucleic acid (ANA). The method comprises: (a)
CC   using an mRNA sequence of varying regions in which a numerical value (NV)
CC   is assigned to a target region, where the size of NV depends on the
CC   possibility of forming a truly complementary double strand (DS) between
CC   two regions, and (b) preparing ANA with a nucleic acid containing a base
CC   sequence which is truly complementary to a sequence which has a low NV,
CC   where NV assigned to the ability to form DS is based on the difference of
CC   the complementary base sequence to the target. ANA can be used for the
CC   preparation of diagnostic and therapeutic agents. The method can easily
CC   predict ANA target site, therefore enabling easy and rapid preparation of
CC   ANA
XX
SQ   Sequence 20 BP; 0 A; 9 C; 0 G; 11 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAACAGGA 1562
              || || ||||||| ||||
Db         19 AGAAGAGAAGGAAGAGGA 2


RESULT 616
AAZ18220
ID   AAZ18220 standard; DNA; 20 BP.
XX
AC   AAZ18220;
XX
DT   11-OCT-1999  (first entry)
XX
DE   Tyrosine phosphatase gene specific primer.
XX
KW   Genetic proximity; gene expression; cell characterisation; homeobox gene;
KW   genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
KW   kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
KW   primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9934016-A2.
XX
PD   08-JUL-1999.
XX
PF   28-DEC-1998;   98WO-IL000625.
XX
PR   29-DEC-1997;   97IL-00122793.
PR   16-OCT-1998;   98IL-00126627.
XX
PA   (GENE-) GENENA LTD.
XX
PI   Vider B;
XX
DR   WPI; 1999-419113/35.
DR   P-PSDB; AAY14754.
XX
PT   Identifying and characterizing cells by comparing the pattern of gene
PT   expression in a selected gene family.
XX
PS   Claim 4; Page 48; 102pp; English.
XX
CC   The invention provides a new method for identifying and characterising
CC   cells. The method for determining the genetic proximity of a first cell
CC   and a second cell comprises: (a) obtaining the first cell and the second
CC   cell; (b) determining in the first cell and the second cell the pattern
CC   of expression of genes in a selected gene family; and (c) calculating a
CC   proximity index using a specified formula. The methods can be used for
CC   characterising cells, e.g. for determining the origin of a cell, its
CC   genetic status, whether it carries a genetic defect, or whether it is
CC   transformed. They can be used for detecting a selected genetic defect in
CC   an individual, e.g. a fetus. They can also be used for determining the
CC   effect of a selected treatment on a test cell. They can also be used for
CC   obtaining cells capable of expressing an homeobox related desired
CC   property. The method uses reverse transcriptase polymerase chain reaction
CC   (RT-PCR) for determining the pattern of gene expression in a selected
CC   gene family. Sequences AAZ17803-Z18342 represent primers that can be used
CC   in the RT-PCR reactions to determine the pattern of gene expression. The
CC   gene family can be selected from a set of homeobox genes, kinase genes,
CC   protein phosphatase genes, P450 enzyme genes, steroid receptor
```

```
CC   superfamily genes or cadherin superfamily genes
XX
SQ   Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGGC 1754
              || ||||| | |||||||
Db          2 AATGTGACCATTACTGGC 19


RESULT 617
AAV99217
ID   AAV99217 standard; DNA; 20 BP.
XX
AC   AAV99217;
XX
DT   09-MAR-1999  (first entry)
XX
DE   Sense primer for intron boundary mapping of DNA MeTase exon 38-39.
XX
KW   DNA methyltransferase; DNA MeTase; antisense oligonucleotide; human;
KW   cellular growth; tumour growth inhibition; silenced gene activation;
KW   beta thalassemia; sickle cell anemia; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9854313-A2.
XX
PD   03-DEC-1998.
XX
PF   29-MAY-1998;   98WO-IB001107.
XX
PR   30-MAY-1997;   97US-00866340.
PR   17-DEC-1997;   97US-0069865P.
XX
PA   (UYMC-) UNIV MCGILL.
XX
PI   Szyf M,  Bigey P,  Ramchandani S;
XX
DR   WPI; 1999-059833/05.
XX
PT   New DNA methyltransferase nucleotide sequences - used particularly to
PT   develop antisense oligonucleotides for diagnostic and therapeutic
PT   purposes, particularly for inhibiting tumour growth.
XX
PS   Example 8; Page 32; 108pp; English.
XX
CC   PCR primers AAV99163-220 were used to map the intron boundaries of the
CC   exons of DNA methyltransferase (DNA MeTase) genomic sequence. Antisense
CC   oligonucleotides which inhibit inhibit DNA MeTase expression can be
CC   derived from the genomic DNA MeTase sequence. The antisense
CC   oligonucleotides can be used in investigating the role of DNA MeTase in
CC   cellular growth. They can be administered at different points in the cell
CC   cycle, or in conjugation with promoters or inhibitors of cell growth to
CC   determine the role of DNA MeTase in the growth of the cell type of
CC   interest. The antisense oligonucleotides can also be used for inhibiting
CC   tumour growth in a mammal, or to activate silenced genes to provide a
CC   missing gene function. This ameliorates disease symptoms, e.g. in beta
CC   thalassemia and sickle cell anemia. The antisense oligonucleotides can
CC   also be used an analytical and diagnostic tools and a potentiators of
CC   transgenic plant and animal studies
XX
SQ   Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGGCTCTT 1758
              ||||| ||| |||||||
Db          2 TGACACCTACCGGCTCTT 19


RESULT 618
AAX22626
ID   AAX22626 standard; DNA; 20 BP.
XX
AC   AAX22626;
XX
DT   27-MAY-1999  (first entry)
XX
DE   Human protein kinase C antisense oligonucleotide #65.
XX
KW   Protein kinase C; PKC; human; antisense; primer; inhibitor; treatment;
KW   hyperproliferative condition; cancer; colorectal; breast; bladder; lung;
KW   brain; glioblastoma multiforme; skin; psoriasis; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5885970-A.
XX
PD   23-MAR-1999.
XX
PF   07-JUN-1995;   95US-00488177.
XX
PR   16-MAR-1992;   92US-00852852.
PR   09-JUL-1993;   93US-00089996.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean N,  Bennett CF;
XX
DR   WPI; 1999-228583/19.
XX
PT   New human protein kinase C antisense oligonucleotides - useful for
PT   treating PKC-related hyperproliferative conditions e.g. cancer and
PT   psoriasis.
XX
PS   Example 15; Col 20; 55pp; English.
XX
CC   This invention describes antisense oligonucleotides that specifically
CC   bind to human protein kinase C (PKC) mRNA. These oligonucleotides can be
CC   used to inhibit PKC mRNA and therefore be used to treat PKC-related
CC   hyperproliferative conditions, e.g. cancer, especially colorectal cancer,
CC   breast cancer, bladder cancer, lung cancer, or brain cancer (preferably
CC   glioblastoma multiforme). The products of the invention may also be used
CC   to treat skin cancer and psoriasis
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 619
AAX15611
ID   AAX15611 standard; cDNA to mRNA; 20 BP.
XX
AC   AAX15611;
XX
DT   07-MAY-1999  (first entry)
XX
DE   Fragment of upstream sequence of coding region for VEGF.
XX
KW   Vascular endothelial cell growth factor; VEGF; antisense oligonucleotide;
KW   solid tumor growth; anticancer agent; rheumatic arthritis;
```

```
KW   diabetic retinitis; ss.
XX
OS   Unidentified.
XX
PN   JP11042091-A.
XX
PD   16-FEB-1999.
XX
PF   25-JUL-1997;   97JP-00213838.
XX
PR   25-JUL-1997;   97JP-00213838.
XX
PA   (TOAG ) TOA GOSEI CHEM IND LTD.
XX
DR   WPI; 1999-197823/17.
XX
PT   An antisense nucleic acid compound against vascular endothelial cell
PT   growth factor (VEGF) - useful as an anticancer agent, and for treatment
PT   of rheumatic arthritis and diabetic retinitis.
XX
PS   Example 2; Page 12; 16pp; English.
XX
CC   The present sequence represents the a fragment of the upstream sequence
CC   of the coding region for vascular endothelial cell growth factor (VEGF).
CC   Antisense oligonucleotides targeted to this region inhibit at least 50 %
CC   of VEGF expression by the cell. The antisense oligonucleotides can
CC   inhibit the growth of solid tumor and are useful as anticancer agents and
CC   for treating rheumatic arthritis and diabetic retinitis
XX
SQ   Sequence 20 BP; 11 A; 0 C; 9 G; 0 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAACAGGA 1562
              || || ||||||| ||||
Db          2 AGAAGAGAAGGAAGAGGA 19


RESULT 620
AAX15778/c
ID   AAX15778 standard; cDNA to mRNA; 20 BP.
XX
AC   AAX15778;
XX
DT   07-MAY-1999  (first entry)
XX
DE   Antisense oligonucleotide targeted to upstream sequence of VEGF.
XX
KW   Vascular endothelial cell growth factor; VEGF; antisense oligonucleotide;
KW   solid tumor growth; anticancer agent; rheumatic arthritis;
KW   diabetic retinitis; ss.
XX
OS   Synthetic.
XX
PN   JP11042091-A.
XX
PD   16-FEB-1999.
XX
PF   25-JUL-1997;   97JP-00213838.
XX
PR   25-JUL-1997;   97JP-00213838.
XX
PA   (TOAG ) TOA GOSEI CHEM IND LTD.
XX
DR   WPI; 1999-197823/17.
XX
PT   An antisense nucleic acid compound against vascular endothelial cell
PT   growth factor (VEGF) - useful as an anticancer agent, and for treatment
PT   of rheumatic arthritis and diabetic retinitis.
XX
PS   Example 1; Page 7; 16pp; English.
XX
CC   AAX15764-81 represent antisense oligonucleotides targeted to the upstream
CC   sequence of the coding region for vascular endothelial cell growth factor
CC   (VEGF). Antisense oligonucleotides targeted to this region inhibit at
CC   least 50 % of VEGF expression by the cell. The antisense oligonucleotides
CC   can inhibit the growth of solid tumor and are useful as anticancer agents
CC   and for treating rheumatic arthritis and diabetic retinitis
XX
SQ   Sequence 20 BP; 0 A; 9 C; 0 G; 11 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAACAGGA 1562
              || || ||||||| ||||
Db         19 AGAAGAGAAGGAAGAGGA 2


RESULT 621
AAZ31341
ID   AAZ31341 standard; DNA; 20 BP.
XX
AC   AAZ31341;
XX
DT   24-JAN-2000  (first entry)
XX
DE   CXCR4 gene inhibiting antisense oligo AS(s)-98.
XX
KW   HIV cofactor inhibitor; HIV infection; CXCR4 gene; CCR5 gene;
KW   drug composition; antisense; ss.
XX
OS   Synthetic.
XX
PN   WO9951751-A1.
XX
PD   14-OCT-1999.
XX
PF   01-APR-1999;   99WO-JP001722.
XX
PR   02-APR-1998;   98JP-00125452.
XX
PA   (MARI-) MARINE BIO CO LTD.
XX
PI   Takaku H,  Yamamoto N,  Kimura T,  Takai K,  Wada A;
XX
DR   WPI; 1999-620207/53.
XX
PT   Antisense oligonucleotide-based HIV cofactor inhibitors, as drug
PT   compositions for treatment of HIV infection.
XX
PS   Claim 6; Page 18; 59pp; Japanese.
XX
CC   The invention provides HIV cofactor inhibitors that contain
CC   oligonucleotides with a base sequence complementary to the CXCR4 or CCR5
CC   genes. Such inhibitors can be formulated into drug compositions for
CC   prevention or treatment of HIV infection, with inhibition of expression
CC   of CXCR4 or/and CCR5 gene. Sequences AAZ31307-362 represent antisense
CC   oligonucleotides to the CXCR4 gene
XX
SQ   Sequence 20 BP; 2 A; 6 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1622 TTGTTACCTACCTTACTA 1639
              |||||  || ||||||||
Db          2 TTGTTGGCTGCCTTACTA 19


RESULT 622
AAV73096
```

```
ID   AAV73096 standard; DNA; 20 BP.
XX
AC   AAV73096;
XX
DT   09-FEB-1999  (first entry)
XX
DE   Human ras oncogene mutant detecting oligomer H-61 p3.
XX
KW   Ras oncogene; probe; point mutation; detection; cancer; ss.
XX
OS   Synthetic.
XX
PN   US5847095-A.
XX
PD   08-DEC-1998.
XX
PF   03-JAN-1997;   97US-00778543.
XX
PR   23-JUL-1985;   85US-00758104.
PR   04-AUG-1987;   87US-00081490.
PR   21-APR-1992;   92US-00873352.
PR   23-JUN-1994;   94US-00264425.
XX
PA   (UYLE-) RIJKSUNIV LEIDEN.
XX
PI   Bos JL,  Van Der Eb AJ;
XX
DR   WPI; 1999-059149/05.
XX
PT   Probes for detecting ras oncogene point mutations - useful for the
PT   diagnosis of cancer associated with single base mutations.
XX
PS   Disclosure; Col 19-20; 18pp; English.
XX
CC   AAV73084-V73145 are oligomers used in a method to detect a single-base
CC   mutation in a human ras oncogene. These probes comprise 12-43 nucleotides
CC   of formula 5'-B-Q-D-3', Q = 3 nucleotides complementary to the mutated
CC   codon, and B and D each = 0-20 nucleotides complementary to the ras
CC   sequences flanking the mutated codon. The probes are useful for detecting
CC   cancers associated with point mutations
XX
SQ   Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1597 ACCCCTCCTGGCCTGGGG 1614
              || |||||||||| | ||
Db          2 ACTCCTCCTGGCCGGCGG 19


RESULT 623
AAX78588
ID   AAX78588 standard; DNA; 20 BP.
XX
AC   AAX78588;
XX
DT   03-SEP-1999  (first entry)
XX
DE   Human PKC-delta oligonucleotide primer ISIS # 10301.
XX
KW   PKC; human; PKC-alpha; primer; protein kinase C; expression modulator;
KW   PKC-beta type I; PKC-beta type II; PKC-gamma; PKC-eta; PKC-delta;
KW   PKC-epsilon; PKC-zeta; anti-inflammatory; cytostatic;
KW   antisense targeting; isozyme; growth control; hyperproliferative disease;
KW   colon cancer; glioblastoma; bladder cancer; inflammatory condition;
KW   psoriasis; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5922686-A.
XX
PD   13-JUL-1999.
XX
PF   14-JUN-1996;   96US-00664336.
XX
PR   16-MAR-1992;   92US-00852852.
PR   09-JUL-1993;   93US-00089996.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean N,  Bennett CF;
XX
DR   WPI; 1999-404471/34.
XX
PT   Oligonucleotides targetted against nucleic acids encoding protein kinase
PT   C.
XX
PS   Example 15; Col 55-56; 56pp; English.
XX
CC   This invention describes novel oligonucleotides (AAX78524-X78644) having
CC   up to 50 nucleotides hybridisable with, and able to modulate the
CC   expression of, a nucleic acid encoding protein kinase C and its isozymes
CC   alpha, beta type I, beta type II, gamma, eta, delta, epsilon and zeta.
CC   The oligonucleotides of the invention have anti-inflammatory and
CC   cytostatic activity and are used for antisense targeting to modulate the
CC   expression of PKC or of a particular PKC isozyme or set of isozymes in
CC   cells or tissues. The products of the invention also hybridise with
CC   nucleic acids involved in the modulation of PKC expression, which is
CC   known to be involved growth control in hyperproliferative diseases e.g.
CC   colon cancer, glioblastoma and bladder cancer as well as in inflammatory
CC   conditions e.g. psoriasis. Due to their specificity the oligonucleotides
CC   are able to overcome the problems of toxicity associated with previous
CC   agents designed to modulate PKC expression
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 624
AAZ05834/c
ID   AAZ05834 standard; DNA; 20 BP.
XX
AC   AAZ05834;
XX
DT   07-OCT-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW   Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW   paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW   nongonococcal uretritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW   bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS   Synthetic.
OS   Chlamydia trachomatis.
XX
PN   WO9928475-A2.
XX
PD   10-JUN-1999.
XX
PF   27-NOV-1998;   98WO-IB001939.
XX
PR   28-NOV-1997;   97FR-00015041.
PR   17-DEC-1997;   97FR-00016034.
PR   04-NOV-1998;   98US-0107077P.
XX
```

```
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-371125/31.
XX
PT   Genome sequence of Chlamydia trachomatis.
XX
PS   Disclosure; Page 1803; 1755pp; English.
XX
CC   PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC   (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC   encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC   against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC   be used to control growth of the microorganism. Chlamydia trachomatis is
CC   responsible for a large number of diseases, e.g. eye diseases such as
CC   conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC   conjunctivitis; genital diseases such as nongonococcal uretritis,
CC   epidymitis, cervicitis, salpingitis, perihepatitis, bartholinitis;
CC   pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC   The polypeptides of the invention may be of use in treating these
CC   diseases
XX
SQ   Sequence 20 BP; 2 A; 5 C; 4 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1586 ACAGACTGGGAACCCCTC 1603
              ||||| |||||| | |||
Db         20 ACAGAATGGGAAACACTC 3


RESULT 625
AAZ04608
ID   AAZ04608 standard; DNA; 20 BP.
XX
AC   AAZ04608;
XX
DT   07-OCT-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW   Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW   paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW   nongonococcal uretritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW   bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS   Synthetic.
OS   Chlamydia trachomatis.
XX
PN   WO9928475-A2.
XX
PD   10-JUN-1999.
XX
PF   27-NOV-1998;   98WO-IB001939.
XX
PR   28-NOV-1997;   97FR-00015041.
PR   17-DEC-1997;   97FR-00016034.
PR   04-NOV-1998;   98US-0107077P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-371125/31.
XX
PT   Genome sequence of Chlamydia trachomatis.
XX
PS   Disclosure; Page 1702; 1755pp; English.
XX
CC   PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC   (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC   encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC   against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC   be used to control growth of the microorganism. Chlamydia trachomatis is
CC   responsible for a large number of diseases, e.g. eye diseases such as
CC   conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC   conjunctivitis; genital diseases such as nongonococcal uretritis,
CC   epidymitis, cervicitis, salpingitis, perihepatitis, bartholinitis;
CC   pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC   The polypeptides of the invention may be of use in treating these
CC   diseases
XX
SQ   Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1724 GACCTATTATCAGAAGGT 1741
              | ||| |||||||| |||
Db          1 GGCCTCTTATCAGATGGT 18


RESULT 626
AAZ04719/c
ID   AAZ04719 standard; DNA; 20 BP.
XX
AC   AAZ04719;
XX
DT   07-OCT-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KW   Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
KW   paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
KW   nongonococcal uretritis; epidymitis; cervicitis; salpingitis; PCR primer;
KW   bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS   Synthetic.
OS   Chlamydia trachomatis.
XX
PN   WO9928475-A2.
XX
PD   10-JUN-1999.
XX
PF   27-NOV-1998;   98WO-IB001939.
XX
PR   28-NOV-1997;   97FR-00015041.
PR   17-DEC-1997;   97FR-00016034.
PR   04-NOV-1998;   98US-0107077P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-371125/31.
XX
PT   Genome sequence of Chlamydia trachomatis.
XX
PS   Disclosure; Page 1711; 1755pp; English.
XX
CC   PCR primers AAZ01426-Z06209 were used to amplify open reading frames
CC   (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC   encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC   against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC   be used to control growth of the microorganism. Chlamydia trachomatis is
CC   responsible for a large number of diseases, e.g. eye diseases such as
CC   conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC   conjunctivitis; genital diseases such as nongonococcal uretritis,
CC   epidymitis, cervicitis, salpingitis, perihepatitis, bartholinitis;
CC   pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
CC   The polypeptides of the invention may be of use in treating these
CC   diseases
```

```
XX
SQ   Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1568 AAAATCCTTCTCCACCGC 1585
              |||||||||| || | ||
Db         19 AAAATCCTTCACCTCAGC 2


RESULT 627
AAX83696
ID   AAX83696 standard; DNA; 20 BP.
XX
AC   AAX83696;
XX
DT   27-AUG-1999  (first entry)
XX
DE   Human protein kinase C antisense oligonucleotide SEQ ID NO:65.
XX
KW   Human; protein kinase C; PKC; antisense oligonucleotide; diagnosis; ss;
KW   hybridisation; cancer; psoriasis; hyperproliferative disease; tumour.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5916807-A.
XX
PD   29-JUN-1999.
XX
PF   07-JUN-1995;   95US-00481072.
XX
PR   16-MAR-1992;   92US-00852852.
PR   09-JUL-1993;   93US-00089996.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean N,  Bennett CF;
XX
DR   WPI; 1999-403817/34.
XX
PT   New antisense oligonucleotides specific for human protein kinase C useful
PT   for diagnosis and treatment of cancer and psoriasis.
XX
PS   Claim 1; Col 21; 54pp; English.
XX
CC   The present invention describes a method of inhibiting the expression of
CC   human protein kinase C (PKC) in cells. The method comprises contacting
CC   the cells with an antisense oligonucleotide which has up to 50 nucleotide
CC   units. AAX83633 to AAX83720 represent specifically claimed antisense
CC   oligonucleotides for use in the method of the invention. The antisense
CC   oligonucleotides modulate hybridize to messenger RNA from the PKC gene
CC   which results in modulation of expression of the PKC gene. This means
CC   they can be used for diagnosis, therapeutic or prophylactic treatment of
CC   PKC associated diseases such as cancer and psoriasis, and as research
CC   agents. Abnormal proliferative states in tissue from patients suspected
CC   of having a hyperproliferative disease e.g. cancer, psoriasis can be
CC   diagnosed. Tumours associated with PKC can be distinguished from tumours
CC   which are not PKC associated to allow an efficacious treatment regime to
CC   be used. The antisense oligonucleotides have specific activity so are
CC   able to modulate PKC activity without producing side effects and with
CC   greater effectiveness than observed from administration of current
CC   agents. AAX83721 to AAX83753 represent other oligonucleotides used in
CC   examples from the present invention
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 628
AAX93012
ID   AAX93012 standard; DNA; 20 BP.
XX
AC   AAX93012;
XX
DT   13-SEP-1999  (first entry)
XX
DE   PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
KW   Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW   sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW   neutralising epitope; PCR primer; ss.
XX
OS   Synthetic.
OS   Chlamydophila pneumoniae.
XX
PN   WO9927105-A2.
XX
PD   03-JUN-1999.
XX
PF   20-NOV-1998;   98WO-IB001890.
XX
PR   21-NOV-1997;   97FR-00014673.
PR   04-NOV-1998;   98US-0107078P.
XX
PA   (GEST ) GENSET.
XX
PI   Griffais R;
XX
DR   WPI; 1999-357842/30.
XX
PT   Genome sequence of Chlamydia pneumoniae.
XX
PS   Page 1556; Disclosure; 1912pp; English.
XX
CC   AAX91991-X97517 represent PCR primers used to amplify open reading frames
CC   and other nucleic acid sequences from the genome of Chlamydia pneumoniae
CC   (see AAX91990). C. pneumoniae causes respiratory disease such as
CC   pneumonia and bronchitis and is thought to be a contributing factor in
CC   heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC   nodosum or pharyngitis. The polypeptides encoded by the open reading
CC   frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
CC   in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC   nucleotides sequences can also be used as immunogenic compositions,
CC   especially where the vector directs the expression of a neutralising
CC   epitope of C. pneumoniae
XX
SQ   Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2046 TCTGCTTAGCAACTAGTT 2063
              ||||||||| |||| | |
Db          3 TCTGCTTAGGAACTTGCT 20


RESULT 629
AAX79152
ID   AAX79152 standard; DNA; 20 BP.
XX
AC   AAX79152;
XX
DT   17-AUG-1999  (first entry)
XX
DE   Primer NGA106-R for A.thaliana SSLP marker.
```

XX
KW MSH6; MutS homologue; plant; DNA mismatch repair; genetic variation;
KW characteristic; microsatellite; primer; PCR; amplification; SSLP; ss;
KW simple sequence length polymorphism.
XX
OS Synthetic.
OS Arabidopsis thaliana.
XX
PN WO9919492-A2.
XX
PD 22-APR-1999.
XX
PF 09-OCT-1998; 98WO-EP006977.
XX
PR 10-OCT-1997; 97AU-00009745.
XX
PA (RHON) RHONE-POULENC AGROCHIMIE.
XX
PI Doutriaux M, Betzner AS, Freyssinet G, Perez P;
XX
DR WPI; 1999-277644/23.
XX
PT DNA encoding protein functionally involved in the DNA mismatch repair
PT system of a plant.
XX
PS Example 3; Page 29; 117pp; English.
XX
CC The invention relates to the isolation of the Arabidopsis thaliana MSH3
CC (AAX79066) and MSH6 (AAX79067) genes. These genes are MutS homologues
CC (MSH) from plants and are involved in DNA mismatch repair. The DNA
CC sequence can be used in processes for at least partially inactivating a
CC DNA mismatch repair system of a plant, for increasing genetic variation
CC in a plant, and for obtaining a plant with a desired characteristic.
CC Primers AAX79105-X79160 represent 28 primer pairs used to amplify short
CC allelic repeat fragments designated Simple Sequence Length Polymorphisms
CC (SSLP). These fragments can be used as markers in the analysis of
CC homologous recombination between genomes of A.thaliana subspecies
XX
SQ Sequence 20 BP; 1 A; 7 C; 2 G; 10 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1785 CCCCATTCTTTCCTTCTC 1802
||||||| | | ||||||
Db 3 CCCCATTTTGTTCTTCTC 20

RESULT 630
AAX19191
ID AAX19191 standard; DNA; 20 BP.
XX
AC AAX19191;
XX
DT 20-MAR-2003 (revised)
DT 14-MAY-1999 (first entry)
XX
DE Human PKC-delta antisense oligonucleotide SEQ ID NO:65.
XX
KW Human; PKC; protein kinase C; diagnosis; antisense oligonucleotide;
KW phosphorothioate linkage; hyperproliferative disease; cancer; psoriasis;
KW tumour; inhibition; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5882927-A.
XX
PD 16-MAR-1999.
XX
PF 07-JUN-1995; 95US-00478178.
XX
PR 16-MAR-1992; 92US-00852852.
PR 09-JUL-1993; 93US-00089996.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Dean N, Bennett CF;
XX
DR WPI; 1999-214073/18.
XX
PT New synthetic oligonucleotides inhibiting expression of protein kinase C
PT (PKC)-alpha - useful for treating and diagnosing conditions associated
PT with abnormal PKC expression.
XX
PS Example 15; Col 21; 56pp; English.
XX
CC The present invention specifically describes antisense oligonucleotides
CC of up to 50 nucleotides in length which specifically bind human protein
CC kinase C-alpha (PKC-alpha) mRNA. AAX19127 to AAX19247 represent antisense
CC oligonucleotides from the present invention which bind human PKC-alpha, -
CC beta, -gamma, -delta, -epsilon, -zeta and -eta. The antisense
CC oligonucleotides modulate the expression of the PKC gene (i.e. inhibit
CC the PKC gene). The antisense oligonucleotides can be used to diagnose
CC abnormal proliferative states in tissue or other samples from patients
CC suspected of having a hyperproliferative disease e.g cancer or psoriasis.
CC The antisense oligonucleotides can be used to distinguish PKC-associated
CC tumours and to detect and diagnose PKC expression (through the use of 32P
CC labeled antisense oligonucleotides). Radiolabeled antisense
CC oligonucleotides can also be used to perform autoradiography of tissues
CC to determine the localization, distribution and quantitation of PKC
CC expression for research, diagnostic and therapeutic purposes. The use of
CC the antisense oligonucleotides eliminate the side effects associated with
CC prior art methods because it modulates the amount of PKC protein made
CC from the gene rather than inhibiting the enzyme itself. (Updated on 20-
CC MAR-2003 to correct PF field.)
XX
SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1660 TCTGCATCACCCGCCCCT 1677
|||| || || |||||||
Db 2 TCTGGATGACGCGCCCCT 19

RESULT 631
AAZ27330
ID AAZ27330 standard; DNA; 20 BP.
XX
AC AAZ27330;
XX
DT 01-DEC-1999 (first entry)
XX
DE Human protein kinase C delta antisense oligonucleotide #3.
XX
KW Human; protein kinase C; PKC; diagnosis; antisense oligonucleotide;
KW phosphorothioate; hybridisation; isozyme; target; inflammation;
KW hyperproliferative disorder; psoriasis; tumour; cancer; glioblastoma; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5959096-A.
XX
PD 28-SEP-1999.
XX
PF 07-JUN-1995; 95US-00481066.
XX
PR 16-MAR-1992; 92US-00852852.
PR 09-JUL-1993; 93US-00089996.
XX
PA (ISIS-) ISIS PHARM INC.

```
XX
PI   Bennett CF,  Dean N;
XX
DR   WPI; 1999-561076/47.
XX
PT   Antisense oligonucleotides useful for treatment of hyperproliferative and
PT   inflammatory conditions including psoriasis, tumors and cancer.
XX
PS   Example 15; Col 22; 56pp; English.
XX
CC   The present invention describes antisense oligonucleotides up to 50
CC   nucleotides in length which specifically bind mRNA encoding human protein
CC   kinase C (PKC). AAZ27266 to AAZ27386 represent human PKC antisense
CC   oligonucleotides used in the exemplification of the present invention.
CC   The antisense oligonucleotides are useful for the treatment of diseases
CC   associated with PKC expression, such as hyperproliferative and
CC   inflammatory conditions including psoriasis, tumours and cancer
CC   (glioblastoma, bladder, breast, colon and lung cancer)
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 632
AAZ89062
ID   AAZ89062 standard; DNA; 20 BP.
XX
AC   AAZ89062;
XX
DT   01-JUN-2000  (first entry)
XX
DE   Human nibrin PCR primer BR23 F.
XX
KW   Nibrin; human; DNA double strand break repair protein; diagnosis;
KW   therapy; Nijmegen Breakage Syndrome; gene therapy; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   DE19818680-C1.
XX
PD   09-MAR-2000.
XX
PF   27-APR-1998;   98DE-01018680.
XX
PR   27-APR-1998;   98DE-01018680.
XX
PA   (UYBE ) UNIV BERLIN HUMBOLDT.
XX
DR   WPI; 2000-196117/18.
XX
PT   A DNA double strand break repair protein, Nibrin, and related DNA useful
PT   for diagnosis and therapy of Nijmegen Breakage Syndrome and other
PT   diseases influenced by DNA-double-strand break repair.
XX
PS   Claim 5; Fig 3A; 32pp; German.
XX
CC   This invention describes a novel DNA double strand break repair protein,
CC   Nibrin. Nibrin and DNA encoding it are useful for diagnosis and/or
CC   therapy of diseases influenced by repair of DNA-double strand breaks, in
CC   particular Nijmegen Breakage Syndrome. The product of the invention has
CC   applications in gene therapy. AAZ89048-Z89103 represent PCR primers used
CC   in the amplification of the human nibrin protein described in the
CC   invention
XX
SQ   Sequence 20 BP; 5 A; 5 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTAT 1817
              || | ||| |||||||||
Db          3 CTATCAAATTGGTGCTAT 20


RESULT 633
AAZ37137
ID   AAZ37137 standard; cDNA; 20 BP.
XX
AC   AAZ37137;
XX
DT   01-FEB-2000  (first entry)
XX
DE   Primer used for amplifying human TANGO 125 (T125) gene.
XX
KW   TANGO 125; T125; alternative splice variant; EGF domain; antibody;
KW   secreted protein; agonist; antagonist; predictive medicine; treatment;
KW   forensic biology; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954437-A2.
XX
PD   28-OCT-1999.
XX
PF   23-APR-1999;   99WO-US008900.
XX
PR   23-APR-1998;   98US-00065363.
PR   23-APR-1999;   99US-00298531.
XX
PA   (MILL-) MILLENNIUM BIOTHERAPEUTICS INC.
XX
PI   Holtzman DA;
XX
DR   WPI; 2000-013240/01.
XX
PT   Novel polynucleotides and polypeptides used to modulate a variety of
PT   cellular processes.
XX
PS   Disclosure; Page 22; 120pp; English.
XX
CC   PCR primers AAZ37136-Z37137 are used to amplify the TANGO 125 (T125) gene
CC   (AAZ37131). The T125 protein has two epidermal growth factor (EGF)-like
CC   domains at amino acids 107-134 and 141-176 and is predicted to have a
CC   molecular weight of approximately 30kD. T125 is predicted to have no
CC   transmembrane domains and appears to be a secreted protein. There are
CC   three alternatively spliced forms of T125: T125a, T125b and T125c
CC   (AAZ37132-Z37135). The sequences of all variants of T125 are used in the
CC   invention to create antibodies which selectively bind to T125. The T125
CC   polypeptide is used to modulate a variety of cellular processes. It can
CC   be used to produce fusion proteins. The protein may also be used to
CC   produce antibodies, and to identify T125 antagonists and agonists. The
CC   T125 polynucleotides, polypeptides, homologues and antibodies can be used
CC   in screening assays; predictive medicine; and methods of treatment of
CC   T125 associated disorders. The T125 polynucleotides can be used to
CC   express the protein; to detect T125 mRNA; to detect genetic alterations
CC   in the T125 gene; in forensic biology; and as a source of primers and
CC   probes
XX
SQ   Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGG 1613
              | |||||| ||||||| |
Db          1 AGCCCCTCATGGCCTGTG 18
```

```
RESULT 634
AAZ54547
ID   AAZ54547 standard; DNA; 20 BP.
XX
AC   AAZ54547;
XX
DT   21-MAR-2000  (first entry)
XX
DE   Neisseria chromosomal DNA PCR primer 919.1 #1.
XX
KW   Neisseria meningitidis; Neisseria gonorrheae; antigen; vaccine;
KW   antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;
KW   antibacterial; gene therapy; PCR primer; ss.
XX
OS   Synthetic.
OS   Neisseria sp.
XX
PN   WO9957280-A2.
XX
PD   11-NOV-1999.
XX
PF   30-APR-1999;   99WO-US009346.
XX
PR   01-MAY-1998;   98US-0083758P.
PR   31-JUL-1998;   98US-0094869P.
PR   02-SEP-1998;   98US-0098994P.
PR   02-SEP-1998;   98US-0099062P.
PR   09-OCT-1998;   98US-0103749P.
PR   09-OCT-1998;   98US-0103794P.
PR   09-OCT-1998;   98US-0103796P.
PR   25-FEB-1999;   99US-0121528P.
XX
PA   (CHIR ) CHIRON CORP.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Fraser C,  Galeotti C,  Grandi G,  Hickey E,  Masignani V,  Mora M;
PI   Petersen J,  Pizza M,  Rappuoli R,  Ratti G,  Scalato E,  Scarselli M;
PI   Tettelin H,  Venter JC;
XX
DR   WPI; 2000-062150/05.
XX
PT   Novel Neisserial polypeptides predicted to be useful antigens for
PT   vaccines and diagnostics.
XX
PS   Disclosure; Page 70; 1453pp; English.
XX
CC   AAZ53015 to AAZ54536, AAZ54577 to AAZ54615, and AAY74253 to AAY75941
CC   represent novel Neisseria meningitis and N. gonorrheae polynucleotides
CC   and polypeptides. AAZ54537 to AAZ54576 and AAZ54616 to AAZ55473 represent
CC   PCR primers used in the exemplification of the present invention. The
CC   polypeptides, the polynucleotides, antibodies and compositions of the
CC   invention can be used as vaccines, as diagnostic reagents, and as
CC   immunogenic compositions. The polypeptides can be used in the manufacture
CC   of medicaments for treating or preventing infection due to Neisserial
CC   bacteria (e.g. meningitis and septicaemia), to detect the presence of
CC   Neisseria bacteria, or to raise antibodies. They may also be used to
CC   screen for agonists or antagonists, which may themselves have use as
CC   antibacterial agents. The polynucleotides of the invention may also be
CC   used in gene therapy protocols
XX
SQ   Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1568 AAAATCCTTCTCCACCGC 1585
              ||||| | ||||||| ||
Db          1 AAAATGCCTCTCCACGGC 18


RESULT 635
```

```
AAZ54539
ID   AAZ54539 standard; DNA; 20 BP.
XX
AC   AAZ54539;
XX
DT   21-MAR-2000  (first entry)
XX
DE   Neisseria chromosomal DNA PCR primer 919.1 #1.
XX
KW   Neisseria meningitidis; Neisseria gonorrheae; antigen; vaccine;
KW   antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;
KW   antibacterial; gene therapy; PCR primer; ss.
XX
OS   Synthetic.
OS   Neisseria sp.
XX
PN   WO9957280-A2.
XX
PD   11-NOV-1999.
XX
PF   30-APR-1999;   99WO-US009346.
XX
PR   01-MAY-1998;   98US-0083758P.
PR   31-JUL-1998;   98US-0094869P.
PR   02-SEP-1998;   98US-0098994P.
PR   02-SEP-1998;   98US-0099062P.
PR   09-OCT-1998;   98US-0103749P.
PR   09-OCT-1998;   98US-0103794P.
PR   09-OCT-1998;   98US-0103796P.
PR   25-FEB-1999;   99US-0121528P.
XX
PA   (CHIR ) CHIRON CORP.
PA   (GENO-) INST GENOMIC RES.
XX
PI   Fraser C,  Galeotti C,  Grandi G,  Hickey E,  Masignani V,  Mora M;
PI   Petersen J,  Pizza M,  Rappuoli R,  Ratti G,  Scalato E,  Scarselli M;
PI   Tettelin H,  Venter JC;
XX
DR   WPI; 2000-062150/05.
XX
PT   Novel Neisserial polypeptides predicted to be useful antigens for
PT   vaccines and diagnostics.
XX
PS   Disclosure; Page 69; 1453pp; English.
XX
CC   AAZ53015 to AAZ54536, AAZ54577 to AAZ54615, and AAY74253 to AAY75941
CC   represent novel Neisseria meningitis and N. gonorrheae polynucleotides
CC   and polypeptides. AAZ54537 to AAZ54576 and AAZ54616 to AAZ55473 represent
CC   PCR primers used in the exemplification of the present invention. The
CC   polypeptides, the polynucleotides, antibodies and compositions of the
CC   invention can be used as vaccines, as diagnostic reagents, and as
CC   immunogenic compositions. The polypeptides can be used in the manufacture
CC   of medicaments for treating or preventing infection due to Neisserial
CC   bacteria (e.g. meningitis and septicaemia), to detect the presence of
CC   Neisseria bacteria, or to raise antibodies. They may also be used to
CC   screen for agonists or antagonists, which may themselves have use as
CC   antibacterial agents. The polynucleotides of the invention may also be
CC   used in gene therapy protocols
XX
SQ   Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1568 AAAATCCTTCTCCACCGC 1585
              ||||| | ||||||| ||
Db          1 AAAATGCCTCTCCACGGC 18


RESULT 636
AAA54278/c
ID   AAA54278 standard; DNA; 20 BP.
```

```
XX
AC   AAA54278;
XX
DT   26-FEB-2001  (first entry)
XX
DE   Antisense oligonucleotide directed against hTRBF-1.
XX
KW   Human telomeric repeat binding factor 1; hTRBF-1; antisense; disease;
KW   modulation; expression; prophylaxis; infection; inflammation;
KW   anti-inflammatory; tumour; diagnostic; ss.
XX
OS   Synthetic.
XX
PN   US6130088-A.
XX
PD   10-OCT-2000.
XX
PF   21-JUL-1999;   99US-00358384.
XX
PR   21-JUL-1999;   99US-00358384.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2000-664192/64.
XX
PT   New antisense compounds that hybridizes with and inhibits the expression
PT   of human telomeric repeat binding factor 1 (TRBF-1), useful for treating
PT   conditions or diseases associated with TRBF-1 expression.
XX
PS   Example 15; Col 63; 34pp; English.
XX
CC   Antisense compounds directed against the start codon, 3' untranslated
CC   region, nucleotides 78-374, 560-681, 965-1334 of the coding region or the
CC   stop codon of the human Telomeric Repeat Binding Factor 1 (hTRBF-1) can
CC   be used to inhibit the expression of hTRBF-1. The antisense compounds are
CC   used for treating a patient suspected of having or being prone to a
CC   disease or condition associated with expression of TRBF-1 by modulating
CC   its expression. They may also be used prophylactically to prevent or
CC   delay infection, inflammation or tumour formation, or as research
CC   reagents and diagnostics, e.g. to distinguish between functions of
CC   various members of a biological pathway. The antisense oligonucleotides
CC   disclosed are described in GENESEQ records AAA54242-A54280, AAA54385
XX
SQ   Sequence 20 BP; 10 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1921 CTTTTTTTTCAGTGTTAA 1938
              ||||| || ||||||| |
Db         19 CTTTTGTTCCAGTGTTTA 2


RESULT 637
AAZ88724
ID   AAZ88724 standard; DNA; 20 BP.
XX
AC   AAZ88724;
XX
DT   11-MAY-2000  (first entry)
XX
DE   Human CD95 receptor promoter DNA p53 binding fragment #2.
XX
KW   p53; CD95 receptor; human; screening; apoptosis-modulation;
KW   cancer chemotherapy; ss.
XX
OS   Homo sapiens.
XX
PN   DE19847779-C1.
XX
PD   03-FEB-2000.
XX
PF   16-OCT-1998;   98DE-01047779.
XX
PR   16-OCT-1998;   98DE-01047779.
XX
PA   (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
XX
PI   Krammer P,  Mueller-Schilling M,  Oren M;
XX
DR   WPI; 2000-162245/15.
XX
PT   Novel receptor DNA useful for identifying apoptosis-modulating substances
PT   potentially useful for cancer chemotherapy.
XX
PS   Claim 2; Fig 5; 12pp; German.
XX
CC   This invention describes a novel p53-binding region of a human CD95
CC   receptor DNA molecule. The p53-binding region, or a vector containing it,
CC   can be used to screen for apoptosis-modulating substances potentially
CC   useful for cancer chemotherapy. This sequence represents a fragment of
CC   the human CD95 receptor promoter which is capable of binding p53
XX
SQ   Sequence 20 BP; 4 A; 2 C; 3 G; 11 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTTT 1776
              | ||  ||||||||||||
Db          3 TGTTGCTTAAGCTTTTTT 20


RESULT 638
AAZ69731/c
ID   AAZ69731 standard; DNA; 20 BP.
XX
AC   AAZ69731;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:4087.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1102; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
```

CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 20 BP; 10 A; 2 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1681 CTTCTTAGTTGTTTCTCT 1698
              ||||  |||||||| |||
Db         20 CTTCCAAGTTGTTTTTCT 3
```

RESULT 639
AAA78230/c
ID AAA78230 standard; DNA; 20 BP.
XX
AC AAA78230;
XX
DT 16-NOV-2000 (first entry)
XX
DE Anti-human Fas antibody CH11 H chain cDNA specific primer SHR-2.
XX
KW Antirheumatic agent; immunoglobulin M; IgM; apoptosis inducer;
KW immunosuppression; autoimmune disease; treatment; rheumatism;
KW anti-Fas antibody; primer; ss.
XX
OS Synthetic.
XX
PN JP2000154149-A.
XX
PD 06-JUN-2000.
XX
PF 17-SEP-1999; 99JP-00263984.
XX
PR 18-SEP-1998; 98JP-00264598.
XX
PA (SANY) SANKYO CO LTD.
XX
DR WPI; 2000-454476/40.
XX
PT Anti-human Fas humanizing antibody-containing antirheumatic agents.
XX
PS Disclosure; Page 16; 109pp; Japanese.
XX
CC The present invention relates to antirheumatic agents which comprise as
CC active ingredients an immunoglobulin M (IgM) protein. The IgM protein
CC does not include a J segment, has apoptosis inducing activity, and
CC consists of a light and heavy chain polypeptide produced synthetically.
CC The agents of the invention exhibit antirheumatic and immunosuppressive
CC activity and can be used to treat autoimmune diseases, especially
CC rheumatism. The IgM molecule used in the invention has human Fas-antigen
CC binding properties. Included in the invention are nucleotide sequences of
CC the IgM light and heavy chains (see AAA78267-A78272) and the
CC corresponding protein sequences (see AAB12913-B12918 and AAB12919), and
CC nucleotide sequences of the humanised anti-human Fas Ig CH11 (see
CC AAA78202-A78206) and protein sequences (see AAB12908-B12910). Also
CC included are anti-human Fas antibody CDR peptides (AAB12902-B12907).
CC Primers specific for the anti-human Fas antibody, light, heavy and kappa
CC chains used in the invention are represented by sequences AAA78213-
CC A78266. Primers used for sequencing the human Ig DNA used in the
CC invention are represented by sequences AAA78277-A78318 and AAA78335-
CC A78337, while humanised anti-Fas Ig DNA sequencing primers are
CC represented by sequences AAA78321-A78334 and AAA78338-A78367. Primer
CC sequences AAA78207-A78212 are specific for murine Ig DNA, and are used in
CC the production of the agent of the invention
XX
SQ Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1643 AAAGAGCCTTCACTGGTT 1660
              ||||||||||| | ||| |
Db         18 AAAGAGCCTTGAGTGGAT 1
```

RESULT 640
AAA75141/c
ID AAA75141 standard; cDNA; 20 BP.
XX
AC AAA75141;
XX
DT 15-JAN-2001 (first entry)
XX
DE PCR primer for cDNA encoding a murine Dickkopf (Dkk)-3 protein.
XX
KW Human; Dickkopf-3 protein; Dkk-3 protein; Soggy protein; optic disorder;
KW cysteine-rich secreted protein; glaucoma; conjunctivitis; brain disorder;
KW Alzheimer's disease; epilepsy; amnesia; inflammation; pulmonary disorder;
KW skeletal muscle disorder; Goodpasture's syndrome; PCR primer;
KW cardiovascular disorder; hyperproliferative disorder; cancer; ss.
XX
OS Mus sp.
XX
PN WO200052047-A2.
XX
PD 08-SEP-2000.
XX
PF 03-MAR-2000; 2000WO-US005452.
XX
PR 05-MAR-1999; 99US-00263022.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Mccarthy S;
XX
DR WPI; 2000-579276/54.
XX
PT Human Dickkopf (hDkk) and Soggy nucleic acids and proteins, useful as
PT modulating agents in regulating cellular processes and particularly for
PT treating disorders characterized by aberrant expression or activity of
PT Dkk, e.g. Alzheimer's,.
XX
PS Example 2; Page 123; 208pp; English.
XX
CC PCR primers AAA75141-42 were used to amplify cDNA encoding a murine
CC Dickkopf (Dkk)-3 protein. The specification also describes Soggy (Dkk-
CC related) sequences. Dkk is a cysteine-rich secreted protein. The Dkk
CC nucleic acids and proteins are useful as modulating agents in regulating
CC cellular processes. They are particularly useful in treating subjects
CC having a disorder characterized by aberrant expression or activity of Dkk
CC such as optic disorders (glaucoma, conjunctivitis), brain disorders
CC (Alzheimer's disease, epilepsy, amnesia), inflammation, skeletal muscle
CC disorders, pulmonary disorders (Goodpasture's syndrome), cardiovascular
CC disorders, and hyperproliferative disorders (cancer). The Dkk proteins
CC and nucleic acids may also be used for research purposes, such as for
CC chromosome mapping, tissue typing and in screening assays to identify
CC modulators
XX
SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGACTG 1593
              ||||||| ||||  ||||
Db         18 TCTCCACAGCACTCACTG 1


RESULT 641
AAH56624
ID   AAH56624 standard; DNA; 20 BP.
XX
AC   AAH56624;
XX
DT   06-SEP-2001  (first entry)
XX
DE   Streptococcus pyogenes groEL antisense oligonucleotide SEQ ID NO:272.
XX
KW   Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
KW   microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
KW   Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
KW   antibacterial; antiviral; antiproliferative; antisense therapy;
KW   microbial infection; ss.
XX
OS   Streptococcus pyogenes.
XX
PN   WO200136625-A2.
XX
PD   25-MAY-2001.
XX
PF   20-NOV-2000; 2000WO-CA001347.
XX
PR   18-NOV-1999;   99US-0166249P.
XX
PA   (GENE-) GENESENSE TECHNOLOGIES INC.
XX
PI   Wright JA,  Young AH,  Dugourd D;
XX
DR   WPI; 2001-355633/37.
XX
PT   Novel antisense compounds targeting nucleic acid encoding groEL or groES
PT   gene of microorganism, which hybridize with and inhibit expression of the
PT   genes, useful to inhibit growth of microorganism having the genes.
XX
PS   Claim 3; Page 48; 110pp; English.
XX
CC   The present invention specifically claims AAH56368 to AAH56832 which are
CC   antisense oligonucleotides to nucleotide sequences encoding groE. More
CC   generally, antisense compounds (I) comprising antisense oligonucleotides
CC   of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC   shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
CC   microorganism, where the antisense compound is complementary to GL or GS
CC   of a microorganism and specifically hybridises with and inhibits the
CC   expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
CC   antiproliferative activities, and can be used in antisense therapy and
CC   for inhibition of expression of groES or groEL. (I) are useful for
CC   inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
CC   also useful for inhibiting the growth of a microorganism, or inhibiting
CC   the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC   virus) having a GL or GS gene which involves administering to the
CC   microorganism or to a cell infected with the microorganism, (I). (I) are
CC   also useful for treating a mammalian pathological condition mediated by
CC   the microorganisms which involves identifying a eukaryotic organism
CC   having a pathological condition mediated by microorganisms having a GL or
CC   GS gene and administering (I) such that the growth of microorganism is
CC   inhibited. The antisense compounds are utilised for diagnostics,
CC   therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC   prevent or delay microbial infections in humans. They are also useful as
CC   molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC   represent PCR primers for groE sequences which are used in the
CC   exemplification of the present invention. AAH56855 to AAH56870 represent
CC   groE nucleotide sequence given in the present invention
XX
SQ   Sequence 20 BP; 3 A; 4 C; 2 G; 11 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCTG 1804
              ||||| |||| || ||||
Db          2 CCATTTTTTCATTGTCTG 19


RESULT 642
AAF87049
ID   AAF87049 standard; DNA; 20 BP.
XX
AC   AAF87049;
XX
DT   18-SEP-2001  (first entry)
XX
DE   PCR primer for Nkx2.2 gene.
XX
KW   PCR primer; neuroectoderm cell; cell production; Parkinson's disease;
KW   early primitive ectoderm-like cell; EPL cell; cell therapy;
KW   transgenic animal; gene therapy; neuronal disease; Huntington's disease;
KW   lysosomal storage disease; multiple sclerosis; memory disorder;
KW   behavioural disorder; Alzheimer's disease; organ transplant;
KW   spinal cord disorder; Nkx2.2; ss.
XX
OS   Unidentified.
XX
PN   WO200151611-A1.
XX
PD   19-JUL-2001.
XX
PF   12-JAN-2001; 2001WO-AU000030.
XX
PR   14-JAN-2000; 2000AU-00005098.
PR   20-APR-2000; 2000AU-00007045.
PR   27-APR-2000; 2000AU-00007143.
XX
PA   (BRES-) BRESAGEN LTD.
XX
PI   Rathjen PD,  Rathjen J;
XX
DR   WPI; 2001-432908/46.
XX
PT   Producing neuroectoderm cells for treatment of Parkinson's and
PT   Alzheimer's and for transplantation comprises culturing early primitive
PT   ectoderm-like cells in conditioned medium.
XX
PS   Example 3; Page 42; 91pp; English.
XX
CC   This sequence represents a PCR primer for the Nkx2.2 gene, used within
CC   the scope of the invention. The invention relates to a method for
CC   producing neuroectoderm cells (I) comprises: (a) providing a source of
CC   early primitive ectoderm-like (EPL) cells and a neural-inducing
CC   conditioned medium (CM) or extract of it; and (b) contacting the EPL
CC   cells with the CM or extract for a time sufficient to generate controlled
CC   differentiation to (I). The cells or partially differentiated progeny are
CC   useful in human, or animal cell therapy, transgenic animal production,
CC   human or animal gene therapy, the screening of pharmaceutical that induce
CC   a biological response in neuroectoderm cells or their partially
CC   differentiated progeny and evaluation of biological molecules that direct
CC   differentiation of neural cells. The method is useful for producing
CC   neuroectoderm cells. It is also useful for producing differentiated or
CC   partially differentiated cells from neural ectoderm cells. The method can
CC   is also useful for maintaining neuroectoderm cells in vitro in
CC   homogeneous cell populations. It can also be used for producing
CC   genetically modified neuroectoderm cells. The cells can be used in the
CC   treatment of neuronal diseases, including Parkinson's disease,
CC   Huntington's disease, lysosomal storage diseases, multiple sclerosis,
CC   memory and behavioural disorders, and Alzheimer's disease. The method can
```

```
CC   also be used for preparation of tissue or organs for transplant. Neural
CC   crest cells produced by the method are useful for the treatment of spinal
CC   cord disorders and Schwann cells produced by the method are used for the
CC   treatment of multiple sclerosis
XX
SQ   Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1574 CTTCTCCACCGCACAGAC 1591
              ||||||||  || |||||
Db          3 CTTCTCCAAAGCGCAGAC 20


RESULT 643
AAC84225
ID   AAC84225 standard; DNA; 20 BP.
XX
AC   AAC84225;
XX
DT   19-MAR-2001  (first entry)
XX
DE   Human PKC-delta mRNA inhibiting antisense oligo ISIS no. 10301.
XX
KW   Antisense; human; protein kinase C-delta; PKC-delta; antipsoriatic;
KW   cytostatic; immunosuppressive; antidiabetic; neuroprotective; cancer;
KW   antiinflammatory; antirheumatic; antiarthritic; hepatotropic; hepatitis;
KW   inflammatory bowel disease; multiple sclerosis; pancreatitis; ss.
XX
OS   Homo sapiens.
XX
PN   WO200070091-A1.
XX
PD   23-NOV-2000.
XX
PF   11-MAY-2000; 2000WO-US013170.
XX
PR   18-MAY-1999;   99US-00313930.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM;
XX
DR   WPI; 2001-025027/03.
XX
PT   Antisense oligonucleotide for modulating human protein kinase C-delta and
PT   treating diseases such as cancer, diabetes, comprises nucleotides
PT   specifically hybridizable with nucleic acid encoding the protein kinase.
XX
PS   Claim 6; Page 48; 84pp; English.
XX
CC   The invention provides antisense oligonucleotides that specifically
CC   hybridize with human protein kinase C-delta (PKC-delta) polynucleotide.
CC   The antisense oligonucleotides are useful for modulating the expression
CC   of human PKC-delta in cells or tissues, especially adipose tissues which
CC   express human PKC-delta, for inhibiting hyperproliferation of cells and
CC   treating or preventing an abnormal proliferative condition such as
CC   hyperproliferative disorder, especially psoriasis or cancer such as
CC   leukemia. They are also useful for reducing an inflammatory response of
CC   human cells and treating an animal having a disease or condition
CC   associated with tumour necrosis factor-alpha (TNF-alpha), especially
CC   overexpression of TNF-alpha, such as inflammatory or autoimmune disease
CC   or a condition which is infectious, diabetes, inflammatory bowel disease,
CC   multiple sclerosis, pancreatitis, rheumatoid arthritis, hepatitis, atopic
CC   dermatitis or allograft rejection and for reducing the blood glucose
CC   level in a human. Sequences AAC84223-240 represent antisense
CC   oligonucleotides for inhibiting human PKC-delta mRNA
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 644
AAS10290
ID   AAS10290 standard; DNA; 20 BP.
XX
AC   AAS10290;
XX
DT   09-SEP-2004  (revised)
DT   24-OCT-2001  (first entry)
XX
DE   Antisense oligonucleotide for human integrin alpha 4, ISIS 107242.
XX
KW   Integrin alpha 4; antisense; very late antigen 4; VLA4;
KW   autoimmune disease; inflammatory disease; rheumatoid arthritis;
KW   multiple sclerosis; tumour metastasis; melanoma; asthma; psoriasis;
KW   allergy; Grave's disease; Hashimoto's thyroiditis; oligonucleotide;
KW   systemic lupus erythematosus; allograft rejection; ISIS 107242; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "Other= Phosphorothioate backbone and  All 2'
FT                   methoxyethoxy cytosines are 5-methylcytosines"
FT   modified_base   1. .3
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Other= 2' methoxyethoxy residues"
FT   modified_base   4. .12
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "Other= 2' deoxy residues"
FT   modified_base   13. .20
FT                   /*tag=  d
FT                   /mod_base= OTHER
FT                   /note= "Other= 2' methoxyethoxy residues"
XX
PN   US6258790-B1.
XX
PD   10-JUL-2001.
XX
PF   19-AUG-1999;   99US-00377309.
XX
PR   05-OCT-1998;   98US-00166203.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Condon TP,  Cowsert LM;
XX
DR   WPI; 2001-450381/48.
XX
PT   Composition for treating inflammatory and autoimmune diseases, comprises
PT   antisense compound targeted to nucleic acid molecule encoding integrin
PT   alpha4 and inhibit expression of integrin alpha4.
XX
PS   Claim 12; Col 49; 49pp; English.
XX
CC   The sequence is an antisense oligonucleotide targetting human integrin 4,
CC   a protein involved in autoimmune and inflammatory diseases. The invention
CC   relates to antisense inhibitors of integrin alpha 4 which target and
CC   inhibit expression of integrin alpha 4. The antisense molecules are
CC   useful for inhibiting the expression of integrin alpha4 in human cells or
CC   tissues, treating an animal having a disease or condition associated with
```

```
CC   expression of integrin alpha4, e.g., inflammatory disease or condition,
CC   autoimmune disease or condition including rheumatoid arthritis, multiple
CC   sclerosis and tumour metastases, melanoma, asthma, psoriasis, allergy,
CC   Grave's disease, Hashimoto's thyroiditis, systemic lupus erythematosus
CC   and allograft rejection, and diseases or conditions characterised by
CC   leukocyte migration into affected tissues, preferably central nervous
CC   system tissues. The antisense molecules are also useful for reducing the
CC   levels of VLA-4 and alpha4beta7 integrin in human cells or tissues, and
CC   reducing the adherence of cells of a first type e.g., melanoma cells or
CC   lymphocytes, to cells of a second type e.g., endothelial cells, by
CC   inhibiting integrin alpha4 expression and thus decreasing adhesion of
CC   cells
CC
CC   Revised record issued on 09-SEP-2004 : Correction to feature table key
XX
SQ   Sequence 20 BP; 10 A; 3 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCAACAA 1917
              ||||||||||| ||||
Db          3 AGATCAACAGAAGTACAA 20


RESULT 645
ABA82593
ID   ABA82593 standard; DNA; 20 BP.
XX
AC   ABA82593;
XX
DT   25-JAN-2002  (first entry)
XX
DE   Zmax1 gene region physical map preparation STS marker #552.
XX
KW   Human; high bone mass; HBM gene; Zmax1 gene; chromosome 11; 11q13.3;
KW   sequence tagged site; STS; osteoporosis; osteopathic; gene therapy;
KW   antisense therapy; vaccine; bone disorder; Paget's disease; adapter;
KW   sclerostosis; osteomalacia; fibrous dysplasia; PCR primer; linker; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177327-A1.
XX
PD   18-OCT-2001.
XX
PF   21-JUN-2000; 2000WO-US016951.
XX
PR   05-APR-2000; 2000US-00543771.
PR   05-APR-2000; 2000US-00544398.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Carulli JP,  Little RD,  Recker RR,  Johnson ML;
XX
DR   WPI; 2001-657171/75.
XX
PT   New high bone mass (HBM) and Zmax1 genes and proteins useful for
PT   modulating bone mass for the treatment of e.g. osteoporosis.
XX
PS   Disclosure; Page 37; 443pp; English.
XX
CC   The present invention describes the human Zmax1 gene and the high bone
CC   mass (HBM) gene,which are found on chromosome 11q13.3. The Zmax1 and HBM
CC   genes have osteopathic activities. The genes can be used in gene therapy,
CC   antisense therapy and in the production of vaccines. They can be used in
CC   the diagnosis and treatment of bone disorders including osteoporosis,
CC   Paget's disease, sclerostosis, osteomalacia and fibrous dysplasia.
CC   ABA82038 to ABA82700 and AAG68168 to AAG68193 represent sequences used in
CC   the exemplification of the present invention
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTATC 2047
              ||||||| | ||||| ||
Db          2 GGAGGCACAAGTTCTTTC 19


RESULT 646
ABT13242
ID   ABT13242 standard; DNA; 20 BP.
XX
AC   ABT13242;
XX
DT   30-JAN-2003  (first entry)
XX
DE   Fanconi anaemia FANCD exon amplifying PCR primer SEQ ID No 145.
XX
KW   Cytostatic; dermatological; vasotropic; anti-anaemic; FA pathway defect;
KW   Fanconi anaemia protein complex; FANCD; DNA repair; Cockayne's syndrome;
KW   cell cycle abnormality; Fanconi anaemia; ataxia telangiectasia; cancer;
KW   Bloom's syndrome; Hereditary non-polyposis colon cancer; gene therapy;
KW   Xeroderma pigmentosum; PCR; primer; ss.
XX
OS   Unidentified.
XX
PN   WO200236761-A2.
XX
PD   10-MAY-2002.
XX
PF   02-NOV-2001; 2001WO-US045561.
XX
PR   03-NOV-2000; 2000US-0245756P.
XX
PA   (DAND ) DANA FARBER CANCER INST INC.
XX
PI   D'andrea AD,  Taniguchi T,  Timmers C,  Grompe M;
XX
DR   WPI; 2002-519251/55.
XX
PT   Novel isolated Fanconi anemia protein complex polypeptide, termed FANCD2,
PT   useful for treating Fanconi anemia pathway defect in cell target or for
PT   treating patient with defective FANCD2 gene.
XX
PS   Claim 8; Page 55; 103pp; English.
XX
CC   The invention relates to an isolated Fanconi anaemia protein complex
CC   (FANCD2) polypeptide. The FANCD2 protein comprises a sequence of 1472
CC   amino acids fully defined in the specification, its 90% identical
CC   sequence, a sequence encoded by a polynucleotide that is at least 90%
CC   identical to sequences given in specification such as a 5127 base pair
CC   sequence, or a fragment which is at least 50 amino acids in length. The
CC   FANCD2 protein is useful for treating an FA pathway defect in a cell
CC   target or for treating a patient with a defective FANCD2 gene. The FANCD2
CC   gene is useful for making a recombinant expression vector. The FANCD2
CC   protein and its gene are useful as a novel target for therapeutic
CC   development, and in diagnostic test and screening assays for diseases
CC   associated with DNA repair and cell cycle abnormalities such as Fanconi
CC   anaemia, Bloom's syndrome, Cockayne's syndrome, Hereditary non-polyposis
CC   colon cancer, ataxia telangiectasia and Xeroderma pigmentosum. The FANCD2
CC   gene is useful in producing probes and primers for screening patients in
CC   genetic based test, for diagnosing Fanconi anaemia and cancer, for
CC   preparing an experimental mouse model for use in screening new
CC   therapeutics for treating conditions involving defective DNA repair, and
CC   in gene therapy methods. A recombinant vector containing the FANCD2 gene
CC   of the invention is useful in gene therapy. This polynucleotide sequence
CC   represents a PCR primer for amplifying a FANCD exon relating to the
CC   invention
XX
SQ   Sequence 20 BP; 2 A; 6 C; 3 G; 9 T; 0 U; 0 Other;
```

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTG 1934
              ||||||| |||| | |||
Db          2 ATACCTTCTTTTGCTGTG 19
```

RESULT 647
AAS97783/c
ID AAS97783 standard; DNA; 20 BP.
XX
AC AAS97783;
XX
DT 12-MAR-2002 (first entry)
XX
DE Murine SAC1 gene-specific oligonucleotide PCR primer #350.
XX
KW Human; mouse; SAC1; carbohydrate; sweetener; ethanol; alcoholism; ss;
KW obesity; diabetes; transgenic embryo; body tissue; body fluid; pancreas;
KW blood; tongue; PCR primer; anorectic; antidiabetic; gene therapy;
KW protein replacement therapy.
XX
OS Mus sp.
XX
PN WO200183749-A2.
XX
PD 08-NOV-2001.
XX
PF 25-APR-2001; 2001WO-US013387.
XX
PR 28-APR-2000; 2000US-0200794P.
PR 28-JUL-2000; 2000US-0221419P.
PR 10-NOV-2000; 2000US-0247443P.
XX
PA (WARN) WARNER LAMBERT CO.
PA (MONE-) MONELL CHEM SENSES CENT.
XX
PI Bachmanov AA, Beauchamp GK, Chatterjee A, De Jong PJ, Li S, Li X;
PI Ohmen JD, Reed DR, Ross D, Tordoff MG;
XX
DR WPI; 2002-075162/10.
XX
PT Novel isolated polypeptide comprising variant form of mouse or human SAC1
PT polypeptide, and is associated with altered preference for carbohydrates
PT or other sweeteners, useful for preventing obesity, diabetes, alcoholism.
XX
PS Claim 14; Page 87; 239pp; English.
XX
CC The invention relates to an isolated polypeptide, comprising a variant
CC form of mouse or human SAC1 polypeptide. The variant form is associated
CC with altered preference for carbohydrates, other sweeteners or ethanol.
CC The polypeptide and its associated DNA sequence can be produced by
CC recombinant techniques and is useful for preventing obesity, diabetes or
CC alcoholism associated with SAC1 expression. The sequences are useful in
CC screening for drugs and sweeteners. Recombinant cell lines and transgenic
CC embryos may be used in screening for and identifying agents that induce
CC or repress function of SAC1. Predisposition to diabetes, obesity or
CC alcoholism can be ascertained by testing any fluid or tissue of a human
CC (such as blood, pancreas or tongue) for sequence variations of the SAC1
CC gene. A sequence variation of the SAC1 locus may indicate a
CC predisposition to diabetes, obesity and/or alcoholism and may provide a
CC diagnostic mark. The polynucleotide can be detected in a biological
CC sample by contacting the DNA with a probe to form a hybridisation complex
CC which is then detected. The sequences represent cDNA encoding human and
CC mouse SAC1 polypeptides and PCR primers specific for the SCA1 genes
XX
SQ Sequence 20 BP; 5 A; 0 C; 9 G; 6 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCACA 1588
              |||||| |||||| || |
Db         20 ATCCTTTTCCACCCCAAA 3
```

RESULT 648
ABL90918
ID ABL90918 standard; DNA; 20 BP.
XX
AC ABL90918;
XX
DT 27-MAY-2002 (first entry)
XX
DE Human protein kinase C-delta antisense oligonucleotide 3.
XX
KW Human; PKC antisense oligonucleotide; protein kinase C; PKC; PKC-alpha;
KW PKC-beta type I; PKC-beta type II; PKC-gamma; PKC-delta; PKC-epsilon;
KW PKC-zeta; PKC-eta; PKC expression modulation; ss;
KW hyperproliferative condition; tumour; glioblastoma; bladder cancer;
KW breast cancer; colon cancer; lung cancer; inflammatory condition;
KW psoriasis; phosphorothioate backbone.
XX
OS Homo sapiens.
XX
PN US6339066-B1.
XX
PD 15-JAN-2002.
XX
PF 31-MAR-1997; 97US-00829637.
XX
PR 11-JAN-1990; 90US-00463358.
PR 13-AUG-1990; 90US-00566977.
PR 11-JAN-1991; 91WO-US000243.
PR 15-OCT-1991; 91US-00777760.
PR 16-OCT-1991; 91US-00777007.
PR 16-MAR-1992; 92US-00852852.
PR 05-MAY-1993; 93US-00058023.
PR 09-JUL-1993; 93US-00089996.
PR 29-AUG-1994; 94US-00297703.
PR 07-JUN-1995; 95US-00481066.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Dean NM, Cook PD, Hoke G;
XX
DR WPI; 2002-215022/27.
XX
PT New antisense oligonucleotide having nucleoside units which specifically
PT binds mRNA encoding human protein kinase C isoform, useful for treating
PT hyperproliferative and inflammatory diseases e.g. psoriasis, tumor and
PT cancer.
XX
PS Example 15; Col 47-48; 77pp; English.
XX
CC The invention comprises antisense oligonucleotides designed to bind mRNA
CC encoding a human protein kinase C (PKC) isoform (i.e. PKC-alpha, PKC-beta
CC type I, PKC-beta type II, PKC-gamma, PKC-delta, PKC-epsilon, PKC-zeta,
CC and PKC-eta). The antisense oligonucleotides of the invention are useful
CC for modulating the expression of the PKC isoforms. The antisense
CC oligonucleotides are useful for treating hyperproliferative conditions
CC (e.g. tumour, glioblastoma, bladder cancer, breast cancer, colon cancer
CC and lung cancer), and inflammatory conditions (e.g. psoriasis). The
CC antisense oligonucleotides of the invention are also useful for detection
CC and diagnosis of PKC expression. The present sequence represents a human
CC PKC antisense oligonucleotide of the invention. NOTE: The present
CC sequence contains a phosphorothioate backbone
XX
SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
```

```
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 649
ABS97478/c
ID   ABS97478 standard; DNA; 20 BP.
XX
AC   ABS97478;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human epoxide hydroxylase 2 PCR primer #5.
XX
KW   Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
KW   cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW   adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW   aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW   cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW   epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW   glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW   HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW   NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
KW   UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW   UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW   multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW   multidrug resistance associated protein 3; cancer; prostate;
KW   acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW   altered drug metabolism; cardiovascular function; colorectal tumour;
KW   central nervous system; pulmonary; immunological.
XX
OS   Homo sapiens.
XX
PN   WO200257410-A2.
XX
PD   25-JUL-2002.
XX
PF   28-NOV-2001; 2001WO-US044838.
XX
PR   28-NOV-2000; 2000US-00724389.
XX
PA   (DNAS-) DNA SCI LAB INC.
XX
PI   Guida M,  Hall J;
XX
DR   WPI; 2002-698522/75.
XX
PT   Isolated nucleic acid molecules having polymorphisms in known human genes
PT   e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
PT   for locating, identifying and characterizing the genes responsible for
PT   disorder-related traits.
XX
PS   Example 10; Page 116; 714pp; English.
XX
CC   This invention relates to the sequence of an isolated nucleic acid
CC   molecule comprising at least one base variation from that of a known
CC   human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
CC   cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
CC   aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC   (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
CC   inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
CC   protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
CC   transferase (HNMT), (kallikrein 2) KLK2, nicotinamide -N-methyl
CC   transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
CC   sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC   (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC   transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
CC   (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC   (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
CC   receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC   The polymorphisms in the human genes cited in the invention are useful as
CC   genetic linkage markers for locating and characterising the genes that
CC   are responsible for specific traits within the genome and eventually
CC   identifying the genes responsible for a variety of disorder-related
CC   traits as a result of their e.g., overexpression, constitutive
CC   expression, mutation or underexpression, which may be used in diagnosing
CC   and/or treating the disorders. The nucleic acid molecules comprising the
CC   polymorphic sequences contained in CYP4501A1, CYPP4501A2, CYP4502E1,
CC   ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
CC   MDR1 and/or MDR3 are useful for screening individuals for altered drug
CC   metabolism. The polymorphic sequences contained in CYP4501A1, CYPP4501A2,
CC   AHR, MDR1 and/or MDR3 may also be used to screen individuals for
CC   susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
CC   used to screen for altered cardiovascular function, in COX2 for altered
CC   susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
CC   nervous system function, in FLAP and HNMT for altered pulmonary,
CC   immunological or haematological function, in KLK2 for altered serine
CC   protease activity in the prostate, in LTF for altered immunological or
CC   haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC   peripheral nervous system function. The present sequence represents a PCR
CC   primer used to amplify the sequences of the invention
XX
SQ   Sequence 20 BP; 6 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGGCC 1852
              | ||||||||||||| | |
Db         19 ATATACATTCCCTGTGAC 2


RESULT 650
ABK23390
ID   ABK23390 standard; DNA; 20 BP.
XX
AC   ABK23390;
XX
DT   09-APR-2002  (first entry)
XX
DE   Human Zmax1 cDNA reverse PCR primer #276.
XX
KW   Human; mouse; Zmax1; HBM; high bone mass gene; lipid regulation; stroke;
KW   lipid-associated condition; arteriosclerosis; cardiovascular disease; ss;
KW   osteoporosis; atherosclerosis; diabetic atherosclerosis; plaque build-up;
KW   neurovascular condition; wound healing; gene therapy; PCR primer; probe;
KW   bone development disorder; antiarteriosclerotic; cardiovascular;
KW   osteopathic; cerebroprotective.
XX
OS   Homo sapiens.
XX
PN   WO200192891-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016946.
XX
PR   26-MAY-2000; 2000US-00578900.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
PA   (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
XX
PI   Carulli JP,  Little RD,  Recker RR,  Johnson ML;
XX
DR   WPI; 2002-097784/13.
XX
PT   Identifying molecules involved in lipid regulation, useful for
PT   diagnosing, treating or preventing e.g., arteriosclerosis, comprises
PT   identifying a molecule that binds to high bone mass gene or its
PT   corresponding wild type gene.
XX
PS   Disclosure; Page 42; 409pp; English.
```

```
XX
CC   The invention relates to a method for identifying a molecule involved in
CC   lipid regulation comprising identifying a molecule that binds to or
CC   inhibits binding of a molecule to high bone mass (HBM) or its wild type
CC   gene, Zmax1. Compounds identified by the method are useful for treating,
CC   diagnosing, preventing or screening for normal and abnormal lipid-
CC   associated conditions, including arteriosclerosis, cardiovascular
CC   disease, stroke, and osteoporosis. The compounds may also be used in the
CC   treatment or prevention of diabetic atherosclerosis, neurovascular
CC   conditions caused by plaque build-up, poor circulation due to plaque
CC   build-up and associated poor wound healing. The methods may be used in
CC   gene therapy, pharmaceutical development, and diagnostic assays for bone
CC   development disorders. Molecules identified by comparison of Zmax1 and
CC   HBM systems can be used as surrogate markers in pharmaceutical
CC   development, in diagnosis of human or animal bone disease, and in the
CC   treatment of bone diseases. Sequences ABK22776-ABK23411 represent cDNA
CC   molecules encoding human Zmax1 and HBM, and PCR primers, probes, linkers
CC   and adapters of the invention
XX
SQ   Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTATC 2047
              ||||||| | ||||| ||
Db          2 GGAGGCACAAGTTCTTTC 19


RESULT 651
ABK12363/c
ID   ABK12363 standard; DNA; 20 BP.
XX
AC   ABK12363;
XX
DT   05-JUN-2002  (first entry)
XX
DE   Human tumour suppressor gene PTX1, exon 3 5'splice junction.
XX
KW   Human; tumour suppressor protein; PTX1; chromosome 12; cancer;
KW   prostate cancer; tumour suppressor gene; cellular differentiation;
KW   tumourigenesis; cytostatic; ds.
XX
OS   Homo sapiens.
XX
PN   WO200216385-A1.
XX
PD   28-FEB-2002.
XX
PF   22-AUG-2001; 2001WO-US026213.
XX
PR   22-AUG-2000; 2000US-0226993P.
XX
PA   (EINS-) EINSTEIN HEALTHCARE NETWORK ALBERT.
XX
PI   Kwok S,  Daskal I;
XX
DR   WPI; 2002-280903/32.
XX
PT   Novel tumor suppressor gene encoding PTX1 protein, useful for identifying
PT   mutation in a nucleic acid sequence in a patient sample, and for use in
PT   the diagnosis, prognosis and treatment of cancer.
XX
PS   Example 1; Fig 9; 74pp; English.
XX
CC   The present invention relates to the isolation of a novel polynucleotide
CC   sequence encoding a human tumour suppressor protein termed PTX1. The PTX1
CC   gene maps to chromosome 12. The sequences of the invention can be used in
CC   the diagnosis, prognosis, and treatment of cancer, particularly prostate
CC   cancer. They are also useful as research tools to identify other tumour
CC   suppressor genes. The polynucleotide sequence is useful for identifying a
CC   mutation in a nucleic acid sequence in a patient sample. PTX1 molecules
CC   are useful for identification, detection and/or molecular
CC   characterisation of components involved in the regulation of cellular
CC   differentiation and tumourigenesis. ABK12359-ABK12384 represent the exon-
CC   intron junctions of the human PTX1 gene
XX
SQ   Sequence 20 BP; 4 A; 2 C; 2 G; 12 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAAA 1982
              ||||  |||||| |||||
Db         18 AAATGATTACCTAGAAAA 1


RESULT 652
AAD33542
ID   AAD33542 standard; DNA; 20 BP.
XX
AC   AAD33542;
XX
DT   01-JUL-2002  (first entry)
XX
DE   PCR primer #4 used in the invention.
XX
KW   Haematopoiesis; clotting; kidney failure; wound healing; cancer;
KW   neoplasia; pancreatic disorder; pancreatitis; cerebrovascular disease;
KW   heart disorder; ischaemic heart disease; neuroprotective; vulnerary;
KW   cardiovascular disorder; ischaemic heart disease; immunosuppressive;
KW   glomerular disease; glomerulonephritis; uterine disorder; hyperplasia;
KW   fetal spleen; prostate disorder; inflammatory disease; Crohn's disease;
KW   proliferative disorder; gynaecological; haemostatic; antibacterial;
KW   systemic lupus erythematosus; immunodeficiency disorder; antiasthmatic;
KW   cytostatic; nephrotropic; antidiabetic; cerebroprotective; tranquilliser;
KW   hypotensive; tumour; injury; trauma; antianginal; vasotropic; antiulcer;
KW   apoptotic disorder; rheumatoid arthritis; cardiant; renal disorder;
KW   hepatotropic; antipsoriatic; antiallergic; dermatological; virucide; PCR;
KW   primer; ss.
XX
OS   Unidentified.
XX
PN   US2002028508-A1.
XX
PD   07-MAR-2002.
XX
PF   21-FEB-2001; 2001US-00790264.
XX
PR   23-APR-1998;   98US-00065363.
PR   23-APR-1998;   98US-00065661.
PR   22-JUN-1998;   98US-00102705.
PR   29-JUL-1998;   98US-00124538.
PR   23-APR-1999;   99US-00298531.
PR   22-JUN-1999;   99US-00337930.
PR   29-JUL-1999;   99US-00363630.
XX
PA   (HOLT/) HOLTZMAN D A.
PA   (GOOD/) GOODEARL A D J.
PA   (MCCA/) MCCARTHY S A.
XX
PI   Holtzman DA,  Goodearl ADJ,  Mccarthy SA;
XX
DR   WPI; 2002-303420/34.
XX
PT   Novel TANGO polypeptides and nucleic acid molecules useful as modulating
PT   agents in regulating cellular processes and for diagnosing and treating
PT   heart, liver, lung, kidney, inflammatory and cellular proliferative
PT   disorders.
XX
PS   Disclosure; Page 65; 138pp; English.
XX
CC   The invention relates to nucleic acids encoding a variety of proteins
CC   human T139 (TANGO-139), T125 (TANGO-125), T110 (TANGO-110), murine T175
```

```
CC   (TANGO-175), human T175 or murine WDNM-2, having diagnostic, preventive,
CC   therapeutic and other uses. Polypeptide of the invention has the ability
CC   to inhibit a proteinase activity, to modulate cell-cell interactions,
CC   haematopoiesis and the ability to modulate clotting. Polypeptide and
CC   polynucleotide of the invention are useful for diagnosing and treating
CC   disorder characterised by their aberrant expression or activity. The
CC   antibodies are useful as modulating agents in regulating a variety of
CC   cellular processes e.g. cell proliferation and/or cell differentiation.
CC   TANGO-139 is useful for treating kidney defects such as kidney failure,
CC   TANGO-125 is useful in wound healing and for treating cancer, TANGO-110
CC   is useful for treating neoplasia, TANGO-177 or WDNM-2 is useful for
CC   treating cancer, are useful to treat pancreatic disorders, such as
CC   pancreatitis, cerebrovascular disease, and tumours, and injury or trauma
CC   to the brain. TANG0-125, 110, 175 molecules treat heart disorders, e.g.,
CC   ischaemic heart disease, cardiovascular disorders, such as ischaemic
CC   heart disease. TANGO-139, 125, 110 and 175 molecules are useful to treat
CC   renal (kidney) disorders, such as glomerular disease (e.g., acute and
CC   chronic glomerulonephritis), TANGO-175 is useful to treat uterine
CC   disorders, hyperplasia of the endometrium. TANGO-110 is useful to treat
CC   spleen, e.g., the fetal spleen, associated diseases and disorder. TANGO-
CC   125 treats prostate disorders, such as inflammatory diseases, Crohn's
CC   disease and tumours. TANGO-139, 125, 110, 175 or WDNM-2 are useful for
CC   treating proliferative disorders, inflammatory disorders. TANGO-175, or
CC   WDNM-2 activity also include apoptotic disorders, rheumatoid arthritis,
CC   systemic lupus erythematosus, insulin-dependent diabetes mellitus, immune
CC   -related disorders, e.g., immunodeficiency disorders, viral disorders,
CC   cell growth disorders, e.g., cancers and inflammatory disorders and
CC   apoptotic disorders. The nucleic acids of the invention are used in gene
CC   therapy. The present sequence is a PCR primer used in the invention
XX
SQ   Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGG 1613
              | |||||| ||||||| |
Db          1 AGCCCCTCATGGCCTGTG 18


RESULT 653
ABS73441/c
ID   ABS73441 standard; DNA; 20 BP.
XX
AC   ABS73441;
XX
DT   03-DEC-2002  (first entry)
XX
DE   Chimeric phosphorotioate oligonucleotide #22.
XX
KW   Human; glioma-associated oncogene-2; antisense compound; infection;
KW   inflammation; tumour formation; antiinflammatory; antitumour;
KW   inhibitor of human glioma-associated oncogene-2 expression;
KW   antisense gene therapy; phosphorothioate; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
OS   Chimeric.
XX
PN   US6440739-B1.
XX
PD   27-AUG-2002.
XX
PF   17-JUL-2001; 2001US-00907843.
XX
PR   17-JUL-2001; 2001US-00907843.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Freier SM;
XX
DR   WPI; 2002-697096/75.
XX
PT   Novel antisense compound that hybridizes and inhibits nucleic acid
PT   encoding human glioma-associated oncogene-2, useful for treatment of
PT   diseases associated with human glioma-associated oncogene-2.
XX
PS   Claim 3; Col 45; 43pp; English.
XX
CC   The present invention relates to a new antisense compound targeted to
CC   human glioma-associated oncogene-2. The invention is useful for
CC   inhibiting the expression of human glioma-associated oncogene-2 in cells
CC   or tissues. The invention is also is useful for treatment of diseases
CC   associated with human glioma-associated oncogene-2. The invention is
CC   further useful for diagnostics, therapeutics, prophylaxis, as research
CC   reagents and kits, for distinguishing functions of various members of a
CC   biological pathway, and in antisense gene therapy. The invention is also
CC   useful prophylactically, e.g., to prevent or delay infection,
CC   inflammation or tumour formation. The present nucleic acid sequence
CC   represents an oligonucleotide that was used in the methods of the
CC   invention to inhibit human glioma-associated oncogene-2
XX
SQ   Sequence 20 BP; 3 A; 2 C; 8 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACCG 1584
              | ||| |||||||||  ||
Db         18 ACAAAGCCTTCTCCAACG 1


RESULT 654
ABX34041/c
ID   ABX34041 standard; DNA; 20 BP.
XX
AC   ABX34041;
XX
DT   10-FEB-2003  (first entry)
XX
DE   Human cancer suppressing protein PP7298 PCR primer #1.
XX
KW   Human; primer; ss; cancer suppressing protein; cancer; PCR.
XX
OS   Homo sapiens.
XX
PN   CN1351081-A.
XX
PD   29-MAY-2002.
XX
PF   31-OCT-2000; 2000CN-00127102.
XX
PR   31-OCT-2000; 2000CN-00127102.
XX
PA   (SHAN-) SHANGHAI INST ONCOLOGY.
XX
PI   Gu J;
XX
DR   WPI; 2002-609437/66.
XX
PT   New human protein with cancer cell growth suppressing function and a
PT   polynucleotide encoding it, for treating diseases, such as, cancer.
XX
PS   Example 2; Page 11 (disclosure); 39pp; Chinese.
XX
CC   This invention relates to the cDNA and protein sequences of a novel human
CC   protein with cancer suppressing function. The invention also comprises a
CC   method for preparing the polypeptide by recombination, and an application
CC   of the polypeptide in treating diseases such as cancer, etc. Also
CC   disclosed in an antagonist of the polypeptide and its medical action. The
CC   present sequence represents a PCR primer used to amplify a cDNA encoding
CC   a cancer suppressing protein of the invention
XX
SQ   Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
```

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGCCTG 1611
              |||||   ||||||||||
Db         18 GGAACTAGTCCTGGCCTG 1


RESULT 655
ABK69368/c
ID   ABK69368 standard; DNA; 20 BP.
XX
AC   ABK69368;
XX
DT   15-JUL-2002  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #120 for caspase 9 inhibition.
XX
KW   Antisense compound; caspase 9; C9; hyperproliferative disorder; stroke;
KW   haematopoietic disorder; cholesterol disorder; bone metabolism disorder;
KW   brain injury; neurodegenerative disease; infection; inflammation; tumour;
KW   phosphorothioate backbone linkage; 2'-methoxyethyl; 2'-MOE; ss.
XX
OS   Mus musculus.
OS   Synthetic.
OS   Chimeric.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate nucleotides, all cytidine
FT                    residues are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO200222641-A1.
XX
PD   21-MAR-2002.
XX
PF   10-SEP-2001; 2001WO-US028233.
XX
PR   11-SEP-2000; 2000US-00659845.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Zhang H,  Watt AT;
XX
DR   WPI; 2002-351874/38.
XX
PT   New antisense oligonucleotide which modulates expression of caspase 9,
PT   useful to treat tumor, inflammation or to prevent infection in humans.
XX
PS   Claim 26; Page 95; 145pp; English.
XX
CC   The present invention relates to a new antisense compound targeted to a
CC   nucleic acid molecule encoding caspase 9 (C9). The compound specifically
CC   hybridises with and inhibits the expression of caspase 9. The invention
CC   also describes an antisense compound that specifically hybridises with an
CC   8 nucleotide portion of an active site of the nucleic acid. The invention
CC   is useful for inhibiting the expression of C9 in cells or tissues and is
CC   also useful for treating an animal having a disease or condition
CC   associated with C9, including a hyperproliferative, haematopoietic or
CC   cholesterol disorder, bone metabolism disorder, stroke, brain injury or
CC   neurodegenerative disease. The compound is commonly useful as a research
CC   and diagnostics reagent. It is also useful to distinguish between
CC   functions of various members of a biological pathway. The invention is
CC   also be useful prophylactically e.g. to prevent or delay infection,
CC   inflammation or tumour formation. The antisense compound of the invention
CC   is often preferred over native form because of enhanced cellular uptake,
CC   enhanced affinity for nucleic acid target and increased stability in
CC   presence of nucleases. The present nucleic acid sequence represents one
CC   of a collection (ABK69249-ABK69396) of chimeric phosphorothioate
CC   oligonucleotides having 2'-methoxyethyl (2'-MOE) wings. This sequence was
CC   used in the methods of the invention for inhibition of caspase 9
XX
SQ   Sequence 20 BP; 7 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1674 CCCTGGACTTCTTAGTTG 1691
              |||||||||  ||| || |
Db         18 CCCTGGACTGCTTTGTGG 1


RESULT 656
AAD48416/c
ID   AAD48416 standard; DNA; 20 BP.
XX
AC   AAD48416;
XX
DT   24-FEB-2003  (first entry)
XX
DE   Forward PCR primer #15 used for LOH analysis.
XX
KW   Breast tumour; loss of heterozygosity; LOH; tumour; neoplastic disease;
KW   PCR; primer; ss.
XX
OS   Unidentified.
XX
PN   WO200276286-A2.
XX
PD   03-OCT-2002.
XX
PF   20-MAR-2002; 2002WO-US009068.
XX
PR   23-MAR-2001; 2001US-00816460.
XX
PA   (CALP-) CALIFORNIA PACIFIC MEDICAL CENT RES INST.
XX
PI   Dairkee SH,  Li Z;
XX
DR   WPI; 2003-046744/04.
XX
PT   Determining the likelihood of tumor re-occurrence in a patient previously
PT   diagnosed with a breast tumor to determine treatment modalities,
PT   comprises analyzing the cell sample for loss of heterozygosity to
PT   chromosomal locus 3p24.3.
XX
PS   Example 1; Page 41; 42pp; English.
XX
CC   The invention relates to a method of determining the likelihood of tumour
CC   re-occurrence in a patient previously diagnosed with a breast tumour. The
CC   method involves analysing the target cell sample for loss of
CC   heterozygosity (LOH) to chromosomal locus 3p24.3. The method is useful
CC   for determining the likelihood of tumour re-occurrence in a patient
CC   previously diagnosed with a breast tumour and subsequently useful in
CC   determining the degree of aggressive treatment indicated. The prognostic
CC   method is especially useful in making decisions concerning treatment
CC   modalities, including therapeutic intervention, diagnostic criteria such
CC   as disease staging and disease monitoring and surveillance for metastasis
CC   or recurrence of neoplastic disease. The present sequence is a PCR primer
CC   used for LOH analysis. This primer is used to illustrate the method of
CC   the invention
XX
SQ   Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
```

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTCT 2044
              | |||||| |||| ||||
Db         20 GCAGGAGGGAAAGTTTCT 3


RESULT 657
ABZ77182
ID   ABZ77182 standard; DNA; 20 BP.
XX
AC   ABZ77182;
XX
DT   08-MAY-2003  (first entry)
XX
DE   Geranylgeranyl diphosphate synthase PCR primer SEQ ID NO:22.
XX
KW   Phoma betae; aphidicolin biosynthase cluster; aphidicolin; GGDP synthase;
KW   aphidicolan-1,6 beta-ol synthase; geranylgeranyl diphosphate synthase;
KW   cytochrome P450 hydroxylase; P450-1; P450-2; transporter protein; TP;
KW   DNA polymerase alpha-specific inhibitor; replication; enzyme; PCR primer;
KW   ss.
XX
OS   Phoma betae.
OS   Synthetic.
XX
PN   WO2003000902-A1.
XX
PD   03-JAN-2003.
XX
PF   02-MAY-2002; 2002WO-JP004381.
XX
PR   21-JUN-2001; 2001JP-00188465.
XX
PA   (NISC-) JAPAN SCI & TECHNOLOGY CORP.
XX
PI   Oikawa H,  Sassa T,  Toyomasu T;
XX
DR   WPI; 2003-175292/17.
XX
PT   New gene encoding an aphidicolan-1,6beta-ol synthase protein for
PT   producing transformants to produce the DNA polymer alpha-specific
PT   inhibitor aphidicolin, applicable in e.g. drugs for controlling
PT   replication of eukaryotes.
XX
PS   Example 2; Page 17; 74pp; Japanese.
XX
CC   The present invention describes genes required in the production of
CC   aphidicolin, which is a DNA polymerase alpha-specific inhibitor which
CC   plays an important role in the replication of eukaryotes. Genes involved
CC   in an aphidicolin biosynthase cluster are: aphidicolan-1,6 beta-ol
CC   synthase; geranylgeranyl diphosphate (GGDP) synthase; cytochrome P450
CC   hydroxylase (P450-1); transporter protein (TP) and cytochrome P450
CC   hydroxylase (P450-2). The genes are used for constructing transformants
CC   to produce a DNA polymer alpha-specific inhibitor aphidicolin by
CC   fermentation, applicable in reagents and drugs for cell cycle problems
CC   during co-culturing or for controlling replication of eukaryotes. With
CC   the transformants, aphidicolin can be in produced in large quantities,
CC   and with high yield. The present sequence represents a PCR primer for
CC   GGDP synthase isolated from Phoma betae, which is used in an example from
CC   the present invention
XX
SQ   Sequence 20 BP; 5 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1908 AGATCAACAATACCTTTT 1925
              |||||||  || ||||||
Db          1 AGATCAAGTATTCCTTTT 18


RESULT 658
ABV76820/c
ID   ABV76820 standard; DNA; 20 BP.
XX
AC   ABV76820;
XX
DT   12-FEB-2003  (first entry)
XX
DE   PCR primer used to amplify a human cDNA sequence.
XX
KW   Rheumatoid arthritis; onset risk; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200279466-A1.
XX
PD   10-OCT-2002.
XX
PF   29-MAR-2002; 2002WO-JP003191.
XX
PR   30-MAR-2001; 2001JP-00102006.
XX
PA   (SHIO/) SHIOZAWA S.
XX
PI   Shiozawa S,  Komai K,  Yagi H,  Matsuura N;
XX
DR   WPI; 2003-046814/04.
XX
PT   Genomic DNAs participating in rheumatoid arthritis, applicable in
PT   diagnosis as well as judging onset risks of and screening drugs for the
PT   disease based on gene mutation.
XX
PS   Example 1; Page 7; 25pp; Japanese.
XX
CC   The specification describes a genomic DNA sequence which participates in
CC   rheumatoid arthritis. The DNA is applicable in diagnosis as well as
CC   judging onset risks of, and screening drugs for treating or preventing,
CC   rheumatoid arthritis. The present PCR primer was used in the course of
CC   the invention
XX
SQ   Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1730 TTATCAGAAGGTGACAAG 1747
              ||| || ||||||| |||
Db         18 TTACCACAAGGTGAGAAG 1


RESULT 659
ACC45973
ID   ACC45973 standard; DNA; 20 BP.
XX
AC   ACC45973;
XX
DT   02-JUN-2003  (first entry)
XX
DE   Human HBM STS marker reverse primer #276.
XX
KW   Human; high bone mass; HBM; LRP5; LRP6; transgenic; bone mass modulation;
KW   gene therapy; bone density modulation; bone strength; trabecular number;
KW   bone size; bone tissue connectivity; bone disease; osteoporosis; PCR;
KW   osteomalacia; rickets; Paget's disease; neoplasm of the bone; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200292764-A2.
XX
```

PD 21-NOV-2002.
XX
PF 13-MAY-2002; 2002WO-US014876.
XX
PR 11-MAY-2001; 2001US-0290071P.
PR 17-MAY-2001; 2001US-0291311P.
PR 01-FEB-2002; 2002US-0353058P.
PR 04-MAR-2002; 2002US-0361293P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (AMHP) WYETH.
XX
PI Babij P, Bex FJ, Yaworsky PJ, Bodine PV;
XX
DR WPI; 2003-129278/12.
XX
PT New transgenic animals (e.g. mice), useful as models for studying bone
PT density modulation, developing drugs for treating or preventing bone
PT diseases (e.g. osteoporosis), or diagnosing diseases characterized by
PT reduced bone density.
XX
PS Disclosure; Page 58; 603pp; English.
XX
CC The invention relates to novel transgenic animals expressing the high
CC bone mass (HBM) gene, expressing the corresponding wild type HBM gene,
CC comprising an alteration of the gene encoding LRP5 or LRP6, or expressing
CC an LRP5 that is modulated by an altered gene control sequence introduced
CC by homologous or non-homologous recombination. The transgenic animals are
CC for the study of bone density modulation or bone mass modulation. The
CC invention has osteopathic and cytostatic activity. The polynucleotides of
CC the invention may have a use in gene therapy. The transgenic animals and
CC nucleic acids are for the study of bone density modulation, where the
CC bone mass is modulated relative to non-transgenic animals of the same
CC species in more than one parameter selected from bone density, bone
CC strength, trabecular number, bone size, or bone tissue connectivity. The
CC transgenic animals, nucleic acids and methods are useful for identifying
CC molecules involved in bone development, and for developing pharmaceutical
CC compositions, which may be employed for treating or preventing bone
CC diseases, e.g. osteoporosis, osteomalacia, rickets, Paget's disease, or
CC neoplasms of the bone. The transgenic animals and nucleic acids are also
CC useful in methods for diagnosing diseases involved in bone development,
CC or characterised by reduced bone density or mass. The present sequence is
CC used in the exemplification of the invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2030 GGAGGCAAAGGTTCTATC 2047
||||||| | ||||| ||
Db 2 GGAGGCACAAGTTCTTTC 19

RESULT 660
ACF06330
ID ACF06330 standard; DNA; 20 BP.
XX
AC ACF06330;
XX
DT 07-OCT-2003 (first entry)
XX
DE Zebrafish EGFP PCR primer SEQ ID NO:6.
XX
KW Zebrafish; fish embryo cell line; chimeric fish; genetic; human disease;
KW EGFP; PCR primer; ss.
XX
OS Danio rerio.
OS Synthetic.
XX
PN WO2003051109-A1.
XX
PD 26-JUN-2003.
XX
PF 13-DEC-2002; 2002WO-US039913.
XX
PR 13-DEC-2001; 2001US-0341355P.
PR 12-FEB-2002; 2002CA-02371460.
XX
PA (PURD) PURDUE RES FOUND.
XX
PI Collodi P, Fan L, Ma C;
XX
DR WPI; 2003-532958/50.
XX
PT New zebrafish embryo cell line, which becomes a germ cell when introduced
PT to a fish embryo, useful for making a germ line chimeric zebrafish, which
PT is a valuable model for genetic studies of human diseases.
XX
PS Example 3; Page 31; 45pp; English.
XX
CC The present invention describes a fish embryo cell line, where a cell of
CC the fish embryo cell line, after incubation in vitro for at least 24
CC hours, will become a germ cell when introduced to a fish embryo. Also
CC described: (1) making the fish embryo cell line; (2) an isolated fish
CC embryo cell line obtained by the method of (1); (3) making a germ line
CC chimeric fish; (4) a germ line chimeric fish obtained by the method of
CC (3); and (5) cell culture media comprising a growth factor and fish cell
CC conditioned medium, or a growth factor and a fish cell, where the growth
CC factor is fibroblast growth factor or epidermal growth factor. The fish
CC embryo cell line is useful for making a germ line chimeric fish,
CC particularly zebrafish, which is a valuable model for genetic studies of
CC human diseases. The present sequence represents a PCR primer for
CC zebrafish EGFP, which is used in an example from the present invention
XX
SQ Sequence 20 BP; 2 A; 3 C; 8 G; 7 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1932 GTGTTAAGGTAATGGTTG 1949
||| | ||||| ||||||
Db 1 GTGCTCAGGTAGTGGTTG 18

RESULT 661
ACH11197
ID ACH11197 standard; DNA; 20 BP.
XX
AC ACH11197;
XX
DT 08-OCT-2003 (first entry)
XX
DE Human protein kinase C-delta targeted oligonucleotide ISIS#10301.
XX
KW Human; ss; antisense; PKC; protein kinase C; hyperproliferation; tumour;
KW inflammation; psoriasis; cancer; non-small cell lung cancer; lung cancer;
KW non-Hodgkin's lymphoma; glioblastoma; bladder cancer; colon cancer;
KW breast cancer; ovarian cancer; pancreatic cancer.
XX
OS Homo sapiens.
XX
PN US6537973-B1.
XX
PD 25-MAR-2003.
XX
PF 18-DEC-2001; 2001US-00025139.
XX
PR 16-MAR-1992; 92US-00852852.
PR 09-JUL-1993; 93US-00089996.
PR 07-JUN-1995; 95US-00478178.
PR 31-MAR-1997; 97US-00829637.
XX
PA (ISIS-) ISIS PHARM INC.

```
XX
PI   Bennett CF,  Dean NM,  Holmlund JT,  Dorr FA;
XX
DR   WPI; 2003-531084/50.
XX
PT   New pharmaceutical composition, useful for treating cancer, e.g., non-
PT   small cell lung cancer or non-Hodgkin's lymphoma.
XX
PS   Example 15; Col 21; 56pp; English.
XX
CC   The invention relates to a new pharmaceutical composition comprising: (a)
CC   an oligonucleotide sequence having up to 50 base pairs (bp); and (b)
CC   carboplatin and paclitaxel, cisplatin and gemcitabine, 5-fluorouracil and
CC   leucovorin, or docetaxel. The pharmaceutical composition is useful for
CC   treating diseases associated with protein kinase C such as
CC   hyperproliferative and inflammatory conditions e.g. psoriasis, tumours
CC   and cancer e.g. non-small cell lung cancer, non-Hodgkin's lymphoma,
CC   glioblastoma, bladder cancer, lung cancer, colon cancer, breast cancer,
CC   ovarian cancer and pancreatic cancer. The present sequence represents an
CC   antisense oligonucleotide targeted against protein kinase C
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 662
ABT43829
ID   ABT43829 standard; DNA; 20 BP.
XX
AC   ABT43829;
XX
DT   16-OCT-2003  (first entry)
XX
DE   Human PIP5KIa antisense oligonucleotide Seq ID81.
XX
KW   Human; phosphatidylinositol-4-phosphate 5-kinase Ialpha; PIP5KIalpha;
KW   antiinflammatory; antitumour; cytostatic; gene therapy; tumour;
KW   antisense oligonucleotide; hyperproliferative disorder;
KW   inflammatory disorder; infection; inflammation; 2'-methoxyethyl wing;
KW   2'-MOE wing; phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003050309-A1.
XX
PD   19-JUN-2003.
XX
PF   04-DEC-2002; 2002WO-US038615.
XX
PR   06-DEC-2001; 2001US-00003354.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Freier SM;
XX
DR   WPI; 2003-627257/59.
XX
PT   New antisense compound useful for treating diseases such as
PT   hyperproliferative or inflammatory disorders, hybridizes and inhibits
PT   nucleic acid encoding phosphatidylinositol-4-phosphate 5-kinase, I alpha.
XX
PS   Example 15; Page 83; 117pp; English.
XX
CC   This invention relates to the novel antisense compounds, particularly
CC   antisense oligonucleotides, for the modulation of phosphatidylinositol-4-
CC   phosphate 5-kinase Ialpha (PIP5KIa) expression. The oligonucleotides of
CC   the invention may have antiinflammatory, antitumour or cytostatic
CC   activities through use in a gene therapy method. As a result the
CC   antisense oligonucleotides may be of use for the treatment of an animal
CC   having a disease associated with PIP5KIa such as a hyperproliferative or
CC   inflammatory disorder through inhibition of PIP5KIa expression. The
CC   oligonucleotides of the invention may also be used prophylactically to
CC   prevent or delay infection, inflammation or tumour formation. They may
CC   also be useful for diagnostics, therapeutics, prevention, as research
CC   reagents and kits or for distinguishing functions of various members of a
CC   biological pathway. The present sequence is that of an antisense
CC   oligonucleotide of the invention. The oligonucleotide is a chimeric
CC   phosphorothioate oligonucleotide which has five nucleotide 2'-
CC   methoxyethyl (2'-MOE) wings with a ten nucleotide deoxynucleotide gap.
CC   The oligonucleotide backbone is phosphorothioate throughout
XX
SQ   Sequence 20 BP; 9 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1556 AACAGGACTGCAAAAATC 1573
              ||||||| | ||| ||||
Db          1 AACAGGAATTCAACAATC 18


RESULT 663
ACH66461
ID   ACH66461 standard; DNA; 20 BP.
XX
AC   ACH66461;
XX
DT   16-OCT-2003  (first entry)
XX
DE   Sense PCR primer used to amplify CCNE1.
XX
KW   PCR; primer; ss; genomic DNA; gDNA; untranslated region; UTR;
KW   DNA high-density microarray; biosite; large scale production; gDNA probe;
KW   microarray; Type II primer.
XX
OS   Homo sapiens.
XX
PN   US2003073085-A1.
XX
PD   17-APR-2003.
XX
PF   05-OCT-2001; 2001US-00972469.
XX
PR   05-OCT-2001; 2001US-00972469.
XX
PA   (LAIF/) LAI F.
PA   (ZHOU/) ZHOU D.
XX
PI   Lai F,  Zhou D;
XX
DR   WPI; 2003-555942/52.
XX
PT   Amplifying expressed genetic sequences from genomic DNA of mammalian or
PT   higher order plant species for printing on DNA microarrays, involves
PT   using the 3' untranslated region of the gene sequence.
XX
PS   Disclosure; Page 7; 15pp; English.
XX
CC   The invention discloses a method for amplifying expressed genetic
CC   sequences from genomic DNA (gDNA) from mammalian or higher order plant
CC   species. The method involves identifying a 3' untranslated region (UTR)
CC   of a gDNA sequence, designing probe, performing PCR, separating the
CC   product by size differentiation and performing a second PCR to amplify
CC   the predetermined sequence. Also claimed is a biological analysis device,
CC   comprising a substrate and an array of a set of expressed genetic
CC   sequences, located on the substrate, which are generated by the method
CC   above and a DNA high-density microarray comprising a substrate upon which
CC   are deposited an array of biosites of genomic DNA fragments having the
```

CC sequence of at least one exon, and absent polyadenine and vector
CC sequences, where the genomic DNA fragments have a sequence length of from
CC about 75-2000 nucleotides. The method is efficient for amplifying gene
CC sequences, enables large-scale production of gDNA sequences, generates
CC large quantities of gDNA probes, which enables greater efficiency for
CC printing in microarray formats, fabricates high-density DNA arrays of
CC enhanced, widely varying genetic content and abstains from using RNA-
CC derived sequences by simple PCR amplifications without cloning. The
CC method produces amplified sequences that have greater specificity and
CC size consistency than that observed with cDNA fragments, and allows for
CC greater signal sensitivity than oligonucleotides. The sequence presented
CC is a Type II gene specific primer
XX
SQ Sequence 20 BP; 6 A; 9 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1571 ATCCTTCTCCACCGCACA 1588
||||||||||||| | |
Db 3 ATCCTTCTCCACCAAAGA 20

RESULT 664
ACH66616/c
ID ACH66616 standard; DNA; 20 BP.
XX
AC ACH66616;
XX
DT 16-OCT-2003 (first entry)
XX
DE Antisense PCR primer used to amplify USP5.
XX
KW PCR; primer; ss; genomic DNA; gDNA; untranslated region; UTR;
KW DNA high-density microarray; biosite; large scale production; gDNA probe;
KW microarray; Type II primer.
XX
OS Homo sapiens.
XX
PN US2003073085-A1.
XX
PD 17-APR-2003.
XX
PF 05-OCT-2001; 2001US-00972469.
XX
PR 05-OCT-2001; 2001US-00972469.
XX
PA (LAIF/) LAI F.
PA (ZHOU/) ZHOU D.
XX
PI Lai F, Zhou D;
XX
DR WPI; 2003-555942/52.
XX
PT Amplifying expressed genetic sequences from genomic DNA of mammalian or
PT higher order plant species for printing on DNA microarrays, involves
PT using the 3' untranslated region of the gene sequence.
XX
PS Disclosure; Page 8; 15pp; English.
XX
CC The invention discloses a method for amplifying expressed genetic
CC sequences from genomic DNA (gDNA) from mammalian or higher order plant
CC species. The method involves identifying a 3' untranslated region (UTR)
CC of a gDNA sequence, designing probe, performing PCR, separating the
CC product by size differentiation and performing a second PCR to amplify
CC the predetermined sequence. Also claimed is a biological analysis device,
CC comprising a substrate and an array of a set of expressed genetic
CC sequences, located on the substrate, which are generated by the method
CC above and a DNA high-density microarray comprising a substrate upon which
CC are deposited an array of biosites of genomic DNA fragments having the
CC sequence of at least one exon, and absent polyadenine and vector
CC sequences, where the genomic DNA fragments have a sequence length of from
CC about 75-2000 nucleotides. The method is efficient for amplifying gene
CC sequences, enables large-scale production of gDNA sequences, generates
CC large quantities of gDNA probes, which enables greater efficiency for
CC printing in microarray formats, fabricates high-density DNA arrays of
CC enhanced, widely varying genetic content and abstains from using RNA-
CC derived sequences by simple PCR amplifications without cloning. The
CC method produces amplified sequences that have greater specificity and
CC size consistency than that observed with cDNA fragments, and allows for
CC greater signal sensitivity than oligonucleotides. The sequence presented
CC is a Type II gene specific primer
XX
SQ Sequence 20 BP; 7 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1793 TTTCCTTCTCTGAAAGTG 1810
| |||||||||| || ||
Db 20 TGTCCTTCTCTGGAAATG 3

RESULT 665
ADB98671
ID ADB98671 standard; DNA; 20 BP.
XX
AC ADB98671;
XX
DT 04-DEC-2003 (first entry)
XX
DE Sequence tagged site #552 used to prepare Zmax1 (LRP5) gene region map.
XX
KW Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW bone mass modulation; osteoporosis; STS; sequence tagged site; ds.
XX
OS Homo sapiens.
XX
PN WO200292000-A2.
XX
PD 21-NOV-2002.
XX
PF 13-MAY-2002; 2002WO-US014877.
XX
PR 11-MAY-2001; 2001US-0290071P.
PR 17-MAY-2001; 2001US-0291311P.
PR 01-FEB-2002; 2002US-0353058P.
PR 04-MAR-2002; 2002US-0361293P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (AMHP) WYETH.
XX
PI Allen K, Anisowicz A, Graham JR, Morales A, Yaworsky PJ, Liu W;
XX
DR WPI; 2003-129214/12.
XX
PT New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT diagnosing a HBM-like phenotype in a subject and for preparing a
PT composition for modulating bone mass and/or lipid levels in a subject
PT suffering from e.g. osteoporosis.
XX
PS Example 2; Page 65; 629pp; English.
XX
CC The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC level modulation. The invention is useful for diagnosing a HBM-like
CC phenotype in a subject and for preparing a composition for modulating
CC bone mass and/or lipid levels in a subject suffering from e.g.
CC osteoporosis. The present sequence is a Sequence Tagged Site (STS)
CC marker, which was used to prepare a physical map of the Zmax1 (LRP5) gene
CC region.
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTATC 2047
              ||||||| | ||||| ||
Db          2 GGAGGCACAAGTTCTTTC 19


RESULT 666
ADB32050/c
ID   ADB32050 standard; DNA; 20 BP.
XX
AC   ADB32050;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human FCTR5 cDNA reverse PCR primer.
XX
KW   Human; PCR; ss; FCTR5; colorectal cancer; adenomatous polyposis coli;
KW   myelogenous leukaemia; congenital neonatal autoimmune thrombocytopenia;
KW   ovarian cancer; brain tumour; breast cancer; glioma; astrocytoma;
KW   renal cell carcinoma; melanoma; clear cell carcinoma;
KW   granular cell carcinoma; neurological disorder;
KW   neurodegenerative disorder; nerve trauma;
KW   familial myelodysplastic syndrome; Charcot-Marie-Tooth neuropathy;
KW   Gardner syndrome; mental health condition; immunological disorder;
KW   allergy; asthma; lung disease; reproductive disorder; deafness;
KW   glycoprotein deficiency; desmoid tumour; turcot syndrome;
KW   liver cirrhosis; hepatitis C; gastric disorder; pancreatic disease;
KW   diabetes; schistosoma mansoni infection; spinocerebellar ataxia;
KW   plasmodium falciparum infection; Groenouw's corneal dystrophy;
KW   lattice corneal dystrophy; primer.
XX
OS   Homo sapiens.
XX
PN   US2003087816-A1.
XX
PD   08-MAY-2003.
XX
PF   05-MAR-2001; 2001US-00800198.
XX
PR   03-MAR-2000; 2000US-0186592P.
XX
PA   (VERM/) VERMET C.
PA   (FERN/) FERNANDES E.
PA   (SHIM/) SHIMKETS R.
PA   (HERR/) HERRMANN J.
PA   (MAJU/) MAJUMDER K.
PA   (MACD/) MACDOUGALL J.
PA   (MISH/) MISHRA V.
PA   (MEZE/) MEZES P S.
PA   (RAST/) RASTELLI L.
XX
PI   Vermet C,  Fernandes E,  Shimkets R,  Herrmann J,  Majumder K;
PI   Macdougall J,  Mishra V,  Mezes PS,  Rastelli L;
XX
DR   WPI; 2003-625633/59.
XX
PT   New FCTRX polypeptide and encoding polynucleotide, useful for preventing
PT   or treating FCTRX-related disorders, such as cancer, autoimmune,
PT   neurodegenerative, gastrointestinal, reproductive and inflammatory
PT   diseases.
XX
PS   Example 2; Page 146; 155pp; English.
XX
CC   The invention relates to FCTRX polypeptides and the polynucleotides
CC   encoding them. The sequences of the invention are useful for the
CC   manufacture of a medicament for diagnosing and treating disorders
CC   associated with the FCTRX polypeptide, such as colorectal cancer,
CC   adenomatous polyposis coli, myelogenous leukaemia, congenital neonatal
CC   autoimmune thrombocytopenia, malignant ovarian tumours, malignant brain
CC   tumours, mammary tumours, human gliomas, astrocytomas, renal cell
CC   carcinoma, breast adenocarcinoma, ovarian carcinoma, melanomas, clear
CC   cell and granular cell carcinomas, neurological disorders,
CC   neurodegenerative disorders, nerve trauma, familial myelodysplastic
CC   syndrome, Charcot-Marie-Tooth neuropathy, Gardner syndrome, mental health
CC   conditions, immunological disorders, allergy and infection, asthma, lung
CC   diseases, male and female reproductive disorders, deafness, glycoprotein
CC   deficiency, desmoid tumour, turcot syndrome, liver cirrhosis, hepatitis
CC   C, gastric disorders, pancreatic diseases, diabetes, schistosoma mansoni
CC   infection, spinocerebellar ataxia, plasmodium falciparum infection,
CC   Groenouw's corneal dystrophy and lattice corneal dystrophy. This sequence
CC   represents a PCR primer used to amplify cDNA encoding an FCTRX
CC   polypeptide of the invention.
XX
SQ   Sequence 20 BP; 2 A; 3 C; 9 G; 5 T; 0 U; 1 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   78.9%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACACTTAGCC 1873
              || ||||||  || |||||
Db         19 CANACCCACTGACGTAGCC 1

RESULT 667
ADC42479
ID   ADC42479 standard; DNA; 20 BP.
XX
AC   ADC42479;
XX
DT   18-DEC-2003  (first entry)
XX
DE   FANCD2 PCR primer MG779 SEQ ID NO:145.
XX
KW   cancer; Fanconi Anaemia; FA; BRCA; cytostatic; microarray;
KW   chemosensitising; ss; PCR; primer.
XX
OS   Synthetic.
XX
PN   WO2003039327-A2.
XX
PD   15-MAY-2003.
XX
PF   06-JUN-2002; 2002WO-US018153.
XX
PR   02-NOV-2001; 2001US-00998027.
PR   02-NOV-2001; 2001WO-US045561.
XX
PA   (DAND ) DANA FARBER CANCER INST.
PA   (UYOR-) UNIV OREGON HEALTH SCI.
XX
PI   D'andrea AD,  Taniguchi T,  Timmers C,  Grompe M,  Fox EA;
XX
DR   WPI; 2003-441436/41.
XX
PT   Diagnosing or determining cancer or increased risk of cancer in a
PT   patient, by testing Fanconi Anemia/BRCA pathway gene or protein for a
PT   cancer-associated defect, that indicates cancer or increased risk of
PT   cancer.
XX
PS   Claim 11; SEQ ID NO 145; 160pp; English.
XX
CC   The invention relates to a novel method of diagnosing or determining if a
CC   patient has cancer or is at increased risk of cancer, involving testing a
CC   Fanconi Anaemia (FA)/BRCA pathway gene or protein for the presence of a
CC   cancer-associated defect, where the presence of one or more cancer-
CC   associated defects is indicative of cancer or an increased risk of cancer
CC   in the patient. The method of the invention has cytostatic activity. The
CC   method is useful for determining if a patient has cancer, or is at
CC   increased risk of developing cancer, e.g. breast, ovarian or prostate
CC   cancer. A microarray of the invention is useful for determining if a
CC   patient has cancer, or is at increased risk of developing cancer, by
```

CC hybridising a nucleic acid sample to the nucleic acid sequences from the
CC array, and detecting the presence of mutations in FA/BRCA pathway genes
CC in the nucleic acid sample from the patient, where detecting the presence
CC of mutations is indicative of a patient who has cancer, or is at
CC increased risk of developing cancer. A method of the invention is useful
CC for screening a chemosensitising agent, and the agent obtained is useful
CC for treating a patient having a cancer. The present sequence is used in
CC the exemplification of the invention.
XX
SQ Sequence 20 BP; 2 A; 6 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1917 ATACCTTTTTTTCAGTG 1934
||||||| |||| | |||
Db 2 ATACCTTCTTTTGCTGTG 19

RESULT 668
ADD20028
ID ADD20028 standard; DNA; 20 BP.
XX
AC ADD20028;
XX
DT 15-JAN-2004 (first entry)
XX
DE Oreochromis niloticus microsatellite primer SEQ ID NO:663.
XX
KW single nucleotide polymorphism; SNP; fish; Salmo salar;
KW Orechromis niloticus; Atlantic halibut; microsatellite; cod;
KW polymorphic site; seabass; salmonidae; Tilapia; rainbow trout; halibut;
KW detection; primer; ss.
XX
OS Synthetic.
OS Oreochromis niloticus.
XX
PN WO2003060160-A2.
XX
PD 24-JUL-2003.
XX
PF 17-JAN-2003; 2003WO-IB000112.
XX
PR 18-JAN-2002; 2002US-0349950P.
PR 16-AUG-2002; 2002US-0404200P.
XX
PA (GENO-) GENOMAR ASA.
XX
PI Lie O, Slettan A, Hoyum M, Lingaas F;
XX
DR WPI; 2003-627388/59.
XX
PT Novel isolated nucleic acid molecule comprising single nucleotide
PT polymorphism associated with fish, useful for forming PCR primers which
PT are used for detecting single nucleotide polymorphisms in fish nucleic
PT acids.
XX
PS Claim 18; SEQ ID NO 663; 233pp; English.
XX
CC The present invention describes an isolated nucleic acid (I) comprising a
CC single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of
CC Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs;
CC and (ii) a nucleic acid having nucleotide sequence that hybridises to
CC (i), or its complement under highly stringent hybridisation conditions.
CC Also described: (1) an isolated oligonucleotide (II) comprising at least
CC 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O.
CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
CC polymorphic sites and seabass polymorphic sites, or their complement; (2)
CC a primer pair (III) suitable for use in PCR, comprising two (II) capable
CC of amplifying a nucleotide sequence chosen from S. salar SNPs and, O.
CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
CC polymorphic sites and seabass polymorphic sites; and determining (M1) the
CC origin of fish sample comprising providing a parentage genotype database
CC comprising a collection of candidate parent genotypes, where each of the
CC candidate parent genotype represents a distinct origin, and comparing a
CC sample genotype to the parentage genotype database, where a match between
CC the sample genotype and one of the candidate parent genotype identifies
CC to the origin of the sample. (M1) is useful for determining the origin of
CC a fish sample such as family salmonidae, S. salar, Tilapia, O. niloticus,
CC rainbow trout, halibut, seabass and Atlantic cod. (II) is useful for
CC detecting nucleic acid molecule comprising SNP in a sample, which
CC involves contacting the sample containing nucleic acids with one or more
CC (II) derived from nucleotide sequence of S. salar SNPs and O. niloticus
CC SNPs, and identifying nucleic acid that hybridises to (II). (II) is
CC useful for detecting nucleic acid molecule comprising a polymorphic
CC sequence in a sample, comprising contacting the sample containing nucleic
CC acids with one or more (II) which is derived from O. niloticus
CC microsatellite, O. niloticus SNPs, Atlantic halibut SNPs, cod polymorphic
CC sites or seabass polymorphic sites, and identifying a nucleic acid that
CC hybridises to (II). (III) is useful for detecting nucleic acid molecule
CC comprising a microsatellite sequence in sample. The present sequence is
CC used in the exemplification of the present invention.
XX
SQ Sequence 20 BP; 0 A; 9 C; 1 G; 10 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1786 CCCATTCTTTCCTTCTCT 1803
| | ||||| ||||||||
Db 3 CGCCTTCTTCCCTTCTCT 20

RESULT 669
AAD61440
ID AAD61440 standard; DNA; 20 BP.
XX
AC AAD61440;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human TANGO cDNA related PCR primer #4.
XX
KW Human; TANGO; kidney failure; hyperplasia; inflammatory disorder; cancer;
KW angiogenesis; haematopoietic disorder; pancreatic disorder; hypertension;
KW heart disorder; hepatic disorder; diabetes mellitus; placental disorder;
KW cerebrovascular disease; Goodpasture's syndrome; cardiovascular disorder;
KW foetal spleen associated disease; reproductive disorder; atherosclerosis;
KW glomerular disease; intestinal disorder; proliferative disorder; tumour;
KW ovulation disorder; testicular disorder; lung disorder; Crohn's disease;
KW prostate disorder; Whipple's disease; haemophilia; anaemia; thalassaemia;
KW gene therapy; tranquillizer; vulnerary; vasotropic; psoriasis; leukaemia;
KW jaundice; immunosuppressive; abortion; ischaemia; arthritis; allergy;
KW asthma; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US2003104447-A1.
XX
PD 05-JUN-2003.
XX
PF 11-OCT-2002; 2002US-00269353.
XX
PR 23-APR-1998; 98US-00065661.
PR 23-APR-1999; 99US-00298531.
PR 21-FEB-2001; 2001US-00790264.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Holtzman DA, Goodearl ADJ, Mccarthy SA;
XX
DR WPI; 2003-787050/74.
XX
PT New TANGO polypeptides useful as modulating agents in regulating cellular

```
PT   processes and for diagnosing, treating heart, liver, lung, kidney,
PT   inflammatory and cellular proliferative disorders.
XX
PS   Disclosure; Page 65; 0pp; English.
XX
CC   The invention relates to an isolated polypeptide termed human T139 (TANGO
CC   -139), T125, T110, murine T175, human T175 or murine WDNM-2. T139 is
CC   useful for treating kidney defects such as kidney failure or hyperplasia,
CC   T125 is useful for treating wound healing and cancer, T110 is useful for
CC   treating neoplasia, inappropriate angiogenesis or tissue regeneration and
CC   T177 or WDNM-2 is useful for treating cancer, inflammatory disorders and
CC   haematopoietic disorders. T125 and 110 are useful to treat pancreatic
CC   disorders such as pancreatitis, diabetes mellitus, and Zollinger-Ellison
CC   syndrome, placental disorders such as placentitis or abortion and
CC   disorders of the brain such as cerebral edema, cerebrovascular disease
CC   and tumours and injury or trauma to the brain. T125, 110, 175 molecules
CC   treat heart disorders e.g., ischaemic heart disease, atherosclerosis,
CC   hypertension, angina pectoris, pulmonary (lung) disorders such as
CC   rheumatoid lung disease, bronchial asthma and Goodpasture's syndrome,
CC   disorders of skeletal muscle such as muscular dystrophy, motor neuron
CC   disease e.g., amyotrophic lateral sclerosis, cardiovascular disorders
CC   such as rheumatic heart disease or myocardial disease, hepatic disorder
CC   including jaundice, hepatic failure, Crigler-Naijar syndromes or
CC   malignant tumours. T139, 125, 110 and 175 molecules are useful to treat
CC   renal (kidney) disorders such as glomerular disease (e.g., acute and
CC   chronic glomerulonephritis) and reproductive disorders including
CC   ovulation disorder, disorders due to infections and ovarian disorders.
CC   T139, 125 and 175 are useful to treat testicular disorders and sperm cell
CC   disorders. T175 is useful to treat uterine disorders, hyperplasia of the
CC   endometrium, uterine cancer, bone marrow, blood and haematopoietic
CC   associated diseases and disorders, e.g., acute myeloid leukaemia,
CC   haemophilia, anaemia and thalassaemia. T-110 is useful to treat spleen
CC   e.g., the foetal spleen associated diseases and disorder e.g., splenic
CC   lymphoma and/or splenomegaly. T125 treats prostate disorders such as
CC   inflammatory diseases, ovarian disorders such as ovarian endometriosis,
CC   non-neoplastic cysts and tumours, intestinal disorders such as infective
CC   enterocolitis, Crohn's disease and Whipple's disease, colonic disorders
CC   such as congenital anomalies and tumours. T139, 125, 110, 175 or WDNM-2
CC   are useful for treating proliferative disorders, inflammatory disorders
CC   e.g., bacterial infection, psoriasis, e.g., ulcerative colitis, arthritis
CC   and allergic inflammatory disorders (e.g., asthma, psoriasis). The
CC   invention is useful in gene therapy. The present sequence is human TANGO
CC   cDNA related PCR primer
XX
SQ   Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCCTGGG 1613
              | |||||| ||||||| |
Db          1 AGCCCCTCATGGCCTGTG 18


RESULT 670
AAD61209
ID   AAD61209 standard; DNA; 20 BP.
XX
AC   AAD61209;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Human Ship-1 antisense oligonucleotide ISIS #168290.
XX
KW   Human; Ship-1; SH2-containing phosphatidylinositol phosphatase-1; INPP5D;
KW   insensitivity to apoptotic signal; developmental disorder; inflammation;
KW   immunosuppressive; autoimmune disorder; antisense therapy; antisense;
KW   phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone; All cytidines are 5-
FT                    methyl cytidines"
FT   modified_base    1. .5
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "2'-O-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'-O-methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2003114401-A1.
XX
PD   19-JUN-2003.
XX
PF   06-DEC-2001; 2001US-00003919.
XX
PR   06-DEC-2001; 2001US-00003919.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Freier SM;
XX
DR   WPI; 2003-801302/75.
XX
PT   Antisense compounds targeted to nucleic acid molecule encoding Ship-1,
PT   useful for treating diseases associated with expression of Ship-1, such
PT   as autoimmune and developmental disorders.
XX
PS   Claim 3; Page 25; 0pp; English.
XX
CC   The present invention provides antisense compounds targetted to nucleic
CC   acid molecule encoding Ship-1 (also known as SH2-containing
CC   phosphatidylinositol phosphatase-1 and INPP5D) to modulate/inhibit the
CC   expression of Ship-1. The invention is useful in treatment of diseases
CC   such as insensitivity to apoptotic signals, autoimmune disorders,
CC   developmental disorders and inflammatory disorders. The present sequence
CC   is human Ship-1 antisense oligonucleotide
XX
SQ   Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1670 CCGCCCCTGGACTTCTTA 1687
              || || ||||||||||||
Db          2 CCATCCTTGGACTTCTTA 19


RESULT 671
AAD61230/c
ID   AAD61230 standard; DNA; 20 BP.
XX
AC   AAD61230;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Human Ship-1 antisense oligonucleotide ISIS #168311.
XX
KW   Human; Ship-1; SH2-containing phosphatidylinositol phosphatase-1; INPP5D;
KW   insensitivity to apoptotic signal; developmental disorder; inflammation;
KW   immunosuppressive; autoimmune disorder; antisense therapy; antisense;
KW   phosphorothioate backbone; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
```

```
FT   modified_base   1. .20
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone; All cytidines are 5-
FT                   methyl cytidines"
FT   modified_base   1. .5
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2003114401-A1.
XX
PD   19-JUN-2003.
XX
PF   06-DEC-2001; 2001US-00003919.
XX
PR   06-DEC-2001; 2001US-00003919.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Freier SM;
XX
DR   WPI; 2003-801302/75.
XX
PT   Antisense compounds targeted to nucleic acid molecule encoding Ship-1,
PT   useful for treating diseases associated with expression of Ship-1, such
PT   as autoimmune and developmental disorders.
XX
PS   Claim 3; Page 25; 0pp; English.
XX
CC   The present invention provides antisense compounds targetted to nucleic
CC   acid molecule encoding Ship-1 (also known as SH2-containing
CC   phosphatidylinositol phosphatase-1 and INPP5D) to modulate/inhibit the
CC   expression of Ship-1. The invention is useful in treatment of diseases
CC   such as insensitivity to apoptotic signals, autoimmune disorders,
CC   developmental disorders and inflammatory disorders. The present sequence
CC   is human Ship-1 antisense oligonucleotide
XX
SQ   Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTGGTAG 2030
              || | |||||||||| ||
Db         20 GACCGAGTCCTCTGGAAG 3


RESULT 672
ABZ86926/c
ID   ABZ86926 standard; DNA; 20 BP.
XX
AC   ABZ86926;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Claim 15; SEQ ID NO 2168; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1583 CGCACAGACTGGGAACCC 1600
              ||| || |||||| ||||
Db         19 CGCTCAAACTGGGGACCC 2


RESULT 673
ABZ99348
ID   ABZ99348 standard; DNA; 20 BP.
XX
AC   ABZ99348;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human PDE4C oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
```

```
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 14590; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAGAGTT 1622
              |||||| |||  ||||||
Db          2 TGGCCTTGGGCGAGAGTT 19


RESULT 674
ABZ93531
ID   ABZ93531 standard; DNA; 20 BP.
XX
AC   ABZ93531;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
```

```
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 8773; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATCA 1913
              ||||  || |||||||||
Db          1 CCCTGAATTAACAGATCA 18


RESULT 675
ABZ86346
ID   ABZ86346 standard; DNA; 20 BP.
XX
AC   ABZ86346;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
```

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 1588; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1994 TGTATCTAGCTTCTTCAG 2011
||||||| ||||||| ||
Db 3 TGTATCCAGCTTCTGAAG 20

RESULT 676
ABZ87246
ID ABZ87246 standard; DNA; 20 BP.
XX
AC ABZ87246;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 2488; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1679 GACTTCTTAGTTGTTTCT 1696
||| ||| ||||| ||||
Db 2 GACCTCTGAGTTGCTTCT 19

RESULT 677
ABZ86049
ID ABZ86049 standard; DNA; 20 BP.
XX
AC ABZ86049;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 1291; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1602 TCCTGGCCTGGGGGAAGA 1619
||||||| || | |||||
Db 1 TCCTGGCTTGAGTGAAGA 18

RESULT 678
ABZ99307/c
ID ABZ99307 standard; DNA; 20 BP.
XX
AC ABZ99307;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human PDE4C oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 14549; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1843 TCCCTGGGCCAACAGACC 1860
| ||||| ||| ||||||
Db 19 TTCCTGGACCAGCAGACC 2

RESULT 679
ABZ90050/c
ID ABZ90050 standard; DNA; 20 BP.
XX
AC ABZ90050;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 5292; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1589 GACTGGGAACCCCTCCTG 1606
| | |||||||| |||||
Db 18 GTCAGGGAACCCTTCCTG 1

RESULT 680
ABZ93124/c
ID ABZ93124 standard; DNA; 20 BP.
XX
AC ABZ93124;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 8366; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1666 TCACCCGCCCCTGGACTT 1683
| || ||||||||||||
Db 18 TGACAGGCCCCTGGACTT 1

RESULT 681
ABZ85806
ID ABZ85806 standard; DNA; 20 BP.
XX
AC ABZ85806;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 1048; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 2 C; 3 G; 13 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1766 TAAGCTTTTTTTTTTGA 1783
| |||||||| ||||| |
Db 3 TTAGCTTTTTGTTTTTCA 20

RESULT 682
ABZ92234/c
ID ABZ92234 standard; DNA; 20 BP.
XX
AC ABZ92234;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 7476; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 9 A; 2 C; 2 G; 6 T; 0 U; 1 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1744 CAAGTACTGGCTCTTTATT 1762
||| || || ||||||||
Db 20 CAANTATAGGATCTTTATT 2

RESULT 683
ABZ92608/c
ID ABZ92608 standard; DNA; 20 BP.
XX
AC ABZ92608;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 7850; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 6 C; 10 G; 1 T; 0 U; 1 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1661 CTGCATCACCCGCCCCTGG 1679
||||| | | ||||||||
Db 19 CTGCANCCGCGGCCCCTGG 1

RESULT 684
ABZ76978/c
ID ABZ76978 standard; DNA; 20 BP.
XX
AC ABZ76978;
XX
DT 07-MAY-2003 (first entry)
XX
DE Bovine DGAT PCR primer #14.
XX
KW Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14; bovine;
KW milk; meat marbling; low fat; polymorphic; SNP;
KW single nucleotide polymorphism; PCR primer; ss.
XX
OS Bos taurus.
OS Synthetic.
XX
PN WO2003004630-A2.
XX
PD 16-JAN-2003.
XX
PF 05-JUL-2002; 2002WO-EP007520.
XX
PR 06-JUL-2001; 2001EP-00116412.
PR 13-MAY-2002; 2002US-0379412P.
XX
PA (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
XX
PI Fries H, Winter A;
XX
DR WPI; 2003-239205/23.
XX
PT New nucleic acid molecule comprising a sequence of an allele of a
PT polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
PT testing a mammal for its predisposition for fat content of milk and for
PT meat marbling.
XX
PS Example 1; Page 36; 91pp; English.
XX
CC The present invention describes a nucleic acid molecule (NA) (I) encoding
CC a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
CC indicative for low fat content of milk and to low meat marbling
CC (intramuscular fat content). Human DGAT is located to chromosome 8, and
CC bovine DGAT is located to chromosome 14. (I) is useful for testing a
CC mammal for its predisposition for fat content of milk and/or its
CC predisposition for meat marbling. The method comprises analysing the gene
CC encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
CC polymorphisms (SNPs)) which are connected with the predisposition. The
CC nucleotide polymorphisms are located in the coding region of the DGAT
CC gene and result in substitution, deletion and/or addition of an amino
CC acid sequence of the polypeptide which is encoded by the gene. The
CC nucleic acid molecule has at the position 10433 and 10434 of the DGAT
CC gene a guanine and a cytosine residue, at position 3343 a cytosine or
CC guanine, 11030 a guanine, 11048 a cytosine or thymine and 11093 a
CC thymine, which correlate with a predisposition for low fat content of
CC milk and low meat marbling. The nucleic acid molecule has at the position
CC corresponding to position 10433 and 10434 of the DGAT gene two adenine
CC residues which correlate with a predisposition for high content of milk
CC and high meat marbling. The nucleotide polymorphisms are located in a
CC region which is responsible for the regulation of the expression of the
CC product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
CC ABP96046 represent sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2007 TTCAGAGATCAAGTCCTC 2024
|| |||||||| | ||||
Db 19 TTGAGAGATCAGGGCCTC 2

RESULT 685
ABD22576
ID ABD22576 standard; DNA; 20 BP.
XX
AC ABD22576;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human cathepsin C-derived oligo SEQ ID 1588.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 1588; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1994 TGTATCTAGCTTCTTCAG 2011
|||||| ||||||| ||
Db 3 TGTATCCAGCTTCTGAAG 20

RESULT 686
ABD32338/c
ID ABD32338 standard; DNA; 20 BP.
XX
AC ABD32338;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human PDE4C-derived oligonucleotide SEQ ID 14549.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 14549; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1843 TCCCTGGGCCAACAGACC 1860
                 |||||| ||| ||||||
Db         19 TTCCTGGACCAGCAGACC 2
```

RESULT 687
ABD22036
ID ABD22036 standard; DNA; 20 BP.
XX
AC ABD22036;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human stanniocalcin-derived oligo SEQ ID 1048.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 1048; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 2 A; 2 C; 3 G; 13 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1766 TAAGCTTTTTTTTTTGA 1783
                 |||||||| ||||| |
Db          3 TTAGCTTTTGTTTTTCA 20
```

RESULT 688
ABD23156/c
ID ABD23156 standard; DNA; 20 BP.
XX
AC ABD23156;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human myosin X-derived oligonucleotide SEQ ID 2168.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 2168; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,

```
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1583 CGCACAGACTGGGAACCC 1600
              ||| || |||||| ||||
Db         19 CGCTCAAACTGGGGACCC 2


RESULT 689
ABD23476
ID   ABD23476 standard; DNA; 20 BP.
XX
AC   ABD23476;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human myosin X-derived oligonucleotide SEQ ID 2488.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 2488; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1679 GACTTCTTAGTTGTTTCT 1696
              ||| ||| ||||| ||||
Db          2 GACCTCTGAGTTGCTTCT 19


RESULT 690
ABD28838/c
ID   ABD28838 standard; DNA; 20 BP.
XX
AC   ABD28838;
XX
DT   29-JUL-2004  (first entry)
XX
DE   W81570-derived oligonucleotide SEQ ID 7850.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
```

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 7850; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 2 A; 6 C; 10 G; 1 T; 0 U; 1 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1661 CTGCATCACCCGCCCCTGG 1679
||||| | | ||||||||
Db 19 CTGCANCCGCGGCCCCTGG 1

RESULT 691
ABD29354/c
ID ABD29354 standard; DNA; 20 BP.
XX
AC ABD29354;
XX
DT 29-JUL-2004 (first entry)
XX
DE AA001432-derived oligonucleotide SEQ ID 8366.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 8366; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1666 TCACCCGCCCCTGGACTT 1683
| || ||||||||||||
Db 18 TGACAGGCCCCTGGACTT 1

RESULT 692
ABD28464/c
ID ABD28464 standard; DNA; 20 BP.
XX
AC ABD28464;
XX
DT 29-JUL-2004 (first entry)

XX
DE R33851-derived oligonucleotide SEQ ID 7476.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 7476; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 9 A; 2 C; 2 G; 6 T; 0 U; 1 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 78.9%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1744 CAAGTACTGGCTCTTTATT 1762
||| || || ||||||||
Db 20 CAANTATAGGATCTTTATT 2

RESULT 693
ABD26280/c
ID ABD26280 standard; DNA; 20 BP.
XX
AC ABD26280;
XX
DT 29-JUL-2004 (first entry)
XX
DE AA425700-derived oligonucleotide SEQ ID 5292.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 5292; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1589 GACTGGGAACCCCTCCTG 1606
| | |||||||| |||||
Db 18 GTCAGGGAACCCTTCCTG 1

RESULT 694
ABD22279
ID ABD22279 standard; DNA; 20 BP.
XX
AC ABD22279;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human stanniocalcin-derived oligo SEQ ID 1291.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 1291; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1602 TCCTGGCCTGGGGGAAGA 1619
||||||| || | |||||
Db 1 TCCTGGCTTGAGTGAAGA 18

RESULT 695
ABD29761
ID ABD29761 standard; DNA; 20 BP.
XX
AC ABD29761;
XX
DT 29-JUL-2004 (first entry)
XX
DE R37953-derived oligonucleotide SEQ ID 8773.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 8773; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,

```
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 8 A; 5 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATCA 1913
              ||||  || |||||||||
Db          1 CCCTGAATTAACAGATCA 18


RESULT 696
ABD32379
ID   ABD32379 standard; DNA; 20 BP.
XX
AC   ABD32379;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human PDE4C-derived oligonucleotide SEQ ID 14590.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 14590; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAGAGTT 1622
              |||||| |||  ||||||
Db          2 TGGCCTTGGGCGAGAGTT 19


RESULT 697
ADO84933
ID   ADO84933 standard; DNA; 20 BP.
XX
AC   ADO84933;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human BRCA 1 and BRCA 2 mutation-related oligonucleotide probe SeqID38.
XX
KW   mutation; BRCA 1; BRCA 2; diagnosis; breast cancer; ovarian cancer;
KW   detection; predisposition; susceptibility; cancer; probe; ss; human.
XX
OS   Homo sapiens.
XX
PN   KR2003017894-A.
XX
PD   04-MAR-2003.
XX
PF   25-AUG-2001; 2001KR-00051510.
```

```
XX
PR   25-AUG-2001; 2001KR-00051510.
XX
PA   (MYDN-) MYDNA CO LTD.
XX
PI   Cho DY,  Cho HM,  Kang CS,  Kim JG,  Oh BG,  Song GH,  Yoon GS;
XX
DR   WPI; 2003-501054/47.
XX
PT   Mutations of BRCA 1 and BRCA 2 useful for diagnosis of breast and ovarian
PT   cancers, and detection method of predisposition and susceptibility of the
PT   cancers using the same.
XX
PS   Claim 4; SEQ ID NO 38; 1pp; Korean.
XX
CC   This invention relates to novel mutations of BRCA 1 and BRCA 2 genes
CC   useful for the diagnosis of breast and ovarian cancers. In addition, the
CC   invention also relates to a detection method of predisposition and
CC   susceptibility of the cancers using the same. The present sequence is
CC   that of an oligonucleotide probe which may be used for detection of the
CC   human BRCA mutations of the invention.
XX
SQ   Sequence 20 BP; 8 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1804 GAAAGTGGTGCTATAAGT 1821
              |||| || ||||||| ||
Db          3 GAAAATGCTGCTATACGT 20


RESULT 698
ADH47972
ID   ADH47972 standard; DNA; 20 BP.
XX
AC   ADH47972;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Protein kinase C delta antisense oligonucleotide seq id 65.
XX
KW   cytostatic; protein-kinase-inhibitor-C-alpha; gene therapy; carboplatin;
KW   paclitaxel; docetaxel; cisplatin; gemcitabine; 5-fluorouracil;
KW   leucovorin; protein kinase C alpha inhibitor; PKC-alpha inhibitor;
KW   cancer; non-small cell lung cancer; non-Hodgkin's lymphoma;
KW   antisense technology; ss; PKC-delta.
XX
OS   Synthetic.
XX
PN   US2003148989-A1.
XX
PD   07-AUG-2003.
XX
PF   21-JAN-2003; 2003US-00348485.
XX
PR   16-MAR-1992;   92US-00852852.
PR   09-JUL-1993;   93US-00089996.
PR   07-JUN-1995;   95US-00478178.
PR   31-MAR-1997;   97US-00829637.
PR   18-DEC-2001; 2001US-00025139.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Dean NM,  Holmlund JT,  Dorr FA;
XX
DR   WPI; 2004-106519/11.
XX
PT   New pharmaceutical compositions comprising oligonucleotide in combination
PT   with e.g. arboplatin or cisplatin, useful for inhibiting protein kinase C
PT   expression, particularly for treating cancer, e.g. non-Hodgkin's
PT   lymphoma.
XX
PS   Example 15; SEQ ID NO 65; 52pp; English.
XX
CC   The invention describes new pharmaceutical compositions comprising an
CC   oligonucleotide up to 50 nucleotide units in length of a sequence having
CC   20 bp (dna1), in combination with any of the following: carboplatin and
CC   paclitaxel; docetaxel; cisplatin and gemcitabine; or 5-fluorouracil and
CC   leucovorin. Also described are: a method of inhibiting protein kinase C
CC   (PKC)-alpha expression in human cells by contacting the cells with any of
CC   the pharmaceutical compositions; and methods of treating a condition
CC   associated with expression of human PKC-alpha by administering to an
CC   animal, or its cells, tissues or bodily fluid any of the pharmaceutical
CC   compositions. The compositions are useful for inhibiting PKC-alpha
CC   expression in human cells. The compositions are useful for treating a
CC   condition associated with the expression of human PKC-alpha, particularly
CC   cancer. In particular, the compositions are useful for treating non-small
CC   cell lung cancer or non-Hodgkin's lymphoma in a human. This sequence
CC   represents a human protein kinase C antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 699
ADH44450
ID   ADH44450 standard; DNA; 20 BP.
XX
AC   ADH44450;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Rb2/p130 DNA target sequence #14.
XX
KW   Antisense therapy; human; Rb2/p130; hyperproliferative disorder;
KW   breast cancer; ovarian cancer; hepatocellular cancer; prostate cancer;
KW   developmental disorder; aberrant apoptosis; cytostatic; antiinflammatory;
KW   antimicrobial; ds.
XX
OS   Homo sapiens.
XX
PN   US2003225015-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00161983.
XX
PR   31-MAY-2002; 2002US-00161983.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Ward DT,  Freier SM;
XX
DR   WPI; 2004-042170/04.
XX
PT   New antisense oligonucleotides inhibiting the expression of Rb2/p130,
PT   useful for preventing or treating diseases associated with Rb2/p130, such
PT   as developmental or hyperproliferative disorders, infection or
PT   inflammation.
XX
PS   Example 15; SEQ ID NO 61; 47pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding Rb2/p130. The antisense compound comprises an
CC   antisense oligonucleotide that specifically hybridises with the nucleic
CC   acid and inhibits the expression of Rb2/p130. The antisense
CC   oligonucleotide is a chimeric oligonucleotide. The antisense
```

```
CC   oligonucleotide comprises at least one modified internucleoside linkage,
CC   preferably a phosphorothioate linkage. It also comprises at least one
CC   modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar
CC   moiety. The antisense oligonucleotide further comprises at least one
CC   modified nucleobase, preferably a 5-methylcytosine. The antisense
CC   oligonucleotides are useful for the treatment of diseases such as
CC   hyperproliferative disorders, preferably cancer (particularly breast
CC   cancer, ovarian cancer, hepatocellular cancer or prostate cancer),
CC   developmental disorders, and disorders associated with aberrant
CC   apoptosis. The present sequence represents a human Rb2/p130 DNA target
CC   sequence for an antisense oligonucleotide.
XX
SQ   Sequence 20 BP; 8 A; 1 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTC 1844
              ||| ||| ||||| ||||
Db          3 AATGTTTGAAATATATTC 20


RESULT 700
ADH44418/c
ID   ADH44418 standard; DNA; 20 BP.
XX
AC   ADH44418;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human Rb2/p130 DNA, antisense oligonucleotide #19.
XX
KW   Antisense therapy; human; Rb2/p130; hyperproliferative disorder;
KW   breast cancer; ovarian cancer; hepatocellular cancer; prostate cancer;
KW   developmental disorder; aberrant apoptosis; cytostatic; antiinflammatory;
KW   antimicrobial; phosphorothioate; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "This oligonucleotide has a phosphorothioate
FT                    backbone and 2'-methyoxyethyl (2'-MOE) wings at the 5'
FT                    and 3' ends, which are 5 nucleotides in length at each
FT                    end. All cytidine residues are 5-methylcytidines"
XX
PN   US2003225015-A1.
XX
PD   04-DEC-2003.
XX
PF   31-MAY-2002; 2002US-00161983.
XX
PR   31-MAY-2002; 2002US-00161983.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Ward DT,  Freier SM;
XX
DR   WPI; 2004-042170/04.
XX
PT   New antisense oligonucleotides inhibiting the expression of Rb2/p130,
PT   useful for preventing or treating diseases associated with Rb2/p130, such
PT   as developmental or hyperproliferative disorders, infection or
PT   inflammation.
XX
PS   Example 15; SEQ ID NO 29; 47pp; English.
XX
CC   The present invention relates to antisense compounds targeted to a
CC   nucleic acid encoding Rb2/p130. The antisense compound comprises an
CC   antisense oligonucleotide that specifically hybridises with the nucleic
CC   acid and inhibits the expression of Rb2/p130. The antisense
CC   oligonucleotide is a chimeric oligonucleotide. The antisense
CC   oligonucleotide comprises at least one modified internucleoside linkage,
CC   preferably a phosphorothioate linkage. It also comprises at least one
CC   modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar
CC   moiety. The antisense oligonucleotide further comprises at least one
CC   modified nucleobase, preferably a 5-methylcytosine. The antisense
CC   oligonucleotides are useful for the treatment of diseases such as
CC   hyperproliferative disorders, preferably cancer (particularly breast
CC   cancer, ovarian cancer, hepatocellular cancer or prostate cancer),
CC   developmental disorders, and disorders associated with aberrant
CC   apoptosis. The present sequence represents an antisense oligonucleotide
CC   used in the examples of the present invention.
XX
SQ   Sequence 20 BP; 8 A; 3 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTC 1844
              ||| ||| ||||| ||||
Db         18 AATGTTTGAAATATATTC 1


RESULT 701
ADH63855
ID   ADH63855 standard; DNA; 20 BP.
XX
AC   ADH63855;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #689.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 689; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 1 A; 2 C; 7 G; 10 T; 0 U; 0 Other;
```

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1947 TTGGTTTTTGTGTCCGCT 1964
              |||| ||| ||||||| |
Db          3 TTGGGTTTAGTGTCCGGT 20


RESULT 702
ADH64498
ID   ADH64498 standard; DNA; 20 BP.
XX
AC   ADH64498;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #1332.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 1332; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1950 GTTTTTGTGTCCGCTAAA 1967
              | ||| ||||||| ||||
Db          1 GGTTTAGTGTCCGGTAAA 18


RESULT 703
ADH66033
ID   ADH66033 standard; DNA; 20 BP.
XX
AC   ADH66033;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #2867.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 2867; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 7 A; 2 C; 0 G; 11 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAAT 1838
              ||||| |||| ||| |||
Db          3 TTTTACAATCATTTTAAT 20


RESULT 704
ADH63700/c
ID   ADH63700 standard; DNA; 20 BP.
XX
AC   ADH63700;
XX
DT   25-MAR-2004  (first entry)
XX
DE   Human glucocorticoid receptor-specific antisense oligonucleotide #534.
XX
KW   antisense oligonucleotide; glucocorticoid receptor; infection;
KW   inflammation; tumour formation; diabetes; obesity;
KW   cardiovascular disorder; hyperlipidaemia; Cushing's syndrome; human; ss;
KW   phosphorothioate backbone; 2'-methoxyethyl; 2'-MOE.
XX
OS   Homo sapiens.
XX
PN   WO2003099215-A2.
XX
PD   04-DEC-2003.
```

```
XX
PF   20-MAY-2003; 2003WO-US016084.
XX
PR   20-MAY-2002; 2002US-0381857P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Crosby SD,  Nalseth AE;
XX
DR   WPI; 2004-035034/03.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   mammalian glucocorticoid receptor, useful for treating diabetes, obesity,
PT   cardiovascular disorder, hyperlipidemia or Cushing's syndrome.
XX
PS   Claim 4; SEQ ID NO 534; 985pp; English.
XX
CC   The invention comprises an antisense oligonucleotides that are targeted
CC   to nucleic acids encoding a mammalian glucocorticoid receptor. The
CC   antisense oligonucleotides of the invention are useful for preventing or
CC   delaying infection, inflammation or tumour formation. The antisense
CC   oligonucleotides are also useful for treating diabetes, obesity,
CC   cardiovascular disorders, hyperlipidaemia or Cushing's syndrome. The
CC   present DNA sequence represents an antisense oligonucleotide that targets
CC   the human glucocorticoid receptor gene. NOTE: The present sequence
CC   contains 2'-methoxyethyl (2'-MOE) wings and a phosphorothioate backbone.
XX
SQ   Sequence 20 BP; 10 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1994 TGTATCTAGCTTCTTCAG 2011
              ||||| || || ||||||
Db         19 TGTATATATCTGCTTCAG 2

RESULT 705
ADI80100/c
ID   ADI80100 standard; DNA; 20 BP.
XX
AC   ADI80100;
XX
DT   22-APR-2004  (first entry)
XX
DE   Mouse transforming growth factor-beta 2 antisense oligo, SEQ ID No 101.
XX
KW   antisense; transforming growth factor; TGF; beta 2; TGF-beta 2;
KW   cytostatic; nootropic; neuroprotective; immunosuppressive;
KW   hyperproliferative disorder; cancer; neurodegenerative; hyperactivation;
KW   immune; ss; mouse; murine.
XX
OS   Mus musculus.
XX
PN   US2004006030-A1.
XX
PD   08-JAN-2004.
XX
PF   02-JUL-2002; 2002US-00189267.
XX
PR   02-JUL-2002; 2002US-00189267.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Freier SM,  Dobie KW;
XX
DR   WPI; 2004-081742/08.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding TGF-beta 2, useful for treating cancer, a
PT   neurodegenerative disorder, or a disease involving hyperactivation of
PT   immune response.
XX
PS   Example 16; SEQ ID NO 101; 135pp; English.
XX
CC   The invention relates to a novel antisense compound of 8-80 nucleobases
CC   in length targeted to, and which specifically hybridizes with, a nucleic
CC   acid molecule encoding transforming growth factor (TGF)-beta 2, and
CC   inhibits the expression of TGF-beta 2. The invention further relates to:
CC   a compound 8-80 nucleobases in length that specifically hybridizes with
CC   at least an 8-nucleobase portion of an active site on a nucleic acid
CC   molecule encoding TGF-beta 2; a composition comprising the compound and a
CC   carrier or diluent; inhibiting the expression of TGF-beta 2 in cells or
CC   tissues by contacting the cells or tissues with the compound so that
CC   expression of TGF-beta 2 is inhibited; treating an animal having a
CC   disease or condition associated with TGF-beta 2 by administering to the
CC   animal a therapeutic or prophylactic amount of the compound so that
CC   expression of TGF-beta 2 is inhibited; and screening an antisense
CC   compound. The antisense compound has cytostatic, nootropic,
CC   neuroprotective, and immunosuppressive activities. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with TGF-beta 2, such as a hyperproliferative disorder e.g.
CC   cancer, a neurodegenerative disorder, or a disease or condition involving
CC   hyperactivation of an immune response. This polynucleotide sequence
CC   represents an antisense oligonucleotide of the invention.
XX
SQ   Sequence 20 BP; 7 A; 1 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1830 CTTTTAAATACATTCCCT 1847
              |||||||| |||| | ||
Db         18 CTTTTAAAAACATGCACT 1

RESULT 706
ADJ31752/c
ID   ADJ31752 standard; DNA; 20 BP.
XX
AC   ADJ31752;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human amyloid beta precursor antisense oligonucleotide ISIS #156334.
XX
KW   Amyloid beta protein precursor; neurodegenerative disorder;
KW   Alzheimer's disease; apoptosis; diagnosis; therapy; human; antisense; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "Phosphorothioate backbone where all cytidines are
FT                    5'- methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "2'- methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "2'- methoxyethyl (2'-MOE) nucleotides"
XX
PN   US2003232435-A1.
XX
PD   18-DEC-2003.
XX
PF   14-JUN-2002; 2002US-00173208.
XX
PR   14-JUN-2002; 2002US-00173208.
```

```
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-061283/06.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding an amyloid beta protein precursor, useful for
PT   treating Alzheimer's disease or a disease involving aberrant apoptosis.
XX
PS   Claim 1; SEQ ID NO 25; 48pp; English.
XX
CC   The presentinvention is directed to antisense oligonucleotides targetted
CC   to a nucleic acid encoding amyloid beta protein precursor and which
CC   modulates the expression of amyloid beta protein precursor. The invention
CC   is useful for treating a disease or condition associated with amyloid
CC   beta protein precursor such as a neurodegenerative disorder e.g.
CC   Alzheimer's disease or a disease or condition involving aberrant
CC   apoptosis. They are also useful in research and diagnostics for
CC   modulating the expression of amyloid beta protein precursor. The present
CC   sequence is human amyloid beta protein precursor antisense
CC   oligonucleotide.
XX
SQ   Sequence 20 BP; 6 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTTTGT 1625
              ||  ||||  |||||||||
Db         20 CCGAGGGGTAGAGTTTGT 3


RESULT 707
ADJ31788
ID   ADJ31788 standard; DNA; 20 BP.
XX
AC   ADJ31788;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human amyloid beta precursor target oligonucleotide #14.
XX
KW   Amyloid beta protein precursor; neurodegenerative disorder;
KW   Alzheimer's disease; apoptosis; diagnosis; therapy; human; ss.
XX
OS   Homo sapiens.
XX
PN   US2003232435-A1.
XX
PD   18-DEC-2003.
XX
PF   14-JUN-2002; 2002US-00173208.
XX
PR   14-JUN-2002; 2002US-00173208.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-061283/06.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding an amyloid beta protein precursor, useful for
PT   treating Alzheimer's disease or a disease involving aberrant apoptosis.
XX
PS   Example 15; SEQ ID NO 61; 48pp; English.
XX
CC   The presentinvention is directed to antisense oligonucleotides targetted
CC   to a nucleic acid encoding amyloid beta protein precursor and which
CC   modulates the expression of amyloid beta protein precursor. The invention
CC   is useful for treating a disease or condition associated with amyloid
CC   beta protein precursor such as a neurodegenerative disorder e.g.
CC   Alzheimer's disease or a disease or condition involving aberrant
CC   apoptosis. They are also useful in research and diagnostics for
CC   modulating the expression of amyloid beta protein precursor. The present
CC   sequence is human amyloid beta protein precursor target oligonucleotide.
XX
SQ   Sequence 20 BP; 3 A; 2 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTTTGT 1625
              ||  ||||  |||||||||
Db          1 CCGAGGGGTAGAGTTTGT 18


RESULT 708
ADI25098/c
ID   ADI25098 standard; DNA; 20 BP.
XX
AC   ADI25098;
XX
DT   22-APR-2004  (first entry)
XX
DE   Human ARHGEF10 exon 3 mutation analysis reverse PCR primer.
XX
KW   dominant negative mutant RAB7; dominant negative mutant ARHGEF10;
KW   peripheral neuropathy; human; ARHGEF10; chromosome 8; mutation analysis;
KW   PCR; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004005541-A1.
XX
PD   15-JAN-2004.
XX
PF   08-JUL-2003; 2003WO-EP050290.
XX
PR   09-JUL-2002; 2002EP-00077724.
PR   08-APR-2003; 2003EP-00076033.
XX
PA   (VLAA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI   Van Broeckhoven C,  De Jonghe P,  Timmerman V,  Verhoeven K;
XX
DR   WPI; 2004-091384/09.
XX
PT   New isolated nucleic acid coding for a dominant negative, mutant RAB7
PT   polypeptide and/or a dominant negative, mutant ARHGEF10 polypeptide,
PT   useful for detecting the presence of peripheral neuropathy in a human.
XX
PS   Example; Page 23; 38pp; English.
XX
CC   The present invention describes an isolated nucleic acid (I) coding for a
CC   dominant negative, mutant RAB7 polypeptide and/or a dominant negative,
CC   mutant ARHGEF10 polypeptide. (I) contains in comparison to the wild type
CC   RAB7 encoding sequence comprising 624 bp (SEQ ID NO: 1, ADI25025) and/or
CC   to the wild type ARHGEF10 encoding sequence comprising 3366 bp (SEQ ID
CC   NO: 3, ADI25027), one or more mutations, where the presence of the
CC   nucleic acids is indicative for a predisposition or presence of a
CC   peripheral neuropathy. Also described: (1) a nucleic acid probe which is
CC   a fragment of (I); (2) a recombinant vector comprising (I); (3) a host
CC   cell comprising a recombinant vector of (2); (4) a method for the
CC   preparation of a diagnostic assay to detect the presence of a peripheral
CC   neuropathy in a human; and (5) a transgenic non-human animal comprising
CC   the vector of (2). (I) is useful for isolating and detecting human
CC   peripheral neuropathy causing or predisposing genes. The diagnostic assay
CC   is useful for detecting the presence of peripheral neuropathy in a human.
CC   The present sequence represents a PCR primer for the mutation analysis of
CC   human ARHGEF10, which is used in the exemplification of the present
```

```
CC   invention. The human ARHGEF10 gene is located on chromosome 8.
XX
SQ   Sequence 20 BP; 1 A; 5 C; 7 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACACTTAGC 1872
              ||||||||  |||| |||
Db         20 CAGACCCAAGCACTGAGC 3


RESULT 709
ADJ53580/c
ID   ADJ53580 standard; DNA; 20 BP.
XX
AC   ADJ53580;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human PPP3CB DNA antisense oligonucleotide target region #31.
XX
KW   Human; PPP3CB; ss; antisense oligonucleotide; phosphorothioate linkage;
KW   2'-O-methoxyethyl sugar moiety; 5-methylcytosine; autoimmune disorder;
KW   Alzheimer's disease; immunosuppressive; nootropic; neuroprotective.
XX
OS   Homo sapiens.
XX
PN   US2004023382-A1.
XX
PD   05-FEB-2004.
XX
PF   31-JUL-2002; 2002US-00210723.
XX
PR   31-JUL-2002; 2002US-00210723.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Bennett CF,  Dobie KW;
XX
DR   WPI; 2004-142663/14.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding PPP3CB, useful for treating an autoimmune disorder,
PT   or Alzheimer's disease.
XX
PS   Example 15; SEQ ID NO 116; 91pp; English.
XX
CC   The invention relates to an antisense oligonucleotide targeted to a
CC   nucleic acid encoding the human PPP3CB polypeptide and inhibits
CC   expression of the PPP3CB polypeptide. The antisense oligonucleotide
CC   comprises at least one modified internucleoside linkage, i.e. a
CC   phosphorothioate linkage, at least one modified sugar moiety, preferably
CC   a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC   comprising a 5-methylcytosine. The antisense oligonucleotides are useful
CC   for inhibiting expression of the PPP3CB polypeptide and in preparation of
CC   a composition for treating autoimmune disorders or Alzheimer's disease.
CC   This sequence represents an antisense oligonucleotide target region of
CC   the invention.
XX
SQ   Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTTGT 1692
              ||||||  ||| ||||||
Db         19 CCTGGAGCTCTGAGTTGT 2


RESULT 710
ADJ53511
ID   ADJ53511 standard; DNA; 20 BP.
XX
AC   ADJ53511;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human PPP3CB DNA antisense oligonucleotide #34.
XX
KW   Human; PPP3CB; ss; antisense oligonucleotide; phosphorothioate linkage;
KW   2'-O-methoxyethyl sugar moiety; 5-methylcytosine; autoimmune disorder;
KW   Alzheimer's disease; immunosuppressive; nootropic; neuroprotective.
XX
OS   Homo sapiens.
XX
PN   US2004023382-A1.
XX
PD   05-FEB-2004.
XX
PF   31-JUL-2002; 2002US-00210723.
XX
PR   31-JUL-2002; 2002US-00210723.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Bennett CF,  Dobie KW;
XX
DR   WPI; 2004-142663/14.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding PPP3CB, useful for treating an autoimmune disorder,
PT   or Alzheimer's disease.
XX
PS   Example 15; SEQ ID NO 47; 91pp; English.
XX
CC   The invention relates to an antisense oligonucleotide targeted to a
CC   nucleic acid encoding the human PPP3CB polypeptide and inhibits
CC   expression of the PPP3CB polypeptide. The antisense oligonucleotide
CC   comprises at least one modified internucleoside linkage, i.e. a
CC   phosphorothioate linkage, at least one modified sugar moiety, preferably
CC   a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC   comprising a 5-methylcytosine. The antisense oligonucleotides are useful
CC   for inhibiting expression of the PPP3CB polypeptide and in preparation of
CC   a composition for treating autoimmune disorders or Alzheimer's disease.
CC   This sequence represents an antisense oligonucleotide of the invention.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTTGT 1692
              ||||||  ||| ||||||
Db          2 CCTGGAGCTCTGAGTTGT 19


RESULT 711
ADJ47533
ID   ADJ47533 standard; DNA; 20 BP.
XX
AC   ADJ47533;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human IGF2 gene DMR PCR primer SEQ ID NO:28.
XX
KW   loss of imprinting; IGF2; hypomethylation;
KW   differentially methylated region; DMR; cancer; human; PCR; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
```

PN WO2004010850-A2.
XX
PD 05-FEB-2004.
XX
PF 28-JUL-2003; 2003WO-US023725.
XX
PR 26-JUL-2002; 2002US-0398660P.
PR 03-JAN-2003; 2003US-00336552.
XX
PA (UYJO) UNIV JOHNS HOPKINS.
XX
PI Feinberg AP;
XX
DR WPI; 2004-143710/14.
XX
PT Identifying loss of imprinting of the IGF2 gene to determine increased
PT risk of developing cancer comprises analyzing biological sample from the
PT subject for hypomethylation of a differentially methylated region (DMR)
PT of the H19 or IGF2 gene.
XX
PS Claim 9; SEQ ID NO 28; 122pp; English.
XX
CC The present invention describes a method for identifying loss of
CC imprinting of the IGF2 gene in a subject. The method comprises analysing
CC a biological sample from the subject for hypomethylation of a
CC differentially methylated region (DMR) of at least one of the H19 gene
CC and the IGF2 gene. Also described: (1) identifying an increased risk of
CC developing cancer in a human subject; and (2) a kit for determining a
CC methylation status of a differentially methylated region (DMR) of IGF2 or
CC H19 comprising the primer pair. The method is useful for identifying loss
CC of imprinting of the IGF2 gene to determine an increased risk of
CC developing cancer in a subject. The present sequence represents a PCR
CC primer for the DMR of the human IGF2 gene, which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 20 BP; 6 A; 10 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1568 AAAATCCTTCTCCACCGC 1585
|||| ||| ||||||| |
Db 2 AAAAACCTCCTCCACCTC 19

RESULT 712
ADJ61192/c
ID ADJ61192 standard; DNA; 20 BP.
XX
AC ADJ61192;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to PDE4C #258.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 2048; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1843 TCCCTGGGCCAACAGACC 1860
| ||||| ||| ||||||
Db 19 TTCCTGGACCAGCAGACC 2

RESULT 713
ADJ61233
ID ADJ61233 standard; DNA; 20 BP.
XX
AC ADJ61233;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to PDE4C #299.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.

```
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 2089; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g,
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAGAGTT 1622
              |||||| |||  ||||||
Db          2 TGGCCTTGGGCGAGAGTT 19


RESULT 714
ADJ16956/c
ID   ADJ16956 standard; DNA; 20 BP.
XX
AC   ADJ16956;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 1506.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 1506; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1890 GATGTGCCCTAGATCAAC 1907
              |||||||||| |  |||
Db         19 GATGTGCCCTATAATAAC 2


RESULT 715
ADJ17890/c
ID   ADJ17890 standard; DNA; 20 BP.
XX
AC   ADJ17890;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 2440.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
```

```
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 2440; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 6 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1890 GATGTGCCCTAGATCAAC 1907
              |||||||||| |  |||
Db         20 GATGTGCCCTATAATAAC 3


RESULT 716
ADJ16415/c
ID   ADJ16415 standard; DNA; 20 BP.
XX
AC   ADJ16415;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 965.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 965; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
```

```
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1890 GATGTGCCCTAGATCAAC 1907
              ||||||||||| |  |||
Db         18 GATGTGCCCTATAATAAC 1


RESULT 717
ADJ16904
ID   ADJ16904 standard; DNA; 20 BP.
XX
AC   ADJ16904;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Antisense DNA oligo used to modulate human LRH1 expression SeqID 1454.
XX
KW   human; ss; liver related homologue-1; LRH1; NR5A2; antisense;
KW   phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;
KW   low HDL; high density lipoprotein; high LDL; hypercholesterolaemia;
KW   gall stone; triglyceridaemia; obesity; hepatitis;
KW   hepatocellular carcinoma; aromatase; cytostatic; antilipaemic;
KW   antiarteriosclerotic; anorectic; hepatotropic; litholytic;
KW   antiinflammatory; virucidal.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /label= OTHER= phosphorothioate backbone
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   WO2004003201-A2.
XX
PD   08-JAN-2004.
XX
PF   01-JUL-2003; 2003WO-US020865.
XX
PR   01-JUL-2002; 2002US-0392813P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-083058/08.
XX
PT   New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT   related homologue-1 (LRH1), useful for treating breast cancer,
PT   dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX
PS   Example 15; SEQ ID NO 1454; 909pp; English.
XX
CC   This invention relates to novel antisense compounds useful for modulating
CC   the expression of liver related homologue-1 (LRH1) and splice variants
CC   thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC   length that target a portion of an active site on the nucleic acid
CC   molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC   nuclear receptor protein that functions as a tissue specific
CC   transcription factor. The present invention describes antisense
CC   oligonucleotides that comprise at least one modified internucleoside
CC   linkage, a phosphorothioate linkage; at least one modified sugar moiety,
CC   a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC   methylcytidine. These antisense compounds are useful for treating or
CC   diagnosing a disease associated with LRH1, such as breast cancer,
CC   dyslipidaemia, atherosclerosis, low HDL (high density lipoprotein), high
CC   LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC   triglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC   hepatitis, as well as hepatocellular carcinoma or a condition associated
CC   with aromatase activity. Accordingly, these compositions exhibit
CC   cytostatic, antilipaemic, antiarteriosclerotic, anorectic, hepatotropic,
CC   litholytic, antiinflammatory and virucidal activities. This
CC   oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC   expression of the human LRH1 protein of the invention.
XX
SQ   Sequence 20 BP; 11 A; 2 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAAG 1991
              | ||||  ||||||||||
Db          3 CATTGAGCAAAAGAAAAG 20


RESULT 718
ADJ23122
ID   ADJ23122 standard; DNA; 20 BP.
XX
AC   ADJ23122;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human endothelial lipase antisense oligonucleotide, SEQ ID 1520.
XX
KW   Antilipaemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW   Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW   cardiovascular disorder; metabolic syndrome X; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "This oligonucleotide has a phosphorothioate
FT                   backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT                   and 3' ends, which are 4 nucleotides in length. Also all
FT                   cytidine residues are 5-methylcytidines"
XX
PN   WO2004009541-A2.
XX
PD   29-JAN-2004.
XX
PF   18-JUL-2003; 2003WO-US022410.
XX
PR   19-JUL-2002; 2002US-0397106P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Bhat BG;
XX
DR   WPI; 2004-132912/13.
XX
PT   New antisense oligonucleotide for modulating endothelial lipase
PT   expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
```

PT high density lipoprotein or cardiovascular disorders.
XX
PS Claim 3; SEQ ID NO 1520; 1007pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2065 ATAAGTGGTATCTGACAC 2082
||||| ||| |||||||
Db 3 ATAAGGTGTAACTGACAC 20

RESULT 719
ADJ23492
ID ADJ23492 standard; DNA; 20 BP.
XX
AC ADJ23492;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human endothelial lipase antisense oligonucleotide, SEQ ID 1890.
XX
KW Antilipaemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW cardiovascular disorder; metabolic syndrome X; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1. .20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2-'methyoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 4 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
PN WO2004009541-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022410.
XX
PR 19-JUL-2002; 2002US-0397106P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Bhat BG;
XX
DR WPI; 2004-132912/13.
XX
PT New antisense oligonucleotide for modulating endothelial lipase
PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.
XX
PS Claim 3; SEQ ID NO 1890; 1007pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2066 TAAGTGGTATCTGACACA 2083
|||| ||| ||||||||
Db 1 TAAGGTGTAACTGACACA 18

RESULT 720
ADK81738/c
ID ADK81738 standard; DNA; 20 BP.
XX
AC ADK81738;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #9072.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 9072; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 10 A; 2 C; 4 G; 4 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCTT 1772
              ||||||||||  | ||||
Db         18 TCTTTATTCAGCATGCTT 1


RESULT 721
ADK78354
ID   ADK78354 standard; DNA; 20 BP.
XX
AC   ADK78354;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #5688.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 5688; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 7 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              | ||| ||||| ||||||
Db          1 TGGAAACTTTTTAATACA 18


RESULT 722
ADK75591/c
ID   ADK75591 standard; DNA; 20 BP.
XX
AC   ADK75591;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2925.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 2925; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 8 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTC 1844
              |||||  ||||| |||||
Db         19 AATCTAATAAATCCATTC 2


RESULT 723
ADK81648/c
ID   ADK81648 standard; DNA; 20 BP.
XX
AC   ADK81648;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8982.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
```

KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 8982; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 10 A; 2 C; 4 G; 4 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCTT 1772
              ||||||||||  | ||||
Db         19 TCTTTATTCAGCATGCTT 2
```

RESULT 724
ADK75747/c
ID ADK75747 standard; DNA; 20 BP.
XX
AC ADK75747;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #3081.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 3081; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 7 A; 0 C; 4 G; 9 T; 0 U; 0 Other;

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTC 1844
              |||||  ||||| |||||
Db         20 AATCTAATAAATCCATTC 3
```

RESULT 725
ADK79271
ID ADK79271 standard; DNA; 20 BP.
XX
AC ADK79271;
XX
DT 20-MAY-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #6605.
XX
KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
OS Synthetic.
XX
PN WO2004016754-A2.
XX
PD 26-FEB-2004.
XX
PF 14-AUG-2003; 2003WO-US025465.
XX
PR 14-AUG-2002; 2002US-0403416P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding

```
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 6605; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 8 A; 3 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              | ||| ||||| ||||||
Db          2 TGGAAACTTTTTAATACA 19


RESULT 726
ADK79667
ID   ADK79667 standard; DNA; 20 BP.
XX
AC   ADK79667;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #7001.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 7001; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
XX
SQ   Sequence 20 BP; 9 A; 2 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              | ||| ||||| ||||||
Db          3 TGGAAACTTTTTAATACA 20


RESULT 727
ADK76252/c
ID   ADK76252 standard; DNA; 20 BP.
XX
AC   ADK76252;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide to target Nav1.3 #3586.
XX
KW   Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW   diabetic neuropathy; arthritic pain; migraine headache;
KW   infantile epilepsy; ataxia; ss.
XX
OS   Synthetic.
XX
PN   WO2004016754-A2.
XX
PD   26-FEB-2004.
XX
PF   14-AUG-2003; 2003WO-US025465.
XX
PR   14-AUG-2002; 2002US-0403416P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Roberds SL;
XX
DR   WPI; 2004-203785/19.
XX
PT   New antisense compound targeted to a nucleic acid molecule encoding
PT   Nav1.3, useful for useful for treating a disease or condition associated
PT   with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT   disorder, or ataxia.
XX
PS   Claim 4; SEQ ID NO 3586; 417pp; English.
XX
CC   The present invention relates to an antisense compound targeted to a
CC   nucleic acid molecule encoding Nav1.3, where the antisense compound
CC   specifically hybridizes with and inhibits the expression of Nav1.3. The
CC   compound and composition are useful for treating a disease or condition
CC   associated with Nav1.3, e.g. pain including but not limited to
CC   neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC   diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC   pain from burns, migraine headache, cluster headache, mild-to-moderate
CC   headache; seizure disorder such as childhood seizure disorder, including
CC   but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC   sequence represents a chimeric phosphorothioate oligonucleotide with
CC   2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC   human Nav1.3 expression, the oligonucleotides are designed to target
CC   different regions of the human Nav1.3 RNA.
```

```
XX
SQ   Sequence 20 BP; 7 A; 1 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTC 1844
              ||||| ||||| |||||
Db         18 AATCTAATAAATCCATTC 1

RESULT 728
ADL01102
ID   ADL01102 standard; DNA; 20 BP.
XX
AC   ADL01102;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human VEGF co-regulated chemokine-1 DNA antisense oligonucleotide #635.
XX
KW   Human; VEGF co-regulated chemokine-1; VCC-1;
KW   vascular endothelial growth factor; ss; antisense compound;
KW   phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KW   5-methylcytosine; antisense oligonucleotide; diabetes;
KW   immunological disorder; cardiovascular disorder; neurological disorder;
KW   ischaemia; reperfusion injury; cancer; angiogenic disorder; haemangioma;
KW   tumour angiogenesis; rheumatoid arthritis; atherosclerosis; psoriasis;
KW   fibrosis; myocardial infarction; wound healing; bone fracture;
KW   cartilage damage; tissue regeneration; organ regeneration;
KW   periodontal disease; gut regeneration; atrial fibrillation.
XX
OS   Homo sapiens.
XX
PN   WO2004016224-A2.
XX
PD   26-FEB-2004.
XX
PF   19-AUG-2003; 2003WO-US025891.
XX
PR   19-AUG-2002; 2002US-0404484P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ;
XX
DR   WPI; 2004-192065/18.
XX
PT   New antisense compounds targeted to a nucleic acid molecule encoding
PT   vascular endothelial growth factor co-regulated chemokine-1 (VCC-1),
PT   useful for treating VCC-1-associated disorders, e.g. diabetes or a
PT   neurologic disorder.
XX
PS   Claim 4; SEQ ID NO 635; 336pp; English.
XX
CC   The invention relates to an antisense compound targeted to a nucleic acid
CC   molecule encoding human vascular endothelial growth factor (VEGF) co-
CC   regulated chemokine-1 (VCC-1), and which specifically hybridises with and
CC   inhibits the expression of VCC-1. The invention also relates to a
CC   composition comprising the antisense compound, a method of inhibiting the
CC   expression of VCC-1 in cells or tissues comprising contacting the cells
CC   or tissues with the antisense compound and a method of treating a human
CC   having a disease or condition associated with VCC-1 comprising
CC   administering the antisense compound to an animal to inhibit expression
CC   of VCC-1. The antisense oligonucleotide comprises at least one modified
CC   internucleoside linkage, preferably a phosphorothioate linkage. It also
CC   comprises at least one modified sugar moiety, preferably a 2'-O-
CC   methoxyethyl sugar moiety, and at least one modified nucleobase,
CC   specifically a 5-methylcytosine. The antisense oligonucleotide preferably
CC   is a chimeric oligonucleotide. The antisense compound is useful for
CC   treating a disease or condition associated with VCC-1, such as diabetes,
CC   an immunological disorder, a cardiovascular disorder, a neurological
CC   disorder, ischaemia, reperfusion injury, cancer or an angiogenic
CC   disorder, e.g. haemangioma, tumour angiogenesis, rheumatoid arthritis,
CC   atherosclerosis, psoriasis or fibrosis after myocardial infarction. VCC-1
CC   antisense oligonucleotides may also be used for wound healing, for
CC   healing of bone fractures and cartilage damage, for regeneration of
CC   tissues or organs, for treating periodontal diseases, for gut protection
CC   or regeneration, for treatment of lung or liver fibrosis or for
CC   management of atrial fibrillation. This sequence represents an antisense
CC   oligonucleotide targeted to DNA encoding the human VCC-1 polypeptide of
CC   the invention.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1865 CACTTAGCCATTGAAATG 1882
              ||| | ||| ||||||||
Db          3 CACATTGCCCTTGAAATG 20

RESULT 729
ADL01119
ID   ADL01119 standard; DNA; 20 BP.
XX
AC   ADL01119;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human VEGF co-regulated chemokine-1 DNA antisense oligonucleotide #652.
XX
KW   Human; VEGF co-regulated chemokine-1; VCC-1;
KW   vascular endothelial growth factor; ss; antisense compound;
KW   phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KW   5-methylcytosine; antisense oligonucleotide; diabetes;
KW   immunological disorder; cardiovascular disorder; neurological disorder;
KW   ischaemia; reperfusion injury; cancer; angiogenic disorder; haemangioma;
KW   tumour angiogenesis; rheumatoid arthritis; atherosclerosis; psoriasis;
KW   fibrosis; myocardial infarction; wound healing; bone fracture;
KW   cartilage damage; tissue regeneration; organ regeneration;
KW   periodontal disease; gut regeneration; atrial fibrillation.
XX
OS   Homo sapiens.
XX
PN   WO2004016224-A2.
XX
PD   26-FEB-2004.
XX
PF   19-AUG-2003; 2003WO-US025891.
XX
PR   19-AUG-2002; 2002US-0404484P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ;
XX
DR   WPI; 2004-192065/18.
XX
PT   New antisense compounds targeted to a nucleic acid molecule encoding
PT   vascular endothelial growth factor co-regulated chemokine-1 (VCC-1),
PT   useful for treating VCC-1-associated disorders, e.g. diabetes or a
PT   neurologic disorder.
XX
PS   Claim 4; SEQ ID NO 652; 336pp; English.
XX
CC   The invention relates to an antisense compound targeted to a nucleic acid
CC   molecule encoding human vascular endothelial growth factor (VEGF) co-
CC   regulated chemokine-1 (VCC-1), and which specifically hybridises with and
CC   inhibits the expression of VCC-1. The invention also relates to a
CC   composition comprising the antisense compound, a method of inhibiting the
CC   expression of VCC-1 in cells or tissues comprising contacting the cells
CC   or tissues with the antisense compound and a method of treating a human
```

CC having a disease or condition associated with VCC-1 comprising
CC administering the antisense compound to an animal to inhibit expression
CC of VCC-1. The antisense oligonucleotide comprises at least one modified
CC internucleoside linkage, preferably a phosphorothioate linkage. It also
CC comprises at least one modified sugar moiety, preferably a 2'-O-
CC methoxyethyl sugar moiety, and at least one modified nucleobase,
CC specifically a 5-methylcytosine. The antisense oligonucleotide preferably
CC is a chimeric oligonucleotide. The antisense compound is useful for
CC treating a disease or condition associated with VCC-1, such as diabetes,
CC an immunological disorder, a cardiovascular disorder, a neurological
CC disorder, ischaemia, reperfusion injury, cancer or an angiogenic
CC disorder, e.g. haemangioma, tumour angiogenesis, rheumatoid arthritis,
CC atherosclerosis, psoriasis or fibrosis after myocardial infarction. VCC-1
CC antisense oligonucleotides may also be used for wound healing, for
CC healing of bone fractures and cartilage damage, for regeneration of
CC tissues or organs, for treating periodontal diseases, for gut protection
CC or regeneration, for treatment of lung or liver fibrosis or for
CC management of atrial fibrillation. This sequence represents an antisense
CC oligonucleotide targeted to DNA encoding the human VCC-1 polypeptide of
CC the invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1865 CACTTAGCCATTGAAATG 1882
||| | ||| ||||||||
Db 1 CACATTGCCCTTGAAATG 18

RESULT 730
ADL01083
ID ADL01083 standard; DNA; 20 BP.
XX
AC ADL01083;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human VEGF co-regulated chemokine-1 DNA antisense oligonucleotide #616.
XX
KW Human; VEGF co-regulated chemokine-1; VCC-1;
KW vascular endothelial growth factor; ss; antisense compound;
KW phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KW 5-methylcytosine; antisense oligonucleotide; diabetes;
KW immunological disorder; cardiovascular disorder; neurological disorder;
KW ischaemia; reperfusion injury; cancer; angiogenic disorder; haemangioma;
KW tumour angiogenesis; rheumatoid arthritis; atherosclerosis; psoriasis;
KW fibrosis; myocardial infarction; wound healing; bone fracture;
KW cartilage damage; tissue regeneration; organ regeneration;
KW periodontal disease; gut regeneration; atrial fibrillation.
XX
OS Homo sapiens.
XX
PN WO2004016224-A2.
XX
PD 26-FEB-2004.
XX
PF 19-AUG-2003; 2003WO-US025891.
XX
PR 19-AUG-2002; 2002US-0404484P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Weinstein EJ;
XX
DR WPI; 2004-192065/18.
XX
PT New antisense compounds targeted to a nucleic acid molecule encoding
PT vascular endothelial growth factor co-regulated chemokine-1 (VCC-1),
PT useful for treating VCC-1-associated disorders, e.g. diabetes or a
PT neurologic disorder.
XX
PS Claim 4; SEQ ID NO 616; 336pp; English.
XX
CC The invention relates to an antisense compound targeted to a nucleic acid
CC molecule encoding human vascular endothelial growth factor (VEGF) co-
CC regulated chemokine-1 (VCC-1), and which specifically hybridises with and
CC inhibits the expression of VCC-1. The invention also relates to a
CC composition comprising the antisense compound, a method of inhibiting the
CC expression of VCC-1 in cells or tissues comprising contacting the cells
CC or tissues with the antisense compound and a method of treating a human
CC having a disease or condition associated with VCC-1 comprising
CC administering the antisense compound to an animal to inhibit expression
CC of VCC-1. The antisense oligonucleotide comprises at least one modified
CC internucleoside linkage, preferably a phosphorothioate linkage. It also
CC comprises at least one modified sugar moiety, preferably a 2'-O-
CC methoxyethyl sugar moiety, and at least one modified nucleobase,
CC specifically a 5-methylcytosine. The antisense oligonucleotide preferably
CC is a chimeric oligonucleotide. The antisense compound is useful for
CC treating a disease or condition associated with VCC-1, such as diabetes,
CC an immunological disorder, a cardiovascular disorder, a neurological
CC disorder, ischaemia, reperfusion injury, cancer or an angiogenic
CC disorder, e.g. haemangioma, tumour angiogenesis, rheumatoid arthritis,
CC atherosclerosis, psoriasis or fibrosis after myocardial infarction. VCC-1
CC antisense oligonucleotides may also be used for wound healing, for
CC healing of bone fractures and cartilage damage, for regeneration of
CC tissues or organs, for treating periodontal diseases, for gut protection
CC or regeneration, for treatment of lung or liver fibrosis or for
CC management of atrial fibrillation. This sequence represents an antisense
CC oligonucleotide targeted to DNA encoding the human VCC-1 polypeptide of
CC the invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1865 CACTTAGCCATTGAAATG 1882
||| | ||| ||||||||
Db 2 CACATTGCCCTTGAAATG 19

RESULT 731
ADK13907/c
ID ADK13907 standard; DNA; 20 BP.
XX
AC ADK13907;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human methyl-CpG-binding protein 2, MECP2, PCR primer #9.
XX
KW human; Rett syndrome; methyl-CpG-binding protein 2; MECP2;
KW neurodevelopmental disease; autism; non-syndromic mental retardation;
KW idiopathic neonatal encephalopathy; idiopathic infantile spasm;
KW idiopathic cerebral palsy; Angelman syndrome; schizophrenia; ss; primer;
KW PCR.
XX
OS Homo sapiens.
XX
PN US6709817-B1.
XX
PD 23-MAR-2004.
XX
PF 07-SEP-2000; 2000US-00657013.
XX
PR 07-SEP-1999; 99US-0152778P.
XX
PA (BAYU) BAYLOR COLLEGE MEDICINE.
XX
PI Zoghbi HY, Van Den Veyver IB, Amir R, Francke U;
XX
DR WPI; 2004-256068/24.

```
XX
PT   Screening human for Rett syndrome comprises detecting mutation in nucleic
PT   acid sequence encoding methyl-CpG-binding protein 2 (MECP2).
XX
PS   Claim 3; SEQ ID NO 9; 125pp; English.
XX
CC   The invention relates to a method of screening a human for Rett syndrome
CC   comprising detecting a mutation in a nucleic acid sequence encoding
CC   methyl-CpG-binding protein 2 (MECP2). The method is useful for screening
CC   a human for Rett syndrome. The method is useful for screening
CC   neurodevelopmental diseases such as Rett syndrome, autism, non-syndromic
CC   mental retardation, idiopathic neonatal encephalopathy, idiopathic
CC   infantile spasms, idiopathic cerebral palsy, Angelman syndrome and
CC   schizophrenia. The present sequence represents a human methyl-CpG-binding
CC   protein 2, MECP2, PCR primer.
XX
SQ   Sequence 20 BP; 10 A; 7 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1677 TGGACTTCTTAGTTGTTT 1694
              ||| |||||||| || ||
Db         18 TGGGCTTCTTAGGTGGTT 1


RESULT 732
ADL58499/c
ID   ADL58499 standard; DNA; 20 BP.
XX
AC   ADL58499;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 748.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "OTHER= phosphorothioate backbone. All cytidine
FT                    residues are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 748; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1615 GAAGAGTTTGTTACCTAC 1632
              |||||||||| || || |
Db         19 GAAGAGTTTGGTATCTGC 2


RESULT 733
ADL58076
ID   ADL58076 standard; DNA; 20 BP.
XX
AC   ADL58076;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 325.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "OTHER= phosphorothioate backbone. All cytidine
FT                    residues are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
```

```
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 325; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 5 A; 4 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1680 ACTTCTTAGTTGTTTCTC 1697
              ||||||||| | | ||||
Db          3 ACTTCTTAGATTTATCTC 20


RESULT 734
ADL59085/c
ID   ADL59085 standard; DNA; 20 BP.
XX
AC   ADL59085;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1334.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1334; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 9 A; 7 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGTTA 1627
              | || |||||||||| ||
Db         18 TTGGTGAAGAGTTTGGTA 1


RESULT 735
ADL58560/c
ID   ADL58560 standard; DNA; 20 BP.
XX
AC   ADL58560;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 809.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
```

```
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 809; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 6 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1615 GAAGAGTTTGTTACCTAC 1632
              |||||||||| || || |
Db         20 GAAGAGTTTGGTATCTGC 3


RESULT 736
ADL58842/c
ID   ADL58842 standard; DNA; 20 BP.
XX
AC   ADL58842;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1091.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "OTHER= phosphorothioate backbone. All cytidine
FT                    residues are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base    16. .20
FT                    /*tag=  c
FT                    /mod_base= OTHER
FT                    /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1091; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 9 A; 7 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGTTA 1627
              | || |||||||||| ||
Db         19 TTGGTGAAGAGTTTGGTA 2


RESULT 737
ADL58546
ID   ADL58546 standard; DNA; 20 BP.
XX
AC   ADL58546;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 795.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .20
FT                    /*tag=  b
FT                    /mod_base= OTHER
FT                    /note= "OTHER= phosphorothioate backbone. All cytidine
FT                    residues are 5-methylcytidines"
FT   modified_base    1. .5
FT                    /*tag=  a
```

```
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ,  Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 795; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 4 A; 4 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1681 CTTCTTAGTTGTTTCTCT 1698
              ||||||| | | |||||
Db          1 CTTCTTAGATTTATCTCT 18


RESULT 738
ADJ10298/c
ID   ADJ10298 standard; DNA; 20 BP.
XX
AC   ADJ10298;
XX
DT   17-JUN-2004  (first entry)
XX
DE   Phosphorothioate antisense DNA oligo to modulate human GGPS1 SeqID 47.
XX
KW   antisense; ss; human; geranylgeranyl diphosphate synthase 1; GGPS1;
KW   geranylgeranyl pyrophosphate synthetase; GGPPS; ggppsase;
KW   geranyltranstransferase; embryonic development; cell differentiation;
KW   apoptosis; 2' MOE wing; phosphorothioate backbone; developmental;
KW   hyperproliferative disorder; cancer; cytostatic.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT                   cytidine nucleobases are 5-methylcytidine."
XX
PN   US2004005570-A1.
XX
PD   08-JAN-2004.
XX
PF   02-JUL-2002; 2002US-00189268.
XX
PR   02-JUL-2002; 2002US-00189268.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dean NM,  Bennett CF,  Dobie KW;
XX
DR   WPI; 2004-201146/19.
XX
PT   New antisense oligonucleotides for modulating geranylgeranyl diphosphate
PT   synthase 1 expression, useful for diagnosing, preventing or treating
PT   conditions associated with the protein, e.g. cancer.
XX
PS   Example 15; SEQ ID NO 47; 76pp; English.
XX
CC   This invention relates to a novel antisense compounds that modulate the
CC   expression of human geranylgeranyl diphosphate synthase 1 (also known as
CC   GGPS1, geranylgeranyl pyrophosphate synthetase, GGPPS, ggppsase and
CC   geranyltranstransferase) and located on chromosome 1p43. Specifically, it
CC   refers to compositions useful for inhibiting the expression of GGPS1,
CC   which normally participates in embryonic development, cell
CC   differentiation and stimulates apoptosis via caspase-3 activation. The
CC   present invention describes antisense oligonucleotides that comprise at
CC   least one modified sugar moiety, a 2'-O-methoxyethyl (2' MOE) and at
CC   least one modified nucleobase, a 5-methylcytosine. Accordingly, these
CC   compounds are useful for treating a disease or condition associated with
CC   GGPS1 such as a developmental or hyperproliferative disorder (e.g.
CC   cancer) that arise as a result of aberrant apoptosis. As such, these
CC   compositions exhibit cytostatic activity and are useful for diagnostics,
CC   prophylaxis, research reagents and various kits. This oligonucleotide
CC   sequence is a phosphorothioate antisense DNA oligo used to modulate human
CC   geranylgeranyl diphosphate synthase 1 expression in an exemplification of
CC   the invention.
XX
SQ   Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              |||  |||||| ||||||
Db         19 TAGGTTCTTTTGAATACA 2


RESULT 739
ADM15107
ID   ADM15107 standard; DNA; 20 BP.
XX
AC   ADM15107;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1294.
XX
```

```
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1294; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 5 A; 10 C; 5 G; 0 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACACAC 1867
             ||| | ||||||||||  |
Db          1 GCCCAGAGACCCACACGC 18


RESULT 740
ADM15156
ID   ADM15156 standard; DNA; 20 BP.
XX
AC   ADM15156;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1343.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1343; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
```

```
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 11 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1853 AACAGACCCACACACTTA 1870
                ||||  || ||||||| ||
Db          1 AACATACACACACACATA 18


RESULT 741
ADM14040
ID   ADM14040 standard; DNA; 20 BP.
XX
AC   ADM14040;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:227.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 227; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 7 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2012 AGATCAAGTCCTCTGGTA 2029
                 | |||||||| | ||||
Db          1 ACATCAAGTCCCCAGGTA 18


RESULT 742
ADM13933
ID   ADM13933 standard; DNA; 20 BP.
XX
AC   ADM13933;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:120.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
```

```
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 120; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 7 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match           2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2012 AGATCAAGTCCTCTGGTA 2029
              | ||||||||| | ||||
Db          3 ACATCAAGTCCCCAGGTA 20


RESULT 743
ADM15179
ID   ADM15179 standard; DNA; 20 BP.
XX
AC   ADM15179;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1366.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1366; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 11 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

  Query Match           2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1853 AACAGACCCACACACTTA 1870
              |||| || ||||||| ||
Db          2 AACATACACACACACATA 19


RESULT 744
ADM13976
ID   ADM13976 standard; DNA; 20 BP.
```

```
XX
AC   ADM13976;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:163.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 163; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 7 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2012 AGATCAAGTCCTCTGGTA 2029
              | ||||||||| | ||||
Db          2 ACATCAAGTCCCCAGGTA 19


RESULT 745
ADM15180
ID   ADM15180 standard; DNA; 20 BP.
XX
AC   ADM15180;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1367.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1367; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
```

```
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 11 A; 6 C; 1 G; 2 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1853 AACAGACCCACACACTTA 1870
              |||| || ||||||| ||
Db          3 AACATACACACACACATA 20


RESULT 746
ADM14935
ID   ADM14935 standard; DNA; 20 BP.
XX
AC   ADM14935;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1122.
XX
KW   chimeric; antisense oligonucleotide; phosphorothioate; human;
KW   microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW   microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW   immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW   neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW   immunomodulatory; cardiovascular; gene therapy; inflammation;
KW   Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW   reperfusion injury; ophthalmic disorder; immunological disorder;
KW   cardiovascular disorder; neurological disorder; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "phosphorothioate linkages and all cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methocyethyls"
FT   modified_base   16. .20
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-methoxyethyls"
XX
PN   WO2004028458-A2.
XX
PD   08-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030374.
XX
PR   25-SEP-2002; 2002US-0413549P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Gierse JK;
XX
DR   WPI; 2004-305094/28.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT   inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT   ischemia.
XX
PS   Claim 4; SEQ ID NO 1122; 132pp; English.
XX
CC   The present sequence represents a chimeric antisense oligonucleotide
CC   targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC   human mPGES-1 gene is located on chromosome 9, more specifically to
CC   9q34.3. The present invention also describes: (1) antisense compounds,
CC   having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC   mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC   inhibits its expression; (2) a method of inhibiting the expression of
CC   mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC   having a disease or condition associated with mPGES-1. MPGES-1 chimeric
CC   antisense oligonucleotides and antisense compounds have cytostatic,
CC   antidiabetic, immunomodulator, cardiant, neuroprotective,
CC   antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC   ophthalmological, immunomodulatory and cardiovascular activities, and can
CC   be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC   can be used for preparing a composition for treating a disease or
CC   condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC   disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC   ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ   Sequence 20 BP; 5 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACACAC 1867
              ||| | |||||||||| |
Db          2 GCCCAGAGACCCACACGC 19


RESULT 747
ADO46623
ID   ADO46623 standard; DNA; 20 BP.
XX
AC   ADO46623;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #1989.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
XX
PF   25-JUL-2003; 2003US-00627930.
XX
```

PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 2089; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1605 TGGCCTGGGGGAAGAGTT 1622
|||||| ||| ||||||
Db 2 TGGCCTTGGGCGAGAGTT 19

RESULT 748
ADO46582/c
ID ADO46582 standard; DNA; 20 BP.
XX
AC ADO46582;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1948.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
PN US2004049022-A1.
XX
PD 11-MAR-2004.
XX
PF 25-JUL-2003; 2003US-00627930.
XX
PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 2048; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.4%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1843 TCCCTGGGCCAACAGACC 1860
| ||||| ||| ||||||
Db 19 TTCCTGGACCAGCAGACC 2

```
RESULT 749
ADM16123/c
ID   ADM16123 standard; DNA; 20 BP.
XX
AC   ADM16123;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Murine SAC1 DNA PCR primer #350.
XX
KW   Mouse; SAC1; PCR; ss; carbohydrate; sweetener; ethanol; obesity;
KW   diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;
KW   primer.
XX
OS   Mus musculus.
XX
PN   US2004081964-A1.
XX
PD   29-APR-2004.
XX
PF   25-OCT-2002; 2002US-00280183.
XX
PR   25-OCT-2002; 2002US-00280183.
XX
PA   (BACH/) BACHMANOV A A.
PA   (BEAU/) BEAUCHAMP G K.
PA   (LISS/) LI S.
PA   (LIXX/) LI X.
PA   (REED/) REED D R.
PA   (TORD/) TORDOFF M G.
PA   (ROSS/) ROSS D A.
PA   (OHMA/) OHMAN J D.
PA   (CHAT/) CHATTERJEE A.
PA   (DJON/) DE JONG P J.
XX
PI   Bachmanov AA, Beauchamp GK, Li S, Li X, Reed DR, Tordoff MG;
PI   Ross DA, Ohman JD, Chatterjee A, De Jong PJ;
XX
DR   WPI; 2004-340133/31.
XX
PT   New isolated polynucleotides for sensing carbohydrates, other sweeteners,
PT   or ethanol, useful for screening drugs for inhibition or restoration of
PT   gene function as antidiabetic, antiobesity or antialcohol consumption
PT   therapies.
XX
PS   Example 12; SEQ ID NO 393; 148pp; English.
XX
CC   The invention relates to SAC1 polypeptides and the polynucleotides
CC   encoding them. The polynucleotides contain a variation associated with
CC   sensing carbohydrates, other sweeteners or ethanol. The invention also
CC   relates to a method for analysing a biomolecule in a biological sample,
CC   comprising altering SAC1 activity in the sample and measuring the
CC   activity, a method for analysing a polynucleotide in a biological sample,
CC   comprising contacting a polynucleotide in a biological sample with a
CC   probe where the probe hybridises to a SAC1 polynucleotide to form a
CC   hybridisation complex and detecting the hybridisation complex, a method
CC   of identifying susceptibility to obesity or diabetes comprising comparing
CC   the nucleotide sequence of the suspected SAC1 allele with a wild type
CC   nucleotide sequence, where the difference between the suspected allele
CC   and the wild-type sequence identifies a sequence variation of the SAC1
CC   nucleotide sequence, and a method of treating or preventing obesity,
CC   diabetes or alcoholism associated with expression of SAC1, comprising
CC   administering to a subject a pharmaceutical composition and a transgenic
CC   animal that carries an altered SAC1 allele. The methods and compositions
CC   of the invention are useful for screening drugs for inhibition or
CC   restoration of gene function as antidiabetic, antiobesity or antialcohol
CC   consumption therapies and for identifying sweeteners and alcohols. This
CC   sequence represents a PCR primer used to amplify murine SAC1 DNA of the
CC   invention.
XX
SQ   Sequence 20 BP; 5 A; 0 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCACA 1588
              |||||| |||||| || |
Db         20 ATCCTTTTCCACCCCAAA 3


RESULT 750
ADN06668
ID   ADN06668 standard; DNA; 20 BP.
XX
AC   ADN06668;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human FLAP related microsatellite marker SEQ ID NO:318.
XX
KW   leukotriene synthesis inhibitor; myocardial infarction;
KW   acute coronary syndrome; antiatherosclerotic; cardiant; antianginal;
KW   leukotriene biosynthesis inhibitor; leukotriene receptor antagonist;
KW   5-lipoxygenase activating protein; FLAP; human; chromosome 13;
KW   chromosome 13q12; polymorphism; 5-lipoxygenase gene promoter;
KW   5-LO gene promoter; diabetes; hypertension; hypercholesterolaemia;
KW   obesity; inflammatory marker; low density lipoprotein; cholesterol;
KW   high density lipoprotein; angina; atherosclerosis; microsatellite marker;
KW   ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004035741-A2.
XX
PD   29-APR-2004.
XX
PF   16-OCT-2003; 2003WO-US032556.
XX
PR   17-OCT-2002; 2002US-0419433P.
PR   21-FEB-2003; 2003US-0449331P.
XX
PA   (DECO-) DECODE GENETICS EHF.
XX
PI   Helgadottir A, Gurney ME, Gulcher JR;
XX
DR   WPI; 2004-357211/33.
XX
PT   Use of leukotriene synthesis inhibitor for manufacture of a medicament
PT   for treatment for myocardial infarction or susceptibility to myocardial
PT   infarction in individual.
XX
PS   Disclosure; SEQ ID NO 318; 306pp; English.
XX
CC   The present invention describes using a leukotriene synthesis inhibitor
CC   (I) for the manufacture of a medicament for the treatment of myocardial
CC   infarction or susceptibility to myocardial infarction in an individual.
CC   Also described is a method (M1) for the treatment of acute coronary
CC   syndrome (ACS) in an individual comprising administering (I). (I) has
CC   antiatherosclerotic, cardiant and antianginal activities, and can be used
CC   as a leukotriene biosynthesis inhibitor, and a leukotriene receptor
CC   antagonist. (I) can be use for the manufacture of a medicament for the
CC   treatment of myocardial infarction or susceptibility to myocardial
CC   infarction in an individual who has at least one risk factor chosen from
CC   an at-risk haplotype for myocardial infarction, an at-risk haplotype in
CC   the 5-lipoxygenase activating protein (FLAP) gene, a polymorphism in a
CC   FLAP nucleic acid and an at-risk polymorphism in the 5-lipoxygenase (5-
CC   LO) gene promoter; in an individual who has at least one risk factor
CC   chosen from diabetes, hypertension, hypercholesterolaemia, elevated
CC   1p(a), obesity, past or current smoker; in an individual having elevated
CC   inflammatory marker chosen from C-reactive protein (CRP), serum amyloid
CC   A, fibrinogen, leukotriene, leukotriene metabolite, interleukin-6, tissue
CC   necrosis factor-alpha, soluble vascular cell adhesion molecule (sVCAM),.
```

```
CC   soluble intervascular adhesion molecule (sICAM), E-selectin, matrix
CC   metalloprotease type-1, matrix metalloprotease type-2, matrix
CC   metalloprotease type-3 and matrix metalloprotease type-9; in an
CC   individual having increased low density lipoprotein (LDL) cholesterol
CC   and/or decreased high density lipoprotein (HDL) cholesterol; in an
CC   individual having increased leukotriene synthesis; in an individual
CC   having previous myocardial infarction or acute coronary syndrome (ACS)
CC   event, stable angina; or in an individual who has atherosclerosis or who
CC   requires treatment to restore blood flow in arteries. (M1) is useful for
CC   treating an individual suffering from acute coronary syndrome chosen from
CC   unstable angina, non-ST-elevation myocardial infarction (NSTEMI) and ST-
CC   elevation myocardial infarction (STEMI). The human FLAP gene is located
CC   on chromosome 13, more specifically to 13q12. The present sequence
CC   represents a microsatellite marker used in the exemplification of the
CC   present invention.
XX
SQ   Sequence 20 BP; 10 A; 0 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||  | ||||||||||
Db          3 AGGAAGGAAGGGAAGGAA 20


RESULT 751
ADO53936
ID   ADO53936 standard; DNA; 20 BP.
XX
AC   ADO53936;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1309.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1309; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 6 A; 3 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTTT 1776
              ||||||| ||| ||| ||
Db          1 TATTCATCAAGATTTCTT 18


RESULT 752
ADO52938
ID   ADO52938 standard; DNA; 20 BP.
XX
AC   ADO52938;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #311.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 311; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
```

```
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 5 A; 5 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1890 GATGTGCCCTAGATCAAC 1907
              ||| | |||||| |||||
Db          3 GATTTTCCCTAGTTCAAC 20


RESULT 753
ADO53992
ID   ADO53992 standard; DNA; 20 BP.
XX
AC   ADO53992;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1365.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1365; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 6 A; 3 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTTT 1776
              ||||||| ||| ||| ||
Db          2 TATTCATCAAGATTTCTT 19


RESULT 754
ADO54060
ID   ADO54060 standard; DNA; 20 BP.
XX
AC   ADO54060;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Farnesoid X receptor gene expression antisense inhibitory oligo #1433.
XX
KW   ss; antidiabetic; immunosuppressive; cardiovascular; antilipemic;
KW   antiarteriosclerotic; hepatotropic; litholytic; anorectic;
KW   neuroprotective; vasotropic; antisense; gene therapy;
KW   Farnesoid X receptor; diabetes; immunological disorder;
KW   cardiovascular disorder; dyslipidemia; atherosclerosis;
KW   high density lipoprotein; low density lipoprotein; hypercholesterolemia;
KW   gallstones; hypertriglyceridemia; obesity; neurological disorder;
KW   ischemia; reperfusion; diagnostics; prophylaxis.
XX
OS   Homo sapiens.
XX
PN   WO2004030750-A1.
XX
PD   15-APR-2004.
XX
PF   25-SEP-2003; 2003WO-US030353.
XX
PR   25-SEP-2002; 2002US-0413588P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Kane CD;
XX
DR   WPI; 2004-347928/32.
XX
PT   New antisense oligonucleotides useful for modulating expression of
PT   Farnesoid X Receptor (FXR) or for treating diseases associated with FXR,
PT   e.g. diabetes, immunological disorders, cardiovascular disorders,
PT   gallstones or obesity.
XX
PS   Claim 4; SEQ ID NO 1433; 150pp; English.
XX
CC   The invention relates to an antisense compound 8-30 nucleobases in length
CC   targeted to a nucleic acid molecule encoding Farnesoid X receptor (FXR),
CC   where the antisense compound specifically hybridizes with and inhibits
CC   the expression of FXR. The composition and methods are useful for
CC   inhibiting the expression of FXR (Farnesoid X receptor) in cells or
CC   tissues, or for treating diseases or conditions associated with FXR, such
CC   as diabetes, immunological disorders, cardiovascular disorders, e.g.
CC   dyslipidemia and its symptoms, atherosclerosis, low HDL (high density
CC   lipoprotein), elevated LDL (low density lipoprotein) or
CC   hypercholesterolemia, gallstones, hypertriglyceridemia, obesity,
CC   neurological disorders, or ischemia/reperfusion injury. In addition, the
CC   composition is used for diagnostics, prophylaxis, or as research reagents
CC   or kits. This sequence corresponds to an antisense oligonucleotide of the
CC   invention.
XX
SQ   Sequence 20 BP; 7 A; 3 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
```

```
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTTT 1776
              ||||||| ||| ||| ||
Db          3 TATTCATCAAGATTTCTT 20


RESULT 755
ADO16356
ID   ADO16356 standard; DNA; 20 BP.
XX
AC   ADO16356;
XX
DT   29-JUL-2004  (first entry)
XX
DE   4 synthesis-period of neuroblastoma related primer, SEQ ID 618.
XX
KW   Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
XX
OS   Synthetic.
XX
PN   WO2004039975-A1.
XX
PD   13-MAY-2004.
XX
PF   30-OCT-2003; 2003WO-JP013932.
XX
PR   30-OCT-2002; 2002JP-00316586.
XX
PA   (HISM ) HISAMITSU PHARM CO LTD.
PA   (CHIB-) CHIBA PREFECTURE.
XX
PI   Nakagawara A,  Ohira M;
XX
DR   WPI; 2004-390323/36.
XX
PT   Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
PT   cells useful for prognosing and determining progress stage of
PT   neuroblastomas.
XX
PS   Claim 8; SEQ ID NO 618; 455pp; Japanese.
XX
CC   The present invention relates to human nucleic acid sequences (I;
CC   ADO15739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
CC   neuroblastoma cell. (I) is useful for prognosing and determining the
CC   progress stage of 4 synthesis-period of neuroblastoma. The present
CC   sequence is a primer, used to illustrate the invention.
XX
SQ   Sequence 20 BP; 5 A; 0 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGTTA 1627
              ||||| |||| ||||| |
Db          1 TGGGGAAAGATTTTGTGA 18


RESULT 756
ADP78340
ID   ADP78340 standard; DNA; 20 BP.
XX
AC   ADP78340;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #2139.
XX
KW   GFAT; Antidiabetic; Cardiant;
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag=  a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag=  b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO,  Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 2139; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              ||||||||||   |||||
Db          2 TAGAATCTTTCTGATACA 19


RESULT 757
ADP78566
ID   ADP78566 standard; DNA; 20 BP.
XX
AC   ADP78566;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #2365.
XX
KW   GFAT; Antidiabetic; Cardiant;
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
```

```
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag= a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag= b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO, Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 2365; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              ||||||||||   |||||
Db          1 TAGAATCTTTCTGATACA 18


RESULT 758
ADP78056
ID   ADP78056 standard; DNA; 20 BP.
XX
AC   ADP78056;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Chimeric phosphorothioate oligonucleotide #1855.
XX
KW   GFAT; Antidiabetic; Cardiant;
KW   Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW   reperfusion; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .4
FT                   /*tag= a
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
FT   modified_base   17. .20
FT                   /*tag= b
FT                   /mod_base= other
FT                   /note= "2-methoxyethyl wing"
XX
PN   WO2004035763-A2.
XX
PD   29-APR-2004.
XX
PF   02-OCT-2003; 2003WO-US033332.
XX
PR   17-OCT-2002; 2002US-0419268P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Broschat KO, Crosby SD;
XX
DR   WPI; 2004-348453/32.
XX
PT   New compounds, particularly antisense oligonucleotides targeted to a
PT   nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
PT   (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
PT   ischemia/reperfusion injury.
XX
PS   Claim 4; SEQ ID NO 1855; 175pp; English.
XX
CC   The present invention relates to a compound which specifically hybridizes
CC   with a nucleic acid molecule encoding GFAT, and inhibits the expression
CC   of GFAT. Specifically claimed are antisense oligonucleotides capable of
CC   modulating the expression of GFAT, and which comprise any of the 3063
CC   sequences of 20 base pairs, given in the specification. The compound,
CC   composition and methods are useful for treating a disease or condition
CC   associated with GFAT, such as a disease or condition, e.g. diabetes, a
CC   cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC   They are also useful in research and diagnostics for modulating the
CC   expression of GFAT. The present sequence represents a chimeric
CC   phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC   oligonucleotides inhibit human GFAT expression.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACA 1841
              ||||||||||   |||||
Db          3 TAGAATCTTTCTGATACA 20


RESULT 759
ADP10954/c
ID   ADP10954 standard; DNA; 20 BP.
XX
AC   ADP10954;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Set 1 left PCR primer for marker probe #299.
XX
KW   transplant rejection; immune system; rheumatoid arthritis; lupus;
KW   inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO2004042346-A2.
XX
PD   21-MAY-2004.
XX
PF   24-APR-2003; 2003WO-US012946.
```

```
XX
PR   24-APR-2002; 2002US-00131831.
PR   20-DEC-2002; 2002US-00325899.
XX
PA   (EXPR-) EXPRESSION DIAGNOSTICS INC.
XX
PI   Wohlgemuth J,  Fry K,  Woodward R,  Ly N,  Prentice J,  Morris M;
PI   Rosenberg S;
XX
DR   WPI; 2004-400724/37.
XX
PT   Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,
PT   pancreas, pancreatic islet, lung, bone marrow or stem cell transplant
PT   rejection, in an individual, comprises detecting the expression level of
PT   the genes.
XX
PS   Claim 58; SEQ ID NO 963; 1762pp; English.
XX
CC   The present invention relates to diagnosing or monitoring transplant
CC   rejection, e.g. cardiac or kidney transplant rejection, in an individual
CC   comprises detecting the expression level of one or more genes. The
CC   methods, system and kits are useful in diagnosing or monitoring
CC   transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic
CC   islet, lung, bone marrow or stem cell transplant rejection,
CC   xenotransplant rejection or mechanical organ replacement rejection, in an
CC   individual. The method is also useful in assessing the immune status of
CC   an individual. The methods are also useful in diagnosing and monitoring
CC   diseases that involve the immune system, e.g. rheumatoid arthritis,
CC   lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or
CC   viral, bacterial or fungal infection. The present sequence represents a
CC   primer for a 50 mer oligonucleotide marker for diagnosis and monitoring
CC   of allograft rejection and other disorders.
XX
SQ   Sequence 20 BP; 6 A; 2 C; 10 G; 2 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1706 AGCTATCTCCTAACTTTG 1723
                ||||  ||||| ||||||
Db         19 AGCTCCCTCCTCACTTTG 2


RESULT 760
ADP11852
ID   ADP11852 standard; DNA; 20 BP.
XX
AC   ADP11852;
XX
DT   12-AUG-2004  (first entry)
XX
DE   Set 2 left PCR primer for marker probe #204.
XX
KW   transplant rejection; immune system; rheumatoid arthritis; lupus;
KW   inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO2004042346-A2.
XX
PD   21-MAY-2004.
XX
PF   24-APR-2003; 2003WO-US012946.
XX
PR   24-APR-2002; 2002US-00131831.
PR   20-DEC-2002; 2002US-00325899.
XX
PA   (EXPR-) EXPRESSION DIAGNOSTICS INC.
XX
PI   Wohlgemuth J,  Fry K,  Woodward R,  Ly N,  Prentice J,  Morris M;
PI   Rosenberg S;
XX
DR   WPI; 2004-400724/37.
XX
PT   Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,
PT   pancreas, pancreatic islet, lung, bone marrow or stem cell transplant
PT   rejection, in an individual, comprises detecting the expression level of
PT   the genes.
XX
PS   Claim 58; SEQ ID NO 1861; 1762pp; English.
XX
CC   The present invention relates to diagnosing or monitoring transplant
CC   rejection, e.g. cardiac or kidney transplant rejection, in an individual
CC   comprises detecting the expression level of one or more genes. The
CC   methods, system and kits are useful in diagnosing or monitoring
CC   transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic
CC   islet, lung, bone marrow or stem cell transplant rejection,
CC   xenotransplant rejection or mechanical organ replacement rejection, in an
CC   individual. The method is also useful in assessing the immune status of
CC   an individual. The methods are also useful in diagnosing and monitoring
CC   diseases that involve the immune system, e.g. rheumatoid arthritis,
CC   lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or
CC   viral, bacterial or fungal infection. The present sequence represents a
CC   primer for a 50 mer oligonucleotide marker for diagnosis and monitoring
CC   of allograft rejection and other disorders.
XX
SQ   Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCAAGT 2020
                ||||||||| || | |||
Db          3 CTTCTTCAGCGAACGAGT 20


RESULT 761
ADP44531
ID   ADP44531 standard; DNA; 20 BP.
XX
AC   ADP44531;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Human ABCC5 DNA antisense oligonucleotide target region #69.
XX
KW   Human; ABCC5; ss; antisense oligonucleotide; phosphorothioate linkage;
KW   2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW   hyperproliferative disorder; cancer; cytostatic.
XX
OS   Homo sapiens.
XX
PN   US2004115649-A1.
XX
PD   17-JUN-2004.
XX
PF   12-DEC-2002; 2002US-00319893.
XX
PR   12-DEC-2002; 2002US-00319893.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-449386/42.
XX
PT   New oligonucleotide compound that inhibits expression of ABCC5, useful
PT   for preparing a composition for treating hyperproliferative disorder,
PT   e.g., cancer.
XX
PS   Example 15; SEQ ID NO 157; 57pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid molecule
CC   encoding the human ABCC5 polypeptide. The compound is an antisense
```

```
CC   oligonucleotide that specifically hybridises with the nucleic acid and
CC   inhibits expression of the polypeptide. The antisense oligonucleotide
CC   comprises at least one modified internucleoside linkage i.e. a
CC   phosphorothioate linkage, at least one modified sugar moiety, preferably
CC   a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC   comprising a 5-methylcytosine. The antisense compounds are useful for
CC   modulating the expression of the human ABCC5 polypeptide and in
CC   preparation of a composition for treating hyperproliferative disorders,
CC   e.g. cancer. This sequence represents a human ABCC5 DNA antisense
CC   oligonucleotide target region of the invention.
XX
SQ   Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAGATCAAG 2019
              ||| || |||||| ||||
Db          2 GCTGCTGCAGAGAACAAG 19


RESULT 762
ADP44462/c
ID   ADP44462 standard; DNA; 20 BP.
XX
AC   ADP44462;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Human ABCC5 DNA antisense oligonucleotide #78.
XX
KW   Human; ABCC5; ss; antisense oligonucleotide; phosphorothioate linkage;
KW   2'-O-methoxyethyl sugar moiety; 5-methylcytosine;
KW   hyperproliferative disorder; cancer; cytostatic.
XX
OS   Homo sapiens.
XX
PN   US2004115649-A1.
XX
PD   17-JUN-2004.
XX
PF   12-DEC-2002; 2002US-00319893.
XX
PR   12-DEC-2002; 2002US-00319893.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Dobie KW;
XX
DR   WPI; 2004-449386/42.
XX
PT   New oligonucleotide compound that inhibits expression of ABCC5, useful
PT   for preparing a composition for treating hyperproliferative disorder,
PT   e.g., cancer.
XX
PS   Example 15; SEQ ID NO 88; 57pp; English.
XX
CC   The invention relates to a compound targeted to a nucleic acid molecule
CC   encoding the human ABCC5 polypeptide. The compound is an antisense
CC   oligonucleotide that specifically hybridises with the nucleic acid and
CC   inhibits expression of the polypeptide. The antisense oligonucleotide
CC   comprises at least one modified internucleoside linkage i.e. a
CC   phosphorothioate linkage, at least one modified sugar moiety, preferably
CC   a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
CC   comprising a 5-methylcytosine. The antisense compounds are useful for
CC   modulating the expression of the human ABCC5 polypeptide and in
CC   preparation of a composition for treating hyperproliferative disorders,
CC   e.g. cancer. This sequence represents an antisense oligonucleotide
CC   targeted to DNA encoding the human ABCC5 polypeptide of the invention.
XX
SQ   Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2002 GCTTCTTCAGAGATCAAG 2019
              ||| || |||||| ||||
Db         19 GCTGCTGCAGAGAACAAG 2

RESULT 763
ADQ91497/c
ID   ADQ91497 standard; DNA; 20 BP.
XX
AC   ADQ91497;
XX
DT   23-SEP-2004  (first entry)
XX
DE   PCR primer G1 used for GHR-exon 3 genotyping test.
XX
KW   growth hormone receptor; GHR; obesity; diabetes; infection; acromegaly;
KW   gigantism; sodium retention; water retention; metabolic syndrome;
KW   mood disorder; sleep disorder; cancer; cardiac disease; hypertension;
KW   PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2004056864-A1.
XX
PD   08-JUL-2004.
XX
PF   10-NOV-2003; 2003WO-IB005111.
XX
PR   19-DEC-2002; 2002US-0434861P.
XX
PA   (PHAA ) PHARMACIA AB.
XX
PI   Bougneres P;
XX
DR   WPI; 2004-500285/47.
XX
PT   Predicting a subject's response to an agent capable of binding to a
PT   growth hormone receptor (GHR) protein comprises determining in the
PT   subject the presence or absence of an allele of the GHR gene.
XX
PS   Disclosure; Fig 3A; 116pp; English.
XX
CC   The specification describes a method for predicting a subject's response
CC   to an agent capable of binding to a growth hormone receptor (GHR)
CC   protein. The method comprises determining in the subject the presence or
CC   absence of an allele of the GHR gene, where the allele is correlated with
CC   a likelihood of having an increased or decreased positive response to the
CC   agent, to identify the subject as having an increased or decreased
CC   likelihood of responding to treatment with the agent. The method is
CC   useful in predicting a subject's response to an agent capable of binding
CC   to a GHR protein for treating a subject suffering from obesity, diabetes,
CC   infection, acromegaly or gigantism conditions, as well as conditions
CC   associated with abnormal sodium or water retention, metabolic syndrome,
CC   mood or sleep disorder, cancer, cardiac disease or hypertension. PCR
CC   primers ADQ91497-ADQ91499 were used for a GHR-exon 3 genotyping test, to
CC   identify deletions in exon 3 leading to a mutant GHR.
XX
SQ   Sequence 20 BP; 0 A; 3 C; 8 G; 9 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1849 GGCCAACAGACCCACACA 1866
              | ||||||||||  ||||
Db         18 GACCAACAGACCAGCACA 1

RESULT 764
```

```
ADQ25821
ID   ADQ25821 standard; DNA; 20 BP.
XX
AC   ADQ25821;
XX
DT   23-SEP-2004  (first entry)
XX
DE   Chimaeric zebrafish EGFP gene PCR primer SEQ ID NO: 2.
XX
KW   ss; primer; EGFP; PCR; zebrafish; homologous recombination;
KW   germline chimaeric fish.
XX
OS   Danio rerio.
XX
PN   WO2004054357-A1.
XX
PD   01-JUL-2004.
XX
PF   12-DEC-2003; 2003WO-US039516.
XX
PR   13-DEC-2002; 2002US-00319221.
PR   17-DEC-2002; 2002US-0434318P.
XX
PA   (PURD ) PURDUE RES FOUND.
XX
PI   Collodi P,  Fan L;
XX
DR   WPI; 2004-487972/46.
XX
PT   Integrating a polynucleotide into a fish cell by introducing a modifying
PT   polynucleotide having a first and a second homologous region that will
PT   undergo homologous recombination with a first and second region of the
PT   target polynucleotide.
XX
PS   Example 1; SEQ ID NO 2; 47pp; English.
XX
CC   The present invention relates to a method of integrating a polynucleotide
CC   into a fish cell, comprising introducing a modifying polynucleotide
CC   comprising a first homologous region that will undergo homologous
CC   recombination with a first region of the target polynucleotide, and a
CC   second homologous region that will undergo homologous recombination with
CC   a second region of the target polynucleotide. The method is useful for
CC   integrating a polynucleotide into a fish cell, for making a germline
CC   chimaeric fish, or for making a fish heterozygous or homozygous for a
CC   mutation. The present sequence is a PCR primer used to demonstrate the
CC   method of the invention.
XX
SQ   Sequence 20 BP; 2 A; 3 C; 8 G; 7 T; 0 U; 0 Other;

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 4.3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1932 GTGTTAAGGTAATGGTTG 1949
              ||| | ||||| ||||||
Db          1 GTGCTCAGGTAGTGGTTG 18


RESULT 765
ABF14533/c
ID   ABF14533 standard; DNA; 13 BP.
XX
AC   ABF14533;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 114530 for detecting SNP TSC0028669.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 114530; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 2 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1532 GAAAGGTTAGGAG 1544
              |||||||||||||
Db         13 GAAAGGTTAGGAG 1


RESULT 766
ABF01171/c
ID   ABF01171 standard; DNA; 13 BP.
XX
AC   ABF01171;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 101168 for detecting SNP TSC0025168.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
```

```
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 101168; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1943 ATGGTTGGTTTTT 1955
              |||||||||||||
Db         13 ATGGTTGGTTTTT 1


RESULT 767
ABH16496
ID   ABH16496 standard; DNA; 13 BP.
XX
AC   ABH16496;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 216473 for detecting SNP TSC0052642.
XX
KW   SNP; single nucleotide polymorphism; human;.diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 216473; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGT 1992
              |||||||||||||
Db          1 AAAAAAGAAAAGT 13


RESULT 768
ABF39622/c
ID   ABF39622 standard; DNA; 13 BP.
XX
AC   ABF39622;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 139619 for detecting SNP TSC0034954.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 139619; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1914 ACAATACCTTTTT 1926
              |||||||||||||
Db         13 ACAATACCTTTTT 1
```

RESULT 769
ABC68356
ID ABC68356 standard; DNA; 13 BP.
XX
AC ABC68356;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 68373 for detecting SNP TSC0017829.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 68373; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 11 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

```
  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
              |||||||||||||
Db          1 AAAAAAAGAAAAG 13
```

RESULT 770
ABF39623
ID ABF39623 standard; DNA; 13 BP.
XX
AC ABF39623;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 139620 for detecting SNP TSC0034954.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 139620; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

```
  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1914 ACAATACCTTTTT 1926
              |||||||||||||
Db          1 ACAATACCTTTTT 13
```

RESULT 771
ABC68357/c
ID ABC68357 standard; DNA; 13 BP.
XX
AC ABC68357;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 68374 for detecting SNP TSC0017829.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

```
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 68374; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 0 A; 2 C; 0 G; 11 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
              |||||||||||||
Db         13 AAAAAAAGAAAAG 1


RESULT 772
ABF01170
ID   ABF01170 standard; DNA; 13 BP.
XX
AC   ABF01170;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 101167 for detecting SNP TSC0025168.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 101167; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1943 ATGGTTGGTTTTT 1955
              |||||||||||||
Db          1 ATGGTTGGTTTTT 13


RESULT 773
ABH59369/c
ID   ABH59369 standard; DNA; 13 BP.
XX
AC   ABH59369;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 259346 for detecting SNP TSC0062989.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 259346; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
```

```
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1816 ATAAGTTTTAGAA 1828
              |||||||||||||
Db         13 ATAAGTTTTAGAA 1


RESULT 774
ABH65388
ID   ABH65388 standard; DNA; 13 BP.
XX
AC   ABH65388;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 265365 for detecting SNP TSC0064305.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 265365; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 11 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAA 1990
              |||||||||||||
Db          1 GAAAAAAAGAAAA 13


RESULT 775
ABC03683/c
ID   ABC03683 standard; DNA; 13 BP.
XX
AC   ABC03683;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 3674 for detecting SNP TSC0001405.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 3674; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTT 1948
              |||||||||||||
Db          13 TAAGGTAATGGTT 1


RESULT 776
ABH59368
ID   ABH59368 standard; DNA; 13 BP.
XX
AC   ABH59368;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 259345 for detecting SNP TSC0062989.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 259345; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1816 ATAAGTTTTAGAA 1828
||||||||||||
Db 1 ATAAGTTTTAGAA 13

RESULT 777
ABC48299
ID ABC48299 standard; DNA; 13 BP.
XX
AC ABC48299;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 48316 for detecting SNP TSC0013785.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 48316; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 7 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1785 CCCCATTCTTTCC 1797
||||||||||||
Db 1 CCCCATTCTTTCC 13

RESULT 778
ABH65389/c
ID ABH65389 standard; DNA; 13 BP.
XX
AC ABH65389;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 265366 for detecting SNP TSC0064305.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 265366; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

```
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 0 A; 2 C; 0 G; 11 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAA 1990
              |||||||||||||
Db         13 GAAAAAAAGAAAA 1


RESULT 779
ABF14532
ID   ABF14532 standard; DNA; 13 BP.
XX
AC   ABF14532;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 114529 for detecting SNP TSC0028669.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 114529; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1532 GAAAGGTTAGGAG 1544
              |||||||||||||
Db          1 GAAAGGTTAGGAG 13


RESULT 780
ABH16497/c
ID   ABH16497 standard; DNA; 13 BP.
XX
AC   ABH16497;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 216474 for detecting SNP TSC0052642.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 216474; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 1 A; 2 C; 0 G; 10 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGT 1992
              |||||||||||||
Db         13 AAAAAAGAAAAGT 1


RESULT 781
ABC48298/c
ID   ABC48298 standard; DNA; 13 BP.
XX
```

```
AC   ABC48298;
XX
DT   21-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 48315 for detecting SNP TSC0013785.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 48315; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCC 1797
              |||||||||||||
Db         13 CCCCATTCTTTCC 1


RESULT 782
ABC03682
ID   ABC03682 standard; DNA; 13 BP.
XX
AC   ABC03682;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 3673 for detecting SNP TSC0001405.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 3673; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTT 1948
              |||||||||||||
Db          1 TAAGGTAATGGTT 13


RESULT 783
AAD26689
ID   AAD26689 standard; DNA; 15 BP.
XX
AC   AAD26689;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Human GPR31 gene polymorphism detecting ASO primer #12.
XX
KW   Human; G-protein coupled receptor 31; GPR31 protein; haplotyping;
KW   genotyping; gene therapy; cancer; polymorphism; ASO; primer;
KW   allele-specific oligonucleotide; ss.
XX
OS   Homo sapiens.
XX
PN   WO200190124-A2.
XX
PD   29-NOV-2001.
XX
PF   23-MAY-2001; 2001WO-US016908.
XX
PR   23-MAY-2000; 2000US-0206572P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bieglecki KM,  Duda A,  Kazemi A,  Lee HH,  Messer C;
XX
DR   WPI; 2002-089915/12.
XX
```

```
PT   Novel genetic variants of G-protein coupled receptor gene useful in
PT   studying expression and function of the protein, and for screening drugs
PT   to treat diseases e.g. cancer.
XX
PS   Claim 16; Page 13; 75pp; English.
XX
CC   The invention relates to genetic variants of human G-protein coupled
CC   receptor 31 (GPR31) gene. The invention also relates to compositions and
CC   methods for haplotyping and/or genotyping the GPR31 gene in an
CC   individual. Polynucleotides of the invention are useful in studying the
CC   expression and function of GPR31, and in expressing GPR31 protein for use
CC   in screening candidate drugs to treat diseases related to GPR31 activity
CC   and in studying the effect of the variation on the biological activity of
CC   GPR31 as well as on the binding affinity of candidate drugs targetting
CC   GPR31 for the treatment of cancer. They are also used in gene therapy.
CC   The haplotyping method is useful for improving the efficiency and
CC   reliability of several steps in the discovery and development of drugs
CC   for treating diseases associated with GPR31 activity e.g. cancer. This
CC   method is also useful for haplotyping GPR31 gene in an individual, which
CC   can also be used by the pharmaceutical research scientist to validate
CC   GPR31 as a candidate target for, and in design of clinical trials of
CC   candidate drugs, for treating a specific condition drugs or disease
CC   predicted to be associated with GPR31 activity. The present sequence is
CC   an allele specific oligonucleotide (ASO) primer used to detect human
CC   GPR31 gene polymorphisms
XX
SQ   Sequence 15 BP; 2 A; 7 C; 3 G; 2 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1663 GCATCACCCGCCCCT 1677
                ||||||||||  ||:|
Db          1 GCATCACCCGGCCST 15


RESULT 784
ABQ72847
ID   ABQ72847 standard; DNA; 15 BP.
XX
AC   ABQ72847;
XX
DT   06-SEP-2002  (first entry)
XX
DE   Human GRM8 allele-specific oligonucleotide (ASO) primer, SEQ ID NO:51.
XX
KW   Human; glutamate receptor metabotropic 8; GRM8; receptor;
KW   chromosome 7q31.3-32.1; neurotransmission; glutamate-mediated;
KW   Smith-Lemli-Opitz syndrome; retinitis pigmentosa;
KW   neuropathological disorder; neuroprotective; ophthalmological;
KW   gene therapy; haplotyping; genotyping; haplotype; genetic variant;
KW   single nucleotide polymorphism; SNP; drug screening; drug discovery;
KW   allele-specific oligonucleotide; ASO; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200238587-A2.
XX
PD   16-MAY-2002.
XX
PF   09-NOV-2001; 2001WO-US047325.
XX
PR   09-NOV-2000; 2000US-0247576P.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bieglecki KM,  Chew A,  Choi JY,  Koshy B,  Parks KE;
XX
DR   WPI; 2002-519291/55.
XX
PT   Genetic variants of Glutamate Receptor, Metabotropic 8 isogenes, useful
PT   for improving efficiency and reliability in drug development for treating
PT   neuropathological conditions and retinitis pigmentosa.
XX
PS   Claim 15; Page 14; 110pp; English.
XX
CC   The invention relates to a method for haplotyping the glutamate receptor,
CC   metabotropic 8 (GRM8) gene (ABQ72798, ABQ72905) of an individual, and
CC   also describes 21 novel polymorphic sites within the human GRM8 gene. The
CC   GRM8 gene is located on chromosome 7q31.3-32.1 and contains 10 exons
CC   which encode a 908 amino acid protein (ABB09564). GRM8 is involved in
CC   glutamate-mediated neurotransmission, being a member of a subfamily of
CC   metabotropic glutamate receptors that inhibit the activity of adenylate
CC   cyclase in response to glutamate stimulation. The chromosomal location of
CC   the GRM8 gene encompasses regions linked to Smith-Lemli-Opitz syndrome
CC   and a form of retinitis pigmentosa. GRM8 nucleic acid sequences are
CC   useful in studying the expression and function of GRM8, and in expressing
CC   GRM8 protein for use in screening drugs for the treatment of GRM8-
CC   associated diseases (e.g., neuropathological disorders, Smith-Lemli-Opitz
CC   syndrome and retinitis pigmentosa). GRM8 nucleic acids and proteins are
CC   also useful in studying the effect of polymorphisms on the biological
CC   activity of GRM8. Polymorphisms in the target region may be determined by
CC   the use of allele-specific oligonucleotides (ASOs; ABQ72800-ABQ72862) as
CC   probes and primers, and by primer extension using oligonucleotide primers
CC   comprising sequences ABQ72863-ABQ72904. The method of the invention is
CC   useful for haplotyping the GRM8 gene in populations and in individuals,
CC   enabling decisions to be made as to whether GRM8 is a likely therapeutic
CC   target for a disease of interest, and in the design of clinical trials of
CC   candidate drugs for treating GRM8-associated disorders. In addition,
CC   transgenic animals comprising a human GRM8 gene are useful for studying
CC   the expression of GRM8 isogenes in vivo, for in vivo screening and
CC   testing of drugs targeted to GRM8, and for testing the efficacy of
CC   therapeutic agents and compounds for treating GRM8-associated conditions
CC   in a biological system. Sequences ABQ72821-ABQ72862 represent
CC   specifically claimed allele-specific oligonucleotide (ASO) primers used
CC   for detecting polymorphisms in the GRM8 gene
XX
SQ   Sequence 15 BP; 2 A; 1 C; 1 G; 10 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4e+02;
  Matches   13;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAA 1784
                ||||||| |||||:|
Db          1 CTTTTTTATTTTGMA 15


RESULT 785
ADG65452
ID   ADG65452 standard; DNA; 15 BP.
XX
AC   ADG65452;
XX
DT   11-MAR-2004  (first entry)
XX
DE   UCP2 allele specific oligonucleotide probe seq id 48.
XX
KW   anorectic; antidiabetic; immunomodulator; gene therapy; haplotyping;
KW   uncoupling protein 2; mitochondrial; proton carrier; UCP2;
KW   polymorphic site; haplotype; haplotype pair; obesity; diabetes;
KW   immunological disorder; body mass defect; thermoregulation defect; human;
KW   ASO; allele specific oligonucleotide; primer; ss.
XX
OS   Homo sapiens.
XX
PN   US2003207284-A1.
XX
PD   06-NOV-2003.
XX
PF   16-JUL-2002; 2002US-00197019.
XX
PR   25-JAN-2001; 2001WO-US002485.
XX
PA   (CHEW/) CHEW A.
```

PA (DENT/) DENTON R R.
PA (GILS/) GILSON C R.
PA (NAND/) NANDABALAN K.
PA (PARK/) PARKS K E.
XX
PI Chew A, Denton RR, Gilson CR, Nandabalan K, Parks KE;
XX
DR WPI; 2004-051505/05.
XX
PT Haplotyping Uncoupling Protein 2 gene of an individual comprises
PT identifying the phased sequence of nucleotides at polymorphic sites of
PT the gene and assigning a haplotype or haplotype pair consistent with the
PT phased sequence.
XX
PS Disclosure; SEQ ID NO 48; 64pp; English.
XX
CC The invention describes haplotyping the uncoupling protein 2
CC (mitochondrial, proton carrier) (UCP2) gene of an individual comprising
CC identifying the phased sequence of nucleotides at polymorphic sites (PS)1
CC -23 for at least one copy of the individual's UCP2 gene and assigning to
CC the individual a UCP2 haplotype or haplotype pair that is consistent with
CC the phased sequence. The composition and methods are useful in
CC haplotyping and/or genotyping the UCP2 gene in an individual to e.g.
CC screen for drugs targeting the UCP2 protein to treat a condition or
CC disease predicted to be associated with UCP2 activity. The disease or
CC condition may include obesity, diabetes, immunological disorders and
CC other diseases associated with defects in body mass and thermoregulation.
CC This sequence represents an allele specific oligonucleotide primer used
CC for detecting human uncoupling protein 2 (UCP2) gene polymorphisms.
XX
SQ Sequence 15 BP; 1 A; 4 C; 2 G; 7 T; 0 U; 1 Other;

Query Match 2.3%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1920 CCTTTTTTTTCAGTG 1934
||||||| |||| :|
Db 1 CCTTTTTTCTCAGKG 15

RESULT 786
AAH95600/c
ID AAH95600 standard; RNA; 17 BP.
XX
AC AAH95600;
XX
DT 09-OCT-2001 (first entry)
XX
DE Human Chk1 ribozyme substrate SEQ ID NO: 1025.
XX
KW Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW RNA cleavage; cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200157206-A2.
XX
PD 09-AUG-2001.
XX
PF 02-FEB-2001; 2001WO-US003504.
XX
PR 03-FEB-2000; 2000US-0179983P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (FATT/) FATTAEY A R.
XX
PI Fattaey AR, Jarvis T, Mcswiggen J, Booher RN, Holman PS;
XX
DR WPI; 2001-496922/54.
XX
PT Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulates expression of a checkpoint kinase-1 gene,
PT useful for treating colorectal, lung, breast or prostate cancers.
XX
PS Claim 4; Page 78; 115pp; English.
XX
CC The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,
CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention
XX
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1654 ACTGGTTCTGCAT 1666
||||||||||||
Db 14 ACTGGTTCTGCAT 2

RESULT 787
ABA79481/c
ID ABA79481 standard; DNA; 17 BP.
XX
AC ABA79481;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2327.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 177; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,

CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 6 A; 5 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||||
Db 16 GGAAGAGTTTGTT 4

RESULT 788
ABA79480
ID ABA79480 standard; DNA; 17 BP.
XX
AC ABA79480;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2326.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 177; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 5 A; 1 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||||
Db 2 GGAAGAGTTTGTT 14

RESULT 789
ABA79476
ID ABA79476 standard; DNA; 17 BP.
XX
AC ABA79476;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2322.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 177; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic

CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 5 A; 1 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||
Db 1 GGAAGAGTTTGTT 13

RESULT 790
ABA79477/c
ID ABA79477 standard; DNA; 17 BP.
XX
AC ABA79477;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2323.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 177; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 5 A; 6 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||
Db 17 GGAAGAGTTTGTT 5

RESULT 791
ABA79468
ID ABA79468 standard; DNA; 17 BP.
XX
AC ABA79468;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2314.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 176; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can

CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 4 A; 1 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||||
Db 4 GGAAGAGTTTGTT 16

RESULT 792
ABA79469/c
ID ABA79469 standard; DNA; 17 BP.
XX
AC ABA79469;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2315.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 176; 294pp; English.
XX

CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 7 A; 5 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||||
Db 14 GGAAGAGTTTGTT 2

RESULT 793
ABA79472
ID ABA79472 standard; DNA; 17 BP.
XX
AC ABA79472;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2318.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 176; 294pp; English.

XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 4 A; 1 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||||
Db 4 GGAAGAGTTTGTT 16

RESULT 794
ABA79473/c
ID ABA79473 standard; DNA; 17 BP.
XX
AC ABA79473;
XX
DT 24-JAN-2002 (first entry)
XX
DE Factor IX mutation correcting oligonucleotide SEQ ID NO: 2319.
XX
KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
KW antilipemic; ss.
XX
OS Homo sapiens.
XX
PN WO200173002-A2.
XX
PD 04-OCT-2001.
XX
PF 27-MAR-2001; 2001WO-US009761.
XX
PR 27-MAR-2000; 2000US-0192176P.
PR 27-MAR-2000; 2000US-0192179P.
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC;
XX
DR WPI; 2001-639230/73.
XX
PT Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification.
XX
PS Claim 7; Page 176; 294pp; English.
XX
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting
CC oligonucleotides of the invention
XX
SQ Sequence 17 BP; 7 A; 5 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1614 GGAAGAGTTTGTT 1626
||||||||||||||
Db 14 GGAAGAGTTTGTT 2

RESULT 795
ABQ64257/c
ID ABQ64257 standard; DNA; 17 BP.
XX
AC ABQ64257;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 970.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-479509/51.

```
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 284; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACT 1751
              |||||||||||||
Db         13 GGTGACAAGTACT 1


RESULT 796
ABQ64251/c
ID   ABQ64251 standard; DNA; 17 BP.
XX
AC   ABQ64251;
XX
DT   20-AUG-2002  (first entry)
XX
DE   Human KTOM1a portion (ABQ63232) probe # 964.
XX
KW   Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW   gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW   kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200224750-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US029656.
XX
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   28-AUG-2001; 2001US-0315676P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhang J;
XX
DR   WPI; 2002-479509/51.
XX
PT   New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT   acids encoding the protein, useful for treating subjects having defects
PT   in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT   e.g., liver or bone.
XX
PS   Example 2; Page 284; 418pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid encoding human
CC   KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC   invention has cytostatic activity. The nucleotide may have a use in gene
CC   therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC   monitor a disease caused by altered expression of human KTOM1.
CC   Compositions comprising the nucleic acids, proteins or antibodies may be
CC   used to treat subjects having defects in KTOM1 which can manifest as
CC   cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC   heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC   function. The sequence represents a probe used in the invention to scan
CC   the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ   Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGG 1753
              |||||||||||||
Db         17 TGACAAGTACTGG 5


RESULT 797
ABV90244/c
ID   ABV90244 standard; DNA; 17 BP.
XX
AC   ABV90244;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 957.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
```

```
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 957; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 8 A; 1 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         15 TATCTCCTAACTT 3


RESULT 798
ABV90245/c
ID   ABV90245 standard; DNA; 17 BP.
XX
AC   ABV90245;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 958.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 958; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 8 A; 1 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         14 TATCTCCTAACTT 2


RESULT 799
ABV90243/c
ID   ABV90243 standard; DNA; 17 BP.
XX
AC   ABV90243;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 956.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
```

```
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 956; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 7 A; 1 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         16 TATCTCCTAACTT 4


RESULT 800
ABV90242/c
ID   ABV90242 standard; DNA; 17 BP.
XX
AC   ABV90242;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 955.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 955; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 7 A; 1 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         17 TATCTCCTAACTT 5


RESULT 801
ABV90246/c
ID   ABV90246 standard; DNA; 17 BP.
XX
AC   ABV90246;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 959.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
```

```
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 959; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 8 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         13 TATCTCCTAACTT 1

RESULT 802
ACC65383/c
ID   ACC65383 standard; DNA; 17 BP.
XX
AC   ACC65383;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 2630.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 338; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 3 A; 3 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGTG 1993
              |||||||||||||
Db         16 AAAAAGAAAAGTG 4

RESULT 803
ACC65669
ID   ACC65669 standard; DNA; 17 BP.
XX
AC   ACC65669;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 2916.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 371; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
```

```
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 6 A; 6 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2074 ATCTGACACACTC 2086
              |||||||||||||
Db          2 ATCTGACACACTC 14


RESULT 804
ABZ59602
ID   ABZ59602 standard; DNA; 17 BP.
XX
AC   ABZ59602;
XX
DT   22-APR-2003  (first entry)
XX
DE   Human parvovirus B19 PCR primer VSP1 SEQ ID NO:60.
XX
KW   Human parvovirus B19; parvovirus B19; infection; virus; blood; plasma;
KW   PCR primer; ss.
XX
OS   B19 virus.
OS   Synthetic.
XX
PN   WO2003002753-A2.
XX
PD   09-JAN-2003.
XX
PF   28-JUN-2002; 2002WO-US020684.
XX
PR   28-JUN-2001; 2001US-0302077P.
PR   19-MAR-2002; 2002US-0365956P.
PR   29-MAR-2002; 2002US-0369224P.
XX
PA   (CHIR ) CHIRON CORP.
XX
PI   Pichuantes S,  Shyamala V;
XX
DR   WPI; 2003-201510/19.
XX
PT   Detecting a human parvovirus B19 infection in a biological sample to
PT   prevent viral transmission, comprises reacting a parvovirus B19 nucleic
PT   acid with a primer complementary to the 3'-terminal portion of the RNA
PT   target sequence.
XX
PS   Example 5; Page 53; 148pp; English.
XX
CC   The present invention describes a method for detecting a human parvovirus
CC   B19 infection in a biological sample. The method comprises reacting the
CC   isolated parvovirus B19 nucleic acid with a first oligonucleotide
CC   consisting of a first primer containing a complexing sequence
CC   sufficiently complementary to the 3'-terminal portion of the RNA target
CC   sequence to complex with. Also described: (1) amplifying a target
CC   parvovirus B19 nucleotide sequence; (2) a polynucleotide comprising one
CC   of 47 700 base pair sequences (see ABZ59549 to ABZ59569, and ABZ59604 to
CC   ABZ59629); (3) a polynucleotide comprising either of 2 4678 base pair
CC   sequences (see ABZ59570 and ABZ59571); (4) an oligonucleotide primer
CC   consisting of a promoter region recognised by a DNA-dependent RNA
CC   polymerase operably linked to a human parvovirus B19-specific complexing
CC   sequence of 10-75 nucleotides; (5) an oligonucleotide probe comprising a
CC   parvovirus B19-specific hybridising sequence of 10-50 nucleotides linked
CC   to an acridinium ester label; and (6) a diagnostic test kit comprising an
CC   oligonucleotide primer of (4), and instructions for conducting the
CC   diagnostic test. The method is useful for detecting parvovirus infection
CC   in a biological sample, such as in blood products, to prevent
CC   transmission of the virus through blood and plasma derivatives or by
CC   close personal contact. ABZ59549 to ABZ59634 and ABP57262 to ABP57267
CC   represent sequences used in the exemplification of the present invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTT 2042
              |||||||||||||
Db          1 GGAGGCAAAGGTT 13


RESULT 805
ADB44145/c
ID   ADB44145 standard; DNA; 17 BP.
XX
AC   ADB44145;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #4468.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 554; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or réversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
```

```
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 8 A; 3 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGA 1805
              |||||||||||||
Db         15 TTTCCTTCTCTGA 3


RESULT 806
AAA57790/c
ID   AAA57790 standard; DNA; 18 BP.
XX
AC   AAA57790;
XX
DT   20-OCT-2000  (first entry)
XX
DE   Antisense oligonucleotide for the human PDE4C gene.
XX
KW   Antisense oligonucleotide; phosphodiesterase 4; PDE4; cystic fibrosis;
KW   acid resistant polymer; nuclease resistance; depression; thrombosis;
KW   pulmonary hypertension; glaucoma; multiple sclerosis; gastric lesion;
KW   atopic dermatitis; asthma; allergy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200040714-A2.
XX
PD   13-JUL-2000.
XX
PF   15-DEC-1999;   99WO-US029976.
XX
PR   30-DEC-1998;   98US-00223586.
PR   29-JUL-1999;   99US-00364626.
XX
PA   (OLIG-) OLIGOS ETC INC.
XX
PI   Dale RMK,  Arrow A,  Thompson T;
XX
DR   WPI; 2000-465980/40.
XX
PT   New acid resistant polymer complementary to phosphodiesterase 4 for
PT   treating depression, thrombosis, cystic fibrosis, gastric lesions,
PT   pulmonary hypertension, glaucoma, multiple sclerosis, atopic dermatitis
PT   and asthma.
XX
PS   Claim 7; Page 16; 48pp; English.
XX
CC   The present sequence represents an antisense oligonucleotide, directed
CC   against the phosphodiesterase 4C (PDE4C) gene. The oligonucleotide is
CC   used to construct the polymer of the invention. The specification
CC   describes an acid resistant polymer which is complementary to PDE4, and
CC   comprises a nucleic acid with a backbone structure that is modified from
CC   that of a naturally occurring nucleotide polymer and a blocking chemical
CC   modification at or near one end of the nucleic acid. The acid resistant
CC   polymer is characterized by a pH stability of an hour at pH 0.01 to 10
CC   and a nuclease resistance of twice that of naturally occurring nucleic
CC   acids which have the same number of nucleotides. The polymers are used to
CC   inhibit the expression of genes encoding PDE4. They are useful as
CC   analytical tools in the study of individual PDE isoforms and can treat
CC   depression, thrombosis, cystic fibrosis, gastric lesions, pulmonary
CC   hypertension, glaucoma, multiple sclerosis, atopic dermatitis, asthma,
CC   and other allergic disorders. Other illnesses in which an increase of
CC   cyclic AMP or decrease in phosphodiesterase levels is useful, can also be
CC   treated
XX
SQ   Sequence 18 BP; 2 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1735 AGAAGGTGACAAG 1747
              |||||||||||||
Db         18 AGAAGGTGACAAG 6


RESULT 807
AAX57180/c
ID   AAX57180 standard; DNA; 19 BP.
XX
AC   AAX57180;
XX
DT   26-JUL-1999  (first entry)
XX
DE   Porcine Oct-4 exon 4 PCR primer DA37.
XX
KW   Oct-4; porcine; selectable marker construct; promoter; stem cell;
KW   differential expression; selective isolation; pluripotent; propagation;
KW   cell surface membrane protein; rejection; xenotransplantation;
KW   transgenic pig; organ; transplant; programmed cell death; PCR primer; ss.
XX
OS   Synthetic.
OS   Sus scrofa.
XX
PN   WO9919469-A1.
XX
PD   22-APR-1999.
XX
PF   09-OCT-1998;   98WO-US021289.
XX
PR   09-OCT-1997;   97US-00948113.
XX
PA   (BIOT-) BIOTRANSPLANT INC.
XX
PI   Baetscher MW,  Akiyoshi DE,  Kaplan RA;
XX
DR   WPI; 1999-312473/26.
XX
PT   Porcine stem cells comprising a marker gene under an Oct-4 promoter.
XX
PS   Example 1; Page 15; 69pp; English.
XX
CC   This sequence describes novel methods where a genetic selectable marker
CC   construct operatively linked to a porcine promoter is introduced into a
CC   source of cells that contain porcine stem cells under conditions that
CC   allows for differential expression of the marker and hence the selective
CC   isolation and/or propagation of desired porcine stem cells. The methods
CC   are used to isolate and/or enrich and/or selectively propagate
CC   pluripotent porcine cells and to genetically modify porcine cells. The
CC   embryonic stem cells could be altered so as to not express a cell surface
CC   membrane protein that may cause rejection of porcine cells after
CC   xenotransplantation. Transgenic pigs generated through the modified
CC   porcine stem cells are useful for providing organs suitable for
CC   transplants. The methods overcome the problem of prior art methods
CC   associated with the continuing presence of certain differentiated cell
CC   types that can cause elimination of stem cells from the culture by
CC   inducing their differentiation of programmed cell death. The invention
CC   specifically describes the use of the porcine Oct-4 promoter
CC   polynucleotide sequence
XX
SQ   Sequence 19 BP; 4 A; 5 C; 5 G; 2 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACCCGCC 1674
              ||||||||:| |  :||:|
Db         19 TGGTTCTGYAACCGSCGSC 1
```

```
RESULT 808
AAA84663
ID   AAA84663 standard; DNA; 19 BP.
XX
AC   AAA84663;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin E ribozyme binding site #196.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 80; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 4 A; 11 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db          5 ATCCTTCTCCACC 17


RESULT 809
AAA84664
ID   AAA84664 standard; DNA; 19 BP.
XX
AC   AAA84664;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin E ribozyme binding site #197.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 80; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 5 A; 10 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db          4 ATCCTTCTCCACC 16


RESULT 810
AAH59825
ID   AAH59825 standard; DNA; 19 BP.
XX
AC   AAH59825;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cyclin E ribozyme binding site SEQ ID NO:2249.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
```

```
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 235; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 4 A; 11 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db          5 ATCCTTCTCCACC 17


RESULT 811
AAH59826
ID   AAH59826 standard; DNA; 19 BP.
XX
AC   AAH59826;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cyclin E ribozyme binding site SEQ ID NO:2250.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 235; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 5 A; 10 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db          4 ATCCTTCTCCACC 16


RESULT 812
ADF49462
ID   ADF49462 standard; RNA; 19 BP.
XX
AC   ADF49462;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human BCL2 siNA lower sequence SEQ ID NO:190.
XX
KW   ss; siNA; human; BCL2; short interfering nucleic acid; RNA interference;
KW   cytostatic; immunosuppressive; virucide; anti-HIV; cancer;
KW   autoimmune disease; viral infection; HIV.
XX
OS   Homo sapiens.
XX
PN   WO2003070969-A2.
XX
PD   28-AUG-2003.
XX
PF   18-FEB-2003; 2003WO-US004908.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   18-JUL-2002; 2002US-0396905P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
```

```
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-712622/67.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer or autoimmune disease, downregulates expression of
PT   the BCL2 gene.
XX
PS   Example 3; SEQ ID NO 190; 148pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of the BCL2 gene by RNA interference. A
CC   siNA of the invention has cytostatic, immunosuppressive, virucide, and
CC   anti-HIV activity. The siNA are useful for modulation (inhibition) of
CC   expression or activity of BCL2 by RNA interference. siNA are used to
CC   modulate expression of BCL2 genes, in cells, tissue explants or
CC   organisms, e.g. for treating cancer, autoimmune diseases and viral
CC   infections (including by HIV) but also for drug screening, diagnosis,
CC   target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function and gene mapping (e.g. of single
CC   -nucleotide polymorphisms). The sequences shown in ADF49273-ADF50143
CC   represent siNA of the invention.
XX
SQ   Sequence 19 BP; 8 A; 1 C; 8 G; 0 T; 2 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAG 1560
              |||||||||||||
Db          6 AGGGAAGGAACAG 18


RESULT 813
ADF49876/c
ID   ADF49876 standard; RNA; 19 BP.
XX
AC   ADF49876;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human BCL2 siNA lower sequence SEQ ID NO:604.
XX
KW   ss; siNA; human; BCL2; short interfering nucleic acid; RNA interference;
KW   cytostatic; immunosuppressive; virucide; anti-HIV; cancer;
KW   autoimmune disease; viral infection; HIV.
XX
OS   Homo sapiens.
XX
PN   WO2003070969-A2.
XX
PD   28-AUG-2003.
XX
PF   18-FEB-2003; 2003WO-US004908.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   18-JUL-2002; 2002US-0396905P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-712622/67.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer or autoimmune disease, downregulates expression of
PT   the BCL2 gene.
XX
PS   Example 3; SEQ ID NO 604; 148pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of the BCL2 gene by RNA interference. A
CC   siNA of the invention has cytostatic, immunosuppressive, virucide, and
CC   anti-HIV activity. The siNA are useful for modulation (inhibition) of
CC   expression or activity of BCL2 by RNA interference. siNA are used to
CC   modulate expression of BCL2 genes, in cells, tissue explants or
CC   organisms, e.g. for treating cancer, autoimmune diseases and viral
CC   infections (including by HIV) but also for drug screening, diagnosis,
CC   target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function and gene mapping (e.g. of single
CC   -nucleotide polymorphisms). The sequences shown in ADF49273-ADF50143
CC   represent siNA of the invention.
XX
SQ   Sequence 19 BP; 2 A; 8 C; 1 G; 0 T; 8 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAG 1560
              |||||||||||||
Db         14 AGGGAAGGAACAG 2


RESULT 814
ADM80438
ID   ADM80438 standard; DNA; 19 BP.
XX
AC   ADM80438;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human HERV-H PCR primer retrocdrfor SEQ ID NO:22.
XX
KW   PCR; human; ss; HERV-H; cancer; human endogenous retroviral elements;
KW   HERV; cytostatic; immunostimulant; gene therapy; vaccine; immunotherapy;
KW   primer.
XX
OS   Homo sapiens.
XX
PN   EP1338606-A1.
XX
PD   27-AUG-2003.
XX
PF   22-FEB-2002; 2002EP-00003989.
XX
PR   22-FEB-2002; 2002EP-00003989.
XX
PA   (VKNE/) VON KNEBEL D M.
XX
PI   Von Knebel Doeberitz M,  Wentzensen N,  Gebert J,  Linnebacher M;
XX
DR   WPI; 2003-682116/65.
XX
PT   New cancer-associated human endogenous retroviral elements (HERV)-H
PT   polypeptides and nucleic acids, useful for immunotherapy for treating
PT   cancer, e.g. gastrointestinal cancer or anogenital cancer.
XX
PS   Example 2; SEQ ID NO 22; 46pp; English.
XX
CC   The invention relates to a novel nucleic acid encoding a cancer-
CC   associated human endogenous retroviral elements (HERV)-H polypeptide or a
CC   polypeptide exhibiting a biological activity of a cancer-associated HERV-
CC   H polypeptide. A protein of the invention has cytostatic and
CC   immunostimulant activity. A HERV-H polynucleotide may have a use in gene
CC   therapy, and in a vaccine. The polynucleotide, polypeptide, the
CC   recombinant vector, the antisense RNA sequence, the ribozyme, the binding
CC   agent, the antibody, or the activator/agonist or inhibitor/antagonist of
```

CC HERV-H is useful for the preparation of a pharmaceutical composition for
CC immunotherapy for the treatment of cancer, e.g. gastrointestinal cancer
CC or anogenital cancer. The method of detecting HERV-H ORF molecules in a
CC biological sample may be used for the detection of cancer, a precursor of
CC a cancer, or disposition to cancer, or for monitoring the progression of
CC cancer in a patient. The method may also be used for the detection of a
CC minimal residual disease. The present sequence represents a PCR primer
CC used to amplify the HERV-H gene of the invention.
XX
SQ Sequence 19 BP; 6 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1585 CACAGACTGGGAA 1597
||||||||||||||
Db 2 CACAGACTGGGAA 14

RESULT 815
ADM80423
ID ADM80423 standard; DNA; 19 BP.
XX
AC ADM80423;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human HERV-H PCR primer 2 SEQ ID NO:7.
XX
KW PCR; human; ss; HERV-H; cancer; human endogenous retroviral elements;
KW HERV; cytostatic; immunostimulant; gene therapy; vaccine; immunotherapy;
KW primer.
XX
OS Homo sapiens.
XX
PN EP1338606-A1.
XX
PD 27-AUG-2003.
XX
PF 22-FEB-2002; 2002EP-00003989.
XX
PR 22-FEB-2002; 2002EP-00003989.
XX
PA (VKNE/) VON KNEBEL D M.
XX
PI Von Knebel Doeberitz M, Wentzensen N, Gebert J, Linnebacher M;
XX
DR WPI; 2003-682116/65.
XX
PT New cancer-associated human endogenous retroviral elements (HERV)-H
PT polypeptides and nucleic acids, useful for immunotherapy for treating
PT cancer, e.g. gastrointestinal cancer or anogenital cancer.
XX
PS Example 2; SEQ ID NO 7; 46pp; English.
XX
CC The invention relates to a novel nucleic acid encoding a cancer-
CC associated human endogenous retroviral elements (HERV)-H polypeptide or a
CC polypeptide exhibiting a biological activity of a cancer-associated HERV-
CC H polypeptide. A protein of the invention has cytostatic and
CC immunostimulant activity. A HERV-H polynucleotide may have a use in gene
CC therapy, and in a vaccine. The polynucleotide, polypeptide, the
CC recombinant vector, the antisense RNA sequence, the ribozyme, the binding
CC agent, the antibody, or the activator/agonist or inhibitor/antagonist of
CC HERV-H is useful for the preparation of a pharmaceutical composition for
CC immunotherapy for the treatment of cancer, e.g. gastrointestinal cancer
CC or anogenital cancer. The method of detecting HERV-H ORF molecules in a
CC biological sample may be used for the detection of cancer, a precursor of
CC a cancer, or disposition to cancer, or for monitoring the progression of
CC cancer in a patient. The method may also be used for the detection of a
CC minimal residual disease. The present sequence represents a PCR primer
CC used to amplify the HERV-H gene of the invention.
XX
SQ Sequence 19 BP; 6 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1585 CACAGACTGGGAA 1597
||||||||||||||
Db 2 CACAGACTGGGAA 14

RESULT 816
ADH01664/c
ID ADH01664 standard; RNA; 19 BP.
XX
AC ADH01664;
XX
DT 11-MAR-2004 (first entry)
XX
DE Protein tyrosine phosphatase siRNA sequence, SEQ ID No 276.
XX
KW small interfering RNA; siRNA; protein tyrosine phosphatase; PTP; PTP1B;
KW insulin receptor protein phosphorylation; Jak2; antidiabetic; anorectic;
KW antiinflammatory; neuroprotective; cytostatic; immunosuppressive;
KW antimicrobial; gene therapy; ss; siRNA.
XX
OS Unidentified.
XX
PN WO2003099227-A2.
XX
PD 04-DEC-2003.
XX
PF 23-MAY-2003; 2003WO-US016651.
XX
PR 23-MAY-2002; 2002US-0383249P.
PR 14-APR-2003; 2003US-0462942P.
XX
PA (CEPT-) CEPTYR INC.
XX
PI Lewis SP, Klinghoffer R, Wilson LK;
XX
DR WPI; 2004-035036/03.
XX
PT New small interfering polynucleotide that modulates protein tyrosine
PT phosphatase (PTP)1B polypeptide signal transduction, useful for treating
PT disorders associated with altered PTP1B signal transduction, e.g.
PT diabetes or cancer.
XX
PS Example 3; SEQ ID NO 276; 234pp; English.
XX
CC The invention relates to a novel isolated small interfering RNA (siRNA)
CC polynucleotide, comprising at least one nucleotide sequence from any of
CC the 20 fully defined sequences given in the specification. The invention
CC further relates to: a pharmaceutical composition comprising a new siRNA
CC polynucleotide and a physiological carrier; a recombinant nucleic acid
CC construct, comprising a polynucleotide that is capable of directing
CC transcription of an siRNA; a host cell transformed or transfected with
CC the above recombinant nucleic acid construct; a method for interfering
CC with expression of a protein tyrosine phosphatase (PTP)1B polypeptide, or
CC its variant; a method for identifying a component of a PTP1B signal
CC transduction pathway; a method for modulating an insulin receptor protein
CC phosphorylation state in a cell; a method for altering a Jak2 protein
CC phosphorylation state in a cell; and a method for treating a Jak2-
CC associated disorder. The siRNA has the following activities:
CC antidiabetic, anorectic, antiinflammatory, neuroprotective, cytostatic,
CC immunosuppressive, and antimicrobial. The novel siRNA polynucleotides can
CC be used in gene therapy to treat disorders. The composition and methods
CC are useful in treating disorders associated with PTP1B-mediated signal
CC transduction, such as diabetes, obesity, hyperglycaemia-induced
CC apoptosis, inflammation, neurodegenerative disorders, cancer, autoimmune
CC diseases or infection. This polynucleotide sequence represents an siRNA
CC used for modulating the signal transduction of a protein tyrosine
CC phosphatase of the invention.

```
XX
SQ   Sequence 19 BP; 6 A; 3 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2006 CTTCAGAGATCAA 2018
              |||||||||||||
Db         19 CTTCAGAGATCAA 7


RESULT 817
ADK72436/c
ID   ADK72436 standard; DNA; 19 BP.
XX
AC   ADK72436;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Cycloclasticus gyrB gene primer, pCG-r.
XX
KW   detection; quantification; Cycloclasticus; beta-subunit; DNA gyrase;
KW   microbial-flora; petroleum-degrading; oil; contamination; primer; ss.
XX
OS   Cycloclasticus.
XX
PN   JP2004024221-A.
XX
PD   29-JAN-2004.
XX
PF   26-JUN-2002; 2002JP-00222158.
XX
PR   26-JUN-2002; 2002JP-00222158.
XX
PA   (KAIY-) KAIYO BIOTECHNOLOGY KENKYUSHO KK.
XX
DR   WPI; 2004-161480/16.
XX
PT   Detecting or quantifying bacteria of Cycloclasticus genus, useful for
PT   detecting petroleum degrading microbes, involves amplifying gene encoding
PT   beta-subunit of DNA gyrase.
XX
PS   Claim 1; SEQ ID NO 2; 13pp; Japanese.
XX
CC   The invention relates to a novel method for detecting or quantifying
CC   bacteria of Cycloclasticus genus involves amplifying the gene encoding
CC   the beta-subunit of DNA gyrase. The novel method is useful for detecting
CC   the microbial-flora structure of petroleum-degrading microorganisms at
CC   the time of an offshore oil contamination. This polynucleotide sequence
CC   represents a primer used in the exemplification of the invention.
XX
SQ   Sequence 19 BP; 2 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAA 1746
              |||||||||||||
Db         19 CAGAAGGTGACAA 7


RESULT 818
ADQ27935/c
ID   ADQ27935 standard; DNA; 19 BP.
XX
AC   ADQ27935;
XX
DT   26-AUG-2004  (first entry)
XX
DE   RNA interference target sequence #843.
XX
KW   ss; detection; RNA interference; siRNA; gene silencing; gene expression;
KW   cytotoxicity.
XX
OS   Homo sapiens.
XX
PN   WO2004048566-A1.
XX
PD   10-JUN-2004.
XX
PF   21-NOV-2003; 2003WO-JP014893.
XX
PR   22-NOV-2002; 2002JP-00340053.
XX
PA   (NATO/) NATORI Y.
PA   (SAIG/) SAIGO K.
PA   (TEIK/) TEI K.
PA   (NAIT/) NAITO Y.
XX
PI   Saigo K,  Tei K,  Naito Y;
XX
DR   WPI; 2004-487423/46.
XX
PT   Detecting sequence of RNA interference useful for synthesizing siRNA, by
PT   detecting regions in sequence fulfilling specific criteria such as base
PT   at 3' terminal is adenine, thymine or uracil, base at 5' terminal is
PT   guanine or cytosine.
XX
PS   Disclosure; SEQ ID NO 857; 325pp; Japanese.
XX
CC   The invention relates to a method of detecting the base sequence for RNA
CC   interference by detecting the regions in the DNA sequence fulfilling the
CC   following requirements such as: (i) the base at 3' terminal is adenine,
CC   thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine;
CC   (iii) the seven base sequence at 3' terminal is rich in adenine, thymine
CC   and uracil, and; (iv) there are bases in a such a number that it causes
CC   RNA interference without showing cytotoxicity. The method is used for
CC   designing and synthesizing siRNA causing RNA interference. This sequence
CC   corresponds to an RNA interference target sequence of the invention.
XX
SQ   Sequence 19 BP; 9 A; 1 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 4.6e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTC 2009
              |||||||||||||
Db         13 ATCTAGCTTCTTC 1


RESULT 819
AAQ56478
ID   AAQ56478 standard; DNA; 20 BP.
XX
AC   AAQ56478;
XX
DT   25-MAR-2003  (revised)
DT   29-JUL-1994  (first entry)
XX
DE   E1 positive strand primer TYP06.
XX
KW   Human papilloma virus; amplification; polymerase chain reaction; PCR;
KW   detection; assay; genital; ss.
XX
OS   Synthetic.
XX
PN   US5283171-A.
XX
PD   01-FEB-1994.
XX
PF   15-FEB-1991;   91US-00651356.
XX
PR   09-SEP-1988;   88US-00243486.
```

```
PR   10-MAR-1989;   89US-00322550.
PR   29-AUG-1989;   89WO-US003747.
XX
PA   (UYRP ) UNIV ROCHESTER.
PA   (HOFF ) HOFFMANN LA ROCHE INC.
XX
PI   Wolinsky SM,  Broker TR,  Ting Y,  Manos MM,  Wright DK;
XX
DR   WPI; 1994-048082/06.
XX
PT   Detection of genital human papilloma virus - by PCR amplification using
PT   defined consensus primer pairs.
XX
PS   Disclosure; Page 10; 13pp; English.
XX
CC   The sequence is that of the human papilloma virus (HPV) E1 positive
CC   strand primer TYP06 which was used in the amplification by PCR of HPV
CC   DNA. It may be used as part of a simple and rapid assay method for
CC   detecting and typing HPV in biological samples. (Updated on 25-MAR-2003
CC   to correct PF field.)
XX
SQ   Sequence 20 BP; 2 A; 0 C; 7 G; 8 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db          2 GTAMWGGMTGGTTTATG 18


RESULT 820
AAQ56484/c
ID   AAQ56484 standard; DNA; 20 BP.
XX
AC   AAQ56484;
XX
DT   25-MAR-2003  (revised)
DT   29-JUL-1994  (first entry)
XX
DE   E1 negative strand primer TYN06.
XX
KW   Human papilloma virus; amplification; polymerase chain reaction; PCR;
KW   detection; assay; genital; ss.
XX
OS   Synthetic.
XX
PN   US5283171-A.
XX
PD   01-FEB-1994.
XX
PF   15-FEB-1991;   91US-00651356.
XX
PR   09-SEP-1988;   88US-00243486.
PR   10-MAR-1989;   89US-00322550.
PR   29-AUG-1989;   89WO-US003747.
XX
PA   (UYRP ) UNIV ROCHESTER.
PA   (HOFF ) HOFFMANN LA ROCHE INC.
XX
PI   Wolinsky SM,  Broker TR,  Ting Y,  Manos MM,  Wright DK;
XX
DR   WPI; 1994-048082/06.
XX
PT   Detection of genital human papilloma virus - by PCR amplification using
PT   defined consensus primer pairs.
XX
PS   Disclosure; Page 10; 13pp; English.
XX
CC   The sequence is that of the human papilloma virus (HPV) E1 negative
CC   strand primer TYN06 which was used in the amplification by PCR of HPV
CC   DNA. It may be used as part of a simple and rapid assay method for
CC   detecting and typing HPV in biological samples. (Updated on 25-MAR-2003
CC   to correct PF field.)
XX
SQ   Sequence 20 BP; 8 A; 7 C; 0 G; 2 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db         19 GTAMWGGMTGGTTTATG 3


RESULT 821
AAQ83955/c
ID   AAQ83955 standard; DNA; 20 BP.
XX
AC   AAQ83955;
XX
DT   25-MAR-2003  (revised)
DT   10-OCT-1995  (first entry)
XX
DE   Cyclic-GMP stimulated nucleotide PDE PCR primer PCR-2S.
XX
KW   Cyclic-GMP stimulated nucleotide phospho-diesterase; PCR-2S;
KW   bovine brain; hormones; neurotransmitters; transmission regulation;
KW   antibodies; enzyme purification; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   US5389527-A.
XX
PD   14-FEB-1995.
XX
PF   20-APR-1992;   92US-00872644.
XX
PR   19-APR-1991;   91US-00688356.
XX
PA   (UNIW ) UNIV WASHINGTON.
XX
PI   Sonnenburg WK,  Charbonneau H,  Beavo JA;
XX
DR   WPI; 1995-090205/12.
XX
PT   New nucleic acid encoding cyclic-GMP stimulated nucleotide phospho-
PT   di:esterase - and related vectors and transformed cells, useful for
PT   screening cpds. for phospho-di:esterase modulating activity.
XX
PS   Example 1; Col 9; 69pp; English.
XX
CC   AAQ83955 and AAQ83956 are a pair of primers for the PCR amplification of
CC   a nucleotide sequence encoding a bovine brain cyclic-GMP stimulated
CC   nucleotide phospho-diesterase (CaM PDE). Eukaryotic cells that express
CC   CaM PDE can be used to screen cpds. for the ability to modulate CaM PDE
CC   activity. CaM PDEs are involved in regulating the transmission of
CC   information from hormones, neurotransmitters or other systems that use
CC   cyclic nucleotides as messengers. Antibodies raised against CaM PDE can
CC   be used for enzyme purifcn., or determination. (Updated on 25-MAR-2003 to
CC   correct PF field.)
XX
SQ   Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 822
```

```
AAT44867/c
ID   AAT44867 standard; DNA; 20 BP.
XX
AC   AAT44867;
XX
DT   25-MAR-2003  (revised)
DT   05-FEB-1997  (first entry)
XX
DE   HPV E1 consensus negative primer TYN06.
XX
KW   Probe; primer; PCR; polymerase chain reaction; amplification;
KW   human papillomavirus; consensus; ss.
XX
OS   Synthetic.
XX
PN   US5527898-A.
XX
PD   18-JUN-1996.
XX
PF   07-JUN-1995;   95US-00474542.
XX
PR   09-SEP-1988;   88US-00243486.
PR   10-MAR-1989;   89US-00322550.
PR   09-SEP-1989;   89WO-US003747.
PR   14-NOV-1990;   90US-00613142.
PR   20-APR-1993;   93US-00050743.
PR   24-SEP-1993;   93US-00126452.
XX
PA   (HOFF ) HOFFMANN LA ROCHE INC.
XX
PI   Bauer HM,  Resnick RM,  Greer CE,  Manos MM,  Zhang TY,  Gravitt PE;
XX
DR   WPI; 1996-299903/30.
XX
PT   Nucleic acid hybridisation probes - specific for selected human papilloma
PT   virus types.
XX
PS   Disclosure; Col 43-44; 96pp; English.
XX
CC   The invention relates to new oligonucleotide probes and primers used for
CC   the detection of human papillomaviruses (HPV) which are not genital types
CC   6, 11, 16, 18 or 33. The probes and primers AAT44608-T44693 are esp. used
CC   to detect HPV types 26, 31, 31B, 35, 39, 40, 43, 45, 51-59 and 68. The
CC   primers can be used to detect these HPV types in conjunction with the
CC   consensus primers and typing probes AAT44733-T44906, which are based on
CC   and amplify fragments of the L1, E6, E7 and E1 regions of the HPV
CC   sequences. Detection of the amplification prods. is done with probes
CC   derived from consensus sequences found in all characterised HPV
CC   sequences. The negative strand primers AAT44862-9 are used with the
CC   positive strand primers AAT44859-62 to amplify a region of the E1 region
CC   of HPV sequences. However the E1 region is well conserved between among
CC   HPVs so detection of the E1 region is more readily accomplished when the
CC   E6 or E7 region is included. Thus the primers can be used with the E6 and
CC   E7 primers AAT44813-32. Detection of these E6/E1 or E7/E1 amplification
CC   prods. uses probes AAT44870-1. (Updated on 25-MAR-2003 to correct PF
CC   field.)
XX
SQ   Sequence 20 BP; 8 A; 7 C; 0 G; 2 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| ||||||  ||
Db         19 GTAMWGGMTGGTTTATG 3


RESULT 823
AAT44861
ID   AAT44861 standard; DNA; 20 BP.
XX
AC   AAT44861;
XX
DT   25-MAR-2003  (revised)
DT   05-FEB-1997  (first entry)
XX
DE   HPV E1 consensus positive strand primer TYP06.
XX
KW   Probe; primer; PCR; polymerase chain reaction; amplification;
KW   human papillomavirus; consensus; ss.
XX
OS   Synthetic.
XX
PN   US5527898-A.
XX
PD   18-JUN-1996.
XX
PF   07-JUN-1995;   95US-00474542.
XX
PR   09-SEP-1988;   88US-00243486.
PR   10-MAR-1989;   89US-00322550.
PR   09-SEP-1989;   89WO-US003747.
PR   14-NOV-1990;   90US-00613142.
PR   20-APR-1993;   93US-00050743.
PR   24-SEP-1993;   93US-00126452.
XX
PA   (HOFF ) HOFFMANN LA ROCHE INC.
XX
PI   Bauer HM,  Resnick RM,  Greer CE,  Manos MM,  Zhang TY,  Gravitt PE;
XX
DR   WPI; 1996-299903/30.
XX
PT   Nucleic acid hybridisation probes - specific for selected human papilloma
PT   virus types.
XX
PS   Disclosure; Col 43-44; 96pp; English.
XX
CC   The invention relates to new oligonucleotide probes and primers used for
CC   the detection of human papillomaviruses (HPV) which are not genital types
CC   6, 11, 16, 18 or 33. The probes and primers AAT44608-T44693 are esp. used
CC   to detect HPV types 26, 31, 31B, 35, 39, 40, 43, 45, 51-59 and 68. The
CC   primers can be used to detect these HPV types in conjunction with the
CC   consensus primers and typing probes AAT44733-T44906, which are based on
CC   and amplify fragments of the L1, E6, E7 and E1 regions of the HPV
CC   sequences. Detection of the amplification prods. is done with probes
CC   derived from consensus sequences found in all characterised HPV
CC   sequences. The positive strand primers AAT44856-61 are used with the
CC   negative strand primers AAT44862-9 to amplify a region of the E1 region
CC   of HPV sequences. However the E1 region is well conserved between among
CC   HPVs so detection of the E1 region is more readily accomplished when the
CC   E6 or E7 region is included. Thus the primers can be used with the E6 and
CC   E7 primers AAT44813-32. Detection of these E6/E1 or E7/E1 amplification
CC   prods. uses probes AAT44870-1. (Updated on 25-MAR-2003 to correct PF
CC   field.)
XX
SQ   Sequence 20 BP; 2 A; 0 C; 7 G; 8 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| ||||||  ||
Db         2 GTAMWGGMTGGTTTATG 18


RESULT 824
AAT51092/c
ID   AAT51092 standard; cDNA; 20 BP.
XX
AC   AAT51092;
XX
DT   25-MAR-2003  (revised)
DT   17-MAR-1997  (first entry)
XX
```

```
DE   Primer #1 for calcium/calmodulin dependent phosphodiesterase.
XX
KW   Cyclic GMP stimulated phosphodiesterase; cGS-PDE; bovine; brain; cAMP;
KW   adrenal gland; transmembrane signal; extracellular hormone; antibody;
KW   neurotransmitter; cGMP; calcium/calmodulin dependent phosphotriesterase;
KW   CaM-PDE; polymerase chain reaction; PCR; primer; amplify; ss.
XX
OS   Synthetic.
XX
PN   US5580771-A.
XX
PD   03-DEC-1996.
XX
PF   29-AUG-1994;   94US-00297494.
XX
PR   19-APR-1991;   91US-00688356.
PR   20-APR-1992;   92US-00872644.
XX
PA   (UNIW ) UNIV WASHINGTON.
XX
PI   Charbonneau H,  Sonnenburg WK,  Beavo JA;
XX
DR   WPI; 1997-033573/03.
XX
PT   DNA encoding cGMP-stimulated phospho:di:esterase - for prodn. of
PT   recombinant enzyme.
XX
PS   Example 1; Col 8; 68pp; English.
XX
CC   AAT51092 and AAT51093 represent amplification primers for the coding
CC   sequence for the calcium/calmodulin dependent phosphodiesterase (CaM-PDE)
CC   isolated from bovine brain (see AAT51094). The cyclic nucleotide
CC   phosphodiesterases (PDEs) catalyse the hydrolysis of 3', 5' cyclic
CC   nucleotides, such as cAMP and cGMP, to their corresponding 5'-nucleotide
CC   monophosphates. The PDEs are therefore important in the control of the
CC   cellular concentration of cyclic nucleotides. The PDEs are, in turn,
CC   regulated by transmembrane signals or second messenger ligands such as
CC   calcium ion or cGMP. The PDEs therefore have a central role in regulating
CC   the flow of information from extracellular hormones, neurotransmitters,
CC   or other signals that use the cyclic nucleotides as messengers. PDEs are
CC   present in most of the cells and tissues of eukaryotic organisms, but
CC   only in trace amounts. CaM-PDEs are responsive to intracellular calcium,
CC   which leads to a decreased intracellular concentration of cAMP, and/or
CC   cGMP. The amplified sequence can be used for the production of
CC   recombinant CaM-PDE, which may have therapeutic and diagnostic uses. The
CC   encoded protein may also be useful for diagnostic antibody production.
CC   (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ   Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 825
AAT77976
ID   AAT77976 standard; DNA; 20 BP.
XX
AC   AAT77976;
XX
DT   25-MAR-2003  (revised)
DT   06-OCT-1997  (first entry)
XX
DE   Human papillomavirus E1 positive strand specific primer TYP06.
XX
KW   Human; papillomavirus; HPV; primer; amplification; PCR;
KW   polymerase chain reaction; E1; positive strand; detection; ss.
XX
OS   Synthetic.
XX
PN   US5639871-A.
XX
PD   17-JUN-1997.
XX
PF   01-JUN-1995;   95US-00457648.
XX
PR   09-SEP-1988;   88US-00243486.
PR   10-MAR-1989;   89US-00322550.
PR   29-AUG-1989;   89WO-US003747.
PR   14-NOV-1990;   90US-00613142.
PR   20-APR-1993;   93US-00050743.
PR   24-SEP-1993;   93US-00126452.
XX
PA   (HOFF ) ROCHE MOLECULAR SYSTEMS INC.
XX
PI   Impraim CC,  Manos MM,  Bauer HM,  Zhang TY,  Greer CE,  Resnick RM;
PI   Gravitt PE;
XX
DR   WPI; 1997-332084/30.
XX
PT   New oligo:nucleotide probes for human papilloma-virus - used for
PT   detecting and typing HPV and for detecting previously unknown HPV types
PT   and subtypes.
XX
PS   Disclosure; Col 103-104; 94pp; English.
XX
CC   The present sequence is a human papillomavirus (HPV) E1 positive strand
CC   specific primer. (Updated on 25-MAR-2003 to correct PF field.) (Updated
CC   on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 20 BP; 2 A; 0 C; 7 G; 8 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db          2 GTAMWGGMTGGTTTATG 18


RESULT 826
AAT77982/c
ID   AAT77982 standard; DNA; 20 BP.
XX
AC   AAT77982;
XX
DT   25-MAR-2003  (revised)
DT   06-OCT-1997  (first entry)
XX
DE   Human papillomavirus E1 negative strand specific primer TYN06.
XX
KW   Human; papillomavirus; HPV; primer; amplification; PCR;
KW   polymerase chain reaction; E1; negative strand; detection; ss.
XX
OS   Synthetic.
XX
PN   US5639871-A.
XX
PD   17-JUN-1997.
XX
PF   01-JUN-1995;   95US-00457648.
XX
PR   09-SEP-1988;   88US-00243486.
PR   10-MAR-1989;   89US-00322550.
PR   29-AUG-1989;   89WO-US003747.
PR   14-NOV-1990;   90US-00613142.
PR   20-APR-1993;   93US-00050743.
PR   24-SEP-1993;   93US-00126452.
XX
PA   (HOFF ) ROCHE MOLECULAR SYSTEMS INC.
```

```
XX
PI   Impraim CC,  Manos MM,  Bauer HM,  Zhang TY,  Greer CE,  Resnick RM;
PI   Gravitt PE;
XX
DR   WPI; 1997-332084/30.
XX
PT   New oligo:nucleotide probes for human papilloma-virus - used for
PT   detecting and typing HPV and for detecting previously unknown HPV types
PT   and subtypes.
XX
PS   Disclosure; Col 105-106; 94pp; English.
XX
CC   The present sequence is a human papillomavirus (HPV) E1 negative strand
CC   specific primer. (Updated on 25-MAR-2003 to correct PF field.) (Updated
CC   on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 20 BP; 8 A; 7 C; 0 G; 2 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db         19 GTAMWGGMTGGTTTATG 3


RESULT 827
AAT67204/c
ID   AAT67204 standard; cDNA; 20 BP.
XX
AC   AAT67204;
XX
DT   25-MAR-2003  (revised)
DT   31-JUL-1997  (first entry)
XX
DE   Bovine brain 61 kDa CaM-PDE PCR sense primer CaM PCR-2S.
XX
KW   Ca2+/calmodulin stimulated cyclic nucleotide phosphodiesterase enzyme;
KW   calcium ion; antibody; cow; polymerase chain reaction; ss.
XX
OS   Synthetic.
XX
PN   US5602019-A.
XX
PD   11-FEB-1997.
XX
PF   29-AUG-1994;   94US-00297510.
XX
PR   19-APR-1991;   91US-00688356.
PR   20-APR-1992;   92US-00872644.
XX
PA   (UNIW ) UNIV WASHINGTON.
XX
PI   Sonnenburg WK,  Charbonneau H,  Bentley JK,  Beavo JA;
XX
DR   WPI; 1997-131799/12.
XX
PT   DNA encoding bovine and human phosphodiesterase enzymes - stimulated by
PT   calcium/calmodulin, useful for recombinant prodn. of the enzymes.
XX
PS   Example 1; Col 8; 69pp; English.
XX
CC   The present sequence represents the PCR sense primer designated Ca PCR-2S
CC   for amplifying a 612 bp Ca2+/calmodulin-stimulated cyclic nucleotide
CC   phosphodiesterase (CaM-PDE) cDNA fragment derived from bovine brain. The
CC   DNA sequences of the CaM-PDE's are used for the production of the
CC   recombinant enzymes, which in turn may be used for antibody production
CC   and to screen for compounds that modulate phosphodiesterase activity.
CC   (Updated on 25-MAR-2003 to correct PF field.) (Updated on 25-MAR-2003 to
CC   correct PI field.)
XX
SQ   Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 828
AAV54738/c
ID   AAV54738 standard; DNA; 20 BP.
XX
AC   AAV54738;
XX
DT   29-OCT-1998  (first entry)
XX
DE   PCR primer CaM PCR-2S used to amplify 61 kDa CaM-PDE DNA.
XX
KW   Ca2+/calmodulin sensitive cyclic nucleotide phosphodiesterase; CaM-PDE;
KW   assay; identification; modification; enzymatic activity; modulator;
KW   PCR primer; ss.
XX
OS   Synthetic.
OS   Bos sp.
XX
PN   US5800987-A.
XX
PD   01-SEP-1998.
XX
PF   31-MAY-1995;   95US-00455525.
XX
PR   19-APR-1991;   91US-00688356.
PR   20-APR-1992;   92US-00872644.
PR   29-AUG-1994;   94US-00297494.
XX
PA   (UNIW ) UNIV WASHINGTON.
XX
PI   Sonnenburg WK,  Charbonneau H,  Beavo JA,  Bentley JK;
XX
DR   WPI; 1998-494762/42.
XX
PT   Identification of modulators of Calcium/calmodulin sensitive cyclic
PT   nucleotide phosphodiesterase - uses recombinant cells expressing the
PT   enzyme and monitoring protein expression in the presence of potential
PT   modulators.
XX
PS   Example 1; Col 8; 69pp; English.
XX
CC   PCR primers AAV54738-39 were used to amplify DNA encoding the 61 kDa
CC   Ca2+/calmodulin sensitive cyclic nucleotide phosphodiesterase (CaM-PDE)
CC   from bovine brain. CaM-PDE enzymes catalyse the hydrolysis of cyclic
CC   nucleotides and as such control their intracellular level. They are
CC   controlled by second messengers e.g. Ca2+ and calmodulin and
CC   transmembrane signals and through pathways involving these, regulate flow
CC   of information from extracellular hormones, neurotransmitters and other
CC   signals using cyclic nucleotides as messengers. The specification
CC   describes an assay for identifying a chemical agent which modifies the
CC   enzymatic activity of a mammalian CaM-PDE. The assays are useful for
CC   identifying modulators of CaM-PDEs. The assay is carried out by
CC   incubating cells expressing CaM-PDE with the suspected modulator and
CC   measuring its effect e.g. monitoring the hydrolysis of cAMP and/or cGMP
XX
SQ   Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1
```

```
RESULT 829
AAV17463/c
ID   AAV17463 standard; DNA; 20 BP.
XX
AC   AAV17463;
XX
DT   25-MAR-2003  (revised)
DT   04-JUN-1998  (first entry)
XX
DE   Primer TYN06 for human papillomavirus typing.
XX
KW   Human papillomavirus; HPV; HPV detection; HPV typing;
KW   E1 type-specific probe; PCR primer; ss.
XX
OS   Synthetic.
OS   Human papillomavirus.
XX
PN   US5705627-A.
XX
PD   06-JAN-1998.
XX
PF   26-MAY-1995;   95US-00452055.
XX
PR   09-SEP-1988;   88US-00243486.
PR   10-MAR-1989;   89US-00322550.
PR   14-NOV-1990;   90US-00613142.
PR   20-APR-1993;   93US-00050743.
XX
PA   (HOFF ) ROCHE MOLECULAR SYSTEMS INC.
XX
PI   Ting Y,  Resnick RM,  Greer CE,  Bauer HM,  Manos MM;
XX
DR   WPI; 1998-192210/17.
XX
PT   Human papilloma probes and primers - useful for, e.g. detecting and
PT   typing of human papilloma viruses.
XX
PS   Claim 8; Col 23-24; 37pp; English.
XX
CC   This sequence represents a human papillomavirus (HPV) E1 type-specific
CC   primer of the invention. This sequence may be used in conjuncture with L1
CC   specific probes for detecting and typing HPV. Identification and typing
CC   of HPV is important as different types of HPV pose different risks for
CC   infected individuals. HPV16 and HPV18 have been more consistently
CC   identified in higher grades of cervical dysplasia and carcinoma than
CC   other HPV types. (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 20 BP; 8 A; 7 C; 0 G; 2 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db         19 GTAMWGGMTGGTTTATG 3


RESULT 830
AAV17471
ID   AAV17471 standard; DNA; 20 BP.
XX
AC   AAV17471;
XX
DT   25-MAR-2003  (revised)
DT   04-JUN-1998  (first entry)
XX
DE   Primer TYP06 for human papillomavirus typing.
XX
KW   Human papillomavirus; HPV; HPV detection; HPV typing;
KW   E1 type-specific probe; PCR primer; ss.
XX
OS   Synthetic.
OS   Human papillomavirus.
XX
PN   US5705627-A.
XX
PD   06-JAN-1998.
XX
PF   26-MAY-1995;   95US-00452055.
XX
PR   09-SEP-1988;   88US-00243486.
PR   10-MAR-1989;   89US-00322550.
PR   14-NOV-1990;   90US-00613142.
PR   20-APR-1993;   93US-00050743.
XX
PA   (HOFF ) ROCHE MOLECULAR SYSTEMS INC.
XX
PI   Ting Y,  Resnick RM,  Greer CE,  Bauer HM,  Manos MM;
XX
DR   WPI; 1998-192210/17.
XX
PT   Human papilloma probes and primers - useful for, e.g. detecting and
PT   typing of human papilloma viruses.
XX
PS   Claim 8; Col 23-24; 37pp; English.
XX
CC   This sequence represents a human papillomavirus (HPV) E1 type-specific
CC   primer of the invention. This sequence may be used in conjuncture with L1
CC   specific probes for detecting and typing HPV. Identification and typing
CC   of HPV is important as different types of HPV pose different risks for
CC   infected individuals. HPV16 and HPV18 have been more consistently
CC   identified in higher grades of cervical dysplasia and carcinoma than
CC   other HPV types. (Updated on 25-MAR-2003 to correct PR field.)
XX
SQ   Sequence 20 BP; 2 A; 0 C; 7 G; 8 T; 0 U; 3 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db          2 GTAMWGGMTGGTTTATG 18


RESULT 831
AAV48182/c
ID   AAV48182 standard; DNA; 20 BP.
XX
AC   AAV48182;
XX
DT   09-NOV-1998  (first entry)
XX
DE   Ca2+/calmodulin stimulated phosphodiesterase primer CaM PCR-2S.
XX
KW   ss; PCR; primer; amplification; cow; Ca2+ stimulated phosphodiesterase;
KW   Calmodulin stimulated phosphodiesterase; therapeutic; antibody.
XX
OS   Synthetic.
OS   Bos sp.
XX
PN   US5789553-A.
XX
PD   04-AUG-1998.
XX
PF   31-MAY-1995;   95US-00455526.
XX
PR   19-APR-1991;   91US-00688356.
PR   20-APR-1992;   92US-00872644.
PR   29-AUG-1994;   94US-00297494.
XX
PA   (UNIW ) UNIV WASHINGTON.
XX
```

PI Sonnenburg WK, Charbonneau H, Beavo JA, Bentley JK;
XX
DR WPI; 1998-446185/38.
XX
PT Antibody to phosphodiesterase polypeptide - useful for purification or
PT detection of polypeptide.
XX
PS Example 1; Col 8; 68pp; English.
XX
CC The primers AAV48182-V48183 were used in the isolation of a 61 KDa
CC Ca2+/calmodulin stimulated phosphodiesterase from bovine brain tissue.
CC The phosphodiesterases isolated in this invention were used to transform
CC host cells, preferably mammalian or yeast cells. The recombinant proteins
CC and fragments produced can be used for therapeutic, diagnostic, and
CC prognostic purposes and will provide the basis for preparation of
CC monoclonal and polyclonal antibodies. An antibody specific for the
CC Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE)
CC polypeptide is useful for affinity purification or detection of the
CC polypeptide and is selective only for the Ca2+/calmodulin stimulated
CC cyclic nucleotide PDE polypeptide
XX
SQ Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

Query Match 2.3%; Score 13; DB 1; Length 20;
Best Local Similarity 65.0%; Pred. No. 4.8e+02;
Matches 13; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 1774 TTTTTTTTGAACCCCATTCT 1793
||:||:|| | |||||: |
Db 20 TTYTTYTTCATNCCCATYTT 1

RESULT 832
AAV36135/c
ID AAV36135 standard; DNA; 20 BP.
XX
AC AAV36135;
XX
DT 07-SEP-1998 (first entry)
XX
DE Primer CaM PCR-2S used to amplify a 612 bp fragment of bovine CaM-PDE.
XX
KW Bovine; decrease; intracellular concentration; cAMP; cGMP;
KW calcium ion/calmodulin stimulated cyclic nucleotide phosphodiesterase;
KW CaM-PDE; therapy; prognosis; diagnosis; specific modulator;
KW CaM-PDE activity; identification; signalling; extracellular hormone;
KW neurotransmitter; selective inhibitor; cardiotonic; antidepressant;
KW antihypertensive; antithrombotic agent; PCR primer; ss.
XX
OS Synthetic.
OS Bos sp.
XX
PN US5776752-A.
XX
PD 07-JUL-1998.
XX
PF 07-JUN-1995; 95US-00479532.
XX
PR 19-APR-1991; 91US-00688356.
PR 20-APR-1992; 92US-00872644.
PR 29-AUG-1994; 94US-00297494.
XX
PA (UNIW) UNIV WASHINGTON.
XX
PI Sonnenburg WK, Charbonneau H, Bentley JK, Beavo JA;
XX
DR WPI; 1998-398038/34.
XX
PT New calmodulin and calcium stimulated cyclic nucleotide phosphodiesterase
PT - used e.g to identify selective modulators, potentially useful as e.g.
PT cardiotonic, antidepressant, antihypertensive agents.
XX
PS Example 1; Col 8; 69pp; English.
XX
CC PCR primers AAV36135-36 were used to amplify a 612 bp cDNA fragment from
CC bovine brain encoding calcium ion/calmodulin stimulated cyclic nucleotide
CC phosphodiesterase (CaM-PDE) polypeptide. The full length CaM-PDE cDNA is
CC 61 kDa (see AAV36137). CaM-PDEs are characterised by their responsiveness
CC to intracellular calcium, which leads to a decreased intracellular
CC concentration of cAMP and/or cGMP. CaM-PDEs, and their fragments or
CC synthetic peptides, are used in therapy, prognosis and diagnosis. They
CC are also used to generate specific antibodies useful as immunoassay
CC reagents for detecting the protein or for affinity purification and for
CC identifying specific modulators of CaM-PDE activity. CaM-PDEs are
CC implicated in signalling involving extracellular hormones and
CC neurotransmitters, so selective inhibitors are potentially useful as
CC cardiotonic, antidepressant, antihypertensive and antithrombotic agents
XX
SQ Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

Query Match 2.3%; Score 13; DB 1; Length 20;
Best Local Similarity 65.0%; Pred. No. 4.8e+02;
Matches 13; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 1774 TTTTTTTTGAACCCCATTCT 1793
||:||:|| | |||||: |
Db 20 TTYTTYTTCATNCCCATYTT 1

RESULT 833
AAZ90358/c
ID AAZ90358 standard; DNA; 20 BP.
XX
AC AAZ90358;
XX
DT 05-JUN-2000 (first entry)
XX
DE Bovine 61 kD CaM-PDE degenerate PCR primer, SEQ ID NO:1.
XX
KW Phosphodiesterase; calcium; calmodulin; cyclic guanidine monophosphate;
KW cGMP; cyclic nucleotide; messenger; signal transduction; regulation;
KW inhibitor; cardiotonic; antidepressant; antihypertensive; antithrombotic;
KW PCR primer; ss.
XX
OS Bos taurus.
XX
PN US6015677-A.
XX
PD 18-JAN-2000.
XX
PF 25-AUG-1998; 98US-00139491.
XX
PR 19-APR-1991; 91US-00688356.
PR 20-APR-1992; 92US-00872644.
PR 29-AUG-1994; 94US-00297494.
PR 31-MAY-1995; 95US-00455525.
XX
PA (UNIW) UNIV WASHINGTON.
XX
PI Charbonneau H, Sonnenburg WK, Bentley KJ, Beavo JA;
XX
DR WPI; 2000-181142/16.
DR P-PSDB; AAY80966.
XX
PT Assay for inhibitors of cyclic guanidine monophosphate-stimulated
PT nucleotide phosphodiesterase, potentially useful as cardiotonic agents,
PT from their ability to alter a heat-shock phenotype.
XX
PS Example I; Col 8; 69pp; English.
XX
CC The invention relates to purified and isolated nucleotide sequences
CC encoding mammalian Ca2+/calmodulin-stimulated phosphodiesterases (CaM-
CC PDEs) and cyclic guanidine monophosphate (cGMP)-stimulated
CC phosphodiesterases (cGS-PDEs). In particular the invention relates to an
CC assay for identifying chemicals that modify the enzymatic activity of a
CC mammalian cGS-PDE. The PDEs catalyse the hydrolysis of of cyclic

CC nucleotides to their corresponding 5'-nucleoside monophosphates. In this
CC way they control the cellular concentration of cyclic nucleotides,
CC thereby regulating the flow of information from extracellular hormones,
CC neurotransmitters or other signals that use cyclic nucleotides as
CC messengers. The PDEs in turn are regulated by transmembrane signals or
CC second messsenger ligands such as Ca2+ or cGMP. Inhibitors of these
CC enzymes are potentially useful as cardiotonics, antidepressants,
CC antihypertensives or antithrombotics. The method of the invention can
CC identify specific inhibitors of particular isoforms of cGS-PDEs.
CC Sequences AAZ90360, AAZ90367, AAZ90370, AAZ90372, AAZ90377, AAZ90380-
CC Z90381 and AAZ90383-Z90385 represent cDNA clones encoding isoforms of CaM
CC -PDEs and cGS-PDEs from bovines and humans. The present sequence
CC represents a PCR primer used in an exemplification of the present
CC invention to isolate and amplify DNA encoding a PDE
XX
SQ Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

Query Match 2.3%; Score 13; DB 1; Length 20;
Best Local Similarity 65.0%; Pred. No. 4.8e+02;
Matches 13; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 1774 TTTTTTTTGAACCCCATTCT 1793
||:||:|| | |||||: |
Db 20 TTYTTYTTCATNCCCATYTT 1

RESULT 834
AAF27130/c
ID AAF27130 standard; DNA; 20 BP.
XX
AC AAF27130;
XX
DT 06-APR-2001 (first entry)
XX
DE Human cyclin E antisense oligonucleotide ANG 1048, SEQ ID NO:5.
XX
KW Human cyclin E gene; 3' UTR; 3' untranslated region; cell cycle control;
KW G1 phase cyclin; S phase entry; cellular proliferation; antisense;
KW expression inhibition; antiproliferative; antipsoriatic; cytostatic;
KW restenosis; cancer; psoriasis; phosphorothioate; ss.
XX
OS Homo sapiens.
XX
PN WO200100821-A1.
XX
PD 04-JAN-2001.
XX
PF 19-JAN-2000; 2000WO-CA000049.
XX
PR 23-JUN-1999; 99US-0140446P.
XX
PA (ANGI-) ANGIOGENE INC.
XX
PI Levesque L;
XX
DR WPI; 2001-112453/12.
XX
PT Antisense oligonucleotide, useful for modulating human cyclin E gene
PT expression and inhibiting cellular proliferation caused by restenosis and
PT cancer, has a sequence complementary to the 5' or 3' untranslated region
PT of cyclin E gene.
XX
PS Claim 3; Page 13; 52pp; English.
XX
CC Sequences AAF27128-AAF27139 represent antisense oligonucleotides
CC targetted to the 5' or 3' UTR (untranslated region) of the human cyclin E
CC gene. Cyclin E is a G1 phase cell cycle protein which regulates the entry
CC of cells into the S phase. The antisense oligonucleotides of the
CC invention inhibit the expression of cyclin E, thereby inhibiting cellular
CC proliferation. The antisense oligonucleotides are useful for inhibiting
CC or preventing cellular proliferation, and can thus be used in the
CC treatment of restenosis, cancer and psoriasis. The antisense
CC oligonucleotides are also useful for the manufacture of a medicament for
CC inhibiting cellular proliferation
XX
SQ Sequence 20 BP; 4 A; 0 C; 13 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1571 ATCCTTCTCCACC 1583
||||||||||||
Db 13 ATCCTTCTCCACC 1

RESULT 835
ABQ93273
ID ABQ93273 standard; DNA; 20 BP.
XX
AC ABQ93273;
XX
DT 29-AUG-2003 (revised)
DT 21-OCT-2002 (first entry)
XX
DE T. tauschii/wheat D genome microsatellite cfa2193 right PCR primer.
XX
KW Microsatellite marker; wheat; D genome; mapping; genotyping;
KW polymorphism; phenotypic trait; QTL; quantitative trait locus;
KW disease-associated gene; development factor; quality factor;
KW resistance factor; wheat product; identification; detection;
KW genetically modified wheat; PCR; primer; ss.
XX
OS Aegilops tauschii.
OS Triticum aestivum.
XX
PN EP1217079-A1.
XX
PD 26-JUN-2002.
XX
PF 22-DEC-2000; 2000EP-00403659.
XX
PR 22-DEC-2000; 2000EP-00403659.
XX
PA (INRG) INRA INST NAT RECH AGRONOMIQUE.
XX
PI Bernard M, Sourdille P, Guyomarch H;
XX
DR WPI; 2002-550410/59.
XX
PT Map of wheat D genome comprising the genome location of a microsatellite
PT marker, useful for e.g. identifying genes responsible for a desired
PT phenotypic trait, especially quantitative trait loci in wheat, and
PT diseases.
XX
PS Claim 4; Page 10; 105pp; English.
XX
CC The invention relates to a map of the bread wheat D genome comprising the
CC genome location of a microsatellite marker selected from a group of 185
CC such markers (ABQ92733-ABQ92917). The invention also encompasses the use
CC of left (ABQ92918-ABQ93102) and right (ABQ93103-ABQ93287) primers to
CC amplify and detect the microsatellite markers, and to identify genes
CC responsible for a phenotypic trait of interest in wheat. Wheat is an
CC allohexaploid species consisting of 3 diploid genomes designated A, B and
CC D, resulting from two successive intercrossings involving at least three
CC different species. The D genome is thought to have been introduced in the
CC most recent intercrossing, between the amphiploid AABB and Triticum
CC tauschii (DD), probably involving only a limited number of genotypes of
CC both species. Due to its polyploid genome, the large size of its genome,
CC and its low level of polymorphism, the genetic mapping of wheat has to
CC date been difficult. Microsatellites are tandemly repeated sequences
CC between one and six nucleotides long, and are very polymorphic in length,
CC mainly due to polymerase slippage during replication. This high degree of
CC polymorphism makes them especially suitable for the genetic mapping of
CC species which show little intraspecies polymorphism, such as wheat. In
CC addition, microsatellites are codominant, and exhibit Mendelian

```
CC   inheritance. The 185 microsatellite markers of the invention are
CC   developed from the ancestral diploid donor species Triticum tauschii and
CC   map to the wheat D genome, which is less polymorphic than the A or B
CC   genomes. These microsatellite markers thus help to overcome some of the
CC   problems associated with the genetic mapping of wheat. The wheat D genome
CC   map and the microsatellite markers and associated primers of the
CC   invention are useful for identifying genes responsible for a phenotypic
CC   trait of interest, most notably QTLs (quantitative trait loci). In
CC   particular they may be used for analysing genes and alleles implicated in
CC   disease and for identifying development factors, quality factors and
CC   factors conferring resistance to pathogens and xenobiotics. The
CC   microsatellite markers, and associated primers may be also be used in
CC   mapping and genotyping diploid and polyploid species of Triticum,
CC   particularly Aegilops, Triticum monococcum, Triticum durum, Triticum
CC   aestivum, or related species; for identifying cultivars and hybrids of
CC   Triticum and related species; to assess whether or not a product
CC   comprises wheat or a related species; and to assess whether or not a
CC   product comprises genetically modified wheat. The present sequence
CC   represents a specifically claimed Triticum tauschii/wheat genome D
CC   microsatellite marker right PCR primer of the invention. (Updated on 29-
CC   AUG-2003 to standardise OS field)
XX
SQ   Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1782 GAACCCCATTCTT 1794
              |||||||||||||
Db          7 GAACCCCATTCTT 19


RESULT 836
ABX78835/c
ID   ABX78835 standard; DNA; 20 BP.
XX
AC   ABX78835;
XX
DT   15-APR-2003  (first entry)
XX
DE   Bovine 61kDa CaM-PDE degenerate PCR primer, PCR2S.
XX
KW   Cow; ss; PCR primer; Ca2+/calmodulin stimulated phosphodiesterase;
KW   CaM-PDE; 59KDa CaM-PDE; 61kDa CaM-PDE; 63kDa CaM-PDE; cGS-PDE;
KW   cyclic-GMP-stimulated phosphodiesterase; cardiotonic agent;
KW   antidepressant; anti-hypertensive; anti-thrombotic.
XX
OS   Bos taurus.
XX
PN   US2002151024-A1.
XX
PD   17-OCT-2002.
XX
PF   18-JUN-2001; 2001US-00883825.
XX
PR   19-APR-1991;   91US-00688356.
PR   20-APR-1992;   92US-00872644.
PR   31-MAY-1995;   95US-00455526.
PR   28-JUL-1998;   98US-00123783.
XX
PA   (UNIW ) UNIV WASHINGTON.
XX
PI   Beavo JA,  Bentley JK,  Charbonneau H,  Sonnenburg WK;
XX
DR   WPI; 2003-198291/19.
DR   P-PSDB; ABU58705.
XX
PT   New purified and isolated DNA sequence encoding a mammalian
PT   calcium/calmodulin- or cyclic GMP-stimulated cyclic nucleotide
PT   phosphodiesterase polypeptide, useful for therapeutic, diagnostic and
PT   prognostic applications.
XX
PS   Example 1; Page 5; 71pp; English.
XX
CC   The invention relates to purified and isolated polynucleotide sequence
CC   encoding a mammalian Ca^2+/calmodulin- or cyclic GMP-stimulated cyclic
CC   nucleotide phosphodiesterase polypeptide (CaMP-PDE and cGS-PDE). Also
CC   included are a DNA vector comprising the novel DNA sequence, a host cell
CC   transformed with the polynucleotide sequence, a polypeptide product of
CC   the expression in the transformed host cell, an antibody specifically
CC   immunoreactive with the polypeptide and assay methods for identifying a
CC   chemical agent which modifies the enzymatic activity of a mammalian CaMP-
CC   PDE or cGS-PDE. Disclosed are the cDNA and protein sequences of bovine
CC   59KDa CaM-PDE, 61kDa CaM-PDE, 63kDa CaM-PDE, cGS-PDE and human 61kDa CaM-
CC   PDE and cGS-PDE. The DNA sequence is useful for producing a polypeptide
CC   having the enzymatic activity of a mammalian CaM-PDE or cGS-PDE which is
CC   used in therapeutic, diagnostic and prognostic applications and in the
CC   preparation of antibodies. Isolated chemical agents which are inhibitors
CC   of PDEs may have anti-depressant, anti- hypertensive or anti-thrombotic
CC   activities or may be cardiotonic agents. The present sequence is a PCR
CC   primer used in the isolation of the CaM-PDE or cGS-PDE cDNAs of the
CC   invention
XX
SQ   Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 837
ABZ88892/c
ID   ABZ88892 standard; DNA; 20 BP.
XX
AC   ABZ88892;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human oligonucleotide sequence.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 4134; 872pp; English.
XX
```

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 2 C; 1 G; 12 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1980 AAAAAAGAAAAGT 1992
||||||||||||||
Db 15 AAAAAAGAAAAGT 3

RESULT 838
ABZ89699
ID ABZ89699 standard; DNA; 20 BP.
XX
AC ABZ89699;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 4941; 872pp; English.
XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 1 C; 2 G; 12 T; 0 U; 0 Other;

Query Match 2.3%; Score 13; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1831 TTTTAAATACATT 1843
||||||||||||||
Db 3 TTTTAAATACATT 15

RESULT 839
ABD25929
ID ABD25929 standard; DNA; 20 BP.
XX
AC ABD25929;
XX
DT 29-JUL-2004 (first entry)
XX
DE AA505075-derived oligonucleotide SEQ ID 4941.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX

```
PS   Claim 15; SEQ ID NO 4941; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 5 A; 1 C; 2 G; 12 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1831 TTTTAAATACATT 1843
              |||||||||||||
Db          3 TTTTAAATACATT 15


RESULT 840
ABD25122/c
ID   ABD25122 standard; DNA; 20 BP.
XX
AC   ABD25122;
XX
DT   29-JUL-2004  (first entry)
XX
DE   AI041482-derived oligonucleotide SEQ ID 4134.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 4134; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 20 BP; 5 A; 2 C; 1 G; 12 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGT 1992
              |||||||||||||
Db         15 AAAAAAGAAAAGT 3


RESULT 841
ADL59472
ID   ADL59472 standard; DNA; 20 BP.
XX
AC   ADL59472;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Human ESM-1 antisense oligonucleotide seqid 1721.
XX
KW   cytostatic; antidiabetic; immunomodulator; cardiant; neuroprotective;
KW   gene therapy; endothelial specific molecule-1; ESM-1;
KW   ESM-1 related disorder; diabetes; cancer; ischaemia; reperfusion injury;
KW   angiogenic disorder; immunological disorder; cardiovascular disorder;
KW   neurological disorder; antisense technology; ss.
XX
OS   Homo sapiens.
```

```
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .20
FT                   /*tag= b
FT                   /mod_base= OTHER
FT                   /note= "OTHER= phosphorothioate backbone. All cytidine
FT                   residues are 5-methylcytidines"
FT   modified_base   1. .5
FT                   /*tag= a
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
FT   modified_base   16. .20
FT                   /*tag= c
FT                   /mod_base= OTHER
FT                   /note= "OTHER= 2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN   WO2004021978-A2.
XX
PD   18-MAR-2004.
XX
PF   19-AUG-2003; 2003WO-US025833.
XX
PR   19-AUG-2002; 2002US-0404495P.
XX
PA   (PHAA ) PHARMACIA CORP.
XX
PI   Weinstein EJ, Griggs DW;
XX
DR   WPI; 2004-248358/23.
XX
PT   New antisense compound, having a sequence targeted to a nucleic acid
PT   encoding endothelial specific molecule-1 (ESM-1), useful for preparing a
PT   composition for treating e.g., diabetes, cancer or cardiovascular
PT   disorder.
XX
PS   Claim 3; SEQ ID NO 1721; 555pp; English.
XX
CC   The invention describes a new antisense compound, having a sequence
CC   comprising 8-30 bp targeted to a nucleic acid encoding endothelial
CC   specific molecule-1 (ESM-1), that specifically hybridises with the
CC   nucleic acid ESM-1 and inhibits its expression. Also described are: a
CC   composition; inhibiting the expression of ESM-1 in cells or tissues; and
CC   treating an animal having a disease or condition associated with ESM-1.
CC   The compound is useful for preparing a composition for treating diabetes,
CC   cancer, ischaemia or reperfusion injury, or angiogenic, immunological,
CC   cardiovascular or neurological disorder. This sequence represents an
CC   antisense oligonucleotide that can be used to modulate expression of
CC   endothelial specific molecule-1 (ESM-1).
XX
SQ   Sequence 20 BP; 10 A; 2 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match          2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCT 1976
              |||||||||||||
Db          8 TAAATATTTACCT 20


RESULT 842
ADQ94921/c
ID   ADQ94921 standard; DNA; 20 BP.
XX
AC   ADQ94921;
XX
DT   23-SEP-2004  (first entry)
XX
DE   Bovine 61 kDa CaM-PDE DNA amplifying PCR primer, CaM PCR-2S.
XX
KW   CaM-PDE;
KW   Ca 2+/ calmodulin stimulated cyclic nucleotide phosphodiesterase; cGMP;
KW   cyclic-guanosine monophosphate; cGS-PDE;
KW   cyclic-GMP stimulated cyclic nucleotide phosphodiesterase; bovine; PCR;
KW   primer; ss.
XX
OS   Bos sp.
XX
PN   US2004126866-A1.
XX
PD   01-JUL-2004.
XX
PF   30-OCT-2003; 2003US-00697894.
XX
PR   19-APR-1991;   91US-00688356.
PR   20-APR-1992;   92US-00872644.
PR   29-AUG-1994;   94US-00297494.
PR   31-MAY-1995;   95US-00455526.
PR   28-JUL-1998;   98US-00123783.
PR   18-JUN-2001; 2001US-00883825.
XX
PA   (BEAV/) BEAVO J A.
PA   (BENT/) BENTLEY J K.
PA   (CHAR/) CHARBONNEAU H.
PA   (SONN/) SONNENBURG W K.
XX
PI   Beavo JA, Bentley JK, Charbonneau H, Sonnenburg WK;
XX
DR   WPI; 2004-516912/49.
XX
PT   Novel mammalian calcium/calmodulin stimulated cyclic phosphodiesterase
PT   nucleotide sequence useful for identifying chemical agent that modifies
PT   enzymatic activity of calcium/calmodulin stimulated cyclic
PT   phosphodiesterase polypeptide.
XX
PS   Example 1; SEQ ID NO 1; 72pp; English.
XX
CC   The present invention provides a mammalian Ca 2+/ calmodulin stimulated
CC   cyclic nucleotide phosphodiesterase (CaM-PDE) and cyclic-guanosine
CC   monophosphate (cGMP) stimulated cyclic nucleotide phosphodiesterase (cGS-
CC   PDE) polypeptide and its polynucleotide. The invention is useful for
CC   producing a polypeptide having enzymatic activity of mammalian CaM-PDE
CC   and cGS-PDE. The invention is also useful for identifying a chemical
CC   agent that modifies the enzymatic activity of mammalian CaM-PDE and cGS-
CC   PDE. The present sequence is bovine CaM-PDE DNA amplifying PCR primer.
XX
SQ   Sequence 20 BP; 10 A; 0 C; 4 G; 2 T; 0 U; 4 Other;

  Query Match          2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 843
AAT27053
ID   AAT27053 standard; DNA; 16 BP.
XX
AC   AAT27053;
XX
DT   15-OCT-1996  (first entry)
XX
DE   Telomerase template sequence for telomere GT-rich region insertion.
XX
KW   Yeast; telomerase; RNA template; TLC1; telomerase component-1;
KW   ribonucleoprotein; telomere; replication; reverse transcription; tumour;
KW   pathogen; sperm; ovum; reporter gene; drug screening; antibody;
KW   immunoassay; antitumour; antiseptic; contraceptive; infertility;
KW   diagnostic; gene therapy; ss.
XX
OS   Saccharomyces cerevisiae.
XX
PN   WO9612811-A2.
```

```
XX
PD   02-MAY-1996.
XX
PF   20-OCT-1995;   95WO-US013801.
XX
PR   20-OCT-1994;   94US-00326781.
PR   28-APR-1995;   95US-00431080.
XX
PA   (ARCH-) ARCH DEV CORP.
XX
PI   Gottschling DE,  Singer MS;
XX
DR   WPI; 1996-239169/24.
XX
PT   Novel telomerase associated polypeptide(s) and related nucleic acid -
PT   useful for detecting e.g. tumour cells or pathogens.
XX
PS   Claim 39; Page 10; 349pp; English.
XX
CC   This sequence encodes the Saccharomyces cerevisiae telomerase RNA
CC   template sequence, and is present in the TLC1 (telomerase component-1,
CC   STR2) gene (AAT27045). Telomerase is a ribonucleoprotein required for
CC   telomere replication. The CA-rich template sequence allows a GT-rich
CC   sequence (AAT27054) to be inserted into the telomere via reverse
CC   transcription, for subsequent elongation by telomerase. The sequence may
CC   be used to detect non-ciliate telomerase-associated genes, e.g. in
CC   tumour, pathogen, sperm or ovum cells. New telomerase-associated
CC   sequences may be detected by a reporter gene expression system linked to
CC   an expression-repressing telomere sequence, and binding compounds, e.g.
CC   antibodies, may be detected by complex formation with telomerase
CC   components. The products may be used as antitumour, antiseptic or
CC   contraceptive agents, in infertility diagnosis, or in gene therapy
XX
SQ   Sequence 16 BP; 6 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 4.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
                || ||  ||||||||||
Db          1 CACCACACCCACACAC 16


RESULT 844
AAT91229/c
ID   AAT91229 standard; RNA; 16 BP.
XX
AC   AAT91229;
XX
DT   18-DEC-1997  (first entry)
XX
DE   Hairpin ribozyme recognition site in human hepatitis B virus 999.
XX
KW   Hairpin ribozyme; inhibition; replication; infectivity; HBV;
KW   hepatitis B virus; hepatic; human; ss.
XX
OS   Hepatitis B virus.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    5. .6
FT                   /*tag=  a
FT                   /standard_name= "Cleavage_Site"
XX
PN   WO9708309-A2.
XX
PD   06-MAR-1997.
XX
PF   29-AUG-1996;   96WO-US013975.
XX
PR   29-AUG-1995;   95US-00521255.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Goldenberg T,  Yu M,  Welch PJ,  Barber JR;
XX
DR   WPI; 1997-179266/16.
XX
PT   New hairpin ribozyme - for inhibiting replication and infectivity of
PT   hepatitis B virus.
XX
PS   Example 1; Page 17; 34pp; English.
XX
CC   A new hairpin ribozyme has been developed which is able to inhibit
CC   replication and infectivity of hepatitis B virus (HBV). The present
CC   sequence represents a hairpin ribozyme recognition site in human HBV. The
CC   hairpin ribozyme, and the nucleic acid encoding it, can be introduced
CC   into a cell infected with HBV, or susceptible to infection, to inhibit
CC   the replication/infectivity of HBV. Alternatively, cells transduced with
CC   a vector ex vivo are administered to a patient. Hairpin ribozymes act on
CC   pregenomic RNA and so are potentially capable of eliminating
CC   (extra)hepatic replication and transport of HBV in all infected patients,
CC   including chronic carriers. Also infection by hepatitis D (which requires
CC   HBV surface antigen as its envelope) is prevented
XX
SQ   Sequence 16 BP; 0 A; 2 C; 7 G; 0 T; 7 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 4.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1849 GGCCAACAGACCCACA 1864
                | ||||  |||||||||
Db         16 GCCCAAAAGACCCACA 1


RESULT 845
AAV18124/c
ID   AAV18124 standard; DNA; 16 BP.
XX
AC   AAV18124;
XX
DT   04-SEP-1998  (first entry)
XX
DE   Human HNG gene exon 13/intron 13 splice donor site.
XX
KW   Hydronephrosis gene; HNG gene; USF2 gene; renal disease; renal aplasia;
KW   vesical-ureteral reflux; pelvi-ureteral junction obstruction;
KW   multicystic renal dysplasia; renal agenesis; hydronephrosis; MRD;
KW   Von Mayer-Rokitansky-Kuester disorder; bifid ureter; ss.
XX
OS   Homo sapiens.
XX
PN   WO9815650-A2.
XX
PD   16-APR-1998.
XX
PF   09-OCT-1997;   97WO-EP005583.
XX
PR   09-OCT-1996;   96EP-00202820.
XX
PA   (VLAA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI   Van De Ven WJM,  Fryns JPGJ,  Groenen PMA;
XX
DR   WPI; 1998-240833/21.
XX
PT   Hydronephrosis gene - useful to treat or diagnose renal diseases and
PT   disorders, e.g. vesical-ureteral reflux, pelvi-ureteral junction
PT   obstruction, multicystic renal dysplasia or renal agenesis.
XX
PS   Example 3; Fig 10; 73pp; English.
XX
CC   Sequences shown in AAV18100 to AAV18129 represent the nucleotide
CC   sequences of the intron-exon junctions of the human hydronephrosis (HNG)
CC   gene. A translocation partner to this HNG gene on chromosome 6 is the
```

```
CC   chromosome 19 USF2 gene. The HNG gene can be used as a starting point to
CC   design suitable compounds or techniques for the treatment of renal
CC   diseases or disorders, or nucleotide probes for diagnosing cells involved
CC   in renal diseases or disorders. A protein or a fragment encoded by HNG
CC   gene can be used as a starting point for preparing suitable antibodies
CC   for diagnosing cells involved in renal diseases and disorders. The
CC   products and method can be used to treat or diagnose renal diseases and
CC   disorders selected from vesical-ureteral reflux, uni or bilateral pelvi-
CC   ureteral junction obstruction, multicystic renal dysplasia (MRD), renal
CC   agenesis, renal aplasia, hydronephrosis, Von Mayer-Rokitansky-Kuester
CC   disorder and bifid ureter
XX
SQ   Sequence 16 BP; 8 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 4.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTTT 1926
              ||||  ||||||||||
Db         16 TCAATCATACCTTTTT 1

RESULT 846
AAV28957
ID   AAV28957 standard; DNA; 16 BP.
XX
AC   AAV28957;
XX
DT   06-AUG-1998  (first entry)
XX
DE   in vitro mutagenesis primer from WO9812336 Example 2.
XX
KW   Artificial chromosome; yeast; YAC; telomere; centromere; human genome;
KW   alphoid; genetic engineering; gene therapy; in vitro mutagenesis; primer;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO9812336-A1.
XX
PD   26-MAR-1998.
XX
PF   18-SEP-1997;   97WO-JP003305.
XX
PR   18-SEP-1996;   96JP-00246749.
XX
PA   (DNAV-) DNAVEC RES INC.
XX
PI   Ishikawa F,  Hasegawa M;
XX
DR   WPI; 1998-217272/19.
XX
PT   Artificial chromosome with mammalian type telomere sequence - useful in
PT   genetic engineering and gene therapy.
XX
PS   Example 2; Page 8; 18pp; Japanese.
XX
CC   The present sequence represents a primer used for in vitro mutagenesis,
CC   used in an example of the present invention. The present invention
CC   describes an artificial chromosome having an added mammalian type
CC   telomere sequence at the end terminal. The hybrid telomerase comprises an
CC   RNA containing a sequence complimentary to a mammalian type telomere
CC   sequence, and a telomerase protein of non-mammalian biological origin.
CC   Preparation of a hybrid telomerase comprises producing a RNA containing a
CC   sequence complimentary to a mammalian type telomere sequence in a non-
CC   mammalian host. The method, which is useful in genetic engineering and
CC   gene therapy is useful for the preparation of hybrid telomerase and
CC   artificial chromosomes
XX
SQ   Sequence 16 BP; 6 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 4.6e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
              || || ||||||||||
Db          1 CACCACACCCACACAC 16

RESULT 847
AAQ94630
ID   AAQ94630 standard; DNA; 17 BP.
XX
AC   AAQ94630;
XX
DT   25-MAR-2003  (revised)
DT   20-NOV-1995  (first entry)
XX
DE   Brush-1 gene primer.
XX
KW   Brush-1; tumor suppressor gene; breast cancer; mamma carcinoma;
KW   diagnosis; gene therapy; polymerase chain reaction; PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   WO9515334-A1.
XX
PD   08-JUN-1995.
XX
PF   30-NOV-1994;   94WO-US013823.
XX
PR   30-NOV-1993;   93US-00160088.
PR   27-SEP-1994;   94US-00314598.
XX
PA   (CALP-) CALIFORNIA PACIFIC MEDICAL CENT RES INST.
XX
PI   Schott DR,  Smith HS,  Chang J;
XX
DR   WPI; 1995-215228/28.
XX
PT   New cDNA sequences from the Brush-1 tumour suppressor gene - useful as
PT   probes for detecting tumours and pre:malignant cells, esp. of the breast,
PT   and therapeutically.
XX
PS   Disclosure; Page 7; 39pp; English.
XX
CC   PCR using the primers given in AAQ94626-27, AAQ94628-29 and AAQ94630-31
CC   was used to amplify cDNAs for beta-actin, retinoblastoma RB1 and breast
CC   tumor suppressor Brush-1. Actin-1 mRNA was detected in normal breast
CC   tissue and in breast cancer lines. RB1 mRNA was detected in normal breast
CC   tissue and in 12 of 13 breast cancer cell lines. Brush-1 mRNA showed more
CC   differential expression than RB1 mRNA in these cancer cells, expression
CC   being greatly reduced in 6 of the 13 cell lines. (Updated on 25-MAR-2003
CC   to correct PN field.)
XX
SQ   Sequence 17 BP; 3 A; 3 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1748 TACTGGCTCTTTATTC 1763
              || |||| ||||||||
Db          2 TAGTGGCACTTTATTC 17

RESULT 848
AAT81245
ID   AAT81245 standard; RNA; 17 BP.
XX
AC   AAT81245;
XX
DT   05-OCT-1997  (first entry)
XX
```

```
DE   Human c-myb hammerhead ribozyme target sequence (nt. position 1539).
XX
KW   Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW   smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW   coronary angioplasty; ss.
XX
OS   Homo sapiens.
XX
PN   WO9531541-A2.
XX
PD   23-NOV-1995.
XX
PF   18-MAY-1995;   95WO-US006368.
XX
PR   18-MAY-1994;   94US-00245466.
PR   13-JAN-1995;   95US-00373124.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Draper K,  Mcswiggen J,  Jarvis T;
XX
DR   WPI; 1996-010927/01.
XX
PT   New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT   for treating restenosis or cancer.
XX
PS   Claim 1; Page 69; 128pp; English.
XX
CC   The present sequence represents the preferred target sequence for an
CC   enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC   the human c-myb sequence at the base position indicated in the descriptor
CC   line. The c-myb sequence was screened for optimal ribozyme target sites
CC   using a computer folding algorithm, and regions of the mRNA which did not
CC   form secondary folding structures and contained potential ribozyme
CC   cleavage sites were identified. Ribozymes were synthesised and their
CC   activities optimised by either varying the length of the binding arms or
CC   by modification to prevent degradation by nucleases. The ribozymes cleave
CC   the c-myb sequence and can be used to prevent smooth muscle cell
CC   hyperproliferation in restenosis, especially after coronary angioplasty,
CC   and in cancers
XX
SQ   Sequence 17 BP; 4 A; 5 C; 2 G; 0 T; 6 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 4.7e+02;
  Matches    8;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCA 1789
              : ::::: ||||||||
Db          2 UGUUUUUAGAACCCCA 17


RESULT 849
AAX63970/c
ID   AAX63970 standard; RNA; 17 BP.
XX
AC   AAX63970;
XX
DT   20-JUL-1999  (first entry)
XX
DE   Rabbit stromelysin hammerhead target SEQ ID NO:602.
XX
KW   Arthritic condition; graft tolerance; immune response; target; cleavage;
KW   hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW   stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW   rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW   diagnosis; ss.
XX
OS   Oryctolagus cuniculus.
XX
PN   WO9618736-A2.
XX
PD   20-JUN-1996.
XX
PF   22-NOV-1995;   95WO-US015516.
XX
PR   13-DEC-1994;   94US-00354920.
PR   23-DEC-1994;   94US-00363253.
PR   23-DEC-1994;   94US-00363254.
PR   17-FEB-1995;   95US-00390850.
PR   20-APR-1995;   95US-00426124.
PR   02-MAY-1995;   95US-00432874.
PR   04-MAY-1995;   95US-00434509.
PR   07-JUL-1995;   95US-0000951P.
PR   07-JUL-1995;   95US-0000974P.
PR   07-AUG-1995;   95US-00512861.
PR   05-OCT-1995;   95US-00541365.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Beigelman L,  Stinchcomb DT,  Jarvis T,  Draper K,  Pavco P;
PI   Mcswiggen J,  Gustofson J,  Usman N,  Wincott F,  Matulic-Adamic J;
PI   Karpeisky A,  Thompson JD,  Modak A,  Burgin A;
XX
DR   WPI; 1996-300653/30.
XX
PT   Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT   the treatment of arthritis, induction of graft tolerance or treatment of
PT   auto-immune diseases.
XX
PS   Example 1; Page 155; 307pp; English.
XX
CC   The present invention describes a novel enzymatic nucleic acid (ENA)
CC   having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC   ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC   ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC   can inhibit collagenase and stromelysin production in the synovial
CC   membrane of joints for the treatment or prevention of arthritis,
CC   particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC   be used to treat antigen presenting cells of a donor to induce tolerance
CC   in a recipient to an alloantigen of a donor. They can also be used for
CC   enhancing graft tolerance or for treating autoimmune disease, and for
CC   treating allergies and other inflammatory conditions. The ENA's can also
CC   be used in diagnosis. Ribozyme therapy impacts on the expression of
CC   stromelysin without introducing the non-specific effects upon gene
CC   expression which accompany treatment with retinoids and dexamethasone.
CC   The concentration of ribozyme required to affect a therapeutic treatment
CC   is lower than that required of antisense molecules, and is highly
CC   specific. The present sequence is used in the exemplification of the
CC   present invention
XX
SQ   Sequence 17 BP; 6 A; 1 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTGAAA 1807
              |||||||| || ||||
Db         16 CTTTCCTTATCAGAAA 1


RESULT 850
AAX64047
ID   AAX64047 standard; RNA; 17 BP.
XX
AC   AAX64047;
XX
DT   20-JUL-1999  (first entry)
XX
DE   Rabbit stromelysin hammerhead target SEQ ID NO:679.
XX
KW   Arthritic condition; graft tolerance; immune response; target; cleavage;
KW   hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW   stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW   rheumatoid arthritis; autoimmune disease; allergy; inflammation;
```

```
KW   diagnosis; ss.
XX
OS   Oryctolagus cuniculus.
XX
PN   WO9618736-A2.
XX
PD   20-JUN-1996.
XX
PF   22-NOV-1995;   95WO-US015516.
XX
PR   13-DEC-1994;   94US-00354920.
PR   23-DEC-1994;   94US-00363253.
PR   23-DEC-1994;   94US-00363254.
PR   17-FEB-1995;   95US-00390850.
PR   20-APR-1995;   95US-00426124.
PR   02-MAY-1995;   95US-00432874.
PR   04-MAY-1995;   95US-00434509.
PR   07-JUL-1995;   95US-0000951P.
PR   07-JUL-1995;   95US-0000974P.
PR   07-AUG-1995;   95US-00512861.
PR   05-OCT-1995;   95US-00541365.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Beigelman L,  Stinchcomb DT,  Jarvis T,  Draper K,  Pavco P;
PI   Mcswiggen J,  Gustofson J,  Usman N,  Wincott F,  Matulic-Adamic J;
PI   Karpeisky A,  Thompson JD,  Modak A,  Burgin A;
XX
DR   WPI; 1996-300653/30.
XX
PT   Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT   the treatment of arthritis, induction of graft tolerance or treatment of
PT   auto-immune diseases.
XX
PS   Example 1; Page 156; 307pp; English.
XX
CC   The present invention describes a novel enzymatic nucleic acid (ENA)
CC   having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC   ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC   ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC   can inhibit collagenase and stromelysin production in the synovial
CC   membrane of joints for the treatment or prevention of arthritis,
CC   particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC   be used to treat antigen presenting cells of a donor to induce tolerance
CC   in a recipient to an alloantigen of a donor. They can also be used for
CC   enhancing graft tolerance or for treating autoimmune disease, and for
CC   treating allergies and other inflammatory conditions. The ENA's can also
CC   be used in diagnosis. Ribozyme therapy impacts on the expression of
CC   stromelysin without introducing the non-specific effects upon gene
CC   expression which accompany treatment with retinoids and dexamethasone.
CC   The concentration of ribozyme required to affect a therapeutic treatment
CC   is lower than that required of antisense molecules, and is highly
CC   specific. The present sequence is used in the exemplification of the
CC   present invention
XX
SQ   Sequence 17 BP; 5 A; 3 C; 3 G; 0 T; 6 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 4.7e+02;
  Matches    8;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1989 AAGTGTGTATCTAGCT 2004
              || :|:|:|:|:| |:
Db          1 AACUGUGUAUCUAACU 16


RESULT 851
AAX69768
ID   AAX69768 standard; RNA; 17 BP.
XX
AC   AAX69768;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human flt1 VEGF receptor hammerhead ribozyme substrate #1063.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 78; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 1 A; 4 C; 2 G; 0 T; 10 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   31.2%;  Pred. No. 4.7e+02;
  Matches    5;  Conservative    9;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCT 1698
              :|:: |::|:: |:|:
Db          2 UCUUUGUUGUUCCUCU 17


RESULT 852
AAX73282/c
ID   AAX73282 standard; RNA; 17 BP.
XX
AC   AAX73282;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #715.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
```

PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 145; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1543 AGAGTAGGGAAGGAAC 1558
||||| ||||||||
Db 17 AGAGTCCGGAAGGAAC 2

RESULT 853
AAX69483/c
ID AAX69483 standard; RNA; 17 BP.
XX
AC AAX69483;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human flt1 VEGF receptor hammerhead ribozyme substrate #778.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 70; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1870 AGCCATTGAAATGTCA 1885
||||| ||||||| ||
Db 17 AGCCACTGAAATGGCA 2

RESULT 854
AAX69454/c
ID AAX69454 standard; RNA; 17 BP.
XX
AC AAX69454;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human flt1 VEGF receptor hammerhead ribozyme substrate #749.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 69; 218pp; English.
XX

```
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 6 A; 2 C; 4 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGAG 1707
              ||||||||  | |||||
Db         16 TTTCTCTAACACTGAG 1


RESULT 855
AAX69484/c
ID   AAX69484 standard; RNA; 17 BP.
XX
AC   AAX69484;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Human flt1 VEGF receptor hammerhead ribozyme substrate #779.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Homo sapiens.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 70; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| |||||||  ||
Db         16 AGCCACTGAAATGGCA 1


RESULT 856
AAV97765
ID   AAV97765 standard; RNA; 17 BP.
XX
AC   AAV97765;
XX
DT   17-MAR-1999  (first entry)
XX
DE   Human EGF-R target sequence nucleotide position 4308.
XX
KW   Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW   hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW   cancer; genetic drift; detection; mutation; ss.
XX
OS   Homo sapiens.
XX
PN   WO9833893-A2.
XX
PD   06-AUG-1998.
XX
PF   14-JAN-1998;   98WO-US000730.
XX
PR   31-JAN-1997;   97US-0036476P.
PR   04-DEC-1997;   97US-00985162.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (UYAS-) UNIV ASTON.
XX
PI   Akhtar S,  Fell P,  Mcswiggen JA;
XX
DR   WPI; 1998-437449/37.
XX
PT   Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT   growth factor receptor, useful for inhibiting cell proliferation and for
PT   treating cancers.
XX
PS   Claim 5; Page 79; 109pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules (NAMs)
CC   which specifically cleave RNA derived from an epidermal growth factor
CC   receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC   represent specifically claimed target sequence from human EGF-R. AAV98044
CC   to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC   hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
CC   cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC   expression levels e.g. to inhibit cell proliferation in the prevention or
CC   treatment of cancers. The NAMs can also be used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of EGF-R RNA in a cell
XX
SQ   Sequence 17 BP; 2 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 4.7e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              ||  :||::|:||  :||
Db          2 CAGUGGUUCUGCUUCA 17


RESULT 857
```

```
AAV97766
ID   AAV97766 standard; RNA; 17 BP.
XX
AC   AAV97766;
XX
DT   17-MAR-1999  (first entry)
XX
DE   Human EGF-R target sequence nucleotide position 4309.
XX
KW   Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW   hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW   cancer; genetic drift; detection; mutation; ss.
XX
OS   Homo sapiens.
XX
PN   WO9833893-A2.
XX
PD   06-AUG-1998.
XX
PF   14-JAN-1998;   98WO-US000730.
XX
PR   31-JAN-1997;   97US-0036476P.
PR   04-DEC-1997;   97US-00985162.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (UYAS-) UNIV ASTON.
XX
PI   Akhtar S,  Fell P,  Mcswiggen JA;
XX
DR   WPI; 1998-437449/37.
XX
PT   Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT   growth factor receptor, useful for inhibiting cell proliferation and for
PT   treating cancers.
XX
PS   Claim 5; Page 79; 109pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules (NAMs)
CC   which specifically cleave RNA derived from an epidermal growth factor
CC   receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC   represent specifically claimed target sequence from human EGF-R. AAV98044
CC   to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC   hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
CC   cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC   expression levels e.g. to inhibit cell proliferation in the prevention or
CC   treatment of cancers. The NAMs can also be used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of EGF-R RNA in a cell
XX
SQ   Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   56.2%;  Pred. No. 4.7e+02;
  Matches    9;  Conservative    5;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || :||::|:|| :||
Db          1 CAGUGGUUCUGCUUCA 16


RESULT 858
AAV95640/c
ID   AAV95640 standard; RNA; 17 BP.
XX
AC   AAV95640;
XX
DT   01-MAR-1999  (first entry)
XX
DE   Solanidine glucosyltransferase target sequence position 67.
XX
KW   Solanidine; glucosyltransferase; potato; citrate synthase; target;
KW   hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW   flower formation; cleavage; solanaceous plant; ss.
XX
OS   Solanum tuberosum.
XX
PN   WO9832843-A2.
XX
PD   30-JUL-1998.
XX
PF   14-JAN-1998;   98WO-US000738.
XX
PR   28-JAN-1997;   97US-0036545P.
PR   28-JAN-1997;   97US-0036599P.
PR   24-NOV-1997;   97US-00979416.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Zwick MG,  Mcswiggen JA;
XX
DR   WPI; 1998-427939/36.
XX
PT   New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT   biosynthesis or regulating flowering.
XX
PS   Claim 13; Page 45; 79pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   -cleaving activity (e.g. ribozymes) which are capable of modulating the
CC   expression of plant genes: (i) involved in biosynthesis of alkaloids; or
CC   (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
CC   AAV96354 represent potato solanidine glucosyltransferase hammerhead and
CC   hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
CC   AAV96734 represent potato solanidine glucosyltransferase target
CC   sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
CC   potato citrate synthase hammerhead and hairpin ribozymes, respectively.
CC   AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
CC   synthase target sequences. Ribozymes of the present invention can be used
CC   to inhibit the synthesis of toxic alkaloids in solanaceous plants,
CC   particularly potato but also tomato, pepper, aubergine and ditura or to
CC   inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
CC   arugula, kale, collards, chard, beet, turnip, sweet potato and turf
CC   grass. Also the ribozymes can be used for RNA manipulation in the same
CC   way that restriction endonucleases are for DNA, as well as to examine
CC   genetic drift and mutations in plants and to detect specific RNA. The
CC   ribozymes can be targeted to specific genes or to consensus sequences
CC   within a family of related genes, and being catalytic need to be present
CC   at only very low concentrations
XX
SQ   Sequence 17 BP; 0 A; 7 C; 0 G; 0 T; 10 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAACAG 1560
              || |||||||||| ||
Db         16 AGAAGGGAAGGAAAAG 1


RESULT 859
AAV95949
ID   AAV95949 standard; RNA; 17 BP.
XX
AC   AAV95949;
XX
DT   01-MAR-1999  (first entry)
XX
DE   Solanidine glucosyltransferase target sequence position 1461.
XX
KW   Solanidine; glucosyltransferase; potato; citrate synthase; target;
KW   hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW   flcwer formation; cleavage; solanaceous plant; ss.
XX
OS   Solanum tuberosum.
XX
```

```
PN   WO9832843-A2.
XX
PD   30-JUL-1998.
XX
PF   14-JAN-1998;   98WO-US000738.
XX
PR   28-JAN-1997;   97US-0036545P.
PR   28-JAN-1997;   97US-0036599P.
PR   24-NOV-1997;   97US-00979416.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Zwick MG,  Mcswiggen JA;
XX
DR   WPI; 1998-427939/36.
XX
PT   New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT   biosynthesis or regulating flowering.
XX
PS   Claim 13; Page 50; 79pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   -cleaving activity (e.g. ribozymes) which are capable of modulating the
CC   expression of plant genes: (i) involved in biosynthesis of alkaloids; or
CC   (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
CC   AAV96354 represent potato solanidine glucosyltransferase hammerhead and
CC   hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
CC   AAV96734 represent potato solanidine glucosyltransferase target
CC   sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
CC   potato citrate synthase hammerhead and hairpin ribozymes, respectively.
CC   AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
CC   synthase target sequences. Ribozymes of the present invention can be used
CC   to inhibit the synthesis of toxic alkaloids in solanaceous plants,
CC   particularly potato but also tomato, pepper, aubergine and ditura or to
CC   inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
CC   arugula, kale, collards, chard, beet, turnip, sweet potato and turf
CC   grass. Also the ribozymes can be used for RNA manipulation in the same
CC   way that restriction endonucleases are for DNA, as well as to examine
CC   genetic drift and mutations in plants and to detect specific RNA. The
CC   ribozymes can be targeted to specific genes or to consensus sequences
CC   within a family of related genes, and being catalytic need to be present
CC   at only very low concentrations
XX
SQ   Sequence 17 BP; 8 A; 3 C; 1 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   68.8%;  Pred. No. 4.7e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1903 TCAACAGATCAACAAT 1918
              :||||| |:||| ||:
Db          2 UCAACAUAUCAAGAAU 17


RESULT 860
AAV95638/c
ID   AAV95638 standard; RNA; 17 BP.
XX
AC   AAV95638;
XX
DT   01-MAR-1999  (first entry)
XX
DE   Solanidine glucosyltransferase target sequence position 63.
XX
KW   Solanidine; glucosyltransferase; potato; citrate synthase; target;
KW   hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW   flower formation; cleavage; solanaceous plant; ss.
XX
OS   Solanum tuberosum.
XX
PN   WO9832843-A2.
XX
PD   30-JUL-1998.
XX
PF   14-JAN-1998;   98WO-US000738.
XX
PR   28-JAN-1997;   97US-0036545P.
PR   28-JAN-1997;   97US-0036599P.
PR   24-NOV-1997;   97US-00979416.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Zwick MG,  Mcswiggen JA;
XX
DR   WPI; 1998-427939/36.
XX
PT   New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT   biosynthesis or regulating flowering.
XX
PS   Claim 13; Page 45; 79pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   -cleaving activity (e.g. ribozymes) which are capable of modulating the
CC   expression of plant genes: (i) involved in biosynthesis of alkaloids; or
CC   (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
CC   AAV96354 represent potato solanidine glucosyltransferase hammerhead and
CC   hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
CC   AAV96734 represent potato solanidine glucosyltransferase target
CC   sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
CC   potato citrate synthase hammerhead and hairpin ribozymes, respectively.
CC   AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
CC   synthase target sequences. Ribozymes of the present invention can be used
CC   to inhibit the synthesis of toxic alkaloids in solanaceous plants,
CC   particularly potato but also tomato, pepper, aubergine and ditura or to
CC   inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
CC   arugula, kale, collards, chard, beet, turnip, sweet potato and turf
CC   grass. Also the ribozymes can be used for RNA manipulation in the same
CC   way that restriction endonucleases are for DNA, as well as to examine
CC   genetic drift and mutations in plants and to detect specific RNA. The
CC   ribozymes can be targeted to specific genes or to consensus sequences
CC   within a family of related genes, and being catalytic need to be present
CC   at only very low concentrations
XX
SQ   Sequence 17 BP; 0 A; 6 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGAC 1563
              |||||||||| || ||
Db         17 AGGGAAGGAAAAGAAC 2


RESULT 861
AAV95639/c
ID   AAV95639 standard; RNA; 17 BP.
XX
AC   AAV95639;
XX
DT   01-MAR-1999  (first entry)
XX
DE   Solanidine glucosyltransferase target sequence position 64.
XX
KW   Solanidine; glucosyltransferase; potato; citrate synthase; target;
KW   hammerhead ribozyme; hairpin ribozyme; alkaloid biosynthesis;
KW   flower formation; cleavage; solanaceous plant; ss.
XX
OS   Solanum tuberosum.
XX
PN   WO9832843-A2.
XX
PD   30-JUL-1998.
XX
PF   14-JAN-1998;   98WO-US000738.
XX
```

```
PR   28-JAN-1997;   97US-0036545P.
PR   28-JAN-1997;   97US-0036599P.
PR   24-NOV-1997;   97US-00979416.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Zwick MG,  Mcswiggen JA;
XX
DR   WPI; 1998-427939/36.
XX
PT   New enzymatic nucleic acid(s) - useful for, e.g. reducing alkaloid
PT   biosynthesis or regulating flowering.
XX
PS   Claim 13; Page 45; 79pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   -cleaving activity (e.g. ribozymes) which are capable of modulating the
CC   expression of plant genes: (i) involved in biosynthesis of alkaloids; or
CC   (ii) involved in flower formation. AAV95982 to AAV96334, and AAV96335 to
CC   AAV96354 represent potato solanidine glucosyltransferase hammerhead and
CC   hairpin ribozymes, respectively. AAV95629 to AAV95981, and AAV96355 to
CC   AAV96734 represent potato solanidine glucosyltransferase target
CC   sequences. AAV96773 to AAV97170, and AAV97171 to AAV97195 represent
CC   potato citrate synthase hammerhead and hairpin ribozymes, respectively.
CC   AAV96735 to AAV96772, and AAV97196 to AAV97220 represent potato citrate
CC   synthase target sequences. Ribozymes of the present invention can be used
CC   to inhibit the synthesis of toxic alkaloids in solanaceous plants,
CC   particularly potato but also tomato, pepper, aubergine and ditura or to
CC   inhibit flowering in potato, lettuce, spinach, cabbage, brussel sprouts,
CC   arugula, kale, collards, chard, beet, turnip, sweet potato and turf
CC   grass. Also the ribozymes can be used for RNA manipulation in the same
CC   way that restriction endonucleases are for DNA, as well as to examine
CC   genetic drift and mutations in plants and to detect specific RNA. The
CC   ribozymes can be targeted to specific genes or to consensus sequences
CC   within a family of related genes, and being catalytic need to be present
CC   at only very low concentrations
XX
SQ   Sequence 17 BP; 0 A; 6 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match              2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGAC 1563
              |||||||||| || ||
Db         16 AGGGAAGGAAAAGAAC 1


RESULT 862
AAV48869
ID   AAV48869 standard; DNA; 17 BP.
XX
AC   AAV48869;
XX
DT   15-OCT-1998  (first entry)
XX
DE   ErbB-2 gene antisense oligonucleotide ErbB-2-N-78.
XX
KW   ErbB-2; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Example 4; Fig 6d; 286pp; English.
XX
CC   AAV48709-886 represent antisense oligonucleotides directed against the
CC   ErbB-2 gene. Of these, only oligonucleotides AAV48709-91 resulted in
CC   significant redcution in ErbB-2 protein expression, while
CC   oligonucleotides AAV48792-886 had little effect. The oligonucleotides
CC   exemplify the invention. The specification describes oligonucleotides
CC   that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC   can each form three hydrogen bonds to cytosine; do not contain four
CC   consecutive nucleotides able to form three H-bonds each to four
CC   consecutive cytosines; do not contain two sequences of three consecutive
CC   nucleotides each able to form three H-bonds to three consecutive
CC   cytosines, and the ratio between residues able to form two H-bonds each
CC   (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC   oligonucleotides are used to modulate expression of genes, particularly
CC   the genes for p53, ErB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC   proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC   kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC   oligonucleotides can also be used to analyse function of proteins (by
CC   altering their expression or activity) and therapeutically, e.g. in cases
CC   of cancer or (targeting TGF) for stimulating the immune system
XX
SQ   Sequence 17 BP; 11 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match              2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAAA 1990
              ||| ||||||| ||||
Db          1 CTTTAAAAAAACAAAA 16


RESULT 863
AAA18484/c
ID   AAA18484 standard; RNA; 17 BP.
XX
AC   AAA18484;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Human TIE-2 substrate sequence SEQ ID NO:1710.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
```

```
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 56; Page 98; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 9 A; 0 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTTT 1926
                | | ||||||||||||
Db         16 TAATCAATACCTTTTT 1


RESULT 864
AAA25113
ID   AAA25113 standard; DNA; 17 BP.
XX
AC   AAA25113;
XX
DT   19-JUL-2000  (first entry)
XX
DE   Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1611.
XX
KW   Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW   hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW   gene expression modification; cancer; phosphorothioate; endonuclease;
KW   anticancer; breast cancer; endometrium cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954459-A2.
XX
PD   28-OCT-1999.
XX
PF   19-APR-1999;   99WO-US008547.
XX
PR   20-APR-1998;   98US-0082404P.
PR   23-JUN-1998;   98US-00103636.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Thompson JD,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Bellon L;
PI   Reynolds M,  Zwick M,  Jarvis T,  Woolf T,  Haeberli P;
PI   Matulic-Adamic J;
XX
DR   WPI; 2000-013248/01.
XX
PT   New nucleic acids that interact, and optionally cleave, target sequences,
PT   used to treat cancer.
XX
PS   Claim 77; Page 68; 148pp; English.
XX
CC   The present invention describes nucleic acids (A) that interact stably
CC   with a target sequence and contain at least one phosphoro(di)thioate
CC   link, having endonuclease activity. (A), and more generally any catalytic
CC   nucleic acid (A') that modulates expression of the oestrogen receptor
CC   gene, are used to treat cancer (particularly of breast or endometrium),
CC   in vivo or by transforming cells ex vivo and implanting treated cells, or
CC   for other conditions associated with levels of oestrogen receptor.
CC   Because of the high selectivity for targeted RNA, (A) can also be used to
CC   correlate inhibition of gene expression with alterations in phenotype,
CC   particularly for identification of therapeutic targets, and as research
CC   reagents (for RNA, in the same way that restriction endonucleases are
CC   used with DNA). The combination of modifications in (A) improves
CC   resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC   AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC   AAA24748 to AAA25992 represent their corresponding target sequences.
CC   AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC   sequences, and AAA26107 to AAA26218 represent their corresponding target
CC   sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC   antisense oligonucleotides used in the exemplification of the present
CC   invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1795 TCCTTCTCTGAAAGTG 1810
                ||||| | ||||||||
Db          2 TCCTTTTATGAAAGTG 17


RESULT 865
AAF03259
ID   AAF03259 standard; DNA; 17 BP.
XX
AC   AAF03259;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #1554.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
```

```
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 91; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 4 A; 2 C; 2 G; 9 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTG 1782
              ||||||| ||||| ||
Db          2 AAGCTTTCTTTTTATG 17


RESULT 866
AAF06265
ID   AAF06265 standard; DNA; 17 BP.
XX
AC   AAF06265;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3062.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 126; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 6 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 4.7e+02;
  Matches    8;  Conservative    6;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAAG 1808
              :::||::| |: ||||
Db          2 UUUCCUUCCCUCAAAG 17


RESULT 867
AAF02870/c
ID   AAF02870 standard; DNA; 17 BP.
XX
AC   AAF02870;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #1165.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 82; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 2 A; 11 C; 1 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGG 1551
              || | ||||||||||||
Db         17 GGCTGGGAGAGTAGGG 2


RESULT 868
AAF02937
ID   AAF02937 standard; DNA; 17 BP.
XX
AC   AAF02937;
XX
DT   16-FEB-2001  (first entry)
XX
```

DE Hammerhead ribozyme substrate #1232.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 84; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 6 A; 7 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1565 GCAAAAATCCTTCTCC 1580
||||||| |||| ||
Db 1 GCAAAAATACTTCCCC 16

RESULT 869
ABK03204/c
ID ABK03204 standard; RNA; 17 BP.
XX
AC ABK03204;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CD20 Inozyme #155.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 30; Page 148; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an inozyme of the invention
XX
SQ Sequence 17 BP; 1 A; 6 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2024 CTGGTAGGAGGCAAAG 2039
|||| || ||||||||
Db 17 CTGGAAGAAGGCAAAG 2

RESULT 870
ABK02445/c
ID ABK02445 standard; RNA; 17 BP.
XX

```
AC   ABK02445;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Amberzyme #117.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 133; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an amberzyme molecule of the invention
XX
SQ   Sequence 17 BP; 9 A; 3 C; 4 G; 0 T; 1 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTGA 1805
                || || ||||||||||
Db         16 TTTTTGCCTTCTCTGA 1


RESULT 871
ABK02838/c
ID   ABK02838 standard; RNA; 17 BP.
XX
AC   ABK02838;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human CD20 Hammerhead ribozyme #137.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 30; Page 142; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
```

```
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a hammerhead ribozyme of the invention
XX
SQ   Sequence 17 BP; 1 A; 6 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match              2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2024 CTGGTAGGAGGCAAAG 2039
              |||| || ||||||||
Db         16 CTGGAAGAAGGCAAAG 1


RESULT 872
AAH91870
ID   AAH91870 standard; DNA; 17 BP.
XX
AC   AAH91870;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Human inflammatory bowel disease associated polymorphic site #945.
XX
KW   Human; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
KW   single nucleotide polymorphism; SNP; chromosome 19p13; paternity test;
KW   chromosome 5q31-33; forensic test; gene therapy; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    9
FT                   /*tag=  a
FT                   /note= "SNP, optionally T or A at this position"
XX
PN   WO200142511-A2.
XX
PD   14-JUN-2001.
XX
PF   11-DEC-2000; 2000WO-US033632.
XX
PR   10-DEC-1999;   99US-0170257P.
PR   10-APR-2000; 2000US-0196046P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (ELLI-) ELLIPSIS BIOTHERAPEUTICS CORP.
XX
PI   Daly M,  Hudson TJ,  Lander ES,  Rioux J,  Siminovitch K;
XX
DR   WPI; 2001-367874/38.
XX
PT   Testing for the presence of polymorphisms associated with inflammatory
PT   bowel disease, using a hybridization assay.
XX
PS   Claim 1; Page 78; 463pp; English.
XX
CC   The present invention describes a method for detecting the presence of
CC   polymorphisms associated with inflammatory bowel diseases such as
CC   ulcerative colitis and Crohn's disease. The methods can be used to detect
CC   the presence of genetic polymorphisms associated with inflammatory bowel
CC   disease and correlating their occurrence with disease states. They may be
CC   used in this way for phenotypic correlations, forensics, paternity
CC   testing, medicine and genetic analysis. The present sequence is a
CC   polymorphic site described in the exemplification of the invention
XX
SQ   Sequence 17 BP; 6 A; 2 C; 1 G; 7 T; 0 U; 1 Other;

  Query Match              2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATT 1843
              |||||||  | ||||||
Db          1 AATCTTTANAGTACATT 17


RESULT 873
ABN01355/c
ID   ABN01355 standard; DNA; 17 BP.
XX
AC   ABN01355;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1347.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
```

```
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1347; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 7 A; 1 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
              ||||||  ||||||||
Db         16 CCCCATCTTTTCCTTC 1


RESULT 874
ABN01588/c
ID   ABN01588 standard; DNA; 17 BP.
XX
AC   ABN01588;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1580.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1580; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
              ||||||||||  |||
Db         17 ATCCTTCTCCAGAGCA 2


RESULT 875
ABN07965
ID   ABN07965 standard; DNA; 17 BP.
XX
AC   ABN07965;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7957.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
```

```
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7957; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          2 GCCCTTGAGCAACAGA 17


RESULT 876
ABN07649/c
ID   ABN07649 standard; DNA; 17 BP.
XX
AC   ABN07649;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7641.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7641; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1686 TAGTTGTTTCTCTAGC 1701
              | |||| |||||||||
Db         17 TTGTTGGTTCTCTAGC 2
```

```
RESULT 877
ABN07966
ID   ABN07966 standard; DNA; 17 BP.
XX
AC   ABN07966;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7958.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7958; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          1 GCCCTTGAGCAACAGA 16


RESULT 878
ABN01589/c
ID   ABN01589 standard; DNA; 17 BP.
XX
AC   ABN01589;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1581.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1581; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
```

```
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 2 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
                ||||||||||  |||
Db         16 ATCCTTCTCCAGAGCA 1


RESULT 879
ABN01353/c
ID   ABN01353 standard; DNA; 17 BP.
XX
AC   ABN01353;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1345.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 1345; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 9 A; 0 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCT 1801
                |||||  |||||||||
Db         17 CCCATCTTTTCCTTCT 2


RESULT 880
ABN07652/c
ID   ABN07652 standard; DNA; 17 BP.
XX
AC   ABN07652;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7644.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
```

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 7644; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 9 A; 3 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1684 CTTAGTTGTTTCTCTA 1699
||| |||| |||||||
Db 16 CTTTGTTGGTTCTCTA 1

RESULT 881
ABK26167
ID ABK26167 standard; DNA; 17 BP.
XX
AC ABK26167;
XX
DT 09-APR-2002 (first entry)
XX
DE Increased starch production genome altering oligonucleotide #19.
XX
KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyric herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;
KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX
OS Arabidopsis thaliana.
OS Synthetic.
XX
PN WO200192512-A2.
XX
PD 06-DEC-2001.
XX
PF 01-JUN-2001; 2001WO-US017672.
XX
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC, Kim J;
XX
DR WPI; 2002-106307/14.
XX
PT New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX
PS Claim 7; Page 136; 220pp; English.
XX
CC The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyric herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX
SQ Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2030 GGAGGCAAAGGTTCTA 2045
|||||||||| |||
Db 1 GGAGGCAAAGGAGCTA 16

RESULT 882
ABK26168/c
ID ABK26168 standard; DNA; 17 BP.
XX
AC ABK26168;
XX
DT 09-APR-2002 (first entry)
XX
DE Increased starch production genome altering oligonucleotide #20.
XX
KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
KW o-methyl modification; LNA modification; phosphorothioate linkage;
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
KW amino acid over production; herbicide resistance; glyphosate resistance;
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
KW porphyric herbicide resistance; triazine resistance; disease resistance;
KW modified oil production; modified starch production; waxy starch;
KW altered floral morphology; male-sterile plant; albino mutant;

KW modified fatty acid content; reduced palmitate production; albino plant;
KW increased stearate production; reduced linolenic acid production;
KW photosynthetic process.
XX
OS Arabidopsis thaliana.
OS Synthetic.
XX
PN WO200192512-A2.
XX
PD 06-DEC-2001.
XX
PF 01-JUN-2001; 2001WO-US017672.
XX
PR 01-JUN-2000; 2000US-0208538P.
PR 30-OCT-2000; 2000US-0244989P.
PR 27-MAR-2001; 2001US-00818875.
XX
PA (UYDE) UNIV DELAWARE.
XX
PI Kmiec EB, Gamper HB, Rice MC, Kim J;
XX
DR WPI; 2002-106307/14.
XX
PT New oligonucleotides with modified nuclease-resistant termini, useful for
PT creating plants with desired phenotypes, e.g. stress tolerance, improved
PT nutritional value, herbicide or disease resistance, or modified oil
PT production.
XX
PS Claim 7; Page 136; 220pp; English.
XX
CC The invention relates to an oligonucleotide for targeted alteration of a
CC genetic sequence, which comprises a single-stranded oligonucleotide
CC having a DNA domain. The DNA domain has at least one mismatch with
CC respect to the genetic sequence to be altered and further comprises
CC chemical modifications of the oligonucleotide. The chemical modifications
CC consist of o-methyl modification, an LNA modification, two or more
CC phosphorothioate linkages on a terminus, or a combination of any two or
CC more of these modifications. The oligonucleotides are useful for
CC directing repair or alteration of plant genetic information. The
CC oligonucleotides are particularly useful for creating plants with desired
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
CC nutritional value (e.g. altering amino acid content of plants or
CC conferring amino acid over production), herbicide resistance (e.g.
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
CC resistance, porphyric herbicide resistance or triazine resistance),
CC disease resistance, modified oil production, modified starch production
CC (e.g. increased starch or production of waxy starch), altered floral
CC morphology (e.g. male-sterile plants) or modified fatty acid content
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
CC The oligonucleotides are also useful for producing albino mutants for the
CC analysis of photosynthetic processes. This sequence represents a genome
CC altering oligonucleotide of the invention
XX
SQ Sequence 17 BP; 1 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTA 2045
              ||||||||||| |||
Db         17 GGAGGCAAAGGAGCTA 2
```

RESULT 883
ABV79923
ID ABV79923 standard; DNA; 17 BP.
XX
AC ABV79923;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 1169.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 217; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potenial therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 7 A; 2 C; 3 G; 5 T; 0 U; 0 Other;

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
              ||  ||||||||||||
Db          1 TTGGCCTTGAAAAAAA 16
```

RESULT 884
ABV79922
ID ABV79922 standard; DNA; 17 BP.
XX
AC ABV79922;
XX
DT 03-JAN-2003 (first entry)

XX
DE Human HTPL scanning oligonucleotide SEQ ID 1168.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 216; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potenial therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 7 A; 3 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1970 TTTACCTTGAAAAAAA 1985
|| |||||||||||
Db 2 TTGGCCTTGAAAAAAA 17

RESULT 885
ABS74786
ID ABS74786 standard; DNA; 17 BP.
XX
AC ABS74786;
XX
DT 24-DEC-2002 (first entry)
XX
DE Human PAPP-Ea associated 17-mer SEQ ID 312.
XX
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
KW dysgenetic pregnancy; primer; ss.
XX
OS Homo sapiens.
XX
PN US2002102252-A1.
XX
PD 01-AUG-2002.
XX
PF 06-APR-2001; 2001US-00827998.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PA (GUYY/) GU Y.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Shannon ME;
XX
DR WPI; 2002-697817/75.
XX
PT New isolated nucleic acid encoding an isoform of human pregnancy
PT associated plasma protein E, for preventing or aborting pregnancy.
XX
PS Example 2; Page 116; 353pp; English.
XX
CC This invention describes a novel isolated nucleic acid that encodes one
CC of three new isoforms of human pregnancy associated plasma protein E,
CC hPAPP-E. The products of the invention have abortive and contraceptive
CC activity and can be used for gene therapy or in a vaccine. The nucleic
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAPP-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAPP-E genes described in the disclosure of the invention
XX
SQ Sequence 17 BP; 8 A; 0 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1547 TAGGGAAGGAACAGGA 1562
|||||||||||
Db 1 TAGGGAAGGAAGAAGA 16

RESULT 886
ABS74785
ID ABS74785 standard; DNA; 17 BP.
XX
AC ABS74785;
XX
DT 24-DEC-2002 (first entry)
XX
DE Human PAPP-Ea associated 17-mer SEQ ID 311.
XX
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
KW dysgenetic pregnancy; primer; ss.
XX
OS Homo sapiens.
XX
PN US2002102252-A1.

XX
PD 01-AUG-2002.
XX
PF 06-APR-2001; 2001US-00827998.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PA (GUYY/) GU Y.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Shannon ME;
XX
DR WPI; 2002-697817/75.
XX
PT New isolated nucleic acid encoding an isoform of human pregnancy
PT associated plasma protein E, for preventing or aborting pregnancy.
XX
PS Example 2; Page 116; 353pp; English.
XX
CC This invention describes a novel isolated nucleic acid that encodes one
CC of three new isoforms of human pregnancy associated plasma protein E,
CC hPAPP-E. The products of the invention have abortive and contraceptive
CC activity and can be used for gene therapy or in a vaccine. The nucleic
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAPP-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAPP-E genes described in the disclosure of the invention
XX
SQ Sequence 17 BP; 8 A; 1 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1547 TAGGGAAGGAACAGGA 1562
||||||||||| | ||
Db 2 TAGGGAAGGAAGAAGA 17

RESULT 887
ABL31614
ID ABL31614 standard; DNA; 17 BP.
XX
AC ABL31614;
XX
DT 21-MAR-2002 (first entry)
XX
DE Human HLA genotyping oligonucleotide SEQ ID NO 1103.
XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
OS Homo sapiens.
XX
PN WO200192572-A1.
XX
PD 06-DEC-2001.
XX
PF 01-JUN-2001; 2001WO-JP004662.
XX
PR 01-JUN-2000; 2000JP-00164798.
XX
PA (NISN) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
DR WPI; 2002-122074/16.
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT individuals e.g. by determining immunogenetic differences when
PT transplanting between them.
XX
PS Claim 10; Page 302; 345pp; Japanese.
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals
XX
SQ Sequence 17 BP; 8 A; 5 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1906 ACAGATCAACAATACC 1921
||||||| |||| |||
Db 1 ACAGATCTACAAGACC 16

RESULT 888
ACN08987/c
ID ACN08987 standard; RNA; 17 BP.
XX
AC ACN08987;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8990.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 8990; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

```
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTTT 1623
              ||||||| |||||| |
Db         17 CCTGGGGAAAGAGTAT 2


RESULT 889
ACD00706
ID   ACD00706 standard; DNA; 17 BP.
XX
AC   ACD00706;
XX
DT   28-JUL-2003  (first entry)
XX
DE   G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1179.
XX
KW   Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW   G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003031621-A2.
XX
PD   17-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032599.
XX
PR   12-OCT-2001; 2001US-0329000P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Zhang J;
XX
DR   WPI; 2003-381720/36.
XX
PT   New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT   investigating and/or treating disorders associated with aberrant
PT   expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS   Example 2; SEQ ID NO 1203; 156pp; English.
XX
CC   The invention describes an isolated nucleic acid encoding a G protein
CC   coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC   2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC   409 residue amino acid sequence, all given in the specification, with or
CC   without conservative amino acid substitutions, or complements of the
CC   sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC   length. The methods and compositions of the present invention are useful
CC   for diagnosing, investigating and/or treating disorders associated with
CC   aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC   This sequence represents an oligonucleotide used to analyse the gene
CC   encoding human G-protein coupled receptor GPCR-A-1
XX
SQ   Sequence 17 BP; 3 A; 3 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAAC 1785
              |||| |||||||| ||
Db          1 CTTTATTTTTTTGCAC 16


RESULT 890
ACD00705
ID   ACD00705 standard; DNA; 17 BP.
XX
AC   ACD00705;
XX
DT   28-JUL-2003  (first entry)
XX
DE   G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1178.
XX
KW   Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW   G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003031621-A2.
XX
PD   17-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032599.
XX
PR   12-OCT-2001; 2001US-0329000P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Zhang J;
XX
DR   WPI; 2003-381720/36.
XX
PT   New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT   investigating and/or treating disorders associated with aberrant
PT   expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS   Example 2; SEQ ID NO 1202; 156pp; English.
XX
CC   The invention describes an isolated nucleic acid encoding a G protein
CC   coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC   2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC   409 residue amino acid sequence, all given in the specification, with or
CC   without conservative amino acid substitutions, or complements of the
CC   sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC   length. The methods and compositions of the present invention are useful
CC   for diagnosing, investigating and/or treating disorders associated with
CC   aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC   This sequence represents an oligonucleotide used to analyse the gene
CC   encoding human G-protein coupled receptor GPCR-A-1
XX
SQ   Sequence 17 BP; 3 A; 3 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAAC 1785
              |||| |||||||| ||
Db          2 CTTTATTTTTTTGCAC 17


RESULT 891
ABT36453
ID   ABT36453 standard; DNA; 17 BP.
XX
AC   ABT36453;
XX
```

DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 2090.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 277; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 7 A; 1 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1828 ATCTTTTAAATACATT 1843
|||| ||||||| |||
Db 2 ATCTGTTAAATAAATT 17

RESULT 892
ABT38296
ID ABT38296 standard; DNA; 17 BP.
XX
AC ABT38296;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3933.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 493; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 1 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1789 ATTCTTTCCTTCTCTG 1804
|| |||| ||||||||
Db 2 ATCCTTTGCTTCTCTG 17

RESULT 893
ABT35540
ID ABT35540 standard; DNA; 17 BP.
XX
AC ABT35540;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 1177.
XX

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 170; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 3 A; 4 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1710 ATCTCCTAACTTTGGA 1725
||||| || |||||||
Db 2 ATCTCTTACCTTTGGA 17

RESULT 894
ABT40056
ID ABT40056 standard; DNA; 17 BP.
XX
AC ABT40056;
XX
DT 13-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5693.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 699; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 2 A; 1 C; 3 G; 11 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1768 AGCTTTTTTTTTTTGA 1783
| |||||| |||||||
Db 2 ATCTTTTTGTTTTTGA 17

RESULT 895
ABZ60557
ID ABZ60557 standard; RNA; 17 BP.
XX
AC ABZ60557;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNAzyme substrate #669.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX

```
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 97; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 2 G; 0 T; 8 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 4.7e+02;
  Matches    7;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCTT 1772
              :: |::||: ||||::
Db          2 UUAAUUCAUGAAGCUU 17


RESULT 896
ABZ60346
ID   ABZ60346 standard; RNA; 17 BP.
XX
AC   ABZ60346;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #458.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 93; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 6 A; 3 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 4.7e+02;
  Matches    7;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTT 1833
              |||::::| ||:|: :
Db          2 AAGUUUUACAAUCUCU 17


RESULT 897
ABZ60792
ID   ABZ60792 standard; RNA; 17 BP.
XX
AC   ABZ60792;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #904.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
```

```
PS   Claim 58; Page 102; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 3 A; 0 C; 5 G; 0 T; 9 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   43.8%;  Pred. No. 4.7e+02;
  Matches    7;  Conservative    7;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1933 TGTTAAGGTAATGGTT 1948
              : ::||||:| :||::
Db          2 UUUUAAGGUAGUGGUU 17


RESULT 898
ABZ62044/c
ID   ABZ62044 standard; RNA; 17 BP.
XX
AC   ABZ62044;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #835.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 129; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGGGA 1616
              |||||||||| ||| |
Db         16 CTCCTGGCCTCGGGAA 1


RESULT 899
ABZ65512
ID   ABZ65512 standard; RNA; 17 BP.
XX
AC   ABZ65512;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human HER2 DNAzyme substrate #969.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 4; Page 151; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 8 A; 2 C; 6 G; 0 T; 1 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 4.7e+02;
  Matches   13;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTG 1565
```

```
              ||||||||||| | :|
Db          2 GGAAGGAACAGCAAUG 17


RESULT 900
ACC67200
ID   ACC67200 standard; DNA; 17 BP.
XX
AC   ACC67200;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 4447.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 550; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 6 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              ||||| |||| |||||
Db          2 ATCTTCTAAAGACATT 17


RESULT 901
ACC64381/c
ID   ACC64381 standard; DNA; 17 BP.
XX
AC   ACC64381;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 1628.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 221; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 6 A; 2 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTT 1690
              |||| ||||||||| |
Db         17 CCTGAACTTCTTAGAT 2


RESULT 902
ACC65861/c
ID   ACC65861 standard; DNA; 17 BP.
XX
AC   ACC65861;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 3108.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
```

```
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 394; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 6 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1933 TGTTAAGGTAATGGTT 1948
              ||||||| |||||| |
Db         17 TGTTAAGCTAATGGAT 2


RESULT 903
ACC66597
ID   ACC66597 standard; DNA; 17 BP.
XX
AC   ACC66597;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 3844.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 480; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2040 GTTCTATCTGCTTAGC 2055
              | |||| |||||||||
Db          1 GATCTAGCTGCTTAGC 16


RESULT 904
ADB40425/c
ID   ADB40425 standard; DNA; 17 BP.
XX
AC   ADB40425;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #748.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 119; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
```

```
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 4 A; 3 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1877 GAAATGTCAAATTGAT 1892
              ||||||| |||| |||
Db         17 GAAATGTAAAATAGAT 2


RESULT 905
ADB41070
ID   ADB41070 standard; DNA; 17 BP.
XX
AC   ADB41070;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #1393.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 194; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1627 ACCTACCTTACTATTT 1642
              | |||||| |||||||
Db          2 ATCTACCTCACTATTT 17


RESULT 906
ADB42768
ID   ADB42768 standard; DNA; 17 BP.
XX
AC   ADB42768;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #3091.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 393; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
```

```
XX
SQ   Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1665 ATCACCCGCCCCTGGA 1680
              ||| || |||||||||
Db          2 ATCCCCTGCCCCTGGA 17


RESULT 907
ADC37718/c
ID   ADC37718 standard; DNA; 17 BP.
XX
AC   ADC37718;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:67.
XX
KW   human; angiomotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW   AMLP1a; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003037931-A2.
XX
PD   08-MAY-2003.
XX
PF   01-NOV-2002; 2002WO-US035129.
XX
PR   01-NOV-2001; 2001US-0334773P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Shannon M,  Phan T;
XX
DR   WPI; 2003-430501/40.
XX
PT   New isolated nucleic acid molecule encoding a human angiomotin-like
PT   protein, useful for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of AMLP1.
XX
PS   Example 2; SEQ ID NO 67; 172pp; English.
XX
CC   The present invention describes the human angiomotin-like protein 1
CC   (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC   therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC   compositions of the present invention can be used for treating or
CC   preventing a disorder associated with decreased or increased expression
CC   or activity of AMLP1. The present sequence represents a scanning
CC   oligonucleotide for human AMLP1a, which is used in an example from the
CC   present invention.
XX
SQ   Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              ||| |||| |||||||
Db         17 CTGTTTCTCCATCACC 2


RESULT 908
ADC37719/c
ID   ADC37719 standard; DNA; 17 BP.
XX
AC   ADC37719;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:68.
XX
KW   human; angiomotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW   AMLP1a; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003037931-A2.
XX
PD   08-MAY-2003.
XX
PF   01-NOV-2002; 2002WO-US035129.
XX
PR   01-NOV-2001; 2001US-0334773P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Shannon M,  Phan T;
XX
DR   WPI; 2003-430501/40.
XX
PT   New isolated nucleic acid molecule encoding a human angiomotin-like
PT   protein, useful for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of AMLP1.
XX
PS   Example 2; SEQ ID NO 68; 172pp; English.
XX
CC   The present invention describes the human angiomotin-like protein 1
CC   (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC   therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC   compositions of the present invention can be used for treating or
CC   preventing a disorder associated with decreased or increased expression
CC   or activity of AMLP1. The present sequence represents a scanning
CC   oligonucleotide for human AMLP1a, which is used in an example from the
CC   present invention.
XX
SQ   Sequence 17 BP; 6 A; 1 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              ||| |||| |||||||
Db         16 CTGTTTCTCCATCACC 1


RESULT 909
ADB45705
ID   ADB45705 standard; DNA; 17 BP.
XX
AC   ADB45705;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #6028.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
```

XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 736; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 2 A; 1 C; 3 G; 11 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1768 AGCTTTTTTTTTTTGA 1783
|| |||||| |||||||
Db 2 ATCTTTTTGTTTTTGA 17

RESULT 910
ADB44190/c
ID ADB44190 standard; DNA; 17 BP.
XX
AC ADB44190;
XX
DT 18-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #4513.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 559; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 2 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1897 CCTAGATCAACAGATC 1912
|||||| || ||||||
Db 16 CCTAGACCAGCAGATC 1

RESULT 911
ADB45019
ID ADB45019 standard; DNA; 17 BP.
XX
AC ADB45019;
XX
DT 18-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #5342.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.

```
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 656; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 9 A; 1 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1732 ATCAGAAGGTGACAAG 1747
              ||||||||| || |||
Db          2 ATCAGAAGGAGAAAAG 17


RESULT 912
ADF64454
ID   ADF64454 standard; DNA; 17 BP.
XX
AC   ADF64454;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2358.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 2358; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 1 A; 0 C; 5 G; 11 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1944 TGGTTGGTTTTTGTGT 1959
              ||||| | ||||||||
Db          2 TGGTTTGATTTTGTGT 17


RESULT 913
ADF64455
ID   ADF64455 standard; DNA; 17 BP.
XX
AC   ADF64455;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2359.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 2359; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
```

```
SQ   Sequence 17 BP; 2 A; 0 C; 5 G; 10 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1944 TGGTTGGTTTTTGTGT 1959
              |||||| | ||||||||
Db          1 TGGTTTGATTTTGTGT 16


RESULT 914
ADI49767
ID   ADI49767 standard; DNA; 17 BP.
XX
AC   ADI49767;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID2270.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 2270; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAGA 2012
              |||||| |||| ||||
Db          2 ATCTAGGTTCTCCAGA 17


RESULT 915
ADI47542
ID   ADI47542 standard; DNA; 17 BP.
XX
AC   ADI47542;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID45.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 45; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACA 1916
              |||||| ||| |||||
Db          1 GATCAATAGACCAACA 16


RESULT 916
ADI49784
ID   ADI49784 standard; DNA; 17 BP.
XX
AC   ADI49784;
```

```
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID2287.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 2287; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 3 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match              2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAGA 2012
              |||| ||| |||||||
Db          2 ATCTTGCTCCTTCAGA 17


RESULT 917
ADI51285
ID   ADI51285 standard; DNA; 17 BP.
XX
AC   ADI51285;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID3788.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 3788; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 2 A; 1 C; 3 G; 11 T; 0 U; 0 Other;

  Query Match              2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTGA 1783
              | |||||| |||||||
Db          2 ATCTTTTTGTTTTTGA 17


RESULT 918
ABZ76061/c
ID   ABZ76061 standard; DNA; 17 BP.
XX
AC   ABZ76061;
XX
DT   29-MAY-2003  (first entry)
XX
DE   Antigene inhibiting adenovirus type 5 IR pairing.
XX
KW   Cruciform; DNA replication; antigene; antibacterial; virucide; fungicide;
KW   protozoazide; antihelminthic; anti-HIV; cytostatic; gene therapy;
KW   adenovirus; inverted repeat; ds.
XX
OS   Synthetic.
XX
PN   WO2003012097-A2.
XX
PD   13-FEB-2003.
XX
PF   30-JUL-2002; 2002WO-IB003667.
```

```
XX
PR   30-JUL-2001; 2001US-0308636P.
XX
PA   (PRIC/) PRICE G B.
PA   (ZANN/) ZANNIS-HADJOPOULOS M.
XX
PI   Price GB,  Zannis-Hadjopoulos M;
XX
DR   WPI; 2003-248179/24.
XX
PT   Inhibiting DNA replication or cell proliferation, useful for treating
PT   tumors, comprises contacting a DNA molecule with a nucleic acid antigene
PT   that specifically hybridizes to a portion of the DNA molecule having dyad
PT   symmetry.
XX
PS   Claim 11; Page 21; 54pp; English.
XX
CC   The invention relates to inhibiting DNA replication and involves
CC   contacting a DNA molecule with a nucleic acid antigene comprising at
CC   least 12 nucleobases selected from natural nucleobases, modified
CC   nucleobases, and their mixture. The antigene specifically hybridizes to a
CC   portion of the DNA molecule having dyad symmetry. The method is useful in
CC   inhibiting DNA replication and, thus, inhibiting the growth of bacteria,
CC   virus (e.g. HIV), fungi, protozoa, helminths and insects. The method is
CC   also useful in inhibiting cell proliferation of tumour cells. The present
CC   sequence represents an antigene inhibiting the inverted repeat (IR)
CC   pairing of adenovirus type 5
XX
SQ   Sequence 17 BP; 2 A; 2 C; 10 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCCC 1676
              || | ||||||||||
Db         16 CTACGTCACCCGCCCC 1


RESULT 919
ACC51590
ID   ACC51590 standard; DNA; 17 BP.
XX
AC   ACC51590;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #357.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 122; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 3 A; 4 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              | || ||||||||||||
Db          2 ATCACTACCTTTTTTT 17


RESULT 920
ADK12618
ID   ADK12618 standard; DNA; 17 BP.
XX
AC   ADK12618;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human NAC-1 gene-specific probe #102.
XX
KW   human; NAC-1; NAC-1 associated disorder; drug addiction; cancer; probe;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   US2003100495-A1.
XX
PD   29-MAY-2003.
XX
PF   02-AUG-2002; 2002US-00211059.
XX
PR   08-AUG-2001; 2001US-0311034P.
XX
PA   (ZHAN/) ZHANG J.
XX
PI   Zhang J;
XX
DR   WPI; 2003-787024/74.
XX
PS   Example 2; SEQ ID NO 118; 96pp; English.
XX
CC   The invention comprises the amino acid and coding sequences of the human
CC   NAC-1 protein. The DNA and protein sequences of the invention are useful
CC   for treating or preventing a disorder associated with decreased or
CC   increased expression or activity of human NAC-1. The DNA and protein
CC   sequences are also useful for treating drug addiction and cancer. The
CC   present DNA sequence represents a probe for the human NAC-1 gene.
XX
SQ   Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1587 CAGACTGGGAACCCCT 1602
              |||| |||||||| ||
Db          1 CAGATTGGGAACCGCT 16


RESULT 921
ADK12617
ID   ADK12617 standard; DNA; 17 BP.
```

```
XX
AC   ADK12617;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human NAC-1 gene-specific probe #101.
XX
KW   human; NAC-1; NAC-1 associated disorder; drug addiction; cancer; probe;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   US2003100495-A1.
XX
PD   29-MAY-2003.
XX
PF   02-AUG-2002; 2002US-00211059.
XX
PR   08-AUG-2001; 2001US-0311034P.
XX
PA   (ZHAN/) ZHANG J.
XX
PI   Zhang J;
XX
DR   WPI; 2003-787024/74.
XX
PS   Example 2; SEQ ID NO 117; 96pp; English.
XX
CC   The invention comprises the amino acid and coding sequences of the human
CC   NAC-1 protein. The DNA and protein sequences of the invention are useful
CC   for treating or preventing a disorder associated with decreased or
CC   increased expression or activity of human NAC-1. The DNA and protein
CC   sequences are also useful for treating drug addiction and cancer. The
CC   present DNA sequence represents a probe for the human NAC-1 gene.
XX
SQ   Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1587 CAGACTGGGAACCCCT 1602
                ||||  |||||||| ||
Db          2 CAGATTGGGAACCGCT 17


RESULT 922
ADL48853/c
ID   ADL48853 standard; RNA; 17 BP.
XX
AC   ADL48853;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human IKK-gamma substrate sequence #1363.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 2386; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human IKK-
CC   gamma substrate sequence.
XX
SQ   Sequence 17 BP; 6 A; 2 C; 7 G; 0 T; 2 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
                ||||||||||  ||||
Db         16 CCCCATTCTTGACTTC 1


RESULT 923
ADL49568
ID   ADL49568 standard; RNA; 17 BP.
XX
AC   ADL49568;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PKR substrate sequence #682.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
```

PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 3101; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 3 C; 1 G; 0 T; 11 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 25.0%; Pred. No. 4.7e+02;
Matches 4; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1765 TTAAGCTTTTTTTTTT 1780
              ::|||| :: ::::::
Db          2 UUAAGCCUUCUUUUUU 17
```

RESULT 924
ADL50564
ID ADL50564 standard; RNA; 17 BP.
XX
AC ADL50564;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1678.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX

PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4097; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 4.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1729 ATTATCAGAAGGTGAC 1744
              |: |:| |||||:|||
Db          2 AUCAUCUGAAGGUGAC 17
```

RESULT 925
ADL48933
ID ADL48933 standard; RNA; 17 BP.
XX
AC ADL48933;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #47.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX

```
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 2466; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 2 A; 4 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   25.0%;  Pred. No. 4.7e+02;
  Matches    4;  Conservative   10;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTT 1780
              ::|||| :: ::::::
Db          1 UUAAGCCUUCUUUUUU 16


RESULT 926
ADL82289
ID   ADL82289 standard; DNA; 17 BP.
XX
AC   ADL82289;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human ER+ breast cancer differentially expressed sequence #259.
XX
KW   gene therapy; ds; breast cancer; human; ER+ breast cancer.
XX
OS   Homo sapiens.
XX
PN   US2003166026-A1.
XX
PD   04-SEP-2003.
XX
PF   08-JAN-2003; 2003US-00339782.
XX
PR   09-JAN-2002; 2002US-0348053P.
XX
PA   (LYNX-) LYNX THERAPEUTICS INC.
XX
PI   Goodman LJ,  Bowen BA;
XX
DR   WPI; 2004-069003/07.
XX
PT   Vector containing nucleic acid associated with breast cancer, useful for
PT   treating, diagnosing and characterizing breast cancer, also related
PT   polypeptides and antibodies.
XX
PS   Claim 1; SEQ ID NO 260; 61pp; English.
XX
CC   The invention relates to a composition which contains at least one vector
CC   (B) containing a nucleic acid (I) associated with breast cancer. The
CC   vector (B), also polypeptides (II) encoded by (I), are used for treatment
CC   of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
CC   -specific antibodies (Ab) are used to predict characteristics (e.g.
CC   invasiveness or stage) of breast cancer, and (I), or its fragments, are
CC   used to modulate characteristics of such cells; to identify breast cancer
CC   genes and to detect breast cancer (by detecting polymorphic nucleic acid
CC   or its products). The present sequence represents a human ER+ breast
CC   cancer differentially expressed sequence.
XX
SQ   Sequence 17 BP; 1 A; 10 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1595 GAACCCCTCCTGGCCT 1610
              || |||||||| |||
Db          1 GATCCCCTCCTGCCCT 16


RESULT 927
ADN44859/c
ID   ADN44859 standard; DNA; 17 BP.
XX
AC   ADN44859;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Mutant cell identification-related mutagenic oligonucleotide SeqID1528.
XX
KW   cell identification; oligonucleotide-directed sequence alteration;
KW   selectable phenotype; transgenic plant; herbicide resistance;
KW   sterile plant; abiotic stress tolerance; albino plant;
KW   amino acid production; ss.
XX
OS   Arabidopsis thaliana.
OS   Synthetic.
XX
PN   WO2004033708-A2.
XX
PD   22-APR-2004.
XX
PF   07-OCT-2003; 2003WO-US031862.
XX
PR   07-OCT-2002; 2002US-0416983P.
PR   07-MAR-2003; 2003US-0453360P.
XX
PA   (UYDE ) UNIV DELAWARE.
PA   (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
PI   Kmiec EB,  Van Brabant A;
XX
DR   WPI; 2004-340941/31.
XX
PT   Identifying a cell with a desired oligonucleotide-directed sequence
PT   alteration at a nucleic acid target site within the cell by identifying
PT   the desired sequence alteration in cells selected for the presence of a
PT   selectable phenotype.
XX
PS   Example 28; SEQ ID NO 1528; 303pp; English.
XX
CC   This invention relates to a novel method of identifying a cell having a
CC   desired oligonucleotide-directed sequence alteration at a first nucleic
CC   acid target site within the cell. The method comprises identifying the
```

```
CC   desired sequence alteration in cells that have been selected for the
CC   presence of a selectable phenotype conferred by a concurrent
CC   oligonucleotide-directed sequence alteration at a second nucleic acid
CC   target site within the cells. The method is useful in identifying a cell
CC   having a desired oligonucleotide-directed sequence alteration at a first
CC   nucleic acid target site within the cell. The method may be useful for
CC   the production of plants with herbicide resistance, male or female
CC   sterile plants, abiotic stress tolerance, albino plants or plants with
CC   altered amino acid production as well as for use in mammalian cell lines.
CC   The present sequence is that of a mutagenic oligonucleotide which was
CC   used in the exemplification of the invention.
XX
SQ   Sequence 17 BP; 1 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTA 2045
              ||||||||||| |||
Db         17 GGAGGCAAAGGAGCTA 2


RESULT 928
ADN44858
ID   ADN44858 standard; DNA; 17 BP.
XX
AC   ADN44858;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Mutant cell identification-related mutagenic oligonucleotide SeqID1527.
XX
KW   cell identification; oligonucleotide-directed sequence alteration;
KW   selectable phenotype; transgenic plant; herbicide resistance;
KW   sterile plant; abiotic stress tolerance; albino plant;
KW   amino acid production; ss.
XX
OS   Arabidopsis thaliana.
OS   Synthetic.
XX
PN   WO2004033708-A2.
XX
PD   22-APR-2004.
XX
PF   07-OCT-2003; 2003WO-US031862.
XX
PR   07-OCT-2002; 2002US-0416983P.
PR   07-MAR-2003; 2003US-0453360P.
XX
PA   (UYDE ) UNIV DELAWARE.
PA   (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
PI   Kmiec EB,  Van Brabant A;
XX
DR   WPI; 2004-340941/31.
XX
PT   Identifying a cell with a desired oligonucleotide-directed sequence
PT   alteration at a nucleic acid target site within the cell by identifying
PT   the desired sequence alteration in cells selected for the presence of a
PT   selectable phenotype.
XX
PS   Example 28; SEQ ID NO 1527; 303pp; English.
XX
CC   This invention relates to a novel method of identifying a cell having a
CC   desired oligonucleotide-directed sequence alteration at a first nucleic
CC   acid target site within the cell. The method comprises identifying the
CC   desired sequence alteration in cells that have been selected for the
CC   presence of a selectable phenotype conferred by a concurrent
CC   oligonucleotide-directed sequence alteration at a second nucleic acid
CC   target site within the cells. The method is useful in identifying a cell
CC   having a desired oligonucleotide-directed sequence alteration at a first
CC   nucleic acid target site within the cell. The method may be useful for
CC   the production of plants with herbicide resistance, male or female
CC   sterile plants, abiotic stress tolerance, albino plants or plants with
CC   altered amino acid production as well as for use in mammalian cell lines.
CC   The present sequence is that of a mutagenic oligonucleotide which was
CC   used in the exemplification of the invention.
XX
SQ   Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 4.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTA 2045
              ||||||||||| |||
Db          1 GGAGGCAAAGGAGCTA 16


RESULT 929
AAT73318
ID   AAT73318 standard; DNA; 18 BP.
XX
AC   AAT73318;
XX
DT   24-NOV-1997  (first entry)
XX
DE   Primer 22-cSTS10 for DiGeorge Syndrome chromosomal region DGS-J.
XX
KW   Primer; polymerase chain reaction; PCR; amplification;
KW   transcription unit; minimal; DiGeorge Syndrome; DGS;
KW   Velo-Cardio-Facial Syndrome; VCFS; chromosomal region; mDGCR;
KW   chromosome 22q11; probe; primer pair; detection; diagnosis; mutation;
KW   cleft palate; ss.
XX
OS   Synthetic.
XX
PN   WO9711088-A1.
XX
PD   27-MAR-1997.
XX
PF   20-SEP-1996;   96WO-US015020.
XX
PR   20-SEP-1995;   95US-0004033P.
PR   20-SEP-1996;   96US-00717400.
XX
PA   (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX
PI   Gong W,  Emanuel BS,  Budarf ML,  Roe B;
XX
DR   WPI; 1997-202809/18.
XX
PT   New isolated transcription units of chromosome 22q11 - used to detect
PT   mutation(s) involved in DiGeorge Syndrome, velo-cardio-facial syndrome
PT   and cleft palate.
XX
PS   Claim 12; Page 23; 37pp; English.
XX
CC   The present sequence is a primer for the PCR amplification of a
CC   transcription unit encoded in the minimal DiGeorge Syndrome (DGS)/Velo-
CC   Cardio-Facial Syndrome (VCFS) chromosomal region (mDGCR) DGS-J
CC   (chromosome 22q11 c2C3). Probes and primer pairs complementary to the
CC   transcription unit can be used to detect and diagnose mutations involved
CC   in DGS, VCFS and cleft palate
XX
SQ   Sequence 18 BP; 3 A; 10 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCCC 1676
              |||||||||| ||||
Db          1 CTGCATCACCTTCCCC 16
```

```
RESULT 930
AAX76900/c
ID   AAX76900 standard; DNA; 18 BP.
XX
AC   AAX76900;
XX
DT   17-OCT-2003  (revised)
DT   05-AUG-1999  (first entry)
XX
DE   Hz-1 Pag1 gene direct repeat sequence.
XX
KW   Hz-1 pag1 promoter; persistence-associated gene 1; insect cell;
KW   constitutive expression promoter; direct repeat; ss.
XX
OS   Heliothis zea virus 1.
XX
PN   US5911982-A.
XX
PD   15-JUN-1999.
XX
PF   18-APR-1996;   96US-00634350.
XX
PR   06-OCT-1995;   95US-0004894P.
PR   11-OCT-1995;   95US-0005128P.
XX
PA   (NASC-) NAT SCI COUNCIL.
XX
PI   Chao Y;
XX
DR   WPI; 1999-357167/30.
XX
PT   HZ-1 virus persistence-associated gene promoter.
XX
PS   Example 1; Fig 3c; 56pp; English.
XX
CC   This sequence represents a direct repeat from the Hz-1 persistence-
CC   associated gene 1 (Hz-1 pag1). The invention relates to the Hz-1 pag1
CC   promoter. The pag1 gene promoter is useful in insect cells for driving
CC   constitutive expression of e.g. genes encoding foreign proteins. The
CC   promoter of the pag1 gene is constitutively expressed and stronger than
CC   that of the polyhedrin gene in insect cells, enabling it to express
CC   foreign genes more strongly e.g. lacZ and luciferase, in addition to
CC   which it can be expressed more prominently as a short promoter. (Updated
CC   on 17-OCT-2003 to standardise OS field)
XX
SQ   Sequence 18 BP; 8 A; 1 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              | |||||||||| |||
Db         16 ACCAATACCTTTGTTT 1


RESULT 931
AAA60110
ID   AAA60110 standard; DNA; 18 BP.
XX
AC   AAA60110;
XX
DT   17-JAN-2001  (first entry)
XX
DE   Oligonucleotide # 1 used in PR domain peptide analysis.
XX
KW   Rb-interacting zinc finger; RIZ; retinoblastoma; heart disease;
KW   cell proliferation; cell differentiation; tissue repair; PR domain;
KW   transcription regulator; breast cancer; gene therapy; melanoma;
KW   neuroblastoma; leukaemia; Parkinson's disease; Huntingdon's disease;
KW   Alzheimer's disease; paralysis; motor neurone disorder; ss.
XX
OS   Unidentified.
XX
PN   US6069231-A.
XX
PD   30-MAY-2000.
XX
PF   18-AUG-1995;   95US-00516859.
XX
PR   18-AUG-1994;   94US-00292683.
PR   06-MAR-1995;   95US-00399411.
XX
PA   (LJOL-) LA JOLLA CANCER RES FOUND.
XX
PI   Huang S;
XX
DR   WPI; 2000-410879/35.
XX
PT   New PR domain peptides comprising amino acid sequences from, for example
PT   retinoblastoma-interacting zinc finger, or egl-43 proteins, for
PT   regulating gene transcription and controlling cell proliferation and
PT   differentiation.
XX
PS   Disclosure; Col 85-86; 91pp; English.
XX
CC   Retinoblastoma (Rb)-interacting zinc finger (RIZ) protein is a nuclear
CC   phosphoprotein that acts as a cell differentiation factor. RIZ can
CC   modulate cell growth by binding to Rb protein, which is involved in
CC   regulating cell proliferation. In addition, RIZ can act to regulate
CC   transcription. RIZ functions to maintain cells in the G1 phase of the
CC   cell cycle, by interacting with Rb through the cr2 domain of RIZ. RIZ
CC   protein is a PR domain protein and is present primarily in the cell
CC   nucleus. RIZ gene mutations may be implicated in various cancers such as
CC   melanoma, neuroblastoma, leukaemia and breast cancer, and so the RIZ gene
CC   may be used in gene therapy for these disorders. Since RIZ protein is
CC   implicated in cell cycle arrest, inhibition of RIZ activity may be useful
CC   in neurodegenerative disorder therapy e.g. for Parkinson's, Huntingdon's
CC   or Alzheimer's disease, paralysis or motor neurone disorders, or cardiac
CC   disorders e.g. heart disease, where the ability to induce neural/ cardiac
CC   tissue proliferation would be useful. The present sequence is an
CC   oligonucleotide used in the analysis of PR domain peptides of the present
CC   invention
XX
SQ   Sequence 18 BP; 4 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 932
AAZ77174
ID   AAZ77174 standard; DNA; 18 BP.
XX
AC   AAZ77174;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:11530.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
```

```
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 9; Page 2688; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 18 BP; 1 A; 4 C; 5 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTTGTGTC 1960
              ||||||||||||  ||
Db          3 GGTTGGTTTTTGCCTC 18


RESULT 933
AAZ73513/c
ID   AAZ73513 standard; DNA; 18 BP.
XX
AC   AAZ73513;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:7869.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1908; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 18 BP; 6 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1939 GGTAATGGTTGGTTTT 1954
              |||||  ||||||| ||
Db         18 GGTAAGGGTTGGTGTT 3


RESULT 934
AAA67054
ID   AAA67054 standard; DNA; 18 BP.
XX
AC   AAA67054;
XX
DT   19-OCT-2000  (first entry)
XX
DE   Human leukocyte antigen B allele DNA probe BL272A SEQ ID NO:112.
XX
KW   Human leukocyte antigen; HLA; class I allele type; probe; PCR primer;
KW   amplification; hybridisation; organ transplant; gene typing; diagnosis;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200031295-A1.
XX
PD   02-JUN-2000.
XX
PF   07-OCT-1999;   99WO-JP005527.
XX
PR   26-NOV-1998;   98JP-00335151.
XX
PA   (SHIO ) SHIONOGI & CO LTD.
XX
PI   Moribe T,  Kaneshige T;
XX
DR   WPI; 2000-400097/34.
XX
PT   Simple, rapid and accurate method for distinguishing HLA class I allele
PT   type with possibility of mechanization and automation, applicable in
PT   judging donor-recipient compatibility during organ transplant and disease
PT   diagnosis.
XX
PS   Claim 8; Page 75; 83pp; Japanese.
```

```
XX
CC   The present invention describes a method for distinguishing a human
CC   leukocyte antigen (HLA) class I antigen or allele by a combination of
CC   polymerase chain reaction (PCR) using a primer pair whereby all HLA-A, -B
CC   or -C alleles can be amplified or using reverse hybridisation analysis
CC   comprising a DNA probe covalently bonded to microtitre plate wells which
CC   are hybridisable specifically with the base sequence of at least one
CC   specific HLA-A, -B or -C allele. The method is applicable in gene typing,
CC   judging donor-recipient compatibility during organ transplant and
CC   correlation analysis for diagnosis of various diseases. The method is
CC   simple, rapid and accurate, with possibility of mechanisation and
CC   automation, without the problems encountered by using the prior-art
CC   techniques. AAA66943 to AAA67072 represent oligonucleotide probes and PCR
CC   primers for use in the method of the present invention
XX
SQ   Sequence 18 BP; 9 A; 5 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1906 ACAGATCAACAATACC 1921
              ||||||| |||| |||
Db          1 ACAGATCTACAAGACC 16


RESULT 935
AAC63013
ID   AAC63013 standard; DNA; 18 BP.
XX
AC   AAC63013;
XX
DT   05-FEB-2001  (first entry)
XX
DE   Human IL-1 alpha gene allele 1 oligonucleotide #8.
XX
KW   Generalised onset periodontal disease; interleukin-1alpha; IL-1A;
KW   interleukin-1beta; IL-1B; polymorphism; disease diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   US6130042-A.
XX
PD   10-OCT-2000.
XX
PF   05-MAR-1998;   98US-00035220.
XX
PR   05-MAR-1998;   98US-00035220.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Diehl SR,  Schenkein HA,  Wang Y;
XX
DR   WPI; 2000-637836/61.
XX
PT   Predicting or diagnosing (susceptibility to) early-onset periodontal
PT   disease comprises detecting genetic polymorphisms of interleukin 1B.
XX
PS   Disclosure; Col 12; 30pp; English.
XX
CC   The present sequence was used in a method for predicting susceptibility
CC   to generalised onset periodontal disease. The method comprises detecting
CC   genetic polymorphisms in the interleukin (IL) 1alpha (1A) or 1beta (1B)
CC   genes. The high risk genotypes are those where the individual is
CC   homozygous for allele 1 for IL-1A or for IL-1B. The method allows early
CC   monitoring and therapeutic intervention of generalised onset periodontal
CC   disease
XX
SQ   Sequence 18 BP; 5 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1644 AAGAGCCTTCACTGGT 1659
              | |||||||||| ||||
Db          3 ATGAGCCTTCAATGGT 18


RESULT 936
ABA82425
ID   ABA82425 standard; DNA; 18 BP.
XX
AC   ABA82425;
XX
DT   25-JAN-2002  (first entry)
XX
DE   Zmax1 gene region physical map preparation STS marker #384.
XX
KW   Human; high bone mass; HBM gene; Zmax1 gene; chromosome 11; 11q13.3;
KW   sequence tagged site; STS; osteoporosis; osteopathic; gene therapy;
KW   antisense therapy; vaccine; bone disorder; Paget's disease; adapter;
KW   sclerostosis; osteomalacia; fibrous dysplasia; PCR primer; linker; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177327-A1.
XX
PD   18-OCT-2001.
XX
PF   21-JUN-2000; 2000WO-US016951.
XX
PR   05-APR-2000; 2000US-00543771.
PR   05-APR-2000; 2000US-00544398.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Carulli JP,  Little RD,  Recker RR,  Johnson ML;
XX
DR   WPI; 2001-657171/75.
XX
PT   New high bone mass (HBM) and Zmax1 genes and proteins useful for
PT   modulating bone mass for the treatment of e.g. osteoporosis.
XX
PS   Disclosure; Page 36; 443pp; English.
XX
CC   The present invention describes the human Zmax1 gene and the high bone
CC   mass (HBM) gene,which are found on chromosome 11q13.3. The Zmax1 and HBM
CC   genes have osteopathic activities. The genes can be used in gene therapy,
CC   antisense therapy and in the production of vaccines. They can be used in
CC   the diagnosis and treatment of bone disorders including osteoporosis,
CC   Paget's disease, sclerostosis, osteomalacia and fibrous dysplasia.
CC   ABA82038 to ABA82700 and AAG68168 to AAG68193 represent sequences used in
CC   the exemplification of the present invention
XX
SQ   Sequence 18 BP; 3 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1782 GAACCCCATTCTTTCC 1797
              ||| ||| ||||||||
Db          2 GAATCCCTTTCTTTCC 17


RESULT 937
ABK28903/c
ID   ABK28903 standard; DNA; 18 BP.
XX
AC   ABK28903;
XX
DT   09-APR-2002  (first entry)
XX
DE   HPV blocker probe PE-2.
```

XX
KW HSV-1; HSV-2; HPV; HBV; ss; probe; microorganism classification;
KW infectious disease; genetic abnormality; cancer; capture sequence;
KW blocker probe.
XX
OS Human papillomavirus.
XX
PN WO200196608-A1.
XX
PD 20-DEC-2001.
XX
PF 15-JUN-2001; 2001WO-US019353.
XX
PR 15-JUN-2000; 2000US-00594839.
XX
PA (DIGE-) DIGENE CORP.
XX
PI Anthony J, Lorincz A, Williams I, Troy J, Tang Y;
XX
DR WPI; 2002-130748/17.
XX
PT Detecting a target nucleic acid, for identifying microorganisms,
PT diagnosing infections or detecting genetic abnormalities, comprises
PT producing and detecting double-stranded hybrids between probes and the
PT target nucleic acid.
XX
PS Claim 53; Page 25; 128pp; English.
XX
CC The invention relates to detecting a target nucleic acid comprising (a)
CC hybridising a single-stranded or partially single-stranded target nucleic
CC acid to a capture sequence probe and a signal sequence probe to form
CC double-stranded hybrids between the probes and the target nucleic acid,
CC where the capture sequence probe and the signal sequence probe are
CC capable of hybridising to non-overlapping regions within the target
CC nucleic acid and not hybridising to each other, (b) adding a blocker
CC probe to the hybridisation reaction, where the blocker probe hybridises
CC to excess non-hybridised capture sequence probes, (c) binding the hybrid
CC to a solid phase to form a bound hybrid, and (d) detecting the bound
CC hybrid. The method is used to detecting a target nucleic acid. The method
CC is useful for identifying and classifying microorganisms, diagnosing
CC infectious diseases, detecting and characterising genetic abnormalities,
CC identifying genetic changes associated with cancer, studying genetic
CC susceptibility to disease, and measuring response to various types of
CC treatment. The method is also useful for detecting the presence of
CC nucleic acid in test samples. The method is not only rapid and sensitive,
CC but is also highly specific and capable of discriminating highly
CC homologous nucleic acid target sequences. Blocker probes comprising
CC oligonucleotides complementary to the capture sequence probes are used in
CC the method to eliminate excess capture sequence probe, thus reducing the
CC background signal in detection and increasing specificity of the assay.
CC The present sequence is a blocker probe derived from HSV-1, HSV-2, HPV or
CC HBV sequences
XX
SQ Sequence 18 BP; 7 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1702 GCTGAGCTATCTCCTA 1717
                ||||||| ||| |||
Db         18 GCTGAGCTTTCTACTA 3
```

RESULT 938
ABV73436
ID ABV73436 standard; DNA; 18 BP.
XX
AC ABV73436;
XX
DT 19-DEC-2002 (first entry)
XX
DE Human V1a vasopressin receptor reverse RT PCR primer SEQ ID NO 2.
XX
KW Human; osteopathic; gynaecological; antidiabetic; cytostatic; vulnerary;
KW antialcoholic; antiarthritic; antirheumatic; osteoporosis; osteopenia;
KW bone; oxytocin receptor; OTR; oxytocin; osteoblast; cystic fibrosis;
KW diabetes mellitus; leukaemia; rheumatoid arthritis; RT PCR;
KW ribosomal L19 protein; V1a vasopressin receptor; primer; ss.
XX
OS Homo sapiens.
XX
PN US6333313-B1.
XX
PD 25-DEC-2001.
XX
PF 29-OCT-1999; 99US-00430114.
XX
PR 29-OCT-1998; 98US-0106134P.
XX
PA (TEXA) UNIV TEXAS SYSTEM.
XX
PI Copland JA, Ives KL, Simmons DJ, Soloff M;
XX
DR WPI; 2002-641405/69.
XX
PT Use of oxytocin or its analog for treating e.g. osteoporosis.
XX
PS Example 1; Col 15; 17pp; English.
XX
CC The invention relates to treatment of osteoporosis, osteopenia, bone loss
CC or accentuating bone healing involving formulating an oxytocin receptor
CC (OTR) stimulator (preferably oxytocin or its analogue) into a formulation
CC and administering to stimulate osteoblast function, to maintain or
CC increase bone formation and/or inhibit bone resorption. An agent that
CC stimulates endogenous oxytocin release may also be used in the
CC formulation. The invention relates to treating osteoporosis or osteopenia
CC secondary to anorexia nervosa, exercise induced amenorrhoea, Turner
CC Syndrome, cystic fibrosis, diabetes mellitus, hyperthyroidism, Cushing's
CC Syndrome, glucocorticoid excess, acute lymphoblastic leukaemia,
CC Klinefelter's and Kallman's syndromes, alcohol abuse, cigarette smoking,
CC connective tissue disease, osteoarthritis or rheumatoid arthritis; bone
CC loss associated with osteogenesis imperfecta, vitamin D deficiency, bone
CC reconstruction, wound healing or soft skeletal tissue repair and
CC accentuating bone healing. Also for treating bone fractures and for bone
CC remodeling surgery. The present sequence is that of a RT PCR primer used
CC to assess the comparative expression levels of OTR with that of the V1a
CC vasopressin receptor, using the expression of the ribosomal L19 protein
CC as a positive control. OTR mRNA is expressed in undifferentiated
CC osteoblastic cells, differentiated osteoblasts and human osteosarcoma
CC Saos-2 cells
XX
SQ Sequence 18 BP; 1 A; 2 C; 8 G; 7 T; 0 U; 0 Other;

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1939 GGTAATGGTTGGTTTT 1954
                ||| ||||| ||||||
Db          1 GGTGATGGTGGGTTTT 16
```

RESULT 939
ABK23222
ID ABK23222 standard; DNA; 18 BP.
XX
AC ABK23222;
XX
DT 09-APR-2002 (first entry)
XX
DE Human Zmax1 cDNA reverse PCR primer #192.
XX
KW Human; mouse; Zmax1; HBM; high bone mass gene; lipid regulation; stroke;
KW lipid-associated condition; arteriosclerosis; cardiovascular disease; ss;
KW osteoporosis; atherosclerosis; diabetic atherosclerosis; plaque build-up;

KW neurovascular condition; wound healing; gene therapy; PCR primer; probe;
KW bone development disorder; antiarteriosclerotic; cardiovascular;
KW osteopathic; cerebroprotective.
XX
OS Homo sapiens.
XX
PN WO200192891-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016946.
XX
PR 26-MAY-2000; 2000US-00578900.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
XX
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2002-097784/13.
XX
PT Identifying molecules involved in lipid regulation, useful for
PT diagnosing, treating or preventing e.g., arteriosclerosis, comprises
PT identifying a molecule that binds to high bone mass gene or its
PT corresponding wild type gene.
XX
PS Disclosure; Page 41; 409pp; English.
XX
CC The invention relates to a method for identifying a molecule involved in
CC lipid regulation comprising identifying a molecule that binds to or
CC inhibits binding of a molecule to high bone mass (HBM) or its wild type
CC gene, Zmax1. Compounds identified by the method are useful for treating,
CC diagnosing, preventing or screening for normal and abnormal lipid-
CC associated conditions, including arteriosclerosis, cardiovascular
CC disease, stroke, and osteoporosis. The compounds may also be used in the
CC treatment or prevention of diabetic atherosclerosis, neurovascular
CC conditions caused by plaque build-up, poor circulation due to plaque
CC build-up and associated poor wound healing. The methods may be used in
CC gene therapy, pharmaceutical development, and diagnostic assays for bone
CC development disorders. Molecules identified by comparison of Zmax1 and
CC HBM systems can be used as surrogate markers in pharmaceutical
CC development, in diagnosis of human or animal bone disease, and in the
CC treatment of bone diseases. Sequences ABK22776-ABK23411 represent cDNA
CC molecules encoding human Zmax1 and HBM, and PCR primers, probes, linkers
CC and adapters of the invention
XX
SQ Sequence 18 BP; 3 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1782 GAACCCCATTCTTTCC 1797
||| ||| ||||||||
Db 2 GAATCCCTTTCTTTCC 17

RESULT 940
ABL40874/c
ID ABL40874 standard; DNA; 18 BP.
XX
AC ABL40874;
XX
DT 03-JUL-2002 (first entry)
XX
DE Nucleotide sequence of a primer #8.
XX
KW Nucleic acid detection; transcription factor; cytostatic; reporter gene;
KW neuroprotective; cancer diagnosis; Li-Fraumeni syndrome; memory loss;
KW PCR primer; ss.
XX
OS Synthetic.
XX
PN WO200229043-A1.
XX
PD 11-APR-2002.
XX
PF 28-SEP-2001; 2001WO-JP008576.
XX
PR 02-OCT-2000; 2000JP-00302100.
XX
PA (HELI-) HELIX RES INST.
XX
PI Oda T, Muramatsu M;
XX
DR WPI; 2002-340106/37.
XX
PT Identifying target gene of transcription factor for isolation in cells
PT with vectors expressing fused protein of transcription factor with its
PT activator and specific reporter gene, useful in cancer diagnosis and
PT therapy.
XX
PS Example 4; Page 14; 32pp; Japanese.
XX
CC The invention relates to a method of detecting the target gene of a
CC specific transcription factor. The method involves (a) supplying cells
CC containing a vector expressing a fused protein of the transcription
CC factor with an activator of this transcription factor and another vector
CC containing a reporter gene; (b) separating cells; and (c) comparing the
CC gene expression dose of the cells. The method is for identifying a target
CC gene of transcription factor for isolation, which is used for application
CC in cancer diagnosis and drug development for e.g. Li-Fraumeni syndrome
CC and long-term memory loss. With expression of the reporter gene as
CC indication, the identification and isolation can be efficiently carried
CC out because its enlarged expression dose in a cell is induced by the
CC transcription factor. Sequences ABL40867-874 represents primers used in
CC the course of the invention
XX
SQ Sequence 18 BP; 3 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1587 CAGACTGGGAACCCCT 1602
|||||||||| || ||
Db 17 CAGACTGGGAGCCTCT 2

RESULT 941
ABK17341
ID ABK17341 standard; DNA; 18 BP.
XX
AC ABK17341;
XX
DT 26-MAR-2002 (first entry)
XX
DE Rat Rb-interacting zinc finger (RIZ) cDNA PCR primer #1.
XX
KW Rat; human; retinoblastoma protein-interacting zinc finger protein; RIZ;
KW ss; PRDI-BF1; human positive regulatory domain I-binding factor 1; EVI-1;
KW human ecotropic viral integration site-1 myeloid transforming gene; Rb;
KW Caenorhabditis elegans; egl-43; retinoblastoma protein; cardiac muscle;
KW cell proliferation; cancer; cell proliferation; neural cell; paralysis;
KW neurodegenerative disease; Parkinson's disease; Huntington's disease;
KW Alzheimer's disease; motor neuron disorder; PCR primer; mouse; E1A;
KW mutagenesis primer.
XX
OS Rattus sp.
XX
PN US6323335-B1.
XX
PD 27-NOV-2001.
XX
PF 01-JUN-2000; 2000US-00586472.
XX

```
PR   18-AUG-1994;   94US-00292683.
PR   06-MAR-1995;   95US-00399411.
PR   18-AUG-1995;   95US-00516859.
PR   17-MAR-2000; 2000US-00528706.
XX
PA   (HUAN/) HUANG S.
XX
PI   Huang S;
XX
DR   WPI; 2002-096600/13.
XX
PT   Novel nucleic acid molecule comprises the code for a conserved domain of
PT   retinoblastoma protein-interacting zinc finger protein, positive
PT   regulatory domain I-binding factor involved in regulating gene
PT   transcription.
XX
PS   Example 4; Col 36; 93pp; English.
XX
CC   The invention relates to a nucleic acid molecule encoding a PR domain
CC   peptide present in human and rat retinoblastoma protein-interacting zinc
CC   finger protein (RIZ), PRDI-BF1 (human positive regulatory domain I-
CC   binding factor 1), EVI-1 (human ecotropic viral integration site-1
CC   myeloid transforming gene product) or Caenorhabditis elegans egl-43 gene
CC   product. The DNA of the invention is involved in regulating transcription
CC   of a target gene. RIZ acts as a cell-differentiation factor and modulates
CC   a function of a cell by binding to retinoblastoma (Rb) protein, which is
CC   involved in regulating cell proliferation in various human diseases or
CC   conditions, e.g. cancer. RIZ regulates the growth of normal adult cardiac
CC   muscle cells and prevents proliferation of surviving cells following
CC   cardiac muscle cell death. RIZ is expressed in neural cells. This is
CC   useful for healing after injury of neural tissue and for treating
CC   neurodegenerative diseases such as Parkinson's, Huntington's or
CC   Alzheimer's disease and paralysis, or motor neuron disorders through
CC   induced or decreased proliferation of neural cells. The PR domain or RIZ
CC   active fragment containing a PR domain is useful as a probe to identify
CC   transcription factors or oncogenic proteins in a cell that bind the PR
CC   domain. Sequences ABK17334-ABK17353 represent DNA molecules and primers
CC   of the invention
XX
SQ   Sequence 18 BP; 4 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
             ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 942
ACF62961/c
ID   ACF62961 standard; DNA; 18 BP.
XX
AC   ACF62961;
XX
DT   09-OCT-2003  (first entry)
XX
DE   Human p16 PCR primer SEQ ID NO:210.
XX
KW   Human; colon cancer; oestrogen receptor; myoglobin; p21; p27; p16; p53;
KW   progesterone receptor; pcna; CEA; cdc2; c-erbB2; methylation; CpG;
KW   characterisation; classification; diagnosis; differentiation;
KW   colon cell proliferative disorder; PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003014388-A2.
XX
PD   20-FEB-2003.
XX
PF   09-AUG-2002; 2002WO-EP008939.
XX
PR   09-AUG-2001; 2001DE-01039283.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Distler J,  Model F,  Taubert H;
XX
DR   WPI; 2003-256600/25.
XX
PT   Determining methylation status of CpG dinucleotides using modified
PT   genomic sequences, oligonucleotides and/or PNA-oligomers, useful in the
PT   characterization, grading, staging and/or diagnosis of colon cancer.
XX
PS   Claim 26; Page 158; 219pp; English.
XX
CC   The present invention describes a method for determining the methylation
CC   status of CpG dinucleotides within the genes for oestrogen receptor, p21,
CC   p27, p16, progesterone receptor, myoglobin, pcna, cdc2, c-erB2, p53
CC   and/or CEA, which comprises contacting the target nucleic acid with a
CC   reagent that distinguishes between methylated and non-methylated CpG
CC   dinucleotides, and determining from the methylation status of the CpG
CC   positions the presence of a colon cancer. A set of oligomers or peptide
CC   nucleic acid (PNA)-oligomers can be used as probes for determining the
CC   cytosine methylation state and/or single nucleotide polymorphisms (SNP)
CC   of a corresponding genomic DNA by analysis of a chemically pretreated
CC   genomic DNA. The pretreated genomic DNA is useful for the determination
CC   of the methylation status of a corresponding genomic DNA and/or detection
CC   of SNPs. The methods and pretreated genomic DNA are also useful for the
CC   characterisation, classification, diagnosis and differentiation of colon
CC   cell proliferative disorders. ACF62752 to ACF63278 represent sequences
CC   used in the exemplification of the present invention
XX
SQ   Sequence 18 BP; 8 A; 1 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
                ||||||||| ||| ||
Db         18 TTTAAATACGTTCACT 3


RESULT 943
ACF62963
ID   ACF62963 standard; DNA; 18 BP.
XX
AC   ACF62963;
XX
DT   09-OCT-2003  (first entry)
XX
DE   Human p16 PCR primer SEQ ID NO:212.
XX
KW   Human; colon cancer; oestrogen receptor; myoglobin; p21; p27; p16; p53;
KW   progesterone receptor; pcna; CEA; cdc2; c-erbB2; methylation; CpG;
KW   characterisation; classification; diagnosis; differentiation;
KW   colon cell proliferative disorder; PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003014388-A2.
XX
PD   20-FEB-2003.
XX
PF   09-AUG-2002; 2002WO-EP008939.
XX
PR   09-AUG-2001; 2001DE-01039283.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Distler J,  Model F,  Taubert H;
XX
```

```
DR   WPI; 2003-256600/25.
XX
PT   Determining methylation status of CpG dinucleotides using modified
PT   genomic sequences, oligonucleotides and/or PNA-oligomers, useful in the
PT   characterization, grading, staging and/or diagnosis of colon cancer.
XX
PS   Claim 26; Page 158; 219pp; English.
XX
CC   The present invention describes a method for determining the methylation
CC   status of CpG dinucleotides within the genes for oestrogen receptor, p21,
CC   p27, p16, progesterone receptor, myoglobin, pcna, cdc2, c-erB2, p53
CC   and/or CEA, which comprises contacting the target nucleic acid with a
CC   reagent that distinguishes between methylated and non-methylated CpG
CC   dinucleotides, and determining from the methylation status of the CpG
CC   positions the presence of a colon cancer. A set of oligomers or peptide
CC   nucleic acid (PNA)-oligomers can be used as probes for determining the
CC   cytosine methylation state and/or single nucleotide polymorphisms (SNP)
CC   of a corresponding genomic DNA by analysis of a chemically pretreated
CC   genomic DNA. The pretreated genomic DNA is useful for the determination
CC   of the methylation status of a corresponding genomic DNA and/or detection
CC   of SNPs. The methods and pretreated genomic DNA are also useful for the
CC   characterisation, classification, diagnosis and differentiation of colon
CC   cell proliferative disorders. ACF62752 to ACF63278 represent sequences
CC   used in the exemplification of the present invention
XX
SQ   Sequence 18 BP; 5 A; 4 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              |||||||||| ||| ||
Db          1 TTTAAATACGTTCACT 16


RESULT 944
ABZ10476
ID   ABZ10476 standard; DNA; 18 BP.
XX
AC   ABZ10476;
XX
DT   16-JAN-2003  (first entry)
XX
DE   Haematopoietic cell proliferation disorder related oligonucleotide #616.
XX
KW   Human; haematopoietic cell proliferation disorder; cytostatic;
KW   gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW   cytosine methylation state; probe; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200277272-A2.
XX
PD   03-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-EP003401.
XX
PR   26-MAR-2001; 2001US-0278333P.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Berlin K,  Braun A,  Distler J,  Guetig D,  Howe A,  Mueller J;
PI   Olek A,  Piepenbrock C,  Adorjan P,  Grabs G,  Lesche R,  Leu E;
PI   Lewin A,  Lipscher E,  Maier S,  Model F,  Mueller V,  Otto T,  Pelet C;
PI   Schwope I,  Ziebarth H;
XX
DR   WPI; 2003-018942/01.
XX
PT   Detecting and differentiating between hematopoietic cell proliferative
PT   disorders, comprises contacting a target nucleic acid with a reagent that
PT   distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS   Claim 15; Page 45; 117pp; English.
XX
CC   The present invention describes a method for detecting and
CC   differentiating between haematopoietic cell proliferative disorders
CC   associated with at least 1 gene and/or their regulatory regions in a
CC   subject. The method comprises contacting a target nucleic acid in a
CC   biological sample obtained from the subject with at least 1 reagent,
CC   which distinguishes between methylated and non-methylated CpG
CC   dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC   represent specifically claimed nucleotide sequences from the present
CC   invention. Oligonucleotides from the present invention can be used: for
CC   differentiating between healthy haematopoietic cells and proliferative
CC   disorder haematopoietic cells; for differentiating between acute
CC   lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC   determining the cytosine methylation state and/or single nucleotide
CC   polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC   related sequences and their complements; and as primers for the
CC   amplification of haematopoietic cell proliferation disorder related DNA
CC   sequences. The nucleotide sequences from the present invention can also
CC   be used for detecting a predisposition to, differentiation between
CC   subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC   haematopoietic cell proliferative disorders. The present method enables a
CC   highly specific classification of haematopoietic cell proliferative
CC   disorders allowing for improved and informed treatment of patients
XX
SQ   Sequence 18 BP; 2 A; 0 C; 8 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1808 GTGGTGCTATAAGTTT 1823
              |||||| | |||||||
Db          2 GTGGTGGTGTAAGTTT 17


RESULT 945
ABZ10569/c
ID   ABZ10569 standard; DNA; 18 BP.
XX
AC   ABZ10569;
XX
DT   16-JAN-2003  (first entry)
XX
DE   Haematopoietic cell proliferation disorder related oligonucleotide #709.
XX
KW   Human; haematopoietic cell proliferation disorder; cytostatic;
KW   gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW   cytosine methylation state; probe; primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200277272-A2.
XX
PD   03-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-EP003401.
XX
PR   26-MAR-2001; 2001US-0278333P.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Berlin K,  Braun A,  Distler J,  Guetig D,  Howe A,  Mueller J;
PI   Olek A,  Piepenbrock C,  Adorjan P,  Grabs G,  Lesche R,  Leu E;
PI   Lewin A,  Lipscher E,  Maier S,  Model F,  Mueller V,  Otto T,  Pelet C;
PI   Schwope I,  Ziebarth H;
XX
DR   WPI; 2003-018942/01.
XX
PT   Detecting and differentiating between hematopoietic cell proliferative
PT   disorders, comprises contacting a target nucleic acid with a reagent that
```

PT distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS Claim 15; Page 50; 117pp; English.
XX
CC The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related DNA
CC sequences. The nucleotide sequences from the present invention can also
CC be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables a
CC highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients
XX
SQ Sequence 18 BP; 8 A; 1 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1832 TTTAAATACATTCCCT 1847
||||||||| ||| ||
Db 18 TTTAAATACGTTCACT 3

RESULT 946
ABZ11028/c
ID ABZ11028 standard; DNA; 18 BP.
XX
AC ABZ11028;
XX
DT 16-JAN-2003 (first entry)
XX
DE Haematopoietic cell proliferation disorder related oligonucleotide #1168.
XX
KW Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200277272-A2.
XX
PD 03-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-EP003401.
XX
PR 26-MAR-2001; 2001US-0278333P.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
PI Schwope I, Ziebarth H;
XX
DR WPI; 2003-018942/01.
XX
PT Detecting and differentiating between hematopoietic cell proliferative
PT disorders, comprises contacting a target nucleic acid with a reagent that
PT distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS Claim 15; Page 77; 117pp; English.
XX
CC The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related DNA
CC sequences. The nucleotide sequences from the present invention can also
CC be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables a
CC highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients
XX
SQ Sequence 18 BP; 3 A; 0 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1859 CCCACACACTTAGCCA 1874
||||| |||||| |||
Db 16 CCCACCCACTTACCCA 1

RESULT 947
ABZ11030
ID ABZ11030 standard; DNA; 18 BP.
XX
AC ABZ11030;
XX
DT 16-JAN-2003 (first entry)
XX
DE Haematopoietic cell proliferation disorder related oligonucleotide #1170.
XX
KW Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200277272-A2.
XX
PD 03-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-EP003401.
XX
PR 26-MAR-2001; 2001US-0278333P.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
PI Schwope I, Ziebarth H;
XX
DR WPI; 2003-018942/01.
XX

PT Detecting and differentiating between hematopoietic cell proliferative
PT disorders, comprises contacting a target nucleic acid with a reagent that
PT distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS Claim 15; Page 77; 117pp; English.
XX
CC The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related DNA
CC sequences. The nucleotide sequences from the present invention can also
CC be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables a
CC highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients
XX
SQ Sequence 18 BP; 4 A; 11 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1859 CCCACACACTTAGCCA 1874
||||| |||||| |||
Db 3 CCCACCCACTTACCCA 18

RESULT 948
ACC45805
ID ACC45805 standard; DNA; 18 BP.
XX
AC ACC45805;
XX
DT 02-JUN-2003 (first entry)
XX
DE Human HBM STS marker reverse primer #192.
XX
KW Human; high bone mass; HBM; LRP5; LRP6; transgenic; bone mass modulation;
KW gene therapy; bone density modulation; bone strength; trabecular number;
KW bone size; bone tissue connectivity; bone disease; osteoporosis; PCR;
KW osteomalacia; rickets; Paget's disease; neoplasm of the bone; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200292764-A2.
XX
PD 21-NOV-2002.
XX
PF 13-MAY-2002; 2002WO-US014876.
XX
PR 11-MAY-2001; 2001US-0290071P.
PR 17-MAY-2001; 2001US-0291311P.
PR 01-FEB-2002; 2002US-0353058P.
PR 04-MAR-2002; 2002US-0361293P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (AMHP) WYETH.
XX
PI Babij P, Bex FJ, Yaworsky PJ, Bodine PV;
XX
DR WPI; 2003-129278/12.
XX
PT New transgenic animals (e.g. mice), useful as models for studying bone
PT density modulation, developing drugs for treating or preventing bone
PT diseases (e.g. osteoporosis), or diagnosing diseases characterized by
PT reduced bone density.
XX
PS Disclosure; Page 57; 603pp; English.
XX
CC The invention relates to novel transgenic animals expressing the high
CC bone mass (HBM) gene, expressing the corresponding wild type HBM gene,
CC comprising an alteration of the gene encoding LRP5 or LRP6, or expressing
CC an LRP5 that is modulated by an altered gene control sequence introduced
CC by homologous or non-homologous recombination. The transgenic animals are
CC for the study of bone density modulation or bone mass modulation. The
CC invention has osteopathic and cytostatic activity. The polynucleotides of
CC the invention may have a use in gene therapy. The transgenic animals and
CC nucleic acids are for the study of bone density modulation, where the
CC bone mass is modulated relative to non-transgenic animals of the same
CC species in more than one parameter selected from bone density, bone
CC strength, trabecular number, bone size, or bone tissue connectivity. The
CC transgenic animals, nucleic acids and methods are useful for identifying
CC molecules involved in bone development, and for developing pharmaceutical
CC compositions, which may be employed for treating or preventing bone
CC diseases, e.g. osteoporosis, osteomalacia, rickets, Paget's disease, or
CC neoplasms of the bone. The transgenic animals and nucleic acids are also
CC useful in methods for diagnosing diseases involved in bone development,
CC or characterised by reduced bone density or mass. The present sequence is
CC used in the exemplification of the invention
XX
SQ Sequence 18 BP; 3 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1782 GAACCCCATTCTTTCC 1797
||| ||| ||||||||
Db 2 GAATCCCTTTCTTTCC 17

RESULT 949
ADB98503
ID ADB98503 standard; DNA; 18 BP.
XX
AC ADB98503;
XX
DT 04-DEC-2003 (first entry)
XX
DE Sequence tagged site #384 used to prepare Zmax1 (LRP5) gene region map.
XX
KW Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW bone mass modulation; osteoporosis; STS; sequence tagged site; ds.
XX
OS Homo sapiens.
XX
PN WO200292000-A2.
XX
PD 21-NOV-2002.
XX
PF 13-MAY-2002; 2002WO-US014877.
XX
PR 11-MAY-2001; 2001US-0290071P.
PR 17-MAY-2001; 2001US-0291311P.
PR 01-FEB-2002; 2002US-0353058P.
PR 04-MAR-2002; 2002US-0361293P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (AMHP) WYETH.
XX
PI Allen K, Anisowicz A, Graham JR, Morales A, Yaworsky PJ, Liu W;
XX
DR WPI; 2003-129214/12.

```
XX
PT   New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT   diagnosing a HBM-like phenotype in a subject and for preparing a
PT   composition for modulating bone mass and/or lipid levels in a subject
PT   suffering from e.g. osteoporosis.
XX
PS   Example 2; Page 63; 629pp; English.
XX
CC   The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC   LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC   cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC   level modulation. The invention is useful for diagnosing a HBM-like
CC   phenotype in a subject and for preparing a composition for modulating
CC   bone mass and/or lipid levels in a subject suffering from e.g.
CC   osteoporosis. The present sequence is a Sequence Tagged Site (STS)
CC   marker, which was used to prepare a physical map of the Zmax1 (LRP5) gene
CC   region.
XX
SQ   Sequence 18 BP; 3 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1782 GAACCCCATTCTTTCC 1797
              ||| ||| ||||||||
Db          2 GAATCCCTTTCTTTCC 17


RESULT 950
ADB54056/c
ID   ADB54056 standard; DNA; 18 BP.
XX
AC   ADB54056;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Oligonucleotide 48 used to analyse CpG positions within genomic DNA.
XX
KW   colon cell proliferative disorder; non methylated CpG dinucleotide;
KW   cytostatic; cancer; adenoma; carcinoma; cytosine methylation state; ss.
XX
OS   Unidentified.
XX
PN   WO2003072821-A2.
XX
PD   04-SEP-2003.
XX
PF   27-FEB-2003; 2003WO-EP002035.
XX
PR   27-FEB-2002; 2002EP-00004551.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Adorjan P,  Burger M,  Maier S,  Nimmrich I,  Becker E,  Lesche R;
PI   Rujan T,  Schmitt A;
XX
DR   WPI; 2003-731620/69.
XX
PT   Detecting and differentiating between colon cell proliferative disorders
PT   associated with a gene or its regulatory regions comprises contacting a
PT   target nucleic acid in a biological sample obtained from the subject with
PT   a reagent.
XX
PS   Claim 41; SEQ ID NO 112; 74pp; English.
XX
CC   The invention relates to a novel method for detecting and differentiating
CC   between colon cell proliferative disorders associated with at least one
CC   gene or its regulatory regions. The method comprises contacting a target
CC   nucleic acid in a biological sample obtained from the subject with at
CC   least one reagent or a series of reagents, where the reagent or series of
CC   reagents, distinguishes between methylated and non methylated CpG
CC   dinucleotides within the target nucleic acid. The molecules of the
CC   invention demonstrate cytostatic activity whilst the method may useful
CC   for detecting and differentiating between colon cell proliferative
CC   disorders, including cancers such as colon adenoma and colon carcinoma.
CC   The PNA (peptide nucleic acid)-oligomers are useful as probes for
CC   determining cytosine methylation state or single nucleotide
CC   polymorphisms. The current sequence is that of the oligonucleotide of the
CC   invention which was used to analyse the CpG positions within the genomic
CC   DNA regions. This sequence is not shown within the specification but is
CC   taken from Wipoweb.
XX
SQ   Sequence 18 BP; 4 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2044 TATCTGCTTAGCAACT 2059
              |||||||  |||||||
Db         16 TATCTGCGGAGCAACT 1


RESULT 951
ADB54571/c
ID   ADB54571 standard; DNA; 18 BP.
XX
AC   ADB54571;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Hybridisation oligonucleotide 109 used to analyse genomic DNA region.
XX
KW   colon cell proliferative disorder; non methylated CpG dinucleotide;
KW   cytostatic; cancer; adenoma; carcinoma; cytosine methylation state; ss;
KW   probe.
XX
OS   Unidentified.
XX
PN   WO2003072821-A2.
XX
PD   04-SEP-2003.
XX
PF   27-FEB-2003; 2003WO-EP002035.
XX
PR   27-FEB-2002; 2002EP-00004551.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Adorjan P,  Burger M,  Maier S,  Nimmrich I,  Becker E,  Lesche R;
PI   Rujan T,  Schmitt A;
XX
DR   WPI; 2003-731620/69.
XX
PT   Detecting and differentiating between colon cell proliferative disorders
PT   associated with a gene or its regulatory regions comprises contacting a
PT   target nucleic acid in a biological sample obtained from the subject with
PT   a reagent.
XX
PS   Claim 36; Page 32; 74pp; English.
XX
CC   The invention relates to a novel method for detecting and differentiating
CC   between colon cell proliferative disorders associated with at least one
CC   gene or its regulatory regions. The method comprises contacting a target
CC   nucleic acid in a biological sample obtained from the subject with at
CC   least one reagent or a series of reagents, where the reagent or series of
CC   reagents, distinguishes between methylated and non methylated CpG
CC   dinucleotides within the target nucleic acid. The molecules of the
CC   invention demonstrate cytostatic activity whilst the method may useful
CC   for detecting and differentiating between colon cell proliferative
CC   disorders, including cancers such as colon adenoma and colon carcinoma.
CC   The PNA (peptide nucleic acid)-oligomers are useful as probes for
CC   determining cytosine methylation state or single nucleotide
CC   polymorphisms. The current sequence is that of the hybridisation
CC   oligonucleotide of the invention which was used to analyse the genomic
```

```
CC   DNA region.
XX
SQ   Sequence 18 BP; 8 A; 1 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||| ||| ||
Db         18 TTTAAATACGTTCACT 3


RESULT 952
ADC70086/c
ID   ADC70086 standard; DNA; 18 BP.
XX
AC   ADC70086;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Primer oligo used for analysing CpG islands in genomic DNA (SeqID 576).
XX
KW   PCR; primer; ss; lung cell proliferative disorder; CpG dinucleotide;
KW   adenocarcinoma; squamous cell carcinoma; cytostatic; probe; PNA-oligomer;
KW   cytosine methylation state.
XX
OS   Unidentified.
XX
PN   WO2003052135-A2.
XX
PD   26-JUN-2003.
XX
PF   10-DEC-2002; 2002WO-EP014026.
XX
PR   14-DEC-2001; 2001DE-01061625.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Burger M,  Field JK,  Genc B,  Liloglou T,  Lipscher E,  Maier S;
PI   Nimmrich I;
XX
DR   WPI; 2003-533029/50.
XX
PT   Detecting and differentiating cytosine methylation state of genomic DNA,
PT   useful for diagnosing, treating prognosticating and/or monitoring lung
PT   cell proliferative disorders e.g. adenocarcinoma and squamous cell
PT   carcinoma.
XX
PS   Claim 15; SEQ ID NO 576; 58pp; English.
XX
CC   This invention relates to a novel method for detecting and
CC   differentiating between lung cell proliferative disorders associated with
CC   at least one gene and/or their regulatory regions. Specifically, it
CC   refers to a method comprising contacting a target nucleic acid in a
CC   biological sample with at least one reagent, wherein the reagent is able
CC   to distinguish between methylated and non-methylated CpG dinucleotides
CC   present in the target DNA. As such, it is possible to further
CC   differentiate and diagnose medical conditions including adenocarcinoma
CC   and squamous cell carcinoma, and their respective adjacent lung tissue.
CC   The present invention describes cytostatic oligomers and PNA-oligomers
CC   that are useful as probes for determining the cytosine methylation state
CC   or single nucleotide polymorphisms (SNPs) of the target sequence. This
CC   oligonucleotide sequence is a primer oligomer used for the analysis of
CC   CpG positions within genomic DNA, used in an exemplification of the
CC   invention.
XX
SQ   Sequence 18 BP; 8 A; 1 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||| ||| ||
Db         18 TTTAAATACGTTCACT 3


RESULT 953
ADE84624
ID   ADE84624 standard; DNA; 18 BP.
XX
AC   ADE84624;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Mammalian RIZ protein fragment PCR primer seq id 15.
XX
KW   cytostatic; tumor; gene therapy;
KW   retinoblastoma protein-interacting zinc protein; RIZ; neuroblastoma;
KW   melanoma; cardiac cell growth inducer; neuronal cell growth inducer; PCR;
KW   primer; ss; RIZ.
XX
OS   Mammalia.
XX
PN   US6468985-B1.
XX
PD   22-OCT-2002.
XX
PF   17-MAR-2000; 2000US-00528706.
XX
PR   18-AUG-1994;   94US-00292683.
PR   06-MAR-1995;   95US-00399411.
PR   18-AUG-1995;   95US-00516859.
XX
PA   (BURN-) BURNHAM INST.
XX
PI   Huang S;
XX
DR   WPI; 2003-147106/14.
XX
PT   Reducing the growth of tumor cell having mammalian retinoblastoma protein
PT   -interacting zinc finger proteins in a subject, comprises administering
PT   nucleic acid molecule encoding RIZ at or adjacent to the site of tumor.
XX
PS   Example 4; SEQ ID NO 15; 49pp; English.
XX
CC   The invention describes a method of reducing growth of a tumour cell
CC   having a mutant mammalian retinoblastoma (Rb) protein-interacting zinc
CC   finger (RIZ) protein in a subject The method comprises administering a
CC   nucleic acid molecule (I) encoding RIZ at or adjacent to tumour site. (I)
CC   is administered at the site of the tumour. The method is useful for
CC   reducing the growth of a tumour cell e.g. neuroblastoma or melanoma cell
CC   having mutant RIZ protein. The method is useful for inducing growth of a
CC   cardiac cell or a neuronal cell in a subject, and for effecting normal
CC   growth control to a tumour cell or causing differentiation of tumour
CC   cells. This sequence represents a primer used to isolate a fragment of
CC   mammalian RIZ protein DNA for studying the DNA and GTp-binding activities
CC   of RIZ.
XX
SQ   Sequence 18 BP; 4 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 954
ADE84360
ID   ADE84360 standard; DNA; 18 BP.
XX
AC   ADE84360;
```

```
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human lymphoid cell proliferative disorder gene CpG analysis oligo #66.
XX
KW   lymphoid cell proliferative disorder; methylation;
KW   methylated CpG dinucleotide; single nucleotide polymorphism; SNP;
KW   diffuse large B-cell lymphoma; mantle cell lymphoma;
KW   chronic lymphocytic leukemia; small lymphocytic lymphoma;
KW   follicular lymphoma; diagnosis; prognosis; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003044226-A2.
XX
PD   30-MAY-2003.
XX
PF   25-NOV-2002; 2002WO-EP013265.
XX
PR   23-NOV-2001; 2001DE-01057491.
PR   28-DEC-2001; 2001DE-01064501.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Burger M,  Caldwell C,  Genc B,  Becker E,  Maier S,  Nimmrich I;
XX
DR   WPI; 2003-457621/43.
XX
PT   Detecting and differentiating between lymphoid cell proliferative
PT   disorders comprises contacting a target nucleic acid with at least one
PT   reagent that distinguishes between methylated and non-methylated CpG
PT   dinucleotides.
XX
PS   Claim 30; SEQ ID NO 356; 448pp; English.
XX
CC   The invention relates to a method of detecting and differentiating
CC   between lymphoid cell proliferative disorders associated with at least
CC   one gene and/or their regulatory regions in a subject by contacting a
CC   target nucleic acid in a biological sample obtained from the subject with
CC   at least one reagent or series of reagents that distinguish between
CC   methylated and non-methylated CpG dinucleotides within the target nucleic
CC   acid. The genes and/or their regulatory regions are preferably selected
CC   from MDR1, CSNK2B, EGR4, AR, CDK4, RB2, CDC25A, GPIb beta, MYOD1, CDH3,
CC   MYCL1, ELK1, ABL1, APC, BCL2, CDH1, CDKN1A, CDKN1B, CDKN2a, CDKN2B, FOS,
CC   GSTP1, HIC-1, MGMT, MLH1, MOS, MYC, PTEN, RBL2, TGFBR2, TP73, CDKNIC,
CC   GSK3beta, ESR1, APAF1, BAK1, BAX or HOXA5. Oligomers, peptide nucleic
CC   acid (PNA)-oligomers and/or isolated nucleic acids based on the sequences
CC   of the genes are useful for detecting the methylation state of all the
CC   CpG dinucleotides within one or more the sequences, or their complements,
CC   for determining the cytosine methylation state and or single nucleotide
CC   polymorphisms (SNPs), and for differentiating at least two of the medical
CC   conditions such as diffuse large B-cell lymphoma, mantle cell lymphoma,
CC   chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular
CC   lymphoma. They are also useful for detecting of a predisposition to,
CC   differentiation between subclasses, diagnosis, prognosis, treating and/or
CC   monitoring of lymphoid cell proliferative disorder. This sequence
CC   represents an oligonucleotide used to analyse of CpG positions within the
CC   above mentioned genes.
XX
SQ   Sequence 18 BP; 2 A; 0 C; 8 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1808 GTGGTGCTATAAGTTT 1823
                ||||||  | |||||||
Db          2 GTGGTGGTGTAAGTTT 17


RESULT 955
ABZ77008/c
ID   ABZ77008 standard; DNA; 18 BP.
XX
AC   ABZ77008;
XX
DT   07-MAY-2003  (first entry)
XX
DE   Bovine DGAT PCR primer #44.
XX
KW   Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14; bovine;
KW   milk; meat marbling; low fat; polymorphic; SNP;
KW   single nucleotide polymorphism; PCR primer; ss.
XX
OS   Bos taurus.
OS   Synthetic.
XX
PN   WO2003004630-A2.
XX
PD   16-JAN-2003.
XX
PF   05-JUL-2002; 2002WO-EP007520.
XX
PR   06-JUL-2001; 2001EP-00116412.
PR   13-MAY-2002; 2002US-0379412P.
XX
PA   (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
XX
PI   Fries H,  Winter A;
XX
DR   WPI; 2003-239205/23.
XX
PT   New nucleic acid molecule comprising a sequence of an allele of a
PT   polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
PT   testing a mammal for its predisposition for fat content of milk and for
PT   meat marbling.
XX
PS   Example 1; Page 36; 91pp; English.
XX
CC   The present invention describes a nucleic acid molecule (NA) (I) encoding
CC   a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
CC   indicative for low fat content of milk and to low meat marbling
CC   (intramuscular fat content). Human DGAT is located to chromosome 8, and
CC   bovine DGAT is located to chromosome 14. (I) is useful for testing a
CC   mammal for its predisposition for fat content of milk and/or its
CC   predisposition for meat marbling. The method comprises analysing the gene
CC   encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
CC   polymorphisms (SNPs)) which are connected with the predisposition. The
CC   nucleotide polymorphisms are located in the coding region of the DGAT
CC   gene and result in substitution, deletion and/or addition of an amino
CC   acid sequence of the polypeptide which is encoded by the gene. The
CC   nucleic acid molecule has at the position 10433 and 10434 of the DGAT
CC   gene a guanine and a cytosine residue, at position 3343 a cytosine or
CC   guanine, 11030 a guanine, 11048 a cytosine or thymine and 11093 a
CC   thymine, which correlate with a predisposition for low fat content of
CC   milk and low meat marbling. The nucleic acid molecule has at the position
CC   corresponding to position 10433 and 10434 of the DGAT gene two adenine
CC   residues which correlate with a predisposition for high content of milk
CC   and high meat marbling. The nucleotide polymorphisms are located in a
CC   region which is responsible for the regulation of the expression of the
CC   product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
CC   ABP96046 represent sequences used in the exemplification of the present
CC   invention
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTG 1565
                ||| ||| ||||||||
Db         16 GGAGGGAGCAGGACTG 1


RESULT 956
```

```
ABZ76952/c
ID   ABZ76952 standard; DNA; 18 BP.
XX
AC   ABZ76952;
XX
DT   07-MAY-2003  (first entry)
XX
DE   Bovine DGAT BAC-DNA sequencing primer #25.
XX
KW   Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14; bovine;
KW   milk; meat marbling; low fat; polymorphic; SNP;
KW   single nucleotide polymorphism; PCR primer; ss.
XX
OS   Bos taurus.
OS   Synthetic.
XX
PN   WO2003004630-A2.
XX
PD   16-JAN-2003.
XX
PF   05-JUL-2002; 2002WO-EP007520.
XX
PR   06-JUL-2001; 2001EP-00116412.
PR   13-MAY-2002; 2002US-0379412P.
XX
PA   (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
XX
PI   Fries H,  Winter A;
XX
DR   WPI; 2003-239205/23.
XX
PT   New nucleic acid molecule comprising a sequence of an allele of a
PT   polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
PT   testing a mammal for its predisposition for fat content of milk and for
PT   meat marbling.
XX
PS   Example 1; Page 35; 91pp; English.
XX
CC   The present invention describes a nucleic acid molecule (NA) (I) encoding
CC   a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
CC   indicative for low fat content of milk and to low meat marbling
CC   (intramuscular fat content). Human DGAT is located to chromosome 8, and
CC   bovine DGAT is located to chromosome 14. (I) is useful for testing a
CC   mammal for its predisposition for fat content of milk and/or its
CC   predisposition for meat marbling. The method comprises analysing the gene
CC   encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
CC   polymorphisms (SNPs)) which are connected with the predisposition. The
CC   nucleotide polymorphisms are located in the coding region of the DGAT
CC   gene and result in substitution, deletion and/or addition of an amino
CC   acid sequence of the polypeptide which is encoded by the gene. The
CC   nucleic acid molecule has at the position 10433 and 10434 of the DGAT
CC   gene a guanine and a cytosine residue, at position 3343 a cytosine or
CC   guanine, 11030 a guanine, 11048 a cytosine or thymine and 11093 a
CC   thymine, which correlate with a predisposition for low fat content of
CC   milk and low meat marbling. The nucleic acid molecule has at the position
CC   corresponding to position 10433 and 10434 of the DGAT gene two adenine
CC   residues which correlate with a predisposition for high content of milk
CC   and high meat marbling. The nucleotide polymorphisms are located in a
CC   region which is responsible for the regulation of the expression of the
CC   product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
CC   ABP96046 represent sequences used in the exemplification of the present
CC   invention
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTG 1565
              ||| ||| ||||||||
Db         16 GGAGGGAGCAGGACTG 1
```

```
RESULT 957
ADN35838/c
ID   ADN35838 standard; DNA; 18 BP.
XX
AC   ADN35838;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Human NSCLC gene antisense-S oligonucleotide #49.
XX
KW   ss; cytostatic; gene therapy; vaccine; non-small cell lung cancer; NSCLC;
KW   diagnosis; cancer; URLC1; antisense.
XX
OS   Homo sapiens.
XX
PN   WO2004031413-A2.
XX
PD   15-APR-2004.
XX
PF   22-SEP-2003; 2003WO-JP012072.
XX
PR   30-SEP-2002; 2002US-0414673P.
PR   28-FEB-2003; 2003US-0451374P.
PR   28-APR-2003; 2003US-0466100P.
XX
PA   (ONCO-) ONCOTHERAPY SCI INC.
PA   (UYTY ) UNIV TOKYO.
XX
PI   Nakamura Y,  Daigo Y,  Nakatsuru S;
XX
DR   WPI; 2004-330206/30.
XX
PT   Diagnosing, preventing and treating non-small cell lung cancer (NSCLC)
PT   comprises determining an expression level of an NSCLC-associated gene in
PT   a sample.
XX
PS   Disclosure; SEQ ID NO 519; 394pp; English.
XX
CC   The invention relates to a method of diagnosing non-small cell lung
CC   cancer (NSCLC) or a predisposition to developing NSCLC in a subject by
CC   determining the expression level of a NSCLC-associated gene in a
CC   biological sample derived from the subject, where an increase or decrease
CC   of the level compared to a normal control level of the gene indicates
CC   that the subject suffers from or is at risk of developing NSCLC. The
CC   method is useful in diagnosing NSCLC or a predisposition to developing
CC   NSCLC in a subject. The compound, polynucleotide and the encoded
CC   polypeptide and composition are useful in treating or preventing NSCLC.
CC   This sequence corresponds to an antisense oligonucleotide of genes that
CC   are differentially expressed in NSCLC cells.
XX
SQ   Sequence 18 BP; 9 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 4.9e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAGA 2012
              |||||  |||||||||
Db         16 ATCTATTTTCTTCAGA 1
```

```
RESULT 958
AAT76153/c
ID   AAT76153 standard; DNA; 19 BP.
XX
AC   AAT76153;
XX
DT   12-SEP-1997  (first entry)
XX
DE   Human vascular cell adhesion molecule-1 antisense oligonucleotide.
XX
KW   Asthma; airway epithelium; adenosine free; cystic fibrosis;
```

KW chronic obstructive pulmonary disease; bronchitis; ss.
XX
OS Synthetic.
XX
PN WO9640162-A1.
XX
PD 19-DEC-1996.
XX
PF 06-JUN-1996; 96WO-US009306.
XX
PR 07-JUN-1995; 95US-00474497.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW, Metzger WJ;
XX
DR WPI; 1997-051871/05.
XX
PT Treatment of airway diseases such as asthma - by topically applying
PT adenosine-free antisense oligo:nucleotide to airway epithelium of
PT subject.
XX
PS Claim 5; Page 28; 71pp; English.
XX
CC A method for treating airway disease in a subject has been produced,
CC which involves the topical administration of an essentially adenosine
CC free antisense oligonucleotide (ON) to the airway epithelium of the
CC subject. The present sequence is an antisense oligonucleotide HSVCAM1AS1
CC specific for the human vascular cell adhesion molecule-1 (VCAM-1). The
CC method can be used to treat airway diseases such as cystic fibrosis,
CC asthma, chronic obstructive pulmonary disease, bronchitis and other
CC airway diseases characterised by an inflammatory response. By eliminating
CC adenosine from the antisense ON, its liberation upon antisense
CC degradation is prevented, thereby preventing adenosine- induced
CC bronchoconstriction in patients with hyper-reactive airways
XX
SQ Sequence 19 BP; 0 A; 7 C; 1 G; 11 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1978 GAAAAAAAGAAAAGTG 1993
||||||| ||||||| |
Db 17 GAAAAACAGAAAAGAG 2

RESULT 959
AAX09851/c
ID AAX09851 standard; DNA; 19 BP.
XX
AC AAX09851;
XX
DT 24-MAR-1999 (first entry)
XX
DE Human biallelic polymorphic marker downstream primer #157.
XX
KW Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW detection; phenotypic typing; characteristic; infection; hereditary;
KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW treatment; marker; primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9820165-A2.
XX
PD 14-MAY-1998.
XX
PF 05-NOV-1997; 97WO-US020313.
XX
PR 06-NOV-1996; 96US-0030455P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Lander ES, Wang D, Hudson T;
XX
DR WPI; 1998-286974/25.
XX
PT New isolated nucleic acid segments from the human genome - used for
PT determining polymorphic forms for use in e.g. forensics, paternity
PT testing or phenotypic typing for disease.
XX
PS Claim 16; Page 65; 310pp; English.
XX
CC AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC isolation of various biallelic polymorphic markers found in the human
CC genome (represented in AAX10269-X12937). These primers can be used in a
CC method for determining polymorphic forms in an individual for use in e.g.
CC forensics, paternity testing or for phenotypic typing for diseases such
CC as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial
CC hypercholesterolemia, polycystic kidney disease, hereditary
CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC autoimmune diseases, inflammation, cancer, diseases of the nervous
CC system, infection by pathogenic microorganisms, and characteristics such
CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC endurance, fertility, and susceptibility or receptivity to particular
CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC segments can also be used to produce medicaments for the treatment or
CC prophylaxis of such diseases
XX
SQ Sequence 19 BP; 8 A; 9 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1939 GGTAATGGTTGGTTTT 1954
|||| ||||||||| |
Db 17 GGTATTGGTTGGTTGT 2

RESULT 960
AAX91457/c
ID AAX91457 standard; DNA; 19 BP.
XX
AC AAX91457;
XX
DT 24-SEP-1999 (first entry)
XX
DE T. gondii OC-2 gene specific internal primer.
XX
KW Immunogenic protein; Toxoplasma gondii protein; oocyst shedding; cat;
KW T. gondii infection; enteric apicomplexa oocyst; Cryptosporidium oocyst;
KW Toxoplasma oocyst; PCR primer; ss.
XX
OS Synthetic.
OS Toxoplasma gondii.
XX
PN WO9932633-A1.
XX
PD 01-JUL-1999.
XX
PF 18-DEC-1998; 98WO-US027137.
XX
PR 19-DEC-1997; 97US-00994825.
XX
PA (HESK-) HESKA CORP.
XX
PI Milhausen MJ, Lutz SB, Ng RK;
XX
DR WPI; 1999-418930/35.
XX

```
PT   New isolated Toxoplasma gondii nucleic acids used, e.g. to treat
PT   infection caused by this microorganism.
XX
PS   Example 12; Page 361; 381pp; English.
XX
CC   The invention provides isolated Toxoplasma gondii nucleic acids that
CC   encode immunogenic polypeptides. The T. gondii nucleic acid molecules,
CC   immunogenic proteins and antibodies to the proteins can be used to
CC   inhibit T. gondii oocyst shedding in a cat due to infection with T.
CC   gondii. They can be used for preventing T. gondii infection and for
CC   preventing the spread of T. gondii infection. They can also be used for
CC   detecting T. gondii infection. The detection method can be used to detect
CC   parasite cysts or oocysts in feces, e.g. from enteric apicomplexa oocysts
CC   such as Cryptosporidium oocysts and Toxoplasma oocysts. The present
CC   sequence represents a primer used in PCR amplification of a DNA encoding
CC   immunogenic T. gondii protein
XX
SQ   Sequence 19 BP; 7 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1648 GCCTTCACTGGTTCTG 1663
              ||||| |||| |||||
Db         19 GCCTTGACTGCTTCTG 4


RESULT 961
AAX53950/c
ID   AAX53950 standard; DNA; 19 BP.
XX
AC   AAX53950;
XX
DT   05-JUL-1999  (first entry)
XX
DE   Vascular cell adhesion molecule-1 (VCAM-1) antisense oligonucleotide.
XX
KW   Antisense oligonucleotide; multiple target; antisense treatment;
KW   impaired respiration; inflammation; lung disease;
KW   pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW   acute asthma; allergy; asthma; impeded respiration;
KW   respiratory distress syndrome; pain; cystic fibrosis;
KW   pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW   chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW   colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW   hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW   prostate cancer; ss.
XX
OS   Synthetic.
XX
PN   WO9913886-A1.
XX
PD   25-MAR-1999.
XX
PF   17-SEP-1998;   98WO-US019419.
XX
PR   17-SEP-1997;   97US-0059160P.
PR   09-JUN-1998;   98US-00093972.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
XX
PI   Nyce JW;
XX
DR   WPI; 1999-229400/19.
XX
PT   New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT   vasoconstriction.
XX
PS   Disclosure; Page 47; 120pp; English.
XX
CC   The specification describes antisense oligonucleotides (AAX52869-X55271)
CC   directed against at least 2 mRNAs selected from target genes, coding and
CC   non-coding regions of RNAs corresponding to target genes, gene initiation
CC   codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'
CC   -end and the juxta-section between coding and non-coding regions and all
CC   segments of RNAs encoding proteins associated with one or more diseases,
CC   conditions or mixtures. The antisense oligonucleotides may be derived
CC   from sequences AAX55272-74. These multiple target oligonucleotides
CC   (specifically AAX55180-271) can be used for the antisense treatment of
CC   diseases and conditions. Typical diseases and conditions are those
CC   associated with impaired respiration and inflammation, including lung
CC   diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC   acute asthma, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC   pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC   disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC   colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC   hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC   well as all types of cancers which may metastasize or have metastasized
CC   to the lungs, including breast and prostate cancer
XX
SQ   Sequence 19 BP; 0 A; 7 C; 1 G; 11 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAAGTG 1993
              |||||| ||||||| |
Db         17 GAAAAACAGAAAAGAG 2


RESULT 962
AAZ34529
ID   AAZ34529 standard; DNA; 19 BP.
XX
AC   AAZ34529;
XX
DT   01-FEB-2000  (first entry)
XX
DE   Transporter protein splice variant TAP2 exon 10-based probe.
XX
KW   TAP2iso; transporter associated with antigen protein; TAP;
KW   splice variant; vaccine; diagnosis; therapy; autoimmune disease;
KW   diabetes; cancer; probe; PCR; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9952928-A1.
XX
PD   21-OCT-1999.
XX
PF   15-APR-1999;   99WO-US008205.
XX
PR   16-APR-1998;   98US-00061764.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Faustman DL;
XX
DR   WPI; 1999-633819/54.
XX
PT   Nucleic acid encoding splice variants of transporter associated with
PT   antigen processing proteins, useful for improving the immune responses.
XX
PS   Example 1; Page 59; 77pp; English.
XX
CC   This oligonucleotide is based on exon 10 of the human TAP2 (transporter
CC   associated with antigen processing 2) gene. It was used to screen a human
CC   splenic cDNA library. cDNA (see AAZ34527) encoding a novel TAP2 splice
CC   variant, TAP2iso (see AAY32133), was isolated. The oligonucleotide was
CC   also used as a 5' primer in the RT-PCR amplification of RNA from various
CC   human cell lines in order to determine the expression pattern of TAP2iso.
CC   The discovery of splice variant TAP subunits alters the prior theory of
```

CC immune response and introduces a cellular mechanism for diversification
CC of antigen display to the CD8-positive T cells of the immune system.
CC Methods for diagnosis and treatment of diseases or conditions associated
CC with abnormal TAP isoform expression, or of expanding the repertoire of
CC antigen peptides to which an individual's immune system is capable of
CC responding, are also disclosed
XX
SQ Sequence 19 BP; 7 A; 0 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1539 TAGGAGAGTAGGGAAG 1554
|||| ||| |||||||
Db 4 TAGGGGAGAAGGGAAG 19

RESULT 963
AAA33393/c
ID AAA33393 standard; DNA; 19 BP.
XX
AC AAA33393;
XX
DT 28-JUL-2000 (first entry)
XX
DE Low adenosine antisense oligonucleotide SEQ ID NO:1082.
XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US017712.
XX
PR 03-AUG-1998; 98US-0095212P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstruction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
XX
PS Claim 18; Page 400; 1343pp; English.
XX
CC The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antiasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impeded respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasise to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of the
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC AAA33992) are specifically claimed ONs from the present invention. N.B.
CC Sequences given in the disclosure of the present invention do not match
CC up with their corresponding SEQ ID NO: sequences given in the sequence
CC listing
XX
SQ Sequence 19 BP; 0 A; 7 C; 1 G; 11 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1978 GAAAAAAAGAAAAGTG 1993
|||||| ||||||| |
Db 17 GAAAAACAGAAAAGAG 2

RESULT 964
AAA83970
ID AAA83970 standard; DNA; 19 BP.
XX
AC AAA83970;
XX
DT 04-DEC-2000 (first entry)
XX
DE Cyclin A2 ribozyme binding site #148.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 69; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1659 TTCTGCATCACCCGCC 1674
              |||||||||| | |||
Db          2 TTCTGCATCAGCAGCC 17
```

RESULT 965
AAA84404/c
ID AAA84404 standard; DNA; 19 BP.
XX
AC AAA84404;
XX
DT 04-DEC-2000 (first entry)
XX
DE Cyclin D3 ribozyme binding site #16.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 76; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1607 GCCTGGGGGAAGAGTT 1622
              ||| ||||||||| ||
Db         19 GCCAGGGGGAAGACTT 4
```

RESULT 966
AAZ76823/c
ID AAZ76823 standard; DNA; 19 BP.
XX
AC AAZ76823;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:11179.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 9; Page 2614; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 1 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1540 AGGAGAGTAGGGAAGG 1555
              ||||||| || |||||
Db         18 AGGAGAGAAGAGAAGG 3
```

RESULT 967
AAZ69691
ID AAZ69691 standard; DNA; 19 BP.
XX
AC AAZ69691;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker upstream amplification primer SEQ ID NO:4047.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX

PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 1094; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 8 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1532 GAAAGGTTAGGAGAGT 1547
||||| |||||||||
Db 3 GAAAGAATAGGAGAGT 18

RESULT 968
AAF19515/c
ID AAF19515 standard; DNA; 19 BP.
XX
AC AAF19515;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human VCAM-1 polynucleotide fragment #1082.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
PF 24-MAR-2000; 2000WO-US008020.
XX
PR 06-APR-1999; 99US-0127958P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J.W.
XX
PI Nyce JW;
XX
DR WPI; 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX
PS Claim 14; Page 145; 1592pp; English.
XX
CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention
XX
SQ Sequence 19 BP; 0 A; 7 C; 1 G; 11 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1978 GAAAAAAAGAAAAGTG 1993
|||||| ||||||| |
Db 17 GAAAAACAGAAAAGAG 2

RESULT 969
AAA28678
ID AAA28678 standard; DNA; 19 BP.
XX
AC AAA28678;
XX
DT 29-AUG-2000 (first entry)
XX
DE Calreticulin promoter ERSE4-like sequence.
XX
KW Endoplasmic reticulum; stress; ER; transcription factor; transcription;
KW regulatory element; ERSE; bZIP; chaperone; treatment; prophylaxis;
KW cancer; arteriosclerosis; ischaemia; wound healing; cystic fibrosis;
KW ulcer; gene therapy; recombinant gene; gene expression; GRP;
KW glucose regulated protein; promoter; ss.
XX
OS Ricinus communis.
XX

```
PN   WO200029429-A2.
XX
PD   25-MAY-2000.
XX
PF   12-NOV-1999;   99WO-JP006305.
XX
PR   13-NOV-1998;   98JP-00324227.
PR   09-JUN-1999;   99JP-00163112.
XX
PA   (HSPR-) HSP RES INST INC.
XX
PI   Haze K,  Yoshida H,  Mori K,  Yanagi H,  Yura T;
XX
DR   WPI; 2000-387736/33.
XX
PT   New endoplasmic reticulum stress transcription factor (known as bZIP) for
PT   controlling expression of endoplasmic reticulum chaperone, useful for
PT   treating cancers, arteriosclerosis, cystic fibrosis, ischemic diseases,
PT   wounds and ulcers.
XX
PS   Example 1; Fig 5; 157pp; English.
XX
CC   An endoplasmic reticulum stress transcription factor (bZIP) capable of
CC   regulating transcription inducing activity exhibited by an element (ERSE)
CC   can be used in a method for controlling expression of an endoplasmic
CC   reticulum chaperone. The method comprises expressing bZIP. The method can
CC   be used for expression of a foreign protein by positively regulating
CC   expression of an endoplasmic reticulum chaperone gene. bZIP is useful for
CC   controlling the expression of endoplasmic reticulum chaperone either
CC   positively or negatively in cells and therefore is useful for treatment
CC   or prophylaxis of cancers, arteriosclerosis, cystic fibrosis, ischaemic
CC   diseases, wounds and ulcers. bZIP also maintains the correct conformation
CC   of the endoplasmic reticulum chaperone and thereby increases the
CC   expression of a foreign protein. This sequence taken from the
CC   calreticulin (CRT) promoter contains an ERSE like sequence
XX
SQ   Sequence 19 BP; 2 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTC 1802
              ||||||||| || |||
Db          1 CCATTCTTTGCTGCTC 16


RESULT 970
AAC72827/c
ID   AAC72827 standard; DNA; 19 BP.
XX
AC   AAC72827;
XX
DT   09-FEB-2001  (first entry)
XX
DE   Single nucleotide polymorphism PCR primer #1771.
XX
KW   Single nucleotide polymorphism; SNP; human; genetic disease;
KW   disease susceptibility; cardiovascular system; endocrine system;
KW   neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200058519-A2.
XX
PD   05-OCT-2000.
XX
PF   30-MAR-2000; 2000WO-US008440.
XX
PR   31-MAR-1999;   99US-0127248P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Altshuler D,  Cargill M,  Daley GQ,  Ireland JS,  Lander ES;
PI   Lipshutz RJ,  Patil N,  Sklar P;
XX
DR   WPI; 2000-611722/58.
XX
PT   Nucleic acid selected from one of 106 genes comprising single nucleotide
PT   polymorphisms, allele-specific oligonucleotides to the genes are useful
PT   for phenotypic correlations, forensics, paternity testing, medicine and
PT   genetic analysis.
XX
PS   Claim 8; Fig 5; 214pp; English.
XX
CC   The present invention is concerned with a number of human single
CC   nucleotide polymorphisms (SNPs) which the inventors identified in human
CC   genes. These SNPs can be used in disease diagnosis and prediction of an
CC   individual's susceptibility to disease, in forensic and paternity testing
CC   and in genetic mapping. In particular, the SNPs of the invention can be
CC   used to diagnose susceptibility to diseases of the cardiovascular,
CC   endocrine and neurological systems, such as coronary artery disease,
CC   schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC   diseases
XX
SQ   Sequence 19 BP; 5 A; 3 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCT 1605
              |||||  |||||||||
Db         19 ACTGGTGACCCCTCCT 4


RESULT 971
AAC72812/c
ID   AAC72812 standard; DNA; 19 BP.
XX
AC   AAC72812;
XX
DT   09-FEB-2001  (first entry)
XX
DE   Single nucleotide polymorphism PCR primer #1761.
XX
KW   Single nucleotide polymorphism; SNP; human; genetic disease;
KW   disease susceptibility; cardiovascular system; endocrine system;
KW   neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200058519-A2.
XX
PD   05-OCT-2000.
XX
PF   30-MAR-2000; 2000WO-US008440.
XX
PR   31-MAR-1999;   99US-0127248P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Altshuler D,  Cargill M,  Daley GQ,  Ireland JS,  Lander ES;
PI   Lipshutz RJ,  Patil N,  Sklar P;
XX
DR   WPI; 2000-611722/58.
XX
PT   Nucleic acid selected from one of 106 genes comprising single nucleotide
PT   polymorphisms, allele-specific oligonucleotides to the genes are useful
PT   for phenotypic correlations, forensics, paternity testing, medicine and
PT   genetic analysis.
XX
PS   Claim 8; Fig 5; 214pp; English.
XX
```

```
CC   The present invention is concerned with a number of human single
CC   nucleotide polymorphisms (SNPs) which the inventors identified in human
CC   genes. These SNPs can be used in disease diagnosis and prediction of an
CC   individual's susceptibility to disease, in forensic and paternity testing
CC   and in genetic mapping. In particular, the SNPs of the invention can be
CC   used to diagnose susceptibility to diseases of the cardiovascular,
CC   endocrine and neurological systems, such as coronary artery disease,
CC   schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC   diseases
XX
SQ   Sequence 19 BP; 5 A; 3 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCT 1605
              |||||  |||||||||
Db         19 ACTGGTGACCCCTCCT 4


RESULT 972
AAA59141/c
ID   AAA59141 standard; DNA; 19 BP.
XX
AC   AAA59141;
XX
DT   07-NOV-2000  (first entry)
XX
DE   PCR primer used to amplify tumour suppressor gene hGHITS.
XX
KW   Human; growth hormone inhibited tumour suppressor protein; hGHITS;
KW   antineoplastic; dwarfism; gigantism; acromegaly; angiopathy;
KW   diabetic nephropathy; cardiopathy; tumour; breast cancer;
KW   renal adenocarcinoma; colorectal cancer; leukaemia; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1022333-A1.
XX
PD   26-JUL-2000.
XX
PF   07-OCT-1999;   99EP-00119199.
XX
PR   25-JAN-1999;   99JP-00016223.
XX
PA   (JCRP-) JCR PHARM CO LTD.
XX
PI   Koga J,  Kono K,  Zolotaryov FN;
XX
DR   WPI; 2000-516013/47.
XX
PT   New human growth hormone inhibited tumor suppressor genes 1 and 2 for
PT   diagnosis of dwarfism, gigantism, acromegaly, angiopathy, diabetic
PT   nephropathy or cardiopathy.
XX
PS   Example; Page 9; 59pp; English.
XX
CC   The present sequence represents a PCR primer used to amplify a human
CC   growth hormone inhibited tumour suppressor (hGHITS) gene. The hGHITS
CC   proteins can be used in an antineoplastic pharmaceutical preparation.
CC   Probes for the hGHITS DNA sequences can be used in diagnostic
CC   pharmaceutical preparations. The diagnostic pharmaceutical preparations
CC   can be used for examining expression of hGHITS genes in dwarfism,
CC   gigantism, acromegaly, angiopathy, diabetic nephropathy or cardiopathy,
CC   or in malignant tumours including breast cancer, renal adenocarcinoma,
CC   colorectal cancer, and leukaemia. Antibodies against the proteins can be
CC   used in a diagnostic pharmaceutical preparation for examining expression
CC   of a tumour suppressor gene
XX
SQ   Sequence 19 BP; 2 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAGG 2040
              |||||||| ||||| |
Db         18 TGGTAGGACGCAAACG 3


RESULT 973
AAS42780/c
ID   AAS42780 standard; DNA; 19 BP.
XX
AC   AAS42780;
XX
DT   17-DEC-2001  (first entry)
XX
DE   T. gondii immunogenic protein OC-2 PCR primer #3.
XX
KW   Immunogenic protein; oocyst; faeces; ss; enteric apicomplexa oocyst;
KW   Cryptosporidium oocyst; Toxoplasma oocyst; Giardia cyst; vaccine;
KW   oocyte shedding; PCR primer.
XX
OS   Toxoplasma gondii.
XX
PN   US2001014447-A1.
XX
PD   16-AUG-2001.
XX
PF   18-DEC-1998;   98US-00216393.
XX
PR   19-DEC-1997;   97US-00994825.
XX
PA   (MILH/) MILHAUSEN M J.
XX
PI   Milhausen MJ;
XX
DR   WPI; 2001-529100/58.
XX
PT   Detecting parasite oocysts or cysts in feces, comprises eluting DNA from
PT   sample into aqueous solution by heating, amplifying DNA with primers
PT   specific for oocysts or cysts being detected, and detecting amplification
PT   product.
XX
PS   Example 12; Page 39; 188pp; English.
XX
CC   The invention relates to detection of parasite oocysts or cysts in a
CC   faeces sample comprising contacting the sample with a solid support,
CC   drying and then washing the sample with an aqueous wash solution, adding
CC   an aqueous elution solution and eluting DNA from the sample by heating
CC   and amplifying by PCR oocyst/cyst-specific DNA and detecting the
CC   amplification products. The method is useful for detecting parasite
CC   oocysts e.g., enteric apicomplexa oocysts such as Cryptosporidium oocysts
CC   or Toxoplasma oocysts, or for detecting parasite cysts e.g. Giardia
CC   cysts. The method is also useful for developing vaccines to prevent
CC   oocyte shedding in cats. The present sequence is a PCR primer used to
CC   isolate DNAs encoding immunogenic proteins from Toxoplasma gondii
XX
SQ   Sequence 19 BP; 7 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1648 GCCTTCACTGGTTCTG 1663
              ||||| |||| |||||
Db         19 GCCTTGACTGCTTCTG 4


RESULT 974
AAS45556/c
ID   AAS45556 standard; DNA; 19 BP.
XX
AC   AAS45556;
```

```
XX
DT   18-DEC-2001  (first entry)
XX
DE   Tumour-specific IgV region kappa chain, PCR primer Vkappa4.
XX
KW   Human; B cell lymphoma; cytostatic; immunostimulator; self-antigen;
KW   tumour-specific vaccine; tumour; polyclonal immune response;
KW   idiotype-specific anti-lymphoma immune response; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200168682-A1.
XX
PD   20-SEP-2001.
XX
PF   13-OCT-2000; 2000WO-US028362.
XX
PR   10-MAR-2000; 2000US-00522900.
XX
PA   (LARG-) LARGE SCALE BIOLOGY CORP.
PA   (MCCO/) MCCORMICK A A.
PA   (TUSE/) TUSE D.
XX
PI   Reinl SJ,  Turpen TH;
XX
DR   WPI; 2001-596903/67.
XX
PT   Novel polypeptide vaccine produced in plants, useful for inducing an
PT   immune response to a self-antigen on the surface of certain tumor cells.
XX
PS   Disclosure; Page 30; 89pp; English.
XX
CC   The invention relates to a novel polypeptide self-antigen (I) useful as a
CC   tumour-specific vaccine in a subject with a tumour or at risk of
CC   developing a tumour. (I) includes an epitope or epitopes unique to, or
CC   over expressed by, cells of the tumour, thereby distinguishing the tumour
CC   from all other tumours of the same or different histological type, or in
CC   the subject or in another member of the subject's species. (I) is
CC   epitopes in their native form. (I) is capable of inducing an immune
CC   response in a mammal, when used as an individual-specific immunogenic
CC   product comprising (I); and as a vaccine composition useful for inducing
CC   a tumour-specific immune response, idiotype-specific anti-lymphoma immune
CC   response, a polyclonal immune response to at least one idiotype of a
CC   surface immunoglobulin or a polyclonal immune response to an idiotype.
CC   The vaccine composition is useful for inducing a tumour-specific immune
CC   antibody response in a tumour-bearing subject or a subject who had a
CC   tumour e.g. B-cell lymphoma, and was treated so that no tumour is
CC   clinically or radiographically evident. (I) is useful for inducing a
CC   protective antitumour immune response. (I) can be produced at high
CC   levels, is easy to purify and can be appropriately folded to mimic the
CC   conformation of the native epitopes displayed at the tumour cell surface.
CC   AAS45529-AAS45579 represent B cell lymphoma self antigen vaccine linker
CC   sequences and PCR primers of the invention
XX
SQ   Sequence 19 BP; 4 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              |||| |||||| ||||
Db         18 CTGGGTCTGCAACACC 3


RESULT 975
AAS05706
ID   AAS05706 standard; DNA; 19 BP.
XX
AC   AAS05706;
XX
DT   09-SEP-2004  (revised)
DT   07-SEP-2001  (first entry)
XX
DE   Polypyrimidine region of SNP DYS271 RP-TFO.
XX
KW   reverse phase triplex forming oligonucleotide; RP-TFO;
KW   protected nucleic acid sequence; PNAS; single nucleotide polymorphism;
KW   SNP; short tandem repeat; cancer; SNP DYS271; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_base   11
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Other= Inosine or hypoxanthine"
XX
PN   WO200132929-A1.
XX
PD   10-MAY-2001.
XX
PF   03-NOV-2000; 2000WO-US030534.
XX
PR   03-NOV-1999;   99US-0163356P.
PR   03-NOV-1999;   99US-0163416P.
PR   21-DEC-1999;   99US-0171348P.
PR   07-JUL-2000; 2000US-0216579P.
XX
PA   (CYGE-) CYGENE INC.
PA   (OSTE/) OSTE C C.
XX
PI   Oste CC,  Ramberg ER;
XX
DR   WPI; 2001-343488/36.
XX
PT   Analyzing target nucleic acid sequences, useful for population genetics,
PT   drug development and diagnosing cancer, comprises hybridizing triple
PT   forming oligonucleotide and probe to target sequence.
XX
PS   Example 1; Page 64; 141pp; English.
XX
CC   The sequence is the polypyrimidine region of a reverse phase triplex
CC   forming oligonucleotide, RP-TFO used to analyse SNP DYS271 using the
CC   method of the invention. The invention relates to analysing target
CC   nucleic acid sequences comprising restricting isolated DNA, hybridising
CC   at least one triplex forming oligonucleotide (TFO), adding a 3' to 5'
CC   exonuclease to form a protected nucleic acid sequence (PNAS) tail
CC   structure, hybridising the captured structure with a single nucleotide
CC   polymorphisms (SNP) identification probe and determining the SNP score.
CC   The methods can be used for analysing target nucleic acid sequences,
CC   especially genomic DNA sequences, to determine if they contain SNPs or
CC   short tandem repeats (STRs). The methods can be used to detect SNPs for
CC   use in population genetics, drug development, forensics, cancer, genetic
CC   disease research, genomic analysis, diagnostics and therapeutics in
CC   humans, plants and animals
CC
CC   Revised record issued on 09-SEP-2004 : Correction to Feature Table Key
XX
SQ   Sequence 19 BP; 0 A; 9 C; 0 G; 9 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   82.4%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              |||  ||||| ||||||
Db          1 CCCTCTTCTTNCCTTCT 17


RESULT 976
AAS95216
ID   AAS95216 standard; DNA; 19 BP.
XX
AC   AAS95216;
XX
```

DT 14-FEB-2002 (first entry)
XX
DE Otoferlin exon PCR primer #5.
XX
KW Human; mouse; otoferlin; OTOF; brain; auditory function; PCR primer;
KW autosomal nonsyndromic prelingual deafness; DFNB9; ss.
XX
OS Homo sapiens.
XX
PN WO200170972-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-IB000578.
XX
PR 24-MAR-2000; 2000US-0191738P.
XX
PA (INSP) INST PASTEUR.
PA (CNRS) CNRS CENT NAT RECH SCI.
XX
PI Yasunaga S, Grati M, Cohen-Salmon M, El Amraoui A, Petit C;
PI Weil D;
XX
DR WPI; 2001-611499/70.
XX
PT Novel human gene Otoferlin, underlying an autosomal recessive
PT nonsyndromic prelingual deafness, DFNB9, and proteins encoded by the
PT gene, implicated in deafness.
XX
PS Claim 25; Page 31; 99pp; English.
XX
CC The invention relates to a purified polynucleotide (I) encoding a protein
CC sequence (II) encoded by a novel human gene, otoferlin (OTOF) or the long
CC human otoferlin isoform in brain. (I) was identified as underlying an
CC autosomal nonsyndromic prelingual deafness DFNB9, and is thus useful for
CC detecting deafness disease in humans and for characterising the functions
CC of proteins and genes encoding them in auditory function. AAS95022-
CC AAS95248 represent human and mouse otoferlin coding sequences, PCR
CC primers and related sequences of the invention
XX
SQ Sequence 19 BP; 3 A; 2 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1535 AGGTTAGGAGAGTAGG 1550
||||| |||| |||||
Db 1 AGGTTGGGAGTGTAGG 16

RESULT 977
AAH59132
ID AAH59132 standard; DNA; 19 BP.
XX
AC AAH59132;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin A2 ribozyme binding site SEQ ID NO:1556.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 185; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1659 TTCTGCATCACCCGCC 1674
|||||||||| | |||
Db 2 TTCTGCATCAGCAGCC 17

RESULT 978
AAH59566/c
ID AAH59566 standard; DNA; 19 BP.
XX
AC AAH59566;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin D3 ribozyme binding site SEQ ID NO:1990.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.

XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 216; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 3 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1607 GCCTGGGGGAAGAGTT 1622
                ||| ||||||||| ||
Db         19 GCCAGGGGGAAGACTT 4
```

RESULT 979
ABL43091/c
ID ABL43091 standard; DNA; 19 BP.
XX
AC ABL43091;
XX
DT 11-APR-2002 (first entry)
XX
DE Human chromosome 1p36-35 PCR primer SEQ ID NO:135.
XX
KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.
XX
OS Homo sapiens.
XX
PN JP2001321190-A.
XX
PD 20-NOV-2001.
XX
PF 12-MAR-2001; 2001JP-00068285.
XX
PR 10-MAR-2000; 2000JP-00066716.
XX
PA (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
XX
DR WPI; 2002-144136/19.
XX
PT Arraying genome clones.
XX
PS Claim 4; Page 7; 528pp; Japanese.
XX
CC The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
SQ Sequence 19 BP; 10 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy       1767 AAGCTTTTTTTTTTG 1782
                ||||||||||| || ||
Db         17 AAGCTTTTTGTTCTG 2
```

RESULT 980
ABL58835/c
ID ABL58835 standard; DNA; 19 BP.
XX
AC ABL58835;
XX
DT 29-JUL-2002 (first entry)
XX
DE Staphylococcus PCR primer sea SEQ ID NO 13.
XX
KW Staphylococcus; enterotoxin; antibiotic; methicillin; MRSA; PCR; primer;
KW ss.
XX
OS Staphylococcus sp.
XX
PN DE10051174-A1.
XX
PD 02-MAY-2002.
XX
PF 16-OCT-2000; 2000DE-01051174.
XX
PR 16-OCT-2000; 2000DE-01051174.
XX
PA (MICR-) MICRODIAGNOSTICS AG.
XX
PI Wassill L;

```
XX
DR   WPI; 2002-418109/45.
XX
PT   Detecting Staphylococcus by nucleic acid amplification, useful for
PT   testing e.g. clinical samples, can identify simultaneously enterotoxin
PT   and methicillin-resistance genes.
XX
PS   Claim 6; Fig 2; 26pp; German.
XX
CC   The invention relates to a method for detecting Staphylococcus DNA in a
CC   sample by nucleic acid amplification using various primers (ABL58823-
CC   ABL58848) or their variants. The method is used to detect staphylococci
CC   that produce enterotoxins and/or are resistant to antibiotics
CC   (methicillin), e.g. in blood or tissue samples, foods, water and
CC   bacterial cultures. The method allows simultaneous determination of many
CC   genes since the specified primers are functional under the same
CC   conditions and it eliminates the need for a lengthy culture stage
XX
SQ   Sequence 19 BP; 8 A; 1 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1910 ATCAACAATACCTTTT 1925
                ||||||||||  | |||
Db         17 ATCAACAATATCCTTT 2


RESULT 981
ACD40350/c
ID   ACD40350 standard; DNA; 19 BP.
XX
AC   ACD40350;
XX
DT   03-SEP-2003  (first entry)
XX
DE   Tumour IgV PCR 5' primer Vkappa4.
XX
KW   Human; ss; primer; PCR; reverse transcriptase; gene therapy; vaccine;
KW   tumour; immunoglobulin V; IgV.
XX
OS   Homo sapiens.
XX
PN   US2003035807-A1.
XX
PD   20-FEB-2003.
XX
PF   08-FEB-2002; 2002US-00067790.
XX
PR   24-SEP-1999;   99US-0155979P.
PR   10-MAR-2000; 2000US-00522900.
XX
PA   (MCCO/) MCCORMICK A A.
PA   (TUSE/) TUSE D.
PA   (REIN/) REINL S J.
PA   (LIND/) LINDBO J A.
PA   (TURP/) TURPEN T H.
XX
PI   Mccormick AA,  Tuse D,  Reinl SJ,  Lindbo JA,  Turpen TH;
XX
DR   WPI; 2003-492106/46.
XX
PT   Use of a polypeptide self-antigen as a tumor-specific vaccine.
XX
PS   Disclosure; Page 12; 47pp; English.
XX
CC   The invention relates to a polypeptide self-antigen useful as a tumour-
CC   specific vaccine in a subject with a tumour or at risk of developing a
CC   tumour and is encoded at least in part by a nucleic acid in the cells of
CC   the tumour. The polypeptide self antigen is useful for treating or
CC   preventing tumour. The present sequence represents a tumour
CC   immunoglobulin V, IgV, PCR primer
XX
SQ   Sequence 19 BP; 4 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
                ||||  ||||||  ||||
Db         18 CTGGGTCTGCAACACC 3


RESULT 982
ACA98667
ID   ACA98667 standard; DNA; 19 BP.
XX
AC   ACA98667;
XX
DT   28-JUL-2003  (first entry)
XX
DE   Human CYP2C8 SNP detection PCR primer #107.
XX
KW   Cytochrome P450 polypeptide 2C8; CYP2C8; arachidonic acid metabolism;
KW   cancer; cardiovascular disease; cytostatic; cardiovascular; gene therapy;
KW   single nucleotide polymorphism detection; SNP detection; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200299099-A2.
XX
PD   12-DEC-2002.
XX
PF   31-MAY-2002; 2002WO-EP006000.
XX
PR   01-JUN-2001; 2001EP-00112899.
XX
PA   (EPID-) EPIDAUROS BIOTECHNOLOGIE AG..
XX
PI   Penger A,  Sprenger R,  Brinkmann U;
XX
DR   WPI; 2003-167344/16.
XX
PT   New polymorphic variants of the gene encoding Cytochrome P450 polypeptide
PT   2C8 (CYP2C8), useful for diagnosing or treating a disease, e.g.
PT   arachidonic acid metabolism, cancer or cardiovascular diseases.
XX
PS   Example 2; Page 51; 178pp; English.
XX
CC   The invention describes a new polynucleotide comprises a polynucleotide:
CC   (a) having any of 101 nucleic acid sequences with 18-19 bp fully defined
CC   in the specification; (b) encoding any of seven polypeptides having 7
CC   amino acids, or a polypeptide with 3 amino acids; (c) capable of
CC   hybridising to a Cytochrome P450 polypeptide 2C8 (CYP2C8) gene; (d)
CC   encoding a molecular CYP2C8 variant polypeptide or its fragment. The
CC   polynucleotide, gene, vector, polypeptide or antibody is useful for
CC   diagnosing or treating a disease, for preparing a diagnostic composition
CC   for diagnosing a disease, or for preparing a pharmaceutical composition
CC   for treating a disease. This disease includes arachidonic acid
CC   metabolism, cancer or cardiovascular diseases. This sequence represents a
CC   primer used to isolate regions of the human cytochrome P450 polypetide
CC   2C8 gene (CYP2C8) in order to identify the single nucleotide polymorphism
CC   (SNP) in that region of different individuals useful in disease diagnosis
XX
SQ   Sequence 19 BP; 3 A; 2 C; 4 G; 9 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTG 1934
                ||||  ||||:|  | ||||
Db          1 ATACTTTTTKTCTGAGTG 18
```

```
RESULT 983
ACA98664/c
ID   ACA98664 standard; DNA; 19 BP.
XX
AC   ACA98664;
XX
DT   28-JUL-2003  (first entry)
XX
DE   Human CYP2C8 SNP detection PCR primer #104.
XX
KW   Cytochrome P450 polypeptide 2C8; CYP2C8; arachidonic acid metabolism;
KW   cancer; cardiovascular disease; cytostatic; cardiovascular; gene therapy;
KW   single nucleotide polymorphism detection; SNP detection; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200299099-A2.
XX
PD   12-DEC-2002.
XX
PF   31-MAY-2002; 2002WO-EP006000.
XX
PR   01-JUN-2001; 2001EP-00112899.
XX
PA   (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX
PI   Penger A,  Sprenger R,  Brinkmann U;
XX
DR   WPI; 2003-167344/16.
XX
PT   New polymorphic variants of the gene encoding Cytochrome P450 polypeptide
PT   2C8 (CYP2C8), useful for diagnosing or treating a disease, e.g.
PT   arachidonic acid metabolism, cancer or cardiovascular diseases.
XX
PS   Example 2; Page 50; 178pp; English.
XX
CC   The invention describes a new polynucleotide comprises a polynucleotide:
CC   (a) having any of 101 nucleic acid sequences with 18-19 bp fully defined
CC   in the specification; (b) encoding any of seven polypeptides having 7
CC   amino acids, or a polypeptide with 3 amino acids; (c) capable of
CC   hybridising to a Cytochrome P450 polypeptide 2C8 (CYP2C8) gene; (d)
CC   encoding a molecular CYP2C8 variant polypeptide or its fragment. The
CC   polynucleotide, gene, vector, polypeptide or antibody is useful for
CC   diagnosing or treating a disease, for preparing a diagnostic composition
CC   for diagnosing a disease, or for preparing a pharmaceutical composition
CC   for treating a disease. This disease includes arachidonic acid
CC   metabolism, cancer or cardiovascular diseases. This sequence represents a
CC   primer used to isolate regions of the human cytochrome P450 polypetide
CC   2C8 gene (CYP2C8) in order to identify the single nucleotide polymorphism
CC   (SNP) in that region of different individuals useful in disease diagnosis
XX
SQ   Sequence 19 BP; 9 A; 4 C; 2 G; 3 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTG 1934
              |||| ||||:| | ||||
Db         19 ATACTTTTTKTCTGAGTG 2


RESULT 984
ACD06865/c
ID   ACD06865 standard; DNA; 19 BP.
XX
AC   ACD06865;
XX
DT   06-AUG-2003  (first entry)
XX
DE   Tumour immunoglobulin variable region gene PCR primer #28.
XX
KW   Tumour; immunoglobulin variable region; anti-tumour; cytostatic; vaccine;
KW   self-antigen; tumour-specific vaccine; B-cell lymphoma-specific vaccine;
KW   B-cell lymphoma; PCR; primer; ss; single chain antibody polypeptide.
XX
OS   Homo sapiens.
XX
PN   US2003044420-A1.
XX
PD   06-MAR-2003.
XX
PF   08-FEB-2002; 2002US-00067893.
XX
PR   24-SEP-1999;   99US-0155979P.
PR   10-MAR-2000; 2000US-00522900.
XX
PA   (MCCO/) MCCORMICK A A.
PA   (TUSE/) TUSE D.
PA   (REIN/) REINL S J.
PA   (LIND/) LINDBO J A.
PA   (TURP/) TURPEN T H.
XX
PI   Mccormick AA,  Tuse D,  Reinl SJ,  Lindbo JA,  Turpen TH;
XX
DR   WPI; 2003-456552/43.
XX
PT   Novel polypeptide self-antigen useful as tumor-specific vaccine in
PT   mammals, is produced in plants and mimics one or more epitopes of antigen
PT   uniquely expressed by cells of tumor.
XX
PS   Disclosure; Page 12; 47pp; English.
XX
CC   The invention describes a polypeptide self-antigen (I) useful as a tumour
CC   -specific vaccine in a subject with a tumour or at risk of developing a
CC   tumour, encoded by a nucleic acid (NA) in the cells of the tumour,
CC   including an epitope to, or overexpressed by tumour cells; produced in a
CC   cell or organism that has been transfected with NA and in a correctly
CC   folded form; and capable of inducing an immune response in a mammal. (I)
CC   is useful as a tumour-specific vaccine, especially a B-cell lymphoma-
CC   specific vaccine. A vaccine is useful for inducing a tumour-specific
CC   immune antibody response in a tumour-bearing subject, preferably human or
CC   a subject who had a tumour and was treated so that no tumour is
CC   clinically or radiographically evident, where the tumour is B-cell
CC   lymphoma. This sequence represents a primer used to isolate DNA encoding
CC   tumour associated single chain antibody polypeptides
XX
SQ   Sequence 19 BP; 4 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              |||| |||||| ||||
Db         18 CTGGGTCTGCAACACC 3


RESULT 985
ACD06123/c
ID   ACD06123 standard; DNA; 19 BP.
XX
AC   ACD06123;
XX
DT   06-AUG-2003  (first entry)
XX
DE   Tumour immunoglobulin variable region gene PCR primer #28.
XX
KW   Tumour; immunoglobulin variable region; anti-tumour; cytostatic; vaccine;
KW   inducer of immune response; self-antigen; B-cell lymphoma;
KW   tumour-specific vaccine; single chain antibody polypeptide; PCR; primer;
KW   ss.
XX
OS   Homo sapiens.
XX
```

PN US2003044417-A1.
XX
PD 06-MAR-2003.
XX
PF 31-MAR-2000; 2000US-00539382.
XX
PR 24-SEP-1999; 99US-0155979P.
XX
PA (MCCO/) MCCORMICK A A.
PA (TUSE/) TUSE D.
PA (REIN/) REINL S J.
PA (LIND/) LINDBO J A.
PA (TURP/) TURPEN T H.
XX
PI Mccormick AA, Tuse D, Reinl SJ, Lindbo JA, Turpen TH;
XX
DR WPI; 2003-456551/43.
XX
PT Novel polypeptide self-antigen useful as tumor-specific vaccine in
PT mammals, is produced in plants and mimics one or more epitopes of antigen
PT uniquely expressed by cells of tumor.
XX
PS Example 2; Page 12; 37pp; English.
XX
CC The invention describes a polypeptide self-antigen (I) useful as a tumour
CC - specific vaccine in a subject with a tumour or at risk of developing a
CC tumour, encoded by a nucleic acid in the cells of the tumour, including
CC an epitope to, or overexpressed by tumour cells; produced in a cell or
CC organism that has been transfected with nucleic acid and in a correctly
CC folded form; and capable of inducing an immune response in a mammal. (I)
CC is useful as a tumour-specific vaccine, especially a B-cell lymphoma-
CC specific vaccine. A vaccine composition is useful for inducing a tumour-
CC specific immune antibody response in a tumour-bearing subject, preferably
CC human or a subject who had a tumour and was treated so that no tumour is
CC clinically or radiographically evident, where the tumour is B-cell
CC lymphoma. This sequence represents a primer used to generate DNA
CC representing tumour immunoglobulin variable region genes
XX
SQ Sequence 19 BP; 4 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1655 CTGGTTCTGCATCACC 1670
|||| |||||| ||||
Db 18 CTGGGTCTGCAACACC 3

RESULT 986
ACD45075/c
ID ACD45075 standard; DNA; 19 BP.
XX
AC ACD45075;
XX
DT 10-SEP-2003 (first entry)
XX
DE B-cell lymphona variable region gene fragment primer #28.
XX
KW Self-antigen; tumour-specific vaccine; tumour; immune response;
KW anti-tumour immune response; vaccine; B-cell lymphoma;
KW transient viral expression; transgenic plant;
KW variable region gene fragment; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US2003039659-A1.
XX
PD 27-FEB-2003.
XX
PF 08-FEB-2002; 2002US-00067892.
XX
PR 24-SEP-1999; 99US-0155979P.
XX
PR 10-MAR-2000; 2000US-00522900.
XX
PA (MCCO/) MCCORMICK A A.
PA (TUSE/) TUSE D.
PA (REIN/) REINL S J.
PA (LIND/) LINDBO J A.
PA (TURP/) TURPEN T H.
XX
PI Mccormick AA, Tuse D, Reinl SJ, Lindbo JA, Turpen TH;
XX
DR WPI; 2003-492153/46.
XX
PT Novel polypeptide antigen which includes epitope overexpressed by tumor
PT cells e.g. B-cell lymphoma, and is capable of inducing immune response in
PT mammal without need for adjuvant, useful as anti-tumor vaccine component.
XX
PS Example 2; Page 11; 48pp; English.
XX
CC The invention describes a polypeptide self-antigen (I) useful as tumour-
CC specific vaccine in subject with a tumour, including an epitope or
CC epitope unique to, or overexpressed by, cells of the tumour, is produced
CC in a cell or organism that has been transformed or transfected with the
CC nucleic acid derived from the tumour of subject, and is capable of
CC inducing an immune response in a mammal without a need for adjuvant or
CC other immunostimulatory materials. (I) is useful for inducing an immune
CC response, preferably a protective anti-tumour immune response in a
CC mammal, preferably human. A vaccine composition comprising (I) is useful
CC for inducing a tumour-specific immune antibody response in a tumour-
CC bearing subject (preferably human) or a subject who had a tumour and was
CC treated so that no tumour is clinically radiographically evident. The
CC vaccines are preferably useful for inducing immune antibody response
CC against B-cell lymphoma. The polypeptide is produced without the need for
CC denaturation or renaturation. (I) is rapidly produced in plants by
CC transient viral expression. Plant samples expressing the desired protein
CC can be positively identified by both enzyme linked immunosorbent assay
CC (ELISA) and Western blotting 4 weeks after molecular cloning. Thus, (I)
CC is expressed rapidly and easily in plants. This sequence represents a
CC primer used to isolate B-cell lymphona associated variable region gene
CC fragments for use in creation of the self-antigen
XX
SQ Sequence 19 BP; 4 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1655 CTGGTTCTGCATCACC 1670
|||| |||||| ||||
Db 18 CTGGGTCTGCAACACC 3

RESULT 987
ADD20080
ID ADD20080 standard; DNA; 19 BP.
XX
AC ADD20080;
XX
DT 15-JAN-2004 (first entry)
XX
DE Oreochromis niloticus microsatellite primer SEQ ID NO:715.
XX
KW single nucleotide polymorphism; SNP; fish; Salmo salar;
KW Orechromis niloticus; Atlantic halibut; microsatellite; cod;
KW polymorphic site; seabass; salmonidae; Tilapia; rainbow trout; halibut;
KW detection; primer; ss.
XX
OS Synthetic.
OS Oreochromis niloticus.
XX
PN WO2003060160-A2.
XX
PD 24-JUL-2003.
XX

PF 17-JAN-2003; 2003WO-IB000112.
XX
PR 18-JAN-2002; 2002US-0349950P.
PR 16-AUG-2002; 2002US-0404200P.
XX
PA (GENO-) GENOMAR ASA.
XX
PI Lie O, Slettan A, Hoyum M, Lingaas F;
XX
DR WPI; 2003-627388/59.
XX
PT Novel isolated nucleic acid molecule comprising single nucleotide
PT polymorphism associated with fish, useful for forming PCR primers which
PT are used for detecting single nucleotide polymorphisms in fish nucleic
PT acids.
XX
PS Claim 18; SEQ ID NO 715; 233pp; English.
XX
CC The present invention describes an isolated nucleic acid (I) comprising a
CC single nucleotide polymorphism (SNP) chosen from: (i) a nucleic acid of
CC Salmo salar SNPs, Oreochromis niloticus SNPs or Atlantic halibut SNPs;
CC and (ii) a nucleic acid having nucleotide sequence that hybridises to
CC (i), or its complement under highly stringent hybridisation conditions.
CC Also described: (1) an isolated oligonucleotide (II) comprising at least
CC 17 contiguous nucleotides of a nucleotide sequence of S. salar SNPs, O.
CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
CC polymorphic sites and seabass polymorphic sites, or their complement; (2)
CC a primer pair (III) suitable for use in PCR, comprising two (II) capable
CC of amplifying a nucleotide sequence chosen from S. salar SNPs and, O.
CC niloticus SNPs, O. niloticus microsatellites, Atlantic halibut SNPs, cod
CC polymorphic sites and seabass polymorphic sites; and determining (M1) the
CC origin of fish sample comprising providing a parentage genotype database
CC comprising a collection of candidate parent genotypes, where each of the
CC candidate parent genotype represents a distinct origin, and comparing a
CC sample genotype to the parentage genotype database, where a match between
CC the sample genotype and one of the candidate parent genotype identifies
CC to the origin of the sample. (M1) is useful for determining the origin of
CC a fish sample such as family salmonidae, S. salar, Tilapia, O. niloticus,
CC rainbow trout, halibut, seabass and Atlantic cod. (II) is useful for
CC detecting nucleic acid molecule comprising SNP in a sample, which
CC involves contacting the sample containing nucleic acids with one or more
CC (II) derived from nucleotide sequence of S. salar SNPs and O. niloticus
CC SNPs, and identifying nucleic acid that hybridises to (II). (II) is
CC useful for detecting nucleic acid molecule comprising a polymorphic
CC sequence in a sample, comprising contacting the sample containing nucleic
CC acids with one or more (II) which is derived from O. niloticus
CC microsatellite, O. niloticus SNPs, Atlantic halibut SNPs, cod polymorphic
CC sites or seabass polymorphic sites, and identifying a nucleic acid that
CC hybridises to (II). (III) is useful for detecting nucleic acid molecule
CC comprising a microsatellite sequence in sample. The present sequence is
CC used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 9 A; 3 C; 7 G; 0 T; 0 U; 0 Other;

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAACA 1559
              ||| || |||||||||
Db          4 GAGCAGAGAAGGAACA 19
```

RESULT 988
ADF36408
ID ADF36408 standard; RNA; 19 BP.
XX
AC ADF36408;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:697.
XX
KW double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070910-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005022.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Pavco P;
XX
DR WPI; 2003-679876/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
PS Example 3; SEQ ID NO 697; 207pp; English.
XX
CC The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 19 BP; 6 A; 4 C; 5 G; 0 T; 4 U; 0 Other;

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| :||||:| ||
Db          1 AGCCACUGAAAUGGCA 16
```

```
RESULT 989
ADF35981/c
ID   ADF35981 standard; RNA; 19 BP.
XX
AC   ADF35981;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:270.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 270; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 4 A; 5 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match          2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity  87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         19 AGCCACTGAAATGGCA 4


RESULT 990
ADF69468
ID   ADF69468 standard; DNA; 19 BP.
XX
AC   ADF69468;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Tapesia yallundae Ib PCR primer SEQ ID NO:26.
XX
KW   detection; wheat; barley; fungus; fungal pathogen; fungicide; cereal;
KW   Tapesia yallundae; Tapesia acuformis; eyespot disease; PCR primer; ss.
XX
OS   Synthetic.
OS   Oculimacula yallundae.
XX
PN   WO2003085378-A2.
XX
PD   16-OCT-2003.
XX
PF   27-MAR-2003; 2003WO-US009706.
XX
PR   03-APR-2002; 2002US-0369796P.
XX
PA   (SYGN ) SYNGENTA PARTICIPATIONS AG.
XX
PI   Barnett CJ,  Beck JJ;
XX
DR   WPI; 2003-804348/75.
XX
PT   New nucleic acid molecules useful for detecting a fungal pathogen, for
PT   monitoring disease development in plant populations and for deriving
PT   primers for polymerase chain reaction-based diagnostic assays.
XX
PS   Claim 3; SEQ ID NO 26; 41pp; English.
XX
CC   The present invention describes a method for detecting wheat and barley
CC   fungal pathogens which are resistant to certain fungicides. The wheat and
CC   barley fungi are Tapesia yallundae and Tapesia acuformis, which cause
CC   eyespot disease. The present invention describes nucleic acid molecules,
CC   a kit and a method which are useful for detecting the fungal pathogen,
CC   and can be used for monitoring disease development in plant populations.
CC   The present sequence is used in the exemplification of the present
CC   invention.
XX
SQ   Sequence 19 BP; 1 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

  Query Match          2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity  87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1671 CGCCCCTGGACTTCTT 1686
              ||||| ||||| ||||
Db          3 CGCCCTTGGACCTCTT 18


RESULT 991
ADG35660
ID   ADG35660 standard; RNA; 19 BP.
XX
AC   ADG35660;
XX
DT   26-FEB-2004  (first entry)
```

```
XX
DE   HIV siNA oligonucleotide SEQ ID NO:503.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss; target sequence.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 503; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   upper strand of HIV-targeted double-stranded siNA, which is identical to
CC   the HIV transcript target sequence.
XX
SQ   Sequence 19 BP; 6 A; 9 C; 4 G; 0 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1848 GGGCCAACAGACCCAC 1863
                | |||||||| |||||
Db          1 GAGCCAACAGCCCCAC 16


RESULT 992
ADG35300
ID   ADG35300 standard; RNA; 19 BP.
XX
AC   ADG35300;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:143.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss; target sequence.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 143; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
```

```
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   upper strand of HIV-targeted double-stranded siNA, which is identical to
CC   the HIV transcript target sequence.
XX
SQ   Sequence 19 BP; 7 A; 4 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match          2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGAC 1744
              |::|:|||||| | |
Db          4 AUUAUCAGAAGGAGCC 19


RESULT 993
ADG36398/c
ID   ADG36398 standard; RNA; 19 BP.
XX
AC   ADG36398;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:1241.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 1241; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   lower strand of an HIV-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 0 A; 4 C; 9 G; 0 T; 6 U; 0 Other;

  Query Match          2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1848 GGGCCAACAGACCCAC 1863
              | |||||||| |||||
Db         19 GAGCCAACAGCCCCAC 4


RESULT 994
ADG36038/c
ID   ADG36038 standard; RNA; 19 BP.
XX
AC   ADG36038;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:881.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
```

```
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 881; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   lower strand of an HIV-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 3 A; 5 C; 4 G; 0 T; 7 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGAC 1744
              ||||||||||||  | |
Db         16 ATTATCAGAAGGAGCC 1


RESULT 995
ADG36051/c
ID   ADG36051 standard; RNA; 19 BP.
XX
AC   ADG36051;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:894.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 894; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   lower strand of an HIV-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 3 A; 4 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1730 TTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         19 TTATCAGAAGGAGCCA 4


RESULT 996
ADG35313
ID   ADG35313 standard; RNA; 19 BP.
XX
AC   ADG35313;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:156.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss; target sequence.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
```

```
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 156; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   upper strand of HIV-targeted double-stranded siNA, which is identical to
CC   the HIV transcript target sequence.
XX
SQ   Sequence 19 BP; 6 A; 6 C; 4 G; 0 T; 3 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   68.8%;  Pred. No. 5.1e+02;
  Matches   11;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1730 TTATCAGAAGGTGACA 1745
              ::|:|||||||  | ||
Db          1 UUAUCAGAAGGAGCCA 16


RESULT 997
ADF84778
ID   ADF84778 standard; RNA; 19 BP.
XX
AC   ADF84778;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 1072.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 1072; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human ABL1-targeted siRNA of the invention.
XX
SQ   Sequence 19 BP; 3 A; 8 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   75.0%;  Pred. No. 5.1e+02;
  Matches   12;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGGGG 1614
              ||| ||:||||:|| |
Db          1 CCCACCUGGCCUGGAG 16


RESULT 998
ADF84459/c
ID   ADF84459 standard; RNA; 19 BP.
XX
AC   ADF84459;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 753.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
```

XX
PF 20-FEB-2003; 2003WO-US005234.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B;
XX
DR WPI; 2003-679889/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
PS Example 7; SEQ ID NO 753; 197pp; English.
XX
CC The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human ABL1-targeted siRNA of the invention.
XX
SQ Sequence 19 BP; 2 A; 6 C; 8 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1599 CCCTCCTGGCCTGGGG 1614
||| |||||||||| |
Db 19 CCCACCTGGCCTGGAG 4

RESULT 999
ADG17387/c
ID ADG17387 standard; DNA; 19 BP.
XX
AC ADG17387;
XX
DT 26-FEB-2004 (first entry)
XX
DE T. gondii PCR primer #6.
XX
KW Toxoplasma gondii; oocyst shedding; genetic vaccine; vaccine; ss; primer;
KW PCR.
XX
OS Toxoplasma gondii.
XX
PN US2003194393-A1.
XX
PD 16-OCT-2003.
XX
PF 17-DEC-2002; 2002US-00321856.
XX
PR 19-DEC-1997; 97US-00994825.
PR 18-DEC-1998; 98US-00216393.
XX
PA (MILH/) MILHAUSEN M J.
XX
PI Milhausen MJ;
XX
DR WPI; 2003-899768/82.
XX
PT Novel immunogenic Toxoplasma gondii proteins useful for inhibiting oocyst
PT shedding by cats infected with Toxoplasma gondii.
XX
PS Example 12; SEQ ID NO 337; 198pp; English.
XX
CC The invention relates to an isolated Toxoplasma gondii protein. The
CC protein is useful for inhibit oocyst shedding by cats infected with
CC Toxoplasma gondii. The protein is useful for preventing or ameliorating
CC diseases caused by infection with T. gondii. The nucleic acid can be used
CC as genetic vaccine which encodes the protein. The protein and the nucleic
CC acid are used as diagnostic reagents for detection of T. gondii
CC infection. The present sequence is used in the exemplification of the
CC invention.
XX
SQ Sequence 19 BP; 7 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.8; DB 1; Length 19;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1648 GCCTTCACTGGTTCTG 1663
||||| |||| |||||
Db 19 GCCTTGACTGCTTCTG 4

RESULT 1000
ABZ95209/c
ID ABZ95209 standard; DNA; 19 BP.
XX
AC ABZ95209;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human VCAM-1 oligonucleotide fragment no.1074.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 10451; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

```
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 19 BP; 0 A; 7 C; 1 G; 11 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAAGTG 1993
              |||||| ||||||| |
Db         17 GAAAAACAGAAAAGAG 2


RESULT 1001
ADN34190
ID   ADN34190 standard; RNA; 19 BP.
XX
AC   ADN34190;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Upper strand of cyclin D1 targeted double stranded siNA #210.
XX
KW   short interfering nucleic acid; siNA; cyclin; Cytostatic; Vasotropic;
KW   cancer; cell-proliferation disorder; restenosis; drug screening;
KW   genetic engineering; pharmacogenomics; gene mapping;
KW   single nucleotide polymorphisms; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003072705-A2.
XX
PD   04-SEP-2003.
XX
PF   06-FEB-2003; 2003WO-US003662.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   17-SEP-2002; 2002US-0411275P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Thompson J,  Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-689983/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer and restenosis, down regulates expression of at least
PT   one cyclin gene.
XX
PS   Example 3; SEQ ID NO 210; 144pp; English.
XX
CC   The present invention relates to a short interfering nucleic acid (siNA)
CC   that down regulates expression of at least one cyclin gene by RNA
CC   interference. siNA are used to modulate expression of cyclin genes, in
CC   cells, tissue explants or organisms, e.g. for treating a wide range of
CC   cancers and other cell-proliferation disorders such as restenosis, but
CC   also for drug screening, diagnosis, target identification and validation;
CC   genetic engineering, pharmacogenomics, studying gene function and gene
CC   mapping (e.g. of single-nucleotide polymorphisms). The present sequence
CC   represents the upper strand of cyclin D1 targeted double stranded siNA
CC   which is identical to the cyclin D1 transcript target sequence.
XX
SQ   Sequence 19 BP; 9 A; 3 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   62.5%;  Pred. No. 5.1e+02;
  Matches   10;  Conservative    4;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1639 ATTTAAAGAGCCTTCA 1654
              |:::|||||| |: ||
Db          3 AUUUAAAGAGACUCCA 18


RESULT 1002
ADN34429/c
ID   ADN34429 standard; RNA; 19 BP.
XX
AC   ADN34429;
XX
DT   01-JUL-2004  (first entry)
XX
DE   Lower strand of cyclin D1 targeted double stranded siNA #210.
XX
KW   short interfering nucleic acid; siNA; cyclin; Cytostatic; Vasotropic;
KW   cancer; cell-proliferation disorder; restenosis; drug screening;
KW   genetic engineering; pharmacogenomics; gene mapping;
KW   single nucleotide polymorphisms; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003072705-A2.
XX
PD   04-SEP-2003.
XX
PF   06-FEB-2003; 2003WO-US003662.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   17-SEP-2002; 2002US-0411275P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Thompson J,  Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-689983/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer and restenosis, down regulates expression of at least
PT   one cyclin gene.
XX
PS   Example 3; SEQ ID NO 449; 144pp; English.
XX
CC   The present invention relates to a short interfering nucleic acid (siNA)
CC   that down regulates expression of at least one cyclin gene by RNA
CC   interference. siNA are used to modulate expression of cyclin genes, in
CC   cells, tissue explants or organisms, e.g. for treating a wide range of
CC   cancers and other cell-proliferation disorders such as restenosis, but
CC   also for drug screening, diagnosis, target identification and validation;
CC   genetic engineering, pharmacogenomics, studying gene function and gene
CC   mapping (e.g. of single-nucleotide polymorphisms). The present sequence
```

```
CC   represents the lower strand of cyclin D1 targeted double stranded siNA.
XX
SQ   Sequence 19 BP; 5 A; 2 C; 3 G; 0 T; 9 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1639 ATTTAAAGAGCCTTCA 1654
              |||||||||| || ||
Db         17 ATTTAAAGAGACTCCA 2


RESULT 1003
ABD19154/c
ID   ABD19154 standard; DNA; 19 BP.
XX
AC   ABD19154;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human VCAM-1 DNA fragment 1074.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 10451; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 19 BP; 0 A; 7 C; 1 G; 11 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAAGTG 1993
              |||||| ||||||| |
Db         17 GAAAAACAGAAAAGAG 2


RESULT 1004
ADH28072
ID   ADH28072 standard; DNA; 19 BP.
XX
AC   ADH28072;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Human chromosome 1 SNP PCR primer.
XX
KW   genetic alteration; diagnosis; malignant disease; tumour; metastasis;
KW   single nucleotide polymorphism; SNP; cancer; PCR primer; detection;
KW   human; chromosome 1; ss.
XX
OS   Synthetic.
XX
PN   WO2004001016-A2.
XX
PD   31-DEC-2003.
XX
PF   25-JUN-2003; 2003WO-US019926.
XX
PR   25-JUN-2002; 2002US-0391515P.
XX
PA   (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX
PI   Fortina P,  Maris JM,  Gelfand CA;
XX
DR   WPI; 2004-071731/07.
XX
PT   Detecting genetic alterations associated with cancer comprises providing
PT   a target nucleic acid from a patient sample having a predetermined
PT   sequence in the normal population, and assessing the nucleic acid for
PT   loss of heterozygosity.
XX
PS   Example 1; SEQ ID NO 191; 50pp; English.
XX
CC   The present invention describes a method for determining a genetic
CC   alteration in a nucleic acid for the diagnosis and management of
CC   malignant disease. The method comprises providing a target nucleic acid
CC   from a patient sample, the target nucleic acid having a predetermined
CC   sequence in the normal population; and assessing the target nucleic acid
CC   for the extent of loss of heterozygosity relative to predetermined loci,
CC   an increased loss of heterozygosity being correlated with enhanced tumour
CC   invasiveness and metastasis. Also described is a method for determining
CC   the presence or absence of at least one specific nucleotide in a target
CC   nucleic acid for the diagnosis and management of malignant disease. The
CC   methods are useful in detecting genetic alterations (e.g. single
```

```
CC   nucleotide polymorphisms (SNPs)) in a defined polynucleotide region as a
CC   means to diagnose and manage malignant diseases such as cancer. The
CC   present sequence represents a PCR primer used to amplify genomic DNA
CC   corresponding to known SNPs located in predetermined regions of human
CC   chromosome 1, which is used in an example from the present invention.
XX
SQ   Sequence 19 BP; 8 A; 4 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1553 AGGAACAGGACTGCAA 1568
              ||||||||||  ||||
Db          2 AGGAACAGGAACGCAA 17


RESULT 1005
ADL15516/c
ID   ADL15516 standard; DNA; 19 BP.
XX
AC   ADL15516;
XX
DT   20-MAY-2004  (first entry)
XX
DE   PCR primer 26 used during mutational analysis of human nephroretinin.
XX
KW   nephrotropic; nephroretinin; nephphrocystin-4; NPHP4; gene therapy;
KW   cystic kidney disease; human; ss; PCR; primer.
XX
OS   Homo sapiens.
XX
PN   WO2004018702-A2.
XX
PD   04-MAR-2004.
XX
PF   26-AUG-2003; 2003WO-US026507.
XX
PR   26-AUG-2002; 2002US-0406001P.
XX
PA   (UNMI ) UNIV MICHIGAN.
XX
PI   Hildebrandt F,  Otto E,  Hoefele J,  Ruf R,  Mueller AM,  Hiller KS;
PI   Wolf MTF,  Schuermann MJ,  Becker A;
XX
DR   WPI; 2004-226861/21.
XX
PT   New isolated and purified nucleic acid encoding nephroretinin or
PT   nephrocystin-4, useful for treating cystic kidney disease or for drug
PT   screening applications.
XX
PS   Example 1; SEQ ID NO 48; 175pp; English.
XX
CC   The invention relates to a novel isolated and purified nucleic acid. The
CC   nucleic acid of the invention demonstrates nephrotropic activity and may
CC   be useful for drug screening applications for compounds that alter
CC   signaling within the nephroretinin (nephphrocystin-4; NPHP4) pathway, as
CC   well as in yeast two-hybrid screening assays and gene therapy. The
CC   nucleic acid may also be used for treating cystic kidney disease. The
CC   current sequence is that of a PCR primer used during mutational analysis
CC   of human nephroretinin of the invention.
XX
SQ   Sequence 19 BP; 5 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1937 AAGGTAATGGTTGGTT 1952
              ||||| |||| |||||
Db         18 AAGGTCATGGGTGGTT 3


RESULT 1006
ADO18674
ID   ADO18674 standard; DNA; 19 BP.
XX
AC   ADO18674;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Analytical probe chip of the invention #433.
XX
KW   analytical chip; bacterial 16S-rRNA; genotypic characterization; probe;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO2004033720-A2.
XX
PD   22-APR-2004.
XX
PF   24-SEP-2003; 2003WO-EP010626.
XX
PR   09-OCT-2002; 2002EP-00022631.
XX
PA   (UYGE-) UNIV GENEVE HOPITAUX.
XX
PI   Schrenzel J,  Francois P,  Charbonnier Y,  Jacquet JG,  Utinger D;
PI   Kresbach GM,  Abel A,  Ehrat M;
XX
DR   WPI; 2004-375537/35.
XX
PT   Analytical chip useful for simultaneous determination of one or more
PT   different bacterial 16S-rRNA in liquid sample, comprising evanescent
PT   field measurement platform as solid carrier and several specific
PT   recognition elements.
XX
PS   Claim 146; SEQ ID NO 433; 82pp; English.
XX
CC   The present invention relates to an analytical chip for simultaneous
CC   determination of one or more different bacterial 16S-rRNA in liquid
CC   sample. The chip is useful for detecting one or more bacterial 16S-rRNA,
CC   derived from bacteria such as Achromobacter xylosoxidans , Acinetobacter
CC   baumannii , Actinomyces israelii , Aerococcus viridans , Aeromonas
CC   hydrophilia , Agrobacterium radiobacter , Bacillus sp. , Bacteroides
CC   ovatus , Campylobacter fetus , Citrobacter freundii , Enterococcus avium
CC   , Eubacterium lentum , Escherichia coli , Flavobacterium breve ,
CC   Fusobacterium nucleatum , Gemella morbillorum , Gardnerella vaginalis ,
CC   Haemophilus influenzae , Hafnia alvei , Kingella sp. , Klebsiella oxytoca
CC   , Lactobacillus acidophilus , Legionella pneumophila , Moraxella
CC   catarrhalis , Mycobacterium avium , Neisseria cinerea , Nocardia sp. ,
CC   Ochrobactrum anthropi , Pasteurella multocida , Peptostreptococcus magnus
CC   , Salmonella typhi , Shigella sonnei , Veillonella parvula , Veillonella
CC   sp. or Yersinia enterocolitica . The chip is useful for detecting
CC   clinically relevant bacteria. The chip enables determination of one or
CC   more different bacterial 16S-rRNA in a liquid sample, simultaneously and
CC   enables rapid, accurate, easy and reliable identification of bacteria by
CC   genotypic characterization in a provided sample and also enables
CC   identification of a bacterium even in a complex biological sample. The
CC   chip which is produced at reduced cost, enables determination of 16S-rRNA
CC   in a sample with reduced experimental error and variation. The present
CC   sequence represents a probe of the invention used as an analytical chip.
XX
SQ   Sequence 19 BP; 7 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2055 CAACTAGTTAATAAGT 2070
              ||||||| |||| |||
Db          1 CAACTAGCTAATCAGT 16


RESULT 1007
```

```
ADO18433
ID   ADO18433 standard; DNA; 19 BP.
XX
AC   ADO18433;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Analytical probe chip of the invention #192.
XX
KW   analytical chip; bacterial 16S-rRNA; genotypic characterization; probe;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO2004033720-A2.
XX
PD   22-APR-2004.
XX
PF   24-SEP-2003; 2003WO-EP010626.
XX
PR   09-OCT-2002; 2002EP-00022631.
XX
PA   (UYGE-) UNIV GENEVE HOPITAUX.
XX
PI   Schrenzel J,  Francois P,  Charbonnier Y,  Jacquet JG,  Utinger D;
PI   Kresbach GM,  Abel A,  Ehrat M;
XX
DR   WPI; 2004-375537/35.
XX
PT   Analytical chip useful for simultaneous determination of one or more
PT   different bacterial 16S-rRNA in liquid sample, comprising evanescent
PT   field measurement platform as solid carrier and several specific
PT   recognition elements.
XX
PS   Claim 1; SEQ ID NO 192; 82pp; English.
XX
CC   The present invention relates to an analytical chip for simultaneous
CC   determination of one or more different bacterial 16S-rRNA in liquid
CC   sample. The chip is useful for detecting one or more bacterial 16S-rRNA,
CC   derived from bacteria such as Achromobacter xylosoxidans , Acinetobacter
CC   baumannii , Actinomyces israelii , Aerococcus viridans , Aeromonas
CC   hydrophilia , Agrobacterium radiobacter , Bacillus sp. , Bacteroides
CC   ovatus , Campylobacter fetus , Citrobacter freundii , Enterococcus avium
CC   , Eubacterium lentum , Escherichia coli , Flavobacterium breve ,
CC   Fusobacterium nucleatum , Gemella morbillorum , Gardnerella vaginalis ,
CC   Haemophilus influenzae , Hafnia alvei , Kingella sp. , Klebsiella oxytoca
CC   , Lactobacillus acidophilus , Legionella pneumophila , Moraxella
CC   catarrhalis , Mycobacterium avium , Neisseria cinerea , Nocardia sp. ,
CC   Ochrobactrum anthropi , Pasteurella multocida , Peptostreptococcus magnus
CC   , Salmonella typhi , Shigella sonnei , Veillonella parvula , Veillonella
CC   sp. or Yersinia enterocolitica . The chip is useful for detecting
CC   clinically relevant bacteria. The chip enables determination of one or
CC   more different bacterial 16S-rRNA in a liquid sample, simultaneously and
CC   enables rapid, accurate, easy and reliable identification of bacteria by
CC   genotypic characterization in a provided sample and also enables
CC   identification of a bacterium even in a complex biological sample. The
CC   chip which is produced at reduced cost, enables determination of 16S-rRNA
CC   in a sample with reduced experimental error and variation. The present
CC   sequence represents a probe of the invention used as an analytical chip.
XX
SQ   Sequence 19 BP; 7 A; 4 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2055 CAACTAGTTAATAAGT 2070
              ||||||| |||| |||
Db          1 CAACTAGCTAATCAGT 16


RESULT 1008
ADO18410
ID   ADO18410 standard; DNA; 19 BP.
XX
AC   ADO18410;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Analytical probe chip of the invention #169.
XX
KW   analytical chip; bacterial 16S-rRNA; genotypic characterization; probe;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO2004033720-A2.
XX
PD   22-APR-2004.
XX
PF   24-SEP-2003; 2003WO-EP010626.
XX
PR   09-OCT-2002; 2002EP-00022631.
XX
PA   (UYGE-) UNIV GENEVE HOPITAUX.
XX
PI   Schrenzel J,  Francois P,  Charbonnier Y,  Jacquet JG,  Utinger D;
PI   Kresbach GM,  Abel A,  Ehrat M;
XX
DR   WPI; 2004-375537/35.
XX
PT   Analytical chip useful for simultaneous determination of one or more
PT   different bacterial 16S-rRNA in liquid sample, comprising evanescent
PT   field measurement platform as solid carrier and several specific
PT   recognition elements.
XX
PS   Claim 1; SEQ ID NO 169; 82pp; English.
XX
CC   The present invention relates to an analytical chip for simultaneous
CC   determination of one or more different bacterial 16S-rRNA in liquid
CC   sample. The chip is useful for detecting one or more bacterial 16S-rRNA,
CC   derived from bacteria such as Achromobacter xylosoxidans , Acinetobacter
CC   baumannii , Actinomyces israelii , Aerococcus viridans , Aeromonas
CC   hydrophilia , Agrobacterium radiobacter , Bacillus sp. , Bacteroides
CC   ovatus , Campylobacter fetus , Citrobacter freundii , Enterococcus avium
CC   , Eubacterium lentum , Escherichia coli , Flavobacterium breve ,
CC   Fusobacterium nucleatum , Gemella morbillorum , Gardnerella vaginalis ,
CC   Haemophilus influenzae , Hafnia alvei , Kingella sp. , Klebsiella oxytoca
CC   , Lactobacillus acidophilus , Legionella pneumophila , Moraxella
CC   catarrhalis , Mycobacterium avium , Neisseria cinerea , Nocardia sp. ,
CC   Ochrobactrum anthropi , Pasteurella multocida , Peptostreptococcus magnus
CC   , Salmonella typhi , Shigella sonnei , Veillonella parvula , Veillonella
CC   sp. or Yersinia enterocolitica . The chip is useful for detecting
CC   clinically relevant bacteria. The chip enables determination of one or
CC   more different bacterial 16S-rRNA in a liquid sample, simultaneously and
CC   enables rapid, accurate, easy and reliable identification of bacteria by
CC   genotypic characterization in a provided sample and also enables
CC   identification of a bacterium even in a complex biological sample. The
CC   chip which is produced at reduced cost, enables determination of 16S-rRNA
CC   in a sample with reduced experimental error and variation. The present
CC   sequence represents a probe of the invention used as an analytical chip.
XX
SQ   Sequence 19 BP; 6 A; 2 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1879 AATGTCAAATTGATGT 1894
              || ||||| |||||||
Db          3 AACGTCAATTTGATGT 18


RESULT 1009
ADO18584
ID   ADO18584 standard; DNA; 19 BP.
```

```
XX
AC   ADO18584;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Analytical probe chip of the invention #343.
XX
KW   analytical chip; bacterial 16S-rRNA; genotypic characterization; probe;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO2004033720-A2.
XX
PD   22-APR-2004.
XX
PF   24-SEP-2003; 2003WO-EP010626.
XX
PR   09-OCT-2002; 2002EP-00022631.
XX
PA   (UYGE-) UNIV GENEVE HOPITAUX.
XX
PI   Schrenzel J,  Francois P,  Charbonnier Y,  Jacquet JG,  Utinger D;
PI   Kresbach GM,  Abel A,  Ehrat M;
XX
DR   WPI; 2004-375537/35.
XX
PT   Analytical chip useful for simultaneous determination of one or more
PT   different bacterial 16S-rRNA in liquid sample, comprising evanescent
PT   field measurement platform as solid carrier and several specific
PT   recognition elements.
XX
PS   Claim 56; SEQ ID NO 343; 82pp; English.
XX
CC   The present invention relates to an analytical chip for simultaneous
CC   determination of one or more different bacterial 16S-rRNA in liquid
CC   sample. The chip is useful for detecting one or more bacterial 16S-rRNA,
CC   derived from bacteria such as Achromobacter xylosoxidans , Acinetobacter
CC   baumannii , Actinomyces israelii , Aerococcus viridans , Aeromonas
CC   hydrophilia , Agrobacterium radiobacter , Bacillus sp. , Bacteroides
CC   ovatus , Campylobacter fetus , Citrobacter freundii , Enterococcus avium
CC   , Eubacterium lentum , Escherichia coli , Flavobacterium breve ,
CC   Fusobacterium nucleatum , Gemella morbillorum , Gardnerella vaginalis ,
CC   Haemophilus influenzae , Hafnia alvei , Kingella sp. , Klebsiella oxytoca
CC   , Lactobacillus acidophilus , Legionella pneumophila , Moraxella
CC   catarrhalis , Mycobacterium avium , Neisseria cinerea , Nocardia sp. ,
CC   Ochrobactrum anthropi , Pasteurella multocida , Peptostreptococcus magnus
CC   , Salmonella typhi , Shigella sonnei , Veillonella parvula , Veillonella
CC   sp. or Yersinia enterocolitica . The chip is useful for detecting
CC   clinically relevant bacteria. The chip enables determination of one or
CC   more different bacterial 16S-rRNA in a liquid sample, simultaneously and
CC   enables rapid, accurate, easy and reliable identification of bacteria by
CC   genotypic characterization in a provided sample and also enables
CC   identification of a bacterium even in a complex biological sample. The
CC   chip which is produced at reduced cost, enables determination of 16S-rRNA
CC   in a sample with reduced experimental error and variation. The present
CC   sequence represents a probe of the invention used as an analytical chip.
XX
SQ   Sequence 19 BP; 6 A; 2 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 5.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1879 AATGTCAAATTGATGT 1894
              || ||||| |||||||
Db          3 AACGTCAATTTGATGT 18


RESULT 1010
ABC37874
ID   ABC37874 standard; DNA; 13 BP.
XX
AC   ABC37874;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 37891 for detecting SNP TSC0011764.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 37891; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 0 C; 2 G; 5 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATC 1830
              |||||||||||:
Db          1 AAGTTTTAGAATY 13


RESULT 1011
ABC14546/c
ID   ABC14546 standard; DNA; 13 BP.
XX
AC   ABC14546;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 14553 for detecting SNP TSC0003284.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
```

```
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 14553; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 1 Other;

  Query Match              2.3%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAAT 1838
              :|||||||||||||
Db         13 RAATCTTTTAAAT 1


RESULT 1012
ABC36865
ID   ABC36865 standard; DNA; 13 BP.
XX
AC   ABC36865;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 36882 for detecting SNP TSC0011532.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 36882; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 3 A; 3 C; 0 G; 6 T; 0 U; 1 Other;

  Query Match              2.3%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1914 ACAATACCTTTTT 1926
              :|||||||||||||
Db          1 RCAATACCTTTTT 13


RESULT 1013
ABC14547
ID   ABC14547 standard; DNA; 13 BP.
XX
AC   ABC14547;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 14554 for detecting SNP TSC0003284.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 14554; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
```

```
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1826 GAATCTTTTAAAT 1838
              :||||||||||||
Db          1 RAATCTTTTAAAT 13


RESULT 1014
ABF78869
ID   ABF78869 standard; DNA; 13 BP.
XX
AC   ABF78869;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 178866 for detecting SNP TSC0044298.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 178866; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATA 1839
              :||||||||||||
Db          1 RATCTTTTAAATA 13


RESULT 1015
ABC36864/c
ID   ABC36864 standard; DNA; 13 BP.
XX
AC   ABC36864;
XX
DT   20-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 36881 for detecting SNP TSC0011532.
XX
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW   central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS   Homo sapiens.
XX
PN   WO200177384-A2.
XX
PD   18-OCT-2001.
XX
PF   06-APR-2001; 2001WO-IB000713.
XX
PR   07-APR-2000; 2000DE-01019173.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Piepenbrock C,  Berlin K;
XX
DR   WPI; 2001-657177/75.
XX
PT   Set of oligonucleotides, useful for diagnosis and cell typing, is
PT   designed to detect single-nucleotide polymorphisms and cytosine
PT   methylation status.
XX
PS   Claim 1; SEQ ID NO 36881; 29pp + Sequence Listing; German.
XX
CC   This invention describes novel oligonucleotide primers or peptide nucleic
CC   acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC   and cytosine methylation status in chemically pretreated genomic DNA. The
CC   oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC   range of diseases including immune system, gastrointestinal, respiratory,
CC   central nervous system, cardiovascular and metabolic disorders. The
CC   oligomers are also used for detecting cell type differentiation. ABC00010
CC   -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC   represent the oligomers described in the invention. NOTE: The sequence
CC   data for this patent did not form part of the printed specification, but
CC   was obtained in electronic format from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 13 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 13;
  Best Local Similarity   92.3%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1914 ACAATACCTTTTT 1926
              :||||||||||||
Db         13 RCAATACCTTTTT 1


RESULT 1016
ABF78868/c
ID   ABF78868 standard; DNA; 13 BP.
XX
AC   ABF78868;
XX
DT   22-FEB-2002  (first entry)
XX
DE   Oligonucleotide SEQ ID NO 178865 for detecting SNP TSC0044298.
```

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 178865; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 1 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 4.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1827 AATCTTTTAAATA 1839
:||||||||||||
Db 13 RATCTTTTAAATA 1

RESULT 1017
ABC37875/c
ID ABC37875 standard; DNA; 13 BP.
XX
AC ABC37875;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 37892 for detecting SNP TSC0011764.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 37892; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 1 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 4.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1818 AAGTTTTAGAATC 1830
||||||||||||:
Db 13 AAGTTTTAGAATY 1

RESULT 1018
AAD47752
ID AAD47752 standard; DNA; 15 BP.
XX
AC AAD47752;
XX
DT 24-FEB-2003 (first entry)
XX
DE Human GNB3 gene polymorphisms detecting ASO primer #4.
XX
KW Human; guanine nucleotide binding protein beta polypeptide 3; G protein;
KW GNB3; polymorphism; obesity; left ventricular hypertrophy; hypertension;
KW drug discovery; cardiovascular; development process; asthma; anorectic;
KW gene therapy; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200277284-A1.
XX
PD 03-OCT-2002.
XX
PF 21-MAR-2001; 2001WO-US008961.
XX
PR 21-MAR-2001; 2001WO-US008961.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Bentivegna SC, Choi JY, Kliem SE, Koshy B;
XX
DR WPI; 2003-018947/01.
XX
PT New genetic variants having polymorphisms in the G protein, GNB3 gene,
PT useful for treating disorders with abnormal expression or function of the
PT GNB3 gene, such as asthma, obesity, hypertension and left ventricular
PT hypertrophy.

```
XX
PS   Claim 16; Page 14; 88pp; English.
XX
CC   The invention relates to an isolated polypeptide which comprises a first
CC   nucleotide sequence which is a polymorphic variant of a reference
CC   sequence for the guanine nucleotide binding protein (G protein), beta
CC   polypeptide 3 (GNB3) gene or fragment. Polymorphic variants of the GNB3
CC   gene are useful in studying the expression and biological function of
CC   GNB3 and in identifying drugs targetting GNB3 protein for treating
CC   disorders associated with abnormal expression or function of GNB3, e.g.
CC   hypertension, obesity, asthma and left ventricular hypertrophy.
CC   Polynucleotides comprising a polymorphic gene variant or fragment may be
CC   used for therapeutic purposes, where a patient could benefit from
CC   expression or increased expression of a particular GNB3 gene isoform or
CC   an expression vector encoding the isoform may be administered to the
CC   patient. Haplotype information is useful in improving the efficiency and
CC   output of several steps in drug discovery and development process,
CC   including target validation, identifying lead compounds and early phase
CC   clinical trials. The invention is used in gene therapy. The present
CC   sequence is human GNB3 gene polymorphisms detecting ASO (allele specific
CC   oligonucleotide) primer
XX
SQ   Sequence 15 BP; 4 A; 3 C; 4 G; 3 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.8e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGA 1596
              ||||||||||:|
Db          3 GCACAGACTGGRA 15


RESULT 1019
AAD47739
ID   AAD47739 standard; DNA; 15 BP.
XX
AC   AAD47739;
XX
DT   24-FEB-2003  (first entry)
XX
DE   Human GNB3 gene polymorphisms detecting ASO probe #7.
XX
KW   Human; guanine nucleotide binding protein beta polypeptide 3; G protein;
KW   GNB3; polymorphism; obesity; left ventricular hypertrophy; hypertension;
KW   drug discovery; cardiovascular; development process; asthma; anorectic;
KW   gene therapy; probe; ss.
XX
OS   Homo sapiens.
XX
PN   WO200277284-A1.
XX
PD   03-OCT-2002.
XX
PF   21-MAR-2001; 2001WO-US008961.
XX
PR   21-MAR-2001; 2001WO-US008961.
XX
PA   (GENA-) GENAISSANCE PHARM INC.
XX
PI   Bentivegna SC,  Choi JY,  Kliem SE,  Koshy B;
XX
DR   WPI; 2003-018947/01.
XX
PT   New genetic variants having polymorphisms in the G protein, GNB3 gene,
PT   useful for treating disorders with abnormal expression or function of the
PT   GNB3 gene, such as asthma, obesity, hypertension and left ventricular
PT   hypertrophy.
XX
PS   Claim 16; Page 14; 88pp; English.
XX
CC   The invention relates to an isolated polypeptide which comprises a first
CC   nucleotide sequence which is a polymorphic variant of a reference
CC   sequence for the guanine nucleotide binding protein (G protein), beta
CC   polypeptide 3 (GNB3) gene or fragment. Polymorphic variants of the GNB3
CC   gene are useful in studying the expression and biological function of
CC   GNB3 and in identifying drugs targetting GNB3 protein for treating
CC   disorders associated with abnormal expression or function of GNB3, e.g.
CC   hypertension, obesity, asthma and left ventricular hypertrophy.
CC   Polynucleotides comprising a polymorphic gene variant or fragment may be
CC   used for therapeutic purposes, where a patient could benefit from
CC   expression or increased expression of a particular GNB3 gene isoform or
CC   an expression vector encoding the isoform may be administered to the
CC   patient. Haplotype information is useful in improving the efficiency and
CC   output of several steps in drug discovery and development process,
CC   including target validation, identifying lead compounds and early phase
CC   clinical trials. The invention is used in gene therapy. The present
CC   sequence is human GNB3 gene polymorphisms detecting ASO (allele specific
CC   oligonucleotide) probe
XX
SQ   Sequence 15 BP; 0 A; 6 C; 3 G; 5 T; 0 U; 1 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.8e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGG 1612
              |||||||:|||||
Db          1 CCTCCTGKCCTGG 13


RESULT 1020
AAT16992
ID   AAT16992 standard; DNA; 17 BP.
XX
AC   AAT16992;
XX
DT   10-JUL-1996  (first entry)
XX
DE   E-Dex integrin inhibitor 1 PCR primer No. 1770.
XX
KW   Integrin inhibitor; E-Dex; neutrophil; leukocyte; trans-migration;
KW   cell adhesion; tick-derived antiinflammatory protein; Ixodes pacificus;
KW   Amblyomma americanum; polymerase chain reaction; PCR; primer; ss.
XX
OS   Synthetic.
XX
PN   WO9605304-A1.
XX
PD   22-FEB-1996.
XX
PF   08-AUG-1995;   95WO-US010138.
XX
PR   09-AUG-1994;   94US-00287730.
XX
PA   (ATHE-) ATHENA NEUROSCIENCES INC.
XX
PI   Bard F,  Yednock TA,  Keim PS,  Basi GS;
XX
DR   WPI; 1996-139700/14.
XX
PT   Tick derived anti-inflammatory proteins E-Dex and Y/A-Dex - used to
PT   inhibit leukocyte trans-migration and in the treatment of inflammatory
PT   disease.
XX
PS   Example; Fig 3A; 76pp; English.
XX
CC   Degenerate sense PCR primers (AAT16990-94) are based on the 5' end of a
CC   sequence coding for a peptide fragment of novel tick-derived
CC   antiinflammatory protein E-Dex (see also AAR81794). They were used with
CC   antisense primers (AAT16995-99) complementary to the 3' end of the
CC   sequence for the RT-PCR amplification of tick salivary gland mRNA.
CC   Partial cDNA clones were obtd. and used to screen a cDNA library to
CC   obtain a full-length cDNA clone (AAT16988) coding for E-Dex
XX
SQ   Sequence 17 BP; 9 A; 0 C; 3 G; 2 T; 0 U; 3 Other;
```

```
  Query Match             2.3%;  Score 12.6;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 5.2e+02;
  Matches   12;  Conservative    3;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAAGTGT 1994
              ||: |:||:|||| |||
Db          1 GARGARAARAAAAATGT 17


RESULT 1021
AAV02659/c
ID   AAV02659 standard; DNA; 19 BP.
XX
AC   AAV02659;
XX
DT   25-MAR-2003  (revised)
DT   08-APR-1998  (first entry)
XX
DE   Eukaryotic 18S rRNA gene PCR primer P1b.
XX
KW   Intergenic spacer region; 16S rRNA; 23S rRNA; 18S rRNA; mastitis;
KW   diagnosis; inflammation; infection; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO9732038-A2.
XX
PD   04-SEP-1997.
XX
PF   26-FEB-1997;   97WO-FI000126.
XX
PR   27-FEB-1996;   96US-00607384.
XX
PA   (OULU-) OULUTECH LTD.
XX
PI   Alatossava J,  Tilsala-Timisjaervi AK,  Forsman PT;
XX
DR   WPI; 1997-448698/41.
XX
PT   Detecting mastitis by identifying in milk DNA indicating inflammation and
PT   bacterial infection - also DNA indicative of antibiotic resistance,
PT   provides rapid diagnosis, identifies causative agent and suggests
PT   suitable treatment.
XX
PS   Example 7; Page 20; 56pp; English.
XX
CC   PCR primers AAV02659 and AAV02660 are used to amplify a eukaryotic 18S
CC   rRNA gene which is used in a novel assay to diagnose mastitis in milk.
CC   The method involves the detection of a 16S-23S rRNA intergenic spacer
CC   region from pathogenic bacteria known to be a common cause of bovine
CC   mastitis. This amplified 18S rRNA region is used to distinguish
CC   eukaryotic DNA from prokaryotic and viral DNA which allows an estimation
CC   of somatic cell count and therefore an indication of inflammation. This
CC   method is particularly useful for the detection of mastitis caused by
CC   Streptococcus or Staphylococcus species. The method is rapid, does not
CC   involve isolation of cells or bacteria and may allow the causative agent
CC   to be identified. (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ   Sequence 19 BP; 6 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCCCT 1602
              ||||  |||||||  |||
Db         19 GCACTTACTGGGAATTCCT 1


RESULT 1022
AAT78425/c
ID   AAT78425 standard; DNA; 19 BP.
XX
AC   AAT78425;
XX
DT   17-MAR-1998  (first entry)
XX
DE   Antisense oligonucleotide spA4-antiRSV3'-3'T/(51-69).
XX
KW   Antisense oligonucleotide; respiratory syncytial virus; RSV; ss.
XX
OS   Synthetic.
OS   Human respiratory syncytial virus.
XX
FH   Key             Location/Qualifiers
FT   modified_base   19
FT                   /*tag=  a
FT                   /note= "thymine attached to 3'-terminal base in 3'-5'
FT                   orientation"
XX
PN   WO9729757-A1.
XX
PD   21-AUG-1997.
XX
PF   14-FEB-1997;   97WO-US002531.
XX
PR   15-FEB-1996;   96US-0011725P.
XX
PA   (CLEV-) CLEVELAND CLINIC FOUND.
PA   (USSH ) US NAT INST OF HEALTH.
XX
PI   Torrence PF,  Silverman RH,  Cirino NM,  Li G,  Xiao W;
XX
DR   WPI; 1997-424748/39.
XX
PT   Polynucleotide containing sequence anti-sense to region of RSV -
PT   connected via a linker to an activator of RNaseL, used to treat RSV
PT   infections.
XX
PS   Example 11; Page 29; 89pp; English.
XX
CC   The present sequence is an antisense oligonucleotide, that is
CC   complementary to the anti-genomic RNA strand of a respiratory syncytial
CC   virus (RSV)
XX
SQ   Sequence 19 BP; 6 A; 3 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1732 ATCAGAAGGTGACAAGTAC 1750
              || ||||  ||| ||||||
Db         19 ATAAGAATTTGATAAGTAC 1


RESULT 1023
AAV54628
ID   AAV54628 standard; DNA; 19 BP.
XX
AC   AAV54628;
XX
DT   25-MAR-2003  (revised)
DT   30-OCT-1998  (first entry)
XX
DE   LU105 EST-specific clones sequencing primer 5.
XX
KW   LU105; lung disease marker; immunoassay; lung disease; cancer; blood;
KW   plasma; serum; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9833926-A1.
XX
```

```
PD   06-AUG-1998.
XX
PF   30-JAN-1998;   98WO-US001766.
XX
PR   31-JAN-1997;   97US-00791710.
XX
PA   (ABBO ) ABBOTT LAB.
XX
PI   Billing-Medel PA,  Cohen M,  Colpitts TL,  Friedman PN,  Gordon J;
PI   Granados EN,  Hodges SC,  Klass MR,  Kratochvil JD,  Robertsrapp L;
PI   Russell JC,  Stroupe SD;
XX
DR   WPI; 1998-437479/37.
XX
PT   New nucleic acid for the lung disease marker LU105 - polypeptides,
PT   antibodies and genes, used for diagnosis, prevention, treatment of lung
PT   disease, specifically cancer.
XX
PS   Example 2; Page 95; 123pp; English.
XX
CC   This primer is used for the sequencing of the LU105 specific
CC   polynucleotide sequences shown in AAV54616 to AAV54621. The LU105
CC   speciific sequences are used in the method of the invention for detecting
CC   target LU105 nucleic acid. The method comprises treating a sample with at
CC   least one LU105 specific nucleic acid, or its complement which is at
CC   least 50 percent identical with the LU105 specific nucleic acid sequences
CC   (AAV54616 to AAV54621). LU105 is a lung disease marker. Cells transformed
CC   with a recombinant expression system that contains LU105 specific nucleic
CC   acid fragments, are used to express recombinant LU105 polypeptides which
CC   are used to raise antibodies. The antibodies are used to detect the LU105
CC   antigen, and correspondingly this antigen is used to detect specific
CC   antibodies, in usual immunoassays. The LU105 polypeptides and nucleic
CC   acid sequences are used for diagnosis, staging, monitoring, prognosis,
CC   prevention, treatment and determination of susceptibility to, lung
CC   disease, specifically cancer. The LU105 polypeptides are also used to
CC   screen for specific binding agents, useful therapeutically. LU105 is a
CC   marker for lung disease (present at high concentration, in altered form
CC   or in an unusual body compartment). LU105 can be detected in blood,
CC   plasma or serum in an inexpensive, non-invasive test. (Updated on 25-MAR-
CC   2003 to correct PI field.)
XX
SQ   Sequence 19 BP; 5 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACACTT 1869
                ||| |  | ||||||||||
Db          1 CCAGCTCAGCCACACACTT 19


RESULT 1024
AAX09160/c
ID   AAX09160 standard; DNA; 19 BP.
XX
AC   AAX09160;
XX
DT   24-MAR-1999  (first entry)
XX
DE   Human biallelic polymorphic marker upstream primer #40.
XX
KW   Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW   detection; phenotypic typing; characteristic; infection; hereditary;
KW   autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW   treatment; marker; primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9820165-A2.
XX
PD   14-MAY-1998.
XX
PF   05-NOV-1997;   97WO-US020313.
XX
PR   06-NOV-1996;   96US-0030455P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
PI   Lander ES,  Wang D,  Hudson T;
XX
DR   WPI; 1998-286974/25.
XX
PT   New isolated nucleic acid segments from the human genome - used for
PT   determining polymorphic forms for use in e.g. forensics, paternity
PT   testing or phenotypic typing for disease.
XX
PS   Claim 15; Page 50; 310pp; English.
XX
CC   AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC   isolation of various biallelic polymorphic markers found in the human
CC   genome (represented in AAX10269-X12937). These primers can be used in a
CC   method for determining polymorphic forms in an individual for use in e.g.
CC   forensics, paternity testing or for phenotypic typing for diseases such
CC   as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC   dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial
CC   hypercholesterolemia, polycystic kidney disease, hereditary
CC   spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC   haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC   syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC   autoimmune diseases, inflammation, cancer, diseases of the nervous
CC   system, infection by pathogenic microorganisms, and characteristics such
CC   as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC   endurance, fertility, and susceptibility or receptivity to particular
CC   drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC   segments can also be used to produce medicaments for the treatment or
CC   prophylaxis of such diseases
XX
SQ   Sequence 19 BP; 9 A; 2 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTGAACCCCA 1789
                ||||  |||||  ||  ||||
Db         19 TTTTGTTTTTGCAAACCCA 1

RESULT 1025
AAX59691/c
ID   AAX59691 standard; DNA; 19 BP.
XX
AC   AAX59691;
XX
DT   26-JUL-1999  (first entry)
XX
DE   Activator-antisense complex for RSV.
XX
KW   Antisense oligonucleotide; negative-strand RNA virus; activator; RNase L;
KW   respiratory syncytial virus; RSV; influenza; mumps; rabies; ss.
XX
OS   Synthetic.
XX
PN   WO9922742-A1.
XX
PD   14-MAY-1999.
XX
PF   02-NOV-1998;   98WO-US023391.
XX
PR   03-NOV-1997;   97US-00962690.
XX
PA   (CLEV-) CLEVELAND CLINIC FOUND.
PA   (USSH ) US NAT INST OF HEALTH.
XX
```

```
PI   Torrence PF,  Silverman RH,  Cirino NM,  Li G,  Xiao W,  Player MR;
XX
DR   WPI; 1999-326917/27.
XX
PT   New composition useful for inhibiting or treating infections against
PT   negative-strand RNA virus.
XX
PS   Disclosure; Page 20; 98pp; English.
XX
CC   The specification describes a composition comprising a polynucleotide
CC   consisting of an antisense oligonucleotide containing a hydroxy group,
CC   complementary to the genomic or antigenomic strand of a negative-strand
CC   RNA virus; and an activator of RNase L. The polynucleotide is used to
CC   inhibit, or treat, infection by negative-strand RNA viruses, specifically
CC   respiratory syncytial virus (RSV) but also (para)influenza, mumps, and
CC   rabies. The polynucleotide can cross cell membranes without requiring
CC   carriers or permeabilizing agents, and can selectively cleave the RNA
CC   targeted by the oligonucleotide. The present sequence represents an
CC   activator-antisense complex of the invention
XX
SQ   Sequence 19 BP; 6 A; 3 C; 1 G; 9 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1732 ATCAGAAGGTGACAAGTAC 1750
              || ||||  ||| ||||||
Db         19 ATAAGAATTTGATAAGTAC 1


RESULT 1026
AAX34643
ID   AAX34643 standard; DNA; 19 BP.
XX
AC   AAX34643;
XX
DT   05-JUL-1999  (first entry)
XX
DE   cDNA clone BED1 cloning degenerate primer NTS3'.
XX
KW   Starch biosynthetic pathway; cereal plant; enzyme; SBE; SSS; DBE; GBSS;
KW   starch branching enzyme; starch soluble synthase; debranching enzyme;
KW   endosperm; wheat; barley; granule-bound synthase; glutenin; starch;
KW   grain softness protein I; bacterial isoamylase; glycogen synthase;
KW   wSBE I-D4 gene; PCR primer; ss.
XX
OS   Synthetic.
OS   Aegilops tauschii.
XX
PN   WO9914314-A1.
XX
PD   25-MAR-1999.
XX
PF   11-SEP-1998;   98WO-AU000743.
XX
PR   12-SEP-1997;   97AU-00009108.
PR   20-MAR-1998;   98AU-00002509.
XX
PA   (CSIR ) COMMONWEALTH SCI & IND RES ORG.
PA   (AUSU ) UNIV AUSTRALIAN NAT.
PA   (GOOD-) GOODMAN FIELDER LTD.
PA   (LIMA-) GRP LIMAGRAIN PACIFIC PTY LTD.
XX
PI   Li Z,  Morell M,  Rahman S;
XX
DR   WPI; 1999-229525/19.
XX
PT   New isolated cereal plant enzyme genes used for, e.g. expression of
PT   antisense sequences of granule bound synthase.
XX
PS   Example 6; Page 26; 171pp; English.
XX
CC   The invention relates to a novel enzyme of starch biosynthetic pathway in
CC   a cereal plant, where the enzyme is selected from starch branching enzyme
CC   (SBE) I , SBE II, starch soluble synthase (SSS) I, and debranching enzyme
CC   (DBE), with the proviso that the enzyme is not SSS I of rice, or SBE I of
CC   rice or maize. The methods and products can be used for targeting
CC   expression specifically to the endosperm of the seeds of cereal plants
CC   such as wheat or barley. They can be used for the expression of e.g.
CC   antisense sequences of granule-bound synthase (GBSS), SBE II, low mol.
CC   wt. glutenin, grain softness protein I, bacterial isoamylase, bacterial
CC   glycogen synthase, and wheat high mol. wt. glutenin Bx17. They can be
CC   used for modifying the characteristics of starch produced by a plant.
CC   Primers AAX34642-45 are used for the cloning of the cDNA corresponding to
CC   the wSBE I-D4 gene
XX
SQ   Sequence 19 BP; 4 A; 6 C; 1 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1838 TACATTCCCTGGGCCAACA 1856
              |||||| ||| | ||| ||
Db          1 TACATTTCCTTGTCCATCA 19


RESULT 1027
AAA85836
ID   AAA85836 standard; DNA; 19 BP.
XX
AC   AAA85836;
XX
DT   04-DEC-2000  (first entry)
XX
DE   Cyclin B1 ribozyme binding site #165.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Disclosure; Page 98; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 19 BP; 4 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;
```

```
Qy       2038 AGGTTCTATCTGCTTAGCA 2056
              ||| || | |||||||||
Db          1 AGGAGCTTTTTGCTTAGCA 19
```

RESULT 1028
AAA83806
ID AAA83806 standard; DNA; 19 BP.
XX
AC AAA83806;
XX
DT 04-DEC-2000 (first entry)
XX
DE cdk-we-hu ribozyme binding site #281.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 67; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 9 A; 3 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1970 TTTACCTTGAAAAAAAGAA 1988
              || || || | ||||||||
Db          1 TTCACTTTTACAAAAAGAA 19
```

RESULT 1029
AAA83805
ID AAA83805 standard; DNA; 19 BP.
XX
AC AAA83805;
XX
DT 04-DEC-2000 (first entry)
XX
DE cdk-we-hu ribozyme binding site #280.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 67; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 9 A; 3 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1969 ATTTACCTTGAAAAAAAGA 1987
              ||| || || | |||||||
Db          1 ATTCACTTTTACAAAAAGA 19
```

RESULT 1030
AAZ74780/c
ID AAZ74780 standard; DNA; 19 BP.
XX
AC AAZ74780;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:9136.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.

```
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 2178; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 19 BP; 7 A; 2 C; 8 G; 2 T; 0 U; 0 Other;

  Query Match              2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1859 CCCACACACTTAGCCATTG 1877
                || ||  ||||| ||| |||
Db         19 CCTACTCACTTTGCCCTTG 1


RESULT 1031
AAZ74546/c
ID   AAZ74546 standard; DNA; 19 BP.
XX
AC   AAZ74546;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:8902.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 2128; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 19 BP; 10 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match              2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTTGTT 1693
                ||| |||||  |  ||||||
Db         19 CCTTGACTTATGTGTTGTT 1


RESULT 1032
AAA95932
ID   AAA95932 standard; DNA; 19 BP.
XX
AC   AAA95932;
XX
DT   02-FEB-2001  (first entry)
XX
DE   Human NES1 gene PCR primer NAS.
XX
KW   Human; KLK-L1; KLK-L2; KLK-L3; KLK-L4; KLK-L5; KLK-L6; NES1;
KW   normal epithelia cell-specific 1; kallikrein-like protein;
KW   serine protease; cytostatic; cancer; prostrate cancer; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200053776-A2.
XX
PD   14-SEP-2000.
XX
PF   09-MAR-2000; 2000WO-CA000258.
XX
PR   11-MAR-1999;   99US-0124260P.
PR   01-APR-1999;   99US-0127386P.
PR   21-JUL-1999;   99US-0144919P.
XX
PA   (MOUN ) MOUNT SINAI HOSPITAL.
XX
PI   Yousef GM,  Diamandis EP;
XX
DR   WPI; 2000-587440/55.
XX
PT   New kallikrein-like (KLK-L) proteins for diagnosing and treating KLK-L
PT   protein mediated disorders, especially cancer.
XX
PS   Example 4; Page 79; 184pp; English.
XX
CC   The present sequence is a PCR primer used for gene-specific amplification
CC   of the normal epithelia cell-specific 1 (NES1) gene. It was amplified as
CC   a control in a method for amplifying kallikrein genes. Kallikreins and
CC   kallikrein-like proteins are a subgroup of the serine protease enzyme
CC   family. They catalyse the selective cleavage of specific polypeptide
CC   precursors to release peptides with potent biological activity. Nucleic
CC   acids encoding kallikrein-like proteins KLK-L1, KLK-L2, KLK-L3, KLK-L4,
CC   KLK-L5 and KLK-L6 have been isolated. The proteins are useful in the
CC   treatment, monitoring and diagnosis of cancers, especially prostrate
CC   cancer. They can also be used to identify a substance that can associate
CC   with or mediate the biological activity of the proteins. Antibodies can
```

```
CC   be used to treat conditions mediated by the kallikrein-like proteins
XX
SQ   Sequence 19 BP; 1 A; 8 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1691 GTTTCTCTAGCGCTGAGCT 1709
              | ||| ||| ||||| |||
Db          1 GCTTCCCTACCGCTGTGCT 19


RESULT 1033
AAH27389/c
ID   AAH27389 standard; DNA; 19 BP.
XX
AC   AAH27389;
XX
DT   08-AUG-2001  (first entry)
XX
DE   PCR primer #58.
XX
KW   Tumour suppressor gene 16; TSG16; immune response modulator;
KW   inflammatory response modulator; signal transduction activator;
KW   cytokine inhibitor; gene therapy; anticancer; anti-inflammatory;
KW   autoimmune disorder; infection; chromosome 16q24.3; human;
KW   cellular proliferation suppressor; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200132861-A1.
XX
PD   10-MAY-2001.
XX
PF   30-OCT-2000; 2000WO-AU001329.
XX
PR   29-OCT-1999;   99AU-00003771.
XX
PA   (WOME-) WOMEN'S & CHILDREN'S HOSPITAL.
XX
PI   Callen DF,  Whitmore SA,  Kremmidiotis G,  Kochetkova M,  Crawford J;
XX
DR   WPI; 2001-316439/33.
XX
PT   New nucleic acid representing the human tumor suppressor gene TSG16,
PT   useful e.g. for diagnosis and treatment of tumors, inflammatory and
PT   immunological disorders.
XX
PS   Disclosure; Page 198; 215pp; English.
XX
CC   The present invention relates to human tumour suppressor gene 16 (TSG16;
CC   see AAH23688). TSG16 was isolated from chromosome 16q24.3. TSG16
CC   suppresses cellular proliferation. TSG16 is useful for treating disorders
CC   associated with decreased expression or activity of TSG16, e.g. cancers,
CC   (auto)immune disorders, inflammation, complications of wound healing and
CC   infections (by viruses, bacteria, fungi, parasites, protozoa or
CC   helminths). The present sequence is a PCR primer, which was used in the
CC   present invention
XX
SQ   Sequence 19 BP; 3 A; 3 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACAGAC 1591
              || |||||||| || || |
Db         19 CCATCTCCACCTCAGAGGC 1


RESULT 1034
AAS42887
ID   AAS42887 standard; DNA; 19 BP.
XX
AC   AAS42887;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human G Protein-Coupled Receptor (GPCR) PCR primer #21.
XX
KW   Human; G-protein coupled receptor; GPCR; mental disorder; schizophrenia;
KW   attention deficit disorder; anxiety; depression; bipolar disorder; ss;
KW   neurological disorder; Huntington's disease; dementia; obesity; anorexia;
KW   metabolic disorder; Parkinson's disease; Tourette's syndrome; thrombosis;
KW   type 2 diabetes; cardiovascular disorder; myocardial infarction; cancer;
KW   cardiomyopathy; atherosclerosis; human immunodeficiency virus; HIV;
KW   viral infection; immunostimulant; neuroleptic; nootropic; tranquiliser;
KW   antidepressant; anorectic; PCR primer; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200162797-A2.
XX
PD   30-AUG-2001.
XX
PF   23-FEB-2001; 2001WO-US005676.
XX
PR   23-FEB-2000; 2000US-0184247P.
PR   23-FEB-2000; 2000US-0184303P.
PR   23-FEB-2000; 2000US-0184304P.
PR   23-FEB-2000; 2000US-0184305P.
PR   23-FEB-2000; 2000US-0184397P.
PR   02-MAR-2000; 2000US-0186457P.
PR   03-MAR-2000; 2000US-0186810P.
PR   09-MAR-2000; 2000US-0188064P.
PR   13-MAR-2000; 2000US-0188880P.
PR   03-APR-2000; 2000US-0194344P.
PR   23-JUN-2000; 2000US-0213861P.
PR   11-JUL-2000; 2000US-0217369P.
PR   11-JUL-2000; 2000US-0217370P.
PR   14-JUL-2000; 2000US-0218337P.
PR   20-JUL-2000; 2000US-0218492P.
XX
PA   (PHAA ) PHARMACIA & UPJOHN CO.
XX
PI   Vogeli G,  Wood LS,  Parodi LA,  Lind P;
XX
DR   WPI; 2001-570628/64.
XX
PT   New isolated nucleic acid encoding a new G-protein coupled receptor
PT   polypeptide for detecting receptor modulators that can treat mental
PT   disorders, such as schizophrenia, anxiety, depression, or obesity.
XX
PS   Example 2; Page 109; 279pp; English.
XX
CC   Sequences AAS42806-AAS42926 represent cDNA molecules and PCR primers for
CC   cDNA molecules encoding human G-protein coupled receptor (GPCR)
CC   polypeptides. The protein and DNA sequences of the invention can be used
CC   to identify compounds which bind to GPCR polypeptides and in screening
CC   for compounds that modulate GPCR activity. By screening a human subject
CC   for the presence of mutations in GPCR DNA, a GPCR-related disorder or a
CC   genetic predisposition can be diagnosed. The sequences can also be used
CC   for treatment and prevention of mental disorders such as schizophrenia,
CC   attention deficit disorder, anxiety, depression, dementia and bipolar
CC   disorder, neurological disorders such as Huntington's disease,
CC   Parkinson's disease and Tourette's syndrome, metabolic disorders such as
CC   obesity, anorexia and type 2 diabetes, cardiovascular disorders such as
CC   thrombosis, myocardial infarction, cardiomyopathy and atherosclerosis,
CC   viral infections caused by HIV and cancers
XX
SQ   Sequence 19 BP; 2 A; 8 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;
```

```
Qy       1649 CCTTCACTGGTTCTGCATC 1667
              ||| |||| || || ||||
Db          1 CCTCCACTTGTGCTTCATC 19
```

RESULT 1035
AAH58968
ID AAH58968 standard; DNA; 19 BP.
XX
AC AAH58968;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cdk-we-hu ribozyme binding site SEQ ID NO:1392.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 173; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 9 A; 3 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1970 TTTACCTTGAAAAAAAGAA 1988
              || || || | ||||||||
Db          1 TTCACTTTTACAAAAAGAA 19
```

RESULT 1036
AAH60998
ID AAH60998 standard; DNA; 19 BP.
XX
AC AAH60998;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin B1 ribozyme binding site SEQ ID NO:3422.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 320; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 4 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

```
  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2038 AGGTTCTATCTGCTTAGCA 2056
              ||| || | |||||||||
Db          1 AGGAGCTTTTTGCTTAGCA 19


RESULT 1037
AAH58967
ID   AAH58967 standard; DNA; 19 BP.
XX
AC   AAH58967;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cdk-we-hu ribozyme binding site SEQ ID NO:1391.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;   99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Example 1; Page 173; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 9 A; 3 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAAGA 1987
              ||| || || | |||||||
Db          1 ATTCACTTTTACAAAAAGA 19


RESULT 1038
ABK41500
ID   ABK41500 standard; DNA; 19 BP.
XX
AC   ABK41500;
XX
DT   21-MAY-2002  (first entry)
XX
DE   Human CTNNA3 gene splice acceptor #14.
XX
KW   Human; alpha-catenin; ds; cytostatic; antiinfertility; CTNNA3;
KW   cadherin-catenin related pathway; heart testis; cancer; gene therapy;
KW   cadherin-catenin related disease; specifically dilated cardiomyopathy;
KW   cardiomyopathy; male infertility; splice donor; splice acceptor;
KW   alpha T-catenin.
XX
OS   Homo sapiens.
XX
PN   WO200204636-A1.
XX
PD   17-JAN-2002.
XX
PF   28-JUN-2001; 2001WO-EP007392.
XX
PR   12-JUL-2000; 2000EP-00202472.
PR   14-JUL-2000; 2000US-0218309P.
XX
PA   (VLAA-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI   Van Roy F,  Goossens S,  Janssens B,  Vanpoucke G;
XX
DR   WPI; 2002-171717/22.
XX
PT   New alpha catenin polypeptides and polynucleotides encoding them, useful
PT   for predicting, diagnosing or treating cadherin-catenin related diseases,
PT   particularly cardiomyopathies, cancer and male infertility.
XX
PS   Example; Page 34; 132pp; English.
XX
CC   The invention relates to human and mouse alpha-catenin polypeptides and
CC   their associated polynucleotides. The polypeptides and related antibodies
CC   are useful for modulating the cadherin-catenin related pathway in
CC   selected organs, such as the heart and testis. The nucleic acids and the
CC   antibodies are useful in the diagnosis and/or prediction of the
CC   likelihood of developing cadherin-catenin related diseases. The nucleic
CC   acids may also be used to predict the likelihood of developing cancer or
CC   in diagnosing cancer, and in gene therapy. The polypeptide, the nucleic
CC   acid or the antibody is useful in manufacturing a medicament for treating
CC   cadherin-catenin related diseases, such as cancer, cardiomyopathy,
CC   specifically dilated cardiomyopathy, and male infertility. Sequences
CC   ABK41474-ABK41509 represent splice donors and splice acceptors of the
CC   CTNNA3 gene which encodes human alpha T-catenin
XX
SQ   Sequence 19 BP; 4 A; 5 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCCCA 1789
              || ||||| | | ||||||
```

```
Db          1 TTCTTTTTATAGGACCCCA 19


RESULT 1039
AAF88975
ID   AAF88975 standard; DNA; 19 BP.
XX
AC   AAF88975;
XX
DT   20-JAN-2003  (first entry)
XX
DE   Human GSTPi Peptide nucleic acid blocking probe-associated primer #1.
XX
KW   Human; cytosine methylation; methylation status; CpG; infection; cancer;
KW   diagnosis; side-effect; cardiovascular disease; gastrointestinal disease;
KW   inflammation; cell differentiation; primer; GTSp1; ss.
XX
OS   Homo sapiens.
XX
PN   WO200272880-A2.
XX
PD   19-SEP-2002.
XX
PF   08-MAR-2002; 2002WO-EP002572.
XX
PR   09-MAR-2001; 2001DE-01012515.
PR   19-NOV-2001; 2001DE-01058283.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Olek A,  Berlin K;
XX
DR   WPI; 2002-723373/78.
XX
PT   Detecting methylation status of test DNA in a mixture, useful for
PT   diagnosis and prognosis of disease, comprises bisulfite treatment then
PT   selective amplification of test DNA.
XX
PS   Example 2; Page 39; 82pp; German.
XX
CC   This invention describes a novel method for detecting cytosine
CC   methylation in DNA samples by: (i) chemically treating a genomic sample
CC   to convert all non-methylated cytosines to uracil while leaving
CC   methylated cytosines unchanged; (ii) amplification with 2 primer
CC   oligonucleotides and a polymerase; and (iii) analysis of the amplicon and
CC   deducing the methylation status of test DNA. The method is used for
CC   determining the methylation status at different CpG positions, which is
CC   used for diagnosis and/or prognosis of a very wide range of disorders,
CC   e.g. side-effects of pharmaceuticals, cancer, cardiovascular or
CC   gastrointestinal diseases, infections, inflammation, etc. The method is
CC   also useful for differentiating between cell and tissue types and for
CC   investigating cell differentiation. The method: (i) provides a
CC   quantitative indication of the different methylated positions, and thus a
CC   very accurate classification; and (ii) eliminates interference from
CC   background DNA, making it suitable for analysis of serum or body fluids
CC   (which contain background DNA in large excess). This sequence represents
CC   a primer used in the detection of cytosine methylation in the human GSTp1
CC   gene (glutathione-S-transferase p1) described in the disclosure of the
CC   invention
XX
SQ   Sequence 19 BP; 7 A; 0 C; 8 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2026 GGTAGGAGGCAAAGGTTCT 2044
              || | |||| ||||||| |
Db          1 GGAAAGAGGGAAAGGTTTT 19


RESULT 1040
ABL45146
ID   ABL45146 standard; DNA; 19 BP.
XX
AC   ABL45146;
XX
DT   11-APR-2002  (first entry)
XX
DE   Human chromosome 1p36-35 PCR primer SEQ ID NO:2190.
XX
KW   Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP2001321190-A.
XX
PD   20-NOV-2001.
XX
PF   12-MAR-2001; 2001JP-00068285.
XX
PR   10-MAR-2000; 2000JP-00066716.
XX
PA   (RIKA ) RIKAGAKU KENKYUSHO.
PA   (GENO-) GENOTEX YG.
XX
DR   WPI; 2002-144136/19.
XX
PT   Arraying genome clones.
XX
PS   Claim 4; Page 48; 528pp; Japanese.
XX
CC   The present invention describes a method of arraying genome clones. The
CC   method comprises: (a) clones of the genomic libraries contained in
CC   multiwell plates numbered for discrimination are mixed in each of the
CC   multiwell plates; (b) a primer designed based on the chromosome marker
CC   sequence is added to the mixture to carry out an amplification reaction;
CC   (c) a signal corresponding to the marker is detected from the resultant
CC   amplified product to specify the discrimination Nos. of the multiwell
CC   plates containing the clones having said marker sequence; (d) the order
CC   of the markers is changed so that the same discrimination Nos. succeed to
CC   the maximum in the specified discrimination Nos. to array the multiwell
CC   plates; (e) the clones in the multiwell plates of the specified
CC   discrimination Nos. are mixed respectively in each wells of longitudinal
CC   and lateral directions; (f) the mixed clones are cultured and the
CC   resultant cultures are amplified by using the above primer; (g) signals
CC   are detected from the amplified products; (h) the clones in the multiwell
CC   plates are specified from the detected result; and (i) the clones are
CC   reconstituted as the positions on the chromosome and arrayed. The
CC   microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC   PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC   represent PCR primers for human chromosome 21q22.1, which are
CC   specifically claimed for use in the present invention
XX
SQ   Sequence 19 BP; 9 A; 4 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1556 AACAGGACTGCAAAAATCC 1574
              |||||||  ||||||  ||
Db          1 AACAGGAAGGCAAAATGCC 19


RESULT 1041
ABX72477
ID   ABX72477 standard; DNA; 19 BP.
XX
AC   ABX72477;
XX
DT   03-JUN-2003  (first entry)
XX
DE   Human NOVX DNA PCR primer #135.
XX
```

KW Human; NOVX; PCR; ss; metabolic disorder; cardiomyopathy; diabetes; ASD;
KW hypertension; congenital heart defect; aortic stenosis; valve disease;
KW atrial septal defect; atrioventricular canal defect; ductus arteriosus;
KW pulmonary stenosis; subaortic stenosis; ventricular septal defect; VSD;
KW tuberous sclerosis; scleroderma; atherosclerosis; infectious disease;
KW obesity; anorexia; neurodegenerative disorder; Alzheimer's disease;
KW Parkinson's disease; immune disorder; haematopoietic disorder; primer;
KW haemophilia; hypercoagulation; Crohn's disease; cancer.
XX
OS Homo sapiens.
XX
PN WO200281498-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010780.
XX
PR 03-APR-2001; 2001US-0281086P.
PR 03-APR-2001; 2001US-0281136P.
PR 05-APR-2001; 2001US-0281863P.
PR 05-APR-2001; 2001US-0281906P.
PR 06-APR-2001; 2001US-0282020P.
PR 10-APR-2001; 2001US-0282930P.
PR 10-APR-2001; 2001US-0282934P.
PR 12-APR-2001; 2001US-0283512P.
PR 13-APR-2001; 2001US-0283710P.
PR 17-APR-2001; 2001US-0284234P.
PR 19-APR-2001; 2001US-0285325P.
PR 20-APR-2001; 2001US-0285381P.
PR 20-APR-2001; 2001US-0285609P.
PR 23-APR-2001; 2001US-0285748P.
PR 23-APR-2001; 2001US-0285890P.
PR 24-APR-2001; 2001US-0286068P.
PR 25-APR-2001; 2001US-0286292P.
PR 27-APR-2001; 2001US-0287213P.
PR 02-MAY-2001; 2001US-0288257P.
PR 29-MAY-2001; 2001US-0294164P.
PR 30-MAY-2001; 2001US-0294484P.
PR 18-JUN-2001; 2001US-0298952P.
PR 19-JUN-2001; 2001US-0299237P.
PR 19-JUN-2001; 2001US-0299276P.
PR 12-SEP-2001; 2001US-0318750P.
PR 25-SEP-2001; 2001US-0324800P.
PR 25-SEP-2001; 2001US-0324802P.
PR 27-SEP-2001; 2001US-0325684P.
PR 17-OCT-2001; 2001US-0330143P.
PR 14-NOV-2001; 2001US-0332131P.
PR 14-NOV-2001; 2001US-0332240P.
PR 14-NOV-2001; 2001US-0332779P.
PR 21-NOV-2001; 2001US-0332115P.
PR 04-DEC-2001; 2001US-0337621P.
PR 03-JAN-2002; 2002US-0345783P.
PR 16-JAN-2002; 2002US-0350251P.
PR 02-APR-2002; 2002US-00114270.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Guo X, Kekuda R, Miller CE, Malyankar UM, Spytek KA;
PI Patturajan M, Liu X, Gusev VY, Li L, Vernet CAM, Zerhusen BD;
PI Gorman L, Shenoy SG, Pena CEA, Smithson G, Burgess CE, Gerlach V;
PI Padigaru M, Shimkets RA, Gangolli EA, Taupier RJ, Casman SJ, Ji W;
PI Anderson DW, Leite MW, Rastelli L, Edinger SR, Stone DJ;
PI Macdougall JR, Rothenberg ME, Mazur A, Millet I, Peyman JA;
PI Ellerman K;
XX
DR WPI; 2003-046858/04.
XX
PT New isolated NOVX polypeptide useful for treating atherosclerosis,
PT metabolic disorders, diabetes, obesity, infectious disease, anorexia,
PT neurodegenerative disorders, Alzheimer's disease and cancer.
XX
PS Example 83; Page 566; 666pp; English.
XX
CC The invention relates to human polypeptides, termed NOVX, and the
CC polynucleotides encoding them. The polypeptides and polynucleotides are
CC useful for diagnosing disease, and screening for potential therapeutic
CC agents. The sequences are useful for treating metabolic disorders,
CC cardiomyopathy, diabetes, hypertension, congenital heart defects, aortic
CC stenosis, atrial septal defect (ASD), atrioventricular canal defect,
CC ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular
CC septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma,
CC atherosclerosis, obesity, infectious disease, anorexia, neurodegenerative
CC disorders, Alzheimer's disease, Parkinson's disease, immune disorders,
CC haematopoietic disorders, haemophilia, hypercoagulation, Crohn's disease
CC and cancer. This sequence represents a PCR primer used to amplify a human
CC NOVX polynucleotide of the invention
XX
SQ Sequence 19 BP; 6 A; 9 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1846 CTGGGCCAACAGACCCACA 1864
|||| || ||| || ||||
Db 1 CTGGACCCACACACTCACA 19

RESULT 1042
ADE65586/c
ID ADE65586 standard; RNA; 19 BP.
XX
AC ADE65586;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human c-fos transcript target sequence/siNA upper strand, SEQ ID NO:41.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW central nervous system disorder; Alzheimer's disease;
KW Parkinson's disease; Huntington's disease; epilepsy; dementia;
KW amyotrophic lateral sclerosis; cancer; proliferative disease; restenosis;
KW polycystic kidney disease; inflammatory disease; allergic disease;
KW viral infection; HIV infection; autoimmune disease; transplant rejection;
KW vasotropic; nootropic; antiparkinsonian; neuroprotective; cytostatic;
KW antiinflammatory; antiallergic; virucide; anti-HIV; immunosuppressive;
KW anticonvulsant; nephrotropic; human; c-fos; target sequence; ss.
XX
OS Homo sapiens.
XX
PN WO2003070914-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005162.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L;
XX
DR WPI; 2003-679877/64.
XX
PT New short interfering nucleic acid downregulates expression of the c-fos
PT gene useful for treatment and diagnosis of diseases, e.g. cancer and

PT inflammation.
XX
PS Example 3; SEQ ID NO 41; 145pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human c-fos gene by RNA interference. The
CC siNAs may or may not comprise ribonucleotides and may be double or single
CC stranded. They further comprise sense and antisense regions, or
CC alternatively are assembled from a sense oligonucleotide and an antisense
CC oligonucleotide. Specifically, the siNAs include short interfering RNA
CC (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA
CC (shRNA). The siNAs can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNAs are used to modulate
CC expression of the c-fos gene in cells, tissue explants or organisms
CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC treatment of a variety of conditions. They may be used for treating
CC central nervous system lesions and injuries (e.g., Alzheimer's disease,
CC Parkinson's disease, Huntington's disease, epilepsy, dementia or
CC amyotrophic lateral sclerosis); various cancers; other proliferative
CC diseases (e.g., restenosis and polycystic kidney disease); inflammatory
CC and/or allergic diseases; viral infections (including HIV infection);
CC autoimmune diseases; and transplant rejection. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human c-fos-
CC targeted double-stranded siNA, which is identical to the c-fos transcript
CC target sequence.
XX
SQ Sequence 19 BP; 10 A; 2 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1781 TGAACCCCATTCTTTCCTT 1799
              ||||| | | | |||||||
Db         19 TGAACTCTAGTTTTTCCTT 1
```

RESULT 1043
ADE65702
ID ADE65702 standard; RNA; 19 BP.
XX
AC ADE65702;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human c-fos siNA lower strand, SEQ ID NO:157.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW central nervous system disorder; Alzheimer's disease;
KW Parkinson's disease; Huntington's disease; epilepsy; dementia;
KW amyotrophic lateral sclerosis; cancer; proliferative disease; restenosis;
KW polycystic kidney disease; inflammatory disease; allergic disease;
KW viral infection; HIV infection; autoimmune disease; transplant rejection;
KW vasotropic; nootropic; antiparkinsonian; neuroprotective; cytostatic;
KW antiinflammatory; antiallergic; virucide; anti-HIV; immunosuppressive;
KW anticonvulsant; nephrotropic; human; c-fos; ss.
XX
OS Homo sapiens.
XX
PN WO2003070914-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005162.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Mcswiggen J, Beigelman L;
XX
DR WPI; 2003-679877/64.
XX
PT New short interfering nucleic acid downregulates expression of the c-fos
PT gene useful for treatment and diagnosis of diseases, e.g. cancer and
PT inflammation.
XX
PS Example 3; SEQ ID NO 157; 145pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human c-fos gene by RNA interference. The
CC siNAs may or may not comprise ribonucleotides and may be double or single
CC stranded. They further comprise sense and antisense regions, or
CC alternatively are assembled from a sense oligonucleotide and an antisense
CC oligonucleotide. Specifically, the siNAs include short interfering RNA
CC (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA
CC (shRNA). The siNAs can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNAs are used to modulate
CC expression of the c-fos gene in cells, tissue explants or organisms
CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC treatment of a variety of conditions. They may be used for treating
CC central nervous system lesions and injuries (e.g., Alzheimer's disease,
CC Parkinson's disease, Huntington's disease, epilepsy, dementia or
CC amyotrophic lateral sclerosis); various cancers; other proliferative
CC diseases (e.g., restenosis and polycystic kidney disease); inflammatory
CC and/or allergic diseases; viral infections (including HIV infection);
CC autoimmune diseases; and transplant rejection. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human c-fos-
CC targeted double-stranded siNA.
XX
SQ Sequence 19 BP; 3 A; 4 C; 2 G; 0 T; 10 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 42.1%; Pred. No. 5.6e+02;
Matches 8; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

```
Qy       1781 TGAACCCCATTCTTTCCTT 1799
              :|||| | | : :::||::
Db          1 UGAACUCUAGUUUUUCCUU 19
```

RESULT 1044
ADE06873/c
ID ADE06873 standard; DNA; 19 BP.
XX
AC ADE06873;
XX
DT 29-JAN-2004 (first entry)
XX
DE Cancer-related allelic imbalance detection primer #96.
XX
KW in vitro detection; cancer; tumor cell; allelic imbalance;
KW chromosome marker; quantitative multiplex amplification; bladder tumor;
KW urine; blood; primer; ss; chromosome 2q; chromosome 3p; chromosome 4p;

```
KW   chromosome 4q; chromosome 5q; chromosome 6q; chromosome 8p;
KW   chromosome 9p; chromosome 9q; chromosome 10q; chromosome 11q;
KW   chromosome 11p; chromosome 13q; chromosome 14q; chromosome 16q;
KW   chromosome 17p; chromosome 18q.
XX
OS   Homo sapiens.
XX
PN   WO2003072823-A2.
XX
PD   04-SEP-2003.
XX
PF   25-FEB-2003; 2003WO-FR000609.
XX
PR   25-FEB-2002; 2002FR-00002380.
XX
PA   (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI   Grandchamp B,  Mentre F;
XX
DR   WPI; 2003-697769/66.
XX
PT   In vitro detection of tumor cells, in a biological sample, uses a
PT   highlight of allelic imbalance in insertion-deletion chromosome markers.
XX
PS   Claim 15; SEQ ID NO 96; 51pp; French.
XX
CC   The invention relates to a method of in vitro detection of cancer tumor
CC   cells, in a biological sample, where allelic imbalances are highlighted
CC   in insertion-deletion chromosome markers. The markers are given a
CC   quantitative multiplex amplification by polymerase chain reaction (PCR),
CC   triggered by heat. A calculation is made of a global statistical score
CC   for all the markers being studied, for comparison with a fixed normal
CC   threshold. The technique is especially for the detection of bladder tumor
CC   cells in a urine sample, using a blood sample as the reference. The non-
CC   invasive method gives evidence of an allelic imbalance with at least 15
CC   chromosome insertion-deletion markers and preferably 18, or at least 30
CC   or at least 40 markers. This sequence represents a primer used in the
CC   method of the invention.
XX
SQ   Sequence 19 BP; 3 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCTCCTG 1606
              | |||||  || |||||||
Db         19 AAACTGGCCACACCTCCTG 1

RESULT 1045
ADE29480/c
ID   ADE29480 standard; RNA; 19 BP.
XX
AC   ADE29480;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:102.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition;
KW   mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW   cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW   immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW   antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW   inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW   psoriasis; inflammatory bowel disease; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
XX
OS   Synthetic.
XX
PN   WO2003072590-A1.
XX
PD   04-SEP-2003.
XX
PF   28-JAN-2003; 2003WO-US002510.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N,  Haeberli P,  Chowrira B;
XX
DR   WPI; 2003-689980/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of mitogen-activated
PT   protein kinase genes.
XX
PS   Example 3; SEQ ID NO 102; 164pp; English.
XX
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of a mitogen-activated protein kinase
CC   (MAPK) genes by RNA interference. Also described: (1) a method for
CC   modulating expression of MAPK genes in cells, tissue explants or
CC   organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC   vectors that express siNA and cells containing these vectors. MAPK siNAs
CC   have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC   antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC   antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC   siNAs can be used to modulate the expression of MAPK genes, in cells,
CC   tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC   and II; a wide range of tumours, and inflammatory diseases (asthma,
CC   septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC   disease). They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents a MAPK siNA which is used
CC   in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 4 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGAG 1620
              |||||  |||||| || ||
Db         19 TCCTGCTCTGGGGAAACAG 1

RESULT 1046
ADE29643
ID   ADE29643 standard; RNA; 19 BP.
XX
AC   ADE29643;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:265.
XX
KW   short interfering nucleic acid; siNA; downregulation; inhibition;
KW   mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
KW   cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
KW   immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW   antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW   inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW   psoriasis; inflammatory bowel disease; drug screening;
KW   genetic engineering; pharmacogenomic; gene mapping; ss.
```

```
XX
OS   Synthetic.
XX
PN   WO2003072590-A1.
XX
PD   04-SEP-2003.
XX
PF   28-JAN-2003; 2003WO-US002510.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N,  Haeberli P,  Chowrira B;
XX
DR   WPI; 2003-689980/65.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer, downregulates expression of mitogen-activated
PT   protein kinase genes.
XX
PS   Example 3; SEQ ID NO 265; 164pp; English.
XX
CC   The present invention describes a short interfering nucleic acid (siNA)
CC   that downregulates expression of a mitogen-activated protein kinase
CC   (MAPK) genes by RNA interference. Also described: (1) a method for
CC   modulating expression of MAPK genes in cells, tissue explants or
CC   organisms by introduction of siNA; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
CC   vectors that express siNA and cells containing these vectors. MAPK siNAs
CC   have cytostatic, anorectic, antidiabetic, antiinflammatory,
CC   antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
CC   antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
CC   siNAs can be used to modulate the expression of MAPK genes, in cells,
CC   tissue explants or organisms, e.g. for treating obesity; diabetes types I
CC   and II; a wide range of tumours, and inflammatory diseases (asthma,
CC   septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC   disease). They can also be used for drug screening; diagnosis; target
CC   identification and validation; genetic engineering; pharmacogenomics;
CC   studying gene function and gene mapping (e.g. of single-nucleotide
CC   polymorphisms). The present sequence represents a MAPK siNA which is used
CC   in the exemplification of the present invention.
XX
SQ   Sequence 19 BP; 4 A; 5 C; 6 G; 0 T; 4 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.6e+02;
  Matches   12;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGAG 1620
              :||:|  |:|||| || ||
Db          1 UCCUGCUCUGGGGAAACAG 19


RESULT 1047
ADF37136
ID   ADF37136 standard; RNA; 19 BP.
XX
AC   ADF37136;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1425.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1425; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 11 A; 4 C; 2 G; 0 T; 2 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 5.6e+02;
  Matches   14;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1551 GAAGGAACAGGACTGCAAA 1569
              ||| |||||  ||: ||||
Db          1 GAAAGAACAACACUUCAAA 19


RESULT 1048
ADF36812/c
ID   ADF36812 standard; RNA; 19 BP.
```

```
XX
AC   ADF36812;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1101.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1101; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 2 A; 2 C; 4 G; 0 T; 11 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1551 GAAGGAACAGGACTGCAAA 1569
              ||| ||||| ||| ||||
Db         19 GAAAGAACAACACTTCAAA 1


RESULT 1049
ADF71282
ID   ADF71282 standard; RNA; 19 BP.
XX
AC   ADF71282;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID No 67.
XX
KW   short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070886-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004347.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697606/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer , downregulates expression of a protein tyrosine
PT   phosphatase type IVa gene.
XX
PS   Example 3; SEQ ID NO 67; 131pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of a protein tyrosine phosphatase type IV
CC   (PRL3) gene by RNA interference. The invention further relates to
CC   modulating the expression of PRL3 genes in cells, tissue explants or
CC   organisms by the introduction of an siNA; kits for in vitro or in vivo
CC   delivery of an siNA; conjugates and/or complexes of siNA; and vectors
CC   that express siNA. The novel siNA's of the invention have cytostatic
CC   activity. siNA's are used to modulate expression of PRL3 genes, in cells,
CC   tissue explants or organisms, e.g. for treating cancer but also for drug
CC   screening; diagnosis; target identification and validation; genetic
CC   engineering; pharmacogenomics; studying gene function and gene mapping
CC   (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC   represents a short interfering nucleic acid for downregulating the
CC   expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC   invention.
XX
SQ   Sequence 19 BP; 4 A; 1 C; 6 G; 0 T; 8 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   52.6%;  Pred. No. 5.6e+02;
  Matches   10;  Conservative    5;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGTTAC 1628
              :||||| | | :::|: ||
```

```
Db          1 UGGGGGUAUAUUUUGUAAC 19


RESULT 1050
ADF71356/c
ID   ADF71356 standard; RNA; 19 BP.
XX
AC   ADF71356;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID No 141.
XX
KW   short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070886-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004347.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697606/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer , downregulates expression of a protein tyrosine
PT   phosphatase type IVa gene.
XX
PS   Example 3; SEQ ID NO 141; 131pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of a protein tyrosine phosphatase type IV
CC   (PRL3) gene by RNA interference. The invention further relates to
CC   modulating the expression of PRL3 genes in cells, tissue explants or
CC   organisms by the introduction of an siNA; kits for in vitro or in vivo
CC   delivery of an siNA; conjugates and/or complexes of siNA; and vectors
CC   that express siNA. The novel siNA's of the invention have cytostatic
CC   activity. siNA's are used to modulate expression of PRL3 genes, in cells,
CC   tissue explants or organisms, e.g. for treating cancer but also for drug
CC   screening; diagnosis; target identification and validation; genetic
CC   engineering; pharmacogenomics; studying gene function and gene mapping
CC   (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC   represents a short interfering nucleic acid for downregulating the
CC   expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC   invention.
XX
SQ   Sequence 19 BP; 8 A; 6 C; 1 G; 0 T; 4 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGTTAC 1628
              |||||| | | ||||| ||
Db         19 TGGGGGTATATTTTGTAAC 1


RESULT 1051
ADF92637/c
ID   ADF92637 standard; RNA; 19 BP.
XX
AC   ADF92637;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human CHK-1 transcript target sequence/siNA upper strand, SEQ ID 107.
XX
KW   Human; Checkpoint Kinase-1; CHK-1; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy; cancer;
KW   restenosis; drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; cytostatic;
KW   vasotropic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070888-A2.
XX
PD   28-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-US004448.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   05-AUG-2002; 2002US-0401093P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-679873/64.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer and restenosis, downregulates expression of a
PT   checkpoint kinase gene.
XX
PS   Example 7; Page 115; 135pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human Checkpoint Kinase-1 (CHK-1) gene by
CC   RNA interference. The siNAs may or may not comprise ribonucleotides and
CC   may be double or single stranded. They further comprise sense and
CC   antisense regions, or alternatively are assembled from a sense
CC   oligonucleotide and an antisense oligonucleotide. Specifically, the siNAs
CC   include short interfering RNA (siRNA), double-stranded RNA, micro-RNA
CC   (miRNA) and short hairpin RNA (shRNA). The siNAs can be unmodified or
CC   chemically modified, can contain deoxyribonucleotides, and can be
CC   chemically synthesised, expressed from a vector or enzymatically
CC   synthesised. The invention also relates to kits for the in vitro or in
CC   vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors
CC   that express siNA. The siNAs are used to modulate expression of the CHK-1
CC   gene in cells, tissue explants or organisms (e.g., by ex vivo gene
CC   therapy), or in grafts and transplants for the treatment of a variety of
CC   conditions. They may be used for treating cancer and restenosis. The
CC   siNAs are also useful for drug screening, diagnosis, therapeutic target
CC   identification and validation, genetic engineering, pharmacogenomics,
CC   studying gene function, and gene mapping (e.g., of single nucleotide
CC   polymorphisms). The present sequence represents the upper strand of a
CC   human CHK-1-targeted double stranded siNA, which is identical to the CHK-
CC   1 transcript target sequence.
XX
SQ   Sequence 19 BP; 5 A; 5 C; 1 G; 0 T; 8 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;
```

```
Qy       1979 AAAAAAAGAAAAGTGTGTA 1997
              ||||  ||| | |||||||
Db         19 AAAATGAGATACGTGTGTA 1

RESULT 1052
ADF92749
ID   ADF92749 standard; RNA; 19 BP.
XX
AC   ADF92749;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human CHK-1 siNA lower strand, SEQ ID 219.
XX
KW   Human; Checkpoint Kinase-1; CHK-1; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy; cancer;
KW   restenosis; drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; cytostatic;
KW   vasotropic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070888-A2.
XX
PD   28-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-US004448.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   05-AUG-2002; 2002US-0401093P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J, . Beigelman L;
XX
DR   WPI; 2003-679873/64.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer and restenosis, downregulates expression of a
PT   checkpoint kinase gene.
XX
PS   Example 7; Page 115; 135pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human Checkpoint Kinase-1 (CHK-1) gene by
CC   RNA interference. The siNAs may or may not comprise ribonucleotides and
CC   may be double or single stranded. They further comprise sense and
CC   antisense regions, or alternatively are assembled from a sense
CC   oligonucleotide and an antisense oligonucleotide. Specifically, the siNAs
CC   include short interfering RNA (siRNA), double-stranded RNA, micro-RNA
CC   (miRNA) and short hairpin RNA (shRNA). The siNAs can be unmodified or
CC   chemically modified, can contain deoxyribonucleotides, and can be
CC   chemically synthesised, expressed from a vector or enzymatically
CC   synthesised. The invention also relates to kits for the in vitro or in
CC   vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors
CC   that express siNA. The siNAs are used to modulate expression of the CHK-1
CC   gene in cells, tissue explants or organisms (e.g., by ex vivo gene
CC   therapy), or in grafts and transplants for the treatment of a variety of
CC   conditions. They may be used for treating cancer and restenosis. The
CC   siNAs are also useful for drug screening, diagnosis, therapeutic target
CC   identification and validation, genetic engineering, pharmacogenomics,
CC   studying gene function, and gene mapping (e.g., of single nucleotide
CC   polymorphisms). The present sequence represents the lower strand of a
CC   human CHK-1-targeted double stranded siNA.
XX
SQ   Sequence 19 BP; 8 A; 1 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match          2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.6e+02;
  Matches   12;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTGTA 1997
              ||||  ||| | |:|:|:|
Db          1 AAAAUGAGAUACGUGUGUA 19

RESULT 1053
ADG34976/c
ID   ADG34976 standard; RNA; 19 BP.
XX
AC   ADG34976;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human TNF receptor siNA oligonucleotide SEQ ID NO:328.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping;
KW   tumour necrosis factor receptor; TNF receptor; human; DNA-RNA hybrid; ss;
KW   antibacterial; immunosuppressive; antirheumatic; antiarthritic; anti-HIV;
KW   antipsoriatic; antiinflammatory; septic shock; rheumatoid arthritis;
KW   HIV/AIDS; psoriasis; inflammation; autoimmune disease.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070897-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US004741.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   28-NOV-2002; 2002US-0429359P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-697609/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of septic shock or rheumatoid arthritis, downregulates
PT   expression of the tumor necrosis factor gene.
XX
PS   Example 3; SEQ ID NO 328; 141pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human tumour necrosis factor (TNF)
CC   receptor gene by RNA interference. The siNAs may or may not comprise
CC   ribonucleotides and may be double or single stranded. They further
CC   comprise sense and antisense regions, or alternatively are assembled from
CC   a sense oligonucleotide and an antisense oligonucleotide. Specifically,
CC   the siNAs include short interfering RNA (siRNA), double-stranded RNA,
CC   micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be
CC   unmodified or chemically modified, can contain deoxyribonucleotides, and
CC   can be chemically synthesised, expressed from a vector or enzymatically
CC   synthesised. The invention also relates to kits for the in vitro or in
```

CC vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors
CC that express siNA. The siNAs are used to modulate expression of the TNF
CC receptor gene in cells, tissue explants or organisms (e.g., by ex vivo
CC gene therapy), or in grafts and transplants for the treatment of a
CC variety of conditions. The TNF receptor siNAs have antibacterial,
CC immunosuppressive, antirheumatic, antiarthritic, anti-HIV, antipsoriatic
CC and antiinflammatory activities. They may be used for treating septic
CC shock, rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and
CC autoimmune diseases. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the lower strand of a human TNF receptor-targeted double-
CC stranded siNA.
XX
SQ Sequence 19 BP; 2 A; 8 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1549 GGGAAGGAACAGGACTGCA 1567
||| |||| |||||||
Db 19 GGGCAGGATACGGACTGCA 1

RESULT 1054
ADG34853
ID ADG34853 standard; RNA; 19 BP.
XX
AC ADG34853;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TNF receptor siNA oligonucleotide SEQ ID NO:205.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW tumour necrosis factor receptor; TNF receptor; human; DNA-RNA hybrid; ss;
KW antibacterial; immunosuppressive; antirheumatic; antiarthritic; anti-HIV;
KW antipsoriatic; antiinflammatory; septic shock; rheumatoid arthritis;
KW HIV/AIDS; psoriasis; inflammation; autoimmune disease; target sequence.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070897-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US004741.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 28-NOV-2002; 2002US-0429359P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
DR WPI; 2003-697609/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of septic shock or rheumatoid arthritis, downregulates
PT expression of the tumor necrosis factor gene.
XX
PS Example 3; SEQ ID NO 205; 141pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human tumour necrosis factor (TNF)
CC receptor gene by RNA interference. The siNAs may or may not comprise
CC ribonucleotides and may be double or single stranded. They further
CC comprise sense and antisense regions, or alternatively are assembled from
CC a sense oligonucleotide and an antisense oligonucleotide. Specifically,
CC the siNAs include short interfering RNA (siRNA), double-stranded RNA,
CC micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be
CC unmodified or chemically modified, can contain deoxyribonucleotides, and
CC can be chemically synthesised, expressed from a vector or enzymatically
CC synthesised. The invention also relates to kits for the in vitro or in
CC vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors
CC that express siNA. The siNAs are used to modulate expression of the TNF
CC receptor gene in cells, tissue explants or organisms (e.g., by ex vivo
CC gene therapy), or in grafts and transplants for the treatment of a
CC variety of conditions. The TNF receptor siNAs have antibacterial,
CC immunosuppressive, antirheumatic, antiarthritic, anti-HIV, antipsoriatic
CC and antiinflammatory activities. They may be used for treating septic
CC shock, rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and
CC autoimmune diseases. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the upper strand of a human TNF receptor-targeted double-
CC stranded siNA, which is identical to the TNF receptor transcript target
CC sequence.
XX
SQ Sequence 19 BP; 5 A; 4 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 5.6e+02;
Matches 14; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1549 GGGAAGGAACAGGACTGCA 1567
||| |||| ||||:|||
Db 1 GGGCAGGAUACGGACUGCA 19

RESULT 1055
ADG35062
ID ADG35062 standard; RNA; 19 BP.
XX
AC ADG35062;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TNF receptor siNA oligonucleotide SEQ ID NO:414.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW tumour necrosis factor receptor; TNF receptor; human; DNA-RNA hybrid; ss;
KW antibacterial; immunosuppressive; antirheumatic; antiarthritic; anti-HIV;
KW antipsoriatic; antiinflammatory; septic shock; rheumatoid arthritis;
KW HIV/AIDS; psoriasis; inflammation; autoimmune disease.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070897-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US004741.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.

PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 28-NOV-2002; 2002US-0429359P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
DR WPI; 2003-697609/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of septic shock or rheumatoid arthritis, downregulates
PT expression of the tumor necrosis factor gene.
XX
PS Example 3; SEQ ID NO 414; 141pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human tumour necrosis factor (TNF)
CC receptor gene by RNA interference. The siNAs may or may not comprise
CC ribonucleotides and may be double or single stranded. They further
CC comprise sense and antisense regions, or alternatively are assembled from
CC a sense oligonucleotide and an antisense oligonucleotide. Specifically,
CC the siNAs include short interfering RNA (siRNA), double-stranded RNA,
CC micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be
CC unmodified or chemically modified, can contain deoxyribonucleotides, and
CC can be chemically synthesised, expressed from a vector or enzymatically
CC synthesised. The invention also relates to kits for the in vitro or in
CC vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors
CC that express siNA. The siNAs are used to modulate expression of the TNF
CC receptor gene in cells, tissue explants or organisms (e.g., by ex vivo
CC gene therapy), or in grafts and transplants for the treatment of a
CC variety of conditions. The TNF receptor siNAs have antibacterial,
CC immunosuppressive, antirheumatic, antiarthritic, anti-HIV, antipsoriatic
CC and antiinflammatory activities. They may be used for treating septic
CC shock, rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and
CC autoimmune diseases. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the lower strand of a human TNF receptor-targeted double-
CC stranded siNA.
XX
SQ Sequence 19 BP; 6 A; 4 C; 8 G; 0 T; 1 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 5.6e+02;
Matches 14; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1551 GAAGGAACAGGACTGCAAA 1569
|| || |||||| :|| ||
Db 1 GAGGGCACAGGAGUGCCAA 19

RESULT 1056
ADG34939/c
ID ADG34939 standard; RNA; 19 BP.
XX
AC ADG34939;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TNF receptor siNA oligonucleotide SEQ ID NO:291.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW tumour necrosis factor receptor; TNF receptor; human; DNA-RNA hybrid; ss;
KW antibacterial; immunosuppressive; antirheumatic; antiarthritic; anti-HIV;
KW antipsoriatic; antiinflammatory; septic shock; rheumatoid arthritis;
KW HIV/AIDS; psoriasis; inflammation; autoimmune disease; target sequence.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003070897-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US004741.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 28-NOV-2002; 2002US-0429359P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
DR WPI; 2003-697609/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of septic shock or rheumatoid arthritis, downregulates
PT expression of the tumor necrosis factor gene.
XX
PS Example 3; SEQ ID NO 291; 141pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human tumour necrosis factor (TNF)
CC receptor gene by RNA interference. The siNAs may or may not comprise
CC ribonucleotides and may be double or single stranded. They further
CC comprise sense and antisense regions, or alternatively are assembled from
CC a sense oligonucleotide and an antisense oligonucleotide. Specifically,
CC the siNAs include short interfering RNA (siRNA), double-stranded RNA,
CC micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be
CC unmodified or chemically modified, can contain deoxyribonucleotides, and
CC can be chemically synthesised, expressed from a vector or enzymatically
CC synthesised. The invention also relates to kits for the in vitro or in
CC vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors
CC that express siNA. The siNAs are used to modulate expression of the TNF
CC receptor gene in cells, tissue explants or organisms (e.g., by ex vivo
CC gene therapy), or in grafts and transplants for the treatment of a
CC variety of conditions. The TNF receptor siNAs have antibacterial,
CC immunosuppressive, antirheumatic, antiarthritic, anti-HIV, antipsoriatic
CC and antiinflammatory activities. They may be used for treating septic
CC shock, rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and
CC autoimmune diseases. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the upper strand of a human TNF receptor-targeted double-
CC stranded siNA, which is identical to the TNF receptor transcript target
CC sequence.
XX
SQ Sequence 19 BP; 1 A; 8 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1551 GAAGGAACAGGACTGCAAA 1569
|| || |||||| ||| ||
Db 19 GAGGGCACAGGAGTGCCAA 1

RESULT 1057
ADH79299
ID ADH79299 standard; DNA; 19 BP.

```
XX
AC   ADH79299;
XX
DT   22-APR-2004  (first entry)
XX
DE   Horse probe SEQ ID NO:104.
XX
KW   RNA T7 polymerase; probe; array; ss; probe; horse.
XX
OS   Equus caballus.
XX
PN   FR2834521-A1.
XX
PD   11-JUL-2003.
XX
PF   10-JAN-2002; 2002FR-00000265.
XX
PR   10-JAN-2002; 2002FR-00000265.
XX
PA   (INMR ) BIO MERIEUX.
XX
PI   Mabilat C,  Desvarenne S,  Babola O,  Lacroix B;
XX
DR   WPI; 2003-571829/54.
XX
PT   Determining origin of an animal sample, useful e.g. for detecting
PT   adulteration of food, by testing hybridization of sample DNA with set of
PT   species-specific reagents.
XX
PS   Claim 1; SEQ ID NO 104; 98pp; French.
XX
CC   The invention relates to a novel method for determining the animal
CC   species that is the origin of a sample. The method is very general, quick
CC   and easy to do. It can detect material from a species even when present
CC   in small amounts in presence of materials from several other species, and
CC   the species being tested do not have to be known a priori. DNA was
CC   isolated from an animal sample and amplified by PCR using two primers.
CC   The amplicon, containing a promoter for RNA T7 polymerase (present in one
CC   of the primers) was transcribed with incorporation of a fluorescent
CC   ribonucleotide, then transcripts cleaved to fragments of 20 nucleotides.
CC   These were tested for hybridisation to a DNA chip carrying 17-mer capture
CC   probes, specific for different animal species. The present sequence
CC   represents a probe of the invention.
XX
SQ   Sequence 19 BP; 3 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1751 TGGCTCTTTATTCATTAAG 1769
              || |||||||||||   ||
Db          1 TGCCTCTTTATTCACGTAG 19


RESULT 1058
ADJ66393/c
ID   ADJ66393 standard; RNA; 19 BP.
XX
AC   ADJ66393;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human TGFb-R siNA lower strand, SEQ ID NO:231.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; human;
KW   antidiabetic; nephrotropic; hepatotropic; cytostatic;
KW   transforming growth factor beta receptor; TGFb; TGFb-R;
KW   diabetic nephropathy; chronic liver disease; pulmonary fibrosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070197-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US007273.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   12-NOV-2002; 2002US-0425559P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-697557/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of diabetic nephropathy, which downregulates expression of the
PT   transforming growth factor-beta receptor gene.
XX
PS   Example 3; SEQ ID NO 231; 137pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human transforming growth factor beta
CC   (TGFb) receptor (TGFb-R) gene by RNA interference. The siNAs may or may
CC   not comprise ribonucleotides and may be double or single stranded. They
CC   further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the TGFb-R gene in cells, tissue explants or organisms
CC   (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC   treatment of a variety of conditions. They may be used for treating
CC   diabetic nephropathy, chronic liver disease or pulmonary fibrosis. The
CC   siNAs are also useful for drug screening, diagnosis, therapeutic target
CC   identification and validation, genetic engineering, pharmacogenomics,
CC   studying gene function, and gene mapping (e.g., of single nucleotide
CC   polymorphisms). The present sequence represents the lower strand of a
CC   human TGFb-R-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 9 A; 1 C; 2 G; 0 T; 7 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1910 ATCAACAATACCTTTTTTT 1928
              || ||||| || | |||||
Db         19 ATTAACAAAACTTGTTTTT 1


RESULT 1059
ADJ66265
ID   ADJ66265 standard; RNA; 19 BP.
XX
AC   ADJ66265;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human TGFb-R transcript target sequence/siNA upper strand, SEQ ID NO:103.
```

```
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; human;
KW   antidiabetic; nephrotropic; hepatotropic; cytostatic;
KW   transforming growth factor beta receptor; TGFb; TGFb-R;
KW   diabetic nephropathy; chronic liver disease; pulmonary fibrosis;
KW   target sequence; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070197-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US007273.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   12-NOV-2002; 2002US-0425559P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L;
XX
DR   WPI; 2003-697557/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of diabetic nephropathy, which downregulates expression of the
PT   transforming growth factor-beta receptor gene.
XX
PS   Example 3; SEQ ID NO 103; 137pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of the human transforming growth factor beta
CC   (TGFb) receptor (TGFb-R) gene by RNA interference. The siNAs may or may
CC   not comprise ribonucleotides and may be double or single stranded. They
CC   further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the TGFb-R gene in cells, tissue explants or organisms
CC   (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC   treatment of a variety of conditions. They may be used for treating
CC   diabetic nephropathy, chronic liver disease or pulmonary fibrosis. The
CC   siNAs are also useful for drug screening, diagnosis, therapeutic target
CC   identification and validation, genetic engineering, pharmacogenomics,
CC   studying gene function, and gene mapping (e.g., of single nucleotide
CC   polymorphisms). The present sequence represents the upper strand of a
CC   human TGFb-R-targeted double-stranded siNA, which is identical to the
CC   TGFb-R transcript target sequence.
XX
SQ   Sequence 19 BP; 7 A; 2 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   42.1%;  Pred. No. 5.6e+02;
  Matches    8;  Conservative    7;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1910 ATCAACAATACCTTTTTTT 1928
              |: ||||| || : :::::
Db          1 AUUAACAAAACUUGUUUUU 19
```

```
RESULT 1060
ADM92878/c
ID   ADM92878 standard; DNA; 19 BP.
XX
AC   ADM92878;
XX
DT   03-JUN-2004  (first entry)
XX
DE   SNP-containing cardiovascular associated gene primer #209.
XX
KW   SNP; single nucleotide polymorphism; cardiovascular associated gene;
KW   allelic variation; atherosclerosis; ischemia; reperfusion; hypertension;
KW   restenosis; arterial inflammation; myocardial infarction; stroke; primer;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2003057911-A2.
XX
PD   17-JUL-2003.
XX
PF   07-JAN-2003; 2003WO-EP000060.
XX
PR   08-JAN-2002; 2002EP-00000153.
XX
PA   (FARB ) BAYER AG.
XX
PI   Stropp U,  Schwers S,  Kallabis H;
XX
DR   WPI; 2003-577532/54.
XX
PT   New isolated polynucleotides comprising single nucleotide polymorphisms
PT   of the cardiovascular gene, useful for assessing predisposition or
PT   susceptibility to a cardiovascular disease, e.g. atherosclerosis,
PT   restenosis or stroke.
XX
PS   Disclosure; Page 74; 187pp; English.
XX
CC   The invention relates an isolated polynucleotide (I) encoded by a
CC   cardiovascular associated (CA) gene, having allelic variation contained
CC   in a functional surrounding like full length cDNA for CA gene
CC   polypeptide, and with or without the CA gene promoter sequence. (I) is a
CC   polynucleotide comprising single nucleotide polymorphisms predicting
CC   cardiovascular disease. The polynucleotides are useful for assessing
CC   predisposition or susceptibility to a cardiovascular disease, e.g.
CC   atherosclerosis, ischemia/reperfusion, hypertension, restenosis, arterial
CC   inflammation, myocardial infarction, and stroke. These may also be used
CC   to predict personal medication schemes omitting adverse drug reactions,
CC   or as probes for detecting genetic polymorphisms and as templates for the
CC   recombinant production of normal or variant peptides/polypeptides encoded
CC   by the genes. This sequence corresponds to a PCR primer to amplify one of
CC   the genes of the invention.
XX
SQ   Sequence 19 BP; 3 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAAGTGTGT 1996
              || | || || ||||||||
Db         19 GAGACAAGGACAAGTGTGT 1

RESULT 1061
ADM77344
ID   ADM77344 standard; DNA; 19 BP.
XX
AC   ADM77344;
XX
DT   03-JUN-2004  (first entry)
```

```
XX
DE   Human fibrocystin (PKHD1) gene DHPLC PCR primer #52.
XX
KW   human; fibrocystin;
KW   treating autosomal recessive polycystic kidney disease; PKHD1; DHPLC PCR;
KW   ss; primer.
XX
OS   Homo sapiens.
XX
PN   WO2003062453-A2.
XX
PD   31-JUL-2003.
XX
PF   23-JAN-2003; 2003WO-US002038.
XX
PR   23-JAN-2002; 2002US-0351110P.
XX
PA   (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX
PI   Harris PC,  Ward CJ,  Rossetti S,  Torres VE;
XX
DR   WPI; 2003-618286/58.
XX
PT   New isolated nucleic acid comprising a sequence encoding a fibrocystin
PT   polypeptide, useful for diagnosing and treating autosomal recessive
PT   polycystic kidney disease.
XX
PS   Example 4; SEQ ID NO 99; 136pp; English.
XX
CC   The invention comprises the amino acid and coding sequences of
CC   fibrocystin proteins. The DNA and protein sequences of the invention are
CC   useful for diagnosing and treating autosomal recessive polycystic kidney
CC   disease. The present DNA sequence represents a DHPLC PCR primer that was
CC   used to screen for mutations in the human fibrocystin (PKHD1) gene.
XX
SQ   Sequence 19 BP; 5 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1586 ACAGACTGGGAACCCCTCC 1604
              ||| |||| ||  ||||||
Db          1 ACATACTGTGAGACCCTCC 19


RESULT 1062
ADH01866
ID   ADH01866 standard; RNA; 19 BP.
XX
AC   ADH01866;
XX
DT   11-MAR-2004  (first entry)
XX
DE   Protein tyrosine phosphatase siRNA sequence, SEQ ID No 478.
XX
KW   small interfering RNA; siRNA; protein tyrosine phosphatase; PTP; PTP1B;
KW   insulin receptor protein phosphorylation; Jak2; antidiabetic; anorectic;
KW   antiinflammatory; neuroprotective; cytostatic; immunosuppressive;
KW   antimicrobial; gene therapy; ss; siRNA.
XX
OS   Unidentified.
XX
PN   WO2003099227-A2.
XX
PD   04-DEC-2003.
XX
PF   23-MAY-2003; 2003WO-US016651.
XX
PR   23-MAY-2002; 2002US-0383249P.
PR   14-APR-2003; 2003US-0462942P.
XX
PA   (CEPT-) CEPTYR INC.
XX
PI   Lewis SP,  Klinghoffer R,  Wilson LK;
XX
DR   WPI; 2004-035036/03.
XX
PT   New small interfering polynucleotide that modulates protein tyrosine
PT   phosphatase (PTP)1B polypeptide signal transduction, useful for treating
PT   disorders associated with altered PTP1B signal transduction, e.g.
PT   diabetes or cancer.
XX
PS   Example 3; SEQ ID NO 478; 234pp; English.
XX
CC   The invention relates to a novel isolated small interfering RNA (siRNA)
CC   polynucleotide, comprising at least one nucleotide sequence from any of
CC   the 20 fully defined sequences given in the specification. The invention
CC   further relates to: a pharmaceutical composition comprising a new siRNA
CC   polynucleotide and a physiological carrier; a recombinant nucleic acid
CC   construct, comprising a polynucleotide that is capable of directing
CC   transcription of an siRNA; a host cell transformed or transfected with
CC   the above recombinant nucleic acid construct; a method for interfering
CC   with expression of a protein tyrosine phosphatase (PTP)1B polypeptide, or
CC   its variant; a method for identifying a component of a PTP1B signal
CC   transduction pathway; a method for modulating an insulin receptor protein
CC   phosphorylation state in a cell; a method for altering a Jak2 protein
CC   phosphorylation state in a cell; and a method for treating a Jak2-
CC   associated disorder. The siRNA has the following activities:
CC   antidiabetic, anorectic, antiinflammatory, neuroprotective, cytostatic,
CC   immunosuppressive, and antimicrobial. The novel siRNA polynucleotides can
CC   be used in gene therapy to treat disorders. The composition and methods
CC   are useful in treating disorders associated with PTP1B-mediated signal
CC   transduction, such as diabetes, obesity, hyperglycaemia-induced
CC   apoptosis, inflammation, neurodegenerative disorders, cancer, autoimmune
CC   diseases or infection. This polynucleotide sequence represents an siRNA
CC   used for modulating the signal transduction of a protein tyrosine
CC   phosphatase of the invention.
XX
SQ   Sequence 19 BP; 2 A; 7 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   63.2%;  Pred. No. 5.6e+02;
  Matches   12;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1591 CTGGGAACCCCTCCTGGCC 1609
              |:|| | ||| :||:|| |
Db          1 CUGGAAGCCCUUCCUGGUC 19


RESULT 1063
ADL18581
ID   ADL18581 standard; DNA; 19 BP.
XX
AC   ADL18581;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human cytochrome P450 CYP3A4 SNP c15721g DNA.
XX
KW   drug metabolic activity; CYP3A4; human; cytochrome P450; SNP;
KW   single nucleotide polymorphism; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(9,G)
FT                   /*tag=  a
FT                   /label= Single nucleotide polymorphism (SNP)
XX
PN   JP2004000004-A.
XX
PD   08-JAN-2004.
XX
PF   23-APR-2002; 2002JP-00120246.
XX
```

PR 23-APR-2002; 2002JP-00120246.
XX
PA (KOKU-) KOKURITSU IYAKUHIN SHOKUHIN EISEI KENKYU.
PA (IYAK-) IYAKUHIN FUKUSAYO HIGAI KYUSAI KENKYU SH.
XX
DR WPI; 2004-085203/09.
XX
PT Testing the drug metabolic activity of CYP3A4 such as testosterone
PT hydroxylase activity by detecting the CYP3A4 gene polymorphisms in which
PT the drug metabolic activity of CYP3A4 is reduced.
XX
PS Example 1; SEQ ID NO 5; 48pp; Japanese.
XX
CC The invention relates to a novel method for testing the drug metabolic
CC activity of CYP3A4 by detecting the CYP3A4 gene polymorphisms in which
CC the drug metabolic activity of CYP3A4 is reduced. The method of the
CC invention may be useful for testing the possibility of a side effect
CC resulting from a drug metabolised by CYP3A4 in a subject. The current
CC sequence is that of the human cytochrome P450 CYP3A4 SNP c15721g DNA of
CC the invention.
XX
SQ Sequence 19 BP; 6 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1890 GATGTGCCCTAGATCAACA 1908
||||||| |||| || ||
Db 1 GATGTGCACTAGCACATCA 19

RESULT 1064
ADM32949/c
ID ADM32949 standard; DNA; 19 BP.
XX
AC ADM32949;
XX
DT 17-JUN-2004 (first entry)
XX
DE PCR primer To32-300-2-AS used to amplify a fragment of To32 cDNA.
XX
KW protein production; moss; protoplast; To32 protein;
KW thaumatin-like protein; PCR; primer; ss.
XX
OS Synthetic.
XX
PN WO2004024927-A1.
XX
PD 25-MAR-2004.
XX
PF 08-SEP-2003; 2003WO-EP009959.
XX
PR 12-SEP-2002; 2002EP-00020382.
PR 11-JUL-2003; 2003EP-00015881.
XX
PA (GREE-) GREENOVATION BIOTECH GMBH.
XX
PI Gorr G, Launhardt H, Berg B;
XX
DR WPI; 2004-270051/25.
XX
PT Achieving transient expression of at least an extracellular non-plant
PT protein from a heterologous nucleotide sequence in moss protoplast
PT comprises transiently introducing into the protoplast a heterologous
PT nucleic acid construct.
XX
PS Disclosure; Page 17; 49pp; English.
XX
CC The specification describes a method for the production of extracellular
CC non-plant protein from moss protoplasts. The method comprises transiently
CC introducing into the protoplast a heterologous nucleic acid construct
CC comprising a heterologous nucleotide sequence operably linked to a
CC promoter. The heterologous nucleotide sequence encodes a protein selected
CC from heterodimer, fusion antibody, immunoglobulin or single-chain
CC antibody. The method is useful for protein production. PCR primers
CC ADM32948-ADM32949 were used to amplify a fragment of cDNA encoding a
CC plant thaumatin-like To32 protein, in the course of the invention.
XX
SQ Sequence 19 BP; 3 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1850 GCCAACAGACCCACACACT 1868
|||||| || | ||||||
Db 19 GCCAACTGAGCTGCACACT 1

RESULT 1065
ADN75395/c
ID ADN75395 standard; RNA; 19 BP.
XX
AC ADN75395;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human CD45 CR region siRNA oligonucleotide SEQ ID 220.
XX
KW small interfering RNA; siRNA; protein-tyrosine-phosphatase; PTP;
KW cytostatic; immunomodulator; antimicrobial; antiinflammatory;
KW antidiabetic; anorectic; cancer; autoimmune disease; infection;
KW inflammation; diabetes; obesity; RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004016735-A2.
XX
PD 26-FEB-2004.
XX
PF 23-MAY-2003; 2003WO-US016632.
XX
PR 23-MAY-2002; 2002US-0383249P.
PR 14-APR-2003; 2003US-0462942P.
XX
PA (CEPT-) CEPTYR INC.
PA (COLD-) COLD SPRING HARBOR LAB.
XX
PI Klinghoffer R, Lewis SP, Tonks NK, Meng T;
XX
DR WPI; 2004-203773/19.
XX
PT New isolated small interfering RNA (siRNA) polynucleotide useful for
PT treating diseases with aberrant activity of the protein tyrosine
PT phosphatase, such as cancer, autoimmune disease, infection, inflammation,
PT diabetes and obesity.
XX
PS Example 2; SEQ ID NO 220; 392pp; English.
XX
CC This invention describes novel small interfering RNA (siRNA)
CC polynucleotides capable of interfering with expression of a polypeptide
CC having protein-tyrosine-phosphatase (PTP) activity. The products of the
CC invention have cytostatic, immunomodulator, antimicrobial,
CC antiinflammatory, antidiabetic and anorectic activity. The methods and
CC compositions of the present invention are useful for treating diseases or
CC conditions associated with aberrant expression or activity of the protein
CC tyrosine phosphatase, such as cancer, autoimmune diseases, infection,
CC inflammation, diabetes and obesity. This sequence represents a siRNA
CC directed against dual specificity phosphatase (DSP) expression.
XX
SQ Sequence 19 BP; 7 A; 5 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 2.3%; Score 12.6; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 5.6e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```
Qy       2010 AGAGATCAAGTCCTCTGGT 2028
              |||||| || ||||  |||
Db         19 AGAGATTAATTCCTTGGGT 1


RESULT 1066
ADO49828/c
ID   ADO49828 standard; DNA; 19 BP.
XX
AC   ADO49828;
XX
DT   29-JUL-2004  (first entry)
XX
DE   H. pylori strain J99 genome fragment SEQ ID NO:451.
XX
KW   ds; stroke; phosphodiesterase 4D; PDE4D.
XX
OS   Helicobacter pylori.
XX
PN   US2004091865-A1.
XX
PD   13-MAY-2004.
XX
PF   25-SEP-2002; 2002US-00255120.
XX
PR   19-MAR-2001; 2001US-00811352.
PR   04-FEB-2002; 2002US-00067514.
XX
PA   (DECO-) DECODE GENETICS EHF.
XX
PI   Gretarsdottir S,  Jonsdottir S,  Reynisdottir ST,  Thorleifsson G;
XX
DR   WPI; 2004-374932/35.
XX
PT   Diagnosing susceptibility to a stroke in an individual comprising
PT   screening for an at-risk haplotype in the phosphodiesterase 4D gene.
XX
PS   Disclosure; SEQ ID NO 451; 574pp; English.
XX
CC   The invention relates to a method of diagnosing susceptibility to a
CC   stroke in an individual comprising screening for an at-risk haplotype in
CC   the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
CC   an individual susceptible to stroke (affected) compared to a healthy
CC   individual (control), where the at-risk haplotype increases risk of
CC   stroke significantly. The composition, methods and kit are useful for
CC   diagnosing, predicting of clinical course and treating stroke using
CC   polymorphisms in the PDE4D gene. These may also be used in identifying
CC   agents that enhance or inhibit PDE4D polypeptide expression or activity.
CC   The present sequence represents a fragment of H. pylori strain J99 genome
CC   which is not referred to at all in the main body of the specification.
XX
SQ   Sequence 19 BP; 13 A; 1 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1761 TTCATTAAGCTTTTTTTTT 1779
              ||  | ||||| |||||||
Db         19 TTTTTCAAGCTCTTTTTTT 1


RESULT 1067
ADQ27450/c
ID   ADQ27450 standard; DNA; 19 BP.
XX
AC   ADQ27450;
XX
DT   26-AUG-2004  (first entry)
XX
DE   RNA interference target sequence #358.
XX
KW   ss; detection; RNA interference; siRNA; gene silencing; gene expression;
KW   cytotoxicity.
XX
OS   Homo sapiens.
XX
PN   WO2004048566-A1.
XX
PD   10-JUN-2004.
XX
PF   21-NOV-2003; 2003WO-JP014893.
XX
PR   22-NOV-2002; 2002JP-00340053.
XX
PA   (NATO/) NATORI Y.
PA   (SAIG/) SAIGO K.
PA   (TEIK/) TEI K.
PA   (NAIT/) NAITO Y.
XX
PI   Saigo K,  Tei K,  Naito Y;
XX
DR   WPI; 2004-487423/46.
XX
PT   Detecting sequence of RNA interference useful for synthesizing siRNA, by
PT   detecting regions in sequence fulfilling specific criteria such as base
PT   at 3' terminal is adenine, thymine or uracil, base at 5' terminal is
PT   guanine or cytosine.
XX
PS   Disclosure; SEQ ID NO 372; 325pp; Japanese.
XX
CC   The invention relates to a method of detecting the base sequence for RNA
CC   interference by detecting the regions in the DNA sequence fulfilling the
CC   following requirements such as: (i) the base at 3' terminal is adenine,
CC   thymine or uracil; (ii) the base at 5' terminal is guanine or cytosine;
CC   (iii) the seven base sequence at 3' terminal is rich in adenine, thymine
CC   and uracil, and; (iv) there are bases in a such a number that it causes
CC   RNA interference without showing cytotoxicity. The method is used for
CC   designing and synthesizing siRNA causing RNA interference. This sequence
CC   corresponds to an RNA interference target sequence of the invention.
XX
SQ   Sequence 19 BP; 6 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1879 AATGTCAAATTGATGTGCC 1897
              || ||||| || ||| |||
Db         19 AAAGTCAATTTTATGGGCC 1


RESULT 1068
ADQ62357
ID   ADQ62357 standard; RNA; 19 BP.
XX
AC   ADQ62357;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Anti-CASP10 siRNA SEQ ID NO:2059.
XX
KW   ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW   RNA interference.
XX
OS   Synthetic.
XX
PN   WO2004045543-A2.
XX
PD   03-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-US036787.
XX
PR   14-NOV-2002; 2002US-0426137P.
PR   10-SEP-2003; 2003US-0502050P.
```

```
XX
PA   (DHAR-) DHARMACON INC.
XX
PI   Anastasia K,  Angela R,  Devin L,  William M,  Stephen S;
XX
DR   WPI; 2004-420527/39.
XX
PT   Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT   by selecting a target gene and measuring the functionality of the
PT   nucleotide sequences that are complementary to a stretch of nucleotides
PT   of the target sequence.
XX
PS   Example 12; SEQ ID NO 2059; 199pp; English.
XX
CC   The invention relates to a novel method for selecting siRNA (short
CC   interfering RNA) comprising selecting an siRNA molecule of 19-25
CC   nucleoside bases by selecting a target gene and measuring the
CC   functionality of sequences of 19-25 nucleotides in length that are
CC   substantially complementary to a stretch of nucleotides of the target
CC   sequence, where the functionality is dependent upon non-target specific
CC   criteria. Also claimed are methods for gene-silencing, developing an
CC   siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC   functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC   effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC   siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC   sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC   GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC   CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC   GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC   comprises a sense strand and an anti-sense strand. The siRNA molecule
CC   comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC   pairs. The kit comprises at least two siRNA, comprising a first optimised
CC   siRNA and a second optimised siRNA. The method is useful in selecting
CC   siRNA for generating a gene silencing reagent. The present sequence is
CC   used in the exemplification of the invention.
XX
SQ   Sequence 19 BP; 4 A; 3 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   47.4%;  Pred. No. 5.6e+02;
  Matches    9;  Conservative    6;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2035 CAAAGGTTCTATCTGCTTA 2053
              |||||| : : :|:| ::|
Db          1 CAAAGGGUUUCUCUGUUUA 19


RESULT 1069
ADQ62566
ID   ADQ62566 standard; RNA; 19 BP.
XX
AC   ADQ62566;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Anti-TAP1 siRNA SEQ ID NO:2269.
XX
KW   ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW   RNA interference.
XX
OS   Synthetic.
XX
PN   WO2004045543-A2.
XX
PD   03-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-US036787.
XX
PR   14-NOV-2002; 2002US-0426137P.
PR   10-SEP-2003; 2003US-0502050P.
XX
PA   (DHAR-) DHARMACON INC.
XX
PI   Anastasia K,  Angela R,  Devin L,  William M,  Stephen S;
XX
DR   WPI; 2004-420527/39.
XX
PT   Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT   by selecting a target gene and measuring the functionality of the
PT   nucleotide sequences that are complementary to a stretch of nucleotides
PT   of the target sequence.
XX
PS   Example 12; SEQ ID NO 2269; 199pp; English.
XX
CC   The invention relates to a novel method for selecting siRNA (short
CC   interfering RNA) comprising selecting an siRNA molecule of 19-25
CC   nucleoside bases by selecting a target gene and measuring the
CC   functionality of sequences of 19-25 nucleotides in length that are
CC   substantially complementary to a stretch of nucleotides of the target
CC   sequence, where the functionality is dependent upon non-target specific
CC   criteria. Also claimed are methods for gene-silencing, developing an
CC   siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC   functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC   effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC   siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC   sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC   GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC   CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC   GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC   comprises a sense strand and an anti-sense strand. The siRNA molecule
CC   comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC   pairs. The kit comprises at least two siRNA, comprising a first optimised
CC   siRNA and a second optimised siRNA. The method is useful in selecting
CC   siRNA for generating a gene silencing reagent. The present sequence is
CC   used in the exemplification of the invention.
XX
SQ   Sequence 19 BP; 9 A; 5 C; 4 G; 0 T; 1 U; 0 Other;

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   73.7%;  Pred. No. 5.6e+02;
  Matches   14;  Conservative    1;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACACTTA 1870
              ||||||| ||| |||  :|
Db          1 CAACAGAACCAGACAGGUA 19


RESULT 1070
ADQ60763
ID   ADQ60763 standard; RNA; 19 BP.
XX
AC   ADQ60763;
XX
DT   09-SEP-2004  (first entry)
XX
DE   Anti-AKT1 siRNA related DNA sequence SEQ ID NO:465.
XX
KW   ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW   RNA interference.
XX
OS   Synthetic.
XX
PN   WO2004045543-A2.
XX
PD   03-JUN-2004.
XX
PF   14-NOV-2003; 2003WO-US036787.
XX
PR   14-NOV-2002; 2002US-0426137P.
PR   10-SEP-2003; 2003US-0502050P.
XX
PA   (DHAR-) DHARMACON INC.
XX
PI   Anastasia K,  Angela R,  Devin L,  William M,  Stephen S;
XX
DR   WPI; 2004-420527/39.
```

```
XX
PT   Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT   by selecting a target gene and measuring the functionality of the
PT   nucleotide sequences that are complementary to a stretch of nucleotides
PT   of the target sequence.
XX
PS   Example 12; SEQ ID NO 465; 199pp; English.
XX
CC   The invention relates to a novel method for selecting siRNA (short
CC   interfering RNA) comprising selecting an siRNA molecule of 19-25
CC   nucleoside bases by selecting a target gene and measuring the
CC   functionality of sequences of 19-25 nucleotides in length that are
CC   substantially complementary to a stretch of nucleotides of the target
CC   sequence, where the functionality is dependent upon non-target specific
CC   criteria. Also claimed are methods for gene-silencing, developing an
CC   siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC   functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC   effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC   siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC   sequence consisting of GGGAGAUAGUGAUGAAGUA; GAAGUACAUCCAUUAUAAG;
CC   GUACGACAACCGGGAGAUA; AGAUAGUGAUGAAGUACAU; UGAAGACUCUGCUCAGUUU;
CC   CAUGCGGCCUCUGUUUGA; UGCGGCCUCUGUUUGAUUU; GAGAUAGUGAUGAAGUACA;
CC   GGAGAUAGUGAUGAAGUAC; and GAAGACUCUGCUCAGUUUG. The siRNA molecule
CC   comprises a sense strand and an anti-sense strand. The siRNA molecule
CC   comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC   pairs. The kit comprises at least two siRNA, comprising a first optimised
CC   siRNA and a second optimised siRNA. The method is useful in selecting
CC   siRNA for generating a gene silencing reagent. The present sequence is
CC   used in the exemplification of the invention. The sequence is shown in
CC   the specification as DNA, but described as siRNA.
XX
SQ   Sequence 19 BP; 7 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

  Query Match              2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 5.6e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1742 GACAAGTACTGGCTCTTTA 1760
              |||||| || ||| | |||
Db          1 GACAAGGACGGGCACATTA 19


RESULT 1071
AAV11925/c
ID   AAV11925 standard; DNA; 14 BP.
XX
AC   AAV11925;
XX
DT   13-AUG-1998  (first entry)
XX
DE   Hepatocyte growth factor inhibiting oligonucleotide #17.
XX
KW   Hepatocyte growth factor; HGF; c-Met; modulator; inhibitor;
KW   antitumour agent; anti-metastasis agent; primer; ss.
XX
OS   Synthetic.
XX
PN   JP10127286-A.
XX
PD   19-MAY-1998.
XX
PF   01-NOV-1996;   96JP-00291499.
XX
PR   01-NOV-1996;   96JP-00291499.
XX
PA   (TERU ) TERUMO CORP.
XX
DR   WPI; 1998-340665/30.
XX
PT   Oligo:nucleotide inhibiting HGF production - useful as antitumour and
PT   anti-metastatic agent.
XX
PS   Claim 10; Page 10; 15pp; Japanese.
XX
CC   AAV11909-V11925, AAV11927 and AAV11928 are oligonucleotide primers used
CC   to identify sequences which modulate or inhibit expression, production or
CC   reception of hepatocyte growth factor (HGF) or expression of c-Met. Such
CC   oligonucleotides are useful as antitumour or anti-metastasis agents
XX
SQ   Sequence 14 BP; 0 A; 8 C; 0 G; 6 T; 0 U; 0 Other;

  Query Match              2.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAA 1557
              ||| ||||||||||
Db         14 GAGGAGGGAAGGAA 1


RESULT 1072
AAV11924
ID   AAV11924 standard; DNA; 14 BP.
XX
AC   AAV11924;
XX
DT   13-AUG-1998  (first entry)
XX
DE   Hepatocyte growth factor inhibiting oligonucleotide #16.
XX
KW   Hepatocyte growth factor; HGF; c-Met; modulator; inhibitor;
KW   antitumour agent; anti-metastasis agent; primer; ss.
XX
OS   Synthetic.
XX
PN   JP10127286-A.
XX
PD   19-MAY-1998.
XX
PF   01-NOV-1996;   96JP-00291499.
XX
PR   01-NOV-1996;   96JP-00291499.
XX
PA   (TERU ) TERUMO CORP.
XX
DR   WPI; 1998-340665/30.
XX
PT   Oligo:nucleotide inhibiting HGF production - useful as antitumour and
PT   anti-metastatic agent.
XX
PS   Claim 10; Page 10; 15pp; Japanese.
XX
CC   AAV11909-V11925, AAV11927 and AAV11928 are oligonucleotide primers used
CC   to identify sequences which modulate or inhibit expression, production or
CC   reception of hepatocyte growth factor (HGF) or expression of c-Met. Such
CC   oligonucleotides are useful as antitumour or anti-metastasis agents
XX
SQ   Sequence 14 BP; 6 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match              2.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAA 1557
              ||| ||||||||||
Db          1 GAGGAGGGAAGGAA 14


RESULT 1073
AAT57313/c
ID   AAT57313 standard; RNA; 15 BP.
XX
AC   AAT57313;
XX
DT   27-AUG-2003  (revised)
DT   25-MAR-2003  (revised)
```

```
DT   15-MAR-1997  (first entry)
XX
DE   RSV N hammerhead ribozyme target sequence (nt. position 741).
XX
KW   Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW   gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW   intercellular adhesion molecule; rel A; tumour necrosis factor;
KW   TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW   translocation; chronic myelogenous leukaemia; CML; cancer;
KW   Philadelphia chromosome; inflammation; autoimmune disease;
KW   atherosclerosis; myocardial infarction; stroke; restenosis;
KW   transplant rejection; rheumatoid arthritis; psoriasis;
KW   myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW   human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW   ss.
XX
OS   Respiratory syncytial virus.
XX
PN   WO9523225-A2.
XX
PD   31-AUG-1995.
XX
PF   23-FEB-1995;   95WO-IB000156.
XX
PR   23-FEB-1994;   94US-00201109.
PR   29-MAR-1994;   94US-00218934.
PR   04-APR-1994;   94US-00222795.
PR   07-APR-1994;   94US-00224483.
PR   15-APR-1994;   94US-00227958.
PR   15-APR-1994;   94US-00228041.
PR   18-MAY-1994;   94US-00245736.
PR   06-JUL-1994;   94US-00271280.
PR   15-AUG-1994;   94US-00291932.
PR   16-AUG-1994;   94US-00291433.
PR   17-AUG-1994;   94US-00292620.
PR   19-AUG-1994;   94US-00293520.
PR   02-SEP-1994;   94US-00300000.
PR   08-SEP-1994;   94US-00303039.
PR   23-SEP-1994;   94US-00311486.
PR   23-SEP-1994;   94US-00311749.
PR   28-SEP-1994;   94US-00314397.
PR   03-OCT-1994;   94US-00316771.
PR   07-OCT-1994;   94US-00319492.
PR   11-OCT-1994;   94US-00321993.
PR   04-NOV-1994;   94US-00334847.
PR   10-NOV-1994;   94US-00337608.
PR   28-NOV-1994;   94US-00345516.
PR   16-DEC-1994;   94US-00357577.
PR   23-DEC-1994;   94US-00363233.
PR   30-JAN-1995;   95US-00380734.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Chowrira B,  Direnzo A,  Draper KG,  Dudycz LW;
PI   Grimm S,  Karpeisky A,  Kisich K,  Matulic-Adamic J,  Mcswiggen JA;
PI   Modak A,  Pavco P,  Beigleman L,  Sullivan SM,  Sweedler D,  Thompson JD;
PI   Tracz D,  Usman N,  Wincott FE,  Woolf T;
XX
DR   WPI; 1995-351090/45.
XX
PT   Ribozymes having modified bases and methods for producing them - for use
PT   in inhibiting disease related genes.
XX
PS   Claim 2; Page 275; 407pp; English.
XX
CC   The present sequence represents a preferred target sequence for an
CC   enzymatic nucleic acid (i.e. a ribozyme) which cleaves mRNA coding for a
CC   protein of respiratory syncytial virus (RSV) at the nucleotide base
CC   position indicated in the DE line. Regions of the mRNA that do not form
CC   secondary folding structures and that contain potential hammerhead and
CC   hairpin ribozyme cleavage sites were identified by computer analysis.
CC   Ribozymes directed against these mRNA sequences were designed and
CC   synthesised with modifications that improve their nuclease resistance.
CC   The ribozymes cleave the target sequences and can be used for treatment
CC   and diagnosis of RSV infection. (Updated on 25-MAR-2003 to correct PI
CC   field.). (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ   Sequence 15 BP; 3 A; 1 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTT 1576
                ||||||||||||  |
Db         14 CTGCAAAAATCCCT 1


RESULT 1074
AAT57311/c
ID   AAT57311 standard; RNA; 15 BP.
XX
AC   AAT57311;
XX
DT   27-AUG-2003  (revised)
DT   25-MAR-2003  (revised)
DT   15-MAR-1997  (first entry)
XX
DE   RSV N hammerhead ribozyme target sequence (nt. position 740).
XX
KW   Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW   gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW   intercellular adhesion molecule; rel A; tumour necrosis factor;
KW   TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW   translocation; chronic myelogenous leukaemia; CML; cancer;
KW   Philadelphia chromosome; inflammation; autoimmune disease;
KW   atherosclerosis; myocardial infarction; stroke; restenosis;
KW   transplant rejection; rheumatoid arthritis; psoriasis;
KW   myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW   human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW   ss.
XX
OS   Respiratory syncytial virus.
XX
PN   WO9523225-A2.
XX
PD   31-AUG-1995.
XX
PF   23-FEB-1995;   95WO-IB000156.
XX
PR   23-FEB-1994;   94US-00201109.
PR   29-MAR-1994;   94US-00218934.
PR   04-APR-1994;   94US-00222795.
PR   07-APR-1994;   94US-00224483.
PR   15-APR-1994;   94US-00227958.
PR   15-APR-1994;   94US-00228041.
PR   18-MAY-1994;   94US-00245736.
PR   06-JUL-1994;   94US-00271280.
PR   15-AUG-1994;   94US-00291932.
PR   16-AUG-1994;   94US-00291433.
PR   17-AUG-1994;   94US-00292620.
PR   19-AUG-1994;   94US-00293520.
PR   02-SEP-1994;   94US-00300000.
PR   08-SEP-1994;   94US-00303039.
PR   23-SEP-1994;   94US-00311486.
PR   23-SEP-1994;   94US-00311749.
PR   28-SEP-1994;   94US-00314397.
PR   03-OCT-1994;   94US-00316771.
PR   07-OCT-1994;   94US-00319492.
PR   11-OCT-1994;   94US-00321993.
PR   04-NOV-1994;   94US-00334847.
PR   10-NOV-1994;   94US-00337608.
PR   28-NOV-1994;   94US-00345516.
PR   16-DEC-1994;   94US-00357577.
PR   23-DEC-1994;   94US-00363233.
PR   30-JAN-1995;   95US-00380734.
```

```
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Chowrira B,  Direnzo A,  Draper KG,  Dudycz LW;
PI   Grimm S,  Karpeisky A,  Kisich K,  Matulic-Adamic J,  Mcswiggen JA;
PI   Modak A,  Pavco P,  Beigleman L,  Sullivan SM,  Sweedler D,  Thompson JD;
PI   Tracz D,  Usman N,  Wincott FE,  Woolf T;
XX
DR   WPI; 1995-351090/45.
XX
PT   Ribozymes having modified bases and methods for producing them - for use
PT   in inhibiting disease related genes.
XX
PS   Claim 2; Page 275; 407pp; English.
XX
CC   The present sequence represents a preferred target sequence for an
CC   enzymatic nucleic acid (i.e. a ribozyme) which cleaves mRNA coding for a
CC   protein of respiratory syncytial virus (RSV) at the nucleotide base
CC   position indicated in the DE line. Regions of the mRNA that do not form
CC   secondary folding structures and that contain potential hammerhead and
CC   hairpin ribozyme cleavage sites were identified by computer analysis.
CC   Ribozymes directed against these mRNA sequences were designed and
CC   synthesised with modifications that improve their nuclease resistance.
CC   The ribozymes cleave the target sequences and can be used for treatment
CC   and diagnosis of RSV infection. (Updated on 25-MAR-2003 to correct PI
CC   field.) (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ   Sequence 15 BP; 4 A; 1 C; 5 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTT 1576
              ||||||||||||  |
Db         15 CTGCAAAAATCCCT 2


RESULT 1075
AAA06101/c
ID   AAA06101 standard; DNA; 15 BP.
XX
AC   AAA06101;
XX
DT   14-JUN-2000  (first entry)
XX
DE   CFTR gene analysis oligonucleotide probe SEQ ID NO:111.
XX
KW   CFTR; cystic fibrosis transmembrane conductance regulator; detection;
KW   mutation; probe; human; hybridisation; ss.
XX
OS   Homo sapiens.
XX
PN   US6027880-A.
XX
PD   22-FEB-2000.
XX
PF   10-OCT-1995;   95US-00544381.
XX
PR   26-OCT-1993;   93US-00143312.
PR   02-AUG-1994;   94US-00284064.
PR   26-OCT-1994;   94WO-US012305.
PR   02-AUG-1995;   95US-00510521.
XX
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Huang XC,  Chee M,  Lobban PE,  Hubbell EA,  Sheldon EL,  Miyada CG;
PI   Cronin MT,  Lipshutz RJ,  Morris MS,  Fodor SPA;
XX
DR   WPI; 2000-194825/17.
XX
PT   An array of nucleic acid probes immobilized on a solid support, useful
PT   for identifying mutations in the cystic fibrosis transmembrane
PT   conductance regulator.
XX
PS   Disclosure; Col 107; 114pp; English.
XX
CC   The present invention describes an array of nucleic acid probes
CC   immobilised on a solid support, which comprises: (1) a first probe set,
CC   comprising probes with a segment of at least 6 nucleotides complementary
CC   to the CFTR (cystic fibrosis transmembrane conductance regulator) gene,
CC   where the segment includes at least 1 interrogation position
CC   complementary to a nucleotide in the CFTR gene sequence; and (2) second,
CC   third and fourth probe sets, each comprising probes identical to those in
CC   (1) except that the interrogation position is occupied by a different
CC   nucleotide. AAA05991 to AAA06240 represent CFTR gene analysis
CC   oligonucleotide probes for use in the exemplification of the present
CC   invention. The present invention also describes a method of comparing a
CC   target nucleic acid with a reference sequence consisting of a
CC   predetermined sequence of nucleotides, comprising: (a) hybridising a
CC   sample comprising the target nucleic acid to an array of nucleic acid
CC   probes immobilised on a solid support; (b) comparing the relative
CC   specific binding of two corresponding probes from the first and second
CC   probe sets; (c) assigning a nucleotide in the target sequence as the
CC   complement of the interrogation position of the probe having the greater
CC   specific binding; and (d) repeating (b) and (c) by comparing the relative
CC   specific binding of a further two corresponding probes from the first and
CC   second probe sets until each nucleotide of interest in the target
CC   sequence has been assigned. The array is useful for analysis of the CFTR
CC   gene, e.g. detection of mutations
XX
SQ   Sequence 15 BP; 10 A; 2 C; 2 G; 0 T; 0 U; 1 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1682 TTCTTAGTTGTTTCT 1696
              ||||| || ||||||
Db         15 TTCTTTGTNGTTTCT 1


RESULT 1076
AAF46544
ID   AAF46544 standard; DNA; 15 BP.
XX
AC   AAF46544;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1383.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
```

```
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 43; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 3 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1775 TTTTTTTGAACCCC 1788
              | ||||||||||||
Db          1 TATTTTTGAACCCC 14


RESULT 1077
AAF46539
ID   AAF46539 standard; DNA; 15 BP.
XX
AC   AAF46539;
XX
DT   30-MAR-2001  (first entry)
XX
DE   IGFBP2 oligonucleotide #1378.
XX
KW   Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW   cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW   skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW   IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW   growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
KW   keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW   hyperneovascular condition; hyperplasia; kidney disease;
KW   neovascular condition of the retina; ss.
XX
OS   Homo sapiens.
XX
PN   WO200078341-A1.
XX
PD   28-DEC-2000.
XX
PF   21-JUN-2000; 2000WO-AU000693.
XX
PR   21-JUN-1999;   99US-0140345P.
XX
PA   (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI   Wraight CJ,  Werther GA,  Edmondson SR;
XX
DR   WPI; 2001-041421/05.
XX
PT   Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT   UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT   inhibits or reduces growth factor mediated cell proliferation and/or
PT   inflammation.
XX
PS   Example 6; Page 43; 201pp; English.
XX
CC   The present invention relates to a method for ameliorating the effects of
CC   skin disorders. The method comprises contacting the skin with an
CC   antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC   receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC   inhibiting or reducing growth factor mediated cell proliferation,
CC   inflammation and/or other disorders. The present sequence is an
CC   oligonucleotide which can be used to design the antisense
CC   oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC   F45161). The method is useful for ameliorating the effects of psoriasis,
CC   ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
CC   neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC   hyperneovascular condition such as a neovascular condition of the retina,
CC   brain or skin, growth factor-mediated malignancies, other sclerotic
CC   disease, kidney disease, hyperproliferation of the inside of blood
CC   vessels or any other hyperplasia
XX
SQ   Sequence 15 BP; 4 A; 0 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps,   0;

Qy       1771 TTTTTTTTTTTGAA 1784
              ||||| ||||||||
Db          2 TTTTTATTTTTGAA 15


RESULT 1078
ADF32124
ID   ADF32124 standard; DNA; 15 BP.
XX
AC   ADF32124;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Probe #48 used to illustrate chip detection techniques.
XX
KW   Chip detection; probe; Single Nucleotide Polymorphism; SNP; detection;
KW   ss.
XX
OS   Unidentified.
XX
PN   CN1381590-A.
XX
PD   27-NOV-2002.
XX
PF   13-APR-2001; 2001CN-00105980.
XX
PR   13-APR-2001; 2001CN-00105980.
XX
PA   (MIAO/) MIAO J.
XX
PI   Miao J;
XX
DR   WPI; 2003-249035/25.
XX
PT   Simple and fast technique for detecting single nucleotide polymorphism
PT   (SNP) by high-temp hybridized chip.
XX
PS   Example 1; Page 14; 19pp; Chinese.
XX
CC   The present invention related to an improvement to existing chip
CC   detection techniques. The invention uses DNA oligonucleotide probes
CC   (ADF32077-ADF32266) to detect Single Nucleotide Polymorphisms (SNP) in
CC   genomic DNA. Its advantages are simple process and short time (within 2
CC   hr).
XX
SQ   Sequence 15 BP; 2 A; 0 C; 7 G; 6 T; 0 U; 0 Other;
```

```
  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTT 1623
              ||||||||| ||||
Db          2 TGGGGGAAGTGTTT 15


RESULT 1079
ADF48919/c
ID   ADF48919 standard; DNA; 15 BP.
XX
AC   ADF48919;
XX
DT   12-FEB-2004  (first entry)
XX
DE   DNA array associated oligonucleotide #111.
XX
KW   ss; DNA array; microfabricated array; DNA chip; CFTR gene mutation;
KW   cystic fibrosis gene; uncharacterised mutation identification;
KW   simultaneous screening.
XX
OS   Synthetic.
XX
PN   US2003165823-A1.
XX
PD   04-SEP-2003.
XX
PF   22-FEB-2000; 2000US-00510378.
XX
PR   26-OCT-1993;   93US-00143312.
PR   02-AUG-1994;   94US-00284064.
PR   26-OCT-1994;   94WO-US012305.
PR   02-AUG-1995;   95US-00510521.
PR   10-OCT-1995;   95US-00544381.
XX
PA   (CRON/) CRONIN M T.
PA   (MIYA/) MIYADA C G.
PA   (HUBB/) HUBBELL E A.
PA   (CHEE/) CHEE M.
PA   (FODO/) FODOR S P A.
PA   (HUAN/) HUANG X C.
PA   (LIPS/) LIPSHUTZ R J.
PA   (LOBB/) LOBBAN P E.
PA   (MORR/) MORRIS M S.
PA   (SHEL/) SHELDON E L.
XX
PI   Cronin MT,  Miyada CG,  Hubbell EA,  Chee M,  Fodor SPA,  Huang XC;
PI   Lipshutz RJ,  Lobban PE,  Morris MS,  Sheldon EL;
XX
DR   WPI; 2004-020546/02.
XX
PT   Arrays of oligonucleotide probes immobilized in microfabricated patterns
PT   on chips used for detecting mutations in the cystic fibrosis
PT   transmembrane conductance regulator (CFTR) gene.
XX
PS   Disclosure; SEQ ID NO 111; 123pp; English.
XX
CC   The invention relates to an array of oligonucleotide probes immobilised
CC   on a solid support, the array comprising at least two sets of
CC   oligonucleotide probes (a microfabricated array or DNA chip). The arrays
CC   can be used in methods to detect uncommon mutations in the CFTR gene.
CC   Prior art methods for analysis of the cystic fibrosis gene do not monitor
CC   large regions of the CFTR gene. The invention uses a large number of
CC   probes and therefore permits the identification of uncharacterised
CC   mutations and the simultaneous screening of large numbers of mutations
CC   with a high degree of accuracy. The present sequence is used in the
CC   exemplification of the invention.
XX
SQ   Sequence 15 BP; 10 A; 2 C; 2 G; 0 T; 0 U; 1 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 5.3e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1682 TTCTTAGTTGTTTCT 1696
              ||||| || ||||||
Db         15 TTCTTTGTNGTTTCT 1


RESULT 1080
AAQ43528
ID   AAQ43528 standard; DNA; 16 BP.
XX
AC   AAQ43528;
XX
DT   25-MAR-2003  (revised)
DT   08-NOV-1993  (first entry)
XX
DE   ALL-1 gene exon 6/intron 6 boundary.
XX
KW   Intron; exon; boundary; acute lymphoblastic leukemia; gene; oncogene;
KW   chromosome 11; breakpoint cluster region; 11q23; translocation; ALL-1;
KW   human; acute nonlymphoblastic leukemia; ANLL; interstitial; monocytic;
KW   deletion; reciprocal; t(4:11); chromosome 4; AF-4; acute lymphocytic;
KW   oncogenic fusion protein; translocation breakpoint mapping; diagnosis;
KW   myelomonocytic; treatment; myelogenous; leukemia; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   exon            1. .6
FT                   /*tag=  a
FT                   /note= "Exon 6"
FT   intron          7. .16
FT                   /*tag=  b
FT                   /note= "Intron 6"
XX
PN   WO9312136-A1.
XX
PD   24-JUN-1993.
XX
PF   09-DEC-1992;   92WO-US010930.
XX
PR   11-DEC-1991;   91US-00805093.
PR   27-MAY-1992;   92US-00888839.
PR   30-OCT-1992;   92US-00971094.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Croce CM,  Canaani E;
XX
DR   WPI; 1993-214090/26.
XX
PT   Detection and treatment of acute leukaemia(s) - using prods. derived from
PT   oligo:nucleotide sequences within the ALL-1 gene of chromosome 11.
XX
PS   Disclosure; Fig 10A; 90pp; English.
XX
CC   The sequences given in AAQ43527-40 show the intron/exon boundary
CC   structures of the acute lymphoblastic leukemia gene (ALL-1) of chromosome
CC   11, in the breakpoint cluster region. The chromosomal region 11q23 has
CC   been shown to be involved in different chromosomal translocations in
CC   human ALL and acute nonlymphoblastic leukemia (ANLL). This region may be
CC   rearranged in acute leukemias with interstitial deletions or reciprocal
CC   translocations between this region and chromosomes 1, 2, 4, 6, 9, 10, 15,
CC   17 or 19. The break- point cluster region of the ALL-1 gene spans approx.
CC   8 kb and encompasses several small exons, esp. exons 6-12, most of which
CC   begin in the same phase of the open reading frame. The most common
CC   translocation which occurs is t(4:11) which results in two reciprocal
CC   fusion products coding for chimeric proteins derived from ALL-1 and a
CC   gene from chromosome 4 termed "AF-4" (see also AAQ43541-42). Therefore it
CC   is thought that each 11q23 abnormality gives rise to a specific oncogenic
CC   fusion protein. The ALL-1 gene was isolated by trans- location breakpoint
CC   mapping. Fragments of the ALL-1 cDNA may be used to identify chromosomal
```

```
CC   abnormalities within the ALL-1 gene. These fragments may be used in the
CC   treatment and diagnosis of human leukemias such as acute lymphocytic,
CC   myelomonocytic, monocytic and myelogenous leukemia. (Updated on 25-MAR-
CC   2003 to correct PN field.)
XX
SQ   Sequence 16 BP; 7 A; 0 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              |||||| |||||||
Db          3 AAAGGTGAGGAGAG 16


RESULT 1081
AAQ75196
ID   AAQ75196 standard; DNA; 16 BP.
XX
AC   AAQ75196;
XX
DT   25-MAR-2003  (revised)
DT   04-AUG-1995  (first entry)
XX
DE   ALL-1 breakpoint cluster region exon 6-intron structure.
XX
KW   Acute lymphoblastic leukaemia; acute nonlymphoblastic leukaemia;
KW   chromosomal translocation; chromosome 11; chimeric gene; detection;
KW   acute lymphocytic leukaemia gene; ALL-1; breakpoint cluster region; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   exon            1. .6
FT                   /*tag= a
FT                   /number= 6
FT                   /note= "3'-end of exon"
FT   intron          7. .16
FT                   /*tag= b
FT                   /note= "5'-end of intron"
XX
PN   WO9426930-A1.
XX
PD   24-NOV-1994.
XX
PF   22-APR-1994;   94WO-US004496.
XX
PR   14-MAY-1993;   93US-00062443.
XX
PA   (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI   Croce C,  Canaani E;
XX
DR   WPI; 1995-006818/01.
XX
PT   New acute lymphocytic leukaemia gene prods. - used for the diagnosis and
PT   treatment of leukaemia(s), partic. acute lymphoblastic or
PT   nonlymphoblastic leukaemia.
XX
PS   Disclosure; Fig 10A; 207pp; English.
XX
CC   Clustering of the t(4;11) breakpoints has previously been found within a
CC   small segment of the ALL-1 locus. This region includes 7 coding exons (6-
CC   12) containing 74, 132, 114, 147, 96, 121 and 123 bp, respectively. Exons
CC   8-12 contain four zinc-finger motifs. Exons 7-11 all begin in the first
CC   nucleotide of a codon. Precise mapping of five t(4;11) breakpoints
CC   localised them to introns between exons 6 and 7, 7 and 8, and 8 and 9.
CC   These breaks in chromosome 11 result in removal of the N-terminal 996
CC   amino acids from the ALL-1 protein, as well as in disjoining the 5'-
CC   noncoding region of the gene. (Updated on 25-MAR-2003 to correct PN
CC   field.)
XX
SQ   Sequence 16 BP; 7 A; 0 C; 8 G; 1 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              |||||| |||||||
Db          3 AAAGGTGAGGAGAG 16


RESULT 1082
AAX33869
ID   AAX33869 standard; DNA; 16 BP.
XX
AC   AAX33869;
XX
DT   25-JUN-1999  (first entry)
XX
DE   HPV-16 inhibitor.
XX
KW   HPV-16; inhibitor; antisense oligonucleotide; E6/E7 gene; human;
KW   keratinocyte; cervical cell; cervical tumour; ss.
XX
OS   Synthetic.
OS   Human papillomavirus type 16.
XX
PN   WO9913071-A1.
XX
PD   18-MAR-1999.
XX
PF   03-SEP-1998;   98WO-US018320.
XX
PR   05-SEP-1997;   97US-00929140.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Dipaolo J,  Alvarez-Salas L;
XX
DR   WPI; 1999-243727/20.
XX
PT   New antisense oligonucleotide analogs for inhibiting growth of cervical
PT   tumors.
XX
PS   Claim 4; Page 33; 40pp; English.
XX
CC   This sequence represents an antisense oligonucleotide of the invention.
CC   The antisense oligonucleotide analogs (ONs) have a sequence complementary
CC   to a sequence of nucleotides 415-445 of human papilloma virus-16 (HPV-
CC   16). The antisense ONs can be used to inhibit expression of HPV gene
CC   E6/E7 in living cells, preferably human keratinocytes or human cervical
CC   cells. They bind to E6/E7 mRNA in the cell, prevent mRNA translation and
CC   promote mRNA degradation by intracellular RNase H. They can be used for
CC   preventing transformation of living cells by HPV. The antisense ONs are
CC   used particularly for inhibiting the growth of cervical tumours
XX
SQ   Sequence 16 BP; 5 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCA 2017
              |||||||||| ||
Db          1 TTCTTCAGAGAACA 14


RESULT 1083
AAX33872
ID   AAX33872 standard; RNA; 16 BP.
XX
AC   AAX33872;
XX
```

DT 25-JUN-1999 (first entry)
XX
DE HPV-16 inhibitor.
XX
KW HPV-16; inhibitor; antisense oligonucleotide; E6/E7 gene; human;
KW keratinocyte; cervical cell; cervical tumour; ss.
XX
OS Synthetic.
OS Human papillomavirus type 16.
XX
PN WO9913071-A1.
XX
PD 18-MAR-1999.
XX
PF 03-SEP-1998; 98WO-US018320.
XX
PR 05-SEP-1997; 97US-00929140.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Dipaolo J, Alvarez-Salas L;
XX
DR WPI; 1999-243727/20.
XX
PT New antisense oligonucleotide analogs for inhibiting growth of cervical
PT tumors.
XX
PS Claim 6; Page 33; 40pp; English.
XX
CC This sequence represents an antisense oligonucleotide of the invention.
CC The antisense oligonucleotide analogs (ONs) have a sequence complementary
CC to a sequence of nucleotides 415-445 of human papilloma virus-16 (HPV-
CC 16). The antisense ONs can be used to inhibit expression of HPV gene
CC E6/E7 in living cells, preferably human keratinocytes or human cervical
CC cells. They bind to E6/E7 mRNA in the cell, prevent mRNA translation and
CC promote mRNA degradation by intracellular RNase H. They can be used for
CC preventing transformation of living cells by HPV. The antisense ONs are
CC used particularly for inhibiting the growth of cervical tumours
XX
SQ Sequence 16 BP; 5 A; 3 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 5.5e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2004 TTCTTCAGAGATCA 2017
::|::|||||| ||
Db 1 UUCUUCAGAGAACA 14

RESULT 1084
AAX54337/c
ID AAX54337 standard; DNA; 16 BP.
XX
AC AAX54337;
XX
DT 05-JUL-1999 (first entry)
XX
DE Inducible nitric oxide synthase antisense oligonucleotide.
XX
KW Antisense oligonucleotide; multiple target; antisense treatment;
KW impaired respiration; inflammation; lung disease;
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW prostate cancer; ss.
XX
OS Synthetic.
XX
PN WO9913886-A1.
XX
PD 25-MAR-1999.
XX
PF 17-SEP-1998; 98WO-US019419.
XX
PR 17-SEP-1997; 97US-0059160P.
PR 09-JUN-1998; 98US-00093972.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 1999-229400/19.
XX
PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT vasoconstriction.
XX
PS Disclosure; Page 62; 120pp; English.
XX
CC The specification describes antisense oligonucleotides (AAX52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene initiation
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'
CC -end and the juxta-section between coding and non-coding regions and all
CC segments of RNAs encoding proteins associated with one or more diseases,
CC conditions or mixtures. The antisense oligonucleotides may be derived
CC from sequences AAX55272-74. These multiple target oligonucleotides
CC (specifically AAX55180-271) can be used for the antisense treatment of
CC diseases and conditions. Typical diseases and conditions are those
CC associated with impaired respiration and inflammation, including lung
CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC acute asthma, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC well as all types of cancers which may metastasize or have metastasized
CC to the lungs, including breast and prostate cancer
XX
SQ Sequence 16 BP; 0 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 5.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1851 CCAACAGACCCACA 1864
|||||| ||||||
Db 14 CCAACAGCCCCACA 1

RESULT 1085
AAA33781/c
ID AAA33781 standard; DNA; 16 BP.
XX
AC AAA33781;
XX
DT 28-JUL-2000 (first entry)
XX
DE Low adenosine antisense oligonucleotide SEQ ID NO:1470.
XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX

PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US017712.
XX
PR 03-AUG-1998; 98US-0095212P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstruction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
XX
PS Claim 18; Page 448; 1343pp; English.
XX
CC The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antiasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impeded respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasise to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of the
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC AAA33992) are specifically claimed ONs from the present invention. N.B.
CC Sequences given in the disclosure of the present invention do not match
CC up with their corresponding SEQ ID NO: sequences given in the sequence
CC listing
XX
SQ Sequence 16 BP; 0 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 5.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1851 CCAACAGACCCACA 1864
||||||| ||||||
Db 14 CCAACAGCCCCACA 1

RESULT 1086
AAZ97699/c
ID AAZ97699 standard; DNA; 16 BP.
XX
AC AAZ97699;
XX
DT 15-SEP-2003 (revised)
DT 26-APR-2000 (first entry)
XX
DE HIV-1 protease gene probe SEQ ID NO:189.
XX
KW Human immunodeficiency virus; HIV; protease; probe; detection;
KW drug selected mutation; hybridisation; genotyping; infection;
KW drug resistance; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN WO9967428-A2.
XX
PD 29-DEC-1999.
XX
PF 22-JUN-1999; 99WO-EP004317.
XX
PR 24-JUN-1998; 98EP-00870143.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Stuyver L;
XX
DR WPI; 2000-147219/13.
XX
PT Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.
XX
PS Claim 3; Page 37; 76pp; English.
XX
CC The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC and AAZ97516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC drug resistance. The method may also be used for HIV protease genotyping
CC assays. The probes are able to discriminate between wild type and mutated
CC protease sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)
XX
SQ Sequence 16 BP; 5 A; 1 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 5.5e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1971 TTACCTTGAAAAAA 1984
||||||||| ||||
Db 16 TTACCTTGATAAAA 3

RESULT 1087
AAF19903/c
ID AAF19903 standard; DNA; 16 BP.
XX
AC AAF19903;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human inducible nitric oxide synthase polynucleotide fragment #1470.
XX
KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.
XX
OS Homo sapiens.
XX

```
PN   WO200062736-A2.
XX
PD   26-OCT-2000.
XX
PF   24-MAR-2000; 2000WO-US008020.
XX
PR   06-APR-1999;   99US-0127958P.
XX
PA   (UYEC-) UNIV EAST CAROLINA.
PA   (NYCE/) NYCE J W.
XX
PI   Nyce JW;
XX
DR   WPI; 2000-679539/66.
XX
PT   Low adenosine (A) content antisense oligonucleotides which do not trigger
PT   adenosine receptors during metabolism, useful e.g. for treating cancers
PT   and respiratory obstructions.
XX
PS   Claim 14; Page 256; 1592pp; English.
XX
CC   The present invention describes low adenosine (A) content antisense
CC   oligonucleotides and compositions (I) comprising them. In the antisense
CC   oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC   (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC   immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC   The antisense oligonucleotides and (I) can be used to down-regulate the
CC   expression and or activity of target polypeptides associated with
CC   lung/respiratory disorders and malignancies, such as stimulating and
CC   activating peptide factors and transmitters, transcription factors,
CC   immunoglobulins and antibodies, antibody receptors, cytokines and
CC   chemokines, endogenously produced specific and non-specific enzymes,
CC   binding proteins, adhesion molecules and their receptors, cytokine and
CC   chemokine receptors, adenosine receptors, bradykinin receptors, central
CC   nervous system (CNS) and peripheral nervous and non-nervous system
CC   receptors, CNS and peripheral nervous and non-nervous system peptide
CC   transmitters, defensins, growth factors, vasoactive peptides and
CC   receptors, binding proteins and malignancy associated proteins. The
CC   antisense oligonucleotides may be used in this way to treat disorders
CC   including respiratory obstruction (especially pulmonary obstruction
CC   and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC   surfactant hypoproduction which are associated with a disease or
CC   condition selected from pulmonary vasoconstriction, inflammation,
CC   allergies, asthma, impeded respiration, respiratory distress syndrome
CC   (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC   pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC   and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC   fragments and antisense oligonucleotides used in the exemplification of
CC   the present invention
XX
SQ   Sequence 16 BP; 0 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              ||||||| ||||||
Db         14 CCAACAGCCCCACA 1

RESULT 1088
AAF24327/c
ID   AAF24327 standard; DNA; 16 BP.
XX
AC   AAF24327;
XX
DT   09-APR-2001  (first entry)
XX
DE   Human NFAR-1/NFAR-2 intron/exon junction sequence #27.
XX
KW   Human; nuclear factor associated with dsRNA; NFAR-1; NFAR-2;
KW   transcription regulator; chromosome 19p13.1-13.2; apoptosis;
KW   tumourigenesis; ds.
XX
OS   Homo sapiens.
XX
PN   WO200077205-A1.
XX
PD   21-DEC-2000.
XX
PF   09-JUN-2000; 2000WO-US015767.
XX
PR   11-JUN-1999;   99US-0138612P.
XX
PA   (BARB/) BARBER G N.
PA   (SAUN/) SAUNDERS L.
PA   (PERK/) PERKINS D J.
XX
PI   Barber GN,  Saunders L,  Perkins DJ;
XX
DR   WPI; 2001-080688/09.
XX
PT   Novel isolated human nuclear factor associated with dsRNA polypeptide
PT   useful for determining structure-function relationships and as affinity
PT   tag to identify and isolate interacting proteins that bind to the factor.
XX
PS   Disclosure; Page 62; 73pp; English.
XX
CC   The present invention provides the protein and coding sequences of two
CC   human nuclear factors associated with dsRNA (NFAR-1 and NFAR-2). These
CC   are transcriptional regulators and are thought to play a role in
CC   apoptosis and tumourigenesis. The coding sequence (found on chromosome
CC   19p13.1-13.2) is useful as a probe to detect rearrangements in tumour
CC   cells and the protein is useful for determining structure-function
CC   relationships
XX
SQ   Sequence 16 BP; 3 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1604 CTGGCCTGGGGGAA 1617
              ||||||| ||||||
Db         15 CTGGCCTAGGGGAA 2

RESULT 1089
ADF13651
ID   ADF13651 standard; DNA; 16 BP.
XX
AC   ADF13651;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Chromosome 21 segment HS21C048, BaySNP 900080, PCR primer #1.
XX
KW   Cardiant; antiarteriosclerotic; vasotropic; cerebroprotective;
KW   hypotensive; gene therapy; human; chromosome 21; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003072813-A2.
XX
PD   04-SEP-2003.
XX
PF   14-FEB-2003; 2003WO-EP001514.
XX
PR   27-FEB-2002; 2002EP-00004258.
XX
PA   (FARB ) BAYER AG.
XX
PI   Stropp U,  Schwers S,  Kallabis H;
XX
```

```
DR   WPI; 2003-712738/67.
XX
PT   New isolated polynucleotide encoded by a phenotype-associated gene,
PT   useful for prognosticating statin therapy response, and diagnosing or
PT   treating cardiovascular diseases, such as hypertension, myocardial
PT   infarction and stroke.
XX
PS   Example 1; Page 74; 182pp; English.
XX
CC   The present invention relates to human phenotype-associated (PA) genes (I
CC   ; ADF13307-ADF13386) which contain a Single Nucleotide Polymorphism
CC   (SNP). The SNP is given in the sequence as a variant nucleotide. Also
CC   claimed are methods for screening for agents which regulate the activity
CC   of a PA gene and reagents that modulate the activity of a PA polypeptide
CC   or a polynucleotide where the reagent is identified by the screening
CC   methods. The methods and compositions of the present invention are useful
CC   for prognosticating, diagnosing and treating cardiovascular diseases,
CC   such as atherosclerosis, hypertension, restenosis, arterial inflammation,
CC   myocardial infarction and stroke. The present sequence is a PCR primer,
CC   used in the examples from the invention.
XX
SQ   Sequence 16 BP; 2 A; 9 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1574 CTTCTCCACCGCAC 1587
              || ||||||||||||
Db          1 CTCCTCCACCGCAC 14


RESULT 1090
ADI20606
ID   ADI20606 standard; DNA; 16 BP.
XX
AC   ADI20606;
XX
DT   15-APR-2004  (first entry)
XX
DE   Putative eRNA sequence #15.
XX
KW   ds; eRNA.
XX
OS   Saccharomyces cerevisiae.
XX
PN   WO2003025229-A1.
XX
PD   27-MAR-2003.
XX
PF   19-SEP-2002; 2002WO-AU001286.
XX
PR   19-SEP-2001; 2001US-0324127P.
XX
PA   (UYQU ) UNIV QUEENSLAND.
XX
PI   Mattick J,  Gagen M,  Stanley S;
XX
DR   WPI; 2003-371830/35.
XX
PT   Identifying an eRNA or a DNA sequence comprising an eRNA-encoding
PT   sequence in the nucleome of a eukaryotic cell, comprising identifying non
PT   -protein-encoding nucleotide sequences within an mRNA transcript or a DNA
PT   sequence.
XX
PS   Example 14; SEQ ID NO 96; 137pp; English.
XX
CC   The present invention relates to identifying an eRNA or a DNA sequence
CC   comprising an eRNA-encoding sequence in the nucleome of a eukaryotic cell
CC   comprises identifying non-protein-encoding nucleotide sequences within an
CC   mRNA transcript or a DNA sequence encoding same in the nucleome. The
CC   methods are useful for identifying an eRNA or DNA for modifying a genetic
CC   network in cell to alter the cells phenotype. The present sequence
CC   represents a putative eRNA sequence of the invention.
XX
SQ   Sequence 16 BP; 0 A; 5 C; 0 G; 11 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1788 CATTCTTTCCTTCT 1801
              | ||||||||||||
Db          2 CTTTCTTTCCTTCT 15


RESULT 1091
ABZ95597/c
ID   ABZ95597 standard; DNA; 16 BP.
XX
AC   ABZ95597;
XX
DT   17-OCT-2003  (first entry)
XX
DE   Human inducible nitric oxide synthase antisense fragment no.1461.
XX
KW   Human; antisense; lung dysfunction; nasal airway dysfunction;
KW   antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW   antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW   antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW   adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW   lung inflammation; respiratory disease; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285308-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013135.
XX
PR   24-APR-2001; 2001US-0286137P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-229219/22.
XX
PT   Pharmaceutical composition for treating ailments associated with impaired
PT   respiration, has oligo(s) antisense to specific gene(s) or its
PT   corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT   ubiquinone.
XX
PS   Disclosure; SEQ ID NO 10839; 872pp; English.
XX
CC   The invention relates to a novel pharmaceutical composition, which has a
CC   first active agent comprising an oligonucleotide antisense to the
CC   initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC   5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC   junctions of genes encoding a polypeptide associated with lung and/or
CC   nasal airway dysfunction and a second active agent comprising an
CC   antiinflammatory steroid and ubiquinone. A composition of the invention
CC   has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC   immunosuppressive, and cytostatic activity. The composition may have a
CC   use in antisense gene therapy. The composition is useful for treating or
CC   preventing a respiratory, lung or malignant disease or condition, also
CC   for enhancing the prophylactic or therapeutic respiratory effect of an
CC   antiinflammatory steroid in a subject, for reducing or depleting levels
CC   of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC   receptor, producing bronchodilation, increasing levels of ubiquinone or
CC   lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC   lung inflammation, lung allergies, or a respiratory disease or condition.
CC   Note: The sequence data for this patent is not represented in the printed
CC   specification, but was obtained in electronic format directly from WIPO
```

```
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 16 BP; 0 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              ||||||| ||||||
Db         14 CCAACAGCCCCACA 1


RESULT 1092
ABD19756/c
ID   ABD19756 standard; DNA; 16 BP.
XX
AC   ABD19756;
XX
DT   29-JUL-2004  (first entry)
XX
DE   Human inducible nitric oxide synthase DNA fragment 1461.
XX
KW   Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW   respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW   surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW   analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW   beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW   respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW   emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW   pulmonary transplantation rejection; ds.
XX
OS   Homo sapiens.
XX
PN   WO200285309-A2.
XX
PD   31-OCT-2002.
XX
PF   23-APR-2002; 2002WO-US013143.
XX
PR   24-APR-2001; 2001US-0286036P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Li Y,  Sandrasagra A,  Katz E,  Pabalan J,  Aguilar D;
PI   Miller S,  Tang L,  Shahabuddin S;
XX
DR   WPI; 2003-093058/08.
XX
PT   Pharmaceutical composition for treating asthma, has antisense
PT   oligonucleotide containing less percentage of adenosine, targeted to
PT   nucleic acids associated with lung airway or lung dysfunction, and
PT   bronchodilating agent.
XX
PS   Claim 15; SEQ ID NO 10839; 763pp; English.
XX
CC   This invention describes a novel composition (a) a first active agent,
CC   comprising oligonucleotides, effective for alleviating
CC   bronchoconstriction, respiratory tract inflammation, allergies and
CC   reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC   surfactant depletion or hyposecretion, when administered to a mammal. The
CC   oligonucleotides are derived from a gene encoding or regulating
CC   expression of a target polypeptide associated with lung airway or lung
CC   dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC   The invention also describes a kit, that comprises: (a) a delivery
CC   device, in separate containers, (b) the oligonucleotides, (c)
CC   instructions for adding a carrier and for use of the kit. The composition
CC   of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC   analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC   beta-adrenergic agonist. The composition is useful for preventing or
CC   treating a respiratory, lung or malignant disease. The administered
CC   composition comprises oligo and is administered to reduce the production
CC   or availability, or to increase the degradation of the target mRNA or to
CC   reduce the amount of target polypeptide present in the lungs. The
CC   pulmonary obstruction, and/or bronchoconstriction and/or lung
CC   inflammation, allergies and/or surfactant hypoproduction are associated
CC   with a disease or condition such as pulmonary vasoconstriction,
CC   inflammation, allergies, asthma, impeded respiration, respiratory
CC   distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC   hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC   transplantation rejection, pulmonary infections, bronchitis or cancer.
CC   The reduced adenosine content of the anti-sense oligos corresponding to
CC   thymidines present in the target RNA serves to prevent the breakdown of
CC   the oligonucleotides into products that free adenosine into the system
CC   e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC   prevent any unwanted effects due to it
XX
SQ   Sequence 16 BP; 0 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 5.5e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              ||||||| ||||||
Db         14 CCAACAGCCCCACA 1


RESULT 1093
AAQ98017/c
ID   AAQ98017 standard; DNA; 17 BP.
XX
AC   AAQ98017;
XX
DT   25-MAR-2003  (revised)
DT   19-OCT-1995  (first entry)
XX
DE   PNA oligomer targetting HIV gag/pol gene.
XX
KW   Peptide nucleic acid; PNA; HIV; human immunodeficiency virus; AIDS;
KW   antiviral; antisense; triple helix; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1. .20
FT                   /*tag=  a
FT                   /note= "at least one (and preferably all) of the backbone
FT                   subunits are composed of N-acetyl N-(2-aminoethyl)glycine
FT                   peptide residues, the nucleobase being attached
FT                   covalently to the acetyl group and the peptide linkage
FT                   being formed by condensation of the glycine carboxy group
FT                   of one residue with the amino group of the 2-aminoethyl
FT                   moiety in the next residue"
FT   misc_feature    17
FT                   /*tag=  b
FT                   /mod_base= T-Lys
XX
PN   WO9504068-A1.
XX
PD   09-FEB-1995.
XX
PF   28-JUL-1994;   94WO-US008517.
XX
PR   29-JUL-1993;   93US-00099718.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Ecker DJ;
XX
DR   WPI; 1995-082179/11.
XX
PT   Oligomer hybridisable to HIV sequence and contg. peptide nucleic acid
PT   sub:unit - binds in complementary manner to DNA and RNA, and useful for
PT   modulating HIV viral activity, e.g. in treating AIDS.
XX
```

```
PS   Claim 2; Page 177; 186pp; English.
XX
CC   New peptide nucleic acid (PNA) oligomers are provided which (a) consist
CC   of naturally occurring nucleobases covalently bound to a polyamide
CC   backbone and (b) hybridise to the translation initiation AUG region, 5'
CC   untranslated region (5' UTR), 3' untranslated region (3' UTR), splice
CC   junctions or coding sequence of a human immunodeficiency virus gene
CC   chosen from env, gag, pol, rev and tat. The PNAs can be used to target
CC   RNA and single stranded DNA (ssDNA) to produce antisense-type gene
CC   regulation moieties. They have utility as gene-targetted drugs for
CC   modulating HIV processes. Hence they can be used to treat AIDS and other
CC   viral infections. They are also useful in diagnostic applications and as
CC   research tools. PNA oligomers have high affinity for complementary single
CC   stranded DNA. They are also able to form triple helices in which a first
CC   PNA strand binds with RNA or ssDNA and a second PNA strand binds with the
CC   resulting double helix or with the first PNA strand. The PNAs possess no
CC   significant charge and are water soluble, which facilitates cellular
CC   uptake. Further, since they contain amides of non-biological amino acids,
CC   they are biostable and resistant to enzymatic degradation by proteases.
CC   The present sequence is a specifically claimed PNA sequence (represented
CC   by the sequence of nucleobases) targetting the HIV gag/pol gene. (Updated
CC   on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 17 BP; 0 A; 7 C; 0 G; 10 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGG 1561
              |||||||||| |||
Db         14 AGGGAAGGAAAAGG 1


RESULT 1094
AAX74673
ID   AAX74673 standard; RNA; 17 BP.
XX
AC   AAX74673;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #201.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 161; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 4 A; 8 C; 3 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   78.6%;  Pred. No. 5.7e+02;
  Matches   11;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAACA 1856
              :|||: ||||||||
Db          4 UCCCUCGGCCAACA 17


RESULT 1095
AAA36506/c
ID   AAA36506 standard; DNA; 17 BP.
XX
AC   AAA36506;
XX
DT   26-JUL-2000  (first entry)
XX
DE   Human genomic SNP allele specific oligonucleotide SEQ ID NO:571.
XX
KW   Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW   allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW   genomic classification; identification; DNA fingerprinting;
KW   tumour characterisation; hybridisation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200018960-A2.
XX
PD   06-APR-2000.
XX
PF   24-SEP-1999;   99WO-US022283.
XX
PR   25-SEP-1998;   98US-0101757P.
XX
PA   (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
PI   Landers JE,  Jordan B,  Housman DE,  Charest A;
XX
DR   WPI; 2000-293181/25.
XX
PT   Detection of single nucleotide polymorphisms in genomes by preparation
PT   and analysis of reduced complexity genomes, useful for genotyping,
PT   fingerprinting and determining allele frequency of SNPs.
XX
PS   Disclosure; Page 70; 111pp; English.
XX
CC   A method has been developed for detecting the presence or absence of a
CC   single nucleotide polymorphism (SNP) allele in a genomic sample. The
CC   method comprises preparing a reduced complexity genome (RCG) from the
CC   genomic sample and analysing the RCG for the presence or absence of a SNP
CC   allele. The method can be used to characterise a tumour, to generate a
CC   genomic pattern for an individual genome or to generate a genomic
CC   classification code for a genome. The method can be used to assess
CC   whether a subject is at risk for developing a disease or to identify a
CC   set of SNP alleles associated with a disease. The method can also be used
CC   to perform linkage analysis. AAA35944 to AAA35947 represent sequences
CC   used in the exemplification of the present invention. AAA35948 to
CC   AAA36632 represent nucleotide sequences containing SNPs
XX
```

```
SQ   Sequence 17 BP; 0 A; 3 C; 6 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACGCACACAC 2


RESULT 1096
AAA36505/c
ID   AAA36505 standard; DNA; 17 BP.
XX
AC   AAA36505;
XX
DT   26-JUL-2000  (first entry)
XX
DE   Human genomic SNP allele specific oligonucleotide SEQ ID NO:570.
XX
KW   Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
KW   allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
KW   genomic classification; identification; DNA fingerprinting;
KW   tumour characterisation; hybridisation; ss.
XX
OS   Homo sapiens.
XX
PN   WO200018960-A2.
XX
PD   06-APR-2000.
XX
PF   24-SEP-1999;   99WO-US022283.
XX
PR   25-SEP-1998;   98US-0101757P.
XX
PA   (MASI ) MASSACHUSETTS INST TECHNOLOGY.
XX
PI   Landers JE,  Jordan B,  Housman DE,  Charest A;
XX
DR   WPI; 2000-293181/25.
XX
PT   Detection of single nucleotide polymorphisms in genomes by preparation
PT   and analysis of reduced complexity genomes, useful for genotyping,
PT   fingerprinting and determining allele frequency of SNPs.
XX
PS   Disclosure; Page 70; 111pp; English.
XX
CC   A method has been developed for detecting the presence or absence of a
CC   single nucleotide polymorphism (SNP) allele in a genomic sample. The
CC   method comprises preparing a reduced complexity genome (RCG) from the
CC   genomic sample and analysing the RCG for the presence or absence of a SNP
CC   allele. The method can be used to characterise a tumour, to generate a
CC   genomic pattern for an individual genome or to generate a genomic
CC   classification code for a genome. The method can be used to assess
CC   whether a subject is at risk for developing a disease or to identify a
CC   set of SNP alleles associated with a disease. The method can also be used
CC   to perform linkage analysis. AAA35944 to AAA35947 represent sequences
CC   used in the exemplification of the present invention. AAA35948 to
CC   AAA36632 represent nucleotide sequences containing SNPs
XX
SQ   Sequence 17 BP; 0 A; 2 C; 6 G; 9 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACACACACAC 2


RESULT 1097
AAF06308
ID   AAF06308 standard; DNA; 17 BP.
XX
AC   AAF06308;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3105.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 127; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 4 A; 2 C; 2 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTT 1780
              ||||:::::: :::
Db          4 AAGCUUUUUUAUUU 17


RESULT 1098
AAF02093
ID   AAF02093 standard; DNA; 17 BP.
XX
AC   AAF02093;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #388.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
```

```
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 64; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 4 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1794 TTCCTTCTCTGAAA 1807
              |||| |||||||||
Db          1 TTCCCTCTCTGAAA 14


RESULT 1099
AAF06312
ID   AAF06312 standard; DNA; 17 BP.
XX
AC   AAF06312;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3109.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 42; Page 127; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 1 C; 1 G; 0 T; 12 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   21.4%;  Pred. No. 5.7e+02;
  Matches    3;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTT 1781
              |||:::::: ::::
Db          1 AGCUUUUUUAUUUU 14


RESULT 1100
AAF02092
ID   AAF02092 standard; DNA; 17 BP.
XX
AC   AAF02092;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #387.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 64; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1794 TTCCTTCTCTGAAA 1807
              |||| |||||||||
Db          3 TTCCCTCTCTGAAA 16
```

```
RESULT 1101
AAF03240/c
ID   AAF03240 standard; DNA; 17 BP.
XX
AC   AAF03240;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #1535.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 90; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 5 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTT 1926
              ||||||||| ||||
Db         14 AACAATACCCTTTT 1


RESULT 1102
ABK01749
ID   ABK01749 standard; RNA; 17 BP.
XX
AC   ABK01749;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Zinzyme #71.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 95; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a zinzyme molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 2 C; 3 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   35.7%;  Pred. No. 5.7e+02;
  Matches    5;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
```

```
                ::||::| ::|:|:
Db          3 UUAGUUGAUUCUCU 16


RESULT 1103
ABK02294
ID   ABK02294 standard; RNA; 17 BP.
XX
AC   ABK02294;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO DNAzyme #206.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 116; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a DNAzyme molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 2 C; 3 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   35.7%;  Pred. No. 5.7e+02;
  Matches    5;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
                ::||::| ::|:|:
Db          2 UUAGUUGAUUCUCU 15


RESULT 1104
ABK00595
ID   ABK00595 standard; RNA; 17 BP.
XX
AC   ABK00595;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Hammerhead Ribozyme #595.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
```

```
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 75; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a hammerhead ribozyme of the invention
XX
SQ   Sequence 17 BP; 3 A; 2 C; 3 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   35.7%;  Pred. No. 5.7e+02;
  Matches    5;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
              ::||::| ::|:|:
Db          4 UUAGUUGAUUCUCU 17


RESULT 1105
ABK01278
ID   ABK01278 standard; RNA; 17 BP.
XX
AC   ABK01278;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Inozyme #548.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 86; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an inozyme of the invention
XX
SQ   Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 5.7e+02;
  Matches    6;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAA 1836
              :: |||:|::::||
Db          1 UUGGAAUCUUUUAA 14


RESULT 1106
ABN07647/c
ID   ABN07647 standard; DNA; 17 BP.
```

XX
AC ABN07647;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7639.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 7639; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 6 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1688 GTTGTTTCTCTAGC 1701
||||||||||||||
Db 17 GTTGGTTCTCTAGC 4

RESULT 1107
ABN07648/c
ID ABN07648 standard; DNA; 17 BP.
XX
AC ABN07648;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7640.
XX
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS Disclosure; SEQ ID NO 7640; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

```
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         16 GTTGGTTCTCTAGC 3


RESULT 1108
ABN07198/c
ID   ABN07198 standard; DNA; 17 BP.
XX
AC   ABN07198;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7190.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7190; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         14 TCAGAGGTCAAGTC 1


RESULT 1109
ABN07195/c
ID   ABN07195 standard; DNA; 17 BP.
XX
AC   ABN07195;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7187.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
```

```
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7187; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         17 TCAGAGGTCAAGTC 4


RESULT 1110
ABN07197/c
ID   ABN07197 standard; DNA; 17 BP.
XX
AC   ABN07197;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7189.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7189; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         15 TCAGAGGTCAAGTC 2


RESULT 1111
ABN07196/c
ID   ABN07196 standard; DNA; 17 BP.
XX
AC   ABN07196;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7188.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
```

```
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7188; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         16 TCAGAGGTCAAGTC 3


RESULT 1112
ACN11763/c
ID   ACN11763 standard; RNA; 17 BP.
XX
AC   ACN11763;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11766.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L, Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11766; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 8 A; 2 C; 4 G; 0 T; 3 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGT 1933
              |||||| |||||||
Db         14 CCTTTTGTTTCAGT 1


RESULT 1113
ACN05922
ID   ACN05922 standard; RNA; 17 BP.
XX
AC   ACN05922;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 5925.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
```

XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 5925; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 8 G; 0 T; 1 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 5.7e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1606 GGCCTGGGGGAAGA 1619
              ||||:|||| ||||
Db          4 GGCCUGGGGAAAGA 17
```

RESULT 1114
ACN00281
ID ACN00281 standard; RNA; 17 BP.
XX
AC ACN00281;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Hammerhead Ribozyme substrate SEQ ID NO 271.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 271; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 3 A; 4 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 35.7%; Pred. No. 5.7e+02;
Matches 5; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1920 CCTTTTTTTTCAGT 1933
              ||:::: :::|||:
Db          4 CCUUUUGUUUCAGU 17
```

RESULT 1115
ACN09109/c
ID ACN09109 standard; RNA; 17 BP.
XX
AC ACN09109;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9112.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;

```
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9112; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 4 C; 3 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCA 1913
              ||| ||||||||||
Db         14 AGAACAACAGATCA 1

RESULT 1116
ACN00283
ID   ACN00283 standard; RNA; 17 BP.
XX
AC   ACN00283;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Hammerhead Ribozyme substrate SEQ ID NO 273.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 273; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   35.7%;  Pred. No. 5.7e+02;
  Matches    5;  Conservative    8;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1921 CTTTTTTTTCAGTG 1934
              |:::: :::|||:|
Db          1 CUUUUGUUUCAGUG 14

RESULT 1117
ACN11559/c
ID   ACN11559 standard; RNA; 17 BP.
XX
AC   ACN11559;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11562.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11562; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
```

```
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 8 C; 2 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGA 1619
              ||||||||| ||||
Db         14 GGCCTGGGGAAAGA 1

RESULT 1118
ACN05805
ID   ACN05805 standard; RNA; 17 BP.
XX
AC   ACN05805;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 5808.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC..
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 5808; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 9 A; 4 C; 2 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   85.7%;  Pred. No. 5.7e+02;
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAA 1914
              || |||||||:|||
Db          1 GAACAACAGAUCAA 14

RESULT 1119
ACN01808
ID   ACN01808 standard; RNA; 17 BP.
XX
AC   ACN01808;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Inozyme substrate SEQ ID NO 1798.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 1798; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 9 A; 3 C; 4 G; 0 T; 1 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   85.7%;  Pred. No. 5.7e+02;
```

```
  Matches   12;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCA 1913
              ||| ||||||:||
Db          4 AGAACAACAGAUCA 17


RESULT 1120
ACN09108/c
ID   ACN09108 standard; RNA; 17 BP.
XX
AC   ACN09108;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9111.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9111; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 2 C; 4 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAA 1914
              || ||||||||||
Db         17 GAACAACAGATCAA 4


RESULT 1121
ABT35130
ID   ABT35130 standard; DNA; 17 BP.
XX
AC   ABT35130;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 767.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 122; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 5 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2045 ATCTGCTTAGCAAC 2058
              ||||||| ||||||
Db          2 ATCTGCTGAGCAAC 15


RESULT 1122
ABT39205/c
```

```
ID   ABT39205 standard; DNA; 17 BP.
XX
AC   ABT39205;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 4842.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 600; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 2 A; 3 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTG 1993
              ||||||||| ||||
Db         17 AAAAAAGAACAGTG 4


RESULT 1123
ABT35289/c
ID   ABT35289 standard; DNA; 17 BP.
XX
AC   ABT35289;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 926.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 141; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1868 TTAGCCATTGAAAT 1881
              |||||||||| ||
Db         15 TTAGCCATTGAGAT 2


RESULT 1124
ABT38105
ID   ABT38105 standard; DNA; 17 BP.
XX
AC   ABT38105;
XX
```

DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3742.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 471; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1846 CTGGGCCAACAGAC 1859
||||| |||||||
Db 4 CTGGGTCAACAGAC 17

RESULT 1125
ABT35588
ID ABT35588 standard; DNA; 17 BP.
XX
AC ABT35588;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 1225.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 176; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 8 A; 1 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1828 ATCTTTTAAATACA 1841
|||||||||||| |
Db 2 ATCTTTTAAATAAA 15

RESULT 1126
ABT38195
ID ABT38195 standard; DNA; 17 BP.
XX
AC ABT38195;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3832.
XX

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 482; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 8 A; 2 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1873 CATTGAAATGTCAA 1886
              ||||||||| ||||
Db          4 CATTGAAATATCAA 17
```

RESULT 1127
ABT38459/c
ID ABT38459 standard; DNA; 17 BP.
XX
AC ABT38459;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 4096.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 512; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2003 CTTCTTCAGAGATC 2016
              ||||| ||||||||
Db         14 CTTCTCCAGAGATC 1
```

RESULT 1128
ABZ60793
ID ABZ60793 standard; RNA; 17 BP.
XX
AC ABZ60793;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNAzyme substrate #905.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX

```
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 102; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 5 A; 0 C; 5 G; 0 T; 7 U; 0 Other;

  Query Match              2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   50.0%;  Pred. No. 5.7e+02;
  Matches    7;  Conservative    6;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1935 TTAAGGTAATGGTT 1948
              ::||||:| :||::
Db          1 UUAAGGUAGUGGUU 14


RESULT 1129
ABZ61738
ID   ABZ61738 standard; RNA; 17 BP.
XX
AC   ABZ61738;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #529.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 121; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 0 A; 6 C; 6 G; 0 T; 5 U; 0 Other;

  Query Match              2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   71.4%;  Pred. No. 5.7e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGG 1614
              |:||:||||:| ||
Db          3 CUCCUGGCCUGCGG 16


RESULT 1130
ACD52107/c
ID   ACD52107 standard; RNA; 17 BP.
XX
AC   ACD52107;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HBV inozyme substrate sequence #237.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
```

```
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 154; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 0 A; 1 C; 8 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         14 CCAAAAGACCCACA 1


RESULT 1131
ACD53828/c
ID   ACD53828 standard; RNA; 17 BP.
XX
AC   ACD53828;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HBV zinzyme substrate sequence #49.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 174; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 2 A; 1 C; 6 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         17 CCAAAAGACCCACA 4


RESULT 1132
ACD57252/c
ID   ACD57252 standard; RNA; 17 BP.
XX
AC   ACD57252;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HCV DNAzyme substrate sequence #230.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
```

KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Claim 1; Page 238; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HCV
CC DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC invention
XX
SQ Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2013 GATCAAGTCCTCTG 2026
||||| ||||||||
Db 14 GATCATGTCCTCTG 1

RESULT 1133
ACD52591
ID ACD52591 standard; RNA; 17 BP.
XX
AC ACD52591;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV inozyme substrate sequence #466.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR 08-JUN-2001; 2001US-0296876P.
PR 24-OCT-2001; 2001US-0335059P.
PR 05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEP/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX
DR WPI; 2003-229207/22.
XX
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Example 1; Page 159; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 1 A; 5 C; 1 G; 0 T; 10 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;

```
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
                ::|:::||::|: :
Db          1 UUCUUUCCUUCUAU 14


RESULT 1134
ACD52590
ID   ACD52590 standard; RNA; 17 BP.
XX
AC   ACD52590;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HBV inozyme substrate sequence #465.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 159; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 1 A; 6 C; 0 G; 0 T; 10 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
                ::|:::||::|: :
Db          2 UUCUUUCCUUCUAU 15


RESULT 1135
ACD50754/c
ID   ACD50754 standard; RNA; 17 BP.
XX
AC   ACD50754;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HBV hammerhead ribozyme substrate sequence #220.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 140; 387pp; English.
XX
```

```
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 0 A; 1 C; 8 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
                ||||  |||||||||
Db         15 CCAAAAGACCCACA 2


RESULT 1136
ACD57251/c
ID   ACD57251 standard; RNA; 17 BP.
XX
AC   ACD57251;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HCV DNAzyme substrate sequence #229.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 238; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
                ||||| ||||||||
Db         16 GATCATGTCCTCTG 3


RESULT 1137
ACD51148
ID   ACD51148 standard; RNA; 17 BP.
XX
AC   ACD51148;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HBV hammerhead ribozyme substrate sequence #410.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
```

```
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 144; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 2 A; 5 C; 0 G; 0 T; 10 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          3 UUCUUUCCUUCUAU 16


RESULT 1138
ACD65418
ID   ACD65418 standard; RNA; 17 BP.
XX
AC   ACD65418;
XX
DT   30-SEP-2003  (first entry)
XX
DE   HCV minus strand DNAzyme substrate sequence #2049.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 311; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   64.3%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||:|| |:|||:|
Db          3 GAUCAUGUCCUCUG 16


RESULT 1139
ACD51147
ID   ACD51147 standard; RNA; 17 BP.
XX
AC   ACD51147;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HBV hammerhead ribozyme substrate sequence #409.
XX
```

```
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 144; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 2 A; 5 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          4 UUCUUUCCUUCUAU 17
```

```
RESULT 1140
ACC65425
ID   ACC65425 standard; DNA; 17 BP.
XX
AC   ACC65425;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 2672.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 343; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 6 A; 3 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAA 1914
              |||||||||  ||||
Db          1 GATCAACAGTTCAA 14
```

```
RESULT 1141
ACC68551
ID   ACC68551 standard; DNA; 17 BP.
XX
AC   ACC68551;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 5798.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
```

KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 708; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2013 GATCAAGTCCTCTG 2026
              ||||||||||| ||
Db          1 GATCAAGTCCTTTG 14
```

RESULT 1142
ACC68538
ID ACC68538 standard; DNA; 17 BP.
XX
AC ACC68538;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour supression, SEQ ID 5785.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 707; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2074 ATCTGACACACTCT 2087
              ||||||||| ||||
Db          2 ATCTGACACCCTCT 15
```

RESULT 1143
ACC65316
ID ACC65316 standard; DNA; 17 BP.
XX
AC ACC65316;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour supression, SEQ ID 2563.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 330; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,

```
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGG 1615
              |||||| |||||||
Db          3 TCCTGGACTGGGGG 16


RESULT 1144
ACC66327/c
ID   ACC66327 standard; DNA; 17 BP.
XX
AC   ACC66327;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 3574.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 448; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1891 ATGTGCCCTAGATC 1904
              ||||||| ||||||
Db         14 ATGTGCCATAGATC 1


RESULT 1145
ACC67926/c
ID   ACC67926 standard; DNA; 17 BP.
XX
AC   ACC67926;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 5173.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 635; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 3 A; 4 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGA 1987
              ||||| ||||||||
Db         16 CCTTGGAAAAAAGA 3


RESULT 1146
ADB44162
ID   ADB44162 standard; DNA; 17 BP.
XX
AC   ADB44162;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #4485.
```

XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 556; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2074 ATCTGACACACTCT 2087
|||||| |||||||
Db 2 ATCTGAGACACTCT 15

RESULT 1147
ADB41409
ID ADB41409 standard; DNA; 17 BP.
XX
AC ADB41409;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #1732.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 234; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1571 ATCCTTCTCCACCG 1584
|||||| |||||||
Db 2 ATCCTTGTCCACCG 15

RESULT 1148
ADB41530/c
ID ADB41530 standard; DNA; 17 BP.
XX
AC ADB41530;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #1853.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX

OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 248; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1601 CTCCTGGCCTGGGG 1614
||||||||||||| |
Db 17 CTCCTGGCCTGGTG 4

RESULT 1149
ADB43929
ID ADB43929 standard; DNA; 17 BP.
XX
AC ADB43929;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #4252.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 529; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX
SQ Sequence 17 BP; 8 A; 2 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1873 CATTGAAATGTCAA 1886
||||||||| ||||
Db 4 CATTGAAATATCAA 17

RESULT 1150
ADF62559/c
ID ADF62559 standard; DNA; 17 BP.
XX
AC ADF62559;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 463.
XX
KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW human; ss; probe.
XX
OS Homo sapiens.
XX
PN WO2003050284-A1.
XX
PD 19-JUN-2003.
XX
PF 22-NOV-2002; 2002WO-US037506.
XX

```
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 463; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 8 A; 2 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match              2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1916 AATACCTTTTTTT 1929
              ||||||  |||||||
Db         17 AATACCCTTTTTT 4


RESULT 1151
ADF62560/c
ID   ADF62560 standard; DNA; 17 BP.
XX
AC   ADF62560;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 464.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 464; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 8 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match              2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1916 AATACCTTTTTTT 1929
              ||||||  |||||||
Db         16 AATACCCTTTTTT 3


RESULT 1152
ADF62561/c
ID   ADF62561 standard; DNA; 17 BP.
XX
AC   ADF62561;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 465.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 465; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 9 A; 2 C; 3 G; 3 T; 0 U; 0 Other;
```

```
  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1916 AATACCTTTTTTT 1929
              ||||||  |||||||
Db         15 AATACCCTTTTTT 2


RESULT 1153
ADF62562/c
ID   ADF62562 standard; DNA; 17 BP.
XX
AC   ADF62562;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human PCCP1 DNA fragment SEQ ID 4-directed probe - SEQ ID 466.
XX
KW   chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
KW   prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
KW   human; ss; probe.
XX
OS   Homo sapiens.
XX
PN   WO2003050284-A1.
XX
PD   19-JUN-2003.
XX
PF   22-NOV-2002; 2002WO-US037506.
XX
PR   10-DEC-2001; 2001US-0339764P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Guo J;
XX
DR   WPI; 2003-532916/50.
XX
PT   New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
PT   composition for treating or preventing a disorder associated with
PT   decreased or increased expression or activity of PCCP1 e.g., tumor.
XX
PS   Example 2; SEQ ID NO 466; 164pp; English.
XX
CC   The invention relates to a novel isolated nucleic acid that encodes a
CC   protein with a chromatin organisation modifier (CHROMO) domain. The
CC   polynucleotide of the invention demonstrates cytostatic activity and may
CC   be useful for preparing a composition for treating or preventing a
CC   disorder associated with decreased or increased expression or activity of
CC   PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
CC   during gene therapy and vaccine production procedures. The current
CC   sequence is that of the human PCCP1-related DNA fragment SEQ ID 4-
CC   directed probe of the invention. Note: The current sequence is not shown
CC   within the specification per se but was retrieved from the WipoWeb
CC   database.
XX
SQ   Sequence 17 BP; 9 A; 1 C; 4 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1916 AATACCTTTTTTT 1929
              ||||||  |||||||
Db         14 AATACCCTTTTTT 1


RESULT 1154
ADI50278
ID   ADI50278 standard; DNA; 17 BP.
XX
AC   ADI50278;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID2781.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 2781; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 9 A; 1 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACA 1841
              ||||||||||| |
Db          2 ATCTTTTAAATAAA 15


RESULT 1155
ADI52771/c
ID   ADI52771 standard; DNA; 17 BP.
XX
AC   ADI52771;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID5274.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
```

```
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 5274; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 2 A; 3 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTG 1993
              ||||||||| ||||
Db         17 AAAAAAGAACAGTG 4


RESULT 1156
ADI52732
ID   ADI52732 standard; DNA; 17 BP.
XX
AC   ADI52732;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID5235.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A, Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 5235; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 8 A; 1 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACA 1841
              ||||||||||| |
Db          2 ATCTTTTAAATAAA 15


RESULT 1157
ADI52639
ID   ADI52639 standard; DNA; 17 BP.
XX
AC   ADI52639;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID5142.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
```

```
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 5142; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||||||||| ||
Db          1 GATCAAGTCCTTTG 14


RESULT 1158
ACC54457
ID   ACC54457 standard; DNA; 17 BP.
XX
AC   ACC54457;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #3224.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 784; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 8 A; 1 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACA 1841
              ||||||||||||| |
Db          2 ATCTTTTAAATAAA 15


RESULT 1159
ACC51609/c
ID   ACC51609 standard; DNA; 17 BP.
XX
AC   ACC51609;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #376.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 127; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 2 A; 3 C; 2 G; 10 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTG 1993
              ||||||||| ||||
Db         17 AAAAAAGAACAGTG 4
```

```
RESULT 1160
ADL49336
ID   ADL49336 standard; RNA; 17 BP.
XX
AC   ADL49336;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PKR substrate sequence #450.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 2869; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 5 A; 2 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 5.7e+02;
  Matches    6;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTT 1977
              :| |:|:::|||::
Db          2 UAGAUAUUUACCUU 15
```

```
RESULT 1161
ADL49335
ID   ADL49335 standard; RNA; 17 BP.
XX
AC   ADL49335;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PKR substrate sequence #449.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 2868; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 6 A; 3 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 5.7e+02;
  Matches    6;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTT 1977
              :| |:|:::|||::
Db          4 UAGAUAUUUACCUU 17
```

```
RESULT 1162
ADL49337
ID   ADL49337 standard; RNA; 17 BP.
XX
AC   ADL49337;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PKR substrate sequence #451.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 2870; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 5 A; 2 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   42.9%;  Pred. No. 5.7e+02;
  Matches    6;  Conservative    7;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTT 1977
              :| |:|:::|||::
Db          1 UAGAUAUUUACCUU 14
```

```
RESULT 1163
ADL51044/c
ID   ADL51044 standard; RNA; 17 BP.
XX
AC   ADL51044;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PTGDR substrate sequence #163.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 161; SEQ ID NO 4577; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATC 2016
              ||||||||||| ||
Db         17 CTTCTTCAGAGGTC 4
```

```
RESULT 1164
ADM59570/c
ID   ADM59570 standard; RNA; 17 BP.
XX
AC   ADM59570;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #1704.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 1704; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 2 A; 1 C; 6 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         17 CCAAAAGACCCACA 4


RESULT 1165
ADM58308
ID   ADM58308 standard; RNA; 17 BP.
XX
AC   ADM58308;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #442.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 442; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 2 A; 5 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          4 UUCUUUCCUUCUAU 17


RESULT 1166
ADM59033
```

```
ID   ADM59033 standard; RNA; 17 BP.
XX
AC   ADM59033;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #1167.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 1167; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 1 A; 5 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          1 UUCUUUCCUUCUAU 14


RESULT 1167
ADM58119/c
ID   ADM58119 standard; RNA; 17 BP.
XX
AC   ADM58119;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #253.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 253; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 0 A; 1 C; 8 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         15 CCAAAAGACCCACA 2


RESULT 1168
ADM58309
ID   ADM58309 standard; RNA; 17 BP.
XX
```

```
AC   ADM58309;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #443.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 443; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 2 A; 5 C; 0 G; 0 T; 10 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          3 UUCUUUCCUUCUAU 16


RESULT 1169
ADM59032
ID   ADM59032 standard; RNA; 17 BP.
XX
AC   ADM59032;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #1166.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 1166; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 1 A; 6 C; 0 G; 0 T; 10 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   28.6%;  Pred. No. 5.7e+02;
  Matches    4;  Conservative    9;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCT 1803
              ::|:::||::|: :
Db          2 UUCUUUCCUUCUAU 15


RESULT 1170
ADM58804/c
ID   ADM58804 standard; RNA; 17 BP.
XX
AC   ADM58804;
XX
```

```
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #938.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 938; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 0 A; 1 C; 8 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACA 1864
              |||| |||||||||
Db         14 CCAAAAGACCCACA 1

RESULT 1171
ADI82983/c
ID   ADI82983 standard; RNA; 17 BP.
XX
AC   ADI82983;
XX
DT   03-JUN-2004  (first entry)
XX
DE   HCV DNAzyme substrate sequence #229.
XX
KW   ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW   HCV infection; type I interferon; DNAzyme.
XX
OS   Hepatitis C virus.
XX
PN   US2003125270-A1.
XX
PD   03-JUL-2003.
XX
PF   18-DEC-2000; 2000US-00740332.
XX
PR   18-DEC-2000; 2000US-00740332.
XX
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (ROBE/) ROBERTS E.
PA   (PAVC/) PAVCO P A.
PA   (MACE/) MACEJACK D.
XX
PI   Blatt L,  Mcswiggen J,  Roberts E,  Pavco PA,  Macejack D;
XX
DR   WPI; 2004-031273/03.
XX
PT   Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT   from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT   especially in combination with type I interferon therapy.
XX
PS   Claim 1; SEQ ID NO 229; 198pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule which
CC   specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC   the binding arms of the enzymatic nucleic acid molecule comprises
CC   sequences complementary to any of the defined substrate sequences given
CC   in the specification. The nucleic acid molecule may be administered for
CC   the treatment of HCV infections, especially in combination with type I
CC   interferons. The present sequence represents a HCV DNAzyme substrate
CC   sequence.
XX
SQ   Sequence 17 BP; 6 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||| ||||||||
Db         16 GATCATGTCCTCTG 3

RESULT 1172
ADI87080
ID   ADI87080 standard; RNA; 17 BP.
XX
AC   ADI87080;
XX
DT   03-JUN-2004  (first entry)
XX
DE   HCV DNAzyme substrate sequence #4326.
XX
KW   ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW   HCV infection; type I interferon; DNAzyme.
XX
OS   Hepatitis C virus.
XX
PN   US2003125270-A1.
XX
PD   03-JUL-2003.
XX
PF   18-DEC-2000; 2000US-00740332.
XX
```

```
PR   18-DEC-2000; 2000US-00740332.
XX
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (ROBE/) ROBERTS E.
PA   (PAVC/) PAVCO P A.
PA   (MACE/) MACEJACK D.
XX
PI   Blatt L,  Mcswiggen J,  Roberts E,  Pavco PA,  Macejack D;
XX
DR   WPI; 2004-031273/03.
XX
PT   Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT   from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT   especially in combination with type I interferon therapy.
XX
PS   Claim 1; SEQ ID NO 4326; 198pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule which
CC   specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC   the binding arms of the enzymatic nucleic acid molecule comprises
CC   sequences complementary to any of the defined substrate sequences given
CC   in the specification. The nucleic acid molecule may be administered for
CC   the treatment of HCV infections, especially in combination with type I
CC   interferons. The present sequence represents a HCV DNAzyme substrate
CC   sequence.
XX
SQ   Sequence 17 BP; 3 A; 5 C; 3 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   64.3%;  Pred. No. 5.7e+02;
  Matches    9;  Conservative    4;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||:|| |:||:|:|
Db          3 GAUCAUGUCCUCUG 16


RESULT 1173
ADI82984/c
ID   ADI82984 standard; RNA; 17 BP.
XX
AC   ADI82984;
XX
DT   03-JUN-2004  (first entry)
XX
DE   HCV DNAzyme substrate sequence #230.
XX
KW   ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW   HCV infection; type I interferon; DNAzyme.
XX
OS   Hepatitis C virus.
XX
PN   US2003125270-A1.
XX
PD   03-JUL-2003.
XX
PF   18-DEC-2000; 2000US-00740332.
XX
PR   18-DEC-2000; 2000US-00740332.
XX
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (ROBE/) ROBERTS E.
PA   (PAVC/) PAVCO P A.
PA   (MACE/) MACEJACK D.
XX
PI   Blatt L,  Mcswiggen J,  Roberts E,  Pavco PA,  Macejack D;
XX
DR   WPI; 2004-031273/03.
XX
PT   Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT   from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT   especially in combination with type I interferon therapy.
XX
PS   Claim 1; SEQ ID NO 230; 198pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule which
CC   specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC   the binding arms of the enzymatic nucleic acid molecule comprises
CC   sequences complementary to any of the defined substrate sequences given
CC   in the specification. The nucleic acid molecule may be administered for
CC   the treatment of HCV infections, especially in combination with type I
CC   interferons. The present sequence represents a HCV DNAzyme substrate
CC   sequence.
XX
SQ   Sequence 17 BP; 6 A; 3 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 5.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||| ||||||||
Db         14 GATCATGTCCTCTG 1


RESULT 1174
AAZ43635
ID   AAZ43635 standard; DNA; 18 BP.
XX
AC   AAZ43635;
XX
DT   22-FEB-2000  (first entry)
XX
DE   Human familial dysautonomia D9S310 marker PCR primer 1.
XX
KW   Detection; polymorphism; familial dysautonomia; human; chromosome 9;
KW   D9S53; D9S105; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5998133-A.
XX
PD   07-DEC-1999.
XX
PF   07-JUN-1995;   95US-00480655.
XX
PR   29-MAY-1992;   92US-00890719.
PR   16-APR-1993;   93US-00049678.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Breakefield XO,  Slaugenhaupt S,  Blumenfeld A,  Gusella JF;
XX
DR   WPI; 2000-052539/04.
XX
PT   Detecting polymorphisms linked to a gene associated with familial
PT   dysautonomia.
XX
PS   Claim 8; Col 43-44; 33pp; English.
XX
CC   This invention describes a novel method for detecting the presence in a
CC   subject of a polymorphism linked to a gene associated with familial
CC   dysautonomia comprising analyzing human chromosome 9. The method
CC   comprises analyzing human chromosome 9 for the presence of a polymorphism
CC   located between D9S53 and D9S105 inclusive and linked to the gene
CC   associated with familial dysautonomia where the presence of a
CC   polymorphism is indicative of carriers of a gene associated with familial
CC   dysautonomia. The methods allow characterization of simple sequence
CC   repeat polymorphisms using less DNA, typically only 10 nanograms of
CC   genomic DNA, and is faster than restriction fragment length polymorphism
CC   analysis. AAZ43609-Z43642 represent PCR primers used in the detection
CC   method described in the method of the invention
XX
```

```
SQ   Sequence 18 BP; 6 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 CCTGGGCCAACAGA 1858
              ||||||| ||||||
Db          2 CCTGGGCAAACAGA 15


RESULT 1175
AAA10565
ID   AAA10565 standard; DNA; 18 BP.
XX
AC   AAA10565;
XX
DT   29-JUN-2000  (first entry)
XX
DE   Smad2 antisense oligonucleotide sequence #18 (ISIS# 27795).
XX
KW   Smad2; MADH2; MADR2; hMAD2; JV18-1; transcription factor; inflammation;
KW   chromosome 18q21; antisense compound; treat; prevent; infection; tumour;
KW   diagnostic reagent; research reagent; ss; cancer.
XX
OS   Synthetic.
XX
PN   US6037142-A.
XX
PD   14-MAR-2000.
XX
PF   23-FEB-1999;   99US-00255912.
XX
PR   23-FEB-1999;   99US-00255912.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 2000-269886/23.
XX
PT   New antisense compound that inhibits human Smad2, useful e.g. for
PT   treating or preventing infection, inflammation and tumors.
XX
PS   Claim 11; Col 39; 31pp; English.
XX
CC   This sequence represents an antisense nucleotide sequence targeting human
CC   Smad2. Smad2 is also known as MADH2, MADR2, hMAD2 and JV18-1, and is a
CC   member of a subgroup of Smad family transcription factors which are
CC   cytosolic proteins regulated by transforming growth factor-beta (TGF-
CC   beta) and activins. Smads exist as monomers in unstimulated cells as homo
CC   - or heterodimerise and translocate to the nucleus and activate target
CC   gene transcription upon ligand binding. The Smad2 gene is located on
CC   chromosome 18q21. The invention relates to antisense compounds (see
CC   AAA10548-A10587) targeted to the Smad2 nucleotide sequence. The antisense
CC   oligonucleotide sequences inhibit Smad2 expression by hybridising to DNA
CC   or RNA. The antisense nucleotides are used to treat or prevent diseases
CC   associated with expression of Smad2, e.g. infection, inflammation and
CC   tumours. The oligonucleotides can also be used as diagnostic or research
CC   reagents
XX
SQ   Sequence 18 BP; 4 A; 2 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1799 TCTCTGAAAGTGGT 1812
              ||||||| ||||||
Db          1 TCTCTGATAGTGGT 14


RESULT 1176
AAZ70501
ID   AAZ70501 standard; DNA; 18 BP.
XX
AC   AAZ70501;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:4857.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1266; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 18 BP; 1 A; 8 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCT 1798
              | ||||||||||||
Db          2 CTCCATTCTTTCCT 15


RESULT 1177
AAZ70322
ID   AAZ70322 standard; DNA; 18 BP.
XX
AC   AAZ70322;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:4678.
```

XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 1228; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 18 BP; 6 A; 0 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1533 AAAGGTTAGGAGAG 1546
||||||| ||||||
Db 5 AAAGGTTTGGAGAG 18

RESULT 1178
AAZ98488
ID AAZ98488 standard; DNA; 18 BP.
XX
AC AAZ98488;
XX
DT 19-JUN-2000 (first entry)
XX
DE H. discus derived sequence #6.
XX
KW Satellite sequence; DNA fragmentation; microsatellite DNA; DNA marker;
KW Haliotis discus; ss.
XX
OS Haliotis discus.
XX
PN WO200011156-A1.
XX
PD 02-MAR-2000.
XX
PF 01-JUL-1999; 99WO-JP003551.
XX
PR 18-AUG-1998; 98JP-00232153.
XX
PA (NORQ) JAPAN MIN AGRIC FORESTRY & FISHERIES.
XX
PI Takahashi H, Sekino M;
XX
DR WPI; 2000-224692/19.
XX
PT Isolation of satellite sequences from genomic DNA for use as DNA markers
PT comprises isolating a library with high homogeneity by DNA fragmentation.
XX
PS Example 5; Page 14; 35pp; Japanese.
XX
CC The invention provides a novel method for isolation of satellite
CC sequences from genomic DNA that comprises fragmentation of the DNA by a
CC method which is not dependent on base sequences, then selection of the
CC satellite sequences from the obtained genomic library of high
CC homogeneity. The method is useful for the isolation of microsatellite DNA
CC sequences which can be used as DNA markers. The new method markedly
CC improves the efficiency of isolation of satellite sequences in comparison
CC to prior art methods which are reliant on base sequences. Sequences
CC AAZ98483-514 represent sequences from Haliotis discus, used in the method
CC of the invention
XX
SQ Sequence 18 BP; 9 A; 6 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1854 ACAGACCCACACAC 1867
|||||| |||||||
Db 4 ACAGACACACACAC 17

RESULT 1179
AAA95181
ID AAA95181 standard; DNA; 18 BP.
XX
AC AAA95181;
XX
DT 12-JAN-2001 (first entry)
XX
DE Reverse primer used to amplify exon 1 of TNFR1 gene.
XX
KW TNFR1; tumour necrosis factor receptor; polymorphism; human; tumour;
KW cancer; apoptosis; bacterial infection; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200050436-A1.
XX
PD 31-AUG-2000.
XX
PF 23-FEB-2000; 2000WO-US004606.
XX
PR 23-FEB-1999; 99US-0121314P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
PA (NAND/) NANDABALAN K.
PA (SCHU/) SCHULZ V P.
PA (STEP/) STEPHENS J C.
PA (CHEW/) CHEW A.
XX
PI Nandabalan K, Schulz VP, Stephens JC, Chew A;
XX
DR WPI; 2000-543909/49.
XX
PT Polynucleotides comprising polymorphic variants of a reference sequence

PT for tumor necrosis factor receptor 1 (TNFR1), useful for studying the
PT biological function of TNFR1 and identifying drugs targeting the protein
PT for treating disorders.
XX
PS Example 1; Page 30; 79pp; English.
XX
CC The present invention relates to polymorphic variants of the tumour
CC necrosis factor receptor 1 (TNFR1) gene. The sequence of the gene is
CC given in AAA95102, AAA95103 and AAA95104. The polymorphisms were
CC identified by amplifying and sequencing regions of the gene. Twelve
CC polymorphic loci were discovered. Of these twelve polymorphisms, four can
CC cause a change in the TNFR1 protein. The present sequence is a primer
CC used to amplify part of the TNFR1 gene. The TNFR1 polymorphisms may be
CC useful for studying the biological function of TNFR1 as well as for
CC identifying drugs targeting the protein for treatment of disorders
CC related to its abnormal expression or function such as tumours, apoptosis
CC related disorders and bacterial infection
XX
SQ Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1839 ACATTCCCTGGGCC 1852
||||||||| ||||
Db 1 ACATTCCCTTGGCC 14

RESULT 1180
AAH56595
ID AAH56595 standard; DNA; 18 BP.
XX
AC AAH56595;
XX
DT 06-SEP-2001 (first entry)
XX
DE S. pneumoniae groE operon antisense oligonucleotide SEQ ID NO:243.
XX
KW Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
KW microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
KW Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
KW antibacterial; antiviral; antiproliferative; antisense therapy;
KW microbial infection; ss.
XX
OS Streptococcus pneumoniae.
XX
PN WO200136625-A2.
XX
PD 25-MAY-2001.
XX
PF 20-NOV-2000; 2000WO-CA001347.
XX
PR 18-NOV-1999; 99US-0166249P.
XX
PA (GENE-) GENESENSE TECHNOLOGIES INC.
XX
PI Wright JA, Young AH, Dugourd D;
XX
DR WPI; 2001-355633/37.
XX
PT Novel antisense compounds targeting nucleic acid encoding groEL or groES
PT gene of microorganism, which hybridize with and inhibit expression of the
PT genes, useful to inhibit growth of microorganism having the genes.
XX
PS Claim 3; Page 47; 110pp; English.
XX
CC The present invention specifically claims AAH56368 to AAH56832 which are
CC antisense oligonucleotides to nucleotide sequences encoding groE. More
CC generally, antisense compounds (I) comprising antisense oligonucleotides
CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
CC microorganism, where the antisense compound is complementary to GL or GS
CC of a microorganism and specifically hybridises with and inhibits the
CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
CC antiproliferative activities, and can be used in antisense therapy and
CC for inhibition of expression of groES or groEL. (I) are useful for
CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
CC also useful for inhibiting the growth of a microorganism, or inhibiting
CC the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC virus) having a GL or GS gene which involves administering to the
CC microorganism or to a cell infected with the microorganism, (I). (I) are
CC also useful for treating a mammalian pathological condition mediated by
CC the microorganisms which involves identifying a eukaryotic organism
CC having a pathological condition mediated by microorganisms having a GL or
CC GS gene and administering (I) such that the growth of microorganism is
CC inhibited. The antisense compounds are utilised for diagnostics,
CC therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC prevent or delay microbial infections in humans. They are also useful as
CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC represent PCR primers for groE sequences which are used in the
CC exemplification of the present invention. AAH56855 to AAH56870 represent
CC groE nucleotide sequence given in the present invention
XX
SQ Sequence 18 BP; 7 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1913 AACAATACCTTTTT 1926
||||||||||| ||
Db 1 AACAATACCTTCTT 14

RESULT 1181
AAH56823
ID AAH56823 standard; DNA; 18 BP.
XX
AC AAH56823;
XX
DT 06-SEP-2001 (first entry)
XX
DE S. aureus groE operon antisense oligonucleotide SEQ ID NO:471.
XX
KW Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
KW microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
KW Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
KW antibacterial; antiviral; antiproliferative; antisense therapy;
KW microbial infection; ss.
XX
OS Staphylococcus aureus.
XX
PN WO200136625-A2.
XX
PD 25-MAY-2001.
XX
PF 20-NOV-2000; 2000WO-CA001347.
XX
PR 18-NOV-1999; 99US-0166249P.
XX
PA (GENE-) GENESENSE TECHNOLOGIES INC.
XX
PI Wright JA, Young AH, Dugourd D;
XX
DR WPI; 2001-355633/37.
XX
PT Novel antisense compounds targeting nucleic acid encoding groEL or groES
PT gene of microorganism, which hybridize with and inhibit expression of the
PT genes, useful to inhibit growth of microorganism having the genes.
XX
PS Claim 3; Page 54; 110pp; English.
XX
CC The present invention specifically claims AAH56368 to AAH56832 which are
CC antisense oligonucleotides to nucleotide sequences encoding groE. More
CC generally, antisense compounds (I) comprising antisense oligonucleotides

```
CC   of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC   shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
CC   microorganism, where the antisense compound is complementary to GL or GS
CC   of a microorganism and specifically hybridises with and inhibits the
CC   expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
CC   antiproliferative activities, and can be used in antisense therapy and
CC   for inhibition of expression of groES or groEL. (I) are useful for
CC   inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
CC   also useful for inhibiting the growth of a microorganism, or inhibiting
CC   the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC   virus) having a GL or GS gene which involves administering to the
CC   microorganism or to a cell infected with the microorganism, (I). (I) are
CC   also useful for treating a mammalian pathological condition mediated by
CC   the microorganisms which involves identifying a eukaryotic organism
CC   having a pathological condition mediated by microorganisms having a GL or
CC   GS gene and administering (I) such that the growth of microorganism is
CC   inhibited. The antisense compounds are utilised for diagnostics,
CC   therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC   prevent or delay microbial infections in humans. They are also useful as
CC   molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC   represent PCR primers for groE sequences which are used in the
CC   exemplification of the present invention. AAH56855 to AAH56870 represent
CC   groE nucleotide sequence given in the present invention
XX
SQ   Sequence 18 BP; 7 A; 6 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match              2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTT 1926
              ||||||||||| ||
Db          1 AACAATACCTTCTT 14


RESULT 1182
AAS09265
ID   AAS09265 standard; DNA; 18 BP.
XX
AC   AAS09265;
XX
DT   24-OCT-2001  (first entry)
XX
DE   PCR primer #1 for marker D9S310 associated with familial dysautonomia.
XX
KW   Human; familial dysautonomia; chromosome 9q31-q33; Riley-Day syndrome;
KW   FD; developmental loss of neuron; nervous system; DNA marker D9S310;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   US6262250-B1.
XX
PD   17-JUL-2001.
XX
PF   07-DEC-1999;   99US-00455683.
XX
PR   29-MAY-1992;   92US-00890719.
PR   16-APR-1993;   93US-00049678.
PR   07-JUN-1995;   95US-00480655.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
XX
PI   Blumenfeld A,  Gusella JF,  Breakefield XO,  Slaugenhaupt S;
XX
DR   WPI; 2001-450493/48.
XX
PT   Kit for detecting presence of polymorphisms linked to gene associated
PT   with familial dysautonomia (FD), comprises specific primers which detect
PT   polymorphisms, D9S309 and D9S310 identified in candidate region for FD
PT   gene.
XX
PS   Claim 1; Col 15; 28pp; English.
XX
CC   The present sequence for PCR primer #1 is used with PCR primer #2
CC   (AAS09266) to amplify DNA marker D9S310. Various oligonucleotide
CC   sequences (AAS09239-AAS09272) are described in an invention relating to
CC   the detection of polymorphisms associated with familial dysautonomia
CC   (FD). The FD gene has been mapped to chromosome 9q31-q33 by linkage with
CC   10 DNA markers in 26 FD families. A kit to detect the presence of
CC   polymorphisms linked to a gene associated with FD, the Riley-Day syndrome
CC   (an autosomal recessive disorder characterised by developmental loss of
CC   neurons from sensory and autonomic nervous system) in an individual,
CC   comprises a nucleic acid primer of at least 15 contiguous nucleotides and
CC   at least one other reagent. The kits are useful for diagnosing familial
CC   dysautonomia and the test can be used prenatally to screen a foetus, or
CC   presymptomatically to screen a subject at risk in affected FD families
XX
SQ   Sequence 18 BP; 6 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match              2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 CCTGGGCCAACAGA 1858
              ||||||| ||||||
Db          2 CCTGGGCAAACAGA 15


RESULT 1183
ABA82497/c
ID   ABA82497 standard; DNA; 18 BP.
XX
AC   ABA82497;
XX
DT   25-JAN-2002  (first entry)
XX
DE   Zmax1 gene region physical map preparation STS marker #456.
XX
KW   Human; high bone mass; HBM gene; Zmax1 gene; chromosome 11; 11q13.3;
KW   sequence tagged site; STS; osteoporosis; osteopathic; gene therapy;
KW   antisense therapy; vaccine; bone disorder; Paget's disease; adapter;
KW   sclerostosis; osteomalacia; fibrous dysplasia; PCR primer; linker; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177327-A1.
XX
PD   18-OCT-2001.
XX
PF   21-JUN-2000; 2000WO-US016951.
XX
PR   05-APR-2000; 2000US-00543771.
PR   05-APR-2000; 2000US-00544398.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Carulli JP,  Little RD,  Recker RR,  Johnson ML;
XX
DR   WPI; 2001-657171/75.
XX
PT   New high bone mass (HBM) and Zmax1 genes and proteins useful for
PT   modulating bone mass for the treatment of e.g. osteoporosis.
XX
PS   Disclosure; Page 36; 443pp; English.
XX
CC   The present invention describes the human Zmax1 gene and the high bone
CC   mass (HBM) gene,which are found on chromosome 11q13.3. The Zmax1 and HBM
CC   genes have osteopathic activities. The genes can be used in gene therapy,
CC   antisense therapy and in the production of vaccines. They can be used in
CC   the diagnosis and treatment of bone disorders including osteoporosis,
CC   Paget's disease, sclerostosis, osteomalacia and fibrous dysplasia.
CC   ABA82038 to ABA82700 and AAG68168 to AAG68193 represent sequences used in
CC   the exemplification of the present invention
XX
```

```
SQ   Sequence 18 BP; 2 A; 6 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAA 2038
              ||||||| |||||
Db         15 TGGTAGGAAGCAAA 2


RESULT 1184
ABA82113/c
ID   ABA82113 standard; DNA; 18 BP.
XX
AC   ABA82113;
XX
DT   25-JAN-2002  (first entry)
XX
DE   Zmax1 gene region physical map preparation STS marker #72.
XX
KW   Human; high bone mass; HBM gene; Zmax1 gene; chromosome 11; 11q13.3;
KW   sequence tagged site; STS; osteoporosis; osteopathic; gene therapy;
KW   antisense therapy; vaccine; bone disorder; Paget's disease; adapter;
KW   sclerostosis; osteomalacia; fibrous dysplasia; PCR primer; linker; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200177327-A1.
XX
PD   18-OCT-2001.
XX
PF   21-JUN-2000; 2000WO-US016951.
XX
PR   05-APR-2000; 2000US-00543771.
PR   05-APR-2000; 2000US-00544398.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
XX
PI   Carulli JP,  Little RD,  Recker RR,  Johnson ML;
XX
DR   WPI; 2001-657171/75.
XX
PT   New high bone mass (HBM) and Zmax1 genes and proteins useful for
PT   modulating bone mass for the treatment of e.g. osteoporosis.
XX
PS   Disclosure; Page 33; 443pp; English.
XX
CC   The present invention describes the human Zmax1 gene and the high bone
CC   mass (HBM) gene,which are found on chromosome 11q13.3. The Zmax1 and HBM
CC   genes have osteopathic activities. The genes can be used in gene therapy,
CC   antisense therapy and in the production of vaccines. They can be used in
CC   the diagnosis and treatment of bone disorders including osteoporosis,
CC   Paget's disease, sclerostosis, osteomalacia and fibrous dysplasia.
CC   ABA82038 to ABA82700 and AAG68168 to AAG68193 represent sequences used in
CC   the exemplification of the present invention
XX
SQ   Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGA 1616
              |||||||||||  ||
Db         15 CCTGGCCTGGGTGA 2


RESULT 1185
AAI67723
ID   AAI67723 standard; DNA; 18 BP.
XX
AC   AAI67723;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Adenovirus-2 E1 alterations generating oligonucleotide.
XX
KW   Adenoassociated virus; rAAV; virion; E4; E2A; E1A; E1B; adenovirus; ss.
XX
OS   Synthetic.
XX
PN   WO200183797-A2.
XX
PD   08-NOV-2001.
XX
PF   20-APR-2001; 2001WO-US040561.
XX
PR   28-APR-2000; 2000US-0200453P.
XX
PA   (AVIG-) AVIGEN INC.
XX
PI   Colosi P;
XX
DR   WPI; 2002-049353/06.
XX
PT   New nucleic acids, useful in recombinant adeno-associated virus virion
PT   production, comprises adenoviral coding region of VA RNA, E4 ORF6, E2A
PT   72kD and E1A, and E1B region lacking intact E1B55K coding region.
XX
PS   Example 1; Page 32; 61pp; English.
XX
CC   The invention relates to a nucleic acid molecule which provides one or
CC   more accessory functions for supporting recombinant adenoassociated virus
CC   (rAAV) virion production in a suitable host cell. The molecule comprises
CC   a VA RNA coding region, E4 open reading frame (ORF) 6 coding region, E2A
CC   72kD coding region, E1A coding region and E1B region lacking an intact
CC   E1B55K coding region of an adenovirus (AV). An accessory function vector
CC   comprising the molecule is useful for producing rAAV. The method
CC   comprises introducing AAV vector into a suitable host cell, introducing
CC   an AAV helper construct into the cell, where the helper construct
CC   comprises AAV coding regions that are expressed in the host cell to
CC   complement AAV helper functions missing from AAV vector, introducing the
CC   accessory function vector into the cell; and culturing the cell to
CC   produce rAAV virions. The method can alternately be performed by two
CC   other methods. The molecule yields significant levels of rAAV particles
CC   without also generating significant levels of infectious helper virus or
CC   contaminating by-products. Sequences AAI67722-23 represent oligos used
CC   for causing E1A alterations
XX
SQ   Sequence 18 BP; 5 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2057 ACTAGTTAATAAGT 2070
              |||||||||| |||
Db          5 ACTAGTTAATTAGT 18


RESULT 1186
AAI67722/c
ID   AAI67722 standard; DNA; 18 BP.
XX
AC   AAI67722;
XX
DT   27-FEB-2002  (first entry)
XX
DE   Adenovirus-2 E1 alterations generating oligonucleotide.
XX
KW   Adenoassociated virus; rAAV; virion; E4; E2A; E1A; E1B; adenovirus; ss.
XX
OS   Synthetic.
XX
```

PN WO200183797-A2.
XX
PD 08-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US040561.
XX
PR 28-APR-2000; 2000US-0200453P.
XX
PA (AVIG-) AVIGEN INC.
XX
PI Colosi P;
XX
DR WPI; 2002-049353/06.
XX
PT New nucleic acids, useful in recombinant adeno-associated virus virion
PT production, comprises adenoviral coding region of VA RNA, E4 ORF6, E2A
PT 72kD and E1A, and E1B region lacking intact E1B55K coding region.
XX
PS Example 1; Page 32; 61pp; English.
XX
CC The invention relates to a nucleic acid molecule which provides one or
CC more accessory functions for supporting recombinant adenoassociated virus
CC (rAAV) virion production in a suitable host cell. The molecule comprises
CC a VA RNA coding region, E4 open reading frame (ORF) 6 coding region, E2A
CC 72kD coding region, E1A coding region and E1B region lacking an intact
CC E1B55K coding region of an adenovirus (AV). An accessory function vector
CC comprising the molecule is useful for producing rAAV. The method
CC comprises introducing AAV vector into a suitable host cell, introducing
CC an AAV helper construct into the cell, where the helper construct
CC comprises AAV coding regions that are expressed in the host cell to
CC complement AAV helper functions missing from AAV vector, introducing the
CC accessory function vector into the cell; and culturing the cell to
CC produce rAAV virions. The method can alternately be performed by two
CC other methods. The molecule yields significant levels of rAAV particles
CC without also generating significant levels of infectious helper virus or
CC contaminating by-products. Sequences AAI67722-23 represent oligos used
CC for causing E1A alterations
XX
SQ Sequence 18 BP; 6 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2057 ACTAGTTAATAAGT 2070
||||||||||| |||
Db 18 ACTAGTTAATTAGT 5

RESULT 1187
AAI67727
ID AAI67727 standard; DNA; 18 BP.
XX
AC AAI67727;
XX
DT 27-FEB-2002 (first entry)
XX
DE Adenovirus-2 E1B55K alterations generating oligonucleotide.
XX
KW Adenoassociated virus; rAAV; virion; E4; E2A; E1A; E1B; adenovirus; ss.
XX
OS Synthetic.
XX
PN WO200183797-A2.
XX
PD 08-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US040561.
XX
PR 28-APR-2000; 2000US-0200453P.
XX
PA (AVIG-) AVIGEN INC.
XX
PI Colosi P;
XX
DR WPI; 2002-049353/06.
XX
PT New nucleic acids, useful in recombinant adeno-associated virus virion
PT production, comprises adenoviral coding region of VA RNA, E4 ORF6, E2A
PT 72kD and E1A, and E1B region lacking intact E1B55K coding region.
XX
PS Example 1; Page 32; 61pp; English.
XX
CC The invention relates to a nucleic acid molecule which provides one or
CC more accessory functions for supporting recombinant adenoassociated virus
CC (rAAV) virion production in a suitable host cell. The molecule comprises
CC a VA RNA coding region, E4 open reading frame (ORF) 6 coding region, E2A
CC 72kD coding region, E1A coding region and E1B region lacking an intact
CC E1B55K coding region of an adenovirus (AV). An accessory function vector
CC comprising the molecule is useful for producing rAAV. The method
CC comprises introducing AAV vector into a suitable host cell, introducing
CC an AAV helper construct into the cell, where the helper construct
CC comprises AAV coding regions that are expressed in the host cell to
CC complement AAV helper functions missing from AAV vector, introducing the
CC accessory function vector into the cell; and culturing the cell to
CC produce rAAV virions. The method can alternately be performed by two
CC other methods. The molecule yields significant levels of rAAV particles
CC without also generating significant levels of infectious helper virus or
CC contaminating by-products. Sequences AAI67726-27 represent oligos used
CC for causing E1B55K alterations
XX
SQ Sequence 18 BP; 6 A; 2 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2057 ACTAGTTAATAAGT 2070
||||||||||| |||
Db 5 ACTAGTTAATTAGT 18

RESULT 1188
ABL88822/c
ID ABL88822 standard; DNA; 18 BP.
XX
AC ABL88822;
XX
DT 22-MAY-2002 (first entry)
XX
DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:44.
XX
KW Binding molecule; HIV-1; human immunodeficiency virus type 1;
KW reverse transcriptase; binding group; ss.
XX
OS Human immunodeficiency virus 1.
OS Synthetic.
XX
PN EP1174518-A1.
XX
PD 23-JAN-2002.
XX
PF 20-JUL-2000; 2000EP-00202611.
XX
PR 20-JUL-2000; 2000EP-00202611.
XX
PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
PI Loukachov VV, Van Gemen B, Goudsmit J;
XX
DR WPI; 2002-156696/21.
XX
PT Collection of binding groups for determining or typing samples,
PT especially clinical samples, has groups capable to identify essentially
PT all members of the family of nucleic acids of relatively high
PT significance.

XX
PS Disclosure; Page 17; 166pp; English.
XX
CC The present invention describes a collection of binding groups for a
CC family of nucleic acids comprising members of relative high and relative
CC low significance, where the binding groups are selected to be capable to
CC identify, alone or in combination, essentially all members of the family
CC of nucleic acids of relatively high significance. The collection of
CC binding groups is useful for typing of nucleic acid in a clinical sample,
CC by contacting the nucleic acid with the collection and determining
CC whether one or more binding groups bound to the nucleic acid of the
CC sample. This method is useful for determining whether the sample
CC comprises at least a part of a member of relatively high significance of
CC a family of nucleic acids. The collection of binding groups is useful for
CC diagnosing the severity of a disease caused by a pathogen containing a
CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC oligonucleotide sequences used in the exemplification of the present
CC invention
XX
SQ Sequence 18 BP; 7 A; 1 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1793 TTTCCTTCTCTGAA 1806
||||| ||||||||
Db 15 TTTCCATCTCTGAA 2

RESULT 1189
ABL61267
ID ABL61267 standard; DNA; 18 BP.
XX
AC ABL61267;
XX
DT 03-SEP-2002 (first entry)
XX
DE HIV Pol sequencing primer SEQ ID 5.
XX
KW Pol gene; primer; viral protease; reverse transcriptase; genotyping;
KW HIV infection; detection; drug resistance mutation; ss.
XX
OS Human immunodeficiency virus.
XX
PN US6379957-B1.
XX
PD 30-APR-2002.
XX
PF 21-SEP-1998; 98US-00158695.
XX
PR 21-SEP-1998; 98US-00158695.
XX
PA (JOHN/) JOHNSTON-DOW L A.
PA (DEME/) DEMETER L.
PA (WHIT/) WHITE C B.
PA (SONG/) SONG K.
PA (KOHL/) KOHLENBERGER R.
PA (CONR/) CONRAD M.
PA (MYER/) MYERS A.
XX
PI Johnston-Dow LA, Demeter L, White CB, Song K, Kohlenberger R;
PI Conrad M, Myers A;
XX
DR WPI; 2002-506465/54.
XX
PT Amplifying the HIV pol region using specific primers and a sequencing the
PT product using specific sequence primers allows detection of known drug
PT resistance mutations and so determination of viral genotype.
XX
PS Claim 8; Col 13-14; 12pp; English.
XX
CC This invention describes a novel method of analysing an HIV target
CC nucleic acid which comprises amplifying the target sequence using primers
CC specific for the HIV pol region (encoding the viral protease and reverse
CC transcriptase) and analysing the amplified product. The invention is used
CC to determine viral genotype of HIV infections by detecting known drug
CC resistance mutations in the HIV pol gene. The detection of mutations
CC conferring drug resistance in the HIV pol gene is significant in
CC determining drug sensitivity of the virus. A 1.57 kilobase region of the
CC HIV pol gene is a particularly important region containing clinically
CC relevant mutation. This sequence represents a seqencing primer used in
CC the detection of clinically important regions of the HIV pol gene
CC described in the invention
XX
SQ Sequence 18 BP; 6 A; 9 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1850 GCCAACAGACCCAC 1863
||||||| |||||
Db 2 GCCAACAGCCCCAC 15

RESULT 1190
ABK22910/c
ID ABK22910 standard; DNA; 18 BP.
XX
AC ABK22910;
XX
DT 09-APR-2002 (first entry)
XX
DE Human Zmax1 cDNA reverse PCR primer #36.
XX
KW Human; mouse; Zmax1; HBM; high bone mass gene; lipid regulation; stroke;
KW lipid-associated condition; arteriosclerosis; cardiovascular disease; ss;
KW osteoporosis; atherosclerosis; diabetic atherosclerosis; plaque build-up;
KW neurovascular condition; wound healing; gene therapy; PCR primer; probe;
KW bone development disorder; antiarteriosclerotic; cardiovascular;
KW osteopathic; cerebroprotective.
XX
OS Homo sapiens.
XX
PN WO200192891-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016946.
XX
PR 26-MAY-2000; 2000US-00578900.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
XX
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2002-097784/13.
XX
PT Identifying molecules involved in lipid regulation, useful for
PT diagnosing, treating or preventing e.g., arteriosclerosis, comprises
PT identifying a molecule that binds to high bone mass gene or its
PT corresponding wild type gene.
XX
PS Disclosure; Page 38; 409pp; English.
XX
CC The invention relates to a method for identifying a molecule involved in
CC lipid regulation comprising identifying a molecule that binds to or
CC inhibits binding of a molecule to high bone mass (HBM) or its wild type
CC gene, Zmax1. Compounds identified by the method are useful for treating,
CC diagnosing, preventing or screening for normal and abnormal lipid-
CC associated conditions, including arteriosclerosis, cardiovascular
CC disease, stroke, and osteoporosis. The compounds may also be used in the
CC treatment or prevention of diabetic atherosclerosis, neurovascular
CC conditions caused by plaque build-up, poor circulation due to plaque

CC build-up and associated poor wound healing. The methods may be used in
CC gene therapy, pharmaceutical development, and diagnostic assays for bone
CC development disorders. Molecules identified by comparison of Zmax1 and
CC HBM systems can be used as surrogate markers in pharmaceutical
CC development, in diagnosis of human or animal bone disease, and in the
CC treatment of bone diseases. Sequences ABK22776-ABK23411 represent cDNA
CC molecules encoding human Zmax1 and HBM, and PCR primers, probes, linkers
CC and adapters of the invention
XX
SQ Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1603 CCTGGCCTGGGGGA 1616
||||||||||| ||
Db 15 CCTGGCCTGGGTGA 2

RESULT 1191
ABK23294/c
ID ABK23294 standard; DNA; 18 BP.
XX
AC ABK23294;
XX
DT 09-APR-2002 (first entry)
XX
DE Human Zmax1 cDNA reverse PCR primer #228.
XX
KW Human; mouse; Zmax1; HBM; high bone mass gene; lipid regulation; stroke;
KW lipid-associated condition; arteriosclerosis; cardiovascular disease; ss;
KW osteoporosis; atherosclerosis; diabetic atherosclerosis; plaque build-up;
KW neurovascular condition; wound healing; gene therapy; PCR primer; probe;
KW bone development disorder; antiarteriosclerotic; cardiovascular;
KW osteopathic; cerebroprotective.
XX
OS Homo sapiens.
XX
PN WO200192891-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016946.
XX
PR 26-MAY-2000; 2000US-00578900.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
PA (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
XX
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2002-097784/13.
XX
PT Identifying molecules involved in lipid regulation, useful for
PT diagnosing, treating or preventing e.g., arteriosclerosis, comprises
PT identifying a molecule that binds to high bone mass gene or its
PT corresponding wild type gene.
XX
PS Disclosure; Page 41; 409pp; English.
XX
CC The invention relates to a method for identifying a molecule involved in
CC lipid regulation comprising identifying a molecule that binds to or
CC inhibits binding of a molecule to high bone mass (HBM) or its wild type
CC gene, Zmax1. Compounds identified by the method are useful for treating,
CC diagnosing, preventing or screening for normal and abnormal lipid-
CC associated conditions, including arteriosclerosis, cardiovascular
CC disease, stroke, and osteoporosis. The compounds may also be used in the
CC treatment or prevention of diabetic atherosclerosis, neurovascular
CC conditions caused by plaque build-up, poor circulation due to plaque
CC build-up and associated poor wound healing. The methods may be used in
CC gene therapy, pharmaceutical development, and diagnostic assays for bone
CC development disorders. Molecules identified by comparison of Zmax1 and
CC HBM systems can be used as surrogate markers in pharmaceutical
CC development, in diagnosis of human or animal bone disease, and in the
CC treatment of bone diseases. Sequences ABK22776-ABK23411 represent cDNA
CC molecules encoding human Zmax1 and HBM, and PCR primers, probes, linkers
CC and adapters of the invention
XX
SQ Sequence 18 BP; 2 A; 6 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2025 TGGTAGGAGGCAAA 2038
||||||||| |||||
Db 15 TGGTAGGAAGCAAA 2

RESULT 1192
ABK11999
ID ABK11999 standard; DNA; 18 BP.
XX
AC ABK11999;
XX
DT 05-JUN-2002 (first entry)
XX
DE Human D9S310 genetic marker PCR Primer #1.
XX
KW Human; linkage; familial dysautonomia; FD; D9S310 neuronal loss;
KW chromosome 9q31-q33; prenatal diagnosis; Riley-Day syndrome; ss; PCR;
KW primer.
XX
OS Homo sapiens.
XX
PN US2002025528-A1.
XX
PD 28-FEB-2002.
XX
PF 17-JUL-2001; 2001US-00907190.
XX
PR 29-MAY-1992; 92US-00890719.
PR 16-APR-1993; 93US-00049678.
PR 07-JUN-1995; 95US-00480655.
PR 07-DEC-1999; 99US-00455683.
XX
PA (BLUM/) BLUMENFELD A.
PA (GUSE/) GUSELLA J F.
PA (BREA/) BREAKFIELD X O.
PA (SLAU/) SLAUGENHAUPT S.
XX
PI Blumenfeld A, Gusella JF, Breakfield XO, Slaugenhaupt S;
XX
DR WPI; 2002-267528/31.
XX
PT Detecting a polymorphism linked to a gene associated with familial
PT dysautonomia, involves analyzing human chromosome 9 for the presence of
PT the polymorphism.
XX
PS Claim 14; Page 10; 17pp; English.
XX
CC This invention relates to a novel method for detecting a polymorphism
CC linked to a gene associated with familial dysautonomia (FD). Familial
CC dysautonomia is an autosomal recessive disorder characterised by the
CC developmental loss of neurons from the sensory and autonomic nervous
CC system. The method of the invention comprises analysing human chromosome
CC 9 and detecting the presence of a polymorphism located between the
CC genetic markers D9S53 and D9S105 inclusive, and linked to the gene
CC associated with familial dysautonomia. The invention also includes
CC nucleotide sequences for detecting a polymorphism associated with
CC familial dysautonomia. Using the method of the invention it was possible
CC to show that the gene for FD is located on human chromosome 9q31-q33. The
CC method and sequences of the invention are useful for the diagnosis of
CC familial dysautonomia and for the identification of carriers of the
CC disease gene, such information will facilitate prenatal diagnosis and

```
CC   help reduce the number of new cases of FD. The present sequences
CC   represent an oligonucleotide primer that can be used to screen for the
CC   D9S310 genetic marker on chromosome 9, this primer is used in the method
CC   of the invention to screen for the familial dysotonomia gene
XX
SQ   Sequence 18 BP; 6 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 CCTGGGCCAACAGA 1858
              ||||||| ||||||
Db          2 CCTGGGCAAACAGA 15


RESULT 1193
ACF63006/c
ID   ACF63006 standard; DNA; 18 BP.
XX
AC   ACF63006;
XX
DT   09-OCT-2003  (first entry)
XX
DE   Human progesterone receptor PCR primer SEQ ID NO:255.
XX
KW   Human; colon cancer; oestrogen receptor; myoglobin; p21; p27; p16; p53;
KW   progesterone receptor; pcna; CEA; cdc2; c-erbB2; methylation; CpG;
KW   characterisation; classification; diagnosis; differentiation;
KW   colon cell proliferative disorder; PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003014388-A2.
XX
PD   20-FEB-2003.
XX
PF   09-AUG-2002; 2002WO-EP008939.
XX
PR   09-AUG-2001; 2001DE-01039283.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Distler J,  Model F,  Taubert H;
XX
DR   WPI; 2003-256600/25.
XX
PT   Determining methylation status of CpG dinucleotides using modified
PT   genomic sequences, oligonucleotides and/or PNA-oligomers, useful in the
PT   characterization, grading, staging and/or diagnosis of colon cancer.
XX
PS   Claim 26; Page 167; 219pp; English.
XX
CC   The present invention describes a method for determining the methylation
CC   status of CpG dinucleotides within the genes for oestrogen receptor, p21,
CC   p27, p16, progesterone receptor, myoglobin, pcna, cdc2, c-erB2, p53
CC   and/or CEA, which comprises contacting the target nucleic acid with a
CC   reagent that distinguishes between methylated and non-methylated CpG
CC   dinucleotides, and determining from the methylation status of the CpG
CC   positions the presence of a colon cancer. A set of oligomers or peptide
CC   nucleic acid (PNA)-oligomers can be used as probes for determining the
CC   cytosine methylation state and/or single nucleotide polymorphisms (SNP)
CC   of a corresponding genomic DNA by analysis of a chemically pretreated
CC   genomic DNA. The pretreated genomic DNA is useful for the determination
CC   of the methylation status of a corresponding genomic DNA and/or detection
CC   of SNPs. The methods and pretreated genomic DNA are also useful for the
CC   characterisation, classification, diagnosis and differentiation of colon
CC   cell proliferative disorders. ACF62752 to ACF63278 represent sequences
CC   used in the exemplification of the present invention
XX
SQ   Sequence 18 BP; 9 A; 0 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTTT 1722
              ||||||| ||||||
Db         17 TATCTCCCAACTTT 4


RESULT 1194
ACF63008
ID   ACF63008 standard; DNA; 18 BP.
XX
AC   ACF63008;
XX
DT   09-OCT-2003  (first entry)
XX
DE   Human progesterone receptor PCR primer SEQ ID NO:257.
XX
KW   Human; colon cancer; oestrogen receptor; myoglobin; p21; p27; p16; p53;
KW   progesterone receptor; pcna; CEA; cdc2; c-erbB2; methylation; CpG;
KW   characterisation; classification; diagnosis; differentiation;
KW   colon cell proliferative disorder; PCR primer; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2003014388-A2.
XX
PD   20-FEB-2003.
XX
PF   09-AUG-2002; 2002WO-EP008939.
XX
PR   09-AUG-2001; 2001DE-01039283.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Distler J,  Model F,  Taubert H;
XX
DR   WPI; 2003-256600/25.
XX
PT   Determining methylation status of CpG dinucleotides using modified
PT   genomic sequences, oligonucleotides and/or PNA-oligomers, useful in the
PT   characterization, grading, staging and/or diagnosis of colon cancer.
XX
PS   Claim 26; Page 167; 219pp; English.
XX
CC   The present invention describes a method for determining the methylation
CC   status of CpG dinucleotides within the genes for oestrogen receptor, p21,
CC   p27, p16, progesterone receptor, myoglobin, pcna, cdc2, c-erB2, p53
CC   and/or CEA, which comprises contacting the target nucleic acid with a
CC   reagent that distinguishes between methylated and non-methylated CpG
CC   dinucleotides, and determining from the methylation status of the CpG
CC   positions the presence of a colon cancer. A set of oligomers or peptide
CC   nucleic acid (PNA)-oligomers can be used as probes for determining the
CC   cytosine methylation state and/or single nucleotide polymorphisms (SNP)
CC   of a corresponding genomic DNA by analysis of a chemically pretreated
CC   genomic DNA. The pretreated genomic DNA is useful for the determination
CC   of the methylation status of a corresponding genomic DNA and/or detection
CC   of SNPs. The methods and pretreated genomic DNA are also useful for the
CC   characterisation, classification, diagnosis and differentiation of colon
CC   cell proliferative disorders. ACF62752 to ACF63278 represent sequences
CC   used in the exemplification of the present invention
XX
SQ   Sequence 18 BP; 3 A; 6 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTTT 1722
              ||||||| ||||||
Db          2 TATCTCCCAACTTT 15
```

```
RESULT 1195
ACC45877/c
ID   ACC45877 standard; DNA; 18 BP.
XX
AC   ACC45877;
XX
DT   02-JUN-2003  (first entry)
XX
DE   Human HBM STS marker reverse primer #228.
XX
KW   Human; high bone mass; HBM; LRP5; LRP6; transgenic; bone mass modulation;
KW   gene therapy; bone density modulation; bone strength; trabecular number;
KW   bone size; bone tissue connectivity; bone disease; osteoporosis; PCR;
KW   osteomalacia; rickets; Paget's disease; neoplasm of the bone; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200292764-A2.
XX
PD   21-NOV-2002.
XX
PF   13-MAY-2002; 2002WO-US014876.
XX
PR   11-MAY-2001; 2001US-0290071P.
PR   17-MAY-2001; 2001US-0291311P.
PR   01-FEB-2002; 2002US-0353058P.
PR   04-MAR-2002; 2002US-0361293P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
PA   (AMHP ) WYETH.
XX
PI   Babij P,  Bex FJ,  Yaworsky PJ,  Bodine PV;
XX
DR   WPI; 2003-129278/12.
XX
PT   New transgenic animals (e.g. mice), useful as models for studying bone
PT   density modulation, developing drugs for treating or preventing bone
PT   diseases (e.g. osteoporosis), or diagnosing diseases characterized by
PT   reduced bone density.
XX
PS   Disclosure; Page 57; 603pp; English.
XX
CC   The invention relates to novel transgenic animals expressing the high
CC   bone mass (HBM) gene, expressing the corresponding wild type HBM gene,
CC   comprising an alteration of the gene encoding LRP5 or LRP6, or expressing
CC   an LRP5 that is modulated by an altered gene control sequence introduced
CC   by homologous or non-homologous recombination. The transgenic animals are
CC   for the study of bone density modulation or bone mass modulation. The
CC   invention has osteopathic and cytostatic activity. The polynucleotides of
CC   the invention may have a use in gene therapy. The transgenic animals and
CC   nucleic acids are for the study of bone density modulation, where the
CC   bone mass is modulated relative to non-transgenic animals of the same
CC   species in more than one parameter selected from bone density, bone
CC   strength, trabecular number, bone size, or bone tissue connectivity. The
CC   transgenic animals, nucleic acids and methods are useful for identifying
CC   molecules involved in bone development, and for developing pharmaceutical
CC   compositions, which may be employed for treating or preventing bone
CC   diseases, e.g. osteoporosis, osteomalacia, rickets, Paget's disease, or
CC   neoplasms of the bone. The transgenic animals and nucleic acids are also
CC   useful in methods for diagnosing diseases involved in bone development,
CC   or characterised by reduced bone density or mass. The present sequence is
CC   used in the exemplification of the invention
XX
SQ   Sequence 18 BP; 2 A; 6 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAA 2038
              |||||||| |||||
Db         15 TGGTAGGAAGCAAA 2

RESULT 1196
ACC45493/c
ID   ACC45493 standard; DNA; 18 BP.
XX
AC   ACC45493;
XX
DT   02-JUN-2003  (first entry)
XX
DE   Human HBM STS marker reverse primer #36.
XX
KW   Human; high bone mass; HBM; LRP5; LRP6; transgenic; bone mass modulation;
KW   gene therapy; bone density modulation; bone strength; trabecular number;
KW   bone size; bone tissue connectivity; bone disease; osteoporosis; PCR;
KW   osteomalacia; rickets; Paget's disease; neoplasm of the bone; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200292764-A2.
XX
PD   21-NOV-2002.
XX
PF   13-MAY-2002; 2002WO-US014876.
XX
PR   11-MAY-2001; 2001US-0290071P.
PR   17-MAY-2001; 2001US-0291311P.
PR   01-FEB-2002; 2002US-0353058P.
PR   04-MAR-2002; 2002US-0361293P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
PA   (AMHP ) WYETH.
XX
PI   Babij P,  Bex FJ,  Yaworsky PJ,  Bodine PV;
XX
DR   WPI; 2003-129278/12.
XX
PT   New transgenic animals (e.g. mice), useful as models for studying bone
PT   density modulation, developing drugs for treating or preventing bone
PT   diseases (e.g. osteoporosis), or diagnosing diseases characterized by
PT   reduced bone density.
XX
PS   Disclosure; Page 54; 603pp; English.
XX
CC   The invention relates to novel transgenic animals expressing the high
CC   bone mass (HBM) gene, expressing the corresponding wild type HBM gene,
CC   comprising an alteration of the gene encoding LRP5 or LRP6, or expressing
CC   an LRP5 that is modulated by an altered gene control sequence introduced
CC   by homologous or non-homologous recombination. The transgenic animals are
CC   for the study of bone density modulation or bone mass modulation. The
CC   invention has osteopathic and cytostatic activity. The polynucleotides of
CC   the invention may have a use in gene therapy. The transgenic animals and
CC   nucleic acids are for the study of bone density modulation, where the
CC   bone mass is modulated relative to non-transgenic animals of the same
CC   species in more than one parameter selected from bone density, bone
CC   strength, trabecular number, bone size, or bone tissue connectivity. The
CC   transgenic animals, nucleic acids and methods are useful for identifying
CC   molecules involved in bone development, and for developing pharmaceutical
CC   compositions, which may be employed for treating or preventing bone
CC   diseases, e.g. osteoporosis, osteomalacia, rickets, Paget's disease, or
CC   neoplasms of the bone. The transgenic animals and nucleic acids are also
CC   useful in methods for diagnosing diseases involved in bone development,
CC   or characterised by reduced bone density or mass. The present sequence is
CC   used in the exemplification of the invention
XX
SQ   Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGA 1616
```

```
                ||||||||||| ||
Db          15 CCTGGCCTGGGTGA 2


RESULT 1197
ADB98191/c
ID   ADB98191 standard; DNA; 18 BP.
XX
AC   ADB98191;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Sequence tagged site #72 used to prepare map of Zmax1 (LRP5) gene region.
XX
KW   Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW   bone mass modulation; osteoporosis; STS; sequence tagged site; ds.
XX
OS   Homo sapiens.
XX
PN   WO200292000-A2.
XX
PD   21-NOV-2002.
XX
PF   13-MAY-2002; 2002WO-US014877.
XX
PR   11-MAY-2001; 2001US-0290071P.
PR   17-MAY-2001; 2001US-0291311P.
PR   01-FEB-2002; 2002US-0353058P.
PR   04-MAR-2002; 2002US-0361293P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
PA   (AMHP ) WYETH.
XX
PI   Allen K,  Anisowicz A,  Graham JR,  Morales A,  Yaworsky PJ,  Liu W;
XX
DR   WPI; 2003-129214/12.
XX
PT   New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT   diagnosing a HBM-like phenotype in a subject and for preparing a
PT   composition for modulating bone mass and/or lipid levels in a subject
PT   suffering from e.g. osteoporosis.
XX
PS   Example 2; Page 61; 629pp; English.
XX
CC   The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC   LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC   cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC   level modulation. The invention is useful for diagnosing a HBM-like
CC   phenotype in a subject and for preparing a composition for modulating
CC   bone mass and/or lipid levels in a subject suffering from e.g.
CC   osteoporosis. The present sequence is a Sequence Tagged Site (STS)
CC   marker, which was used to prepare a physical map of the Zmax1 (LRP5) gene
CC   region.
XX
SQ   Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGA 1616
                ||||||||||| ||
Db         15 CCTGGCCTGGGTGA 2


RESULT 1198
ADB98575/c
ID   ADB98575 standard; DNA; 18 BP.
XX
AC   ADB98575;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Sequence tagged site #456 used to prepare Zmax1 (LRP5) gene region map.
XX
KW   Osteopathic; Gene therapy; High Bone Mass; HBM; LRP5; Zmax1; LRP6;
KW   bone mass modulation; osteoporosis; STS; sequence tagged site; ds.
XX
OS   Homo sapiens.
XX
PN   WO200292000-A2.
XX
PD   21-NOV-2002.
XX
PF   13-MAY-2002; 2002WO-US014877.
XX
PR   11-MAY-2001; 2001US-0290071P.
PR   17-MAY-2001; 2001US-0291311P.
PR   01-FEB-2002; 2002US-0353058P.
PR   04-MAR-2002; 2002US-0361293P.
XX
PA   (GENO-) GENOME THERAPEUTICS CORP.
PA   (AMHP ) WYETH.
XX
PI   Allen K,  Anisowicz A,  Graham JR,  Morales A,  Yaworsky PJ,  Liu W;
XX
DR   WPI; 2003-129214/12.
XX
PT   New nucleic acid comprising a mutation in LRP5 or LRP6, useful for
PT   diagnosing a HBM-like phenotype in a subject and for preparing a
PT   composition for modulating bone mass and/or lipid levels in a subject
PT   suffering from e.g. osteoporosis.
XX
PS   Example 2; Page 64; 629pp; English.
XX
CC   The present invention relates to High Bone Mass (HBM), LRP5 (Zmax1) and
CC   LRP6 mutants, which results in a HBM-like phenotype when expressed in a
CC   cell. The HBM-like phenotype results in bone mass modulation and/or lipid
CC   level modulation. The invention is useful for diagnosing a HBM-like
CC   phenotype in a subject and for preparing a composition for modulating
CC   bone mass and/or lipid levels in a subject suffering from e.g.
CC   osteoporosis. The present sequence is a Sequence Tagged Site (STS)
CC   marker, which was used to prepare a physical map of the Zmax1 (LRP5) gene
CC   region.
XX
SQ   Sequence 18 BP; 2 A; 6 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAA 2038
                ||||||||| |||||
Db         15 TGGTAGGAAGCAAA 2


RESULT 1199
ADE14972/c
ID   ADE14972 standard; DNA; 18 BP.
XX
AC   ADE14972;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Beer spoilage-associated primer SEQ ID 167.
XX
KW   ss; primer; detection; beer-spoilage; lactic acid bacteria;
KW   Gram-negative bacteria; spoilage bacteria.
XX
OS   Lactobacillus buchneri.
XX
PN   WO2002103043-A2.
XX
PD   27-DEC-2002.
XX
PF   19-JUN-2002; 2002WO-EP006808.
```

```
XX
PR   19-JUN-2001; 2001DE-01029410.
XX
PA   (VERM-) VERMICON AG.
XX
PI   Beimfohr C,  Snaidr J;
XX
DR   WPI; 2003-175243/17.
XX
PT   New oligonucleotides, useful for rapid detection of beer-spoilage
PT   bacteria by in situ hybridization, are specific for type, genus or
PT   species.
XX
PS   Claim 1; SEQ ID NO 167; 88pp; German.
XX
CC   This invention describes novel oligonucleotides used in a method for
CC   detecting beer-spoilage bacteria in a sample. The bacteria detected
CC   include lactic acid bacteria of the genera Lactobacillus or Pediococcus,
CC   especially the species L. coryniformis, L. perolens, L. buchneri, L.
CC   plantarum, L. fructivorans, L. lindneri, L. casei, L. brevis or P.
CC   damnosus or Gram-negative bacteria of the genera Pectinatus and
CC   Megasphaera, specifically P. frisingensis, P. cerevisiiphilus and M.
CC   cerevisiae. The oligonucleotides of the invention provide rapid detection
CC   of spoilage bacteria (typically within 48 hours, compared with 7-12 days
CC   for conventional culture methods), can detect all relevant bacteria in
CC   parallel, can differentiate between species of the same genus, and are
CC   easy to use. ADE14806-ADE15247 represent the oligonucleotides used in the
CC   method of the invention.
XX
SQ   Sequence 18 BP; 1 A; 5 C; 4 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAAC 1558
              |||||||||| |||
Db         18 AGTAGGGAAGCAAC 5


RESULT 1200
ADE77591/c
ID   ADE77591 standard; DNA; 18 BP.
XX
AC   ADE77591;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human probe SSP16 used for a model HLA typing reaction.
XX
KW   SSP16; probe; ss; human; single nucleotide polymorphism; SNP; CFTR;
KW   human leukocyte antigen; HLA; genetic testing; carrier screening;
KW   genotyping; profiling; polymorphic; multiplexed elongation assay;
KW   enzymatic recognition;
KW   cystic fibrosis conductance transmembrane regulator.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   variation       replace(18,g)
FT                   /*tag=  a
FT                   /standard_name= "Single nucleotide polymorphism"
XX
PN   WO2003034029-A2.
XX
PD   24-APR-2003.
XX
PF   15-OCT-2002; 2002WO-US033012.
XX
PR   15-OCT-2001; 2001US-0329427P.
PR   15-OCT-2001; 2001US-0329428P.
PR   15-OCT-2001; 2001US-0329619P.
PR   15-OCT-2001; 2001US-0329620P.
PR   14-MAR-2002; 2002US-0364416P.
XX
PA   (BIOA-) BIOARRAY SOLUTIONS LTD.
XX
PI   Li AX,  Hashmi G,  Seul M;
XX
DR   WPI; 2003-393553/37.
XX
PT   Concurrent interrogation of a number of polymorphic sites, useful for
PT   genetic testing, carrier screening, genetic profiling, and identity
PT   testing, comprises conducting a multiplexed elongation assay using
PT   probes.
XX
PS   Example 6; Page 44; 143pp; English.
XX
CC   This invention relates to a novel method for the concurrent interrogation
CC   of a number of polymorphic sites in the presence of, and without
CC   interference from, non-designated polymorphic sites. Specifically, it
CC   comprises conducting a multiplexed elongation assay by applying one or
CC   more temperature cycles to achieve linear amplification of the target or
CC   a combination of annealing and elongation steps under temperature-
CC   controlled conditions. Furthermore, this detection method uses probe
CC   extension or elongation and relies on enzymatic recognition, a superior
CC   technique that no longer depends on differential hybridisation. The
CC   present invention describes probes and methods useful for identifying or
CC   detecting polymorphisms at one or more designated sites, such that they
CC   can identify mutations within the cystic fibrosis conductance
CC   transmembrane regulator (CFTR) or the human leukocyte antigen (HLA)
CC   genes. In addition, concurrent interrogation of a multiplicity of
CC   polymorphic sites is useful for genetic testing, carrier screening,
CC   genotyping or genetic profiling, and identity testing. This
CC   oligonucleotide is human probe SSP16, one member of a pair of probes
CC   containing a single nucleotide polymorphism at the 3' terminus that is
CC   used in a model HLA typing reaction, in an exemplification of the
CC   invention.
XX
SQ   Sequence 18 BP; 6 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGG 1607
              ||||| ||||||||
Db         18 GGAACTCCTCCTGG 5


RESULT 1201
ADI34074
ID   ADI34074 standard; DNA; 18 BP.
XX
AC   ADI34074;
XX
DT   22-APR-2004  (first entry)
XX
DE   HIV pol region DNA sequencing primer #1.
XX
KW   DNA amplification; sequencing; HIV pol; genotyping; sequence analysis;
KW   heterozygosity; primer; ss.
XX
OS   Human immunodeficiency virus.
XX
PN   US6531588-B1.
XX
PD   11-MAR-2003.
XX
PF   05-MAR-2002; 2002US-00092022.
XX
PR   21-SEP-1998;   98US-00158695.
XX
PA   (APPL-) APPLERA CORP.
XX
```

PI Johnston-Dow LA, Demeter L, White CB, Song K, Kohlenberger R;
PI Conrad M, Myers A;
XX
DR WPI; 2003-539710/51.
XX
PT New kit comprising first and second primers, and a temperature-stable DNA
PT polymerase, useful for HIV sequencing and genotyping, and for automated
PT sequence analysis and determination of heterozygosity.
XX
PS Claim 3; SEQ ID NO 5; 11pp; English.
XX
CC The present invention relates to a method for amplifying and sequencing
CC HIV pol region DNA. Also disclosed is a kit comprising first and second
CC primers, and a temperature-stable DNA polymerase. The invention also
CC discloses a method for obtaining de novo sequence information for
CC different HIV quasi-species present in a patient's sample. The kit is
CC useful for HIV sequencing and genotyping, particularly for amplifying
CC regions of the HIV pol gene. It is also useful for automated sequence
CC analysis and determination of heterozygosity. The present sequence
CC represents a sequencing primer for HIV pol region DNA.
XX
SQ Sequence 18 BP; 6 A; 9 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1850 GCCAACAGACCCAC 1863
||||||||| |||||
Db 2 GCCAACAGCCCCAC 15

RESULT 1202
ABZ97363
ID ABZ97363 standard; DNA; 18 BP.
XX
AC ABZ97363;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human IL4-R oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 12605; 872pp; English.
XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1573 CCTTCTCCACCGCA 1586
||| ||||||||||
Db 2 CCTGCTCCACCGCA 15

RESULT 1203
ABZ97260
ID ABZ97260 standard; DNA; 18 BP.
XX
AC ABZ97260;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human nucleic acid sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 12502; 872pp; English.
XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1573 CCTTCTCCACCGCA 1586
||| ||||||||||
Db 2 CCTGCTCCACCGCA 15

RESULT 1204
ADM06769/c
ID ADM06769 standard; DNA; 18 BP.
XX
AC ADM06769;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PCR primer SEQ ID NO:5454.
XX
KW human; gene therapy; diagnostic marker; pharmaceutical; ss; PCR; primer.
XX
OS Homo sapiens.
XX
PN EP1347046-A1.
XX
PD 24-SEP-2003.
XX
PF 12-APR-2002; 2002EP-00008400.
XX
PR 22-MAR-2002; 2002JP-00137785.
XX
PA (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;
XX
DR WPI; 2003-723558/69.
XX
PT New polynucleotides and polypeptides are useful in gene therapy, for
PT developing a diagnostic marker or medicines for regulating their
PT expression and activity, or as a target of gene therapy.
XX
PS Example 8; SEQ ID NO 5454; 305pp; English.
XX
CC The invention relates to a novel human polynucleotide and the encoded
CC polypeptide. A polynucleotide of the invention may have a use in gene
CC therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful
CC as a primer for synthesizing the polynucleotide or as a probe for
CC detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are
CC useful in gene therapy, for developing a diagnostic marker or medicines
CC for regulating their expression and activity, or as a target of gene
CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
CC are useful as pharmaceutical agents. The present sequence represents an
CC oligonucleotide used in the invention.
XX
SQ Sequence 18 BP; 5 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1798 TTCTCTGAAAGTGG 1811
|||||| |||||||
Db 14 TTCTCTCAAAGTGG 1

RESULT 1205
ADM06632/c
ID ADM06632 standard; DNA; 18 BP.
XX
AC ADM06632;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PCR primer SEQ ID NO:5317.
XX
KW human; gene therapy; diagnostic marker; pharmaceutical; ss; PCR; primer.
XX
OS Homo sapiens.
XX
PN EP1347046-A1.
XX
PD 24-SEP-2003.
XX
PF 12-APR-2002; 2002EP-00008400.
XX
PR 22-MAR-2002; 2002JP-00137785.
XX
PA (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
PI Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;
XX
DR WPI; 2003-723558/69.
XX
PT New polynucleotides and polypeptides are useful in gene therapy, for
PT developing a diagnostic marker or medicines for regulating their
PT expression and activity, or as a target of gene therapy.
XX
PS Example 8; SEQ ID NO 5317; 305pp; English.
XX
CC The invention relates to a novel human polynucleotide and the encoded
CC polypeptide. A polynucleotide of the invention may have a use in gene
CC therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful
CC as a primer for synthesizing the polynucleotide or as a probe for
CC detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are
CC useful in gene therapy, for developing a diagnostic marker or medicines
CC for regulating their expression and activity, or as a target of gene
CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
CC are useful as pharmaceutical agents. The present sequence represents an
CC oligonucleotide used in the invention.
XX
SQ Sequence 18 BP; 4 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1675 CCTGGACTTCTTAG 1688
|| ||||||||||
Db 14 CCAGGACTTCTTAG 1

RESULT 1206
ABD30394
ID ABD30394 standard; DNA; 18 BP.
XX
AC ABD30394;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human IL4-R derived oligonucleotide SEQ ID 12605.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 12605; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1573 CCTTCTCCACCGCA 1586
||| ||||||||||
Db 2 CCTGCTCCACCGCA 15

RESULT 1207
ADH02714
ID ADH02714 standard; DNA; 18 BP.
XX
AC ADH02714;
XX
DT 11-MAR-2004 (first entry)
XX
DE Sequencing primer #1 for HIV pol gene.
XX
KW HIV; pol gene; drug mutation; HIV sequencing; HIV genotyping; primer; ss.
XX
OS Human immunodeficiency virus.
XX
PN US2003219725-A1.
XX
PD 27-NOV-2003.
XX
PF 31-DEC-2002; 2002US-00335059.
XX
PR 21-SEP-1998; 98US-00158695.
PR 05-MAR-2002; 2002US-00092022.
XX
PA (JOHN/) JOHNSTON-DOW L A.
PA (DEME/) DEMETER L.
PA (WHIT/) WHITE C B.
PA (SONG/) SONG K.
PA (KOHL/) KOHLENBERGER R.
PA (CONR/) CONRAD M.
PA (MYER/) MYERS A.
XX
PI Johnston-Dow LA, Demeter L, White CB, Song K, Kohlenberger R;
PI Conrad M, Myers A;
XX
DR WPI; 2004-010863/01.
XX
PT Analyzing an HIV target nucleic acid sequence by amplifying the double-
PT stranded nucleic acid template derived from HIV to produce amplified
PT target sequences and analyzing the amplified target sequences.
XX
PS Claim 8; SEQ ID NO 5; 14pp; English.
XX
CC The present invention relates to a method for analysing a HIV pol gene
CC nucleic acid sequence. The method comprises combining a double-stranded
CC nucleic acid template derived from HIV, first and second primers, a
CC temperature-stable DNA polymerase and deoxyribonucleotides, amplifying
CC the double-stranded nucleic acid template to produce amplified target
CC sequences, and analysing the amplified target sequences. The determined
CC sequence can be compared to the sequence of known drug mutations in the
CC HIV pol gene. The method of the invention is useful for HIV sequencing
CC and genotyping. The present sequence represents a sequencing primer used
CC in the method of the invention.
XX
SQ Sequence 18 BP; 6 A; 9 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1850 GCCAACAGACCCAC 1863
              ||||||||| |||||
Db          2 GCCAACAGCCCCAC 15


RESULT 1208
ADJ59182
ID   ADJ59182 standard; DNA; 18 BP.
XX
AC   ADJ59182;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Oligonucleotide associated to IL 4R #37.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Claim 2; SEQ ID NO 38; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCA 1586
              ||| ||||||||||
Db          2 CCTGCTCCACCGCA 15


RESULT 1209
ADJ61652
ID   ADJ61652 standard; DNA; 18 BP.
XX
AC   ADJ61652;
XX
DT   06-MAY-2004  (first entry)
XX
DE   IL-4Ra receptor #9.
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO2004011613-A2.
XX
PD   05-FEB-2004.
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
PI   Nyce JW,  Tang L,  Sandrasagra A,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-203534/19.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
PS   Example 5; SEQ ID NO 2508; 85pp; English.
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents a receptor of the invention.
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCA 1586
              ||| ||||||||||
Db          2 CCTGCTCCACCGCA 15


RESULT 1210
ADO44672
ID   ADO44672 standard; DNA; 18 BP.
XX
AC   ADO44672;
XX
```

```
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #38.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
XX
PF   25-JUL-2003; 2003US-00627930.
XX
PR   23-APR-2002; 2002WO-US013135.
PR   23-APR-2002; 2002WO-US013143.
XX
PA   (NYCE/) NYCE J W.
PA   (SAND/) SANDRASAGRA A.
PA   (TANG/) TANG L.
PA   (AGUI/) AGUILAR D.
PA   (MILL/) MILLER S.
PA   (SHAH/) SHAHABUDDIN S.
PA   (LUHH/) LU H.
PA   (CONG/) CONG H.
XX
PI   Nyce JW,  Sandrasagra A,  Tang L,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-293804/27.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT   RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT   asthma.
XX
PS   Claim 2; SEQ ID NO 38; 174pp; English.
XX
CC   The invention relates to oligonucleotides anti-sense to an initiation
CC   codon, coding region, 5' or 3' intron-exon junction, intron or region
CC   with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC   chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC   -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC   tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC   also relates to a method of screening a candidate compound that binds to
CC   one or more nucleic acid target(s) or expressed product(s), for the
CC   prevention and/or treatment of a respiratory or lung disease. The
CC   oligonucleotides are useful for reducing or inhibiting expression of a
CC   gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC   CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC   tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC   useful for preventing or treating a respiratory or lung disease. The
CC   respiratory or lung disease is associated with hyper-responsiveness to
CC   and/or increased levels of, adenosine and/or levels of adenosine A
CC   receptor(s), and/or asthma and/or lung allergies associated with
CC   inflammation or an inflammatory disease. The respiratory or lung disease
CC   is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC   cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC   allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC   hypertension, lung inflammation, bronchitis, airway obstruction or
CC   bronchoconstriction. This sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCA 1586
              ||| ||||||||||
Db          2 CCTGCTCCACCGCA 15


RESULT 1211
ADO47043
ID   ADO47043 standard; DNA; 18 BP.
XX
AC   ADO47043;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Human oligonucleotide #2409.
XX
KW   Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW   CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW   tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW   lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW   asthma; lung allergy; inflammation; inflammatory disease;
KW   airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW   chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW   acute respiratory distress syndrome; pulmonary hypertension;
KW   lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS   Homo sapiens.
XX
PN   US2004049022-A1.
XX
PD   11-MAR-2004.
XX
PF   25-JUL-2003; 2003US-00627930.
XX
PR   23-APR-2002; 2002WO-US013135.
PR   23-APR-2002; 2002WO-US013143.
XX
PA   (NYCE/) NYCE J W.
PA   (SAND/) SANDRASAGRA A.
PA   (TANG/) TANG L.
PA   (AGUI/) AGUILAR D.
PA   (MILL/) MILLER S.
PA   (SHAH/) SHAHABUDDIN S.
PA   (LUHH/) LU H.
PA   (CONG/) CONG H.
XX
PI   Nyce JW,  Sandrasagra A,  Tang L,  Aguilar D,  Miller S;
PI   Shahabuddin S,  Lu H,  Cong H;
XX
DR   WPI; 2004-293804/27.
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT   RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT   asthma.
XX
PS   Example 5; Page 163; 174pp; English.
XX
CC   The invention relates to oligonucleotides anti-sense to an initiation
CC   codon, coding region, 5' or 3' intron-exon junction, intron or region
CC   with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC   chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC   -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC   tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC   also relates to a method of screening a candidate compound that binds to
CC   one or more nucleic acid target(s) or expressed product(s), for the
CC   prevention and/or treatment of a respiratory or lung disease. The
CC   oligonucleotides are useful for reducing or inhibiting expression of a
CC   gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC   CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
```

```
CC   tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC   useful for preventing or treating a respiratory or lung disease. The
CC   respiratory or lung disease is associated with hyper-responsiveness to
CC   and/or increased levels of, adenosine and/or levels of adenosine A
CC   receptor(s), and/or asthma and/or lung allergies associated with
CC   inflammation or an inflammatory disease. The respiratory or lung disease
CC   is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC   cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC   allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC   hypertension, lung inflammation, bronchitis, airway obstruction or
CC   bronchoconstriction. This sequence represents an oligonucleotide of the
CC   invention.
XX
SQ   Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 5.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCA 1586
              ||| ||||||||||
Db          2 CCTGCTCCACCGCA 15


RESULT 1212
AAQ85824/c
ID   AAQ85824 standard; DNA; 19 BP.
XX
AC   AAQ85824;
XX
DT   25-MAR-2003  (revised)
DT   08-NOV-1995  (first entry)
XX
DE   Anti-mseICAM 2'-O-alkylamino-containing oligomer #81.
XX
KW   Alkylamino group; ribofuranosyl sugar; antisense therapy; virus; HIV;
KW   herpes; papilloma; antiviral; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1. .19
FT                   /note= "contains phosphorothioate linkages between
FT                   nucleosides"
FT   modified_base   1
FT                   /*tag=  a
FT                   /note= "2'-O-hexylphthalimido-uridine"
XX
PN   WO9506659-A1.
XX
PD   09-MAR-1995.
XX
PF   02-SEP-1994;   94WO-US010131.
XX
PR   03-SEP-1993;   93US-00117363.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cook PD,  Manoharan M,  Guinosso CJ;
XX
DR   WPI; 1995-115397/15.
XX
PT   New amine-derivatised nucleoside(s) and oligo:nucleoside(s) - useful as
PT   diagnostics, therapeutics and research reagents, partic. in anti-sense
PT   therapy.
XX
PS   Example 44; Page 57; 117pp; English.
XX
CC   This sequence is generated to contain a 2'-O-hexylphthalimido functional
CC   group at the 5' end of the oligomer as opposed to a cholesterol or
CC   fluorescein functional group (see AAQ85818). This sequence is an analogue
CC   of an antisense sequence to the mse-ICAM. The modified nucleosides are
CC   used to increase the half-life of the oligomers in cell extract assays
CC   for the inhibition of specific genes. The modified oligomer is an example
CC   of a compound (see AAQ85799-Q85839 for other examples) e.g. a nucleoside
CC   or oligonucleoside, which contains a ribofuranosyl sugar portion and a
CC   base portion, such that at least one of the nucleoside contains at a 2'-O
CC   -, 3'-O- or 5'-O-position, a substitution (see AAQ85799 for details of
CC   the substitutions). The compounds are useful in diagnostics, therapeutics
CC   and as research reagents particularly in antisense therapy for killing
CC   cells and viruses such as HIV, herpes or papilloma viruses. (Updated on
CC   25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 19 BP; 4 A; 10 C; 3 G; 1 T; 0 U; 1 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
              |||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 1213
AAT36525/c
ID   AAT36525 standard; DNA; 19 BP.
XX
AC   AAT36525;
XX
DT   10-FEB-1997  (first entry)
XX
DE   Thermophilic Campylobacter general probe.
XX
KW   c-gtp; guanosine 5'-triphosphatase; GTPase; enzyme; probe;
KW   GTP-binding protein; primer; detection; differentiation; microorganism;
KW   biological sample; thermophilic; veterinary; Campylobacter; jejuni; coli;
KW   lari; upsaliensis; human; pathogen; diarrhoea; infection; fetus;
KW   hyointestinalis; mucosalis; ss.
XX
OS   Synthetic.
XX
PN   WO9613608-A2.
XX
PD   09-MAY-1996.
XX
PF   30-OCT-1995;   95WO-EP004264.
XX
PR   28-OCT-1994;   94EP-00870171.
XX
PA   (INNO-) INNOGENETICS NV.
PA   (DELF-) DELFT DIAGNOSTIC LAB BV.
XX
PI   Giesendorf B,  Quint W,  Van Doorn L;
XX
DR   WPI; 1996-239513/24.
XX
PT   GTPase gene family sequences derived from Campylobacter species - for use
PT   in the detection and differentiation of thermophilic and veterinary
PT   species of Campylobacter.
XX
PS   Claim 16; Page 39; 104pp; English.
XX
CC   The present sequence is a thermophilic Campylobacter c-gtp gene general
CC   probe. The c-gtp gene encodes a guanosine 5'-triphosphatase (GTPase)
CC   enzyme, or GTP-binding protein. The gene can be used in the prepn. of
CC   probes and primers, i.e. the present sequence, for the detection and
CC   differentiation of microorganisms in biological samples. Thermophilic and
CC   veterinary Campylobacter sp. can be detected with probes or primers
CC   derived from the c-gtp-1 and c-gtp-2 gene families, respectively.
CC   Thermophilic Campylobacter sp. include C. jejuni, C. coli, C. lari and C.
CC   upsaliensis, which are human pathogens involved in diarrhoea causing
CC   infections. Veterinary Campylobacter sp., encompass sp. which are
CC   important in veterinary infections, e.g. C. fetus, C. hyointestinalis and
CC   C. mucosalis
XX
```

```
SQ   Sequence 19 BP; 11 A; 2 C; 2 G; 2 T; 0 U; 2 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCTAG 1700
              | ||| |:|| |||||:|
Db         19 TTTTATTKGTATCTCTWG 2


RESULT 1214
AAT79957
ID   AAT79957 standard; DNA; 19 BP.
XX
AC   AAT79957;
XX
DT   03-MAR-1998  (first entry)
XX
DE   Immunoglobulin heavy chain (IgH) amplifcation primer FR4.
XX
KW   immunoglobulin heavy chain; IgH; myeloma; genetic probe; detection;
KW   enriched cell complex; foetal abnormality; PCR primer; screening; cancer;
KW   AIDS; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9726324-A1.
XX
PD   24-JUL-1997.
XX
PF   17-JAN-1997;   97WO-AU000020.
XX
PR   17-JAN-1996;   96US-0010113P.
XX
PA   (FLIN-) FLINDERS TECHNOLOGIES PTY LTD.
XX
PI   Kalionis B;
XX
DR   WPI; 1997-385329/35.
XX
PT   Enriched cell complex with target cell component hybridised to detection
PT   agent - used to isolate specific cells from a mixed population, e.g.
PT   foetal cells from maternal blood for genetic abnormality analysis.
XX
PS   Example 2; Page 63; 91pp; English.
XX
CC   This primer FR4 is used for PCR amplification of a segment of
CC   immunoglobulin heavy chain (IgH) gene which is used as a genetic probe.
CC   This IgH genetic probe is specific for 5T33 myeloma cells. This is used
CC   in the formation of a novel enriched cell complex which comprises of a
CC   specific cell having a selected intracellular component to which a
CC   detection agent coupled to a solid support can hybridise to. The 5T33
CC   myeloma cells are enriched using an intracellular messenger RNA for the
CC   IgH gene followed by in situ hybridisation by the IgH genetic probe.
CC   Formation of a novel enriched complex is used to enrich cells from a
CC   mixed population, particularly as a preliminary to in situ hybridisation
CC   for quantification or detection of nucleic acid or proteins, e.g. for
CC   diagnosis or prognosis of diseases and infection, for characterisation of
CC   cell metabolism and differentiation and for therapeutic use. Typical
CC   applications are detecting foetal abnormalities (by enriching foetal
CC   cells from maternal blood), early diagnosis of cancer, screening for HIV
CC   or other infections, detecting predisposition to cancer, heart disease
CC   and, by detecting cancer cells in the circulation, assessing metastatic
CC   potential. The method can also be used to estimate the efficacy of
CC   therapy and for treatment of AIDS, leukaemia, blood-borne parasitic
CC   diseases by depleting affected cells
XX
SQ   Sequence 19 BP; 4 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTG 1813
              |||||| |||||||
Db          6 CTCTGAGAGTGGTG 19


RESULT 1215
AAV27778
ID   AAV27778 standard; DNA; 19 BP.
XX
AC   AAV27778;
XX
DT   24-SEP-1998  (first entry)
XX
DE   Monamine oxidase A primer 11.
XX
KW   ss; PCR; primer; amplification; monamine oxidase A; abnormal behaviour;
KW   serotonin; dopamine; noradrenaline; mental retardation;
KW   impulsive aggression.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5783680-A.
XX
PD   21-JUL-1998.
XX
PF   06-OCT-1993;   93US-00132168.
XX
PR   06-OCT-1993;   93US-00132168.
XX
PA   (GEHO ) GEN HOSPITAL CORP.
PA   (UYKA-) UNIV STICHTING KATHOLIEKE.
XX
PI   Brunner HG,  Breakefield XO;
XX
DR   WPI; 1998-427102/36.
XX
PT   Genetic diagnosis of impulsive aggression - uses mutant forms of
PT   mono:amine oxidase enzyme.
XX
PS   Example 5; Column 29/30; 30pp; English.
XX
CC   The primers AAV27768-V27795 are used to amplify the fifteen monamine
CC   oxidase A (MAD) exons for SSCP analysis to detect mutations. A genetic
CC   defect linked to p11-p21 of the X chromosome, especially mutation C936T
CC   in exon 8 is related to abnormal behaviour. MAD metabolises serotonin,
CC   dopamine and noradrenaline, neurotransmitters whose metabolism is known
CC   to affect behaviour. Disregulation of these transmitters leads to
CC   borderline mental retardation and abnormal behaviour (including impulsive
CC   aggression). Probes based on the mutated sequence can be used for the
CC   genetic diagnosis of abnormal behaviour
XX
SQ   Sequence 19 BP; 2 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1621 TTTGTTACCTACCT 1634
              ||| ||||||||||
Db          2 TTTCTTACCTACCT 15


RESULT 1216
AAV49018/c
ID   AAV49018 standard; DNA; 19 BP.
XX
AC   AAV49018;
XX
DT   15-OCT-1998  (first entry)
XX
```

```
DE   rb gene antisense oligonucleotide rb-11.
XX
KW   rb gene; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Claim 10; Fig 9a; 286pp; English.
XX
CC   AAV49008-236 represent antisense oligonucleotides directed against the rb
CC   gene. Of these, only oligonucleotides AAV49008-52 resulted in effective
CC   downregulation of negative growth control by rb, while oligonucleotides
CC   AAV49052-236 had little effect. The oligonucleotides exemplify the
CC   invention. The specification describes oligonucleotides that contain 8-30
CC   nucleotides, which contain at most 8 nucleotides that can each form three
CC   hydrogen bonds to cytosine; do not contain four consecutive nucleotides
CC   able to form three H-bonds each to four consecutive cytosines; do not
CC   contain two sequences of three consecutive nucleotides each able to form
CC   three H-bonds to three consecutive cytosines, and the ratio between
CC   residues able to form two H-bonds each (2R) or three such bonds (3R) is
CC   given by 2R/3R = 0.33-0.72. The oligonucleotides are used to modulate
CC   expression of genes, particularly the genes for p53, ErB-2, junB, junD,
CC   TGF-beta 1 or beta 2 to control proliferation of primary cell cultures
CC   (e.g. bone marrow stem, liver or kidney cells, osteoclasts, osteoblasts
CC   and/or keratinocytes). The oligonucleotides can also be used to analyse
CC   function of proteins (by altering their expression or activity) and
CC   therapeutically, e.g. in cases of cancer or (targeting TGF) for
CC   stimulating the immune system
XX
SQ   Sequence 19 BP; 7 A; 6 C; 2 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1810 GGTGCTATAAGTTT 1823
             ||||||| ||||||
Db         19 GGTGCTAAAAGTTT 6


RESULT 1217
AAZ01250
ID   AAZ01250 standard; DNA; 19 BP.
XX
AC   AAZ01250;
XX
DT   27-SEP-1999  (first entry)
XX
DE   PCR primer for PG1 biallelic marker 99-134-362.
XX
KW   PG1 gene; biallelic marker; PCR primer; PG1-related biallelic marker;
KW   cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
KW   PSA; human; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9932644-A2.
XX
PD   01-JUL-1999.
XX
PF   22-DEC-1998;   98WO-IB002133.
XX
PR   22-DEC-1997;   97US-00996306.
PR   09-SEP-1998;   98US-0099658P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I,  Bougueleret L;
XX
DR   WPI; 1999-405178/34.
XX
PT   Use of a prostate cancer associated gene and biallelic markers derived
PT   from it.
XX
PS   Claim 4; Page 357; 385pp; English.
XX
CC   The invention relates to a mammalian PG1 gene and protein, and a set of
CC   PG1 biallelic markers. The PG1 polynucleotide and biallelic markers are
CC   used in a hybridisation assay, a sequencing assay, or in an allele-
CC   specific amplification assay for determining the identity of a nucleotide
CC   at a PG1-related biallelic marker. The methods can be used to detect and
CC   to assess the risk of developing cancer or prostate cancer. Early-stage
CC   diagnosis of prostate cancer relies on prostate specific antigen (PSA)
CC   dosage. However, the effectiveness of this is limited due to its
CC   inability to discriminate between malignant and non-malignant affections
CC   of the organ. A need exists for both a reliable diagnostic procedure
CC   which would enable early-stage diagnosis, and for preventative and
CC   curative treatments of the disease. The PG1 gene can be used for
CC   detection of prostate cancer, and the risk of developing it in the
CC   future, and can also be used to determine therapies for the disease
XX
SQ   Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2034 GCAAAGGTTCTATC 2047
              ||||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 1218
AAZ87048/c
ID   AAZ87048 standard; DNA; 19 BP.
XX
AC   AAZ87048;
XX
DT   16-MAY-2000  (first entry)
XX
DE   RBP-7 microsequencing primer for marker 5-140-348.
XX
KW   RBP-7; retinoblastoma binding protein-7; abnormal cell proliferation;
KW   diagnosis; therapy; cell differentiation; thyroid hyperplasia; psoriasis;
KW   benign prostate hypertrophy; cancer; sarcoma; neoplasm; leukaemia;
KW   lymphoma; biallelic marker; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200000607-A1.
XX
PD   06-JAN-2000.
XX
PF   30-JUN-1999;   99WO-IB001242.
XX
```

PR 30-JUN-1998; 98US-0091315P.
PR 10-DEC-1998; 98US-0111909P.
XX
PA (GEST) GENSET.
XX
PI Bougueleret L;
XX
DR WPI; 2000-117170/10.
XX
PT Novel nucleic acid and polymorphic markers used for diagnosis of
PT diseases, especially those involving abnormal cell proliferation and
PT differentiation.
XX
PS Claim 15; Page 215; 223pp; English.
XX
CC This sequence represents a microsequencing primer for a biallelic marker
CC from the retinoblastoma binding protein-7 (RBP-7) genomic sequence
CC (AAZ86967) of the invention. The RBP-7 coding sequence and regulatory
CC sequences are useful for the recombinant production of the protein and
CC for expressing heterologous nucleic acids. Primers and probes derived
CC from the RBP-7 nucleotide sequence (such as this sequence) are useful for
CC DNA amplification and detection methods. RBP-7 biallelic markers (see
CC AAZ86993-Z87034) are useful for diagnosis of disease related to
CC alteration in the regulation or in the coding regions of the RBP-7 gene
CC and for prognosis/diagnosis of an eventual treatment with therapeutic
CC agents, especially agents acting on pathologies involving abnormal cell
CC proliferation and/or differentiation, these include thyroid hyperplasia,
CC psoriasis, benign prostate hypertrophy, cancers, including breast cancer,
CC sarcomas and other neoplasms, bladder cancer, colon cancer, lung cancer,
CC prostate cancer, various leukaemias, and lymphomas. RBP-7 antibodies are
CC useful as diagnostic agents
XX
SQ Sequence 19 BP; 9 A; 4 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1967 ATATTTACCTTGAA 1980
|| ||||||||||
Db 15 ATGTTTACCTTGAA 2

RESULT 1219
AAA82421
ID AAA82421 standard; DNA; 19 BP.
XX
AC AAA82421;
XX
DT 04-DEC-2000 (first entry)
XX
DE cdk1 ribozyme binding site #7.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 46; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 4 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1594 GGAACCCCTCCTGG 1607
||||||||||||
Db 1 GGAACCCCTCCTTG 14

RESULT 1220
AAA84778
ID AAA84778 standard; DNA; 19 BP.
XX
AC AAA84778;
XX
DT 04-DEC-2000 (first entry)
XX
DE Cyclin F ribozyme binding site #46.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
DR WPI; 2000-412314/35.
XX
PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 82; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 1 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1998 TCTAGCTTCTTCAG 2011
              ||| ||||||||||
Db          3 TCTCGCTTCTTCAG 16


RESULT 1221
AAZ71422
ID   AAZ71422 standard; DNA; 19 BP.
XX
AC   AAZ71422;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:5778.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1463; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 19 BP; 1 A; 4 C; 4 G; 10 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1948 TGGTTTTTGTGTCC 1961
              |||||||| |||||
Db          2 TGGTTTTTCTGTCC 15


RESULT 1222
AAZ74732
ID   AAZ74732 standard; DNA; 19 BP.
XX
AC   AAZ74732;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:9088.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 2168; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 19 BP; 1 A; 5 C; 2 G; 11 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTT 1781
              |||||||||| |||
Db          3 AGCTTTTTTTCTTT 16


RESULT 1223
AAZ75405/c
ID   AAZ75405 standard; DNA; 19 BP.
XX
AC   AAZ75405;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:9761.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
```

KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 2311; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 2 A; 8 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1543 AGAGTAGGGAAGGA 1556
| ||||||||||||
Db 16 AAAGTAGGGAAGGA 3

RESULT 1224
AAZ73694
ID AAZ73694 standard; DNA; 19 BP.
XX
AC AAZ73694;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker downstream amplification primer SEQ ID NO:8050.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 8; Page 1947; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2034 GCAAAGGTTCTATC 2047
||||||||| ||||
Db 6 GCAAAGGTTATATC 19

RESULT 1225
AAZ44184
ID AAZ44184 standard; DNA; 19 BP.
XX
AC AAZ44184;
XX
DT 24-MAR-2000 (first entry)
XX
DE Human neuropsin DNA primer 1s.
XX
KW Neuropsin; human; neuron growth; brain information transfer;
KW brain function; primer; ss.
XX
OS Homo sapiens.
XX
PN JP11318461-A.
XX
PD 24-NOV-1999.
XX
PF 15-MAY-1998; 98JP-00133615.
XX
PR 15-MAY-1998; 98JP-00133615.
XX
PA (SHIO/) SHIOZAKA S.
PA (IGAK-) IGAKU SEIBUTSUGAKU KENKYUSHO KK.
XX
DR WPI; 2000-090526/08.

XX
PT Human neuropsine, its DNA sequence, its gene and its primer - for
PT research into growth of neurons, information transfer and brain
PT functions.
XX
PS Disclosure; Page 8; 12pp; Japanese.
XX
CC This invention describes a novel human neuropsin. Human neuropsin is
CC useful for researches on the growth of neurons, information transfer and
CC brain functions. AAZ44184-Z44191 represent primers used in the isolation
CC of the human neuropsin described in the method of the invention
XX
SQ Sequence 19 BP; 2 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1669 CCCGCCCCTGGACT 1682
||||||||||||
Db 6 CCCGCCCCTGGATT 19

RESULT 1226
AAH59940
ID AAH59940 standard; DNA; 19 BP.
XX
AC AAH59940;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin F ribozyme binding site SEQ ID NO:2364.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 243; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnerary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 1 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1998 TCTAGCTTCTTCAG 2011
||| ||||||||||
Db 3 TCTCGCTTCTTCAG 16

RESULT 1227
AAH57583
ID AAH57583 standard; DNA; 19 BP.
XX
AC AAH57583;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cell-cycle dependent kinase cdk1 ribozyme binding site SEQ ID NO:7.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
PR 26-OCT-1999; 99US-0161532P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Robbins JM, Tritz R;
XX
DR WPI; 2001-300427/31.
XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 72; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle

```
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 19 BP; 4 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGG 1607
              ||||||||||||  |
Db          1 GGAACCCCTCCTTG 14


RESULT 1228
AAD38665
ID   AAD38665 standard; DNA; 19 BP.
XX
AC   AAD38665;
XX
DT   23-SEP-2002  (first entry)
XX
DE   Human CDKN1A promoter-5' UTR amplifying forward PCR primer.
XX
KW   Human; genotyping; candidate region; mismatch scanning; CDKN1A gene;
KW   detection; PCR; primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200234948-A2.
XX
PD   02-MAY-2002.
XX
PF   25-OCT-2001; 2001WO-US042810.
XX
PR   25-OCT-2000; 2000US-0242725P.
XX
PA   (CITY ) CITY OF HOPE.
XX
PI   Krontiris TG,  Beaulieu M,  Flanagan SD;
XX
DR   WPI; 2002-471445/50.
XX
PT   Genotyping or detecting mutation in DNA sample by candidate region
PT   mismatch scanning, comprises amplifying, denaturing, reannealing,
PT   digesting DNA with Escherichia coli mismatch detection enzymes to cleave
PT   mismatch-containing DNA.
XX
PS   Example 3; Page 35; 71pp; English.
XX
CC   The invention relates to a method for genotyping or detecting mutation in
CC   DNA sample by candidate region mismatch scanning. The method involves
CC   amplifying candidate region of the DNA that includes 5' GATC 3' site,
CC   denaturing and reannealing the amplified DNA, digesting the reannealed
CC   DNA with the Escherichia coli mismatch detection enzymes, MutS, MutL and
CC   MutH, to cleave mismatch-containing DNA at 5' GATC 3' site and
CC   determining fraction of DNA cleaved. The invention also provides a method
CC   for determining allele-sharing status between sibs by candidate region
CC   mismatch scanning. The present sequence is a PCR primer used to amplify
CC   human CDKN1A promoter-5' UTR region. This primer is used in the
CC   exemplification of the invention
XX
SQ   Sequence 19 BP; 2 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1574 CTTCTCCACCGCAC 1587
              || ||||||||||
Db          1 CTGCTCCACCGCAC 14


RESULT 1229
ABS51273/c
ID   ABS51273 standard; DNA; 19 BP.
XX
AC   ABS51273;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human CADPKL DNA PCR primer #56.
XX
KW   Human; calcium/calmodulin-dependent protein kinase-like gene; CADPKL; ss;
KW   PCR; neuropsychiatric disorder; attention deficit disorder; ADD; primer;
KW   schizoaffective disorder; bipolar disorder; unipolar affective disorder;
KW   schizophrenia; adolescent conduct disorder; pharmacogenomics;
KW   fingerprinting; paternity testing; antidepressant; neuroleptic.
XX
OS   Homo sapiens.
XX
PN   WO200254939-A2.
XX
PD   18-JUL-2002.
XX
PF   07-JAN-2002; 2002WO-US000367.
XX
PR   09-JAN-2001; 2001US-00757300.
PR   23-AUG-2001; 2001US-00935464.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Meyer JM,  Barrington-Martin R,  Parker A;
XX
DR   WPI; 2002-590643/63.
XX
PT   New variants of calcium/calmodulin-dependent protein kinase-like nucleic
PT   acids and polypeptides, useful for diagnosing and treating
PT   neuropsychiatric disorders, e.g. schizophrenia, schizoaffective disorder,
PT   and bipolar disorder.
XX
PS   Claim 17; Page 99; 223pp; English.
XX
CC   The invention relates to a nucleic acid comprising a polymorphic region
CC   of a Calcium/Calmodulin-dependent protein kinase-like gene (CADPKL)
CC   allelic variant, and the polypeptide it encodes. CADPKL allelic variants
CC   are useful in determining whether a subject has or is at risk of
CC   developing a neuropsychiatric disorder, such as schizophrenia, attention
CC   deficit disorder (ADD), schizoaffective disorder, bipolar disorder,
CC   unipolar affective disorder and adolescent conduct disorder. The
CC   polypeptides, polynucleotides, antibodies and modulators of the CADPKL
CC   allelic variants are useful for diagnosing or treating these
CC   neuropsychiatric disorders. The polypeptides may be used to raise
CC   antibodies to a CADPKL polypeptide. The nucleic acids may be used as
CC   probes or primers, in pharmacogenomics for designing therapies for the
CC   disorders, and in fingerprinting for detection of different individuals
CC   with the same species (e.g. paternity testing). This sequence represents
CC   a PCR primer used to amplify human CADPKL DNA of the invention
XX
SQ   Sequence 19 BP; 2 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
```

```
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAA 1557
              |||| |||||||||
Db         16 GAGTGGGGAAGGAA 3


RESULT 1230
ADF36876/c
ID   ADF36876 standard; RNA; 19 BP.
XX
AC   ADF36876;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1165.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1165; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 10 A; 1 C; 2 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAA 1784
              |||| |||||||||
Db         17 TTTTCTTTTTTGAA 4


RESULT 1231
ADF37200
ID   ADF37200 standard; RNA; 19 BP.
XX
AC   ADF37200;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1489.
XX
KW   double-stranded short interfering nucleic acid;
KW   short interfering nucleic acid; siNA; downregulation;
KW   vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW   cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW   nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW   diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW   arthritis; psoriasis; endometriosis; angiofibroma;
KW   polycystic kidney disease; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO2003070910-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005022.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   29-MAY-2002; 2002WO-US017674.
PR   06-JUN-2002; 2002US-0386782P.
PR   03-JUL-2002; 2002US-0393796P.
PR   29-JUL-2002; 2002US-0399348P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   04-NOV-2002; 2002US-00287949.
PR   27-NOV-2002; 2002US-00306747.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Pavco P;
XX
DR   WPI; 2003-679876/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of cancer, downregulates the vascular endothelial growth
PT   factor receptor gene.
XX
PS   Example 3; SEQ ID NO 1489; 207pp; English.
XX
CC   The present invention describes a double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the vascular
CC   endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
```

```
CC   siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC   delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC   that express siNA; and (5) single-stranded siNA with similar properties.
CC   The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC   ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC   gynaecological activities. The siNA are useful for modulating
CC   (downregulating) the expression of VEGFR genes. The siNA are potentially
CC   useful for treating a wide range of angiogenesis-associated conditions,
CC   particularly cancers, diabetic retinopathy, macular degeneration,
CC   neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC   and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC   drug screening, target identification and validation, genetic
CC   engineering, studying gene function, and also for gene mapping (e.g. of
CC   single-nucleotide polymorphisms). The present sequence is used in the
CC   exemplification of the present invention.
XX
SQ   Sequence 19 BP; 6 A; 2 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   21.4%;  Pred. No. 6.1e+02;
  Matches    3;  Conservative   10;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAA 1784
              :::: ::::::|||
Db          3 UUUUCUUUUUUGAA 16


RESULT 1232
ADF71335/c
ID   ADF71335 standard; RNA; 19 BP.
XX
AC   ADF71335;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID No 120.
XX
KW   short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070886-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004347.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697606/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer , downregulates expression of a protein tyrosine
PT   phosphatase type IVa gene.
XX
PS   Example 3; SEQ ID NO 120; 131pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of a protein tyrosine phosphatase type IV
CC   (PRL3) gene by RNA interference. The invention further relates to
CC   modulating the expression of PRL3 genes in cells, tissue explants or
CC   organisms by the introduction of an siNA; kits for in vitro or in vivo
CC   delivery of an siNA; conjugates and/or complexes of siNA; and vectors
CC   that express siNA. The novel siNA's of the invention have cytostatic
CC   activity. siNA's are used to modulate expression of PRL3 genes, in cells,
CC   tissue explants or organisms, e.g. for treating cancer but also for drug
CC   screening; diagnosis; target identification and validation; genetic
CC   engineering; pharmacogenomics; studying gene function and gene mapping
CC   (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC   represents a short interfering nucleic acid for downregulating the
CC   expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC   invention.
XX
SQ   Sequence 19 BP; 1 A; 2 C; 8 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
                | ||||||||||||
Db         17 AAAGACCCACACAC 4


RESULT 1233
ADF71261
ID   ADF71261 standard; RNA; 19 BP.
XX
AC   ADF71261;
XX
DT   12-FEB-2004  (first entry)
XX
DE   Protein tyrosine phosphatase type IV (PRL3) gene siNA, SEQ ID No 46.
XX
KW   short interfering nucleic acid; siNA;
KW   protein tyrosine phosphatase type IV; PRL3; RNA interference; cytostatic;
KW   cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003070886-A2.
XX
PD   28-AUG-2003.
XX
PF   11-FEB-2003; 2003WO-US004347.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Usman N;
XX
DR   WPI; 2003-697606/66.
XX
PT   New short interfering nucleic acid, useful e.g. for treatment and
PT   diagnosis of cancer , downregulates expression of a protein tyrosine
PT   phosphatase type IVa gene.
XX
PS   Example 3; SEQ ID NO 46; 131pp; English.
XX
CC   The invention relates to a novel short interfering nucleic acid (siNA)
CC   that downregulates expression of a protein tyrosine phosphatase type IV
CC   (PRL3) gene by RNA interference. The invention further relates to
CC   modulating the expression of PRL3 genes in cells, tissue explants or
CC   organisms by the introduction of an siNA; kits for in vitro or in vivo
CC   delivery of an siNA; conjugates and/or complexes of siNA; and vectors
CC   that express siNA. The novel siNA's of the invention have cytostatic
CC   activity. siNA's are used to modulate expression of PRL3 genes, in cells,
```

```
CC   tissue explants or organisms, e.g. for treating cancer but also for drug
CC   screening; diagnosis; target identification and validation; genetic
CC   engineering; pharmacogenomics; studying gene function and gene mapping
CC   (e.g. of single-nucleotide polymorphisms). This polynucleotide sequence
CC   represents a short interfering nucleic acid for downregulating the
CC   expression of a protein tyrosine phosphatase type IV (PRL3) gene of the
CC   invention.
XX
SQ   Sequence 19 BP; 8 A; 8 C; 2 G; 0 T; 1 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
                | ||||||||||||
Db          3 AAAGACCCACACAC 16


RESULT 1234
ADF70357/c
ID   ADF70357 standard; DNA; 19 BP.
XX
AC   ADF70357;
XX
DT   12-FEB-2004  (first entry)
XX
DE   ICAM antisense oligonucleotide SeqID71.
XX
KW   expression modulation; hepatic system; sterol group; hepatotropic;
KW   gene therapy; hepatic disease; antisense therapy; ss; ICAM;
KW   intercellular adhesion molecule.
XX
OS   Unidentified.
XX
PN   WO2003072711-A2.
XX
PD   04-SEP-2003.
XX
PF   21-FEB-2003; 2003WO-US005066.
XX
PR   22-FEB-2002; 2002US-00080979.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Cook PD,  Manoharan M,  Bennett FC;
XX
DR   WPI; 2003-679947/64.
XX
PT   Modulating the expression of a nucleic acid in the hepatic system, useful
PT   for treating hepatic disorders, comprises administering to the mammal an
PT   oligonucleotide that hybridizes to the nucleic acid to modulate its
PT   expression.
XX
PS   Example 7; SEQ ID NO 71; 98pp; English.
XX
CC   This invention relates to a novel method of modulating the expression of
CC   a nucleic acid in the hepatic system of a mammal which comprises
CC   administering to the mammal an oligonucleotide that hybridises to the
CC   nucleic acid to modulate the expression of the nucleic acid, where the
CC   oligonucleotide has two sterol groups that are covalently bonded. The
CC   invention may be useful for the development of a compound with
CC   hepatotropic activity whilst the genetic sequences of the invention may
CC   prove useful for gene therapy. The methods are useful for treating
CC   hepatic disease or disorder associated with a protein encoded by a gene.
CC   Note: These oligonucleotides may have one or more of several
CC   modifications which are detailed in the specification, including having a
CC   phosphorothioate backbone or having ribonucleoside bases.
XX
SQ   Sequence 19 BP; 4 A; 10 C; 3 G; 1 T; 1 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
                ||||||||||||  |
Db         16 TGGCCTGGGGGATG 3


RESULT 1235
ADG36105/c
ID   ADG36105 standard; RNA; 19 BP.
XX
AC   ADG36105;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:948.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 948; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
```

```
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   lower strand of an HIV-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 4 A; 5 C; 3 G; 0 T; 7 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTG 1742
              ||||||||||||| |
Db         14 ATTATCAGAAGGAG 1


RESULT 1236
ADG35367
ID   ADG35367 standard; RNA; 19 BP.
XX
AC   ADG35367;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:210.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss; target sequence.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 210; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   upper strand of HIV-targeted double-stranded siNA, which is identical to
CC   the HIV transcript target sequence.
XX
SQ   Sequence 19 BP; 7 A; 3 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   71.4%;  Pred. No. 6.1e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTG 1742
              |::|:||||||| |
Db          6 AUUAUCAGAAGGAG 19


RESULT 1237
ADG36003/c
ID   ADG36003 standard; RNA; 19 BP.
XX
AC   ADG36003;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:846.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
```

```
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 846; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   lower strand of an HIV-targeted double-stranded siNA.
XX
SQ   Sequence 19 BP; 3 A; 5 C; 4 G; 0 T; 7 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTG 1742
              ||||||||||||| |
Db         15 ATTATCAGAAGGAG 2


RESULT 1238
ADG35265
ID   ADG35265 standard; RNA; 19 BP.
XX
AC   ADG35265;
XX
DT   26-FEB-2004  (first entry)
XX
DE   HIV siNA oligonucleotide SEQ ID NO:108.
XX
KW   RNA interference; short interfering nucleic acid; siNA;
KW   short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW   short hairpin RNA; shRNA; expression modulation; gene therapy;
KW   drug screening; diagnosis; therapeutic target identification;
KW   pharmacogenomics; gene function analysis; gene mapping; HIV; anti-HIV;
KW   HIV replication inhibition; HIV infection; ss; target sequence.
XX
OS   Synthetic.
OS   Human immunodeficiency virus 1.
XX
PN   WO2003070193-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005190.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   22-APR-2002; 2002US-0374722P.
PR   29-MAY-2002; 2002US-00157580.
PR   06-JUN-2002; 2002US-0386782P.
PR   23-JUL-2002; 2002US-0398036P.
PR   21-AUG-2002; 2002US-00225023.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (SIRN-) SIRNA THERAPEUTICS INC.
PA   (MCSW/) MCSWIGGEN J.
XX
PI   Mcswiggen J,  Beigelman L,  Macejak D;
XX
DR   WPI; 2003-679850/64.
XX
PT   New double-stranded short interfering nucleic acid, useful for treating
PT   infection with human immune deficiency virus, comprises sugar-modified
PT   pyrimidine bases.
XX
PS   Example 3; SEQ ID NO 108; 170pp; English.
XX
CC   The invention relates to short interfering nucleic acids (siNA) which
CC   downregulate expression of HIV gene by RNA interference. The siNAs may or
CC   may not comprise ribonucleotides and may be double or single stranded.
CC   They further comprise sense and antisense regions, or alternatively are
CC   assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC   Specifically, the siNAs include short interfering RNA (siRNA), double-
CC   stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC   can be unmodified or chemically modified, can contain
CC   deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC   vector or enzymatically synthesised. The invention also relates to kits
CC   for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC   of siNA; and vectors that express siNA. The siNAs are used to modulate
CC   expression of the HIV gene in cells, tissue explants or organisms (e.g.,
CC   by ex vivo gene therapy), or in grafts and transplants for the treatment
CC   of a variety of conditions. HIV siNAs have anti-HIV activity. They may be
CC   used for inhibiting replication of HIV and may be used to treat HIV
CC   infection. The siNAs are also useful for drug screening, diagnosis,
CC   therapeutic target identification and validation, genetic engineering,
CC   pharmacogenomics, studying gene function, and gene mapping (e.g., of
CC   single nucleotide polymorphisms). The present sequence represents the
CC   upper strand of HIV-targeted double-stranded siNA, which is identical to
CC   the HIV transcript target sequence.
XX
SQ   Sequence 19 BP; 7 A; 4 C; 5 G; 0 T; 3 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   71.4%;  Pred. No. 6.1e+02;
  Matches   10;  Conservative    3;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTG 1742
              |::|:|||||||| |
Db          5 AUUAUCAGAAGGAG 18


RESULT 1239
ADF84558
ID   ADF84558 standard; RNA; 19 BP.
XX
AC   ADF84558;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 852.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
```

```
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 852; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human ABL1-targeted siRNA of the invention.
XX
SQ   Sequence 19 BP; 2 A; 11 C; 4 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   78.6%;  Pred. No. 6.1e+02;
  Matches   11;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCC 1609
              | ||||:|||:||||
Db          2 ACCCCCUCCUGGCC 15


RESULT 1240
ADF84239/c
ID   ADF84239 standard; RNA; 19 BP.
XX
AC   ADF84239;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 533.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
DR   WPI; 2003-679889/64.
XX
PT   New double-stranded interfering nucleic acid, useful e.g. for treatment
PT   and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT   cluster region-Abelson (BCR-ABL) gene.
XX
PS   Example 7; SEQ ID NO 533; 197pp; English.
XX
CC   The invention relates to a novel double-stranded short interfering
CC   nucleic acid (siNA) that downregulates expression of the breakpoint
CC   cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC   (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC   activity and may be useful for modulating expression of the BCR-ABL gene,
CC   as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC   screening, target identification and validation, genetic engineering,
CC   gene function studies and gene mapping. The current sequence is that of
CC   the human ABL1-targeted siRNA of the invention.
XX
SQ   Sequence 19 BP; 2 A; 4 C; 11 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1596 AACCCCTCCTGGCC 1609
              | ||||||||||||
Db         18 ACCCCCTCCTGGCC 5


RESULT 1241
ADF84506/c
ID   ADF84506 standard; RNA; 19 BP.
XX
AC   ADF84506;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human ABL1-targeted siRNA - SEQ ID 800.
XX
KW   short interfering nucleic acid; siNA; breakpoint cluster region;
KW   v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW   cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS   Homo sapiens.
XX
PN   WO2003070972-A2.
XX
PD   28-AUG-2003.
XX
PF   20-FEB-2003; 2003WO-US005234.
XX
PR   20-FEB-2002; 2002US-0358580P.
PR   11-MAR-2002; 2002US-0363124P.
PR   06-JUN-2002; 2002US-0386782P.
PR   15-AUG-2002; 2002US-0404039P.
PR   29-AUG-2002; 2002US-0406784P.
PR   05-SEP-2002; 2002US-0408378P.
PR   09-SEP-2002; 2002US-0409293P.
PR   14-JAN-2003; 2003US-0439922P.
PR   15-JAN-2003; 2003US-0440129P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J,  Beigelman L,  Chowrira B;
XX
```

DR WPI; 2003-679889/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
PS Example 7; SEQ ID NO 800; 197pp; English.
XX
CC The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human ABL1-targeted siRNA of the invention.
XX
SQ Sequence 19 BP; 1 A; 8 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 92.9%; Pred. No. 6.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1553 AGGAACAGGACTGC 1566
|||| |||||||||
Db 19 AGGACCAGGACTGC 6

RESULT 1242
ADF84825
ID ADF84825 standard; RNA; 19 BP.
XX
AC ADF84825;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human ABL1-targeted siRNA - SEQ ID 1119.
XX
KW short interfering nucleic acid; siNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
OS Homo sapiens.
XX
PN WO2003070972-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-US005234.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Chowrira B;
XX
DR WPI; 2003-679889/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
PS Example 7; SEQ ID NO 1119; 197pp; English.
XX
CC The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human ABL1-targeted siRNA of the invention.
XX
SQ Sequence 19 BP; 5 A; 5 C; 8 G; 0 T; 1 U; 0 Other;

Query Match 2.2%; Score 12.4; DB 1; Length 19;
Best Local Similarity 85.7%; Pred. No. 6.1e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1553 AGGAACAGGACTGC 1566
|||| ||||||:||
Db 1 AGGACCAGGACUGC 14

RESULT 1243
ABX77193
ID ABX77193 standard; DNA; 19 BP.
XX
AC ABX77193;
XX
DT 25-APR-2003 (first entry)
XX
DE Mouse alpha-1-acid glycoprotein PCR primer AGP12F.
XX
KW Human; ss; transgenic; drug metabolism; behaviour; PCR; primer; mouse;
KW pharmacokinetic assay; pharmacodynamic assay; toxicology; serum albumin;
KW alpha-acidic glycoprotein; CYP; multidrug resistance protein; MRP;
KW uridine diphosphoglucuronosyl transferase; UGT; cytochrome P450.
XX
OS Mus sp.
XX
PN WO200283897-A1.
XX
PD 24-OCT-2002.
XX
PF 18-APR-2002; 2002WO-AU000485.
XX
PR 18-APR-2001; 2001AU-00004467.
XX
PA (GENE-) GENE STREAM PTY LTD.
XX
PI Daly JM;
XX
DR WPI; 2003-093021/08.
XX
PT New transgenic non-human animal expressing a foreign polypeptide
PT associated with drug behavior and/or metabolism, useful for studying the
PT behavior and/or metabolism of a drug in other animals.
XX
PS Example 2A; Page 54; 408pp; English.
XX
CC This invention relates to a transgenic non-human animal which may be used
CC for assessing the behaviour and/or metabolism of a drug in another animal
CC and which expresses a foreign polypeptide associated with drug behaviour
CC and/or metabolism. The invention also comprises a nucleic acid construct
CC for use in producing the above transgenic non-human animal and a method
CC of assessing the metabolism and/or behavior of a drug in an animal of
CC interest, comprising administering a test agent to the transgenic animal
CC and conducting analytical tests to determine drug metabolism and/or
CC behaviour. The transgenic animal is useful in studying drug metabolism
CC and/or behaviour in other animals. The nucleic acid construct is useful
CC in producing the above transgenic animal and the methods are used for
CC producing, breeding and using transgenic animals for pharmacological
CC (e.g. pharmacokinetic or pharmacodynamic assays) and/or toxicological
CC studies. Nucleic acid sequences used within the invention are serum
CC albumin; alpha-acidic glycoprotein; cytochrome P450 (CYP); uridine

```
CC   diphosphoglucuronosyl transferase (UGT); multidrug resistance proteins
CC   and (MRP's). The present sequence represents a PCR primer used to create
CC   a transgenic animal within the scope of the invention
XX
SQ   Sequence 19 BP; 7 A; 1 C; 9 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 6.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAG 1747
              |||||||||| |||
Db          2 CAGAAGGTGAGAAG 15


RESULT 1244
AAQ36432/c
ID   AAQ36432 standard; DNA; 17 BP.
XX
AC   AAQ36432;
XX
DT   25-MAR-2003  (revised)
DT   05-MAR-1993  (first entry)
XX
DE   GRP-R primer (EXT 2).
XX
KW   Gastrin releasing peptide; GRP; bombesin; neuromedin B; NMB; ranatensin;
KW   RBP; bombesin-like peptide; R1BP; R2BP; R2BP; receptor; agonist;
KW   antagonist; ligand; antibody; cancer; ss.
XX
OS   Synthetic.
XX
PN   WO9216623-A2.
XX
PD   01-OCT-1992.
XX
PF   13-MAR-1992;   92WO-US002091.
XX
PR   15-MAR-1991;   91US-00670603.
PR   03-OCT-1991;   91US-00771332.
XX
PA   (BERL-) BERLEX LAB INC.
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICE.
XX
PI   Battey JF,  Corjay MH,  Fathi Z,  Feldman RI,  Harkin RN;
PI   Slattery TK,  Wada E,  Wu JM;
XX
DR   WPI; 1992-349208/42.
XX
PT   Receptors for bombesin-like peptide(s) and their DNA - useful for
PT   screening for agonists and antagonists of the receptor ligands, also for
PT   treating or diagnosing cancer.
XX
PS   Example 12; Page 85-91; 173pp; English.
XX
CC   The primers of AAQ36431-32 were used in the identification of cDNA clone
CC   encoding the Swiss 3T3 GRP Receptor. EXT 3 (AAQ36431) was used as a gene-
CC   specific primer for reverse transcription of Swiss 3T3 mRNA, and EXT 2
CC   (AAQ36432) was used as a gene specific primer for Taq DNA polymerase
CC   catalysed PCR. The DNA sequences encoding mouse R1BP; human R1BP; rat
CC   R2BP; human R2BP and human R3BP are given in AAQ29158-62 respectively.
CC   The receptor gene and encoded polypeptide are used for screening for
CC   agonists and antagonists of the receptor ligands, for producing
CC   diagnostic or therapeutic reagents, and for producing antibodies. Hosts
CC   suffering from abnormal receptor function, e.g. proliferative cell
CC   conditions such as cancers, may be treated. The mouse GRP receptor was
CC   isolated from Swiss 3T3 fibroblasts and sequenced. The sequence was used
CC   to design oligonucleotide probes to isolate DNA encoding mouse GRP
CC   receptor from a Swiss 3T3 cDNA library. This DNA was then used as a probe
CC   to isolate rat NMB receptor, human GRP receptor, human NMB receptor and
CC   human R3BP (incompletely characterised homologous putative receptor) from
CC   DNA libraries. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCTGG 1849
              | |||| |||||| |||
Db         17 TAAAATCCATTCCATGG 1


RESULT 1245
AAX74647/c
ID   AAX74647 standard; RNA; 17 BP.
XX
AC   AAX74647;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #175.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 160; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 8 A; 2 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCA 1654
              | |||||| |||||| |
Db         17 TTTTTAAATAGCCTTGA 1
```

```
RESULT 1246
AAX74992
ID   AAX74992 standard; RNA; 17 BP.
XX
AC   AAX74992;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #520.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 170; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 5 A; 4 C; 2 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 6.3e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTGCC 1897
              : :||||:: |:| |||
Db          1 UUUCAAAUUCAUGAGCC 17


RESULT 1247
AAX75261
ID   AAX75261 standard; RNA; 17 BP.
XX
AC   AAX75261;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #789.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 179; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 5 A; 2 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 6.3e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTT 1775
              :|:: |::|||| :::
Db          1 UAUUUAUUAAGCACUUU 17


RESULT 1248
AAX75407
ID   AAX75407 standard; RNA; 17 BP.
XX
AC   AAX75407;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #935.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
```

```
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 183; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 2 A; 4 C; 3 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 6.3e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              :| |:||::|:|| : |
Db          1 UCUCUGGUUCUGCUUAA 17


RESULT 1249
AAX72881
ID   AAX72881 standard; RNA; 17 BP.
XX
AC   AAX72881;
XX
DT   28-JUL-1999  (first entry)
XX
DE   Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #314.
XX
KW   Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW   KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW   tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW   fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW   foetal liver kinase 1; ss.
XX
OS   Mus sp.
XX
PN   WO9715662-A2.
XX
PD   01-MAY-1997.
XX
PF   25-OCT-1996;   96WO-US017480.
XX
PR   26-OCT-1995;   95US-0005974P.
PR   11-JAN-1996;   96US-00584040.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (CHIR ) CHIRON CORP.
XX
PI   Pavco P,  Mcswiggen J,  Stinchcomb D,  Escobedo J;
XX
DR   WPI; 1997-259017/23.
XX
PT   Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT   stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT   rheumatoid arthritis, etc., in a human patient.
XX
PS   Claim 4; Page 132; 218pp; English.
XX
CC   The present invention describes nucleic acid molecules which modulate the
CC   synthesis, expression and/or stability of a mRNA encoding 1 or more
CC   receptors of vascular endothelial growth factor (VEGF). A patient
CC   (preferably human) having a condition associated with the level of the
CC   fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC   receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC   angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC   treated by administering the nucleic acid molecule or the expression
CC   vector to the patient. AAX67275 to AAX75752 represent specific examples
CC   of nucleic acid molecules from the present invention
XX
SQ   Sequence 17 BP; 5 A; 4 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6.3e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGGC 1851
              ||| |||:: ||:|| |
Db          1 AAAGACAUUGCCUGGUC 17


RESULT 1250
AAV97970
ID   AAV97970 standard; RNA; 17 BP.
XX
AC   AAV97970;
XX
DT   17-MAR-1999  (first entry)
XX
DE   Human EGF-R target sequence nucleotide position 5250.
XX
KW   Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW   hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW   cancer; genetic drift; detection; mutation; ss.
XX
OS   Homo sapiens.
XX
PN   WO9833893-A2.
XX
PD   06-AUG-1998.
XX
PF   14-JAN-1998;   98WO-US000730.
XX
PR   31-JAN-1997;   97US-0036476P.
PR   04-DEC-1997;   97US-00985162.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (UYAS-) UNIV ASTON.
XX
PI   Akhtar S,  Fell P,  Mcswiggen JA;
XX
DR   WPI; 1998-437449/37.
XX
PT   Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT   growth factor receptor, useful for inhibiting cell proliferation and for
PT   treating cancers.
XX
PS   Claim 5; Page 83; 109pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules (NAMs)
CC   which specifically cleave RNA derived from an epidermal growth factor
CC   receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC   represent specifically claimed target sequence from human EGF-R. AAV98044
CC   to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC   hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
```

```
CC   cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC   expression levels e.g. to inhibit cell proliferation in the prevention or
CC   treatment of cancers. The NAMs can also be used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of EGF-R RNA in a cell
XX
SQ   Sequence 17 BP; 3 A; 6 C; 0 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 6.3e+02;
  Matches    7;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              |||||:: :::||:  :|
Db          1 CCCAUUUUUUCCUAAUC 17


RESULT 1251
AAV97972
ID   AAV97972 standard; RNA; 17 BP.
XX
AC   AAV97972;
XX
DT   17-MAR-1999  (first entry)
XX
DE   Human EGF-R target sequence nucleotide position 5252.
XX
KW   Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW   hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW   cancer; genetic drift; detection; mutation; ss.
XX
OS   Homo sapiens.
XX
PN   WO9833893-A2.
XX
PD   06-AUG-1998.
XX
PF   14-JAN-1998;   98WO-US000730.
XX
PR   31-JAN-1997;   97US-0036476P.
PR   04-DEC-1997;   97US-00985162.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (UYAS-) UNIV ASTON.
XX
PI   Akhtar S,  Fell P,  Mcswiggen JA;
XX
DR   WPI; 1998-437449/37.
XX
PT   Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT   growth factor receptor, useful for inhibiting cell proliferation and for
PT   treating cancers.
XX
PS   Claim 5; Page 83; 109pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules (NAMs)
CC   which specifically cleave RNA derived from an epidermal growth factor
CC   receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC   represent specifically claimed target sequence from human EGF-R. AAV98044
CC   to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC   hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
CC   cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC   expression levels e.g. to inhibit cell proliferation in the prevention or
CC   treatment of cancers. The NAMs can also be used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of EGF-R RNA in a cell
XX
SQ   Sequence 17 BP; 3 A; 4 C; 1 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 6.3e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1788 CATTCTTTCCTTCTCTG 1804
              ||:: :::||:  :|:|
Db          1 CAUUUUUUCCUAAUCUG 17


RESULT 1252
AAV97971
ID   AAV97971 standard; RNA; 17 BP.
XX
AC   AAV97971;
XX
DT   17-MAR-1999  (first entry)
XX
DE   Human EGF-R target sequence nucleotide position 5251.
XX
KW   Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW   hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW   cancer; genetic drift; detection; mutation; ss.
XX
OS   Homo sapiens.
XX
PN   WO9833893-A2.
XX
PD   06-AUG-1998.
XX
PF   14-JAN-1998;   98WO-US000730.
XX
PR   31-JAN-1997;   97US-0036476P.
PR   04-DEC-1997;   97US-00985162.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (UYAS-) UNIV ASTON.
XX
PI   Akhtar S,  Fell P,  Mcswiggen JA;
XX
DR   WPI; 1998-437449/37.
XX
PT   Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT   growth factor receptor, useful for inhibiting cell proliferation and for
PT   treating cancers.
XX
PS   Claim 5; Page 83; 109pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules (NAMs)
CC   which specifically cleave RNA derived from an epidermal growth factor
CC   receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC   represent specifically claimed target sequence from human EGF-R. AAV98044
CC   to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC   hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
CC   cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC   expression levels e.g. to inhibit cell proliferation in the prevention or
CC   treatment of cancers. The NAMs can also be used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of EGF-R RNA in a cell
XX
SQ   Sequence 17 BP; 3 A; 5 C; 0 G; 0 T; 9 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   35.3%;  Pred. No. 6.3e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              |||:: :::||:  :|:
Db          1 CCAUUUUUUCCUAAUCU 17


RESULT 1253
AAV95150
ID   AAV95150 standard; RNA; 17 BP.
XX
AC   AAV95150;
XX
DT   24-FEB-1999  (first entry)
```

XX
DE Canine IL-2 receptor g-chain substrate position 628.
XX
KW Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
KW autoimmune disease; psoriasis; allergy; inflammatory disease;
KW graft rejection; ss.
XX
OS Synthetic.
OS Canis sp.
XX
PN WO9824913-A2.
XX
PD 11-JUN-1998.
XX
PF 02-DEC-1997; 97WO-US021748.
XX
PR 03-DEC-1996; 96US-00758306.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Stinchcomb DT, Mcswiggen JA;
XX
DR WPI; 1998-333332/29.
XX
PT Ribozymes targetted to interleukin 2 - useful for treating e.g. cancer,
PT autoimmune disease and allergies.
XX
PS Claim 4; Page 46; 61pp; English.
XX
CC The present sequence invention describes ribozymes targeted to modulate
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.
CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
CC from the present invention. The ribozymes can be used for the treatment
CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy
CC and other inflammatory conditions. The ribozymes are also used to induce
CC tolerance in a recipient to alloantigen from a donor
XX
SQ Sequence 17 BP; 1 A; 7 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 6.3e+02;
Matches 8; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

Qy 2039 GGTTCTATCTGCTTAGC 2055
| ::|: :|:|| :|||
Db 1 GCUUCUCUCUGCCUAGC 17

RESULT 1254
AAA22484/c
ID AAA22484 standard; RNA; 17 BP.
XX
AC AAA22484;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5710.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
PS Claim 54; Page 223; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 11 A; 0 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1759 TATTCATTAAGCTTTTT 1775
|||||| ||| |||||
Db 17 TATTCACTAATTTTTTT 1

RESULT 1255
AAA22485/c
ID AAA22485 standard; RNA; 17 BP.
XX
AC AAA22485;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5711.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;

KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
PS Claim 54; Page 223; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 11 A; 0 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1758 TTATTCATTAAGCTTTT 1774
||||||| ||| ||||
Db 17 TTATTCACTAATTTTTT 1

RESULT 1256
AAA23040
ID AAA23040 standard; RNA; 17 BP.
XX
AC AAA23040;
XX
DT 19-JUN-2000 (first entry)
XX
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6266.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
XX
DR WPI; 1999-591315/50.
XX
PT Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
PS Claim 54; Page 258; 305pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 4 A; 2 C; 1 G; 0 T; 10 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 6.3e+02;
Matches 5; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

Qy 1763 CATTAAGCTTTTTTTTT 1779
||: ||| ::::: :::
Db 1 CAUCAAGUUUUUUAUUU 17

RESULT 1257
AAA20575
ID AAA20575 standard; RNA; 17 BP.
XX
AC AAA20575;
XX
DT 19-JUN-2000 (first entry)
XX

```
DE   Integrin alpha 6 subunit substrate sequence SEQ ID NO:3801.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 55; Page 154; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 4 A; 3 C; 2 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 6.3e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTTTGGA 1725
              :|:| ||: | :::|||
Db          1 UAUCACCUUAUUUUGGA 17


RESULT 1258
AAA23041
ID   AAA23041 standard; RNA; 17 BP.
XX
AC   AAA23041;
XX
DT   19-JUN-2000  (first entry)
XX
DE   Integrin subunit beta 3 substrate sequence SEQ ID NO:6267.
XX
KW   Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW   integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW   hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW   ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW   dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW   age related macular degeneration; inflammation; neovascular glaucoma;
KW   myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW   tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW   Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS   Homo sapiens.
XX
PN   WO9950403-A2.
XX
PD   07-OCT-1999.
XX
PF   24-MAR-1999;   99WO-US006507.
XX
PR   27-MAR-1998;   98US-0079678P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Pavco PA,  Roberts E,  Jarvis T,  Coeshott C,  Mcswiggen JA;
XX
DR   WPI; 1999-591315/50.
XX
PT   Novel ribozymes for modulating the synthesis, expression and/or stability
PT   of an mRNA encoding an angiogenic factors.
XX
PS   Claim 54; Page 258; 305pp; English.
XX
CC   The present invention describes enzymatic nucleic acid molecules with RNA
CC   cleaving activity, which specifically cleave RNA encoded by an aryl
CC   hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC   gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC   AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC   and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC   corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC   AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC   and AAA19155 to AAA19222 represent their corresponding target sequences;
CC   AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC   sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC   AAA21596 to AAA21688 represent their corresponding target sequences;
CC   AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC   for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC   AAA23422 represent their corresponding target sequences. The ribozymes of
CC   the invention are used for modulating the synthesis, expression and/or
CC   stability of an mRNA encoding angiogenic factor, especially ARNT,
CC   integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC   especially used to treat cancer, diabetic retinopathy, age related
CC   macular degeneration (ARMD), inflammation, and arthritis, as well as
CC   neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC   angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC   syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC   and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC   integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ   Sequence 17 BP; 4 A; 1 C; 1 G; 0 T; 11 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   23.5%;  Pred. No. 6.3e+02;
  Matches    4;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1764 ATTAAGCTTTTTTTTTT 1780
              |: ||| ::::: ::::
Db          1 AUCAAGUUUUUUAUUUU 17
```

```
RESULT 1259
AAV91293/c
ID   AAV91293 standard; RNA; 17 BP.
XX
AC   AAV91293;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human C-raf target site nucleotide position 2296.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 152; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 1 A; 10 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGGAC 1563
              | |||| ||| ||||||
Db         17 TGGGGAGGGAGCAGGAC 1

RESULT 1260
AAV93691
ID   AAV93691 standard; RNA; 17 BP.
XX
AC   AAV93691;
XX
DT   18-FEB-1999  (first entry)
XX
DE   Human B-raf substrate nucleotide position 2380.
XX
KW   Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW   target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW   screening; identification; synthesis; deprotection; purification; cancer;
KW   inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW   restenosis; rheumatoid arthritis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9850530-A2.
XX
PD   12-NOV-1998.
XX
PF   05-MAY-1998;   98WO-US009249.
XX
PR   09-MAY-1997;   97US-0046059P.
PR   09-JUN-1997;   97US-0049002P.
PR   03-JUL-1997;   97US-0051718P.
PR   22-AUG-1997;   97US-0056808P.
PR   02-OCT-1997;   97US-0061321P.
PR   02-OCT-1997;   97US-0061324P.
PR   05-NOV-1997;   97US-0064866P.
PR   19-DEC-1997;   97US-0068212P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Jarvis T,  Matulic-Adamic J,  Reynolds M,  Kisich K,  Bellon L;
PI   Parry T,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Burgin A;
PI   Thompson J,  Workman CT,  Beaudry A,  Sweedler D;
XX
DR   WPI; 1999-009494/01.
XX
PT   Identifying new catalytic nucleic acid that modulates selected processes
PT   - especially ribozymes that cleave Raf RNA for treating cancer,
PT   restenosis, and also new ribozymes and modified nucleoside triphosphates
PT   used as antiviral agents and synthons.
XX
PS   Claim 177; Page 172; 259pp; English.
XX
CC   A method has been developed for the identification of a nucleic acid
CC   capable of modulating a process in a biological system. The method
CC   comprises: (a) introducing into the system a random library of nucleic
CC   acid catalysts (NAC) having a substrate binding domain (SBD), comprising
CC   a random sequence, and a catalytic domain (CD); and (b) identifying NAC
CC   in systems where modulation has occurred and/or determining the sequence
CC   of at least part of the SBDs in such systems. Nucleic acid molecules with
CC   endonuclease activity and catalytic activity, from the present invention,
CC   are used to modulate gene expression in plant and mammalian cells and to
CC   cleave target nucleic acid, particularly for treating systemic diseases
CC   caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC   ascites and infection. They may also be used to detect genetic drift and
CC   mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC   with RNA-cleaving activity that modulate expression of the Raf gene, are
CC   used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC   generally any condition associated with the level of c-raf. Introduction
CC   of sugar/phosphate modifications increases stability against nuclease and
```

```
CC   activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC   method, specifically for modulating the expression of a Raf gene
XX
SQ   Sequence 17 BP; 6 A; 1 C; 7 G; 0 T; 3 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 6.3e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGT 1547
              ||| || : |||||||:
Db          1 AGAGAGUUCAGGAGAGU 17


RESULT 1261
AAA25379
ID   AAA25379 standard; DNA; 17 BP.
XX
AC   AAA25379;
XX
DT   19-JUL-2000  (first entry)
XX
DE   Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1877.
XX
KW   Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW   hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW   gene expression modification; cancer; phosphorothioate; endonuclease;
KW   anticancer; breast cancer; endometrium cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954459-A2.
XX
PD   28-OCT-1999.
XX
PF   19-APR-1999;   99WO-US008547.
XX
PR   20-APR-1998;   98US-0082404P.
PR   23-JUN-1998;   98US-00103636.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Thompson JD,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Bellon L;
PI   Reynolds M,  Zwick M,  Jarvis T,  Woolf T,  Haeberli P;
PI   Matulic-Adamic J;
XX
DR   WPI; 2000-013248/01.
XX
PT   New nucleic acids that interact, and optionally cleave, target sequences,
PT   used to treat cancer.
XX
PS   Claim 77; Page 77; 148pp; English.
XX
CC   The present invention describes nucleic acids (A) that interact stably
CC   with a target sequence and contain at least one phosphoro(di)thioate
CC   link, having endonuclease activity. (A), and more generally any catalytic
CC   nucleic acid (A') that modulates expression of the oestrogen receptor
CC   gene, are used to treat cancer (particularly of breast or endometrium),
CC   in vivo or by transforming cells ex vivo and implanting treated cells, or
CC   for other conditions associated with levels of oestrogen receptor.
CC   Because of the high selectivity for targeted RNA, (A) can also be used to
CC   correlate inhibition of gene expression with alterations in phenotype,
CC   particularly for identification of therapeutic targets, and as research
CC   reagents (for RNA, in the same way that restriction endonucleases are
CC   used with DNA). The combination of modifications in (A) improves
CC   resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC   AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC   AAA24748 to AAA25992 represent their corresponding target sequences.
CC   AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC   sequences, and AAA26107 to AAA26218 represent their corresponding target
CC   sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC   antisense oligonucleotides used in the exemplification of the present
CC   invention
XX
SQ   Sequence 17 BP; 4 A; 1 C; 5 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAATG 1945
              || |||||||||  |||
Db          1 TCTGTGTTAAGGATATG 17


RESULT 1262
AAA25550
ID   AAA25550 standard; DNA; 17 BP.
XX
AC   AAA25550;
XX
DT   19-JUL-2000  (first entry)
XX
DE   Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2048.
XX
KW   Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW   hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW   gene expression modification; cancer; phosphorothioate; endonuclease;
KW   anticancer; breast cancer; endometrium cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954459-A2.
XX
PD   28-OCT-1999.
XX
PF   19-APR-1999;   99WO-US008547.
XX
PR   20-APR-1998;   98US-0082404P.
PR   23-JUN-1998;   98US-00103636.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Thompson JD,  Beigelman L,  Mcswiggen JA,  Karpeisky A,  Bellon L;
PI   Reynolds M,  Zwick M,  Jarvis T,  Woolf T,  Haeberli P;
PI   Matulic-Adamic J;
XX
DR   WPI; 2000-013248/01.
XX
PT   New nucleic acids that interact, and optionally cleave, target sequences,
PT   used to treat cancer.
XX
PS   Claim 77; Page 83; 148pp; English.
XX
CC   The present invention describes nucleic acids (A) that interact stably
CC   with a target sequence and contain at least one phosphoro(di)thioate
CC   link, having endonuclease activity. (A), and more generally any catalytic
CC   nucleic acid (A') that modulates expression of the oestrogen receptor
CC   gene, are used to treat cancer (particularly of breast or endometrium),
CC   in vivo or by transforming cells ex vivo and implanting treated cells, or
CC   for other conditions associated with levels of oestrogen receptor.
CC   Because of the high selectivity for targeted RNA, (A) can also be used to
CC   correlate inhibition of gene expression with alterations in phenotype,
CC   particularly for identification of therapeutic targets, and as research
CC   reagents (for RNA, in the same way that restriction endonucleases are
CC   used with DNA). The combination of modifications in (A) improves
CC   resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC   AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC   AAA24748 to AAA25992 represent their corresponding target sequences.
CC   AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC   sequences, and AAA26107 to AAA26218 represent their corresponding target
CC   sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC   antisense oligonucleotides used in the exemplification of the present
CC   invention
XX
SQ   Sequence 17 BP; 8 A; 1 C; 0 G; 8 T; 0 U; 0 Other;
```

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAA 1985
              |||| | || |||||||
Db          1 ATTTTCTTTTAAAAAAA 17


RESULT 1263
AAC70187/c
ID   AAC70187 standard; DNA; 17 BP.
XX
AC   AAC70187;
XX
DT   09-FEB-2001  (first entry)
XX
DE   Single nucleotide polymorphism PCR primer #12.
XX
KW   Single nucleotide polymorphism; SNP; human; genetic disease;
KW   disease susceptibility; cardiovascular system; endocrine system;
KW   neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200058519-A2.
XX
PD   05-OCT-2000.
XX
PF   30-MAR-2000; 2000WO-US008440.
XX
PR   31-MAR-1999;   99US-0127248P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Altshuler D,  Cargill M,  Daley GQ,  Ireland JS,  Lander ES;
PI   Lipshutz RJ,  Patil N,  Sklar P;
XX
DR   WPI; 2000-611722/58.
XX
PT   Nucleic acid selected from one of 106 genes comprising single nucleotide
PT   polymorphisms, allele-specific oligonucleotides to the genes are useful
PT   for phenotypic correlations, forensics, paternity testing, medicine and
PT   genetic analysis.
XX
PS   Claim 8; Fig 5; 214pp; English.
XX
CC   The present invention is concerned with a number of human single
CC   nucleotide polymorphisms (SNPs) which the inventors identified in human
CC   genes. These SNPs can be used in disease diagnosis and prediction of an
CC   individual's susceptibility to disease, in forensic and paternity testing
CC   and in genetic mapping. In particular, the SNPs of the invention can be
CC   used to diagnose susceptibility to diseases of the cardiovascular,
CC   endocrine and neurological systems, such as coronary artery disease,
CC   schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC   diseases
XX
SQ   Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTTT 1623
              |||||||| ||| || |
Db         17 GCCTGGGGTAAGTGTGT 1


RESULT 1264
AAC70178/c
ID   AAC70178 standard; DNA; 17 BP.
XX
AC   AAC70178;
XX
DT   09-FEB-2001  (first entry)
XX
DE   Single nucleotide polymorphism PCR primer #6.
XX
KW   Single nucleotide polymorphism; SNP; human; genetic disease;
KW   disease susceptibility; cardiovascular system; endocrine system;
KW   neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200058519-A2.
XX
PD   05-OCT-2000.
XX
PF   30-MAR-2000; 2000WO-US008440.
XX
PR   31-MAR-1999;   99US-0127248P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Altshuler D,  Cargill M,  Daley GQ,  Ireland JS,  Lander ES;
PI   Lipshutz RJ,  Patil N,  Sklar P;
XX
DR   WPI; 2000-611722/58.
XX
PT   Nucleic acid selected from one of 106 genes comprising single nucleotide
PT   polymorphisms, allele-specific oligonucleotides to the genes are useful
PT   for phenotypic correlations, forensics, paternity testing, medicine and
PT   genetic analysis.
XX
PS   Claim 8; Fig 5; 214pp; English.
XX
CC   The present invention is concerned with a number of human single
CC   nucleotide polymorphisms (SNPs) which the inventors identified in human
CC   genes. These SNPs can be used in disease diagnosis and prediction of an
CC   individual's susceptibility to disease, in forensic and paternity testing
CC   and in genetic mapping. In particular, the SNPs of the invention can be
CC   used to diagnose susceptibility to diseases of the cardiovascular,
CC   endocrine and neurological systems, such as coronary artery disease,
CC   schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC   diseases
XX
SQ   Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTTT 1623
              |||||||| ||| || |
Db         17 GCCTGGGGTAAGTGTGT 1


RESULT 1265
AAC70184/c
ID   AAC70184 standard; DNA; 17 BP.
XX
AC   AAC70184;
XX
DT   09-FEB-2001  (first entry)
XX
DE   Single nucleotide polymorphism PCR primer #10.
XX
KW   Single nucleotide polymorphism; SNP; human; genetic disease;
KW   disease susceptibility; cardiovascular system; endocrine system;
KW   neurological system; forensic testing; paternity testing; PCR primer; ss.
XX
OS   Homo sapiens.
XX
```

```
PN   WO200058519-A2.
XX
PD   05-OCT-2000.
XX
PF   30-MAR-2000; 2000WO-US008440.
XX
PR   31-MAR-1999;   99US-0127248P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Altshuler D,  Cargill M,  Daley GQ,  Ireland JS,  Lander ES;
PI   Lipshutz RJ,  Patil N,  Sklar P;
XX
DR   WPI; 2000-611722/58.
XX
PT   Nucleic acid selected from one of 106 genes comprising single nucleotide
PT   polymorphisms, allele-specific oligonucleotides to the genes are useful
PT   for phenotypic correlations, forensics, paternity testing, medicine and
PT   genetic analysis.
XX
PS   Claim 8; Fig 5; 214pp; English.
XX
CC   The present invention is concerned with a number of human single
CC   nucleotide polymorphisms (SNPs) which the inventors identified in human
CC   genes. These SNPs can be used in disease diagnosis and prediction of an
CC   individual's susceptibility to disease, in forensic and paternity testing
CC   and in genetic mapping. In particular, the SNPs of the invention can be
CC   used to diagnose susceptibility to diseases of the cardiovascular,
CC   endocrine and neurological systems, such as coronary artery disease,
CC   schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
CC   diseases
XX
SQ   Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTTT 1623
              ||||||| ||| || |
Db         17 GCCTGGGGTAAGTGTGT 1


RESULT 1266
AAF04549
ID   AAF04549 standard; DNA; 17 BP.
XX
AC   AAF04549;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #2065.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 4; Page 103; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 8 A; 1 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAA 1981
              |||| ||||| || |||
Db          1 AAATTTTTACTTTAAAA 17


RESULT 1267
AAF07408/c
ID   AAF07408 standard; DNA; 17 BP.
XX
AC   AAF07408;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3665.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 54; Page 140; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
```

```
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1773 TTTTTTTTTGAACCCCA 1789
              |||| |||| || ||||
Db         17 TTTTCTTTTAAAGCCCA 1


RESULT 1268
AAF02869/c
ID   AAF02869 standard; DNA; 17 BP.
XX
AC   AAF02869;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #1164.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 82; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 2 A; 10 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAGG 1555
              | |||||||||||  | |
Db         17 TGGGAGAGTAGGGGAAG 1


RESULT 1269
AAF06965/c
ID   AAF06965 standard; DNA; 17 BP.
XX
AC   AAF06965;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3222.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 54; Page 130; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 8 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATTC 1844
              |||||||  | ||||||
Db         17 ATCTTTTGTAGACATTC 1


RESULT 1270
AAF02473
ID   AAF02473 standard; DNA; 17 BP.
XX
AC   AAF02473;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #768.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
```

```
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 73; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 5 C; 0 G; 9 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
                | ||  ||||||||||
Db          1 CAATATTTTCCTTCTCT 17


RESULT 1271
AAF02650/c
ID   AAF02650 standard; DNA; 17 BP.
XX
AC   AAF02650;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #945.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 37; Page 77; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1581 ACCGCACAGACTGGGAA 1597
                | |||||  ||||| |||
Db         17 ATCGCACTGACTGAGAA 1


RESULT 1272
AAF04597/c
ID   AAF04597 standard; DNA; 17 BP.
XX
AC   AAF04597;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #2113.
XX
KW   Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW   interferon alpha; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061729-A2.
XX
PD   19-OCT-2000.
XX
PF   11-APR-2000; 2000WO-US009721.
XX
PR   12-APR-1999;   99US-0129390P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Zwick M,  Pavco P,  Mcswiggen J;
XX
DR   WPI; 2000-647423/62.
XX
PT   Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT   useful for producing e.g. granulocyte colony stimulating factor protein,
PT   interferon alpha and erythropoietin.
XX
PS   Claim 4; Page 104; 164pp; English.
XX
CC   The present invention relates to enzymatic and antisense nucleic acid
CC   molecules that act as inhibitors of the expression of repressor genes
CC   encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC   factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC   Inhibition of the repressors removes prevents inhibition (and
CC   consequently increases expression of) genes involved in the production of
CC   erythropoietin, granulocyte colony stimulating factor protein and
CC   interferon alpha
XX
SQ   Sequence 17 BP; 3 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
                || ||||  ||||||||
Db         17 ATAATCAAGAGGTGACA 1


RESULT 1273
AAF06328/c
ID   AAF06328 standard; DNA; 17 BP.
XX
AC   AAF06328;
XX
DT   16-FEB-2001  (first entry)
XX
DE   Hammerhead ribozyme substrate #3125.
```

XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 42; Page 127; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 7 A; 2 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1964 TAAATATTTACCTTGAA 1980
|| | ||||||||||
Db 17 TAGAATTTTACCTTGAA 1

RESULT 1274
AAF02363/c
ID AAF02363 standard; DNA; 17 BP.
XX
AC AAF02363;
XX
DT 16-FEB-2001 (first entry)
XX
DE Hammerhead ribozyme substrate #658.
XX
KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
KW interferon alpha; ss.
XX
OS Homo sapiens.
XX
PN WO200061729-A2.
XX
PD 19-OCT-2000.
XX
PF 11-APR-2000; 2000WO-US009721.
XX
PR 12-APR-1999; 99US-0129390P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
XX
DR WPI; 2000-647423/62.
XX
PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX
PS Claim 37; Page 70; 164pp; English.
XX
CC The present invention relates to enzymatic and antisense nucleic acid
CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAATT Displacement Protein (CDP).
CC Inhibition of the repressors removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha
XX
SQ Sequence 17 BP; 9 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1759 TATTCATTAAGCTTTTT 1775
||||| |||| ||| ||
Db 17 TATTCCTTAAACTTCTT 1

RESULT 1275
AAA97982
ID AAA97982 standard; DNA; 17 BP.
XX
AC AAA97982;
XX
DT 15-SEP-2003 (revised)
DT 26-JAN-2001 (first entry)
XX
DE B. brevis NRPS gene A domain PCR primer SEQ ID No: 23.
XX
KW NPRS; non-ribosomal peptide synthetase; adenylation domain; A domain;
KW PCR primer; antibiotic; immunosuppressant; cytostatic; antiviral;
KW antihelminthic; fungicidal; ss.
XX
OS Brevibacillus brevis.
XX
PN WO200052152-A1.
XX
PD 08-SEP-2000.
XX
PF 28-FEB-2000; 2000WO-EP001652.
XX
PR 03-MAR-1999; 99DE-01009146.
XX
PA (MARA/) MARAHIEL M A.
PA (STAC/) STACHELHAUS T.
PA (MOOT/) MOOTZ H.
PA (KONZ/) KONZ D.
XX
PI Marahiel MA, Stachelhaus T, Mootz H, Konz D;
XX
DR WPI; 2000-572182/53.
XX
PT Non-ribosomal synthesis of peptides, e.g. antibiotics or
PT immunosuppressants, using non-ribosomal peptide synthase with targeted
PT modifications in adenylation domains.
XX
PS Example 1; Page 41; 52pp; German.
XX
CC This invention describes a novel method for the targeted non-ribosomal
CC synthesis of peptides (I) of required structure, comprising altering one
CC or more A (adenylation) domain-encoding DNA segments (II) that encodes a
CC non-ribosomal peptide synthetase so that the expression product of the
CC altered (II) can produce (I), is new. Alterations in the A-domains are

```
CC   made according to a non-ribosomal code reproduced in the specification.
CC   The method is used to synthesize (I) with antibiotic, immunosuppressant,
CC   cytostatic, antiviral, antihelminthic, fungicidal or surface-active
CC   properties, and to alter specificity and/or activity of known
CC   biologically active compounds, e.g. to improve their solubility by
CC   replacing hydrophobic amino acids with hydrophilic ones, or vice versa.
CC   AAA97960-A97995 represent PCR primers used to illustrate the method of
CC   the invention. (Updated on 15-SEP-2003 to standardise OS field)
XX
SQ   Sequence 17 BP; 2 A; 3 C; 6 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1687 AGTTGTTTCTCTAGCGC 1703
              |||||||||  ||| ||
Db          1 AGTTGTTTCCGTAGGGC 17


RESULT 1276
AAH95021/c
ID   AAH95021 standard; RNA; 17 BP.
XX
AC   AAH95021;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Human Chk1 ribozyme substrate SEQ ID NO: 446.
XX
KW   Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW   RNA cleavage; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157206-A2.
XX
PD   09-AUG-2001.
XX
PF   02-FEB-2001; 2001WO-US003504.
XX
PR   03-FEB-2000; 2000US-0179983P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (FATT/) FATTAEY A R.
XX
PI   Fattaey AR,  Jarvis T,  Mcswiggen J,  Booher RN,  Holman PS;
XX
DR   WPI; 2001-496922/54.
XX
PT   Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT   molecules, which downregulates expression of a checkpoint kinase-1 gene,
PT   useful for treating colorectal, lung, breast or prostate cancers.
XX
PS   Claim 4; Page 61; 115pp; English.
XX
CC   The present invention provides nucleic acid molecules capable of
CC   downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC   gene. These may be antisense or ribozyme sequences, and are useful in the
CC   treatment of diseases associated with conditions affected by Chk1 levels,
CC   including cancer. The present sequence is an oligonucleotide described in
CC   the exemplification of the invention
XX
SQ   Sequence 17 BP; 5 A; 3 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1649 CCTTCACTGGTTCTGCA 1665
              | |  ||||||||||||
Db         17 CATCAACTGGTTCTGCA 1


RESULT 1277
ABK03203/c
ID   ABK03203 standard; RNA; 17 BP.
XX
AC   ABK03203;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human CD20 Inozyme #154.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 30; Page 148; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
```

```
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an inozyme of the invention
XX
SQ   Sequence 17 BP; 2 A; 6 C; 1 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAGGT 2041
              ||| || ||||||||| |
Db         17 TGGAAGAAGGCAAAGAT 1


RESULT 1278
ABK02209/c
ID   ABK02209 standard; RNA; 17 BP.
XX
AC   ABK02209;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO DNAzyme #121.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 114; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a DNAzyme molecule of the invention
XX
SQ   Sequence 17 BP; 9 A; 2 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTGA 1783
              ||||||| ||| ||| |
Db         17 AAGCTTTGTTTCTTTAA 1


RESULT 1279
ABK02206/c
ID   ABK02206 standard; RNA; 17 BP.
XX
AC   ABK02206;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO DNAzyme #118.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
```

PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 114; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a DNAzyme molecule of the invention
XX
SQ Sequence 17 BP; 8 A; 3 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1768 AGCTTTTTTTTTTTGAA 1784
||||| | ||| |||||
Db 17 AGCTTCTGTTTCTTGAA 1

RESULT 1280
ABK01982/c
ID ABK01982 standard; RNA; 17 BP.
XX
AC ABK01982;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Zinzyme #304.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-AUG-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
DR WPI; 2001-607195/69.
XX
PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 88; Page 100; 200pp; English.
XX
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),

```
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is a zinzyme molecule of the invention
XX
SQ   Sequence 17 BP; 9 A; 2 C; 4 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              |||||||  ||| ||||
Db         17 CCTTTTTGCTCAATGTT 1

RESULT 1281
ABK00845
ID   ABK00845 standard; RNA; 17 BP.
XX
AC   ABK00845;
XX
DT   12-MAR-2002  (first entry)
XX
DE   Human NOGO Inozyme #115.
XX
KW   Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW   cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW   muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW   DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW   B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW   human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW   MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW   inflammatory arthropathy; central nervous system injury;
KW   cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW   chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW   Parkinson's disease; ataxia; Huntington's disease;
KW   Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200159103-A2.
XX
PD   16-AUG-2001.
XX
PF   09-FEB-2001; 2001WO-US004273.
XX
PR   11-FEB-2000; 2000US-0181797P.
PR   28-FEB-2000; 2000US-0185516P.
PR   06-MAR-2000; 2000US-0187128P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (CHOW/) CHOWRIRA B M.
XX
PI   Blatt L,  Mcswiggen J,  Chowrira BM;
XX
DR   WPI; 2001-607195/69.
XX
PT   Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT   constructs, which down regulate expression of a CD20 gene or neurite
PT   growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT   central nervous system injury.
XX
PS   Claim 88; Page 79; 200pp; English.
XX
CC   The invention relates to a nucleic acid molecule which down regulates
CC   expression of a CD20 gene and a nucleic acid molecule which down
CC   regulates expression of a neurite growth inhibitor gene (NOGO). The
CC   nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC   DNAzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC   possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC   an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC   with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC   of CD20 in the presence of a divalent cation that is preferably Mg^2^+.
CC   Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC   the cell and treat a patient having a condition associated with the level
CC   of CD20. The treatment may further comprise the use of one or more
CC   therapies. In particular, the CD20 targetting nucleic acid may be used to
CC   treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC   Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC   leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC   lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC   immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC   targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC   presence of a divalent cation that is preferably Mg^2^+. Furthermore, the
CC   nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC   cell and treat a patient having a condition associated with the level of
CC   NOGO. The treatment may further comprise the use of one or more
CC   therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC   treat central nervous system (CNS) injury and cerebrovascular accident
CC   (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC   chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC   Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC   disease, muscular dystrophy, and/or other neurodegenerative disease
CC   states which respond to the modulation of NOGO expression. The present
CC   sequence is an inozyme of the invention
XX
SQ   Sequence 17 BP; 1 A; 8 C; 7 G; 0 T; 1 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1593 GGGAACCCCTCCTGGCC 1609
              |||  |||||: | ||||
Db          1 GGGGACCCCUGCCGGCC 17

RESULT 1282
ABN02792/c
ID   ABN02792 standard; DNA; 17 BP.
XX
AC   ABN02792;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2784.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
```

```
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2784; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 8 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1804 GAAAGTGGTGCTATAAG 1820
              ||| ||||||||  |||
Db         17 GAAGGTGGTGCTTGAAG 1

RESULT 1283
ABN10552/c
ID   ABN10552 standard; DNA; 17 BP.
XX
AC   ABN10552;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10544.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 10544; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 10 A; 1 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCT 1771
              | ||| ||||||| |||
Db         17 TATTTCTTCATTATGCT 1

RESULT 1284
ABN07964
ID   ABN07964 standard; DNA; 17 BP.
XX
AC   ABN07964;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7956.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
```

```
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7956; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1893 GTGCCCTAGATCAACAG 1909
              | ||||| || ||||||
Db          1 GCGCCCTTGAGCAACAG 17


RESULT 1285
ABN02116/c
ID   ABN02116 standard; DNA; 17 BP.
XX
AC   ABN02116;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2108.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 2108; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 3 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
```

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACCC 1671
              ||||||| ||| | |||
Db         17 CTGGTTCAGCAGCGCCC 1

RESULT 1286
ABN07968
ID   ABN07968 standard; DNA; 17 BP.
XX
AC   ABN07968;
XX
DT   29-MAY-2002  (first entry)
XX
DE   Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7960.
XX
KW   Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW   muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW   skeletal muscle disorder; amplicon; screening; ss.
XX
OS   Homo sapiens.
XX
PN   WO200192524-A2.
XX
PD   06-DEC-2001.
XX
PF   25-MAY-2001; 2001WO-US016981.
XX
PR   26-MAY-2000; 2000US-0207456P.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
PR   30-JAN-2001; 2001WO-US000661.
PR   30-JAN-2001; 2001WO-US000662.
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   05-FEB-2001; 2001US-0266860P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Gu Y,  Ji Y,  Penn SG,  Hanzel DK,  Rank DR,  Chen W,  Shannon ME;
XX
DR   WPI; 2002-179446/23.
XX
PT   New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT   or as specific biomolecule capture probes for surface-enhanced laser
PT   desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
PS   Disclosure; SEQ ID NO 7960; 214pp; English.
XX
CC   The present invention describes a human genome-derived myosin-like
CC   protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC   1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC   nucleic acids can be used as probes to detect, characterise and quantify
CC   hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC   provide initial substrates for the recombinant engineering of hGDMLP-1
CC   protein variants having desired phenotypic improvements, and for
CC   expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC   used as immunogens to raise antibodies that specifically recognise hGDMLP
CC   -1 proteins, as standards in assays used to determine the concentration
CC   and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC   capture probes for surface-enhanced laser desorption ionisation, as
CC   therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC   production, and in vaccines or for replacement therapy. The
CC   polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC   disorder associated with the expression of hGDMLP-1, in particular heart
CC   and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC   The present sequence represents an oligomer used in the screening of the
CC   hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC   The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequence
XX
SQ   Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAA 1990
              ||||||  || ||||||
Db          1 CCTTGAGCAACAGAAAA 17

RESULT 1287
ABV79921
ID   ABV79921 standard; DNA; 17 BP.
XX
AC   ABV79921;
XX
DT   03-JAN-2003  (first entry)
XX
DE   Human HTPL scanning oligonucleotide SEQ ID 1167.
XX
KW   Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW   human testis expressed Patched like protein; testis; adrenal; liver;
KW   male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW   prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS   Homo sapiens.
XX
PN   EP1229046-A2.
XX
PD   07-AUG-2002.
XX
PF   28-JAN-2002; 2002EP-00001167.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   23-MAY-2001; 2001US-00864761.
PR   09-OCT-2001; 2001US-0327898P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Zhan J;
XX
DR   WPI; 2002-676582/73.
XX
PT   Novel isolated human testis expressed Patched like protein (HTPL), useful
PT   for identifying agonist and antagonist and specific binding partners, and
PT   for treating subjects having defects in HTPL.
XX
PS   Example 2; Page 216; 718pp; English.
XX
CC   The present invention relates to human testis expressed Patched like
CC   protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC   has two isoforms, with a few single base pair differences between the
CC   two. One of the single base pair changes introduces a premature stop
CC   codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC   shares an overall structure organisation with the Patched protein. The
CC   shared structural features strongly imply that HTPL plays a role similar
CC   to that of Patched, and is a potential tumour suppressor. HTPL is
CC   important in regulating male germ cell development, and the HTPL gene was
```

CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potenial therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1968 TATTTACCTTGAAAAAA 1984
| || ||||||||||
Db 1 TCTTGGCCTTGAAAAAA 17

RESULT 1288
ABV79920
ID ABV79920 standard; DNA; 17 BP.
XX
AC ABV79920;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 1166.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 216; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potenial therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1967 ATATTTACCTTGAAAAA 1983
|| || ||||||||||
Db 1 ATCTTGGCCTTGAAAAA 17

RESULT 1289
ABQ99673/c
ID ABQ99673 standard; DNA; 17 BP.
XX
AC ABQ99673;
XX
DT 08-NOV-2002 (first entry)
XX
DE Murine Ikbkap exon 13 acceptor site.
XX
KW Murine; IKBKAP; Familial Dysautonomia; FD; Riley-Day syndrome; ds;
KW Hereditary Sensory and Autonomic Neuropathy Type III; carrier screening.
XX
OS Mus sp.
XX
PN WO200259381-A2.
XX
PD 01-AUG-2002.
XX
PF 07-JAN-2002; 2002WO-US000473.
XX
PR 06-JAN-2001; 2001US-0260080P.
XX
PA (GEHO) GEN HOSPITAL CORP.
XX
PI Slaugenhaupt S, Gusella JF;
XX
DR WPI; 2002-674806/72.
XX
PT New IKBKAP genes.with mutations, useful for identifying a subject with
PT familial dysautonomia (FD), or for rapid carrier screening in the
PT Ashkenazi Jewish population, e.g. screening presymptomatic homozygotes or
PT prenatal diagnosis.
XX
PS Disclosure; Fig 11; 109pp; English.
XX
CC The present invention relates to methods and compositions useful for
CC detecting mutations which cause Familial Dysautonomia (FD, Riley-Day
CC syndrome, Hereditary Sensory and Autonomic Neuropathy Type III) [OMIM
CC 223900]. It was found that mutations in the IKBKAP gene (see ABQ80565)
CC are associated with FD. The mutation associated with the major haplotype
CC of FD, FD1 mutation, is a base pair (bp) mutation, where the thymine
CC nucleotide located at bp 6 of intron 20 in the IKBKAP gene is replaced
CC with a cytosine. This results in skipping of exon 20 in the mRNA from FD
CC patients, although they continue to express varying levels of wild-type
CC message in a tissue-specific manner. The mutation associated with the
CC minor haplotype, FD2 mutation, is a bp mutation, where the guanine
CC nucleotide at bp 2397 (bp 73 of exon 19) is replaced with a cytosine.
CC This bp mutation causes an arginine to proline missense mutation (R696P)

CC in the IKBKAP protein, which is predicted to disrupt a potential
CC phosphorylation site. The IKBKAP nucleic acid sequences are useful for
CC identifying a subject with FD and for rapid carrier screening. The IKBKAP
CC gene maps to chromosome 9q31. A mouse model of FD was created in an
CC example from the invention. Expression of murine Ikbkap was examined
CC using both mouse embryo and adult mouse multiple tissue Northern blots.
CC The blots were probes with a 1045bp PCR fragent that contains exons 2
CC through 11, which was generated using PCR primers ABQ80563-ABQ80564.
CC ABQ99662-ABQ99733 are the murine Ikbkap exon and intron boundaries
XX
SQ Sequence 17 BP; 1 A; 1 C; 3 G; 12 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1973 ACCTTGAAAAAAAGAAA 1989
|||| ||||| || |||
Db 17 ACCTAGAAAACAAAAAA 1

RESULT 1290
ABK17691/c
ID ABK17691 standard; RNA; 17 BP.
XX
AC ABK17691;
XX
DT 09-APR-2002 (first entry)
XX
DE Human ERG hammerhead ribozyme target sequence, Seq ID No 338.
XX
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
KW amberzyme.
XX
OS Homo sapiens.
XX
PN WO200188124-A2.
XX
PD 22-NOV-2001.
XX
PF 16-MAY-2001; 2001WO-US015866.
XX
PR 16-MAY-2000; 2000US-00572021.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, Mclaughlin F, Randi AM;
XX
DR WPI; 2002-082995/11.
XX
PT Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX
PS Claim 4; Page 64; 149pp; English.
XX
CC The invention relates to a nucleic acid molecule (I) which down regulates
CC expression of an Ets-related gene (ERG). (I) is useful for treating
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
CC treating a patient having a condition associated with the level of ERG,
CC by contacting cells of the patient with (I) under conditions suitable for
CC the treatment. The method comprises the use of one or more therapies
CC under conditions suitable for the treatment. Leukaemia or tumour
CC angiogenesis is treated by administering (I) to the patient in
CC conjunction with one or more of other therapies such as radiation or
CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
CC diseases related to the expression of ERG, and as diagnostic tool to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ERG RNA in a cell. (I) is useful for specifically
CC targeting genes that share homology with ERG gene or ERG fusion genes.
CC ABK17354-ABK22719 represent nucleic acids, including antisense and
CC enzymatic nucleic acid molecules which regulate expression of ERG, and
CC related PCR primers of the invention
XX
SQ Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1708 CTATCTCCTAACTTTGG 1724
|| ||||||||| |||
Db 17 CTTTCTCCTAACACTGG 1

RESULT 1291
ABV91218
ID ABV91218 standard; DNA; 17 BP.
XX
AC ABV91218;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1931.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 1931; 60pp + Sequence Listing; English.
XX

```
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 1 A; 10 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1593 GGGAACCCCTCCTGGCC 1609
              |||| ||||||||  ||
Db          1 GGGATCCCCTCCTCCCC 17


RESULT 1292
ABV90240
ID   ABV90240 standard; DNA; 17 BP.
XX
AC   ABV90240;
XX
DT   23-DEC-2002  (first entry)
XX
DE   Human POSHL1 scanning oligonucleotide SEQ ID NO 953.
XX
KW   Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW   Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW   gene therapy; transgenic; ss.
XX
OS   Homo sapiens.
XX
PN   EP1239051-A2.
XX
PD   11-SEP-2002.
XX
PF   28-JAN-2002; 2002EP-00001165.
XX
PR   30-JAN-2001; 2001WO-US000663.
PR   30-JAN-2001; 2001WO-US000664.
PR   30-JAN-2001; 2001WO-US000665.
PR   30-JAN-2001; 2001WO-US000666.
PR   30-JAN-2001; 2001WO-US000667.
PR   30-JAN-2001; 2001WO-US000668.
PR   30-JAN-2001; 2001WO-US000669.
PR   30-JAN-2001; 2001WO-US000670.
PR   23-MAY-2001; 2001US-00864761.
PR   10-OCT-2001; 2001US-0328205P.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M;
XX
DR   WPI; 2002-684061/74.
XX
PT   Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT   -1, useful for treating disorders associated with decreased expression or
PT   activity of human POSHL1.
XX
PS   Example 2; SEQ ID NO 953; 60pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated SH3 domain (POSH)-like signalling
CC   protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC   acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC   (S1) having 95% deviations, especially conservative substitutions or a
CC   fragment of the sequences comprising at least 8 contiguous amino acids.
CC   Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC   adaptor protein that interacts with Rho family small GTPases as well as
CC   downstream components of the signal transduction pathway. (I) is useful
CC   for identifying a specific binding partner. (I) and nucleic acids (II)
CC   encoding (I) are useful for diagnosing, monitoring disease and treating
CC   caused by altered expression of human POSHL1 including diagnosing and
CC   treating cancer, they useful in the development of vaccines and (II) is
CC   useful in gene therapy. (II) is useful for constructing microarrays which
CC   are useful for measuring and for surveying gene expression and creating
CC   transgenic non-human animals capable of producing the proteins. The
CC   present sequence is that of a scanning oligonucleotide useful in examples
CC   of the invention. Note: The present sequence did not form part of the
CC   printed specification, but is based on sequence information supplied to
CC   Derwent by the European Patent Office
XX
SQ   Sequence 17 BP; 7 A; 1 C; 7 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGAGA 1545
              ||||  | |||||||||
Db          1 GAAGGCAAGTTAGGAGA 17


RESULT 1293
ABK57390
ID   ABK57390 standard; RNA; 17 BP.
XX
AC   ABK57390;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #1761.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
```

PS Claim 4; Page 112; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 3 A; 9 C; 0 G; 0 T; 5 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 6.3e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy 1563 CTGCAAAAATCCTTCTC 1579
|: | |||:||::|:|
Db 1 CUCCCCAAAUCCUUCUC 17

RESULT 1294
ABK56824
ID ABK56824 standard; RNA; 17 BP.
XX
AC ABK56824;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #1195.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 82; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 6 A; 1 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 6.3e+02;
Matches 7; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

Qy 1953 TTTGTGTCCGCTAAATA 1969
::: :|:| | :|||:|
Db 1 UUUUUGUCAGAUAAAUA 17

RESULT 1295
ABK56171/c
ID ABK56171 standard; RNA; 17 BP.
XX
AC ABK56171;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #542.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 62; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic

CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 9 A; 1 C; 0 G; 0 T; 7 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1821 TTTTAGAATCTTTTAAA 1837
              |||||||| ||||| |
Db         17 TTTTAGAAAATTTTATA 1
```

RESULT 1296
ABK56480
ID ABK56480 standard; RNA; 17 BP.
XX
AC ABK56480;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #851.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 72; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 7 A; 3 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 6.3e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1877 GAAATGTCAAATTGATG 1893
              ||||: :| || :||:|
Db          1 GAAAUAUCCAACUGAUG 17
```

RESULT 1297
ABK56161
ID ABK56161 standard; RNA; 17 BP.
XX
AC ABK56161;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #532.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 62; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises

CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 4 C; 0 G; 0 T; 11 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 23.5%; Pred. No. 6.3e+02;
Matches 4; Conservative 10; Mismatches 3; Indels 0; Gaps 0;

Qy 1762 TCATTAAGCTTTTTTTT 1778
:||:: | | :::::::
Db 1 UCAUUCAUCCUUUUUUU 17

RESULT 1298
ABK56575/c
ID ABK56575 standard; RNA; 17 BP.
XX
AC ABK56575;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #946.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 75; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 0 T; 2 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1949 GGTTTTTGTGTCCGCTA 1965
||| ||| ||||| |||
Db 17 GGTGTTTTTGTCCACTA 1

RESULT 1299
ABK56066/c
ID ABK56066 standard; RNA; 17 BP.
XX
AC ABK56066;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #437.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US024970.
XX
PR 09-AUG-2000; 2000US-0224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS Claim 4; Page 60; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an

```
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 3 C; 2 G; 0 T; 7 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1908 AGATCAACAATACCTTT 1924
              ||||||| ||||| | |
Db         17 AGATCAAGAATACTTGT 1

RESULT 1300
ABK55996
ID   ABK55996 standard; RNA; 17 BP.
XX
AC   ABK55996;
XX
DT   02-JUL-2002  (first entry)
XX
DE   Human CLCA1 gene enzymatic nucleic acid #367.
XX
KW   Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW   antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW   chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW   oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW   acetylcysteine.
XX
OS   Homo sapiens.
XX
PN   WO200211674-A2.
XX
PD   14-FEB-2002.
XX
PF   09-AUG-2001; 2001WO-US024970.
XX
PR   09-AUG-2000; 2000US-0224383P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (SYNT ) SYNTEX USA LLC.
PA   (THOM/) THOMPSON J.
XX
PI   Thompson J,  Mcswiggen J,  Mckenzie T,  Ayers D,  Szymkowski DE;
PI   Grupe A;
XX
DR   WPI; 2002-217145/27.
XX
PT   Enzymatic polynucleotide that down regulates expression of chloride
PT   channel calcium activated gene, useful for treating Chronic obstructive
PT   pulmonary disease (COPD), chronic bronchitis and asthma.
XX
PS   Claim 4; Page 59; 152pp; English.
XX
CC   The invention relates to enzymatic nucleic acid molecules that down
CC   regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC   by cleaving RNA derived from the genes. The nucleic acid sequences are
CC   useful as pharmaceutical agents for treating conditions such as chronic
CC   obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC   fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC   that are related to or will respond to the levels of CLCA1 in a cell or
CC   tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC   hence, are useful for treatment of a patient having a condition
CC   associated with the level of CLCA1, where the invention further comprises
CC   the use of one or more therapies under conditions suitable for the
CC   treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC   antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC   nucleic acids of the invention are also used as diagnostic tools to
CC   examine genetic drift and mutations within diseased cells or to detect
CC   the presence of CLCA1 RNA in a cell. This sequence represents an
CC   enzymatic nucleic acid molecule of the invention
XX
SQ   Sequence 17 BP; 7 A; 3 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 6.3e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAA 1981
              ||| | ::|||::| ||
Db          1 AAACAGUUACCUUGGAA 17

RESULT 1301
ACN07093
ID   ACN07093 standard; RNA; 17 BP.
XX
AC   ACN07093;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 7096.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 7096; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6.3e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1882 GTCAAATTGATGTGCCC 1898
              |: ||| :||:| ||||
```

```
Db          1 GUGAAAGUGAUGCGCCC 17


RESULT 1302
ACN08703
ID   ACN08703 standard; RNA; 17 BP.
XX
AC   ACN08703;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8706.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 8706; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 7 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   58.8%;  Pred. No. 6.3e+02;
  Matches   10;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1659 TTCTGCATCACCCGCCC 1675
              ::|:|||:|||   |||
Db          1 UUCUGCAUCACUUUCCC 17


RESULT 1303
ACN11244/c
ID   ACN11244 standard; RNA; 17 BP.
XX
AC   ACN11244;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11247.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11247; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 5 C; 1 G; 0 T; 10 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGTG 1993
              || |||||||||| | |
Db         17 TGCAAAAAAGAAAGGAG 1


RESULT 1304
ACN09402
ID   ACN09402 standard; RNA; 17 BP.
XX
AC   ACN09402;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9405.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
```

```
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9405; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 7 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   70.6%;  Pred. No. 6.3e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGGA 1680
              ||:||||  ||| :|||
Db          1 CAUCACCUUCCCUUGGA 17


RESULT 1305
ACN09416
ID   ACN09416 standard; RNA; 17 BP.
XX
AC   ACN09416;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9419.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9419; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 0 A; 8 C; 2 G; 0 T; 7 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   41.2%;  Pred. No. 6.3e+02;
  Matches    7;  Conservative    7;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              ||  :|:::||: |:|:
Db          1 CCGGUCUUUCCUCCUCU 17


RESULT 1306
ACN08986/c
ID   ACN08986 standard; RNA; 17 BP.
XX
AC   ACN08986;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8989.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
```

```
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 8989; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 6 A; 6 C; 0 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGTT 1626
              ||||| |||||| | ||
Db         17 TGGGGAAAGAGTATTTT 1


RESULT 1307
ACN14358/c
ID   ACN14358 standard; RNA; 17 BP.
XX
AC   ACN14358;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Amberzyme substrate SEQ ID NO 14361.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 14361; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 1 A; 7 C; 7 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGGGAA 1617
              | || |||||||||| |
Db         17 CACCCGGCCTGGGGGCA 1


RESULT 1308
ACN07705/c
ID   ACN07705 standard; RNA; 17 BP.
XX
AC   ACN07705;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7708.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 7708; 495pp; English.
```

```
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 3 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1882 GTCAAATTGATGTGCCC 1898
              || ||| ||||| ||||
Db         17 GTGAAAGTGATGCGCCC 1

RESULT 1309
ACN11556/c
ID   ACN11556 standard; RNA; 17 BP.
XX
AC   ACN11556;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11559.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11559; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 6 C; 1 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTTGT 1625
              |||||| |||||| | |
Db         17 CTGGGGAAAGAGTATTT 1

RESULT 1310
ACN03124
ID   ACN03124 standard; RNA; 17 BP.
XX
AC   ACN03124;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Inozyme substrate SEQ ID NO 3127.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 3127; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
```

```
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 2 A; 7 C; 7 G; 0 T; 1 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGGGAA 1617
              | || |||||:||||| |
Db          1 CACCCGGCCUGGGGGCA 17


RESULT 1311
ACN04456
ID   ACN04456 standard; RNA; 17 BP.
XX
AC   ACN04456;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Zinzyme substrate SEQ ID NO 4459.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 4459; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 7 A; 2 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   76.5%;  Pred. No. 6.3e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGTAC 1750
              ||||||| |  |||:||
Db          1 CAGAAGGAGUGAAGUAC 17


RESULT 1312
ACN06186/c
ID   ACN06186 standard; RNA; 17 BP.
XX
AC   ACN06186;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 6189.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 6189; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 7 A; 1 C; 7 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1659 TTCTGCATCACCCGCCC 1675
              ||||||||||   |||
Db         17 TTCTGCATCACTTTCCC 1


RESULT 1313
```

```
ACN09914/c
ID   ACN09914 standard; RNA; 17 BP.
XX
AC   ACN09914;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 9917.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 9917; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 4 A; 6 C; 3 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTGCC 1897
              ||| ||| ||||| |||
Db         17 TGTGAAAGTGATGCGCC 1


RESULT 1314
ACN11555/c
ID   ACN11555 standard; RNA; 17 BP.
XX
AC   ACN11555;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV minus strand Inozyme substrate SEQ ID NO 11558.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 11558; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 6 C; 0 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1611 GGGGGAAGAGTTTGTTA 1627
              |||| |||||| | |||
Db         17 GGGGAAAGAGTATTTTA 1


RESULT 1315
ACN05926
ID   ACN05926 standard; RNA; 17 BP.
XX
AC   ACN05926;
XX
DT   22-APR-2004  (first entry)
XX
DE   WNV Amberzyme substrate SEQ ID NO 5929.
XX
KW   WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW   virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW   encephalitis; myocarditis; meningitis; infection; hepatitis;
KW   liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW   Amberzyme; Zinzyme; ss.
```

```
XX
OS   West Nile Virus.
XX
PN   WO200268637-A2.
XX
PD   06-SEP-2002.
XX
PF   19-OCT-2001; 2001WO-US048350.
XX
PR   20-OCT-2000; 2000US-0242411P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
XX
PI   Blatt L,  Mcswiggen JA;
XX
DR   WPI; 2002-706994/76.
XX
PT   New nucleic acid molecule that modulates replication of West Nile Virus
PT   (WNV), useful for treating a condition related to WNV infection e.g.
PT   pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS   Claim 23; SEQ ID NO 5929; 495pp; English.
XX
CC   The invention relates to nucleic acid molecules that modulate replication
CC   of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC   treating a condition related to WNV infection e.g. pancreatitis,
CC   encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC   liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC   molecule is selected from the group of ribozymes consisting of
CC   Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC   nucleic acid molecules further comprise at least five ribose residues, at
CC   least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC   least three of the 5' terminal nucleotides and a 3' end modification of a
CC   3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC   are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC   in the specification. The present sequence is that of a nucleic acid
CC   molecule of the invention
XX
SQ   Sequence 17 BP; 5 A; 0 C; 6 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 6.3e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTGTT 1626
              :|||| |||||: : ::
Db          1 UGGGGAAAGAGUAUUUU 17


RESULT 1316
ACD00530/c
ID   ACD00530 standard; DNA; 17 BP.
XX
AC   ACD00530;
XX
DT   28-JUL-2003  (first entry)
XX
DE   G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1003.
XX
KW   Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW   G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003031621-A2.
XX
PD   17-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032599.
XX
PR   12-OCT-2001; 2001US-0329000P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Zhang J;
XX
DR   WPI; 2003-381720/36.
XX
PT   New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT   investigating and/or treating disorders associated with aberrant
PT   expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS   Example 2; SEQ ID NO 1027; 156pp; English.
XX
CC   The invention describes an isolated nucleic acid encoding a G protein
CC   coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC   2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC   409 residue amino acid sequence, all given in the specification, with or
CC   without conservative amino acid substitutions, or complements of the
CC   sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC   length. The methods and compositions of the present invention are useful
CC   for diagnosing, investigating and/or treating disorders associated with
CC   aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC   This sequence represents an oligonucleotide used to analyse the gene
CC   encoding human G-protein coupled receptor GPCR-A-1
XX
SQ   Sequence 17 BP; 9 A; 2 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1748 TACTGGCTCTTTATTCA 1764
              |||| ||| || |||||
Db         17 TACTTGCTTTTGATTCA 1


RESULT 1317
ACD00895/c
ID   ACD00895 standard; DNA; 17 BP.
XX
AC   ACD00895;
XX
DT   28-JUL-2003  (first entry)
XX
DE   G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1368.
XX
KW   Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW   G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS   Homo sapiens.
XX
PN   WO2003031621-A2.
XX
PD   17-APR-2003.
XX
PF   11-OCT-2002; 2002WO-US032599.
XX
PR   12-OCT-2001; 2001US-0329000P.
XX
PA   (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI   Zhang J;
XX
DR   WPI; 2003-381720/36.
XX
PT   New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT   investigating and/or treating disorders associated with aberrant
PT   expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS   Example 2; SEQ ID NO 1392; 156pp; English.
XX
CC   The invention describes an isolated nucleic acid encoding a G protein
CC   coupled receptor (GPCR), mutations of which cause cancer, comprising a
```

CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kbase in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumours and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 10 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1829 TCTTTTAAATACATTCC 1845
||||||| || |||||
Db 17 TCTTTTATATCTATTCC 1

RESULT 1318
ABT38163/c
ID ABT38163 standard; DNA; 17 BP.
XX
AC ABT38163;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3800.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 478; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 5 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1563 CTGCAAAAATCCTTCTC 1579
||| ||||||||| ||
Db 17 CTGTAAAAATCCTGATC 1

RESULT 1319
ABT35153/c
ID ABT35153 standard; DNA; 17 BP.
XX
AC ABT35153;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 790.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 125; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these

```
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 4 A; 3 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match              2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATC 1999
              ||||||||  | ||  |||
Db         17 AAAGAAAACTTTGGATC 1

RESULT 1320
ABT35973/c
ID   ABT35973 standard; DNA; 17 BP.
XX
AC   ABT35973;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 1610.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 221; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 9 A; 2 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match              2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1711 TCTCCTAACTTTGGACC 1727
              ||||||  | ||||||  |
Db         17 TCTCCTTATTTTGGATC 1

RESULT 1321
ABT34449/c
ID   ABT34449 standard; DNA; 17 BP.
XX
AC   ABT34449;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 86.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 44; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
```

```
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 7 A; 2 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1711 TCTCCTAACTTTGGACC 1727
              ||| ||||||| ||| |
Db         17 TCTTCTAACTTAGGATC 1


RESULT 1322
ABT38381/c
ID   ABT38381 standard; DNA; 17 BP.
XX
AC   ABT38381;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 4018.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 503; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATC 1912
              ||||| | || ||||||
Db         17 CCCTATAGCACCAGATC 1


RESULT 1323
ABT39157
ID   ABT39157 standard; DNA; 17 BP.
XX
AC   ABT39157;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 4794.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 594; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 3 A; 3 C; 2 G; 9 T; 0 U; 0 Other;
```

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1753 GCTCTTTATTCATTAAG 1769
              | ||||| |||||| ||
Db          1 GATCTTTTTTCATTCAG 17


RESULT 1324
ABT35103/c
ID   ABT35103 standard; DNA; 17 BP.
XX
AC   ABT35103;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 740.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 120; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              | || ||| ||||||||
Db         17 TGGCATCTGCAGAGATC 1


RESULT 1325
ABT36551
ID   ABT36551 standard; DNA; 17 BP.
XX
AC   ABT36551;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Tumour suppression related human fukutin oligo SEQ ID No 2188.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW   antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; protein chip; gene therapy; tumour suppression;
KW   human fukutin; ds.
XX
OS   Homo sapiens.
XX
PN   WO2003025175-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004208.
XX
PR   17-SEP-2001; 2001FR-00011978.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313353/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 288; 720pp; French.
XX
CC   The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC   given in the specification, a sequence containing at least 15 consecutive
CC   nucleotides from the 17 mer sequence, a sequence with, after optimal
CC   alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC   hybridizes to them under highly stringent conditions, or the complement
CC   of any of them, or the corresponding RNA. The novel isolated nucleic
CC   acids of the invention are useful as probes and primers for detecting,
CC   identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC   component of a gene chip, in vitro as (anti)sense reagents, and for
CC   production of recombinant polypeptides. Any of the nucleic acids,
CC   polypeptides, vectors containing the nucleic acids, cells containing the
CC   vector or antibodies directed against the polypeptides are useful for
CC   preparation of pharmaceuticals for prevention and/or treatment of viral
CC   diseases that are characterised by development of tumours or cell
CC   degeneration, specifically cancer but also Alzheimer's disease and
CC   schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC   patient samples is useful for diagnosis and/or prognosis of these
CC   diseases. The polypeptides can also be used to generate antibodies, and
CC   both the polypeptide and antibodies are useful as components of protein
CC   chips. The nucleic acid sequences of the invention can be used in gene
CC   therapy. This polynucleotide sequence represents a tumour suppression
CC   related human fukutin oligonucleotide of the invention
XX
SQ   Sequence 17 BP; 8 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1901 GATCAACAGATCAACAA 1917
              |||| |||||| || ||
Db          1 GATCTACAGATGAATAA 17
```

RESULT 1326
ABT34619/c
ID ABT34619 standard; DNA; 17 BP.
XX
AC ABT34619;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 256.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 64; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 10 A; 3 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1769 GCTTTTTTTTTTTGAAC 1785
              ||||||| ||| ||| |
Db         17 GCTTTTTCTTTGTGATC 1
```

RESULT 1327
ABT34881
ID ABT34881 standard; DNA; 17 BP.
XX
AC ABT34881;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 518.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 94; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       2013 GATCAAGTCCTCTGGTA 2029
              |||||| || | |||||
Db          1 GATCAACTCTTGTGGTA 17
```

RESULT 1328
ABT40205/c
ID ABT40205 standard; DNA; 17 BP.
XX
AC ABT40205;
XX
DT 13-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5842.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 716; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1888 TTGATGTGCCCTAGATC 1904
|| ||| ||| ||||||
Db 17 TTCATGGGCCATAGATC 1

RESULT 1329
ACA07725/c
ID ACA07725 standard; RNA; 17 BP.
XX
AC ACA07725;
XX
DT 03-JUN-2003 (first entry)
XX
DE NFKB sub-unit modulating zinzyme substrate #124.
XX
KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
OS Homo sapiens.
XX
PN US2002177568-A1.
XX
PD 28-NOV-2002.
XX
PF 23-MAY-2001; 2001US-00864785.
XX
PR 07-DEC-1992; 92US-00987132.
PR 18-MAY-1994; 94US-00245466.
PR 15-AUG-1994; 94US-00291932.
PR 23-DEC-1996; 96US-00777916.
XX
PA (STIN/) STINCHCOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
PI Stinchcomb DT, Mcswiggen J, Draper KG;
XX
DR WPI; 2003-340953/32.
XX
PT Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
PS Claim 4; Page 39; 72pp; English.
XX
CC The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg^2^+. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic

```
CC   nucleic acid molecule
XX
SQ   Sequence 17 BP; 1 A; 6 C; 4 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTGC 1566
              |||||| |||| | |||
Db         17 GGAAGGCACAGCAATGC 1


RESULT 1330
ADB00317/c
ID   ADB00317 standard; DNA; 17 BP.
XX
AC   ADB00317;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human MDZ3 scanning oligonucleotide SEQ ID 1303.
XX
KW   Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW   zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW   chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW   developmental disorder; ss.
XX
OS   Homo sapiens.
XX
PN   EP1281758-A2.
XX
PD   05-FEB-2003.
XX
PF   30-JUL-2002; 2002EP-00016874.
XX
PR   02-AUG-2001; 2001US-00922181.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M,  Gu Y,  Nguyen C;
XX
DR   WPI; 2003-423107/40.
XX
PT   New zinc finger-containing proteins and nucleic acids, useful in
PT   manufacturing a medicament for treating or preventing a disorder
PT   associated with decreased or increased expression or activity of MDZ3,
PT   MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS   Example 8; SEQ ID NO 1303; 103pp; English.
XX
CC   The present invention relates to novel human zinc finger-containing
CC   proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC   encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC   MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC   15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC   or in manufacturing a medicament for treating or preventing a disorder
CC   associated with decreased or increased expression or activity of MDZ3,
CC   MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC   acids and proteins are also useful for diagnosing or monitoring a disease
CC   caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC   acids can also be used as probes to detect and characterize gross
CC   alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC   useful in constructing microarrays for measuring gene expression. The
CC   proteins are useful as therapeutic agents for gene therapy or as
CC   vaccines. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 17 BP; 7 A; 3 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              || ||||| || |||||
Db         17 TCTCTGGTGCTTCATCA 1


RESULT 1331
ADB00318/c
ID   ADB00318 standard; DNA; 17 BP.
XX
AC   ADB00318;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human MDZ3 scanning oligonucleotide SEQ ID 1304.
XX
KW   Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW   zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW   chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW   developmental disorder; ss.
XX
OS   Homo sapiens.
XX
PN   EP1281758-A2.
XX
PD   05-FEB-2003.
XX
PF   30-JUL-2002; 2002EP-00016874.
XX
PR   02-AUG-2001; 2001US-00922181.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M,  Gu Y,  Nguyen C;
XX
DR   WPI; 2003-423107/40.
XX
PT   New zinc finger-containing proteins and nucleic acids, useful in
PT   manufacturing a medicament for treating or preventing a disorder
PT   associated with decreased or increased expression or activity of MDZ3,
PT   MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS   Example 8; SEQ ID NO 1304; 103pp; English.
XX
CC   The present invention relates to novel human zinc finger-containing
CC   proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC   encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC   MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC   15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC   or in manufacturing a medicament for treating or preventing a disorder
CC   associated with decreased or increased expression or activity of MDZ3,
CC   MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC   acids and proteins are also useful for diagnosing or monitoring a disease
CC   caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC   acids can also be used as probes to detect and characterize gross
CC   alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC   useful in constructing microarrays for measuring gene expression. The
CC   proteins are useful as therapeutic agents for gene therapy or as
CC   vaccines. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 17 BP; 8 A; 3 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1651 TTCACTGGTTCTGCATC 1667
              ||| ||||| || ||||
Db         17 TTCTCTGGTGCTTCATC 1


RESULT 1332
ADB03129
ID   ADB03129 standard; DNA; 17 BP.
```

```
XX
AC   ADB03129;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human MDZ4 scanning oligonucleotide SEQ ID 4115.
XX
KW   Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW   zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW   chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW   developmental disorder; ss.
XX
OS   Homo sapiens.
XX
PN   EP1281758-A2.
XX
PD   05-FEB-2003.
XX
PF   30-JUL-2002; 2002EP-00016874.
XX
PR   02-AUG-2001; 2001US-00922181.
XX
PA   (AEOM-) AEOMICA INC.
XX
PI   Shannon M,  Gu Y,  Nguyen C;
XX
DR   WPI; 2003-423107/40.
XX
PT   New zinc finger-containing proteins and nucleic acids, useful in
PT   manufacturing a medicament for treating or preventing a disorder
PT   associated with decreased or increased expression or activity of MDZ3,
PT   MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX
PS   Example 8; SEQ ID NO 4115; 103pp; English.
XX
CC   The present invention relates to novel human zinc finger-containing
CC   proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC   encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC   MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC   15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC   or in manufacturing a medicament for treating or preventing a disorder
CC   associated with decreased or increased expression or activity of MDZ3,
CC   MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC   acids and proteins are also useful for diagnosing or monitoring a disease
CC   caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC   acids can also be used as probes to detect and characterize gross
CC   alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC   useful in constructing microarrays for measuring gene expression. The
CC   proteins are useful as therapeutic agents for gene therapy or as
CC   vaccines. The present sequence was used to illustrate the invention.
XX
SQ   Sequence 17 BP; 7 A; 2 C; 5 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1735 AGAAGGTGACAAGTACT 1751
              |||| ||| |||| |||
Db          1 AGAATGTGGCAAGAACT 17


RESULT 1333
ABQ81025
ID   ABQ81025 standard; DNA; 17 BP.
XX
AC   ABQ81025;
XX
DT   10-JAN-2003  (first entry)
XX
DE   Plasmid pXL3676-related oligonucleotide #2.
XX
KW   Triple helix; pXL3676; ds.
XX
OS   Synthetic.
XX
PN   WO200277274-A2.
XX
PD   03-OCT-2002.
XX
PF   25-MAR-2002; 2002WO-FR001034.
XX
PR   23-MAR-2001; 2001FR-00003953.
PR   23-APR-2001; 2001US-0285272P.
XX
PA   (AVET ) AVENTIS PHARMA SA.
XX
PI   Blanche F,  Cameron B;
XX
DR   WPI; 2003-018943/01.
XX
PT   Purifying double-stranded DNA, useful e.g. for isolating plasmids or
PT   therapeutic genes, by triple helix formation with oligonucleotide
PT   directed to a specific target sequence.
XX
PS   Example 6; Page 23; 49pp; French.
XX
CC   The present invention relates to novel double stranded (ds) DNA sequences
CC   which can interact with a third strand to form a stable triple helix. The
CC   invention also relates to a method for purifying a ds DNA molecule,
CC   comprising contact with a third DNA strand that interacts with a target
CC   sequence (TS) in the ds DNA to form a triple helix. The present sequence
CC   is a oligonucleotide used in the construction of plasmid pXL3676, used in
CC   the examples of the invention
XX
SQ   Sequence 17 BP; 10 A; 0 C; 7 G; 0 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGAGA 1545
              |||||||||  || |||
Db          1 GAAGAAAGGAGAGAAGA 17


RESULT 1334
ABZ60237/c
ID   ABZ60237 standard; RNA; 17 BP.
XX
AC   ABZ60237;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #349.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
```

DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 91; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 8 A; 1 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1821 TTTTAGAATCTTTTAAA 1837
| ||| |||||||| ||
Db 17 TGTTAAAATCTTTTCAA 1

RESULT 1335
ABZ60496/c
ID ABZ60496 standard; RNA; 17 BP.
XX
AC ABZ60496;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNAzyme substrate #608.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 96; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2071 GGTATCTGACACACTCT 2087
|||||||| || | |||
Db 17 GGTATCTGTCAGATTCT 1

RESULT 1336
ABZ61926/c
ID ABZ61926 standard; RNA; 17 BP.
XX
AC ABZ61926;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNAzyme target #717.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 124; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 1 A; 10 C; 2 G; 0 T; 4 U; 0 Other;

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAACAG 1560
              |||| ||| |||| |||
Db         17 GAGTGGGGCAGGAGCAG 1


RESULT 1337
ABZ60826
ID   ABZ60826 standard; RNA; 17 BP.
XX
AC   ABZ60826;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #938.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 103; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 6 A; 3 C; 3 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   52.9%;  Pred. No. 6.3e+02;
  Matches    9;  Conservative    5;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1866 ACTTAGCCATTGAAATG 1882
              ||::|| ||:: | |:|
Db          1 ACUUAGGCAUUAACAUG 17


RESULT 1338
ABZ61625/c
ID   ABZ61625 standard; RNA; 17 BP.
XX
AC   ABZ61625;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #416.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 119; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGGGGGA 1616
              |||||||||| | || |
Db         17 CCTCCTGGCCGGCGGTA 1


RESULT 1339
ABZ62022
ID   ABZ62022 standard; RNA; 17 BP.
XX
AC   ABZ62022;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human H-Ras DNAzyme target #813.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
```

```
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 126; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity  70.6%;  Pred. No. 6.3e+02;
  Matches   12;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGG 1614
              ||||: |:| || ||||
Db          1 CCCCUUCUGUCCAGGGG 17


RESULT 1340
ABZ60558
ID   ABZ60558 standard; RNA; 17 BP.
XX
AC   ABZ60558;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #670.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 97; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 4 A; 3 C; 2 G; 0 T; 8 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity  35.3%;  Pred. No. 6.3e+02;
  Matches    6;  Conservative    8;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1761 TTCATTAAGCTTTTTTT 1777
              ::||: ||||::  :::
Db          1 UUCAUGAAGCUUACUUU 17


RESULT 1341
ABZ60559
ID   ABZ60559 standard; RNA; 17 BP.
XX
AC   ABZ60559;
XX
DT   21-MAR-2003  (first entry)
XX
DE   Human K-Ras DNAzyme substrate #671.
XX
KW   Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW   enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW   anti-rheumatic; cancer; AIDS; ss.
XX
OS   Homo sapiens.
XX
PN   WO200297114-A2.
XX
PD   05-DEC-2002.
XX
PF   29-MAY-2002; 2002WO-US016840.
XX
PR   29-MAY-2001; 2001US-0294140P.
PR   06-JUN-2001; 2001US-0296249P.
PR   10-SEP-2001; 2001US-0318471P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Mcswiggen J;
XX
DR   WPI; 2003-140484/13.
XX
PT   Novel short interfering RNA and enzymatic nucleic acid useful for
PT   treating cancer, modulates the expression of a nucleic acid encoding
```

```
PT   HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS   Claim 58; Page 97; 185pp; English.
XX
CC   The invention relates to a novel short interfering RNA (siRNA) nucleic
CC   acid molecule or an enzymatic nucleic acid molecule, that modulates
CC   expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC   human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC   acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC   rheumatic activity. The nucleic acid molecules are useful for reducing
CC   HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC   also useful for treating breast, ovarian, colorectal, lung, prostate,
CC   bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC   shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC   ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC   ribozymes of the invention
XX
SQ   Sequence 17 BP; 3 A; 2 C; 2 G; 0 T; 10 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   23.5%;  Pred. No. 6.3e+02;
  Matches    4;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTTT 1781
              : ||||::  :::::::
Db          1 UGAAGCUUACUUUUUUU 17


RESULT 1342
ACD61203/c
ID   ACD61203 standard; RNA; 17 BP.
XX
AC   ACD61203;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HCV DNAzyme substrate sequence #2221.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 273; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 2 A; 4 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2067 AAGTGGTATCTGACACA 2083
              ||| |||| ||| ||||
Db         17 AAGAGGTACCTGCCACA 1


RESULT 1343
ACD51463
ID   ACD51463 standard; RNA; 17 BP.
XX
AC   ACD51463;
XX
DT   23-SEP-2003  (first entry)
XX
DE   HBV hammerhead ribozyme substrate sequence #572.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
```

```
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 147; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 5 A; 4 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 6.3e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTGA 1979
              |:|||:|::: || : |
Db          1 CUAAAUAUUUGCCCUUA 17


RESULT 1344
ACD60717/c
ID   ACD60717 standard; RNA; 17 BP.
XX
AC   ACD60717;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HCV DNAzyme substrate sequence #1959.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis C virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Claim 1; Page 269; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HCV
CC   DNAzyme or minus strand DNAzyme sequences disclosed in the present
CC   invention
XX
SQ   Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGGCA 2036
              | ||||||| ||| |||
Db         17 TTCTCTGGTTGGACGCA 1


RESULT 1345
ACD52099
ID   ACD52099 standard; RNA; 17 BP.
XX
AC   ACD52099;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HBV inozyme substrate sequence #229.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
```

```
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 154; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 10 A; 1 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6.3e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGTGT 1996
              ||||||  ||| :|:|:
Db          1 AAAAAAUCAAAAUGUGU 17

RESULT 1346
ACD52395/c
ID   ACD52395 standard; RNA; 17 BP.
XX
AC   ACD52395;
XX
DT   24-SEP-2003  (first entry)
XX
DE   HBV inozyme substrate sequence #372.
XX
KW   Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW   RNA stability; RNA expression; RNA synthesis; antisense;
KW   enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW   amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW   HBV reverse transcriptase; Enhancer I region; viral replication;
KW   degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW   liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW   virucide; antiinflammatory; substrate; ss.
XX
OS   Hepatitis B virus.
XX
PN   WO200281494-A1.
XX
PD   17-OCT-2002.
XX
PF   26-MAR-2002; 2002WO-US009187.
XX
PR   26-MAR-2001; 2001US-00817879.
PR   08-JUN-2001; 2001US-00877478.
PR   08-JUN-2001; 2001US-0296876P.
PR   24-OCT-2001; 2001US-0335059P.
PR   05-DEC-2001; 2001US-0337055P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (BLAT/) BLATT L.
PA   (MACE/) MACEJAK D.
PA   (MCSW/) MCSWIGGEN J.
PA   (MORR/) MORRISSEY D.
PA   (PAVC/) PAVCO P.
PA   (LEEP/) LEE P.
PA   (DRAP/) DRAPER K.
PA   (ROBE/) ROBERTS E.
XX
PI   Blatt L,  Macejak D,  Mcswiggen J,  Morrissey D,  Pavco P,  Lee P;
PI   Draper K,  Roberts E;
XX
DR   WPI; 2003-229207/22.
XX
PT   Novel compound useful for treating cirrhosis, liver failure,
PT   hepatocellular carcinoma, or condition associated with hepatitis C virus
PT   infection.
XX
PS   Example 1; Page 157; 387pp; English.
XX
CC   The present invention relates to nucleic acid molecules which modulate
CC   the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC   Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC   and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC   inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
CC   are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC   transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC   as oligonucleotides that specifically bind the Enhancer I region of HBV
CC   DNA. The nucleic acids may be used to modulate the expression of HBV
CC   genes and HBV viral replication. Also disclosed is a method for screening
CC   compounds and/or potential therapies directed against HBV, and compounds
CC   that modulate the expression and/or replication of HCV. The compounds and
CC   methods of the invention are useful for the treatment of degenerative and
CC   disease states related to HBV and HCV infection, replication and gene
CC   expression such as cirrhosis, liver failure, and hepatocellular
CC   carcinoma. The present sequence represents a substrate for one of the HBV
CC   ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC   disclosed in the present invention
XX
SQ   Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;
```

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCC 1600
              ||||||||  ||||  ||
Db         17 GCACAGACGGGGAGTCC 1


RESULT 1347
ACC66076/c
ID   ACC66076 standard; DNA; 17 BP.
XX
AC   ACC66076;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 3323.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 419; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTC 2043
              ||  ||||||||||  ||
Db         17 GTCTGAGGCAAAGGATC 1


RESULT 1348
ACC65570/c
ID   ACC65570 standard; DNA; 17 BP.
XX
AC   ACC65570;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 2817.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 360; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 3 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATC 1912
              |||| | |||| |||||
Db         17 CCCTGGCTCAAAAGATC 1


RESULT 1349
ACC65424
ID   ACC65424 standard; DNA; 17 BP.
XX
AC   ACC65424;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 2671.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
```

```
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 343; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 8 A; 4 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              ||||||||  |||  || |
Db          1 GATCAACAAATCTACTA 17


RESULT 1350
ACC66052/c
ID   ACC66052 standard; DNA; 17 BP.
XX
AC   ACC66052;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 3299.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 416; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 1 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAAC 1558
              ||||  |||||||| |
Db         17 GAGACAAGGGAAGGATC 1


RESULT 1351
ACC66777
ID   ACC66777 standard; DNA; 17 BP.
XX
AC   ACC66777;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 4024.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 501; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
```

```
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 4 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTTTT 1925
              ||||| | | |||||||
Db          1 GATCACCCAGACCTTTT 17


RESULT 1352
ACC68751
ID   ACC68751 standard; DNA; 17 BP.
XX
AC   ACC68751;
XX
DT   01-JUL-2003  (first entry)
XX
DE   Murine oligonucleotide associated with tumour supression, SEQ ID 5998.
XX
KW   Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW   schizophrenia; ss.
XX
OS   Mus musculus.
XX
PN   WO2003025176-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004210.
XX
PR   17-SEP-2001; 2001FR-00011979.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-333167/31.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; Page 732; 738pp; French.
XX
CC   The present invention relates to murine oligonucleotides (ACC62754-
CC   ACC68806), which are associated with tumour suppression, tumour
CC   reversion, apoptosis and virus resistance. The oligonucleotides are
CC   useful as (1) as probes and primers for detecting, identifying,
CC   quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC   gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC   recombinant polypeptides. The oligonucleotides are useful for preparation
CC   of pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ   Sequence 17 BP; 8 A; 5 C; 1 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              |||||||| |||  |||
Db          1 GATCAACAAATCTCCAA 17


RESULT 1353
ADB41339/c
ID   ADB41339 standard; DNA; 17 BP.
XX
AC   ADB41339;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #1662.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 226; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATC 1904
              ||||||||| |  ||||
Db         17 TTGATGTGCTCCTGATC 1


RESULT 1354
ADB42009/c
ID   ADB42009 standard; DNA; 17 BP.
XX
```

```
AC   ADB42009;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #2332.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 304; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAAC 1558
              ||||| |||| |||| |
Db         17 GAGAGCAGGGCAGGATC 1


RESULT 1355
ADB43952/c
ID   ADB43952 standard; DNA; 17 BP.
XX
AC   ADB43952;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #4275.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 531; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 9 A; 2 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              ||| ||||||  |||||
Db         17 TAGTTTCTTCTTAGATC 1


RESULT 1356
ADB41045/c
ID   ADB41045 standard; DNA; 17 BP.
XX
AC   ADB41045;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #1368.
```

```
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 192; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 7 A; 3 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATC 1904
              || |||| |||| ||||
Db         17 TTTATGTCCCCTGGATC 1


RESULT 1357
ADB43429
ID   ADB43429 standard; DNA; 17 BP.
XX
AC   ADB43429;
XX
DT   18-DEC-2003  (revised)
DT   04-DEC-2003  (first entry)
XX
DE   Tumour suppression/reversion associated nucleotide #3752.
XX
KW   cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW   primer; probe; tumour suppression; tumour reversion; apoptosis;
KW   virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW   diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003040369-A2.
XX
PD   15-MAY-2003.
XX
PF   17-SEP-2002; 2002WO-IB004219.
XX
PR   17-SEP-2001; 2001FR-00011981.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-441574/41.
XX
PT   New nucleic acid encoding human prostate membrane-specific antigen,
PT   useful e.g. for treatment of tumors and viral infection, also related
PT   polypeptide and antibodies.
XX
PS   Disclosure; Page 470; 771pp; French.
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 4 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTTTT 1925
              |||| ||| ||| ||||
Db          1 GATCCACAGTACTTTTT 17


RESULT 1358
ADC04074
ID   ADC04074 standard; DNA; 17 BP.
XX
AC   ADC04074;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human Na/H exchanger-like protein 1 gene oligonucleotide #521.
XX
KW   ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW   NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS   Homo sapiens.
XX
PN   EP1273660-A2.
```

XX
PD 08-JAN-2003.
XX
PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y;
XX
DR WPI; 2003-302724/30.
XX
PT New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHELP1.
XX
PS Example 2; SEQ ID NO 561; 468pp; English.
XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHELP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 5 A; 2 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1717 AACTTTGGACCTATTAT 1733
||||| ||| ||||| |
Db 1 AACTTAGGATCTATTTT 17

RESULT 1359
ADC04238/c
ID ADC04238 standard; DNA; 17 BP.
XX
AC ADC04238;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human Na/H exchanger-like protein 1 gene oligonucleotide #685.
XX
KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHELP1; passive replacement therapy; vaccine; diagnosis.
XX
OS Homo sapiens.
XX
PN EP1273660-A2.
XX
PD 08-JAN-2003.
XX
PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y;
XX
DR WPI; 2003-302724/30.
XX
PT New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
PT passive replacement therapy or as a vaccine for treating or preventing
PT disorders associated with aberrant expression or activity of human
PT NHELP1.
XX
PS Example 2; SEQ ID NO 725; 468pp; English.
XX
CC The invention relates to a nucleic acid molecule which encodes a Na+/H+
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide, an antibody against the protein or its antigen-binding
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
CC polypeptide and an agonist are particularly useful for manufacturing a
CC medicament for treating or preventing a disorder associated with
CC decreased expression or activity of human NHELP1. The antibody or its
CC antigen-binding fragment, and an antagonist, are useful for manufacturing
CC a medicament for treating or preventing a disorder associated with
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
CC or protein is useful as passive replacement therapy, as a vaccine, or in
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
CC spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1652 TCACTGGTTCTGCATCA 1668
||||||| |||| | ||
Db 17 TCACTGGATCTGTAGCA 1

RESULT 1360
ADB45521/c
ID ADB45521 standard; DNA; 17 BP.
XX
AC ADB45521;
XX
DT 18-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #5844.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 715; 771pp; French.

```
XX
CC   The invention relates to the isolation of 6327 nucleotide sequences,
CC   fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC   sequence having at least 80% identity, after optimal alignment, with the
CC   nucleotides, a sequence that hybridizes under stringent conditions with
CC   the nucleotides, or the complement, or corresponding RNA, of the
CC   nucleotides. The nucleotides are used as probes or primers for detecting,
CC   identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC   sense and antisense sequences, of nucleotides involved in tumour
CC   suppression or reversion, apoptosis and or viral resistance, to produce
CC   recombinant polypeptides, and to prepare transgenic animals, as
CC   experimental models. The nucleotides (also vectors containing them and
CC   cells containing the vectors), the encoded polypeptides and antibodies
CC   (Ab) against the polypeptide are useful for prevention and/or treatment
CC   of viral infections or diseases characterized by development of tumours
CC   or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC   Analysis of the expression of the nucleotides can be used for diagnosis
CC   and/or prognosis of these diseases. The nucleotides and polypeptides can
CC   also be used to screen for their specific interactive molecules,
CC   potentially useful for treating diseases associated with abnormal
CC   expression of the nucleotides.
XX
SQ   Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              ||||||||  |  |  ||||
Db         17 TAGCTTCTGCCGGGATC 1


RESULT 1361
ADI47782/c
ID   ADI47782 standard; DNA; 17 BP.
XX
AC   ADI47782;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID285.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 285; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 6 A; 2 C; 4 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              ||  |  |||||  ||||||
Db         17 TAACATCTTCTGAGATC 1


RESULT 1362
ADI52201
ID   ADI52201 standard; DNA; 17 BP.
XX
AC   ADI52201;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID4704.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 4704; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
```

```
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 8 A; 5 C; 1 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              |||| ||| | ||||||
Db          1 GATCTACATACCAACAA 17


RESULT 1363
ADI49823
ID   ADI49823 standard; DNA; 17 BP.
XX
AC   ADI49823;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID2326.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 2326; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 8 A; 2 C; 1 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTTTT 1925
              |||||| || || ||||
Db          1 GATCAAAAAAACTTTTT 17


RESULT 1364
ADI51713/c
ID   ADI51713 standard; DNA; 17 BP.
XX
AC   ADI51713;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID4216.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 4216; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              |||||||| | | ||||
Db         17 TAGCTTCTGCCGGGATC 1
```

```
RESULT 1365
ADI47836/c
ID   ADI47836 standard; DNA; 17 BP.
XX
AC   ADI47836;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID339.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 339; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 10 A; 3 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTGAAC 1785
              || ||||| |||||| |
Db         17 GCCTTTTTGTTTTGATC 1


RESULT 1366
ADI48705/c
ID   ADI48705 standard; DNA; 17 BP.
XX
AC   ADI48705;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID1208.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS   Homo sapiens.
XX
PN   WO2003025177-A2.
XX
PD   27-MAR-2003.
XX
PF   17-SEP-2002; 2002WO-IB004523.
XX
PR   17-SEP-2001; 2001FR-00011980.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB.
XX
PI   Telerman A,  Amson R,  Tuijnder M;
XX
DR   WPI; 2003-313354/30.
XX
PT   New isolated nucleic acid, useful for treating viral diseases associated
PT   with tumors and cell degeneration, also related polypeptides, antibodies
PT   and transfected cells.
XX
PS   Disclosure; SEQ ID NO 1208; 30pp; French.
XX
CC   This invention relates to novel isolated nucleic acid sequences involved
CC   in the phenomena of tumour suppression, tumour reversion, apoptosis
CC   and/or resistance to viruses. The invention may be useful for the
CC   development of compounds with a cytostatic, virucide, neuroprotective,
CC   nootropic or neuroleptic activity. The DNA sequences may be useful as
CC   probes and primers for detecting, indentifying, quantifying and/or
CC   amplifying nucleic acid, for example as one component of a gene chip, in
CC   vitro as antisense reagents and for production of recombinant
CC   polypeptides. The invention may therefore be useful for preparation of
CC   pharmaceuticals for prevention and/or treatment of viral diseases that
CC   are characterised by development of tumours or cell degeneration,
CC   specifically cancer but also Alzheimer's disease and schizophrenia. The
CC   present sequence is that of a nucleic acid sequence of the invention.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ   Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              | || ||| ||||||||
Db         17 TGGCATCTGCAGAGATC 1


RESULT 1367
ADI52158
ID   ADI52158 standard; DNA; 17 BP.
XX
AC   ADI52158;
XX
DT   15-APR-2004  (first entry)
XX
DE   Human tumour suppression/reversion-related DNA sequence SeqID4661.
XX
KW   tumour suppression; tumour reversion; apoptosis; virus resistance;
KW   cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW   primer; PCR; gene chip; antisense; viral disease; tumour;
KW   cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
```

OS Homo sapiens.
XX
PN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313354/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; SEQ ID NO 4661; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC nootropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, indentifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 3 A; 4 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       2040 GTTCTATCTGCTTAGCA 2056
              | ||| ||| |||||||
Db          1 GATCTTTCTTCTTAGCA 17
```

RESULT 1368
ACC53104/c
ID ACC53104 standard; DNA; 17 BP.
XX
AC ACC53104;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #1871.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijnder M, Telerman A, Amson R;
XX
DR WPI; 2003-250498/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 472; 798pp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 1 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1542 GAGAGTAGGGAAGGAAC 1558
              ||||| |||| |||| |
Db         17 GAGAGCAGGGCAGGATC 1
```

RESULT 1369
ACC52152
ID ACC52152 standard; DNA; 17 BP.
XX
AC ACC52152;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #919.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijnder M, Telerman A, Amson R;
XX
DR WPI; 2003-250498/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 252; 798pp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The

```
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 4 A; 3 C; 2 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1615 GAAGAGTTTGTTACCTA 1631
              ||  | ||||||||||
Db          1 GATCATTTTGTTACCTA 17


RESULT 1370
ACC52822/c
ID   ACC52822 standard; DNA; 17 BP.
XX
AC   ACC52822;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #1589.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 407; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || |||||| || ||||
Db         17 TAACTTCTTAAGGGATC 1


RESULT 1371
ACC51346
ID   ACC51346 standard; DNA; 17 BP.
XX
AC   ACC51346;
XX
DT   27-JUN-2003  (first entry)
XX
DE   Human tumour suppressor sequence #113.
XX
KW   ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW   tumour regression; apoptosis; virus resistance; diagnosis;
KW   cellular degeneration.
XX
OS   Homo sapiens.
XX
PN   FR2826373-A1.
XX
PD   27-DEC-2002.
XX
PF   20-JUN-2001; 2001FR-00008139.
XX
PR   20-JUN-2001; 2001FR-00008139.
XX
PA   (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI   Tuijnder M,  Telerman A,  Amson R;
XX
DR   WPI; 2003-250498/25.
XX
PT   New nucleic acid sequences associated with tumor suppression, regression,
PT   apoptosis or virus resistance are useful to diagnose and treat viral
PT   disease, development of tumor cells and cell degeneration.
XX
PS   Claim 1; Page 66; 798pp; French.
XX
CC   This sequence represents an isolated nucleic acid sequence associated
CC   with tumour suppression or regression, apoptosis or virus resistance. The
CC   invention relates to these sequences or sequences having at least 80%
CC   identity to them, and polypeptides encoded by the sequences or
CC   polypeptides having 80% identity to the polypeptide sequences. The
CC   invention is used to diagnose or treat viral disease or disease
CC   characterized by development of tumour cells or cellular degeneration
XX
SQ   Sequence 17 BP; 9 A; 4 C; 3 G; 1 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              ||||||||||  | |||
Db          1 GATCAACAGAAGACCAA 17


RESULT 1372
ADK12619
ID   ADK12619 standard; DNA; 17 BP.
XX
AC   ADK12619;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human NAC-1 gene-specific probe #103.
XX
KW   human; NAC-1; NAC-1 associated disorder; drug addiction; cancer; probe;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   US2003100495-A1.
XX
PD   29-MAY-2003.
XX
PF   02-AUG-2002; 2002US-00211059.
XX
PR   08-AUG-2001; 2001US-0311034P.
```

```
XX
PA   (ZHAN/) ZHANG J.
XX
PI   Zhang J;
XX
DR   WPI; 2003-787024/74.
XX
PS   Example 2; SEQ ID NO 119; 96pp; English.
XX
CC   The invention comprises the amino acid and coding sequences of the human
CC   NAC-1 protein. The DNA and protein sequences of the invention are useful
CC   for treating or preventing a disorder associated with decreased or
CC   increased expression or activity of human NAC-1. The DNA and protein
CC   sequences are also useful for treating drug addiction and cancer. The
CC   present DNA sequence represents a probe for the human NAC-1 gene.
XX
SQ   Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCTCC 1604
                ||| |||||||| || |
Db          1 AGATTGGGAACCGCTGC 17


RESULT 1373
ADL48121/c
ID   ADL48121 standard; RNA; 17 BP.
XX
AC   ADL48121;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human IKK-gamma substrate sequence #631.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 1654; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human IKK-
CC   gamma substrate sequence.
XX
SQ   Sequence 17 BP; 6 A; 1 C; 8 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
                |||||||||  |||| |
Db         17 CCCATTCTTGACTTCCC 1


RESULT 1374
ADL49342
ID   ADL49342 standard; RNA; 17 BP.
XX
AC   ADL49342;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PKR substrate sequence #456.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 59; SEQ ID NO 2875; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
```

CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 2 C; 1 G; 0 T; 10 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 6.3e+02;
Matches 5; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

Qy 1918 TACCTTTTTTTTCAGTG 1934
:|||:::: ::: | :|
Db 1 UACCUUUUAUUUUAAUG 17

RESULT 1375
ADL49229
ID ADL49229 standard; RNA; 17 BP.
XX
AC ADL49229;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #343.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2762; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 11 A; 2 C; 0 G; 0 T; 4 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 6.3e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1969 ATTTACCTTGAAAAAAA 1985
|: :|| :: |||||||
Db 1 AUAUACAUUCAAAAAAA 17

RESULT 1376
ADL49343
ID ADL49343 standard; RNA; 17 BP.
XX
AC ADL49343;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #457.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2876; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)

```
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 3 A; 2 C; 1 G; 0 T; 11 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   23.5%;  Pred. No. 6.3e+02;
  Matches    4;  Conservative   10;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||:::: ::: | :|::
Db          1 CCUUUUAUUUUAAUGUU 17


RESULT 1377
ADL51440/c
ID   ADL51440 standard; RNA; 17 BP.
XX
AC   ADL51440;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human PTGDR substrate sequence #559.
XX
KW   antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW   prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW   protein kinase PKR; cerebrovascular accident;
KW   central nervous system injury; CNS injury; spinal cord injury; cancer;
KW   melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW   restenosis; asthma; Crohn's disease; diabetes; obesity;
KW   autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW   graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW   allergy; asthma; allergic rhinitis; atopic dermatitis; human PTGDR;
KW   substrate; ds.
XX
OS   Unidentified.
XX
PN   WO200281628-A2.
XX
PD   17-OCT-2002.
XX
PF   03-APR-2002; 2002WO-US010512.
XX
PR   05-APR-2001; 2001US-00827395.
PR   29-MAY-2001; 2001US-0294412P.
PR   28-AUG-2001; 2001US-0315315P.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Blatt L,  Chowrira B,  Haeberli P,  Mcswiggen J,  Fosnaugh K;
XX
DR   WPI; 2003-058513/05.
XX
PT   Novel enzymatic nucleic acid that down-regulates expression of neurite
PT   growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT   protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS   Claim 161; SEQ ID NO 4973; 317pp; English.
XX
CC   The invention comprises nucleic acids (e.g. antisense oligonucleotides)
```

```
CC   that down regulate the expression or inhibit the function of a receptor
CC   for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC   IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC   invention are useful for treating: cerebrovascular accident, central
CC   nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC   lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC   restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC   disease, lupus, multiple sclerosis, transplant/graft rejection,
CC   ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC   conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC   nucleic acids of the invention are also useful for down-regulating the
CC   expression of a target gene and as a diagnostic tool to examine genetic
CC   drifts and mutations within diseased cells or to detect the presence of a
CC   target RNA in a cell. The present RNA sequence represents a human PKR
CC   substrate sequence.
XX
SQ   Sequence 17 BP; 7 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCAAGT 2020
              |||||||||| ||  ||
Db         17 TTCTTCAGAGGTCCTGT 1


RESULT 1378
ADK13078
ID   ADK13078 standard; DNA; 17 BP.
XX
AC   ADK13078;
XX
DT   20-MAY-2004  (first entry)
XX
DE   Human glioma endothelial marker (GEM) long tag SEQ ID NO:256.
XX
KW   glioma; brain tissue; neoplastic; glioma endothelial marker; GEM;
KW   anticancer; antiglioma; immune response; cytostatic;
KW   multi-drug sensitive glioma; human; long tag; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO2004016758-A2.
XX
PD   26-FEB-2004.
XX
PF   15-AUG-2003; 2003WO-US025614.
XX
PR   15-AUG-2002; 2002US-0403390P.
PR   01-APR-2003; 2003US-0458978P.
XX
PA   (GENZ ) GENZYME CORP.
PA   (UYJO ) UNIV JOHNS HOPKINS.
XX
PI   Madden SI,  Wang CJ,  Cook BP,  Lattera J,  Walter K;
XX
DR   WPI; 2004-247973/23.
XX
PT   Diagnosing glioma by detecting expression product of any one of 255
PT   genes, glioma endothelial markers, in brain tissue sample suspected of
PT   being neoplastic, and comparing the expression with expression in normal
PT   brain tissue sample.
XX
PS   Example 2; SEQ ID NO 256; 114pp; English.
XX
CC   The present invention describes a method (M1) for aiding in the diagnosis
CC   of glioma. (M1) involves detecting an expression product of at least one
CC   gene (I) in a first brain tissue sample (T) suspected of being
CC   neoplastic, where (I) is chosen from any one of 255 genes (glioma
CC   endothelial markers (GEMs)) as given in specification, and comparing the
CC   expression of (I) in (T) with expression of (I) in a second normal brain
```

```
CC   tissue sample (R), where increased expression of (I) in (T) relative to
CC   (R), identifies (T) as likely to be neoplastic. Also described: (1)
CC   treating (M2) glioma involves contacting cells of the glioma with an
CC   antibody that specifically binds to a extracellular epitope; (2)
CC   identifying (M3) a test compound as potential anticancer or antiglioma
CC   drug involves contacting a test compound with the cell which expresses
CC   (I), monitoring an expression product of the at least one gene and
CC   identifying test compound as a potential anticancer drug if it decreases
CC   the expression of at least one gene; (3) identifying (M4) a test compound
CC   as potential anticancer or antiglioma drug involves contacting a test
CC   compound with the cell which expresses mRNA of at least one gene
CC   identified by a tag as described above, monitoring mRNA of the gene, and
CC   identifying the test compound as a potential anticancer drug if it
CC   decreases the expression of at least one gene; and (4) inducing (M5) an
CC   immune response to glioma involves administering to a mammal, a protein
CC   or (I). (I) have cytostatic activities, and can be used to trigger immune
CC   destruction of glioma cells, and as immune response inducers. (M1) is
CC   useful for aiding in diagnosing glioma. (M2) is useful for treating multi
CC   -drug sensitive glioma in a human. (M5) is useful for inducing an immune
CC   response to a glioma in a mammal having glioma or in a mammal who has had
CC   a glioma surgically removed. The present sequence represents a human GEM
CC   long tag oligonucleotide, which is used in the exemplification of the
CC   present invention.
XX
SQ   Sequence 17 BP; 4 A; 8 C; 1 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1569 AAATCCTTCTCCACCGC 1585
              ||| | |||||| ||||
Db          1 AAACCATTCTCCTCCGC 17


RESULT 1379
ADM58939/c
ID   ADM58939 standard; RNA; 17 BP.
XX
AC   ADM58939;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #1073.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 1073; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCC 1600
              ||||||| ||||  ||
Db         17 GCACAGACGGGGAGTCC 1


RESULT 1380
ADM58471
ID   ADM58471 standard; RNA; 17 BP.
XX
AC   ADM58471;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #605.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
```

```
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 605; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 5 A; 4 C; 1 G; 0 T; 7 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   47.1%;  Pred. No. 6.3e+02;
  Matches    8;  Conservative    6;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1963 CTAAATATTTACCTTGA 1979
              |:|||:|::: || : |
Db          1 CUAAAUAUUUGCCCUUA 17


RESULT 1381
ADM58796
ID   ADM58796 standard; RNA; 17 BP.
XX
AC   ADM58796;
XX
DT   03-JUN-2004  (first entry)
XX
DE   Hepatitis B virus (HBV) RNA target sequence #930.
XX
KW   Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
KW   hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
KW   cirrhosis; liver failure; lamivudine; interferon; genetic drift;
KW   virucide; hepatotropic; antiinflammatory; cytostatic.
XX
OS   Hepatitis B virus.
XX
PN   US2004054156-A1.
XX
PD   18-MAR-2004.
XX
PF   15-JAN-2003; 2003US-00342902.
XX
PR   14-MAY-1992;   92US-00882712.
PR   07-FEB-1994;   94US-00193627.
PR   08-NOV-1999;   99US-00436430.
PR   20-MAR-2000; 2000US-00531025.
PR   09-AUG-2000; 2000US-00636385.
PR   24-OCT-2000; 2000US-00696347.
PR   08-JUN-2001; 2001US-00877478.
XX
PA   (DRAP/) DRAPER K.
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J A.
PA   (MORR/) MORRISSEY D.
XX
PI   Draper K,  Blatt L,  Mcswiggen JA,  Morrissey D;
XX
DR   WPI; 2004-247781/23.
XX
PT   Novel enzymatic nucleic acid molecule such as DNAzymes and inozymes
PT   specifically cleaving RNA derived from hepatitis B virus and comprising
PT   one or more binding arms, useful for treating hepatitis and cirrhosis.
XX
PS   Disclosure; SEQ ID NO 930; 122pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule that
CC   specifically cleaves RNA derived from hepatitis B virus (HBV) and
CC   comprising one or more binding arms, without requiring the presence of a
CC   2'-OH group within the molecule for activity. The nucleic acids are
CC   useful for treating hepatitis B virus infection, hepatitis,
CC   hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
CC   combination with other therapies such as lamivudine and interferons. The
CC   nucleic acids are useful as diagnostic tools to examine genetic drift and
CC   mutations within diseased cells, for detecting the presence of HBV RNA in
CC   a cell, for the study of RNA and for down-regulating gene expression of
CC   target genes in bacterial, fungal, viral, plant or mammalian cells. This
CC   sequence represents an HBV RNA target sequence, used in the scope of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 17 BP; 10 A; 1 C; 2 G; 0 T; 4 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   64.7%;  Pred. No. 6.3e+02;
  Matches   11;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGTGT 1996
              ||||||  ||| :|:|:
Db          1 AAAAAAUCAAAAUGUGU 17


RESULT 1382
ADI84975/c
ID   ADI84975 standard; RNA; 17 BP.
XX
AC   ADI84975;
XX
DT   03-JUN-2004  (first entry)
XX
DE   HCV DNAzyme substrate sequence #2221.
XX
KW   ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW   HCV infection; type I interferon; DNAzyme.
XX
OS   Hepatitis C virus.
XX
PN   US2003125270-A1.
XX
PD   03-JUL-2003.
XX
PF   18-DEC-2000; 2000US-00740332.
XX
PR   18-DEC-2000; 2000US-00740332.
XX
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (ROBE/) ROBERTS E.
PA   (PAVC/) PAVCO P A.
PA   (MACE/) MACEJACK D.
XX
PI   Blatt L,  Mcswiggen J,  Roberts E,  Pavco PA,  Macejack D;
XX
DR   WPI; 2004-031273/03.
XX
PT   Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT   from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT   especially in combination with type I interferon therapy.
XX
PS   Claim 1; SEQ ID NO 2221; 198pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule which
CC   specifically cleaves RNA derived from hepatitis C virus (HCV), in which
```

```
CC   the binding arms of the enzymatic nucleic acid molecule comprises
CC   sequences complementary to any of the defined substrate sequences given
CC   in the specification. The nucleic acid molecule may be administered for
CC   the treatment of HCV infections, especially in combination with type I
CC   interferons. The present sequence represents a HCV DNAzyme substrate
CC   sequence.
XX
SQ   Sequence 17 BP; 2 A; 4 C; 5 G; 0 T; 6 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2067 AAGTGGTATCTGACACA 2083
                ||| |||| ||| ||||
Db         17 AAGAGGTACCTGCCACA 1


RESULT 1383
ADI84713/c
ID   ADI84713 standard; RNA; 17 BP.
XX
AC   ADI84713;
XX
DT   03-JUN-2004  (first entry)
XX
DE   HCV DNAzyme substrate sequence #1959.
XX
KW   ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW   HCV infection; type I interferon; DNAzyme.
XX
OS   Hepatitis C virus.
XX
PN   US2003125270-A1.
XX
PD   03-JUL-2003.
XX
PF   18-DEC-2000; 2000US-00740332.
XX
PR   18-DEC-2000; 2000US-00740332.
XX
PA   (BLAT/) BLATT L.
PA   (MCSW/) MCSWIGGEN J.
PA   (ROBE/) ROBERTS E.
PA   (PAVC/) PAVCO P A.
PA   (MACE/) MACEJACK D.
XX
PI   Blatt L,  Mcswiggen J,  Roberts E,  Pavco PA,  Macejack D;
XX
DR   WPI; 2004-031273/03.
XX
PT   Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT   from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT   especially in combination with type I interferon therapy.
XX
PS   Claim 1; SEQ ID NO 1959; 198pp; English.
XX
CC   The invention relates to an enzymatic nucleic acid molecule which
CC   specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC   the binding arms of the enzymatic nucleic acid molecule comprises
CC   sequences complementary to any of the defined substrate sequences given
CC   in the specification. The nucleic acid molecule may be administered for
CC   the treatment of HCV infections, especially in combination with type I
CC   interferons. The present sequence represents a HCV DNAzyme substrate
CC   sequence.
XX
SQ   Sequence 17 BP; 6 A; 5 C; 4 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 6.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGGCA 2036
                | |||||| ||| |||
Db         17 TTCTCTGGTTGGACGCA 1


RESULT 1384
AAQ50936/c
ID   AAQ50936 standard; DNA; 18 BP.
XX
AC   AAQ50936;
XX
DT   25-MAR-2003  (revised)
DT   19-MAY-1994  (first entry)
XX
DE   T-cell antigen receptor J-beta2.3 probe.
XX
KW   RT-PCR; polymerase chain reaction; amplification; SSCP; J-domain;
KW   single-strand conformation polymorphism; joining domain; subtype beta 2;
KW   ss.
XX
OS   Synthetic.
XX
PN   WO9322455-A1.
XX
PD   11-NOV-1993.
XX
PF   30-APR-1993;   93WO-JP000577.
XX
PR   30-APR-1992;   92JP-00111467.
PR   31-JUL-1992;   92JP-00205054.
XX
PA   (TAIS ) TAISHO PHARM CO LTD.
PA   (LTTL-) LTT INST CO LTD.
XX
PI   Yamamoto K,  Mizushima Y,  Nishioka K,  Sakoda H,  Ikeda Y;
XX
DR   WPI; 1993-368813/46.
XX
PT   Detection of expression of T-cell antigen receptor gene - in cancer,
PT   viral or immune disease patients, by polymerase chain reaction
PT   amplification of the gene and SSCP analysis.
XX
PS   Example 1; Page 24; 47pp; Japanese.
XX
CC   Primers corresp. to DNA coding for part of the beta-chain of the T cell
CC   antigen receptor (pref. the Variable region primers AAQ50905- AAQ50926)
CC   are used in PCR to amplify the T cell antigen receptor gene. The
CC   amplified gene is detected by the single-strand conformation polymorphism
CC   method using hybridisation probes corresp. to the beta-chain J domain
CC   (see AAQ50928-Q50940). (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ   Sequence 18 BP; 4 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAACAGAC 1859
                | ||||||||| | ||
Db         18 TGCCTGGGCCAAAATAC 2


RESULT 1385
AAT07600
ID   AAT07600 standard; DNA; 18 BP.
XX
AC   AAT07600;
XX
DT   12-JUN-1996  (first entry)
XX
DE   RT-PCR primer/probe 230, identifies adenosine receptor subtypes.
XX
KW   Primer; probe; reverse transcription polymerase chain reaction; RT-PCR;
KW   in situ hybridisation; adenosine receptor subtype; A3; A1; A2a; A2b;
```

```
KW   human; eosinophil; antagonist; inhibition; adenylate cyclase;
KW   cytokine induced hypersensitivity; allergy; inflammatory disease; asthma;
KW   rhinitis; serum sickness; atopic dermatitis; psoriasis; eczema;
KW   ulcerative colitis; ss.
XX
OS   Synthetic.
XX
PN   GB2288733-A.
XX
PD   01-NOV-1995.
XX
PF   19-APR-1995;   95GB-00007984.
XX
PR   25-APR-1994;   94US-00233009.
XX
PA   (MERI ) MERCK & CO INC.
XX
PI   Jacobson MA,  Johnson RG,  Salvatore CA;
XX
DR   WPI; 1995-360715/47.
XX
PT   Decreasing intracellular cAMP levels in eosinophil(s) - by contacting
PT   cell with antagonist of A3 subtype adenosine receptor.
XX
PS   Claim 16; Page 93; 120pp; English.
XX
CC   The sequences given in AAT07594-621 are primers/probes which were used in
CC   reverse transcription PCR or in situ hybridisation experiments for the
CC   identification of expression of a particular adenosine receptor subtype.
CC   These primers and probes are esp. used in the determination of expression
CC   of the A3 adenosine receptor by human eosinophils. This is used in the
CC   identification of antagonists of A3 subtype adenosine receptors. These
CC   antagonists prevent activation of eosinophils, esp. they prevent A3
CC   inhibition of adenylate cyclase and cytokine induced hypersensitivity.
CC   They may be used for treating or preventing allergic or inflammatory
CC   diseases, e.g. asthma, rhinitis, serum sickness, atopic dermatitis,
CC   psoriasis, eczema, ulcerative colitis etc
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTAT 1640
              ||||||||| | || ||
Db          1 GTTACCTACATCACCAT 17


RESULT 1386
AAT04089/c
ID   AAT04089 standard; DNA; 18 BP.
XX
AC   AAT04089;
XX
DT   16-MAY-1996  (first entry)
XX
DE   Trypsin inhibitory protein cDNA sense primer-5.
XX
KW   Trypsin; inhibitor; human T98G cells; human placenta; pancreatitis;
KW   shock; multiple organ failure; disseminated intravascular coagulation;
KW   DIC; ss.
XX
OS   Synthetic.
XX
PN   JP07242700-A.
XX
PD   19-SEP-1995.
XX
PF   04-MAR-1994;   94JP-00059906.
XX
PR   04-MAR-1994;   94JP-00059906.
XX
PA   (MOCH ) MOCHIDA PHARM CO LTD.
XX
DR   WPI; 1995-355285/46.
XX
PT   Polypeptide having trypsin inhibitory activity - for the treatment of
PT   pancreatitis, shock, multi-organ failure, etc.
XX
PS   Example 10; Page 16; 25pp; Japanese.
XX
CC   A polypeptide having trypsin inhibitory activity, mol.wt. 22-28 kD or 17-
CC   23 kD (as determined by SDS-PAGE under reducing or non- reducing
CC   conditions, respectively) and an N-terminal sequence as in AAR79913 is
CC   claimed. The polypeptide was isolated from human T98G cells and is useful
CC   for treating pancreatitis, shock, multiple organ failure and disseminated
CC   intravascular coagulation. The present sequence is that of a sense primer
CC   used for cloning coding sequences for the full-length polypeptide into
CC   plasmid pUC118
XX
SQ   Sequence 18 BP; 5 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGGGGGA 1616
              || |||||| | |||||
Db         18 CCGCCTGGCTTTGGGGA 2


RESULT 1387
AAQ79507/c
ID   AAQ79507 standard; RNA; 18 BP.
XX
AC   AAQ79507;
XX
DT   25-MAR-2003  (revised)
DT   24-JUL-1995  (first entry)
XX
DE   Beta-globulin intron 2 bp 643-660 antisense oligonucleotide.
XX
KW   Beta-globulin; antisense therapy; aberrant splicing in pre-mRNA;
KW   IVS2(654) beta-thalassemia; ss.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   modified_site    1. .18
FT                    /note= "2'O-methyl-ribonucleotides"
XX
PN   WO9426887-A1.
XX
PD   24-NOV-1994.
XX
PF   10-MAY-1994;   94WO-US005181.
XX
PR   11-MAY-1993;   93US-00062471.
XX
PA   (UYNC-) UNIV NORTH CAROLINA.
XX
PI   Kole R,  Dominski Z;
XX
DR   WPI; 1995-006784/01.
XX
PT   Antisense oligo-nucleotide(s) for combating aberrant splicing in a pre-
PT   mRNA molecule - for the treatment of thalassemia and cystic fibrosis.
XX
PS   Example 2; Page 15; 48pp; English.
XX
CC   AAQ79507 and AAQ79508 are oligonucleotides antisense to beta-globulin pre
CC   -mRNA, they can be used to combat aberrant splicing caused by the
CC   IVS2(654) mutation in intron 2 of the beta-globulin gene. These antisense
CC   sequences can therefore be used in the treatment of IVS2(654) beta-
CC   thalassemia. (Updated on 25-MAR-2003 to correct PN field.)
```

```
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1388
AAT00672
ID   AAT00672 standard; cDNA; 18 BP.
XX
AC   AAT00672;
XX
DT   08-MAY-1996  (first entry)
XX
DE   Primer 230 for human adenosine receptor transcript detection.
XX
KW   Primer 230; PCR; polymerase chain reaction; amplify; probe;
KW   glyceraldehyde-3-phosphate-dehydrogenase; adenosine receptor;
KW   adenosine receptor agonist; autoimmune disease; therapy; ss.
XX
OS   Synthetic.
XX
PN   GB2289218-A.
XX
PD   15-NOV-1995.
XX
PF   01-MAY-1995;   95GB-00008844.
XX
PR   06-MAY-1994;   94US-00239473.
XX
PA   (MERI ) MERCK & CO INC.
XX
PI   Jacobson MA;
XX
DR   WPI; 1995-375695/49.
XX
PT   Inhibiting prodn. of tumour necrosis factor alpha - with adenosine A2b
PT   sub:type receptor agonist, useful for treating auto:immune diseases, also
PT   method for identifying A2b specific cpds.
XX
PS   Example 15; Page 44; 96pp; English.
XX
CC   Primer 230 and primer 236 (AAT00673), based on glyceraldehyde- 3-
CC   phosphate-dehydrogenase, are used with primer pairs 266 + 267 (AAT02662-
CC   63), 253 + 254 (AAT00674-75) and 261 + 262 (AAT00678-79) to detect A3,
CC   A1, A2a and A2b adenosine receptor transcripts (AAT00644-47),
CC   respectively, by reverse transcription polymerase chain reaction. Tumour
CC   necrosis factor-alpha production in monocytes is inhibited by contacting
CC   an adenosine receptor with an adenosine receptor-agonist. The agonists
CC   are used in autoimmune disease therapy, specifically rheumatoid
CC   arthritis, rheumatoid spondylitis, inflammatory bowel disease (ulcerative
CC   colitis and Crohns disease), intestinal pathology associated with graft
CC   vs. host disease, organ transplant reactions, septic shock, fever and
CC   myalgia due to infection and cachexia associated with chronic infections,
CC   malignancy and AIDS, pulmonary diseases e.g. sarcoidosis, silicosis,
CC   chronic pulmonary inflammatory disease, and adult respiratory distress
CC   syndrome
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTAT 1640
              ||||||||| | || ||
Db          1 GTTACCTACATCACCAT 17


RESULT 1389
AAT50619
ID   AAT50619 standard; RNA; 18 BP.
XX
AC   AAT50619;
XX
DT   10-MAR-1997  (first entry)
XX
DE   Human CETP hairpin ribozyme target sequence #726.
XX
KW   Hairpin ribozyme; cholesterol ester transfer protein; mRNA cleavage;
KW   neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW   reverse cholesterol transport; high density lipoprotein; therapy; CETP;
KW   familial hypercholesterolaemia; dyslipidaemia; hypoalphalipoproteinaemia;
KW   peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW   angioplastic restenosis; low density lipoprotein; diabetes; HDL; human;
KW   LDL; ss.
XX
OS   Homo sapiens.
XX
PN   WO9620279-A1.
XX
PD   04-JUL-1996.
XX
PF   11-DEC-1995;   95WO-US016000.
XX
PR   23-DEC-1994;   94US-00363240.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
PA   (WARN ) WARNER LAMBERT CO.
XX
PI   Couture L,  Stinchcomb D,  Mcswiggen J,  Bisgaier C,  Pape M;
XX
DR   WPI; 1996-321852/32.
XX
PT   New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA -
PT   useful for preventing or treating initial development, progression or
PT   regression of vascular diseases, esp. familial hypercholesterolaemia.
XX
PS   Claim 4; Page 53; 72pp; English.
XX
CC   AAT50595-T50642 represent target sequences for the human cholesterol
CC   ester transfer protein (CETP) hairpin ribozymes (see AAT50547-T50594).
CC   CETP is a 74 kD glycoprotein that facilitates neutral lipid transfer
CC   between plasma lipoproteins. The numbering of the targets refers to the
CC   position of the cleavage site in full length CETP. The ribozyme then
CC   binds to 4-6 nucleotides 5', and a variable number 3' of this site. The
CC   ribozymes are able to cleave mRNA from the gene encoding CETP, thereby
CC   blocking synthesis and/or expression of the mRNA. By inhibiting CETP, the
CC   reverse cholesterol transport (RCT) pathway can be inhibited (or
CC   eliminated) thereby preventing the reduction in size density of the high
CC   density lipoproteins (HDL), prolonging HDL half life, and therefore
CC   increasing HDL levels. The ribozymes can be used to treat conditions
CC   associated with abnormal levels of CETP, specifically atherosclerosis,
CC   peripheral vascular disease, hyperbetalipoproteinaemia, dyslipidaemia,
CC   familial hypercholesterolaemia, hypoalphalipoproteinaemia, vascular
CC   complications of diabetes, transplant, atherectomy and angioplastic
CC   restenosis. By inhibiting CETP, the levels of HDL and low density
CC   lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a
CC   decrease in LDL levels, and a corresponding increase in HDL levels). The
CC   ribozymes can also be used diagnostically to study genetic drift and
CC   mutations in diseased cells, and to detect CETP mRNA. As the ribozymes
CC   target specific regions of the CETP gene, they have low non-specific
CC   activity
XX
SQ   Sequence 18 BP; 7 A; 3 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 6.5e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1553 AGGAACAGGACTGCAAA 1569
              ||| ||||  |:|||||
Db          1 AGGGACAGAUCUGCAAA 17
```

RESULT 1390
AAX70283
ID AAX70283 standard; RNA; 18 BP.
XX
AC AAX70283;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human flt1 VEGF receptor hairpin ribozyme substrate #51.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 93; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 18 BP; 3 A; 7 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 47.1%; Pred. No. 6.5e+02;
Matches 8; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | :| : ||::|:|:||
Db          2 ACUCCUGCCUUCUCUGA 18
```

RESULT 1391
AAV40683
ID AAV40683 standard; DNA; 18 BP.
XX
AC AAV40683;
XX
DT 21-SEP-1998 (first entry)
XX
DE Primer BARJAP2R for herbicide resistance fusion gene.
XX
KW PCR primer; fusion gene detection; herbicide resistance;
KW herbicide tolerance; ss.
XX
OS Synthetic.
XX
PN WO9820144-A2.
XX
PD 14-MAY-1998.
XX
PF 31-OCT-1997; 97WO-GB002996.
XX
PR 07-NOV-1996; 96GB-00023248.
PR 13-DEC-1996; 96GB-00025957.
PR 25-FEB-1997; 97GB-00003855.
XX
PA (ZENE) ZENECA LTD.
XX
PI Thompson PA, Knight ME, Jepson I, Thomas PG, Hawkes TR;
XX
DR WPI; 1998-297481/26.
XX
PT New nucleic acid encoding two proteins imparting resistance to different
PT herbicides - and related vectors and transgenic plants, allowing
PT selective weed control using these herbicides.
XX
PS Example 8; Page 36; 90pp; English.
XX
CC This sequence represents a primer used to isolate the polynucleotide of
CC the invention. The polynucleotide of the invention has two regions each
CC expressing a protein, conferring resistance or tolerance (in a plant) to
CC a particular herbicide, provided that: (a) it does not encode a fusion
CC protein of only 5-enol-pyruvyl-3-phosphoshikimate synthetase (EPSPS) and
CC GST; (b) does not comprise only regions expressing superoxide dismutase
CC (SOD) and GST; and (c) does not comprise only regions encoding GST and
CC phosphinothricin acetyltransferase (PAT). The polynucleotide or vectors
CC containing it may be used to produce transgenic plants resistant to
CC herbicides. The polynucleotides are introduced into a wide range of
CC cereals, oilseed crops, fibre plants, fruits, vegetables, plantation
CC crops and trees to selectively control weeds in a crop field by
CC conferring to the crop resistance to the herbicides, allowing greater
CC doses of herbicides to be used. The polynucleotide may also be used for
CC high throughput screening of potential herbicides, particularly when
CC expressed in E. coli or yeast
XX
SQ Sequence 18 BP; 5 A; 2 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1932 GTGTTAAGGTAATGGTT 1948
              || | || |||||||||
Db          1 GTCTCAATGTAATGGTT 17
```

RESULT 1392
AAV28198/c
ID AAV28198 standard; RNA; 18 BP.
XX
AC AAV28198;
XX
DT 08-OCT-1998 (first entry)
XX
DE Antisense oligonucleotide to beta-globin.
XX
KW Purification; oligonucleotide; matrix; affinity unit;
KW affinity purification; antisense; beta-globin; ss.
XX
OS Synthetic.

```
XX
PN   WO9827425-A1.
XX
PD   25-JUN-1998.
XX
PF   18-DEC-1997;   97WO-US023284.
XX
PR   19-DEC-1996;   96US-00769951.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Chen D,  Srivatsa GS,  Cole DL;
XX
DR   WPI; 1998-362922/31.
XX
PT   Matrix for selective separation of oligo:nucleotide - useful for, e.g.
PT   large scale purification of anti-sense agents from their deletion
PT   derivatives formed during synthesis.
XX
PS   Disclosure; Page 100; 183pp; English.
XX
CC   AAV28155-268 represent oligonucleotides which can be purified using the
CC   method of the invention. The specification describes a matrix that
CC   comprises a support and an affinity unit that specifically and reversibly
CC   binds a target oligonucleotide, and comprises a sequence of bases having
CC   the reverse complement of a hybridising portion of the target
CC   oligonucleotide. The matrix is used for affinity purification of
CC   synthetic oligonucleotides, specifically antisense agents, for treatment
CC   of hyperproliferative diseases, for treating a non-pathogen, non-
CC   hyperproliferative disease, e.g. Alzheimer's, for modulating expression
CC   of cell surface proteins, and to inhibit a eukaryotic pathogen,
CC   retrovirus or other viruses
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1393
AAV49126/c
ID   AAV49126 standard; DNA; 18 BP.
XX
AC   AAV49126;
XX
DT   15-OCT-1998  (first entry)
XX
DE   rb gene antisense oligonucleotide rb-N-74.
XX
KW   rb gene; antisense oligonucleotide; modulate; gene expression; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   EP856579-A1.
XX
PD   05-AUG-1998.
XX
PF   31-JAN-1997;   97EP-00101531.
XX
PR   31-JAN-1997;   97EP-00101531.
XX
PA   (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
PI   Schlingensiepen K,  Brysch W;
XX
DR   WPI; 1998-400910/35.
XX
PT   Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT   consecutive guanosine or inosine - and have specific ratio of residues
PT   able to form two or three hydrogen bonds, have greater activity and
PT   reduced toxicity, used therapeutically or to modulate growth of cells in
PT   culture.
XX
PS   Example 7; Fig 9b; 286pp; English.
XX
CC   AAV49008-236 represent antisense oligonucleotides directed against the rb
CC   gene. Of these, only oligonucleotides AAV49008-52 resulted in effective
CC   downregulation of negative growth control by rb, while oligonucleotides
CC   AAV49052-236 had little effect. The oligonucleotides exemplify the
CC   invention. The specification describes oligonucleotides that contain 8-30
CC   nucleotides, which contain at most 8 nucleotides that can each form three
CC   hydrogen bonds to cytosine; do not contain four consecutive nucleotides
CC   able to form three H-bonds each to four consecutive cytosines; do not
CC   contain two sequences of three consecutive nucleotides each able to form
CC   three H-bonds to three consecutive cytosines, and the ratio between
CC   residues able to form two H-bonds each (2R) or three such bonds (3R) is
CC   given by 2R/3R = 0.33-0.72. The oligonucleotides are used to modulate
CC   expression of genes, particularly the genes for p53, ErB-2, junB, junD,
CC   TGF-beta 1 or beta 2 to control proliferation of primary cell cultures
CC   (e.g. bone marrow stem, liver or kidney cells, osteoclasts, osteoblasts
CC   and/or keratinocytes). The oligonucleotides can also be used to analyse
CC   function of proteins (by altering their expression or activity) and
CC   therapeutically, e.g. in cases of cancer or (targeting TGF) for
CC   stimulating the immune system
XX
SQ   Sequence 18 BP; 7 A; 0 C; 1 G; 10 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAA 1985
              ||||| ||| |||| ||
Db         17 ATTTATCTTAAAAATAA 1

RESULT 1394
AAV94837
ID   AAV94837 standard; RNA; 18 BP.
XX
AC   AAV94837;
XX
DT   24-FEB-1999  (first entry)
XX
DE   Human IL-2 receptor g-chain substrate position 587.
XX
KW   Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
KW   hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
KW   autoimmune disease; psoriasis; allergy; inflammatory disease;
KW   graft rejection; ss.
XX
OS   Homo sapiens.
XX
PN   WO9824913-A2.
XX
PD   11-JUN-1998.
XX
PF   02-DEC-1997;   97WO-US021748.
XX
PR   03-DEC-1996;   96US-00758306.
XX
PA   (RIBO-) RIBOZYME PHARM INC.
XX
PI   Stinchcomb DT,  Mcswiggen JA;
XX
DR   WPI; 1998-333332/29.
XX
PT   Ribozymes targetted to interleukin 2 - useful for treating e.g. cancer,
PT   autoimmune disease and allergies.
XX
```

```
PS   Claim 4; Page 38; 61pp; English.
XX
CC   The present sequence invention describes ribozymes targeted to modulate
CC   the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.
CC   AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC   AAV94575 to AAV95260 represent specifically claimed substrate sequences
CC   from the present invention. The ribozymes can be used for the treatment
CC   of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy
CC   and other inflammatory conditions. The ribozymes are also used to induce
CC   tolerance in a recipient to alloantigen from a donor
XX
SQ   Sequence 18 BP; 4 A; 6 C; 6 G; 0 T; 2 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 6.5e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGAAC 1598
              ||| || |||:|||| |
Db          1 CCGGACUGACUGGGACC 17


RESULT 1395
AAZ21406/c
ID   AAZ21406 standard; DNA; 18 BP.
XX
AC   AAZ21406;
XX
DT   02-DEC-1999  (first entry)
XX
DE   Human MEK2 antisense oligonucleotide SEQ ID NO:9.
XX
KW   Human; MEK2; MAP kinase; MAPK/ERK kinase; erk activator kinase;
KW   mitogen activated protein kinase; expression; modulation; antisense;
KW   diagnosis; hepatocellular carcinoma; breast cancer; proliferation;
KW   differentiation; development; detection; probe; primer; tumour;
KW   phosphorothioate; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US5959097-A.
XX
PD   28-SEP-1999.
XX
PF   20-NOV-1998;   98US-00197378.
XX
PR   20-NOV-1998;   98US-00197378.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Monia BP,  Cowsert LM;
XX
DR   WPI; 1999-561077/47.
XX
PT   Antisense oligonucleotides of the MEK2 kinase gene, useful in diagnostic
PT   protocols in vitro and for inhibiting the expression of MEK2 in vivo for
PT   the treatment of human hepatocellular carcinomas and breast carcinomas.
XX
PS   Claim 11; Col 39; 32pp; English.
XX
CC   The present invention describes antisense oligonucleotides (asMEK2) of
CC   the human MEK2 dual specificity kinase gene. The MEK2 gene (also called
CC   MAPKK2, mpk2, MAPK/ERK kinase 2, prmmk2 and erk activator kinase)
CC   represents a convergent target for the regulation of a range of cellular
CC   processes including proliferation, differentiation and development.
CC   asMEK2 may be used to inhibit the expression of MEK2 genes in vivo and/or
CC   in vitro. MEK2 has been shown to be over expressed in some tumour cells.
CC   Therefore, asMEK2 may be administered to a patient to treat
CC   hepatocellular carcinomas and breast carcinomas. asMEK2 may also be used
CC   as a diagnostic tool to specifically inhibit the expression of MEK2
CC   genes. The role of the inhibited genes in cellular pathways may then be
CC   evaluated. They may also be used as probes to detect sequences encoding
CC   MEK2 or as primers for the amplification of those sequences. AAZ21406 to
CC   AAZ21443 represent specifically claimed asMEK2's from the present
CC   invention
XX
SQ   Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAG 1618
              | |||||| || |||||
Db         17 TGCTGGCCCGGAGGAAG 1


RESULT 1396
AAZ24027/c
ID   AAZ24027 standard; DNA; 18 BP.
XX
AC   AAZ24027;
XX
DT   04-FEB-2000  (first entry)
XX
DE   Human GDNF PCR primer HPh1.f.
XX
KW   GDNF; human; glial cell line-derived neurotrophic factor; diagnosis;
KW   treatment; neurodegenerative disease; Alzheimer's disease; detection;
KW   Parkinson's disease; amyotrophic lateral sclerosis; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   DE19816186-A1.
XX
PD   21-OCT-1999.
XX
PF   14-APR-1998;   98DE-01016186.
XX
PR   14-APR-1998;   98DE-01016186.
XX
PA   (UYLU-) UNIV MUENCHEN MAXIMILIANS LUDWIG.
XX
DR   WPI; 1999-591830/51.
XX
PT   Novel nucleic acids used for diagnosis and treatment of neurodegenerative
PT   diseases.
XX
PS   Claim 5; Fig 4; 14pp; German.
XX
CC   This invention describes a novel human DNA (I), encoding glial cell line-
CC   derived neurotrophic factor (GDNF). (I), also its promoter, exon
CC   fragments and primer pairs able to hybridize to it, and GDNF variants
CC   (II) encoded by the exon fragments, are used (i) to investigate
CC   regulation of GDNF at the molecular level, and to design methods for
CC   influencing this regulation and (ii) for diagnosis and treatment of
CC   neurodegenerative diseases, specifically Alzheimer's and Parkinson's
CC   diseases or amyotrophic lateral sclerosis, either by administration of
CC   GDNF variants or by inhibition with e.g. antisense nucleic acid. The
CC   promoter fragment of can also be used to identify agents that regulate
CC   (up or down) GDNF expression. (II) can be used to raise (or detect)
CC   specific antibodies (Ab) for detection of (II), in usual immunoassays. Ab
CC   are also useful therapeutically to inhibit specific GDNF variants.
CC   AAZ24019-Z324040 represent PCR primers used to amplify the human GDNF
CC   sequence described in the method of the invention
XX
SQ   Sequence 18 BP; 3 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGTT 1622
              || | |||| |||||||
```

```
Db         18 GGTCAGGGGCAAGAGTT 2


RESULT 1397
AAZ24033/c
ID   AAZ24033 standard; DNA; 18 BP.
XX
AC   AAZ24033;
XX
DT   04-FEB-2000  (first entry)
XX
DE   Human GDNF PCR primer RT.f.
XX
KW   GDNF; human; glial cell line-derived neurotrophic factor; diagnosis;
KW   treatment; neurodegenerative disease; Alzheimer's disease; detection;
KW   Parkinson's disease; amyotrophic lateral sclerosis; PCR primer; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   DE19816186-A1.
XX
PD   21-OCT-1999.
XX
PF   14-APR-1998;   98DE-01016186.
XX
PR   14-APR-1998;   98DE-01016186.
XX
PA   (UYLU-) UNIV MUENCHEN MAXIMILIANS LUDWIG.
XX
DR   WPI; 1999-591830/51.
XX
PT   Novel nucleic acids used for diagnosis and treatment of neurodegenerative
PT   diseases.
XX
PS   Claim 5; Fig 4; 14pp; German.
XX
CC   This invention describes a novel human DNA (I), encoding glial cell line-
CC   derived neurotrophic factor (GDNF). (I), also its promoter, exon
CC   fragments and primer pairs able to hybridize to it, and GDNF variants
CC   (II) encoded by the exon fragments, are used (i) to investigate
CC   regulation of GDNF at the molecular level, and to design methods for
CC   influencing this regulation and (ii) for diagnosis and treatment of
CC   neurodegenerative diseases, specifically Alzheimer's and Parkinson's
CC   diseases or amyotrophic lateral sclerosis, either by administration of
CC   GDNF variants or by inhibition with e.g. antisense nucleic acid. The
CC   promoter fragment of can also be used to identify agents that regulate
CC   (up or down) GDNF expression. (II) can be used to raise (or detect)
CC   specific antibodies (Ab) for detection of (II), in usual immunoassays. Ab
CC   are also useful therapeutically to inhibit specific GDNF variants.
CC   AAZ24019-Z324040 represent PCR primers used to amplify the human GDNF
CC   sequence described in the method of the invention
XX
SQ   Sequence 18 BP; 3 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGTT 1622
              || | |||| |||||||
Db         18 GGTCAGGGGCAAGAGTT 2


RESULT 1398
AAX14634
ID   AAX14634 standard; DNA; 18 BP.
XX
AC   AAX14634;
XX
DT   24-MAR-1999  (first entry)
XX
DE   Triple helix forming nucleotides 5419-5437 of the n-myc gene.
XX
KW   Triple-helix forming region; Triplex formation; DNA detection;
KW   identification; bacteria; oncogene; virus; ds.
XX
OS   Homo sapiens.
XX
PN   US5861244-A.
XX
PD   19-JAN-1999.
XX
PF   22-DEC-1993;   93US-00173489.
XX
PR   29-OCT-1992;   92US-00968436.
XX
PA   (PROF-) PROFILE DIAGNOSTIC SCI INC.
XX
PI   Hepburn AG,  Wang C;
XX
DR   WPI; 1999-130384/11.
XX
PT   Assay of genetic sequences based on triplex formation from double
PT   stranded analyte - and hybrid of anchor and reporter sequences, with
PT   reporter released if triplex formation occurs, used e.g. to identify
PT   bacteria.
XX
PS   Disclosure; Col 13-14; 168pp; English.
XX
CC   The present sequence represents a potential triple-helix forming region.
CC   It can be used to demonstrate the assay of the invention. The assay
CC   comprises adding a sample containing double-stranded DNA test sequences,
CC   e.g. containing the present sequence, to an aqueous medium containing at
CC   least one complex of anchor DNA, attached to a solid support, and
CC   reporter DNA, where either a part of the anchor DNA or reporter DNA is
CC   designed to form a triple-strand structure with part of the test
CC   sequence. Triplex formation results in displacement of the reporter DNA
CC   which is detected as an indication of the presence of the DNA test
CC   sequence. The method is used to detect DNA sequences, particularly for
CC   identification of bacteria (by detecting genes for ribosomal RNA) in
CC   clinical samples, but also detection of oncogenes and Hepatitis B virus
XX
SQ   Sequence 18 BP; 8 A; 0 C; 10 G; 0 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGA 1556
              ||||||| |||||| |
Db          2 AGGAGAGAGGGGAAGAA 18


RESULT 1399
AAX18731/c
ID   AAX18731 standard; DNA; 18 BP.
XX
AC   AAX18731;
XX
DT   10-MAY-1999  (first entry)
XX
DE   Target beta-thalassemia antisense oligonucleotide 5'ss.
XX
KW   Cellular adhesion protein; proliferation; antisense oligonucleotide;
KW   alimentary canal; transport; gastrointestinal mucosa; cancer;
KW   Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;
KW   inflammation; ss.
XX
OS   Synthetic.
XX
PN   WO9901579-A1.
XX
PD   14-JAN-1999.
XX
PF   01-JUL-1998;   98WO-US013574.
```

XX
PR 01-JUL-1997; 97US-00886829.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Teng C, Hardee G;
XX
DR WPI; 1999-106077/09.
XX
PT Composition comprising nucleic acid and penetration enhancer - used
PT particularly for delivering therapeutic antisense oligonucleotides across
PT the gastrointestinal mucosa, provides high bioavailability.
XX
PS Example 2; Page 94; 115pp; English.
XX
CC A pharmaceutical composition has been developed which comprises a nucleic
CC acid and at least one penetration enhancer. The compositions are used:
CC (i) to treat or prevent any disease or disorder that can be treated with
CC the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,
CC malaria, viral infections (including human immune deficiency virus
CC (HIV)), inflammation, in human or animal medicine; (ii) to investigate
CC the role of a gene or gene product in non-human animals; and (iii) to
CC modulate gene expression in cells, tissues or organs. The compositions
CC provide bioavailability of at least 15, preferably 17-35,%. The
CC penetration enhancer improves: (i) transport of the nucleic acid across
CC the mucosa of the alimentary canal and into cells; and (ii) increases
CC stability of the nucleic acid. Oral administration avoids the
CC complications and expense of intravenous or other methods of
CC administration. AAX18669 to AAX18799 and AAX18801 represent antisense
CC oligonucleotides which can be used as the nucleic acid in the method of
CC the invention
XX
SQ Sequence 18 BP; 5 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1930 CAGTGTTAAGGTAATGG 1946
| | ||||||||||| |
Db 18 CTGGGTTAAGGTAATAG 2

RESULT 1400
AAZ34348/c
ID AAZ34348 standard; RNA; 18 BP.
XX
AC AAZ34348;
XX
DT 14-DEC-1999 (first entry)
XX
DE Nucleic acid-based diagnostic exemplification oligonucleotide #10.
XX
KW Catalytic nucleic acid-based diagnostic method; determination; AIDS;
KW mutation; ribozyme; target; cleavage; amplification; PCR primer; probe;
KW cancer; human immune deficiency virus; cystic fibrosis; HIV; ss.
XX
OS Synthetic.
XX
PN WO9950452-A1.
XX
PD 07-OCT-1999.
XX
PF 16-MAR-1999; 99WO-IB000848.
XX
PR 27-MAR-1998; 98US-0079651P.
XX
PA (JOHJ) JOHNSON & JOHNSON RES PTY LTD.
XX
PI Todd AV, Fuery CJ, Cairns MJ;
XX
DR WPI; 1999-591332/50.
XX
PT Detecting diseases associated with a known mutation by amplification and
PT cleavage with catalytic nucleic acids, particularly for cancer, human
PT immune deficiency virus and cystic fibrosis.
XX
PS Disclosure; Page 18; 57pp; English.
XX
CC The present invention describes a method for determining whether a
CC subject is afflicted with a disorder characterised by the presence of a
CC known nucleic acid. The method comprises: (i) amplifying, in an isolated
CC sample from the subject, the nucleic acid segment that, in an affected
CC individual contains (A), (ii) treating the amplicons with a catalytic
CC nucleic acid (I) that specifically recognizes and cleaves a target
CC sequence present in either the mutated or wild-type segments, but not in
CC both; and (iii) detecting any cleavage caused by (I). Step (ii) may be
CC performed concurrently with (i). The method is specifically used to
CC diagnose cancer (especially), acquired immune deficiency syndrome and
CC cystic fibrosis. (I) recognises as few as two bp to create a cleavage
CC site (contrast at least 4 bp required by enzymes used in restriction
CC fragment length polymorphism (RFLP) analysis); such sites occur more
CC frequently than restriction enzyme sites, and mismatched primers can be
CC used to induce cleavage sites for (I). The method is potentially more
CC flexible than RFLP and does not require any enzymes or toxic compounds.
CC AAZ34339 to AAZ34450 represent oligonucleotide sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 18 BP; 4 A; 6 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1598 CCCCTCCTGGCCTGGGG 1614
| |||||||||| | ||
Db 18 CTCCTCCTGGCCGGCGG 2

RESULT 1401
AAZ34354/c
ID AAZ34354 standard; RNA; 18 BP.
XX
AC AAZ34354;
XX
DT 14-DEC-1999 (first entry)
XX
DE Nucleic acid-based diagnostic exemplification oligonucleotide #16.
XX
KW Catalytic nucleic acid-based diagnostic method; determination; AIDS;
KW mutation; ribozyme; target; cleavage; amplification; PCR primer; probe;
KW cancer; human immune deficiency virus; cystic fibrosis; HIV; ss.
XX
OS Synthetic.
XX
PN WO9950452-A1.
XX
PD 07-OCT-1999.
XX
PF 16-MAR-1999; 99WO-IB000848.
XX
PR 27-MAR-1998; 98US-0079651P.
XX
PA (JOHJ) JOHNSON & JOHNSON RES PTY LTD.
XX
PI Todd AV, Fuery CJ, Cairns MJ;
XX
DR WPI; 1999-591332/50.
XX
PT Detecting diseases associated with a known mutation by amplification and
PT cleavage with catalytic nucleic acids, particularly for cancer, human
PT immune deficiency virus and cystic fibrosis.
XX
PS Disclosure; Page 19; 57pp; English.
XX
CC The present invention describes a method for determining whether a

CC subject is afflicted with a disorder characterised by the presence of a
CC known nucleic acid. The method comprises: (i) amplifying, in an isolated
CC sample from the subject, the nucleic acid segment that, in an affected
CC individual contains (A), (ii) treating the amplicons with a catalytic
CC nucleic acid (I) that specifically recognizes and cleaves a target
CC sequence present in either the mutated or wild-type segments, but not in
CC both; and (iii) detecting any cleavage caused by (I). Step (ii) may be
CC performed concurrently with (i). The method is specifically used to
CC diagnose cancer (especially), acquired immune deficiency syndrome and
CC cystic fibrosis. (I) recognises as few as two bp to create a cleavage
CC site (contrast at least 4 bp required by enzymes used in restriction
CC fragment length polymorphism (RFLP) analysis); such sites occur more
CC frequently than restriction enzyme sites, and mismatched primers can be
CC used to induce cleavage sites for (I). The method is potentially more
CC flexible than RFLP and does not require any enzymes or toxic compounds.
CC AAZ34339 to AAZ34450 represent oligonucleotide sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 18 BP; 4 A; 6 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1598 CCCCTCCTGGCCTGGGG 1614
| |||||||||| | ||
Db 18 CTCCTCCTGGCCGGCGG 2

RESULT 1402
AAZ34351/c
ID AAZ34351 standard; RNA; 18 BP.
XX
AC AAZ34351;
XX
DT 14-DEC-1999 (first entry)
XX
DE Nucleic acid-based diagnostic exemplification oligonucleotide #13.
XX
KW Catalytic nucleic acid-based diagnostic method; determination; AIDS;
KW mutation; ribozyme; target; cleavage; amplification; PCR primer; probe;
KW cancer; human immune deficiency virus; cystic fibrosis; HIV; ss.
XX
OS Synthetic.
XX
PN WO9950452-A1.
XX
PD 07-OCT-1999.
XX
PF 16-MAR-1999; 99WO-IB000848.
XX
PR 27-MAR-1998; 98US-0079651P.
XX
PA (JOHJ) JOHNSON & JOHNSON RES PTY LTD.
XX
PI Todd AV, Fuery CJ, Cairns MJ;
XX
DR WPI; 1999-591332/50.
XX
PT Detecting diseases associated with a known mutation by amplification and
PT cleavage with catalytic nucleic acids, particularly for cancer, human
PT immune deficiency virus and cystic fibrosis.
XX
PS Disclosure; Page 19; 57pp; English.
XX
CC The present invention describes a method for determining whether a
CC subject is afflicted with a disorder characterised by the presence of a
CC known nucleic acid. The method comprises: (i) amplifying, in an isolated
CC sample from the subject, the nucleic acid segment that, in an affected
CC individual contains (A), (ii) treating the amplicons with a catalytic
CC nucleic acid (I) that specifically recognizes and cleaves a target
CC sequence present in either the mutated or wild-type segments, but not in
CC both; and (iii) detecting any cleavage caused by (I). Step (ii) may be
CC performed concurrently with (i). The method is specifically used to
CC diagnose cancer (especially), acquired immune deficiency syndrome and
CC cystic fibrosis. (I) recognises as few as two bp to create a cleavage
CC site (contrast at least 4 bp required by enzymes used in restriction
CC fragment length polymorphism (RFLP) analysis); such sites occur more
CC frequently than restriction enzyme sites, and mismatched primers can be
CC used to induce cleavage sites for (I). The method is potentially more
CC flexible than RFLP and does not require any enzymes or toxic compounds.
CC AAZ34339 to AAZ34450 represent oligonucleotide sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 18 BP; 4 A; 6 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1598 CCCCTCCTGGCCTGGGG 1614
| |||||||||| | ||
Db 18 CTCCTCCTGGCCGGCGG 2

RESULT 1403
AAX23610/c
ID AAX23610 standard; RNA; 18 BP.
XX
AC AAX23610;
XX
DT 18-JUN-1999 (first entry)
XX
DE Deletion sequence oligonucleotide 63.
XX
KW Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KW probe; cellular adhesion modulator; cellular proliferation modulator;
KW human retrovirus; human immunodeficiency virus; non-human retrovirus;
KW HIV; primer; ss.
XX
OS Synthetic.
XX
PN WO9911820-A1.
XX
PD 11-MAR-1999.
XX
PF 01-SEP-1998; 98WO-US018084.
XX
PR 02-SEP-1997; 97US-00923771.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Chen D, Srivatsa GS;
XX
DR WPI; 1999-205198/17.
XX
PT New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion
PT oligonucleotides.
XX
PS Example 9; Page 115; 163pp; English.
XX
CC This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AAX23548-X23709.
CC Oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable

```
CC   characterization of deletion sequence oligonucleotides having related,
CC   but different nucleobase sequences, and quantification of different
CC   species of deletion sequence ("target") oligonucleotides in a mixture.
CC   Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC   its reverse complement is not modified, the method may be performed using
CC   oligodeoxynucleotides
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1404
AAZ37256
ID   AAZ37256 standard; DNA; 18 BP.
XX
AC   AAZ37256;
XX
DT   28-JAN-2000  (first entry)
XX
DE   PCR primer for AV37 antigen coding sequence.
XX
KW   AV37 antigen; monoclonal antibody; hybridoma AV37; vaccine; avian tumour;
KW   oncogenic avian virus; Marek's disease virus; avian leucosis virus;
KW   Rous-associated virus; reticuloendotheliosis virus; therapy; PCR primer;
KW   ss.
XX
OS   Synthetic.
OS   Gallus sp.
XX
PN   WO9955860-A1.
XX
PD   04-NOV-1999.
XX
PF   22-APR-1999;   99WO-GB001238.
XX
PR   29-APR-1998;   98GB-00009070.
XX
PA   (ANIM-) INST ANIMAL HEALTH LTD.
XX
PI   Burgess SC,  Davison TF,  Ross LJN;
XX
DR   WPI; 2000-013437/01.
XX
PT   New polypeptide, useful as a vaccine and to generate monoclonal
PT   antibodies.
XX
PS   Claim 31; Page 39; 63pp; English.
XX
CC   This sequence is a PCR primer for DNA encoding the AV37 antigen protein
CC   of the invention. The protein is recognised by a monoclonal antibody
CC   (MAb) secreted by the hybridoma AV37 deposited at the European Collection
CC   of Cell Cultures (ECACC) accession number 98030304. The polypeptide can
CC   be used to isolate a MAb, produce a hybridoma producing the MAb, and in a
CC   composition for use as a vaccine. The vaccine can be used against
CC   oncogenic avian viruses, including Marek's disease virus, avian leucosis
CC   virus, Rous-associated virus and reticuloendotheliosis virus. The vector
CC   can be used to treat avian tumours
XX
SQ   Sequence 18 BP; 6 A; 1 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1549 GGGAAGGAACAGGACTG 1565
              || ||||||| ||| ||
Db          2 GGAAAGGAACTGGAGTG 18


RESULT 1405
AAD00239
ID   AAD00239 standard; DNA; 18 BP.
XX
AC   AAD00239;
XX
DT   05-SEP-2000  (first entry)
XX
DE   Sense primer for mapping human zil1a4 DNA.
XX
KW   Human interleukin-1; IL-1; zil1a4 protein; inflammation; arthritis;
KW   psoriasis; septic shock; graft-versus-host disease; leukaemia; cancer;
KW   anaemia; inflammatory bowel disease; acute neuropathology; shock;
KW   chronic neuropathology; respiratory disease syndrome; restenosis;
KW   acquired immune deficiency syndrome; AIDS; antiinflammatory; cytostatic;
KW   anti-arthritic; anti-psoriatic; antibacterial; immunosuppressive;
KW   anti-anaemic; neuroprotective; vasotropic; PCR primer;
KW   anti-human immunodeficiency virus; HIV; ss.
XX
OS   Homo sapiens.
XX
PN   WO200024899-A2.
XX
PD   04-MAY-2000.
XX
PF   27-OCT-1999;   99WO-US025038.
XX
PR   27-OCT-1998;   98US-00179614.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   West RR,  Sheppard PO,  Gao Z;
XX
DR   WPI; 2000-350740/30.
XX
PT   Immunomodulatory interleukin-1 homolog zil1a4 proteins, useful for
PT   treatment of e.g. arthritis, psoriasis, septic shock, graft-versus-host
PT   disease, leukemia.
XX
PS   Example 6; Page 88; 88pp; English.
XX
CC   The present sequence is the sense primer used for mapping human zil1a4
CC   DNA. Zil1a4 was mapped to human chromosome 2 using Stanford G3 Radiation
CC   Hybrid Mapping Panel. The zil1a4 proteins modulate inflammation and other
CC   immunological processes and are therefore useful for treatment of
CC   arthritis, psoriasis, septic shock, graft-versus-host disease and
CC   leukaemia. Other diseases that may be modulated by zil1a4 proteins
CC   include cancer, anaemia, inflammatory bowel disease, acute and chronic
CC   neuropathologies, shock, respiratory disease syndrome, restenosis and
CC   acquired immune deficiency syndrome
XX
SQ   Sequence 18 BP; 1 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              ||  |||||||||| ||
Db          2 CCCCTCTTTCCTTCACT 18


RESULT 1406
AAA86579/c
ID   AAA86579 standard; DNA; 18 BP.
XX
AC   AAA86579;
XX
DT   04-DEC-2000  (first entry)
XX
```

```
DE   Cdc 2 kinase hammerhead ribozyme recognitoin site #10.
XX
KW   Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS   Mammalia.
XX
PN   WO200032765-A2.
XX
PD   08-JUN-2000.
XX
PF   06-DEC-1999;   99WO-US028772.
XX
PR   04-DEC-1998;   98US-0110954P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Tritz R,  Welch PJ,  Barber JR,  Robbins JM;
XX
DR   WPI; 2000-412314/35.
XX
PT   New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT   RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT   PCNA and Cyclin B1.
XX
PS   Example 1; Page 17; 109pp; English.
XX
CC   The present invention relates to a hairpin or hammerhead ribozyme,
CC   designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC   other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC   Representative examples of ribozyme recognition sites are given in
CC   AAA82415 to AAA86787. The ribozyme of the invention is useful for
CC   inhibiting restenosis by introduction of the ribozyme into cells. The
CC   ribozyme is resistant to endonuclease activity and hence is efficient in
CC   restenosis treatment
XX
SQ   Sequence 18 BP; 7 A; 5 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2059 TAGTTAATAAGTGGTAT 2075
              |||||| | | ||||||
Db         18 TAGTTAGTCAATGGTAT 2


RESULT 1407
AAZ91416
ID   AAZ91416 standard; DNA; 18 BP.
XX
AC   AAZ91416;
XX
DT   22-MAY-2000  (first entry)
XX
DE   Human Ship-2 phosphorothioate antisense oligonucleotide #30698.
XX
KW   Human; Ship-2; antisense oligonucleotide; phosphorothioate; detection;
KW   inhibition; SH2-containing phosphatidylinositol phosphatase-2; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   modified_base    1. .18
FT                    /*tag=  a
FT                    /note= "phosphorothioate linkages"
XX
PN   US6025198-A.
XX
PD   15-FEB-2000.
XX
PF   25-JUN-1999;   99US-00339964.
XX
PR   25-JUN-1999;   99US-00339964.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF,  Cowsert LM;
XX
DR   WPI; 2000-181819/16.
XX
PT   Antisense oligonucleotides, useful for inhibiting human Ship-2 expression
PT   and for detecting nucleic acids encoding Ship-2.
XX
PS   Example 15; Col 39; 34pp; English.
XX
CC   The present invention describes phosphorothioate antisense
CC   oligonucleotides that specifically hybridise with, and inhibit the
CC   expression of, nucleic acids encoding human Ship-2 (also called SH2-
CC   containing phosphatidylinositol phosphatase-2). Also described is a
CC   method of inhibiting the expression of Ship-2 in human cells or tissues
CC   in vitro comprising contacting the cells with the phosphorothioate
CC   antisense oligonucleotides. The phosphorothioate antisense
CC   oligonucleotides can be used to treat animals (especially humans)
CC   suspected of having or being prone to a disease or condition associated
CC   with Ship-2 expression. The present sequence represents a
CC   phosphorothioate antisense oligonucleotide for human Ship-2, from the
CC   present invention
XX
SQ   Sequence 18 BP; 2 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACAG 1589
              |||| |||||| ||| |
Db          1 CCTTGTCCACCTCACTG 17


RESULT 1408
AAZ71436
ID   AAZ71436 standard; DNA; 18 BP.
XX
AC   AAZ71436;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:5792.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 1466; 2745pp; English.
```

```
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 18 BP; 7 A; 7 C; 1 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACC 1583
              ||| ||| ||| |||||
Db          2 AAACATCATTCACCACC 18


RESULT 1409
AAZ74770
ID   AAZ74770 standard; DNA; 18 BP.
XX
AC   AAZ74770;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker downstream amplification primer SEQ ID NO:9126.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 8; Page 2176; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
XX
SQ   Sequence 18 BP; 7 A; 0 C; 8 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1538 TTAGGAGAGTAGGGAAG 1554
              || |||||| || ||||
Db          2 TTGGGAGAGAAGAGAAG 18


RESULT 1410
AAZ73238/c
ID   AAZ73238 standard; DNA; 18 BP.
XX
AC   AAZ73238;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Human biallelic marker upstream amplification primer SEQ ID NO:7594.
XX
KW   Human genome; biallelic marker; high density disequilibrium map;
KW   genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW   haplotyping; hybridisation; identification; characterisation;
KW   amplification; single nucleotide polymorphism; SNP; PCR primer;
KW   diagnosis; ss.
XX
OS   Homo sapiens.
XX
PN   WO9954500-A2.
XX
PD   28-OCT-1999.
XX
PF   21-APR-1999;   99WO-IB000822.
XX
PR   21-APR-1998;   98US-0082614P.
PR   23-NOV-1998;   98US-0109732P.
XX
PA   (GEST ) GENSET.
XX
PI   Cohen D,  Blumenfeld M,  Chumakov I;
XX
DR   WPI; 2000-013267/01.
XX
PT   Novel biallelic markers used to construct a high density disequilibrium
PT   map of the human genome.
XX
PS   Claim 9; Page 1850; 2745pp; English.
XX
CC   AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC   invention, which contain a polymorphic base at position 24 of their
CC   nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC   primers for the biallelic markers. The biallelic markers of the invention
CC   have a variety of uses: they can be used for high density mapping of the
CC   human genome, and in complex association studies and haplotyping studies
CC   which are useful in determining the genetic basis for disease states.
CC   Compositions and methods of the invention can also be useful for the
CC   identification of the targets for the development of pharmaceutical
CC   agents and diagnostic methods, as well as the characterisation of the
CC   differential efficacious responses to and side effects from
CC   pharmaceutical agents acting on a disease as well as other treatment.
CC   N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC   3367, are not actually given a sequence in the Sequence Listing from the
CC   present invention
```

```
XX
SQ   Sequence 18 BP; 5 A; 8 C; 0 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAGG 1555
              ||  |||||||||| ||
Db         17 TATTAGAGTAGGGATGG 1


RESULT 1411
AAZ49357/c
ID   AAZ49357 standard; DNA; 18 BP.
XX
AC   AAZ49357;
XX
DT   14-MAR-2000  (first entry)
XX
DE   Beta-thalassaemia therapeutic antisense oligonucleotide 5'ss.
XX
KW   Beta-thalassaemia; expression; modulation; antisense; non-parenteral;
KW   delivery; uptake; administration; emulsion; ulcerative colitis;
KW   Crohn's disease; inflammatory bowel disease; cellular proliferation; ss.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   WO9960012-A1.
XX
PD   25-NOV-1999.
XX
PF   20-MAY-1999;   99WO-US011394.
XX
PR   21-MAY-1998;   98US-00082624.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Teng C,  Cook PD,  Tillman L,  Hardee GE,  Ecker DJ,  Manoharan M;
XX
DR   WPI; 2000-072428/06.
XX
PT   New oligonucleotide compositions used for the non-parenteral delivery of
PT   e.g. antisense oligos, ribozymes, peptide nucleic acids, molecular
PT   decoys, external guide sequences or aptamers.
XX
PS   Example 2; Page 124; 133pp; English.
XX
CC   Sequences AAZ49357-Z49358 represent antisense oligonucleotides designed
CC   to have therapeutic activity against beta-thalassaemia. The invention
CC   relates to new compositions for the non-parenteral delivery of
CC   oligonucleotides comprising at least one oligonucleotide in an emulsion.
CC   Oligonucleotides delivered via the compositions of the invention can be
CC   used to modulate expression of a cellular adhesion protein, modulate a
CC   rate of cellular proliferation, or have biological activity against
CC   eukaryotic pathogens or retroviruses. They can be used for treating
CC   conditions including e.g., ulcerative colitis, Crohn's disease,
CC   inflammatory bowel disease or undue cellular proliferation. The
CC   compositions can enhance the local and systemic uptake and delivery of
CC   nucleic acids via non-parenteral routes of administration (e.g., via the
CC   alimentary canal, skin, eyes, pulmonary tract, urethra or vagina)
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1412
AAZ99357
ID   AAZ99357 standard; DNA; 18 BP.
XX
AC   AAZ99357;
XX
DT   03-JUL-2000  (first entry)
XX
DE   Binding/non-binding domain of PTM construct PTM+Sp (targeted).
XX
KW   Pre-mRNA molecule; gene repair; pre-trans-splicing molecule;
KW   gene regulation; targeted cell death;
KW   cystic fibrosis trans-membrane regulator gene; ss.
XX
OS   Synthetic.
XX
PN   WO200009734-A2.
XX
PD   24-FEB-2000.
XX
PF   12-AUG-1999;   99WO-US018371.
XX
PR   13-AUG-1998;   98US-00133717.
PR   23-SEP-1998;   98US-00158863.
XX
PA   (INTR-) INTRONN HOLDINGS LLC.
XX
PI   Mitchell LG,  Garcia-Blanco MA;
XX
DR   WPI; 2000-224360/19.
XX
PT   Novel pre-trans-splicing molecules for use in gene regulation, gene
PT   repair and targeted cell death particularly gene repair of cystic
PT   fibrosis trans-membrane regulator gene.
XX
PS   Example 6; Page 30; 79pp; English.
XX
CC   The present sequence represents a binding/non-binding domain of a PTM
CC   construct of the invention. The specification describes a pre-trans-
CC   splicing molecule (PTM) which contains one or more target binding
CC   domains, a 3' splice region comprising a branch point, a pyrimidine tract
CC   and a 3' splice acceptor site, a spacer region separating the mRNA splice
CC   region from the target binding domain, and a nucleotide sequence to be
CC   trans-spliced. The method is used for the in vivo production of a trans-
CC   spliced molecule in a subset of cells. The PTM is used for producing
CC   chimeric mRNA molecule by contacting it with target pre mRNA which is
CC   useful for gene regulation, gene repair and targeted cell death
CC   particularly repair of cystic fibrosis trans-membrane regulator gene
XX
SQ   Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| |||||||  ||||
Db          1 TGCTTCACCCGGGCCTG 17


RESULT 1413
AAZ99359
ID   AAZ99359 standard; DNA; 18 BP.
XX
AC   AAZ99359;
XX
DT   03-JUL-2000  (first entry)
XX
DE   Binding/non-binding domain of PTM construct PTM+Py(-)AG(-)BP(-).
XX
KW   Pre-mRNA molecule; gene repair; pre-trans-splicing molecule;
KW   gene regulation; targeted cell death;
```

KW cystic fibrosis trans-membrane regulator gene; ss.
XX
OS Synthetic.
XX
PN WO200009734-A2.
XX
PD 24-FEB-2000.
XX
PF 12-AUG-1999; 99WO-US018371.
XX
PR 13-AUG-1998; 98US-00133717.
PR 23-SEP-1998; 98US-00158863.
XX
PA (INTR-) INTRONN HOLDINGS LLC.
XX
PI Mitchell LG, Garcia-Blanco MA;
XX
DR WPI; 2000-224360/19.
XX
PT Novel pre-trans-splicing molecules for use in gene regulation, gene
PT repair and targeted cell death particularly gene repair of cystic
PT fibrosis trans-membrane regulator gene.
XX
PS Example 6; Page 30; 79pp; English.
XX
CC The present sequence represents a binding/non-binding domain of a PTM
CC construct of the invention. The specification describes a pre-trans-
CC splicing molecule (PTM) which contains one or more target binding
CC domains, a 3' splice region comprising a branch point, a pyrimidine tract
CC and a 3' splice acceptor site, a spacer region separating the mRNA splice
CC region from the target binding domain, and a nucleotide sequence to be
CC trans-spliced. The method is used for the in vivo production of a trans-
CC spliced molecule in a subset of cells. The PTM is used for producing
CC chimeric mRNA molecule by contacting it with target pre mRNA which is
CC useful for gene regulation, gene repair and targeted cell death
CC particularly repair of cystic fibrosis trans-membrane regulator gene
XX
SQ Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 TGCATCACCCGCCCCTG 1678
||| ||||||| ||||
Db 1 TGCTTCACCCGGGCCTG 17

RESULT 1414
AAZ99360
ID AAZ99360 standard; DNA; 18 BP.
XX
AC AAZ99360;
XX
DT 03-JUL-2000 (first entry)
XX
DE Binding/non-binding domain of PTM construct PTM+Py(-)AG(-).
XX
KW Pre-mRNA molecule; gene repair; pre-trans-splicing molecule;
KW gene regulation; targeted cell death;
KW cystic fibrosis trans-membrane regulator gene; ss.
XX
OS Synthetic.
XX
PN WO200009734-A2.
XX
PD 24-FEB-2000.
XX
PF 12-AUG-1999; 99WO-US018371.
XX
PR 13-AUG-1998; 98US-00133717.
PR 23-SEP-1998; 98US-00158863.
XX
PA (INTR-) INTRONN HOLDINGS LLC.
XX
PI Mitchell LG, Garcia-Blanco MA;
XX
DR WPI; 2000-224360/19.
XX
PT Novel pre-trans-splicing molecules for use in gene regulation, gene
PT repair and targeted cell death particularly gene repair of cystic
PT fibrosis trans-membrane regulator gene.
XX
PS Example 6; Page 30; 79pp; English.
XX
CC The present sequence represents a binding/non-binding domain of a PTM
CC construct of the invention. The specification describes a pre-trans-
CC splicing molecule (PTM) which contains one or more target binding
CC domains, a 3' splice region comprising a branch point, a pyrimidine tract
CC and a 3' splice acceptor site, a spacer region separating the mRNA splice
CC region from the target binding domain, and a nucleotide sequence to be
CC trans-spliced. The method is used for the in vivo production of a trans-
CC spliced molecule in a subset of cells. The PTM is used for producing
CC chimeric mRNA molecule by contacting it with target pre mRNA which is
CC useful for gene regulation, gene repair and targeted cell death
CC particularly repair of cystic fibrosis trans-membrane regulator gene
XX
SQ Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 TGCATCACCCGCCCCTG 1678
||| ||||||| ||||
Db 1 TGCTTCACCCGGGCCTG 17

RESULT 1415
AAC73474
ID AAC73474 standard; DNA; 18 BP.
XX
AC AAC73474;
XX
DT 02-FEB-2001 (first entry)
XX
DE Reverse primer #101 used in multiplexing PCR/SBE assay.
XX
KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX
OS Unidentified.
XX
PN WO200058516-A2.
XX
PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
DR WPI; 2000-656171/63.
XX
PT Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
PS Example 7; Page 58; 70pp; English.
XX

```
CC   The present invention relates to an oligonucleotide array comprising
CC   oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC   array is useful for genotyping a nucleic acid sample at one or more loci
CC   via single base extension (SBE) reactions. A pair of primers is used to
CC   amplify a polymorphic locus in a sample e.g. a single nucleotide
CC   polymorphism (SNP). The present sequence is one of the primers used in
CC   the method of the present invention to amplify a polymorphic sample. The
CC   amplified nucleic acid product is then used as a template in a SBE
CC   reaction with an extension primer. The SBE reaction products are used to
CC   form the oligonucleotide array
XX
SQ   Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGAAC 1598
              || |  ||||||||||
Db          1 CCTCCGAGACTGGGAAC 17


RESULT 1416
AAC73430/c
ID   AAC73430 standard; DNA; 18 BP.
XX
AC   AAC73430;
XX
DT   02-FEB-2001  (first entry)
XX
DE   Reverse primer #90 used in multiplexing PCR/SBE assay.
XX
KW   Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW   PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX
OS   Unidentified.
XX
PN   WO200058516-A2.
XX
PD   05-OCT-2000.
XX
PF   27-MAR-2000; 2000WO-US008069.
XX
PR   26-MAR-1999;  99US-0126473P.
PR   23-JUN-1999;  99US-0140359P.
XX
PA   (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA   (AFFY-) AFFYMETRIX INC.
XX
PI   Fan J,  Hirschhorn JN,  Huang X,  Kaplan P,  Lander ES,  Lockhart DJ;
PI   Ryder T,  Sklar P;
XX
DR   WPI; 2000-656171/63.
XX
PT   Universal array of oligonucleotides tags attached to a solid substrate
PT   along with locus-specific tagged oligonucleotides useful in genotyping
PT   using single base extension reactions.
XX
PS   Example 7; Page 57; 70pp; English.
XX
CC   The present invention relates to an oligonucleotide array comprising
CC   oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC   array is useful for genotyping a nucleic acid sample at one or more loci
CC   via single base extension (SBE) reactions. A pair of primers is used to
CC   amplify a polymorphic locus in a sample e.g. a single nucleotide
CC   polymorphism (SNP). The present sequence is one of the primers used in
CC   the method of the present invention to amplify a polymorphic sample. The
CC   amplified nucleic acid product is then used as a template in a SBE
CC   reaction with an extension primer. The SBE reaction products are used to
CC   form the oligonucleotide array
XX
SQ   Sequence 18 BP; 2 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACAG 1589
              | | |||||| |||||
Db         18 CATGCTCCACAGCACAG 2


RESULT 1417
AAH61745/c
ID   AAH61745 standard; DNA; 18 BP.
XX
AC   AAH61745;
XX
DT   10-SEP-2001  (first entry)
XX
DE   Cdc 2 kinase hammerhead ribozyme recognition site SEQ ID NO:4169.
XX
KW   Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW   recognition site; target; ribozyme binding site; eye disease; vulnerary;
KW   proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW   cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW   matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW   antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW   antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW   atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW   basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW   sickle cell retinopathy; ss.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200130362-A2.
XX
PD   03-MAY-2001.
XX
PF   26-OCT-2000; 2000WO-US029500.
XX
PR   26-OCT-1999;  99US-0161532P.
XX
PA   (IMMU-) IMMUSOL INC.
XX
PI   Robbins JM,  Tritz R;
XX
DR   WPI; 2001-300427/31.
XX
PT   Treating proliferative skin or eye diseases and scarring, using ribozymes
PT   that cleave RNA encoding cytokines involved in inflammation, matrix
PT   metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS   Disclosure; Page 376; 408pp; English.
XX
CC   The present invention describes a method for treating a proliferative
CC   skin or eye disease and scarring. The method involves administering a
CC   ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC   inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC   dependent kinase, growth factor or a reductase, or administering a
CC   nucleic acid molecule (II) comprising a promoter operably linked to a
CC   nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC   dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC   ophthalmological, vulnerary, keratolytic and virucide activities, and
CC   cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC   in gene therapy. (I) and (II) are useful for treating proliferative skin
CC   diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC   squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC   also be used for treating proliferative eye diseases such as diabetic
CC   retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC   prematurity and retinal detachment, and for treating and preventing
CC   scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC   scar. AAH57577 to AAH62099 represent sequences used in the
CC   exemplification of the present invention
XX
```

```
SQ   Sequence 18 BP; 7 A; 5 C; 1 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2059 TAGTTAATAAGTGGTAT 2075
              |||||| | | ||||||
Db         18 TAGTTAGTCAATGGTAT 2


RESULT 1418
ABK24076
ID   ABK24076 standard; DNA; 18 BP.
XX
AC   ABK24076;
XX
DT   09-APR-2002  (first entry)
XX
DE   B7-related protein, BSL3, PCR primer #9.
XX
KW   Human; immunosuppressive; antirheumatic; antiarthritic; antiulcer;
KW   antianaemic; antipsoriatic; B7-related polypeptide; BSL1; BSL2; BSL3;
KW   autoimmune disease; rheumatoid arthritis; multiple sclerosis;
KW   Hashimoto's thyroiditis; Graves' disease; Crohn's disease; psoriasis;
KW   ulcerative colitis; pernicious anaemia; bone marrow transplantation;
KW   graft versus host disease; organ transplantation; PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   WO200194413-A2.
XX
PD   13-DEC-2001.
XX
PF   06-JUN-2001; 2001WO-US018257.
XX
PR   06-JUN-2000; 2000US-0209811P.
PR   28-FEB-2001; 2001US-0272107P.
XX
PA   (BRIM ) BRISTOL-MYERS SQUIBB CO.
XX
PI   Mikesell GE,  Chang H,  Finger JN,  Yang G,  Lu P,  Zhou X,  Peach R;
XX
DR   WPI; 2002-090141/12.
XX
PT   Nucleic acids encoding B7-related polypeptides, i.e. BSL1, BSL2, or BSL3
PT   polypeptides, useful for treating autoimmune diseases (e.g. rheumatoid
PT   arthritis, multiple sclerosis, and psoriasis), and graft versus host
PT   disease.
XX
PS   Example 5; Page 114; 179pp; English.
XX
CC   The invention relates to novel nucleic acids encoding B7-related
CC   polypeptides. The B7-related polypeptides include the BSL1, BSL2, or BSL3
CC   polypeptides, or their soluble fragments. The nucleic acid, polypeptide,
CC   and antibodies are useful for treating autoimmune diseases (e.g.
CC   rheumatoid arthritis, multiple sclerosis, Hashimoto's thyroiditis,
CC   Graves' disease, Crohn's disease, ulcerative colitis, pernicious anaemia
CC   and psoriasis. They may also be used to treat tissue, bone marrow, and
CC   organ transplantation, and graft versus host disease. ABK24010-ABK24093
CC   represent B7-related proteins, BSL1, BSL2 and BSL3 coding sequences and
CC   PCR primers of the invention
XX
SQ   Sequence 18 BP; 5 A; 3 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1797 CTTCTCTGAAAGTGGTG 1813
              ||| ||||||| || ||
Db          2 CTTATCTGAAATTGCTG 18


RESULT 1419
ABL43686/c
ID   ABL43686 standard; DNA; 18 BP.
XX
AC   ABL43686;
XX
DT   11-APR-2002  (first entry)
XX
DE   Human chromosome 1p36-35 PCR primer SEQ ID NO:730.
XX
KW   Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP2001321190-A.
XX
PD   20-NOV-2001.
XX
PF   12-MAR-2001; 2001JP-00068285.
XX
PR   10-MAR-2000; 2000JP-00066716.
XX
PA   (RIKA ) RIKAGAKU KENKYUSHO.
PA   (GENO-) GENOTEX YG.
XX
DR   WPI; 2002-144136/19.
XX
PT   Arraying genome clones.
XX
PS   Claim 4; Page 19; 528pp; Japanese.
XX
CC   The present invention describes a method of arraying genome clones. The
CC   method comprises: (a) clones of the genomic libraries contained in
CC   multiwell plates numbered for discrimination are mixed in each of the
CC   multiwell plates; (b) a primer designed based on the chromosome marker
CC   sequence is added to the mixture to carry out an amplification reaction;
CC   (c) a signal corresponding to the marker is detected from the resultant
CC   amplified product to specify the discrimination Nos. of the multiwell
CC   plates containing the clones having said marker sequence; (d) the order
CC   of the markers is changed so that the same discrimination Nos. succeed to
CC   the maximum in the specified discrimination Nos. to array the multiwell
CC   plates; (e) the clones in the multiwell plates of the specified
CC   discrimination Nos. are mixed respectively in each wells of longitudinal
CC   and lateral directions; (f) the mixed clones are cultured and the
CC   resultant cultures are amplified by using the above primer; (g) signals
CC   are detected from the amplified products; (h) the clones in the multiwell
CC   plates are specified from the detected result; and (i) the clones are
CC   reconstituted as the positions on the chromosome and arrayed. The
CC   microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC   PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC   represent PCR primers for human chromosome 21q22.1, which are
CC   specifically claimed for use in the present invention
XX
SQ   Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1589 GACTGGGAACCCCTCCT 1605
              |||||||| ||| | ||
Db         17 GACTGGGATCCCTTGCT 1


RESULT 1420
ABL44451/c
ID   ABL44451 standard; DNA; 18 BP.
XX
AC   ABL44451;
XX
DT   11-APR-2002  (first entry)
```

```
XX
DE   Human chromosome 1p36-35 PCR primer SEQ ID NO:1495.
XX
KW   Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW   PCR primer; ss.
XX
OS   Homo sapiens.
XX
PN   JP2001321190-A.
XX
PD   20-NOV-2001.
XX
PF   12-MAR-2001; 2001JP-00068285.
XX
PR   10-MAR-2000; 2000JP-00066716.
XX
PA   (RIKA ) RIKAGAKU KENKYUSHO.
PA   (GENO-) GENOTEX YG.
XX
DR   WPI; 2002-144136/19.
XX
PT   Arraying genome clones.
XX
PS   Claim 4; Page 34; 528pp; Japanese.
XX
CC   The present invention describes a method of arraying genome clones. The
CC   method comprises: (a) clones of the genomic libraries contained in
CC   multiwell plates numbered for discrimination are mixed in each of the
CC   multiwell plates; (b) a primer designed based on the chromosome marker
CC   sequence is added to the mixture to carry out an amplification reaction;
CC   (c) a signal corresponding to the marker is detected from the resultant
CC   amplified product to specify the discrimination Nos. of the multiwell
CC   plates containing the clones having said marker sequence; (d) the order
CC   of the markers is changed so that the same discrimination Nos. succeed to
CC   the maximum in the specified discrimination Nos. to array the multiwell
CC   plates; (e) the clones in the multiwell plates of the specified
CC   discrimination Nos. are mixed respectively in each wells of longitudinal
CC   and lateral directions; (f) the mixed clones are cultured and the
CC   resultant cultures are amplified by using the above primer; (g) signals
CC   are detected from the amplified products; (h) the clones in the multiwell
CC   plates are specified from the detected result; and (i) the clones are
CC   reconstituted as the positions on the chromosome and arrayed. The
CC   microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC   PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC   represent PCR primers for human chromosome 21q22.1, which are
CC   specifically claimed for use in the present invention
XX
SQ   Sequence 18 BP; 1 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1546 GTAGGGAAGGAACAGGA 1562
              |||||| || | |||||
Db         17 GTAGGGCAGAAGCAGGA 1


RESULT 1421
AAL46988/c
ID   AAL46988 standard; DNA; 18 BP.
XX
AC   AAL46988;
XX
DT   15-AUG-2002  (first entry)
XX
DE   Sponge okadaic acid combining protein related PCR primer #10.
XX
KW   Sponge; okadaic acid combining protein; protein dephosphorylase 1;
KW   protein dephosphorylase 2A; okadaic acid; cytotoxicity inactivation; PCR;
KW   primer; ss.
XX
OS   Unidentified.
XX
PN   JP2002101886-A.
XX
PD   09-APR-2002.
XX
PF   28-SEP-2000; 2000JP-00297436.
XX
PR   28-SEP-2000; 2000JP-00297436.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2002-440456/47.
XX
PT   A new protein combining with Okadaic acid and its gene, has no enzymatic
PT   activity of protein dephosphorylase 1 and 2A.
XX
PS   Example 3; Page 8; 12pp; Japanese.
XX
CC   The present invention relates to a protein having combinability to
CC   Okadaic acid and having substantially no enzymatic activity of protein
CC   dephosphorylase 1 and 2A. The protein is useful as a drug for
CC   inactivating cytotoxicity of a substance enzymatic activity-inhibiting
CC   activity such as Okadaic acid. The present sequence is a PCR primer
CC   described in the exemplification of the invention
XX
SQ   Sequence 18 BP; 4 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCAAG 2019
              |||||||| ||| || |
Db         18 CTTCTTCACAGACCAGG 2


RESULT 1422
ABQ73424
ID   ABQ73424 standard; DNA; 18 BP.
XX
AC   ABQ73424;
XX
DT   02-OCT-2002  (first entry)
XX
DE   Pre-trans-splicing molecule related BD/NBD oligonucleotide #3.
XX
KW   Pre-trans-splicing molecule; PTM; spliceosome; cytostatic; gene therapy;
KW   immunosuppressive; antimicrobial; gene regulation; gene repair; cancer;
KW   targeted cell death; genetic disorder; infectious disorder;
KW   autoimmune disease; proliferative disorder; PCR primer; ss.
XX
OS   Synthetic.
XX
PN   WO200253581-A2.
XX
PD   11-JUL-2002.
XX
PF   08-JAN-2002; 2002WO-US000416.
XX
PR   08-JAN-2001; 2001US-00756095.
PR   08-JAN-2001; 2001US-00756096.
PR   08-JAN-2001; 2001US-00756097.
PR   20-APR-2001; 2001US-00838858.
PR   29-AUG-2001; 2001US-00941492.
XX
PA   (INTR-) INTRONN INC.
XX
PI   Mitchell LG,  Garcia-Blanco MA,  Baker CC,  Puttaraju M;
PI   Mansfield GS,  Chao H;
XX
DR   WPI; 2002-566693/60.
XX
PT   Novel cell having pre-trans-splicing molecules with target binding
```

PT domains that target binding of PTM to pre-mRNA, 3' or 5' splice region,
PT spacer region, nucleotide sequence to be trans-spliced to target-pre-
PT mRNA.
XX
PS Example; Page 41; 229pp; English.
XX
CC The present invention describes a cell (I) comprising pre-trans-splicing
CC molecules (PTMs) (II) which have one or more target binding domains (IIa)
CC that target binding of PTM to pre-mRNA, 3' splice region (IIb) that
CC includes branch point pyrimidine tract and 3'splice acceptor site, or 5'
CC splice site (IIc), spacer region (IId) that separates RNA splice site
CC from target binding domain, and nucleotide sequence to (IIe) be trans-
CC spliced to target-pre-mRNA. Optionally, the cell comprises (II) either
CC comprising: (A) (IIb) and (IIe); or (B) (IIc), (IId) and (IIe). The cell
CC may comprise a recombinant vector expressing (II). (I) has cytostatic,
CC immunosuppressive and antimicrobial activities, and can be used in gene
CC therapy. (II) comprising one or more (preferably two or more) (IIa) and
CC (IIb) (or (IIc)), (IId) and (IIe), or (II) comprising either (A) or (B)
CC (excluding (IId)), is useful for producing a chimeric RNA molecule in a
CC cell which involves contacting a target pre-mRNA expressed in the cell
CC with (II) that is recognised by nuclear splicing components. The chimeric
CC RNA produced comprises sequences encoding a toxin or translatable
CC protein. The nucleotide sequence to be trans-spliced to target pre-mRNA
CC preferably comprises nucleotide sequences comprising exons 1-10 of cystic
CC fibrosis trans-membrane conductance regulator (CFTR). The chimeric RNA
CC molecule produced using (II) which either comprises (A) or (B) further
CC comprises a nucleotide sequence tag. (I) can be used for gene regulation,
CC gene repair and targeted cell death. (I) can be used for the treatment of
CC various diseases including genetic, infectious or autoimmune diseases and
CC proliferative disorders such as cancer and to regulate gene expression in
CC plants. ABQ73414 to ABQ73536 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 TGCATCACCCGCCCCTG 1678
||| ||||||| ||||
Db 1 TGCTTCACCCGGGCCTG 17

RESULT 1423
ABQ73425
ID ABQ73425 standard; DNA; 18 BP.
XX
AC ABQ73425;
XX
DT 02-OCT-2002 (first entry)
XX
DE Pre-trans-splicing molecule related BD/NBD oligonucleotide #4.
XX
KW Pre-trans-splicing molecule; PTM; spliceosome; cytostatic; gene therapy;
KW immunosuppressive; antimicrobial; gene regulation; gene repair; cancer;
KW targeted cell death; genetic disorder; infectious disorder;
KW autoimmune disease; proliferative disorder; PCR primer; ss.
XX
OS Synthetic.
XX
PN WO200253581-A2.
XX
PD 11-JUL-2002.
XX
PF 08-JAN-2002; 2002WO-US000416.
XX
PR 08-JAN-2001; 2001US-00756095.
PR 08-JAN-2001; 2001US-00756096.
PR 08-JAN-2001; 2001US-00756097.
PR 20-APR-2001; 2001US-00838858.
PR 29-AUG-2001; 2001US-00941492.
XX
PA (INTR-) INTRONN INC.
XX
PI Mitchell LG, Garcia-Blanco MA, Baker CC, Puttaraju M;
PI Mansfield GS, Chao H;
XX
DR WPI; 2002-566693/60.
XX
PT Novel cell having pre-trans-splicing molecules with target binding
PT domains that target binding of PTM to pre-mRNA, 3' or 5' splice region,
PT spacer region, nucleotide sequence to be trans-spliced to target-pre-
PT mRNA.
XX
PS Example; Page 41; 229pp; English.
XX
CC The present invention describes a cell (I) comprising pre-trans-splicing
CC molecules (PTMs) (II) which have one or more target binding domains (IIa)
CC that target binding of PTM to pre-mRNA, 3' splice region (IIb) that
CC includes branch point pyrimidine tract and 3'splice acceptor site, or 5'
CC splice site (IIc), spacer region (IId) that separates RNA splice site
CC from target binding domain, and nucleotide sequence to (IIe) be trans-
CC spliced to target-pre-mRNA. Optionally, the cell comprises (II) either
CC comprising: (A) (IIb) and (IIe); or (B) (IIc), (IId) and (IIe). The cell
CC may comprise a recombinant vector expressing (II). (I) has cytostatic,
CC immunosuppressive and antimicrobial activities, and can be used in gene
CC therapy. (II) comprising one or more (preferably two or more) (IIa) and
CC (IIb) (or (IIc)), (IId) and (IIe), or (II) comprising either (A) or (B)
CC (excluding (IId)), is useful for producing a chimeric RNA molecule in a
CC cell which involves contacting a target pre-mRNA expressed in the cell
CC with (II) that is recognised by nuclear splicing components. The chimeric
CC RNA produced comprises sequences encoding a toxin or translatable
CC protein. The nucleotide sequence to be trans-spliced to target pre-mRNA
CC preferably comprises nucleotide sequences comprising exons 1-10 of cystic
CC fibrosis trans-membrane conductance regulator (CFTR). The chimeric RNA
CC molecule produced using (II) which either comprises (A) or (B) further
CC comprises a nucleotide sequence tag. (I) can be used for gene regulation,
CC gene repair and targeted cell death. (I) can be used for the treatment of
CC various diseases including genetic, infectious or autoimmune diseases and
CC proliferative disorders such as cancer and to regulate gene expression in
CC plants. ABQ73414 to ABQ73536 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1662 TGCATCACCCGCCCCTG 1678
||| ||||||| ||||
Db 1 TGCTTCACCCGGGCCTG 17

RESULT 1424
ABQ73422
ID ABQ73422 standard; DNA; 18 BP.
XX
AC ABQ73422;
XX
DT 02-OCT-2002 (first entry)
XX
DE Pre-trans-splicing molecule related BD/NBD oligonucleotide #1.
XX
KW Pre-trans-splicing molecule; PTM; spliceosome; cytostatic; gene therapy;
KW immunosuppressive; antimicrobial; gene regulation; gene repair; cancer;
KW targeted cell death; genetic disorder; infectious disorder;
KW autoimmune disease; proliferative disorder; PCR primer; ss.
XX
OS Synthetic.
XX
PN WO200253581-A2.
XX
PD 11-JUL-2002.
XX

```
PF   08-JAN-2002; 2002WO-US000416.
XX
PR   08-JAN-2001; 2001US-00756095.
PR   08-JAN-2001; 2001US-00756096.
PR   08-JAN-2001; 2001US-00756097.
PR   20-APR-2001; 2001US-00838858.
PR   29-AUG-2001; 2001US-00941492.
XX
PA   (INTR-) INTRONN INC.
XX
PI   Mitchell LG, Garcia-Blanco MA, Baker CC, Puttaraju M;
PI   Mansfield GS, Chao H;
XX
DR   WPI; 2002-566693/60.
XX
PT   Novel cell having pre-trans-splicing molecules with target binding
PT   domains that target binding of PTM to pre-mRNA, 3' or 5' splice region,
PT   spacer region, nucleotide sequence to be trans-spliced to target-pre-
PT   mRNA.
XX
PS   Example; Page 41; 229pp; English.
XX
CC   The present invention describes a cell (I) comprising pre-trans-splicing
CC   molecules (PTMs) (II) which have one or more target binding domains (IIa)
CC   that target binding of PTM to pre-mRNA, 3' splice region (IIb) that
CC   includes branch point pyrimidine tract and 3'splice acceptor site, or 5'
CC   splice site (IIc), spacer region (IId) that separates RNA splice site
CC   from target binding domain, and nucleotide sequence to (IIe) be trans-
CC   spliced to target-pre-mRNA. Optionally, the cell comprises (II) either
CC   comprising: (A) (IIb) and (IIe); or (B) (IIc), (IId) and (IIe). The cell
CC   may comprise a recombinant vector expressing (II). (I) has cytostatic,
CC   immunosuppressive and antimicrobial activities, and can be used in gene
CC   therapy. (II) comprising one or more (preferably two or more) (IIa) and
CC   (IIb) (or (IIc)), (IId) and (IIe), or (II) comprising either (A) or (B)
CC   (excluding (IId)), is useful for producing a chimeric RNA molecule in a
CC   cell which involves contacting a target pre-mRNA expressed in the cell
CC   with (II) that is recognised by nuclear splicing components. The chimeric
CC   RNA produced comprises sequences encoding a toxin or translatable
CC   protein. The nucleotide sequence to be trans-spliced to target pre-mRNA
CC   preferably comprises nucleotide sequences comprising exons 1-10 of cystic
CC   fibrosis trans-membrane conductance regulator (CFTR). The chimeric RNA
CC   molecule produced using (II) which either comprises (A) or (B) further
CC   comprises a nucleotide sequence tag. (I) can be used for gene regulation,
CC   gene repair and targeted cell death. (I) can be used for the treatment of
CC   various diseases including genetic, infectious or autoimmune diseases and
CC   proliferative disorders such as cancer and to regulate gene expression in
CC   plants. ABQ73414 to ABQ73536 represent sequences used in the
CC   exemplification of the present invention
XX
SQ   Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| ||||||| ||||
Db          1 TGCTTCACCCGGGCCTG 17


RESULT 1425
ABK98126/c
ID   ABK98126 standard; DNA; 18 BP.
XX
AC   ABK98126;
XX
DT   07-OCT-2002  (first entry)
XX
DE   Triple helix forming associated oligonucleotide #15.
XX
KW   Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW   gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW   pathogenic bacteria; virus; replication; virulence; cancer;
KW   oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
OS   Synthetic.
XX
PN   US6403302-B1.
XX
PD   11-JUN-2002.
XX
PF   16-DEC-1993;   93US-00168920.
XX
PR   17-SEP-1992;   92US-00946976.
XX
PA   (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX
PI   Dervan PB, Beal PA;
XX
DR   WPI; 2002-536030/57.
XX
PT   A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT   oligonucleotide which binds in parallel and antiparallel orientation,
PT   respectively, for targetting sequences on alternate strands of DHNA to
PT   control gene expression.
XX
PS   Example 7; Col 41; 108pp; English.
XX
CC   The present invention relates to methods and oligonucleotides for forming
CC   a triple-helix comprising a double helical nucleic acid comprising first
CC   and second substantially complementary strands, and an oligonucleotide
CC   bound to a purine-rich target sequence within the double helical nucleic
CC   acid, where the oligonucleotide binds in a parallel and antiparallel
CC   orientation, respectively, to target sequences on alternate strands of
CC   the double helical nucleic acid. The method has therapeutic applications,
CC   where gene expression is controlled by selective triple-helix formation
CC   within expression regulatory sequences of a target gene. The
CC   oligonucleotides can be used to form triple-helices, and are useful to
CC   detect the presence or absence of specific sequences within genomic DNA
CC   for diagnostic and therapeutic purposes. The oligonucleotides can be
CC   selected to specifically bind to pathogenic double-stranded DNA including
CC   specific sequences required by pathogenic bacteria or viruses for
CC   replication or virulence, reducing their pathogenicity. Alternatively,
CC   the oligonucleotide can be chosen to target a unique sequence of the
CC   pathogen which is not found in the genome of pathogen's host. The
CC   oligonucleotides can be used in cancer treatment by way of triple-helix
CC   suppression of specific oncogenes including those of endogenous or viral
CC   origin. Such therapeutic oligonucleotides are capable of forming triple-
CC   helices with such sequences in cancerous cells containing the activated
CC   oncogene, so preferentially killing or repressing the cancer causing
CC   cell. The present sequence represents an oligonucleotide used in the
CC   methods of the present invention
XX
SQ   Sequence 18 BP; 0 A; 2 C; 0 G; 14 T; 0 U; 2 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   92.3%;  Pred. No. 6.5e+02;
  Matches   12;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1978 GAAAAAAAGAAAA 1990
              ||||||:||||||
Db         17 GAAAAAHAGAAAA 5


RESULT 1426
ABZ10618
ID   ABZ10618 standard; DNA; 18 BP.
XX
AC   ABZ10618;
XX
DT   16-JAN-2003  (first entry)
XX
DE   Haematopoietic cell proliferation disorder related oligonucleotide #758.
XX
KW   Human; haematopoietic cell proliferation disorder; cytostatic;
KW   gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
```

KW cytosine methylation state; probe; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200277272-A2.
XX
PD 03-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-EP003401.
XX
PR 26-MAR-2001; 2001US-0278333P.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
PI Schwope I, Ziebarth H;
XX
DR WPI; 2003-018942/01.
XX
PT Detecting and differentiating between hematopoietic cell proliferative
PT disorders, comprises contacting a target nucleic acid with a reagent that
PT distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS Claim 15; Page 53; 117pp; English.
XX
CC The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related DNA
CC sequences. The nucleotide sequences from the present invention can also
CC be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables a
CC highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients
XX
SQ Sequence 18 BP; 3 A; 0 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1925 TTTTTCAGTGTTAAGGT 1941
|||| ||||||| |||
Db 1 TTTTAGAGTGTTAGGGT 17

RESULT 1427
ABZ10514
ID ABZ10514 standard; DNA; 18 BP.
XX
AC ABZ10514;
XX
DT 16-JAN-2003 (first entry)
XX
DE Haematopoietic cell proliferation disorder related oligonucleotide #654.
XX
KW Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200277272-A2.
XX
PD 03-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-EP003401.
XX
PR 26-MAR-2001; 2001US-0278333P.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
PI Schwope I, Ziebarth H;
XX
DR WPI; 2003-018942/01.
XX
PT Detecting and differentiating between hematopoietic cell proliferative
PT disorders, comprises contacting a target nucleic acid with a reagent that
PT distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS Claim 15; Page 47; 117pp; English.
XX
CC The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related DNA
CC sequences. The nucleotide sequences from the present invention can also
CC be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables a
CC highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients
XX
SQ Sequence 18 BP; 6 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1821 TTTTAGAATCTTTTAAA 1837
| ||||| | |||||||
Db 1 TATTAGAGTGTTTTAAA 17

RESULT 1428
ABZ10868
ID ABZ10868 standard; DNA; 18 BP.
XX
AC ABZ10868;
XX
DT 16-JAN-2003 (first entry)
XX
DE Haematopoietic cell proliferation disorder related oligonucleotide #1008.
XX

KW Human; haematopoietic cell proliferation disorder; cytostatic;
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
KW cytosine methylation state; probe; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200277272-A2.
XX
PD 03-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-EP003401.
XX
PR 26-MAR-2001; 2001US-0278333P.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
PI Schwope I, Ziebarth H;
XX
DR WPI; 2003-018942/01.
XX
PT Detecting and differentiating between hematopoietic cell proliferative
PT disorders, comprises contacting a target nucleic acid with a reagent that
PT distinguishes between methylated and non-methylated CpG dinucleotides.
XX
PS Claim 15; Page 67; 117pp; English.
XX
CC The present invention describes a method for detecting and
CC differentiating between haematopoietic cell proliferative disorders
CC associated with at least 1 gene and/or their regulatory regions in a
CC subject. The method comprises contacting a target nucleic acid in a
CC biological sample obtained from the subject with at least 1 reagent,
CC which distinguishes between methylated and non-methylated CpG
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
CC represent specifically claimed nucleotide sequences from the present
CC invention. Oligonucleotides from the present invention can be used: for
CC differentiating between healthy haematopoietic cells and proliferative
CC disorder haematopoietic cells; for differentiating between acute
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
CC determining the cytosine methylation state and/or single nucleotide
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
CC related sequences and their complements; and as primers for the
CC amplification of haematopoietic cell proliferation disorder related DNA
CC sequences. The nucleotide sequences from the present invention can also
CC be used for detecting a predisposition to, differentiation between
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
CC haematopoietic cell proliferative disorders. The present method enables a
CC highly specific classification of haematopoietic cell proliferative
CC disorders allowing for improved and informed treatment of patients
XX
SQ Sequence 18 BP; 5 A; 0 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1922 TTTTTTTTCAGTGTTAA 1938
              | |||||| ||| ||||
Db          2 TATTTTTTGAGTTTTAA 18
```

RESULT 1429
ADA83712
ID ADA83712 standard; DNA; 18 BP.
XX
AC ADA83712;
XX
DT 20-NOV-2003 (first entry)
XX
DE Filament forming bacteria detecting probe SEQ ID 31.
XX
KW ss; probe; hybridisation; detection; filamentous bacteria cell;
KW activated sludge.
XX
OS Chloroflexaceae.
XX
PN DE10128400-A1.
XX
PD 19-DEC-2002.
XX
PF 12-JUN-2001; 2001DE-01028400.
XX
PR 12-JUN-2001; 2001DE-01028400.
XX
PA (VERM-) VERMICON AG.
XX
PI Snaidr J, Beimfohr C;
XX
DR WPI; 2003-314735/31.
XX
PT New oligonucleotides are useful to detect filamentous bacteria in
PT samples, particularly in activated sludge.
XX
PS Claim 1; Page 24; 26pp; German.
XX
CC This invention describes a novel oligonucleotide which hybridises with
CC and detects a nucleic acid from a filamentous bacteria cell. The
CC filamentous bacteria can include members of the 021N Kanagawa group I, II
CC or III, 021N-like from BIO33 EU21, Alisphaera europaea EU24 Nostocoida
CC limicola-like, Alisphaera (europaea, PPx3, MC2), Alisphaera MC2 MACOBS-
CC Clone 2 (BIO 36), Bactothrix amylovora (EU3, EU4, EU8, EU9, EU11),
CC Chloroflexus aurantiacus, Curtrnema variabilis (type 0041), Cytophaga,
CC EPTS Australian 021N isolate (EU21), EPTS Australian isolate EU23 from
CC SAN3, Flexibacter, Herpetosiphon, H. aurantiacus, Leptothrix discophora,
CC Megathrix sidereus EU26 Nostocoida/021N-like, M. tenacis (WU12, EU5, EU6,
CC EU15, EU13, EU14 EU1, EU10, EU2), Nostocoida limicolasne (EU24),
CC Nostocoida limicola-like Rhodobacter sphaeroidessne, Thiothrix 021N-
CC group, Thiothrix ramose, Type 0411 (CF) and Type 0803. When detecting
CC filamentous bacteria the oligonucleotide is preferably coupled with a
CC fluorescent, chemiluminescent, radioactive, enzymatic or hapten marker.
CC Detection is by epiflourescence microscopy or flow cytometry. The
CC invention is used to detect filamentous bacteria in a sample,
CC particularly in activated sludge. ADA83682-ADA83723 represent
CC oligonucleotide probes used in the detection method of the invention.
XX
SQ Sequence 18 BP; 3 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1661 CTGCATCACCCGCCCCT 1677
              ||||| |||| |||||
Db          2 CTGCACCACCGACCCCT 18
```

RESULT 1430
ABZ81503/c
ID ABZ81503 standard; DNA; 18 BP.
XX
AC ABZ81503;
XX
DT 09-JUN-2003 (first entry)
XX
DE PCR primer, SEQ ID 5.
XX
KW PCR; primer; rat; renal cancer; chromosome 10; ss.
XX
OS Synthetic.
XX
PN WO2003017757-A1.
XX
PD 06-MAR-2003.

XX
PF 23-AUG-2002; 2002WO-JP008496.
XX
PR 23-AUG-2001; 2001JP-00252283.
XX
PA (NICA-) JAPAN FOUND CANCER RES.
PA (DAIN) DAINIPPON PHARM CO LTD.
XX
PI Hino O, Tanaka K, Kouchi M, Okimoto K;
XX
DR WPI; 2003-278600/27.
XX
PT Rats with causative gene for spontaneous onset of human hereditary renal
PT cancer, useful in clarifying cause of rat renal cancer and developing
PT preventives and remedies for renal cancer.
XX
PS Example 4; Page 22; 38pp; Japanese.
XX
CC The present invention relates to a rat with spontaneous onset of
CC hereditary renal cancer, due to a mutation in a dominant gene located in
CC the telomere side of Tsc2 gene on chromosome 10. The rats are useful in
CC clarifying the cause of rat renal cancer and developing preventives and
CC remedies for cancer especially renal cancer. The present sequence is a
CC PCR primer, which was used in an example from the invention
XX
SQ Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1579 CCACCGCACAGACTGGG 1595
|||| || |||| ||||
Db 17 CCACAGCTCAGAATGGG 1

RESULT 1431
ADB54685/c
ID ADB54685 standard; DNA; 18 BP.
XX
AC ADB54685;
XX
DT 04-DEC-2003 (first entry)
XX
DE Hybridisation oligonucleotide 223 used to analyse genomic DNA region.
XX
KW colon cell proliferative disorder; non methylated CpG dinucleotide;
KW cytostatic; cancer; adenoma; carcinoma; cytosine methylation state; ss;
KW probe.
XX
OS Unidentified.
XX
PN WO2003072821-A2.
XX
PD 04-SEP-2003.
XX
PF 27-FEB-2003; 2003WO-EP002035.
XX
PR 27-FEB-2002; 2002EP-00004551.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Adorjan P, Burger M, Maier S, Nimmrich I, Becker E, Lesche R;
PI Rujan T, Schmitt A;
XX
DR WPI; 2003-731620/69.
XX
PT Detecting and differentiating between colon cell proliferative disorders
PT associated with a gene or its regulatory regions comprises contacting a
PT target nucleic acid in a biological sample obtained from the subject with
PT a reagent.
XX
PS Claim 36; Page 39; 74pp; English.
XX
CC The invention relates to a novel method for detecting and differentiating
CC between colon cell proliferative disorders associated with at least one
CC gene or its regulatory regions. The method comprises contacting a target
CC nucleic acid in a biological sample obtained from the subject with at
CC least one reagent or a series of reagents, where the reagent or series of
CC reagents, distinguishes between methylated and non methylated CpG
CC dinucleotides within the target nucleic acid. The molecules of the
CC invention demonstrate cytostatic activity whilst the method may useful
CC for detecting and differentiating between colon cell proliferative
CC disorders, including cancers such as colon adenoma and colon carcinoma.
CC The PNA (peptide nucleic acid)-oligomers are useful as probes for
CC determining cytosine methylation state or single nucleotide
CC polymorphisms. The current sequence is that of the hybridisation
CC oligonucleotide of the invention which was used to analyse the genomic
CC DNA region.
XX
SQ Sequence 18 BP; 5 A; 2 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1713 TCCTAACTTTGGACCTA 1729
|| |||| || ||||||
Db 18 TCATAACGTTCGACCTA 2

RESULT 1432
ADB54966
ID ADB54966 standard; DNA; 18 BP.
XX
AC ADB54966;
XX
DT 04-DEC-2003 (first entry)
XX
DE Hybridisation oligonucleotide 502 used to analyse genomic DNA region.
XX
KW colon cell proliferative disorder; non methylated CpG dinucleotide;
KW cytostatic; cancer; adenoma; carcinoma; cytosine methylation state; ss;
KW probe.
XX
OS Unidentified.
XX
PN WO2003072821-A2.
XX
PD 04-SEP-2003.
XX
PF 27-FEB-2003; 2003WO-EP002035.
XX
PR 27-FEB-2002; 2002EP-00004551.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Adorjan P, Burger M, Maier S, Nimmrich I, Becker E, Lesche R;
PI Rujan T, Schmitt A;
XX
DR WPI; 2003-731620/69.
XX
PT Detecting and differentiating between colon cell proliferative disorders
PT associated with a gene or its regulatory regions comprises contacting a
PT target nucleic acid in a biological sample obtained from the subject with
PT a reagent.
XX
PS Claim 36; Page 35; 74pp; English.
XX
CC The invention relates to a novel method for detecting and differentiating
CC between colon cell proliferative disorders associated with at least one
CC gene or its regulatory regions. The method comprises contacting a target
CC nucleic acid in a biological sample obtained from the subject with at
CC least one reagent or a series of reagents, where the reagent or series of
CC reagents, distinguishes between methylated and non methylated CpG
CC dinucleotides within the target nucleic acid. The molecules of the

```
CC   invention demonstrate cytostatic activity whilst the method may useful
CC   for detecting and differentiating between colon cell proliferative
CC   disorders, including cancers such as colon adenoma and colon carcinoma.
CC   The PNA (peptide nucleic acid)-oligomers are useful as probes for
CC   determining cytosine methylation state or single nucleotide
CC   polymorphisms. The current sequence is that of the hybridisation
CC   oligonucleotide of the invention which was used to analyse the genomic
CC   DNA region.
XX
SQ   Sequence 18 BP; 3 A; 0 C; 6 G; 9 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||  ||||||| |||
Db          1 TTTTAGAGTGTTAGGGT 17


RESULT 1433
ADC15721
ID   ADC15721 standard; DNA; 18 BP.
XX
AC   ADC15721;
XX
DT   18-DEC-2003  (first entry)
XX
DE   E. intestinalis spore wall protein gene fragment SEQ ID NO:80.
XX
KW   spore wall protein 1; spore wall protein 2; protozoacide; vaccine;
KW   immune response; microsporidia; microsporidiosis; SWP1; SWP2; ds.
XX
OS   Encephalitozoon intestinalis.
XX
PN   WO2003048299-A2.
XX
PD   12-JUN-2003.
XX
PF   04-DEC-2001; 2001WO-US047182.
XX
PR   04-DEC-2001; 2001WO-US047182.
XX
PA   (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI   Hayman JR,  Nash TE;
XX
DR   WPI; 2003-513742/48.
XX
PT   New spore wall protein 1 and spore wall protein 2 of Encephalitozoon
PT   intestinalis, useful for producing an immune response to microsporidia,
PT   or diagnosing, preventing and treating microsporidiosis in a subject.
XX
PS   Claim 8; SEQ ID NO 80; 121pp; English.
XX
CC   The invention relates to a novel isolated spore wall protein 1 and spore
CC   wall protein 2. A protein of the invention has protozoacide activity, and
CC   may be used as a vaccine. The spore wall proteins 1 and 2, nucleic acids
CC   encoding the proteins and the composition are useful for producing an
CC   immune response to microsporidia, or diagnosing, preventing and treating
CC   microsporidiosis in a subject. The present sequence represents a fragment
CC   of a spore wall protein gene of the invention.
XX
SQ   Sequence 18 BP; 2 A; 6 C; 3 G; 7 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1648 GCCTTCACTGGTTCTGC 1664
              |||||||| | || |||
Db          2 GCCTTCACAGCTTTTGC 18


RESULT 1434
ADC70155
ID   ADC70155 standard; DNA; 18 BP.
XX
AC   ADC70155;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Primer oligo used for analysing CpG islands in genomic DNA (SeqID 645).
XX
KW   PCR; primer; ss; lung cell proliferative disorder; CpG dinucleotide;
KW   adenocarcinoma; squamous cell carcinoma; cytostatic; probe; PNA-oligomer;
KW   cytosine methylation state.
XX
OS   Unidentified.
XX
PN   WO2003052135-A2.
XX
PD   26-JUN-2003.
XX
PF   10-DEC-2002; 2002WO-EP014026.
XX
PR   14-DEC-2001; 2001DE-01061625.
XX
PA   (EPIG-) EPIGENOMICS AG.
XX
PI   Burger M,  Field JK,  Genc B,  Liloglou T,  Lipscher E,  Maier S;
PI   Nimmrich I;
XX
DR   WPI; 2003-533029/50.
XX
PT   Detecting and differentiating cytosine methylation state of genomic DNA,
PT   useful for diagnosing, treating prognosticating and/or monitoring lung
PT   cell proliferative disorders e.g. adenocarcinoma and squamous cell
PT   carcinoma.
XX
PS   Claim 15; SEQ ID NO 645; 58pp; English.
XX
CC   This invention relates to a novel method for detecting and
CC   differentiating between lung cell proliferative disorders associated with
CC   at least one gene and/or their regulatory regions. Specifically, it
CC   refers to a method comprising contacting a target nucleic acid in a
CC   biological sample with at least one reagent, wherein the reagent is able
CC   to distinguish between methylated and non-methylated CpG dinucleotides
CC   present in the target DNA. As such, it is possible to further
CC   differentiate and diagnose medical conditions including adenocarcinoma
CC   and squamous cell carcinoma, and their respective adjacent lung tissue.
CC   The present invention describes cytostatic oligomers and PNA-oligomers
CC   that are useful as probes for determining the cytosine methylation state
CC   or single nucleotide polymorphisms (SNPs) of the target sequence. This
CC   oligonucleotide sequence is a primer oligomer used for the analysis of
CC   CpG positions within genomic DNA, used in an exemplification of the
CC   invention.
XX
SQ   Sequence 18 BP; 3 A; 0 C; 6 G; 9 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||  ||||||| |||
Db          1 TTTTAGAGTGTTAGGGT 17


RESULT 1435
ADC70024
ID   ADC70024 standard; DNA; 18 BP.
XX
AC   ADC70024;
XX
DT   18-DEC-2003  (first entry)
```

XX
DE Primer oligo used for analysing CpG islands in genomic DNA (SeqID 513).
XX
KW PCR; primer; ss; lung cell proliferative disorder; CpG dinucleotide;
KW adenocarcinoma; squamous cell carcinoma; cytostatic; probe; PNA-oligomer;
KW cytosine methylation state.
XX
OS Unidentified.
XX
PN WO2003052135-A2.
XX
PD 26-JUN-2003.
XX
PF 10-DEC-2002; 2002WO-EP014026.
XX
PR 14-DEC-2001; 2001DE-01061625.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Burger M, Field JK, Genc B, Liloglou T, Lipscher E, Maier S;
PI Nimmrich I;
XX
DR WPI; 2003-533029/50.
XX
PT Detecting and differentiating cytosine methylation state of genomic DNA,
PT useful for diagnosing, treating prognosticating and/or monitoring lung
PT cell proliferative disorders e.g. adenocarcinoma and squamous cell
PT carcinoma.
XX
PS Claim 15; SEQ ID NO 513; 58pp; English.
XX
CC This invention relates to a novel method for detecting and
CC differentiating between lung cell proliferative disorders associated with
CC at least one gene and/or their regulatory regions. Specifically, it
CC refers to a method comprising contacting a target nucleic acid in a
CC biological sample with at least one reagent, wherein the reagent is able
CC to distinguish between methylated and non-methylated CpG dinucleotides
CC present in the target DNA. As such, it is possible to further
CC differentiate and diagnose medical conditions including adenocarcinoma
CC and squamous cell carcinoma, and their respective adjacent lung tissue.
CC The present invention describes cytostatic oligomers and PNA-oligomers
CC that are useful as probes for determining the cytosine methylation state
CC or single nucleotide polymorphisms (SNPs) of the target sequence. This
CC oligonucleotide sequence is a primer oligomer used for the analysis of
CC CpG positions within genomic DNA, used in an exemplification of the
CC invention.
XX
SQ Sequence 18 BP; 6 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1821 TTTTAGAATCTTTTAAA 1837
              | ||||| | |||||||
Db          1 TATTAGAGTGTTTTAAA 17
```

RESULT 1436
AAD59000/c
ID AAD59000 standard; RNA; 18 BP.
XX
AC AAD59000;
XX
DT 18-DEC-2003 (first entry)
XX
DE 5' antisense RNA used in the treatment of Beta-thalassaemia.
XX
KW Inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
KW cellular proliferation; Beta-thalassaemia; antisense; ss.
XX
OS Unidentified.
XX
PN US2003040497-A1.
XX
PD 27-FEB-2003.
XX
PF 21-DEC-2001; 2001US-00029598.
XX
PR 01-JUL-1997; 97US-00886829.
PR 01-JUL-1998; 98US-00108673.
PR 20-MAY-1999; 99US-00315298.
XX
PA (TENG/) TENG C.
PA (COOK/) COOK P D.
PA (TILL/) TILLMAN L.
PA (HARD/) HARDEE G E.
PA (ECKE/) ECKER D J.
PA (MANO/) MANOHARAN M.
XX
PI Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;
XX
DR WPI; 2003-596370/56.
XX
PT Formulation, useful for treating inflammatory bowel disorder, e.g.
PT ulcerative colitis or Crohn's disease, comprises oligonucleotide for
PT rectal delivery.
XX
PS Example 2; Page 36; 45pp; English.
XX
CC The invention relates to formulations and methods which enhance the local
CC and systemic uptake and delivery of oligonucleotides and nucleic acids
CC via non-parenteral routes of administration. The formulation is used for
CC treating inflammatory bowel disorders, e.g. ulcerative colitis, Crohn's
CC disease or inflammatory bowel disease, in animals (e.g. human). It can
CC also be used for treating undue cellular proliferation. The present
CC sequence is an antisense RNA used in the treatment of Beta- thalassaemia.
CC This sequence is used to illustrate the method of the invention
XX
SQ Sequence 18 BP; 5 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2
```

RESULT 1437
ADC45678/c
ID ADC45678 standard; DNA; 18 BP.
XX
AC ADC45678;
XX
DT 18-DEC-2003 (first entry)
XX
DE PCR primer, PSO 155, used to detect 470R SNP.
XX
KW Allele frequency; allele; pyrophosphate;
KW enzymatic luminometric inorganic pyrophosphate detection assay; ELIDA;
KW single nucleotide polymorphism; SNP; mutation; genetic variation;
KW allelic variant; cancer; trisomy test; ss; PCR; primer.
XX
OS Unidentified.
XX
PN US2003082566-A1.
XX
PD 01-MAY-2003.
XX
PF 27-FEB-2002; 2002US-00085774.
XX
PR 27-FEB-2001; 2001US-0271703P.
XX
PA (SYLV/) SYLVAN A.

XX
PI Sylvan A;
XX
DR WPI; 2003-606060/57.
XX
PT Determining allele frequencies in a nucleic acid molecule population,
PT comprises performing primer extension reaction using a primer that binds
PT at a predetermined site in the nucleic acid molecules to obtain
PT nucleotide incorporation.
XX
PS Example 1; Page 13; 38pp; English.
XX
CC The invention discloses a method for determining the frequency of allele
CC in a population of nucleic acid molecules comprises pooling the nucleic
CC acid molecules of the population, performing primer extension reactions
CC using a primer that binds at a predetermined site located in the nucleic
CC acid molecules, and obtaining a pattern of nucleotide incorporation. Also
CC claimed is a kit carrying out the method above, comprising optionally
CC primer(s) for in vitro amplification, a primer for the primer extension
CC reaction, nucleotides for amplification and/or of the primer extension
CC reaction, a polymerase enzyme for the amplification and/or primer
CC extension reaction, and a means for detecting primer extension,
CC determining the amount of an allele in a sample of nucleic acid
CC molecules, determining which and/or how many nucleotides are incorporated
CC in the reaction and analysing the nucleotide incorporation information
CC obtained to determine the amount of occurrence of the allele in the
CC sample. The primer extension reaction is performed by sequentially adding
CC nucleotides to the reaction mixture, and determining the (non-
CC)incorporation of each nucleotide, where the amount of nucleotide
CC incorporated is determined quantitatively by detecting the release of
CC pyrophosphate. Enzymatic luminometric inorganic pyrophosphate detection
CC assay (ELIDA) detection enzymes are used to detect the release of
CC pyrophosphate, and a nucleotide-degrading enzyme is included during the
CC primer extension reaction. The method is useful for determining allele
CC frequencies for single nucleotide polymorphisms (SNPs) or other mutations
CC or genetic variations (e.g. nucleotide insertions, additions or
CC deletions) in pooled nucleic acid samples or other samples, which may
CC contain allelic variants. The method may also be used to confirm whether
CC an allelic variant is present in a population, in studies of mutations
CC associated with cancer, for testing genetic drift to determine if the
CC frequency of an allele changes over time, for quantification of a
CC gene/allele in human samples for trisomy tests, and to determine the
CC exact sequence of the SNP or allelic variant together with a direct
CC measurement of nucleotide incorporated. The method is accurate, simple,
CC reproducible, reliable and does not need labels or rely on probe binding
CC to the SNP site. The sequence presented is a PCR primer used to detect an
CC SNP.
XX
SQ Sequence 18 BP; 6 A; 8 C; 3 G; 1 T; 0 U; 0 Other;

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAG 1618
              | |||||||| ||| ||
Db         18 TTCTGGCCTGTGGGTAG 2
```

RESULT 1438
ADE84386
ID ADE84386 standard; DNA; 18 BP.
XX
AC ADE84386;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human lymphoid cell proliferative disorder gene CpG analysis oligo #92.
XX
KW lymphoid cell proliferative disorder; methylation;
KW methylated CpG dinucleotide; single nucleotide polymorphism; SNP;
KW diffuse large B-cell lymphoma; mantle cell lymphoma;
KW chronic lymphocytic leukemia; small lymphocytic lymphoma;
KW follicular lymphoma; diagnosis; prognosis; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003044226-A2.
XX
PD 30-MAY-2003.
XX
PF 25-NOV-2002; 2002WO-EP013265.
XX
PR 23-NOV-2001; 2001DE-01057491.
PR 28-DEC-2001; 2001DE-01064501.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Burger M, Caldwell C, Genc B, Becker E, Maier S, Nimmrich I;
XX
DR WPI; 2003-457621/43.
XX
PT Detecting and differentiating between lymphoid cell proliferative
PT disorders comprises contacting a target nucleic acid with at least one
PT reagent that distinguishes between methylated and non-methylated CpG
PT dinucleotides.
XX
PS Claim 30; SEQ ID NO 382; 448pp; English.
XX
CC The invention relates to a method of detecting and differentiating
CC between lymphoid cell proliferative disorders associated with at least
CC one gene and/or their regulatory regions in a subject by contacting a
CC target nucleic acid in a biological sample obtained from the subject with
CC at least one reagent or series of reagents that distinguish between
CC methylated and non-methylated CpG dinucleotides within the target nucleic
CC acid. The genes and/or their regulatory regions are preferably selected
CC from MDR1, CSNK2B, EGR4, AR, CDK4, RB2, CDC25A, GPIb beta, MYOD1, CDH3,
CC MYCL1, ELK1, ABL1, APC, BCL2, CDH1, CDKN1A, CDKN1B, CDKN2a, CDKN2B, FOS,
CC GSTP1, HIC-1, MGMT, MLH1, MOS, MYC, PTEN, RBL2, TGFBR2, TP73, CDKNIC,
CC GSK3beta, ESR1, APAF1, BAK1, BAX or HOXA5. Oligomers, peptide nucleic
CC acid (PNA)-oligomers and/or isolated nucleic acids based on the sequences
CC of the genes are useful for detecting the methylation state of all the
CC CpG dinucleotides within one or more the sequences, or their complements,
CC for determining the cytosine methylation state and or single nucleotide
CC polymorphisms (SNPs), and for differentiating at least two of the medical
CC conditions such as diffuse large B-cell lymphoma, mantle cell lymphoma,
CC chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular
CC lymphoma. They are also useful for detecting of a predisposition to,
CC differentiation between subclasses, diagnosis, prognosis, treating and/or
CC monitoring of lymphoid cell proliferative disorder. This sequence
CC represents an oligonucleotide used to analyse of CpG positions within the
CC above mentioned genes.
XX
SQ Sequence 18 BP; 6 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAA 1837
              | ||||| | |||||||
Db          1 TATTAGAGTGTTTTAAA 17
```

RESULT 1439
ADE84452
ID ADE84452 standard; DNA; 18 BP.
XX
AC ADE84452;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human lymphoid cell proliferative disorder gene CpG analysis oligo #158.
XX
KW lymphoid cell proliferative disorder; methylation;
KW methylated CpG dinucleotide; single nucleotide polymorphism; SNP;

KW diffuse large B-cell lymphoma; mantle cell lymphoma;
KW chronic lymphocytic leukemia; small lymphocytic lymphoma;
KW follicular lymphoma; diagnosis; prognosis; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003044226-A2.
XX
PD 30-MAY-2003.
XX
PF 25-NOV-2002; 2002WO-EP013265.
XX
PR 23-NOV-2001; 2001DE-01057491.
PR 28-DEC-2001; 2001DE-01064501.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Burger M, Caldwell C, Genc B, Becker E, Maier S, Nimmrich I;
XX
DR WPI; 2003-457621/43.
XX
PT Detecting and differentiating between lymphoid cell proliferative
PT disorders comprises contacting a target nucleic acid with at least one
PT reagent that distinguishes between methylated and non-methylated CpG
PT dinucleotides.
XX
PS Claim 30; SEQ ID NO 448; 448pp; English.
XX
CC The invention relates to a method of detecting and differentiating
CC between lymphoid cell proliferative disorders associated with at least
CC one gene and/or their regulatory regions in a subject by contacting a
CC target nucleic acid in a biological sample obtained from the subject with
CC at least one reagent or series of reagents that distinguish between
CC methylated and non-methylated CpG dinucleotides within the target nucleic
CC acid. The genes and/or their regulatory regions are preferably selected
CC from MDR1, CSNK2B, EGR4, AR, CDK4, RB2, CDC25A, GPIb beta, MYOD1, CDH3,
CC MYCL1, ELK1, ABL1, APC, BCL2, CDH1, CDKN1A, CDKN1B, CDKN2a, CDKN2B, FOS,
CC GSTP1, HIC-1, MGMT, MLH1, MOS, MYC, PTEN, RBL2, TGFBR2, TP73, CDKNIC,
CC GSK3beta, ESR1, APAF1, BAK1, BAX or HOXA5. Oligomers, peptide nucleic
CC acid (PNA)-oligomers and/or isolated nucleic acids based on the sequences
CC of the genes are useful for detecting the methylation state of all the
CC CpG dinucleotides within one or more the sequences, or their complements,
CC for determining the cytosine methylation state and or single nucleotide
CC polymorphisms (SNPs), and for differentiating at least two of the medical
CC conditions such as diffuse large B-cell lymphoma, mantle cell lymphoma,
CC chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular
CC lymphoma. They are also useful for detecting of a predisposition to,
CC differentiation between subclasses, diagnosis, prognosis, treating and/or
CC monitoring of lymphoid cell proliferative disorder. This sequence
CC represents an oligonucleotide used to analyse of CpG positions within the
CC above mentioned genes.
XX
SQ Sequence 18 BP; 3 A; 0 C; 6 G; 9 T; 0 U; 0 Other;

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||  ||||||| |||
Db          1 TTTTAGAGTGTTAGGGT 17
```

RESULT 1440
ADF13019/c
ID ADF13019 standard; DNA; 18 BP.
XX
AC ADF13019;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human PCM1 exon 26 splice donor fragment.
XX
KW schizophrenia; chromosome 8p21-22; pericentriolar material 1; PCM1;
KW marker; microsatellite repeat; NT 000501 contig; polymorphic marker;
KW linkage disequilibrium; D8S261; D8S2615; D8S2616;
KW single nucleotide polymorphism; SNP; ds.
XX
OS Homo sapiens.
XX
PN WO2003050301-A2.
XX
PD 19-JUN-2003.
XX
PF 12-DEC-2002; 2002WO-GB005630.
XX
PR 12-DEC-2001; 2001GB-00029758.
XX
PA (GURL/) GURLING H M D.
XX
PI Gurling HMD;
XX
DR WPI; 2003-532919/50.
XX
PT Determining the susceptibility of an individual to a neuropsychiatric
PT disorder (e.g. schizophrenia) or diagnosing or prognosing the disorder
PT comprises using a pericentriolar material 1 marker in the chromosomal
PT region 8p21-22.
XX
PS Claim 9; Fig 6; 108pp; English.
XX
CC This invention describes a novel method of determining the susceptibility
CC to or diagnosis of schizophrenia comprising using a marker located in the
CC chromosomal region 8p21-22. The method involves determining the presence
CC or absence in a test sample of a pericentriolar material 1 (PCM1) marker
CC which is selected from any of the microsatellite repeats present in the
CC NT 000501 contig on chromosome 8p21-22 or a polymorphic marker which is
CC in linkage disequilibrium with the chromosome. The PCM1 marker is
CC preferably D8S261, D8S2615 or D8S2616 and lies within the PCM1 gene. The
CC novel method involves assessing two or more of the PCM1 markers single
CC nucleotide polymorphisms (SNPs). The PCM1 gene is amplified, particularly
CC within the intronic sequence 3' to exon 4, in exon 4, or in the intronic
CC sequence 5' of exon 5. The PCM1 marker is assessed by strand conformation
CC polymorphic marker analysis, heteroduplex analysis or restriction
CC fragment length polymorphism (RFLP) analysis. Schizophrenia therapy
CC comprises screening an individual for a genetic predisposition to
CC schizophrenia, where the predisposition is correlated with the PCM1
CC marker and if a predisposition is identified, providing therapeutic
CC treatment for the individual. Alternatively, the method comprises
CC administering to a patient a substance that modulates the expression from
CC the PCM1 gene or a gene located within 1000 kbase of the PCM1 locus. This
CC sequence represents the human PCM1 exon 26 splice donor region.
XX
SQ Sequence 18 BP; 7 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAA 1982
              ||||| ||||||  |||
Db         18 AATATATACCTTCTAAA 2
```

RESULT 1441
ADF78302/c
ID ADF78302 standard; DNA; 18 BP.
XX
AC ADF78302;
XX
DT 26-FEB-2004 (first entry)
XX
DE Chromosomal abnormality detection-related APC small deletion DNA 48.
XX
KW chromosomal abnormality; maternal locus; genetic disorder; foetus;
KW mutation; translocation; transversion; monosomy; trisomy; trisomy 21;

KW chromosome 21; Down's Syndrome; anueoplodies; chromosome deletion;
KW chromosome addition; chromosome amplification; chromosome translocation;
KW chromosome rearrangement; single nucleotide polymorphism detection;
KW SNP detection; pregnant female; APC; adenomatous polyposis coli; ds.
XX
OS Homo sapiens.
XX
PN WO2003074723-A2.
XX
PD 12-SEP-2003.
XX
PF 28-FEB-2003; 2003WO-US006198.
XX
PR 01-MAR-2002; 2002US-0360232P.
PR 11-MAR-2002; 2002US-00093618.
PR 08-MAY-2002; 2002US-0378354P.
XX
PA (DHAL/) DHALLAN R.
XX
PI Dhallan R;
XX
DR WPI; 2003-845073/78.
XX
PT Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
PT invasively in a fetus, comprises forming a ratio of amounts of alleles at
PT a locus of interest and a different heterozygous locus.
XX
PS Example 7; Page 157; 164pp; English.
XX
CC This invention relates to a novel method of detecting chromosomal
CC abnormalities by determining the sequence of alleles of a locus of
CC interest from template DNA, determining which alleles are present and
CC comparing to amounts of alleles at a different, selected heterozygous
CC locus (for example on another chromosome or a maternal locus); relative
CC amounts are expressed as a ratio indicating presence or absence of the
CC abnormality. The method is useful for the detection of genetic disorders,
CC especially in a foetus, including chromosomal abnormalities and
CC mutations, for example translocations, transversions, monosomies,
CC trisomies (for example trisomy 21 in which an additional copy of
CC chromosome 21 results in Down's Syndrome) and other anueoplodies,
CC deletions, additions, amplifications, translocations and rearrangements.
CC It can be used to detect any alterations in a gene sequence, especially
CC single nucleotide polymorphisms (SNPs), and may be used to detect
CC numerous abnormalities simultaneously, for example if several SNPs are
CC associated with a particular disease. The method provides a rapid, non-
CC invasive method for determining the sequence of DNA from a foetus using a
CC sample from a pregnant female, for example to detect genetic disorders as
CC above or to determine if a foetus is a carrier of a disease or
CC predisposed to a disease.
XX
SQ Sequence 18 BP; 8 A; 5 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1988 AAAGTGTGTATCTAGCT 2004
||||||| | ||| |||
Db 17 AAAGTGTTTGTCTGGCT 1

RESULT 1442
ADH53107/c
ID ADH53107 standard; DNA; 18 BP.
XX
AC ADH53107;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human APC (adenomatous polyposis coli) DNA fragment 47.
XX
KW sequence determination; recognition site; restriction endonuclease;
KW human; APC; adenomatous polyposis coli; chromosome 5q21-22;
KW colorectal cancer; ds.
XX
OS Homo sapiens.
XX
PN WO2003074740-A1.
XX
PD 12-SEP-2003.
XX
PF 28-FEB-2003; 2003WO-US006376.
XX
PR 01-MAR-2002; 2002US-0360232P.
PR 11-MAR-2002; 2002US-00093618.
PR 08-MAY-2002; 2002US-0378354P.
XX
PA (DHAL/) DHALLAN R.
XX
PI Dhallan R;
XX
DR WPI; 2003-756772/71.
XX
PT Determining a sequence of a locus of interest comprises replicating a
PT region of DNA comprising a locus of interest from a template
PT polynucleotide by using a first and a second primer.
XX
PS Example 5; Page 136; 190pp; English.
XX
CC The invention relates to a novel method for determining the sequence of a
CC locus of interest which comprises replicating a region of DNA comprising
CC a locus of interest from a template polynucleotide by using a first and a
CC second primer where the second primer contains a sequence that generates
CC a recognition site for a restriction enzyme such that digestion with the
CC restriction enzyme generates a 5' overhang containing the locus of
CC interest. The method may be useful for determining the sequences of
CC multiple loci of interest concurrently and for determining the sequence
CC of a mutant allele in the presence of a normal allele. The current
CC sequence is that of the human APC (adenomatous polyposis coli) DNA
CC fragment of the invention which is located on chromosome 5q21-22 and in
CC which mutations are associated with colorectal cancer.
XX
SQ Sequence 18 BP; 8 A; 5 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1988 AAAGTGTGTATCTAGCT 2004
||||||| | ||| |||
Db 17 AAAGTGTTTGTCTGGCT 1

RESULT 1443
ADH89104
ID ADH89104 standard; DNA; 18 BP.
XX
AC ADH89104;
XX
DT 22-APR-2004 (first entry)
XX
DE PCR primer #1for human zilla4 DNA.
XX
KW Human; interleukin-1 homologue; IL-1; zilla4; immune response;
KW inflammatory disease; cancer; anaemia; immunomodulator; antiinflammatory;
KW cytostatic; antianaemic; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US2003148467-A1.
XX
PD 07-AUG-2003.
XX
PF 22-NOV-2002; 2002US-00302554.
XX
PR 27-OCT-1998; 98US-0105824P.

```
PR   27-OCT-1999;   99US-00428118.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   West RR,  Sheppard PO,  Gao Z;
XX
DR   WPI; 2003-897576/82.
XX
PT   New interleukin-1 homolog Zil1a4 protein, useful for modulating an immune
PT   response and for treating diseases, e.g., inflammatory diseases, cancer
PT   or anemia.
XX
PS   Example 6; SEQ ID NO 43; 44pp; English.
XX
CC   The present invention relates to the isolation of human interleukin-1 (IL
CC   -1) homologues designated zil1a4, and the polynucleotide sequences that
CC   encode them. The gene encoding human zil1a4 is located on chromosome 2.
CC   Also disclosed is a method of making these proteins and a method of
CC   modulating an immune response. The proteins are useful for treating
CC   diseases such as inflammatory diseases, cancer, and anaemia. The present
CC   sequence represents a PCR primer used in the examples of the present
CC   invention.
XX
SQ   Sequence 18 BP; 1 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              ||  |||||||||| ||
Db          2 CCCCTCTTTCCTTCACT 18


RESULT 1444
AAD50290/c
ID   AAD50290 standard; DNA; 18 BP.
XX
AC   AAD50290;
XX
DT   24-MAR-2003  (first entry)
XX
DE   Cholesterol-conjugated oligonucleotide #5.
XX
KW   Therapy; research reagent; diagnostic; phosphorothioate backbone; ss.
XX
OS   Unidentified.
XX
FH   Key             Location/Qualifiers
FT   modified_base   1. .18
FT                   /*tag=  a
FT                   /mod_base= OTHER
FT                   /note= "Phosphorothioate backbone"
FT   modified_base   1
FT                   /*tag=  b
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rG; Linked to cholesterol"
FT   modified_base   2
FT                   /*tag=  c
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rC"
FT   modified_base   3
FT                   /*tag=  d
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rT"
FT   modified_base   4
FT                   /*tag=  e
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rA"
FT   modified_base   5. .6
FT                   /*tag=  f
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rT"
FT   modified_base   7
FT                   /*tag=  g
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rA"
FT   modified_base   8. .9
FT                   /*tag=  h
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rC"
FT   modified_base   10. .11
FT                   /*tag=  i
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rT"
FT   modified_base   12. .13
FT                   /*tag=  j
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rA"
FT   modified_base   14. .16
FT                   /*tag=  k
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rC"
FT   modified_base   17
FT                   /*tag=  l
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rA"
FT   modified_base   18
FT                   /*tag=  m
FT                   /mod_base= OTHER
FT                   /note= "2'-O-MOE-rG"
XX
PN   WO200279216-A1.
XX
PD   10-OCT-2002.
XX
PF   29-MAR-2002; 2002WO-US010178.
XX
PR   30-MAR-2001; 2001US-00823031.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Manoharan M,  Guzaev A;
XX
DR   WPI; 2003-103258/09.
XX
PT   New method for preparing an oligonucleotide useful e.g. in therapeutics
PT   comprises treating derivatized solid support with acidic reagent to
PT   deblock acid labile hydroxyl protecting group and reacting with
PT   phosphoramidite and conjugate group.
XX
PS   Example 29; Page 69; 111pp; English.
XX
CC   The invention relates to a method for preparing an oligonucleotide by
CC   treating derivatised solid support with acidic reagent to deblock acid
CC   labile hydroxyl protecting group and reacting with phosphoramidite and
CC   conjugate group. The method is useful for preparing compounds containing
CC   phosphorus functionalities and oligomeric compounds containing monomeric
CC   subunits joined by functionalities such as phosphite, phosphodiester,
CC   phosphorothioate and/or phosphorodithioate residue; in diagnostics,
CC   therapeutics and as research reagents and kits; for treating organisms
CC   having a disease characterised by the undesired production of a protein.
CC   The present sequence is an oligonucleotide used to illustrate the method
CC   of the invention
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2
```

```
RESULT 1445
AAD50294/c
ID   AAD50294 standard; RNA; 18 BP.
XX
AC   AAD50294;
XX
DT   24-MAR-2003  (first entry)
XX
DE   Kole654, oligonucleotide used in the invention.
XX
KW   Therapy; research reagent; diagnostic; ss.
XX
OS   Unidentified.
XX
PN   WO200279216-A1.
XX
PD   10-OCT-2002.
XX
PF   29-MAR-2002; 2002WO-US010178.
XX
PR   30-MAR-2001; 2001US-00823031.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Manoharan M,  Guzaev A;
XX
DR   WPI; 2003-103258/09.
XX
PT   New method for preparing an oligonucleotide useful e.g. in therapeutics
PT   comprises treating derivatized solid support with acidic reagent to
PT   deblock acid labile hydroxyl protecting group and reacting with
PT   phosphoramidite and conjugate group.
XX
PS   Example 29; Page 69; 111pp; English.
XX
CC   The invention relates to a method for preparing an oligonucleotide by
CC   treating derivatised solid support with acidic reagent to deblock acid
CC   labile hydroxyl protecting group and reacting with phosphoramidite and
CC   conjugate group. The method is useful for preparing compounds containing
CC   phosphorus functionalities and oligomeric compounds containing monomeric
CC   subunits joined by functionalities such as phosphite, phosphodiester,
CC   phosphorothioate and/or phosphorodithioate residue; in diagnostics,
CC   therapeutics and as research reagents and kits; for treating organisms
CC   having a disease characterised by the undesired production of a protein.
CC   The present sequence is an oligonucleotide used to illustrate the method
CC   of the invention
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 0 T; 5 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1446
ADK96425/c
ID   ADK96425 standard; DNA; 18 BP.
XX
AC   ADK96425;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Primer of the invention #2145.
XX
KW   human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS   Synthetic.
XX
PN   JP2003259875-A.
XX
PD   16-SEP-2003.
XX
PF   08-MAR-2002; 2002JP-00064373.
XX
PR   08-MAR-2002; 2002JP-00064373.
XX
PA   (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR   WPI; 2004-093977/10.
XX
PT   Novel polynucleotide useful for PCR amplification along with two DNA
PT   fragment from another set of sequences, or for detecting single
PT   nucleotide polymorphism in human gene.
XX
PS   Claim 2; SEQ ID NO 5454; 2627pp; Japanese.
XX
CC   The present invention relates to a polynucleotide isolated from a human
CC   gene and is useful for detecting a single nucleotide polymorphism in a
CC   human gene or for diagnosing of disease. The invention enables the
CC   detection of a single nucleotide polymorphism in a human gene. The
CC   present sequence represents a primer of the invention.
XX
SQ   Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1658 GTTCTGCATCACCCGCC 1674
              |||||| |||| | |||
Db         17 GTTCTGGATCAGCAGCC 1


RESULT 1447
ADO47678/c
ID   ADO47678 standard; DNA; 18 BP.
XX
AC   ADO47678;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Antisense oligonucleotide #4.
XX
KW   vaccine; ss; antisense; peptide nucleic acid uptake;
KW   increasing cellular uptake; modulating tissue distribution;
KW   intracellular accumulation; antisense efficacy; tissue distribution;
KW   peptide nucleic acid.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1
FT                   /*tag=  a
FT                   /note= "H modified"
FT   misc_feature    18
FT                   /*tag=  b
FT                   /note= "Lys-NH2 modified"
XX
PN   US2004063618-A1.
XX
PD   01-APR-2004.
XX
PF   30-SEP-2002; 2002US-00261382.
XX
PR   30-SEP-2002; 2002US-00261382.
XX
PA   (MANO/) MANOHARAN M.
XX
PI   Manoharan M;
XX
DR   WPI; 2004-294412/27.
XX
```

```
PT   Modulation of in vivo uptake of a peptide nucleic acid compound useful as
PT   e.g. antisense reagent involves modifying the peptide nucleic acid
PT   molecule with a positively charged conjugate having at least three
PT   positively charged amino acids.
XX
PS   Example 3; SEQ ID NO 4; 14pp; English.
XX
CC   The invention relates to the modulation of in vivo uptake of a peptide
CC   nucleic acid compound which comprises modifying the peptide nucleic acid
CC   molecule with a positively charged conjugate having at least three
CC   positively charged amino acid units. The method is useful for modulating
CC   in vivo uptake of peptide nucleic acid compounds (such as increasing
CC   cellular uptake and modulating tissue distribution, which are useful for
CC   diagnostics and therapeutics, as research reagents and as antisense
CC   reagents. The modified peptide nucleic acid molecule exhibits enhanced
CC   intracellular accumulation, antisense efficacy and tissue distribution
CC   than that of single charged peptide nucleic acid (PNA), neutral PNA
CC   compounds and neutral or anionic charged antigen compounds. The present
CC   sequence represents an antisense oligonucleotide of the invention.
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1448
ADO47677/c
ID   ADO47677 standard; DNA; 18 BP.
XX
AC   ADO47677;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Antisense oligonucleotide #3.
XX
KW   vaccine; ss; antisense; peptide nucleic acid uptake;
KW   increasing cellular uptake; modulating tissue distribution;
KW   intracellular accumulation; antisense efficacy; tissue distribution.
XX
OS   Synthetic.
XX
PN   US2004063618-A1.
XX
PD   01-APR-2004.
XX
PF   30-SEP-2002; 2002US-00261382.
XX
PR   30-SEP-2002; 2002US-00261382.
XX
PA   (MANO/) MANOHARAN M.
XX
PI   Manoharan M;
XX
DR   WPI; 2004-294412/27.
XX
PT   Modulation of in vivo uptake of a peptide nucleic acid compound useful as
PT   e.g. antisense reagent involves modifying the peptide nucleic acid
PT   molecule with a positively charged conjugate having at least three
PT   positively charged amino acids.
XX
PS   Example 3; SEQ ID NO 3; 14pp; English.
XX
CC   The invention relates to the modulation of in vivo uptake of a peptide
CC   nucleic acid compound which comprises modifying the peptide nucleic acid
CC   molecule with a positively charged conjugate having at least three
CC   positively charged amino acid units. The method is useful for modulating
CC   in vivo uptake of peptide nucleic acid compounds (such as increasing
CC   cellular uptake and modulating tissue distribution, which are useful for
CC   diagnostics and therapeutics, as research reagents and as antisense
CC   reagents. The modified peptide nucleic acid molecule exhibits enhanced
CC   intracellular accumulation, antisense efficacy and tissue distribution
CC   than that of single charged peptide nucleic acid (PNA), neutral PNA
CC   compounds and neutral or anionic charged antigen compounds. The present
CC   sequence represents an antisense oligonucleotide of the invention.
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1449
ADO47680/c
ID   ADO47680 standard; DNA; 18 BP.
XX
AC   ADO47680;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Antisense oligonucleotide #6.
XX
KW   vaccine; ss; antisense; peptide nucleic acid uptake;
KW   increasing cellular uptake; modulating tissue distribution;
KW   intracellular accumulation; antisense efficacy; tissue distribution;
KW   peptide nucleic acid.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1
FT                   /*tag=  a
FT                   /note= "H modified"
FT   misc_feature    18
FT                   /*tag=  b
FT                   /note= "(Lys)4-NH2 modified"
XX
PN   US2004063618-A1.
XX
PD   01-APR-2004.
XX
PF   30-SEP-2002; 2002US-00261382.
XX
PR   30-SEP-2002; 2002US-00261382.
XX
PA   (MANO/) MANOHARAN M.
XX
PI   Manoharan M;
XX
DR   WPI; 2004-294412/27.
XX
PT   Modulation of in vivo uptake of a peptide nucleic acid compound useful as
PT   e.g. antisense reagent involves modifying the peptide nucleic acid
PT   molecule with a positively charged conjugate having at least three
PT   positively charged amino acids.
XX
PS   Example 3; SEQ ID NO 6; 14pp; English.
XX
CC   The invention relates to the modulation of in vivo uptake of a peptide
CC   nucleic acid compound which comprises modifying the peptide nucleic acid
CC   molecule with a positively charged conjugate having at least three
CC   positively charged amino acid units. The method is useful for modulating
CC   in vivo uptake of peptide nucleic acid compounds (such as increasing
CC   cellular uptake and modulating tissue distribution, which are useful for
CC   diagnostics and therapeutics, as research reagents and as antisense
CC   reagents. The modified peptide nucleic acid molecule exhibits enhanced
```

```
CC   intracellular accumulation, antisense efficacy and tissue distribution
CC   than that of single charged peptide nucleic acid (PNA), neutral PNA
CC   compounds and neutral or anionic charged antigen compounds. The present
CC   sequence represents an antisense oligonucleotide of the invention.
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1450
ADO47679/c
ID   ADO47679 standard; DNA; 18 BP.
XX
AC   ADO47679;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Antisense oligonucleotide #5.
XX
KW   vaccine; ss; antisense; peptide nucleic acid uptake;
KW   increasing cellular uptake; modulating tissue distribution;
KW   intracellular accumulation; antisense efficacy; tissue distribution;
KW   peptide nucleic acid.
XX
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   misc_feature    1
FT                   /*tag=  a
FT                   /note= "H modified"
FT   misc_feature    18
FT                   /*tag=  b
FT                   /note= "(Lys)2-NH2 modified"
XX
PN   US2004063618-A1.
XX
PD   01-APR-2004.
XX
PF   30-SEP-2002; 2002US-00261382.
XX
PR   30-SEP-2002; 2002US-00261382.
XX
PA   (MANO/) MANOHARAN M.
XX
PI   Manoharan M;
XX
DR   WPI; 2004-294412/27.
XX
PT   Modulation of in vivo uptake of a peptide nucleic acid compound useful as
PT   e.g. antisense reagent involves modifying the peptide nucleic acid
PT   molecule with a positively charged conjugate having at least three
PT   positively charged amino acids.
XX
PS   Example 3; SEQ 'ID NO 5; 14pp; English.
XX
CC   The invention relates to the modulation of in vivo uptake of a peptide
CC   nucleic acid compound which comprises modifying the peptide nucleic acid
CC   molecule with a positively charged conjugate having at least three
CC   positively charged amino acid units. The method is useful for modulating
CC   in vivo uptake of peptide nucleic acid compounds (such as increasing
CC   cellular uptake and modulating tissue distribution, which are useful for
CC   diagnostics and therapeutics, as research reagents and as antisense
CC   reagents. The modified peptide nucleic acid molecule exhibits enhanced
CC   intracellular accumulation, antisense efficacy and tissue distribution
CC   than that of single charged peptide nucleic acid (PNA), neutral PNA
CC   compounds and neutral or anionic charged antigen compounds. The present
CC   sequence represents an antisense oligonucleotide of the invention.
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1451
ADO47676/c
ID   ADO47676 standard; DNA; 18 BP.
XX
AC   ADO47676;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Antisense oligonucleotide #2.
XX
KW   vaccine; ss; antisense; peptide nucleic acid uptake;
KW   increasing cellular uptake; modulating tissue distribution;
KW   intracellular accumulation; antisense efficacy; tissue distribution.
XX
OS   Synthetic.
XX
PN   US2004063618-A1.
XX
PD   01-APR-2004.
XX
PF   30-SEP-2002; 2002US-00261382.
XX
PR   30-SEP-2002; 2002US-00261382.
XX
PA   (MANO/) MANOHARAN M.
XX
PI   Manoharan M;
XX
DR   WPI; 2004-294412/27.
XX
PT   Modulation of in vivo uptake of a peptide nucleic acid compound useful as
PT   e.g. antisense reagent involves modifying the peptide nucleic acid
PT   molecule with a positively charged conjugate having at least three
PT   positively charged amino acids.
XX
PS   Example 3; SEQ ID NO 2; 14pp; English.
XX
CC   The invention relates to the modulation of in vivo uptake of a peptide
CC   nucleic acid compound which comprises modifying the peptide nucleic acid
CC   molecule with a positively charged conjugate having at least three
CC   positively charged amino acid units. The method is useful for modulating
CC   in vivo uptake of peptide nucleic acid compounds (such as increasing
CC   cellular uptake and modulating tissue distribution, which are useful for
CC   diagnostics and therapeutics, as research reagents and as antisense
CC   reagents. The modified peptide nucleic acid molecule exhibits enhanced
CC   intracellular accumulation, antisense efficacy and tissue distribution
CC   than that of single charged peptide nucleic acid (PNA), neutral PNA
CC   compounds and neutral or anionic charged antigen compounds. The present
CC   sequence represents an antisense oligonucleotide of the invention.
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2
```

```
RESULT 1452
ADO47675/c
ID   ADO47675 standard; DNA; 18 BP.
XX
AC   ADO47675;
XX
DT   15-JUL-2004  (first entry)
XX
DE   Antisense oligonucleotide #1.
XX
KW   vaccine; ss; antisense; peptide nucleic acid uptake;
KW   increasing cellular uptake; modulating tissue distribution;
KW   intracellular accumulation; antisense efficacy; tissue distribution.
XX
OS   Synthetic.
XX
PN   US2004063618-A1.
XX
PD   01-APR-2004.
XX
PF   30-SEP-2002; 2002US-00261382.
XX
PR   30-SEP-2002; 2002US-00261382.
XX
PA   (MANO/) MANOHARAN M.
XX
PI   Manoharan M;
XX
DR   WPI; 2004-294412/27.
XX
PT   Modulation of in vivo uptake of a peptide nucleic acid compound useful as
PT   e.g. antisense reagent involves modifying the peptide nucleic acid
PT   molecule with a positively charged conjugate having at least three
PT   positively charged amino acids.
XX
PS   Example 3; SEQ ID NO 1; 14pp; English.
XX
CC   The invention relates to the modulation of in vivo uptake of a peptide
CC   nucleic acid compound which comprises modifying the peptide nucleic acid
CC   molecule with a positively charged conjugate having at least three
CC   positively charged amino acid units. The method is useful for modulating
CC   in vivo uptake of peptide nucleic acid compounds (such as increasing
CC   cellular uptake and modulating tissue distribution, which are useful for
CC   diagnostics and therapeutics, as research reagents and as antisense
CC   reagents. The modified peptide nucleic acid molecule exhibits enhanced
CC   intracellular accumulation, antisense efficacy and tissue distribution
CC   than that of single charged peptide nucleic acid (PNA), neutral PNA
CC   compounds and neutral or anionic charged antigen compounds. The present
CC   sequence represents an antisense oligonucleotide of the invention.
XX
SQ   Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 1453
ADO16641/c
ID   ADO16641 standard; DNA; 18 BP.
XX
AC   ADO16641;
XX
DT   29-JUL-2004  (first entry)
XX
DE   4 synthesis-period of neuroblastoma related primer, SEQ ID 903.
XX
KW   Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
XX
OS   Synthetic.
XX
PN   WO2004039975-A1.
XX
PD   13-MAY-2004.
XX
PF   30-OCT-2003; 2003WO-JP013932.
XX
PR   30-OCT-2002; 2002JP-00316586.
XX
PA   (HISM ) HISAMITSU PHARM CO LTD.
PA   (CHIB-) CHIBA PREFECTURE.
XX
PI   Nakagawara A,  Ohira M;
XX
DR   WPI; 2004-390323/36.
XX
PT   Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
PT   cells useful for prognosing and determining progress stage of
PT   neuroblastomas.
XX
PS   Claim 8; SEQ ID NO 903; 455pp; Japanese.
XX
CC   The present invention relates to human nucleic acid sequences (I;
CC   ADO15739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
CC   neuroblastoma cell. (I) is useful for prognosing and determining the
CC   progress stage of 4 synthesis-period of neuroblastoma. The present
CC   sequence is a primer, used to illustrate the invention.
XX
SQ   Sequence 18 BP; 3 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 6.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCACC 1670
              ||||| |||||| | ||
Db         17 ACTGGATCTGCACCGCC 1


RESULT 1454
ADQ17040
ID   ADQ17040 standard; DNA; 18 BP.
XX
AC   ADQ17040;
XX
DT   23-SEP-2004  (first entry)
XX
DE   Drosophila melanogaster PARP-I and PARP-e amplifying RT-PCR primer, R4.
XX
KW   poly-(ADP) ribose polymerase; PARP; modulate chromatin structure;
KW   gene activation; gene repression; chromatin condensation;
KW   chromatin decondensation; gene therapy; fruit fly; PARP-1; RT-PCR;
KW   reverse transcription; primer; PARP-e; ss.
XX
OS   Drosophila melanogaster.
XX
PN   US2004127444-A1.
XX
PD   01-JUL-2004.
XX
PF   31-JUL-2003; 2003US-00630660.
XX
PR   31-JUL-2002; 2002US-0399460P.
XX
PA   (SPRA/) SPRADLING A C.
PA   (WILL/) WILLIAMS D S.
PA   (TULI/) TULIN A V.
XX
PI   Spradling AC,  Williams DS,  Tulin AV;
XX
DR   WPI; 2004-506457/48.
```

XX
PT New isolated Poly(ADP)-ribose polymerase (PARP-e) nucleic acids and
PT proteins, useful for modulating chromatin structure resulting in
PT modulation of gene activation, gene repression and chromatin condensation
PT or decondensation.
XX
PS Example 7; SEQ ID NO 5; 75pp; English.
XX
CC The present invention relates to the identifiation and cloning of poly-
CC (ADP) ribose polymerase (PARP) polypeptide and its encoding
CC polynucleotide. The invention is useful for modulating chromatin
CC structure resulting in modulation of gene activation, gene repression and
CC chromatin condensation and decondensation by using PARP and its isoforms
CC PARP-e and PARP-1. The invention is therefore useful to specifically
CC manipulate chromatin structure and re-programming so as to effect
CC expression of a gene or genes of interest in order to treat or prevent
CC disease and/or to manipulate biological processes in vivo and in vitro.
CC The invention is also useful in gene therapy. The present sequence is
CC Drosophila melanogaster PARP-I and PARP-e amplifying RT-PCR primer. This
CC sequence is used in the exemplification of the invention.
XX
SQ Sequence 18 BP; 6 A; 3 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.2%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.5e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1776 TTTTTTGAACCCCATTC 1792
              |||| |||| || ||||
Db          1 TTTTATGAAACCAATTC 17
```

Search completed: November 8, 2004, 08:31:08
Job time : 16 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2004, 08:27:26 ; Search time 6 Seconds
(without alignments)
3.836 Million cell updates/sec

Title: US-10-023-782A-3
Perfect score: 559
Sequence: 1 gaagaaaggttaggagagta.....agtggtatctgacacactct 559

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 1157 seqs, 20588 residues

Total number of hits satisfying chosen parameters: 2314

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1173 summaries

Database : rge3.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	18.2	3.3	23	1	AR100207	ACCESSION:AR100207
	2	18.2	3.3	23	1	BD263052	ACCESSION:BD263052
c	3	17	3.0	25	1	AX166683	ACCESSION:AX166683
	4	16.6	3.0	23	1	CQ768165	ACCESSION:CQ768165
	5	16.6	3.0	24	1	AX093547	ACCESSION:AX093547
	6	16.6	3.0	25	1	AR146859	ACCESSION:AR146859
	7	16.6	3.0	25	1	E55072	ACCESSION:E55072
	8	16.6	3.0	25	1	AX000308	ACCESSION:AX000308
	9	16.6	3.0	25	1	AX000331	ACCESSION:AX000331
	10	16.6	3.0	25	1	BD074369	ACCESSION:BD074369
	11	16.6	3.0	25	1	BD074392	ACCESSION:BD074392
	12	16.4	2.9	20	1	AX326966	ACCESSION:AX326966
	13	16.4	2.9	24	1	AR257304	ACCESSION:AR257304
c	14	16.2	2.9	21	1	AR241776	ACCESSION:AR241776
	15	16.2	2.9	21	1	AR296425	ACCESSION:AR296425
c	16	15.8	2.8	20	1	BD168596	ACCESSION:BD168596
	17	15.8	2.8	23	1	AR053253	ACCESSION:AR053253
c	18	15.8	2.8	23	1	AR053257	ACCESSION:AR053257
	19	15.4	2.8	17	1	AX728891	ACCESSION:AX728891
	20	15.4	2.8	21	1	AX095913	ACCESSION:AX095913
	21	15.4	2.8	23	1	AX468432	ACCESSION:AX468432
	22	15.2	2.7	20	1	CQ763459	ACCESSION:CQ763459
	23	15.2	2.7	20	1	AR429749	ACCESSION:AR429749
	24	15.2	2.7	21	1	BD089734	ACCESSION:BD089734
	25	15.2	2.7	22	1	AX817759	ACCESSION:AX817759
c	26	15	2.7	17	1	AX475808	ACCESSION:AX475808
c	27	15	2.7	17	1	AX475809	ACCESSION:AX475809
c	28	15	2.7	17	1	AX475810	ACCESSION:AX475810
c	29	15	2.7	21	1	AX133222	ACCESSION:AX133222
	30	15	2.7	23	1	AX226182	ACCESSION:AX226182
	31	14.8	2.6	18	1	AB069627	ACCESSION:AB069627
	32	14.8	2.6	19	1	A51700	ACCESSION:A51700
	33	14.8	2.6	19	1	A65476	ACCESSION:A65476
	34	14.8	2.6	19	1	AR167579	ACCESSION:AR167579
	35	14.8	2.6	19	1	AR178289	ACCESSION:AR178289
	36	14.8	2.6	19	1	AX016237	ACCESSION:AX016237
	37	14.8	2.6	19	1	AX323371	ACCESSION:AX323371
	38	14.8	2.6	19	1	AX686841	ACCESSION:AX686841
	39	14.8	2.6	19	1	BD135015	ACCESSION:BD135015
	40	14.8	2.6	20	1	A50098	ACCESSION:A50098
	41	14.8	2.6	20	1	AR152574	ACCESSION:AR152574
	42	14.8	2.6	20	1	CQ763394	ACCESSION:CQ763394
	43	14.8	2.6	20	1	CQ763633	ACCESSION:CQ763633
c	44	14.8	2.6	20	1	AR444793	ACCESSION:AR444793
	45	14.6	2.6	22	1	AX380339	ACCESSION:AX380339
	46	14.6	2.6	22	1	AX708078	ACCESSION:AX708078
c	47	14.4	2.6	17	1	BD258525	ACCESSION:BD258525
	48	14.4	2.6	17	1	AX761225	ACCESSION:AX761225
c	49	14.4	2.6	18	1	AX599370	ACCESSION:AX599370
c	50	14.4	2.6	18	1	AX705542	ACCESSION:AX705542
	51	14.4	2.6	18	1	AX705544	ACCESSION:AX705544
c	52	14.4	2.6	18	1	AX796234	ACCESSION:AX796234
c	53	14.4	2.6	18	1	AX822736	ACCESSION:AX822736
c	54	14.4	2.6	18	1	AX826376	ACCESSION:AX826376
	55	14.4	2.6	19	1	AX587498	ACCESSION:AX587498
	56	14.4	2.6	20	1	AR070884	ACCESSION:AR070884
c	57	14.4	2.6	20	1	AR314291	ACCESSION:AR314291
	58	14.4	2.6	20	1	AR315574	ACCESSION:AR315574
	59	14.4	2.6	20	1	AR429446	ACCESSION:AR429446
	60	14.4	2.6	21	1	AR337899	ACCESSION:AR337899
	61	14.4	2.6	22	1	CQ760448	ACCESSION:CQ760448
	62	14.4	2.6	22	1	AX546436	ACCESSION:AX546436
	63	14.4	2.6	22	1	AX557277	ACCESSION:AX557277
	64	14.4	2.6	22	1	AX557361	ACCESSION:AX557361
	65	14.4	2.6	22	1	AX557386	ACCESSION:AX557386
	66	14.4	2.6	22	1	AX591097	ACCESSION:AX591097
	67	14.4	2.6	22	1	AX592487	ACCESSION:AX592487
	68	14.4	2.6	22	1	AX592990	ACCESSION:AX592990
	69	14.4	2.6	22	1	AX593130	ACCESSION:AX593130
	70	14.4	2.6	22	1	AX593465	ACCESSION:AX593465
	71	14.4	2.6	22	1	AX597460	ACCESSION:AX597460
	72	14.4	2.6	22	1	AX601670	ACCESSION:AX601670
	73	14.4	2.6	22	1	AX616971	ACCESSION:AX616971
	74	14.4	2.6	22	1	AX643845	ACCESSION:AX643845
	75	14.4	2.6	22	1	AX696030	ACCESSION:AX696030
	76	14.4	2.6	22	1	AX773003	ACCESSION:AX773003
	77	14.4	2.6	22	1	AX781387	ACCESSION:AX781387
	78	14.4	2.6	22	1	AX794404	ACCESSION:AX794404
	79	14.4	2.6	22	1	AX815443	ACCESSION:AX815443
	80	14.2	2.5	19	1	CQ801936	ACCESSION:CQ801936
c	81	14.2	2.5	19	1	I31281	ACCESSION:I31281
c	82	14.2	2.5	20	1	AR085554	ACCESSION:AR085554
	83	14.2	2.5	20	1	AR130151	ACCESSION:AR130151
	84	14.2	2.5	20	1	CQ763420	ACCESSION:CQ763420
c	85	14.2	2.5	20	1	AR216074	ACCESSION:AR216074
c	86	14.2	2.5	20	1	AR314483	ACCESSION:AR314483
	87	14.2	2.5	20	1	AX716655	ACCESSION:AX716655
c	88	14.2	2.5	20	1	BD101848	ACCESSION:BD101848
	89	14.2	2.5	21	1	BD242493	ACCESSION:BD242493
c	90	14.2	2.5	21	1	I24714	ACCESSION:I24714
	91	14.2	2.5	21	1	AX148061	ACCESSION:AX148061
	92	14.2	2.5	21	1	AX179540	ACCESSION:AX179540
	93	14.2	2.5	21	1	AX241164	ACCESSION:AX241164
c	94	14.2	2.5	21	1	AX353518	ACCESSION:AX353518
c	95	14.2	2.5	21	1	AX449621	ACCESSION:AX449621
	96	14.2	2.5	21	1	AX486786	ACCESSION:AX486786
c	97	14	2.5	17	1	AX475807	ACCESSION:AX475807
c	98	14	2.5	17	1	AX475811	ACCESSION:AX475811
	99	14	2.5	17	1	AX723378	ACCESSION:AX723378
	100	14	2.5	17	1	AX724426	ACCESSION:AX724426
	101	14	2.5	17	1	AX757648	ACCESSION:AX757648
c	102	14	2.5	20	1	AR173005	ACCESSION:AR173005
	103	14	2.5	20	1	AR373640	ACCESSION:AR373640
	104	14	2.5	20	1	AX418637	ACCESSION:AX418637
c	105	13.8	2.5	17	1	BD258524	ACCESSION:BD258524
c	106	13.8	2.5	17	1	CQ616606	ACCESSION:CQ616606

c 107	13.8	2.5	17	1	CQ622902	ACCESSION:CQ622902
c 108	13.8	2.5	17	1	CQ622903	ACCESSION:CQ622903
c 109	13.8	2.5	17	1	AR457669	ACCESSION:AR457669
c 110	13.8	2.5	17	1	AR463965	ACCESSION:AR463965
c 111	13.8	2.5	17	1	AR463966	ACCESSION:AR463966
c 112	13.8	2.5	17	1	AX672581	ACCESSION:AX672581
113	13.8	2.5	17	1	AX724865	ACCESSION:AX724865
114	13.8	2.5	17	1	AX728110	ACCESSION:AX728110
115	13.8	2.5	18	1	AX937390	ACCESSION:AX937390
116	13.8	2.5	19	1	BD196445	ACCESSION:BD196445
117	13.8	2.5	19	1	BD196765	ACCESSION:BD196765
118	13.8	2.5	19	1	AR296121	ACCESSION:AR296121
c 119	13.8	2.5	19	1	AX130773	ACCESSION:AX130773
120	13.8	2.5	19	1	AX378760	ACCESSION:AX378760
c 121	13.8	2.5	20	1	AR010207	ACCESSION:AR010207
122	13.8	2.5	20	1	AR126737	ACCESSION:AR126737
123	13.8	2.5	20	1	AR158934	ACCESSION:AR158934
124	13.8	2.5	20	1	AR158935	ACCESSION:AR158935
125	13.8	2.5	20	1	AR158936	ACCESSION:AR158936
126	13.8	2.5	20	1	AR158937	ACCESSION:AR158937
127	13.8	2.5	20	1	CQ764106	ACCESSION:CQ764106
c 128	13.8	2.5	20	1	CQ764152	ACCESSION:CQ764152
c 129	13.8	2.5	20	1	CQ764283	ACCESSION:CQ764283
c 130	13.8	2.5	20	1	CQ764771	ACCESSION:CQ764771
c 131	13.8	2.5	20	1	CQ764789	ACCESSION:CQ764789
c 132	13.8	2.5	20	1	CQ784105	ACCESSION:CQ784105
c 133	13.8	2.5	20	1	CQ803566	ACCESSION:CQ803566
c 134	13.8	2.5	20	1	E39195	ACCESSION:E39195
c 135	13.8	2.5	20	1	I43323	ACCESSION:I43323
c 136	13.8	2.5	20	1	I95826	ACCESSION:I95826
c 137	13.8	2.5	20	1	AR274662	ACCESSION:AR274662
c 138	13.8	2.5	20	1	AR312181	ACCESSION:AR312181
c 139	13.8	2.5	20	1	AR344858	ACCESSION:AR344858
140	13.8	2.5	20	1	AR438112	ACCESSION:AR438112
c 141	13.8	2.5	20	1	AX397813	ACCESSION:AX397813
c 142	13.8	2.5	20	1	AX452338	ACCESSION:AX452338
c 143	13.8	2.5	20	1	AX613393	ACCESSION:AX613393
c 144	13.8	2.5	20	1	BD000131	ACCESSION:BD000131
c 145	13.8	2.5	20	1	BD128029	ACCESSION:BD128029
c 146	13.8	2.5	21	1	AR296500	ACCESSION:AR296500
147	13.8	2.5	21	1	AR298436	ACCESSION:AR298436
c 148	13.8	2.5	21	1	AR344822	ACCESSION:AR344822
c 149	13.8	2.5	21	1	AR344857	ACCESSION:AR344857
150	13.8	2.5	21	1	AR452394	ACCESSION:AR452394
151	13.8	2.5	21	1	AX201215	ACCESSION:AX201215
c 152	13.8	2.5	21	1	AX397777	ACCESSION:AX397777
c 153	13.8	2.5	21	1	AX397812	ACCESSION:AX397812
c 154	13.8	2.5	21	1	AX555818	ACCESSION:AX555818
c 155	13.8	2.5	21	1	BD056555	ACCESSION:BD056555
c 156	13.6	2.4	20	1	AR103803	ACCESSION:AR103803
157	13.6	2.4	20	1	AR121022	ACCESSION:AR121022
c 158	13.6	2.4	20	1	AR126680	ACCESSION:AR126680
c 159	13.6	2.4	20	1	AR158732	ACCESSION:AR158732
160	13.6	2.4	20	1	AR173039	ACCESSION:AR173039
161	13.6	2.4	20	1	BD272643	ACCESSION:BD272643
162	13.6	2.4	20	1	E29952	ACCESSION:E29952
163	13.6	2.4	20	1	AR203118	ACCESSION:AR203118
164	13.6	2.4	20	1	AR220184	ACCESSION:AR220184
165	13.6	2.4	20	1	AR222265	ACCESSION:AR222265
166	13.6	2.4	20	1	AR294017	ACCESSION:AR294017
c 167	13.6	2.4	20	1	AR300314	ACCESSION:AR300314
c 168	13.6	2.4	20	1	AR373514	ACCESSION:AR373514
c 169	13.6	2.4	20	1	AR373791	ACCESSION:AR373791
170	13.6	2.4	20	1	AX066409	ACCESSION:AX066409
c 171	13.6	2.4	20	1	AX104161	ACCESSION:AX104161
c 172	13.6	2.4	20	1	AX104333	ACCESSION:AX104333
173	13.6	2.4	20	1	AX104584	ACCESSION:AX104584
c 174	13.6	2.4	20	1	AX104663	ACCESSION:AX104663
175	13.6	2.4	20	1	AX149016	ACCESSION:AX149016
c 176	13.6	2.4	20	1	AX294124	ACCESSION:AX294124
177	13.6	2.4	20	1	AX298787	ACCESSION:AX298787
c 178	13.6	2.4	20	1	AX354976	ACCESSION:AX354976
c 179	13.6	2.4	20	1	AX354977	ACCESSION:AX354977
180	13.6	2.4	20	1	AX354981	ACCESSION:AX354981
c 181	13.6	2.4	20	1	AX355514	ACCESSION:AX355514
c 182	13.6	2.4	20	1	AX418788	ACCESSION:AX418788
c 183	13.6	2.4	20	1	AX547214	ACCESSION:AX547214
c 184	13.6	2.4	20	1	AX547386	ACCESSION:AX547386
185	13.6	2.4	20	1	AX547637	ACCESSION:AX547637
c 186	13.6	2.4	20	1	AX547716	ACCESSION:AX547716
187	13.6	2.4	20	1	AX590963	ACCESSION:AX590963
c 188	13.6	2.4	20	1	BD130033	ACCESSION:BD130033
c 189	13.6	2.4	20	1	HSTNRAS14	ACCESSION:Y13522 Y
c 190	13.4	2.4	16	1	BD233092	ACCESSION:BD233092
c 191	13.4	2.4	16	1	AR328462	ACCESSION:AR328462
c 192	13.4	2.4	16	1	AX007646	ACCESSION:AX007646
c 193	13.4	2.4	17	1	AR088824	ACCESSION:AR088824
194	13.4	2.4	17	1	BD201172	ACCESSION:BD201172
195	13.4	2.4	17	1	BD258507	ACCESSION:BD258507
196	13.4	2.4	17	1	BD258508	ACCESSION:BD258508
197	13.4	2.4	17	1	BD258509	ACCESSION:BD258509
c 198	13.4	2.4	17	1	AR186544	ACCESSION:AR186544
c 199	13.4	2.4	17	1	AR186545	ACCESSION:AR186545
c 200	13.4	2.4	17	1	AR186546	ACCESSION:AR186546
c 201	13.4	2.4	17	1	AR323175	ACCESSION:AR323175
c 202	13.4	2.4	17	1	AR323176	ACCESSION:AR323176
c 203	13.4	2.4	17	1	AR323177	ACCESSION:AR323177
204	13.4	2.4	17	1	AX099948	ACCESSION:AX099948
205	13.4	2.4	17	1	AX214956	ACCESSION:AX214956
206	13.4	2.4	17	1	AX216792	ACCESSION:AX216792
c 207	13.4	2.4	17	1	AX227073	ACCESSION:AX227073
c 208	13.4	2.4	17	1	AX227726	ACCESSION:AX227726
c 209	13.4	2.4	17	1	AX732099	ACCESSION:AX732099
c 210	13.4	2.4	17	1	AX737962	ACCESSION:AX737962
c 211	13.4	2.4	17	1	AX759009	ACCESSION:AX759009
c 212	13.4	2.4	17	1	BD015290	ACCESSION:BD015290
c 213	13.4	2.4	18	1	AR087086	ACCESSION:AR087086
c 214	13.4	2.4	18	1	AR181458	ACCESSION:AR181458
c 215	13.4	2.4	18	1	AR181460	ACCESSION:AR181460
216	13.4	2.4	18	1	AR295535	ACCESSION:AR295535
c 217	13.4	2.4	18	1	AX268173	ACCESSION:AX268173
218	13.4	2.4	18	1	AX837788	ACCESSION:AX837788
c 219	13.4	2.4	19	1	BD000756	ACCESSION:BD000756
c 220	13.4	2.4	20	1	CQ764781	ACCESSION:CQ764781
c 221	13.4	2.4	20	1	CQ764797	ACCESSION:CQ764797
222	13.4	2.4	20	1	AR312943	ACCESSION:AR312943
c 223	13.4	2.4	20	1	AR313616	ACCESSION:AR313616
224	13.4	2.4	20	1	AR373738	ACCESSION:AR373738
225	13.4	2.4	20	1	AX149017	ACCESSION:AX149017
226	13.4	2.4	20	1	AX149191	ACCESSION:AX149191
227	13.4	2.4	20	1	AX418735	ACCESSION:AX418735
228	13.4	2.4	20	1	AX613548	ACCESSION:AX613548
c 229	13.2	2.4	18	1	AR160886	ACCESSION:AR160886
230	13.2	2.4	18	1	BD225045	ACCESSION:BD225045
c 231	13.2	2.4	18	1	CQ807870	ACCESSION:CQ807870
232	13.2	2.4	18	1	I83492	ACCESSION:I83492
233	13.2	2.4	18	1	AR211267	ACCESSION:AR211267
c 234	13.2	2.4	18	1	AX469443	ACCESSION:AX469443
235	13.2	2.4	18	1	AX473186	ACCESSION:AX473186
236	13.2	2.4	19	1	CQ801888	ACCESSION:CQ801888
237	13.2	2.4	19	1	AR292807	ACCESSION:AR292807
238	13.2	2.4	19	1	AR342579	ACCESSION:AR342579
c 239	13.2	2.4	19	1	AX130690	ACCESSION:AX130690
240	13.2	2.4	19	1	AX131033	ACCESSION:AX131033
241	13.2	2.4	19	1	AX352872	ACCESSION:AX352872
242	13.2	2.4	19	1	AX362717	ACCESSION:AX362717
c 243	13.2	2.4	19	1	AX643288	ACCESSION:AX643288
244	13.2	2.4	19	1	AX643291	ACCESSION:AX643291
c 245	13.2	2.4	19	1	AX711905	ACCESSION:AX711905
c 246	13.2	2.4	20	1	AR015993	ACCESSION:AR015993
247	13.2	2.4	20	1	AR076700	ACCESSION:AR076700
c 248	13.2	2.4	20	1	AR082034	ACCESSION:AR082034
c 249	13.2	2.4	20	1	AR112680	ACCESSION:AR112680
250	13.2	2.4	20	1	AR153557	ACCESSION:AR153557
251	13.2	2.4	20	1	AR162752	ACCESSION:AR162752
c 252	13.2	2.4	20	1	BD179443	ACCESSION:BD179443

	253	13.2	2.4	20	1	BD189560	ACCESSION:BD189560
	254	13.2	2.4	20	1	BD237728	ACCESSION:BD237728
	255	13.2	2.4	20	1	BD262872	ACCESSION:BD262872
c	256	13.2	2.4	20	1	CQ762347	ACCESSION:CQ762347
	257	13.2	2.4	20	1	CQ762836	ACCESSION:CQ762836
c	258	13.2	2.4	20	1	CQ762888	ACCESSION:CQ762888
c	259	13.2	2.4	20	1	CQ763822	ACCESSION:CQ763822
c	260	13.2	2.4	20	1	CQ766734	ACCESSION:CQ766734
c	261	13.2	2.4	20	1	E15162	ACCESSION:E15162
	262	13.2	2.4	20	1	E22414	ACCESSION:E22414
	263	13.2	2.4	20	1	E29944	ACCESSION:E29944
c	264	13.2	2.4	20	1	E40658	ACCESSION:E40658
c	265	13.2	2.4	20	1	I31432	ACCESSION:I31432
	266	13.2	2.4	20	1	AR182757	ACCESSION:AR182757
c	267	13.2	2.4	20	1	AR224726	ACCESSION:AR224726
c	268	13.2	2.4	20	1	AR265965	ACCESSION:AR265965
c	269	13.2	2.4	20	1	AR292352	ACCESSION:AR292352
	270	13.2	2.4	20	1	AR300837	ACCESSION:AR300837
	271	13.2	2.4	20	1	AR311776	ACCESSION:AR311776
c	272	13.2	2.4	20	1	AR488808	ACCESSION:AR488808
	273	13.2	2.4	20	1	AX004337	ACCESSION:AX004337
	274	13.2	2.4	20	1	AX020603	ACCESSION:AX020603
	275	13.2	2.4	20	1	AX026102	ACCESSION:AX026102
	276	13.2	2.4	20	1	AX149070	ACCESSION:AX149070
	277	13.2	2.4	20	1	AX174999	ACCESSION:AX174999
c	278	13.2	2.4	20	1	AX298759	ACCESSION:AX298759
	279	13.2	2.4	20	1	AX587369	ACCESSION:AX587369
	280	13.2	2.4	20	1	AX613762	ACCESSION:AX613762
	281	13.2	2.4	20	1	AX804495	ACCESSION:AX804495
c	282	13.2	2.4	20	1	BD061540	ACCESSION:BD061540
c	283	13	2.3	13	1	CQ788045	ACCESSION:CQ788045
c	284	13	2.3	13	1	CQ788047	ACCESSION:CQ788047
c	285	13	2.3	13	1	CQ788049	ACCESSION:CQ788049
c	286	13	2.3	17	1	AX227561	ACCESSION:AX227561
	287	13	2.3	17	1	AX264923	ACCESSION:AX264923
c	288	13	2.3	17	1	AX264924	ACCESSION:AX264924
	289	13	2.3	17	1	AX264927	ACCESSION:AX264927
c	290	13	2.3	17	1	AX264928	ACCESSION:AX264928
	291	13	2.3	17	1	AX264931	ACCESSION:AX264931
c	292	13	2.3	17	1	AX264932	ACCESSION:AX264932
	293	13	2.3	17	1	AX264935	ACCESSION:AX264935
c	294	13	2.3	17	1	AX264936	ACCESSION:AX264936
c	295	13	2.3	17	1	AX475806	ACCESSION:AX475806
c	296	13	2.3	17	1	AX475812	ACCESSION:AX475812
c	297	13	2.3	17	1	AX531446	ACCESSION:AX531446
c	298	13	2.3	17	1	AX531447	ACCESSION:AX531447
c	299	13	2.3	17	1	AX531448	ACCESSION:AX531448
c	300	13	2.3	17	1	AX531449	ACCESSION:AX531449
c	301	13	2.3	17	1	AX531450	ACCESSION:AX531450
c	302	13	2.3	17	1	AX724943	ACCESSION:AX724943
	303	13	2.3	17	1	AX725229	ACCESSION:AX725229
c	304	13	2.3	17	1	AX761147	ACCESSION:AX761147
c	305	13	2.3	18	1	BD263129	ACCESSION:BD263129
c	306	13	2.3	19	1	AR256296	ACCESSION:AR256296
	307	13	2.3	19	1	AX131031	ACCESSION:AX131031
	308	13	2.3	19	1	AX131032	ACCESSION:AX131032
	309	13	2.3	19	1	AX817168	ACCESSION:AX817168
	310	13	2.3	19	1	AX817183	ACCESSION:AX817183
	311	13	2.3	19	1	AX824392	ACCESSION:AX824392
c	312	13	2.3	20	1	AR016534	ACCESSION:AR016534
c	313	13	2.3	20	1	AR021254	ACCESSION:AR021254
c	314	13	2.3	20	1	AR036808	ACCESSION:AR036808
	315	13	2.3	20	1	I22624	ACCESSION:I22624
c	316	13	2.3	20	1	I22630	ACCESSION:I22630
c	317	13	2.3	20	1	I30424	ACCESSION:I30424
c	318	13	2.3	20	1	I35668	ACCESSION:I35668
	319	13	2.3	20	1	I47449	ACCESSION:I47449
c	320	13	2.3	20	1	I47455	ACCESSION:I47455
c	321	13	2.3	20	1	AR182967	ACCESSION:AR182967
c	322	13	2.3	20	1	AR428770	ACCESSION:AR428770
c	323	13	2.3	20	1	AX059671	ACCESSION:AX059671
	324	13	2.3	20	1	AX462797	ACCESSION:AX462797
	325	13	2.3	20	1	AX613487	ACCESSION:AX613487
	326	12.8	2.3	16	1	AR087167	ACCESSION:AR087167
	327	12.8	2.3	16	1	AR150613	ACCESSION:AR150613
	328	12.8	2.3	16	1	E36066	ACCESSION:E36066
	329	12.8	2.3	16	1	I42184	ACCESSION:I42184
	330	12.8	2.3	16	1	I49622	ACCESSION:I49622
	331	12.8	2.3	16	1	I85795	ACCESSION:I85795
	332	12.8	2.3	16	1	AR200487	ACCESSION:AR200487
	333	12.8	2.3	16	1	AR209859	ACCESSION:AR209859
	334	12.8	2.3	16	1	AR371293	ACCESSION:AR371293
	335	12.8	2.3	16	1	AR489514	ACCESSION:AR489514
	336	12.8	2.3	16	1	AR491125	ACCESSION:AR491125
	337	12.8	2.3	16	1	AX033374	ACCESSION:AX033374
	338	12.8	2.3	17	1	A88310	ACCESSION:A88310
	339	12.8	2.3	17	1	A90277	ACCESSION:A90277
	340	12.8	2.3	17	1	AR045725	ACCESSION:AR045725
c	341	12.8	2.3	17	1	AR047384	ACCESSION:AR047384
c	342	12.8	2.3	17	1	BD198684	ACCESSION:BD198684
c	343	12.8	2.3	17	1	BD255068	ACCESSION:BD255068
	344	12.8	2.3	17	1	BD255135	ACCESSION:BD255135
	345	12.8	2.3	17	1	BD255457	ACCESSION:BD255457
	346	12.8	2.3	17	1	BD258463	ACCESSION:BD258463
c	347	12.8	2.3	17	1	CQ616605	ACCESSION:CQ616605
c	348	12.8	2.3	17	1	CQ616607	ACCESSION:CQ616607
c	349	12.8	2.3	17	1	CQ616840	ACCESSION:CQ616840
c	350	12.8	2.3	17	1	CQ616841	ACCESSION:CQ616841
c	351	12.8	2.3	17	1	CQ622901	ACCESSION:CQ622901
c	352	12.8	2.3	17	1	CQ622904	ACCESSION:CQ622904
	353	12.8	2.3	17	1	CQ623217	ACCESSION:CQ623217
	354	12.8	2.3	17	1	CQ623218	ACCESSION:CQ623218
c	355	12.8	2.3	17	1	I37589	ACCESSION:I37589
	356	12.8	2.3	17	1	I37666	ACCESSION:I37666
	357	12.8	2.3	17	1	I52777	ACCESSION:I52777
c	358	12.8	2.3	17	1	I54436	ACCESSION:I54436
c	359	12.8	2.3	17	1	I94439	ACCESSION:I94439
	360	12.8	2.3	17	1	I94516	ACCESSION:I94516
c	361	12.8	2.3	17	1	AR186716	ACCESSION:AR186716
c	362	12.8	2.3	17	1	AR186745	ACCESSION:AR186745
c	363	12.8	2.3	17	1	AR186746	ACCESSION:AR186746
	364	12.8	2.3	17	1	AR187030	ACCESSION:AR187030
c	365	12.8	2.3	17	1	AR190544	ACCESSION:AR190544
c	366	12.8	2.3	17	1	AR215128	ACCESSION:AR215128
c	367	12.8	2.3	17	1	AR302370	ACCESSION:AR302370
c	368	12.8	2.3	17	1	AR323347	ACCESSION:AR323347
c	369	12.8	2.3	17	1	AR323376	ACCESSION:AR323376
c	370	12.8	2.3	17	1	AR323377	ACCESSION:AR323377
	371	12.8	2.3	17	1	AR323640	ACCESSION:AR323640
c	372	12.8	2.3	17	1	AR325467	ACCESSION:AR325467
c	373	12.8	2.3	17	1	AR373242	ACCESSION:AR373242
c	374	12.8	2.3	17	1	AR401628	ACCESSION:AR401628
	375	12.8	2.3	17	1	AR402205	ACCESSION:AR402205
	376	12.8	2.3	17	1	AR402206	ACCESSION:AR402206
	377	12.8	2.3	17	1	AR433888	ACCESSION:AR433888
	378	12.8	2.3	17	1	AR433889	ACCESSION:AR433889
c	379	12.8	2.3	17	1	AR442961	ACCESSION:AR442961
c	380	12.8	2.3	17	1	AR457668	ACCESSION:AR457668
c	381	12.8	2.3	17	1	AR457670	ACCESSION:AR457670
c	382	12.8	2.3	17	1	AR457903	ACCESSION:AR457903
c	383	12.8	2.3	17	1	AR457904	ACCESSION:AR457904
c	384	12.8	2.3	17	1	AR463964	ACCESSION:AR463964
c	385	12.8	2.3	17	1	AR463967	ACCESSION:AR463967
	386	12.8	2.3	17	1	AR464280	ACCESSION:AR464280
	387	12.8	2.3	17	1	AR464281	ACCESSION:AR464281
c	388	12.8	2.3	17	1	AX217003	ACCESSION:AX217003
c	389	12.8	2.3	17	1	AX217396	ACCESSION:AX217396
c	390	12.8	2.3	17	1	AX217762	ACCESSION:AX217762
	391	12.8	2.3	17	1	AX325389	ACCESSION:AX325389
c	392	12.8	2.3	17	1	AX325390	ACCESSION:AX325390
	393	12.8	2.3	17	1	AX499861	ACCESSION:AX499861
	394	12.8	2.3	17	1	AX499862	ACCESSION:AX499862
	395	12.8	2.3	17	1	AX615440	ACCESSION:AX615440
	396	12.8	2.3	17	1	AX615441	ACCESSION:AX615441
	397	12.8	2.3	17	1	AX671912	ACCESSION:AX671912
c	398	12.8	2.3	17	1	AX701192	ACCESSION:AX701192

c	399	12.8	2.3	17	1	AX723941	ACCESSION:AX723941
c	400	12.8	2.3	17	1	AX725421	ACCESSION:AX725421
	401	12.8	2.3	17	1	AX726157	ACCESSION:AX726157
	402	12.8	2.3	17	1	AX726760	ACCESSION:AX726760
	403	12.8	2.3	17	1	AX729543	ACCESSION:AX729543
	404	12.8	2.3	17	1	AX730456	ACCESSION:AX730456
	405	12.8	2.3	17	1	AX732299	ACCESSION:AX732299
	406	12.8	2.3	17	1	AX734059	ACCESSION:AX734059
	407	12.8	2.3	17	1	AX734455	ACCESSION:AX734455
	408	12.8	2.3	17	1	AX736680	ACCESSION:AX736680
	409	12.8	2.3	17	1	AX736697	ACCESSION:AX736697
	410	12.8	2.3	17	1	AX738198	ACCESSION:AX738198
	411	12.8	2.3	17	1	AX745237	ACCESSION:AX745237
	412	12.8	2.3	17	1	AX745238	ACCESSION:AX745238
c	413	12.8	2.3	17	1	AX753720	ACCESSION:AX753720
c	414	12.8	2.3	17	1	AX753721	ACCESSION:AX753721
c	415	12.8	2.3	17	1	AX757427	ACCESSION:AX757427
	416	12.8	2.3	17	1	AX758072	ACCESSION:AX758072
	417	12.8	2.3	17	1	AX759770	ACCESSION:AX759770
c	418	12.8	2.3	17	1	AX761192	ACCESSION:AX761192
	419	12.8	2.3	17	1	AX762021	ACCESSION:AX762021
	420	12.8	2.3	17	1	AX762707	ACCESSION:AX762707
	421	12.8	2.3	17	1	AX784027	ACCESSION:AX784027
	422	12.8	2.3	17	1	AX784028	ACCESSION:AX784028
	423	12.8	2.3	17	1	BD065823	ACCESSION:BD065823
	424	12.8	2.3	17	1	BD067705	ACCESSION:BD067705
	425	12.8	2.3	17	1	BD067706	ACCESSION:BD067706
	426	12.8	2.3	17	1	BD104999	ACCESSION:BD104999
	427	12.8	2.3	18	1	A51078	ACCESSION:A51078
	428	12.8	2.3	18	1	AR042375	ACCESSION:AR042375
	429	12.8	2.3	18	1	AR052283	ACCESSION:AR052283
c	430	12.8	2.3	18	1	AR071521	ACCESSION:AR071521
	431	12.8	2.3	18	1	AR112245	ACCESSION:AR112245
c	432	12.8	2.3	18	1	CQ799869	ACCESSION:CQ799869
	433	12.8	2.3	18	1	AR241194	ACCESSION:AR241194
	434	12.8	2.3	18	1	AR262651	ACCESSION:AR262651
c	435	12.8	2.3	18	1	AR296134	ACCESSION:AR296134
	436	12.8	2.3	18	1	AR299795	ACCESSION:AR299795
	437	12.8	2.3	18	1	AX599276	ACCESSION:AX599276
c	438	12.8	2.3	18	1	AX599369	ACCESSION:AX599369
c	439	12.8	2.3	18	1	AX599828	ACCESSION:AX599828
	440	12.8	2.3	18	1	AX599830	ACCESSION:AX599830
c	441	12.8	2.3	18	1	AX705541	ACCESSION:AX705541
	442	12.8	2.3	18	1	AX705543	ACCESSION:AX705543
	443	12.8	2.3	18	1	AX767708	ACCESSION:AX767708
c	444	12.8	2.3	18	1	AX796233	ACCESSION:AX796233
c	445	12.8	2.3	18	1	AX822220	ACCESSION:AX822220
c	446	12.8	2.3	18	1	AX822735	ACCESSION:AX822735
c	447	12.8	2.3	18	1	AX825860	ACCESSION:AX825860
c	448	12.8	2.3	18	1	AX826375	ACCESSION:AX826375
c	449	12.8	2.3	18	1	BD167823	ACCESSION:BD167823
	450	12.8	2.3	19	1	CQ801869	ACCESSION:CQ801869
	451	12.8	2.3	19	1	CQ801892	ACCESSION:CQ801892
c	452	12.8	2.3	19	1	AR279193	ACCESSION:AR279193
	453	12.8	2.3	19	1	AR292312	ACCESSION:AR292312
c	454	12.8	2.3	19	1	AR299444	ACCESSION:AR299444
	455	12.8	2.3	19	1	AR411295	ACCESSION:AR411295
	456	12.8	2.3	19	1	AX130338	ACCESSION:AX130338
c	457	12.8	2.3	19	1	AX130772	ACCESSION:AX130772
c	458	12.8	2.3	19	1	AX250360	ACCESSION:AX250360
c	459	12.8	2.3	19	1	AX643289	ACCESSION:AX643289
	460	12.8	2.3	19	1	AX643292	ACCESSION:AX643292
	461	12.8	2.3	19	1	AX804547	ACCESSION:AX804547
c	462	12.8	2.3	19	1	BD087891	ACCESSION:BD087891
c	463	12.8	2.3	19	1	AB068498	ACCESSION:AB068498
c	464	12.6	2.3	19	1	AR065153	ACCESSION:AR065153
c	465	12.6	2.3	19	1	AR093204	ACCESSION:AR093204
c	466	12.6	2.3	19	1	CQ795418	ACCESSION:CQ795418
c	467	12.6	2.3	19	1	AR297167	ACCESSION:AR297167
c	468	12.6	2.3	19	1	AR297401	ACCESSION:AR297401
	469	12.6	2.3	19	1	AX031263	ACCESSION:AX031263
	470	12.6	2.3	19	1	AX130173	ACCESSION:AX130173
	471	12.6	2.3	19	1	AX130174	ACCESSION:AX130174
	472	12.6	2.3	19	1	AX132204	ACCESSION:AX132204
	473	12.6	2.3	19	1	AX230255	ACCESSION:AX230255
	474	12.6	2.3	19	1	AX353501	ACCESSION:AX353501
	475	12.6	2.3	19	1	AX801965	ACCESSION:AX801965
c	476	12.6	2.3	19	1	AX826874	ACCESSION:AX826874
	477	12.6	2.3	19	1	BD082149	ACCESSION:BD082149
	478	12.6	2.3	19	1	BD089946	ACCESSION:BD089946
	479	12.4	2.2	14	1	E15991	ACCESSION:E15991
c	480	12.4	2.2	14	1	E15992	ACCESSION:E15992
	481	12.4	2.2	15	1	A57014	ACCESSION:A57014
	482	12.4	2.2	15	1	A57026	ACCESSION:A57026
	483	12.4	2.2	15	1	AR084006	ACCESSION:AR084006
	484	12.4	2.2	15	1	AR084018	ACCESSION:AR084018
c	485	12.4	2.2	15	1	I77875	ACCESSION:I77875
c	486	12.4	2.2	15	1	I77876	ACCESSION:I77876
c	487	12.4	2.2	15	1	AX638372	ACCESSION:AX638372
c	488	12.4	2.2	15	1	AX638374	ACCESSION:AX638374
c	489	12.4	2.2	15	1	ATH551615	ACCESSION:AJ551615
	490	12.4	2.2	16	1	BD225192	ACCESSION:BD225192
	491	12.4	2.2	16	1	BD225194	ACCESSION:BD225194
c	492	12.4	2.2	16	1	BD233093	ACCESSION:BD233093
	493	12.4	2.2	16	1	I43728	ACCESSION:I43728
	494	12.4	2.2	16	1	I43762	ACCESSION:I43762
c	495	12.4	2.2	16	1	AX007647	ACCESSION:AX007647
c	496	12.4	2.2	16	1	AX067881	ACCESSION:AX067881
c	497	12.4	2.2	17	1	BD241617	ACCESSION:BD241617
c	498	12.4	2.2	17	1	BD241618	ACCESSION:BD241618
	499	12.4	2.2	17	1	BD254290	ACCESSION:BD254290
	500	12.4	2.2	17	1	BD254291	ACCESSION:BD254291
c	501	12.4	2.2	17	1	BD255438	ACCESSION:BD255438
	502	12.4	2.2	17	1	BD258506	ACCESSION:BD258506
	503	12.4	2.2	17	1	BD258510	ACCESSION:BD258510
c	504	12.4	2.2	17	1	CQ622447	ACCESSION:CQ622447
c	505	12.4	2.2	17	1	CQ622448	ACCESSION:CQ622448
c	506	12.4	2.2	17	1	CQ622449	ACCESSION:CQ622449
c	507	12.4	2.2	17	1	CQ622450	ACCESSION:CQ622450
c	508	12.4	2.2	17	1	CQ622899	ACCESSION:CQ622899
c	509	12.4	2.2	17	1	CQ622900	ACCESSION:CQ622900
	510	12.4	2.2	17	1	AR191935	ACCESSION:AR191935
	511	12.4	2.2	17	1	AR325828	ACCESSION:AR325828
c	512	12.4	2.2	17	1	AR327467	ACCESSION:AR327467
c	513	12.4	2.2	17	1	AR329256	ACCESSION:AR329256
c	514	12.4	2.2	17	1	AR329257	ACCESSION:AR329257
c	515	12.4	2.2	17	1	AR463510	ACCESSION:AR463510
c	516	12.4	2.2	17	1	AR463511	ACCESSION:AR463511
c	517	12.4	2.2	17	1	AR463512	ACCESSION:AR463512
c	518	12.4	2.2	17	1	AR463513	ACCESSION:AR463513
c	519	12.4	2.2	17	1	AR463962	ACCESSION:AR463962
c	520	12.4	2.2	17	1	AR463963	ACCESSION:AR463963
c	521	12.4	2.2	17	1	AR483118	ACCESSION:AR483118
c	522	12.4	2.2	17	1	AR483119	ACCESSION:AR483119
	523	12.4	2.2	17	1	AX215153	ACCESSION:AX215153
	524	12.4	2.2	17	1	AX215836	ACCESSION:AX215836
	525	12.4	2.2	17	1	AX216307	ACCESSION:AX216307
	526	12.4	2.2	17	1	AX216852	ACCESSION:AX216852
	527	12.4	2.2	17	1	AX615438	ACCESSION:AX615438
	528	12.4	2.2	17	1	AX615439	ACCESSION:AX615439
c	529	12.4	2.2	17	1	AX671931	ACCESSION:AX671931
	530	12.4	2.2	17	1	AX674779	ACCESSION:AX674779
	531	12.4	2.2	17	1	AX724876	ACCESSION:AX724876
	532	12.4	2.2	17	1	AX724985	ACCESSION:AX724985
c	533	12.4	2.2	17	1	AX725887	ACCESSION:AX725887
c	534	12.4	2.2	17	1	AX727486	ACCESSION:AX727486
	535	12.4	2.2	17	1	AX728098	ACCESSION:AX728098
	536	12.4	2.2	17	1	AX728111	ACCESSION:AX728111
	537	12.4	2.2	17	1	AX729133	ACCESSION:AX729133
c	538	12.4	2.2	17	1	AX729292	ACCESSION:AX729292
	539	12.4	2.2	17	1	AX729591	ACCESSION:AX729591
	540	12.4	2.2	17	1	AX732108	ACCESSION:AX732108
	541	12.4	2.2	17	1	AX732198	ACCESSION:AX732198
c	542	12.4	2.2	17	1	AX732462	ACCESSION:AX732462
c	543	12.4	2.2	17	1	AX733208	ACCESSION:AX733208
	544	12.4	2.2	17	1	AX737191	ACCESSION:AX737191

	545	12.4	2.2	17	1	AX739552	ACCESSION:AX739552
	546	12.4	2.2	17	1	AX739645	ACCESSION:AX739645
c	547	12.4	2.2	17	1	AX739684	ACCESSION:AX739684
	548	12.4	2.2	17	1	AX758411	ACCESSION:AX758411
c	549	12.4	2.2	17	1	AX758532	ACCESSION:AX758532
	550	12.4	2.2	17	1	AX760931	ACCESSION:AX760931
	551	12.4	2.2	17	1	AX761164	ACCESSION:AX761164
c	552	12.4	2.2	17	1	AX782132	ACCESSION:AX782132
c	553	12.4	2.2	17	1	AX782133	ACCESSION:AX782133
c	554	12.4	2.2	17	1	AX782134	ACCESSION:AX782134
c	555	12.4	2.2	17	1	AX782135	ACCESSION:AX782135
	556	12.4	2.2	18	1	AR091955	ACCESSION:AR091955
c	557	12.4	2.2	18	1	AR157079	ACCESSION:AR157079
	558	12.4	2.2	18	1	CQ807688	ACCESSION:CQ807688
	559	12.4	2.2	18	1	E32204	ACCESSION:E32204
	560	12.4	2.2	18	1	AR208065	ACCESSION:AR208065
	561	12.4	2.2	18	1	AR292943	ACCESSION:AR292943
	562	12.4	2.2	18	1	AR293122	ACCESSION:AR293122
	563	12.4	2.2	18	1	AX149041	ACCESSION:AX149041
	564	12.4	2.2	18	1	AX149269	ACCESSION:AX149269
c	565	12.4	2.2	18	1	AX352838	ACCESSION:AX352838
c	566	12.4	2.2	18	1	AX362683	ACCESSION:AX362683
c	567	12.4	2.2	18	1	AX705586	ACCESSION:AX705586
	568	12.4	2.2	18	1	AX705588	ACCESSION:AX705588
c	569	12.4	2.2	18	1	AX718603	ACCESSION:AX718603
c	570	12.4	2.2	18	1	AX838193	ACCESSION:AX838193
c	571	12.4	2.2	18	1	AX838330	ACCESSION:AX838330
c	572	12.4	2.2	19	1	DOGP34001	ACCESSION:L24222
c	573	12.4	2.2	19	1	A50598	ACCESSION:A50598
c	574	12.4	2.2	19	1	A88459	ACCESSION:A88459
c	575	12.4	2.2	19	1	A90426	ACCESSION:A90426
	576	12.4	2.2	19	1	AR019632	ACCESSION:AR019632
c	577	12.4	2.2	19	1	AR147275	ACCESSION:AR147275
	578	12.4	2.2	19	1	BD196792	ACCESSION:BD196792
c	579	12.4	2.2	19	1	BD221975	ACCESSION:BD221975
	580	12.4	2.2	19	1	E32039	ACCESSION:E32039
	581	12.4	2.2	19	1	I34186	ACCESSION:I34186
c	582	12.4	2.2	19	1	AR181876	ACCESSION:AR181876
c	583	12.4	2.2	19	1	AR211905	ACCESSION:AR211905
	584	12.4	2.2	19	1	AR294043	ACCESSION:AR294043
	585	12.4	2.2	19	1	AR296315	ACCESSION:AR296315
	586	12.4	2.2	19	1	AR297353	ACCESSION:AR297353
c	587	12.4	2.2	19	1	AR298026	ACCESSION:AR298026
	588	12.4	2.2	19	1	AX128789	ACCESSION:AX128789
	589	12.4	2.2	19	1	AX131146	ACCESSION:AX131146
	590	12.4	2.2	19	1	AX511545	ACCESSION:AX511545
c	591	12.4	2.2	19	1	BD065972	ACCESSION:BD065972
c	592	12.2	2.2	17	1	A34261	ACCESSION:A34261
	593	12.2	2.2	17	1	AR040311	ACCESSION:AR040311
c	594	12.2	2.2	17	1	AR047348	ACCESSION:AR047348
	595	12.2	2.2	17	1	BD200775	ACCESSION:BD200775
c	596	12.2	2.2	17	1	BD202684	ACCESSION:BD202684
c	597	12.2	2.2	17	1	BD202685	ACCESSION:BD202685
	598	12.2	2.2	17	1	BD203240	ACCESSION:BD203240
	599	12.2	2.2	17	1	BD203241	ACCESSION:BD203241
	600	12.2	2.2	17	1	BD252017	ACCESSION:BD252017
c	601	12.2	2.2	17	1	BD254561	ACCESSION:BD254561
	602	12.2	2.2	17	1	BD254671	ACCESSION:BD254671
c	603	12.2	2.2	17	1	BD254848	ACCESSION:BD254848
c	604	12.2	2.2	17	1	BD255067	ACCESSION:BD255067
	605	12.2	2.2	17	1	BD256747	ACCESSION:BD256747
c	606	12.2	2.2	17	1	BD256795	ACCESSION:BD256795
c	607	12.2	2.2	17	1	BD258526	ACCESSION:BD258526
c	608	12.2	2.2	17	1	BD259163	ACCESSION:BD259163
c	609	12.2	2.2	17	1	BD259606	ACCESSION:BD259606
c	610	12.2	2.2	17	1	CQ617368	ACCESSION:CQ617368
c	611	12.2	2.2	17	1	CQ618044	ACCESSION:CQ618044
	612	12.2	2.2	17	1	CQ623216	ACCESSION:CQ623216
	613	12.2	2.2	17	1	CQ623220	ACCESSION:CQ623220
c	614	12.2	2.2	17	1	CQ625804	ACCESSION:CQ625804
c	615	12.2	2.2	17	1	I54400	ACCESSION:I54400
	616	12.2	2.2	17	1	AR190143	ACCESSION:AR190143
c	617	12.2	2.2	17	1	AR191909	ACCESSION:AR191909
	618	12.2	2.2	17	1	AR192254	ACCESSION:AR192254
	619	12.2	2.2	17	1	AR192523	ACCESSION:AR192523
	620	12.2	2.2	17	1	AR192669	ACCESSION:AR192669
	621	12.2	2.2	17	1	AR325119	ACCESSION:AR325119
c	622	12.2	2.2	17	1	AR325803	ACCESSION:AR325803
	623	12.2	2.2	17	1	AR326125	ACCESSION:AR326125
	624	12.2	2.2	17	1	AR326392	ACCESSION:AR326392
	625	12.2	2.2	17	1	AR326538	ACCESSION:AR326538
	626	12.2	2.2	17	1	AR327517	ACCESSION:AR327517
	627	12.2	2.2	17	1	AR327898	ACCESSION:AR327898
	628	12.2	2.2	17	1	AR328753	ACCESSION:AR328753
	629	12.2	2.2	17	1	AR328754	ACCESSION:AR328754
	630	12.2	2.2	17	1	AR328797	ACCESSION:AR328797
	631	12.2	2.2	17	1	AR402410	ACCESSION:AR402410
	632	12.2	2.2	17	1	AR402411	ACCESSION:AR402411
	633	12.2	2.2	17	1	AR402412	ACCESSION:AR402412
c	634	12.2	2.2	17	1	AR458431	ACCESSION:AR458431
c	635	12.2	2.2	17	1	AR459107	ACCESSION:AR459107
	636	12.2	2.2	17	1	AR464279	ACCESSION:AR464279
	637	12.2	2.2	17	1	AR464283	ACCESSION:AR464283
c	638	12.2	2.2	17	1	AR466867	ACCESSION:AR466867
	639	12.2	2.2	17	1	AX035608	ACCESSION:AX035608
	640	12.2	2.2	17	1	AX191379	ACCESSION:AX191379
	641	12.2	2.2	17	1	AX215403	ACCESSION:AX215403
c	642	12.2	2.2	17	1	AX216540	ACCESSION:AX216540
c	643	12.2	2.2	17	1	AX216764	ACCESSION:AX216764
c	644	12.2	2.2	17	1	AX216767	ACCESSION:AX216767
c	645	12.2	2.2	17	1	AX217761	ACCESSION:AX217761
c	646	12.2	2.2	17	1	AX227074	ACCESSION:AX227074
c	647	12.2	2.2	17	1	AX422002	ACCESSION:AX422002
	648	12.2	2.2	17	1	AX499859	ACCESSION:AX499859
	649	12.2	2.2	17	1	AX499860	ACCESSION:AX499860
	650	12.2	2.2	17	1	AX531444	ACCESSION:AX531444
	651	12.2	2.2	17	1	AX532422	ACCESSION:AX532422
	652	12.2	2.2	17	1	AX578529	ACCESSION:AX578529
c	653	12.2	2.2	17	1	AX578599	ACCESSION:AX578599
	654	12.2	2.2	17	1	AX578694	ACCESSION:AX578694
c	655	12.2	2.2	17	1	AX578704	ACCESSION:AX578704
	656	12.2	2.2	17	1	AX579013	ACCESSION:AX579013
c	657	12.2	2.2	17	1	AX579108	ACCESSION:AX579108
	658	12.2	2.2	17	1	AX579357	ACCESSION:AX579357
	659	12.2	2.2	17	1	AX579923	ACCESSION:AX579923
	660	12.2	2.2	17	1	AX615475	ACCESSION:AX615475
c	661	12.2	2.2	17	1	AX616009	ACCESSION:AX616009
c	662	12.2	2.2	17	1	AX616010	ACCESSION:AX616010
	663	12.2	2.2	17	1	AX648721	ACCESSION:AX648721
c	664	12.2	2.2	17	1	AX648885	ACCESSION:AX648885
	665	12.2	2.2	17	1	AX671668	ACCESSION:AX671668
	666	12.2	2.2	17	1	AX672474	ACCESSION:AX672474
c	667	12.2	2.2	17	1	AX673144	ACCESSION:AX673144
c	668	12.2	2.2	17	1	AX673426	ACCESSION:AX673426
c	669	12.2	2.2	17	1	AX676068	ACCESSION:AX676068
c	670	12.2	2.2	17	1	AX688571	ACCESSION:AX688571
c	671	12.2	2.2	17	1	AX688572	ACCESSION:AX688572
	672	12.2	2.2	17	1	AX691383	ACCESSION:AX691383
	673	12.2	2.2	17	1	AX724984	ACCESSION:AX724984
c	674	12.2	2.2	17	1	AX725130	ACCESSION:AX725130
c	675	12.2	2.2	17	1	AX725612	ACCESSION:AX725612
c	676	12.2	2.2	17	1	AX725636	ACCESSION:AX725636
	677	12.2	2.2	17	1	AX726337	ACCESSION:AX726337
	678	12.2	2.2	17	1	AX728311	ACCESSION:AX728311
c	679	12.2	2.2	17	1	AX728452	ACCESSION:AX728452
c	680	12.2	2.2	17	1	AX728622	ACCESSION:AX728622
	681	12.2	2.2	17	1	AX728884	ACCESSION:AX728884
c	682	12.2	2.2	17	1	AX729106	ACCESSION:AX729106
c	683	12.2	2.2	17	1	AX729156	ACCESSION:AX729156
c	684	12.2	2.2	17	1	AX729976	ACCESSION:AX729976
	685	12.2	2.2	17	1	AX730554	ACCESSION:AX730554
c	686	12.2	2.2	17	1	AX732166	ACCESSION:AX732166
c	687	12.2	2.2	17	1	AX732384	ACCESSION:AX732384
	688	12.2	2.2	17	1	AX733160	ACCESSION:AX733160
c	689	12.2	2.2	17	1	AX734208	ACCESSION:AX734208
c	690	12.2	2.2	17	1	AX734695	ACCESSION:AX734695

c 691	12.2	2.2	17	1	AX734749	ACCESSION:AX734749
c 692	12.2	2.2	17	1	AX735618	ACCESSION:AX735618
693	12.2	2.2	17	1	AX736736	ACCESSION:AX736736
c 694	12.2	2.2	17	1	AX738626	ACCESSION:AX738626
695	12.2	2.2	17	1	AX739071	ACCESSION:AX739071
696	12.2	2.2	17	1	AX739114	ACCESSION:AX739114
c 697	12.2	2.2	17	1	AX745062	ACCESSION:AX745062
c 698	12.2	2.2	17	1	AX745427	ACCESSION:AX745427
c 699	12.2	2.2	17	1	AX758047	ACCESSION:AX758047
c 700	12.2	2.2	17	1	AX758341	ACCESSION:AX758341
c 701	12.2	2.2	17	1	AX759011	ACCESSION:AX759011
702	12.2	2.2	17	1	AX760431	ACCESSION:AX760431
c 703	12.2	2.2	17	1	AX760954	ACCESSION:AX760954
c 704	12.2	2.2	17	1	AX762523	ACCESSION:AX762523
705	12.2	2.2	17	1	BD067910	ACCESSION:BD067910
706	12.2	2.2	17	1	BD067911	ACCESSION:BD067911
707	12.2	2.2	17	1	BD067912	ACCESSION:BD067912
c 708	12.2	2.2	18	1	A04695	ACCESSION:A04695
c 709	12.2	2.2	18	1	A88567	ACCESSION:A88567
c 710	12.2	2.2	18	1	A89350	ACCESSION:A89350
c 711	12.2	2.2	18	1	A90534	ACCESSION:A90534
712	12.2	2.2	18	1	A92198	ACCESSION:A92198
713	12.2	2.2	18	1	AR029832	ACCESSION:AR029832
714	12.2	2.2	18	1	AR039685	ACCESSION:AR039685
c 715	12.2	2.2	18	1	AR076765	ACCESSION:AR076765
c 716	12.2	2.2	18	1	AR083565	ACCESSION:AR083565
c 717	12.2	2.2	18	1	AR098359	ACCESSION:AR098359
718	12.2	2.2	18	1	AR101748	ACCESSION:AR101748
c 719	12.2	2.2	18	1	AR101833	ACCESSION:AR101833
720	12.2	2.2	18	1	AR166237	ACCESSION:AR166237
c 721	12.2	2.2	18	1	AR174193	ACCESSION:AR174193
c 722	12.2	2.2	18	1	BD192498	ACCESSION:BD192498
723	12.2	2.2	18	1	BD242588	ACCESSION:BD242588
724	12.2	2.2	18	1	BD242696	ACCESSION:BD242696
c 725	12.2	2.2	18	1	BD266392	ACCESSION:BD266392
726	12.2	2.2	18	1	BD266403	ACCESSION:BD266403
c 727	12.2	2.2	18	1	I25095	ACCESSION:I25095
c 728	12.2	2.2	18	1	I49115	ACCESSION:I49115
729	12.2	2.2	18	1	I55011	ACCESSION:I55011
c 730	12.2	2.2	18	1	I64739	ACCESSION:I64739
731	12.2	2.2	18	1	AR187545	ACCESSION:AR187545
c 732	12.2	2.2	18	1	AR201795	ACCESSION:AR201795
c 733	12.2	2.2	18	1	AR201798	ACCESSION:AR201798
c 734	12.2	2.2	18	1	AR201801	ACCESSION:AR201801
735	12.2	2.2	18	1	AR294057	ACCESSION:AR294057
c 736	12.2	2.2	18	1	AR295859	ACCESSION:AR295859
737	12.2	2.2	18	1	AR297391	ACCESSION:AR297391
738	12.2	2.2	18	1	AR324059	ACCESSION:AR324059
739	12.2	2.2	18	1	AX011593	ACCESSION:AX011593
c 740	12.2	2.2	18	1	AX014670	ACCESSION:AX014670
c 741	12.2	2.2	18	1	AX132951	ACCESSION:AX132951
742	12.2	2.2	18	1	AX358029	ACCESSION:AX358029
743	12.2	2.2	18	1	AX599314	ACCESSION:AX599314
744	12.2	2.2	18	1	AX599418	ACCESSION:AX599418
745	12.2	2.2	18	1	AX599668	ACCESSION:AX599668
746	12.2	2.2	18	1	AX708580	ACCESSION:AX708580
747	12.2	2.2	18	1	AX767734	ACCESSION:AX767734
748	12.2	2.2	18	1	AX767800	ACCESSION:AX767800
c 749	12.2	2.2	18	1	AX785452	ACCESSION:AX785452
750	12.2	2.2	18	1	AX796170	ACCESSION:AX796170
751	12.2	2.2	18	1	AX796302	ACCESSION:AX796302
c 752	12.2	2.2	18	1	AX822849	ACCESSION:AX822849
753	12.2	2.2	18	1	AX823130	ACCESSION:AX823130
c 754	12.2	2.2	18	1	AX826489	ACCESSION:AX826489
755	12.2	2.2	18	1	AX826770	ACCESSION:AX826770
756	12.2	2.2	18	1	BD009173	ACCESSION:BD009173
c 757	12.2	2.2	18	1	BD066080	ACCESSION:BD066080
c 758	12.2	2.2	18	1	BD066863	ACCESSION:BD066863
c 759	12.2	2.2	18	1	BD088486	ACCESSION:BD088486
c 760	12.2	2.2	18	1	BD089251	ACCESSION:BD089251
c 761	12.2	2.2	18	1	AB069337	ACCESSION:AB069337
c 762	12.2	2.2	18	1	AB175212	ACCESSION:AB175212
763	12	2.1	13	1	AR029950	ACCESSION:AR029950
c 764	12	2.1	14	1	A87995	ACCESSION:A87995
c 765	12	2.1	14	1	A89962	ACCESSION:A89962
c 766	12	2.1	14	1	AR235566	ACCESSION:AR235566
c 767	12	2.1	14	1	BD065508	ACCESSION:BD065508
c 768	12	2.1	15	1	AR131778	ACCESSION:AR131778
c 769	12	2.1	15	1	AR131779	ACCESSION:AR131779
770	12	2.1	15	1	AR170919	ACCESSION:AR170919
c 771	12	2.1	15	1	AR170920	ACCESSION:AR170920
772	12	2.1	15	1	AR175435	ACCESSION:AR175435
c 773	12	2.1	15	1	AR175436	ACCESSION:AR175436
c 774	12	2.1	15	1	I77877	ACCESSION:I77877
c 775	12	2.1	15	1	I77878	ACCESSION:I77878
776	12	2.1	15	1	AR242246	ACCESSION:AR242246
c 777	12	2.1	15	1	AR242247	ACCESSION:AR242247
c 778	12	2.1	15	1	AX638376	ACCESSION:AX638376
c 779	12	2.1	15	1	AX638378	ACCESSION:AX638378
c 780	12	2.1	16	1	AR087166	ACCESSION:AR087166
c 781	12	2.1	16	1	AR150612	ACCESSION:AR150612
c 782	12	2.1	16	1	E36065	ACCESSION:E36065
c 783	12	2.1	16	1	I42183	ACCESSION:I42183
c 784	12	2.1	16	1	I49621	ACCESSION:I49621
c 785	12	2.1	16	1	AR200486	ACCESSION:AR200486
c 786	12	2.1	16	1	AR371292	ACCESSION:AR371292
c 787	12	2.1	16	1	AR489513	ACCESSION:AR489513
c 788	12	2.1	16	1	AR491124	ACCESSION:AR491124
c 789	12	2.1	16	1	AX255608	ACCESSION:AX255608
c 790	12	2.1	16	1	AX255646	ACCESSION:AX255646
c 791	12	2.1	17	1	AR057475	ACCESSION:AR057475
c 792	12	2.1	17	1	AR057552	ACCESSION:AR057552
c 793	12	2.1	17	1	AR057560	ACCESSION:AR057560
c 794	12	2.1	17	1	AR057660	ACCESSION:AR057660
c 795	12	2.1	17	1	AR057681	ACCESSION:AR057681
c 796	12	2.1	17	1	AR057795	ACCESSION:AR057795
c 797	12	2.1	17	1	AR115233	ACCESSION:AR115233
c 798	12	2.1	17	1	AR115310	ACCESSION:AR115310
c 799	12	2.1	17	1	AR115318	ACCESSION:AR115318
c 800	12	2.1	17	1	AR115418	ACCESSION:AR115418
c 801	12	2.1	17	1	AR115439	ACCESSION:AR115439
c 802	12	2.1	17	1	AR115553	ACCESSION:AR115553
c 803	12	2.1	17	1	BD200686	ACCESSION:BD200686
c 804	12	2.1	17	1	BD200687	ACCESSION:BD200687
805	12	2.1	17	1	BD241563	ACCESSION:BD241563
806	12	2.1	17	1	BD258483	ACCESSION:BD258483
807	12	2.1	17	1	AR483064	ACCESSION:AR483064
808	12	2.1	17	1	AX191823	ACCESSION:AX191823
c 809	12	2.1	17	1	AX475805	ACCESSION:AX475805
c 810	12	2.1	17	1	AX475813	ACCESSION:AX475813
811	12	2.1	17	1	AX499863	ACCESSION:AX499863
812	12	2.1	17	1	AX499864	ACCESSION:AX499864
813	12	2.1	17	1	AX499865	ACCESSION:AX499865
814	12	2.1	17	1	AX499866	ACCESSION:AX499866
c 815	12	2.1	17	1	AX531445	ACCESSION:AX531445
c 816	12	2.1	17	1	AX531451	ACCESSION:AX531451
c 817	12	2.1	17	1	AX634499	ACCESSION:AX634499
c 818	12	2.1	17	1	AX634571	ACCESSION:AX634571
c 819	12	2.1	17	1	AX634652	ACCESSION:AX634652
c 820	12	2.1	17	1	AX634673	ACCESSION:AX634673
c 821	12	2.1	17	1	AX634715	ACCESSION:AX634715
c 822	12	2.1	17	1	AX634845	ACCESSION:AX634845
823	12	2.1	17	1	AX722745	ACCESSION:AX722745
824	12	2.1	17	1	AX731014	ACCESSION:AX731014
c 825	12	2.1	17	1	AX736447	ACCESSION:AX736447
826	12	2.1	17	1	AX737834	ACCESSION:AX737834
c 827	12	2.1	18	1	A87993	ACCESSION:A87993
c 828	12	2.1	18	1	A87994	ACCESSION:A87994
c 829	12	2.1	18	1	A89960	ACCESSION:A89960
c 830	12	2.1	18	1	A89961	ACCESSION:A89961
c 831	12	2.1	18	1	AR051249	ACCESSION:AR051249
c 832	12	2.1	18	1	AR127796	ACCESSION:AR127796
c 833	12	2.1	18	1	I28378	ACCESSION:I28378
834	12	2.1	18	1	AX284054	ACCESSION:AX284054
c 835	12	2.1	18	1	BD065506	ACCESSION:BD065506
c 836	12	2.1	18	1	BD065507	ACCESSION:BD065507

c 837	11.8	2.1	15	1	A58048	ACCESSION:A58048
c 838	11.8	2.1	15	1	AR041352	ACCESSION:AR041352
839	11.8	2.1	15	1	AR041779	ACCESSION:AR041779
840	11.8	2.1	15	1	AR055920	ACCESSION:AR055920
841	11.8	2.1	15	1	AR113678	ACCESSION:AR113678
842	11.8	2.1	15	1	AR132184	ACCESSION:AR132184
843	11.8	2.1	15	1	AR132185	ACCESSION:AR132185
844	11.8	2.1	15	1	AR132186	ACCESSION:AR132186
845	11.8	2.1	15	1	AR132187	ACCESSION:AR132187
c 846	11.8	2.1	15	1	AR141400	ACCESSION:AR141400
847	11.8	2.1	15	1	BD231235	ACCESSION:BD231235
c 848	11.8	2.1	15	1	BD265725	ACCESSION:BD265725
849	11.8	2.1	15	1	E16782	ACCESSION:E16782
850	11.8	2.1	15	1	AR303029	ACCESSION:AR303029
851	11.8	2.1	15	1	AR366465	ACCESSION:AR366465
c 852	11.8	2.1	15	1	AX033759	ACCESSION:AX033759
853	11.8	2.1	15	1	AX633016	ACCESSION:AX633016
c 854	11.8	2.1	15	1	AX636763	ACCESSION:AX636763
855	11.8	2.1	15	1	AX637205	ACCESSION:AX637205
c 856	11.8	2.1	15	1	AX708800	ACCESSION:AX708800
857	11.8	2.1	16	1	A88311	ACCESSION:A88311
c 858	11.8	2.1	16	1	A88458	ACCESSION:A88458
859	11.8	2.1	16	1	A90278	ACCESSION:A90278
c 860	11.8	2.1	16	1	A90425	ACCESSION:A90425
861	11.8	2.1	16	1	AR001291	ACCESSION:AR001291
c 862	11.8	2.1	16	1	AR001291	ACCESSION:AR001291
c 863	11.8	2.1	16	1	AR036759	ACCESSION:AR036759
864	11.8	2.1	16	1	AR036760	ACCESSION:AR036760
865	11.8	2.1	16	1	AR038029	ACCESSION:AR038029
866	11.8	2.1	16	1	AR039127	ACCESSION:AR039127
867	11.8	2.1	16	1	AR050372	ACCESSION:AR050372
868	11.8	2.1	16	1	AR062931	ACCESSION:AR062931
c 869	11.8	2.1	16	1	AR069284	ACCESSION:AR069284
c 870	11.8	2.1	16	1	I18842	ACCESSION:I18842
c 871	11.8	2.1	16	1	I22296	ACCESSION:I22296
872	11.8	2.1	16	1	AR211616	ACCESSION:AR211616
873	11.8	2.1	16	1	AR309064	ACCESSION:AR309064
c 874	11.8	2.1	16	1	AR309064	ACCESSION:AR309064
c 875	11.8	2.1	16	1	AR364124	ACCESSION:AR364124
876	11.8	2.1	16	1	AR364150	ACCESSION:AR364150
877	11.8	2.1	16	1	AR364513	ACCESSION:AR364513
878	11.8	2.1	16	1	AR373159	ACCESSION:AR373159
879	11.8	2.1	16	1	AR373194	ACCESSION:AR373194
880	11.8	2.1	16	1	AR435997	ACCESSION:AR435997
881	11.8	2.1	16	1	AX235092	ACCESSION:AX235092
c 882	11.8	2.1	16	1	AX255618	ACCESSION:AX255618
c 883	11.8	2.1	16	1	AX255661	ACCESSION:AX255661
884	11.8	2.1	16	1	AX535770	ACCESSION:AX535770
885	11.8	2.1	16	1	BD065824	ACCESSION:BD065824
c 886	11.8	2.1	16	1	BD065971	ACCESSION:BD065971
c 887	11.8	2.1	17	1	BD201172	ACCESSION:BD201172
c 888	11.8	2.1	17	1	A34270	ACCESSION:A34270
889	11.8	2.1	17	1	A88312	ACCESSION:A88312
c 890	11.8	2.1	17	1	A89349	ACCESSION:A89349
891	11.8	2.1	17	1	A90279	ACCESSION:A90279
c 892	11.8	2.1	17	1	AR040153	ACCESSION:AR040153
893	11.8	2.1	17	1	AR045723	ACCESSION:AR045723
c 894	11.8	2.1	17	1	AR047386	ACCESSION:AR047386
c 895	11.8	2.1	17	1	AR057727	ACCESSION:AR057727
c 896	11.8	2.1	17	1	AR115485	ACCESSION:AR115485
c 897	11.8	2.1	17	1	BD197738	ACCESSION:BD197738
898	11.8	2.1	17	1	BD201570	ACCESSION:BD201570
c 899	11.8	2.1	17	1	BD202825	ACCESSION:BD202825
c 900	11.8	2.1	17	1	BD202826	ACCESSION:BD202826
901	11.8	2.1	17	1	BD203002	ACCESSION:BD203002
902	11.8	2.1	17	1	BD203003	ACCESSION:BD203003
903	11.8	2.1	17	1	BD203004	ACCESSION:BD203004
904	11.8	2.1	17	1	BD226461	ACCESSION:BD226461
905	11.8	2.1	17	1	BD254672	ACCESSION:BD254672
c 906	11.8	2.1	17	1	BD254953	ACCESSION:BD254953
c 907	11.8	2.1	17	1	BD255069	ACCESSION:BD255069
c 908	11.8	2.1	17	1	BD255449	ACCESSION:BD255449
c 909	11.8	2.1	17	1	BD255450	ACCESSION:BD255450
910	11.8	2.1	17	1	BD255456	ACCESSION:BD255456
911	11.8	2.1	17	1	BD255458	ACCESSION:BD255458
c 912	11.8	2.1	17	1	BD256767	ACCESSION:BD256767
c 913	11.8	2.1	17	1	BD256768	ACCESSION:BD256768
c 914	11.8	2.1	17	1	BD256769	ACCESSION:BD256769
c 915	11.8	2.1	17	1	BD258460	ACCESSION:BD258460
c 916	11.8	2.1	17	1	BD258461	ACCESSION:BD258461
917	11.8	2.1	17	1	BD258462	ACCESSION:BD258462
c 918	11.8	2.1	17	1	BD258523	ACCESSION:BD258523
c 919	11.8	2.1	17	1	CQ616604	ACCESSION:CQ616604
c 920	11.8	2.1	17	1	CQ616608	ACCESSION:CQ616608
c 921	11.8	2.1	17	1	CQ616839	ACCESSION:CQ616839
c 922	11.8	2.1	17	1	CQ616842	ACCESSION:CQ616842
923	11.8	2.1	17	1	CQ616960	ACCESSION:CQ616960
924	11.8	2.1	17	1	CQ616961	ACCESSION:CQ616961
925	11.8	2.1	17	1	CQ616962	ACCESSION:CQ616962
c 926	11.8	2.1	17	1	CQ622905	ACCESSION:CQ622905
927	11.8	2.1	17	1	CQ623219	ACCESSION:CQ623219
c 928	11.8	2.1	17	1	CQ623842	ACCESSION:CQ623842
c 929	11.8	2.1	17	1	CQ623843	ACCESSION:CQ623843
c 930	11.8	2.1	17	1	CQ623844	ACCESSION:CQ623844
c 931	11.8	2.1	17	1	CQ625802	ACCESSION:CQ625802
c 932	11.8	2.1	17	1	CQ625803	ACCESSION:CQ625803
933	11.8	2.1	17	1	I19747	ACCESSION:I19747
c 934	11.8	2.1	17	1	I37696	ACCESSION:I37696
935	11.8	2.1	17	1	I52775	ACCESSION:I52775
c 936	11.8	2.1	17	1	I54438	ACCESSION:I54438
c 937	11.8	2.1	17	1	I94546	ACCESSION:I94546
938	11.8	2.1	17	1	AR186282	ACCESSION:AR186282
939	11.8	2.1	17	1	AR186578	ACCESSION:AR186578
c 940	11.8	2.1	17	1	AR186717	ACCESSION:AR186717
c 941	11.8	2.1	17	1	AR186744	ACCESSION:AR186744
c 942	11.8	2.1	17	1	AR187129	ACCESSION:AR187129
c 943	11.8	2.1	17	1	AR189888	ACCESSION:AR189888
c 944	11.8	2.1	17	1	AR190543	ACCESSION:AR190543
c 945	11.8	2.1	17	1	AR191910	ACCESSION:AR191910
946	11.8	2.1	17	1	AR192255	ACCESSION:AR192255
c 947	11.8	2.1	17	1	AR207642	ACCESSION:AR207642
c 948	11.8	2.1	17	1	AR207652	ACCESSION:AR207652
949	11.8	2.1	17	1	AR322913	ACCESSION:AR322913
950	11.8	2.1	17	1	AR323209	ACCESSION:AR323209
c 951	11.8	2.1	17	1	AR323348	ACCESSION:AR323348
c 952	11.8	2.1	17	1	AR323375	ACCESSION:AR323375
c 953	11.8	2.1	17	1	AR323739	ACCESSION:AR323739
c 954	11.8	2.1	17	1	AR324874	ACCESSION:AR324874
c 955	11.8	2.1	17	1	AR325466	ACCESSION:AR325466
c 956	11.8	2.1	17	1	AR325804	ACCESSION:AR325804
957	11.8	2.1	17	1	AR326126	ACCESSION:AR326126
958	11.8	2.1	17	1	AR327518	ACCESSION:AR327518
c 959	11.8	2.1	17	1	AR327760	ACCESSION:AR327760
960	11.8	2.1	17	1	AR329007	ACCESSION:AR329007
c 961	11.8	2.1	17	1	AR401789	ACCESSION:AR401789
962	11.8	2.1	17	1	AR402407	ACCESSION:AR402407
963	11.8	2.1	17	1	AR402408	ACCESSION:AR402408
964	11.8	2.1	17	1	AR433887	ACCESSION:AR433887
965	11.8	2.1	17	1	AR433890	ACCESSION:AR433890
c 966	11.8	2.1	17	1	AR457667	ACCESSION:AR457667
c 967	11.8	2.1	17	1	AR457671	ACCESSION:AR457671
c 968	11.8	2.1	17	1	AR457902	ACCESSION:AR457902
c 969	11.8	2.1	17	1	AR457905	ACCESSION:AR457905
970	11.8	2.1	17	1	AR458023	ACCESSION:AR458023
971	11.8	2.1	17	1	AR458024	ACCESSION:AR458024
972	11.8	2.1	17	1	AR458025	ACCESSION:AR458025
c 973	11.8	2.1	17	1	AR463968	ACCESSION:AR463968
974	11.8	2.1	17	1	AR464282	ACCESSION:AR464282
c 975	11.8	2.1	17	1	AR464905	ACCESSION:AR464905
c 976	11.8	2.1	17	1	AR464906	ACCESSION:AR464906
c 977	11.8	2.1	17	1	AR464907	ACCESSION:AR464907
c 978	11.8	2.1	17	1	AR466865	ACCESSION:AR466865
c 979	11.8	2.1	17	1	AR466866	ACCESSION:AR466866
c 980	11.8	2.1	17	1	AX215783	ACCESSION:AX215783
c 981	11.8	2.1	17	1	AX215808	ACCESSION:AX215808
982	11.8	2.1	17	1	AX215974	ACCESSION:AX215974

c 983	11.8	2.1	17	1	AX216238	ACCESSION:AX216238
984	11.8	2.1	17	1	AX216292	ACCESSION:AX216292
c 985	11.8	2.1	17	1	AX216319	ACCESSION:AX216319
c 986	11.8	2.1	17	1	AX216423	ACCESSION:AX216423
c 987	11.8	2.1	17	1	AX216867	ACCESSION:AX216867
c 988	11.8	2.1	17	1	AX217002	ACCESSION:AX217002
c 989	11.8	2.1	17	1	AX217044	ACCESSION:AX217044
c 990	11.8	2.1	17	1	AX217045	ACCESSION:AX217045
c 991	11.8	2.1	17	1	AX217397	ACCESSION:AX217397
992	11.8	2.1	17	1	AX326369	ACCESSION:AX326369
c 993	11.8	2.1	17	1	AX326370	ACCESSION:AX326370
994	11.8	2.1	17	1	AX326373	ACCESSION:AX326373
c 995	11.8	2.1	17	1	AX326374	ACCESSION:AX326374
996	11.8	2.1	17	1	AX421959	ACCESSION:AX421959
997	11.8	2.1	17	1	AX422679	ACCESSION:AX422679
998	11.8	2.1	17	1	AX578513	ACCESSION:AX578513
c 999	11.8	2.1	17	1	AX578600	ACCESSION:AX578600
c1000	11.8	2.1	17	1	AX578705	ACCESSION:AX578705
c1001	11.8	2.1	17	1	AX578706	ACCESSION:AX578706
1002	11.8	2.1	17	1	AX579165	ACCESSION:AX579165
1003	11.8	2.1	17	1	AX579166	ACCESSION:AX579166
c1004	11.8	2.1	17	1	AX579280	ACCESSION:AX579280
1005	11.8	2.1	17	1	AX579458	ACCESSION:AX579458
1006	11.8	2.1	17	1	AX579683	ACCESSION:AX579683
c1007	11.8	2.1	17	1	AX579927	ACCESSION:AX579927
1008	11.8	2.1	17	1	AX615442	ACCESSION:AX615442
c1009	11.8	2.1	17	1	AX634806	ACCESSION:AX634806
1010	11.8	2.1	17	1	AX648719	ACCESSION:AX648719
1011	11.8	2.1	17	1	AX648720	ACCESSION:AX648720
c1012	11.8	2.1	17	1	AX648944	ACCESSION:AX648944
c1013	11.8	2.1	17	1	AX648945	ACCESSION:AX648945
c1014	11.8	2.1	17	1	AX648946	ACCESSION:AX648946
c1015	11.8	2.1	17	1	AX649061	ACCESSION:AX649061
c1016	11.8	2.1	17	1	AX649062	ACCESSION:AX649062
c1017	11.8	2.1	17	1	AX649063	ACCESSION:AX649063
c1018	11.8	2.1	17	1	AX671973	ACCESSION:AX671973
c1019	11.8	2.1	17	1	AX672026	ACCESSION:AX672026
1020	11.8	2.1	17	1	AX672284	ACCESSION:AX672284
c1021	11.8	2.1	17	1	AX672469	ACCESSION:AX672469
c1022	11.8	2.1	17	1	AX672489	ACCESSION:AX672489
c1023	11.8	2.1	17	1	AX672976	ACCESSION:AX672976
c1024	11.8	2.1	17	1	AX673050	ACCESSION:AX673050
1025	11.8	2.1	17	1	AX687899	ACCESSION:AX687899
1026	11.8	2.1	17	1	AX687900	ACCESSION:AX687900
1027	11.8	2.1	17	1	AX687901	ACCESSION:AX687901
1028	11.8	2.1	17	1	AX722944	ACCESSION:AX722944
1029	11.8	2.1	17	1	AX723611	ACCESSION:AX723611
c1030	11.8	2.1	17	1	AX724034	ACCESSION:AX724034
1031	11.8	2.1	17	1	AX724909	ACCESSION:AX724909
c1032	11.8	2.1	17	1	AX725510	ACCESSION:AX725510
1033	11.8	2.1	17	1	AX725733	ACCESSION:AX725733
1034	11.8	2.1	17	1	AX726659	ACCESSION:AX726659
1035	11.8	2.1	17	1	AX726954	ACCESSION:AX726954
c1036	11.8	2.1	17	1	AX727473	ACCESSION:AX727473
1037	11.8	2.1	17	1	AX728017	ACCESSION:AX728017
c1038	11.8	2.1	17	1	AX728257	ACCESSION:AX728257
1039	11.8	2.1	17	1	AX728352	ACCESSION:AX728352
c1040	11.8	2.1	17	1	AX728599	ACCESSION:AX728599
1041	11.8	2.1	17	1	AX728696	ACCESSION:AX728696
c1042	11.8	2.1	17	1	AX728759	ACCESSION:AX728759
1043	11.8	2.1	17	1	AX729171	ACCESSION:AX729171
1044	11.8	2.1	17	1	AX729978	ACCESSION:AX729978
1045	11.8	2.1	17	1	AX731241	ACCESSION:AX731241
1046	11.8	2.1	17	1	AX732352	ACCESSION:AX732352
1047	11.8	2.1	17	1	AX732526	ACCESSION:AX732526
c1048	11.8	2.1	17	1	AX733851	ACCESSION:AX733851
c1049	11.8	2.1	17	1	AX733953	ACCESSION:AX733953
c1050	11.8	2.1	17	1	AX734050	ACCESSION:AX734050
c1051	11.8	2.1	17	1	AX734434	ACCESSION:AX734434
1052	11.8	2.1	17	1	AX734727	ACCESSION:AX734727
c1053	11.8	2.1	17	1	AX734927	ACCESSION:AX734927
c1054	11.8	2.1	17	1	AX735296	ACCESSION:AX735296
c1055	11.8	2.1	17	1	AX735360	ACCESSION:AX735360
c1056	11.8	2.1	17	1	AX736207	ACCESSION:AX736207
c1057	11.8	2.1	17	1	AX736439	ACCESSION:AX736439
c1058	11.8	2.1	17	1	AX736524	ACCESSION:AX736524
1059	11.8	2.1	17	1	AX736708	ACCESSION:AX736708
1060	11.8	2.1	17	1	AX736741	ACCESSION:AX736741
c1061	11.8	2.1	17	1	AX736758	ACCESSION:AX736758
c1062	11.8	2.1	17	1	AX736814	ACCESSION:AX736814
1063	11.8	2.1	17	1	AX737367	ACCESSION:AX737367
1064	11.8	2.1	17	1	AX737528	ACCESSION:AX737528
c1065	11.8	2.1	17	1	AX738212	ACCESSION:AX738212
1066	11.8	2.1	17	1	AX738730	ACCESSION:AX738730
1067	11.8	2.1	17	1	AX739078	ACCESSION:AX739078
1068	11.8	2.1	17	1	AX745236	ACCESSION:AX745236
1069	11.8	2.1	17	1	AX745239	ACCESSION:AX745239
c1070	11.8	2.1	17	1	AX753719	ACCESSION:AX753719
c1071	11.8	2.1	17	1	AX753722	ACCESSION:AX753722
c1072	11.8	2.1	17	1	AX756733	ACCESSION:AX756733
1073	11.8	2.1	17	1	AX756964	ACCESSION:AX756964
1074	11.8	2.1	17	1	AX757412	ACCESSION:AX757412
c1075	11.8	2.1	17	1	AX757903	ACCESSION:AX757903
1076	11.8	2.1	17	1	AX758672	ACCESSION:AX758672
c1077	11.8	2.1	17	1	AX760785	ACCESSION:AX760785
1078	11.8	2.1	17	1	AX760812	ACCESSION:AX760812
c1079	11.8	2.1	17	1	AX761197	ACCESSION:AX761197
1080	11.8	2.1	17	1	AX761316	ACCESSION:AX761316
1081	11.8	2.1	17	1	AX762265	ACCESSION:AX762265
c1082	11.8	2.1	17	1	AX762317	ACCESSION:AX762317
c1083	11.8	2.1	17	1	AX762343	ACCESSION:AX762343
c1084	11.8	2.1	17	1	AX762432	ACCESSION:AX762432
c1085	11.8	2.1	17	1	AX762809	ACCESSION:AX762809
1086	11.8	2.1	17	1	AX782161	ACCESSION:AX782161
1087	11.8	2.1	17	1	AX782162	ACCESSION:AX782162
1088	11.8	2.1	17	1	AX782163	ACCESSION:AX782163
1089	11.8	2.1	17	1	AX784026	ACCESSION:AX784026
1090	11.8	2.1	17	1	AX784029	ACCESSION:AX784029
1091	11.8	2.1	17	1	AX824368	ACCESSION:AX824368
1092	11.8	2.1	17	1	BD065825	ACCESSION:BD065825
c1093	11.8	2.1	17	1	BD066862	ACCESSION:BD066862
c1094	11.8	2.1	17	1	BD067289	ACCESSION:BD067289
1095	11.8	2.1	17	1	BD067907	ACCESSION:BD067907
1096	11.8	2.1	17	1	BD067908	ACCESSION:BD067908
c1097	11.8	2.1	17	1	ATH529445	ACCESSION:AJ529445
c1098	11.8	2.1	18	1	A67097	ACCESSION:A67097
1099	11.8	2.1	18	1	AR008536	ACCESSION:AR008536
1100	11.8	2.1	18	1	AR014324	ACCESSION:AR014324
1101	11.8	2.1	18	1	AR039683	ACCESSION:AR039683
1102	11.8	2.1	18	1	AR059317	ACCESSION:AR059317
1103	11.8	2.1	18	1	AR068083	ACCESSION:AR068083
1104	11.8	2.1	18	1	AR071802	ACCESSION:AR071802
1105	11.8	2.1	18	1	AR071803	ACCESSION:AR071803
1106	11.8	2.1	18	1	AR073053	ACCESSION:AR073053
1107	11.8	2.1	18	1	AR080718	ACCESSION:AR080718
c1108	11.8	2.1	18	1	AR085645	ACCESSION:AR085645
1109	11.8	2.1	18	1	AR092843	ACCESSION:AR092843
c1110	11.8	2.1	18	1	AR098803	ACCESSION:AR098803
1111	11.8	2.1	18	1	AR110199	ACCESSION:AR110199
c1112	11.8	2.1	18	1	AR143398	ACCESSION:AR143398
1113	11.8	2.1	18	1	AR162701	ACCESSION:AR162701
1114	11.8	2.1	18	1	BD227761	ACCESSION:BD227761
c1115	11.8	2.1	18	1	BD234749	ACCESSION:BD234749
1116	11.8	2.1	18	1	BD250666	ACCESSION:BD250666
c1117	11.8	2.1	18	1	CQ792276	ACCESSION:CQ792276
1118	11.8	2.1	18	1	CQ799825	ACCESSION:CQ799825
c1119	11.8	2.1	18	1	CQ807650	ACCESSION:CQ807650
c1120	11.8	2.1	18	1	CQ807744	ACCESSION:CQ807744
1121	11.8	2.1	18	1	CQ840412	ACCESSION:CQ840412
c1122	11.8	2.1	18	1	I75091	ACCESSION:I75091
1123	11.8	2.1	18	1	I86170	ACCESSION:I86170
1124	11.8	2.1	18	1	I86880	ACCESSION:I86880
1125	11.8	2.1	18	1	AR181655	ACCESSION:AR181655
1126	11.8	2.1	18	1	AR228142	ACCESSION:AR228142
c1127	11.8	2.1	18	1	AR293221	ACCESSION:AR293221
1128	11.8	2.1	18	1	AR293262	ACCESSION:AR293262

1129	11.8	2.1	18	1	AR293420	ACCESSION:AR293420
c1130	11.8	2.1	18	1	AR293616	ACCESSION:AR293616
1131	11.8	2.1	18	1	AR294034	ACCESSION:AR294034
c1132	11.8	2.1	18	1	AR294136	ACCESSION:AR294136
c1133	11.8	2.1	18	1	AR294358	ACCESSION:AR294358
c1134	11.8	2.1	18	1	AR295827	ACCESSION:AR295827
c1135	11.8	2.1	18	1	AR296069	ACCESSION:AR296069
c1136	11.8	2.1	18	1	AR297152	ACCESSION:AR297152
1137	11.8	2.1	18	1	AR297436	ACCESSION:AR297436
c1138	11.8	2.1	18	1	AR297586	ACCESSION:AR297586
1139	11.8	2.1	18	1	AR297721	ACCESSION:AR297721
c1140	11.8	2.1	18	1	AR390750	ACCESSION:AR390750
c1141	11.8	2.1	18	1	AR390751	ACCESSION:AR390751
c1142	11.8	2.1	18	1	AR488599	ACCESSION:AR488599
c1143	11.8	2.1	18	1	AX058580	ACCESSION:AX058580
c1144	11.8	2.1	18	1	AX132970	ACCESSION:AX132970
c1145	11.8	2.1	18	1	AX590978	ACCESSION:AX590978
c1146	11.8	2.1	18	1	AX599394	ACCESSION:AX599394
1147	11.8	2.1	18	1	AX746337	ACCESSION:AX746337
c1148	11.8	2.1	18	1	AX765929	ACCESSION:AX765929
c1149	11.8	2.1	18	1	AX769708	ACCESSION:AX769708
c1150	11.8	2.1	18	1	AX796182	ACCESSION:AX796182
c1151	11.8	2.1	18	1	AX796278	ACCESSION:AX796278
1152	11.8	2.1	18	1	AX816917	ACCESSION:AX816917
c1153	11.8	2.1	18	1	AX823064	ACCESSION:AX823064
c1154	11.8	2.1	18	1	AX826704	ACCESSION:AX826704
c1155	11.8	2.1	18	1	BD015268	ACCESSION:BD015268
1156	11.8	2.1	18	1	BD064506	ACCESSION:BD064506
c1157	11.8	2.1	18	1	BD102527	ACCESSION:BD102527
1158	11.8	2.1	18	1	BD160908	ACCESSION:BD160908
1159	11.8	2.1	18	1	BD169088	ACCESSION:BD169088
c1160	11.6	2.1	17	1	AX210228	ACCESSION:AX210228
c1161	11.4	2.0	17	1	BD258462	ACCESSION:BD258462
1162	11.4	2.0	17	1	AX673050	ACCESSION:AX673050
1163	11.4	2.0	18	1	AX058580	ACCESSION:AX058580
c1164	11.2	2.0	17	1	A88310	ACCESSION:A88310
c1165	11.2	2.0	17	1	A90277	ACCESSION:A90277
1166	11.2	2.0	17	1	AR186716	ACCESSION:AR186716
1167	11.2	2.0	17	1	AR323347	ACCESSION:AR323347
c1168	11.2	2.0	17	1	AX745237	ACCESSION:AX745237
c1169	11.2	2.0	17	1	BD065823	ACCESSION:BD065823
1170	11.2	2.0	17	1	AX531445	ACCESSION:AX531445
1171	11.2	2.0	17	1	AR186717	ACCESSION:AR186717
1172	11.2	2.0	17	1	AR323348	ACCESSION:AR323348
c1173	11.2	2.0	17	1	AX745236	ACCESSION:AX745236

ALIGNMENTS

RESULT 1
AR100207
LOCUS AR100207 23 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 6 from patent US 6080576.
ACCESSION AR100207
VERSION AR100207.1 GI:12810655
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 23)
AUTHORS Zambrowicz,B., Friedrich,G. and Sands,A.T.
TITLE Vectors for gene trapping and gene activation
JOURNAL Patent: US 6080576-A 6 27-JUN-2000;
FEATURES Location/Qualifiers
source 1. .23
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 3.3%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 34;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1999 CTAGCTTCTTCAGAGATCAAGTC 2021
| || ||||||||||||||||||
Db 1 CCAGAGTCTTCAGAGATCAAGTC 23

RESULT 2
BD263052
LOCUS BD263052 23 bp DNA linear PAT 17-JUL-2003
DEFINITION Vectors for gene mutagenesis and gene discovery by gene trapping.
ACCESSION BD263052
VERSION BD263052.1 GI:33072820
KEYWORDS JP 2002539764-A/17.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 23)
AUTHORS Zambrowicz,B., Friedrich,G.A., Lilleberg,S. and Sands,A.T.
TITLE Vectors for gene mutagenesis and gene discovery by gene trapping
JOURNAL Patent: JP 2002539764-A 17 26-NOV-2002;
LEXICON GENETICS INC
COMMENT OS Mus musculus (mouse)
PN JP 2002539764-A/17
PD 26-NOV-2002
PF 19-NOV-1999 JP 2000584047
PR 20-NOV-1998 US 60/109302,25-MAR-1999 US 09/276533 PI
BRIAN ZAMBROWICZ,GLENN A FRIEDRICH,STAN LILLEBERG,ARTHUR T PI
SANDS
PC C12N15/09,A01K67/027,C12N5/10,C12N7/00//(C12N7/00,C12R1:93),
PC C12N15/00,
PC C12N5/00
CC Vectors for gene mutagenesis and gene discovery by gene CC
trapping
FH Key Location/Qualifiers
FT source 1. .23
FT /organism='Mus musculus (mouse)'.
FEATURES Location/Qualifiers
source 1. .23
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"

Query Match 3.3%; Score 18.2; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 34;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1999 CTAGCTTCTTCAGAGATCAAGTC 2021
| || ||||||||||||||||||
Db 1 CCAGAGTCTTCAGAGATCAAGTC 23

RESULT 3
AX166683/c
LOCUS AX166683 25 bp DNA linear PAT 22-JUN-2001
DEFINITION Sequence 174 from Patent WO0138503.
ACCESSION AX166683
VERSION AX166683.1 GI:14546958
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Plowman,G.D., Whyte,D., Manning,G.S., Sudarsanam,S.S., Martinez,R.,
Planagan,P. and Clary,D.S.
TITLE Novel human protein kinases and protein kinase-like enzymes
JOURNAL Patent: WO 0138503-A 174 31-MAY-2001;
Sugen, Inc. (US)
FEATURES Location/Qualifiers
source 1. .25
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

```
  Query Match             3.0%;  Score 17;  DB 1;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 67;
  Matches   17;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              |||||||||||||||||
Db         19 CCCATTCTTTCCTTCTC 3


RESULT 4
CQ768165
LOCUS       CQ768165                  23 bp    DNA     linear   PAT 04-MAR-2004
DEFINITION  Sequence 11 from Patent WO2004007770.
ACCESSION   CQ768165
VERSION     CQ768165.1  GI:45110822
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Nakamura,Y. and Furukawa,Y.
  TITLE     Method for diagnosis of intestinal-type gastric tumors
  JOURNAL   Patent: WO 2004007770-A 11 22-JAN-2004;
            Oncotherapy Science, Inc. (JP); Japan as represented by The
            President of the University o f Tokyo (JP)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="an artificially synthesized primer sequence"

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 23;
  Best Local Similarity   82.6%;  Pred. No. 74;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTGCAAAAAT 1572
              ||||||| |||||||||  | ||
Db          1 GGAAGGACCAGGACTGCTCATAT 23


RESULT 5
AX093547
LOCUS       AX093547                  24 bp    DNA     linear   PAT 30-MAR-2001
DEFINITION  Sequence 77 from Patent WO0118198.
ACCESSION   AX093547
VERSION     AX093547.1  GI:13509985
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Weissenbach,J. and Hazan,J.
  TITLE     Cloning, expression and characterisation of the spg4 gene
            responsible for the most frequent form of autosomal spastic
            paraplegia
  JOURNAL   Patent: WO 0118198-A 77 15-MAR-2001;
            CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Site accepteur d' pissage du g ne SPG4."

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 24;
  Best Local Similarity   82.6%;  Pred. No. 78;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGAAAGTGG 1811
              | | ||||||| || ||||||||
Db          1 ACTTTTTCCTTGTCAGAAAGTGG 23


RESULT 6
AR146859
LOCUS       AR146859                  25 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 9 from patent US 6218598.
ACCESSION   AR146859
VERSION     AR146859.1  GI:15110048
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Ishige,F., Nishikawa,S. and Oeda,K.
  TITLE     Plant promoter
  JOURNAL   Patent: US 6218598-A 9 17-APR-2001;
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 81;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATCAACAAT 1918
              | ||||||||||  ||||||
Db          2 CTCTAGATCAACACCTCAACATT 24


RESULT 7
E55072
LOCUS       E55072                    25 bp    DNA     linear   PAT 31-JAN-2002
DEFINITION  Plant promoter.
ACCESSION   E55072
VERSION     E55072.1  GI:18625258
KEYWORDS    JP 2000083679-A/9.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Ishige,I., Nishikawa,S. and Oeda,K.
  TITLE     Plant promoter
  JOURNAL   Patent: JP 2000083679-A 9 28-MAR-2000;
            SUMITOMO CHEM CO LTD
COMMENT     OS   Artificial Sequence
            PN   JP 2000083679-A/9
            PD   28-MAR-2000
            PF   12-JUL-1999 JP 1999197240
            PR
            PI   IKUHARU ISHIGE,SATOMI NISHIKAWA,KENJI OEDA
            PC   C12N15/09,A01H5/00,C12N1/21,C12N5/10//(C12N15/09,C12R1:91), PC
              (C12N5/10,C12R1:91),C12N15/00,C12N5/00,(C12N15/00,C12R1:91), PC
            (C12N5/00,C12R1:91)
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .25
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 81;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATCAACAAT 1918
              | ||||||||||  ||||||
Db          2 CTCTAGATCAACACCTCAACATT 24
```

```
RESULT 8
AX000308
LOCUS       AX000308                  25 bp    DNA     linear   PAT 10-MAR-2000
DEFINITION  Sequence 1 from Patent WO9905527.
ACCESSION   AX000308
VERSION     AX000308.1  GI:7240723
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Conrad,B. and Mach,B.
  TITLE     METHODS FOR DIAGNOSIS AND THERAPY OF AUTOIMMUNE DISEASE, SUCH AS
            INSULIN DEPENDENT DIABETES MELLITUS, INVOLVING RETROVIRAL
            SUPERANTIGENS
  JOURNAL   Patent: WO 9905527-A 1 04-FEB-1999;
            MEDIGEN S A (CH); CONRAD BERNARD (CH)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 81;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1951 TTTTTGTGTCCGCTAAATATTTA 1973
              |||||| |||| || | ||||||
Db          1 TTTTTGAGTCCCCTTAGTATTTA 23


RESULT 9
AX000331
LOCUS       AX000331                  25 bp    DNA     linear   PAT 10-MAR-2000
DEFINITION  Sequence 24 from Patent WO9905527.
ACCESSION   AX000331
VERSION     AX000331.1  GI:7240746
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Conrad,B. and Mach,B.
  TITLE     METHODS FOR DIAGNOSIS AND THERAPY OF AUTOIMMUNE DISEASE, SUCH AS
            INSULIN DEPENDENT DIABETES MELLITUS, INVOLVING RETROVIRAL
            SUPERANTIGENS
  JOURNAL   Patent: WO 9905527-A 24 04-FEB-1999;
            MEDIGEN S A (CH); CONRAD BERNARD (CH)
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 81;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1951 TTTTTGTGTCCGCTAAATATTTA 1973
              |||||| |||| || | ||||||
Db          1 TTTTTGAGTCCCCTTAGTATTTA 23


RESULT 10
BD074369
LOCUS       BD074369                  25 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method of diagnosis and treatment of autoimmune disease such as
            insulin-dependent diabetes mellitus containing retroviral
            superantigen.
ACCESSION   BD074369
VERSION     BD074369.1  GI:22619972
KEYWORDS    JP 2001511363-A/1.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Conra,B. and Matthew,B.
  TITLE     Method of diagnosis and treatment of autoimmune disease such as
            insulin-dependent diabetes mellitus containing retroviral
  JOURNAL   Patent: JP 2001511363-A 1 14-AUG-2001;
            NOVIMMUNE SA
COMMENT     OS   Unidentified
            PN   JP 2001511363-A/1
            PD   14-AUG-2001
            PF   22-JUL-1998 JP 2000504461
            PR   22-JUL-1997 EP   97112482.1,23-JUL-1997 EP   97401773.3 PI
            BERNARD CONRA,BERNARD MATTHEW
            PC   C12N15/09,A01K67/027,A61K31/7088,A61K31/7115,A61K39/21,A61P3/
            PC   10,A61P37/00,
            PC   C07K7/00,C07K14/08,C12N5/10,C12N7/00,C12P21/02,C12Q1/02,C12Q1/
            PC   68,
            PC   G01N33/564,G01N33/569,C12N15/00,C12N5/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   /desc = 'DNA (synthetic)'
            CC   /note = 'page 11'
            FH   Key             Location/Qualifiers
            FT   misc_feature    1. .25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 81;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1951 TTTTTGTGTCCGCTAAATATTTA 1973
              |||||| |||| || | ||||||
Db          1 TTTTTGAGTCCCCTTAGTATTTA 23


RESULT 11
BD074392
LOCUS       BD074392                  25 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method of diagnosis and treatment of autoimmune disease such as
            insulin-dependent diabetes mellitus containing retroviral
            superantigen.
ACCESSION   BD074392
VERSION     BD074392.1  GI:22619995
KEYWORDS    JP 2001511363-A/24.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 25)
  AUTHORS   Conra,B. and Matthew,B.
  TITLE     Method of diagnosis and treatment of autoimmune disease such as
            insulin-dependent diabetes mellitus containing retroviral
  JOURNAL   Patent: JP 2001511363-A 24 14-AUG-2001;
            NOVIMMUNE SA
COMMENT     OS   Unidentified
            PN   JP 2001511363-A/24
            PD   14-AUG-2001
            PF   22-JUL-1998 JP 2000504461
            PR   22-JUL-1997 EP   97112482.1,23-JUL-1997 EP   97401773.3 PI
            BERNARD CONRA,BERNARD MATTHEW
            PC   C12N15/09,A01K67/027,A61K31/7088,A61K31/7115,A61K39/21,A61P3/
            PC   10,A61P37/00,
            PC   C07K7/00,C07K14/08,C12N5/10,C12N7/00,C12P21/02,C12Q1/02,C12Q1/
            PC   68,
            PC   G01N33/564,G01N33/569,C12N15/00,C12N5/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
```

```
           CC   /desc = 'SYNTHETIC DNA'
           CC   /note = 'page 52'
           FH   Key             Location/Qualifiers
           FT   misc_feature    1. .25.
FEATURES             Location/Qualifiers
     source          1. .25
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             3.0%;  Score 16.6;  DB 1;  Length 25;
  Best Local Similarity   82.6%;  Pred. No. 81;
  Matches   19;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1951 TTTTTGTGTCCGCTAAATATTTA 1973
              |||||| |||| || | ||||||
Db          1 TTTTTGAGTCCCCTTAGTATTTA 23


RESULT 12
AX326966
LOCUS       AX326966                  20 bp    DNA     linear   PAT 07-JAN-2002
DEFINITION  Sequence 162 from Patent WO0178894.
ACCESSION   AX326966
VERSION     AX326966.1  GI:18097677
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Keith,T.
  TITLE     Novel human gene relating to respiratory diseases, obesity, and
            inflammatory bowel disease
  JOURNAL   Patent: WO 0178894-A 162 25-OCT-2001;
            Genome Therapeutics Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 20;
  Best Local Similarity   94.4%;  Pred. No. 69;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1558 CAGGACTGCAAAAATCCT 1575
              ||||||||||||| |||||
Db          1 CAGGACTGCAAACATCCT 18


RESULT 13
AR257304
LOCUS       AR257304                  24 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 66 from patent US 6486130.
ACCESSION   AR257304
VERSION     AR257304.1  GI:27307146
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 24)
  AUTHORS   Livey,I., Crowe,B. and Dorner,F.
  TITLE     Immunogenic formulation of OSPC antigen vaccines for the prevention
            and treatment of lyme disease and recombinant methods for the
            preparation of such antigens
  JOURNAL   Patent: US 6486130-A 66 26-NOV-2002;
FEATURES             Location/Qualifiers
     source          1. .24
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.9%;  Score 16.4;  DB 1;  Length 24;
  Best Local Similarity   94.4%;  Pred. No. 86;
  Matches   17;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1760 ATTCATTAAGCTTTTTTT 1777
              |||||||||| |||||||
Db          4 ATTCATTAAGGTTTTTTT 21


RESULT 14
AR241776/c
LOCUS       AR241776                  21 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 64 from patent US 6472154.
ACCESSION   AR241776
VERSION     AR241776.1  GI:27287588
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
  TITLE     Polymorphic repeats in human genes
  JOURNAL   Patent: US 6472154-A 64 29-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 81;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1938 AGGTAATGGTTGGTTTTTGTG 1958
              ||| |||||| ||||||| ||
Db         21 AGGGAATGGTGGGTTTTTCTG 1


RESULT 15
AR296425
LOCUS       AR296425                  21 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 8160 from patent US 6537751.
ACCESSION   AR296425
VERSION     AR296425.1  GI:31683709
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 8160 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.9%;  Score 16.2;  DB 1;  Length 21;
  Best Local Similarity   85.7%;  Pred. No. 81;
  Matches   18;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACCGCAC 1587
              || |||| |||||||| ||||
Db          1 AATAATCTTTCTCCACTGCAC 21


RESULT 16
BD168596/c
LOCUS       BD168596                  20 bp    DNA     linear   PAT 17-JAN-2003
DEFINITION  Farnesyl pyrophosphate synthase protein and nuclear and promoter
            domains thereof.
ACCESSION   BD168596
VERSION     BD168596.1  GI:27874408
KEYWORDS    WO 0231164-A/14.
```

```
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Okada,Y. and Ito,K.
  TITLE     Farnesyl pyrophosphate synthase protein and nuclear and promoter
            domains thereof
  JOURNAL   Patent: WO 0231164-A 14 18-APR-2002;
            SAPPORO BREWERIES LTD,YUKIO OKADA,KAZUTOSHI ITO
COMMENT     OS   Artificial Sequence
            PN   WO 0231164-A/14
            PD   18-APR-2002
            PF   05-OCT-2001 WO 2001JP008816
            PR   06-OCT-2000 JP 00P   308054
            PI   YUKIO OKADA,KAZUTOSHI ITO
            PC   C12N15/60,C12N9/88
            CC   Description of Artificial Sequence: synthetic oligo nucleotide
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 20;
  Best Local Similarity   89.5%;  Pred. No. 93;
  Matches   17;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCTTCTC 1579
              | |||| ||||||||||||
Db         20 GGCTGCCAAAATCCTTCTC 2


RESULT 17
AR053253
LOCUS       AR053253                  23 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 3 from patent US 5834193.
ACCESSION   AR053253
VERSION     AR053253.1  GI:5978115
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Kozlowski,M.R., Prowse,K.R., Wang,S.-S., Wong,S., Kim,N.Woo. and
            Allsopp,R.
  TITLE     Methods for measuring telomere length
  JOURNAL   Patent: US 5834193-A 3 10-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 1.1e+02;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db          3 CTCTGAAAGTGGACCWATCAG 23


RESULT 18
AR053257/c
LOCUS       AR053257                  23 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 7 from patent US 5834193.
ACCESSION   AR053257
VERSION     AR053257.1  GI:5978119
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 23)
  AUTHORS   Kozlowski,M.R., Prowse,K.R., Wang,S.-S., Wong,S., Kim,N.Woo. and
            Allsopp,R.
  TITLE     Methods for measuring telomere length
  JOURNAL   Patent: US 5834193-A 7 10-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.8%;  Score 15.8;  DB 1;  Length 23;
  Best Local Similarity   81.0%;  Pred. No. 1.1e+02;
  Matches   17;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTATAAG 1820
              ||||||||||||  |:|| ||
Db         21 CTCTGAAAGTGGACCWATCAG 1


RESULT 19
AX728891
LOCUS       AX728891                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 525 from Patent WO03025175.
ACCESSION   AX728891
VERSION     AX728891.1  GI:30508234
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 525 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 17;
  Best Local Similarity   94.1%;  Pred. No. 94;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTGGTA 2029
              ||||||||| |||||||
Db          1 GATCAAGTCTTCTGGTA 17


RESULT 20
AX095913
LOCUS       AX095913                  21 bp    DNA     linear   PAT 30-MAR-2001
DEFINITION  Sequence 1091 from Patent WO0118250.
ACCESSION   AX095913
VERSION     AX095913.1  GI:13512140
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
            Mccarthy,J.J.
  TITLE     Single nucleotide polymorphisms in genes
  JOURNAL   Patent: WO 0118250-A 1091 15-MAR-2001;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
            Pharmaceuticals, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
```

```
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 1.2e+02;
  Matches   16;  Conservative    1;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCAAGTCC 2022
              | || |||||:||||||||
Db          1 TACTCCAGAGRTCAAGTCC 19


RESULT 21
AX468432
LOCUS       AX468432                 23 bp    DNA     linear   PAT 16-JUL-2002
DEFINITION  Sequence 5 from Patent WO0220759.
ACCESSION   AX468432
VERSION     AX468432.1  GI:21901268
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Eling,T.E. and Baek,S.J.
  TITLE     A non-steroidal anti-inflammatory drug activated gene with
            anti-tumorigenic properties
  JOURNAL   Patent: WO 0220759-A 5 14-MAR-2002;
            THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.8%;  Score 15.4;  DB 1;  Length 23;
  Best Local Similarity   94.1%;  Pred. No. 1.3e+02;
  Matches   16;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1550 GGAAGGAACAGGACTGC 1566
              ||||||| |||||||||
Db          5 GGAAGGACCAGGACTGC 21


RESULT 22
CQ763459
LOCUS       CQ763459                 20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 2077 from Patent WO2004003201.
ACCESSION   CQ763459
VERSION     CQ763459.1  GI:44906695
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 2077 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAAGTG 1993
              | ||||  ||||||||||||
Db          1 CATTGAGCAAAAGAAAAGTG 20


RESULT 23
AR429749
LOCUS       AR429749                 20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 29 from patent US 6645745.
ACCESSION   AR429749
VERSION     AR429749.1  GI:40190087
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Wojnowski,L., Gellner,K. and Eiselt,R.
  TITLE     Identification of a new member of the cytochrome P450 3A (CYP3A)
            gene family: CYP3AX
  JOURNAL   Patent: US 6645745-A 29 11-NOV-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 20;
  Best Local Similarity   85.0%;  Pred. No. 1.2e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1863 CACACTTAGCCATTGAAATG 1882
              || |||| ||||| ||||||
Db          1 CAAACTTTGCCATGGAAATG 20


RESULT 24
BD089734
LOCUS       BD089734                 21 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD089734
VERSION     BD089734.1  GI:22635344
KEYWORDS    JP 2001321190-A/1978.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 1978 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/1978
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .21
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 21;
  Best Local Similarity   85.0%;  Pred. No. 1.3e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1939 GGTAATGGTTGGTTTTTGTG 1958
              ||||||| | |||| |||||
Db          2 GGTAATGATGGGTTGTTGTG 21
```

```
RESULT 25
AX817759
LOCUS       AX817759                  22 bp    DNA     linear   PAT 10-DEC-2003
DEFINITION  Sequence 507 from Patent WO02081517.
ACCESSION   AX817759
VERSION     AX817759.1  GI:39722956
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Decristofaro,M.F., Padigaru,M., Miller,C., Tchernev,V., Zhong,H.,
            Zhong,M., Anderson,D., Ballinger,R., Gerlach,V., Spytek,K.A.,
            Rastelli,L., Kekuda,R., Guo,X., Zerhusen,B., Andrew,D., Mezes,P.,
            Patturajan,M., Burgess,C.E., Eisen,A., Wolenc,A., Baumgartner,J.,
            Shimkets,R.A., Gusev,V., Vernet,C.A., Taupier,R.J., Pena,C.,
            Shenoy,S., Li,L., Casman,S., Bolgog,F., Fernandes,E., Smithson,G.,
            Malyankar,U., Taillon,B. and Liu,X.
  TITLE     Novel polypeptides and nucleic acids encoded thereby
  JOURNAL   Patent: WO 02081517-A 507 17-OCT-2002;
            Curagen Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: PCR Primer
                     sequence"

  Query Match             2.7%;  Score 15.2;  DB 1;  Length 22;
  Best Local Similarity   85.0%;  Pred. No. 1.4e+02;
  Matches   17;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGTTTGT 1625
              ||||||  ||| ||||||||
Db          2 GGCCTGATGGAGGAGTTTGT 21


RESULT 26
AX475808/c
LOCUS       AX475808                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1029 from Patent WO0224750.
ACCESSION   AX475808
VERSION     AX475808.1  GI:22215093
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1029 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACTGG 1753
              |||||||||||||||
Db         17 GGTGACAAGTACTGG 3


RESULT 27
AX475809/c
LOCUS       AX475809                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1030 from Patent WO0224750.
ACCESSION   AX475809
VERSION     AX475809.1  GI:22215094
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1030 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACTGG 1753
              |||||||||||||||
Db         16 GGTGACAAGTACTGG 2


RESULT 28
AX475810/c
LOCUS       AX475810                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1031 from Patent WO0224750.
ACCESSION   AX475810
VERSION     AX475810.1  GI:22215095
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1031 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.7%;  Score 15;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACTGG 1753
              |||||||||||||||
Db         15 GGTGACAAGTACTGG 1


RESULT 29
AX133222/c
LOCUS       AX133222                  21 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 4440 from Patent WO0130362.
ACCESSION   AX133222
VERSION     AX133222.1  GI:14139532
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
```

```
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 4440 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="IL8 ribozyme recognition site"

  Query Match             2.7%;  Score 15;  DB 1;  Length 21;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+02;
  Matches   15;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACA 1866
              |||||||||||||||
Db         16 CAACAGACCCACACA 2


RESULT 30
AX226182
LOCUS       AX226182                 23 bp    DNA     linear   PAT 10-SEP-2001
DEFINITION  Sequence 101 from Patent WO0160856.
ACCESSION   AX226182
VERSION     AX226182.1  GI:15555494
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Vikkula,M.
  TITLE     vmglom gene and its mutations causing disorders with a vascular
            component
  JOURNAL   Patent: WO 0160856-A 101 23-AUG-2001;
            UNIVERSITE CATHOLIQUE DE LOUVAIN (BE)
FEATURES             Location/Qualifiers
     source          1. .23
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="oligonucleotide"

  Query Match             2.7%;  Score 15;  DB 1;  Length 23;
  Best Local Similarity   78.3%;  Pred. No. 1.6e+02;
  Matches   18;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1924 TTTTTTCAGTGTTAAGGTAATGG 1946
              |||||  |||||  ||||||  | |
Db          1 TTTTTGTAGTGTCAAGGTATTAG 23


RESULT 31
AB069627
LOCUS       AB069627                 18 bp    DNA     linear   SYN 21-MAY-2003
DEFINITION  Synthetic construct DNA, reverse primer for human STS sts-N26127 at
            1p36.
ACCESSION   AB069627
VERSION     AB069627.1  GI:15130431
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
            Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
            Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
            and Soeda,E.
  TITLE     A BAC-based STS-content map spanning a 35-Mb region of human
            chromosome 1p35-p36
  JOURNAL   Genomics 74 (1), 55-70 (2001)
  MEDLINE   21269192
   PUBMED   11374902

REFERENCE   2  (bases 1 to 18)
  AUTHORS   Horii,A.
  TITLE     Direct Submission
  JOURNAL   Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
            Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
            Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
            Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
     misc_feature    1. .18
                     /note="reverse primer for human STS sts-N26127 at 1p36
                     sts-N26127 obtained from clones B68J10, B68H10, B30J5,
                     B358I24, B42C4, B151K19, B239O24, Human BAC library
                     RPCI-11"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 18;
  Best Local Similarity   88.9%;  Pred. No. 1.3e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTTTG 1624
              || ||||||||||||  ||
Db          1 GCATGGGGGAAGAGTGTG 18


RESULT 32
A51700
LOCUS       A51700                   19 bp    DNA     linear   PAT 10-MAR-1997
DEFINITION  Sequence 6 from Patent WO9618744.
ACCESSION   A51700
VERSION     A51700.1  GI:2304504
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Crouzet,J., Scherman,D. and Wils,P.
  TITLE     PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN IMMOBILIZED
            OLIGONUCLEOTIDE
  JOURNAL   Patent: WO 9618744-A 6 20-JUN-1996;
            RHONE POULENC RORER SA (FR)
COMMENT     Other publication AU 4178996 960703
            Other publication FR 2728264 960621.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              |||||||  |||||  ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 33
A65476
LOCUS       A65476                   19 bp    DNA     linear   PAT 29-MAR-1999
DEFINITION  Sequence 4 from Patent WO9735002.
ACCESSION   A65476
VERSION     A65476.1  GI:4531211
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Wils,P. and Ollivier,M.
  TITLE     PURIFICATION OF PHARMACEUTICAL-GRADE PLASMID DNA
```

```
  JOURNAL   Patent: WO 9735002-A 4 25-SEP-1997;
            RHONE POULENC RORER SA (FR)
COMMENT     Other publication AU 2166197 19971010
            Other publication FR 2746412 19970926.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 34
AR167579
LOCUS       AR167579                19 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 6 from patent US 6287762.
ACCESSION   AR167579
VERSION     AR167579.1  GI:17903368
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Crouzet,J., Scherman,D. and Wils,P.
  TITLE     Purification of a triple helix formation with an immobilized
            oligonucleotide
  JOURNAL   Patent: US 6287762-A 6 11-SEP-2001;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 35
AR178289
LOCUS       AR178289                19 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 6 from patent US 6319672.
ACCESSION   AR178289
VERSION     AR178289.1  GI:20219427
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Crouzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
  TITLE     Purification of a triple helix formation with an immobilized
            oligonucleotide
  JOURNAL   Patent: US 6319672-A 6 20-NOV-2001;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 36
AX016237
LOCUS       AX016237                19 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 4 from Patent WO9949067.
ACCESSION   AX016237
VERSION     AX016237.1  GI:10041814
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wils,P., Ciolina,C. and Scherman,D.
  TITLE     Nucleic acid transfer vectors, compositions containing same and
            uses
  JOURNAL   Patent: WO 9949067-A 4 30-SEP-1999;
            WILS PIERRE (FR); CIOLINA CAROLE (FR); SCHERMAN DANIEL (FR); RHONE
            POULENC RORER SA (FR)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="misc_binding"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 37
AX323371
LOCUS       AX323371                19 bp    DNA     linear   PAT 07-JAN-2002
DEFINITION  Sequence 6 from Patent WO0192511.
ACCESSION   AX323371
VERSION     AX323371.1  GI:18094133
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Crouzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
  TITLE     Purification of a triple helix formation with an immobilized
            oligonucleotide
  JOURNAL   Patent: WO 0192511-A 6 06-DEC-2001;
            Aventis Pharma (FR)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="synthetic oligonucleotide"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 38
AX686841
LOCUS       AX686841                19 bp    DNA     linear   PAT 29-MAR-2003
DEFINITION  Sequence 6 from Patent EP1281774.
```

```
ACCESSION   AX686841
VERSION     AX686841.1  GI:29372382
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Couzet,J., Scherman,D. and Wils,P.
  TITLE     Purification of a triple helix formation with an immobilized
            oligonucleotide
  JOURNAL   Patent: EP 1281774-A 6 05-FEB-2003;
            Aventis Pharma S.A. (FR)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 39
BD135015
LOCUS       BD135015                 19 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Vector having nucleic acid transferred thereinto, compositions
            containing the vector and utilization thereof.
ACCESSION   BD135015
VERSION     BD135015.1  GI:23229960
KEYWORDS    JP 2002507429-A/4.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Siorina,C., Sherman,D. and Wills,P.
  TITLE     Vector having nucleic acid transferred thereinto, compositions
            containing the vector and utilization thereof
  JOURNAL   Patent: JP 2002507429-A 4 12-MAR-2002;
            AVENTIS PHARMA SA
COMMENT     OS   Unidentified
            PN   JP 2002507429-A/4
            PD   12-MAR-2002
            PF   19-MAR-1999 JP 2000538027
            PR   24-MAR-1998 FR     98/03573,18-MAY-1998 US   60/085 848 PI
            CAROL SIORINA,DANIEL SHERMAN,PIERRE WILLS
            PC   C12N15/09,A61K39/39,A61K48/00,C12N1/15,C12N1/19,C12N5/10, PC
            C12N15/00,
            PC   C12N5/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Vector having nucleic acid transferred thereinto, compositions

            CC           containing
            CC   the vector and utilization thereof
            FH   Key             Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 19;
  Best Local Similarity   88.9%;  Pred. No. 1.4e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAA 1557
              ||||||| ||||| ||||
Db          2 AGGAGAGGAGGGAGGGAA 19


RESULT 40
A50098
LOCUS       A50098                   20 bp    DNA     linear   PAT 07-MAR-1997
DEFINITION  Sequence 2 from Patent WO9612821.
ACCESSION   A50098
VERSION     A50098.1  GI:2303259
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Baird,D.M., Royle,N.J. and Jeffreys,A.J.
  TITLE     METHOD FOR CHARACTERISING VARIABILITY IN TELOMERE DNA BY PCR
  JOURNAL   Patent: WO 9612821-A 2 02-MAY-1996;
            ZENECA LTD (GB)
COMMENT     Other publication GB 2294322 960424.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTAT 1817
              ||||||||||||  ||||
Db          3 CTCTGAAAGTGGACCTAT 20


RESULT 41
AR152574
LOCUS       AR152574                 20 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 2 from patent US 6235468.
ACCESSION   AR152574
VERSION     AR152574.1  GI:15120106
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Baird,D.Martin., Royle,N.Jane. and Jeffreys,A.John.
  TITLE     Method for characterising variability in telomere DNA by PCR
  JOURNAL   Patent: US 6235468-A 2 22-MAY-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGCTAT 1817
              ||||||||||||  ||||
Db          3 CTCTGAAAGTGGACCTAT 20


RESULT 42
CQ763394
LOCUS       CQ763394                 20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 2012 from Patent WO2004003201.
ACCESSION   CQ763394
VERSION     CQ763394.1  GI:44906630
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
```

```
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 2012 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAGTG 1993
              ||||  ||||||||||||
Db          2 TTGAGCAAAAGAAAAGTG 19


RESULT 43
CQ763633
LOCUS       CQ763633                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 2251 from Patent WO2004003201.
ACCESSION   CQ763633
VERSION     CQ763633.1  GI:44906869
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 2251 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAGTG 1993
              ||||  ||||||||||||
Db          1 TTGAGCAAAAGAAAAGTG 18


RESULT 44
AR444793/c
LOCUS       AR444793                  20 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 15 from patent US 6670465.
ACCESSION   AR444793
VERSION     AR444793.1  GI:42672652
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bech-Hansen,T. and Naylor,M.J.
  TITLE     Retinal calcium channel (alpha)1F-subunit gene
  JOURNAL   Patent: US 6670465-A 15 30-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.6%;  Score 14.8;  DB 1;  Length 20;
  Best Local Similarity   88.9%;  Pred. No. 1.5e+02;
  Matches   16;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTGAAA 1807
              ||||||||||||| | ||
Db         18 TTCTTTCCTTCTCCGGAA 1


RESULT 45
AX380339
LOCUS       AX380339                  22 bp    DNA     linear   PAT 18-MAR-2002
DEFINITION  Sequence 22 from Patent WO0198514.
ACCESSION   AX380339
VERSION     AX380339.1  GI:19575303
KEYWORDS    .
SOURCE      Feline leukemia virus
  ORGANISM  Feline leukemia virus
            Viruses; Retroid viruses; Retroviridae; Gammaretrovirus.
REFERENCE   1
  AUTHORS   Roth,M.J. and Bupp,K.
  TITLE     Targeting viral vectors to specific cells
  JOURNAL   Patent: WO 0198514-A 22 27-DEC-2001;
            UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="Feline leukemia virus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:11768"

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTTACCTACCT 1634
              ||| ||||||  ||||||| |
Db          2 GGAGGAGTTTTATACCTACAT 22


RESULT 46
AX708078
LOCUS       AX708078                  22 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 14 from Patent WO03014387.
ACCESSION   AX708078
VERSION     AX708078.1  GI:29564029
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wojnowski,L. and Presecan-Siedel,E.
  TITLE     Polymorphisms in the human gene for cyp1a2 and their use in
            diagnostic and therapeutic applications
  JOURNAL   Patent: WO 03014387-A 14 20-FEB-2003;
            Epidauros Biotechnologie AG (DE)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.6%;  Score 14.6;  DB 1;  Length 22;
  Best Local Similarity   81.0%;  Pred. No. 1.8e+02;
  Matches   17;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTTGTTTC 1695
              ||||| | || |||||| |||
Db          2 CCTGGCCATCCTAGTTGATTC 22


RESULT 47
BD258525/c
LOCUS       BD258525                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258525
```

```
VERSION     BD258525.1  GI:33068295
KEYWORDS    JP 2002541795-A/6318.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6318 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6318
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
              ||||||||||| ||||
Db         17 TTTACCTTGAATAAAA 2


RESULT 48
AX761225
LOCUS       AX761225                 17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4546 from Patent WO03040369.
ACCESSION   AX761225
VERSION     AX761225.1  GI:32255841
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4546 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 17;
  Best Local Similarity   93.8%;  Pred. No. 1.5e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||| ||||||||||||
Db          2 ATCTATTAAATACATT 17


RESULT 49
AX599370/c
LOCUS       AX599370                 18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 710 from Patent WO02077272.
ACCESSION   AX599370
VERSION     AX599370.1  GI:28399514
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 710 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN2a"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              |||||||||||||  ||
Db         18 TTTAAATACATTCACT 3


RESULT 50
AX705542/c
LOCUS       AX705542                 18 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 211 from Patent WO03014388.
ACCESSION   AX705542
VERSION     AX705542.1  GI:29562207
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Distler,J., Model,F. and Taubert,H.
  TITLE     Method and nucleic acids for the analysis of colon cancer
  JOURNAL   Patent: WO 03014388-A 211 20-FEB-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for p16"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              |||||||||||||  ||
Db         18 TTTAAATACATTCACT 3


RESULT 51
AX705544
LOCUS       AX705544                 18 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 213 from Patent WO03014388.
```

```
ACCESSION   AX705544
VERSION     AX705544.1  GI:29562209
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Distler,J., Model,F. and Taubert,H.
  TITLE     Method and nucleic acids for the analysis of colon cancer
  JOURNAL   Patent: WO 03014388-A 213 20-FEB-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for p16"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||||||| ||
Db          1 TTTAAATACATTCACT 16


RESULT 52
AX796234/c
LOCUS       AX796234                  18 bp    DNA     linear   PAT 04-OCT-2003
DEFINITION  Sequence 577 from Patent WO03052135.
ACCESSION   AX796234
VERSION     AX796234.1  GI:37516900
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Field,J.K., Genc,B., Liloglou,T., Lipscher,E., Maier,S.
            and Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lung cell
            proliferative disorder
  JOURNAL   Patent: WO 03052135-A 577 26-JUN-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN2a"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||||||| ||
Db         18 TTTAAATACATTCACT 3


RESULT 53
AX822736/c
LOCUS       AX822736                  18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 628 from Patent EP1340818.
ACCESSION   AX822736
VERSION     AX822736.1  GI:39749372
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: EP 1340818-A 628 03-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN2a"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||||||| ||
Db         18 TTTAAATACATTCACT 3


RESULT 54
AX826376/c
LOCUS       AX826376                  18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 628 from Patent WO03072821.
ACCESSION   AX826376
VERSION     AX826376.1  GI:39751890
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferactive disorder
  JOURNAL   Patent: WO 03072821-A 628 04-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN2a"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 18;
  Best Local Similarity   93.8%;  Pred. No. 1.6e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||||||| ||
Db         18 TTTAAATACATTCACT 3


RESULT 55
AX587498
LOCUS       AX587498                  19 bp    DNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 8 from Patent WO0236751.
ACCESSION   AX587498
VERSION     AX587498.1  GI:27656314
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wernet,P.
  TITLE     Human cord blood derived unrestricted somatic stem cells (ussc)
  JOURNAL   Patent: WO 0236751-A 8 10-MAY-2002;
            Kourion Therapeuthics GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
```

/note="3 primer for the neuofilament gene"

Query Match 2.6%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2024 CTGGTAGGAGGCAAAG 2039
              ||||||||||||||| |
Db          2 CTGGTAGGAGGCAATG 17
```

RESULT 56
AR070884
LOCUS AR070884 20 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 35 from patent US 5908839.
ACCESSION AR070884
VERSION AR070884.1 GI:7221772
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Levitt,R.Clifford. and Nicolaides,N.C.
TITLE Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
JOURNAL Patent: US 5908839-A 35 01-JUN-1999;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.6%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1641 TTAAAGAGCCTTCACT 1656
              ||||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20
```

RESULT 57
AR314291/c
LOCUS AR314291 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 4828 from patent US 6559294.
ACCESSION AR314291
VERSION AR314291.1 GI:31707717
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A., Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 4828 06-MAY-2003;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.6%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1567 AAAAATCCTTCTCCAC 1582
              ||||||||| ||||||
Db         20 AAAAATCCTCCTCCAC 5
```

RESULT 58
AR315574
LOCUS AR315574 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 6111 from patent US 6559294.
ACCESSION AR315574
VERSION AR315574.1 GI:31709000
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A., Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 6111 06-MAY-2003;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.6%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1556 AACAGGACTGCAAAAA 1571
              || |||||||||||||
Db          4 AAGAGGACTGCAAAAA 19
```

RESULT 59
AR429446
LOCUS AR429446 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 35 from patent US 6645492.
ACCESSION AR429446
VERSION AR429446.1 GI:40189653
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Levitt,R.C., Maloy,W.L., Kari,U.P. and Nicolaides,N.C.
TITLE Methods of treating asthma with interleukin-9 receptor antibodies
JOURNAL Patent: US 6645492-A 35 11-NOV-2003;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.6%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1641 TTAAAGAGCCTTCACT 1656
              ||||||||| ||||||
Db          5 TTAAAGAGCATTCACT 20
```

RESULT 60
AR337899
LOCUS AR337899 21 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 1 from patent US 6569423.
ACCESSION AR337899
VERSION AR337899.1 GI:33724541
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Weinstein,D.E.
TITLE Methods of inducing nervous tissue regeneration
JOURNAL Patent: US 6569423-A 1 27-MAY-2003;
FEATURES Location/Qualifiers
source 1. .21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.6%; Score 14.4; DB 1; Length 21;

```
  Best Local Similarity   93.8%;  Pred. No. 1.9e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| ||||||
Db          6 TCTCCACCCCACAGAC 21


RESULT 61
CQ760448
LOCUS       CQ760448                  22 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 5 from Patent WO2004003550.
ACCESSION   CQ760448
VERSION     CQ760448.1  GI:44903961
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with anticoagulants
  JOURNAL   Patent: WO 2004003550-A 5 08-JAN-2004;
            Xanthus Life Sciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 62
AX546436
LOCUS       AX546436                  22 bp    DNA     linear   PAT 26-NOV-2002
DEFINITION  Sequence 5 from Patent WO02073196.
ACCESSION   AX546436
VERSION     AX546436.1  GI:25811627
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with antipsychotics
  JOURNAL   Patent: WO 02073196-A 5 19-SEP-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 63
AX557277
LOCUS       AX557277                  22 bp    DNA     linear   PAT 27-NOV-2002
DEFINITION  Sequence 5 from Patent WO02073197.
ACCESSION   AX557277
VERSION     AX557277.1  GI:25900231
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with antidepressants
  JOURNAL   Patent: WO 02073197-A 5 19-SEP-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 64
AX557361
LOCUS       AX557361                  22 bp    DNA     linear   PAT 27-NOV-2002
DEFINITION  Sequence 5 from Patent WO02073206.
ACCESSION   AX557361
VERSION     AX557361.1  GI:25900270
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Metabolic phenotyping in therapy with anxiolytics
  JOURNAL   Patent: WO 02073206-A 5 19-SEP-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 65
AX557386
LOCUS       AX557386                  22 bp    DNA     linear   PAT 27-NOV-2002
DEFINITION  Sequence 5 from Patent WO02073205.
ACCESSION   AX557386
VERSION     AX557386.1  GI:25900295
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Metabolic phenotyping in therapy with immunosuppressants
  JOURNAL   Patent: WO 02073205-A 5 19-SEP-2002;
```

```
           McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 66
AX591097
LOCUS       AX591097                  22 bp    DNA     linear   PAT 27-JAN-2003
DEFINITION  Sequence 5 from Patent WO02086504.
ACCESSION   AX591097
VERSION     AX591097.1  GI:27949612
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with gastroesophageal reflux disease
            agents
  JOURNAL   Patent: WO 02086504-A 5 31-OCT-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 67
AX592487
LOCUS       AX592487                  22 bp    DNA     linear   PAT 27-JAN-2003
DEFINITION  Sequence 3 from Patent WO02064816.
ACCESSION   AX592487
VERSION     AX592487.1  GI:27950565
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Multiple determinants for metabolic phenotypes
  JOURNAL   Patent: WO 02064816-A 3 22-AUG-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 68
AX592990
LOCUS       AX592990                  22 bp    DNA     linear   PAT 27-JAN-2003
DEFINITION  Sequence 3 from Patent WO02084288.
ACCESSION   AX592990
VERSION     AX592990.1  GI:27950833
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with antiarrhythmics
  JOURNAL   Patent: WO 02084288-A 3 24-OCT-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 69
AX593130
LOCUS       AX593130                  22 bp    DNA     linear   PAT 13-FEB-2003
DEFINITION  Sequence 5 from Patent WO02088753.
ACCESSION   AX593130
VERSION     AX593130.1  GI:28374591
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with erectile dysfunction agents
  JOURNAL   Patent: WO 02088753-A 5 07-NOV-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 70
AX593465
LOCUS       AX593465                  22 bp    DNA     linear   PAT 13-FEB-2003
DEFINITION  Sequence 5 from Patent WO02088714.
```

```
ACCESSION   AX593465
VERSION     AX593465.1  GI:28374828
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with antineoplastic agents
  JOURNAL   Patent: WO 02088714-A 5 07-NOV-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 71
AX597460
LOCUS       AX597460                  22 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 5 from Patent WO02090994.
ACCESSION   AX597460
VERSION     AX597460.1  GI:28397730
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with analgesics
  JOURNAL   Patent: WO 02090994-A 5 14-NOV-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 72
AX601670
LOCUS       AX601670                  22 bp    DNA     linear   PAT 17-FEB-2003
DEFINITION  Sequence 5 from Patent WO02093162.
ACCESSION   AX601670
VERSION     AX601670.1  GI:28401715
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with antibiotic agents
  JOURNAL   Patent: WO 02093162-A 5 21-NOV-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 73
AX616971
LOCUS       AX616971                  22 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 3 from Patent WO02095402.
ACCESSION   AX616971
VERSION     AX616971.1  GI:28447776
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with hyperlipidemia agents
  JOURNAL   Patent: WO 02095402-A 3 28-NOV-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 74
AX643845
LOCUS       AX643845                  22 bp    DNA     linear   PAT 24-FEB-2003
DEFINITION  Sequence 5 from Patent WO02099422.
ACCESSION   AX643845
VERSION     AX643845.1  GI:28551633
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with alzheimer's disease agents
  JOURNAL   Patent: WO 02099422-A 5 12-DEC-2002;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 75
AX696030
LOCUS       AX696030                  22 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 7 from Patent WO03008637.
ACCESSION   AX696030
VERSION     AX696030.1  GI:29419192
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Use of genotyping in the individualization of therapy
  JOURNAL   Patent: WO 03008637-A 7 30-JAN-2003;
            McGill University (CA)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="sequence to be used as a primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 76
AX773003
LOCUS       AX773003                  22 bp    DNA     linear   PAT 09-JUL-2003
DEFINITION  Sequence 5 from Patent WO03046583.
ACCESSION   AX773003
VERSION     AX773003.1  GI:32485172
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with anesthetics
  JOURNAL   Patent: WO 03046583-A 5 05-JUN-2003;
            Xanthus Life Sciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 77
AX781387
LOCUS       AX781387                  22 bp    DNA     linear   PAT 14-JUL-2003
DEFINITION  Sequence 5 from Patent WO03046559.
ACCESSION   AX781387
VERSION     AX781387.1  GI:32698388
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with antiviral agents
  JOURNAL   Patent: WO 03046559-A 5 05-JUN-2003;
            Xanthus Life Sciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 78
AX794404
LOCUS       AX794404                  22 bp    DNA     linear   PAT 04-OCT-2003
DEFINITION  Sequence 5 from Patent WO03052123.
ACCESSION   AX794404
VERSION     AX794404.1  GI:37515482
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with antihistamines
  JOURNAL   Patent: WO 03052123-A 5 26-JUN-2003;
            Xanthus Life Sciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .22
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 79
AX815443
LOCUS       AX815443                  22 bp    DNA     linear   PAT 09-DEC-2003
DEFINITION  Sequence 5 from Patent WO03067257.
ACCESSION   AX815443
VERSION     AX815443.1  GI:39646144
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Leyland-Jones,B.
  TITLE     Individualization of therapy with anxiolitics
  JOURNAL   Patent: WO 03067257-A 5 14-AUG-2003;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .22
```

```
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Sequence to be used as a Primer"

  Query Match             2.6%;  Score 14.4;  DB 1;  Length 22;
  Best Local Similarity   93.8%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||||| |||||||||
Db          5 ATCTTTAAAATACATT 20


RESULT 80
CQ801936
LOCUS       CQ801936                  19 bp    DNA     linear   PAT 05-MAY-2004
DEFINITION  Sequence 253 from Patent WO2004033720.
ACCESSION   CQ801936
VERSION     CQ801936.1  GI:47058517
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Schrenzel,J., Francois,P., Charbonnier,Y., Jacquet,J.G.,
            Utinger,D., Kresbach,G.M., Abel,A. and Ehrat,M.
  TITLE     Analytical chip for the detection of 16s-rrna from clinically
            relevant bacteria and analytical method based thereon
  JOURNAL   Patent: WO 2004033720-A 253 22-APR-2004;
            Hopitaux Universitaires de Geneve (CH)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Probe for CNS (Coagulase Negative Staphylococci)
                     consensus"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2051 TTAGCAACTAGTTAATAAG 2069
              ||| ||||||| ||||| |
Db          1 TTACCAACTAGCTAATACG 19


RESULT 81
I31281/c
LOCUS       I31281                    19 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 193 from patent US 5582979.
ACCESSION   I31281
VERSION     I31281.1  GI:1822072
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 193 10-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 19;
  Best Local Similarity   84.2%;  Pred. No. 1.9e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1727 CTATTATCAGAAGGTGACA 1745
              ||||| |||| ||| ||||
Db         19 CTATTCTCAGCAGGAGACA 1


RESULT 82
AR085554/c
LOCUS       AR085554                  20 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 32 from patent US 5981731.
ACCESSION   AR085554
VERSION     AR085554.1  GI:10012321
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P.
  TITLE     Antisense oligonucleotide modulation of B-raf gene expression
  JOURNAL   Patent: US 5981731-A 32 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 83
AR130151
LOCUS       AR130151                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 54 from patent US 6187587.
ACCESSION   AR130151
VERSION     AR130151.1  GI:14118048
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Popoff,I., Brown-Driver,V.L. and Cowsert,L.M.
  TITLE     Antisense inhibition of e2f transcription factor 1 expression
  JOURNAL   Patent: US 6187587-A 54 13-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2017 AAGTCCTCTGGTAGGAGGC 2035
              || ||||| || |||||||
Db          2 AACTCCTCAGGGAGGAGGC 20


RESULT 84
CQ763420
LOCUS       CQ763420                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 2038 from Patent WO2004003201.
ACCESSION   CQ763420
VERSION     CQ763420.1  GI:44906656
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
```

```
  JOURNAL    Patent: WO 2004003201-A 2038 08-JAN-2004;
             Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAAGT 1992
              | ||||  ||||||||||
Db          2 CATTGAGCAAAAGAAAAGT 20


RESULT 85
AR216074/c
LOCUS       AR216074                  20 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 121 from patent US 6410518.
ACCESSION   AR216074
VERSION     AR216074.1  GI:23314362
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P.
  TITLE     Antisense oligonucleotide inhibition of raf gene expression
  JOURNAL   Patent: US 6410518-A 121 25-JUN-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGAGTAG 1549
              ||| || | ||||||||||
Db         20 AGAGAGTTCAGGAGAGTAG 2


RESULT 86
AR314483/c
LOCUS       AR314483                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5020 from patent US 6559294.
ACCESSION   AR314483
VERSION     AR314483.1  GI:31707909
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
            Sankaran,B. and Fletcher,L.D.
  TITLE     Chlamydia pneumoniae polynucleotides and uses thereof
  JOURNAL   Patent: US 6559294-A 5020 06-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1585 CACAGACTGGGAACCCCTC 1603
              |||||| |||||| ||| |
Db         19 CACAGATTGGGAAGCCCCC 1


RESULT 87
AX716655
LOCUS       AX716655                  20 bp    DNA     linear   PAT 15-APR-2003
DEFINITION  Sequence 3339 from Patent EP1293569.
ACCESSION   AX716655
VERSION     AX716655.1  GI:29889971
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Isogai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S.,
            Yamamoto,J.I., Isono,Y., Hio,Y., Otsuka,K., Nagai,K., Irie,R.,
            Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahari,K. and
            Masuho,Y.
  TITLE     Full-length cDNAs
  JOURNAL   Patent: EP 1293569-A 3339 19-MAR-2003;
            Helix Research Institute (JP) ; Research Association for
            Biotechnology (JP)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="an artificially synthesized primer sequence"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTGT 1935
              ||| || || |||||||||
Db          1 ATAGCTCTTGTTTCAGTGT 19


RESULT 88
BD101848/c
LOCUS       BD101848                  20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kidney repairing factor.
ACCESSION   BD101848
VERSION     BD101848.1  GI:22647422
KEYWORDS    WO 0168817-A/16.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Takeuchi,K., Kato,Y., Sekine,S., Kikuchi,Y. and Sakurad,K.
  TITLE     Kidney repairing factor
  JOURNAL   Patent: WO 0168817-A 16 20-SEP-2001;
            KYOWA HAKKO KOGYO CO LTD,KYOKO TAKEUCHI,YOKO KATO,SUSUMU SEKINE,
            YASUHIRO KIKUCHI,KAZUHIRO SAKURADA
COMMENT     OS   Artificial Sequence
            PN   WO 0168817-A/16
            PD   20-SEP-2001
            PF   16-MAR-2001 WO 2001JP002087
            PR   16-MAR-2000 JP 00P    73632
            PI   KYOKO TAKEUCHI,YOKO KATO,SUSUMU SEKINE,YASUHIRO KIKUCHI, PI
            KAZUHIRO SAKURADA
            PC   C12N15/12,C12N15/63,C12N5/10,C12N5/12,C07K14/47,C07K16/18, PC
             C12Q1/68,
            PC   G01N33/53,A61K38/17,A61K39/395,A61K48/00,A61P13/12,C12P21/02,
            PC   C12P21/08,
            PC   A01K67/027
            CC   forward primer for amplification of human KRGF-1 DNA FH   Key
                      Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
```

```
                     /db_xref="taxon:32630"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 20;
  Best Local Similarity   84.2%;  Pred. No. 2e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGACTGG 1594
              |||| ||| ||||| ||||
Db         19 TCTCAACCTCACAGCCTGG 1


RESULT 89
BD242493
LOCUS       BD242493                  21 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Methylated CpG island amplification (MCA).
ACCESSION   BD242493
VERSION     BD242493.1  GI:33052263
KEYWORDS    JP 2002533061-A/58.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Issa,J.P., Baylin,S. and Toyota,M.
  TITLE     Methylated CpG island amplification (MCA)
  JOURNAL   Patent: JP 2002533061-A 58 08-OCT-2002;
            THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
COMMENT     OS   Artificial Sequence
            PN   JP 2002533061-A/58
            PD   08-OCT-2002
            PF   02-NOV-1999 JP 2000579773
            PR   03-NOV-1998 US    60/106925,10-MAY-1999 US    09/309175 PI
            JEAN PIERRE ISSA,STEPHEN BAYLIN,MINORU TOYOTA PC
            C12N15/09,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12Q1/68,C12N15/ PC
            00,C12N5/00
            CC   primer for PCR
            FH   Key             Location/Qualifiers
            FT   source          1. .21
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGGAAG 1554
              || | ||||||||||| ||
Db          1 GGGTTGGAGAGTAGGGGAG 19


RESULT 90
I24714/c
LOCUS       I24714                    21 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 18 from patent US 5545545.
ACCESSION   I24714
VERSION     I24714.1  GI:1604584
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Gengenbach,B.G., Somers,D.A., Bittel,D.C., Shaver,J.M. and
            Sellner,J.M. deceased.
  TITLE     Lysine-insensitive maize dihydrodipicolinic acid synthase
  JOURNAL   Patent: US 5545545-A 18 13-AUG-1996;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTCTA 2045
              | ||||||| ||||||||
Db         19 GAAGGAGGCCCAGGTTCTA 1


RESULT 91
AX148061
LOCUS       AX148061                  21 bp    DNA     linear   PAT 31-AUG-2001
DEFINITION  Sequence 61 from Patent WO0134848.
ACCESSION   AX148061
VERSION     AX148061.1  GI:14347031
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Brown,B.A., Kilpatrick,D.R., Pallansch,M.A. and Oberste,M.S.
  TITLE     Serotype-specific identification of enterovirus 71 by rt-pcr
  JOURNAL   Patent: WO 0134848-A 61 17-MAY-2001;
            Secretary of the Department of Health and Human Services (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
     modified_base   3
                     /mod_base=i
     modified_base   9
                     /mod_base=i
     modified_base   15
                     /mod_base=i

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1824 TAGAATCTTTTAAATACAT 1842
              ||||||  |||| ||||||
Db          2 TAGAATTATTTACATACAT 20


RESULT 92
AX179540
LOCUS       AX179540                  21 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 1 from Patent WO0132841.
ACCESSION   AX179540
VERSION     AX179540.1  GI:14599152
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Ruiz,M., Kinter,A., Dybul,M., Catanzaro,A. and Fauci,A.S.
  TITLE     Method of in vitro t cell differentiation of cd34?+ progenitor
            cells
  JOURNAL   Patent: WO 0132841-A 1 10-MAY-2001;
            The Secretary of the Department of Health and Human Services (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="PCR Primer"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTCTG 1804
```

```
              | ||  |||||||||||||
Db          3 CACACCCTTTCCTTCTCTG 21


RESULT 93
AX241164
LOCUS       AX241164                  21 bp    DNA     linear   PAT 26-SEP-2001
DEFINITION  Sequence 402 from Patent WO0160975.
ACCESSION   AX241164
VERSION     AX241164.1  GI:15798039
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Roemer,T., Jiang,B., Boone,C. and Bussey,H.
  TITLE     Gene disruption methodologies for drug target discovery
  JOURNAL   Patent: WO 0160975-A 402 23-AUG-2001;
            Elitra Pharmaceuticals, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="DNA primer"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATCAA 1906
              |||||| | || |||||||
Db          1 TTGATGGGTCCGAGATCAA 19


RESULT 94
AX353518/c
LOCUS       AX353518                  21 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 50 from Patent WO0204636.
ACCESSION   AX353518
VERSION     AX353518.1  GI:18618593
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   van Roy,F., Goossens,S., Janssens,B. and Vanpoucke,G.
  TITLE     Novel _g(a) expressed in heart and testis
  JOURNAL   Patent: WO 0204636-A 50 17-JAN-2002;
            Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="lower primer FVR2520"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAAGTGG 1811
              |||| |||||||||  |||
Db         20 TTTCATTCTCTGAACCTGG 2


RESULT 95
AX449621/c
LOCUS       AX449621                  21 bp    DNA     linear   PAT 03-JUL-2002
DEFINITION  Sequence 50 from Patent WO0210216.
ACCESSION   AX449621
VERSION     AX449621.1  GI:21698230
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Padigaru,M., Mezes,P., Mishra,V., Burgess,C., Casman,S.,
            Grosse,W.M., Alsobrook,J.P., Lepley,D.M., Gerlach,V.L.,
            Macdougall,J.R. and Smithson,G.
  TITLE     Proteins and nucleic acids encoding same
  JOURNAL   Patent: WO 0210216-A 50 07-FEB-2002;
            Curagen Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide primers"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1992 TGTGTATCTAGCTTCTTCA 2010
              ||||| |||  ||||||||
Db         20 TGTGTTTCTGCCTTCTTCA 2


RESULT 96
AX486786
LOCUS       AX486786                  21 bp    DNA     linear   PAT 16-AUG-2002
DEFINITION  Sequence 4086 from Patent WO02053728.
ACCESSION   AX486786
VERSION     AX486786.1  GI:22320934
KEYWORDS    .
SOURCE      Candida albicans
  ORGANISM  Candida albicans
            Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
            Saccharomycetales; mitosporic Saccharomycetales; Candida.
REFERENCE   1
  AUTHORS   Roemer,T., Jiang,B., Boone,C., Bussey,H. and Ohlsen,K.L.
  TITLE     Gene disruption methodologies for drug target discovery
  JOURNAL   Patent: WO 02053728-A 4086 11-JUL-2002;
            Elitra Pharmaceuticals, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="Candida albicans"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:5476"

  Query Match             2.5%;  Score 14.2;  DB 1;  Length 21;
  Best Local Similarity   84.2%;  Pred. No. 2.1e+02;
  Matches   16;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATCAA 1906
              |||||| | || |||||||
Db          1 TTGATGGGTCCGAGATCAA 19


RESULT 97
AX475807/c
LOCUS       AX475807                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1028 from Patent WO0224750.
ACCESSION   AX475807
VERSION     AX475807.1  GI:22215092
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1028 28-MAR-2002;
            Aeomica, Inc. (US)
```

```
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1740 GTGACAAGTACTGG 1753
              ||||||||||||||
Db         17 GTGACAAGTACTGG 4


RESULT 98
AX475811/c
LOCUS       AX475811                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1032 from Patent WO0224750.
ACCESSION   AX475811
VERSION     AX475811.1  GI:22215096
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1032 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACTG 1752
              ||||||||||||||
Db         14 GGTGACAAGTACTG 1


RESULT 99
AX723378
LOCUS       AX723378                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1065 from Patent WO03025176.
ACCESSION   AX723378
VERSION     AX723378.1  GI:30423879
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 1065 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2074 ATCTGACACACTCT 2087
              ||||||||||||||
Db          2 ATCTGACACACTCT 15


RESULT 100
AX724426
LOCUS       AX724426                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2113 from Patent WO03025176.
ACCESSION   AX724426
VERSION     AX724426.1  GI:30503769
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2113 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2074 ATCTGACACACTCT 2087
              ||||||||||||||
Db          2 ATCTGACACACTCT 15


RESULT 101
AX757648
LOCUS       AX757648                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 969 from Patent WO03040369.
ACCESSION   AX757648
VERSION     AX757648.1  GI:32252264
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 969 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 14;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1865 CACTTAGCCATTGA 1878
              ||||||||||||||
Db          4 CACTTAGCCATTGA 17


RESULT 102
```

```
AR173005/c
LOCUS       AR173005                  20 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 130 from patent US 6303374.
ACCESSION   AR173005
VERSION     AR173005.1  GI:17912496
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Zhang,H. and Cowsert,L.M.
  TITLE     Antisense modulation of caspase 3 expression
  JOURNAL   Patent: US 6303374-A 130 16-OCT-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAG 2013
             ||||||||||||||
Db         20 TAGCTTCTTCAGAG 7


RESULT 103
AR373640
LOCUS       AR373640                  20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 32 from patent US 6602857.
ACCESSION   AR373640
VERSION     AR373640.1  GI:40076051
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Cowsert,L.M., Wyatt,J., Monia,B.P., Butler,M.M. and McKay,R.
  TITLE     Antisense modulation of PTP1B expression
  JOURNAL   Patent: US 6602857-A 32 05-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
             ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 104
AX418637
LOCUS       AX418637                  20 bp    DNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 32 from Patent WO0210378.
ACCESSION   AX418637
VERSION     AX418637.1  GI:21523500
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Cowsert,L.M., Wyatt,J., Freier,S.M., Monia,B.P., Butler,M.M. and
            Mckay,R.
  TITLE     Antisense modulation of ptp1b expression
  JOURNAL   Patent: WO 0210378-A 32 07-FEB-2002;
            ISIS PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense Oligonucleotide"

  Query Match             2.5%;  Score 14;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   14;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAA 2018
             ||||||||||||||
Db          6 TCTTCAGAGATCAA 19


RESULT 105
BD258524/c
LOCUS       BD258524                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258524
VERSION     BD258524.1  GI:33068294
KEYWORDS    JP 2002541795-A/6317.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6317 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6317
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key              Location/Qualifiers
            FT   source           1. .17
            FT                    /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAAGA 1987
             |||||||||| |||| |
Db         17 TTACCTTGAATAAAATA 1


RESULT 106
CQ616606/c
LOCUS       CQ616606                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1346 from Patent WO0192524.
ACCESSION   CQ616606
VERSION     CQ616606.1  GI:41666824
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```

```
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1346 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              ||||||  |||||||||
Db         17 CCCCATCTTTTCCTTCT 1


RESULT 107
CQ622902/c
LOCUS       CQ622902                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7642 from Patent WO0192524.
ACCESSION   CQ622902
VERSION     CQ622902.1  GI:41673120
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7642 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCTAGC 1701
              ||  ||||  |||||||||
Db         17 TTTGTTGGTTCTCTAGC 1


RESULT 108
CQ622903/c
LOCUS       CQ622903                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7643 from Patent WO0192524.
ACCESSION   CQ622903
VERSION     CQ622903.1  GI:41673121
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7643 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTAG 1700
              |||  ||||  ||||||||
Db         17 CTTTGTTGGTTCTCTAG 1


RESULT 109
AR457669/c
LOCUS       AR457669                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1346 from patent US 6686188.
ACCESSION   AR457669
VERSION     AR457669.1  GI:42692726
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1346 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              ||||||  |||||||||
Db         17 CCCCATCTTTTCCTTCT 1


RESULT 110
AR463965/c
LOCUS       AR463965                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7642 from patent US 6686188.
ACCESSION   AR463965
VERSION     AR463965.1  GI:42699022
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7642 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCTAGC 1701
              ||  ||||  |||||||||
Db         17 TTTGTTGGTTCTCTAGC 1


RESULT 111
```

```
AR463966/c
LOCUS       AR463966                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7643 from patent US 6686188.
ACCESSION   AR463966
VERSION     AR463966.1  GI:42699023
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7643 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTAG 1700
              ||| |||| ||||||||
Db         17 CTTTGTTGGTTCTCTAG 1


RESULT 112
AX672581/c
LOCUS       AX672581                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 1026 from Patent WO03004526.
ACCESSION   AX672581
VERSION     AX672581.1  GI:29330929
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 1026 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATC 1999
              ||||||| ||||| |||
Db         17 AAAGAAATGTGTGGATC 1


RESULT 113
AX724865
LOCUS       AX724865                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2552 from Patent WO03025176.
ACCESSION   AX724865
VERSION     AX724865.1  GI:30504208
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2552 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTGGTA 2029
              |||||||||||| ||| |
Db          1 GATCAAGTCCTTTGGGA 17


RESULT 114
AX728110
LOCUS       AX728110                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5797 from Patent WO03025176.
ACCESSION   AX728110
VERSION     AX728110.1  GI:30507453
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5797 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 17;
  Best Local Similarity   88.2%;  Pred. No. 2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTGGTA 2029
              |||||||||||| || ||
Db          1 GATCAAGTCCTTTGTTA 17


RESULT 115
AX937390
LOCUS       AX937390                  18 bp    DNA     linear   PAT 06-JAN-2004
DEFINITION  Sequence 67 from Patent WO03091388.
ACCESSION   AX937390
VERSION     AX937390.1  GI:40713466
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lancet,D., Menashe,I., Man,O. and Gilad,Y.
  TITLE     Polymorphic olfactory receptor genes and arrays, kits and
            methodsutilizing them
  JOURNAL   Patent: WO 03091388-A 67 06-NOV-2003;
            YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL)
FEATURES             Location/Qualifiers
     source          1. .18
```

```
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Synthtic DNA oligonucleotide"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 18;
  Best Local Similarity   88.2%;  Pred. No. 2.2e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGGCA 2036
              |||||||||  ||||||
Db          2 TCCTCTGGTTTGAGGCA 18


RESULT 116
BD196445
LOCUS       BD196445                  19 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Prostatic cancer gene.
ACCESSION   BD196445
VERSION     BD196445.1  GI:33006215
KEYWORDS    JP 2002516657-A/34.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Blumenfeld,M., Chumakov,I. and Bougueleret,L.
  TITLE     Prostatic cancer gene
  JOURNAL   Patent: JP 2002516657-A 34 11-JUN-2002;
            GENSET
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002516657-A/34
            PD   11-JUN-2002
            PF   22-DEC-1998 JP 2000525562
            PR   22-DEC-1997 US    08/996306,09-SEP-1998 US    60/099658 PI
            DANIEL COHEN,MARTA BLUMENFELD,ILYA CHUMAKOV,LYDIE BOUGUELERET PC
            C12N15/09,C12N15/09,A01K67/027,C07K14/47,C07K16/18,C12N1/15, PC
            C12N1/19,
            PC   C12N1/21,C12N5/10,C12N5/10,C12P21/08,C12Q1/68,G01N33/50 PC
            ,C12N15/00,C12N5/00,
            PC   C12N5/00,C12N15/00
            CC   upstream amplification primer 99-221-PU
            FH   Key             Location/Qualifiers
            FT   primer_bind     1. .19.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              |||||||  ||||  ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 117
BD196765
LOCUS       BD196765                  19 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Prostatic cancer gene.
ACCESSION   BD196765
VERSION     BD196765.1  GI:33006535
KEYWORDS    JP 2002516657-A/354.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Blumenfeld,M., Chumakov,I. and Bougueleret,L.
  TITLE     Prostatic cancer gene
  JOURNAL   Patent: JP 2002516657-A 354 11-JUN-2002;
            GENSET
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002516657-A/354
            PD   11-JUN-2002
            PF   22-DEC-1998 JP 2000525562
            PR   22-DEC-1997 US    08/996306,09-SEP-1998 US    60/099658 PI
            DANIEL COHEN,MARTA BLUMENFELD,ILYA CHUMAKOV,LYDIE BOUGUELERET PC
            C12N15/09,C12N15/09,A01K67/027,C07K14/47,C07K16/18,C12N1/15, PC
            C12N1/19,
            PC   C12N1/21,C12N5/10,C12N5/10,C12P21/08,C12Q1/68,G01N33/50 PC
            ,C12N15/00,C12N5/00,
            PC   C12N5/00,C12N15/00
            CC   upstream amplification primer for SEQ 260, SEQ 337 FH   Key
                     Location/Qualifiers
            FT   primer_bind     1. .19.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              |||||||  ||||  ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 118
AR296121
LOCUS       AR296121                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 7856 from patent US 6537751.
ACCESSION   AR296121
VERSION     AR296121.1  GI:31683405
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 7856 25-MAR-2003;
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unknown"
                      /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              |||||||  ||||  ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 119
AX130773/c
LOCUS       AX130773                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1991 from Patent WO0130362.
ACCESSION   AX130773
VERSION     AX130773.1  GI:14137078
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
```

```
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1991 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin D3 ribozyme binding site"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGTT 1622
              |||| ||||||||| ||
Db         19 GGCCAGGGGGAAGACTT 3


RESULT 120
AX378760
LOCUS       AX378760                  19 bp    DNA     linear   PAT 18-MAR-2002
DEFINITION  Sequence 549 from Patent WO0206525.
ACCESSION   AX378760
VERSION     AX378760.1  GI:19574613
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cohen,D., Blumenfeld,M., Chumakov,I., Abderrahim,H. and Bihain,B.
  TITLE     Obesity associated biallelic marker maps
  JOURNAL   Patent: WO 0206525-A 549 24-JAN-2002;
            GENSET (FR)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
     primer_bind     1. .19
                     /note="upstream amplification primer 99-221 for SEQ 527"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 19;
  Best Local Similarity   88.2%;  Pred. No. 2.3e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              ||||||| |||| ||||
Db          2 CCTTTTTCTTCACTGTT 18


RESULT 121
AR010207/c
LOCUS       AR010207                  20 bp    DNA     linear   PAT 04-DEC-1998
DEFINITION  Sequence 5 from patent US 5756702.
ACCESSION   AR010207
VERSION     AR010207.1  GI:3969012
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Lohman,K.L., Ostrerova,N.V., Van Cleve,M. and Reid,R.Alan.
  TITLE     Detection of nucleic acids in cells by thermophilic strand
            displacement amplification
  JOURNAL   Patent: US 5756702-A 5 26-MAY-1998;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 122
AR126737
LOCUS       AR126737                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 166 from patent US 6180353.
ACCESSION   AR126737
VERSION     AR126737.1  GI:14113330
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dean,N.M. and Cowsert,L.M.
  TITLE     Antisense modulation of daxx expression
  JOURNAL   Patent: US 6180353-A 166 30-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2032 AGGCAAAGGTTCTATCT 2048
              |||||||| ||| ||||
Db          1 AGGCAAAGCTTCCATCT 17


RESULT 123
AR158934
LOCUS       AR158934                  20 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 556 from patent US 6251588.
ACCESSION   AR158934
VERSION     AR158934.1  GI:16221347
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and
            Kincaid,R.H.
  TITLE     Method for evaluating oligonucleotide probe sequences
  JOURNAL   Patent: US 6251588-A 556 26-JUN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          4 TTTTCTTTTTTAACCC 20


RESULT 124
AR158935
LOCUS       AR158935                  20 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 557 from patent US 6251588.
ACCESSION   AR158935
VERSION     AR158935.1  GI:16221349
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and
            Kincaid,R.H.
  TITLE     Method for evaluating oligonucleotide probe sequences
  JOURNAL   Patent: US 6251588-A 557 26-JUN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          3 TTTTTCTTTTTTAACCC 19


RESULT 125
AR158936
LOCUS       AR158936                 20 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 558 from patent US 6251588.
ACCESSION   AR158936
VERSION     AR158936.1  GI:16221351
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and
            Kincaid,R.H.
  TITLE     Method for evaluating oligonucleotide probe sequences
  JOURNAL   Patent: US 6251588-A 558 26-JUN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          2 TTTTTCTTTTTTAACCC 18


RESULT 126
AR158937
LOCUS       AR158937                 20 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 559 from patent US 6251588.
ACCESSION   AR158937
VERSION     AR158937.1  GI:16221353
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and
            Kincaid,R.H.
  TITLE     Method for evaluating oligonucleotide probe sequences
  JOURNAL   Patent: US 6251588-A 559 26-JUN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCC 1787
              ||||| ||||| |||||
Db          1 TTTTTCTTTTTTAACCC 17


RESULT 127
CQ764106
LOCUS       CQ764106                 20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 2724 from Patent WO2004003201.
ACCESSION   CQ764106
VERSION     CQ764106.1  GI:44907342
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 2724 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGTG 1993
              |||  ||||||||||||
Db          1 TGAGCAAAAGAAAAGTG 17


RESULT 128
CQ764152/c
LOCUS       CQ764152                 20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 2770 from Patent WO2004003201.
ACCESSION   CQ764152
VERSION     CQ764152.1  GI:44907388
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 2770 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || |||||||||||| |
Db         20 TATCTTCTTCAGAGAAC 4


RESULT 129
CQ764283/c
LOCUS       CQ764283                 20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 2901 from Patent WO2004003201.
```

```
ACCESSION   CQ764283
VERSION     CQ764283.1  GI:44907519
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 2901 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || |||||||||||| |
Db         19 TATCTTCTTCAGAGAAC 3


RESULT 130
CQ764771/c
LOCUS       CQ764771                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 3389 from Patent WO2004003201.
ACCESSION   CQ764771
VERSION     CQ764771.1  GI:44908007
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 3389 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || |||||||||||| |
Db         18 TATCTTCTTCAGAGAAC 2


RESULT 131
CQ764789/c
LOCUS       CQ764789                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 3407 from Patent WO2004003201.
ACCESSION   CQ764789
VERSION     CQ764789.1  GI:44908025
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 3407 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || |||||||||||| |
Db         17 TATCTTCTTCAGAGAAC 1


RESULT 132
CQ784105/c
LOCUS       CQ784105                  20 bp    DNA     linear   PAT 17-MAR-2004
DEFINITION  Sequence 4245 from Patent EP1396543.
ACCESSION   CQ784105
VERSION     CQ784105.1  GI:45538593
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
            Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
            Koga,H.
  TITLE     Primers for synthesizing full length cDNA clones and their use
  JOURNAL   Patent: EP 1396543-A 4245 10-MAR-2004;
            Research Association for Biotechnology (JP)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: an artificially
                     synthesized primer se q uence"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1647 AGCCTTCACTGGTTCTG 1663
              ||||||| ||| |||||
Db         20 AGCCTTCTCTGTTTCTG 4


RESULT 133
CQ803566/c
LOCUS       CQ803566                  20 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 13 from Patent WO2004035828.
ACCESSION   CQ803566
VERSION     CQ803566.1  GI:47110409
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Pirastu,M., Gianfrancesco,F., Esposito,T. and Ombra,M.N.
  TITLE     Diagnostic and therapeutic means for kidney stone related
            pathologies
  JOURNAL   Patent: WO 2004035828-A 13 29-APR-2004;
            Shardna S.p.A. (IT)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTGAAAG 1808
              ||||||  |||||||||
Db         20 CTTTCCAGCTCTGAAAG 4


RESULT 134
E39195/c
LOCUS       E39195                    20 bp    DNA     linear   PAT 09-JAN-2004
DEFINITION  DNA encoding novel fused protein and process for producing useful
            protein mediating the expression thereof.
ACCESSION   E39195
VERSION     E39195.1  GI:13019269
KEYWORDS    JP 1999341991-A/41.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Seiji,S., Masahiko,H., Toshiyuki,K. and Masaaki,K.
  TITLE     DNA encoding novel fused protein and process for producing useful
            protein mediating the expression thereof
  JOURNAL   Patent: JP 1999341991-A 41 14-DEC-1999;
            ITO HAM KK,JUZO UDAKA
COMMENT     OS   Artificial Sequence
            PN   JP 1999341991-A/41
            PD   14-DEC-1999
            PF   30-MAR-1999 JP 1999089488
            PR
            PI   SEIJI SATO,MASAHIKO HIGASHIKUJI,TOSHIYUKI KUDO,MASAAKI KONDO
            PC   C12N15/09,C12N1/21,C12P21/02,C12P21/02//C07K14/605,C07K14/62,
            PC   C07K14/655,
            PC   C07K19/00,(C12N15/09,C12R1:08),(C12N1/21,C12R1:08),(C12P21/02,
            PC   C12R1:08),
            PC   C12N15/00,(C12N15/00,C12R1:08)
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1934 GTTAAGGTAATGGTTGG 1950
              | |||||  |||||||||
Db         20 GATAAGGGAATGGTTGG 4


RESULT 135
I43323/c
LOCUS       I43323                    20 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 5 from patent US 5631147.
ACCESSION   I43323
VERSION     I43323.1  GI:2468567
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Lohman,K.L., Ostrerova,N.V., Cleve,M.V. and Reid,R.A.
  TITLE     Detection of nucleic acids in cells by thermophilic strand
            displacement amplification
  JOURNAL   Patent: US 5631147-A 5 20-MAY-1997;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||| | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 136
I95826/c
LOCUS       I95826                    20 bp    DNA     linear   PAT 01-DEC-1998
DEFINITION  Sequence 5 from patent US 5733752.
ACCESSION   I95826
VERSION     I95826.1  GI:3940296
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Lohman,K.L., Ostrerova,N.V., Cleve,M.Van. and Reid,R.Alan.
  TITLE     Detection of nucleic acids in cells by thermophilic strand
            displacement amplification
  JOURNAL   Patent: US 5733752-A 5 31-MAR-1998;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||| | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 137
AR274662/c
LOCUS       AR274662                  20 bp    DNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 46 from patent US 6506595.
ACCESSION   AR274662
VERSION     AR274662.1  GI:29707196
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Sato,S., Higashikuni,N., Kudo,T. and Kondo,M.
  TITLE     DNAs encoding new fusion proteins and processes for preparing
            useful polypeptides through expression of the DNAs
  JOURNAL   Patent: US 6506595-A 46 14-JAN-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1934 GTTAAGGTAATGGTTGG 1950
              | |||||  |||||||||
Db         20 GATAAGGGAATGGTTGG 4


RESULT 138
AR312181/c
LOCUS       AR312181                  20 bp    DNA     linear   PAT 12-JUN-2003
```

```
DEFINITION  Sequence 2718 from patent US 6559294.
ACCESSION   AR312181
VERSION     AR312181.1  GI:31705607
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
            Sankaran,B. and Fletcher,L.D.
  TITLE     Chlamydia pneumoniae polynucleotides and uses thereof
  JOURNAL   Patent: US 6559294-A 2718 06-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTG 1606
              |||| ||||||||| ||
Db         17 ACTGCGAACCCCTCTTG 1


RESULT 139
AR344858/c
LOCUS       AR344858                  20 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 47 from patent US 6582920.
ACCESSION   AR344858
VERSION     AR344858.1  GI:33740939
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yang,Y.Y., Brentano,S.T., Babola,O., Tran,N. and Vernet,G.
  TITLE     Amplification of HIV-1 RT sequences for detection of sequences
            associated with drug-resistance mutations
  JOURNAL   Patent: US 6582920-A 47 24-JUN-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||| | ||
Db         20 ATTATCAGAAGGAGCCA 4


RESULT 140
AR438112
LOCUS       AR438112                  20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 5 from patent US 6660906.
ACCESSION   AR438112
VERSION     AR438112.1  GI:40204574
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Tsichlis,P.N.
  TITLE     Tpl2 transgenic knockout mice
  JOURNAL   Patent: US 6660906-A 5 09-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACACTTAG 1871
              ||||||| |||||| ||
Db          4 CAGACCCTCACACTCAG 20


RESULT 141
AX397813/c
LOCUS       AX397813                  20 bp    DNA     linear   PAT 27-MAY-2002
DEFINITION  Sequence 47 from Patent WO0220852.
ACCESSION   AX397813
VERSION     AX397813.1  GI:21260687
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Yang,Y.Y., Brentano,S.T., Babola,O., Tran,N. and Vernet,G.
  TITLE     Amplification of hiv-1 sequences for detection of sequences
            associated with drug-resistance mutations
  JOURNAL   Patent: WO 0220852-A 47 14-MAR-2002;
            Gen-Probe Incorporated Patent Dept (US) ; Biomerieux S.A. (FR)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide primer for Gag target sequence"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||| | ||
Db         20 ATTATCAGAAGGAGCCA 4


RESULT 142
AX452338/c
LOCUS       AX452338                  20 bp    DNA     linear   PAT 06-JUL-2002
DEFINITION  Sequence 24 from Patent WO0242441.
ACCESSION   AX452338
VERSION     AX452338.1  GI:21712249
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Laemmle,B., Gerritsen,H.E., Furlan,M., Turecek,P., Schwarz,H.P.,
            Scheiflinger,F., Antoine,G., Kerschbaumer,R., Tagliavacca,L.,
            Zimmermann,K. and Voelkel,D.
  TITLE     Von willebrand factor (vwf) cleaving protease polypeptide, nucleic
            acid encoding the polypeptide and use of polypeptide
  JOURNAL   Patent: WO 0242441-A 24 30-MAY-2002;
            Baxter Aktiengesellschaft (AT)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
     primer_bind     1. .20

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1591 CTGGGAACCCCTCCTGG 1607
              ||||| |||||||| ||
```

```
Db         17 CTGGGGACCCCTCCAGG 1


RESULT 143
AX613393/c
LOCUS       AX613393                  20 bp    DNA     linear   PAT 17-FEB-2003
DEFINITION  Sequence 4418 from Patent WO02072882.
ACCESSION   AX613393
VERSION     AX613393.1  GI:28408822
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cullen,P. and Seedorf,U.
  TITLE     Coronary chip
  JOURNAL   Patent: WO 02072882-A 4418 19-SEP-2002;
            OGHAM GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAACAG 1560
              ||||||| |||| ||||
Db         17 GAGTAGGTAAGGCACAG 1


RESULT 144
BD000131/c
LOCUS       BD000131                  20 bp    DNA     linear   PAT 31-JAN-2002
DEFINITION  Detection of nucleic acid in cell by thermophilic strand
            substitutive  amplification.
ACCESSION   BD000131
VERSION     BD000131.1  GI:18623210
KEYWORDS    JP 2000300281-A/5.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Romains,K.L., Osutoreroba,N.V., Clive,M.V. and Lead,R.A.
  TITLE     Detection of nucleic acid in cell by thermophilic strand
            substitutive amplification
  JOURNAL   Patent: JP 2000300281-A 5 31-OCT-2000;
            BECTON DICKINSON & CO
COMMENT     OS   Artificial Sequence
            PN   JP 2000300281-A/5
            PD   31-OCT-2000
            PF   03-APR-2000 JP 2000101133
            PR   21-SEP-1995 US    08/531747,21-SEP-1995 US    08/531749 PI
            KENTON L ROMAINS,NATARI V OSUTOREROBA,MARK VAN CLIVE, PI   ROBERT
            ALAN LEAD
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||| | ||
Db         19 ATTATCAGAAGGAGCCA 3


RESULT 145
BD128029/c
LOCUS       BD128029                  20 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Primer for synthesizing full-length cDNA and use thereof.
ACCESSION   BD128029
VERSION     BD128029.1  GI:23222974
KEYWORDS    JP 2002017375-A/3460.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
            Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
            Koga,H.
  TITLE     Primer for synthesizing full-length cDNA and use thereof
  JOURNAL   Patent: JP 2002017375-A 3460 22-JAN-2002;
            HELIX RESEARCH INSTITUTE
COMMENT     OS   Unidentified
            PN   JP 2002017375-A/3460
            PD   22-JAN-2002
            PF   07-JUL-2000 JP 2000253172
            PI   TOSHIO OTA,TETSUO NISHIKAWA,TAKAO ISOGAI,KOJI HAYASHI,SHIZUKO
            PI   ISHII,
            PI   YURI KAWAI,AI WAKAMATSU,TOMOYASU SUGIYAMA,KEIICHI NAGAI, PI
            SHINICHI KOJIMA,
            PI   TETSUJI OTSUKI,HISASHI KOGA
            PC
            C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
             10,
            PC   C12P21/02,C12Q1/68//C12P21/08,G06F17/30,C12N15/00,C12N5/00 CC
             Description of Artificial Sequence: an artificially  CC
            synthesized primer
            CC   sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 20;
  Best Local Similarity   88.2%;  Pred. No. 2.4e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1647 AGCCTTCACTGGTTCTG 1663
              ||||||| ||| |||||
Db         20 AGCCTTCTCTGTTTCTG 4


RESULT 146
AR296500/c
LOCUS       AR296500                  21 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 8235 from patent US 6537751.
ACCESSION   AR296500
VERSION     AR296500.1  GI:31683784
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 8235 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .21
```

```
                /organism="unknown"
                /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2062 TTAATAAGTGGTATCTG 2078
              || |||||| |||||||
Db         19 TTCATAAGTAGTATCTG 3


RESULT 147
AR298436
LOCUS       AR298436                 21 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 10171 from patent US 6537751.
ACCESSION   AR298436
VERSION     AR298436.1  GI:31685720
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 10171 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACC 1583
              ||||| ||| |||||||
Db          1 AAAAAACCTGCTCCACC 17


RESULT 148
AR344822/c
LOCUS       AR344822                 21 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 11 from patent US 6582920.
ACCESSION   AR344822
VERSION     AR344822.1  GI:33740903
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Yang,Y.Y., Brentano,S.T., Babola,O., Tran,N. and Vernet,G.
  TITLE     Amplification of HIV-1 RT sequences for detection of sequences
            associated with drug-resistance mutations
  JOURNAL   Patent: US 6582920-A 11 24-JUN-2003;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 149
AR344857/c
LOCUS       AR344857                 21 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 46 from patent US 6582920.
ACCESSION   AR344857
VERSION     AR344857.1  GI:33740938
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Yang,Y.Y., Brentano,S.T., Babola,O., Tran,N. and Vernet,G.
  TITLE     Amplification of HIV-1 RT sequences for detection of sequences
            associated with drug-resistance mutations
  JOURNAL   Patent: US 6582920-A 46 24-JUN-2003;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              ||||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 150
AR452394
LOCUS       AR452394                 21 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 40 from patent US 6677153.
ACCESSION   AR452394
VERSION     AR452394.1  GI:42684041
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Iversen,P.L.
  TITLE     Antisense antibacterial method and composition
  JOURNAL   Patent: US 6677153-A 40 13-JAN-2004;
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTCCTCT 2025
              |||||| |||| |||||
Db          1 CAGAGAGCAAGCCCTCT 17


RESULT 151
AX201215
LOCUS       AX201215                 21 bp    DNA     linear   PAT 29-AUG-2001
DEFINITION  Sequence 40 from Patent WO0142457.
ACCESSION   AX201215
VERSION     AX201215.1  GI:15390967
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Iversen,P.L.
  TITLE     Antisense antibacterial method and composition
  JOURNAL   Patent: WO 0142457-A 40 14-JUN-2001;
            Avi Biopharma, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
```

```
                     /db_xref="taxon:32630"
                     /note="antisense oligomer"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2009 CAGAGATCAAGTCCTCT 2025
              ||||||  ||||  |||||
Db          1 CAGAGAGCAAGCCCTCT 17


RESULT 152
AX397777/c
LOCUS       AX397777                 21 bp    DNA     linear   PAT 27-MAY-2002
DEFINITION  Sequence 11 from Patent WO0220852.
ACCESSION   AX397777
VERSION     AX397777.1  GI:21260651
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Yang,Y.Y., Brentano,S.T., Babola,O., Tran,N. and Vernet,G.
  TITLE     Amplification of hiv-1 sequences for detection of sequences
            associated with drug-resistance mutations
  JOURNAL   Patent: WO 0220852-A 11 14-MAR-2002;
            Gen-Probe Incorporated Patent Dept (US) ; Biomerieux S.A. (FR)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide primer for Gag target sequence"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 153
AX397812/c
LOCUS       AX397812                 21 bp    DNA     linear   PAT 27-MAY-2002
DEFINITION  Sequence 46 from Patent WO0220852.
ACCESSION   AX397812
VERSION     AX397812.1  GI:21260686
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Yang,Y.Y., Brentano,S.T., Babola,O., Tran,N. and Vernet,G.
  TITLE     Amplification of hiv-1 sequences for detection of sequences
            associated with drug-resistance mutations
  JOURNAL   Patent: WO 0220852-A 46 14-MAR-2002;
            Gen-Probe Incorporated Patent Dept (US) ; Biomerieux S.A. (FR)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide primer for Gag target sequence"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              |||||||||||| | ||
Db         18 ATTATCAGAAGGAGCCA 2


RESULT 154
AX555818/c
LOCUS       AX555818                 21 bp    DNA     linear   PAT 27-NOV-2002
DEFINITION  Sequence 414 from Patent WO02070755.
ACCESSION   AX555818
VERSION     AX555818.1  GI:25899292
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lyamichev,V.I., Kaiser,M.W. and Lyamicheva,N.
  TITLE     Fen endonucleases
  JOURNAL   Patent: WO 02070755-A 414 12-SEP-2002;
            Third Wave Technologies, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTGAA 1784
              ||||  |||  ||||||||
Db         20 AGCTCTTTCTTTTTGAA 4


RESULT 155
BD056555/c
LOCUS       BD056555                 21 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method to diagnose and treat pathological conditions resulting from
            deficient ion transport.
ACCESSION   BD056555
VERSION     BD056555.1  GI:22602161
KEYWORDS    JP 2001508291-A/12.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 21)
  AUTHORS   Lifton,R.P. and Simon,D.B.
  TITLE     Method to diagnose and treat pathological conditions resulting from
            deficient ion transport
  JOURNAL   Patent: JP 2001508291-A 12 26-JUN-2001;
            YALE UNIVERSITY
COMMENT     OS   Artificial Sequence
            PN   JP 2001508291-A/12
            PD   26-JUN-2001
            PF   19-DEC-1997 JP 1998530123
            PR   31-DEC-1996 US    08/778052
            PI   RICHARD P LIFTON,DAVID B SIMON
            PC   C12N15/09,C07K14/435,C07K16/00,C12N1/15,C12N1/19,C12N1/21, PC
             C12N5/10,
            PC   C12P21/02,C12Q1/68,G01N33/53,C12N15/00,C12N5/00 CC   Primer
            for analysis of human TSC gene
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .21
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.5%;  Score 13.8;  DB 1;  Length 21;
  Best Local Similarity   88.2%;  Pred. No. 2.6e+02;
  Matches   15;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1781 TGAACCCCATTCTTTCC 1797
              ||||  |||||||||  ||
```

```
Db         20 TGAATCCCATTCTTCCC 4


RESULT 156
AR103803/c
LOCUS       AR103803                  20 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 327 from patent US 6087485.
ACCESSION   AR103803
VERSION     AR103803.1  GI:12815391
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Brooks-Wilson,A.R., Buckler,A., Cardon,L., Carey,A.H., Galvin,M.,
            Miller,A. and North,M.
  TITLE     Asthma related genes
  JOURNAL   Patent: US 6087485-A 327 11-JUL-2000;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1619 AGTTTGTTACCTACCTTACT 1638
              |||| |||||||||  | ||
Db         20 AGTTAGTTACCTACTGTGCT 1


RESULT 157
AR121022
LOCUS       AR121022                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 43 from patent US 6159694.
ACCESSION   AR121022
VERSION     AR121022.1  GI:14104598
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Karras,J.G.
  TITLE     Antisense modulation of stat3 expression
  JOURNAL   Patent: US 6159694-A 43 12-DEC-2000;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGGCTCTTTA 1760
              ||||||| | ||| ||| ||
Db          1 TGACAAGGAGTGGGTCTCTA 20


RESULT 158
AR126680/c
LOCUS       AR126680                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 109 from patent US 6180353.
ACCESSION   AR126680
VERSION     AR126680.1  GI:14113273
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dean,N.M. and Cowsert,L.M.
  TITLE     Antisense modulation of daxx expression
  JOURNAL   Patent: US 6180353-A 109 30-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1992 TGTGTATCTAGCTTCTTCAG 2011
              ||||| ||| |+| ||| |||
Db         20 TGTGTTTCTGGCCTCTGCAG 1


RESULT 159
AR158732/c
LOCUS       AR158732                  20 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 354 from patent US 6251588.
ACCESSION   AR158732
VERSION     AR158732.1  GI:16220947
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and
            Kincaid,R.H.
  TITLE     Method for evaluating oligonucleotide probe sequences
  JOURNAL   Patent: US 6251588-A 354 26-JUN-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1818 AAGTTTTAGAATCTTTTAAA 1837
              || | |||||  ||||||||
Db         20 AAATCTTAGAGCCTTTTAAA 1


RESULT 160
AR173039
LOCUS       AR173039                  20 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 164 from patent US 6303374.
ACCESSION   AR173039
VERSION     AR173039.1  GI:17912530
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Zhang,H. and Cowsert,L.M.
  TITLE     Antisense modulation of caspase 3 expression
  JOURNAL   Patent: US 6303374-A 164 16-OCT-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1742 GACAAGTACTGGCTCTTTAT 1761
              ||||  |||| |||| ||||
Db          1 GACAGTTACTTGCTCCTTAT 20


RESULT 161
```

```
BD272643
LOCUS       BD272643                  20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Antisense oligonucleotide modulation of STAT3 expression.
ACCESSION   BD272643
VERSION     BD272643.1  GI:33082411
KEYWORDS    JP 2002541784-A/43.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Karras,J.G.
  TITLE     Antisense oligonucleotide modulation of STAT3 expression
  JOURNAL   Patent: JP 2002541784-A 43 10-DEC-2002;
            ISIS PHARMACEUTICALS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002541784-A/43
            PD   10-DEC-2002
            PF   06-APR-2000 JP 2000611544
            PR   08-APR-1999 US    09/288461
            PI   JAMES G KARRAS
            PC   C12N15/09,A61K31/711,A61K48/00,A61P29/00,A61P29/00,A61P35/00,
            PC   A61P37/02,
            PC   A61P43/00,C12N5/06,C12Q1/02,C12N15/00,C12N5/00 CC   Antisense
            oligonucleotide
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGGCTCTTTA 1760
              ||||||| | ||| ||| ||
Db          1 TGACAAGGAGTGGGTCTCTA 20


RESULT 162
E29952
LOCUS       E29952                    20 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  HIV cofactor inhibitor.
ACCESSION   E29952
VERSION     E29952.1  GI:13021347
KEYWORDS    JP 1999292795-A/106.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Hiroshi,T., Naoki,Y., Toru,K., Kazuyuki,T. and Akira,W.
  TITLE     HIV cofactor inhibitor
  JOURNAL   Patent: JP 1999292795-A 106 26-OCT-1999;
            YAMANOUCHI PHARMACEUT CO LTD
COMMENT     OS   Unidentified
            PN   JP 1999292795-A/106
            PD   26-OCT-1999
            PF   02-APR-1998 JP 1998125452
            PR
            PI   HIROSHI TAKAHISA,NAOKI YAMAMOTO,TORU KIMURA,KAZUYUKI TAKAI, PI
              AKIRA WADA
            PC   A61K48/00,A61K31/70,A61K31/70,C12N15/09,C12N15/00 CC
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              || | |||||||||| || |
Db          1 TTGTCTGAACCCCATCCTCT 20


RESULT 163
AR203118
LOCUS       AR203118                  20 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 37 from patent US 6365354.
ACCESSION   AR203118
VERSION     AR203118.1  GI:21499424
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.Frank. and Wyatt,J.
  TITLE     Antisense modulation of lysophospholipase I expression
  JOURNAL   Patent: US 6365354-A 37 02-APR-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1782 GAACCCCATTCTTTCCTTCT 1801
              |||  ||||||||  |||||
Db          1 GAATGCCATTCTTCACTTCT 20


RESULT 164
AR220184
LOCUS       AR220184                  20 bp    DNA     linear   PAT 26-SEP-2002
DEFINITION  Sequence 49 from patent US 6423543.
ACCESSION   AR220184
VERSION     AR220184.1  GI:23324627
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Marcotte,P.A. and Cowsert,L.M.
  TITLE     Antisense modulation of hepsin expression
  JOURNAL   Patent: US 6423543-A 49 23-JUL-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1627 ACCTACCTTACTATTTAAAG 1646
              |||  | ||| |||||||||
Db          1 ACCATCTTTATTATTTAAAG 20


RESULT 165
AR222265
LOCUS       AR222265                  20 bp    DNA     linear   PAT 26-SEP-2002
DEFINITION  Sequence 99 from patent US 6429199.
ACCESSION   AR222265
VERSION     AR222265.1  GI:23329730
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Krieg,A.M. and Hartmann,G.
  TITLE     Immunostimulatory nucleic acid molecules for activating dendritic
            cells
  JOURNAL   Patent: US 6429199-A 99 06-AUG-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 166
AR294017
LOCUS       AR294017                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5752 from patent US 6537751.
ACCESSION   AR294017
VERSION     AR294017.1  GI:31681301
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 5752 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1535 AGGTTAGGAGAGTAGGGAAG 1554
              || | ||||| | |||||||
Db          1 AGATGAGGAGTGGAGGGAAG 20


RESULT 167
AR300314/c
LOCUS       AR300314                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 116 from patent US 6537775.
ACCESSION   AR300314
VERSION     AR300314.1  GI:31687733
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Tournier-Lasserve,E., Joutel,A., Bousser,M.-G. and Bach,J.-F.
  TITLE     Gene involved in cadasil, method of diagnosis and therapeutic
            application
  JOURNAL   Patent: US 6537775-A 116 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGAACA 1559
              |||||||| |   |||||||
Db         20 AGGAGAGTGGCACAGGAACA 1


RESULT 168
AR373514/c
LOCUS       AR373514                  20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 84 from patent US 6602713.
ACCESSION   AR373514
VERSION     AR373514.1  GI:40075643
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Wyatt,J.
  TITLE     Antisense modulation of protein phosphatase 2 catalytic subunit
            beta expression
  JOURNAL   Patent: US 6602713-A 84 05-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTTGAA 1784
              |||  |||| |||| |||||
Db         20 TTATCCTTTATTTTATTGAA 1


RESULT 169
AR373791/c
LOCUS       AR373791                  20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 183 from patent US 6602857.
ACCESSION   AR373791
VERSION     AR373791.1  GI:40076202
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Cowsert,L.M., Wyatt,J., Monia,B.P., Butler,M.M. and McKay,R.
  TITLE     Antisense modulation of PTP1B expression
  JOURNAL   Patent: US 6602857-A 183 05-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
              ||||| | ||| |||||| |
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 170
AX066409
LOCUS       AX066409                  20 bp    DNA     linear   PAT 24-JAN-2001
DEFINITION  Sequence 9 from Patent WO0100823.
ACCESSION   AX066409
VERSION     AX066409.1  GI:12544117
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
```

```
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gannon,F., Denger,S. and Flouriot,G.
  TITLE     Novel isoforms of the human estrogen receptor-_g(a)
  JOURNAL   Patent: WO 0100823-A 9 04-JAN-2001;
            EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1666 TCACCCGCCCCTGGACTTCT 1685
              || | || |||| |||||||
Db          1 TCTCTCGGCCCTTGACTTCT 20


RESULT 171
AX104161/c
LOCUS       AX104161                  20 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 353 from Patent WO0122972.
ACCESSION   AX104161
VERSION     AX104161.1  GI:13920358
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 353 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              ||| |  ||||||||| |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 172
AX104333/c
LOCUS       AX104333                  20 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 525 from Patent WO0122972.
ACCESSION   AX104333
VERSION     AX104333.1  GI:13920530
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 525 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 173
AX104584
LOCUS       AX104584                  20 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 776 from Patent WO0122972.
ACCESSION   AX104584
VERSION     AX104584.1  GI:13920781
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 776 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 174
AX104663/c
LOCUS       AX104663                  20 bp    DNA     linear   PAT 30-APR-2001
DEFINITION  Sequence 855 from Patent WO0122972.
ACCESSION   AX104663
VERSION     AX104663.1  GI:13920860
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Krieg,A.M., Schetter,C. and Vollmer,J.C.
  TITLE     Immunostimulatory nucleic acids
  JOURNAL   Patent: WO 0122972-A 855 05-APR-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
            GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1
```

```
RESULT 175
AX149016
LOCUS       AX149016                  20 bp    DNA     linear   PAT 08-JUN-2001
DEFINITION  Sequence 218 from Patent WO0136625.
ACCESSION   AX149016
VERSION     AX149016.1  GI:14347540
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wright,J.A., Young,A.H. and Dugourd,D.
  TITLE     Antisense oligonucleotide sequences derived from groel and groes as
            inhibitors of microorganisms
  JOURNAL   Patent: WO 0136625-A 218 25-MAY-2001;
            GeneSense Technologies Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense oligonucleotide"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTTTCAG 1932
              ||||||||||| ||   |||
Db          1 AACAATACCTTCTTCAACAG 20


RESULT 176
AX294124/c
LOCUS       AX294124                  20 bp    DNA     linear   PAT 21-NOV-2001
DEFINITION  Sequence 5886 from Patent WO0179548.
ACCESSION   AX294124
VERSION     AX294124.1  GI:17055807
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Barany,F., Zirvi,M., Gerry,N.P., Favis,R. and Kliman,R.
  TITLE     Method of designing addressable array for detection of nucleic acid
            sequence differences using ligase detection reaction
  JOURNAL   Patent: WO 0179548-A 5886 25-OCT-2001;
            CORNELL RESEARCH FOUNDATION, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Hypothetical Probe Sequence"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1593 GGGAACCCCTCCTGGCCTGG 1612
              |||||| | |||| || |||
Db         20 GGGAACTCGTCCTTGCATGG 1


RESULT 177
AX298787
LOCUS       AX298787                  20 bp    DNA     linear   PAT 26-NOV-2001
DEFINITION  Sequence 421 from Patent WO0183749.
ACCESSION   AX298787
VERSION     AX298787.1  GI:17128777
KEYWORDS    .
SOURCE      Mus sp.
  ORGANISM  Mus sp.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,
            Li,X., Ohmen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
  TITLE     Gene and sequence variation associated with sensing carbohydrate
            compounds and other sweeteners
  JOURNAL   Patent: WO 0183749-A 421 08-NOV-2001;
            WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
            (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus sp."
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10095"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCTTCTCCA 1581
              |||||||| |||  |||||
Db          1 ACTGCAAATGTCCAACTCCA 20


RESULT 178
AX354976/c
LOCUS       AX354976                  20 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 4 from Patent WO0197843.
ACCESSION   AX354976
VERSION     AX354976.1  GI:18619643
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Weiner,G. and Hartmann,G.
  TITLE     Methods for enhancing antibody-induced cell lysis and treating
            cancer
  JOURNAL   Patent: WO 0197843-A 4 27-DEC-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide-Chimeric
                     phosphorothioate/phosphodiester backbone with
                     phosphorothioate at 5' and 3' ends"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 179
AX354977/c
LOCUS       AX354977                  20 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 5 from Patent WO0197843.
ACCESSION   AX354977
VERSION     AX354977.1  GI:18619644
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Weiner,G. and Hartmann,G.
  TITLE     Methods for enhancing antibody-induced cell lysis and treating
            cancer
```

```
  JOURNAL   Patent: WO 0197843-A 5 27-DEC-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide~phosphorodithioate
                     backbone"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 180
AX354981
LOCUS       AX354981                  20 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 9 from Patent WO0197843.
ACCESSION   AX354981
VERSION     AX354981.1  GI:18619648
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Weiner,G. and Hartmann,G.
  TITLE     Methods for enhancing antibody-induced cell lysis and treating
            cancer
  JOURNAL   Patent: WO 0197843-A 9 27-DEC-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide~chimeric
                     phosphorothioate/phosphodiester backbone with
                     phosphorothioate at 5' and 3' ends"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              ||  ||  ||  ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 181
AX355514/c
LOCUS       AX355514                  20 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 542 from Patent WO0197843.
ACCESSION   AX355514
VERSION     AX355514.1  GI:18620182
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Weiner,G. and Hartmann,G.
  TITLE     Methods for enhancing antibody-induced cell lysis and treating
            cancer
  JOURNAL   Patent: WO 0197843-A 542 27-DEC-2001;
            UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide~phosphodiester backbone"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              |||  |  |||||||||  |||
Db         20 AGACTGAGGAAGGAACTGGA 1


RESULT 182
AX418788/c
LOCUS       AX418788                  20 bp    DNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 183 from Patent WO0210378.
ACCESSION   AX418788
VERSION     AX418788.1  GI:21523651
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Cowsert,L.M., Wyatt,J., Freier,S.M., Monia,B.P., Butler,M.M. and
            Mckay,R.
  TITLE     Antisense modulation of ptp1b expression
  JOURNAL   Patent: WO 0210378-A 183 07-FEB-2002;
            ISIS PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense Oligonucleotide"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCCTGGCC 1609
              |||||  | |||  ||||||  |
Db         20 ACTGGAAGCCCTTCCTGGTC 1


RESULT 183
AX547214/c
LOCUS       AX547214                  20 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 353 from Patent WO02053141.
ACCESSION   AX547214
VERSION     AX547214.1  GI:25812358
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 353 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAACAGGA 1562
              |||  |  |||||||||  |||
Db         20 AGACTGAGGAAGGAACTGGA 1
```

```
RESULT 184
AX547386/c
LOCUS       AX547386                  20 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 525 from Patent WO02053141.
ACCESSION   AX547386
VERSION     AX547386.1  GI:25812530
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 525 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 185
AX547637
LOCUS       AX547637                  20 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 776 from Patent WO02053141.
ACCESSION   AX547637
VERSION     AX547637.1  GI:25812781
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 776 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAAAA 1985
              || ||  || ||||||||||
Db          1 AAAATCAACGTTGAAAAAAA 20


RESULT 186
AX547716/c
LOCUS       AX547716                  20 bp    DNA     linear   PAT 01-MAR-2003
DEFINITION  Sequence 855 from Patent WO02053141.
ACCESSION   AX547716
VERSION     AX547716.1  GI:25812860
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Bratzler,R.L.
  TITLE     Inhibition of angiogenesis by nucleic acids
  JOURNAL   Patent: WO 02053141-A 855 11-JUL-2002;
            Coley Pharmaceutical Group, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic Sequence"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCTTT 1795
              ||||||||||  |||  |||
Db         20 TTTTTTGAACGTCATGTTTT 1


RESULT 187
AX590963
LOCUS       AX590963                  20 bp    DNA     linear   PAT 27-JAN-2003
DEFINITION  Sequence 403 from Patent WO02086113.
ACCESSION   AX590963
VERSION     AX590963.1  GI:27949513
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Cookson,W.O., Moffat,M.F., Allen,M. and Lench,N.
  TITLE     Enzyme and snp marker for disease
  JOURNAL   Patent: WO 02086113-A 403 31-OCT-2002;
            Isis Innovation Limited (GB)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1630 TACCTTACTATTTAAAGAGC 1649
              ||  ||| |||||||||| |
Db          1 TAAATTAGTATTTAAAGACC 20


RESULT 188
BD130033/c
LOCUS       BD130033                  20 bp    DNA     linear   PAT 18-SEP-2002
DEFINITION  Asthma-associated gene.
ACCESSION   BD130033
VERSION     BD130033.1  GI:23224978
KEYWORDS    JP 2002500895-A/323.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Wilson,A.R.B., Buckler,A., Cardon,L., Carey,A.H., Galvin,M.,
            Miller,A. and North,M.
  TITLE     Asthma-associated gene
  JOURNAL   Patent: JP 2002500895-A 323 15-JAN-2002;
            AXYS PHARMACEUTICALS INC
COMMENT     OS   Unidentified
            PN   JP 2002500895-A/323
            PD   15-JAN-2002
            PF   21-JAN-1998 JP 2000528715
```

```
            PI   ANGELA R BROOKS WILSON,ALAN BUCKLER,LON
            CARDON,ALISOUN H CAREY,
            PI   MARGARET GALVIN,ANDREW MILLER,MICHAEL NORTH
            PC   C12Q1/68,A01K67/027,C07K14/47,C12N15/09,C12N15/00 CC
            Strandedness: Single;
            CC   Topology: Linear;
            CC   Asthma-associated gene
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1619 AGTTTGTTACCTACCTTACT 1638
              |||| |||||||||  | ||
Db         20 AGTTAGTTACCTACTGTGCT 1


RESULT 189
HSTNRAS14/c
LOCUS       HSTNRAS14                 20 bp    DNA     linear   PRI 05-JUN-1997
DEFINITION  Homo sapiens TN-R gene acceptor splice site intron 14.
ACCESSION   Y13522 Y07980
VERSION     Y13522.1  GI:2181887
KEYWORDS    tenascin-R.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Leprini,A., Gherzi,R., Siri,A., Querze,G., Viti,F. and Zardi,L.
  TITLE     The human tenascin-R gene
  JOURNAL   J. Biol. Chem. 271 (49), 31251-31254 (1996)
  MEDLINE   97094894
   PUBMED   8940128
REFERENCE   2  (bases 1 to 20)
  AUTHORS   Zardi,L.
  TITLE     Direct Submission
  JOURNAL   Submitted (11-SEP-1996) L. Zardi, Istituto Nazionale per la Ricerca
            sul Cancro, Laboratory of Cell Biology, Largo R.Benzi, 10, 16132
            Genova, ITALY
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
                     /dev_stage="adult"
     intron          <1. .9
                     /number=14
     gene            10. .20
                     /gene="tenascin-R"
     exon            10. .>20
                     /gene="tenascin-R"
                     /number=15

  Query Match             2.4%;  Score 13.6;  DB 1;  Length 20;
  Best Local Similarity   80.0%;  Pred. No. 2.7e+02;
  Matches   16;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1552 AAGGAACAGGACTGCAAAAA 1571
              | ||  |||||||||||| |
Db         20 AGGGTCCAGGACTGCAAAGA 1


RESULT 190
BD233092/c
LOCUS       BD233092                  16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Method of detecting mutation selected by drug in HIV protease gene.
ACCESSION   BD233092
VERSION     BD233092.1  GI:33042862
KEYWORDS    JP 2002518065-A/188.
SOURCE      Aids-associated retrovirus
  ORGANISM  Aids-associated retrovirus
            Viruses; Retroid viruses; Retroviridae.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Stuyver,L.
  TITLE     Method of detecting mutation selected by drug in HIV protease gene
  JOURNAL   Patent: JP 2002518065-A 188 25-JUN-2002;
            INNOGENETICS NV
COMMENT     OS   Aids-associated retrovirus
            PN   JP 2002518065-A/188
            PD   25-JUN-2002
            PF   22-JUN-1999 JP 2000556068
            PR   24-JUN-1998 EP   98870143.9
            PI   LIEVEN STUYVER
            PC   C12N15/09,C12Q1/68,C12Q1/70,C12N15/00
            CC   Method of detecting mutation selected by drug in HIV protease
            CC           gene
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Aids-associated retrovirus'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Aids-associated retrovirus"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:11966"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAA 1984
              |||||||||| ||||
Db         16 TTTACCTTGATAAAA 2


RESULT 191
AR328462/c
LOCUS       AR328462                  16 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 5864 from patent US 6566127.
ACCESSION   AR328462
VERSION     AR328462.1  GI:33714270
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 5864 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              |||||||||| ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 192
AX007646/c
LOCUS       AX007646                  16 bp    DNA     linear   PAT 06-SEP-2000
DEFINITION  Sequence 188 from Patent WO9967428.
```

```
ACCESSION   AX007646
VERSION     AX007646.1  GI:9995343
KEYWORDS    .
SOURCE      Aids-associated retrovirus
  ORGANISM  Aids-associated retrovirus
            Viruses; Retroid viruses; Retroviridae.
REFERENCE   1
  AUTHORS   Stuyver,L.
  TITLE     Method for detection of drug-selected mutations in the hiv protease
            gene
  JOURNAL   Patent: WO 9967428-A 188 29-DEC-1999;
            INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Aids-associated retrovirus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:11966"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 16;
  Best Local Similarity   93.3%;  Pred. No. 2.3e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAA 1984
              ||||||||||| ||||
Db         16 TTTACCTTGATAAAA 2


RESULT 193
AR088824/c
LOCUS       AR088824                 17 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 5 from patent US 5990294.
ACCESSION   AR088824
VERSION     AR088824.1  GI:10015587
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Murphy,G.P., Boynton,A.L. and Sehgal,A.
  TITLE     Nucleotide and amino acid sequences of C4-2, a tumor suppressor
            gene, and methods of use thereof
  JOURNAL   Patent: US 5990294-A 5 23-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1891 ATGTGCCCTAGATCA 1905
              ||||||| |||||||
Db         16 ATGTGCCTTAGATCA 2


RESULT 194
BD201172
LOCUS       BD201172                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD201172
VERSION     BD201172.1  GI:33010942
KEYWORDS    JP 2002509721-A/4198.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 4198 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/4198
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAA 1985
              | ||||||||||||||
Db         3 TAACCTTGAAAAAAA 17


RESULT 195
BD258507
LOCUS       BD258507                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258507
VERSION     BD258507.1  GI:33068277
KEYWORDS    JP 2002541795-A/6300.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6300 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6300
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"
```

```
  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              ||||||||||| ||||
Db          3 AAGCTTTTTTATTTT 17


RESULT 196
BD258508
LOCUS       BD258508                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258508
VERSION     BD258508.1  GI:33068278
KEYWORDS    JP 2002541795-A/6301.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6301 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6301
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              ||||||||||| ||||
Db          2 AAGCTTTTTTATTTT 16


RESULT 197
BD258509
LOCUS       BD258509                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258509
VERSION     BD258509.1  GI:33068279
KEYWORDS    JP 2002541795-A/6302.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6302 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6302
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              ||||||||||| ||||
Db          1 AAGCTTTTTTATTTT 15


RESULT 198
AR186544/c
LOCUS       AR186544                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2032 from patent US 6346398.
ACCESSION   AR186544
VERSION     AR186544.1  GI:20232509
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2032 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||| ||||
Db         17 GACTGCAAAAGTCCT 3


RESULT 199
AR186545/c
LOCUS       AR186545                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2033 from patent US 6346398.
ACCESSION   AR186545
VERSION     AR186545.1  GI:20232510
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
```

```
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2033 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||| ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 200
AR186546/c
LOCUS       AR186546                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2034 from patent US 6346398.
ACCESSION   AR186546
VERSION     AR186546.1  GI:20232511
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2034 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||| ||||
Db         15 GACTGCAAAAGTCCT 1


RESULT 201
AR323175/c
LOCUS       AR323175                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 577 from patent US 6566127.
ACCESSION   AR323175
VERSION     AR323175.1  GI:33708983
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 577 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||| ||||
Db         17 GACTGCAAAAGTCCT 3


RESULT 202
AR323176/c
LOCUS       AR323176                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 578 from patent US 6566127.
ACCESSION   AR323176
VERSION     AR323176.1  GI:33708984
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 578 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||| ||||
Db         16 GACTGCAAAAGTCCT 2


RESULT 203
AR323177/c
LOCUS       AR323177                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 579 from patent US 6566127.
ACCESSION   AR323177
VERSION     AR323177.1  GI:33708985
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 579 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1561 GACTGCAAAAATCCT 1575
              ||||||||||| ||||
Db         15 GACTGCAAAAGTCCT 1


RESULT 204
AX099948
LOCUS       AX099948                  17 bp    DNA     linear   PAT 02-APR-2001
DEFINITION  Sequence 8 from Patent WO0120034.
ACCESSION   AX099948
VERSION     AX099948.1  GI:13538958
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Voss,J. and Timm,J.
```

```
  TITLE     Methods and compositions for the screening of cell cycle modulators
  JOURNAL   Patent: WO 0120034-A 8 22-MAR-2001;
            BASF AKTIENGESELLSCHAFT (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1984 AAGAAAAGTGTGTAT 1998
              ||||||||| |||||
Db          1 AAGAAAAGTATGTAT 15


RESULT 205
AX214956
LOCUS       AX214956                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 398 from Patent WO0159103.
ACCESSION   AX214956
VERSION     AX214956.1  GI:15524999
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 398 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAA 1836
              ||| ||||||||||||
Db          1 TTTGGAATCTTTTAA 15


RESULT 206
AX216792
LOCUS       AX216792                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2234 from Patent WO0159103.
ACCESSION   AX216792
VERSION     AX216792.1  GI:15526853
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2234 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1822 TTTAGAATCTTTTAA 1836
              ||| ||||||||||||
Db          3 TTTGGAATCTTTTAA 17


RESULT 207
AX227073/c
LOCUS       AX227073                 17 bp    RNA     linear   PAT 10-SEP-2001
DEFINITION  Sequence 445 from Patent WO0157206.
ACCESSION   AX227073
VERSION     AX227073.1  GI:15556214
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Fattaey,A.R., Jarvis,T., Mcswiggen,J., Booher,R.N. and Holman,P.S.
  TITLE     Method and reagent for the inhibition of checkpoint kinase-1 (chk
            1) enzyme
  JOURNAL   Patent: WO 0157206-A 445 09-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         17 ACTGGTTCTGCATGA 3


RESULT 208
AX227726/c
LOCUS       AX227726                 17 bp    RNA     linear   PAT 10-SEP-2001
DEFINITION  Sequence 1098 from Patent WO0157206.
ACCESSION   AX227726
VERSION     AX227726.1  GI:15556867
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Fattaey,A.R., Jarvis,T., Mcswiggen,J., Booher,R.N. and Holman,P.S.
  TITLE     Method and reagent for the inhibition of checkpoint kinase-1 (chk
            1) enzyme
  JOURNAL   Patent: WO 0157206-A 1098 09-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||||||||| |
Db         16 ACTGGTTCTGCATGA 2
```

```
RESULT 209
AX732099/c
LOCUS       AX732099                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3733 from Patent WO03025175.
ACCESSION   AX732099
VERSION     AX732099.1  GI:30511442
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 3733 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              ||||||||||| |||
Db         17 TCTTTCCTTCTTTGA 3


RESULT 210
AX737962/c
LOCUS       AX737962                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3552 from Patent WO03025177.
ACCESSION   AX737962
VERSION     AX737962.1  GI:30517250
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 3552 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              ||||||||||| |||
Db         17 TCTTTCCTTCTTTGA 3


RESULT 211
AX759009/c
LOCUS       AX759009                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 2330 from Patent WO03040369.
ACCESSION   AX759009
VERSION     AX759009.1  GI:32253625
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 2330 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              ||||||||||| |||
Db         17 TCTTTCCTTCTTTGA 3


RESULT 212
BD015290/c
LOCUS       BD015290                  17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method for promoting cell growth.
ACCESSION   BD015290
VERSION     BD015290.1  GI:22556428
KEYWORDS    JP 2001204471-A/3.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Hiramine,Y. and Murakami,Y.
  TITLE     Method for promoting cell growth
  JOURNAL   Patent: JP 2001204471-A 3 31-JUL-2001;
            SUMITOMO CHEMICAL CO LTD
COMMENT     OS   Artificial Sequence
            PN   JP 2001204471-A/3
            PD   31-JUL-2001
            PF   20-JAN-2000 JP 2000011458
            PI   YASUSHI HIRAMINE,YUKO MURAKAMI
            PC   C12N15/09,C07K14/475,C12N5/10,C12P21/02//(C12P21/02,C12R1:91),
            PC   C12N15/00,
            PC   C12N5/00
            CC   Designated oligonucleotide primer to amplify gene FH   Key
                 Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 17;
  Best Local Similarity   93.3%;  Pred. No. 2.5e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGGG 1615
              ||||||| ||||||
Db         16 CTCCTGGCTTGGGGG 2


RESULT 213
AR087086/c
LOCUS       AR087086                  18 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 36 from patent US 5985664.
ACCESSION   AR087086
VERSION     AR087086.1  GI:10013852
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Baker,B.F. and Cowsert,L.M.
  TITLE     Antisense modulation of Sentrin expression
  JOURNAL   Patent: US 5985664-A 36 16-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1753 GCTCTTTATTCATTA 1767
                ||||| ||||||||||
Db         16 GCTCATTATTCATTA 2


RESULT 214
AR181458/c
LOCUS       AR181458                 18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 16 from patent US 6335184.
ACCESSION   AR181458
VERSION     AR181458.1  GI:20223672
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Reyes,A.Arevalo., Wallace,R.Bruce. and Ugozzoli,L.A.
  TITLE     Linked linear amplification of nucleic acids
  JOURNAL   Patent: US 6335184-A 16 01-JAN-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
                ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 215
AR181460/c
LOCUS       AR181460                 18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 18 from patent US 6335184.
ACCESSION   AR181460
VERSION     AR181460.1  GI:20223674
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Reyes,A.Arevalo., Wallace,R.Bruce. and Ugozzoli,L.A.
  TITLE     Linked linear amplification of nucleic acids
  JOURNAL   Patent: US 6335184-A 18 01-JAN-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1936 TAAGGTAATGGTTGG 1950
                ||||| |||||||||
Db         18 TAAGGGAATGGTTGG 4


RESULT 216
AR295535
LOCUS       AR295535                 18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 7270 from patent US 6537751.
ACCESSION   AR295535
VERSION     AR295535.1  GI:31682819
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 7270 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1907 CAGATCAACAATACC 1921
                ||| ||||||||||||
Db          3 CAGCTCAACAATACC 17


RESULT 217
AX268173/c
LOCUS       AX268173                 18 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 59 from Patent WO0168851.
ACCESSION   AX268173
VERSION     AX268173.1  GI:16516641
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Padigaru,M., Vernet,C.A., Fernandes,E., Shimkets,R.A.,
            Spaderna,S.K., Majumder,K. and Li,L.
  TITLE     Polypeptides and nucleic acids encoding same
  JOURNAL   Patent: WO 0168851-A 59 20-SEP-2001;
            Curagen Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide primer"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGA 1616
                ||||||||||| ||||
Db         17 TCCTGGCCTGTGGGA 3


RESULT 218
AX837788
LOCUS       AX837788                 18 bp    DNA     linear   PAT 15-DEC-2003
DEFINITION  Sequence 4912 from Patent EP1347046.
ACCESSION   AX837788
VERSION     AX837788.1  GI:39921480
KEYWORDS    .
SOURCE      unidentified
```

```
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Isogai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S.,
            Yamamoto,J.I., Isono,Y., Hio,Y., Otsuka,K., Nagai,K., Irie,R.,
            Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahari,K. and
            Masuho,Y.
  TITLE     Full-length cDNA sequences
  JOURNAL   Patent: EP 1347046-A 4912 24-SEP-2003;
            Research Association for Biotechnology (JP)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="Description of Artificial Sequence: an artificially
                     synthesized primer se q"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 18;
  Best Local Similarity   93.3%;  Pred. No. 2.6e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1944 TGGTTGGTTTTTGTG 1958
              ||||||| |||||||
Db          3 TGGTTGGATTTTGTG 17


RESULT 219
BD000756/c
LOCUS       BD000756                  19 bp    DNA     linear   PAT 31-JAN-2002
DEFINITION  Chimera gene and chimera protein of p53 family.
ACCESSION   BD000756
VERSION     BD000756.1  GI:18623869
KEYWORDS    JP 2000354488-A/9.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Ikawa,Y., Ikawa,S. and Tatewaki,M.
  TITLE     Chimera gene and chimera protein of p53 family
  JOURNAL   Patent: JP 2000354488-A 9 26-DEC-2000;
            YOJI IGAWA,OTSUKA PHARMACEUTICAL CO LTD
COMMENT     OS   Artificial Sequence
            PN   JP 2000354488-A/9
            PD   26-DEC-2000
            PF   09-APR-1999 JP 1999139034
            PR
            PI   YOJI IKAWA,SHUNTARO IKAWA,MASUO TATEWAKI
            PC   C12N15/09,C07K14/82,C07K19/00,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 19;
  Best Local Similarity   93.3%;  Pred. No. 2.8e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCC 1674
              ||| ||||||||||
Db         18 TCTCCATCACCCGCC 4


RESULT 220
CQ764781/c
LOCUS       CQ764781                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 3399 from Patent WO2004003201.
ACCESSION   CQ764781
VERSION     CQ764781.1  GI:44908017
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 3399 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGA 2014
              || ||||||||||||
Db         15 TATCTTCTTCAGAGA 1


RESULT 221
CQ764797/c
LOCUS       CQ764797                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 3415 from Patent WO2004003201.
ACCESSION   CQ764797
VERSION     CQ764797.1  GI:44908033
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 3415 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGA 2014
              || ||||||||||||
Db         16 TATCTTCTTCAGAGA 2


RESULT 222
AR312943
LOCUS       AR312943                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 3480 from patent US 6559294.
ACCESSION   AR312943
VERSION     AR312943.1  GI:31706369
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
            Sankaran,B. and Fletcher,L.D.
  TITLE     Chlamydia pneumoniae polynucleotides and uses thereof
  JOURNAL   Patent: US 6559294-A 3480 06-MAY-2003;
FEATURES             Location/Qualifiers
```

```
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              ||||||||||||| |
Db          6 AGGGAAGGAACAGAA 20


RESULT 223
AR313616/c
LOCUS       AR313616                 20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4153 from patent US 6559294.
ACCESSION   AR313616
VERSION     AR313616.1  GI:31707042
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
            Sankaran,B. and Fletcher,L.D.
  TITLE     Chlamydia pneumoniae polynucleotides and uses thereof
  JOURNAL   Patent: US 6559294-A 4153 06-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1706 AGCTATCTCCTAACT 1720
              ||||||||||| |||
Db         18 AGCTATCTCCTTACT 4


RESULT 224
AR373738
LOCUS       AR373738                 20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 130 from patent US 6602857.
ACCESSION   AR373738
VERSION     AR373738.1  GI:40076149
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Cowsert,L.M., Wyatt,J., Monia,B.P., Butler,M.M. and McKay,R.
  TITLE     Antisense modulation of PTP1B expression
  JOURNAL   Patent: US 6602857-A 130 05-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | |||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 225
AX149017
LOCUS       AX149017                 20 bp    DNA     linear   PAT 08-JUN-2001
DEFINITION  Sequence 219 from Patent WO0136625.
ACCESSION   AX149017
VERSION     AX149017.1  GI:14347541
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wright,J.A., Young,A.H. and Dugourd,D.
  TITLE     Antisense oligonucleotide sequences derived from groel and groes as
            inhibitors of microorganisms
  JOURNAL   Patent: WO 0136625-A 219 25-MAY-2001;
            GeneSense Technologies Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense oligonucleotide"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1912 CAACAATACCTTTTT 1926
              ||||||||||| ||
Db          2 CAACAATACCTTCTT 16


RESULT 226
AX149191
LOCUS       AX149191                 20 bp    DNA     linear   PAT 08-JUN-2001
DEFINITION  Sequence 393 from Patent WO0136625.
ACCESSION   AX149191
VERSION     AX149191.1  GI:14347715
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wright,J.A., Young,A.H. and Dugourd,D.
  TITLE     Antisense oligonucleotide sequences derived from groel and groes as
            inhibitors of microorganisms
  JOURNAL   Patent: WO 0136625-A 393 25-MAY-2001;
            GeneSense Technologies Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense oligonucleotide"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1912 CAACAATACCTTTTT 1926
              ||||||||||| ||
Db          2 CAACAATACCTTCTT 16


RESULT 227
AX418735
LOCUS       AX418735                 20 bp    DNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 130 from Patent WO0210378.
ACCESSION   AX418735
VERSION     AX418735.1  GI:21523598
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Cowsert,L.M., Wyatt,J., Freier,S.M., Monia,B.P., Butler,M.M. and
```

```
          Mckay,R.
  TITLE     Antisense modulation of ptp1b expression
  JOURNAL   Patent: WO 0210378-A 130 07-FEB-2002;
            ISIS PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense Oligonucleotide"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATCA 2017
              | ||||||||||||||
Db          6 CATCTTCAGAGATCA 20


RESULT 228
AX613548
LOCUS       AX613548                  20 bp    DNA     linear   PAT 17-FEB-2003
DEFINITION  Sequence 4573 from Patent WO02072882.
ACCESSION   AX613548
VERSION     AX613548.1  GI:28408977
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cullen,P. and Seedorf,U.
  TITLE     Coronary chip
  JOURNAL   Patent: WO 02072882-A 4573 19-SEP-2002;
            OGHAM GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.4;  DB 1;  Length 20;
  Best Local Similarity   93.3%;  Pred. No. 2.9e+02;
  Matches   14;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTTAC 1628
              ||||||||||||| |
Db          1 GGAAGAGTTTGTTTC 15


RESULT 229
AR160886/c
LOCUS       AR160886                  18 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 90 from patent US 6255111.
ACCESSION   AR160886
VERSION     AR160886.1  GI:16225883
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,C.Frank. and Cowsert,L.M.
  TITLE     Antisense modulation of Her-4 expression
  JOURNAL   Patent: US 6255111-A 90 03-JUL-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1776 TTTTTTGAACCCCATTCT 1793
              |||| ||||| ||||| |
Db         18 TTTTCTGAACTCCATTTT 1


RESULT 230
BD225045
LOCUS       BD225045                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Antisense modulation of expression of tumor necrosis factor
            receptor-associated factor (TRAF).
ACCESSION   BD225045
VERSION     BD225045.1  GI:33034815
KEYWORDS    JP 2002526095-A/180.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Baker,B.F., Cowsert,L.M., Monia,B.P. and Xu,X.S.
  TITLE     Antisense modulation of expression of tumor necrosis factor
            receptor-associated factor (TRAF)
  JOURNAL   Patent: JP 2002526095-A 180 20-AUG-2002;
            ISIS PHARMACEUTICALS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002526095-A/180
            PD   20-AUG-2002
            PF   05-OCT-1999 JP 2000574546
            PR   06-OCT-1998 US    09/167109
            PI   BRENDA F BAKER,LEX M COWSERT,BRETT P MONIA,XIAOXING S XU PC
            C12N15/09,A61K31/7105,A61K48/00,A61P29/00,A61P35/04,C12N15/00 CC
            antisense sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1565 GCAAAAATCCTTCTCCAC 1582
              |||||| ||| |||| ||
Db          1 GCAAAACTCCGTCTCTAC 18


RESULT 231
CQ807870/c
LOCUS       CQ807870                  18 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 1320 from Patent WO2004035803.
ACCESSION   CQ807870
VERSION     CQ807870.1  GI:47113264
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F.,
            Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and
            Marx,A.
  TITLE     Method and nucleic acids for the improved treatment of breast cell
            proliferative disorders
  JOURNAL   Patent: WO 2004035803-A 1320 29-APR-2004;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for RARB"
```

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1827 AATCTTTTAAATACATTC 1844
              || |||  ||||||||||
Db         18 AACCTTCCAAATACATTC 1


RESULT 232
I83492
LOCUS       I83492                  18 bp    DNA     linear   PAT 10-AUG-1998
DEFINITION  Sequence 28 from patent US 5714329.
ACCESSION   I83492
VERSION     I83492.1  GI:3407022
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Dracopoli,N., Tucker,M. and Goldstein,A.
  TITLE     Methods for the diagnosis of a genetic predisposition to cancer
            associated with variant CDK4 allele
  JOURNAL   Patent: US 5714329-A 28 03-FEB-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1840 CATTCCCTGGGCCAACAG 1857
              | ||||||| ||| ||||
Db          1 CTTTCCCTGTGCCCACAG 18


RESULT 233
AR211267
LOCUS       AR211267                18 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 180 from patent US 6399297.
ACCESSION   AR211267
VERSION     AR211267.1  GI:21514544
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Baker,B.F., Cowsert,L.M., Monia,B.P. and Xu,X.S.
  TITLE     Antisense modulation of expression of tumor necrosis factor
            receptor-associated factors (TRAFs)
  JOURNAL   Patent: US 6399297-A 180 04-JUN-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1565 GCAAAAATCCTTCTCCAC 1582
              |||||| ||| |||| ||
Db          1 GCAAAACTCCGTCTCTAC 18


RESULT 234
AX469443/c
LOCUS       AX469443                18 bp    DNA     linear   PAT 16-JUL-2002
DEFINITION  Sequence 9 from Patent WO0222877.
ACCESSION   AX469443
VERSION     AX469443.1  GI:21901729
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Hill,J.A., Wang,Z.C., Anderson,D.J. and Yunis,E.J.
  TITLE     Variants of il-1 beta gene and cd46 gene for diagnosing unexplained
            recurrent pregnancy loss
  JOURNAL   Patent: WO 0222877-A 9 21-MAR-2002;
            THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) ; DANA-FARBER CANCER
            INSTITUTE, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1751 TGGCTCTTTATTCATTAA 1768
              |||| || | ||||||||
Db         18 TGGCCCTGTCTTCATTAA 1


RESULT 235
AX473186
LOCUS       AX473186                18 bp    DNA     linear   PAT 09-AUG-2002
DEFINITION  Sequence 19 from Patent WO0238727.
ACCESSION   AX473186
VERSION     AX473186.1  GI:22207894
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   van Enckevort,L.J., Jacobsen,E., Stiekema,W.J. and Pereira,A.
  TITLE     Dna sequences encoding proteins conferring phytophthora infestans
            resistance on plants
  JOURNAL   Patent: WO 0238727-A 19 16-MAY-2002;
            Plant Research International B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="primer"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 18;
  Best Local Similarity   83.3%;  Pred. No. 2.9e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTTTC 1930
              |||||| ||||| || ||
Db          1 AACAATGCCTTTCTTCTC 18


RESULT 236
CQ801888
LOCUS       CQ801888                19 bp    DNA     linear   PAT 05-MAY-2004
DEFINITION  Sequence 205 from Patent WO2004033720.
ACCESSION   CQ801888
VERSION     CQ801888.1  GI:47058469
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Schrenzel,J., Francois,P., Charbonnier,Y., Jacquet,J.G.,
            Utinger,D., Kresbach,G.M., Abel,A. and Ehrat,M.
```

```
  TITLE     Analytical chip for the detection of 16s-rrna from clinically
            relevant bacteria and analytical method based thereon
  JOURNAL   Patent: WO 2004033720-A 205 22-APR-2004;
            Hopitaux Universitaires de Geneve (CH)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Probe for Haemophilus influenzae"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1879 AATGTCAAATTGATGTGC 1896
              || ||||| ||||||| |
Db          2 AACGTCAATTTGATGTAC 19


RESULT 237
AR292807
LOCUS       AR292807                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4542 from patent US 6537751.
ACCESSION   AR292807
VERSION     AR292807.1  GI:31680091
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 4542 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAAAAAA 1984
              |||||||||| || | ||
Db          1 ATATTTACCTGGAGAGAA 18


RESULT 238
AR342579
LOCUS       AR342579                  19 bp    DNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 19 from patent US 6576441.
ACCESSION   AR342579
VERSION     AR342579.1  GI:33737750
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Kimura,T. and Kikuchi,K.
  TITLE     Semaphorin Z and gene encoding the same
  JOURNAL   Patent: US 6576441-A 19 10-JUN-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1724 GACCTATTATCAGAAGGT 1741
              || |||||||||| | ||
Db          2 GAACTATTATCAGGACGT 19


RESULT 239
AX130690/c
LOCUS       AX130690                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1908 from Patent WO0130362.
ACCESSION   AX130690
VERSION     AX130690.1  GI:14136995
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1908 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin D2 ribozyme binding site"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAGA 1619
              || ||||| | |||||||
Db         19 TCATGGCCAGAGGGAAGA 2


RESULT 240
AX131033
LOCUS       AX131033                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 2251 from Patent WO0130362.
ACCESSION   AX131033
VERSION     AX131033.1  GI:14137338
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 2251 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin E ribozyme binding site"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCACA 1588
              ||||||||||||  | |
Db          2 ATCCTTCTCCACCAAAGA 19


RESULT 241
AX352872
LOCUS       AX352872                  19 bp    DNA     linear   PAT 06-FEB-2002
```

```
DEFINITION  Sequence 78 from Patent EP1174518.
ACCESSION   AX352872
VERSION     AX352872.1  GI:18617954
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Loukachov,V.V., van Gemen,B. and Goudsmit,J.
  TITLE     Collection of binding molecules
  JOURNAL   Patent: EP 1174518-A 78 23-JAN-2002;
            Amsterdam Support Diagnostics B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="position 62"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAA 1983
              ||||||| || | |||||
Db          2 AATATTTGCCATAAAAAA 19


RESULT 242
AX362717
LOCUS       AX362717                 19 bp    DNA     linear   PAT 15-FEB-2002
DEFINITION  Sequence 78 from Patent WO0208463.
ACCESSION   AX362717
VERSION     AX362717.1  GI:18694857
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Loukachov,V.V., Goudsmit,J. and van Gemen,B.
  TITLE     Collection of binding molecules
  JOURNAL   Patent: WO 0208463-A 78 31-JAN-2002;
            Amsterdam Support Diagnostics B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="position 62"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAAA 1983
              ||||||| || | |||||
Db          2 AATATTTGCCATAAAAAA 19


RESULT 243
AX643288/c
LOCUS       AX643288                 19 bp    DNA     linear   PAT 24-FEB-2003
DEFINITION  Sequence 154 from Patent WO02099099.
ACCESSION   AX643288
VERSION     AX643288.1  GI:28550910
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Penger,A., Sprenger,R. and Brinkmann,U.
  TITLE     Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8
            and their use in diagnostic and therapeutic applications
  JOURNAL   Patent: WO 02099099-A 154 12-DEC-2002;
            Epidauros Biotechnologie AG (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTG 1934
              |||| |||||| | ||||
Db         19 ATACTTTTTTTCTGAGTG 2


RESULT 244
AX643291
LOCUS       AX643291                 19 bp    DNA     linear   PAT 24-FEB-2003
DEFINITION  Sequence 157 from Patent WO02099099.
ACCESSION   AX643291
VERSION     AX643291.1  GI:28550913
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Penger,A., Sprenger,R. and Brinkmann,U.
  TITLE     Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8
            and their use in diagnostic and therapeutic applications
  JOURNAL   Patent: WO 02099099-A 157 12-DEC-2002;
            Epidauros Biotechnologie AG (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTG 1934
              |||| |||||| | ||||
Db          1 ATACTTTTTTTCTGAGTG 18


RESULT 245
AX711905/c
LOCUS       AX711905                 19 bp    DNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 7 from Patent WO02103046.
ACCESSION   AX711905
VERSION     AX711905.1  GI:29787701
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Dear,P.H., Thangavelu,M. and Bankier,A.
  TITLE     Happier mapping
  JOURNAL   Patent: WO 02103046-A 7 27-DEC-2002;
            Medical Research Council (GB)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 19;
  Best Local Similarity   83.3%;  Pred. No. 3e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1579 CCACCGCACAGACTGGGA 1596
              ||| || |||||||| ||
Db         19 CCAACGAACAGACTGCGA 2


RESULT 246
AR015993/c
LOCUS       AR015993                  20 bp    DNA     linear   PAT 05-DEC-1998
DEFINITION  Sequence 13 from patent US 5776672.
ACCESSION   AR015993
VERSION     AR015993.1  GI:3972270
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Hashimoto,K., Ito,K., Ishimori,Y. and Gotoh,M.
  TITLE     Gene detection method
  JOURNAL   Patent: US 5776672-A 13 07-JUL-1998;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1597 ACCCCTCCTGGCCTGGGG 1614
              || |||||||||| | ||
Db         19 ACTCCTCCTGGCCGGCGG 2


RESULT 247
AR076700
LOCUS       AR076700                  20 bp    DNA     linear   PAT 30-AUG-2000
DEFINITION  Sequence 65 from patent US 5959096.
ACCESSION   AR076700
VERSION     AR076700.1  GI:10003446
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.Frank. and Dean,N.
  TITLE     Antisense oligonucleotides against human protein kinase C
  JOURNAL   Patent: US 5959096-A 65 28-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 248
AR082034/c
LOCUS       AR082034                  20 bp    DNA     linear   PAT 31-AUG-2000
DEFINITION  Sequence 13 from patent US 5972692.
ACCESSION   AR082034
VERSION     AR082034.1  GI:10008760
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Hashimoto,K., Ito,K. and Ishimori,Y.
  TITLE     Gene detection method
  JOURNAL   Patent: US 5972692-A 13 26-OCT-1999;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1597 ACCCCTCCTGGCCTGGGG 1614
              || |||||||||| | ||
Db         19 ACTCCTCCTGGCCGGCGG 2


RESULT 249
AR112680/c
LOCUS       AR112680                  20 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 44 from patent US 6130088.
ACCESSION   AR112680
VERSION     AR112680.1  GI:14092580
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Monia,B.P. and Cowsert,L.M.
  TITLE     Antisense modulation of telomeric repeat binding factor 1
            expression
  JOURNAL   Patent: US 6130088-A 44 10-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1921 CTTTTTTTTCAGTGTTAA 1938
              ||||| || ||||||| |
Db         19 CTTTTGTTCCAGTGTTTA 2


RESULT 250
AR153557
LOCUS       AR153557                  20 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 5 from patent US 6235723.
ACCESSION   AR153557
VERSION     AR153557.1  GI:15121089
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dean,N.M.
  TITLE     Antisense oligonucleotide modulation of human protein kinase
            C-.delta. expression
  JOURNAL   Patent: US 6235723-A 5 22-MAY-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19
```

```
RESULT 251
AR162752
LOCUS       AR162752                 20 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 75 from patent US 6258790.
ACCESSION   AR162752
VERSION     AR162752.1  GI:16230091
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.Frank., Condon,T.P. and Cowsert,L.M.
  TITLE     Antisense modulation of integrin .alpha.4 expression
  JOURNAL   Patent: US 6258790-A 75 10-JUL-2001;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1900 AGATCAACAGATCAACAA 1917
              ||||||||||   ||||
Db          3 AGATCAACAGAAGTACAA 20


RESULT 252
BD179443/c
LOCUS       BD179443                 20 bp    DNA     linear   PAT 16-APR-2003
DEFINITION  Genomic DNA participating in rheumatoid arthritis, method of
            diagnosing the same, method of judging the onset risk of the same
            and diagnostic for detecting the same.
ACCESSION   BD179443
VERSION     BD179443.1  GI:30016761
KEYWORDS    WO 02079466-A/8.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Shiozawa,S., Komai,K., Yagi,H. and Matsuura,N.
  TITLE     Genomic DNA participating in rheumatoid arthritis, method of
            diagnosing the same, method of judging the onset risk of the same
            and diagnostic for detecting the same
  JOURNAL   Patent: WO 02079466-A 8 10-OCT-2002;
            SHUNICHI SHIOZAWA,KOICHIRO KOMAI,HIROFUMI YAGI,NAO MATSUURA
COMMENT     OS   Artificial Sequence
            PN   WO 02079466-A/8
            PD   10-OCT-2002
            PF   29-MAR-2002 WO 2002JP003191
            PR   30-MAR-2001 JP 01P   102006
            PI   SHUNICHI SHIOZAWA,KOICHIRO KOMAI,HIROFUMI YAGI,NAO MATSUURA PC
              C12N15/09,C12Q1/68,G01N33/566,G01N33/50
            CC   Synthesized oligonucleotide
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1730 TTATCAGAAGGTGACAAG 1747
              ||| || ||||||| |||
Db         18 TTACCACAAGGTGAGAAG 1


RESULT 253
BD189560
LOCUS       BD189560                 20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Aphidicolin biosynthetic gene cluster.
ACCESSION   BD189560
VERSION     BD189560.1  GI:32999299
KEYWORDS    WO 03000902-A/17.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Oikawa,H., Sassa,T. and Toyomasu,T.
  TITLE     Aphidicolin biosynthetic gene cluster
  JOURNAL   Patent: WO 03000902-A 17 03-JAN-2003;
            JAPAN SCIENCE AND TECHNOLOGY CORP,HIDEAKI OIKAWA,TAKESHI SASSA,
            TOMONOBU TOYOMASU
COMMENT     OS   Artificial Sequence
            PN   WO 03000902-A/17
            PD   03-JAN-2003
            PF   02-MAY-2002 WO 2002JP004381
            PR   21-JUN-2001 JP 01P   188465
            PI   HIDEAKI OIKAWA,TAKESHI SASSA,TOMONOBU TOYOMASU PC
            C12N15/52,C12N5/53,C12N9/02,C12P21/02,C12N1/21,C12N9/00,C12N9/ PC
            10,C12N15/54
            CC   Aphidicolin biosynthetic gene cluster
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1908 AGATCAACAATACCTTTT 1925
              |||||||  ||  ||||||
Db          1 AGATCAAGTATTCCTTTT 18


RESULT 254
BD237728
LOCUS       BD237728                 20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  p53 binding region.
ACCESSION   BD237728
VERSION     BD237728.1  GI:33047498
KEYWORDS    JP 2002527108-A/14.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Krammer,P., Schilling,M.M. and Oren,M.
  TITLE     p53 binding region
  JOURNAL   Patent: JP 2002527108-A 14 27-AUG-2002;
            DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002527108-A/14
            PD   27-AUG-2002
            PF   18-OCT-1999 JP 2000577293
            PR   16-OCT-1998 DE 198 47 779.1
            PI   PETER KRAMMER,MARTINA MUELLER SCHILLING,MOSHE OREN PC
            C12N15/09,C12Q1/66,C12Q1/68,G01N33/566,C12N15/00 CC   p53 binding
            region
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
```

```
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTTT 1776
              | ||  ||||||||||||
Db          3 TGTTGCTTAAGCTTTTTT 20


RESULT 255
BD262872
LOCUS       BD262872                  20 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Antisense oligonucleotide modulation of human protein kinase
            C-delta expression.
ACCESSION   BD262872
VERSION     BD262872.1  GI:33072640
KEYWORDS    JP 2002543853-A/4.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Dean,N.M.
  TITLE     Antisense oligonucleotide modulation of human protein kinase
            C-delta expression
  JOURNAL   Patent: JP 2002543853-A 4 24-DEC-2002;
            ISIS PHARMACEUTICALS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002543853-A/4
            PD   24-DEC-2002
            PF   11-MAY-2000 JP 2000618496
            PR   18-MAY-1999 US    09/313930
            PI   NICHOLAS M DEAN
            PC   C12N15/09,A61K31/7084,A61K31/7088,A61K48/00,A61P1/00,A61P1/16,
            PC   A61P1/18,
            PC   A61P3/10,A61P17/00,A61P17/06,A61P19/02,A61P29/00,A61P29/00, PC
              A61P31/00,
            PC   A61P35/00,A61P35/02,A61P37/00,A61P37/06,C12N15/00 CC
            Synthetic
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 256
CQ762347/c
LOCUS       CQ762347                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 965 from Patent WO2004003201.
ACCESSION   CQ762347
VERSION     CQ762347.1  GI:44905583
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 965 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="Human LRH1 antisense"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1890 GATGTGCCCTAGATCAAC 1907
              |||||||||||  |  |||
Db         18 GATGTGCCCTATAATAAC 1


RESULT 257
CQ762836
LOCUS       CQ762836                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 1454 from Patent WO2004003201.
ACCESSION   CQ762836
VERSION     CQ762836.1  GI:44906072
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 1454 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="Human LRH1 antisense"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAAG 1991
              | ||||  ||||||||||
Db          3 CATTGAGCAAAAGAAAAG 20


RESULT 258
CQ762888/c
LOCUS       CQ762888                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 1506 from Patent WO2004003201.
ACCESSION   CQ762888
VERSION     CQ762888.1  GI:44906124
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 1506 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="Human LRH1 antisense"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
```

```
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1890 GATGTGCCCTAGATCAAC 1907
              ||||||||||| |  |||
Db         19 GATGTGCCCTATAATAAC 2


RESULT 259
CQ763822/c
LOCUS       CQ763822                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 2440 from Patent WO2004003201.
ACCESSION   CQ763822
VERSION     CQ763822.1  GI:44907058
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kane,C.D.
  TITLE     Antisense modulation of lrh1 expression
  JOURNAL   Patent: WO 2004003201-A 2440 08-JAN-2004;
            Pharmacia Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Human LRH1 antisense"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1890 GATGTGCCCTAGATCAAC 1907
              ||||||||||| |  |||
Db         20 GATGTGCCCTATAATAAC 3


RESULT 260
CQ766734/c
LOCUS       CQ766734                  20 bp    DNA     linear   PAT 03-MAR-2004
DEFINITION  Sequence 90 from Patent WO2004005541.
ACCESSION   CQ766734
VERSION     CQ766734.1  GI:44908964
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   van Broeckhoven,C., de Jonghe,P., Timmerman,V. and Verhoeven,K.
  TITLE     Diagnostic tests for the detection of peripheral neuropathy
  JOURNAL   Patent: WO 2004005541-A 90 15-JAN-2004;
            Vlaams Interuniversitair Instituut voor Biotechnologie vz; w. (BE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="reverse primer, exon 3"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1855 CAGACCCACACACTTAGC 1872
              ||||||||  |||| |||
Db         20 CAGACCCAAGCACTGAGC 3


RESULT 261
E15162/c
LOCUS       E15162                    20 bp    DNA     linear   PAT 28-JUL-1999
DEFINITION  Phosphorothioate antisence oligo DNA human VEGF mRNA.
ACCESSION   E15162
VERSION     E15162.1  GI:5709845
KEYWORDS    JP 1998052285-A/7.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Uchida,K.
  TITLE     PREPARATION OF ANTISENSE NUCLEIC ACID
  JOURNAL   Patent: JP 1998052285-A 7 24-FEB-1998;
            TOAGOSEI CO LTD
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1998052285-A/7
            PD   24-FEB-1998
            PF   20-MAY-1997 JP 1997129767
            PR   23-MAY-1996 JP 96P   128192
            PI   UCHIDA KIYOSHI
            PC   C12N15/09,C07H21/02,C07H21/04;
            CC   strandedness: Single;
            CC   topology: Linear;
            CC   hypothetical: No;
            CC   anti-sense: Yes;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .20
            FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAACAGGA 1562
              || || ||||||| ||||
Db         19 AGAAGAGAAGGAAGAGGA 2


RESULT 262
E22414
LOCUS       E22414                    20 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Antisense nucleic acid compound.
ACCESSION   E22414
VERSION     E22414.1  GI:13024057
KEYWORDS    JP 1999042091-A/16.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Kinya,K., Yoko,M. and Kiyoshi,U.
  TITLE     Antisense nucleic acid compound
  JOURNAL   Patent: JP 1999042091-A 16 16-FEB-1999;
            TOAGOSEI CHEM IND CO LTD
COMMENT     OS   Unidentified
            PN   JP 1999042091-A/16
            PD   16-FEB-1999
            PF   25-JUL-1997 JP 1997213838
            PR
            PI   KINYA KAMIYA,YOKO MATSUDA,KIYOSHI UCHIDA
            PC   C12N15/09,A61K31/70,A61K48/00,C12Q1/68,C12N15/00 CC
            Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unidentified"
```

```
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAACAGGA 1562
              || || ||||||| ||||
Db          2 AGAAGAGAAGGAAGAGGA 19


RESULT 263
E29944
LOCUS       E29944                    20 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  HIV cofactor inhibitor.
ACCESSION   E29944
VERSION     E29944.1  GI:13021339
KEYWORDS    JP 1999292795-A/98.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Hiroshi,T., Naoki,Y., Toru,K., Kazuyuki,T. and Akira,W.
  TITLE     HIV cofactor inhibitor
  JOURNAL   Patent: JP 1999292795-A 98 26-OCT-1999;
            YAMANOUCHI PHARMACEUT CO LTD
COMMENT     OS   Unidentified
            PN   JP 1999292795-A/98
            PD   26-OCT-1999
            PF   02-APR-1998 JP 1998125452
            PR
            PI   HIROSHI TAKAHISA,NAOKI YAMAMOTO,TORU KIMURA,KAZUYUKI TAKAI, PI
              AKIRA WADA
            PC   A61K48/00,A61K31/70,A61K31/70,C12N15/09,C12N15/00 CC
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1622 TTGTTACCTACCTTACTA 1639
              |||||  || ||||||||
Db          2 TTGTTGGCTGCCTTACTA 19


RESULT 264
E40658/c
LOCUS       E40658                    20 bp    DNA     linear   PAT 31-JAN-2002
DEFINITION  Antihuman Fas humanized antibody-containing antirheumatic.
ACCESSION   E40658
VERSION     E40658.1  GI:18627247
KEYWORDS    JP 2000154149-A/29.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Serizawa,N., Haruyama,H., Takahashi,W., Nakahara,K. and Yonehara,S.
  TITLE     Antihuman Fas humanized antibody-containing antirheumatic
  JOURNAL   Patent: JP 2000154149-A 29 06-JUN-2000;
            SANKYO CO LTD
COMMENT     OS   Artificial Sequence
            PN   JP 2000154149-A/29
            PD   06-JUN-2000
            PF   17-SEP-1999 JP 1999263984
            PR
            PI   NOBUKI SERIZAWA,HIDEYUKI HARUYAMA,WATARU TAKAHASHI, PI   KAORI
            NAKAHARA,
            PI   SHIN YONEHARA
            PC   A61K39/395,A61P29/00,C12N15/09//C07K16/28,C12P21/02,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .20
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1643 AAAGAGCCTTCACTGGTT 1660
              |||||||||| | ||| |
Db         18 AAAGAGCCTTGAGTGGAT 1


RESULT 265
I31432/c
LOCUS       I31432                    20 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 344 from patent US 5582979.
ACCESSION   I31432
VERSION     I31432.1  GI:1822223
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Weber,J.L.
  TITLE     Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
            method of using the same
  JOURNAL   Patent: US 5582979-A 344 10-DEC-1996;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1996 TATCTAGCTTCTTCAGAG 2013
              ||| ||||  ||||||||
Db         20 TATTTAGCCACTTCAGAG 3


RESULT 266
AR182757
LOCUS       AR182757                  20 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 65 from patent US 6339066.
ACCESSION   AR182757
VERSION     AR182757.1  GI:20225964
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.Frank., Dean,N.M., Cook,P.Dan. and Hoke,G.
  TITLE     Antisense oligonucleotides which have phosphorothioate linkages of
            high chiral purity and which modulate .beta.I, .beta.II, .gamma.,
            .delta., .EPSILON., .zeta. and .eta. isoforms of human protein
            kinase C
  JOURNAL   Patent: US 6339066-A 65 15-JAN-2002;
FEATURES              Location/Qualifiers
     source           1. .20
                      /organism="unknown"
                      /mol_type="unassigned DNA"
```

```
  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 267
AR224726/c
LOCUS       AR224726                  20 bp    DNA     linear   PAT 26-SEP-2002
DEFINITION  Sequence 31 from patent US 6440739.
ACCESSION   AR224726
VERSION     AR224726.1  GI:23333566
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F. and Freier,S.M.
  TITLE     Antisense modulation of glioma-associated oncogene-2 expression
  JOURNAL   Patent: US 6440739-A 31 27-AUG-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACCG 1584
              | ||| |||||||||  ||
Db         18 ACAAAGCCTTCTCCAACG 1


RESULT 268
AR265965/c
LOCUS       AR265965                  20 bp    DNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 146 from patent US 6492170.
ACCESSION   AR265965
VERSION     AR265965.1  GI:29694811
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Watt,A.T.
  TITLE     Antisense modulation of caspase 9 expression
  JOURNAL   Patent: US 6492170-A 146 10-DEC-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1674 CCCTGGACTTCTTAGTTG 1691
              |||||||| ||| || |
Db         18 CCCTGGACTGCTTTGTGG 1


RESULT 269
AR292352/c
LOCUS       AR292352                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4087 from patent US 6537751.
ACCESSION   AR292352
VERSION     AR292352.1  GI:31679636
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 4087 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1681 CTTCTTAGTTGTTTCTCT 1698
              ||||  |||||||| |||
Db         20 CTTCCAAGTTGTTTTTCT 3


RESULT 270
AR300837
LOCUS       AR300837                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 65 from patent US 6537973.
ACCESSION   AR300837
VERSION     AR300837.1  GI:31688404
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bennett,C.F., Dean,N.M., Holmlund,J.T. and Dorr,F.A.
  TITLE     Oligonucleotide inhibition of protein kinase C
  JOURNAL   Patent: US 6537973-A 65 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1660 TCTGCATCACCCGCCCCT 1677
              |||| || || |||||||
Db          2 TCTGGATGACGCGCCCCT 19


RESULT 271
AR311776
LOCUS       AR311776                  20 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 2313 from patent US 6559294.
ACCESSION   AR311776
VERSION     AR311776.1  GI:31705202
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
            Sankaran,B. and Fletcher,L.D.
  TITLE     Chlamydia pneumoniae polynucleotides and uses thereof
  JOURNAL   Patent: US 6559294-A 2313 06-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       2046 TCTGCTTAGCAACTAGTT 2063
              ||||||||| |||| | |
Db          3 TCTGCTTAGGAACTTGCT 20


RESULT 272
AR488808/c
LOCUS       AR488808                  20 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 9 from patent US 6709817.
ACCESSION   AR488808
VERSION     AR488808.1  GI:47255006
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Zoghbi,H.Y., Van den Veyver,I.B., Amir,R. and Francke,U.
  TITLE     Method of screening Rett syndrome by detecting a mutation in MECP2
  JOURNAL   Patent: US 6709817-A 9 23-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1677 TGGACTTCTTAGTTGTTT 1694
              ||| |||||||| || ||
Db         18 TGGGCTTCTTAGGTGGTT 1


RESULT 273
AX004337
LOCUS       AX004337                  20 bp    DNA     linear   PAT 24-AUG-2000
DEFINITION  Sequence 89 from Patent WO9919492.
ACCESSION   AX004337
VERSION     AX004337.1  GI:9927819
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Betzner,A.S. and Doutriaux,M.P.
  TITLE     Methods for obtaining plant varieties
  JOURNAL   Patent: WO 9919492-A 89 22-APR-1999;
            BETZNER ANDREAS STEFAN (AU); DOUTRIAUX MARIE PASCALE (FR)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Reverse primer for PCR amplification of NGA106 SSLP
                     marker in Arabidopsis thaliana subspecies"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCTC 1802
              ||||||| | | ||||||
Db          3 CCCCATTTTGTTCTTCTC 20


RESULT 274
AX020603
LOCUS       AX020603                  20 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 103 from Patent WO9934016.
ACCESSION   AX020603
VERSION     AX020603.1  GI:10044293
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Vider,B.Z.
  TITLE     A method for identifying and characterizing cells and tissues
  JOURNAL   Patent: WO 9934016-A 103 08-JUL-1999;
            GENENA LTD (IL); VIDER BEN ZION (IL)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGGC 1754
              || ||||| | |||||||
Db          2 AATGTGACCATTACTGGC 19


RESULT 275
AX026102
LOCUS       AX026102                  20 bp    DNA     linear   PAT 16-SEP-2000
DEFINITION  Sequence 14 from Patent DE19847779.
ACCESSION   AX026102
VERSION     AX026102.1  GI:10187533
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Mueller-Schilling,M., Krammer,P. and Oren,M.
  TITLE     Novel receptor dna useful for identifying apoptosis-modulating
            substances potentially useful for cancer chemotherapy
  JOURNAL   Patent: DE 19847779-C 14 03-FEB-2000;
            DEUTSCHES KREBSFORSCH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTTT 1776
              | ||  ||||||||||||
Db          3 TGTTGCTTAAGCTTTTTT 20


RESULT 276
AX149070
LOCUS       AX149070                  20 bp    DNA     linear   PAT 08-JUN-2001
DEFINITION  Sequence 272 from Patent WO0136625.
ACCESSION   AX149070
VERSION     AX149070.1  GI:14347594
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wright,J.A., Young,A.H. and Dugourd,D.
  TITLE     Antisense oligonucleotide sequences derived from groel and groes as
            inhibitors of microorganisms
  JOURNAL   Patent: WO 0136625-A 272 25-MAY-2001;
            GeneSense Technologies Inc. (CA)
FEATURES             Location/Qualifiers
```

```
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense oligonucleotide"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCTG 1804
              ||||| |||| || ||||
Db          2 CCATTTTTTCATTGTCTG 19


RESULT 277
AX174999
LOCUS       AX174999                  20 bp    DNA     linear   PAT 03-JUL-2001
DEFINITION  Sequence 9 from Patent WO0143540.
ACCESSION   AX174999
VERSION     AX174999.1  GI:14598471
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Schatten,G.
  TITLE     Methods for producing transgenic animals
  JOURNAL   Patent: WO 0143540-A 9 21-JUN-2001;
            Schatten, Gerald (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1932 GTGTTAAGGTAATGGTTG 1949
              ||| | ||||| ||||||
Db          3 GTGCTCAGGTAGTGGTTG 20


RESULT 278
AX298759/c
LOCUS       AX298759                  20 bp    DNA     linear   PAT 26-NOV-2001
DEFINITION  Sequence 393 from Patent WO0183749.
ACCESSION   AX298759
VERSION     AX298759.1  GI:17128749
KEYWORDS    .
SOURCE      Mus sp.
  ORGANISM  Mus sp.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,
            Li,X., Ohmen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
  TITLE     Gene and sequence variation associated with sensing carbohydrate
            compounds and other sweeteners
  JOURNAL   Patent: WO 0183749-A 393 08-NOV-2001;
            WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
            (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Mus sp."
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10095"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCACA 1588
              |||||| |||||| || |
Db         20 ATCCTTTTCCACCCCAAA 3


RESULT 279
AX587369
LOCUS       AX587369                  20 bp    DNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 145 from Patent WO0236761.
ACCESSION   AX587369
VERSION     AX587369.1  GI:27656234
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   D'Andrea,A.D., Taniguchi,T., Timmers,C. and Grompe,M.
  TITLE     Methods and compositions for the diagnosis of cancer
            susceptibilities and defective dna repair mechanisms and treatment
            thereof
  JOURNAL   Patent: WO 0236761-A 145 10-MAY-2002;
            DANA FARBER CANCER INSTITUTE (US)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="MG779"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTTCAGTG 1934
              ||||||| |||| | |||
Db          2 ATACCTTCTTTTGCTGTG 19


RESULT 280
AX613762
LOCUS       AX613762                  20 bp    DNA     linear   PAT 17-FEB-2003
DEFINITION  Sequence 4787 from Patent WO02072882.
ACCESSION   AX613762
VERSION     AX613762.1  GI:28409191
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cullen,P. and Seedorf,U.
  TITLE     Coronary chip
  JOURNAL   Patent: WO 02072882-A 4787 19-SEP-2002;
            OGHAM GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCCC 1601
              | || |||||||||| ||
Db          1 GGACTGACTGGGAACTCC 18


RESULT 281
AX804495
```

```
LOCUS       AX804495                 20 bp    DNA     linear   PAT 25-NOV-2003
DEFINITION  Sequence 663 from Patent WO03060160.
ACCESSION   AX804495
VERSION     AX804495.1  GI:38521636
KEYWORDS    .
SOURCE      Oreochromis niloticus (Nile tilapia)
  ORGANISM  Oreochromis niloticus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
            Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
            Labroidei; Cichlidae; Oreochromis.
REFERENCE   1
  AUTHORS   Lie,Y., Slettan,A., Hoeyum,M. and Lingaas,F.
  TITLE     Verification of food origin based on nucleic acid pattern
            recognition
  JOURNAL   Patent: WO 03060160-A 663 24-JUL-2003;
            Genomar ASA (NO)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Oreochromis niloticus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:8128"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTCT 1803
              | | ||||| ||||||||
Db          3 CGCCTTCTTCCCTTCTCT 20


RESULT 282
BD061540/c
LOCUS       BD061540                 20 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Method for detecting Rett symdrome and detection kit.
ACCESSION   BD061540
VERSION     BD061540.1  GI:22607145
KEYWORDS    JP 2001292775-A/7.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Yamakawa,K.
  TITLE     Method for detecting Rett symdrome and detection kit
  JOURNAL   Patent: JP 2001292775-A 7 23-OCT-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH
COMMENT     OS   Artificial Sequence
            PN   JP 2001292775-A/7
            PD   23-OCT-2001
            PF   11-APR-2000 JP 2000109638
            PI   KAZUHIRO YAMAKAWA
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC   Synthetic DNA, forward primer for exon 3 amplification FH
            Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.4%;  Score 13.2;  DB 1;  Length 20;
  Best Local Similarity   83.3%;  Pred. No. 3.2e+02;
  Matches   15;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1677 TGGACTTCTTAGTTGTTT 1694
              ||| |||||||| || ||
Db         18 TGGGCTTCTTAGGTGGTT 1


RESULT 283
CQ788045/c
LOCUS       CQ788045                 13 bp    DNA     linear   PAT 24-MAR-2004
DEFINITION  Sequence 351 from Patent WO2004020664.
ACCESSION   CQ788045
VERSION     CQ788045.1  GI:45722997
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Geldermann,H., Preuss,S. and Han,Y.
  TITLE     Polymorphous microsatellite loci in genes for pre-diagnostic
            purposes
  JOURNAL   Patent: WO 2004020664-A 351 11-MAR-2004;
            Universitaet Hohenheim (DE)
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
     satellite       1. .13
                     /note="M11, Allel R (PrP-Gen)"
     repeat_unit     1. .4
                     /note="Anzahl der Wiederholungen: 3"
     repeat_unit     6. .9
                     /note="Anzahl der Wiederholungen: 16"

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
              |||||||||||||
Db         13 AAAAAAAGAAAAG 1


RESULT 284
CQ788047/c
LOCUS       CQ788047                 13 bp    DNA     linear   PAT 24-MAR-2004
DEFINITION  Sequence 353 from Patent WO2004020664.
ACCESSION   CQ788047
VERSION     CQ788047.1  GI:45722999
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Geldermann,H., Preuss,S. and Han,Y.
  TITLE     Polymorphous microsatellite loci in genes for pre-diagnostic
            purposes
  JOURNAL   Patent: WO 2004020664-A 353 11-MAR-2004;
            Universitaet Hohenheim (DE)
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
     satellite       1. .13
                     /note="M11, Allel B (PrP-Gen)"
     repeat_unit     1. .4
                     /note="Anzahl der Wiederholungen: 2"
     repeat_unit     6. .9
                     /note="Anzahl der Wiederholungen: 16"

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
              |||||||||||||
Db         13 AAAAAAAGAAAAG 1
```

```
RESULT 285
CQ788049/c
LOCUS       CQ788049                  13 bp    DNA     linear   PAT 24-MAR-2004
DEFINITION  Sequence 355 from Patent WO2004020664.
ACCESSION   CQ788049
VERSION     CQ788049.1  GI:45723000
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Geldermann,H., Preuss,S. and Han,Y.
  TITLE     Polymorphous microsatellite loci in genes for pre-diagnostic
            purposes
  JOURNAL   Patent: WO 2004020664-A 355 11-MAR-2004;
            Universitaet Hohenheim (DE)
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
     satellite       1. .13
                     /note="M11 Allel D (PrP-Gen)"
     repeat_unit     1. .4
                     /note="Anzahl der Wiederholungen: 3"
     repeat_unit     6. .9
                     /note="Anzahl der Wiederholungen: 17"

  Query Match             2.3%;  Score 13;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAG 1991
              |||||||||||||
Db         13 AAAAAAAGAAAAG 1


RESULT 286
AX227561/c
LOCUS       AX227561                  17 bp    RNA     linear   PAT 10-SEP-2001
DEFINITION  Sequence 933 from Patent WO0157206.
ACCESSION   AX227561
VERSION     AX227561.1  GI:15556702
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Fattaey,A.R., Jarvis,T., Mcswiggen,J., Booher,R.N. and Holman,P.S.
  TITLE     Method and reagent for the inhibition of checkpoint kinase-1 (chk
            1) enzyme
  JOURNAL   Patent: WO 0157206-A 933 09-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCAT 1666
              |||||||||||||
Db         14 ACTGGTTCTGCAT 2


RESULT 287
AX264923
LOCUS       AX264923                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 2314 from Patent WO0173002.
ACCESSION   AX264923
VERSION     AX264923.1  GI:16513722
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 2314 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          4 GGAAGAGTTTGTT 16


RESULT 288
AX264924/c
LOCUS       AX264924                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 2315 from Patent WO0173002.
ACCESSION   AX264924
VERSION     AX264924.1  GI:16513723
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 2315 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         14 GGAAGAGTTTGTT 2


RESULT 289
AX264927
LOCUS       AX264927                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 2318 from Patent WO0173002.
ACCESSION   AX264927
VERSION     AX264927.1  GI:16513726
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
```

```
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 2318 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          4 GGAAGAGTTTGTT 16


RESULT 290
AX264928/c
LOCUS       AX264928                 17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 2319 from Patent WO0173002.
ACCESSION   AX264928
VERSION     AX264928.1  GI:16513727
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 2319 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         14 GGAAGAGTTTGTT 2


RESULT 291
AX264931
LOCUS       AX264931                 17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 2322 from Patent WO0173002.
ACCESSION   AX264931
VERSION     AX264931.1  GI:16513730
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 2322 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          1 GGAAGAGTTTGTT 13


RESULT 292
AX264932/c
LOCUS       AX264932                 17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 2323 from Patent WO0173002.
ACCESSION   AX264932
VERSION     AX264932.1  GI:16513731
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 2323 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         17 GGAAGAGTTTGTT 5


RESULT 293
AX264935
LOCUS       AX264935                 17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 2326 from Patent WO0173002.
ACCESSION   AX264935
VERSION     AX264935.1  GI:16513734
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 2326 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          2 GGAAGAGTTTGTT 14
```

```
RESULT 294
AX264936/c
LOCUS       AX264936                  17 bp    DNA     linear   PAT 26-OCT-2001
DEFINITION  Sequence 2327 from Patent WO0173002.
ACCESSION   AX264936
VERSION     AX264936.1  GI:16513735
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B. and Rice,M.C.
  TITLE     Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
  JOURNAL   Patent: WO 0173002-A 2327 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db         16 GGAAGAGTTTGTT 4


RESULT 295
AX475806/c
LOCUS       AX475806                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1027 from Patent WO0224750.
ACCESSION   AX475806
VERSION     AX475806.1  GI:22215091
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1027 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1741 TGACAAGTACTGG 1753
              |||||||||||||
Db         17 TGACAAGTACTGG 5


RESULT 296
AX475812/c
LOCUS       AX475812                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1033 from Patent WO0224750.
ACCESSION   AX475812
VERSION     AX475812.1  GI:22215097
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1033 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTACT 1751
              |||||||||||||
Db         13 GGTGACAAGTACT 1


RESULT 297
AX531446/c
LOCUS       AX531446                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 955 from Patent EP1239051.
ACCESSION   AX531446
VERSION     AX531446.1  GI:25254670
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 955 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         17 TATCTCCTAACTT 5


RESULT 298
AX531447/c
LOCUS       AX531447                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 956 from Patent EP1239051.
ACCESSION   AX531447
VERSION     AX531447.1  GI:25254672
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 956 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
```

```
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         16 TATCTCCTAACTT 4


RESULT 299
AX531448/c
LOCUS       AX531448                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 957 from Patent EP1239051.
ACCESSION   AX531448
VERSION     AX531448.1  GI:25254674
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 957 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         15 TATCTCCTAACTT 3


RESULT 300
AX531449/c
LOCUS       AX531449                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 958 from Patent EP1239051.
ACCESSION   AX531449
VERSION     AX531449.1  GI:25254676
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 958 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         14 TATCTCCTAACTT 2


.
RESULT 301
AX531450/c
LOCUS       AX531450                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 959 from Patent EP1239051.
ACCESSION   AX531450
VERSION     AX531450.1  GI:25254678
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 959 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTT 1721
              |||||||||||||
Db         13 TATCTCCTAACTT 1


RESULT 302
AX724943/c
LOCUS       AX724943                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2630 from Patent WO03025176.
ACCESSION   AX724943
VERSION     AX724943.1  GI:30504286
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2630 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGTG 1993
              |||||||||||||
Db         16 AAAAAGAAAAGTG 4


RESULT 303
AX725229
LOCUS       AX725229                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2916 from Patent WO03025176.
ACCESSION   AX725229
VERSION     AX725229.1  GI:30504572
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
```

```
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2916 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       2074 ATCTGACACACTC 2086
              |||||||||||||
Db          2 ATCTGACACACTC 14


RESULT 304
AX761147/c
LOCUS       AX761147                 17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4468 from Patent WO03040369.
ACCESSION   AX761147
VERSION     AX761147.1  GI:32255763
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4468 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGA 1805
              |||||||||||||
Db         15 TTTCCTTCTCTGA 3


RESULT 305
BD263129/c
LOCUS       BD263129                 18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Phosphodiesterase inhibitors for therapeutic use.
ACCESSION   BD263129
VERSION     BD263129.1  GI:33072897
KEYWORDS    JP 2002534086-A/23.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Dale,R.M.K., Arrow,A. and Thompson,T.
  TITLE     Phosphodiesterase inhibitors for therapeutic use
  JOURNAL   Patent: JP 2002534086-A 23 15-OCT-2002;
            OLIGOS ETC INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002534086-A/23
            PD   15-OCT-2002
            PF   15-DEC-1999 JP 2000592411
            PR   30-DEC-1998 US    09/223586,29-JUL-1999 US    09/364626 PI
            RODERIC M K DALE,AMY ARROW,TERRY THOMPSON
            PC   C12N15/09,A61K31/7088,A61K48/00,A61P1/00,A61P1/04,A61P3/10, PC
              A61P9/00,
            PC   A61P9/10,A61P11/00,A61P11/06,A61P11/16,A61P13/00,A61P17/04, PC
              A61P17/06,
            PC   A61P19/02,A61P25/00,A61P25/24,A61P25/28,A61P27/14,A61P27/16,
            PC   A61P29/00,
            PC   A61P31/18,A61P33/06,A61P35/00,A61P37/06,A61P43/00,C12N15/00 CC
              Synthesized Oligonucleotide
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.3%;  Score 13;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1735 AGAAGGTGACAAG 1747
              |||||||||||||
Db         18 AGAAGGTGACAAG 6


RESULT 306
AR256296/c
LOCUS       AR256296                 19 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 2 from patent US 6482937.
ACCESSION   AR256296
VERSION     AR256296.1  GI:27305797
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Baetscher,M.W., Akiyoshi,D.E. and Kaplan,R.A.
  TITLE     Porcine Oct-4 promoter
  JOURNAL   Patent: US 6482937-A 2 19-NOV-2002;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   68.4%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    3;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACCCGCC 1674
              ||||||||:| |  :||:|
Db         19 TGGTTCTGYAACCGSCGSC 1


RESULT 307
AX131031
LOCUS       AX131031                 19 bp~   DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 2249 from Patent WO0130362.
ACCESSION   AX131031
VERSION     AX131031.1  GI:14137336
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
```

```
            diseases
  JOURNAL   Patent: WO 0130362-A 2249 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin E ribozyme binding site"

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db          5 ATCCTTCTCCACC 17


RESULT 308
AX131032
LOCUS       AX131032                 19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 2250 from Patent WO0130362.
ACCESSION   AX131032
VERSION     AX131032.1  GI:14137337
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 2250 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin E ribozyme binding site"

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db          4 ATCCTTCTCCACC 16


RESULT 309
AX817168
LOCUS       AX817168                 19 bp    DNA     linear   PAT 10-DEC-2003
DEFINITION  Sequence 7 from Patent EP1338606.
ACCESSION   AX817168
VERSION     AX817168.1  GI:39722569
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   von knebel Doeberitz,M., Wentzensen,N., Gebert,J. and
            Linnebacher,M.
  TITLE     Nucleic acid encoding an herv-h polypeptide for diagnosing
            colorectal cancer
  JOURNAL   Patent: EP 1338606-A 7 27-AUG-2003;
            Von Knebel Doeberitz, Magnus (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of the Artificial Sequence: Primer"

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1585 CACAGACTGGGAA 1597
              |||||||||||||
Db          2 CACAGACTGGGAA 14


RESULT 310
AX817183
LOCUS       AX817183                 19 bp    DNA     linear   PAT 10-DEC-2003
DEFINITION  Sequence 22 from Patent EP1338606.
ACCESSION   AX817183
VERSION     AX817183.1  GI:39722574
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   von knebel Doeberitz,M., Wentzensen,N., Gebert,J. and
            Linnebacher,M.
  TITLE     Nucleic acid encoding an herv-h polypeptide for diagnosing
            colorectal cancer
  JOURNAL   Patent: EP 1338606-A 22 27-AUG-2003;
            Von Knebel Doeberitz, Magnus (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of the Artificial Sequence: Primer"

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1585 CACAGACTGGGAA 1597
              |||||||||||||
Db          2 CACAGACTGGGAA 14


RESULT 311
AX824392
LOCUS       AX824392                 19 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 6 from Patent WO03070757.
ACCESSION   AX824392
VERSION     AX824392.1  GI:39750406
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   von Knebel-Doeberitz,M.C., Wentzensen,N., Gebert,J. and
            Linnebacher,M.
  TITLE     Nucleic acid encoding an herv-h polypeptide for diagnosing
            colorectal cancer
  JOURNAL   Patent: WO 03070757-A 6 28-AUG-2003;
            Von Knebel Doeberitz, Magnus (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of the Artificial Sequence: Primer"
     misc_feature    1. .19
                     /note="(2nd Primer binding to the Sequence depicted in
                     Figure 3)"

  Query Match             2.3%;  Score 13;  DB 1;  Length 19;
```

```
  Best Local Similarity   100.0%;  Pred. No. 3.3e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1585 CACAGACTGGGAA 1597
              |||||||||||||
Db          2 CACAGACTGGGAA 14


RESULT 312
AR016534/c
LOCUS       AR016534                  20 bp    DNA     linear   PAT 05-DEC-1998
DEFINITION  Sequence 1 from patent US 5776752.
ACCESSION   AR016534
VERSION     AR016534.1  GI:3972811
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Beavo,J.A., Bentley,J.Kelley., Charbonneau,H. and Sonnenburg,W.K.
  TITLE     Isolated and purified calcium/calmodulin stimulated cyclic
            nucleotide phosphodiesterases
  JOURNAL   Patent: US 5776752-A 1 07-JUL-1998;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 313
AR021254/c
LOCUS       AR021254                  20 bp    DNA     linear   PAT 05-DEC-1998
DEFINITION  Sequence 1 from patent US 5789553.
ACCESSION   AR021254
VERSION     AR021254.1  GI:3975869
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Beavo,J.A., Bentley,J.Kelley., Charbonneau,H. and Sonnenburg,W.K.
  TITLE     Antibodies specifically immunoreactive with human brain Ca.sup.2+
            /calmodulin cyclic nucleotide phosphodiesterase
  JOURNAL   Patent: US 5789553-A 1 04-AUG-1998;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 314
AR036808/c
LOCUS       AR036808                  20 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1 from patent US 5800987.
ACCESSION   AR036808
VERSION     AR036808.1  GI:5954664
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1' (bases 1 to 20)
  AUTHORS   Beavo,J.A., Bentley,J.Kelley., Charbonneau,H. and Sonnenburg,W.K.
  TITLE     Assay methods using DNA encoding mammalian phosphodiesterases
  JOURNAL   Patent: US 5800987-A 1 01-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 315
I22624
LOCUS       I22624                    20 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 112 from patent US 5527898.
ACCESSION   I22624
VERSION     I22624.1  GI:1602978
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bauer,H.M., Gravitt,P.E., Greer,C.E., Manos,M.Michele.,
            Resnick,R.M. and Zhang,T.Y.
  TITLE     Detection of human papillomavirus by the polymerase chain reaction
  JOURNAL   Patent: US 5527898-A 112 18-JUN-1996;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| ||||||  ||
Db          2 GTAMWGGMTGGTTTATG 18


RESULT 316
I22630/c
LOCUS       I22630                    20 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 118 from patent US 5527898.
ACCESSION   I22630
VERSION     I22630.1  GI:1602984
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bauer,H.M., Gravitt,P.E., Greer,C.E., Manos,M.Michele.,
            Resnick,R.M. and Zhang,T.Y.
  TITLE     Detection of human papillomavirus by the polymerase chain reaction
  JOURNAL   Patent: US 5527898-A 118 18-JUN-1996;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db         19 GTAMWGGMTGGTTTATG 3


RESULT 317
I30424/c
LOCUS       I30424                  20 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 1 from patent US 5580771.
ACCESSION   I30424
VERSION     I30424.1  GI:1821215
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Beavo,J.A., Charbonneau,H. and Sonnenburg,W.K.
  TITLE     DNA encoding mammalian phosphodiesterases
  JOURNAL   Patent: US 5580771-A 1 03-DEC-1996;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 318
I35668/c
LOCUS       I35668                  20 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 1 from patent US 5602019.
ACCESSION   I35668
VERSION     I35668.1  GI:2087519
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Beavo,J.A., Bentley,K.J., Charbonneau,H. and Sonnenburg,W.K.
  TITLE     DNA encoding mammalian phosphodiesterases
  JOURNAL   Patent: US 5602019-A 1 11-FEB-1997;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 319
I47449
LOCUS       I47449                  20 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 112 from patent US 5639871.
ACCESSION   I47449
VERSION     I47449.1  GI:2471414
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bauer,H.M., Gravitt,P.E., Greer,C.E., Impraim,C.C.,
            Manos,M.Michele., Resnick,R.M. and Zhang,T.Yi.
  TITLE     Detection of human papillomavirus by the polymerase chain reaction
  JOURNAL   Patent: US 5639871-A 112 17-JUN-1997;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db          2 GTAMWGGMTGGTTTATG 18


RESULT 320
I47455/c
LOCUS       I47455                  20 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 118 from patent US 5639871.
ACCESSION   I47455
VERSION     I47455.1  GI:2471420
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Bauer,H.M., Gravitt,P.E., Greer,C.E., Impraim,C.C.,
            Manos,M.Michele., Resnick,R.M. and Zhang,T.Yi.
  TITLE     Detection of human papillomavirus by the polymerase chain reaction
  JOURNAL   Patent: US 5639871-A 118 17-JUN-1997;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   76.5%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    2;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTTTG 1956
              |||::|| |||||| ||
Db         19 GTAMWGGMTGGTTTATG 3


RESULT 321
AR182967/c
LOCUS       AR182967                20 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 5 from patent US 6339071.
ACCESSION   AR182967
VERSION     AR182967.1  GI:20226174
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Levesque,L.
  TITLE     Antisense oligonucleotide modulating cyclin E gene expression and
            therapeutic uses thereof
  JOURNAL   Patent: US 6339071-A 5 15-JAN-2002;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
```

```
Db         13 ATCCTTCTCCACC 1


RESULT 322
AR428770/c
LOCUS       AR428770                  20 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 1 from patent US 6642040.
ACCESSION   AR428770
VERSION     AR428770.1  GI:40188531
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 20)
  AUTHORS   Beavo,J.A., Bentley,K.J., Charbonneau,H. and Sonnenburg,W.K.
  TITLE     Human cGMP-stimulated cyclic nucleotide phosphodiesterase
  JOURNAL   Patent: US 6642040-A 1 04-NOV-2003;
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   65.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    3;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCATTCT 1793
              ||:||:|| |  |||||: |
Db         20 TTYTTYTTCATNCCCATYTT 1


RESULT 323
AX059671/c
LOCUS       AX059671                  20 bp    DNA     linear   PAT 22-JAN-2001
DEFINITION  Sequence 5 from Patent WO0100821.
ACCESSION   AX059671
VERSION     AX059671.1  GI:12405468
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Levesque,L.
  TITLE     Antisense oligonucleotide modulating cyclin e gene expression and
            therapeutic uses thereof
  JOURNAL   Patent: WO 0100821-A 5 04-JAN-2001;
            Angiogene, Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense oligonucleotide"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACC 1583
              |||||||||||||
Db         13 ATCCTTCTCCACC 1


RESULT 324
AX462797
LOCUS       AX462797                  20 bp    DNA     linear   PAT 15-JUL-2002
DEFINITION  Sequence 541 from Patent EP1217079.
ACCESSION   AX462797
VERSION     AX462797.1  GI:21886023
KEYWORDS    .
SOURCE      Aegilops tauschii
  ORGANISM  Aegilops tauschii
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Pooideae; Triticeae; Aegilops.
REFERENCE   1
  AUTHORS   Bernard,M., Sourdille,P. and Guyomarch,H.
  TITLE     Microsatellite markers from Triticum tauschii
  JOURNAL   Patent: EP 1217079-A 541 26-JUN-2002;
            INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) (FR)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Aegilops tauschii"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:37682"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1782 GAACCCCATTCTT 1794
              |||||||||||||
Db          7 GAACCCCATTCTT 19


RESULT 325
AX613487
LOCUS       AX613487                  20 bp    DNA     linear   PAT 17-FEB-2003
DEFINITION  Sequence 4512 from Patent WO02072882.
ACCESSION   AX613487
VERSION     AX613487.1  GI:28408916
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Cullen,P. and Seedorf,U.
  TITLE     Coronary chip
  JOURNAL   Patent: WO 02072882-A 4512 19-SEP-2002;
            OGHAM GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .20
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 13;  DB 1;  Length 20;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+02;
  Matches   13;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1614 GGAAGAGTTTGTT 1626
              |||||||||||||
Db          5 GGAAGAGTTTGTT 17


RESULT 326
AR087167
LOCUS       AR087167                  16 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 37 from patent US 5986053.
ACCESSION   AR087167
VERSION     AR087167.1  GI:10013930
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ecker,D.J., Buchardt,O., Egholm,M., Nielsen,P.E., Berg,R.H. and
            Mollegaard,N.E.
  TITLE     Peptide nucleic acids complexes of two peptide nucleic acid strands
            and one nucleic acid strand
  JOURNAL   Patent: US 5986053-A 37 16-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 327
AR150613
LOCUS       AR150613                 16 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 32 from patent US 6228982.
ACCESSION   AR150613
VERSION     AR150613.1  GI:15115204
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Norden,B., Wittung,P., Buchardt,O., Egholm,M., Nielsen,P.E. and
            Berg,R.
  TITLE     Double-stranded peptide nucleic acids
  JOURNAL   Patent: US 6228982-A 32 08-MAY-2001;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 328
E36066
LOCUS       E36066                   16 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Higher-order structure and binding of peptide nucleic acid.
ACCESSION   E36066
VERSION     E36066.1  GI:13022468
KEYWORDS    JP 1999236396-A/11.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Bushato,O., Eguhorumu,M., Nielsen,P.A., Berg,R.H., Ekka,D.J. and
            Morugado,N.A.
  TITLE     Higher-order structure and binding of peptide nucleic acid
  JOURNAL   Patent: JP 1999236396-A 11 31-AUG-1999;
            ISIS PHARMACEUTICALS INC,BUCHARDT DORUTE,EGUHORUMU MICHAEL, IELSEN
            PATER A, BERGH RORUFU HO
COMMENT     OS   Unidentified
            PN   JP 1999236396-A/11
            PD   31-AUG-1999
            PF   14-OCT-1998 JP 1998291590
            PR   02-JUL-1993 US       088658
            PI   BUSHATO ORE,EGUHORUMU MICHAEL,NIELSEN PATER A,BERG RORUFU HO,
            PI   EKKA DAVID JAY,MORUGADO NILUS A
            PC   C07H21/04,A61K31/00,A61K31/00,A61K31/00,A61K31/70,A61K48/00,
            PC   C07H21/02,
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 329
I42184
LOCUS       I42184                   16 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 19 from patent US 5629152.
ACCESSION   I42184
VERSION     I42184.1  GI:2467679
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ravikumar,V.
  TITLE     Trisubstituted .beta.-lactams and oligo .beta.-lactamamides
  JOURNAL   Patent: US 5629152-A 19 13-MAY-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 330
I49622
LOCUS       I49622                   16 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 37 from patent US 5641625.
ACCESSION   I49622
VERSION     I49622.1  GI:2471842
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ecker,D.J., Buchardt,O., Egholm,M., Nielsen,P.E., Berg,R.H. and
            Mollegaard,N.E.
  TITLE     Cleaving double-stranded DNA with peptide nucleic acids
  JOURNAL   Patent: US 5641625-A 37 24-JUN-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 331
I85795
LOCUS       I85795                   16 bp    DNA     linear   PAT 10-JUN-1998
```

```
DEFINITION  Sequence 3 from patent US 5698686.
ACCESSION   I85795
VERSION     I85795.1  GI:3205513
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Gottschling,D.E. and Singer,M.S.
  TITLE     Yeast telomerase compositions
  JOURNAL   Patent: US 5698686-A 3 16-DEC-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
              || || ||||||||||
Db          1 CACCACACCCACACAC 16


RESULT 332
AR200487
LOCUS       AR200487                 16 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 30 from patent US 6357163.
ACCESSION   AR200487
VERSION     AR200487.1  GI:20251375
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Buchardt,O., Egholm,M., Nielsen,P.E. and Berg,R.H.
  TITLE     Use of nucleic acid analogues in diagnostics and analytical
            procedures
  JOURNAL   Patent: US 6357163-A 30 19-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 333
AR209859
LOCUS       AR209859                 16 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 3 from patent US 6387619.
ACCESSION   AR209859
VERSION     AR209859.1  GI:21511939
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Gottschling,D.E. and Singer,M.S.
  TITLE     Telomerase compositions and methods
  JOURNAL   Patent: US 6387619-A 3 14-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
              || || ||||||||||
Db          1 CACCACACCCACACAC 16


RESULT 334
AR371293
LOCUS       AR371293                 16 bp    DNA     linear   PAT 12-SEP-2003
DEFINITION  Sequence 30 from patent US 6395474.
ACCESSION   AR371293
VERSION     AR371293.1  GI:34608225
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Buchardt,O., Egholm,M., Nielsen,P.E. and Berg,R.H.
  TITLE     Peptide nucleic acids
  JOURNAL   Patent: US 6395474-A 30 28-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 335
AR489514
LOCUS       AR489514                 16 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 30 from patent US 6710163.
ACCESSION   AR489514
VERSION     AR489514.1  GI:47256539
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Buchardt,O., Egholm,M., Nielsen,P.E. and Berg,R.H.
  TITLE     Peptide nucleic acid synthons
  JOURNAL   Patent: US 6710163-A 30 23-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 336
AR491125
LOCUS       AR491125                 16 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 30 from patent US 6713602.
ACCESSION   AR491125
VERSION     AR491125.1  GI:47258985
KEYWORDS    .
SOURCE      Unknown.
```

```
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Buchardt,O., Buchardt,D., Egholm,M., Nielsen,P.E. and Berg,R.H.
  TITLE     Synthetic procedures for peptide nucleic acids
  JOURNAL   Patent: US 6713602-A 30 30-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              | || ||||||||||
Db          1 TCGACAAAAAGAAAAG 16


RESULT 337
AX033374
LOCUS       AX033374                  16 bp    RNA     linear   PAT 21-SEP-2000
DEFINITION  Sequence 6 from Patent WO0046601.
ACCESSION   AX033374
VERSION     AX033374.1  GI:10280148
KEYWORDS    .
SOURCE      Saccharomyces cerevisiae (baker's yeast)
  ORGANISM  Saccharomyces cerevisiae
            Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
            Saccharomycetales; Saccharomycetaceae; Saccharomyces.
REFERENCE   1
  AUTHORS   Larsen,F. and Skaanseng,M.
  TITLE     Detecting telomerase activity
  JOURNAL   Patent: WO 0046601-A 6 10-AUG-2000;
            LARSEN FRANK (NO) ; SKAANSENG MARIANNE (NO)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Saccharomyces cerevisiae"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:4932"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 16;
  Best Local Similarity   87.5%;  Pred. No. 3.1e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1852 CAACAGACCCACACAC 1867
              || || ||||||||||
Db          1 CACCACACCCACACAC 16


RESULT 338
A88310
LOCUS       A88310                    17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 458 from Patent WO9833904.
ACCESSION   A88310
VERSION     A88310.1  GI:6736880
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 458 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAAA 1990
              ||| ||||||| ||||
Db          1 CTTTAAAAAAACAAAA 16


RESULT 339
A90277
LOCUS       A90277                    17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 458 from Patent EP0856579.
ACCESSION   A90277
VERSION     A90277.1  GI:6738791
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 458 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAAA 1990
              ||| ||||||| ||||
Db          1 CTTTAAAAAAACAAAA 16


RESULT 340
AR045725
LOCUS       AR045725                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 518 from patent US 5817796.
ACCESSION   AR045725
VERSION     AR045725.1  GI:5967190
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 518 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCA 1789
              | ||||| ||||||||
Db          2 TGTTTTTAGAACCCCA 17


RESULT 341
AR047384/c
LOCUS       AR047384                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 2177 from patent US 5817796.
ACCESSION   AR047384
VERSION     AR047384.1  GI:5968849
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 2177 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              |||| |||| ||||||
Db         16 TTGACAAAAGGAAAAG 1

RESULT 342
BD198684/c
LOCUS       BD198684                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD198684
VERSION     BD198684.1  GI:33008454
KEYWORDS    JP 2002509721-A/1710.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 1710 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/1710
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTTT 1926
              | | ||||||||||||
Db         16 TAATCAATACCTTTTT 1

RESULT 343
BD255068/c
LOCUS       BD255068                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255068
VERSION     BD255068.1  GI:33064838
KEYWORDS    JP 2002541795-A/2861.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2861 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2861
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGGG 1551
              || | ||||||||||||
Db         17 GGCTGGGAGAGTAGGG 2

RESULT 344
BD255135
LOCUS       BD255135                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255135
VERSION     BD255135.1  GI:33064905
KEYWORDS    JP 2002541795-A/2928.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2928 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2928
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
```

```
           PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
           PC   A61K37/02,
           PC   (C12N5/00,C12R1:91)
           CC   Regulation of repressor genes using nucleic acid molecules FH
            Key             Location/Qualifiers
           FT   source          1. .17
           FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1565 GCAAAAATCCTTCTCC 1580
              |||||||| |||| ||
Db          1 GCAAAAATACTTCCCC 16


RESULT 345
BD255457
LOCUS       BD255457                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255457
VERSION     BD255457.1  GI:33065227
KEYWORDS    JP 2002541795-A/3250.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 3250 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/3250
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTTG 1782
              ||||||| ||||| ||
Db          2 AAGCTTTCTTTTTATG 17


RESULT 346
BD258463
LOCUS       BD258463                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258463
VERSION     BD258463.1  GI:33068233
KEYWORDS    JP 2002541795-A/6256.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6256 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6256
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAAG 1808
              |||||||| || ||||
Db          2 TTTCCTTCCCTCAAAG 17


RESULT 347
CQ616605/c
LOCUS       CQ616605                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1345 from Patent WO0192524.
ACCESSION   CQ616605
VERSION     CQ616605.1  GI:41666823
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1345 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCT 1801
```

```
              ||||| |||||||||
Db         17 CCCATCTTTTCCTTCT 2


RESULT 348
CQ616607/c
LOCUS       CQ616607                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1347 from Patent WO0192524.
ACCESSION   CQ616607
VERSION     CQ616607.1  GI:41666825
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1347 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
              |||||| ||||||||
Db         16 CCCCATCTTTTCCTTC 1


RESULT 349
CQ616840/c
LOCUS       CQ616840                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1580 from Patent WO0192524.
ACCESSION   CQ616840
VERSION     CQ616840.1  GI:41667058
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1580 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
              |||||||||||  |||
Db         17 ATCCTTCTCCAGAGCA 2


RESULT 350
CQ616841/c
LOCUS       CQ616841                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1581 from Patent WO0192524.
ACCESSION   CQ616841
VERSION     CQ616841.1  GI:41667059
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1581 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
              |||||||||||  |||
Db         16 ATCCTTCTCCAGAGCA 1


RESULT 351
CQ622901/c
LOCUS       CQ622901                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7641 from Patent WO0192524.
ACCESSION   CQ622901
VERSION     CQ622901.1  GI:41673119
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7641 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1686 TAGTTGTTTCTCTAGC 1701
              | |||| |||||||||
Db         17 TTGTTGGTTCTCTAGC 2


RESULT 352
CQ622904/c
LOCUS       CQ622904                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7644 from Patent WO0192524.
ACCESSION   CQ622904
VERSION     CQ622904.1  GI:41673122
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
```

```
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7644 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTA 1699
              ||| |||| |||||||
Db         16 CTTTGTTGGTTCTCTA 1

RESULT 353
CQ623217
LOCUS       CQ623217                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7957 from Patent WO0192524.
ACCESSION   CQ623217
VERSION     CQ623217.1  GI:41673435
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7957 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          2 GCCCTTGAGCAACAGA 17

RESULT 354
CQ623218
LOCUS       CQ623218                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7958 from Patent WO0192524.
ACCESSION   CQ623218
VERSION     CQ623218.1  GI:41673436
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7958 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          1 GCCCTTGAGCAACAGA 16

RESULT 355
I37589/c
LOCUS       I37589                    17 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 602 from patent US 5612215.
ACCESSION   I37589
VERSION     I37589.1  GI:2085549
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
            Stinchcomb,D.T.
  TITLE     Stromelysin targeted ribozymes
  JOURNAL   Patent: US 5612215-A 602 18-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTGAAA 1807
              |||||||| || ||||
Db         16 CTTTCCTTATCAGAAA 1

RESULT 356
I37666
LOCUS       I37666                    17 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 679 from patent US 5612215.
ACCESSION   I37666
VERSION     I37666.1  GI:2085626
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
            Stinchcomb,D.T.
  TITLE     Stromelysin targeted ribozymes
  JOURNAL   Patent: US 5612215-A 679 18-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1989 AAGTGTGTATCTAGCT 2004
              || ||||||||| ||
Db          1 AACTGTGTATCTAACT 16

RESULT 357
I52777
LOCUS       I52777                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 518 from patent US 5646042.
ACCESSION   I52777
VERSION     I52777.1  GI:2473978
```

```
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 518 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCCA 1789
              | ||||| ||||||||
Db          2 TGTTTTTAGAACCCCA 17


RESULT 358
I54436/c
LOCUS       I54436                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 2177 from patent US 5646042.
ACCESSION   I54436
VERSION     I54436.1  GI:2475639
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 2177 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAAG 1991
              |||| |||| ||||||
Db         16 TTGACAAAAGGAAAAG 1


RESULT 359
I94439/c
LOCUS       I94439                    17 bp    DNA     linear   PAT 01-DEC-1998
DEFINITION  Sequence 602 from patent US 5731295.
ACCESSION   I94439
VERSION     I94439.1  GI:3938909
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
            Stinchcomb,D.T.
  TITLE     Method of reducing stromelysin RNA via ribozymes
  JOURNAL   Patent: US 5731295-A 602 24-MAR-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1792 CTTTCCTTCTCTGAAA 1807
              |||||||| || ||||
Db         16 CTTTCCTTATCAGAAA 1


RESULT 360
I94516
LOCUS       I94516                    17 bp    DNA     linear   PAT 01-DEC-1998
DEFINITION  Sequence 679 from patent US 5731295.
ACCESSION   I94516
VERSION     I94516.1  GI:3938986
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
            Stinchcomb,D.T.
  TITLE     Method of reducing stromelysin RNA via ribozymes
  JOURNAL   Patent: US 5731295-A 679 24-MAR-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1989 AAGTGTGTATCTAGCT 2004
              || ||||||||||  ||
Db          1 AACTGTGTATCTAACT 16


RESULT 361
AR186716/c
LOCUS       AR186716                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2204 from patent US 6346398.
ACCESSION   AR186716
VERSION     AR186716.1  GI:20232681
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2204 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGAG 1707
              |||||||| | |||||
Db         16 TTTCTCTAACACTGAG 1


RESULT 362
AR186745/c
LOCUS       AR186745                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2233 from patent US 6346398.
ACCESSION   AR186745
VERSION     AR186745.1  GI:20232710
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
```

```
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2233 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         17 AGCCACTGAAATGGCA 2


RESULT 363
AR186746/c
LOCUS       AR186746                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2234 from patent US 6346398.
ACCESSION   AR186746
VERSION     AR186746.1  GI:20232711
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2234 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         16 AGCCACTGAAATGGCA 1


RESULT 364
AR187030
LOCUS       AR187030                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2518 from patent US 6346398.
ACCESSION   AR187030
VERSION     AR187030.1  GI:20232995
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2518 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCT 1698
              |||| |||||| ||||
Db          2 TCTTTGTTGTTCCTCT 17


RESULT 365
AR190544/c
LOCUS       AR190544                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 6032 from patent US 6346398.
ACCESSION   AR190544
VERSION     AR190544.1  GI:20236509
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 6032 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAAC 1558
              |||||  |||||||||
Db         17 AGAGTCCGGAAGGAAC 2


RESULT 366
AR215128/c
LOCUS       AR215128                  17 bp    DNA     linear   PAT 25-SEP-2002
DEFINITION  Sequence 32 from patent US 6410266.
ACCESSION   AR215128
VERSION     AR215128.1  GI:23313256
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Harrington,J.J. and Rundlett,S.
  TITLE     Compositions and methods for non-targeted activation of endogenous
            genes
  JOURNAL   Patent: US 6410266-A 32 25-JUN-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 367
AR302370/c
LOCUS       AR302370                  17 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 32 from patent US 6541221.
ACCESSION   AR302370
VERSION     AR302370.1  GI:31690624
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
```

```
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Harrington,J.J., Sherf,B. and Rundlett,S.
  TITLE     Compositions and methods for non-targeted activation of endogenous
            genes
  JOURNAL   Patent: US 6541221-A 32 01-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 368
AR323347/c
LOCUS       AR323347                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 749 from patent US 6566127.
ACCESSION   AR323347
VERSION     AR323347.1  GI:33709155
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 749 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGAG 1707
              |||||||| | |||||
Db         16 TTTCTCTAACACTGAG 1


RESULT 369
AR323376/c
LOCUS       AR323376                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 778 from patent US 6566127.
ACCESSION   AR323376
VERSION     AR323376.1  GI:33709184
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 778 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         17 AGCCACTGAAATGGCA 2


RESULT 370
AR323377/c
LOCUS       AR323377                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 779 from patent US 6566127.
ACCESSION   AR323377
VERSION     AR323377.1  GI:33709185
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 779 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTCA 1885
              ||||| ||||||| ||
Db         16 AGCCACTGAAATGGCA 1


RESULT 371
AR323640
LOCUS       AR323640                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 1042 from patent US 6566127.
ACCESSION   AR323640
VERSION     AR323640.1  GI:33709448
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 1042 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCT 1698
              |||| |||||| ||||
Db          2 TCTTTGTTGTTCCTCT 17


RESULT 372
AR325467/c
LOCUS       AR325467                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2869 from patent US 6566127.
ACCESSION   AR325467
VERSION     AR325467.1  GI:33711275
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
```

```
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2869 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAAC 1558
              |||||  |||||||||
Db         17 AGAGTCCGGAAGGAAC 2


RESULT 373
AR373242/c
LOCUS       AR373242                 17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 32 from patent US 6602686.
ACCESSION   AR373242
VERSION     AR373242.1  GI:40075250
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Harrington,J.J., Sherf,B. and Rundlett,S.
  TITLE     Compositions and method for non-targeted activation of endogenous
            genes
  JOURNAL   Patent: US 6602686-A 32 05-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 374
AR401628/c
LOCUS       AR401628                 17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 32 from patent US 6623958.
ACCESSION   AR401628
VERSION     AR401628.1  GI:40149076
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Harrington,J.J., Sherf,B. and Rundlett,S.
  TITLE     Compositions and methods for non-targeted activation of endogenous
            genes
  JOURNAL   Patent: US 6623958-A 32 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              ||||||| |||| |||
Db         17 CATCACCTGCCCATGG 2


RESULT 375
AR402205
LOCUS       AR402205                 17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 545 from patent US 6623962.
ACCESSION   AR402205
VERSION     AR402205.1  GI:40149655
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 545 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || |||||||| |||
Db          2 CAGTGGTTCTGCTTCA 17


RESULT 376
AR402206
LOCUS       AR402206                 17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 546 from patent US 6623962.
ACCESSION   AR402206
VERSION     AR402206.1  GI:40149656
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 546 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || |||||||| |||
Db          1 CAGTGGTTCTGCTTCA 16


RESULT 377
AR433888
LOCUS       AR433888                 17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 311 from patent US 6656700.
ACCESSION   AR433888
VERSION     AR433888.1  GI:40196731
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y. and Shannon,M.E.
```

```
  TITLE     Isoforms of human pregnancy-associated protein-E
  JOURNAL   Patent: US 6656700-A 311 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGGA 1562
              |||||||||||  | ||
Db          2 TAGGGAAGGAAGAAGA 17


RESULT 378
AR433889
LOCUS       AR433889                  17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 312 from patent US 6656700.
ACCESSION   AR433889
VERSION     AR433889.1  GI:40196732
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y. and Shannon,M.E.
  TITLE     Isoforms of human pregnancy-associated protein-E
  JOURNAL   Patent: US 6656700-A 312 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGGA 1562
              |||||||||||  | ||
Db          1 TAGGGAAGGAAGAAGA 16


RESULT 379
AR442961/c
LOCUS       AR442961                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 32 from patent US 6670185.
ACCESSION   AR442961
VERSION     AR442961.1  GI:42670506
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Harrington,J.J., Sherf,B. and Rundlett,S.
  TITLE     Compositions and methods for non-targeted activation of endogenous
            genes
  JOURNAL   Patent: US 6670185-A 32 30-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1664 CATCACCCGCCCCTGG 1679
              |||||||  ||||  |||
Db         17 CATCACCTGCCCATGG 2


RESULT 380
AR457668/c
LOCUS       AR457668                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1345 from patent US 6686188.
ACCESSION   AR457668
VERSION     AR457668.1  GI:42692725
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1345 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCT 1801
              |||||  |||||||||
Db         17 CCCATCTTTTCCTTCT 2


RESULT 381
AR457670/c
LOCUS       AR457670                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1347 from patent US 6686188.
ACCESSION   AR457670
VERSION     AR457670.1  GI:42692727
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1347 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTC 1800
              ||||||  ||||||||
Db         16 CCCCATCTTTTCCTTC 1


RESULT 382
AR457903/c
LOCUS       AR457903                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1580 from patent US 6686188.
ACCESSION   AR457903
VERSION     AR457903.1  GI:42692960
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
```

```
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1580 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
              ||||||||||| |||
Db         17 ATCCTTCTCCAGAGCA 2


RESULT 383
AR457904/c
LOCUS       AR457904                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1581 from patent US 6686188.
ACCESSION   AR457904
VERSION     AR457904.1  GI:42692961
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1581 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGCA 1586
              ||||||||||| |||
Db         16 ATCCTTCTCCAGAGCA 1


RESULT 384
AR463964/c
LOCUS       AR463964                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7641 from patent US 6686188.
ACCESSION   AR463964
VERSION     AR463964.1  GI:42699021
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7641 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1686 TAGTTGTTTCTCTAGC 1701
                | |||| |||||||||
Db         17 TTGTTGGTTCTCTAGC 2


RESULT 385
AR463967/c
LOCUS       AR463967                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7644 from patent US 6686188.
ACCESSION   AR463967
VERSION     AR463967.1  GI:42699024
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7644 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCTA 1699
              ||| |||| |||||||
Db         16 CTTTGTTGGTTCTCTA 1


RESULT 386
AR464280
LOCUS       AR464280                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7957 from patent US 6686188.
ACCESSION   AR464280
VERSION     AR464280.1  GI:42699337
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7957 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          2 GCCCTTGAGCAACAGA 17


RESULT 387
AR464281
LOCUS       AR464281                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7958 from patent US 6686188.
ACCESSION   AR464281
VERSION     AR464281.1  GI:42699338
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
```

```
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7958 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1895 GCCCTAGATCAACAGA 1910
              ||||| || |||||||
Db          1 GCCCTTGAGCAACAGA 16


RESULT 388
AX217003/c
LOCUS       AX217003                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2445 from Patent WO0159103.
ACCESSION   AX217003
VERSION     AX217003.1  GI:15527064
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2445 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTGA 1805
              || || ||||||||||
Db         16 TTTTTGCCTTCTCTGA 1


RESULT 389
AX217396/c
LOCUS       AX217396                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2838 from Patent WO0159103.
ACCESSION   AX217396
VERSION     AX217396.1  GI:15527457
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2838 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2024 CTGGTAGGAGGCAAAG 2039
              |||| || ||||||||
Db         16 CTGGAAGAAGGCAAAG 1


RESULT 390
AX217762/c
LOCUS       AX217762                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 3204 from Patent WO0159103.
ACCESSION   AX217762
VERSION     AX217762.1  GI:15527823
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 3204 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2024 CTGGTAGGAGGCAAAG 2039
              |||| || ||||||||
Db         17 CTGGAAGAAGGCAAAG 2


RESULT 391
AX325389
LOCUS       AX325389                  17 bp    DNA     linear   PAT 02-SEP-2002
DEFINITION  Sequence 1527 from Patent WO0192512.
ACCESSION   AX325389
VERSION     AX325389.1  GI:18096145
KEYWORDS    .
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
  TITLE     Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
  JOURNAL   Patent: WO 0192512-A 1527 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Arabidopsis thaliana"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:3702"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
```

```
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTA 2045
              ||||||||||| |||
Db          1 GGAGGCAAAGGAGCTA 16


RESULT 392
AX325390/c
LOCUS       AX325390                  17 bp    DNA     linear   PAT 02-SEP-2002
DEFINITION  Sequence 1528 from Patent WO0192512.
ACCESSION   AX325390
VERSION     AX325390.1  GI:18096146
KEYWORDS    .
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
  TITLE     Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
  JOURNAL   Patent: WO 0192512-A 1528 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Arabidopsis thaliana"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:3702"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2030 GGAGGCAAAGGTTCTA 2045
              ||||||||||| |||
Db         17 GGAGGCAAAGGAGCTA 2


RESULT 393
AX499861
LOCUS       AX499861                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1168 from Patent EP1229046.
ACCESSION   AX499861
VERSION     AX499861.1  GI:23382154
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1168 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
              ||  ||||||||||||
Db          2 TTGGCCTTGAAAAAAA 17


RESULT 394
AX499862
LOCUS       AX499862                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1169 from Patent EP1229046.
ACCESSION   AX499862
VERSION     AX499862.1  GI:23382155
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1169 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAA 1985
              ||  ||||||||||||
Db          1 TTGGCCTTGAAAAAAA 16


RESULT 395
AX615440
LOCUS       AX615440                  17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 247 from Patent EP1262488.
ACCESSION   AX615440
VERSION     AX615440.1  GI:28446486
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 247 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGGCA 2036
              || |||||||||| |
Db          2 CCACTGGTAGGAGGAA 17


RESULT 396
AX615441
LOCUS       AX615441                  17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 248 from Patent EP1262488.
ACCESSION   AX615441
VERSION     AX615441.1  GI:28446487
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
```

```
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 248 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGGCA 2036
              || |||||||||||  |
Db          1 CCACTGGTAGGAGGAA 16


RESULT 397
AX671912
LOCUS       AX671912                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 357 from Patent WO03004526.
ACCESSION   AX671912
VERSION     AX671912.1  GI:29330260
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 357 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              | ||  ||||||||||||
Db          2 ATCACTACCTTTTTTT 17


RESULT 398
AX701192/c
LOCUS       AX701192                  17 bp    DNA     linear   PAT 03-APR-2003
DEFINITION  Sequence 28 from Patent WO03012097.
ACCESSION   AX701192
VERSION     AX701192.1  GI:29536962
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Price,G.B. and Zannis-Hadjopoulos,M.
  TITLE     Methods of inhibiting dna replication
  JOURNAL   Patent: WO 03012097-A 28 13-FEB-2003;
            Price, Gerald B. (CA) ; Zannis-Hadjopoulos, Maria (CA)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCCC 1676
              || | ||||||||||||
Db         16 CTACGTCACCCGCCCC 1


RESULT 399
AX723941/c
LOCUS       AX723941                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1628 from Patent WO03025176.
ACCESSION   AX723941
VERSION     AX723941.1  GI:30503284
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 1628 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTT 1690
              |||| |||||||||  |
Db         17 CCTGAACTTCTTAGAT 2


RESULT 400
AX725421/c
LOCUS       AX725421                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3108 from Patent WO03025176.
ACCESSION   AX725421
VERSION     AX725421.1  GI:30504764
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3108 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1933 TGTTAAGGTAATGGTT 1948
              ||||||| |||||| |
Db         17 TGTTAAGCTAATGGAT 2
```

```
RESULT 401
AX726157
LOCUS       AX726157                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3844 from Patent WO03025176.
ACCESSION   AX726157
VERSION     AX726157.1  GI:30505500
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3844 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2040 GTTCTATCTGCTTAGC 2055
              | |||| |||||||||
Db          1 GATCTAGCTGCTTAGC 16


RESULT 402
AX726760
LOCUS       AX726760                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4447 from Patent WO03025176.
ACCESSION   AX726760
VERSION     AX726760.1  GI:30506103
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 4447 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              ||||| |||| |||||
Db          2 ATCTTCTAAAGACATT 17


RESULT 403
AX729543
LOCUS       AX729543                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1177 from Patent WO03025175.
ACCESSION   AX729543
VERSION     AX729543.1  GI:30508886
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 1177 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1710 ATCTCCTAACTTTGGA 1725
              ||||| || |||||||
Db          2 ATCTCTTACCTTTGGA 17


RESULT 404
AX730456
LOCUS       AX730456                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2090 from Patent WO03025175.
ACCESSION   AX730456
VERSION     AX730456.1  GI:30509799
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 2090 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATT 1843
              |||| ||||||| |||
Db          2 ATCTGTTAAATAAATT 17


RESULT 405
AX732299
LOCUS       AX732299                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3933 from Patent WO03025175.
ACCESSION   AX732299
VERSION     AX732299.1  GI:30511642
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
```

```
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 3933 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTG 1804
              || |||| ||||||||
Db          2 ATCCTTTGCTTCTCTG 17


RESULT 406
AX734059
LOCUS       AX734059                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5693 from Patent WO03025175.
ACCESSION   AX734059
VERSION     AX734059.1  GI:30513402
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5693 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTGA 1783
              | ||||||| |||||||
Db          2 ATCTTTTTGTTTTTGA 17


RESULT 407
AX734455
LOCUS       AX734455                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 45 from Patent WO03025177.
ACCESSION   AX734455
VERSION     AX734455.1  GI:30513732
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 45 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACA 1916
              |||||| ||| |||||
Db          1 GATCAATAGACCAACA 16


RESULT 408
AX736680
LOCUS       AX736680                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2270 from Patent WO03025177.
ACCESSION   AX736680
VERSION     AX736680.1  GI:30515968
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2270 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAGA 2012
              |||||| |||| ||||
Db          2 ATCTAGGTTCTCCAGA 17


RESULT 409
AX736697
LOCUS       AX736697                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2287 from Patent WO03025177.
ACCESSION   AX736697
VERSION     AX736697.1  GI:30515985
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2287 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
```

```
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAGA 2012
              |||| ||| |||||||
Db          2 ATCTTGCTCCTTCAGA 17


RESULT 410
AX738198
LOCUS       AX738198                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3788 from Patent WO03025177.
ACCESSION   AX738198
VERSION     AX738198.1  GI:30517486
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 3788 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTGA 1783
              | |||||| |||||||
Db          2 ATCTTTTTGTTTTTGA 17


RESULT 411
AX745237
LOCUS       AX745237                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1202 from Patent WO03031621.
ACCESSION   AX745237
VERSION     AX745237.1  GI:30723904
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1202 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAAC 1785
              |||| |||||||| ||
Db          2 CTTTATTTTTTTGCAC 17


RESULT 412
AX745238
LOCUS       AX745238                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1203 from Patent WO03031621.
ACCESSION   AX745238
VERSION     AX745238.1  GI:30723905
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1203 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAAC 1785
              |||| |||||||| ||
Db          1 CTTTATTTTTTTGCAC 16


RESULT 413
AX753720/c
LOCUS       AX753720                  17 bp    DNA     linear   PAT 23-JUN-2003
DEFINITION  Sequence 67 from Patent WO03037931.
ACCESSION   AX753720
VERSION     AX753720.1  GI:32166417
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M. and Phan,T.
  TITLE     Human angiomotin-like protein 1
  JOURNAL   Patent: WO 03037931-A 67 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              ||| |||| |||||||
Db         17 CTGTTTCTCCATCACC 2


RESULT 414
AX753721/c
LOCUS       AX753721                  17 bp    DNA     linear   PAT 23-JUN-2003
DEFINITION  Sequence 68 from Patent WO03037931.
ACCESSION   AX753721
VERSION     AX753721.1  GI:32166418
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M. and Phan,T.
```

```
  TITLE     Human angiomotin-like protein 1
  JOURNAL   Patent: WO 03037931-A 68 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              ||| |||| |||||||
Db         16 CTGTTTCTCCATCACC 1


RESULT 415
AX757427/c
LOCUS       AX757427                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 748 from Patent WO03040369.
ACCESSION   AX757427
VERSION     AX757427.1  GI:32252043
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 748 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1877 GAAATGTCAAATTGAT 1892
              ||||||| |||| |||
Db         17 GAAATGTAAAATAGAT 2


RESULT 416
AX758072
LOCUS       AX758072                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 1393 from Patent WO03040369.
ACCESSION   AX758072
VERSION     AX758072.1  GI:32252688
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 1393 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1627 ACCTACCTTACTATTT 1642
              | |||||| |||||||
Db          2 ATCTACCTCACTATTT 17


RESULT 417
AX759770
LOCUS       AX759770                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 3091 from Patent WO03040369.
ACCESSION   AX759770
VERSION     AX759770.1  GI:32254386
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 3091 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1665 ATCACCCGCCCCTGGA 1680
              ||| || |||||||||
Db          2 ATCCCCTGCCCCTGGA 17


RESULT 418
AX761192/c
LOCUS       AX761192                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4513 from Patent WO03040369.
ACCESSION   AX761192
VERSION     AX761192.1  GI:32255808
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4513 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1897 CCTAGATCAACAGATC 1912
```

```
              |||||| || ||||||
Db         16 CCTAGACCAGCAGATC 1


RESULT 419
AX762021
LOCUS       AX762021                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 5342 from Patent WO03040369.
ACCESSION   AX762021
VERSION     AX762021.1  GI:32256637
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 5342 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1732 ATCAGAAGGTGACAAG 1747
              |||||||||| || |||
Db          2 ATCAGAAGGAGAAAAG 17


RESULT 420
AX762707
LOCUS       AX762707                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 6028 from Patent WO03040369.
ACCESSION   AX762707
VERSION     AX762707.1  GI:32257323
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 6028 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTGA 1783
              | |||||| |||||||
Db          2 ATCTTTTTGTTTTTGA 17


RESULT 421
AX784027
LOCUS       AX784027                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 2358 from Patent WO03050284.
ACCESSION   AX784027
VERSION     AX784027.1  GI:32951876
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 2358 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1944 TGGTTGGTTTTTGTGT 1959
              ||||| | ||||||||
Db          2 TGGTTTGATTTTGTGT 17


RESULT 422
AX784028
LOCUS       AX784028                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 2359 from Patent WO03050284.
ACCESSION   AX784028
VERSION     AX784028.1  GI:32951877
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 2359 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1944 TGGTTGGTTTTTGTGT 1959
              ||||| | ||||||||
Db          1 TGGTTTGATTTTGTGT 16


RESULT 423
BD065823
LOCUS       BD065823                  17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065823
VERSION     BD065823.1  GI:22611426
KEYWORDS    JP 2001511000-A/458.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 458 07-AUG-2001;
```

```
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/458
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAAA 1990
              ||| ||||||| ||||
Db          1 CTTTAAAAAAACAAAA 16


RESULT 424
BD067705
LOCUS       BD067705                 17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067705
VERSION     BD067705.1  GI:22613308
KEYWORDS    JP 2001511003-A/545.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 545 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/545
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                       related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || |||||||| |||
Db          2 CAGTGGTTCTGCTTCA 17


RESULT 425
BD067706
LOCUS       BD067706                 17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067706
VERSION     BD067706.1  GI:22613309
KEYWORDS    JP 2001511003-A/546.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 546 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/546
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                       related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1653 CACTGGTTCTGCATCA 1668
              || |||||||| |||
Db          1 CAGTGGTTCTGCTTCA 16


RESULT 426
BD104999
LOCUS       BD104999                 17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Kit and method for determining HLA type.
ACCESSION   BD104999
VERSION     BD104999.1  GI:22650573
KEYWORDS    WO 0192572-A/1103.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
            Nishida,M.
  TITLE     Kit and method for determining HLA type
  JOURNAL   Patent: WO 0192572-A 1103 06-DEC-2001;
            NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
            KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
            NISHIDA
COMMENT     OS   Artificial Sequence
            PN   WO 0192572-A/1103
            PD   06-DEC-2001
            PF   01-JUN-2001 WO 2001JP004662
            PR   01-JUN-2000 JP 00P   164798
            PI   HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI  PI
            MATSUMURA,
```

```
           PI   SHOGO MORIYA,MICHIO NISHIDA
           PC   C12Q1/68,C12M1/00,C12N15/09,G01N33/53
           CC   Description of Artificial Sequence:capture
           FH   Key             Location/Qualifiers
           FT   source          1. .17
           FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 17;
  Best Local Similarity   87.5%;  Pred. No. 3.3e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1906 ACAGATCAACAATACC 1921
              ||||||| |||| |||
Db          1 ACAGATCTACAAGACC 16


RESULT 427
A51078
LOCUS       A51078                   18 bp    DNA     linear   PAT 10-MAR-1997
DEFINITION  Sequence 30 from Patent WO9616171.
ACCESSION   A51078
VERSION     A51078.1  GI:2303855
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Windass,J.D., Duncan,R.E., Baule,V.J. and Christian,P.D.
  TITLE     TOXINS FROM THE WASP BRACON HEBETOR
  JOURNAL   Patent: WO 9616171-A 30 30-MAY-1996;
            ZENECA LTD (GB)
COMMENT     Other publication AU 3877795 960617.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1862 ACACACTTAGCCATTG 1877
              ||||| ||||||| ||
Db          1 ACACAATTAGCCACTG 16


RESULT 428
AR042375
LOCUS       AR042375                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 15 from patent US 5811304.
ACCESSION   AR042375
VERSION     AR042375.1  GI:5962871
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Huang,S.
  TITLE     Nucleic acid molecules encoding retinoblastoma protein-interacting
            zinc finger proteins
  JOURNAL   Patent: US 5811304-A 15 22-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 429
AR052283
LOCUS       AR052283                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 15 from patent US 5831008.
ACCESSION   AR052283
VERSION     AR052283.1  GI:5975647
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Huang,S.
  TITLE     Retinoblastoma protein-interacting zinc finger proteins
  JOURNAL   Patent: US 5831008-A 15 03-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 430
AR071521/c
LOCUS       AR071521                 18 bp    DNA     linear   PAT 18-FEB-2000
DEFINITION  Sequence 21 from patent US 5911982.
ACCESSION   AR071521
VERSION     AR071521.1  GI:7222409
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Chao,Y.-C.
  TITLE     Hz-1 virus persistence-associated-gene 1 (PAG1) promoter uses
            therefor, and compositions containing same or products therefrom
  JOURNAL   Patent: US 5911982-A 21 15-JUN-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTTTT 1928
              | |||||||||| |||
Db         16 ACCAATACCTTTGTTT 1


RESULT 431
AR112245
LOCUS       AR112245                 18 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 13 from patent US 6130042.
ACCESSION   AR112245
VERSION     AR112245.1  GI:14092145
KEYWORDS    .
SOURCE      Unknown.
```

```
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Diehl,S.R., Schenkein,H.A. and Wang,Y.-F.
  TITLE     Compositions and methods for diagnosing periodontal disease
  JOURNAL   Patent: US 6130042-A 13 10-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1644 AAGAGCCTTCACTGGT 1659
              | |||||||||| ||||
Db          3 ATGAGCCTTCAATGGT 18


RESULT 432
CQ799869/c
LOCUS       CQ799869                 18 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 519 from Patent WO2004031413.
ACCESSION   CQ799869
VERSION     CQ799869.1  GI:46848816
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Nakamura,Y., Daigo,Y. and Nakatsuru,S.
  TITLE     Method for diagnosing non-small cell lung cancers
  JOURNAL   Patent: WO 2004031413-A 519 15-APR-2004;
            Oncotherapy Science, Inc. (JP); Japan as represented by the
            president of the university of Tokyo (JP)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Artificially synthesized S-oligonucleotide sequence
                     for antisense method"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAGA 2012
              |||||  |||||||||
Db         16 ATCTATTTCTTCAGA 1


RESULT 433
AR241194
LOCUS       AR241194                 18 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 15 from patent US 6468985.
ACCESSION   AR241194
VERSION     AR241194.1  GI:27286424
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Huang,S.
  TITLE     Retinoblastoma protein-interacting zinc finger proteins
  JOURNAL   Patent: US 6468985-A 15 22-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 434
AR262651
LOCUS       AR262651                 18 bp    DNA     linear   PAT 29-JAN-2003
DEFINITION  Sequence 15 from patent US 6323335.
ACCESSION   AR262651
VERSION     AR262651.1  GI:28074193
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Huang,S.
  TITLE     Retinoblastoma protein-interacting zinc finger proteins
  JOURNAL   Patent: US 6323335-A 15 27-NOV-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGAC 1591
              ||||||| |||||| |
Db          1 TCTCCACAGCACAGCC 16


RESULT 435
AR296134/c
LOCUS       AR296134                 18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 7869 from patent US 6537751.
ACCESSION   AR296134
VERSION     AR296134.1  GI:31683418
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 7869 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1939 GGTAATGGTTGGTTTT 1954
              ||||| ||||||| ||
Db         18 GGTAAGGGTTGGTGTT 3


RESULT 436
AR299795
LOCUS       AR299795                 18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 11530 from patent US 6537751.
ACCESSION   AR299795
VERSION     AR299795.1  GI:31687079
KEYWORDS    .
SOURCE      Unknown.
```

```
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 11530 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTTGTGTC 1960
              ||||||||||||  ||
Db          3 GGTTGGTTTTTGCCTC 18


RESULT 437
AX599276
LOCUS       AX599276                  18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 616 from Patent WO02077272.
ACCESSION   AX599276
VERSION     AX599276.1  GI:28399418
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 616 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDH3"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1808 GTGGTGCTATAAGTTT 1823
              ||||||  | |||||||
Db          2 GTGGTGGTGTAAGTTT 17


RESULT 438
AX599369/c
LOCUS       AX599369                  18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 709 from Patent WO02077272.
ACCESSION   AX599369
VERSION     AX599369.1  GI:28399513
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 709 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN2a"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              |||||||| ||| ||
Db         18 TTTAAATACGTTCACT 3


RESULT 439
AX599828/c
LOCUS       AX599828                  18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 1168 from Patent WO02077272.
ACCESSION   AX599828
VERSION     AX599828.1  GI:28399976
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 1168 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDC25A"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1859 CCCACACACTTAGCCA 1874
              ||||| |||||| |||
Db         16 CCCACCCACTTACCCA 1


RESULT 440
AX599830
LOCUS       AX599830                  18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 1170 from Patent WO02077272.
ACCESSION   AX599830
VERSION     AX599830.1  GI:28399978
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 1170 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
```

```
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDC25A"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1859 CCCACACACTTAGCCA 1874
              ||||| |||||| |||
Db          3 CCCACCCACTTACCCA 18


RESULT 441
AX705541/c
LOCUS       AX705541                  18 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 210 from Patent WO03014388.
ACCESSION   AX705541
VERSION     AX705541.1  GI:29562206
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Distler,J., Model,F. and Taubert,H.
  TITLE     Method and nucleic acids for the analysis of colon cancer
  JOURNAL   Patent: WO 03014388-A 210 20-FEB-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for p16"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||| ||| ||
Db         18 TTTAAATACGTTCACT 3


RESULT 442
AX705543
LOCUS       AX705543                  18 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 212 from Patent WO03014388.
ACCESSION   AX705543
VERSION     AX705543.1  GI:29562208
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Distler,J., Model,F. and Taubert,H.
  TITLE     Method and nucleic acids for the analysis of colon cancer
  JOURNAL   Patent: WO 03014388-A 212 20-FEB-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for p16"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||| ||| ||
Db          1 TTTAAATACGTTCACT 16


RESULT 443
AX767708
LOCUS       AX767708                  18 bp    DNA     linear   PAT 02-JUL-2003
DEFINITION  Sequence 356 from Patent WO03044226.
ACCESSION   AX767708
VERSION     AX767708.1  GI:32436313
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Caldwell,C., Genc,B., Becker,E., Maier,S. and
            Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lymphoid cell
            proliferative disorder
  JOURNAL   Patent: WO 03044226-A 356 30-MAY-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDH3"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1808 GTGGTGCTATAAGTTT 1823
              |||||| | |||||||
Db          2 GTGGTGGTGTAAGTTT 17


RESULT 444
AX796233/c
LOCUS       AX796233                  18 bp    DNA     linear   PAT 04-OCT-2003
DEFINITION  Sequence 576 from Patent WO03052135.
ACCESSION   AX796233
VERSION     AX796233.1  GI:37516899
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Field,J.K., Genc,B., Liloglou,T., Lipscher,E., Maier,S.
            and Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lung cell
            proliferative disorder
  JOURNAL   Patent: WO 03052135-A 576 26-JUN-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN2a"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||| ||| ||
Db         18 TTTAAATACGTTCACT 3


RESULT 445
AX822220/c
LOCUS       AX822220                  18 bp    DNA     linear   PAT 11-DEC-2003
```

```
DEFINITION  Sequence 112 from Patent EP1340818.
ACCESSION   AX822220
VERSION     AX822220.1  GI:39748848
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: EP 1340818-A 112 03-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2044 TATCTGCTTAGCAACT 2059
              ||||||| |||||||
Db         16 TATCTGCGGAGCAACT 1


RESULT 446
AX822735/c
LOCUS       AX822735                 18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 627 from Patent EP1340818.
ACCESSION   AX822735
VERSION     AX822735.1  GI:39749371
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: EP 1340818-A 627 03-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN2a"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||| ||| ||
Db         18 TTTAAATACGTTCACT 3


RESULT 447
AX825860/c
LOCUS       AX825860                 18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 112 from Patent WO03072821.
ACCESSION   AX825860
VERSION     AX825860.1  GI:39751374
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: WO 03072821-A 112 04-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2044 TATCTGCTTAGCAACT 2059
              ||||||| |||||||
Db         16 TATCTGCGGAGCAACT 1


RESULT 448
AX826375/c
LOCUS       AX826375                 18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 627 from Patent WO03072821.
ACCESSION   AX826375
VERSION     AX826375.1  GI:39751889
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: WO 03072821-A 627 04-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDKN2a"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1832 TTTAAATACATTCCCT 1847
              ||||||||| ||| ||
Db         18 TTTAAATACGTTCACT 3


RESULT 449
BD167823/c
LOCUS       BD167823                 18 bp    DNA     linear   PAT 17-JAN-2003
DEFINITION  Method of identifying target gene of transcriptional factor and
            method of isolating the same.
ACCESSION   BD167823
VERSION     BD167823.1  GI:27873635
KEYWORDS    WO 0229043-A/8.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Oda,T. and Muramatsu,M.
  TITLE     Method of identifying target gene of transcriptional factor and
            method of isolating the same
  JOURNAL   Patent: WO 0229043-A 8 11-APR-2002;
            HELIX RESEARCH INSTITUTE,TSUKASA ODA,MASAAKI MURAMATSU
```

```
COMMENT     OS   Artificial Sequence
            PN   WO 0229043-A/8
            PD   11-APR-2002
            PF   28-SEP-2001 WO 2001JP008576
            PR   02-OCT-2000 JP 00P   302100
            PI   TSUKASA ODA,MASAAKI MURAMATSU
            PC   C12N15/09,C12Q1/68,C12N5/10
            CC   Description of Artificial Sequence:Artificially Synthesized CC
              Primer Sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 18;
  Best Local Similarity   87.5%;  Pred. No. 3.5e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1587 CAGACTGGGAACCCCT 1602
              |||||||||| || ||
Db         17 CAGACTGGGAGCCTCT 2


RESULT 450
CQ801869
LOCUS       CQ801869                  19 bp    DNA     linear   PAT 05-MAY-2004
DEFINITION  Sequence 185 from Patent WO2004033720.
ACCESSION   CQ801869
VERSION     CQ801869.1  GI:47058450
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Schrenzel,J., Francois,P., Charbonnier,Y., Jacquet,J.G.,
            Utinger,D., Kresbach,G.M., Abel,A. and Ehrat,M.
  TITLE     Analytical chip for the detection of 16s-rrna from clinically
            relevant bacteria and analytical method based thereon
  JOURNAL   Patent: WO 2004033720-A 185 22-APR-2004;
            Hopitaux Universitaires de Geneve (CH)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Probe for Haemophilus influenzae"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1879 AATGTCAAATTGATGT 1894
              || ||||| |||||||
Db          3 AACGTCAATTTGATGT 18


RESULT 451
CQ801892
LOCUS       CQ801892                  19 bp    DNA     linear   PAT 05-MAY-2004
DEFINITION  Sequence 209 from Patent WO2004033720.
ACCESSION   CQ801892
VERSION     CQ801892.1  GI:47058473
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Schrenzel,J., Francois,P., Charbonnier,Y., Jacquet,J.G.,
            Utinger,D., Kresbach,G.M., Abel,A. and Ehrat,M.
  TITLE     Analytical chip for the detection of 16s-rrna from clinically
            relevant bacteria and analytical method based thereon
  JOURNAL   Patent: WO 2004033720-A 209 22-APR-2004;
            Hopitaux Universitaires de Geneve (CH)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Probe for Eikenella corrodens"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2055 CAACTAGTTAATAAGT 2070
              ||||||| |||| |||
Db          1 CAACTAGCTAATCAGT 16


RESULT 452
AR279193/c
LOCUS       AR279193                  19 bp    DNA     linear   PAT 10-APR-2003
DEFINITION  Sequence 337 from patent US 6514694.
ACCESSION   AR279193
VERSION     AR279193.1  GI:29713836
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Milhausen,M.J.
  TITLE     Methods for the detection of encysted parasites
  JOURNAL   Patent: US 6514694-A 337 04-FEB-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1648 GCCTTCACTGGTTCTG 1663
              ||||| |||| |||||
Db         19 GCCTTGACTGCTTCTG 4


RESULT 453
AR292312
LOCUS       AR292312                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4047 from patent US 6537751.
ACCESSION   AR292312
VERSION     AR292312.1  GI:31679596
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 4047 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1532 GAAAGGTTAGGAGAGT 1547
```

```
              ||||| |||||||||
Db          3 GAAAGAATAGGAGAGT 18


RESULT 454
AR299444/c
LOCUS       AR299444                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 11179 from patent US 6537751.
ACCESSION   AR299444
VERSION     AR299444.1  GI:31686728
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 11179 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGG 1555
              ||||||| || |||||
Db         18 AGGAGAGAAGAGAAGG 3


RESULT 455
AR411295
LOCUS       AR411295                  19 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 52 from patent US 6635751.
ACCESSION   AR411295
VERSION     AR411295.1  GI:40163382
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Haze,K., Yoshida,H., Mori,K., Yanagi,H. and Yura,T.
  TITLE     Isolated nucleic acids encoding activated and suppressive forms of
            ATF6
  JOURNAL   Patent: US 6635751-A 52 21-OCT-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTC 1802
              ||||||||| || |||
Db          1 CCATTCTTTGCTGCTC 16


RESULT 456
AX130338
LOCUS       AX130338                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1556 from Patent WO0130362.
ACCESSION   AX130338
VERSION     AX130338.1  GI:14136643
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1556 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin A2 ribozyme binding site"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1659 TTCTGCATCACCCGCC 1674
              |||||||||| | |||
Db          2 TTCTGCATCAGCAGCC 17


RESULT 457
AX130772/c
LOCUS       AX130772                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1990 from Patent WO0130362.
ACCESSION   AX130772
VERSION     AX130772.1  GI:14137077
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1990 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin D3 ribozyme binding site"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAGAGTT 1622
              ||| |||||||||| ||
Db         19 GCCAGGGGGAAGACTT 4


RESULT 458
AX250360/c
LOCUS       AX250360                  19 bp    DNA     linear   PAT 05-OCT-2001
DEFINITION  Sequence 28 from Patent WO0168682.
ACCESSION   AX250360
VERSION     AX250360.1  GI:15984127
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Reinl,S.J. and Turpen,T.H.
  TITLE     Self antigen vaccines for treating b cell lymphomas and other
            cancers
  JOURNAL   Patent: WO 0168682-A 28 20-SEP-2001;
            Large Scale Biology Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .19
```

```
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="primer"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACC 1670
              |||| |||||| ||||
Db         18 CTGGGTCTGCAACACC 3


RESULT 459
AX643289/c
LOCUS       AX643289                 19 bp    DNA     linear   PAT 24-FEB-2003
DEFINITION  Sequence 155 from Patent WO02099099.
ACCESSION   AX643289
VERSION     AX643289.1  GI:28550911
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Penger,A., Sprenger,R. and Brinkmann,U.
  TITLE     Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8
            and their use in diagnostic and therapeutic applications
  JOURNAL   Patent: WO 02099099-A 155 12-DEC-2002;
            Epidauros Biotechnologie AG (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="m=a or c"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTCAGTG 1934
              |||| ||||:| | ||||
Db         19 ATACTTTTTKTCTGAGTG 2


RESULT 460
AX643292
LOCUS       AX643292                 19 bp    DNA     linear   PAT 24-FEB-2003
DEFINITION  Sequence 158 from Patent WO02099099.
ACCESSION   AX643292
VERSION     AX643292.1  GI:28550915
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Penger,A., Sprenger,R. and Brinkmann,U.
  TITLE     Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8
            and their use in diagnostic and therapeutic applications
  JOURNAL   Patent: WO 02099099-A 158 12-DEC-2002;
            Epidauros Biotechnologie AG (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="k=g or t"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   77.8%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1917 ATACCTTTTTTTCAGTG 1934
              |||| ||||:| | ||||
Db          1 ATACTTTTTKTCTGAGTG 18


RESULT 461
AX804547
LOCUS       AX804547                 19 bp    DNA     linear   PAT 25-NOV-2003
DEFINITION  Sequence 715 from Patent WO03060160.
ACCESSION   AX804547
VERSION     AX804547.1  GI:38521688
KEYWORDS    .
SOURCE      Oreochromis niloticus (Nile tilapia)
  ORGANISM  Oreochromis niloticus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
            Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
            Labroidei; Cichlidae; Oreochromis.
REFERENCE   1
  AUTHORS   Lie,Y., Slettan,A., Hoeyum,M. and Lingaas,F.
  TITLE     Verification of food origin based on nucleic acid pattern
            recognition
  JOURNAL   Patent: WO 03060160-A 715 24-JUL-2003;
            Genomar ASA (NO)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Oreochromis niloticus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:8128"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAACA 1559
              ||| || |||||||||
Db          4 GAGCAGAGAAGGAACA 19


RESULT 462
BD087891/c
LOCUS       BD087891                 19 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD087891
VERSION     BD087891.1  GI:22633501
KEYWORDS    JP 2001321190-A/135.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 135 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/135
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
```

```
  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTG 1782
              ||||||||||  || ||
Db         17 AAGCTTTTTTGTTCTG 2


RESULT 463
AB068498/c
LOCUS       AB068498                 19 bp    DNA     linear   SYN 21-MAY-2003
DEFINITION  Synthetic construct DNA, forward primer for human STS sts-A004P01
            at 1p36.
ACCESSION   AB068498
VERSION     AB068498.1  GI:15129302
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
            Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
            Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
            and Soeda,E.
  TITLE     A BAC-based STS-content map spanning a 35-Mb region of human
            chromosome 1p35-p36
  JOURNAL   Genomics 74 (1), 55-70 (2001)
  MEDLINE   21269192
   PUBMED   11374902
REFERENCE   2  (bases 1 to 19)
  AUTHORS   Horii,A.
  TITLE     Direct Submission
  JOURNAL   Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
            Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
            Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
            Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
     misc_feature    1. .19
                     /note="forward primer for human STS sts-A004P01 at 1p36
                     sts-A004P01 obtained from clones B182I15, B196P5, B235M4,
                     B350L18, B367B2, B378P15, Human BAC library RPCI-11"

  Query Match             2.3%;  Score 12.8;  DB 1;  Length 19;
  Best Local Similarity   87.5%;  Pred. No. 3.7e+02;
  Matches   14;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTG 1782
              ||||||||||  || ||
Db         17 AAGCTTTTTTGTTCTG 2


RESULT 464
AR065153/c
LOCUS       AR065153                 19 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 40 from patent US 5849488.
ACCESSION   AR065153
VERSION     AR065153.1  GI:5995369
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Alatossava,J.Tapani., Forsman,P.Tuulikki. and
            Tilsala-Timisjarvi,A.Kyllikki.
  TITLE     DNA-sequence-based diagnosis of mastitis from a milk sample
  JOURNAL   Patent: US 5849488-A 40 15-DEC-1998;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAACCCCT 1602
              ||||  ||||||||  |||
Db         19 GCACTTACTGGGAATTCCT 1


RESULT 465
AR093204/c
LOCUS       AR093204                 19 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 8 from patent US 5998602.
ACCESSION   AR093204
VERSION     AR093204.1  GI:10019955
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Torrence,P.F., Silverman,R.Hugh., Cirino,N.Mario., Li,G. and
            Xiao,W.
  TITLE     RNase L activators and antisense oligonucleotides effective to
            treat RSV infections
  JOURNAL   Patent: US 5998602-A 8 07-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1732 ATCAGAAGGTGACAAGTAC 1750
              ||  ||||  |||  ||||||
Db         19 ATAAGAATTTGATAAGTAC 1


RESULT 466
CQ795418/c
LOCUS       CQ795418                 19 bp    DNA     linear   PAT 19-APR-2004
DEFINITION  Sequence 6 from Patent WO2004024927.
ACCESSION   CQ795418
VERSION     CQ795418.1  GI:46407508
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Gorr,G., Launhardt,H. and Berg,B.
  TITLE     Protein production method
  JOURNAL   Patent: WO 2004024927-A 6 25-MAR-2004;
            Greenovation Biotech GmbH (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: 3'-primer
                     To32-300-2-AS, indicated on page 17, lines 3-4"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACACACT 1868
              ||||||  ||  |  ||||||
Db         19 GCCAACTGAGCTGCACACT 1
```

```
RESULT 467
AR297167/c
LOCUS       AR297167                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 8902 from patent US 6537751.
ACCESSION   AR297167
VERSION     AR297167.1  GI:31684451
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 8902 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGTTGTT 1693
              ||| ||||| |  ||||||
Db         19 CCTTGACTTATGTGTTGTT 1


RESULT 468
AR297401/c
LOCUS       AR297401                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 9136 from patent US 6537751.
ACCESSION   AR297401
VERSION     AR297401.1  GI:31684685
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 9136 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1859 CCCACACACTTAGCCATTG 1877
              || || ||||| ||| |||
Db         19 CCTACTCACTTTGCCCTTG 1


RESULT 469
AX031263
LOCUS       AX031263                  19 bp    DNA     linear   PAT 20-SEP-2000
DEFINITION  Sequence 2 from Patent WO9914314.
ACCESSION   AX031263
VERSION     AX031263.1  GI:10278596
KEYWORDS    .
SOURCE      Aegilops tauschii
  ORGANISM  Aegilops tauschii
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Pooideae; Triticeae; Aegilops.
REFERENCE   1
  AUTHORS   Li,Z., Morell,M. and Rahman,S.
  TITLE     Regulation of gene expression in plants
  JOURNAL   Patent: WO 9914314-A 2 25-MAR-1999;
            GOODMAN FIELDER LTD (AU) ; LI ZHONGYI (AU) ; MORELL MATTHEW (AU) ;
            RAHMAN SADEQUR (AU) ; UNIV AUSTRALIAN (AU) ; COMMW SCIENT IND RES
            ORG (AU) ; GROUPE LIMAGRAIN PACIFIC PTY L (AU)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Aegilops tauschii"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:37682"
                     /tissue_type="ENDOSPERM"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1838 TACATTCCCTGGGCCAACA 1856
              |||||| ||| | ||| ||
Db          1 TACATTTCCTTGTCCATCA 19


RESULT 470
AX130173
LOCUS       AX130173                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1391 from Patent WO0130362.
ACCESSION   AX130173
VERSION     AX130173.1  GI:14136478
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1391 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cdk-we-hu ribozyme binding site"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAAGA 1987
              ||| || || | |||||||
Db          1 ATTCACTTTTACAAAAAGA 19


RESULT 471
AX130174
LOCUS       AX130174                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 1392 from Patent WO0130362.
ACCESSION   AX130174
VERSION     AX130174.1  GI:14136479
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 1392 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
```

```
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cdk-we-hu ribozyme binding site"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1970 TTTACCTTGAAAAAAAGAA 1988
              || || || | ||||||||
Db          1 TTCACTTTTACAAAAAGAA 19


RESULT 472
AX132204
LOCUS       AX132204                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 3422 from Patent WO0130362.
ACCESSION   AX132204
VERSION     AX132204.1  GI:14138509
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 3422 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin B1 ribozyme binding site"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       2038 AGGTTCTATCTGCTTAGCA 2056
              |||  || | |||||||||
Db          1 AGGAGCTTTTTGCTTAGCA 19


RESULT 473
AX230255
LOCUS       AX230255                  19 bp    DNA     linear   PAT 11-SEP-2001
DEFINITION  Sequence 142 from Patent WO0162797.
ACCESSION   AX230255
VERSION     AX230255.1  GI:15592214
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Vogeli,G., Wood,L.S., Parodi,L.A. and Lind,P.
  TITLE     Novel g protein-coupled receptors
  JOURNAL   Patent: WO 0162797-A 142 30-AUG-2001;
            PHARMACIA & UPJOHN COMPANY (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1649 CCTTCACTGGTTCTGCATC 1667
              ||| |||| || || ||||
Db          1 CCTCCACTTGTGCTTCATC 19


RESULT 474
AX353501
LOCUS       AX353501                  19 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 33 from Patent WO0204636.
ACCESSION   AX353501
VERSION     AX353501.1  GI:18618576
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   van Roy,F., Goossens,S., Janssens,B. and Vanpoucke,G.
  TITLE     Novel _g(a) expressed in heart and testis
  JOURNAL   Patent: WO 0204636-A 33 17-JAN-2002;
            Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="splice acceptor 13"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAACCCCA 1789
              || ||||| | | ||||||
Db          1 TTCTTTTTATAGGACCCCA 19


RESULT 475
AX801965
LOCUS       AX801965                  19 bp    DNA     linear   PAT 24-NOV-2003
DEFINITION  Sequence 104 from Patent WO03057913.
ACCESSION   AX801965
VERSION     AX801965.1  GI:38500889
KEYWORDS    .
SOURCE      Equus caballus (horse)
  ORGANISM  Equus caballus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Perissodactyla; Equidae; Equus.
REFERENCE   1
  AUTHORS   Mabilat,C., Desvarenne,S., Babola,O., Lacroix,B. and bello Pigem,N.
  TITLE     Method for the detection and/or identification of the original
            animal species in animal matter contained in a sample
  JOURNAL   Patent: WO 03057913-A 104 17-JUL-2003;
            BIO MERIEUX (FR)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Equus caballus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9796"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1751 TGGCTCTTTATTCATTAAG 1769
              || ||||||||||   ||
Db          1 TGCCTCTTTATTCACGTAG 19


RESULT 476
AX826874/c
LOCUS       AX826874                  19 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 96 from Patent WO03072823.
```

```
ACCESSION   AX826874
VERSION     AX826874.1  GI:39752388
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Grandchamp,B. and Mentre,F.
  TITLE     Method for in vitro detection of cancers by highlighting allelic
            imbalances in insertion/deletion markers
  JOURNAL   Patent: WO 03072823-A 96 04-SEP-2003;
            ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="SEQUENCE DESCRIPTION artificielle: amorce"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCTCCTG 1606
              | |||||  || |||||||
Db         19 AAACTGGCCACACCTCCTG 1

RESULT 477
BD082149
LOCUS       BD082149                  19 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Reagents and methods useful for detecting diseases of the lung.
ACCESSION   BD082149
VERSION     BD082149.1  GI:22627759
KEYWORDS    JP 2001522225-A/13.
SOURCE      Zea mays
  ORGANISM  Zea mays
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
            clade; Panicoideae; Andropogoneae; Zea.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Medel,P.A.B., Cohen,M., Colpitts,T.L., Friedman,P.N., Gordon,J.,
            Granados,E.N., Hodges,S.C., Klass,M.R., Kratochvil,J.D., Rapp,L.R.,
            Russell,J.C. and Stroupe,S.D.
  TITLE     Reagents and methods useful for detecting diseases of the lung
  JOURNAL   Patent: JP 2001522225-A 13 13-NOV-2001;
            ABBOTT LABORATORIES
COMMENT     PN   JP 2001522225-A/13
            PD   13-NOV-2001
            PF   30-JAN-1998 JP 1998533078
            PR   31-JAN-1997 US    08/791710
            PI   PATRICIA A BILLING MEDEL,MAURICE COHEN,TRACEY L COLPITTS,PAULA

            PI   N FRIEDMAN,
            PI   JULIAN GORDON,EDWARD N GRANADOS,STEVEN C HODGES,MICHAEL R  PI
             KLASS,
            PI   JON D KRATOCHVIL,LISA ROBERTS RAPP,JOHN C RUSSELL,STEPHEN D
            PI   STROUPE
            PC   C12N15/63,C12N5/10,C12Q1/68,C07K14/47//C07K16/30,G01N33/574 CC
              Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Zea mays"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:4577"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1851 CCAACAGACCCACACACTT 1869
              ||| |  | ||||||||||
Db          1 CCAGCTCAGCCACACACTT 19

RESULT 478
BD089946
LOCUS       BD089946                  19 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD089946
VERSION     BD089946.1  GI:22635556
KEYWORDS    JP 2001321190-A/2190.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 2190 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/2190
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.3%;  Score 12.6;  DB 1;  Length 19;
  Best Local Similarity   78.9%;  Pred. No. 4e+02;
  Matches   15;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy       1556 AACAGGACTGCAAAAATCC 1574
              |||||||  ||||||  ||
Db          1 AACAGGAAGGCAAAATGCC 19

RESULT 479
E15991
LOCUS       E15991                    14 bp    DNA     linear   PAT 28-JUL-1999
DEFINITION  Oligonucleotide which modulates expression,production or reception
            of hepatocyte growth factor or expression of c-Met.
ACCESSION   E15991
VERSION     E15991.1  GI:5710674
KEYWORDS    JP 1998127286-A/16.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Ishikawa,T., Shigematsu,T. and Yamamoto,A.
  TITLE     OLIGONUCLEOTIDE FOR SUPPRESSING PRODUCTION OF HGF
  JOURNAL   Patent: JP 1998127286-A 16 19-MAY-1998;
            TERUMO CORP
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1998127286-A/16
            PD   19-MAY-1998
            PF   01-NOV-1996 JP 1996291499
            PI   ISHIKAWA TETSUYA, SHIGEMATSU TAKASHI, YAMAMOTO AKIHIRO PC
            C12N15/09,A61K31/70,A61K31/70,C07H21/04;
            CC   strandedness: Single;
            CC   topology: Linear;
            CC   hypothetical: No;
```

```
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .14
            FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 3.2e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAA 1557
              ||| ||||||||||
Db          1 GAGGAGGGAAGGAA 14


RESULT 480
E15992/c
LOCUS       E15992                    14 bp    DNA     linear   PAT 28-JUL-1999
DEFINITION  Oligonucleotide which modulates expression,production or reception
            of hepatocyte growth factor or expression of c-Met.
ACCESSION   E15992
VERSION     E15992.1  GI:5710675
KEYWORDS    JP 1998127286-A/17.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Ishikawa,T., Shigematsu,T. and Yamamoto,A.
  TITLE     OLIGONUCLEOTIDE FOR SUPPRESSING PRODUCTION OF HGF
  JOURNAL   Patent: JP 1998127286-A 17 19-MAY-1998;
            TERUMO CORP
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1998127286-A/17
            PD   19-MAY-1998
            PF   01-NOV-1996 JP 1996291499
            PI   ISHIKAWA TETSUYA, SHIGEMATSU TAKASHI, YAMAMOTO AKIHIRO PC
            C12N15/09,A61K31/70,A61K31/70,C07H21/04;
            CC   strandedness: Single;
            CC   topology: Linear;
            CC   hypothetical: No;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .14
            FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 14;
  Best Local Similarity   92.9%;  Pred. No. 3.2e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAA 1557
              ||| ||||||||||
Db         14 GAGGAGGGAAGGAA 1


RESULT 481
A57014
LOCUS       A57014                    15 bp    DNA     linear   PAT 03-MAR-1998
DEFINITION  Sequence 9 from Patent WO9629399.
ACCESSION   A57014
VERSION     A57014.1  GI:3712997
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Pirotzky,E. and Colote,S.
  TITLE     ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING HELICOBACTER PYLORI
            ACTIVITY
  JOURNAL   Patent: WO 9629399-A 9 26-SEP-1996;
            SOD CONSEILS RECH APPLIC (FR)
COMMENT     Other publication AU 5149796 961008.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 TTGGACCTATTATC 1734
              ||||| ||||||||
Db          1 TTGGAACTATTATC 14


RESULT 482
A57026
LOCUS       A57026                    15 bp    DNA     linear   PAT 03-MAR-1998
DEFINITION  Sequence 21 from Patent WO9629399.
ACCESSION   A57026
VERSION     A57026.1  GI:3713009
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Pirotzky,E. and Colote,S.
  TITLE     ANTISENSE OLIGONUCLEOTIDES FOR INHIBITING HELICOBACTER PYLORI
            ACTIVITY
  JOURNAL   Patent: WO 9629399-A 21 26-SEP-1996;
            SOD CONSEILS RECH APPLIC (FR)
COMMENT     Other publication AU 5149796 961008.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 TTGGACCTATTATC 1734
              ||||| ||||||||
Db          1 TTGGAACTATTATC 14


RESULT 483
AR084006
LOCUS       AR084006                  15 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 9 from patent US 5977340.
ACCESSION   AR084006
VERSION     AR084006.1  GI:10010777
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Pirotzky,E. and Colote,S.
  TITLE     Antisense oligonucleotides for inhibiting helicobacter pylori
            activity
  JOURNAL   Patent: US 5977340-A 9 02-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
```

```
                    /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 TTGGACCTATTATC 1734
             ||||| ||||||||
Db          1 TTGGAACTATTATC 14


RESULT 484
AR084018
LOCUS       AR084018                 15 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 21 from patent US 5977340.
ACCESSION   AR084018
VERSION     AR084018.1  GI:10010789
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Pirotzky,E. and Colote,S.
  TITLE     Antisense oligonucleotides for inhibiting helicobacter pylori
            activity
  JOURNAL   Patent: US 5977340-A 21 02-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1721 TTGGACCTATTATC 1734
             ||||| ||||||||
Db          1 TTGGAACTATTATC 14


RESULT 485
I77875/c
LOCUS       I77875                   15 bp    DNA     linear   PAT 03-APR-1998
DEFINITION  Sequence 582 from patent US 5693532.
ACCESSION   I77875
VERSION     I77875.1  GI:3014029
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
  TITLE     Respiratory syncytial virus ribozymes
  JOURNAL   Patent: US 5693532-A 582 02-DEC-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTT 1576
             ||||||||||||| |
Db         15 CTGCAAAAATCCCT 2


RESULT 486
I77876/c
LOCUS       I77876                   15 bp    DNA     linear   PAT 03-APR-1998
DEFINITION  Sequence 583 from patent US 5693532.
ACCESSION   I77876
VERSION     I77876.1  GI:3014030
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
  TITLE     Respiratory syncytial virus ribozymes
  JOURNAL   Patent: US 5693532-A 583 02-DEC-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTT 1576
             ||||||||||||| |
Db         14 CTGCAAAAATCCCT 1


RESULT 487
AX638372/c
LOCUS       AX638372                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 5511 from Patent EP1260586.
ACCESSION   AX638372
VERSION     AX638372.1  GI:28473986
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 5511 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTT 1576
             ||||||||||||| |
Db         15 CTGCAAAAATCCCT 2


RESULT 488
AX638374/c
LOCUS       AX638374                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 5513 from Patent EP1260586.
ACCESSION   AX638374
VERSION     AX638374.1  GI:28473988
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
```

```
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 5513 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="unidentified"
                      /mol_type="unassigned RNA"
                      /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTT 1576
              ||||||||||||  |
Db         14 CTGCAAAAATCCCT 1


RESULT 489
ATH551615/c
LOCUS       ATH551615                 15 bp    DNA     linear   PLN 29-MAR-2003
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            298A05.
ACCESSION   AJ551615
VERSION     AJ551615.1  GI:29367748
KEYWORDS    left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 15)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES              Location/Qualifiers
     source           1. .15
                      /organism="Arabidopsis thaliana"
                      /mol_type="genomic DNA"
                      /cultivar="Wassillewskija"
                      /db_xref="taxon:3702"
                      /clone="298A05"
                      /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature     1. .15
                      /note="T-DNA flanking sequence
                      left border"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 15;
  Best Local Similarity   92.9%;  Pred. No. 3.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCC 1580
              |||||||  ||||||
Db         14 AAAAATCTTTCTCC 1


RESULT 490
BD225192
LOCUS       BD225192                  16 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Human papilloma virus inhibition by antisense oligonucleotides.
ACCESSION   BD225192
VERSION     BD225192.1  GI:33034962
KEYWORDS    JP 2002509692-A/5.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Dipaolo,J. and Salas,L.A.
  TITLE     Human papilloma virus inhibition by antisense oligonucleotides
  JOURNAL   Patent: JP 2002509692-A 5 02-APR-2002;
            THE UNITED STATES OF AMERICA
COMMENT     OS   Human papilloma virus 16
            PN   JP 2002509692-A/5
            PD   02-APR-2002
            PF   03-SEP-1998 JP 2000510858
            PR   05-SEP-1997 US    08/929140
            PI   JOSEPH DIPAOLO,LUIS ALVAREZ SALAS
            PC
            C12N15/09,A61K31/7125,A61K48/00,A61P35/00//C07K14/025,C12N9/00, PC
             C12N15/00
            CC   Human papilloma virus inhibition by antisense oligonucleotides
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Human papilloma virus 16'.
FEATURES              Location/Qualifiers
     source           1. .16
                      /organism="unidentified"
                      /mol_type="genomic RNA"
                      /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCA 2017
              |||||||||||  ||
Db          1 TTCTTCAGAGAACA 14


RESULT 491
BD225194
LOCUS       BD225194                  16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Human papilloma virus inhibition by antisense oligonucleotides.
ACCESSION   BD225194
VERSION     BD225194.1  GI:33034964
KEYWORDS    JP 2002509692-A/7.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Dipaolo,J. and Salas,L.A.
  TITLE     Human papilloma virus inhibition by antisense oligonucleotides
  JOURNAL   Patent: JP 2002509692-A 7 02-APR-2002;
            THE UNITED STATES OF AMERICA
COMMENT     OS   Human papilloma virus 16
            PN   JP 2002509692-A/7
            PD   02-APR-2002
            PF   03-SEP-1998 JP 2000510858
            PR   05-SEP-1997 US    08/929140
            PI   JOSEPH DIPAOLO,LUIS ALVAREZ SALAS
            PC
            C12N15/09,A61K31/7125,A61K48/00,A61P35/00//C07K14/025,C12N9/00, PC
             C12N15/00
```

```
            CC   Human papilloma virus inhibition by antisense oligonucleotides
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Human papilloma virus 16'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCA 2017
              ||||||||||| ||
Db          1 TTCTTCAGAGAACA 14


RESULT 492
BD233093/c
LOCUS       BD233093                 16 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Method of detecting mutation selected by drug in HIV protease gene.
ACCESSION   BD233093
VERSION     BD233093.1  GI:33042863
KEYWORDS    JP 2002518065-A/189.
SOURCE      Aids-associated retrovirus
  ORGANISM  Aids-associated retrovirus
            Viruses; Retroid viruses; Retroviridae.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Stuyver,L.
  TITLE     Method of detecting mutation selected by drug in HIV protease gene
  JOURNAL   Patent: JP 2002518065-A 189 25-JUN-2002;
            INNOGENETICS NV
COMMENT     OS   Aids-associated retrovirus
            PN   JP 2002518065-A/189
            PD   25-JUN-2002
            PF   22-JUN-1999 JP 2000556068
            PR   24-JUN-1998 EP   98870143.9
            PI   LIEVEN STUYVER
            PC   C12N15/09,C12Q1/68,C12Q1/70,C12N15/00
            CC   Method of detecting mutation selected by drug in HIV protease
            CC        gene
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Aids-associated retrovirus'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Aids-associated retrovirus"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:11966"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAA 1984
              ||||||||| ||||
Db         16 TTACCTTGATAAAA 3


RESULT 493
I43728
LOCUS       I43728                   16 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 6 from patent US 5633135.
ACCESSION   I43728
VERSION     I43728.1  GI:2468826
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Croce,C. and Canaani,E.
  TITLE     Chimeric nucleic acids and proteins resulting from ALL-1 region
            chromosome abnormalities
  JOURNAL   Patent: US 5633135-A 6 27-MAY-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              |||||| |||||||
Db          3 AAAGGTGAGGAGAG 16


RESULT 494
I43762
LOCUS       I43762                   16 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 6 from patent US 5633136.
ACCESSION   I43762
VERSION     I43762.1  GI:2468860
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Croce,C. and Canaani,E.
  TITLE     ALL-1 polynucleotides for leukemia detection and treatment
  JOURNAL   Patent: US 5633136-A 6 27-MAY-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              |||||| |||||||
Db          3 AAAGGTGAGGAGAG 16


RESULT 495
AX007647/c
LOCUS       AX007647                 16 bp    DNA     linear   PAT 06-SEP-2000
DEFINITION  Sequence 189 from Patent WO9967428.
ACCESSION   AX007647
VERSION     AX007647.1  GI:9995344
KEYWORDS    .
SOURCE      Aids-associated retrovirus
  ORGANISM  Aids-associated retrovirus
            Viruses; Retroid viruses; Retroviridae.
REFERENCE   1
  AUTHORS   Stuyver,L.
  TITLE     Method for detection of drug-selected mutations in the hiv protease
            gene
  JOURNAL   Patent: WO 9967428-A 189 29-DEC-1999;
            INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Aids-associated retrovirus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:11966"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAA 1984
              ||||||||| ||||
```

```
Db         16 TTACCTTGATAAAA 3


RESULT 496
AX067881/c
LOCUS       AX067881                  16 bp    DNA     linear   PAT 19-JAN-2001
DEFINITION  Sequence 22 from Patent WO0077205.
ACCESSION   AX067881
VERSION     AX067881.1  GI:12329738
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Barber,G.N., Saunders,L. and Perkins,D.
  TITLE     Human nuclear factors associated with dsrna (nfar)
  JOURNAL   Patent: WO 0077205-A 22 21-DEC-2000;
            Barber, Glen N. (US) ; Saunders, Laura (US) ; Perkins, Darren (US)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 16;
  Best Local Similarity   92.9%;  Pred. No. 3.7e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1604 CTGGCCTGGGGGAA 1617
              ||||||| ||||||
Db         15 CTGGCCTAGGGGAA 2


RESULT 497
BD241617/c
LOCUS       BD241617                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Methods and products related to genotyping and DNA analysis.
ACCESSION   BD241617
VERSION     BD241617.1  GI:33051387
KEYWORDS    JP 2002525127-A/564.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: JP 2002525127-A 564 13-AUG-2002;
            MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002525127-A/564
            PD   13-AUG-2002
            PF   24-SEP-1999 JP 2000572407
            PR   25-SEP-1998 US    60/101757
            PI   JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
              C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
            G01N37/00,
            PC   C12N15/00
            CC   Methods and products related to genotyping and DNA analysis FH
              Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACACACACAC 2


RESULT 498
BD241618/c
LOCUS       BD241618                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Methods and products related to genotyping and DNA analysis.
ACCESSION   BD241618
VERSION     BD241618.1  GI:33051388
KEYWORDS    JP 2002525127-A/565.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: JP 2002525127-A 565 13-AUG-2002;
            MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002525127-A/565
            PD   13-AUG-2002
            PF   24-SEP-1999 JP 2000572407
            PR   25-SEP-1998 US    60/101757
            PI   JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
              C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
            G01N37/00,
            PC   C12N15/00
            CC   Methods and products related to genotyping and DNA analysis FH
              Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACGCACACAC 2


RESULT 499
BD254290
LOCUS       BD254290                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254290
VERSION     BD254290.1  GI:33064060
KEYWORDS    JP 2002541795-A/2083.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2083 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2083
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
```

```
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1794 TTCCTTCTCTGAAA 1807
              |||| |||||||||
Db          3 TTCCCTCTCTGAAA 16


RESULT 500
BD254291
LOCUS       BD254291                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254291
VERSION     BD254291.1  GI:33064061
KEYWORDS    JP 2002541795-A/2084.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2084 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2084
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1794 TTCCTTCTCTGAAA 1807
              |||| |||||||||
Db          1 TTCCCTCTCTGAAA 14


RESULT 501
BD255438/c
LOCUS       BD255438                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255438
VERSION     BD255438.1  GI:33065208
KEYWORDS    JP 2002541795-A/3231.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 3231 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/3231
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTT 1926
              ||||||||| ||||
Db         14 AACAATACCCTTTT 1


RESULT 502
BD258506
LOCUS       BD258506                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258506
VERSION     BD258506.1  GI:33068276
KEYWORDS    JP 2002541795-A/6299.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6299 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6299
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
```

```
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTT 1780
              |||||||||| |||
Db          4 AAGCTTTTTTATTT 17


RESULT 503
BD258510
LOCUS       BD258510                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258510
VERSION     BD258510.1  GI:33068280
KEYWORDS    JP 2002541795-A/6303.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6303 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6303
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTT 1781
              |||||||||| ||||
Db          1 AGCTTTTTTATTTT 14


RESULT 504
CQ622447/c
LOCUS       CQ622447                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7187 from Patent WO0192524.
ACCESSION   CQ622447
VERSION     CQ622447.1  GI:41672665
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7187 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         17 TCAGAGGTCAAGTC 4


RESULT 505
CQ622448/c
LOCUS       CQ622448                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7188 from Patent WO0192524.
ACCESSION   CQ622448
VERSION     CQ622448.1  GI:41672666
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7188 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         16 TCAGAGGTCAAGTC 3


RESULT 506
CQ622449/c
LOCUS       CQ622449                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7189 from Patent WO0192524.
ACCESSION   CQ622449
VERSION     CQ622449.1  GI:41672667
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
```

```
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7189 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         15 TCAGAGGTCAAGTC 2


RESULT 507
CQ622450/c
LOCUS       CQ622450                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7190 from Patent WO0192524.
ACCESSION   CQ622450
VERSION     CQ622450.1  GI:41672668
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7190 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         14 TCAGAGGTCAAGTC 1


RESULT 508
CQ622899/c
LOCUS       CQ622899                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7639 from Patent WO0192524.
ACCESSION   CQ622899
VERSION     CQ622899.1  GI:41673117
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7639 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         17 GTTGGTTCTCTAGC 4


RESULT 509
CQ622900/c
LOCUS       CQ622900                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7640 from Patent WO0192524.
ACCESSION   CQ622900
VERSION     CQ622900.1  GI:41673118
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7640 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         16 GTTGGTTCTCTAGC 3


RESULT 510
AR191935
LOCUS       AR191935                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 7423 from patent US 6346398.
ACCESSION   AR191935
VERSION     AR191935.1  GI:20237900
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 7423 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAACA 1856
              ||||| ||||||||
Db          4 TCCCTCGGCCAACA 17


RESULT 511
```

```
AR325828
LOCUS       AR325828                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3230 from patent US 6566127.
ACCESSION   AR325828
VERSION     AR325828.1  GI:33711636
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3230 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAACA 1856
              ||||| ||||||||
Db          4 TCCCTCGGCCAACA 17


RESULT 512
AR327467/c
LOCUS       AR327467                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 4869 from patent US 6566127.
ACCESSION   AR327467
VERSION     AR327467.1  GI:33713275
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 4869 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCT 1575
              ||||||||| ||||
Db         17 ACTGCAAAAGTCCT 4


RESULT 513
AR329256/c
LOCUS       AR329256                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6658 from patent US 6566127.
ACCESSION   AR329256
VERSION     AR329256.1  GI:33715064
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6658 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGG 1612
              |||||||||| |||
Db         16 CCCTCCTGGCTTGG 3


RESULT 514
AR329257/c
LOCUS       AR329257                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6659 from patent US 6566127.
ACCESSION   AR329257
VERSION     AR329257.1  GI:33715065
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6659 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1599 CCCTCCTGGCCTGG 1612
              |||||||||| |||
Db         15 CCCTCCTGGCTTGG 2


RESULT 515
AR463510/c
LOCUS       AR463510                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7187 from patent US 6686188.
ACCESSION   AR463510
VERSION     AR463510.1  GI:42698567
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7187 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         17 TCAGAGGTCAAGTC 4


RESULT 516
```

```
AR463511/c
LOCUS       AR463511                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7188 from patent US 6686188.
ACCESSION   AR463511
VERSION     AR463511.1  GI:42698568
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7188 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         16 TCAGAGGTCAAGTC 3


RESULT 517
AR463512/c
LOCUS       AR463512                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7189 from patent US 6686188.
ACCESSION   AR463512
VERSION     AR463512.1  GI:42698569
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7189 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         15 TCAGAGGTCAAGTC 2


RESULT 518
AR463513/c
LOCUS       AR463513                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7190 from patent US 6686188.
ACCESSION   AR463513
VERSION     AR463513.1  GI:42698570
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7190 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2008 TCAGAGATCAAGTC 2021
              |||||| |||||||
Db         14 TCAGAGGTCAAGTC 1


RESULT 519
AR463962/c
LOCUS       AR463962                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7639 from patent US 6686188.
ACCESSION   AR463962
VERSION     AR463962.1  GI:42699019
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7639 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
Db         17 GTTGGTTCTCTAGC 4


RESULT 520
AR463963/c
LOCUS       AR463963                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7640 from patent US 6686188.
ACCESSION   AR463963
VERSION     AR463963.1  GI:42699020
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7640 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1688 GTTGTTTCTCTAGC 1701
              |||| |||||||||
```

```
Db         16 GTTGGTTCTCTAGC 3


RESULT 521
AR483118/c
LOCUS       AR483118                  17 bp    DNA     linear   PAT 14-MAY-2004
DEFINITION  Sequence 564 from patent US 6703228.
ACCESSION   AR483118
VERSION     AR483118.1  GI:47245641
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: US 6703228-A 564 09-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACACACACAC 2


RESULT 522
AR483119/c
LOCUS       AR483119                  17 bp    DNA     linear   PAT 14-MAY-2004
DEFINITION  Sequence 565 from patent US 6703228.
ACCESSION   AR483119
VERSION     AR483119.1  GI:47245642
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: US 6703228-A 565 09-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db         15 ACAGACGCACACAC 2


RESULT 523
AX215153
LOCUS       AX215153                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 595 from Patent WO0159103.
ACCESSION   AX215153
VERSION     AX215153.1  GI:15525196
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 595 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
              ||||||| ||||||
Db          4 TTAGTTGATTCTCT 17


RESULT 524
AX215836
LOCUS       AX215836                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1278 from Patent WO0159103.
ACCESSION   AX215836
VERSION     AX215836.1  GI:15525879
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1278 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAA 1836
              || ||||||||||||
Db          1 TTGGAATCTTTTAA 14


RESULT 525
AX216307
LOCUS       AX216307                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1749 from Patent WO0159103.
ACCESSION   AX216307
VERSION     AX216307.1  GI:15526368
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1749 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
```

```
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
              ||||||| ||||||
Db          3 TTAGTTGATTCTCT 16


RESULT 526
AX216852
LOCUS       AX216852                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2294 from Patent WO0159103.
ACCESSION   AX216852
VERSION     AX216852.1  GI:15526913
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2294 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1685 TTAGTTGTTTCTCT 1698
              ||||||| ||||||
Db          2 TTAGTTGATTCTCT 15


RESULT 527
AX615438
LOCUS       AX615438                  17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 245 from Patent EP1262488.
ACCESSION   AX615438
VERSION     AX615438.1  GI:28446484
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 245 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGG 2034
              || ||||||||||||
Db          4 CCACTGGTAGGAGG 17


RESULT 528
AX615439
LOCUS       AX615439                  17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 246 from Patent EP1262488.
ACCESSION   AX615439
VERSION     AX615439.1  GI:28446485
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 246 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2021 CCTCTGGTAGGAGG 2034
              || ||||||||||||
Db          3 CCACTGGTAGGAGG 16


RESULT 529
AX671931/c
LOCUS       AX671931                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 376 from Patent WO03004526.
ACCESSION   AX671931
VERSION     AX671931.1  GI:29330279
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 376 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTG 1993
              ||||||||| ||||
Db         17 AAAAAAGAACAGTG 4


RESULT 530
AX674779
LOCUS       AX674779                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 3224 from Patent WO03004526.
ACCESSION   AX674779
VERSION     AX674779.1  GI:29333127
```

```
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 3224 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACA 1841
              ||||||||||||  |
Db          2 ATCTTTTAAATAAA 15


RESULT 531
AX724876
LOCUS       AX724876                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2563 from Patent WO03025176.
ACCESSION   AX724876
VERSION     AX724876.1  GI:30504219
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2563 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGG 1615
              ||||||  |||||||
Db          3 TCCTGGACTGGGGG 16


RESULT 532
AX724985
LOCUS       AX724985                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2672 from Patent WO03025176.
ACCESSION   AX724985
VERSION     AX724985.1  GI:30504328
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2672 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAA 1914
              |||||||||  ||||
Db          1 GATCAACAGTTCAA 14


RESULT 533
AX725887/c
LOCUS       AX725887                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3574 from Patent WO03025176.
ACCESSION   AX725887
VERSION     AX725887.1  GI:30505230
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3574 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1891 ATGTGCCCTAGATC 1904
              |||||||  ||||||
Db         14 ATGTGCCATAGATC 1


RESULT 534
AX727486/c
LOCUS       AX727486                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5173 from Patent WO03025176.
ACCESSION   AX727486
VERSION     AX727486.1  GI:30506829
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5173 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
```

```
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGA 1987
              ||||| ||||||||
Db         16 CCTTGGAAAAAAGA 3


RESULT 535
AX728098
LOCUS       AX728098                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5785 from Patent WO03025176.
ACCESSION   AX728098
VERSION     AX728098.1  GI:30507441
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5785 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2074 ATCTGACACACTCT 2087
              ||||||||| ||||
Db          2 ATCTGACACCCTCT 15


RESULT 536
AX728111
LOCUS       AX728111                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5798 from Patent WO03025176.
ACCESSION   AX728111
VERSION     AX728111.1  GI:30507454
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5798 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              ||||||||||| ||
Db          1 GATCAAGTCCTTTG 14


RESULT 537
AX729133
LOCUS       AX729133                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 767 from Patent WO03025175.
ACCESSION   AX729133
VERSION     AX729133.1  GI:30508476
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 767 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2045 ATCTGCTTAGCAAC 2058
              ||||||| ||||||
Db          2 ATCTGCTGAGCAAC 15


RESULT 538
AX729292/c
LOCUS       AX729292                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 926 from Patent WO03025175.
ACCESSION   AX729292
VERSION     AX729292.1  GI:30508635
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 926 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1868 TTAGCCATTGAAAT 1881
              |||||||||| ||
Db         15 TTAGCCATTGAGAT 2


RESULT 539
```

```
AX729591
LOCUS       AX729591                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1225 from Patent WO03025175.
ACCESSION   AX729591
VERSION     AX729591.1  GI:30508934
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 1225 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACA 1841
              ||||||||||||| |
Db          2 ATCTTTTAAATAAA 15


RESULT 540
AX732108
LOCUS       AX732108                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3742 from Patent WO03025175.
ACCESSION   AX732108
VERSION     AX732108.1  GI:30511451
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 3742 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGAC 1859
              ||||| ||||||||
Db          4 CTGGGTCAACAGAC 17


RESULT 541
AX732198
LOCUS       AX732198                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3832 from Patent WO03025175.
ACCESSION   AX732198
VERSION     AX732198.1  GI:30511541
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 3832 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1873 CATTGAAATGTCAA 1886
              ||||||||| ||||
Db          4 CATTGAAATATCAA 17


RESULT 542
AX732462/c
LOCUS       AX732462                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4096 from Patent WO03025175.
ACCESSION   AX732462
VERSION     AX732462.1  GI:30511805
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 4096 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2003 CTTCTTCAGAGATC 2016
              ||||| ||||||||
Db         14 CTTCTCCAGAGATC 1


RESULT 543
AX733208/c
LOCUS       AX733208                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4842 from Patent WO03025175.
ACCESSION   AX733208
VERSION     AX733208.1  GI:30512551
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
```

```
            medicines
  JOURNAL   Patent: WO 03025175-A 4842 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTG 1993
              ||||||||| ||||
Db         17 AAAAAAGAACAGTG 4


RESULT 544
AX737191
LOCUS       AX737191                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2781 from Patent WO03025177.
ACCESSION   AX737191
VERSION     AX737191.1  GI:30516479
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2781 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACA 1841
              ||||||||||||| |
Db          2 ATCTTTTAAATAAA 15


RESULT 545
AX739552
LOCUS       AX739552                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5142 from Patent WO03025177.
ACCESSION   AX739552
VERSION     AX739552.1  GI:30518849
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 5142 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTG 2026
              |||||||||||  ||
Db          1 GATCAAGTCCTTTG 14


RESULT 546
AX739645
LOCUS       AX739645                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5235 from Patent WO03025177.
ACCESSION   AX739645
VERSION     AX739645.1  GI:30518942
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 5235 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACA 1841
              ||||||||||||| |
Db          2 ATCTTTTAAATAAA 15


RESULT 547
AX739684/c
LOCUS       AX739684                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5274 from Patent WO03025177.
ACCESSION   AX739684
VERSION     AX739684.1  GI:30518981
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 5274 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTG 1993
```

```
              ||||||||| ||||
Db         17 AAAAAAGAACAGTG 4


RESULT 548
AX758411
LOCUS       AX758411                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 1732 from Patent WO03040369.
ACCESSION   AX758411
VERSION     AX758411.1  GI:32253027
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 1732 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCG 1584
              |||||| |||||||
Db          2 ATCCTTGTCCACCG 15


RESULT 549
AX758532/c
LOCUS       AX758532                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 1853 from Patent WO03040369.
ACCESSION   AX758532
VERSION     AX758532.1  GI:32253148
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 1853 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGG 1614
              ||||||||||||| |
Db         17 CTCCTGGCCTGGTG 4


RESULT 550
AX760931
LOCUS       AX760931                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4252 from Patent WO03040369.
ACCESSION   AX760931
VERSION     AX760931.1  GI:32255547
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4252 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1873 CATTGAAATGTCAA 1886
              ||||||||| ||||
Db          4 CATTGAAATATCAA 17


RESULT 551
AX761164
LOCUS       AX761164                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4485 from Patent WO03040369.
ACCESSION   AX761164
VERSION     AX761164.1  GI:32255780
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4485 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2074 ATCTGACACACTCT 2087
              |||||| |||||||
Db          2 ATCTGAGACACTCT 15


RESULT 552
AX782132/c
LOCUS       AX782132                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 463 from Patent WO03050284.
ACCESSION   AX782132
VERSION     AX782132.1  GI:32949981
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 463 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1916 AATACCTTTTTTT 1929
              ||||||  |||||||
Db         17 AATACCCTTTTTT 4


RESULT 553
AX782133/c
LOCUS       AX782133                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 464 from Patent WO03050284.
ACCESSION   AX782133
VERSION     AX782133.1  GI:32949982
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 464 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1916 AATACCTTTTTTT 1929
              ||||||  |||||||
Db         16 AATACCCTTTTTT 3


RESULT 554
AX782134/c
LOCUS       AX782134                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 465 from Patent WO03050284.
ACCESSION   AX782134
VERSION     AX782134.1  GI:32949983
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 465 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1916 AATACCTTTTTTT 1929
              ||||||  |||||||
Db         15 AATACCCTTTTTT 2


RESULT 555
AX782135/c
LOCUS       AX782135                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 466 from Patent WO03050284.
ACCESSION   AX782135
VERSION     AX782135.1  GI:32949984
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 466 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 17;
  Best Local Similarity   92.9%;  Pred. No. 3.9e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1916 AATACCTTTTTTT 1929
              ||||||  |||||||
Db         14 AATACCCTTTTTT 1


RESULT 556
AR091955
LOCUS       AR091955                 18 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 27 from patent US 5998133.
ACCESSION   AR091955
VERSION     AR091955.1  GI:10018709
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Blumenfeld,A., Gusella,J.F., Breakefield,X.O. and Slaugenhaupt,S.
  TITLE     Use of genetic markers to diagnose familial dysautonomia
  JOURNAL   Patent: US 5998133-A 27 07-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1845 CCTGGGCCAACAGA 1858
              |||||||  ||||||
Db          2 CCTGGGCAAACAGA 15


RESULT 557
AR157079/c
LOCUS       AR157079                 18 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 2 from patent US 6242589.
```

```
ACCESSION   AR157079
VERSION     AR157079.1  GI:15125783
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cook,P.Dan. and Manoharan,M.
  TITLE     Phosphorothioate oligonucleotides having modified internucleoside
            linkages
  JOURNAL   Patent: US 6242589-A 2 05-JUN-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
              ||||||||||||| |
Db         16 TGGCCTGGGGGATG 3


RESULT 558
CQ807688
LOCUS       CQ807688                 18 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 1138 from Patent WO2004035803.
ACCESSION   CQ807688
VERSION     CQ807688.1  GI:47113082
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F.,
            Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and
            Marx,A.
  TITLE     Method and nucleic acids for the improved treatment of breast cell
            proliferative disorders
  JOURNAL   Patent: WO 2004035803-A 1138 29-APR-2004;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for CDH1"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2062 TTAATAAGTGGTAT 2075
              ||||| ||||||||
Db          1 TTAATTAGTGGTAT 14


RESULT 559
E32204
LOCUS       E32204                   18 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Method for isolating satellite sequence.
ACCESSION   E32204
VERSION     E32204.1  GI:13021743
KEYWORDS    JP 2000060559-A/6.
SOURCE      Haliotis discus discus
  ORGANISM  Haliotis discus discus
            Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
            Vetigastropoda; Haliotoidea; Haliotidae; Haliotis.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Hideaki,T. and Masashi,S.
  TITLE     Method for isolating satellite sequence
  JOURNAL   Patent: JP 2000060559-A 6 29-FEB-2000;
            NATL INST OF AGROBIOLOGICAL RESOUCES
COMMENT     OS   Haliotis discus discus
            PN   JP 2000060559-A/6
            PD   29-FEB-2000
            PF   18-AUG-1998 JP 1998232153
            PR
            PI   HIDEAKI TAKAHASHI,MASASHI SEKINO
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Haliotis discus discus'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Haliotis discus discus"
                     /mol_type="genomic DNA"
                     /sub_species="discus"
                     /db_xref="taxon:91233"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACAC 1867
              |||||| |||||||
Db          4 ACAGACACACACAC 17


RESULT 560
AR208065
LOCUS       AR208065                 18 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 5 from patent US 6379957.
ACCESSION   AR208065
VERSION     AR208065.1  GI:21507984
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Johnston-Dow,L.A., Demeter,L., White,C.B., Song,K.,
            Kohlenberger,R., Conrad,M. and Myers,A.
  TITLE     Methods for HIV sequencing and genotyping
  JOURNAL   Patent: US 6379957-A 5 30-APR-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCAC 1863
              |||||||| |||||
Db          2 GCCAACAGCCCCAC 15


RESULT 561
AR292943
LOCUS       AR292943                 18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4678 from patent US 6537751.
ACCESSION   AR292943
VERSION     AR292943.1  GI:31680227
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 4678 25-MAR-2003;
```

```
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1533 AAAGGTTAGGAGAG 1546
              ||||||| ||||||
Db          5 AAAGGTTTGGAGAG 18


RESULT 562
AR293122
LOCUS       AR293122                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4857 from patent US 6537751.
ACCESSION   AR293122
VERSION     AR293122.1  GI:31680406
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 4857 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCT 1798
              | ||||||||||||
Db          2 CTCCATTCTTTCCT 15


RESULT 563
AX149041
LOCUS       AX149041                  18 bp    DNA     linear   PAT 08-JUN-2001
DEFINITION  Sequence 243 from Patent WO0136625.
ACCESSION   AX149041
VERSION     AX149041.1  GI:14347565
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wright,J.A., Young,A.H. and Dugourd,D.
  TITLE     Antisense oligonucleotide sequences derived from groel and groes as
            inhibitors of microorganisms
  JOURNAL   Patent: WO 0136625-A 243 25-MAY-2001;
            GeneSense Technologies Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense oligonucleotide"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTT 1926
              |||||||||| ||
Db          1 AACAATACCTTCTT 14


RESULT 564
AX149269
LOCUS       AX149269                  18 bp    DNA     linear   PAT 08-JUN-2001
DEFINITION  Sequence 471 from Patent WO0136625.
ACCESSION   AX149269
VERSION     AX149269.1  GI:14347793
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Wright,J.A., Young,A.H. and Dugourd,D.
  TITLE     Antisense oligonucleotide sequences derived from groel and groes as
            inhibitors of microorganisms
  JOURNAL   Patent: WO 0136625-A 471 25-MAY-2001;
            GeneSense Technologies Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Antisense oligonucleotide"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTTTT 1926
              |||||||||| ||
Db          1 AACAATACCTTCTT 14


RESULT 565
AX352838/c
LOCUS       AX352838                  18 bp    DNA     linear   PAT 06-FEB-2002
DEFINITION  Sequence 44 from Patent EP1174518.
ACCESSION   AX352838
VERSION     AX352838.1  GI:18617920
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Loukachov,V.V., van Gemen,B. and Goudsmit,J.
  TITLE     Collection of binding molecules
  JOURNAL   Patent: EP 1174518-A 44 23-JAN-2002;
            Amsterdam Support Diagnostics B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="position 41"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAA 1806
              ||||| ||||||||
Db         15 TTTCCATCTCTGAA 2


RESULT 566
AX362683/c
LOCUS       AX362683                  18 bp    DNA     linear   PAT 15-FEB-2002
DEFINITION  Sequence 44 from Patent WO0208463.
ACCESSION   AX362683
VERSION     AX362683.1  GI:18694823
KEYWORDS    .
SOURCE      synthetic construct
```

```
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Loukachov,V.V., Goudsmit,J. and van Gemen,B.
  TITLE     Collection of binding molecules
  JOURNAL   Patent: WO 0208463-A 44 31-JAN-2002;
            Amsterdam Support Diagnostics B.V. (NL)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="position 41"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAA 1806
              ||||| ||||||||
Db         15 TTTCCATCTCTGAA 2


RESULT 567
AX705586/c
LOCUS       AX705586                  18 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 255 from Patent WO03014388.
ACCESSION   AX705586
VERSION     AX705586.1  GI:29562251
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Distler,J., Model,F. and Taubert,H.
  TITLE     Method and nucleic acids for the analysis of colon cancer
  JOURNAL   Patent: WO 03014388-A 255 20-FEB-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for PGR"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTTT 1722
              ||||||| ||||||
Db         17 TATCTCCCAACTTT 4


RESULT 568
AX705588
LOCUS       AX705588                  18 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 257 from Patent WO03014388.
ACCESSION   AX705588
VERSION     AX705588.1  GI:29562253
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Distler,J., Model,F. and Taubert,H.
  TITLE     Method and nucleic acids for the analysis of colon cancer
  JOURNAL   Patent: WO 03014388-A 257 20-FEB-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for PGR"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTTT 1722
              ||||||| ||||||
Db          2 TATCTCCCAACTTT 15


RESULT 569
AX718603/c
LOCUS       AX718603                  18 bp    DNA     linear   PAT 15-APR-2003
DEFINITION  Sequence 167 from Patent WO02103043.
ACCESSION   AX718603
VERSION     AX718603.1  GI:29891169
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Beimfohr,C. and Snaidr,J.
  TITLE     Method for the specific fast detection of bacteria which is harmful
            to beer
  JOURNAL   Patent: WO 02103043-A 167 27-DEC-2002;
            Vermicon AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonukleotid"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1545 AGTAGGGAAGGAAC 1558
              |||||||||| |||
Db         18 AGTAGGGAAGCAAC 5


RESULT 570
AX838193/c
LOCUS       AX838193                  18 bp    DNA     linear   PAT 15-DEC-2003
DEFINITION  Sequence 5317 from Patent EP1347046.
ACCESSION   AX838193
VERSION     AX838193.1  GI:39921885
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Isogai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S.,
            Yamamoto,J.I., Isono,Y., Hio,Y., Otsuka,K., Nagai,K., Irie,R.,
            Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahari,K. and
            Masuho,Y.
  TITLE     Full-length cDNA sequences
  JOURNAL   Patent: EP 1347046-A 5317 24-SEP-2003;
            Research Association for Biotechnology (JP)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="Description of Artificial Sequence: an artificially
                     synthesized primer se q"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
```

```
Qy       1675 CCTGGACTTCTTAG 1688
              || ||||||||||||
Db         14 CCAGGACTTCTTAG 1

RESULT 571
AX838330/c
LOCUS       AX838330                18 bp    DNA     linear   PAT 15-DEC-2003
DEFINITION  Sequence 5454 from Patent EP1347046.
ACCESSION   AX838330
VERSION     AX838330.1  GI:39922022
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Isogai,T., Sugiyama,T., Otsuki,T., Wakamatsu,A., Sato,H., Ishii,S.,
            Yamamoto,J.I., Isono,Y., Hio,Y., Otsuka,K., Nagai,K., Irie,R.,
            Tamechika,I., Seki,N., Yoshikawa,T., Otsuka,M., Nagahari,K. and
            Masuho,Y.
  TITLE     Full-length cDNA sequences
  JOURNAL   Patent: EP 1347046-A 5454 24-SEP-2003;
            Research Association for Biotechnology (JP)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
                     /note="Description of Artificial Sequence: an artificially
                     synthesized primer se q"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 18;
  Best Local Similarity   92.9%;  Pred. No. 4.1e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1798 TTCTCTGAAAGTGG 1811
              |||||| |||||||
Db         14 TTCTCTCAAAGTGG 1

RESULT 572
DOGP34001/c
LOCUS       DOGP34001               19 bp    DNA     linear   MAM 28-FEB-1996
DEFINITION  Dog (Clone: CXX.340) primer for STS 340, 5' end.
ACCESSION   L24222
VERSION     L24222.1  GI:401876
KEYWORDS    PCR identification; PCR primer; STS.
SEGMENT     1 of 2
SOURCE      Canis familiaris (dog)
  ORGANISM  Canis familiaris
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Ostrander,E.A., Mapa,F.A., Yee,M. and Rine,J.
  TITLE     One hundred and one new simple sequence repeat-based markers for
            the canine genome
  JOURNAL   Mamm. Genome 6 (3), 192-195 (1995)
  MEDLINE   95268214
   PUBMED   7749226
COMMENT     Original source text: Canis familiaris (library: E. Ostrander, in
            pBluescript+) adult spleen DNA.
            Submitted by:
            Fred Hutchinson Cancer Research Center
            Transplantation Biology Dept
            1124 Columbia; Mailstop M318
            Seattle, WA 98104, USA
            e-mail: EAOstrander@lbl.gov
            PCR Buffer: PCR buffer (Perkin-Elmer/Cetus)
            PCR Profile:  Denaturation:    94 degrees C for 1.00 minute
            Annealing:       55 or 59 degrees C for 0.45 minutes
            Polymerization:  74 degrees C for 1.00 minutes
            PCR Cycles:      33
            Final Extension:  74 degrees C for 5.00 minutes.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Canis familiaris"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9615"
                     /tissue_type="spleen"
                     /dev_stage="adult"
                     /tissue_lib="E. Ostrander, in pBluescript+"
     primer_bind     1. .19

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1589 GACTGGGAACCCCT 1602
              ||||||||| ||||
Db         14 GACTGGGAAACCCT 1

RESULT 573
A50598/c
LOCUS       A50598                  19 bp    DNA     linear   PAT 07-MAR-1997
DEFINITION  Sequence 40 from Patent WO9613608.
ACCESSION   A50598
VERSION     A50598.1  GI:2303478
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Giesendorf,B., Quint,W. and Van,D.L.
  TITLE     NEW POLYNUCLEIC ACID SEQUENCES FOR USE IN THE DETECTION AND
            DIFFERENTIATION OF PROKARYOTIC ORGANISMS
  JOURNAL   Patent: WO 9613608-A 40 09-MAY-1996;
            INNOGENETICS NV (BE)
COMMENT     Other publication AU 3845795 960523.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCTAG 1700
              | ||| |:|| |||||:|
Db         19 TTTTATTKGTATCTCTWG 2

RESULT 574
A88459/c
LOCUS       A88459                  19 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 607 from Patent WO9833904.
ACCESSION   A88459
VERSION     A88459.1  GI:6737029
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 607 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"
```

```
  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1810 GGTGCTATAAGTTT 1823
              ||||||| ||||||
Db         19 GGTGCTAAAAGTTT 6


RESULT 575
A90426/c
LOCUS       A90426                    19 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 607 from Patent EP0856579.
ACCESSION   A90426
VERSION     A90426.1  GI:6738940
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 607 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1810 GGTGCTATAAGTTT 1823
              ||||||| ||||||
Db         19 GGTGCTAAAAGTTT 6


RESULT 576
AR019632
LOCUS       AR019632                  19 bp    DNA     linear   PAT 05-DEC-1998
DEFINITION  Sequence 11 from patent US 5783680.
ACCESSION   AR019632
VERSION     AR019632.1  GI:3974746
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Brunner,H.G. and Breakefield,X.O.
  TITLE     Genetic diagnosis and treatment for impulsive aggression
  JOURNAL   Patent: US 5783680-A 11 21-JUL-1998;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1621 TTTGTTACCTACCT 1634
              ||| ||||||||||
Db          2 TTTCTTACCTACCT 15


RESULT 577
AR147275/c
LOCUS       AR147275                  19 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 40 from patent US 6221582.
ACCESSION   AR147275
VERSION     AR147275.1  GI:15111078
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Giesendorf,B., Quint;W. and Van Doorn,L.-J.
  TITLE     Polynucleic acid sequences for use in the detection and
            differentiation of prokaryotic organisms
  JOURNAL   Patent: US 6221582-A 40 24-APR-2001;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   72.2%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    2;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTCTAG 1700
              | ||| |:|| |||||:|
Db         19 TTTTATTKGTATCTCTWG 2


RESULT 578
BD196792
LOCUS       BD196792                  19 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Prostatic cancer gene.
ACCESSION   BD196792
VERSION     BD196792.1  GI:33006562
KEYWORDS    JP 2002516657-A/381.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Blumenfeld,M., Chumakov,I. and Bougueleret,L.
  TITLE     Prostatic cancer gene
  JOURNAL   Patent: JP 2002516657-A 381 11-JUN-2002;
            GENSET
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002516657-A/381
            PD   11-JUN-2002
            PF   22-DEC-1998 JP 2000525562
            PR   22-DEC-1997 US    08/996306,09-SEP-1998 US    60/099658 PI
            DANIEL COHEN,MARTA BLUMENFELD,ILYA CHUMAKOV,LYDIE BOUGUELERET PC
            C12N15/09,C12N15/09,A01K67/027,C07K14/47,C07K16/18,C12N1/15, PC
            C12N1/19,
            PC   C12N1/21,C12N5/10,C12N5/10,C12P21/08,C12Q1/68,G01N33/50 PC
            ,C12N15/00,C12N5/00,
            PC   C12N5/00,C12N15/00
            CC   downstream amplification primer for SEQ 235, SEQ 312 FH   Key
                    Location/Qualifiers
            FT   primer_bind     1. .19.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2034 GCAAAGGTTCTATC 2047
              ||||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 579
BD221975/c
LOCUS       BD221975                  19 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Nucleic acid encoding retinoblastoma-binding protein (RBP-7) and
            polymorphic marker relating to the nucleic acid.
```

```
ACCESSION   BD221975
VERSION     BD221975.1  GI:33031745
KEYWORDS    JP 2002519027-A/114.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Bougueleret,L.
  TITLE     Nucleic acid encoding retinoblastoma-binding protein (RBP-7) and
            polymorphic marker relating to the nucleic acid
  JOURNAL   Patent: JP 2002519027-A 114 02-JUL-2002;
            GENSET
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002519027-A/114
            PD   02-JUL-2002
            PF   30-JUN-1999 JP 2000557360
            PR   30-JUN-1998 US    60/091315,10-DEC-1998 US    60/111909 PI
            LYDIE BOUGUELERET
            PC   C12N15/09,C12N15/09,A01K67/027,C07K14/47,C07K16/18,C12N5/10,
            PC   C12Q1/68,
            PC   G01N33/53,G01N33/566,C12N15/00,C12N5/00,C12N15/00 CC
            microsequencing oligo for 5-140-348.mis1
            FH   Key             Location/Qualifiers
            FT   primer_bind     1. .19.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="Homo sapiens"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAA 1980
              || ||||||||||
Db         15 ATGTTTACCTTGAA 2


RESULT 580
E32039
LOCUS       E32039                    19 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Human neuropsin, DNA sequence thereof, gene thereof and primer
            thereof.
ACCESSION   E32039
VERSION     E32039.1  GI:13017459
KEYWORDS    JP 1999318461-A/3.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Sadao,S. and Naritaka,Y.
  TITLE     Human neuropsin, DNA sequence thereof, gene thereof and primer
  JOURNAL   Patent: JP 1999318461-A 3 24-NOV-1999;
            SADAO SHIOSAKA,MEDICAL & BIOLOGICAL LAB CO LTD
COMMENT     OS   Unidentified
            PN   JP 1999318461-A/3
            PD   24-NOV-1999
            PF   15-MAY-1998 JP 1998133615
            PR
            PI   SADAO SHIOSAKA,NARITAKA YOSHIDA
            PC   C12N15/09,C07K14/47,C12N9/76//A61K38/00,C12N15/00,A61K37/02 CC
              Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1669 CCCGCCCCTGGACT 1682
              ||||||||||||| |
Db          6 CCCGCCCCTGGATT 19


RESULT 581
I34186
LOCUS       I34186                    19 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 2 from patent US 5595899.
ACCESSION   I34186
VERSION     I34186.1  GI:1824977
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Sato,M. and Tada,N.
  TITLE     Methods of introducing foreign DNA into cells
  JOURNAL   Patent: US 5595899-A 2 21-JAN-1997;
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAA 1988
              ||||| ||||||||
Db          1 CTTGACAAAAAGAA 14


RESULT 582
AR181876/c
LOCUS       AR181876                  19 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 1 from patent US 6335434.
ACCESSION   AR181876
VERSION     AR181876.1  GI:20224090
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Guzaev,A.P., Cook,P.Dan., Manoharan,M. and Bhat,B.
  TITLE     Nucleosidic and non-nucleosidic folate conjugates
  JOURNAL   Patent: US 6335434-A 1 01-JAN-2002;
FEATURES              Location/Qualifiers
     source           1. .19
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1605 TGGCCTGGGGGAAG 1618
              ||||||||||||| |
Db         15 TGGCCTGGGGGATG 2


RESULT 583
AR211905/c
LOCUS       AR211905                  19 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 115 from patent US 6399373.
ACCESSION   AR211905
VERSION     AR211905.1  GI:21515350
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Bougueleret,L.
  TITLE     Nucleic acid encoding a retinoblastoma binding protein (RBP-7) and
            polymorphic markers associated with said nucleic acid
  JOURNAL   Patent: US 6399373-A 115 04-JUN-2002;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAA 1980
              || ||||||||||||
Db         15 ATGTTTACCTTGAA 2


RESULT 584
AR294043
LOCUS       AR294043                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5778 from patent US 6537751.
ACCESSION   AR294043
VERSION     AR294043.1  GI:31681327
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 5778 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1948 TGGTTTTTGTGTCC 1961
              |||||||| |||||
Db          2 TGGTTTTTCTGTCC 15


RESULT 585
AR296315
LOCUS       AR296315                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 8050 from patent US 6537751.
ACCESSION   AR296315
VERSION     AR296315.1  GI:31683599
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 8050 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       2034 GCAAAGGTTCTATC 2047
              ||||||||| ||||
Db          6 GCAAAGGTTATATC 19


RESULT 586
AR297353
LOCUS       AR297353                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 9088 from patent US 6537751.
ACCESSION   AR297353
VERSION     AR297353.1  GI:31684637
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 9088 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTT 1781
              |||||||||| |||
Db          3 AGCTTTTTTCTTT 16


RESULT 587
AR298026/c
LOCUS       AR298026                  19 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 9761 from patent US 6537751.
ACCESSION   AR298026
VERSION     AR298026.1  GI:31685310
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 9761 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGA 1556
              | ||||||||||||
Db         16 AAAGTAGGGAAGGA 3


RESULT 588
AX128789
LOCUS       AX128789                  19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 7 from Patent WO0130362.
ACCESSION   AX128789
VERSION     AX128789.1  GI:14135094
KEYWORDS    .
SOURCE      Homo sapiens (human)
```

```
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 7 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cdk1 ribozyme binding site"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGG 1607
              ||||||||||||  |
Db          1 GGAACCCCTCCTTG 14


RESULT 589
AX131146
LOCUS       AX131146                19 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 2364 from Patent WO0130362.
ACCESSION   AX131146
VERSION     AX131146.1  GI:14137451
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 2364 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Cyclin F ribozyme binding site"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1998 TCTAGCTTCTTCAG 2011
              ||| ||||||||||
Db          3 TCTCGCTTCTTCAG 16


RESULT 590
AX511545
LOCUS       AX511545                19 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 6 from Patent WO0234948.
ACCESSION   AX511545
VERSION     AX511545.1  GI:23392384
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Krontiris,T.G., Beaulieu,M. and Flanagan,S.D.
  TITLE     Candidate region mismatch scanning for genotyping and mutation
            detection
  JOURNAL   Patent: WO 0234948-A 6 02-MAY-2002;
            City of Hope (US)
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="PCR Primer"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1574 CTTCTCCACCGCAC`1587
              || ||||||||||
Db          1 CTGCTCCACCGCAC 14


RESULT 591
BD065972/c
LOCUS       BD065972                19 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065972
VERSION     BD065972.1  GI:22611575
KEYWORDS    JP 2001511000-A/607.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 19)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 607 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/607
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .19
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .19
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.4;  DB 1;  Length 19;
  Best Local Similarity   92.9%;  Pred. No. 4.4e+02;
  Matches   13;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1810 GGTGCTATAAGTTT 1823
              ||||||| ||||||
Db         19 GGTGCTAAAAGTTT 6


RESULT 592
A34261/c
LOCUS       A34261                  17 bp    DNA     linear   PAT 03-JUL-2002
DEFINITION  Synthetic sequencing primer.
ACCESSION   A34261
VERSION     A34261.1  GI:21694213
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Odink,K.G., Tarcsay,L., Brueggen,J., Wiesendanger,W., Cerletti,N.,
            Sorg,C., DeWolf-Peeters,C. and Delabie,J.
  TITLE     Novel cytokines
  JOURNAL   Patent: EP 0412050-A 21 06-FEB-1991;
```

```
           CIBA-GEIGY AG
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1705 GAGCTATCTCCTAACTT 1721
              ||| |||||||| || |
Db         17 GAGTTATCTCCTGACAT 1


RESULT 593
AR040311
LOCUS       AR040311                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1159 from patent US 5807743.
ACCESSION   AR040311
VERSION     AR040311.1  GI:5959674
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T. and McSwiggen,J.A.
  TITLE     Interleukin-2 receptor gamma-chain ribozymes
  JOURNAL   Patent: US 5807743-A 1159 15-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2039 GGTTCTATCTGCTTAGC 2055
              | |||| ||||| ||||
Db          1 GCTTCTCTCTGCCTAGC 17


RESULT 594
AR047348/c
LOCUS       AR047348                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 2141 from patent US 5817796.
ACCESSION   AR047348
VERSION     AR047348.1  GI:5968813
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 2141 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              ||||| | |||||| ||
Db         17 AAAAATAAAAAAGTCTG 1


RESULT 595
BD200775
LOCUS       BD200775                  17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD200775
VERSION     BD200775.1  GI:33010545
KEYWORDS    JP 2002509721-A/3801.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 3801 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/3801
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACTTTGGA 1725
              |||| ||| | ||||||
Db          1 TATCACCTTATTTTGGA 17


RESULT 596
BD202684/c
LOCUS       BD202684                  17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD202684
VERSION     BD202684.1  GI:33012454
KEYWORDS    JP 2002509721-A/5710.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 5710 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/5710
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
```

```
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTT 1775
              |||||| |||  |||||
Db         17 TATTCACTAATTTTTTT 1


RESULT 597
BD202685/c
LOCUS       BD202685                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD202685
VERSION     BD202685.1  GI:33012455
KEYWORDS    JP 2002509721-A/5711.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 5711 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/5711
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1758 TTATTCATTAAGCTTTT 1774
              ||||||| |||  ||||
Db         17 TTATTCACTAATTTTTT 1


RESULT 598
BD203240
LOCUS       BD203240                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD203240
VERSION     BD203240.1  GI:33013010
KEYWORDS    JP 2002509721-A/6266.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 6266 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/6266
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1763 CATTAAGCTTTTTTTTT 1779
              ||| ||| ||||| |||
Db          1 CATCAAGTTTTTTATTT 17


RESULT 599
BD203241
LOCUS       BD203241                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD203241
VERSION     BD203241.1  GI:33013011
KEYWORDS    JP 2002509721-A/6267.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
```

```
  JOURNAL   Patent: JP 2002509721-A 6267 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/6267
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Homo sapiens"
                      /mol_type="genomic RNA"
                      /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1764 ATTAAGCTTTTTTTTT 1780
              || ||| ||||| ||||
Db          1 ATCAAGTTTTTTATTTT 17


RESULT 600
BD252017
LOCUS       BD252017                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Nonribosomal peptide synthetase, process for producing the same and
            utilization thereof.
ACCESSION   BD252017
VERSION     BD252017.1  GI:33061787
KEYWORDS    JP 2002537806-A/23.
SOURCE      Brevibacillus brevis
  ORGANISM  Brevibacillus brevis
            Bacteria; Firmicutes; Bacillales; Paenibacillaceae; Brevibacillus.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Marahiel,M.A., Stachelhaus,T., Mootz,H. and Konz,D.
  TITLE     Nonribosomal peptide synthetase, process for producing the same and
            utilization thereof
  JOURNAL   Patent: JP 2002537806-A 23 12-NOV-2002;
            MOHAMED A MARAHIEL,TORSTEN STACHELHAUS,HENNING MOOTZ,DIRK KONZ
COMMENT     OS   Bacillus brevis
            PN   JP 2002537806-A/23
            PD   12-NOV-2002
            PF   28-FEB-2000 JP 2000602764
            PR   03-MAR-1999 DE 199 09 146.3
            PI   MOHAMED A MARAHIEL,TORSTEN STACHELHAUS,HENNING MOOTZ,DIRK KONZ
            PC   C12N15/09,C07K14/00//C12N9/00,C12N15/00
            CC   Nonribosomal peptide synthetase, process for producing the  CC
                   same and
            CC   utilization thereof
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Bacillus brevis'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Brevibacillus brevis"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:1393"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1687 AGTTGTTTCTCTAGCGC 1703
              ||||||||| ||| ||
Db          1 AGTTGTTTCCGTAGGGC 17


RESULT 601
BD254561/c
LOCUS       BD254561                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254561
VERSION     BD254561.1  GI:33064331
KEYWORDS    JP 2002541795-A/2354.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2354 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2354
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTT 1775
              ||||| |||| ||| ||
Db         17 TATTCCTTAAACTTCTT 1


RESULT 602
BD254671
LOCUS       BD254671                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254671
VERSION     BD254671.1  GI:33064441
KEYWORDS    JP 2002541795-A/2464.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2464 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2464
            PD   10-DEC-2002
```

```
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              | ||  ||||||||||||
Db          1 CAATATTTTCCTTCTCT 17


RESULT 603
BD254848/c
LOCUS       BD254848                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254848
VERSION     BD254848.1  GI:33064618
KEYWORDS    JP 2002541795-A/2641.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2641 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2641
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1581 ACCGCACAGACTGGGAA 1597
              | ||||| ||||| |||
Db         17 ATCGCACTGACTGAGAA 1


RESULT 604
BD255067/c
LOCUS       BD255067                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255067
VERSION     BD255067.1  GI:33064837
KEYWORDS    JP 2002541795-A/2860.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2860 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2860
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAGG 1555
              | |||||||||||| | |
Db         17 TGGGAGAGTAGGGGAAG 1


RESULT 605
BD256747
LOCUS       BD256747                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD256747
VERSION     BD256747.1  GI:33066517
KEYWORDS    JP 2002541795-A/4540.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 4540 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/4540
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
```

```
          PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
          C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
          C12P21/02,
          PC
          C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
           C12R1:91),
          PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
          PC   A61K37/02,
          PC   (C12N5/00,C12R1:91)
          CC   Regulation of repressor genes using nucleic acid molecules FH
           Key             Location/Qualifiers
          FT   source          1. .17
          FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAA 1981
              |||| ||||| || |||
Db          1 AAATTTTTACTTTAAAA 17


RESULT 606
BD256795/c
LOCUS       BD256795                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD256795
VERSION     BD256795.1  GI:33066565
KEYWORDS    JP 2002541795-A/4588.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 4588 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/4588
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGACA 1745
              || ||||  ||||||||
Db          1 ATAATCAAGAGGTGACA 17


RESULT 607
BD258526/c
LOCUS       BD258526                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258526
VERSION     BD258526.1  GI:33068296
KEYWORDS    JP 2002541795-A/6319.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6319 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6319
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1964 TAAATATTTACCTTGAA 1980
              || |  ||||||||||
Db         17 TAGAATTTTACCTTGAA 1


RESULT 608
BD259163/c
LOCUS       BD259163                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD259163
VERSION     BD259163.1  GI:33068933
KEYWORDS    JP 2002541795-A/6956.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6956 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6956
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
```

```
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACATTC 1844
              ||||||| | ||||||
Db         17 ATCTTTTGTAGACATTC 1


RESULT 609
BD259606/c
LOCUS       BD259606                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD259606
VERSION     BD259606.1  GI:33069376
KEYWORDS    JP 2002541795-A/7399.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 7399 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/7399
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1773 TTTTTTTTTGAACCCCA 1789
              |||| |||| || ||||
Db         17 TTTTCTTTTAAAGCCCA 1


RESULT 610
CQ617368/c
LOCUS       CQ617368                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 2108 from Patent WO0192524.
ACCESSION   CQ617368
VERSION     CQ617368.1  GI:41667586
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2108 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACCC 1671
              ||||||| ||| | |||
Db         17 CTGGTTCAGCAGCGCCC 1


RESULT 611
CQ618044/c
LOCUS       CQ618044                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 2784 from Patent WO0192524.
ACCESSION   CQ618044
VERSION     CQ618044.1  GI:41668262
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 2784 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1804 GAAAGTGGTGCTATAAG 1820
              ||| |||||||| |||
Db         17 GAAGGTGGTGCTTGAAG 1


RESULT 612
CQ623216
LOCUS       CQ623216                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7956 from Patent WO0192524.
ACCESSION   CQ623216
VERSION     CQ623216.1  GI:41673434
KEYWORDS    .
SOURCE      Homo sapiens (human)
```

```
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7956 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1893 GTGCCCTAGATCAACAG 1909
              | ||||| || ||||||
Db          1 GCGCCCTTGAGCAACAG 17


RESULT 613
CQ623220
LOCUS       CQ623220                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7960 from Patent WO0192524.
ACCESSION   CQ623220
VERSION     CQ623220.1  GI:41673438
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7960 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAA 1990
              |||||| || ||||||
Db          1 CCTTGAGCAACAGAAAA 17


RESULT 614
CQ625804/c
LOCUS       CQ625804                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10544 from Patent WO0192524.
ACCESSION   CQ625804
VERSION     CQ625804.1  GI:41676022
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10544 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCT 1771
              | ||| ||||||| |||
Db         17 TATTTCTTCATTATGCT 1


RESULT 615
I54400/c
LOCUS       I54400                    17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 2141 from patent US 5646042.
ACCESSION   I54400
VERSION     I54400.1  GI:2475603
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 2141 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              ||||| | |||||| ||
Db         17 AAAAATAAAAAAGTCTG 1


RESULT 616
AR190143
LOCUS       AR190143                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 5631 from patent US 6346398.
ACCESSION   AR190143
VERSION     AR190143.1  GI:20236108
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 5631 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGGC 1851
              ||| ||||| ||||| |
Db          1 AAAGACATTGCCTGGTC 17


RESULT 617
```

```
AR191909/c
LOCUS       AR191909                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 7397 from patent US 6346398.
ACCESSION   AR191909
VERSION     AR191909.1  GI:20237874
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 7397 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCA 1654
              | ||||||| ||||||| |
Db         17 TTTTTAAATAGCCTTGA 1

RESULT 618
AR192254
LOCUS       AR192254                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 7742 from patent US 6346398.
ACCESSION   AR192254
VERSION     AR192254.1  GI:20238219
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 7742 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTGCC 1897
              | ||||||| ||| |||
Db          1 TTTCAAATTCATGAGCC 17

RESULT 619
AR192523
LOCUS       AR192523                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 8011 from patent US 6346398.
ACCESSION   AR192523
VERSION     AR192523.1  GI:20238488
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 8011 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTT 1775
              |||| |||||||  |||
Db          1 TATTTATTAAGCACTTT 17

RESULT 620
AR192669
LOCUS       AR192669                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 8157 from patent US 6346398.
ACCESSION   AR192669
VERSION     AR192669.1  GI:20238634
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 8157 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              || |||||||||| | |
Db          1 TCTCTGGTTCTGCTTAA 17

RESULT 621
AR325119
LOCUS       AR325119                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2521 from patent US 6566127.
ACCESSION   AR325119
VERSION     AR325119.1  GI:33710927
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2521 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1835 AAATACATTCCCTGGGC 1851
              ||| ||||| ||||| |
Db          1 AAAGACATTGCCTGGTC 17

RESULT 622
AR325803/c
```

```
LOCUS       AR325803                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3205 from patent US 6566127.
ACCESSION   AR325803
VERSION     AR325803.1  GI:33711611
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3205 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTTCA 1654
              | |||||| |||||| |
Db         17 TTTTTAAATAGCCTTGA 1

RESULT 623
AR326125
LOCUS       AR326125                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3527 from patent US 6566127.
ACCESSION   AR326125
VERSION     AR326125.1  GI:33711933
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3527 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1881 TGTCAAATTGATGTGCC 1897
              | ||||||| ||| |||
Db          1 TTTCAAATTCATGAGCC 17

RESULT 624
AR326392
LOCUS       AR326392                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3794 from patent US 6566127.
ACCESSION   AR326392
VERSION     AR326392.1  GI:33712200
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3794 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTTTT 1775
              |||| |||||||   |||
Db          1 TATTTATTAAGCACTTT 17

RESULT 625
AR326538
LOCUS       AR326538                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3940 from patent US 6566127.
ACCESSION   AR326538
VERSION     AR326538.1  GI:33712346
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3940 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              || |||||||||| | |
Db          1 TCTCTGGTTCTGCTTAA 17

RESULT 626
AR327517
LOCUS       AR327517                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 4919 from patent US 6566127.
ACCESSION   AR327517
VERSION     AR327517.1  GI:33713325
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 4919 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | || | ||||||||||
Db          1 ACTCCTGCCTTCTCTGA 17

RESULT 627
AR327898
LOCUS       AR327898                 17 bp    RNA     linear   PAT 17-AUG-2003
```

```
DEFINITION  Sequence 5300 from patent US 6566127.
ACCESSION   AR327898
VERSION     AR327898.1  GI:33713706
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 5300 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1642 TAAAGAGCCTTCACTGG 1658
              ||| ||||| ||||| |
Db          1 TAATGAGCCATCACTAG 17


RESULT 628
AR328753
LOCUS       AR328753                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6155 from patent US 6566127.
ACCESSION   AR328753
VERSION     AR328753.1  GI:33714561
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6155 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1719 CTTTGGACCTATTATCA 1735
              |||||| || || ||||
Db          1 CTTTGGCCCAATAATCA 17


RESULT 629
AR328754
LOCUS       AR328754                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6156 from patent US 6566127.
ACCESSION   AR328754
VERSION     AR328754.1  GI:33714562
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6156 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1720 TTTGGACCTATTATCAG 1736
              ||||| || || |||||
Db          1 TTTGGCCCAATAATCAG 17


RESULT 630
AR328797
LOCUS       AR328797                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6199 from patent US 6566127.
ACCESSION   AR328797
VERSION     AR328797.1  GI:33714605
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6199 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              | ||||| |||| ||||
Db          1 ACAAAAACAAAACTGTG 17


RESULT 631
AR402410
LOCUS       AR402410                 17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 750 from patent US 6623962.
ACCESSION   AR402410
VERSION     AR402410.1  GI:40149860
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 750 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              |||||| ||||||  ||
Db          1 CCCATTTTTTCCTAATC 17


RESULT 632
AR402411
LOCUS       AR402411                 17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 751 from patent US 6623962.
```

```
ACCESSION   AR402411
VERSION     AR402411.1  GI:40149861
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 751 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              ||||| ||||||  |||
Db          1 CCATTTTTTCCTAATCT 17


RESULT 633
AR402412
LOCUS       AR402412                  17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 752 from patent US 6623962.
ACCESSION   AR402412
VERSION     AR402412.1  GI:40149862
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 752 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1788 CATTCTTTCCTTCTCTG 1804
              |||| ||||||  ||||
Db          1 CATTTTTTCCTAATCTG 17


RESULT 634
AR458431/c
LOCUS       AR458431                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2108 from patent US 6686188.
ACCESSION   AR458431
VERSION     AR458431.1  GI:42693488
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2108 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCACCC 1671
              ||||||| ||| | |||
Db         17 CTGGTTCAGCAGCGCCC 1


RESULT 635
AR459107/c
LOCUS       AR459107                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 2784 from patent US 6686188.
ACCESSION   AR459107
VERSION     AR459107.1  GI:42694164
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 2784 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1804 GAAAGTGGTGCTATAAG 1820
              ||| ||||||||  |||
Db         17 GAAGGTGGTGCTTGAAG 1


RESULT 636
AR464279
LOCUS       AR464279                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7956 from patent US 6686188.
ACCESSION   AR464279
VERSION     AR464279.1  GI:42699336
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7956 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1893 GTGCCCTAGATCAACAG 1909
              | ||||| || ||||||
Db          1 GCGCCCTTGAGCAACAG 17


RESULT 637
AR464283
```

```
LOCUS       AR464283                 17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7960 from patent US 6686188.
ACCESSION   AR464283
VERSION     AR464283.1  GI:42699340
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7960 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAAGAAAA 1990
              ||||||  || ||||||
Db          1 CCTTGAGCAACAGAAAA 17


RESULT 638
AR466867/c
LOCUS       AR466867                 17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10544 from patent US 6686188.
ACCESSION   AR466867
VERSION     AR466867.1  GI:42701924
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10544 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAGCT 1771
              | |||  ||||||| |||
Db         17 TATTTCTTCATTATGCT 1


RESULT 639
AX035608
LOCUS       AX035608                 17 bp    DNA     linear   PAT 15-NOV-2000
DEFINITION  Sequence 23 from Patent WO0052152.
ACCESSION   AX035608
VERSION     AX035608.1  GI:11191203
KEYWORDS    .
SOURCE      Brevibacillus brevis
  ORGANISM  Brevibacillus brevis
            Bacteria; Firmicutes; Bacillales; Paenibacillaceae; Brevibacillus.
REFERENCE   1
  AUTHORS   Stachelhaus,T., Konz,D., Mootz,H. and Marahiel,M.A.
  TITLE     Non-ribosomal peptide synthetases, method for producing same and
            the use thereof
  JOURNAL   Patent: WO 0052152-A 23 08-SEP-2000;
            STACHELHAUS TORSTEN (DE) ; KONZ DIRK (DE) ; MOOTZ HENNING (DE) ;
            MARAHIEL MOHAMED A (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Brevibacillus brevis"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:1393"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1687 AGTTGTTTCTCTAGCGC 1703
              |||||||||  ||| ||
Db          1 AGTTGTTTCCGTAGGGC 17


RESULT 640
AX191379
LOCUS       AX191379                 17 bp    DNA     linear   PAT 15-AUG-2001
DEFINITION  Sequence 4 from Patent WO0149852.
ACCESSION   AX191379
VERSION     AX191379.1  GI:15209599
KEYWORDS    .
SOURCE      Zea mays
  ORGANISM  Zea mays
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
            clade; Panicoideae; Andropogoneae; Zea.
REFERENCE   1
  AUTHORS   Schmidt,R.J., Moose,S.P. and Vicente-Carbajosa,J.
  TITLE     Transgenic maize comprising recombinant pbf genes
  JOURNAL   Patent: WO 0149852-A 4 12-JUL-2001;
            THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Zea mays"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:4577"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1876 TGAAATGTCAAATTGAT 1892
              ||| |||| || |||||
Db          1 TGACATGTAAAGTTGAT 17


RESULT 641
AX215403
LOCUS       AX215403                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 845 from Patent WO0159103.
ACCESSION   AX215403
VERSION     AX215403.1  GI:15525446
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 845 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"
```

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1593 GGGAACCCCTCCTGGCC 1609
              ||| |||||| | ||||
Db          1 GGGGACCCCTGCCGGCC 17


RESULT 642
AX216540/c
LOCUS       AX216540                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1982 from Patent WO0159103.
ACCESSION   AX216540
VERSION     AX216540.1  GI:15526601
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1982 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1920 CCTTTTTTTTCAGTGTT 1936
              |||||||  ||| ||||
Db         17 CCTTTTTGCTCAATGTT 1


RESULT 643
AX216764/c
LOCUS       AX216764                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2206 from Patent WO0159103.
ACCESSION   AX216764
VERSION     AX216764.1  GI:15526825
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2206 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTGAA 1784
              ||||| | ||| |||||
Db         17 AGCTTCTGTTTCTTGAA 1


RESULT 644
AX216767/c
LOCUS       AX216767                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2209 from Patent WO0159103.
ACCESSION   AX216767
VERSION     AX216767.1  GI:15526828
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2209 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTGA 1783
              ||||||| ||| ||| |
Db         17 AAGCTTTGTTTCTTTAA 1


RESULT 645
AX217761/c
LOCUS       AX217761                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 3203 from Patent WO0159103.
ACCESSION   AX217761
VERSION     AX217761.1  GI:15527822
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 3203 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAGGT 2041
              ||| || |||||||| |
Db         17 TGGAAGAAGGCAAAGAT 1


RESULT 646
AX227074/c
LOCUS       AX227074                  17 bp    RNA     linear   PAT 10-SEP-2001
DEFINITION  Sequence 446 from Patent WO0157206.
ACCESSION   AX227074
```

```
VERSION     AX227074.1  GI:15556215
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Fattaey,A.R., Jarvis,T., Mcswiggen,J., Booher,R.N. and Holman,P.S.
  TITLE     Method and reagent for the inhibition of checkpoint kinase-1 (chk
            1) enzyme
  JOURNAL   Patent: WO 0157206-A 446 09-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1649 CCTTCACTGGTTCTGCA 1665
              | |  ||||||||||||
Db         17 CATCAACTGGTTCTGCA 1


RESULT 647
AX422002/c
LOCUS       AX422002                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 338 from Patent WO0188124.
ACCESSION   AX422002
VERSION     AX422002.1  GI:21525384
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 338 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1708 CTATCTCCTAACTTTGG 1724
              || |||||||||  |||
Db         17 CTTTCTCCTAACACTGG 1


RESULT 648
AX499859
LOCUS       AX499859                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1166 from Patent EP1229046.
ACCESSION   AX499859
VERSION     AX499859.1  GI:23382152
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1166 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1967 ATATTTACCTTGAAAAA 1983
              || ||  ||||||||||
Db         1 ATCTTGGCCTTGAAAAA 17


RESULT 649
AX499860
LOCUS       AX499860                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1167 from Patent EP1229046.
ACCESSION   AX499860
VERSION     AX499860.1  GI:23382153
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1167 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1968 TATTTACCTTGAAAAAA 1984
              | ||  ||||||||||||
Db         1 TCTTGGCCTTGAAAAAA 17


RESULT 650
AX531444
LOCUS       AX531444                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 953 from Patent EP1239051.
ACCESSION   AX531444
VERSION     AX531444.1  GI:25254666
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 953 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1529 GAAGAAAGGTTAGGAGA 1545
              ||||  | |||||||||
Db          1 GAAGGCAAGTTAGGAGA 17


RESULT 651
AX532422
LOCUS       AX532422                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 1931 from Patent EP1239051.
ACCESSION   AX532422
VERSION     AX532422.1  GI:25256619
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 1931 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1593 GGGAACCCCTCCTGGCC 1609
              |||| ||||||||  ||
Db          1 GGGATCCCCTCCTCCCC 17


RESULT 652
AX578529
LOCUS       AX578529                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 367 from Patent WO0211674.
ACCESSION   AX578529
VERSION     AX578529.1  GI:27647731
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 367 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAA 1981
              ||| | |||||||| ||
Db          1 AAACAGTTACCTTGGAA 17


RESULT 653
AX578599/c
LOCUS       AX578599                  17 bp    RNA     linear   PAT 11-JAN-2003
DEFINITION  Sequence 437 from Patent WO0211674.
ACCESSION   AX578599
VERSION     AX578599.1  GI:27647801
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 437 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1908 AGATCAACAATACCTTT 1924
              ||||||| ||||| | |
Db         17 AGATCAAGAATACTTGT 1


RESULT 654
AX578694
LOCUS       AX578694                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 532 from Patent WO0211674.
ACCESSION   AX578694
VERSION     AX578694.1  GI:27647896
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 532 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1762 TCATTAAGCTTTTTTTT 1778
              ||||| | | |||||||
Db          1 TCATTCATCCTTTTTTT 17


RESULT 655
AX578704/c
LOCUS       AX578704                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 542 from Patent WO0211674.
ACCESSION   AX578704
VERSION     AX578704.1  GI:27647906
KEYWORDS    .
SOURCE      Homo sapiens (human)
```

```
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 542 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAA 1837
              ||||||||  ||||| |
Db         17 TTTTAGAAAATTTTATA 1


RESULT 656
AX579013
LOCUS       AX579013                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 851 from Patent WO0211674.
ACCESSION   AX579013
VERSION     AX579013.1  GI:27648215
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 851 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1877 GAAATGTCAAATTGATG 1893
              |||||  ||  ||  |||||
Db          1 GAAATATCCAACTGATG 17


RESULT 657
AX579108/c
LOCUS       AX579108                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 946 from Patent WO0211674.
ACCESSION   AX579108
VERSION     AX579108.1  GI:27648310
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 946 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1949 GGTTTTTGTGTCCGCTA 1965
              ||| ||| ||||| |||
Db         17 GGTGTTTTTGTCCACTA 1


RESULT 658
AX579357
LOCUS       AX579357                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1195 from Patent WO0211674.
ACCESSION   AX579357
VERSION     AX579357.1  GI:27648559
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1195 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1953 TTTGTGTCCGCTAAATA 1969
              ||| |||| | ||||||
Db          1 TTTTTGTCAGATAAATA 17


RESULT 659
AX579923
LOCUS       AX579923                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1761 from Patent WO0211674.
ACCESSION   AX579923
VERSION     AX579923.1  GI:27649125
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1761 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
```

```
          Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTTCTC 1579
              || |  ||||||||||
Db          1 CTCCCCAAATCCTTCTC 17


RESULT 660
AX615475
LOCUS       AX615475                 17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 282 from Patent EP1262488.
ACCESSION   AX615475
VERSION     AX615475.1  GI:28446521
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 282 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1965 AAATATTTACCTTGAAA 1981
              ||| || |||||| |||
Db          1 AAAGATCTACCTTTAAA 17


RESULT 661
AX616009/c
LOCUS       AX616009                 17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 816 from Patent EP1262488.
ACCESSION   AX616009
VERSION     AX616009.1  GI:28447055
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 816 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              ||||| | ||||| |||
Db         17 CCCATCCCTTCCTGCTC 1


RESULT 662
AX616010/c
LOCUS       AX616010                 17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 817 from Patent EP1262488.
ACCESSION   AX616010
VERSION     AX616010.1  GI:28447056
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 817 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTTCT 1801
              |||||| | ||||| ||
Db         17 CCCCATCCCTTCCTGCT 1


RESULT 663
AX648721
LOCUS       AX648721                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 561 from Patent EP1273660.
ACCESSION   AX648721
VERSION     AX648721.1  GI:29151539
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 561 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1717 AACTTTGGACCTATTAT 1733
              ||||| ||| ||||| |
Db          1 AACTTAGGATCTATTTT 17


RESULT 664
AX648885/c
LOCUS       AX648885                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 725 from Patent EP1273660.
ACCESSION   AX648885
VERSION     AX648885.1  GI:29151703
```

```
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 725 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              ||||||| |||| | ||
Db         17 TCACTGGATCTGTAGCA 1


RESULT 665
AX671668
LOCUS       AX671668                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 113 from Patent WO03004526.
ACCESSION   AX671668
VERSION     AX671668.1  GI:29330016
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 113 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              ||||||||||  | |||
Db          1 GATCAACAGAAGACCAA 17


RESULT 666
AX672474
LOCUS       AX672474                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 919 from Patent WO03004526.
ACCESSION   AX672474
VERSION     AX672474.1  GI:29330822
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 919 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1615 GAAGAGTTTGTTACCTA 1631
              ||  | ||||||||||||
Db          1 GATCATTTTGTTACCTA 17


RESULT 667
AX673144/c
LOCUS       AX673144                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 1589 from Patent WO03004526.
ACCESSION   AX673144
VERSION     AX673144.1  GI:29331492
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 1589 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || |||||| || ||||
Db         17 TAACTTCTTAAGGGATC 1


RESULT 668
AX673426/c
LOCUS       AX673426                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 1871 from Patent WO03004526.
ACCESSION   AX673426
VERSION     AX673426.1  GI:29331774
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 1871 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
```

```
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAAC 1558
              ||||| |||| |||| |
Db         17 GAGAGCAGGGCAGGATC 1


RESULT 669
AX676068/c
LOCUS       AX676068                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 21 from Patent WO02059381.
ACCESSION   AX676068
VERSION     AX676068.1  GI:29333752
KEYWORDS    .
SOURCE      Mus sp.
  ORGANISM  Mus sp.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Slaugenhaupt,S. and Gusella,J.F.
  TITLE     Gene for identifying individuals with familial dysautonomia
  JOURNAL   Patent: WO 02059381-A 21 01-AUG-2002;
            The General Hospital Corporation (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus sp."
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10095"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1973 ACCTTGAAAAAAAGAAA 1989
              |||| ||||| || |||
Db         17 ACCTAGAAAACAAAAAA 1


RESULT 670
AX688571/c
LOCUS       AX688571                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 1303 from Patent EP1281758.
ACCESSION   AX688571
VERSION     AX688571.1  GI:29411273
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 1303 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1652 TCACTGGTTCTGCATCA 1668
              || ||||| || |||||
Db         17 TCTCTGGTGCTTCATCA 1


RESULT 671
AX688572/c
LOCUS       AX688572                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 1304 from Patent EP1281758.
ACCESSION   AX688572
VERSION     AX688572.1  GI:29411274
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 1304 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1651 TTCACTGGTTCTGCATC 1667
              ||| ||||| || ||||
Db         17 TTCTCTGGTGCTTCATC 1


RESULT 672
AX691383
LOCUS       AX691383                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 4115 from Patent EP1281758.
ACCESSION   AX691383
VERSION     AX691383.1  GI:29414319
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 4115 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1735 AGAAGGTGACAAGTACT 1751
              |||| ||| |||| |||
Db          1 AGAATGTGGCAAGAACT 17


RESULT 673
AX724984
LOCUS       AX724984                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2671 from Patent WO03025176.
ACCESSION   AX724984
VERSION     AX724984.1  GI:30504327
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
```

```
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2671 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              ||||||| ||| || |
Db          1 GATCAACAAATCTACTA 17


RESULT 674
AX725130/c
LOCUS       AX725130                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2817 from Patent WO03025176.
ACCESSION   AX725130
VERSION     AX725130.1  GI:30504473
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2817 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATC 1912
              |||| | |||| |||||
Db         17 CCCTGGCTCAAAAGATC 1


RESULT 675
AX725612/c
LOCUS       AX725612                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3299 from Patent WO03025176.
ACCESSION   AX725612
VERSION     AX725612.1  GI:30504955
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3299 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAAC 1558
              ||||  ||||||||| |
Db         17 GAGACAAGGGAAGGATC 1


RESULT 676
AX725636/c
LOCUS       AX725636                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3323 from Patent WO03025176.
ACCESSION   AX725636
VERSION     AX725636.1  GI:30504979
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3323 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2027 GTAGGAGGCAAAGGTTC 2043
              ||  |||||||||| ||
Db         17 GTCTGAGGCAAAGGATC 1


RESULT 677
AX726337
LOCUS       AX726337                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4024 from Patent WO03025176.
ACCESSION   AX726337
VERSION     AX726337.1  GI:30505680
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 4024 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
```

```
                    /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTTTT 1925
              ||||| | | |||||||
Db          1 GATCACCCAGACCTTTT 17


RESULT 678
AX728311
LOCUS       AX728311                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5998 from Patent WO03025176.
ACCESSION   AX728311
VERSION     AX728311.1  GI:30507654
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5998 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              |||||||| |||  |||
Db          1 GATCAACAAATCTCCAA 17


RESULT 679
AX728452/c
LOCUS       AX728452                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 86 from Patent WO03025175.
ACCESSION   AX728452
VERSION     AX728452.1  GI:30507795
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 86 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1711 TCTCCTAACTTTGGACC 1727
              ||| ||||||| ||| |
Db         17 TCTTCTAACTTAGGATC 1


RESULT 680
AX728622/c
LOCUS       AX728622                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 256 from Patent WO03025175.
ACCESSION   AX728622
VERSION     AX728622.1  GI:30507965
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 256 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTTGAAC 1785
              ||||||| ||| ||| |
Db         17 GCTTTTTCTTTGTGATC 1


RESULT 681
AX728884
LOCUS       AX728884                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 518 from Patent WO03025175.
ACCESSION   AX728884
VERSION     AX728884.1  GI:30508227
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 518 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2013 GATCAAGTCCTCTGGTA 2029
              |||||| || | |||||
Db          1 GATCAACTCTTGTGGTA 17


RESULT 682
AX729106/c
LOCUS       AX729106                  17 bp    DNA     linear   PAT 08-MAY-2003
```

```
DEFINITION  Sequence 740 from Patent WO03025175.
ACCESSION   AX729106
VERSION     AX729106.1  GI:30508449
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 740 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              | || ||| ||||||||
Db         17 TGGCATCTGCAGAGATC 1


RESULT 683
AX729156/c
LOCUS       AX729156                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 790 from Patent WO03025175.
ACCESSION   AX729156
VERSION     AX729156.1  GI:30508499
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 790 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTATC 1999
              |||||||| | || |||
Db         17 AAAGAAAACTTTGGATC 1


RESULT 684
AX729976/c
LOCUS       AX729976                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1610 from Patent WO03025175.
ACCESSION   AX729976
VERSION     AX729976.1  GI:30509319
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 1610 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1711 TCTCCTAACTTTGGACC 1727
              |||||| | |||||| |
Db         17 TCTCCTTATTTTGGATC 1


RESULT 685
AX730554
LOCUS       AX730554                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2188 from Patent WO03025175.
ACCESSION   AX730554
VERSION     AX730554.1  GI:30509897
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 2188 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              |||| |||||| || ||
Db         1 GATCTACAGATGAATAA 17


RESULT 686
AX732166/c
LOCUS       AX732166                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3800 from Patent WO03025175.
ACCESSION   AX732166
VERSION     AX732166.1  GI:30511509
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 3800 27-MAR-2003;
```

```
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCCTTCTC 1579
              ||| |||||||||  ||
Db         17 CTGTAAAAATCCTGATC 1


RESULT 687
AX732384/c
LOCUS       AX732384                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4018 from Patent WO03025175.
ACCESSION   AX732384
VERSION     AX732384.1  GI:30511727
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 4018 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGATC 1912
              ||||| | || ||||||
Db         17 CCCTATAGCACCAGATC 1


RESULT 688
AX733160
LOCUS       AX733160                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4794 from Patent WO03025175.
ACCESSION   AX733160
VERSION     AX733160.1  GI:30512503
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 4794 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1753 GCTCTTTATTCATTAAG 1769
              | ||||| |||||| ||
Db          1 GATCTTTTTTCATTCAG 17


RESULT 689
AX734208/c
LOCUS       AX734208                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5842 from Patent WO03025175.
ACCESSION   AX734208
VERSION     AX734208.1  GI:30513551
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5842 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATC 1904
              || ||| ||| ||||||
Db         17 TTCATGGGCCATAGATC 1


RESULT 690
AX734695/c
LOCUS       AX734695                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 285 from Patent WO03025177.
ACCESSION   AX734695
VERSION     AX734695.1  GI:30513972
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 285 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              || | ||||| ||||||
Db         17 TAACATCTTCTGAGATC 1
```

```
RESULT 691
AX734749/c
LOCUS       AX734749                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 339 from Patent WO03025177.
ACCESSION   AX734749
VERSION     AX734749.1  GI:30514026
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 339 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTGAAC 1785
              || ||||| |||||| |
Db         17 GCCTTTTTGTTTTGATC 1


RESULT 692
AX735618/c
LOCUS       AX735618                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1208 from Patent WO03025177.
ACCESSION   AX735618
VERSION     AX735618.1  GI:30514895
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 1208 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              | || ||| ||||||||
Db         17 TGGCATCTGCAGAGATC 1


RESULT 693
AX736736
LOCUS       AX736736                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2326 from Patent WO03025177.
ACCESSION   AX736736
VERSION     AX736736.1  GI:30516024
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2326 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTTTT 1925
              |||||| || || ||||
Db          1 GATCAAAAAAACTTTTT 17


RESULT 694
AX738626/c
LOCUS       AX738626                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4216 from Patent WO03025177.
ACCESSION   AX738626
VERSION     AX738626.1  GI:30517916
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 4216 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              |||||||| | | ||||
Db         17 TAGCTTCTGCCGGGATC 1


RESULT 695
AX739071
LOCUS       AX739071                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4661 from Patent WO03025177.
ACCESSION   AX739071
VERSION     AX739071.1  GI:30518368
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
```

```
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 4661 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2040 GTTCTATCTGCTTAGCA 2056
              | ||| ||| |||||||
Db          1 GATCTTTCTTCTTAGCA 17


RESULT 696
AX739114
LOCUS       AX739114                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4704 from Patent WO03025177.
ACCESSION   AX739114
VERSION     AX739114.1  GI:30518411
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 4704 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1901 GATCAACAGATCAACAA 1917
              |||| ||| | ||||||
Db          1 GATCTACATACCAACAA 17


RESULT 697
AX745062/c
LOCUS       AX745062                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1027 from Patent WO03031621.
ACCESSION   AX745062
VERSION     AX745062.1  GI:30723729
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1027 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1748 TACTGGCTCTTTATTCA 1764
              |||| ||| || |||||
Db         17 TACTTGCTTTTGATTCA 1


RESULT 698
AX745427/c
LOCUS       AX745427                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1392 from Patent WO03031621.
ACCESSION   AX745427
VERSION     AX745427.1  GI:30724094
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1392 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1829 TCTTTTAAATACATTCC 1845
              ||||||| ||  |||||
Db         17 TCTTTTATATCTATTCC 1


RESULT 699
AX758047/c
LOCUS       AX758047                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 1368 from Patent WO03040369.
ACCESSION   AX758047
VERSION     AX758047.1  GI:32252663
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 1368 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATC 1904
              || |||| |||| ||||
```

```
Db         17 TTTATGTCCCCTGGATC 1


RESULT 700
AX758341/c
LOCUS       AX758341                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 1662 from Patent WO03040369.
ACCESSION   AX758341
VERSION     AX758341.1  GI:32252957
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 1662 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1888 TTGATGTGCCCTAGATC 1904
              ||||||||| |  ||||
Db         17 TTGATGTGCTCCTGATC 1


RESULT 701
AX759011/c
LOCUS       AX759011                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 2332 from Patent WO03040369.
ACCESSION   AX759011
VERSION     AX759011.1  GI:32253627
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 2332 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1542 GAGAGTAGGGAAGGAAC 1558
              ||||| |||| |||| |
Db         17 GAGAGCAGGGCAGGATC 1


RESULT 702
AX760431
LOCUS       AX760431                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 3752 from Patent WO03040369.
ACCESSION   AX760431
VERSION     AX760431.1  GI:32255047
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 3752 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTTTT 1925
              |||| ||| ||| ||||
Db          1 GATCCACAGTACTTTTT 17


RESULT 703
AX760954/c
LOCUS       AX760954                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4275 from Patent WO03040369.
ACCESSION   AX760954
VERSION     AX760954.1  GI:32255570
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4275 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              ||| ||||||  |||||
Db         17 TAGTTTCTTCTTAGATC 1


RESULT 704
AX762523/c
LOCUS       AX762523                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 5844 from Patent WO03040369.
ACCESSION   AX762523
VERSION     AX762523.1  GI:32257139
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```

```
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 5844 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2000 TAGCTTCTTCAGAGATC 2016
              ||||||||  |  |  ||||
Db         17 TAGCTTCTGCCGGGATC 1


RESULT 705
BD067910
LOCUS       BD067910                  17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067910
VERSION     BD067910.1  GI:22613513
KEYWORDS    JP 2001511003-A/750.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 750 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/750
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                   related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTCTC 1802
              ||||||  ||||||  ||
Db          1 CCCATTTTTTCCTAATC 17


RESULT 706
BD067911
LOCUS       BD067911                  17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067911
VERSION     BD067911.1  GI:22613514
KEYWORDS    JP 2001511003-A/751.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 751 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/751
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                   related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              |||||  ||||||  |||
Db          1 CCATTTTTTCCTAATCT 17


RESULT 707
BD067912
LOCUS       BD067912                  17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067912
VERSION     BD067912.1  GI:22613515
KEYWORDS    JP 2001511003-A/752.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 752 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/752
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                   related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
```

```
           FT   source          1. .17
           FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 17;
  Best Local Similarity   82.4%;  Pred. No. 4.3e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1788 CATTCTTTCCTTCTCTG 1804
              |||| ||||||  ||||
Db          1 CATTTTTTCCTAATCTG 17


RESULT 708
A04695/c
LOCUS       A04695                    18 bp    DNA     linear   PAT 21-MAY-1993
DEFINITION  oligonucleotide TG596.
ACCESSION   A04695
VERSION     A04695.1  GI:413605
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Degryse,E:
  TITLE     Process for stabilizing a plasmid contained in a bacterial strain,
            and strain obtained
  JOURNAL   Patent: EP 0258118-A 2 02-MAR-1988;
            TRANSGENE S.A
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2055 CAACTAGTTAATAAGTG 2071
              ||||| |||| |||| |
Db         18 CAACTCGTTATTAAGCG 2


RESULT 709
A88567/c
LOCUS       A88567                    18 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 715 from Patent WO9833904.
ACCESSION   A88567
VERSION     A88567.1  GI:6737137
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 715 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAA 1985
              ||||| ||| |||| ||
Db         17 ATTTATCTTAAAAATAA 1


RESULT 710
A89350/c
LOCUS       A89350                    18 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 1498 from Patent WO9833904.
ACCESSION   A89350
VERSION     A89350.1  GI:6737920
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 1498 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1877 GAAATGTCAAATTGATG 1893
              |||||||| || ||| |
Db         18 GAAATGTCCAAATGAAG 2


RESULT 711
A90534/c
LOCUS       A90534                    18 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 715 from Patent EP0856579.
ACCESSION   A90534
VERSION     A90534.1  GI:6739048
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 715 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAA 1985
              ||||| ||| |||| ||
Db         17 ATTTATCTTAAAAATAA 1


RESULT 712
A92198
LOCUS       A92198                    18 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 32 from Patent WO9820144.
ACCESSION   A92198
VERSION     A92198.1  GI:6740993
KEYWORDS    .
SOURCE      unidentified
```

```
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Hawkes,T.R. and Knight,M.E.
  TITLE     HERBICIDE RESISTANT PLANTS
  JOURNAL   Patent: WO 9820144-A 32 14-MAY-1998;
            HAWKES TIMOTHY ROBERT (GB); KNIGHT MARY ELIZABETH (GB)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1932 GTGTTAAGGTAATGGTT 1948
              || | || |||||||||
Db          1 GTCTCAATGTAATGGTT 17


RESULT 713
AR029832
LOCUS       AR029832                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 21 from patent US 5861244.
ACCESSION   AR029832
VERSION     AR029832.1  GI:5943046
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Wang,C.-G. and Hepburn,A.G.
  TITLE     Genetic sequence assay using DNA triple strand formation
  JOURNAL   Patent: US 5861244-A 21 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAGGA 1556
              |||||||  |||||| |
Db          2 AGGAGAGAGGGGAAGAA 18


RESULT 714
AR039685
LOCUS       AR039685                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 533 from patent US 5807743.
ACCESSION   AR039685
VERSION     AR039685.1  GI:5959048
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stinchcomb,D.T. and McSwiggen,J.A.
  TITLE     Interleukin-2 receptor gamma-chain ribozymes
  JOURNAL   Patent: US 5807743-A 533 15-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGAAC 1598
              ||| || |||||||| |
Db          1 CCGGACTGACTGGGACC 17


RESULT 715
AR076765/c
LOCUS       AR076765                 18 bp    DNA     linear   PAT 30-AUG-2000
DEFINITION  Sequence 9 from patent US 5959097.
ACCESSION   AR076765
VERSION     AR076765.1  GI:10003511
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Monia,B.P. and Cowsert,L.M.
  TITLE     Antisense modulation of MEK2 expression
  JOURNAL   Patent: US 5959097-A 9 28-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGAAG 1618
              | |||||| || |||||
Db         17 TGCTGGCCCGGAGGAAG 1


RESULT 716
AR083565/c
LOCUS       AR083565                 18 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 5 from patent US 5976879.
ACCESSION   AR083565
VERSION     AR083565.1  GI:10010338
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kole,R. and Dominski,Z.
  TITLE     Antisense oligonucleotides which combat aberrant splicing and
            methods of using the same
  JOURNAL   Patent: US 5976879-A 5 02-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | |||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 717
AR098359/c
LOCUS       AR098359                 18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 19 from patent US 6075123.
ACCESSION   AR098359
VERSION     AR098359.1  GI:12807616
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
```

```
  AUTHORS   Lahti,J.M. and Kidd,V.J.
  TITLE     Cyclin-C variants, and diagnostic and therapeutic uses thereof
  JOURNAL   Patent: US 6075123-A 19 13-JUN-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1702 GCTGAGCTATCTCCTAA 1718
              ||||||||||||  | |
Db         18 GCTGAGCTATCTGTTGA 2


RESULT 718
AR101748
LOCUS       AR101748                 18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 10 from patent US 6083702.
ACCESSION   AR101748
VERSION     AR101748.1  GI:12812546
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Mitchell,L.G. and Garcia-Blanco,M.A.
  TITLE     Methods and compositions for use in spliceosome mediated RNA
            trans-splicing
  JOURNAL   Patent: US 6083702-A 10 04-JUL-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| |||||||  ||||
Db          1 TGCTTCACCCGGGCCTG 17


RESULT 719
AR101833/c
LOCUS       AR101833                 18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 24 from patent US 6083713.
ACCESSION   AR101833
VERSION     AR101833.1  GI:12812631
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Manly,S.P., Kozlowski,M.R. and Neve,R.L.
  TITLE     Cloning and expression of .beta.APP-C100 receptor (C100-R)
  JOURNAL   Patent: US 6083713-A 24 04-JUL-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1765 TTAAGCTTTTTTTTTTT 1781
              ||  |||||| ||||||
Db         18 TTTGCTTTGTTTTTT 2


RESULT 720
AR166237
LOCUS       AR166237                 18 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 10 from patent US 6280978.
ACCESSION   AR166237
VERSION     AR166237.1  GI:16241471
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Mitchell,L.G. and Garcia-Blanco,M.A.
  TITLE     Methods and compositions for use in spliceosome mediated RNA
            trans-splicing
  JOURNAL   Patent: US 6280978-A 10 28-AUG-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1662 TGCATCACCCGCCCCTG 1678
              ||| |||||||  ||||
Db          1 TGCTTCACCCGGGCCTG 17


RESULT 721
AR174193/c
LOCUS       AR174193                 18 bp    DNA     linear   PAT 17-DEC-2001
DEFINITION  Sequence 19 from patent US 6306648.
ACCESSION   AR174193
VERSION     AR174193.1  GI:17914513
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Lahti,J.M. and Kidd,V.J.
  TITLE     Cyclin-C variants, and diagnostic and therapeutic uses thereof
  JOURNAL   Patent: US 6306648-A 19 23-OCT-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1702 GCTGAGCTATCTCCTAA 1718
              ||||||||||||  | |
Db         18 GCTGAGCTATCTGTTGA 2


RESULT 722
BD192498/c
LOCUS       BD192498                 18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Compositions and methods for the delivery of oligonucleotides via
            the alimentary canal.
ACCESSION   BD192498
VERSION     BD192498.1  GI:33002237
KEYWORDS    JP 2002510319-A/63.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Teng,C.L. and Hardee,G.
  TITLE     Compositions and methods for the delivery of oligonucleotides via
            the alimentary canal
```

```
  JOURNAL   Patent: JP 2002510319-A 63 02-APR-2002;
            ISIS PHARMACEUTICALS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002510319-A/63
            PD   02-APR-2002
            PF   01-JUL-1998 JP 1999507295
            PR   01-JUL-1997 US    08/886829
            PI   CHING LEOU TENG,GREG HARDEE
            PC   C12Q1/68,A61K9/127,A61K48/00,C07H21/04
            CC   Description of Combined DNA/RNA Molecule:
            U at positions 3,5,6,
            CC             10 and 11
            CC   are RNA
            CC   Description of Artificial Sequence: Novel Sequence FH   Key
                     Location/Qualifiers.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 723
BD242588
LOCUS       BD242588                 18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Host-encoded protein expressed by Marek's disease virus
            (MDV)-infected cell, and antibody against it.
ACCESSION   BD242588
VERSION     BD242588.1  GI:33052358
KEYWORDS    JP 2002518995-A/2.
SOURCE      Gallus sp.
  ORGANISM  Gallus sp.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
            Phasianinae; Gallus.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Burgess,S.C., Davison,T.F. and Ross,L.J.N.
  TITLE     Host-encoded protein expressed by Marek's disease virus
            (MDV)-infected cell, and antibody against it
  JOURNAL   Patent: JP 2002518995-A 2 02-JUL-2002;
            INSTITUTE FOR ANIMAL HEALTH LTD
COMMENT     OS   Gallus sp. (chicken)
            PN   JP 2002518995-A/2
            PD   02-JUL-2002
            PF   22-APR-1999 JP 2000546004
            PR   29-APR-1998 GB    9809070.7
            PI   SHANE CAMPBELL BURGESS,THORNTON FREDERICK
            DAVISON,LOUIS JOSEPH
            PI   NORMAN ROSS
            PC   C12N15/09,A61K38/00,A61K39/395,A61P31/12,C07K14/055,C07K16/08,
            PC   C12N1/15,
            PC   C12N1/19,C12N1/21,C12N5/10,C12P21/02,C12P21/08//(C12P21/08, PC
              C12R1:91),
            PC   C12N15/00,A61K37/02,C12N5/00
            CC   Host-encoded protein expressed by Marek's disease virus (MDV)-
            CC             infected
            CC   cell, and antibody against it
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Gallus sp. (chicken)'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Gallus sp."
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9036"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1549 GGGAAGGAACAGGACTG 1565
              || ||||||| ||| ||
Db          2 GGAAAGGAACTGGAGTG 18


RESULT 724
BD242696
LOCUS       BD242696                 18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Interleukin-1 homolog ZIL1A4.
ACCESSION   BD242696
VERSION     BD242696.1  GI:33052466
KEYWORDS    JP 2002528079-A/30.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   West,R.R., Sheppard,P.O. and Gao,Z.
  TITLE     Interleukin-1 homolog ZIL1A4
  JOURNAL   Patent: JP 2002528079-A 30 03-SEP-2002;
            ZYMOGENETICS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002528079-A/30
            PD   03-SEP-2002
            PF   27-OCT-1999 JP 2000578451
            PR   27-OCT-1998 US    09/179614
            PI   ROBERT R WEST,PAUL O SHEPPARD,ZEREN GAO
            PC   C12N15/09,A61K38/00,A61P37/02,C07K14/545,C12N1/15,C12N1/19, PC
              C12N1/21,
            PC   C12N5/10,C12P21/02,C12N15/00,C12N5/00,A61K37/02 CC
            oligonucleotide primer ZC20,360
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCTCT 1803
              ||  |||||||||| ||
Db          2 CCCCTCTTTCCTTCACT 18


RESULT 725
BD266392/c
LOCUS       BD266392                 18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Universal arrays.
ACCESSION   BD266392
VERSION     BD266392.1  GI:33076160
KEYWORDS    JP 2002539849-A/392.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
            Lockhart,D.J., Ryder,T. and Sklar,P.
  TITLE     Universal arrays
  JOURNAL   Patent: JP 2002539849-A 392 26-NOV-2002;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002539849-A/392
            PD   26-NOV-2002
            PF   27-MAR-2000 JP 2000608794
```

```
            PR   26-MAR-1999 US    60/126473,23-JUN-1999 US    60/140359 PI
            JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
            HUANG,PAUL KAPLAN,ERIC
            PI   S LANDER,
            PI   DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
            PC   C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
             G01N33/566,
            PC   G01N37/00,C12N15/00,C12N15/00,C12N15/00
            CC   Primer
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1573 CCTTCTCCACCGCACAG 1589
              | | |||||| ||||||
Db         18 CATGCTCCACAGCACAG 2


RESULT 726
BD266403
LOCUS       BD266403                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Universal arrays.
ACCESSION   BD266403
VERSION     BD266403.1  GI:33076171
KEYWORDS    JP 2002539849-A/403.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
            Lockhart,D.J., Ryder,T. and Sklar,P.
  TITLE     Universal arrays
  JOURNAL   Patent: JP 2002539849-A 403 26-NOV-2002;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002539849-A/403
            PD   26-NOV-2002
            PF   27-MAR-2000 JP 2000608794
            PR   26-MAR-1999 US    60/126473,23-JUN-1999 US    60/140359 PI
            JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
            HUANG,PAUL KAPLAN,ERIC
            PI   S LANDER,
            PI   DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
            PC   C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
             G01N33/566,
            PC   G01N37/00,C12N15/00,C12N15/00,C12N15/00
            CC   Primer
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGAAC 1598
              || |  ||||||||||||
Db          1 CCTCCGAGACTGGGAAC 17


RESULT 727
I25095/c
LOCUS       I25095                    18 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 17 from patent US 5547867.
ACCESSION   I25095
VERSION     I25095.1  GI:1604965
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kara,B.V., Hockney,R.C. and Fitton,J.E.
  TITLE     Fermentation processes for preparing soluble ricin A
  JOURNAL   Patent: US 5547867-A 17 20-AUG-1996;
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAAGTGTG 1995
              ||  |||||||| ||||
Db         18 AAGCAAAGAAAACTGTG 2


RESULT 728
I49115/c
LOCUS       I49115                    18 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 5 from patent US 5627274.
ACCESSION   I49115
VERSION     I49115.1  GI:2467578
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kole,R. and Dominski,Z.
  TITLE     Antisense oligonucleotides which combat aberrant splicing and
            methods of using the same
  JOURNAL   Patent: US 5627274-A 5 06-MAY-1997;
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="unknown"
                      /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 729
I55011
LOCUS       I55011                    18 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 35 from patent US 5646156.
ACCESSION   I55011
VERSION     I55011.1  GI:2476214
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Jacobson,M.A., Johnson,R.G. and Salvatore,C.A.
  TITLE     Inhibition of eosinophil activation through A3 adenosine receptor
            antagonism
  JOURNAL   Patent: US 5646156-A 35 08-JUL-1997;
```

```
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1624 GTTACCTACCTTACTAT 1640
              ||||||||| | || ||
Db          1 GTTACCTACATCACCAT 17


RESULT 730
I64739/c
LOCUS       I64739                  18 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 5 from patent US 5665593.
ACCESSION   I64739
VERSION     I64739.1  GI:2481633
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kole,R. and Dominski,Z.
  TITLE     Antisense oligonucleotides which combat aberrant splicing and
            methods of using the same
  JOURNAL   Patent: US 5665593-A 5 09-SEP-1997;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1930 CAGTGTTAAGGTAATGG 1946
              | | ||||||||||| |
Db         18 CTGGGTTAAGGTAATAG 2


RESULT 731
AR187545
LOCUS       AR187545                18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 3033 from patent US 6346398.
ACCESSION   AR187545
VERSION     AR187545.1  GI:20233510
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 3033 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | || | ||||||||||
Db          2 ACTCCTGCCTTCTCTGA 18


RESULT 732
AR201795/c
LOCUS       AR201795                18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 10 from patent US 6361941.
ACCESSION   AR201795
VERSION     AR201795.1  GI:20256334
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Todd,A.V., Fuery,C.J. and Cairns,M.J.
  TITLE     Catalytic nucleic acid-based diagnostic methods
  JOURNAL   Patent: US 6361941-A 10 26-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGG 1614
              | ||||||||||| | ||
Db         18 CTCCTCCTGGCCGGCGG 2


RESULT 733
AR201798/c
LOCUS       AR201798                18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 13 from patent US 6361941.
ACCESSION   AR201798
VERSION     AR201798.1  GI:20256337
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Todd,A.V., Fuery,C.J. and Cairns,M.J.
  TITLE     Catalytic nucleic acid-based diagnostic methods
  JOURNAL   Patent: US 6361941-A 13 26-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGG 1614
              | ||||||||||| | ||
Db         18 CTCCTCCTGGCCGGCGG 2


RESULT 734
AR201801/c
LOCUS       AR201801                18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 16 from patent US 6361941.
ACCESSION   AR201801
VERSION     AR201801.1  GI:20256340
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Todd,A.V., Fuery,C.J. and Cairns,M.J.
  TITLE     Catalytic nucleic acid-based diagnostic methods
  JOURNAL   Patent: US 6361941-A 16 26-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

```
  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCCTGGGG 1614
              | |||||||||| | ||
Db         18 CTCCTCCTGGCCGGCGG 2


RESULT 735
AR294057
LOCUS       AR294057                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5792 from patent US 6537751.
ACCESSION   AR294057
VERSION     AR294057.1  GI:31681341
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 5792 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCTCCACC 1583
              ||| ||| ||| |||||
Db          2 AAACATCATTCACCACC 18


RESULT 736
AR295859/c
LOCUS       AR295859                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 7594 from patent US 6537751.
ACCESSION   AR295859
VERSION     AR295859.1  GI:31683143
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 7594 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1539 TAGGAGAGTAGGGAAGG 1555
              ||  |||||||||| ||
Db         17 TATTAGAGTAGGGATGG 1


RESULT 737
AR297391
LOCUS       AR297391                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 9126 from patent US 6537751.
ACCESSION   AR297391
VERSION     AR297391.1  GI:31684675
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 9126 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1538 TTAGGAGAGTAGGGAAG 1554
              || |||||| || ||||
Db          2 TTGGGAGAGAAGAGAAG 18


RESULT 738
AR324059
LOCUS       AR324059                  18 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 1461 from patent US 6566127.
ACCESSION   AR324059
VERSION     AR324059.1  GI:33709867
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 1461 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCTGA 1805
              | || | ||||||||||
Db          2 ACTCCTGCCTTCTCTGA 18


RESULT 739
AX011593
LOCUS       AX011593                  18 bp    DNA     linear   PAT 06-SEP-2000
DEFINITION  Sequence 6 from Patent WO9955860.
ACCESSION   AX011593
VERSION     AX011593.1  GI:9998117
KEYWORDS    .
SOURCE      Gallus sp.
  ORGANISM  Gallus sp.
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
            Phasianinae; Gallus.
REFERENCE   1
  AUTHORS   Burgess,S.C., Davison,T.F. and Ross,L.J.
  TITLE     Host-encoded protein expressed on marek's disease (mdv)-infected
            cells and antibody thereto
  JOURNAL   Patent: WO 9955860-A 6 04-NOV-1999;
            ANIMAL HEALTH INST (GB); BURGESS SHANE CAMPBELL (GB); DAVISON
            THORNTON FREDERICK (GB); ROSS LOUIS JOSEPH NORMAN (GB)
FEATURES             Location/Qualifiers
```

```
    source          1. .18
                    /organism="Gallus sp."
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9036"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1549 GGGAAGGAACAGGACTG 1565
              || ||||||| ||| ||
Db          2 GGAAAGGAACTGGAGTG 18


RESULT 740
AX014670/c
LOCUS       AX014670                 18 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 7 from Patent WO9953091.
ACCESSION   AX014670
VERSION     AX014670.1  GI:10040944
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Holinski-Feder,E., Grimm,L., Ueffing,M. and Meitinger,T.
  TITLE     Dna coding for gdnf, parts of said dna and gdnf variants
  JOURNAL   Patent: WO 9953091-A 7 21-OCT-1999;
            HOLINSKI FEDER ELKE (DE); GRIMM LENA (DE); UEFFING MARIUS (DE);
            LUDWIG MAXIMILIANS UNI MUENCHE (DE); MEITINGER THOMAS (DE)
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAGTT 1622
              || | |||| |||||||
Db         18 GGTCAGGGGCAAGAGTT 2


RESULT 741
AX132951/c
LOCUS       AX132951                 18 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 4169 from Patent WO0130362.
ACCESSION   AX132951
VERSION     AX132951.1  GI:14139261
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 4169 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="Homo sapiens"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:9606"
                      /note="Hammerhead ribozyme recognition site for cdc 2
                      kinase"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2059 TAGTTAATAAGTGGTAT 2075
              |||||| | | ||||||
Db         18 TAGTTAGTCAATGGTAT 2


RESULT 742
AX358029
LOCUS       AX358029                 18 bp    DNA     linear   PAT 13-FEB-2002
DEFINITION  Sequence 75 from Patent WO0194413.
ACCESSION   AX358029
VERSION     AX358029.1  GI:18674800
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Mikesell,G.E., Chang,H., Finger,J.N., Yang,G., Lu,P., Zhou,X.D. and
            Peach,R.
  TITLE     B7-related nucleic acids and polypeptides and their uses for
            immunomodulation
  JOURNAL   Patent: WO 0194413-A 75 13-DEC-2001;
            Bristol-Myers Squibb Company (US)
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="Primer"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1797 CTTCTCTGAAAGTGGTG 1813
              ||| ||||||| || ||
Db          2 CTTATCTGAAATTGCTG 18


RESULT 743
AX599314
LOCUS       AX599314                 18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 654 from Patent WO02077272.
ACCESSION   AX599314
VERSION     AX599314.1  GI:28399456
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 654 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32630"
                      /note="Detection oligonucleotide for APC"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAA 1837
              | ||||| | |||||||
Db          1 TATTAGAGTGTTTTAAA 17
```

```
RESULT 744
AX599418
LOCUS       AX599418                  18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 758 from Patent WO02077272.
ACCESSION   AX599418
VERSION     AX599418.1  GI:28399562
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 758 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for HIC-1"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||  ||||||| |||
Db          1 TTTTAGAGTGTTAGGGT 17


RESULT 745
AX599668
LOCUS       AX599668                  18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 1008 from Patent WO02077272.
ACCESSION   AX599668
VERSION     AX599668.1  GI:28399816
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 1008 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for N-MYC"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1922 TTTTTTTTCAGTGTTAA 1938
              | ||||||  ||| ||||
Db          2 TATTTTTTGAGTTTTAA 18


RESULT 746
AX708580
LOCUS       AX708580                  18 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 31 from Patent WO02101089.
ACCESSION   AX708580
VERSION     AX708580.1  GI:29564347
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Snaidr,J. and Beimfohr,C.
  TITLE     Method for specific, fast detection of threadlike bacteria
  JOURNAL   Patent: WO 02101089-A 31 19-DEC-2002;
            Vermicon AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonukleotid"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1661 CTGCATCACCCGCCCCT 1677
              ||||| ||||  |||||
Db          2 CTGCACCACCGACCCCT 18


RESULT 747
AX767734
LOCUS       AX767734                  18 bp    DNA     linear   PAT 02-JUL-2003
DEFINITION  Sequence 382 from Patent WO03044226.
ACCESSION   AX767734
VERSION     AX767734.1  GI:32436339
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Caldwell,C., Genc,B., Becker,E., Maier,S. and
            Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lymphoid cell
            proliferative disorder
  JOURNAL   Patent: WO 03044226-A 382 30-MAY-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for APC"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAA 1837
              | ||||| | |||||||
Db          1 TATTAGAGTGTTTTAAA 17


RESULT 748
AX767800
LOCUS       AX767800                  18 bp    DNA     linear   PAT 02-JUL-2003
DEFINITION  Sequence 448 from Patent WO03044226.
ACCESSION   AX767800
VERSION     AX767800.1  GI:32436486
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
```

```
  AUTHORS   Burger,M., Caldwell,C., Genc,B., Becker,E., Maier,S. and
            Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lymphoid cell
            proliferative disorder
  JOURNAL   Patent: WO 03044226-A 448 30-MAY-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for HIC-1"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||  ||||||| |||
Db          1 TTTTAGAGTGTTAGGGT 17


RESULT 749
AX785452/c
LOCUS       AX785452                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 63 from Patent WO03050301.
ACCESSION   AX785452
VERSION     AX785452.1  GI:32953072
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gurling,H.M.
  TITLE     Susceptibility locus for schizophrenia
  JOURNAL   Patent: WO 03050301-A 63 19-JUN-2003;
            Gurling, Hugh Malcolm Douglas (GB)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAAAA 1982
              ||||| ||||||  |||
Db         18 AATATATACCTTCTAAA 2


RESULT 750
AX796170
LOCUS       AX796170                  18 bp    DNA     linear   PAT 04-OCT-2003
DEFINITION  Sequence 513 from Patent WO03052135.
ACCESSION   AX796170
VERSION     AX796170.1  GI:37516836
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Field,J.K., Genc,B., Liloglou,T., Lipscher,E., Maier,S.
            and Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lung cell
            proliferative disorder
  JOURNAL   Patent: WO 03052135-A 513 26-JUN-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for APC"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTAAA 1837
              | ||||| | |||||||
Db          1 TATTAGAGTGTTTTAAA 17


RESULT 751
AX796302
LOCUS       AX796302                  18 bp    DNA     linear   PAT 04-OCT-2003
DEFINITION  Sequence 645 from Patent WO03052135.
ACCESSION   AX796302
VERSION     AX796302.1  GI:37516968
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Field,J.K., Genc,B., Liloglou,T., Lipscher,E., Maier,S.
            and Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lung cell
            proliferative disorder
  JOURNAL   Patent: WO 03052135-A 645 26-JUN-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for HIC-1"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||  ||||||| |||
Db          1 TTTTAGAGTGTTAGGGT 17


RESULT 752
AX822849/c
LOCUS       AX822849                  18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 741 from Patent EP1340818.
ACCESSION   AX822849
VERSION     AX822849.1  GI:39749485
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: EP 1340818-A 741 03-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for SFN"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;
```

```
Qy       1713 TCCTAACTTTGGACCTA 1729
              || |||| || ||||||
Db         18 TCATAACGTTCGACCTA 2


RESULT 753
AX823130
LOCUS       AX823130                  18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 1022 from Patent EP1340818.
ACCESSION   AX823130
VERSION     AX823130.1  GI:39749766
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: EP 1340818-A 1022 03-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for HIC-1"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||  ||||||| |||
Db          1 TTTTAGAGTGTTAGGGT 17


RESULT 754
AX826489/c
LOCUS       AX826489                  18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 741 from Patent WO03072821.
ACCESSION   AX826489
VERSION     AX826489.1  GI:39752003
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferactive disorder
  JOURNAL   Patent: WO 03072821-A 741 04-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for SFN"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1713 TCCTAACTTTGGACCTA 1729
              || |||| || ||||||
Db         18 TCATAACGTTCGACCTA 2


RESULT 755
AX826770
LOCUS       AX826770                  18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 1022 from Patent WO03072821.
ACCESSION   AX826770
VERSION     AX826770.1  GI:39752284
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferactive disorder
  JOURNAL   Patent: WO 03072821-A 1022 04-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for HIC-1"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1925 TTTTTCAGTGTTAAGGT 1941
              ||||  ||||||| |||
Db          1 TTTTAGAGTGTTAGGGT 17


RESULT 756
BD009173
LOCUS       BD009173                  18 bp    DNA     linear   PAT 31-JAN-2002
DEFINITION  Herbicide resistant plants.
ACCESSION   BD009173
VERSION     BD009173.1  GI:18637546
KEYWORDS    JP 2001503625-A/29.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Thompson,P.A., Knight,M.E., Jepson,I., Thomas,P.G. and Hawkes,T.R.
  TITLE     Herbicide resistant plants
  JOURNAL   Patent: JP 2001503625-A 29 21-MAR-2001;
            ZENECA LTD
COMMENT     OS   Unidentified
            PN   JP 2001503625-A/29
            PD   21-MAR-2001
            PF   31-OCT-1997 JP 1998521131
            PR   07-NOV-1996 GB    9623248.3,13-DEC-1996 GB    9625957.7 PR
            25-FEB-1997 GB    9703855.8
            PI   PAUL ANTHONY THOMPSON,MARY ELIZABETH KNIGHT,IAN JEPSON, PI
            PAUL GRAHAM THOMAS,
            PI   TIMOTHY ROBERT HAWKES
            PC   C12N15/82,C12N15/53,C12N15/54,C12N15/55,C12N15/60,A01H5/00 CC
             Strandedness: Unknown;
            CC   Topology: Unknown;
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1932 GTGTTAAGGTAATGGTT 1948
```

```
              || | || |||||||||
Db          1 GTCTCAATGTAATGGTT 17


RESULT 757
BD066080/c
LOCUS       BD066080                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066080
VERSION     BD066080.1  GI:22611683
KEYWORDS    JP 2001511000-A/715.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 715 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/715
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Unknown'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1969 ATTTACCTTGAAAAAAA 1985
              ||||| ||| |||| ||
Db         17 ATTTATCTTAAAAATAA 1


RESULT 758
BD066863/c
LOCUS       BD066863                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066863
VERSION     BD066863.1  GI:22612466
KEYWORDS    JP 2001511000-A/1498.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 1498 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/1498
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Unknown'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1877 GAAATGTCAAATTGATG 1893
              |||||||| || ||| |
Db         18 GAAATGTCCAAATGAAG 2


RESULT 759
BD088486/c
LOCUS       BD088486                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD088486
VERSION     BD088486.1  GI:22634096
KEYWORDS    JP 2001321190-A/730.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 730 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/730
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                  Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1589 GACTGGGAACCCCTCCT 1605
              |||||||| ||| | ||
Db         17 GACTGGGATCCCTTGCT 1


RESULT 760
BD089251/c
LOCUS       BD089251                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD089251
VERSION     BD089251.1  GI:22634861
KEYWORDS    JP 2001321190-A/1495.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Soeda,E.
  TITLE     A method of arraying genome clone
  JOURNAL   Patent: JP 2001321190-A 1495 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
            GENOTECHS
COMMENT     OS   Artificial Sequence
```

```
            PN   JP 2001321190-A/1495
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
                   Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1546 GTAGGGAAGGAACAGGA 1562
              |||||| || | |||||
Db         17 GTAGGGCAGAAGCAGGA 1


RESULT 761
AB069337/c
LOCUS       AB069337                 18 bp    DNA     linear   SYN 21-MAY-2003
DEFINITION  Synthetic construct DNA, reverse primer for human STS sts-D87845 at
            1p36.
ACCESSION   AB069337
VERSION     AB069337.1  GI:15130141
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
            Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
            Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
            and Soeda,E.
  TITLE     A BAC-based STS-content map spanning a 35-Mb region of human
            chromosome 1p35-p36
  JOURNAL   Genomics 74 (1), 55-70 (2001)
  MEDLINE   21269192
   PUBMED   11374902
REFERENCE   2  (bases 1 to 18)
  AUTHORS   Horii,A.
  TITLE     Direct Submission
  JOURNAL   Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
            Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
            Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
            Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
     misc_feature    1. .18
                     /note="reverse primer for human STS sts-D87845 at 1p36
                     sts-D87845 obtained from clones B39G19, B137C20, B137C19,
                     B370D21, B229A14, B111D20, B329I20, B329H5, B39J18,
                     B143J21, Human BAC library RPCI-11"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1589 GACTGGGAACCCCTCCT 1605
              |||||||| ||| | ||
Db         17 GACTGGGATCCCTTGCT 1


RESULT 762
AB175212/c
LOCUS       AB175212                 18 bp    DNA     linear   SYN 26-MAR-2004
DEFINITION  Synthetic construct DNA, reverse primer for Japanese flounder
            microsatellite sequence Poli21HFS-M.
ACCESSION   AB175212
VERSION     AB175212.1  GI:45752535
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Fuji,K., Kobayashi,K., Mizuta,A., Hasegawa,O., Tabata,K.,
            Sakamoto,T. and Okamoto,N.
  TITLE     A genetic linkage map of the Japanease Flounder, (Paralichthys
            olivaceus)
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 18)
  AUTHORS   Mizuta,A., Tabata,K., Kobayashi,K., Fuji,K., Sakamoto,T. and
            Okamoto,N.
  TITLE     Direct Submission
  JOURNAL   Submitted (24-MAR-2004) Nobuaki Okamoto, Tokyo University of Marine
            Science and Technology, Department of Marine Biosciences; 4-5-7
            Konan, Minato-ku, Tokyo 108-8477, Japan
            (E-mail:nokamoto@s.kaiyodai.ac.jp, Tel:81-3-5463-0547,
            Fax:81-3-5463-0552)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="other DNA"
                     /db_xref="taxon:32630"
     misc_feature    1. .18
                     /note="reverse primer for Japanese flounder microsatellite
                     sequence Poli21MHFS"

  Query Match             2.2%;  Score 12.2;  DB 1;  Length 18;
  Best Local Similarity   82.4%;  Pred. No. 4.5e+02;
  Matches   14;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2011 GAGATCAAGTCCTCTGG 2027
              ||  |||| ||||||||
Db         18 GACTTCAACTCCTCTGG 2


RESULT 763
AR029950
LOCUS       AR029950                 13 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 139 from patent US 5861244.
ACCESSION   AR029950
VERSION     AR029950.1  GI:5943164
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 13)
  AUTHORS   Wang,C.-G. and Hepburn,A.G.
  TITLE     Genetic sequence assay using DNA triple strand formation
  JOURNAL   Patent: US 5861244-A 139 19-JAN-1999;
FEATURES             Location/Qualifiers
     source          1. .13
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCT 1801
              ||||||||||||
Db          2 TTCTTTCCTTCT 13
```

```
RESULT 764
A87995/c
LOCUS       A87995                    14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 143 from Patent WO9833904.
ACCESSION   A87995
VERSION     A87995.1  GI:6736565
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 143 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         14 CCCCTCCTGGCC 3


RESULT 765
A89962/c
LOCUS       A89962                    14 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 143 from Patent EP0856579.
ACCESSION   A89962
VERSION     A89962.1  GI:6738476
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 143 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         14 CCCCTCCTGGCC 3


RESULT 766
AR235566/c
LOCUS       AR235566                  14 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 65 from patent US 6461810.
ACCESSION   AR235566
VERSION     AR235566.1  GI:27278787
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Fresco,J.R. and Johnson,M.D.
  TITLE     Triplex in-situ hybridization
  JOURNAL   Patent: US 6461810-A 65 08-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1572 TCCTTCTCCACC 1583
              ||||||||||||
Db         12 TCCTTCTCCACC 1


RESULT 767
BD065508/c
LOCUS       BD065508                  14 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065508
VERSION     BD065508.1  GI:22611111
KEYWORDS    JP 2001511000-A/143.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 14)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 143 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/143
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .14
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .14
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         14 CCCCTCCTGGCC 3


RESULT 768
AR131778/c
LOCUS       AR131778                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 203 from patent US 6194150.
ACCESSION   AR131778
VERSION     AR131778.1  GI:14120681
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 203 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
```

/mol_type="unassigned DNA"

Query Match 2.1%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1935 TTAAGGTAATGG 1946
||||||||||||
Db 15 TTAAGGTAATGG 4

RESULT 769
AR131779/c
LOCUS AR131779 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 204 from patent US 6194150.
ACCESSION AR131779
VERSION AR131779.1 GI:14120682
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 204 27-FEB-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.1%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1935 TTAAGGTAATGG 1946
||||||||||||
Db 14 TTAAGGTAATGG 3

RESULT 770
AR170919
LOCUS AR170919 15 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 1 from patent US 6297006.
ACCESSION AR170919
VERSION AR170919.1 GI:17909869
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Drmanac,R.T., Drmanac,S., Hou,A. and Hauser,B.
TITLE Methods for sequencing repetitive sequences and for determining the order of sequence subfragments
JOURNAL Patent: US 6297006-A 1 02-OCT-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.1%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 4.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1770 CTTTTTTTTTTG 1782
|||||| ||||||
Db 2 CTTTTTNTTTTG 14

RESULT 771
AR170920/c
LOCUS AR170920 15 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 2 from patent US 6297006.
ACCESSION AR170920
VERSION AR170920.1 GI:17909870
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Drmanac,R.T., Drmanac,S., Hou,A. and Hauser,B.
TITLE Methods for sequencing repetitive sequences and for determining the order of sequence subfragments
JOURNAL Patent: US 6297006-A 2 02-OCT-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.1%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 4.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1770 CTTTTTTTTTTG 1782
|||||| ||||||
Db 14 CTTTTTNTTTTG 2

RESULT 772
AR175435
LOCUS AR175435 15 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 2 from patent US 6309824.
ACCESSION AR175435
VERSION AR175435.1 GI:17916734
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Drmanac,R.T.
TITLE Methods for analyzing a target nucleic acid using immobilized heterogeneous mixtures of oligonucleotide probes
JOURNAL Patent: US 6309824-A 2 30-OCT-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 2.1%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 4.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1770 CTTTTTTTTTTG 1782
|||||| ||||||
Db 2 CTTTTTNTTTTG 14

RESULT 773
AR175436/c
LOCUS AR175436 15 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 3 from patent US 6309824.
ACCESSION AR175436
VERSION AR175436.1 GI:17916735
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Drmanac,R.T.
TITLE Methods for analyzing a target nucleic acid using immobilized heterogeneous mixtures of oligonucleotide probes
JOURNAL Patent: US 6309824-A 3 30-OCT-2001;
FEATURES Location/Qualifiers
source 1. .15
/organism="unknown"
/mol_type="unassigned DNA"

```
  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db         14 CTTTTTNTTTTTG 2


RESULT 774
I77877/c
LOCUS       I77877                   15 bp    DNA     linear   PAT 03-APR-1998
DEFINITION  Sequence 584 from patent US 5693532.
ACCESSION   I77877
VERSION     I77877.1  GI:3014031
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
  TITLE     Respiratory syncytial virus ribozymes
  JOURNAL   Patent: US 5693532-A 584 02-DEC-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCC 1574
              ||||||||||||
Db         13 CTGCAAAAATCC 2


RESULT 775
I77878/c
LOCUS       I77878                   15 bp    DNA     linear   PAT 03-APR-1998
DEFINITION  Sequence 585 from patent US 5693532.
ACCESSION   I77878
VERSION     I77878.1  GI:3014032
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
  TITLE     Respiratory syncytial virus ribozymes
  JOURNAL   Patent: US 5693532-A 585 02-DEC-1997;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCC 1574
              ||||||||||||
Db         12 CTGCAAAAATCC 1


RESULT 776
AR242246
LOCUS       AR242246                 15 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 9 from patent US 6472173.
ACCESSION   AR242246
VERSION     AR242246.1  GI:27288069
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Ford,J. and Yeung,G.
  TITLE     Chemokine receptor obtained from a cDNA library of fetal
            liver-spleen
  JOURNAL   Patent: US 6472173-A 9 29-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db          2 CTTTTTNTTTTTG 14


RESULT 777
AR242247/c
LOCUS       AR242247                 15 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 10 from patent US 6472173.
ACCESSION   AR242247
VERSION     AR242247.1  GI:27288070
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Ford,J. and Yeung,G.
  TITLE     Chemokine receptor obtained from a cDNA library of fetal
            liver-spleen
  JOURNAL   Patent: US 6472173-A 10 29-OCT-2002;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   92.3%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTG 1782
              |||||| ||||||
Db         14 CTTTTTNTTTTTG 2


RESULT 778
AX638376/c
LOCUS       AX638376                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 5515 from Patent EP1260586.
ACCESSION   AX638376
VERSION     AX638376.1  GI:28473990
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 5515 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
```

```
                /mol_type="unassigned RNA"
                /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCC 1574
                ||||||||||||
Db         13 CTGCAAAAATCC 2


RESULT 779
AX638378/c
LOCUS       AX638378                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 5517 from Patent EP1260586.
ACCESSION   AX638378
VERSION     AX638378.1  GI:28473992
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 5517 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1563 CTGCAAAAATCC 1574
                ||||||||||||
Db         12 CTGCAAAAATCC 1


RESULT 780
AR087166/c
LOCUS       AR087166                 16 bp    DNA     linear   PAT 07-SEP-2000
DEFINITION  Sequence 36 from patent US 5986053.
ACCESSION   AR087166
VERSION     AR087166.1  GI:10013929
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ecker,D.J., Buchardt,O., Egholm,M., Nielsen,P.E., Berg,R.H. and
            Mollegaard,N.E.
  TITLE     Peptide nucleic acids complexes of two peptide nucleic acid strands
            and one nucleic acid strand
  JOURNAL   Patent: US 5986053-A 36 16-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
                ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 781
AR150612/c
LOCUS       AR150612                 16 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 31 from patent US 6228982.
ACCESSION   AR150612
VERSION     AR150612.1  GI:15115203
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Norden,B., Wittung,P., Buchardt,O., Egholm,M., Nielsen,P.E. and
            Berg,R.
  TITLE     Double-stranded peptide nucleic acids
  JOURNAL   Patent: US 6228982-A 31 08-MAY-2001;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
                ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 782
E36065/c
LOCUS       E36065                   16 bp    DNA     linear   PAT 18-JUN-2001
DEFINITION  Higher-order structure and binding of peptide nucleic acid.
ACCESSION   E36065
VERSION     E36065.1  GI:13022467
KEYWORDS    JP 1999236396-A/10.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Bushato,O., Eguhorumu,M., Nielsen,P.A., Berg,R.H., Ekka,D.J. and
            Morugado,N.A.
  TITLE     Higher-order structure and binding of peptide nucleic acid
  JOURNAL   Patent: JP 1999236396-A 10 31-AUG-1999;
            ISIS PHARMACEUTICALS INC,BUCHARDT DORUTE,EGUHORUMU MICHAEL, IELSEN
            PATER A, BERGH RORUFU HO
COMMENT     OS   Unidentified
            PN   JP 1999236396-A/10
            PD   31-AUG-1999
            PF   14-OCT-1998 JP 1998291590
            PR   02-JUL-1993 US       088658
            PI   BUSHATO ORE,EGUHORUMU MICHAEL,NIELSEN PATER A,BERG RORUFU HO,
            PI   EKKA DAVID JAY,MORUGADO NILUS A
            PC   C07H21/04,A61K31/00,A61K31/00,A61K31/00,A61K31/70,A61K48/00,
            PC   C07H21/02,
            PC   C12N15/09,C12Q1/68,C12N15/00
            CC   Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Unidentified'.
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
```

```
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 783
I42183/c
LOCUS       I42183                   16 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 18 from patent US 5629152.
ACCESSION   I42183
VERSION     I42183.1  GI:2467678
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ravikumar,V.
  TITLE     Trisubstituted .beta.-lactams and oligo .beta.-lactamamides
  JOURNAL   Patent: US 5629152-A 18 13-MAY-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 784
I49621/c
LOCUS       I49621                   16 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 36 from patent US 5641625.
ACCESSION   I49621
VERSION     I49621.1  GI:2471841
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ecker,D.J., Buchardt,O., Egholm,M., Nielsen,P.E., Berg,R.H. and
            Mollegaard,N.E.
  TITLE     Cleaving double-stranded DNA with peptide nucleic acids
  JOURNAL   Patent: US 5641625-A 36 24-JUN-1997;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 785
AR200486/c
LOCUS       AR200486                 16 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 29 from patent US 6357163.
ACCESSION   AR200486
VERSION     AR200486.1  GI:20251374
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Buchardt,O., Egholm,M., Nielsen,P.E. and Berg,R.H.
  TITLE     Use of nucleic acid analogues in diagnostics and analytical
            procedures
  JOURNAL   Patent: US 6357163-A 29 19-MAR-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 786
AR371292/c
LOCUS       AR371292                 16 bp    DNA     linear   PAT 12-SEP-2003
DEFINITION  Sequence 29 from patent US 6395474.
ACCESSION   AR371292
VERSION     AR371292.1  GI:34608224
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Buchardt,O., Egholm,M., Nielsen,P.E. and Berg,R.H.
  TITLE     Peptide nucleic acids
  JOURNAL   Patent: US 6395474-A 29 28-MAY-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 787
AR489513/c
LOCUS       AR489513                 16 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 29 from patent US 6710163.
ACCESSION   AR489513
VERSION     AR489513.1  GI:47256538
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Buchardt,O., Egholm,M., Nielsen,P.E. and Berg,R.H.
  TITLE     Peptide nucleic acid synthons
  JOURNAL   Patent: US 6710163-A 29 23-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
              ||||||||||||
```

```
Db         15 AAAAAGAAAAGT 4


RESULT 788
AR491124/c
LOCUS       AR491124                  16 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 29 from patent US 6713602.
ACCESSION   AR491124
VERSION     AR491124.1  GI:47258984
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Buchardt,O., Buchardt,D., Egholm,M., Nielsen,P.E. and Berg,R.H.
  TITLE     Synthetic procedures for peptide nucleic acids
  JOURNAL   Patent: US 6713602-A 29 30-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1981 AAAAAGAAAAGT 1992
             ||||||||||||
Db         15 AAAAAGAAAAGT 4


RESULT 789
AX255608/c
LOCUS       AX255608                  16 bp    RNA     linear   PAT 10-OCT-2001
DEFINITION  Sequence 29 from Patent WO0170982.
ACCESSION   AX255608
VERSION     AX255608.1  GI:16074664
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Beger,C., Barber,J. and Wong-Staal,F.
  TITLE     Brca-1 regulators and methods of use
  JOURNAL   Patent: WO 0170982-A 29 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATC 1667
             ||||||||||||
Db         15 TGGTTCTGCATC 4


RESULT 790
AX255646/c
LOCUS       AX255646                  16 bp    DNA     linear   PAT 10-OCT-2001
DEFINITION  Sequence 67 from Patent WO0170982.
ACCESSION   AX255646
VERSION     AX255646.1  GI:16074702
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Beger,C., Barber,J. and Wong-Staal,F.
  TITLE     Brca-1 regulators and methods of use
  JOURNAL   Patent: WO 0170982-A 67 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATC 1667
             ||||||||||||
Db         15 TGGTTCTGCATC 4


RESULT 791
AR057475/c
LOCUS       AR057475                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1679 from patent US 5837542.
ACCESSION   AR057475
VERSION     AR057475.1  GI:5983052
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 1679 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
             ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 792
AR057552/c
LOCUS       AR057552                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1756 from patent US 5837542.
ACCESSION   AR057552
VERSION     AR057552.1  GI:5983129
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 1756 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 793
AR057560/c
LOCUS       AR057560                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1764 from patent US 5837542.
ACCESSION   AR057560
VERSION     AR057560.1  GI:5983137
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 1764 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 794
AR057660/c
LOCUS       AR057660                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1864 from patent US 5837542.
ACCESSION   AR057660
VERSION     AR057660.1  GI:5983237
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 1864 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 795
AR057681/c
LOCUS       AR057681                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1885 from patent US 5837542.
ACCESSION   AR057681
VERSION     AR057681.1  GI:5983258
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 1885 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 796
AR057795/c
LOCUS       AR057795                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1999 from patent US 5837542.
ACCESSION   AR057795
VERSION     AR057795.1  GI:5983372
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 1999 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 797
AR115233/c
LOCUS       AR115233                  17 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 1679 from patent US 6132967.
ACCESSION   AR115233
VERSION     AR115233.1  GI:14095555
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 1679 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 798
AR115310/c
LOCUS       AR115310                  17 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 1756 from patent US 6132967.
ACCESSION   AR115310
VERSION     AR115310.1  GI:14095632
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 1756 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 799
AR115318/c
LOCUS       AR115318                  17 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 1764 from patent US 6132967.
ACCESSION   AR115318
VERSION     AR115318.1  GI:14095640
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 1764 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 800
AR115418/c
LOCUS       AR115418                  17 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 1864 from patent US 6132967.
ACCESSION   AR115418
VERSION     AR115418.1  GI:14095740
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 1864 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 801
AR115439/c
LOCUS       AR115439                  17 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 1885 from patent US 6132967.
ACCESSION   AR115439
VERSION     AR115439.1  GI:14095761
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 1885 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 802
AR115553/c
LOCUS       AR115553                  17 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 1999 from patent US 6132967.
ACCESSION   AR115553
VERSION     AR115553.1  GI:14095875
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 1999 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"
```

```
  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 803
BD200686/c
LOCUS       BD200686                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD200686
VERSION     BD200686.1  GI:33010456
KEYWORDS    JP 2002509721-A/3712.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 3712 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/3712
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTT 1924
              ||||||||||||
Db         14 AACAATACCTTT 3


RESULT 804
BD200687/c
LOCUS       BD200687                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD200687
VERSION     BD200687.1  GI:33010457
KEYWORDS    JP 2002509721-A/3713.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 3713 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/3713
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1913 AACAATACCTTT 1924
              ||||||||||||
Db         12 AACAATACCTTT 1


RESULT 805
BD241563
LOCUS       BD241563                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Methods and products related to genotyping and DNA analysis.
ACCESSION   BD241563
VERSION     BD241563.1  GI:33051333
KEYWORDS    JP 2002525127-A/510.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J.E., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: JP 2002525127-A 510 13-AUG-2002;
            MASSACHUSETTS INSTITUTE OF TECHNOLOGY
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002525127-A/510
            PD   13-AUG-2002
            PF   24-SEP-1999 JP 2000572407
            PR   25-SEP-1998 US    60/101757
            PI   JOHN E LANDERS,BARBARA JORDAN,DAVID E HOUSMAN,ALAIN CHAREST PC
              C12N15/09,C12Q1/68,G01N33/53,G01N33/566,G01N33/58,G01N37/00, PC
            G01N37/00,
            PC   C12N15/00
            CC   Methods and products related to genotyping and DNA analysis FH
              Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAA 1854
             ||||||||||||
Db          1 TCCCTGGGCCAA 12


RESULT 806
BD258483
LOCUS       BD258483                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258483
VERSION     BD258483.1  GI:33068253
KEYWORDS    JP 2002541795-A/6276.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6276 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6276
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1567 AAAAATCCTTCT 1578
             ||||||||||||
Db          3 AAAAATCCTTCT 14


RESULT 807
AR483064
LOCUS       AR483064                 17 bp    DNA     linear   PAT 14-MAY-2004
DEFINITION  Sequence 510 from patent US 6703228.
ACCESSION   AR483064
VERSION     AR483064.1  GI:47245587
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Landers,J., Jordan,B., Housman,D.E. and Charest,A.
  TITLE     Methods and products related to genotyping and DNA analysis
  JOURNAL   Patent: US 6703228-A 510 09-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1843 TCCCTGGGCCAA 1854
             ||||||||||||
Db          1 TCCCTGGGCCAA 12


RESULT 808
AX191823
LOCUS       AX191823                 17 bp    DNA     linear   PAT 15-AUG-2001
DEFINITION  Sequence 105 from Patent WO0149775.
ACCESSION   AX191823
VERSION     AX191823.1  GI:15209992
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Iversen,P.L.
  TITLE     Antisense antibacterial cell division composition and method
  JOURNAL   Patent: WO 0149775-A 105 12-JUL-2001;
            Avi Biopharma, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="oligonucleotide"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATT 1766
             ||||||||||||
Db          5 TCTTTATTCATT 16


RESULT 809
AX475805/c
LOCUS       AX475805                 17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1026 from Patent WO0224750.
ACCESSION   AX475805
VERSION     AX475805.1  GI:22215090
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1026 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1742 GACAAGTACTGG 1753
             ||||||||||||
Db         17 GACAAGTACTGG 6
```

```
RESULT 810
AX475813/c
LOCUS       AX475813                  17 bp    DNA     linear   PAT 12-AUG-2002
DEFINITION  Sequence 1034 from Patent WO0224750.
ACCESSION   AX475813
VERSION     AX475813.1  GI:22215098
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     Human kidney tumor overexpressed membrane protein 1
  JOURNAL   Patent: WO 0224750-A 1034 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1739 GGTGACAAGTAC 1750
              ||||||||||||
Db         12 GGTGACAAGTAC 1


RESULT 811
AX499863
LOCUS       AX499863                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1170 from Patent EP1229046.
ACCESSION   AX499863
VERSION     AX499863.1  GI:23382156
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1170 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAA 1985
              ||||||||||||
Db          4 CCTTGAAAAAAA 15


RESULT 812
AX499864
LOCUS       AX499864                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1171 from Patent EP1229046.
ACCESSION   AX499864
VERSION     AX499864.1  GI:23382157
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1171 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAA 1985
              ||||||||||||
Db          3 CCTTGAAAAAAA 14


RESULT 813
AX499865
LOCUS       AX499865                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1172 from Patent EP1229046.
ACCESSION   AX499865
VERSION     AX499865.1  GI:23382158
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1172 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAA 1985
              ||||||||||||
Db          2 CCTTGAAAAAAA 13


RESULT 814
AX499866
LOCUS       AX499866                  17 bp    DNA     linear   PAT 27-SEP-2002
DEFINITION  Sequence 1173 from Patent EP1229046.
ACCESSION   AX499866
VERSION     AX499866.1  GI:23382159
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhan,J.
  TITLE     Human testis expressed patched like protein
  JOURNAL   Patent: EP 1229046-A 1173 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1974 CCTTGAAAAAAA 1985
              ||||||||||||
Db          1 CCTTGAAAAAAA 12


RESULT 815
AX531445/c
LOCUS       AX531445                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 954 from Patent EP1239051.
ACCESSION   AX531445
VERSION     AX531445.1  GI:25254668
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 954 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1710 ATCTCCTAACTT 1721
              ||||||||||||
Db         17 ATCTCCTAACTT 6


RESULT 816
AX531451/c
LOCUS       AX531451                  17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 960 from Patent EP1239051.
ACCESSION   AX531451
VERSION     AX531451.1  GI:25254680
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 960 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1709 TATCTCCTAACT 1720
              ||||||||||||
Db         12 TATCTCCTAACT 1


RESULT 817
AX634499/c
LOCUS       AX634499                  17 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1638 from Patent EP1260586.
ACCESSION   AX634499
VERSION     AX634499.1  GI:28470113
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 1638 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 818
AX634571/c
LOCUS       AX634571                  17 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1710 from Patent EP1260586.
ACCESSION   AX634571
VERSION     AX634571.1  GI:28470185
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 1710 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 819
AX634652/c
LOCUS       AX634652                  17 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1791 from Patent EP1260586.
```

```
ACCESSION   AX634652
VERSION     AX634652.1  GI:28470266
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 1791 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 820
AX634673/c
LOCUS       AX634673                 17 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1812 from Patent EP1260586.
ACCESSION   AX634673
VERSION     AX634673.1  GI:28470287
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 1812 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 821
AX634715/c
LOCUS       AX634715                 17 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1854 from Patent EP1260586.
ACCESSION   AX634715
VERSION     AX634715.1  GI:28470329
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 1854 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 822
AX634845/c
LOCUS       AX634845                 17 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1984 from Patent EP1260586.
ACCESSION   AX634845
VERSION     AX634845.1  GI:28470459
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 1984 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1607 GCCTGGGGGAAG 1618
              ||||||||||||
Db         17 GCCTGGGGGAAG 6


RESULT 823
AX722745
LOCUS       AX722745                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 432 from Patent WO03025176.
ACCESSION   AX722745
VERSION     AX722745.1  GI:30423246
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 432 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1586 ACAGACTGGGAA 1597
              ||||||||||||
Db          6 ACAGACTGGGAA 17


RESULT 824
AX731014
LOCUS       AX731014                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2648 from Patent WO03025175.
ACCESSION   AX731014
VERSION     AX731014.1  GI:30510357
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 2648 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGT 1894
              ||||||||||||
Db          3 TCAAATTGATGT 14


RESULT 825
AX736447/c
LOCUS       AX736447                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2037 from Patent WO03025177.
ACCESSION   AX736447
VERSION     AX736447.1  GI:30515735
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2037 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1979 AAAAAAAGAAAA 1990
              ||||||||||||
Db         17 AAAAAAAGAAAA 6


RESULT 826
AX737834
LOCUS       AX737834                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3424 from Patent WO03025177.
ACCESSION   AX737834
VERSION     AX737834.1  GI:30517122
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 3424 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 12;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 4.7e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGT 1894
              ||||||||||||
Db          3 TCAAATTGATGT 14


RESULT 827
A87993/c
LOCUS       A87993                    18 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 141 from Patent WO9833904.
ACCESSION   A87993
VERSION     A87993.1  GI:6736563
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 141 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         13 CCCCTCCTGGCC 2


RESULT 828
A87994/c
LOCUS       A87994                   18 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 142 from Patent WO9833904.
ACCESSION   A87994
VERSION     A87994.1  GI:6736564
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 142 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         15 CCCCTCCTGGCC 4


RESULT 829
A89960/c
LOCUS       A89960                   18 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 141 from Patent EP0856579.
ACCESSION   A89960
VERSION     A89960.1  GI:6738474
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 141 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         13 CCCCTCCTGGCC 2


RESULT 830
A89961/c
LOCUS       A89961                   18 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 142 from Patent EP0856579.
ACCESSION   A89961
VERSION     A89961.1  GI:6738475
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 142 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         15 CCCCTCCTGGCC 4


RESULT 831
AR051249/c
LOCUS       AR051249                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 17 from patent US 5830658.
ACCESSION   AR051249
VERSION     AR051249.1  GI:5974613
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Gryaznov,S.M.
  TITLE     Convergent synthesis of branched and multiply connected
            macromolecular structures
  JOURNAL   Patent: US 5830658-A 17 03-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTG 1993
              ||||||||||||
Db         12 AAAAGAAAAGTG 1


RESULT 832
AR127796/c
LOCUS       AR127796                 18 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 17 from patent US 6180777.
ACCESSION   AR127796
VERSION     AR127796.1  GI:14114391
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Horn,T.
  TITLE     Synthesis of branched nucleic acids
  JOURNAL   Patent: US 6180777-A 17 30-JAN-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
```

```
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTG 1993
              ||||||||||||
Db         12 AAAAGAAAAGTG 1


RESULT 833
I28378/c
LOCUS       I28378                    18 bp    DNA     linear   PAT 06-FEB-1997
DEFINITION  Sequence 17 from patent US 5571677.
ACCESSION   I28378
VERSION     I28378.1  GI:1819154
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Gryaznov,S.M.
  TITLE     Convergent synthesis of branched and multiply connected
            macromomolecular structures
  JOURNAL   Patent: US 5571677-A 17 05-NOV-1996;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1982 AAAAGAAAAGTG 1993
              ||||||||||||
Db         12 AAAAGAAAAGTG 1


RESULT 834
AX284054
LOCUS       AX284054                  18 bp    DNA     linear   PAT 20-NOV-2001
DEFINITION  Sequence 19 from Patent WO0179487.
ACCESSION   AX284054
VERSION     AX284054.1  GI:17044764
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Degitz,K.K. and Besch,R.
  TITLE     Polydesoxyribonucleotides for inhibiting the expression of the
            icam-1-gene
  JOURNAL   Patent: WO 0179487-A 19 25-OCT-2001;
            Degitz, Klaus Karl (DE) ; Besch, Robert (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Beschreibung der kunstlichen
                     Sequenz:Polydesoxyribonukleotid"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGA 1619
              ||||||||||||
Db          4 CCTGGGGGAAGA 15


RESULT 835
BD065506/c
LOCUS       BD065506                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065506
VERSION     BD065506.1  GI:22611109
KEYWORDS    JP 2001511000-A/141.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 141 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/141
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         13 CCCCTCCTGGCC 2


RESULT 836
BD065507/c
LOCUS       BD065507                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065507
VERSION     BD065507.1  GI:22611110
KEYWORDS    JP 2001511000-A/142.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 142 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/142
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 12;  DB 1;  Length 18;
  Best Local Similarity   100.0%;  Pred. No. 5e+02;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy       1598 CCCCTCCTGGCC 1609
              ||||||||||||
Db         15 CCCCTCCTGGCC 4


RESULT 837
A58048/c
LOCUS       A58048                    15 bp    DNA     linear   PAT 05-MAR-1998
DEFINITION  Sequence 57 from Patent EP0745691.
ACCESSION   A58048
VERSION     A58048.1  GI:3713797
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Mabilat,C. and Ruimy,R.
  TITLE     16s Ribosomal RNA nucleotide fragments from coryne-bacteria, probes
            and primers derived therefrom, reagent and method for detection
  JOURNAL   Patent: EP 0745691-A 57 04-DEC-1996;
            BIO MERIEUX (FR)
COMMENT     Other publication FR 2733755 961108
            Other publication CA 2175515 961104.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1856 AGACCCACACACTTA 1870
              |||||| ||||| ||
Db         15 AGACCCTCACACCTA 1


RESULT 838
AR041352/c
LOCUS       AR041352                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 142 from patent US 5811300.
ACCESSION   AR041352
VERSION     AR041352.1  GI:5961848
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
  TITLE     TNF-.alpha. ribozymes
  JOURNAL   Patent: US 5811300-A 142 22-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1679 GACTTCTTAGTTGTT 1693
              || |||||||| |||
Db         15 GAATTCTTAGTGGTT 1


RESULT 839
AR041779
LOCUS       AR041779                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 569 from patent US 5811300.
ACCESSION   AR041779
VERSION     AR041779.1  GI:5962275
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
  TITLE     TNF-.alpha. ribozymes
  JOURNAL   Patent: US 5811300-A 569 22-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1856 AGACCCACACACTTA 1870
              |||||| |||||| |
Db         1 AGACCCTCACACTCA 15


RESULT 840
AR055920
LOCUS       AR055920                  15 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 124 from patent US 5837542.
ACCESSION   AR055920
VERSION     AR055920.1  GI:5981497
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 124 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGAA 1617
              || ||| ||||||||
Db         1 CCAGGCTTGGGGGAA 15


RESULT 841
AR113678
LOCUS       AR113678                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 124 from patent US 6132967.
ACCESSION   AR113678
VERSION     AR113678.1  GI:14094000
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 124 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
```

```
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGAA 1617
              || ||| ||||||||
Db          1 CCAGGCTTGGGGGAA 15


RESULT 842
AR132184
LOCUS       AR132184                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 609 from patent US 6194150.
ACCESSION   AR132184
VERSION     AR132184.1  GI:14121089
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 609 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              ||||| | |||||||
Db          1 TCTTACTAGTTTCTC 15


RESULT 843
AR132185
LOCUS       AR132185                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 610 from patent US 6194150.
ACCESSION   AR132185
VERSION     AR132185.1  GI:14121090
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 610 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              ||||| | |||||||
Db          1 TCTTACTAGTTTCTC 15


RESULT 844
AR132186
LOCUS       AR132186                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 611 from patent US 6194150.
ACCESSION   AR132186
VERSION     AR132186.1  GI:14121091
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 611 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              ||||| | |||||||
Db          1 TCTTACTAGTTTCTC 15


RESULT 845
AR132187
LOCUS       AR132187                  15 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 612 from patent US 6194150.
ACCESSION   AR132187
VERSION     AR132187.1  GI:14121092
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
  TITLE     Nucleic acid based inhibition of CD40
  JOURNAL   Patent: US 6194150-A 612 27-FEB-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1683 TCTTAGTTGTTTCTC 1697
              ||||| | |||||||
Db          1 TCTTACTAGTTTCTC 15


RESULT 846
AR141400/c
LOCUS       AR141400                  15 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 18 from patent US 6146848.
ACCESSION   AR141400
VERSION     AR141400.1  GI:15100916
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Wong,W.Keung. and Lam,K.Hon.
  TITLE     Bacterial expression system
  JOURNAL   Patent: US 6146848-A 18 14-NOV-2000;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db         15 CTTAATTAATTAAGC 1
```

```
RESULT 847
BD231235
LOCUS       BD231235                  15 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Interferon-epsilon.
ACCESSION   BD231235
VERSION     BD231235.1  GI:33041005
KEYWORDS    JP 2002526078-A/21.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Conklin,D.C., Grant,F.J., Rixon,M. and Kindsvogel,W.
  TITLE     Interferon-epsilon
  JOURNAL   Patent: JP 2002526078-A 21 20-AUG-2002;
            ZYMOGENETICS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002526078-A/21
            PD   20-AUG-2002
            PF   16-SEP-1999 JP 2000574260
            PR   18-SEP-1998 US    09/157068,05-FEB-1999 US    09/245293 PR
            08-JUL-1999 US    09/350232
            PI   DARRELL C CONKLIN,FRANCIS J GRANT,MARK RIXON,WAYNE KINDSVOGEL
            PC   C12N15/09,A61K38/00,A61K38/21,A61K48/00,A61P9/00,A61P9/10, PC
             A61P15/08,
            PC   A61P25/00,A61P25/16,A61P25/18,A61P25/22,A61P25/24,A61P25/28,
            PC   A61P29/00,
            PC   A61P31/12,A61P31/18,A61P35/00,A61P35/02,A61P37/02,A61P37/04,
            PC   C07K14/555,
            PC   C07K16/00,C07K16/24,C07K19/00,C12N1/15,C12N1/19,C12N1/21 PC
            ,C12N5/10,C12N7/00,
            PC   C12P21/02,C12Q1/02,C12Q1/68,G01N33/53//A61K35/76,C12P21/08, PC
              C12N15/00,
            PC   C12N5/00,A61K37/02,A61K37/66
            CC   Mutated coding sequence.
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1857 GACCCACACACTTAG 1871
              |||||| || |||||
Db          1 GACCCAGACCCTTAG 15


RESULT 848
BD265725/c
LOCUS       BD265725                  15 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Heat-inducible promoter.
ACCESSION   BD265725
VERSION     BD265725.1  GI:33075493
KEYWORDS    JP 2002536020-A/4.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Romano,I., Gellissen,G. and Virgilio,C.D.
  TITLE     Heat-inducible promoter
  JOURNAL   Patent: JP 2002536020-A 4 29-OCT-2002;
            RHEIN BIOTECH GESELLSCHAFT FUER NEUE BIOTECHNOLOGISCHE PROZESSE UND
            PRODUKTE MBH
COMMENT     OS   Artificial Sequence
            PN   JP 2002536020-A/4
            PD   29-OCT-2002
            PF   11-FEB-2000 JP 2000598645
            PR   11-FEB-1999 CH       279/99
            PI   IVANO ROMANO,GERD GELLISSEN,CLAUDIO DE VIRGILIO PC
            C12N15/09,C12N1/19,C12P21/02//(C12N1/19,C12R1:78),(C12P21/02, PC
            C12R1:78),
            PC   C12N15/00
            CC   Description of the artificial sequence: nucleic acid sequence
            CC        of a heat
            CC   schock element
            FH   Key             Location/Qualifiers
            FT   source          1. .15
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1640 TTTAAAGAGCCTTCA 1654
              ||| ||||| |||||
Db         15 TTTCAAGAGGCTTCA 1


RESULT 849
E16782
LOCUS       E16782                    15 bp    DNA     linear   PAT 28-JUL-1999
DEFINITION  PCR primer for detecting BCR EX2 mRNA.
ACCESSION   E16782
VERSION     E16782.1  GI:5711465
KEYWORDS    JP 1998215897-A/15.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Koshimoto,H., Sato,Y. and Tsuji,A.
  TITLE     DETECTION OF MUTANT CELL BY CHROMOSOMAL RECIPROCAL TRANSLOCATION,
            PROBE KIT FOR THE SAME DETECTION AND DETECTOR THEREFOR
  JOURNAL   Patent: JP 1998215897-A 15 18-AUG-1998;
            BUNSHI BIO PHOTONICS KENKYUSHO:KK
COMMENT     OS   None
            OC   Artificial sequences.
            PN   JP 1998215897-A/15
            PD   18-AUG-1998
            PF   05-FEB-1997 JP 1997022950
            PI   KOSHIMOTO HIROYUKI, SATO YOSHIHIRO, TSUJI AKIHIKO PC
            C12Q1/68,C07H21/04,C12N15/09,G01N21/78;
            CC   strandedness: Single;
            CC   topology: Linear;
            CC   hypothetical: No;
            CC   anti-sense: No;
            FH   Key             Location/Qualifiers
            FH
            FT   source          1. .15
            FT                   /organism='Artificial sequences'.
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1865 CACTTAGCCATTGAA 1879
              |||| ||||| ||||
Db          1 CACTCAGCCACTGAA 15


RESULT 850
```

```
AR303029
LOCUS       AR303029                 15 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 28 from patent US 6544505.
ACCESSION   AR303029
VERSION     AR303029.1  GI:31691643
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Conklin,D.C., Grant,F.J., Rixon,M.W. and Kindsvogel,W.
  TITLE     Interferon-epsilon
  JOURNAL   Patent: US 6544505-A 28 08-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1857 GACCCACACACTTAG 1871
              |||||| || |||||
Db          1 GACCCAGACCCTTAG 15


RESULT 851
AR366465
LOCUS       AR366465                 15 bp    DNA     linear   PAT 12-SEP-2003
DEFINITION  Sequence 28 from patent US 6329175.
ACCESSION   AR366465
VERSION     AR366465.1  GI:34598941
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 15)
  AUTHORS   Conklin,D.C., Grant,F.J., Rixon,M.W. and Kindsvogel,W.
  TITLE     Interferon-.epsilon
  JOURNAL   Patent: US 6329175-A 28 11-DEC-2001;
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1857 GACCCACACACTTAG 1871
              |||||| || |||||
Db          1 GACCCAGACCCTTAG 15


RESULT 852
AX033759/c
LOCUS       AX033759                 15 bp    DNA     linear   PAT 21-SEP-2000
DEFINITION  Sequence 4 from Patent CH690127.
ACCESSION   AX033759
VERSION     AX033759.1  GI:10280390
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Romano,I.
  JOURNAL   Patent: CH 690127-A 4 15-MAY-2000;
            RHEINBIOTECH GMBH (DE)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="NUCLEIC ACIDsequenz eines Heatschock-Elementes"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1640 TTTAAAGAGCCTTCA 1654
              ||| ||||| |||||
Db         15 TTTCAAGAGGCTTCA 1


RESULT 853
AX633016
LOCUS       AX633016                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 155 from Patent EP1260586.
ACCESSION   AX633016
VERSION     AX633016.1  GI:28468630
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 155 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1603 CCTGGCCTGGGGGAA 1617
              || ||| ||||||||
Db          1 CCAGGCTTGGGGGAA 15


RESULT 854
AX636763/c
LOCUS       AX636763                 15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 3902 from Patent EP1260586.
ACCESSION   AX636763
VERSION     AX636763.1  GI:28472377
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 3902 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"
```

```
  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1679 GACTTCTTAGTTGTT 1693
              || |||||||| |||
Db         15 GAATTCTTAGTGGTT 1


RESULT 855
AX637205
LOCUS       AX637205                  15 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 4344 from Patent EP1260586.
ACCESSION   AX637205
VERSION     AX637205.1  GI:28472819
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 4344 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1856 AGACCCACACACTTA 1870
              |||||| |||||| |
Db          1 AGACCCTCACACTCA 15


RESULT 856
AX708800/c
LOCUS       AX708800                  15 bp    DNA     linear   PAT 04-APR-2003
DEFINITION  Sequence 16 from Patent WO02095071.
ACCESSION   AX708800
VERSION     AX708800.1  GI:29564527
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Plasterk,R.H.
  TITLE     Means and methods for identifying genes and proteins involved in
            the prevention and/or repair of a replication error
  JOURNAL   Patent: WO 02095071-A 16 28-NOV-2002;
            Koninklijke Nederlandse Akademie van Wetenschappen (NL)
FEATURES             Location/Qualifiers
     source          1. .15
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Unc-93 (e1500) mutation in C. elegans msh-6"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 15;
  Best Local Similarity   86.7%;  Pred. No. 4.5e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAA 1784
              ||| ||||||| |||
Db         15 CTTCTTTTTTTGGAA 1


RESULT 857
A88311
LOCUS       A88311                    16 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 459 from Patent WO9833904.
ACCESSION   A88311
VERSION     A88311.1  GI:6736881
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 459 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAA 1989
              ||| ||||||| |||
Db          2 CTTTAAAAAAACAAA 16


RESULT 858
A88458/c
LOCUS       A88458                    16 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 606 from Patent WO9833904.
ACCESSION   A88458
VERSION     A88458.1  GI:6737028
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 606 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1807 AGTGGTGCTATAAGT 1821
              | |||||||| ||||
Db         15 ATTGGTGCTAAAAGT 1


RESULT 859
A90278
LOCUS       A90278                    16 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 459 from Patent EP0856579.
ACCESSION   A90278
VERSION     A90278.1  GI:6738792
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
```

```
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 459 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAA 1989
              ||| ||||||| |||
Db          2 CTTTAAAAAAACAAA 16


RESULT 860
A90425/c
LOCUS       A90425                   16 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 606 from Patent EP0856579.
ACCESSION   A90425
VERSION     A90425.1  GI:6738939
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 606 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1807 AGTGGTGCTATAAGT 1821
              | ||||||| ||||
Db         15 ATTGGTGCTAAAAGT 1


RESULT 861
AR001291
LOCUS       AR001291                 16 bp    DNA     linear   PAT 04-DEC-1998
DEFINITION  Sequence 21 from patent US 5739025.
ACCESSION   AR001291
VERSION     AR001291.1  GI:3963358
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Fukazawa,C.
  TITLE     Method for producing an asparaginyl endoprotease
  JOURNAL   Patent: US 5739025-A 21 14-APR-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db          2 CTTAATTAATTAAGC 16


RESULT 862
AR001291/c
LOCUS       AR001291                 16 bp    DNA     linear   PAT 04-DEC-1998
DEFINITION  Sequence 21 from patent US 5739025.
ACCESSION   AR001291
VERSION     AR001291.1  GI:3963358
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Fukazawa,C.
  TITLE     Method for producing an asparaginyl endoprotease
  JOURNAL   Patent: US 5739025-A 21 14-APR-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db         15 CTTAATTAATTAAGC 1


RESULT 863
AR036759/c
LOCUS       AR036759                 16 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1 from patent US 5800984.
ACCESSION   AR036759
VERSION     AR036759.1  GI:5954615
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Vary,C.P.H.
  TITLE     Nucleic acid sequence detection by triple helix formation at primer
            site in amplification reactions
  JOURNAL   Patent: US 5800984-A 1 01-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTC 1800
              | | ||||||||||||
Db         16 CTCCTTCTTTCCTTC 2


RESULT 864
AR036760
LOCUS       AR036760                 16 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 2 from patent US 5800984.
ACCESSION   AR036760
VERSION     AR036760.1  GI:5954616
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
```

```
  AUTHORS   Vary,C.P.H.
  TITLE     Nucleic acid sequence detection by triple helix formation at primer
            site in amplification reactions
  JOURNAL   Patent: US 5800984-A 2 01-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1786 CCCATTCTTTCCTTC 1800
              | | ||||||||||||
Db          1 CTCCTTCTTTCCTTC 15


RESULT 865
AR038029
LOCUS       AR038029                 16 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 37 from patent US 5804407.
ACCESSION   AR038029
VERSION     AR038029.1  GI:5956746
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Tamaoki,T. and Nakabayashi,H.
  TITLE     Method of expressing genes in mammalian cells
  JOURNAL   Patent: US 5804407-A 37 08-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
              || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 866
AR039127
LOCUS       AR039127                 16 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 37 from patent US 5807738.
ACCESSION   AR039127
VERSION     AR039127.1  GI:5958490
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Tamaoki,T. and Nakabayashi,H.
  TITLE     Method of expressing genes in mammalian cells
  JOURNAL   Patent: US 5807738-A 37 15-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
              || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 867
AR050372
LOCUS       AR050372                 16 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 37 from patent US 5827686.
ACCESSION   AR050372
VERSION     AR050372.1  GI:5973097
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Tamaoki,T. and Nakabayashi,H.
  TITLE     Method of expressing genes in mammalian cells
  JOURNAL   Patent: US 5827686-A 37 27-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
              || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 868
AR062931
LOCUS       AR062931                 16 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 37 from patent US 5843776.
ACCESSION   AR062931
VERSION     AR062931.1  GI:5990622
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Tamaoki,T. and Nakabayashi,H.
  TITLE     Method of expressing genes in mammalian cells
  JOURNAL   Patent: US 5843776-A 37 01-DEC-1998;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1734 CAGAAGGTGACAAGT 1748
              || |||||||| |||
Db          1 CAAAAGGTGACTAGT 15


RESULT 869
AR069284/c
LOCUS       AR069284                 16 bp    DNA     linear   PAT 18-FEB-2000
DEFINITION  Sequence 23 from patent US 5891631.
ACCESSION   AR069284
VERSION     AR069284.1  GI:7220172
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Goldstein,J.L., Brown,M.S., Briggs,M.R. and Wang,X.
  TITLE     Methods relating tosterol regulatory element binding proteins
  JOURNAL   Patent: US 5891631-A 23 06-APR-1999;
FEATURES             Location/Qualifiers
     source          1. .16
```

```
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db         15 CAGGGGGAGGAGTTT 1


RESULT 870
I18842/c
LOCUS       I18842                  16 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 23 from patent US 5498696.
ACCESSION   I18842
VERSION     I18842.1  GI:1599197
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Briggs,M.R., Brown,M.S., Goldstein,J.L. and Wang,X.
  TITLE     Sterol regulatory element binding proteins and their use in
            screening assays
  JOURNAL   Patent: US 5498696-A 23 12-MAR-1996;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db         15 CAGGGGGAGGAGTTT 1


RESULT 871
I22296/c
LOCUS       I22296                  16 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 23 from patent US 5527690.
ACCESSION   I22296
VERSION     I22296.1  GI:1602650
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Goldstein,J.L., Brown,M.S., Briggs,M.R. and Wang,X.
  TITLE     Methods and compositions relating to sterol regulatory element
            binding proteins
  JOURNAL   Patent: US 5527690-A 23 18-JUN-1996;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db         15 CAGGGGGAGGAGTTT 1


RESULT 872
AR211616
LOCUS       AR211616                16 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 35 from patent US 6399340.
ACCESSION   AR211616
VERSION     AR211616.1  GI:21514985
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Saito,Y., Noguchi,Y., Yoshikawa,K. and Soeda,S.
  TITLE     Vector derivatives of gluconobacter plasmid pF4
  JOURNAL   Patent: US 6399340-A 35 04-JUN-2002;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1532 GAAAGGTTAGGAGAG 1546
              ||| |||| ||||||
Db          1 GAACGGTTCGGAGAG 15


RESULT 873
AR309064
LOCUS       AR309064                16 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 6 from patent US 6555370.
ACCESSION   AR309064
VERSION     AR309064.1  GI:31700853
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Lupton,S.D.
  TITLE     Bifunctional selectable fusion genes
  JOURNAL   Patent: US 6555370-A 6 29-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db          2 CTTAATTAATTAAGC 16


RESULT 874
AR309064/c
LOCUS       AR309064                16 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 6 from patent US 6555370.
ACCESSION   AR309064
VERSION     AR309064.1  GI:31700853
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Lupton,S.D.
  TITLE     Bifunctional selectable fusion genes
  JOURNAL   Patent: US 6555370-A 6 29-APR-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
```

```
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db         15 CTTAATTAATTAAGC 1


RESULT 875
AR364124/c
LOCUS       AR364124                  16 bp    DNA     linear   PAT 03-SEP-2003
DEFINITION  Sequence 4 from patent US 5256545.
ACCESSION   AR364124
VERSION     AR364124.1  GI:34426450
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brown,M.S., Goldstein,J.L., Russell,D.W. and Sudhof,T.C.
  TITLE     Sterol Regulatory Elements
  JOURNAL   Patent: US 5256545-A 4 26-OCT-1993;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db         15 CAGGGGGAGGAGTTT 1


RESULT 876
AR364150
LOCUS       AR364150                  16 bp    DNA     linear   PAT 03-SEP-2003
DEFINITION  Sequence 33 from patent US 5256545.
ACCESSION   AR364150
VERSION     AR364150.1  GI:34426476
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Brown,M.S., Goldstein,J.L., Russell,D.W. and Sudhof,T.C.
  TITLE     Sterol Regulatory Elements
  JOURNAL   Patent: US 5256545-A 33 26-OCT-1993;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1609 CTGGGGGAAGAGTTT 1623
              | |||||| ||||||
Db          2 CAGGGGGAGGAGTTT 16


RESULT 877
AR364513
LOCUS       AR364513`                 16 bp    DNA     linear   PAT 03-SEP-2003
DEFINITION  Sequence 9 from patent US 5312912.
ACCESSION   AR364513
VERSION     AR364513.1  GI:34427242
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Hadwiger,L.A., Chiang,C.C. and Horovitz,D.A.
  TITLE     Procedures and regulatory DNA sequences for genetically engineering
            disease resistance and other inducible traits in plants
  JOURNAL   Patent: US 5312912-A 9 17-MAY-1994;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1868 TTAGCCATTGAAATG 1882
              | | ||||||||||||
Db          2 TAAACCATTGAAATG 16


RESULT 878
AR373159
LOCUS       AR373159                  16 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 13 from patent US 6602681.
ACCESSION   AR373159
VERSION     AR373159.1  GI:40075130
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ohsuye,K., Kitano,K., Tanaka,S., Matsuo,H. and Mizuno,K.
  TITLE     Enzymatic production of a C-terminal .alpha.-amidated peptide or
            protein
  JOURNAL   Patent: US 6602681-A 13 05-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1756 CTTTATTCATTAAGC 1770
              ||| ||| |||||||
Db          1 CTTAATTAATTAAGC 15


RESULT 879
AR373194
LOCUS       AR373194                  16 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 70 from patent US 6602681.
ACCESSION   AR373194
VERSION     AR373194.1  GI:40075165
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Ohsuye,K., Kitano,K., Tanaka,S., Matsuo,H. and Mizuno,K.
  TITLE     Enzymatic production of a C-terminal .alpha.-amidated peptide or
            protein
  JOURNAL   Patent: US 6602681-A 70 05-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1756 CTTTATTCATTAAGC 1770
                ||| ||| |||||||
Db          1 CTTAATTAATTAAGC 15


RESULT 880
AR435997
LOCUS       AR435997                  16 bp    RNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 256 from patent US 6656731.
ACCESSION   AR435997
VERSION     AR435997.1  GI:40199081
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Eckstein,F., Ludwig,J. and Beigelman,L.
  TITLE     Nucleic acid catalysts with endonuclease activity
  JOURNAL   Patent: US 6656731-A 256 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
                || ||||||| |||||
Db          2 TTAATTCATGAAGCT 16


RESULT 881
AX235092
LOCUS       AX235092                  16 bp    DNA     linear   PAT 11-SEP-2001
DEFINITION  Sequence 49 from Patent WO0163540.
ACCESSION   AX235092
VERSION     AX235092.1  GI:15593740
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Bureau,T.
  TITLE     Method for identifying transposons from a nucleic acid database
  JOURNAL   Patent: WO 0163540-A 49 30-AUG-2001;
            McGILL UNIVERSITY (CA)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="sequence from gi 4662640"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1825 AGAATCTTTTAAATA 1839
                ||||  |||||||||
Db          1 AGAAATTTTTAAATA 15


RESULT 882
AX255618/c
LOCUS       AX255618                  16 bp    RNA     linear   PAT 10-OCT-2001
DEFINITION  Sequence 39 from Patent WO0170982.
ACCESSION   AX255618
VERSION     AX255618.1  GI:16074674
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Beger,C., Barber,J. and Wong-Staal,F.
  TITLE     Brca-1 regulators and methods of use
  JOURNAL   Patent: WO 0170982-A 39 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Synthetic oligonucleotide"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1679 GACTTCTTAGTTGTT 1693
                ||||||||| || ||
Db         15 GACTTCTTAATTTTT 1


RESULT 883
AX255661/c
LOCUS       AX255661                  16 bp    DNA     linear   PAT 10-OCT-2001
DEFINITION  Sequence 82 from Patent WO0170982.
ACCESSION   AX255661
VERSION     AX255661.1  GI:16074717
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Beger,C., Barber,J. and Wong-Staal,F.
  TITLE     Brca-1 regulators and methods of use
  JOURNAL   Patent: WO 0170982-A 82 27-SEP-2001;
            Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1679 GACTTCTTAGTTGTT 1693
                ||||||||| || ||
Db         15 GACTTCTTAATTTTT 1


RESULT 884
AX535770
LOCUS       AX535770                  16 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 9 from Patent WO02068684.
ACCESSION   AX535770
VERSION     AX535770.1  GI:25262213
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Lundeberg,J., Ahmadian,A. and Nyren,P.
  TITLE     Allele-specific primer extension assay
  JOURNAL   Patent: WO 02068684-A 9 06-SEP-2002;
            Pyrosequencing AB (SE) ; DZIEGLEWSKA, Hanna Eva (GB)
FEATURES             Location/Qualifiers
     source          1. .16
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
```

```
                    /note="Primer"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1760 ATTCATTAAGCTTTT 1774
              |||  ||||||||||
Db          2 ATTTGTTAAGCTTTT 16


RESULT 885
BD065824
LOCUS       BD065824                  16 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065824
VERSION     BD065824.1  GI:22611427
KEYWORDS    JP 2001511000-A/459.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 459 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/459
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Unknown'.
FEATURES            Location/Qualifiers
     source         1. .16
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAA 1989
              ||| ||||||| |||
Db          2 CTTTAAAAAAACAAA 16


RESULT 886
BD065971/c
LOCUS       BD065971                  16 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065971
VERSION     BD065971.1  GI:22611574
KEYWORDS    JP 2001511000-A/606.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 16)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 606 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/606
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .16
            FT                   /organism='Unknown'.
FEATURES            Location/Qualifiers
     source         1. .16
                    /organism="unidentified"
                    /mol_type="genomic DNA"
                    /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 16;
  Best Local Similarity   86.7%;  Pred. No. 4.8e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1807 AGTGGTGCTATAAGT 1821
              | ||||||||| ||||
Db         15 ATTGGTGCTAAAAGT 1


RESULT 887
BD201172/c
LOCUS       BD201172                  17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD201172
VERSION     BD201172.1  GI:33010942
KEYWORDS    JP 2002509721-A/4198.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 4198 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/4198
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES            Location/Qualifiers
     source         1. .17
                    /organism="Homo sapiens"
                    /mol_type="genomic RNA"
                    /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1923 TTTTTTTCAGTGTTA 1937
              |||||||||  ||||
Db         17 TTTTTTTCAAGGTTA 3


RESULT 888
A34270/c
```

```
LOCUS       A34270                    17 bp    DNA     linear   PAT 03-JUL-2002
DEFINITION  Synthetic sequencing primer.
ACCESSION   A34270
VERSION     A34270.1  GI:21694222
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Odink,K.G., Tarcsay,L., Brueggen,J., Wiesendanger,W., Cerletti,N.,
            Sorg,C., DeWolf-Peeters,C. and Delabie,J.
  TITLE     Novel cytokines
  JOURNAL   Patent: EP 0412050-A 30 06-FEB-1991;
            CIBA-GEIGY AG
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGA 1590
              ||||||| ||||||
Db         15 TCTCCACGACACAGA 1


RESULT 889
A88312
LOCUS       A88312                    17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 460 from Patent WO9833904.
ACCESSION   A88312
VERSION     A88312.1  GI:6736882
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 460 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAA 1989
              ||| ||||||| |||
Db          3 CTTTAAAAAAACAAA 17


RESULT 890
A89349/c
LOCUS       A89349                    17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 1497 from Patent WO9833904.
ACCESSION   A89349
VERSION     A89349.1  GI:6737919
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 1497 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source .        1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1876 TGAAATGTCAAATTG 1890
              ||||||||| || ||
Db         15 TGAAATGTCCAAATG 1


RESULT 891
A90279
LOCUS       A90279                    17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 460 from Patent EP0856579.
ACCESSION   A90279
VERSION     A90279.1  GI:6738793
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 460 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1975 CTTGAAAAAAAGAAA 1989
              ||| ||||||| |||
Db          3 CTTTAAAAAAACAAA 17


RESULT 892
AR040153/c
LOCUS       AR040153                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1001 from patent US 5807743.
ACCESSION   AR040153
VERSION     AR040153.1  GI:5959516
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T. and McSwiggen,J.A.
  TITLE     Interleukin-2 receptor gamma-chain ribozymes
  JOURNAL   Patent: US 5807743-A 1001 15-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2065 ATAAGTGGTATCTGA 2079
              ||||| || ||||||
Db         17 ATAAGAGGGATCTGA 3
```

```
RESULT 893
AR045723
LOCUS       AR045723                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 516 from patent US 5817796.
ACCESSION   AR045723
VERSION     AR045723.1  GI:5967188
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 516 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCC 1788
              | ||||| |||||||
Db          3 TGTTTTTAGAACCCC 17


RESULT 894
AR047386/c
LOCUS       AR047386                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 2179 from patent US 5817796.
ACCESSION   AR047386
VERSION     AR047386.1  GI:5968851
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb ribozymes having 2'-5'-linked adenylate residues
  JOURNAL   Patent: US 5817796-A 2179 06-OCT-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAA 1990
              |||| |||| |||||
Db         15 TTGACAAAAGGAAAA 1


RESULT 895
AR057727/c
LOCUS       AR057727                  17 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 1931 from patent US 5837542.
ACCESSION   AR057727
VERSION     AR057727.1  GI:5983304
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL   Patent: US 5837542-A 1931 17-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCA 2036
              || ||| ||||||||
Db         15 CTGTGGGAGGAGGCA 1


RESULT 896
AR115485/c
LOCUS       AR115485                  17 bp    DNA     linear   PAT 16-MAY-2001
DEFINITION  Sequence 1931 from patent US 6132967.
ACCESSION   AR115485
VERSION     AR115485.1  GI:14095807
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
            Draper,K.G.
  TITLE     Ribozyme treatment of diseases or conditions related to levels of
            intercellular adhesion molecule-1 (ICAM-1)
  JOURNAL   Patent: US 6132967-A 1931 17-OCT-2000;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCA 2036
              || ||| ||||||||
Db         15 CTGTGGGAGGAGGCA 1


RESULT 897
BD197738/c
LOCUS       BD197738                  17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD197738
VERSION     BD197738.1  GI:33007508
KEYWORDS    JP 2002509721-A/764.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 764 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/764
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
```

```
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              ||||||||  | ||||
Db         17 AGGGAAGGGAGAGGA 3


RESULT 898
BD201570
LOCUS       BD201570                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD201570
VERSION     BD201570.1  GI:33011340
KEYWORDS    JP 2002509721-A/4596.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 4596 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/4596
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1675 CCTGGACTTCTTAGT 1689
              | ||||  ||||||||
Db          1 CTTGGAATTCTTAGT 15


RESULT 899
BD202825/c
LOCUS       BD202825                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD202825
VERSION     BD202825.1  GI:33012595
KEYWORDS    JP 2002509721-A/5851.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 5851 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/5851
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2029 AGGAGGCAAAGGTTC 2043
              ||||||||||  ||
Db         17 AGGAGGCAAAGCCTC 3


RESULT 900
BD202826/c
LOCUS       BD202826                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD202826
VERSION     BD202826.1  GI:33012596
KEYWORDS    JP 2002509721-A/5852.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 5852 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/5852
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
```

```
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2029 AGGAGGCAAAGGTTC 2043
              ||||||||||| ||
Db         16 AGGAGGCAAAGCCTC 2


RESULT 901
BD203002
LOCUS       BD203002                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD203002
VERSION     BD203002.1  GI:33012772
KEYWORDS    JP 2002509721-A/6028.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 6028 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/6028
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTG 1782
              | |||||||| ||||
Db          3 ATCTTTTTTGTTTG 17


RESULT 902
BD203003
LOCUS       BD203003                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD203003
VERSION     BD203003.1  GI:33012773
KEYWORDS    JP 2002509721-A/6029.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
  JOURNAL   Patent: JP 2002509721-A 6029 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/6029
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTG 1782
              | |||||||| ||||
Db          2 ATCTTTTTTGTTTG 16


RESULT 903
BD203004
LOCUS       BD203004                 17 bp    RNA     linear   PAT 17-JUL-2003
DEFINITION  Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION   BD203004
VERSION     BD203004.1  GI:33012774
KEYWORDS    JP 2002509721-A/6030.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
  TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
```

```
  JOURNAL   Patent: JP 2002509721-A 6030 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Homo sapiens (human)
            PN   JP 2002509721-A/6030
            PD   02-APR-2002
            PF   24-MAR-1999 JP 2000541291
            PR   27-MAR-1998 US    60/079678
            PI   PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PI   JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
             A61P29/00,
            PC   A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
              C12N5/00
            CC   Method and reagent for treating diseases or conditions  CC
                   concerning molecule
            CC   participating in vasculogenic response
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Homo sapiens (human)'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTG 1782
              | ||||||||  ||||
Db          1 ATCTTTTTTTGTTTG 15


RESULT 904
BD226461
LOCUS       BD226461                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Method and probes for the detection of chromosome aberrations.
ACCESSION   BD226461
VERSION     BD226461.1  GI:33036231
KEYWORDS    JP 2002513587-A/7.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Dongen,J.J.M.V., Pluzek,K.J., Nielsen,K.V. and Adelhorst,K.
  TITLE     Method and probes for the detection of chromosome aberrations
  JOURNAL   Patent: JP 2002513587-A 7 14-MAY-2002;
            DAKO AS
COMMENT     OS   Artificial Sequence
            PN   JP 2002513587-A/7
            PD   14-MAY-2002
            PF   04-MAY-1999 JP 2000547260
            PR   04-MAY-1998 DK      0615/98
            PI   JACOBS JOHANNES MARIA VAN DONGEN,KARL JOHAN PLUZEK,KIRSTEN  PI
              VANG NIELSEN,
            PI   KIM ADELHORST
            PC   C12N15/09,C07H21/00,C12Q1/68,G01N33/53,G01N33/566,C12N15/00 CC
              Description of Artificial Sequence:PNA probe, mbr, exon CC   4,
            position 416-400
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1628 CCTACCTTACTATTT 1642
              ||| |||| ||||||
Db          3 CCTTCCTTCCTATTT 17


RESULT 905
BD254672
LOCUS       BD254672                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254672
VERSION     BD254672.1  GI:33064442
KEYWORDS    JP 2002541795-A/2465.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2465 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2465
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1789 ATTCTTTCCTTCTCT 1803
              ||  ||||||||||||
Db          2 ATATTTTCCTTCTCT 16


RESULT 906
BD254953/c
LOCUS       BD254953                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD254953
VERSION     BD254953.1  GI:33064723
KEYWORDS    JP 2002541795-A/2746.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2746 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2746
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
```

```
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTT 1622
              ||||||||| ||||
Db         16 CCTGGGGGAGAAGTT 2


RESULT 907
BD255069/c
LOCUS       BD255069                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255069
VERSION     BD255069.1  GI:33064839
KEYWORDS    JP 2002541795-A/2862.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 2862 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/2862
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1536 GGTTAGGAGAGTAGG 1550
              || | ||||||||||
Db         15 GGCTGGGAGAGTAGG 1


RESULT 908
BD255449/c
LOCUS       BD255449                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255449
VERSION     BD255449.1  GI:33065219
KEYWORDS    JP 2002541795-A/3242.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 3242 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/3242
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAAC 1558
              ||  ||||||||||||
Db         17 GAAAAGGGAAGGAAC 3


RESULT 909
BD255450/c
LOCUS       BD255450                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255450
VERSION     BD255450.1  GI:33065220
KEYWORDS    JP 2002541795-A/3243.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 3243 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/3243
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
```

```
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAAC 1558
              ||  ||||||||||||
Db         16 GAAAAGGGAAGGAAC 2


RESULT 910
BD255456
LOCUS       BD255456                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255456
VERSION     BD255456.1  GI:33065226
KEYWORDS    JP 2002541795-A/3249.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 3249 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/3249
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              |||||||  |||||  |
Db          3 AAGCTTTCTTTTTAT 17


RESULT 911
BD255458
LOCUS       BD255458                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD255458
VERSION     BD255458.1  GI:33065228
KEYWORDS    JP 2002541795-A/3251.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 3251 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/3251
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTG 1782
              |||||| |||||  ||
Db          1 AGCTTTCTTTTTATG 15


RESULT 912
BD256767/c
LOCUS       BD256767                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD256767
VERSION     BD256767.1  GI:33066537
KEYWORDS    JP 2002541795-A/4560.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 4560 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/4560
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
```

```
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCTT 1576
              ||| ||||||| |||
Db         17 ACTTCAAAAATTCTT 3


RESULT 913
BD256768/c
LOCUS       BD256768                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD256768
VERSION     BD256768.1  GI:33066538
KEYWORDS    JP 2002541795-A/4561.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 4561 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/4561
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCTT 1576
              ||| ||||||| |||
Db         16 ACTTCAAAAATTCTT 2


RESULT 914
BD256769/c
LOCUS       BD256769                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD256769
VERSION     BD256769.1  GI:33066539
KEYWORDS    JP 2002541795-A/4562.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 4562 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/4562
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1562 ACTGCAAAAATCCTT 1576
              ||| ||||||| |||
Db         15 ACTTCAAAAATTCTT 1


RESULT 915
BD258460/c
LOCUS       BD258460                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258460
VERSION     BD258460.1  GI:33068230
KEYWORDS    JP 2002541795-A/6253.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6253 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6253
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
```

```
           C12R1:91),
           PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
           PC   A61K37/02,
           PC   (C12N5/00,C12R1:91)
           CC   Regulation of repressor genes using nucleic acid molecules FH
            Key             Location/Qualifiers
           FT   source          1. .17
           FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              ||||||||||  || |
Db         17 AGGGAAGGAAAAGTA 3


RESULT 916
BD258461/c
LOCUS       BD258461                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258461
VERSION     BD258461.1  GI:33068231
KEYWORDS    JP 2002541795-A/6254.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6254 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6254
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              ||||||||||  || |
Db         16 AGGGAAGGAAAAGTA 2


RESULT 917
BD258462
LOCUS       BD258462                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258462
VERSION     BD258462.1  GI:33068232
KEYWORDS    JP 2002541795-A/6255.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6255 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6255
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAA 1807
              |||||||| || |||
Db          3 TTTCCTTCCCTCAAA 17


RESULT 918
BD258523/c
LOCUS       BD258523                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258523
VERSION     BD258523.1  GI:33068293
KEYWORDS    JP 2002541795-A/6316.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6316 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6316
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
```

```
           PC   A61K37/02,
           PC   (C12N5/00,C12R1:91)
           CC   Regulation of repressor genes using nucleic acid molecules FH
            Key             Location/Qualifiers
           FT   source          1. .17
           FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1973 ACCTTGAAAAAAAGA 1987
              ||||||||  |||| |
Db         17 ACCTTGAATAAAATA 3


RESULT 919
CQ616604/c
LOCUS       CQ616604                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1344 from Patent WO0192524.
ACCESSION   CQ616604
VERSION     CQ616604.1  GI:41666822
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1344 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCT 1801
              ||||  |||||||||
Db         17 CCATCTTTTCCTTCT 3


RESULT 920
CQ616608/c
LOCUS       CQ616608                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1348 from Patent WO0192524.
ACCESSION   CQ616608
VERSION     CQ616608.1  GI:41666826
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1348 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTT 1799
              ||||||  |||||||
Db         15 CCCCATCTTTTCCTT 1


RESULT 921
CQ616839/c
LOCUS       CQ616839                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1579 from Patent WO0192524.
ACCESSION   CQ616839
VERSION     CQ616839.1  GI:41667057
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1579 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1572 TCCTTCTCCACCGCA 1586
              ||||||||||  |||
Db         17 TCCTTCTCCAGAGCA 3


RESULT 922
CQ616842/c
LOCUS       CQ616842                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1582 from Patent WO0192524.
ACCESSION   CQ616842
VERSION     CQ616842.1  GI:41667060
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1582 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGC 1585
              ||||||||||  ||
```

```
Db         15 ATCCTTCTCCAGAGC 1


RESULT 923
CQ616960
LOCUS       CQ616960                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1700 from Patent WO0192524.
ACCESSION   CQ616960
VERSION     CQ616960.1  GI:41667178
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1700 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
             ||||| |||||| ||
Db          3 TGGTATGAGGCAGAG 17


RESULT 924
CQ616961
LOCUS       CQ616961                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1701 from Patent WO0192524.
ACCESSION   CQ616961
VERSION     CQ616961.1  GI:41667179
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1701 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
             ||||| |||||| ||
Db          2 TGGTATGAGGCAGAG 16


RESULT 925
CQ616962
LOCUS       CQ616962                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 1702 from Patent WO0192524.
ACCESSION   CQ616962
VERSION     CQ616962.1  GI:41667180
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 1702 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
             ||||| |||||| ||
Db          1 TGGTATGAGGCAGAG 15


RESULT 926
CQ622905/c
LOCUS       CQ622905                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7645 from Patent WO0192524.
ACCESSION   CQ622905
VERSION     CQ622905.1  GI:41673123
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 7645 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCT 1698
              ||| |||| ||||||
Db         15 CTTTGTTGGTTCTCT 1


RESULT 927
CQ623219
LOCUS       CQ623219                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 7959 from Patent WO0192524.
ACCESSION   CQ623219
VERSION     CQ623219.1  GI:41673437
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
```

```
  JOURNAL   Patent: WO 0192524-A 7959 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
              |||| || |||||||
Db          1 CCCTTGAGCAACAGA 15


RESULT 928
CQ623842/c
LOCUS       CQ623842                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 8582 from Patent WO0192524.
ACCESSION   CQ623842
VERSION     CQ623842.1  GI:41674060
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 8582 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         17 TGCTTCTGCATCAGC 3


RESULT 929
CQ623843/c
LOCUS       CQ623843                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 8583 from Patent WO0192524.
ACCESSION   CQ623843
VERSION     CQ623843.1  GI:41674061
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 8583 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         16 TGCTTCTGCATCAGC 2


RESULT 930
CQ623844/c
LOCUS       CQ623844                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 8584 from Patent WO0192524.
ACCESSION   CQ623844
VERSION     CQ623844.1  GI:41674062
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 8584 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         15 TGCTTCTGCATCAGC 1


RESULT 931
CQ625802/c
LOCUS       CQ625802                  17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10542 from Patent WO0192524.
ACCESSION   CQ625802
VERSION     CQ625802.1  GI:41676020
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10542 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
              ||| ||||||| |||
Db         17 TTTCTTCATTATGCT 3


RESULT 932
```

```
CQ625803/c
LOCUS       CQ625803                 17 bp    DNA     linear   PAT 02-FEB-2004
DEFINITION  Sequence 10543 from Patent WO0192524.
ACCESSION   CQ625803
VERSION     CQ625803.1  GI:41676021
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Myosin-like gene expressed in human heart and muscle
  JOURNAL   Patent: WO 0192524-A 10543 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
              ||| ||||||| |||
Db         16 TTTCTTCATTATGCT 2


RESULT 933
I19747
LOCUS       I19747                   17 bp    DNA     linear   PAT 07-OCT-1996
DEFINITION  Sequence 3 from patent US 5512439.
ACCESSION   I19747
VERSION     I19747.1  GI:1600102
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Hornes,E. and Korsnes,L.
  TITLE     Oligonucleotide-linked magnetic particles and uses thereof
  JOURNAL   Patent: US 5512439-A 3 30-APR-1996;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1555 GAACAGGACTGCAAA 1569
              |||  ||||||||||
Db          2 GAATTGGACTGCAAA 16


RESULT 934
I37696/c
LOCUS       I37696                   17 bp    DNA     linear   PAT 13-MAY-1997
DEFINITION  Sequence 709 from patent US 5612215.
ACCESSION   I37696
VERSION     I37696.1  GI:2085656
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
            Stinchcomb,D.T.
  TITLE     Stromelysin targeted ribozymes
  JOURNAL   Patent: US 5612215-A 709 18-MAR-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1754 CTCTTTATTCATTAA 1768
              ||||||||| | |||
Db         17 CTCTTTATTAAATAA 3


RESULT 935
I52775
LOCUS       I52775                   17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 516 from patent US 5646042.
ACCESSION   I52775
VERSION     I52775.1  GI:2473976
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 516 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1774 TTTTTTTTGAACCCC 1788
              | ||||| |||||||
Db          3 TGTTTTTAGAACCCC 17


RESULT 936
I54438/c
LOCUS       I54438                   17 bp    DNA     linear   PAT 07-OCT-1997
DEFINITION  Sequence 2179 from patent US 5646042.
ACCESSION   I54438
VERSION     I54438.1  GI:2475641
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE     C-myb targeted ribozymes
  JOURNAL   Patent: US 5646042-A 2179 08-JUL-1997;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1976 TTGAAAAAAAGAAAA 1990
              |||| |||| |||||
Db         15 TTGACAAAAGGAAAA 1


RESULT 937
I94546/c
```

```
LOCUS       I94546                  17 bp    DNA     linear   PAT 01-DEC-1998
DEFINITION  Sequence 709 from patent US 5731295.
ACCESSION   I94546
VERSION     I94546.1  GI:3939016
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
            Stinchcomb,D.T.
  TITLE     Method of reducing stromelysin RNA via ribozymes
  JOURNAL   Patent: US 5731295-A 709 24-MAR-1998;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1754 CTCTTTATTCATTAA 1768
              ||||||||| | |||
Db         17 CTCTTTATTAAATAA 3


RESULT 938
AR186282
LOCUS       AR186282                17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 1770 from patent US 6346398.
ACCESSION   AR186282
VERSION     AR186282.1  GI:20232247
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 1770 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAA 1985
              ||| |||| ||||||
Db          3 TTAACTTGGAAAAAA 17


RESULT 939
AR186578
LOCUS       AR186578                17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2066 from patent US 6346398.
ACCESSION   AR186578
VERSION     AR186578.1  GI:20232543
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2066 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              || | ||||||||||
Db          1 TCCTGCCTTCTCTGA 15


RESULT 940
AR186717/c
LOCUS       AR186717                17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2205 from patent US 6346398.
ACCESSION   AR186717
VERSION     AR186717.1  GI:20232682
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2205 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGA 1706
              |||||||| | ||||
Db         15 TTTCTCTAACACTGA 1


RESULT 941
AR186744/c
LOCUS       AR186744                17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2232 from patent US 6346398.
ACCESSION   AR186744
VERSION     AR186744.1  GI:20232709
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2232 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCA 1885
              |||| ||||||| ||
Db         17 GCCACTGAAATGGCA 3


RESULT 942
AR187129/c
LOCUS       AR187129                17 bp    DNA     linear   PAT 20-APR-2002
```

```
DEFINITION  Sequence 2617 from patent US 6346398.
ACCESSION   AR187129
VERSION     AR187129.1  GI:20233094
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2617 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAG 1769
              ||||| | |||||||
Db         15 TCTTTCTACATTAAG 1


RESULT 943
AR189888/c
LOCUS       AR189888                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 5376 from patent US 6346398.
ACCESSION   AR189888
VERSION     AR189888.1  GI:20235853
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 5376 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| ||||||| |||
Db         16 TCACCAATACCCTTT 2


RESULT 944
AR190543/c
LOCUS       AR190543                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 6031 from patent US 6346398.
ACCESSION   AR190543
VERSION     AR190543.1  GI:20236508
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 6031 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAAC 1558
              ||||  |||||||||
Db         17 GAGTCCGGAAGGAAC 3


RESULT 945
AR191910/c
LOCUS       AR191910                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 7398 from patent US 6346398.
ACCESSION   AR191910
VERSION     AR191910.1  GI:20237875
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 7398 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTT 1652
              | |||||| ||||||
Db         15 TTTTTAAATAGCCTT 1


RESULT 946
AR192255
LOCUS       AR192255                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 7743 from patent US 6346398.
ACCESSION   AR192255
VERSION     AR192255.1  GI:20238220
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 7743 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCC 1897
              ||||||| ||| |||
Db         2 TCAAATTCATGAGCC 16


RESULT 947
AR207642/c
LOCUS       AR207642                 17 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 4 from patent US 6379892.
```

```
ACCESSION   AR207642
VERSION     AR207642.1  GI:21507449
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kacena,K.
  TITLE     Methods, kits and compositions of matter useful for determining
            Chlamydia pneumoniae
  JOURNAL   Patent: US 6379892-A 4 30-APR-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGA 1545
              |||||| | ||||||
Db         15 AGAAAGTTAAGGAGA 1


RESULT 948
AR207652/c
LOCUS       AR207652                 17 bp    DNA     linear   PAT 20-JUN-2002
DEFINITION  Sequence 14 from patent US 6379892.
ACCESSION   AR207652
VERSION     AR207652.1  GI:21507462
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Kacena,K.
  TITLE     Methods, kits and compositions of matter useful for determining
            Chlamydia pneumoniae
  JOURNAL   Patent: US 6379892-A 14 30-APR-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1531 AGAAAGGTTAGGAGA 1545
              |||||| | ||||||
Db         15 AGAAAGTTAAGGAGA 1


RESULT 949
AR322913
LOCUS       AR322913                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 315 from patent US 6566127.
ACCESSION   AR322913
VERSION     AR322913.1  GI:33708721
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 315 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1971 TTACCTTGAAAAAAA 1985
              ||| |||| ||||||
Db          3 TTAACTTGGAAAAAA 17


RESULT 950
AR323209
LOCUS       AR323209                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 611 from patent US 6566127.
ACCESSION   AR323209
VERSION     AR323209.1  GI:33709017
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 611 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              || | ||||||||||
Db          1 TCCTGCCTTCTCTGA 15


RESULT 951
AR323348/c
LOCUS       AR323348                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 750 from patent US 6566127.
ACCESSION   AR323348
VERSION     AR323348.1  GI:33709156
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 750 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1692 TTTCTCTAGCGCTGA 1706
              |||||||| | ||||
Db         15 TTTCTCTAACACTGA 1


RESULT 952
AR323375/c
LOCUS       AR323375                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 777 from patent US 6566127.
ACCESSION   AR323375
```

```
VERSION     AR323375.1  GI:33709183
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 777 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1871 GCCATTGAAATGTCA 1885
              |||| ||||||| ||
Db         17 GCCACTGAAATGGCA 3


RESULT 953
AR323739/c
LOCUS       AR323739                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 1141 from patent US 6566127.
ACCESSION   AR323739
VERSION     AR323739.1  GI:33709547
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 1141 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1755 TCTTTATTCATTAAG 1769
              ||||| | |||||||
Db         15 TCTTTCTACATTAAG 1


RESULT 954
AR324874/c
LOCUS       AR324874                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2276 from patent US 6566127.
ACCESSION   AR324874
VERSION     AR324874.1  GI:33710682
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2276 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| ||||||| |||
Db         16 TCACCAATACCCTTT 2


RESULT 955
AR325466/c
LOCUS       AR325466                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 2868 from patent US 6566127.
ACCESSION   AR325466
VERSION     AR325466.1  GI:33711274
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 2868 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1544 GAGTAGGGAAGGAAC 1558
              ||||  |||||||||
Db         17 GAGTCCGGAAGGAAC 3


RESULT 956
AR325804/c
LOCUS       AR325804                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3206 from patent US 6566127.
ACCESSION   AR325804
VERSION     AR325804.1  GI:33711612
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3206 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1638 TATTTAAAGAGCCTT 1652
              | ||||| ||||||
Db         15 TTTTTAAATAGCCTT 1


RESULT 957
AR326126
LOCUS       AR326126                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 3528 from patent US 6566127.
ACCESSION   AR326126
VERSION     AR326126.1  GI:33711934
```

```
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 3528 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCC 1897
              ||||||| ||| |||
Db          2 TCAAATTCATGAGCC 16


RESULT 958
AR327518
LOCUS       AR327518                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 4920 from patent US 6566127.
ACCESSION   AR327518
VERSION     AR327518.1  GI:33713326
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 4920 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              || | ||||||||||
Db          2 TCCTGCCTTCTCTGA 16


RESULT 959
AR327760/c
LOCUS       AR327760                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 5162 from patent US 6566127.
ACCESSION   AR327760
VERSION     AR327760.1  GI:33713568
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 5162 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1870 AGCCATTGAAATGTC 1884
              ||||| ||||||| |
Db         15 AGCCACTGAAATGGC 1


RESULT 960
AR329007
LOCUS       AR329007                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 6409 from patent US 6566127.
ACCESSION   AR329007
VERSION     AR329007.1  GI:33714815
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 6409 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1980 AAAAAAGAAAAGTGT 1994
              |||||| |||| |||
Db          2 AAAAAACAAAACTGT 16


RESULT 961
AR401789/c
LOCUS       AR401789                  17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 129 from patent US 6623962.
ACCESSION   AR401789
VERSION     AR401789.1  GI:40149239
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 129 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| |||||||| ||
Db         16 TCACCAATACCTATT 2


RESULT 962
AR402407
LOCUS       AR402407                  17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 747 from patent US 6623962.
ACCESSION   AR402407
VERSION     AR402407.1  GI:40149857
KEYWORDS    .
```

```
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 747 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | |||||| ||||||
Db          2 AGCCCATTTTTTCCT 16


RESULT 963
AR402408
LOCUS       AR402408                  17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 748 from patent US 6623962.
ACCESSION   AR402408
VERSION     AR402408.1  GI:40149858
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and McSwiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: US 6623962-A 748 23-SEP-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | |||||| ||||||
Db          1 AGCCCATTTTTTCCT 15


RESULT 964
AR433887
LOCUS       AR433887                  17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 310 from patent US 6656700.
ACCESSION   AR433887
VERSION     AR433887.1  GI:40196730
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y. and Shannon,M.E.
  TITLE     Isoforms of human pregnancy-associated protein-E
  JOURNAL   Patent: US 6656700-A 310 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1547 TAGGGAAGGAACAGG 1561
              | |||||||||| | |
Db          3 TAGGGAAGGAAGAAG 17


RESULT 965
AR433890
LOCUS       AR433890                  17 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 313 from patent US 6656700.
ACCESSION   AR433890
VERSION     AR433890.1  GI:40196733
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y. and Shannon,M.E.
  TITLE     Isoforms of human pregnancy-associated protein-E
  JOURNAL   Patent: US 6656700-A 313 02-DEC-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAGGA 1562
              |||||||||| | ||
Db          1 AGGGAAGGAAGAAGA 15


RESULT 966
AR457667/c
LOCUS       AR457667                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1344 from patent US 6686188.
ACCESSION   AR457667
VERSION     AR457667.1  GI:42692724
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1344 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1787 CCATTCTTTCCTTCT 1801
              ||||  |||||||||
Db         17 CCATCTTTTCCTTCT 3


RESULT 967
AR457671/c
LOCUS       AR457671                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1348 from patent US 6686188.
ACCESSION   AR457671
VERSION     AR457671.1  GI:42692728
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
```

```
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1348 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1785 CCCCATTCTTTCCTT 1799
              ||||||  |||||||
Db         15 CCCCATCTTTTCCTT 1

RESULT 968
AR457902/c
LOCUS       AR457902                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1579 from patent US 6686188.
ACCESSION   AR457902
VERSION     AR457902.1  GI:42692959
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1579 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1572 TCCTTCTCCACCGCA 1586
              ||||||||||  |||
Db         17 TCCTTCTCCAGAGCA 3

RESULT 969
AR457905/c
LOCUS       AR457905                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1582 from patent US 6686188.
ACCESSION   AR457905
VERSION     AR457905.1  GI:42692962
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1582 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1571 ATCCTTCTCCACCGC 1585
              ||||||||||  ||
Db         15 ATCCTTCTCCAGAGC 1

RESULT 970
AR458023
LOCUS       AR458023                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1700 from patent US 6686188.
ACCESSION   AR458023
VERSION     AR458023.1  GI:42693080
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1700 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
              ||||| ||||||  ||
Db          3 TGGTATGAGGCAGAG 17

RESULT 971
AR458024
LOCUS       AR458024                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1701 from patent US 6686188.
ACCESSION   AR458024
VERSION     AR458024.1  GI:42693081
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1701 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
              ||||| ||||||  ||
Db          2 TGGTATGAGGCAGAG 16

RESULT 972
AR458025
LOCUS       AR458025                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 1702 from patent US 6686188.
ACCESSION   AR458025
```

```
VERSION     AR458025.1  GI:42693082
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 1702 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2025 TGGTAGGAGGCAAAG 2039
              ||||| |||||| ||
Db          1 TGGTATGAGGCAGAG 15


RESULT 973
AR463968/c
LOCUS       AR463968                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7645 from patent US 6686188.
ACCESSION   AR463968
VERSION     AR463968.1  GI:42699025
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7645 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1684 CTTAGTTGTTTCTCT 1698
              ||| |||| ||||||
Db         15 CTTTGTTGGTTCTCT 1


RESULT 974
AR464282
LOCUS       AR464282                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 7959 from patent US 6686188.
ACCESSION   AR464282
VERSION     AR464282.1  GI:42699339
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 7959 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
              |||| || |||||||
Db          1 CCCTTGAGCAACAGA 15


RESULT 975
AR464905/c
LOCUS       AR464905                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 8582 from patent US 6686188.
ACCESSION   AR464905
VERSION     AR464905.1  GI:42699962
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 8582 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         17 TGCTTCTGCATCAGC 3


RESULT 976
AR464906/c
LOCUS       AR464906                17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 8583 from patent US 6686188.
ACCESSION   AR464906
VERSION     AR464906.1  GI:42699963
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 8583 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         16 TGCTTCTGCATCAGC 2


RESULT 977
```

```
AR464907/c
LOCUS       AR464907                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 8584 from patent US 6686188.
ACCESSION   AR464907
VERSION     AR464907.1  GI:42699964
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 8584 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||||||||| |
Db         15 TGCTTCTGCATCAGC 1


RESULT 978
AR466865/c
LOCUS       AR466865                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10542 from patent US 6686188.
ACCESSION   AR466865
VERSION     AR466865.1  GI:42701922
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10542 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
              ||| ||||||| |||
Db         17 TTTCTTCATTATGCT 3


RESULT 979
AR466866/c
LOCUS       AR466866                  17 bp    DNA     linear   PAT 20-FEB-2004
DEFINITION  Sequence 10543 from patent US 6686188.
ACCESSION   AR466866
VERSION     AR466866.1  GI:42701923
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
  TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
  JOURNAL   Patent: US 6686188-A 10543 03-FEB-2004;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1757 TTTATTCATTAAGCT 1771
              ||| ||||||| |||
Db         16 TTTCTTCATTATGCT 2


RESULT 980
AX215783/c
LOCUS       AX215783                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1225 from Patent WO0159103.
ACCESSION   AX215783
VERSION     AX215783.1  GI:15525826
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1225 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              ||||||| ||| |||
Db         15 AAGCTTTGTTTCTTT 1


RESULT 981
AX215808/c
LOCUS       AX215808                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1250 from Patent WO0159103.
ACCESSION   AX215808
VERSION     AX215808.1  GI:15525851
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1250 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"
```

```
  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||| | ||||
Db         17 ACTGGTTCAGAATCA 3


RESULT 982
AX215974
LOCUS       AX215974                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1416 from Patent WO0159103.
ACCESSION   AX215974
VERSION     AX215974.1  GI:15526017
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1416 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1838 TACATTCCCTGGGCC 1852
              |||||| ||| ||||
Db          1 TACATTGCCTTGGCC 15


RESULT 983
AX216238/c
LOCUS       AX216238                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1680 from Patent WO0159103.
ACCESSION   AX216238
VERSION     AX216238.1  GI:15526281
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1680 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1654 ACTGGTTCTGCATCA 1668
              ||||||| | ||||
Db         16 ACTGGTTCAGAATCA 2


RESULT 984
AX216292
LOCUS       AX216292                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1734 from Patent WO0159103.
ACCESSION   AX216292
VERSION     AX216292.1  GI:15526353
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1734 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1838 TACATTCCCTGGGCC 1852
              |||||| ||| ||||
Db          3 TACATTGCCTTGGCC 17


RESULT 985
AX216319/c
LOCUS       AX216319                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1761 from Patent WO0159103.
ACCESSION   AX216319
VERSION     AX216319.1  GI:15526380
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1761 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTT 1773
              | |||||| ||||||
Db         17 TTTTCATTCAGCTTT 3


RESULT 986
AX216423/c
LOCUS       AX216423                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 1865 from Patent WO0159103.
ACCESSION   AX216423
```

```
VERSION     AX216423.1  GI:15526484
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 1865 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1790 TTCTTTCCTTCTCTG 1804
              || || |||||||||
Db         15 TTTTTGCCTTCTCTG 1


RESULT 987
AX216867/c
LOCUS       AX216867                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2309 from Patent WO0159103.
ACCESSION   AX216867
VERSION     AX216867.1  GI:15526928
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2309 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1759 TATTCATTAAGCTTT 1773
              | |||||| ||||||
Db         15 TTTTCATTCAGCTTT 1


RESULT 988
AX217002/c
LOCUS       AX217002                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2444 from Patent WO0159103.
ACCESSION   AX217002
VERSION     AX217002.1  GI:15527063
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2444 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAA 1807
              || |||||||||| |
Db         16 TTGCCTTCTCTGAGA 2


RESULT 989
AX217044/c
LOCUS       AX217044                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2486 from Patent WO0159103.
ACCESSION   AX217044
VERSION     AX217044.1  GI:15527105
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2486 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1626 TACCTACCTTACTAT 1640
              || || |||||||||
Db         16 TATCTTCCTTACTAT 2


RESULT 990
AX217045/c
LOCUS       AX217045                  17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2487 from Patent WO0159103.
ACCESSION   AX217045
VERSION     AX217045.1  GI:15527106
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2487 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
```

```
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match           2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1626 TACCTACCTTACTAT 1640
              || || |||||||||
Db         15 TATCTTCCTTACTAT 1


RESULT 991
AX217397/c
LOCUS       AX217397                 17 bp    RNA     linear   PAT 07-SEP-2001
DEFINITION  Sequence 2839 from Patent WO0159103.
ACCESSION   AX217397
VERSION     AX217397.1  GI:15527458
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Blatt,L., Mcswiggen,J. and Chowrira,B.M.
  TITLE     Method and reagent for the modulation and diagnosis of cd20 and
            nogo gene expression
  JOURNAL   Patent: WO 0159103-A 2839 16-AUG-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
            McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32630"
                     /note="Nucleic Acid"

  Query Match           2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2024 CTGGTAGGAGGCAAA 2038
              |||| || |||||||
Db         15 CTGGAAGAAGGCAAA 1


RESULT 992
AX326369
LOCUS       AX326369                 17 bp    DNA     linear   PAT 02-SEP-2002
DEFINITION  Sequence 2507 from Patent WO0192512.
ACCESSION   AX326369
VERSION     AX326369.1  GI:18097133
KEYWORDS    .
SOURCE      Ricinus communis (castor bean)
  ORGANISM  Ricinus communis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids I; Malpighiales; Euphorbiaceae; Acalyphoideae;
            Acalypheae; Ricinus.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
  TITLE     Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
  JOURNAL   Patent: WO 0192512-A 2507 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Ricinus communis"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:3988"

  Query Match           2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTG 1742
              |||||| |||| |||
Db          3 TATTATGAGAATGTG 17


RESULT 993
AX326370/c
LOCUS       AX326370                 17 bp    DNA     linear   PAT 02-SEP-2002
DEFINITION  Sequence 2508 from Patent WO0192512.
ACCESSION   AX326370
VERSION     AX326370.1  GI:18097134
KEYWORDS    .
SOURCE      Ricinus communis (castor bean)
  ORGANISM  Ricinus communis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids I; Malpighiales; Euphorbiaceae; Acalyphoideae;
            Acalypheae; Ricinus.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
  TITLE     Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
  JOURNAL   Patent: WO 0192512-A 2508 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Ricinus communis"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:3988"

  Query Match           2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTG 1742
              |||||| |||| |||
Db         15 TATTATGAGAATGTG 1


RESULT 994
AX326373
LOCUS       AX326373                 17 bp    DNA     linear   PAT 02-SEP-2002
DEFINITION  Sequence 2511 from Patent WO0192512.
ACCESSION   AX326373
VERSION     AX326373.1  GI:18097137
KEYWORDS    .
SOURCE      Ricinus communis (castor bean)
  ORGANISM  Ricinus communis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids I; Malpighiales; Euphorbiaceae; Acalyphoideae;
            Acalypheae; Ricinus.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
  TITLE     Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
  JOURNAL   Patent: WO 0192512-A 2511 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Ricinus communis"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:3988"

  Query Match           2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTG 1742
              |||||||| || |||
```

```
Db          1 TATTATCATAATGTG 15


RESULT 995
AX326374/c
LOCUS       AX326374                  17 bp    DNA     linear   PAT 02-SEP-2002
DEFINITION  Sequence 2512 from Patent WO0192512.
ACCESSION   AX326374
VERSION     AX326374.1  GI:18097138
KEYWORDS    .
SOURCE      Ricinus communis (castor bean)
  ORGANISM  Ricinus communis
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids I; Malpighiales; Euphorbiaceae; Acalyphoideae;
            Acalypheae; Ricinus.
REFERENCE   1
  AUTHORS   Kmiec,E.B., Gamper,H.B., Rice,M.C. and Kim,J.
  TITLE     Targeted chromosomal genomic alterations in plants using modified
            single stranded oligonucleotides
  JOURNAL   Patent: WO 0192512-A 2512 06-DEC-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Ricinus communis"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:3988"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1728 TATTATCAGAAGGTG 1742
              ||||||| || |||
Db         17 TATTATCATAATGTG 3


RESULT 996
AX421959
LOCUS       AX421959                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 295 from Patent WO0188124.
ACCESSION   AX421959
VERSION     AX421959.1  GI:21525341
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 295 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCT 1847
              | |||||||||||  |
Db          3 TCAAATACATTCCGT 17


RESULT 997
AX422679
LOCUS       AX422679                  17 bp    RNA     linear   PAT 18-JUN-2002
DEFINITION  Sequence 1015 from Patent WO0188124.
ACCESSION   AX422679
VERSION     AX422679.1  GI:21526061
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and
            Randi,A.M.
  TITLE     Method and reagent for the inhibition of erg
  JOURNAL   Patent: WO 0188124-A 1015 22-NOV-2001;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCT 1847
              | |||||||||||  |
Db          1 TCAAATACATTCCGT 15


RESULT 998
AX578513
LOCUS       AX578513                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 351 from Patent WO0211674.
ACCESSION   AX578513
VERSION     AX578513.1  GI:27647715
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 351 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2016 CAAGTCCTCTGGTAG 2030
              | || ||||||||||
Db          1 CCAGCCCTCTGGTAG 15


RESULT 999
AX578600/c
LOCUS       AX578600                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 438 from Patent WO0211674.
ACCESSION   AX578600
VERSION     AX578600.1  GI:27647802
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```

```
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 438 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1908 AGATCAACAATACCT 1922
              ||||||| ||||| |
Db         16 AGATCAAGAATACTT 2


RESULT 1000
AX578705/c
LOCUS       AX578705                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 543 from Patent WO0211674.
ACCESSION   AX578705
VERSION     AX578705.1  GI:27647907
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 543 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTA 1835
              ||||||||  |||||
Db         16 TTTTAGAAAATTTTA 2


RESULT 1001
AX578706/c
LOCUS       AX578706                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 544 from Patent WO0211674.
ACCESSION   AX578706
VERSION     AX578706.1  GI:27647908
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 544 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1821 TTTTAGAATCTTTTA 1835
              ||||||||  |||||
Db         15 TTTTAGAAAATTTTA 1


RESULT 1002
AX579165
LOCUS       AX579165                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1003 from Patent WO0211674.
ACCESSION   AX579165
VERSION     AX579165.1  GI:27648367
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1003 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2016 CAAGTCCTCTGGTAG 2030
              | || ||||||||||
Db          3 CCAGCCCTCTGGTAG 17


RESULT 1003
AX579166
LOCUS       AX579166                 17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1004 from Patent WO0211674.
ACCESSION   AX579166
VERSION     AX579166.1  GI:27648368
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1004 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
```

```
                    /organism="Homo sapiens"
                    /mol_type="unassigned RNA"
                    /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2016 CAAGTCCTCTGGTAG 2030
              | || ||||||||||
Db          2 CCAGCCCTCTGGTAG 16


RESULT 1004
AX579280/c
LOCUS       AX579280                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1118 from Patent WO0211674.
ACCESSION   AX579280
VERSION     AX579280.1  GI:27648482
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1118 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1908 AGATCAACAATACCT 1922
              ||||||| ||||| |
Db         15 AGATCAAGAATACTT 1


RESULT 1005
AX579458
LOCUS       AX579458                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1296 from Patent WO0211674.
ACCESSION   AX579458
VERSION     AX579458.1  GI:27648660
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1296 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1805 AAAGTGGTGCTATAA 1819
              |||||||||| || |
Db          1 AAAGTGGTGCCATCA 15


RESULT 1006
AX579683
LOCUS       AX579683                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1521 from Patent WO0211674.
ACCESSION   AX579683
VERSION     AX579683.1  GI:27648885
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1521 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1805 AAAGTGGTGCTATAA 1819
              |||||||||| || |
Db          3 AAAGTGGTGCCATCA 17


RESULT 1007
AX579927/c
LOCUS       AX579927                  17 bp    RNA     linear   PAT 10-JAN-2003
DEFINITION  Sequence 1765 from Patent WO0211674.
ACCESSION   AX579927
VERSION     AX579927.1  GI:27649129
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
            and Grupe,A.
  TITLE     Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
  JOURNAL   Patent: WO 0211674-A 1765 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1947 TTGGTTTTTGTGTCC 1961
              ||||| ||| |||||
```

```
Db         15 TTGGTGTTTTTGTCC 1


RESULT 1008
AX615442
LOCUS       AX615442                 17 bp    DNA     linear   PAT 20-FEB-2003
DEFINITION  Sequence 249 from Patent EP1262488.
ACCESSION   AX615442
VERSION     AX615442.1  GI:28446488
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y. and Nguyen,C.T.
  TITLE     Human lccl-domain containing protein
  JOURNAL   Patent: EP 1262488-A 249 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCA 2036
              | ||||||||||| |
Db          1 CACTGGTAGGAGGAA 15


RESULT 1009
AX634806/c
LOCUS       AX634806                 17 bp    RNA     linear   PAT 21-FEB-2003
DEFINITION  Sequence 1945 from Patent EP1260586.
ACCESSION   AX634806
VERSION     AX634806.1  GI:28470420
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
            Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
            Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
  TITLE     Method and reagent for inhibiting the expression of disease related
            genes
  JOURNAL   Patent: EP 1260586-A 1945 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned RNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2022 CTCTGGTAGGAGGCA 2036
              || ||| ||||||||
Db         15 CTGTGGGAGGAGGCA 1


RESULT 1010
AX648719
LOCUS       AX648719                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 559 from Patent EP1273660.
ACCESSION   AX648719
VERSION     AX648719.1  GI:29151537
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 559 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 AACTTTGGACCTATT 1731
              ||||| ||| |||||
Db          3 AACTTAGGATCTATT 17


RESULT 1011
AX648720
LOCUS       AX648720                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 560 from Patent EP1273660.
ACCESSION   AX648720
VERSION     AX648720.1  GI:29151538
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 560 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1717 AACTTTGGACCTATT 1731
              ||||| ||| |||||
Db          2 AACTTAGGATCTATT 16


RESULT 1012
AX648944/c
LOCUS       AX648944                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 784 from Patent EP1273660.
ACCESSION   AX648944
VERSION     AX648944.1  GI:29151762
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 784 08-JAN-2003;
```

```
           Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTA 1997
              ||| || ||||||||
Db         17 AAACAAGAGTGTGTA 3


RESULT 1013
AX648945/c
LOCUS       AX648945                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 785 from Patent EP1273660.
ACCESSION   AX648945
VERSION     AX648945.1  GI:29151763
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 785 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTA 1997
              ||| || ||||||||
Db         16 AAACAAGAGTGTGTA 2


RESULT 1014
AX648946/c
LOCUS       AX648946                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 786 from Patent EP1273660.
ACCESSION   AX648946
VERSION     AX648946.1  GI:29151764
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 786 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1983 AAAGAAAAGTGTGTA 1997
              ||| || ||||||||
Db         15 AAACAAGAGTGTGTA 1


RESULT 1015
AX649061/c
LOCUS       AX649061                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 901 from Patent EP1273660.
ACCESSION   AX649061
VERSION     AX649061.1  GI:29151879
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 901 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGA 1596
              || |||||||||| |
Db         17 CCCCACAGACTGGAA 3


RESULT 1016
AX649062/c
LOCUS       AX649062                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 902 from Patent EP1273660.
ACCESSION   AX649062
VERSION     AX649062.1  GI:29151880
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 902 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGA 1596
              || |||||||||| |
Db         16 CCCCACAGACTGGAA 2


RESULT 1017
AX649063/c
LOCUS       AX649063                 17 bp    DNA     linear   PAT 22-MAR-2003
DEFINITION  Sequence 903 from Patent EP1273660.
ACCESSION   AX649063
VERSION     AX649063.1  GI:29151881
```

```
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Gu,Y.
  TITLE     Human sodium-hydrogen exchanger like protein 1
  JOURNAL   Patent: EP 1273660-A 903 08-JAN-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1582 CCGCACAGACTGGGA 1596
              || |||||||||| |
Db         15 CCCCACAGACTGGAA 1


RESULT 1018
AX671973/c
LOCUS       AX671973                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 418 from Patent WO03004526.
ACCESSION   AX671973
VERSION     AX671973.1  GI:29330321
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 418 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              |||||| || |||||
Db         17 TCTTTCTTTTTCTGA 3


RESULT 1019
AX672026/c
LOCUS       AX672026                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 471 from Patent WO03004526.
ACCESSION   AX672026
VERSION     AX672026.1  GI:29330374
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 471 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              ||| | ||||||||||
Db         17 TCTCTGCTTCTCTGA 3


RESULT 1020
AX672284
LOCUS       AX672284                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 729 from Patent WO03004526.
ACCESSION   AX672284
VERSION     AX672284.1  GI:29330632
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 729 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACAT 1842
              ||| | |||||||||
Db          2 ATCATCTAAATACAT 16


RESULT 1021
AX672469/c
LOCUS       AX672469                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 914 from Patent WO03004526.
ACCESSION   AX672469
VERSION     AX672469.1  GI:29330817
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 914 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
```

```
                    /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1878 AAATGTCAAATTGAT 1892
                || ||||||| ||||
Db         16 AACTGTCAAAATGAT 2


RESULT 1022
AX672489/c
LOCUS       AX672489                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 934 from Patent WO03004526.
ACCESSION   AX672489
VERSION     AX672489.1  GI:29330837
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 934 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1813 GCTATAAGTTTTAGA 1827
                ||||||| |||| ||
Db         17 GCTATAAATTTTGGA 3


RESULT 1023
AX672976/c
LOCUS       AX672976                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 1421 from Patent WO03004526.
ACCESSION   AX672976
VERSION     AX672976.1  GI:29331324
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 1421 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAAC 1598
                ||| ||||||||| |
Db         15 GCAGAGACTGGGATC 1


RESULT 1024
AX673050/c
LOCUS       AX673050                  17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 1495 from Patent WO03004526.
ACCESSION   AX673050
VERSION     AX673050.1  GI:29331398
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 1495 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGA 1616
                ||| |||| ||||||
Db         17 TCCAGGCCAGGGGGA 3


RESULT 1025
AX687899
LOCUS       AX687899                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 631 from Patent EP1281758.
ACCESSION   AX687899
VERSION     AX687899.1  GI:29410597
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 631 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTT 1622
                ||||||| | |||||
Db          3 CCTGGGGAAGGAGTT 17


RESULT 1026
AX687900
LOCUS       AX687900                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 632 from Patent EP1281758.
```

```
ACCESSION   AX687900
VERSION     AX687900.1  GI:29410598
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 632 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTT 1622
              ||||||| | |||||
Db          2 CCTGGGGAAGGAGTT 16


RESULT 1027
AX687901
LOCUS       AX687901                  17 bp    DNA     linear   PAT 31-MAR-2003
DEFINITION  Sequence 633 from Patent EP1281758.
ACCESSION   AX687901
VERSION     AX687901.1  GI:29410599
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M., Gu,Y. and Nguyen,C.T.
  TITLE     Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
            mdz12
  JOURNAL   Patent: EP 1281758-A 633 05-FEB-2003;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1608 CCTGGGGGAAGAGTT 1622
              ||||||| | |||||
Db          1 CCTGGGGAAGGAGTT 15


RESULT 1028
AX722944
LOCUS       AX722944                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 631 from Patent WO03025176.
ACCESSION   AX722944
VERSION     AX722944.1  GI:30423445
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 631 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1713 TCCTAACTTTGGACC 1727
              ||||||| |||| |
Db          3 TCCTAACTGTGGAAC 17


RESULT 1029
AX723611
LOCUS       AX723611                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1298 from Patent WO03025176.
ACCESSION   AX723611
VERSION     AX723611.1  GI:30424112
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 1298 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1646 GAGCCTTCACTGGTT 1660
              || ||||| ||||||
Db          1 GATCCTTCCCTGGTT 15


RESULT 1030
AX724034/c
LOCUS       AX724034                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1721 from Patent WO03025176.
ACCESSION   AX724034
VERSION     AX724034.1  GI:30503377
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 1721 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
```

```
                    /organism="Mus musculus"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1612 GGGGAAGAGTTTGTT 1626
              ||||||||  |||| |
Db         16 GGGGAAGACTTTGAT 2


RESULT 1031
AX724909
LOCUS       AX724909                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2596 from Patent WO03025176.
ACCESSION   AX724909
VERSION     AX724909.1  GI:30504252
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 2596 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGGTGA 1743
              ||  ||||||||||||
Db          2 ATCCTCAGAAGGTGA 16


RESULT 1032
AX725510/c
LOCUS       AX725510                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3197 from Patent WO03025176.
ACCESSION   AX725510
VERSION     AX725510.1  GI:30504853
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3197 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2029 AGGAGGCAAAGGTTC 2043
              ||||||||| || ||
Db         15 AGGAGGCAAGGGATC 1


RESULT 1033
AX725733
LOCUS       AX725733                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3420 from Patent WO03025176.
ACCESSION   AX725733
VERSION     AX725733.1  GI:30505076
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 3420 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1639 ATTTAAAGAGCCTTC 1653
              || ||| ||||||||
Db          2 ATCTAATGAGCCTTC 16


RESULT 1034
AX726659
LOCUS       AX726659                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4346 from Patent WO03025176.
ACCESSION   AX726659
VERSION     AX726659.1  GI:30506002
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 4346 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1576 TCTCCACCGCACAGA 1590
              || ||| ||||||||
Db          3 TCACCAACGCACAGA 17


RESULT 1035
```

```
AX726954
LOCUS       AX726954                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4641 from Patent WO03025176.
ACCESSION   AX726954
VERSION     AX726954.1  GI:30506297
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 4641 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1713 TCCTAACTTTGGACC 1727
              ||| |||| ||||||
Db          3 TCCGAACTCTGGACC 17


RESULT 1036
AX727473/c
LOCUS       AX727473                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5160 from Patent WO03025176.
ACCESSION   AX727473
VERSION     AX727473.1  GI:30506816
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5160 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1602 TCCTGGCCTGGGGGA 1616
              |||||||||| | ||
Db         17 TCCTGGCCTGAGAGA 3


RESULT 1037
AX728017
LOCUS       AX728017                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5704 from Patent WO03025176.
ACCESSION   AX728017
VERSION     AX728017.1  GI:30507360
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5704 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAG 2011
              |||||| || |||||
Db          2 ATCTAGATTTTTCAG 16


RESULT 1038
AX728257/c
LOCUS       AX728257                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5944 from Patent WO03025176.
ACCESSION   AX728257
VERSION     AX728257.1  GI:30507600
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025176-A 5944 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              ||| | |||||||||
Db         17 TCTCTGCTTCTCTGA 3


RESULT 1039
AX728352
LOCUS       AX728352                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 6039 from Patent WO03025176.
ACCESSION   AX728352
VERSION     AX728352.1  GI:30507695
KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
```

```
            medicines
  JOURNAL   Patent: WO 03025176-A 6039 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Mus musculus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:10090"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1631 ACCTTACTATTTAAA 1645
              | ||| |||||||||
Db          2 ATCTTTCTATTTAAA 16


RESULT 1040
AX728599/c
LOCUS       AX728599                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 233 from Patent WO03025175.
ACCESSION   AX728599
VERSION     AX728599.1  GI:30507942
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 233 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1538 TTAGGAGAGTAGGGA 1552
              |||||| ||| ||||
Db         17 TTAGGAAAGTTGGGA 3


RESULT 1041
AX728696
LOCUS       AX728696                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 330 from Patent WO03025175.
ACCESSION   AX728696
VERSION     AX728696.1  GI:30508039
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 330 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACAT 1842
              ||||||||||| | ||
Db          2 ATCTTTTAAAAAGAT 16


RESULT 1042
AX728759/c
LOCUS       AX728759                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 393 from Patent WO03025175.
ACCESSION   AX728759
VERSION     AX728759.1  GI:30508102
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 393 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1529 GAAGAAAGGTTAGGA 1543
              ||||||||||  |||
Db         17 GAAGAAAGGTCTGGA 3


RESULT 1043
AX729171
LOCUS       AX729171                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 805 from Patent WO03025175.
ACCESSION   AX729171
VERSION     AX729171.1  GI:30508514
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 805 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTT 1923
```

```
              |||||| ||||| ||
Db          1 GATCAATAATACATT 15


RESULT 1044
AX729978
LOCUS       AX729978                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1612 from Patent WO03025175.
ACCESSION   AX729978
VERSION     AX729978.1  GI:30509321
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 1612 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAAA 1837
              | |||||| ||||||
Db          3 TCAGAATCATTTAAA 17


RESULT 1045
AX731241
LOCUS       AX731241                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2875 from Patent WO03025175.
ACCESSION   AX731241
VERSION     AX731241.1  GI:30510584
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 2875 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTG 1782
              | |||||| ||||||
Db          2 ATCTTTTTGTTTTTG 16


RESULT 1046
AX732352
LOCUS       AX732352                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3986 from Patent WO03025175.
ACCESSION   AX732352
VERSION     AX732352.1  GI:30511695
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 3986 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1713 TCCTAACTTTGGACC 1727
              |||| |||||| |||
Db          3 TCCTGACTTTGCACC 17


RESULT 1047
AX732526
LOCUS       AX732526                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4160 from Patent WO03025175.
ACCESSION   AX732526
VERSION     AX732526.1  GI:30511869
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 4160 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2020 TCCTCTGGTAGGAGG 2034
              |||||||||| || |
Db          3 TCCTCTGGTATGATG 17


RESULT 1048
AX733851/c
LOCUS       AX733851                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5485 from Patent WO03025175.
ACCESSION   AX733851
VERSION     AX733851.1  GI:30513194
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5485 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1751 TGGCTCTTTATTCAT 1765
              ||||| |||||| ||
Db         16 TGGCTGTTTATTGAT 2


RESULT 1049
AX733953/c
LOCUS       AX733953                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5587 from Patent WO03025175.
ACCESSION   AX733953
VERSION     AX733953.1  GI:30513296
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5587 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAAC 1598
              ||| ||||||||| |
Db         15 GCAGAGACTGGGATC 1


RESULT 1050
AX734050/c
LOCUS       AX734050                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 5684 from Patent WO03025175.
ACCESSION   AX734050
VERSION     AX734050.1  GI:30513393
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
  JOURNAL   Patent: WO 03025175-A 5684 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1898 CTAGATCAACAGATC 1912
              ||  ||||||||||
Db         15 CTTTATCAACAGATC 1


RESULT 1051
AX734434/c
LOCUS       AX734434                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 24 from Patent WO03025177.
ACCESSION   AX734434
VERSION     AX734434.1  GI:30513711
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 24 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1922 TTTTTTTTCAGTGTT 1936
              |||||| |||||| |
Db         16 TTTTTTCTCAGTGAT 2


RESULT 1052
AX734727
LOCUS       AX734727                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 317 from Patent WO03025177.
ACCESSION   AX734727
VERSION     AX734727.1  GI:30514004
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 317 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
```

```
  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAG 2011
              |||| | ||||||||
Db          2 ATCTGGTTTCTTCAG 16


RESULT 1053
AX734927/c
LOCUS       AX734927                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 517 from Patent WO03025177.
ACCESSION   AX734927
VERSION     AX734927.1  GI:30514204
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 517 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1898 CTAGATCAACAGATC 1912
              ||| ||| |||||||
Db         15 CTAAATCCACAGATC 1


RESULT 1054
AX735296/c
LOCUS       AX735296                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 886 from Patent WO03025177.
ACCESSION   AX735296
VERSION     AX735296.1  GI:30514573
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 886 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1878 AAATGTCAAATTGAT 1892
              || ||||||| ||||
Db         16 AACTGTCAAAATGAT 2


RESULT 1055
AX735360/c
LOCUS       AX735360                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 950 from Patent WO03025177.
ACCESSION   AX735360
VERSION     AX735360.1  GI:30514637
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 950 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1816 ATAAGTTTTAGAATC 1830
              |||| |||||| |||
Db         15 ATAAATTTTAGGATC 1


RESULT 1056
AX736207/c
LOCUS       AX736207                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 1797 from Patent WO03025177.
ACCESSION   AX736207
VERSION     AX736207.1  GI:30515484
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 1797 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1538 TTAGGAGAGTAGGGA 1552
              |||||| ||| ||||
Db         17 TTAGGAAAGTTGGGA 3


RESULT 1057
AX736439/c
LOCUS       AX736439                 17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2029 from Patent WO03025177.
ACCESSION   AX736439
```

```
VERSION     AX736439.1  GI:30515727
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2029 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1998 TCTAGCTTCTTCAGA 2012
              || ||||||| ||||
Db         17 TCCAGCTTCTCCAGA 3


RESULT 1058
AX736524/c
LOCUS       AX736524                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2114 from Patent WO03025177.
ACCESSION   AX736524
VERSION     AX736524.1  GI:30515812
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2114 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1813 GCTATAAGTTTTAGA 1827
              ||||||| |||| ||
Db         17 GCTATAAATTTTGGA 3


RESULT 1059
AX736708
LOCUS       AX736708                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2298 from Patent WO03025177.
ACCESSION   AX736708
VERSION     AX736708.1  GI:30515996
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2298 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACAT 1842
              |||||||||| | ||
Db          2 ATCTTTTAAAAAGAT 16


RESULT 1060
AX736741
LOCUS       AX736741                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2331 from Patent WO03025177.
ACCESSION   AX736741
VERSION     AX736741.1  GI:30516029
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2331 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1823 TTAGAATCTTTTAAA 1837
              | |||||| ||||||
Db          3 TCAGAATCATTTAAA 17


RESULT 1061
AX736758/c
LOCUS       AX736758                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2348 from Patent WO03025177.
ACCESSION   AX736758
VERSION     AX736758.1  GI:30516046
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2348 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
```

```
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1679 GACTTCTTAGTTGTT 1693
              |||||| |||||| |
Db         16 GACTTCATAGTTGAT 2


RESULT 1062
AX736814/c
LOCUS       AX736814                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2404 from Patent WO03025177.
ACCESSION   AX736814
VERSION     AX736814.1  GI:30516102
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2404 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1825 AGAATCTTTTAAATA 1839
              ||||| ||||||| |
Db         17 AGAATGTTTTAAAGA 3


RESULT 1063
AX737367
LOCUS       AX737367                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 2957 from Patent WO03025177.
ACCESSION   AX737367
VERSION     AX737367.1  GI:30516655
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 2957 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1631 ACCTTACTATTTAAA 1645
              | |||||||||| ||
Db          2 ATCTTACTATTTGAA 16


RESULT 1064
AX737528
LOCUS       AX737528                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3118 from Patent WO03025177.
ACCESSION   AX737528
VERSION     AX737528.1  GI:30516816
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 3118 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1883 TCAAATTGATGTGCC 1897
              |||||||| |||| |
Db          3 TCAAATTGCTGTGTC 17


RESULT 1065
AX738212/c
LOCUS       AX738212                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 3802 from Patent WO03025177.
ACCESSION   AX738212
VERSION     AX738212.1  GI:30517500
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 3802 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1985 AGAAAAGTGTGTATC 1999
              | |||||||||| |||
Db         15 ATAAAAGTGTGGATC 1
```

```
RESULT 1066
AX738730
LOCUS       AX738730                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4320 from Patent WO03025177.
ACCESSION   AX738730
VERSION     AX738730.1  GI:30518020
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 4320 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1724 GACCTATTATCAGAA 1738
              || ||||||||| ||
Db          1 GATCTATTATCAAAA 15


RESULT 1067
AX739078
LOCUS       AX739078                  17 bp    DNA     linear   PAT 08-MAY-2003
DEFINITION  Sequence 4668 from Patent WO03025177.
ACCESSION   AX739078
VERSION     AX739078.1  GI:30518375
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
  JOURNAL   Patent: WO 03025177-A 4668 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1762 TCATTAAGCTTTTTT 1776
              ||||||| || ||||
Db          3 TCATTAAACTGTTTT 17


RESULT 1068
AX745236
LOCUS       AX745236                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1201 from Patent WO03031621.
ACCESSION   AX745236
VERSION     AX745236.1  GI:30723903
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1201 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1770 CTTTTTTTTTTTGAA 1784
              |||| |||||||| |
Db          3 CTTTATTTTTTTGCA 17


RESULT 1069
AX745239
LOCUS       AX745239                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1204 from Patent WO03031621.
ACCESSION   AX745239
VERSION     AX745239.1  GI:30723906
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1204 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1771 TTTTTTTTTTTGAAC 1785
              ||| |||||||| ||
Db          1 TTTATTTTTTGCAC 15


RESULT 1070
AX753719/c
LOCUS       AX753719                  17 bp    DNA     linear   PAT 23-JUN-2003
DEFINITION  Sequence 66 from Patent WO03037931.
ACCESSION   AX753719
VERSION     AX753719.1  GI:32166416
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M. and Phan,T.
  TITLE     Human angiomotin-like protein 1
  JOURNAL   Patent: WO 03037931-A 66 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
```

```
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1656 TGGTTCTGCATCACC 1670
              || |||| |||||||
Db         17 TGTTTCTCCATCACC 3


RESULT 1071
AX753722/c
LOCUS       AX753722                  17 bp    DNA     linear   PAT 23-JUN-2003
DEFINITION  Sequence 69 from Patent WO03037931.
ACCESSION   AX753722
VERSION     AX753722.1  GI:32166419
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M. and Phan,T.
  TITLE     Human angiomotin-like protein 1
  JOURNAL   Patent: WO 03037931-A 69 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1655 CTGGTTCTGCATCAC 1669
              ||| |||| ||||||
Db         15 CTGTTTCTCCATCAC 1


RESULT 1072
AX756733/c
LOCUS       AX756733                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 54 from Patent WO03040369.
ACCESSION   AX756733
VERSION     AX756733.1  GI:32251287
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 54 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1846 CTGGGCCAACAGACC 1860
              ||||||| ||||| |
Db         15 CTGGGCCCACAGATC 1


RESULT 1073
AX756964
LOCUS       AX756964                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 285 from Patent WO03040369.
ACCESSION   AX756964
VERSION     AX756964.1  GI:32251518
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 285 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1768 AGCTTTTTTTTTTTG 1782
              | |||||| ||||||
Db          2 ATCTTTTTGTTTTTG 16


RESULT 1074
AX757412
LOCUS       AX757412                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 733 from Patent WO03040369.
ACCESSION   AX757412
VERSION     AX757412.1  GI:32252028
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 733 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1828 ATCTTTTAAATACAT 1842
              ||||| |||| ||||
Db          2 ATCTTATAAAAACAT 16


RESULT 1075
AX757903/c
LOCUS       AX757903                  17 bp    DNA     linear   PAT 25-JUN-2003
```

```
DEFINITION  Sequence 1224 from Patent WO03040369.
ACCESSION   AX757903
VERSION     AX757903.1  GI:32252519
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 1224 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1898 CTAGATCAACAGATC 1912
              ||| || ||||||||
Db         15 CTACATAAACAGATC 1


RESULT 1076
AX758672
LOCUS       AX758672                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 1993 from Patent WO03040369.
ACCESSION   AX758672
VERSION     AX758672.1  GI:32253288
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 1993 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAG 2011
              |||||||||||  | |
Db          2 ATCTAGCTTCTGCCG 16


RESULT 1077
AX760785/c
LOCUS       AX760785                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4106 from Patent WO03040369.
ACCESSION   AX760785
VERSION     AX760785.1  GI:32255401
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4106 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              | ||| |||||||||
Db         17 TATTTTCTTCTCTGA 3


RESULT 1078
AX760812
LOCUS       AX760812                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4133 from Patent WO03040369.
ACCESSION   AX760812
VERSION     AX760812.1  GI:32255428
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4133 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAG 2011
              |||| ||| ||||||
Db          2 ATCTGGCTGCTTCAG 16


RESULT 1079
AX761197/c
LOCUS       AX761197                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4518 from Patent WO03040369.
ACCESSION   AX761197
VERSION     AX761197.1  GI:32255813
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4518 15-MAY-2003;
```

```
           Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2014 ATCAAGTCCTCTGGT 2028
              ||||||||  |||| |
Db         16 ATCAAGTCTTCTGAT 2


RESULT 1080
AX761316
LOCUS       AX761316                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 4637 from Patent WO03040369.
ACCESSION   AX761316
VERSION     AX761316.1  GI:32255932
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 4637 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1909 GATCAACAATACCTT 1923
              ||||  ||||||  |||
Db          1 GATCCACAATAACTT 15


RESULT 1081
AX762265
LOCUS       AX762265                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 5586 from Patent WO03040369.
ACCESSION   AX762265
VERSION     AX762265.1  GI:32256881
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 5586 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1997 ATCTAGCTTCTTCAG 2011
              . ||||||  |||||  ||
Db          2 ATCTAGGTTCTTTAG 16


RESULT 1082
AX762317/c
LOCUS       AX762317                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 5638 from Patent WO03040369.
ACCESSION   AX762317
VERSION     AX762317.1  GI:32256933
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 5638 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              ||||||  ||  |||||
Db         17 TCTTTCTTTTTCTGA 3


RESULT 1083
AX762343/c
LOCUS       AX762343                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 5664 from Patent WO03040369.
ACCESSION   AX762343
VERSION     AX762343.1  GI:32256959
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 5664 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCTGA 1805
              |||  | |||||||||
Db         17 TCTCTGCTTCTCTGA 3
```

```
RESULT 1084
AX762432/c
LOCUS       AX762432                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 5753 from Patent WO03040369.
ACCESSION   AX762432
VERSION     AX762432.1  GI:32257048
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 5753 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1803 TGAAAGTGGTGCTAT 1817
              || |||||||||  ||
Db         16 TGCAAGTGGTGCGAT 2


RESULT 1085
AX762809/c
LOCUS       AX762809                  17 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 6130 from Patent WO03040369.
ACCESSION   AX762809
VERSION     AX762809.1  GI:32257425
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
  JOURNAL   Patent: WO 03040369-A 6130 15-MAY-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1898 CTAGATCAACAGATC 1912
              |||||  ||||||||
Db         15 CTAGAGAAACAGATC 1


RESULT 1086
AX782161
LOCUS       AX782161                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 492 from Patent WO03050284.
ACCESSION   AX782161
VERSION     AX782161.1  GI:32950010
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 492 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1733 TCAGAAGGTGACAAG 1747
              |||| |||||||| |
Db          3 TCAGGAGGTGACAGG 17


RESULT 1087
AX782162
LOCUS       AX782162                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 493 from Patent WO03050284.
ACCESSION   AX782162
VERSION     AX782162.1  GI:32950011
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 493 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1733 TCAGAAGGTGACAAG 1747
              |||| |||||||| |
Db          2 TCAGGAGGTGACAGG 16


RESULT 1088
AX782163
LOCUS       AX782163                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 494 from Patent WO03050284.
ACCESSION   AX782163
VERSION     AX782163.1  GI:32950012
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 494 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
```

```
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1733 TCAGAAGGTGACAAG 1747
              |||| |||||||| |
Db          1 TCAGGAGGTGACAGG 15


RESULT 1089
AX784026
LOCUS       AX784026                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 2357 from Patent WO03050284.
ACCESSION   AX784026
VERSION     AX784026.1  GI:32951875
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 2357 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1944 TGGTTGGTTTTTGTG 1958
              ||||| | |||||||
Db          3 TGGTTTGATTTTGTG 17


RESULT 1090
AX784029
LOCUS       AX784029                  17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Sequence 2360 from Patent WO03050284.
ACCESSION   AX784029
VERSION     AX784029.1  GI:32951878
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Guo,J.
  TITLE     Human prostate cancer candidate protein 1
  JOURNAL   Patent: WO 03050284-A 2360 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1945 GGTTGGTTTTTGTGT 1959
              |||| | ||||||||
Db          1 GGTTTGATTTTGTGT 15


RESULT 1091
AX824368
LOCUS       AX824368                  17 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 45 from Patent WO03070941.
ACCESSION   AX824368
VERSION     AX824368.1  GI:39750391
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Bumann,D.
  TITLE     Method for the identification of tissue-specific regulatory
            sequences
  JOURNAL   Patent: WO 03070941-A 45 28-AUG-2003;
            Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Beschreibung der kuenstlichen Sequenz: Primer
                     #mut_down#"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1740 GTGACAAGTACTGGC 1754
              ||||||||| ||||
Db          2 GTGACAAGTGTTGGC 16


RESULT 1092
BD065825
LOCUS       BD065825                  17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065825
VERSION     BD065825.1  GI:22611428
KEYWORDS    JP 2001511000-A/460.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 460 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/460
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;
```

```
Qy       1975 CTTGAAAAAAAGAAA 1989
              ||| ||||||| |||
Db          3 CTTTAAAAAAACAAA 17


RESULT 1093
BD066862/c
LOCUS       BD066862                 17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD066862
VERSION     BD066862.1  GI:22612465
KEYWORDS    JP 2001511000-A/1497.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 1497 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/1497
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                  Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unknown'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unidentified"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1876 TGAAATGTCAAATTG 1890
              ||||||||| || ||
Db         15 TGAAATGTCCAAATG 1


RESULT 1094
BD067289/c
LOCUS       BD067289                 17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067289
VERSION     BD067289.1  GI:22612892
KEYWORDS    JP 2001511003-A/129.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 129 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/129
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                      related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unidentified"
                      /mol_type="genomic RNA"
                      /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1911 TCAACAATACCTTTT 1925
              ||| |||||||| ||
Db         16 TCACCAATACCTATT 2


RESULT 1095
BD067907
LOCUS       BD067907                 17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067907
VERSION     BD067907.1  GI:22613510
KEYWORDS    JP 2001511003-A/747.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 747 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/747
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                      related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unidentified"
                      /mol_type="genomic RNA"
                      /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | |||||| ||||||
Db         2 AGCCCATTTTTTCCT 16


RESULT 1096
BD067908
LOCUS       BD067908                 17 bp    RNA     linear   PAT 27-AUG-2002
DEFINITION  Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION   BD067908
```

```
VERSION     BD067908.1  GI:22613511
KEYWORDS    JP 2001511003-A/748.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Akhtar,S., Fell,P. and Mcswiggen,J.A.
  TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
  JOURNAL   Patent: JP 2001511003-A 748 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS   Unidentified
            PN   JP 2001511003-A/748
            PD   07-AUG-2001
            PF   14-JAN-1998 JP 1998532913
            PR   31-JAN-1997 US    60/036476,04-DEC-1997 US    08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC   Strandedness: Single;
            CC   Topology: Linear;
            CC   Enzymatic nucleic acid treatment of diseases or conditions  CC
                 related to
            CC   levels of epidermal growth factor receptors
            FH   Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unidentified'.
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="unidentified"
                      /mol_type="genomic RNA"
                      /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1784 ACCCCATTCTTTCCT 1798
              | |||||| ||||||
Db          1 AGCCCATTTTTTCCT 15


RESULT 1097
ATH529445/c
LOCUS       ATH529445                 17 bp    DNA     linear   PLN 29-MAR-2003
DEFINITION  Arabidopsis thaliana T-DNA flanking sequence, left border, clone
            187B12.
ACCESSION   AJ529445
VERSION     AJ529445.1  GI:26797705
KEYWORDS    left border; T-DNA flanking sequence.
SOURCE      Arabidopsis thaliana (thale cress)
  ORGANISM  Arabidopsis thaliana
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE   1
  AUTHORS   Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
            Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
            Lepiniec,L., Caboche,M. and Lecharny,A.
  TITLE     T-DNA integration into the Arabidopsis genome depends on sequences
            of pre-insertion sites
  JOURNAL   EMBO Rep. 3 (12), 1152-1157 (2002)
  MEDLINE   22363535
   PUBMED   12446565
REFERENCE   2  (bases 1 to 17)
  AUTHORS   Balzergue,S.
  TITLE     Direct Submission
  JOURNAL   Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue
            Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT     PCR was performed on DNA from transformants of Arabidopsis thaliana
            plants from INRA (Versailles). The DNA fragment(s) resulting from
            the PCR were directly sequenced from the left or the right border
            to determine the genomic sequence flanking the insertion. T-DNA
            derived sequences were removed. Information to order the
            corresponding mutant line and a link to a database providing a
            graphical display of the insertion site are available at
            http://dbsgap.versailles.inra.fr/publiclines/. This sequence has
            been generated in the framework of the French plant genomics
            program 'Genoplante' (http://www.genoplante.com and
            http://genoplante-info.infobiogen.fr).
FEATURES              Location/Qualifiers
     source           1. .17
                      /organism="Arabidopsis thaliana"
                      /mol_type="genomic DNA"
                      /cultivar="Wassillewskija"
                      /db_xref="taxon:3702"
                      /clone="187B12"
                      /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
     misc_feature     1. .17
                      /note="T-DNA flanking sequence
                      left border"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 17;
  Best Local Similarity   86.7%;  Pred. No. 5.1e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1767 AAGCTTTTTTTTTTT 1781
              || |||||| |||||
Db         15 AAACTTTTTGTTTTT 1


RESULT 1098
A67097/c
LOCUS       A67097                    18 bp    DNA     linear   PAT 29-MAR-1999
DEFINITION  Sequence 264 from Patent WO9740193.
ACCESSION   A67097
VERSION     A67097.1  GI:4538468
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stuyver,L., Rossau,R. and Maertens,G.
  TITLE     METHOD FOR TYPING AND DETECTING HBV
  JOURNAL   Patent: WO 9740193-A 264 30-OCT-1997;
            INNOGENETICS NV (BE)
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="unidentified"
                      /mol_type="unassigned DNA"
                      /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1905 AACAGATCAACAATA 1919
              | ||||||| |||||
Db         17 ACCAGATCATCAATA 3


RESULT 1099
AR008536
LOCUS       AR008536                  18 bp    DNA     linear   PAT 04-DEC-1998
DEFINITION  Sequence 20 from patent US 5753502.
ACCESSION   AR008536
VERSION     AR008536.1  GI:3967645
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kilgannon,P.D. and Gallatin,W.Michael.
  TITLE     Neuron-specific ICAM-4 promoter
  JOURNAL   Patent: US 5753502-A 20 19-MAY-1998;
FEATURES              Location/Qualifiers
     source           1. .18
```

```
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 1100
AR014324
LOCUS       AR014324                 18 bp    DNA     linear   PAT 05-DEC-1998
DEFINITION  Sequence 20 from patent US 5773293.
ACCESSION   AR014324
VERSION     AR014324.1  GI:3971778
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kilgannon,P.D. and Gallatin,W.Michael.
  TITLE     Anti-ICAM-4 antibodies and hybridomas
  JOURNAL   Patent: US 5773293-A 20 30-JUN-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 1101
AR039683
LOCUS       AR039683                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 531 from patent US 5807743.
ACCESSION   AR039683
VERSION     AR039683.1  GI:5959046
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stinchcomb,D.T. and McSwiggen,J.A.
  TITLE     Interleukin-2 receptor gamma-chain ribozymes
  JOURNAL   Patent: US 5807743-A 531 15-SEP-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1581 ACCGCACAGACTGGG 1595
              |||| || |||||||
Db          4 ACCGGACTGACTGGG 18


RESULT 1102
AR059317
LOCUS       AR059317                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 22 from patent US 5840300.
ACCESSION   AR059317
VERSION     AR059317.1  GI:5985767
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Williams,W.V. and Weiner,D.B.
  TITLE     Methods and compositions comprising single chain recombinant
            antibodies
  JOURNAL   Patent: US 5840300-A 22 24-NOV-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1816 ATAAGTTTTAGAATC 1830
              ||||| |||||| ||
Db          4 ATAAGATTTAGATTC 18


RESULT 1103
AR068083
LOCUS       AR068083                 18 bp    DNA     linear   PAT 29-SEP-1999
DEFINITION  Sequence 20 from patent US 5852170.
ACCESSION   AR068083
VERSION     AR068083.1  GI:5999305
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kilgannon,P.D. and Gallatin,W.Michael.
  TITLE     ICAM-4 materials and methods
  JOURNAL   Patent: US 5852170-A 20 22-DEC-1998;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 1104
AR071802
LOCUS       AR071802                 18 bp    DNA     linear   PAT 18-FEB-2000
DEFINITION  Sequence 31 from patent US 5912147.
ACCESSION   AR071802
VERSION     AR071802.1  GI:7222690
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stoler,D., Basik,M. and Anderson,G.
  TITLE     Rapid means of quantitating genomic instability
  JOURNAL   Patent: US 5912147-A 31 15-JUN-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
```

```
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACT 1868
              ||| || ||||||||
Db          4 ACACACACACACACT 18


RESULT 1105
AR071803
LOCUS       AR071803                  18 bp    DNA     linear   PAT 18-FEB-2000
DEFINITION  Sequence 32 from patent US 5912147.
ACCESSION   AR071803
VERSION     AR071803.1  GI:7222691
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stoler,D., Basik,M. and Anderson,G.
  TITLE     Rapid means of quantitating genomic instability
  JOURNAL   Patent: US 5912147-A 32 15-JUN-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1854 ACAGACCCACACACT 1868
              ||| || ||||||||
Db          4 ACACACACACACACT 18


RESULT 1106
AR073053
LOCUS       AR073053                  18 bp    DNA     linear   PAT 28-AUG-2000
DEFINITION  Sequence 26 from patent US 5948680.
ACCESSION   AR073053
VERSION     AR073053.1  GI:9999816
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Baker,B.F. and Cowsert,L.M.
  TITLE .   Antisense inhibition of Elk-1 expression
  JOURNAL   Patent: US 5948680-A 26 07-SEP-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2069 GTGGTATCTGACACA 2083
              ||||| |||| ||||
Db          4 GTGGTTTCTGGCACA 18


RESULT 1107
AR080718
LOCUS       AR080718                  18 bp    DNA     linear   PAT 31-AUG-2000
DEFINITION  Sequence 23 from patent US 5968826.
ACCESSION   AR080718
VERSION     AR080718.1  GI:10007448
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,C.Frank., Condon,T.P. and Cowsert,L.M.
  TITLE     Antisense inhibition of integrin .alpha.4 expression
  JOURNAL   Patent: US 5968826-A 23 19-OCT-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1579 CCACCGCACAGACTG 1593
              |||| |||||||| |
Db          1 CCACAGCACAGACAG 15


RESULT 1108
AR085645/c
LOCUS       AR085645                  18 bp    DNA     linear   PAT 01-SEP-2000
DEFINITION  Sequence 81 from patent US 5981732.
ACCESSION   AR085645
VERSION     AR085645.1  GI:10012412
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cowsert,L.M.
  TITLE     Antisense modulation of G-alpha-13 expression
  JOURNAL   Patent: US 5981732-A 81 09-NOV-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1820 GTTTTAGAATCTTTT 1834
              ||||||  |||||||
Db         15 GTTTTAATATCTTTT 1


RESULT 1109
AR092843
LOCUS       AR092843                  18 bp    DNA     linear   PAT 08-SEP-2000
DEFINITION  Sequence 58 from patent US 5998206.
ACCESSION   AR092843
VERSION     AR092843.1  GI:10019595
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cowsert,L.M.
  TITLE     Antisense inhibiton of human G-alpha-12 expression
  JOURNAL   Patent: US 5998206-A 58 07-DEC-1999;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1594 GGAACCCCTCCTGGC 1608
              |||||| || |||||
Db          3 GGAACCACTTCTGGC 17
```

```
RESULT 1110
AR098803/c
LOCUS       AR098803                  18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 58 from patent US 6077672.
ACCESSION   AR098803
VERSION     AR098803.1  GI:12808569
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Monia,B.P. and Cowsert,L.M.
  TITLE     Antisense modulation of TRADD expression
  JOURNAL   Patent: US 6077672-A 58 20-JUN-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1668 ACCCGCCCCTGGACT 1682
              ||||| | |||||||
Db         16 ACCCGGCGCTGGACT 2


RESULT 1111
AR110199
LOCUS       AR110199                  18 bp    DNA     linear   PAT 14-FEB-2001
DEFINITION  Sequence 6 from patent US 6114306.
ACCESSION   AR110199
VERSION     AR110199.1  GI:12826475
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   de Medicis,E. and Larochelle,A.
  TITLE     Cytokine related to hemolytic anemia and method of use
  JOURNAL   Patent: US 6114306-A 6 05-SEP-2000;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1601 CTCCTGGCCTGGGGG 1615
              ||||||| ||||| |
Db          3 CTCCTGGGCTGGGCG 17


RESULT 1112
AR143398/c
LOCUS       AR143398                  18 bp    DNA     linear   PAT 08-AUG-2001
DEFINITION  Sequence 43 from patent US 6204252.
ACCESSION   AR143398
VERSION     AR143398.1  GI:15104684
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Murphy,C., Storey,J., Beltz,G.A. and Coughlin,R.T.
  TITLE     Characterization of granulocytic ehrlichia and methods of use
  JOURNAL   Patent: US 6204252-A 43 20-MAR-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1896 CCCTAGATCAACAGA 1910
              ||||| | |||||||
Db         16 CCCTATAGCAACAGA 2


RESULT 1113
AR162701
LOCUS       AR162701                  18 bp    DNA     linear   PAT 17-OCT-2001
DEFINITION  Sequence 23 from patent US 6258790.
ACCESSION   AR162701
VERSION     AR162701.1  GI:16230027
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,C.Frank., Condon,T.P. and Cowsert,L.M.
  TITLE     Antisense modulation of integrin .alpha.4 expression
  JOURNAL   Patent: US 6258790-A 23 10-JUL-2001;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1579 CCACCGCACAGACTG 1593
              |||| |||||||| |
Db          1 CCACAGCACAGACAG 15


RESULT 1114
BD227761
LOCUS       BD227761                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Antisense modulation of integrin alph 4 expression.
ACCESSION   BD227761
VERSION     BD227761.1  GI:33037531
KEYWORDS    JP 2002526555-A/23.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,F.C., Condon,T.P. and Cowsert,L.M.
  TITLE     Antisense modulation of integrin alph 4 expression
  JOURNAL   Patent: JP 2002526555-A 23 20-AUG-2002;
            ISIS PHARMACEUTICALS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002526555-A/23
            PD   20-AUG-2002
            PF   19-AUG-1999 JP 2000574727
            PR   05-OCT-1998 US    09/166203
            PI   FRANK C BENNETT,THOMAS P CONDON,LEX M COWSERT PC
            C07H21/04,A61K31/7115,A61K31/712,A61K31/7125,A61K48/00,A61P1/ PC
            00,A61P1/16,
            PC   A61P3/00,A61P11/06,A61P25/28,A61P29/00,A61P29/00,A61P35/00, PC
              A61P35/04,
            PC   A61P37/06,A61P43/00,C12N15/09,C12Q1/02,C12Q1/68,C12N15/00 CC
            antisense sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
```

```
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1579 CCACCGCACAGACTG 1593
              |||| |||||||| |
Db          1 CCACAGCACAGACAG 15


RESULT 1115
BD234749/c
LOCUS       BD234749                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Desaturase gene for modifying lipid profile in corn.
ACCESSION   BD234749
VERSION     BD234749.1  GI:33044519
KEYWORDS    JP 2002517984-A/5.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Shen,J.B.J.
  TITLE     Desaturase gene for modifying lipid profile in corn
  JOURNAL   Patent: JP 2002517984-A 5 25-JUN-2002;
            EI DU PONT DE NEMOURS AND CO
COMMENT     OS   Artificial Sequence
            PN   JP 2002517984-A/5
            PD   25-JUN-2002
            PF   09-JUN-1999 JP 2000553569
            PR   11-JUN-1998 US    60/088987
            PI   JENNIE BIH JIEN SHEN
            PC   C12N15/09,A01H5/00,A23D7/00,A23D9/00,C12N5/10,C12N15/00,C12N5/
            PC   00
            CC   Description of Artificial Sequence: SYNTHETIC OLIGONUCLEOTIDE
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   61.1%;  Pred. No. 5.4e+02;
  Matches   11;  Conservative    4;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       2004 TTCTTCAGAGATCAAGTC 2021
              :||:|| | :|||| :||
Db         18 YTCYTCNGTDATCATRTC 1


RESULT 1116
BD250666
LOCUS       BD250666                  18 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Identification of genetic targets for modulation by
            oligonucleotides and generation of oligonucleotides for gene
            modulation.
ACCESSION   BD250666
VERSION     BD250666.1  GI:33060436
KEYWORDS    JP 2002511276-A/220.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cowsert,L.M., Baker,B.F., Mcneil,J., Freier,S.M., Sasmor,H.M.,
            Brooks,D.G., Ohasi,C., Wyatt,J.R., Borchers,A.H. and Vikkars,T.A.
  TITLE     Identification of genetic targets for modulation by
            oligonucleotides and generation of oligonucleotides for gene
            modulation
  JOURNAL   Patent: JP 2002511276-A 220 16-APR-2002;
            ISIS PHARMACEUTICALS INC
COMMENT     OS   Artificial Sequence
            PN   JP 2002511276-A/220
            PD   16-APR-2002
            PF   13-APR-1999 JP 2000543647
            PR   13-APR-1998 US    60/081483,28-APR-1998 US    09/067638 PI
            LEX M COWSERT,BRENDA F BAKER,JOHN MCNEIL,SUSAN M FREIER,HENRI  PI
            M SASMOR,
            PI   DOUGLAS G BROOKS,CARA OHASI,JACQUELINE R WYATT,ALEXANDER H  PI
              BORCHERS,
            PI   TIMOTHY A VIKKARS
            PC   C12N15/09,C07B61/00,C07B61/00,C12Q1/68,G06F17/30,G06F17/50, PC
              C12N15/00
            CC   Antisense Oligonucleotide
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2069 GTGGTATCTGACACA 2083
              ||||| |||| ||||
Db          4 GTGGTTTCTGGCACA 18


RESULT 1117
CQ792276/c
LOCUS       CQ792276                  18 bp    DNA     linear   PAT 29-MAR-2004
DEFINITION  Sequence 21 from Patent WO2004020642.
ACCESSION   CQ792276
VERSION     CQ792276.1  GI:45823804
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Mccourt,P., Ghassemian,M., Cutler,S. and Bonetta,D.
  TITLE     Stress tolerance and delayed senescence in plants
  JOURNAL   Patent: WO 2004020642-A 21 11-MAR-2004;
            Performance Plants, Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Description of Artificial Sequence: PCR primer"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAG 1620
              ||| ||| |||||||
Db         16 GGCATGGAGGAAGAG 2


RESULT 1118
CQ799825
LOCUS       CQ799825                  18 bp    DNA     linear   PAT 28-APR-2004
DEFINITION  Sequence 475 from Patent WO2004031413.
ACCESSION   CQ799825
VERSION     CQ799825.1  GI:46848772
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
```

```
REFERENCE   1
  AUTHORS   Nakamura,Y., Daigo,Y. and Nakatsuru,S.
  TITLE     Method for diagnosing non-small cell lung cancers
  JOURNAL   Patent: WO 2004031413-A 475 15-APR-2004;
            Oncotherapy Science, Inc. (JP); Japan as represented by the
            president of the university of Tokyo (JP)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Artificially synthesized S-oligonucleotide sequence
                     for antisense method"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1966 AATATTTACCTTGAA 1980
                ||||  |||||||| |
Db          1 AATAATTACCTTGTA 15


RESULT 1119
CQ807650/c
LOCUS       CQ807650                  18 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 1100 from Patent WO2004035803.
ACCESSION   CQ807650
VERSION     CQ807650.1  GI:47113044
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F.,
            Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and
            Marx,A.
  TITLE     Method and nucleic acids for the improved treatment of breast cell
            proliferative disorders
  JOURNAL   Patent: WO 2004035803-A 1100 29-APR-2004;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for ARHI"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1856 AGACCCACACACTTA 1870
                | || ||||||||||
Db         16 AAACTCACACACTTA 2


RESULT 1120
CQ807744/c
LOCUS       CQ807744                  18 bp    DNA     linear   PAT 10-MAY-2004
DEFINITION  Sequence 1194 from Patent WO2004035803.
ACCESSION   CQ807744
VERSION     CQ807744.1  GI:47113138
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F.,
            Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and
            Marx,A.
  TITLE     Method and nucleic acids for the improved treatment of breast cell
            proliferative disorders
  JOURNAL   Patent: WO 2004035803-A 1194 29-APR-2004;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for DAPK1"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCT 1847
                | ||||||| |||||
Db         17 TAAAATACACTCCCT 3


RESULT 1121
CQ840412
LOCUS       CQ840412                  18 bp    DNA     linear   PAT 29-JUL-2004
DEFINITION  Sequence 97 from Patent WO2004057021.
ACCESSION   CQ840412
VERSION     CQ840412.1  GI:50838161
KEYWORDS    .
SOURCE      Human metapneumovirus
  ORGANISM  Human metapneumovirus
            Viruses; ssRNA negative-strand viruses; Mononegavirales;
            Paramyxoviridae; Pneumovirinae; Metapneumovirus.
REFERENCE   1
  AUTHORS   Boivin,G.
  TITLE     Molecular methods and compositions for detecting and quantifying
            respiratory viruses
  JOURNAL   Patent: WO 2004057021-A 97 08-JUL-2004;
            Universite Laval (CA)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Human metapneumovirus"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:162145"
                     /note="primer no 59"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1799 TCTCTGAAAGTGGTG 1813
                |||  ||||||||||
Db          4 TCTTGGAAAGTGGTG 18


RESULT 1122
I75091/c
LOCUS       I75091                    18 bp    DNA     linear   PAT 03-APR-1998
DEFINITION  Sequence 21 from patent US 5689040.
ACCESSION   I75091
VERSION     I75091.1  GI:3011232
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Harada,J.J., Zhang,J.Z. and Laudencia-Chingcuanco,D.
  TITLE     Plant promoter sequences useful for gene expression in seeds and
            seedlings
  JOURNAL   Patent: US 5689040-A 21 18-NOV-1997;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
```

```
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1820 GTTTTAGAATCTTTT 1834
              ||| || ||||||||
Db         18 GTTATATAATCTTTT 4


RESULT 1123
I86170
LOCUS       I86170                   18 bp    DNA     linear   PAT 10-JUN-1998
DEFINITION  Sequence 20 from patent US 5700658.
ACCESSION   I86170
VERSION     I86170.1  GI:3205888
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kilgannon,P.D. and Gallatin,W.Michael.
  TITLE     ICAM-4 materials and methods
  JOURNAL   Patent: US 5700658-A 20 23-DEC-1997;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 1124
I86880
LOCUS       I86880                   18 bp    DNA     linear   PAT 10-JUN-1998
DEFINITION  Sequence 20 from patent US 5702917.
ACCESSION   I86880
VERSION     I86880.1  GI:3206598
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kilgannon,P.D. and Gallatin,W.Michael.
  TITLE     Polynucleotides encoding human ICAM-4
  JOURNAL   Patent: US 5702917-A 20 30-DEC-1997;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 1125
AR181655
LOCUS       AR181655                 18 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 117 from patent US 6335194.
ACCESSION   AR181655
VERSION     AR181655.1  GI:20223869
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Bennett,C.Frank., Ackermann,E.J., Swayze,E.E. and Cowsert,L.M.
  TITLE     Antisense modulation of survivin expression
  JOURNAL   Patent: US 6335194-A 117 01-JAN-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1800 CTCTGAAAGTGGTGC 1814
              | ||| ||||||||||
Db          3 CCCTGGAAGTGGTGC 17


RESULT 1126
AR228142
LOCUS       AR228142                 18 bp    DNA     linear   PAT 20-DEC-2002
DEFINITION  Sequence 43 from patent US 6448003.
ACCESSION   AR228142
VERSION     AR228142.1  GI:27266888
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Guida,M. and Kurth,J.
  TITLE     Genotyping the human phenol sulfotransferbase 2 gene STP2
  JOURNAL   Patent: US 6448003-A 43 10-SEP-2002;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1677 TGGACTTCTTAGTTG 1691
              ||||| |||| ||||
Db          4 TGGACCTCTTGGTTG 18


RESULT 1127
AR293221/c
LOCUS       AR293221                 18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4956 from patent US 6537751.
ACCESSION   AR293221
VERSION     AR293221.1  GI:31680505
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 4956 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1864 ACACTTAGCCATTGA 1878
              |||||||||| || |
Db         17 ACACTTAGCCTTTCA 3
```

```
RESULT 1128
AR293262
LOCUS       AR293262                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 4997 from patent US 6537751.
ACCESSION   AR293262
VERSION     AR293262.1  GI:31680546
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 4997 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1775 TTTTTTTGAACCCCA 1789
              ||||||||  |||||
Db          2 TTTTTTTGTCCCCCA 16


RESULT 1129
AR293420
LOCUS       AR293420                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5155 from patent US 6537751.
ACCESSION   AR293420
VERSION     AR293420.1  GI:31680704
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 5155 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1540 AGGAGAGTAGGGAAG 1554
              | |||||||||  |||
Db          4 ATGAGAGTAGGAAAG 18


RESULT 1130
AR293616/c
LOCUS       AR293616                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5351 from patent US 6537751.
ACCESSION   AR293616
VERSION     AR293616.1  GI:31680900
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 5351 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1940 GTAATGGTTGGTTTT 1954
              | ||||||  ||||||
Db         16 GAAATGGTGGGTTTT 2


RESULT 1131
AR294034
LOCUS       AR294034                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5769 from patent US 6537751.
ACCESSION   AR294034
VERSION     AR294034.1  GI:31681318
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 5769 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1610 TGGGGGAAGAGTTTG 1624
              ||||  ||||||  |||
Db          4 TGGGAGAAGAGATTG 18


RESULT 1132
AR294136/c
LOCUS       AR294136                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 5871 from patent US 6537751.
ACCESSION   AR294136
VERSION     AR294136.1  GI:31681420
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 5871 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1793 TTTCCTTCTCTGAAA 1807
              || || |||||||||
Db         16 TTGCCCTCTCTGAAA 2
```

```
RESULT 1133
AR294358/c
LOCUS       AR294358                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 6093 from patent US 6537751.
ACCESSION   AR294358
VERSION     AR294358.1  GI:31681642
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 6093 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1850 GCCAACAGACCCACA 1864
                ||||||||||  |||
Db         16 GCCAACAGACAAACA 2


RESULT 1134
AR295827/c
LOCUS       AR295827                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 7562 from patent US 6537751.
ACCESSION   AR295827
VERSION     AR295827.1  GI:31683111
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 7562 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1658 GTTCTGCATCACCCG 1672
                ||||||||||  ||
Db         18 GTTCTGCATCAATCG 4


RESULT 1135
AR296069/c
LOCUS       AR296069                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 7804 from patent US 6537751.
ACCESSION   AR296069
VERSION     AR296069.1  GI:31683353
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 7804 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1650 CTTCACTGGTTCTGC 1664
                ||||  |||  ||||||
Db         18 CTTCCCTGATTCTGC 4


RESULT 1136
AR297152/c
LOCUS       AR297152                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 8887 from patent US 6537751.
ACCESSION   AR297152
VERSION     AR297152.1  GI:31684436
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 8887 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2035 CAAAGGTTCTATCTG 2049
                |||||||||  ||  ||
Db         18 CAAAGGTTCCATGTG 4


RESULT 1137
AR297436
LOCUS       AR297436                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 9171 from patent US 6537751.
ACCESSION   AR297436
VERSION     AR297436.1  GI:31684720
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 9171 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2045 ATCTGCTTAGCAACT 2059
                |  |||||  |||||||
Db          1 AACTGCTCAGCAACT 15
```

```
RESULT 1138
AR297586/c
LOCUS       AR297586                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 9321 from patent US 6537751.
ACCESSION   AR297586
VERSION     AR297586.1  GI:31684870
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 9321 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1588 AGACTGGGAACCCCT 1602
              ||||||||||| | |
Db         15 AGACTGGGAACTCAT 1


RESULT 1139
AR297721
LOCUS       AR297721                  18 bp    DNA     linear   PAT 12-JUN-2003
DEFINITION  Sequence 9456 from patent US 6537751.
ACCESSION   AR297721
VERSION     AR297721.1  GI:31685005
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Cohen,D., Chumakov,I. and Blumenfeld,M.
  TITLE     Biallelic markers for use in constructing a high density
            disequilibrium map of the human genome
  JOURNAL   Patent: US 6537751-A 9456 25-MAR-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1836 AATACATTCCCTGGG 1850
              || |||||| |||||
Db          3 AAAACATTCTCTGGG 17


RESULT 1140
AR390750/c
LOCUS       AR390750                  18 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 2 from patent US 6610841.
ACCESSION   AR390750
VERSION     AR390750.1  GI:40113090
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Warren,S.
  TITLE     Nucleotide-based prodrugs
  JOURNAL   Patent: US 6610841-A 2 26-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1902 ATCAACAGATCAACA 1916
              || ||||||| ||||
Db         18 ATAAACAGATAAACA 4


RESULT 1141
AR390751/c
LOCUS       AR390751                  18 bp    DNA     linear   PAT 18-DEC-2003
DEFINITION  Sequence 3 from patent US 6610841.
ACCESSION   AR390751
VERSION     AR390751.1  GI:40113091
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Warren,S.
  TITLE     Nucleotide-based prodrugs
  JOURNAL   Patent: US 6610841-A 3 26-AUG-2003;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1902 ATCAACAGATCAACA 1916
              || ||||||| ||||
Db         18 ATAAACAGATAAACA 4


RESULT 1142
AR488599/c
LOCUS       AR488599                  18 bp    DNA     linear   PAT 15-MAY-2004
DEFINITION  Sequence 264 from patent US 6709812.
ACCESSION   AR488599
VERSION     AR488599.1  GI:47254651
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Stuyver,L., Rossau,R. and Maertens,G.
  TITLE     Method for typing and detecting HBV
  JOURNAL   Patent: US 6709812-A 264 23-MAR-2004;
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unknown"
                     /mol_type="genomic DNA"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1905 AACAGATCAACAATA 1919
              | ||||||| |||||
Db         17 ACCAGATCATCAATA 3


RESULT 1143
AX058580/c
LOCUS       AX058580                  18 bp    DNA     linear   PAT 17-JAN-2001
DEFINITION  Sequence 32 from Patent WO0077250.
```

```
ACCESSION   AX058580
VERSION     AX058580.1  GI:12310922
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Escude,C., Garestier,T., Helene,C. and Roulon,T.
  TITLE     Method for circularizing oligonucleotides around a double stranded
            nucleic acid, resulting structures and uses thereof
  JOURNAL   Patent: WO 0077250-A 32 21-DEC-2000;
            INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
            (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1543 AGAGTAGGGAAGGAA 1557
              | || ||||||||||
Db         18 AAAGAAGGGAAGGAA 4


RESULT 1144
AX132970/c
LOCUS       AX132970                 18 bp    DNA     linear   PAT 15-MAY-2001
DEFINITION  Sequence 4188 from Patent WO0130362.
ACCESSION   AX132970
VERSION     AX132970.1  GI:14139280
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Robbins,J.M. and Tritz,R.
  TITLE     Ribozyme therapy for the treatment of proliferative skin and eye
            diseases
  JOURNAL   Patent: WO 0130362-A 4188 03-MAY-2001;
            IMMUSOL, INC. (US)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"
                     /note="Hammerhead ribozyme recognition site for cdc 2
                     kinase"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1590 ACTGGGAACCCCTCC 1604
              ||| |||||||||  |
Db         15 ACTAGGAACCCCTTC 1


RESULT 1145
AX590978/c
LOCUS       AX590978                 18 bp    DNA     linear   PAT 27-JAN-2003
DEFINITION  Sequence 418 from Patent WO02086113.
ACCESSION   AX590978
VERSION     AX590978.1  GI:27949528
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Cookson,W.O., Moffat,M.F., Allen,M. and Lench,N.
  TITLE     Enzyme and snp marker for disease
  JOURNAL   Patent: WO 02086113-A 418 31-OCT-2002;
            Isis Innovation Limited (GB)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2005 TCTTCAGAGATCAAG 2019
              ||  ||||||||||||
Db         18 TCCACAGAGATCAAG 4


RESULT 1146
AX599394/c
LOCUS       AX599394                 18 bp    DNA     linear   PAT 14-FEB-2003
DEFINITION  Sequence 734 from Patent WO02077272.
ACCESSION   AX599394
VERSION     AX599394.1  GI:28399538
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,
            Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,
            Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,
            Pelet,C. and Ziebarth,H.
  TITLE     Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
  JOURNAL   Patent: WO 02077272-A 734 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for DAPK1"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCT 1847
              | ||||||| |||||
Db         17 TAAAATACACTCCCT 3


RESULT 1147
AX746337
LOCUS       AX746337                 18 bp    DNA     linear   PAT 13-JUN-2003
DEFINITION  Sequence 20 from Patent EP1308514.
ACCESSION   AX746337
VERSION     AX746337.1  GI:31746273
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Kilgannon,P.D. and Gallatin,M.W.
  TITLE     ICAM-4 materials and methods
  JOURNAL   Patent: EP 1308514-A 20 07-MAY-2003;
            ICOS CORPORATION (US)
FEATURES             Location/Qualifiers
     source          1. .18
```

```
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
                     /note="3' antisense primer, Spot714AS"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 1148
AX765929/c
LOCUS       AX765929                  18 bp    DNA     linear   PAT 25-JUN-2003
DEFINITION  Sequence 15 from Patent WO02097097.
ACCESSION   AX765929
VERSION     AX765929.1  GI:32260059
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Huang,Y., Chalifoux,M., Wang,Y., Kuzma,M.D. and Gilley,A.P.
  TITLE     Compositions and methods of increasing stress tolerance in plants
  JOURNAL   Patent: WO 02097097-A 15 05-DEC-2002;
            Performance Plants, Inc. (CA)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="PCR Primer"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1606 GGCCTGGGGGAAGAG 1620
              ||| ||| |||||||
Db         16 GGCATGGAGGAAGAG 2


RESULT 1149
AX769708/c
LOCUS       AX769708                  18 bp    DNA     linear   PAT 02-JUL-2003
DEFINITION  Sequence 46 from Patent WO03020976.
ACCESSION   AX769708
VERSION     AX769708.1  GI:32437416
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Karlsen,F.
  TITLE     Oligonucleotides for use in detection of human papillomavirus E7
            mRNA
  JOURNAL   Patent: WO 03020976-A 46 13-MAR-2003;
            Norchip A/S (NO)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="HPV primer"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1876 TGAAATGTCAAATTG 1890
                ||| ||||||||||
Db         16 TGAGCTGTCAAATTG 2


RESULT 1150
AX796182/c
LOCUS       AX796182                  18 bp    DNA     linear   PAT 04-OCT-2003
DEFINITION  Sequence 525 from Patent WO03052135.
ACCESSION   AX796182
VERSION     AX796182.1  GI:37516848
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Field,J.K., Genc,B., Liloglou,T., Lipscher,E., Maier,S.
            and Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lung cell
            proliferative disorder
  JOURNAL   Patent: WO 03052135-A 525 26-JUN-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for ARHI"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1856 AGACCCACACACTTA 1870
              | || ||||||||||
Db         15 AAACTCACACACTTA 1


RESULT 1151
AX796278/c
LOCUS       AX796278                  18 bp    DNA     linear   PAT 04-OCT-2003
DEFINITION  Sequence 621 from Patent WO03052135.
ACCESSION   AX796278
VERSION     AX796278.1  GI:37516944
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Burger,M., Field,J.K., Genc,B., Liloglou,T., Lipscher,E., Maier,S.
            and Nimmrich,I.
  TITLE     Method and nucleic acids for the analysis of a lung cell
            proliferative disorder
  JOURNAL   Patent: WO 03052135-A 621 26-JUN-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for DAPK1"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCT 1847
              | ||||||| |||||
Db         17 TAAAATACACTCCCT 3


RESULT 1152
AX816917
LOCUS       AX816917                  18 bp    DNA     linear   PAT 09-DEC-2003
```

```
DEFINITION  Sequence 20 from Patent EP1338896.
ACCESSION   AX816917
VERSION     AX816917.1  GI:39647194
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1
  AUTHORS   Kilgannon,P.D. and Gallatin,M.W.
  TITLE     Icam-4 and diagnostic uses thereof
  JOURNAL   Patent: EP 1338896-A 20 27-AUG-2003;
            ICOS CORPORATION (US)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 1153
AX823064/c
LOCUS       AX823064                 18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 956 from Patent EP1340818.
ACCESSION   AX823064
VERSION     AX823064.1  GI:39749700
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferative disorder
  JOURNAL   Patent: EP 1340818-A 956 03-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for DAPK1"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCT 1847
              | ||||||| |||||
Db         17 TAAAATACACTCCCT 3


RESULT 1154
AX826704/c
LOCUS       AX826704                 18 bp    DNA     linear   PAT 11-DEC-2003
DEFINITION  Sequence 956 from Patent WO03072821.
ACCESSION   AX826704
VERSION     AX826704.1  GI:39752218
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1
  AUTHORS   Adorjan,P., Burger,M., Maier,S., Nimmrich,I., Becker,E., Lesche,R.,
            Rujan,T. and Schmitt,A.
  TITLE     Method and nucleic acids for the analysis of a colon cell
            proliferactive disorder
  JOURNAL   Patent: WO 03072821-A 956 04-SEP-2003;
            Epigenomics AG (DE)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Detection oligonucleotide for DAPK1"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1833 TTAAATACATTCCCT 1847
              | ||||||| |||||
Db         17 TAAAATACACTCCCT 3


RESULT 1155
BD015268/c
LOCUS       BD015268                 18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  DNA vaccine.
ACCESSION   BD015268
VERSION     BD015268.1  GI:22556075
KEYWORDS    JP 2001169784-A/8.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Matano,T.
  TITLE     DNA vaccine
  JOURNAL   Patent: JP 2001169784-A 8 26-JUN-2001;
            DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIONS DISEASES,
            TETSURO MATANO
COMMENT     OS   Other DNA
            PN   JP 2001169784-A/8
            PD   26-JUN-2001
            PF   26-SEP-2000 JP 2000291792
            PI   TETSURO MATANO
            PC   C12N15/09,A61K31/713,A61K39/21,A61K48/00,A61P31/18,C12N7/00,
            PC   C12N15/00
            CC   DNA vaccine
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Other DNA'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAAC 1598
              |||||| || |||||
Db         18 GCACAGGCTTGGAAC 4


RESULT 1156
BD064506
LOCUS       BD064506                 18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  ICAM-4 and diagnostic uses thereof.
ACCESSION   BD064506
VERSION     BD064506.1  GI:22610109
KEYWORDS    JP 2001508181-A/18.
SOURCE      Vaccinia virus
  ORGANISM  Vaccinia virus
            Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
            Orthopoxvirus.
```

```
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kilgannon,P.D. and Gallatin,M.W.
  TITLE     ICAM-4 and diagnostic uses thereof
  JOURNAL   Patent: JP 2001508181-A 18 19-JUN-2001;
            ICOS CORP
COMMENT     PN   JP 2001508181-A/18
            PD   19-JUN-2001
            PF   02-OCT-1998 JP 1999522146
            PR   02-OCT-1997 US    08/942867
            PI   PATRICK D KILGANNON,MICHAEL W GALLATIN
            PC   G01N33/68//C07K16/28
            CC   Strandedness: Single;
            CC   Topology: Linear;
            FH   Key             Location/Qualifiers.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="Vaccinia virus"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:10245"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   76.5%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1737 AAGGTGACAAGTACTGG 1753
              |:|||||||||  || |
Db          2 ARGGTGACAAGGGCTCG 18


RESULT 1157
BD102527/c
LOCUS       BD102527                  18 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  Aids virus vaccines using sendai virus vector.
ACCESSION   BD102527
VERSION     BD102527.1  GI:22648101
KEYWORDS    WO 0172340-A/18.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Kano,M., Matano,T., Kato,A., Nagai,Y. and Hasegaw,M.
  TITLE     Aids virus vaccines using sendai virus vector
  JOURNAL   Patent: WO 0172340-A 18 04-OCT-2001;
            DNAVEC RESEARCH INC, JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF
            NATIONAL INSTITUTE OF INFECTIOUS DISEASES
COMMENT     OS   Artificial Sequence
            PN   WO 0172340-A/18
            PD   04-OCT-2001
            PF   30-MAR-2001 WO 2001JP002769
            PR   30-MAR-2000 US    60/193127
            PI   MUNEHIDE KANO,TETSURO MATANO,ATSUSHI KATO,YOSHIYUKI NAGAI, PI
             MAMORU HASEGAWA
            PC   A61K48/00,A61K39/21,A61K35/76,A61P31/18//C12N7/01,C12N15/48,
            PC   C12N15/86
            CC   Description of Artificial Sequence: artificially synthesized
            CC            sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1584 GCACAGACTGGGAAC 1598
              ||||||  || |||||
Db         18 GCACAGGCTTGGAAC 4


RESULT 1158
BD160908
LOCUS       BD160908                  18 bp    DNA     linear   PAT 17-JAN-2003
DEFINITION  Gene Hd3a deriving flowering of plant and utilization thereof.
ACCESSION   BD160908
VERSION     BD160908.1  GI:27866666
KEYWORDS    JP 2002153283-A/20.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Yano,M. and Kojima,A.
  TITLE     Gene Hd3a deriving flowering of plant and utilization thereof
  JOURNAL   Patent: JP 2002153283-A 20 28-MAY-2002;
            DIRECTOR GENERAL OF NATIONAL INSTITUTE OF AGROBIOLOGICAL RESOURCES
            MINISTRY OF AGRICULTURE FORESTRY AND FISHERIES, BIO ORIENTED
            TECHNOLOGY RESEARCH ADVANCEMENT INSTITUTION, SOCIETY FOR TECHNO
            INNOVATION OF AGRICULTURE FORESTRY AND FISHERIES
COMMENT     OS   Artificial Sequence
            PN   JP 2002153283-A/20
            PD   28-MAY-2002
            PF   24-NOV-2000 JP 2000356839
            PI   MASAHIRO YANO,AKIKO KOJIMA
            PC   C12N15/09,A01H5/00,C12N5/10,C12N9/22//(C12N15/09,C12R1:91), PC
              (C12N5/10,C12R1:91),C12N15/00,C12N5/00,(C12N15/00,C12R1:91), PC
            (C12N5/00,C12R1:91)
            CC   Description of Artificial Sequence:an artificially synthesized

            CC            primer
            CC   sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES              Location/Qualifiers
     source           1. .18
                      /organism="synthetic construct"
                      /mol_type="genomic DNA"
                      /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2049 GCTTAGCAACTAGTT 2063
              ||| |||||| ||||
Db          2 GCTCAGCAACGAGTT 16


RESULT 1159
BD169088
LOCUS       BD169088                  18 bp    DNA     linear   PAT 17-JAN-2003
DEFINITION  Gene Hd3a inducing plant flowering and utilization thereof.
ACCESSION   BD169088
VERSION     BD169088.1  GI:27874900
KEYWORDS    WO 0242475-A/20.
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
REFERENCE   1  (bases 1 to 18)
  AUTHORS   Yano,M. and Kojima,S.
  TITLE     Gene Hd3a inducing plant flowering and utilization thereof
  JOURNAL   Patent: WO 0242475-A 20 30-MAY-2002;
            NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES, BIO ORIENTED
            TECHNOLOGY RESEARCH ADVANCEMENT INSTITUTION, MASAHIRO YANO, SHOKO
            KOJIMA
COMMENT     OS   Artificial Sequence
            PN   WO 0242475-A/20
            PD   30-MAY-2002
            PF   22-NOV-2001 WO 2001JP010237
            PR   24-NOV-2000 JP 00P   356839
            PI   MASAHIRO YANO,SHOKO KOJIMA
            PC   C12N15/29,C12N5/14,C07K14/415,A01H5/00
```

```
            CC   Description of Artificial Sequence:an artificially synthesized

            CC            primer
            CC   sequence
            FH   Key             Location/Qualifiers
            FT   source          1. .18
            FT                   /organism='Artificial Sequence'.
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

  Query Match             2.1%;  Score 11.8;  DB 1;  Length 18;
  Best Local Similarity   86.7%;  Pred. No. 5.4e+02;
  Matches   13;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       2049 GCTTAGCAACTAGTT 2063
              ||| |||||| ||||
Db          2 GCTCAGCAACGAGTT 16


RESULT 1160
AX210228/c
LOCUS       AX210228                 17 bp    DNA     linear   PAT 31-AUG-2001
DEFINITION  Sequence 35 from Patent WO0157245.
ACCESSION   AX210228
VERSION     AX210228.1  GI:15424553
KEYWORDS    .
SOURCE      Human immunodeficiency virus 1 (HIV-1)
  ORGANISM  Human immunodeficiency virus 1
            Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE   1
  AUTHORS   Witvrouw,M., Fikkert,V., Pannecouque,C., Cherepanov,P., van
            Laethem,K., de Clercq,E., Vandamme,A.M. and Debyser,Z.
  TITLE     Hiv-1 resistance assay
  JOURNAL   Patent: WO 0157245-A 35 09-AUG-2001;
            K.U.Leuven Research & Development (BE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Human immunodeficiency virus 1"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:11676"
                     /note="NL4.3 (Adachi et al., 1986)"

  Query Match             2.1%;  Score 11.6;  DB 1;  Length 17;
  Best Local Similarity   91.7%;  Pred. No. 5.6e+02;
  Matches   11;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1729 ATTATCAGAAGG 1740
              |||||||||:||
Db         13 ATTATCAGARGG 2


RESULT 1161
BD258462/c
LOCUS       BD258462                 17 bp    DNA     linear   PAT 17-JUL-2003
DEFINITION  Regulation of repressor genes using nucleic acid molecules.
ACCESSION   BD258462
VERSION     BD258462.1  GI:33068232
KEYWORDS    JP 2002541795-A/6255.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
  TITLE     Regulation of repressor genes using nucleic acid molecules
  JOURNAL   Patent: JP 2002541795-A 6255 10-DEC-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT     OS   Eukaryote
            PN   JP 2002541795-A/6255
            PD   10-DEC-2002
            PF   11-APR-2000 JP 2000611654
            PR   12-APR-1999 US    60/129390
            PI   LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
            C12N15/09,A61K38/00,A61K48/00,A61P43/00,A61P43/00,C12N5/10, PC
            C12P21/02,
            PC
            C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC
             C12R1:91),
            PC   (C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
            PC   A61K37/02,
            PC   (C12N5/00,C12R1:91)
            CC   Regulation of repressor genes using nucleic acid molecules FH
             Key             Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Eukaryote'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 6.1e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1548 AGGGAAGGAACAG 1560
              |||||||||| ||
Db         13 AGGGAAGGAAAAG 1


RESULT 1162
AX673050
LOCUS       AX673050                 17 bp    DNA     linear   PAT 27-MAR-2003
DEFINITION  Sequence 1495 from Patent WO03004526.
ACCESSION   AX673050
VERSION     AX673050.1  GI:29331398
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Telerman,A., Amson,R. and Tuijnder,M.
  TITLE     Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and their use as
            medicines
  JOURNAL   Patent: WO 03004526-A 1495 16-JAN-2003;
            Molecular Engines Laboratories (FR)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 17;
  Best Local Similarity   92.3%;  Pred. No. 6.1e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1600 CCTCCTGGCCTGG 1612
              || ||||||||||
Db          4 CCCCCTGGCCTGG 16


RESULT 1163
AX058580
LOCUS       AX058580                 18 bp    DNA     linear   PAT 17-JAN-2001
DEFINITION  Sequence 32 from Patent WO0077250.
ACCESSION   AX058580
VERSION     AX058580.1  GI:12310922
KEYWORDS    .
SOURCE      synthetic construct
  ORGANISM  synthetic construct
            artificial sequences.
```

```
REFERENCE   1
  AUTHORS   Escude,C., Garestier,T., Helene,C. and Roulon,T.
  TITLE     Method for circularizing oligonucleotides around a double stranded
            nucleic acid, resulting structures and uses thereof
  JOURNAL   Patent: WO 0077250-A 32 21-DEC-2000;
            INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
            (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
FEATURES             Location/Qualifiers
     source          1. .18
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Oligonucleotide"

  Query Match             2.0%;  Score 11.4;  DB 1;  Length 18;
  Best Local Similarity   92.3%;  Pred. No. 6.4e+02;
  Matches   12;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1791 TCTTTCCTTCTCT 1803
              ||||||||||  ||
Db          1 TCTTTCCTTCCCT 13


RESULT 1164
A88310/c
LOCUS       A88310                    17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 458 from Patent WO9833904.
ACCESSION   A88310
VERSION     A88310.1  GI:6736880
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W. and Schlingensiepen,K.
  TITLE     AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
  JOURNAL   Patent: WO 9833904-A 458 06-AUG-1998;
            BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTTGAA 1784
              | ||| ||||||| ||
Db         17 GTTTTGTTTTTTTAAA 2


RESULT 1165
A90277/c
LOCUS       A90277                    17 bp    DNA     linear   PAT 22-JAN-2000
DEFINITION  Sequence 458 from Patent EP0856579.
ACCESSION   A90277
VERSION     A90277.1  GI:6738791
KEYWORDS    .
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Brysch,W.D. and Schlingensiepen,K.D.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: EP 0856579-A 458 05-AUG-1998;
            BIOGNOSTIK GES (DE)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32644"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTTGAA 1784
              | ||| ||||||| ||
Db         17 GTTTTGTTTTTTTAAA 2


RESULT 1166
AR186716
LOCUS       AR186716                  17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2204 from patent US 6346398.
ACCESSION   AR186716
VERSION     AR186716.1  GI:20232681
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2204 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              |||||||||  | |||
Db          2 TCAGTGTTAGAGAAAT 17


RESULT 1167
AR323347
LOCUS       AR323347                  17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 749 from patent US 6566127.
ACCESSION   AR323347
VERSION     AR323347.1  GI:33709155
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 749 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              |||||||||  | |||
Db          2 TCAGTGTTAGAGAAAT 17


RESULT 1168
AX745237/c
LOCUS       AX745237                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1202 from Patent WO03031621.
ACCESSION   AX745237
```

```
VERSION     AX745237.1  GI:30723904
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1202 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGT 1992
              || ||||||  |||||
Db         16 TGCAAAAAAATAAAGT 1


RESULT 1169
BD065823/c
LOCUS       BD065823                 17 bp    DNA     linear   PAT 27-AUG-2002
DEFINITION  An antisense oligonucleotide preparation method.
ACCESSION   BD065823
VERSION     BD065823.1  GI:22611426
KEYWORDS    JP 2001511000-A/458.
SOURCE      unidentified
  ORGANISM  unidentified
            unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Schlingensiepen,K.H. and Brysch,W.
  TITLE     An antisense oligonucleotide preparation method
  JOURNAL   Patent: JP 2001511000-A 458 07-AUG-2001;
            BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT     OS   Unknown
            PN   JP 2001511000-A/458
            PD   07-AUG-2001
            PF   30-JAN-1998 JP 1998532533
            PR   31-JAN-1997 EP   97101531.8
            PI   KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
            PC   C12N15/11,C07H21/04,A61K31/70
            CC   An antisense oligonucleotide preparation method FH   Key
                 Location/Qualifiers
            FT   source          1. .17
            FT                   /organism='Unknown'.
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1769 GCTTTTTTTTTTTGAA 1784
              | ||| ||||||| ||
Db         17 GTTTTGTTTTTTTAAA 2


RESULT 1170
AX531445
LOCUS       AX531445                 17 bp    DNA     linear   PAT 22-NOV-2002
DEFINITION  Sequence 954 from Patent EP1239051.
ACCESSION   AX531445
VERSION     AX531445.1  GI:25254668
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Shannon,M.
  TITLE     Human posh-like protein 1
  JOURNAL   Patent: EP 1239051-A 954 11-SEP-2002;
            Aeomica, Inc. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1530 AAGAAAGGTTAGGAGA 1545
              |||  | ||||||||||
Db         1 AAGGCAAGTTAGGAGA 16


RESULT 1171
AR186717
LOCUS       AR186717                 17 bp    DNA     linear   PAT 20-APR-2002
DEFINITION  Sequence 2205 from patent US 6346398.
ACCESSION   AR186717
VERSION     AR186717.1  GI:20232682
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6346398-A 2205 12-FEB-2002;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned DNA"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              |||||||||  | |||
Db         1 TCAGTGTTAGAGAAAT 16


RESULT 1172
AR323348
LOCUS       AR323348                 17 bp    RNA     linear   PAT 17-AUG-2003
DEFINITION  Sequence 750 from patent US 6566127.
ACCESSION   AR323348
VERSION     AR323348.1  GI:33709156
KEYWORDS    .
SOURCE      Unknown.
  ORGANISM  Unknown.
            Unclassified.
REFERENCE   1  (bases 1 to 17)
  AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
  TITLE     Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
  JOURNAL   Patent: US 6566127-A 750 20-MAY-2003;
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="unknown"
                     /mol_type="unassigned RNA"
```

```
  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1929 TCAGTGTTAAGGTAAT 1944
              |||||||||  | |||
Db          1 TCAGTGTTAGAGAAAT 16


RESULT 1173
AX745236/c
LOCUS       AX745236                  17 bp    DNA     linear   PAT 14-MAY-2003
DEFINITION  Sequence 1201 from Patent WO03031621.
ACCESSION   AX745236
VERSION     AX745236.1  GI:30723903
KEYWORDS    .
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
  AUTHORS   Zhang,J.
  TITLE     A human G protein coupled receptor
  JOURNAL   Patent: WO 03031621-A 1201 17-APR-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES             Location/Qualifiers
     source          1. .17
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"

  Query Match             2.0%;  Score 11.2;  DB 1;  Length 17;
  Best Local Similarity   81.2%;  Pred. No. 6.7e+02;
  Matches   13;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1977 TGAAAAAAAGAAAAGT 1992
              || ||||||  |||||
Db         17 TGCAAAAAAATAAAGT 2


Search completed: November  8, 2004, 08:27:37
Job time : 11 secs
```